<SEC-DOCUMENT>0000886163-22-000030.txt : 20220228
<SEC-HEADER>0000886163-22-000030.hdr.sgml : 20220228
<ACCEPTANCE-DATETIME>20220228172737
ACCESSION NUMBER:		0000886163-22-000030
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		93
CONFORMED PERIOD OF REPORT:	20211231
FILED AS OF DATE:		20220228
DATE AS OF CHANGE:		20220228

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			LIGAND PHARMACEUTICALS INC
		CENTRAL INDEX KEY:			0000886163
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				770160744
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-33093
		FILM NUMBER:		22691689

	BUSINESS ADDRESS:	
		STREET 1:		3911 SORRENTO VALLEY BLVD
		STREET 2:		SUITE 110
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121
		BUSINESS PHONE:		858-550-7500

	MAIL ADDRESS:	
		STREET 1:		3911 SORRENTO VALLEY BLVD
		STREET 2:		SUITE 110
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>lgnd-20211231.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2022 Workiva--><!--r:d46a5cfc-72eb-4b3a-bd09-c8907e0f4c5d,g:058bd086-7924-4675-b3eb-d4a9ba4991e0,d:0fa6f906fb2e4e30bc5e873d2bb6a82c--><html xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns="http://www.w3.org/1999/xhtml" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:lgnd="http://www.ligand.com/20211231" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>lgnd-20211231</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231" name="dei:AmendmentFlag" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY180L2ZyYWc6ODEzYTY0YmJkNjgyNGQ0MmI0M2UwYzUyMTA0MTA0ODQvdGFibGU6ZjY0NGM3OTc0MzdjNDlmN2I0YzU2YmI5MTVlNzRjNjcvdGFibGVyYW5nZTpmNjQ0Yzc5NzQzN2M0OWY3YjRjNTZiYjkxNWU3NGM2N18xLTEtMS0xLTQxMjk0_5fb31aee-39d1-4c52-945a-0980472c4286">FALSE</ix:nonNumeric><ix:nonNumeric contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY180L2ZyYWc6ODEzYTY0YmJkNjgyNGQ0MmI0M2UwYzUyMTA0MTA0ODQvdGFibGU6ZjY0NGM3OTc0MzdjNDlmN2I0YzU2YmI5MTVlNzRjNjcvdGFibGVyYW5nZTpmNjQ0Yzc5NzQzN2M0OWY3YjRjNTZiYjkxNWU3NGM2N18yLTEtMS0xLTQxMjk0_c454efb4-3b22-4e1f-adcd-8427640e8592">2021</ix:nonNumeric><ix:nonNumeric contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY180L2ZyYWc6ODEzYTY0YmJkNjgyNGQ0MmI0M2UwYzUyMTA0MTA0ODQvdGFibGU6ZjY0NGM3OTc0MzdjNDlmN2I0YzU2YmI5MTVlNzRjNjcvdGFibGVyYW5nZTpmNjQ0Yzc5NzQzN2M0OWY3YjRjNTZiYjkxNWU3NGM2N18zLTEtMS0xLTQxMjk0_775d2eb4-2871-45db-b874-b57de26ef190">FY</ix:nonNumeric><ix:nonNumeric contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY180L2ZyYWc6ODEzYTY0YmJkNjgyNGQ0MmI0M2UwYzUyMTA0MTA0ODQvdGFibGU6ZjY0NGM3OTc0MzdjNDlmN2I0YzU2YmI5MTVlNzRjNjcvdGFibGVyYW5nZTpmNjQ0Yzc5NzQzN2M0OWY3YjRjNTZiYjkxNWU3NGM2N180LTEtMS0xLTQxMzky_a0ef9304-b618-4c0e-9879-2a7a8fe1e4a7">0000886163</ix:nonNumeric><ix:nonNumeric contextRef="ie6c3b69702e9429aaeed46bdb9bbb9c1_D20190101-20191231" name="us-gaap:AccountingStandardsUpdateExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183My9mcmFnOmQzNzc2MmZiMDI0ZDRjNWE5MjMxODNkNmUxMTdjM2Q1L3RhYmxlOjU2ZjRlNzRkOTUxZDRhM2NiNDRhMzVjOGM0OWFmN2M0L3RhYmxlcmFuZ2U6NTZmNGU3NGQ5NTFkNGEzY2I0NGEzNWM4YzQ5YWY3YzRfMTctMC0xLTEtNDg2MjE_f0956f56-e3b9-4151-8fc0-a01564d4dcdb">http://fasb.org/us-gaap/2021-01-31#AccountingStandardsUpdate201613Member</ix:nonNumeric><ix:nonNumeric contextRef="i5258348dd679493ba1253e4703ac77de_D20210101-20211231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RleHRyZWdpb246MDE1MzU3NWExNzUxNDlhMGJlMjM2NzA3MzMyMzJiNjlfNjcyNw_c91288e2-cf87-4740-a1f7-845dfc930514">P3Y</ix:nonNumeric><ix:nonFraction unitRef="number" contextRef="i011775edbe77465dad2b4242ab130485_D20210101-20211231" decimals="4" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184NS9mcmFnOjgwZjdhYjc0MmVmMTQ4ZWJhYWQ2NWMxNGI4MTIzNTU1L3RhYmxlOjJkZmU4Y2E0Y2M2MzRjZDc5Y2M4OTM1ZDAyNTM4Njk1L3RhYmxlcmFuZ2U6MmRmZThjYTRjYzYzNGNkNzljYzg5MzVkMDI1Mzg2OTVfMS0xLTEtMS00MTI5NA_e761052f-75df-4244-b2fe-c04036514efd">12.50</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="i05cb34ed326948caae6c1e7e7cb67165_D20210101-20211231" decimals="4" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184NS9mcmFnOjgwZjdhYjc0MmVmMTQ4ZWJhYWQ2NWMxNGI4MTIzNTU1L3RhYmxlOjJkZmU4Y2E0Y2M2MzRjZDc5Y2M4OTM1ZDAyNTM4Njk1L3RhYmxlcmFuZ2U6MmRmZThjYTRjYzYzNGNkNzljYzg5MzVkMDI1Mzg2OTVfMi0xLTEtMS00MTI5NA_f3790e7f-8a4a-4d7a-b6f3-401e66ad3a52">2.08</ix:nonFraction><ix:nonNumeric contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231" name="us-gaap:FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDAvZnJhZzpmNDRmMTQwOTY3NGU0MzVkYWNmMjkzYWVjOTgxYmE2NS90YWJsZToyNmY5ZDQ2ZjdiYTI0Y2E3OWY3YzM1YWYzY2NhMjdkMC90YWJsZXJhbmdlOjI2ZjlkNDZmN2JhMjRjYTc5ZjdjMzVhZjNjY2EyN2QwXzExLTAtMS0xLTQxMjk0_189a0b16-c5f6-426a-9fe4-540e7d6227de">http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesNoncurrent</ix:nonNumeric><ix:nonNumeric contextRef="i7462d0db8f4248fcb9fd8f1deae439f3_I20201231" name="us-gaap:FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDAvZnJhZzpmNDRmMTQwOTY3NGU0MzVkYWNmMjkzYWVjOTgxYmE2NS90YWJsZToyNmY5ZDQ2ZjdiYTI0Y2E3OWY3YzM1YWYzY2NhMjdkMC90YWJsZXJhbmdlOjI2ZjlkNDZmN2JhMjRjYTc5ZjdjMzVhZjNjY2EyN2QwXzExLTAtMS0xLTQxMjk0_2ee456c7-520d-4723-b00d-a8a6a8da65cf">http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesNoncurrent</ix:nonNumeric><ix:nonFraction unitRef="number" contextRef="ied7021ca8f6e4678a12f1acdf2315468_D20140801-20140831" decimals="INF" name="us-gaap:DebtInstrumentConvertibleConversionRatio1" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDYvZnJhZzo5M2Q5YTVhN2Q1NWM0ODI3ODk1ZGQ3MGJiM2M0ZjI2NC90YWJsZTo5Mzc2ZjJmNmU0MTI0MDk5OTQzMWUwNWI3ZDAwMDQyNy90YWJsZXJhbmdlOjkzNzZmMmY2ZTQxMjQwOTk5NDMxZTA1YjdkMDAwNDI3XzItMS0xLTEtNDEyOTQ_4f6acaa5-a28a-4dc6-af4a-6831b864d395">0.0133251</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="i6cacda44cb2c4af291db0ef24394bf54_D20180501-20180531" decimals="INF" name="us-gaap:DebtInstrumentConvertibleConversionRatio1" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDYvZnJhZzo5M2Q5YTVhN2Q1NWM0ODI3ODk1ZGQ3MGJiM2M0ZjI2NC90YWJsZTo5Mzc2ZjJmNmU0MTI0MDk5OTQzMWUwNWI3ZDAwMDQyNy90YWJsZXJhbmdlOjkzNzZmMmY2ZTQxMjQwOTk5NDMxZTA1YjdkMDAwNDI3XzItMi0xLTEtNDEyOTQ_bd6a68ce-2e79-4014-84ee-930202b29b77">0.0040244</ix:nonFraction><ix:nonNumeric contextRef="i5258348dd679493ba1253e4703ac77de_D20210101-20211231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90ZXh0cmVnaW9uOjhkMWM4MjU1M2QwNzQ1ODVhMDJmY2U3NDA0ZGE4ZTE5XzIwODU_49dc7d90-487d-4145-93b5-5005d27536fa">P3Y</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="lgnd-20211231.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i8de36dd6935847019123fffb990b7008_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i46357a7c22b94af48beacbd35008717a_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="i3ed4f52b1ed24e778aa7185aa1e8bb90_I20220223"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-02-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="i9217b15ab4cb456c8c63180298ed612e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7462d0db8f4248fcb9fd8f1deae439f3_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="id759bc1766674b9fb61441df044bc82f_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if3c33038f43443e48bceca35aafc84c2_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3bced838db93465eb75b31bbd5690a49_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1477966cad0140da81a9947fe9bab347_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:MaterialSalesCaptisolMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia7b5c3c10a34465088f2fa15825a2c42_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:MaterialSalesCaptisolMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i75309306f08c443f8965a9846c0fb0fc_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:MaterialSalesCaptisolMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i11e3d543e376468e8dda481609ac67e8_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:ContractRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if06efbad02a54e9d92b23a3ff376910e_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:ContractRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idea9b96f20cf4c28aea8b365b1b2069c_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:ContractRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib3597315a63d441f8f128abd7ed8840e_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie6c3b69702e9429aaeed46bdb9bbb9c1_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i85c760e4f98147f79ecf9fc666a45595_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:VernalisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibb5d6e3d481646168203ad91e5a3ab1c_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:VernalisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id75620cd2ae8495a9c4aff23e56271fa_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:VernalisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id5ccedf4402b42a79d8bd7ff8d46fd9a_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:PromactaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic02ae2c8af73463a961944407c02e1da_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:PromactaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i21165c6e7ed34bec9a1abbd4497ce88b_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:PromactaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id0ff3295defe46b8bccc6c795953b0dd_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie8198f30811b402385fed871033fac83_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i24530d11bf3d4226b1bfc80e52009811_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2157f3f9f915470d94164dbf83569db0_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if1aac4d81ad94163b33117197afe0895_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iba40247e0e614545939d340c24ba1378_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia8c2096f420a462b813274a320529a34_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i11614604a0e24aa78e71eb02f9b1c21d_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id787fbb79cf94df2b867ff01039dd7ee_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i91bf098d468945ce94255ad9187b03e5_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib5f40ec88b5f46f8a400c8577e872e35_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i32ab127ed5c44358939fcb7eab76b6a6_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaa27b23fe5ac43dab25e6b1f5344211e_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ida3ec05a32644c2db1bb9f71f76c567f_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibb59da98705b4964a37154673c8ed2be_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7e24f17963584a8a8d751afa02b1b0c9_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia7e3cc749ec443c7b6a42c35ebdbd292_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibd8ac2d6daad403e8a1f73426f5256a2_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if67a2cd7a5e7447e8e1765371f5225b9_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3a721e0ae7354a8da5ec3fc43557bc99_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i00775ac58cda4124ad52707038f57ba7_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i98685891da6a4235a4c08510b2fafca9_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibd8887ddedbb409e8ee0b01a14c47927_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie12d7c9cbefd4947bbe0a3c6cb0e902e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3fe3de32a504463798a10b16d8710835_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i86f3192c999a48e18bfbb2d3da1eee99_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib1ca68e3b91b44f0a9d75354b9a561c3_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2a0bf241e5df45f3b9a295da0a033225_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4893aa820b6e400e86aa2f8639ddb077_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i460189e17625434e8a5a65a7ad36197f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i35055051f1cc48e3880e5291e4e63132_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if714890c34114ccca202fde217c2acc5_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="segment"><xbrli:measure>lgnd:segment</xbrli:measure></xbrli:unit><xbrli:context id="i8b1b6cbf7db84387abc05c19c397f3e1_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">lgnd:PartnerAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="i779fbae243e046e6a31b9eaa2c179124_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">lgnd:PartnerAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i32323a9d8b2a49eca1eebf5fa5da97be_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">lgnd:PartnerBMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib29fdd94f38f445bbfcbf8d17a9b0d2c_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">lgnd:PartnerBMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i19caa64fec87477596a2cd5d23955ee8_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">lgnd:PartnerBMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6a70ae97ec4641b88ce641ff76d8edd7_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">lgnd:PartnerCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i874c2ad63f1a4f0295a0ad715157a00e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:MaterialSalesCaptisolMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6a5b82872f4b4205b4cb36e3a7e65b00_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:MaterialSalesCaptisolMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5258348dd679493ba1253e4703ac77de_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i55156c07b9684b9185860bad3331609a_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia9a9eb80fb244862b401f0cf7734c9d9_I20201001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:PfenexMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i66fd5bb596fe4dc0a209f580f37be1bd_I20200401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:IcagenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-04-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2c4e300f1b0640468a246731197ac061_I20100131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:MetabasisTherapeuticsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2010-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="right"><xbrli:measure>lgnd:right</xbrli:measure></xbrli:unit><xbrli:context id="i24643322fd3648c280f9180082f606c7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:AziyoandCorMatrixMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieddf490290904ecbb766659c22b6325c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:AziyoandCorMatrixMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib6ab5af36644400fb3b934151581597a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:SelexisAndDianomiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8dab692d024a4e0f97bf65fe83fb703b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:SelexisAndDianomiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia8308d0606a54c10ac4769b1a226d54c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i302f4f37e71b4505a330b599087d6bee_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icc93824bf0be4b7495cbbfa00019602d_D20190501-20190531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:NovanMolluscumProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-05-01</xbrli:startDate><xbrli:endDate>2019-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4984262bb27142918e72ba7426eaa00b_I20190531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:NovanMolluscumProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:RoyaltyAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i76ec8fc1e4724884824d0d65bebbf615_I20190531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:NovanMolluscumProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:RoyaltyAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iac16870509044b14afde2112b0270ad8_I20190531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:NovanMolluscumProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:RoyaltyAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifc86d31013124f84b716699c6235c139_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:RoyaltyAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:PalvellaTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i00496d61e75e4c03bdeb6272892386e7_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:RoyaltyAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:PalvellaTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i059cb8a459af48f6b7c8f8245f0a8818_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:RoyaltyAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:PalvellaTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8efe50fcb86a4eaf887009631ddd44d0_D20181201-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:PalvellaTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id85f4282e429462997cf6658ec77093b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:PalvellaTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id5f878ad057d4dbcba2c34a61c1d4b07_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:ContractRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:PalvellaTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iabc0130cdf4e432a836d766b1ae349c3_D20170531-20170531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:AziyoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:RoyaltyAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-05-31</xbrli:startDate><xbrli:endDate>2017-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib3ba73729c164d36b827967a2afe6719_I20170531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:AziyoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:RoyaltyAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idfd3cb0e5e65402da94f6b645760f254_I20170531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:RoyaltyAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iceabba67d48a469eb549559806d7e623_I20170531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:AziyoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:RoyaltyAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if1c8698b58b240d19cf54dff3bafb373_I20170531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:RoyaltyAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:CorMatrixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1345b3a472be45ab8492e940ed55ac1a_D20170531-20170531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:RoyaltyAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:CorMatrixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-05-31</xbrli:startDate><xbrli:endDate>2017-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie0f36a67ac4b474f8a329695884951fa_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:AziyoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:RoyaltyAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i10f57c9a0a354a7c81c9266418797f1c_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:SelexisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:RoyaltyAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i744b30e425414018a238f9fbbb17b855_I20200101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201613Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id39ac2bcc6964f1cbe6799ea3c6e4480_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:RoyaltyKyprolisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3f42318fa27c4162a9de72f632806f73_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:RoyaltyKyprolisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie833d3fbd7ae41c78acdb6743a4958e5_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:RoyaltyKyprolisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6ec735166d6041df97f7f723bd52feac_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:RoyaltyEvomelaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ice15212256394a4a8bc6d0cdb5b93616_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:RoyaltyEvomelaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id98579a29cc3406ea0d48ffd0c8920f0_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:RoyaltyEvomelaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id6a4e064f17b4a32bbb585543d61d513_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:RoyaltyOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i70fab51ef90247fbb75a99fde6e756cd_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:RoyaltyOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icd3e128d210744fda465cb5dacddcdc6_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:RoyaltyOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if954ceb872c04e719899033296d6f686_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:RoyaltyPromactaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ice7144c706244526b337a36e827284e4_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia59aec17df534655ac72afe661d88b8c_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i946a606b7d2e4c08bc42b0378e0181dd_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ied5134c8bab44b978f6b885c1c70cbed_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:LicenseFeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4f517a8e06cc46728b8724172527ebda_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:LicenseFeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i11ba1ec739d34b82ba4433ba722bc361_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:LicenseFeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if4e90d7c48b94ff3a4921a0579c9e4e9_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:MilestoneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i757afef6fc544b019aa6e8d1c80f94f9_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:MilestoneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie9a1b09dbf574bec9cc40c8f1897cdc6_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:MilestoneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8436481b04714386944e45524f22e5a1_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:LicenseFeesMilestonesAndOtherProductOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i76d02ee85f37479bbbf7ef17aae36e40_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:LicenseFeesMilestonesAndOtherProductOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i46edba4f2dc546d19c17b95467b928d8_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:LicenseFeesMilestonesAndOtherProductOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i03b53fe74b3e44e5aed9677e0c396b22_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i63ea5dae35714601b3840baed12e6429_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iefe3140ed86e45ff99888b95c61cc3e7_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib017566aacfb4b59a18b47770cb8359c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibf4833a4427a446eaf4af9794277325c_D20070101-20071231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2007-01-01</xbrli:startDate><xbrli:endDate>2007-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i011775edbe77465dad2b4242ab130485_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lgnd:TwoThousandTwoStockIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">lgnd:VestingPeriodOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i05cb34ed326948caae6c1e7e7cb67165_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">lgnd:VestingPeriodTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lgnd:TwoThousandTwoStockIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i995925b4edc84004834a7204d8ca1593_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">lgnd:RestrictedStockUnitsAndPerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7c39587d4c0e42b7ba5b9574b3926bff_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lgnd:TwoThousandTwoStockIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia70ff35785434b4585314e733c4b42c1_I20180531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lgnd:ConvertibleSeniorNotesDue2023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1e8f1b6ddb0a48e7b819cababb4487da_I20140831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lgnd:ConvertibleSeniorNotesDue2019Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2014-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0a30e5369c8e4124bba63c2b980273be_I20190815"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lgnd:ConvertibleSeniorNotesDue2019Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-08-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6a0717c8be2147b0b92f9327bf1814fd_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifcdd30f034184cecb366b0b9b1bd9c55_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6a0c3b111e7c4e828d7eda58eb7efe37_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i58f6278b54d04be0bf0b9577c087f56c_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0b2d2a0659724a0394359a72b0ded635_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i97af3b7b1f564d4d911c3d6134e64410_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i891b87647a30477eb27e9edd4fc735ea_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iad8d570ea6b24d73b93cc3ae9b3901e3_D20201202-20201202"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">lgnd:VernalisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-02</xbrli:startDate><xbrli:endDate>2020-12-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie32796c2a612452280599ec9bc39e8e9_I20201201"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">lgnd:VernalisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if68046f8a22f4e8cb3ae551bf1b6614f_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">lgnd:VernalisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie5330d9159b84212968447e2b2771f1b_D20190306-20190306"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">lgnd:PromactaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-03-06</xbrli:startDate><xbrli:endDate>2019-03-06</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i46cec39d09204b19b6661eeb7995f45f_I20190306"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">lgnd:PromactaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-06</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i13ee716c8db44abb8505546f32fd4579_D20190101-20190306"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">lgnd:PromactaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-06</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic9f4e1d55a994ce397ebaba69b0e0499_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">lgnd:VikingTherapeuticsInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie623d2726f914332a2f5295e06936e94_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0ccc7acfbbaf4714aeb414b4d316cace_D20190101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="acquisition"><xbrli:measure>lgnd:acquisition</xbrli:measure></xbrli:unit><xbrli:context id="i05ca320ae7ad4dcaa5874e31460a42ed_D20201001-20201001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:PfenexMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-10-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic9ff8c1b8ef04c2a949db89fa926c247_I20201001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:PfenexMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i88f2f47e22764022b5dec2243aa219c7_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:PfenexMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i66bc35f78f7042ebafa5e4807cf87b90_D20201001-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:PfenexMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i95cf6d8d9303402492315ef907402a1a_I20201001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:PfenexMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">lgnd:ContractualRelationshipsAlvogenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3639b90349a0416597ac3b2345fcfd8b_D20201001-20201001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:PfenexMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">lgnd:ContractualRelationshipsAlvogenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-10-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6618eb064ffd4735b65d23c002f29a3d_I20201001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:PfenexMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">lgnd:ContractualRelationshipsMerckMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia025b98444b84bf38bee7c4b59d60941_D20201001-20201001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:PfenexMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">lgnd:ContractualRelationshipsMerckMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-10-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9687ebeaf03c4246885f9a884dc564ee_I20201001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:PfenexMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">lgnd:ContractualRelationshipsJazzMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i74a5e3f1fdec4b96b148fb5871cc991f_D20201001-20201001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:PfenexMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">lgnd:ContractualRelationshipsJazzMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-10-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8d2ed9e3e4254c8aa989182cdea6b83e_I20201001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:PfenexMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">lgnd:ContractualRelationshipsSIIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5263ecacba2e40a0bef60af7f8f3323f_D20201001-20201001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:PfenexMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">lgnd:ContractualRelationshipsSIIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-10-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i77b01aad4684478a851c8f13a0d12891_I20201001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:PfenexMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">lgnd:ContractualRelationshipsArcellxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id59883d6b9fe4a63b608829d498699ce_D20201001-20201001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:PfenexMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">lgnd:ContractualRelationshipsArcellxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-10-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i65ac1d8a3b63426baa11a41236151bd8_I20201001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TechnologyBasedIntangibleAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:PfenexMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id301d12eff0d4b76a98f1b19b7aa97fd_D20201001-20201001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TechnologyBasedIntangibleAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:PfenexMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-10-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib687713e39394d8883330adccb1296e4_D20201001-20201001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TechnologyBasedIntangibleAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:PfenexMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-10-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4c77fc6eecd341e48bc7b99f95972ddf_D20200401-20200401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:PfenexMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-04-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if97f9e0769b54e6a845f9f9fc59f0a1a_D20200401-20200401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:PfenexMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-04-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i81ce7b0c06a94e61a7d245d6544346aa_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:PfenexMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i981dcf3e258143ef926ca153a290587b_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:PfenexMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i77d1ae0e9cea4bc5be7e9ef1c1f3a41d_D20200909-20200909"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:TaurusBiosciencesLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-09-09</xbrli:startDate><xbrli:endDate>2020-09-09</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4dba26cb1a1841e88daa2e5a24a15dd4_I20200909"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:TaurusBiosciencesLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">lgnd:ContingentValueRightForInternalResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-09</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i473bb8ab24bf433bb5e1980d2a87164e_I20200909"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:TaurusBiosciencesLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">lgnd:ContingentValueRightOnProductRevenuesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-09</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i27ca37b8f6ed451391cf76d3832dccdb_D20200909-20200909"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:TaurusBiosciencesLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">lgnd:ContingentValueRightOnProductRevenuesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-09-09</xbrli:startDate><xbrli:endDate>2020-09-09</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i36eaffe97d9f4ad9b8c509ecec687717_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:TaurusBiosciencesLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i37f8f2fb62fb45eda8a94c6014fb06c3_I20200909"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:TaurusBiosciencesLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-09</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1decdab2b3ad4d5f9e9970051e074f04_D20200909-20200909"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TechnologyBasedIntangibleAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:TaurusBiosciencesLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-09-09</xbrli:startDate><xbrli:endDate>2020-09-09</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieb689a5898414155944b7e894ecf5662_D20200908-20200908"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:XCellaBiosciencesIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-09-08</xbrli:startDate><xbrli:endDate>2020-09-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i37beeb694dea43279d1ea72ec2fb6fa3_I20200908"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">lgnd:EarnoutRightsForPartnerResearchAndDevelopmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:XCellaBiosciencesIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i48c587ca12364b2ebe41d4a23afdf0a5_I20200908"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">lgnd:MilestonePaymentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:XCellaBiosciencesIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i00b4cfcf8fab454fa5cb35a4499bd18e_D20200908-20200908"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">lgnd:MilestonePaymentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:XCellaBiosciencesIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-09-08</xbrli:startDate><xbrli:endDate>2020-09-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic3f66dd3dd704775a2c678c7d07ce665_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:XCellaBiosciencesIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib2d89a76397d4f8fa55ad5491b92151e_I20200908"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:XCellaBiosciencesIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i27406e0d0a0147c28467e0891905560f_D20200908-20200908"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TechnologyBasedIntangibleAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:XCellaBiosciencesIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-09-08</xbrli:startDate><xbrli:endDate>2020-09-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ied333fd0de2c4cf4a2b4948199619825_D20200401-20200401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:IcagenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-04-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8b9c129486844e46be95446917936d16_I20200401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:IcagenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-04-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i187c5df306a349e38267335b0f796d41_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:IcagenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2c2f23bb705c43f999e98dd9cfeedb0a_I20200401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:IcagenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-04-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i50397a39865e428d8b5ec1d1e3e72da9_I20200401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TechnologyBasedIntangibleAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:IcagenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-04-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if2f9b634b34f4572ac8de5159f8e63fb_D20200401-20200401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:IcagenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-04-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i797a1a3c49bb44aba3b71fee73a5a78f_D20200401-20200401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TechnologyBasedIntangibleAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:IcagenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-04-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i559e6316ff5f46eeae72eb8202827fdd_D20190723-20190723"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:AbInitioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-23</xbrli:startDate><xbrli:endDate>2019-07-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2391e1562f894a61a00bffbaac6457ea_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:AbInitioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib84e53f0d01a493a86dc0aed964fe45a_I20190723"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:AbInitioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-07-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i609b4c3a45a041b1856484ca0935a9fc_D20190723-20190723"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TechnologyBasedIntangibleAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:AbInitioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-23</xbrli:startDate><xbrli:endDate>2019-07-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i06eb91dd76a2457bac33ba1c3af251f5_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieccd194c6cad463fa107525565469c36_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i03010ea07e48483686f97632e65cacf7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iae4bca14f93e4328aa90c2fce8fbaae3_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4367fea4a9a64e5a983f1e1a7761535c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6d6fdee1dc984b5fa799d65fefdb8a09_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i640373e7d8124d24b670e247208e7234_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i01a1659f9184445ca7e9d321e7b29f6d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i83d2c94c6e0b4e79aceeeff3efa78c20_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2a0bee3568b44a9bb12563aeaa8528f5_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7d8c9f4eb5724240a7b9559155e19d8f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i33b5cd64b00744faaf121a59ccec8a90_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i84a81b7b22eb417e910d5485bba6df55_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lgnd:LiabilityForContingentValueRightsCompanyCydexMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie6401005419049dc9000250436aca434_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lgnd:LiabilityForContingentValueRightsCompanyCydexMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0f8a682fcdf94c3d884f17cb17ab868c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lgnd:LiabilityForContingentValueRightsCompanyCydexMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5346db50523e458fa6677b7418028935_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lgnd:LiabilityForContingentValueRightsCompanyCydexMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i761befb7871948fea7097d919ba453c9_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lgnd:LiabilityForContingentValueRightsCompanyMetabasisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ief7b3a15b9ee435cbec80f843a28571c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lgnd:LiabilityForContingentValueRightsCompanyMetabasisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaae0909eafc24451b37ac98a3e7c4186_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lgnd:LiabilityForContingentValueRightsCompanyMetabasisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0c03158e62e14e9d93bc8351b82e61d2_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lgnd:LiabilityForContingentValueRightsCompanyMetabasisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i05df3e58efe24ec7831e64257f22be53_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lgnd:LiabilityForContingentValueRightsCompanyIcagenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i518bc06c25204d4482b4301cdd1766e5_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lgnd:LiabilityForContingentValueRightsCompanyIcagenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaac590afaaf54948a1215ada11b67e6c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lgnd:LiabilityForContingentValueRightsCompanyIcagenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5a59fb8107e140aaad7a5aeb9e7c180b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lgnd:LiabilityForContingentValueRightsCompanyIcagenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i36dc23d032314fa8a07bbd180231487a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lgnd:LiabilityForRestrictedInvestmentsOwedToFormerLicenseesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i01b8d0c82ed84b4ca4d821ca4a42eeba_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lgnd:LiabilityForRestrictedInvestmentsOwedToFormerLicenseesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic60c56fc16f0480485730f8ab7210dd9_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lgnd:LiabilityForRestrictedInvestmentsOwedToFormerLicenseesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iffa6d45b279f45088e9ebcb1bda002cc_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lgnd:LiabilityForRestrictedInvestmentsOwedToFormerLicenseesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibc51353676e643b3841a0d97b6e09df4_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2e29fab916b04659a0092e93e4ce0c0f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icb7f607e997042d6b7cb2a76b14c89ff_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieef2fe5db0a5418095a2663aac7e9433_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4d9e2c86e31846918735fb68e1980c7b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4633e33cdaf74da5bab73b86a73c762b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5465f391d98d450686c03b0526a9298e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i64e87aeff0584255b5155e1fb7330377_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9fde372ecc73482ea79fc251841260be_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iad3afe93dc254f3a87134b83bff3a320_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if82c17ea55e64548ab7c37f50afc7954_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5ec6e8e1b38040ff9f9c4e67b129466c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if603e492b3b54ca58c52c72f0db1a614_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i04c0a503b677413e90c282c029cef0df_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i90e770e8ee9247f492c911fccc5f09ee_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8c5d55bf4e3a4a18a904ad6c106afe1b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i89bb63fa9a9347e5b89eddf911a574ec_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lgnd:LiabilityForContingentValueRightsCompanyCrystalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic8dbef5f05d649cfa20404b188f90797_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lgnd:LiabilityForContingentValueRightsCompanyCrystalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4b774db056ca4e6fbb86b328cdf6ec7e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lgnd:LiabilityForContingentValueRightsCompanyCrystalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i49c492d399144f8f95065abe6a77d858_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lgnd:LiabilityForContingentValueRightsCompanyCrystalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i09e78cdf01344954a110ff4100c16b89_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lgnd:LiabilityForContingentValueRightsCompanyCydexMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i641dc2acfdc24382ac77f797d0b878dc_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lgnd:LiabilityForContingentValueRightsCompanyCydexMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i94796a987fa04da6b4328a1f6396c729_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lgnd:LiabilityForContingentValueRightsCompanyCydexMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5ab1ef46b3dc4b3687c20938c246e8e1_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lgnd:LiabilityForContingentValueRightsCompanyCydexMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i64ddda8f7dd340a6a66150fe9da6ac8f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lgnd:LiabilityForContingentValueRightsCompanyMetabasisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3a14312c0d7a4b6ab188c0d69af3db1b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lgnd:LiabilityForContingentValueRightsCompanyMetabasisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4994043653b246e6825b1757a960c104_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lgnd:LiabilityForContingentValueRightsCompanyMetabasisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i11062dc1f4334dbda82a1482afce4add_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lgnd:LiabilityForContingentValueRightsCompanyMetabasisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5a6efdc157074e8abf3dbebb0b3ad1b2_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lgnd:LiabilityForContingentValueRightsCompanyIcagenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i766d5476b4ed450888509671880dd88e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lgnd:LiabilityForContingentValueRightsCompanyIcagenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i32ce3f371084478bae9051b730d767d9_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lgnd:LiabilityForContingentValueRightsCompanyIcagenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3c716beea168465687c12c65fb1f22bc_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lgnd:LiabilityForContingentValueRightsCompanyIcagenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i795fda855e164fe998d1404c211cfeff_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lgnd:LiabilityForContingentValueRightsCompanyPfenexMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9ea2d72079aa4831af7d9061421a7429_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lgnd:LiabilityForContingentValueRightsCompanyPfenexMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ice7abf01eb9f42f5b54f5a4e479520a1_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lgnd:LiabilityForContingentValueRightsCompanyPfenexMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie0fd39b8e1ac4faebf9a08fe57ba3937_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lgnd:LiabilityForContingentValueRightsCompanyPfenexMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if2d95711871a49dda3f26e3f6251690b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lgnd:LiabilityForRestrictedInvestmentsOwedToFormerLicenseesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id1294f5d7b1847e0a6d5e6dbe332860f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lgnd:LiabilityForRestrictedInvestmentsOwedToFormerLicenseesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib3682c8c511e421faf31bc8dcde15b42_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lgnd:LiabilityForRestrictedInvestmentsOwedToFormerLicenseesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idcc241ac9ac54103a54cc0d5e60c4f58_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lgnd:LiabilityForRestrictedInvestmentsOwedToFormerLicenseesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i417532a79d3e4320bfa35df66295546e_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lgnd:LiabilityForContingentValueRightsCompanyCrystalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="agreement"><xbrli:measure>lgnd:agreement</xbrli:measure></xbrli:unit><xbrli:context id="iedd254aeb5ed46a0bbbbaec3521899ab_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:DevelopmentRegulatoryCommercialMilestonesAndTieredRoyaltiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5b1dfac6d5ae4926a0e3356f1fb10e83_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:Phase3ClinicalTrialMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib43ce77d810a40fc9387e9ee784e9e68_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lgnd:LiabilityForContingentValueRightsCompanyIcagenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8c54435dabbb4bf1accc9ff53169d37a_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lgnd:LiabilityForContingentValueRightsCompanyPfenexMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iac18f57f540e4a9a8a4f9d6ca432b9ee_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i34b45bfb1f924acb8a8e2d99bc22a5fc_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5044d29e95d74c3fb4dfe5dd2471e761_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3573e853130f4f1fbcdabc617380abaf_D20201001-20201031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:MaterialSalesCaptisolMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia2b01f0961da4bb18dfb8e25a49046e9_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3280169138e848a0ba04a73dbb57193a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ied7021ca8f6e4678a12f1acdf2315468_D20140801-20140831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lgnd:ConvertibleSeniorNotesDue2019Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2014-08-01</xbrli:startDate><xbrli:endDate>2014-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1183d582f8ce4971a5581dbc8a1e1af3_D20140801-20140831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lgnd:ConvertibleSeniorNotesDue2019Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2014-08-01</xbrli:startDate><xbrli:endDate>2014-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="trading_day"><xbrli:measure>lgnd:trading_day</xbrli:measure></xbrli:unit><xbrli:context id="i6ba1b63d92a042cf85e08ce77d22918b_D20140801-20140831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lgnd:ConvertibleSeniorNotesDue2019Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2014-08-01</xbrli:startDate><xbrli:endDate>2014-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="day"><xbrli:measure>lgnd:day</xbrli:measure></xbrli:unit><xbrli:context id="iebcfeb3afbe54bc3ae6cb6224e5b1f1a_D20180522-20180522"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lgnd:ConvertibleSeniorNotesDue2019Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-05-22</xbrli:startDate><xbrli:endDate>2018-05-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i64f0f378c0fc4cf4ae62d78c8b6e22d1_D20181231-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lgnd:ConvertibleSeniorNotesDue2019Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie12f8a2703764c3c9b2157933d860bf3_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lgnd:ConvertibleSeniorNotesDue2019Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0b01059b43af404594129aa6cbdd9a86_D20180301-20180430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lgnd:ConvertibleSeniorNotesDue2019Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-03-01</xbrli:startDate><xbrli:endDate>2018-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id614d6af476c4bf9847c470856137006_D20180701-20180831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lgnd:ConvertibleSeniorNotesDue2019Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-07-01</xbrli:startDate><xbrli:endDate>2018-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4f364a39025b407697747d1d13afd5d0_D20181001-20181130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lgnd:ConvertibleSeniorNotesDue2019Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-10-01</xbrli:startDate><xbrli:endDate>2018-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iea9bdffff69d41b2bab859af4b604cca_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lgnd:ConvertibleSeniorNotesDue2019Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icc1c18173ae448ee9cc6a4cfa0f63d46_D20190601-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lgnd:ConvertibleSeniorNotesDue2019Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-06-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i299d7fb1915643c9bd662d97a56f9224_D20190815-20190815"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lgnd:ConvertibleSeniorNotesDue2019Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-08-15</xbrli:startDate><xbrli:endDate>2019-08-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie2cb0a952fa043858638ccca94aafee7_I20190815"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lgnd:ConvertibleSeniorNotesDue2019Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-08-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic3fce11822d74ffb9e96e89bebb23277_I20140831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2014-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if35894c7763245fd8dfbcdb677a1a22e_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lgnd:ConvertibleSeniorNotesDue2019Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9807ff46d0594f389be4314eae9d0d00_I20180522"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lgnd:ConvertibleSeniorNotesDue2023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-05-22</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6cacda44cb2c4af291db0ef24394bf54_D20180501-20180531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lgnd:ConvertibleSeniorNotesDue2023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-05-01</xbrli:startDate><xbrli:endDate>2018-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2b189f2223d941889569bd209d33b64c_D20180501-20180531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lgnd:ConvertibleSeniorNotesDue2023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-05-01</xbrli:startDate><xbrli:endDate>2018-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6dd7d2a8849547b0b84667b449a38485_D20180501-20180531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lgnd:ConvertibleSeniorNotesDue2023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-05-01</xbrli:startDate><xbrli:endDate>2018-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i75c40fa8303240178bae96b5323104b2_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lgnd:ConvertibleSeniorNotesDue2023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iad6270f46e2a419fb81396b4dde75fb8_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lgnd:ConvertibleSeniorNotesDue2023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic40084c55a8f45ed806b36e3520df3db_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lgnd:ConvertibleSeniorNotesDue2023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9d6e6be3ae854425ba0e34565fd2b9c3_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lgnd:ConvertibleSeniorNotesDue2023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie28d293ededa44009f8568af6cd22fe9_I20220228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lgnd:ConvertibleSeniorNotesDue2023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i106a64ab6c044b39a19f90f252c7361a_D20220201-20220228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lgnd:ConvertibleSeniorNotesDue2023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-02-01</xbrli:startDate><xbrli:endDate>2022-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4bff4ceb2aad46e4b1484d0f72c5d0dc_D20180522-20180522"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lgnd:ConvertibleSeniorNotesDue2023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-05-22</xbrli:startDate><xbrli:endDate>2018-05-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i304fdd56fb5543218317f467b86ae411_I20180531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lgnd:ConvertibleSeniorNotesDue2023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieab8e7c78f9745d2b71d10dcba9ea01a_I20200430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lgnd:ConvertibleSeniorNotesDue2023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1c98a85d32c34724861a5ba3589972ee_D20200401-20200430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lgnd:ConvertibleSeniorNotesDue2023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i71ea8f3e306b4086bfbeaaedfe295b98_I20210131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lgnd:ConvertibleSeniorNotesDue2023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if357845be5954c78ac67d659d089ca0c_D20210101-20210131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lgnd:ConvertibleSeniorNotesDue2023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="option"><xbrli:measure>lgnd:option</xbrli:measure></xbrli:unit><xbrli:context id="i00a18868ce4d4197a8afb1f39a028208_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MutualFundMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4ee078f3c41f42a0b0e253d5572cce12_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:DemandDepositsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaf06af7ed8174cf3bef274cca762d884_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8cbd4d6b4d6042bca716c614bfd4632a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7e8a90585c134dbb98e6aecf3894a4ee_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibba9764388ba4ab5b3742c104cad8606_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie389523012a64039b933f60b96d0b103_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibe91b170813b4c308d6df67cdcda5ea8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib7bfc8139cbb425fb7edf200713433a4_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MutualFundMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i201f7376cfcf403b9594a167f61024eb_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:DemandDepositsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1751a1fa85af462cabdcd01341cd31d6_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if6d8d88efb7d45d5b666348e93e722c9_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iec0af917487f48e3b637625d1c5d4563_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:AgencySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i05f7d42438c243028010745501c74c06_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6a5d7b087f09490db4f5fa4e098ee683_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6243ca7a24ef40909c79d484e6b2cf6a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i17e3d08da23d4db99c73bbe97ce55cbd_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i20c406b0b22b496398fdf16c484061b8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DemandDepositsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id5e251d71959460ba39674664cd46959_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i057c89a152c14f40b506b184456d7b2b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6fbb980b9e7c4be4bd3c3376bc2bfda4_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib7f6e9d91bc84543b6ae3503d8d78f6b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DemandDepositsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i24d8d13bc1ac4681b103e921e023e7ba_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1a14cdb03cd74fd3800f47006e6564e8_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="position"><xbrli:measure>lgnd:position</xbrli:measure></xbrli:unit><xbrli:context id="i9f0a5635602742c38606929f85d0bc8e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2ef3fe1366ce4c63b1d61301c2c7cbb5_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9733272dc36042e6ba12faba3f716e92_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i95f33c3ebaeb4778a9c2db6a6f6bf294_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4c5205ea5f084dac8c4dea9fdfadee02_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">lgnd:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4a16585689be4389b9863317f3aa3977_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">lgnd:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8dc42c0d5a094b05bae7e120852bb210_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentedTechnologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6b8810ae90624e1cbd1c4a5c1b42b223_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentedTechnologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ida5c64ee227a46869554690587da8f25_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5e9a6867858343a7a292fb11a532ee7e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i89bdb805a8644de089fac518b7ea8048_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i427cd915d4f24352b4c76d892b21bbe5_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iea59787485c24e82bc3497c81a2ced53_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ContractualRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0aba44ce07e94134b8623377b4bd1f1b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ContractualRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i96479b1570dc4ab694a9ba99ff1921f3_I20100131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2010-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i03ae11f17dbd4fa8abcc1e76cf940016_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:CydexPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i995ed554220d4c41bec3af6e81ce0850_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:CydexPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0526771434af45b0b8fabceb89eea2cc_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:CydexPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9a7cf59bd85847db8f5d973e93d748f7_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:CydexPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i460273d884cd42ba9f38e5fa9863bd88_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:CydexPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icaf2965868e840808ef1852e02d910af_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:MetabasisTherapeuticsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9bc6c029e12c43b59b76212780726386_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:MetabasisTherapeuticsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2e4b849ac2f8499fb341e31d46f606a1_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:MetabasisTherapeuticsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1d4b5cb9bf0848cd952b53016008c4d8_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:MetabasisTherapeuticsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i83cae13058624959a293b420f9d495a2_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:MetabasisTherapeuticsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9e883877c50c4dd5bae0f1a39a6a0e41_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:CrystalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9b2336871c004529976d951e9de999e1_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:CrystalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i99bcc19c12eb4a95abbe38b2a1c1ee09_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:CrystalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i46955c33e54e4edc9a5157b092d74d96_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:CrystalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaad967943e174bfb992a030f8843e4a9_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:CrystalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if61e02a9d9f3443a954dd4ff1b746645_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:IcagenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idcfaeb9f6dcd4e36923251345eeb6ca6_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:IcagenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3fbebdcfd15e4645b3afda1206ded002_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:IcagenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7fb9df0f2e264716b9f5ee2e301fba56_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:IcagenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9c2bd0e95a2b4600bd5178475b6ab429_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:PfenexMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2e80589fd36648dfa6f6d8fa79c9c970_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:PfenexMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ida7de17e10b54528aa29a691195fafa4_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:PfenexMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i017d8efa6ba94abf99a9dc5f29b93ac6_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:XCellaBiosciencesIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id1b889a729444f17b1b5cebb42dc2471_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:XCellaBiosciencesIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if9bfbbb794834d7fba1e6252029a297d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:XCellaBiosciencesIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9eeb792ea9ad40c3915226866d3115db_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:XCellaBiosciencesIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i448245714de441abb40ff86cd51987ac_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iacfc069f04d74d5284905aeca908935c_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i25d150502e6343c683387b66fba49489_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iee6a37781cce4dbf871fcd529222b482_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5795881ca2b5425d88c92353925e817c_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0cf2334cbb0c4ac8b2c4b765ea0668aa_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i67c3913252f44310913216625ca1c514_D20201201-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lgnd:TwoThousandTwoStockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib571bf67523d458e92549c7f222ea20c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lgnd:TwoThousandTwoStockIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if81036550c4349c78f4732ee0154191c_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibb76fff21d1145a2aa988019605605d7_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">lgnd:ExercisePriceRangeOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2d5b9274891c4530b4756d9f6d78384d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">lgnd:ExercisePriceRangeOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i42d7e1e14d514ee5ac131e49d67d3ae9_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">lgnd:ExercisePriceRangeTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if56255ad310d4a3bbccede5e1c84b2ec_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">lgnd:ExercisePriceRangeTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1583b4003fe544649fbe7acf591bc7c2_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">lgnd:ExercisePriceRangeThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3186ef0fac614fe4a3a83b4e3df1fac4_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">lgnd:ExercisePriceRangeThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9203228b9f3a4a258d1dd418f1ff9fab_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">lgnd:ExercisePriceRangeFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i65a6d24f5a314cbba76284b24732fb3c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">lgnd:ExercisePriceRangeFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i708cf622e450455095803a651785b9f8_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">lgnd:ExercisePriceRangeFiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1cf30bd35d974a5688e936ed32ee1917_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">lgnd:ExercisePriceRangeFiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i193ec162b3f648aaaca6368e35169ea0_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">lgnd:ExercisePriceRangeSixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i80a561831894449e862692a33049b0b5_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">lgnd:ExercisePriceRangeSixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i08eb127d3b5c4ecd8f5f19d8b095a195_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">lgnd:ExercisePriceRangeSevenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i546fb8a918cb476380308420e935eec1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">lgnd:ExercisePriceRangeSevenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i39fc20505d3849c9ae3fc61f12edf580_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">lgnd:ExercisePriceRangeEightMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1d0ce9ddb0d9422b8e6592ab0500d1ab_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">lgnd:ExercisePriceRangeEightMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9d3219f8f79f4fb685decb79b150bd06_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">lgnd:ExercisePriceRangeNineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id7afd511815d4bc394f6e2368abd4dca_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">lgnd:ExercisePriceRangeNineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i828b95c8a1d249729b55e04082a16fbe_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">lgnd:ExercisePriceRangeTenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie43fa1c2f29449588c86ec647c987e14_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">lgnd:ExercisePriceRangeTenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i331ce2c9b57a41af9de97ff9994cb5b5_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">lgnd:ExercisePriceRangeElevenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6d7b08b9d22043d5932cf089d69eba52_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">lgnd:ExercisePriceRangeElevenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8c53cef7494647d29b8ef30c6695cfb2_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0addec58007345efb57ddbad8ce96022_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id82d912299e647bab45143f83254b4e2_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9d152e0e9dfd4aad8d4279f7424f28d5_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0f9a89ad3d5346e3b8b17b7dfbcb9f78_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i45bcdaf84c91401486b1d0398942843d_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5adbf2e3e4984848b67e5715f6848f1d_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ice6ab2e1895644b3904facb98212b670_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibc879451c38048cb9a8e8aa28472a4b5_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i22382abe9f7a467bbc034256835a449a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lgnd:AmendedESPPMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0776b86882ee4f22a11770402d0e2885_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lgnd:AmendedESPPMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i535be16f293842b4b59ed978a4dea350_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lgnd:AmendedESPPMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie6271140c911499083fbafdeb97da802_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lgnd:AmendedESPPMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i66cf645fedeb4e3f9127e1557bedf870_I20190911"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-09-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4f38082a14de4b7eb626c9119b5258a9_D20190911-20190911"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-09-11</xbrli:startDate><xbrli:endDate>2019-09-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4cf8373f29714ddb8d2a41d990b0fb42_I20190123"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-01-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i93652c87888744bc90a296c0d62c6b8e_D20191029-20191029"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">lgnd:LupinPatentInfringementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-29</xbrli:startDate><xbrli:endDate>2019-10-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="patent"><xbrli:measure>lgnd:patent</xbrli:measure></xbrli:unit><xbrli:context id="idcb9c868c1be4dc8bc733f81708def2c_D20191031-20191031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">lgnd:USDistrictCourtForTheNorthernDistrictOfOhioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-31</xbrli:startDate><xbrli:endDate>2019-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="civil_complaint"><xbrli:measure>lgnd:civil_complaint</xbrli:measure></xbrli:unit><xbrli:context id="ia4b200a8f2e64db69b4c7fc8145284e5_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i961668aace3a442bba4c79a8ec70d54a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if699be6e6c984e4f92ca3d8242313e6d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5ec01ca4f07749ee939ef64e906c8950_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">lgnd:CaliforniaAndNewJerseyResearchTaxCreditCarryforwardMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1d36cbe0fb424f31b1fc285dc4c6570b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0c31a24c4fde4de983ed94eb8e6c8a18_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:CapitalLossCarryforwardMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icb55a00b3ea6419c93f1e2c6128879a1_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i451ae05e4ee04e718c1da5b566a1bbc5_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:CapitalLossCarryforwardMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i0fa6f906fb2e4e30bc5e873d2bb6a82c_1"></div><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">_____________________________________________________________________________________________</span></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xL2ZyYWc6MmY2MWRiOTUwNGNkNDliM2E4MWMxYTQyZmUyNTZkZjUvdGV4dHJlZ2lvbjoyZjYxZGI5NTA0Y2Q0OWIzYTgxYzFhNDJmZTI1NmRmNV80MDQ4_6b09f94d-2133-4c42-9b01-d71a43ab7c60">10-K</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">_____________________________________________________________________________________________</span></div><div style="margin-top:2pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:2.717%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:95.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231" name="dei:DocumentAnnualReport" format="ixt:fixed-true" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xL2ZyYWc6MmY2MWRiOTUwNGNkNDliM2E4MWMxYTQyZmUyNTZkZjUvdGFibGU6ZGQ5MzNjYTdkMGNlNGIxYWJkZDU4ZTlkODQxZGRhOGMvdGFibGVyYW5nZTpkZDkzM2NhN2QwY2U0YjFhYmRkNThlOWQ4NDFkZGE4Y18wLTAtMS0xLTQxMjk0_301e6b1b-95e1-47fb-bd7e-c94ecb81729d">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">For the Fiscal Year Ended <ix:nonNumeric contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xL2ZyYWc6MmY2MWRiOTUwNGNkNDliM2E4MWMxYTQyZmUyNTZkZjUvdGV4dHJlZ2lvbjoyZjYxZGI5NTA0Y2Q0OWIzYTgxYzFhNDJmZTI1NmRmNV8zMDQ_75c5e435-e0fa-4d50-9327-9faedcf8efde"><ix:nonNumeric contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231" name="dei:CurrentFiscalYearEndDate" format="ixt:date-monthname-day-en" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xL2ZyYWc6MmY2MWRiOTUwNGNkNDliM2E4MWMxYTQyZmUyNTZkZjUvdGV4dHJlZ2lvbjoyZjYxZGI5NTA0Y2Q0OWIzYTgxYzFhNDJmZTI1NmRmNV8zMDQ_6a5332b3-fa87-4a28-803c-69fc3b2111ac">December 31</ix:nonNumeric>, 2021</ix:nonNumeric></span></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">OR</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"><tr><td style="width:1.0%"></td><td style="width:2.857%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.943%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231" name="dei:DocumentTransitionReport" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xL2ZyYWc6MmY2MWRiOTUwNGNkNDliM2E4MWMxYTQyZmUyNTZkZjUvdGFibGU6MDBiOWVjYzU5ZjAyNGVjYmI4NTYxZDgxYWYxZGZmOTcvdGFibGVyYW5nZTowMGI5ZWNjNTlmMDI0ZWNiYjg1NjFkODFhZjFkZmY5N18wLTAtMS0xLTQxMjk0_511a4697-798e-4e3d-9f45-5f158387f9c0">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">For the transition period from &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; to &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;.</span></div><div style="margin-top:2pt;text-align:center"><span><br/></span></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Commission File No.&#160;<ix:nonNumeric contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xL2ZyYWc6MmY2MWRiOTUwNGNkNDliM2E4MWMxYTQyZmUyNTZkZjUvdGV4dHJlZ2lvbjoyZjYxZGI5NTA0Y2Q0OWIzYTgxYzFhNDJmZTI1NmRmNV80MDQz_6fe61333-dd8c-4cce-bef2-7ac3373c94fb">001-33093</ix:nonNumeric></span></div><div style="margin-top:2pt;text-align:center"><img src="lgnd-20211231_g1.jpg" alt="lgnd-20211231_g1.jpg" style="height:100px;margin-bottom:5pt;vertical-align:text-bottom;width:250px"/></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xL2ZyYWc6MmY2MWRiOTUwNGNkNDliM2E4MWMxYTQyZmUyNTZkZjUvdGV4dHJlZ2lvbjoyZjYxZGI5NTA0Y2Q0OWIzYTgxYzFhNDJmZTI1NmRmNV80MDUw_19ce0d23-1eb3-4493-b882-1f2be53da81c">LIGAND PHARMACEUTICALS INC</ix:nonNumeric>ORPORATED</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Exact name of registrant as specified in its charter)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:80.555%"><tr><td style="width:1.0%"></td><td style="width:65.869%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.707%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.024%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xL2ZyYWc6MmY2MWRiOTUwNGNkNDliM2E4MWMxYTQyZmUyNTZkZjUvdGFibGU6YzY1NWE1NWRmM2ZiNGZhYTg0N2ZhN2NiMTM0M2MyNDEvdGFibGVyYW5nZTpjNjU1YTU1ZGYzZmI0ZmFhODQ3ZmE3Y2IxMzQzYzI0MV8wLTAtMS0xLTQxMjk0_682bfd82-3bad-4e76-b63d-572771868fee">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xL2ZyYWc6MmY2MWRiOTUwNGNkNDliM2E4MWMxYTQyZmUyNTZkZjUvdGFibGU6YzY1NWE1NWRmM2ZiNGZhYTg0N2ZhN2NiMTM0M2MyNDEvdGFibGVyYW5nZTpjNjU1YTU1ZGYzZmI0ZmFhODQ3ZmE3Y2IxMzQzYzI0MV8wLTItMS0xLTQxMjk0_b17bf0dc-1219-472e-919f-9dd30bf1da40">77-0160744</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(State or other jurisdiction of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">incorporation or organization)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(IRS Employer</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Identification No.)</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xL2ZyYWc6MmY2MWRiOTUwNGNkNDliM2E4MWMxYTQyZmUyNTZkZjUvdGFibGU6YzY1NWE1NWRmM2ZiNGZhYTg0N2ZhN2NiMTM0M2MyNDEvdGFibGVyYW5nZTpjNjU1YTU1ZGYzZmI0ZmFhODQ3ZmE3Y2IxMzQzYzI0MV8zLTAtMS0xLTQxMjk0_2d12d7be-fcaa-465e-bb21-17eb105bd9a0">5980 Horton Street, Suite 405</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xL2ZyYWc6MmY2MWRiOTUwNGNkNDliM2E4MWMxYTQyZmUyNTZkZjUvdGFibGU6YzY1NWE1NWRmM2ZiNGZhYTg0N2ZhN2NiMTM0M2MyNDEvdGFibGVyYW5nZTpjNjU1YTU1ZGYzZmI0ZmFhODQ3ZmE3Y2IxMzQzYzI0MV80LTAtMS0xLTQxMjk0_fdfa573f-5f7b-450c-ade4-f94b62cea63b">Emeryville</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xL2ZyYWc6MmY2MWRiOTUwNGNkNDliM2E4MWMxYTQyZmUyNTZkZjUvdGFibGU6YzY1NWE1NWRmM2ZiNGZhYTg0N2ZhN2NiMTM0M2MyNDEvdGFibGVyYW5nZTpjNjU1YTU1ZGYzZmI0ZmFhODQ3ZmE3Y2IxMzQzYzI0MV81LTAtMS0xLTQxMjk0_7922b15b-96ab-43c4-8b03-0ce35216c527">CA</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xL2ZyYWc6MmY2MWRiOTUwNGNkNDliM2E4MWMxYTQyZmUyNTZkZjUvdGFibGU6YzY1NWE1NWRmM2ZiNGZhYTg0N2ZhN2NiMTM0M2MyNDEvdGFibGVyYW5nZTpjNjU1YTU1ZGYzZmI0ZmFhODQ3ZmE3Y2IxMzQzYzI0MV81LTItMS0xLTQxMjk0_622d6bf2-d1a5-4d31-90a0-48e6412b6762">94608</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Address of Principal Executive Offices)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Zip Code)</span></td></tr></table></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Registrant&#8217;s telephone number, including area code: (<ix:nonNumeric contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xL2ZyYWc6MmY2MWRiOTUwNGNkNDliM2E4MWMxYTQyZmUyNTZkZjUvdGV4dHJlZ2lvbjoyZjYxZGI5NTA0Y2Q0OWIzYTgxYzFhNDJmZTI1NmRmNV80MDUx_8e30ed5d-a210-496c-be7d-42115b51f37d">858</ix:nonNumeric>)&#160;<ix:nonNumeric contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xL2ZyYWc6MmY2MWRiOTUwNGNkNDliM2E4MWMxYTQyZmUyNTZkZjUvdGV4dHJlZ2lvbjoyZjYxZGI5NTA0Y2Q0OWIzYTgxYzFhNDJmZTI1NmRmNV80MDQ0_c98be2e5-6ac6-4b7b-a506-b14e1a0c2174">550-7500</ix:nonNumeric></span></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Securities registered pursuant to Section&#160;12(b) of the Act:</span></div><div style="margin-top:2pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.467%"><tr><td style="width:1.0%"></td><td style="width:36.419%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.979%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.302%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Title of Each Class</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Trading Symbol</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Name of Each Exchange on Which Registered</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xL2ZyYWc6MmY2MWRiOTUwNGNkNDliM2E4MWMxYTQyZmUyNTZkZjUvdGFibGU6MzRhNTAyODExMmIxNDI4Njg0NGY5OTc4ZmM1MjA0Y2EvdGFibGVyYW5nZTozNGE1MDI4MTEyYjE0Mjg2ODQ0Zjk5NzhmYzUyMDRjYV8xLTAtMS0xLTQxMjk0_fdd2bdd6-ed32-4118-9037-bfc2f847d281">Common Stock, par value $.001 per share</ix:nonNumeric></span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xL2ZyYWc6MmY2MWRiOTUwNGNkNDliM2E4MWMxYTQyZmUyNTZkZjUvdGFibGU6MzRhNTAyODExMmIxNDI4Njg0NGY5OTc4ZmM1MjA0Y2EvdGFibGVyYW5nZTozNGE1MDI4MTEyYjE0Mjg2ODQ0Zjk5NzhmYzUyMDRjYV8xLTEtMS0xLTQxMjk0_81aed8d0-19b7-41a1-af8c-e4cdbc511f1d">LGND</ix:nonNumeric></span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xL2ZyYWc6MmY2MWRiOTUwNGNkNDliM2E4MWMxYTQyZmUyNTZkZjUvdGFibGU6MzRhNTAyODExMmIxNDI4Njg0NGY5OTc4ZmM1MjA0Y2EvdGFibGVyYW5nZTozNGE1MDI4MTEyYjE0Mjg2ODQ0Zjk5NzhmYzUyMDRjYV8xLTItMS0xLTQxMjk0_9a16dceb-bd85-457b-a2b3-a3664abc2f66">The Nasdaq Global Market</ix:nonNumeric></span></td></tr><tr style="height:13pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Securities registered pursuant to Section&#160;12(g) of the Act:</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">None</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231" name="dei:EntityWellKnownSeasonedIssuer" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xL2ZyYWc6MmY2MWRiOTUwNGNkNDliM2E4MWMxYTQyZmUyNTZkZjUvdGV4dHJlZ2lvbjoyZjYxZGI5NTA0Y2Q0OWIzYTgxYzFhNDJmZTI1NmRmNV80MDUy_4ad23e08-f6eb-45b0-8bf3-c4f50f526377">Yes</ix:nonNumeric>&#160;&#160;&#9746;&#160;&#160;&#160;&#160;No&#160;&#160;&#9744;&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Indicate by check mark if the registrant is not required to file reports pursuant to Section&#160;13 or Section&#160;15(d) of the Securities Exchange Act of 1934.&#160;&#160;&#160;&#160;Yes&#160;&#160;&#9744;&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231" name="dei:EntityVoluntaryFilers" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xL2ZyYWc6MmY2MWRiOTUwNGNkNDliM2E4MWMxYTQyZmUyNTZkZjUvdGV4dHJlZ2lvbjoyZjYxZGI5NTA0Y2Q0OWIzYTgxYzFhNDJmZTI1NmRmNV80MDUz_b9c80773-a2dc-49e8-aac0-f6722753021a">No</ix:nonNumeric>&#160;&#160;&#9746;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">I</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ndicate by check mark whether the registrant: (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90 days.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xL2ZyYWc6MmY2MWRiOTUwNGNkNDliM2E4MWMxYTQyZmUyNTZkZjUvdGV4dHJlZ2lvbjoyZjYxZGI5NTA0Y2Q0OWIzYTgxYzFhNDJmZTI1NmRmNV80MDQ1_8038b135-0287-49da-be3a-a401df23c453">Yes</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9746;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167; 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xL2ZyYWc6MmY2MWRiOTUwNGNkNDliM2E4MWMxYTQyZmUyNTZkZjUvdGV4dHJlZ2lvbjoyZjYxZGI5NTA0Y2Q0OWIzYTgxYzFhNDJmZTI1NmRmNV80MDQ2_682ccc4a-6ef6-47a9-992f-60a880616efc">Yes</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9746;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span></div><div style="margin-top:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definition of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221;  &#8220;smaller reporting company&#8221; and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">emerging growth company</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> in Rule 12b-2 of the Exchange Act. </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:15.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.853%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.198%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.853%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.980%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.853%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.055%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.413%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.055%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.857%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231" name="dei:EntityFilerCategory" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xL2ZyYWc6MmY2MWRiOTUwNGNkNDliM2E4MWMxYTQyZmUyNTZkZjUvdGFibGU6MzM3ZmE2YWU2NjdhNDYwMGI3MjlhNzc2NDc3NTZiYzMvdGFibGVyYW5nZTozMzdmYTZhZTY2N2E0NjAwYjcyOWE3NzY0Nzc1NmJjM18wLTAtMS0xLTQxMjk0_e1ab3bb8-c644-4a5c-ab66-0493794962c5">Large Accelerated Filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9746;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accelerated&#160;Filer </span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-accelerated&#160;Filer&#160;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Smaller&#160;reporting&#160;company</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231" name="dei:EntitySmallBusiness" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xL2ZyYWc6MmY2MWRiOTUwNGNkNDliM2E4MWMxYTQyZmUyNTZkZjUvdGFibGU6MzM3ZmE2YWU2NjdhNDYwMGI3MjlhNzc2NDc3NTZiYzMvdGFibGVyYW5nZTozMzdmYTZhZTY2N2E0NjAwYjcyOWE3NzY0Nzc1NmJjM18wLTgtMS0xLTQxMjk0_5ccf1690-cc67-41c9-86b1-c35af6eeb8d3">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xL2ZyYWc6MmY2MWRiOTUwNGNkNDliM2E4MWMxYTQyZmUyNTZkZjUvdGFibGU6MzM3ZmE2YWU2NjdhNDYwMGI3MjlhNzc2NDc3NTZiYzMvdGFibGVyYW5nZTozMzdmYTZhZTY2N2E0NjAwYjcyOWE3NzY0Nzc1NmJjM18wLTEwLTEtMS00MTI5NA_48d5da0a-37aa-49e4-bafb-4366e3494fd2">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span></div><div style="margin-top:2pt;text-indent:18pt"><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231" name="dei:IcfrAuditorAttestationFlag" format="ixt:fixed-true" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xL2ZyYWc6MmY2MWRiOTUwNGNkNDliM2E4MWMxYTQyZmUyNTZkZjUvdGV4dHJlZ2lvbjoyZjYxZGI5NTA0Y2Q0OWIzYTgxYzFhNDJmZTI1NmRmNV80MDQ3_06437992-cc61-4954-bfd8-829219f060bf">&#9746;</ix:nonNumeric></span></div><div style="text-indent:18pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Indicate by check mark whether the registrant is a shell company (as defined in Exchange Act Rule 12b-2 of the Exchange Act).&#160;&#160;&#160;&#160;Yes&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231" name="dei:EntityShellCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xL2ZyYWc6MmY2MWRiOTUwNGNkNDliM2E4MWMxYTQyZmUyNTZkZjUvdGV4dHJlZ2lvbjoyZjYxZGI5NTA0Y2Q0OWIzYTgxYzFhNDJmZTI1NmRmNV80MDU0_5add4c3a-861f-43a1-8514-e11d483c3339">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9746;</span></div><div style="margin-top:2pt;text-indent:18pt"><span><br/></span></div><div style="margin-top:2pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The aggregate market value of the Registrant&#8217;s voting and non-voting stock held by non-affiliates was approximately $<ix:nonFraction unitRef="usd" contextRef="i46357a7c22b94af48beacbd35008717a_I20210630" decimals="-8" name="dei:EntityPublicFloat" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xL2ZyYWc6MmY2MWRiOTUwNGNkNDliM2E4MWMxYTQyZmUyNTZkZjUvdGV4dHJlZ2lvbjoyZjYxZGI5NTA0Y2Q0OWIzYTgxYzFhNDJmZTI1NmRmNV8yOTA0_a1b53a64-9db5-4bac-912f-f4e9670ce0e2">1.8</ix:nonFraction> billion based on the last sales price of the Registrant&#8217;s Common Stock on the Nasdaq Global Market of the Nasdaq Stock Market LLC on June&#160;30, 2021. For purposes of this calculation, shares of Common Stock held by directors, officers and 10% stockholders known to the Registrant have been deemed to be owned by affiliates which should not be construed to indicate that any such person possesses the power, direct or indirect, to direct or cause the direction of the management or policies of the Registrant or that such person is controlled by or under common control with the Registrant.</span></div><div style="margin-top:2pt;text-indent:18pt"><span><br/></span></div><div style="margin-top:2pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As of February&#160;23, 2022, the Registrant had <ix:nonFraction unitRef="shares" contextRef="i3ed4f52b1ed24e778aa7185aa1e8bb90_I20220223" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xL2ZyYWc6MmY2MWRiOTUwNGNkNDliM2E4MWMxYTQyZmUyNTZkZjUvdGV4dHJlZ2lvbjoyZjYxZGI5NTA0Y2Q0OWIzYTgxYzFhNDJmZTI1NmRmNV8zNTE3_60bb6b06-3165-47da-8bdd-2ea850e5d721">16,852,650</ix:nonFraction> shares of Common Stock outstanding.</span></div><div style="margin-top:2pt;text-indent:18pt"><span><br/></span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">DOCUMENTS INCORPORATED BY REFERENCE</span></div><div style="margin-top:5pt;text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231" name="dei:DocumentsIncorporatedByReferenceTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xL2ZyYWc6MmY2MWRiOTUwNGNkNDliM2E4MWMxYTQyZmUyNTZkZjUvdGV4dHJlZ2lvbjoyZjYxZGI5NTA0Y2Q0OWIzYTgxYzFhNDJmZTI1NmRmNV8zODQ4MjkwNzAxMjgy_1af2f84e-af20-4736-90b1-df87c2a30770" escape="true">Portions of the Proxy Statement for the Registrant&#8217;s 2021 Annual Meeting of Stockholders to be filed with the Commission within 120 days of December&#160;31, 2021 are incorporated by reference in Part&#160;III of this Annual Report on Form&#160;10-K.&#160;With the exception of those portions that are specifically incorporated by reference in this Annual Report on Form&#160;10-K, such Proxy Statement shall not be deemed filed as part of this Report or incorporated by reference herein.</ix:nonNumeric></span></div><div style="margin-top:2pt"><span><br/></span></div><div style="margin-top:2pt;text-indent:18pt"><span><br/></span></div><div id="i0fa6f906fb2e4e30bc5e873d2bb6a82c_7"></div><div style="text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Table of Contents</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:7.111%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:84.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.766%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Part I</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;1.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0fa6f906fb2e4e30bc5e873d2bb6a82c_13">Business</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0fa6f906fb2e4e30bc5e873d2bb6a82c_13">1</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;1A.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0fa6f906fb2e4e30bc5e873d2bb6a82c_16">Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0fa6f906fb2e4e30bc5e873d2bb6a82c_16">25</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;1B.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0fa6f906fb2e4e30bc5e873d2bb6a82c_19">Unresolved Staff Comments</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0fa6f906fb2e4e30bc5e873d2bb6a82c_19">40</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;2.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0fa6f906fb2e4e30bc5e873d2bb6a82c_22">Properties</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0fa6f906fb2e4e30bc5e873d2bb6a82c_22">40</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;3.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0fa6f906fb2e4e30bc5e873d2bb6a82c_25">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0fa6f906fb2e4e30bc5e873d2bb6a82c_25">40</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;4.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0fa6f906fb2e4e30bc5e873d2bb6a82c_28">Mine Safety Disclosures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0fa6f906fb2e4e30bc5e873d2bb6a82c_28">40</a></span></div></td></tr><tr style="height:15pt"><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Part II</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;5.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0fa6f906fb2e4e30bc5e873d2bb6a82c_34">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters, and Issuer Purchases of Equity Securities</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0fa6f906fb2e4e30bc5e873d2bb6a82c_34">40</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;6.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0fa6f906fb2e4e30bc5e873d2bb6a82c_37">[Reserved]</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0fa6f906fb2e4e30bc5e873d2bb6a82c_37">42</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;7.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0fa6f906fb2e4e30bc5e873d2bb6a82c_40">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0fa6f906fb2e4e30bc5e873d2bb6a82c_40">42</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;7A.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0fa6f906fb2e4e30bc5e873d2bb6a82c_52">Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0fa6f906fb2e4e30bc5e873d2bb6a82c_52">49</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;8.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0fa6f906fb2e4e30bc5e873d2bb6a82c_55">Consolidated Financial Statements and Supplementary Data</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0fa6f906fb2e4e30bc5e873d2bb6a82c_55">50</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;9.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0fa6f906fb2e4e30bc5e873d2bb6a82c_124">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0fa6f906fb2e4e30bc5e873d2bb6a82c_124">91</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;9A.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0fa6f906fb2e4e30bc5e873d2bb6a82c_127">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0fa6f906fb2e4e30bc5e873d2bb6a82c_127">91</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 9B.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0fa6f906fb2e4e30bc5e873d2bb6a82c_130">Other Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0fa6f906fb2e4e30bc5e873d2bb6a82c_127">91</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 9C.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0fa6f906fb2e4e30bc5e873d2bb6a82c_748">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0fa6f906fb2e4e30bc5e873d2bb6a82c_127">91</a></span></div></td></tr><tr style="height:15pt"><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Part III</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;10.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0fa6f906fb2e4e30bc5e873d2bb6a82c_136">Directors, Executive Officers and Corporate Governance</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0fa6f906fb2e4e30bc5e873d2bb6a82c_136">95</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;11.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0fa6f906fb2e4e30bc5e873d2bb6a82c_139">Executive Compensation</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0fa6f906fb2e4e30bc5e873d2bb6a82c_139">95</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;12.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0fa6f906fb2e4e30bc5e873d2bb6a82c_142">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0fa6f906fb2e4e30bc5e873d2bb6a82c_142">95</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;13.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0fa6f906fb2e4e30bc5e873d2bb6a82c_145">Certain Relationships and Related Transactions, and Director Independence</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0fa6f906fb2e4e30bc5e873d2bb6a82c_145">95</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;14.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0fa6f906fb2e4e30bc5e873d2bb6a82c_148">Principal Accountant Fees and Services</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0fa6f906fb2e4e30bc5e873d2bb6a82c_148">95</a></span></div></td></tr><tr style="height:15pt"><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Part IV</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;15.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0fa6f906fb2e4e30bc5e873d2bb6a82c_154">Exhibits, Financial Statement Schedules</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0fa6f906fb2e4e30bc5e873d2bb6a82c_154">96</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 16.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0fa6f906fb2e4e30bc5e873d2bb6a82c_157">Form 10-K - Summary</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0fa6f906fb2e4e30bc5e873d2bb6a82c_154">96</a></span></div></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0fa6f906fb2e4e30bc5e873d2bb6a82c_160">Signatures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0fa6f906fb2e4e30bc5e873d2bb6a82c_160">101</a></span></div></td></tr></table></div><div style="margin-top:9pt;text-indent:24pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;text-indent:24pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.630%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:73.170%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">GLOSSARY OF TERMS AND ABBREVIATIONS</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Abbreviation</span></td><td colspan="3" style="border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Definition</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2019 Notes</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$245.0 million aggregate principal amount of convertible senior unsecured notes due 2019</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023 Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$750.0 million aggregate principal amount of convertible senior unsecured notes due 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Ab Initio</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Ab Initio Biotherapeutics, Inc.</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Abvivo</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Abvivo, LLC</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Aldeyra</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Aldeyra Therapeutics, Inc.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Amgen</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Amgen, Inc.</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ANDA</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Abbreviated New Drug Application</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">API</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Active pharmaceutical ingredient</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Aptevo</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Aptevo Therapeutics</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Arcus </span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Arcus Biosciences, Inc.</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ASC</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounting Standards Codification</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ASCO</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">American Society of Clinical Oncology</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ASCT</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Autologous Stem Cell Transplantation</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ASU</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounting Standards Update </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Aurobindo</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Aurobindo Pharma Ltd</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Aziyo</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Aziyo Med, LLC</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Baxter</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Baxter International, Inc.</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">BendaRx</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">BendaRx Corp.</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Bexson Biomedical</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Bexson Biomedical, Inc.</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">BLA</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Biologics license application</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">CStone</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">CStone Pharmaceuticals (Suzhou) Co., Ltd. </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">CASI</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">CASI Pharmaceuticals, Inc.</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">CI-AKI</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Contrast-induced acute kidney injury</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Code of Conduct</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Code of Conduct and Ethics Policy</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">CoM</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Composition of Matter</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Company</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ligand Pharmaceuticals Incorporated, including subsidiaries</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Convertible Note</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Senior Convertible Promissory Note</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">COPD</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Chronic obstructive pulmonary disease </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cormatrix</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cormatrix Cardiovascular, Inc. </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corvus</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corvus Pharmaceuticals, Inc.</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">COSO</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Committee of Sponsoring Organizations of the Treadway Commission</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">CRO</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contract Research Organization</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Crystal</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Crystal Bioscience, Inc.</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Cumulus</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Cumulus Oncology, Ltd.</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">CVR</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contingent value right</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">CyDex</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">CyDex Pharmaceuticals, Inc.</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Daiichi Sankyo</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Daiichi Sankyo Company, Ltd.</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Dianomi</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Dianomi Therapeutics, Inc.</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">DMF</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Drug Master File</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ESG</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Environmental, Social and Governance</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Eisai</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Eisai Inc.</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Eli Lilly</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Eli Lilly and Company</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ECM</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Extracellular matrix</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">EPA</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Environmental Protection Agency</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ESPP</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Employee Stock Purchase Plan, as amended and restated</span></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;text-indent:24pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.630%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:73.170%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">EU</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">European Union</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exelixis </span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exelixis, Inc.</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">FASB</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Financial Accounting Standards Board</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">FDA</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. Food and Drug Administration</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">FSGS</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Focal segmental glomerulosclerosis</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">GAAP</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Generally accepted accounting principles in the United States</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Genagon</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Genagon Therapeutics AB</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">GCSF</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Granulocyte-colony stimulating factor</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">GigaGen</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">GigaGen, Inc.</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Gilead</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Gilead Sciences, Inc.</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">GPCR</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">G-protein coupled receptor</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">GRA</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Glucagon receptor antagonist </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">HanAll</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">HanAll Biopharma Co., Ltd.</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Harbour</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Harbour BioMed Shanghai Co., Ltd.</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">HBV</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Hepatitis B Virus</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Hikma</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Hikma Pharmaceuticals PLC</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Hovione</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Hovione FarmCiencia, S.A.</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Icagen</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Icagen, Inc.</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">IPR&amp;D</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">In-Process Research and Development</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">IRS</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Internal Revenue Service</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">IV</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Intravenous</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Immunovant</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Immunovant Sciences GmbH</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">IND</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Investigational New Drug</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Jazz</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Jazz Pharmaceuticals, Inc.</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ligand</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ligand Pharmaceuticals Incorporated, including subsidiaries</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">LTP</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Liver targeting prodrug</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Lundbeck</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Lundbeck A/S</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Marinus </span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Marinus Pharmaceuticals, Inc.</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Melinta</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Melinta Therapeutics, Inc.</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Merck</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Merck &amp; Co., Inc.</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Metabasis</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Metabasis Therapeutics, Inc.</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Millennium</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Millennium Pharmaceuticals, Inc.</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NASH</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-alcoholic steatohepatitis</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NDA</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">New Drug Application</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NOLs</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net Operating Losses</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Novan</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Novan, Inc.</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Novartis</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Novartis AG</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Nucorion </span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Nucorion Pharmaceuticals, Inc.</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">OMT</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Open Monoclonal Technology, Inc.</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ono</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ono Pharmaceutical Co., Ltd.</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Opthea</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Opthea Limited</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Orange Book</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Publication identifying drug products approved by the FDA based on safety and effectiveness</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Original Interest Purchase Agreement</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Interest Purchase Agreement, dated May 3, 2016, between the Company and CorMatrix Cardiovascular, Inc.</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Palvella</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Palvella Therapeutics, Inc.</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Par</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Par Pharmaceutical, Inc.</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pfenex</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pfenex Inc.</span></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;text-indent:24pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.630%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:73.170%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pfizer</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pfizer, Inc.</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">PFS</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Progression-free Survival</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pharmacopeia</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pharmacopeia, Inc.</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Phoenix Tissue</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Phoenix Tissue Repair</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">PPD</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Post-Partum Depression</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">PSU</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Performance stock unit</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">R&amp;D</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Research and Development</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Roivant</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Roivant Sciences GMBH</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">RSU </span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restricted stock unit</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">SAGE</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Sage Therapeutics, Inc.</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">SARM</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selective Androgen Receptor Modulator</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">SEC</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Securities and Exchange Commission</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Sedor</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Sedor Pharmaceuticals, Inc., or RODES, Inc.</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Seelos</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Seelos Therapeutics, Inc.</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selexis</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selexis, SA</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Sermonix</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Sermonix Pharmaceuticals, LLC</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">SII</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Serum Institute of India</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">SQ Innovation</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">SQ Innovation, Inc.</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Sunshine Lake Pharma</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Sunshine Lake Pharma Co., Ltd.</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Takeda</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Takeda Pharmaceuticals Company Limited</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Talem </span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Talem Therapeutics LLC</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Taurus</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Taurus Biosciences LLC</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tax Act</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">The Tax Cuts and Jobs Act</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Teva</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Teva Pharmaceuticals USA, Inc., Teva Pharmaceutical Industries Ltd. and Actavis, LLC </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Travere</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Travere Inc.</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">TR-Beta</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Thyroid hormone receptor beta</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Valanbio</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Valanbio Therapeutics, Inc.</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">VDP</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vernalis Design Platform</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">VentiRx</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">VentiRx Pharmaceuticals, Inc.</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vernalis</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vernalis plc</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Verona</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Verona Pharma plc</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Viking</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Viking Therapeutics</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">WuXi</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">WuXi Biologics Ireland Limited</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">WuXi Agreement</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">The Platform License Agreement, dated March 23, 2015, by and between Ligand and WuXi, as amended</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Xi'an Xintong</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Xi'an Xintong Medicine Research</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">X-ALD</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">X-linked adrenoleukodystrophy</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">xCella Biosciences</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">xCella Biosciences, Inc.</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Zydus Cadila</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Zydus Cadila Healthcare, Ltd</span></td></tr></table></div><div style="margin-top:9pt"><span><br/></span></div><div id="i0fa6f906fb2e4e30bc5e873d2bb6a82c_10"></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I</span></div><div id="i0fa6f906fb2e4e30bc5e873d2bb6a82c_13"></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Cautionary Note Regarding Forward-Looking Statements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">: </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">You should read the following report together with the more detailed information regarding our company, our common stock and our financial statements and notes to those statements appearing elsewhere in this document. </span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">This report contains forward-looking statements that involve a number of risks and uncertainties. Although our forward-looking statements reflect the good faith judgment of our management, these statements can only be based on facts and factors currently known by us. Consequently, these forward-looking statements are inherently subject to risks and uncertainties, and actual results and outcomes may differ materially from results and outcomes discussed in the forward-looking statements.</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Forward-looking statements can be identified by the use of forward-looking words such as &#8220;believes,&#8221; &#8220;expects,&#8221; &#8220;may,&#8221; &#8220;will,&#8221; &#8220;plan,&#8221; &#8220;intends,&#8221; &#8220;estimates,&#8221; &#8220;would,&#8221; &#8220;continue,&#8221; &#8220;seeks,&#8221; &#8220;pro forma,&#8221; or &#8220;anticipates,&#8221; or other similar words (including their use in the negative), or by discussions of future matters such as those related to our future results of operations and financial position, royalties and milestones under license agreements, Captisol material sales, product development, and product regulatory filings and approvals, and the timing thereof, as well as other statements that are not historical. You should be aware that the occurrence of any of the events discussed under the caption &#8220;Risk Factors&#8221; could negatively affect our results of operations and financial condition and the trading price of our stock.</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The cautionary statements made in this report are intended to be applicable to all related forward-looking statements wherever they may appear in this report. We urge you not to place undue reliance on these forward-looking statements, which speak only as of the date of this report. Except as required by law, we assume no obligation to update our forward-looking statements, even if new information becomes available in the future. This caution is made under the safe harbor provisions of Section&#160;21E of the Securities Exchange Act of 1934, as amended.</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">References to &#8220;Ligand Pharmaceuticals Incorporated,&#8221; &#8220;Ligand,&#8221; the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;our&#8221; and &#8220;us&#8221; include Ligand Pharmaceuticals Incorporated and our wholly-owned subsidiaries.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Partner Information</span></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Information regarding partnered products and programs comes from information publicly released by our partners and licensees.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Trademarks</span></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our trademarks, trade names and service marks referenced herein include Ligand&#174;, 3 Species, 1 License&#174;, Absolutely Omniab&#8482;, Advasep&#174;, Animal Intelligence&#8482;, BEPro&#8482;, Biological Intelligence&#8482;, Bonsity&#174;, Captisol&#174;, CyDex&#174;, Icagen&#174;, LTP&#174;, LTP Technology&#8482;, Naturally Optimized Human Antibodies&#174;, OmniAb&#174;, OmniChicken&#174;, OmniClic&#174;, OmniDab&#8482;, OmniDeep&#174;, OmniFlic&#174;, OmniMouse&#174;, OmniRat&#174;, OmniTaur&#8482;, Pelican Expression Technology&#8482;, PeliCRM&#8482;, Pfenex Expression Technology&#8482;, Picobodies&#8482;, Three Species, One License&#174;, xCella Biosciences&#174;, XPloration&#174; and XRPro&#174;, which are protected under applicable intellectual property laws and are our property. All other trademarks, trade names and service marks including Kyprolis&#174;, Evomela&#174;, Veklury&#174;, Livogiva&#174;, Zulresso&#174;, Rylaze&#8482;, VAXNEUVANCE&#8482;, Pneumosil&#174;, Minnebro&#174;, Baxdela&#174;, Carnexiv&#8482;, Conbriza&#174;, Nexterone&#174;, Noxafil&#174; and Duavee&#174;, are the property of their respective owners. Solely for convenience, trademarks, trade names and service marks referred to in this report may appear without the &#174;, &#8482; or SM symbols, but such references are not intended to indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights or the right of the applicable licensor to such trademarks, trade names and service marks. Use or display by us of other parties&#8217; trademarks, trade dress or products is not intended to and does not imply a relationship with, or endorsement or sponsorship of, us by the trademark or trade dress owners.</span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:9.750%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:88.050%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Item&#160;1.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Business</span></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a biopharmaceutical company focused on developing or acquiring technologies that help pharmaceutical companies discover and develop medicines. We employ research technologies such as antibody discovery technologies, ion channel discovery technology, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Pseudomonas fluorescens</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> protein expression technology, formulation science and liver targeted pro-drug technologies to assist companies in their work toward securing prescription drug and biologic approvals. We currently have partnerships and license agreements with over 140 pharmaceutical and biotechnology companies. Over 400 programs are in various stages of commercialization, development or research and are fully funded by our collaboration partners and licensees. We have contributed novel research and technologies for approved medicines that treat cancer, osteoporosis, fungal infections and postpartum depression, among others. Our collaboration partners and licensees have programs currently in clinical development targeting cancer, seizure, diabetes, cardiovascular disease, muscle wasting, liver disease, and kidney disease, among others. We have over 1,600 issued patents worldwide.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We&#160;have assembled our large portfolio of fully-funded programs either by licensing our own proprietary drug development programs, licensing our platform technologies such as Captisol or OmniAb to partners for use with their proprietary programs, or acquiring existing partnered programs from other companies. Fully-funded programs, which we refer to as &#8220;shots on goal,&#8221; are those for which our partners pay all of the development and commercialization costs. For our internal programs, we generally plan to advance drug candidates through early-stage drug development or clinical proof-of-concept and then seek partners to continue development and potential commercialization.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business model creates value for stockholders by providing a diversified portfolio of biotech and pharmaceutical product revenue streams that are supported by an efficient and low corporate cost structure. Our goal is to offer investors an opportunity to participate in the promise of the biotech industry in a profitable, diversified and lower-risk business, in contrast to a typical biotech company. Our business model is based on doing what we do best: drug discovery, early-stage drug development, product reformulation and partnering. We partner with other pharmaceutical companies to leverage what they do best (late-stage development, regulatory management and commercialization) to ultimately generate our revenue. We believe that focusing on discovery and early-stage drug development while benefiting from our partners&#8217; development and commercialization expertise will reduce our internal expenses and allow us to have a larger number of drug candidates progress to later stages of drug development.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our revenue consists of three primary elements: royalties from commercialized products, sales of Captisol material, and contract revenue from license, milestone and other service payments. In addition to discovering and developing our own proprietary drugs, we selectively pursue acquisitions to bring in new assets, pipelines, and technologies to aid in generating additional potential new revenue streams.</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Impact of COVID-19 Pandemic</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Please see impact of COVID-19 pandemic described in Item 8. Consolidated Financial Statements -Note 1, &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Basis of Presentation and Summary of Significant Accounting Policies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;. For additional information on the various risks posed by COVID-19 pandemic, please read </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Item 1A. Risk Factors</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> included in this report.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span><br/></span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Technologies</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A variety of technology platforms that enable elements of drug discovery or development form the basis of our portfolio of fully-funded shots on goal. Platform technologies or individual drugs discovered by Ligand are related to a broad estate of intellectual property that includes over 1,600 patents issued worldwide.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">OmniAb Technologies</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The OmniAb platform creates and screens diverse antibody pools and is designed to quickly identify optimal antibodies for our partners&#8217; drug development efforts. We harness the power of Biological Intelligence, which we built into our proprietary transgenic animals and paired with our high-throughput screening technologies, to enable the discovery of high-quality, fully-human antibody therapeutic candidates. We believe these antibodies are high quality because they are naturally optimized in our proprietary host systems for affinity, specificity, developability and functional performance. Our partners have access to these antibody therapeutic candidates that are based on unmatched biological diversity and optimized through integration across a full range of technologies, including antigen design, transgenic animals, deep screening and characterization. We provide our partners both integrated end-to-end capabilities and highly customizable offerings, which address critical industry challenges and provide optimized antibody discovery solutions.  </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021, OmniAb had 57 partners and over 250 active discovery programs, including 25 OmniAb-derived antibodies in clinical development and two approved products, including zimberelimab, which was approved in China for the treatment of recurrent or refractory classical Hodgkin&#8217;s lymphoma, and sugemalimab, which was approved in China for the first-line treatment of metastatic (stage IV) nonsmall cell lung cancer in combination with chemotherapy.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Pelican Expression Technology&#8482; Platform</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Pelican Expression Technology platform is a robust, validated, cost-effective and scalable platform for recombinant protein production, and is especially well-suited for complex, large-scale protein production. Global manufacturers have demonstrated consistent success with the platform and the technology is currently out-licensed for multiple commercial and development-stage programs. The versatility of the platform has been demonstrated in the production of enzymes, peptides, antibody derivatives and engineered non-natural proteins. Partners seek the platform as it contributes significant value to biopharmaceutical development programs by reducing timelines and costs associated with research and development through commercial manufacturing of therapeutics and vaccines. Given pharmaceutical industry trends toward large molecules with increased structural complexities, the Pelican Expression Technology platform is well positioned to meet these growing needs as the most comprehensive and broadly available, commercially validated protein production platform in the industry.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We acquired the Pelican Expression Technology through our acquisition of Pfenex in October 2020.  As of December 31, 2021, we have agreements with more than 20 partners using this technology in more than 30 active programs. Several of our partners have commercial products and late stage clinical product candidates utilizing Pelican Expression Technology.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Captisol Technology</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Captisol is a patent-protected, chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. Captisol was invented and initially developed by scientists in the laboratories of Dr. Valentino Stella, University Distinguished Professor at the University of Kansas&#8217; Higuchi Biosciences Center for specific use in drug development and formulation. This unique technology has enabled several FDA-approved products, including Gilead&#8217;s Veklury</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Amgen&#8217;s Kyprolis</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Baxter International&#8217;s Nexterone</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Acrotech Biopharma L.L.C.&#8217;s and CASI Pharmaceuticals&#8217; Evomela</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Melinta Therapeutics&#8217; Baxdela&#174; and Sage Therapeutics&#8217; Zulresso&#174; There are many Captisol-enabled products currently in various stages of development. We maintain a broad global patent portfolio for Captisol with approximately 440 issued patents worldwide relating to the technology (including 45 in the U.S.) and with the latest expiration date in 2035. Other patent applications covering methods of making Captisol, if issued, extend to 2041.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to solid Captisol powder, we offer our partners access to cGMP manufactured aqueous Captisol concentrate. This product offering was established in 2017 to reduce cycle time and increase Captisol production capacity for large volume drug products. We maintain both Type IV and Type V DMFs with the FDA. These DMFs contain manufacturing and safety information relating to Captisol that our licensees can reference when developing Captisol-enabled drugs. We also have active DMFs in Japan, China and Canada. As of December 31, 2021, Captisol-enabled drugs were being marketed in more than 70 countries, and over 50 partners had Captisol-enabled drugs in development.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">HepDirect, LTP, and BEPro Technology Platform</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The HepDirect and LTP platforms are our proprietary liver-targeting prodrug technologies that can deliver many different chemical classes of drugs to the liver by using a chemical modification that renders an API biologically inactive until cleaved by a liver-specific enzyme. These technologies may improve the efficacy and/or safety of certain drugs and can be applied to marketed or new drug products to treat liver diseases or diseases caused by hemostasis imbalance of circulating molecules controlled by the liver. As of December 31, 2021, we had active HepDirect/LTP programs with three partners using these technologies across five programs.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The BEPro technology platform is a next generation prodrug technology distinct from HepDirect and LTP prodrug technologies, expanding use to non-liver related diseases. BEPro is specifically applicable to nucleotides and nucleotide analogs for the development of compounds with improved product profiles. Ligand has demonstrated improvements in cell penetration and oral, intravenous and inhaled pharmacokinetics with BEPro-enabled nucleotide analogs. As of December 31, 2021, we have one partner using this technology.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">SUREtechnology Platform (owned by Selexis)</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We acquired economic rights to various SURE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">technology</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Platform programs from Selexis. The SURE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">technology</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Platform, developed and owned by Selexis, is a novel technology that improves the way that cells are utilized in the development and manufacturing of recombinant proteins and drugs. As of December 31, 2021, we are entitled to certain economic rights to SUREtechnology Platform license agreements with 11 partners developing or having commercialized 17 programs.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:174%">2021 and Recent Major Business Highlights</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The Separation and Distribution of OmniAb Business</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2021, we announced plans to explore multiple paths for OmniAb to become a stand-alone public company, with the leading option under consideration at that time being an IPO and eventual distribution of OmniAb shares to Ligand shareholders. We now expect to pursue separation of OmniAb through a direct spin-off of 100% of OmniAb equity to shareholders with Ligand capitalizing the OmniAb business directly with $70 million. OmniAb expects to file a Form 10 with the Securities and Exchange Commission and complete its separation in the first half of 2022. The distribution is expected to qualify as a tax-free transaction for U.S. federal income tax purposes to both Ligand and its shareholders. The separation remains subject to final approval by Ligand&#8217;s Board of Directors, and Ligand will continue to evaluate other options to optimize value and ensure flexibility to invest in growth. There can be no assurance that this process will result in Ligand pursuing a particular transaction or consummating any such transaction, or that the anticipated benefits of a separation will materialize should the separation be completed.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">OmniAb Technology Platform and Partner Updates</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CStone Pharmaceuticals received approval from China&#8217;s NMPA for Celjemy&#174; (sugemalimab), an OmniAb-derived anti-PD-L1 monoclonal antibody for the first-line treatment of advanced non-small cell lung cancer (NSCLC) in combination with chemotherapy. Sugemalimab is the second OmniAb-derived antibody to receive regulatory approval. CStone announced complete enrollment in two Phase 3 registrational clinical trials investigating sugemalimab in combination with chemotherapy for the first-line treatment of metastatic gastric adenocarcinoma/gastro-esophageal junction adenocarcinoma or esophageal squamous cell carcinoma. CStone and its partner EQRx announced the publication of positive results from  two Phase 3 trials with sugemalimab in Stage III and Stage IV NSCLC in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The Lancet Oncology</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. CStone also announced that its Phase 2 GEMSTONE-201 trial met the primary endpoint of objective response rate in patients with relapsed/refractory (R/R) extranodal natural killer/T-cell lymphoma. </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Janssen submitted a BLA to the U.S. FDA in December 2021 seeking approval for teclistamab in R/R multiple myeloma. Teclistamab is an OmniAb-derived bispecific antibody targeting BCMA and CD3. Janssen also presented new data at the American Society of Hematology 2021 conference (ASH) from the MajesTEC-1 study, which showed continued deep and durable response in heavily pretreated patients with multiple myeloma. Janssen previously announced that teclistamab had received U.S. FDA Breakthrough Designation for treatment of R/R multiple myeloma.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Immunovant announced alignment with the FDA on the design of a Phase 3 trial for batoclimab in patients with myasthenia gravis. Immunovant plans to start the Phase 3 study in the first half of 2022, and also expects to initiate pivotal trials in two additional indications during 2022.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ligand expanded an existing collaboration and license agreement with GlaxoSmithKline (GSK) to leverage Ligand&#8217;s Icagen Ion Channel Technology to target neurological diseases. Ligand received an upfront payment of $10 million and is eligible for milestones of up to $247.5 million, and tiered royalties on net sales of any drug from the collaboration commercialized by GSK.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Pelican Platform Updates</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Merck announced European Commission approval of VAXNEUVANCE&#8482; for adults 18 years of age and older. VAXNEUVANCE is a 15-valent pneumococcal vaccine utilizing CRM197 vaccine carrier protein produced using the Pelican Expression Technology platform. Additionally, Merck announced the U.S. FDA accepted for priority review the supplemental Biologics License Application (sBLA) for VAXNEUVANCE in infants and children.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Jazz Pharmaceuticals announced submission of an sBLA to the FDA seeking approval for a Monday/Wednesday/Friday (M/W/F) intramuscular dosing schedule for Rylaze&#8482;, as a component of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LBL) in adult and pediatric patients one month and older who have developed hypersensitivity to E. coli-derived asparaginase. Jazz presented initial results at ASH from a Phase 2/3 study of Ryalze in adult and pediatric ALL and LBL patients showing Rylaze maintained clinically meaningful level of asparaginase activity throughout the entire duration of treatment on a M/W/F dosing schedule.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Arcellx recently announced the pricing of a $123.8 million initial public offering with proceeds planned to be used to advance their pipeline. Arcellx uses the Pelican Expression Technology platform for the expression of certain proprietary sparX proteins which are used in Arcellx's ARC-SparX platform.</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Captisol Technology Updates</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amgen announced U.S. FDA approval of a new Kyprolis&#174; combination regimen with DARZALEX FASPRO and dexamethasone for patients with multiple myeloma at first or subsequent relapse. Additionally, Amgen presented results from a </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Phase 1b study at ASH showing Captisol-enabled Kyprolis in combination with vincristine, dexamethasone, PEG-asparaginase, daunorubicin (VXLD) induction therapy showed positive efficacy results in highly advanced relapsed/refractory pediatric ALL. </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gilead announced the U.S. FDA granted accelerated approval of a supplemental NDA for Veklury in non-hospitalized patients at high risk of disease progression.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Business Updates</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Travere Therapeutics provided an update on their plans for regulatory submission of sparsentan. Travere plans to submit a NDA to the FDA seeking accelerated approval of sparsentan for IgA nephropathy in the first quarter of 2022 and for FSGS in mid-2022. Travere, in collaboration with its partner Vifor Pharma, plans to submit a combined IgA nephropathy and FSGS Marketing Authorization Application in mid-2022 seeking conditional marketing authorization in Europe.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Verona Pharma announced completion of enrollment in the Phase 3 ENHANCE-1 and ENHANCE-2 randomized trials evaluating ensifentrine for the maintenance treatment of COPD with top-line data expected by the end of 2022 and in the third quarter of 2022, respectively. Verona also reported ensifentrine met all safety objectives in a thorough QT study designed to evaluate effects, if any, of ensifentrine on cardiac conduction in healthy individuals. The results from these studies will support the planned NDA submission of ensifentrine for the maintenance treatment of COPD.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sermonix Pharmaceuticals closed a $40 million financing with proceeds planned to advance lasofoxifene through late-stage clinical development as an oral SERM to treat women with ESR1 breast cancer mutations. Topline data are expected in the first half of 2022 for the Phase 2 ELAINE 1 trial assessing oral lasofoxifene versus intramuscular fulvestrant and the Phase 2 ELAINE 2 trial of oral lasofoxifene in combination with Eli Lilly and Company's CDK4 and 6 inhibitor Verzenio&#174; (abemaciclib) for the treatment of ER+/HER2- breast cancer in patients with an ESR1 mutation.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Corporate and Governance Highlights</span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are committed to policies and practices focused on environmental sustainability, positively impacting our social community and maintaining and cultivating good corporate governance. By focusing on such ESG policies and practices, we believe we can affect a meaningful and positive change in our community and maintain our open, collaborative corporate culture. We will continue our proactive shareholder and employee engagement in 2022.  See www.ligand.com for information about our ESG policies and practices.</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Partners and Licensees</span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently have partnerships and license agreements with over 140 pharmaceutical and biotechnology companies. Below is a list of our disclosed partners.</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:19.983%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.983%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.983%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.712%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Big Pharma</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Ticker</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Biotech</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Ticker</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Biotech, continued</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Ticker</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Abbott</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ABT</span></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ABBA</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private</span></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Melinta</span></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AstraZeneca</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AZN</span></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Abvivo</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private</span></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Menarini</span></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Baxter</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BAX</span></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adept</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private</span></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nanjing King-Friend</span></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">603707</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Boehringer Ingelheim</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private</span></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Aldeyra</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ALDX</span></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Neuritek</span></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Eisai</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4523</span></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ALX Oncology</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ALXO</span></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Novan</span></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NOVN</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">GSK</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">GSK</span></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amgen</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AMGN</span></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nucorion</span></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Janssen</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">JNJ</span></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Anebulo</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private</span></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ohara</span></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jazz</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">JAZZ</span></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Aptevo</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">APVO</span></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Oncternal</span></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ONCT</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Merck</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MRK</span></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Arcellx</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ACLX</span></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">OnKure</span></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Merck KGaA</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MRK.DE</span></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Arcus</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RCUS</span></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Opthea</span></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">OPT</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Novartis</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NVS</span></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asahi Kasei</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3407</span></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outlook</span></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">OTLK</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ono</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4528</span></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ascella</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private</span></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Palvella</span></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pfizer</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PFE</span></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BendaRx</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private</span></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pandion</span></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MRK</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Roche</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RHHBY</span></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bexson Biomedical</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private</span></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phoenix Tissue</span></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sanofi</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SNY</span></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Biocity</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private</span></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pierre-Fabre</span></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Takeda</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4502</span></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cantex</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private</span></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Praxis</span></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PRAX</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corvus</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CRVS</span></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Precision Biologics</span></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CStone</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2616.HK</span></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revision</span></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private</span></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-indent:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:19.983%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.983%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.983%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.712%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Specialty Pharma</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Ticker</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CSL</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private</span></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RubrYc</span></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acrotech (Aurobindo)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AUROPHARMA</span></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CR Double-Crane</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private</span></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sage</span></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SAGE</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Genovac</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private</span></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cumulus</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private</span></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Salubris Bio</span></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Aytu Bioscience</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AYTU</span></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Curon</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private</span></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Seagen</span></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SGEN</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Aziyo</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AZYO</span></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Daxor</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DXR</span></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Seelos</span></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SEEL</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beloteca</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private</span></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denovo</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private</span></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sepsia</span></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BF Bioscience</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private</span></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Electra</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private</span></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Servier</span></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CASI</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CASI</span></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Elevation</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private</span></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Serum Inst. of India</span></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CorMatrix</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private</span></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exelixis</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EXEL</span></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Softkemo</span></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EQRx</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EQRX</span></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foghorn</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">FHTX</span></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sunshine Lake</span></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ferring</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private</span></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Genmab</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">GMAB</span></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Talem</span></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gloria</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2437</span></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Genagon</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private</span></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tizona</span></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodness Growth</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">VRNOF</span></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Genentech (Roche)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RHHBY</span></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Travere</span></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TVTX</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lundbeck</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LUN</span></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Genovac</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private</span></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tremeau</span></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sedor</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private</span></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">GigaGen</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private</span></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unity</span></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">UBX</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sermonix</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private</span></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gilead Sciences</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">GILD</span></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valanbio</span></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shionogi</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SGIOY</span></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gordian</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private</span></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vaxxas</span></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SQ Innovation</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private</span></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Halo</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private</span></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vega</span></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">HanAll</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9420</span></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">VenBio</span></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Generics</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Ticker</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Harbour</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2142</span></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">VentiRx</span></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Alvogen</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IBC Generium</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Verona</span></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">VRNA</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adalvo</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ichnos</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Viking</span></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">VKTX</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Apotex</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">iMetabolic</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Xi'an Xintong</span></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BioCad</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Immunovant</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IMVT</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">WuXi</span></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2269</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gufic</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">GUFICBIO</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Innolake Biopharm</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Zhilkang Hongyi</span></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hetero</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interventional Analgesix</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hikma</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">HIK</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">J-Pharma</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indofarma</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">INAF</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jupiter</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jubilant</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kangchen</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mylan</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">VTRS</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kira</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Par</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marinus</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MRNS</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Zydus Cadila</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CADILAHC</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MEI</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MEIP</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commercial and Clinical Stage Partnered Portfolio</span></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a large portfolio of current and future potential revenue-generating programs, including over 400 fully-funded by our partners. Each white dot on our partnered pipeline chart below represents a fully-funded partnered program, with each section of the chart representing a major Ligand technology or platform.</span></div><div style="text-indent:27pt"><span><br/></span></div><div><img src="lgnd-20211231_g2.jpg" alt="lgnd-20211231_g2.jpg" style="height:405px;margin-bottom:5pt;vertical-align:text-bottom;width:684px"/></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.444%"><tr><td style="width:1.0%"></td><td style="width:36.051%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.324%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.325%"></td><td style="width:0.1%"></td></tr><tr><td colspan="9" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Approved</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Partner Name</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Program</span></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Therapeutic Area</span></td></tr><tr style="height:8pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acrotech/CASI</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Evomela</span></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancer</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Alvogen/Adalvo</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Teriparatide</span></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Women's Health</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Alvogen/Hikma/Nanjing King-Friend</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Voriconazole</span></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Infectious Disease</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amgen/Beigene/Ono</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kyprolis</span></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancer</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Aytu</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tuzistra</span></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Infectious Disease</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Aziyo</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ECM portfolio</span></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medical device/Cardiology</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Baxter</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nexterone</span></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardiovascular</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BendaRx</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bendamustine</span></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancer</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BF Bio/Gufic/Hetero/Indofarma/Jubilant/Zydus</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Generic Remdesivir</span></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Infectious Disease</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Biocad</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Teberif</span></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inflammatory/Metabolic</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">C-Stone/Pfizer</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sugemalimab</span></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancer</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exelixis/Daiichi-Sankyo</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Minnebro</span></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardiovascular</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gilead</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Veklury</span></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Infectious Disease</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gloria/EQRx</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Zimberelimab</span></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancer</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IBC Generium</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">GNR-008</span></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Severe and Rare</span></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-indent:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.444%"><tr><td style="width:1.0%"></td><td style="width:36.051%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.324%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.325%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jazz</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rylaze</span></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancer</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lundbeck</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carnexiv</span></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Central Nervous System</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Melinta</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Baxdela</span></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Infectious Disease</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Menarini</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Frovatriptan</span></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Central Nervous System</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Merck</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noxafil-IV</span></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Infectious Disease</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Merck</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vaxneuvance</span></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Infectious Disease</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Par</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Posaconazole</span></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Infectious Disease</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pfizer</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Viviant/Conbriza</span></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inflammatory/Metabolic</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pfizer</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Duavee</span></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inflammatory/Metabolic</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pfizer</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vfend-IV</span></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Infectious Disease</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SAGE</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Zulresso</span></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Central Nervous System</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sedor</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sesquient</span></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Central Nervous System</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Serum Institute of India</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pneumosil</span></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Infectious Disease</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Zydus Cadila</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vivitra</span></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancer</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Zydus Cadila</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bryxta/ZyBev</span></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancer</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Zydus Cadila</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maropitant</span></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Central Nervous System</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Zydus Cadila</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exemptia</span></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inflammatory/Metabolic</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Zydus Cadila</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vortuxi</span></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inflammatory/Metabolic</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="9" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Phase 3/Pivotal or Regulatory Submission Stage</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Partner Name</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Program</span></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Therapeutic Area</span></td></tr><tr style="height:5pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Aldeyra</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reproxalap</span></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other/Undisclosed</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Arcus</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Zimberelimab</span></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancer</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Aytu Bioscience</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CCP-07 and CCP-08</span></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Infectious disease</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Eisai</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">FYCOMPA</span></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Central Nervous System</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Harbour</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Batoclimab</span></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancer</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Janssen</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Teclistamab</span></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancer</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jazz</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rylaze</span></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancer</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marinus</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ganaxalone IV</span></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Central Nervous System</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Novan</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SB206</span></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Infectious Disease</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Novartis</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mekinist (CE-Trametinib)</span></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancer</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Opthea</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">OPT-302</span></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ophthalmology</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outlook Therapeutics</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ONS-5010</span></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other/Undisclosed</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Palvella</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PTX-022</span></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other/Undisclosed</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sage</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Zulresso</span></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Infectious disease</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Serum Institute</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CRM197</span></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Infectious Disease</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SQ Innovation</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CE-Furosemide</span></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardiovascular disease</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sunshine Lake</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vilazodone</span></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Central Nervous System</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Takeda</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pevonedistat</span></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancer</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Travere</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sparsentan</span></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Severe and Rare</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Verona</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ensifentrine (RPL554)</span></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Respiratory Disease</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Various</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Teriparatide</span></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Women's Health</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Xi'an Xintong</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pradefovir</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Infectious Disease</span></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-indent:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.444%"><tr><td style="width:1.0%"></td><td style="width:36.051%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.324%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.325%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="9" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Phase 2</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Partner Name</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Program</span></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Therapeutic Area</span></td></tr><tr style="height:6pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cantex</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CX-01</span></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancer</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corvus</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ciforadenant</span></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancer</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DeNovo</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lisfensine</span></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Neurology</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Elevation Oncology</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Seribantumab</span></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancer</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Genmab</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gen1046</span></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancer</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Immunovant</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Batoclimab</span></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inflammatory/Metabolic</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Janssen</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Teclistimab</span></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancer</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Merck</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Berzosertib</span></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancer</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Merck</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">V116</span></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Infectious Disease</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Novartis</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ECF843</span></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inflammatory/Metabolic</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Oncternal</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cirmtuzumab</span></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancer</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Palvella</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PTX-022</span></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other/Undisclosed</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phoenix Tissue</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PTR-01</span></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Genetic Disease</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Precision Biologics</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NPC-1C</span></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancer</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Seelos</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Aplindore</span></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Central Nervous System</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sermonix</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lasofoxifene</span></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancer</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">VentiRx</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Motolimod</span></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancer</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Various</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">JPH-203</span></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancer</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Viking</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">VK5211</span></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inflammatory/Metabolic</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Viking</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">VK2809</span></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inflammatory/Metabolic</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Viking</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">VK0612</span></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inflammatory/Metabolic</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="9" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Phase 1</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Partner Name</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Program</span></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Therapeutic Area</span></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amgen</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AMG-330</span></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancer</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Apotex</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Meloxicam</span></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Migraine</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Aptevo</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">APVO436</span></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancer</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Boehringer Ingelheim</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Undisclosed</span></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other/Undisclosed</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CSL</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CSL-324</span></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Immunology</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Curon</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CN1</span></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancer</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Daxor</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">I131</span></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardiovascular disease</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foghorn</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">FHD-609/BRD9</span></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancer</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Halo</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CE-Oleic acid</span></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Infectious disease</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hanall</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Batoclimab</span></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancer</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Janssen</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">JNJ-78306358</span></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancer</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Janssen</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">JNJ-67371244</span></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancer</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Janssen</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">JNJ-70218902</span></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancer</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jupiter Bioscience</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Viright</span></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancer</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MEI Pharma</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ME-344</span></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancer</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Merck</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">M6233</span></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancer</span></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-indent:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.444%"><tr><td style="width:1.0%"></td><td style="width:36.051%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.324%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.325%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Novartis</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MIK-665</span></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancer</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Novartis</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BCL-201</span></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancer</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nucorion</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NUC-1010</span></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Infectious disease</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revision Therapeutics</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rev0100</span></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ophthalmology</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sage</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SAGE-689</span></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Central Nervous System</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SalubrisBio</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SAL003</span></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Metabolic disease</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Symphogen/Servier</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SYM022/SYM023/SYM024/S095029</span></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancer</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Takeda</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TAK-925</span></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Severe and Rare</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Takeda</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TAK-243</span></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancer</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vaxxas</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nanopatch</span></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Infectious Disease</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Viking</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">VK-0214</span></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Genetic Disease</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Xi'an Xintong</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MB07133</span></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancer</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Zhilkang Hongyi</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Anti-4-1BB</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancer</span></td></tr></table></div><div style="margin-bottom:12pt;text-indent:27pt"><span><br/></span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Selected Commercial Programs</span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have multiple programs under license with other companies that have products that are already being commercialized. The following programs represent components of our current portfolio of revenue-generating assets and potential for near-term growth in royalty and other revenue. For information about the royalties owed to us for these programs, see &#8220;Royalties&#8221; later in this business section.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Kyprolis (Amgen)</span></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We supply Captisol to Amgen for use with Kyprolis (carfilzomib), and granted Amgen an exclusive product-specific license under our patent rights with respect to Captisol. Kyprolis is formulated with Ligand&#8217;s Captisol technology and is approved in the United States for the following:</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.02pt">In combination with dexamethasone, lenalidomide plus dexamethasone, daratumumab plus dexamethasone, or daratumumab and hyaluronidase-fihj and dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma who have received one to three lines of therapy.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">As a single agent for the treatment of patients with relapsed or refractory multiple myeloma who have received one or more lines of therapy.</span></div><div style="margin-bottom:3pt;padding-left:72pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:42.982%"><tr><td style="width:1.0%"></td><td style="width:11.144%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.144%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.144%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.457%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.611%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="9" rowspan="5" style="padding:0 1pt;text-indent:27pt"></td><td colspan="6" style="border-left:2pt solid #000000;border-right:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#ff6600;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Kyprolis (Amgen)</span></td></tr><tr style="height:12pt"><td colspan="3" style="border-left:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&lt; $250 million</span></td><td colspan="3" style="border-right:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5%</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;border-left:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$250 to $500 million</span></td><td colspan="3" style="background-color:#cceeff;border-right:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.0%</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$500 to $750 million</span></td><td colspan="3" style="border-right:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.5%</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-left:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&gt;$750 million</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-right:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0%</span></td></tr></table></div><div style="margin-bottom:3pt;padding-left:72pt"><span><br/></span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our agreement with Amgen may be terminated by either party in the event of material breach or bankruptcy, or unilaterally by Amgen with prior written notice, subject to certain surviving obligations. Absent early termination, the agreement will terminate upon expiration of the obligation to pay royalties. Under this agreement, we are entitled to receive revenue from clinical and commercial Captisol material sales and royalties on annual net sales of Kyprolis.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Veklury (Gilead)</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We supply Captisol to Gilead for sales of Veklury (remdesivir). Gilead received marketing approval from the FDA in October 2020. Veklury is the first and only antiviral treatment of COVID-19 that is FDA approved. The product has regulatory approvals for the treatment of moderate or severe COVID-19 in over 50 countries and is included in more than 60 ongoing clinical trials. We are supplying Captisol to Gilead under a recently signed 10-year supply agreement. We are also supplying Captisol to Gilead&#8217;s voluntary licensing generic partners who are manufacturing remdesivir for 127 low- and middle-income countries. We receive our commercial compensation for this program through the sale of Captisol.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Teriparatide Injection Product (PF708) (Alvogen/Adalvo/Kangchen)</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We acquired the Teriparatide Injection product with the acquisition of Pfenex Inc. in October 2020. Teriparatide Injection is a drug indicated for uses including the treatment of osteoporosis in certain patients at high risk for fracture. Teriparatide Injection was developed using our Pelican Expression Technology and was approved by the FDA in 2019 in accordance with the 505(b)(2) regulatory pathway, with FORTEO as the reference product. Our partner, Alvogen launched the product in June 2020 in the United States. For information regarding the CVR issued to Pfenex equityholders, see note 1, &#8220;Basis of Presentation and Summary of Significant accounting Policies&#8212;Contingent Liabilities.&#8221;</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outside the United States, PF708 received marketing authorization throughout the EU in August 2020 under the tradename Livogiva&#174;, was approved in Saudi Arabia in December 2020 under the name Bonteo and is in various stages of regulatory and marketing application processes around the globe and, upon approval, may be marketed as Teriparatide Injection or under various tradenames, such as Bonsity or Livogiva. </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our partner Alvogen has exclusively licensed the rights to commercialize and manufacture the teriparatide injection product in the United States, while their Adalvo business has the rights to commercialize in the EU, certain countries in the Middle East and North Africa (MENA), and the rest of world (ROW) territories (the latter defined as all countries outside of the EU, U.S. and MENA, excluding Mainland China, Hong Kong, Singapore, Malaysia and Thailand). Kangchen has exclusively licensed to commercialize PF708, upon receipt of applicable marketing authorizations, in Mainland China, Hong Kong, Singapore, Malaysia and Thailand and granted a non-exclusive right to conduct development activities in such countries with respect to PF708. Kangchen is responsible for all regulatory submissions, development costs and costs associated with regulatory approvals in these countries.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with our agreements with Alvogen, we are eligible to receive tiered royalties on net sales between 25% and 40% prior to an &#8220;A&#8221; therapeutic equivalence designation, which increases to a flat 50% if an &#8220;A&#8221; rating is achieved.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with our EU, MENA and ROW agreements with Adalvo, we may be eligible to receive additional upfront and milestone payments of $1.5 million and may also be eligible to receive up to 60% of gross profit derived from product sales and regional license fees, if approved, depending on geography, cost of goods sold and sublicense fees.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with our agreement with Kangchen, we may be eligible to receive additional payments of up to $22.5 million upon the achievement of certain development, regulatory, and sales-related milestones. We may be eligible to receive double-digit royalties on any net sales of PF708 in Kangchen&#8217;s territory. </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Evomela (Acrotech and CASI)</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We supply Captisol to Acrotech Biopharma for sales of Evomela in the U.S. and to CASI Pharmaceuticals for sales of Evomela in China. Evomela received market approval by the China National Medical Products Administration (NMPA). It is the only approved and commercially available melphalan product in China. Evomela is a Captisol-enabled melphalan IV formulation which is approved by the FDA for use in two indications:</span></div><div style="margin-bottom:6pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a high-dose conditioning treatment prior to ASCT in patients with multiple myeloma; and </span></div><div style="margin-bottom:6pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">for the palliative treatment of patients with multiple myeloma for whom oral therapy is not appropriate.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Evomela has been granted Orphan Designation by the FDA for use as a high-dose conditioning regimen for patients with multiple myeloma undergoing ASCT. The Evomela formulation avoids the use of propylene glycol, which has been reported to cause renal and cardiac side-effects that limit the ability to deliver higher quantities of therapeutic compounds. The use of the Captisol technology to reformulate melphalan is anticipated to allow for longer administration durations and slower infusion rates, potentially enabling clinicians to safely achieve a higher dose intensity of pre-transplant chemotherapy.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the license agreement, Acrotech Biopharma has marketing rights worldwide excluding China and CASI Pharmaceuticals has rights to market in China. We are eligible to receive over $50 million in potential milestone payments under this agreement, royalties on global net sales of the Captisol-enabled melphalan product and revenue from Captisol material sales. Acrotech and CASI&#8217;s obligation to pay royalties will expire at the end of the life of the relevant patents or when a competing product is launched, whichever is earlier, but in no event within ten years of the commercial launch. Our patents and applications relating to the Captisol component of melphalan are not expected to expire until 2033. As described herein, we have entered into a settlement agreement with Teva and Acrotech Biopharma (the holder of the NDA for Evomela) which will allow Teva to market a generic version of Evomela in the United States on June 1, 2026, or earlier under certain circumstances. Absent early termination, the agreement will terminate upon expiration of the obligation to pay royalties. The agreement may be terminated by either party for an uncured material breach or unilaterally by Acrotech and CASI by prior written notice.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Vaxneuvance (V114) </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 16, 2021, Merck announced FDA approval of Vaxneuvance, a 15-valent pneumococcal conjugate vaccine, also </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">known as V114, for the prevention of invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F and 33F in adults 18 years of age and older. VAXNEUVANCE is a 15-valent pneumococcal vaccine utilizing CRM197 vaccine carrier protein, which is produced using the patent-protected Pelican Expression Technology&#8482; platform. V114 previously received Breakthrough Therapy Designation from the FDA for the prevention of invasive pneumococcal disease in pediatric patients 6 weeks to 18 years of age and adults 18 years of age and older. Pneumococcal disease in adults is on the rise in many countries, and V114 consists of pneumococcal polysaccharides from 15 serotypes conjugated to CRM197 carrier protein, including serotypes 22F and 33F, which are commonly associated with invasive pneumococcal disease in older adults. On October 20, 2021, Merck announced that the CDC Advisory Committee on Immunization Practices (ACIP) unanimously voted in favor of updates to the pneumococcal vaccination recommendations for adults 65 years and older, and for adults ages 19 to 64 with certain underlying medical conditions or other disease risk factors. In both groups the ACIP voted to provisionally recommend vaccination with either a sequential regimen of Vaxneuvance&#8482; and Pneumovax_23&#174; or a single dose of 20-valent pneumococcal conjugate vaccine. On January 28, 2022, final recommendations were published in the CDC&#8217;s Morbidity and Mortality Weekly Report (MMWR). On December 1, 2021, Merck announced the FDA accepted for priority review a sBLA for Vaxneuvance for the prevention of invasive pneumococcal disease in children 6 weeks through 17 years of age, with a PDUFA date of April 1, 2022.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 15, 2021, Merck announced the European Commission approval of Vaxneuvance for the prevention of invasive disease and pneumonia caused by Streptococcus pneumoniae in individuals 18 years and older. The approval allows marketing of VAXNEUVANCE in all 27 EU Member States plus Iceland, Norway and Lichtenstein. We are entitled to low single digit royalties derived from net sales, depending on the territory.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Pneumosil (Serum Institute of India, SII)</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SII began commercialization of its 10-valent pneumococcal conjugate vaccine, Pneumosil, which is produced using CRM197 made in the Pelican Expression Technology platform, in the second quarter of 2020. Pneumosil is designed primarily to help fight against pneumococcal pneumonia among children, with an advantage of targeting the most prevalent serotypes of the bacterium causing serious illness in developing countries. Pneumosil achieved WHO Prequalification in December 2019, allowing the product to be procured by United Nations agencies and Gavi, the Vaccine Alliance, and subsequently achieved Indian Marketing Authorization in July 2020, and SII announced commercial launch of the product in India in December 2020. </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Rylaze(JZP-458) (Jazz Pharmaceuticals)</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2021, Jazz announced the launch of Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn), previously referred to as JZP458. Rylaze, which was approved by the FDA in June 2021, is a recombinant erwinia asparaginase used as a component of a multi-agent chemotherapeutic regimen for the treatment of ALL or LBL in adult and pediatric patients one month or older who have developed hypersensitivity to E. coli-derived asparaginase.  Additionally, Jazz is utilizing our technology for the development of PF745 (JZP341), a long-acting Erwinia asparaginase for the treatment of acute lymphoblastic leukemia and other hematological malignancies. Jazz has worldwide rights to develop and commercialize PF745.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ligand is eligible to receive up to an additional $155.5 million in milestone payments and tiered low to mid-single digit royalties based on worldwide net sales of any products resulting from this collaboration, including Rylaze.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Nexterone (Baxter)</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a license agreement with Baxter, related to Baxter's Nexterone, a Captisol-enabled formulation of amiodarone, which is marketed in the United States and Canada. We supply Captisol to Baxter for use in accordance with the terms of the license agreement under a separate supply agreement. Under the terms of the license agreement, we will continue to earn milestone payments, royalties, and revenue from Captisol material sales. We are entitled to earn royalties on sales of Nexterone through early 2033.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Zulresso (SAGE)</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a license agreement with SAGE, related to SAGE's Zulresso, a Captisol-enabled formulation of brexanolone for the treatment of postpartum depression (PPD). Under the terms of the agreement, we receive royalties and revenue from Captisol material sales.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Noxafil-IV (Merck)</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a supply agreement with Merck related to Merck&#8217;s NOXAFIL-IV, a Captisol-enabled formulation of posaconazole for IV use. NOXAFIL-IV is marketed in the United States, EU and Canada. We receive our commercial compensation for this program through the sale of Captisol. </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Duavee or Duavive (bazedoxifene/conjugated estrogens) and Viviant/Conbriza (Pfizer)</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pfizer is marketing bazedoxifene, a selective estrogen receptor modulator, under the brand names Viviant</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and Conbriza in various territories for the treatment of postmenopausal osteoporosis. Pfizer is responsible for the marketing of bazedoxifene, </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a synthetic drug specifically designed to reduce the risk of osteoporotic fractures while also protecting uterine tissue. Pfizer has combined bazedoxifene with the active ingredient in Premarin to create a combination therapy for the treatment of post-menopausal symptoms in women. Pfizer is marketing the combination treatment under the brand names Duavee and Duavive in various territories. Net royalties on annual net sales of Viviant/Conbriza and Duavee/Duavive are each payable to us through the life of the relevant patents or ten years from the first commercial sale, whichever is longer, on a country by country basis.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Aziyo Portfolio (Aziyo)</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We receive a share of revenue from the currently marketed Aziyo portfolio of commercial pericardial repair and CanGaroo&#174;&#160;Envelope ECM products. In addition, we have the potential to receive a share of revenue and potential milestones from the currently marketed CanGaroo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;ECM Envelope for cardiac implantable electronic devices.&#160;Aziyo&#8217;s products are medical devices that are designed to permit the development and regrowth of human tissue.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Exemptia, Vivitra, Zybev and Bryxta (Zydus Cadila)</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Zydus Cadila&#8217;s Exemptia (adalimumab biosimilar) is marketed in India for autoimmune diseases. Zydus Cadila uses the Selexis technology platform for Exemptia. We are entitled to earn royalties on sales by Zydus Cadila for ten years following the first commercial sale.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Zydus Cadila&#8217;s Vivitra (trastuzumab biosimilar) is marketed in India for breast cancer. Zydus Cadila uses the Selexis technology platform for Vivitra. We are entitled to earn royalties on sales by Zydus Cadila for ten years following the first commercial sale.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Zydus Cadila&#8217;s Bryxta and Zybev (bevacizumab biosimilar) is marketed in India for various indications. Zydus Cadila uses the Selexis technology platform for Bryxta and Zybev. We are entitled to earn royalties on sales by Zydus Cadila for ten years following the first commercial sale.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Minnebro (Exelixis)</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Minnebro is marketed in Japan for the treatment of hypertension. Our partner, Exelixis, entered into a collaboration agreement with Daiichi Sankyo for the development of esaxerenone, a mineralocorticoid receptor antagonist. Under the terms of the agreement with Exelixis, we are entitled to receive a royalty on future sales.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Summary of Selected Development Stage Programs</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have multiple fully-funded partnered programs that are either in or nearing the regulatory approval process, or given the area of research or value of the license terms, we consider particularly noteworthy. We are eligible to receive milestone payments and royalties on these programs. This list does not include all of our partnered programs. For information about the royalties owed to Ligand for these programs, see &#8220;Royalties&#8221; later in this business section. In the case of Captisol-related programs, we are also eligible to receive revenue for the sale of Captisol material supply.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sparsentan (Travere) </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our partner, Travere, is developing sparsentan for orphan indications of severe kidney diseases and is running an on-going global pivotal Phase 3 clinical trial (DUPLEX) for sparsentan for the treatment of FSGS. Additionally, Travere is running a global pivotal Phase 3 clinical trial (PROTECT) evaluating the long-term nephroprotective potential of sparsentan for the treatment of IgAN nephropathy, a rare, immune complex mediated chronic glomerular disease. Certain patient groups with severely compromised renal function, including those with FSGS and IgAN, exhibit extreme proteinuria resulting in progression to dialysis and a high mortality rate. Sparsentan, with its unique dual blockade of angiotensin and endothelin receptors, is expected to provide meaningful clinical benefits in mitigating proteinuria in indications where there are no approved therapies.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February of 2021, Travere announced that sparsentan achieved its pre-specified interim FSGS partial remission of proteinuria endpoint (FPRE) in the DUPLEX Phase 3 study after 36 weeks of treatment. Sparsentan demonstrated a statistically significant response on FPRE compared to the active control, irbesartan (p=0.0094). Preliminary results from the interim analysis suggest that sparsentan has been generally well-tolerated and has shown a comparable safety profile to irbesartan. Travere plans to submit an NDA seeking accelerated approval of sparsentan for FSGS in the United States in mid-2022 after obtaining additional estimated glomerular filtration rate (eGFR) data from the DUPLEX Study.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August of 2021, Travere announced positive topline interim results from the ongoing Phase 3 PROTECT study of sparsentan in IgAN. Sparsentan treatment demonstrated a statistically significant mean reduction of proteinuria from baseline after 36 weeks, more than threefold the reduction of active comparator irbesartan (p&lt;0.0001). In the first quarter of 2022, Travere expects to submit an NDA seeking accelerated approval of sparsentan for IgAN in the United States.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, Travere and Vifor Pharma entered into a licensing agreement in September of 2021 for the commercialization of sparsentan in Europe, Australia and New Zealand. Traver and Vifor expect to submit a combined IgAN and FSGS Marketing Authorisation Application (MAA) in mid-2022 for conditional marketing authorization of sparsentan in Europe.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under our license agreement with Travere, we may be entitled to receive potential milestones of over $70 million and net royalties on future worldwide sales by Travere. The royalty term is expected to be 10 years following the first commercial sale. Travere is responsible for all development costs related to the program.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:113%">TR-Beta - VK2809 and VK0214 (Viking) </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.788%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.291%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr style="height:36pt"><td colspan="3" rowspan="4" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our partner, Viking, is developing VK2809, a novel selective TR-Beta agonist with potential in multiple indications, including hypercholesterolemia, dyslipidemia and NASH. VK2809 is currently in a Phase 2b clinical trial (the VOYAGE study) in patients with biopsy-confirmed NASH. Viking has previously announced positive results from a Phase 2a trial of VK2809 in hypercholesterolemia and fatty liver disease. VK0214 is currently in Phase 1 clinical development, and had been granted orphan drug study by the FDA for the treatment of X-ALD. Under the terms of the agreement with Viking, we may be entitled to up to $375 million of development, regulatory and commercial milestones and tiered royalties on potential future sales. Our TR Beta programs partnered with Viking are subject to CVR sharing and a portion of the cash received will be paid out to CVR holders.</span></div></td><td colspan="6" style="border-left:2pt solid #000000;border-right:2pt solid #000;border-top:2pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:12pt;text-align:center"><span style="color:#ff6600;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">TR-Beta - VK2809 and VK0214</span><span style="color:#ff6600;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> (Viking)</span></div></td></tr><tr style="height:36pt"><td colspan="3" style="border-left:2pt solid #000;border-top:2pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&lt; $500 million</span></td><td colspan="3" style="border-right:2pt solid #000;border-top:2pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.5%</span></td></tr><tr style="height:36pt"><td colspan="3" style="background-color:#cceeff;border-left:2pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$500 to $750 million</span></td><td colspan="3" style="background-color:#cceeff;border-right:2pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.5%</span></td></tr><tr style="height:36pt"><td colspan="3" style="border-bottom:2pt solid #000;border-left:2pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&gt;$750 million</span></td><td colspan="3" style="border-bottom:2pt solid #000;border-right:2pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.5%</span></td></tr></table></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Batoclimab (HanAll, Immunovant, and Harbour)</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our partner, HanAll has granted Immunovant an exclusive license for the development, manufacture and marketing of Batoclimab for the treatment of pathogenic IgG-mediated autoimmune diseases in the U.S., Canada, Mexico, the EU, the United Kingdom, Switzerland, Latin America, the Middle East and North Africa. Immunovant recently announced  the initiation of a Phase 3 trial in H2 in myasthenia gravis (MG) in the first half of 2022 and another one in another inflammatory disease while expanding into two new indications to be announced by Q3. Additionally, HanAll and Harbour BioMed, are collaborating to develop Batoclimab for similar treatment in China and Korea. Harbour is currently conducting three registrational Phase 2/3 trials in China in MG, thyroid eye disease and Primary Immune Thrombocytopenia. HanAll retains the rights to Batoclimab in Korea and Harbour will control the marketing in China. As part of our agreement with HanAll, we are entitled to development and regulatory milestones and royalties on potential future sales from HanAll and sublicense revenues from Immunovant and Harbour based on amounts received by HanAll.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">CRM197</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CRM197 is a non-toxic mutant of diphtheria toxin. It is a well characterized protein and functions as a carrier for polysaccharides and haptens, making them immunogenic. CRM197 is used in prophylactic and therapeutic vaccine candidates. We have developed CRM197 production strains using our Protein Expression Technology platform and supply preclinical grade and cGMP CRM197 (PeliCRM&#8482;) to several vaccine development focused pharmaceutical customers. </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our partners Merck and SII have exclusively licensed unique production strains for use in their conjugate vaccine products and candidates for pneumococcal and meningitis bacterial infections. Pneumococcus bacterium (Streptococcus pneumoniae) is a leading cause of severe pneumonia and major cause of morbidity and mortality worldwide. In accordance with our CRM197 commercial license agreements with Merck, we are eligible to earn an additional $8 million in development and regulatory milestones and low single digit royalties derived from net sales, depending on territory. CRM-197 made in the Pelican Expression Technology platform is also used by Merck in its investigational vaccine candidates, including the V116.  Additionally, in 2021 SII completed a Phase 3 study of a pentavalent meningococcal conjugate vaccine candidate (NmCV-5) that utilizes CRM197 made in the Pelican Expression Technology platform. NmCV-5 prequalification by WHO is projected as early as the third quarter of 2022.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Ensifentrine &#8211; RPL554 (Verona)</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our partner, Verona, is currently conducting a comprehensive Phase 3 clinical trial to evaluate the efficacy and safety of nebulized ensifentrine in patients with moderate to severe COPD with top-line results expected in 2022. Under the terms of our agreement with Verona, we are entitled to development and regulatory milestones, including a &#163;5.0 million payment upon the first approval by any regulatory authority, and royalties on potential future sales.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Teclistamab (Janssen</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">)</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our partner, Janssen, is developing Teclistamab, an off-the-shelf T-cell redirecting , bispecific antibody targeting BCMAxCD3 that was discovered in part with the OmniAb platform technology. Janssen announced that it submitted a BLA on December 29, 2021 for the treatment of patients with relapsed or refractory multiple myeloma. The application was supported by the data from the MajesTEC-1 Phase 2 trial that showed continued deep and durable responses. Teclistamab is also currently conducting several Phase 1 trials in multiple myeloma, as a single agent and in combination with daratumumab or talquetamab or Tecentriq. We are entitled to receive a $25 million milestone payment upon first commercial sale of Teclistamab in the U.S.</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">JNJ-67371244 (Janssen</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">)</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Janssen is also developing JNJ-67371244, an anti-CD33xCD3 antibody discovered in part with the OmniAb platform technology. Janssen is currently conducting a Phase I trial for cancer therapy. We are entitled to earn development and regulatory milestones based on the development of JNJ-67371244.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">JNJ-70218902 (Janssen)</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Janssen is also developing JNJ-70218902, a T-cell redirecting agent antibody discovered in part with the OmniAb platform technology. Janssen is currently conducting a Phase I trial for cancer therapy for patients with metastatic castration resistant prostate cancer. We are entitled to earn development and regulatory milestones based on the development of JNJ-70218902.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">JNJ-78306358 (Janssen)</span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Janssen is also developing JNJ-78306358, a T-cell redirecting bispecific antibody targeting HLA-G, discovered in part with the OmniAb platform technology. Janssen is currently conducting a Phase 1 trial in patients with advanced solid tumors. We are entitled to earn development and regulatory milestones based on the development of JNJ-78306358.</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">M6223 (Merck KGaA)</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our partner, Merck KGaA, is currently conducting a Phase 1 trial of M6223, an anti-TIGIT antibody discovered with the OmniAb platform, in patients with metastatic or locally advanced solid unresectable tumors in combination with bintrafusp alfa. Under the terms of the agreement, we are entitled to sublicense revenues, milestones and royalties on potential future net sales.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">SARM - VK5211 (Viking) </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:65.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.790%"></td><td style="width:0.1%"></td></tr><tr style="height:32pt"><td colspan="3" rowspan="4" style="padding:2px 1pt;text-align:left;text-indent:27pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Viking is also developing VK5211, a novel, potentially best-in-class SARM for patients recovering from hip-fracture. SARMs retain the beneficial properties of androgens without undesired side-effects of steroids or other less selective androgens. In a Phase 2 clinical trial, VK5211 demonstrated statistically significant, dose dependent increases in lean body mass. Under the terms of the agreement with Viking, we may be entitled to up to $270 million of development, regulatory and commercial milestones as well as tiered royalties on potential future sales.</span></td><td colspan="6" style="border-left:2pt solid #000000;border-right:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#ff6600;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">SARM - VK5211 (Viking)</span></td></tr><tr style="height:20pt"><td colspan="3" style="border-left:2pt solid #000;border-top:2pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&lt; $500 million</span></td><td colspan="3" style="border-right:2pt solid #000;border-top:2pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.25%</span></td></tr><tr style="height:20pt"><td colspan="3" style="background-color:#cceeff;border-left:2pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$500 to $750 million</span></td><td colspan="3" style="background-color:#cceeff;border-right:2pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.25%</span></td></tr><tr style="height:20pt"><td colspan="3" style="border-bottom:2pt solid #000;border-left:2pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&gt;$750 million</span></td><td colspan="3" style="border-bottom:2pt solid #000;border-right:2pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.25%</span></td></tr></table></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Ganaxalone IV (Marinus)</span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our partner, Marinus, is conducting Phase 3 clinical trials with Captisol-enabled ganaxolone IV in patients with refractory status epilepticus. Marinus has exclusive worldwide rights to Captisol-enabled ganaxolone, a GABA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:112%;position:relative;top:1.4pt;vertical-align:baseline">A</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> receptor modulator, for use in humans. We are entitled to development and regulatory milestones, revenue from Captisol material sales, and royalties on potential future sales.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">APVO436 (Aptevo)</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our partner, Aptevo, is currently conducting a Phase 1 trial of APVO436, a bispecific anti-CD123xCD3 for the treatment of acute myeloid leukemia and high-grade myelodysplastic syndrome. There is a high unmet medical need for targeted immunotherapies such as APVO436, that can potentially treat patients with relapsed or refractory disease, or patients who cannot tolerate traditional chemotherapy. Under the terms of the agreement with Aptevo, we are entitled to development and regulatory milestones and royalties on potential future net sales.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">GEN1046 (GenMab)</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our partner, Genmab, in collaboration with BioNTech is currently conducting two Phase 2 trials of GEN1046, a bispecific targeting PD-L1 and 4-1BB, as monotherapy or in combination for use in patients with relapsed/refractory metastatic </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">non-small cell lung cancer (NSCLC) or malignant solid tumors. Under the terms of the agreement with Genmab, we are entitled to clinical and regulatory milestones and royalties on potential future sales.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">GEN1047 (Genmab)</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Genmab is also developing GEN1047, an anti-B7H4xCD3 bispecific antibody, in part isolated from OmniAb platform technology. Genmab is currently conducting a Phase 1/2 trial in solid tumors. Under the terms of the agreement with Genmab, we are entitled to clinical and regulatory milestones and royalties on potential future sales.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sym022 and Sym023 (Symphogen/Servier)</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our partner, Symphogen (acquired by Servier), is currently conducting Phase 1 trials of SYM022 and SYM023 to determine if they are safe and tolerable for patients with locally advanced/unresectable or metastatic solid tumor malignancies or lymphomas that are refractory to available therapy for which no standard therapy is available. Under the terms of the agreement with Symphogen, we are entitled to sublicense revenues, milestones and royalties on potential future net sales.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sym024 (Symphogen/Servier)</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Symphogen/Servier is also developing an anti-CD73 antibody, developed with OmniAb platform technology, in Phase I trial to assess the safety and tolerability in patients with solid tumors as a monotherapy or in combination with Sym021 (anti-PD-1).  Under the terms of the agreement with Symphogen, we are entitled to sublicense revenues, milestones and royalties on potential future net sales.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sym025/S095029 (Symphogen/Servier)</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Symphogen/Servier is also developing an anti-NKG2A antibody, developed with OmniAb platform technology, in Phase 1a/1b trial to assess the safety, tolerability and preliminary anti-neoplastic activity in patients with solid tumors as a monotherapy or in combination with Sym021 (anti-PD-1) or anti-HER2 or anti-EGFR. Under the terms of the agreement with Symphogen, we are entitled to sublicense revenues, milestones and royalties on potential future net sales.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">WuXi Partnership</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the WuXi Agreement, we have granted WuXi a non-exclusive license to use our OmniRat, OmniMouse and OmniFlic platforms solely to research, develop and make antibodies, and we have agreed to use commercially reasonable efforts to deliver to WuXi animals from such platforms to support WuXi&#8217;s licensing rights under the WuXi Agreement. Further, WuXi has the right to out-license antibodies it discovers (whether for itself or at the direction of out-licensees) under the WuXi Agreement to out-licensees worldwide. We are entitled to royalties in the low single digits on net sales of products. Unless earlier terminated, the term of the WuXi Agreement shall continue indefinitely. Either party may terminate the WuXi Agreement upon specified notice of the other party's uncured material breach of the WuXi Agreement. In addition, we have the right to terminate the WuXi Agreement if WuXi or one of its out-licensees challenges the validity of one of our patents covering the platform and WuXi has the right to terminate the WuXi Agreement for convenience following a specified period after notice of termination.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to other earlier stage programs, the following programs have been licensed pursuant to the WuXi Agreement: </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Zimberelimab AB122/GLS010 (Arcus and Gloria)</span></div><div style="margin-bottom:6pt;padding-left:27pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our partner, WuXi, has outlicensed the rights to certain programs using the OmniAb technology to Arcus and Gloria. Arcus is conducting multiple Phase 1 and Phase 2 trials to evaluate the safety and tolerability and efficacy of Zimberelimab in subjects with advanced solid tumors as monotherapy or in combination with Etrumadenant, domvanalimab. Additionally, Gloria, has announced approval in China for zimberelimab for the treatment of recurrent or refractory classical Hodgkin&#8217;s lymphoma. Gloria is also conducting a Phase 2 of zimberelimab monotherapy in patients with recurrent or metastatic cervical cancer. Under the terms of our agreement with WuXi, we are entitled to royalties on potential future sales.</span></div><div style="margin-bottom:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Sugemalimab CS1001 (CStone)</span></div><div style="margin-bottom:6pt;padding-left:27pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">WuXi has also outlicensed the rights to certain programs using the OmniAb technology to CStone. CStone announced approval in China for Sugemalimab (brand name Cejemly&#174;) for first-line treatment of metastatic NSCLC. Pfizer is responsible for the commercialization in China via a 2020 strategic collaboration with CStone while EQRx has licensed exclusive rights to sugemalimab for the development and commercialization outside of China. CStone  is currently conducting multiple Phase 2 and Phase 3 trials to evaluate the efficacy and safety of Sugemalimab to treat patients with natural killer cell/T-cell lymphoma and classical Hodgkin&#8217;s lymphoma, second line treatment in NSCLC, and gastric or esophageal cancers. Under the terms of our agreement with WuXi, we are entitled to royalties on potential future sales.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Ciforadenant &#8211; CPI-444 (Corvus)</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our partner, Corvus, is conducting a Phase 1b/2 clinical trial in patients with renal cell carcinoma and metastatic castration resistant prostate cancer to evaluate Ciforadenant, an antagonist of adenosine A2A, in combination with the immunotherapy drug atezolizumab. Positive preliminary data was presented in February at ASCO 2020 Genitourinary Cancers Symposium (ASCO-GU) and additional data was presented at ASCO 2020 in May/June. Ciforadenant is also being evaluated in a Phase 1b/2 trial in combination with atezolizumab in patients with non-small cell lung cancer who have failed no more than two prior regimens. Under the terms of our agreement with Corvus, we are entitled to development and regulatory milestones and tiered royalties on potential future sales. The aggregate potential milestone payments from Corvus are approximately $220 million for all indications.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">FYCOMPA IV (Eisai)</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our partner, Eisai, recently completed an open-label, single group assignment, multicenter, Phase 2 study in Japan to evaluate the safety and tolerability of intravenous perampanel, formulated with Captisol, as substitute for oral tablets as an adjunctive therapy in patients with partial onset seizures (including secondarily generalized seizures) or primary generalized tonic-clonic seizures. The primary endpoint was the number of patients with adverse events and serious adverse events. We are entitled to revenue from Captisol material sales and tiered royalties on potential future sales.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Pevonedistat - TAK-924 (Millennium/Takeda) </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our partner, Millennium/Takeda, is currently conducting Phase 3 trials for the development of pevonedistat for the treatment of acute myeloid leukemia. Pevonedistat is a Captisol-enabled Nedd8-Activating Enzyme Inhibitor. Under the terms of the clinical-stage agreement, we may be entitled to over $25 million in regulatory and development milestones from Millennium/Takeda, revenue from Captisol material sales and royalties on potential future net sales.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">SB206 (Novan) </span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We acquired certain economic rights to SB206 (KINSOLUS&#8482;) from Novan in May 2019. SB206 is a topical nitric-oxide antiviral gel for the treatment of viral skin infections, including molluscum contagiosum (MC). MC is an infection which causes skin lesions that affect approximately 6 million people in the United States annually, with the greatest incidence in children aged one to 14 years. In June of 2021, Novan reported positive topline efficacy and favorable safety data at Week 12 from the B-SIMPLE4 pivotal Phase 3 clinical study of SB206 for the treatment of MC, with primary endpoint achieving statistical significance (p-value &lt; 0.0001) and no serious adverse events related to treatment with SB206. Novan intends to submit an NDA to the FDA for the treatment of MC in the fourth quarter of 2022.</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">PTX - 022 (Palvella)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:65.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.790%"></td><td style="width:0.1%"></td></tr><tr style="height:18pt"><td colspan="3" rowspan="5" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;We acquired the economic rights to PTX-022 from Palvella in December 2018. PTX-022 is a novel, topical formulation comprising high-strength rapamycin in development to treat pachyonychia congenita (PC).  PC is a serious, chronically debilitating lifelong monogenic rare skin disease with no approved treatment. </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Palvella is conducting the Phase 3 VAPAUS study to evaluate the safety and efficacy of PTX-022 (QTORIN 3.9% rapamycin anhydrous gel) in the treatment of adults with PC.</span></div></td><td colspan="6" style="border-left:2pt solid #000000;border-right:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#ff6600;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PTX - 022 (Palvella)</span></td></tr><tr style="height:18pt"><td colspan="3" style="border-left:2pt solid #000;border-top:2pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&lt; $50 million</span></td><td colspan="3" style="border-right:2pt solid #000;border-top:2pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.00%</span></td></tr><tr style="height:18pt"><td colspan="3" style="background-color:#cceeff;border-left:2pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$50 to $100 million</span></td><td colspan="3" style="background-color:#cceeff;border-right:2pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.50%</span></td></tr><tr style="height:18pt"><td colspan="3" style="border-left:2pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&gt;$100 million</span></td><td colspan="3" style="border-right:2pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.80%</span></td></tr><tr style="height:18pt"><td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Lasofoxifene (Sermonix) </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lasofoxifene is a selective estrogen receptor modulator for osteoporosis treatment and other diseases, discovered through the research collaboration between Pfizer and us. Our partner, Sermonix has a license for the development of oral lasofoxifene for the United States and additional territories. Under the terms of the agreement, we are entitled to receive over $45 million in potential regulatory and commercial milestone payments as well as royalties on potential future net sales. Sermonix is conducting the Phase 2 ELAINE 1 trial assessing oral lasofoxifene versus intramuscular fulvestrant for the treatment of ER+/HER2- breast cancer in patients with an ESR1 mutation. Lasofoxifene is also being studied in ELAINE 2 trial in combination with Eli Lilly and Company's CDK4 and 6 inhibitor, Verzenio&#174; (abemaciclib). Topline data are expected for both ELAINE trials in the first half of 2022. </span></div><div style="text-indent:27pt"><span><br/></span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Pradefovir (Xi'an Xintong)</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Chinese licensee, Xi'an Xintong Medicine Research (following its acquisition of Chiva Pharmaceuticals), is developing pradefovir, an oral liver-targeting prodrug of the HBV DNA polymerase/reverse transcriptase inhibitor adefovir, for the potential treatment of HBV infection. Pradefovir was developed using Ligand&#8217;s HepDirect technology. In September 2019, Xi'an Xintong Medicine Research reported positive results from a Phase 2 trial of pradefovir, showing good efficacy, safety and tolerability. At the dose of 75 mg, the reduction of DNA viral load, the percentage of no viral load detected, and HBeAg </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">negative conversion rate were better than tenofovir disoproxil fumarate (TDF) after 24 weeks of treatment. Overall incidence of side effects was less than TDF and there was no renal or skeletal toxicity. Xi'an Xintong Medicine Research is currently conducting a Phase 3 trial. We are entitled to an annual licensing maintenance fee and royalties on potential future sales.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">MB07133 (Xi'an Xintong)</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chinese licensee Xi'an Xintong Medicine Research is also developing MB07133, a liver specific, HepDirect prodrug of cytarabine monophosphate, for the potential treatment of hepatocellular carcinoma and intrahepatic cholangiocarcinoma. MB07133 is currently in Phase 1 in China. We are entitled to an annual licensing maintenance fee and royalties on potential future sales.</span></div><div><span><br/></span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Summary of Selected Collaborations</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">GSK Collaboration</span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2020, we entered into a license and collaboration agreement with GSK to leverage our unique expertise in small molecule therapeutics targeting transmembrane proteins. The goal of this collaboration is to identify and develop inhibitors of a specific, genetically validated molecular target relevant to neurological diseases. Under the terms of the agreement, we received an upfront payment of $7.0 million and could receive additional development, regulatory and commercialization milestones of up to $154.5 million. We are also entitled to receive tiered royalties should any drug from the collaboration be commercialized. We will be responsible for the majority of preclinical activities up to lead optimization with both Ligand and GSK collaborating to identify candidates for IND-enabling studies. GSK has the exclusive option to license any identified inhibitors and will be responsible for further development and commercialization of any drug candidates identified through the collaboration. In December 2021, we entered into a second collaborative drug discovery program for a new genetically validated molecular target. We received an upfront payment of $10 million and could receive additional development, regulatory and commercialization milestones of up to $247.5 million. We are also entitled to receive tiered royalties should a drug from the collaboration on the second program be commercialized.</span></div><div style="margin-bottom:6pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Roche Collaboration</span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2018, we entered into a license and collaboration agreement with Roche to develop and commercialize small molecule ion channel modulators for the treatment of neurological disorders and in May 2020 amended the license and collaboration agreement to include a second target. These programs incorporate our technology platform for ion channel drug discovery and are directed at specific ion channel targets expressed in neurons. Under the terms of the agreement, Roche paid us on a per target basis an upfront payment for program exclusivity and research funding. In addition, we are eligible to potentially receive development and commercial milestone payments of up to $274 million per program and royalty payments if a drug is commercialized. We will be responsible for most preclinical activities up to lead optimization with both us and Roche applying resources to identify candidates for entry into late stage preclinical and IND enabling studies. Thereafter, Roche will be responsible for the further development and commercialization of the programs. In June 2021, we entered into a collaboration on a third program. We are eligible to potentially receive development and commercial milestone payments of $274 million on this program and royalty payments if a drug is commercialized. For all programs we will be responsible for most preclinical activities up to lead optimization with both us and Roche applying resources to identify candidates for entry into late stage preclinical and IND enabling studies. Thereafter, Roche will be responsible for the further development and commercialization of the programs.</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cystic Fibrosis Foundation Collaboration</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2018, we announced an award of up to $11 million from the Cystic Fibrosis Foundation for a project focused on the discovery of therapeutics to treat patients with cystic fibrosis (CF) caused by nonsense mutations. Nonsense mutations in the Cystic Fibrosis Transmembrane Conductance Regulator (&#8220;CFTR&#8221;) gene result in the premature termination of protein synthesis and the formation of truncated, non-functional CFTR. Patients with these mutations in both copies of their CFTR genes currently have no therapies that treat the underlying cause of their disease. The aim of this program is to provide these patients with a transformative therapeutic that will markedly improve their quality of life and lifespan. The award is to support an integrated, multi-year drug discovery initiative. At the North American Cystic Fibrosis Conference in October 2020, we reported the identification and characterization of a class of small molecule agents that enhance CFTR-PTC mutant readthrough and enable functional CFTR currents in combination with aminoglycosides.</span></div><div><span><br/></span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Royalties</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have multiple programs under license with other companies that have products that are already being commercialized. In addition to the table below, we have generally described a typical Captisol and OmniAb royalty arrangement as low- to mid-single digit royalties. The following table represents substantially all of the disclosed information about our royalty arrangements:</span></div><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Royalty Table</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.298%"><tr><td style="width:1.0%"></td><td style="width:28.822%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.977%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.901%"></td><td style="width:0.1%"></td></tr><tr><td colspan="9" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#333399;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Ligand Licenses With Tiered Royalties</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ff6600;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Program</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ff6600;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Licensee</span></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ff6600;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalty Rate</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CE-Meloxicam</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sedor</span></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.0% - 10.0%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ciforadenant</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corvus</span></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mid-single digit to low-teen royalty</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DGAT-1</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Viking</span></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0% - 7.0%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Duavee</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pfizer</span></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5% - 2.5%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ensifentrine (RPL554)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Verona</span></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Low to mid-single digit royalty</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">FBPase Inhibitor (VK0612)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Viking</span></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.5% - 9.5%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kyprolis</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amgen</span></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5% - 3.0%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lasofoxifene</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sermonix</span></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.0% - 10.0%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">OmniAb-Genagon</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Genagon</span></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.0% - 6.0%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">OmniAb-GigaGen</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">GigaGen</span></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mid-single digit royalty</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">OmniAb-iMetabolic</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">iMetabolic</span></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&lt;6%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">OmniAb-Kira</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kira</span></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Low to mid-single digit royalty</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">OmniAb-Takeda</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Takeda</span></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Low single digit royalty</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Oral EPO</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Viking</span></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5% - 8.5%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PTX-022</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Palvella</span></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.0% - 9.8%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SARM (VK5211)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Viking</span></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.25% - 9.25%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SB206</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Novan </span></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.0% - 10.0%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TR Beta (VK2809 and VK0214)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Viking</span></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.5% - 7.5%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Viviant/Conbriza</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pfizer</span></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5% - 2.5%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Various</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nucorion</span></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.0% - 9.0%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Various</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Seelos</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.0% - 10.0%</span></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.298%"><tr><td style="width:1.0%"></td><td style="width:28.822%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.977%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.901%"></td><td style="width:0.1%"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#333399;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Ligand Licenses With Fixed Royalties</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ff6600;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Program</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ff6600;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Licensee</span></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ff6600;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalty Rate</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4-1BB</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Zhilkang Hongyi</span></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Low single digit royalty</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AB122</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Arcus</span></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Low single digit royalty</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Baxdela</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Melinta</span></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.5%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CE-Fosphenytoin</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sedor</span></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sugemalimab</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CStone</span></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Evomela</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acrotech/CASI</span></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">V114</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Merck</span></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Low single digit royalty</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pneumosil</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Serum Institute</span></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Low single digit royalty</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MB07133</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Xi'an Xintong</span></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ME-344</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MEI Pharma</span></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Low single digit royalty</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pradefovir</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Xi'an Xintong</span></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reproxalap</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Aldeyra Therapeutics</span></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Low single digit royalty</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sparsentan</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Travere</span></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Various</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gloria</span></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Low single digit royalty</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Zulresso</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SAGE</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3%</span></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Milestone Payments</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our programs under license with our partners may generate milestone payments to us if our partners reach certain development, regulatory and commercial milestones. The following table represents the maximum value of our milestone payment pipeline by development stage, technology and partner (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.152%"><tr><td style="width:1.0%"></td><td style="width:14.427%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.427%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.576%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.427%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.427%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.042%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.427%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.247%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Technology*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Stage*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Partner*</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">OmniAb</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&gt; $1,600,000</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Preclinical</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&gt; $10,000</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Viking</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$1,500,000</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pelican</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&gt;$240,000</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Clinical</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&gt; $530,000</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Roche</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$543,000</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Captisol</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&gt; $220,000</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Regulatory</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&gt; $1,900,000</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">GSK</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$367,000</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">LTP/Hep Direct</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&gt; $280,000</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&gt; $1,950,000</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Janssen</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$208,000</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NCE/Other</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&gt; $2,100,000</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&gt; $30,000</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Neuritek</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$246,000</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&gt;$4,400,000</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&gt;$4,400,000</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Jazz</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$150,000</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Seelos</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$139,000</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Travere</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$70,000</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&gt;$1,180,000</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&gt;$4,400,000</span></td></tr></table></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">*All tables exclude any annual access fees and collaboration revenue for development work.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:174%">Summary of Selected Internal Development Programs </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a number of internal development or unpartnered programs focused on a wide-range of potential indications or disease. </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Captisol-enabled (CE)-Iohexol program was established in January 2018 to develop a next-generation contrast agent for diagnostic imaging with a reduced risk of renal toxicity. Contrast-induced acute kidney injury (CI-AKI) is the acute impairment of renal function following intravascular administration of an iodinated contrast agent, and occurs most frequently following coronary angiography, percutaneous coronary intervention and contrast-enhanced computed tomography, especially among patients at risk of renal injury such as those with advanced age, diabetes or heart failure. Currently no products are approved to prevent or treat CI-AKI in this setting, and therefore we believe a significant opportunity exists for a safer formulation of contrast agents. The goal is for CE-Iohexol to improve upon the limitations of existing contrast agents and enable a future partner to gain meaningful market share. In July 2019, we announced positive top-line results from a Phase 1 clinical trial CE-Iohexol conducted in Canada. The trial achieved the primary endpoint by demonstrating pharmacokinetic bioequivalence of CE-Iohexol injection and a reference Iohexol injection (OMNIPAQUE&#8482;) after IV administration in healthy adults. CE-Iohexol injection was well tolerated, and adverse events were in line with the known safety profile of OMNIPAQUE. We submitted an IND with the FDA in November and received a &#8220;Study May Proceed&#8221; letter in December 2020 along with feedback from the FDA on the clinical plan. Initiation of the Phase 2 clinical trial has been deferred as we assess potential partner interest.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Luminespib/Hsp90 Inhibitor is a Phase 2-ready Hsp90 inhibitor, previously investigated in clinical trials for cancer. Third-party academic drug analyses suggest a potential role for heat shock protein 90 (Hsp90) inhibitors in treating COVID-19 infection. Based on these studies, we are evaluating potential collaborations or partnerships relating to intravenous luminespib (AUY-922) as a potential treatment for patients with COVID-19. </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our primary research and development efforts are led by our teams in Emeryville, California, San Diego, California, and Durham, North Carolina. The following table represents internal programs eligible for further development or partnership:</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;text-indent:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.619%"><tr><td style="width:1.0%"></td><td style="width:44.087%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.452%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.944%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.778%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.039%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Program</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Development Stage</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Targeted Indication or Disease</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CE-Iohexol</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase 2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diagnostics</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Luminespib/Hsp90 Inhibitor</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase 2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Oncology</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CE-Sertraline, Oral Concentrate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase 1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depression</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PF530 Interferon Beta</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase 1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Immunomodulatory</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PF582 Ranibizumab</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase 1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ocular</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CCR1 Antagonist</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preclinical</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Oncology</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CE-Busulfan</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preclinical</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Oncology</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CE-Cetirizine Injection</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preclinical</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allergy</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CE-Silymarin for Topical formulation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preclinical</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sun damage</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">FLT3 Kinase Inhibitors</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preclinical</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Oncology</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">GCSF Receptor Agonist</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preclinical</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Blood disorders</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Anti-B7-H3</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preclinical</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Oncology</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Anti-TIM3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preclinical</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Oncology</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Anti-TIGIT</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preclinical</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Oncology</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Anti-CD38</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preclinical</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Oncology</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Anti-BDNF</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preclinical</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Oncology</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PF529 Pegfilgrastim</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preclinical</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Oncology</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PF810 Recombinant Peptide</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preclinical</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Endocrine System</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:17pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Manufacturing</span></div><div style="margin-bottom:6pt;text-indent:24pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We contract with a third party manufacturer, Hovione, for Captisol production. Hovione operates FDA-inspected sites in the United States, Macau, Ireland and Portugal. Manufacturing and distribution operations for Captisol are performed primarily at Hovione's Portugal and Ireland facilities. We believe we maintain adequate inventory of Captisol to meet our current and future partner needs.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the event of a Captisol supply interruption, we are permitted to designate and, with Hovione&#8217;s assistance, qualify one or more alternate suppliers.&#160;If the supply interruption continues beyond a designated period, we may terminate the agreement.&#160;In addition, if Hovione cannot supply our requirements of Captisol due to an uncured force majeure event, we may also obtain Captisol from a third party and have previously identified such parties.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The current term of the agreement with Hovione is through December 2024. The agreement will automatically renew for successive two year renewal terms unless either party gives written notice of its intention to terminate the agreement no less than two years prior to the expiration of the initial term or renewal term. In addition, either party may terminate the agreement for the uncured material breach or bankruptcy of the other party or an extended force majeure event. We may terminate the agreement for extended supply interruption, regulatory action related to Captisol or other specified events. We have ongoing minimum purchase commitments under the agreement.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Competition</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some of the drugs we and our licensees and partners are developing may compete with existing therapies or other drugs in development by other companies. Furthermore, academic institutions, government agencies and other public and private organizations conducting research may seek patent protection with respect to potentially competing products or technologies and may establish collaborative arrangements with our competitors.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Captisol business may face competition from other suppliers of similar cyclodextrin excipients or other technologies that are aimed to increase solubility or stability of APIs. Our OmniAb antibody technology faces competition from suppliers of other transgenic animal systems that are also available for antibody drug discovery such as AbCellera Biologics.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our competitive position also depends upon our ability to obtain patent protection or otherwise develop proprietary products or processes. For a discussion of the risks associated with competition, see below under </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8220;Item 1A. Risk Factors.&#8221;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Environmental, Health and Safety (EHS)</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are committed to providing a safe and healthy workplace, promoting environmental excellence in our communities, and complying with all relevant regulations and industry standards. We establish and monitor programs to reduce pollution, prevent injuries, and maintain compliance with applicable regulations. By focusing on such practices, we believe we can affect a meaningful, positive change in our community and maintain a healthy and safe environment. Our animal health facility in Emeryville, California, has accreditation from the Association for Assessment and Accreditation of Laboratory Animal Care, a nonprofit organization that promotes the humane treatment of animals in science through voluntary accreditation and assessment programs. We expect to continue our effort and to refine our EHS policies and practices in 2022. More information on our EHS policies and initiatives is available on our website at www.ligand.com.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Government Regulation</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The research and development, manufacturing and marketing of pharmaceutical products are subject to regulation by numerous governmental authorities in the United States and other countries.&#160;We and our partners, depending on specific activities performed, are subject to these regulations. In the United States, pharmaceuticals are subject to regulation by both federal and various state authorities, including the FDA. The Federal Food, Drug and Cosmetic Act and the Public Health Service Act govern the testing, manufacture, safety, efficacy, labeling, storage, record keeping, approval, advertising and promotion of pharmaceutical&#160;products. These activities are subject to additional regulations that apply at the state level. There are similar regulations in other countries as well. For both currently marketed products and products in development, failure to comply with applicable regulatory requirements can, among other things, result in delays, the suspension of regulatory approvals, as well as possible civil and criminal sanctions. In addition, changes in existing regulations could have a material adverse effect on us or our partners. For a discussion of the risks associated with government regulations, see below under &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Item 1A. Risk Factors.&#8221;</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Patents and Proprietary Rights</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that patents and other proprietary rights are important to our business. Our policy is to file patent applications to protect technology, inventions and improvements to our inventions that are considered important to the development of our business. We also rely upon trade secrets, know-how, continuing technological innovations and licensing opportunities to develop and maintain our competitive position.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patents are issued or pending for the following key products or product families. The scope and type of patent protection provided by each patent family is defined by the claims in the various patents. Patent term may vary by jurisdiction and depend on a number of factors including potential patent term adjustments, patent term extensions, and terminal disclaimers. For each product or product family, the patents and/or applications referred to are in force in at least the United States, and for most products and product families, the patents and/or applications are also in force in European jurisdictions, Japan and other jurisdictions.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Captisol</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">  </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patents and pending patent applications covering Captisol and methods of making Captisol are owned by us. The patents covering the Captisol product with the latest expiration date is set to be in 2033 (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">see, e.g</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">., U.S. Patent No. 9,493,582 (expires Feb. 27, 2033)). Other patent applications covering methods of making Captisol, if issued, potentially have terms to 2041. We have asserted U.S. Patents 8,410,077, 9,200,088, and 9,493,582 against Teva in connection with their attempt to obtain FDA approval to manufacture and sell a generic version of Evomela</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We also own several patents and pending patent applications covering drug products containing Captisol as a component. Globally, we own approximately 440 issued patents covering all of the foregoing Captisol compositions, methods and related technology. </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Seven Captisol patents in several families are listed in the Orange Book in connection with numerous prescription drugs currently on the market. These Captisol-enabled drugs include Nexterone (Baxter), Kyprolis (Amgen), Noxafil (Merck), Evomela (Acrotech/CASI), Baxdela (Melinta) and Zulresso (Sage). These patents are listed in the table below, and each patent family containing these patents has pending and/or granted counterparts in Europe, China and Japan.</span></div><div style="text-indent:27pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:61.180%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.884%"></td><td style="width:0.1%"></td></tr><tr><td colspan="12" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Orange Book-listed Captisol Patents and Selected Foreign Patents</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Country</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Patent No.</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Title</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Expiration (nominal)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:112%;position:relative;top:-3.15pt;vertical-align:baseline"> &#8225;</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">United States</span></div></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">7635773</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Sulfoalkyl Ether Cyclodextrin Compositions</span></div></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">03/13/2029</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">United States</span></div></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">8410077</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Sulfoalkyl Ether Cyclodextrin Compositions</span></div></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">03/13/2029</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">United States</span></div></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">9200088</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Sulfoalkyl Ether Cyclodextrin Compositions</span></div></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">03/13/2029</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">United States</span></div></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">10117951</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Sulfoalkyl Ether Cyclodextrin Compositions</span></div></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">03/13/2029</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">United States</span></div></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">9750822</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Sulfoalkyl Ether Cyclodextrin Compositions</span></div></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">03/13/2029</span></div></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:61.180%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.884%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">United States</span></div></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">9493582</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Alkylated Cyclodextrin Compositions And Processes For Preparing And Using The Same</span></div></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">2/27/2033</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">United States</span></div></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">10040872</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Alkylated Cyclodextrin Compositions And Processes For Preparing And Using The Same</span></div></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">10/21/2033</span></div></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#8225;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Expiration dates are calculated as 20 years from the earliest nonprovisional filing date to which priority is claimed, and do not take into account disclaimers or extensions that are or may be available in these jurisdictions.</span></div><div><span><br/></span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Subject to compliance with the terms of the respective agreements, our rights to receive royalty payments under our licenses with our exclusive licensors typically extend for the life of the patents covering such developments. For a discussion of the risks associated with patent and proprietary rights, see below under </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">&#8220;Item 1A. Risk Factors.&#8221;</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Kyprolis </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patents protecting Kyprolis include those owned by Amgen and those owned by us. The United States patent listed in the Orange Book relating to Kyprolis with the latest expiration date is not expected to expire until 2029. Patents and applications owned by Ligand relating to the Captisol component of Kyprolis are not expected to expire until 2033. Amgen filed suit against several generic drug companies over their applications to make generic versions of Kyprolis. Several generics have settled with Amgen on confidential terms. However, it has been publicly reported that the U.S. launch date for at least Breckenridge Pharmaceuticals&#8217; generic product will be on a date that is held as confidential in 2027 or sooner, depending on certain occurrences. One generic company, Cipla Limited/Cipla USA, Inc. chose not to settle the litigation with Amgen, and proceeded to trial. The District Court upheld the validity of patent claims from three of the patents and the judgment was upheld on appeal.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">OmniAb</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the heart of the OmniAb technology stack are our proprietary transgenic animals, including OmniRat, OmniMouse and OmniChicken, which have been genetically modified to generate antibodies with human sequences to facilitate development of human therapeutic candidates. OmniFlic and OmniClic are common light-chain rats and chickens, respectively, designed to generate bispecific antibodies. OmniTaur provides cow-inspired antibodies with unique structural characteristics for challenging targets. To our knowledge, we are the industry&#8217;s only four-species in vivo antibody discovery platform, making OmniAb the most diverse host system available in the industry. </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have received patent protection on OmniAb animals and methods in over 40 jurisdictions, including the United States, multiple countries throughout Europe, Japan and China. These platform patents and applications owned by us are expected to expire between 2028 and 2039 and partners are able to use the OmniAb patented technology to generate novel antibodies, which may be entitled to additional patent protection.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">OmniAb&#8217;s business will include the Ab Initio computational antigen design technology, Icagen&#8217;s ion channel technology, the xPloration high-throughput screening technology, in addition to the suite of OmniAb transgenic animals used for antibody discovery.  Ab Initio owns a portfolio of issued patents and pending patent applications directed to SIRP-gamma polypeptides and apelin (APJ) receptor binding domains that includes issued patents in the United States and Europe and patent applications in the United States and multiple other countries.  The patents and applications in Ab Initio&#8217;s owned portfolio are expected to expire between 2036 and 2040. Icagen owns a portfolio of issued patent and pending patent applications directed to X-ray fluorescence-based detection of binding events and transport across barriers and related inventions, including 22 issued patents in the Unites States and patents issued in Europe, Japan and China as well as pending patent applications in the U.S. and Europe. The patents and applications in Icagen&#8217;s portfolio are expected to expire between 2023 and 2040.  xCella&#8217;s technology includes a microcapillary platform that can screen single B cells for specificity and bioactivity, which expand our existing single- B cell assay capabilities in the OmniAb technology platform. xCella owns a patent portfolio that includes three issued patents in the United States and pending patent applications in the U.S. and multiple other countries. The patents and applications in xCella&#8217;s owned portfolio are expected to expire between 2036 and 2040.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">OmniAb&#8217;s intellectual property will remain with OmniAb following the planned separation of OmniAb into a new public company. For more information regarding the OmniAb separation, see &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business&#8212;2021 and Recent Major Business Highlights&#8212;The Separation and Distribution of OmniAb Business.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Ligand UK Development Limited</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of our sale of Vernalis (R&amp;D) Limited to HitGen in December 2020, Ligand retained a portfolio of fully-funded shots on goal, which now include S65487, a Bcl-2 inhibitor, and S64315, an Mcl-1 inhibitor for treatment of cancers, both of which are partnered with Servier in collaboration with Novartis, VER250840 (an oral, selective Chk1 inhibitor for treatment of cancer), and V158866, a novel, oral, selective fatty acid amide hydrolase (FAAH) inhibitor for CNS disorders, partnered with Neuritek Therapeutics. These programs and their IP are now owned by Ligand UK Development Limited, which </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">has a worldwide patent portfolio of over 200 granted patents in over 70 countries. This patent portfolio is mature, with expected expiry dates between 2022 and 2033.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Pelican Expression Technology Platform</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We acquired the Pelican Expression Technology platform through acquisition of Pfenex Inc. in October 2020. This acquisition brought a robust portfolio of patents and patent applications along with substantial know-how and trade secrets which protect various aspects of our core Pelican Expression Technology business. As of December 31, 2021, we were the sole owner of a patent portfolio that consisted of over 200 patents and 50 pending patent applications worldwide that provide material coverage for our platform technology, licensed products and product candidates. Our U.S. issued patents expire during the time period beginning in 2025 and ending in 2038. Our owned and exclusively licensed patent portfolio includes claims directed to methods for recombinant protein production and methods for rapid screening of an array of expression systems, tools for protein expression such as P. fluorescens promoters, secretion leaders, plasmid maintenance systems, improved methods for non-standard amino acid incorporation and fusion partners for peptide production. In addition, our IP covers methods for producing certain classes of proteins such as cytokines, growth factors and antibody derivatives, as well as expression strains and methods for production, purification and formulation of certain vaccine antigens, peptides, therapeutic enzymes, human cytokines, etc.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Human Capital Management</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize and take care of our employees by offering a wide range of competitive pay, recognition, and benefit programs. We are proud to provide our employees the opportunity to grow and advance as we invest in their education and career development. As of December 31, 2021, we have 154 employees, of whom 118 are involved directly in scientific research and development activities. </span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely on skilled, experienced, and innovative employees to conduct the operations of our company. Our key human capital objectives include identifying, recruiting, retaining, incentivizing and integrating our existing and new employees. We frequently benchmark our compensation practices and benefits programs against those of comparable industries and in the geographic areas where our facilities are located. We believe that our compensation and employee benefits are competitive and allow us to attract and retain skilled labor throughout our organization. Our notable health, welfare and retirement benefits include:</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">equity awards through our 2002 Stock Incentive Plan;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">subsidized health insurance;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">401(k) Plan with matching contributions;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">tuition assistance program; and</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">paid time off.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We strive to maintain an inclusive environment free from discrimination of any kind, including sexual or other discriminatory harassment. Our employees have multiple avenues available through which inappropriate behavior can be reported, including a confidential hotline. All reports of inappropriate behavior are promptly investigated with appropriate action taken to stop such behavior.</span></div><div style="margin-bottom:10pt;margin-top:14pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Investor Information</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial and other information about us is available on our website at www.ligand.com. We make available on our website, without charge, copies of our Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and amendments to those reports filed or furnished pursuant to Section 13(a) or 15(d) of the Exchange Act as soon as reasonably practicable after we electronically file such material with, or furnish it to, the SEC. You may obtain copies of these documents by visiting the SEC&#8217;s website at www.sec.gov. In addition, we use Twitter (@Ligand_LGND) and our investor relations website as a means of disclosing material non-public information and for complying with our disclosure obligations under Regulation FD.  Investors should monitor our Twitter account and our website, in addition to following our press releases, SEC filings, public conference calls and webcasts. These website addresses and the information accessible through out Twitter account are not intended to function as hyperlinks, and the information contained in our website and in the SEC&#8217;s website is not intended to be a part of this filing. </span></div><div style="text-indent:27pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">24</span></div></div></div><div id="i0fa6f906fb2e4e30bc5e873d2bb6a82c_16"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:10.776%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.024%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ITEM&#160;1A.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">RISK FACTORS</span></td></tr></table></div><div style="margin-top:5pt;text-indent:24pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The following is a summary description of some of the many risks we face in our business. You should carefully review these risks in evaluating our business, including the businesses of our subsidiaries. You should also consider the other information described in this report. Additional risks not presently known to us or that we currently deem immaterial also may impair our business.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Risks Related to Our Business Operations and Reliance on Third Parties:</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:81%">Future revenue based on Kyprolis and Evomela, as well as royalties from our other partnered products, may be lower than expected.</span></div><div style="text-indent:45pt"><span><br/></span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A significant portion of our royalty revenue is based on sales of Kyprolis by Amgen and sales of Evomela by Acrotech Biopharma. Royalties, including payments from Amgen and Acrotech Biopharma, are expected to be a substantial portion of our ongoing revenues for the foreseeable future. Any setback that may occur with respect to any of our partners' products, and in particular Kyprolis, could significantly impair our operating results and/or reduce our revenue and the market price of our stock. Setbacks for the products could include problems with shipping, distribution, manufacturing, product safety, marketing, government regulation or reimbursement, licenses and approvals, intellectual property rights, including Amgen's or Acrotech Biopharma's failure to enforce their respective intellectual property rights, competition with existing or new products and physician or patient acceptance of the products, as well as higher than expected total rebates, returns, discounts, or unfavorable exchange rates. These products also are or may become subject to generic competition. For example, we entered into a settlement agreement with Teva and Acrotech Biopharma (the holder of the NDA for Evomela) which will allow Teva to market a generic version of Evomela in the United States on June 1, 2026, or earlier under certain circumstances. The entry of generic competition for Evomela may materially and adversely affect the revenue we derive from Evomela sales. Also, Amgen has settled patent litigation related to Kyprolis on confidential terms with several parties, but it has been publicly reported that the U.S. launch date for at least Breckenridge Pharmaceuticals&#8217; applicable generic product will be &#8220;on a date that is held as confidential in 2027 or sooner, depending on certain occurrences.&#8221; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">   </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Future revenue from sales of Captisol material to our license partners may be lower than expected.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues from sales of Captisol material to our collaborative partners, including Amgen, Gilead and the Gilead consortium, represent a significant portion of our current revenues. Any setback that may occur with respect to Captisol could significantly impair our operating results and/or reduce the market price of our stock. Setbacks for Captisol could include problems with shipping, distribution, manufacturing, product safety, marketing, government regulation or reimbursement, licenses and approvals, intellectual property rights, competition with existing or new products and physician or patient acceptance of the products using Captisol. In addition, revenue from Captisol sales related to remdesivir may not continue or materially increase due to a number of factors, including: if Gilead successfully develops or manufactures an alternative formulation of remdesivir that does not incorporate Captisol or uses less Captisol in such formulation; if remdesivir is later shown to not be effective or safe for the treatment of COVID-19; the FDA revises or revokes its approval of remdesivir; if alternative therapies or vaccines are approved, including potential treatments for COVID-19 in pill or other forms that are being developed or which may be developed by other companies; or the risk of COVID-19 infection significantly diminishes, in which case the commercial opportunity could be materially and adversely affected. For example, Gilead has announced plans to develop an inhaled dosage form of remdesivir that uses less Captisol than the current formulation and expects results from an ongoing proof-of-concept study later this year.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">If products or product candidates incorporating Captisol material were to cause any unexpected adverse events, the perception of Captisol safety could be seriously harmed. If this were to occur, we may not be able to sell Captisol unless and until we are able to demonstrate that the adverse event was unrelated to Captisol, which we may not be able to do. Further, the FDA could require us to submit additional information for regulatory review or approval, including data from extensive safety testing or clinical testing of products using Captisol. This would be expensive and it may delay the marketing of Captisol-enabled products and receipt of revenue related to those products, which could significantly impair our operating results and/or reduce the market price of our stock.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We obtain Captisol from Hovione, our third party manufacturer, primarily at their facilities in Ireland and Portugal.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If Hovione were to cease to be able, for any reason, to supply Captisol to us in the amounts we require, or decline to supply Captisol to us, we would be required to seek an alternative source, which could potentially take a considerable length of time and impact our revenue and customer relationships. In the event of a Captisol supply interruption, we are permitted to designate and, with Hovione&#8217;s assistance, qualify one or more alternate suppliers, although there is no assurance that we could do so timely or at an acceptable costs, if at all. In addition to manufacturing at Hovione&#8217;s facilities in Ireland and Portugal, we have now added final step processing capacity for Captisol in both the United States and England.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain inventory of Captisol, which has a five year shelf life, at three geographically dispersed storage locations in the United States and Europe. If we were to encounter problems maintaining our inventory, such as natural disasters, at one or more of these locations, it could lead to supply interruptions. In addition, we will rely on Hovione to expand manufacturing capacity of Captisol and any failure by Hovione to timely implement such increased capacity could adversely affect our ability to supply Captisol to our partners. While we believe we maintain adequate inventory of Captisol to meet our current partner needs, and our planned expansion of Captisol capacity will be sufficient to meet future partner needs, our estimates and projections for Captisol demand may not be correct and any supply interruptions could materially adversely impact our operating results. In addition, our plan to invest additional capital for the expansion of Captisol manufacturing capacity may not yield a return on investment if future Captisol sales fall below our expectations.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently depend on our arrangements with our partners and licensees to sell products using our Captisol technology. These agreements generally provide that our partners may terminate the agreements at will. If our partners discontinue sales of products using Captisol, fail to obtain regulatory approval for products using Captisol, fail to satisfy their obligations under their agreements with us, choose to utilize a competing product, or if we are unable to establish new licensing and marketing relationships, our financial results and growth prospects would be materially affected. Furthermore, we maintain significant accounts receivable balances with certain customers purchasing Captisol materials, which may result in the concentration of credit risk. We generally do not require any collateral from our customers to secure payment of these accounts receivable. If any of our major customers were to default in the payment of their obligations to us, our business, operating results and cash flows could be adversely affected.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, under most of our Captisol outlicenses, the amount of royalties we receive will be reduced or will cease when the relevant patent expires. Our low-chloride patents and foreign equivalents are not expected to expire until 2033, our high purity patents and foreign equivalents, are not expected to expire until 2029 and our morphology patents and foreign equivalents, are not expected to expire until 2026 in the United States, but the initially filed patents relating to Captisol expired starting in 2010 in the United States and in 2016 in most countries outside the United States. If our other intellectual property rights are not sufficient to prevent a generic form of Captisol from coming to market and if in such case our partners choose to terminate their agreements with us, our Captisol revenue may decrease significantly.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We rely heavily on collaboration relationships to generate milestone and royalty payments and our collaboration partners have significant discretion when deciding whether to pursue any development program, and any failure by our partners to successfully develop a product candidate or a termination or breach of any of the related agreements could reduce our milestone and license fee revenue, and potentially reduce future royalties.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our strategy for developing and commercializing many of our product candidates includes entering into collaboration agreements, outlicenses, and development funding and royalty purchase agreements with corporate partners and others. These agreements give our collaboration partners significant discretion when deciding whether or not to pursue any development program. Our existing collaborations may not continue or be successful, and we may be unable to enter into future collaboration arrangements to develop and commercialize our unpartnered assets.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, our collaborators may develop products, either alone or with others that compete with the types of products they are developing with us (or that we are developing on our own). This would result in increased competition for our or our partners' programs. If product candidates are approved for marketing under our collaboration programs, revenues we receive will depend on the manufacturing, marketing and sales efforts of our collaboration partners, who generally retain commercialization rights under the collaboration agreements. Generally, our current collaboration partners also have the right to terminate their collaborations at will or under specified circumstances. If any of our collaboration partners breach (for example, by not making required payments when due, or at all) or terminate their agreements with us or otherwise fail to conduct their collaboration activities successfully, including due to insolvency events, ongoing product development under these agreements will be delayed or terminated. Disputes or litigation may also arise with our collaborators (with us and/or with one or more third parties), including those over ownership rights to intellectual property, know-how or technologies developed with our collaborators. Such disputes or litigation could adversely affect our rights to one or more of our product candidates. Any such dispute or litigation could delay, interrupt or terminate the collaboration research, development and commercialization of certain potential products, create uncertainty as to ownership rights of intellectual property, or could result in litigation or arbitration. The occurrence of any of these problems could be time-consuming and expensive and could adversely affect our business.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our collaboration partners may change their strategy or the focus of their development and commercialization efforts with respect to our partnered programs, and the success of our partnered programs could be adversely affected.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If our collaboration partners terminate their collaborations with us or do not commit sufficient resources to the development, manufacture, marketing or distribution of our partnered programs, we could be required to devote additional resources to our partnered programs, seek new collaboration partners or abandon such partnered programs, all of which could reduce our revenues and otherwise have an adverse effect on our business. For example, several of our collaboration partners </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">using our OmniAb antibody platform have terminated their contracts or substantially reduced their investment in the antibodies discovered based on the platform. Although we expect growth in the net number of partners with one more active programs based on antibodies discovered using our OmniAb platform, there can be no assurance that our partners will continue their programs or that we will be able to find new collaboration partners interested in discovering antibodies based on our OmniAb platform.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, biopharmaceutical development is inherently uncertain and very few therapeutic candidates ultimately progress through clinical development and receive approval for commercialization. If our partners do not receive regulatory approval for a sufficient number of therapeutic candidates originating from our partnerships, we may not be able to sustain our business model. </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our product candidates, and the product candidates of our partners, face significant development and regulatory hurdles prior to partnering and/or marketing which could delay or prevent licensing, sales-based royalties and/or milestone revenue.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Before we or our partners obtain the approvals necessary to sell any of our unpartnered assets or partnered programs, we must show through preclinical studies and human testing that each potential product is safe and effective. We and/or our partners have a number of partnered programs and unpartnered assets moving toward or currently awaiting regulatory action.  Failure to show any product's safety and effectiveness could delay or prevent regulatory approval of a product and could adversely affect our business. The product development and clinical trials process is complex and uncertain.  For example, the results of preclinical studies and initial clinical trials may not necessarily predict the results from later large-scale clinical trials.  In addition, clinical trials may not demonstrate a product's safety and effectiveness to the satisfaction of the regulatory authorities. A number of companies have suffered significant setbacks in advanced clinical trials or in seeking regulatory approvals, despite promising results in earlier trials. The FDA may also require additional clinical trials after regulatory approvals are received.  Such additional trials may be expensive and time-consuming, and failure to successfully conduct those trials could jeopardize continued commercialization of a product.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The speed at which we and our partners complete our scientific studies and clinical trials depends on many factors, including, but not limited to, the ability to obtain adequate supplies of the products to be tested and patient enrollment. Patient enrollment is a function of many factors, including the size of the patient population, the proximity of patients to clinical sites, the eligibility criteria for the trial and other potential drug candidates being studied. Delays in patient enrollment for our or our partners&#8217; trials may result in increased costs and longer development times. In addition, our partners have rights to control product development and clinical programs for products developed under our collaborations. As a result, these partners may conduct these programs more slowly or in a different manner than expected.  Moreover, even if clinical trials are completed, we or our partners still may not apply for FDA or foreign regulatory approval in a timely manner or the FDA or foreign regulatory authority still may not grant approval.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our product candidate discovery, early-stage development, and product reformulation programs may require substantial additional capital to complete successfully.  Our partners&#8217; development programs may require substantial additional capital to complete successfully, arising from costs to: conduct research, preclinical testing and human studies; establish pilot scale and commercial scale manufacturing processes and facilities; and establish and develop quality control, regulatory, marketing, sales and administrative capabilities to support these programs. While we expect to fund our research and development activities from cash generated from operations to the extent possible, if we are unable to do so, we may need to complete additional equity or debt financings or seek other external means of financing. These financings could depress our stock price. If additional funds are required to support our operations and we are unable to obtain them on terms favorable to us, we may be required to cease or reduce further development or commercialization of our products, to sell some or all of our technology or assets or to merge with another entity.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our OmniAb antibody platform faces specific risks, including the quality of our antibody discovery platform and technological capabilities and their acceptance by new and existing partners in our market.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We utilize our OmniAb technology platform to discover antibodies for further development and potential commercialization by our partners. As a result, the quality and sophistication of our platform is critical to our ability to conduct our research discovery activities and to deliver more promising antibodies and other drugs and to accelerate and lower the costs of discovery as compared to traditional methods for our partnerships. Failure of antibodies discovered using our platform can occur at any stage of discovery, preclinical or clinical development, and any such failures may reduce our partners&#8217; confidence in our platform. We also believe that pharmaceutical and biotechnology companies are likely to be particularly sensitive to defects and errors in the use of our platform, including if our platform fails to deliver meaningful acceleration of certain research timelines accompanied by results at least as good as the results generated using legacy or other alternative technologies. There can be no guarantee that our platform will meet the expectations of pharmaceutical and biotechnology companies. If we are unsuccessful in achieving and maintaining market acceptance of our platform, our business, financial condition, results of operations and prospects could be adversely affected.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, we face significant competition from other companies selling human antibody-generating rodents, especially mice which compete with our OmniMouse platform, including the VelocImmune mouse, the AlivaMab mouse, the Alloy mouse and the Kymouse. Many of our competitors have greater financial, technical and human resources than we do and may be better equipped to develop, manufacture and market competing antibody platforms. Our competitors may render our OmniAb antibody platform obsolete, or limit the commercial value of any product candidates developed using our platform, by advances in existing technological approaches or the development of new or different approaches, potentially eliminating the advantages that we believe our platform offers.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The OmniAb antibody platform could become subject to more extensive government regulation than we currently anticipate, and regulatory compliance obligations and the investigational exemption and approval processes to which our animals may become subject are expensive, time-consuming and uncertain both in timing and in outcome.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe our OmniAb platform operations are currently subject to limited direct regulation by the FDA, EMA, comparable foreign authorities or other regulatory bodies. However, our business could in future become subject to more direct oversight by the FDA, EMA or other comparable domestic or international agencies. For example, we may be subject to evolving and variable regulations governing the production of genetically engineered organisms. In particular, the FDA regulates animals whose genomes have been intentionally altered, and the FDA considers such alterations to be new animal drugs that may require approvals or exemptions in order to be commercially marketed or for investigational use in the United States. For example, we have been in communication with the FDA regarding the regulatory requirements applicable to our OmniChickens designed to produce human immunoglobulins, and the FDA has advised us that such approvals or exemptions are not required in light of the early stage of our research. However, the FDA may determine that we are not in compliance with the conditions imposed upon us to avoid the requirement for such approvals or exemptions at present or we may later become subject to such approvals or exemptions. Furthermore, while we have no active plans to operate a manufacturing facility designed to comply with current good manufacturing practices (cGMPs), future market pressures or the lack of available capacity at cGMP manufacturing facilities may necessitate our entry into this market. Complying with such regulations may be expensive, time-consuming and uncertain, and if we fail to comply with any applicable requirements enforced by the FDA with respect to our intentionally genetically altered animals or otherwise, we may be subject to administratively or judicially imposed sanctions, including restrictions on our products or operations, warning or untitled letters, civil or criminal penalties, injunctions, product seizures, product detentions, import bans, product recalls, or adverse publicity requirements, any of which could have an adverse effect on our business, financial condition and operating results.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our OmniAb antibody platform utilizes various species of animals that could contract disease or die and could otherwise subject us to controversy and adverse publicity, which may interrupt our business operations or harm our reputation.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our OmniAb platform utilizes animals to discover and produce antibodies. We cannot completely eliminate the risks of animals contracting disease, which from time to time has occurred, or a natural or manmade disaster that could cause death to valuable production animals, in our vivarium facilities, which house our chickens, or those of the contract research organizations (CROs) that maintain our mouse and rat colonies. We cannot make any assurance that we or our CROs will be able to contain or reverse any such instance of disease. Although we maintain backup colonies of our animals, disease or death on a broad scale could materially interrupt business operations as animals are a key part of our antibody discovery programs, which could have a material adverse effect on our results of operations and financial condition.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, genetic engineering and testing of animals has been the subject of controversy and adverse publicity. Animal rights groups and other organizations and individuals have attempted to stop animal testing</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">activities by pressing for legislation and regulation in these areas and by disrupting these activities through protests and other means. To the extent the activities of these groups are successful, our research and development activities and the ability for us and our partners to use our technology platform could be interrupted or delayed, our costs could increase and our reputation could be harmed.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our plan to separate into two independent, publicly traded companies is subject to various risks and uncertainties and may not be completed in accordance with the expected plans or anticipated timeline, or at all and may not achieve the intended benefits, and will involve significant time, expense and management attention, any of which could negatively impact our businesses, financial condition and results of operations.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2021, we announced our intention to split Ligand into two separate, publicly traded companies with one featuring the OmniAb business, including Ab Initio computational antigen design, Icagen&#8217;s ion channel technology, xPloration high-throughput screening technology, and the suite of OmniAb animals used for antibody discovery and the other featuring Ligand&#8217;s existing collection of core royalties, technologies, pipeline and contracts associated with the Pelican protein expression platform and the Captisol business. Although an IPO and eventual distribution of OmniAb shares to Ligand shareholders was the leading option under consideration at that time, due to market conditions and further review from management and advisors, we expect to achieve the separation through a direct spin of 100% of OmniAb equity to shareholders with Ligand capitalizing the OmniAb business directly. Although we currently are pursuing a direct spin, we will continue to evaluate other options to optimize value and ensure flexibility to invest in growth, including keeping the business together. We </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">expect OmniAb to file a Form 10 with the SEC and complete its separation in the first half of 2022. The separation, if pursued, will be subject to market, tax and legal considerations, final approval by our Board of Directors and other customary requirements, and may not occur on the expected timeframe, or at all. Unanticipated developments, including difficulty in separating the assets and resources of our OmniAb business from the rest of our assets and resources, changes to the competitive environment for OmniAb&#8217;s or our respective businesses, possible delays in obtaining or failure to obtain tax opinions, regulatory or other approvals or clearances to approve or facilitate the separation, uncertainty in financial markets and other challenges in executing the separation, as planned, could delay or cause the separation to occur on terms or conditions that are different or less favorable than expected.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Executing the proposed separation also requires significant time and attention from management and other employees, which could distract them from other tasks in operating our business. Our plans to pursue the separation may also have negative effects on relationships with our employees, partners, suppliers, and other third parties, disruptions in operations and ultimately harm our businesses, financial condition, results of operations and prospects. Even if the separation is completed, we may not realize some or all of the anticipated strategic, operational and financial benefits from the separation. Following the proposed separation, the combined value of the common stock of the two publicly-traded companies may not be equal to or greater than what the value of our common stock would have been had the proposed separation not occurred.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business is subject to risks arising from epidemic diseases, such as the recent COVID-19 pandemic, which has impacted and could continue to impact our business.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The current COVID-19 worldwide pandemic has presented substantial public health and economic challenges and is affecting our employees and partners, patients, communities and business operations, as well as the U.S. and global economy and financial markets. International and U.S. governmental authorities in impacted regions continue to take actions in an effort to slow the spread of COVID-19, including issuing varying forms of &#8220;stay-at-home&#8221; orders, and restricting business functions outside of one&#8217;s home. In response, at various times during the pandemic, we have restricted in-person access to our executive offices, our administrative employees are mostly working remotely, and we have limited the number of staff in our research and development laboratories and other facilities.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we have since lifted most of the restrictions we previously imposed and currently do not believe the COVID-19 pandemic is having a material impact on our business, we cannot guarantee that the COVID-19 pandemic, or a similar event, will not impact our operations in the future.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Several of our partners have reported that their operations have been impacted including delays in research and development programs and deprioritizing clinical trials in favor of treating patients who have contracted the virus or to prevent the spread of the virus. This may lead to clinical trial protocol deviations or to discontinuation of treatment for patients who are currently enrolled in the clinical trials being conducted by us or our partners. In addition, certain of our partners have reported negative impacts on product sales which will impact our royalty revenues. Although we believe that we and our partners have adjusted our business practices to the impacts of the COVID-19 pandemic, we may experience disruptions that could severely impact our business, drug manufacturing and supply chain, nonclinical activities and clinical trials and our partners&#8217; business may be impacted in similar ways, including due to:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">delays or difficulties in enrolling patients in clinical trials;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">delays or difficulties in clinical site initiation, including difficulties in recruiting or supporting clinical site investigators and clinical site staff;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">diversion of healthcare resources away from the conduct of clinical trials, including the diversion of hospitals serving as clinical trial sites and hospital staff supporting the conduct of clinical trials;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">interruption of key clinical trial activities, such as clinical trial site monitoring, due to limitations on travel imposed or recommended by federal or state governments, employers and others or interruption of clinical trial subject visits and study procedures, which may impact the integrity of subject data and clinical study endpoints;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">interruption or delays in the operations of the FDA or other regulatory authorities, which may impact review and approval timelines;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">interruption of, or delays in receiving, supplies of Captisol or other product or product candidates from contract manufacturing organizations due to staffing shortages, production slowdowns or stoppages and disruptions in delivery systems, which may result in cancellations of Captisol orders or refunds if we fail to deliver Captisol timely;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">delays in clinical sites receiving the supplies and materials needed to conduct clinical trials and interruption in global shipping that may affect the transport of clinical trial materials;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">interruptions in nonclinical studies due to restricted or limited operations at laboratory facility or those of outsourced service providers;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">limitations on employee resources that would otherwise be focused on the conduct of nonclinical studies or clinical trials, including because of sickness of employees or their families or the desire of employees to avoid contact with large groups of people;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">delays in receiving approval from local regulatory authorities to initiate planned clinical trials;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">changes in local regulations as part of a response to COVID-19 which may require us to change the ways in which clinical trials are conducted, which may result in unexpected costs, or to discontinue the clinical trials altogether;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">delays in necessary interactions with local regulators, ethics committees and other important agencies and contractors due to limitations in employee resources or forced furlough of government employees;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">refusal of the FDA to accept data from clinical trials in affected geographies outside the United States; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">interruption or delays to discovery and development pipelines; and </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">difficulties launching or commercializing products, including due to reduced access to doctors as a result of social distancing protocols. </span></div><div><span><br/></span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, if COVID-19 infects our genetically modified animals which form the basis of our OmniAb platform, or if there is an outbreak among our employees who maintain and care for these animals, we and our partners may be unable to produce antibodies for development. Further, the spread of COVID-19 has had and may continue to severely impact the trading price of shares of our common stock and could further severely impact our ability to raise additional capital on a timely basis or at all.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The COVID-19 pandemic continues to evolve. The extent to which the COVID-19 may impact our business, including our drug manufacturing and supply chain, nonclinical activities, clinical trials and financial condition, including due to impacts on our partners&#8217; businesses, will depend on future developments, which are highly uncertain and cannot be predicted with confidence, the duration of the pandemic, travel restrictions and social distancing in the United States and other countries, business closures or business disruptions and the effectiveness of actions taken in the United States and other countries to contain and treat the disease.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Risks Related to Intellectual Property:</span></div><div><span><br/></span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Third party intellectual property may prevent us or our partners from developing our potential products; our and our partners&#8217; intellectual property may not prevent competition; and any intellectual property issues may be expensive and time consuming to resolve.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The manufacture, use or sale of our potential products or our licensees' products or potential products may infringe the patent rights of others.  If others obtain patents with conflicting claims, we may be required to obtain licenses to those patents or to develop or obtain alternative technology. We may not be able to obtain any such licenses on acceptable terms, or at all.  Any failure to obtain such licenses could delay or prevent us from pursuing the development or commercialization of our potential products.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Generally, our success will depend on our ability and the ability of our partners to obtain and maintain patents and other intellectual property rights for our and their potential products. Our patent position is uncertain and involves complex legal and technical questions for which legal principles are unresolved.&#160;Even if we or our partners do obtain patents, such patents may not adequately protect the technology we own or have licensed.&#160; </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We permit our partners to list our patents that cover their branded products in the Orange Book. If a third party submits an NDA or ANDA for a generic drug product that relies in whole or in part on studies contained in our partner&#8217;s NDA for their branded product, the third party will have the option to certify to the FDA that, in the opinion of that third party, the patents listed in the Orange Book for our partner&#8217;s branded product are invalid, unenforceable, or will not be infringed by the manufacture, use or sale of the third party&#8217;s generic drug product. A third party certification that a new product will not infringe Orange Book-listed patents, or that such patents are invalid, is called a paragraph IV patent certification. If the third party submits a paragraph IV patent certification to the FDA, a notice of the paragraph IV patent certification must be sent to the NDA owner and the owner of the patents that are subject to the paragraph IV patent certification notice once the third-party&#8217;s NDA or ANDA is accepted for filing by the FDA. A lawsuit may then be initiated to defend the patents identified in the notice. The filing of a patent infringement lawsuit within 45 days of the receipt of notice of a paragraph IV patent certification automatically prevents the FDA from approving the generic NDA or ANDA until the earlier of the expiration of a 30-month period, the expiration of the patents, the entry of a settlement order stating that the patents are invalid or not infringed, a decision in the infringement case that is favorable to the NDA or ANDA applicant, or such shorter or longer period as the court may order. If a patent infringement lawsuit is not initiated within the required 45-day period, the third-party&#8217;s NDA or ANDA will not be subject to the 30-month stay.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Several third-parties have challenged, and additional third parties may challenge, the patents covering our partner&#8217;s branded products, including Kyprolis and Evomela, which could result in the invalidation or unenforceability of some or all of the relevant patent claims. We may from time to time become party to litigation or other proceedings as a result of Paragraph IV certifications. For example, as a result of the settlement of one such matter, Teva will be permitted to market a generic version of Evomela</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the United States on June 1, 2026 or earlier under certain circumstances. The terms of the settlement agreement are otherwise confidential. Also, as noted above, Amgen has settled patent litigation related to Kyprolis on confidential terms with several parties, but it has been publicly reported that the U.S. launch date for at least Breckenridge Pharmaceuticals&#8217; applicable generic product will be &#8220;on a date that is held as confidential in 2027 or sooner, depending on certain occurrences.&#8221; </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we cannot assure you that all of the potentially relevant prior art information that was or is deemed available to a person of skill in the relevant art prior to the priority date of the claimed invention-relating to our and our partners&#8217; patents and patent applications has been found. If such prior art exists, it can invalidate a patent or prevent a patent from issuing from a pending patent application, and we or our partners may be subject to a third party pre-issuance submission of prior art to the United States Patent and Trademark Office. Even if patents do successfully issue and even if such patents cover our or our partner&#8217;s products or potential products, third parties may initiate litigation or opposition, interference, re-examination, post-grant review, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">inter partes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> review, nullification or derivation action in court or before patent offices, or similar proceedings challenging the validity, enforceability or scope of such patents, which may result in the patent claims being narrowed or invalidated, may allow third parties to commercialize our or our partners&#8217; products and compete directly with us and our partners, without payment to us or our partners, or limit the duration of the patent protection of our and our partners&#8217; technology and products. </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Litigation or other proceedings to enforce or defend intellectual property rights are often very complex in nature, may be very expensive and time-consuming, may divert our management&#8217;s attention from our core business, and may result in unfavorable results that could adversely impact our ability to prevent third parties from competing with our partner&#8217;s products. Any adverse outcome of such litigation or other proceedings could result in one or more or our patents being held invalid or unenforceable, which could adversely affect our ability to successfully execute our business strategy and negatively impact our financial condition and results of operations. However, given the unpredictability inherent in litigation, we cannot predict or guarantee the outcome of these matters or any other litigation. Regardless of how these matters are ultimately resolved, these matters may be costly, time-consuming and distracting to our management, which could have a material adverse effect on our business.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, periodic maintenance fees, renewal fees, annuity fees and various other governmental fees on patents and or applications will be due to the U.S. and various foreign patent offices at various points over the lifetime of our and our licensees&#8217; patents and/or applications. We have systems in place to remind us to pay these fees, and we rely on our outside patent annuity service to pay these fees when due. Additionally, the U.S. and various foreign patent offices require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process. We employ reputable law firms and other professionals to help us comply, and in many cases, an inadvertent lapse can be cured by payment of a late fee or by other means in accordance with rules applicable to the particular jurisdiction. However, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. If such an event were to occur, it could have a material adverse effect on our business.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any conflicts with the patent rights of others could significantly reduce the coverage of our patents or limit our ability to obtain meaningful patent protection.  For example, our European patent related to Agglomerated forms of Captisol was limited during an opposition proceeding, and the rejection of our European patent application related to High Purity Captisol was upheld on appeal.  In addition, any determination that our patent rights are invalid may result in early termination of our agreements with our license partners and could adversely affect our ability to enter into new license agreements. We also rely on unpatented trade secrets and know-how to protect and maintain our competitive position. We require our employees, consultants, licensees and others to sign confidentiality agreements when they begin their relationship with us. These agreements may be breached, and we may not have adequate remedies for any breach.  In addition, our competitors may independently discover our trade secrets.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may also need to initiate litigation, which could be time-consuming and expensive, to enforce our proprietary rights or to determine the scope and validity of others' rights.  If this occurs, a court may find our patents or those of our licensors invalid or may find that we have infringed on a competitor's rights. In addition, if any of our competitors have filed patent applications in the United States which claim technology we also have invented, the United States Patent and Trademark Office may require us to participate in expensive interference proceedings to determine who has the right to a patent for the technology.  </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The occurrence of any of the foregoing problems could be time-consuming and expensive and could adversely affect our financial position, liquidity and results of operations.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The validity, scope and enforceability of any patents that cover our partners&#8217; biologic product candidate can be challenged by third parties.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For biologics, the Biologics Price Competition and Innovation Act of 2009, BPCIA, provides a mechanism for one or more third parties to seek FDA approval to manufacture or sell biosimilar or interchangeable versions of brand name biological products. Due to the large size and complexity of biological products, as compared to small molecules, a biosimilar must be &#8220;highly similar&#8221; to the reference product with &#8220;no clinically meaningful differences between the two.&#8221; The BPCIA does not require reference product sponsors to list patents in an Orange Book and does not include an automatic 30-month stay of FDA approval upon the timely filing of a lawsuit. The BPCIA, however, does require a formal pre-litigation process which includes the exchange of information between a biosimilar applicant and a reference biologic sponsor that includes the identification of relevant patents and each parties&#8217; basis for infringement and invalidity. After the exchange of this information, sponsors may then initiate a lawsuit within 30 days to defend the patents identified in the exchange. If the biosimilar applicant successfully challenges the asserted patent claims it could result in the invalidation of, or render unenforceable, some or all of the relevant patent claims or result in a finding of non-infringement. Such litigation or other proceedings to enforce or defend intellectual property rights are often very complex in nature, may be very expensive and time-consuming, may divert our management&#8217;s attention from our core business, and may result in unfavorable results that could limit our partners&#8217; ability to prevent third parties from competing with their products or product candidates.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Risks Related to Government Regulation and Legal Proceedings:</span></div><div><span><br/></span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Market acceptance and sales of any approved product will depend significantly on the availability and adequacy of coverage and reimbursement from third-party payors and may be affected by existing and future healthcare reform measures.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales of the products we license to our collaboration partners and the royalties we receive will depend in large part on the extent to which coverage and reimbursement is available from government and health administration authorities, private health maintenance organizations and health insurers, and other healthcare payors. Significant uncertainty exists as to the reimbursement status of healthcare products. Healthcare payors, including Medicare, are challenging the prices charged for medical products and services. Government and other healthcare payors are increasingly attempting to contain healthcare costs by limiting both coverage and the level of reimbursement for medical products. Even if a product is approved by the FDA, insurance coverage may not be available, and reimbursement levels may be inadequate, to cover the costs associated with the research, development, marketing and sale of the product. If government and other healthcare payors do not provide adequate coverage and reimbursement levels for any product, market acceptance and any sales could be reduced.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, legislation is implemented to reign in rising healthcare expenditures. By way of example, in March 2010, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, or collectively, the ACA, was enacted, which included a number of provisions affecting the pharmaceutical industry, including, among other things, annual, non-deductible fees on any entity that manufactures or imports some types of branded prescription drugs and increases in Medicaid rebates owed by manufacturers under the Medicaid Drug Rebate Program. Since its enactment, there have been judicial, executive and Congressional challenges to certain aspects of the ACA. On June 17, 2021, the U.S. Supreme Court dismissed the most recent judicial challenge to the ACA brought by several states without specifically ruling on the constitutionality of the ACA. Prior to the Supreme Court&#8217;s decision, President Biden had issued an executive order to initiate a special enrollment period from February 15, 2021 through August 15, 2021 for purposes of obtaining health insurance coverage through the ACA marketplace. The executive order also instructed certain governmental agencies to review and reconsider their existing policies and rules that limit access to healthcare, including among others, reexamining Medicaid demonstration projects and waiver programs that include work requirements, and policies that create unnecessary barriers to obtaining access to health insurance coverage through Medicaid or the ACA.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other legislative changes have been proposed and adopted since the ACA was enacted, including aggregate reductions of Medicare payments to providers of 2% per fiscal year, which was temporarily suspended from March 1, 2020 through March 31, 2022, and reduced payments to several types of Medicare providers. Moreover, there has recently been heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products, which has resulted in several Congressional inquiries and proposed bills designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drug products. Individual states in the United States have also become increasingly active in implementing regulations designed to control pharmaceutical product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. We cannot predict whether other legislative changes will be adopted, if any, or how such changes would affect our operations or financial condition.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we or our commercialization partners market products in a manner that violates healthcare laws, we may be subject to civil or criminal penalties.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and our collaboration partners are subject to federal and state healthcare laws, including fraud and abuse, anti-kickback, false claims, physician payment transparency and civil monetary penalties. These laws may impact, among other things, financial arrangements with physicians, sales, marketing and education programs and the manner in which any of those activities are implemented. If our operations or those of our collaboration partners are found to be in violation of any of those laws or any other applicable governmental regulations, we or our collaboration partners may be subject to penalties, including civil and criminal penalties, damages, fines, imprisonment, exclusion from government healthcare programs or the curtailment or restructuring of operations, any of which could adversely affect our ability to operate our business and our financial condition.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in and actual or perceived failures to comply with applicable data privacy, security and protection laws, regulations, standards and contractual obligations may adversely affect our business, operations and financial performance.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and our partners may be subject to federal, state, and foreign laws and regulations that govern data privacy and security. The legislative and regulatory landscape for privacy and data protection continues to evolve, and there has been an increasing focus on privacy and data protection issues, which may affect our business and may increase our compliance costs and exposure to liability. In the United States, numerous federal and state laws and regulations govern the collection, use, disclosure, and protection of personal information, including state data breach notification laws, federal and state health information privacy laws, and federal and state consumer protection laws. Each of these laws is subject to varying interpretations by courts and government agencies, creating complex compliance issues. If we fail to comply with applicable laws and regulations we could be subject to penalties or sanctions, including criminal penalties if we knowingly obtain or disclose individually identifiable health information from a covered entity in a manner that is not authorized or permitted by HIPAA or applicable state laws.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also or may become subject to rapidly evolving data protection laws, rules and regulations in foreign jurisdictions. For example, the European Union General Data Protection Regulation (GDPR) governs certain collection and other processing activities involving personal data about individuals in the European Economic Area (EEA). Among other requirements, the GDPR regulates transfers of personal data subject to the GDPR to third countries that have not been found to provide adequate protection to such personal data, including the United States; in July 2020, the Court of Justice of the European Union (CJEU) limited how organizations could lawfully transfer personal data from the EU/EEA to the United States by invalidating the Privacy Shield for purposes of international transfers and imposing further restrictions on the use of standard contractual clauses (SCCs). The European Commission issued revised SCCs on June 4, 2021 to account for the decision of the CJEU and recommendations made by the European Data Protection Board. The revised SCCs must be used for relevant new data transfers from September 27, 2021; existing standard contractual clauses arrangements must be migrated to the revised clauses by December 27, 2022. The new SCCs apply only to the transfer of personal data outside of the EEA and not the United Kingdom; the UK&#8217;s Information Commissioner&#8217;s Office launched a public consultation on its draft revised data transfers mechanisms in August 2021 and laid its proposal before Parliament, with the UK SCCs expected to come into force in March 2022, with a two-year grace period. There is some uncertainty around whether the revised clauses can be used for all types of data transfers, particularly whether they can be relied on for data transfers to non-EEA entities subject to the GDPR. As supervisory authorities issue further guidance on personal data export mechanisms, including circumstances where the SCCs cannot be used, and/or start taking enforcement action, we could suffer additional costs, complaints and/or regulatory investigations or fines, and/or if we are otherwise unable to transfer personal data between and among countries and regions in which we operate, it could affect the manner in which we provide our services, the geographical location or segregation of our relevant systems and operations, and could adversely affect our financial results. </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Compliance with applicable data privacy and security laws, rules and regulations could require us to take on more onerous obligations in our contracts, require us to engage in costly compliance exercises, restrict our ability to collect, use and disclose data, or in some cases, impact our or our partners&#8217; ability to operate in certain jurisdictions. Each of these constantly evolving laws can be subject to varying interpretations. If we fail to comply with any such laws, rules or regulations, we may face government investigations and/or enforcement actions, fines, civil or criminal penalties, private litigation or adverse publicity that could adversely affect our business, financial condition and results of operations.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in funding for the FDA and other government agencies could hinder their ability to hire and retain key leadership and other personnel, or otherwise prevent new products and services from being developed or commercialized in a timely manner, which could negatively impact our business or the business of our partners.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding levels, ability to hire and retain key personnel and accept the payment of user fees, and statutory, regulatory, and policy changes. Average review times at the FDA have fluctuated in recent years as a result. In addition, government funding of other government agencies that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Disruptions at the FDA and other agencies may also slow the time necessary for new drugs and biologics to be reviewed and/or approved by necessary government agencies, which would adversely affect our business or the business of our partners. For example, over the last several years, the U.S. government has shut down several times and certain regulatory agencies, such as the FDA, have had to furlough critical FDA employees and stop critical activities. If a prolonged government shutdown occurs, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our business. If the timing of FDA&#8217;s review and approval of new products is delayed, the timing of our or our partners&#8217; development process may be delayed which would result in delayed milestone revenues and materially harm our operations of business.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Separately, in response to the COVID-19 pandemic, in March 2020, the FDA announced its intention to postpone most inspections of foreign manufacturing facilities, and on March 18, 2020, the FDA temporarily postponed routine surveillance inspections of domestic manufacturing facilities. Subsequently, in July 2020, the FDA resumed certain on-site inspections of domestic manufacturing facilities subject to a risk-based prioritization system. The FDA utilized this risk-based assessment system to assist in determining when and where it was safest to conduct prioritized domestic inspections. Additionally, on April 15, 2021, the FDA issued a guidance document in which the FDA described its plans to conduct voluntary remote interactive evaluations of certain drug manufacturing facilities and clinical research sites, among other facilities. According to the guidance, the FDA may request such remote interactive evaluations where the FDA determines that  remote evaluation would be appropriate based on mission needs and travel limitations. In May 2021, the FDA outlined a detailed plan to move toward a more consistent state of inspectional operations, and in July 2021, the FDA resumed standard inspectional operations of domestic facilities and was continuing to maintain this level of operation as of September 2021. More recently, the FDA has continued to monitor and implement changes to its inspectional activities to ensure the safety of its employees and those of the firms it regulates as it adapts to the evolving COVID-19 pandemic. Regulatory authorities outside the United States may adopt similar restrictions or other policy measures in response to the COVID-19 pandemic. If a prolonged government shutdown occurs, or if global health concerns continue to hinder or prevent the FDA or other regulatory authorities from conducting their regular inspections, reviews, or other regulatory activities, it could significantly impact the ability of the FDA or other regulatory authorities to timely review and process our regulatory submissions, which could have a material adverse effect on our business. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">If plaintiffs bring product liability lawsuits against us or our partners, we or our partners may incur substantial liabilities and may be required to limit commercialization of our approved products and product candidates.</span></div><div><span><br/></span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As is common in our industry, our partners and we face an inherent risk of product liability as a result of the clinical testing of our product candidates in clinical trials and face an even greater risk for commercialized products. Although we are not currently a party to product liability litigation, if we are sued, we may be held liable if any product or product candidate we develop causes injury or is found otherwise unsuitable during product testing, manufacturing, marketing or sale. Regardless of merit or eventual outcome, liability claims may result in decreased demand for any product candidates, partnered products or products that we may develop, injury to our reputation, discontinuation of clinical trials, costs to defend litigation, substantial monetary awards to clinical trial participants or patients, loss of revenue and product recall or withdrawal from the market and the inability to commercialize any products that we develop. We have product liability insurance that covers our clinical trials up to a $10.0&#160;million annual limit. Our insurance coverage may not be sufficient to cover all of our product liability related expenses or losses and may not cover us for any expenses or losses we may suffer. If we are sued for any injury caused by our product candidates, partnered products or any future products, our liability could exceed our total assets.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We face risks related to handling of hazardous materials and other regulations governing environmental safety.</span></div><div><span><br/></span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operations are subject to complex and stringent environmental, health, safety and other governmental laws and regulations that both public officials and private individuals may seek to enforce. Our activities that are subject to these regulations include, among other things, our use of hazardous materials and the generation, transportation and storage of waste. Although we have secured clearance from the EPA historically, and currently are operating in material compliance with applicable EPA rules and regulations, our business could be adversely affected if we discover that we or an acquired business is not in material compliance with these rules and regulations. In the future, we may pursue the use of other surfactant substances that will require clearance from the EPA, and we may fail to obtain such clearance. Existing laws and regulations may also be revised or reinterpreted, or new laws and regulations may become applicable to us, whether retroactively or prospectively, that may have a negative effect on our business and results of operations. It is also impossible to eliminate completely the risk of accidental environmental contamination or injury to individuals. In such an event, we could be liable for any damages that result, which could adversely affect our business.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Risk Related to Our Strategic Transactions:</span></div><div><span><br/></span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Any difficulties from strategic acquisitions could adversely affect our stock price, operating results and results of operations.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may acquire companies, businesses and products that complement or augment our existing business. We may not be able to integrate any acquired business successfully or operate any acquired business profitably. Integrating any newly acquired business could be expensive and time-consuming. Integration efforts often take a significant amount of time, place a significant strain on managerial, operational and financial resources and could prove to be more difficult or expensive than we predict. The diversion of our management's attention and any delay or difficulties encountered in connection with any future acquisitions we may consummate could result in the disruption of our ongoing business or inconsistencies in standards and controls that could negatively affect our ability to maintain third-party relationships. Moreover, we may need to raise additional funds through public or private debt or equity financing, or issue additional shares, to acquire any businesses or products, which may result in dilution for stockholders or the incurrence of indebtedness.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of our efforts to acquire companies, business or product candidates or to enter into other significant transactions, we conduct business, legal and financial due diligence with the goal of identifying and evaluating material risks involved in the transaction. Despite our efforts, we ultimately may be unsuccessful in ascertaining or evaluating all such risks and, as a result, might not realize the intended advantages of the transaction. If we fail to realize the expected benefits from acquisitions we may consummate in the future or have consummated in the past, whether as a result of unidentified risks, integration difficulties, regulatory setbacks, litigation with current or former employees and other events, our business, results of operations and financial condition could be adversely affected. If we acquire product candidates, we will also need to make certain assumptions about, among other things, development costs, the likelihood of receiving regulatory approval and the market for such product candidates. Our assumptions may prove to be incorrect, which could cause us to fail to realize the anticipated benefits of these transactions.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we will likely experience significant charges to earnings in connection with our efforts, if any, to consummate acquisitions. For transactions that are ultimately not consummated, these charges may include fees and expenses for investment bankers, attorneys, accountants and other advisors in connection with our efforts. Even if our efforts are successful, we may incur, as part of a transaction, substantial charges for closure costs associated with elimination of duplicate operations and facilities and acquired IPR&amp;D charges. In either case, the incurrence of these charges could adversely affect our results of operations for particular quarterly or annual periods.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recently acquired Pfenex, as well as Taurus and xCella. We may not be able to integrate these acquired businesses successfully, achieve the expected growth prospects and synergies, expected royalties and other economics or operate such businesses profitably.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, such acquisitions may disrupt our current plans and operations, we may not be able to retain key personnel or preserve existing business relationships following such acquisitions, and may incur unexpected costs, charges or expenses resulting from completion of the acquisitions. </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also recently announced the disposition of Vernalis (R&amp;D) Limited. We may not realize expected future benefits from the Vernalis transaction, including from retained licenses and collaboration economics and as a result of indemnification claims under the Vernalis Purchase Agreement and our retention of certain liabilities associated with the Vernalis business. </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we fail to realize the expected benefits from these acquisitions and Vernalis disposition, our business, results of operations and financial condition could be adversely affected.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Other Risks:</span></div><div><span><br/></span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our operating results may fluctuate significantly, which makes our future operating results difficult to predict and could cause our operating results to fall below expectations or any guidance we may provide.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our quarterly and annual operating results may fluctuate significantly, which makes it difficult for us to predict our future operating results. These fluctuations may occur due to a variety of factors, many of which are outside of our control, including, but not limited to:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">the royalties from the sales of Kyprolis, Evomela and other products sold by our partners; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">the success of our collaboration partners&#8217; preclinical and clinical programs;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">the timing of Captisol purchases for use in clinical trials and commercial products; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">the timing and cost of, and level of investment in, research, development, regulatory approval and commercialization activities relating to our internal development programs, which may change from time to time;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">expenditures that we may incur to acquire or develop additional product candidates and platform technologies; and</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">future accounting pronouncements or changes in our accounting policies. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The cumulative effects of these factors could result in large fluctuations and unpredictability in our quarterly and annual operating results and revenues. This variability and unpredictability could result in our failing to meet the expectations of industry or financial analysts or investors for any period. If our revenue or operating results fall below the expectations of analysts or investors or below any forecasts we may provide to the market, or if the forecasts we provide to the market are below the expectations of analysts or investors, the price of our common stock could decline substantially. Such a stock price decline could occur even when we have met any previously publicly stated revenue or earnings guidance we may provide.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Changes or modifications in financial accounting standards, including those related to revenue recognition, may harm our results of operations.</span></div><div><span><br/></span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the FASB either alone or jointly with other organizations, promulgates new accounting principles that could have an adverse impact on our results of operations. For example, in May 2014, FASB issued an accounting standard for revenue recognition-Accounting Standards Codification Topic 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, or ASC 606-that supersedes most current revenue recognition guidance. The guidance requires a company to recognize revenue upon transfer of goods or services to a customer at an amount that reflects the expected consideration to be received in exchange for those goods or services.  The guidance became effective in fiscal 2018. </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under ASC 606, Ligand estimates and books royalties in the same quarter that our partners report the sale of the underlying product. We rely on our partners&#8217; earning releases and other information from our partners to determine the sales of our partners&#8217; products and to estimate the related royalty revenues. If our partners report incorrect sales, or if our partners delay reporting of their earnings release, our royalty estimates may need to be revised and/or our financial reporting may be delayed. </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our ability to use our net operating loss carryforwards and certain other tax attributes to offset future taxable income may be subject to certain limitations. </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, we had U.S. federal and state net operating loss carryforwards (NOLs) of approximately $119.6 million and $176.3 million, respectively.  Our federal NOLs expire through </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2037 and our state NOLs begin to expire in 2032</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, if not utilized. Under the Tax Act, any federal NOLs arising in taxable years ending after December 31, 2017 will carry forward indefinitely. As of December&#160;31, 2021, we had federal and California research and development tax credit carryforwards of approximately $9.8 million and $29.7 million, respectively. The federal research and development tax credit carryforwards expire in various years through 2041, if not utilized. The California research and development credit will carry forward indefinitely. Under Sections 382 and 383 of Internal Revenue Code of 1986, as amended (Code) if a corporation undergoes an &#8220;ownership change,&#8221; the corporation&#8217;s ability to use its pre-change NOLs and other pre-change tax attributes, such as research tax credits, to offset its future post-change income and taxes may be limited. In general, an &#8220;ownership change&#8221; occurs if there is a cumulative change in our ownership by &#8220;5% shareholders&#8221; that exceeds 50 percentage points over a rolling three-year period. Similar rules may apply under state tax laws. We believe we have experienced certain ownership changes in the past and have reduced our deferred tax assets related to NOLs and research and development tax credit carryforwards accordingly. In the event that it is determined that we have in the past experienced additional ownership changes, or if we experience one or more ownership changes as a result future transactions in our stock, then we may be further limited in our ability to use our NOLs and other tax assets to reduce taxes owed on the net taxable income that we earn in the event that we attain profitability. Furthermore, under the Tax Act, although the treatment of tax losses generated in tax years beginning before December 31, 2017 has generally not changed, tax losses generated in tax years beginning after December 31, 2017 may only offset 80% of our taxable income. This change may require us to pay federal income taxes in future years despite having potentially generated a loss for federal income tax purposes in prior years. Any such limitations on the ability to use our NOLs and other tax assets could adversely impact our business, financial condition and operating results.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The occurrence of a catastrophic disaster could disrupt our business, damage our facilities beyond insurance limits or increase our costs and expenses.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are vulnerable to damage and business disruptions from natural or man-made disasters, such as earthquakes, tornadoes, severe weather conditions, power loss, fire, floods and similar events, as well as from accidental loss or destruction. If any disaster were to occur, our ability to operate our business could be seriously impaired. We have property, liability, and business interruption insurance which may not be adequate to cover our losses resulting from disasters or other similar significant business interruptions, and we do not plan to purchase additional insurance to cover such losses due to the cost of obtaining such coverage. Any significant losses that are not recoverable under our insurance policies could seriously impair our business, financial condition and prospects. Our ability to obtain Captisol supply from our third-party manufactures could be disrupted if the operations of these manufacturers were affected by a natural or man-made disaster or other business interruption. In addition, we rely on our partners to generate most of our revenues through royalties, Captisol sales and development activities and any disruptions to their business as a result of such disasters could negatively impact our revenues.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We rely on information technology and any failure, inadequacy, interruption or security lapse of that technology, including any cyber security incidents, could harm our ability to operate our business effectively.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business is increasingly dependent on critical, complex and interdependent information technology systems, including internet-based systems, to support business processes as well as internal and external communications. We operate some of these systems and networks, but we also rely on third-party providers for various products and services across our operations. Despite the implementation of security measures, our information technology systems and those of our partners and third party service providers are vulnerable to damage from cyber-attacks, computer viruses and malware (e.g. ransomware), security breaches, unauthorized access, natural disasters, terrorism, war and telecommunication and electrical failures. </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Attacks upon information technology systems are increasing in their frequency, levels of persistence, sophistication and intensity, and are being conducted by sophisticated and organized groups and individuals with a wide range of motives and expertise. Furthermore, because the technologies used to obtain unauthorized access to, or to sabotage or disrupt, systems change frequently and often are not recognized until launched against a target, we may be unable to anticipate these techniques or implement adequate preventative measures. We may also experience security breaches that may remain undetected for an extended period.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if identified, we may be unable to adequately investigate or remediate incidents or breaches due to attackers increasingly using tools and techniques that are designed to circumvent controls, to avoid detection, and to remove or obfuscate forensic evidence.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of the COVID-19 pandemic, we may also face increased cybersecurity risks due to our reliance on internet technology and the number of our and our service providers&#8217; employees who are (and may continue to be) working remotely, which may create additional opportunities for cybercriminals to exploit vulnerabilities. The White House, SEC and other regulators have also increased their focus on companies&#8217; cybersecurity vulnerabilities and risks.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and certain of our service providers are from time to time, subject to cyberattacks and security incidents. While we do not believe that we have experienced any significant system failures, accidents or security breaches, if such an event were to occur and cause interruptions in our or our critical third parties&#8217; operations, it could lead to the loss of trade secrets or other intellectual property, as well as the public exposure of personal information of our employees and others, and could result in a material disruption of our clinical and commercialization activities and business operations, in addition to possibly requiring substantial expenditures to remedy. To the extent that any disruption or security breach were to result in a loss of, or damage to, our data or applications, or inappropriate disclosure of confidential or proprietary information, we could incur liability and our business, reputation, and financial condition could be harmed. Any losses, costs or liabilities may not be covered by, or may exceed the coverage limits of, any or all applicable insurance policies.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The occurrence of a catastrophic disaster could damage our facilities beyond insurance limits or we could lose key data which could cause us to curtail or cease operations.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are vulnerable to damage and/or loss of vital data from natural disasters, such as earthquakes, tornadoes, power loss, fire, floods and similar events, as well as from accidental loss or destruction. If any disaster were to occur, our ability to operate our business could be seriously impaired. We have property, liability, and business interruption insurance which may not be adequate to cover our losses resulting from disasters or other similar significant business interruptions, and we do not plan to purchase additional insurance to cover such losses due to the cost of obtaining such coverage. Any significant losses that are not recoverable under our insurance policies could seriously impair our business, financial condition and prospects.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Conversion of our outstanding convertible notes may result in losses, result in the dilution of existing stockholders, create downward pressure on the price of our common stock, and restrict our ability to take advantage of future opportunities.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2018, we issued $750.0 million principal amount of the 2023 Notes. The sale of the 2023 Notes may affect our earnings per share figures, as accounting procedures require that we include in our calculation of earnings per share the number of shares of our common stock into which the 2023 Notes are convertible. The convertible notes may be converted into cash and shares of our common stock, if any (subject to our right or obligation to pay cash in lieu of all or a portion of such shares).  If shares of our common stock are issued to the holders of the convertible notes upon conversion, there will be dilution to our shareholders equity and the market price of our shares may decrease due to the additional selling pressure in the market. Any downward pressure on the price of our common stock caused by the sale or potential sale of shares issuable upon conversion of the convertible notes could also encourage short sales by third parties, creating additional selling pressure on our stock. Upon the occurrence of certain circumstances, holders of the convertible notes may require us to purchase all or a portion of their notes for cash, which may require the use of a substantial amount of cash. If such cash is not available, we may be required to sell other assets or enter into alternate financing arrangements at terms that may or may not be desirable. The existence of the convertible notes and the obligations that we incurred by issuing them may restrict our ability to take advantage of certain future opportunities, such as engaging in future debt or equity financing activities. </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, we had $343.3 million aggregate principal amount of 2023 Notes. The notes are convertible into cash, and if applicable, shares of our common stock under certain circumstances, including trading price conditions related to our common stock. Upon conversion, we are required to record a gain or loss for the difference between the fair value of the notes to be extinguished and their corresponding net carrying value. The fair value of the notes to be extinguished depends on our current incremental borrowing rate. If our incremental borrowing rate at the time of conversion is lower than the implied interest rate of the notes, we will record a loss in our consolidated statement of income during the period in which the notes are converted. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment charges pertaining to goodwill, identifiable intangible assets or other long-lived assets from our mergers and acquisitions could have an adverse impact on our results of operations and the market value of our common stock.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total purchase price pertaining to our acquisitions in recent years have been allocated to net tangible assets, identifiable intangible assets, in-process research and development and goodwill. To the extent the value of goodwill or identifiable intangible assets or other long-lived assets become impaired, we will be required to incur material charges relating to the impairment. Any impairment charges could have a material adverse impact on our results of operations and the market value of our common stock.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our investments are subject to market and credit risks that could diminish their value and these risks could be greater during periods of extreme volatility or disruption in the financial and credit markets, which could adversely impact our business, financial condition, results of operations, liquidity and cash flows.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our investments are subject to risks of credit defaults and changes in market values. Periods of macroeconomic weakness or recession, heightened volatility or disruption in the financial and credit markets could increase these risks, potentially resulting in other than temporary impairment of assets in our investment portfolio. Any event reducing the estimated fair value of these securities, other than on a temporary basis, could have a material and adverse effect on our business, results of operations, financial condition, liquidity and cash flows. If our investment manager, fails to react appropriately to difficult market, economic and geopolitical conditions, our investment portfolio could incur material losses.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a risk management framework in place to identify, assess and prioritize risks, including the market and credit risks to which our investments are subject. As part of that framework, we test our investment portfolio based on various market scenarios. Under certain stressed market scenarios, unrealized losses on our investment portfolio could lead to material reductions in its carrying value.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A decline in fair value below the amortized cost of a security requires management to assess whether an impairment has occurred. The decision on whether to record an impairment is determined in part by our assessment of the financial condition and prospects of a particular issuer, projections of future cash flows and recoverability of the particular security as well as management&#8217;s assertion of whether it is more likely than not that we will sell the particular security before recovery.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our charter documents and concentration of ownership may hinder or prevent change of control transactions.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Provisions contained in our certificate of incorporation and bylaws may discourage transactions involving an actual or potential change in our ownership.  In addition, our Board of Directors may issue shares of common or preferred stock without any further action by the stockholders. Our directors and certain of our institutional investors collectively beneficially own a significant portion of our outstanding common stock. Such provisions and issuances may have the effect of delaying or preventing a change in our ownership. If changes in our ownership are discouraged, delayed or prevented, it would be more difficult for our current Board of Directors to be removed and replaced, even if you or our other stockholders believe that such actions are in the best interests of us and our stockholders.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our amended and restated bylaws provide that the Court of Chancery of the State of Delaware will be the exclusive forum for substantially all disputes between us and our stockholders, which could limit our stockholders&#8217; ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees.</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our amended and restated bylaws provide that the Court of Chancery of the State of Delaware is the exclusive forum for (i) any derivative action or proceeding brought on our behalf, (ii) any action asserting a claim of breach of a fiduciary duty owed by our directors, officers or other employees to us or our stockholders, (iii) any action asserting a claim arising pursuant to any provision of the General Corporation Law of Delaware or our amended and restated certificate of incorporation or amended and restated bylaws, or (iv) any action asserting a claim governed by the internal affairs doctrine. To the extent that any such claims may be based upon federal law claims, Section 27 of the Exchange Act creates exclusive federal jurisdiction over all suits brought to enforce any duty or liability created by the Exchange Act or the rules and regulations thereunder. Furthermore, Section 22 of the Securities Act provides for concurrent jurisdiction for federal and state courts over all suits brought to enforce any duty or liability created by the Securities Act or the rules and regulations thereunder, and as such, the exclusive jurisdiction clauses set forth above would not apply to such suits. The choice of forum provisions in our amended and restated bylaws may limit a stockholder&#8217;s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers or other employees, which may discourage such lawsuits against us and our directors, officers and other employees. By agreeing to these provisions, however, stockholders will not be deemed to have waived our compliance with the federal securities laws and the rules and regulations thereunder. Furthermore, the enforceability of similar choice of forum provisions in other companies&#8217; certificates of incorporation and bylaws has been challenged in legal proceedings, and it is possible that a court could find these types of provisions to be inapplicable or unenforceable. If a court were to find the choice of forum provisions in our amended and restated bylaws to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving such action in other jurisdictions, which could adversely affect our business and financial condition.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our stock price has been volatile and could experience a sudden decline in value.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The market prices for securities of biotechnology and pharmaceutical companies have historically been highly volatile, and the market has recently experienced significant price and volume fluctuations that are unrelated to the operating performance of particular companies. Continued volatility in the overall capital markets could reduce the market price of our common stock in spite of our operating performance. Further, high stock price volatility could result in higher share-based compensation expense.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our common stock has experienced significant price and volume fluctuations and may continue to experience volatility in the future. Many factors may have a significant impact on the market price of our common stock, including, but not limited to, the following factors: results of or delays in our preclinical studies and clinical trials; the success of our collaboration agreements; publicity regarding actual or potential medical results relating to products under development by us or others; announcements of technological innovations or new commercial products by us or others; developments in patent or other proprietary rights by us or others; market perception of our plan to spin out the OmniAb business; comments or opinions by securities analysts or major stockholders or changed securities analysts' reports or recommendations; future sales or shorting of our common stock by existing stockholders; regulatory developments or changes in regulatory guidance; litigation or threats of litigation; economic and other external factors or other disaster or crises; the departure of any of our officers, directors or key employees; period-to-period fluctuations in financial results; and price and volume fluctuations in the overall stock market.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our results of operations and liquidity needs could be materially negatively affected by market fluctuations and economic downturn.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our results of operations could be materially negatively affected by economic conditions generally, both in the United States and elsewhere around the world. Concerns over inflation, energy costs, geopolitical issues, public health emergencies, the availability and cost of credit, and the U.S. financial markets have in the past contributed to, and may continue in the future to contribute to, increased volatility and diminished expectations for the economy and the markets. For example, the outbreak of a novel strain of coronavirus has affected the People&#8217;s Republic of China and elsewhere and has affected worldwide equity markets. Domestic and international equity markets periodically experience heightened volatility and turmoil. These events may have an adverse effect on us. In the event of a market downturn, our results of operations could be adversely affected by those factors in many ways, including making it more difficult for us to raise funds if necessary, and our stock price may further decline. We cannot provide assurance that our investments are not subject to adverse changes in market value. If our investments experience adverse changes in market value, we may have less capital to fund our operations.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span><br/></span></div><div id="i0fa6f906fb2e4e30bc5e873d2bb6a82c_19"></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:9.750%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:88.050%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Item&#160;1B.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unresolved Staff Comments</span></td></tr></table></div><div style="margin-top:5pt;text-indent:24pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:400;line-height:120%">&#160;</span></div><div id="i0fa6f906fb2e4e30bc5e873d2bb6a82c_22"></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:9.750%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:88.050%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Item&#160;2.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Properties</span></td></tr></table></div><div style="margin-top:5pt;text-indent:24pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our principal facilities leased as of December&#160;31, 2021, including the location and size of each facility, and their designated use. We also lease facilities in other locations. In 2022, we are expanding our office and research and development facilities in Emeryville and will lease approximately 35,000 square feet of space under leases expiring in 2032. We believe our facilities are adequate for our current and near-term needs, and we will be able to locate additional facilities, as needed. </span></div><div style="margin-top:5pt;text-indent:24pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.058%"><tr><td style="width:1.0%"></td><td style="width:13.835%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.568%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:42.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.791%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Location</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Approximate <br/>Square Feet</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operation</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Lease Expiration Date</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">San Diego, CA</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,000</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office and laboratory</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2024</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Emeryville, CA</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,000</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate headquarter office and laboratory</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2032</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Durham, NC</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,000</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office and laboratory</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 2029</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Las Vegas, NV</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,100</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2022</span></td></tr></table></div><div style="margin-top:5pt;text-indent:24pt"><span><br/></span></div><div id="i0fa6f906fb2e4e30bc5e873d2bb6a82c_25"></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:9.750%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:88.050%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Item&#160;3.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Legal Proceedings</span></td></tr></table></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Item 8. Financial Statements and Supplementary Data&#8212;Notes to Consolidated Financial Statements&#8212;Note (10), Commitments and Contingencies&#8212;Legal Proceedings.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;</span></div><div><span><br/></span></div><div id="i0fa6f906fb2e4e30bc5e873d2bb6a82c_28"></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:9.750%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:88.050%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Item&#160;4.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Mine Safety Disclosures</span></td></tr></table></div><div style="margin-top:5pt;text-indent:24pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="i0fa6f906fb2e4e30bc5e873d2bb6a82c_31"></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div id="i0fa6f906fb2e4e30bc5e873d2bb6a82c_34"></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:9.750%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:88.050%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Item&#160;5.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters, and Issuer Purchases of Equity Securities</span></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><span><br/></span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our common stock is traded on the Nasdaq Global Market under the symbol &#8220;LGND.&#8221; As of February&#160;23, 2022, there were approximately 398 holders of record of the common stock.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Except for 2007, during which we declared a cash dividend on our common stock of $2.50 per share, we have not paid any dividends on our common stock in the past and currently do not expect to pay cash dividends or make any other distributions on common stock in the future. We expect to retain our future earnings, if any, for use in the operation and expansion of our business, to pay down debt and potentially for share repurchases. Any future determination to pay dividends on common stock will be at the discretion of our board of directors and will depend upon our financial condition, results of operations, capital requirements and such other factors as the board deems relevant. </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the fiscal year ended December&#160;31, 2021, we did not repurchase any shares of our common stock under the stock repurchase program approved by our board of directors in September 2019, under which we may acquire up to $500 million of our common stock in open market and negotiated purchases for a period of up to three years. Authorization to repurchase $248.8 million of our common stock remained available as of December&#160;31, 2021.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by Item 201(d) of Regulation S-K is incorporated by reference to the 2022 Annual Meeting Proxy Statement as defined in Item 10 below.</span></div><div style="margin-bottom:6pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Performance Graph</span></div><div style="margin-bottom:6pt;text-indent:24pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The graph below shows the five-year cumulative total stockholder return assuming the investment of $100 and is based on the returns of the component companies weighted monthly according to their market capitalizations. The graph compares total stockholder returns of our common stock, of all companies traded on the Nasdaq Stock market, as represented by the Nasdaq Composite</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Index, and of the Nasdaq Biotechnology Stock Index, as prepared by The Nasdaq Stock Market Inc.</span></div><div style="margin-bottom:6pt;text-indent:24pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The stockholder return shown on the graph below is not necessarily indicative of future performance and we will not make or endorse any predictions as to future stockholder returns.</span></div><div style="margin-top:9pt;text-indent:24pt"><img src="lgnd-20211231_g3.jpg" alt="lgnd-20211231_g3.jpg" style="height:367px;margin-bottom:5pt;vertical-align:text-bottom;width:684px"/></div><div style="margin-top:9pt;text-align:right;text-indent:24pt"><span><br/></span></div><div style="margin-top:9pt;text-align:center;text-indent:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Value of $100 Invested Over Time</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.497%"><tr><td style="width:1.0%"></td><td style="width:37.833%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.607%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:8.269%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.446%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.269%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.607%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.269%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.607%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.108%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.607%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.593%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.607%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.278%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12/31/2016</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12/31/2017</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12/31/2018</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12/31/2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12/31/2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12/31/2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Ligand</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100.00&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">134.76&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">133.55&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">102.64&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">97.87&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">152.01&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">NASDAQ Composite-Total Return</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100.00&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">129.64&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">125.96&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">172.18&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">249.51&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">304.85&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">NASDAQ Biotechnology Index</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">121.66&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">110.88&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">138.72&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">175.38&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">175.41&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">41</span></div></div></div><div id="i0fa6f906fb2e4e30bc5e873d2bb6a82c_37"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:9.750%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:88.050%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Item&#160;6.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">[RESERVED]</span></td></tr></table></div><div style="margin-bottom:6pt;text-indent:24pt"><span><br/></span></div><div style="margin-bottom:6pt"><span><br/></span></div><div id="i0fa6f906fb2e4e30bc5e873d2bb6a82c_40"></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:9.750%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:88.050%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Item&#160;7.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></td></tr></table></div><div><span><br/></span></div><div id="i0fa6f906fb2e4e30bc5e873d2bb6a82c_43"></div><div style="margin-bottom:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Management's Discussion and Analysis of Financial Condition and Results of Operations (MD&amp;A) will help readers understand our results of operations, financial condition, and cash flows. It is provided in addition to the accompanying consolidated financial statements and notes. Comparisons under this heading refer to twelve months ended December&#160;31, 2021 and 2020, respectively, unless otherwise indicated. </span></div><div style="margin-bottom:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our MD&amp;A is organized as follows:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Results of Operations.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Detailed discussion of our revenue and expenses for twelve months ended December&#160;31, 2021 and 2020. A comparison of our results of operations for twelve months ended December&#160;31, 2020 and 2019 can be found under &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; in our Annual Report on Form 10-K for the fiscal year ended December 31, 2020, filed with the SEC on February 24, 2021.</span></div><div><span><br/></span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Liquidity and Capital Resources.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Discussion of key aspects of our consolidated statements of cash flows, changes in our financial position, and our financial commitments.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Critical Accounting Policies and Estimates. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Discussion of significant changes we believe are important to understand the assumptions and judgments underlying our consolidated financial statements.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Recent Accounting Pronouncements.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> For summary of recent accounting pronouncements applicable to our consolidated financial statements, see &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Item 8. Financial Statements and Supplementary Data&#8212;Notes to Consolidated Financial Statements&#8212;Note (1), Basis of Presentation and Summary of Significant Accounting Policies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.&#8221;</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations</span></div><div><span><br/></span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial results for the year ended December 31, 2021 in this report differ from those included in our earnings release issued February 17, 2022 in that the earnings did not reflect an adjustment to the income tax benefit of $0.4 million that we identified subsequent to the issuance of our earnings release. </span></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.222%"><tr><td style="width:1.0%"></td><td style="width:59.200%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.072%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.551%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.072%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.551%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.072%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.551%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.072%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.559%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">% Change</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalties</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,927&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,796&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,131&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Captisol Sales</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">164,250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109,959&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,291&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract Revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,956&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,664&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,292&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">277,133&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">186,419&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90,714&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div><div style="text-indent:27pt"><span><br/></span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Royalty revenue is a function of our partners' product sales and the applicable royalty rate. Kyprolis royalty rate is under a tiered royalty rate structure with the highest being 3.0%. Evomela has a fixed royalty rate of 20%. Royalty revenue increased in 2021 as compared to 2020 driven primarily by increases in sales of Evomela and Kryprolis plus the additional royalties from the sale of drugs using the Pelican platform - Rylaze, Pneumosil and Teriparatide. Captisol sales increased year over year in 2021 primarily due to shipments to Gilead for manufacturing Veklury (remdesivir). Contract revenue increased year over year in 2021 due to the continued growth in the OmniAb discovery platform as well as milestone revenue from the acquisitions of Icagen in April 2020 and Pfenex in October 2020.</span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table represents royalty revenue by program:</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:22.800%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.949%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.656%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.070%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.706%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.949%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.897%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.073%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021 Estimated Partner Product Sales</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Effective Royalty Rate</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021 Royalty Revenue </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020 Estimated Partner Product Sales</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Effective Royalty Rate</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020 Royalty Revenue</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Kyprolis</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,148.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.4%</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,094.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.3%</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Evomela</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">50.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20.0%</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20.0%</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">288.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.9%</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">178.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.2%</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,488.1&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">48.9&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,305.7&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33.8&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating Costs and Expenses</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:55.058%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.070%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.310%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.724%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.139%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(Dollars in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">% Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of Captisol</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">62,176&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30,419&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31,757&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">104&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of intangibles</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">47,167&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23,442&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23,725&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">69,012&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">59,392&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,620&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">57,483&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">64,435&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6,952)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other operating income </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(37,600)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(37,600)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total operating costs and expenses</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">198,238&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">177,688&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,550&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div><span><br/></span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total operating costs and expenses for 2021 increased $20.6 million or 12% compared with 2020. </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of Captisol increased year over year in 2021 primarily due to higher sales of Captisol during 2021. </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization of intangibles increased year over year in 2021 primarily due to the acquisition of Pfenex in October 2020. </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At any one time, we are working on multiple programs. As such, we generally do not track our R&amp;D expenses on a specific program basis. Our R&amp;D expenses increased year over year in 2021 due to the acquisitions of Icagen in April 2020 and Pfenex in October 2020, which primarily consisted of salaries and lab costs associated with Icagen ($16.5 million) and Pfenex ($22.7 million). </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses increased year over year in 2020 primarily due to $20.7 million acquisition and integration related expenses associated with the Pfenex acquisition. </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other operating income in 2021 was due to reducing the fair value of the CVR liability associated to the acquisition of Pfenex to zero, as the CVR payment expiration date passed on December 31, 2021 without achieving the triggering event. We did not have any other operating income in 2020.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not provide forward-looking estimates of costs and time to complete our ongoing research and development projects as such estimates would involve a high degree of uncertainty. Uncertainties include our inability to predict the outcome of research and clinical studies, regulatory requirements placed upon us by regulatory authorities such as the FDA and EMA, our inability to predict the decisions of our partners, our ability to fund research and development programs, competition from other entities of which we may become aware in future periods, predictions of market potential for products that may be derived from our work, and our ability to recruit and retain personnel or third-party contractors with the necessary knowledge and skills to perform certain research. Refer to &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Item 1A. Risk Factors</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; for additional discussion of the uncertainties surrounding our research and development initiatives.</span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other income (expense)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.122%"><tr><td style="width:1.0%"></td><td style="width:60.404%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.339%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.749%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.897%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(Dollars in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">% Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gain (loss) from short-term investments</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,997)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(16,933)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,936&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(76)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">886&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,078&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7,192)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(89)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(19,626)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(27,420)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,794&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other expense, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8,860)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(108)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8,752)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8104)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total other income (expense), net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(31,597)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(36,383)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,786&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div><span><br/></span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fluctuation in the gain (loss) from short-term investments is primarily driven by the changes in the fair value of our ownership in Viking common stock (an unrealized loss of $9.6 million in 2021 as compared to an unrealized loss of $19.0 million in 2020). </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest income consists primarily of interest earned on our short-term investments. The year over year decrease in 2021 resulted from the decrease in our short-term investment balances due to the usage of funds for the 2023 Notes repurchases.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense includes the 0.75% coupon cash interest expense in addition to the non-cash accretion of discount (including the amortization of debt issuance costs) on our 2023 Notes. The year over year decrease in 2021 was primarily due to lower average debt outstanding balance as compared to the prior year. The 2019 Notes were paid off upon the maturity date in August 2019. During 2021, we repurchased $152.0&#160;million in principal of the 2023 Notes for $156.0&#160;million in cash, including accrued interest of $0.3&#160;million. See &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Item 8. Financial Statements and Supplementary Data&#8212;Notes to Consolidated Financial Statements&#8212;Note (7), Convertible Senior Notes.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other expense, net, increased year over year in 2021 primarily due to a $7.3 million loss on our debt extinguishments compared to $2.5 million loss on debt extinguishments in 2020. See additional information in &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Item 8. Financial Statements and Supplementary Data&#8212;Notes to Consolidated Financial Statements&#8212;Note (1), Basis of Presentation and Summary of Significant Accounting Policies - Commercial License and Other Economic Rights.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;  </span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income tax benefit (expense)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.660%"><tr><td style="width:1.0%"></td><td style="width:58.181%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.548%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.780%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.548%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.548%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.035%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(Dollars in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">% Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income before income tax expense (benefit)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">47,298&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(10,538)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">57,836&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(549)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income tax benefit (expense)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,840&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,553&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,287&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">57,138&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,985)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">60,123&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,014)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Effective Tax Rate</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our effective tax rate for 2021 and 2020 was (21)% and 72%, respectively. Our tax rate is affected by recurring items, such as the U.S. federal and state statutory tax rates and the relative amounts of income we earn in those jurisdictions, which we expect to be fairly consistent in the near term. It is also affected by discrete items that may occur in any given year, but are not consistent from year to year. In 2021, the variance from the U.S. federal statutory rate of 21% was primarily attributable to the mix of earnings in jurisdictions with lower statutory rates than the U.S. federal statutory tax rate, primarily due to excess benefits from shared-based compensation. In 2020, the variance from the U.S. federal statutory rate of 21% was primarily attributable to the mix of earnings in jurisdictions with lower statutory rates than the U.S. federal statutory tax rate, primarily the United Kingdom. The items below also had an impact on the difference between our statutory U.S. rate.</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">$11.9 million (25.2%) decrease due to excess tax benefits from share-based compensation which are recorded as a discrete item within the provision for income tax pursuant to ASU 2016-09</span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">$8.2 million (17.3%) decrease due to the revaluation of contingent value rights</span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">$3.2 million (6.8%) increase from Section 162(m) limitation</span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">$2.7 million (5.7%) decrease from research and development tax credits</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="padding-left:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2020</span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">$2.4 million (22.9%) increase from Section 162(m) limitation</span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">$1.7 million (15.7%) decrease from the foreign-derived intangible income deduction</span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">$1.5 million (13.8%) increase from state income taxes</span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">$0.9 million (8.3%) increase due to non-deductible transaction costs primarily related to the acquisition of Pfenex</span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">$0.7 million (6.6%) decrease from research and development tax credits</span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">$0.3 million (3.4%) decrease due to excess tax benefits from share-based compensation which are recorded as a discrete item within the provision for income tax pursuant to ASU 2016-09</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt"><span><br/></span></div><div style="text-indent:36pt"><span><br/></span></div><div id="i0fa6f906fb2e4e30bc5e873d2bb6a82c_46"></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2021, we had approximately $341.1 million in cash, cash equivalents, and short-term investments</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Cash and cash equivalents and short-term investments decreased by $70.1 million from last year, due to factors described in the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash Flow Summary</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> below. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our primary source of liquidity, other than our holdings of cash, cash equivalents, and investments, which decreased during 2021 primarily from extinguishment of debt, has been cash flows from operations. Our ability to generate cash from operations provides us with the financial flexibility we need to meet operating, investing, and financing needs.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Historically, we have liquidated our short-term investments and/or issued debt and equity securities to finance our business needs as a supplement to cash provided by operating activities. Our short-term investments include U.S. government debt securities, investment-grade corporate debt securities, mutual funds and certificates of deposit. We have established guidelines relative to diversification and maturities of our investments in order to provide both safety and liquidity. These guidelines are periodically reviewed and modified to take advantage of trends in yields and interest rates. Additionally, we own certain securities which are classified as short-term investments that we received as a result of a milestone and an upfront license payment as well as 6.7 million shares of common stock in Viking.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2014, we issued the 2019 Notes with aggregate principal amount of $245.0 million. During 2018, $217.7 million in principal of the 2019 Notes were converted into cash. In June 2019, we received notices for conversion of $1.0 million of principal amount of the 2019 Notes, which were settled in cash upon the 2019 Notes' maturity date in August 2019. On August 15, 2019, the 2019 Notes maturity date, we paid the noteholders the remaining $26.3 million principal amount. </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2018, we issued the 2023 Notes with an aggregate principal amount of $750.0 million. A portion of the proceeds from such issuance totaling $49.7 million were used to repurchase 260,000 shares of our common stock. During 2020, we repurchased $254.7 million in principal of the 2023 Notes for $222.8 million in cash, including accrued interest of $0.6 million. During 2021, we repurchased $152.0 million in principal of the 2023 Notes for $156.0 million in cash, including accrued interest of $0.3 million. After the repurchases, $343.3 million in principal amount of the 2023 Notes remain outstanding as of December 31, 2021. During February 2022, we repurchased additional $125.5&#160;million in principal of the 2023 Notes for $123.9&#160;million in cash, including accrued interest of $0.3&#160;million. </span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may continue to use cash on hand to repurchase additional 2023 Notes through open-market transactions, including through Rule 10b5-1 trading plan to facilitate open-market repurchases, or otherwise, from time to time. The timing and amount of repurchase transactions will be determined by management based on the evaluation of market conditions, trading price of the 2023 Notes, legal requirements and other factors. The 2023 Notes were not convertible as of December&#160;31, 2021. It is our intent and policy to settle conversions through combination settlement, which essentially involves payment in cash equal to the principal portion and delivery of shares of common stock for the excess of the conversion value over the principal portion. See detail in &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Item 8. Financial Statements and Supplementary Data&#8212;Notes to Consolidated Financial Statements&#8212;Note (7), Convertible Senior Notes.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are obligated to make payments to operating leases, including rental commitments on leases that have not yet commenced. For information on these obligations, see detail in &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Item 8. Financial Statements and Supplementary Data&#8212;Notes to Consolidated Financial Statements&#8212;Note (6), Leases.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also have commitments under our supply agreement with Hovione for Capitsol purchases. Total purchase obligation as of December 31, 2021 was $40.9 million, of which $24.0 million is expected to be paid within a year and the remain amount is expected to be paid between 1 to 3 years.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2018, our Board of Directors authorized us to repurchase up to $200.0 million of our common stock from time to time over a period of up to three years. On January 23, 2019, our Board of Directors increased the share repurchase authorization by $150.0 million. The available amount under the $350.0 million repurchase plan was fully utilized during the third quarter of 2019.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 11, 2019, our Board of Directors approved a stock repurchase program authorizing the repurchase of up to $500.0 million of our common stock from time to time over the next three years. We expect to acquire shares primarily through open-market transactions and have entered into a Rule 10b5-1 trading plan, and may enter into additional Rule 10b5-1 trading plans in the future, to facilitate open-market repurchases. The timing and amount of repurchase transactions will be determined by management based on our evaluation of market conditions, share price, legal requirements and other factors. Our prior $350.0 million stock repurchase program mentioned above was terminated in connection with the approval of the new stock repurchase program. Authorization to repurchase $248.8 million of our common stock remained available as of December&#160;31, 2021. See &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Item 5. Market for Registrant's Common Equity, Related Stockholder Matters, and Issuer Purchase of Equity Securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.&#8221;</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that existing funds, cash generated from operations and existing sources of and access to financing are adequate to satisfy our needs for working capital; capital expenditure and debt service requirements; continued advancement of research and development efforts; potential stock repurchases; and other business initiatives we plan to strategically pursue, including acquisitions and strategic investments. </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, we had $11.1 million in fair value of contingent consideration liabilities associated with the acquisitions to be settled in future periods.</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Flow Summary</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.391%"><tr><td style="width:1.0%"></td><td style="width:58.335%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.542%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.678%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.542%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.678%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.542%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.683%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash provided by (used in):</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Operating activities</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">78,798&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">54,586&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(29,336)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Investing activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30,523&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">231,648&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">466,918&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Financing activities</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(137,761)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(310,545)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(485,172)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2021, we generated cash from operations, primarily from issuance of common stock under employee stock plans.  During the year we generated cash from investing activities due to the proceeds from the sale and maturity of short-term investments.  We used cash for financing activities, including the payments related to the extinguishment of certain 2023 Notes.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, we generated cash from operations, from the sale of Vernalis R&amp;D business and from issuance of common stock under employee stock plans. During the year we used cash for investing activities, including the acquisition of Pfenex, Icagen, xCella and Taurus. We also used cash for financing activities, including the payments related to the extinguishment of certain 2023 Notes and stock repurchases.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2019, we generated $827 million from the sale of the Promacta license (including $14.2 million recorded to revenue related to the Promacta royalty for the period between January 1, 2019 and March 6, 2019), used cash for net purchases of short-term investments, used $453.0 million to repurchase our common stock, used $103.8 million to pay federal and state estimated income taxes, paid off the remaining balance of the 2019 Notes in the amount of $27.3 million, paid $12.0 million for the purchase of Novan economic rights and paid $11.8 million for the Ab Initio acquisition (net of cash acquired).</span></div><div id="i0fa6f906fb2e4e30bc5e873d2bb6a82c_49"></div><div style="margin-top:14pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Policies and Estimates</span></div><div style="text-indent:24pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with GAAP requires estimates and assumptions that affect the reported amounts of assets and liabilities, revenues and expenses, and related disclosures of contingent liabilities in the consolidated financial statements and accompanying notes. The SEC has defined a company&#8217;s critical accounting policies as the ones that are most important to the portrayal of the company&#8217;s financial condition and results of operations, and which require the company to make its most difficult and subjective judgments, often as a result of the need to make estimates of matters that are inherently uncertain. Based on this definition, we have identified the critical accounting policies and judgments addressed below. We also have other key accounting policies, which involve the use of estimates, judgments, and assumptions that are significant to understanding our results. For additional information, see &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Item 8. Financial Statements and Supplementary Data&#8212;Notes to Consolidated Financial Statements&#8212;Note (1), Basis of Presentation and Summary of Significant Accounting Policies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.&#8221; Although we believe that our estimates, assumptions, and judgments are reasonable, they are based upon information presently available. Actual results may differ significantly from these estimates under different assumptions, judgments, or conditions.</span></div><div style="text-indent:27pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div><span><br/></span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We apply the following five-step model in accordance with ASC 606 in order to determine the revenue: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations, including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We receive royalty revenue on sales by our partners of products covered by patents that we or our partners own under contractual agreements. We do not have future performance obligations under these license arrangements. We generally satisfy our obligation to grant intellectual property rights on the effective date of the contract. However, we apply the royalty recognition constraint required under the guidance for sales-based royalties which requires a royalty to be recorded no sooner than the underlying sale occurs. Therefore, royalties on sales of products commercialized by our partners are recognized in the quarter the product is sold. Our partners generally report sales information to us on a one quarter lag. Thus, we estimate the expected royalty proceeds based on an analysis of historical experience and interim data provided by our partners including their publicly announced sales. Differences between actual and estimated royalty revenues, which have not been material, are adjusted in the period in which they become known, typically the following quarter. </span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our contracts with customers often will include variable consideration in the form of contingent milestone-based payments. We include contingent milestone based payments in the estimated transaction price when it is probable a significant reversal in the amount of cumulative revenue recognized will not occur. These estimates are based on historical experience, </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">anticipated results and our best judgment at the time. If the contingent milestone based payment is sales-based, we apply the royalty recognition constraint and record revenue when the underlying sale has taken place. Significant judgments must be made in determining the transaction price for our sales of intellectual property. Because of the risk that products in development with our partners will not reach development based milestones or receive regulatory approval, we generally recognize any contingent payments that would be due to us upon the development milestone or regulatory approval. Depending on the terms of the arrangement, we may also defer a portion of the consideration received if we have to satisfy a future obligation, which typically occurs with our contracts for R&amp;D services.</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For R&amp;D services we recognize revenue over time and we measure our progress using an input method. The input methods we use are based on the effort we expend or costs we incur toward the satisfaction of our performance obligation. We estimate the amount of effort we expend, including the time it will take us to complete the activities, or the costs we may incur in a given period, relative to the estimated total effort or costs to satisfy the performance obligation. This results in a percentage that we multiply by the transaction price to determine the amount of revenue we recognize each period. This approach requires us to make numerous estimates and use significant judgement. If our estimates or judgements change over the course of the collaboration, they may affect the timing and amount of revenue that we recognize in the current and future periods.</span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Revenue from Captisol sales is recognized when control of Captisol material or intellectual property license rights is transferred to our customers in an amount that reflects the consideration we expect to receive from our customers in exchange for those products. A performance obligation is considered distinct from other obligations in a contract when it provides a benefit to the customer either on its own or together with other resources that are readily available to the customer and is separately identified in the contract. For Captisol material, we consider our performance obligation is satisfied at a point in time, once we have transferred control of the product, meaning the customer has the ability to use and obtain the benefit of the Captisol material or intellectual property license right. We recognize revenue for satisfied performance obligations only when we determine there are no uncertainties regarding payment terms or transfer of control. Sales tax and other taxes we collect concurrent with revenue-producing activities are excluded from revenue. We have elected to recognize the cost of freight and shipping when control over Captisol material has transferred to the customer as an expense in Cost of Captisol. We expense incremental costs of obtaining a contract when incurred if the expected amortization period of the asset that we would have recognized is one year or less or the amount is immaterial. We did not incur any incremental costs of obtaining a contract during the periods reported.</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We occasionally have sub-license obligations related to arrangements for which we receive license fees, milestones and royalties. We evaluate the determination of gross as a principal versus net as an agent reporting based on each individual agreement.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intangible Assets and Other Long-Lived Assets &#8212; Impairment Assessments</span></div><div><span><br/></span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We regularly perform reviews to determine if an event occurred that may indicate the carrying values of our intangible and other long-lived assets are impaired. If indicators of impairment exist, we assess the recoverability of the affected long-lived assets by comparing its carrying amounts to its undiscounted cash flows. If the affected assets are not recoverable, we estimate the fair value of the assets and record an impairment loss if the carrying value exceeds the fair value. Factors that may indicate potential impairment include a significant decline in our stock price and market capitalization compared to net book value, significant changes in the ability of an asset to generate positive cash flows and the pattern of utilization of a particular asset.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to estimate the fair value of identifiable intangible assets and other long-lived assets, we estimate the present value of future cash flows from those assets. The key assumptions that we use in our discounted cash flow model are the amount and timing of estimated future cash flows to be generated by the asset over an extended period of time and a rate of return that considers the relative risk of achieving the cash flows, the time value of money, and other factors that a willing market participant would consider. Significant judgment is required to estimate the amount and timing of future cash flows and the relative risk of achieving those cash flows. </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assumptions and estimates about future values and remaining useful lives are complex and often subjective. They can be affected by a variety of factors, including external factors such as industry and economic trends, and internal factors such as changes in our business strategy and our internal forecasts. For example, if our future operating results do not meet current forecasts or if we experience a sustained decline in our market capitalization that is determined to be indicative of a reduction in fair value of our reporting unit, we may be required to record future impairment charges for purchased intangible assets. Impairment charges could materially decrease our future net income and result in lower asset values on our balance sheet.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingent Liabilities</span></div><div><span><br/></span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In connection with our acquisition of Metabasis in January 2010, we issued Metabasis stockholders four tradable CVRs, one CVR from each of four respective series of CVR, for each Metabasis share. The CVRs entitle Metabasis stockholders to </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">cash payments as proceeds are received by us from the sale or partnering of any of the Metabasis drug development programs. The fair values of the CVRs are remeasured at each reporting date through the term of the related agreement. Changes in the fair values are reported in the statement of operations as income (decreases) or expense (increases). The carrying amount of the liability may fluctuate significantly based upon quoted market prices and actual amounts paid under the agreements may be materially different than the carrying amount of the liability.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 1, 2020, we acquired the core assets, including its partnered programs and ion channel technology from Icagen and certain of its affiliates for total cash consideration of $15.1 million, and a contingent earn-out payment of up to $25.0 million based on certain revenue milestones with an estimated fair value upon acquisition of $4.8 million. The fair value of the earn-out liability was determined using a probability weighted income approach incorporating the estimated future cash flows from expected future milestones. These cash flows were then discounted to present value using a discount rate based on the market participants' cost of debt reflective of Icagen. The fair value of the liability is assessed at each reporting date and the change in fair value is recorded in our consolidated statements of operations. The carrying amount of the liability may fluctuate significantly and actual amounts paid may be materially different than the carrying amount of the liability. The fair value of the&#160;contingent&#160;consideration liability&#160;as of December 31, 2021 was $7.4 million.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 1, 2020, we acquired Pfenex, which develops next-generation and novel protein therapeutics to improve existing therapies and create new therapies for biological targets linked to critical, unmet diseases using a protein expression technology platform.  The purchase price of $465.1 million included $429.6 million cash consideration paid upon acquisition, and a CVR payment of up to $77.8 million of cash payments based on certain specified milestones with an estimated initial fair value of $37.0 million, net of $1.5 million recorded as post-acquisition expenses based on double trigger accelerate feature. The fair value of the CVR liability was determined using a probability adjusted income approach. These cash flows were then discounted to present value using a discount rate based on the market participants' cost of debt reflective of Pfenex. The liability is periodically assessed based on events and circumstances related to the underlying milestone, and any change in fair value is recorded in our consolidated statements of operations. The fair value of the&#160;CVR liability&#160;as of December 31, 2021 was reduced to zero as the CVR payment expiration date passed on December 31, 2021 without achieving the payment triggering event.  </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See additional information in &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Item 8. Financial Statements and Supplementary Data&#8212;Notes to Consolidated Financial Statements&#8212;Note (5), Fair Value Measurement.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes   </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">                                                                                                                                                                                          </span></div><div style="margin-bottom:6pt;margin-top:14pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our provision for income taxes, deferred tax assets and liabilities, and reserves for unrecognized tax benefits reflect our best assessment of estimated future taxes to be paid. Significant judgments and estimates based on interpretations of existing tax laws or regulations in the United States are required in determining our provision for income taxes. Changes in tax laws, statutory tax rates, and estimates of our future taxable income could impact the deferred tax assets and liabilities provided for in the consolidated financial statements and would require an adjustment to the provision for income taxes. </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred tax assets are regularly assessed to determine the likelihood they will be recovered from future taxable income. A valuation allowance is established when we believe it is more likely than not the future realization of all or some of a deferred tax asset will not be achieved. In evaluating our ability to recover deferred tax assets within the jurisdiction which they arise, we consider all available positive and negative evidence. Factors reviewed include the cumulative pre-tax book income for the past three years, scheduled reversals of deferred tax liabilities, our history of earnings and reliability of our forecasts, projections of pre-tax book income over the foreseeable future, and the impact of any feasible and prudent tax planning strategies. </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize the impact of a tax position in our financial statements only if that position is more likely than not of being sustained upon examination by taxing authorities, based on the technical merits of the position. Tax authorities regularly examine our returns in the jurisdictions in which we do business and we regularly assess the tax risk of our return filing positions. Due to the complexity of some of the uncertainties, the ultimate resolution may result in payments that are materially different from our current estimate of the tax liability. These differences, as well as any interest and penalties, will be reflected in the provision for income taxes in the period in which they are determined.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share-Based Compensation</span></div><div><span><br/></span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We incur share-based compensation expense related to restricted stock, ESPP, and stock options.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted stock unit (RSU) and performance stock unit (PSU) are all considered restricted stock. The fair value of restricted stock is determined by the closing market price of our common stock on the date of grant. We recognize share-based compensation expense based on the fair value on a straight-line basis over the requisite service periods of the awards, taking into consideration of forfeitures as they occur. PSU generally represents a right to receive a certain number of shares of common stock based on the achievement of corporate performance goals and continued employment during the vesting period. At each reporting period, we reassess the probability of the achievement of such corporate performance goals and any expense change resulting from an adjustment in the estimated shares to be released are treated as a cumulative catch-up in the period of adjustment. A limited amount of PSUs contain a market condition dependent upon the Company&#8217;s relative and absolute total stockholder return over a three-year period, with a range of 0% to 200% of the target amount granted to be issued under the award. Share-based compensation expense for these PSUs is measured using the Monte-Carlo simulation valuation model and is not adjusted for the achievement, or lack thereof, of the market conditions.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use the Black-Scholes-Merton option-pricing model to estimate the fair value of stock purchases under ESPP and stock options granted. The model assumptions include expected volatility, term, dividends, and the risk-free interest rate. We look to historical and implied volatilities of our stock to determine the expected volatility. The expected term of an award is based on historical forfeiture experience, exercise activity, and on the terms and conditions of the stock awards. The expected dividend yield is determined to be 0% given that except for 2007, during which we declared a cash dividend on our common stock of $2.50 per share, we have not paid any dividends on our common stock in the past and currently do not expect to pay cash dividends or make any other distributions on common stock in the future. The risk-free interest rate is based upon U.S. Treasury securities with remaining terms similar to the expected term of the share-based awards.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We grant options, RSUs and PSUs to employees and non-employee directors. Non-employee directors are accounted for as employees. Options and RSUs granted to certain non-employee directors typically vest one year from the date of grant. Options granted to employees typically vest 1/8 on the six month anniversary of the date of grant, and 1/48 each month thereafter for forty-two months. RSUs and PSUs granted to employees vest over three years. All option awards generally expire ten years from the date of grant.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Share-based compensation expense for awards to employees and non-employee directors is recognized on a straight-line basis over the vesting period until the last tranche vests. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the summary of recent accounting pronouncements applicable to our consolidated financial statements, see &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Item 8. Financial Statements and Supplementary Data&#8212;Notes to Consolidated Financial Statements&#8212;Note (1), Basis of Presentation and Summary of Significant Accounting Policies.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;</span></div><div style="text-indent:27pt"><span><br/></span></div><div id="i0fa6f906fb2e4e30bc5e873d2bb6a82c_52"></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:9.750%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:88.050%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Item&#160;7A.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Quantitative and Qualitative Disclosures About Market Risk</span></td></tr></table></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to market risk from interest rates and equity prices which could affect our results of operations, financial condition and cash flows. We manage our exposure to these market risks through our regular operating and financing activities.</span></div><div style="text-indent:27pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investment Portfolio Risk</span></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2021, our investment portfolio included investments in available-for-sale securities of $321.6 million, including the investment in Viking common stock and warrants of $30.9 million. These securities are subject to market risk and may decline in value based on market conditions.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Equity Price Risk</span></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our 2023 Notes include conversion and settlement provisions that are based on the price of our common stock at conversion or maturity of the notes, as applicable. As of December&#160;31, 2021, the &#8220;if-converted value&#8221; did not exceed the principal amount of the 2023 Notes. See detail in &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Item 8. Financial Statements and Supplementary Data&#8212;Notes to Consolidated Financial Statements&#8212;Note (7), Convertible Senior Notes.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Risk</span></div><div><span><br/></span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Through our licensing and business operations, we are exposed to foreign currency risk. Foreign currency exposures arise from transactions denominated in a currency other than the functional currency and from foreign denominated revenues </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and profit translated into U.S. dollars. Our license partners sell our products worldwide in currencies other than the U.S. dollar. Because of this, our revenues from royalty payments are subject to risk from changes in exchange rates. </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We purchase Captisol from Hovione, located in Lisbon, Portugal. Payments to Hovione are denominated and paid in U.S. dollars; however, the unit price of Captisol contains an adjustment factor which is based on the sharing of foreign currency risk between the two parties. The effect of an immediate 10% change in foreign exchange rates would not have a material impact on our financial condition, results of operations or cash flows. We do not currently hedge our exposures to foreign currency fluctuations.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Rate Risk</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to changes in interest rates related primarily to our investment portfolio. Our investment policy and strategy are focused on the preservation of capital and supporting our liquidity requirements. We use a combination of internal and external management to execute our investment strategy. We typically invest in highly rated securities, with the primary objective of minimizing the risk of principal loss. Our investment policy generally requires securities to be investment grade and limits the amount of credit exposure to any one issuer. We have historically maintained a relatively short average maturity for our investment portfolio, and we believe a hypothetical 100 basis point adverse move in interest rates across all maturities would not materially impact the fair market value of the portfolio in either period. </span></div><div style="text-indent:27pt"><span><br/></span></div><div id="i0fa6f906fb2e4e30bc5e873d2bb6a82c_55"></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:9.750%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:88.050%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Item&#160;8.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Consolidated Financial Statements and Supplementary Data</span></td></tr></table></div><div><span><br/></span></div><div><span><br/></span></div><div id="i0fa6f906fb2e4e30bc5e873d2bb6a82c_58"></div><div style="margin-top:9pt;text-align:center"><span><br/></span></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INDEX TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:94.061%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.739%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Page</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0fa6f906fb2e4e30bc5e873d2bb6a82c_61">Report of Independent Registered Public Accounting Firm</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (PCAOB ID: <ix:nonNumeric contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231" name="dei:AuditorFirmId" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY181OC9mcmFnOmJiYzNjNDJjNzM0MDQxMWZiY2RhYmJlNTQzNjgyNmJiL3RhYmxlOmU2OThlYjM2NmU5MDQ4ZWJiMGJjNjA0MjQyNmU0NzE3L3RhYmxlcmFuZ2U6ZTY5OGViMzY2ZTkwNDhlYmIwYmM2MDQyNDI2ZTQ3MTdfMS0wLTEtMS01MDE5NS90ZXh0cmVnaW9uOmM3YmY1NjY2N2U2ZjRlYTBiOTljZTY2N2IxN2Q2YTc4XzEzNzQzODk1MzQ3Mjgx_c5e81bce-0aed-4294-8987-98f7e0f49ed1">42</ix:nonNumeric>)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0fa6f906fb2e4e30bc5e873d2bb6a82c_61">52</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0fa6f906fb2e4e30bc5e873d2bb6a82c_64">Consolidated Balance Sheets</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0fa6f906fb2e4e30bc5e873d2bb6a82c_64">53</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0fa6f906fb2e4e30bc5e873d2bb6a82c_67">Consolidated Statements of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0fa6f906fb2e4e30bc5e873d2bb6a82c_67">54</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0fa6f906fb2e4e30bc5e873d2bb6a82c_70">Consolidated Statements of Comprehensive Income (Loss)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0fa6f906fb2e4e30bc5e873d2bb6a82c_70">55</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0fa6f906fb2e4e30bc5e873d2bb6a82c_73">Consolidated Statements of Stockholders&#8217; Equity</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0fa6f906fb2e4e30bc5e873d2bb6a82c_73">57</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0fa6f906fb2e4e30bc5e873d2bb6a82c_76">Consolidated Statements of Cash Flows</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0fa6f906fb2e4e30bc5e873d2bb6a82c_76">57</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0fa6f906fb2e4e30bc5e873d2bb6a82c_79">Notes to Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0fa6f906fb2e4e30bc5e873d2bb6a82c_79">59</a></span></div></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">51</span></div></div></div><div id="i0fa6f906fb2e4e30bc5e873d2bb6a82c_61"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Report of Independent Registered Public Accounting Firm</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">To the Stockholders and the Board of Directors of Ligand Pharmaceuticals Incorporated</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Opinion on the Financial Statements</span></div><div><span><br/></span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have audited the accompanying consolidated balance sheets of Ligand Pharmaceuticals Incorporated (the Company) as of December 31, 2021 and 2020, and the related consolidated statements of operations, comprehensive income (loss), stockholders&#8217; equity and cash flows for each of the three years in the period ended December 31, 2021, and the related notes, (collectively referred to as the &#8220;consolidated financial statements&#8221;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2021 and 2020, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2021, in conformity with U.S. generally accepted accounting principles.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company's internal control over financial reporting as of December 31, 2021, based on criteria established in Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) and our report dated February&#160;28, 2022 expressed an unqualified opinion thereon.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis for Opinion</span></div><div><span><br/></span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</span></div><div><span><br/></span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Critical Audit Matter</span></div><div><span><br/></span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The critical audit matter communicated below is a matter arising from the current period audit of the financial statements that was communicated or required to be communicated to the audit committee and that: (1) relates to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective or complex judgments. The communication of the critical audit matter does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:12.966%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.446%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:82.188%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Impairment assessment of finite-lived intangibles </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Description of the Matter</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December 31, 2021, the Company&#8217;s finite-lived intangible assets totaled $551.0 million. As discussed in Note 1 to the consolidated financial statements, the Company reviews finite-lived intangible assets for impairment whenever events or changes in circumstances indicate that the finite-lived intangibles are not expected to be recovered through future undiscounted cash flows. The Company did not identify indicators of impairment for its finite-lived intangibles at December 31, 2021. </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Auditing management&#8217;s assessment of impairment is challenging due to the high degree of subjective auditor judgment necessary in evaluating management&#8217;s identification of indicators of potential impairment and the related assessment of the severity of such indicators in determining whether a triggering event has occurred that requires the Company to evaluate the recoverability of the asset. A high degree of auditor judgment was required to evaluate the significant inputs used in the assessment for potential triggering events which included market conditions, industry and economic trends, changes in regulations, clinical success and historical and forecasted financial results. These possible triggering events could have a significant effect on the Company&#8217;s impairment assessment and the determination of whether further quantitative analysis of finite-lived intangible impairment was required.</span></div><div><span><br/></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">How We Addressed the Matter in Our Audit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We obtained an understanding of management&#8217;s process to identify indicators of impairment, including the qualitative analysis and related inputs and assumptions used in performing the analyses. We evaluated the design and tested the operating effectiveness of the controls that address the identification of indicators of impairment. For example, we tested controls over management&#8217;s assessment of indicators of impairment. </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To test the Company&#8217;s evaluation of indicators of impairment for finite-lived intangibles, our audit procedures included, among others, assessing the methodologies and testing the completeness and accuracy of the Company&#8217;s analysis of events or changes in circumstances. As part of our evaluation, we considered market conditions, industry and economic trends, changes in regulations, clinical success and historical and forecasted financial results, in assessing whether an indicator of impairments exists. </span></div><div><span><br/></span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span><br/></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ <ix:nonNumeric contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231" name="dei:AuditorName" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182MS9mcmFnOjkyMGRjNjIxMDIwMzQ4MWFhOGY3ZWMxYWM1YWIwZDg3L3RleHRyZWdpb246OTIwZGM2MjEwMjAzNDgxYWE4ZjdlYzFhYzVhYjBkODdfMjE5OTAyMzI1OTUxMg_9175fa12-8ccf-4fae-9739-8be00cd67b54">Ernst&#160;&amp; Young&#160;LLP</ix:nonNumeric></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have served as the Company's auditor since 2016.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231" name="dei:AuditorLocation" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182MS9mcmFnOjkyMGRjNjIxMDIwMzQ4MWFhOGY3ZWMxYWM1YWIwZDg3L3RleHRyZWdpb246OTIwZGM2MjEwMjAzNDgxYWE4ZjdlYzFhYzVhYjBkODdfMjE5OTAyMzI1OTUxNA_3d6c490a-3fdf-42a7-aa3e-4292046cc588">San Diego, California</ix:nonNumeric></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">February&#160;28, 2022</span></div><div id="i0fa6f906fb2e4e30bc5e873d2bb6a82c_64"></div><div style="text-align:center;text-indent:36pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">LIGAND PHARMACEUTICALS INCORPORATED</span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED BALANCE SHEETS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except par value)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:72.908%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.528%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.530%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">ASSETS</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash and cash equivalents </span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182NC9mcmFnOjE5MmJkY2FiNmJhNTRhMWI5ZTYxNzY3OWU4Nzk0YzQ1L3RhYmxlOjJiN2M5MDcyMTc5MTQzYjA4ZjRiZTdlMzgxZTZmY2FkL3RhYmxlcmFuZ2U6MmI3YzkwNzIxNzkxNDNiMDhmNGJlN2UzODFlNmZjYWRfNC0xLTEtMS00MTI5NA_d818a256-5a78-4d08-907d-2b129bc39e6f">19,522</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7462d0db8f4248fcb9fd8f1deae439f3_I20201231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182NC9mcmFnOjE5MmJkY2FiNmJhNTRhMWI5ZTYxNzY3OWU4Nzk0YzQ1L3RhYmxlOjJiN2M5MDcyMTc5MTQzYjA4ZjRiZTdlMzgxZTZmY2FkL3RhYmxlcmFuZ2U6MmI3YzkwNzIxNzkxNDNiMDhmNGJlN2UzODFlNmZjYWRfNC0zLTEtMS00MTI5NA_b88a699d-c9a3-46b4-a46c-0c555d4713ad">47,619</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231" decimals="-3" name="us-gaap:ShortTermInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182NC9mcmFnOjE5MmJkY2FiNmJhNTRhMWI5ZTYxNzY3OWU4Nzk0YzQ1L3RhYmxlOjJiN2M5MDcyMTc5MTQzYjA4ZjRiZTdlMzgxZTZmY2FkL3RhYmxlcmFuZ2U6MmI3YzkwNzIxNzkxNDNiMDhmNGJlN2UzODFlNmZjYWRfNS0xLTEtMS00MTI5NA_4acccf20-e366-48fb-b4a0-044a4783f5e3">321,586</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7462d0db8f4248fcb9fd8f1deae439f3_I20201231" decimals="-3" name="us-gaap:ShortTermInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182NC9mcmFnOjE5MmJkY2FiNmJhNTRhMWI5ZTYxNzY3OWU4Nzk0YzQ1L3RhYmxlOjJiN2M5MDcyMTc5MTQzYjA4ZjRiZTdlMzgxZTZmY2FkL3RhYmxlcmFuZ2U6MmI3YzkwNzIxNzkxNDNiMDhmNGJlN2UzODFlNmZjYWRfNS0zLTEtMS00MTI5NA_a4ad6365-01b6-45e6-854e-405f38205dab">363,567</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182NC9mcmFnOjE5MmJkY2FiNmJhNTRhMWI5ZTYxNzY3OWU4Nzk0YzQ1L3RhYmxlOjJiN2M5MDcyMTc5MTQzYjA4ZjRiZTdlMzgxZTZmY2FkL3RhYmxlcmFuZ2U6MmI3YzkwNzIxNzkxNDNiMDhmNGJlN2UzODFlNmZjYWRfNi0xLTEtMS00MTI5NA_a15a59b7-cd0c-450a-9dd8-6cd53a787869">85,453</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7462d0db8f4248fcb9fd8f1deae439f3_I20201231" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182NC9mcmFnOjE5MmJkY2FiNmJhNTRhMWI5ZTYxNzY3OWU4Nzk0YzQ1L3RhYmxlOjJiN2M5MDcyMTc5MTQzYjA4ZjRiZTdlMzgxZTZmY2FkL3RhYmxlcmFuZ2U6MmI3YzkwNzIxNzkxNDNiMDhmNGJlN2UzODFlNmZjYWRfNi0zLTEtMS00MTI5NA_8855f18e-1fee-4438-add1-cc99a31cdea8">56,847</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182NC9mcmFnOjE5MmJkY2FiNmJhNTRhMWI5ZTYxNzY3OWU4Nzk0YzQ1L3RhYmxlOjJiN2M5MDcyMTc5MTQzYjA4ZjRiZTdlMzgxZTZmY2FkL3RhYmxlcmFuZ2U6MmI3YzkwNzIxNzkxNDNiMDhmNGJlN2UzODFlNmZjYWRfNy0xLTEtMS00MTI5NA_4c934f86-705c-4139-9117-85c758dd5985">27,326</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7462d0db8f4248fcb9fd8f1deae439f3_I20201231" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182NC9mcmFnOjE5MmJkY2FiNmJhNTRhMWI5ZTYxNzY3OWU4Nzk0YzQ1L3RhYmxlOjJiN2M5MDcyMTc5MTQzYjA4ZjRiZTdlMzgxZTZmY2FkL3RhYmxlcmFuZ2U6MmI3YzkwNzIxNzkxNDNiMDhmNGJlN2UzODFlNmZjYWRfNy0zLTEtMS00MTI5NA_7c802c7b-0c26-46d9-889d-3ceb37695751">26,487</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income taxes receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231" decimals="-3" name="us-gaap:IncomeTaxesReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182NC9mcmFnOjE5MmJkY2FiNmJhNTRhMWI5ZTYxNzY3OWU4Nzk0YzQ1L3RhYmxlOjJiN2M5MDcyMTc5MTQzYjA4ZjRiZTdlMzgxZTZmY2FkL3RhYmxlcmFuZ2U6MmI3YzkwNzIxNzkxNDNiMDhmNGJlN2UzODFlNmZjYWRfOC0xLTEtMS00MTI5NA_8d797c17-621f-43fb-a03a-1cbefce6f30f">6,193</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7462d0db8f4248fcb9fd8f1deae439f3_I20201231" decimals="-3" name="us-gaap:IncomeTaxesReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182NC9mcmFnOjE5MmJkY2FiNmJhNTRhMWI5ZTYxNzY3OWU4Nzk0YzQ1L3RhYmxlOjJiN2M5MDcyMTc5MTQzYjA4ZjRiZTdlMzgxZTZmY2FkL3RhYmxlcmFuZ2U6MmI3YzkwNzIxNzkxNDNiMDhmNGJlN2UzODFlNmZjYWRfOC0zLTEtMS00MTI5NA_e1a3babf-963c-4012-a943-4b20f5b92222">2,217</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231" decimals="-3" name="us-gaap:OtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182NC9mcmFnOjE5MmJkY2FiNmJhNTRhMWI5ZTYxNzY3OWU4Nzk0YzQ1L3RhYmxlOjJiN2M5MDcyMTc5MTQzYjA4ZjRiZTdlMzgxZTZmY2FkL3RhYmxlcmFuZ2U6MmI3YzkwNzIxNzkxNDNiMDhmNGJlN2UzODFlNmZjYWRfOS0xLTEtMS00MTI5NA_3cbc4712-2b70-4d01-bfd3-a71e3b3a49a9">4,671</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7462d0db8f4248fcb9fd8f1deae439f3_I20201231" decimals="-3" name="us-gaap:OtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182NC9mcmFnOjE5MmJkY2FiNmJhNTRhMWI5ZTYxNzY3OWU4Nzk0YzQ1L3RhYmxlOjJiN2M5MDcyMTc5MTQzYjA4ZjRiZTdlMzgxZTZmY2FkL3RhYmxlcmFuZ2U6MmI3YzkwNzIxNzkxNDNiMDhmNGJlN2UzODFlNmZjYWRfOS0zLTEtMS00MTI5NA_bec9da79-8dbf-45af-975e-2be036c3aaac">3,822</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182NC9mcmFnOjE5MmJkY2FiNmJhNTRhMWI5ZTYxNzY3OWU4Nzk0YzQ1L3RhYmxlOjJiN2M5MDcyMTc5MTQzYjA4ZjRiZTdlMzgxZTZmY2FkL3RhYmxlcmFuZ2U6MmI3YzkwNzIxNzkxNDNiMDhmNGJlN2UzODFlNmZjYWRfMTAtMS0xLTEtNDEyOTQ_231586fc-d6be-40d8-ae7c-d65755e4470d">464,751</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7462d0db8f4248fcb9fd8f1deae439f3_I20201231" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182NC9mcmFnOjE5MmJkY2FiNmJhNTRhMWI5ZTYxNzY3OWU4Nzk0YzQ1L3RhYmxlOjJiN2M5MDcyMTc5MTQzYjA4ZjRiZTdlMzgxZTZmY2FkL3RhYmxlcmFuZ2U6MmI3YzkwNzIxNzkxNDNiMDhmNGJlN2UzODFlNmZjYWRfMTAtMy0xLTEtNDEyOTQ_636353fa-33c1-42db-bbe4-88ea5d5dba08">500,559</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred income taxes, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231" decimals="-3" name="us-gaap:DeferredIncomeTaxAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182NC9mcmFnOjE5MmJkY2FiNmJhNTRhMWI5ZTYxNzY3OWU4Nzk0YzQ1L3RhYmxlOjJiN2M5MDcyMTc5MTQzYjA4ZjRiZTdlMzgxZTZmY2FkL3RhYmxlcmFuZ2U6MmI3YzkwNzIxNzkxNDNiMDhmNGJlN2UzODFlNmZjYWRfMTEtMS0xLTEtNDEyOTQ_0d39d47e-ccab-46bf-8de0-db8f34239700">34,482</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7462d0db8f4248fcb9fd8f1deae439f3_I20201231" decimals="-3" name="us-gaap:DeferredIncomeTaxAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182NC9mcmFnOjE5MmJkY2FiNmJhNTRhMWI5ZTYxNzY3OWU4Nzk0YzQ1L3RhYmxlOjJiN2M5MDcyMTc5MTQzYjA4ZjRiZTdlMzgxZTZmY2FkL3RhYmxlcmFuZ2U6MmI3YzkwNzIxNzkxNDNiMDhmNGJlN2UzODFlNmZjYWRfMTEtMy0xLTEtNDEyOTQ_02853767-1a5e-43fa-98a6-faee8350498d">24,320</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Intangible assets, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231" decimals="-3" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182NC9mcmFnOjE5MmJkY2FiNmJhNTRhMWI5ZTYxNzY3OWU4Nzk0YzQ1L3RhYmxlOjJiN2M5MDcyMTc5MTQzYjA4ZjRiZTdlMzgxZTZmY2FkL3RhYmxlcmFuZ2U6MmI3YzkwNzIxNzkxNDNiMDhmNGJlN2UzODFlNmZjYWRfMTItMS0xLTEtNDEyOTQ_adbdc74f-4154-4a8e-ad18-ba95b6ee4a60">551,040</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7462d0db8f4248fcb9fd8f1deae439f3_I20201231" decimals="-3" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182NC9mcmFnOjE5MmJkY2FiNmJhNTRhMWI5ZTYxNzY3OWU4Nzk0YzQ1L3RhYmxlOjJiN2M5MDcyMTc5MTQzYjA4ZjRiZTdlMzgxZTZmY2FkL3RhYmxlcmFuZ2U6MmI3YzkwNzIxNzkxNDNiMDhmNGJlN2UzODFlNmZjYWRfMTItMy0xLTEtNDEyOTQ_cad66721-bdf8-49cc-aa63-d9559674cbea">595,330</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182NC9mcmFnOjE5MmJkY2FiNmJhNTRhMWI5ZTYxNzY3OWU4Nzk0YzQ1L3RhYmxlOjJiN2M5MDcyMTc5MTQzYjA4ZjRiZTdlMzgxZTZmY2FkL3RhYmxlcmFuZ2U6MmI3YzkwNzIxNzkxNDNiMDhmNGJlN2UzODFlNmZjYWRfMTMtMS0xLTEtNDEyOTQ_9db52d62-e0c9-482a-b86d-4a8025b2ad8f">181,206</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7462d0db8f4248fcb9fd8f1deae439f3_I20201231" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182NC9mcmFnOjE5MmJkY2FiNmJhNTRhMWI5ZTYxNzY3OWU4Nzk0YzQ1L3RhYmxlOjJiN2M5MDcyMTc5MTQzYjA4ZjRiZTdlMzgxZTZmY2FkL3RhYmxlcmFuZ2U6MmI3YzkwNzIxNzkxNDNiMDhmNGJlN2UzODFlNmZjYWRfMTMtMy0xLTEtNDEyOTQ_9ab94e3a-3703-4086-ad9c-fbf8d7861984">189,662</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Commercial license and other economic rights</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231" decimals="-3" name="lgnd:CommercialLicenseRights" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182NC9mcmFnOjE5MmJkY2FiNmJhNTRhMWI5ZTYxNzY3OWU4Nzk0YzQ1L3RhYmxlOjJiN2M5MDcyMTc5MTQzYjA4ZjRiZTdlMzgxZTZmY2FkL3RhYmxlcmFuZ2U6MmI3YzkwNzIxNzkxNDNiMDhmNGJlN2UzODFlNmZjYWRfMTQtMS0xLTEtNDEyOTQ_3f35bf58-fa01-42bd-8c9f-79cc4a92a5ed">10,110</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7462d0db8f4248fcb9fd8f1deae439f3_I20201231" decimals="-3" name="lgnd:CommercialLicenseRights" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182NC9mcmFnOjE5MmJkY2FiNmJhNTRhMWI5ZTYxNzY3OWU4Nzk0YzQ1L3RhYmxlOjJiN2M5MDcyMTc5MTQzYjA4ZjRiZTdlMzgxZTZmY2FkL3RhYmxlcmFuZ2U6MmI3YzkwNzIxNzkxNDNiMDhmNGJlN2UzODFlNmZjYWRfMTQtMy0xLTEtNDEyOTQ_188a84da-5ada-4ebd-84e2-60593ea7a28e">10,979</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182NC9mcmFnOjE5MmJkY2FiNmJhNTRhMWI5ZTYxNzY3OWU4Nzk0YzQ1L3RhYmxlOjJiN2M5MDcyMTc5MTQzYjA4ZjRiZTdlMzgxZTZmY2FkL3RhYmxlcmFuZ2U6MmI3YzkwNzIxNzkxNDNiMDhmNGJlN2UzODFlNmZjYWRfMTUtMS0xLTEtNDEyOTQ_09ab660f-be3f-413d-8559-8a6c0df7b0e4">20,511</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7462d0db8f4248fcb9fd8f1deae439f3_I20201231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182NC9mcmFnOjE5MmJkY2FiNmJhNTRhMWI5ZTYxNzY3OWU4Nzk0YzQ1L3RhYmxlOjJiN2M5MDcyMTc5MTQzYjA4ZjRiZTdlMzgxZTZmY2FkL3RhYmxlcmFuZ2U6MmI3YzkwNzIxNzkxNDNiMDhmNGJlN2UzODFlNmZjYWRfMTUtMy0xLTEtNDEyOTQ_e7b949ff-2f43-45bf-9b3d-401f0f4ae455">14,434</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating lease assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182NC9mcmFnOjE5MmJkY2FiNmJhNTRhMWI5ZTYxNzY3OWU4Nzk0YzQ1L3RhYmxlOjJiN2M5MDcyMTc5MTQzYjA4ZjRiZTdlMzgxZTZmY2FkL3RhYmxlcmFuZ2U6MmI3YzkwNzIxNzkxNDNiMDhmNGJlN2UzODFlNmZjYWRfMTYtMS0xLTEtNDEyOTQ_6d1ab5af-49db-4349-a362-0144c3fd7f0a">16,542</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7462d0db8f4248fcb9fd8f1deae439f3_I20201231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182NC9mcmFnOjE5MmJkY2FiNmJhNTRhMWI5ZTYxNzY3OWU4Nzk0YzQ1L3RhYmxlOjJiN2M5MDcyMTc5MTQzYjA4ZjRiZTdlMzgxZTZmY2FkL3RhYmxlcmFuZ2U6MmI3YzkwNzIxNzkxNDNiMDhmNGJlN2UzODFlNmZjYWRfMTYtMy0xLTEtNDEyOTQ_6dffdc3d-9003-4813-9f87-8a890595c6ae">6,892</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Finance lease assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231" decimals="-3" name="us-gaap:FinanceLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182NC9mcmFnOjE5MmJkY2FiNmJhNTRhMWI5ZTYxNzY3OWU4Nzk0YzQ1L3RhYmxlOjJiN2M5MDcyMTc5MTQzYjA4ZjRiZTdlMzgxZTZmY2FkL3RhYmxlcmFuZ2U6MmI3YzkwNzIxNzkxNDNiMDhmNGJlN2UzODFlNmZjYWRfMTctMS0xLTEtNDEyOTQ_b89739f6-175a-4794-8493-5a45267295e3">16,207</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7462d0db8f4248fcb9fd8f1deae439f3_I20201231" decimals="-3" name="us-gaap:FinanceLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182NC9mcmFnOjE5MmJkY2FiNmJhNTRhMWI5ZTYxNzY3OWU4Nzk0YzQ1L3RhYmxlOjJiN2M5MDcyMTc5MTQzYjA4ZjRiZTdlMzgxZTZmY2FkL3RhYmxlcmFuZ2U6MmI3YzkwNzIxNzkxNDNiMDhmNGJlN2UzODFlNmZjYWRfMTctMy0xLTEtNDEyOTQ_da6cb585-870e-4126-9489-5123a469640c">15,842</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182NC9mcmFnOjE5MmJkY2FiNmJhNTRhMWI5ZTYxNzY3OWU4Nzk0YzQ1L3RhYmxlOjJiN2M5MDcyMTc5MTQzYjA4ZjRiZTdlMzgxZTZmY2FkL3RhYmxlcmFuZ2U6MmI3YzkwNzIxNzkxNDNiMDhmNGJlN2UzODFlNmZjYWRfMTgtMS0xLTEtNDEyOTQ_06be126d-3094-42ab-afea-88bbb06d6178">2,741</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7462d0db8f4248fcb9fd8f1deae439f3_I20201231" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182NC9mcmFnOjE5MmJkY2FiNmJhNTRhMWI5ZTYxNzY3OWU4Nzk0YzQ1L3RhYmxlOjJiN2M5MDcyMTc5MTQzYjA4ZjRiZTdlMzgxZTZmY2FkL3RhYmxlcmFuZ2U6MmI3YzkwNzIxNzkxNDNiMDhmNGJlN2UzODFlNmZjYWRfMTgtMy0xLTEtNDEyOTQ_38d3f331-35a4-46fd-8fd0-e62938605f66">4,267</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182NC9mcmFnOjE5MmJkY2FiNmJhNTRhMWI5ZTYxNzY3OWU4Nzk0YzQ1L3RhYmxlOjJiN2M5MDcyMTc5MTQzYjA4ZjRiZTdlMzgxZTZmY2FkL3RhYmxlcmFuZ2U6MmI3YzkwNzIxNzkxNDNiMDhmNGJlN2UzODFlNmZjYWRfMTktMS0xLTEtNDEyOTQ_dc98a5e0-d9ba-4356-9419-99c731d0d3f9">1,297,590</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7462d0db8f4248fcb9fd8f1deae439f3_I20201231" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182NC9mcmFnOjE5MmJkY2FiNmJhNTRhMWI5ZTYxNzY3OWU4Nzk0YzQ1L3RhYmxlOjJiN2M5MDcyMTc5MTQzYjA4ZjRiZTdlMzgxZTZmY2FkL3RhYmxlcmFuZ2U6MmI3YzkwNzIxNzkxNDNiMDhmNGJlN2UzODFlNmZjYWRfMTktMy0xLTEtNDEyOTQ_d0004785-b765-4a01-80c6-b327cab01a67">1,362,285</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY </span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182NC9mcmFnOjE5MmJkY2FiNmJhNTRhMWI5ZTYxNzY3OWU4Nzk0YzQ1L3RhYmxlOjJiN2M5MDcyMTc5MTQzYjA4ZjRiZTdlMzgxZTZmY2FkL3RhYmxlcmFuZ2U6MmI3YzkwNzIxNzkxNDNiMDhmNGJlN2UzODFlNmZjYWRfMjItMS0xLTEtNDEyOTQ_dacfeeee-b628-45f6-875e-51fefb34c63d">8,403</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7462d0db8f4248fcb9fd8f1deae439f3_I20201231" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182NC9mcmFnOjE5MmJkY2FiNmJhNTRhMWI5ZTYxNzY3OWU4Nzk0YzQ1L3RhYmxlOjJiN2M5MDcyMTc5MTQzYjA4ZjRiZTdlMzgxZTZmY2FkL3RhYmxlcmFuZ2U6MmI3YzkwNzIxNzkxNDNiMDhmNGJlN2UzODFlNmZjYWRfMjItMy0xLTEtNDEyOTQ_e40c0cd4-1d8c-4a05-ab8d-eb404b6475f8">3,784</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182NC9mcmFnOjE5MmJkY2FiNmJhNTRhMWI5ZTYxNzY3OWU4Nzk0YzQ1L3RhYmxlOjJiN2M5MDcyMTc5MTQzYjA4ZjRiZTdlMzgxZTZmY2FkL3RhYmxlcmFuZ2U6MmI3YzkwNzIxNzkxNDNiMDhmNGJlN2UzODFlNmZjYWRfMjMtMS0xLTEtNDEyOTQ_acc5d97a-bd2f-4231-bbb7-4fcbece4e306">17,579</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7462d0db8f4248fcb9fd8f1deae439f3_I20201231" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182NC9mcmFnOjE5MmJkY2FiNmJhNTRhMWI5ZTYxNzY3OWU4Nzk0YzQ1L3RhYmxlOjJiN2M5MDcyMTc5MTQzYjA4ZjRiZTdlMzgxZTZmY2FkL3RhYmxlcmFuZ2U6MmI3YzkwNzIxNzkxNDNiMDhmNGJlN2UzODFlNmZjYWRfMjMtMy0xLTEtNDEyOTQ_9a8aac4c-5dfe-4c13-a510-840cc590612d">18,530</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current contingent liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231" decimals="-3" name="lgnd:CurrentPortionOfLiabilityForContingentValueRights" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182NC9mcmFnOjE5MmJkY2FiNmJhNTRhMWI5ZTYxNzY3OWU4Nzk0YzQ1L3RhYmxlOjJiN2M5MDcyMTc5MTQzYjA4ZjRiZTdlMzgxZTZmY2FkL3RhYmxlcmFuZ2U6MmI3YzkwNzIxNzkxNDNiMDhmNGJlN2UzODFlNmZjYWRfMjQtMS0xLTEtNDEyOTQ_f9cc95b7-04b0-4c1c-985b-116a6adc6c73">2,588</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7462d0db8f4248fcb9fd8f1deae439f3_I20201231" decimals="-3" name="lgnd:CurrentPortionOfLiabilityForContingentValueRights" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182NC9mcmFnOjE5MmJkY2FiNmJhNTRhMWI5ZTYxNzY3OWU4Nzk0YzQ1L3RhYmxlOjJiN2M5MDcyMTc5MTQzYjA4ZjRiZTdlMzgxZTZmY2FkL3RhYmxlcmFuZ2U6MmI3YzkwNzIxNzkxNDNiMDhmNGJlN2UzODFlNmZjYWRfMjQtMy0xLTEtNDEyOTQ_bb59de50-a669-45ca-b7f3-de427548c338">39,884</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;Deferred revenue   </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182NC9mcmFnOjE5MmJkY2FiNmJhNTRhMWI5ZTYxNzY3OWU4Nzk0YzQ1L3RhYmxlOjJiN2M5MDcyMTc5MTQzYjA4ZjRiZTdlMzgxZTZmY2FkL3RhYmxlcmFuZ2U6MmI3YzkwNzIxNzkxNDNiMDhmNGJlN2UzODFlNmZjYWRfMjUtMS0xLTEtNDEyOTQ_d05c1f6a-9e78-494e-aef1-f4748a7c4ebe">10,996</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7462d0db8f4248fcb9fd8f1deae439f3_I20201231" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182NC9mcmFnOjE5MmJkY2FiNmJhNTRhMWI5ZTYxNzY3OWU4Nzk0YzQ1L3RhYmxlOjJiN2M5MDcyMTc5MTQzYjA4ZjRiZTdlMzgxZTZmY2FkL3RhYmxlcmFuZ2U6MmI3YzkwNzIxNzkxNDNiMDhmNGJlN2UzODFlNmZjYWRfMjUtMy0xLTEtNDEyOTQ_827fdf2d-6cc7-47d6-bee5-201ac1cc5e36">29,435</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182NC9mcmFnOjE5MmJkY2FiNmJhNTRhMWI5ZTYxNzY3OWU4Nzk0YzQ1L3RhYmxlOjJiN2M5MDcyMTc5MTQzYjA4ZjRiZTdlMzgxZTZmY2FkL3RhYmxlcmFuZ2U6MmI3YzkwNzIxNzkxNDNiMDhmNGJlN2UzODFlNmZjYWRfMjYtMS0xLTEtNDEyOTQ_b9ad93d0-279c-4918-b5a4-0bec26fb128c">2,053</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7462d0db8f4248fcb9fd8f1deae439f3_I20201231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182NC9mcmFnOjE5MmJkY2FiNmJhNTRhMWI5ZTYxNzY3OWU4Nzk0YzQ1L3RhYmxlOjJiN2M5MDcyMTc5MTQzYjA4ZjRiZTdlMzgxZTZmY2FkL3RhYmxlcmFuZ2U6MmI3YzkwNzIxNzkxNDNiMDhmNGJlN2UzODFlNmZjYWRfMjYtMy0xLTEtNDEyOTQ_471b6efb-a48a-4459-a052-3be0a704db5a">1,885</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current finance lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231" decimals="-3" name="us-gaap:FinanceLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182NC9mcmFnOjE5MmJkY2FiNmJhNTRhMWI5ZTYxNzY3OWU4Nzk0YzQ1L3RhYmxlOjJiN2M5MDcyMTc5MTQzYjA4ZjRiZTdlMzgxZTZmY2FkL3RhYmxlcmFuZ2U6MmI3YzkwNzIxNzkxNDNiMDhmNGJlN2UzODFlNmZjYWRfMjctMS0xLTEtNDEyOTQ_7f5a81c9-21c3-48cd-a989-19ec627e8729">46</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7462d0db8f4248fcb9fd8f1deae439f3_I20201231" decimals="-3" name="us-gaap:FinanceLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182NC9mcmFnOjE5MmJkY2FiNmJhNTRhMWI5ZTYxNzY3OWU4Nzk0YzQ1L3RhYmxlOjJiN2M5MDcyMTc5MTQzYjA4ZjRiZTdlMzgxZTZmY2FkL3RhYmxlcmFuZ2U6MmI3YzkwNzIxNzkxNDNiMDhmNGJlN2UzODFlNmZjYWRfMjctMy0xLTEtNDEyOTQ_c1516387-94c1-4be8-bbb1-5892179eb9c8">6,593</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182NC9mcmFnOjE5MmJkY2FiNmJhNTRhMWI5ZTYxNzY3OWU4Nzk0YzQ1L3RhYmxlOjJiN2M5MDcyMTc5MTQzYjA4ZjRiZTdlMzgxZTZmY2FkL3RhYmxlcmFuZ2U6MmI3YzkwNzIxNzkxNDNiMDhmNGJlN2UzODFlNmZjYWRfMjgtMS0xLTEtNDEyOTQ_cb13249e-3307-40a0-a946-439bb92dd8a7">41,665</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7462d0db8f4248fcb9fd8f1deae439f3_I20201231" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182NC9mcmFnOjE5MmJkY2FiNmJhNTRhMWI5ZTYxNzY3OWU4Nzk0YzQ1L3RhYmxlOjJiN2M5MDcyMTc5MTQzYjA4ZjRiZTdlMzgxZTZmY2FkL3RhYmxlcmFuZ2U6MmI3YzkwNzIxNzkxNDNiMDhmNGJlN2UzODFlNmZjYWRfMjgtMy0xLTEtNDEyOTQ_f915535d-dab3-441a-9c32-8c0e1d94c5fb">100,111</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023 convertible senior notes, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231" decimals="-3" name="us-gaap:ConvertibleDebtNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182NC9mcmFnOjE5MmJkY2FiNmJhNTRhMWI5ZTYxNzY3OWU4Nzk0YzQ1L3RhYmxlOjJiN2M5MDcyMTc5MTQzYjA4ZjRiZTdlMzgxZTZmY2FkL3RhYmxlcmFuZ2U6MmI3YzkwNzIxNzkxNDNiMDhmNGJlN2UzODFlNmZjYWRfMjktMS0xLTEtNDEyOTQ_a2312bb3-92cf-4285-b0a6-e54e27555d34">320,717</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7462d0db8f4248fcb9fd8f1deae439f3_I20201231" decimals="-3" name="us-gaap:ConvertibleDebtNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182NC9mcmFnOjE5MmJkY2FiNmJhNTRhMWI5ZTYxNzY3OWU4Nzk0YzQ1L3RhYmxlOjJiN2M5MDcyMTc5MTQzYjA4ZjRiZTdlMzgxZTZmY2FkL3RhYmxlcmFuZ2U6MmI3YzkwNzIxNzkxNDNiMDhmNGJlN2UzODFlNmZjYWRfMjktMy0xLTEtNDEyOTQ_31b39473-de69-4c0d-84d1-6cd1e81d60d1">442,293</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Long-term contingent liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231" decimals="-3" name="lgnd:LiabilityForContingentValueRights" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182NC9mcmFnOjE5MmJkY2FiNmJhNTRhMWI5ZTYxNzY3OWU4Nzk0YzQ1L3RhYmxlOjJiN2M5MDcyMTc5MTQzYjA4ZjRiZTdlMzgxZTZmY2FkL3RhYmxlcmFuZ2U6MmI3YzkwNzIxNzkxNDNiMDhmNGJlN2UzODFlNmZjYWRfMzAtMS0xLTEtNDEyOTQ_fae8b3ae-5705-4645-a92d-54c76ecb20cf">8,483</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7462d0db8f4248fcb9fd8f1deae439f3_I20201231" decimals="-3" name="lgnd:LiabilityForContingentValueRights" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182NC9mcmFnOjE5MmJkY2FiNmJhNTRhMWI5ZTYxNzY3OWU4Nzk0YzQ1L3RhYmxlOjJiN2M5MDcyMTc5MTQzYjA4ZjRiZTdlMzgxZTZmY2FkL3RhYmxlcmFuZ2U6MmI3YzkwNzIxNzkxNDNiMDhmNGJlN2UzODFlNmZjYWRfMzAtMy0xLTEtNDEyOTQ_925351b0-3f0d-4fa8-be36-119f1ef5ea2b">9,249</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred income taxes, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182NC9mcmFnOjE5MmJkY2FiNmJhNTRhMWI5ZTYxNzY3OWU4Nzk0YzQ1L3RhYmxlOjJiN2M5MDcyMTc5MTQzYjA4ZjRiZTdlMzgxZTZmY2FkL3RhYmxlcmFuZ2U6MmI3YzkwNzIxNzkxNDNiMDhmNGJlN2UzODFlNmZjYWRfMzEtMS0xLTEtNDEyOTQ_78ffbf8e-2e27-4ff5-bc07-065463cabac2">59,095</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7462d0db8f4248fcb9fd8f1deae439f3_I20201231" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182NC9mcmFnOjE5MmJkY2FiNmJhNTRhMWI5ZTYxNzY3OWU4Nzk0YzQ1L3RhYmxlOjJiN2M5MDcyMTc5MTQzYjA4ZjRiZTdlMzgxZTZmY2FkL3RhYmxlcmFuZ2U6MmI3YzkwNzIxNzkxNDNiMDhmNGJlN2UzODFlNmZjYWRfMzEtMy0xLTEtNDEyOTQ_7f35dd89-c8e8-4610-939e-151ec1b4c8e3">64,598</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Long-term operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182NC9mcmFnOjE5MmJkY2FiNmJhNTRhMWI5ZTYxNzY3OWU4Nzk0YzQ1L3RhYmxlOjJiN2M5MDcyMTc5MTQzYjA4ZjRiZTdlMzgxZTZmY2FkL3RhYmxlcmFuZ2U6MmI3YzkwNzIxNzkxNDNiMDhmNGJlN2UzODFlNmZjYWRfMzItMS0xLTEtNDEyOTQ_20380017-28cd-4446-9882-553a67242f34">15,494</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7462d0db8f4248fcb9fd8f1deae439f3_I20201231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182NC9mcmFnOjE5MmJkY2FiNmJhNTRhMWI5ZTYxNzY3OWU4Nzk0YzQ1L3RhYmxlOjJiN2M5MDcyMTc5MTQzYjA4ZjRiZTdlMzgxZTZmY2FkL3RhYmxlcmFuZ2U6MmI3YzkwNzIxNzkxNDNiMDhmNGJlN2UzODFlNmZjYWRfMzItMy0xLTEtNDEyOTQ_e8875dbd-bcdb-4178-8a86-36e1615bd76f">5,643</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182NC9mcmFnOjE5MmJkY2FiNmJhNTRhMWI5ZTYxNzY3OWU4Nzk0YzQ1L3RhYmxlOjJiN2M5MDcyMTc5MTQzYjA4ZjRiZTdlMzgxZTZmY2FkL3RhYmxlcmFuZ2U6MmI3YzkwNzIxNzkxNDNiMDhmNGJlN2UzODFlNmZjYWRfMzMtMS0xLTEtNDEyOTQ_52f6e280-a268-4e69-abb7-8c0cdf761c91">30,977</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7462d0db8f4248fcb9fd8f1deae439f3_I20201231" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182NC9mcmFnOjE5MmJkY2FiNmJhNTRhMWI5ZTYxNzY3OWU4Nzk0YzQ1L3RhYmxlOjJiN2M5MDcyMTc5MTQzYjA4ZjRiZTdlMzgxZTZmY2FkL3RhYmxlcmFuZ2U6MmI3YzkwNzIxNzkxNDNiMDhmNGJlN2UzODFlNmZjYWRfMzMtMy0xLTEtNDEyOTQ_895f3b32-9404-4894-8055-5a43274fb689">30,866</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182NC9mcmFnOjE5MmJkY2FiNmJhNTRhMWI5ZTYxNzY3OWU4Nzk0YzQ1L3RhYmxlOjJiN2M5MDcyMTc5MTQzYjA4ZjRiZTdlMzgxZTZmY2FkL3RhYmxlcmFuZ2U6MmI3YzkwNzIxNzkxNDNiMDhmNGJlN2UzODFlNmZjYWRfMzQtMS0xLTEtNDEyOTQ_cec2a48f-8dc2-4917-b047-f79168cbc027">476,431</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7462d0db8f4248fcb9fd8f1deae439f3_I20201231" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182NC9mcmFnOjE5MmJkY2FiNmJhNTRhMWI5ZTYxNzY3OWU4Nzk0YzQ1L3RhYmxlOjJiN2M5MDcyMTc5MTQzYjA4ZjRiZTdlMzgxZTZmY2FkL3RhYmxlcmFuZ2U6MmI3YzkwNzIxNzkxNDNiMDhmNGJlN2UzODFlNmZjYWRfMzQtMy0xLTEtNDEyOTQ_bb85b27f-e5b4-4f46-8fb7-40f7da48862d">652,760</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Commitments and contingencies</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182NC9mcmFnOjE5MmJkY2FiNmJhNTRhMWI5ZTYxNzY3OWU4Nzk0YzQ1L3RhYmxlOjJiN2M5MDcyMTc5MTQzYjA4ZjRiZTdlMzgxZTZmY2FkL3RhYmxlcmFuZ2U6MmI3YzkwNzIxNzkxNDNiMDhmNGJlN2UzODFlNmZjYWRfMzUtMS0xLTEtNDEyOTQ_94087f28-3c39-4087-ba8f-6f20029a71b6"></ix:nonFraction></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i7462d0db8f4248fcb9fd8f1deae439f3_I20201231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182NC9mcmFnOjE5MmJkY2FiNmJhNTRhMWI5ZTYxNzY3OWU4Nzk0YzQ1L3RhYmxlOjJiN2M5MDcyMTc5MTQzYjA4ZjRiZTdlMzgxZTZmY2FkL3RhYmxlcmFuZ2U6MmI3YzkwNzIxNzkxNDNiMDhmNGJlN2UzODFlNmZjYWRfMzUtMy0xLTEtNDEyOTQ_fe7f019a-08fe-4126-afa6-3b926be9ce9e"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stockholders&#8217; equity:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;Preferred stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182NC9mcmFnOjE5MmJkY2FiNmJhNTRhMWI5ZTYxNzY3OWU4Nzk0YzQ1L3RhYmxlOjJiN2M5MDcyMTc5MTQzYjA4ZjRiZTdlMzgxZTZmY2FkL3RhYmxlcmFuZ2U6MmI3YzkwNzIxNzkxNDNiMDhmNGJlN2UzODFlNmZjYWRfMzctMC0xLTEtNDEyOTQvdGV4dHJlZ2lvbjoyZDM0NGNhMTlkYjE0MjE3YTdhM2U1MGFhZjdhM2E1MV8yNw_58ae8625-e36e-4fd0-8893-5b3fecf1139c"><ix:nonFraction unitRef="usdPerShare" contextRef="i7462d0db8f4248fcb9fd8f1deae439f3_I20201231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182NC9mcmFnOjE5MmJkY2FiNmJhNTRhMWI5ZTYxNzY3OWU4Nzk0YzQ1L3RhYmxlOjJiN2M5MDcyMTc5MTQzYjA4ZjRiZTdlMzgxZTZmY2FkL3RhYmxlcmFuZ2U6MmI3YzkwNzIxNzkxNDNiMDhmNGJlN2UzODFlNmZjYWRfMzctMC0xLTEtNDEyOTQvdGV4dHJlZ2lvbjoyZDM0NGNhMTlkYjE0MjE3YTdhM2U1MGFhZjdhM2E1MV8yNw_bfa2ba8b-e70c-4c83-851c-7dc3c4bd98bf">0.001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="i7462d0db8f4248fcb9fd8f1deae439f3_I20201231" decimals="-3" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182NC9mcmFnOjE5MmJkY2FiNmJhNTRhMWI5ZTYxNzY3OWU4Nzk0YzQ1L3RhYmxlOjJiN2M5MDcyMTc5MTQzYjA4ZjRiZTdlMzgxZTZmY2FkL3RhYmxlcmFuZ2U6MmI3YzkwNzIxNzkxNDNiMDhmNGJlN2UzODFlNmZjYWRfMzctMC0xLTEtNDEyOTQvdGV4dHJlZ2lvbjoyZDM0NGNhMTlkYjE0MjE3YTdhM2U1MGFhZjdhM2E1MV80MQ_338574f8-51b8-4784-8aa7-8c11c1ef0a3e"><ix:nonFraction unitRef="shares" contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231" decimals="-3" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182NC9mcmFnOjE5MmJkY2FiNmJhNTRhMWI5ZTYxNzY3OWU4Nzk0YzQ1L3RhYmxlOjJiN2M5MDcyMTc5MTQzYjA4ZjRiZTdlMzgxZTZmY2FkL3RhYmxlcmFuZ2U6MmI3YzkwNzIxNzkxNDNiMDhmNGJlN2UzODFlNmZjYWRfMzctMC0xLTEtNDEyOTQvdGV4dHJlZ2lvbjoyZDM0NGNhMTlkYjE0MjE3YTdhM2U1MGFhZjdhM2E1MV80MQ_40a32e19-bd69-4a7c-8b41-a1a9697a4ab8">5,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="shares" contextRef="i7462d0db8f4248fcb9fd8f1deae439f3_I20201231" decimals="-3" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182NC9mcmFnOjE5MmJkY2FiNmJhNTRhMWI5ZTYxNzY3OWU4Nzk0YzQ1L3RhYmxlOjJiN2M5MDcyMTc5MTQzYjA4ZjRiZTdlMzgxZTZmY2FkL3RhYmxlcmFuZ2U6MmI3YzkwNzIxNzkxNDNiMDhmNGJlN2UzODFlNmZjYWRfMzctMC0xLTEtNDEyOTQvdGV4dHJlZ2lvbjoyZDM0NGNhMTlkYjE0MjE3YTdhM2U1MGFhZjdhM2E1MV82Mw_6cbfdd67-7fd5-42f0-8942-c6998246b94a"><ix:nonFraction unitRef="shares" contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231" decimals="-3" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182NC9mcmFnOjE5MmJkY2FiNmJhNTRhMWI5ZTYxNzY3OWU4Nzk0YzQ1L3RhYmxlOjJiN2M5MDcyMTc5MTQzYjA4ZjRiZTdlMzgxZTZmY2FkL3RhYmxlcmFuZ2U6MmI3YzkwNzIxNzkxNDNiMDhmNGJlN2UzODFlNmZjYWRfMzctMC0xLTEtNDEyOTQvdGV4dHJlZ2lvbjoyZDM0NGNhMTlkYjE0MjE3YTdhM2U1MGFhZjdhM2E1MV82Mw_8b453d1c-62bf-4e02-a393-774c94f16305"><ix:nonFraction unitRef="shares" contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231" decimals="-3" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182NC9mcmFnOjE5MmJkY2FiNmJhNTRhMWI5ZTYxNzY3OWU4Nzk0YzQ1L3RhYmxlOjJiN2M5MDcyMTc5MTQzYjA4ZjRiZTdlMzgxZTZmY2FkL3RhYmxlcmFuZ2U6MmI3YzkwNzIxNzkxNDNiMDhmNGJlN2UzODFlNmZjYWRfMzctMC0xLTEtNDEyOTQvdGV4dHJlZ2lvbjoyZDM0NGNhMTlkYjE0MjE3YTdhM2U1MGFhZjdhM2E1MV82Mw_924cae15-73fe-49d8-b008-dcd209b734ed"><ix:nonFraction unitRef="shares" contextRef="i7462d0db8f4248fcb9fd8f1deae439f3_I20201231" decimals="-3" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182NC9mcmFnOjE5MmJkY2FiNmJhNTRhMWI5ZTYxNzY3OWU4Nzk0YzQ1L3RhYmxlOjJiN2M5MDcyMTc5MTQzYjA4ZjRiZTdlMzgxZTZmY2FkL3RhYmxlcmFuZ2U6MmI3YzkwNzIxNzkxNDNiMDhmNGJlN2UzODFlNmZjYWRfMzctMC0xLTEtNDEyOTQvdGV4dHJlZ2lvbjoyZDM0NGNhMTlkYjE0MjE3YTdhM2U1MGFhZjdhM2E1MV82Mw_c8320e88-7ae0-4d13-b198-5a55af220c6c">zero</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> issued and outstanding at December 31, 2021 and 2020</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182NC9mcmFnOjE5MmJkY2FiNmJhNTRhMWI5ZTYxNzY3OWU4Nzk0YzQ1L3RhYmxlOjJiN2M5MDcyMTc5MTQzYjA4ZjRiZTdlMzgxZTZmY2FkL3RhYmxlcmFuZ2U6MmI3YzkwNzIxNzkxNDNiMDhmNGJlN2UzODFlNmZjYWRfMzctMS0xLTEtNDEyOTQ_abb50155-30f9-4716-9445-1cd998f2173c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7462d0db8f4248fcb9fd8f1deae439f3_I20201231" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182NC9mcmFnOjE5MmJkY2FiNmJhNTRhMWI5ZTYxNzY3OWU4Nzk0YzQ1L3RhYmxlOjJiN2M5MDcyMTc5MTQzYjA4ZjRiZTdlMzgxZTZmY2FkL3RhYmxlcmFuZ2U6MmI3YzkwNzIxNzkxNDNiMDhmNGJlN2UzODFlNmZjYWRfMzctMy0xLTEtNDEyOTQ_cc25d293-8f2a-4f29-8559-b578412f0678">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i7462d0db8f4248fcb9fd8f1deae439f3_I20201231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182NC9mcmFnOjE5MmJkY2FiNmJhNTRhMWI5ZTYxNzY3OWU4Nzk0YzQ1L3RhYmxlOjJiN2M5MDcyMTc5MTQzYjA4ZjRiZTdlMzgxZTZmY2FkL3RhYmxlcmFuZ2U6MmI3YzkwNzIxNzkxNDNiMDhmNGJlN2UzODFlNmZjYWRfMzgtMC0xLTEtNDEyOTQvdGV4dHJlZ2lvbjpmYzZjMmE2NmIwYTU0YmMwOWJlNTliYWMxOGFjZGQyZF8xOQ_273c7d2c-f26f-4495-8029-3810b9722339"><ix:nonFraction unitRef="usdPerShare" contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182NC9mcmFnOjE5MmJkY2FiNmJhNTRhMWI5ZTYxNzY3OWU4Nzk0YzQ1L3RhYmxlOjJiN2M5MDcyMTc5MTQzYjA4ZjRiZTdlMzgxZTZmY2FkL3RhYmxlcmFuZ2U6MmI3YzkwNzIxNzkxNDNiMDhmNGJlN2UzODFlNmZjYWRfMzgtMC0xLTEtNDEyOTQvdGV4dHJlZ2lvbjpmYzZjMmE2NmIwYTU0YmMwOWJlNTliYWMxOGFjZGQyZF8xOQ_a9c89ef7-0ba6-49e4-8e0f-04d4defc7d37">0.001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231" decimals="-3" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182NC9mcmFnOjE5MmJkY2FiNmJhNTRhMWI5ZTYxNzY3OWU4Nzk0YzQ1L3RhYmxlOjJiN2M5MDcyMTc5MTQzYjA4ZjRiZTdlMzgxZTZmY2FkL3RhYmxlcmFuZ2U6MmI3YzkwNzIxNzkxNDNiMDhmNGJlN2UzODFlNmZjYWRfMzgtMC0xLTEtNDEyOTQvdGV4dHJlZ2lvbjpmYzZjMmE2NmIwYTU0YmMwOWJlNTliYWMxOGFjZGQyZF8zMw_1fbecc58-3aeb-45ab-8dde-fdd7772b1e9c"><ix:nonFraction unitRef="shares" contextRef="i7462d0db8f4248fcb9fd8f1deae439f3_I20201231" decimals="-3" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182NC9mcmFnOjE5MmJkY2FiNmJhNTRhMWI5ZTYxNzY3OWU4Nzk0YzQ1L3RhYmxlOjJiN2M5MDcyMTc5MTQzYjA4ZjRiZTdlMzgxZTZmY2FkL3RhYmxlcmFuZ2U6MmI3YzkwNzIxNzkxNDNiMDhmNGJlN2UzODFlNmZjYWRfMzgtMC0xLTEtNDEyOTQvdGV4dHJlZ2lvbjpmYzZjMmE2NmIwYTU0YmMwOWJlNTliYWMxOGFjZGQyZF8zMw_83cf6256-3452-4a1a-9387-49a45db79334">60,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="shares" contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182NC9mcmFnOjE5MmJkY2FiNmJhNTRhMWI5ZTYxNzY3OWU4Nzk0YzQ1L3RhYmxlOjJiN2M5MDcyMTc5MTQzYjA4ZjRiZTdlMzgxZTZmY2FkL3RhYmxlcmFuZ2U6MmI3YzkwNzIxNzkxNDNiMDhmNGJlN2UzODFlNmZjYWRfMzgtMC0xLTEtNDEyOTQvdGV4dHJlZ2lvbjpmYzZjMmE2NmIwYTU0YmMwOWJlNTliYWMxOGFjZGQyZF81NQ_2edf7342-7552-464a-ba7d-2eab7d3c1f52"><ix:nonFraction unitRef="shares" contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231" decimals="-3" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182NC9mcmFnOjE5MmJkY2FiNmJhNTRhMWI5ZTYxNzY3OWU4Nzk0YzQ1L3RhYmxlOjJiN2M5MDcyMTc5MTQzYjA4ZjRiZTdlMzgxZTZmY2FkL3RhYmxlcmFuZ2U6MmI3YzkwNzIxNzkxNDNiMDhmNGJlN2UzODFlNmZjYWRfMzgtMC0xLTEtNDEyOTQvdGV4dHJlZ2lvbjpmYzZjMmE2NmIwYTU0YmMwOWJlNTliYWMxOGFjZGQyZF81NQ_c1be99da-ac79-4f7d-9271-d140a4f929ee">16,767</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i7462d0db8f4248fcb9fd8f1deae439f3_I20201231" decimals="-3" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182NC9mcmFnOjE5MmJkY2FiNmJhNTRhMWI5ZTYxNzY3OWU4Nzk0YzQ1L3RhYmxlOjJiN2M5MDcyMTc5MTQzYjA4ZjRiZTdlMzgxZTZmY2FkL3RhYmxlcmFuZ2U6MmI3YzkwNzIxNzkxNDNiMDhmNGJlN2UzODFlNmZjYWRfMzgtMC0xLTEtNDEyOTQvdGV4dHJlZ2lvbjpmYzZjMmE2NmIwYTU0YmMwOWJlNTliYWMxOGFjZGQyZF82Mg_659ec51d-fb4f-4677-990f-0aef0afb0ddb"><ix:nonFraction unitRef="shares" contextRef="i7462d0db8f4248fcb9fd8f1deae439f3_I20201231" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182NC9mcmFnOjE5MmJkY2FiNmJhNTRhMWI5ZTYxNzY3OWU4Nzk0YzQ1L3RhYmxlOjJiN2M5MDcyMTc5MTQzYjA4ZjRiZTdlMzgxZTZmY2FkL3RhYmxlcmFuZ2U6MmI3YzkwNzIxNzkxNDNiMDhmNGJlN2UzODFlNmZjYWRfMzgtMC0xLTEtNDEyOTQvdGV4dHJlZ2lvbjpmYzZjMmE2NmIwYTU0YmMwOWJlNTliYWMxOGFjZGQyZF82Mg_debe66dc-4946-48e8-8ecd-1a91b2d3fb58">16,080</ix:nonFraction></ix:nonFraction> shares issued and outstanding at December&#160;31, 2021 and 2020, respectively</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182NC9mcmFnOjE5MmJkY2FiNmJhNTRhMWI5ZTYxNzY3OWU4Nzk0YzQ1L3RhYmxlOjJiN2M5MDcyMTc5MTQzYjA4ZjRiZTdlMzgxZTZmY2FkL3RhYmxlcmFuZ2U6MmI3YzkwNzIxNzkxNDNiMDhmNGJlN2UzODFlNmZjYWRfMzgtMS0xLTEtNDEyOTQ_ea3032e5-2572-4ae0-b7b0-ec72a4bea21b">17</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7462d0db8f4248fcb9fd8f1deae439f3_I20201231" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182NC9mcmFnOjE5MmJkY2FiNmJhNTRhMWI5ZTYxNzY3OWU4Nzk0YzQ1L3RhYmxlOjJiN2M5MDcyMTc5MTQzYjA4ZjRiZTdlMzgxZTZmY2FkL3RhYmxlcmFuZ2U6MmI3YzkwNzIxNzkxNDNiMDhmNGJlN2UzODFlNmZjYWRfMzgtMy0xLTEtNDEyOTQ_9574ed40-2bf4-401e-a4af-503a3ec12a74">16</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182NC9mcmFnOjE5MmJkY2FiNmJhNTRhMWI5ZTYxNzY3OWU4Nzk0YzQ1L3RhYmxlOjJiN2M5MDcyMTc5MTQzYjA4ZjRiZTdlMzgxZTZmY2FkL3RhYmxlcmFuZ2U6MmI3YzkwNzIxNzkxNDNiMDhmNGJlN2UzODFlNmZjYWRfMzktMS0xLTEtNDEyOTQ_649bdc95-0a02-45f0-bf3d-a55c33672434">372,969</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7462d0db8f4248fcb9fd8f1deae439f3_I20201231" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182NC9mcmFnOjE5MmJkY2FiNmJhNTRhMWI5ZTYxNzY3OWU4Nzk0YzQ1L3RhYmxlOjJiN2M5MDcyMTc5MTQzYjA4ZjRiZTdlMzgxZTZmY2FkL3RhYmxlcmFuZ2U6MmI3YzkwNzIxNzkxNDNiMDhmNGJlN2UzODFlNmZjYWRfMzktMy0xLTEtNDEyOTQ_32367c97-3ed0-4cd7-9ff5-3e55943a6261">318,358</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182NC9mcmFnOjE5MmJkY2FiNmJhNTRhMWI5ZTYxNzY3OWU4Nzk0YzQ1L3RhYmxlOjJiN2M5MDcyMTc5MTQzYjA4ZjRiZTdlMzgxZTZmY2FkL3RhYmxlcmFuZ2U6MmI3YzkwNzIxNzkxNDNiMDhmNGJlN2UzODFlNmZjYWRfNDAtMS0xLTEtNDEyOTQ_b0249463-fca7-4c09-b689-dd8efe4771ad">917</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7462d0db8f4248fcb9fd8f1deae439f3_I20201231" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182NC9mcmFnOjE5MmJkY2FiNmJhNTRhMWI5ZTYxNzY3OWU4Nzk0YzQ1L3RhYmxlOjJiN2M5MDcyMTc5MTQzYjA4ZjRiZTdlMzgxZTZmY2FkL3RhYmxlcmFuZ2U6MmI3YzkwNzIxNzkxNDNiMDhmNGJlN2UzODFlNmZjYWRfNDAtMy0xLTEtNDEyOTQ_80f23b2f-c988-40f6-b28c-10262fe3c8ed">801</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Retained earnings</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231" decimals="-3" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182NC9mcmFnOjE5MmJkY2FiNmJhNTRhMWI5ZTYxNzY3OWU4Nzk0YzQ1L3RhYmxlOjJiN2M5MDcyMTc5MTQzYjA4ZjRiZTdlMzgxZTZmY2FkL3RhYmxlcmFuZ2U6MmI3YzkwNzIxNzkxNDNiMDhmNGJlN2UzODFlNmZjYWRfNDEtMS0xLTEtNDEyOTQ_30898963-0f6f-4229-989e-4c52005d0f3a">449,090</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7462d0db8f4248fcb9fd8f1deae439f3_I20201231" decimals="-3" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182NC9mcmFnOjE5MmJkY2FiNmJhNTRhMWI5ZTYxNzY3OWU4Nzk0YzQ1L3RhYmxlOjJiN2M5MDcyMTc5MTQzYjA4ZjRiZTdlMzgxZTZmY2FkL3RhYmxlcmFuZ2U6MmI3YzkwNzIxNzkxNDNiMDhmNGJlN2UzODFlNmZjYWRfNDEtMy0xLTEtNDEyOTQ_7abea5d5-75a9-4869-a38c-d6fc4c016180">391,952</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total stockholders&#8217; equity</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182NC9mcmFnOjE5MmJkY2FiNmJhNTRhMWI5ZTYxNzY3OWU4Nzk0YzQ1L3RhYmxlOjJiN2M5MDcyMTc5MTQzYjA4ZjRiZTdlMzgxZTZmY2FkL3RhYmxlcmFuZ2U6MmI3YzkwNzIxNzkxNDNiMDhmNGJlN2UzODFlNmZjYWRfNDItMS0xLTEtNDEyOTQ_9a81b84c-d5d3-4ba8-8175-228a185a584f">821,159</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7462d0db8f4248fcb9fd8f1deae439f3_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182NC9mcmFnOjE5MmJkY2FiNmJhNTRhMWI5ZTYxNzY3OWU4Nzk0YzQ1L3RhYmxlOjJiN2M5MDcyMTc5MTQzYjA4ZjRiZTdlMzgxZTZmY2FkL3RhYmxlcmFuZ2U6MmI3YzkwNzIxNzkxNDNiMDhmNGJlN2UzODFlNmZjYWRfNDItMy0xLTEtNDEyOTQ_07daf109-583a-4351-9de3-d6a1f6a52d10">709,525</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;Total liabilities and stockholders&#8217; equity </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182NC9mcmFnOjE5MmJkY2FiNmJhNTRhMWI5ZTYxNzY3OWU4Nzk0YzQ1L3RhYmxlOjJiN2M5MDcyMTc5MTQzYjA4ZjRiZTdlMzgxZTZmY2FkL3RhYmxlcmFuZ2U6MmI3YzkwNzIxNzkxNDNiMDhmNGJlN2UzODFlNmZjYWRfNDMtMS0xLTEtNDEyOTQ_4e58d3cb-693a-4232-a6da-331c6bda96fd">1,297,590</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7462d0db8f4248fcb9fd8f1deae439f3_I20201231" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182NC9mcmFnOjE5MmJkY2FiNmJhNTRhMWI5ZTYxNzY3OWU4Nzk0YzQ1L3RhYmxlOjJiN2M5MDcyMTc5MTQzYjA4ZjRiZTdlMzgxZTZmY2FkL3RhYmxlcmFuZ2U6MmI3YzkwNzIxNzkxNDNiMDhmNGJlN2UzODFlNmZjYWRfNDMtMy0xLTEtNDEyOTQ_e68a7afd-0f0d-4e41-a151-e9bf7ba45742">1,362,285</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying notes to these consolidated financial statements.</span></div><div id="i0fa6f906fb2e4e30bc5e873d2bb6a82c_67"></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">54</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">LIGAND PHARMACEUTICALS INCORPORATED</span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF OPERATIONS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except per share amounts)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:62.723%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.664%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.370%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.373%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Revenues:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Royalties</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id759bc1766674b9fb61441df044bc82f_D20210101-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182Ny9mcmFnOmYzZTY4ZDllY2E0ODQ3ZDBhMTEzNmVlNGZlMzY4NGJlL3RhYmxlOjgzMDA4NWQwN2ZjZDQ1NGE5YzZiNDA1MjZiNGYwYzUzL3RhYmxlcmFuZ2U6ODMwMDg1ZDA3ZmNkNDU0YTljNmI0MDUyNmI0ZjBjNTNfMy0xLTEtMS00MTI5NA_d2306939-5160-4c94-87b8-3530a661cf10">48,927</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3c33038f43443e48bceca35aafc84c2_D20200101-20201231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182Ny9mcmFnOmYzZTY4ZDllY2E0ODQ3ZDBhMTEzNmVlNGZlMzY4NGJlL3RhYmxlOjgzMDA4NWQwN2ZjZDQ1NGE5YzZiNDA1MjZiNGYwYzUzL3RhYmxlcmFuZ2U6ODMwMDg1ZDA3ZmNkNDU0YTljNmI0MDUyNmI0ZjBjNTNfMy0zLTEtMS00MTI5NA_5250d258-6cb3-421f-9232-d63ae0a32303">33,796</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3bced838db93465eb75b31bbd5690a49_D20190101-20191231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182Ny9mcmFnOmYzZTY4ZDllY2E0ODQ3ZDBhMTEzNmVlNGZlMzY4NGJlL3RhYmxlOjgzMDA4NWQwN2ZjZDQ1NGE5YzZiNDA1MjZiNGYwYzUzL3RhYmxlcmFuZ2U6ODMwMDg1ZDA3ZmNkNDU0YTljNmI0MDUyNmI0ZjBjNTNfMy01LTEtMS00MTI5NA_a7b4bf93-64c1-473a-a797-9733b7fe16a0">46,976</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Captisol</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1477966cad0140da81a9947fe9bab347_D20210101-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182Ny9mcmFnOmYzZTY4ZDllY2E0ODQ3ZDBhMTEzNmVlNGZlMzY4NGJlL3RhYmxlOjgzMDA4NWQwN2ZjZDQ1NGE5YzZiNDA1MjZiNGYwYzUzL3RhYmxlcmFuZ2U6ODMwMDg1ZDA3ZmNkNDU0YTljNmI0MDUyNmI0ZjBjNTNfNC0xLTEtMS00MTI5NA_d5cde1ac-6f81-44be-9250-5b7608954f3a">164,250</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7b5c3c10a34465088f2fa15825a2c42_D20200101-20201231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182Ny9mcmFnOmYzZTY4ZDllY2E0ODQ3ZDBhMTEzNmVlNGZlMzY4NGJlL3RhYmxlOjgzMDA4NWQwN2ZjZDQ1NGE5YzZiNDA1MjZiNGYwYzUzL3RhYmxlcmFuZ2U6ODMwMDg1ZDA3ZmNkNDU0YTljNmI0MDUyNmI0ZjBjNTNfNC0zLTEtMS00MTI5NA_08708d36-6ca2-48ff-a617-b56dfa47e8e8">109,959</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75309306f08c443f8965a9846c0fb0fc_D20190101-20191231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182Ny9mcmFnOmYzZTY4ZDllY2E0ODQ3ZDBhMTEzNmVlNGZlMzY4NGJlL3RhYmxlOjgzMDA4NWQwN2ZjZDQ1NGE5YzZiNDA1MjZiNGYwYzUzL3RhYmxlcmFuZ2U6ODMwMDg1ZDA3ZmNkNDU0YTljNmI0MDUyNmI0ZjBjNTNfNC01LTEtMS00MTI5NA_4b62efb1-0b21-4695-bca7-b53753ab83bb">31,489</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contract revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11e3d543e376468e8dda481609ac67e8_D20210101-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182Ny9mcmFnOmYzZTY4ZDllY2E0ODQ3ZDBhMTEzNmVlNGZlMzY4NGJlL3RhYmxlOjgzMDA4NWQwN2ZjZDQ1NGE5YzZiNDA1MjZiNGYwYzUzL3RhYmxlcmFuZ2U6ODMwMDg1ZDA3ZmNkNDU0YTljNmI0MDUyNmI0ZjBjNTNfNS0xLTEtMS00MTI5NA_7adfc46e-c3e1-4418-9614-d18883ca4a67">63,956</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if06efbad02a54e9d92b23a3ff376910e_D20200101-20201231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182Ny9mcmFnOmYzZTY4ZDllY2E0ODQ3ZDBhMTEzNmVlNGZlMzY4NGJlL3RhYmxlOjgzMDA4NWQwN2ZjZDQ1NGE5YzZiNDA1MjZiNGYwYzUzL3RhYmxlcmFuZ2U6ODMwMDg1ZDA3ZmNkNDU0YTljNmI0MDUyNmI0ZjBjNTNfNS0zLTEtMS00MTI5NA_fe2d193c-db4f-42c9-ba41-3fc3ac3c3a4b">42,664</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idea9b96f20cf4c28aea8b365b1b2069c_D20190101-20191231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182Ny9mcmFnOmYzZTY4ZDllY2E0ODQ3ZDBhMTEzNmVlNGZlMzY4NGJlL3RhYmxlOjgzMDA4NWQwN2ZjZDQ1NGE5YzZiNDA1MjZiNGYwYzUzL3RhYmxlcmFuZ2U6ODMwMDg1ZDA3ZmNkNDU0YTljNmI0MDUyNmI0ZjBjNTNfNS01LTEtMS00MTI5NA_0240bf7b-a97f-4f60-beae-efa111985b79">41,817</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182Ny9mcmFnOmYzZTY4ZDllY2E0ODQ3ZDBhMTEzNmVlNGZlMzY4NGJlL3RhYmxlOjgzMDA4NWQwN2ZjZDQ1NGE5YzZiNDA1MjZiNGYwYzUzL3RhYmxlcmFuZ2U6ODMwMDg1ZDA3ZmNkNDU0YTljNmI0MDUyNmI0ZjBjNTNfNi0xLTEtMS00MTI5NA_022bf06f-a0f7-40d4-b7b2-00273590d30e">277,133</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3597315a63d441f8f128abd7ed8840e_D20200101-20201231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182Ny9mcmFnOmYzZTY4ZDllY2E0ODQ3ZDBhMTEzNmVlNGZlMzY4NGJlL3RhYmxlOjgzMDA4NWQwN2ZjZDQ1NGE5YzZiNDA1MjZiNGYwYzUzL3RhYmxlcmFuZ2U6ODMwMDg1ZDA3ZmNkNDU0YTljNmI0MDUyNmI0ZjBjNTNfNi0zLTEtMS00MTI5NA_51aa782e-4c4a-4c84-9dcf-eba714833480">186,419</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6c3b69702e9429aaeed46bdb9bbb9c1_D20190101-20191231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182Ny9mcmFnOmYzZTY4ZDllY2E0ODQ3ZDBhMTEzNmVlNGZlMzY4NGJlL3RhYmxlOjgzMDA4NWQwN2ZjZDQ1NGE5YzZiNDA1MjZiNGYwYzUzL3RhYmxlcmFuZ2U6ODMwMDg1ZDA3ZmNkNDU0YTljNmI0MDUyNmI0ZjBjNTNfNi01LTEtMS00MTI5NA_de24d407-24e1-444b-9a47-af90eecebc6d">120,282</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating costs and expenses:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cost of Captisol</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231" decimals="-3" name="us-gaap:CostDirectMaterial" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182Ny9mcmFnOmYzZTY4ZDllY2E0ODQ3ZDBhMTEzNmVlNGZlMzY4NGJlL3RhYmxlOjgzMDA4NWQwN2ZjZDQ1NGE5YzZiNDA1MjZiNGYwYzUzL3RhYmxlcmFuZ2U6ODMwMDg1ZDA3ZmNkNDU0YTljNmI0MDUyNmI0ZjBjNTNfOC0xLTEtMS00MTI5NA_34a4e2c4-9713-46b7-9322-be83910e6220">62,176</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3597315a63d441f8f128abd7ed8840e_D20200101-20201231" decimals="-3" name="us-gaap:CostDirectMaterial" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182Ny9mcmFnOmYzZTY4ZDllY2E0ODQ3ZDBhMTEzNmVlNGZlMzY4NGJlL3RhYmxlOjgzMDA4NWQwN2ZjZDQ1NGE5YzZiNDA1MjZiNGYwYzUzL3RhYmxlcmFuZ2U6ODMwMDg1ZDA3ZmNkNDU0YTljNmI0MDUyNmI0ZjBjNTNfOC0zLTEtMS00MTI5NA_ee19bcb3-9b02-4d6a-a749-5ae3c47764a8">30,419</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6c3b69702e9429aaeed46bdb9bbb9c1_D20190101-20191231" decimals="-3" name="us-gaap:CostDirectMaterial" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182Ny9mcmFnOmYzZTY4ZDllY2E0ODQ3ZDBhMTEzNmVlNGZlMzY4NGJlL3RhYmxlOjgzMDA4NWQwN2ZjZDQ1NGE5YzZiNDA1MjZiNGYwYzUzL3RhYmxlcmFuZ2U6ODMwMDg1ZDA3ZmNkNDU0YTljNmI0MDUyNmI0ZjBjNTNfOC01LTEtMS00MTI5NA_c8fe7538-77ee-4155-950d-6c3d61a05dd4">11,347</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization of intangibles</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSoldAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182Ny9mcmFnOmYzZTY4ZDllY2E0ODQ3ZDBhMTEzNmVlNGZlMzY4NGJlL3RhYmxlOjgzMDA4NWQwN2ZjZDQ1NGE5YzZiNDA1MjZiNGYwYzUzL3RhYmxlcmFuZ2U6ODMwMDg1ZDA3ZmNkNDU0YTljNmI0MDUyNmI0ZjBjNTNfOS0xLTEtMS00MTI5NA_20b874c4-38ff-41cd-a9da-af5d2379d2ec">47,167</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3597315a63d441f8f128abd7ed8840e_D20200101-20201231" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSoldAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182Ny9mcmFnOmYzZTY4ZDllY2E0ODQ3ZDBhMTEzNmVlNGZlMzY4NGJlL3RhYmxlOjgzMDA4NWQwN2ZjZDQ1NGE5YzZiNDA1MjZiNGYwYzUzL3RhYmxlcmFuZ2U6ODMwMDg1ZDA3ZmNkNDU0YTljNmI0MDUyNmI0ZjBjNTNfOS0zLTEtMS00MTI5NA_dd233803-3c89-4f6a-8bce-87be6d88f01a">23,442</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6c3b69702e9429aaeed46bdb9bbb9c1_D20190101-20191231" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSoldAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182Ny9mcmFnOmYzZTY4ZDllY2E0ODQ3ZDBhMTEzNmVlNGZlMzY4NGJlL3RhYmxlOjgzMDA4NWQwN2ZjZDQ1NGE5YzZiNDA1MjZiNGYwYzUzL3RhYmxlcmFuZ2U6ODMwMDg1ZDA3ZmNkNDU0YTljNmI0MDUyNmI0ZjBjNTNfOS01LTEtMS00MTI5NA_d5d54818-316f-4554-8adc-4794aa766c09">16,864</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182Ny9mcmFnOmYzZTY4ZDllY2E0ODQ3ZDBhMTEzNmVlNGZlMzY4NGJlL3RhYmxlOjgzMDA4NWQwN2ZjZDQ1NGE5YzZiNDA1MjZiNGYwYzUzL3RhYmxlcmFuZ2U6ODMwMDg1ZDA3ZmNkNDU0YTljNmI0MDUyNmI0ZjBjNTNfMTAtMS0xLTEtNDEyOTQ_98779b9c-864b-490d-a560-f09b597ba950">69,012</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3597315a63d441f8f128abd7ed8840e_D20200101-20201231" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182Ny9mcmFnOmYzZTY4ZDllY2E0ODQ3ZDBhMTEzNmVlNGZlMzY4NGJlL3RhYmxlOjgzMDA4NWQwN2ZjZDQ1NGE5YzZiNDA1MjZiNGYwYzUzL3RhYmxlcmFuZ2U6ODMwMDg1ZDA3ZmNkNDU0YTljNmI0MDUyNmI0ZjBjNTNfMTAtMy0xLTEtNDEyOTQ_f05d5eaa-2e43-4ed6-8393-fef2be5bcd05">59,392</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6c3b69702e9429aaeed46bdb9bbb9c1_D20190101-20191231" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182Ny9mcmFnOmYzZTY4ZDllY2E0ODQ3ZDBhMTEzNmVlNGZlMzY4NGJlL3RhYmxlOjgzMDA4NWQwN2ZjZDQ1NGE5YzZiNDA1MjZiNGYwYzUzL3RhYmxlcmFuZ2U6ODMwMDg1ZDA3ZmNkNDU0YTljNmI0MDUyNmI0ZjBjNTNfMTAtNS0xLTEtNDEyOTQ_753dae27-2394-49dd-85e6-6769c4541a2b">55,908</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182Ny9mcmFnOmYzZTY4ZDllY2E0ODQ3ZDBhMTEzNmVlNGZlMzY4NGJlL3RhYmxlOjgzMDA4NWQwN2ZjZDQ1NGE5YzZiNDA1MjZiNGYwYzUzL3RhYmxlcmFuZ2U6ODMwMDg1ZDA3ZmNkNDU0YTljNmI0MDUyNmI0ZjBjNTNfMTEtMS0xLTEtNDEyOTQ_b811ecf8-3083-4d45-baaa-7533d31f7ea4">57,483</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3597315a63d441f8f128abd7ed8840e_D20200101-20201231" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182Ny9mcmFnOmYzZTY4ZDllY2E0ODQ3ZDBhMTEzNmVlNGZlMzY4NGJlL3RhYmxlOjgzMDA4NWQwN2ZjZDQ1NGE5YzZiNDA1MjZiNGYwYzUzL3RhYmxlcmFuZ2U6ODMwMDg1ZDA3ZmNkNDU0YTljNmI0MDUyNmI0ZjBjNTNfMTEtMy0xLTEtNDEyOTQ_4b4be6f7-5076-4880-aa45-7eb5771d8a81">64,435</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6c3b69702e9429aaeed46bdb9bbb9c1_D20190101-20191231" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182Ny9mcmFnOmYzZTY4ZDllY2E0ODQ3ZDBhMTEzNmVlNGZlMzY4NGJlL3RhYmxlOjgzMDA4NWQwN2ZjZDQ1NGE5YzZiNDA1MjZiNGYwYzUzL3RhYmxlcmFuZ2U6ODMwMDg1ZDA3ZmNkNDU0YTljNmI0MDUyNmI0ZjBjNTNfMTEtNS0xLTEtNDEyOTQ_b4651e93-7cf7-4471-8a9a-b4f4f6fb2b18">41,884</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other operating income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231" decimals="-3" name="us-gaap:OtherOperatingIncome" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182Ny9mcmFnOmYzZTY4ZDllY2E0ODQ3ZDBhMTEzNmVlNGZlMzY4NGJlL3RhYmxlOjgzMDA4NWQwN2ZjZDQ1NGE5YzZiNDA1MjZiNGYwYzUzL3RhYmxlcmFuZ2U6ODMwMDg1ZDA3ZmNkNDU0YTljNmI0MDUyNmI0ZjBjNTNfMTItMS0xLTEtNTE3NDM_9e362b0b-c3a1-4d7a-a8b8-5a6a44bad7ae">37,600</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3597315a63d441f8f128abd7ed8840e_D20200101-20201231" decimals="-3" name="us-gaap:OtherOperatingIncome" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182Ny9mcmFnOmYzZTY4ZDllY2E0ODQ3ZDBhMTEzNmVlNGZlMzY4NGJlL3RhYmxlOjgzMDA4NWQwN2ZjZDQ1NGE5YzZiNDA1MjZiNGYwYzUzL3RhYmxlcmFuZ2U6ODMwMDg1ZDA3ZmNkNDU0YTljNmI0MDUyNmI0ZjBjNTNfMTItMy0xLTEtNTE3NjA_df31161f-a649-4410-842f-332e6f923457">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6c3b69702e9429aaeed46bdb9bbb9c1_D20190101-20191231" decimals="-3" name="us-gaap:OtherOperatingIncome" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182Ny9mcmFnOmYzZTY4ZDllY2E0ODQ3ZDBhMTEzNmVlNGZlMzY4NGJlL3RhYmxlOjgzMDA4NWQwN2ZjZDQ1NGE5YzZiNDA1MjZiNGYwYzUzL3RhYmxlcmFuZ2U6ODMwMDg1ZDA3ZmNkNDU0YTljNmI0MDUyNmI0ZjBjNTNfMTItNS0xLTEtNTIwNjg_debd8e36-d50f-4bcf-9c4f-0f77eef0eb1e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total operating costs and expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231" decimals="-3" name="us-gaap:OperatingCostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182Ny9mcmFnOmYzZTY4ZDllY2E0ODQ3ZDBhMTEzNmVlNGZlMzY4NGJlL3RhYmxlOjgzMDA4NWQwN2ZjZDQ1NGE5YzZiNDA1MjZiNGYwYzUzL3RhYmxlcmFuZ2U6ODMwMDg1ZDA3ZmNkNDU0YTljNmI0MDUyNmI0ZjBjNTNfMTItMS0xLTEtNDEyOTQ_13d189b2-fd15-437b-a13c-f1c100ff8031">198,238</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3597315a63d441f8f128abd7ed8840e_D20200101-20201231" decimals="-3" name="us-gaap:OperatingCostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182Ny9mcmFnOmYzZTY4ZDllY2E0ODQ3ZDBhMTEzNmVlNGZlMzY4NGJlL3RhYmxlOjgzMDA4NWQwN2ZjZDQ1NGE5YzZiNDA1MjZiNGYwYzUzL3RhYmxlcmFuZ2U6ODMwMDg1ZDA3ZmNkNDU0YTljNmI0MDUyNmI0ZjBjNTNfMTItMy0xLTEtNDEyOTQ_cc5e3b80-f9e4-441e-a306-dd7528efb915">177,688</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6c3b69702e9429aaeed46bdb9bbb9c1_D20190101-20191231" decimals="-3" name="us-gaap:OperatingCostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182Ny9mcmFnOmYzZTY4ZDllY2E0ODQ3ZDBhMTEzNmVlNGZlMzY4NGJlL3RhYmxlOjgzMDA4NWQwN2ZjZDQ1NGE5YzZiNDA1MjZiNGYwYzUzL3RhYmxlcmFuZ2U6ODMwMDg1ZDA3ZmNkNDU0YTljNmI0MDUyNmI0ZjBjNTNfMTItNS0xLTEtNDEyOTQ_6757d12b-fada-4bb7-8b31-8f5e483ce71e">126,003</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gain from sale of Vernalis R&amp;D</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i85c760e4f98147f79ecf9fc666a45595_D20210101-20211231" decimals="-3" name="us-gaap:GainLossOnDispositionOfIntangibleAssets" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182Ny9mcmFnOmYzZTY4ZDllY2E0ODQ3ZDBhMTEzNmVlNGZlMzY4NGJlL3RhYmxlOjgzMDA4NWQwN2ZjZDQ1NGE5YzZiNDA1MjZiNGYwYzUzL3RhYmxlcmFuZ2U6ODMwMDg1ZDA3ZmNkNDU0YTljNmI0MDUyNmI0ZjBjNTNfMTMtMS0xLTEtNDEyOTQ_56bcb15d-d776-4440-8c3a-6a424011cc2f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb5d6e3d481646168203ad91e5a3ab1c_D20200101-20201231" decimals="-3" name="us-gaap:GainLossOnDispositionOfIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182Ny9mcmFnOmYzZTY4ZDllY2E0ODQ3ZDBhMTEzNmVlNGZlMzY4NGJlL3RhYmxlOjgzMDA4NWQwN2ZjZDQ1NGE5YzZiNDA1MjZiNGYwYzUzL3RhYmxlcmFuZ2U6ODMwMDg1ZDA3ZmNkNDU0YTljNmI0MDUyNmI0ZjBjNTNfMTMtMy0xLTEtNDEyOTQ_dac6b3e0-2b4c-47c3-b86e-b6bff531bfc6">17,114</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id75620cd2ae8495a9c4aff23e56271fa_D20190101-20191231" decimals="-3" name="us-gaap:GainLossOnDispositionOfIntangibleAssets" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182Ny9mcmFnOmYzZTY4ZDllY2E0ODQ3ZDBhMTEzNmVlNGZlMzY4NGJlL3RhYmxlOjgzMDA4NWQwN2ZjZDQ1NGE5YzZiNDA1MjZiNGYwYzUzL3RhYmxlcmFuZ2U6ODMwMDg1ZDA3ZmNkNDU0YTljNmI0MDUyNmI0ZjBjNTNfMTMtNS0xLTEtNDEyOTQ_8144c2b9-6ed3-4294-a15f-8f7913c85631">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gain from sale of Promacta license</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5ccedf4402b42a79d8bd7ff8d46fd9a_D20210101-20211231" decimals="-3" name="us-gaap:GainLossOnDispositionOfIntangibleAssets" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182Ny9mcmFnOmYzZTY4ZDllY2E0ODQ3ZDBhMTEzNmVlNGZlMzY4NGJlL3RhYmxlOjgzMDA4NWQwN2ZjZDQ1NGE5YzZiNDA1MjZiNGYwYzUzL3RhYmxlcmFuZ2U6ODMwMDg1ZDA3ZmNkNDU0YTljNmI0MDUyNmI0ZjBjNTNfMTQtMS0xLTEtNDEyOTQ_125124a7-3538-4327-ac93-cb3c072898c9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic02ae2c8af73463a961944407c02e1da_D20200101-20201231" decimals="-3" name="us-gaap:GainLossOnDispositionOfIntangibleAssets" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182Ny9mcmFnOmYzZTY4ZDllY2E0ODQ3ZDBhMTEzNmVlNGZlMzY4NGJlL3RhYmxlOjgzMDA4NWQwN2ZjZDQ1NGE5YzZiNDA1MjZiNGYwYzUzL3RhYmxlcmFuZ2U6ODMwMDg1ZDA3ZmNkNDU0YTljNmI0MDUyNmI0ZjBjNTNfMTQtMy0xLTEtNDEyOTQ_bf47a9b5-76c5-4baf-8f0e-55d1a1e993da">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21165c6e7ed34bec9a1abbd4497ce88b_D20190101-20191231" decimals="-3" name="us-gaap:GainLossOnDispositionOfIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182Ny9mcmFnOmYzZTY4ZDllY2E0ODQ3ZDBhMTEzNmVlNGZlMzY4NGJlL3RhYmxlOjgzMDA4NWQwN2ZjZDQ1NGE5YzZiNDA1MjZiNGYwYzUzL3RhYmxlcmFuZ2U6ODMwMDg1ZDA3ZmNkNDU0YTljNmI0MDUyNmI0ZjBjNTNfMTQtNS0xLTEtNDEyOTQ_e034f610-d7e4-4c1c-9b84-31da075f56b3">812,797</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income from operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231" decimals="-3" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182Ny9mcmFnOmYzZTY4ZDllY2E0ODQ3ZDBhMTEzNmVlNGZlMzY4NGJlL3RhYmxlOjgzMDA4NWQwN2ZjZDQ1NGE5YzZiNDA1MjZiNGYwYzUzL3RhYmxlcmFuZ2U6ODMwMDg1ZDA3ZmNkNDU0YTljNmI0MDUyNmI0ZjBjNTNfMTUtMS0xLTEtNDEyOTQ_0a47b190-6b77-4544-9f99-6e6861582026">78,895</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3597315a63d441f8f128abd7ed8840e_D20200101-20201231" decimals="-3" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182Ny9mcmFnOmYzZTY4ZDllY2E0ODQ3ZDBhMTEzNmVlNGZlMzY4NGJlL3RhYmxlOjgzMDA4NWQwN2ZjZDQ1NGE5YzZiNDA1MjZiNGYwYzUzL3RhYmxlcmFuZ2U6ODMwMDg1ZDA3ZmNkNDU0YTljNmI0MDUyNmI0ZjBjNTNfMTUtMy0xLTEtNDEyOTQ_ef623ce1-9e53-4334-891a-6f740be970d2">25,845</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6c3b69702e9429aaeed46bdb9bbb9c1_D20190101-20191231" decimals="-3" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182Ny9mcmFnOmYzZTY4ZDllY2E0ODQ3ZDBhMTEzNmVlNGZlMzY4NGJlL3RhYmxlOjgzMDA4NWQwN2ZjZDQ1NGE5YzZiNDA1MjZiNGYwYzUzL3RhYmxlcmFuZ2U6ODMwMDg1ZDA3ZmNkNDU0YTljNmI0MDUyNmI0ZjBjNTNfMTUtNS0xLTEtNDEyOTQ_a1ce7e3f-45ea-4c5b-bb09-b5b7b48f5bfc">807,076</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other income (expense):</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gain (loss) from short-term investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:GainLossOnInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182Ny9mcmFnOmYzZTY4ZDllY2E0ODQ3ZDBhMTEzNmVlNGZlMzY4NGJlL3RhYmxlOjgzMDA4NWQwN2ZjZDQ1NGE5YzZiNDA1MjZiNGYwYzUzL3RhYmxlcmFuZ2U6ODMwMDg1ZDA3ZmNkNDU0YTljNmI0MDUyNmI0ZjBjNTNfMTctMS0xLTEtNDEyOTQ_45e43b27-5cf2-41ed-9229-0b0ff4f3604b">3,997</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib3597315a63d441f8f128abd7ed8840e_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:GainLossOnInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182Ny9mcmFnOmYzZTY4ZDllY2E0ODQ3ZDBhMTEzNmVlNGZlMzY4NGJlL3RhYmxlOjgzMDA4NWQwN2ZjZDQ1NGE5YzZiNDA1MjZiNGYwYzUzL3RhYmxlcmFuZ2U6ODMwMDg1ZDA3ZmNkNDU0YTljNmI0MDUyNmI0ZjBjNTNfMTctMy0xLTEtNDEyOTQ_ad50c358-77dc-4b46-a1af-95e9d3350c60">16,933</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6c3b69702e9429aaeed46bdb9bbb9c1_D20190101-20191231" decimals="-3" name="us-gaap:GainLossOnInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182Ny9mcmFnOmYzZTY4ZDllY2E0ODQ3ZDBhMTEzNmVlNGZlMzY4NGJlL3RhYmxlOjgzMDA4NWQwN2ZjZDQ1NGE5YzZiNDA1MjZiNGYwYzUzL3RhYmxlcmFuZ2U6ODMwMDg1ZDA3ZmNkNDU0YTljNmI0MDUyNmI0ZjBjNTNfMTctNS0xLTEtNDEyOTQ_3c40ec36-59f4-454a-8dbe-942e32db5c7c">1,049</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231" decimals="-3" name="us-gaap:InvestmentIncomeInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182Ny9mcmFnOmYzZTY4ZDllY2E0ODQ3ZDBhMTEzNmVlNGZlMzY4NGJlL3RhYmxlOjgzMDA4NWQwN2ZjZDQ1NGE5YzZiNDA1MjZiNGYwYzUzL3RhYmxlcmFuZ2U6ODMwMDg1ZDA3ZmNkNDU0YTljNmI0MDUyNmI0ZjBjNTNfMTgtMS0xLTEtNDEyOTQ_c068756a-d52d-4bda-a0fd-73ebdab6d01e">886</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3597315a63d441f8f128abd7ed8840e_D20200101-20201231" decimals="-3" name="us-gaap:InvestmentIncomeInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182Ny9mcmFnOmYzZTY4ZDllY2E0ODQ3ZDBhMTEzNmVlNGZlMzY4NGJlL3RhYmxlOjgzMDA4NWQwN2ZjZDQ1NGE5YzZiNDA1MjZiNGYwYzUzL3RhYmxlcmFuZ2U6ODMwMDg1ZDA3ZmNkNDU0YTljNmI0MDUyNmI0ZjBjNTNfMTgtMy0xLTEtNDEyOTQ_90b440e0-f722-4f86-bb00-adcab81e2de1">8,078</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6c3b69702e9429aaeed46bdb9bbb9c1_D20190101-20191231" decimals="-3" name="us-gaap:InvestmentIncomeInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182Ny9mcmFnOmYzZTY4ZDllY2E0ODQ3ZDBhMTEzNmVlNGZlMzY4NGJlL3RhYmxlOjgzMDA4NWQwN2ZjZDQ1NGE5YzZiNDA1MjZiNGYwYzUzL3RhYmxlcmFuZ2U6ODMwMDg1ZDA3ZmNkNDU0YTljNmI0MDUyNmI0ZjBjNTNfMTgtNS0xLTEtNDEyOTQ_d1bae809-7bdb-42a7-a653-d091b82eeaa2">28,430</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231" decimals="-3" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182Ny9mcmFnOmYzZTY4ZDllY2E0ODQ3ZDBhMTEzNmVlNGZlMzY4NGJlL3RhYmxlOjgzMDA4NWQwN2ZjZDQ1NGE5YzZiNDA1MjZiNGYwYzUzL3RhYmxlcmFuZ2U6ODMwMDg1ZDA3ZmNkNDU0YTljNmI0MDUyNmI0ZjBjNTNfMTktMS0xLTEtNDEyOTQ_7686c270-6820-48a3-b4fc-187932ff78e8">19,626</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib3597315a63d441f8f128abd7ed8840e_D20200101-20201231" decimals="-3" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182Ny9mcmFnOmYzZTY4ZDllY2E0ODQ3ZDBhMTEzNmVlNGZlMzY4NGJlL3RhYmxlOjgzMDA4NWQwN2ZjZDQ1NGE5YzZiNDA1MjZiNGYwYzUzL3RhYmxlcmFuZ2U6ODMwMDg1ZDA3ZmNkNDU0YTljNmI0MDUyNmI0ZjBjNTNfMTktMy0xLTEtNDEyOTQ_657a50e6-4641-4c93-b62d-e1f21d75113b">27,420</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie6c3b69702e9429aaeed46bdb9bbb9c1_D20190101-20191231" decimals="-3" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182Ny9mcmFnOmYzZTY4ZDllY2E0ODQ3ZDBhMTEzNmVlNGZlMzY4NGJlL3RhYmxlOjgzMDA4NWQwN2ZjZDQ1NGE5YzZiNDA1MjZiNGYwYzUzL3RhYmxlcmFuZ2U6ODMwMDg1ZDA3ZmNkNDU0YTljNmI0MDUyNmI0ZjBjNTNfMTktNS0xLTEtNDEyOTQ_0f08cdcd-6537-4250-8c2b-461b4843c48e">35,745</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other expense, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182Ny9mcmFnOmYzZTY4ZDllY2E0ODQ3ZDBhMTEzNmVlNGZlMzY4NGJlL3RhYmxlOjgzMDA4NWQwN2ZjZDQ1NGE5YzZiNDA1MjZiNGYwYzUzL3RhYmxlcmFuZ2U6ODMwMDg1ZDA3ZmNkNDU0YTljNmI0MDUyNmI0ZjBjNTNfMjAtMS0xLTEtNDEyOTQ_9aea6a7b-0d96-4389-b709-db1e30792f80">8,860</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib3597315a63d441f8f128abd7ed8840e_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182Ny9mcmFnOmYzZTY4ZDllY2E0ODQ3ZDBhMTEzNmVlNGZlMzY4NGJlL3RhYmxlOjgzMDA4NWQwN2ZjZDQ1NGE5YzZiNDA1MjZiNGYwYzUzL3RhYmxlcmFuZ2U6ODMwMDg1ZDA3ZmNkNDU0YTljNmI0MDUyNmI0ZjBjNTNfMjAtMy0xLTEtNDEyOTQ_e416b288-86ad-439a-bccc-68eeec820a24">108</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie6c3b69702e9429aaeed46bdb9bbb9c1_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182Ny9mcmFnOmYzZTY4ZDllY2E0ODQ3ZDBhMTEzNmVlNGZlMzY4NGJlL3RhYmxlOjgzMDA4NWQwN2ZjZDQ1NGE5YzZiNDA1MjZiNGYwYzUzL3RhYmxlcmFuZ2U6ODMwMDg1ZDA3ZmNkNDU0YTljNmI0MDUyNmI0ZjBjNTNfMjAtNS0xLTEtNDEyOTQ_41307f59-40bc-4917-acb7-1da2cd644185">4,171</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total other expense, net</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182Ny9mcmFnOmYzZTY4ZDllY2E0ODQ3ZDBhMTEzNmVlNGZlMzY4NGJlL3RhYmxlOjgzMDA4NWQwN2ZjZDQ1NGE5YzZiNDA1MjZiNGYwYzUzL3RhYmxlcmFuZ2U6ODMwMDg1ZDA3ZmNkNDU0YTljNmI0MDUyNmI0ZjBjNTNfMjEtMS0xLTEtNDEyOTQ_3dfc84ad-28ea-4dc1-907a-c0dd4105b25b">31,597</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib3597315a63d441f8f128abd7ed8840e_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182Ny9mcmFnOmYzZTY4ZDllY2E0ODQ3ZDBhMTEzNmVlNGZlMzY4NGJlL3RhYmxlOjgzMDA4NWQwN2ZjZDQ1NGE5YzZiNDA1MjZiNGYwYzUzL3RhYmxlcmFuZ2U6ODMwMDg1ZDA3ZmNkNDU0YTljNmI0MDUyNmI0ZjBjNTNfMjEtMy0xLTEtNDEyOTQ_c9ef2262-b861-45a9-9b96-69467bf9330e">36,383</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie6c3b69702e9429aaeed46bdb9bbb9c1_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182Ny9mcmFnOmYzZTY4ZDllY2E0ODQ3ZDBhMTEzNmVlNGZlMzY4NGJlL3RhYmxlOjgzMDA4NWQwN2ZjZDQ1NGE5YzZiNDA1MjZiNGYwYzUzL3RhYmxlcmFuZ2U6ODMwMDg1ZDA3ZmNkNDU0YTljNmI0MDUyNmI0ZjBjNTNfMjEtNS0xLTEtNDEyOTQ_60931e5e-a826-445c-b543-03ac591cdf70">10,437</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income (loss) before income tax</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182Ny9mcmFnOmYzZTY4ZDllY2E0ODQ3ZDBhMTEzNmVlNGZlMzY4NGJlL3RhYmxlOjgzMDA4NWQwN2ZjZDQ1NGE5YzZiNDA1MjZiNGYwYzUzL3RhYmxlcmFuZ2U6ODMwMDg1ZDA3ZmNkNDU0YTljNmI0MDUyNmI0ZjBjNTNfMjItMS0xLTEtNDEyOTQ_ae00a327-f274-49f6-9107-f4372e837c25">47,298</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib3597315a63d441f8f128abd7ed8840e_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182Ny9mcmFnOmYzZTY4ZDllY2E0ODQ3ZDBhMTEzNmVlNGZlMzY4NGJlL3RhYmxlOjgzMDA4NWQwN2ZjZDQ1NGE5YzZiNDA1MjZiNGYwYzUzL3RhYmxlcmFuZ2U6ODMwMDg1ZDA3ZmNkNDU0YTljNmI0MDUyNmI0ZjBjNTNfMjItMy0xLTEtNDEyOTQ_a6e43256-897c-436b-8bed-b2fffccfc7ec">10,538</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6c3b69702e9429aaeed46bdb9bbb9c1_D20190101-20191231" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182Ny9mcmFnOmYzZTY4ZDllY2E0ODQ3ZDBhMTEzNmVlNGZlMzY4NGJlL3RhYmxlOjgzMDA4NWQwN2ZjZDQ1NGE5YzZiNDA1MjZiNGYwYzUzL3RhYmxlcmFuZ2U6ODMwMDg1ZDA3ZmNkNDU0YTljNmI0MDUyNmI0ZjBjNTNfMjItNS0xLTEtNDEyOTQ_b06bda6b-7b9f-438b-8d55-de11f63e28f8">796,639</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income tax benefit (expense)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182Ny9mcmFnOmYzZTY4ZDllY2E0ODQ3ZDBhMTEzNmVlNGZlMzY4NGJlL3RhYmxlOjgzMDA4NWQwN2ZjZDQ1NGE5YzZiNDA1MjZiNGYwYzUzL3RhYmxlcmFuZ2U6ODMwMDg1ZDA3ZmNkNDU0YTljNmI0MDUyNmI0ZjBjNTNfMjMtMS0xLTEtNDEyOTQ_06c71c78-cab8-4f92-9695-925b8fe52094">9,840</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3597315a63d441f8f128abd7ed8840e_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182Ny9mcmFnOmYzZTY4ZDllY2E0ODQ3ZDBhMTEzNmVlNGZlMzY4NGJlL3RhYmxlOjgzMDA4NWQwN2ZjZDQ1NGE5YzZiNDA1MjZiNGYwYzUzL3RhYmxlcmFuZ2U6ODMwMDg1ZDA3ZmNkNDU0YTljNmI0MDUyNmI0ZjBjNTNfMjMtMy0xLTEtNDEyOTQ_f26a49ad-4279-4706-8cc4-cc18f35b443b">7,553</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie6c3b69702e9429aaeed46bdb9bbb9c1_D20190101-20191231" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182Ny9mcmFnOmYzZTY4ZDllY2E0ODQ3ZDBhMTEzNmVlNGZlMzY4NGJlL3RhYmxlOjgzMDA4NWQwN2ZjZDQ1NGE5YzZiNDA1MjZiNGYwYzUzL3RhYmxlcmFuZ2U6ODMwMDg1ZDA3ZmNkNDU0YTljNmI0MDUyNmI0ZjBjNTNfMjMtNS0xLTEtNDEyOTQ_c8fb2ac4-c049-4273-961e-b98a8fbdb5ae">167,337</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net income (loss)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182Ny9mcmFnOmYzZTY4ZDllY2E0ODQ3ZDBhMTEzNmVlNGZlMzY4NGJlL3RhYmxlOjgzMDA4NWQwN2ZjZDQ1NGE5YzZiNDA1MjZiNGYwYzUzL3RhYmxlcmFuZ2U6ODMwMDg1ZDA3ZmNkNDU0YTljNmI0MDUyNmI0ZjBjNTNfMjQtMS0xLTEtNDEyOTQ_4dc9fd1c-f6f2-4901-aeed-d03d6cfefb7b">57,138</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib3597315a63d441f8f128abd7ed8840e_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182Ny9mcmFnOmYzZTY4ZDllY2E0ODQ3ZDBhMTEzNmVlNGZlMzY4NGJlL3RhYmxlOjgzMDA4NWQwN2ZjZDQ1NGE5YzZiNDA1MjZiNGYwYzUzL3RhYmxlcmFuZ2U6ODMwMDg1ZDA3ZmNkNDU0YTljNmI0MDUyNmI0ZjBjNTNfMjQtMy0xLTEtNDEyOTQ_10609f4a-ffdc-4113-b3a1-c1fefa42faed">2,985</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6c3b69702e9429aaeed46bdb9bbb9c1_D20190101-20191231" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182Ny9mcmFnOmYzZTY4ZDllY2E0ODQ3ZDBhMTEzNmVlNGZlMzY4NGJlL3RhYmxlOjgzMDA4NWQwN2ZjZDQ1NGE5YzZiNDA1MjZiNGYwYzUzL3RhYmxlcmFuZ2U6ODMwMDg1ZDA3ZmNkNDU0YTljNmI0MDUyNmI0ZjBjNTNfMjQtNS0xLTEtNDEyOTQ_1db6dbde-71aa-46e8-ac4d-fe0df760e843">629,302</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:11pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Basic net income (loss) per share</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182Ny9mcmFnOmYzZTY4ZDllY2E0ODQ3ZDBhMTEzNmVlNGZlMzY4NGJlL3RhYmxlOjgzMDA4NWQwN2ZjZDQ1NGE5YzZiNDA1MjZiNGYwYzUzL3RhYmxlcmFuZ2U6ODMwMDg1ZDA3ZmNkNDU0YTljNmI0MDUyNmI0ZjBjNTNfMjYtMS0xLTEtNDEyOTQ_a2617f02-b232-434f-b5fe-6a9f146eda4a">3.44</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ib3597315a63d441f8f128abd7ed8840e_D20200101-20201231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182Ny9mcmFnOmYzZTY4ZDllY2E0ODQ3ZDBhMTEzNmVlNGZlMzY4NGJlL3RhYmxlOjgzMDA4NWQwN2ZjZDQ1NGE5YzZiNDA1MjZiNGYwYzUzL3RhYmxlcmFuZ2U6ODMwMDg1ZDA3ZmNkNDU0YTljNmI0MDUyNmI0ZjBjNTNfMjYtMy0xLTEtNDEyOTQ_7d2062b4-2762-46d1-9277-b631811b4b4c">0.18</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ie6c3b69702e9429aaeed46bdb9bbb9c1_D20190101-20191231" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182Ny9mcmFnOmYzZTY4ZDllY2E0ODQ3ZDBhMTEzNmVlNGZlMzY4NGJlL3RhYmxlOjgzMDA4NWQwN2ZjZDQ1NGE5YzZiNDA1MjZiNGYwYzUzL3RhYmxlcmFuZ2U6ODMwMDg1ZDA3ZmNkNDU0YTljNmI0MDUyNmI0ZjBjNTNfMjYtNS0xLTEtNDEyOTQ_2c8dad24-c197-4ad1-be37-8c33e18c1070">33.13</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shares used in basic per share calculation</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182Ny9mcmFnOmYzZTY4ZDllY2E0ODQ3ZDBhMTEzNmVlNGZlMzY4NGJlL3RhYmxlOjgzMDA4NWQwN2ZjZDQ1NGE5YzZiNDA1MjZiNGYwYzUzL3RhYmxlcmFuZ2U6ODMwMDg1ZDA3ZmNkNDU0YTljNmI0MDUyNmI0ZjBjNTNfMjctMS0xLTEtNDEyOTQ_caca7f72-8b5f-427b-a7ca-71787b5450c4">16,630</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib3597315a63d441f8f128abd7ed8840e_D20200101-20201231" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182Ny9mcmFnOmYzZTY4ZDllY2E0ODQ3ZDBhMTEzNmVlNGZlMzY4NGJlL3RhYmxlOjgzMDA4NWQwN2ZjZDQ1NGE5YzZiNDA1MjZiNGYwYzUzL3RhYmxlcmFuZ2U6ODMwMDg1ZDA3ZmNkNDU0YTljNmI0MDUyNmI0ZjBjNTNfMjctMy0xLTEtNDEyOTQ_22998466-7045-474a-bc30-74cf35d65c97">16,185</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie6c3b69702e9429aaeed46bdb9bbb9c1_D20190101-20191231" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182Ny9mcmFnOmYzZTY4ZDllY2E0ODQ3ZDBhMTEzNmVlNGZlMzY4NGJlL3RhYmxlOjgzMDA4NWQwN2ZjZDQ1NGE5YzZiNDA1MjZiNGYwYzUzL3RhYmxlcmFuZ2U6ODMwMDg1ZDA3ZmNkNDU0YTljNmI0MDUyNmI0ZjBjNTNfMjctNS0xLTEtNDEyOTQ_22659a1c-fcfd-43f6-bc9a-a948de365031">18,995</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Diluted net income (loss) per share</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182Ny9mcmFnOmYzZTY4ZDllY2E0ODQ3ZDBhMTEzNmVlNGZlMzY4NGJlL3RhYmxlOjgzMDA4NWQwN2ZjZDQ1NGE5YzZiNDA1MjZiNGYwYzUzL3RhYmxlcmFuZ2U6ODMwMDg1ZDA3ZmNkNDU0YTljNmI0MDUyNmI0ZjBjNTNfMjktMS0xLTEtNDEyOTQ_e3b7f96b-fd73-477e-a2c9-9a8126a277b4">3.31</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ib3597315a63d441f8f128abd7ed8840e_D20200101-20201231" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182Ny9mcmFnOmYzZTY4ZDllY2E0ODQ3ZDBhMTEzNmVlNGZlMzY4NGJlL3RhYmxlOjgzMDA4NWQwN2ZjZDQ1NGE5YzZiNDA1MjZiNGYwYzUzL3RhYmxlcmFuZ2U6ODMwMDg1ZDA3ZmNkNDU0YTljNmI0MDUyNmI0ZjBjNTNfMjktMy0xLTEtNDEyOTQ_6bc05ca2-6601-471e-8903-189ce16cd038">0.18</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ie6c3b69702e9429aaeed46bdb9bbb9c1_D20190101-20191231" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182Ny9mcmFnOmYzZTY4ZDllY2E0ODQ3ZDBhMTEzNmVlNGZlMzY4NGJlL3RhYmxlOjgzMDA4NWQwN2ZjZDQ1NGE5YzZiNDA1MjZiNGYwYzUzL3RhYmxlcmFuZ2U6ODMwMDg1ZDA3ZmNkNDU0YTljNmI0MDUyNmI0ZjBjNTNfMjktNS0xLTEtNDEyOTQ_d3d6fffa-6207-4a11-a378-4bdd4933c5b4">31.85</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shares used in diluted per share calculation</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182Ny9mcmFnOmYzZTY4ZDllY2E0ODQ3ZDBhMTEzNmVlNGZlMzY4NGJlL3RhYmxlOjgzMDA4NWQwN2ZjZDQ1NGE5YzZiNDA1MjZiNGYwYzUzL3RhYmxlcmFuZ2U6ODMwMDg1ZDA3ZmNkNDU0YTljNmI0MDUyNmI0ZjBjNTNfMzAtMS0xLTEtNDEyOTQ_e73a0511-dd4e-4146-8b1f-923c97c95577">17,246</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib3597315a63d441f8f128abd7ed8840e_D20200101-20201231" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182Ny9mcmFnOmYzZTY4ZDllY2E0ODQ3ZDBhMTEzNmVlNGZlMzY4NGJlL3RhYmxlOjgzMDA4NWQwN2ZjZDQ1NGE5YzZiNDA1MjZiNGYwYzUzL3RhYmxlcmFuZ2U6ODMwMDg1ZDA3ZmNkNDU0YTljNmI0MDUyNmI0ZjBjNTNfMzAtMy0xLTEtNDEyOTQ_d71ac87d-0d11-4161-8e79-4ac651f096c2">16,185</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie6c3b69702e9429aaeed46bdb9bbb9c1_D20190101-20191231" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182Ny9mcmFnOmYzZTY4ZDllY2E0ODQ3ZDBhMTEzNmVlNGZlMzY4NGJlL3RhYmxlOjgzMDA4NWQwN2ZjZDQ1NGE5YzZiNDA1MjZiNGYwYzUzL3RhYmxlcmFuZ2U6ODMwMDg1ZDA3ZmNkNDU0YTljNmI0MDUyNmI0ZjBjNTNfMzAtNS0xLTEtNDEyOTQ_53dbaebd-61d7-4e41-9e26-a5d546898a50">19,757</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:3pt"><span><br/></span></div><div style="margin-top:3pt"><span><br/></span></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying notes to these consolidated financial statements.</span></div><div id="i0fa6f906fb2e4e30bc5e873d2bb6a82c_70"></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">55</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">LIGAND PHARMACEUTICALS INCORPORATED</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">)</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:67.181%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.713%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31, </span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183MC9mcmFnOmE0MzI4NjZjNWM2MTRhMTc4NGQxY2RlZDAzNTdiNzc1L3RhYmxlOmEyZGRiMjFlMzQyZDRmN2JiZjYxNDZjYWY0ODY5YzExL3RhYmxlcmFuZ2U6YTJkZGIyMWUzNDJkNGY3YmJmNjE0NmNhZjQ4NjljMTFfMi0xLTEtMS00MTI5NA_1ae7905c-6172-4df9-8a26-620635358555">57,138</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib3597315a63d441f8f128abd7ed8840e_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183MC9mcmFnOmE0MzI4NjZjNWM2MTRhMTc4NGQxY2RlZDAzNTdiNzc1L3RhYmxlOmEyZGRiMjFlMzQyZDRmN2JiZjYxNDZjYWY0ODY5YzExL3RhYmxlcmFuZ2U6YTJkZGIyMWUzNDJkNGY3YmJmNjE0NmNhZjQ4NjljMTFfMi0zLTEtMS00MTI5NA_03a602b2-6f37-4e22-b06a-30d94de11bb8">2,985</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6c3b69702e9429aaeed46bdb9bbb9c1_D20190101-20191231" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183MC9mcmFnOmE0MzI4NjZjNWM2MTRhMTc4NGQxY2RlZDAzNTdiNzc1L3RhYmxlOmEyZGRiMjFlMzQyZDRmN2JiZjYxNDZjYWY0ODY5YzExL3RhYmxlcmFuZ2U6YTJkZGIyMWUzNDJkNGY3YmJmNjE0NmNhZjQ4NjljMTFfMi01LTEtMS00MTI5NA_393f8fd2-9373-4162-9f31-d342ad1e7c0d">629,302</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized net gain (loss) on available-for-sale securities, net of tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183MC9mcmFnOmE0MzI4NjZjNWM2MTRhMTc4NGQxY2RlZDAzNTdiNzc1L3RhYmxlOmEyZGRiMjFlMzQyZDRmN2JiZjYxNDZjYWY0ODY5YzExL3RhYmxlcmFuZ2U6YTJkZGIyMWUzNDJkNGY3YmJmNjE0NmNhZjQ4NjljMTFfMy0xLTEtMS00MTI5NA_4213fae2-a915-434f-8d4a-4d276721a775">116</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib3597315a63d441f8f128abd7ed8840e_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183MC9mcmFnOmE0MzI4NjZjNWM2MTRhMTc4NGQxY2RlZDAzNTdiNzc1L3RhYmxlOmEyZGRiMjFlMzQyZDRmN2JiZjYxNDZjYWY0ODY5YzExL3RhYmxlcmFuZ2U6YTJkZGIyMWUzNDJkNGY3YmJmNjE0NmNhZjQ4NjljMTFfMy0zLTEtMS00MTI5NA_554f4880-a1e0-49e9-a713-90829a0fa1a7">162</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6c3b69702e9429aaeed46bdb9bbb9c1_D20190101-20191231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183MC9mcmFnOmE0MzI4NjZjNWM2MTRhMTc4NGQxY2RlZDAzNTdiNzc1L3RhYmxlOmEyZGRiMjFlMzQyZDRmN2JiZjYxNDZjYWY0ODY5YzExL3RhYmxlcmFuZ2U6YTJkZGIyMWUzNDJkNGY3YmJmNjE0NmNhZjQ4NjljMTFfMy01LTEtMS00MTI5NA_a4ede031-ec83-483d-afbc-9397862dd7d5">200</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign currency translation adjustment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183MC9mcmFnOmE0MzI4NjZjNWM2MTRhMTc4NGQxY2RlZDAzNTdiNzc1L3RhYmxlOmEyZGRiMjFlMzQyZDRmN2JiZjYxNDZjYWY0ODY5YzExL3RhYmxlcmFuZ2U6YTJkZGIyMWUzNDJkNGY3YmJmNjE0NmNhZjQ4NjljMTFfNC0xLTEtMS00MTI5NA_446d64a0-cf54-41c6-948c-800e43a8496d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib3597315a63d441f8f128abd7ed8840e_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183MC9mcmFnOmE0MzI4NjZjNWM2MTRhMTc4NGQxY2RlZDAzNTdiNzc1L3RhYmxlOmEyZGRiMjFlMzQyZDRmN2JiZjYxNDZjYWY0ODY5YzExL3RhYmxlcmFuZ2U6YTJkZGIyMWUzNDJkNGY3YmJmNjE0NmNhZjQ4NjljMTFfNC0zLTEtMS00MTI5NA_1930c930-4757-450c-9927-4552c5456aba">423</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6c3b69702e9429aaeed46bdb9bbb9c1_D20190101-20191231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183MC9mcmFnOmE0MzI4NjZjNWM2MTRhMTc4NGQxY2RlZDAzNTdiNzc1L3RhYmxlOmEyZGRiMjFlMzQyZDRmN2JiZjYxNDZjYWY0ODY5YzExL3RhYmxlcmFuZ2U6YTJkZGIyMWUzNDJkNGY3YmJmNjE0NmNhZjQ4NjljMTFfNC01LTEtMS00MTI5NA_509a4a0d-d7cd-440a-8294-c8c7e92895fe">608</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Comprehensive income (loss)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231" decimals="-3" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183MC9mcmFnOmE0MzI4NjZjNWM2MTRhMTc4NGQxY2RlZDAzNTdiNzc1L3RhYmxlOmEyZGRiMjFlMzQyZDRmN2JiZjYxNDZjYWY0ODY5YzExL3RhYmxlcmFuZ2U6YTJkZGIyMWUzNDJkNGY3YmJmNjE0NmNhZjQ4NjljMTFfNS0xLTEtMS00MTI5NA_d5dc3e4c-8177-45bf-9a88-f297f5d4ece7">57,022</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib3597315a63d441f8f128abd7ed8840e_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183MC9mcmFnOmE0MzI4NjZjNWM2MTRhMTc4NGQxY2RlZDAzNTdiNzc1L3RhYmxlOmEyZGRiMjFlMzQyZDRmN2JiZjYxNDZjYWY0ODY5YzExL3RhYmxlcmFuZ2U6YTJkZGIyMWUzNDJkNGY3YmJmNjE0NmNhZjQ4NjljMTFfNS0zLTEtMS00MTI5NA_adae0b15-6dd4-446d-8e0c-048d64ef5c83">3,570</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6c3b69702e9429aaeed46bdb9bbb9c1_D20190101-20191231" decimals="-3" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183MC9mcmFnOmE0MzI4NjZjNWM2MTRhMTc4NGQxY2RlZDAzNTdiNzc1L3RhYmxlOmEyZGRiMjFlMzQyZDRmN2JiZjYxNDZjYWY0ODY5YzExL3RhYmxlcmFuZ2U6YTJkZGIyMWUzNDJkNGY3YmJmNjE0NmNhZjQ4NjljMTFfNS01LTEtMS00MTI5NA_20bf0a3e-274f-453e-89ab-eba6072e2d7e">630,110</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying notes to these consolidated financial statements.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">56</span></div></div></div><div id="i0fa6f906fb2e4e30bc5e873d2bb6a82c_73"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">LIGAND PHARMACEUTICALS INCORPORATED</span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENT OF STOCKHOLDERS&#8217; EQUITY </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:33.256%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.987%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.287%"></td><td style="width:0.1%"></td></tr><tr style="height:21pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">Additional</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">paid-in</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">capital</span></div></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">Accumulated</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">other</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">comprehensive</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">income (loss)</span></div></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">Retain earnings (accumulated</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">deficit)</span></div></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">Total</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">stockholders&#8217;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">equity</span></div></td></tr><tr style="height:10pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Balance at December 31, 2018</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id0ff3295defe46b8bccc6c795953b0dd_I20181231" decimals="-3" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183My9mcmFnOmQzNzc2MmZiMDI0ZDRjNWE5MjMxODNkNmUxMTdjM2Q1L3RhYmxlOjU2ZjRlNzRkOTUxZDRhM2NiNDRhMzVjOGM0OWFmN2M0L3RhYmxlcmFuZ2U6NTZmNGU3NGQ5NTFkNGEzY2I0NGEzNWM4YzQ5YWY3YzRfMi0xLTEtMS00MTI5NA_a36e5dd9-e5a1-46f1-bf58-6a779971e0ad">20,766</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0ff3295defe46b8bccc6c795953b0dd_I20181231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183My9mcmFnOmQzNzc2MmZiMDI0ZDRjNWE5MjMxODNkNmUxMTdjM2Q1L3RhYmxlOjU2ZjRlNzRkOTUxZDRhM2NiNDRhMzVjOGM0OWFmN2M0L3RhYmxlcmFuZ2U6NTZmNGU3NGQ5NTFkNGEzY2I0NGEzNWM4YzQ5YWY3YzRfMi0zLTEtMS00MTI5NA_8064504c-65e6-4f92-bd2e-399b13ad8a51">21</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie8198f30811b402385fed871033fac83_I20181231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183My9mcmFnOmQzNzc2MmZiMDI0ZDRjNWE5MjMxODNkNmUxMTdjM2Q1L3RhYmxlOjU2ZjRlNzRkOTUxZDRhM2NiNDRhMzVjOGM0OWFmN2M0L3RhYmxlcmFuZ2U6NTZmNGU3NGQ5NTFkNGEzY2I0NGEzNWM4YzQ5YWY3YzRfMi01LTEtMS00MTI5NA_e1ff62db-c90c-4c92-a5b5-685167ad407b">791,114</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i24530d11bf3d4226b1bfc80e52009811_I20181231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183My9mcmFnOmQzNzc2MmZiMDI0ZDRjNWE5MjMxODNkNmUxMTdjM2Q1L3RhYmxlOjU2ZjRlNzRkOTUxZDRhM2NiNDRhMzVjOGM0OWFmN2M0L3RhYmxlcmFuZ2U6NTZmNGU3NGQ5NTFkNGEzY2I0NGEzNWM4YzQ5YWY3YzRfMi03LTEtMS00MTI5NA_013f39f5-40bf-4ce6-b1a0-d06d9f0c597a">1,024</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2157f3f9f915470d94164dbf83569db0_I20181231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183My9mcmFnOmQzNzc2MmZiMDI0ZDRjNWE5MjMxODNkNmUxMTdjM2Q1L3RhYmxlOjU2ZjRlNzRkOTUxZDRhM2NiNDRhMzVjOGM0OWFmN2M0L3RhYmxlcmFuZ2U6NTZmNGU3NGQ5NTFkNGEzY2I0NGEzNWM4YzQ5YWY3YzRfMi05LTEtMS00MTI5NA_be278b9c-4bb2-423c-9119-f53c4a6bb76c">229,197</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1aac4d81ad94163b33117197afe0895_I20181231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183My9mcmFnOmQzNzc2MmZiMDI0ZDRjNWE5MjMxODNkNmUxMTdjM2Q1L3RhYmxlOjU2ZjRlNzRkOTUxZDRhM2NiNDRhMzVjOGM0OWFmN2M0L3RhYmxlcmFuZ2U6NTZmNGU3NGQ5NTFkNGEzY2I0NGEzNWM4YzQ5YWY3YzRfMi0xMi0xLTEtNDEyOTQ_6283ab08-cddc-4e3c-b7f3-0d0265aea8fc">560,914</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Issuance of common stock under employee stock compensation plans, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iba40247e0e614545939d340c24ba1378_D20190101-20191231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183My9mcmFnOmQzNzc2MmZiMDI0ZDRjNWE5MjMxODNkNmUxMTdjM2Q1L3RhYmxlOjU2ZjRlNzRkOTUxZDRhM2NiNDRhMzVjOGM0OWFmN2M0L3RhYmxlcmFuZ2U6NTZmNGU3NGQ5NTFkNGEzY2I0NGEzNWM4YzQ5YWY3YzRfMy0xLTEtMS00MTI5NA_adc821ab-695b-467d-920d-bd73cc96c970">180</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia8c2096f420a462b813274a320529a34_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183My9mcmFnOmQzNzc2MmZiMDI0ZDRjNWE5MjMxODNkNmUxMTdjM2Q1L3RhYmxlOjU2ZjRlNzRkOTUxZDRhM2NiNDRhMzVjOGM0OWFmN2M0L3RhYmxlcmFuZ2U6NTZmNGU3NGQ5NTFkNGEzY2I0NGEzNWM4YzQ5YWY3YzRfMy01LTEtMS00MTI5NA_52e8cb9a-dc82-4815-9825-9f4d1f7356db">1,421</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie6c3b69702e9429aaeed46bdb9bbb9c1_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183My9mcmFnOmQzNzc2MmZiMDI0ZDRjNWE5MjMxODNkNmUxMTdjM2Q1L3RhYmxlOjU2ZjRlNzRkOTUxZDRhM2NiNDRhMzVjOGM0OWFmN2M0L3RhYmxlcmFuZ2U6NTZmNGU3NGQ5NTFkNGEzY2I0NGEzNWM4YzQ5YWY3YzRfMy0xMi0xLTEtNDEyOTQ_1baefca0-5011-4579-a039-45c79bd53118">1,421</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8c2096f420a462b813274a320529a34_D20190101-20191231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183My9mcmFnOmQzNzc2MmZiMDI0ZDRjNWE5MjMxODNkNmUxMTdjM2Q1L3RhYmxlOjU2ZjRlNzRkOTUxZDRhM2NiNDRhMzVjOGM0OWFmN2M0L3RhYmxlcmFuZ2U6NTZmNGU3NGQ5NTFkNGEzY2I0NGEzNWM4YzQ5YWY3YzRfNC01LTEtMS00MTI5NA_d9d4db7f-d4cc-4ea5-a965-6e158ca5552f">24,515</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6c3b69702e9429aaeed46bdb9bbb9c1_D20190101-20191231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183My9mcmFnOmQzNzc2MmZiMDI0ZDRjNWE5MjMxODNkNmUxMTdjM2Q1L3RhYmxlOjU2ZjRlNzRkOTUxZDRhM2NiNDRhMzVjOGM0OWFmN2M0L3RhYmxlcmFuZ2U6NTZmNGU3NGQ5NTFkNGEzY2I0NGEzNWM4YzQ5YWY3YzRfNC0xMi0xLTEtNDEyOTQ_26f94dc0-57bf-411d-9641-a64a706db672">24,515</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Repurchase of common stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="iba40247e0e614545939d340c24ba1378_D20190101-20191231" decimals="-3" name="us-gaap:StockRepurchasedDuringPeriodShares" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183My9mcmFnOmQzNzc2MmZiMDI0ZDRjNWE5MjMxODNkNmUxMTdjM2Q1L3RhYmxlOjU2ZjRlNzRkOTUxZDRhM2NiNDRhMzVjOGM0OWFmN2M0L3RhYmxlcmFuZ2U6NTZmNGU3NGQ5NTFkNGEzY2I0NGEzNWM4YzQ5YWY3YzRfNS0xLTEtMS00ODEzMg_937dad95-d39b-466a-8f24-165affd88fec">4,122</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iba40247e0e614545939d340c24ba1378_D20190101-20191231" decimals="-3" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183My9mcmFnOmQzNzc2MmZiMDI0ZDRjNWE5MjMxODNkNmUxMTdjM2Q1L3RhYmxlOjU2ZjRlNzRkOTUxZDRhM2NiNDRhMzVjOGM0OWFmN2M0L3RhYmxlcmFuZ2U6NTZmNGU3NGQ5NTFkNGEzY2I0NGEzNWM4YzQ5YWY3YzRfNS0zLTEtMS00ODEzMg_b6cdc7a7-191b-4734-8754-a6ef398ba93f">4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia8c2096f420a462b813274a320529a34_D20190101-20191231" decimals="-3" name="us-gaap:StockRepurchasedDuringPeriodValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183My9mcmFnOmQzNzc2MmZiMDI0ZDRjNWE5MjMxODNkNmUxMTdjM2Q1L3RhYmxlOjU2ZjRlNzRkOTUxZDRhM2NiNDRhMzVjOGM0OWFmN2M0L3RhYmxlcmFuZ2U6NTZmNGU3NGQ5NTFkNGEzY2I0NGEzNWM4YzQ5YWY3YzRfNS01LTEtMS00MTI5NA_d0bb7969-9722-46f9-b1ec-039ca0f96b28">448,429</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie6c3b69702e9429aaeed46bdb9bbb9c1_D20190101-20191231" decimals="-3" name="us-gaap:StockRepurchasedDuringPeriodValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183My9mcmFnOmQzNzc2MmZiMDI0ZDRjNWE5MjMxODNkNmUxMTdjM2Q1L3RhYmxlOjU2ZjRlNzRkOTUxZDRhM2NiNDRhMzVjOGM0OWFmN2M0L3RhYmxlcmFuZ2U6NTZmNGU3NGQ5NTFkNGEzY2I0NGEzNWM4YzQ5YWY3YzRfNS0xMi0xLTEtNDEyOTQ_f0e97b6f-e29a-479e-b17c-67094c95f46a">448,433</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Unrealized net gain on available-for-sale securities, net of deferred tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11614604a0e24aa78e71eb02f9b1c21d_D20190101-20191231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183My9mcmFnOmQzNzc2MmZiMDI0ZDRjNWE5MjMxODNkNmUxMTdjM2Q1L3RhYmxlOjU2ZjRlNzRkOTUxZDRhM2NiNDRhMzVjOGM0OWFmN2M0L3RhYmxlcmFuZ2U6NTZmNGU3NGQ5NTFkNGEzY2I0NGEzNWM4YzQ5YWY3YzRfNi03LTEtMS00ODEzMg_779bbc30-0171-4f98-90a6-a5ca7e5cd90c">200</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6c3b69702e9429aaeed46bdb9bbb9c1_D20190101-20191231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183My9mcmFnOmQzNzc2MmZiMDI0ZDRjNWE5MjMxODNkNmUxMTdjM2Q1L3RhYmxlOjU2ZjRlNzRkOTUxZDRhM2NiNDRhMzVjOGM0OWFmN2M0L3RhYmxlcmFuZ2U6NTZmNGU3NGQ5NTFkNGEzY2I0NGEzNWM4YzQ5YWY3YzRfNi0xMi0xLTEtNDEyOTQ_5fe83389-2136-4951-a219-032f07c2b368">200</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Foreign currency translation adjustment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11614604a0e24aa78e71eb02f9b1c21d_D20190101-20191231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183My9mcmFnOmQzNzc2MmZiMDI0ZDRjNWE5MjMxODNkNmUxMTdjM2Q1L3RhYmxlOjU2ZjRlNzRkOTUxZDRhM2NiNDRhMzVjOGM0OWFmN2M0L3RhYmxlcmFuZ2U6NTZmNGU3NGQ5NTFkNGEzY2I0NGEzNWM4YzQ5YWY3YzRfNy03LTEtMS00MTI5NA_9a4ae3e3-2925-40ec-9223-19a1e128b9c7">608</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6c3b69702e9429aaeed46bdb9bbb9c1_D20190101-20191231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183My9mcmFnOmQzNzc2MmZiMDI0ZDRjNWE5MjMxODNkNmUxMTdjM2Q1L3RhYmxlOjU2ZjRlNzRkOTUxZDRhM2NiNDRhMzVjOGM0OWFmN2M0L3RhYmxlcmFuZ2U6NTZmNGU3NGQ5NTFkNGEzY2I0NGEzNWM4YzQ5YWY3YzRfNy0xMi0xLTEtNDEyOTQ_6bcb7a85-9f86-4a5d-8d66-660053b7fd7b">608</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Other tax adjustments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8c2096f420a462b813274a320529a34_D20190101-20191231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalOther" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183My9mcmFnOmQzNzc2MmZiMDI0ZDRjNWE5MjMxODNkNmUxMTdjM2Q1L3RhYmxlOjU2ZjRlNzRkOTUxZDRhM2NiNDRhMzVjOGM0OWFmN2M0L3RhYmxlcmFuZ2U6NTZmNGU3NGQ5NTFkNGEzY2I0NGEzNWM4YzQ5YWY3YzRfOC01LTEtMS00ODEzMg_e1b2096f-d6fb-4ed9-a243-6fd3a32a8311">1,547</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6c3b69702e9429aaeed46bdb9bbb9c1_D20190101-20191231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalOther" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183My9mcmFnOmQzNzc2MmZiMDI0ZDRjNWE5MjMxODNkNmUxMTdjM2Q1L3RhYmxlOjU2ZjRlNzRkOTUxZDRhM2NiNDRhMzVjOGM0OWFmN2M0L3RhYmxlcmFuZ2U6NTZmNGU3NGQ5NTFkNGEzY2I0NGEzNWM4YzQ5YWY3YzRfOC0xMi0xLTEtNDEyOTQ_9b40a5bd-ed61-4100-af4b-1309ad9f026b">1,547</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id787fbb79cf94df2b867ff01039dd7ee_D20190101-20191231" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183My9mcmFnOmQzNzc2MmZiMDI0ZDRjNWE5MjMxODNkNmUxMTdjM2Q1L3RhYmxlOjU2ZjRlNzRkOTUxZDRhM2NiNDRhMzVjOGM0OWFmN2M0L3RhYmxlcmFuZ2U6NTZmNGU3NGQ5NTFkNGEzY2I0NGEzNWM4YzQ5YWY3YzRfOS05LTEtMS00MTI5NA_32fdc158-ac16-4430-b842-f404bb7ccc0c">629,302</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6c3b69702e9429aaeed46bdb9bbb9c1_D20190101-20191231" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183My9mcmFnOmQzNzc2MmZiMDI0ZDRjNWE5MjMxODNkNmUxMTdjM2Q1L3RhYmxlOjU2ZjRlNzRkOTUxZDRhM2NiNDRhMzVjOGM0OWFmN2M0L3RhYmxlcmFuZ2U6NTZmNGU3NGQ5NTFkNGEzY2I0NGEzNWM4YzQ5YWY3YzRfOS0xMi0xLTEtNDEyOTQ_5dcb07af-5580-46df-8b38-c40992506477">629,302</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Balance at December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i91bf098d468945ce94255ad9187b03e5_I20191231" decimals="-3" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183My9mcmFnOmQzNzc2MmZiMDI0ZDRjNWE5MjMxODNkNmUxMTdjM2Q1L3RhYmxlOjU2ZjRlNzRkOTUxZDRhM2NiNDRhMzVjOGM0OWFmN2M0L3RhYmxlcmFuZ2U6NTZmNGU3NGQ5NTFkNGEzY2I0NGEzNWM4YzQ5YWY3YzRfMTAtMS0xLTEtNDg1NzA_e77103f8-d0fb-45a3-8465-2349d90636d5">16,824</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91bf098d468945ce94255ad9187b03e5_I20191231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183My9mcmFnOmQzNzc2MmZiMDI0ZDRjNWE5MjMxODNkNmUxMTdjM2Q1L3RhYmxlOjU2ZjRlNzRkOTUxZDRhM2NiNDRhMzVjOGM0OWFmN2M0L3RhYmxlcmFuZ2U6NTZmNGU3NGQ5NTFkNGEzY2I0NGEzNWM4YzQ5YWY3YzRfMTAtMy0xLTEtNDg1NzA_72b5f036-60a5-4913-8e20-b368ea5a4d80">17</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5f40ec88b5f46f8a400c8577e872e35_I20191231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183My9mcmFnOmQzNzc2MmZiMDI0ZDRjNWE5MjMxODNkNmUxMTdjM2Q1L3RhYmxlOjU2ZjRlNzRkOTUxZDRhM2NiNDRhMzVjOGM0OWFmN2M0L3RhYmxlcmFuZ2U6NTZmNGU3NGQ5NTFkNGEzY2I0NGEzNWM4YzQ5YWY3YzRfMTAtNS0xLTEtNDEyOTQ_7e5b10b0-5800-4e2a-bf1f-68195ab6a88f">367,326</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i32ab127ed5c44358939fcb7eab76b6a6_I20191231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183My9mcmFnOmQzNzc2MmZiMDI0ZDRjNWE5MjMxODNkNmUxMTdjM2Q1L3RhYmxlOjU2ZjRlNzRkOTUxZDRhM2NiNDRhMzVjOGM0OWFmN2M0L3RhYmxlcmFuZ2U6NTZmNGU3NGQ5NTFkNGEzY2I0NGEzNWM4YzQ5YWY3YzRfMTAtNy0xLTEtNDg1NzA_7b8904a8-e501-41f6-9206-43d01f2d46de">216</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa27b23fe5ac43dab25e6b1f5344211e_I20191231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183My9mcmFnOmQzNzc2MmZiMDI0ZDRjNWE5MjMxODNkNmUxMTdjM2Q1L3RhYmxlOjU2ZjRlNzRkOTUxZDRhM2NiNDRhMzVjOGM0OWFmN2M0L3RhYmxlcmFuZ2U6NTZmNGU3NGQ5NTFkNGEzY2I0NGEzNWM4YzQ5YWY3YzRfMTAtOS0xLTEtNDgxNzQ_08549454-4d54-4653-83ba-920a13ea26e5">400,105</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ida3ec05a32644c2db1bb9f71f76c567f_I20191231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183My9mcmFnOmQzNzc2MmZiMDI0ZDRjNWE5MjMxODNkNmUxMTdjM2Q1L3RhYmxlOjU2ZjRlNzRkOTUxZDRhM2NiNDRhMzVjOGM0OWFmN2M0L3RhYmxlcmFuZ2U6NTZmNGU3NGQ5NTFkNGEzY2I0NGEzNWM4YzQ5YWY3YzRfMTAtMTItMS0xLTQxMjk0_d71ee157-f882-4bf1-9dfc-5e948aaa157c">767,232</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Issuance of common stock under employee stock compensation plans, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibb59da98705b4964a37154673c8ed2be_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183My9mcmFnOmQzNzc2MmZiMDI0ZDRjNWE5MjMxODNkNmUxMTdjM2Q1L3RhYmxlOjU2ZjRlNzRkOTUxZDRhM2NiNDRhMzVjOGM0OWFmN2M0L3RhYmxlcmFuZ2U6NTZmNGU3NGQ5NTFkNGEzY2I0NGEzNWM4YzQ5YWY3YzRfMTEtMS0xLTEtNDg1Nzk_87c37481-61e8-4b98-a4ba-7025528e8371">190</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e24f17963584a8a8d751afa02b1b0c9_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183My9mcmFnOmQzNzc2MmZiMDI0ZDRjNWE5MjMxODNkNmUxMTdjM2Q1L3RhYmxlOjU2ZjRlNzRkOTUxZDRhM2NiNDRhMzVjOGM0OWFmN2M0L3RhYmxlcmFuZ2U6NTZmNGU3NGQ5NTFkNGEzY2I0NGEzNWM4YzQ5YWY3YzRfMTEtNS0xLTEtNDEyOTQ_722ef89a-f932-4aa6-84c8-d1e0a371dac1">1,535</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3597315a63d441f8f128abd7ed8840e_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183My9mcmFnOmQzNzc2MmZiMDI0ZDRjNWE5MjMxODNkNmUxMTdjM2Q1L3RhYmxlOjU2ZjRlNzRkOTUxZDRhM2NiNDRhMzVjOGM0OWFmN2M0L3RhYmxlcmFuZ2U6NTZmNGU3NGQ5NTFkNGEzY2I0NGEzNWM4YzQ5YWY3YzRfMTEtMTItMS0xLTQxMjk0_7894d72a-00f6-41dd-b694-c260f0a85aad">1,535</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e24f17963584a8a8d751afa02b1b0c9_D20200101-20201231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183My9mcmFnOmQzNzc2MmZiMDI0ZDRjNWE5MjMxODNkNmUxMTdjM2Q1L3RhYmxlOjU2ZjRlNzRkOTUxZDRhM2NiNDRhMzVjOGM0OWFmN2M0L3RhYmxlcmFuZ2U6NTZmNGU3NGQ5NTFkNGEzY2I0NGEzNWM4YzQ5YWY3YzRfMTItNS0xLTEtNDEyOTQ_36cd7be2-9867-4c64-8767-966263952851">30,727</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3597315a63d441f8f128abd7ed8840e_D20200101-20201231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183My9mcmFnOmQzNzc2MmZiMDI0ZDRjNWE5MjMxODNkNmUxMTdjM2Q1L3RhYmxlOjU2ZjRlNzRkOTUxZDRhM2NiNDRhMzVjOGM0OWFmN2M0L3RhYmxlcmFuZ2U6NTZmNGU3NGQ5NTFkNGEzY2I0NGEzNWM4YzQ5YWY3YzRfMTItMTItMS0xLTQxMjk0_ee6468fc-b807-4d7f-bc99-41462dcc5d8a">30,727</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Repurchase of common stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ibb59da98705b4964a37154673c8ed2be_D20200101-20201231" decimals="-3" name="us-gaap:StockRepurchasedDuringPeriodShares" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183My9mcmFnOmQzNzc2MmZiMDI0ZDRjNWE5MjMxODNkNmUxMTdjM2Q1L3RhYmxlOjU2ZjRlNzRkOTUxZDRhM2NiNDRhMzVjOGM0OWFmN2M0L3RhYmxlcmFuZ2U6NTZmNGU3NGQ5NTFkNGEzY2I0NGEzNWM4YzQ5YWY3YzRfMTMtMS0xLTEtNDg1OTk_f561c9b6-73ec-47d0-9865-e0471f4169fe">934</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibb59da98705b4964a37154673c8ed2be_D20200101-20201231" decimals="-3" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183My9mcmFnOmQzNzc2MmZiMDI0ZDRjNWE5MjMxODNkNmUxMTdjM2Q1L3RhYmxlOjU2ZjRlNzRkOTUxZDRhM2NiNDRhMzVjOGM0OWFmN2M0L3RhYmxlcmFuZ2U6NTZmNGU3NGQ5NTFkNGEzY2I0NGEzNWM4YzQ5YWY3YzRfMTMtMy0xLTEtNDg2MDI_5562435d-9d49-4e14-9a55-51b5c8c6957f">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7e24f17963584a8a8d751afa02b1b0c9_D20200101-20201231" decimals="-3" name="us-gaap:StockRepurchasedDuringPeriodValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183My9mcmFnOmQzNzc2MmZiMDI0ZDRjNWE5MjMxODNkNmUxMTdjM2Q1L3RhYmxlOjU2ZjRlNzRkOTUxZDRhM2NiNDRhMzVjOGM0OWFmN2M0L3RhYmxlcmFuZ2U6NTZmNGU3NGQ5NTFkNGEzY2I0NGEzNWM4YzQ5YWY3YzRfMTMtNS0xLTEtNDEyOTQ_68b018b5-6fd1-4eaa-b3ba-e519138e5f65">77,997</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib3597315a63d441f8f128abd7ed8840e_D20200101-20201231" decimals="-3" name="us-gaap:StockRepurchasedDuringPeriodValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183My9mcmFnOmQzNzc2MmZiMDI0ZDRjNWE5MjMxODNkNmUxMTdjM2Q1L3RhYmxlOjU2ZjRlNzRkOTUxZDRhM2NiNDRhMzVjOGM0OWFmN2M0L3RhYmxlcmFuZ2U6NTZmNGU3NGQ5NTFkNGEzY2I0NGEzNWM4YzQ5YWY3YzRfMTMtMTItMS0xLTQxMjk0_12a9493e-9c3c-44a9-8420-220f254543ed">77,998</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Unrealized net loss on available-for-sale securities, net of deferred tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia7e3cc749ec443c7b6a42c35ebdbd292_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183My9mcmFnOmQzNzc2MmZiMDI0ZDRjNWE5MjMxODNkNmUxMTdjM2Q1L3RhYmxlOjU2ZjRlNzRkOTUxZDRhM2NiNDRhMzVjOGM0OWFmN2M0L3RhYmxlcmFuZ2U6NTZmNGU3NGQ5NTFkNGEzY2I0NGEzNWM4YzQ5YWY3YzRfMTQtNy0xLTEtNDg2MTA_56e115f9-8182-430b-bb86-17f5324b0d5b">162</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib3597315a63d441f8f128abd7ed8840e_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183My9mcmFnOmQzNzc2MmZiMDI0ZDRjNWE5MjMxODNkNmUxMTdjM2Q1L3RhYmxlOjU2ZjRlNzRkOTUxZDRhM2NiNDRhMzVjOGM0OWFmN2M0L3RhYmxlcmFuZ2U6NTZmNGU3NGQ5NTFkNGEzY2I0NGEzNWM4YzQ5YWY3YzRfMTQtMTItMS0xLTQxMjk0_2ebd443f-56e2-437c-a3bf-2529e6257092">162</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Foreign currency translation adjustment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia7e3cc749ec443c7b6a42c35ebdbd292_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183My9mcmFnOmQzNzc2MmZiMDI0ZDRjNWE5MjMxODNkNmUxMTdjM2Q1L3RhYmxlOjU2ZjRlNzRkOTUxZDRhM2NiNDRhMzVjOGM0OWFmN2M0L3RhYmxlcmFuZ2U6NTZmNGU3NGQ5NTFkNGEzY2I0NGEzNWM4YzQ5YWY3YzRfMTUtNy0xLTEtNDg2MTM_629022e9-a6ea-42e7-b37e-6a9e8fee4bb4">423</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib3597315a63d441f8f128abd7ed8840e_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183My9mcmFnOmQzNzc2MmZiMDI0ZDRjNWE5MjMxODNkNmUxMTdjM2Q1L3RhYmxlOjU2ZjRlNzRkOTUxZDRhM2NiNDRhMzVjOGM0OWFmN2M0L3RhYmxlcmFuZ2U6NTZmNGU3NGQ5NTFkNGEzY2I0NGEzNWM4YzQ5YWY3YzRfMTUtMTItMS0xLTQxMjk0_a0eca2c4-faaa-409a-8daf-3c534ebdc108">423</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Reacquisition of equity due to 2023 debt extinguishment, net of tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7e24f17963584a8a8d751afa02b1b0c9_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183My9mcmFnOmQzNzc2MmZiMDI0ZDRjNWE5MjMxODNkNmUxMTdjM2Q1L3RhYmxlOjU2ZjRlNzRkOTUxZDRhM2NiNDRhMzVjOGM0OWFmN2M0L3RhYmxlcmFuZ2U6NTZmNGU3NGQ5NTFkNGEzY2I0NGEzNWM4YzQ5YWY3YzRfMTYtNS0xLTEtNDEyOTQ_3192bc6e-b397-4dcf-8129-ba71604c84bc">3,236</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib3597315a63d441f8f128abd7ed8840e_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183My9mcmFnOmQzNzc2MmZiMDI0ZDRjNWE5MjMxODNkNmUxMTdjM2Q1L3RhYmxlOjU2ZjRlNzRkOTUxZDRhM2NiNDRhMzVjOGM0OWFmN2M0L3RhYmxlcmFuZ2U6NTZmNGU3NGQ5NTFkNGEzY2I0NGEzNWM4YzQ5YWY3YzRfMTYtMTItMS0xLTQxMjk0_652d61c3-9a15-4f74-b873-e3baa148c2e0">3,236</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183My9mcmFnOmQzNzc2MmZiMDI0ZDRjNWE5MjMxODNkNmUxMTdjM2Q1L3RhYmxlOjU2ZjRlNzRkOTUxZDRhM2NiNDRhMzVjOGM0OWFmN2M0L3RhYmxlcmFuZ2U6NTZmNGU3NGQ5NTFkNGEzY2I0NGEzNWM4YzQ5YWY3YzRfMTctMC0xLTEtNDg2MjE_f0956f56-e3b9-4151-8fc0-a01564d4dcdb">Cumulative-effect adjustment from adoption of&#160;ASU 2016-13, net of tax</span></span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibd8ac2d6daad403e8a1f73426f5256a2_I20191231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183My9mcmFnOmQzNzc2MmZiMDI0ZDRjNWE5MjMxODNkNmUxMTdjM2Q1L3RhYmxlOjU2ZjRlNzRkOTUxZDRhM2NiNDRhMzVjOGM0OWFmN2M0L3RhYmxlcmFuZ2U6NTZmNGU3NGQ5NTFkNGEzY2I0NGEzNWM4YzQ5YWY3YzRfMTctOS0xLTEtNDg2MjY_bad4e6e3-1ffa-4f32-a2ed-457ceb9a1cff">5,168</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if67a2cd7a5e7447e8e1765371f5225b9_I20191231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183My9mcmFnOmQzNzc2MmZiMDI0ZDRjNWE5MjMxODNkNmUxMTdjM2Q1L3RhYmxlOjU2ZjRlNzRkOTUxZDRhM2NiNDRhMzVjOGM0OWFmN2M0L3RhYmxlcmFuZ2U6NTZmNGU3NGQ5NTFkNGEzY2I0NGEzNWM4YzQ5YWY3YzRfMTctMTItMS0xLTQxMjk0_f37460d3-5c48-40a5-b100-30c22952b6c3">5,168</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Other tax adjustments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e24f17963584a8a8d751afa02b1b0c9_D20200101-20201231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalOther" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183My9mcmFnOmQzNzc2MmZiMDI0ZDRjNWE5MjMxODNkNmUxMTdjM2Q1L3RhYmxlOjU2ZjRlNzRkOTUxZDRhM2NiNDRhMzVjOGM0OWFmN2M0L3RhYmxlcmFuZ2U6NTZmNGU3NGQ5NTFkNGEzY2I0NGEzNWM4YzQ5YWY3YzRfMTgtNS0xLTEtNDEyOTQ_fce102dd-6a57-4b96-96bd-2e6240171a6c">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3597315a63d441f8f128abd7ed8840e_D20200101-20201231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalOther" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183My9mcmFnOmQzNzc2MmZiMDI0ZDRjNWE5MjMxODNkNmUxMTdjM2Q1L3RhYmxlOjU2ZjRlNzRkOTUxZDRhM2NiNDRhMzVjOGM0OWFmN2M0L3RhYmxlcmFuZ2U6NTZmNGU3NGQ5NTFkNGEzY2I0NGEzNWM4YzQ5YWY3YzRfMTgtMTItMS0xLTQxMjk0_4a22946b-f2c1-4e57-a5fb-f6e07294a4a2">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3a721e0ae7354a8da5ec3fc43557bc99_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183My9mcmFnOmQzNzc2MmZiMDI0ZDRjNWE5MjMxODNkNmUxMTdjM2Q1L3RhYmxlOjU2ZjRlNzRkOTUxZDRhM2NiNDRhMzVjOGM0OWFmN2M0L3RhYmxlcmFuZ2U6NTZmNGU3NGQ5NTFkNGEzY2I0NGEzNWM4YzQ5YWY3YzRfMTktOS0xLTEtNDEyOTQ_493458c4-7a45-43b1-b65e-2439efa86a9a">2,985</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib3597315a63d441f8f128abd7ed8840e_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183My9mcmFnOmQzNzc2MmZiMDI0ZDRjNWE5MjMxODNkNmUxMTdjM2Q1L3RhYmxlOjU2ZjRlNzRkOTUxZDRhM2NiNDRhMzVjOGM0OWFmN2M0L3RhYmxlcmFuZ2U6NTZmNGU3NGQ5NTFkNGEzY2I0NGEzNWM4YzQ5YWY3YzRfMTktMTItMS0xLTQxMjk0_adf2b939-b963-4b6a-9c32-928f3035f9b1">2,985</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Balance at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i00775ac58cda4124ad52707038f57ba7_I20201231" decimals="-3" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183My9mcmFnOmQzNzc2MmZiMDI0ZDRjNWE5MjMxODNkNmUxMTdjM2Q1L3RhYmxlOjU2ZjRlNzRkOTUxZDRhM2NiNDRhMzVjOGM0OWFmN2M0L3RhYmxlcmFuZ2U6NTZmNGU3NGQ5NTFkNGEzY2I0NGEzNWM4YzQ5YWY3YzRfMjAtMS0xLTEtNDg1NzM_1c1ae2f4-1864-413c-979e-804489069061">16,080</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00775ac58cda4124ad52707038f57ba7_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183My9mcmFnOmQzNzc2MmZiMDI0ZDRjNWE5MjMxODNkNmUxMTdjM2Q1L3RhYmxlOjU2ZjRlNzRkOTUxZDRhM2NiNDRhMzVjOGM0OWFmN2M0L3RhYmxlcmFuZ2U6NTZmNGU3NGQ5NTFkNGEzY2I0NGEzNWM4YzQ5YWY3YzRfMjAtMy0xLTEtNDg1NzM_80ec26a8-a12c-4bbb-9fc6-56fd294e4cb0">16</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98685891da6a4235a4c08510b2fafca9_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183My9mcmFnOmQzNzc2MmZiMDI0ZDRjNWE5MjMxODNkNmUxMTdjM2Q1L3RhYmxlOjU2ZjRlNzRkOTUxZDRhM2NiNDRhMzVjOGM0OWFmN2M0L3RhYmxlcmFuZ2U6NTZmNGU3NGQ5NTFkNGEzY2I0NGEzNWM4YzQ5YWY3YzRfMjAtNS0xLTEtNDg1NzM_f5592c7a-1579-4f64-927e-5155c7e49861">318,358</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibd8887ddedbb409e8ee0b01a14c47927_I20201231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183My9mcmFnOmQzNzc2MmZiMDI0ZDRjNWE5MjMxODNkNmUxMTdjM2Q1L3RhYmxlOjU2ZjRlNzRkOTUxZDRhM2NiNDRhMzVjOGM0OWFmN2M0L3RhYmxlcmFuZ2U6NTZmNGU3NGQ5NTFkNGEzY2I0NGEzNWM4YzQ5YWY3YzRfMjAtNy0xLTEtNDg1NzM_6217f3ce-b594-4659-bf83-aa24e360a591">801</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie12d7c9cbefd4947bbe0a3c6cb0e902e_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183My9mcmFnOmQzNzc2MmZiMDI0ZDRjNWE5MjMxODNkNmUxMTdjM2Q1L3RhYmxlOjU2ZjRlNzRkOTUxZDRhM2NiNDRhMzVjOGM0OWFmN2M0L3RhYmxlcmFuZ2U6NTZmNGU3NGQ5NTFkNGEzY2I0NGEzNWM4YzQ5YWY3YzRfMjAtOS0xLTEtNDEyOTQ_d9360eb9-9d43-4469-9363-220a92f04bbe">391,952</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7462d0db8f4248fcb9fd8f1deae439f3_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183My9mcmFnOmQzNzc2MmZiMDI0ZDRjNWE5MjMxODNkNmUxMTdjM2Q1L3RhYmxlOjU2ZjRlNzRkOTUxZDRhM2NiNDRhMzVjOGM0OWFmN2M0L3RhYmxlcmFuZ2U6NTZmNGU3NGQ5NTFkNGEzY2I0NGEzNWM4YzQ5YWY3YzRfMjAtMTItMS0xLTQxMjk0_cba70cfd-c3af-4e40-8213-1bb9ef8eb348">709,525</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Issuance of common stock under employee stock compensation plans, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3fe3de32a504463798a10b16d8710835_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183My9mcmFnOmQzNzc2MmZiMDI0ZDRjNWE5MjMxODNkNmUxMTdjM2Q1L3RhYmxlOjU2ZjRlNzRkOTUxZDRhM2NiNDRhMzVjOGM0OWFmN2M0L3RhYmxlcmFuZ2U6NTZmNGU3NGQ5NTFkNGEzY2I0NGEzNWM4YzQ5YWY3YzRfMjEtMS0xLTEtNDEyOTQ_0b2780db-5718-4a0b-9728-8d2cda0b0fef">687</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3fe3de32a504463798a10b16d8710835_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183My9mcmFnOmQzNzc2MmZiMDI0ZDRjNWE5MjMxODNkNmUxMTdjM2Q1L3RhYmxlOjU2ZjRlNzRkOTUxZDRhM2NiNDRhMzVjOGM0OWFmN2M0L3RhYmxlcmFuZ2U6NTZmNGU3NGQ5NTFkNGEzY2I0NGEzNWM4YzQ5YWY3YzRfMjEtMy0xLTEtNDEyOTQ_373e2591-f04d-4298-b2bf-6ebd6a5a9a5c">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86f3192c999a48e18bfbb2d3da1eee99_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183My9mcmFnOmQzNzc2MmZiMDI0ZDRjNWE5MjMxODNkNmUxMTdjM2Q1L3RhYmxlOjU2ZjRlNzRkOTUxZDRhM2NiNDRhMzVjOGM0OWFmN2M0L3RhYmxlcmFuZ2U6NTZmNGU3NGQ5NTFkNGEzY2I0NGEzNWM4YzQ5YWY3YzRfMjEtNS0xLTEtNDEyOTQ_3445fde8-b53f-4151-bb19-c4467d5f0c20">27,744</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183My9mcmFnOmQzNzc2MmZiMDI0ZDRjNWE5MjMxODNkNmUxMTdjM2Q1L3RhYmxlOjU2ZjRlNzRkOTUxZDRhM2NiNDRhMzVjOGM0OWFmN2M0L3RhYmxlcmFuZ2U6NTZmNGU3NGQ5NTFkNGEzY2I0NGEzNWM4YzQ5YWY3YzRfMjEtMTItMS0xLTQxMjk0_55cf86c1-af27-4de8-ae93-1ad99f1a73bd">27,745</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86f3192c999a48e18bfbb2d3da1eee99_D20210101-20211231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183My9mcmFnOmQzNzc2MmZiMDI0ZDRjNWE5MjMxODNkNmUxMTdjM2Q1L3RhYmxlOjU2ZjRlNzRkOTUxZDRhM2NiNDRhMzVjOGM0OWFmN2M0L3RhYmxlcmFuZ2U6NTZmNGU3NGQ5NTFkNGEzY2I0NGEzNWM4YzQ5YWY3YzRfMjItNS0xLTEtNDEyOTQ_08ce7802-7422-41ba-bbaf-d72501a52f7d">38,783</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183My9mcmFnOmQzNzc2MmZiMDI0ZDRjNWE5MjMxODNkNmUxMTdjM2Q1L3RhYmxlOjU2ZjRlNzRkOTUxZDRhM2NiNDRhMzVjOGM0OWFmN2M0L3RhYmxlcmFuZ2U6NTZmNGU3NGQ5NTFkNGEzY2I0NGEzNWM4YzQ5YWY3YzRfMjItMTItMS0xLTQxMjk0_6f4b6115-5374-4c66-b80d-a6543201f0fb">38,783</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Unrealized net loss on available-for-sale securities, net of deferred tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib1ca68e3b91b44f0a9d75354b9a561c3_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183My9mcmFnOmQzNzc2MmZiMDI0ZDRjNWE5MjMxODNkNmUxMTdjM2Q1L3RhYmxlOjU2ZjRlNzRkOTUxZDRhM2NiNDRhMzVjOGM0OWFmN2M0L3RhYmxlcmFuZ2U6NTZmNGU3NGQ5NTFkNGEzY2I0NGEzNWM4YzQ5YWY3YzRfMjQtNy0xLTEtNDgyNDM_ae8170dd-a22f-4f04-9435-40a365607578">116</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183My9mcmFnOmQzNzc2MmZiMDI0ZDRjNWE5MjMxODNkNmUxMTdjM2Q1L3RhYmxlOjU2ZjRlNzRkOTUxZDRhM2NiNDRhMzVjOGM0OWFmN2M0L3RhYmxlcmFuZ2U6NTZmNGU3NGQ5NTFkNGEzY2I0NGEzNWM4YzQ5YWY3YzRfMjQtMTItMS0xLTQxMjk0_6b7a9a2e-eba7-4357-867d-5eac9bd23bbd">116</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Reacquisition of equity due to 2023 debt extinguishment, net of tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i86f3192c999a48e18bfbb2d3da1eee99_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183My9mcmFnOmQzNzc2MmZiMDI0ZDRjNWE5MjMxODNkNmUxMTdjM2Q1L3RhYmxlOjU2ZjRlNzRkOTUxZDRhM2NiNDRhMzVjOGM0OWFmN2M0L3RhYmxlcmFuZ2U6NTZmNGU3NGQ5NTFkNGEzY2I0NGEzNWM4YzQ5YWY3YzRfMjYtNS0xLTEtNDgyNDM_13f52c8c-fdc6-441c-921c-9cc301e885de">12,407</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183My9mcmFnOmQzNzc2MmZiMDI0ZDRjNWE5MjMxODNkNmUxMTdjM2Q1L3RhYmxlOjU2ZjRlNzRkOTUxZDRhM2NiNDRhMzVjOGM0OWFmN2M0L3RhYmxlcmFuZ2U6NTZmNGU3NGQ5NTFkNGEzY2I0NGEzNWM4YzQ5YWY3YzRfMjYtMTItMS0xLTQxMjk0_7d2fbb83-7e6f-40be-9cba-baca576486be">12,407</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Warrant and bond hedge unwind transactions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86f3192c999a48e18bfbb2d3da1eee99_D20210101-20211231" decimals="-3" name="lgnd:AdjustmentsToAdditionalPaidInCapitalWarrantAndBondHedgeUnwindTransactions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183My9mcmFnOmQzNzc2MmZiMDI0ZDRjNWE5MjMxODNkNmUxMTdjM2Q1L3RhYmxlOjU2ZjRlNzRkOTUxZDRhM2NiNDRhMzVjOGM0OWFmN2M0L3RhYmxlcmFuZ2U6NTZmNGU3NGQ5NTFkNGEzY2I0NGEzNWM4YzQ5YWY3YzRfMjYtNS0xLTEtNTE4OTE_82612c94-c050-4983-a53f-20cb4c77d981">491</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231" decimals="-3" name="lgnd:AdjustmentsToAdditionalPaidInCapitalWarrantAndBondHedgeUnwindTransactions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183My9mcmFnOmQzNzc2MmZiMDI0ZDRjNWE5MjMxODNkNmUxMTdjM2Q1L3RhYmxlOjU2ZjRlNzRkOTUxZDRhM2NiNDRhMzVjOGM0OWFmN2M0L3RhYmxlcmFuZ2U6NTZmNGU3NGQ5NTFkNGEzY2I0NGEzNWM4YzQ5YWY3YzRfMjYtMTItMS0xLTUyMDg1_40b8e752-4c9d-42f1-b695-5dce03d6a985">491</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a0bf241e5df45f3b9a295da0a033225_D20210101-20211231" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183My9mcmFnOmQzNzc2MmZiMDI0ZDRjNWE5MjMxODNkNmUxMTdjM2Q1L3RhYmxlOjU2ZjRlNzRkOTUxZDRhM2NiNDRhMzVjOGM0OWFmN2M0L3RhYmxlcmFuZ2U6NTZmNGU3NGQ5NTFkNGEzY2I0NGEzNWM4YzQ5YWY3YzRfMjktOS0xLTEtNDEyOTQ_d1466784-d42d-49af-8f77-727e09206649">57,138</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183My9mcmFnOmQzNzc2MmZiMDI0ZDRjNWE5MjMxODNkNmUxMTdjM2Q1L3RhYmxlOjU2ZjRlNzRkOTUxZDRhM2NiNDRhMzVjOGM0OWFmN2M0L3RhYmxlcmFuZ2U6NTZmNGU3NGQ5NTFkNGEzY2I0NGEzNWM4YzQ5YWY3YzRfMjktMTItMS0xLTQxMjk0_2495f044-dff9-472c-a53c-65aad0347386">57,138</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Balance at December 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4893aa820b6e400e86aa2f8639ddb077_I20211231" decimals="-3" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183My9mcmFnOmQzNzc2MmZiMDI0ZDRjNWE5MjMxODNkNmUxMTdjM2Q1L3RhYmxlOjU2ZjRlNzRkOTUxZDRhM2NiNDRhMzVjOGM0OWFmN2M0L3RhYmxlcmFuZ2U6NTZmNGU3NGQ5NTFkNGEzY2I0NGEzNWM4YzQ5YWY3YzRfMzAtMS0xLTEtNDEyOTQ_173d3b11-6d5f-47c3-884f-66934749d29d">16,767</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4893aa820b6e400e86aa2f8639ddb077_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183My9mcmFnOmQzNzc2MmZiMDI0ZDRjNWE5MjMxODNkNmUxMTdjM2Q1L3RhYmxlOjU2ZjRlNzRkOTUxZDRhM2NiNDRhMzVjOGM0OWFmN2M0L3RhYmxlcmFuZ2U6NTZmNGU3NGQ5NTFkNGEzY2I0NGEzNWM4YzQ5YWY3YzRfMjgtMy0xLTEtNDg1NzU_e2402210-09f3-4d43-a0f9-44c53f7fad42">17</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i460189e17625434e8a5a65a7ad36197f_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183My9mcmFnOmQzNzc2MmZiMDI0ZDRjNWE5MjMxODNkNmUxMTdjM2Q1L3RhYmxlOjU2ZjRlNzRkOTUxZDRhM2NiNDRhMzVjOGM0OWFmN2M0L3RhYmxlcmFuZ2U6NTZmNGU3NGQ5NTFkNGEzY2I0NGEzNWM4YzQ5YWY3YzRfMzAtNS0xLTEtNDEyOTQ_0745f314-d1f0-47e7-aef4-27d5c67f5451">372,969</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i35055051f1cc48e3880e5291e4e63132_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183My9mcmFnOmQzNzc2MmZiMDI0ZDRjNWE5MjMxODNkNmUxMTdjM2Q1L3RhYmxlOjU2ZjRlNzRkOTUxZDRhM2NiNDRhMzVjOGM0OWFmN2M0L3RhYmxlcmFuZ2U6NTZmNGU3NGQ5NTFkNGEzY2I0NGEzNWM4YzQ5YWY3YzRfMjgtNy0xLTEtNDg1NzU_a109c75d-2ec5-4776-9538-dfd686d4b75d">917</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if714890c34114ccca202fde217c2acc5_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183My9mcmFnOmQzNzc2MmZiMDI0ZDRjNWE5MjMxODNkNmUxMTdjM2Q1L3RhYmxlOjU2ZjRlNzRkOTUxZDRhM2NiNDRhMzVjOGM0OWFmN2M0L3RhYmxlcmFuZ2U6NTZmNGU3NGQ5NTFkNGEzY2I0NGEzNWM4YzQ5YWY3YzRfMjgtOS0xLTEtNDg1NzU_6ee7ea45-7d91-4da8-af3a-78c073a88ac9">449,090</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183My9mcmFnOmQzNzc2MmZiMDI0ZDRjNWE5MjMxODNkNmUxMTdjM2Q1L3RhYmxlOjU2ZjRlNzRkOTUxZDRhM2NiNDRhMzVjOGM0OWFmN2M0L3RhYmxlcmFuZ2U6NTZmNGU3NGQ5NTFkNGEzY2I0NGEzNWM4YzQ5YWY3YzRfMzAtMTItMS0xLTQxMjk0_bf14a331-8ee6-4d5f-91f9-e941bca01915">821,159</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">See accompanying notes to these consolidated financial statements.</span></div><div id="i0fa6f906fb2e4e30bc5e873d2bb6a82c_76"></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">LIGAND PHARMACEUTICALS INCORPORATED</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">57</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF CASH FLOWS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:59.488%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.547%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.547%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.548%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year&#160;Ended&#160;December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231" decimals="-3" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfMy0xLTEtMS00MTI5NA_35f2f2d3-e43f-4dbf-aac8-de344b664036">57,138</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib3597315a63d441f8f128abd7ed8840e_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfMy0zLTEtMS00MTI5NA_652f0dad-31f7-4e43-b831-40363e028d45">2,985</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6c3b69702e9429aaeed46bdb9bbb9c1_D20190101-20191231" decimals="-3" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfMy01LTEtMS00MTI5NA_50676c0d-60c9-4f5e-8cd8-27663e44fda4">629,302</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gain from sale of Promacta license</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231" decimals="-3" name="us-gaap:GainLossOnSaleOfOtherAssets" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfNS0xLTEtMS00MTI5NA_18d694f7-9bc3-40bc-97ac-c936ff27b5a3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3597315a63d441f8f128abd7ed8840e_D20200101-20201231" decimals="-3" name="us-gaap:GainLossOnSaleOfOtherAssets" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfNS0zLTEtMS00MTI5NA_3b727d2f-ea2f-4519-b1fb-137ab07df2e1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie6c3b69702e9429aaeed46bdb9bbb9c1_D20190101-20191231" decimals="-3" name="us-gaap:GainLossOnSaleOfOtherAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfNS01LTEtMS00MTI5NA_4c837d03-5dbd-4117-814c-e06885dc1c4b">812,797</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gain from sale of Vernalis R&amp;D</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231" decimals="-3" name="us-gaap:GainLossOnSaleOfBusiness" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfNi0xLTEtMS00MTI5NA_a517d332-23d0-4b6a-ae88-1a0f25de64c5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib3597315a63d441f8f128abd7ed8840e_D20200101-20201231" decimals="-3" name="us-gaap:GainLossOnSaleOfBusiness" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfNi0zLTEtMS00MTI5NA_65e068fb-7d28-44da-995d-9c4626fa62f5">17,114</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6c3b69702e9429aaeed46bdb9bbb9c1_D20190101-20191231" decimals="-3" name="us-gaap:GainLossOnSaleOfBusiness" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfNi01LTEtMS00MTI5NA_b1067c03-c800-4239-a568-9713caa98b55">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Change in estimated fair value of contingent liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231" decimals="-3" name="lgnd:NonCashChangeInEstimatedFairValueOfContingentValueRights" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfNy0xLTEtMS00MTI5NA_4be66006-1e66-4f3a-b859-812a099adec8">36,962</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3597315a63d441f8f128abd7ed8840e_D20200101-20201231" decimals="-3" sign="-" name="lgnd:NonCashChangeInEstimatedFairValueOfContingentValueRights" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfNy0zLTEtMS00MTI5NA_89720b0b-6202-46db-bfa5-39432800f986">963</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie6c3b69702e9429aaeed46bdb9bbb9c1_D20190101-20191231" decimals="-3" name="lgnd:NonCashChangeInEstimatedFairValueOfContingentValueRights" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfNy01LTEtMS00MTI5NA_e79414af-b074-471d-8e7e-df8cfd2601da">30</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Depreciation of fixed assets and amortization of intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfOC0xLTEtMS00MTI5NA_0403765d-542c-4ab5-8232-b540dd30d91b">51,071</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3597315a63d441f8f128abd7ed8840e_D20200101-20201231" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfOC0zLTEtMS00MTI5NA_7a455c60-ef07-4ad1-b26b-6602a7a41574">25,691</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6c3b69702e9429aaeed46bdb9bbb9c1_D20190101-20191231" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfOC01LTEtMS00MTI5NA_9eea8c43-3a6f-44d7-a49b-9717ee60a731">18,361</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loss (gain) short-term investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231" decimals="-3" sign="-" name="lgnd:GainLossOnShortTermInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfOS0xLTEtMS00MTI5NA_64003b9a-b67d-4d75-a902-82830b750f1e">3,997</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3597315a63d441f8f128abd7ed8840e_D20200101-20201231" decimals="-3" sign="-" name="lgnd:GainLossOnShortTermInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfOS0zLTEtMS00MTI5NA_a056e48b-f2dc-4eb6-b6a2-8b91e59048c2">16,933</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie6c3b69702e9429aaeed46bdb9bbb9c1_D20190101-20191231" decimals="-3" name="lgnd:GainLossOnShortTermInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfOS01LTEtMS00MTI5NA_3d616d8d-6b03-47b7-aec9-9378cda474b7">1,049</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization/accretion of premium (discount) on investments, net</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfMTAtMS0xLTEtNDEyOTQ_a8869553-d903-4f6c-9498-94192913cca6">111</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3597315a63d441f8f128abd7ed8840e_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfMTAtMy0xLTEtNDEyOTQ_1458d4f6-108a-490a-a13a-4c40307e7e3c">1,479</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie6c3b69702e9429aaeed46bdb9bbb9c1_D20190101-20191231" decimals="-3" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfMTAtNS0xLTEtNDEyOTQ_c053fcf0-5180-4382-b395-b28e63c87d6a">10,274</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization of debt discount and issuance fees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231" decimals="-3" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfMTEtMS0xLTEtNDEyOTQ_4e09074e-d2f7-461c-ae9e-735e03044d94">16,692</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3597315a63d441f8f128abd7ed8840e_D20200101-20201231" decimals="-3" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfMTEtMy0xLTEtNDEyOTQ_592ae330-124d-4c73-bc3a-190e1214231e">23,077</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6c3b69702e9429aaeed46bdb9bbb9c1_D20190101-20191231" decimals="-3" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfMTEtNS0xLTEtNDEyOTQ_65717d09-cfa6-4a4b-9d4a-6040b29464f4">29,988</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loss on debt extinguishment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfMTItMS0xLTEtNTIwOTM_28e2bd19-cdf4-4b1c-b40d-ecb41ae44b21">7,303</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3597315a63d441f8f128abd7ed8840e_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfMTItMy0xLTEtNTIwOTM_ab256681-4a15-455c-ba5c-bcada6f87ce4">2,466</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6c3b69702e9429aaeed46bdb9bbb9c1_D20190101-20191231" decimals="-3" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfMTItNS0xLTEtNTIwOTM_fdbcba83-c595-4164-85dd-df95dae78bb0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization of commercial license and other economic rights</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231" decimals="-3" sign="-" name="lgnd:AmortizationOfCommercialLicenseAndOtherEconomicRights" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfMTItMS0xLTEtNDEyOTQ_bc1b3358-b1fc-4f96-84c9-d500a5952687">125</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3597315a63d441f8f128abd7ed8840e_D20200101-20201231" decimals="-3" name="lgnd:AmortizationOfCommercialLicenseAndOtherEconomicRights" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfMTItMy0xLTEtNDEyOTQ_eae9f70e-86c4-4408-a9b7-763099ea3f89">2,275</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6c3b69702e9429aaeed46bdb9bbb9c1_D20190101-20191231" decimals="-3" name="lgnd:AmortizationOfCommercialLicenseAndOtherEconomicRights" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfMTItNS0xLTEtNDEyOTQ_baf83880-87b0-405d-a219-a2cdced0afac">25,370</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfMTMtMS0xLTEtNDEyOTQ_f2b16ca2-89bb-41a7-8892-f75fa063e111">38,783</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3597315a63d441f8f128abd7ed8840e_D20200101-20201231" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfMTMtMy0xLTEtNDEyOTQ_18fa8c7d-9592-45f0-96dc-9e3dd8ac53e2">30,727</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6c3b69702e9429aaeed46bdb9bbb9c1_D20190101-20191231" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfMTMtNS0xLTEtNDEyOTQ_cd846fd4-7bb8-4a7b-a6a6-6cf531c95014">24,515</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred income taxes, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231" decimals="-3" name="us-gaap:IncreaseDecreaseInDeferredIncomeTaxes" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfMTQtMS0xLTEtNDEyOTQ_c21ae106-ace6-4c4c-9c5b-67c7c5520a03">8,618</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib3597315a63d441f8f128abd7ed8840e_D20200101-20201231" decimals="-3" name="us-gaap:IncreaseDecreaseInDeferredIncomeTaxes" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfMTQtMy0xLTEtNDEyOTQ_e6ad7ced-a012-46df-988e-2c2c997aa283">19,053</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6c3b69702e9429aaeed46bdb9bbb9c1_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInDeferredIncomeTaxes" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfMTQtNS0xLTEtNDEyOTQ_f6d5d9bf-99cc-4fff-9b0e-09cc80e652a0">74,829</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231" decimals="-3" name="us-gaap:OtherOperatingActivitiesCashFlowStatement" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfMTYtMS0xLTEtNDEyOTQ_3b5cd8ef-607c-4262-bf99-b2048be84b0c">1,572</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3597315a63d441f8f128abd7ed8840e_D20200101-20201231" decimals="-3" name="us-gaap:OtherOperatingActivitiesCashFlowStatement" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfMTYtMy0xLTEtNDEyOTQ_d2584167-ca75-41eb-9a45-175bacaf6d57">191</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie6c3b69702e9429aaeed46bdb9bbb9c1_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:OtherOperatingActivitiesCashFlowStatement" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfMTYtNS0xLTEtNDEyOTQ_c63a2290-ce0a-43d2-b6de-f0d2a139280c">3,498</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities, net of acquisitions:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfMTgtMS0xLTEtNDEyOTQ_c53c25d4-8f0c-4053-9399-3cb0e090ea43">28,616</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib3597315a63d441f8f128abd7ed8840e_D20200101-20201231" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfMTgtMy0xLTEtNDEyOTQ_389b9092-d63d-427d-80e1-1c56ac556dc6">26,061</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6c3b69702e9429aaeed46bdb9bbb9c1_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfMTgtNS0xLTEtNDEyOTQ_54278125-eb27-4b9d-a051-f41dae1196f2">25,463</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231" decimals="-3" name="us-gaap:IncreaseDecreaseInInventories" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfMTktMS0xLTEtNDEyOTQ_f2166b74-cc2b-4bd5-93d4-cf8b371f7721">427</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib3597315a63d441f8f128abd7ed8840e_D20200101-20201231" decimals="-3" name="us-gaap:IncreaseDecreaseInInventories" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfMTktMy0xLTEtNDEyOTQ_043558e9-84b0-4129-820b-5c1e7486b2ad">17,799</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie6c3b69702e9429aaeed46bdb9bbb9c1_D20190101-20191231" decimals="-3" name="us-gaap:IncreaseDecreaseInInventories" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfMTktNS0xLTEtNDEyOTQ_eafa911e-4b47-44da-95ce-745a23e4baf8">2,061</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts payable and accrued liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfMjAtMS0xLTEtNDEyOTQ_af2235a5-5c02-4dd7-b28f-b806b35be916">2,810</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib3597315a63d441f8f128abd7ed8840e_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfMjAtMy0xLTEtNDEyOTQ_bf97fd7d-f8f6-4cb0-abdb-9a20dba220ce">1,245</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie6c3b69702e9429aaeed46bdb9bbb9c1_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfMjAtNS0xLTEtNDEyOTQ_1f967744-de89-48c6-8b28-7d5cbb13e2cc">6,664</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income taxes receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231" decimals="-3" name="us-gaap:IncreaseDecreaseInIncomeTaxesReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfMjEtMS0xLTEtNDEyOTQ_ca9b9fbe-8dd8-4537-91a7-0c15ab858d82">3,976</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3597315a63d441f8f128abd7ed8840e_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInIncomeTaxesReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfMjEtMy0xLTEtNDEyOTQ_a414c32c-2e75-4757-aacd-0c0292bb4e0d">9,144</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie6c3b69702e9429aaeed46bdb9bbb9c1_D20190101-20191231" decimals="-3" name="us-gaap:IncreaseDecreaseInIncomeTaxesReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfMjEtNS0xLTEtNDEyOTQ_e67cb11a-71dd-4104-af78-02e9170119a8">11,219</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other economic rights</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231" decimals="-3" name="lgnd:IncreaseDecreaseInOtherEconomicRights" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfMjItMS0xLTEtNDEyOTQ_5678caf8-5422-4eb8-8739-b12434fb3346">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3597315a63d441f8f128abd7ed8840e_D20200101-20201231" decimals="-3" name="lgnd:IncreaseDecreaseInOtherEconomicRights" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfMjItMy0xLTEtNDEyOTQ_f53b67ef-8827-49d4-bef7-92e7e9b7ded6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie6c3b69702e9429aaeed46bdb9bbb9c1_D20190101-20191231" decimals="-3" sign="-" name="lgnd:IncreaseDecreaseInOtherEconomicRights" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfMjItNS0xLTEtNDEyOTQ_4c2b9e75-0f66-43df-8c28-def9a4742de4">12,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfMjMtMS0xLTEtNDEyOTQ_bacb6bd9-1027-4eef-a649-928c28d3ae81">17,870</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3597315a63d441f8f128abd7ed8840e_D20200101-20201231" decimals="-3" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfMjMtMy0xLTEtNDEyOTQ_b3b38284-3450-4ca7-b402-f39762d73b09">29,236</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie6c3b69702e9429aaeed46bdb9bbb9c1_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfMjMtNS0xLTEtNDEyOTQ_c7ae1aed-f050-4ee1-9e59-a89ca093ba09">1,147</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherCurrentLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfMjQtMS0xLTEtNDEyOTQ_2e523a40-d687-493b-8695-70349cdb8c38">4,085</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib3597315a63d441f8f128abd7ed8840e_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherCurrentLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfMjQtMy0xLTEtNDEyOTQ_b40c0e7c-05b3-4ade-910a-a3191b36b08f">3,339</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6c3b69702e9429aaeed46bdb9bbb9c1_D20190101-20191231" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherCurrentLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfMjQtNS0xLTEtNDEyOTQ_2959d17e-0589-41ec-a094-8c6793b0f15f">3,575</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net cash provided by (used in) operating activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231" decimals="-3" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfMjUtMS0xLTEtNDEyOTQ_e9901377-11c6-4d67-8559-d709d1af4fcd">78,798</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3597315a63d441f8f128abd7ed8840e_D20200101-20201231" decimals="-3" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfMjUtMy0xLTEtNDEyOTQ_ce7d2fc2-b2b7-4d04-b731-15edc57b834c">54,586</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie6c3b69702e9429aaeed46bdb9bbb9c1_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfMjUtNS0xLTEtNDEyOTQ_e2a50c01-89a2-4298-9ddf-c001abeaba94">29,336</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Investing activities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from sale of Promacta license</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231" decimals="-3" name="us-gaap:ProceedsFromSaleOfIntangibleAssets" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfMjctMS0xLTEtNDEyOTQ_0c592d84-9dd5-450d-8229-252a43cdb535">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3597315a63d441f8f128abd7ed8840e_D20200101-20201231" decimals="-3" name="us-gaap:ProceedsFromSaleOfIntangibleAssets" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfMjctMy0xLTEtNDEyOTQ_9429ebac-50f9-482e-968a-ce3e9bba5503">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6c3b69702e9429aaeed46bdb9bbb9c1_D20190101-20191231" decimals="-3" name="us-gaap:ProceedsFromSaleOfIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfMjctNS0xLTEtNDEyOTQ_8d2cb7fe-570d-4207-bc48-d9450c0b89ff">812,797</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash paid for acquisition, net of cash and restricted cash acquired</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231" decimals="-3" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfMjktMS0xLTEtNDEyOTQ_202071c4-3eb3-485a-8348-abf3cc584da4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib3597315a63d441f8f128abd7ed8840e_D20200101-20201231" decimals="-3" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfMjktMy0xLTEtNDEyOTQ_569a38c7-de2a-4a86-b052-cfe6696dce54">404,884</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie6c3b69702e9429aaeed46bdb9bbb9c1_D20190101-20191231" decimals="-3" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfMjktNS0xLTEtNDEyOTQ_294d4e7d-e7c4-4816-b2ab-417192a76ef4">11,840</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchases of property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfMzAtMS0xLTEtNDEyOTQ_85214034-dd7f-4878-8e49-a1e003411ebd">8,761</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib3597315a63d441f8f128abd7ed8840e_D20200101-20201231" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfMzAtMy0xLTEtNDEyOTQ_5fc0e4ab-53ee-4d30-9fa4-97eac75cbaa8">4,458</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie6c3b69702e9429aaeed46bdb9bbb9c1_D20190101-20191231" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfMzAtNS0xLTEtNDEyOTQ_da97840d-1ec4-424e-815e-b2de04c2aa90">2,553</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchases of short-term investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231" decimals="-3" name="us-gaap:PaymentsToAcquireShortTermInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfMzEtMS0xLTEtNDEyOTQ_dd59c61c-5ced-4ba7-a95c-d2d7e3c77803">181,325</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib3597315a63d441f8f128abd7ed8840e_D20200101-20201231" decimals="-3" name="us-gaap:PaymentsToAcquireShortTermInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfMzEtMy0xLTEtNDEyOTQ_676d39d9-a175-400c-a207-243a27081c84">422,523</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie6c3b69702e9429aaeed46bdb9bbb9c1_D20190101-20191231" decimals="-3" name="us-gaap:PaymentsToAcquireShortTermInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfMzEtNS0xLTEtNDEyOTQ_eb466472-e890-4f2a-be87-cc18967d101e">2,356,545</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from commercial license rights</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231" decimals="-3" name="lgnd:ProceedsFromCommercialLicenseRights" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfMzItMS0xLTEtNDEyOTQ_89a087d0-b94a-4648-b20c-65fb3c9a057f">494</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3597315a63d441f8f128abd7ed8840e_D20200101-20201231" decimals="-3" name="lgnd:ProceedsFromCommercialLicenseRights" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfMzItMy0xLTEtNDEyOTQ_5a83c2eb-91c8-47ec-bfae-e0bbc87e50ef">1,358</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6c3b69702e9429aaeed46bdb9bbb9c1_D20190101-20191231" decimals="-3" name="lgnd:ProceedsFromCommercialLicenseRights" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfMzItNS0xLTEtNDEyOTQ_d0cff412-6e96-4345-be2b-ab6fd369887a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from sale of short-term investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231" decimals="-3" name="us-gaap:ProceedsFromSaleOfShortTermInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfMzMtMS0xLTEtNDEyOTQ_4da00c23-c4e3-4eac-b980-46154f0b541d">154,230</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3597315a63d441f8f128abd7ed8840e_D20200101-20201231" decimals="-3" name="us-gaap:ProceedsFromSaleOfShortTermInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfMzMtMy0xLTEtNDEyOTQ_f7c13605-1085-4fbb-84fd-de168c6cd669">394,539</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6c3b69702e9429aaeed46bdb9bbb9c1_D20190101-20191231" decimals="-3" name="us-gaap:ProceedsFromSaleOfShortTermInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfMzMtNS0xLTEtNDEyOTQ_fd0f7db2-14f7-41d9-8514-406992f5e76f">535,877</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from maturity of short-term investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231" decimals="-3" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfMzQtMS0xLTEtNDEyOTQ_77095e3e-2fed-4ea3-b28e-b99099ff05b8">67,105</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3597315a63d441f8f128abd7ed8840e_D20200101-20201231" decimals="-3" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfMzQtMy0xLTEtNDEyOTQ_cdf9955d-3cd6-424a-b7c3-db1ccc5735b6">644,155</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6c3b69702e9429aaeed46bdb9bbb9c1_D20190101-20191231" decimals="-3" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfMzQtNS0xLTEtNDEyOTQ_109eeb8b-40be-4ba6-9d15-07c611e93d44">1,494,851</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash paid for equity method investment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231" decimals="-3" name="us-gaap:PaymentsToAcquireEquityMethodInvestments" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfMzYtMS0xLTEtNDEyOTQ_f682dcc6-15f7-4caf-b3e7-d85e4b20fbb5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib3597315a63d441f8f128abd7ed8840e_D20200101-20201231" decimals="-3" name="us-gaap:PaymentsToAcquireEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfMzYtMy0xLTEtNDEyOTQ_25732127-80d2-4c43-8279-663779e0c411">500</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie6c3b69702e9429aaeed46bdb9bbb9c1_D20190101-20191231" decimals="-3" name="us-gaap:PaymentsToAcquireEquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfMzYtNS0xLTEtNDEyOTQ_ee769173-aeba-49dd-b289-9c750ee2c898">1,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds on sale of Vernalis R&amp;D, net </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231" decimals="-3" name="us-gaap:ProceedsFromDivestitureOfBusinesses" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfMzctMS0xLTEtNDEyOTQ_0dcec7d6-3cff-4781-bfe6-8170020cf9ef">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3597315a63d441f8f128abd7ed8840e_D20200101-20201231" decimals="-3" name="us-gaap:ProceedsFromDivestitureOfBusinesses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfMzctMy0xLTEtNDEyOTQ_490c4391-b487-4e06-908f-717fb1d5fed7">22,061</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6c3b69702e9429aaeed46bdb9bbb9c1_D20190101-20191231" decimals="-3" name="us-gaap:ProceedsFromDivestitureOfBusinesses" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfMzctNS0xLTEtNDEyOTQ_63225a70-bccd-4618-a746-e7d9351bd47e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231" decimals="-3" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfMzgtMS0xLTEtNDEyOTQ_69578339-c62a-4ca1-887d-0e0879a6360f">1,220</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3597315a63d441f8f128abd7ed8840e_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfMzgtMy0xLTEtNDEyOTQ_e8874b60-4dbf-489d-ac8c-9f156ea04971">1,900</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie6c3b69702e9429aaeed46bdb9bbb9c1_D20190101-20191231" decimals="-3" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfMzgtNS0xLTEtNDEyOTQ_eb03b588-38e6-4e7d-9fc6-02ace6d40f39">4,669</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net cash provided by investing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231" decimals="-3" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfMzktMS0xLTEtNDEyOTQ_d69e041e-d0e6-46ac-9cdc-721f2428bc69">30,523</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3597315a63d441f8f128abd7ed8840e_D20200101-20201231" decimals="-3" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfMzktMy0xLTEtNDEyOTQ_a723d417-6038-4193-b99f-6d99d34c8ca7">231,648</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6c3b69702e9429aaeed46bdb9bbb9c1_D20190101-20191231" decimals="-3" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfMzktNS0xLTEtNDEyOTQ_7c5f4ad6-1e59-4db4-a536-72454d57704c">466,918</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Financing activities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Repayment of debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231" decimals="-3" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfNDEtMS0xLTEtNDEyOTQ_27ef7d33-ef0d-46a1-adc2-de08d5093305">155,760</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib3597315a63d441f8f128abd7ed8840e_D20200101-20201231" decimals="-3" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfNDEtMy0xLTEtNDEyOTQ_b62b9497-c6ea-4d5d-8879-a39d1f5b30b3">222,209</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie6c3b69702e9429aaeed46bdb9bbb9c1_D20190101-20191231" decimals="-3" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfNDEtNS0xLTEtNDEyOTQ_b59145ed-64ab-4aa0-8b3c-2397b8b6ffc6">27,323</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payments under finance lease obligations </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231" decimals="-3" name="us-gaap:FinanceLeasePrincipalPayments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfNDItMS0xLTEtNDEyOTQ_53ba774d-6539-4ba5-828e-14eca681ed20">9,188</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib3597315a63d441f8f128abd7ed8840e_D20200101-20201231" decimals="-3" name="us-gaap:FinanceLeasePrincipalPayments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfNDItMy0xLTEtNDEyOTQ_c3e2ebce-ab58-47d2-80d5-9c24e2a28357">9,549</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6c3b69702e9429aaeed46bdb9bbb9c1_D20190101-20191231" decimals="-3" name="us-gaap:FinanceLeasePrincipalPayments" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfNDItNS0xLTEtNDEyOTQ_1bba6442-c125-4ee7-a575-09daae504f16">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from bond hedge settlement</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231" decimals="-3" name="us-gaap:ProceedsFromHedgeFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfNDctMS0xLTEtNDEyOTQ_36bb19cb-4590-4bf4-8e5f-0d12256292d8">18,938</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3597315a63d441f8f128abd7ed8840e_D20200101-20201231" decimals="-3" name="us-gaap:ProceedsFromHedgeFinancingActivities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfNDctMy0xLTEtNDEyOTQ_889e7ad5-f528-4c0d-a6e5-9d39eb05ef49">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6c3b69702e9429aaeed46bdb9bbb9c1_D20190101-20191231" decimals="-3" name="us-gaap:ProceedsFromHedgeFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfNDctNS0xLTEtNDEyOTQ_d8ada786-f8c0-4f26-a636-a56e759b4c5c">12,401</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payments to convert holders for bond conversion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231" decimals="-3" name="us-gaap:PaymentsForHedgeFinancingActivities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfNDgtMS0xLTEtNDEyOTQ_279feb81-4637-4780-a732-cec408932af1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3597315a63d441f8f128abd7ed8840e_D20200101-20201231" decimals="-3" name="us-gaap:PaymentsForHedgeFinancingActivities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfNDgtMy0xLTEtNDEyOTQ_64570f53-8b45-474b-be55-8d925b04276b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie6c3b69702e9429aaeed46bdb9bbb9c1_D20190101-20191231" decimals="-3" name="us-gaap:PaymentsForHedgeFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfNDgtNS0xLTEtNDEyOTQ_27767f85-b6b3-48c0-8135-551ee480fecb">12,401</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net proceeds from stock option exercises and ESPP</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfNDktMS0xLTEtNDEyOTQ_f21b6cfb-0e46-437c-b625-38cb0356843b">33,763</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3597315a63d441f8f128abd7ed8840e_D20200101-20201231" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfNDktMy0xLTEtNDEyOTQ_1a25ef45-32a1-4ad0-92c6-fc46f81f4743">3,017</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6c3b69702e9429aaeed46bdb9bbb9c1_D20190101-20191231" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfNDktNS0xLTEtNDEyOTQ_f26b7c6b-32bd-4c71-8580-a4ead498f810">2,997</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Taxes paid related to net share settlement of equity awards</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231" decimals="-3" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfNTAtMS0xLTEtNDEyOTQ_e1364d8e-f835-4030-a1a2-4e2581e46af6">6,018</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib3597315a63d441f8f128abd7ed8840e_D20200101-20201231" decimals="-3" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfNTAtMy0xLTEtNDEyOTQ_0cfd8882-b519-4645-9326-bc45f0fe251e">1,481</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie6c3b69702e9429aaeed46bdb9bbb9c1_D20190101-20191231" decimals="-3" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfNTAtNS0xLTEtNDEyOTQ_2bbad079-f9f6-4d97-9a42-4cb79d83f02c">4,418</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share repurchases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231" decimals="-3" name="us-gaap:PaymentsForRepurchaseOfCommonStock" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfNTEtMS0xLTEtNDEyOTQ_e06a4702-530b-419e-94ca-743fb75e1b1c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib3597315a63d441f8f128abd7ed8840e_D20200101-20201231" decimals="-3" name="us-gaap:PaymentsForRepurchaseOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfNTEtMy0xLTEtNDEyOTQ_8bf7f455-7471-4e31-80b5-3eca7bba23a2">77,998</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie6c3b69702e9429aaeed46bdb9bbb9c1_D20190101-20191231" decimals="-3" name="us-gaap:PaymentsForRepurchaseOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfNTEtNS0xLTEtNDEyOTQ_1cdd4e79-3534-474a-a109-c40838ff4731">453,048</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Repurchase of warrants</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231" decimals="-3" name="us-gaap:PaymentsForRepurchaseOfWarrants" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfNTItMS0xLTEtNDEyOTQ_7e88c1b5-bf7c-4727-8ab4-0b78172d464c">18,446</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3597315a63d441f8f128abd7ed8840e_D20200101-20201231" decimals="-3" name="us-gaap:PaymentsForRepurchaseOfWarrants" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfNTItMy0xLTEtNDEyOTQ_38b5fde6-3834-4df4-854b-1999cdde7e22">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie6c3b69702e9429aaeed46bdb9bbb9c1_D20190101-20191231" decimals="-3" name="us-gaap:PaymentsForRepurchaseOfWarrants" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfNTItNS0xLTEtNDEyOTQ_fc194f9f-31f2-4b5c-8d8e-706ce1ba6f47">380</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payments to CVR Holders</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231" decimals="-3" name="lgnd:PaymentsToContingentValueRightHoldersFinancingActivity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfNTMtMS0xLTEtNDEyOTQ_8e565403-19a7-4d48-b782-3e620d005950">1,050</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib3597315a63d441f8f128abd7ed8840e_D20200101-20201231" decimals="-3" name="lgnd:PaymentsToContingentValueRightHoldersFinancingActivity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfNTMtMy0xLTEtNDEyOTQ_e894d6f2-d641-4a4a-b735-731db3ff7f41">2,325</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie6c3b69702e9429aaeed46bdb9bbb9c1_D20190101-20191231" decimals="-3" name="lgnd:PaymentsToContingentValueRightHoldersFinancingActivity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfNTMtNS0xLTEtNDEyOTQ_a9562ac2-114a-4268-a450-dff7cf608039">3,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net cash used in financing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfNTQtMS0xLTEtNDEyOTQ_330cdbef-37d2-4961-bf2d-8ec0395cb594">137,761</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib3597315a63d441f8f128abd7ed8840e_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfNTQtMy0xLTEtNDEyOTQ_1c5dbaea-414e-4c06-99bd-654947271002">310,545</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie6c3b69702e9429aaeed46bdb9bbb9c1_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfNTQtNS0xLTEtNDEyOTQ_044ed183-1c80-4469-bdfa-82c4bd469b36">485,172</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net decrease in cash, cash equivalents, and restricted cash</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfNTUtMS0xLTEtNDEyOTQ_23f44388-6b21-4e42-98a6-a5d679f92291">28,440</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib3597315a63d441f8f128abd7ed8840e_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfNTUtMy0xLTEtNDEyOTQ_32ef6a78-e783-40fd-b2f4-9d2361ee49ab">24,311</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie6c3b69702e9429aaeed46bdb9bbb9c1_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfNTUtNS0xLTEtNDEyOTQ_1e14cc32-80cb-4593-b78d-49aa0941ab3c">47,590</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Effect of exchange rate changes on cash</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231" decimals="-3" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfNTYtMS0xLTEtNDEyOTQ_c999c4a5-e5d8-4418-a1b0-beb08b00b84d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3597315a63d441f8f128abd7ed8840e_D20200101-20201231" decimals="-3" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfNTYtMy0xLTEtNDEyOTQ_e93b82b3-f881-4536-95c6-863985eab1e4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6c3b69702e9429aaeed46bdb9bbb9c1_D20190101-20191231" decimals="-3" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfNTYtNS0xLTEtNDEyOTQ_ff1320bd-7a67-46eb-9bd9-597ac711c08b">83</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash at beginning of year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7462d0db8f4248fcb9fd8f1deae439f3_I20201231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfNTctMS0xLTEtNDEyOTQ_c4ddae35-cab3-452a-8916-49d50884fd78">47,962</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ida3ec05a32644c2db1bb9f71f76c567f_I20191231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfNTctMy0xLTEtNDEyOTQ_4d7da5a8-d029-4a66-bc3a-690fe3a8ad54">72,273</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1aac4d81ad94163b33117197afe0895_I20181231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfNTctNS0xLTEtNDEyOTQ_f8acda0a-1a8f-4131-9a1e-a5612ba97f01">119,780</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash at end of year</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfNTgtMS0xLTEtNDEyOTQ_76656a83-eb6b-4486-9428-c85996b1dac1">19,522</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7462d0db8f4248fcb9fd8f1deae439f3_I20201231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfNTgtMy0xLTEtNDEyOTQ_35224601-25ae-4cb6-87c6-4281153d66c2">47,962</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ida3ec05a32644c2db1bb9f71f76c567f_I20191231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfNTgtNS0xLTEtNDEyOTQ_09abb43d-05e7-42c5-9a31-4f6589247978">72,273</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">58</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:59.488%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.547%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.547%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.548%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Supplemental disclosure of cash flow information</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash paid during the year:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest paid</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231" decimals="-3" name="us-gaap:InterestPaidNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfNjEtMS0xLTEtNDEyOTQ_52e217a6-3b1e-4885-b3b1-99c9100000f9">3,028</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3597315a63d441f8f128abd7ed8840e_D20200101-20201231" decimals="-3" name="us-gaap:InterestPaidNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfNjEtMy0xLTEtNDEyOTQ_5cc48da1-2702-4cc1-af34-5fa8135f3cbb">4,463</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6c3b69702e9429aaeed46bdb9bbb9c1_D20190101-20191231" decimals="-3" name="us-gaap:InterestPaidNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfNjEtNS0xLTEtNDEyOTQ_ca51ed85-085d-4a61-8025-5d80a75aa240">5,827</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Taxes paid</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231" decimals="-3" name="us-gaap:IncomeTaxesPaid" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfNjItMS0xLTEtNDEyOTQ_7e8030ca-b0ec-4272-9603-5fd3dec77851">3,722</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3597315a63d441f8f128abd7ed8840e_D20200101-20201231" decimals="-3" name="us-gaap:IncomeTaxesPaid" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfNjItMy0xLTEtNDEyOTQ_4ea374a8-c97b-4e29-b3af-49ec623166b5">2,130</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6c3b69702e9429aaeed46bdb9bbb9c1_D20190101-20191231" decimals="-3" name="us-gaap:IncomeTaxesPaid" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfNjItNS0xLTEtNDEyOTQ_ed121337-0b8d-4f57-a772-5c5736559fda">103,817</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restricted cash in other current assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231" decimals="-3" name="us-gaap:RestrictedCashCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfNjMtMS0xLTEtNDEyOTQ_98d88674-b33f-4023-85c2-4f9fa3b017c9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7462d0db8f4248fcb9fd8f1deae439f3_I20201231" decimals="-3" name="us-gaap:RestrictedCashCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfNjMtMy0xLTEtNDEyOTQ_5c318041-5548-4ce6-b407-68d665a20ef6">343</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ida3ec05a32644c2db1bb9f71f76c567f_I20191231" decimals="-3" name="us-gaap:RestrictedCashCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfNjMtNS0xLTEtNDEyOTQ_8e1949e7-9d1b-47e8-8224-0ed92c4be265">730</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Supplemental schedule of non-cash investing and financing activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued inventory purchases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231" decimals="-3" name="lgnd:AccruedInventoryPurchases" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfNjUtMS0xLTEtNDEyOTQ_6fbffa6d-a39a-4495-97fd-b03e7c58718d">1,974</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3597315a63d441f8f128abd7ed8840e_D20200101-20201231" decimals="-3" name="lgnd:AccruedInventoryPurchases" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfNjUtMy0xLTEtNDEyOTQ_ade6b3d5-5897-46c9-a367-ee1ce81b6193">1,562</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6c3b69702e9429aaeed46bdb9bbb9c1_D20190101-20191231" decimals="-3" name="lgnd:AccruedInventoryPurchases" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfNjUtNS0xLTEtNDEyOTQ_20f6431e-4f3c-4252-bf74-10a19d9f3eea">170</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized (loss) gain on available-for-sale investments</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:UnrealizedGainLossOnInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfNjYtMS0xLTEtNDEyOTQ_ca67ad37-e770-421a-b21b-60fed24c157c">221</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib3597315a63d441f8f128abd7ed8840e_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:UnrealizedGainLossOnInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfNjYtMy0xLTEtNDEyOTQ_7bc27552-b922-468f-99c1-dffc80772f1b">212</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6c3b69702e9429aaeed46bdb9bbb9c1_D20190101-20191231" decimals="-3" name="us-gaap:UnrealizedGainLossOnInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfNjYtNS0xLTEtNDEyOTQ_9f78ee55-d1aa-40ed-a2af-77c3b22a5ca3">256</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchase of fixed assets recorded in accounts payable </span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfNjctMS0xLTEtNDEyOTQ_2cb1cf84-2eae-45ba-a636-921865b1e844">1,567</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3597315a63d441f8f128abd7ed8840e_D20200101-20201231" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfNjctMy0xLTEtNDEyOTQ_c2feaac4-66a2-423a-98d0-37d1fc01b236">249</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6c3b69702e9429aaeed46bdb9bbb9c1_D20190101-20191231" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfNjctNS0xLTEtNDEyOTQ_94c972b3-8587-489c-ba59-624176ca8d27">495</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying notes to these consolidated financial statements.</span></div><div id="i0fa6f906fb2e4e30bc5e873d2bb6a82c_79"></div><div style="text-align:center"><span><br/></span></div><div id="i0fa6f906fb2e4e30bc5e873d2bb6a82c_82"></div><div style="margin-top:14pt;text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Unless the context requires otherwise, references in this report to &#8220;Ligand,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; the &#8220;Company,&#8221; and &#8220;our&#8221; refer to Ligand Pharmaceuticals Incorporated and its consolidated subsidiaries.</span></div><div><span><br/></span></div><div style="margin-top:14pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1. <ix:nonNumeric contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RleHRyZWdpb246MDE1MzU3NWExNzUxNDlhMGJlMjM2NzA3MzMyMzJiNjlfNTM2OTc_d6c94466-beba-4cd7-b3e6-a27ece948cd0" continuedAt="ide28d4fc9a9a4ac68c7295c6840096fa" escape="true">Basis of Presentation and Summary of Significant Accounting Policies</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="ide28d4fc9a9a4ac68c7295c6840096fa" continuedAt="i88c0b22e3a7a41a683d5e163ef6fcf2b"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Business</span></div><div style="text-indent:24pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a biopharmaceutical company focused on developing or acquiring technologies that help pharmaceutical companies discover and develop medicines. We operate in <ix:nonFraction unitRef="segment" contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231" decimals="INF" name="us-gaap:NumberOfOperatingSegments" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RleHRyZWdpb246MDE1MzU3NWExNzUxNDlhMGJlMjM2NzA3MzMyMzJiNjlfMjE5OTAyMzMyOTU4OA_bcff7911-ad9f-43f6-82eb-b1b3f6449dea">one</ix:nonFraction> business segment: development and licensing of biopharmaceutical assets.</span></div><div><span><br/></span></div><ix:nonNumeric contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231" name="us-gaap:ConsolidationPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RleHRyZWdpb246MDE1MzU3NWExNzUxNDlhMGJlMjM2NzA3MzMyMzJiNjlfNTM2NzM_06489cdd-abff-454e-935f-d17e54a4b27c" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Principles of Consolidation</span></div><div style="text-indent:24pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying consolidated financial statements include Ligand and its wholly-owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation.</span></div></ix:nonNumeric><div><span><br/></span></div><ix:nonNumeric contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RleHRyZWdpb246MDE1MzU3NWExNzUxNDlhMGJlMjM2NzA3MzMyMzJiNjlfNTM3MDI_ef10855a-1f69-4f41-94fb-c01698100673" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our consolidated financial statements have been prepared in accordance with U.S. GAAP and include the accounts of our parent company and its wholly-owned subsidiaries. All intercompany transactions and balances have been eliminated in consolidation.</span></div></ix:nonNumeric><div><span><br/></span></div><ix:nonNumeric contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RleHRyZWdpb246MDE1MzU3NWExNzUxNDlhMGJlMjM2NzA3MzMyMzJiNjlfNTM3MDM_d1b74458-9de9-4b83-8f59-f65794ea21af" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="text-indent:24pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of consolidated financial statements in conformity with U.S. GAAP requires the use of estimates and assumptions that affect the amounts reported in the consolidated financial statements and the accompanying notes. Actual results may differ from those estimates.</span></div></ix:nonNumeric><div style="text-indent:24pt"><span><br/></span></div><ix:nonNumeric contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231" name="us-gaap:ConcentrationRiskCreditRisk" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RleHRyZWdpb246MDE1MzU3NWExNzUxNDlhMGJlMjM2NzA3MzMyMzJiNjlfNTM2OTA_1a307767-2b26-4ae2-9682-2be786643961" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentrations of Business Risk</span></div><div style="text-indent:24pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject us to significant concentrations of credit risk consist primarily of cash equivalents and investments. We invest excess cash principally in United States government debt securities, investment grade corporate debt securities, mutual funds and certificates of deposit. We maintain some cash and cash equivalents balances with financial institutions that are in excess of the Federal Deposit Insurance Corporation insurance limits. We have established guidelines relative to diversification and maturities that maintain safety and liquidity. These guidelines are periodically reviewed and modified to take advantage of trends in yields and interest rates.</span></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">59</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i88c0b22e3a7a41a683d5e163ef6fcf2b" continuedAt="ie88daeffc9fe4e1e85b9ba7cff0e8d56"><div><ix:nonNumeric contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231" name="us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RleHRyZWdpb246MDE1MzU3NWExNzUxNDlhMGJlMjM2NzA3MzMyMzJiNjlfNTM2OTE_46c3a373-10b6-415b-aa28-946d8eb03728" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue from significant partners, which is defined as 10% or more of our total revenue, was as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:53.578%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.524%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year-ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Partner A</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8b1b6cbf7db84387abc05c19c397f3e1_D20210101-20211231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RhYmxlOmVjNDE2ZDEwOWQ0MDQzZWQ5ZmJjM2FlNTYxNmJlOTk2L3RhYmxlcmFuZ2U6ZWM0MTZkMTA5ZDQwNDNlZDlmYmMzYWU1NjE2YmU5OTZfMi0xLTEtMS00MTI5NA_43c48750-9f72-48a7-93d4-e864347342b9">41</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i779fbae243e046e6a31b9eaa2c179124_D20200101-20201231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RhYmxlOmVjNDE2ZDEwOWQ0MDQzZWQ5ZmJjM2FlNTYxNmJlOTk2L3RhYmxlcmFuZ2U6ZWM0MTZkMTA5ZDQwNDNlZDlmYmMzYWU1NjE2YmU5OTZfMi0zLTEtMS00MTI5NA_b533c274-0dd3-45c7-93b4-2e0ade574ed6">45</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Partner B</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i32323a9d8b2a49eca1eebf5fa5da97be_D20210101-20211231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RhYmxlOmVjNDE2ZDEwOWQ0MDQzZWQ5ZmJjM2FlNTYxNmJlOTk2L3RhYmxlcmFuZ2U6ZWM0MTZkMTA5ZDQwNDNlZDlmYmMzYWU1NjE2YmU5OTZfMy0xLTEtMS00MTI5NA_3e773a2e-af71-4274-8f49-23bfcb76f340">14</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib29fdd94f38f445bbfcbf8d17a9b0d2c_D20200101-20201231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RhYmxlOmVjNDE2ZDEwOWQ0MDQzZWQ5ZmJjM2FlNTYxNmJlOTk2L3RhYmxlcmFuZ2U6ZWM0MTZkMTA5ZDQwNDNlZDlmYmMzYWU1NjE2YmU5OTZfMy0zLTEtMS00MTI5NA_f7c2ef70-711a-4dda-b31f-a038b14f4d62">17</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i19caa64fec87477596a2cd5d23955ee8_D20190101-20191231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RhYmxlOmVjNDE2ZDEwOWQ0MDQzZWQ5ZmJjM2FlNTYxNmJlOTk2L3RhYmxlcmFuZ2U6ZWM0MTZkMTA5ZDQwNDNlZDlmYmMzYWU1NjE2YmU5OTZfMy01LTEtMS00MTI5NA_ad5c838a-67aa-48ed-9d1c-0696b0f6fce7">27</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Partner C</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&lt;10%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&lt;10%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6a70ae97ec4641b88ce641ff76d8edd7_D20190101-20191231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RhYmxlOmVjNDE2ZDEwOWQ0MDQzZWQ5ZmJjM2FlNTYxNmJlOTk2L3RhYmxlcmFuZ2U6ZWM0MTZkMTA5ZDQwNDNlZDlmYmMzYWU1NjE2YmU5OTZfNC01LTEtMS01NzExMw_2709ec50-4d4b-4e72-887d-04beb6f00ad8">13</ix:nonFraction>%</span></td></tr></table></ix:nonNumeric></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We obtain Captisol primarily from two sites related to a single supplier, Hovione.&#160;If this supplier were not able to supply the requested amounts of Captisol from each site, and if our safety stocks of material were depleted, we would be unable to continue to derive revenues from the sale of Captisol until we obtained material from an alternative source, which could take a considerable length of time.</span></div><div><span><br/></span></div><ix:nonNumeric contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231" name="lgnd:CashCashEquivalentsandShorttermInvestmentsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RleHRyZWdpb246MDE1MzU3NWExNzUxNDlhMGJlMjM2NzA3MzMyMzJiNjlfNTM2ODM_766266e1-3e5e-48e0-b7a6-c6f258fb4fd3" continuedAt="i044b7a44549748268ea1981b21c4279c" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Equivalents </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Cash equivalents consist of highly liquid investments with maturities of <ix:nonNumeric contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231" name="lgnd:MaturityPeriodOfHighlyLiquidSecuritiesMaximum" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RleHRyZWdpb246MDE1MzU3NWExNzUxNDlhMGJlMjM2NzA3MzMyMzJiNjlfMzU4OA_e6af90ce-05e7-49ba-b584-1a1b8cea5b71">three months</ix:nonNumeric> or less from the date of acquisition. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Short-term Investments</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Short-term investments primarily consist of investments in debt and equity securities. We classify our short-term investments as &#8220;available-for-sale&#8221;. Such investments are carried at fair value, with unrealized gains and losses on debt securities included in the statement of comprehensive income (loss), net of tax, and unrealized gains and losses on equity securities included the consolidated statement of operations. We determine the cost of investments based on the specific identification method. We determine the realized gains or losses on the sale of available-for-sale securities using the specific identification method and includes net realized gains and losses as a component of other income or expense within the consolidated statements of operations.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Debt securities consist of certificates of deposit, corporate debt securities, and securities of government-sponsored entities have effective maturities greater than&#160;three&#160;months and less than twelve months from the date of acquisition. Debt securities securities available-for-sale in an unrealized loss position are assessed for the current expected credit losses methodology. We start by assessing whether we intend to sell the security, or whether it is more likely than not that we will be required to sell the security before recovery of its amortized cost basis. If either of the criteria regarding intent or requirement to sell is met, the security&#8217;s amortized cost basis is written down to fair value through earnings. For debt securities available-for-sale that do not meet the aforementioned criteria, we evaluate whether the decline in fair value has resulted from credit losses or other factors. In making this assessment, we consider the extent to which fair value is less than amortized cost, any changes in interest rates, and any changes to the rating of the security by a rating agency, among other factors. If this assessment indicates that a credit loss exists, the present value of cash flows expected to be collected from the security is compared to the amortized cost basis of the security. If the present value of cash flows expected to be collected is less than the amortized cost basis, a credit loss exists and an allowance for credit losses is recorded, limited by the amount that the fair value is less than the amortized cost basis. Any impairment that has not been recorded through an allowance for credit losses is recognized in other comprehensive income or loss, as applicable.</span></div></ix:nonNumeric><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i044b7a44549748268ea1981b21c4279c">Equity securities are mutual funds, investments in privately held companies (non-marketable equity securities), and companies that have completed initial public offerings (marketable equity securities). Mutual funds are valued at their publicly quoted net asset value (NAV) price on the last day of the period. Our non-marketable equity securities without readily determinable market values are initially measured at cost and adjusted to fair value for observable transactions for identical or similar investments of the same issuer or impairment. Our marketable equity securities are measured at fair value. Equity investments are classified as short-term investments, or non-current other assets, based on the nature of the securities and their availability for use in current operations.</ix:continuation> </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"><ix:nonNumeric contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231" name="us-gaap:ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RleHRyZWdpb246MDE1MzU3NWExNzUxNDlhMGJlMjM2NzA3MzMyMzJiNjlfNTM3MDc_f412bad7-1f36-4591-907c-184dafa87332" continuedAt="i6eaa43f3ba7e4d2098d88d4310436a0a" escape="true">Accounts Receivable </ix:nonNumeric></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i6eaa43f3ba7e4d2098d88d4310436a0a">Our accounts receivable arise primarily from sales on credit to customers. We establish an allowance for credit losses to present the net amount of accounts receivable expected to be collected. The allowance is determined by using the loss-rate method, which requires an estimation of loss rates based upon historical loss experience adjusted for factors that are relevant to determining the expected collectability of accounts receivable. Some of these factors include macroeconomic conditions that correlate with historical loss experience, delinquency trends, aging behavior of receivables and credit and liquidity quality indicators for industry groups, customer classes or individual customers.</ix:continuation> </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">60</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ie88daeffc9fe4e1e85b9ba7cff0e8d56" continuedAt="i9056d7f606a044d6a4300b713d1261d4"><div style="margin-top:14pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231" name="us-gaap:InventoryPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RleHRyZWdpb246MDE1MzU3NWExNzUxNDlhMGJlMjM2NzA3MzMyMzJiNjlfNTM2OTg_a9d0aa77-cc42-4917-98ce-4d1397367a8b" continuedAt="i3fe377331a084063992f648f53184f70" escape="true">Inventory</ix:nonNumeric></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"><ix:continuation id="i3fe377331a084063992f648f53184f70">Inventory, which consists of finished goods, is stated at the lower of cost or net realizable value. We determine cost using the first-in, first-out method or the specific identification method. We analyze our inventory levels periodically and write down inventory to net realizable value if it has become obsolete, has a cost basis in excess of its expected net realizable value or is in excess of expected requirements.</ix:continuation> There were <ix:nonFraction unitRef="usd" contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231" decimals="INF" name="us-gaap:InventoryWriteDown" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RleHRyZWdpb246MDE1MzU3NWExNzUxNDlhMGJlMjM2NzA3MzMyMzJiNjlfNjQ0NQ_3bc47895-feb5-4903-a4b2-ece830500940"><ix:nonFraction unitRef="usd" contextRef="ie6c3b69702e9429aaeed46bdb9bbb9c1_D20190101-20191231" decimals="INF" name="us-gaap:InventoryWriteDown" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RleHRyZWdpb246MDE1MzU3NWExNzUxNDlhMGJlMjM2NzA3MzMyMzJiNjlfNjQ0NQ_4a8a0e16-cfb3-4634-ab45-cca57fb220e1"><ix:nonFraction unitRef="usd" contextRef="ib3597315a63d441f8f128abd7ed8840e_D20200101-20201231" decimals="INF" name="us-gaap:InventoryWriteDown" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RleHRyZWdpb246MDE1MzU3NWExNzUxNDlhMGJlMjM2NzA3MzMyMzJiNjlfNjQ0NQ_b493f9b2-04c4-46ef-ab24-eb72ebf2ffd5">no</ix:nonFraction></ix:nonFraction></ix:nonFraction> write downs related to obsolete inventory recorded for the years ended December&#160;31, 2021, 2020 and 2019.  As of December 31, 2021 and 2020, inventory consist of Captisol prepayments of $<ix:nonFraction unitRef="usd" contextRef="i874c2ad63f1a4f0295a0ad715157a00e_I20211231" decimals="-5" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RleHRyZWdpb246MDE1MzU3NWExNzUxNDlhMGJlMjM2NzA3MzMyMzJiNjlfNzY5NjU4MTUwNTk4MQ_e852efd8-126d-4ccd-b3cc-8e2200da35b9">24.6</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i6a5b82872f4b4205b4cb36e3a7e65b00_I20201231" decimals="-5" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RleHRyZWdpb246MDE1MzU3NWExNzUxNDlhMGJlMjM2NzA3MzMyMzJiNjlfNzY5NjU4MTUwNTk5Ng_18b6013b-abe1-4b5b-ac02-755af44ec9f2">26.1</ix:nonFraction>&#160;million, respectively. </span></div><ix:nonNumeric contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RleHRyZWdpb246MDE1MzU3NWExNzUxNDlhMGJlMjM2NzA3MzMyMzJiNjlfNTM3MDg_f5f612be-7dae-4dfb-b1b2-09126d6ec5f2" escape="true"><div style="margin-top:14pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment are stated at cost, subject to review for impairment, and depreciated over the estimated useful lives of the assets, which generally range from <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RleHRyZWdpb246MDE1MzU3NWExNzUxNDlhMGJlMjM2NzA3MzMyMzJiNjlfNjcyNw_c91288e2-cf87-4740-a1f7-845dfc930514">three</span> to <ix:nonNumeric contextRef="i55156c07b9684b9185860bad3331609a_D20210101-20211231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RleHRyZWdpb246MDE1MzU3NWExNzUxNDlhMGJlMjM2NzA3MzMyMzJiNjlfMzg0ODI5MDc1MDkzNg_a3b2d52b-5dc1-46c7-ab7f-54eb66493826">ten years</ix:nonNumeric>, using the straight-line method. Amortization of leasehold improvements is recorded over the shorter of the lease term or estimated useful life of the related asset. Maintenance and repairs are charged to operations as incurred. When assets are sold, or otherwise disposed of, the cost and related accumulated depreciation are removed from the accounts and any gain or loss is included in operating income or expense.</span></div></ix:nonNumeric><div><span><br/></span></div><ix:nonNumeric contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231" name="us-gaap:BusinessCombinationsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RleHRyZWdpb246MDE1MzU3NWExNzUxNDlhMGJlMjM2NzA3MzMyMzJiNjlfNTM2OTk_13a4bf73-4b31-40e6-becb-8bc4bc8d47a5" continuedAt="i4b4713ef0f0e4c6c9a3de8a6f1af7cae" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Acquisitions</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We first determine whether a set of assets acquired constitute a business and should be accounted for as a business combination. If the assets acquired are not a business, we account for the transaction as an asset acquisition. Business combinations are accounted for by using the acquisition method of accounting which requires us to use significant estimates and assumptions, especially with respect to intangible assets. We record the excess consideration over the aggregate fair value of tangible and intangible assets, net of liabilities assumed, as goodwill.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the acquisition method of accounting, we recognize separately from goodwill the identifiable assets acquired, the liabilities assumed, including contingent consideration and all contractual contingencies, generally at the acquisition date fair value. Contingent purchase consideration to be settled in cash are remeasured to estimated fair value at each reporting period with the change in fair value recorded in statement of operations. Costs that we incur to complete the business combination such as investment banking, legal and other professional fees are not considered part of consideration and we charge them to general and administrative expense as they are incurred. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Should the initial accounting for a business combination be incomplete by the end of a reporting period that falls within the measurement period, we report provisional amounts in our financial statements. During the measurement period, we adjust the provisional amounts recognized at the acquisition date to reflect new information obtained about facts and circumstances that existed as of the acquisition date that, if known, would have affected the measurement of the amounts recognized as of that date and we record those adjustments to our financial statements in the period of change, if any.</span></div></ix:nonNumeric><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i4b4713ef0f0e4c6c9a3de8a6f1af7cae">Under the acquisition method of accounting for business combinations, if we identify changes to acquired deferred tax asset valuation allowances or liabilities related to uncertain tax positions during the measurement period and they relate to new information obtained about facts and circumstances that existed as of the acquisition date, those changes are considered a measurement period adjustment and we record the offset to goodwill. We record all other changes to deferred tax asset valuation allowances and liabilities related to uncertain tax positions in current period income tax expense.</ix:continuation> </span></div><div style="margin-top:14pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingent Liabilities</span></div><div style="text-indent:24pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the acquisition of Pfenex in October 2020, we entered into a CVR agreement pursuant to which former equity holders of Pfenex received one nontransferable contractual right entitling such holder to receive $<ix:nonFraction unitRef="usdPerShare" contextRef="ia9a9eb80fb244862b401f0cf7734c9d9_I20201001" decimals="INF" name="lgnd:BusinessCombinationContingentConsiderationLiabilityAmountPerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RleHRyZWdpb246MDE1MzU3NWExNzUxNDlhMGJlMjM2NzA3MzMyMzJiNjlfMzg0ODI5MDc3MTIwNA_99d6a5cd-1b17-4e64-ac0e-6efde13a5f70">2.00</ix:nonFraction> per share (or approximately $<ix:nonFraction unitRef="usd" contextRef="ia9a9eb80fb244862b401f0cf7734c9d9_I20201001" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RleHRyZWdpb246MDE1MzU3NWExNzUxNDlhMGJlMjM2NzA3MzMyMzJiNjlfMzg0ODI5MDc3MTIxMQ_a5ea1096-3c67-481d-a795-b8fc1c067745">77.8</ix:nonFraction>&#160;million total) in the event that Pfenex&#8217;s teriparatide injection product received notice from the FDA that such product is therapeutically equivalent with respect to FORTEO&#174; (teriparatide injection) on or before December 31, 2021. The FDA did not provide notice of such event prior to the CVR expiration date and as a result, the Pfenex CVRs expired without payment.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the acquisition of Icagen in April 2020, Icagen selling shareholders will be entitled to receive up to an additional $<ix:nonFraction unitRef="usd" contextRef="i66fd5bb596fe4dc0a209f580f37be1bd_I20200401" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RleHRyZWdpb246MDE1MzU3NWExNzUxNDlhMGJlMjM2NzA3MzMyMzJiNjlfMTA4NjM_5a2066c9-512f-421c-a40a-ffacb7e114b1">25</ix:nonFraction>&#160;million of cash payments based on certain revenue achievements.</span></div><div style="text-indent:24pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the acquisition of CyDex in January 2011, we recorded a contingent liability for amounts potentially due to holders of the CyDex CVRs and former license holders. The liability is periodically assessed based on events and circumstances related to the underlying milestones, royalties and material sales. </span></div></ix:continuation><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">61</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i9056d7f606a044d6a4300b713d1261d4" continuedAt="if1f448726e0443ca9c11f5e61d1f2b04"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the acquisition of Metabasis in January 2010, we issued Metabasis stockholders <ix:nonFraction unitRef="right" contextRef="i2c4e300f1b0640468a246731197ac061_I20100131" decimals="INF" name="lgnd:NumberOfContingentValueRightsIssued" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RleHRyZWdpb246MDE1MzU3NWExNzUxNDlhMGJlMjM2NzA3MzMyMzJiNjlfMTE1NjA_488bad91-a2af-4d8d-b69c-719c281c38b7">four</ix:nonFraction> tradable CVRs for each Metabasis share. The fair values of the CVRs are remeasured at each reporting date through the term of the related agreement. </span></div><div style="text-indent:24pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any change in fair value is recorded in our consolidated statement of operations. For additional information, see &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note (5), Fair Value Measurement and Note (8), Balance Sheet Account Details</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.&#8221;   </span></div><div><span><br/></span></div><ix:nonNumeric contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231" name="us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RleHRyZWdpb246MDE1MzU3NWExNzUxNDlhMGJlMjM2NzA3MzMyMzJiNjlfNTM2Nzc_da10ef7a-61a3-4a26-bb47-d8f6f03e3c39" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill, Intangible Assets and Other Long-Lived Assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill, which has an indefinite useful life, represents the excess of cost over fair value of net assets acquired. Goodwill is reviewed for impairment at least annually during the fourth quarter, or more frequently if an event occurs indicating the potential for impairment. During the goodwill impairment review, we assess qualitative factors to determine whether it is more likely than not that the fair value of our reporting unit is less than the carrying amount, including goodwill. We operate in one reporting unit. The qualitative factors include, but are not limited to, macroeconomic conditions, industry and market considerations, and the overall financial performance. If, after assessing the totality of these qualitative factors, we determine that it is not more likely than not that the fair value of our reporting unit is less than the carrying amount, then no additional assessment is deemed necessary. Otherwise, we proceed to perform the quantitative assessment. We will then evaluate goodwill for impairment by comparing the estimated fair value of the reporting unit to its carrying value, including the associated goodwill. To determine the fair value, we generally use a combination of market approach based on Ligand and comparable publicly traded companies in similar lines of businesses and the income approach based on estimated discounted future cash flows. Our cash flow assumptions consider historical and forecasted revenue, operating costs and other relevant factors. We may also elect to bypass the qualitative assessment in a period and elect to proceed to perform the quantitative assessment for the goodwill impairment test. We performed the annual assessment for goodwill impairment during the fourth quarter of 2021, noting no impairment. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our identifiable intangible assets are typically composed of acquired core technologies, licensed technologies, contractual relationships, customer relationships and trade names. The cost of identifiable intangible assets with finite lives is generally amortized on a straight-line basis over the assets&#8217; respective estimated useful lives. We regularly perform reviews to determine if any event has occurred that may indicate that intangible assets with finite useful lives and other long-lived assets are potentially impaired. If indicators of impairment exist, an impairment test is performed to assess the recoverability of the affected assets by determining whether the carrying amount of such assets exceeds the undiscounted expected future cash flows. If the affected assets are not recoverable, we estimate the fair value of the assets and record an impairment loss if the carrying value of the assets exceeds the fair value. Factors that may indicate potential impairment include market conditions, industry and economic trends, changes in regulations, clinical success, historical and forecasted financial results, market capitalization, significant changes in the ability of a particular asset to generate positive cash flows, and the pattern of utilization of a particular asset. We did not identify indicators of impairment for the finite-lived intangibles at December&#160;31, 2021.</span></div></ix:nonNumeric><div><span><br/></span></div><ix:nonNumeric contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231" name="lgnd:CommercialLicenseRightsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RleHRyZWdpb246MDE1MzU3NWExNzUxNDlhMGJlMjM2NzA3MzMyMzJiNjlfNTM3MDk_e1eddc71-771e-4bf7-a429-2b85588003ae" continuedAt="i2a25adeee3a6450787a135502a76c0d8" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Commercial license and other economic rights</span></div><div><span><br/></span></div><ix:nonNumeric contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231" name="lgnd:ScheduleofCommercialLicenseRightsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RleHRyZWdpb246MDE1MzU3NWExNzUxNDlhMGJlMjM2NzA3MzMyMzJiNjlfNTM2NzU_fc9dac32-3e26-46a1-b9d0-2103bc5b640d" continuedAt="id615273eab0f404ca2fb18e7ce6d4947" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021 and 2020, commercial license and other economic rights consist of the following (in thousands):</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.338%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.607%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Adjustments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Adjustments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Aziyo and CorMatrix</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i24643322fd3648c280f9180082f606c7_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RhYmxlOjZjMjM5MjZkZjU4ZTQwZTVhMTY3OGJhZDc0YzA3ZTM4L3RhYmxlcmFuZ2U6NmMyMzkyNmRmNThlNDBlNWExNjc4YmFkNzRjMDdlMzhfMi0yLTEtMS00MTI5NA_ff522116-2eac-4294-8ce2-bc62fb336408">17,696</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i24643322fd3648c280f9180082f606c7_I20211231" decimals="-3" name="lgnd:FiniteLivedIntangibleAssetsAccumulatedAmortizationResearchDevelopmentExpenseAndCreditLossAdjustments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RhYmxlOjZjMjM5MjZkZjU4ZTQwZTVhMTY3OGJhZDc0YzA3ZTM4L3RhYmxlcmFuZ2U6NmMyMzkyNmRmNThlNDBlNWExNjc4YmFkNzRjMDdlMzhfMi00LTEtMS00MTI5NA_31ed32fc-e3c7-4fd4-960e-07899a0d5f4a">9,461</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i24643322fd3648c280f9180082f606c7_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RhYmxlOjZjMjM5MjZkZjU4ZTQwZTVhMTY3OGJhZDc0YzA3ZTM4L3RhYmxlcmFuZ2U6NmMyMzkyNmRmNThlNDBlNWExNjc4YmFkNzRjMDdlMzhfMi02LTEtMS00MTI5NA_1efc52c2-5a95-490e-a376-671fe2148e45">8,235</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieddf490290904ecbb766659c22b6325c_I20201231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RhYmxlOjZjMjM5MjZkZjU4ZTQwZTVhMTY3OGJhZDc0YzA3ZTM4L3RhYmxlcmFuZ2U6NmMyMzkyNmRmNThlNDBlNWExNjc4YmFkNzRjMDdlMzhfMi04LTEtMS00MTI5NA_3f893847-7db0-41c1-adac-386833525369">17,696</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieddf490290904ecbb766659c22b6325c_I20201231" decimals="-3" name="lgnd:FiniteLivedIntangibleAssetsAccumulatedAmortizationResearchDevelopmentExpenseAndCreditLossAdjustments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RhYmxlOjZjMjM5MjZkZjU4ZTQwZTVhMTY3OGJhZDc0YzA3ZTM4L3RhYmxlcmFuZ2U6NmMyMzkyNmRmNThlNDBlNWExNjc4YmFkNzRjMDdlMzhfMi0xMC0xLTEtNDEyOTQ_d54b1893-3783-49b2-9480-a8a476594222">9,588</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieddf490290904ecbb766659c22b6325c_I20201231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RhYmxlOjZjMjM5MjZkZjU4ZTQwZTVhMTY3OGJhZDc0YzA3ZTM4L3RhYmxlcmFuZ2U6NmMyMzkyNmRmNThlNDBlNWExNjc4YmFkNzRjMDdlMzhfMi0xMi0xLTEtNDEyOTQ_4a8b4e9c-7338-4685-8447-4354127e5388">8,108</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Selexis and Dianomi</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6ab5af36644400fb3b934151581597a_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RhYmxlOjZjMjM5MjZkZjU4ZTQwZTVhMTY3OGJhZDc0YzA3ZTM4L3RhYmxlcmFuZ2U6NmMyMzkyNmRmNThlNDBlNWExNjc4YmFkNzRjMDdlMzhfNC0yLTEtMS00MTI5NA_b5b37599-d048-4d01-91e2-4b72afea3536">10,602</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib6ab5af36644400fb3b934151581597a_I20211231" decimals="-3" name="lgnd:FiniteLivedIntangibleAssetsAccumulatedAmortizationResearchDevelopmentExpenseAndCreditLossAdjustments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RhYmxlOjZjMjM5MjZkZjU4ZTQwZTVhMTY3OGJhZDc0YzA3ZTM4L3RhYmxlcmFuZ2U6NmMyMzkyNmRmNThlNDBlNWExNjc4YmFkNzRjMDdlMzhfNC00LTEtMS00MTI5NA_6c84c62d-d3ea-4988-8684-a6a3082b943c">8,727</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6ab5af36644400fb3b934151581597a_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RhYmxlOjZjMjM5MjZkZjU4ZTQwZTVhMTY3OGJhZDc0YzA3ZTM4L3RhYmxlcmFuZ2U6NmMyMzkyNmRmNThlNDBlNWExNjc4YmFkNzRjMDdlMzhfNC02LTEtMS00MTI5NA_d419bd45-32f0-4f11-b9da-af8c817a833d">1,875</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8dab692d024a4e0f97bf65fe83fb703b_I20201231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RhYmxlOjZjMjM5MjZkZjU4ZTQwZTVhMTY3OGJhZDc0YzA3ZTM4L3RhYmxlcmFuZ2U6NmMyMzkyNmRmNThlNDBlNWExNjc4YmFkNzRjMDdlMzhfNC04LTEtMS00MTI5NA_f0e1c28a-11ff-4a92-a116-8c134b6fec3a">10,602</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8dab692d024a4e0f97bf65fe83fb703b_I20201231" decimals="-3" name="lgnd:FiniteLivedIntangibleAssetsAccumulatedAmortizationResearchDevelopmentExpenseAndCreditLossAdjustments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RhYmxlOjZjMjM5MjZkZjU4ZTQwZTVhMTY3OGJhZDc0YzA3ZTM4L3RhYmxlcmFuZ2U6NmMyMzkyNmRmNThlNDBlNWExNjc4YmFkNzRjMDdlMzhfNC0xMC0xLTEtNDEyOTQ_2247cf6b-69a2-4b8b-847e-6b73b207a2c4">7,731</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8dab692d024a4e0f97bf65fe83fb703b_I20201231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RhYmxlOjZjMjM5MjZkZjU4ZTQwZTVhMTY3OGJhZDc0YzA3ZTM4L3RhYmxlcmFuZ2U6NmMyMzkyNmRmNThlNDBlNWExNjc4YmFkNzRjMDdlMzhfNC0xMi0xLTEtNDEyOTQ_f0609774-730e-4f97-bc41-21fbff7e0e71">2,871</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8308d0606a54c10ac4769b1a226d54c_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RhYmxlOjZjMjM5MjZkZjU4ZTQwZTVhMTY3OGJhZDc0YzA3ZTM4L3RhYmxlcmFuZ2U6NmMyMzkyNmRmNThlNDBlNWExNjc4YmFkNzRjMDdlMzhfNS0yLTEtMS00MTI5NA_1487b668-6eff-4db9-893d-f48d22f0c15a">28,298</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia8308d0606a54c10ac4769b1a226d54c_I20211231" decimals="-3" name="lgnd:FiniteLivedIntangibleAssetsAccumulatedAmortizationResearchDevelopmentExpenseAndCreditLossAdjustments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RhYmxlOjZjMjM5MjZkZjU4ZTQwZTVhMTY3OGJhZDc0YzA3ZTM4L3RhYmxlcmFuZ2U6NmMyMzkyNmRmNThlNDBlNWExNjc4YmFkNzRjMDdlMzhfNS00LTEtMS00MTI5NA_0582eb2b-daed-4b3a-ace5-f2fd0498332f">18,188</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8308d0606a54c10ac4769b1a226d54c_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RhYmxlOjZjMjM5MjZkZjU4ZTQwZTVhMTY3OGJhZDc0YzA3ZTM4L3RhYmxlcmFuZ2U6NmMyMzkyNmRmNThlNDBlNWExNjc4YmFkNzRjMDdlMzhfNS02LTEtMS00MTI5NA_b13f087d-692c-441e-abd9-4df172f6377c">10,110</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i302f4f37e71b4505a330b599087d6bee_I20201231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RhYmxlOjZjMjM5MjZkZjU4ZTQwZTVhMTY3OGJhZDc0YzA3ZTM4L3RhYmxlcmFuZ2U6NmMyMzkyNmRmNThlNDBlNWExNjc4YmFkNzRjMDdlMzhfNS04LTEtMS00MTI5NA_1b9c44bf-833f-4495-96f0-673a2427fa15">28,298</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i302f4f37e71b4505a330b599087d6bee_I20201231" decimals="-3" name="lgnd:FiniteLivedIntangibleAssetsAccumulatedAmortizationResearchDevelopmentExpenseAndCreditLossAdjustments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RhYmxlOjZjMjM5MjZkZjU4ZTQwZTVhMTY3OGJhZDc0YzA3ZTM4L3RhYmxlcmFuZ2U6NmMyMzkyNmRmNThlNDBlNWExNjc4YmFkNzRjMDdlMzhfNS0xMC0xLTEtNDEyOTQ_b2b19bec-6e5a-4248-a69a-2bad446e1cff">17,319</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i302f4f37e71b4505a330b599087d6bee_I20201231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RhYmxlOjZjMjM5MjZkZjU4ZTQwZTVhMTY3OGJhZDc0YzA3ZTM4L3RhYmxlcmFuZ2U6NmMyMzkyNmRmNThlNDBlNWExNjc4YmFkNzRjMDdlMzhfNS0xMi0xLTEtNDEyOTQ_a38ea748-74ca-4b70-a4b4-224aa4583e78">10,979</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%">(1) Amounts represent accumulated amortization to principal of $<ix:nonFraction unitRef="usd" contextRef="ia8308d0606a54c10ac4769b1a226d54c_I20211231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RleHRyZWdpb246MDE1MzU3NWExNzUxNDlhMGJlMjM2NzA3MzMyMzJiNjlfMTA5OTUxMTcwNjA5OQ_2bb39a44-783f-47a4-9320-095596400196">11.7</ix:nonFraction> million and credit loss adjustments of $<ix:nonFraction unitRef="usd" contextRef="ia8308d0606a54c10ac4769b1a226d54c_I20211231" decimals="-5" name="lgnd:FiniteLivedIntangibleAssetsCreditLossAdjustments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RleHRyZWdpb246MDE1MzU3NWExNzUxNDlhMGJlMjM2NzA3MzMyMzJiNjlfMTA5OTUxMTcwNjEwNw_ad732201-3bec-4bfc-a08a-9ccc7209ba31">6.5</ix:nonFraction> million as of December 31, 2021. </span></div></ix:nonNumeric><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%"><ix:continuation id="id615273eab0f404ca2fb18e7ce6d4947">(2) Amounts represent accumulated amortization to principal of $<ix:nonFraction unitRef="usd" contextRef="i302f4f37e71b4505a330b599087d6bee_I20201231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RleHRyZWdpb246MDE1MzU3NWExNzUxNDlhMGJlMjM2NzA3MzMyMzJiNjlfMzI5ODUzNDkzNzg2MQ_82c98087-bfb5-40c1-8d66-f42ec6157e8c">11.3</ix:nonFraction> million and credit loss adjustments of $<ix:nonFraction unitRef="usd" contextRef="i302f4f37e71b4505a330b599087d6bee_I20201231" decimals="-5" name="lgnd:FiniteLivedIntangibleAssetsCreditLossAdjustments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RleHRyZWdpb246MDE1MzU3NWExNzUxNDlhMGJlMjM2NzA3MzMyMzJiNjlfMzI5ODUzNDkzNzg3Mw_cee54688-5ee2-44c3-89ed-360cab836e67">6.0</ix:nonFraction> million as of December 31, 2020.</ix:continuation> </span></div><div style="padding-left:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commercial license and other economic rights as of December&#160;31, 2021 represent a portfolio of future milestone and royalty payment rights acquired from Selexis in April 2013 and April 2015, CorMatrix in May 2016, and Dianomi in January 2019. Commercial license rights acquired are accounted for as financial assets, and other economic rights are accounted for as funded research and developments as further discussed below. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2019, we entered into a development funding and royalties agreement with Novan, pursuant to which we would receive certain payments at specified milestones, as well as royalties on any future net sales of SB206, a product candidate being developed to treat molluscum contagiosum, and any other Novan products used for the treatment of molluscum (&#8220;Novan Molluscum Products&#8221;). We paid Novan an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="icc93824bf0be4b7495cbbfa00019602d_D20190501-20190531" decimals="-5" name="lgnd:LicenseUpfrontPayment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RleHRyZWdpb246MDE1MzU3NWExNzUxNDlhMGJlMjM2NzA3MzMyMzJiNjlfMTY1NTI_9e77a7d7-fb59-4d9e-bcc9-9fe5db7ca4e7">12.0</ix:nonFraction> million, which Novan is required to use to fund the development of SB206. We are not obligated to provide additional funding to Novan for the development or commercialization </span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">62</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="if1f448726e0443ca9c11f5e61d1f2b04" continuedAt="i7bc207fd24a6485d9dc7656323ce4f55"><ix:continuation id="i2a25adeee3a6450787a135502a76c0d8" continuedAt="ic4037c3a7b724a8895a71a4501f28c29"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of SB206. Pursuant to the agreement, we would receive up to $<ix:nonFraction unitRef="usd" contextRef="i4984262bb27142918e72ba7426eaa00b_I20190531" decimals="INF" name="lgnd:AdditionalRoyaltiesReceivableUnderSalesbasedMilestones" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RleHRyZWdpb246MDE1MzU3NWExNzUxNDlhMGJlMjM2NzA3MzMyMzJiNjlfMTY3ODI_ac9c88f7-f582-4e5a-b42d-362e10c1fd67">20.0</ix:nonFraction> million of milestone payments upon the achievement by Novan of certain regulatory milestones for SB206 or any other Novan Molluscum Product and commercial milestones. In addition to the milestone payments, Novan will pay us tiered royalties from <ix:nonFraction unitRef="number" contextRef="i76ec8fc1e4724884824d0d65bebbf615_I20190531" decimals="INF" name="lgnd:ProductRoyaltyPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RleHRyZWdpb246MDE1MzU3NWExNzUxNDlhMGJlMjM2NzA3MzMyMzJiNjlfMTcwMjM_a86a0846-1bba-4c66-a9b6-75d536f00b80">7.0</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="iac16870509044b14afde2112b0270ad8_I20190531" decimals="INF" name="lgnd:ProductRoyaltyPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RleHRyZWdpb246MDE1MzU3NWExNzUxNDlhMGJlMjM2NzA3MzMyMzJiNjlfMTcwMjk_de1e5ff2-a15e-416a-abff-02044782e69e">10.0</ix:nonFraction>% based on aggregate annual net sales of SB206 or any other Novan Molluscum Product in North America. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2018, we entered into a development funding and royalties agreement with Palvella. Pursuant to the agreement, we will receive up to $<ix:nonFraction unitRef="usd" contextRef="ifc86d31013124f84b716699c6235c139_I20181231" decimals="INF" name="lgnd:AdditionalRoyaltiesReceivableUnderSalesbasedMilestones" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RleHRyZWdpb246MDE1MzU3NWExNzUxNDlhMGJlMjM2NzA3MzMyMzJiNjlfMTc3MzU_21b9db70-9ea5-4e2b-9808-8a73855c9a81">8.0</ix:nonFraction> million of milestone payments upon the achievement by Palvella of certain corporate, financing and regulatory milestones for PTX-022, a product candidate being developed to treat pachyonychia congenita. In addition to the milestone payments, Palvella will pay us tiered royalties from <ix:nonFraction unitRef="number" contextRef="i00496d61e75e4c03bdeb6272892386e7_I20181231" decimals="INF" name="lgnd:ProductRoyaltyPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RleHRyZWdpb246MDE1MzU3NWExNzUxNDlhMGJlMjM2NzA3MzMyMzJiNjlfMTgwMTU_a1e6a60b-815b-4e83-83b2-559619e7ecff">5.0</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="i059cb8a459af48f6b7c8f8245f0a8818_I20181231" decimals="INF" name="lgnd:ProductRoyaltyPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RleHRyZWdpb246MDE1MzU3NWExNzUxNDlhMGJlMjM2NzA3MzMyMzJiNjlfMTgwMjE_01370727-1bf0-490e-9cdf-9beb8fb3211c">9.8</ix:nonFraction>% based on aggregate annual worldwide net sales of any PTX-022 products, if approved, subject to Palvella&#8217;s right to reduce the royalty rates by making payments in certain circumstances. We made an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="i8efe50fcb86a4eaf887009631ddd44d0_D20181201-20181231" decimals="-5" name="lgnd:LicenseUpfrontPayment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RleHRyZWdpb246MDE1MzU3NWExNzUxNDlhMGJlMjM2NzA3MzMyMzJiNjlfMTgyMzk_74fba7b8-6c4e-44ea-9425-490017d9b7a4">10.0</ix:nonFraction> million, which Palvella is required to use to fund the development of PTX-022. We are not obligated to provide additional funding to Palvella for development or commercialization of PTX-022. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determined the economic rights related to Novan and Palvella should be characterized as a funded research and development arrangement, thus we account for them in accordance with ASC 730-20, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Arrangement, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and reduce our asset as the funds are expended by Novan and Palvella. As of December 31, 2019, Novan had used up the $<ix:nonFraction unitRef="usd" contextRef="icc93824bf0be4b7495cbbfa00019602d_D20190501-20190531" decimals="-5" name="lgnd:LicenseUpfrontPayment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RleHRyZWdpb246MDE1MzU3NWExNzUxNDlhMGJlMjM2NzA3MzMyMzJiNjlfMTA5OTUxMTc0NjAzMg_9e77a7d7-fb59-4d9e-bcc9-9fe5db7ca4e7">12.0</ix:nonFraction> million upfront payment provided by us. As such, our other economic rights related to Novan had been fully amortized as of December 31, 2019. As of December 31, 2020, the fund has been fully expended by Palvella and our cost basis for the asset has been reduced to <ix:nonFraction unitRef="usd" contextRef="id85f4282e429462997cf6658ec77093b_I20201231" decimals="INF" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RleHRyZWdpb246MDE1MzU3NWExNzUxNDlhMGJlMjM2NzA3MzMyMzJiNjlfMTg3NzU_aa423d34-7ffd-4f73-96f0-d4eeca4426ed">zero</ix:nonFraction>, and therefore we will recognize milestones and royalties as revenue when earned. During 2020, we recorded a $<ix:nonFraction unitRef="usd" contextRef="id5f878ad057d4dbcba2c34a61c1d4b07_D20200101-20201231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RleHRyZWdpb246MDE1MzU3NWExNzUxNDlhMGJlMjM2NzA3MzMyMzJiNjlfMTg4ODc_4071ed1b-7b51-4d7e-9203-48cbf98f47e1">3.0</ix:nonFraction> million milestone from Palvella under contract revenue, which has been included in our consolidated statement of operations for the year ended December&#160;31, 2020.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2017, we entered into a royalty agreement with Aziyo pursuant to which we will receive royalties from certain marketed products that Aziyo acquired from CorMatrix. Pursuant to the agreement, we received $<ix:nonFraction unitRef="usd" contextRef="iabc0130cdf4e432a836d766b1ae349c3_D20170531-20170531" decimals="-5" name="us-gaap:ProceedsFromRoyaltiesReceived" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RleHRyZWdpb246MDE1MzU3NWExNzUxNDlhMGJlMjM2NzA3MzMyMzJiNjlfMTkyNDA_4b26a860-0853-4635-a012-7165206ee5a2">10.0</ix:nonFraction> million in 2017 from Aziyo to buydown the royalty rates on the products CorMatrix sold to Aziyo. The agreement closed on May 31, 2017, in connection with the closing of the asset sale from CorMatrix to Aziyo (the &#8220;CorMatrix Asset Sale&#8221;). Per the agreement, we will receive a <ix:nonFraction unitRef="number" contextRef="ib3ba73729c164d36b827967a2afe6719_I20170531" decimals="INF" name="lgnd:ProductRoyaltyPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RleHRyZWdpb246MDE1MzU3NWExNzUxNDlhMGJlMjM2NzA3MzMyMzJiNjlfMTk1MTA_9e3290b3-fab0-4db2-9e41-9ea584934354">5</ix:nonFraction>% royalty on the products Aziyo acquired in the CorMatrix Asset Sale, reduced from the original <ix:nonFraction unitRef="number" contextRef="idfd3cb0e5e65402da94f6b645760f254_I20170531" decimals="INF" name="lgnd:ProductRoyaltyPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RleHRyZWdpb246MDE1MzU3NWExNzUxNDlhMGJlMjM2NzA3MzMyMzJiNjlfMTk2MDc_1d96b78f-0db3-471a-bfe4-4e88966c53f6">20</ix:nonFraction>% royalty from CorMatrix pursuant to the previously disclosed interest purchase agreement, dated May 3, 2016 (the &#8220;Original Interest Purchase Agreement&#8221;) between CorMatrix and us. In addition, Aziyo has agreed to pay us up to $<ix:nonFraction unitRef="usd" contextRef="iceabba67d48a469eb549559806d7e623_I20170531" decimals="INF" name="lgnd:AdditionalRoyaltiesReceivableUnderSalesbasedMilestones" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RleHRyZWdpb246MDE1MzU3NWExNzUxNDlhMGJlMjM2NzA3MzMyMzJiNjlfMTk4MzQ_78012e41-24f8-4c0e-a2be-eb78b2ce7eb5">10.0</ix:nonFraction> million of additional milestones tied to cumulative net sales of the products Aziyo acquired in the CorMatrix Asset Sale and to extend the term on these royalties by one year. The royalty agreement will terminate on May 31, 2027. In addition, in May 2017, we entered into an amended and restated interest purchase agreement (the &#8220;Amended Interest Purchase Agreement&#8221;) with CorMatrix, which supersedes in its entirety the Original Interest Purchase Agreement. Other than removing the commercial products sold to Aziyo in the CorMatrix Sale, the terms of the Amended Interest Purchase Agreement remain unchanged with respect to the CorMatrix developmental pipeline products, including the royalty rate of <ix:nonFraction unitRef="number" contextRef="if1c8698b58b240d19cf54dff3bafb373_I20170531" decimals="INF" name="lgnd:ProductRoyaltyPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RleHRyZWdpb246MDE1MzU3NWExNzUxNDlhMGJlMjM2NzA3MzMyMzJiNjlfMjA1MzI_0b0738b4-4e68-4aa9-ac51-69da05c59236">5</ix:nonFraction>% on such pipeline products. The Amended Interest Purchase Agreement will terminate <ix:nonNumeric contextRef="i1345b3a472be45ab8492e940ed55ac1a_D20170531-20170531" name="lgnd:RoyaltyAgreementExpirationPeriod" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RleHRyZWdpb246MDE1MzU3NWExNzUxNDlhMGJlMjM2NzA3MzMyMzJiNjlfMjA2MTc_cee71fe6-1c81-48e1-a194-137f6d50be4f">10</ix:nonNumeric> years from the date of the first commercial sale of such products. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for the Aziyo commercial license right as a financial asset in accordance with ASC 310, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Receivables</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and amortize the commercial license right using the effective interest method whereby we forecast expected cash flows over the term of the arrangement to arrive at an annualized effective interest. The annual effective interest associated with the forecasted cash flows from the royalty agreement with Aziyo as of December&#160;31, 2021 is <ix:nonFraction unitRef="number" contextRef="ie0f36a67ac4b474f8a329695884951fa_D20210101-20211231" decimals="3" name="lgnd:ForecastedCashFlowsEffectiveInterestRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RleHRyZWdpb246MDE1MzU3NWExNzUxNDlhMGJlMjM2NzA3MzMyMzJiNjlfMjExMTU_840eeb1c-143d-4da4-9326-32637b660cca">21.6</ix:nonFraction>%. Revenue is calculated by multiplying the carrying value of the commercial license right by the effective interest. The payments received in 2021 were accordingly allocated between revenue and the amortization of the commercial license rights.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to 2020, we accounted for commercial license rights related to developmental pipeline products such as Selexis and Dianomi on a non-accrual basis. These developmental pipeline products are non-commercialized, non-approved products that require FDA or other regulatory approval, and thus have uncertain cash flows. The developmental pipeline products are on a non-accrual basis as we are not yet able to forecast future cash flows given their pre-commercial stages of development. We will prospectively update the yield model under the effective interest method once the underlying products are commercialized and we can reliably forecast expected cash flows. Income will be calculated by multiplying the carrying value of the commercial license right by the effective interest rate. We regularly perform reviews to determine if any event has occurred that may indicate the carrying value of these commercial license rights are potentially impaired. If the affected commercial license rights are not recoverable, we estimate the fair value of the assets and record an impairment loss if the carrying value of the assets exceeds the fair value. During 2020, given the expected cash flow from the Selexis program, we started to account for the Selexis commercial license right as a financial asset in accordance with ASC 310, and amortize the commercial license right using the effective interest method whereby we forecast expected cash flows over the term of the arrangement to arrive at an annualized effective interest. The annual effective interest associated with the forecasted cash flows from the royalty agreement with Selexis as of December&#160;31, 2021 is <ix:nonFraction unitRef="number" contextRef="i10f57c9a0a354a7c81c9266418797f1c_D20210101-20211231" decimals="2" name="lgnd:ForecastedCashFlowsEffectiveInterestRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RleHRyZWdpb246MDE1MzU3NWExNzUxNDlhMGJlMjM2NzA3MzMyMzJiNjlfMjMwMTQ_d4031d04-87b9-47ab-9201-5a1e986ab747">21</ix:nonFraction>%. Revenue is calculated by multiplying the carrying value of the commercial license right by the effective interest. The payments received in the year ended December&#160;31, 2021 and 2020 were allocated </span></div></ix:continuation></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">63</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i7bc207fd24a6485d9dc7656323ce4f55" continuedAt="i254df858f241413da7fd8bd2e91a6380"><ix:continuation id="ic4037c3a7b724a8895a71a4501f28c29"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">accordingly between revenue and the amortization of the commercial license rights. We still accounted for commercial license rights related to Dianomi on a non-accrual basis as of December&#160;31, 2021.</span></div><div><span><br/></span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For commercial license rights, we have elected a prospective approach to account for changes in estimated cash flows and selected a method for determining when an impairment would be recognized and how to measure that impairment. In circumstances where our new estimate of expected cash flows is greater than previously expected, we will update our yield prospectively. In circumstances where our new estimate of expected cash flows is less than previously expected and below our original estimated yield we record an impairment. Impairment is recognized by reducing the financial asset to an amount that represents the present value of our most recent estimate of expected cash flows discounted by the original effective interest rate.&#160;In circumstances where our new estimate of expected cash flows is less than previously expected, but not below our original estimated yield, we update our yield prospectively.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As a result of adopting ASU 2016-13, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Financial Instruments &#8211; Credit Losses: Measurement of Credit losses on Financial Instruments (Topic 326)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, we now recognize an allowance for current expected credit losses on the commercial license rights subject to credit risk. We recorded a $<ix:nonFraction unitRef="usd" contextRef="i744b30e425414018a238f9fbbb17b855_I20200101" decimals="-5" name="lgnd:FiniteLivedIntangibleAssetsCreditLossAdjustments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RleHRyZWdpb246MDE1MzU3NWExNzUxNDlhMGJlMjM2NzA3MzMyMzJiNjlfMjQ0NTA_31014a41-634b-4872-8347-d716a4396ab0">5.5</ix:nonFraction> million pre-tax reserve for credit losses upon adoption of the standard on January 1, 2020. We estimated the credit losses at the individual asset level by considering the performance against the programs, the company operating performance and the macroeconomic forecast. In addition, we have judgmentally applied credit loss risk factors to the future expected payments with consideration given to the timing of the payment. Given the higher inherent credit risk associated with longer term receivables, we applied a lower risk factor to the earlier years and progressively higher risk factors to the later years. During the twelve months ended December&#160;31, 2021 and 2020, we further considered the current and expected future economic and market conditions surrounding novel coronavirus (COVID-19) pandemic, along with other factors, and recorded an additional $<ix:nonFraction unitRef="usd" contextRef="ib3597315a63d441f8f128abd7ed8840e_D20200101-20201231" decimals="-5" name="lgnd:AccountsReceivableCreditLossExpenseReversalCOVID19" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RleHRyZWdpb246MDE1MzU3NWExNzUxNDlhMGJlMjM2NzA3MzMyMzJiNjlfMzI5ODUzNDkzNzkyMg_0f664376-c911-4c0f-9059-ca3d46800568"><ix:nonFraction unitRef="usd" contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231" decimals="-5" name="lgnd:AccountsReceivableCreditLossExpenseReversalCOVID19" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RleHRyZWdpb246MDE1MzU3NWExNzUxNDlhMGJlMjM2NzA3MzMyMzJiNjlfMzI5ODUzNDkzNzkyMg_5fd562d6-7472-43ba-882e-645984323c83">0.5</ix:nonFraction></ix:nonFraction>&#160;million each year, for credit losses in other expense, net, in our consolidated statements of operations.</span></div></ix:continuation><div><span><br/></span></div><ix:nonNumeric contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RleHRyZWdpb246MDE1MzU3NWExNzUxNDlhMGJlMjM2NzA3MzMyMzJiNjlfNTM2OTM_bd0427e5-dff4-4b9f-8a1d-be886a210603" continuedAt="i8e89f1b5f70e46879a9ee729e5eaae46" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our revenue is generated primarily from royalties on sales of products commercialized by our partners, Captisol material sales, and contract revenue for services, license fees and development, regulatory and sales based milestone payments.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We apply the following five-step model in accordance with ASC 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in order to determine the revenue: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations, including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation.</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Royalties</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We receive royalty revenue on sales by our partners of products covered by patents that we or our partners own under contractual agreements. We do not have future performance obligations under these license arrangements. We generally satisfy our obligation to grant intellectual property rights on the effective date of the contract. However, we apply the royalty recognition constraint required under the guidance for sales-based royalties which requires a royalty to be recorded no sooner than the underlying sale occurs. Therefore, royalties on sales of products commercialized by our partners are recognized in the quarter the product is sold. Our partners generally report sales information to us on a one quarter lag. Thus, we estimate the expected royalty proceeds based on an analysis of historical experience and interim data provided by our partners including their publicly announced sales. Differences between actual and estimated royalty revenues, which have not been material, are adjusted in the period in which they become known, typically the following quarter. </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Captisol Sales</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue from Captisol sales is recognized when control of Captisol material or intellectual property license rights is transferred to our customers in an amount that reflects the consideration we expect to receive from our customers in exchange for those products. A performance obligation is considered distinct from other obligations in a contract when it provides a benefit to the customer either on its own or together with other resources that are readily available to the customer and is separately identified in the contract. For Captisol material, we consider our performance obligation is satisfied at a point in time, once we have transferred control of the product, meaning the customer has the ability to use and obtain the benefit of the Captisol material or intellectual property license right. We recognize revenue for satisfied performance obligations only when we determine there are no uncertainties regarding payment terms or transfer of control. Sales tax and other taxes we collect concurrent with revenue-producing activities are excluded from revenue. We have elected to recognize the cost of freight and shipping when control over Captisol material has transferred to the customer as an expense in Cost of Captisol. We expense incremental costs of obtaining a contract when incurred if the expected amortization period of the asset that we would have recognized is one year or less or the amount is immaterial. We did not incur any incremental costs of obtaining a contract during the periods reported.</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">64</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i254df858f241413da7fd8bd2e91a6380" continuedAt="ie24214610762402f8ad24baf13ff35bf"><ix:continuation id="i8e89f1b5f70e46879a9ee729e5eaae46" continuedAt="id86c0dcfe4f940cc99495301e4bd6292"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Contract Revenue</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our contracts with customers often will include variable consideration in the form of contingent milestone-based payments. We include contingent milestone based payments in the estimated transaction price when it is probable a significant reversal in the amount of cumulative revenue recognized will not occur. These estimates are based on historical experience, anticipated results and our best judgment at the time. If the contingent milestone based payment is sales-based, we apply the royalty recognition constraint and record revenue when the underlying sale has taken place. Significant judgments must be made in determining the transaction price for our sales of intellectual property. Because of the risk that products in development with our partners will not reach development based milestones or receive regulatory approval, we generally recognize any contingent payments that would be due to us upon the development milestone or regulatory approval. Depending on the terms of the arrangement, we may also defer a portion of the consideration received if we have to satisfy a future obligation, which typically occurs with our contracts for R&amp;D services.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For R&amp;D services we recognize revenue over time and we measure our progress using an input method. The input methods we use are based on the effort we expend or costs we incur toward the satisfaction of our performance obligation. We estimate the amount of effort we expend, including the time it will take us to complete the activities, or the costs we may incur in a given period, relative to the estimated total effort or costs to satisfy the performance obligation. This results in a percentage that we multiply by the transaction price to determine the amount of revenue we recognize each period. This approach requires us to make numerous estimates and use significant judgement. If our estimates or judgements change over the course of the collaboration, they may affect the timing and amount of revenue that we recognize in the current and future periods.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We occasionally have sub-license obligations related to arrangements for which we receive license fees, milestones and royalties. We evaluate the determination of gross as a principal versus net as an agent reporting based on each individual agreement.</span></div><div><span><br/></span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Deferred Revenue</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Depending on the terms of the arrangement, we may also defer a portion of the consideration received if we have to satisfy a future obligation.</span></div></ix:continuation><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="id86c0dcfe4f940cc99495301e4bd6292">The timing of revenue recognition, billings and cash collections results in billed accounts receivable, unbilled receivables (contract assets), and customer advances and deposits (contract liabilities) on the consolidated balance sheet. Except for royalty revenue, we generally receive payment at the point we satisfy our obligation or soon after. Therefore, we do not generally carry a contract asset balance. Any fees billed in advance of being earned are recorded as deferred revenue.</ix:continuation> During the twelve months ended December&#160;31, 2021, the amount recognized as revenue that was previously deferred at December 31, 2020 was $<ix:nonFraction unitRef="usd" contextRef="ib3597315a63d441f8f128abd7ed8840e_D20200101-20201231" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RleHRyZWdpb246MDE1MzU3NWExNzUxNDlhMGJlMjM2NzA3MzMyMzJiNjlfMzI5ODUzNDkzNzkzOA_cb002dcf-2b31-4102-a015-d4d978618e1d">30.1</ix:nonFraction> million. During the twelve months ended December&#160;31, 2020, the amount recognized as revenue that was previously deferred at December 31, 2019 was $<ix:nonFraction unitRef="usd" contextRef="ie6c3b69702e9429aaeed46bdb9bbb9c1_D20190101-20191231" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RleHRyZWdpb246MDE1MzU3NWExNzUxNDlhMGJlMjM2NzA3MzMyMzJiNjlfMzI5ODUzNDkzNzk0Nw_df30daa2-18be-482b-ae3c-faf30b92985c">0.9</ix:nonFraction> million.</span></div><div><span><br/></span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Disaggregation of Revenue </span></div><ix:nonNumeric contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231" name="us-gaap:DisaggregationOfRevenueTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RleHRyZWdpb246MDE1MzU3NWExNzUxNDlhMGJlMjM2NzA3MzMyMzJiNjlfNTM3MDA_44e51e3f-417a-454e-87c0-3b324fb8a587" continuedAt="i9f908cc476f7403fb06e65dc18d4a158" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Royalty revenue for 2021, 2020 and 2019 are reported as below (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:61.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.601%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kyprolis</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id39ac2bcc6964f1cbe6799ea3c6e4480_D20210101-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RhYmxlOjE1MWVhZDVmNjFlMjQzZTY4M2ViMGFmZmZmZTZjMGZjL3RhYmxlcmFuZ2U6MTUxZWFkNWY2MWUyNDNlNjgzZWIwYWZmZmZlNmMwZmNfMy0yLTEtMS00MTI5NA_fab0d062-d565-4965-92f9-3f7f25a009e4">27,472</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f42318fa27c4162a9de72f632806f73_D20200101-20201231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RhYmxlOjE1MWVhZDVmNjFlMjQzZTY4M2ViMGFmZmZmZTZjMGZjL3RhYmxlcmFuZ2U6MTUxZWFkNWY2MWUyNDNlNjgzZWIwYWZmZmZlNmMwZmNfMy00LTEtMS00MTI5NA_a0db6465-f973-4c9b-beeb-d2721912205e">25,164</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie833d3fbd7ae41c78acdb6743a4958e5_D20190101-20191231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RhYmxlOjE1MWVhZDVmNjFlMjQzZTY4M2ViMGFmZmZmZTZjMGZjL3RhYmxlcmFuZ2U6MTUxZWFkNWY2MWUyNDNlNjgzZWIwYWZmZmZlNmMwZmNfMy02LTEtMS00MTI5NA_4961b6c1-ce5c-4ae0-b541-a60697ec2311">25,046</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Evomela</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ec735166d6041df97f7f723bd52feac_D20210101-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RhYmxlOjE1MWVhZDVmNjFlMjQzZTY4M2ViMGFmZmZmZTZjMGZjL3RhYmxlcmFuZ2U6MTUxZWFkNWY2MWUyNDNlNjgzZWIwYWZmZmZlNmMwZmNfNC0yLTEtMS00MTI5NA_72c3f84f-018d-49c6-bbf4-8b0cd76b32c0">10,079</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice15212256394a4a8bc6d0cdb5b93616_D20200101-20201231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RhYmxlOjE1MWVhZDVmNjFlMjQzZTY4M2ViMGFmZmZmZTZjMGZjL3RhYmxlcmFuZ2U6MTUxZWFkNWY2MWUyNDNlNjgzZWIwYWZmZmZlNmMwZmNfNC00LTEtMS00MTI5NA_60e38e42-980f-4551-8cad-3990eaf141c9">6,377</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id98579a29cc3406ea0d48ffd0c8920f0_D20190101-20191231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RhYmxlOjE1MWVhZDVmNjFlMjQzZTY4M2ViMGFmZmZmZTZjMGZjL3RhYmxlcmFuZ2U6MTUxZWFkNWY2MWUyNDNlNjgzZWIwYWZmZmZlNmMwZmNfNC02LTEtMS00MTI5NA_687a651f-39e4-402c-97db-2c9537404cf8">5,171</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6a4e064f17b4a32bbb585543d61d513_D20210101-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RhYmxlOjE1MWVhZDVmNjFlMjQzZTY4M2ViMGFmZmZmZTZjMGZjL3RhYmxlcmFuZ2U6MTUxZWFkNWY2MWUyNDNlNjgzZWIwYWZmZmZlNmMwZmNfNS0yLTEtMS00MTI5NA_57a482b3-81b5-4943-ac7d-b99cca998f1e">11,376</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70fab51ef90247fbb75a99fde6e756cd_D20200101-20201231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RhYmxlOjE1MWVhZDVmNjFlMjQzZTY4M2ViMGFmZmZmZTZjMGZjL3RhYmxlcmFuZ2U6MTUxZWFkNWY2MWUyNDNlNjgzZWIwYWZmZmZlNmMwZmNfNS00LTEtMS00MTI5NA_90270b68-3985-4b09-b98f-63d48e48fb20">2,255</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd3e128d210744fda465cb5dacddcdc6_D20190101-20191231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RhYmxlOjE1MWVhZDVmNjFlMjQzZTY4M2ViMGFmZmZmZTZjMGZjL3RhYmxlcmFuZ2U6MTUxZWFkNWY2MWUyNDNlNjgzZWIwYWZmZmZlNmMwZmNfNS02LTEtMS00MTI5NA_9151bf7a-d38c-4dfc-958e-af7d508e082f">2,566</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Promacta</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if954ceb872c04e719899033296d6f686_D20190101-20191231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RhYmxlOjE1MWVhZDVmNjFlMjQzZTY4M2ViMGFmZmZmZTZjMGZjL3RhYmxlcmFuZ2U6MTUxZWFkNWY2MWUyNDNlNjgzZWIwYWZmZmZlNmMwZmNfNi02LTEtMS00MTI5NA_9ca4af67-9bc4-4b93-abca-59eed5502be2">14,193</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id759bc1766674b9fb61441df044bc82f_D20210101-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RhYmxlOjE1MWVhZDVmNjFlMjQzZTY4M2ViMGFmZmZmZTZjMGZjL3RhYmxlcmFuZ2U6MTUxZWFkNWY2MWUyNDNlNjgzZWIwYWZmZmZlNmMwZmNfNy0yLTEtMS00MTI5NA_6a6169f2-3457-4354-a044-f5fd2530cbf8">48,927</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3c33038f43443e48bceca35aafc84c2_D20200101-20201231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RhYmxlOjE1MWVhZDVmNjFlMjQzZTY4M2ViMGFmZmZmZTZjMGZjL3RhYmxlcmFuZ2U6MTUxZWFkNWY2MWUyNDNlNjgzZWIwYWZmZmZlNmMwZmNfNy00LTEtMS00MTI5NA_8031607c-437c-4d3d-acfe-0d6d2cb2a92a">33,796</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3bced838db93465eb75b31bbd5690a49_D20190101-20191231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RhYmxlOjE1MWVhZDVmNjFlMjQzZTY4M2ViMGFmZmZmZTZjMGZjL3RhYmxlcmFuZ2U6MTUxZWFkNWY2MWUyNDNlNjgzZWIwYWZmZmZlNmMwZmNfNy02LTEtMS00MTI5NA_8f58f9ce-188a-48f7-89f4-42253ea900ae">46,976</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table represents disaggregation of Captisol and Contract Revenue (in thousands):</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">65</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ie24214610762402f8ad24baf13ff35bf" continuedAt="ia910e90976374f3fa6dd95e0a17d50cd"><div><ix:continuation id="i9f908cc476f7403fb06e65dc18d4a158"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:61.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.601%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Captisol</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1477966cad0140da81a9947fe9bab347_D20210101-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RhYmxlOjA4ZGQ2ZjM4NzQxYjRmN2FhODY0MjZiMDRlNjBhZDVkL3RhYmxlcmFuZ2U6MDhkZDZmMzg3NDFiNGY3YWE4NjQyNmIwNGU2MGFkNWRfMi0yLTEtMS00MTI5NA_d5cde1ac-6f81-44be-9250-5b7608954f3a">164,250</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7b5c3c10a34465088f2fa15825a2c42_D20200101-20201231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RhYmxlOjA4ZGQ2ZjM4NzQxYjRmN2FhODY0MjZiMDRlNjBhZDVkL3RhYmxlcmFuZ2U6MDhkZDZmMzg3NDFiNGY3YWE4NjQyNmIwNGU2MGFkNWRfMi00LTEtMS00MTI5NA_eb2f4d43-aaea-4b2d-85d8-4dccbcaab427">109,959</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75309306f08c443f8965a9846c0fb0fc_D20190101-20191231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RhYmxlOjA4ZGQ2ZjM4NzQxYjRmN2FhODY0MjZiMDRlNjBhZDVkL3RhYmxlcmFuZ2U6MDhkZDZmMzg3NDFiNGY3YWE4NjQyNmIwNGU2MGFkNWRfMi02LTEtMS00MTI5NA_5b9b04e3-3735-4f98-803b-98e41d90e1cb">31,489</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:5pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Service Revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice7144c706244526b337a36e827284e4_D20210101-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RhYmxlOjA4ZGQ2ZjM4NzQxYjRmN2FhODY0MjZiMDRlNjBhZDVkL3RhYmxlcmFuZ2U6MDhkZDZmMzg3NDFiNGY3YWE4NjQyNmIwNGU2MGFkNWRfNS0yLTEtMS00MTI5NA_63e567da-573a-4127-ae68-efa030e2e5e5">23,712</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia59aec17df534655ac72afe661d88b8c_D20200101-20201231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RhYmxlOjA4ZGQ2ZjM4NzQxYjRmN2FhODY0MjZiMDRlNjBhZDVkL3RhYmxlcmFuZ2U6MDhkZDZmMzg3NDFiNGY3YWE4NjQyNmIwNGU2MGFkNWRfNS00LTEtMS00MTI5NA_15a1ce22-a3f0-4ff3-a224-ef916b6aea6e">21,803</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i946a606b7d2e4c08bc42b0378e0181dd_D20190101-20191231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RhYmxlOjA4ZGQ2ZjM4NzQxYjRmN2FhODY0MjZiMDRlNjBhZDVkL3RhYmxlcmFuZ2U6MDhkZDZmMzg3NDFiNGY3YWE4NjQyNmIwNGU2MGFkNWRfNS02LTEtMS00MTI5NA_823ea13c-6017-4853-a0d1-a19689319848">16,776</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;License Fees</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied5134c8bab44b978f6b885c1c70cbed_D20210101-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RhYmxlOjA4ZGQ2ZjM4NzQxYjRmN2FhODY0MjZiMDRlNjBhZDVkL3RhYmxlcmFuZ2U6MDhkZDZmMzg3NDFiNGY3YWE4NjQyNmIwNGU2MGFkNWRfNi0yLTEtMS00MTI5NA_7bada92c-bbb3-442a-929f-dd915205b01b">5,084</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f517a8e06cc46728b8724172527ebda_D20200101-20201231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RhYmxlOjA4ZGQ2ZjM4NzQxYjRmN2FhODY0MjZiMDRlNjBhZDVkL3RhYmxlcmFuZ2U6MDhkZDZmMzg3NDFiNGY3YWE4NjQyNmIwNGU2MGFkNWRfNi00LTEtMS00MTI5NA_ce99ce0d-5fec-414e-b48a-4e9bfbf51fcb">4,378</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11ba1ec739d34b82ba4433ba722bc361_D20190101-20191231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RhYmxlOjA4ZGQ2ZjM4NzQxYjRmN2FhODY0MjZiMDRlNjBhZDVkL3RhYmxlcmFuZ2U6MDhkZDZmMzg3NDFiNGY3YWE4NjQyNmIwNGU2MGFkNWRfNi02LTEtMS00MTI5NA_4ea55270-fb70-48fd-b040-2303dd9d937c">6,199</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Milestone</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4e90d7c48b94ff3a4921a0579c9e4e9_D20210101-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RhYmxlOjA4ZGQ2ZjM4NzQxYjRmN2FhODY0MjZiMDRlNjBhZDVkL3RhYmxlcmFuZ2U6MDhkZDZmMzg3NDFiNGY3YWE4NjQyNmIwNGU2MGFkNWRfNy0yLTEtMS00MTI5NA_836d6b6e-fb0b-4404-a6f9-9a3f9b405e90">28,748</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i757afef6fc544b019aa6e8d1c80f94f9_D20200101-20201231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RhYmxlOjA4ZGQ2ZjM4NzQxYjRmN2FhODY0MjZiMDRlNjBhZDVkL3RhYmxlcmFuZ2U6MDhkZDZmMzg3NDFiNGY3YWE4NjQyNmIwNGU2MGFkNWRfNy00LTEtMS00MTI5NA_35674b8b-03c8-44d5-8475-5ee3f7187905">11,516</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9a1b09dbf574bec9cc40c8f1897cdc6_D20190101-20191231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RhYmxlOjA4ZGQ2ZjM4NzQxYjRmN2FhODY0MjZiMDRlNjBhZDVkL3RhYmxlcmFuZ2U6MDhkZDZmMzg3NDFiNGY3YWE4NjQyNmIwNGU2MGFkNWRfNy02LTEtMS00MTI5NA_83bbb733-c1a0-4ad6-9120-fc69c8b52560">17,173</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8436481b04714386944e45524f22e5a1_D20210101-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RhYmxlOjA4ZGQ2ZjM4NzQxYjRmN2FhODY0MjZiMDRlNjBhZDVkL3RhYmxlcmFuZ2U6MDhkZDZmMzg3NDFiNGY3YWE4NjQyNmIwNGU2MGFkNWRfOC0yLTEtMS00MTI5NA_0ffb9f05-0376-4c36-aaf6-d054061e6105">6,412</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i76d02ee85f37479bbbf7ef17aae36e40_D20200101-20201231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RhYmxlOjA4ZGQ2ZjM4NzQxYjRmN2FhODY0MjZiMDRlNjBhZDVkL3RhYmxlcmFuZ2U6MDhkZDZmMzg3NDFiNGY3YWE4NjQyNmIwNGU2MGFkNWRfOC00LTEtMS00MTI5NA_4f1800d1-048f-40ec-bed8-f8ce1357e583">4,967</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46edba4f2dc546d19c17b95467b928d8_D20190101-20191231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RhYmxlOjA4ZGQ2ZjM4NzQxYjRmN2FhODY0MjZiMDRlNjBhZDVkL3RhYmxlcmFuZ2U6MDhkZDZmMzg3NDFiNGY3YWE4NjQyNmIwNGU2MGFkNWRfOC02LTEtMS00MTI5NA_aba08317-ce8f-44ea-a492-0d1657b94ed4">1,669</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11e3d543e376468e8dda481609ac67e8_D20210101-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RhYmxlOjA4ZGQ2ZjM4NzQxYjRmN2FhODY0MjZiMDRlNjBhZDVkL3RhYmxlcmFuZ2U6MDhkZDZmMzg3NDFiNGY3YWE4NjQyNmIwNGU2MGFkNWRfOS0yLTEtMS00MTI5NA_fe10e957-c357-48e0-9fc2-955bd1c064bf">63,956</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if06efbad02a54e9d92b23a3ff376910e_D20200101-20201231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RhYmxlOjA4ZGQ2ZjM4NzQxYjRmN2FhODY0MjZiMDRlNjBhZDVkL3RhYmxlcmFuZ2U6MDhkZDZmMzg3NDFiNGY3YWE4NjQyNmIwNGU2MGFkNWRfOS00LTEtMS00MTI5NA_08dc3af5-ac64-4161-abfb-c0c8b69f78e9">42,664</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idea9b96f20cf4c28aea8b365b1b2069c_D20190101-20191231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RhYmxlOjA4ZGQ2ZjM4NzQxYjRmN2FhODY0MjZiMDRlNjBhZDVkL3RhYmxlcmFuZ2U6MDhkZDZmMzg3NDFiNGY3YWE4NjQyNmIwNGU2MGFkNWRfOS02LTEtMS00MTI5NA_1d2f5a7b-fcb7-4d45-9485-4cffa595d5d8">41,817</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RleHRyZWdpb246MDE1MzU3NWExNzUxNDlhMGJlMjM2NzA3MzMyMzJiNjlfNTM3MDU_449f2086-d919-49c9-a52f-4200eb5e2e87" continuedAt="ib9b3e79567b04fb0a2157942f1d05880" escape="true">Research and Development Expenses</ix:nonNumeric></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ib9b3e79567b04fb0a2157942f1d05880">Research and development expense consists of labor, material, equipment, and allocated facilities costs of our scientific staff who are working pursuant to our collaborative agreements and other research and development projects. Also included in research and development expenses are third-party costs incurred for our research programs including in-licensing costs, CRO costs and costs incurred by other research and development service vendors. We expense these costs as they are incurred. When we make payments for research and development services prior to the services being rendered, we record those amounts as prepaid assets on our consolidated balance sheet and we expense them as the services are provided.</ix:continuation> </span></div><div><span><br/></span></div><ix:nonNumeric contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RleHRyZWdpb246MDE1MzU3NWExNzUxNDlhMGJlMjM2NzA3MzMyMzJiNjlfNTM2ODc_75bde28a-26a3-4934-a180-3e299361e987" continuedAt="i99a12b2cf4864720b616719b7ad9fe4f" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share-Based Compensation</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We incur share-based compensation expense related to restricted stock, ESPP, and stock options.</span></div><div style="text-indent:45pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted stock unit (RSU) and performance stock unit (PSU) are all considered restricted stock. The fair value of restricted stock is determined by the closing market price of our common stock on the date of grant. We recognize share-based compensation expense based on the fair value on a straight-line basis over the requisite service periods of the awards, taking into consideration of forfeitures as they occur. PSU generally represents a right to receive a certain number of shares of common stock based on the achievement of corporate performance goals and continued employment during the vesting period. At each reporting period, we reassess the probability of the achievement of such corporate performance goals and any expense change resulting from an adjustment in the estimated shares to be released are treated as a cumulative catch-up in the period of adjustment. A limited amount of PSUs contain a market condition dependent upon the Company&#8217;s relative and absolute total stockholder return over a <ix:nonNumeric contextRef="i03b53fe74b3e44e5aed9677e0c396b22_D20210101-20211231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RleHRyZWdpb246MDE1MzU3NWExNzUxNDlhMGJlMjM2NzA3MzMyMzJiNjlfMjE5OTAyMzM4MTQ4MA_48a530b9-6443-416b-b68e-ca3abd07e4a4">three-year</ix:nonNumeric> period, with a range of <ix:nonFraction unitRef="number" contextRef="i63ea5dae35714601b3840baed12e6429_D20210101-20211231" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RleHRyZWdpb246MDE1MzU3NWExNzUxNDlhMGJlMjM2NzA3MzMyMzJiNjlfMjE5OTAyMzM4MTQ1Ng_4d7d0693-e377-44f3-aa3b-7c6d7a123204">0</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="iefe3140ed86e45ff99888b95c61cc3e7_D20210101-20211231" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RleHRyZWdpb246MDE1MzU3NWExNzUxNDlhMGJlMjM2NzA3MzMyMzJiNjlfMjE5OTAyMzM4MTQ2MA_f43bca56-6a1b-4a72-b5e4-114eb6245313">200</ix:nonFraction>% of the target amount granted to be issued under the award. Share-based compensation expense for these PSUs is measured using the Monte-Carlo simulation valuation model and is not adjusted for the achievement, or lack thereof, of the market conditions.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Black-Scholes-Merton option-pricing model is used to estimate the fair value of stock purchases under our ESPP and stock options granted. The model assumptions include expected volatility, term, dividends, and the risk-free interest rate. We look to historical and implied volatilities of our stock to determine the expected volatility. The expected term of an award is based on historical forfeiture experience, exercise activity, and on the terms and conditions of the stock awards. The expected dividend yield is determined to be <ix:nonFraction unitRef="number" contextRef="ib017566aacfb4b59a18b47770cb8359c_I20211231" decimals="2" name="us-gaap:EquitySecuritiesFvNiMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RleHRyZWdpb246MDE1MzU3NWExNzUxNDlhMGJlMjM2NzA3MzMyMzJiNjlfMzU3NDU_bea44ccc-3b1a-4d21-b09e-0054904e84e2">0</ix:nonFraction>% given that except for 2007, during which we declared a cash dividend on our common stock of $<ix:nonFraction unitRef="usdPerShare" contextRef="ibf4833a4427a446eaf4af9794277325c_D20070101-20071231" decimals="INF" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RleHRyZWdpb246MDE1MzU3NWExNzUxNDlhMGJlMjM2NzA3MzMyMzJiNjlfMzU4NDA_eaf9292f-53fd-43d0-8362-0dba74dfc5d7">2.50</ix:nonFraction> per share, we have not paid any dividends on our common stock in the past and currently do not expect to pay cash dividends or make any other distributions on common stock in the future. The risk-free interest rate is based upon U.S. Treasury securities with remaining terms similar to the expected term of the share-based awards.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We grant options, RSUs and PSUs to employees and non-employee directors. Non-employee directors are accounted for as employees. Options and RSUs granted to certain non-employee directors typically vest one year from the date of grant. Options granted to employees typically vest 1/8 on the <ix:nonNumeric contextRef="i011775edbe77465dad2b4242ab130485_D20210101-20211231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RleHRyZWdpb246MDE1MzU3NWExNzUxNDlhMGJlMjM2NzA3MzMyMzJiNjlfMzg0ODI5MDc1MDkzNw_2d162961-650a-45dc-95d3-c0f5243736a8">six month</ix:nonNumeric> anniversary of the date of grant, and 1/48 each month thereafter for <ix:nonNumeric contextRef="i05cb34ed326948caae6c1e7e7cb67165_D20210101-20211231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RleHRyZWdpb246MDE1MzU3NWExNzUxNDlhMGJlMjM2NzA3MzMyMzJiNjlfMzg0ODI5MDc1MDkzOA_cdd060f8-8655-43b5-a630-2ef8a4ce8066">forty-two months</ix:nonNumeric>. RSUs and PSUs granted to employees vest over <ix:nonNumeric contextRef="i995925b4edc84004834a7204d8ca1593_D20210101-20211231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RleHRyZWdpb246MDE1MzU3NWExNzUxNDlhMGJlMjM2NzA3MzMyMzJiNjlfMzY1OTk_07caa280-cfdd-40a8-a8c2-7476d2e4c434">three years</ix:nonNumeric>. All option awards generally expire <ix:nonNumeric contextRef="i7c39587d4c0e42b7ba5b9574b3926bff_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RleHRyZWdpb246MDE1MzU3NWExNzUxNDlhMGJlMjM2NzA3MzMyMzJiNjlfMzY2Mzg_fd236d44-443e-4f63-913b-4585003a25f0">ten years</ix:nonNumeric> from the date of grant.</span></div></ix:nonNumeric><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i99a12b2cf4864720b616719b7ad9fe4f">Share-based compensation expense for awards to employees and non-employee directors is recognized on a straight-line basis over the vesting period until the last tranche vests.</ix:continuation> </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231" name="us-gaap:DerivativesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RleHRyZWdpb246MDE1MzU3NWExNzUxNDlhMGJlMjM2NzA3MzMyMzJiNjlfNTM2OTY_4a544fdd-9204-4b73-b9a3-8c0a2623055c" continuedAt="i3fd0ea42c507488cbb4cfdded6d86c77" escape="true">Derivatives</ix:nonNumeric></span></div></ix:continuation><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">66</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ia910e90976374f3fa6dd95e0a17d50cd" continuedAt="i058c81aefcde49a58c0bdf247a200c43"><ix:continuation id="i3fd0ea42c507488cbb4cfdded6d86c77"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2018, we issued $<ix:nonFraction unitRef="usd" contextRef="ia70ff35785434b4585314e733c4b42c1_I20180531" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RleHRyZWdpb246MDE1MzU3NWExNzUxNDlhMGJlMjM2NzA3MzMyMzJiNjlfMzY4ODE_e1377021-785a-4149-a79f-8d6d51794c37">750.0</ix:nonFraction> million aggregate principal amount of 2023 Notes, bearing cash interest at a rate of <ix:nonFraction unitRef="number" contextRef="ia70ff35785434b4585314e733c4b42c1_I20180531" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RleHRyZWdpb246MDE1MzU3NWExNzUxNDlhMGJlMjM2NzA3MzMyMzJiNjlfMzY5NjE_d7046b3d-fdf0-404b-b406-7350777fde83">0.75</ix:nonFraction>% per year, payable semi-annually, as further described in &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note (7), Convertible Senior Notes.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; Concurrently with the issuance of the notes, we entered into a series of convertible note hedge and warrant transactions which in combination are designed to reduce the potential dilution to our stockholders and/or offset the cash payments we are required to make in excess of the principal amount upon conversion of the notes. The conversion option associated with the 2023 Notes temporarily met the criteria for an embedded derivative liability which required bifurcation and separate accounting. In addition, the note hedge and warrants were also temporarily classified as a derivative asset and liability, respectively, on our consolidated balance sheet. As a result of shareholder approval to increase the number of authorized shares of our common stock on June 19, 2018, as discussed in &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note (7), Convertible Senior Notes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,&#8221; the derivative asset and liabilities were reclassified to additional paid-in capital. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with our 2019 Notes, which we issued in August 2014 for $<ix:nonFraction unitRef="usd" contextRef="i1e8f1b6ddb0a48e7b819cababb4487da_I20140831" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RleHRyZWdpb246MDE1MzU3NWExNzUxNDlhMGJlMjM2NzA3MzMyMzJiNjlfMzgyMjg_9fc680f6-5cb8-410d-911a-25e3db4f1d70">245.0</ix:nonFraction> million aggregate principal amount, on May 22, 2018, we amended it making an irrevocable election to settle the entire note in cash. As a result, we reclassified from equity to derivative liability the fair value of the conversion premium as of May 22, 2018. Amounts paid in excess of the principal amount would be offset by an equal receipt of cash under the corresponding convertible bond hedge. As a result, we reclassified from equity to derivative asset the fair value of the bond hedge as of May 22, 2018. Changes in the fair value of these derivatives are reflected in other expense, net, in our consolidated statements of operations.</span></div></ix:continuation><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the payoff of the 2019 Notes in August 15, 2019, the bond hedge was settled and accordingly, the derivative asset and derivative liability were settled to <ix:nonFraction unitRef="usd" contextRef="i0a30e5369c8e4124bba63c2b980273be_I20190815" decimals="INF" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RleHRyZWdpb246MDE1MzU3NWExNzUxNDlhMGJlMjM2NzA3MzMyMzJiNjlfMzkwNDA_35180363-9d98-48e3-a2e2-64e22cf4e647"><ix:nonFraction unitRef="usd" contextRef="i0a30e5369c8e4124bba63c2b980273be_I20190815" decimals="INF" name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RleHRyZWdpb246MDE1MzU3NWExNzUxNDlhMGJlMjM2NzA3MzMyMzJiNjlfMzkwNDA_ba1f859b-5d38-463f-91ca-9609f6240f4d">zero</ix:nonFraction></ix:nonFraction>. See detail in &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note (7), Convertible Senior Notes.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;</span></div><div><span><br/></span></div><ix:nonNumeric contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231" name="us-gaap:IncomeTaxPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RleHRyZWdpb246MDE1MzU3NWExNzUxNDlhMGJlMjM2NzA3MzMyMzJiNjlfNTM2ODA_7365240b-25f9-4c16-90ea-3251f30589b5" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The provision for income taxes is computed using the asset and liability method, under which deferred tax assets and liabilities are recognized for the expected future tax consequences of temporary differences between the financial reporting and tax bases of assets and liabilities, and for the expected future tax benefit to be derived from tax loss and credit carryforwards. Deferred tax assets and liabilities are determined using the enacted tax rates in effect for the years in which those tax assets are expected to be realized. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in the provision for income taxes in the period that includes the enactment date. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred tax assets are regularly assessed to determine the likelihood they will be recovered from future taxable income. A valuation allowance is established when we believe it is more likely than not the future realization of all or some of a deferred tax asset will not be achieved. In evaluating the ability to recover deferred tax assets within the jurisdiction which they arise we consider all available positive and negative evidence. Factors reviewed include the cumulative pre-tax book income for the past three years, scheduled reversals of deferred tax liabilities, history of earnings and reliable forecasting, projections of pre-tax book income over the foreseeable future, and the impact of any feasible and prudent tax planning strategies.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize the impact of a tax position in our financial statements only if that position is more likely than not of being sustained upon examination by taxing authorities, based on the technical merits of the position. Tax authorities regularly examine our returns in the jurisdictions in which we do business and we regularly assess the tax risk of our return filing positions. Due to the complexity of some of the uncertainties, the ultimate resolution may result in payments that are materially different from our current estimate of the tax liability. These differences, as well as any interest and penalties, will be reflected in the provision for income taxes in the period in which they are determined.</span></div></ix:nonNumeric><div><span><br/></span></div><ix:nonNumeric contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231" name="us-gaap:EarningsPerSharePolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RleHRyZWdpb246MDE1MzU3NWExNzUxNDlhMGJlMjM2NzA3MzMyMzJiNjlfNTM2ODk_003b3096-910a-40e3-8c90-45590401ec8e" continuedAt="i88be1513922a443bbbd2a36d7cdf0f0e" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income (Loss) Per Share</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic income (loss) per share is calculated by dividing net income (loss) by the weighted-average number of common shares outstanding during the period. Diluted income per share is computed based on the sum of the weighted average number of common shares and potentially dilutive common shares outstanding during the period. Diluted loss per share is computed based on the sum of the weighted average number of common shares outstanding during the period.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Potentially dilutive common shares consist of shares issuable under 2023 convertible senior notes, stock options and restricted stock. 2023 convertible senior notes have a dilutive impact when the average market price of the Company&#8217;s common stock exceeds the applicable conversion price of the respective notes. It is our intent and policy to settle conversions through combination settlement, which essentially involves payment in cash equal to the principal portion and delivery of shares of common stock for the excess of the conversion value over the principal portion. Potentially dilutive common shares from stock options and restricted stock are determined using the average share price for each period under the treasury stock method. In addition, the following amounts are assumed to be used to repurchase shares: proceeds from exercise of stock options and the average amount of unrecognized compensation expense for stock options and restricted stock. In loss periods, basic net loss per </span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">67</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i058c81aefcde49a58c0bdf247a200c43" continuedAt="i5756b36d40cf43a98262c5aa410d79c9"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:continuation id="i88be1513922a443bbbd2a36d7cdf0f0e">share and diluted net loss per share are identical since the effect of otherwise dilutive potential common shares is anti-dilutive and therefore excluded.</ix:continuation></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">For the twelve months ended December 31, 2020, all of the <ix:nonFraction unitRef="shares" contextRef="i6a0717c8be2147b0b92f9327bf1814fd_D20200101-20201231" decimals="-5" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RleHRyZWdpb246MDE1MzU3NWExNzUxNDlhMGJlMjM2NzA3MzMyMzJiNjlfNzY5NjU4MTUxMjIwNQ_1a88a4af-7f0c-406e-9d44-3c2204609cde">0.6</ix:nonFraction>&#160;million weighted average shares of outstanding equity awards as of December 31, 2020 were anti-dilutive due to the net loss for the period.</span></div><div><span><br/></span></div><div><ix:nonNumeric contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RleHRyZWdpb246MDE1MzU3NWExNzUxNDlhMGJlMjM2NzA3MzMyMzJiNjlfNTM2OTQ_74cf877f-2892-4216-9db9-d7158aaa5945" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the calculation of weighted average shares used to calculate basic and diluted income (loss) per share (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:62.189%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.649%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares outstanding:</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RhYmxlOjFmNmQxMTIzY2M1ZTQwODFiYTcwMDNlODhjZTFmZjc5L3RhYmxlcmFuZ2U6MWY2ZDExMjNjYzVlNDA4MWJhNzAwM2U4OGNlMWZmNzlfMi0xLTEtMS00MTI5NA_caca7f72-8b5f-427b-a7ca-71787b5450c4">16,630</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib3597315a63d441f8f128abd7ed8840e_D20200101-20201231" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RhYmxlOjFmNmQxMTIzY2M1ZTQwODFiYTcwMDNlODhjZTFmZjc5L3RhYmxlcmFuZ2U6MWY2ZDExMjNjYzVlNDA4MWJhNzAwM2U4OGNlMWZmNzlfMi0zLTEtMS00MTI5NA_22998466-7045-474a-bc30-74cf35d65c97">16,185</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie6c3b69702e9429aaeed46bdb9bbb9c1_D20190101-20191231" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RhYmxlOjFmNmQxMTIzY2M1ZTQwODFiYTcwMDNlODhjZTFmZjc5L3RhYmxlcmFuZ2U6MWY2ZDExMjNjYzVlNDA4MWJhNzAwM2U4OGNlMWZmNzlfMi01LTEtMS00MTI5NA_85b87757-a14e-4a74-9724-250720e61aba">18,995</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dilutive potential common shares:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Restricted stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ifcdd30f034184cecb366b0b9b1bd9c55_D20210101-20211231" decimals="INF" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RhYmxlOjFmNmQxMTIzY2M1ZTQwODFiYTcwMDNlODhjZTFmZjc5L3RhYmxlcmFuZ2U6MWY2ZDExMjNjYzVlNDA4MWJhNzAwM2U4OGNlMWZmNzlfNC0xLTEtMS00MTI5NA_fc842e03-cb86-4d96-a65b-16e3fdc376a5">96</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6a0c3b111e7c4e828d7eda58eb7efe37_D20200101-20201231" decimals="INF" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RhYmxlOjFmNmQxMTIzY2M1ZTQwODFiYTcwMDNlODhjZTFmZjc5L3RhYmxlcmFuZ2U6MWY2ZDExMjNjYzVlNDA4MWJhNzAwM2U4OGNlMWZmNzlfNC0zLTEtMS00MTI5NA_9131d3df-082a-4297-9683-06e1f67e15c4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i58f6278b54d04be0bf0b9577c087f56c_D20190101-20191231" decimals="INF" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RhYmxlOjFmNmQxMTIzY2M1ZTQwODFiYTcwMDNlODhjZTFmZjc5L3RhYmxlcmFuZ2U6MWY2ZDExMjNjYzVlNDA4MWJhNzAwM2U4OGNlMWZmNzlfNC01LTEtMS00MTI5NA_42bf1bac-2e79-4a4b-b325-2612e3c33ee2">43</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Stock options</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0b2d2a0659724a0394359a72b0ded635_D20210101-20211231" decimals="INF" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RhYmxlOjFmNmQxMTIzY2M1ZTQwODFiYTcwMDNlODhjZTFmZjc5L3RhYmxlcmFuZ2U6MWY2ZDExMjNjYzVlNDA4MWJhNzAwM2U4OGNlMWZmNzlfNS0xLTEtMS00MTI5NA_1f5cbc5b-36d1-4b6a-95e0-462a36f321a5">520</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i97af3b7b1f564d4d911c3d6134e64410_D20200101-20201231" decimals="INF" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RhYmxlOjFmNmQxMTIzY2M1ZTQwODFiYTcwMDNlODhjZTFmZjc5L3RhYmxlcmFuZ2U6MWY2ZDExMjNjYzVlNDA4MWJhNzAwM2U4OGNlMWZmNzlfNS0zLTEtMS00MTI5NA_496786e3-409d-4521-b2e1-795a93eb0cc9">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i891b87647a30477eb27e9edd4fc735ea_D20190101-20191231" decimals="INF" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RhYmxlOjFmNmQxMTIzY2M1ZTQwODFiYTcwMDNlODhjZTFmZjc5L3RhYmxlcmFuZ2U6MWY2ZDExMjNjYzVlNDA4MWJhNzAwM2U4OGNlMWZmNzlfNS01LTEtMS00MTI5NA_929b814c-016b-498c-a5ca-7deff1e2a831">719</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares used to compute diluted income (loss) per share</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RhYmxlOjFmNmQxMTIzY2M1ZTQwODFiYTcwMDNlODhjZTFmZjc5L3RhYmxlcmFuZ2U6MWY2ZDExMjNjYzVlNDA4MWJhNzAwM2U4OGNlMWZmNzlfOC0xLTEtMS00MTI5NA_7f3817fb-a397-4b29-81b7-5e9f31838ff1">17,246</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib3597315a63d441f8f128abd7ed8840e_D20200101-20201231" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RhYmxlOjFmNmQxMTIzY2M1ZTQwODFiYTcwMDNlODhjZTFmZjc5L3RhYmxlcmFuZ2U6MWY2ZDExMjNjYzVlNDA4MWJhNzAwM2U4OGNlMWZmNzlfOC0zLTEtMS00MTI5NA_ae96b10b-6ea9-43f3-b2aa-6ac6b29c81e9">16,185</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie6c3b69702e9429aaeed46bdb9bbb9c1_D20190101-20191231" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RhYmxlOjFmNmQxMTIzY2M1ZTQwODFiYTcwMDNlODhjZTFmZjc5L3RhYmxlcmFuZ2U6MWY2ZDExMjNjYzVlNDA4MWJhNzAwM2U4OGNlMWZmNzlfOC01LTEtMS00MTI5NA_5c6f2990-b519-4a85-a0d9-b43f30413832">19,757</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Potentially dilutive shares excluded from calculation due to anti-dilutive effect</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RhYmxlOjFmNmQxMTIzY2M1ZTQwODFiYTcwMDNlODhjZTFmZjc5L3RhYmxlcmFuZ2U6MWY2ZDExMjNjYzVlNDA4MWJhNzAwM2U4OGNlMWZmNzlfOS0xLTEtMS00MTI5NA_9b1e5121-736f-46c9-bdc6-4b0bf5112803">4,793</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib3597315a63d441f8f128abd7ed8840e_D20200101-20201231" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RhYmxlOjFmNmQxMTIzY2M1ZTQwODFiYTcwMDNlODhjZTFmZjc5L3RhYmxlcmFuZ2U6MWY2ZDExMjNjYzVlNDA4MWJhNzAwM2U4OGNlMWZmNzlfOS0zLTEtMS00MTI5NA_8d0a9f53-5c00-4a07-a0c9-2782868a5b7f">8,458</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie6c3b69702e9429aaeed46bdb9bbb9c1_D20190101-20191231" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RhYmxlOjFmNmQxMTIzY2M1ZTQwODFiYTcwMDNlODhjZTFmZjc5L3RhYmxlcmFuZ2U6MWY2ZDExMjNjYzVlNDA4MWJhNzAwM2U4OGNlMWZmNzlfOS01LTEtMS00MTI5NA_98fd9378-6e49-49e3-9c3c-53fd4ab11ca7">8,926</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div><span><br/></span></div><ix:nonNumeric contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231" name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RleHRyZWdpb246MDE1MzU3NWExNzUxNDlhMGJlMjM2NzA3MzMyMzJiNjlfNTM2Nzg_a4d8fd80-df8d-4c10-8feb-5fca266f50a4" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comprehensive Income (Loss)</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Comprehensive income (loss) represents net income (loss) adjusted for the change during the periods presented in unrealized gains and losses on available-for-sale debt securities, foreign currency translation adjustments, and reclassification adjustments for realized gains or losses included in net income (loss). The unrealized gains or losses are reported on the Consolidated Statements of Comprehensive Income (Loss).</span></div></ix:nonNumeric><div><span><br/></span></div><ix:nonNumeric contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RleHRyZWdpb246MDE1MzU3NWExNzUxNDlhMGJlMjM2NzA3MzMyMzJiNjlfNTM2OTU_75d36755-48f1-4dc9-b3e4-f484ab39438c" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Translation</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The British Pound Sterling was the functional currency of our subsidiary, Vernalis, which was sold in fourth quarter of the year ended December 31, 2020. For the years ended December 31, 2020 and 2019 the corresponding financial statements have been translated into U.S. Dollars in accordance with ASC 830-30, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Translation of Financial Statements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">. Assets and liabilities are translated at end-of-period rates while revenues and expenses are translated at average rates in effect during the period in which the activity took place. Equity is translated at historical rates and the resulting cumulative translation adjustments are included as a component of accumulated other comprehensive income (loss).</span></div></ix:nonNumeric><div style="text-indent:24pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impact of COVID-19 Pandemic</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, we have not experienced material disruptions in our business operations or financial impacts as a result of the COVID-19 pandemic. While it is not possible at this time to estimate the impact that COVID-19 could have on our business in the future, the continued spread of COVID-19 and variants of the virus, the rate of vaccinations regionally and globally and the measures taken by the government authorities, and any future epidemic disease outbreaks, could: disrupt the supply chain and the manufacture or shipment of products and supplies for use by us in our discovery activities and by our partners for their discovery and development activities; delay, limit or prevent us or our partners&#8217; from continuing research and development activities; impede our negotiations with partners and potential partners; impede testing, monitoring, data collection and analysis and other related activities, by us and our partners; interrupt or delay the operations of the FDA or other regulatory authorities, which may impact review and approval timelines for initiation of clinical trials or marketing; impede the launch or commercialization of any approved products; any of which could delay our partnership programs, increase our operating costs, and have a material adverse effect on our business, financial condition and results of operations. In addition, if COVID-19 infects our genetically modified animals, which form the basis of our platform, or if there is an outbreak among our employees who maintain and care for these animals, we and our partners may be unable to produce antibodies for development.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some of our partners are working to develop drugs to treat COVID-19. For example, we are supplying Captisol to partners, including Gilead for Veklury (remdesivir), the first FDA-approved treatment for COVID-19 for the treatment of patients with COVID-19 requiring hospitalization and, as a result, we have extended our Captisol supply agreement with Gilead until September 2030 and worked to increase our manufacturing of Captisol to meet this increased demand. In addition, certain of our OmniAb and other license partners have initiated antibody discovery programs for the potential treatment of COVID-19.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The full extent to which the COVID-19 pandemic will directly or indirectly impact our business, the businesses of our partners, our results of operations and our financial condition will depend on future developments that are highly uncertain and cannot be </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">68</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i5756b36d40cf43a98262c5aa410d79c9"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">accurately predicted, including new information that may emerge concerning COVID-19, the actions taken to contain it or treat its impact, including the timing and extent of governments reopening or further restricting activities, and the economic impact on local, regional, national and international markets.</span></div><div><span><br/></span></div><ix:nonNumeric contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RleHRyZWdpb246MDE1MzU3NWExNzUxNDlhMGJlMjM2NzA3MzMyMzJiNjlfNTM3MDY_1ed234ad-5a75-4d97-9af8-6c86f415b75d" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Accounting Standards Not Yet Adopted</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In August 2020, the FASB issued ASU 2020-06, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Debt &#8211; Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging &#8211; Contracts in Entity&#8217;s Own Equity (Subtopic 815 &#8211; 40)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, which simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts on an entity&#8217;s own equity. This guidance is part of the FASB&#8217;s simplification initiative, which aims to reduce unnecessary complexity in U.S. GAAP. The ASU is effective for public entities for fiscal years beginning after December 15, 2021, and interim periods within those fiscal years. Effective January 1, 2022, we will adopt ASU 2020-06. We are finalizing our analysis of certain assumptions that will be utilized at the transition and expects the effect of adopting ASU 2020-06 will result in an increase to retained earnings, a decrease to additional paid-in capital, and an increase to the convertible senior notes. We expect that interest expense recognized in future periods will be reduced as a result of accounting for the convertible debt instrument as a single liability measured at its amortized cost. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We do not believe that any other recently issued, but not yet effective accounting pronouncements, if adopted, would have a material impact on our consolidated financial statements or disclosures.</span></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div id="i0fa6f906fb2e4e30bc5e873d2bb6a82c_88"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2. <ix:nonNumeric contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231" name="us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184OC9mcmFnOmZjMWQ4ZmMzMDZiODQ5ZDE4YTlkZjE1OTljZmQ2MjUzL3RleHRyZWdpb246ZmMxZDhmYzMwNmI4NDlkMThhOWRmMTU5OWNmZDYyNTNfMjgxNA_c8aa8b42-f8ea-4485-b421-58e18085fa0b" continuedAt="i9203df80d46c42b58e944815bdfc8040" escape="true">Sale of Vernalis R&amp;D and Promacta License</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="i9203df80d46c42b58e944815bdfc8040"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Vernalis R&amp;D</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On October 11, 2020, we entered into an Agreement for the Sale and Purchase of the Entire Issued Share Capital of Vernalis (R&amp;D) Limited (the &#8220;Purchase and Sale Agreement&#8221;) with HitGen UK Ltd (&#8220;Buyer&#8221;). Under the terms of the Purchase and Sale Agreement, we transferred certain intellectual property on completed collaboration licenses to Ligand UK Limited, which is a subsidiary of the Company, which we retain rights and interest to and are entitled to receive future milestones and royalties. Under the Purchase and Sale Agreement, we are also entitled to a share of the economic rights on current research collaboration contracts. In addition, Vernalis will continue to support certain existing Ligand partnerships. On December 2, 2020, we completed the sale. Pursuant to the terms of the Purchase and Sale Agreement, at the closing of the transaction, Buyer paid $<ix:nonFraction unitRef="usd" contextRef="iad8d570ea6b24d73b93cc3ae9b3901e3_D20201202-20201202" decimals="-5" name="us-gaap:ProceedsFromDivestitureOfBusinesses" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184OC9mcmFnOmZjMWQ4ZmMzMDZiODQ5ZDE4YTlkZjE1OTljZmQ2MjUzL3RleHRyZWdpb246ZmMxZDhmYzMwNmI4NDlkMThhOWRmMTU5OWNmZDYyNTNfOTM0_a4a0d28c-8503-4b3a-a2c1-2b3fa5526cc7">26.7</ix:nonFraction>&#160;million in cash, following adjustment for debt, cash and net working capital. As Vernalis R&amp;D has the input, process and output elements defined in ASC 805, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Business Combinations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, we concluded the sale qualifies as a sale of business. Net assets sold, net of working capital adjustment, was $<ix:nonFraction unitRef="usd" contextRef="ie32796c2a612452280599ec9bc39e8e9_I20201201" decimals="-5" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184OC9mcmFnOmZjMWQ4ZmMzMDZiODQ5ZDE4YTlkZjE1OTljZmQ2MjUzL3RleHRyZWdpb246ZmMxZDhmYzMwNmI4NDlkMThhOWRmMTU5OWNmZDYyNTNfMTIyMA_0abb4e62-04a8-4811-8461-e57b144fb070">6.1</ix:nonFraction>&#160;million, goodwill allocated to the selling business that was written off was $<ix:nonFraction unitRef="usd" contextRef="iad8d570ea6b24d73b93cc3ae9b3901e3_D20201202-20201202" decimals="-5" name="us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184OC9mcmFnOmZjMWQ4ZmMzMDZiODQ5ZDE4YTlkZjE1OTljZmQ2MjUzL3RleHRyZWdpb246ZmMxZDhmYzMwNmI4NDlkMThhOWRmMTU5OWNmZDYyNTNfMTI5Mg_cb98f3a0-552d-4b12-831d-da9d5bf25292">3.5</ix:nonFraction>&#160;million, resulting in a $<ix:nonFraction unitRef="usd" contextRef="if68046f8a22f4e8cb3ae551bf1b6614f_D20210101-20211231" decimals="-5" name="us-gaap:GainLossOnDispositionOfIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184OC9mcmFnOmZjMWQ4ZmMzMDZiODQ5ZDE4YTlkZjE1OTljZmQ2MjUzL3RleHRyZWdpb246ZmMxZDhmYzMwNmI4NDlkMThhOWRmMTU5OWNmZDYyNTNfMTMxMQ_812a606f-a4b3-4da2-a5c2-0f41ef3c9b5c">17.1</ix:nonFraction> million gain from sale of Vernalis R&amp;D recorded to income from operations.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Promacta License</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On March 5, 2019, we entered into an Asset Purchase Agreement (the &#8220;Asset Purchase Agreement&#8221;) with RPI Finance Trust (&#8220;RPI&#8221;), doing business as &#8220;Royalty Pharma&#8221;, who is not an affiliate. Under the Asset Purchase Agreement, we sold, transferred, assigned and conveyed to RPI, and RPI purchased, acquired and accepted from us, all of our rights, title and interest in and to the Purchased Assets, which include among other things the intellectual property and related know-how generated by us in connection with the license agreement (collectively, the &#8220;Purchased Assets&#8221;), dated December 29, 1994, by and between Novartis (as successor in interest to SmithKline Beecham Corporation) and Ligand, which allowed us to receive a royalty on net sales of Promacta. We concluded the sale does not qualify as a sale of a business, but as a sale of a non-financial asset. At the closing on March 6, 2019, RPI paid us $<ix:nonFraction unitRef="usd" contextRef="ie5330d9159b84212968447e2b2771f1b_D20190306-20190306" decimals="-5" name="us-gaap:ProceedsFromDivestitureOfBusinesses" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184OC9mcmFnOmZjMWQ4ZmMzMDZiODQ5ZDE4YTlkZjE1OTljZmQ2MjUzL3RleHRyZWdpb246ZmMxZDhmYzMwNmI4NDlkMThhOWRmMTU5OWNmZDYyNTNfMjMwOA_bb0838d4-6c9e-4037-ac15-77059c9f4fd4">827.0</ix:nonFraction>&#160;million in cash and we do not have any remaining performance obligations related to Novartis or RPI for Promacta. The carrying value of our Promacta asset as of March 6, 2019 was <ix:nonFraction unitRef="usd" contextRef="i46cec39d09204b19b6661eeb7995f45f_I20190306" decimals="-5" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184OC9mcmFnOmZjMWQ4ZmMzMDZiODQ5ZDE4YTlkZjE1OTljZmQ2MjUzL3RleHRyZWdpb246ZmMxZDhmYzMwNmI4NDlkMThhOWRmMTU5OWNmZDYyNTNfMjQ4Mg_74a1a2db-2e69-4640-92c3-57c209ee0ed7">zero</ix:nonFraction>. Of the total cash proceeds from the sale, $<ix:nonFraction unitRef="usd" contextRef="i13ee716c8db44abb8505546f32fd4579_D20190101-20190306" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184OC9mcmFnOmZjMWQ4ZmMzMDZiODQ5ZDE4YTlkZjE1OTljZmQ2MjUzL3RleHRyZWdpb246ZmMxZDhmYzMwNmI4NDlkMThhOWRmMTU5OWNmZDYyNTNfMjUyOA_af3a3528-781a-4b3d-8264-50be5fd24232">14.2</ix:nonFraction>&#160;million was recorded to revenue related to the Promacta royalty for the period between January 1, 2019 and March 6, 2019, and the remaining $<ix:nonFraction unitRef="usd" contextRef="i13ee716c8db44abb8505546f32fd4579_D20190101-20190306" decimals="-5" name="us-gaap:GainLossOnDispositionOfIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184OC9mcmFnOmZjMWQ4ZmMzMDZiODQ5ZDE4YTlkZjE1OTljZmQ2MjUzL3RleHRyZWdpb246ZmMxZDhmYzMwNmI4NDlkMThhOWRmMTU5OWNmZDYyNTNfMjY2Mw_608a1486-3eb6-4641-8b83-5d3d4ed80bbe">812.8</ix:nonFraction>&#160;million was recorded to income from operations in accordance with ASC 610-20,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"> Other Income - Gains and Losses from the Derecognition of Nonfinancial Assets.</span></div></ix:continuation><div><span><br/></span></div><div id="i0fa6f906fb2e4e30bc5e873d2bb6a82c_91"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3.  <ix:nonNumeric contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231" name="us-gaap:VariableInterestEntityDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185MS9mcmFnOjBiNmQwN2Q2OWI2ZTQxYjY4MTA5MThiY2ZiYmU1ZjQ5L3RleHRyZWdpb246MGI2ZDA3ZDY5YjZlNDFiNjgxMDkxOGJjZmJiZTVmNDlfODc2_248bd201-eb63-468f-b7b9-2acd44cc912b" continuedAt="i975bc0a464d64c80943c393e095dd0fa" escape="true">Short-term Investments: Investment in Viking</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="i975bc0a464d64c80943c393e095dd0fa" continuedAt="i4284a245716a4734b97f72417b679440"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ownership in Viking was approximately <ix:nonFraction unitRef="number" contextRef="ic9f4e1d55a994ce397ebaba69b0e0499_D20210101-20211231" decimals="3" name="us-gaap:LimitedLiabilityCompanyLLCOrLimitedPartnershipLPMembersOrLimitedPartnersOwnershipInterest" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185MS9mcmFnOjBiNmQwN2Q2OWI2ZTQxYjY4MTA5MThiY2ZiYmU1ZjQ5L3RleHRyZWdpb246MGI2ZDA3ZDY5YjZlNDFiNjgxMDkxOGJjZmJiZTVmNDlfOTc_bacace52-996d-4bb4-a6b8-724361ab0207">8.6</ix:nonFraction>% as of December&#160;31, 2021, and we account for it as an investment in available-for-sale equity securities, which is measured at fair value, with changes in fair value recognized in net income. Viking is considered a related party as we maintain a seat on Viking's board of directors and we do not exert significant influence over Viking. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, we have <ix:nonFraction unitRef="usd" contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231" decimals="-5" name="us-gaap:WarrantsAndRightsOutstanding" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185MS9mcmFnOjBiNmQwN2Q2OWI2ZTQxYjY4MTA5MThiY2ZiYmU1ZjQ5L3RleHRyZWdpb246MGI2ZDA3ZDY5YjZlNDFiNjgxMDkxOGJjZmJiZTVmNDlfMjYzODgyNzkwNjg5MDE_0da76c06-65af-4e7e-bd7f-150df650db5c">zero</ix:nonFraction> Viking warrants outstanding. As of December&#160;31, 2021 and December&#160;31, 2020, we recorded our common stock in Viking in &#8220;short-term investments&#8221; at fair value of $<ix:nonFraction unitRef="usd" contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231" decimals="-5" name="us-gaap:EquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185MS9mcmFnOjBiNmQwN2Q2OWI2ZTQxYjY4MTA5MThiY2ZiYmU1ZjQ5L3RleHRyZWdpb246MGI2ZDA3ZDY5YjZlNDFiNjgxMDkxOGJjZmJiZTVmNDlfNTE2_35572fe7-d5a0-4dea-ae42-0fcafedec1f1">30.9</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i7462d0db8f4248fcb9fd8f1deae439f3_I20201231" decimals="-5" name="us-gaap:EquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185MS9mcmFnOjBiNmQwN2Q2OWI2ZTQxYjY4MTA5MThiY2ZiYmU1ZjQ5L3RleHRyZWdpb246MGI2ZDA3ZDY5YjZlNDFiNjgxMDkxOGJjZmJiZTVmNDlfNTIz_d38e9449-d2c0-4593-ab1d-267753fc9a7d">32.8</ix:nonFraction> million, respectively. </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">69</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><ix:continuation id="i4284a245716a4734b97f72417b679440" continuedAt="i0843cbe405e94401855f3ecfbfebc2b9"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2020, we owned warrants to purchase up to <ix:nonFraction unitRef="usd" contextRef="i7462d0db8f4248fcb9fd8f1deae439f3_I20201231" decimals="-5" name="us-gaap:WarrantsAndRightsOutstanding" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185MS9mcmFnOjBiNmQwN2Q2OWI2ZTQxYjY4MTA5MThiY2ZiYmU1ZjQ5L3RleHRyZWdpb246MGI2ZDA3ZDY5YjZlNDFiNjgxMDkxOGJjZmJiZTVmNDlfNzY5NjU4MTM5NTYxOQ_f4d9a3ca-3e77-4ead-b723-db558474d827">1.5</ix:nonFraction> million shares of Viking's common stock at an exercise price of  $<ix:nonFraction unitRef="usdPerShare" contextRef="i7462d0db8f4248fcb9fd8f1deae439f3_I20201231" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185MS9mcmFnOjBiNmQwN2Q2OWI2ZTQxYjY4MTA5MThiY2ZiYmU1ZjQ5L3RleHRyZWdpb246MGI2ZDA3ZDY5YjZlNDFiNjgxMDkxOGJjZmJiZTVmNDlfNzY5NjU4MTM5NTY4MA_1b2126fa-e671-4b6a-8295-973717b31036">1.50</ix:nonFraction> per share, and during the year ended December&#160;31, 2021 we exercised all outstanding Viking warrants. As of December&#160;31, 2021, we have <ix:nonFraction unitRef="usd" contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231" decimals="-5" name="us-gaap:WarrantsAndRightsOutstanding" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185MS9mcmFnOjBiNmQwN2Q2OWI2ZTQxYjY4MTA5MThiY2ZiYmU1ZjQ5L3RleHRyZWdpb246MGI2ZDA3ZDY5YjZlNDFiNjgxMDkxOGJjZmJiZTVmNDlfMjE5OTAyMzI1NzA2OQ_aa27c701-53db-4efd-851d-c4f3dc44233b">zero</ix:nonFraction> Viking warrants outstanding. During the year ended December&#160;31, 2021, we also sold <ix:nonFraction unitRef="shares" contextRef="ic9f4e1d55a994ce397ebaba69b0e0499_D20210101-20211231" decimals="-5" name="lgnd:NumberOfSharesSoldOfEquityMethodInvestee" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185MS9mcmFnOjBiNmQwN2Q2OWI2ZTQxYjY4MTA5MThiY2ZiYmU1ZjQ5L3RleHRyZWdpb246MGI2ZDA3ZDY5YjZlNDFiNjgxMDkxOGJjZmJiZTVmNDlfMzg0ODI5MDY5OTQ3OQ_37c45f9e-0738-4365-8c03-5930eb73b428">0.6</ix:nonFraction>&#160;million Viking shares. We recorded the warrants in &#8220;Short-term investments&#8221; in our consolidated balance sheet at fair value of $<ix:nonFraction unitRef="usd" contextRef="ie623d2726f914332a2f5295e06936e94_I20201231" decimals="-5" name="lgnd:InvestmentInVikingCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185MS9mcmFnOjBiNmQwN2Q2OWI2ZTQxYjY4MTA5MThiY2ZiYmU1ZjQ5L3RleHRyZWdpb246MGI2ZDA3ZDY5YjZlNDFiNjgxMDkxOGJjZmJiZTVmNDlfNzY5NjU4MTM5NTkyNw_ca6f9456-1bd2-45f6-b48e-d55af3a2bbc1">6.3</ix:nonFraction> million at December&#160;31, 2020. See further discussion in &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note (5), Fair Value Measurement.</span></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i0843cbe405e94401855f3ecfbfebc2b9">&#8221;</ix:continuation> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span></div><div><span><br/></span></div><div id="i0fa6f906fb2e4e30bc5e873d2bb6a82c_94"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4.  <ix:nonNumeric contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231" name="us-gaap:BusinessCombinationDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185NC9mcmFnOmMzY2U4MjkwNTcxZTRkZWE4ZDI5ZjIzMWE1NzA2YjhlL3RleHRyZWdpb246YzNjZTgyOTA1NzFlNGRlYThkMjlmMjMxYTU3MDZiOGVfMTQ5Njc_0747a6a8-74a4-4b5e-b5fd-28c0a4110eb8" continuedAt="i15424d89925242f9b6e39501a84244a3" escape="true">Acquisitions</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="i15424d89925242f9b6e39501a84244a3" continuedAt="i616b3c5e157e44c1ad4e5fca3b7b763f"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As set forth below, we completed <ix:nonFraction unitRef="acquisition" contextRef="i0ccc7acfbbaf4714aeb414b4d316cace_D20190101-20211231" decimals="INF" name="lgnd:NumberOfAcquisitions" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185NC9mcmFnOmMzY2U4MjkwNTcxZTRkZWE4ZDI5ZjIzMWE1NzA2YjhlL3RleHRyZWdpb246YzNjZTgyOTA1NzFlNGRlYThkMjlmMjMxYTU3MDZiOGVfNTY_851f4fa7-1686-47fb-8eb1-f249602801b7">five</ix:nonFraction> acquisitions from January 1, 2019 through December 31, 2021, of which <ix:nonFraction unitRef="acquisition" contextRef="i0ccc7acfbbaf4714aeb414b4d316cace_D20190101-20211231" decimals="INF" name="us-gaap:NumberOfBusinessesAcquired" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185NC9mcmFnOmMzY2U4MjkwNTcxZTRkZWE4ZDI5ZjIzMWE1NzA2YjhlL3RleHRyZWdpb246YzNjZTgyOTA1NzFlNGRlYThkMjlmMjMxYTU3MDZiOGVfMTA5OTUxMTY0NjE1MA_069763a5-a6c7-4a3a-ac4e-b685a97188fd">three</ix:nonFraction> (Pfenex, Icagen and Ab Initio) were accounted for as business combinations and <ix:nonFraction unitRef="acquisition" contextRef="i0ccc7acfbbaf4714aeb414b4d316cace_D20190101-20211231" decimals="INF" name="lgnd:NumberOfAssetAcquisitions" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185NC9mcmFnOmMzY2U4MjkwNTcxZTRkZWE4ZDI5ZjIzMWE1NzA2YjhlL3RleHRyZWdpb246YzNjZTgyOTA1NzFlNGRlYThkMjlmMjMxYTU3MDZiOGVfMjE5OTAyMzI3MzIwOQ_27095709-c495-465c-add8-98a87f30706e">two</ix:nonFraction> (Taurus and xCella) were accounted for as asset acquisitions. For business combinations, we applied the acquisition method of accounting. Accordingly, we recorded the tangible and intangible assets acquired and liabilities assumed at their estimated fair values as of the applicable date of acquisition. Except for the Pfenex acquisition, for all other acquisitions, we did not incur any material acquisition related costs.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Pfenex Acquisition </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 1, 2020, we acquired Pfenex, which develops next-generation and novel protein therapeutics to improve existing therapies and create new therapies for biological targets linked to critical, unmet diseases using a protein expression technology platform.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The purchase price of $<ix:nonFraction unitRef="usd" contextRef="i05ca320ae7ad4dcaa5874e31460a42ed_D20201001-20201001" decimals="-5" name="us-gaap:BusinessCombinationConsiderationTransferred1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185NC9mcmFnOmMzY2U4MjkwNTcxZTRkZWE4ZDI5ZjIzMWE1NzA2YjhlL3RleHRyZWdpb246YzNjZTgyOTA1NzFlNGRlYThkMjlmMjMxYTU3MDZiOGVfOTcz_af032b42-6928-49f2-a4fb-36d915c26ac9">465.1</ix:nonFraction> million included $<ix:nonFraction unitRef="usd" contextRef="i05ca320ae7ad4dcaa5874e31460a42ed_D20201001-20201001" decimals="-5" name="us-gaap:PaymentsToAcquireBusinessesGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185NC9mcmFnOmMzY2U4MjkwNTcxZTRkZWE4ZDI5ZjIzMWE1NzA2YjhlL3RleHRyZWdpb246YzNjZTgyOTA1NzFlNGRlYThkMjlmMjMxYTU3MDZiOGVfOTg1_59d7e938-8e3d-4b70-83a2-60018f23a94c">429.6</ix:nonFraction> million cash consideration paid upon acquisition, and a contingent CVR payment of up to $<ix:nonFraction unitRef="usd" contextRef="ia9a9eb80fb244862b401f0cf7734c9d9_I20201001" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185NC9mcmFnOmMzY2U4MjkwNTcxZTRkZWE4ZDI5ZjIzMWE1NzA2YjhlL3RleHRyZWdpb246YzNjZTgyOTA1NzFlNGRlYThkMjlmMjMxYTU3MDZiOGVfMTA2OA_3885344b-4c7b-468c-a928-b880b3153371">77.8</ix:nonFraction> million in cash based on a certain specified milestone with an estimated initial fair value of $<ix:nonFraction unitRef="usd" contextRef="ia9a9eb80fb244862b401f0cf7734c9d9_I20201001" decimals="-5" name="lgnd:BusinessCombinationContingentConsiderationLiabilityFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185NC9mcmFnOmMzY2U4MjkwNTcxZTRkZWE4ZDI5ZjIzMWE1NzA2YjhlL3RleHRyZWdpb246YzNjZTgyOTA1NzFlNGRlYThkMjlmMjMxYTU3MDZiOGVfMTE1OA_25892dc7-ab3c-44ed-86a8-4e886cf21727">37.0</ix:nonFraction> million. The CVR will only be paid in full if the milestone is achieved by December 31, 2021. The amount of the CVR included in purchase price was reduced by $<ix:nonFraction unitRef="usd" contextRef="ia9a9eb80fb244862b401f0cf7734c9d9_I20201001" decimals="-5" name="us-gaap:BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185NC9mcmFnOmMzY2U4MjkwNTcxZTRkZWE4ZDI5ZjIzMWE1NzA2YjhlL3RleHRyZWdpb246YzNjZTgyOTA1NzFlNGRlYThkMjlmMjMxYTU3MDZiOGVfMTMxMQ_f40ac4ad-1c2b-4477-b8ac-a38369d548e7">1.5</ix:nonFraction>&#160;million which was determined to be post-combination expense. The fair value of the CVR liability was determined using a probability adjusted income approach. These cash flows were then discounted to present value using a discount rate based on market participants' cost of debt reflective of the Company, which was <ix:nonFraction unitRef="number" contextRef="ic9ff8c1b8ef04c2a949db89fa926c247_I20201001" decimals="3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185NC9mcmFnOmMzY2U4MjkwNTcxZTRkZWE4ZDI5ZjIzMWE1NzA2YjhlL3RleHRyZWdpb246YzNjZTgyOTA1NzFlNGRlYThkMjlmMjMxYTU3MDZiOGVfMTYyMQ_bf31a5ef-4885-4a11-9c50-05d3fb6fe56d">7.1</ix:nonFraction>%. The liability is periodically assessed based on events and circumstances related to the underlying milestone, and any change in fair value is recorded in our consolidated statements of operations. During the year ended December&#160;31, 2021, we wrote off the entire CVR liability of $<ix:nonFraction unitRef="usd" contextRef="i88f2f47e22764022b5dec2243aa219c7_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185NC9mcmFnOmMzY2U4MjkwNTcxZTRkZWE4ZDI5ZjIzMWE1NzA2YjhlL3RleHRyZWdpb246YzNjZTgyOTA1NzFlNGRlYThkMjlmMjMxYTU3MDZiOGVfNzY5NjU4MTQxMzM5Ng_009827ae-6b27-403d-b863-232e0fab0ab5">37.6</ix:nonFraction>&#160;million to other operation income, primarily due to not achieving the specific development and regulatory milestone by December 31, 2021 as defined by Pfenex CVR.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In connection with the acquisition, a portion of Pfenex's equity awards that were outstanding and unvested prior to the acquisition became fully vested per the terms of the merger agreement. The acceleration of vesting required us to allocate the fair value of the equity attributable to pre-combination service to the purchase price and the remaining amount was considered our post-combination expense. We paid $<ix:nonFraction unitRef="usd" contextRef="i05ca320ae7ad4dcaa5874e31460a42ed_D20201001-20201001" decimals="-5" name="lgnd:PaymentsToAcquireBusinessesGrossAttributableToVestedPortionOfStockOptions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185NC9mcmFnOmMzY2U4MjkwNTcxZTRkZWE4ZDI5ZjIzMWE1NzA2YjhlL3RleHRyZWdpb246YzNjZTgyOTA1NzFlNGRlYThkMjlmMjMxYTU3MDZiOGVfMjIzNg_52613896-6f1c-4460-a56b-a0cdb238c39e">17.3</ix:nonFraction> million in cash for equity compensation, which is attributable to pre-combination services and is reflected as a component of the total purchase price paid of $<ix:nonFraction unitRef="usd" contextRef="i05ca320ae7ad4dcaa5874e31460a42ed_D20201001-20201001" decimals="-5" name="us-gaap:PaymentsToAcquireBusinessesGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185NC9mcmFnOmMzY2U4MjkwNTcxZTRkZWE4ZDI5ZjIzMWE1NzA2YjhlL3RleHRyZWdpb246YzNjZTgyOTA1NzFlNGRlYThkMjlmMjMxYTU3MDZiOGVfMjM5MA_59d7e938-8e3d-4b70-83a2-60018f23a94c">429.6</ix:nonFraction> million. In addition, the fair value of equity compensation attributable to the post-combination service period was $<ix:nonFraction unitRef="usd" contextRef="i66bc35f78f7042ebafa5e4807cf87b90_D20201001-20201231" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185NC9mcmFnOmMzY2U4MjkwNTcxZTRkZWE4ZDI5ZjIzMWE1NzA2YjhlL3RleHRyZWdpb246YzNjZTgyOTA1NzFlNGRlYThkMjlmMjMxYTU3MDZiOGVfMjUwMQ_a69a7aaf-9efb-48d7-b9a1-b383e25802fd">8.7</ix:nonFraction> million. These amounts were associated with the accelerated vesting of stock options previously granted to Pfenex employees and were fully paid in cash, which was recognized as general and administrative expenses during the fourth quarter of 2020. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recorded $<ix:nonFraction unitRef="usd" contextRef="i05ca320ae7ad4dcaa5874e31460a42ed_D20201001-20201001" decimals="-5" name="us-gaap:BusinessCombinationAcquisitionRelatedCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185NC9mcmFnOmMzY2U4MjkwNTcxZTRkZWE4ZDI5ZjIzMWE1NzA2YjhlL3RleHRyZWdpb246YzNjZTgyOTA1NzFlNGRlYThkMjlmMjMxYTU3MDZiOGVfMjc1Nw_a5850e12-6c40-49ff-a4e7-a8f1a0db59a5">20.7</ix:nonFraction> million of acquisition-related costs for legal, severance and other costs in connection with the acquisition within operating expenses in our consolidated statement of operations for 2020. <ix:nonNumeric contextRef="i88f2f47e22764022b5dec2243aa219c7_D20210101-20211231" name="us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185NC9mcmFnOmMzY2U4MjkwNTcxZTRkZWE4ZDI5ZjIzMWE1NzA2YjhlL3RleHRyZWdpb246YzNjZTgyOTA1NzFlNGRlYThkMjlmMjMxYTU3MDZiOGVfMTQ5NjE_cf2733d1-03a4-410f-aa7e-1b6d28e52496" continuedAt="i6a6ef07687fb43c382baea1f78968c70" escape="true">The following table sets forth an allocation of the purchase price to the identifiable tangible and intangible assets acquired and liabilities assumed, with the excess recorded to goodwill (in thousands):</ix:nonNumeric></span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">70</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i616b3c5e157e44c1ad4e5fca3b7b763f" continuedAt="ie0914ef2adc74f648d0a3df7e0ef7983"><div><ix:continuation id="i6a6ef07687fb43c382baea1f78968c70" continuedAt="ia76de9de2c4943af83afd906be348bda"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.449%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.351%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash </span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9a9eb80fb244862b401f0cf7734c9d9_I20201001" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185NC9mcmFnOmMzY2U4MjkwNTcxZTRkZWE4ZDI5ZjIzMWE1NzA2YjhlL3RhYmxlOjAzNzhiODQzYjM0YjQxZjA4MTUzMzQwMGRlY2VkYzQ3L3RhYmxlcmFuZ2U6MDM3OGI4NDNiMzRiNDFmMDgxNTMzNDAwZGVjZWRjNDdfMC0xLTEtMS00MTI5NA_32212071-04c2-4522-af36-19d05f49a392">51,407</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9a9eb80fb244862b401f0cf7734c9d9_I20201001" decimals="-3" name="lgnd:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185NC9mcmFnOmMzY2U4MjkwNTcxZTRkZWE4ZDI5ZjIzMWE1NzA2YjhlL3RhYmxlOjAzNzhiODQzYjM0YjQxZjA4MTUzMzQwMGRlY2VkYzQ3L3RhYmxlcmFuZ2U6MDM3OGI4NDNiMzRiNDFmMDgxNTMzNDAwZGVjZWRjNDdfMS0xLTEtMS00MTI5NA_2c70c81a-1fd9-4d67-a4e4-d1a71e618a81">200</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts and unbilled receivables</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9a9eb80fb244862b401f0cf7734c9d9_I20201001" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185NC9mcmFnOmMzY2U4MjkwNTcxZTRkZWE4ZDI5ZjIzMWE1NzA2YjhlL3RhYmxlOjAzNzhiODQzYjM0YjQxZjA4MTUzMzQwMGRlY2VkYzQ3L3RhYmxlcmFuZ2U6MDM3OGI4NDNiMzRiNDFmMDgxNTMzNDAwZGVjZWRjNDdfMi0xLTEtMS00MTI5NA_eb65500c-1271-4b0e-bfb0-24312b15615e">1,359</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9a9eb80fb244862b401f0cf7734c9d9_I20201001" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185NC9mcmFnOmMzY2U4MjkwNTcxZTRkZWE4ZDI5ZjIzMWE1NzA2YjhlL3RhYmxlOjAzNzhiODQzYjM0YjQxZjA4MTUzMzQwMGRlY2VkYzQ3L3RhYmxlcmFuZ2U6MDM3OGI4NDNiMzRiNDFmMDgxNTMzNDAwZGVjZWRjNDdfMy0xLTEtMS00MTI5NA_c8fc10f5-d7d4-4deb-9e64-f16f0d0ea0d8">7,823</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use asset</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9a9eb80fb244862b401f0cf7734c9d9_I20201001" decimals="-3" name="lgnd:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185NC9mcmFnOmMzY2U4MjkwNTcxZTRkZWE4ZDI5ZjIzMWE1NzA2YjhlL3RhYmxlOjAzNzhiODQzYjM0YjQxZjA4MTUzMzQwMGRlY2VkYzQ3L3RhYmxlcmFuZ2U6MDM3OGI4NDNiMzRiNDFmMDgxNTMzNDAwZGVjZWRjNDdfNC0xLTEtMS00MTI5NA_7c5add1d-f429-40b5-885a-094aa054a2d3">3,070</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9a9eb80fb244862b401f0cf7734c9d9_I20201001" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185NC9mcmFnOmMzY2U4MjkwNTcxZTRkZWE4ZDI5ZjIzMWE1NzA2YjhlL3RhYmxlOjAzNzhiODQzYjM0YjQxZjA4MTUzMzQwMGRlY2VkYzQ3L3RhYmxlcmFuZ2U6MDM3OGI4NDNiMzRiNDFmMDgxNTMzNDAwZGVjZWRjNDdfNS0xLTEtMS00MTI5NA_8bc7a9e0-29eb-4154-8dd9-ed689e65cf41">1,338</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangibles acquired</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9a9eb80fb244862b401f0cf7734c9d9_I20201001" decimals="-3" name="lgnd:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185NC9mcmFnOmMzY2U4MjkwNTcxZTRkZWE4ZDI5ZjIzMWE1NzA2YjhlL3RhYmxlOjAzNzhiODQzYjM0YjQxZjA4MTUzMzQwMGRlY2VkYzQ3L3RhYmxlcmFuZ2U6MDM3OGI4NDNiMzRiNDFmMDgxNTMzNDAwZGVjZWRjNDdfNi0xLTEtMS00MTI5NA_4659f685-9a21-4d2f-a62a-2d0dd6705365">385,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9a9eb80fb244862b401f0cf7734c9d9_I20201001" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185NC9mcmFnOmMzY2U4MjkwNTcxZTRkZWE4ZDI5ZjIzMWE1NzA2YjhlL3RhYmxlOjAzNzhiODQzYjM0YjQxZjA4MTUzMzQwMGRlY2VkYzQ3L3RhYmxlcmFuZ2U6MDM3OGI4NDNiMzRiNDFmMDgxNTMzNDAwZGVjZWRjNDdfNy0xLTEtMS00MTI5NA_d1023425-22d5-4b50-a60e-301c97452ca1">82,303</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia9a9eb80fb244862b401f0cf7734c9d9_I20201001" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185NC9mcmFnOmMzY2U4MjkwNTcxZTRkZWE4ZDI5ZjIzMWE1NzA2YjhlL3RhYmxlOjAzNzhiODQzYjM0YjQxZjA4MTUzMzQwMGRlY2VkYzQ3L3RhYmxlcmFuZ2U6MDM3OGI4NDNiMzRiNDFmMDgxNTMzNDAwZGVjZWRjNDdfOC0xLTEtMS00MTI5NA_a3b82e74-4e2c-4945-95ce-c4283d436591">6,814</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia9a9eb80fb244862b401f0cf7734c9d9_I20201001" decimals="-3" name="lgnd:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185NC9mcmFnOmMzY2U4MjkwNTcxZTRkZWE4ZDI5ZjIzMWE1NzA2YjhlL3RhYmxlOjAzNzhiODQzYjM0YjQxZjA4MTUzMzQwMGRlY2VkYzQ3L3RhYmxlcmFuZ2U6MDM3OGI4NDNiMzRiNDFmMDgxNTMzNDAwZGVjZWRjNDdfOS0xLTEtMS00MTI5NA_93553fe9-d92b-4bb1-a434-aba9c514dae4">9,606</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia9a9eb80fb244862b401f0cf7734c9d9_I20201001" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185NC9mcmFnOmMzY2U4MjkwNTcxZTRkZWE4ZDI5ZjIzMWE1NzA2YjhlL3RhYmxlOjAzNzhiODQzYjM0YjQxZjA4MTUzMzQwMGRlY2VkYzQ3L3RhYmxlcmFuZ2U6MDM3OGI4NDNiMzRiNDFmMDgxNTMzNDAwZGVjZWRjNDdfMTAtMS0xLTEtNDEyOTQ_9a1f3910-a2a9-4a5d-9bb2-6c709fca0637">3,908</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia9a9eb80fb244862b401f0cf7734c9d9_I20201001" decimals="-3" name="lgnd:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLeaseLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185NC9mcmFnOmMzY2U4MjkwNTcxZTRkZWE4ZDI5ZjIzMWE1NzA2YjhlL3RhYmxlOjAzNzhiODQzYjM0YjQxZjA4MTUzMzQwMGRlY2VkYzQ3L3RhYmxlcmFuZ2U6MDM3OGI4NDNiMzRiNDFmMDgxNTMzNDAwZGVjZWRjNDdfMTEtMS0xLTEtNDEyOTQ_6d8f74cc-0ef9-4ff7-81c2-24578a3ac5f9">3,070</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia9a9eb80fb244862b401f0cf7734c9d9_I20201001" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185NC9mcmFnOmMzY2U4MjkwNTcxZTRkZWE4ZDI5ZjIzMWE1NzA2YjhlL3RhYmxlOjAzNzhiODQzYjM0YjQxZjA4MTUzMzQwMGRlY2VkYzQ3L3RhYmxlcmFuZ2U6MDM3OGI4NDNiMzRiNDFmMDgxNTMzNDAwZGVjZWRjNDdfMTItMS0xLTEtNDEyOTQ_f0b33175-22b1-4df7-abb3-b6a9e5a46385">1,382</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia9a9eb80fb244862b401f0cf7734c9d9_I20201001" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185NC9mcmFnOmMzY2U4MjkwNTcxZTRkZWE4ZDI5ZjIzMWE1NzA2YjhlL3RhYmxlOjAzNzhiODQzYjM0YjQxZjA4MTUzMzQwMGRlY2VkYzQ3L3RhYmxlcmFuZ2U6MDM3OGI4NDNiMzRiNDFmMDgxNTMzNDAwZGVjZWRjNDdfMTMtMS0xLTEtNDEyOTQ_808ef26b-d30a-4fcc-b262-1786773f66c1">42,622</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 61pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total consideration</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9a9eb80fb244862b401f0cf7734c9d9_I20201001" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185NC9mcmFnOmMzY2U4MjkwNTcxZTRkZWE4ZDI5ZjIzMWE1NzA2YjhlL3RhYmxlOjAzNzhiODQzYjM0YjQxZjA4MTUzMzQwMGRlY2VkYzQ3L3RhYmxlcmFuZ2U6MDM3OGI4NDNiMzRiNDFmMDgxNTMzNDAwZGVjZWRjNDdfMTQtMS0xLTEtNDEyOTQ_abf4ebaa-48d0-490d-bda3-6e94644f0b45">465,098</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%"><ix:continuation id="ia76de9de2c4943af83afd906be348bda">(1) Goodwill represents the excess of the purchase price over the preliminary fair value of the underlying assets acquired and liabilities assumed. Goodwill is attributable to the assembled workforce of experienced personnel at Pfenex and expected synergies. None of the goodwill is deductible for tax purposes.</ix:continuation> </span></div><div><span><br/></span></div><ix:nonNumeric contextRef="i88f2f47e22764022b5dec2243aa219c7_D20210101-20211231" name="us-gaap:ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185NC9mcmFnOmMzY2U4MjkwNTcxZTRkZWE4ZDI5ZjIzMWE1NzA2YjhlL3RleHRyZWdpb246YzNjZTgyOTA1NzFlNGRlYThkMjlmMjMxYTU3MDZiOGVfMTQ5NjI_138fa0f7-dd69-40c6-869d-f50c947d6335" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The intangibles acquired and their weighted average useful life are as follows (in thousands, except useful lives):</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.707%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.497%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Approximate<br/>Fair Value</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Estimated useful life<br/>(in years)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contractual Relationships:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Alvogen</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95cf6d8d9303402492315ef907402a1a_I20201001" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185NC9mcmFnOmMzY2U4MjkwNTcxZTRkZWE4ZDI5ZjIzMWE1NzA2YjhlL3RhYmxlOmYyN2QxODFlYTFkNzQyMTRiNjgxOGJhOWYzMzI2YWNiL3RhYmxlcmFuZ2U6ZjI3ZDE4MWVhMWQ3NDIxNGI2ODE4YmE5ZjMzMjZhY2JfMi0xLTEtMS00MTI5NA_deb5ebb8-7c4a-4d6f-9d48-b5c35cbbfe4e">114,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i3639b90349a0416597ac3b2345fcfd8b_D20201001-20201001" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185NC9mcmFnOmMzY2U4MjkwNTcxZTRkZWE4ZDI5ZjIzMWE1NzA2YjhlL3RhYmxlOmYyN2QxODFlYTFkNzQyMTRiNjgxOGJhOWYzMzI2YWNiL3RhYmxlcmFuZ2U6ZjI3ZDE4MWVhMWQ3NDIxNGI2ODE4YmE5ZjMzMjZhY2JfMi0yLTEtMS00MTI5NA_7d924aa0-1c95-4276-926d-3f807305b561">12</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Merck</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6618eb064ffd4735b65d23c002f29a3d_I20201001" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185NC9mcmFnOmMzY2U4MjkwNTcxZTRkZWE4ZDI5ZjIzMWE1NzA2YjhlL3RhYmxlOmYyN2QxODFlYTFkNzQyMTRiNjgxOGJhOWYzMzI2YWNiL3RhYmxlcmFuZ2U6ZjI3ZDE4MWVhMWQ3NDIxNGI2ODE4YmE5ZjMzMjZhY2JfMy0xLTEtMS00MTI5NA_c3585f4c-efda-4fb7-b22d-c27ff40f95a2">117,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ia025b98444b84bf38bee7c4b59d60941_D20201001-20201001" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185NC9mcmFnOmMzY2U4MjkwNTcxZTRkZWE4ZDI5ZjIzMWE1NzA2YjhlL3RhYmxlOmYyN2QxODFlYTFkNzQyMTRiNjgxOGJhOWYzMzI2YWNiL3RhYmxlcmFuZ2U6ZjI3ZDE4MWVhMWQ3NDIxNGI2ODE4YmE5ZjMzMjZhY2JfMy0yLTEtMS00MTI5NA_cf6045e6-7acf-4636-8364-edd27256644a">12</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jazz</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9687ebeaf03c4246885f9a884dc564ee_I20201001" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185NC9mcmFnOmMzY2U4MjkwNTcxZTRkZWE4ZDI5ZjIzMWE1NzA2YjhlL3RhYmxlOmYyN2QxODFlYTFkNzQyMTRiNjgxOGJhOWYzMzI2YWNiL3RhYmxlcmFuZ2U6ZjI3ZDE4MWVhMWQ3NDIxNGI2ODE4YmE5ZjMzMjZhY2JfNC0xLTEtMS00MTI5NA_9217bcf6-fb34-47ea-a4bb-fee88e89766c">80,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i74a5e3f1fdec4b96b148fb5871cc991f_D20201001-20201001" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185NC9mcmFnOmMzY2U4MjkwNTcxZTRkZWE4ZDI5ZjIzMWE1NzA2YjhlL3RhYmxlOmYyN2QxODFlYTFkNzQyMTRiNjgxOGJhOWYzMzI2YWNiL3RhYmxlcmFuZ2U6ZjI3ZDE4MWVhMWQ3NDIxNGI2ODE4YmE5ZjMzMjZhY2JfNC0yLTEtMS00MTI5NA_4c98e215-b669-4ca3-a85c-88aed3e2489e">17</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SII</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d2ed9e3e4254c8aa989182cdea6b83e_I20201001" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185NC9mcmFnOmMzY2U4MjkwNTcxZTRkZWE4ZDI5ZjIzMWE1NzA2YjhlL3RhYmxlOmYyN2QxODFlYTFkNzQyMTRiNjgxOGJhOWYzMzI2YWNiL3RhYmxlcmFuZ2U6ZjI3ZDE4MWVhMWQ3NDIxNGI2ODE4YmE5ZjMzMjZhY2JfNS0xLTEtMS00MTI5NA_017c8f9c-16bd-4fb8-8c68-818724599722">49,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i5263ecacba2e40a0bef60af7f8f3323f_D20201001-20201001" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185NC9mcmFnOmMzY2U4MjkwNTcxZTRkZWE4ZDI5ZjIzMWE1NzA2YjhlL3RhYmxlOmYyN2QxODFlYTFkNzQyMTRiNjgxOGJhOWYzMzI2YWNiL3RhYmxlcmFuZ2U6ZjI3ZDE4MWVhMWQ3NDIxNGI2ODE4YmE5ZjMzMjZhY2JfNS0yLTEtMS00MTI5NA_ec87116d-120b-44d3-b387-4b6a6cd81746">10</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Arcellx</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i77b01aad4684478a851c8f13a0d12891_I20201001" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185NC9mcmFnOmMzY2U4MjkwNTcxZTRkZWE4ZDI5ZjIzMWE1NzA2YjhlL3RhYmxlOmYyN2QxODFlYTFkNzQyMTRiNjgxOGJhOWYzMzI2YWNiL3RhYmxlcmFuZ2U6ZjI3ZDE4MWVhMWQ3NDIxNGI2ODE4YmE5ZjMzMjZhY2JfNi0xLTEtMS00MTI5NA_6a5af3f8-8d64-4c68-a699-5fd8f81b0738">2,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="id59883d6b9fe4a63b608829d498699ce_D20201001-20201001" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185NC9mcmFnOmMzY2U4MjkwNTcxZTRkZWE4ZDI5ZjIzMWE1NzA2YjhlL3RhYmxlOmYyN2QxODFlYTFkNzQyMTRiNjgxOGJhOWYzMzI2YWNiL3RhYmxlcmFuZ2U6ZjI3ZDE4MWVhMWQ3NDIxNGI2ODE4YmE5ZjMzMjZhY2JfNi0yLTEtMS00MTI5NA_cc149041-d23d-4f8e-b521-9361edce1538">17</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired Technologies</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65ac1d8a3b63426baa11a41236151bd8_I20201001" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185NC9mcmFnOmMzY2U4MjkwNTcxZTRkZWE4ZDI5ZjIzMWE1NzA2YjhlL3RhYmxlOmYyN2QxODFlYTFkNzQyMTRiNjgxOGJhOWYzMzI2YWNiL3RhYmxlcmFuZ2U6ZjI3ZDE4MWVhMWQ3NDIxNGI2ODE4YmE5ZjMzMjZhY2JfNy0xLTEtMS00MTI5NA_501f726c-1c1b-41cd-8b08-b596cef613b6">23,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="id301d12eff0d4b76a98f1b19b7aa97fd_D20201001-20201001" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185NC9mcmFnOmMzY2U4MjkwNTcxZTRkZWE4ZDI5ZjIzMWE1NzA2YjhlL3RhYmxlOmYyN2QxODFlYTFkNzQyMTRiNjgxOGJhOWYzMzI2YWNiL3RhYmxlcmFuZ2U6ZjI3ZDE4MWVhMWQ3NDIxNGI2ODE4YmE5ZjMzMjZhY2JfNy0yLTEtMS00MTI5NC90ZXh0cmVnaW9uOjhmN2Q5NDM4ZjUzODQ3MTNiZDAzODA4NWRiYjE3MjFmXzQ_6c6cdf7e-b6e7-4af5-804a-3849ab07cd48">10</ix:nonNumeric>-<ix:nonNumeric contextRef="ib687713e39394d8883330adccb1296e4_D20201001-20201001" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185NC9mcmFnOmMzY2U4MjkwNTcxZTRkZWE4ZDI5ZjIzMWE1NzA2YjhlL3RhYmxlOmYyN2QxODFlYTFkNzQyMTRiNjgxOGJhOWYzMzI2YWNiL3RhYmxlcmFuZ2U6ZjI3ZDE4MWVhMWQ3NDIxNGI2ODE4YmE5ZjMzMjZhY2JfNy0yLTEtMS00MTI5NC90ZXh0cmVnaW9uOjhmN2Q5NDM4ZjUzODQ3MTNiZDAzODA4NWRiYjE3MjFmXzc_13315e8e-bd8b-4e7e-9567-991a6079cd17">19</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9a9eb80fb244862b401f0cf7734c9d9_I20201001" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185NC9mcmFnOmMzY2U4MjkwNTcxZTRkZWE4ZDI5ZjIzMWE1NzA2YjhlL3RhYmxlOmYyN2QxODFlYTFkNzQyMTRiNjgxOGJhOWYzMzI2YWNiL3RhYmxlcmFuZ2U6ZjI3ZDE4MWVhMWQ3NDIxNGI2ODE4YmE5ZjMzMjZhY2JfOC0xLTEtMS00MTI5NA_e531122f-c866-42bc-baf0-ee7089b63349">385,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of the contractual relationships were based on the discounted cash flow method that estimated the present value of the potential royalties, milestones and collaboration revenue streams derived from the licensing of the related technologies over the estimated contractual relationship period. The fair values of the acquired technologies were based on the discounted cash flow method that estimated the present value of the potential royalties, milestones, collaboration and product revenue streams derived from the licensing of the related technologies over the estimated useful lives. These projected cash flows were discounted to present value using discount rate, which varies from <ix:nonFraction unitRef="number" contextRef="i4c77fc6eecd341e48bc7b99f95972ddf_D20200401-20200401" decimals="INF" name="lgnd:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185NC9mcmFnOmMzY2U4MjkwNTcxZTRkZWE4ZDI5ZjIzMWE1NzA2YjhlL3RleHRyZWdpb246YzNjZTgyOTA1NzFlNGRlYThkMjlmMjMxYTU3MDZiOGVfNDMwOQ_0a7af5b9-5aad-4e09-9455-418ada80d9eb">12</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="if97f9e0769b54e6a845f9f9fc59f0a1a_D20200401-20200401" decimals="INF" name="lgnd:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185NC9mcmFnOmMzY2U4MjkwNTcxZTRkZWE4ZDI5ZjIzMWE1NzA2YjhlL3RleHRyZWdpb246YzNjZTgyOTA1NzFlNGRlYThkMjlmMjMxYTU3MDZiOGVfNDMxNQ_3ff8e6d8-a635-49b9-9df0-a6ac72915957">15</ix:nonFraction>%. The intangible assets acquired are being amortized on a straight-line basis over the estimated useful life. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Approximately $<ix:nonFraction unitRef="usd" contextRef="i81ce7b0c06a94e61a7d245d6544346aa_D20200101-20201231" decimals="-5" name="us-gaap:BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185NC9mcmFnOmMzY2U4MjkwNTcxZTRkZWE4ZDI5ZjIzMWE1NzA2YjhlL3RleHRyZWdpb246YzNjZTgyOTA1NzFlNGRlYThkMjlmMjMxYTU3MDZiOGVfNDgzNQ_cb5532bf-8001-4f92-9dd5-e2a13eee7c62">2.0</ix:nonFraction> million of revenue and $<ix:nonFraction unitRef="usd" contextRef="i81ce7b0c06a94e61a7d245d6544346aa_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185NC9mcmFnOmMzY2U4MjkwNTcxZTRkZWE4ZDI5ZjIzMWE1NzA2YjhlL3RleHRyZWdpb246YzNjZTgyOTA1NzFlNGRlYThkMjlmMjMxYTU3MDZiOGVfNDg1Mw_3a7c2b1c-7952-4f94-99ca-2e1c6875d9d0">19.3</ix:nonFraction> million of loss before income taxes of Pfenex were included in the consolidated statement of operations for the year ended December 31, 2020. The following summary presents our unaudited pro forma consolidated results of operations for the years ended December 31, 2020 and December 31, 2019 as if the Pfenex acquisition had occurred on January 1, 2019, which gives effect to certain transaction accounting adjustments, including amortization of acquired intangibles and stock based compensation expense for retained Pfenex employees. The transaction accounting adjustments do not include non-recurring adjustments related to Pfenex's executive salary, board of director compensation, and salary of Pfenex employees involved in the reduction of force as part of the acquisition, estimated to be $<ix:nonFraction unitRef="usd" contextRef="i81ce7b0c06a94e61a7d245d6544346aa_D20200101-20201231" decimals="-5" name="us-gaap:BusinessCombinationIntegrationRelatedCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185NC9mcmFnOmMzY2U4MjkwNTcxZTRkZWE4ZDI5ZjIzMWE1NzA2YjhlL3RleHRyZWdpb246YzNjZTgyOTA1NzFlNGRlYThkMjlmMjMxYTU3MDZiOGVfNTU5OA_df1553b4-ed80-4ced-a652-0d7886dc9a59">7.1</ix:nonFraction> million in 2020 and $<ix:nonFraction unitRef="usd" contextRef="i981dcf3e258143ef926ca153a290587b_D20190101-20191231" decimals="-5" name="us-gaap:BusinessCombinationIntegrationRelatedCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185NC9mcmFnOmMzY2U4MjkwNTcxZTRkZWE4ZDI5ZjIzMWE1NzA2YjhlL3RleHRyZWdpb246YzNjZTgyOTA1NzFlNGRlYThkMjlmMjMxYTU3MDZiOGVfNTYxMw_7d23bbaf-786f-4809-87da-e88a6332f2a8">4.8</ix:nonFraction>&#160;million in 2019. <ix:nonNumeric contextRef="i88f2f47e22764022b5dec2243aa219c7_D20210101-20211231" name="us-gaap:BusinessAcquisitionProFormaInformationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185NC9mcmFnOmMzY2U4MjkwNTcxZTRkZWE4ZDI5ZjIzMWE1NzA2YjhlL3RleHRyZWdpb246YzNjZTgyOTA1NzFlNGRlYThkMjlmMjMxYTU3MDZiOGVfMTQ5NjA_6bf770d2-dec1-46fc-9877-ed33108a24cf" continuedAt="i9c64906b3420403d9ce9bc393bb8935a" escape="true">The pro forma financial information is not necessarily indicative of the operating results that would have occurred had the acquisition been consummated as if the date indicated, nor is it necessarily indicative of future operating results (in thousands, except per share amounts):</ix:nonNumeric></span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">71</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ie0914ef2adc74f648d0a3df7e0ef7983" continuedAt="iff2afa6d345f46c0aa7295728c825a99"><div><ix:continuation id="i9c64906b3420403d9ce9bc393bb8935a"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.707%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.497%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Unaudited)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88f2f47e22764022b5dec2243aa219c7_D20210101-20211231" decimals="-3" name="us-gaap:BusinessAcquisitionsProFormaRevenue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185NC9mcmFnOmMzY2U4MjkwNTcxZTRkZWE4ZDI5ZjIzMWE1NzA2YjhlL3RhYmxlOjhhMWEyNTY5MjNhMTRjY2ViMjZiM2ZlY2RlMDI4MDZjL3RhYmxlcmFuZ2U6OGExYTI1NjkyM2ExNGNjZWIyNmIzZmVjZGUwMjgwNmNfMi0xLTEtMS00MTI5NA_d2e37e6c-1377-4333-b35f-4ea50ef95f37">189,203</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81ce7b0c06a94e61a7d245d6544346aa_D20200101-20201231" decimals="-3" name="us-gaap:BusinessAcquisitionsProFormaRevenue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185NC9mcmFnOmMzY2U4MjkwNTcxZTRkZWE4ZDI5ZjIzMWE1NzA2YjhlL3RhYmxlOjhhMWEyNTY5MjNhMTRjY2ViMjZiM2ZlY2RlMDI4MDZjL3RhYmxlcmFuZ2U6OGExYTI1NjkyM2ExNGNjZWIyNmIzZmVjZGUwMjgwNmNfMi0yLTEtMS00MTI5NA_cf5cca03-95c0-49af-a50b-b577dc4df3cc">170,608</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net Income (loss)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i88f2f47e22764022b5dec2243aa219c7_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185NC9mcmFnOmMzY2U4MjkwNTcxZTRkZWE4ZDI5ZjIzMWE1NzA2YjhlL3RhYmxlOjhhMWEyNTY5MjNhMTRjY2ViMjZiM2ZlY2RlMDI4MDZjL3RhYmxlcmFuZ2U6OGExYTI1NjkyM2ExNGNjZWIyNmIzZmVjZGUwMjgwNmNfMy0xLTEtMS00MTI5NA_9c6f1a28-f7d2-4fe4-8a53-feb8125f654e">60,059</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81ce7b0c06a94e61a7d245d6544346aa_D20200101-20201231" decimals="-3" name="us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185NC9mcmFnOmMzY2U4MjkwNTcxZTRkZWE4ZDI5ZjIzMWE1NzA2YjhlL3RhYmxlOjhhMWEyNTY5MjNhMTRjY2ViMjZiM2ZlY2RlMDI4MDZjL3RhYmxlcmFuZ2U6OGExYTI1NjkyM2ExNGNjZWIyNmIzZmVjZGUwMjgwNmNfMy0yLTEtMS00MTI5NA_4d2587cc-10eb-46f7-96e1-5e83fb57a5e3">594,941</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net income (loss) per common share:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Basic</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i88f2f47e22764022b5dec2243aa219c7_D20210101-20211231" decimals="2" sign="-" name="us-gaap:BusinessAcquisitionProFormaEarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185NC9mcmFnOmMzY2U4MjkwNTcxZTRkZWE4ZDI5ZjIzMWE1NzA2YjhlL3RhYmxlOjhhMWEyNTY5MjNhMTRjY2ViMjZiM2ZlY2RlMDI4MDZjL3RhYmxlcmFuZ2U6OGExYTI1NjkyM2ExNGNjZWIyNmIzZmVjZGUwMjgwNmNfNS0xLTEtMS00MTI5NA_8ef1aba0-40ab-4a52-ac55-10206585e3d2">3.71</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i81ce7b0c06a94e61a7d245d6544346aa_D20200101-20201231" decimals="2" name="us-gaap:BusinessAcquisitionProFormaEarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185NC9mcmFnOmMzY2U4MjkwNTcxZTRkZWE4ZDI5ZjIzMWE1NzA2YjhlL3RhYmxlOjhhMWEyNTY5MjNhMTRjY2ViMjZiM2ZlY2RlMDI4MDZjL3RhYmxlcmFuZ2U6OGExYTI1NjkyM2ExNGNjZWIyNmIzZmVjZGUwMjgwNmNfNS0yLTEtMS00MTI5NA_32cd0c04-5c98-4f98-8ad6-70690149de65">31.32</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Diluted</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i88f2f47e22764022b5dec2243aa219c7_D20210101-20211231" decimals="2" sign="-" name="us-gaap:BusinessAcquisitionProFormaEarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185NC9mcmFnOmMzY2U4MjkwNTcxZTRkZWE4ZDI5ZjIzMWE1NzA2YjhlL3RhYmxlOjhhMWEyNTY5MjNhMTRjY2ViMjZiM2ZlY2RlMDI4MDZjL3RhYmxlcmFuZ2U6OGExYTI1NjkyM2ExNGNjZWIyNmIzZmVjZGUwMjgwNmNfNi0xLTEtMS00MTI5NA_70cb6f28-c254-4d6c-ad87-bd02fa70c7d0">3.71</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i81ce7b0c06a94e61a7d245d6544346aa_D20200101-20201231" decimals="2" name="us-gaap:BusinessAcquisitionProFormaEarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185NC9mcmFnOmMzY2U4MjkwNTcxZTRkZWE4ZDI5ZjIzMWE1NzA2YjhlL3RhYmxlOjhhMWEyNTY5MjNhMTRjY2ViMjZiM2ZlY2RlMDI4MDZjL3RhYmxlcmFuZ2U6OGExYTI1NjkyM2ExNGNjZWIyNmIzZmVjZGUwMjgwNmNfNi0yLTEtMS00MTI5NA_2625508e-fa06-40a6-a1ae-f702d70354b6">30.11</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Taurus Acquisition</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 9, 2020, we acquired Taurus, which discovers and develops novel antibodies from immunized cows and cow-derived libraries. These antibodies feature some of the longest CDR3s of any species, with unique genetic and structural diversity that can enable binding to challenging antigens with application in therapeutics, diagnostics and research.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The purchase price of  $<ix:nonFraction unitRef="usd" contextRef="i77d1ae0e9cea4bc5be7e9ef1c1f3a41d_D20200909-20200909" decimals="-5" name="us-gaap:BusinessCombinationConsiderationTransferred1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185NC9mcmFnOmMzY2U4MjkwNTcxZTRkZWE4ZDI5ZjIzMWE1NzA2YjhlL3RleHRyZWdpb246YzNjZTgyOTA1NzFlNGRlYThkMjlmMjMxYTU3MDZiOGVfNjMxMQ_a2d408be-6b03-4b98-82da-99cb9e6b5981">5.1</ix:nonFraction> million included $<ix:nonFraction unitRef="usd" contextRef="i77d1ae0e9cea4bc5be7e9ef1c1f3a41d_D20200909-20200909" decimals="-5" name="us-gaap:PaymentsToAcquireBusinessesGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185NC9mcmFnOmMzY2U4MjkwNTcxZTRkZWE4ZDI5ZjIzMWE1NzA2YjhlL3RleHRyZWdpb246YzNjZTgyOTA1NzFlNGRlYThkMjlmMjMxYTU3MDZiOGVfNjMyMw_8be3d7d3-10ff-4adb-8ec7-766a824cbf31">4.6</ix:nonFraction> million in cash, and a $<ix:nonFraction unitRef="usd" contextRef="i77d1ae0e9cea4bc5be7e9ef1c1f3a41d_D20200909-20200909" decimals="-5" name="lgnd:BusinessCombinationConsiderationTransferredHoldback" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185NC9mcmFnOmMzY2U4MjkwNTcxZTRkZWE4ZDI5ZjIzMWE1NzA2YjhlL3RleHRyZWdpb246YzNjZTgyOTA1NzFlNGRlYThkMjlmMjMxYTU3MDZiOGVfNjM0MQ_19a75eed-f00f-4c47-995c-cf2577537ed1">0.5</ix:nonFraction> million holdback to satisfy indemnification obligations which will be settled by September 2021. We also issued nontransferable CVRs for up to $<ix:nonFraction unitRef="usd" contextRef="i4dba26cb1a1841e88daa2e5a24a15dd4_I20200909" decimals="INF" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185NC9mcmFnOmMzY2U4MjkwNTcxZTRkZWE4ZDI5ZjIzMWE1NzA2YjhlL3RleHRyZWdpb246YzNjZTgyOTA1NzFlNGRlYThkMjlmMjMxYTU3MDZiOGVfNjQ3OQ_6099147d-8f0f-45d5-a92f-110ec1cf277c">4.5</ix:nonFraction> million tied to partnered and internal research and development and for up to $<ix:nonFraction unitRef="usd" contextRef="i473bb8ab24bf433bb5e1980d2a87164e_I20200909" decimals="INF" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185NC9mcmFnOmMzY2U4MjkwNTcxZTRkZWE4ZDI5ZjIzMWE1NzA2YjhlL3RleHRyZWdpb246YzNjZTgyOTA1NzFlNGRlYThkMjlmMjMxYTU3MDZiOGVfNjU1Mg_e520db15-b3de-4479-a6e7-97c6a83a5d69">25.0</ix:nonFraction> million as a <ix:nonFraction unitRef="number" contextRef="i27ca37b8f6ed451391cf76d3832dccdb_D20200909-20200909" decimals="INF" name="lgnd:BusinessCombinationContingentConsiderationLiabilityPercentageOfAcquireeRevenues" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185NC9mcmFnOmMzY2U4MjkwNTcxZTRkZWE4ZDI5ZjIzMWE1NzA2YjhlL3RleHRyZWdpb246YzNjZTgyOTA1NzFlNGRlYThkMjlmMjMxYTU3MDZiOGVfNjU2MA_9d49d563-12d7-48c3-844a-2ad9175a6e13">25</ix:nonFraction>% share of post-clinical Taurus product revenues (including milestone payments) received by us. We accounted for this transaction as an asset acquisition as we concluded that substantially all of the fair value of the gross assets acquired was concentrated in the acquired core technology. </span></div><div><span><br/></span></div><ix:nonNumeric contextRef="i36eaffe97d9f4ad9b8c509ecec687717_D20210101-20211231" name="us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185NC9mcmFnOmMzY2U4MjkwNTcxZTRkZWE4ZDI5ZjIzMWE1NzA2YjhlL3RleHRyZWdpb246YzNjZTgyOTA1NzFlNGRlYThkMjlmMjMxYTU3MDZiOGVfMTQ5NjM_274715ee-7e7d-4913-bbd1-82fbf6b02823" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The allocation of the consideration was allocated to the acquisition date fair values of acquired assets as follows (in thousands)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.303%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.497%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37f8f2fb62fb45eda8a94c6014fb06c3_I20200909" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185NC9mcmFnOmMzY2U4MjkwNTcxZTRkZWE4ZDI5ZjIzMWE1NzA2YjhlL3RhYmxlOjNmOTEzYTFiZTQ5ODQ2ZWVhZGUxMjJhY2MyMDkzYmRkL3RhYmxlcmFuZ2U6M2Y5MTNhMWJlNDk4NDZlZWFkZTEyMmFjYzIwOTNiZGRfMC0xLTEtMS00MTI5NA_6363f2a2-88a2-464d-a2a5-21db8bb2fc4e">47</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangibles assets with finite-life - core technologies</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37f8f2fb62fb45eda8a94c6014fb06c3_I20200909" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185NC9mcmFnOmMzY2U4MjkwNTcxZTRkZWE4ZDI5ZjIzMWE1NzA2YjhlL3RhYmxlOjNmOTEzYTFiZTQ5ODQ2ZWVhZGUxMjJhY2MyMDkzYmRkL3RhYmxlcmFuZ2U6M2Y5MTNhMWJlNDk4NDZlZWFkZTEyMmFjYzIwOTNiZGRfMS0xLTEtMS00MTI5NA_ce2b9a70-2bf5-45ae-b236-b7f66876026d">5,005</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37f8f2fb62fb45eda8a94c6014fb06c3_I20200909" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185NC9mcmFnOmMzY2U4MjkwNTcxZTRkZWE4ZDI5ZjIzMWE1NzA2YjhlL3RhYmxlOjNmOTEzYTFiZTQ5ODQ2ZWVhZGUxMjJhY2MyMDkzYmRkL3RhYmxlcmFuZ2U6M2Y5MTNhMWJlNDk4NDZlZWFkZTEyMmFjYzIwOTNiZGRfMi0xLTEtMS00MTI5NA_ae42990e-f633-4dca-85e6-1e0247a01715">5,052</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The core technology is being amortized on a straight-line basis over the estimated useful life of <ix:nonNumeric contextRef="i1decdab2b3ad4d5f9e9970051e074f04_D20200909-20200909" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185NC9mcmFnOmMzY2U4MjkwNTcxZTRkZWE4ZDI5ZjIzMWE1NzA2YjhlL3RleHRyZWdpb246YzNjZTgyOTA1NzFlNGRlYThkMjlmMjMxYTU3MDZiOGVfNzA4Ng_fe455325-22d3-440b-a395-9593af6f6e13">10</ix:nonNumeric> years. We account for the CVRs in accordance with ASC 450, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contingencies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, when the contingency is resolved and the liability becomes payable. <ix:nonFraction unitRef="usd" contextRef="i37f8f2fb62fb45eda8a94c6014fb06c3_I20200909" decimals="INF" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185NC9mcmFnOmMzY2U4MjkwNTcxZTRkZWE4ZDI5ZjIzMWE1NzA2YjhlL3RleHRyZWdpb246YzNjZTgyOTA1NzFlNGRlYThkMjlmMjMxYTU3MDZiOGVfNzIyNQ_89b5e0d0-2a70-4731-9aca-1a1999ee0425">None</ix:nonFraction> of the CVRs are recognized as of the acquisition date.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">xCella Acquisition</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 8, 2020, we acquired xCella, an antibody discovery company. xCella's xPloration platform is a proprietary microcapillary platform that can screen single B cells for specificity and bioactivity and will increase Ligand&#8217;s antibody discovery throughput and efficiency. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We paid $<ix:nonFraction unitRef="usd" contextRef="ieb689a5898414155944b7e894ecf5662_D20200908-20200908" decimals="-5" name="us-gaap:BusinessCombinationConsiderationTransferred1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185NC9mcmFnOmMzY2U4MjkwNTcxZTRkZWE4ZDI5ZjIzMWE1NzA2YjhlL3RleHRyZWdpb246YzNjZTgyOTA1NzFlNGRlYThkMjlmMjMxYTU3MDZiOGVfNzU5NA_99147251-365a-444b-8dca-946feb604b5e">7.1</ix:nonFraction> million in cash (including a $<ix:nonFraction unitRef="usd" contextRef="ieb689a5898414155944b7e894ecf5662_D20200908-20200908" decimals="-5" name="lgnd:BusinessCombinationConsiderationTransferredHoldback" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185NC9mcmFnOmMzY2U4MjkwNTcxZTRkZWE4ZDI5ZjIzMWE1NzA2YjhlL3RleHRyZWdpb246YzNjZTgyOTA1NzFlNGRlYThkMjlmMjMxYTU3MDZiOGVfNzYxOA_5429013f-90ec-4a94-a9c1-a48a31bb412f">0.5</ix:nonFraction> million holdback to satisfy indemnification obligations which will be settled by September 2021), and issued earnout rights for up to $<ix:nonFraction unitRef="usd" contextRef="i37beeb694dea43279d1ea72ec2fb6fa3_I20200908" decimals="INF" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185NC9mcmFnOmMzY2U4MjkwNTcxZTRkZWE4ZDI5ZjIzMWE1NzA2YjhlL3RleHRyZWdpb246YzNjZTgyOTA1NzFlNGRlYThkMjlmMjMxYTU3MDZiOGVfNzc0Nw_f2a738e6-2282-412e-b31a-da42bf5430ec">5.0</ix:nonFraction> million tied to our use of the xCella technology for partnered research and development and for up to $<ix:nonFraction unitRef="usd" contextRef="i48c587ca12364b2ebe41d4a23afdf0a5_I20200908" decimals="INF" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185NC9mcmFnOmMzY2U4MjkwNTcxZTRkZWE4ZDI5ZjIzMWE1NzA2YjhlL3RleHRyZWdpb246YzNjZTgyOTA1NzFlNGRlYThkMjlmMjMxYTU3MDZiOGVfNzg0NA_f1c41085-b6f8-4cae-a44b-25f1096c84ae">25.75</ix:nonFraction> million as a <ix:nonFraction unitRef="number" contextRef="i00b4cfcf8fab454fa5cb35a4499bd18e_D20200908-20200908" decimals="INF" name="lgnd:BusinessCombinationContingentConsiderationLiabilityPercentageOfAcquireeRevenues" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185NC9mcmFnOmMzY2U4MjkwNTcxZTRkZWE4ZDI5ZjIzMWE1NzA2YjhlL3RleHRyZWdpb246YzNjZTgyOTA1NzFlNGRlYThkMjlmMjMxYTU3MDZiOGVfNzg1Mg_1a844297-c6f5-4264-aa6c-0685fa129799">25</ix:nonFraction>% share of any future milestone payments we received under a certain existing xCella partner arrangement. We evaluated this acquisition in accordance with ASC 805, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Business Combinations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, to discern whether the assets and operations of xCella met the definition of a business. We accounted for this transaction as an asset acquisition as we concluded that substantially all of the fair value of the gross assets acquired was concentrated in the acquired core technology.</span></div><div><span><br/></span></div><ix:nonNumeric contextRef="ic3f66dd3dd704775a2c678c7d07ce665_D20210101-20211231" name="us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185NC9mcmFnOmMzY2U4MjkwNTcxZTRkZWE4ZDI5ZjIzMWE1NzA2YjhlL3RleHRyZWdpb246YzNjZTgyOTA1NzFlNGRlYThkMjlmMjMxYTU3MDZiOGVfMTQ5Njg_4732174c-eb2e-42e1-b540-e3ec76677106" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The allocation of the consideration was allocated to the acquisition date fair values of acquired assets and assumed liabilities as follows (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.303%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.497%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and other assets</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2d89a76397d4f8fa55ad5491b92151e_I20200908" decimals="-3" name="lgnd:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndCurrentAssetsOther" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185NC9mcmFnOmMzY2U4MjkwNTcxZTRkZWE4ZDI5ZjIzMWE1NzA2YjhlL3RhYmxlOjU4ZWFmYjAzMDg0MjRiMGZiNWRjNWMwODkyMmQ5ZjU3L3RhYmxlcmFuZ2U6NThlYWZiMDMwODQyNGIwZmI1ZGM1YzA4OTIyZDlmNTdfMC0xLTEtMS00MTI5NA_fa09e0be-ce35-4577-bdfd-24f8a01e3497">240</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib2d89a76397d4f8fa55ad5491b92151e_I20200908" decimals="-3" name="lgnd:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185NC9mcmFnOmMzY2U4MjkwNTcxZTRkZWE4ZDI5ZjIzMWE1NzA2YjhlL3RhYmxlOjU4ZWFmYjAzMDg0MjRiMGZiNWRjNWMwODkyMmQ5ZjU3L3RhYmxlcmFuZ2U6NThlYWZiMDMwODQyNGIwZmI1ZGM1YzA4OTIyZDlmNTdfMS0xLTEtMS00MTI5NA_439dba71-85b9-4c32-8540-44ffc60dc3d5">142</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib2d89a76397d4f8fa55ad5491b92151e_I20200908" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185NC9mcmFnOmMzY2U4MjkwNTcxZTRkZWE4ZDI5ZjIzMWE1NzA2YjhlL3RhYmxlOjU4ZWFmYjAzMDg0MjRiMGZiNWRjNWMwODkyMmQ5ZjU3L3RhYmxlcmFuZ2U6NThlYWZiMDMwODQyNGIwZmI1ZGM1YzA4OTIyZDlmNTdfMi0xLTEtMS00MTI5NA_b1dbc6d0-8c86-4a9b-a23d-b03676b898d8">604</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangibles assets with finite-life - core technology</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2d89a76397d4f8fa55ad5491b92151e_I20200908" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185NC9mcmFnOmMzY2U4MjkwNTcxZTRkZWE4ZDI5ZjIzMWE1NzA2YjhlL3RhYmxlOjU4ZWFmYjAzMDg0MjRiMGZiNWRjNWMwODkyMmQ5ZjU3L3RhYmxlcmFuZ2U6NThlYWZiMDMwODQyNGIwZmI1ZGM1YzA4OTIyZDlmNTdfMy0xLTEtMS00MTI5NA_31ed57df-b807-4057-8445-9f18f8d66b3d">7,582</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2d89a76397d4f8fa55ad5491b92151e_I20200908" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185NC9mcmFnOmMzY2U4MjkwNTcxZTRkZWE4ZDI5ZjIzMWE1NzA2YjhlL3RhYmxlOjU4ZWFmYjAzMDg0MjRiMGZiNWRjNWMwODkyMmQ5ZjU3L3RhYmxlcmFuZ2U6NThlYWZiMDMwODQyNGIwZmI1ZGM1YzA4OTIyZDlmNTdfNC0xLTEtMS00MTI5NA_93248104-8e33-4c2c-aba0-5ef48f8a6efd">7,076</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">72</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="iff2afa6d345f46c0aa7295728c825a99" continuedAt="ib3157338e108452c869606b16279705f"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The core technology is being amortized on a straight-line basis over the estimated useful life of <ix:nonNumeric contextRef="i27406e0d0a0147c28467e0891905560f_D20200908-20200908" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185NC9mcmFnOmMzY2U4MjkwNTcxZTRkZWE4ZDI5ZjIzMWE1NzA2YjhlL3RleHRyZWdpb246YzNjZTgyOTA1NzFlNGRlYThkMjlmMjMxYTU3MDZiOGVfODU4Mg_7a1a691e-7c6a-4fbe-a0de-d911b7d51ad9">15</ix:nonNumeric> years. We account for the earnout rights in accordance with ASC 450, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contingencies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, when the contingency is resolved and the liability becomes payable. <ix:nonFraction unitRef="usd" contextRef="ib2d89a76397d4f8fa55ad5491b92151e_I20200908" decimals="INF" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185NC9mcmFnOmMzY2U4MjkwNTcxZTRkZWE4ZDI5ZjIzMWE1NzA2YjhlL3RleHRyZWdpb246YzNjZTgyOTA1NzFlNGRlYThkMjlmMjMxYTU3MDZiOGVfODczMQ_4be45083-fb32-4ff8-b71e-07f289ed5b25">None</ix:nonFraction> of the earnout rights are recognized as of the acquisition date.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Icagen Acquisition</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 1, 2020, we acquired the core assets, including its partnered programs and ion channel technology from Icagen and certain of its affiliates. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The purchase price of $<ix:nonFraction unitRef="usd" contextRef="ied333fd0de2c4cf4a2b4948199619825_D20200401-20200401" decimals="-5" name="us-gaap:BusinessCombinationConsiderationTransferred1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185NC9mcmFnOmMzY2U4MjkwNTcxZTRkZWE4ZDI5ZjIzMWE1NzA2YjhlL3RleHRyZWdpb246YzNjZTgyOTA1NzFlNGRlYThkMjlmMjMxYTU3MDZiOGVfODk5NQ_f8315397-dccb-4ea4-a478-25c76fd67b7c">19.9</ix:nonFraction>&#160;million included $<ix:nonFraction unitRef="usd" contextRef="ied333fd0de2c4cf4a2b4948199619825_D20200401-20200401" decimals="-5" name="us-gaap:PaymentsToAcquireBusinessesGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185NC9mcmFnOmMzY2U4MjkwNTcxZTRkZWE4ZDI5ZjIzMWE1NzA2YjhlL3RleHRyZWdpb246YzNjZTgyOTA1NzFlNGRlYThkMjlmMjMxYTU3MDZiOGVfOTAwNw_7b69d995-c0f4-44ba-8db2-240832757db0">15.1</ix:nonFraction> million cash consideration paid upon acquisition, and a CVR of up to $<ix:nonFraction unitRef="usd" contextRef="i66fd5bb596fe4dc0a209f580f37be1bd_I20200401" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185NC9mcmFnOmMzY2U4MjkwNTcxZTRkZWE4ZDI5ZjIzMWE1NzA2YjhlL3RleHRyZWdpb246YzNjZTgyOTA1NzFlNGRlYThkMjlmMjMxYTU3MDZiOGVfOTA3MQ_97aef128-4b99-4a1d-8d3d-b27fbbe3e79d">25.0</ix:nonFraction> million of cash payments based on certain revenue milestones with an estimated fair value of $<ix:nonFraction unitRef="usd" contextRef="i66fd5bb596fe4dc0a209f580f37be1bd_I20200401" decimals="-5" name="lgnd:BusinessCombinationContingentConsiderationLiabilityFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185NC9mcmFnOmMzY2U4MjkwNTcxZTRkZWE4ZDI5ZjIzMWE1NzA2YjhlL3RleHRyZWdpb246YzNjZTgyOTA1NzFlNGRlYThkMjlmMjMxYTU3MDZiOGVfOTE1OQ_9fd14f6a-7473-4ed4-b485-2817f6cf7bc4">4.8</ix:nonFraction> million. The fair value of the earn-out liability was determined using a probability weighted income approach incorporating the estimated future cash flows from expected future milestones. These cash flows were then discounted to present value using a discount rate based on the market participants' cost of debt reflective of the Company, which was <ix:nonFraction unitRef="number" contextRef="i8b9c129486844e46be95446917936d16_I20200401" decimals="3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185NC9mcmFnOmMzY2U4MjkwNTcxZTRkZWE4ZDI5ZjIzMWE1NzA2YjhlL3RleHRyZWdpb246YzNjZTgyOTA1NzFlNGRlYThkMjlmMjMxYTU3MDZiOGVfOTUwNA_5489e7eb-200b-46c1-9003-aa859ae3d1d4">5.5</ix:nonFraction>%. The liability is periodically assessed based on events and circumstances related to the underlying milestones, and any change in fair value is recorded in our consolidated statements of operations. The carrying amount of the liability may fluctuate significantly and actual amount paid may be materially different than the carrying amount of the liability. As the acquisition is not considered significant, pro forma information has not been provided. The results of Icagen have been included in our results of operations since the date of acquisition.</span></div><div><span><br/></span></div><ix:nonNumeric contextRef="i187c5df306a349e38267335b0f796d41_D20210101-20211231" name="us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185NC9mcmFnOmMzY2U4MjkwNTcxZTRkZWE4ZDI5ZjIzMWE1NzA2YjhlL3RleHRyZWdpb246YzNjZTgyOTA1NzFlNGRlYThkMjlmMjMxYTU3MDZiOGVfMTQ5NjU_6eee9bcc-4b80-45ea-943d-540e843ca199" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The allocation of the consideration was allocated to the acquisition date fair values of acquired assets and assumed liabilities as follows (in thousands):</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.303%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.497%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66fd5bb596fe4dc0a209f580f37be1bd_I20200401" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185NC9mcmFnOmMzY2U4MjkwNTcxZTRkZWE4ZDI5ZjIzMWE1NzA2YjhlL3RhYmxlOjE5MzJmYTRkZmQ4MDRmNjU4NjIxNmMxMjRiZmIxNTQwL3RhYmxlcmFuZ2U6MTkzMmZhNGRmZDgwNGY2NTg2MjE2YzEyNGJmYjE1NDBfMC0xLTEtMS00MTI5NA_de7e04b5-957a-4e92-a20f-e7c506ae1cff">1,173</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaids and other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66fd5bb596fe4dc0a209f580f37be1bd_I20200401" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185NC9mcmFnOmMzY2U4MjkwNTcxZTRkZWE4ZDI5ZjIzMWE1NzA2YjhlL3RhYmxlOjE5MzJmYTRkZmQ4MDRmNjU4NjIxNmMxMjRiZmIxNTQwL3RhYmxlcmFuZ2U6MTkzMmZhNGRmZDgwNGY2NTg2MjE2YzEyNGJmYjE1NDBfMS0xLTEtMS00MTI5NA_8ace71c9-c8fe-4f3a-a10c-ecd2ea510b4d">588</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities assumed</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i66fd5bb596fe4dc0a209f580f37be1bd_I20200401" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185NC9mcmFnOmMzY2U4MjkwNTcxZTRkZWE4ZDI5ZjIzMWE1NzA2YjhlL3RhYmxlOjE5MzJmYTRkZmQ4MDRmNjU4NjIxNmMxMjRiZmIxNTQwL3RhYmxlcmFuZ2U6MTkzMmZhNGRmZDgwNGY2NTg2MjE2YzEyNGJmYjE1NDBfMi0xLTEtMS00MTI5NA_b8a3c752-203d-4964-a861-f5adea84a50a">812</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i66fd5bb596fe4dc0a209f580f37be1bd_I20200401" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185NC9mcmFnOmMzY2U4MjkwNTcxZTRkZWE4ZDI5ZjIzMWE1NzA2YjhlL3RhYmxlOjE5MzJmYTRkZmQ4MDRmNjU4NjIxNmMxMjRiZmIxNTQwL3RhYmxlcmFuZ2U6MTkzMmZhNGRmZDgwNGY2NTg2MjE2YzEyNGJmYjE1NDBfMy0xLTEtMS00MTI5NA_eb85a3f8-ec68-4ba7-a96b-e3e9fba30743">3,685</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66fd5bb596fe4dc0a209f580f37be1bd_I20200401" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185NC9mcmFnOmMzY2U4MjkwNTcxZTRkZWE4ZDI5ZjIzMWE1NzA2YjhlL3RhYmxlOjE5MzJmYTRkZmQ4MDRmNjU4NjIxNmMxMjRiZmIxNTQwL3RhYmxlcmFuZ2U6MTkzMmZhNGRmZDgwNGY2NTg2MjE2YzEyNGJmYjE1NDBfNC0xLTEtMS00MTI5NA_8ca5b4d9-b9b3-49fd-b5a4-c952b522ac97">861</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired intangibles</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66fd5bb596fe4dc0a209f580f37be1bd_I20200401" decimals="-3" name="lgnd:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185NC9mcmFnOmMzY2U4MjkwNTcxZTRkZWE4ZDI5ZjIzMWE1NzA2YjhlL3RhYmxlOjE5MzJmYTRkZmQ4MDRmNjU4NjIxNmMxMjRiZmIxNTQwL3RhYmxlcmFuZ2U6MTkzMmZhNGRmZDgwNGY2NTg2MjE2YzEyNGJmYjE1NDBfNS0xLTEtMS00MTI5NA_0fcb8c64-ab33-4d46-8d9f-fa62d9bae02b">12,800</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66fd5bb596fe4dc0a209f580f37be1bd_I20200401" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185NC9mcmFnOmMzY2U4MjkwNTcxZTRkZWE4ZDI5ZjIzMWE1NzA2YjhlL3RhYmxlOjE5MzJmYTRkZmQ4MDRmNjU4NjIxNmMxMjRiZmIxNTQwL3RhYmxlcmFuZ2U6MTkzMmZhNGRmZDgwNGY2NTg2MjE2YzEyNGJmYjE1NDBfNi0xLTEtMS00MTI5NA_17beb110-532e-4e85-b560-b35dd147f060">9,015</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66fd5bb596fe4dc0a209f580f37be1bd_I20200401" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185NC9mcmFnOmMzY2U4MjkwNTcxZTRkZWE4ZDI5ZjIzMWE1NzA2YjhlL3RhYmxlOjE5MzJmYTRkZmQ4MDRmNjU4NjIxNmMxMjRiZmIxNTQwL3RhYmxlcmFuZ2U6MTkzMmZhNGRmZDgwNGY2NTg2MjE2YzEyNGJmYjE1NDBfNy0xLTEtMS00MTI5NA_47c6a305-1b2d-47b8-99c3-cb3c5bbbd1ec">19,940</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%">(1) Goodwill represents the excess of the purchase price over the preliminary fair value of the underlying assets acquired and liabilities assumed. Goodwill is attributable to the assembled workforce of experienced personnel at Icagen and expected synergies.</span></div></ix:nonNumeric><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The majority of the goodwill is deductible for tax purposes. Acquired intangibles include $<ix:nonFraction unitRef="usd" contextRef="i2c2f23bb705c43f999e98dd9cfeedb0a_I20200401" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185NC9mcmFnOmMzY2U4MjkwNTcxZTRkZWE4ZDI5ZjIzMWE1NzA2YjhlL3RleHRyZWdpb246YzNjZTgyOTA1NzFlNGRlYThkMjlmMjMxYTU3MDZiOGVfMTA1ODQ_7c1b6ccd-c75d-4eed-8154-a253139fc30c">11.1</ix:nonFraction> million of customer relationships and $<ix:nonFraction unitRef="usd" contextRef="i50397a39865e428d8b5ec1d1e3e72da9_I20200401" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185NC9mcmFnOmMzY2U4MjkwNTcxZTRkZWE4ZDI5ZjIzMWE1NzA2YjhlL3RleHRyZWdpb246YzNjZTgyOTA1NzFlNGRlYThkMjlmMjMxYTU3MDZiOGVfMTA2MTc_ce3589c5-ebc5-4129-adc8-4251e129e03f">1.7</ix:nonFraction> million of core technology. The fair values of the customer relationships were based on a discounted cash flow analysis incorporating the estimated future cash flows from these relationships during the contractual term. These cash flows were then discounted to present value using a discount rate of <ix:nonFraction unitRef="number" contextRef="if2f9b634b34f4572ac8de5159f8e63fb_D20200401-20200401" decimals="INF" name="lgnd:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185NC9mcmFnOmMzY2U4MjkwNTcxZTRkZWE4ZDI5ZjIzMWE1NzA2YjhlL3RleHRyZWdpb246YzNjZTgyOTA1NzFlNGRlYThkMjlmMjMxYTU3MDZiOGVfMTA5MTI_a082ba72-bdae-44a9-b824-58bbc8152cfa">17</ix:nonFraction>%. The fair value of the customer relationships is being amortized on a straight-line basis over the weighted average estimated useful life of <ix:nonNumeric contextRef="if2f9b634b34f4572ac8de5159f8e63fb_D20200401-20200401" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185NC9mcmFnOmMzY2U4MjkwNTcxZTRkZWE4ZDI5ZjIzMWE1NzA2YjhlL3RleHRyZWdpb246YzNjZTgyOTA1NzFlNGRlYThkMjlmMjMxYTU3MDZiOGVfMTEwNTY_6baa15ba-f0b5-4aa7-842a-b6f63d42cc53">9.6</ix:nonNumeric> years. The fair value of the core technology was based on the discounted cash flow method that estimated the present value of the potential royalties, milestones, and collaboration revenue streams derived from the licensing of the related technologies. These projected cash flows were discounted to present value using a discount rate of <ix:nonFraction unitRef="number" contextRef="if2f9b634b34f4572ac8de5159f8e63fb_D20200401-20200401" decimals="INF" name="lgnd:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185NC9mcmFnOmMzY2U4MjkwNTcxZTRkZWE4ZDI5ZjIzMWE1NzA2YjhlL3RleHRyZWdpb246YzNjZTgyOTA1NzFlNGRlYThkMjlmMjMxYTU3MDZiOGVfMTEzOTE_a082ba72-bdae-44a9-b824-58bbc8152cfa">17</ix:nonFraction>%. The fair value of the core technology is being amortized on a straight-line basis over the estimated useful life of <ix:nonNumeric contextRef="i797a1a3c49bb44aba3b71fee73a5a78f_D20200401-20200401" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185NC9mcmFnOmMzY2U4MjkwNTcxZTRkZWE4ZDI5ZjIzMWE1NzA2YjhlL3RleHRyZWdpb246YzNjZTgyOTA1NzFlNGRlYThkMjlmMjMxYTU3MDZiOGVfMTE1MTE_90ba4a9a-9ead-41b8-be46-6787a0f63268">10</ix:nonNumeric> years. The total acquired intangibles are being amortized on a straight-line basis over the estimated useful life of <ix:nonNumeric contextRef="ied333fd0de2c4cf4a2b4948199619825_D20200401-20200401" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185NC9mcmFnOmMzY2U4MjkwNTcxZTRkZWE4ZDI5ZjIzMWE1NzA2YjhlL3RleHRyZWdpb246YzNjZTgyOTA1NzFlNGRlYThkMjlmMjMxYTU3MDZiOGVfMTE2MjU_9cb45c43-4a73-41a6-8508-3ff80756e7c3">9.7</ix:nonNumeric> years.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Ab Initio Acquisition</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 23, 2019, we acquired privately-held Ab Initio, an antigen-discovery company located in South San Francisco, California. Ab Initio has a patented antigen technology that is synergistic with the OmniAb</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">therapeutic antibody discovery platform, providing our current and potential new partners enhanced capabilities for the discovery of therapeutic antibodies against difficult-to-access cellular targets. Ab Initio has a collaboration agreement with Pfizer to discover novel therapeutic antibodies against an undisclosed target in the GPCR superfamily.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The purchase price of $<ix:nonFraction unitRef="usd" contextRef="i559e6316ff5f46eeae72eb8202827fdd_D20190723-20190723" decimals="-5" name="us-gaap:BusinessCombinationConsiderationTransferred1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185NC9mcmFnOmMzY2U4MjkwNTcxZTRkZWE4ZDI5ZjIzMWE1NzA2YjhlL3RleHRyZWdpb246YzNjZTgyOTA1NzFlNGRlYThkMjlmMjMxYTU3MDZiOGVfMTI2Mjg_3876e55e-51de-436b-890e-5aa2e6dc832f">12.0</ix:nonFraction> million included $<ix:nonFraction unitRef="usd" contextRef="i559e6316ff5f46eeae72eb8202827fdd_D20190723-20190723" decimals="-5" name="us-gaap:PaymentsToAcquireBusinessesGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185NC9mcmFnOmMzY2U4MjkwNTcxZTRkZWE4ZDI5ZjIzMWE1NzA2YjhlL3RleHRyZWdpb246YzNjZTgyOTA1NzFlNGRlYThkMjlmMjMxYTU3MDZiOGVfMTI2NDA_5fec832c-1a08-4ccb-ba43-e28f443e4189">11.9</ix:nonFraction> million cash consideration paid upon acquisition, net of cash acquired, and $<ix:nonFraction unitRef="usd" contextRef="i559e6316ff5f46eeae72eb8202827fdd_D20190723-20190723" decimals="-4" name="lgnd:BusinessCombinationCashHoldbackForPotentialIndemnificationClaims" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185NC9mcmFnOmMzY2U4MjkwNTcxZTRkZWE4ZDI5ZjIzMWE1NzA2YjhlL3RleHRyZWdpb246YzNjZTgyOTA1NzFlNGRlYThkMjlmMjMxYTU3MDZiOGVfMTI3MTE_30515022-9672-4fb7-ace6-c9bc80375442">0.15</ix:nonFraction> million cash holdback for potential indemnification claims. As the acquisition is not considered significant, pro forma information has not been provided.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">73</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><ix:continuation id="ib3157338e108452c869606b16279705f"><ix:nonNumeric contextRef="i2391e1562f894a61a00bffbaac6457ea_D20210101-20211231" name="us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185NC9mcmFnOmMzY2U4MjkwNTcxZTRkZWE4ZDI5ZjIzMWE1NzA2YjhlL3RleHRyZWdpb246YzNjZTgyOTA1NzFlNGRlYThkMjlmMjMxYTU3MDZiOGVfMTQ5NjY_a39219bf-52c2-4aae-ac0b-5a9f231fbaea" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The final purchase consideration was allocated to the acquisition date fair values of acquired assets and assumed liabilities as follows (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.303%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.497%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and other assets</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib84e53f0d01a493a86dc0aed964fe45a_I20190723" decimals="-3" name="lgnd:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndCurrentAssetsOther" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185NC9mcmFnOmMzY2U4MjkwNTcxZTRkZWE4ZDI5ZjIzMWE1NzA2YjhlL3RhYmxlOjYxYjEyY2Q3MmY5MTRmZDdhOTg0NjAyZjBjYTM1OWFiL3RhYmxlcmFuZ2U6NjFiMTJjZDcyZjkxNGZkN2E5ODQ2MDJmMGNhMzU5YWJfMC0xLTEtMS00MTI5NA_e1ce2416-468c-495e-86f2-e7db15240178">28</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and accrued liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib84e53f0d01a493a86dc0aed964fe45a_I20190723" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185NC9mcmFnOmMzY2U4MjkwNTcxZTRkZWE4ZDI5ZjIzMWE1NzA2YjhlL3RhYmxlOjYxYjEyY2Q3MmY5MTRmZDdhOTg0NjAyZjBjYTM1OWFiL3RhYmxlcmFuZ2U6NjFiMTJjZDcyZjkxNGZkN2E5ODQ2MDJmMGNhMzU5YWJfMS0xLTEtMS00MTI5NA_d39499b6-3b02-40ae-be29-79bfe4ee5dde">83</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib84e53f0d01a493a86dc0aed964fe45a_I20190723" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185NC9mcmFnOmMzY2U4MjkwNTcxZTRkZWE4ZDI5ZjIzMWE1NzA2YjhlL3RhYmxlOjYxYjEyY2Q3MmY5MTRmZDdhOTg0NjAyZjBjYTM1OWFiL3RhYmxlcmFuZ2U6NjFiMTJjZDcyZjkxNGZkN2E5ODQ2MDJmMGNhMzU5YWJfMi0xLTEtMS00MTI5NA_9569ecaf-f051-47e4-95c6-da1af7b3cc47">146</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangibles assets with finite-life - core technologies</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib84e53f0d01a493a86dc0aed964fe45a_I20190723" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185NC9mcmFnOmMzY2U4MjkwNTcxZTRkZWE4ZDI5ZjIzMWE1NzA2YjhlL3RhYmxlOjYxYjEyY2Q3MmY5MTRmZDdhOTg0NjAyZjBjYTM1OWFiL3RhYmxlcmFuZ2U6NjFiMTJjZDcyZjkxNGZkN2E5ODQ2MDJmMGNhMzU5YWJfMy0xLTEtMS00MTI5NA_a6a6c68e-3f6b-41eb-a660-289dba953c81">7,400</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib84e53f0d01a493a86dc0aed964fe45a_I20190723" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185NC9mcmFnOmMzY2U4MjkwNTcxZTRkZWE4ZDI5ZjIzMWE1NzA2YjhlL3RhYmxlOjYxYjEyY2Q3MmY5MTRmZDdhOTg0NjAyZjBjYTM1OWFiL3RhYmxlcmFuZ2U6NjFiMTJjZDcyZjkxNGZkN2E5ODQ2MDJmMGNhMzU5YWJfNC0xLTEtMS00MTI5NA_c4e7ac81-9509-4cae-9e0f-08b8f176aaac">4,812</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib84e53f0d01a493a86dc0aed964fe45a_I20190723" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185NC9mcmFnOmMzY2U4MjkwNTcxZTRkZWE4ZDI5ZjIzMWE1NzA2YjhlL3RhYmxlOjYxYjEyY2Q3MmY5MTRmZDdhOTg0NjAyZjBjYTM1OWFiL3RhYmxlcmFuZ2U6NjFiMTJjZDcyZjkxNGZkN2E5ODQ2MDJmMGNhMzU5YWJfNS0xLTEtMS00MTI5NA_85070a85-1c4a-4e2e-bab6-c49eb1651851">12,011</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%">(1) Goodwill represents the excess of the purchase price over the fair value of the underlying assets acquired and liabilities assumed. Goodwill is attributable to the assembled workforce of experienced personnel at Ab Initio and expected synergies.</span></div></ix:nonNumeric><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ib84e53f0d01a493a86dc0aed964fe45a_I20190723" decimals="INF" name="us-gaap:BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185NC9mcmFnOmMzY2U4MjkwNTcxZTRkZWE4ZDI5ZjIzMWE1NzA2YjhlL3RleHRyZWdpb246YzNjZTgyOTA1NzFlNGRlYThkMjlmMjMxYTU3MDZiOGVfMjE5OTAyMzI3MzkxMA_bf135955-bcaf-4f28-bf66-c7f8d9d423f5">None</ix:nonFraction> of the goodwill is deductible for tax purposes. The fair value of the core technologies was determined based on the discounted cash flow method that estimated the present value of the hypothetical royalty/ milestone streams from the licensing of the antigen-discovery technology and collaboration agreement. These projected cash flows were discounted to present value using a discount rate of <ix:nonFraction unitRef="number" contextRef="ib84e53f0d01a493a86dc0aed964fe45a_I20190723" decimals="3" name="lgnd:BusinessCombinationAssumptionsUsedEstimatedFutureCashFlowsDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185NC9mcmFnOmMzY2U4MjkwNTcxZTRkZWE4ZDI5ZjIzMWE1NzA2YjhlL3RleHRyZWdpb246YzNjZTgyOTA1NzFlNGRlYThkMjlmMjMxYTU3MDZiOGVfMTM2Njc_f57b0378-ccd5-4fd5-bfa2-72052031bd20">12.0</ix:nonFraction>%. The fair value of the core technologies is being amortized on a straight-line basis over the weighted average estimated useful life of approximately <ix:nonNumeric contextRef="i609b4c3a45a041b1856484ca0935a9fc_D20190723-20190723" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185NC9mcmFnOmMzY2U4MjkwNTcxZTRkZWE4ZDI5ZjIzMWE1NzA2YjhlL3RleHRyZWdpb246YzNjZTgyOTA1NzFlNGRlYThkMjlmMjMxYTU3MDZiOGVfMTM4MjA_e09c9d5d-4bdf-4059-a84a-2cef999845da">20</ix:nonNumeric> years.</span></div></ix:continuation><div><span><br/></span></div><div><span><br/></span></div><div id="i0fa6f906fb2e4e30bc5e873d2bb6a82c_97"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5. <ix:nonNumeric contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231" name="us-gaap:FinancialInstrumentsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185Ny9mcmFnOmRmZjk3MmRkZDM3NDQ5NzNiY2U4YjMwMmJlMzhjNjdhL3RleHRyZWdpb246ZGZmOTcyZGRkMzc0NDk3M2JjZThiMzAyYmUzOGM2N2FfNjkyOQ_ed07af8c-c792-4267-be63-636044b1d9b4" continuedAt="id34c1bf4e8314ca884ceda3961b7cf12" escape="true">Fair Value Measurement</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="id34c1bf4e8314ca884ceda3961b7cf12" continuedAt="i2017604027674ffc8a696e806e260dfb"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We measure certain financial assets and liabilities at fair value on a recurring basis. Fair value is a market-based measurement that should be determined using assumptions that market participants would use in pricing an asset or liability. We establish a three-level hierarchy to prioritize the inputs used in measuring fair value. The levels are described in the below with level 1 having the highest priority and level 3 having the lowest:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1 - Observable inputs such as quoted prices in active markets </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2 - Inputs other than the quoted prices in active markets that are observable either directly or indirectly </span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 3 - Unobservable inputs in which there is little or no market data, which require the Company to develop its own assumptions</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">74</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i2017604027674ffc8a696e806e260dfb" continuedAt="i6293728540d94c4291dd64f6c81bb280"><ix:nonNumeric contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185Ny9mcmFnOmRmZjk3MmRkZDM3NDQ5NzNiY2U4YjMwMmJlMzhjNjdhL3RleHRyZWdpb246ZGZmOTcyZGRkMzc0NDk3M2JjZThiMzAyYmUzOGM2N2FfNjkyNQ_9e9cb1c9-a48d-471f-a7d0-89cae37abcf8" continuedAt="i3a973327c1794a1e81b0dbecdf6b36af" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a summary of the assets and liabilities that are measured at fair value on a recurring basis as of December&#160;31, 2021 and 2020 (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.829%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.624%"></td><td style="width:0.1%"></td></tr><tr><td colspan="24" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements at Reporting Date Using</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted Prices in</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Active Markets</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">for Identical</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Assets</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Observable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Inputs</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unobservable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Inputs</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level&#160;1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level&#160;2)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level&#160;3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06eb91dd76a2457bac33ba1c3af251f5_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185Ny9mcmFnOmRmZjk3MmRkZDM3NDQ5NzNiY2U4YjMwMmJlMzhjNjdhL3RhYmxlOjlmOTRjMTMwZTY4ZDQwYWM4ZGU2NjRlNjk0OTg1ZjZkL3RhYmxlcmFuZ2U6OWY5NGMxMzBlNjhkNDBhYzhkZTY2NGU2OTQ5ODVmNmRfNC0xLTEtMS00NjIwNw_f8651290-9199-4ef8-ba0d-3bf2501f482d">290,697</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieccd194c6cad463fa107525565469c36_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185Ny9mcmFnOmRmZjk3MmRkZDM3NDQ5NzNiY2U4YjMwMmJlMzhjNjdhL3RhYmxlOjlmOTRjMTMwZTY4ZDQwYWM4ZGU2NjRlNjk0OTg1ZjZkL3RhYmxlcmFuZ2U6OWY5NGMxMzBlNjhkNDBhYzhkZTY2NGU2OTQ5ODVmNmRfNC0zLTEtMS00NDc1Mw_12cc6baf-5bbe-40f6-9efa-fbc0e2e3d3b7">9,735</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03010ea07e48483686f97632e65cacf7_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185Ny9mcmFnOmRmZjk3MmRkZDM3NDQ5NzNiY2U4YjMwMmJlMzhjNjdhL3RhYmxlOjlmOTRjMTMwZTY4ZDQwYWM4ZGU2NjRlNjk0OTg1ZjZkL3RhYmxlcmFuZ2U6OWY5NGMxMzBlNjhkNDBhYzhkZTY2NGU2OTQ5ODVmNmRfNC01LTEtMS00NDc2MA_ecb5866c-db38-4021-b2bd-c7781772257e">280,553</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae4bca14f93e4328aa90c2fce8fbaae3_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185Ny9mcmFnOmRmZjk3MmRkZDM3NDQ5NzNiY2U4YjMwMmJlMzhjNjdhL3RhYmxlOjlmOTRjMTMwZTY4ZDQwYWM4ZGU2NjRlNjk0OTg1ZjZkL3RhYmxlcmFuZ2U6OWY5NGMxMzBlNjhkNDBhYzhkZTY2NGU2OTQ5ODVmNmRfNC03LTEtMS00NDc2Ng_e70a7c7c-ad90-40d9-8f71-b11a225df184">409</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in Viking common stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4367fea4a9a64e5a983f1e1a7761535c_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185Ny9mcmFnOmRmZjk3MmRkZDM3NDQ5NzNiY2U4YjMwMmJlMzhjNjdhL3RhYmxlOjlmOTRjMTMwZTY4ZDQwYWM4ZGU2NjRlNjk0OTg1ZjZkL3RhYmxlcmFuZ2U6OWY5NGMxMzBlNjhkNDBhYzhkZTY2NGU2OTQ5ODVmNmRfNS0xLTEtMS00NjIwNw_50a9bd40-9d64-41cb-8d5a-7c014d7d452f">30,889</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d6fdee1dc984b5fa799d65fefdb8a09_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185Ny9mcmFnOmRmZjk3MmRkZDM3NDQ5NzNiY2U4YjMwMmJlMzhjNjdhL3RhYmxlOjlmOTRjMTMwZTY4ZDQwYWM4ZGU2NjRlNjk0OTg1ZjZkL3RhYmxlcmFuZ2U6OWY5NGMxMzBlNjhkNDBhYzhkZTY2NGU2OTQ5ODVmNmRfNS0zLTEtMS00NDc3NQ_888bd4d1-7268-4476-91a2-2d2e52831e1f">30,889</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i640373e7d8124d24b670e247208e7234_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185Ny9mcmFnOmRmZjk3MmRkZDM3NDQ5NzNiY2U4YjMwMmJlMzhjNjdhL3RhYmxlOjlmOTRjMTMwZTY4ZDQwYWM4ZGU2NjRlNjk0OTg1ZjZkL3RhYmxlcmFuZ2U6OWY5NGMxMzBlNjhkNDBhYzhkZTY2NGU2OTQ5ODVmNmRfNS01LTEtMS00NjIwNw_334b72c6-eaed-40f6-abdd-3f905da65be2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i01a1659f9184445ca7e9d321e7b29f6d_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185Ny9mcmFnOmRmZjk3MmRkZDM3NDQ5NzNiY2U4YjMwMmJlMzhjNjdhL3RhYmxlOjlmOTRjMTMwZTY4ZDQwYWM4ZGU2NjRlNjk0OTg1ZjZkL3RhYmxlcmFuZ2U6OWY5NGMxMzBlNjhkNDBhYzhkZTY2NGU2OTQ5ODVmNmRfNS03LTEtMS00NjIwNw_f4945c3c-7b10-4ff2-8552-ed4a1710e33d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83d2c94c6e0b4e79aceeeff3efa78c20_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185Ny9mcmFnOmRmZjk3MmRkZDM3NDQ5NzNiY2U4YjMwMmJlMzhjNjdhL3RhYmxlOjlmOTRjMTMwZTY4ZDQwYWM4ZGU2NjRlNjk0OTg1ZjZkL3RhYmxlcmFuZ2U6OWY5NGMxMzBlNjhkNDBhYzhkZTY2NGU2OTQ5ODVmNmRfNi0xLTEtMS00NjIxMA_6259482b-373a-458d-a9f7-027456d4998f">321,586</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a0bee3568b44a9bb12563aeaa8528f5_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185Ny9mcmFnOmRmZjk3MmRkZDM3NDQ5NzNiY2U4YjMwMmJlMzhjNjdhL3RhYmxlOjlmOTRjMTMwZTY4ZDQwYWM4ZGU2NjRlNjk0OTg1ZjZkL3RhYmxlcmFuZ2U6OWY5NGMxMzBlNjhkNDBhYzhkZTY2NGU2OTQ5ODVmNmRfNi0zLTEtMS00NjIxMA_e4d4b2e2-92b1-4290-af33-268608ddc8b4">40,624</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d8c9f4eb5724240a7b9559155e19d8f_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185Ny9mcmFnOmRmZjk3MmRkZDM3NDQ5NzNiY2U4YjMwMmJlMzhjNjdhL3RhYmxlOjlmOTRjMTMwZTY4ZDQwYWM4ZGU2NjRlNjk0OTg1ZjZkL3RhYmxlcmFuZ2U6OWY5NGMxMzBlNjhkNDBhYzhkZTY2NGU2OTQ5ODVmNmRfNi01LTEtMS00NjIxMA_3f4f9de8-1a6f-404c-9b6f-df857bd58f8d">280,553</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33b5cd64b00744faaf121a59ccec8a90_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185Ny9mcmFnOmRmZjk3MmRkZDM3NDQ5NzNiY2U4YjMwMmJlMzhjNjdhL3RhYmxlOjlmOTRjMTMwZTY4ZDQwYWM4ZGU2NjRlNjk0OTg1ZjZkL3RhYmxlcmFuZ2U6OWY5NGMxMzBlNjhkNDBhYzhkZTY2NGU2OTQ5ODVmNmRfNi03LTEtMS00NjIxMA_c812132a-3e1c-4b03-aa3c-6bd90229d42a">409</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent liabilities - Cydex</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i84a81b7b22eb417e910d5485bba6df55_I20211231" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185Ny9mcmFnOmRmZjk3MmRkZDM3NDQ5NzNiY2U4YjMwMmJlMzhjNjdhL3RhYmxlOjlmOTRjMTMwZTY4ZDQwYWM4ZGU2NjRlNjk0OTg1ZjZkL3RhYmxlcmFuZ2U6OWY5NGMxMzBlNjhkNDBhYzhkZTY2NGU2OTQ5ODVmNmRfOS0xLTEtMS00NjIxMg_70713e7d-97fd-4e19-b3a0-ae37ca21c223">349</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6401005419049dc9000250436aca434_I20211231" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185Ny9mcmFnOmRmZjk3MmRkZDM3NDQ5NzNiY2U4YjMwMmJlMzhjNjdhL3RhYmxlOjlmOTRjMTMwZTY4ZDQwYWM4ZGU2NjRlNjk0OTg1ZjZkL3RhYmxlcmFuZ2U6OWY5NGMxMzBlNjhkNDBhYzhkZTY2NGU2OTQ5ODVmNmRfOS0zLTEtMS00NjIxMg_3f7456dd-13e6-4254-99a8-679cdc712f78">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f8a682fcdf94c3d884f17cb17ab868c_I20211231" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185Ny9mcmFnOmRmZjk3MmRkZDM3NDQ5NzNiY2U4YjMwMmJlMzhjNjdhL3RhYmxlOjlmOTRjMTMwZTY4ZDQwYWM4ZGU2NjRlNjk0OTg1ZjZkL3RhYmxlcmFuZ2U6OWY5NGMxMzBlNjhkNDBhYzhkZTY2NGU2OTQ5ODVmNmRfOS01LTEtMS00NjIxMg_589efa19-14e9-4cbc-a94a-c24fb893c68e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5346db50523e458fa6677b7418028935_I20211231" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185Ny9mcmFnOmRmZjk3MmRkZDM3NDQ5NzNiY2U4YjMwMmJlMzhjNjdhL3RhYmxlOjlmOTRjMTMwZTY4ZDQwYWM4ZGU2NjRlNjk0OTg1ZjZkL3RhYmxlcmFuZ2U6OWY5NGMxMzBlNjhkNDBhYzhkZTY2NGU2OTQ5ODVmNmRfOS03LTEtMS00NDgwOA_2fc9af41-8c98-40a2-98db-a73a55f82ddd">349</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent liabilities - Metabasis </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i761befb7871948fea7097d919ba453c9_I20211231" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185Ny9mcmFnOmRmZjk3MmRkZDM3NDQ5NzNiY2U4YjMwMmJlMzhjNjdhL3RhYmxlOjlmOTRjMTMwZTY4ZDQwYWM4ZGU2NjRlNjk0OTg1ZjZkL3RhYmxlcmFuZ2U6OWY5NGMxMzBlNjhkNDBhYzhkZTY2NGU2OTQ5ODVmNmRfMTAtMS0xLTEtNDYyMTI_0ddef795-ceee-4475-96ef-33d771f9395f">3,358</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief7b3a15b9ee435cbec80f843a28571c_I20211231" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185Ny9mcmFnOmRmZjk3MmRkZDM3NDQ5NzNiY2U4YjMwMmJlMzhjNjdhL3RhYmxlOjlmOTRjMTMwZTY4ZDQwYWM4ZGU2NjRlNjk0OTg1ZjZkL3RhYmxlcmFuZ2U6OWY5NGMxMzBlNjhkNDBhYzhkZTY2NGU2OTQ5ODVmNmRfMTAtMy0xLTEtNDYyMTI_054a038b-e010-4630-a61b-fabad197f239">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaae0909eafc24451b37ac98a3e7c4186_I20211231" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185Ny9mcmFnOmRmZjk3MmRkZDM3NDQ5NzNiY2U4YjMwMmJlMzhjNjdhL3RhYmxlOjlmOTRjMTMwZTY4ZDQwYWM4ZGU2NjRlNjk0OTg1ZjZkL3RhYmxlcmFuZ2U6OWY5NGMxMzBlNjhkNDBhYzhkZTY2NGU2OTQ5ODVmNmRfMTAtNS0xLTEtNDQ3ODg_4e8cf975-8d78-4e4c-ab7f-4cb4a99ace40">3,358</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c03158e62e14e9d93bc8351b82e61d2_I20211231" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185Ny9mcmFnOmRmZjk3MmRkZDM3NDQ5NzNiY2U4YjMwMmJlMzhjNjdhL3RhYmxlOjlmOTRjMTMwZTY4ZDQwYWM4ZGU2NjRlNjk0OTg1ZjZkL3RhYmxlcmFuZ2U6OWY5NGMxMzBlNjhkNDBhYzhkZTY2NGU2OTQ5ODVmNmRfMTAtNy0xLTEtNDYyMTI_d1dba684-51b9-445f-9804-48ce49aef8ac">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent liabilities - Icagen </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05df3e58efe24ec7831e64257f22be53_I20211231" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185Ny9mcmFnOmRmZjk3MmRkZDM3NDQ5NzNiY2U4YjMwMmJlMzhjNjdhL3RhYmxlOjlmOTRjMTMwZTY4ZDQwYWM4ZGU2NjRlNjk0OTg1ZjZkL3RhYmxlcmFuZ2U6OWY5NGMxMzBlNjhkNDBhYzhkZTY2NGU2OTQ5ODVmNmRfMTEtMS0xLTEtNDYyMTI_da07fea8-4bb7-4706-b880-e4b6a818e03f">7,364</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i518bc06c25204d4482b4301cdd1766e5_I20211231" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185Ny9mcmFnOmRmZjk3MmRkZDM3NDQ5NzNiY2U4YjMwMmJlMzhjNjdhL3RhYmxlOjlmOTRjMTMwZTY4ZDQwYWM4ZGU2NjRlNjk0OTg1ZjZkL3RhYmxlcmFuZ2U6OWY5NGMxMzBlNjhkNDBhYzhkZTY2NGU2OTQ5ODVmNmRfMTEtMy0xLTEtNDYyMTI_e9d3f728-6b70-4936-a360-340fed74e883">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaac590afaaf54948a1215ada11b67e6c_I20211231" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185Ny9mcmFnOmRmZjk3MmRkZDM3NDQ5NzNiY2U4YjMwMmJlMzhjNjdhL3RhYmxlOjlmOTRjMTMwZTY4ZDQwYWM4ZGU2NjRlNjk0OTg1ZjZkL3RhYmxlcmFuZ2U6OWY5NGMxMzBlNjhkNDBhYzhkZTY2NGU2OTQ5ODVmNmRfMTEtNS0xLTEtNDYyMTI_19d539d1-1f46-40c1-b0e6-be1189a2cf2c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a59fb8107e140aaad7a5aeb9e7c180b_I20211231" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185Ny9mcmFnOmRmZjk3MmRkZDM3NDQ5NzNiY2U4YjMwMmJlMzhjNjdhL3RhYmxlOjlmOTRjMTMwZTY4ZDQwYWM4ZGU2NjRlNjk0OTg1ZjZkL3RhYmxlcmFuZ2U6OWY5NGMxMzBlNjhkNDBhYzhkZTY2NGU2OTQ5ODVmNmRfMTEtNy0xLTEtNDQ3OTc_84a247a5-f377-468b-9c73-2c114905d031">7,364</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liability for amounts owed to a former licensor</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36dc23d032314fa8a07bbd180231487a_I20211231" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185Ny9mcmFnOmRmZjk3MmRkZDM3NDQ5NzNiY2U4YjMwMmJlMzhjNjdhL3RhYmxlOjlmOTRjMTMwZTY4ZDQwYWM4ZGU2NjRlNjk0OTg1ZjZkL3RhYmxlcmFuZ2U6OWY5NGMxMzBlNjhkNDBhYzhkZTY2NGU2OTQ5ODVmNmRfMTMtMS0xLTEtNDYyMTU_fbbb3ff2-2d26-4d1b-adad-497856a7f856">86</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i01b8d0c82ed84b4ca4d821ca4a42eeba_I20211231" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185Ny9mcmFnOmRmZjk3MmRkZDM3NDQ5NzNiY2U4YjMwMmJlMzhjNjdhL3RhYmxlOjlmOTRjMTMwZTY4ZDQwYWM4ZGU2NjRlNjk0OTg1ZjZkL3RhYmxlcmFuZ2U6OWY5NGMxMzBlNjhkNDBhYzhkZTY2NGU2OTQ5ODVmNmRfMTMtMy0xLTEtNDQ4MjA_e1bea77c-b5b9-43f1-8792-094ad5ebad96">86</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic60c56fc16f0480485730f8ab7210dd9_I20211231" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185Ny9mcmFnOmRmZjk3MmRkZDM3NDQ5NzNiY2U4YjMwMmJlMzhjNjdhL3RhYmxlOjlmOTRjMTMwZTY4ZDQwYWM4ZGU2NjRlNjk0OTg1ZjZkL3RhYmxlcmFuZ2U6OWY5NGMxMzBlNjhkNDBhYzhkZTY2NGU2OTQ5ODVmNmRfMTMtNS0xLTEtNDYyMTU_9f662105-ea17-43ba-a934-80c607a036f2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iffa6d45b279f45088e9ebcb1bda002cc_I20211231" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185Ny9mcmFnOmRmZjk3MmRkZDM3NDQ5NzNiY2U4YjMwMmJlMzhjNjdhL3RhYmxlOjlmOTRjMTMwZTY4ZDQwYWM4ZGU2NjRlNjk0OTg1ZjZkL3RhYmxlcmFuZ2U6OWY5NGMxMzBlNjhkNDBhYzhkZTY2NGU2OTQ5ODVmNmRfMTMtNy0xLTEtNDYyMTU_c83656aa-c732-4f76-a69d-2d8276dbc936">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83d2c94c6e0b4e79aceeeff3efa78c20_I20211231" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185Ny9mcmFnOmRmZjk3MmRkZDM3NDQ5NzNiY2U4YjMwMmJlMzhjNjdhL3RhYmxlOjlmOTRjMTMwZTY4ZDQwYWM4ZGU2NjRlNjk0OTg1ZjZkL3RhYmxlcmFuZ2U6OWY5NGMxMzBlNjhkNDBhYzhkZTY2NGU2OTQ5ODVmNmRfMTQtMS0xLTEtNDYyMTU_5c642bc7-74b8-4988-b95f-46d2045063a1">11,157</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a0bee3568b44a9bb12563aeaa8528f5_I20211231" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185Ny9mcmFnOmRmZjk3MmRkZDM3NDQ5NzNiY2U4YjMwMmJlMzhjNjdhL3RhYmxlOjlmOTRjMTMwZTY4ZDQwYWM4ZGU2NjRlNjk0OTg1ZjZkL3RhYmxlcmFuZ2U6OWY5NGMxMzBlNjhkNDBhYzhkZTY2NGU2OTQ5ODVmNmRfMTQtMy0xLTEtNDYyMTU_9e5b4a53-e7ca-457f-9f0f-2b942c38c22f">86</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d8c9f4eb5724240a7b9559155e19d8f_I20211231" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185Ny9mcmFnOmRmZjk3MmRkZDM3NDQ5NzNiY2U4YjMwMmJlMzhjNjdhL3RhYmxlOjlmOTRjMTMwZTY4ZDQwYWM4ZGU2NjRlNjk0OTg1ZjZkL3RhYmxlcmFuZ2U6OWY5NGMxMzBlNjhkNDBhYzhkZTY2NGU2OTQ5ODVmNmRfMTQtNS0xLTEtNDYyMTU_34435a7a-7916-4cfc-a1e2-1395c854e5fa">3,358</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33b5cd64b00744faaf121a59ccec8a90_I20211231" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185Ny9mcmFnOmRmZjk3MmRkZDM3NDQ5NzNiY2U4YjMwMmJlMzhjNjdhL3RhYmxlOjlmOTRjMTMwZTY4ZDQwYWM4ZGU2NjRlNjk0OTg1ZjZkL3RhYmxlcmFuZ2U6OWY5NGMxMzBlNjhkNDBhYzhkZTY2NGU2OTQ5ODVmNmRfMTQtNy0xLTEtNDYyMTU_7d767b0a-5647-400a-87f8-de87a0a7e8fe">7,713</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.268%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.473%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.473%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.473%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.623%"></td><td style="width:0.1%"></td></tr><tr><td colspan="24" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements at Reporting Date Using</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted Prices in</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Active Markets</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">for Identical</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Assets</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Observable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Inputs</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unobservable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Inputs</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level&#160;1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level&#160;2)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level&#160;3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc51353676e643b3841a0d97b6e09df4_I20201231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185Ny9mcmFnOmRmZjk3MmRkZDM3NDQ5NzNiY2U4YjMwMmJlMzhjNjdhL3RhYmxlOmEzZGEzNzRmZGQyZjQ2YWQ4YzYyZjVjZDFmNTM5YmM5L3RhYmxlcmFuZ2U6YTNkYTM3NGZkZDJmNDZhZDhjNjJmNWNkMWY1MzliYzlfNC0xLTEtMS00MTI5NA_80a06898-be18-46f2-8c53-06a89e079826">324,478</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e29fab916b04659a0092e93e4ce0c0f_I20201231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185Ny9mcmFnOmRmZjk3MmRkZDM3NDQ5NzNiY2U4YjMwMmJlMzhjNjdhL3RhYmxlOmEzZGEzNzRmZGQyZjQ2YWQ4YzYyZjVjZDFmNTM5YmM5L3RhYmxlcmFuZ2U6YTNkYTM3NGZkZDJmNDZhZDhjNjJmNWNkMWY1MzliYzlfNC0zLTEtMS00MTI5NA_fc3113f8-0a8e-4ba2-95a6-28163704ec81">3,438</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb7f607e997042d6b7cb2a76b14c89ff_I20201231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185Ny9mcmFnOmRmZjk3MmRkZDM3NDQ5NzNiY2U4YjMwMmJlMzhjNjdhL3RhYmxlOmEzZGEzNzRmZGQyZjQ2YWQ4YzYyZjVjZDFmNTM5YmM5L3RhYmxlcmFuZ2U6YTNkYTM3NGZkZDJmNDZhZDhjNjJmNWNkMWY1MzliYzlfNC01LTEtMS00MTI5NA_ab117a60-2b3a-4c98-908e-7d5155bb1d41">320,647</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieef2fe5db0a5418095a2663aac7e9433_I20201231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185Ny9mcmFnOmRmZjk3MmRkZDM3NDQ5NzNiY2U4YjMwMmJlMzhjNjdhL3RhYmxlOmEzZGEzNzRmZGQyZjQ2YWQ4YzYyZjVjZDFmNTM5YmM5L3RhYmxlcmFuZ2U6YTNkYTM3NGZkZDJmNDZhZDhjNjJmNWNkMWY1MzliYzlfNC03LTEtMS00MTI5NA_5eee8ae1-e838-48eb-b559-47da95b56bc9">393</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in Viking common stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d9e2c86e31846918735fb68e1980c7b_I20201231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185Ny9mcmFnOmRmZjk3MmRkZDM3NDQ5NzNiY2U4YjMwMmJlMzhjNjdhL3RhYmxlOmEzZGEzNzRmZGQyZjQ2YWQ4YzYyZjVjZDFmNTM5YmM5L3RhYmxlcmFuZ2U6YTNkYTM3NGZkZDJmNDZhZDhjNjJmNWNkMWY1MzliYzlfNS0xLTEtMS00MTI5NA_04fd4e95-e5c4-47fd-a61b-34e457aa2ff3">32,763</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4633e33cdaf74da5bab73b86a73c762b_I20201231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185Ny9mcmFnOmRmZjk3MmRkZDM3NDQ5NzNiY2U4YjMwMmJlMzhjNjdhL3RhYmxlOmEzZGEzNzRmZGQyZjQ2YWQ4YzYyZjVjZDFmNTM5YmM5L3RhYmxlcmFuZ2U6YTNkYTM3NGZkZDJmNDZhZDhjNjJmNWNkMWY1MzliYzlfNS0zLTEtMS00MTI5NA_4b884e6c-d0cd-442b-897f-5fb556d3a426">32,763</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5465f391d98d450686c03b0526a9298e_I20201231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185Ny9mcmFnOmRmZjk3MmRkZDM3NDQ5NzNiY2U4YjMwMmJlMzhjNjdhL3RhYmxlOmEzZGEzNzRmZGQyZjQ2YWQ4YzYyZjVjZDFmNTM5YmM5L3RhYmxlcmFuZ2U6YTNkYTM3NGZkZDJmNDZhZDhjNjJmNWNkMWY1MzliYzlfNS01LTEtMS00MTI5NA_ffc63f23-19d3-4f3a-9f67-4ed4c9758511">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64e87aeff0584255b5155e1fb7330377_I20201231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185Ny9mcmFnOmRmZjk3MmRkZDM3NDQ5NzNiY2U4YjMwMmJlMzhjNjdhL3RhYmxlOmEzZGEzNzRmZGQyZjQ2YWQ4YzYyZjVjZDFmNTM5YmM5L3RhYmxlcmFuZ2U6YTNkYTM3NGZkZDJmNDZhZDhjNjJmNWNkMWY1MzliYzlfNS03LTEtMS00MTI5NA_141b599d-6188-44e1-8a53-1e6869a45b18">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in Viking warrants </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9fde372ecc73482ea79fc251841260be_I20201231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185Ny9mcmFnOmRmZjk3MmRkZDM3NDQ5NzNiY2U4YjMwMmJlMzhjNjdhL3RhYmxlOmEzZGEzNzRmZGQyZjQ2YWQ4YzYyZjVjZDFmNTM5YmM5L3RhYmxlcmFuZ2U6YTNkYTM3NGZkZDJmNDZhZDhjNjJmNWNkMWY1MzliYzlfNi0xLTEtMS00MTI5NA_4a36c28b-1960-463b-aa28-95bf20d1d60f">6,326</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad3afe93dc254f3a87134b83bff3a320_I20201231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185Ny9mcmFnOmRmZjk3MmRkZDM3NDQ5NzNiY2U4YjMwMmJlMzhjNjdhL3RhYmxlOmEzZGEzNzRmZGQyZjQ2YWQ4YzYyZjVjZDFmNTM5YmM5L3RhYmxlcmFuZ2U6YTNkYTM3NGZkZDJmNDZhZDhjNjJmNWNkMWY1MzliYzlfNi0zLTEtMS00MTI5NA_313d0c61-b5c5-4183-9511-99e89f473482">6,326</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if82c17ea55e64548ab7c37f50afc7954_I20201231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185Ny9mcmFnOmRmZjk3MmRkZDM3NDQ5NzNiY2U4YjMwMmJlMzhjNjdhL3RhYmxlOmEzZGEzNzRmZGQyZjQ2YWQ4YzYyZjVjZDFmNTM5YmM5L3RhYmxlcmFuZ2U6YTNkYTM3NGZkZDJmNDZhZDhjNjJmNWNkMWY1MzliYzlfNi01LTEtMS00MTI5NA_1dc7d050-b234-429a-84eb-840f67ca5812">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ec6e8e1b38040ff9f9c4e67b129466c_I20201231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185Ny9mcmFnOmRmZjk3MmRkZDM3NDQ5NzNiY2U4YjMwMmJlMzhjNjdhL3RhYmxlOmEzZGEzNzRmZGQyZjQ2YWQ4YzYyZjVjZDFmNTM5YmM5L3RhYmxlcmFuZ2U6YTNkYTM3NGZkZDJmNDZhZDhjNjJmNWNkMWY1MzliYzlfNi03LTEtMS00MTI5NA_c6e4f421-f622-41dd-b0d0-b55080e3d6b5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if603e492b3b54ca58c52c72f0db1a614_I20201231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185Ny9mcmFnOmRmZjk3MmRkZDM3NDQ5NzNiY2U4YjMwMmJlMzhjNjdhL3RhYmxlOmEzZGEzNzRmZGQyZjQ2YWQ4YzYyZjVjZDFmNTM5YmM5L3RhYmxlcmFuZ2U6YTNkYTM3NGZkZDJmNDZhZDhjNjJmNWNkMWY1MzliYzlfNy0xLTEtMS00MTI5NA_55143552-302b-42d2-a442-3d5e20d1b216">363,567</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04c0a503b677413e90c282c029cef0df_I20201231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185Ny9mcmFnOmRmZjk3MmRkZDM3NDQ5NzNiY2U4YjMwMmJlMzhjNjdhL3RhYmxlOmEzZGEzNzRmZGQyZjQ2YWQ4YzYyZjVjZDFmNTM5YmM5L3RhYmxlcmFuZ2U6YTNkYTM3NGZkZDJmNDZhZDhjNjJmNWNkMWY1MzliYzlfNy0zLTEtMS00MTI5NA_258db80e-90a4-4cfe-a027-ef090fc428cb">42,527</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90e770e8ee9247f492c911fccc5f09ee_I20201231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185Ny9mcmFnOmRmZjk3MmRkZDM3NDQ5NzNiY2U4YjMwMmJlMzhjNjdhL3RhYmxlOmEzZGEzNzRmZGQyZjQ2YWQ4YzYyZjVjZDFmNTM5YmM5L3RhYmxlcmFuZ2U6YTNkYTM3NGZkZDJmNDZhZDhjNjJmNWNkMWY1MzliYzlfNy01LTEtMS00MTI5NA_ed72575a-474f-4443-b3b0-48c9caa1fd10">320,647</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c5d55bf4e3a4a18a904ad6c106afe1b_I20201231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185Ny9mcmFnOmRmZjk3MmRkZDM3NDQ5NzNiY2U4YjMwMmJlMzhjNjdhL3RhYmxlOmEzZGEzNzRmZGQyZjQ2YWQ4YzYyZjVjZDFmNTM5YmM5L3RhYmxlcmFuZ2U6YTNkYTM3NGZkZDJmNDZhZDhjNjJmNWNkMWY1MzliYzlfNy03LTEtMS00MTI5NA_622d2bf0-f2c5-43d3-9357-8554796cbff4">393</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent liabilities - Crystal </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89bb63fa9a9347e5b89eddf911a574ec_I20201231" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185Ny9mcmFnOmRmZjk3MmRkZDM3NDQ5NzNiY2U4YjMwMmJlMzhjNjdhL3RhYmxlOmEzZGEzNzRmZGQyZjQ2YWQ4YzYyZjVjZDFmNTM5YmM5L3RhYmxlcmFuZ2U6YTNkYTM3NGZkZDJmNDZhZDhjNjJmNWNkMWY1MzliYzlfOS0xLTEtMS00MTI5NA_25d44c91-adef-4f16-8ff7-c6b6195addf7">800</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8dbef5f05d649cfa20404b188f90797_I20201231" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185Ny9mcmFnOmRmZjk3MmRkZDM3NDQ5NzNiY2U4YjMwMmJlMzhjNjdhL3RhYmxlOmEzZGEzNzRmZGQyZjQ2YWQ4YzYyZjVjZDFmNTM5YmM5L3RhYmxlcmFuZ2U6YTNkYTM3NGZkZDJmNDZhZDhjNjJmNWNkMWY1MzliYzlfOS0zLTEtMS00MTI5NA_0940da18-7918-4236-bc62-c73b46715366">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b774db056ca4e6fbb86b328cdf6ec7e_I20201231" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185Ny9mcmFnOmRmZjk3MmRkZDM3NDQ5NzNiY2U4YjMwMmJlMzhjNjdhL3RhYmxlOmEzZGEzNzRmZGQyZjQ2YWQ4YzYyZjVjZDFmNTM5YmM5L3RhYmxlcmFuZ2U6YTNkYTM3NGZkZDJmNDZhZDhjNjJmNWNkMWY1MzliYzlfOS01LTEtMS00MTI5NA_b958df0d-3f64-40bf-a7d6-95e4c4ed89b6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49c492d399144f8f95065abe6a77d858_I20201231" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185Ny9mcmFnOmRmZjk3MmRkZDM3NDQ5NzNiY2U4YjMwMmJlMzhjNjdhL3RhYmxlOmEzZGEzNzRmZGQyZjQ2YWQ4YzYyZjVjZDFmNTM5YmM5L3RhYmxlcmFuZ2U6YTNkYTM3NGZkZDJmNDZhZDhjNjJmNWNkMWY1MzliYzlfOS03LTEtMS00MTI5NA_93263cdd-97bf-473e-b5f9-261bec899818">800</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent liabilities - Cydex</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i09e78cdf01344954a110ff4100c16b89_I20201231" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185Ny9mcmFnOmRmZjk3MmRkZDM3NDQ5NzNiY2U4YjMwMmJlMzhjNjdhL3RhYmxlOmEzZGEzNzRmZGQyZjQ2YWQ4YzYyZjVjZDFmNTM5YmM5L3RhYmxlcmFuZ2U6YTNkYTM3NGZkZDJmNDZhZDhjNjJmNWNkMWY1MzliYzlfMTAtMS0xLTEtNDEyOTQ_70f7333e-0fbd-40c1-be6d-1ed056b01ce7">508</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i641dc2acfdc24382ac77f797d0b878dc_I20201231" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185Ny9mcmFnOmRmZjk3MmRkZDM3NDQ5NzNiY2U4YjMwMmJlMzhjNjdhL3RhYmxlOmEzZGEzNzRmZGQyZjQ2YWQ4YzYyZjVjZDFmNTM5YmM5L3RhYmxlcmFuZ2U6YTNkYTM3NGZkZDJmNDZhZDhjNjJmNWNkMWY1MzliYzlfMTAtMy0xLTEtNDEyOTQ_0ab1eff0-4764-46ac-a57b-615bdae67116">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94796a987fa04da6b4328a1f6396c729_I20201231" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185Ny9mcmFnOmRmZjk3MmRkZDM3NDQ5NzNiY2U4YjMwMmJlMzhjNjdhL3RhYmxlOmEzZGEzNzRmZGQyZjQ2YWQ4YzYyZjVjZDFmNTM5YmM5L3RhYmxlcmFuZ2U6YTNkYTM3NGZkZDJmNDZhZDhjNjJmNWNkMWY1MzliYzlfMTAtNS0xLTEtNDEyOTQ_024a3e02-8725-48fd-9d9c-db56e6ec2a2b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ab1ef46b3dc4b3687c20938c246e8e1_I20201231" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185Ny9mcmFnOmRmZjk3MmRkZDM3NDQ5NzNiY2U4YjMwMmJlMzhjNjdhL3RhYmxlOmEzZGEzNzRmZGQyZjQ2YWQ4YzYyZjVjZDFmNTM5YmM5L3RhYmxlcmFuZ2U6YTNkYTM3NGZkZDJmNDZhZDhjNjJmNWNkMWY1MzliYzlfMTAtNy0xLTEtNDEyOTQ_7dca6394-183f-4962-b8ce-fa84bad5d643">508</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent liabilities - Metabasis </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64ddda8f7dd340a6a66150fe9da6ac8f_I20201231" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185Ny9mcmFnOmRmZjk3MmRkZDM3NDQ5NzNiY2U4YjMwMmJlMzhjNjdhL3RhYmxlOmEzZGEzNzRmZGQyZjQ2YWQ4YzYyZjVjZDFmNTM5YmM5L3RhYmxlcmFuZ2U6YTNkYTM3NGZkZDJmNDZhZDhjNjJmNWNkMWY1MzliYzlfMTEtMS0xLTEtNDEyOTQ_9a2422e3-8fff-4e5b-aaa4-156903e065a2">3,821</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a14312c0d7a4b6ab188c0d69af3db1b_I20201231" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185Ny9mcmFnOmRmZjk3MmRkZDM3NDQ5NzNiY2U4YjMwMmJlMzhjNjdhL3RhYmxlOmEzZGEzNzRmZGQyZjQ2YWQ4YzYyZjVjZDFmNTM5YmM5L3RhYmxlcmFuZ2U6YTNkYTM3NGZkZDJmNDZhZDhjNjJmNWNkMWY1MzliYzlfMTEtMy0xLTEtNDEyOTQ_d50fdc3a-2fdd-4df5-9abd-52e366441f5f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4994043653b246e6825b1757a960c104_I20201231" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185Ny9mcmFnOmRmZjk3MmRkZDM3NDQ5NzNiY2U4YjMwMmJlMzhjNjdhL3RhYmxlOmEzZGEzNzRmZGQyZjQ2YWQ4YzYyZjVjZDFmNTM5YmM5L3RhYmxlcmFuZ2U6YTNkYTM3NGZkZDJmNDZhZDhjNjJmNWNkMWY1MzliYzlfMTEtNS0xLTEtNDEyOTQ_484b01d2-060d-4f42-90b5-0306dd31c7d5">3,821</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11062dc1f4334dbda82a1482afce4add_I20201231" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185Ny9mcmFnOmRmZjk3MmRkZDM3NDQ5NzNiY2U4YjMwMmJlMzhjNjdhL3RhYmxlOmEzZGEzNzRmZGQyZjQ2YWQ4YzYyZjVjZDFmNTM5YmM5L3RhYmxlcmFuZ2U6YTNkYTM3NGZkZDJmNDZhZDhjNjJmNWNkMWY1MzliYzlfMTEtNy0xLTEtNDEyOTQ_2f8c7248-fc94-4198-981d-ba98364a88d1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent liabilities - Icagen </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a6efdc157074e8abf3dbebb0b3ad1b2_I20201231" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185Ny9mcmFnOmRmZjk3MmRkZDM3NDQ5NzNiY2U4YjMwMmJlMzhjNjdhL3RhYmxlOmEzZGEzNzRmZGQyZjQ2YWQ4YzYyZjVjZDFmNTM5YmM5L3RhYmxlcmFuZ2U6YTNkYTM3NGZkZDJmNDZhZDhjNjJmNWNkMWY1MzliYzlfMTItMS0xLTEtNDQ3MDU_98aeca10-49f3-41ff-9c88-dab1065666ef">6,404</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i766d5476b4ed450888509671880dd88e_I20201231" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185Ny9mcmFnOmRmZjk3MmRkZDM3NDQ5NzNiY2U4YjMwMmJlMzhjNjdhL3RhYmxlOmEzZGEzNzRmZGQyZjQ2YWQ4YzYyZjVjZDFmNTM5YmM5L3RhYmxlcmFuZ2U6YTNkYTM3NGZkZDJmNDZhZDhjNjJmNWNkMWY1MzliYzlfMTItMy0xLTEtNDYyMDU_6947df1f-383b-41cd-bdfc-0df71033c65d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i32ce3f371084478bae9051b730d767d9_I20201231" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185Ny9mcmFnOmRmZjk3MmRkZDM3NDQ5NzNiY2U4YjMwMmJlMzhjNjdhL3RhYmxlOmEzZGEzNzRmZGQyZjQ2YWQ4YzYyZjVjZDFmNTM5YmM5L3RhYmxlcmFuZ2U6YTNkYTM3NGZkZDJmNDZhZDhjNjJmNWNkMWY1MzliYzlfMTItNS0xLTEtNDYyMDU_efcb7ecd-5e3c-4aa0-989f-9f5cb1fb667d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3c716beea168465687c12c65fb1f22bc_I20201231" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185Ny9mcmFnOmRmZjk3MmRkZDM3NDQ5NzNiY2U4YjMwMmJlMzhjNjdhL3RhYmxlOmEzZGEzNzRmZGQyZjQ2YWQ4YzYyZjVjZDFmNTM5YmM5L3RhYmxlcmFuZ2U6YTNkYTM3NGZkZDJmNDZhZDhjNjJmNWNkMWY1MzliYzlfMTItNy0xLTEtNDQ2ODk_acb1b34d-e343-45dc-9a0e-cc2ad7493ec7">6,404</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent liabilities - Pfenex </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(6)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i795fda855e164fe998d1404c211cfeff_I20201231" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185Ny9mcmFnOmRmZjk3MmRkZDM3NDQ5NzNiY2U4YjMwMmJlMzhjNjdhL3RhYmxlOmEzZGEzNzRmZGQyZjQ2YWQ4YzYyZjVjZDFmNTM5YmM5L3RhYmxlcmFuZ2U6YTNkYTM3NGZkZDJmNDZhZDhjNjJmNWNkMWY1MzliYzlfMTMtMS0xLTEtNDQ3MDY_a0ea8656-fd3e-42da-8b79-4a4904fd4973">37,600</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ea2d72079aa4831af7d9061421a7429_I20201231" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185Ny9mcmFnOmRmZjk3MmRkZDM3NDQ5NzNiY2U4YjMwMmJlMzhjNjdhL3RhYmxlOmEzZGEzNzRmZGQyZjQ2YWQ4YzYyZjVjZDFmNTM5YmM5L3RhYmxlcmFuZ2U6YTNkYTM3NGZkZDJmNDZhZDhjNjJmNWNkMWY1MzliYzlfMTMtMy0xLTEtNDYyMDU_ea40fb10-fa02-4fbc-8cb4-3a293772f8b7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice7abf01eb9f42f5b54f5a4e479520a1_I20201231" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185Ny9mcmFnOmRmZjk3MmRkZDM3NDQ5NzNiY2U4YjMwMmJlMzhjNjdhL3RhYmxlOmEzZGEzNzRmZGQyZjQ2YWQ4YzYyZjVjZDFmNTM5YmM5L3RhYmxlcmFuZ2U6YTNkYTM3NGZkZDJmNDZhZDhjNjJmNWNkMWY1MzliYzlfMTMtNS0xLTEtNDYyMDU_3fee455e-0e4c-4a91-8ab9-0c031f0e04e8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0fd39b8e1ac4faebf9a08fe57ba3937_I20201231" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185Ny9mcmFnOmRmZjk3MmRkZDM3NDQ5NzNiY2U4YjMwMmJlMzhjNjdhL3RhYmxlOmEzZGEzNzRmZGQyZjQ2YWQ4YzYyZjVjZDFmNTM5YmM5L3RhYmxlcmFuZ2U6YTNkYTM3NGZkZDJmNDZhZDhjNjJmNWNkMWY1MzliYzlfMTMtNy0xLTEtNDQ2ODk_e517fbb9-961a-4cf4-8a0c-d7ecca4c3e3e">37,600</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liability for amounts owed to a former licensor</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2d95711871a49dda3f26e3f6251690b_I20201231" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185Ny9mcmFnOmRmZjk3MmRkZDM3NDQ5NzNiY2U4YjMwMmJlMzhjNjdhL3RhYmxlOmEzZGEzNzRmZGQyZjQ2YWQ4YzYyZjVjZDFmNTM5YmM5L3RhYmxlcmFuZ2U6YTNkYTM3NGZkZDJmNDZhZDhjNjJmNWNkMWY1MzliYzlfMTItMS0xLTEtNDEyOTQ_1ff137c0-c7bb-48c4-80fc-8ae1a72bb185">60</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1294f5d7b1847e0a6d5e6dbe332860f_I20201231" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185Ny9mcmFnOmRmZjk3MmRkZDM3NDQ5NzNiY2U4YjMwMmJlMzhjNjdhL3RhYmxlOmEzZGEzNzRmZGQyZjQ2YWQ4YzYyZjVjZDFmNTM5YmM5L3RhYmxlcmFuZ2U6YTNkYTM3NGZkZDJmNDZhZDhjNjJmNWNkMWY1MzliYzlfMTItMy0xLTEtNDEyOTQ_b997e78c-767a-45f1-92ea-c80ee8bdc7a4">60</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3682c8c511e421faf31bc8dcde15b42_I20201231" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185Ny9mcmFnOmRmZjk3MmRkZDM3NDQ5NzNiY2U4YjMwMmJlMzhjNjdhL3RhYmxlOmEzZGEzNzRmZGQyZjQ2YWQ4YzYyZjVjZDFmNTM5YmM5L3RhYmxlcmFuZ2U6YTNkYTM3NGZkZDJmNDZhZDhjNjJmNWNkMWY1MzliYzlfMTItNS0xLTEtNDEyOTQ_a768df4e-ba34-4c3d-9b44-c5860732a223">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idcc241ac9ac54103a54cc0d5e60c4f58_I20201231" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185Ny9mcmFnOmRmZjk3MmRkZDM3NDQ5NzNiY2U4YjMwMmJlMzhjNjdhL3RhYmxlOmEzZGEzNzRmZGQyZjQ2YWQ4YzYyZjVjZDFmNTM5YmM5L3RhYmxlcmFuZ2U6YTNkYTM3NGZkZDJmNDZhZDhjNjJmNWNkMWY1MzliYzlfMTItNy0xLTEtNDEyOTQ_ac3f2a42-6d9c-433c-be82-ea0773e9fd71">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if603e492b3b54ca58c52c72f0db1a614_I20201231" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185Ny9mcmFnOmRmZjk3MmRkZDM3NDQ5NzNiY2U4YjMwMmJlMzhjNjdhL3RhYmxlOmEzZGEzNzRmZGQyZjQ2YWQ4YzYyZjVjZDFmNTM5YmM5L3RhYmxlcmFuZ2U6YTNkYTM3NGZkZDJmNDZhZDhjNjJmNWNkMWY1MzliYzlfMTMtMS0xLTEtNDEyOTQ_6656574f-a6f7-4c69-a87e-c6564e13a3e8">49,193</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04c0a503b677413e90c282c029cef0df_I20201231" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185Ny9mcmFnOmRmZjk3MmRkZDM3NDQ5NzNiY2U4YjMwMmJlMzhjNjdhL3RhYmxlOmEzZGEzNzRmZGQyZjQ2YWQ4YzYyZjVjZDFmNTM5YmM5L3RhYmxlcmFuZ2U6YTNkYTM3NGZkZDJmNDZhZDhjNjJmNWNkMWY1MzliYzlfMTMtMy0xLTEtNDEyOTQ_e7429cdb-aa7a-40e3-9352-9df4c72a141d">60</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90e770e8ee9247f492c911fccc5f09ee_I20201231" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185Ny9mcmFnOmRmZjk3MmRkZDM3NDQ5NzNiY2U4YjMwMmJlMzhjNjdhL3RhYmxlOmEzZGEzNzRmZGQyZjQ2YWQ4YzYyZjVjZDFmNTM5YmM5L3RhYmxlcmFuZ2U6YTNkYTM3NGZkZDJmNDZhZDhjNjJmNWNkMWY1MzliYzlfMTMtNS0xLTEtNDEyOTQ_791158db-ac8f-4255-9db0-32f7c2730480">3,821</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c5d55bf4e3a4a18a904ad6c106afe1b_I20201231" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185Ny9mcmFnOmRmZjk3MmRkZDM3NDQ5NzNiY2U4YjMwMmJlMzhjNjdhL3RhYmxlOmEzZGEzNzRmZGQyZjQ2YWQ4YzYyZjVjZDFmNTM5YmM5L3RhYmxlcmFuZ2U6YTNkYTM3NGZkZDJmNDZhZDhjNjJmNWNkMWY1MzliYzlfMTMtNy0xLTEtNDEyOTQ_b03da12b-67b1-42d8-a435-07d8f24ab1f4">45,312</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">(1) Excluding our investment in Viking, our short-term investments in marketable debt and equity securities are classified as available-for-sale securities based on management's intentions and are at level 2 of the fair value hierarchy, as these investment securities are valued based upon quoted prices for identical or similar instruments in markets that are not active, and model-based valuation techniques for which all significant assumptions are observable in the market. Short-term investments in mutual funds are valued at their net asset value (NAV) on the last day of the period. We have classified marketable securities with original maturities of greater than one year as short-term investments based upon our ability and intent to use any and all of those marketable securities to satisfy the liquidity needs of our current operations. In addition, we have investment in warrants resulting from Seelos Therapeutics Inc. milestone payments that were settled in shares during the first quarter of 2019 and are at level 3 of the fair value hierarchy, based on Black Scholes value estimated by management on the last day of the period.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2) Investment in Viking warrants, which we received as a result of Viking&#8217;s partial repayment of the Viking note receivable and our purchase of Viking common stock and warrants in April 2016, is classified as level 1 as the fair value is determined using quoted market prices in active markets for the same securities. The change of the fair value is recorded in &#8220;gain (loss) from short-term investments&#8221; in our consolidated statement of operations. See further discussion in &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note (3), Short-term Investments: Investment in Viking.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221;  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3) The fair value of Crystal contingent liabilities was determined using a probability weighted income approach. Most of the contingent payments are based on development or regulatory milestones as defined in the merger agreement with Crystal. The fair value is subjective and is affected by changes in inputs to the valuation model including management&#8217;s estimates regarding the timing and probability of achievement of certain developmental and regulatory milestones. During the twelve months ended December&#160;31, 2020, we paid $<ix:nonFraction unitRef="usd" contextRef="i417532a79d3e4320bfa35df66295546e_D20200101-20201231" decimals="-5" name="us-gaap:PaymentForContingentConsiderationLiabilityOperatingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185Ny9mcmFnOmRmZjk3MmRkZDM3NDQ5NzNiY2U4YjMwMmJlMzhjNjdhL3RleHRyZWdpb246ZGZmOTcyZGRkMzc0NDk3M2JjZThiMzAyYmUzOGM2N2FfMzEzNQ_795b4bbf-080d-41e3-9325-02775e06db13">1.8</ix:nonFraction> million contingent liability on development milestones to former Crystal shareholders. </span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">75</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><ix:continuation id="i6293728540d94c4291dd64f6c81bb280" continuedAt="i2c0fcf373f8b4c318c1949f69359b262"><ix:continuation id="i3a973327c1794a1e81b0dbecdf6b36af"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(4) In connection with our acquisition of Metabasis in January 2010, we issued Metabasis stockholders <ix:nonFraction unitRef="agreement" contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231" decimals="INF" name="lgnd:NumberOfContingentValueRightAgreements" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185Ny9mcmFnOmRmZjk3MmRkZDM3NDQ5NzNiY2U4YjMwMmJlMzhjNjdhL3RleHRyZWdpb246ZGZmOTcyZGRkMzc0NDk3M2JjZThiMzAyYmUzOGM2N2FfMjE5OTAyMzI3Mjk5OA_3829b469-449a-4b0e-9a69-35b9ce44b0d8">four</ix:nonFraction> tradable CVRs, one CVR from each of four respective series of CVR, for each Metabasis share. The CVRs entitle Metabasis stockholders to cash payments as frequently as every six months as cash is received by us from proceeds from the sale or partnering of any of the Metabasis drug development programs, among other triggering events. The liability for the CVRs is determined using quoted prices in a market that is not active for the underlying CVR. The carrying amount of the liability may fluctuate significantly based upon quoted market prices and actual amounts paid under the agreements may be materially differ than the carrying amount of the liability. Several of the Metabasis drug development programs have been outlicensed to Viking, including VK2809. VK2809 is a novel selective TR-&#946; agonist with potential in multiple indications, including hypercholesterolemia, dyslipidemia, NASH, and X-ALD. Under the terms of the agreement with Viking, we may be entitled to up to $<ix:nonFraction unitRef="usd" contextRef="iedd254aeb5ed46a0bbbbaec3521899ab_I20211231" decimals="INF" name="us-gaap:Investments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185Ny9mcmFnOmRmZjk3MmRkZDM3NDQ5NzNiY2U4YjMwMmJlMzhjNjdhL3RleHRyZWdpb246ZGZmOTcyZGRkMzc0NDk3M2JjZThiMzAyYmUzOGM2N2FfNDMwNg_2d65c14f-8d6d-4cd3-bebf-ac18f4f5ed82">375.0</ix:nonFraction> million of development, regulatory and commercial milestones and tiered royalties on potential future sales including a $<ix:nonFraction unitRef="usd" contextRef="i5b1dfac6d5ae4926a0e3356f1fb10e83_I20211231" decimals="-5" name="us-gaap:ContractWithCustomerAssetGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185Ny9mcmFnOmRmZjk3MmRkZDM3NDQ5NzNiY2U4YjMwMmJlMzhjNjdhL3RleHRyZWdpb246ZGZmOTcyZGRkMzc0NDk3M2JjZThiMzAyYmUzOGM2N2FfNDQyMQ_5911e281-3856-42be-a8dc-009a904a0b80">10.0</ix:nonFraction> million payment upon initiation of a Phase 3 clinical trial.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(5) The fair value of Icagen contingent liabilities was determined using a probability weighted income approach. Most of the contingent payments are based on certain revenue milestones as defined in the asset purchase agreement with Icagen. The fair value is subjective and is affected by changes in inputs to the valuation model including management&#8217;s estimates regarding the timing and probability of achievement of certain developmental and regulatory milestones. Changes in these estimates may materially affect the fair value. During the year-end December 31, 2021, we paid a $<ix:nonFraction unitRef="usd" contextRef="ib43ce77d810a40fc9387e9ee784e9e68_D20210101-20211231" decimals="-5" name="us-gaap:PaymentForContingentConsiderationLiabilityOperatingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185Ny9mcmFnOmRmZjk3MmRkZDM3NDQ5NzNiY2U4YjMwMmJlMzhjNjdhL3RleHRyZWdpb246ZGZmOTcyZGRkMzc0NDk3M2JjZThiMzAyYmUzOGM2N2FfNTA1NA_46a947c1-15e8-4988-81da-b33b039d055e">1.1</ix:nonFraction> million contingent liability based on revenue milestones to Icagen.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(6) The fair value of the Pfenex contingent liability was determined using a probability adjusted income approach. These cash flows were then discounted to present value using a discount rate based on the market participants' cost of debt reflective of the Company. During the year-end December 31, 2021, we reduced the contingent liability by $<ix:nonFraction unitRef="usd" contextRef="i8c54435dabbb4bf1accc9ff53169d37a_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185Ny9mcmFnOmRmZjk3MmRkZDM3NDQ5NzNiY2U4YjMwMmJlMzhjNjdhL3RleHRyZWdpb246ZGZmOTcyZGRkMzc0NDk3M2JjZThiMzAyYmUzOGM2N2FfNzY5NjU4MTQxMTY4NA_e75465f0-0234-4214-892f-a60b597a4887">37.6</ix:nonFraction>&#160;million primarily due to the lower probability of achieving the specific development and regulatory milestone by December 31, 2021 as defined by the Pfenex CVR. See further detail on Pfenex CVR in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 4, Acquisitions</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</span></div></ix:continuation><div><span><br/></span></div><ix:nonNumeric contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185Ny9mcmFnOmRmZjk3MmRkZDM3NDQ5NzNiY2U4YjMwMmJlMzhjNjdhL3RleHRyZWdpb246ZGZmOTcyZGRkMzc0NDk3M2JjZThiMzAyYmUzOGM2N2FfNjkyNA_d52b0cab-45cb-44f5-a288-1b82d3c81742" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the level 3 financial instruments as of December&#160;31, 2021 is as follows (in thousands):</span></div><div style="text-align:center;text-indent:45pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.303%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.497%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of level 3 financial instruments as of December 31, 2020</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac18f57f540e4a9a8a4f9d6ca432b9ee_I20201231" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185Ny9mcmFnOmRmZjk3MmRkZDM3NDQ5NzNiY2U4YjMwMmJlMzhjNjdhL3RhYmxlOjNlODZjOWQ4ZjZhMDQ2Y2M5NDEwM2YzZDk3MGRhNDk3L3RhYmxlcmFuZ2U6M2U4NmM5ZDhmNmEwNDZjYzk0MTAzZjNkOTcwZGE0OTdfMS0xLTEtMS00MTI5NA_14294040-7362-4616-850a-05159b8ee263">45,312</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments to CVR holders and other contingency payments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i34b45bfb1f924acb8a8e2d99bc22a5fc_D20210101-20211231" decimals="-3" name="lgnd:PaymentsToContingentValueRightHolders" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185Ny9mcmFnOmRmZjk3MmRkZDM3NDQ5NzNiY2U4YjMwMmJlMzhjNjdhL3RhYmxlOjNlODZjOWQ4ZjZhMDQ2Y2M5NDEwM2YzZDk3MGRhNDk3L3RhYmxlcmFuZ2U6M2U4NmM5ZDhmNmEwNDZjYzk0MTAzZjNkOTcwZGE0OTdfMi0xLTEtMS00MTI5NA_ec99fe76-065b-4c38-a94c-7df62322805f">1,770</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value adjustments to contingent liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i34b45bfb1f924acb8a8e2d99bc22a5fc_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185Ny9mcmFnOmRmZjk3MmRkZDM3NDQ5NzNiY2U4YjMwMmJlMzhjNjdhL3RhYmxlOjNlODZjOWQ4ZjZhMDQ2Y2M5NDEwM2YzZDk3MGRhNDk3L3RhYmxlcmFuZ2U6M2U4NmM5ZDhmNmEwNDZjYzk0MTAzZjNkOTcwZGE0OTdfMy0xLTEtMS00MTI5NA_57a64f1b-549b-4164-8f40-7b217c493a76">36,549</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent liabilities from xCella asset acquisition</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34b45bfb1f924acb8a8e2d99bc22a5fc_D20210101-20211231" decimals="-3" name="lgnd:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityContingentConsiderationFromAcquisition" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185Ny9mcmFnOmRmZjk3MmRkZDM3NDQ5NzNiY2U4YjMwMmJlMzhjNjdhL3RhYmxlOjNlODZjOWQ4ZjZhMDQ2Y2M5NDEwM2YzZDk3MGRhNDk3L3RhYmxlcmFuZ2U6M2U4NmM5ZDhmNmEwNDZjYzk0MTAzZjNkOTcwZGE0OTdfNC0xLTEtMS00MTI5NA_811678c0-b981-4163-8bfa-1f991a0b5805">720</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of level 3 financial instruments as of December&#160;31, 2021</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5044d29e95d74c3fb4dfe5dd2471e761_I20211231" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185Ny9mcmFnOmRmZjk3MmRkZDM3NDQ5NzNiY2U4YjMwMmJlMzhjNjdhL3RhYmxlOjNlODZjOWQ4ZjZhMDQ2Y2M5NDEwM2YzZDk3MGRhNDk3L3RhYmxlcmFuZ2U6M2U4NmM5ZDhmNmEwNDZjYzk0MTAzZjNkOTcwZGE0OTdfNS0xLTEtMS00MTI5NA_cc3b32bc-a8ab-46f3-86ae-75bfca07be87">7,713</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Assets Measured on a Non-Recurring Basis</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We apply fair value techniques on a non-recurring basis associated with valuing potential impairment losses related to our goodwill, indefinite-lived intangible assets, and long-lived assets.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We evaluate goodwill and indefinite-lived intangible assets annually for impairment and whenever circumstances occur indicating that goodwill might be impaired. We determine the fair value of our reporting unit based on a combination of inputs, including the market capitalization of Ligand, as well as Level 3 inputs such as discounted cash flows, which are not observable from the market, directly or indirectly. We determine the fair value of our indefinite-lived intangible assets using the income approach based on Level 3 inputs.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There was <ix:nonFraction unitRef="usd" contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231" decimals="INF" name="us-gaap:AssetImpairmentCharges" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185Ny9mcmFnOmRmZjk3MmRkZDM3NDQ5NzNiY2U4YjMwMmJlMzhjNjdhL3RleHRyZWdpb246ZGZmOTcyZGRkMzc0NDk3M2JjZThiMzAyYmUzOGM2N2FfNjM5Mw_7fcb692a-662d-40f2-a240-501a608d9e4c">no</ix:nonFraction> impairment of our goodwill, indefinite-lived assets, or long-lived assets recorded during the twelve months ended December&#160;31, 2021.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value of Financial Instruments</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2014 and May 2018, we issued the 2019 Notes and 2023 Notes, respectively. We use quoted market rates in an inactive market, which are classified as a Level 2 input, to estimate the fair value of our 2019 and 2023 Notes. The carrying value of the notes does not reflect the market rate. See &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note (7), Convertible Senior Notes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; for additional information related to the fair value.</span></div></ix:continuation><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i2c0fcf373f8b4c318c1949f69359b262">In addition, our accounts receivable, accounts payable, accrued liabilities, current deferred revenue, current operating lease liabilities, current financing lease liabilities are financial instruments and are recorded at cost in the consolidated balance sheets. The estimated fair value of these financial instruments approximates their carrying value due to their short-term nature.</ix:continuation> </span></div><div id="i0fa6f906fb2e4e30bc5e873d2bb6a82c_100"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6.  <ix:nonNumeric contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231" name="us-gaap:LesseeOperatingLeasesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDAvZnJhZzpmNDRmMTQwOTY3NGU0MzVkYWNmMjkzYWVjOTgxYmE2NS90ZXh0cmVnaW9uOmY0NGYxNDA5Njc0ZTQzNWRhY2YyOTNhZWM5ODFiYTY1XzM4NDc_74e4f42a-c3f5-4584-816c-2247cbd92046" continuedAt="id32392cc3b2349f5988523ed675f1b89" escape="true"><ix:nonNumeric contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231" name="us-gaap:LesseeFinanceLeasesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDAvZnJhZzpmNDRmMTQwOTY3NGU0MzVkYWNmMjkzYWVjOTgxYmE2NS90ZXh0cmVnaW9uOmY0NGYxNDA5Njc0ZTQzNWRhY2YyOTNhZWM5ODFiYTY1XzM4NDc_ae8456e1-a1e4-4ae1-bc31-da9ebb9cdd0e" continuedAt="iaf1c10d669b34ce5aee970786d20f2a6" escape="true">Leases</ix:nonNumeric></ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="id32392cc3b2349f5988523ed675f1b89" continuedAt="ie297ce8930e242c3a44549fd7fa81bcb"><ix:continuation id="iaf1c10d669b34ce5aee970786d20f2a6" continuedAt="i48f50f7369d74c03a5b366f65811b2a4"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Finance lease</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In May 2020 and January 2021, we entered into an agreement and the first amendment with Hovione, our third-party manufacturer, to increase our manufacturing of Captisol, respectively. The agreements are considered to include an embedded finance lease under ASC 842, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Leases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, as it provides the Company the right to use the underlying equipment to exclusively </span></div></ix:continuation></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">76</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ie297ce8930e242c3a44549fd7fa81bcb" continuedAt="i3f9983564b8a410d9f337db626d7ce89"><ix:continuation id="i48f50f7369d74c03a5b366f65811b2a4" continuedAt="i129e542d86b049f2aae1cee0545e997d"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">manufacture Captisol. As of December&#160;31, 2021, we have fully paid consideration of $<ix:nonFraction unitRef="usd" contextRef="i874c2ad63f1a4f0295a0ad715157a00e_I20211231" decimals="-5" name="lgnd:PurchaseCommitmentConsiderationPaidToDate" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDAvZnJhZzpmNDRmMTQwOTY3NGU0MzVkYWNmMjkzYWVjOTgxYmE2NS90ZXh0cmVnaW9uOmY0NGYxNDA5Njc0ZTQzNWRhY2YyOTNhZWM5ODFiYTY1Xzc2OTY1ODE0MDIyODA_b6d39685-eeba-4a20-ae7c-7a8809718e83">69.1</ix:nonFraction>&#160;million for prepaid inventory and capacity ramp-up fee. We allocated consideration in the agreements between lease and non-lease components using relative standalone prices. Since the inception of the agreements, we have allocated $<ix:nonFraction unitRef="usd" contextRef="i874c2ad63f1a4f0295a0ad715157a00e_I20211231" decimals="-5" name="lgnd:PurchaseCommitmentConsiderationPaidAllocatedToInventory" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDAvZnJhZzpmNDRmMTQwOTY3NGU0MzVkYWNmMjkzYWVjOTgxYmE2NS90ZXh0cmVnaW9uOmY0NGYxNDA5Njc0ZTQzNWRhY2YyOTNhZWM5ODFiYTY1Xzk4OTU2MDQ2NjE4NTE_917c057c-347c-465e-8d03-c008428870a4">50.2</ix:nonFraction>&#160;million of the consideration paid to the non-lease component which is accounted for as prepaid inventory and being amortized to cost of Captisol based on the usage.  As of December&#160;31, 2021 the Hovione finance lease has <ix:nonFraction unitRef="usd" contextRef="i874c2ad63f1a4f0295a0ad715157a00e_I20211231" decimals="INF" name="us-gaap:FinanceLeaseLiability" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDAvZnJhZzpmNDRmMTQwOTY3NGU0MzVkYWNmMjkzYWVjOTgxYmE2NS90ZXh0cmVnaW9uOmY0NGYxNDA5Njc0ZTQzNWRhY2YyOTNhZWM5ODFiYTY1Xzc2OTY1ODE0MDIyOTc_f0c5d3ee-748a-4dae-a175-4c41a0520a98">no</ix:nonFraction> remaining lease liability and the right of use asset balance is $<ix:nonFraction unitRef="usd" contextRef="i3573e853130f4f1fbcdabc617380abaf_D20201001-20201031" decimals="-5" name="us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDAvZnJhZzpmNDRmMTQwOTY3NGU0MzVkYWNmMjkzYWVjOTgxYmE2NS90ZXh0cmVnaW9uOmY0NGYxNDA5Njc0ZTQzNWRhY2YyOTNhZWM5ODFiYTY1Xzc2OTY1ODE0MDUwNjk_e6a96e6e-f025-461b-b0af-0057cb12b89a">16.1</ix:nonFraction>&#160;million. The right of use asset is to be amortized straight-line over the remaining <ix:nonNumeric contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231" name="us-gaap:LesseeFinanceLeaseRemainingLeaseTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDAvZnJhZzpmNDRmMTQwOTY3NGU0MzVkYWNmMjkzYWVjOTgxYmE2NS90ZXh0cmVnaW9uOmY0NGYxNDA5Njc0ZTQzNWRhY2YyOTNhZWM5ODFiYTY1XzM4NDgyOTA3MDc5ODQ_4cab26ac-7796-4d50-9b2f-ae1fa8225e75">seven year</ix:nonNumeric> lease term. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Operating lease </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We lease certain office facilities and equipment primarily under various operating leases. Our operating leases have remaining contractual terms up to <ix:nonNumeric contextRef="ia2b01f0961da4bb18dfb8e25a49046e9_I20211231" name="us-gaap:LesseeOperatingLeaseRemainingLeaseTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDAvZnJhZzpmNDRmMTQwOTY3NGU0MzVkYWNmMjkzYWVjOTgxYmE2NS90ZXh0cmVnaW9uOmY0NGYxNDA5Njc0ZTQzNWRhY2YyOTNhZWM5ODFiYTY1XzE5MA_e4991621-bdc7-44d9-b794-e0df62167137">ten years</ix:nonNumeric>, some of which include options to extend the leases for up to <ix:nonNumeric contextRef="ia2b01f0961da4bb18dfb8e25a49046e9_I20211231" name="us-gaap:LesseeOperatingLeaseRenewalTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDAvZnJhZzpmNDRmMTQwOTY3NGU0MzVkYWNmMjkzYWVjOTgxYmE2NS90ZXh0cmVnaW9uOmY0NGYxNDA5Njc0ZTQzNWRhY2YyOTNhZWM5ODFiYTY1XzI1NQ_f523503f-03b3-4cd5-9420-58b8d740a29c">ten years</ix:nonNumeric>. Our lease agreements do not contain any material residual value guarantees, material restrictive covenants, or material termination options. Our operating lease costs are primarily related to facility leases for administration offices and research and development facilities.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease assets and lease liabilities are recognized at the commencement of an arrangement where it is determined at inception that a lease exists. Lease assets represent the right to use an underlying asset for the lease term, and lease liabilities represent the obligation to make lease payments arising from the lease. These assets and liabilities are initially recognized based on the present value of lease payments over the lease term calculated using our incremental borrowing rate generally applicable to the location of the lease asset, unless the implicit rate is readily determinable. Lease assets also include any upfront lease payments made and lease incentives. Lease terms include options to extend or terminate the lease when it is reasonably certain that those options will be exercised.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to base rent, certain of our operating leases require variable payments, such as insurance and common area maintenance. These variable lease costs, other than those dependent upon an index or rate, are expensed when the obligation for those payments is incurred. Leases with an initial term of 12 months or less are not recorded on the balance sheet, and the expense for these short-term leases and for operating leases is recognized on a straight-line basis over the lease term.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The depreciable life of lease assets and leasehold improvements is limited by the expected lease term, unless there is a transfer of title or purchase option reasonably certain of exercise.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2021, we entered into several new lease agreements including our Emeryville headquarter and animal facility expansion and a new Icagen office lease, which resulted in an increase in operating lease right of use assets of $<ix:nonFraction unitRef="usd" contextRef="i3280169138e848a0ba04a73dbb57193a_I20211231" decimals="-5" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDAvZnJhZzpmNDRmMTQwOTY3NGU0MzVkYWNmMjkzYWVjOTgxYmE2NS90ZXh0cmVnaW9uOmY0NGYxNDA5Njc0ZTQzNWRhY2YyOTNhZWM5ODFiYTY1Xzc2OTY1ODE0MDYzMjY_4ccdfe46-7a8b-476f-9a8e-1fbedd52ac15">12.7</ix:nonFraction>&#160;million  and lease liabilities of $<ix:nonFraction unitRef="usd" contextRef="i3280169138e848a0ba04a73dbb57193a_I20211231" decimals="-5" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDAvZnJhZzpmNDRmMTQwOTY3NGU0MzVkYWNmMjkzYWVjOTgxYmE2NS90ZXh0cmVnaW9uOmY0NGYxNDA5Njc0ZTQzNWRhY2YyOTNhZWM5ODFiYTY1XzM4NDgyOTA3MDE1NDQ_532e3d7c-0df5-48b1-8d52-588eff975435">13.2</ix:nonFraction>&#160;million as of December&#160;31, 2021 for the portion of the lease with a starting accounting lease commencement date during the period. </span></div><div><span><br/></span></div><ix:nonNumeric contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231" name="lgnd:AssetsAndLiabilitiesLesseeTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDAvZnJhZzpmNDRmMTQwOTY3NGU0MzVkYWNmMjkzYWVjOTgxYmE2NS90ZXh0cmVnaW9uOmY0NGYxNDA5Njc0ZTQzNWRhY2YyOTNhZWM5ODFiYTY1XzM4NDk_349c323e-9bbd-46fd-9f63-d5dd9a48c94a" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Operating and Finance Lease Assets and Liabilities (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.683%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.498%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating lease assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDAvZnJhZzpmNDRmMTQwOTY3NGU0MzVkYWNmMjkzYWVjOTgxYmE2NS90YWJsZToyNmY5ZDQ2ZjdiYTI0Y2E3OWY3YzM1YWYzY2NhMjdkMC90YWJsZXJhbmdlOjI2ZjlkNDZmN2JhMjRjYTc5ZjdjMzVhZjNjY2EyN2QwXzItMS0xLTEtNDEyOTQ_6d1ab5af-49db-4349-a362-0144c3fd7f0a">16,542</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7462d0db8f4248fcb9fd8f1deae439f3_I20201231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDAvZnJhZzpmNDRmMTQwOTY3NGU0MzVkYWNmMjkzYWVjOTgxYmE2NS90YWJsZToyNmY5ZDQ2ZjdiYTI0Y2E3OWY3YzM1YWYzY2NhMjdkMC90YWJsZXJhbmdlOjI2ZjlkNDZmN2JhMjRjYTc5ZjdjMzVhZjNjY2EyN2QwXzItMy0xLTEtNDEyOTQ_6dffdc3d-9003-4813-9f87-8a890595c6ae">6,892</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Finance lease assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231" decimals="-3" name="us-gaap:FinanceLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDAvZnJhZzpmNDRmMTQwOTY3NGU0MzVkYWNmMjkzYWVjOTgxYmE2NS90YWJsZToyNmY5ZDQ2ZjdiYTI0Y2E3OWY3YzM1YWYzY2NhMjdkMC90YWJsZXJhbmdlOjI2ZjlkNDZmN2JhMjRjYTc5ZjdjMzVhZjNjY2EyN2QwXzMtMS0xLTEtNDEyOTQ_fab60e52-3d40-4736-a4f7-28ef55eda14a">16,207</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7462d0db8f4248fcb9fd8f1deae439f3_I20201231" decimals="-3" name="us-gaap:FinanceLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDAvZnJhZzpmNDRmMTQwOTY3NGU0MzVkYWNmMjkzYWVjOTgxYmE2NS90YWJsZToyNmY5ZDQ2ZjdiYTI0Y2E3OWY3YzM1YWYzY2NhMjdkMC90YWJsZXJhbmdlOjI2ZjlkNDZmN2JhMjRjYTc5ZjdjMzVhZjNjY2EyN2QwXzMtMy0xLTEtNDEyOTQ_178c3372-1198-4d8e-8c99-5b8ac9aa2af6">15,842</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total lease assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231" decimals="-3" name="lgnd:LeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDAvZnJhZzpmNDRmMTQwOTY3NGU0MzVkYWNmMjkzYWVjOTgxYmE2NS90YWJsZToyNmY5ZDQ2ZjdiYTI0Y2E3OWY3YzM1YWYzY2NhMjdkMC90YWJsZXJhbmdlOjI2ZjlkNDZmN2JhMjRjYTc5ZjdjMzVhZjNjY2EyN2QwXzQtMS0xLTEtNDEyOTQ_327d9a6b-9984-47c8-8e47-5065a823f48a">32,749</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7462d0db8f4248fcb9fd8f1deae439f3_I20201231" decimals="-3" name="lgnd:LeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDAvZnJhZzpmNDRmMTQwOTY3NGU0MzVkYWNmMjkzYWVjOTgxYmE2NS90YWJsZToyNmY5ZDQ2ZjdiYTI0Y2E3OWY3YzM1YWYzY2NhMjdkMC90YWJsZXJhbmdlOjI2ZjlkNDZmN2JhMjRjYTc5ZjdjMzVhZjNjY2EyN2QwXzQtMy0xLTEtNDEyOTQ_50f397f7-8a4b-4858-97ad-32a2ff39e430">22,734</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current operating lease liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDAvZnJhZzpmNDRmMTQwOTY3NGU0MzVkYWNmMjkzYWVjOTgxYmE2NS90YWJsZToyNmY5ZDQ2ZjdiYTI0Y2E3OWY3YzM1YWYzY2NhMjdkMC90YWJsZXJhbmdlOjI2ZjlkNDZmN2JhMjRjYTc5ZjdjMzVhZjNjY2EyN2QwXzctMS0xLTEtNDEyOTQ_b9ad93d0-279c-4918-b5a4-0bec26fb128c">2,053</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7462d0db8f4248fcb9fd8f1deae439f3_I20201231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDAvZnJhZzpmNDRmMTQwOTY3NGU0MzVkYWNmMjkzYWVjOTgxYmE2NS90YWJsZToyNmY5ZDQ2ZjdiYTI0Y2E3OWY3YzM1YWYzY2NhMjdkMC90YWJsZXJhbmdlOjI2ZjlkNDZmN2JhMjRjYTc5ZjdjMzVhZjNjY2EyN2QwXzctMy0xLTEtNDEyOTQ_471b6efb-a48a-4459-a052-3be0a704db5a">1,885</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current finance lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231" decimals="-3" name="us-gaap:FinanceLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDAvZnJhZzpmNDRmMTQwOTY3NGU0MzVkYWNmMjkzYWVjOTgxYmE2NS90YWJsZToyNmY5ZDQ2ZjdiYTI0Y2E3OWY3YzM1YWYzY2NhMjdkMC90YWJsZXJhbmdlOjI2ZjlkNDZmN2JhMjRjYTc5ZjdjMzVhZjNjY2EyN2QwXzgtMS0xLTEtNDEyOTQ_7f5a81c9-21c3-48cd-a989-19ec627e8729">46</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7462d0db8f4248fcb9fd8f1deae439f3_I20201231" decimals="-3" name="us-gaap:FinanceLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDAvZnJhZzpmNDRmMTQwOTY3NGU0MzVkYWNmMjkzYWVjOTgxYmE2NS90YWJsZToyNmY5ZDQ2ZjdiYTI0Y2E3OWY3YzM1YWYzY2NhMjdkMC90YWJsZXJhbmdlOjI2ZjlkNDZmN2JhMjRjYTc5ZjdjMzVhZjNjY2EyN2QwXzgtMy0xLTEtNDEyOTQ_c1516387-94c1-4be8-bbb1-5892179eb9c8">6,593</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231" decimals="-3" name="lgnd:LeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDAvZnJhZzpmNDRmMTQwOTY3NGU0MzVkYWNmMjkzYWVjOTgxYmE2NS90YWJsZToyNmY5ZDQ2ZjdiYTI0Y2E3OWY3YzM1YWYzY2NhMjdkMC90YWJsZXJhbmdlOjI2ZjlkNDZmN2JhMjRjYTc5ZjdjMzVhZjNjY2EyN2QwXzktMS0xLTEtNDEyOTQ_8a6bbaa9-5727-4b24-935c-964a1d1d79f6">2,099</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7462d0db8f4248fcb9fd8f1deae439f3_I20201231" decimals="-3" name="lgnd:LeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDAvZnJhZzpmNDRmMTQwOTY3NGU0MzVkYWNmMjkzYWVjOTgxYmE2NS90YWJsZToyNmY5ZDQ2ZjdiYTI0Y2E3OWY3YzM1YWYzY2NhMjdkMC90YWJsZXJhbmdlOjI2ZjlkNDZmN2JhMjRjYTc5ZjdjMzVhZjNjY2EyN2QwXzktMy0xLTEtNDEyOTQ_852f4c04-224f-447b-86c8-774c3d4f7168">8,478</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Long-term operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDAvZnJhZzpmNDRmMTQwOTY3NGU0MzVkYWNmMjkzYWVjOTgxYmE2NS90YWJsZToyNmY5ZDQ2ZjdiYTI0Y2E3OWY3YzM1YWYzY2NhMjdkMC90YWJsZXJhbmdlOjI2ZjlkNDZmN2JhMjRjYTc5ZjdjMzVhZjNjY2EyN2QwXzEwLTEtMS0xLTQxMjk0_20380017-28cd-4446-9882-553a67242f34">15,494</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7462d0db8f4248fcb9fd8f1deae439f3_I20201231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDAvZnJhZzpmNDRmMTQwOTY3NGU0MzVkYWNmMjkzYWVjOTgxYmE2NS90YWJsZToyNmY5ZDQ2ZjdiYTI0Y2E3OWY3YzM1YWYzY2NhMjdkMC90YWJsZXJhbmdlOjI2ZjlkNDZmN2JhMjRjYTc5ZjdjMzVhZjNjY2EyN2QwXzEwLTMtMS0xLTQxMjk0_e8875dbd-bcdb-4178-8a86-36e1615bd76f">5,643</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDAvZnJhZzpmNDRmMTQwOTY3NGU0MzVkYWNmMjkzYWVjOTgxYmE2NS90YWJsZToyNmY5ZDQ2ZjdiYTI0Y2E3OWY3YzM1YWYzY2NhMjdkMC90YWJsZXJhbmdlOjI2ZjlkNDZmN2JhMjRjYTc5ZjdjMzVhZjNjY2EyN2QwXzExLTAtMS0xLTQxMjk0_189a0b16-c5f6-426a-9fe4-540e7d6227de"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDAvZnJhZzpmNDRmMTQwOTY3NGU0MzVkYWNmMjkzYWVjOTgxYmE2NS90YWJsZToyNmY5ZDQ2ZjdiYTI0Y2E3OWY3YzM1YWYzY2NhMjdkMC90YWJsZXJhbmdlOjI2ZjlkNDZmN2JhMjRjYTc5ZjdjMzVhZjNjY2EyN2QwXzExLTAtMS0xLTQxMjk0_2ee456c7-520d-4723-b00d-a8a6a8da65cf">Long-term finance lease liabilities</span></span></span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231" decimals="-3" name="us-gaap:FinanceLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDAvZnJhZzpmNDRmMTQwOTY3NGU0MzVkYWNmMjkzYWVjOTgxYmE2NS90YWJsZToyNmY5ZDQ2ZjdiYTI0Y2E3OWY3YzM1YWYzY2NhMjdkMC90YWJsZXJhbmdlOjI2ZjlkNDZmN2JhMjRjYTc5ZjdjMzVhZjNjY2EyN2QwXzExLTEtMS0xLTQxMjk0_35382d81-d04d-4911-92d9-5cd178a4adfa">58</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7462d0db8f4248fcb9fd8f1deae439f3_I20201231" decimals="-3" name="us-gaap:FinanceLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDAvZnJhZzpmNDRmMTQwOTY3NGU0MzVkYWNmMjkzYWVjOTgxYmE2NS90YWJsZToyNmY5ZDQ2ZjdiYTI0Y2E3OWY3YzM1YWYzY2NhMjdkMC90YWJsZXJhbmdlOjI2ZjlkNDZmN2JhMjRjYTc5ZjdjMzVhZjNjY2EyN2QwXzExLTMtMS0xLTQxMjk0_5a321e64-34ae-4326-9662-5724e5e0c9c3">112</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total lease liabilities   </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231" decimals="-3" name="lgnd:LeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDAvZnJhZzpmNDRmMTQwOTY3NGU0MzVkYWNmMjkzYWVjOTgxYmE2NS90YWJsZToyNmY5ZDQ2ZjdiYTI0Y2E3OWY3YzM1YWYzY2NhMjdkMC90YWJsZXJhbmdlOjI2ZjlkNDZmN2JhMjRjYTc5ZjdjMzVhZjNjY2EyN2QwXzEyLTEtMS0xLTQxMjk0_997b0332-3da7-46c8-ac58-87a57880c5da">17,651</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7462d0db8f4248fcb9fd8f1deae439f3_I20201231" decimals="-3" name="lgnd:LeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDAvZnJhZzpmNDRmMTQwOTY3NGU0MzVkYWNmMjkzYWVjOTgxYmE2NS90YWJsZToyNmY5ZDQ2ZjdiYTI0Y2E3OWY3YzM1YWYzY2NhMjdkMC90YWJsZXJhbmdlOjI2ZjlkNDZmN2JhMjRjYTc5ZjdjMzVhZjNjY2EyN2QwXzEyLTMtMS0xLTQxMjk0_f0985c1d-ffa8-41af-91bf-5021c8222b61">14,233</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div><ix:nonNumeric contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231" name="us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDAvZnJhZzpmNDRmMTQwOTY3NGU0MzVkYWNmMjkzYWVjOTgxYmE2NS90ZXh0cmVnaW9uOmY0NGYxNDA5Njc0ZTQzNWRhY2YyOTNhZWM5ODFiYTY1XzM4NDY_416e6819-bd6a-4d00-87de-032fdbcdd1ef" continuedAt="ib64d350484d04a2fba80ef681db11dc4" escape="true"><ix:nonNumeric contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDAvZnJhZzpmNDRmMTQwOTY3NGU0MzVkYWNmMjkzYWVjOTgxYmE2NS90ZXh0cmVnaW9uOmY0NGYxNDA5Njc0ZTQzNWRhY2YyOTNhZWM5ODFiYTY1XzM4NDY_a7656ee5-dd8c-40c7-a8e8-e474d245d5f7" continuedAt="i8de1a0a84118433da8379329d8263163" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Maturity of Operating and Finance Lease Liabilities as of December&#160;31, 2021</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(in thousands):</span></ix:nonNumeric></ix:nonNumeric></div></ix:continuation></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">77</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i3f9983564b8a410d9f337db626d7ce89"><ix:continuation id="i129e542d86b049f2aae1cee0545e997d"><div><ix:continuation id="ib64d350484d04a2fba80ef681db11dc4"><ix:continuation id="i8de1a0a84118433da8379329d8263163"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.391%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.499%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Maturity Dates</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating Leases</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Finance Leases</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDAvZnJhZzpmNDRmMTQwOTY3NGU0MzVkYWNmMjkzYWVjOTgxYmE2NS90YWJsZTpjNDViMGUzNzU3OGM0OTgzYmY0ODkwMTA3NjVmMDMzMS90YWJsZXJhbmdlOmM0NWIwZTM3NTc4YzQ5ODNiZjQ4OTAxMDc2NWYwMzMxXzEtMi0xLTEtNDEyOTQ_66fe697c-3b05-49d1-b00f-66a467203f60">3,653</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231" decimals="-3" name="us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDAvZnJhZzpmNDRmMTQwOTY3NGU0MzVkYWNmMjkzYWVjOTgxYmE2NS90YWJsZTpjNDViMGUzNzU3OGM0OTgzYmY0ODkwMTA3NjVmMDMzMS90YWJsZXJhbmdlOmM0NWIwZTM3NTc4YzQ5ODNiZjQ4OTAxMDc2NWYwMzMxXzEtNC0xLTEtNDEyOTQ_3a563c08-5b2f-4137-b1a8-c3a96757de03">56</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDAvZnJhZzpmNDRmMTQwOTY3NGU0MzVkYWNmMjkzYWVjOTgxYmE2NS90YWJsZTpjNDViMGUzNzU3OGM0OTgzYmY0ODkwMTA3NjVmMDMzMS90YWJsZXJhbmdlOmM0NWIwZTM3NTc4YzQ5ODNiZjQ4OTAxMDc2NWYwMzMxXzItMi0xLTEtNDEyOTQ_7ac93833-56d5-4c56-ae57-4367f9ab52c2">3,414</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231" decimals="-3" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDAvZnJhZzpmNDRmMTQwOTY3NGU0MzVkYWNmMjkzYWVjOTgxYmE2NS90YWJsZTpjNDViMGUzNzU3OGM0OTgzYmY0ODkwMTA3NjVmMDMzMS90YWJsZXJhbmdlOmM0NWIwZTM3NTc4YzQ5ODNiZjQ4OTAxMDc2NWYwMzMxXzItNC0xLTEtNDEyOTQ_e92292f6-0ad6-4894-adc8-d3a4161f8396">49</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDAvZnJhZzpmNDRmMTQwOTY3NGU0MzVkYWNmMjkzYWVjOTgxYmE2NS90YWJsZTpjNDViMGUzNzU3OGM0OTgzYmY0ODkwMTA3NjVmMDMzMS90YWJsZXJhbmdlOmM0NWIwZTM3NTc4YzQ5ODNiZjQ4OTAxMDc2NWYwMzMxXzMtMi0xLTEtNDEyOTQ_faabf3a6-1fec-4709-9567-11f8f9f159f9">2,716</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231" decimals="-3" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDAvZnJhZzpmNDRmMTQwOTY3NGU0MzVkYWNmMjkzYWVjOTgxYmE2NS90YWJsZTpjNDViMGUzNzU3OGM0OTgzYmY0ODkwMTA3NjVmMDMzMS90YWJsZXJhbmdlOmM0NWIwZTM3NTc4YzQ5ODNiZjQ4OTAxMDc2NWYwMzMxXzMtNC0xLTEtNDEyOTQ_9f290136-2644-456e-813e-5fdfcfe3c135">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDAvZnJhZzpmNDRmMTQwOTY3NGU0MzVkYWNmMjkzYWVjOTgxYmE2NS90YWJsZTpjNDViMGUzNzU3OGM0OTgzYmY0ODkwMTA3NjVmMDMzMS90YWJsZXJhbmdlOmM0NWIwZTM3NTc4YzQ5ODNiZjQ4OTAxMDc2NWYwMzMxXzQtMi0xLTEtNDEyOTQ_a89243c9-67d5-4c72-8da2-1162eb09b4ee">2,614</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231" decimals="-3" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearFour" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDAvZnJhZzpmNDRmMTQwOTY3NGU0MzVkYWNmMjkzYWVjOTgxYmE2NS90YWJsZTpjNDViMGUzNzU3OGM0OTgzYmY0ODkwMTA3NjVmMDMzMS90YWJsZXJhbmdlOmM0NWIwZTM3NTc4YzQ5ODNiZjQ4OTAxMDc2NWYwMzMxXzQtNC0xLTEtNDEyOTQ_276cd143-88fc-4815-9970-7af2ee476bfb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDAvZnJhZzpmNDRmMTQwOTY3NGU0MzVkYWNmMjkzYWVjOTgxYmE2NS90YWJsZTpjNDViMGUzNzU3OGM0OTgzYmY0ODkwMTA3NjVmMDMzMS90YWJsZXJhbmdlOmM0NWIwZTM3NTc4YzQ5ODNiZjQ4OTAxMDc2NWYwMzMxXzUtMi0xLTEtNDEyOTQ_c8b8ec9e-3cfd-4b94-b0d7-62d0d15f256b">2,670</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231" decimals="-3" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearFive" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDAvZnJhZzpmNDRmMTQwOTY3NGU0MzVkYWNmMjkzYWVjOTgxYmE2NS90YWJsZTpjNDViMGUzNzU3OGM0OTgzYmY0ODkwMTA3NjVmMDMzMS90YWJsZXJhbmdlOmM0NWIwZTM3NTc4YzQ5ODNiZjQ4OTAxMDc2NWYwMzMxXzUtNC0xLTEtNDEyOTQ_36d3540a-f8e6-4f01-9873-d49a60f01618">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDAvZnJhZzpmNDRmMTQwOTY3NGU0MzVkYWNmMjkzYWVjOTgxYmE2NS90YWJsZTpjNDViMGUzNzU3OGM0OTgzYmY0ODkwMTA3NjVmMDMzMS90YWJsZXJhbmdlOmM0NWIwZTM3NTc4YzQ5ODNiZjQ4OTAxMDc2NWYwMzMxXzYtMi0xLTEtNDEyOTQ_84db26d6-4b1b-41c0-b630-455048c1b19e">10,832</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231" decimals="-3" name="us-gaap:FinanceLeaseLiabilityPaymentsDueAfterYearFive" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDAvZnJhZzpmNDRmMTQwOTY3NGU0MzVkYWNmMjkzYWVjOTgxYmE2NS90YWJsZTpjNDViMGUzNzU3OGM0OTgzYmY0ODkwMTA3NjVmMDMzMS90YWJsZXJhbmdlOmM0NWIwZTM3NTc4YzQ5ODNiZjQ4OTAxMDc2NWYwMzMxXzYtNC0xLTEtNDEyOTQ_c2a68d2e-1e70-43eb-8462-9823d116993b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDAvZnJhZzpmNDRmMTQwOTY3NGU0MzVkYWNmMjkzYWVjOTgxYmE2NS90YWJsZTpjNDViMGUzNzU3OGM0OTgzYmY0ODkwMTA3NjVmMDMzMS90YWJsZXJhbmdlOmM0NWIwZTM3NTc4YzQ5ODNiZjQ4OTAxMDc2NWYwMzMxXzctMi0xLTEtNDEyOTQ_94fa87b8-6c50-4993-831d-12723bd3d705">25,899</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231" decimals="-3" name="us-gaap:FinanceLeaseLiabilityPaymentsDue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDAvZnJhZzpmNDRmMTQwOTY3NGU0MzVkYWNmMjkzYWVjOTgxYmE2NS90YWJsZTpjNDViMGUzNzU3OGM0OTgzYmY0ODkwMTA3NjVmMDMzMS90YWJsZXJhbmdlOmM0NWIwZTM3NTc4YzQ5ODNiZjQ4OTAxMDc2NWYwMzMxXzctNC0xLTEtNDEyOTQ_df0bd807-eb30-49de-8cb4-94d62fabda36">109</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less tenant improvement allowance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231" decimals="-3" name="lgnd:LesseeOperatingLeaseLiabilityTenantImprovementAllowance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDAvZnJhZzpmNDRmMTQwOTY3NGU0MzVkYWNmMjkzYWVjOTgxYmE2NS90YWJsZTpjNDViMGUzNzU3OGM0OTgzYmY0ODkwMTA3NjVmMDMzMS90YWJsZXJhbmdlOmM0NWIwZTM3NTc4YzQ5ODNiZjQ4OTAxMDc2NWYwMzMxXzgtMi0xLTEtNTIzOTU_1f60bae6-5cd9-47f7-840b-d8577834fed9">4,327</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231" decimals="-3" name="lgnd:FinanceLeaseLiabilityTenantImprovementAllowance" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDAvZnJhZzpmNDRmMTQwOTY3NGU0MzVkYWNmMjkzYWVjOTgxYmE2NS90YWJsZTpjNDViMGUzNzU3OGM0OTgzYmY0ODkwMTA3NjVmMDMzMS90YWJsZXJhbmdlOmM0NWIwZTM3NTc4YzQ5ODNiZjQ4OTAxMDc2NWYwMzMxXzgtNC0xLTEtNTM3OTI_c6b00381-7ff7-4b85-8dcc-ddc09d7722c6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less imputed interest</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDAvZnJhZzpmNDRmMTQwOTY3NGU0MzVkYWNmMjkzYWVjOTgxYmE2NS90YWJsZTpjNDViMGUzNzU3OGM0OTgzYmY0ODkwMTA3NjVmMDMzMS90YWJsZXJhbmdlOmM0NWIwZTM3NTc4YzQ5ODNiZjQ4OTAxMDc2NWYwMzMxXzgtMi0xLTEtNDEyOTQ_a7db336d-581f-4075-9f57-3621a01872b5">4,025</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231" decimals="-3" name="us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDAvZnJhZzpmNDRmMTQwOTY3NGU0MzVkYWNmMjkzYWVjOTgxYmE2NS90YWJsZTpjNDViMGUzNzU3OGM0OTgzYmY0ODkwMTA3NjVmMDMzMS90YWJsZXJhbmdlOmM0NWIwZTM3NTc4YzQ5ODNiZjQ4OTAxMDc2NWYwMzMxXzgtNC0xLTEtNDEyOTQ_30224bde-0dd2-4fe0-bdff-2fe866629f84">5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Present value of lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDAvZnJhZzpmNDRmMTQwOTY3NGU0MzVkYWNmMjkzYWVjOTgxYmE2NS90YWJsZTpjNDViMGUzNzU3OGM0OTgzYmY0ODkwMTA3NjVmMDMzMS90YWJsZXJhbmdlOmM0NWIwZTM3NTc4YzQ5ODNiZjQ4OTAxMDc2NWYwMzMxXzktMi0xLTEtNDEyOTQ_6895c019-2aff-4db3-974e-085612f6c055">17,547</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231" decimals="-3" name="us-gaap:FinanceLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDAvZnJhZzpmNDRmMTQwOTY3NGU0MzVkYWNmMjkzYWVjOTgxYmE2NS90YWJsZTpjNDViMGUzNzU3OGM0OTgzYmY0ODkwMTA3NjVmMDMzMS90YWJsZXJhbmdlOmM0NWIwZTM3NTc4YzQ5ODNiZjQ4OTAxMDc2NWYwMzMxXzktNC0xLTEtNDEyOTQ_1d862fc2-5894-4a85-af8d-b2e2f8821263">104</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></ix:continuation></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, our operating leases have a weighted-average remaining lease term of <ix:nonNumeric contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDAvZnJhZzpmNDRmMTQwOTY3NGU0MzVkYWNmMjkzYWVjOTgxYmE2NS90ZXh0cmVnaW9uOmY0NGYxNDA5Njc0ZTQzNWRhY2YyOTNhZWM5ODFiYTY1XzMyNDk_4e990f24-5c15-4468-b562-306242489d43">8.1</ix:nonNumeric> years and a weighted-average discount rate of <ix:nonFraction unitRef="number" contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDAvZnJhZzpmNDRmMTQwOTY3NGU0MzVkYWNmMjkzYWVjOTgxYmE2NS90ZXh0cmVnaW9uOmY0NGYxNDA5Njc0ZTQzNWRhY2YyOTNhZWM5ODFiYTY1XzMyOTI_49f447b3-2623-4da3-a24a-f9b02944aba6">4.1</ix:nonFraction>%. As of December&#160;31, 2020, our operating leases have a weighted-average remaining lease term of <ix:nonNumeric contextRef="i7462d0db8f4248fcb9fd8f1deae439f3_I20201231" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDAvZnJhZzpmNDRmMTQwOTY3NGU0MzVkYWNmMjkzYWVjOTgxYmE2NS90ZXh0cmVnaW9uOmY0NGYxNDA5Njc0ZTQzNWRhY2YyOTNhZWM5ODFiYTY1Xzc2OTY1ODE0MDc1ODY_4cc21896-3091-4c10-a05e-254f3af04c49">4.4</ix:nonNumeric> years and a weighted-average discount rate of <ix:nonFraction unitRef="number" contextRef="i7462d0db8f4248fcb9fd8f1deae439f3_I20201231" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDAvZnJhZzpmNDRmMTQwOTY3NGU0MzVkYWNmMjkzYWVjOTgxYmE2NS90ZXh0cmVnaW9uOmY0NGYxNDA5Njc0ZTQzNWRhY2YyOTNhZWM5ODFiYTY1Xzc2OTY1ODE0MDc2MDI_23f11824-1422-4a19-a772-6d907be1945f">5.7</ix:nonFraction>%. Cash paid for amounts included in the measurement of operating lease liabilities was $<ix:nonFraction unitRef="usd" contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231" decimals="-5" name="us-gaap:OperatingLeasePayments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDAvZnJhZzpmNDRmMTQwOTY3NGU0MzVkYWNmMjkzYWVjOTgxYmE2NS90ZXh0cmVnaW9uOmY0NGYxNDA5Njc0ZTQzNWRhY2YyOTNhZWM5ODFiYTY1XzMzODE_ad14d694-f026-4bbb-8b03-2c9fa7e15d6a">2.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ib3597315a63d441f8f128abd7ed8840e_D20200101-20201231" decimals="-5" name="us-gaap:OperatingLeasePayments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDAvZnJhZzpmNDRmMTQwOTY3NGU0MzVkYWNmMjkzYWVjOTgxYmE2NS90ZXh0cmVnaW9uOmY0NGYxNDA5Njc0ZTQzNWRhY2YyOTNhZWM5ODFiYTY1XzgyNDYzMzcyMjI2MDE_b119c0fe-b662-48bc-9b84-683cb87bd340">2.4</ix:nonFraction>&#160;million for the twelve months ended December&#160;31, 2021 and 2020, respectively. Operating lease expense was $<ix:nonFraction unitRef="usd" contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231" decimals="-5" name="us-gaap:OperatingLeaseExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDAvZnJhZzpmNDRmMTQwOTY3NGU0MzVkYWNmMjkzYWVjOTgxYmE2NS90ZXh0cmVnaW9uOmY0NGYxNDA5Njc0ZTQzNWRhY2YyOTNhZWM5ODFiYTY1XzM0Mjc_8cf60a1c-fdcc-494a-b391-0addb9b69753">2.6</ix:nonFraction> million (net of sublease income of $<ix:nonFraction unitRef="usd" contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231" decimals="-5" name="us-gaap:SubleaseIncome" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDAvZnJhZzpmNDRmMTQwOTY3NGU0MzVkYWNmMjkzYWVjOTgxYmE2NS90ZXh0cmVnaW9uOmY0NGYxNDA5Njc0ZTQzNWRhY2YyOTNhZWM5ODFiYTY1XzM0NTc_c9d0256b-8196-45d6-9007-5aa2cdceb469">0.4</ix:nonFraction> million) and $<ix:nonFraction unitRef="usd" contextRef="ib3597315a63d441f8f128abd7ed8840e_D20200101-20201231" decimals="-5" name="us-gaap:OperatingLeaseExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDAvZnJhZzpmNDRmMTQwOTY3NGU0MzVkYWNmMjkzYWVjOTgxYmE2NS90ZXh0cmVnaW9uOmY0NGYxNDA5Njc0ZTQzNWRhY2YyOTNhZWM5ODFiYTY1XzM0NjU_6f07b3c9-0e7c-4414-a103-06f4e33bff47">2.1</ix:nonFraction> million (net of sublease income of $<ix:nonFraction unitRef="usd" contextRef="ib3597315a63d441f8f128abd7ed8840e_D20200101-20201231" decimals="-5" name="us-gaap:SubleaseIncome" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDAvZnJhZzpmNDRmMTQwOTY3NGU0MzVkYWNmMjkzYWVjOTgxYmE2NS90ZXh0cmVnaW9uOmY0NGYxNDA5Njc0ZTQzNWRhY2YyOTNhZWM5ODFiYTY1XzM0OTU_0f835546-c039-434d-bf94-ecc624943dae">0.3</ix:nonFraction> million) for the twelve months ended December&#160;31, 2021 and 2020, respectively.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, our finance leases have a weighted-average remaining lease term of <ix:nonNumeric contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231" name="us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDAvZnJhZzpmNDRmMTQwOTY3NGU0MzVkYWNmMjkzYWVjOTgxYmE2NS90ZXh0cmVnaW9uOmY0NGYxNDA5Njc0ZTQzNWRhY2YyOTNhZWM5ODFiYTY1XzM2MTU_522a2a0e-6afc-4a55-a146-7563de54ecbb">7.0</ix:nonNumeric> years and a weighted-average discount rate of <ix:nonFraction unitRef="number" contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231" decimals="3" name="us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDAvZnJhZzpmNDRmMTQwOTY3NGU0MzVkYWNmMjkzYWVjOTgxYmE2NS90ZXh0cmVnaW9uOmY0NGYxNDA5Njc0ZTQzNWRhY2YyOTNhZWM5ODFiYTY1XzM2NTg_3cce65b0-5f81-4f71-bf87-1be07a16dc17">3.0</ix:nonFraction>%. As of December&#160;31, 2020, our finance leases have a weighted-average remaining lease term of <ix:nonNumeric contextRef="i7462d0db8f4248fcb9fd8f1deae439f3_I20201231" name="us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDAvZnJhZzpmNDRmMTQwOTY3NGU0MzVkYWNmMjkzYWVjOTgxYmE2NS90ZXh0cmVnaW9uOmY0NGYxNDA5Njc0ZTQzNWRhY2YyOTNhZWM5ODFiYTY1XzEwOTk1MTE2NDI2NzE_6f99cc42-0c37-4f59-a6cc-906b138b9b09">7.9</ix:nonNumeric> years and a weighted-average discount rate of <ix:nonFraction unitRef="number" contextRef="i7462d0db8f4248fcb9fd8f1deae439f3_I20201231" decimals="3" name="us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDAvZnJhZzpmNDRmMTQwOTY3NGU0MzVkYWNmMjkzYWVjOTgxYmE2NS90ZXh0cmVnaW9uOmY0NGYxNDA5Njc0ZTQzNWRhY2YyOTNhZWM5ODFiYTY1Xzc2OTY1ODE0MDc4NTk_c40c4c55-abb3-456b-bcc6-525489e20e1a">3.5</ix:nonFraction>%. Cash paid for amounts included in the measurement of these finance lease liabilities was $<ix:nonFraction unitRef="usd" contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231" decimals="-5" name="us-gaap:FinanceLeaseInterestPaymentOnLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDAvZnJhZzpmNDRmMTQwOTY3NGU0MzVkYWNmMjkzYWVjOTgxYmE2NS90ZXh0cmVnaW9uOmY0NGYxNDA5Njc0ZTQzNWRhY2YyOTNhZWM5ODFiYTY1XzM3NDU_037df526-92fc-4f88-b290-9cf14cfb6273">9.3</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="ib3597315a63d441f8f128abd7ed8840e_D20200101-20201231" decimals="-5" name="us-gaap:FinanceLeaseInterestPaymentOnLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDAvZnJhZzpmNDRmMTQwOTY3NGU0MzVkYWNmMjkzYWVjOTgxYmE2NS90ZXh0cmVnaW9uOmY0NGYxNDA5Njc0ZTQzNWRhY2YyOTNhZWM5ODFiYTY1XzgyNDYzMzcyMjI3NTQ_5a7542eb-5a6c-4b31-9dfb-20a7a1975e72">9.7</ix:nonFraction>&#160;million for the twelve months ended December&#160;31, 2021 and 2020, respectively. Finance lease expense was $<ix:nonFraction unitRef="usd" contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231" decimals="-5" name="us-gaap:FinanceLeaseInterestExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDAvZnJhZzpmNDRmMTQwOTY3NGU0MzVkYWNmMjkzYWVjOTgxYmE2NS90ZXh0cmVnaW9uOmY0NGYxNDA5Njc0ZTQzNWRhY2YyOTNhZWM5ODFiYTY1XzM4MzA_2f676760-b0ed-4339-bbc1-53f93da1bd0a">2.3</ix:nonFraction> million and <ix:nonFraction unitRef="usd" contextRef="ib3597315a63d441f8f128abd7ed8840e_D20200101-20201231" decimals="-5" name="us-gaap:FinanceLeaseInterestExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDAvZnJhZzpmNDRmMTQwOTY3NGU0MzVkYWNmMjkzYWVjOTgxYmE2NS90ZXh0cmVnaW9uOmY0NGYxNDA5Njc0ZTQzNWRhY2YyOTNhZWM5ODFiYTY1XzgyNDYzMzcyMjI5NTA_a5851b02-b084-4eb3-b6f5-e22adf60af33">0.2</ix:nonFraction>&#160;million for the twelve months ended December&#160;31, 2021 and 2020, respectively.</span></div></ix:continuation></ix:continuation><div id="i0fa6f906fb2e4e30bc5e873d2bb6a82c_103"></div><div style="margin-top:14pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7. <ix:nonNumeric contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231" name="us-gaap:DebtDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDMvZnJhZzpkZjUxYWY2NmMyMWY0YjkxODdjMWU4ODA5OWNlN2IyYS90ZXh0cmVnaW9uOmRmNTFhZjY2YzIxZjRiOTE4N2MxZTg4MDk5Y2U3YjJhXzE3NDEx_f219bb7c-1cf8-41d6-8af1-73296dd04669" continuedAt="i22a889f3bcdb4d4abc21ab786e35a01d" escape="true">Convertible Senior Notes</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="i22a889f3bcdb4d4abc21ab786e35a01d" continuedAt="ic517935fdd7a42f3877b72de9ba1c271"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">0.75% Convertible Senior Notes due 2019</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2014, we issued $<ix:nonFraction unitRef="usd" contextRef="i1e8f1b6ddb0a48e7b819cababb4487da_I20140831" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDMvZnJhZzpkZjUxYWY2NmMyMWY0YjkxODdjMWU4ODA5OWNlN2IyYS90ZXh0cmVnaW9uOmRmNTFhZjY2YzIxZjRiOTE4N2MxZTg4MDk5Y2U3YjJhXzEwMQ_9fc680f6-5cb8-410d-911a-25e3db4f1d70">245.0</ix:nonFraction> million aggregate principal amount of 2019 Notes, resulting in net proceeds of $<ix:nonFraction unitRef="usd" contextRef="ied7021ca8f6e4678a12f1acdf2315468_D20140801-20140831" decimals="-5" name="us-gaap:ProceedsFromDebtNetOfIssuanceCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDMvZnJhZzpkZjUxYWY2NmMyMWY0YjkxODdjMWU4ODA5OWNlN2IyYS90ZXh0cmVnaW9uOmRmNTFhZjY2YzIxZjRiOTE4N2MxZTg4MDk5Y2U3YjJhXzE3NQ_a87f41fd-9a74-4d12-ba43-7a2f6341daf9">239.3</ix:nonFraction> million. The implied estimated effective rate of the liability component of the 2019 Notes was <ix:nonFraction unitRef="number" contextRef="i1e8f1b6ddb0a48e7b819cababb4487da_I20140831" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDMvZnJhZzpkZjUxYWY2NmMyMWY0YjkxODdjMWU4ODA5OWNlN2IyYS90ZXh0cmVnaW9uOmRmNTFhZjY2YzIxZjRiOTE4N2MxZTg4MDk5Y2U3YjJhXzI2NQ_dc1d81ed-86e7-463c-b2c1-9f4c75b02523">5.83</ix:nonFraction>%. The 2019 Notes are convertible into common stock at an initial conversion rate of 13.3251 shares per $1,000 principal amount of convertible notes, subject to adjustment upon certain events, which is equivalent to an initial conversion price of approximately $<ix:nonFraction unitRef="usdPerShare" contextRef="i1e8f1b6ddb0a48e7b819cababb4487da_I20140831" decimals="2" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDMvZnJhZzpkZjUxYWY2NmMyMWY0YjkxODdjMWU4ODA5OWNlN2IyYS90ZXh0cmVnaW9uOmRmNTFhZjY2YzIxZjRiOTE4N2MxZTg4MDk5Y2U3YjJhXzUxOA_43bd388b-1d4f-4f5f-bcb7-d1ea408df0f3">75.05</ix:nonFraction> per share of common stock. The notes bear cash interest at a rate of <ix:nonFraction unitRef="number" contextRef="i1e8f1b6ddb0a48e7b819cababb4487da_I20140831" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDMvZnJhZzpkZjUxYWY2NmMyMWY0YjkxODdjMWU4ODA5OWNlN2IyYS90ZXh0cmVnaW9uOmRmNTFhZjY2YzIxZjRiOTE4N2MxZTg4MDk5Y2U3YjJhXzU5MA_6d66e71f-bb7a-4a9c-a686-2f2254f8e99f">0.75</ix:nonFraction>% per year, payable semi-annually. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Holders of the 2019 Notes may convert the notes at any time prior to the close of business on the business day immediately preceding May 15, 2019, under any of the following circumstances: </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) during any fiscal quarter (and only during such fiscal quarter) commencing after December&#160;31, 2014, if,</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for at least <ix:nonFraction unitRef="trading_day" contextRef="i1183d582f8ce4971a5581dbc8a1e1af3_D20140801-20140831" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdTradingDays" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDMvZnJhZzpkZjUxYWY2NmMyMWY0YjkxODdjMWU4ODA5OWNlN2IyYS90ZXh0cmVnaW9uOmRmNTFhZjY2YzIxZjRiOTE4N2MxZTg4MDk5Y2U3YjJhXzk0MA_adfaee5f-c0db-4372-872e-3c92dfd4c7a7">20</ix:nonFraction> trading days (whether or not consecutive) during the <ix:nonFraction unitRef="trading_day" contextRef="i1183d582f8ce4971a5581dbc8a1e1af3_D20140801-20140831" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDMvZnJhZzpkZjUxYWY2NmMyMWY0YjkxODdjMWU4ODA5OWNlN2IyYS90ZXh0cmVnaW9uOmRmNTFhZjY2YzIxZjRiOTE4N2MxZTg4MDk5Y2U3YjJhXzk5Ng_130972fd-c27a-4f24-a18a-7a846a40728d">30</ix:nonFraction> consecutive trading day period ending on the last trading day of the immediately preceding fiscal quarter, the last reported sale price of our common stock on such trading day is greater than <ix:nonFraction unitRef="number" contextRef="i1183d582f8ce4971a5581dbc8a1e1af3_D20140801-20140831" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDMvZnJhZzpkZjUxYWY2NmMyMWY0YjkxODdjMWU4ODA5OWNlN2IyYS90ZXh0cmVnaW9uOmRmNTFhZjY2YzIxZjRiOTE4N2MxZTg4MDk5Y2U3YjJhXzExOTE_7600e139-0dd0-4155-8bb4-ae5548616533">130</ix:nonFraction>% of the conversion price on such trading day; </span></div><div style="padding-left:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2) during the <ix:nonFraction unitRef="day" contextRef="i6ba1b63d92a042cf85e08ce77d22918b_D20140801-20140831" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdTradingDays" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDMvZnJhZzpkZjUxYWY2NmMyMWY0YjkxODdjMWU4ODA5OWNlN2IyYS90ZXh0cmVnaW9uOmRmNTFhZjY2YzIxZjRiOTE4N2MxZTg4MDk5Y2U3YjJhXzEyNTY_f78599ad-75c4-4c7f-a49e-250a4cd6d2ba">five</ix:nonFraction> business day period immediately following any <ix:nonFraction unitRef="trading_day" contextRef="i6ba1b63d92a042cf85e08ce77d22918b_D20140801-20140831" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDMvZnJhZzpkZjUxYWY2NmMyMWY0YjkxODdjMWU4ODA5OWNlN2IyYS90ZXh0cmVnaW9uOmRmNTFhZjY2YzIxZjRiOTE4N2MxZTg4MDk5Y2U3YjJhXzEzMDU_1e4e58ed-3d6d-4239-9a1a-3a531f6f4a66">10</ix:nonFraction> consecutive trading day period, in which the trading price per $1,000 principal amount of notes was less than <ix:nonFraction unitRef="number" contextRef="i6ba1b63d92a042cf85e08ce77d22918b_D20140801-20140831" decimals="INF" name="lgnd:DebtInstrumentConvertibleMaximumThresholdPercentageofDebtTradingPriceTrigger" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDMvZnJhZzpkZjUxYWY2NmMyMWY0YjkxODdjMWU4ODA5OWNlN2IyYS90ZXh0cmVnaW9uOmRmNTFhZjY2YzIxZjRiOTE4N2MxZTg4MDk5Y2U3YjJhXzE0MTg_e01149e9-4925-495b-963a-74f1ea8036a1">98</ix:nonFraction>% of the product of the last reported sale price of our common stock on such trading day and the conversion rate on each such trading day; or </span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3) upon the occurrence of certain specified corporate events as specified in the indenture governing the notes. </span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 22, 2018, we entered into a supplemental indenture whereby we made an irrevocable election to settle the entire 2019 Notes in cash. As such, we would have been required to deliver cash to settle the principal and any premium due upon conversion. As a result of the requirement to deliver cash to settle any premium due upon conversion, on May 22, 2018, we reclassified from equity to liability the conversion option (a derivative) fair value of $<ix:nonFraction unitRef="usd" contextRef="iebcfeb3afbe54bc3ae6cb6224e5b1f1a_D20180522-20180522" decimals="-5" name="us-gaap:DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDMvZnJhZzpkZjUxYWY2NmMyMWY0YjkxODdjMWU4ODA5OWNlN2IyYS90ZXh0cmVnaW9uOmRmNTFhZjY2YzIxZjRiOTE4N2MxZTg4MDk5Y2U3YjJhXzIxMzA_46673c64-e986-4444-b723-410e23235da2">341.6</ix:nonFraction> million. In accordance with ASC 815, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivatives and Hedging</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the derivative was adjusted to its fair value as of December 31, 2018 to $<ix:nonFraction unitRef="usd" contextRef="i64f0f378c0fc4cf4ae62d78c8b6e22d1_D20181231-20181231" decimals="-5" name="us-gaap:DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDMvZnJhZzpkZjUxYWY2NmMyMWY0YjkxODdjMWU4ODA5OWNlN2IyYS90ZXh0cmVnaW9uOmRmNTFhZjY2YzIxZjRiOTE4N2MxZTg4MDk5Y2U3YjJhXzIyNjA_fc7c2366-2296-4b61-be21-fd0c948a4711">23.4</ix:nonFraction> million with the resulting $<ix:nonFraction unitRef="usd" contextRef="ie12f8a2703764c3c9b2157933d860bf3_D20180101-20181231" decimals="-5" name="lgnd:DebtInstrumentConvertibleIncreaseDecreaseIfConvertedValueInExcessOfPrincipal" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDMvZnJhZzpkZjUxYWY2NmMyMWY0YjkxODdjMWU4ODA5OWNlN2IyYS90ZXh0cmVnaW9uOmRmNTFhZjY2YzIxZjRiOTE4N2MxZTg4MDk5Y2U3YjJhXzIyODI_911baf28-91c9-4a4b-a789-b86438b62db4">118.7</ix:nonFraction> million increase, net of payments made, reflected in other expense, net, in our consolidated statements of operations for the year ended December 31, 2018.  </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">78</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ic517935fdd7a42f3877b72de9ba1c271" continuedAt="i5de4f47c5af14fa3b5418285ea71a699"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">   </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">                                                                                                                               </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March and April 2018, we received notices for conversion of $<ix:nonFraction unitRef="usd" contextRef="i0b01059b43af404594129aa6cbdd9a86_D20180301-20180430" decimals="-5" name="us-gaap:DebtConversionConvertedInstrumentAmount1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDMvZnJhZzpkZjUxYWY2NmMyMWY0YjkxODdjMWU4ODA5OWNlN2IyYS90ZXh0cmVnaW9uOmRmNTFhZjY2YzIxZjRiOTE4N2MxZTg4MDk5Y2U3YjJhXzI2Mjk_e81ab9ba-f026-4952-8d62-145171feb202">21.8</ix:nonFraction> million of principal amount of the 2019 Notes which were settled in May and June 2018. We paid the noteholders the conversion value of the notes in cash, up to the principal amount of the 2019 Notes. The excess of the conversion value over the principal amount, totaling $<ix:nonFraction unitRef="usd" contextRef="i0b01059b43af404594129aa6cbdd9a86_D20180301-20180430" decimals="-5" name="us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDMvZnJhZzpkZjUxYWY2NmMyMWY0YjkxODdjMWU4ODA5OWNlN2IyYS90ZXh0cmVnaW9uOmRmNTFhZjY2YzIxZjRiOTE4N2MxZTg4MDk5Y2U3YjJhXzI4OTU_d024d573-2f56-40e8-b24c-ef4b81158c5b">31.6</ix:nonFraction> million, was paid in shares of common stock. In July and August 2018, we received notices for conversion of $<ix:nonFraction unitRef="usd" contextRef="id614d6af476c4bf9847c470856137006_D20180701-20180831" decimals="-5" name="us-gaap:DebtConversionConvertedInstrumentAmount1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDMvZnJhZzpkZjUxYWY2NmMyMWY0YjkxODdjMWU4ODA5OWNlN2IyYS90ZXh0cmVnaW9uOmRmNTFhZjY2YzIxZjRiOTE4N2MxZTg4MDk5Y2U3YjJhXzI5OTg_80e856d7-f53a-4880-9357-e27dfb14fcff">195.9</ix:nonFraction> million of principal amount of the 2019 Notes which were settled in October and November 2018. We paid the noteholders the $<ix:nonFraction unitRef="usd" contextRef="id614d6af476c4bf9847c470856137006_D20180701-20180831" decimals="-5" name="us-gaap:DebtConversionConvertedInstrumentAmount1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDMvZnJhZzpkZjUxYWY2NmMyMWY0YjkxODdjMWU4ODA5OWNlN2IyYS90ZXh0cmVnaW9uOmRmNTFhZjY2YzIxZjRiOTE4N2MxZTg4MDk5Y2U3YjJhXzMxMTY_8c3acbe9-e88d-4714-96a8-4b0bac027e66">195.9</ix:nonFraction> million principal amount and the excess of conversion value over the principal amount, totaling $<ix:nonFraction unitRef="usd" contextRef="i4f364a39025b407697747d1d13afd5d0_D20181001-20181130" decimals="-5" name="us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDMvZnJhZzpkZjUxYWY2NmMyMWY0YjkxODdjMWU4ODA5OWNlN2IyYS90ZXh0cmVnaW9uOmRmNTFhZjY2YzIxZjRiOTE4N2MxZTg4MDk5Y2U3YjJhXzMyMDc_7b9bfe11-1385-443d-923f-87779cbefaef">439.6</ix:nonFraction> million, in cash. The equity dilution and cash conversion premium payment upon conversion of the 2019 Notes was offset by the reacquisition of the shares and cash under the convertible bond hedge transactions entered into in connection with the offering of the 2019 Notes. As a result of the conversions, we recorded a $<ix:nonFraction unitRef="usd" contextRef="iea9bdffff69d41b2bab859af4b604cca_D20190101-20191231" decimals="-5" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDMvZnJhZzpkZjUxYWY2NmMyMWY0YjkxODdjMWU4ODA5OWNlN2IyYS90ZXh0cmVnaW9uOmRmNTFhZjY2YzIxZjRiOTE4N2MxZTg4MDk5Y2U3YjJhXzM1MjE_391d897f-f340-4f3e-ba42-ea975d65ed2a">3.2</ix:nonFraction> million loss on extinguishment of debt calculated as the difference between the estimated fair value of the debt and the carrying value of the 2019 Notes as of the settlement dates. To measure the fair value of the converted 2019 Notes as of the settlement dates, the applicable interest rates were estimated using Level 2 observable inputs and applied to the converted notes using the same methodology as in the issuance date valuation.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2019, we received notices for conversion of $<ix:nonFraction unitRef="usd" contextRef="icc1c18173ae448ee9cc6a4cfa0f63d46_D20190601-20190630" decimals="-5" name="us-gaap:DebtConversionConvertedInstrumentAmount1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDMvZnJhZzpkZjUxYWY2NmMyMWY0YjkxODdjMWU4ODA5OWNlN2IyYS90ZXh0cmVnaW9uOmRmNTFhZjY2YzIxZjRiOTE4N2MxZTg4MDk5Y2U3YjJhXzQwMDc_eacb1a0c-88c5-4cc6-ad93-4399e83fa610">1.0</ix:nonFraction> million of principal amount of the 2019 Notes, which were settled in cash upon the 2019 Notes' maturity date in August 2019. As a result, we paid the noteholders (1) the $<ix:nonFraction unitRef="usd" contextRef="icc1c18173ae448ee9cc6a4cfa0f63d46_D20190601-20190630" decimals="-5" name="us-gaap:DebtConversionConvertedInstrumentAmount1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDMvZnJhZzpkZjUxYWY2NmMyMWY0YjkxODdjMWU4ODA5OWNlN2IyYS90ZXh0cmVnaW9uOmRmNTFhZjY2YzIxZjRiOTE4N2MxZTg4MDk5Y2U3YjJhXzQxNzI_92829ab4-fb00-4ebf-ac99-444874e24fcb">1.0</ix:nonFraction> million principal amount, and (2) the excess of conversion value over the principal portion in an amount of $<ix:nonFraction unitRef="usd" contextRef="icc1c18173ae448ee9cc6a4cfa0f63d46_D20190601-20190630" decimals="-5" name="us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDMvZnJhZzpkZjUxYWY2NmMyMWY0YjkxODdjMWU4ODA5OWNlN2IyYS90ZXh0cmVnaW9uOmRmNTFhZjY2YzIxZjRiOTE4N2MxZTg4MDk5Y2U3YjJhXzQyNzU_358f8fb2-b397-4544-a24c-e9c03e6ab735">0.5</ix:nonFraction> million in cash.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 15, 2019, the 2019 Notes maturity date, we paid the noteholders the remaining $<ix:nonFraction unitRef="usd" contextRef="i299d7fb1915643c9bd662d97a56f9224_D20190815-20190815" decimals="-5" name="us-gaap:RepaymentsOfNotesPayable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDMvZnJhZzpkZjUxYWY2NmMyMWY0YjkxODdjMWU4ODA5OWNlN2IyYS90ZXh0cmVnaW9uOmRmNTFhZjY2YzIxZjRiOTE4N2MxZTg4MDk5Y2U3YjJhXzQzNzY_12beddee-a49f-4a09-87d7-d5ab0c9c525e">26.3</ix:nonFraction> million principal amount and $<ix:nonFraction unitRef="usd" contextRef="ie2cb0a952fa043858638ccca94aafee7_I20190815" decimals="-5" name="us-gaap:DebtInstrumentUnamortizedPremium" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDMvZnJhZzpkZjUxYWY2NmMyMWY0YjkxODdjMWU4ODA5OWNlN2IyYS90ZXh0cmVnaW9uOmRmNTFhZjY2YzIxZjRiOTE4N2MxZTg4MDk5Y2U3YjJhXzQ0MDA_52045f7e-55df-4ba5-b3ec-46ed3d7664cd">11.9</ix:nonFraction> million bond premium, which was classified as a derivative liability, in cash. We recorded the decrease in fair value of the derivative liability of $<ix:nonFraction unitRef="usd" contextRef="iea9bdffff69d41b2bab859af4b604cca_D20190101-20191231" decimals="-5" sign="-" name="us-gaap:DerivativeGainLossOnDerivativeNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDMvZnJhZzpkZjUxYWY2NmMyMWY0YjkxODdjMWU4ODA5OWNlN2IyYS90ZXh0cmVnaW9uOmRmNTFhZjY2YzIxZjRiOTE4N2MxZTg4MDk5Y2U3YjJhXzQ1NDQ_bc1b63fb-7d65-4ca5-8bb7-e67a92be0606">11.0</ix:nonFraction> million in other expense, net, in our consolidated statements of operations for the twelve months ended December 31, 2019.                                                             </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Convertible Bond Hedge and Warrant Transactions</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2014, we entered into convertible bond hedges and sold warrants covering <ix:nonFraction unitRef="shares" contextRef="ic3fce11822d74ffb9e96e89bebb23277_I20140831" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDMvZnJhZzpkZjUxYWY2NmMyMWY0YjkxODdjMWU4ODA5OWNlN2IyYS90ZXh0cmVnaW9uOmRmNTFhZjY2YzIxZjRiOTE4N2MxZTg4MDk5Y2U3YjJhXzU1MzE_c138a23d-4a56-4faf-b077-6cbcb293384a">3,264,643</ix:nonFraction> shares of our common stock to minimize the impact of potential dilution to our common stock and/or offset the cash payments we were required to make in excess of the principal amount upon conversion of the 2019 Notes. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The convertible bond hedges had an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="ic3fce11822d74ffb9e96e89bebb23277_I20140831" decimals="INF" name="lgnd:ExercisePriceofConvertibleBondHedge" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDMvZnJhZzpkZjUxYWY2NmMyMWY0YjkxODdjMWU4ODA5OWNlN2IyYS90ZXh0cmVnaW9uOmRmNTFhZjY2YzIxZjRiOTE4N2MxZTg4MDk5Y2U3YjJhXzU4MDc_afbc95ba-2832-454d-b456-7fbe78ba72f5">75.05</ix:nonFraction> per share and are exercisable when and if the 2019 Notes were converted. If upon conversion of the 2019 Notes, the price of our common stock was above the exercise price of the convertible bond hedges, the counterparties would have delivered shares of common stock and/or cash with an aggregate value approximately equal to the difference between the price of common stock at the conversion date and the exercise price, multiplied by the number of shares of common stock related to the convertible bond hedge transaction being exercised. The convertible bond hedges and warrants described below were separate transactions entered into by us and were not part of the terms of the 2019 Notes. Holders of the 2019 Notes and warrants did not have any rights with respect to the convertible bond hedges.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of the irrevocable cash election, conversion notices received relating to the 2019 Notes after May 22, 2018 must be fully settled in cash and amounts paid in excess of the principal amount would be offset by an equal receipt of cash under the convertible bond hedge. Upon the 2019 Notes payoff on August 15, 2019, the bond hedge was settled, with the remaining $<ix:nonFraction unitRef="usd" contextRef="if35894c7763245fd8dfbcdb677a1a22e_D20190101-20191231" decimals="-5" sign="-" name="us-gaap:DerivativeGainLossOnDerivativeNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDMvZnJhZzpkZjUxYWY2NmMyMWY0YjkxODdjMWU4ODA5OWNlN2IyYS90ZXh0cmVnaW9uOmRmNTFhZjY2YzIxZjRiOTE4N2MxZTg4MDk5Y2U3YjJhXzc1MzQ_8baf607e-bf77-4042-8ce1-09df962c63ba">10.2</ix:nonFraction> million fair value decrease reflected in other expense, net, in our consolidated statement of operations for the twelve months ended December 31, 2019.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Concurrently with the convertible bond hedge transactions, we entered into warrant transactions whereby we sold warrants to acquire <ix:nonFraction unitRef="shares" contextRef="ic3fce11822d74ffb9e96e89bebb23277_I20140831" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDMvZnJhZzpkZjUxYWY2NmMyMWY0YjkxODdjMWU4ODA5OWNlN2IyYS90ZXh0cmVnaW9uOmRmNTFhZjY2YzIxZjRiOTE4N2MxZTg4MDk5Y2U3YjJhXzc3ODI_b2f69558-37bb-4a79-8663-373cdc6a8900">3,264,643</ix:nonFraction> shares of common stock with an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="ic3fce11822d74ffb9e96e89bebb23277_I20140831" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDMvZnJhZzpkZjUxYWY2NmMyMWY0YjkxODdjMWU4ODA5OWNlN2IyYS90ZXh0cmVnaW9uOmRmNTFhZjY2YzIxZjRiOTE4N2MxZTg4MDk5Y2U3YjJhXzc4MzQ_bc55c5aa-506c-4c4f-8088-3d7ee421e032">125.08</ix:nonFraction> per share, subject to certain adjustments. The warrants had expired between November 13, 2019 and April 22, 2020. The warrants have a dilutive effect to the extent the market price per share of common stock exceeds the applicable exercise price of the warrants, as measured under the terms of the warrant transactions. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">0.75% Convertible Senior Notes due 2023</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2018, we issued $<ix:nonFraction unitRef="usd" contextRef="i9807ff46d0594f389be4314eae9d0d00_I20180522" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDMvZnJhZzpkZjUxYWY2NmMyMWY0YjkxODdjMWU4ODA5OWNlN2IyYS90ZXh0cmVnaW9uOmRmNTFhZjY2YzIxZjRiOTE4N2MxZTg4MDk5Y2U3YjJhXzkwNDc_63b79035-bb94-4021-b963-852097dfe215">750</ix:nonFraction> million aggregate principal amount of 2023 Notes, bearing cash interest at a rate of <ix:nonFraction unitRef="number" contextRef="i9807ff46d0594f389be4314eae9d0d00_I20180522" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDMvZnJhZzpkZjUxYWY2NmMyMWY0YjkxODdjMWU4ODA5OWNlN2IyYS90ZXh0cmVnaW9uOmRmNTFhZjY2YzIxZjRiOTE4N2MxZTg4MDk5Y2U3YjJhXzkxMjc_30645648-7fc0-4226-93c4-963c49bec63a">0.75</ix:nonFraction>% per year, payable semi-annually. The net proceeds from the offering, after deducting the initial purchasers' discount and offering expenses, were approximately $<ix:nonFraction unitRef="usd" contextRef="i6cacda44cb2c4af291db0ef24394bf54_D20180501-20180531" decimals="-5" name="us-gaap:ProceedsFromDebtNetOfIssuanceCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDMvZnJhZzpkZjUxYWY2NmMyMWY0YjkxODdjMWU4ODA5OWNlN2IyYS90ZXh0cmVnaW9uOmRmNTFhZjY2YzIxZjRiOTE4N2MxZTg4MDk5Y2U3YjJhXzkyOTA_94fad20b-bb67-4ddc-9629-ec1992a820c8">733.1</ix:nonFraction> million. The 2023 Notes will be convertible into cash, shares of common stock, or a combination of cash and shares of common stock, at our election, based on an initial conversion rate, subject to adjustment, of 4.0244 shares per $1,000 principal amount of the 2023 Notes which represents an initial conversion price of approximately $<ix:nonFraction unitRef="usdPerShare" contextRef="i9807ff46d0594f389be4314eae9d0d00_I20180522" decimals="2" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDMvZnJhZzpkZjUxYWY2NmMyMWY0YjkxODdjMWU4ODA5OWNlN2IyYS90ZXh0cmVnaW9uOmRmNTFhZjY2YzIxZjRiOTE4N2MxZTg4MDk5Y2U3YjJhXzk2MTE_e1be444e-1229-4b56-8c35-de40bbc8e6bd">248.48</ix:nonFraction> per share.</span></div></ix:continuation><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">79</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i5de4f47c5af14fa3b5418285ea71a699" continuedAt="ie1bf1551d47a4df6bce62411f8f47923"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Holders of the 2023 Notes may convert the notes at any time prior to the close of business on the business day immediately preceding November 15, 2022, under any of the following circumstances:</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) during any fiscal quarter (and only during such fiscal quarter) commencing after September 30, 2018, if, for at least <ix:nonFraction unitRef="trading_day" contextRef="i2b189f2223d941889569bd209d33b64c_D20180501-20180531" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdTradingDays" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDMvZnJhZzpkZjUxYWY2NmMyMWY0YjkxODdjMWU4ODA5OWNlN2IyYS90ZXh0cmVnaW9uOmRmNTFhZjY2YzIxZjRiOTE4N2MxZTg4MDk5Y2U3YjJhXzk5NDM_956078c3-674f-4017-9119-5104bd7c66aa">20</ix:nonFraction> trading days (whether or not consecutive) during the <ix:nonFraction unitRef="trading_day" contextRef="i2b189f2223d941889569bd209d33b64c_D20180501-20180531" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDMvZnJhZzpkZjUxYWY2NmMyMWY0YjkxODdjMWU4ODA5OWNlN2IyYS90ZXh0cmVnaW9uOmRmNTFhZjY2YzIxZjRiOTE4N2MxZTg4MDk5Y2U3YjJhXzk5OTk_e79c660e-60bc-49ee-8132-0a5fe750cb06">30</ix:nonFraction> consecutive trading day period ending on the last trading day of the immediately preceding fiscal quarter, the last reported sale price of our common stock on such trading day is greater than <ix:nonFraction unitRef="number" contextRef="i2b189f2223d941889569bd209d33b64c_D20180501-20180531" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDMvZnJhZzpkZjUxYWY2NmMyMWY0YjkxODdjMWU4ODA5OWNlN2IyYS90ZXh0cmVnaW9uOmRmNTFhZjY2YzIxZjRiOTE4N2MxZTg4MDk5Y2U3YjJhXzEwMTk0_7e5fc95b-ed0e-4f4e-bfb3-ae2ec187c58e">130</ix:nonFraction>% of the conversion price on such trading day;</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2) during the <ix:nonFraction unitRef="trading_day" contextRef="i6dd7d2a8849547b0b84667b449a38485_D20180501-20180531" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdTradingDays" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDMvZnJhZzpkZjUxYWY2NmMyMWY0YjkxODdjMWU4ODA5OWNlN2IyYS90ZXh0cmVnaW9uOmRmNTFhZjY2YzIxZjRiOTE4N2MxZTg4MDk5Y2U3YjJhXzEwMjU4_a7edcebd-d9f1-4c2d-9f42-66c7b837c1cc">five</ix:nonFraction> business day period immediately following any <ix:nonFraction unitRef="trading_day" contextRef="i6dd7d2a8849547b0b84667b449a38485_D20180501-20180531" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDMvZnJhZzpkZjUxYWY2NmMyMWY0YjkxODdjMWU4ODA5OWNlN2IyYS90ZXh0cmVnaW9uOmRmNTFhZjY2YzIxZjRiOTE4N2MxZTg4MDk5Y2U3YjJhXzEwMzA3_21b4cf19-8199-49a9-9319-d6cc1fe31418">10</ix:nonFraction> consecutive trading day period, in which the trading price per $1,000 principal amount of notes was less than <ix:nonFraction unitRef="number" contextRef="i6dd7d2a8849547b0b84667b449a38485_D20180501-20180531" decimals="INF" name="lgnd:DebtInstrumentConvertibleMaximumThresholdPercentageofDebtTradingPriceTrigger" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDMvZnJhZzpkZjUxYWY2NmMyMWY0YjkxODdjMWU4ODA5OWNlN2IyYS90ZXh0cmVnaW9uOmRmNTFhZjY2YzIxZjRiOTE4N2MxZTg4MDk5Y2U3YjJhXzEwNDIw_faa48df0-70a2-42aa-af5a-8f4012dc10ce">98</ix:nonFraction>% of the product of the last reported sale price of our common stock on such trading day and the conversion rate on each such trading day; or</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3) upon the occurrence of certain specified corporate events as specified in the indenture governing the notes.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The notes will have a dilutive effect to the extent the average market price per share of common stock for a given reporting period exceeds the conversion price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i9807ff46d0594f389be4314eae9d0d00_I20180522" decimals="2" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDMvZnJhZzpkZjUxYWY2NmMyMWY0YjkxODdjMWU4ODA5OWNlN2IyYS90ZXh0cmVnaW9uOmRmNTFhZjY2YzIxZjRiOTE4N2MxZTg4MDk5Y2U3YjJhXzExOTU2_88d3e361-1cf5-4834-af29-c3027ccf3d07">248.48</ix:nonFraction>. As of December&#160;31, 2021, the &#8220;if-converted value&#8221; did not exceed the principal amount of the 2023 Notes.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the issuance of the 2023 Notes, we incurred $<ix:nonFraction unitRef="usd" contextRef="i75c40fa8303240178bae96b5323104b2_I20211231" decimals="-5" name="us-gaap:DeferredFinanceCostsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDMvZnJhZzpkZjUxYWY2NmMyMWY0YjkxODdjMWU4ODA5OWNlN2IyYS90ZXh0cmVnaW9uOmRmNTFhZjY2YzIxZjRiOTE4N2MxZTg4MDk5Y2U3YjJhXzEyMTE0_4a24fbec-4fdd-4abf-a705-dc8d89f2e023">16.9</ix:nonFraction> million of issuance costs, which primarily consisted of underwriting, legal and other professional fees. The portion of these costs allocated to the liability component totaling $<ix:nonFraction unitRef="usd" contextRef="i75c40fa8303240178bae96b5323104b2_I20211231" decimals="-5" name="us-gaap:DebtInstrumentUnamortizedPremium" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDMvZnJhZzpkZjUxYWY2NmMyMWY0YjkxODdjMWU4ODA5OWNlN2IyYS90ZXh0cmVnaW9uOmRmNTFhZjY2YzIxZjRiOTE4N2MxZTg4MDk5Y2U3YjJhXzEyNDA5_97bd6e4c-3838-4cda-bf91-c1271e4fe722">13.7</ix:nonFraction> million is amortized to interest expense using the effective interest method over the five year expected life of the 2023 Notes.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is our intent and policy to settle conversions through combination settlement, which essentially involves payment in cash equal to the principal portion and delivery of shares of common stock for the excess of the conversion value over the principal portion.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">During 2020, we repurchased $<ix:nonFraction unitRef="usd" contextRef="iad6270f46e2a419fb81396b4dde75fb8_I20201231" decimals="-5" name="us-gaap:DebtInstrumentRepurchaseAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDMvZnJhZzpkZjUxYWY2NmMyMWY0YjkxODdjMWU4ODA5OWNlN2IyYS90ZXh0cmVnaW9uOmRmNTFhZjY2YzIxZjRiOTE4N2MxZTg4MDk5Y2U3YjJhXzEyODI1_32400df6-0cee-4792-aae8-2a3e486c1fc1">254.7</ix:nonFraction> million in principal of the 2023 Notes for $<ix:nonFraction unitRef="usd" contextRef="ic40084c55a8f45ed806b36e3520df3db_D20200101-20201231" decimals="-5" name="us-gaap:RepaymentsOfNotesPayable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDMvZnJhZzpkZjUxYWY2NmMyMWY0YjkxODdjMWU4ODA5OWNlN2IyYS90ZXh0cmVnaW9uOmRmNTFhZjY2YzIxZjRiOTE4N2MxZTg4MDk5Y2U3YjJhXzEyODYz_6ca4c78d-28c0-472f-82ae-2412fd7a1f18">222.8</ix:nonFraction> million in cash, including accrued interest of $<ix:nonFraction unitRef="usd" contextRef="ic40084c55a8f45ed806b36e3520df3db_D20200101-20201231" decimals="-5" name="lgnd:RepaymentsOfNotesPayableInterestPortion" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDMvZnJhZzpkZjUxYWY2NmMyMWY0YjkxODdjMWU4ODA5OWNlN2IyYS90ZXh0cmVnaW9uOmRmNTFhZjY2YzIxZjRiOTE4N2MxZTg4MDk5Y2U3YjJhXzEyOTA1_cfd92c7a-bf05-4cd0-9e87-606575e08199">0.6</ix:nonFraction> million. We accounted for the repurchase as a debt extinguishment, which resulted (1) a loss of $<ix:nonFraction unitRef="usd" contextRef="ic40084c55a8f45ed806b36e3520df3db_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDMvZnJhZzpkZjUxYWY2NmMyMWY0YjkxODdjMWU4ODA5OWNlN2IyYS90ZXh0cmVnaW9uOmRmNTFhZjY2YzIxZjRiOTE4N2MxZTg4MDk5Y2U3YjJhXzEyOTk2_192b0a3d-eef1-400e-87ab-c73fc2205b77">2.5</ix:nonFraction> million reflected in other expense, net, in our consolidated statement of operations for the year ended December&#160;31, 2020; (2) a $<ix:nonFraction unitRef="usd" contextRef="ic40084c55a8f45ed806b36e3520df3db_D20200101-20201231" decimals="-5" sign="-" name="lgnd:IncreaseDecreaseInDebtDiscount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDMvZnJhZzpkZjUxYWY2NmMyMWY0YjkxODdjMWU4ODA5OWNlN2IyYS90ZXh0cmVnaW9uOmRmNTFhZjY2YzIxZjRiOTE4N2MxZTg4MDk5Y2U3YjJhXzEzMTA2_56d86f96-53d8-4bf1-9cc1-abb7f909d544">35.0</ix:nonFraction> million reduction in debt discount, and (3) a $<ix:nonFraction unitRef="usd" contextRef="ic40084c55a8f45ed806b36e3520df3db_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDMvZnJhZzpkZjUxYWY2NmMyMWY0YjkxODdjMWU4ODA5OWNlN2IyYS90ZXh0cmVnaW9uOmRmNTFhZjY2YzIxZjRiOTE4N2MxZTg4MDk5Y2U3YjJhXzEzMTQ3_290d56f6-2f0d-4060-a3c7-9f9a668e5d19">3.2</ix:nonFraction> million reduction to additional paid-in-capital, net of tax, related to the reacquisition of the equity component in our condensed consolidated balance sheet as of December&#160;31, 2020. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2021, we repurchased $<ix:nonFraction unitRef="usd" contextRef="i75c40fa8303240178bae96b5323104b2_I20211231" decimals="-5" name="us-gaap:DebtInstrumentRepurchaseAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDMvZnJhZzpkZjUxYWY2NmMyMWY0YjkxODdjMWU4ODA5OWNlN2IyYS90ZXh0cmVnaW9uOmRmNTFhZjY2YzIxZjRiOTE4N2MxZTg4MDk5Y2U3YjJhXzc2OTY1ODE0MTI1NjQ_56419352-7739-46db-b131-b94590ebb92b">152.0</ix:nonFraction>&#160;million in principal of the 2023 Notes for $<ix:nonFraction unitRef="usd" contextRef="i9d6e6be3ae854425ba0e34565fd2b9c3_D20210101-20211231" decimals="-5" name="us-gaap:RepaymentsOfNotesPayable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDMvZnJhZzpkZjUxYWY2NmMyMWY0YjkxODdjMWU4ODA5OWNlN2IyYS90ZXh0cmVnaW9uOmRmNTFhZjY2YzIxZjRiOTE4N2MxZTg4MDk5Y2U3YjJhXzc2OTY1ODE0MTI1ODA_e6821cea-76cb-47a9-a867-f688a0472199">156.0</ix:nonFraction>&#160;million in cash, including accrued interest of $<ix:nonFraction unitRef="usd" contextRef="i9d6e6be3ae854425ba0e34565fd2b9c3_D20210101-20211231" decimals="-5" name="lgnd:RepaymentsOfNotesPayableInterestPortion" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDMvZnJhZzpkZjUxYWY2NmMyMWY0YjkxODdjMWU4ODA5OWNlN2IyYS90ZXh0cmVnaW9uOmRmNTFhZjY2YzIxZjRiOTE4N2MxZTg4MDk5Y2U3YjJhXzc2OTY1ODE0MTI1OTY_2883fe16-3e24-439c-8079-f5fe784c5e04">0.3</ix:nonFraction>&#160;million. We accounted for the repurchase as a debt extinguishment, which resulted in (1) a loss of $<ix:nonFraction unitRef="usd" contextRef="i9d6e6be3ae854425ba0e34565fd2b9c3_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDMvZnJhZzpkZjUxYWY2NmMyMWY0YjkxODdjMWU4ODA5OWNlN2IyYS90ZXh0cmVnaW9uOmRmNTFhZjY2YzIxZjRiOTE4N2MxZTg4MDk5Y2U3YjJhXzc2OTY1ODE0MTI2MTA_3c95e2f3-b38d-4d97-a10d-9fcad669bfad">7.3</ix:nonFraction>&#160;million reflected in other expense, net, in our condensed consolidated statement of operations for the year ended December&#160;31, 2021, (2) a $<ix:nonFraction unitRef="usd" contextRef="i9d6e6be3ae854425ba0e34565fd2b9c3_D20210101-20211231" decimals="-5" sign="-" name="lgnd:IncreaseDecreaseInDebtDiscount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDMvZnJhZzpkZjUxYWY2NmMyMWY0YjkxODdjMWU4ODA5OWNlN2IyYS90ZXh0cmVnaW9uOmRmNTFhZjY2YzIxZjRiOTE4N2MxZTg4MDk5Y2U3YjJhXzc2OTY1ODE0MTI3MzQ_e5f324c7-40e8-40e1-a11c-55f7cf28d6fc">13.7</ix:nonFraction>&#160;million reduction in debt discount, and (3) a $<ix:nonFraction unitRef="usd" contextRef="i9d6e6be3ae854425ba0e34565fd2b9c3_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDMvZnJhZzpkZjUxYWY2NmMyMWY0YjkxODdjMWU4ODA5OWNlN2IyYS90ZXh0cmVnaW9uOmRmNTFhZjY2YzIxZjRiOTE4N2MxZTg4MDk5Y2U3YjJhXzc2OTY1ODE0MTI3NDk_60418113-8f31-4d6d-8b82-442e5460dbe4">10.2</ix:nonFraction>&#160;million reduction to additional paid in capital, net of tax, related to the reacquisition of the equity component in our condensed consolidated balance sheet as of December&#160;31, 2021. After the repurchases, approximately $<ix:nonFraction unitRef="usd" contextRef="i75c40fa8303240178bae96b5323104b2_I20211231" decimals="-5" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDMvZnJhZzpkZjUxYWY2NmMyMWY0YjkxODdjMWU4ODA5OWNlN2IyYS90ZXh0cmVnaW9uOmRmNTFhZjY2YzIxZjRiOTE4N2MxZTg4MDk5Y2U3YjJhXzc2OTY1ODE0MTI4OTk_965d83a3-186a-4bfe-a278-b394b41f2adf">343.3</ix:nonFraction> million in principal amount of the 2023 Notes remain outstanding. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During February 2022, we repurchased $<ix:nonFraction unitRef="usd" contextRef="ie28d293ededa44009f8568af6cd22fe9_I20220228" decimals="-5" name="us-gaap:DebtInstrumentRepurchaseAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDMvZnJhZzpkZjUxYWY2NmMyMWY0YjkxODdjMWU4ODA5OWNlN2IyYS90ZXh0cmVnaW9uOmRmNTFhZjY2YzIxZjRiOTE4N2MxZTg4MDk5Y2U3YjJhXzc2OTY1ODE0MjA4NTU_6854cef5-7847-4941-abce-529ebace3a45">125.5</ix:nonFraction>&#160;million in principal of the 2023 Notes for $<ix:nonFraction unitRef="usd" contextRef="i106a64ab6c044b39a19f90f252c7361a_D20220201-20220228" decimals="-5" name="us-gaap:RepaymentsOfNotesPayable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDMvZnJhZzpkZjUxYWY2NmMyMWY0YjkxODdjMWU4ODA5OWNlN2IyYS90ZXh0cmVnaW9uOmRmNTFhZjY2YzIxZjRiOTE4N2MxZTg4MDk5Y2U3YjJhXzc2OTY1ODE0MjA4NzE_34e2c65b-4559-4380-ba85-ec348aeb96b1">123.9</ix:nonFraction>&#160;million in cash, including accrued interest of $<ix:nonFraction unitRef="usd" contextRef="i106a64ab6c044b39a19f90f252c7361a_D20220201-20220228" decimals="-5" name="lgnd:RepaymentsOfNotesPayableInterestPortion" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDMvZnJhZzpkZjUxYWY2NmMyMWY0YjkxODdjMWU4ODA5OWNlN2IyYS90ZXh0cmVnaW9uOmRmNTFhZjY2YzIxZjRiOTE4N2MxZTg4MDk5Y2U3YjJhXzc2OTY1ODE0MjA4ODc_a5dce733-843a-44b2-bb2b-2ddaef298722">0.3</ix:nonFraction>&#160;million. </span></div><div style="text-indent:27pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Convertible Bond Hedge and Warrant Transactions</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In conjunction with the 2023 Notes, in May 2018, we entered into convertible bond hedges and sold warrants covering <ix:nonFraction unitRef="shares" contextRef="i9807ff46d0594f389be4314eae9d0d00_I20180522" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDMvZnJhZzpkZjUxYWY2NmMyMWY0YjkxODdjMWU4ODA5OWNlN2IyYS90ZXh0cmVnaW9uOmRmNTFhZjY2YzIxZjRiOTE4N2MxZTg4MDk5Y2U3YjJhXzEzNTc1_0ce9214c-646d-49b3-b903-3f6855d88986">3,018,327</ix:nonFraction> shares of our common stock to minimize the impact of potential dilution to our common stock and/or offset the cash payments we are required to make in excess of the principal amount upon conversion of the 2023 Notes. The convertible bond hedges have an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i9807ff46d0594f389be4314eae9d0d00_I20180522" decimals="2" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDMvZnJhZzpkZjUxYWY2NmMyMWY0YjkxODdjMWU4ODA5OWNlN2IyYS90ZXh0cmVnaW9uOmRmNTFhZjY2YzIxZjRiOTE4N2MxZTg4MDk5Y2U3YjJhXzEzODQ5_e1521810-1d3c-45be-add0-18d4b65574d4">248.48</ix:nonFraction> per share and are exercisable when and if the 2023 Notes are converted. We paid $<ix:nonFraction unitRef="usd" contextRef="i4bff4ceb2aad46e4b1484d0f72c5d0dc_D20180522-20180522" decimals="-5" name="lgnd:PaymentsforConvertibleBondHedges" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDMvZnJhZzpkZjUxYWY2NmMyMWY0YjkxODdjMWU4ODA5OWNlN2IyYS90ZXh0cmVnaW9uOmRmNTFhZjY2YzIxZjRiOTE4N2MxZTg4MDk5Y2U3YjJhXzEzOTMy_a929e2dc-a993-4b8b-86a5-f847ae8ae092">140.3</ix:nonFraction> million for these convertible bond hedges. If upon conversion of the 2023 Notes, the price of our common stock is above the exercise price of the convertible bond hedges, the counterparties will deliver shares of common stock and/or cash with an aggregate value approximately equal to the difference between the price of common stock at the conversion date and the exercise price, multiplied by the number of shares of common stock related to the convertible bond hedge transaction being exercised. The convertible bond hedges and warrants described below are separate transactions entered into by us and are not part of the terms of the 2023 Notes. Holders of the 2023 Notes and warrants will not have any rights with respect to the convertible bond hedges.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Concurrently with the convertible bond hedge transactions, we entered into warrant transactions whereby we sold warrants covering <ix:nonFraction unitRef="shares" contextRef="i304fdd56fb5543218317f467b86ae411_I20180531" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDMvZnJhZzpkZjUxYWY2NmMyMWY0YjkxODdjMWU4ODA5OWNlN2IyYS90ZXh0cmVnaW9uOmRmNTFhZjY2YzIxZjRiOTE4N2MxZTg4MDk5Y2U3YjJhXzE0ODE3_8d6cd83e-c422-4f04-993c-b19f7a6a8ce9">3,018,327</ix:nonFraction> shares of common stock with an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i9807ff46d0594f389be4314eae9d0d00_I20180522" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDMvZnJhZzpkZjUxYWY2NmMyMWY0YjkxODdjMWU4ODA5OWNlN2IyYS90ZXh0cmVnaW9uOmRmNTFhZjY2YzIxZjRiOTE4N2MxZTg4MDk5Y2U3YjJhXzE0ODY5_6f00e43a-60b6-4547-b275-a0d84897d37d">315.38</ix:nonFraction> per share, subject to certain adjustments. We received $<ix:nonFraction unitRef="usd" contextRef="i4bff4ceb2aad46e4b1484d0f72c5d0dc_D20180522-20180522" decimals="-5" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDMvZnJhZzpkZjUxYWY2NmMyMWY0YjkxODdjMWU4ODA5OWNlN2IyYS90ZXh0cmVnaW9uOmRmNTFhZjY2YzIxZjRiOTE4N2MxZTg4MDk5Y2U3YjJhXzE0OTI3_6edfb751-fc3f-4cdf-a903-0a22677fbcff">90.0</ix:nonFraction> million for these warrants. The warrants have various expiration dates ranging from August 15, 2023 to </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">80</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ie1bf1551d47a4df6bce62411f8f47923"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">February 6, 2024. The warrants will have a dilutive effect to the extent the market price per share of common stock exceeds the applicable exercise price of the warrants, as measured under the terms of the warrant transactions. The common stock issuable upon exercise of the warrants will be in unregistered shares, and we do not have the obligation and do not intend to file any registration statement with the SEC registering the issuance of the shares under the warrants.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2020, in connection with the repurchases of $<ix:nonFraction unitRef="usd" contextRef="ieab8e7c78f9745d2b71d10dcba9ea01a_I20200430" decimals="-5" name="us-gaap:DebtInstrumentRepurchaseAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDMvZnJhZzpkZjUxYWY2NmMyMWY0YjkxODdjMWU4ODA5OWNlN2IyYS90ZXh0cmVnaW9uOmRmNTFhZjY2YzIxZjRiOTE4N2MxZTg4MDk5Y2U3YjJhXzE2MDI2_d586f411-1096-412a-80d1-f68d38c59298">234.4</ix:nonFraction>&#160;million in principal of the 2023 Notes for $<ix:nonFraction unitRef="usd" contextRef="i1c98a85d32c34724861a5ba3589972ee_D20200401-20200430" decimals="-5" name="us-gaap:RepaymentsOfNotesPayable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDMvZnJhZzpkZjUxYWY2NmMyMWY0YjkxODdjMWU4ODA5OWNlN2IyYS90ZXh0cmVnaW9uOmRmNTFhZjY2YzIxZjRiOTE4N2MxZTg4MDk5Y2U3YjJhXzE2MDY0_b3cab196-aa84-4212-a4b1-ea86a444b9a8">203.8</ix:nonFraction>&#160;million in cash, including accrued interest of $<ix:nonFraction unitRef="usd" contextRef="i1c98a85d32c34724861a5ba3589972ee_D20200401-20200430" decimals="-5" name="lgnd:RepaymentsOfNotesPayableInterestPortion" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDMvZnJhZzpkZjUxYWY2NmMyMWY0YjkxODdjMWU4ODA5OWNlN2IyYS90ZXh0cmVnaW9uOmRmNTFhZjY2YzIxZjRiOTE4N2MxZTg4MDk5Y2U3YjJhXzE2MTA2_1781d5dd-f20d-4aef-bb18-2b186a8a8eb9">0.6</ix:nonFraction>&#160;million, during the quarter ended March 31, 2020, we entered into amendments with Barclays Bank PLC, Deutsche Bank AG, London Branch, and Goldman Sachs &amp; Co. LLC to the convertible note hedges transactions we initially entered into in connection with the issuance of the 2023 Notes. The amendments provide that the options under the convertible note hedges corresponding to such repurchased 2023 Notes will remain outstanding notwithstanding such repurchase.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In January 2021, in connection with the repurchases of approximately $<ix:nonFraction unitRef="usd" contextRef="i71ea8f3e306b4086bfbeaaedfe295b98_I20210131" decimals="-5" name="us-gaap:DebtInstrumentRepurchaseAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDMvZnJhZzpkZjUxYWY2NmMyMWY0YjkxODdjMWU4ODA5OWNlN2IyYS90ZXh0cmVnaW9uOmRmNTFhZjY2YzIxZjRiOTE4N2MxZTg4MDk5Y2U3YjJhXzE2NjM0_0e69e88c-df5c-47b6-81ee-9ec4031a6fa5">20.3</ix:nonFraction>&#160;million in principal of the 2023 Notes for approximately $<ix:nonFraction unitRef="usd" contextRef="if357845be5954c78ac67d659d089ca0c_D20210101-20210131" decimals="-5" name="us-gaap:RepaymentsOfNotesPayable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDMvZnJhZzpkZjUxYWY2NmMyMWY0YjkxODdjMWU4ODA5OWNlN2IyYS90ZXh0cmVnaW9uOmRmNTFhZjY2YzIxZjRiOTE4N2MxZTg4MDk5Y2U3YjJhXzE2Njg2_573cf8e1-8e03-4882-9edb-dde21b31ed9a">19.1</ix:nonFraction>&#160;million in cash, including accrued interest of $<ix:nonFraction unitRef="usd" contextRef="if357845be5954c78ac67d659d089ca0c_D20210101-20210131" decimals="-5" name="lgnd:RepaymentsOfNotesPayableInterestPortion" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDMvZnJhZzpkZjUxYWY2NmMyMWY0YjkxODdjMWU4ODA5OWNlN2IyYS90ZXh0cmVnaW9uOmRmNTFhZjY2YzIxZjRiOTE4N2MxZTg4MDk5Y2U3YjJhXzE2NzI4_b7f15874-d61d-4b61-9ac8-48017d19f2b8">0.1</ix:nonFraction>&#160;million, during the quarter ended December 31, 2020, we entered into amendments with Barclays Bank PLC, Deutsche Bank AG, London Branch, and Goldman Sachs &amp; Co. LLC to the convertible note hedges transactions we initially entered into in connection with the issuance of the 2023 Notes. The amendments provide that the options under the convertible note hedges corresponding to such repurchased 2023 Notes will remain outstanding notwithstanding such repurchase.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2021, in connection with the repurchases of $<ix:nonFraction unitRef="usd" contextRef="i75c40fa8303240178bae96b5323104b2_I20211231" decimals="-5" name="us-gaap:DebtInstrumentRepurchaseAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDMvZnJhZzpkZjUxYWY2NmMyMWY0YjkxODdjMWU4ODA5OWNlN2IyYS90ZXh0cmVnaW9uOmRmNTFhZjY2YzIxZjRiOTE4N2MxZTg4MDk5Y2U3YjJhXzc2OTY1ODE0MTQwMjk_56419352-7739-46db-b131-b94590ebb92b">152.0</ix:nonFraction>&#160;million in principal of the 2023 Notes for $<ix:nonFraction unitRef="usd" contextRef="i9d6e6be3ae854425ba0e34565fd2b9c3_D20210101-20211231" decimals="-5" name="us-gaap:RepaymentsOfNotesPayable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDMvZnJhZzpkZjUxYWY2NmMyMWY0YjkxODdjMWU4ODA5OWNlN2IyYS90ZXh0cmVnaW9uOmRmNTFhZjY2YzIxZjRiOTE4N2MxZTg4MDk5Y2U3YjJhXzc2OTY1ODE0MTQwNDY_e6821cea-76cb-47a9-a867-f688a0472199">156.0</ix:nonFraction>&#160;million in cash, including accrued interest of $<ix:nonFraction unitRef="usd" contextRef="i9d6e6be3ae854425ba0e34565fd2b9c3_D20210101-20211231" decimals="-5" name="lgnd:RepaymentsOfNotesPayableInterestPortion" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDMvZnJhZzpkZjUxYWY2NmMyMWY0YjkxODdjMWU4ODA5OWNlN2IyYS90ZXh0cmVnaW9uOmRmNTFhZjY2YzIxZjRiOTE4N2MxZTg4MDk5Y2U3YjJhXzc2OTY1ODE0MTQwNjE_2883fe16-3e24-439c-8079-f5fe784c5e04">0.3</ix:nonFraction>&#160;million, we entered into Warrant Early Unwind Agreements and Bond Hedge Unwind Agreements with Barclays Bank PLC, Deutsche Bank AG, and Goldman Sachs &amp; Co. LLC to unwind a portion of the convertible note hedges transactions we initially entered into in connection with the issuance of the 2023 Notes. We paid $<ix:nonFraction unitRef="usd" contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231" decimals="-5" name="lgnd:PaymentsToUnwindWarrants" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDMvZnJhZzpkZjUxYWY2NmMyMWY0YjkxODdjMWU4ODA5OWNlN2IyYS90ZXh0cmVnaW9uOmRmNTFhZjY2YzIxZjRiOTE4N2MxZTg4MDk5Y2U3YjJhXzc2OTY1ODE0MTQwNjQ_4910dc73-6bb0-4447-9226-4d5102a85c93">18.4</ix:nonFraction>&#160;million as part of the Warrant Early Unwind Agreements reducing the number of shares covered by the warrants from <ix:nonFraction unitRef="shares" contextRef="i304fdd56fb5543218317f467b86ae411_I20180531" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDMvZnJhZzpkZjUxYWY2NmMyMWY0YjkxODdjMWU4ODA5OWNlN2IyYS90ZXh0cmVnaW9uOmRmNTFhZjY2YzIxZjRiOTE4N2MxZTg4MDk5Y2U3YjJhXzc2OTY1ODE0MTQwODg_8d6cd83e-c422-4f04-993c-b19f7a6a8ce9">3,018,327</ix:nonFraction> to <ix:nonFraction unitRef="shares" contextRef="i75c40fa8303240178bae96b5323104b2_I20211231" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDMvZnJhZzpkZjUxYWY2NmMyMWY0YjkxODdjMWU4ODA5OWNlN2IyYS90ZXh0cmVnaW9uOmRmNTFhZjY2YzIxZjRiOTE4N2MxZTg4MDk5Y2U3YjJhXzc2OTY1ODE0MTQwOTE_f2709235-3ccf-4783-b4cf-3c3a3512a302">2,559,254</ix:nonFraction>. We received $<ix:nonFraction unitRef="usd" contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231" decimals="-5" name="lgnd:ProceedsFromUnwindingConvertibleBondHedges" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDMvZnJhZzpkZjUxYWY2NmMyMWY0YjkxODdjMWU4ODA5OWNlN2IyYS90ZXh0cmVnaW9uOmRmNTFhZjY2YzIxZjRiOTE4N2MxZTg4MDk5Y2U3YjJhXzc2OTY1ODE0MTQxMDI_685c4d87-64bb-493b-87a8-e25397539a65">18.9</ix:nonFraction>&#160;million as part of the Bond Hedge Early Unwind Agreements reducing the number of options under the convertible bond hedges to <ix:nonFraction unitRef="option" contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231" decimals="INF" name="lgnd:NumberOfOptionsUnderConvertibleBondHedges" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDMvZnJhZzpkZjUxYWY2NmMyMWY0YjkxODdjMWU4ODA5OWNlN2IyYS90ZXh0cmVnaW9uOmRmNTFhZjY2YzIxZjRiOTE4N2MxZTg4MDk5Y2U3YjJhXzc2OTY1ODE0MTQxMTc_4d1cd857-6dd4-4392-99fe-c54252ef5ba8">598,021</ix:nonFraction>. These unwind transactions resulted in a $<ix:nonFraction unitRef="usd" contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231" decimals="-5" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDMvZnJhZzpkZjUxYWY2NmMyMWY0YjkxODdjMWU4ODA5OWNlN2IyYS90ZXh0cmVnaW9uOmRmNTFhZjY2YzIxZjRiOTE4N2MxZTg4MDk5Y2U3YjJhXzc2OTY1ODE0MTQxMjY_f378cabd-e915-478e-a60e-04f9d664f984">0.5</ix:nonFraction>&#160;million net increase in additional paid-in-capital in our condensed consolidated balance sheet as of December&#160;31, 2021.</span></div><div><span><br/></span></div><div><ix:nonNumeric contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231" name="us-gaap:ScheduleOfDebtTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDMvZnJhZzpkZjUxYWY2NmMyMWY0YjkxODdjMWU4ODA5OWNlN2IyYS90ZXh0cmVnaW9uOmRmNTFhZjY2YzIxZjRiOTE4N2MxZTg4MDk5Y2U3YjJhXzE3NDE0_e059c29e-f1b3-40c5-9429-c47c7e7eef12" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes information about the equity and liability components of the 2023 Notes (in thousands).</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.683%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.499%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Principal amount of 2023 Notes outstanding</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75c40fa8303240178bae96b5323104b2_I20211231" decimals="-3" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDMvZnJhZzpkZjUxYWY2NmMyMWY0YjkxODdjMWU4ODA5OWNlN2IyYS90YWJsZTpjZDZmN2U3ZGVhYTk0NjdjYmM1NjEwYzBmMmQ5MTdiYS90YWJsZXJhbmdlOmNkNmY3ZTdkZWFhOTQ2N2NiYzU2MTBjMGYyZDkxN2JhXzEtMS0xLTEtNDEyOTQ_b4f90c08-3428-48f8-b108-00192f0fa2db">343,301</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad6270f46e2a419fb81396b4dde75fb8_I20201231" decimals="-3" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDMvZnJhZzpkZjUxYWY2NmMyMWY0YjkxODdjMWU4ODA5OWNlN2IyYS90YWJsZTpjZDZmN2U3ZGVhYTk0NjdjYmM1NjEwYzBmMmQ5MTdiYS90YWJsZXJhbmdlOmNkNmY3ZTdkZWFhOTQ2N2NiYzU2MTBjMGYyZDkxN2JhXzEtMy0xLTEtNDEyOTQ_1fc66aa8-1234-4bb4-a40f-25d1519104ca">495,280</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized discount (including unamortized debt issuance cost)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i75c40fa8303240178bae96b5323104b2_I20211231" decimals="-3" name="us-gaap:DebtInstrumentUnamortizedDiscount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDMvZnJhZzpkZjUxYWY2NmMyMWY0YjkxODdjMWU4ODA5OWNlN2IyYS90YWJsZTpjZDZmN2U3ZGVhYTk0NjdjYmM1NjEwYzBmMmQ5MTdiYS90YWJsZXJhbmdlOmNkNmY3ZTdkZWFhOTQ2N2NiYzU2MTBjMGYyZDkxN2JhXzItMS0xLTEtNDEyOTQ_ce36571b-f233-4011-83d0-5b838549dafa">22,584</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iad6270f46e2a419fb81396b4dde75fb8_I20201231" decimals="-3" name="us-gaap:DebtInstrumentUnamortizedDiscount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDMvZnJhZzpkZjUxYWY2NmMyMWY0YjkxODdjMWU4ODA5OWNlN2IyYS90YWJsZTpjZDZmN2U3ZGVhYTk0NjdjYmM1NjEwYzBmMmQ5MTdiYS90YWJsZXJhbmdlOmNkNmY3ZTdkZWFhOTQ2N2NiYzU2MTBjMGYyZDkxN2JhXzItMy0xLTEtNDEyOTQ_47815b0a-76e9-496f-b47b-7ed6a4eff274">52,987</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total long-term portion of notes payable</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75c40fa8303240178bae96b5323104b2_I20211231" decimals="-3" name="us-gaap:LongTermNotesPayable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDMvZnJhZzpkZjUxYWY2NmMyMWY0YjkxODdjMWU4ODA5OWNlN2IyYS90YWJsZTpjZDZmN2U3ZGVhYTk0NjdjYmM1NjEwYzBmMmQ5MTdiYS90YWJsZXJhbmdlOmNkNmY3ZTdkZWFhOTQ2N2NiYzU2MTBjMGYyZDkxN2JhXzMtMS0xLTEtNDEyOTQ_646704af-742e-4b50-ad43-9e65a0d2b814">320,717</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad6270f46e2a419fb81396b4dde75fb8_I20201231" decimals="-3" name="us-gaap:LongTermNotesPayable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDMvZnJhZzpkZjUxYWY2NmMyMWY0YjkxODdjMWU4ODA5OWNlN2IyYS90YWJsZTpjZDZmN2U3ZGVhYTk0NjdjYmM1NjEwYzBmMmQ5MTdiYS90YWJsZXJhbmdlOmNkNmY3ZTdkZWFhOTQ2N2NiYzU2MTBjMGYyZDkxN2JhXzMtMy0xLTEtNDEyOTQ_96b28825-5eca-452f-9f7b-ea30ba8007d0">442,293</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying value of equity component of 2023 Notes</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75c40fa8303240178bae96b5323104b2_I20211231" decimals="-3" name="us-gaap:DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDMvZnJhZzpkZjUxYWY2NmMyMWY0YjkxODdjMWU4ODA5OWNlN2IyYS90YWJsZTpjZDZmN2U3ZGVhYTk0NjdjYmM1NjEwYzBmMmQ5MTdiYS90YWJsZXJhbmdlOmNkNmY3ZTdkZWFhOTQ2N2NiYzU2MTBjMGYyZDkxN2JhXzQtMS0xLTEtNDEyOTQ_79ee1f4e-f319-4d98-a9f3-a88ae3cb7cce">20,627</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad6270f46e2a419fb81396b4dde75fb8_I20201231" decimals="-3" name="us-gaap:DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDMvZnJhZzpkZjUxYWY2NmMyMWY0YjkxODdjMWU4ODA5OWNlN2IyYS90YWJsZTpjZDZmN2U3ZGVhYTk0NjdjYmM1NjEwYzBmMmQ5MTdiYS90YWJsZXJhbmdlOmNkNmY3ZTdkZWFhOTQ2N2NiYzU2MTBjMGYyZDkxN2JhXzQtMy0xLTEtNDEyOTQ_bbb40511-aa67-479d-a28d-7c18bea2b5b5">48,397</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of convertible senior notes outstanding (Level 2)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75c40fa8303240178bae96b5323104b2_I20211231" decimals="-3" name="us-gaap:ConvertibleDebtFairValueDisclosures" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDMvZnJhZzpkZjUxYWY2NmMyMWY0YjkxODdjMWU4ODA5OWNlN2IyYS90YWJsZTpjZDZmN2U3ZGVhYTk0NjdjYmM1NjEwYzBmMmQ5MTdiYS90YWJsZXJhbmdlOmNkNmY3ZTdkZWFhOTQ2N2NiYzU2MTBjMGYyZDkxN2JhXzUtMS0xLTEtNDEyOTQ_4fd9a197-7ba2-4ff8-a3ba-7c81c9df2771">341,801</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad6270f46e2a419fb81396b4dde75fb8_I20201231" decimals="-3" name="us-gaap:ConvertibleDebtFairValueDisclosures" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDMvZnJhZzpkZjUxYWY2NmMyMWY0YjkxODdjMWU4ODA5OWNlN2IyYS90YWJsZTpjZDZmN2U3ZGVhYTk0NjdjYmM1NjEwYzBmMmQ5MTdiYS90YWJsZXJhbmdlOmNkNmY3ZTdkZWFhOTQ2N2NiYzU2MTBjMGYyZDkxN2JhXzUtMy0xLTEtNDEyOTQ_643e6582-af1b-4c8d-bafc-0cd1c0b0e84c">466,053</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, there were no events of default or violation of any covenants under our financing obligations.</span></div></ix:continuation><div id="i0fa6f906fb2e4e30bc5e873d2bb6a82c_109"></div><div style="margin-top:14pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8. <ix:nonNumeric contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231" name="us-gaap:SupplementalBalanceSheetDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90ZXh0cmVnaW9uOjhkMWM4MjU1M2QwNzQ1ODVhMDJmY2U3NDA0ZGE4ZTE5XzQxMzU_c39d931e-127a-478f-b726-8d58d6cbc87b" continuedAt="ibb36498c39f44420847673923e8a490e" escape="true">Balance Sheet Account Details</ix:nonNumeric></span></div><div style="margin-top:5pt;text-indent:24pt"><span><br/></span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:continuation id="ibb36498c39f44420847673923e8a490e" continuedAt="ia994e169adbe4effa2d96ccb238b3a58">Short-term Investments</ix:continuation></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">81</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ia994e169adbe4effa2d96ccb238b3a58" continuedAt="i42a22ea439434daf867e444a74ea67ef"><div style="margin-top:5pt"><ix:nonNumeric contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231" name="us-gaap:MarketableSecuritiesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90ZXh0cmVnaW9uOjhkMWM4MjU1M2QwNzQ1ODVhMDJmY2U3NDA0ZGE4ZTE5XzQxNDE_01f0832a-d513-498a-bb4f-310c4b2d63d3" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Excluding our investments in Viking, the following table summarizes the various investment categories at December&#160;31, 2021 and 2020 (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.321%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.501%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross unrealized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">gains</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross unrealized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">losses</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">fair value</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mutual Fund</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00a18868ce4d4197a8afb1f39a028208_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpjY2RiMDBhM2MyZjc0MDYzODcyMGY4Y2M4ZGQ0MTEwZS90YWJsZXJhbmdlOmNjZGIwMGEzYzJmNzQwNjM4NzIwZjhjYzhkZDQxMTBlXzMtMS0xLTEtNDEyOTQ_2e347f5b-00b5-4a56-9efe-3815b962db17">152,136</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00a18868ce4d4197a8afb1f39a028208_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpjY2RiMDBhM2MyZjc0MDYzODcyMGY4Y2M4ZGQ0MTEwZS90YWJsZXJhbmdlOmNjZGIwMGEzYzJmNzQwNjM4NzIwZjhjYzhkZDQxMTBlXzMtMy0xLTEtNDEyOTQ_a769710a-8f04-484b-9dce-3902ba7ebcc9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i00a18868ce4d4197a8afb1f39a028208_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpjY2RiMDBhM2MyZjc0MDYzODcyMGY4Y2M4ZGQ0MTEwZS90YWJsZXJhbmdlOmNjZGIwMGEzYzJmNzQwNjM4NzIwZjhjYzhkZDQxMTBlXzMtNS0xLTEtNDEyOTQ_ba950145-50d0-451f-ad3f-69f553d4869b">249</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00a18868ce4d4197a8afb1f39a028208_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpjY2RiMDBhM2MyZjc0MDYzODcyMGY4Y2M4ZGQ0MTEwZS90YWJsZXJhbmdlOmNjZGIwMGEzYzJmNzQwNjM4NzIwZjhjYzhkZDQxMTBlXzMtNy0xLTEtNDEyOTQ_2a8d3086-8fbf-4689-96ac-ee77b8ac3255">151,887</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bank deposits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ee078f3c41f42a0b0e253d5572cce12_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpjY2RiMDBhM2MyZjc0MDYzODcyMGY4Y2M4ZGQ0MTEwZS90YWJsZXJhbmdlOmNjZGIwMGEzYzJmNzQwNjM4NzIwZjhjYzhkZDQxMTBlXzQtMS0xLTEtNDEyOTQ_e40467f3-bc36-4a44-a5b9-6620e2e470b6">63,389</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ee078f3c41f42a0b0e253d5572cce12_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpjY2RiMDBhM2MyZjc0MDYzODcyMGY4Y2M4ZGQ0MTEwZS90YWJsZXJhbmdlOmNjZGIwMGEzYzJmNzQwNjM4NzIwZjhjYzhkZDQxMTBlXzQtMy0xLTEtNDEyOTQ_31acdb7e-faaf-40c8-a2bb-9982c6a1e3f6">13</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4ee078f3c41f42a0b0e253d5572cce12_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpjY2RiMDBhM2MyZjc0MDYzODcyMGY4Y2M4ZGQ0MTEwZS90YWJsZXJhbmdlOmNjZGIwMGEzYzJmNzQwNjM4NzIwZjhjYzhkZDQxMTBlXzQtNS0xLTEtNDEyOTQ_f86aaa1e-1be8-403f-b9f0-d9687a54958d">21</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ee078f3c41f42a0b0e253d5572cce12_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpjY2RiMDBhM2MyZjc0MDYzODcyMGY4Y2M4ZGQ0MTEwZS90YWJsZXJhbmdlOmNjZGIwMGEzYzJmNzQwNjM4NzIwZjhjYzhkZDQxMTBlXzQtNy0xLTEtNDEyOTQ_c9bb8c2f-7af5-4836-91a9-b9c0c09ab524">63,381</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf06af7ed8174cf3bef274cca762d884_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpjY2RiMDBhM2MyZjc0MDYzODcyMGY4Y2M4ZGQ0MTEwZS90YWJsZXJhbmdlOmNjZGIwMGEzYzJmNzQwNjM4NzIwZjhjYzhkZDQxMTBlXzUtMS0xLTEtNDEyOTQ_8659cf15-e9b9-4cae-9fa4-0f2bdf71b244">36,008</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf06af7ed8174cf3bef274cca762d884_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpjY2RiMDBhM2MyZjc0MDYzODcyMGY4Y2M4ZGQ0MTEwZS90YWJsZXJhbmdlOmNjZGIwMGEzYzJmNzQwNjM4NzIwZjhjYzhkZDQxMTBlXzUtMy0xLTEtNDEyOTQ_05a54db2-1032-4878-b219-3d9804f25abb">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaf06af7ed8174cf3bef274cca762d884_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpjY2RiMDBhM2MyZjc0MDYzODcyMGY4Y2M4ZGQ0MTEwZS90YWJsZXJhbmdlOmNjZGIwMGEzYzJmNzQwNjM4NzIwZjhjYzhkZDQxMTBlXzUtNS0xLTEtNDEyOTQ_ab8cb2eb-603b-4c76-b8f2-1b6ae2e2f74a">12</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf06af7ed8174cf3bef274cca762d884_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpjY2RiMDBhM2MyZjc0MDYzODcyMGY4Y2M4ZGQ0MTEwZS90YWJsZXJhbmdlOmNjZGIwMGEzYzJmNzQwNjM4NzIwZjhjYzhkZDQxMTBlXzUtNy0xLTEtNDEyOTQ_163a4814-45f2-4395-b792-282cdc73d944">35,998</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8cbd4d6b4d6042bca716c614bfd4632a_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpjY2RiMDBhM2MyZjc0MDYzODcyMGY4Y2M4ZGQ0MTEwZS90YWJsZXJhbmdlOmNjZGIwMGEzYzJmNzQwNjM4NzIwZjhjYzhkZDQxMTBlXzYtMS0xLTEtNDEyOTQ_e7626039-9593-45e0-888f-03aaea65eca7">29,308</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8cbd4d6b4d6042bca716c614bfd4632a_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpjY2RiMDBhM2MyZjc0MDYzODcyMGY4Y2M4ZGQ0MTEwZS90YWJsZXJhbmdlOmNjZGIwMGEzYzJmNzQwNjM4NzIwZjhjYzhkZDQxMTBlXzYtMy0xLTEtNDEyOTQ_5d2dc6f5-d191-4ae5-960b-0a4cc1af5d10">17</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8cbd4d6b4d6042bca716c614bfd4632a_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpjY2RiMDBhM2MyZjc0MDYzODcyMGY4Y2M4ZGQ0MTEwZS90YWJsZXJhbmdlOmNjZGIwMGEzYzJmNzQwNjM4NzIwZjhjYzhkZDQxMTBlXzYtNS0xLTEtNDEyOTQ_f61dbe77-1c5b-44d0-a77a-84850ecb4bf7">38</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8cbd4d6b4d6042bca716c614bfd4632a_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpjY2RiMDBhM2MyZjc0MDYzODcyMGY4Y2M4ZGQ0MTEwZS90YWJsZXJhbmdlOmNjZGIwMGEzYzJmNzQwNjM4NzIwZjhjYzhkZDQxMTBlXzYtNy0xLTEtNDEyOTQ_034e4d92-d7eb-4237-a04d-336d65710afc">29,287</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e8a90585c134dbb98e6aecf3894a4ee_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpjY2RiMDBhM2MyZjc0MDYzODcyMGY4Y2M4ZGQ0MTEwZS90YWJsZXJhbmdlOmNjZGIwMGEzYzJmNzQwNjM4NzIwZjhjYzhkZDQxMTBlXzctMS0xLTEtNDEyOTQ_0cdf0373-fabe-42df-89c9-8081480ff28c">5,807</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e8a90585c134dbb98e6aecf3894a4ee_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpjY2RiMDBhM2MyZjc0MDYzODcyMGY4Y2M4ZGQ0MTEwZS90YWJsZXJhbmdlOmNjZGIwMGEzYzJmNzQwNjM4NzIwZjhjYzhkZDQxMTBlXzctMy0xLTEtNDEyOTQ_3ad868b8-8939-4632-b274-4ae15cea8847">402</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7e8a90585c134dbb98e6aecf3894a4ee_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpjY2RiMDBhM2MyZjc0MDYzODcyMGY4Y2M4ZGQ0MTEwZS90YWJsZXJhbmdlOmNjZGIwMGEzYzJmNzQwNjM4NzIwZjhjYzhkZDQxMTBlXzctNS0xLTEtNDEyOTQ_3cf85b8f-83d5-4ca3-bac4-6895dc6f93b5">2,027</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e8a90585c134dbb98e6aecf3894a4ee_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpjY2RiMDBhM2MyZjc0MDYzODcyMGY4Y2M4ZGQ0MTEwZS90YWJsZXJhbmdlOmNjZGIwMGEzYzJmNzQwNjM4NzIwZjhjYzhkZDQxMTBlXzctNy0xLTEtNDEyOTQ_c47e89ac-7285-4ed8-8fcb-423286759c8e">4,182</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibba9764388ba4ab5b3742c104cad8606_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpjY2RiMDBhM2MyZjc0MDYzODcyMGY4Y2M4ZGQ0MTEwZS90YWJsZXJhbmdlOmNjZGIwMGEzYzJmNzQwNjM4NzIwZjhjYzhkZDQxMTBlXzgtMS0xLTEtNDEyOTQ_336cd6e4-bff5-4758-b313-5d17eaa9059c">5,577</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibba9764388ba4ab5b3742c104cad8606_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpjY2RiMDBhM2MyZjc0MDYzODcyMGY4Y2M4ZGQ0MTEwZS90YWJsZXJhbmdlOmNjZGIwMGEzYzJmNzQwNjM4NzIwZjhjYzhkZDQxMTBlXzgtMy0xLTEtNDEyOTQ_2de09b41-a0cc-4e2b-8c1b-37628061b423">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibba9764388ba4ab5b3742c104cad8606_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpjY2RiMDBhM2MyZjc0MDYzODcyMGY4Y2M4ZGQ0MTEwZS90YWJsZXJhbmdlOmNjZGIwMGEzYzJmNzQwNjM4NzIwZjhjYzhkZDQxMTBlXzgtNS0xLTEtNDEyOTQ_07a284b9-40db-4b77-8fb9-c2d9db6a1c2e">23</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibba9764388ba4ab5b3742c104cad8606_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpjY2RiMDBhM2MyZjc0MDYzODcyMGY4Y2M4ZGQ0MTEwZS90YWJsZXJhbmdlOmNjZGIwMGEzYzJmNzQwNjM4NzIwZjhjYzhkZDQxMTBlXzgtNy0xLTEtNDEyOTQ_7a88eb0b-1185-4b52-bd4a-6295eff1855c">5,554</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie389523012a64039b933f60b96d0b103_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpjY2RiMDBhM2MyZjc0MDYzODcyMGY4Y2M4ZGQ0MTEwZS90YWJsZXJhbmdlOmNjZGIwMGEzYzJmNzQwNjM4NzIwZjhjYzhkZDQxMTBlXzktMS0xLTEtNTgwODI_e5e75056-04de-4292-a0d2-c83865d4ab2b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie389523012a64039b933f60b96d0b103_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpjY2RiMDBhM2MyZjc0MDYzODcyMGY4Y2M4ZGQ0MTEwZS90YWJsZXJhbmdlOmNjZGIwMGEzYzJmNzQwNjM4NzIwZjhjYzhkZDQxMTBlXzktMy0xLTEtNTc5NDQ_2c10a35b-cc18-4fe5-8af8-dd3d87606817">408</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie389523012a64039b933f60b96d0b103_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpjY2RiMDBhM2MyZjc0MDYzODcyMGY4Y2M4ZGQ0MTEwZS90YWJsZXJhbmdlOmNjZGIwMGEzYzJmNzQwNjM4NzIwZjhjYzhkZDQxMTBlXzktNS0xLTEtNTgwODI_6d768da9-9ce2-4b80-a551-9a36b3ea95fa">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie389523012a64039b933f60b96d0b103_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpjY2RiMDBhM2MyZjc0MDYzODcyMGY4Y2M4ZGQ0MTEwZS90YWJsZXJhbmdlOmNjZGIwMGEzYzJmNzQwNjM4NzIwZjhjYzhkZDQxMTBlXzktNy0xLTEtNTgwODI_e9845b6f-19db-4c63-ac19-86b77226c134">408</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe91b170813b4c308d6df67cdcda5ea8_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpjY2RiMDBhM2MyZjc0MDYzODcyMGY4Y2M4ZGQ0MTEwZS90YWJsZXJhbmdlOmNjZGIwMGEzYzJmNzQwNjM4NzIwZjhjYzhkZDQxMTBlXzExLTEtMS0xLTQxMjk0_8e0c78b1-b323-46c7-bb0a-c3b54077dd67">292,225</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe91b170813b4c308d6df67cdcda5ea8_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpjY2RiMDBhM2MyZjc0MDYzODcyMGY4Y2M4ZGQ0MTEwZS90YWJsZXJhbmdlOmNjZGIwMGEzYzJmNzQwNjM4NzIwZjhjYzhkZDQxMTBlXzExLTMtMS0xLTQxMjk0_96dbe76d-9a91-473d-b070-36342bf5077e">842</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibe91b170813b4c308d6df67cdcda5ea8_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpjY2RiMDBhM2MyZjc0MDYzODcyMGY4Y2M4ZGQ0MTEwZS90YWJsZXJhbmdlOmNjZGIwMGEzYzJmNzQwNjM4NzIwZjhjYzhkZDQxMTBlXzExLTUtMS0xLTQxMjk0_af914e11-6087-4216-b01c-666d8e421667">2,370</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe91b170813b4c308d6df67cdcda5ea8_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpjY2RiMDBhM2MyZjc0MDYzODcyMGY4Y2M4ZGQ0MTEwZS90YWJsZXJhbmdlOmNjZGIwMGEzYzJmNzQwNjM4NzIwZjhjYzhkZDQxMTBlXzExLTctMS0xLTQxMjk0_4b3176a2-28af-4398-b3aa-a5268d19ea3e">290,697</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Mutual fund</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7bfc8139cbb425fb7edf200713433a4_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpjY2RiMDBhM2MyZjc0MDYzODcyMGY4Y2M4ZGQ0MTEwZS90YWJsZXJhbmdlOmNjZGIwMGEzYzJmNzQwNjM4NzIwZjhjYzhkZDQxMTBlXzE0LTEtMS0xLTQ1ODQ5_741cdef6-abb2-498e-8bb5-cef5931abb8a">151,512</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7bfc8139cbb425fb7edf200713433a4_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpjY2RiMDBhM2MyZjc0MDYzODcyMGY4Y2M4ZGQ0MTEwZS90YWJsZXJhbmdlOmNjZGIwMGEzYzJmNzQwNjM4NzIwZjhjYzhkZDQxMTBlXzE0LTMtMS0xLTQ1ODQ5_7a7c23a0-474a-4cd4-bc44-28d64df3affc">386</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7bfc8139cbb425fb7edf200713433a4_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpjY2RiMDBhM2MyZjc0MDYzODcyMGY4Y2M4ZGQ0MTEwZS90YWJsZXJhbmdlOmNjZGIwMGEzYzJmNzQwNjM4NzIwZjhjYzhkZDQxMTBlXzE0LTUtMS0xLTQ1ODQ5_b491eb9b-5874-48af-b0cd-00f0cb84efcf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7bfc8139cbb425fb7edf200713433a4_I20201231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpjY2RiMDBhM2MyZjc0MDYzODcyMGY4Y2M4ZGQ0MTEwZS90YWJsZXJhbmdlOmNjZGIwMGEzYzJmNzQwNjM4NzIwZjhjYzhkZDQxMTBlXzE0LTctMS0xLTQ1ODQ5_b5b0df07-64ae-4616-8c89-c12db968d021">151,898</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Bank deposits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i201f7376cfcf403b9594a167f61024eb_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpjY2RiMDBhM2MyZjc0MDYzODcyMGY4Y2M4ZGQ0MTEwZS90YWJsZXJhbmdlOmNjZGIwMGEzYzJmNzQwNjM4NzIwZjhjYzhkZDQxMTBlXzE0LTEtMS0xLTQ1ODI3_fab653c0-ebfb-407b-81f9-44d86e8d74be">84,120</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i201f7376cfcf403b9594a167f61024eb_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpjY2RiMDBhM2MyZjc0MDYzODcyMGY4Y2M4ZGQ0MTEwZS90YWJsZXJhbmdlOmNjZGIwMGEzYzJmNzQwNjM4NzIwZjhjYzhkZDQxMTBlXzE0LTMtMS0xLTQ1ODI3_db64ef67-3f2c-427c-841e-b2cfe170cfa6">35</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i201f7376cfcf403b9594a167f61024eb_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpjY2RiMDBhM2MyZjc0MDYzODcyMGY4Y2M4ZGQ0MTEwZS90YWJsZXJhbmdlOmNjZGIwMGEzYzJmNzQwNjM4NzIwZjhjYzhkZDQxMTBlXzE0LTUtMS0xLTQ1ODI3_11592962-6ca5-4ca1-a2f8-de6e26d0a65f">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i201f7376cfcf403b9594a167f61024eb_I20201231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpjY2RiMDBhM2MyZjc0MDYzODcyMGY4Y2M4ZGQ0MTEwZS90YWJsZXJhbmdlOmNjZGIwMGEzYzJmNzQwNjM4NzIwZjhjYzhkZDQxMTBlXzE0LTctMS0xLTQ1ODI3_66e611b9-6cb5-4523-bf25-84f6751e87e3">84,154</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Commercial paper  </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1751a1fa85af462cabdcd01341cd31d6_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpjY2RiMDBhM2MyZjc0MDYzODcyMGY4Y2M4ZGQ0MTEwZS90YWJsZXJhbmdlOmNjZGIwMGEzYzJmNzQwNjM4NzIwZjhjYzhkZDQxMTBlXzE0LTEtMS0xLTQxMjk0_16c64670-447d-4364-8314-569093bb22a5">45,459</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1751a1fa85af462cabdcd01341cd31d6_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpjY2RiMDBhM2MyZjc0MDYzODcyMGY4Y2M4ZGQ0MTEwZS90YWJsZXJhbmdlOmNjZGIwMGEzYzJmNzQwNjM4NzIwZjhjYzhkZDQxMTBlXzE0LTMtMS0xLTQxMjk0_95a27784-1a96-4df4-abab-2f92cd625e48">27</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1751a1fa85af462cabdcd01341cd31d6_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpjY2RiMDBhM2MyZjc0MDYzODcyMGY4Y2M4ZGQ0MTEwZS90YWJsZXJhbmdlOmNjZGIwMGEzYzJmNzQwNjM4NzIwZjhjYzhkZDQxMTBlXzE0LTUtMS0xLTQxMjk0_4f0f9d61-b8c3-4b6f-bf14-10188f4d09e1">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1751a1fa85af462cabdcd01341cd31d6_I20201231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpjY2RiMDBhM2MyZjc0MDYzODcyMGY4Y2M4ZGQ0MTEwZS90YWJsZXJhbmdlOmNjZGIwMGEzYzJmNzQwNjM4NzIwZjhjYzhkZDQxMTBlXzE0LTctMS0xLTQxMjk0_25ddae09-27ba-40a3-8d27-21d06cbbf300">45,485</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Corporate bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6d8d88efb7d45d5b666348e93e722c9_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpjY2RiMDBhM2MyZjc0MDYzODcyMGY4Y2M4ZGQ0MTEwZS90YWJsZXJhbmdlOmNjZGIwMGEzYzJmNzQwNjM4NzIwZjhjYzhkZDQxMTBlXzE1LTEtMS0xLTQxMjk0_c9a00fa3-1baa-4ac4-997f-360ac074e572">30,512</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6d8d88efb7d45d5b666348e93e722c9_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpjY2RiMDBhM2MyZjc0MDYzODcyMGY4Y2M4ZGQ0MTEwZS90YWJsZXJhbmdlOmNjZGIwMGEzYzJmNzQwNjM4NzIwZjhjYzhkZDQxMTBlXzE1LTMtMS0xLTQxMjk0_88c2eb8b-b065-41d1-bb9d-a0c4e4fd90ae">99</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if6d8d88efb7d45d5b666348e93e722c9_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpjY2RiMDBhM2MyZjc0MDYzODcyMGY4Y2M4ZGQ0MTEwZS90YWJsZXJhbmdlOmNjZGIwMGEzYzJmNzQwNjM4NzIwZjhjYzhkZDQxMTBlXzE1LTUtMS0xLTQxMjk0_206b5f4f-9c15-498f-b1a2-50208c5716e1">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6d8d88efb7d45d5b666348e93e722c9_I20201231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpjY2RiMDBhM2MyZjc0MDYzODcyMGY4Y2M4ZGQ0MTEwZS90YWJsZXJhbmdlOmNjZGIwMGEzYzJmNzQwNjM4NzIwZjhjYzhkZDQxMTBlXzE1LTctMS0xLTQxMjk0_1474ca45-6fea-4378-9b3c-7fe3a9e71e9d">30,610</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Agency bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec0af917487f48e3b637625d1c5d4563_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpjY2RiMDBhM2MyZjc0MDYzODcyMGY4Y2M4ZGQ0MTEwZS90YWJsZXJhbmdlOmNjZGIwMGEzYzJmNzQwNjM4NzIwZjhjYzhkZDQxMTBlXzE2LTEtMS0xLTQxMjk0_2bb41202-afb7-4ca5-8b29-911bc9bd6bc9">4,499</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec0af917487f48e3b637625d1c5d4563_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpjY2RiMDBhM2MyZjc0MDYzODcyMGY4Y2M4ZGQ0MTEwZS90YWJsZXJhbmdlOmNjZGIwMGEzYzJmNzQwNjM4NzIwZjhjYzhkZDQxMTBlXzE2LTMtMS0xLTQxMjk0_41ace6f5-3a2e-4188-873e-1251931b138f">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec0af917487f48e3b637625d1c5d4563_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpjY2RiMDBhM2MyZjc0MDYzODcyMGY4Y2M4ZGQ0MTEwZS90YWJsZXJhbmdlOmNjZGIwMGEzYzJmNzQwNjM4NzIwZjhjYzhkZDQxMTBlXzE2LTUtMS0xLTQxMjk0_c6606e7e-3bd9-4f40-80c0-548d388fe550">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec0af917487f48e3b637625d1c5d4563_I20201231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpjY2RiMDBhM2MyZjc0MDYzODcyMGY4Y2M4ZGQ0MTEwZS90YWJsZXJhbmdlOmNjZGIwMGEzYzJmNzQwNjM4NzIwZjhjYzhkZDQxMTBlXzE2LTctMS0xLTQxMjk0_0b8fdc69-d80f-44f0-98dd-0bf73cd1ea38">4,501</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Corporate equity securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05f7d42438c243028010745501c74c06_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpjY2RiMDBhM2MyZjc0MDYzODcyMGY4Y2M4ZGQ0MTEwZS90YWJsZXJhbmdlOmNjZGIwMGEzYzJmNzQwNjM4NzIwZjhjYzhkZDQxMTBlXzE5LTEtMS0xLTQ1ODg5_197c366b-b341-448d-8eef-91913906cd0b">4,466</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05f7d42438c243028010745501c74c06_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpjY2RiMDBhM2MyZjc0MDYzODcyMGY4Y2M4ZGQ0MTEwZS90YWJsZXJhbmdlOmNjZGIwMGEzYzJmNzQwNjM4NzIwZjhjYzhkZDQxMTBlXzE5LTMtMS0xLTQ1OTI3_4da71c6e-020c-4e5b-ad64-dfc59f9bb2fc">360</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i05f7d42438c243028010745501c74c06_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpjY2RiMDBhM2MyZjc0MDYzODcyMGY4Y2M4ZGQ0MTEwZS90YWJsZXJhbmdlOmNjZGIwMGEzYzJmNzQwNjM4NzIwZjhjYzhkZDQxMTBlXzE5LTUtMS0xLTQ1OTMx_36d4b082-70d2-4db9-adab-cf7e3e6f681a">1,388</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05f7d42438c243028010745501c74c06_I20201231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpjY2RiMDBhM2MyZjc0MDYzODcyMGY4Y2M4ZGQ0MTEwZS90YWJsZXJhbmdlOmNjZGIwMGEzYzJmNzQwNjM4NzIwZjhjYzhkZDQxMTBlXzE3LTctMS0xLTQ2MjE5_914ed3c8-36f1-496e-b7bd-d58876d268e6">3,438</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Treasury bills</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a5d7b087f09490db4f5fa4e098ee683_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpjY2RiMDBhM2MyZjc0MDYzODcyMGY4Y2M4ZGQ0MTEwZS90YWJsZXJhbmdlOmNjZGIwMGEzYzJmNzQwNjM4NzIwZjhjYzhkZDQxMTBlXzE3LTEtMS0xLTQxMjk0_8d02b6fd-36c8-4271-bd6c-4617f465ac53">3,999</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a5d7b087f09490db4f5fa4e098ee683_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpjY2RiMDBhM2MyZjc0MDYzODcyMGY4Y2M4ZGQ0MTEwZS90YWJsZXJhbmdlOmNjZGIwMGEzYzJmNzQwNjM4NzIwZjhjYzhkZDQxMTBlXzE3LTMtMS0xLTQxMjk0_a0c6ba36-b90e-4290-83b5-501a4db0b4fb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a5d7b087f09490db4f5fa4e098ee683_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpjY2RiMDBhM2MyZjc0MDYzODcyMGY4Y2M4ZGQ0MTEwZS90YWJsZXJhbmdlOmNjZGIwMGEzYzJmNzQwNjM4NzIwZjhjYzhkZDQxMTBlXzE3LTUtMS0xLTQxMjk0_9e6b4280-b52a-4e5d-b414-103242ccd8e3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a5d7b087f09490db4f5fa4e098ee683_I20201231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpjY2RiMDBhM2MyZjc0MDYzODcyMGY4Y2M4ZGQ0MTEwZS90YWJsZXJhbmdlOmNjZGIwMGEzYzJmNzQwNjM4NzIwZjhjYzhkZDQxMTBlXzE3LTctMS0xLTQxMjk0_c234845b-e3b9-4846-a2db-8104e567fee2">3,999</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Warrants</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6243ca7a24ef40909c79d484e6b2cf6a_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpjY2RiMDBhM2MyZjc0MDYzODcyMGY4Y2M4ZGQ0MTEwZS90YWJsZXJhbmdlOmNjZGIwMGEzYzJmNzQwNjM4NzIwZjhjYzhkZDQxMTBlXzE4LTEtMS0xLTQxMjk0_077fe98a-479c-4267-9cd8-6842994d390e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6243ca7a24ef40909c79d484e6b2cf6a_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpjY2RiMDBhM2MyZjc0MDYzODcyMGY4Y2M4ZGQ0MTEwZS90YWJsZXJhbmdlOmNjZGIwMGEzYzJmNzQwNjM4NzIwZjhjYzhkZDQxMTBlXzE4LTMtMS0xLTQxMjk0_8320af96-9ce9-4267-8d69-dc31a531c49e">393</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6243ca7a24ef40909c79d484e6b2cf6a_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpjY2RiMDBhM2MyZjc0MDYzODcyMGY4Y2M4ZGQ0MTEwZS90YWJsZXJhbmdlOmNjZGIwMGEzYzJmNzQwNjM4NzIwZjhjYzhkZDQxMTBlXzE4LTUtMS0xLTQxMjk0_0a0e5fe0-127d-4b55-8685-2853d4e96707">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6243ca7a24ef40909c79d484e6b2cf6a_I20201231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpjY2RiMDBhM2MyZjc0MDYzODcyMGY4Y2M4ZGQ0MTEwZS90YWJsZXJhbmdlOmNjZGIwMGEzYzJmNzQwNjM4NzIwZjhjYzhkZDQxMTBlXzE4LTctMS0xLTQxMjk0_6fb3886b-e01b-4673-b440-3edf507354fc">393</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17e3d08da23d4db99c73bbe97ce55cbd_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpjY2RiMDBhM2MyZjc0MDYzODcyMGY4Y2M4ZGQ0MTEwZS90YWJsZXJhbmdlOmNjZGIwMGEzYzJmNzQwNjM4NzIwZjhjYzhkZDQxMTBlXzIwLTEtMS0xLTQxMjk0_1af5101b-7ca2-41dd-91a6-390c86110c0d">324,567</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17e3d08da23d4db99c73bbe97ce55cbd_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpjY2RiMDBhM2MyZjc0MDYzODcyMGY4Y2M4ZGQ0MTEwZS90YWJsZXJhbmdlOmNjZGIwMGEzYzJmNzQwNjM4NzIwZjhjYzhkZDQxMTBlXzIwLTMtMS0xLTQxMjk0_b6dc0b59-fc79-400b-bfcd-9675116e9997">1,302</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i17e3d08da23d4db99c73bbe97ce55cbd_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpjY2RiMDBhM2MyZjc0MDYzODcyMGY4Y2M4ZGQ0MTEwZS90YWJsZXJhbmdlOmNjZGIwMGEzYzJmNzQwNjM4NzIwZjhjYzhkZDQxMTBlXzIwLTUtMS0xLTQxMjk0_6c83d304-dd79-4c51-a5b6-213b6f2acf8d">1,391</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17e3d08da23d4db99c73bbe97ce55cbd_I20201231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpjY2RiMDBhM2MyZjc0MDYzODcyMGY4Y2M4ZGQ0MTEwZS90YWJsZXJhbmdlOmNjZGIwMGEzYzJmNzQwNjM4NzIwZjhjYzhkZDQxMTBlXzIwLTctMS0xLTQxMjk0_ee1f0a2d-011b-466f-b465-510ae28340a6">324,478</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div style="margin-top:5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Gain (loss) from short-term investments on our consolidated statements of operations includes both realized and unrealized gain (loss) from our short-term investments in public equity and warrant securities, and realized gain (loss) from available-for-sale debt securities. </span></div><div><span><br/></span></div><div><ix:nonNumeric contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231" name="us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90ZXh0cmVnaW9uOjhkMWM4MjU1M2QwNzQ1ODVhMDJmY2U3NDA0ZGE4ZTE5XzQxMzM_05009a6a-9547-4ead-b6da-ede2d3f2368c" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our available-for-sale debt securities by contractual maturity (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.976%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.498%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Within one year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTozOGY3NWViNjZlODE0ZmY4YmQ1MWRjZDlhMGEwN2FjZC90YWJsZXJhbmdlOjM4Zjc1ZWI2NmU4MTRmZjhiZDUxZGNkOWEwYTA3YWNkXzItMS0xLTEtNDEyOTQ_193ae2b3-26d6-4bc7-8ded-b2cef03d51b8">111,334</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTozOGY3NWViNjZlODE0ZmY4YmQ1MWRjZDlhMGEwN2FjZC90YWJsZXJhbmdlOjM4Zjc1ZWI2NmU4MTRmZjhiZDUxZGNkOWEwYTA3YWNkXzItMy0xLTEtNDEyOTQ_ca26aac2-f367-4f27-b2e9-195fde341826">111,315</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">After one year through five years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTozOGY3NWViNjZlODE0ZmY4YmQ1MWRjZDlhMGEwN2FjZC90YWJsZXJhbmdlOjM4Zjc1ZWI2NmU4MTRmZjhiZDUxZGNkOWEwYTA3YWNkXzMtMS0xLTEtNDEyOTQ_98c0a4a4-a654-4e91-b25c-18a7af0e0d20">24,952</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTozOGY3NWViNjZlODE0ZmY4YmQ1MWRjZDlhMGEwN2FjZC90YWJsZXJhbmdlOjM4Zjc1ZWI2NmU4MTRmZjhiZDUxZGNkOWEwYTA3YWNkXzMtMy0xLTEtNDEyOTQ_edeae0ef-2494-45e1-9c43-74e64ee9cf6b">24,909</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">After five years</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231" decimals="-3" name="lgnd:DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateAfterYearFive" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTozOGY3NWViNjZlODE0ZmY4YmQ1MWRjZDlhMGEwN2FjZC90YWJsZXJhbmdlOjM4Zjc1ZWI2NmU4MTRmZjhiZDUxZGNkOWEwYTA3YWNkXzQtMS0xLTEtNDEyOTQ_e711a1a0-3bea-4f7b-889e-71ee7b7541bc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231" decimals="-3" name="lgnd:DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearFive" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTozOGY3NWViNjZlODE0ZmY4YmQ1MWRjZDlhMGEwN2FjZC90YWJsZXJhbmdlOjM4Zjc1ZWI2NmU4MTRmZjhiZDUxZGNkOWEwYTA3YWNkXzQtMy0xLTEtNDEyOTQ_45d9b04b-c3f2-4967-82a7-95b2348d6c26">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231" decimals="-3" name="us-gaap:HeldToMaturitySecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTozOGY3NWViNjZlODE0ZmY4YmQ1MWRjZDlhMGEwN2FjZC90YWJsZXJhbmdlOjM4Zjc1ZWI2NmU4MTRmZjhiZDUxZGNkOWEwYTA3YWNkXzUtMS0xLTEtNDEyOTQ_ae99d070-bf0c-47d9-9eb9-8752e4e47abc">136,286</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTozOGY3NWViNjZlODE0ZmY4YmQ1MWRjZDlhMGEwN2FjZC90YWJsZXJhbmdlOjM4Zjc1ZWI2NmU4MTRmZjhiZDUxZGNkOWEwYTA3YWNkXzUtMy0xLTEtNDEyOTQ_78b5ba66-af4c-466c-a9bb-c17b5fa35626">136,224</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90ZXh0cmVnaW9uOjhkMWM4MjU1M2QwNzQ1ODVhMDJmY2U3NDA0ZGE4ZTE5XzQxMzE_ce62bdbd-4547-46dd-9fb3-141d6ee1e992" continuedAt="i09cd72cf75ab49e6a7e09aab1acfaac9" escape="true">The following table summarizes our available-for-sale debt securities in an unrealized loss position (in thousands):</ix:nonNumeric></span></div></ix:continuation><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">82</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i42a22ea439434daf867e444a74ea67ef" continuedAt="i9816b62f0d4a4970881543dddeb5e2c4"><div><ix:continuation id="i09cd72cf75ab49e6a7e09aab1acfaac9"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:18.783%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.772%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Less than 12 months</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12 months or greater</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Estimated<br/>Fair Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Estimated<br/>Fair Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Estimated<br/>Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bank deposits</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i20c406b0b22b496398fdf16c484061b8_I20211231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpiMGRjNDIzMzM2YzE0NWYwOWQ4MDQ2NDFhOWViOTNjZC90YWJsZXJhbmdlOmIwZGM0MjMzMzZjMTQ1ZjA5ZDgwNDY0MWE5ZWI5M2NkXzMtMS0xLTEtNDEyOTQ_e7edd020-5dec-4f13-9e62-2656cff801ae">13</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20c406b0b22b496398fdf16c484061b8_I20211231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpiMGRjNDIzMzM2YzE0NWYwOWQ4MDQ2NDFhOWViOTNjZC90YWJsZXJhbmdlOmIwZGM0MjMzMzZjMTQ1ZjA5ZDgwNDY0MWE5ZWI5M2NkXzMtMy0xLTEtNDEyOTQ_6882a4ec-04f2-4cb3-a065-acc027d62dae">20,008</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20c406b0b22b496398fdf16c484061b8_I20211231" decimals="-3" name="us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpiMGRjNDIzMzM2YzE0NWYwOWQ4MDQ2NDFhOWViOTNjZC90YWJsZXJhbmdlOmIwZGM0MjMzMzZjMTQ1ZjA5ZDgwNDY0MWE5ZWI5M2NkXzMtNS0xLTEtNDEyOTQ_b28b1f08-f1a6-4124-978c-feb0968195d5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20c406b0b22b496398fdf16c484061b8_I20211231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpiMGRjNDIzMzM2YzE0NWYwOWQ4MDQ2NDFhOWViOTNjZC90YWJsZXJhbmdlOmIwZGM0MjMzMzZjMTQ1ZjA5ZDgwNDY0MWE5ZWI5M2NkXzMtNy0xLTEtNDEyOTQ_13c3afcd-cbf6-4a40-a395-8b38303be8f3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i20c406b0b22b496398fdf16c484061b8_I20211231" decimals="-3" name="us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionAccumulatedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpiMGRjNDIzMzM2YzE0NWYwOWQ4MDQ2NDFhOWViOTNjZC90YWJsZXJhbmdlOmIwZGM0MjMzMzZjMTQ1ZjA5ZDgwNDY0MWE5ZWI5M2NkXzMtOS0xLTEtNDEyOTQ_40ddb92e-a1a3-4c4e-a1fe-c84c12f9fb90">13</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20c406b0b22b496398fdf16c484061b8_I20211231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpiMGRjNDIzMzM2YzE0NWYwOWQ4MDQ2NDFhOWViOTNjZC90YWJsZXJhbmdlOmIwZGM0MjMzMzZjMTQ1ZjA5ZDgwNDY0MWE5ZWI5M2NkXzMtMTEtMS0xLTQxMjk0_51e70be7-9dc4-43fc-b7c5-30145cfcee74">20,008</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id5e251d71959460ba39674664cd46959_I20211231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpiMGRjNDIzMzM2YzE0NWYwOWQ4MDQ2NDFhOWViOTNjZC90YWJsZXJhbmdlOmIwZGM0MjMzMzZjMTQ1ZjA5ZDgwNDY0MWE5ZWI5M2NkXzQtMS0xLTEtNDEyOTQ_80d91769-9520-45fa-8c9f-2b57d1f8c6ba">15</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5e251d71959460ba39674664cd46959_I20211231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpiMGRjNDIzMzM2YzE0NWYwOWQ4MDQ2NDFhOWViOTNjZC90YWJsZXJhbmdlOmIwZGM0MjMzMzZjMTQ1ZjA5ZDgwNDY0MWE5ZWI5M2NkXzQtMy0xLTEtNDEyOTQ_68dfe41e-0365-4359-bfd3-d2c60bb7176c">27,252</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id5e251d71959460ba39674664cd46959_I20211231" decimals="-3" name="us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpiMGRjNDIzMzM2YzE0NWYwOWQ4MDQ2NDFhOWViOTNjZC90YWJsZXJhbmdlOmIwZGM0MjMzMzZjMTQ1ZjA5ZDgwNDY0MWE5ZWI5M2NkXzQtNS0xLTEtNDEyOTQ_34bab588-f68a-49e9-ae5a-62ab29ab924a">5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5e251d71959460ba39674664cd46959_I20211231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpiMGRjNDIzMzM2YzE0NWYwOWQ4MDQ2NDFhOWViOTNjZC90YWJsZXJhbmdlOmIwZGM0MjMzMzZjMTQ1ZjA5ZDgwNDY0MWE5ZWI5M2NkXzQtNy0xLTEtNDEyOTQ_d730134b-567e-459e-9738-026c3ef2bd4b">2,996</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id5e251d71959460ba39674664cd46959_I20211231" decimals="-3" name="us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionAccumulatedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpiMGRjNDIzMzM2YzE0NWYwOWQ4MDQ2NDFhOWViOTNjZC90YWJsZXJhbmdlOmIwZGM0MjMzMzZjMTQ1ZjA5ZDgwNDY0MWE5ZWI5M2NkXzQtOS0xLTEtNDEyOTQ_c2b2de09-5708-4dbf-8ea9-da8cbca72c8e">20</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5e251d71959460ba39674664cd46959_I20211231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpiMGRjNDIzMzM2YzE0NWYwOWQ4MDQ2NDFhOWViOTNjZC90YWJsZXJhbmdlOmIwZGM0MjMzMzZjMTQ1ZjA5ZDgwNDY0MWE5ZWI5M2NkXzQtMTEtMS0xLTQxMjk0_b10f5320-ec3a-4f6c-8f51-e2a8c18aa6a6">30,248</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i057c89a152c14f40b506b184456d7b2b_I20211231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpiMGRjNDIzMzM2YzE0NWYwOWQ4MDQ2NDFhOWViOTNjZC90YWJsZXJhbmdlOmIwZGM0MjMzMzZjMTQ1ZjA5ZDgwNDY0MWE5ZWI5M2NkXzUtMS0xLTEtNDEyOTQ_28681560-fd6c-4773-9eba-ddd266bf97e1">6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i057c89a152c14f40b506b184456d7b2b_I20211231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpiMGRjNDIzMzM2YzE0NWYwOWQ4MDQ2NDFhOWViOTNjZC90YWJsZXJhbmdlOmIwZGM0MjMzMzZjMTQ1ZjA5ZDgwNDY0MWE5ZWI5M2NkXzUtMy0xLTEtNDEyOTQ_2a6cbb67-1d5c-4434-a4fc-67dda2cbff10">6,689</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i057c89a152c14f40b506b184456d7b2b_I20211231" decimals="-3" name="us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpiMGRjNDIzMzM2YzE0NWYwOWQ4MDQ2NDFhOWViOTNjZC90YWJsZXJhbmdlOmIwZGM0MjMzMzZjMTQ1ZjA5ZDgwNDY0MWE5ZWI5M2NkXzUtNS0xLTEtNDEyOTQ_7ea67341-694d-4da9-a741-a1288d785a26">32</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i057c89a152c14f40b506b184456d7b2b_I20211231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpiMGRjNDIzMzM2YzE0NWYwOWQ4MDQ2NDFhOWViOTNjZC90YWJsZXJhbmdlOmIwZGM0MjMzMzZjMTQ1ZjA5ZDgwNDY0MWE5ZWI5M2NkXzUtNy0xLTEtNDEyOTQ_a59f2d1e-f0ed-4168-a45a-5f85a9749813">10,125</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i057c89a152c14f40b506b184456d7b2b_I20211231" decimals="-3" name="us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionAccumulatedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpiMGRjNDIzMzM2YzE0NWYwOWQ4MDQ2NDFhOWViOTNjZC90YWJsZXJhbmdlOmIwZGM0MjMzMzZjMTQ1ZjA5ZDgwNDY0MWE5ZWI5M2NkXzUtOS0xLTEtNDEyOTQ_1ae0887c-9c1d-4f51-9e25-53343f9a2f8d">38</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i057c89a152c14f40b506b184456d7b2b_I20211231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpiMGRjNDIzMzM2YzE0NWYwOWQ4MDQ2NDFhOWViOTNjZC90YWJsZXJhbmdlOmIwZGM0MjMzMzZjMTQ1ZjA5ZDgwNDY0MWE5ZWI5M2NkXzUtMTEtMS0xLTQxMjk0_eeca4ed8-09b8-4209-aac1-c3dfa7e309ec">16,814</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Government Securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6fbb980b9e7c4be4bd3c3376bc2bfda4_I20211231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpiMGRjNDIzMzM2YzE0NWYwOWQ4MDQ2NDFhOWViOTNjZC90YWJsZXJhbmdlOmIwZGM0MjMzMzZjMTQ1ZjA5ZDgwNDY0MWE5ZWI5M2NkXzYtMS0xLTEtNDQzNzU_7eafee7f-b861-4fe5-a984-0c2492f5ce45">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6fbb980b9e7c4be4bd3c3376bc2bfda4_I20211231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpiMGRjNDIzMzM2YzE0NWYwOWQ4MDQ2NDFhOWViOTNjZC90YWJsZXJhbmdlOmIwZGM0MjMzMzZjMTQ1ZjA5ZDgwNDY0MWE5ZWI5M2NkXzYtMy0xLTEtNDQzODc_48d57b29-dabd-403e-89db-5220e0db4078">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6fbb980b9e7c4be4bd3c3376bc2bfda4_I20211231" decimals="-3" name="us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpiMGRjNDIzMzM2YzE0NWYwOWQ4MDQ2NDFhOWViOTNjZC90YWJsZXJhbmdlOmIwZGM0MjMzMzZjMTQ1ZjA5ZDgwNDY0MWE5ZWI5M2NkXzYtNS0xLTEtNDQ0NjM_4b11ae10-7cdd-46b5-aee2-b057c7a46c6b">23</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6fbb980b9e7c4be4bd3c3376bc2bfda4_I20211231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpiMGRjNDIzMzM2YzE0NWYwOWQ4MDQ2NDFhOWViOTNjZC90YWJsZXJhbmdlOmIwZGM0MjMzMzZjMTQ1ZjA5ZDgwNDY0MWE5ZWI5M2NkXzYtNy0xLTEtNDQ0ODA_49331253-3d04-4a2e-ae34-beff872eee9b">5,553</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6fbb980b9e7c4be4bd3c3376bc2bfda4_I20211231" decimals="-3" name="us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionAccumulatedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpiMGRjNDIzMzM2YzE0NWYwOWQ4MDQ2NDFhOWViOTNjZC90YWJsZXJhbmdlOmIwZGM0MjMzMzZjMTQ1ZjA5ZDgwNDY0MWE5ZWI5M2NkXzYtOS0xLTEtNDQ0NzA_53435d57-8971-40dc-8eca-0222bc35e1f5">23</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6fbb980b9e7c4be4bd3c3376bc2bfda4_I20211231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpiMGRjNDIzMzM2YzE0NWYwOWQ4MDQ2NDFhOWViOTNjZC90YWJsZXJhbmdlOmIwZGM0MjMzMzZjMTQ1ZjA5ZDgwNDY0MWE5ZWI5M2NkXzYtMTEtMS0xLTQ2MjU0_9613a37d-6cd4-40f0-bc6b-6bb37dd3a51c">5,553</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpiMGRjNDIzMzM2YzE0NWYwOWQ4MDQ2NDFhOWViOTNjZC90YWJsZXJhbmdlOmIwZGM0MjMzMzZjMTQ1ZjA5ZDgwNDY0MWE5ZWI5M2NkXzYtMS0xLTEtNDEyOTQ_dffa3987-f89e-4591-a3d5-3d8a0864bdf5">34</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpiMGRjNDIzMzM2YzE0NWYwOWQ4MDQ2NDFhOWViOTNjZC90YWJsZXJhbmdlOmIwZGM0MjMzMzZjMTQ1ZjA5ZDgwNDY0MWE5ZWI5M2NkXzYtMy0xLTEtNDEyOTQ_2c9820db-270b-4278-add8-9a7ed3e676ad">53,949</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231" decimals="-3" name="us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpiMGRjNDIzMzM2YzE0NWYwOWQ4MDQ2NDFhOWViOTNjZC90YWJsZXJhbmdlOmIwZGM0MjMzMzZjMTQ1ZjA5ZDgwNDY0MWE5ZWI5M2NkXzYtNS0xLTEtNDEyOTQ_2b8f6ca0-2ac5-4f77-aa3f-43a74bb8cc80">60</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpiMGRjNDIzMzM2YzE0NWYwOWQ4MDQ2NDFhOWViOTNjZC90YWJsZXJhbmdlOmIwZGM0MjMzMzZjMTQ1ZjA5ZDgwNDY0MWE5ZWI5M2NkXzYtNy0xLTEtNDEyOTQ_020b3833-06ee-43a5-8b6e-eb962174137a">18,674</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231" decimals="-3" name="us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionAccumulatedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpiMGRjNDIzMzM2YzE0NWYwOWQ4MDQ2NDFhOWViOTNjZC90YWJsZXJhbmdlOmIwZGM0MjMzMzZjMTQ1ZjA5ZDgwNDY0MWE5ZWI5M2NkXzYtOS0xLTEtNDEyOTQ_41ce7745-1530-4bab-b1a0-df3881510de4">94</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpiMGRjNDIzMzM2YzE0NWYwOWQ4MDQ2NDFhOWViOTNjZC90YWJsZXJhbmdlOmIwZGM0MjMzMzZjMTQ1ZjA5ZDgwNDY0MWE5ZWI5M2NkXzYtMTEtMS0xLTQxMjk0_8308087f-3244-46f1-99e8-74eb9e6bbae4">72,623</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">December 31, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bank deposits</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib7f6e9d91bc84543b6ae3503d8d78f6b_I20201231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpiMGRjNDIzMzM2YzE0NWYwOWQ4MDQ2NDFhOWViOTNjZC90YWJsZXJhbmdlOmIwZGM0MjMzMzZjMTQ1ZjA5ZDgwNDY0MWE5ZWI5M2NkXzktMS0xLTEtNDEyOTQ_c2c1448f-fc04-4ba0-9d88-aa20a94d0c25">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7f6e9d91bc84543b6ae3503d8d78f6b_I20201231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpiMGRjNDIzMzM2YzE0NWYwOWQ4MDQ2NDFhOWViOTNjZC90YWJsZXJhbmdlOmIwZGM0MjMzMzZjMTQ1ZjA5ZDgwNDY0MWE5ZWI5M2NkXzktMy0xLTEtNDEyOTQ_5d016907-c66e-4c48-b302-33b229565bc2">14,013</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7f6e9d91bc84543b6ae3503d8d78f6b_I20201231" decimals="-3" name="us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpiMGRjNDIzMzM2YzE0NWYwOWQ4MDQ2NDFhOWViOTNjZC90YWJsZXJhbmdlOmIwZGM0MjMzMzZjMTQ1ZjA5ZDgwNDY0MWE5ZWI5M2NkXzktNS0xLTEtNDEyOTQ_7aa69574-89fe-480b-a24c-56272730a442">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7f6e9d91bc84543b6ae3503d8d78f6b_I20201231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpiMGRjNDIzMzM2YzE0NWYwOWQ4MDQ2NDFhOWViOTNjZC90YWJsZXJhbmdlOmIwZGM0MjMzMzZjMTQ1ZjA5ZDgwNDY0MWE5ZWI5M2NkXzktNy0xLTEtNDEyOTQ_17429276-b4e0-4983-b7b5-5cb83b246b0a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib7f6e9d91bc84543b6ae3503d8d78f6b_I20201231" decimals="-3" name="us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionAccumulatedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpiMGRjNDIzMzM2YzE0NWYwOWQ4MDQ2NDFhOWViOTNjZC90YWJsZXJhbmdlOmIwZGM0MjMzMzZjMTQ1ZjA5ZDgwNDY0MWE5ZWI5M2NkXzktOS0xLTEtNDEyOTQ_cb54dfea-f1f2-42f9-8325-5db14ed7accb">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7f6e9d91bc84543b6ae3503d8d78f6b_I20201231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpiMGRjNDIzMzM2YzE0NWYwOWQ4MDQ2NDFhOWViOTNjZC90YWJsZXJhbmdlOmIwZGM0MjMzMzZjMTQ1ZjA5ZDgwNDY0MWE5ZWI5M2NkXzktMTEtMS0xLTQxMjk0_9826c5cf-cc0d-402f-b199-b44b360d4008">14,013</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i24d8d13bc1ac4681b103e921e023e7ba_I20201231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpiMGRjNDIzMzM2YzE0NWYwOWQ4MDQ2NDFhOWViOTNjZC90YWJsZXJhbmdlOmIwZGM0MjMzMzZjMTQ1ZjA5ZDgwNDY0MWE5ZWI5M2NkXzEwLTEtMS0xLTQ0MzI3_91699d05-20b6-4b53-837e-91073e6d1638">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i24d8d13bc1ac4681b103e921e023e7ba_I20201231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpiMGRjNDIzMzM2YzE0NWYwOWQ4MDQ2NDFhOWViOTNjZC90YWJsZXJhbmdlOmIwZGM0MjMzMzZjMTQ1ZjA5ZDgwNDY0MWE5ZWI5M2NkXzEwLTMtMS0xLTQ0MzM0_66779be7-735d-4ad0-a7a5-57d4ad3aead8">4,526</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i24d8d13bc1ac4681b103e921e023e7ba_I20201231" decimals="-3" name="us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpiMGRjNDIzMzM2YzE0NWYwOWQ4MDQ2NDFhOWViOTNjZC90YWJsZXJhbmdlOmIwZGM0MjMzMzZjMTQ1ZjA5ZDgwNDY0MWE5ZWI5M2NkXzExLTUtMS0xLTQ2MjUx_d87ba30d-b841-4cb5-a9d4-0df358af9572">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i24d8d13bc1ac4681b103e921e023e7ba_I20201231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpiMGRjNDIzMzM2YzE0NWYwOWQ4MDQ2NDFhOWViOTNjZC90YWJsZXJhbmdlOmIwZGM0MjMzMzZjMTQ1ZjA5ZDgwNDY0MWE5ZWI5M2NkXzExLTctMS0xLTQ2MjUx_4599cc99-8faf-4bc9-8392-88752cdd895c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i24d8d13bc1ac4681b103e921e023e7ba_I20201231" decimals="-3" name="us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionAccumulatedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpiMGRjNDIzMzM2YzE0NWYwOWQ4MDQ2NDFhOWViOTNjZC90YWJsZXJhbmdlOmIwZGM0MjMzMzZjMTQ1ZjA5ZDgwNDY0MWE5ZWI5M2NkXzExLTktMS0xLTQ2MjUx_1e5ec187-636a-4ffc-9b87-4e890d98d62d">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i24d8d13bc1ac4681b103e921e023e7ba_I20201231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpiMGRjNDIzMzM2YzE0NWYwOWQ4MDQ2NDFhOWViOTNjZC90YWJsZXJhbmdlOmIwZGM0MjMzMzZjMTQ1ZjA5ZDgwNDY0MWE5ZWI5M2NkXzExLTExLTEtMS00NjI1MQ_f37a79e6-58ad-4d88-82c7-362827b3e7e5">4,526</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1a14cdb03cd74fd3800f47006e6564e8_I20201231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpiMGRjNDIzMzM2YzE0NWYwOWQ4MDQ2NDFhOWViOTNjZC90YWJsZXJhbmdlOmIwZGM0MjMzMzZjMTQ1ZjA5ZDgwNDY0MWE5ZWI5M2NkXzEwLTEtMS0xLTQxMjk0_e0b3a938-02f1-4f10-86cf-3aeec4d1229d">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a14cdb03cd74fd3800f47006e6564e8_I20201231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpiMGRjNDIzMzM2YzE0NWYwOWQ4MDQ2NDFhOWViOTNjZC90YWJsZXJhbmdlOmIwZGM0MjMzMzZjMTQ1ZjA5ZDgwNDY0MWE5ZWI5M2NkXzEwLTMtMS0xLTQxMjk0_19151b1c-5c66-4348-b0dc-6c980d433f9a">7,693</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a14cdb03cd74fd3800f47006e6564e8_I20201231" decimals="-3" name="us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpiMGRjNDIzMzM2YzE0NWYwOWQ4MDQ2NDFhOWViOTNjZC90YWJsZXJhbmdlOmIwZGM0MjMzMzZjMTQ1ZjA5ZDgwNDY0MWE5ZWI5M2NkXzEwLTUtMS0xLTQxMjk0_b8d16f70-68ad-4165-94c6-574957262403">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a14cdb03cd74fd3800f47006e6564e8_I20201231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpiMGRjNDIzMzM2YzE0NWYwOWQ4MDQ2NDFhOWViOTNjZC90YWJsZXJhbmdlOmIwZGM0MjMzMzZjMTQ1ZjA5ZDgwNDY0MWE5ZWI5M2NkXzEwLTctMS0xLTQxMjk0_f4526c52-32c4-467d-af7c-9a25c41b20ea">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1a14cdb03cd74fd3800f47006e6564e8_I20201231" decimals="-3" name="us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionAccumulatedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpiMGRjNDIzMzM2YzE0NWYwOWQ4MDQ2NDFhOWViOTNjZC90YWJsZXJhbmdlOmIwZGM0MjMzMzZjMTQ1ZjA5ZDgwNDY0MWE5ZWI5M2NkXzEwLTktMS0xLTQxMjk0_6586c2c3-bd4c-475b-81a7-24ddaf70f1d4">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a14cdb03cd74fd3800f47006e6564e8_I20201231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpiMGRjNDIzMzM2YzE0NWYwOWQ4MDQ2NDFhOWViOTNjZC90YWJsZXJhbmdlOmIwZGM0MjMzMzZjMTQ1ZjA5ZDgwNDY0MWE5ZWI5M2NkXzEwLTExLTEtMS00MTI5NA_e4b8ac0b-d467-4d4c-b2eb-eb9864a3b228">7,693</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7462d0db8f4248fcb9fd8f1deae439f3_I20201231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpiMGRjNDIzMzM2YzE0NWYwOWQ4MDQ2NDFhOWViOTNjZC90YWJsZXJhbmdlOmIwZGM0MjMzMzZjMTQ1ZjA5ZDgwNDY0MWE5ZWI5M2NkXzExLTEtMS0xLTQxMjk0_c2af9784-97c2-40fe-b860-b2bb60b96ae1">3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7462d0db8f4248fcb9fd8f1deae439f3_I20201231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpiMGRjNDIzMzM2YzE0NWYwOWQ4MDQ2NDFhOWViOTNjZC90YWJsZXJhbmdlOmIwZGM0MjMzMzZjMTQ1ZjA5ZDgwNDY0MWE5ZWI5M2NkXzExLTMtMS0xLTQxMjk0_b627c0e4-4beb-4a50-a9ac-f9515dade750">26,232</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7462d0db8f4248fcb9fd8f1deae439f3_I20201231" decimals="-3" name="us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpiMGRjNDIzMzM2YzE0NWYwOWQ4MDQ2NDFhOWViOTNjZC90YWJsZXJhbmdlOmIwZGM0MjMzMzZjMTQ1ZjA5ZDgwNDY0MWE5ZWI5M2NkXzExLTUtMS0xLTQxMjk0_e8f5aa3d-b68c-4096-a6fd-81c18753d59b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7462d0db8f4248fcb9fd8f1deae439f3_I20201231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpiMGRjNDIzMzM2YzE0NWYwOWQ4MDQ2NDFhOWViOTNjZC90YWJsZXJhbmdlOmIwZGM0MjMzMzZjMTQ1ZjA5ZDgwNDY0MWE5ZWI5M2NkXzExLTctMS0xLTQxMjk0_7367b806-4c67-4f75-9cb2-ce9b053f38c6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7462d0db8f4248fcb9fd8f1deae439f3_I20201231" decimals="-3" name="us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionAccumulatedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpiMGRjNDIzMzM2YzE0NWYwOWQ4MDQ2NDFhOWViOTNjZC90YWJsZXJhbmdlOmIwZGM0MjMzMzZjMTQ1ZjA5ZDgwNDY0MWE5ZWI5M2NkXzExLTktMS0xLTQxMjk0_9c8cb7e4-1555-4ac2-8246-40500512a077">3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7462d0db8f4248fcb9fd8f1deae439f3_I20201231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpiMGRjNDIzMzM2YzE0NWYwOWQ4MDQ2NDFhOWViOTNjZC90YWJsZXJhbmdlOmIwZGM0MjMzMzZjMTQ1ZjA5ZDgwNDY0MWE5ZWI5M2NkXzExLTExLTEtMS00MTI5NA_8ef2c925-6254-47c5-8f08-5bfac86b3eb6">26,232</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our investment policy is capital preservation and we only invested in U.S.-dollar denominated investments. We held a total of <ix:nonFraction unitRef="position" contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90ZXh0cmVnaW9uOjhkMWM4MjU1M2QwNzQ1ODVhMDJmY2U3NDA0ZGE4ZTE5XzEyMTA_b8eb71ce-19bf-4259-970d-11e2551ac250">55</ix:nonFraction> positions which were in an unrealized loss position as of December&#160;31, 2021. We believe that we will collect the principal and interest due on our debt securities that have an amortized cost in excess of fair value. The unrealized losses are largely due to changes in interest rates and not to unfavorable changes in the credit quality associated with these securities that impacted our assessment on collectability of principal and interest. We do not intend to sell these securities nor do we believe that we will be required to sell these securities before the recovery of the amortized cost basis. Accordingly, no credit losses were recognized for the twelve months ended December&#160;31, 2021.</span></div><div><span><br/></span></div><div style="margin-top:5pt"><ix:nonNumeric contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90ZXh0cmVnaW9uOjhkMWM4MjU1M2QwNzQ1ODVhMDJmY2U3NDA0ZGE4ZTE5XzQxMzY_1b9de7a2-0672-4f13-b866-0b2b90c9f4a2" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and equipment are stated at cost and consists of the following (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.976%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.498%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lab and office equipment</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f0a5635602742c38606929f85d0bc8e_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTphMDcwMTU2YTMyNDA0MjliOTRmNTFhZDFjM2Y4N2U5Mi90YWJsZXJhbmdlOmEwNzAxNTZhMzI0MDQyOWI5NGY1MWFkMWMzZjg3ZTkyXzItMS0xLTEtNDEyOTQ_c61fa836-6b8f-43da-a312-2901c07fba6a">20,183</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ef3fe1366ce4c63b1d61301c2c7cbb5_I20201231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTphMDcwMTU2YTMyNDA0MjliOTRmNTFhZDFjM2Y4N2U5Mi90YWJsZXJhbmdlOmEwNzAxNTZhMzI0MDQyOWI5NGY1MWFkMWMzZjg3ZTkyXzItMy0xLTEtNDEyOTQ_6c6026fb-a4ed-4eb8-bf18-3018bd46e0aa">14,666</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9733272dc36042e6ba12faba3f716e92_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTphMDcwMTU2YTMyNDA0MjliOTRmNTFhZDFjM2Y4N2U5Mi90YWJsZXJhbmdlOmEwNzAxNTZhMzI0MDQyOWI5NGY1MWFkMWMzZjg3ZTkyXzMtMS0xLTEtNDEyOTQ_27d77309-0bf8-422f-b3de-ef9970fbd2c6">7,983</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95f33c3ebaeb4778a9c2db6a6f6bf294_I20201231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTphMDcwMTU2YTMyNDA0MjliOTRmNTFhZDFjM2Y4N2U5Mi90YWJsZXJhbmdlOmEwNzAxNTZhMzI0MDQyOWI5NGY1MWFkMWMzZjg3ZTkyXzMtMy0xLTEtNDEyOTQ_168fac8a-0471-4b66-80aa-618b2e8b69fe">3,519</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment and software</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c5205ea5f084dac8c4dea9fdfadee02_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTphMDcwMTU2YTMyNDA0MjliOTRmNTFhZDFjM2Y4N2U5Mi90YWJsZXJhbmdlOmEwNzAxNTZhMzI0MDQyOWI5NGY1MWFkMWMzZjg3ZTkyXzQtMS0xLTEtNDEyOTQ_76616ea2-8b3d-4402-8d87-d638e89cf83c">1,056</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a16585689be4389b9863317f3aa3977_I20201231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTphMDcwMTU2YTMyNDA0MjliOTRmNTFhZDFjM2Y4N2U5Mi90YWJsZXJhbmdlOmEwNzAxNTZhMzI0MDQyOWI5NGY1MWFkMWMzZjg3ZTkyXzQtMy0xLTEtNDEyOTQ_03268a94-7a4e-4b28-8ec7-c9ac484c8bbc">1056</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTphMDcwMTU2YTMyNDA0MjliOTRmNTFhZDFjM2Y4N2U5Mi90YWJsZXJhbmdlOmEwNzAxNTZhMzI0MDQyOWI5NGY1MWFkMWMzZjg3ZTkyXzUtMS0xLTEtNDEyOTQ_b593e001-c61e-4d8c-81df-52219d6f5363">29,222</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7462d0db8f4248fcb9fd8f1deae439f3_I20201231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTphMDcwMTU2YTMyNDA0MjliOTRmNTFhZDFjM2Y4N2U5Mi90YWJsZXJhbmdlOmEwNzAxNTZhMzI0MDQyOWI5NGY1MWFkMWMzZjg3ZTkyXzUtMy0xLTEtNDEyOTQ_fe6ec001-f314-4157-bec9-de5737f3e4c5">19,241</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTphMDcwMTU2YTMyNDA0MjliOTRmNTFhZDFjM2Y4N2U5Mi90YWJsZXJhbmdlOmEwNzAxNTZhMzI0MDQyOWI5NGY1MWFkMWMzZjg3ZTkyXzYtMS0xLTEtNDEyOTQ_4b5bf506-b684-400e-9ee2-086bca38fd50">8,711</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7462d0db8f4248fcb9fd8f1deae439f3_I20201231" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTphMDcwMTU2YTMyNDA0MjliOTRmNTFhZDFjM2Y4N2U5Mi90YWJsZXJhbmdlOmEwNzAxNTZhMzI0MDQyOWI5NGY1MWFkMWMzZjg3ZTkyXzYtMy0xLTEtNDEyOTQ_47a2dc4a-7325-46f2-8dbe-231e12560415">4,807</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTphMDcwMTU2YTMyNDA0MjliOTRmNTFhZDFjM2Y4N2U5Mi90YWJsZXJhbmdlOmEwNzAxNTZhMzI0MDQyOWI5NGY1MWFkMWMzZjg3ZTkyXzctMS0xLTEtNDEyOTQ_a91d576b-05e7-4b42-85e8-d4c85a83ebc8">20,511</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7462d0db8f4248fcb9fd8f1deae439f3_I20201231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTphMDcwMTU2YTMyNDA0MjliOTRmNTFhZDFjM2Y4N2U5Mi90YWJsZXJhbmdlOmEwNzAxNTZhMzI0MDQyOWI5NGY1MWFkMWMzZjg3ZTkyXzctMy0xLTEtNDEyOTQ_e69b09bf-3497-492b-952f-4db7c590a50f">14,434</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation of equipment is computed using the straight-line method over the estimated useful lives of the assets which ranges from <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90ZXh0cmVnaW9uOjhkMWM4MjU1M2QwNzQ1ODVhMDJmY2U3NDA0ZGE4ZTE5XzIwODU_49dc7d90-487d-4145-93b5-5005d27536fa">three</span> to <ix:nonNumeric contextRef="i55156c07b9684b9185860bad3331609a_D20210101-20211231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90ZXh0cmVnaW9uOjhkMWM4MjU1M2QwNzQ1ODVhMDJmY2U3NDA0ZGE4ZTE5XzIwOTE_ed3dbd98-5770-4859-9d8a-6d49a318c8e3">ten years</ix:nonNumeric>. Leasehold improvements are amortized using the straight-line method over their estimated useful lives or their related lease term, whichever is shorter. Depreciation expense of $<ix:nonFraction unitRef="usd" contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231" decimals="-5" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90ZXh0cmVnaW9uOjhkMWM4MjU1M2QwNzQ1ODVhMDJmY2U3NDA0ZGE4ZTE5XzIyNzM_3c0c38da-98c7-4c12-85ea-2473da7da6d8">3.9</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="ib3597315a63d441f8f128abd7ed8840e_D20200101-20201231" decimals="-5" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90ZXh0cmVnaW9uOjhkMWM4MjU1M2QwNzQ1ODVhMDJmY2U3NDA0ZGE4ZTE5XzIyNzc_70037f7a-ed58-4e36-a151-2c122936b416">1.8</ix:nonFraction> million, and $<ix:nonFraction unitRef="usd" contextRef="ie6c3b69702e9429aaeed46bdb9bbb9c1_D20190101-20191231" decimals="-5" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90ZXh0cmVnaW9uOjhkMWM4MjU1M2QwNzQ1ODVhMDJmY2U3NDA0ZGE4ZTE5XzIyODU_d6a6b581-373a-4fb0-8fd1-48b587f55c72">1.5</ix:nonFraction> million was recognized for the twelve months ended December&#160;31, 2021, 2020, and 2019, respectively, and was included in operating expenses.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">83</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt;text-indent:24pt"><span><br/></span></div><ix:continuation id="i9816b62f0d4a4970881543dddeb5e2c4" continuedAt="i65d28245a5fc4baba24b412b56b603f6"><div style="margin-top:5pt"><ix:nonNumeric contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231" name="us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90ZXh0cmVnaW9uOjhkMWM4MjU1M2QwNzQ1ODVhMDJmY2U3NDA0ZGE4ZTE5XzQxNDM_4e29fcf9-5d59-46d1-8fc3-1b86a770ea41" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill and identifiable intangible assets consist of the following (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.976%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.498%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indefinite-lived intangible assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Goodwill</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZToyZTNmODAyYWEyM2E0MzlhOGRlZGI4NzExOWE2YWM1ZC90YWJsZXJhbmdlOjJlM2Y4MDJhYTIzYTQzOWE4ZGVkYjg3MTE5YTZhYzVkXzMtMS0xLTEtNDEyOTQ_f9412273-bf18-4595-82c5-0fbcc97b9d22">181,206</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7462d0db8f4248fcb9fd8f1deae439f3_I20201231" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZToyZTNmODAyYWEyM2E0MzlhOGRlZGI4NzExOWE2YWM1ZC90YWJsZXJhbmdlOjJlM2Y4MDJhYTIzYTQzOWE4ZGVkYjg3MTE5YTZhYzVkXzMtMy0xLTEtNDEyOTQ_8cc641ed-92b1-4e15-a0a8-5ba7da8d23f3">189,662</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Definite-lived intangible assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Complete technology</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8dc42c0d5a094b05bae7e120852bb210_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZToyZTNmODAyYWEyM2E0MzlhOGRlZGI4NzExOWE2YWM1ZC90YWJsZXJhbmdlOjJlM2Y4MDJhYTIzYTQzOWE4ZGVkYjg3MTE5YTZhYzVkXzUtMS0xLTEtNDEyOTQ_20403af0-b857-4625-8c27-f50a518f8ef6">280,617</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b8810ae90624e1cbd1c4a5c1b42b223_I20201231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZToyZTNmODAyYWEyM2E0MzlhOGRlZGI4NzExOWE2YWM1ZC90YWJsZXJhbmdlOjJlM2Y4MDJhYTIzYTQzOWE4ZGVkYjg3MTE5YTZhYzVkXzUtMy0xLTEtNDEyOTQ_e56b3af3-3488-49f8-a6a3-befa05947a3f">277,740</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Less: Accumulated amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8dc42c0d5a094b05bae7e120852bb210_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZToyZTNmODAyYWEyM2E0MzlhOGRlZGI4NzExOWE2YWM1ZC90YWJsZXJhbmdlOjJlM2Y4MDJhYTIzYTQzOWE4ZGVkYjg3MTE5YTZhYzVkXzYtMS0xLTEtNDEyOTQ_07f796c5-ce5a-4e69-a03e-95a90688e51d">78,991</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6b8810ae90624e1cbd1c4a5c1b42b223_I20201231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZToyZTNmODAyYWEyM2E0MzlhOGRlZGI4NzExOWE2YWM1ZC90YWJsZXJhbmdlOjJlM2Y4MDJhYTIzYTQzOWE4ZGVkYjg3MTE5YTZhYzVkXzYtMy0xLTEtNDEyOTQ_435320af-8c50-42e5-a2da-4327055c2fd5">63,600</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Trade name</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ida5c64ee227a46869554690587da8f25_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZToyZTNmODAyYWEyM2E0MzlhOGRlZGI4NzExOWE2YWM1ZC90YWJsZXJhbmdlOjJlM2Y4MDJhYTIzYTQzOWE4ZGVkYjg3MTE5YTZhYzVkXzctMS0xLTEtNDEyOTQ_824235af-0665-4d19-b999-ec8e6078050b">2,642</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e9a6867858343a7a292fb11a532ee7e_I20201231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZToyZTNmODAyYWEyM2E0MzlhOGRlZGI4NzExOWE2YWM1ZC90YWJsZXJhbmdlOjJlM2Y4MDJhYTIzYTQzOWE4ZGVkYjg3MTE5YTZhYzVkXzctMy0xLTEtNDEyOTQ_8f0ac400-cfad-4bff-ba29-9a9fba896dc8">2,642</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Less: Accumulated amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ida5c64ee227a46869554690587da8f25_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZToyZTNmODAyYWEyM2E0MzlhOGRlZGI4NzExOWE2YWM1ZC90YWJsZXJhbmdlOjJlM2Y4MDJhYTIzYTQzOWE4ZGVkYjg3MTE5YTZhYzVkXzgtMS0xLTEtNDEyOTQ_5305daab-6f34-4f89-93f4-f4501225b142">1,444</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5e9a6867858343a7a292fb11a532ee7e_I20201231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZToyZTNmODAyYWEyM2E0MzlhOGRlZGI4NzExOWE2YWM1ZC90YWJsZXJhbmdlOjJlM2Y4MDJhYTIzYTQzOWE4ZGVkYjg3MTE5YTZhYzVkXzgtMy0xLTEtNDEyOTQ_b4581bd0-7c25-411c-989e-4732ab877f13">1,312</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Customer relationships</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89bdb805a8644de089fac518b7ea8048_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZToyZTNmODAyYWEyM2E0MzlhOGRlZGI4NzExOWE2YWM1ZC90YWJsZXJhbmdlOjJlM2Y4MDJhYTIzYTQzOWE4ZGVkYjg3MTE5YTZhYzVkXzktMS0xLTEtNDEyOTQ_d454f3ab-0dd9-4a5f-ac3a-0e2318fef8bc">40,700</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i427cd915d4f24352b4c76d892b21bbe5_I20201231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZToyZTNmODAyYWEyM2E0MzlhOGRlZGI4NzExOWE2YWM1ZC90YWJsZXJhbmdlOjJlM2Y4MDJhYTIzYTQzOWE4ZGVkYjg3MTE5YTZhYzVkXzktMy0xLTEtNDEyOTQ_f269b578-9c89-4da8-92b1-0632c88da7b0">40,700</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Less: Accumulated amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i89bdb805a8644de089fac518b7ea8048_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZToyZTNmODAyYWEyM2E0MzlhOGRlZGI4NzExOWE2YWM1ZC90YWJsZXJhbmdlOjJlM2Y4MDJhYTIzYTQzOWE4ZGVkYjg3MTE5YTZhYzVkXzEwLTEtMS0xLTQxMjk0_a55d4067-b68e-4f88-a068-3391ab3d12c9">18,267</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i427cd915d4f24352b4c76d892b21bbe5_I20201231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZToyZTNmODAyYWEyM2E0MzlhOGRlZGI4NzExOWE2YWM1ZC90YWJsZXJhbmdlOjJlM2Y4MDJhYTIzYTQzOWE4ZGVkYjg3MTE5YTZhYzVkXzEwLTMtMS0xLTQxMjk0_61b41ac7-83ba-4b9e-8c8b-7b5f09ab5880">15,597</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Contractual relationships</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea59787485c24e82bc3497c81a2ced53_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZToyZTNmODAyYWEyM2E0MzlhOGRlZGI4NzExOWE2YWM1ZC90YWJsZXJhbmdlOjJlM2Y4MDJhYTIzYTQzOWE4ZGVkYjg3MTE5YTZhYzVkXzExLTEtMS0xLTQxMjk0_6713beee-57bb-4233-808b-f1413028e040">362,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0aba44ce07e94134b8623377b4bd1f1b_I20201231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZToyZTNmODAyYWEyM2E0MzlhOGRlZGI4NzExOWE2YWM1ZC90YWJsZXJhbmdlOjJlM2Y4MDJhYTIzYTQzOWE4ZGVkYjg3MTE5YTZhYzVkXzExLTMtMS0xLTQxMjk0_8a9b6c77-b9d1-4901-b6f2-d9615531bd98">362,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Accumulated amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iea59787485c24e82bc3497c81a2ced53_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZToyZTNmODAyYWEyM2E0MzlhOGRlZGI4NzExOWE2YWM1ZC90YWJsZXJhbmdlOjJlM2Y4MDJhYTIzYTQzOWE4ZGVkYjg3MTE5YTZhYzVkXzEyLTEtMS0xLTQxMjk0_be14784b-ab68-4358-adec-f2f7976ce9ea">36,217</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0aba44ce07e94134b8623377b4bd1f1b_I20201231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZToyZTNmODAyYWEyM2E0MzlhOGRlZGI4NzExOWE2YWM1ZC90YWJsZXJhbmdlOjJlM2Y4MDJhYTIzYTQzOWE4ZGVkYjg3MTE5YTZhYzVkXzEyLTMtMS0xLTQxMjk0_c5f8cf43-4729-4980-b489-d921792fdddd">7,243</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total goodwill and other identifiable intangible assets, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231" decimals="-3" name="us-gaap:IntangibleAssetsNetIncludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZToyZTNmODAyYWEyM2E0MzlhOGRlZGI4NzExOWE2YWM1ZC90YWJsZXJhbmdlOjJlM2Y4MDJhYTIzYTQzOWE4ZGVkYjg3MTE5YTZhYzVkXzEzLTEtMS0xLTQxMjk0_a9bc85c5-1d66-4390-be13-3fb98eb12684">732,246</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7462d0db8f4248fcb9fd8f1deae439f3_I20201231" decimals="-3" name="us-gaap:IntangibleAssetsNetIncludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZToyZTNmODAyYWEyM2E0MzlhOGRlZGI4NzExOWE2YWM1ZC90YWJsZXJhbmdlOjJlM2Y4MDJhYTIzYTQzOWE4ZGVkYjg3MTE5YTZhYzVkXzEzLTMtMS0xLTQxMjk0_07923f33-7ee9-4cd7-96e7-95499611502d">784,992</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></ix:nonNumeric></div><div style="text-indent:24pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization of finite-lived intangible assets is computed using the straight-line method over the estimated useful life of the asset of up to <ix:nonNumeric contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90ZXh0cmVnaW9uOjhkMWM4MjU1M2QwNzQ1ODVhMDJmY2U3NDA0ZGE4ZTE5XzI2MTA_5517544f-6824-403b-8063-977bdbb162d1">20</ix:nonNumeric> years. Amortization expense of $<ix:nonFraction unitRef="usd" contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90ZXh0cmVnaW9uOjhkMWM4MjU1M2QwNzQ1ODVhMDJmY2U3NDA0ZGE4ZTE5XzI2Mzg_a020c458-a642-461a-ae2a-01fa25425b2c">47.2</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="ib3597315a63d441f8f128abd7ed8840e_D20200101-20201231" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90ZXh0cmVnaW9uOjhkMWM4MjU1M2QwNzQ1ODVhMDJmY2U3NDA0ZGE4ZTE5XzI2NDI_456ec17e-5225-4892-853d-6f796507b8e4">23.4</ix:nonFraction> million, and $<ix:nonFraction unitRef="usd" contextRef="ie6c3b69702e9429aaeed46bdb9bbb9c1_D20190101-20191231" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90ZXh0cmVnaW9uOjhkMWM4MjU1M2QwNzQ1ODVhMDJmY2U3NDA0ZGE4ZTE5XzI2NTA_14ee68ae-35fa-4a6e-88da-adf2d0cf8bea">16.9</ix:nonFraction> million was recognized for the years ended December&#160;31, 2021, 2020, and 2019, respectively. Estimated amortization expense for the years ending December&#160;31, 2022 through 2026 is $<ix:nonFraction unitRef="usd" contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90ZXh0cmVnaW9uOjhkMWM4MjU1M2QwNzQ1ODVhMDJmY2U3NDA0ZGE4ZTE5XzI4MDc_03c3d4a3-5e0c-422f-8f79-ef48a85e3897"><ix:nonFraction unitRef="usd" contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90ZXh0cmVnaW9uOjhkMWM4MjU1M2QwNzQ1ODVhMDJmY2U3NDA0ZGE4ZTE5XzI4MDc_4e387351-b417-45aa-892d-c7e9967b61c1"><ix:nonFraction unitRef="usd" contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90ZXh0cmVnaW9uOjhkMWM4MjU1M2QwNzQ1ODVhMDJmY2U3NDA0ZGE4ZTE5XzI4MDc_8e429b1f-8e04-44cc-b0ad-2728d3f809f3"><ix:nonFraction unitRef="usd" contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90ZXh0cmVnaW9uOjhkMWM4MjU1M2QwNzQ1ODVhMDJmY2U3NDA0ZGE4ZTE5XzI4MDc_c882f072-4681-43ea-8528-f4525e96111e">47.0</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> million per year. For each of the years ended December&#160;31, 2021, 2021, and 2019, there was <ix:nonFraction unitRef="usd" contextRef="ib3597315a63d441f8f128abd7ed8840e_D20200101-20201231" decimals="INF" name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90ZXh0cmVnaW9uOjhkMWM4MjU1M2QwNzQ1ODVhMDJmY2U3NDA0ZGE4ZTE5XzI4NzQ_2a0077be-1a1f-493d-bc09-19672fea6768"><ix:nonFraction unitRef="usd" contextRef="ie6c3b69702e9429aaeed46bdb9bbb9c1_D20190101-20191231" decimals="INF" name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90ZXh0cmVnaW9uOjhkMWM4MjU1M2QwNzQ1ODVhMDJmY2U3NDA0ZGE4ZTE5XzI4NzQ_7a044a15-9261-48c6-b17f-2b511bf9e5f3"><ix:nonFraction unitRef="usd" contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231" decimals="INF" name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90ZXh0cmVnaW9uOjhkMWM4MjU1M2QwNzQ1ODVhMDJmY2U3NDA0ZGE4ZTE5XzI4NzQ_ae04c644-2e3f-40c7-b440-281c20f7c4bc">no</ix:nonFraction></ix:nonFraction></ix:nonFraction> material impairment of intangible assets with finite lives.</span></div><div style="text-indent:24pt"><span><br/></span></div><div style="text-indent:36pt"><span><br/></span></div><div><ix:nonNumeric contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90ZXh0cmVnaW9uOjhkMWM4MjU1M2QwNzQ1ODVhMDJmY2U3NDA0ZGE4ZTE5XzQxMzI_5852e9d0-bc46-4c52-aec3-cfad29f041b7" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accrued liabilities consist of the following (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.976%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.498%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Compensation</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpkMDg3Yjg2OGEzOWM0YzczOGQ4NjgwNTk2MDdiMDQzZS90YWJsZXJhbmdlOmQwODdiODY4YTM5YzRjNzM4ZDg2ODA1OTYwN2IwNDNlXzItMS0xLTEtNDEyOTQ_451aad17-987c-4d2f-b9e1-eb55a62afc19">6,532</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7462d0db8f4248fcb9fd8f1deae439f3_I20201231" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpkMDg3Yjg2OGEzOWM0YzczOGQ4NjgwNTk2MDdiMDQzZS90YWJsZXJhbmdlOmQwODdiODY4YTM5YzRjNzM4ZDg2ODA1OTYwN2IwNDNlXzItMy0xLTEtNDEyOTQ_b5d5ee79-5d86-4368-9289-4c707a340ed4">8,810</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Professional fees</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231" decimals="-3" name="us-gaap:AccruedProfessionalFeesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpkMDg3Yjg2OGEzOWM0YzczOGQ4NjgwNTk2MDdiMDQzZS90YWJsZXJhbmdlOmQwODdiODY4YTM5YzRjNzM4ZDg2ODA1OTYwN2IwNDNlXzMtMS0xLTEtNDEyOTQ_7e733da7-4b92-439d-9640-57d2d030a3f0">2,046</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7462d0db8f4248fcb9fd8f1deae439f3_I20201231" decimals="-3" name="us-gaap:AccruedProfessionalFeesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpkMDg3Yjg2OGEzOWM0YzczOGQ4NjgwNTk2MDdiMDQzZS90YWJsZXJhbmdlOmQwODdiODY4YTM5YzRjNzM4ZDg2ODA1OTYwN2IwNDNlXzMtMy0xLTEtNDEyOTQ_134a957d-b2fb-46a2-bc36-420ba3504458">977</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts owed to former licensees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231" decimals="-3" name="us-gaap:AccruedSalesCommissionCurrentAndNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpkMDg3Yjg2OGEzOWM0YzczOGQ4NjgwNTk2MDdiMDQzZS90YWJsZXJhbmdlOmQwODdiODY4YTM5YzRjNzM4ZDg2ODA1OTYwN2IwNDNlXzQtMS0xLTEtNDEyOTQ_edc69c43-9d1a-4ad9-8d3c-304dbf668543">630</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7462d0db8f4248fcb9fd8f1deae439f3_I20201231" decimals="-3" name="us-gaap:AccruedSalesCommissionCurrentAndNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpkMDg3Yjg2OGEzOWM0YzczOGQ4NjgwNTk2MDdiMDQzZS90YWJsZXJhbmdlOmQwODdiODY4YTM5YzRjNzM4ZDg2ODA1OTYwN2IwNDNlXzQtMy0xLTEtNDEyOTQ_535c5c12-2d34-465f-9958-48162fb04b29">421</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalties owed to third parties</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231" decimals="-3" name="us-gaap:AccruedRoyaltiesCurrentAndNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpkMDg3Yjg2OGEzOWM0YzczOGQ4NjgwNTk2MDdiMDQzZS90YWJsZXJhbmdlOmQwODdiODY4YTM5YzRjNzM4ZDg2ODA1OTYwN2IwNDNlXzUtMS0xLTEtNDEyOTQ_9b18f611-2b09-4a68-8582-02abcc4bb974">149</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7462d0db8f4248fcb9fd8f1deae439f3_I20201231" decimals="-3" name="us-gaap:AccruedRoyaltiesCurrentAndNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpkMDg3Yjg2OGEzOWM0YzczOGQ4NjgwNTk2MDdiMDQzZS90YWJsZXJhbmdlOmQwODdiODY4YTM5YzRjNzM4ZDg2ODA1OTYwN2IwNDNlXzUtMy0xLTEtNDEyOTQ_d06080b8-be96-4714-9b02-29c8ab44f1d4">693</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Return reserve and customer refunds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231" decimals="-3" name="lgnd:AccruedSalesReturns" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpkMDg3Yjg2OGEzOWM0YzczOGQ4NjgwNTk2MDdiMDQzZS90YWJsZXJhbmdlOmQwODdiODY4YTM5YzRjNzM4ZDg2ODA1OTYwN2IwNDNlXzYtMS0xLTEtNDEyOTQ_0c5289fe-c2e1-44cd-8c6f-a07ec05b0749">2,420</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7462d0db8f4248fcb9fd8f1deae439f3_I20201231" decimals="-3" name="lgnd:AccruedSalesReturns" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpkMDg3Yjg2OGEzOWM0YzczOGQ4NjgwNTk2MDdiMDQzZS90YWJsZXJhbmdlOmQwODdiODY4YTM5YzRjNzM4ZDg2ODA1OTYwN2IwNDNlXzYtMy0xLTEtNDEyOTQ_64eb83b1-c22e-45ad-a7b9-6f227f8e0f53">687</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition related liabilities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231" decimals="-3" name="lgnd:AccruedAssetAcquisitionsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpkMDg3Yjg2OGEzOWM0YzczOGQ4NjgwNTk2MDdiMDQzZS90YWJsZXJhbmdlOmQwODdiODY4YTM5YzRjNzM4ZDg2ODA1OTYwN2IwNDNlXzctMS0xLTEtNDEyOTQ_87489421-4cce-4a6e-b68a-16d3e882fcde">1,000</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7462d0db8f4248fcb9fd8f1deae439f3_I20201231" decimals="-3" name="lgnd:AccruedAssetAcquisitionsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpkMDg3Yjg2OGEzOWM0YzczOGQ4NjgwNTk2MDdiMDQzZS90YWJsZXJhbmdlOmQwODdiODY4YTM5YzRjNzM4ZDg2ODA1OTYwN2IwNDNlXzctMy0xLTEtNDEyOTQ_341dc107-5259-45c7-8cfe-98b2b54cbdb3">1,500</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Subcontractor</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231" decimals="-3" name="lgnd:AccruedSubcontractorExpensesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpkMDg3Yjg2OGEzOWM0YzczOGQ4NjgwNTk2MDdiMDQzZS90YWJsZXJhbmdlOmQwODdiODY4YTM5YzRjNzM4ZDg2ODA1OTYwN2IwNDNlXzgtMS0xLTEtNDEyOTQ_e72db46b-28ca-4919-a860-a9bfc8aefc7c">1,759</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7462d0db8f4248fcb9fd8f1deae439f3_I20201231" decimals="-3" name="lgnd:AccruedSubcontractorExpensesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpkMDg3Yjg2OGEzOWM0YzczOGQ4NjgwNTk2MDdiMDQzZS90YWJsZXJhbmdlOmQwODdiODY4YTM5YzRjNzM4ZDg2ODA1OTYwN2IwNDNlXzgtMy0xLTEtNDEyOTQ_72262c87-618c-41ad-a36d-65f9b0f71708">733</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Supplier</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231" decimals="-3" name="lgnd:AccruedSupplierExpensesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpkMDg3Yjg2OGEzOWM0YzczOGQ4NjgwNTk2MDdiMDQzZS90YWJsZXJhbmdlOmQwODdiODY4YTM5YzRjNzM4ZDg2ODA1OTYwN2IwNDNlXzktMS0xLTEtNDEyOTQ_fe4f0cd3-2945-4dc2-a373-ce4c187e05d2">848</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7462d0db8f4248fcb9fd8f1deae439f3_I20201231" decimals="-3" name="lgnd:AccruedSupplierExpensesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpkMDg3Yjg2OGEzOWM0YzczOGQ4NjgwNTk2MDdiMDQzZS90YWJsZXJhbmdlOmQwODdiODY4YTM5YzRjNzM4ZDg2ODA1OTYwN2IwNDNlXzktMy0xLTEtNDEyOTQ_70b5fdf8-026f-43e5-8b1a-2a0888c29fe9">604</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpkMDg3Yjg2OGEzOWM0YzczOGQ4NjgwNTk2MDdiMDQzZS90YWJsZXJhbmdlOmQwODdiODY4YTM5YzRjNzM4ZDg2ODA1OTYwN2IwNDNlXzEwLTEtMS0xLTQxMjk0_84f21be8-91d3-482c-af65-9789199f5cfc">2,195</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7462d0db8f4248fcb9fd8f1deae439f3_I20201231" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpkMDg3Yjg2OGEzOWM0YzczOGQ4NjgwNTk2MDdiMDQzZS90YWJsZXJhbmdlOmQwODdiODY4YTM5YzRjNzM4ZDg2ODA1OTYwN2IwNDNlXzEwLTMtMS0xLTQxMjk0_132f1df1-afca-4ccc-b6e7-ab8e60913044">4,105</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpkMDg3Yjg2OGEzOWM0YzczOGQ4NjgwNTk2MDdiMDQzZS90YWJsZXJhbmdlOmQwODdiODY4YTM5YzRjNzM4ZDg2ODA1OTYwN2IwNDNlXzExLTEtMS0xLTQxMjk0_cead6e29-acf6-40f7-bd52-a5fc33deb0f8">17,579</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7462d0db8f4248fcb9fd8f1deae439f3_I20201231" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpkMDg3Yjg2OGEzOWM0YzczOGQ4NjgwNTk2MDdiMDQzZS90YWJsZXJhbmdlOmQwODdiODY4YTM5YzRjNzM4ZDg2ODA1OTYwN2IwNDNlXzExLTMtMS0xLTQxMjk0_d05df960-0b0e-4b34-a3d5-e02a6da76d00">18,530</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingent liabilities:</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the acquisition of Crystal in October 2017, we entered into contingent liabilities based on achievement of certain research and business milestones as well as certain revenue goal.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the acquisition of CyDex in January 2011, we issued a series of CVRs and also assumed certain contingent liabilities. We may be required to make additional payments upon achievement of certain clinical and regulatory milestones to the CyDex shareholders and former license holders.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the acquisition of Metabasis in January 2010, we entered into <ix:nonFraction unitRef="agreement" contextRef="i96479b1570dc4ab694a9ba99ff1921f3_I20100131" decimals="INF" name="lgnd:NumberOfContingentValueRightAgreements" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90ZXh0cmVnaW9uOjhkMWM4MjU1M2QwNzQ1ODVhMDJmY2U3NDA0ZGE4ZTE5XzIxOTkwMjMyNjA4MDA_aa5f0290-8b86-4b20-b153-001c3a02d27e">four</ix:nonFraction> CVR agreements with Metabasis shareholders. The CVRs entitle the holders to cash payments as frequently as every six months as proceeds are received by us upon the sale or licensing of any of the Metabasis drug development programs and upon the achievement of specified milestones.</span></div></ix:continuation><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">84</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i65d28245a5fc4baba24b412b56b603f6"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For CVRs associated with the Pfenex and Icagen acquisitions, see &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note (4), Acquisitions</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; for more information.</span></div><div><span><br/></span></div><ix:nonNumeric contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231" name="lgnd:ScheduleofContingentLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90ZXh0cmVnaW9uOjhkMWM4MjU1M2QwNzQ1ODVhMDJmY2U3NDA0ZGE4ZTE5XzQxMzk_05d8c352-c277-4f9a-b8a3-07bbc7fd4d1e" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes roll-forward of contingent liabilities as of December 2021 and 2020 (in thousands):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:6.356%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.964%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:7.525%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.115%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2019</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Additional Contingent Liabilities</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Payments</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair Value Adjustment</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Repurchases</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Payments</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair Value Adjustment</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Repurchases</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cydex</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03ae11f17dbd4fa8abcc1e76cf940016_I20191231" decimals="-3" name="lgnd:BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZToyMTA1OTJhYWFmMGY0OTkyYjkyM2UyNzEzYThlOWRlNy90YWJsZXJhbmdlOjIxMDU5MmFhYWYwZjQ5OTJiOTIzZTI3MTNhOGU5ZGU3XzEtMS0xLTEtNDEyOTQ_cc2165ce-6b4f-4dff-8ed9-73a6c68ac3be">348</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i995ed554220d4c41bec3af6e81ce0850_D20200101-20201231" decimals="-3" name="lgnd:BusinessAcquisitionContingentConsiderationPotentialCashPaymentAdditions" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZToyMTA1OTJhYWFmMGY0OTkyYjkyM2UyNzEzYThlOWRlNy90YWJsZXJhbmdlOjIxMDU5MmFhYWYwZjQ5OTJiOTIzZTI3MTNhOGU5ZGU3XzEtMi0xLTEtNDEyOTQ_294e6ad3-8613-4fca-99ec-ccd39283d90e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i995ed554220d4c41bec3af6e81ce0850_D20200101-20201231" decimals="-3" name="lgnd:PaymentsToContingentValueRightHolders" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZToyMTA1OTJhYWFmMGY0OTkyYjkyM2UyNzEzYThlOWRlNy90YWJsZXJhbmdlOjIxMDU5MmFhYWYwZjQ5OTJiOTIzZTI3MTNhOGU5ZGU3XzEtMy0xLTEtNDEyOTQ_ecab0643-143b-42b3-9cf7-67ebfb1f94aa">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i995ed554220d4c41bec3af6e81ce0850_D20200101-20201231" decimals="-3" name="lgnd:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZToyMTA1OTJhYWFmMGY0OTkyYjkyM2UyNzEzYThlOWRlNy90YWJsZXJhbmdlOjIxMDU5MmFhYWYwZjQ5OTJiOTIzZTI3MTNhOGU5ZGU3XzEtNC0xLTEtNDc2NzI_fb9b549c-787d-45c0-bf34-1b0985502ac7">160</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i995ed554220d4c41bec3af6e81ce0850_D20200101-20201231" decimals="-3" name="lgnd:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityRepurchasesContingentLiabilities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZToyMTA1OTJhYWFmMGY0OTkyYjkyM2UyNzEzYThlOWRlNy90YWJsZXJhbmdlOjIxMDU5MmFhYWYwZjQ5OTJiOTIzZTI3MTNhOGU5ZGU3XzEtNS0xLTEtNDEyOTQ_b7c93671-4252-4a3b-b351-73eae253322c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0526771434af45b0b8fabceb89eea2cc_I20201231" decimals="-3" name="lgnd:BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZToyMTA1OTJhYWFmMGY0OTkyYjkyM2UyNzEzYThlOWRlNy90YWJsZXJhbmdlOjIxMDU5MmFhYWYwZjQ5OTJiOTIzZTI3MTNhOGU5ZGU3XzEtNi0xLTEtNDEyOTQ_99dde1c3-b43e-4185-8650-ad5dd8693aaf">508</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9a7cf59bd85847db8f5d973e93d748f7_D20210101-20211231" decimals="-3" name="lgnd:PaymentsToContingentValueRightHolders" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZToyMTA1OTJhYWFmMGY0OTkyYjkyM2UyNzEzYThlOWRlNy90YWJsZXJhbmdlOjIxMDU5MmFhYWYwZjQ5OTJiOTIzZTI3MTNhOGU5ZGU3XzEtOS0xLTEtNDEyOTQ_e2b77820-6c11-4f25-b6fd-7b5fa4a7cd88">50</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9a7cf59bd85847db8f5d973e93d748f7_D20210101-20211231" decimals="-3" sign="-" name="lgnd:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZToyMTA1OTJhYWFmMGY0OTkyYjkyM2UyNzEzYThlOWRlNy90YWJsZXJhbmdlOjIxMDU5MmFhYWYwZjQ5OTJiOTIzZTI3MTNhOGU5ZGU3XzEtMTAtMS0xLTQxMjk0_e5a34b2d-3e11-4897-8dc7-93a0229a1355">108</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a7cf59bd85847db8f5d973e93d748f7_D20210101-20211231" decimals="-3" name="lgnd:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityRepurchasesContingentLiabilities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZToyMTA1OTJhYWFmMGY0OTkyYjkyM2UyNzEzYThlOWRlNy90YWJsZXJhbmdlOjIxMDU5MmFhYWYwZjQ5OTJiOTIzZTI3MTNhOGU5ZGU3XzEtMTEtMS0xLTQxMjk0_41fa0019-364b-492d-8633-4defed73e838">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i460273d884cd42ba9f38e5fa9863bd88_I20211231" decimals="-3" name="lgnd:BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZToyMTA1OTJhYWFmMGY0OTkyYjkyM2UyNzEzYThlOWRlNy90YWJsZXJhbmdlOjIxMDU5MmFhYWYwZjQ5OTJiOTIzZTI3MTNhOGU5ZGU3XzEtMTItMS0xLTQxMjk0_f0c8c138-d8e0-4134-83f8-379257ea8901">350</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Metabasis</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icaf2965868e840808ef1852e02d910af_I20191231" decimals="-3" name="lgnd:BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZToyMTA1OTJhYWFmMGY0OTkyYjkyM2UyNzEzYThlOWRlNy90YWJsZXJhbmdlOjIxMDU5MmFhYWYwZjQ5OTJiOTIzZTI3MTNhOGU5ZGU3XzItMS0xLTEtNDEyOTQ_5d705a12-fef5-463e-913b-f2154bff697a">5,935</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9bc6c029e12c43b59b76212780726386_D20200101-20201231" decimals="-3" name="lgnd:BusinessAcquisitionContingentConsiderationPotentialCashPaymentAdditions" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZToyMTA1OTJhYWFmMGY0OTkyYjkyM2UyNzEzYThlOWRlNy90YWJsZXJhbmdlOjIxMDU5MmFhYWYwZjQ5OTJiOTIzZTI3MTNhOGU5ZGU3XzItMi0xLTEtNDEyOTQ_37af44d3-21c4-4938-9b36-5a03156fe712">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9bc6c029e12c43b59b76212780726386_D20200101-20201231" decimals="-3" name="lgnd:PaymentsToContingentValueRightHolders" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZToyMTA1OTJhYWFmMGY0OTkyYjkyM2UyNzEzYThlOWRlNy90YWJsZXJhbmdlOjIxMDU5MmFhYWYwZjQ5OTJiOTIzZTI3MTNhOGU5ZGU3XzItMy0xLTEtNDEyOTQ_dbba6854-8793-48e8-8c4d-308cd751e1fe">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9bc6c029e12c43b59b76212780726386_D20200101-20201231" decimals="-3" sign="-" name="lgnd:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZToyMTA1OTJhYWFmMGY0OTkyYjkyM2UyNzEzYThlOWRlNy90YWJsZXJhbmdlOjIxMDU5MmFhYWYwZjQ5OTJiOTIzZTI3MTNhOGU5ZGU3XzItNC0xLTEtNDc2NzI_d8a9bbbe-c9d9-4275-b1c8-844c94df5c6a">1,867</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9bc6c029e12c43b59b76212780726386_D20200101-20201231" decimals="-3" name="lgnd:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityRepurchasesContingentLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZToyMTA1OTJhYWFmMGY0OTkyYjkyM2UyNzEzYThlOWRlNy90YWJsZXJhbmdlOjIxMDU5MmFhYWYwZjQ5OTJiOTIzZTI3MTNhOGU5ZGU3XzItNS0xLTEtNDEyOTQ_cafb045f-56ba-4f9e-99c3-cc4f4a3cce47">247</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e4b849ac2f8499fb341e31d46f606a1_I20201231" decimals="-3" name="lgnd:BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZToyMTA1OTJhYWFmMGY0OTkyYjkyM2UyNzEzYThlOWRlNy90YWJsZXJhbmdlOjIxMDU5MmFhYWYwZjQ5OTJiOTIzZTI3MTNhOGU5ZGU3XzItNi0xLTEtNDEyOTQ_08f59ab8-689e-42b8-bc01-343bed21766b">3,821</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d4b5cb9bf0848cd952b53016008c4d8_D20210101-20211231" decimals="-3" name="lgnd:PaymentsToContingentValueRightHolders" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZToyMTA1OTJhYWFmMGY0OTkyYjkyM2UyNzEzYThlOWRlNy90YWJsZXJhbmdlOjIxMDU5MmFhYWYwZjQ5OTJiOTIzZTI3MTNhOGU5ZGU3XzItOS0xLTEtNDEyOTQ_087f98df-e371-494e-90f6-598d6612597d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1d4b5cb9bf0848cd952b53016008c4d8_D20210101-20211231" decimals="-3" sign="-" name="lgnd:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZToyMTA1OTJhYWFmMGY0OTkyYjkyM2UyNzEzYThlOWRlNy90YWJsZXJhbmdlOjIxMDU5MmFhYWYwZjQ5OTJiOTIzZTI3MTNhOGU5ZGU3XzItMTAtMS0xLTQxMjk0_c141bbf0-6904-4bcc-b710-8d4f23082ba1">464</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d4b5cb9bf0848cd952b53016008c4d8_D20210101-20211231" decimals="-3" name="lgnd:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityRepurchasesContingentLiabilities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZToyMTA1OTJhYWFmMGY0OTkyYjkyM2UyNzEzYThlOWRlNy90YWJsZXJhbmdlOjIxMDU5MmFhYWYwZjQ5OTJiOTIzZTI3MTNhOGU5ZGU3XzItMTEtMS0xLTQxMjk0_aeda575b-6ff9-45ff-84ba-762ba29775dc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83cae13058624959a293b420f9d495a2_I20211231" decimals="-3" name="lgnd:BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZToyMTA1OTJhYWFmMGY0OTkyYjkyM2UyNzEzYThlOWRlNy90YWJsZXJhbmdlOjIxMDU5MmFhYWYwZjQ5OTJiOTIzZTI3MTNhOGU5ZGU3XzItMTItMS0xLTQxMjk0_aed24ea7-e20b-406b-bd7b-b02620a84b01">3,357</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Crystal</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e883877c50c4dd5bae0f1a39a6a0e41_I20191231" decimals="-3" name="lgnd:BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZToyMTA1OTJhYWFmMGY0OTkyYjkyM2UyNzEzYThlOWRlNy90YWJsZXJhbmdlOjIxMDU5MmFhYWYwZjQ5OTJiOTIzZTI3MTNhOGU5ZGU3XzMtMS0xLTEtNDEyOTQ_02e6aaf3-aabd-4ac6-b27f-4873172e2a7c">2,659</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b2336871c004529976d951e9de999e1_D20200101-20201231" decimals="-3" name="lgnd:BusinessAcquisitionContingentConsiderationPotentialCashPaymentAdditions" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZToyMTA1OTJhYWFmMGY0OTkyYjkyM2UyNzEzYThlOWRlNy90YWJsZXJhbmdlOjIxMDU5MmFhYWYwZjQ5OTJiOTIzZTI3MTNhOGU5ZGU3XzMtMi0xLTEtNDEyOTQ_0c00374f-cacc-437e-a6af-6af7fe9715f5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9b2336871c004529976d951e9de999e1_D20200101-20201231" decimals="-3" name="lgnd:PaymentsToContingentValueRightHolders" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZToyMTA1OTJhYWFmMGY0OTkyYjkyM2UyNzEzYThlOWRlNy90YWJsZXJhbmdlOjIxMDU5MmFhYWYwZjQ5OTJiOTIzZTI3MTNhOGU5ZGU3XzMtMy0xLTEtNDEyOTQ_0973edba-34e6-4706-8e34-a14e386cc497">1,800</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9b2336871c004529976d951e9de999e1_D20200101-20201231" decimals="-3" sign="-" name="lgnd:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZToyMTA1OTJhYWFmMGY0OTkyYjkyM2UyNzEzYThlOWRlNy90YWJsZXJhbmdlOjIxMDU5MmFhYWYwZjQ5OTJiOTIzZTI3MTNhOGU5ZGU3XzMtNC0xLTEtNDc2NzI_c986a8f6-9ae3-448b-89fc-f7241ab1ffcc">59</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b2336871c004529976d951e9de999e1_D20200101-20201231" decimals="-3" name="lgnd:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityRepurchasesContingentLiabilities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZToyMTA1OTJhYWFmMGY0OTkyYjkyM2UyNzEzYThlOWRlNy90YWJsZXJhbmdlOjIxMDU5MmFhYWYwZjQ5OTJiOTIzZTI3MTNhOGU5ZGU3XzMtNS0xLTEtNDEyOTQ_db9ea173-5f34-4c4b-ad4d-e2089671a8b2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99bcc19c12eb4a95abbe38b2a1c1ee09_I20201231" decimals="-3" name="lgnd:BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZToyMTA1OTJhYWFmMGY0OTkyYjkyM2UyNzEzYThlOWRlNy90YWJsZXJhbmdlOjIxMDU5MmFhYWYwZjQ5OTJiOTIzZTI3MTNhOGU5ZGU3XzMtNi0xLTEtNDEyOTQ_e8bbce1b-214b-4290-935d-9c91c50b4805">800</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46955c33e54e4edc9a5157b092d74d96_D20210101-20211231" decimals="-3" name="lgnd:PaymentsToContingentValueRightHolders" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZToyMTA1OTJhYWFmMGY0OTkyYjkyM2UyNzEzYThlOWRlNy90YWJsZXJhbmdlOjIxMDU5MmFhYWYwZjQ5OTJiOTIzZTI3MTNhOGU5ZGU3XzMtOS0xLTEtNDEyOTQ_bdd0be41-4704-4f6f-9a02-2857639af993">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i46955c33e54e4edc9a5157b092d74d96_D20210101-20211231" decimals="-3" sign="-" name="lgnd:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZToyMTA1OTJhYWFmMGY0OTkyYjkyM2UyNzEzYThlOWRlNy90YWJsZXJhbmdlOjIxMDU5MmFhYWYwZjQ5OTJiOTIzZTI3MTNhOGU5ZGU3XzMtMTAtMS0xLTQxMjk0_4454a136-c101-4141-ab9a-e04c00abfcb3">800</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46955c33e54e4edc9a5157b092d74d96_D20210101-20211231" decimals="-3" name="lgnd:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityRepurchasesContingentLiabilities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZToyMTA1OTJhYWFmMGY0OTkyYjkyM2UyNzEzYThlOWRlNy90YWJsZXJhbmdlOjIxMDU5MmFhYWYwZjQ5OTJiOTIzZTI3MTNhOGU5ZGU3XzMtMTEtMS0xLTQxMjk0_d8bacca5-dc3d-435f-bdc7-c57619f04e15">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaad967943e174bfb992a030f8843e4a9_I20211231" decimals="-3" name="lgnd:BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZToyMTA1OTJhYWFmMGY0OTkyYjkyM2UyNzEzYThlOWRlNy90YWJsZXJhbmdlOjIxMDU5MmFhYWYwZjQ5OTJiOTIzZTI3MTNhOGU5ZGU3XzMtMTItMS0xLTQxMjk0_dc247685-6a60-4028-9407-0c6929a0e26d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Icagen</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if61e02a9d9f3443a954dd4ff1b746645_I20191231" decimals="-3" name="lgnd:BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZToyMTA1OTJhYWFmMGY0OTkyYjkyM2UyNzEzYThlOWRlNy90YWJsZXJhbmdlOjIxMDU5MmFhYWYwZjQ5OTJiOTIzZTI3MTNhOGU5ZGU3XzQtMS0xLTEtNDEyOTQ_4e9d0c0d-f0dc-4121-9b21-1c3f3c6cb395">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idcfaeb9f6dcd4e36923251345eeb6ca6_D20200101-20201231" decimals="-3" name="lgnd:BusinessAcquisitionContingentConsiderationPotentialCashPaymentAdditions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZToyMTA1OTJhYWFmMGY0OTkyYjkyM2UyNzEzYThlOWRlNy90YWJsZXJhbmdlOjIxMDU5MmFhYWYwZjQ5OTJiOTIzZTI3MTNhOGU5ZGU3XzQtMi0xLTEtNDEyOTQ_ae1e4a1a-77d5-4d3f-ae77-f39dcc4a8462">4,800</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idcfaeb9f6dcd4e36923251345eeb6ca6_D20200101-20201231" decimals="-3" name="lgnd:PaymentsToContingentValueRightHolders" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZToyMTA1OTJhYWFmMGY0OTkyYjkyM2UyNzEzYThlOWRlNy90YWJsZXJhbmdlOjIxMDU5MmFhYWYwZjQ5OTJiOTIzZTI3MTNhOGU5ZGU3XzQtMy0xLTEtNDEyOTQ_c098db18-9469-4c81-b199-3cd504a39b1c">525</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idcfaeb9f6dcd4e36923251345eeb6ca6_D20200101-20201231" decimals="-3" name="lgnd:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZToyMTA1OTJhYWFmMGY0OTkyYjkyM2UyNzEzYThlOWRlNy90YWJsZXJhbmdlOjIxMDU5MmFhYWYwZjQ5OTJiOTIzZTI3MTNhOGU5ZGU3XzQtNC0xLTEtNDc2NzI_1ad824be-12d4-4dd1-82cc-a4a63697f378">2,129</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idcfaeb9f6dcd4e36923251345eeb6ca6_D20200101-20201231" decimals="-3" name="lgnd:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityRepurchasesContingentLiabilities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZToyMTA1OTJhYWFmMGY0OTkyYjkyM2UyNzEzYThlOWRlNy90YWJsZXJhbmdlOjIxMDU5MmFhYWYwZjQ5OTJiOTIzZTI3MTNhOGU5ZGU3XzQtNS0xLTEtNDc2ODY_ab387270-5c51-4500-8693-c8e8e5fe6c64">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3fbebdcfd15e4645b3afda1206ded002_I20201231" decimals="-3" name="lgnd:BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZToyMTA1OTJhYWFmMGY0OTkyYjkyM2UyNzEzYThlOWRlNy90YWJsZXJhbmdlOjIxMDU5MmFhYWYwZjQ5OTJiOTIzZTI3MTNhOGU5ZGU3XzQtNi0xLTEtNDEyOTQ_caee7659-8bce-4f50-9162-e82f3c869510">6,404</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i187c5df306a349e38267335b0f796d41_D20210101-20211231" decimals="-3" name="lgnd:PaymentsToContingentValueRightHolders" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZToyMTA1OTJhYWFmMGY0OTkyYjkyM2UyNzEzYThlOWRlNy90YWJsZXJhbmdlOjIxMDU5MmFhYWYwZjQ5OTJiOTIzZTI3MTNhOGU5ZGU3XzQtOS0xLTEtNDEyOTQ_3e3505d7-eb6f-4f3a-b1b3-b4e4c179161a">1,050</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i187c5df306a349e38267335b0f796d41_D20210101-20211231" decimals="-3" name="lgnd:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZToyMTA1OTJhYWFmMGY0OTkyYjkyM2UyNzEzYThlOWRlNy90YWJsZXJhbmdlOjIxMDU5MmFhYWYwZjQ5OTJiOTIzZTI3MTNhOGU5ZGU3XzQtMTAtMS0xLTQxMjk0_52bc5387-cc13-4ca0-8ebb-2f8e54f49946">2,010</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i187c5df306a349e38267335b0f796d41_D20210101-20211231" decimals="-3" name="lgnd:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityRepurchasesContingentLiabilities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZToyMTA1OTJhYWFmMGY0OTkyYjkyM2UyNzEzYThlOWRlNy90YWJsZXJhbmdlOjIxMDU5MmFhYWYwZjQ5OTJiOTIzZTI3MTNhOGU5ZGU3XzQtMTEtMS0xLTQxMjk0_258ca4f9-3acc-45ca-847a-1e3b822a7b2c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fb9df0f2e264716b9f5ee2e301fba56_I20211231" decimals="-3" name="lgnd:BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZToyMTA1OTJhYWFmMGY0OTkyYjkyM2UyNzEzYThlOWRlNy90YWJsZXJhbmdlOjIxMDU5MmFhYWYwZjQ5OTJiOTIzZTI3MTNhOGU5ZGU3XzQtMTItMS0xLTQxMjk0_b1c88dd2-8701-4d9b-94a1-3b968540c61d">7,364</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pfenex</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c2bd0e95a2b4600bd5178475b6ab429_I20191231" decimals="-3" name="lgnd:BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZToyMTA1OTJhYWFmMGY0OTkyYjkyM2UyNzEzYThlOWRlNy90YWJsZXJhbmdlOjIxMDU5MmFhYWYwZjQ5OTJiOTIzZTI3MTNhOGU5ZGU3XzUtMS0xLTEtNDEyOTQ_6718cd01-4d5e-469e-8630-962f98f01176">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81ce7b0c06a94e61a7d245d6544346aa_D20200101-20201231" decimals="-3" name="lgnd:BusinessAcquisitionContingentConsiderationPotentialCashPaymentAdditions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZToyMTA1OTJhYWFmMGY0OTkyYjkyM2UyNzEzYThlOWRlNy90YWJsZXJhbmdlOjIxMDU5MmFhYWYwZjQ5OTJiOTIzZTI3MTNhOGU5ZGU3XzUtMi0xLTEtNDEyOTQ_83d7205f-8b18-40e7-9db7-cba6d767bd40">37,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81ce7b0c06a94e61a7d245d6544346aa_D20200101-20201231" decimals="-3" name="lgnd:PaymentsToContingentValueRightHolders" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZToyMTA1OTJhYWFmMGY0OTkyYjkyM2UyNzEzYThlOWRlNy90YWJsZXJhbmdlOjIxMDU5MmFhYWYwZjQ5OTJiOTIzZTI3MTNhOGU5ZGU3XzUtMy0xLTEtNDEyOTQ_0789fa4c-3a71-429b-b7de-c1275324595d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81ce7b0c06a94e61a7d245d6544346aa_D20200101-20201231" decimals="-3" name="lgnd:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZToyMTA1OTJhYWFmMGY0OTkyYjkyM2UyNzEzYThlOWRlNy90YWJsZXJhbmdlOjIxMDU5MmFhYWYwZjQ5OTJiOTIzZTI3MTNhOGU5ZGU3XzUtNC0xLTEtNDc2NzI_3409bdc1-4a0d-4b30-a201-ea78f81d6052">600</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81ce7b0c06a94e61a7d245d6544346aa_D20200101-20201231" decimals="-3" name="lgnd:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityRepurchasesContingentLiabilities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZToyMTA1OTJhYWFmMGY0OTkyYjkyM2UyNzEzYThlOWRlNy90YWJsZXJhbmdlOjIxMDU5MmFhYWYwZjQ5OTJiOTIzZTI3MTNhOGU5ZGU3XzUtNS0xLTEtNDc2ODY_985a9f10-2912-4341-a476-3322c6390951">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e80589fd36648dfa6f6d8fa79c9c970_I20201231" decimals="-3" name="lgnd:BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZToyMTA1OTJhYWFmMGY0OTkyYjkyM2UyNzEzYThlOWRlNy90YWJsZXJhbmdlOjIxMDU5MmFhYWYwZjQ5OTJiOTIzZTI3MTNhOGU5ZGU3XzUtNi0xLTEtNDEyOTQ_a07096eb-bdc5-4ae7-853e-809f216dac83">37,600</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88f2f47e22764022b5dec2243aa219c7_D20210101-20211231" decimals="-3" name="lgnd:PaymentsToContingentValueRightHolders" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZToyMTA1OTJhYWFmMGY0OTkyYjkyM2UyNzEzYThlOWRlNy90YWJsZXJhbmdlOjIxMDU5MmFhYWYwZjQ5OTJiOTIzZTI3MTNhOGU5ZGU3XzUtOS0xLTEtNDEyOTQ_98d9be17-0361-4dee-982d-68703c782d62">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i88f2f47e22764022b5dec2243aa219c7_D20210101-20211231" decimals="-3" sign="-" name="lgnd:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZToyMTA1OTJhYWFmMGY0OTkyYjkyM2UyNzEzYThlOWRlNy90YWJsZXJhbmdlOjIxMDU5MmFhYWYwZjQ5OTJiOTIzZTI3MTNhOGU5ZGU3XzUtMTAtMS0xLTQxMjk0_4293a07d-1063-4d23-923b-7eb887769129">37,600</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88f2f47e22764022b5dec2243aa219c7_D20210101-20211231" decimals="-3" name="lgnd:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityRepurchasesContingentLiabilities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZToyMTA1OTJhYWFmMGY0OTkyYjkyM2UyNzEzYThlOWRlNy90YWJsZXJhbmdlOjIxMDU5MmFhYWYwZjQ5OTJiOTIzZTI3MTNhOGU5ZGU3XzUtMTEtMS0xLTQxMjk0_00c7dff7-2405-452e-978f-ec696bc32f71">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ida7de17e10b54528aa29a691195fafa4_I20211231" decimals="-3" name="lgnd:BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZToyMTA1OTJhYWFmMGY0OTkyYjkyM2UyNzEzYThlOWRlNy90YWJsZXJhbmdlOjIxMDU5MmFhYWYwZjQ5OTJiOTIzZTI3MTNhOGU5ZGU3XzUtMTItMS0xLTQxMjk0_4ce5a35a-a643-4ee9-86ad-a70e85e9ab29">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">xCella</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i017d8efa6ba94abf99a9dc5f29b93ac6_I20191231" decimals="-3" name="lgnd:BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZToyMTA1OTJhYWFmMGY0OTkyYjkyM2UyNzEzYThlOWRlNy90YWJsZXJhbmdlOjIxMDU5MmFhYWYwZjQ5OTJiOTIzZTI3MTNhOGU5ZGU3XzYtMS0xLTEtNTM3OTk_c18ae7cd-c4d2-4b98-8eb7-a6b1007dd4e1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1b889a729444f17b1b5cebb42dc2471_D20200101-20201231" decimals="-3" name="lgnd:BusinessAcquisitionContingentConsiderationPotentialCashPaymentAdditions" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZToyMTA1OTJhYWFmMGY0OTkyYjkyM2UyNzEzYThlOWRlNy90YWJsZXJhbmdlOjIxMDU5MmFhYWYwZjQ5OTJiOTIzZTI3MTNhOGU5ZGU3XzYtMi0xLTEtNTM3OTk_21600bb3-9f51-4539-b600-434b93716218">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1b889a729444f17b1b5cebb42dc2471_D20200101-20201231" decimals="-3" name="lgnd:PaymentsToContingentValueRightHolders" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZToyMTA1OTJhYWFmMGY0OTkyYjkyM2UyNzEzYThlOWRlNy90YWJsZXJhbmdlOjIxMDU5MmFhYWYwZjQ5OTJiOTIzZTI3MTNhOGU5ZGU3XzYtMy0xLTEtNTM3OTk_fe685cb3-e876-451e-8a61-ef61a261b7a0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1b889a729444f17b1b5cebb42dc2471_D20200101-20201231" decimals="-3" name="lgnd:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZToyMTA1OTJhYWFmMGY0OTkyYjkyM2UyNzEzYThlOWRlNy90YWJsZXJhbmdlOjIxMDU5MmFhYWYwZjQ5OTJiOTIzZTI3MTNhOGU5ZGU3XzYtNC0xLTEtNTM3OTk_8d6321c2-b026-4be0-9fd4-9d05818837ac">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1b889a729444f17b1b5cebb42dc2471_D20200101-20201231" decimals="-3" name="lgnd:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityRepurchasesContingentLiabilities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZToyMTA1OTJhYWFmMGY0OTkyYjkyM2UyNzEzYThlOWRlNy90YWJsZXJhbmdlOjIxMDU5MmFhYWYwZjQ5OTJiOTIzZTI3MTNhOGU5ZGU3XzYtNS0xLTEtNTM3OTk_4183e629-3436-4f80-9ef0-32883b9299cb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9bfbbb794834d7fba1e6252029a297d_I20201231" decimals="-3" name="lgnd:BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZToyMTA1OTJhYWFmMGY0OTkyYjkyM2UyNzEzYThlOWRlNy90YWJsZXJhbmdlOjIxMDU5MmFhYWYwZjQ5OTJiOTIzZTI3MTNhOGU5ZGU3XzYtNi0xLTEtNTM3OTk_2e7712fb-a67f-41bf-839e-62fe00ec0010">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic3f66dd3dd704775a2c678c7d07ce665_D20210101-20211231" decimals="-3" name="lgnd:PaymentsToContingentValueRightHolders" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZToyMTA1OTJhYWFmMGY0OTkyYjkyM2UyNzEzYThlOWRlNy90YWJsZXJhbmdlOjIxMDU5MmFhYWYwZjQ5OTJiOTIzZTI3MTNhOGU5ZGU3XzYtOS0xLTEtNTM1NTY_bca42596-7211-4d04-851f-7f1564b44e07">720</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3f66dd3dd704775a2c678c7d07ce665_D20210101-20211231" decimals="-3" name="lgnd:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZToyMTA1OTJhYWFmMGY0OTkyYjkyM2UyNzEzYThlOWRlNy90YWJsZXJhbmdlOjIxMDU5MmFhYWYwZjQ5OTJiOTIzZTI3MTNhOGU5ZGU3XzYtMTAtMS0xLTUzNTYy_52dada59-c243-4622-9bbc-570bf022b44d">720</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3f66dd3dd704775a2c678c7d07ce665_D20210101-20211231" decimals="-3" name="lgnd:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityRepurchasesContingentLiabilities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZToyMTA1OTJhYWFmMGY0OTkyYjkyM2UyNzEzYThlOWRlNy90YWJsZXJhbmdlOjIxMDU5MmFhYWYwZjQ5OTJiOTIzZTI3MTNhOGU5ZGU3XzYtMTEtMS0xLTUzNzk5_bab32006-408e-4985-8d83-543d70b19c60">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9eeb792ea9ad40c3915226866d3115db_I20211231" decimals="-3" name="lgnd:BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZToyMTA1OTJhYWFmMGY0OTkyYjkyM2UyNzEzYThlOWRlNy90YWJsZXJhbmdlOjIxMDU5MmFhYWYwZjQ5OTJiOTIzZTI3MTNhOGU5ZGU3XzYtMTItMS0xLTUzNzk5_fac26523-a228-4886-a281-459788d21c57">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ida3ec05a32644c2db1bb9f71f76c567f_I20191231" decimals="-3" name="lgnd:BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZToyMTA1OTJhYWFmMGY0OTkyYjkyM2UyNzEzYThlOWRlNy90YWJsZXJhbmdlOjIxMDU5MmFhYWYwZjQ5OTJiOTIzZTI3MTNhOGU5ZGU3XzYtMS0xLTEtNDEyOTQ_382f9b54-523d-4573-b288-a1a373431b70">8,942</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3597315a63d441f8f128abd7ed8840e_D20200101-20201231" decimals="-3" name="lgnd:BusinessAcquisitionContingentConsiderationPotentialCashPaymentAdditions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZToyMTA1OTJhYWFmMGY0OTkyYjkyM2UyNzEzYThlOWRlNy90YWJsZXJhbmdlOjIxMDU5MmFhYWYwZjQ5OTJiOTIzZTI3MTNhOGU5ZGU3XzYtMi0xLTEtNDEyOTQ_3357505a-c8a3-4078-bc03-c20395d5c7cb">41,800</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib3597315a63d441f8f128abd7ed8840e_D20200101-20201231" decimals="-3" name="lgnd:PaymentsToContingentValueRightHolders" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZToyMTA1OTJhYWFmMGY0OTkyYjkyM2UyNzEzYThlOWRlNy90YWJsZXJhbmdlOjIxMDU5MmFhYWYwZjQ5OTJiOTIzZTI3MTNhOGU5ZGU3XzYtMy0xLTEtNDEyOTQ_e0a98de8-7b3b-4cab-99c1-01a782c04566">2,325</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3597315a63d441f8f128abd7ed8840e_D20200101-20201231" decimals="-3" name="lgnd:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZToyMTA1OTJhYWFmMGY0OTkyYjkyM2UyNzEzYThlOWRlNy90YWJsZXJhbmdlOjIxMDU5MmFhYWYwZjQ5OTJiOTIzZTI3MTNhOGU5ZGU3XzYtNC0xLTEtNDg2NjI_797857aa-869f-45ff-a8bb-0d10298087fa">963</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib3597315a63d441f8f128abd7ed8840e_D20200101-20201231" decimals="-3" name="lgnd:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityRepurchasesContingentLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZToyMTA1OTJhYWFmMGY0OTkyYjkyM2UyNzEzYThlOWRlNy90YWJsZXJhbmdlOjIxMDU5MmFhYWYwZjQ5OTJiOTIzZTI3MTNhOGU5ZGU3XzYtNS0xLTEtNDEyOTQ_34848523-faee-4406-9ab4-efd6ad47a08c">247</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7462d0db8f4248fcb9fd8f1deae439f3_I20201231" decimals="-3" name="lgnd:BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZToyMTA1OTJhYWFmMGY0OTkyYjkyM2UyNzEzYThlOWRlNy90YWJsZXJhbmdlOjIxMDU5MmFhYWYwZjQ5OTJiOTIzZTI3MTNhOGU5ZGU3XzYtNi0xLTEtNDEyOTQ_91ac623a-778a-4527-9406-0b9b54b73b68">49,133</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231" decimals="-3" name="lgnd:PaymentsToContingentValueRightHolders" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZToyMTA1OTJhYWFmMGY0OTkyYjkyM2UyNzEzYThlOWRlNy90YWJsZXJhbmdlOjIxMDU5MmFhYWYwZjQ5OTJiOTIzZTI3MTNhOGU5ZGU3XzYtOS0xLTEtNDEyOTQ_0f113caf-13d3-4652-9bcc-eba20194e435">1,820</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231" decimals="-3" sign="-" name="lgnd:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZToyMTA1OTJhYWFmMGY0OTkyYjkyM2UyNzEzYThlOWRlNy90YWJsZXJhbmdlOjIxMDU5MmFhYWYwZjQ5OTJiOTIzZTI3MTNhOGU5ZGU3XzYtMTAtMS0xLTQxMjk0_8eb53edd-b395-4f0d-ae84-9046a92a6ab2">36,242</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231" decimals="-3" name="lgnd:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityRepurchasesContingentLiabilities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZToyMTA1OTJhYWFmMGY0OTkyYjkyM2UyNzEzYThlOWRlNy90YWJsZXJhbmdlOjIxMDU5MmFhYWYwZjQ5OTJiOTIzZTI3MTNhOGU5ZGU3XzYtMTEtMS0xLTQxMjk0_a62dbb14-22ed-4280-8d46-2b4b3a0432cb">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231" decimals="-3" name="lgnd:BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZToyMTA1OTJhYWFmMGY0OTkyYjkyM2UyNzEzYThlOWRlNy90YWJsZXJhbmdlOjIxMDU5MmFhYWYwZjQ5OTJiOTIzZTI3MTNhOGU5ZGU3XzYtMTItMS0xLTQxMjk0_65065cd3-47f9-4acd-8130-374e9de1a4ce">11,071</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="i0fa6f906fb2e4e30bc5e873d2bb6a82c_112"></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9. <ix:nonNumeric contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90ZXh0cmVnaW9uOjk1MzhkNjI5YTc4YTQ4ZmY4NmJhMjZmMzlkMjRiMWI5XzM2MTI_7d6f550d-c30f-4d31-b23e-876d25facbc5" continuedAt="idf919f5384a4453c81aa400ede142c49" escape="true">Stockholders&#8217; Equity</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="idf919f5384a4453c81aa400ede142c49" continuedAt="ie2f559c6b9c44d4fa01113204db062eb"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share-based Compensation Expense</span></div><div><span><br/></span></div><div style="margin-top:5pt"><ix:nonNumeric contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231" name="us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90ZXh0cmVnaW9uOjk1MzhkNjI5YTc4YTQ4ZmY4NmJhMjZmMzlkMjRiMWI5XzM2MTQ_20dd43d6-eed9-4258-812f-057c0af9e639" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes non-cash share-based compensation expense (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:64.002%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.043%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.043%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.046%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation expense as a component of:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expenses</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i448245714de441abb40ff86cd51987ac_D20210101-20211231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTpjZGUwOTNlYmFkOTQ0Y2UwYTljYzllNjc3ZWFmZDBhZS90YWJsZXJhbmdlOmNkZTA5M2ViYWQ5NDRjZTBhOWNjOWU2NzdlYWZkMGFlXzMtMS0xLTEtNDEyOTQ_337dae03-ca47-478a-a210-973ac2fa32c4">17,436</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iacfc069f04d74d5284905aeca908935c_D20200101-20201231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTpjZGUwOTNlYmFkOTQ0Y2UwYTljYzllNjc3ZWFmZDBhZS90YWJsZXJhbmdlOmNkZTA5M2ViYWQ5NDRjZTBhOWNjOWU2NzdlYWZkMGFlXzMtMy0xLTEtNDEyOTQ_09453c9d-49b8-414d-9f4e-9837ed1dab44">13,497</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25d150502e6343c683387b66fba49489_D20190101-20191231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTpjZGUwOTNlYmFkOTQ0Y2UwYTljYzllNjc3ZWFmZDBhZS90YWJsZXJhbmdlOmNkZTA5M2ViYWQ5NDRjZTBhOWNjOWU2NzdlYWZkMGFlXzMtNS0xLTEtNDEyOTQ_a6b1439f-1ad8-4c7f-9acd-12132d5c560a">9,641</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee6a37781cce4dbf871fcd529222b482_D20210101-20211231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTpjZGUwOTNlYmFkOTQ0Y2UwYTljYzllNjc3ZWFmZDBhZS90YWJsZXJhbmdlOmNkZTA5M2ViYWQ5NDRjZTBhOWNjOWU2NzdlYWZkMGFlXzQtMS0xLTEtNDEyOTQ_f2b616a9-2dd9-473a-bc35-d097cf9d6bfc">21,347</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5795881ca2b5425d88c92353925e817c_D20200101-20201231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTpjZGUwOTNlYmFkOTQ0Y2UwYTljYzllNjc3ZWFmZDBhZS90YWJsZXJhbmdlOmNkZTA5M2ViYWQ5NDRjZTBhOWNjOWU2NzdlYWZkMGFlXzQtMy0xLTEtNDEyOTQ_e195d30f-51f9-4a87-9c93-ad43cb03f000">17,230</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0cf2334cbb0c4ac8b2c4b765ea0668aa_D20190101-20191231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTpjZGUwOTNlYmFkOTQ0Y2UwYTljYzllNjc3ZWFmZDBhZS90YWJsZXJhbmdlOmNkZTA5M2ViYWQ5NDRjZTBhOWNjOWU2NzdlYWZkMGFlXzQtNS0xLTEtNDEyOTQ_22f10a44-25ec-4047-a6ba-ceb8374eab79">14,874</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTpjZGUwOTNlYmFkOTQ0Y2UwYTljYzllNjc3ZWFmZDBhZS90YWJsZXJhbmdlOmNkZTA5M2ViYWQ5NDRjZTBhOWNjOWU2NzdlYWZkMGFlXzUtMS0xLTEtNDEyOTQ_95a1253e-b57f-4a92-8f73-ed625817fb95">38,783</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3597315a63d441f8f128abd7ed8840e_D20200101-20201231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTpjZGUwOTNlYmFkOTQ0Y2UwYTljYzllNjc3ZWFmZDBhZS90YWJsZXJhbmdlOmNkZTA5M2ViYWQ5NDRjZTBhOWNjOWU2NzdlYWZkMGFlXzUtMy0xLTEtNDEyOTQ_a586b2df-6ee8-46ef-8409-ed6680969f79">30,727</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6c3b69702e9429aaeed46bdb9bbb9c1_D20190101-20191231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTpjZGUwOTNlYmFkOTQ0Y2UwYTljYzllNjc3ZWFmZDBhZS90YWJsZXJhbmdlOmNkZTA5M2ViYWQ5NDRjZTBhOWNjOWU2NzdlYWZkMGFlXzUtNS0xLTEtNDEyOTQ_adbc914f-9b3f-4599-bcc9-fbf0f554c9a1">24,515</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Plans</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2020, our 2002 Stock Incentive Plan was amended to increase the number of shares available for issuance by <ix:nonFraction unitRef="shares" contextRef="i67c3913252f44310913216625ca1c514_D20201201-20201231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90ZXh0cmVnaW9uOjk1MzhkNjI5YTc4YTQ4ZmY4NmJhMjZmMzlkMjRiMWI5XzI4OQ_6855e063-d3af-4553-aa49-d0cf60a83020">1.1</ix:nonFraction> million shares. As of December&#160;31, 2021, there were <ix:nonFraction unitRef="shares" contextRef="ib571bf67523d458e92549c7f222ea20c_I20211231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90ZXh0cmVnaW9uOjk1MzhkNjI5YTc4YTQ4ZmY4NmJhMjZmMzlkMjRiMWI5XzMyMQ_1d3513c7-5525-4758-807a-897c72f16eed">0.7</ix:nonFraction> million shares available for future option grants or direct issuance under the Amended 2002 Plan.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">85</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ie2f559c6b9c44d4fa01113204db062eb" continuedAt="i1274d0cd0fb7406baac09ba34c02891e"><ix:nonNumeric contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90ZXh0cmVnaW9uOjk1MzhkNjI5YTc4YTQ4ZmY4NmJhMjZmMzlkMjRiMWI5XzM2MTU_94e06f8e-620e-4743-b290-20a36be337f8" escape="true"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following is a summary of our stock option plan activity and related information:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:49.120%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.976%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.976%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.976%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.244%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exercise</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Price</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Remaining</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contractual</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Term in</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Intrinsic</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Value</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at January&#160;1, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if1aac4d81ad94163b33117197afe0895_I20181231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTo1ZGMzZjk5MDYyYjk0OWUzYmU0YjljZDViNGZkOWJhYS90YWJsZXJhbmdlOjVkYzNmOTkwNjJiOTQ5ZTNiZTRiOWNkNWI0ZmQ5YmFhXzUtMS0xLTEtNDQyNDc_22732226-e3f5-4ad1-b696-301cee3492cf">1,736,304</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="if1aac4d81ad94163b33117197afe0895_I20181231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTo1ZGMzZjk5MDYyYjk0OWUzYmU0YjljZDViNGZkOWJhYS90YWJsZXJhbmdlOjVkYzNmOTkwNjJiOTQ5ZTNiZTRiOWNkNWI0ZmQ5YmFhXzUtMy0xLTEtNDEyOTQ_796a9a1a-a3ef-41fe-848a-d15239a237d2">66.71</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="if81036550c4349c78f4732ee0154191c_D20180101-20181231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTo1ZGMzZjk5MDYyYjk0OWUzYmU0YjljZDViNGZkOWJhYS90YWJsZXJhbmdlOjVkYzNmOTkwNjJiOTQ5ZTNiZTRiOWNkNWI0ZmQ5YmFhXzUtNS0xLTEtNDEyOTQ_55d156b0-0707-46a8-b4a7-48b7d8c0d775">5.47</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1aac4d81ad94163b33117197afe0895_I20181231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTo1ZGMzZjk5MDYyYjk0OWUzYmU0YjljZDViNGZkOWJhYS90YWJsZXJhbmdlOjVkYzNmOTkwNjJiOTQ5ZTNiZTRiOWNkNWI0ZmQ5YmFhXzUtNy0xLTEtNDEyOTQ_f11a695d-bcce-4a50-b925-4f967738c625">125,858</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie6c3b69702e9429aaeed46bdb9bbb9c1_D20190101-20191231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTo1ZGMzZjk5MDYyYjk0OWUzYmU0YjljZDViNGZkOWJhYS90YWJsZXJhbmdlOjVkYzNmOTkwNjJiOTQ5ZTNiZTRiOWNkNWI0ZmQ5YmFhXzgtMS0xLTEtNDEyOTQ_39fbf4e2-3f30-47cd-81cc-04dffa33615e">338,617</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ie6c3b69702e9429aaeed46bdb9bbb9c1_D20190101-20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTo1ZGMzZjk5MDYyYjk0OWUzYmU0YjljZDViNGZkOWJhYS90YWJsZXJhbmdlOjVkYzNmOTkwNjJiOTQ5ZTNiZTRiOWNkNWI0ZmQ5YmFhXzgtMy0xLTEtNDEyOTQ_8fe872cf-1b0f-4f37-bc7a-71333ad42f85">116.69</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ie6c3b69702e9429aaeed46bdb9bbb9c1_D20190101-20191231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTo1ZGMzZjk5MDYyYjk0OWUzYmU0YjljZDViNGZkOWJhYS90YWJsZXJhbmdlOjVkYzNmOTkwNjJiOTQ5ZTNiZTRiOWNkNWI0ZmQ5YmFhXzktMS0xLTEtNDEyOTQ_98e02232-8f31-42f6-a8dd-c6f6205d573b">112,011</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ie6c3b69702e9429aaeed46bdb9bbb9c1_D20190101-20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTo1ZGMzZjk5MDYyYjk0OWUzYmU0YjljZDViNGZkOWJhYS90YWJsZXJhbmdlOjVkYzNmOTkwNjJiOTQ5ZTNiZTRiOWNkNWI0ZmQ5YmFhXzktMy0xLTEtNDEyOTQ_311b8263-f94c-41f2-83a9-d9820974c167">23.65</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ie6c3b69702e9429aaeed46bdb9bbb9c1_D20190101-20191231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTo1ZGMzZjk5MDYyYjk0OWUzYmU0YjljZDViNGZkOWJhYS90YWJsZXJhbmdlOjVkYzNmOTkwNjJiOTQ5ZTNiZTRiOWNkNWI0ZmQ5YmFhXzEwLTEtMS0xLTQxMjk0_78bc581c-5e67-4781-bfe9-5d055145d748">6,531</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ie6c3b69702e9429aaeed46bdb9bbb9c1_D20190101-20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTo1ZGMzZjk5MDYyYjk0OWUzYmU0YjljZDViNGZkOWJhYS90YWJsZXJhbmdlOjVkYzNmOTkwNjJiOTQ5ZTNiZTRiOWNkNWI0ZmQ5YmFhXzEwLTMtMS0xLTQxMjk0_763b1d52-1a2a-451e-8482-65903b4c0672">139.37</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ida3ec05a32644c2db1bb9f71f76c567f_I20191231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTo1ZGMzZjk5MDYyYjk0OWUzYmU0YjljZDViNGZkOWJhYS90YWJsZXJhbmdlOjVkYzNmOTkwNjJiOTQ5ZTNiZTRiOWNkNWI0ZmQ5YmFhXzExLTEtMS0xLTQxMjk0_e39c7ae3-3bb5-46f7-a937-1eb2258e1779">1,956,379</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ida3ec05a32644c2db1bb9f71f76c567f_I20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTo1ZGMzZjk5MDYyYjk0OWUzYmU0YjljZDViNGZkOWJhYS90YWJsZXJhbmdlOjVkYzNmOTkwNjJiOTQ5ZTNiZTRiOWNkNWI0ZmQ5YmFhXzExLTMtMS0xLTQxMjk0_168ae4ff-2a06-4f9c-b35f-844e2171f813">77.54</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ie6c3b69702e9429aaeed46bdb9bbb9c1_D20190101-20191231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTo1ZGMzZjk5MDYyYjk0OWUzYmU0YjljZDViNGZkOWJhYS90YWJsZXJhbmdlOjVkYzNmOTkwNjJiOTQ5ZTNiZTRiOWNkNWI0ZmQ5YmFhXzExLTUtMS0xLTQxMjk0_e1daa995-726a-44ab-ab7d-235afdeee09f">5.45</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ida3ec05a32644c2db1bb9f71f76c567f_I20191231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTo1ZGMzZjk5MDYyYjk0OWUzYmU0YjljZDViNGZkOWJhYS90YWJsZXJhbmdlOjVkYzNmOTkwNjJiOTQ5ZTNiZTRiOWNkNWI0ZmQ5YmFhXzExLTctMS0xLTQxMjk0_e60e7882-98c7-4d1f-8655-39222fb54b24">72,002</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at December&#160;31, 2019</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ida3ec05a32644c2db1bb9f71f76c567f_I20191231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTo1ZGMzZjk5MDYyYjk0OWUzYmU0YjljZDViNGZkOWJhYS90YWJsZXJhbmdlOjVkYzNmOTkwNjJiOTQ5ZTNiZTRiOWNkNWI0ZmQ5YmFhXzEyLTEtMS0xLTQxMjk0_e2b057cd-85b5-4166-976e-75cf317cf57c">1,454,726</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ida3ec05a32644c2db1bb9f71f76c567f_I20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTo1ZGMzZjk5MDYyYjk0OWUzYmU0YjljZDViNGZkOWJhYS90YWJsZXJhbmdlOjVkYzNmOTkwNjJiOTQ5ZTNiZTRiOWNkNWI0ZmQ5YmFhXzEyLTMtMS0xLTQxMjk0_fe9d2b19-940d-4feb-838d-5de8815ac58f">61.82</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ie6c3b69702e9429aaeed46bdb9bbb9c1_D20190101-20191231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTo1ZGMzZjk5MDYyYjk0OWUzYmU0YjljZDViNGZkOWJhYS90YWJsZXJhbmdlOjVkYzNmOTkwNjJiOTQ5ZTNiZTRiOWNkNWI0ZmQ5YmFhXzEyLTUtMS0xLTQxMjk0_45d2a823-3f07-42a7-be8f-aa016eb57dee">4.42</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ida3ec05a32644c2db1bb9f71f76c567f_I20191231" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTo1ZGMzZjk5MDYyYjk0OWUzYmU0YjljZDViNGZkOWJhYS90YWJsZXJhbmdlOjVkYzNmOTkwNjJiOTQ5ZTNiZTRiOWNkNWI0ZmQ5YmFhXzEyLTctMS0xLTQxMjk0_6b4ed437-0cd0-421f-ab46-e4f664e6cf10">70,345</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options vested and expected to vest as of December&#160;31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ida3ec05a32644c2db1bb9f71f76c567f_I20191231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTo1ZGMzZjk5MDYyYjk0OWUzYmU0YjljZDViNGZkOWJhYS90YWJsZXJhbmdlOjVkYzNmOTkwNjJiOTQ5ZTNiZTRiOWNkNWI0ZmQ5YmFhXzEzLTEtMS0xLTQxMjk0_9a0fd8e6-8379-4e8e-ae83-fce2ed1b65c4">1,956,379</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ida3ec05a32644c2db1bb9f71f76c567f_I20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTo1ZGMzZjk5MDYyYjk0OWUzYmU0YjljZDViNGZkOWJhYS90YWJsZXJhbmdlOjVkYzNmOTkwNjJiOTQ5ZTNiZTRiOWNkNWI0ZmQ5YmFhXzEzLTMtMS0xLTQxMjk0_6dc1cc40-0807-48d0-be5c-7079b2e5f0d8">77.54</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ie6c3b69702e9429aaeed46bdb9bbb9c1_D20190101-20191231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTo1ZGMzZjk5MDYyYjk0OWUzYmU0YjljZDViNGZkOWJhYS90YWJsZXJhbmdlOjVkYzNmOTkwNjJiOTQ5ZTNiZTRiOWNkNWI0ZmQ5YmFhXzEzLTUtMS0xLTQxMjk0_7958fba8-129d-4459-b73f-aca50aa6bb16">5.45</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ida3ec05a32644c2db1bb9f71f76c567f_I20191231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTo1ZGMzZjk5MDYyYjk0OWUzYmU0YjljZDViNGZkOWJhYS90YWJsZXJhbmdlOjVkYzNmOTkwNjJiOTQ5ZTNiZTRiOWNkNWI0ZmQ5YmFhXzEzLTctMS0xLTQxMjk0_6332c9fa-ba83-4c1e-b090-b0a7090da0d7">72,002</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib3597315a63d441f8f128abd7ed8840e_D20200101-20201231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTo1ZGMzZjk5MDYyYjk0OWUzYmU0YjljZDViNGZkOWJhYS90YWJsZXJhbmdlOjVkYzNmOTkwNjJiOTQ5ZTNiZTRiOWNkNWI0ZmQ5YmFhXzE0LTEtMS0xLTQxMjk0_0e6a6896-c3de-45c0-90c7-84c5383c11e7">806,300</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ib3597315a63d441f8f128abd7ed8840e_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTo1ZGMzZjk5MDYyYjk0OWUzYmU0YjljZDViNGZkOWJhYS90YWJsZXJhbmdlOjVkYzNmOTkwNjJiOTQ5ZTNiZTRiOWNkNWI0ZmQ5YmFhXzE0LTMtMS0xLTQxMjk0_cd72b213-9de4-4bc5-953c-97db187f7349">92.93</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ib3597315a63d441f8f128abd7ed8840e_D20200101-20201231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTo1ZGMzZjk5MDYyYjk0OWUzYmU0YjljZDViNGZkOWJhYS90YWJsZXJhbmdlOjVkYzNmOTkwNjJiOTQ5ZTNiZTRiOWNkNWI0ZmQ5YmFhXzE1LTEtMS0xLTQxMjk0_a1b3b6f7-cb3c-44a2-a2f2-c9dc27539b30">156,845</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ib3597315a63d441f8f128abd7ed8840e_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTo1ZGMzZjk5MDYyYjk0OWUzYmU0YjljZDViNGZkOWJhYS90YWJsZXJhbmdlOjVkYzNmOTkwNjJiOTQ5ZTNiZTRiOWNkNWI0ZmQ5YmFhXzE1LTMtMS0xLTQxMjk0_487ae073-b9c5-486c-8d79-3a0dcdde2b93">21.26</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ib3597315a63d441f8f128abd7ed8840e_D20200101-20201231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTo1ZGMzZjk5MDYyYjk0OWUzYmU0YjljZDViNGZkOWJhYS90YWJsZXJhbmdlOjVkYzNmOTkwNjJiOTQ5ZTNiZTRiOWNkNWI0ZmQ5YmFhXzE2LTEtMS0xLTQxMjk0_0bd4d5cc-c33f-4f72-91be-958ae65ad345">44,012</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ib3597315a63d441f8f128abd7ed8840e_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTo1ZGMzZjk5MDYyYjk0OWUzYmU0YjljZDViNGZkOWJhYS90YWJsZXJhbmdlOjVkYzNmOTkwNjJiOTQ5ZTNiZTRiOWNkNWI0ZmQ5YmFhXzE2LTMtMS0xLTQxMjk0_3dd6504f-cad2-48ef-afec-d9380e09c33a">91.30</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7462d0db8f4248fcb9fd8f1deae439f3_I20201231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTo1ZGMzZjk5MDYyYjk0OWUzYmU0YjljZDViNGZkOWJhYS90YWJsZXJhbmdlOjVkYzNmOTkwNjJiOTQ5ZTNiZTRiOWNkNWI0ZmQ5YmFhXzE3LTEtMS0xLTQxMjk0_325dc830-b8d9-4b59-91b9-684db763cfbe">2,561,822</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i7462d0db8f4248fcb9fd8f1deae439f3_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTo1ZGMzZjk5MDYyYjk0OWUzYmU0YjljZDViNGZkOWJhYS90YWJsZXJhbmdlOjVkYzNmOTkwNjJiOTQ5ZTNiZTRiOWNkNWI0ZmQ5YmFhXzE3LTMtMS0xLTQxMjk0_5cdcad0e-e7b2-44e8-bb6f-fe39687bff4a">85.59</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ib3597315a63d441f8f128abd7ed8840e_D20200101-20201231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTo1ZGMzZjk5MDYyYjk0OWUzYmU0YjljZDViNGZkOWJhYS90YWJsZXJhbmdlOjVkYzNmOTkwNjJiOTQ5ZTNiZTRiOWNkNWI0ZmQ5YmFhXzE3LTUtMS0xLTQxMjk0_27801756-da47-402c-88f6-7366eda1db60">6.09</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7462d0db8f4248fcb9fd8f1deae439f3_I20201231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTo1ZGMzZjk5MDYyYjk0OWUzYmU0YjljZDViNGZkOWJhYS90YWJsZXJhbmdlOjVkYzNmOTkwNjJiOTQ5ZTNiZTRiOWNkNWI0ZmQ5YmFhXzE3LTctMS0xLTQxMjk0_c2836375-417a-4d2d-8fa8-755df205acb5">59,033</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at December&#160;31, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7462d0db8f4248fcb9fd8f1deae439f3_I20201231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTo1ZGMzZjk5MDYyYjk0OWUzYmU0YjljZDViNGZkOWJhYS90YWJsZXJhbmdlOjVkYzNmOTkwNjJiOTQ5ZTNiZTRiOWNkNWI0ZmQ5YmFhXzE4LTEtMS0xLTQxMjk0_c439067d-59b5-4f22-9eb7-4dad18a60c37">1,611,830</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i7462d0db8f4248fcb9fd8f1deae439f3_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTo1ZGMzZjk5MDYyYjk0OWUzYmU0YjljZDViNGZkOWJhYS90YWJsZXJhbmdlOjVkYzNmOTkwNjJiOTQ5ZTNiZTRiOWNkNWI0ZmQ5YmFhXzE4LTMtMS0xLTQxMjk0_0e6b6eae-92af-4df7-8004-c452e06cb8cc">76.05</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ib3597315a63d441f8f128abd7ed8840e_D20200101-20201231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTo1ZGMzZjk5MDYyYjk0OWUzYmU0YjljZDViNGZkOWJhYS90YWJsZXJhbmdlOjVkYzNmOTkwNjJiOTQ5ZTNiZTRiOWNkNWI0ZmQ5YmFhXzE4LTUtMS0xLTQxMjk0_79b8d938-5f4e-49e6-9e88-e51083b59b5e">4.54</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7462d0db8f4248fcb9fd8f1deae439f3_I20201231" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTo1ZGMzZjk5MDYyYjk0OWUzYmU0YjljZDViNGZkOWJhYS90YWJsZXJhbmdlOjVkYzNmOTkwNjJiOTQ5ZTNiZTRiOWNkNWI0ZmQ5YmFhXzE4LTctMS0xLTQxMjk0_c0a55fc9-6318-48fa-b55e-7c807cc3a2e6">53,286</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options vested and expected to vest as of December&#160;31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7462d0db8f4248fcb9fd8f1deae439f3_I20201231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTo1ZGMzZjk5MDYyYjk0OWUzYmU0YjljZDViNGZkOWJhYS90YWJsZXJhbmdlOjVkYzNmOTkwNjJiOTQ5ZTNiZTRiOWNkNWI0ZmQ5YmFhXzE5LTEtMS0xLTQxMjk0_d780c8c8-f4b4-45f5-bd3c-1cf3309436ff">2,561,822</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i7462d0db8f4248fcb9fd8f1deae439f3_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTo1ZGMzZjk5MDYyYjk0OWUzYmU0YjljZDViNGZkOWJhYS90YWJsZXJhbmdlOjVkYzNmOTkwNjJiOTQ5ZTNiZTRiOWNkNWI0ZmQ5YmFhXzE5LTMtMS0xLTQxMjk0_a10c8057-077f-4976-8321-d7755ccd7bb7">85.59</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ib3597315a63d441f8f128abd7ed8840e_D20200101-20201231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTo1ZGMzZjk5MDYyYjk0OWUzYmU0YjljZDViNGZkOWJhYS90YWJsZXJhbmdlOjVkYzNmOTkwNjJiOTQ5ZTNiZTRiOWNkNWI0ZmQ5YmFhXzE5LTUtMS0xLTQxMjk0_ce67ed0f-4476-4d4f-ba5a-e383c3ac2ea5">6.09</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7462d0db8f4248fcb9fd8f1deae439f3_I20201231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTo1ZGMzZjk5MDYyYjk0OWUzYmU0YjljZDViNGZkOWJhYS90YWJsZXJhbmdlOjVkYzNmOTkwNjJiOTQ5ZTNiZTRiOWNkNWI0ZmQ5YmFhXzE5LTctMS0xLTQxMjk0_000b1b6e-1bcf-4e6f-a671-8662a19ca9c1">59,033</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTo1ZGMzZjk5MDYyYjk0OWUzYmU0YjljZDViNGZkOWJhYS90YWJsZXJhbmdlOjVkYzNmOTkwNjJiOTQ5ZTNiZTRiOWNkNWI0ZmQ5YmFhXzIwLTEtMS0xLTQ1MDYw_f1ce0cfe-92d6-4bdc-a029-8eb65c9c024e">393,589</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTo1ZGMzZjk5MDYyYjk0OWUzYmU0YjljZDViNGZkOWJhYS90YWJsZXJhbmdlOjVkYzNmOTkwNjJiOTQ5ZTNiZTRiOWNkNWI0ZmQ5YmFhXzIwLTMtMS0xLTQ1MTI2_24dd30df-0090-4dc1-82d7-21bf0338d79c">159.12</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTo1ZGMzZjk5MDYyYjk0OWUzYmU0YjljZDViNGZkOWJhYS90YWJsZXJhbmdlOjVkYzNmOTkwNjJiOTQ5ZTNiZTRiOWNkNWI0ZmQ5YmFhXzIxLTEtMS0xLTQ1MDYw_31f0126e-f7bc-443a-a948-63718041e4a0">619,731</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTo1ZGMzZjk5MDYyYjk0OWUzYmU0YjljZDViNGZkOWJhYS90YWJsZXJhbmdlOjVkYzNmOTkwNjJiOTQ5ZTNiZTRiOWNkNWI0ZmQ5YmFhXzIxLTMtMS0xLTQ1MTI2_e79e1e2b-155e-4037-b550-96f898b4258c">54.28</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTo1ZGMzZjk5MDYyYjk0OWUzYmU0YjljZDViNGZkOWJhYS90YWJsZXJhbmdlOjVkYzNmOTkwNjJiOTQ5ZTNiZTRiOWNkNWI0ZmQ5YmFhXzIyLTEtMS0xLTQ1MDYw_9ddc510b-f339-4a69-abaf-cfceb01d9325">136,082</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTo1ZGMzZjk5MDYyYjk0OWUzYmU0YjljZDViNGZkOWJhYS90YWJsZXJhbmdlOjVkYzNmOTkwNjJiOTQ5ZTNiZTRiOWNkNWI0ZmQ5YmFhXzIyLTMtMS0xLTQ1MTI2_e436c9aa-1c19-4360-ad3d-b7089b305b6f">110.83</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2021 </span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTo1ZGMzZjk5MDYyYjk0OWUzYmU0YjljZDViNGZkOWJhYS90YWJsZXJhbmdlOjVkYzNmOTkwNjJiOTQ5ZTNiZTRiOWNkNWI0ZmQ5YmFhXzE3LTEtMS0xLTQ2MjU4_31ce14a9-5e3c-496e-a137-e07f216ea58e">2,199,598</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTo1ZGMzZjk5MDYyYjk0OWUzYmU0YjljZDViNGZkOWJhYS90YWJsZXJhbmdlOjVkYzNmOTkwNjJiOTQ5ZTNiZTRiOWNkNWI0ZmQ5YmFhXzIzLTMtMS0xLTQ1MTI2_32bd5375-89dc-4b4b-a35e-f91fe815da72">106.00</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTo1ZGMzZjk5MDYyYjk0OWUzYmU0YjljZDViNGZkOWJhYS90YWJsZXJhbmdlOjVkYzNmOTkwNjJiOTQ5ZTNiZTRiOWNkNWI0ZmQ5YmFhXzIzLTUtMS0xLTQ1MTYz_10067209-ee16-4555-a4f8-f1e65f63e81e">6.34</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTo1ZGMzZjk5MDYyYjk0OWUzYmU0YjljZDViNGZkOWJhYS90YWJsZXJhbmdlOjVkYzNmOTkwNjJiOTQ5ZTNiZTRiOWNkNWI0ZmQ5YmFhXzIzLTctMS0xLTQ1MTc5_66617241-ba61-4145-b60f-bc1a87705d1e">113,302</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at December&#160;31, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTo1ZGMzZjk5MDYyYjk0OWUzYmU0YjljZDViNGZkOWJhYS90YWJsZXJhbmdlOjVkYzNmOTkwNjJiOTQ5ZTNiZTRiOWNkNWI0ZmQ5YmFhXzI0LTEtMS0xLTQ1MTEz_797ac795-c91a-479b-b2b0-166d8c4c2232">1,391,952</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTo1ZGMzZjk5MDYyYjk0OWUzYmU0YjljZDViNGZkOWJhYS90YWJsZXJhbmdlOjVkYzNmOTkwNjJiOTQ5ZTNiZTRiOWNkNWI0ZmQ5YmFhXzI0LTMtMS0xLTQ1MTU1_7d8e685f-16f8-4ebb-a211-9b7d58a58e54">98.16</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTo1ZGMzZjk5MDYyYjk0OWUzYmU0YjljZDViNGZkOWJhYS90YWJsZXJhbmdlOjVkYzNmOTkwNjJiOTQ5ZTNiZTRiOWNkNWI0ZmQ5YmFhXzI0LTUtMS0xLTQ1MTYz_c6db42c5-5370-4be8-870d-f14d6f7a7dcc">5.12</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTo1ZGMzZjk5MDYyYjk0OWUzYmU0YjljZDViNGZkOWJhYS90YWJsZXJhbmdlOjVkYzNmOTkwNjJiOTQ5ZTNiZTRiOWNkNWI0ZmQ5YmFhXzI0LTctMS0xLTQ1MTc5_c8e8651a-6c57-41cd-a11b-54039071374c">80,849</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options vested and expected to vest as of December&#160;31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTo1ZGMzZjk5MDYyYjk0OWUzYmU0YjljZDViNGZkOWJhYS90YWJsZXJhbmdlOjVkYzNmOTkwNjJiOTQ5ZTNiZTRiOWNkNWI0ZmQ5YmFhXzE5LTEtMS0xLTQ2MjU4_b5dee570-a1c2-4c8b-886b-005a0d24e98b">2,199,598</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTo1ZGMzZjk5MDYyYjk0OWUzYmU0YjljZDViNGZkOWJhYS90YWJsZXJhbmdlOjVkYzNmOTkwNjJiOTQ5ZTNiZTRiOWNkNWI0ZmQ5YmFhXzE5LTMtMS0xLTQ2MjU4_bec630f4-8227-4939-84a4-12cfa874a475">106.00</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTo1ZGMzZjk5MDYyYjk0OWUzYmU0YjljZDViNGZkOWJhYS90YWJsZXJhbmdlOjVkYzNmOTkwNjJiOTQ5ZTNiZTRiOWNkNWI0ZmQ5YmFhXzE5LTUtMS0xLTQ2MjU4_efedec4e-0bb1-4592-98b9-d4b5216d40bb">6.34</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTo1ZGMzZjk5MDYyYjk0OWUzYmU0YjljZDViNGZkOWJhYS90YWJsZXJhbmdlOjVkYzNmOTkwNjJiOTQ5ZTNiZTRiOWNkNWI0ZmQ5YmFhXzE5LTctMS0xLTQ2MjU4_94efc78c-e1d8-4f6a-b521-d19bced9d2fb">113,302</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="text-indent:24pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average grant-date fair value of all stock options granted during 2021, 2020 and 2019 was $<ix:nonFraction unitRef="usdPerShare" contextRef="i0b2d2a0659724a0394359a72b0ded635_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90ZXh0cmVnaW9uOjk1MzhkNjI5YTc4YTQ4ZmY4NmJhMjZmMzlkMjRiMWI5XzU5OA_f56d98ea-d067-4993-98fb-78a90ee08d78">80.08</ix:nonFraction>, $<ix:nonFraction unitRef="usdPerShare" contextRef="i97af3b7b1f564d4d911c3d6134e64410_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90ZXh0cmVnaW9uOjk1MzhkNjI5YTc4YTQ4ZmY4NmJhMjZmMzlkMjRiMWI5XzYwMg_e89889a2-e4cd-4286-8652-ce72cdf4842f">41.39</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="i891b87647a30477eb27e9edd4fc735ea_D20190101-20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90ZXh0cmVnaW9uOjk1MzhkNjI5YTc4YTQ4ZmY4NmJhMjZmMzlkMjRiMWI5XzYwOQ_a1c6e422-40c0-438a-8562-056ade6c5915">48.65</ix:nonFraction> per share, respectively. The total intrinsic value of all options exercised during 2021, 2020 and 2019 was approximately $<ix:nonFraction unitRef="usd" contextRef="i0b2d2a0659724a0394359a72b0ded635_D20210101-20211231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90ZXh0cmVnaW9uOjk1MzhkNjI5YTc4YTQ4ZmY4NmJhMjZmMzlkMjRiMWI5XzcyNw_de363ffd-5559-4b50-b592-a1807b9b433f">77.3</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i97af3b7b1f564d4d911c3d6134e64410_D20200101-20201231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90ZXh0cmVnaW9uOjk1MzhkNjI5YTc4YTQ4ZmY4NmJhMjZmMzlkMjRiMWI5XzczMQ_2fc90504-2d1d-46ec-a186-981fb005f1b6">11.9</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i891b87647a30477eb27e9edd4fc735ea_D20190101-20191231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90ZXh0cmVnaW9uOjk1MzhkNjI5YTc4YTQ4ZmY4NmJhMjZmMzlkMjRiMWI5XzczOA_7a961725-444c-4d55-959e-8b2e632c34e7">10.4</ix:nonFraction> million, respectively. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash received from options exercised, net of fees paid, in 2021, 2020 and 2019 was $<ix:nonFraction unitRef="usd" contextRef="i0b2d2a0659724a0394359a72b0ded635_D20210101-20211231" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90ZXh0cmVnaW9uOjk1MzhkNjI5YTc4YTQ4ZmY4NmJhMjZmMzlkMjRiMWI5XzgzNA_ece4eb13-c050-48e3-ba23-017e87ade1d7">33.0</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i97af3b7b1f564d4d911c3d6134e64410_D20200101-20201231" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90ZXh0cmVnaW9uOjk1MzhkNjI5YTc4YTQ4ZmY4NmJhMjZmMzlkMjRiMWI5XzgzOA_62683e17-18b7-4bbb-8388-04cdf3c322a6">2.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i891b87647a30477eb27e9edd4fc735ea_D20190101-20191231" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90ZXh0cmVnaW9uOjk1MzhkNjI5YTc4YTQ4ZmY4NmJhMjZmMzlkMjRiMWI5Xzg0NQ_4da2dda6-e2d3-4258-ad6f-23c0aa451af5">2.6</ix:nonFraction> million, respectively. </span></div><ix:nonNumeric contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231" name="us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90ZXh0cmVnaW9uOjk1MzhkNjI5YTc4YTQ4ZmY4NmJhMjZmMzlkMjRiMWI5XzM2MTk_80df4952-9c43-4e3c-9d88-fbfe9aff975d" escape="true"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following is a further breakdown of the options outstanding as of December&#160;31, 2021:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:30.040%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.057%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.057%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.057%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.057%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.212%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Range of exercise prices</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Options</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">outstanding</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">remaining&#160; life</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">in&#160;years</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted&#160;average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">exercise price</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Options</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">exercisable</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted&#160;average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">exercise&#160;price</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="ibb76fff21d1145a2aa988019605605d7_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTo2NmRhZGMxYWRhOTE0NjZlODY0NWYwNDc0OTE2MjJhYy90YWJsZXJhbmdlOjY2ZGFkYzFhZGE5MTQ2NmU4NjQ1ZjA0NzQ5MTYyMmFjXzEtMC0xLTEtNDEyOTQvdGV4dHJlZ2lvbjo4MDU2NzRlNTIzZjE0ZGE4YTQ0NzVjNmQzYTY0MzVmMF80_4fd955c0-5acf-4bd6-aa73-7f9365e273a1">12.53</ix:nonFraction>-$<ix:nonFraction unitRef="usdPerShare" contextRef="ibb76fff21d1145a2aa988019605605d7_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTo2NmRhZGMxYWRhOTE0NjZlODY0NWYwNDc0OTE2MjJhYy90YWJsZXJhbmdlOjY2ZGFkYzFhZGE5MTQ2NmU4NjQ1ZjA0NzQ5MTYyMmFjXzEtMC0xLTEtNDEyOTQvdGV4dHJlZ2lvbjo4MDU2NzRlNTIzZjE0ZGE4YTQ0NzVjNmQzYTY0MzVmMF83_d00aae65-ec3f-4017-8247-bf2a3c0826b1">56.26</ix:nonFraction></span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2d5b9274891c4530b4756d9f6d78384d_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTo2NmRhZGMxYWRhOTE0NjZlODY0NWYwNDc0OTE2MjJhYy90YWJsZXJhbmdlOjY2ZGFkYzFhZGE5MTQ2NmU4NjQ1ZjA0NzQ5MTYyMmFjXzEtMS0xLTEtNDEyOTQ_5fbcf927-bd38-4f97-b742-92281aa5991f">253,824</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ibb76fff21d1145a2aa988019605605d7_D20210101-20211231" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTo2NmRhZGMxYWRhOTE0NjZlODY0NWYwNDc0OTE2MjJhYy90YWJsZXJhbmdlOjY2ZGFkYzFhZGE5MTQ2NmU4NjQ1ZjA0NzQ5MTYyMmFjXzEtMy0xLTEtNDEyOTQ_59f0ff0c-a181-4c68-8409-f20e10e05fff">1.94</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i2d5b9274891c4530b4756d9f6d78384d_I20211231" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTo2NmRhZGMxYWRhOTE0NjZlODY0NWYwNDc0OTE2MjJhYy90YWJsZXJhbmdlOjY2ZGFkYzFhZGE5MTQ2NmU4NjQ1ZjA0NzQ5MTYyMmFjXzEtNS0xLTEtNDEyOTQ_94082e22-20aa-45e9-b2e6-56d13a789a17">37.55</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2d5b9274891c4530b4756d9f6d78384d_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTo2NmRhZGMxYWRhOTE0NjZlODY0NWYwNDc0OTE2MjJhYy90YWJsZXJhbmdlOjY2ZGFkYzFhZGE5MTQ2NmU4NjQ1ZjA0NzQ5MTYyMmFjXzEtNy0xLTEtNDEyOTQ_fa613ea5-0bb6-4e57-a379-7092a14ac6d9">239,824</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i2d5b9274891c4530b4756d9f6d78384d_I20211231" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTo2NmRhZGMxYWRhOTE0NjZlODY0NWYwNDc0OTE2MjJhYy90YWJsZXJhbmdlOjY2ZGFkYzFhZGE5MTQ2NmU4NjQ1ZjA0NzQ5MTYyMmFjXzEtOS0xLTEtNDEyOTQ_fe9ef5d0-b064-466e-aa5c-103dfd582005">38.90</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i42d7e1e14d514ee5ac131e49d67d3ae9_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTo2NmRhZGMxYWRhOTE0NjZlODY0NWYwNDc0OTE2MjJhYy90YWJsZXJhbmdlOjY2ZGFkYzFhZGE5MTQ2NmU4NjQ1ZjA0NzQ5MTYyMmFjXzItMC0xLTEtNDEyOTQvdGV4dHJlZ2lvbjpiOTgxYzBhM2E2NDQ0MDU1OWUwNjU5NjczNzE2MDJmYV80_a606560a-39a5-44f9-9977-3998bc123b41">67.53</ix:nonFraction>-$<ix:nonFraction unitRef="usdPerShare" contextRef="i42d7e1e14d514ee5ac131e49d67d3ae9_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTo2NmRhZGMxYWRhOTE0NjZlODY0NWYwNDc0OTE2MjJhYy90YWJsZXJhbmdlOjY2ZGFkYzFhZGE5MTQ2NmU4NjQ1ZjA0NzQ5MTYyMmFjXzItMC0xLTEtNDEyOTQvdGV4dHJlZ2lvbjpiOTgxYzBhM2E2NDQ0MDU1OWUwNjU5NjczNzE2MDJmYV83_56c99941-4ef3-43bd-9edf-38c2f75b5c35">74.42</ix:nonFraction></span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if56255ad310d4a3bbccede5e1c84b2ec_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTo2NmRhZGMxYWRhOTE0NjZlODY0NWYwNDc0OTE2MjJhYy90YWJsZXJhbmdlOjY2ZGFkYzFhZGE5MTQ2NmU4NjQ1ZjA0NzQ5MTYyMmFjXzItMS0xLTEtNDEyOTQ_8ecb0fa9-7e32-425b-92de-f46d39b45b5a">278,281</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i42d7e1e14d514ee5ac131e49d67d3ae9_D20210101-20211231" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTo2NmRhZGMxYWRhOTE0NjZlODY0NWYwNDc0OTE2MjJhYy90YWJsZXJhbmdlOjY2ZGFkYzFhZGE5MTQ2NmU4NjQ1ZjA0NzQ5MTYyMmFjXzItMy0xLTEtNDEyOTQ_e5554e6e-2807-4bd4-b76d-e7395b405570">4.04</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="if56255ad310d4a3bbccede5e1c84b2ec_I20211231" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTo2NmRhZGMxYWRhOTE0NjZlODY0NWYwNDc0OTE2MjJhYy90YWJsZXJhbmdlOjY2ZGFkYzFhZGE5MTQ2NmU4NjQ1ZjA0NzQ5MTYyMmFjXzItNS0xLTEtNDEyOTQ_2f69d105-a752-46f0-9f68-a2bb3e575572">72.10</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if56255ad310d4a3bbccede5e1c84b2ec_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTo2NmRhZGMxYWRhOTE0NjZlODY0NWYwNDc0OTE2MjJhYy90YWJsZXJhbmdlOjY2ZGFkYzFhZGE5MTQ2NmU4NjQ1ZjA0NzQ5MTYyMmFjXzItNy0xLTEtNDEyOTQ_4796b6ab-b201-4a80-b44f-5911f4744158">217,587</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="if56255ad310d4a3bbccede5e1c84b2ec_I20211231" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTo2NmRhZGMxYWRhOTE0NjZlODY0NWYwNDc0OTE2MjJhYy90YWJsZXJhbmdlOjY2ZGFkYzFhZGE5MTQ2NmU4NjQ1ZjA0NzQ5MTYyMmFjXzItOS0xLTEtNDEyOTQ_a256e17d-2c0d-429a-920d-842f7f459861">73.17</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i1583b4003fe544649fbe7acf591bc7c2_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTo2NmRhZGMxYWRhOTE0NjZlODY0NWYwNDc0OTE2MjJhYy90YWJsZXJhbmdlOjY2ZGFkYzFhZGE5MTQ2NmU4NjQ1ZjA0NzQ5MTYyMmFjXzMtMC0xLTEtNDEyOTQvdGV4dHJlZ2lvbjpjMWRiZjA4NDljODE0YjZmYjJmOTUyZDJmZDk2NjU5MF80_3e14eb0e-a9f5-4a4c-b1ec-c2e9d7bb8267">82.90</ix:nonFraction>-$<ix:nonFraction unitRef="usdPerShare" contextRef="i1583b4003fe544649fbe7acf591bc7c2_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTo2NmRhZGMxYWRhOTE0NjZlODY0NWYwNDc0OTE2MjJhYy90YWJsZXJhbmdlOjY2ZGFkYzFhZGE5MTQ2NmU4NjQ1ZjA0NzQ5MTYyMmFjXzMtMC0xLTEtNDEyOTQvdGV4dHJlZ2lvbjpjMWRiZjA4NDljODE0YjZmYjJmOTUyZDJmZDk2NjU5MF83_f63359af-ddd1-4317-b694-0f635226bea5">95.35</ix:nonFraction></span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3186ef0fac614fe4a3a83b4e3df1fac4_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTo2NmRhZGMxYWRhOTE0NjZlODY0NWYwNDc0OTE2MjJhYy90YWJsZXJhbmdlOjY2ZGFkYzFhZGE5MTQ2NmU4NjQ1ZjA0NzQ5MTYyMmFjXzMtMS0xLTEtNDEyOTQ_9abbcc94-4cb6-4128-a57f-c90e2cd03926">159,988</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i1583b4003fe544649fbe7acf591bc7c2_D20210101-20211231" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTo2NmRhZGMxYWRhOTE0NjZlODY0NWYwNDc0OTE2MjJhYy90YWJsZXJhbmdlOjY2ZGFkYzFhZGE5MTQ2NmU4NjQ1ZjA0NzQ5MTYyMmFjXzMtMy0xLTEtNDEyOTQ_cde5e65a-1c28-48d3-9336-a3b8e78795cb">5.06</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i3186ef0fac614fe4a3a83b4e3df1fac4_I20211231" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTo2NmRhZGMxYWRhOTE0NjZlODY0NWYwNDc0OTE2MjJhYy90YWJsZXJhbmdlOjY2ZGFkYzFhZGE5MTQ2NmU4NjQ1ZjA0NzQ5MTYyMmFjXzMtNS0xLTEtNDEyOTQ_f1d7d3cc-5338-4750-8567-9fd0e0eeeb7b">86.11</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3186ef0fac614fe4a3a83b4e3df1fac4_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTo2NmRhZGMxYWRhOTE0NjZlODY0NWYwNDc0OTE2MjJhYy90YWJsZXJhbmdlOjY2ZGFkYzFhZGE5MTQ2NmU4NjQ1ZjA0NzQ5MTYyMmFjXzMtNy0xLTEtNDEyOTQ_c979066a-2257-4054-848b-96c8eaa21de5">132,963</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i3186ef0fac614fe4a3a83b4e3df1fac4_I20211231" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTo2NmRhZGMxYWRhOTE0NjZlODY0NWYwNDc0OTE2MjJhYy90YWJsZXJhbmdlOjY2ZGFkYzFhZGE5MTQ2NmU4NjQ1ZjA0NzQ5MTYyMmFjXzMtOS0xLTEtNDEyOTQ_25365ce9-7a1f-49fc-830d-a3bd17532c2a">86.24</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i9203228b9f3a4a258d1dd418f1ff9fab_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTo2NmRhZGMxYWRhOTE0NjZlODY0NWYwNDc0OTE2MjJhYy90YWJsZXJhbmdlOjY2ZGFkYzFhZGE5MTQ2NmU4NjQ1ZjA0NzQ5MTYyMmFjXzQtMC0xLTEtNDEyOTQvdGV4dHJlZ2lvbjo5MGM5YzExOTYzOWY0YjI4OWRiMjhkZWM0MzAzOTM5MF80_8e9b7b97-d0d8-42b9-b716-134d625e4745">95.68</ix:nonFraction></span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i65a6d24f5a314cbba76284b24732fb3c_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTo2NmRhZGMxYWRhOTE0NjZlODY0NWYwNDc0OTE2MjJhYy90YWJsZXJhbmdlOjY2ZGFkYzFhZGE5MTQ2NmU4NjQ1ZjA0NzQ5MTYyMmFjXzQtMS0xLTEtNDEyOTQ_e14d3c8b-c65b-474d-8a1a-2f19d95fca91">266,263</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i9203228b9f3a4a258d1dd418f1ff9fab_D20210101-20211231" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTo2NmRhZGMxYWRhOTE0NjZlODY0NWYwNDc0OTE2MjJhYy90YWJsZXJhbmdlOjY2ZGFkYzFhZGE5MTQ2NmU4NjQ1ZjA0NzQ5MTYyMmFjXzQtMy0xLTEtNDEyOTQ_f14e1de9-887c-4716-a037-dcf2f68e8885">8.12</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i65a6d24f5a314cbba76284b24732fb3c_I20211231" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTo2NmRhZGMxYWRhOTE0NjZlODY0NWYwNDc0OTE2MjJhYy90YWJsZXJhbmdlOjY2ZGFkYzFhZGE5MTQ2NmU4NjQ1ZjA0NzQ5MTYyMmFjXzQtNS0xLTEtNDEyOTQ_dca2e172-bca5-4ce8-bdc1-295362e77a34">95.68</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i65a6d24f5a314cbba76284b24732fb3c_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTo2NmRhZGMxYWRhOTE0NjZlODY0NWYwNDc0OTE2MjJhYy90YWJsZXJhbmdlOjY2ZGFkYzFhZGE5MTQ2NmU4NjQ1ZjA0NzQ5MTYyMmFjXzQtNy0xLTEtNDEyOTQ_83d96965-0f26-41c3-b24b-c8cf5abcc41e">109,154</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i65a6d24f5a314cbba76284b24732fb3c_I20211231" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTo2NmRhZGMxYWRhOTE0NjZlODY0NWYwNDc0OTE2MjJhYy90YWJsZXJhbmdlOjY2ZGFkYzFhZGE5MTQ2NmU4NjQ1ZjA0NzQ5MTYyMmFjXzQtOS0xLTEtNDEyOTQ_91a0f409-899b-41c5-a2fc-caf3ea8d8577">95.68</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i708cf622e450455095803a651785b9f8_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTo2NmRhZGMxYWRhOTE0NjZlODY0NWYwNDc0OTE2MjJhYy90YWJsZXJhbmdlOjY2ZGFkYzFhZGE5MTQ2NmU4NjQ1ZjA0NzQ5MTYyMmFjXzUtMC0xLTEtNDEyOTQvdGV4dHJlZ2lvbjoxZGE5MDNhOGNjZTE0MmNiYTM3NmRjOGU0NjgyNDRmNF83Njk2NTgxMzk0NDcw_162b10a2-23a8-4f68-917f-b54d9f6c508b">98.20</ix:nonFraction>-$<ix:nonFraction unitRef="usdPerShare" contextRef="i708cf622e450455095803a651785b9f8_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTo2NmRhZGMxYWRhOTE0NjZlODY0NWYwNDc0OTE2MjJhYy90YWJsZXJhbmdlOjY2ZGFkYzFhZGE5MTQ2NmU4NjQ1ZjA0NzQ5MTYyMmFjXzUtMC0xLTEtNDEyOTQvdGV4dHJlZ2lvbjoxZGE5MDNhOGNjZTE0MmNiYTM3NmRjOGU0NjgyNDRmNF83Njk2NTgxMzk0NDc0_1cf163f7-57af-4979-ae37-12c5fbe48a15">100.38</ix:nonFraction></span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1cf30bd35d974a5688e936ed32ee1917_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTo2NmRhZGMxYWRhOTE0NjZlODY0NWYwNDc0OTE2MjJhYy90YWJsZXJhbmdlOjY2ZGFkYzFhZGE5MTQ2NmU4NjQ1ZjA0NzQ5MTYyMmFjXzUtMS0xLTEtNDEyOTQ_3609ae54-57ad-4e64-b791-1917a0cb7eac">294,772</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i708cf622e450455095803a651785b9f8_D20210101-20211231" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTo2NmRhZGMxYWRhOTE0NjZlODY0NWYwNDc0OTE2MjJhYy90YWJsZXJhbmdlOjY2ZGFkYzFhZGE5MTQ2NmU4NjQ1ZjA0NzQ5MTYyMmFjXzUtMy0xLTEtNDEyOTQ_e064ab3a-a88f-4504-a23f-2453d83b21d1">7.33</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i1cf30bd35d974a5688e936ed32ee1917_I20211231" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTo2NmRhZGMxYWRhOTE0NjZlODY0NWYwNDc0OTE2MjJhYy90YWJsZXJhbmdlOjY2ZGFkYzFhZGE5MTQ2NmU4NjQ1ZjA0NzQ5MTYyMmFjXzUtNS0xLTEtNDEyOTQ_6aa21bf2-bdfe-462c-97b9-55f73cd05b57">99.10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1cf30bd35d974a5688e936ed32ee1917_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTo2NmRhZGMxYWRhOTE0NjZlODY0NWYwNDc0OTE2MjJhYy90YWJsZXJhbmdlOjY2ZGFkYzFhZGE5MTQ2NmU4NjQ1ZjA0NzQ5MTYyMmFjXzUtNy0xLTEtNDEyOTQ_4a11d1ca-13c2-4d7a-9c6d-54d5b522c91b">160,120</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i1cf30bd35d974a5688e936ed32ee1917_I20211231" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTo2NmRhZGMxYWRhOTE0NjZlODY0NWYwNDc0OTE2MjJhYy90YWJsZXJhbmdlOjY2ZGFkYzFhZGE5MTQ2NmU4NjQ1ZjA0NzQ5MTYyMmFjXzUtOS0xLTEtNDEyOTQ_e2dd18e8-a54e-44bb-ac95-7f16aca684f8">99.79</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i193ec162b3f648aaaca6368e35169ea0_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTo2NmRhZGMxYWRhOTE0NjZlODY0NWYwNDc0OTE2MjJhYy90YWJsZXJhbmdlOjY2ZGFkYzFhZGE5MTQ2NmU4NjQ1ZjA0NzQ5MTYyMmFjXzYtMC0xLTEtNDEyOTQvdGV4dHJlZ2lvbjoyYTZhOWNiOGVmNjE0ODFkYjQ0Y2ZmMWQxMjAyYTllN183Njk2NTgxMzk0NDcy_df76dc0e-fceb-4389-9e2b-a5408d2d8f5b">101.07</ix:nonFraction>-$<ix:nonFraction unitRef="usdPerShare" contextRef="i193ec162b3f648aaaca6368e35169ea0_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTo2NmRhZGMxYWRhOTE0NjZlODY0NWYwNDc0OTE2MjJhYy90YWJsZXJhbmdlOjY2ZGFkYzFhZGE5MTQ2NmU4NjQ1ZjA0NzQ5MTYyMmFjXzYtMC0xLTEtNDEyOTQvdGV4dHJlZ2lvbjoyYTZhOWNiOGVmNjE0ODFkYjQ0Y2ZmMWQxMjAyYTllN183Njk2NTgxMzk0NDc2_f68c4a5c-97b0-411d-8e27-d23ac1565a35">117.58</ix:nonFraction></span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i80a561831894449e862692a33049b0b5_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTo2NmRhZGMxYWRhOTE0NjZlODY0NWYwNDc0OTE2MjJhYy90YWJsZXJhbmdlOjY2ZGFkYzFhZGE5MTQ2NmU4NjQ1ZjA0NzQ5MTYyMmFjXzYtMS0xLTEtNDEyOTQ_7cee17a7-213b-4855-af6e-ecc48cd99c23">159,204</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i193ec162b3f648aaaca6368e35169ea0_D20210101-20211231" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTo2NmRhZGMxYWRhOTE0NjZlODY0NWYwNDc0OTE2MjJhYy90YWJsZXJhbmdlOjY2ZGFkYzFhZGE5MTQ2NmU4NjQ1ZjA0NzQ5MTYyMmFjXzYtMy0xLTEtNDEyOTQ_154c359a-8d6c-4734-816e-e1b0199b06b4">7.45</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i80a561831894449e862692a33049b0b5_I20211231" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTo2NmRhZGMxYWRhOTE0NjZlODY0NWYwNDc0OTE2MjJhYy90YWJsZXJhbmdlOjY2ZGFkYzFhZGE5MTQ2NmU4NjQ1ZjA0NzQ5MTYyMmFjXzYtNS0xLTEtNDEyOTQ_09a594c7-8594-40a6-837d-4186d0ebac8b">111.26</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i80a561831894449e862692a33049b0b5_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTo2NmRhZGMxYWRhOTE0NjZlODY0NWYwNDc0OTE2MjJhYy90YWJsZXJhbmdlOjY2ZGFkYzFhZGE5MTQ2NmU4NjQ1ZjA0NzQ5MTYyMmFjXzYtNy0xLTEtNDEyOTQ_c7b7aac4-288c-4546-a340-6db1583cbe06">99,488</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i80a561831894449e862692a33049b0b5_I20211231" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTo2NmRhZGMxYWRhOTE0NjZlODY0NWYwNDc0OTE2MjJhYy90YWJsZXJhbmdlOjY2ZGFkYzFhZGE5MTQ2NmU4NjQ1ZjA0NzQ5MTYyMmFjXzYtOS0xLTEtNDEyOTQ_8a415eb0-ead6-4676-a525-e1850e585d41">111.18</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i08eb127d3b5c4ecd8f5f19d8b095a195_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTo2NmRhZGMxYWRhOTE0NjZlODY0NWYwNDc0OTE2MjJhYy90YWJsZXJhbmdlOjY2ZGFkYzFhZGE5MTQ2NmU4NjQ1ZjA0NzQ5MTYyMmFjXzctMC0xLTEtNDEyOTQ_13b2fd94-9002-498d-9f79-044d1b6f741f"><ix:nonFraction unitRef="usdPerShare" contextRef="i08eb127d3b5c4ecd8f5f19d8b095a195_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTo2NmRhZGMxYWRhOTE0NjZlODY0NWYwNDc0OTE2MjJhYy90YWJsZXJhbmdlOjY2ZGFkYzFhZGE5MTQ2NmU4NjQ1ZjA0NzQ5MTYyMmFjXzctMC0xLTEtNDEyOTQ_e3543ffe-1334-4515-933a-7f0ed8a56fbb">117.97</ix:nonFraction></ix:nonFraction></span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i546fb8a918cb476380308420e935eec1_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTo2NmRhZGMxYWRhOTE0NjZlODY0NWYwNDc0OTE2MjJhYy90YWJsZXJhbmdlOjY2ZGFkYzFhZGE5MTQ2NmU4NjQ1ZjA0NzQ5MTYyMmFjXzctMS0xLTEtNDEyOTQ_4a605df4-f25b-4a8b-8c33-10385288799d">237,292</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i08eb127d3b5c4ecd8f5f19d8b095a195_D20210101-20211231" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTo2NmRhZGMxYWRhOTE0NjZlODY0NWYwNDc0OTE2MjJhYy90YWJsZXJhbmdlOjY2ZGFkYzFhZGE5MTQ2NmU4NjQ1ZjA0NzQ5MTYyMmFjXzctMy0xLTEtNDEyOTQ_4b9b7b29-c93f-4435-b4f2-f9dd2a5c227b">7.12</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i546fb8a918cb476380308420e935eec1_I20211231" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTo2NmRhZGMxYWRhOTE0NjZlODY0NWYwNDc0OTE2MjJhYy90YWJsZXJhbmdlOjY2ZGFkYzFhZGE5MTQ2NmU4NjQ1ZjA0NzQ5MTYyMmFjXzctNS0xLTEtNDEyOTQ_4c7c0267-013d-44a5-bdb3-3b2edfa8c909">117.97</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i546fb8a918cb476380308420e935eec1_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTo2NmRhZGMxYWRhOTE0NjZlODY0NWYwNDc0OTE2MjJhYy90YWJsZXJhbmdlOjY2ZGFkYzFhZGE5MTQ2NmU4NjQ1ZjA0NzQ5MTYyMmFjXzctNy0xLTEtNDEyOTQ_956f3793-96ab-4b8f-9847-3a0198c489ed">158,958</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i546fb8a918cb476380308420e935eec1_I20211231" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTo2NmRhZGMxYWRhOTE0NjZlODY0NWYwNDc0OTE2MjJhYy90YWJsZXJhbmdlOjY2ZGFkYzFhZGE5MTQ2NmU4NjQ1ZjA0NzQ5MTYyMmFjXzctOS0xLTEtNDEyOTQ_c7b81e06-fabb-4865-a6b3-f4c172414749">117.97</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i39fc20505d3849c9ae3fc61f12edf580_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTo2NmRhZGMxYWRhOTE0NjZlODY0NWYwNDc0OTE2MjJhYy90YWJsZXJhbmdlOjY2ZGFkYzFhZGE5MTQ2NmU4NjQ1ZjA0NzQ5MTYyMmFjXzgtMC0xLTEtNDEyOTQvdGV4dHJlZ2lvbjoxMGUxNDZhNDM1M2Y0ZWNlYTkwYjgwOWJmOGQwZjQ4Ml80_cf7dc826-7f46-40a3-9799-5ece63ea999e">119.08</ix:nonFraction>-$<ix:nonFraction unitRef="usdPerShare" contextRef="i39fc20505d3849c9ae3fc61f12edf580_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTo2NmRhZGMxYWRhOTE0NjZlODY0NWYwNDc0OTE2MjJhYy90YWJsZXJhbmdlOjY2ZGFkYzFhZGE5MTQ2NmU4NjQ1ZjA0NzQ5MTYyMmFjXzgtMC0xLTEtNDEyOTQvdGV4dHJlZ2lvbjoxMGUxNDZhNDM1M2Y0ZWNlYTkwYjgwOWJmOGQwZjQ4Ml83_24278ead-6a39-438c-adbd-64bdede89c19">159.01</ix:nonFraction></span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1d0ce9ddb0d9422b8e6592ab0500d1ab_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTo2NmRhZGMxYWRhOTE0NjZlODY0NWYwNDc0OTE2MjJhYy90YWJsZXJhbmdlOjY2ZGFkYzFhZGE5MTQ2NmU4NjQ1ZjA0NzQ5MTYyMmFjXzgtMS0xLTEtNDEyOTQ_9f1b2564-5f94-40c8-b991-124ed57ed819">299,585</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i39fc20505d3849c9ae3fc61f12edf580_D20210101-20211231" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTo2NmRhZGMxYWRhOTE0NjZlODY0NWYwNDc0OTE2MjJhYy90YWJsZXJhbmdlOjY2ZGFkYzFhZGE5MTQ2NmU4NjQ1ZjA0NzQ5MTYyMmFjXzgtMy0xLTEtNDEyOTQ_2419443b-a3b7-43e2-847d-34782876256f">7.00</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i1d0ce9ddb0d9422b8e6592ab0500d1ab_I20211231" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTo2NmRhZGMxYWRhOTE0NjZlODY0NWYwNDc0OTE2MjJhYy90YWJsZXJhbmdlOjY2ZGFkYzFhZGE5MTQ2NmU4NjQ1ZjA0NzQ5MTYyMmFjXzgtNS0xLTEtNDEyOTQ_87a0168b-388b-4cd1-9216-284141a40f9a">149.40</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1d0ce9ddb0d9422b8e6592ab0500d1ab_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTo2NmRhZGMxYWRhOTE0NjZlODY0NWYwNDc0OTE2MjJhYy90YWJsZXJhbmdlOjY2ZGFkYzFhZGE5MTQ2NmU4NjQ1ZjA0NzQ5MTYyMmFjXzgtNy0xLTEtNDEyOTQ_fe202c11-0e30-46a0-94c9-16f379393f9c">205,098</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i1d0ce9ddb0d9422b8e6592ab0500d1ab_I20211231" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTo2NmRhZGMxYWRhOTE0NjZlODY0NWYwNDc0OTE2MjJhYy90YWJsZXJhbmdlOjY2ZGFkYzFhZGE5MTQ2NmU4NjQ1ZjA0NzQ5MTYyMmFjXzgtOS0xLTEtNDEyOTQ_9a7a0dfa-197a-42f6-ac46-937700c3e279">152.50</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i9d3219f8f79f4fb685decb79b150bd06_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTo2NmRhZGMxYWRhOTE0NjZlODY0NWYwNDc0OTE2MjJhYy90YWJsZXJhbmdlOjY2ZGFkYzFhZGE5MTQ2NmU4NjQ1ZjA0NzQ5MTYyMmFjXzktMC0xLTEtNDEyOTQvdGV4dHJlZ2lvbjo4NjQ2ODk4NDU1MGM0NjQ3YWRlYjJiMzVmMzMzMjA0NF83Njk2NTgxMzk0NDU4_32ea0568-4a51-41e7-90c2-bbd33ebd7f3f">159.81</ix:nonFraction>-$<ix:nonFraction unitRef="usdPerShare" contextRef="i9d3219f8f79f4fb685decb79b150bd06_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTo2NmRhZGMxYWRhOTE0NjZlODY0NWYwNDc0OTE2MjJhYy90YWJsZXJhbmdlOjY2ZGFkYzFhZGE5MTQ2NmU4NjQ1ZjA0NzQ5MTYyMmFjXzktMC0xLTEtNDEyOTQvdGV4dHJlZ2lvbjo4NjQ2ODk4NDU1MGM0NjQ3YWRlYjJiMzVmMzMzMjA0NF83Njk2NTgxMzk0NDYy_9f3c2cbd-5d1a-4217-8da9-25ac756d2150">171.28</ix:nonFraction></span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id7afd511815d4bc394f6e2368abd4dca_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTo2NmRhZGMxYWRhOTE0NjZlODY0NWYwNDc0OTE2MjJhYy90YWJsZXJhbmdlOjY2ZGFkYzFhZGE5MTQ2NmU4NjQ1ZjA0NzQ5MTYyMmFjXzktMS0xLTEtNDEyOTQ_c6d8ea3a-5e12-4d42-b66b-59c43617d992">6,881</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i9d3219f8f79f4fb685decb79b150bd06_D20210101-20211231" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTo2NmRhZGMxYWRhOTE0NjZlODY0NWYwNDc0OTE2MjJhYy90YWJsZXJhbmdlOjY2ZGFkYzFhZGE5MTQ2NmU4NjQ1ZjA0NzQ5MTYyMmFjXzktMy0xLTEtNDEyOTQ_2ce372ca-6346-4cea-a349-78ad4e5a46b3">6.51</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="id7afd511815d4bc394f6e2368abd4dca_I20211231" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTo2NmRhZGMxYWRhOTE0NjZlODY0NWYwNDc0OTE2MjJhYy90YWJsZXJhbmdlOjY2ZGFkYzFhZGE5MTQ2NmU4NjQ1ZjA0NzQ5MTYyMmFjXzktNS0xLTEtNDEyOTQ_ab920968-fee2-48f9-bb39-a4dd7155515c">166.28</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id7afd511815d4bc394f6e2368abd4dca_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTo2NmRhZGMxYWRhOTE0NjZlODY0NWYwNDc0OTE2MjJhYy90YWJsZXJhbmdlOjY2ZGFkYzFhZGE5MTQ2NmU4NjQ1ZjA0NzQ5MTYyMmFjXzktNy0xLTEtNDEyOTQ_54bbf658-8528-4ba2-8051-affdfcd8eb10">5,828</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="id7afd511815d4bc394f6e2368abd4dca_I20211231" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTo2NmRhZGMxYWRhOTE0NjZlODY0NWYwNDc0OTE2MjJhYy90YWJsZXJhbmdlOjY2ZGFkYzFhZGE5MTQ2NmU4NjQ1ZjA0NzQ5MTYyMmFjXzktOS0xLTEtNDEyOTQ_f44ccb3e-219b-4af4-b735-73be82a216ec">165.62</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i828b95c8a1d249729b55e04082a16fbe_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTo2NmRhZGMxYWRhOTE0NjZlODY0NWYwNDc0OTE2MjJhYy90YWJsZXJhbmdlOjY2ZGFkYzFhZGE5MTQ2NmU4NjQ1ZjA0NzQ5MTYyMmFjXzEwLTAtMS0xLTQxMjk0L3RleHRyZWdpb246NzFhNGJkMTNjNDk3NDc3N2JmMWRjZmY0MzRlMGVkNGZfNA_72ca4646-adff-4a37-9c5f-81af877e5a1e">177.50</ix:nonFraction>-$<ix:nonFraction unitRef="usdPerShare" contextRef="i828b95c8a1d249729b55e04082a16fbe_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTo2NmRhZGMxYWRhOTE0NjZlODY0NWYwNDc0OTE2MjJhYy90YWJsZXJhbmdlOjY2ZGFkYzFhZGE5MTQ2NmU4NjQ1ZjA0NzQ5MTYyMmFjXzEwLTAtMS0xLTQxMjk0L3RleHRyZWdpb246NzFhNGJkMTNjNDk3NDc3N2JmMWRjZmY0MzRlMGVkNGZfNw_7bda48b2-7ed4-411e-b7b6-ad813a375ea9">195.91</ix:nonFraction></span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie43fa1c2f29449588c86ec647c987e14_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTo2NmRhZGMxYWRhOTE0NjZlODY0NWYwNDc0OTE2MjJhYy90YWJsZXJhbmdlOjY2ZGFkYzFhZGE5MTQ2NmU4NjQ1ZjA0NzQ5MTYyMmFjXzEwLTEtMS0xLTQxMjk0_901de54b-bcd4-4d52-b967-21ca99fea15a">243,508</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i828b95c8a1d249729b55e04082a16fbe_D20210101-20211231" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTo2NmRhZGMxYWRhOTE0NjZlODY0NWYwNDc0OTE2MjJhYy90YWJsZXJhbmdlOjY2ZGFkYzFhZGE5MTQ2NmU4NjQ1ZjA0NzQ5MTYyMmFjXzEwLTMtMS0xLTQxMjk0_6dbb385b-c81c-4330-871c-c13dc4513439">8.91</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ie43fa1c2f29449588c86ec647c987e14_I20211231" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTo2NmRhZGMxYWRhOTE0NjZlODY0NWYwNDc0OTE2MjJhYy90YWJsZXJhbmdlOjY2ZGFkYzFhZGE5MTQ2NmU4NjQ1ZjA0NzQ5MTYyMmFjXzEwLTUtMS0xLTQxMjk0_bafa13f0-c1c0-41b2-9c4a-03562f452553">178.62</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie43fa1c2f29449588c86ec647c987e14_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTo2NmRhZGMxYWRhOTE0NjZlODY0NWYwNDc0OTE2MjJhYy90YWJsZXJhbmdlOjY2ZGFkYzFhZGE5MTQ2NmU4NjQ1ZjA0NzQ5MTYyMmFjXzEwLTctMS0xLTQxMjk0_e62a5b20-33fc-4c46-b6e7-56835086910d">62,932</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ie43fa1c2f29449588c86ec647c987e14_I20211231" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTo2NmRhZGMxYWRhOTE0NjZlODY0NWYwNDc0OTE2MjJhYy90YWJsZXJhbmdlOjY2ZGFkYzFhZGE5MTQ2NmU4NjQ1ZjA0NzQ5MTYyMmFjXzEwLTktMS0xLTQxMjk0_fcfa4f3c-c439-48b9-a5e2-fe7350286528">181.84</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i331ce2c9b57a41af9de97ff9994cb5b5_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTo2NmRhZGMxYWRhOTE0NjZlODY0NWYwNDc0OTE2MjJhYy90YWJsZXJhbmdlOjY2ZGFkYzFhZGE5MTQ2NmU4NjQ1ZjA0NzQ5MTYyMmFjXzExLTEtMS0xLTQxMjk0_8c6e41c6-6ec7-46a3-8aa6-5eabe68b5098">2,199,598</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i6d7b08b9d22043d5932cf089d69eba52_D20210101-20211231" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTo2NmRhZGMxYWRhOTE0NjZlODY0NWYwNDc0OTE2MjJhYy90YWJsZXJhbmdlOjY2ZGFkYzFhZGE5MTQ2NmU4NjQ1ZjA0NzQ5MTYyMmFjXzExLTMtMS0xLTQxMjk0_a82229b7-bfa1-41bd-90bf-2c7b8eef6025">6.34</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i331ce2c9b57a41af9de97ff9994cb5b5_I20211231" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTo2NmRhZGMxYWRhOTE0NjZlODY0NWYwNDc0OTE2MjJhYy90YWJsZXJhbmdlOjY2ZGFkYzFhZGE5MTQ2NmU4NjQ1ZjA0NzQ5MTYyMmFjXzExLTUtMS0xLTQxMjk0_15e750f2-a35c-4c41-b964-8d56e3ee9a2d">106.00</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i331ce2c9b57a41af9de97ff9994cb5b5_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTo2NmRhZGMxYWRhOTE0NjZlODY0NWYwNDc0OTE2MjJhYy90YWJsZXJhbmdlOjY2ZGFkYzFhZGE5MTQ2NmU4NjQ1ZjA0NzQ5MTYyMmFjXzExLTctMS0xLTQxMjk0_dd6b5e48-8531-4421-bcb0-1526a025eb93">1,391,952</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i331ce2c9b57a41af9de97ff9994cb5b5_I20211231" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTo2NmRhZGMxYWRhOTE0NjZlODY0NWYwNDc0OTE2MjJhYy90YWJsZXJhbmdlOjY2ZGFkYzFhZGE5MTQ2NmU4NjQ1ZjA0NzQ5MTYyMmFjXzExLTktMS0xLTQxMjk0_0c1a86a7-02cb-4f70-a4a1-2c693bc3a684">98.16</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">86</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i1274d0cd0fb7406baac09ba34c02891e" continuedAt="i90cb430dc51e426a9b2f18107a6628a0"><ix:nonNumeric contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90ZXh0cmVnaW9uOjk1MzhkNjI5YTc4YTQ4ZmY4NmJhMjZmMzlkMjRiMWI5XzM2MTY_7e0a75bb-6bd2-40c2-b3f1-a5006380ad6e" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The assumptions used for the specified reporting periods and the resulting estimates of weighted-average grant date fair value per share of options granted:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.538%"><tr><td style="width:1.0%"></td><td style="width:52.609%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.440%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.986%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.440%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.541%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.440%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="18" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i5258348dd679493ba1253e4703ac77de_D20210101-20211231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTozMjJjMTIwZjEyNGM0ZWQyOTczNzAxYjQyNzhlYjk3My90YWJsZXJhbmdlOjMyMmMxMjBmMTI0YzRlZDI5NzM3MDFiNDI3OGViOTczXzItMS0xLTEtNDEyOTQvdGV4dHJlZ2lvbjoxNWZlZmRiZjc0NzE0NThjYTc3NTYwYjBmZTEwZmFlN180_17a26447-5f78-4f94-a0e0-861dadaf5687">0.4</ix:nonFraction>%-<ix:nonFraction unitRef="number" contextRef="i55156c07b9684b9185860bad3331609a_D20210101-20211231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTozMjJjMTIwZjEyNGM0ZWQyOTczNzAxYjQyNzhlYjk3My90YWJsZXJhbmdlOjMyMmMxMjBmMTI0YzRlZDI5NzM3MDFiNDI3OGViOTczXzItMS0xLTEtNDEyOTQvdGV4dHJlZ2lvbjoxNWZlZmRiZjc0NzE0NThjYTc3NTYwYjBmZTEwZmFlN183_2036c923-7605-4259-b5b2-64966166176e">1.2</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8c53cef7494647d29b8ef30c6695cfb2_D20200101-20201231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTozMjJjMTIwZjEyNGM0ZWQyOTczNzAxYjQyNzhlYjk3My90YWJsZXJhbmdlOjMyMmMxMjBmMTI0YzRlZDI5NzM3MDFiNDI3OGViOTczXzItMy0xLTEtNDEyOTQvdGV4dHJlZ2lvbjo4ZGFhNGFhY2YwY2E0MDhjYjk0OWM5MjNiOGQ0Y2JlZl80_c90da793-3be5-49dd-a4b5-5763bfd7f5c1">0.2</ix:nonFraction>%-<ix:nonFraction unitRef="number" contextRef="i0addec58007345efb57ddbad8ce96022_D20200101-20201231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTozMjJjMTIwZjEyNGM0ZWQyOTczNzAxYjQyNzhlYjk3My90YWJsZXJhbmdlOjMyMmMxMjBmMTI0YzRlZDI5NzM3MDFiNDI3OGViOTczXzItMy0xLTEtNDEyOTQvdGV4dHJlZ2lvbjo4ZGFhNGFhY2YwY2E0MDhjYjk0OWM5MjNiOGQ0Y2JlZl83_77724b1f-12eb-4830-9437-4005e2fa57c6">1.4</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id82d912299e647bab45143f83254b4e2_D20190101-20191231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTozMjJjMTIwZjEyNGM0ZWQyOTczNzAxYjQyNzhlYjk3My90YWJsZXJhbmdlOjMyMmMxMjBmMTI0YzRlZDI5NzM3MDFiNDI3OGViOTczXzItNS0xLTEtNDEyOTQvdGV4dHJlZ2lvbjo5Y2E2ZTVjZDRlMDA0ODJkYjYyODViYzUyYzgyMmJkZl80_baa39e95-a66e-40bf-86dc-2aa0d3e4a1c1">1.4</ix:nonFraction>%-<ix:nonFraction unitRef="number" contextRef="i9d152e0e9dfd4aad8d4279f7424f28d5_D20190101-20191231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTozMjJjMTIwZjEyNGM0ZWQyOTczNzAxYjQyNzhlYjk3My90YWJsZXJhbmdlOjMyMmMxMjBmMTI0YzRlZDI5NzM3MDFiNDI3OGViOTczXzItNS0xLTEtNDEyOTQvdGV4dHJlZ2lvbjo5Y2E2ZTVjZDRlMDA0ODJkYjYyODViYzUyYzgyMmJkZl83_3645d263-a716-4267-998e-46dcc6042aee">2.6</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i5258348dd679493ba1253e4703ac77de_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTozMjJjMTIwZjEyNGM0ZWQyOTczNzAxYjQyNzhlYjk3My90YWJsZXJhbmdlOjMyMmMxMjBmMTI0YzRlZDI5NzM3MDFiNDI3OGViOTczXzMtMS0xLTEtNDEyOTQvdGV4dHJlZ2lvbjo3MTE4OGU1MmY0YTk0ODdiOGIwNDU3MWI0ZWViZGFkOV80_089c02e1-9098-4530-b3f3-c0071599fdf3">47</ix:nonFraction>%-<ix:nonFraction unitRef="number" contextRef="i55156c07b9684b9185860bad3331609a_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTozMjJjMTIwZjEyNGM0ZWQyOTczNzAxYjQyNzhlYjk3My90YWJsZXJhbmdlOjMyMmMxMjBmMTI0YzRlZDI5NzM3MDFiNDI3OGViOTczXzMtMS0xLTEtNDEyOTQvdGV4dHJlZ2lvbjo3MTE4OGU1MmY0YTk0ODdiOGIwNDU3MWI0ZWViZGFkOV83_2b71a5ae-d6e3-4fb2-801f-198c112b36f2">63</ix:nonFraction>%</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8c53cef7494647d29b8ef30c6695cfb2_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTozMjJjMTIwZjEyNGM0ZWQyOTczNzAxYjQyNzhlYjk3My90YWJsZXJhbmdlOjMyMmMxMjBmMTI0YzRlZDI5NzM3MDFiNDI3OGViOTczXzMtMy0xLTEtNDEyOTQvdGV4dHJlZ2lvbjo3YTczMTJhOTcwNWQ0NDJhOTRmY2JiMjI2NDRkZjU2Ml80_4d1fc16e-df47-4edd-862b-7b91ca3e002a">47</ix:nonFraction>%-<ix:nonFraction unitRef="number" contextRef="i0addec58007345efb57ddbad8ce96022_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTozMjJjMTIwZjEyNGM0ZWQyOTczNzAxYjQyNzhlYjk3My90YWJsZXJhbmdlOjMyMmMxMjBmMTI0YzRlZDI5NzM3MDFiNDI3OGViOTczXzMtMy0xLTEtNDEyOTQvdGV4dHJlZ2lvbjo3YTczMTJhOTcwNWQ0NDJhOTRmY2JiMjI2NDRkZjU2Ml83_b9d40fe6-adbe-40fb-8312-fe5f2892c689">71</ix:nonFraction>%</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id82d912299e647bab45143f83254b4e2_D20190101-20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTozMjJjMTIwZjEyNGM0ZWQyOTczNzAxYjQyNzhlYjk3My90YWJsZXJhbmdlOjMyMmMxMjBmMTI0YzRlZDI5NzM3MDFiNDI3OGViOTczXzMtNS0xLTEtNDEyOTQvdGV4dHJlZ2lvbjo2NTg4OWFhN2IzYmE0MGQxYjhhZjhhODAzNDQ3YzJiYl80_a354e227-47a7-49d5-93b9-55fe47faeb4e">40</ix:nonFraction>%-<ix:nonFraction unitRef="number" contextRef="i9d152e0e9dfd4aad8d4279f7424f28d5_D20190101-20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTozMjJjMTIwZjEyNGM0ZWQyOTczNzAxYjQyNzhlYjk3My90YWJsZXJhbmdlOjMyMmMxMjBmMTI0YzRlZDI5NzM3MDFiNDI3OGViOTczXzMtNS0xLTEtNDEyOTQvdGV4dHJlZ2lvbjo2NTg4OWFhN2IzYmE0MGQxYjhhZjhhODAzNDQ3YzJiYl83_07c2a8fe-8a21-44f4-96fc-dc6f9fbc5caf">49</ix:nonFraction>%</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i5258348dd679493ba1253e4703ac77de_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTozMjJjMTIwZjEyNGM0ZWQyOTczNzAxYjQyNzhlYjk3My90YWJsZXJhbmdlOjMyMmMxMjBmMTI0YzRlZDI5NzM3MDFiNDI3OGViOTczXzQtMS0xLTEtNDEyOTQvdGV4dHJlZ2lvbjpkMDQyMjRhMDljZGI0ZDQ1YmE4ZTQzYmVjNWRkOGZkOV80_03d55ac4-83a4-4d1f-b17e-a499a0e071d0">4.7</ix:nonNumeric> to <ix:nonNumeric contextRef="i55156c07b9684b9185860bad3331609a_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTozMjJjMTIwZjEyNGM0ZWQyOTczNzAxYjQyNzhlYjk3My90YWJsZXJhbmdlOjMyMmMxMjBmMTI0YzRlZDI5NzM3MDFiNDI3OGViOTczXzQtMS0xLTEtNDEyOTQvdGV4dHJlZ2lvbjpkMDQyMjRhMDljZGI0ZDQ1YmE4ZTQzYmVjNWRkOGZkOV8xMA_3063dceb-1bc4-4cb9-827d-38b31692b86b">6.3</ix:nonNumeric> years</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i8c53cef7494647d29b8ef30c6695cfb2_D20200101-20201231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTozMjJjMTIwZjEyNGM0ZWQyOTczNzAxYjQyNzhlYjk3My90YWJsZXJhbmdlOjMyMmMxMjBmMTI0YzRlZDI5NzM3MDFiNDI3OGViOTczXzQtMy0xLTEtNDEyOTQvdGV4dHJlZ2lvbjo5OWIxNTc0YWY4Y2E0YTczYmUxYTI0YWE1OTM0ZTE0ZF80_5400b9d7-4640-44e9-b224-334e8b8d0bb6">4.7</ix:nonNumeric> to <ix:nonNumeric contextRef="i0addec58007345efb57ddbad8ce96022_D20200101-20201231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTozMjJjMTIwZjEyNGM0ZWQyOTczNzAxYjQyNzhlYjk3My90YWJsZXJhbmdlOjMyMmMxMjBmMTI0YzRlZDI5NzM3MDFiNDI3OGViOTczXzQtMy0xLTEtNDEyOTQvdGV4dHJlZ2lvbjo5OWIxNTc0YWY4Y2E0YTczYmUxYTI0YWE1OTM0ZTE0ZF8xMA_eeecbc45-4b25-43d5-8291-7151614ed278">5.1</ix:nonNumeric> years</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="id82d912299e647bab45143f83254b4e2_D20190101-20191231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTozMjJjMTIwZjEyNGM0ZWQyOTczNzAxYjQyNzhlYjk3My90YWJsZXJhbmdlOjMyMmMxMjBmMTI0YzRlZDI5NzM3MDFiNDI3OGViOTczXzQtNS0xLTEtNDEyOTQvdGV4dHJlZ2lvbjoyNGIxMzFhOTU2ZjY0YmE5OWYyYjRmMTgwZTI2YjdhY180_89c3e5c1-c16e-4f4a-aabc-5a1e7dd82aec">4.6</ix:nonNumeric> to <ix:nonNumeric contextRef="i9d152e0e9dfd4aad8d4279f7424f28d5_D20190101-20191231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTozMjJjMTIwZjEyNGM0ZWQyOTczNzAxYjQyNzhlYjk3My90YWJsZXJhbmdlOjMyMmMxMjBmMTI0YzRlZDI5NzM3MDFiNDI3OGViOTczXzQtNS0xLTEtNDEyOTQvdGV4dHJlZ2lvbjoyNGIxMzFhOTU2ZjY0YmE5OWYyYjRmMTgwZTI2YjdhY18xMA_375c4d39-cd66-4bad-ae5a-de106f979d65">5.9</ix:nonNumeric> years</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="text-indent:27pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, there was $<ix:nonFraction unitRef="usd" contextRef="i0f9a89ad3d5346e3b8b17b7dfbcb9f78_I20211231" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90ZXh0cmVnaW9uOjk1MzhkNjI5YTc4YTQ4ZmY4NmJhMjZmMzlkMjRiMWI5XzExMjA_42882426-c5b1-4184-bbb0-fff7bcbada01">40.7</ix:nonFraction> million of total unrecognized compensation cost related to non-vested stock options.  That cost is expected to be recognized over a weighted average period of <ix:nonNumeric contextRef="i0b2d2a0659724a0394359a72b0ded635_D20210101-20211231" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90ZXh0cmVnaW9uOjk1MzhkNjI5YTc4YTQ4ZmY4NmJhMjZmMzlkMjRiMWI5XzEyNzQ_0b694ac3-042b-4e1f-ab94-c9239b7ef221">2.4</ix:nonNumeric> years.</span></div><div style="margin-top:14pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock Activity</span></div><ix:nonNumeric contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231" name="us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90ZXh0cmVnaW9uOjk1MzhkNjI5YTc4YTQ4ZmY4NmJhMjZmMzlkMjRiMWI5XzM2MjE_6aef95ae-e721-4c1a-8e9d-f18aba36d613" escape="true"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of our restricted stock activity and related information:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:69.929%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.458%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.578%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Grant&#160;Date Fair</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Value</span></div></td></tr><tr style="height:12pt"><td colspan="12" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at January 1, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i45bcdaf84c91401486b1d0398942843d_I20181231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZToxM2ZlNjM5MjgyMjk0M2QwYWNmM2I4N2FmNjJiYmU2Mi90YWJsZXJhbmdlOjEzZmU2MzkyODIyOTQzZDBhY2YzYjg3YWY2MmJiZTYyXzItMS0xLTEtNDEyOTQ_757e8986-f79d-4984-b32e-a3e74cd5aa48">132,273</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i45bcdaf84c91401486b1d0398942843d_I20181231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZToxM2ZlNjM5MjgyMjk0M2QwYWNmM2I4N2FmNjJiYmU2Mi90YWJsZXJhbmdlOjEzZmU2MzkyODIyOTQzZDBhY2YzYjg3YWY2MmJiZTYyXzItMy0xLTEtNDEyOTQ_382d1026-7edb-4866-9064-0324d1d410c8">130.63</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i58f6278b54d04be0bf0b9577c087f56c_D20190101-20191231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZToxM2ZlNjM5MjgyMjk0M2QwYWNmM2I4N2FmNjJiYmU2Mi90YWJsZXJhbmdlOjEzZmU2MzkyODIyOTQzZDBhY2YzYjg3YWY2MmJiZTYyXzMtMS0xLTEtNDEyOTQ_11ba626e-7710-4f16-b6e2-585d3d2f2995">118,498</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i58f6278b54d04be0bf0b9577c087f56c_D20190101-20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZToxM2ZlNjM5MjgyMjk0M2QwYWNmM2I4N2FmNjJiYmU2Mi90YWJsZXJhbmdlOjEzZmU2MzkyODIyOTQzZDBhY2YzYjg3YWY2MmJiZTYyXzMtMy0xLTEtNDEyOTQ_c22a1f01-868f-40f6-8516-7e659d500b02">115.90</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i58f6278b54d04be0bf0b9577c087f56c_D20190101-20191231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZToxM2ZlNjM5MjgyMjk0M2QwYWNmM2I4N2FmNjJiYmU2Mi90YWJsZXJhbmdlOjEzZmU2MzkyODIyOTQzZDBhY2YzYjg3YWY2MmJiZTYyXzQtMS0xLTEtNDEyOTQ_7d21fd66-0098-47c0-ae73-f0017c181868">102,846</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i58f6278b54d04be0bf0b9577c087f56c_D20190101-20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZToxM2ZlNjM5MjgyMjk0M2QwYWNmM2I4N2FmNjJiYmU2Mi90YWJsZXJhbmdlOjEzZmU2MzkyODIyOTQzZDBhY2YzYjg3YWY2MmJiZTYyXzQtMy0xLTEtNDEyOTQ_3e5089e2-5523-4003-9792-a792096303d7">121.55</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i58f6278b54d04be0bf0b9577c087f56c_D20190101-20191231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZToxM2ZlNjM5MjgyMjk0M2QwYWNmM2I4N2FmNjJiYmU2Mi90YWJsZXJhbmdlOjEzZmU2MzkyODIyOTQzZDBhY2YzYjg3YWY2MmJiZTYyXzUtMS0xLTEtNDEyOTQ_3f2213c6-35ea-4290-82fd-83ce0f2af1c8">666</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i58f6278b54d04be0bf0b9577c087f56c_D20190101-20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZToxM2ZlNjM5MjgyMjk0M2QwYWNmM2I4N2FmNjJiYmU2Mi90YWJsZXJhbmdlOjEzZmU2MzkyODIyOTQzZDBhY2YzYjg3YWY2MmJiZTYyXzUtMy0xLTEtNDEyOTQ_5f1cffd1-3492-4e83-9cc2-67559bce6a59">134.36</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December&#160;31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5adbf2e3e4984848b67e5715f6848f1d_I20191231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZToxM2ZlNjM5MjgyMjk0M2QwYWNmM2I4N2FmNjJiYmU2Mi90YWJsZXJhbmdlOjEzZmU2MzkyODIyOTQzZDBhY2YzYjg3YWY2MmJiZTYyXzYtMS0xLTEtNDQyNTA_1797c792-3285-421e-b116-dbe16c6e5cdd">147,259</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i5adbf2e3e4984848b67e5715f6848f1d_I20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZToxM2ZlNjM5MjgyMjk0M2QwYWNmM2I4N2FmNjJiYmU2Mi90YWJsZXJhbmdlOjEzZmU2MzkyODIyOTQzZDBhY2YzYjg3YWY2MmJiZTYyXzYtMy0xLTEtNDEyOTQ_2b07e6cc-0772-481f-9c1c-667aa348c066">125.11</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6a0c3b111e7c4e828d7eda58eb7efe37_D20200101-20201231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZToxM2ZlNjM5MjgyMjk0M2QwYWNmM2I4N2FmNjJiYmU2Mi90YWJsZXJhbmdlOjEzZmU2MzkyODIyOTQzZDBhY2YzYjg3YWY2MmJiZTYyXzctMS0xLTEtNDEyOTQ_917b574e-d102-4815-ade7-692162a7b094">111,306</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i6a0c3b111e7c4e828d7eda58eb7efe37_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZToxM2ZlNjM5MjgyMjk0M2QwYWNmM2I4N2FmNjJiYmU2Mi90YWJsZXJhbmdlOjEzZmU2MzkyODIyOTQzZDBhY2YzYjg3YWY2MmJiZTYyXzctMy0xLTEtNDEyOTQ_44e844c6-8ff0-4494-9f5d-a1d025d668db">89.73</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i6a0c3b111e7c4e828d7eda58eb7efe37_D20200101-20201231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZToxM2ZlNjM5MjgyMjk0M2QwYWNmM2I4N2FmNjJiYmU2Mi90YWJsZXJhbmdlOjEzZmU2MzkyODIyOTQzZDBhY2YzYjg3YWY2MmJiZTYyXzgtMS0xLTEtNDEyOTQ_b722cafe-d262-4a3e-97f2-60f0bd7b20cb">52,363</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i6a0c3b111e7c4e828d7eda58eb7efe37_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZToxM2ZlNjM5MjgyMjk0M2QwYWNmM2I4N2FmNjJiYmU2Mi90YWJsZXJhbmdlOjEzZmU2MzkyODIyOTQzZDBhY2YzYjg3YWY2MmJiZTYyXzgtMy0xLTEtNDEyOTQ_2eff9bb0-6758-4e37-91c7-ae8f4c12b385">121.69</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6a0c3b111e7c4e828d7eda58eb7efe37_D20200101-20201231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZToxM2ZlNjM5MjgyMjk0M2QwYWNmM2I4N2FmNjJiYmU2Mi90YWJsZXJhbmdlOjEzZmU2MzkyODIyOTQzZDBhY2YzYjg3YWY2MmJiZTYyXzktMS0xLTEtNDEyOTQ_e1e724f8-b039-4606-8d38-ad8016c82658">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i6a0c3b111e7c4e828d7eda58eb7efe37_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZToxM2ZlNjM5MjgyMjk0M2QwYWNmM2I4N2FmNjJiYmU2Mi90YWJsZXJhbmdlOjEzZmU2MzkyODIyOTQzZDBhY2YzYjg3YWY2MmJiZTYyXzktMy0xLTEtNDEyOTQ_d463bdaa-3d64-4931-ab77-7e8d841884fc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December&#160;31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ice6ab2e1895644b3904facb98212b670_I20201231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZToxM2ZlNjM5MjgyMjk0M2QwYWNmM2I4N2FmNjJiYmU2Mi90YWJsZXJhbmdlOjEzZmU2MzkyODIyOTQzZDBhY2YzYjg3YWY2MmJiZTYyXzEwLTEtMS0xLTQ0MjUy_f7f0420f-0bcc-462a-9de4-96b014c8436a">206,202</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ice6ab2e1895644b3904facb98212b670_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZToxM2ZlNjM5MjgyMjk0M2QwYWNmM2I4N2FmNjJiYmU2Mi90YWJsZXJhbmdlOjEzZmU2MzkyODIyOTQzZDBhY2YzYjg3YWY2MmJiZTYyXzEwLTMtMS0xLTQxMjk0_8501bac5-0e88-44e9-a440-e788daf56c62">106.88</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ifcdd30f034184cecb366b0b9b1bd9c55_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZToxM2ZlNjM5MjgyMjk0M2QwYWNmM2I4N2FmNjJiYmU2Mi90YWJsZXJhbmdlOjEzZmU2MzkyODIyOTQzZDBhY2YzYjg3YWY2MmJiZTYyXzExLTEtMS0xLTQxMjk0_fd890faf-df60-4c7b-8068-39bd687cbefa">167,292</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ifcdd30f034184cecb366b0b9b1bd9c55_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZToxM2ZlNjM5MjgyMjk0M2QwYWNmM2I4N2FmNjJiYmU2Mi90YWJsZXJhbmdlOjEzZmU2MzkyODIyOTQzZDBhY2YzYjg3YWY2MmJiZTYyXzExLTMtMS0xLTQxMjk0_e6c998e6-9779-479c-ad56-6efd758f7fab">169.63</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ifcdd30f034184cecb366b0b9b1bd9c55_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZToxM2ZlNjM5MjgyMjk0M2QwYWNmM2I4N2FmNjJiYmU2Mi90YWJsZXJhbmdlOjEzZmU2MzkyODIyOTQzZDBhY2YzYjg3YWY2MmJiZTYyXzEyLTEtMS0xLTQxMjk0_46fdeef3-a373-47b6-884a-bde719b59e8a">98,501</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ifcdd30f034184cecb366b0b9b1bd9c55_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZToxM2ZlNjM5MjgyMjk0M2QwYWNmM2I4N2FmNjJiYmU2Mi90YWJsZXJhbmdlOjEzZmU2MzkyODIyOTQzZDBhY2YzYjg3YWY2MmJiZTYyXzEyLTMtMS0xLTQxMjk0_f89253f3-8855-46b1-b8e0-66549182be3e">125.59</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ifcdd30f034184cecb366b0b9b1bd9c55_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZToxM2ZlNjM5MjgyMjk0M2QwYWNmM2I4N2FmNjJiYmU2Mi90YWJsZXJhbmdlOjEzZmU2MzkyODIyOTQzZDBhY2YzYjg3YWY2MmJiZTYyXzEzLTEtMS0xLTQxMjk0_f696c10d-f0a0-479a-866a-f0a4f3fbfd1f">10,850</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ifcdd30f034184cecb366b0b9b1bd9c55_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZToxM2ZlNjM5MjgyMjk0M2QwYWNmM2I4N2FmNjJiYmU2Mi90YWJsZXJhbmdlOjEzZmU2MzkyODIyOTQzZDBhY2YzYjg3YWY2MmJiZTYyXzEzLTMtMS0xLTQxMjk0_26dc45e4-78a9-4540-8635-d703c8bda000">141.85</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December&#160;31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibc879451c38048cb9a8e8aa28472a4b5_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZToxM2ZlNjM5MjgyMjk0M2QwYWNmM2I4N2FmNjJiYmU2Mi90YWJsZXJhbmdlOjEzZmU2MzkyODIyOTQzZDBhY2YzYjg3YWY2MmJiZTYyXzE0LTEtMS0xLTQ0MjU0_b5392dd4-0a36-4132-89d3-51c5ea10c910">264,143</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ibc879451c38048cb9a8e8aa28472a4b5_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZToxM2ZlNjM5MjgyMjk0M2QwYWNmM2I4N2FmNjJiYmU2Mi90YWJsZXJhbmdlOjEzZmU2MzkyODIyOTQzZDBhY2YzYjg3YWY2MmJiZTYyXzE0LTMtMS0xLTQxMjk0_e406bd58-75db-4c15-94e2-340246f89ced">138.21</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, unrecognized compensation cost related to non-vested stock awards amounted to $<ix:nonFraction unitRef="usd" contextRef="ibc879451c38048cb9a8e8aa28472a4b5_I20211231" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90ZXh0cmVnaW9uOjk1MzhkNjI5YTc4YTQ4ZmY4NmJhMjZmMzlkMjRiMWI5XzE0ODA_b2f92086-621c-44cc-9130-16949e98969f">20.6</ix:nonFraction>&#160;million. That cost is expected to be recognized over a weighted average period of <ix:nonNumeric contextRef="ifcdd30f034184cecb366b0b9b1bd9c55_D20210101-20211231" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90ZXh0cmVnaW9uOjk1MzhkNjI5YTc4YTQ4ZmY4NmJhMjZmMzlkMjRiMWI5XzE1NTc_ef2c532b-4f3a-4106-a489-3194e51fca0a">1.6</ix:nonNumeric> years.</span></div><div style="text-indent:24pt"><span><br/></span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Employee Stock Purchase Plan</span></div><div style="text-indent:24pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, <ix:nonFraction unitRef="shares" contextRef="i22382abe9f7a467bbc034256835a449a_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90ZXh0cmVnaW9uOjk1MzhkNjI5YTc4YTQ4ZmY4NmJhMjZmMzlkMjRiMWI5XzE2MDI_ca7c3880-a776-412f-8501-07cfbdb630be">44,360</ix:nonFraction> shares of our common stock are available for future issuance under the Amended Employee Stock Purchase Plan, or ESPP. The ESPP permits eligible employees to purchase up to <ix:nonFraction unitRef="shares" contextRef="i0776b86882ee4f22a11770402d0e2885_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90ZXh0cmVnaW9uOjk1MzhkNjI5YTc4YTQ4ZmY4NmJhMjZmMzlkMjRiMWI5XzE3Nzc_8184b00a-57c6-40b8-9ea7-5443940c432d">1,250</ix:nonFraction> shares of Ligand common stock per calendar year at a discount through payroll deductions. The price at which stock is purchased under the ESPP is equal to <ix:nonFraction unitRef="number" contextRef="i0776b86882ee4f22a11770402d0e2885_D20210101-20211231" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90ZXh0cmVnaW9uOjk1MzhkNjI5YTc4YTQ4ZmY4NmJhMjZmMzlkMjRiMWI5XzE5MzU_61c76c8a-b8c7-4677-bfbf-e901d0c212b8">85</ix:nonFraction>% of the fair market value of the common stock on the first of a six month offering period or purchase date, whichever is lower. There were <ix:nonFraction unitRef="shares" contextRef="i0776b86882ee4f22a11770402d0e2885_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90ZXh0cmVnaW9uOjk1MzhkNjI5YTc4YTQ4ZmY4NmJhMjZmMzlkMjRiMWI5XzIwNzY_2b20f346-f342-4637-8850-3b648f6eb5b8">8,448</ix:nonFraction>, <ix:nonFraction unitRef="shares" contextRef="i535be16f293842b4b59ed978a4dea350_D20200101-20201231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90ZXh0cmVnaW9uOjk1MzhkNjI5YTc4YTQ4ZmY4NmJhMjZmMzlkMjRiMWI5XzIwODA_547f1936-460d-4a72-a813-c9c54af71e20">6,455</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="ie6271140c911499083fbafdeb97da802_D20190101-20191231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90ZXh0cmVnaW9uOjk1MzhkNjI5YTc4YTQ4ZmY4NmJhMjZmMzlkMjRiMWI5XzIwODc_f2d72be6-bd88-47a0-937d-ca8947cb3911">4,745</ix:nonFraction> shares issued under the ESPP in 2021, 2020 and 2019, respectively. </span></div><div style="text-indent:24pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share Repurchases </span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 11, 2019, our Board of Directors approved a stock repurchase program authorizing the repurchase of up to $<ix:nonFraction unitRef="usd" contextRef="i66cf645fedeb4e3f9127e1557bedf870_I20190911" decimals="INF" name="us-gaap:StockRepurchaseProgramAuthorizedAmount1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90ZXh0cmVnaW9uOjk1MzhkNjI5YTc4YTQ4ZmY4NmJhMjZmMzlkMjRiMWI5XzI4MDg_bc3d0a93-480e-448d-9967-e17426f6836a">500.0</ix:nonFraction> million of our common stock from time to time over the next <ix:nonNumeric contextRef="i4f38082a14de4b7eb626c9119b5258a9_D20190911-20190911" name="us-gaap:StockRepurchaseProgramPeriodInForce1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90ZXh0cmVnaW9uOjk1MzhkNjI5YTc4YTQ4ZmY4NmJhMjZmMzlkMjRiMWI5XzI4NjM_250e5d2a-e2ef-4986-98ec-ec9bb1986c3b">three years</ix:nonNumeric>. We expect to acquire shares primarily through open-market transactions and have entered into a Rule 10b5-1 trading plan, and may enter into additional Rule 10b5-1 trading plans in the future, to facilitate open-market repurchases. The timing and amount of repurchase transactions will be determined by management based on our evaluation of market conditions, share price, legal requirements and other factors. Our prior $<ix:nonFraction unitRef="usd" contextRef="i4cf8373f29714ddb8d2a41d990b0fb42_I20190123" decimals="INF" name="us-gaap:StockRepurchaseProgramAuthorizedAmount1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90ZXh0cmVnaW9uOjk1MzhkNjI5YTc4YTQ4ZmY4NmJhMjZmMzlkMjRiMWI5XzMyODc_40aa2f53-5909-49ac-b514-1a7cd6b014ac">350.0</ix:nonFraction> million stock repurchase program was terminated in connection with the approval of the new stock repurchase program. Authorization to repurchase $<ix:nonFraction unitRef="usd" contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231" decimals="-5" name="us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90ZXh0cmVnaW9uOjk1MzhkNjI5YTc4YTQ4ZmY4NmJhMjZmMzlkMjRiMWI5XzM0NDM_fe145922-dae5-42fe-af64-10bd03b16818">248.8</ix:nonFraction> million of our common stock remained available as of December&#160;31, 2021.</span></div></ix:continuation><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">87</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i90cb430dc51e426a9b2f18107a6628a0">During the twelve months ended December&#160;31, 2021, we did <ix:nonFraction unitRef="usd" contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231" decimals="-5" name="us-gaap:StockRepurchasedDuringPeriodValue" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90ZXh0cmVnaW9uOjk1MzhkNjI5YTc4YTQ4ZmY4NmJhMjZmMzlkMjRiMWI5XzIxOTkwMjMyNTk4MTc_6cdc2055-ec5d-457a-8fac-d12eea400434">no</ix:nonFraction>t repurchase any common stock. During the twelve months ended December&#160;31, 2020 and 2019, we repurchased <ix:nonFraction unitRef="shares" contextRef="ib3597315a63d441f8f128abd7ed8840e_D20200101-20201231" decimals="INF" name="us-gaap:StockRepurchasedDuringPeriodShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90ZXh0cmVnaW9uOjk1MzhkNjI5YTc4YTQ4ZmY4NmJhMjZmMzlkMjRiMWI5XzM1NTg_710283a0-9a41-4679-9c5f-44c1e9bce94f">934,079</ix:nonFraction> shares for $<ix:nonFraction unitRef="usd" contextRef="ib3597315a63d441f8f128abd7ed8840e_D20200101-20201231" decimals="-5" name="us-gaap:StockRepurchasedDuringPeriodValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90ZXh0cmVnaW9uOjk1MzhkNjI5YTc4YTQ4ZmY4NmJhMjZmMzlkMjRiMWI5XzM1NzI_c8569fbc-26e3-4b1a-9c0d-20b32e20589f">78.0</ix:nonFraction> million, and <ix:nonFraction unitRef="shares" contextRef="ie6c3b69702e9429aaeed46bdb9bbb9c1_D20190101-20191231" decimals="INF" name="us-gaap:StockRepurchasedDuringPeriodShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90ZXh0cmVnaW9uOjk1MzhkNjI5YTc4YTQ4ZmY4NmJhMjZmMzlkMjRiMWI5XzM1ODA_f7e382db-b94c-4326-9f61-0dd406488f7c">4,122,133</ix:nonFraction> shares for $<ix:nonFraction unitRef="usd" contextRef="ie6c3b69702e9429aaeed46bdb9bbb9c1_D20190101-20191231" decimals="-5" name="us-gaap:StockRepurchasedDuringPeriodValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90ZXh0cmVnaW9uOjk1MzhkNjI5YTc4YTQ4ZmY4NmJhMjZmMzlkMjRiMWI5XzM1OTQ_b100d521-1327-462a-b0a6-036a2bba5953">448.4</ix:nonFraction> million, respectively.</ix:continuation>  </span></div><div id="i0fa6f906fb2e4e30bc5e873d2bb6a82c_115"></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10.  <ix:nonNumeric contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTUvZnJhZzo1MjlkZGUzNDYzMzY0NTAzODBhMzY5YWM3M2E5YWE0Mi90ZXh0cmVnaW9uOjUyOWRkZTM0NjMzNjQ1MDM4MGEzNjlhYzczYTlhYTQyXzY3OTg_ef8def16-04a4-4bc4-9b16-b55e9cecda56" continuedAt="if2264502b99449cf9ea6dac2ac496ae8" escape="true">Commitment and Contingencies: Legal Proceedings</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="if2264502b99449cf9ea6dac2ac496ae8" continuedAt="i4cfe6c649149463da9cc16ce3774f537"><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record an estimate of a loss when the loss is considered probable and estimable. Where a liability is probable and there is a range of estimated loss and no amount in the range is more likely than any other number in the range, we record the minimum estimated liability related to the claim in accordance with </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASC 450,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Contingencies</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. As additional information becomes available, we assess the potential liability related to our pending litigation and revises our estimates. Revisions in our estimates of potential liability could materially impact our results of operations.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 9, 2019, CyDex, our wholly-owned subsidiary, received a Paragraph IV certification Notice Letter from Alembic Global Holdings SA (&#8220;Alembic&#8221;) stating that Alembic had submitted an ANDA to the FDA, seeking approval to manufacture, offer to sell, and sell a generic version of EVOMELA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> prior to the expiration of any of the &#8217;077 patent; the &#8217;088 patent, the &#8217;582 patent, or U.S. Patent No. 10,040,872 (&#8220;the &#8217;872 patent&#8221;), and alleging that these patents, each of which relates to Captisol, are invalid, unenforceable, and/or would not be infringed by Alembic&#8217;s ANDA product. On May 23, 2019, CyDex filed a complaint against Alembic, Alembic Pharmaceuticals, Ltd., and Alembic Pharmaceuticals, Inc. in the U.S. District Court for the District of Delaware, asserting that the filing of Alembic&#8217;s ANDA constitutes infringement of each of the &#8217;088 patent and the &#8217;582 patent. The parties entered into a settlement agreement on June 1, 2021 and the lawsuit has been dismissed.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 16, 2019, CyDex received a Paragraph IV certification Notice Letter from Lupin Ltd. (&#8220;Lupin&#8221;) stating that Lupin had submitted an ANDA to the FDA, seeking approval to manufacture, offer to sell, and sell a generic version of EVOMELA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> prior to the expiration of any of the &#8217;077 patent; the &#8217;088 patent, the &#8217;582 patent, or the &#8217;872 patent, and alleging that these patents, each of which relates to Captisol, are invalid, unenforceable, and/or would not be infringed by Lupin&#8217;s ANDA product. CyDex filed a complaint on October 29, 2019, alleging patent infringement against Lupin. Lupin filed an answer on December 11, 2019 and counterclaimed for declaratory judgments of invalidity and non-infringement as to all <ix:nonFraction unitRef="patent" contextRef="i93652c87888744bc90a296c0d62c6b8e_D20191029-20191029" decimals="INF" name="us-gaap:GainContingencyPatentsAllegedlyInfringedUponNumber" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTUvZnJhZzo1MjlkZGUzNDYzMzY0NTAzODBhMzY5YWM3M2E5YWE0Mi90ZXh0cmVnaW9uOjUyOWRkZTM0NjMzNjQ1MDM4MGEzNjlhYzczYTlhYTQyXzM4NDgyOTA3MTY4NzM_9d0d6d52-b1e3-45aa-8fb7-4658aa4a42b4">four</ix:nonFraction> patents and CyDex filed its answer to Lupin&#8217;s counterclaims on January 2, 2020. The parties entered into a settlement agreement on April 26, 2021 and the lawsuit has been dismissed.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 31, 2019, we received <ix:nonFraction unitRef="civil_complaint" contextRef="idcb9c868c1be4dc8bc733f81708def2c_D20191031-20191031" decimals="INF" name="us-gaap:LossContingencyNewClaimsFiledNumber" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTUvZnJhZzo1MjlkZGUzNDYzMzY0NTAzODBhMzY5YWM3M2E5YWE0Mi90ZXh0cmVnaW9uOjUyOWRkZTM0NjMzNjQ1MDM4MGEzNjlhYzczYTlhYTQyXzM4NDgyOTA3MTY4NTE_97bf168b-bd04-4b19-92c4-5c31b4c2b1ac">three</ix:nonFraction> civil complaints filed in the U.S. District Court for the Northern District of Ohio on behalf of several Indian tribes. The Northern District of Ohio is the Court that the Judicial Panel on Multi-District Litigation (&#8220;JPML&#8221;) has assigned more than one thousand civil cases which have been designated as a Multi-District Litigation (&#8220;MDL&#8221;) and captioned In Re: National Prescription Opiate Litigation. The allegations in these complaints focus on the activities of defendants other than the company and no individualized factual allegations have been advanced against us in any of the <ix:nonFraction unitRef="civil_complaint" contextRef="idcb9c868c1be4dc8bc733f81708def2c_D20191031-20191031" decimals="INF" name="us-gaap:LossContingencyNewClaimsFiledNumber" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTUvZnJhZzo1MjlkZGUzNDYzMzY0NTAzODBhMzY5YWM3M2E5YWE0Mi90ZXh0cmVnaW9uOjUyOWRkZTM0NjMzNjQ1MDM4MGEzNjlhYzczYTlhYTQyXzM4NDgyOTA3MTY4NjI_11b5ae51-b267-4f92-9929-1fc202cee592">three</ix:nonFraction> complaints. We reject all claims raised in the complaints and intend to vigorously defend these matters.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 12, 2021, Abvivo submitted a JAMS arbitration demand naming the Company as respondent. Abvivo claimed that the Company was in violation of the assignment provision of that certain Commercial Platform License and Services Agreement (&#8220;CPLSA&#8221;), dated October 9, 2019, by and among OMT and Crystal, on the one hand, and Abvivo, on the other hand because the Company allegedly withheld its consent to a proposed assignment required for Abvivo to negotiate a discovery and development alliance with certain third parties. On January 26, 2021, we submitted a response to the demand, denying all claims and alleging counterclaims against Abvivo and Brian Lundstrom, a Company employee and the sole owner of Abvivo. We alleged that Mr. Lundstrom breached his fiduciary duty of loyalty to the Company and that Abvivo and Mr. Lundstrom fraudulently induced the Company, OMT and Crystal into certain business transactions and contracts. Abvivo and Mr. Lundstrom&#8217;s response to these counterclaims was due on February 9, 2021, but they did not submit a response. Under JAMS rules, the counterclaims were deemed denied. On February 22, 2021, Abvivo submitted documents to JAMS which indicated that it sought to dismiss its claim without prejudice. On February 25, 2021, we submitted additional counterclaims against Abvivo and Mr. Lundstrom.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These counterclaims alleged that Abvivo and Mr. Lundstrom made false promises regarding the CPLSA, Abvivo&#8217;s breach of and failure to perform under the CPLSA, and Abvivo&#8217;s infringement of certain Ligand trademarks.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 11, 2021, Abvivo and Mr. Lundstrom submitted an answer to our amended counterclaims denying all of the claims and asserting various affirmative defenses. On June 21, 2021, the parties executed a confidential settlement agreement that settled all claims in this arbitration.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 29, 2021, the parties jointly submitted to JAMS a dismissal with prejudice of all claims by all parties in the arbitration.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CyDex and Baxter Healthcare Corp. (&#8220;Baxter&#8221;) are parties to a license agreement relating to Ligand&#8217;s Captisol</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">technology and, more specifically, relating to Captisol-enabled Nexterone (amiodarone HCl premixed injection). Baxter contends that it has </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">88</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i4cfe6c649149463da9cc16ce3774f537"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">overpaid royalties for several years, and seeks both refunds of those overpayment and a reduced royalty going forward. CyDex contends that Baxter has not paid the royalties due to CyDex under the terms of the license agreement. On April 6, 2021, Baxter initiated an arbitration with the American Arbitration Association pursuant to the arbitration provision of the license agreement. On April 21, 2021, CyDex filed an Answering Statement and Counterdemand. On May 5, 2021, Baxter filed an Answering Statement in response to CyDex&#8217;s Counterdemand. On June 30, 2021, the parties held a Preliminary Hearing before the arbitrator. The parties have completed fact discovery and have exchanged expert witness statements; depositions of the expert witnesses will be completed by the end of March 2022. The arbitration hearing is currently scheduled for May 2022.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we may also become subject to other legal proceedings or claims arising in the ordinary course of our business. We currently believe that none of the claims or actions pending against us is likely to have, individually or in the aggregate, a material adverse effect on our business, financial condition or results of operations. Given the unpredictability inherent in litigation, however, we cannot predict the outcome of these matters.</span></div></ix:continuation><div id="i0fa6f906fb2e4e30bc5e873d2bb6a82c_118"></div><div style="margin-top:14pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">11. <ix:nonNumeric contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTgvZnJhZzphNDZjN2FlZGZkZjU0ZGY3YmYzZmFlNmNlNDFjZGNlNy90ZXh0cmVnaW9uOmE0NmM3YWVkZmRmNTRkZjdiZjNmYWU2Y2U0MWNkY2U3XzUyNzM_174a3899-41b7-4921-b49f-e6b856ccd83e" continuedAt="i0bfd3300d57840c1ab6882be1ab89e0a" escape="true">Income Taxes</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="i0bfd3300d57840c1ab6882be1ab89e0a" continuedAt="ia2cbe0b7b6f94658a549da6639b9aa8c"><div><ix:nonNumeric contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTgvZnJhZzphNDZjN2FlZGZkZjU0ZGY3YmYzZmFlNmNlNDFjZGNlNy90ZXh0cmVnaW9uOmE0NmM3YWVkZmRmNTRkZjdiZjNmYWU2Y2U0MWNkY2U3XzUyNzg_1f77636c-cfa1-4bf2-af62-2091eb2927c9" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of the income tax expense (benefit) for continuing operations are as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:66.403%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.092%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.833%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.092%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.686%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.094%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current expense (benefit):</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:CurrentFederalTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTgvZnJhZzphNDZjN2FlZGZkZjU0ZGY3YmYzZmFlNmNlNDFjZGNlNy90YWJsZTpmZDUyYmM5YzRhZGY0ZmU1YWE1MDg4MzM3ZjIyZjc3YS90YWJsZXJhbmdlOmZkNTJiYzljNGFkZjRmZTVhYTUwODgzMzdmMjJmNzdhXzMtMS0xLTEtNDEyOTQ_cdb6710f-f6d7-4230-902b-7a1d6a06e4c8">1,190</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3597315a63d441f8f128abd7ed8840e_D20200101-20201231" decimals="-3" name="us-gaap:CurrentFederalTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTgvZnJhZzphNDZjN2FlZGZkZjU0ZGY3YmYzZmFlNmNlNDFjZGNlNy90YWJsZTpmZDUyYmM5YzRhZGY0ZmU1YWE1MDg4MzM3ZjIyZjc3YS90YWJsZXJhbmdlOmZkNTJiYzljNGFkZjRmZTVhYTUwODgzMzdmMjJmNzdhXzMtMy0xLTEtNDEyOTQ_b0cc2780-0568-4f3c-b923-a55514f10854">10,889</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6c3b69702e9429aaeed46bdb9bbb9c1_D20190101-20191231" decimals="-3" name="us-gaap:CurrentFederalTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTgvZnJhZzphNDZjN2FlZGZkZjU0ZGY3YmYzZmFlNmNlNDFjZGNlNy90YWJsZTpmZDUyYmM5YzRhZGY0ZmU1YWE1MDg4MzM3ZjIyZjc3YS90YWJsZXJhbmdlOmZkNTJiYzljNGFkZjRmZTVhYTUwODgzMzdmMjJmNzdhXzMtNS0xLTEtNDEyOTQ_da6a7863-fcd3-484a-b510-c4b93a2382e3">89,471</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTgvZnJhZzphNDZjN2FlZGZkZjU0ZGY3YmYzZmFlNmNlNDFjZGNlNy90YWJsZTpmZDUyYmM5YzRhZGY0ZmU1YWE1MDg4MzM3ZjIyZjc3YS90YWJsZXJhbmdlOmZkNTJiYzljNGFkZjRmZTVhYTUwODgzMzdmMjJmNzdhXzQtMS0xLTEtNDEyOTQ_9cde9c60-877a-4c3a-8257-8600d4f13d55">32</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3597315a63d441f8f128abd7ed8840e_D20200101-20201231" decimals="-3" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTgvZnJhZzphNDZjN2FlZGZkZjU0ZGY3YmYzZmFlNmNlNDFjZGNlNy90YWJsZTpmZDUyYmM5YzRhZGY0ZmU1YWE1MDg4MzM3ZjIyZjc3YS90YWJsZXJhbmdlOmZkNTJiYzljNGFkZjRmZTVhYTUwODgzMzdmMjJmNzdhXzQtMy0xLTEtNDEyOTQ_a63f8bde-c09e-4822-8e37-78e2e609892c">589</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6c3b69702e9429aaeed46bdb9bbb9c1_D20190101-20191231" decimals="-3" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTgvZnJhZzphNDZjN2FlZGZkZjU0ZGY3YmYzZmFlNmNlNDFjZGNlNy90YWJsZTpmZDUyYmM5YzRhZGY0ZmU1YWE1MDg4MzM3ZjIyZjc3YS90YWJsZXJhbmdlOmZkNTJiYzljNGFkZjRmZTVhYTUwODgzMzdmMjJmNzdhXzQtNS0xLTEtNDEyOTQ_0c553981-52a9-4967-bea4-bf99a4007215">3,103</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231" decimals="-3" name="us-gaap:CurrentForeignTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTgvZnJhZzphNDZjN2FlZGZkZjU0ZGY3YmYzZmFlNmNlNDFjZGNlNy90YWJsZTpmZDUyYmM5YzRhZGY0ZmU1YWE1MDg4MzM3ZjIyZjc3YS90YWJsZXJhbmdlOmZkNTJiYzljNGFkZjRmZTVhYTUwODgzMzdmMjJmNzdhXzUtMS0xLTEtNDEyOTQ_314aeb8a-a9d5-48ed-b5b8-ac0e285928fd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3597315a63d441f8f128abd7ed8840e_D20200101-20201231" decimals="-3" name="us-gaap:CurrentForeignTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTgvZnJhZzphNDZjN2FlZGZkZjU0ZGY3YmYzZmFlNmNlNDFjZGNlNy90YWJsZTpmZDUyYmM5YzRhZGY0ZmU1YWE1MDg4MzM3ZjIyZjc3YS90YWJsZXJhbmdlOmZkNTJiYzljNGFkZjRmZTVhYTUwODgzMzdmMjJmNzdhXzUtMy0xLTEtNDEyOTQ_db0da602-5e7a-4b6e-aadb-9a885fd9e71a">23</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie6c3b69702e9429aaeed46bdb9bbb9c1_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:CurrentForeignTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTgvZnJhZzphNDZjN2FlZGZkZjU0ZGY3YmYzZmFlNmNlNDFjZGNlNy90YWJsZTpmZDUyYmM5YzRhZGY0ZmU1YWE1MDg4MzM3ZjIyZjc3YS90YWJsZXJhbmdlOmZkNTJiYzljNGFkZjRmZTVhYTUwODgzMzdmMjJmNzdhXzUtNS0xLTEtNDEyOTQ_6301f3b1-c0bb-44c7-b438-2c753764d9f3">66</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:CurrentIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTgvZnJhZzphNDZjN2FlZGZkZjU0ZGY3YmYzZmFlNmNlNDFjZGNlNy90YWJsZTpmZDUyYmM5YzRhZGY0ZmU1YWE1MDg4MzM3ZjIyZjc3YS90YWJsZXJhbmdlOmZkNTJiYzljNGFkZjRmZTVhYTUwODgzMzdmMjJmNzdhXzYtMS0xLTEtNDEyOTQ_2ab81707-8378-47a6-acf9-b094d4fbe472">1,222</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3597315a63d441f8f128abd7ed8840e_D20200101-20201231" decimals="-3" name="us-gaap:CurrentIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTgvZnJhZzphNDZjN2FlZGZkZjU0ZGY3YmYzZmFlNmNlNDFjZGNlNy90YWJsZTpmZDUyYmM5YzRhZGY0ZmU1YWE1MDg4MzM3ZjIyZjc3YS90YWJsZXJhbmdlOmZkNTJiYzljNGFkZjRmZTVhYTUwODgzMzdmMjJmNzdhXzYtMy0xLTEtNDEyOTQ_7afa51a0-6231-46d0-b9b8-9f2260e217a5">11,501</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6c3b69702e9429aaeed46bdb9bbb9c1_D20190101-20191231" decimals="-3" name="us-gaap:CurrentIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTgvZnJhZzphNDZjN2FlZGZkZjU0ZGY3YmYzZmFlNmNlNDFjZGNlNy90YWJsZTpmZDUyYmM5YzRhZGY0ZmU1YWE1MDg4MzM3ZjIyZjc3YS90YWJsZXJhbmdlOmZkNTJiYzljNGFkZjRmZTVhYTUwODgzMzdmMjJmNzdhXzYtNS0xLTEtNDEyOTQ_ce962fb9-3885-4e9f-9cbe-55dcc442aa19">92,508</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred expense (benefit):</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTgvZnJhZzphNDZjN2FlZGZkZjU0ZGY3YmYzZmFlNmNlNDFjZGNlNy90YWJsZTpmZDUyYmM5YzRhZGY0ZmU1YWE1MDg4MzM3ZjIyZjc3YS90YWJsZXJhbmdlOmZkNTJiYzljNGFkZjRmZTVhYTUwODgzMzdmMjJmNzdhXzgtMS0xLTEtNDEyOTQ_04b3a83e-1e07-43e5-a1df-37c8ee672947">7,355</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib3597315a63d441f8f128abd7ed8840e_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTgvZnJhZzphNDZjN2FlZGZkZjU0ZGY3YmYzZmFlNmNlNDFjZGNlNy90YWJsZTpmZDUyYmM5YzRhZGY0ZmU1YWE1MDg4MzM3ZjIyZjc3YS90YWJsZXJhbmdlOmZkNTJiYzljNGFkZjRmZTVhYTUwODgzMzdmMjJmNzdhXzgtMy0xLTEtNDEyOTQ_3ef5de03-1413-4306-a532-89a629cecfcf">15,672</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6c3b69702e9429aaeed46bdb9bbb9c1_D20190101-20191231" decimals="-3" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTgvZnJhZzphNDZjN2FlZGZkZjU0ZGY3YmYzZmFlNmNlNDFjZGNlNy90YWJsZTpmZDUyYmM5YzRhZGY0ZmU1YWE1MDg4MzM3ZjIyZjc3YS90YWJsZXJhbmdlOmZkNTJiYzljNGFkZjRmZTVhYTUwODgzMzdmMjJmNzdhXzgtNS0xLTEtNDEyOTQ_a39d880a-5908-44d8-86b7-8ae7eb58b150">74,627</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTgvZnJhZzphNDZjN2FlZGZkZjU0ZGY3YmYzZmFlNmNlNDFjZGNlNy90YWJsZTpmZDUyYmM5YzRhZGY0ZmU1YWE1MDg4MzM3ZjIyZjc3YS90YWJsZXJhbmdlOmZkNTJiYzljNGFkZjRmZTVhYTUwODgzMzdmMjJmNzdhXzktMS0xLTEtNDEyOTQ_64840095-3f51-4261-9da3-e11a607ac74f">1,263</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib3597315a63d441f8f128abd7ed8840e_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTgvZnJhZzphNDZjN2FlZGZkZjU0ZGY3YmYzZmFlNmNlNDFjZGNlNy90YWJsZTpmZDUyYmM5YzRhZGY0ZmU1YWE1MDg4MzM3ZjIyZjc3YS90YWJsZXJhbmdlOmZkNTJiYzljNGFkZjRmZTVhYTUwODgzMzdmMjJmNzdhXzktMy0xLTEtNDEyOTQ_59d3d4bf-ecde-47b4-8f50-a4821e3bdd4f">3,382</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6c3b69702e9429aaeed46bdb9bbb9c1_D20190101-20191231" decimals="-3" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTgvZnJhZzphNDZjN2FlZGZkZjU0ZGY3YmYzZmFlNmNlNDFjZGNlNy90YWJsZTpmZDUyYmM5YzRhZGY0ZmU1YWE1MDg4MzM3ZjIyZjc3YS90YWJsZXJhbmdlOmZkNTJiYzljNGFkZjRmZTVhYTUwODgzMzdmMjJmNzdhXzktNS0xLTEtNDEyOTQ_b3a6eb38-4d84-48d9-ab21-3d7a4ec2f9a1">202</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTgvZnJhZzphNDZjN2FlZGZkZjU0ZGY3YmYzZmFlNmNlNDFjZGNlNy90YWJsZTpmZDUyYmM5YzRhZGY0ZmU1YWE1MDg4MzM3ZjIyZjc3YS90YWJsZXJhbmdlOmZkNTJiYzljNGFkZjRmZTVhYTUwODgzMzdmMjJmNzdhXzEwLTEtMS0xLTU4MDg1_2fd21a5f-b2f4-4884-8e61-b3b5c2b40f30">8,618</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib3597315a63d441f8f128abd7ed8840e_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTgvZnJhZzphNDZjN2FlZGZkZjU0ZGY3YmYzZmFlNmNlNDFjZGNlNy90YWJsZTpmZDUyYmM5YzRhZGY0ZmU1YWE1MDg4MzM3ZjIyZjc3YS90YWJsZXJhbmdlOmZkNTJiYzljNGFkZjRmZTVhYTUwODgzMzdmMjJmNzdhXzEwLTMtMS0xLTU4MDg1_8f8ca5e0-e8b2-4f5f-93d4-f62acfea7b6e">19,054</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6c3b69702e9429aaeed46bdb9bbb9c1_D20190101-20191231" decimals="-3" name="us-gaap:DeferredIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTgvZnJhZzphNDZjN2FlZGZkZjU0ZGY3YmYzZmFlNmNlNDFjZGNlNy90YWJsZTpmZDUyYmM5YzRhZGY0ZmU1YWE1MDg4MzM3ZjIyZjc3YS90YWJsZXJhbmdlOmZkNTJiYzljNGFkZjRmZTVhYTUwODgzMzdmMjJmNzdhXzEwLTUtMS0xLTU4MDg1_072ed68f-c915-42b5-af26-e58e1b8c18f4">74,829</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total income tax expense (benefit)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTgvZnJhZzphNDZjN2FlZGZkZjU0ZGY3YmYzZmFlNmNlNDFjZGNlNy90YWJsZTpmZDUyYmM5YzRhZGY0ZmU1YWE1MDg4MzM3ZjIyZjc3YS90YWJsZXJhbmdlOmZkNTJiYzljNGFkZjRmZTVhYTUwODgzMzdmMjJmNzdhXzEwLTEtMS0xLTQxMjk0_a911ede9-fec3-4c8b-a8bd-17069cc34500">9,840</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib3597315a63d441f8f128abd7ed8840e_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTgvZnJhZzphNDZjN2FlZGZkZjU0ZGY3YmYzZmFlNmNlNDFjZGNlNy90YWJsZTpmZDUyYmM5YzRhZGY0ZmU1YWE1MDg4MzM3ZjIyZjc3YS90YWJsZXJhbmdlOmZkNTJiYzljNGFkZjRmZTVhYTUwODgzMzdmMjJmNzdhXzEwLTMtMS0xLTQxMjk0_b6bff959-e178-4c7a-8712-a99f1a835600">7,553</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6c3b69702e9429aaeed46bdb9bbb9c1_D20190101-20191231" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTgvZnJhZzphNDZjN2FlZGZkZjU0ZGY3YmYzZmFlNmNlNDFjZGNlNy90YWJsZTpmZDUyYmM5YzRhZGY0ZmU1YWE1MDg4MzM3ZjIyZjc3YS90YWJsZXJhbmdlOmZkNTJiYzljNGFkZjRmZTVhYTUwODgzMzdmMjJmNzdhXzEwLTUtMS0xLTQxMjk0_a7e8ed15-18d2-40a6-bda9-b51a5fea967b">167,337</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div style="text-indent:24pt"><span><br/></span></div><ix:nonNumeric contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTgvZnJhZzphNDZjN2FlZGZkZjU0ZGY3YmYzZmFlNmNlNDFjZGNlNy90ZXh0cmVnaW9uOmE0NmM3YWVkZmRmNTRkZjdiZjNmYWU2Y2U0MWNkY2U3XzUyNzk_1e33aca3-3439-4257-b53d-6de19575c2c5" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of income tax expense (benefit) from continuing operations to the amount computed by applying the statutory federal income tax rate to the net income (loss) from continuing operations is summarized as follows (in thousands):</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:66.841%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.047%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.047%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.682%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.048%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax at federal statutory rate</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231" decimals="-3" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTgvZnJhZzphNDZjN2FlZGZkZjU0ZGY3YmYzZmFlNmNlNDFjZGNlNy90YWJsZToyNGIxMGZmMTc3YmE0ZDRlOTM1MGU3NGUwMmRiYjBlNi90YWJsZXJhbmdlOjI0YjEwZmYxNzdiYTRkNGU5MzUwZTc0ZTAyZGJiMGU2XzItMS0xLTEtNDEyOTQ_b95c3814-2dba-405b-bbbf-ebfd6a091330">9,932</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib3597315a63d441f8f128abd7ed8840e_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTgvZnJhZzphNDZjN2FlZGZkZjU0ZGY3YmYzZmFlNmNlNDFjZGNlNy90YWJsZToyNGIxMGZmMTc3YmE0ZDRlOTM1MGU3NGUwMmRiYjBlNi90YWJsZXJhbmdlOjI0YjEwZmYxNzdiYTRkNGU5MzUwZTc0ZTAyZGJiMGU2XzItMy0xLTEtNDEyOTQ_5770b6c0-ab5e-4447-b864-2e42be65d4a8">2,213</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6c3b69702e9429aaeed46bdb9bbb9c1_D20190101-20191231" decimals="-3" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTgvZnJhZzphNDZjN2FlZGZkZjU0ZGY3YmYzZmFlNmNlNDFjZGNlNy90YWJsZToyNGIxMGZmMTc3YmE0ZDRlOTM1MGU3NGUwMmRiYjBlNi90YWJsZXJhbmdlOjI0YjEwZmYxNzdiYTRkNGU5MzUwZTc0ZTAyZGJiMGU2XzItNS0xLTEtNDEyOTQ_2c3345ce-b95e-4ebe-8adc-6797b3848f25">167,294</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State, net of federal benefit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTgvZnJhZzphNDZjN2FlZGZkZjU0ZGY3YmYzZmFlNmNlNDFjZGNlNy90YWJsZToyNGIxMGZmMTc3YmE0ZDRlOTM1MGU3NGUwMmRiYjBlNi90YWJsZXJhbmdlOjI0YjEwZmYxNzdiYTRkNGU5MzUwZTc0ZTAyZGJiMGU2XzMtMS0xLTEtNDEyOTQ_b327b89c-7c99-4265-82ed-929a6ef90f1e">408</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib3597315a63d441f8f128abd7ed8840e_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTgvZnJhZzphNDZjN2FlZGZkZjU0ZGY3YmYzZmFlNmNlNDFjZGNlNy90YWJsZToyNGIxMGZmMTc3YmE0ZDRlOTM1MGU3NGUwMmRiYjBlNi90YWJsZXJhbmdlOjI0YjEwZmYxNzdiYTRkNGU5MzUwZTc0ZTAyZGJiMGU2XzMtMy0xLTEtNDEyOTQ_75f543d6-5a8b-4aae-a2e3-d2f22abbec3d">1,456</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6c3b69702e9429aaeed46bdb9bbb9c1_D20190101-20191231" decimals="-3" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTgvZnJhZzphNDZjN2FlZGZkZjU0ZGY3YmYzZmFlNmNlNDFjZGNlNy90YWJsZToyNGIxMGZmMTc3YmE0ZDRlOTM1MGU3NGUwMmRiYjBlNi90YWJsZXJhbmdlOjI0YjEwZmYxNzdiYTRkNGU5MzUwZTc0ZTAyZGJiMGU2XzMtNS0xLTEtNDEyOTQ_6c0a7284-9f7c-4b4a-b1a7-b6e08f91178c">2,466</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231" decimals="-3" sign="-" name="lgnd:IncomeTaxReconciliationContingentValueRights" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTgvZnJhZzphNDZjN2FlZGZkZjU0ZGY3YmYzZmFlNmNlNDFjZGNlNy90YWJsZToyNGIxMGZmMTc3YmE0ZDRlOTM1MGU3NGUwMmRiYjBlNi90YWJsZXJhbmdlOjI0YjEwZmYxNzdiYTRkNGU5MzUwZTc0ZTAyZGJiMGU2XzQtMS0xLTEtNDEyOTQ_c4800103-c6db-4c05-a80b-128348bcbdc1">8,161</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib3597315a63d441f8f128abd7ed8840e_D20200101-20201231" decimals="-3" sign="-" name="lgnd:IncomeTaxReconciliationContingentValueRights" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTgvZnJhZzphNDZjN2FlZGZkZjU0ZGY3YmYzZmFlNmNlNDFjZGNlNy90YWJsZToyNGIxMGZmMTc3YmE0ZDRlOTM1MGU3NGUwMmRiYjBlNi90YWJsZXJhbmdlOjI0YjEwZmYxNzdiYTRkNGU5MzUwZTc0ZTAyZGJiMGU2XzQtMy0xLTEtNDEyOTQ_c87ebb66-3096-48d2-8058-925370404fcc">278</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6c3b69702e9429aaeed46bdb9bbb9c1_D20190101-20191231" decimals="-3" name="lgnd:IncomeTaxReconciliationContingentValueRights" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTgvZnJhZzphNDZjN2FlZGZkZjU0ZGY3YmYzZmFlNmNlNDFjZGNlNy90YWJsZToyNGIxMGZmMTc3YmE0ZDRlOTM1MGU3NGUwMmRiYjBlNi90YWJsZXJhbmdlOjI0YjEwZmYxNzdiYTRkNGU5MzUwZTc0ZTAyZGJiMGU2XzQtNS0xLTEtNDEyOTQ_6005dace-06a8-4dfe-bc1f-73be59a2386b">18</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTgvZnJhZzphNDZjN2FlZGZkZjU0ZGY3YmYzZmFlNmNlNDFjZGNlNy90YWJsZToyNGIxMGZmMTc3YmE0ZDRlOTM1MGU3NGUwMmRiYjBlNi90YWJsZXJhbmdlOjI0YjEwZmYxNzdiYTRkNGU5MzUwZTc0ZTAyZGJiMGU2XzUtMS0xLTEtNDEyOTQ_f4251b21-18c9-4c89-b05c-87bfc5b67b79">11,919</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib3597315a63d441f8f128abd7ed8840e_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTgvZnJhZzphNDZjN2FlZGZkZjU0ZGY3YmYzZmFlNmNlNDFjZGNlNy90YWJsZToyNGIxMGZmMTc3YmE0ZDRlOTM1MGU3NGUwMmRiYjBlNi90YWJsZXJhbmdlOjI0YjEwZmYxNzdiYTRkNGU5MzUwZTc0ZTAyZGJiMGU2XzUtMy0xLTEtNDEyOTQ_68f97ef6-aef6-40c1-b98d-1d4ff7875323">362</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie6c3b69702e9429aaeed46bdb9bbb9c1_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTgvZnJhZzphNDZjN2FlZGZkZjU0ZGY3YmYzZmFlNmNlNDFjZGNlNy90YWJsZToyNGIxMGZmMTc3YmE0ZDRlOTM1MGU3NGUwMmRiYjBlNi90YWJsZXJhbmdlOjI0YjEwZmYxNzdiYTRkNGU5MzUwZTc0ZTAyZGJiMGU2XzUtNS0xLTEtNDEyOTQ_1509564f-fef2-4951-adb7-179eb0a528c3">819</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">FDII</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231" decimals="-3" name="lgnd:EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomeAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTgvZnJhZzphNDZjN2FlZGZkZjU0ZGY3YmYzZmFlNmNlNDFjZGNlNy90YWJsZToyNGIxMGZmMTc3YmE0ZDRlOTM1MGU3NGUwMmRiYjBlNi90YWJsZXJhbmdlOjI0YjEwZmYxNzdiYTRkNGU5MzUwZTc0ZTAyZGJiMGU2XzYtMS0xLTEtNDEyOTQ_dd72b6cc-ee8a-41a9-a50d-80182737806e">637</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib3597315a63d441f8f128abd7ed8840e_D20200101-20201231" decimals="-3" name="lgnd:EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomeAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTgvZnJhZzphNDZjN2FlZGZkZjU0ZGY3YmYzZmFlNmNlNDFjZGNlNy90YWJsZToyNGIxMGZmMTc3YmE0ZDRlOTM1MGU3NGUwMmRiYjBlNi90YWJsZXJhbmdlOjI0YjEwZmYxNzdiYTRkNGU5MzUwZTc0ZTAyZGJiMGU2XzYtMy0xLTEtNDEyOTQ_3d9d156a-ca70-4ad7-8456-a389e43e30f0">1,652</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie6c3b69702e9429aaeed46bdb9bbb9c1_D20190101-20191231" decimals="-3" name="lgnd:EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomeAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTgvZnJhZzphNDZjN2FlZGZkZjU0ZGY3YmYzZmFlNmNlNDFjZGNlNy90YWJsZToyNGIxMGZmMTc3YmE0ZDRlOTM1MGU3NGUwMmRiYjBlNi90YWJsZXJhbmdlOjI0YjEwZmYxNzdiYTRkNGU5MzUwZTc0ZTAyZGJiMGU2XzYtNS0xLTEtNDEyOTQ_84727ea7-30c6-4df6-a0ee-25378162af82">402</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231" decimals="-3" sign="-" name="lgnd:EffectiveIncomeTaxRateReconciliationExpiredTaxCreditsResearch" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTgvZnJhZzphNDZjN2FlZGZkZjU0ZGY3YmYzZmFlNmNlNDFjZGNlNy90YWJsZToyNGIxMGZmMTc3YmE0ZDRlOTM1MGU3NGUwMmRiYjBlNi90YWJsZXJhbmdlOjI0YjEwZmYxNzdiYTRkNGU5MzUwZTc0ZTAyZGJiMGU2XzctMS0xLTEtNDEyOTQ_c2de86b8-7c96-49a7-b54e-456749550674">2,692</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib3597315a63d441f8f128abd7ed8840e_D20200101-20201231" decimals="-3" sign="-" name="lgnd:EffectiveIncomeTaxRateReconciliationExpiredTaxCreditsResearch" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTgvZnJhZzphNDZjN2FlZGZkZjU0ZGY3YmYzZmFlNmNlNDFjZGNlNy90YWJsZToyNGIxMGZmMTc3YmE0ZDRlOTM1MGU3NGUwMmRiYjBlNi90YWJsZXJhbmdlOjI0YjEwZmYxNzdiYTRkNGU5MzUwZTc0ZTAyZGJiMGU2XzctMy0xLTEtNDEyOTQ_d3f56378-4534-47d8-a64b-4fad29895cdf">699</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie6c3b69702e9429aaeed46bdb9bbb9c1_D20190101-20191231" decimals="-3" sign="-" name="lgnd:EffectiveIncomeTaxRateReconciliationExpiredTaxCreditsResearch" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTgvZnJhZzphNDZjN2FlZGZkZjU0ZGY3YmYzZmFlNmNlNDFjZGNlNy90YWJsZToyNGIxMGZmMTc3YmE0ZDRlOTM1MGU3NGUwMmRiYjBlNi90YWJsZXJhbmdlOjI0YjEwZmYxNzdiYTRkNGU5MzUwZTc0ZTAyZGJiMGU2XzctNS0xLTEtNDEyOTQ_798c43fe-0c4a-4e07-adab-9c2a7cdc225b">879</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in uncertain tax positions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231" decimals="-3" sign="-" name="lgnd:EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTgvZnJhZzphNDZjN2FlZGZkZjU0ZGY3YmYzZmFlNmNlNDFjZGNlNy90YWJsZToyNGIxMGZmMTc3YmE0ZDRlOTM1MGU3NGUwMmRiYjBlNi90YWJsZXJhbmdlOjI0YjEwZmYxNzdiYTRkNGU5MzUwZTc0ZTAyZGJiMGU2XzgtMS0xLTEtNDEyOTQ_12b451bf-7031-4c27-bbd1-de22d66d9bae">586</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib3597315a63d441f8f128abd7ed8840e_D20200101-20201231" decimals="-3" name="lgnd:EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTgvZnJhZzphNDZjN2FlZGZkZjU0ZGY3YmYzZmFlNmNlNDFjZGNlNy90YWJsZToyNGIxMGZmMTc3YmE0ZDRlOTM1MGU3NGUwMmRiYjBlNi90YWJsZXJhbmdlOjI0YjEwZmYxNzdiYTRkNGU5MzUwZTc0ZTAyZGJiMGU2XzgtMy0xLTEtNDEyOTQ_81f953e6-1827-482b-9a07-255c5e46a6ab">650</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6c3b69702e9429aaeed46bdb9bbb9c1_D20190101-20191231" decimals="-3" sign="-" name="lgnd:EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTgvZnJhZzphNDZjN2FlZGZkZjU0ZGY3YmYzZmFlNmNlNDFjZGNlNy90YWJsZToyNGIxMGZmMTc3YmE0ZDRlOTM1MGU3NGUwMmRiYjBlNi90YWJsZXJhbmdlOjI0YjEwZmYxNzdiYTRkNGU5MzUwZTc0ZTAyZGJiMGU2XzgtNS0xLTEtNDEyOTQ_ab17493e-6d68-4d18-8434-9651ae1394bf">441</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rate change for changes in federal, foreign or state law</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTgvZnJhZzphNDZjN2FlZGZkZjU0ZGY3YmYzZmFlNmNlNDFjZGNlNy90YWJsZToyNGIxMGZmMTc3YmE0ZDRlOTM1MGU3NGUwMmRiYjBlNi90YWJsZXJhbmdlOjI0YjEwZmYxNzdiYTRkNGU5MzUwZTc0ZTAyZGJiMGU2XzktMS0xLTEtNDEyOTQ_e35ed29b-16a3-4480-919d-a9ee25750537">7,963</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib3597315a63d441f8f128abd7ed8840e_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTgvZnJhZzphNDZjN2FlZGZkZjU0ZGY3YmYzZmFlNmNlNDFjZGNlNy90YWJsZToyNGIxMGZmMTc3YmE0ZDRlOTM1MGU3NGUwMmRiYjBlNi90YWJsZXJhbmdlOjI0YjEwZmYxNzdiYTRkNGU5MzUwZTc0ZTAyZGJiMGU2XzktMy0xLTEtNDEyOTQ_f4a289be-d502-4464-b675-783199f8dd21">173</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie6c3b69702e9429aaeed46bdb9bbb9c1_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTgvZnJhZzphNDZjN2FlZGZkZjU0ZGY3YmYzZmFlNmNlNDFjZGNlNy90YWJsZToyNGIxMGZmMTc3YmE0ZDRlOTM1MGU3NGUwMmRiYjBlNi90YWJsZXJhbmdlOjI0YjEwZmYxNzdiYTRkNGU5MzUwZTc0ZTAyZGJiMGU2XzktNS0xLTEtNDEyOTQ_45e839fb-78dd-49e6-bda7-92fdba2a0273">210</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision to return adjustments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231" decimals="-3" name="lgnd:EffectiveIncomeTaxRateReconciliationProvisionToReturnAdjustmentsAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTgvZnJhZzphNDZjN2FlZGZkZjU0ZGY3YmYzZmFlNmNlNDFjZGNlNy90YWJsZToyNGIxMGZmMTc3YmE0ZDRlOTM1MGU3NGUwMmRiYjBlNi90YWJsZXJhbmdlOjI0YjEwZmYxNzdiYTRkNGU5MzUwZTc0ZTAyZGJiMGU2XzEwLTEtMS0xLTQxMjk0_087dd8c8-f34a-445e-aeac-99738a746a6c">617</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib3597315a63d441f8f128abd7ed8840e_D20200101-20201231" decimals="-3" name="lgnd:EffectiveIncomeTaxRateReconciliationProvisionToReturnAdjustmentsAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTgvZnJhZzphNDZjN2FlZGZkZjU0ZGY3YmYzZmFlNmNlNDFjZGNlNy90YWJsZToyNGIxMGZmMTc3YmE0ZDRlOTM1MGU3NGUwMmRiYjBlNi90YWJsZXJhbmdlOjI0YjEwZmYxNzdiYTRkNGU5MzUwZTc0ZTAyZGJiMGU2XzEwLTMtMS0xLTQxMjk0_8518da68-0250-4432-a1ba-27c604fcdb5a">4,803</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie6c3b69702e9429aaeed46bdb9bbb9c1_D20190101-20191231" decimals="-3" name="lgnd:EffectiveIncomeTaxRateReconciliationProvisionToReturnAdjustmentsAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTgvZnJhZzphNDZjN2FlZGZkZjU0ZGY3YmYzZmFlNmNlNDFjZGNlNy90YWJsZToyNGIxMGZmMTc3YmE0ZDRlOTM1MGU3NGUwMmRiYjBlNi90YWJsZXJhbmdlOjI0YjEwZmYxNzdiYTRkNGU5MzUwZTc0ZTAyZGJiMGU2XzEwLTUtMS0xLTQxMjk0_1e6a3537-7842-4d54-9c82-3642ba4c2e55">184</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign tax differential on income/loss of foreign subsidiaries</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTgvZnJhZzphNDZjN2FlZGZkZjU0ZGY3YmYzZmFlNmNlNDFjZGNlNy90YWJsZToyNGIxMGZmMTc3YmE0ZDRlOTM1MGU3NGUwMmRiYjBlNi90YWJsZXJhbmdlOjI0YjEwZmYxNzdiYTRkNGU5MzUwZTc0ZTAyZGJiMGU2XzExLTEtMS0xLTQxMjk0_ffb81df4-adf8-42a2-beab-20a1df018ea3">114</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib3597315a63d441f8f128abd7ed8840e_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTgvZnJhZzphNDZjN2FlZGZkZjU0ZGY3YmYzZmFlNmNlNDFjZGNlNy90YWJsZToyNGIxMGZmMTc3YmE0ZDRlOTM1MGU3NGUwMmRiYjBlNi90YWJsZXJhbmdlOjI0YjEwZmYxNzdiYTRkNGU5MzUwZTc0ZTAyZGJiMGU2XzExLTMtMS0xLTQxMjk0_5d32a482-1314-41cb-93bb-4d59b78428cb">3,839</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6c3b69702e9429aaeed46bdb9bbb9c1_D20190101-20191231" decimals="-3" name="us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTgvZnJhZzphNDZjN2FlZGZkZjU0ZGY3YmYzZmFlNmNlNDFjZGNlNy90YWJsZToyNGIxMGZmMTc3YmE0ZDRlOTM1MGU3NGUwMmRiYjBlNi90YWJsZXJhbmdlOjI0YjEwZmYxNzdiYTRkNGU5MzUwZTc0ZTAyZGJiMGU2XzExLTUtMS0xLTQxMjk0_98c8d2c0-9248-49ab-9052-63b3020199ed">57</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231" decimals="-3" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTgvZnJhZzphNDZjN2FlZGZkZjU0ZGY3YmYzZmFlNmNlNDFjZGNlNy90YWJsZToyNGIxMGZmMTc3YmE0ZDRlOTM1MGU3NGUwMmRiYjBlNi90YWJsZXJhbmdlOjI0YjEwZmYxNzdiYTRkNGU5MzUwZTc0ZTAyZGJiMGU2XzEyLTEtMS0xLTQxMjk0_74021590-2fea-442c-914c-1437142b6add">11,410</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib3597315a63d441f8f128abd7ed8840e_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTgvZnJhZzphNDZjN2FlZGZkZjU0ZGY3YmYzZmFlNmNlNDFjZGNlNy90YWJsZToyNGIxMGZmMTc3YmE0ZDRlOTM1MGU3NGUwMmRiYjBlNi90YWJsZXJhbmdlOjI0YjEwZmYxNzdiYTRkNGU5MzUwZTc0ZTAyZGJiMGU2XzEyLTMtMS0xLTQxMjk0_a2993026-6b16-4fc2-93d1-fcb6d8d1c171">121,876</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie6c3b69702e9429aaeed46bdb9bbb9c1_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTgvZnJhZzphNDZjN2FlZGZkZjU0ZGY3YmYzZmFlNmNlNDFjZGNlNy90YWJsZToyNGIxMGZmMTc3YmE0ZDRlOTM1MGU3NGUwMmRiYjBlNi90YWJsZXJhbmdlOjI0YjEwZmYxNzdiYTRkNGU5MzUwZTc0ZTAyZGJiMGU2XzEyLTUtMS0xLTQxMjk0_ed485356-93f2-4548-b0f8-be23d5492e3e">1,193</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sale of Vernalis R&amp;D</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231" decimals="-3" name="us-gaap:IncomeTaxReconciliationDispositionOfBusiness" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTgvZnJhZzphNDZjN2FlZGZkZjU0ZGY3YmYzZmFlNmNlNDFjZGNlNy90YWJsZToyNGIxMGZmMTc3YmE0ZDRlOTM1MGU3NGUwMmRiYjBlNi90YWJsZXJhbmdlOjI0YjEwZmYxNzdiYTRkNGU5MzUwZTc0ZTAyZGJiMGU2XzEzLTEtMS0xLTQxMjk0_211eba12-db96-43b3-9725-ce474ef669ad">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3597315a63d441f8f128abd7ed8840e_D20200101-20201231" decimals="-3" name="us-gaap:IncomeTaxReconciliationDispositionOfBusiness" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTgvZnJhZzphNDZjN2FlZGZkZjU0ZGY3YmYzZmFlNmNlNDFjZGNlNy90YWJsZToyNGIxMGZmMTc3YmE0ZDRlOTM1MGU3NGUwMmRiYjBlNi90YWJsZXJhbmdlOjI0YjEwZmYxNzdiYTRkNGU5MzUwZTc0ZTAyZGJiMGU2XzEzLTMtMS0xLTQxMjk0_42f74155-0656-408d-9115-579824cb2c86">127,372</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6c3b69702e9429aaeed46bdb9bbb9c1_D20190101-20191231" decimals="-3" name="us-gaap:IncomeTaxReconciliationDispositionOfBusiness" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTgvZnJhZzphNDZjN2FlZGZkZjU0ZGY3YmYzZmFlNmNlNDFjZGNlNy90YWJsZToyNGIxMGZmMTc3YmE0ZDRlOTM1MGU3NGUwMmRiYjBlNi90YWJsZXJhbmdlOjI0YjEwZmYxNzdiYTRkNGU5MzUwZTc0ZTAyZGJiMGU2XzEzLTUtMS0xLTQxMjk0_6be3f919-c1dd-4da7-a49e-d24543009a2c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231" decimals="-3" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTgvZnJhZzphNDZjN2FlZGZkZjU0ZGY3YmYzZmFlNmNlNDFjZGNlNy90YWJsZToyNGIxMGZmMTc3YmE0ZDRlOTM1MGU3NGUwMmRiYjBlNi90YWJsZXJhbmdlOjI0YjEwZmYxNzdiYTRkNGU5MzUwZTc0ZTAyZGJiMGU2XzE2LTEtMS0xLTQxMjk0_3141a0a8-1daf-4855-b684-9de8c46694eb">743</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3597315a63d441f8f128abd7ed8840e_D20200101-20201231" decimals="-3" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTgvZnJhZzphNDZjN2FlZGZkZjU0ZGY3YmYzZmFlNmNlNDFjZGNlNy90YWJsZToyNGIxMGZmMTc3YmE0ZDRlOTM1MGU3NGUwMmRiYjBlNi90YWJsZXJhbmdlOjI0YjEwZmYxNzdiYTRkNGU5MzUwZTc0ZTAyZGJiMGU2XzE2LTMtMS0xLTQxMjk0_20e9ebe9-4727-4273-940f-d630d64aecf8">3,076</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6c3b69702e9429aaeed46bdb9bbb9c1_D20190101-20191231" decimals="-3" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTgvZnJhZzphNDZjN2FlZGZkZjU0ZGY3YmYzZmFlNmNlNDFjZGNlNy90YWJsZToyNGIxMGZmMTc3YmE0ZDRlOTM1MGU3NGUwMmRiYjBlNi90YWJsZXJhbmdlOjI0YjEwZmYxNzdiYTRkNGU5MzUwZTc0ZTAyZGJiMGU2XzE2LTUtMS0xLTQxMjk0_e565e85c-2540-4fea-a9ba-9847447189b8">748</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTgvZnJhZzphNDZjN2FlZGZkZjU0ZGY3YmYzZmFlNmNlNDFjZGNlNy90YWJsZToyNGIxMGZmMTc3YmE0ZDRlOTM1MGU3NGUwMmRiYjBlNi90YWJsZXJhbmdlOjI0YjEwZmYxNzdiYTRkNGU5MzUwZTc0ZTAyZGJiMGU2XzE3LTEtMS0xLTQxMjk0_35363e1c-46d4-47ac-ad09-28f1e4ab7ddc">9,840</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib3597315a63d441f8f128abd7ed8840e_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTgvZnJhZzphNDZjN2FlZGZkZjU0ZGY3YmYzZmFlNmNlNDFjZGNlNy90YWJsZToyNGIxMGZmMTc3YmE0ZDRlOTM1MGU3NGUwMmRiYjBlNi90YWJsZXJhbmdlOjI0YjEwZmYxNzdiYTRkNGU5MzUwZTc0ZTAyZGJiMGU2XzE3LTMtMS0xLTQxMjk0_bc7c0e84-54c1-46c9-9f1e-ad409494dd55">7,553</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6c3b69702e9429aaeed46bdb9bbb9c1_D20190101-20191231" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTgvZnJhZzphNDZjN2FlZGZkZjU0ZGY3YmYzZmFlNmNlNDFjZGNlNy90YWJsZToyNGIxMGZmMTc3YmE0ZDRlOTM1MGU3NGUwMmRiYjBlNi90YWJsZXJhbmdlOjI0YjEwZmYxNzdiYTRkNGU5MzUwZTc0ZTAyZGJiMGU2XzE3LTUtMS0xLTQxMjk0_eba0561a-7379-433b-922d-7b6f99632109">167,337</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We remeasured certain deferred tax assets and liabilities based on the rates at which they are expected to reverse in the future, which is generally 21%. Significant components of our deferred tax assets and liabilities as of December&#160;31, 2021 and 2020 are shown below. We assess the positive and negative evidence to determine if sufficient future taxable income will be generated to </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">89</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ia2cbe0b7b6f94658a549da6639b9aa8c" continuedAt="i048dfb8c44954cfd9b9750336fb7319d"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">use the existing deferred tax assets. Our evaluation of evidence resulted in management concluding that the majority of our deferred tax assets will be realized. However, we maintain a valuation allowance to offset certain net deferred tax assets as management believes realization of such assets are uncertain as of December&#160;31, 2021, 2020 and 2019. The valuation allowance increased $<ix:nonFraction unitRef="usd" contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231" decimals="-5" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTgvZnJhZzphNDZjN2FlZGZkZjU0ZGY3YmYzZmFlNmNlNDFjZGNlNy90ZXh0cmVnaW9uOmE0NmM3YWVkZmRmNTRkZjdiZjNmYWU2Y2U0MWNkY2U3Xzc2OTY1ODEzOTk4MzI_0843ad59-6c97-49ca-8ff3-ad47900fe2aa">11.4</ix:nonFraction> million in 2021, decreased $<ix:nonFraction unitRef="usd" contextRef="ib3597315a63d441f8f128abd7ed8840e_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTgvZnJhZzphNDZjN2FlZGZkZjU0ZGY3YmYzZmFlNmNlNDFjZGNlNy90ZXh0cmVnaW9uOmE0NmM3YWVkZmRmNTRkZjdiZjNmYWU2Y2U0MWNkY2U3XzExMzg_bbba3b48-0638-45a6-a247-ce9a75bf8e67">116.5</ix:nonFraction> million in 2020 and increased $<ix:nonFraction unitRef="usd" contextRef="ie6c3b69702e9429aaeed46bdb9bbb9c1_D20190101-20191231" decimals="-5" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTgvZnJhZzphNDZjN2FlZGZkZjU0ZGY3YmYzZmFlNmNlNDFjZGNlNy90ZXh0cmVnaW9uOmE0NmM3YWVkZmRmNTRkZjdiZjNmYWU2Y2U0MWNkY2U3XzExNjM_2f297999-a8d1-4b79-8f06-72968bdcc6b1">136.9</ix:nonFraction> million in 2019.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We offset all deferred tax assets and liabilities by jurisdiction, as well as any related valuation allowance, and present them on our consolidated balance sheet as a non-current deferred income tax asset or liability (as applicable). <ix:nonNumeric contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTgvZnJhZzphNDZjN2FlZGZkZjU0ZGY3YmYzZmFlNmNlNDFjZGNlNy90ZXh0cmVnaW9uOmE0NmM3YWVkZmRmNTRkZjdiZjNmYWU2Y2U0MWNkY2U3XzUyNzY_2e877d5c-2ec0-4068-b7ec-bd588e63e928" continuedAt="i16d91605d1134f84beceeecad25e9a01" escape="true">Deferred tax assets (liabilities) are comprised of the following:</ix:nonNumeric></span><ix:continuation id="i16d91605d1134f84beceeecad25e9a01"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.807%"><tr><td style="width:1.0%"></td><td style="width:76.478%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.662%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.813%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating loss carryforwards</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTgvZnJhZzphNDZjN2FlZGZkZjU0ZGY3YmYzZmFlNmNlNDFjZGNlNy90YWJsZTpjZGMwODFhYmY2MzA0YTRiYjRmMmRlMWJmMjU3MjVkZS90YWJsZXJhbmdlOmNkYzA4MWFiZjYzMDRhNGJiNGYyZGUxYmYyNTcyNWRlXzQtMS0xLTEtNDEyOTQ_2a54301c-cd50-48da-b4a8-234f4e9dd0e3">64,352</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7462d0db8f4248fcb9fd8f1deae439f3_I20201231" decimals="-3" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTgvZnJhZzphNDZjN2FlZGZkZjU0ZGY3YmYzZmFlNmNlNDFjZGNlNy90YWJsZTpjZGMwODFhYmY2MzA0YTRiYjRmMmRlMWJmMjU3MjVkZS90YWJsZXJhbmdlOmNkYzA4MWFiZjYzMDRhNGJiNGYyZGUxYmYyNTcyNWRlXzQtMy0xLTEtNDEyOTQ_b9d04466-e9d0-42a6-9331-19bd1986fb93">64,147</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research credit carryforwards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTgvZnJhZzphNDZjN2FlZGZkZjU0ZGY3YmYzZmFlNmNlNDFjZGNlNy90YWJsZTpjZGMwODFhYmY2MzA0YTRiYjRmMmRlMWJmMjU3MjVkZS90YWJsZXJhbmdlOmNkYzA4MWFiZjYzMDRhNGJiNGYyZGUxYmYyNTcyNWRlXzUtMS0xLTEtNDEyOTQ_9dd25f87-972d-4f5b-80c7-faa0d487911c">27,797</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7462d0db8f4248fcb9fd8f1deae439f3_I20201231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTgvZnJhZzphNDZjN2FlZGZkZjU0ZGY3YmYzZmFlNmNlNDFjZGNlNy90YWJsZTpjZGMwODFhYmY2MzA0YTRiYjRmMmRlMWJmMjU3MjVkZS90YWJsZXJhbmdlOmNkYzA4MWFiZjYzMDRhNGJiNGYyZGUxYmYyNTcyNWRlXzUtMy0xLTEtNDEyOTQ_b51e432a-6c8b-41da-88fe-e22dbc3d220b">19,623</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTgvZnJhZzphNDZjN2FlZGZkZjU0ZGY3YmYzZmFlNmNlNDFjZGNlNy90YWJsZTpjZGMwODFhYmY2MzA0YTRiYjRmMmRlMWJmMjU3MjVkZS90YWJsZXJhbmdlOmNkYzA4MWFiZjYzMDRhNGJiNGYyZGUxYmYyNTcyNWRlXzYtMS0xLTEtNDEyOTQ_a258201a-a3f2-4d6d-96fc-1c086fed4269">11,374</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7462d0db8f4248fcb9fd8f1deae439f3_I20201231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTgvZnJhZzphNDZjN2FlZGZkZjU0ZGY3YmYzZmFlNmNlNDFjZGNlNy90YWJsZTpjZGMwODFhYmY2MzA0YTRiYjRmMmRlMWJmMjU3MjVkZS90YWJsZXJhbmdlOmNkYzA4MWFiZjYzMDRhNGJiNGYyZGUxYmYyNTcyNWRlXzYtMy0xLTEtNDEyOTQ_b6caa78e-b25c-49fb-b6c5-4f2b46991b81">11,994</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsOther" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTgvZnJhZzphNDZjN2FlZGZkZjU0ZGY3YmYzZmFlNmNlNDFjZGNlNy90YWJsZTpjZGMwODFhYmY2MzA0YTRiYjRmMmRlMWJmMjU3MjVkZS90YWJsZXJhbmdlOmNkYzA4MWFiZjYzMDRhNGJiNGYyZGUxYmYyNTcyNWRlXzctMS0xLTEtNDEyOTQ_b62e17cd-e307-40e6-b182-e5892246e380">19,668</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7462d0db8f4248fcb9fd8f1deae439f3_I20201231" decimals="-3" name="us-gaap:DeferredTaxAssetsOther" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTgvZnJhZzphNDZjN2FlZGZkZjU0ZGY3YmYzZmFlNmNlNDFjZGNlNy90YWJsZTpjZGMwODFhYmY2MzA0YTRiYjRmMmRlMWJmMjU3MjVkZS90YWJsZXJhbmdlOmNkYzA4MWFiZjYzMDRhNGJiNGYyZGUxYmYyNTcyNWRlXzctMy0xLTEtNDEyOTQ_9f1c38eb-fc7a-4449-83c0-658d331f206c">13,120</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTgvZnJhZzphNDZjN2FlZGZkZjU0ZGY3YmYzZmFlNmNlNDFjZGNlNy90YWJsZTpjZGMwODFhYmY2MzA0YTRiYjRmMmRlMWJmMjU3MjVkZS90YWJsZXJhbmdlOmNkYzA4MWFiZjYzMDRhNGJiNGYyZGUxYmYyNTcyNWRlXzgtMS0xLTEtNDEyOTQ_58584d42-1637-470f-9bfd-7053787e7212">123,191</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7462d0db8f4248fcb9fd8f1deae439f3_I20201231" decimals="-3" name="us-gaap:DeferredTaxAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTgvZnJhZzphNDZjN2FlZGZkZjU0ZGY3YmYzZmFlNmNlNDFjZGNlNy90YWJsZTpjZGMwODFhYmY2MzA0YTRiYjRmMmRlMWJmMjU3MjVkZS90YWJsZXJhbmdlOmNkYzA4MWFiZjYzMDRhNGJiNGYyZGUxYmYyNTcyNWRlXzgtMy0xLTEtNDEyOTQ_f0e68f95-1e9a-4e34-a8fe-a28b1ccb95fe">108,884</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance for deferred tax assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTgvZnJhZzphNDZjN2FlZGZkZjU0ZGY3YmYzZmFlNmNlNDFjZGNlNy90YWJsZTpjZGMwODFhYmY2MzA0YTRiYjRmMmRlMWJmMjU3MjVkZS90YWJsZXJhbmdlOmNkYzA4MWFiZjYzMDRhNGJiNGYyZGUxYmYyNTcyNWRlXzktMS0xLTEtNDEyOTQ_c04e0eec-1101-4d55-b594-f01cdd534b5c">36,283</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7462d0db8f4248fcb9fd8f1deae439f3_I20201231" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTgvZnJhZzphNDZjN2FlZGZkZjU0ZGY3YmYzZmFlNmNlNDFjZGNlNy90YWJsZTpjZGMwODFhYmY2MzA0YTRiYjRmMmRlMWJmMjU3MjVkZS90YWJsZXJhbmdlOmNkYzA4MWFiZjYzMDRhNGJiNGYyZGUxYmYyNTcyNWRlXzktMy0xLTEtNDEyOTQ_b47285bd-e8f3-41bb-93f1-a20f88d286c6">24,858</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTgvZnJhZzphNDZjN2FlZGZkZjU0ZGY3YmYzZmFlNmNlNDFjZGNlNy90YWJsZTpjZGMwODFhYmY2MzA0YTRiYjRmMmRlMWJmMjU3MjVkZS90YWJsZXJhbmdlOmNkYzA4MWFiZjYzMDRhNGJiNGYyZGUxYmYyNTcyNWRlXzEwLTEtMS0xLTQxMjk0_24e95324-3aa7-4c5a-a74e-6202aed5f2b5">86,908</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7462d0db8f4248fcb9fd8f1deae439f3_I20201231" decimals="-3" name="us-gaap:DeferredTaxAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTgvZnJhZzphNDZjN2FlZGZkZjU0ZGY3YmYzZmFlNmNlNDFjZGNlNy90YWJsZTpjZGMwODFhYmY2MzA0YTRiYjRmMmRlMWJmMjU3MjVkZS90YWJsZXJhbmdlOmNkYzA4MWFiZjYzMDRhNGJiNGYyZGUxYmYyNTcyNWRlXzEwLTMtMS0xLTQxMjk0_723214cc-0f6a-41e4-9842-1f7e5346c1fe">84,026</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:13pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Identified intangibles</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231" decimals="-3" name="lgnd:DeferredTaxLiabilitiesFiniteLivedIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTgvZnJhZzphNDZjN2FlZGZkZjU0ZGY3YmYzZmFlNmNlNDFjZGNlNy90YWJsZTpjZGMwODFhYmY2MzA0YTRiYjRmMmRlMWJmMjU3MjVkZS90YWJsZXJhbmdlOmNkYzA4MWFiZjYzMDRhNGJiNGYyZGUxYmYyNTcyNWRlXzEzLTEtMS0xLTQxMjk0_7318350c-cb31-4f1c-b370-782c0855a1d9">102,221</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7462d0db8f4248fcb9fd8f1deae439f3_I20201231" decimals="-3" name="lgnd:DeferredTaxLiabilitiesFiniteLivedIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTgvZnJhZzphNDZjN2FlZGZkZjU0ZGY3YmYzZmFlNmNlNDFjZGNlNy90YWJsZTpjZGMwODFhYmY2MzA0YTRiYjRmMmRlMWJmMjU3MjVkZS90YWJsZXJhbmdlOmNkYzA4MWFiZjYzMDRhNGJiNGYyZGUxYmYyNTcyNWRlXzEzLTMtMS0xLTQxMjk0_38eb1e2a-59e4-495a-ac8d-66f80e908322">119,381</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesOther" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTgvZnJhZzphNDZjN2FlZGZkZjU0ZGY3YmYzZmFlNmNlNDFjZGNlNy90YWJsZTpjZGMwODFhYmY2MzA0YTRiYjRmMmRlMWJmMjU3MjVkZS90YWJsZXJhbmdlOmNkYzA4MWFiZjYzMDRhNGJiNGYyZGUxYmYyNTcyNWRlXzE0LTEtMS0xLTQxMjk0_4726ee9c-8765-4d99-8863-c74754d123b3">9,300</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7462d0db8f4248fcb9fd8f1deae439f3_I20201231" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesOther" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTgvZnJhZzphNDZjN2FlZGZkZjU0ZGY3YmYzZmFlNmNlNDFjZGNlNy90YWJsZTpjZGMwODFhYmY2MzA0YTRiYjRmMmRlMWJmMjU3MjVkZS90YWJsZXJhbmdlOmNkYzA4MWFiZjYzMDRhNGJiNGYyZGUxYmYyNTcyNWRlXzE0LTMtMS0xLTQxMjk0_78264c2b-6d6f-486a-9707-2b1d650f6b91">4,923</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax liabilities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTgvZnJhZzphNDZjN2FlZGZkZjU0ZGY3YmYzZmFlNmNlNDFjZGNlNy90YWJsZTpjZGMwODFhYmY2MzA0YTRiYjRmMmRlMWJmMjU3MjVkZS90YWJsZXJhbmdlOmNkYzA4MWFiZjYzMDRhNGJiNGYyZGUxYmYyNTcyNWRlXzE1LTEtMS0xLTQxMjk0_b2e8dde2-9c05-4f8f-98ba-c244863554d9">111,521</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7462d0db8f4248fcb9fd8f1deae439f3_I20201231" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTgvZnJhZzphNDZjN2FlZGZkZjU0ZGY3YmYzZmFlNmNlNDFjZGNlNy90YWJsZTpjZGMwODFhYmY2MzA0YTRiYjRmMmRlMWJmMjU3MjVkZS90YWJsZXJhbmdlOmNkYzA4MWFiZjYzMDRhNGJiNGYyZGUxYmYyNTcyNWRlXzE1LTMtMS0xLTQxMjk0_cb8b5543-cba6-43ae-a0a6-d35c070876d5">124,304</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:13pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income taxes, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231" decimals="-3" name="us-gaap:DeferredTaxLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTgvZnJhZzphNDZjN2FlZGZkZjU0ZGY3YmYzZmFlNmNlNDFjZGNlNy90YWJsZTpjZGMwODFhYmY2MzA0YTRiYjRmMmRlMWJmMjU3MjVkZS90YWJsZXJhbmdlOmNkYzA4MWFiZjYzMDRhNGJiNGYyZGUxYmYyNTcyNWRlXzE3LTEtMS0xLTQxMjk0_689447c2-ddaa-4d74-8700-bca79bbf7c6d">24,613</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7462d0db8f4248fcb9fd8f1deae439f3_I20201231" decimals="-3" name="us-gaap:DeferredTaxLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTgvZnJhZzphNDZjN2FlZGZkZjU0ZGY3YmYzZmFlNmNlNDFjZGNlNy90YWJsZTpjZGMwODFhYmY2MzA0YTRiYjRmMmRlMWJmMjU3MjVkZS90YWJsZXJhbmdlOmNkYzA4MWFiZjYzMDRhNGJiNGYyZGUxYmYyNTcyNWRlXzE3LTMtMS0xLTQxMjk0_4757adaa-827c-4980-859e-334284736333">40,278</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, we had federal net operating loss carryforwards set to expire through 2037 of $<ix:nonFraction unitRef="usd" contextRef="ia4b200a8f2e64db69b4c7fc8145284e5_I20211231" decimals="-5" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTgvZnJhZzphNDZjN2FlZGZkZjU0ZGY3YmYzZmFlNmNlNDFjZGNlNy90ZXh0cmVnaW9uOmE0NmM3YWVkZmRmNTRkZjdiZjNmYWU2Y2U0MWNkY2U3XzE1Njg_493b5ce9-4991-4dca-a495-fefb4d6a27ab">119.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i961668aace3a442bba4c79a8ec70d54a_I20211231" decimals="-5" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTgvZnJhZzphNDZjN2FlZGZkZjU0ZGY3YmYzZmFlNmNlNDFjZGNlNy90ZXh0cmVnaW9uOmE0NmM3YWVkZmRmNTRkZjdiZjNmYWU2Y2U0MWNkY2U3XzE1NzU_6389dcee-74ee-4f04-8abc-8bbbea804757">176.3</ix:nonFraction> million of state net operating loss carryforwards that begin to expire in 2032. We also have $<ix:nonFraction unitRef="usd" contextRef="if699be6e6c984e4f92ca3d8242313e6d_I20211231" decimals="-5" name="us-gaap:TaxCreditCarryforwardAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTgvZnJhZzphNDZjN2FlZGZkZjU0ZGY3YmYzZmFlNmNlNDFjZGNlNy90ZXh0cmVnaW9uOmE0NmM3YWVkZmRmNTRkZjdiZjNmYWU2Y2U0MWNkY2U3XzE2NjE_e8a344e8-489f-41dc-8fa9-583e65f4811e">9.8</ix:nonFraction> million of federal research and development credit carryforwards, which expire through 2041. We have $<ix:nonFraction unitRef="usd" contextRef="i5ec01ca4f07749ee939ef64e906c8950_I20211231" decimals="-5" name="us-gaap:TaxCreditCarryforwardAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTgvZnJhZzphNDZjN2FlZGZkZjU0ZGY3YmYzZmFlNmNlNDFjZGNlNy90ZXh0cmVnaW9uOmE0NmM3YWVkZmRmNTRkZjdiZjNmYWU2Y2U0MWNkY2U3XzE3NTU_3fa174e3-227f-4be3-b3c7-e4a502383762">29.7</ix:nonFraction> million of California research and development credit carryforwards that have no expiration date. In addition, we have approximately $<ix:nonFraction unitRef="usd" contextRef="i1d36cbe0fb424f31b1fc285dc4c6570b_I20211231" decimals="-5" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTgvZnJhZzphNDZjN2FlZGZkZjU0ZGY3YmYzZmFlNmNlNDFjZGNlNy90ZXh0cmVnaW9uOmE0NmM3YWVkZmRmNTRkZjdiZjNmYWU2Y2U0MWNkY2U3XzE4ODM_7a82c24d-5ba0-421b-880c-bf16ec2bd5ee">101.6</ix:nonFraction> million of non-U.S. net operating loss carryovers and approximately $<ix:nonFraction unitRef="usd" contextRef="i0c31a24c4fde4de983ed94eb8e6c8a18_I20211231" decimals="-5" name="us-gaap:TaxCreditCarryforwardAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTgvZnJhZzphNDZjN2FlZGZkZjU0ZGY3YmYzZmFlNmNlNDFjZGNlNy90ZXh0cmVnaW9uOmE0NmM3YWVkZmRmNTRkZjdiZjNmYWU2Y2U0MWNkY2U3XzE5NDY_903ab8ea-2d91-4736-abac-26c38b4caa89">17.5</ix:nonFraction> million of non-U.S. capital loss carryovers that have no expiration date. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December 31, 2020 we had approximately $<ix:nonFraction unitRef="usd" contextRef="icb55a00b3ea6419c93f1e2c6128879a1_I20201231" decimals="-5" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTgvZnJhZzphNDZjN2FlZGZkZjU0ZGY3YmYzZmFlNmNlNDFjZGNlNy90ZXh0cmVnaW9uOmE0NmM3YWVkZmRmNTRkZjdiZjNmYWU2Y2U0MWNkY2U3XzIwNTg_0ea24c0d-8fe9-4109-adfe-0d1413a5cc5c">110.1</ix:nonFraction>&#160;million of non-U.S. net operating loss carryovers and approximately $<ix:nonFraction unitRef="usd" contextRef="i451ae05e4ee04e718c1da5b566a1bbc5_I20201231" decimals="-5" name="us-gaap:TaxCreditCarryforwardAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTgvZnJhZzphNDZjN2FlZGZkZjU0ZGY3YmYzZmFlNmNlNDFjZGNlNy90ZXh0cmVnaW9uOmE0NmM3YWVkZmRmNTRkZjdiZjNmYWU2Y2U0MWNkY2U3XzIxMjE_62ecc4e0-7d91-4b94-bfad-7f5655ad4def">17.6</ix:nonFraction>&#160;million of non-U.S. capital loss carryovers. We have a full valuation allowance against these non-U.S. tax attributes. The year over year decrease in non-U.S. deferred tax assets was attributable to the sale of Vernalis in December 2020. The remaining non-U.S. deferred tax assets as of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2021 were</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> attributable to the portion of the Vernalis business that we did not sell. We have a full valuation allowance against these non-U.S. tax attributes. See detail in &#8220;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note (2), Sale of Vernalis R&amp;D and Promacta License</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">  &#160;&#160; </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to Section 382 and 383 of the Internal Revenue Code of 1986, as amended, utilization of our net operating losses and credits may be subject to annual limitations in the event of any significant future changes in its ownership structure. These annual limitations may result in the expiration of net operating losses and credits prior to utilization. The deferred tax assets as of December&#160;31, 2021 are net of any previous limitations due to Section 382 and 383.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for income taxes by evaluating a probability threshold that a tax position must meet before a financial statement benefit is recognized. The minimum threshold is a tax position that is more likely than not to be sustained upon examination by the applicable taxing authority, including resolution of any related appeals or litigation processes, based on the technical merits of the position. Our remaining liabilities for uncertain tax positions are presented net of the deferred tax asset balances on the accompanying consolidated balance sheet.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">90</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i048dfb8c44954cfd9b9750336fb7319d"><div style="margin-top:9pt"><ix:nonNumeric contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231" name="us-gaap:ScheduleOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForwardTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTgvZnJhZzphNDZjN2FlZGZkZjU0ZGY3YmYzZmFlNmNlNDFjZGNlNy90ZXh0cmVnaW9uOmE0NmM3YWVkZmRmNTRkZjdiZjNmYWU2Y2U0MWNkY2U3XzUyNzc_fe774ad9-5326-4dfe-bb5c-8758d624e61b" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the amount of unrecognized tax benefits at December&#160;31, 2021, 2020 and 2019 is as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.807%"><tr><td style="width:1.0%"></td><td style="width:66.613%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.064%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.064%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.365%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at beginning of year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7462d0db8f4248fcb9fd8f1deae439f3_I20201231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTgvZnJhZzphNDZjN2FlZGZkZjU0ZGY3YmYzZmFlNmNlNDFjZGNlNy90YWJsZTpmNDhmMzcxZGE0NzI0Yzg3OTg2ODg5MmNjYWQ1MGIxOS90YWJsZXJhbmdlOmY0OGYzNzFkYTQ3MjRjODc5ODY4ODkyY2NhZDUwYjE5XzItMS0xLTEtNDEyOTQ_666b9256-68ea-4a00-8a6e-2ec1c4637b77">31,871</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ida3ec05a32644c2db1bb9f71f76c567f_I20191231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTgvZnJhZzphNDZjN2FlZGZkZjU0ZGY3YmYzZmFlNmNlNDFjZGNlNy90YWJsZTpmNDhmMzcxZGE0NzI0Yzg3OTg2ODg5MmNjYWQ1MGIxOS90YWJsZXJhbmdlOmY0OGYzNzFkYTQ3MjRjODc5ODY4ODkyY2NhZDUwYjE5XzItMy0xLTEtNDEyOTQ_0d5acb3e-b599-4064-94a0-3a3c87ff2c1c">28,736</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1aac4d81ad94163b33117197afe0895_I20181231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTgvZnJhZzphNDZjN2FlZGZkZjU0ZGY3YmYzZmFlNmNlNDFjZGNlNy90YWJsZTpmNDhmMzcxZGE0NzI0Yzg3OTg2ODg5MmNjYWQ1MGIxOS90YWJsZXJhbmdlOmY0OGYzNzFkYTQ3MjRjODc5ODY4ODkyY2NhZDUwYjE5XzItNS0xLTEtNDEyOTQ_da6d1721-411f-49b3-8f34-d3db25398c28">30,289</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Additions based on tax positions related to the current year</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTgvZnJhZzphNDZjN2FlZGZkZjU0ZGY3YmYzZmFlNmNlNDFjZGNlNy90YWJsZTpmNDhmMzcxZGE0NzI0Yzg3OTg2ODg5MmNjYWQ1MGIxOS90YWJsZXJhbmdlOmY0OGYzNzFkYTQ3MjRjODc5ODY4ODkyY2NhZDUwYjE5XzMtMS0xLTEtNDEyOTQ_9406076c-a789-4059-a96a-ff30ae06bda0">252</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3597315a63d441f8f128abd7ed8840e_D20200101-20201231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTgvZnJhZzphNDZjN2FlZGZkZjU0ZGY3YmYzZmFlNmNlNDFjZGNlNy90YWJsZTpmNDhmMzcxZGE0NzI0Yzg3OTg2ODg5MmNjYWQ1MGIxOS90YWJsZXJhbmdlOmY0OGYzNzFkYTQ3MjRjODc5ODY4ODkyY2NhZDUwYjE5XzMtMy0xLTEtNDEyOTQ_1779930e-8fc1-4aaf-939a-91cab9d89ca1">3,911</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6c3b69702e9429aaeed46bdb9bbb9c1_D20190101-20191231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTgvZnJhZzphNDZjN2FlZGZkZjU0ZGY3YmYzZmFlNmNlNDFjZGNlNy90YWJsZTpmNDhmMzcxZGE0NzI0Yzg3OTg2ODg5MmNjYWQ1MGIxOS90YWJsZXJhbmdlOmY0OGYzNzFkYTQ3MjRjODc5ODY4ODkyY2NhZDUwYjE5XzMtNS0xLTEtNDEyOTQ_8d945ae5-8b17-4389-9263-09b1ec6ea749">543</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Additions for tax positions of prior years</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTgvZnJhZzphNDZjN2FlZGZkZjU0ZGY3YmYzZmFlNmNlNDFjZGNlNy90YWJsZTpmNDhmMzcxZGE0NzI0Yzg3OTg2ODg5MmNjYWQ1MGIxOS90YWJsZXJhbmdlOmY0OGYzNzFkYTQ3MjRjODc5ODY4ODkyY2NhZDUwYjE5XzQtMS0xLTEtNDEyOTQ_ace095d2-5421-48bf-93b5-2f81d32abc2b">945</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3597315a63d441f8f128abd7ed8840e_D20200101-20201231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTgvZnJhZzphNDZjN2FlZGZkZjU0ZGY3YmYzZmFlNmNlNDFjZGNlNy90YWJsZTpmNDhmMzcxZGE0NzI0Yzg3OTg2ODg5MmNjYWQ1MGIxOS90YWJsZXJhbmdlOmY0OGYzNzFkYTQ3MjRjODc5ODY4ODkyY2NhZDUwYjE5XzQtMy0xLTEtNDEyOTQ_4f97cdfc-cec8-49c0-a7c6-b66c8d851d5f">179</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6c3b69702e9429aaeed46bdb9bbb9c1_D20190101-20191231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTgvZnJhZzphNDZjN2FlZGZkZjU0ZGY3YmYzZmFlNmNlNDFjZGNlNy90YWJsZTpmNDhmMzcxZGE0NzI0Yzg3OTg2ODg5MmNjYWQ1MGIxOS90YWJsZXJhbmdlOmY0OGYzNzFkYTQ3MjRjODc5ODY4ODkyY2NhZDUwYjE5XzQtNS0xLTEtNDEyOTQ_92c3b11d-68c9-454d-a8ac-98d85e9a0f36">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Reductions for tax positions of prior years</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTgvZnJhZzphNDZjN2FlZGZkZjU0ZGY3YmYzZmFlNmNlNDFjZGNlNy90YWJsZTpmNDhmMzcxZGE0NzI0Yzg3OTg2ODg5MmNjYWQ1MGIxOS90YWJsZXJhbmdlOmY0OGYzNzFkYTQ3MjRjODc5ODY4ODkyY2NhZDUwYjE5XzUtMS0xLTEtNDEyOTQ_03182cf8-9561-492b-8216-44cab5a24525">3,072</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib3597315a63d441f8f128abd7ed8840e_D20200101-20201231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTgvZnJhZzphNDZjN2FlZGZkZjU0ZGY3YmYzZmFlNmNlNDFjZGNlNy90YWJsZTpmNDhmMzcxZGE0NzI0Yzg3OTg2ODg5MmNjYWQ1MGIxOS90YWJsZXJhbmdlOmY0OGYzNzFkYTQ3MjRjODc5ODY4ODkyY2NhZDUwYjE5XzUtMy0xLTEtNDEyOTQ_fefaaae8-2021-4dae-a1ed-ee74574f7c55">955</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie6c3b69702e9429aaeed46bdb9bbb9c1_D20190101-20191231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTgvZnJhZzphNDZjN2FlZGZkZjU0ZGY3YmYzZmFlNmNlNDFjZGNlNy90YWJsZTpmNDhmMzcxZGE0NzI0Yzg3OTg2ODg5MmNjYWQ1MGIxOS90YWJsZXJhbmdlOmY0OGYzNzFkYTQ3MjRjODc5ODY4ODkyY2NhZDUwYjE5XzUtNS0xLTEtNDEyOTQ_c1af920d-c9f7-481c-9e1b-cc70c6d6e348">2,096</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at end of year</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTgvZnJhZzphNDZjN2FlZGZkZjU0ZGY3YmYzZmFlNmNlNDFjZGNlNy90YWJsZTpmNDhmMzcxZGE0NzI0Yzg3OTg2ODg5MmNjYWQ1MGIxOS90YWJsZXJhbmdlOmY0OGYzNzFkYTQ3MjRjODc5ODY4ODkyY2NhZDUwYjE5XzYtMS0xLTEtNDEyOTQ_38872b56-3607-494c-9834-ab3e523f936c">29,996</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7462d0db8f4248fcb9fd8f1deae439f3_I20201231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTgvZnJhZzphNDZjN2FlZGZkZjU0ZGY3YmYzZmFlNmNlNDFjZGNlNy90YWJsZTpmNDhmMzcxZGE0NzI0Yzg3OTg2ODg5MmNjYWQ1MGIxOS90YWJsZXJhbmdlOmY0OGYzNzFkYTQ3MjRjODc5ODY4ODkyY2NhZDUwYjE5XzYtMy0xLTEtNDEyOTQ_666b9256-68ea-4a00-8a6e-2ec1c4637b77">31,871</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ida3ec05a32644c2db1bb9f71f76c567f_I20191231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTgvZnJhZzphNDZjN2FlZGZkZjU0ZGY3YmYzZmFlNmNlNDFjZGNlNy90YWJsZTpmNDhmMzcxZGE0NzI0Yzg3OTg2ODg5MmNjYWQ1MGIxOS90YWJsZXJhbmdlOmY0OGYzNzFkYTQ3MjRjODc5ODY4ODkyY2NhZDUwYjE5XzYtNS0xLTEtNDEyOTQ_0d5acb3e-b599-4064-94a0-3a3c87ff2c1c">28,736</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div style="text-indent:24pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Included in the balance of unrecognized tax benefits at December&#160;31, 2021 is $<ix:nonFraction unitRef="usd" contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTgvZnJhZzphNDZjN2FlZGZkZjU0ZGY3YmYzZmFlNmNlNDFjZGNlNy90ZXh0cmVnaW9uOmE0NmM3YWVkZmRmNTRkZjdiZjNmYWU2Y2U0MWNkY2U3XzM3NDc_04872d25-cdd0-4735-8cac-4a9cee00bbdf">28.1</ix:nonFraction> million of tax benefits that, if recognized would impact the effective rate. There are no positions for which it is reasonably possible that the uncertain tax benefit will significantly increase or decrease within twelve months.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize interest and penalties related to uncertain tax positions in income tax expense. As of December&#160;31, 2021 and December&#160;31, 2020, we recognized an immaterial amount of interest and penalties. We file income tax returns in the United States, various state jurisdictions, United Kingdom, and Canada with varying statutes of limitations. The federal statute of limitation remains open for the 2018 tax year to the present.&#160;The state income tax returns generally remain open for the 2017 tax year through the present.&#160;Net operating loss and research credit carryforwards arising prior to these years are also open to examination if and when utilized. No tax returns are currently under examination by any tax authorities. We believe our reserve for unrecognized tax benefits and contingent tax issues is adequate with respect to all open years.</span></div></ix:continuation><div><span><br/></span></div><div><span><br/></span></div><div id="i0fa6f906fb2e4e30bc5e873d2bb6a82c_124"></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:9.750%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:88.050%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Item&#160;9.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</span></td></tr></table></div><div style="margin-top:5pt;text-indent:24pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:400;line-height:120%">&#160;</span></div><div id="i0fa6f906fb2e4e30bc5e873d2bb6a82c_127"></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:9.750%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:88.050%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Item&#160;9A.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Controls and Procedures</span></td></tr></table></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(a) Evaluation of Disclosure Controls and Procedures</span></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are responsible for maintaining disclosure controls and procedures designed to provide reasonable assurance that information required to be disclosed in reports we file under the Exchange Act is recorded, processed, summarized and reported within the specified time periods and accumulated and communicated to management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure. The design of any system of controls is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions; over time, controls may become inadequate because of changes in conditions, or the degree of compliance with policies or procedures may deteriorate. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected. As of the end of the period covered by this Annual Report on Form 10-K, we have carried out an evaluation, under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, of the effectiveness of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, and have concluded our disclosure controls and procedures were effective at a reasonable assurance level as of December&#160;31, 2021.</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no changes in our internal control over financial reporting that occurred during the quarter ended December&#160;31, 2021 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(b) Management&#8217;s Report on Internal Control Over Financial Reporting</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management is responsible for establishing and maintaining adequate internal control over financial reporting for the Company. Internal control over financial reporting is a process to provide reasonable assurance regarding the reliability of our financial reporting for external purposes in accordance with accounting principles generally accepted in the United States of America. Internal control over financial reporting includes maintaining records that in reasonable detail accurately and fairly reflect our transactions; providing reasonable assurance that transactions are recorded as necessary for preparation of our </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">91</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">financial statements in accordance with generally accepted accounting principles; providing reasonable assurance that receipts and expenditures are made in accordance with our management and directors; and providing reasonable assurance that</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">unauthorized acquisition, use or disposition of company assets that could have a material effect on our financial statements would be prevented or detected on a timely basis. Because of its inherent limitations, internal control over financial reporting is not intended to provide absolute assurance that a misstatement of our financial statements would be prevented or detected.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, we conducted an evaluation of the effectiveness of our internal control over financial reporting based on the framework established by the Committee of Sponsoring Organizations of the Treadway Commission (COSO) as set forth in the 2013 Internal Control-Integrated Framework. Based on our evaluation under the 2013 framework in Internal Control - Integrated Framework, management concluded that our internal controls over financial reporting were effective as of December&#160;31, 2021.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ernst&#160;&amp; Young LLP, an independent registered public accounting firm, has audited the Company&#8217;s consolidated financial statements included in this Annual Report on Form 10-K and has issued an attestation report, included herein, on the effectiveness of our internal control over financial reporting as of December&#160;31, 2021.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">92</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Report of Independent Registered Public Accounting Firm</span></div><div style="margin-top:6pt"><span><br/></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Stockholders and Board of Directors of Ligand Pharmaceuticals Incorporated</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Opinion on Internal Control Over Financial Reporting</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have audited Ligand Pharmaceuticals Incorporated&#8217;s internal control over financial reporting as of December 31, 2021, based on criteria established in Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) (the COSO criteria). In our opinion, Ligand Pharmaceuticals Incorporated (the Company) maintained, in all material respects, effective internal control over financial reporting as of December 31, 2021, based on the COSO criteria.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the consolidated balance sheets of the Company as of December&#160;31, 2021 and 2020, the related consolidated statements of operations, comprehensive income (loss), stockholders&#8217; equity and cash flows for each of the three years in the period ended December&#160;31, 2021, and the related notes and our report dated February&#160;28, 2022 expressed an unqualified opinion thereon.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis for Opinion </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting included in the accompanying Management&#8217;s Report on Internal Control Over Financial Reporting. Our responsibility is to express an opinion on the Company&#8217;s internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects.  </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, testing and evaluating the design and operating effectiveness of internal control based on the assessed risk, and performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Definition and Limitations of Internal Control Over Financial Reporting </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A company&#8217;s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company&#8217;s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company&#8217;s assets that could have a material effect on the financial statements. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ Ernst &amp; Young LLP</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">San Diego, California</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">February&#160;28, 2022</span></div><div id="i0fa6f906fb2e4e30bc5e873d2bb6a82c_130"></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:46.198%"><tr><td style="width:1.0%"></td><td style="width:28.330%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:69.470%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Item 9B.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other Information</span></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">      None</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">93</span></div></div></div><div id="i0fa6f906fb2e4e30bc5e873d2bb6a82c_748"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.391%"><tr><td style="width:1.0%"></td><td style="width:14.689%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:83.111%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Item 9C.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</span></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">94</span></div></div></div><div id="i0fa6f906fb2e4e30bc5e873d2bb6a82c_133"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Part III</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div id="i0fa6f906fb2e4e30bc5e873d2bb6a82c_136"></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:9.750%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:88.050%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Item&#160;10.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Directors, Executive Officers and Corporate Governance</span></td></tr></table></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Code of Conduct</span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Board of Directors has adopted a Code of Conduct and Ethics Policy (&#8220;Code of Conduct&#8221;) that applies to all officers, directors and employees. The Company will promptly disclose (1) the nature of any amendment to the Code of Conduct that applies to our principal executive officer, principal financial officer, principal accounting officer or controller or persons performing similar functions and (2) the nature of any waiver, including an implicit waiver, from a provision of our Code of Conduct that is granted to one of these specified officers, the name of such person who is granted the waiver and the date of the waiver on our website in the future. The Code of Conduct can be accessed via our website (http://www.ligand.com), Corporate Overview page. You may also request a free copy by writing to: Investor Relations, Ligand Pharmaceuticals Incorporated, 5980 Horton Street, Suite 405, Emeryville, CA 94608.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The other information under Item&#160;10 is hereby incorporated by reference to Ligand&#8217;s Definitive Proxy Statement to be filed with the SEC within 120 days of December&#160;31, 2021.&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:400;line-height:120%">&#160;</span></div><div id="i0fa6f906fb2e4e30bc5e873d2bb6a82c_139"></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:9.750%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:88.050%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Item&#160;11.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Executive Compensation</span></td></tr></table></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Item&#160;11 is hereby incorporated by reference to Ligand&#8217;s Definitive Proxy Statement to be filed with the SEC within 120 days of December&#160;31, 2021.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:400;line-height:120%">&#160;</span></div><div id="i0fa6f906fb2e4e30bc5e873d2bb6a82c_142"></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:9.750%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:88.050%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Item&#160;12.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</span></td></tr></table></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Item&#160;12 is hereby incorporated by reference to Ligand&#8217;s Definitive Proxy Statement to be filed with the SEC within 120 days of December&#160;31, 2021.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:400;line-height:120%">&#160;</span></div><div id="i0fa6f906fb2e4e30bc5e873d2bb6a82c_145"></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:9.750%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:88.050%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Item&#160;13.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Certain Relationships and Related Transactions, and Director Independence</span></td></tr></table></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Item&#160;13 is hereby incorporated by reference to Ligand&#8217;s Definitive Proxy Statement to be filed with the SEC within 120 days of December&#160;31, 2021.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:400;line-height:120%">&#160;</span></div><div id="i0fa6f906fb2e4e30bc5e873d2bb6a82c_148"></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:9.750%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:88.050%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Item&#160;14.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Principal Accountant Fees and Services</span></td></tr></table></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Item&#160;14 is hereby incorporated by reference to Ligand&#8217;s Definitive Proxy Statement to be filed with the SEC within 120 days of December&#160;31, 2021.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">95</span></div></div></div><div id="i0fa6f906fb2e4e30bc5e873d2bb6a82c_151"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART IV</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div id="i0fa6f906fb2e4e30bc5e873d2bb6a82c_154"></div><div style="-sec-extract:summary"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:9.750%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:88.050%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Item&#160;15.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibits and Financial Statement Schedule</span></td></tr></table></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(a) The following documents are included as part of this Annual Report on Form 10-K.</span></div><div style="margin-top:9pt;padding-left:58.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) Financial statements</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:91.128%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.672%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0fa6f906fb2e4e30bc5e873d2bb6a82c_58">Index to Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0fa6f906fb2e4e30bc5e873d2bb6a82c_58">51</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0fa6f906fb2e4e30bc5e873d2bb6a82c_61">Report of Independent Registered Public Accounting Firm</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0fa6f906fb2e4e30bc5e873d2bb6a82c_61">52</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0fa6f906fb2e4e30bc5e873d2bb6a82c_64">Consolidated Balance Sheets</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0fa6f906fb2e4e30bc5e873d2bb6a82c_64">53</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0fa6f906fb2e4e30bc5e873d2bb6a82c_67">Consolidated Statements of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0fa6f906fb2e4e30bc5e873d2bb6a82c_67">54</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0fa6f906fb2e4e30bc5e873d2bb6a82c_70">Consolidated Statements of Comprehensive Income (Loss)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0fa6f906fb2e4e30bc5e873d2bb6a82c_70">55</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0fa6f906fb2e4e30bc5e873d2bb6a82c_73">Consolidated Statements of Stockholders&#8217; Equity </a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0fa6f906fb2e4e30bc5e873d2bb6a82c_73">57</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0fa6f906fb2e4e30bc5e873d2bb6a82c_76">Consolidated Statements of Cash Flows</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0fa6f906fb2e4e30bc5e873d2bb6a82c_76">57</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0fa6f906fb2e4e30bc5e873d2bb6a82c_79">Notes to Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0fa6f906fb2e4e30bc5e873d2bb6a82c_79">59</a></span></div></td></tr></table></div><div style="margin-top:9pt;padding-left:58.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2) Schedules not included herein have been omitted because they are not applicable or the required information is in the consolidated financial statements or notes thereto.</span></div><div style="margin-top:9pt;padding-left:58.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3) The following exhibits are filed as part of this Form 10-K and this list includes the Exhibit Index.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:8.841%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:35.449%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.794%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.689%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.549%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.260%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Incorporated by Reference</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Exhibit</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Description of Exhibit</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Form</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">File Number</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Date of Filing</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Exhibit </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Filed </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Herewith</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000088616319000043/ex218k3519.htm">2.</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000088616319000043/ex218k3519.htm">1</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asset Purchase Agreement, dated March 5, 2019, by and among Ligand Pharmaceuticals Incorporated and RPI Financial Trust</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-33093</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March 5, 2019</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.1</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/886163/000088616320000061/exhibit21assetpurchase.htm">2.</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/886163/000088616320000061/exhibit21assetpurchase.htm">2</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asset Purchase Agreement, dated February 11, 2020, (as amended on April 1, 2020), by and among Ligand Pharmaceuticals Incorporated, Icagen Inc., Icagen Corp., XRPro Sciences, Inc. and Caldera Discovery, Inc.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-33093</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">May 8, 2020</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.1</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/886163/000119312520215346/d79922dex21.htm">2.</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/886163/000119312520215346/d79922dex21.htm">3</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Agreement and Plan of Merger, dated as of August 10, 2020, by and among Pfenex Inc., Ligand Pharmaceuticals Incorporated and Pelican Acquisition Sub, Inc.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-33093</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">August 11, 2020</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.1</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/886163/000088616320000101/a101ligandxcellaagreem.htm">2.</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/886163/000088616320000101/a101ligandxcellaagreem.htm">4</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Agreement and Plan of Merger, dated September 8, 2020, among Ligand Pharmaceuticals Incorporated, xCella Biosciences, Inc. and Eton Venture Services, Ltd. Co., as stockholders&#8217; representative</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-33093</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">September 10, 2020</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/886163/000088616320000101/a102ligandtaurusagreem.htm">2.</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/886163/000088616320000101/a102ligandtaurusagreem.htm">5</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Agreement and Plan of Merger, dated September 9, 2020, among Ligand Pharmaceuticals Incorporated, Taurus Biosciences, LLC and the other signatories listed therein</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-33093</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">September 10, 2020</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/886163/000088616320000108/exhibit21vineyard-spae.htm">2.</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/886163/000088616320000108/exhibit21vineyard-spae.htm">6</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/886163/000088616320000108/exhibit21vineyard-spae.htm">*</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Agreement for the Sale and Purchase of the Entire Issued Share Capital of Vernalis (R&amp;D) Limited, dated as of October 11, 2020, by and among Ligand Pharmaceuticals Incorporated, Vernalis Limited, HitGen UK Ltd and HitGen Inc.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-33093</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">October 13, 2020</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.1</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/0000936392-98-001000.txt">3.1</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amended and Restated Certificate of Incorporation of the Company. </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">S-4</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">333-58823</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">July 9, 1998</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000088616301000008/0000886163-01-000008-0002.txt">3.2</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Certificate of Amendment of the Amended and Restated Certificate of Incorporation of the Company, dated June 14, 2000 </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0-20720</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March 29, 2001</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.5</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000088616304000015/ex3-6.txt">3.3</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Certificate of Amendment of the Amended and Restated Certificate of Incorporation of the Company, dated June 30, 2004 </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0-20720</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">August 5, 2004</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.6</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">96</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:8.841%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:35.449%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.794%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.689%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.549%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.260%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000119312510264942/dex31.htm">3.4</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Certificate of Amendment of the Amended and Restated Certificate of Incorporation of the Company, dated November 17, 2010</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-33093</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">November&#160;19, 2010</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000088616319000157/exhibit36.htm">3.5</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Certificate of Amendment of the Amended and Restated Certification of Incorporation of the Company, dated June 19, 2018</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">S-8</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">333-233130</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">August 8, 2019</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.6</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/886163/000088616320000116/exhibit31-ligandxfourt.htm">3.6</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fourth Amended and Restated Bylaws of the Company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-33093</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">October 30, 2020</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000088616318000030/lgndexhibi41.htm">4.1</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Specimen stock certificate for shares of the common stock of the Company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-33093</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March 1, 2018</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.1</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000088616318000076/exhibit41.htm">4.2</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Indenture, dated as of May 22, 2018, between the Company and Wilmington Trust, National Association, as trustee, including the form of 0.75% Convertible Senior Notes due 2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-33093</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">May 22, 2018</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.1</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/886163/000088616321000050/exhibit43_ligand-descripti.htm">4.3</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Description of Registered Securities</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-33093</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">February 24, 2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.3</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/886163/000088616321000050/exhibit101_ligand-2002stoc.htm">10.1#</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2002 Stock Incentive Plan (as amended and restated effective December 15, 2020)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-33093</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">February 24, 2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000088616319000063/lgnd-2019annualmeetingproxy.htm#sb6e62536bc644ccb9ea4178e9b4c6808">10.2#</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2002 Employee Stock Purchase Plan (as amended and restated effective June 6, 2019)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">DEF</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-33093</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">April 24, 2019</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Appendix B</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000088616314000031/lgnd-ex105_optionagreement.htm">10.3#</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Form of Stock Option Grant Notice and Stock Option Agreement under the Company&#8217;s 2002 Stock Incentive Plan</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-33093</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">February 24, 2014</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.5</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000095013706000420/a16037orexv10w289.txt">10.4#</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Form of Stock Issuance Agreement for non-employee directors under the Company&#8217;s 2002 Stock Incentive Plan</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">S-1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">333-131029</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">January&#160;13, 2006</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.289</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000088616318000030/formofrsugrantnoticeexhibi.htm">10.5#</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Form of Restricted Stock Unit Grant Notice and Restricted Stock Unit Agreement under the Company&#8217;s 2002 Stock Incentive Plan </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-33093</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March 1, 2018</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.6</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000088616318000030/lgnd-rsugrantnoticeperform.htm">10.6#</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Form of Restricted Stock Unit Grant Notice and Restricted Stock Unit Agreement under the Company&#8217;s 2002 Stock Incentive Plan - Performance-Based RSU Form</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-33093</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March 1, 2018</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.7</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000088616307000132/ex10-1.txt">10.7#</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Form of Executive Officer Change in Control Severance Agreement </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-33093</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">August&#160;22, 2007</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000119312508260208/dex102.htm">10.8#</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amended and Restated Severance Plan, dated December 20, 2008</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-33093</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December&#160;24, 2008</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/886163/000088616320000025/exhibit109final.htm">10.9#</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amended and Restated Director Compensation and Stock Ownership Policy, effective March 28, 2019</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-33093</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">February 27, 2020</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.9</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000119312510015242/dex102.htm">10.10</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">TR Beta Contingent Value Rights Agreement, dated January 27, 2010, among the Company, Metabasis Therapeutics, Inc., David F. Hale and Mellon Investor Services LLC </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-33093</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">January&#160;28, 2010</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000119312510015242/dex104.htm">10.1</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000119312510015242/dex104.htm">1</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">General Contingent Value Rights Agreement, dated January 27, 2010, among the Company, Metabasis Therapeutics, Inc., David F. Hale and Mellon Investor Services LLC </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-33093</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">January&#160;28, 2010</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.4</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000119312511018895/dex101.htm">10.1</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000119312511018895/dex101.htm">2</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amendment of General Contingent Value Rights Agreement, dated January 26, 2011, among the Company, Metabasis Therapeutics, Inc., David F. Hale and Mellon Investor Services LLC </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-33093</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">January&#160;31, 2011</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000088616314000057/amendment_ofxgeneralxcvrxa.htm">10.1</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000088616314000057/amendment_ofxgeneralxcvrxa.htm">3</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amendment of General Contingent Value Rights Agreement dated May 20, 2014 among the Company, Metabasis Therapeutics, Inc., David F. Hale and Computershare Inc.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-33093</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">May 22, 2014</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000088616314000057/amendment_ofxtrxbetaxcvrxa.htm">10.1</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000088616314000057/amendment_ofxtrxbetaxcvrxa.htm">4</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amendment of TR Beta Contingent Value Rights Agreement dated May 20, 2014 among the Company, Metabasis Therapeutics, Inc., David F. Hale and Computershare, Inc.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-33093</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">May 22, 2014</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000119312511055119/dex10100.htm">10.1</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000119312511055119/dex10100.htm">5</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000119312511055119/dex10100.htm">&#8224;</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Captisol&#174; Supply Agreement, dated December&#160;20, 2002, among CyDex, Inc., Hovione&#160;LLC, Hovione FarmaCiencia&#160;S.A., Hovione Pharmascience Limited and Hovione International Limited </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-33093</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March 3, 2011</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">97</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:8.841%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:35.449%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.794%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.689%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.549%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.260%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000119312511055119/dex10101.htm">10.1</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000119312511055119/dex10101.htm">6</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000119312511055119/dex10101.htm">&#8224;</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1st Amendment to Captisol&#174; Supply Agreement, dated July&#160;29, 2005, among CyDex, Inc., Hovione&#160;LLC, Hovione FarmaCiencia&#160;S.A., Hovione Pharmascience Limited and Hovione International Limited </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-33093</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March 3, 2011</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.101</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000119312511055119/dex10102.htm">10.1</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000119312511055119/dex10102.htm">7</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2nd&#160;Amendment to Captisol&#174; Supply Agreement, dated March&#160;1, 2007, among CyDex, Inc., Hovione&#160;LLC, Hovione FarmaCiencia&#160;S.A., Hovione Pharmascience Limited, and Hovione International Limited </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-33093</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March 3, 2011</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.102</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000119312511055119/dex10103.htm">10.</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000119312511055119/dex10103.htm">18</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000119312511055119/dex10103.htm">&#8224;</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3rd&#160;Amendment to Captisol&#174; Supply Agreement, dated January&#160;25, 2008, among CyDex, Inc., Hovione&#160;LLC, Hovione FarmaCiencia&#160;S.A., Hovione Pharmascience Limited, and Hovione International Limited </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-33093</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March 3, 2011</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.103</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000119312511055119/dex10104.htm">10.</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000119312511055119/dex10104.htm">19</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000119312511055119/dex10104.htm">&#8224;</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4th&#160;Amendment to Captisol&#174; Supply Agreement, dated September 28, 2009, among CyDex Pharmaceuticals, Inc., Hovione&#160;LLC, Hovione FarmaCiencia&#160;S.A., Hovione Pharmascience Limited and Hovione International Limited </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-33093</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March 3, 2011</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.104</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000119312511055119/dex10105.htm">10.2</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000119312511055119/dex10105.htm">0</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000119312511055119/dex10105.htm">&#8224;</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">License Agreement, dated September&#160;3, 1993, between CyDex L.C. and The University of Kansas </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-33093</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March 3, 2011</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.105</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000119312511055119/dex10106.htm">10.2</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000119312511055119/dex10106.htm">1</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">First Amendment to License Agreement, dated February 24, 1998, between CyDex, Inc. and The University of Kansas</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-33093</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March 3, 2011</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.106</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000119312511055119/dex10107.htm">10.2</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000119312511055119/dex10107.htm">2</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000119312511055119/dex10107.htm">&#8224;</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Second Amendment to License Agreement, dated August&#160;4, 2004, between CyDex, Inc. and The University of Kansas </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-33093</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March 3, 2011</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.107</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000119312511055119/dex10111.htm">10.2</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000119312511055119/dex10111.htm">3</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000119312511055119/dex10111.htm">&#8224;</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acknowledgement Agreement, dated February 22, 2008, between CyDex, Inc. and The University of Kansas </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-33093</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March 3, 2011</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.111</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000119312511055119/dex10108.htm">10.2</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000119312511055119/dex10108.htm">4</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000119312511055119/dex10108.htm">&#8224;</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exclusive License Agreement, dated June&#160;4, 1996, between Pfizer,&#160;Inc. and The University of Kansas </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-33093</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March 3, 2011</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.108</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000119312511055119/dex10110.htm">10.2</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000119312511055119/dex10110.htm">5</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000119312511055119/dex10110.htm">&#8224;</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Addendum to Nonexclusive License Agreement, dated December&#160;11, 2001, between CyDex, Inc. and Pfizer,&#160;Inc. </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-33093</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March 3, 2011</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.11</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000088616313000040/spectrumlicenseagreement-e.htm">10.</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000088616313000040/spectrumlicenseagreement-e.htm">26</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000088616313000040/spectrumlicenseagreement-e.htm">&#8224;</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">License Agreement, by and between CyDex Pharmaceuticals, Inc. and Spectrum Pharmaceuticals, Inc., dated as of March 8, 2013 </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-33093</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">May 8, 2013</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000088616313000040/spectrumsupplyagreement-ex.htm">10.</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000088616313000040/spectrumsupplyagreement-ex.htm">27</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000088616313000040/spectrumsupplyagreement-ex.htm">&#8224;</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Supply Agreement, by and between CyDex Pharmaceuticals, Inc. and Spectrum Pharmaceuticals, Inc., dated as of March 8, 2013 </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-33093</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">May 8, 2013</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.3</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000088616313000078/ligand-selexisroyaltystrea.htm">10.</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000088616313000078/ligand-selexisroyaltystrea.htm">28</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000088616313000078/ligand-selexisroyaltystrea.htm">&#8224;</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Royalty Stream and Milestone Payments Purchase Agreement, dated April 29, 2013, between the Company and Selexis S.A. </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-33093</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">August 1, 2013</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000088616314000090/ligand-vikingxmasterlicens.htm">10.</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000088616314000090/ligand-vikingxmasterlicens.htm">29</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000088616314000090/ligand-vikingxmasterlicens.htm">&#8224;</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Master License Agreement dated May 21, 2014 among the Company, Metabasis Therapeutics, Inc. and Viking Therapeutics, Inc.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-33093</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">August 5, 2014</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000088616314000110/lgnd-vikingxamendmentno1to.htm">10.3</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000088616314000110/lgnd-vikingxamendmentno1to.htm">0</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000088616314000110/lgnd-vikingxamendmentno1to.htm">&#8224;</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">First Amendment to Master License Agreement dated September 6, 2014 among the Company, Metabasis Therapeutics, Inc. and Viking Therapeutics, Inc.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-33093</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">October 31, 2014</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.9</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000088616315000085/lgndvikingmasterlicenseagr.htm">10.</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000088616315000085/lgndvikingmasterlicenseagr.htm">31</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000088616315000085/lgndvikingmasterlicenseagr.htm">&#8224;</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Second Amendment to Master License Agreement, dated April 8, 2015, among the Company, Metabasis Therapeutics, Inc. and Viking Therapeutics, Inc.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-33093</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">August 5, 2015</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000119312514313479/d775802dex102.htm">10.3</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000119312514313479/d775802dex102.htm">2</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Letter Agreement, dated as of August 12, 2014, between Bank of America, N.A. and the Company regarding the Base Issuer Warrant Transaction </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-33093</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">August 18, 2014</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000119312514313479/d775802dex104.htm">10.3</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000119312514313479/d775802dex104.htm">3</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Letter Agreement, dated as of August 12, 2014, between Deutsche Bank AG, London Branch and the Company regarding the Base Issuer Warrant Transaction </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-33093</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">August 18, 2014</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.4</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000119312514313479/d775802dex106.htm">10.3</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000119312514313479/d775802dex106.htm">4</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Letter Agreement, dated as of August 14, 2014, between Bank of America, N.A. and the Company regarding the Additional Issuer Warrant Transaction </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-33093</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">August 18, 2014</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.6</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">98</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:8.841%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:35.449%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.794%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.689%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.549%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.260%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000119312514313479/d775802dex108.htm">10.3</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000119312514313479/d775802dex108.htm">5</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Letter Agreement, dated as of August 14, 2014, between Deutsche Bank AG, London Branch and the Company regarding the Additional Issuer Warrant Transaction </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-33093</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">August 18, 2014</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.8</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000088616319000041/lgnd123118exhibit1048-.htm">10.</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000088616319000041/lgnd123118exhibit1048-.htm">36</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000088616319000041/lgnd123118exhibit1048-.htm">&#8224;</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Development Funding and Royalties Agreement, dated December 13, 2018, by and between Ligand Pharmaceuticals Incorporated and Palvella Therapeutics, Inc.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-33093</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">February 28, 2019</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.48</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="lgnd_123121xexhibit1037.htm">10.</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="lgnd_123121xexhibit1037.htm">37</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="lgnd_123121xexhibit1037.htm">**</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Sublicense Agreement between the Company, Pharmacopeia, Inc. and Retrophin LLC dated as of February 16, 2012, as amended through Amendment No. 5 to Sublicense Agreement, dated March 20, 2018.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000119312515372802/d30180dex101.htm">10.</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000119312515372802/d30180dex101.htm">38</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000119312515372802/d30180dex101.htm">&#8224;</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Lease, dated November 3, 2015, between the Company and 3911/3931 SVB, LLC </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-33093</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">November 10, 2015</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit1039_ligandpharmace.htm">10.39</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Lease, dated June 8, 2021, between the Company and Emery Station Office II, LLC</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;margin-top:2pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000119312516582835/d178557dex101.htm">10.4</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000119312516582835/d178557dex101.htm">0</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000119312516582835/d178557dex101.htm">&#8224;</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest Purchase Agreement, dated May 3, 2016, between the Company and CorMatrix Cardiovascular, Inc.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8-K/A</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-33093</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">May 9, 2016</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000088616317000091/ex102lgndcormatrixarinte.htm">10.4</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000088616317000091/ex102lgndcormatrixarinte.htm">1</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amended and Restated Interest Purchase Agreement, dated May 31, 2017, between the Company and CorMatrix Cardiovascular, Inc. </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-033093</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">August 9, 2017</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000088616318000076/ex101-basebondhedgebc.htm">10.4</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000088616318000076/ex101-basebondhedgebc.htm">2</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Letter Agreement, dated as of May 17, 2018, between Barclays Capital Inc. and the Company regarding the Base Convertible Note Hedge Transaction</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-00393</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">May 22, 2018</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000088616318000076/ex102-basewarrantbc.htm">10.4</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000088616318000076/ex102-basewarrantbc.htm">3</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Letter Agreement, dated as of May 17, 2018, between Barclays Capital Inc. and the Company regarding the Base Issuer Warrant Transaction </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-00393</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">May 22, 2018</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000088616318000076/ex103-basebondhedgedb.htm">10.4</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000088616318000076/ex103-basebondhedgedb.htm">4</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Letter Agreement, dated as of May 17, 2018, between Deutsche Bank AG and the Company regarding the Base Convertible Note Hedge Transaction</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-00393</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">May 22, 2018</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.3</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000088616318000076/ex104-basewarrantdb.htm">10.4</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000088616318000076/ex104-basewarrantdb.htm">5</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Letter Agreement, dated as of May 17, 2018, between Deutsche Bank AG and the Company regarding the Base Issuer Warrant Transaction</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-00393</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">May 22, 2018</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.4</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000088616318000076/ex105-basebondhedgegs.htm">10.</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000088616318000076/ex105-basebondhedgegs.htm">46</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Letter Agreement, dated as of May 17, 2018, between Goldman Sachs &amp; Co. LLC and the Company regarding the Base Convertible Note Hedge Transaction</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-00393</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">May 22, 2018</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.5</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000088616318000076/ex106-basewarrantgs.htm">10.</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000088616318000076/ex106-basewarrantgs.htm">47</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Letter Agreement, dated as of May 17, 2018, between Goldman Sachs &amp; Co. LLC and the Company regarding the Base Issuer Warrant Transaction</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-00393</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">May 22, 2018</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.6</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000088616318000076/ex107-bondhedgebc.htm">10.</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000088616318000076/ex107-bondhedgebc.htm">48</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Letter Agreement, dated as of May 18, 2018, between Barclays Capital Inc. and the Company regarding the Additional Convertible Note Hedge Transaction</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-00393</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">May 22, 2018</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.7</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000088616318000076/ex108-additionalwarrantbc.htm">10.</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000088616318000076/ex108-additionalwarrantbc.htm">49</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Letter Agreement, dated as of May 18, 2018, between Barclays Capital Inc. and the Company regarding the Additional Warrant Transaction</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-00393</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">May 22, 2018</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.8</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000088616318000076/ex109-bondhedgedb.htm">10.5</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000088616318000076/ex109-bondhedgedb.htm">0</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Letter Agreement, dated as of May 18, 2018, between Deutsche Bank AG and the Company regarding the Additional Convertible Note Hedge Transaction</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-00393</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">May 22, 2018</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.9</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000088616318000076/ex1010-additionalwarrantdb.htm">10.5</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000088616318000076/ex1010-additionalwarrantdb.htm">1</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Letter Agreement, dated as of May 18, 2018, between Deutsche Bank AG and the Company regarding the Additional Warrant Transaction</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-00393</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">May 22, 2018</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.10</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000088616318000076/ex1011-bondhedgegs.htm">10.5</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000088616318000076/ex1011-bondhedgegs.htm">2</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Letter Agreement, dated as of May 18, 2018, between Goldman Sachs &amp; Co. LLC and the Company regarding the Additional Convertible Note Hedge Transaction</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-00393</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">May 22, 2018</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.11</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">99</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:8.841%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:35.449%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.794%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.689%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.549%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.260%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000088616318000076/ex1012-additionalwarrantgs.htm">10.5</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000088616318000076/ex1012-additionalwarrantgs.htm">3</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Letter Agreement, dated as of May 18, 2018, between Goldman Sachs &amp; Co. LLC and the Company regarding the Additional Warrant Transaction </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-00393</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">May 22, 2018</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.12</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000088616318000030/indemnificationagreement-d.htm">10.</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000088616318000030/indemnificationagreement-d.htm">54</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000088616318000030/indemnificationagreement-d.htm">#</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Form of Indemnification Agreement between the Company and each of its directors</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-33093</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March 1, 2018</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.60</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000088616318000030/indemnificationagreement-d.htm">10.</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000088616318000030/indemnificationagreement-d.htm">55</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000088616318000030/indemnificationagreement-d.htm">#</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Form of Indemnification Agreement between the Company and each of its officers</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-33093</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March 1, 2018</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.60</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000088616319000156/exhibit101ligand-amend.htm">10.</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000088616319000156/exhibit101ligand-amend.htm">5</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000088616319000156/exhibit101ligand-amend.htm">6</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000088616319000156/exhibit101ligand-amend.htm">&#8224;</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Addendum, dated May 22, 2019, by and among Ligand Pharmaceuticals Incorporated, CyDex Pharmaceuticals, Inc., and Acrotech Biopharma LLC (as successor-in-interest to Spectrum Pharmaceuticals, Inc.), to that certain License Agreement between Ligand Pharmaceuticals Incorporated and Spectrum Pharmaceuticals, Inc., dated March 8, 2013</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-33093</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">August 8, 2019</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/886163/000088616320000061/ligand-exhibit101tofor.htm">10.</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/886163/000088616320000061/ligand-exhibit101tofor.htm">57</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Call Option Amendment Agreement, dated April 6, 2020, between the Registrant and Barclays Bank PLC</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-33093</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">May 8, 2020</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/886163/000088616320000061/ligand-exhibit102tofor.htm">10.</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/886163/000088616320000061/ligand-exhibit102tofor.htm">58</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Call Option Amendment Agreement, dated April 6, 2020, between the Registrant and Deutsche Bank AG, London Branch</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-33093</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">May 8, 2020</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/886163/000088616320000061/ligand-exhibit103tofor.htm">10.</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/886163/000088616320000061/ligand-exhibit103tofor.htm">59</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Call Option Amendment Agreement, dated April 6, 2020, between the Registrant and Goldman Sachs &amp; Co. LLC</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-33093</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">May 8, 2020</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.3</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/886163/000088616321000050/exhibit1067_bondhedgexbarc.htm">10.6</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/886163/000088616321000050/exhibit1067_bondhedgexbarc.htm">0</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Call Option Amendment Agreement, dated January 28, 2021, between the Registrant and Barclays Bank PLC</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-33093</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">February 24, 2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.67</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/886163/000088616321000050/exhibit1068.htm">10.6</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/886163/000088616321000050/exhibit1068.htm">1</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Call Option Amendment Agreement, dated January 28, 2021, between the Registrant and Deutsche Bank AG, London Branch</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-33093</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">February 24, 2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.68</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/886163/000088616321000050/ligand-ex1069xbondhedgeame.htm">10.6</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/886163/000088616321000050/ligand-ex1069xbondhedgeame.htm">2</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Call Option Amendment Agreement, dated January 28, 2021, between the Registrant and Goldman Sachs &amp; Co. LLC</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-33093</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">February 24, 2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.69</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/886163/000088616320000101/a103ligandtauruscvragr.htm">10.</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/886163/000088616320000101/a103ligandtauruscvragr.htm">63</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contingent Value Rights Agreement, dated September 9, 2020, between Ligand Pharmaceuticals Incorporated and Vaughn Smider, as Members' Representative (regarding Taurus Biosciences, LLC acquisition) (incorporated by reference to Exhibit 10.3 to the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission on September 10, 2020)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-33093</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">September 10, 2020</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.3</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/886163/000088616320000101/a104ligandtaurusminota.htm">10.</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/886163/000088616320000101/a104ligandtaurusminota.htm">64</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial License Agreement, dated September 9, 2020, between Taurus Biosciences, LLC and Minotaur Therapeutics, Inc. (incorporated by reference to Exhibit 10.4 to the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission on September 10, 2020)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-33093</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">September 10, 2020</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.4</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/886163/000088616321000050/ligandcydexex1072_gileadsu.htm">10.</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/886163/000088616321000050/ligandcydexex1072_gileadsu.htm">65</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Supply agreement, dated December 22, 2015, by and between Cydex Pharmaceuticals, Inc. and Gilead Sciences, Inc.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-33093</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">February 24, 2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.72</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/886163/000088616320000122/exhibit102ligandcydexg.htm">10.</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/886163/000088616320000122/exhibit102ligandcydexg.htm">66</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amendment to Supply Agreement, dated September 21, 2020, by and between Cydex Pharmaceuticals, Inc. and Gilead Sciences, Inc., which amends that certain Supply Agreement, dated December 2, 2015, by and between Cydex Pharmaceuticals, Inc. and Gilead Sciences, Inc.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-33093</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">November 6, 2020</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="lgnd_123121xexhibit211.htm">21.1</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Subsidiaries of the Company </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="lgnd_123121xexhibit231.htm">23.1</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Consent of Independent Registered Public Accounting Firm</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="lgnd_123121xexhibit311.htm">31.1</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Certification by Principal Executive Officer, Pursuant to Rules 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">X</span></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">100</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:8.841%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:35.449%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.794%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.689%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.549%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.260%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="lgnd_123121xexhibit312.htm">31.2</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Certification by Principal Financial Officer, Pursuant to Rules 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="lgnd_123121xexhibit321.htm">32.1</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Certifications by Principal Executive Officer and Principal Financial Officer, Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">The following financial information from our Annual Report on Form 10-K for the fiscal year ended December 31, 2020, formatted in iXBRL (inline eXtensible Business Reporting Language): (i) Consolidated Balance Sheets, (ii) Consolidated Statements of Operations, (iii) Consolidated Statement of Comprehensive Income, (iv) Consolidated Statements of Stockholders' Equity, (v) Consolidated Statements of Cash Flows, and (vi) the Notes to Consolidated Financial Statements. </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">The cover page from the Company's Annual Report on Form 10-K for the fiscal year ended </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December&#160;31, 2021</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">, formatted in Inline XBRL and contained in Exhibit 101.</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">X</span></td></tr></table></div><div><span><br/></span></div><div style="padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8224;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Confidential treatment has been requested for portions of this exhibit. These portions have been omitted and submitted separately to the Securities and Exchange Commission.</span></div><div style="padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">#&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicates management contract or compensatory plan.</span></div><div style="padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">*&#160;&#160;&#160;&#160;Certain schedules and annexes have been omitted in accordance with Item 601(b)(2) of Regulation S-K. A copy of any omitted schedule and/or annex will be furnished as a supplement to the U.S. Securities and Exchange Commission upon request.</span></div><div style="padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">**&#160;&#160;&#160;&#160;Pursuant to Item 601(b)(10) of Regulation S-K, certain confidential portions of this exhibit were omitted by means of marking such portions with an asterisk because the identified confidential portions (i) are not material and (ii) would be competitively harmful if publicly disclosed.</span></div><div><span><br/></span></div><div><span><br/></span></div><div id="i0fa6f906fb2e4e30bc5e873d2bb6a82c_157"></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:46.198%"><tr><td style="width:1.0%"></td><td style="width:28.330%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:69.470%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Item 16.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Form 10-K Summary</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None</span></div><div id="i0fa6f906fb2e4e30bc5e873d2bb6a82c_160"></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:9pt;text-indent:24pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of Section&#160;13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</span></div><div style="text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:61.695%"><tr><td style="width:1.0%"></td><td style="width:11.696%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:86.104%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LIGAND&#160;PHARMACEUTICALS&#160;INCORPORATED</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/&#160;&#160;&#160;&#160;J</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">OHN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> L. H</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">IGGINS&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">John L. Higgins,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Chief Executive Officer</span></td></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date: February&#160;28, 2022 </span></div><div style="margin-top:9pt;text-indent:24pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">101</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:38.253%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.750%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.229%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Signature</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Title</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Date</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;&#160;&#160;&#160;J</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">OHN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> L. H</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">IGGINS</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer and Director (Principal Executive Officer)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 28, 2022</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">John L. Higgins</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:21pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/s/&#160;&#160;&#160; MATTHEW KORENBERG</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Executive Vice President, Finance and Chief Financial Officer (Principal Financial and Accounting Officer)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 28, 2022</span></td></tr><tr style="height:14pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Matthew Korenberg</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:4pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/s/&#160;&#160;&#160;&#160;JOHN W. KOZARICH</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director and Chairman of the Board</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 28, 2022</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">John W. Kozarich</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:4pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/s/&#160;&#160;&#160;&#160;JASON M. ARYEH</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 28, 2022</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Jason M. Aryeh</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/s/&#160;&#160;&#160;&#160;SARAH BOYCE</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 28, 2022</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Sarah Boyce</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/s/&#160;&#160;&#160;&#160;JENNIFER COCHRAN</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 28, 2022</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Jennifer Cochran</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/s/&#160;&#160;&#160;&#160;TODD C. DAVIS</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 28, 2022</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Todd C. Davis</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/s/&#160;&#160;&#160;&#160;NANCY R. GRAY</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 28, 2022</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nancy R. Gray</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/s/&#160;&#160;&#160;&#160;JOHN L. LAMATTINA</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 28, 2022</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">John L. LaMattina</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/s/&#160;&#160;&#160;&#160;SUNIL PATEL</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 28, 2022</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Sunil Patel</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/s/&#160;&#160;&#160;&#160;STEPHEN L. SABBA</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 28, 2022</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Stephen L. Sabba</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">102</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.37
<SEQUENCE>2
<FILENAME>lgnd_123121xexhibit1037.htm
<DESCRIPTION>EX-10.37
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="ic4941cc38c7541dc945d6ea6ea5eaf5a_1"></div><div style="min-height:0pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit 10.37</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">*** CERTAIN MATERIAL (INDICATED BY THREE ASTERISKS IN BRACKETS) HAS BEEN OMITTED FROM THIS DOCUMENT BECAUSE IT IS BOTH (1) NOT MATERIAL AND (2) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.</font></div><div><font><br></font></div><div style="margin-bottom:12pt;text-indent:36pt"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SUBLICENSE AGREEMENT</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">THIS SUBLICENSE AGREEMENT</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) is made and entered into effective as of February 16, 2012 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Effective Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) by and between Ligand Pharmaceuticals Incorporated, a corporation organized under the laws of Delaware and having a place of business at 11085 North Torrey Pines Road, Suite 300, La Jolla, CA, 92037 and its wholly owned subsidiary, Pharmacopeia, Inc. (as successor in interest to Pharmacopeia Drug Discovery Inc.) (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">PCOP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), a limited liability company organized under the laws of Delaware and having a place of business at 11085 North Torrey Pines Road, Suite 300, La Jolla, CA, 92037 (collectively, Ligand Pharmaceuticals Incorporated and PCOP shall be known as &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Ligand</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) and Retrophin, LLC, a limited liability company organized under the laws of Delaware and having a place of business at 330 Madison Avenue, 6th Floor, New York, NY, 10017 (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Retrophin</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).  Ligand and Retrophin are each referred to herein by name or individually as a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; or collectively as the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.&#8221;  </font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">RECITALS</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">WHEREAS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, Ligand has in-licensed certain patent rights and know-how rights with respect to the Licensed Compounds (as defined below) and has the right to sublicense the same&#59; </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">WHEREAS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, Retrophin desires to obtain from Ligand sublicenses relating to the Licensed Compounds and Ligand desires to grant such sublicenses to Retrophin, all on the terms and conditions set forth in this Agreement&#59;</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">NOW, THEREFORE</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, in consideration of the foregoing and the mutual covenants and agreements set forth below, the receipt and sufficiency of which is hereby acknowledged, the Parties hereby agree as follows&#58;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Article 1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.73pt"> </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">DEFINITIONS</font></div><div style="margin-bottom:11pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The terms in this Agreement with initial letters capitalized shall have the meaning set forth below or, if not listed below, the meaning designated in places throughout this Agreement.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">AAA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in Section 14.3.1.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Act</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the United States Food, Drug and Cosmetic Act, as amended.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Active Compound</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Appendix 2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> hereto.</font></div><div style="margin-bottom:11pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Affiliate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; of a Person means any other Person which (directly or indirectly) is controlled by, controls or is under common control with such Person.  For the purposes of this definition, the term &#8220;control&#8221; (including, with correlative meanings, the terms &#8220;controlled by&#8221; and &#8220;under common control with&#8221;) as used with respect to a Person means (i) in the case of a corporate entity, direct or indirect ownership of voting securities entitled </font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:0pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:11pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">to cast at least </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> of the votes in the election of directors or (ii) in the case of a non-corporate entity, direct or indirect ownership of at least </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#91;***&#93; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">of the voting securities with the power to direct the management and policies of such entity.</font></div><div style="margin-bottom:11pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in the initial paragraph herein and includes all Appendices attached hereto, as the same may be amended or supplemented from time to time.</font></div><div style="margin-bottom:11pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Approval</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means, with respect to any Licensed Product in any regulatory jurisdiction, approval from the applicable Regulatory Authority sufficient for the manufacture, distribution, use and sale of the Licensed Product in such jurisdiction in accordance with applicable Laws.</font></div><div style="margin-bottom:11pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">BMS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means Bristol-Myers Squibb Company, a Delaware corporation headquartered at 345 Park Avenue, New York, New York 10154.</font></div><div style="margin-bottom:11pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">BMS Know-How</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  BMS Know-How shall not include </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Business Day</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">business day</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means a day other than Saturday, Sunday or any day on which commercial banks located in New York, New York are authorized or obligated by applicable Laws to close.</font></div><div style="margin-bottom:11pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.10</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.11</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.12</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Combination Product</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.13</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Commercialization</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Commercialize</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means activities directed to commercially manufacturing, obtaining pricing and reimbursement approvals, carrying out Phase 4 Trials for, marketing, promoting, distributing, importing or selling a pharmaceutical product.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.14</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Commercially Reasonable Efforts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means, with respect to Licensed Compounds and Licensed Products, the carrying out of Development or Commercialization activities in a </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Without limiting the foregoing, Commercially Reasonable Efforts requires that a Party&#58; (i) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#91;***&#93; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(ii) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (iii) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#91;***&#93; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iv) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#91;***&#93; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(v) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.15</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Competitive Compound</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means any </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#91;***&#93; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">that is </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#91;***&#93; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">unless Ligand has</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Ligand shall not </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.16</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Confidential Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means all trade secrets, processes, formulae, data, know-how, improvements, inventions, chemical or biological materials, assays, techniques, marketing plans, strategies, customer lists, or other information that has been created, discovered, or developed by a Party, or has otherwise become known to a Party, or to which rights have been assigned to a Party, as well as any other information, agreements and materials that are deemed confidential or proprietary to or by a Party (including all information and materials of a Party&#8217;s customers and any other Third Party and their consultants), in each case that are disclosed by such Party to the other Party, regardless of whether any of the foregoing are marked &#8220;confidential&#8221; or &#8220;proprietary&#8221; or communicated to the other by the disclosing Party in oral, written, graphic, or electronic form.  </font></div><div style="margin-bottom:11pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.17</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Controlled</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Controls</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;, when used in reference to intellectual property, means the legal authority or right of a Party hereto (or any of its Affiliates) to grant a </font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:0pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:11pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">license or sublicense of intellectual property rights to another Party, or to otherwise disclose proprietary or trade secret information to such other Party, without breaching the terms of any agreement with a Third Party, or misappropriating the proprietary or trade secret information of a Third Party.</font></div><div style="margin-bottom:11pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.18</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Core Patent Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the patents and patent applications that are listed in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Appendix 1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> hereto and (a) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#91;***&#93; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">that </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#91;***&#93; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">listed in Appendix 1 hereto </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#91;***&#93; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(but in each case, only with respect to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#91;***&#93; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">listed in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Appendix 1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> hereto), (b) all </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#91;***&#93; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">foregoing</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, together with all </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#91;***&#93; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">thereof (but in each case, only with respect to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#91;***&#93; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Appendix 1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> hereto).</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.19</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Cover</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">,&#8221; &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Covered</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Covering</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means, with respect to patent rights, that the making, using, importation, offer for sale or sale of an invention claimed in such patent rights or the conducting of an activity that, in the absence of a license under such patent rights, would infringe at least one Valid Claim of such patent rights whether present in an issued patent or in a patent application if it issued as a patent containing such claim.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.20</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Development</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means non-clinical and clinical drug development activities reasonably related to the development and submission of information to a Regulatory Authority, including toxicology, pharmacology and other discovery and pre-clinical efforts, test method development and stability testing, manufacturing process development, formulation development, delivery system development, quality assurance and quality control development, statistical analysis, clinical studies (including, pre- and post-approval studies and specifically excluding regulatory activities directed to obtaining pricing and reimbursement approvals).  When used as a verb, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Develop</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means to engage in Development.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.21</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Development Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means, with respect to any Licensed Product, a comprehensive, multi-year plan specifying the anticipated timing and technical details of Development activities for such Licensed Product, including the indications to be targeted, line of therapy, timelines for completing key activities, phasing of development, primary endpoints, criteria for continuing activities, study size, comparator drugs, combination drugs, timelines for data preparation and filing of regulatory submissions, toxicology and pharmacology studies and manufacturing process development and scale up.  An outline of the initial Development Plan as of the Effective Date is attached hereto as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Appendix 3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.22</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Dollar</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">$</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the lawful currency of the United States.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.23</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Effective Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in the initial paragraph of this Agreement.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.24</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">EMEA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the European Agency for the Evaluation of Medicinal Products, or any successor agency thereto.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.25</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Excluded Claim</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means a Dispute that concerns (a) the validity or infringement of a patent, trademark or copyright or (b) any antitrust, anti-monopoly or competition law or regulation, whether or not statutory.  </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.26</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">&#8220;Executive</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means for Ligand, the Chief Executive Officer of Ligand (or such individual&#8217;s designee) and for Retrophin, the Chief Executive Officer of Retrophin (or such individual&#8217;s designee).  If either position is vacant or either position does not exist, then the person having the most nearly equivalent position (or such individual&#8217;s designee) shall be deemed to be the Executive of the relevant Party.</font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:0pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.27</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Exit Transaction</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means&#58; (i) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#91;***&#93;</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.28</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">FDA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the U.S. Food and Drug Administration, or any successor agency thereto.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.29</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Field</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the diagnosis, prevention, treatment or control of any human or animal disease, disorder or condition.</font></div><div style="margin-bottom:11pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.30</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">First Commercial Sale</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means, with respect to any Licensed Product, the first sale for use or consumption by the general public of such Licensed Product in any country in the Territory after Approval of such Licensed Product has been granted, or such marketing and sale is otherwise permitted, by the Regulatory Authority of such country.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.31</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">GAAP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means generally accepted accounting principles in the United States.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.32</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">IND</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means an Investigational New Drug Application, as defined in the Act, filed with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">the FDA or its foreign counterparts.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.33</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Indemnification Claim</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in Section 12.3.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.34</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Indemnitee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in Section 12.3.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.35</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Indemnitor</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in Section 12.3.  </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.36</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">JNDA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means a New Drug Application filed with the Koseisho required for marketing approval for the applicable Licensed Product in Japan.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.37</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">JNDA Approval</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the approval of a JNDA by the Koseisho for the applicable Licensed Product in Japan.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.38</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">JNDA Filing</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the submission to the Koseisho of a JNDA for the applicable Licensed Product in Japan.</font></div><div style="margin-bottom:11pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.39</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Know-How</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:11pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.40</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Koseisho</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the Japanese Ministry of Health and Welfare, or any successor agency thereto.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.41</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Laws</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means all laws, statutes, rules, regulations, ordinances and other pronouncements having the effect of law of any federal, national, multinational, state, provincial, county, city or other political subdivision, agency or other body, domestic or foreign.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.42</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">License</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means any agreement transferring rights with respect to any Licensed Compound or any Licensed Product by Retrophin (or an Affiliate of Retrophin) to any Third Party licensee, including any license, sublicense, co-development, co-promotion, distribution, joint venture, development and commercialization collaboration or similar transaction involving a transfer of rights with respect to a Licensed Compound or Licensed Product.  &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">License</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall also include any further transfer of such rights by a Third Party licensee to any other Third Party.  &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">License</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; also refers to the corresponding arrangement for the grant by Retrophin of rights back to BMS and Ligand with respect to one or more Licensed Compound(s) and Licensed Product(s) pursuant to Article 3.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.43</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Licensed Compounds</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means&#58; </font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:0pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#59;</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">any </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#59;</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">any </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#59; and</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">any </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.44</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Licensed Product</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means any pharmaceutical product containing a Licensed Compound (alone or with other active ingredients), in all forms, presentations, formulations and dosage forms.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.45</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Listed Compounds</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means those compounds identified in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Appendix 4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.46</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Losses and Claims</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in Section 12.1.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.47</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">MAA Approval</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means approval by the EMEA of a marketing authorization application (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">MAA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) filed with the EMEA for the applicable Licensed Product under the centralized European procedure.  If the centralized EMEA filing procedure is not used, MAA Approval shall be achieved upon the first Approval for the applicable Licensed Product in any two of the following countries&#58; France, Germany, Italy, Spain or the United Kingdom.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.48</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">MAA Filing</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the submission to the EMEA of a </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">MAA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> for the applicable Licensed Product under the centralized European procedure.  If the centralized EMEA filing procedure is not used, MAA Filing shall be achieved upon the first filing of a marketing authorization application for the applicable Licensed Product in any two of the following countries&#58; France, Germany, Italy, Spain or the United Kingdom.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.49</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Major Market Countries</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Major Market Country</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.50</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">NDA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means a New Drug Application filed with the FDA required for marketing approval for the applicable Licensed Product in the U.S.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.51</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">NDA Approval</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the approval of a NDA by the FDA for the applicable Licensed Product in the U.S.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.52</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">NDA Filing</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the submission to the FDA of a NDA for the applicable Licensed Product.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.53</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Net Sales</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means, with respect to any </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#58;</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">provided, however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, that where any such </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#59; </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#59;</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#59; and</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:11pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Net Sales shall be determined </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  In the case of any Combination Product sold in the Territory, Net Sales for such Combination Product shall be calculated by </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:11pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Net Sales shall not include any </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  </font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:0pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:11pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.54</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Orphan Licensed Product</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means a Licensed Product that receives orphan drug designation from the FDA pursuant to 21 C.F.R. Part 316, or from a Regulatory Authority pursuant to a comparable rule or regulation in a foreign jurisdiction, including the orphan indications set forth in the Development Plan.  </font></div><div style="margin-bottom:11pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.55</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Other Patent Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means (i) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#91;***&#93; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#91;***&#93; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">or (b) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#91;***&#93; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">and (ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> &#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. </font></div><div style="margin-bottom:11pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.56</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Patent Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the Core Patent Rights and the Other Patent Rights.</font></div><div style="margin-bottom:11pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.57</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Person</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means any individual, firm, corporation, partnership, limited liability company, trust, business trust, joint venture company, governmental authority, association or other entity.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.58</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Phase 2 Trial</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means a human clinical trial of a Licensed Product, the principal purpose of which is a determination of safety and efficacy in the target patient population, as described in 21 C.F.R. 312.21(b), or a similar clinical study prescribed by the Regulatory Authorities in a foreign country.  For purposes of this Agreement, &#8220;initiation of a Phase 2 Trial&#8221; for a Licensed Product means the first dosing of such Licensed Product in a human patient in a Phase 2 Trial.  </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.59</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Phase 3 Trial</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means a human clinical trial of a Licensed Product on a sufficient number of subjects that is designed to establish that a pharmaceutical product is safe and efficacious for its intended use, and to determine warnings, precautions, and adverse reactions that are associated with such pharmaceutical product in the dosage range to be prescribed, which trial is intended to support Approval of a Licensed Product, as described in 21 C.F.R. 312.21(c), or a similar clinical study prescribed by the Regulatory Authorities in a foreign country.  For clarity, any human clinical trial may qualify as a Phase 3 Trial if it supports Approval of a Licensed Product without the need to conduct a Phase 3 Trial.  For purposes of this Agreement, &#8220;initiation of a Phase 3 Trial&#8221; for a Licensed Product means the first dosing of such Licensed Product in a human patient in a Phase 3 Trial.  </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.60</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Phase 4 Trial</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means a human clinical trial for a Licensed Product commenced after receipt of Approval in the country for which such trial is being conducted and that is conducted within the parameters of the Approval for the Licensed Product.  Phase 4 Trials may include epidemiological studies, modeling and pharmacoeconomic studies, investigator sponsored clinical trials of the Licensed Product and post-marketing surveillance studies.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.61</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Proprietary Compound of BMS or Ligand</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;  means any compound or other agent being developed or sold, (a) as of the March 27, 2006 or at any time thereafter, by BMS or its Affiliates, or their contractors or collaborators, or (b) as of the Effective Date or any time thereafter, by Ligand or its Affiliates, or their contractors or collaborators.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.62</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Regulatory Authority</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means any national or supranational governmental authority, including the FDA, EMEA or Koseisho (i.e., the Japanese Ministry of Health and Welfare, or any successor agency thereto), that has responsibility in countries in the Territory over the Development and&#47;or Commercialization of Licensed Compounds and Licensed Products.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.63</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Sublicensee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means any Third Party to whom rights are transferred with respect to any Licensed Compound or Licensed Product, including through any license, sublicense, co-development, co-discovery, co-promotion, distribution, joint venture, </font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:0pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Development and Commercialization collaboration or similar transaction between a Party (or an Affiliate of a Party) and a Third Party.  &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Sublicensee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall also include any Third Party to whom such rights are transferred through further sublicense by a Sublicensee.  &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Sublicensee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall include any Third Party that is a party to a License agreement.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.64</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Territory</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means any country in the world.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.65</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Third Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means any Person other than Retrophin, Ligand and their respective Affiliates.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.66</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Title 11</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in Section 13.7.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.67</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">United States</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">U.S.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the United States of America and its territories and possessions (including Puerto Rico).</font></div><div style="margin-bottom:11pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.68</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.69</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Valid Claim</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means a claim of (i) an issued and unexpired patent or a supplementary protection certificate, which claim has not been held invalid or unenforceable by a court or other government agency of competent jurisdiction from which no appeal can be or has been taken and has not been held or admitted to be invalid or unenforceable through re-examination or disclaimer, opposition procedure, nullity suit or otherwise or (ii) a pending patent application&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, that if a claim of a pending patent application shall not have issued within </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#91;***&#93; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">after the earliest filing date from which such claim takes priority, such claim shall not constitute a Valid Claim for the purposes of this Agreement unless and until a patent issues with such claim.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ARTICLE 2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160; </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">LICENSE GRANTS</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Patent Rights and Know-How</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;padding-left:9pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Core Patent Rights and Know-How</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Subject to the terms and conditions set forth in this Agreement (including the reservation of rights in Section 2.5), Ligand hereby grants to Retrophin a non-transferable (except in accordance with Section 15.4), exclusive sublicense, with the right to further sublicense in accordance with Section 2.2, under the Core Patent Rights and Know-How solely to the extent reasonably necessary to, make, use (including in activities directed at the research and Development of Licensed Compounds), have made, sell, have sold, offer to sell, export, import and otherwise exploit or Commercialize Licensed Compounds and Licensed Products in the Field in the Territory.</font></div><div style="margin-bottom:12pt;padding-left:9pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Other Patent Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Subject to the terms and conditions set forth in this Agreement (including the reservation of rights in Section 2.5), Ligand hereby grants to Retrophin a non-transferable (except in accordance with Section 15.4), non-exclusive sublicense, with the right to further sublicense in accordance with Section 2.2, under the Other Patent Rights solely to the extent reasonably necessary or useful to make, use (including in activities directed at the research and Development of Licensed Compounds), have made, sell, offer to sell, export and import and otherwise exploit or Commercialize Licensed Compounds and Licensed Products in the Field in the Territory, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">provided, however,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> that no rights are granted under this Section 2.1.2 (or otherwise under this Agreement) with respect to any Proprietary Compound of BMS or Ligand.  For clarification, no rights are granted under this Section 2.1.2 (or otherwise under this </font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:0pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Agreement) to co-formulate or use in combination a Licensed Compound with any Proprietary Compound of BMS or Ligand.  The rights granted by Ligand to Retrophin under this Section 2.1.2 include the right to make, have made, use (including in activities directed at the research and Development of Licensed Compounds), export and import intermediates and starting materials reasonably necessary for the manufacture of Licensed Compounds, and to practice methods reasonably necessary for the manufacture of Licensed Compounds, and to practice methods reasonably necessary for manufacturing such intermediates and starting materials, but only for the purposes of manufacturing, using, importing or exporting Licensed Compounds in the Field in the Territory.  For clarification, no rights are granted to sell or offer to sell any such intermediates or starting materials, or use such intermediates or starting materials for any purpose other than for the purposes of manufacturing Licensed Compounds. </font></div><div style="margin-bottom:11pt;padding-left:27pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Sublicenses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  </font></div><div style="margin-bottom:12pt;padding-left:9pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.2.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Retrophin shall have the right to grant sublicenses with respect to the rights licensed to Retrophin under Sections 2.1.1 and 2.1.2 to any Affiliate of Retrophin for so long as such Affiliate remains an Affiliate of Retrophin&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">provided, however,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> that (i) such Affiliate shall agree in writing to be bound by and subject to the terms and conditions of this Agreement in the same manner and to the same extent as Retrophin and (ii) Retrophin shall remain responsible for the performance of this Agreement and shall cause such Affiliate to comply with the terms and conditions of this Agreement.  In addition, Retrophin shall have the right to grant sublicenses with respect to the rights licensed to Retrophin under Sections 2.1.1 and 2.1.2 to Third Parties.</font></div><div style="margin-bottom:12pt;padding-left:9pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.2.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Retrophin shall have the right to enter into a License agreement with a Third Party&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">provided, however,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> to the extent any such License agreement grants rights with respect to any Licensed Compound&#58;</font></div><div style="margin-bottom:11pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">such License agreement shall be consistent with the terms and conditions of this Agreement, and shall not limit (A) Retrophin&#8217;s ability to perform its obligations under this Agreement, (B) Ligand&#8217;s rights under this Agreement, (C) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#91;***&#93; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">or (D)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> &#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:11pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">in such License agreement, the Sublicensee shall agree in writing to be bound to Retrophin by terms and conditions that are substantially similar to, or less favorable to the Sublicensee than, or otherwise allow Retrophin to fully perform the corresponding terms and conditions of this Agreement&#59;</font></div><div style="margin-bottom:11pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">such License agreement shall comply with Section 8.10.2 hereof regarding minimum royalty payments&#59; </font></div><div style="margin-bottom:11pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">promptly after the execution of such License agreement, Retrophin shall provide a copy of such License agreement to Ligand, with financial and other confidential or proprietary commercial terms redacted consistent with the public filing of such license agreement with the Securities and Exchange Commission (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">SEC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), or, if not filed with the SEC, then with financial and other confidential or proprietary commercial terms redacted (to the extent that such other commercial terms are not reasonably necessary for Ligand to determine Retrophin&#8217;s compliance with this Agreement).  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#59;</font></div><div style="margin-bottom:11pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(v)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Retrophin shall remain responsible for the performance of this Agreement (including its obligations under Sections 5.1.1 and 6.1), the payment of all </font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:0pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:11pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">payments due, making reports and keeping books and records and shall use commercially reasonable efforts to monitor such Sublicensee&#8217;s compliance with the terms of such License&#59;</font></div><div style="margin-bottom:11pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(vi)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">any sublicense rights granted by Retrophin in a License (to the extent such sublicensed rights are granted to Retrophin in this Agreement) shall terminate on a country-by-country and Licensed Product-by-Licensed Product basis effective upon (i) the termination under Section 13.2 of the license from Ligand to Retrophin with respect to such sublicensed rights or (ii) the termination under Section 13.2 of the license from BMS to Ligand with respect to such sublicensed rights&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">provided, however,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> that such sublicensed rights shall not terminate if, as of the effective date of such termination by Ligand under Section 13.2 of this Agreement or BMS under Section 13.2 of the Upstream License Agreement, the Sublicensee is not in material breach of its obligations to Retrophin under its License agreement, and within </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#91;***&#93; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">days of such termination the Sublicensee agrees in writing to be bound directly to BMS or Ligand, as the case may be, under a license agreement substantially similar to this Agreement </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, as the case may be, with respect to the rights sublicensed hereunder, substituting such Sublicensee for Retrophin or Ligand, as the case may be&#59; and </font></div><div style="margin-bottom:11pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(vii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">such Sublicensees shall have the right to grant further sublicenses with respect to the Development or Commercialization of Licensed Products, provided that such further sublicenses shall be in accordance with and subject to all of the terms and conditions of this Section 2.2.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;For purposes of clarification, the preceding provisions of this Section 2.2.2 shall not apply to Licensed Compounds with respect to which Retrophin </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#91;***&#93; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Ligand a License.</font></div><div><font><br></font></div><div style="margin-bottom:12pt;padding-left:9pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.2.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">In accordance with the foregoing, unless Ligand agrees otherwise in writing, any License shall </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;padding-left:9pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.2.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">It shall be a </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:11pt;text-indent:63pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">No Trademark License</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  No right or license, express or implied, is granted to Retrophin to use any trademark, trade name, trade dress or service mark owned or Controlled by BMS, Ligand or any of their respective Affiliates.  Retrophin, at its sole cost and expense, shall be responsible for the selection, registration and maintenance of all trademarks which it employs in connection with its activities conducted pursuant to this Agreement, if any, and shall own and control such trademarks.</font></div><div style="margin-bottom:11pt;text-indent:63pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">No Implied Licenses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  No license or other right is or shall be created or granted hereunder by implication, estoppel or otherwise.  All such licenses and rights are or shall be granted only as expressly provided in this Agreement.</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Retained Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;padding-left:9pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.5.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Retrophin understands and agrees that BMS shall retain the rights specified in Section 2.5 of the Upstream License Agreement.</font></div><div style="margin-bottom:12pt;padding-left:9pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.5.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Subject to the Upstream License Agreement, all rights not expressly granted under Section 2.1 are reserved by Ligand and may be used by Ligand for any purpose.  Ligand expressly reserves and retains the right (i) to make, have made and use Licensed Compounds for any internal research purposes (including but not </font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:0pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">limited to for purposes of screening in support of Ligand&#8217;s internal research programs), (ii) to support the filing and prosecution of patent applications, and (iii) to make, have made and use any Licensed Compound solely for use as an intermediate or starting material in the manufacture of any compound which is not a Licensed Compound.</font></div><div style="margin-bottom:12pt;padding-left:9pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.5.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Subject to the exclusive rights granted to Retrophin under this Article 2 and subject to the restrictions on use of Retrophin&#8217;s Confidential Information under Article 11,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> &#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  For purposes of clarity, nothing in the foregoing shall be construed to reserve to Ligand the right to engage in the discovery, Development and&#47;or Commercialization of Active Compounds Covered by the Core Patent Rights exclusively licensed to Retrophin hereunder.  </font></div><div style="margin-bottom:12pt;text-indent:63pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Upstream License Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Notwithstanding anything to the contrary in this Agreement, Retrophin understands and agrees (i) that this Agreement is subordinate to the Upstream License Agreement and the sublicense granted to Retrophin under this Agreement is limited in scope to the rights granted to Ligand in the Upstream License Agreement&#59; (ii) this Agreement may be terminated if the Upstream License Agreement is terminated (iii) it will comply with all provisions of the Upstream License Agreement relevant to its activities as a Sublicensee (as defined in the Upstream License Agreement)&#59; (iv) BMS&#8217; exercise of its rights under the Upstream License Agreement shall not constitute a breach hereunder&#59; (v) it will not take any action that would result in a breach of the Upstream License Agreement&#59; and (vi) it will cooperate with and assist Ligand to meet its obligations under the Upstream License Agreement.&#160; Retrophin acknowledges that it has been provided with a copy of the Upstream License Agreement. </font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ARTICLE 3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160; </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">LIGAND RIGHT OF FIRST NEGOTIATION</font></div><div style="margin-bottom:12pt;text-indent:63pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">BMS Right of First Negotiation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  In the event that Retrophin desires to enter into a License arrangement with respect to any Licensed Compound (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Business Opportunity</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), BMS shall be granted the Right of First Negotiation set forth in Article 3 of the Upstream License Agreement.  Retrophin shall comply with the terms set forth in Sections 3.1.1 and 3.1.3-3.1.6 of the Upstream License Agreement.  For the purposes of this Section 3.1, &#8220;Pharmacopeia&#8221; shall be replaced with &#8220;Retrophin&#8221; in Sections 3.1.1 and 3,1.3-3.1.6 of the Upstream License Agreement.   </font></div><div style="margin-bottom:12pt;padding-left:27pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Ligand Right of Second Negotiation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;padding-left:9pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.2.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">In the event that Retrophin desires to enter into a Business Opportunity, before entering into negotiations with any Third Party and after following the procedure set forth in Section 3.1 above, with respect to such License, Retrophin shall notify Ligand and provide Ligand with information necessary or useful to Ligand to evaluate the proposed License arrangement (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Evaluation Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).  The Parties shall negotiate in good faith the terms pursuant to which Ligand may obtain such Business Opportunity for a period of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#91;***&#93; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">days following the date of such notice (such period referred to as the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Ligand Negotiation Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;). </font></div><div style="margin-bottom:12pt;padding-left:9pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.2.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Unless otherwise agreed between the Parties, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  </font></div><div style="margin-bottom:12pt;padding-left:9pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.2.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Any License agreement entered into by Retrophin with a Third Party shall be consistent with the terms and conditions of this Agreement and shall fully enable Retrophin to fully perform all of its obligations under the Agreement which will </font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:0pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">continue in effect.  As set forth in Section 2.2, any Sublicensee shall be bound by the terms and conditions of this Agreement in the same manner as Retrophin.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ARTICLE 4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160; </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">TRANSFER OF KNOW-HOW </font></div><div style="margin-bottom:11pt;text-indent:63pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Documentation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Prior to the Effective Date, Ligand has provided to Retrophin one (1) electronic or paper copy of all documents, data or other information Controlled by Ligand as of the Effective Date to the extent that such documents, data and information are (i) reasonably necessary or useful for the manufacture, Development or Commercialization of the Listed Compounds (including SAR information) and subject to the Know-How license under Section 2.1 and (ii) are reasonably available to Ligand without undue searching&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">provided however,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> that subject to the last sentence of this Section 4.1, the foregoing shall in no event require Ligand to provide copies of manufacturing run records or laboratory notebook records&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">further provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> that if Retrophin determines it needs additional documents, data or information for the manufacture, Development or Commercialization of the Licensed Compounds (including SAR information), Ligand shall use commercially reasonable efforts (at Retrophin&#8217;s cost and expense) to determine whether it has such additional information and if Ligand has such information, it shall provide such information to Retrophin at Retrophin&#8217;s cost and expense.  Such documentation shall be deemed to be the Confidential Information of Ligand and shall not be used by Retrophin for any purpose other than Development, manufacture or Commercialization of Licensed Compounds and Licensed Products in accordance with this Agreement.  Retrophin acknowledges that it has received from Ligand such documents, data and information prior to the Effective Date through access to the electronic data room established by Ligand for the Listed Compound and that Ligand has allowed Retrophin to print such documents.  Ligand shall have no obligation to reformat or otherwise alter or modify any such materials, or to create materials in electronic form, in order to provide them to Retrophin&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, that such information is readable by Retrophin in its current form.  Any and all such materials delivered to Retrophin pursuant to this Section 4.1 are and shall remain, as between the Parties, the sole property of Ligand.  Notwithstanding the foregoing, if at any time during the term of this Agreement Retrophin identifies particular documents, data or information (including laboratory notebook records) that are within the Know-How, but were not previously delivered to Retrophin, and that are reasonably necessary or useful for the continued manufacture, Development or Commercialization of a Licensed Compound or Licensed Product (including materials requested in connection with an audit or other inquiry by a Regulatory Authority), or are reasonably necessary or useful to support the filing and&#47;or prosecution of patent rights Covering the Licensed Compounds or Licensed Products, Ligand shall promptly provide such material to Retrophin upon request to the extent that such items are in Ligand&#8217;s possession and are available without undue searching.</font></div><div style="margin-bottom:11pt;text-indent:63pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Materials</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Ligand shall have no obligation to provide Retrophin with samples of any compounds or other materials (other than the information provided under Section 4.1) under this Agreement, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> that upon written request by Retrophin, Ligand will authorize in writing the transfer by </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#91;***&#93; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">to Retrophin of all existing clinical supplies of Licensed Product and all existing supplies of the active pharmaceutical ingredient of Licensed Product (including other materials that may be provided by or for Ligand to Retrophin pursuant to this Agreement, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Transferred Materials</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).  Retrophin shall be responsible for any and all fees charged by </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> in connection with the transfer of the Transferred Materials to Retrophin.  Any Transferred Materials are provided &#8220;AS IS&#8221;.  Retrophin shall be fully responsible for its and its Affiliates&#8217;, Sublicensees&#8217; and </font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:0pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:11pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">contractors&#8217; use, storage, handling and disposition of the Transferred Materials.  Under no circumstances shall Ligand be liable or responsible for Retrophin&#8217;s or its Affiliates&#8217;, Sublicensees&#8217; and contractors&#8217; use, storage, handling or disposition of the Transferred Materials, and Retrophin assumes sole responsibility for any claims, liabilities, damages and losses that might arise as a result of Retrophin&#8217;s and its Affiliates&#8217;, Sublicensees&#8217; and contractors&#8217; use, storage, handling or disposition of any Transferred Material.  Retrophin shall indemnify, defend and hold harmless Ligand and its Affiliates, and their respective officers, directors, employees, agents, licensors, and their respective successors, heirs and assigns and representatives, from and against any and all damages, liabilities, losses, costs and expenses (including, without limitation, reasonable legal expenses, costs of litigation and reasonable attorney&#8217;s fees) arising in connection with any claims, suits, proceedings, whether for money damages or equitable relief, of any kind, arising out of or relating, directly or indirectly, to Retrophin&#8217;s, or any of its Affiliates&#8217;, Sublicensees&#8217; or contractors&#8217; use, storage, handling or disposition of any Transferred Material.  Transferred Materials may only be provided to Retrophin, its Affiliates, Sublicensees and contractors.  The Transferred Materials shall be used by Retrophin solely for purposes of supporting the Development of the Licensed Compounds and Licensed Products.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ARTICLE 5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160; </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">DEVELOPMENT</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Development and Development Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;padding-left:9pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5.1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Commercially Reasonable Efforts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Retrophin (or its Sublicensees, as applicable) shall use sustained Commercially Reasonable Efforts to Develop at least one Licensed Compound and Licensed Product, including using Commercially Reasonable Efforts to expeditiously carry out the clinical development for the Licensed Compounds and Licensed Products (including expeditiously pursuing regulatory filings and Approvals and marketing authorizations for at least one Licensed Compound and Licensed Product) in accordance with the Development Plan.</font></div><div style="margin-bottom:12pt;padding-left:9pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5.1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Development Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The initial Development Plan is attached hereto as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Appendix 3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> to the Agreement.  </font></div><div style="margin-bottom:11pt;text-indent:63pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Development Reports</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Retrophin will provide Ligand with (a) semi-annual written development reports within </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#91;***&#93; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">days following June and December of each </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#91;***&#93; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">and (b) quarterly telephonic development reports within </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#91;***&#93; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">days following March and September of each </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, in each case presenting a summary of the Development activities accomplished by Retrophin during the applicable period, including as applicable updates to the Development Plan, and significant results, information and data generated with respect to Licensed Compounds and Licensed Products.  Upon reasonable request by Ligand, Retrophin shall also meet in-person with Ligand to review Retrophin&#8217;s Development activities for the Licensed Compounds and Licensed Products.  In addition, prior to Retrophin entering into a License agreement with a Third Party, upon reasonable request by Ligand, but no more than once per </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, Retrophin shall present to Ligand, at Retrophin&#8217;s facilities, summaries of (and, at the request of Ligand, with copies of) clinical protocols, investigator brochures, regulatory submissions and correspondence from regulatory agencies with respect to Licensed Compound and Licensed Product that have been prepared or received by Retrophin as of the date of such request by Ligand.</font></div><div style="margin-bottom:11pt;text-indent:63pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Records</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Retrophin shall maintain complete and accurate records of all work conducted in furtherance of the Development and Commercialization of the Licensed Compounds and Licensed Products and all material results, data and </font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:0pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:11pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">developments made in conducting such activities.  Such records shall be maintained sufficient detail and in good scientific manner appropriate for patent and regulatory purposes.  If Ligand believes in good faith that Retrophin may not be complying with its obligations under this Section 5.3, Ligand shall provide written notice thereof to Retrophin identifying the basis for Ligand&#8217;s belief, and Retrophin shall allow an independent Third Party that has expertise in reviewing the books and records and financial information, obligations and agreements of pre-clinical and clinical stage bio-technology companies, as to which Retrophin has no reasonable objection, to review such records on behalf of Ligand to verify that Retrophin is complying with this Section 5.3.  Such review shall be conducted no more frequently than once per any twelve (12) month period, at Ligand&#8217;s cost and upon reasonable advance notice at mutually agreed upon times during normal business hours&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">provided, however, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">if the independent Third Party determines that Retrophin is not in compliance with this Section 5.3 and Retrophin would owe Ligand at least 10% more in royalties or other payments, Retrophin shall reimburse Ligand for all costs and expenses related to the independent Third Party&#8217;s review.  </font></div><div style="margin-bottom:11pt;text-indent:63pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Development Responsibilities and Costs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Retrophin shall have sole responsibility for, and shall bear the cost of conducting, all Development with respect to the Licensed Compounds and Licensed Products.</font></div><div style="margin-bottom:11pt;text-indent:63pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Regulatory Responsibilities and Costs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Retrophin </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Retrophin shall be responsible for meeting the requirements of all pre-approval inspections required by any Regulatory Authorities.  Except as set forth in Section 13.4, Retrophin or its Affiliate or Sublicensee shall own all INDs, NDAs, Approvals and submissions in connection therewith and all Approvals shall be obtained by and in the name of Retrophin or its Affiliate or Sublicensee.</font></div><div style="margin-bottom:11pt;text-indent:63pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Subcontracting</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Subject to and without limiting Section 2.2, Retrophin may perform any activities in support of its Development or Commercialization of Licensed Compounds and Licensed Products through subcontracting to a Third Party contractor or contract service organization&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">provided, however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#58;  (a) Retrophin shall enter into an appropriate written agreement with any such Third Party subcontractor such that the subcontractor shall be bound by all applicable provisions of this Agreement to the same extent as Retrophin and such that Ligand&#8217;s rights under this Agreement and BMS&#8217; rights under the Upstream License Agreement are not adversely affected&#59; (b) any such Third Party subcontractor to whom Retrophin discloses Confidential Information of Ligand shall enter into an appropriate written agreement obligating such Third Party to be bound by obligations of confidentiality and restrictions on use of such Confidential Information that are no less restrictive than the obligations in this Agreement&#59; (c) Retrophin will obligate such Third Party to agree in writing to assign or license (with the right to grant sublicenses) to Retrophin any inventions (and any patent rights covering such inventions) made by such Third Party in performing such services for Retrophin&#59; and (d) Retrophin shall at all times be responsible for the performance of such subcontractor.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ARTICLE 6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">COMMERCIALIZATION</font></div><div style="margin-bottom:11pt;text-indent:63pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">6.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Retrophin Obligations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Retrophin (or its Sublicensees, as applicable) shall use sustained Commercially Reasonable Efforts to Commercialize at least </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#91;***&#93; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Licensed Product in the Territory, including the Major Market Countries.  Without limiting the foregoing, Retrophin shall&#58; </font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:0pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:9pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">6.1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">use Commercially Reasonable Efforts to obtain Approvals in a Major Market Country with respect to at least </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> Licensed Product and to effect the First Commercial Sale thereof in such country as soon as reasonably practicable after receipt of such Approvals&#59; </font></div><div style="margin-bottom:12pt;padding-left:9pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">6.1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Initiation of a Phase 2 Trial for at least </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#91;***&#93; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Licensed Compound no later than </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#59; </font></div><div style="margin-bottom:12pt;padding-left:9pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">6.1.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">File for Approval for at least </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#91;***&#93; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Orphan Licensed Product no later than </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#59; and</font></div><div style="margin-bottom:12pt;padding-left:9pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">6.1.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">File for Approval for at least </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#91;***&#93; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Licensed Product other than the first Orphan Licensed Product no later than </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:11pt;text-indent:63pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">6.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Continued Availability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Following the First Commercial Sale of a Licensed Product in a Major Market Country in the Territory and until the expiration or termination of this Agreement, Retrophin shall use Commercially Reasonable Efforts to supply and keep such Licensed Product reasonably available to the public in such country.</font></div><div style="margin-bottom:11pt;text-indent:63pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">6.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Marking</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Each Licensed Product Commercialized by Retrophin under this Agreement shall be marked (to the extent not prohibited by applicable Laws)&#58; (i) with a notice that such Licensed Product is sold under a license from BMS and Ligand and (ii) with applicable patent and other intellectual property notices relating to the Core Patent Rights in such a manner as may be required by applicable Law.</font></div><div style="margin-bottom:11pt;text-indent:63pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">6.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Reports</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Retrophin shall provide Ligand with semi-annual written reports within </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#91;***&#93; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">days following the end of June and December of each </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#91;***&#93; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">summarizing significant commercial activities and events with respect to Licensed Products during the just ended six month period.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ARTICLE 7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">MANUFACTURE AND SUPPLY</font></div><div style="margin-bottom:11pt;text-indent:63pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">7.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Manufacture and Supply</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Retrophin shall be solely responsible at its expense for making or having made all of its requirements of the Licensed Compounds and Licensed Products.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ARTICLE 8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160; </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">FINANCIAL TERMS</font></div><div style="margin-bottom:11pt;text-indent:63pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Consideration</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  In partial consideration of the rights granted by Ligand to Retrophin pursuant to this Agreement, Retrophin shall make the payments to Ligand as provided for in this Article 8.</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Development Milestone Payments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;padding-left:9pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8.2.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Development Milestone Payments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Retrophin shall make milestone payments to Ligand upon achievement of each of the milestone events in the amounts set forth below in Table 1.  The first milestone payment shall be payable by Retrophin to Ligand within </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#91;***&#93; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">days of execution of the Agreement.  Notwithstanding Section 15.4 or any other provision herein, the last milestone payment shall be payable by Retrophin to Ligand upon the Closing of Retrophin&#8217;s Exit Transaction.  Subject to Section 8.2.2, the remainder of the milestone payments set forth below will be payable by Retrophin to Ligand within </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#91;***&#93; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">days of the achievement of the specified milestone </font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:0pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">event with respect to each Licensed Compound.  The milestone payments shall not be refundable or returnable in any event, nor shall they be creditable against royalties or other payments. </font></div><div style="margin-bottom:11pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Table 1</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:72.866%"><tr><td style="width:1.0%"></td><td style="width:49.485%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.315%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #00000a;border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:11pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Milestone Event</font></div></td><td colspan="3" style="border-bottom:1pt solid #00000a;border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:11pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Milestone Payment</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:11pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Execution of Agreement</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:11pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$1.15 million</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:11pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:11pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">$&#91;***&#93;</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:11pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:11pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">$&#91;***&#93;</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:11pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:11pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">$&#91;***&#93;</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:11pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:11pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">$&#91;***&#93;</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:11pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:11pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">$&#91;***&#93;</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:11pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">$&#91;***&#93;</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:11pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">$&#91;***&#93;</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:11pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">$&#91;***&#93;</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:11pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">$&#91;***&#93;</font></div></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #00000a;border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:1pt solid #00000a;border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:11pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">$&#91;***&#93;</font></div></td></tr></table></div><div style="margin-bottom:11pt;text-indent:36pt"><font><br></font></div><div style="margin-bottom:11pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;In the event that a milestone event is achieved that triggers a development milestone payment as set forth above, if the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  For example, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:11pt;padding-left:9pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8.2.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  </font></div><div style="margin-bottom:11pt;padding-left:9pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8.2.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Royalty Payments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;padding-left:9pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8.3.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Retrophin shall pay to Ligand in cash the following royalty payments on the total aggregate annual Net Sales in the Territory of all Licensed Products in a particular </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#91;***&#93; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">by Retrophin, its Affiliates, and Sublicensees in the Territory&#58;</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:65.622%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.178%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:11pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Aggregate Annual Worldwide Net Sales of All Licensed Products in a </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#91;***&#93;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:11pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Royalty Rate for Licensed Products in a </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#91;***&#93;</font></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:11pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Up to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#91;***&#93; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Dollars ($</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">)</font></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:11pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#91;***&#93; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">%</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:11pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">More than </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#91;***&#93; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Dollars ($</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">)</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:11pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#91;***&#93; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">%</font></div></td></tr></table></div><div style="margin-bottom:11pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;By way of example, in a given </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, if the aggregate annual worldwide Net Sales for all Licensed Products is $</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, the royalty payment under this Section 8.3.1 would be  calculated in accordance with the following formula&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#91;***&#93; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Million Dollars.</font></div><div style="margin-bottom:11pt;padding-left:9pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8.3.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Royalty Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Royalties shall be payable on a </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#91;***&#93; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">of (i) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#91;***&#93; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">or (ii) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#91;***&#93; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">or (iii) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:0pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:9pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8.3.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Prior to Retrophin or its Sublicensee exercising its </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#91;***&#93; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">under this Section 8.3.3, Retrophin shall provide Ligand with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The Parties shall discuss the best course of action to resolve such potential </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, provided that such discussions shall not limit or delay Retrophin&#8217;s or its Sublicensee&#8217;s right to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:11pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Except as set forth above, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;padding-left:9pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8.3.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Royalty Conditions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The royalties under Section 8.3.1 shall be subject to the following conditions&#58;</font></div><div style="margin-bottom:12pt;padding-left:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">that only one royalty shall be due with respect to the same unit of Licensed Product&#59;</font></div><div style="margin-bottom:12pt;padding-left:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">that no royalties shall be due upon the sale or other transfer among Retrophin, its Affiliates, or Sublicensees, but in such cases the royalty shall be due and calculated upon Retrophin&#8217;s or its Affiliate&#8217;s or Sublicensee&#8217;s Net Sales of Licensed Product to the first independent Third Party&#59; and</font></div><div style="margin-bottom:12pt;padding-left:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">no royalties shall accrue on the disposition of Licensed Product in reasonable quantities by Retrophin, its Affiliates or Sublicensees as part of an expanded access program, as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">bona fide</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> samples, as part of Phase 4 Trials or as donations to non-profit institutions or government agencies for non-commercial purposes&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">provided,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">however,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> in each case, that neither Retrophin, its Affiliate or Sublicensees receives any payment for such Licensed Product.</font></div><div style="margin-bottom:11pt;text-indent:63pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Manner of Payment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  All payments to be made by Retrophin hereunder shall be made in Dollars by wire transfer of immediately available funds to such United States bank account as shall be designated by Ligand.  Late payments shall bear interest at the rate provided in Section 8.9.</font></div><div style="margin-bottom:11pt;text-indent:63pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Sales Reports and Royalty Payments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  After the First Commercial Sale of a Licensed Product and during the term of this Agreement, Retrophin shall furnish to Ligand a written report, within </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#91;***&#93; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">days after the end of each </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#91;***&#93; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(or portion thereof, if this Agreement terminates during a </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">), showing the amount of royalty due for such </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#91;***&#93; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(or portion thereof).  Royalty payments for each </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#91;***&#93; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">shall be due at the same time as such written report for the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  With each </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, Retrophin shall deliver to Ligand a full and accurate accounting to include at least the following information&#58;</font></div><div style="margin-bottom:11pt;padding-left:81pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#91;***&#93;</font></div><div style="margin-bottom:11pt;padding-left:81pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#91;***&#93;</font></div><div style="margin-bottom:11pt;padding-left:81pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#91;***&#93;</font></div><div style="margin-bottom:11pt;padding-left:81pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#91;***&#93;</font></div><div style="margin-bottom:11pt;padding-left:81pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#91;***&#93;</font></div><div style="margin-bottom:11pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">If no royalty or payment is due for any royalty period hereunder, Retrophin shall so report.</font></div><div style="margin-bottom:11pt;text-indent:63pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Sales Record Audit</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Retrophin shall keep, and shall cause each of its Affiliates, and Sublicensees, if any, to keep, full and accurate books of accounting in accordance with GAAP as may be reasonably necessary for the purpose of calculating the royalties payable to Ligand.  Such books of accounting (including those of Retrophin&#8217;s </font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:0pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:11pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Affiliates, and Sublicensees, if any) shall be kept at their principal place of business and, with all necessary supporting data, shall during all reasonable times for the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#91;***&#93; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">years next following the end of the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#91;***&#93; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">to which each shall pertain, be open for inspection at reasonable times upon written notice by Ligand and at Ligand&#8217;s sole cost, no more than once per any </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#91;***&#93; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">month period, by an independent nationally recognized certified public accounting firm selected by Ligand as to which Retrophin has no reasonable objection, for the purpose of verifying royalty statements for compliance with this Agreement.  Such accountant must have agreed in writing to maintain all information learned in confidence, except as necessary to disclose to Ligand such compliance or noncompliance by Retrophin.  The results of each inspection, if any, shall be</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Ligand shall pay for such inspections, except that in the event there is any upward adjustment in aggregate royalties payable for the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#91;***&#93; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">period of such inspection of more than </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#91;***&#93; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">of the amount paid, Retrophin shall pay for the reasonable out-of-pocket costs of such inspection.  Any underpayments shall be paid by Retrophin within </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#91;***&#93; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">of notification of the results of such inspection.  Any overpayments shall be fully creditable against amounts payable in subsequent payment periods or, if no such amounts become payable within </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#91;***&#93; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">days after notification of such results, shall be refunded.</font></div><div style="margin-bottom:11pt;text-indent:63pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Currency Exchange</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  With respect to Net Sales invoiced in Dollars, the Net Sales and the amounts due to Ligand hereunder shall be expressed in Dollars.  With respect to Net Sales invoiced in a currency other than Dollars, the Net Sales shall be expressed in the domestic currency of the entity making the sale, together with the Dollar equivalent, calculated using the arithmetic average of the spot rates on the close of business on the last Business Day of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#91;***&#93; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">in which the Net Sales were made.  The &#8220;closing mid-point rates&#8221; found in the &#8220;dollar spot forward against the dollar&#8221; table published by The Financial Times, or any other publication as may be agreed to by the Parties in writing, shall be used as the source of spot rates to calculate the average as defined in the preceding sentence.  All payments shall be made in Dollars.</font></div><div style="margin-bottom:11pt;text-indent:63pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Tax Withholding</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  In the event that any withholding taxes or similar charges are levied or assessed by any taxing authority in the Territory with respect to payments made by Retrophin to Ligand under this Agreement, Retrophin shall pay such taxes or similar charges to the proper taxing authority.  Retrophin may deduct the amount of such taxes or similar charges paid by Retrophin to such taxing authority from the applicable royalties or other payment otherwise payable to Ligand, subject to the following.  Retrophin shall promptly provide Ligand with evidence of such tax payment obligation together with an original receipt for such tax payments (or a certified copy, if the original is not available) and other documentation as Ligand reasonably determines is required for the purpose of Ligand&#8217;s tax returns.  Retrophin, its Affiliates and Sublicensees shall cooperate with Ligand to enable the claiming of a reduction or exemption from withholding taxes on payments under any applicable convention on the avoidance of double taxation or similar agreement in force and shall provide to Ligand proper evidence of payments of withholding tax and assist Ligand by obtaining or providing in as far as possible the required documentation for the purpose of Ligand&#8217;s tax returns.  Retrophin&#8217;s obligation vis-a-vis the tax authorities shall remain unaffected by the provisions of this Section 8.8.</font></div><div style="margin-bottom:11pt;text-indent:63pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8.9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Interest Due</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Without limiting any other rights or remedies available to Ligand, Retrophin shall pay Ligand interest on any payments that are not paid on or before the date </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#91;***&#93; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">days after the date such payments are due under this Agreement at a rate of one and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#91;***&#93; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">per month or the maximum applicable legal rate, if less, calculated on the total number of days payment is delinquent.</font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:0pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:27pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8.10</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;8.10.1&#160;&#160;&#160;&#160;In addition to the above milestone and royalty payments, Retrophin shall pay to Ligand the following </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#58;</font></div><div style="margin-bottom:12pt;padding-left:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#59; and</font></div><div style="margin-bottom:12pt;padding-left:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. </font></div><div style="margin-bottom:11pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8.10.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#58;</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:65.622%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.178%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:11pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#91;***&#93;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:11pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#91;***&#93;</font></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:11pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#91;***&#93;</font></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:11pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#91;***&#93;</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:11pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#91;***&#93;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:11pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#91;***&#93;</font></div></td></tr></table></div><div style="margin-bottom:11pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;8.10.3&#160;&#160;&#160;&#160;Such </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Such </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#91;***&#93; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">to Ligand shall be due within </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#91;***&#93; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">days following </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:11pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;8.10.4&#160;&#160;&#160;&#160;For purposes of this Section 8.10, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#91;***&#93;, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">but does not include (i) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#91;***&#93; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">or (ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> &#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ARTICLE 9.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">REPRESENTATIONS AND WARRANTIES&#59; DISCLAIMER&#59;  </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">LIMITATION OF LIABILITY</font></div><div style="margin-bottom:11pt;text-indent:63pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">9.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Mutual Representations and Warranties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Each Party represents and warrants to the other Party that (i) it has all requisite corporate power and authority to enter into this Agreement and to perform its obligations under this Agreement, (ii) execution of this Agreement and the performance by such Party of its obligations hereunder have been duly authorized, (iii) this Agreement is legally binding and enforceable on such Party in accordance with its terms and (iv) the performance of this Agreement by it does not create a material breach or material default under any other agreement to which it is a Party.</font></div><div style="margin-bottom:12pt;text-indent:63pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">9.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Representations, Warranties and Covenants of Ligand</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Ligand represents, warrants and covenants that as of the Effective Date&#58; (i) there is no litigation pending, or to the knowledge of Ligand threatened, which alleges, or any written communication alleging, that Ligand&#8217;s activities with respect to the Patent Rights or the Licensed Compounds have infringed or misappropriated any of the intellectual property rights of any Third Party, (ii) all fees (including legal fees) required to be paid by Ligand in order to maintain the Patent Rights have been paid to date, (iii) it has not previously granted, assigned, transferred, conveyed, encumbered, mortgaged, pledged, hypothesized or licensed (or granted an option to assign, transfer, convey, encumber, mortgage, pledge, hypothesize or license) its right, title and interest in the Patent Rights or the Know-How, (iv) all of its actions related to its use of the Patent Rights and Know-How and the Development and Commercialization of the Licensed Compounds and Licensed Products complied with all applicable legal requirements and complied in all material respects with all regulatory requirements (except for the actions of Ligand&#8217;s clinical research organization, Cetero Research, as to which no representations or warranties are made hereunder), (v) to the knowledge of Ligand (A) the Patent Rights and Know-How are subsisting, valid and enforceable and Ligand has not received any notice of a claim alleging that any of the Patent Rights infringes or otherwise violates any intellectual property or proprietary right of any Third Party, (B) the manufacture, Development and </font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:0pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Commercialization of the Listed Compound by Ligand did not interfere with the intellectual property rights of Third Parties, (C) it has not received any notice that any Person is infringing the Patent Rights and (D) it has not received any notice that a patent application within the Patent Rights is the subject of any pending interference, opposition, cancellation, protest or other challenge or adversarial proceeding, (vi) it has complied with the terms and conditions of the Upstream License Agreement in all material respects and has the necessary right, title and power to sublicense the Patent Rights or the Know-How, (vii) it has discontinued its internal drug discovery and development programs for the Listed Compound and that it has no active internal programs for the discovery or development of the Listed Compound  and (vii) other than the Core Patent Rights, Ligand does not Control any patent(s) or patent application(s) that are reasonably necessary or useful for the Development or Commercialization of any Listed Compound or that claims the composition of matter of any Listed Compound or a method of manufacture or use of any Listed Compound.</font></div><div style="margin-bottom:11pt;text-indent:63pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">9.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Representations, Warranties and Covenants of Retrophin</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  </font></div><div style="margin-bottom:12pt;padding-left:9pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">9.3.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Retrophin covenants that (i) all of its activities related to its use of the Patent Rights and Know-How, and the Development and Commercialization of the Licensed Compounds and Licensed Products, pursuant to this Agreement shall comply with all applicable legal and regulatory requirements and (ii) it shall not knowingly engage in any activities (A) that use the Patent Rights and&#47;or  Know-How in a manner that is outside the scope of the license rights granted to it hereunder or (B) that infringe the intellectual property rights of any Third Party.</font></div><div style="margin-top:12pt;padding-left:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">9.3.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Retrophin has not, directly or indirectly, offered, promised, paid, authorized or given, and will not in the future, offer, promise, pay, authorize or give, money or anything of value, directly or indirectly, to any Government Official (as defined below) or Other Covered Party (as defined below) for the purpose of&#58; (i) influencing any act or decision of the Government Official or Other Covered Party&#59; (ii) inducing the Government Official or Other Covered Party to do or omit to do an act in violation of a lawful duty&#59; (iii) securing any improper advantage&#59; or (iv) inducing the Government Official or Other Covered Party to influence the act or decision of a government or government instrumentality, in order to obtain or retain business, or direct business to, any person or entity, in any way related to this Agreement.  For purposes of this Agreement&#58; (i) &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Government Official</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means any official, officer, employee or representative of&#58; (A) any federal, state, provincial, county or municipal government or any department or agency thereof&#59; (B) any public international organization or any department or agency thereof&#59; or (C) any company or other entity owned or controlled by any government&#59; and (ii) &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Other Covered Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means any political party or party official, or any candidate for political office.</font></div><div style="margin-top:12pt;padding-left:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">9.3.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Retrophin maintains and shall maintain a system of internal accounting controls sufficient to provide reasonable assurances that (i) transactions are executed in accordance with management&#8217;s general or specific authorization&#59; (ii) transactions are recorded as necessary to permit preparation of financial statements in conformity with GAAP and to maintain accountability for assets, including records of payments to any third parties, Government Officials and Other Covered Parties&#59; (iii) access to assets is permitted only in accordance with management&#8217;s general or specific authorization&#59; and (iv) the recorded accountability for assets is compared with existing assets at reasonable intervals and appropriate action is taken with respect to any differences.&#160; </font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:0pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-top:12pt;padding-left:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">9.3.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Anti-Corruption Compliance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.&#160; </font></div><div style="padding-left:9pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">9.3.4.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">In performing under this Agreement, Retrophin and its Affiliates agree to comply with all applicable anti-corruption laws, including Foreign Corrupt Practices Act of 1977, as amended (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">FCPA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) and all laws enacted to implement the OECD Convention on Combating Bribery of Foreign Officials in International Business Transactions.&#160; </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">9.3.4.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Any third party who represents Retrophin or its Affiliates in connection with, or who will be involved in performing, this Agreement or any related activity, shall certify to compliance with all applicable anti-corruption laws and the obligations set forth in this Section 9.3.5 prior to any involvement in this Agreement or any related activity.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">9.3.4.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Retrophin is not aware of any Government Official or Other Covered Party having any financial interest in the subject matter of this Agreement or in any way personally benefiting, directly or indirectly, from this Agreement.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">9.3.4.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">No political contributions or charitable donations shall be given, offered, promised or paid at the request of any Government Official or Other Covered Party that is in any way related to this Agreement or any related activity, without Ligand&#8217;s prior written approval.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">9.3.4.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">In the event that Retrophin violates the FCPA or any applicable anti-corruption law or breaches any provision in this Section 9.3, Ligand shall have the right to unilaterally terminate this Agreement.&#160; </font></div><div style="text-align:justify"><font><br></font></div><div style="text-indent:63pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">9.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Disclaimer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  EXCEPT AS EXPRESSLY SET FORTH IN THIS AGREEMENT, NEITHER PARTY MAKES ANY REPRESENTATIONS OR WARRANTIES OF ANY KIND, EITHER EXPRESS OR IMPLIED, INCLUDING ANY EXPRESS OR IMPLIED WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE WITH RESPECT TO ANY PATENT RIGHTS, CONFIDENTIAL INFORMATION OR KNOW-HOW OF SUCH PARTY OR ANY LICENSE GRANTED BY SUCH PARTY HEREUNDER, OR WITH RESPECT TO ANY COMPOUNDS, INCLUDING BUT NOT LIMITED TO THE TRANSFERRED MATERIALS, OR PRODUCTS.  FURTHERMORE, EXCEPT AS EXPRESSLY SET FORTH IN THIS AGREEMENT, NEITHER PARTY MAKES ANY REPRESENTATIONS OR WARRANTIES THAT ANY PATENT, PATENT APPLICATION, OR OTHER PROPRIETARY RIGHTS INCLUDED IN PATENT RIGHTS, CONFIDENTIAL INFORMATION OR KNOW-HOW LICENSED BY SUCH PARTY TO THE OTHER PARTY HEREUNDER ARE VALID OR ENFORCEABLE OR THAT USE OF SUCH PATENT RIGHTS, CONFIDENTIAL INFORMATION OR KNOW-HOW CONTEMPLATED HEREUNDER DOES NOT INFRINGE ANY PATENT RIGHTS OR OTHER INTELLECTUAL PROPERTY RIGHTS OF ANY THIRD PARTY.</font></div><div><font><br></font></div><div style="margin-bottom:11pt;text-indent:63pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">9.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Limitation of Liability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  NOTWITHSTANDING ANYTHING IN THIS AGREEMENT OR OTHERWISE, NEITHER PARTY SHALL BE LIABLE TO THE OTHER WITH RESPECT TO ANY SUBJECT MATTER OF THIS AGREEMENT, WHETHER UNDER ANY CONTRACT, NEGLIGENCE, STRICT LIABILITY OR OTHER LEGAL OR EQUITABLE THEORY, FOR ANY INCIDENTAL, INDIRECT, SPECIAL, EXEMPLARY, PUNITIVE, MULTIPLE, OR CONSEQUENTIAL </font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:0pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:11pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">DAMAGES (INCLUDING CONSEQUENTIAL DAMAGES CONSISTING OF LOST PROFITS, LOSS OF USE, DAMAGE TO GOODWILL, OR LOSS OF BUSINESS) AND, IN ANY CASE, LIGAND SHALL NOT BE LIABLE IN AN AMOUNT GREATER THAN THE AMOUNTS PAID BY RETROPHIN TO LIGAND UNDER ARTICLE 8 OF THIS AGREEMENT&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">PROVIDED</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">HOWEVER</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, THAT THE FOREGOING SHALL NOT APPLY TO ANY BREACH BY RETROPHIN OF THE LICENSES GRANTED TO IT UNDER THIS AGREEMENT THAT IS AN INFRINGEMENT OF PATENT RIGHTS NOT INCLUDED IN THE PATENT RIGHTS LICENSED TO RETROPHIN HEREUNDER, OR ANY BREACH BY EITHER PARTY OF THIS ARTICLE 9  OR ARTICLE 11 HEREOF.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ARTICLE 10.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160; </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">OWNERSHIP&#59; PATENT MAINTENANCE&#59; INFRINGEMENT&#59; EXTENSIONS</font></div><div style="margin-bottom:12pt;text-indent:63pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">10.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Ownership of Inventions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Inventorship of inventions conceived or reduced to practice in the course of activities performed under or contemplated by this Agreement shall be determined by application of United States patent Laws pertaining to inventorship. If such inventions are jointly invented by one or more employees, consultants or contractors of each Party, such inventions shall be jointly owned (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Joint Invention</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), and if one or more claims included in an issued patent or pending patent application which is filed in a patent office in the Territory claim such Joint Invention, such claims shall be jointly owned (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Joint Patent Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;). If such an invention is solely invented by an employee, consultant or contractor of a Party, such invention shall be owned by such Party, and any patent filed claiming such solely owned invention shall also be owned by such Party. Subject to Section 5.6 with respect to contractors, each Party shall enter into binding agreements obligating all employees, consultants and contractors performing activities under or contemplated by this Agreement, including activities related to the Patent Rights, Licensed Compounds or Licensed Products, to assign his&#47;her interest in any invention conceived or reduced to practice in the course of such activities to the Party for which such employee, consultant or contractor is providing its services. This Agreement shall be understood to be a joint research agreement in accordance with 35 U.S.C. &#167; 103(c)(3) to develop the Licensed Compounds and Licensed Products. The filing, prosecution, maintenance and enforcement of Joint Patent Rights which are Core Patent Rights shall be handled in accordance with this Article 10.</font></div><div style="margin-bottom:11pt;text-indent:63pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">10.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Filing, Prosecution and Maintenance of Core Patent Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Retrophin shall be responsible, using outside patent counsel selected by Retrophin and acceptable to Ligand, such acceptance not to be unreasonably withheld or delayed, for the preparation, prosecution (including, without limitation, any interferences, reissue proceedings and reexaminations) and maintenance of Core Patent Rights.  Promptly following the Effective Date, the Parties shall cooperate to expeditiously transfer such responsibility for the further preparation, prosecution and maintenance of Core Patent Rights to such outside patent counsel.  Retrophin shall be responsible for all costs incurred by Retrophin with respect to such preparation, prosecution and maintenance of Core Patent Rights so long as Retrophin remains responsible for such preparation, prosecution and maintenance.  Upon request by Ligand, Retrophin (or its patent counsel) shall provide Ligand with an update of the filing, prosecution and maintenance status for each of the Core Patent Rights.  Each Party shall reasonably consult with and cooperate with the other Party with respect to the preparation, prosecution and maintenance of the Core Patent Rights reasonably prior to any deadline or action with the U.S. Patent &#38; Trademark Office or any foreign patent office, and Retrophin (or its patent counsel) shall furnish to Ligand copies of all relevant documents reasonably in advance of such consultation.  Retrophin (or its patent counsel) shall provide to Ligand </font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:0pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:11pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">copies of any papers relating to the filing, prosecution or maintenance of the Core Patent Rights promptly upon their being filed or received.  Retrophin shall not knowingly take any action during prosecution and maintenance of the Core Patent Rights that would materially adversely affect them (including any reduction in claim scope), without Ligand&#8217;s prior consent, such consent not to be unreasonably withheld, conditioned or delayed.</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">10.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Patent Abandonment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;padding-left:9pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">10.3.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Generally</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  In no event will Retrophin knowingly permit any of the Core Patent Rights to be abandoned in any country in the Territory or elect not to file a new patent application claiming priority to a patent application within the Core Patent Rights either before such patent application&#8217;s issuance or within the time period required for the filing of an international (i.e., Patent Cooperation Treaty), regional (including European Patent Office) or national application, without Ligand first being given an opportunity to assume full responsibility for the continued prosecution and maintenance of such Core Patent Rights, or the filing of such new patent application.  Accordingly, Retrophin (or its patent counsel) shall provide Ligand with notice of the allowance and expected issuance date of any patent within the Core Patent Rights, or any of the aforementioned filing deadlines, and Ligand shall provide Retrophin with prompt notice as to whether Ligand desires Retrophin to file such new patent application.  In the event that Retrophin decides either (i) not to continue the prosecution or maintenance of a patent application or patent within Core Patent Rights in any country or (ii) not to file such new patent application requested to be filed by Ligand, Retrophin shall provide Ligand with notice of this decision at least </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#91;***&#93; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">days prior to any pending lapse or abandonment thereof.</font></div><div style="margin-bottom:11pt;padding-left:9pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">10.3.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Ligand Option to Assume Responsibility</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Ligand shall thereupon have the right, but not the obligation, to assume responsibility for all reasonably documented external costs (subject to Section 10.3.3) thereafter incurred associated with the filing and&#47;or further prosecution and maintenance of such patents and patent applications, on a patent-by-patent and country-by-country basis.  The outside patent counsel selected by Retrophin shall proceed with such filing and&#47;or further prosecution and maintenance promptly upon receipt of written notice from Ligand of its election to assume such responsibility, with such filing to occur prior to the issuance of the patent to which the application claims priority or expiration of the applicable filing deadline, as set forth above.  In the event that Ligand assumes such responsibility for such filing, prosecution and maintenance costs (subject to Section 10.3.3), upon the reasonable request by Ligand, Retrophin shall transfer the responsibility for such filing, prosecution and maintenance of such patent applications and patents to outside patent counsel selected by Ligand&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">provided, however, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Retrophin shall (i) provide sufficient written notice to Ligand of any such election such that the relevant transfer shall not prejudice the filing, prosecution and&#47;or maintenance of patent rights (where possible, such notice shall be provided at least </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> days prior to any pending lapse or abandonment thereof)&#59; (ii) transfer or cause to be transferred to Ligand or its patent counsel the complete prosecution file for the relevant patents and patent applications, including all correspondence and filings with patent authorities with respect thereto&#59; and (iii) at the reasonable request of Ligand and without demanding any further consideration therefore, do all things necessary, proper or advisable, including without limitation the execution, acknowledgment and recordation of specific assignments, oaths, declarations and other documents on a country-by-country basis, to assist Ligand in obtaining, perfecting, sustaining and&#47;or enforcing such patent(s).  Such patent applications and patents shall </font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:0pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:11pt;padding-left:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">otherwise continue to be subject to all of the terms and conditions of the Agreement in the same way as the other Core Patent Rights, as applicable.</font></div><div style="margin-bottom:12pt;padding-left:9pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">10.3.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Retrophin Responsibility for Patent Costs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Notwithstanding anything to the contrary under this Article 10, unless the Parties otherwise agree in writing, Retrophin shall remain responsible for all costs incurred after the Effective Date with respect to preparation, prosecution and maintenance of the Core Patent Rights covering Licensed Compounds.</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">10.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Enforcement of Core Patent Rights Against Infringers</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  </font></div><div style="margin-bottom:12pt;padding-left:9pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">10.4.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Enforcement by Retrophin.</font></div><div style="margin-bottom:12pt;padding-left:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">In the event that Ligand or Retrophin becomes aware of a suspected infringement of any Core Patent Right exclusively licensed to Retrophin under this Agreement, such Party shall notify the other Party promptly, and following such notification, the Parties shall confer.  Retrophin shall have the right, but shall not be obligated, to bring an infringement action with respect to such infringement at its own expense, in its own name and entirely under its own direction and control, subject to the following.  Ligand shall reasonably assist Retrophin (at Retrophin&#8217;s expense) in any action or proceeding being prosecuted if so requested, and shall lend its name to and join as a nominal party in such actions or proceedings if reasonably requested by Retrophin or required by applicable Laws.  Ligand shall have the right to participate and be represented in any such suit by its own counsel at its own expense.  No settlement of any such action or proceeding which restricts the scope, or adversely affects the enforceability, of a Core Patent Right may be entered into by Retrophin without the prior written consent of Ligand, which consent shall not be unreasonably withheld, delayed or conditioned.</font></div><div style="margin-bottom:12pt;padding-left:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Ligand shall have the right at its discretion to grant to Retrophin such rights (including assignment of the applicable Core Patent Rights) as may be necessary for Retrophin to exercise its rights under this Section 10.4 (including defending or enforcing any Core Patent Rights) without Ligand&#8217;s involvement.  In the event of such grant of rights (including assignment) with respect to any Core Patent Rights, such Core Patent Rights shall continue to be treated as Core Patent Rights and shall otherwise continue to be subject to all of the terms and conditions of the Agreement in the same way as the other applicable Core Patent Rights.  For purposes of clarity, election or non-election by Ligand to grant or assign rights to Retrophin under this Section 10.4.1(b) shall not limit Ligand&#8217;s obligations under Section 10.4.1(a) to reasonably assist Retrophin in any action or proceeding, or to join in such action or proceeding upon request by Retrophin if such joinder is necessary under applicable Laws for Retrophin to exercise its rights under this Section 10.4.</font></div><div style="margin-bottom:12pt;padding-left:9pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">10.4.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Enforcement by Ligand</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  If Retrophin elects not to bring any action for infringement described in Section 10.4.1 and so notifies Ligand, then Ligand may bring such action at its own expense, in its own name and entirely under its own direction and control, subject to the following.  Retrophin shall reasonably assist Ligand (at Ligand&#8217;s expense) in any action or proceeding being prosecuted if so requested, and shall lend its name to such actions or proceedings if requested by Ligand or required by applicable Laws.  Retrophin shall have the right to participate and be represented in any such suit by its own counsel at its own expense.  No settlement of any such action or proceeding which restricts the scope, or adversely affects the enforceability, of a Core </font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:0pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Patent Right may be entered into by Ligand without the prior written consent of Retrophin, which consent shall not be unreasonably withheld, delayed or conditioned.</font></div><div style="margin-bottom:11pt;padding-left:9pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">10.4.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Withdrawal</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  If either Party brings an action or proceeding under this Section 10.4 and subsequently ceases to pursue or withdraws from such action or proceeding, it shall promptly notify the other Party and the other Party may substitute itself for the withdrawing Party under the terms of this Section 10.4.</font></div><div style="margin-bottom:11pt;padding-left:9pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">10.4.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Damages</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  In the event that either Party exercises the rights conferred in this Section 10.4 and recovers any damages or other sums in such action, suit or proceeding or in settlement thereof, such damages or other sums recovered shall </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  If such recovery is insufficient </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  If after such </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#91;***&#93; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">any funds shall remain from such damages or other sums recovered, such funds shall be </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#91;***&#93; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">under this Section 10.4&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, that if </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-indent:63pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">10.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Patent Term Extension</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Ligand and Retrophin shall each cooperate with one another and shall use commercially reasonable efforts in obtaining patent term extension (including without limitation, any pediatric exclusivity extensions as may be available) or supplemental protection certificates or their equivalents in any country with respect to patent rights covering the Licensed Products.  If elections with respect to obtaining such patent term extensions are to be made, Retrophin shall have the right to make the election to seek patent term extension or supplemental protection&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">however,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> such election will be made so as to maximize the period of marketing exclusivity for the Licensed Product.  For such purpose, for all Approvals Retrophin shall provide Ligand with written notice of any expected Approval at least </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#91;***&#93; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">days prior to the expected date of Approval, as well as notice within </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#91;***&#93; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> business days of receiving each Approval confirming the date of such Approval.  Notification of the receipt of an Approval shall be in accordance with Section 15.2. </font></div><div style="margin-bottom:12pt;padding-left:27pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">10.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Data Exclusivity and Orange Book Listings</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:11pt;padding-left:9pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">10.6.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">With respect to data exclusivity periods (such as those periods listed in the FDA&#8217;s Orange Book (including without limitation any available pediatric extensions) or periods under national implementations of Article 10.1(a)(iii) of Directive 2001&#47;EC&#47;83, and all international equivalents), Retrophin shall use commercially reasonable efforts consistent with its obligations under applicable Law to seek, maintain and enforce all such data exclusivity periods available for the Licensed Products.  With respect to filings in the FDA Orange Book (and foreign equivalents) for issued patents for a Licensed Product, Retrophin shall, consistent with its obligations under applicable Law, list in a timely manner and maintain all applicable Core Patent Rights and other patents Controlled by Retrophin required to be filed by it, or that it is permitted to file, under applicable Law.  At least </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> days prior to an anticipated deadline for the filing of patent listing information for Core Patent Rights, Retrophin will consult with Ligand regarding the content of such filing.  In the event of a dispute between the Parties as to whether a Core Patent Right can be filed and&#47;or the content of such filing, the Parties will take expedited steps to resolve the dispute as promptly as possible, including seeking advice of an independent legal counsel to guide their decision.  Ligand shall use commercially reasonable efforts consistent with its obligations under applicable Law to provide reasonable cooperation to Retrophin in filing and maintaining such Orange Book (and foreign equivalent) listings.</font></div><div style="margin-bottom:12pt;padding-left:9pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">10.6.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Without limiting the foregoing, Ligand shall have the right at its discretion to grant to Retrophin such rights (including assignment of the applicable Core </font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:0pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Patent Rights) as may be necessary for Retrophin to exercise its rights under this Section 10.6 (including seeking, maintaining and enforcing all data exclusivity periods) without Ligand&#8217;s involvement.  In the event of such grant of rights (including assignment) with respect to any Core Patent Rights, such Core Patent Rights shall continue to be treated as Core Patent Rights and shall otherwise continue to be subject to all of the terms and conditions of the Agreement in the same way as the other applicable Core Patent Rights.  For purposes of clarity, election by Ligand to grant or assign rights to Retrophin under this Section 10.6.2 shall not limit Ligand&#8217;s obligation under Section 10.6.1 to provide reasonable cooperation to Retrophin to the extent such cooperation is reasonably necessary for Retrophin in filing and maintaining such Orange Book (and foreign equivalent) listings.</font></div><div style="margin-bottom:11pt;text-indent:63pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">10.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Notification of Patent Certification</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Each Party shall notify and provide the other Party with copies of any allegations of alleged patent invalidity, enforceability or non-infringement of a Core Patent Right pursuant to a Paragraph IV Patent Certification by a Third Party filing an Abbreviated NDA, an application under &#167;505(b)(2) or other similar patent certification by a Third Party, and any foreign equivalent thereof.  Such notification and copies shall be provided to the other Party within </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#91;***&#93; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">days after such Party receives such certification, and shall be sent to the address set forth in Section 15.2.  In addition, upon request by Ligand, Retrophin shall provide reasonable assistance and cooperation (including, without limitation, making available to Ligand documents possessed by Retrophin that are reasonably required by Ligand and making available personnel for interviews and testimony) in any actions reasonably undertaken by Ligand to contest any such patent certification.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ARTICLE 11.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160; </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">NONDISCLOSURE OF CONFIDENTIAL INFORMATION</font></div><div style="margin-bottom:11pt;text-indent:63pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">11.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Nondisclosure</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Each Party agrees that, for so long as this Agreement is in effect and for a period of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#91;***&#93; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">years thereafter, a Party (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Receiving Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) receiving or possessing Confidential Information of the other Party (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Disclosing Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) (or that has received any such Confidential Information from the other Party prior to the Effective Date) shall (i) maintain in confidence such Confidential Information using not less than the efforts such Receiving Party uses to maintain in confidence its own proprietary information of similar kind and value, but in no event shall the Receiving Party use less than a reasonable standard of care, (ii) not disclose such Confidential Information to any Third Party without the prior written consent of the Disclosing Party, except for disclosures expressly permitted below, and (iii) not use such Confidential Information for any purpose except those permitted by this Agreement (it being understood that this clause (iii) shall not create or imply any rights or licenses not expressly granted hereunder).</font></div><div style="margin-bottom:12pt;padding-left:9pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">11.1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Confidentiality of Know-How for Disclosure Purposes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  During such time as the license to the Know-How granted under Section 2.1 is in effect, solely for disclosure purposes to Third Parties, the Know-How shall be deemed to be Confidential Information of Ligand and Retrophin under Article 11, Ligand and Retrophin shall be deemed to be a Disclosing Party of the Know-How under Article 11, and Ligand and its respective Affiliates shall be deemed not to have known such Know-How prior to disclosure for the purposes of Section 11.1.2(b).  Other than for disclosure purposes to Third Parties, the Know-How shall solely be the Confidential Information of Ligand.</font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:0pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:11pt;padding-left:9pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">11.1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Exceptions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The obligations in Section 11.1 shall not apply with respect to any portion of the Confidential Information that the Receiving Party can show by competent proof&#58;</font></div><div style="margin-bottom:12pt;padding-left:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">is publicly disclosed by the Disclosing Party, either before or after it is disclosed to the Receiving Party hereunder&#59;</font></div><div style="margin-bottom:12pt;padding-left:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">was known to the Receiving Party or any of its Affiliates, without any obligation to keep it confidential or any restriction on its use, prior to disclosure by the Disclosing Party&#59; </font></div><div style="margin-bottom:12pt;padding-left:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">is subsequently disclosed to the Receiving Party or any of its Affiliates by a Third Party lawfully in possession thereof and without any obligation to keep it confidential or any restriction on its use&#59; </font></div><div style="margin-bottom:12pt;padding-left:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">is published by a Third Party or otherwise becomes publicly available or enters the public domain, either before or after it is disclosed to the Receiving Party&#59; or</font></div><div style="margin-bottom:12pt;padding-left:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">has been independently developed after disclosure by the Disclosing Party by employees or contractors of the Receiving Party or any of its Affiliates without the aid, application or use of Confidential Information of the Disclosing Party.</font></div><div style="margin-bottom:11pt;text-indent:63pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">11.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Authorized Disclosure</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The Receiving Party may disclose Confidential Information belonging to the Disclosing Party to the extent (and only to the extent) such disclosure is reasonably necessary in the following instances&#58; </font></div><div style="margin-bottom:12pt;padding-left:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">filing or prosecuting patents&#59;</font></div><div style="margin-bottom:12pt;padding-left:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">regulatory filings&#59;</font></div><div style="margin-bottom:12pt;padding-left:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">prosecuting or defending litigation&#59;</font></div><div style="margin-bottom:12pt;padding-left:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">subject to Section 11.4, complying with applicable governmental Laws and regulations (including the rules and regulations of the Securities and Exchange Commission or any national securities exchange) and with judicial process, if in the reasonable opinion of the Receiving Party&#8217;s counsel, such disclosure is necessary for such compliance&#59; and</font></div><div style="margin-bottom:12pt;padding-left:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">disclosure (i) in connection with the performance of this Agreement and solely on a &#8220;need to know basis&#8221; to Affiliates, potential or actual collaborators (including potential Sublicensees) or employees, contractors or agents&#59; or (ii) solely on a &#8220;need to know basis&#8221; to potential or actual investment bankers, investors, lenders, or acquirers&#59; each of whom in the case of clause (i) or (ii) prior to disclosure must be bound by written obligations of confidentiality and non-use no less restrictive than the obligations set forth in this Article 11&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, that the Receiving Party shall remain responsible for any failure by any Person who receives Confidential Information pursuant to this Article 11 to treat such Confidential Information as required under this Article 11.  </font></div><div style="margin-bottom:11pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;If and whenever any Confidential Information is disclosed in accordance with this Section 11.2, such disclosure shall not cause any such information to cease to be Confidential Information except to the extent that such disclosure results in a public </font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:0pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:11pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">disclosure of such information (otherwise than by breach of this Agreement).  Where reasonably possible and subject to Section 11.4, the Receiving Party shall notify the Disclosing Party of the Receiving Party&#8217;s intent to make such disclosure pursuant to paragraphs (r) through (v) of this Section 11.2 sufficiently prior to making such disclosure so as to allow the Disclosing Party adequate time to take whatever action it may deem appropriate to protect the confidentiality of the information.</font></div><div style="margin-bottom:12pt;text-indent:63pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">11.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Terms of this Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The Parties acknowledge that the terms of this Agreement shall be treated as Confidential Information of both Parties.</font></div><div style="margin-bottom:11pt;text-indent:63pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">11.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Securities Filings</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  In the event either Party proposes to file with the Securities and Exchange Commission or the securities regulators of any state or other jurisdiction a registration statement or any other disclosure document which describes or refers to this Agreement under the Securities Act of 1933, as amended, the Securities Exchange Act of 1934, as amended, or any other applicable Laws, the Party shall notify the other Party of such intention and shall provide such other Party with a copy of relevant portions of the proposed filing not less than </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#91;***&#93; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">business days prior to such filing (and any revisions to such portions of the proposed filing a reasonable time prior to the filing thereof), including any exhibits thereto relating to this Agreement and shall use reasonable efforts to obtain confidential treatment of any information concerning this Agreement that such other Party requests be kept confidential and shall only disclose Confidential Information which it is advised by counsel is legally required to be disclosed.  No such notice shall be required under this Section 11.4 if the substance of the description of or reference to this Agreement contained in the proposed filing has been included in any previous filing made by the other Party hereunder or otherwise approved by the other Party.</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">11.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Publication</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:11pt;padding-left:9pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">11.5.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Publication by Ligand</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Ligand may publish or present data and&#47;or results relating to a Licensed Compound or Licensed Product in scientific journals and&#47;or at scientific conferences, subject to the prior review, comment and approval by Retrophin as follows.  Ligand shall provide Retrophin with the opportunity to review any proposed abstract, manuscript or presentation which discloses information relating to a Licensed Compound or Licensed Product by delivering a copy thereof to Retrophin no less than </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#91;***&#93; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">days before its intended submission for publication or presentation.  Retrophin shall have twenty (20) days from its receipt of any such abstract, manuscript or presentation in which to notify Ligand in writing of any specific objections to the disclosure.  In the event Retrophin objects to the disclosure in writing within such </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#91;***&#93; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">day period, Ligand agrees not to submit the publication or abstract or make the presentation containing the objected-to information until the Parties have agreed to the content of the proposed disclosure and Ligand shall delete from the proposed disclosure any Retrophin Confidential Information or Know-How or the identity of any Licensed Compound or Licensed Product, or any information relating to the Licensed Compound or its improvements that could limit or jeopardize any rights of Retrophin, upon reasonable request by Retrophin.  Failure to object to the disclosure in writing within such </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#91;***&#93; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">day period shall be deemed approval.  Once any such abstract or manuscript is accepted for publication, Ligand will provide Retrophin with a copy of the final version of the manuscript or abstract.  For clarification, this Section 11.5.1 shall not limit or restrict Ligand&#8217;s ability to publish or present publicly information on compounds which are not Licensed Compounds or Licensed Products, provided such publication or presentation does not contain Retrophin Confidential Information or identify any </font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:0pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:11pt;padding-left:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Licensed Compound or Licensed Product.  Retrophin acknowledges BMS&#8217; right to publish or otherwise publicly disclose any licensed BMS Know-How at any time.</font></div><div style="margin-bottom:12pt;padding-left:9pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">11.5.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Publication by Retrophin</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Retrophin may publish or present data and&#47;or results relating to a Licensed Compound or Licensed Product in scientific journals and&#47;or at scientific conferences, subject to attribution to Ligand of any data generated by or on behalf of Ligand prior to the Effective Date as well as the prior review and comment by Ligand as follows.  Retrophin shall provide Ligand with the opportunity to review any proposed abstract, manuscript or presentation which discloses information relating to a Licensed Compound or Licensed Product by delivering a copy thereof to Ligand no less than </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#91;***&#93; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">days before its intended submission for publication or presentation.  Ligand shall have </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#91;***&#93; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">days from its receipt of any such abstract, manuscript or presentation in which to notify Retrophin in writing of any specific objections to the disclosure, such objections to be limited to matters involving the disclosure of Ligand Confidential Information, or a good faith and documented concern by Ligand that such publication would otherwise result in material commercial harm to Ligand.  In the event Ligand objects to the disclosure in writing within such </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#91;***&#93; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">day period, Retrophin agrees not to submit the publication or abstract or make the presentation containing the objected-to information until the Parties have agreed to the content of the proposed disclosure, and Retrophin shall delete from the proposed disclosure any Ligand Confidential Information upon the reasonable request by Ligand.  The Parties agree to take all reasonable steps to address and resolve a notice of objection by Ligand within </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#91;***&#93; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">days of receipt of such notice.  Once any such abstract or manuscript is accepted for publication, Retrophin will provide Ligand with a copy of the final version of the manuscript or abstract, a copy of which may be provided to BMS by Ligand. </font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ARTICLE 12.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160; </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">INDEMNITY</font></div><div style="margin-bottom:11pt;text-indent:63pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">12.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Retrophin Indemnity</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Retrophin shall indemnify, defend and hold harmless Ligand and its Affiliates, and their respective officers, directors, employees, agents, licensors, and their respective successors, heirs and assigns and representatives, from and against any and all claims, damages, losses, suits, proceedings, liabilities, costs (including reasonable legal expenses, costs of litigation and reasonable attorney&#8217;s fees) or judgments, whether for money or equitable relief, of any kind, arising out of any claim, action, lawsuit or other proceeding brought by a Third Party (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Losses and Claims</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) arising out of or relating, directly or indirectly, (i) to the research, Development, Commercialization (including promotion, advertising, offering for sale, sale or other disposition), transfer, importation or exportation, manufacture, labeling, handling or storage, or use of, or exposure to, any Licensed Compound and&#47;or any Licensed Product by or for Retrophin or any of its Affiliates, Sublicensees, agents and&#47;or contractors, (ii) to Retrophin&#8217;s (or its Affiliates&#8217; and&#47;or Sublicensees&#8217;) use and practice otherwise of the Patent Rights or Know-How, including claims based on (A) product liability, bodily injury, risk of bodily injury, death or property damage, (B) infringement or misappropriation of Third Party patents, copyrights, trademarks or other intellectual property rights or (C) the failure to comply with applicable Laws related to the matters referred to in the foregoing clauses (i) and (ii) with respect to any Licensed Compound and&#47;or any Licensed Product, or (iii) Retrophin&#8217;s gross negligence, recklessness or willful misconduct or Retrophin&#8217;s material breach of any representation, warranty or covenant set forth in this Agreement&#59; except in any such case for Losses and Claims to the extent reasonably attributable to Ligand having committed an act or acts of gross negligence, recklessness or willful </font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:0pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:11pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">misconduct or having materially breached any representation or warranty set forth in this Agreement.</font></div><div style="margin-bottom:12pt;text-indent:63pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">12.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Ligand Indemnity</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Ligand shall indemnify, defend and hold harmless Retrophin and its Affiliates, and their respective officers, directors, employees, agents, licensors, and their respective successors, heirs and assigns and representatives, from and against any and all Losses and Claims arising out of or relating, directly or indirectly to (i) Ligand&#8217;s gross negligence, recklessness or willful misconduct or (ii) Ligand&#8217;s material breach of any representation, warranty or covenant set forth in this Agreement&#59; except in any such case for Losses and Claims to the extent reasonably attributable to Retrophin having committed an act or acts of gross negligence, recklessness or willful misconduct or having materially breached any representation or warranty set forth in this Agreement.  For the avoidance of doubt, &#8220;Ligand&#8217;s gross negligence, recklessness or willful misconduct&#8221; shall not include any acts or omissions on the part of any Third Parties, including Ligand&#8217;s clinical research organization, Cetero Research.</font></div><div style="margin-bottom:11pt;text-indent:63pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">12.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Indemnification Procedure</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  A claim to which indemnification applies under Section 12.1 or Section 12.2 shall be referred to herein as an &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Indemnification Claim</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;.  If any Person or Persons (collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Indemnitee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) intends to claim indemnification under this Article 12, the Indemnitee shall notify the other Party (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Indemnitor</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) in writing promptly upon becoming aware of any claim that may be an Indemnification Claim (it being understood and agreed, however, that the failure by an Indemnitee to give such notice shall not relieve the Indemnitor of its indemnification obligation under this Agreement except and only to the extent that the Indemnitor is actually prejudiced as a result of such failure to give notice).  The Indemnitor shall have the right to assume and control the defense of the Indemnification Claim at its own expense with counsel selected by the Indemnitor and reasonably acceptable to the Indemnitee&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, that an Indemnitee shall have the right to retain its own counsel, with the fees and expenses to be paid by the Indemnitee, if representation of such Indemnitee by the counsel retained by the Indemnitor would be inappropriate due to actual or potential differing interests between such Indemnitee and any other party represented by such counsel in such proceedings.  If the Indemnitor does not assume the defense of the Indemnification Claim as aforesaid, the Indemnitee may defend the Indemnification Claim but shall have no obligation to do so.  The Indemnitee shall not settle or compromise the Indemnification Claim without the prior written consent of the Indemnitor, and the Indemnitor shall not settle or compromise the Indemnification Claim in any manner which would have an adverse effect on the Indemnitee&#8217;s interests (including any rights under this Agreement or the scope or enforceability of the Patents Rights or Know-How), without the prior written consent of the Indemnitee, which consent, in each case, shall not be unreasonably withheld or delayed.  The Indemnitee shall reasonably cooperate with the Indemnitor at the Indemnitor&#8217;s expense and shall make available to the Indemnitor all pertinent information under the control of the Indemnitee, which information shall be subject to Article 11.</font></div><div style="margin-bottom:11pt;text-indent:63pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">12.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Insurance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Retrophin shall, beginning with the initiation of the first clinical trial for a Licensed Product, maintain at all times thereafter during the term of the Agreement, and until the later of (i) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#91;***&#93; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">or (ii) the date </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, comprehensive general liability insurance from a recognized, creditworthy insurance company, on a claims-made basis, with endorsements for contractual liability and product liability, and with coverage limits of not less than </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The minimum level of insurance set forth herein shall not be construed to create a limit on Retrophin&#8217;s liability hereunder.  Within </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#91;***&#93; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">days following written request from Ligand, Retrophin shall furnish to Ligand a certificate of insurance </font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:0pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:11pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">evidencing such coverage as of the date.  Retrophin shall use commercially reasonable efforts to cause such certificate of insurance, as well as any certificates evidencing new coverages of Retrophin, to include a provision whereby </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#91;***&#93; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">written notice shall be received by Ligand prior to coverage cancellation by either Retrophin or the insurer and of any new coverage.  In the case of a cancellation of such coverage, Retrophin shall promptly provide Ligand with a new certificate of insurance evidencing that Retrophin&#8217;s coverage meets the requirements in the first sentence of this Section 12.4.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ARTICLE 13.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">TERM AND TERMINATION</font></div><div style="margin-bottom:12pt;text-indent:63pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">13.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  This Agreement shall commence as of the Effective Date and, unless sooner terminated in accordance with the terms hereof or by mutual written consent, shall continue until neither Party has any obligation under this Agreement to make payments to the other Party.</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">13.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Termination By Ligand</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:11pt;padding-left:9pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">13.2.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Insolvency</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Ligand shall have the right to terminate this Agreement with respect to any or all licenses granted to Retrophin pursuant to Article 2 of this Agreement, at Ligand&#8217;s sole discretion, upon delivery of written notice to Retrophin upon the filing by Retrophin in any court or agency pursuant to any statute or regulation of the United States or any other jurisdiction a petition in bankruptcy or insolvency or for reorganization or similar arrangement for the benefit of creditors or for the appointment of a receiver or trustee of Retrophin or its assets, or if Retrophin is served with an involuntary petition against it in any insolvency proceeding, upon the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#91;***&#93; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">day after such service if such involuntary petition has not previously been stayed or dismissed, or upon the making by Retrophin of an assignment of substantially all of its assets for the benefit of its creditors.</font></div><div style="margin-bottom:12pt;padding-left:9pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">13.2.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Breach</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Subject to Section 13.2.4 below, Ligand shall have the right to terminate this Agreement with respect to any or all licenses granted to Retrophin pursuant to Article 2 of this Agreement, at Ligand&#8217;s sole discretion, upon delivery of written notice to Retrophin in the event of any material breach by Retrophin of any terms and conditions of this Agreement (other than failure to use Commercially Reasonable Efforts to Develop or Commercialize the Licensed Compounds and a Licensed Product, which breach is covered under Section 13.2.3)&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">provided, however,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> such breach has not been cured within forty-five (45) days after written notice thereof is given by Ligand to Retrophin specifying the nature of the alleged breach&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, that to the extent such material breach involves the failure to make a payment when due, such breach must be cured within twenty (20)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">days after written notice thereof is given by Ligand to Retrophin.</font></div><div style="margin-bottom:11pt;padding-left:9pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">13.2.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Failure to Use Commercially Reasonable Efforts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Subject to Section 13.2.4 below, Ligand shall have the right to terminate this Agreement with respect to any or all licenses granted to Retrophin pursuant to Article 2 of this Agreement on a country-by-country basis (except as otherwise set forth in this Section 13.2.3), at Ligand&#8217;s sole discretion, in the event that Retrophin (a) fails to use Commercially Reasonable Efforts (by itself or through its Affiliates or Sublicensees) to Develop and Commercialize at least one (1) Licensed Compound and Licensed Product or (b) fails to comply with the specific diligence obligations set forth in Sections 6.1.2 and 6.1.3 of this Agreement&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">provided, however,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> that Retrophin has not exercised such Commercially Reasonable Efforts or complied with such specific diligence obligations in the applicable </font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:0pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:11pt;padding-left:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">country or countries within sixty (60) days following written notice by Ligand.  For clarity, it is understood and acknowledged that Commercially Reasonable Efforts in the Development of a Licensed Compound or Licensed Product in a particular country may include sequential implementation of clinical trials and&#47;or intervals between clinical trials for data interpretation and clinical program planning and any period associated with such program, to the extent such implementation is consistent with the scientific, technical and commercial factors relevant to Development of such Licensed Compound or Licensed Product in such country.</font></div><div style="margin-bottom:12pt;padding-left:9pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">13.2.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Disputed Breach</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  If Retrophin disputes in good faith the existence or materiality of a breach specified in a notice provided by Ligand pursuant to Section 13.2.2, or a failure to use Commercially Reasonable Efforts specified in a notice provided by Ligand pursuant to Section 13.2.3, and Retrophin provides notice to Ligand of such dispute within the applicable forty-five (45) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">day or sixty (60) day period, Ligand shall not have the right to terminate this Agreement unless and until the existence of such material breach or failure by Retrophin has been determined in accordance with Article 14 and Retrophin fails to cure such breach within sixty (60)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">days following such determination (except to the extent such breach involves the failure to make a payment when due, which breach must be cured within five (5) Business Days following such determination).  It is understood and acknowledged that during the pendency of such a dispute, all of the terms and conditions of this Agreement shall remain in effect and the Parties shall continue to perform all of their respective obligations hereunder.  The Parties further agree that any payments that are made by one Party to the other Party pursuant to this Agreement pending resolution of the dispute shall be promptly refunded if an arbitrator or court determines pursuant to Article 14 that such payments are to be refunded by one Party to the other Party.</font></div><div style="margin-bottom:11pt;padding-left:9pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">13.2.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Termination for </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Subject to the terms of this Section 13.2.5, Ligand shall have the right to terminate this Agreement (on a country-by-country or worldwide basis, as Ligand may elect), </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, in the event that (a) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#91;***&#93; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">or (b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> &#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  In the event the Parties are unable to reach agreement regarding whether or not a compound is a </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, and the Parties have not resolved such dispute through good faith discussions, such dispute will be resolved through performance of the relevant scientific determination by an independent Third Party testing provider or other scientific expert who shall be mutually and reasonably selected by both Parties.  The findings of such Third Party scientific expert with respect to such dispute shall be binding on the Parties, and the costs of such testing shall be borne by the Party whom the independent determination does not favor.</font></div><div style="margin-bottom:12pt;padding-left:9pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">13.2.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Termination of Upstream License Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Subject to Section 13.5.1, if the Upstream License Agreement, in whole or in part, is terminated for any reason, the corresponding rights granted to Retrophin shall be terminated effective upon termination of the Upstream License Agreement.</font></div><div style="margin-bottom:12pt;text-indent:63pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">13.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Termination by Retrophin</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Retrophin may terminate this Agreement in the event of material breach by Ligand&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">provided, however,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> that such breach has not been cured within</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">sixty (60)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">days after written notice thereof is given by Retrophin to Ligand.  Notwithstanding the foregoing, if Ligand disputes in good faith the existence or materiality of such breach and provides notice to Retrophin of such dispute within such sixty (60)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">day period, Retrophin shall not have the right to terminate this Agreement in accordance with this Section 13.3 unless and until it has been determined in accordance with Article 14 that this Agreement was materially breached by Ligand and Ligand fails to cure such breach </font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:0pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">within sixty (60)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">days following such determination.  It is understood and acknowledged that during the pendency of such a dispute, all of the terms and conditions of this Agreement shall remain in effect and the Parties shall continue to perform all of their respective obligations hereunder.  The Parties further agree that any payments that are made by one Party to the other Party pursuant to this Agreement pending resolution of the dispute shall be promptly refunded if an arbitrator or court determines pursuant to Article 14 that such payments are to be refunded by one Party to the other Party.</font></div><div style="margin-bottom:12pt;text-indent:63pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">13.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Effect of Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Upon termination of this Agreement or any right or license pursuant to Section 13.2.1, 13.2.2, 13.2.3 or 13.2.5, the rights and obligations of the Parties shall be as set forth in this Section 13.4.</font></div><div style="margin-bottom:12pt;padding-left:9pt;text-indent:63pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">13.4.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Upon termination of this Agreement, either in its entirety or with respect to one or more applicable countries (each, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Terminated Country</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) pursuant to Section 13.2.1, 13.2.2, 13.2.3 or 13.2.5 hereof (the rights and obligations of the Parties as to the remaining countries of the Territory in which termination under Section 13.2.3 or 13.2.5 has not occurred, being unaffected by such termination), the following shall apply&#58;</font></div><div style="margin-bottom:12pt;padding-left:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;padding-left:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;padding-left:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">All amounts due or payable to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#91;***&#93; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">shall remain due and payable.</font></div><div style="margin-bottom:12pt;padding-left:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Should Retrophin have </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, Retrophin shall </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;padding-left:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Should Retrophin have </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;padding-left:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Retrophin shall </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;padding-left:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">If Retrophin has the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;padding-left:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Retrophin shall </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;padding-left:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Retrophin shall </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;padding-left:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">j)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Retrophin hereby</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;padding-left:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">k)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Neither Party shall be relieved of any obligation that accrued prior to the effective date of such termination or expiration.</font></div><div style="margin-bottom:12pt;padding-left:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">l)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Each Party shall have the right to retain all amounts previously paid to it by the other Party, subject to any applicable determination of an arbitrator or court pursuant to Article 14.</font></div><div style="margin-bottom:12pt;padding-left:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">m)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">It is understood and agreed that Ligand shall be entitled to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#91;***&#93; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">as a remedy to enforce the provisions of this Section 13.4, in addition to any other remedy to which it may be entitled by applicable Law.</font></div><div style="margin-bottom:11pt;padding-left:27pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">13.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Termination by BMS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;13.5.1  Any rights granted by Ligand pursuant to this Agreement shall terminate on a country-by-country and Licensed Product-by-Licensed Product basis effective upon termination under Section 13.2 of the Upstream License Agreement with respect to such sublicensed rights&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">provided, however,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> that such sublicensed rights shall not </font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:0pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">terminate if, as of the effective date of such termination by BMS under Section 13.2 of the Upstream License Agreement, Retrophin is not in material breach of its obligations to Ligand under this Agreement, and within sixty (60)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">days of such termination Retrophin agrees in writing to be bound directly to BMS under a license agreement substantially similar to this Agreement with respect to the rights sublicensed hereunder, substituting Retrophin for Ligand.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;13.5.2&#160;&#160;&#160;&#160; BMS may terminate the Upstream License Agreement where (a) Retrophin or its Affiliate (alone or in collaboration with a Third Party) undertakes the clinical development of a product that contains a </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#91;***&#93; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">prior to the first U.S. NDA Approval being obtained for a Licensed Compound or (b) Retrophin or its Affiliate (alone or in collaboration with a Third Party) markets a product that contains a </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#91;***&#93; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">within </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> years following the first U.S. NDA Approval for a Licensed Product.  </font></div><div style="margin-bottom:12pt;padding-left:27pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">13.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Scope of Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Except as otherwise expressly provided herein, termination of this Agreement shall be as to all countries in the Territory and all Licensed Compounds and Licensed Products.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Survival</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The following provisions shall survive termination or expiration of this Agreement, as well as any other provision which by its terms or by the context thereof, is intended to survive such termination&#58; Article 1 (as applicable), Article 5 (with respect to obligations arising prior to expiration or termination of this Agreement), Article 8 (with respect to obligations arising prior to expiration or termination of this Agreement), Section 9.4, Section 9.5, Section 10.1, 10.4.4 (with respect to an action, suit or proceeding commenced prior to termination), Section 10.7, Article 11, Article 12 (with respect to Losses and Claims arising from activities and breaches that take place prior to expiration or termination of this Agreement), this Section 13.6(i), Section 13.7, Article 14 and Article 15.  Termination or expiration of this Agreement shall not relieve the Parties of any liability or obligation which accrued hereunder prior to the effective date of such termination or expiration nor preclude either Party from pursuing all rights and remedies it may have hereunder or at law or in equity, subject to Article 14, with respect to any breach of this Agreement nor prejudice either Party&#8217;s right to obtain performance of any obligation.  All other obligations shall terminate upon expiration of this Agreement.</font></div><div style="margin-bottom:12pt;text-indent:63pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">13.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Bankruptcy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The Parties agree that in the event a Party becomes a debtor under Title 11 of the U.S. Code (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Title 11</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), this Agreement shall be deemed to be, for purposes of Section 365(n) of Title 11, a license to rights to &#8220;intellectual property&#8221; as defined therein.  Each Party as a licensee hereunder shall have the rights and elections as specified in Title 11.  Any agreements supplemental hereto shall be deemed to be &#8220;agreements supplementary to&#8221; this Agreement for purposes of Section 365(n) of Title 11.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ARTICLE 14.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160; </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">DISPUTE RESOLUTION&#59; ARBITRATION</font></div><div style="margin-bottom:12pt;text-indent:63pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">14.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Dispute Resolution</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The Parties agree that the procedures set forth in this Section 14.1 shall be the exclusive mechanism for resolving any bona fide disputes, controversies or claims (collectively, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Disputes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) between the Parties that arise from time to time pursuant to this Agreement relating to any Party&#8217;s rights and&#47;or obligations hereunder that cannot be resolved through good faith negotiation between the Parties.</font></div><div style="margin-bottom:12pt;text-indent:63pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">14.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Executive Mediation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Any Dispute shall first be referred to an Executive from each Party for attempted resolution by good faith negotiations.  Any such Dispute shall be submitted to such Executives no later than </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">days following such </font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:0pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">request by either Party.  Such Executives shall attempt in good faith to resolve any such Dispute within </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#91;***&#93; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">days after submission of the Dispute.  In the event the Executives are unable to resolve the Dispute, the Parties shall otherwise negotiate in good faith and use reasonable efforts to settle.  </font></div><div style="margin-bottom:12pt;padding-left:27pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">14.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Arbitration</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  </font></div><div style="margin-bottom:12pt;padding-left:9pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">14.3.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">If the Parties are not able to fully settle a Dispute pursuant to Section 14.2 above, and a Party wishes to pursue the matter, each such Dispute that is not an Excluded Claim or subject to expedited arbitration in accordance with Section 14.4 below, shall be finally resolved by binding arbitration in accordance with the Commercial Arbitration Rules and Supplementary Procedures for Large Complex Disputes of the American Arbitration Association (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">AAA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), and judgment on the arbitration award may be entered in any court having jurisdiction thereof&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, that the Federal Rules of Evidence shall apply with regard to the admissibility of evidence in such hearing.  </font></div><div style="margin-bottom:12pt;padding-left:9pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">14.3.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The arbitration shall be conducted by a panel of three persons experienced in the pre-clinical and clinical stage pharmaceutical business.  Within </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#91;***&#93; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">days after initiation of arbitration, each Party shall select one person to act as arbitrator and the two Party-selected arbitrators shall select a third arbitrator within </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> days of their appointment.  If the arbitrators selected by the Parties are unable or fail to agree upon the third arbitrator, the third arbitrator shall be appointed by the AAA.  In any case the arbitrator shall not be an Affiliate, employee, consultant, officer, director or stockholder of either Party, or otherwise have any current or previous relationship with either Party or their respective Affiliates.  The Parties shall have the right to be represented by counsel.  The place of arbitration shall be New York, NY.  All proceedings and communications shall be in English.  </font></div><div style="margin-bottom:12pt;padding-left:9pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">14.3.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Either Party may apply to the arbitrators for interim injunctive relief until the arbitration award is rendered or the controversy is otherwise resolved.  Either Party also may, without waiving any remedy under this Agreement, seek from any court having jurisdiction any injunctive or provisional relief necessary to protect the rights or property of that Party pending the arbitration award.  The arbitrators shall have no authority to award punitive or any other type of damages not measured by a Party&#8217;s compensatory damages.  Each Party shall bear its own costs and expenses and attorneys&#8217; fees and an equal share of the arbitrators&#8217; fees and any administrative fees of arbitration.</font></div><div style="margin-bottom:12pt;padding-left:9pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">14.3.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Except to the extent necessary to confirm an award or as may be required by Law, neither a Party nor an arbitrator may disclose the existence, content, or results of an arbitration without the prior written consent of both Parties.  In no event shall an arbitration be initiated after the date when commencement of a legal or equitable proceeding based on the dispute, controversy or claim would be barred by the applicable New York statute of limitations.</font></div><div style="margin-bottom:12pt;padding-left:9pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">14.3.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The arbitrators shall use their commercially reasonable efforts to rule on each disputed issue within days after completion of the hearing described in Section 14.3. The determination of the arbitrators as to the resolution of any dispute shall be binding and conclusive upon all Parties. All rulings of the arbitrator shall be in writing and shall be delivered to the Parties except to the extent that the Commercial Arbitration Rules of the AAA provide otherwise. Nothing contained herein shall be construed to permit the arbitrator to award punitive, exemplary or any similar damages.</font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:0pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:9pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">14.3.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The (i) attorneys&#8217; fees of the Parties in any arbitration, (ii) fees of the arbitrator and (iii) costs and expenses of the arbitration shall be borne by the Parties in a proportion determined by the arbitrator.</font></div><div style="margin-bottom:12pt;padding-left:9pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">14.3.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">For all Excluded Claims, the Parties hereby submit to the exclusive jurisdiction of the Supreme Court of the State of New York, New York County and the United States District Court for the Southern District of New York.  For clarity, each party may seek injunctive or other equitable relief for Excluded Claims in accordance with this Section 14.3.7.  Each Party agrees that service of any process, summons, notice or document by personal delivery, by registered mail, or by a recognized international express delivery service to such Party&#8217;s respective address set forth in Section 15.2 shall be effective service of process for any action, suit or proceeding in the district court or state court with respect to any matters to which it has submitted to jurisdiction in this Section 14.3.7.  Each Party irrevocably and unconditionally waives any objection to the laying of venue of any action, suit or proceeding arising out of this Agreement or the transactions contemplated hereby in the district court or state court, and hereby and thereby further irrevocably and unconditionally waives and agrees not to plead or claim in any such court that any such action, suit or proceeding brought in any such court has been brought in an inconvenient forum.  Each Party hereto also hereby waives to the fullest extent permitted by applicable Laws, any right it may have to a trial by jury in respect to any litigation directly or indirectly arising out of, under or in connection with this Agreement.  Each Party hereto (i) certifies that no representative, agent or attorney of the other Party has represented, expressly or otherwise, that such other Party would not, in the event of litigation, seek to enforce that foregoing waiver and (ii) acknowledges that it and the other Party hereto have been induced to enter into this Agreement, as applicable, by, among other things, the mutual waivers and certifications in this Section 14.3.7.</font></div><div style="margin-bottom:12pt;text-indent:63pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">14.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Expedited Arbitration</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. The Parties agree that it is important to be able to clarify any disputes regarding </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#91;***&#93; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">quickly. Accordingly, if&#58; (i) Ligand </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#59; (ii) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#59; or (iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> &#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#59; then the Parties shall resolve such dispute in accordance with this Section 14.4. Arbitration under this Section 14.4 shall be conducted in the same manner and subject to the same terms and conditions as arbitration under Section 14.3, provided that&#58; (i) the Parties shall designate in writing a single arbitrator within fifteen (15) days of written notice of the dispute&#59; (ii) the arbitrator and the Parties shall meet, and each Party shall provide to the arbitrator a written summary of all disputed issues, such Party&#8217;s position on such disputed issues and such Party&#8217;s proposed ruling on the merits of each such issue within fifteen (15) days after the designation of the arbitrator&#59; (iii) the arbitrator shall use his or her commercially reasonable efforts to rule on each disputed issue within fifteen (15) days after completion of the hearing described in Section 14.3&#59; (d) the arbitrator shall select one of the requested positions as his decision, and shall not have the authority to render any substantive decision other than to so select the position of either Ligand or Retrophin&#59; and (e) the Parties shall use good faith efforts to complete any expedited arbitration pursuant to this Section 14.4 promptly.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ARTICLE 15.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160; </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">MISCELLANEOUS</font></div><div style="margin-bottom:12pt;text-indent:63pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">15.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Severability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  If any one or more of the provisions of this Agreement is held to be invalid or unenforceable, the provision shall be considered severed from this Agreement and shall not serve to invalidate any remaining provisions hereof.  The Parties shall make a good faith effort to replace any invalid or unenforceable provision with a </font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:0pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">valid and enforceable one such that the objectives contemplated by the Parties when entering this Agreement may be realized.</font></div><div style="margin-bottom:12pt;text-indent:63pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">15.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Notices</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Any notice required or permitted to be given by this Agreement shall be in writing and shall be delivered by hand or overnight courier with tracking capabilities or mailed postage prepaid by first class, registered or certified mail addressed as set forth below unless changed by notice so given&#58;</font></div><div style="margin-bottom:12pt;text-indent:63pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">If to Ligand&#58;</font></div><div style="text-indent:63pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Ligand Pharmaceuticals Incorporated</font></div><div style="padding-left:63pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">11085 North Torrey Pines Road, Suite 300 </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">La Jolla, CA 92037</font></div><div style="text-indent:63pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Attention&#58;  General Counsel</font></div><div style="text-indent:63pt"><font><br></font></div><div style="text-align:justify;text-indent:63pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">With a copy to (which shall not constitute notice hereunder)&#58;</font></div><div style="text-align:justify;text-indent:63pt"><font><br></font></div><div style="text-align:justify;text-indent:63pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Latham &#38; Watkins LLP</font></div><div style="text-align:justify;text-indent:63pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">12636 High Bluff Drive, Suite 400</font></div><div style="text-align:justify;text-indent:63pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">San Diego, CA 92130</font></div><div style="text-align:justify;text-indent:63pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Attention&#58;  Faye H. Russell, Esq.</font></div><div style="text-indent:63pt"><font><br></font></div><div style="margin-bottom:12pt;text-indent:63pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">If to Retrophin&#58;</font></div><div style="text-indent:63pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Retrophin LLC</font></div><div style="text-indent:63pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">330 Madison Avenue, 6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> Floor</font></div><div style="text-indent:63pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">New York, NY 10017</font></div><div style="text-indent:63pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Attention&#58;  Martin Shkreli</font></div><div style="text-indent:63pt"><font><br></font></div><div style="text-align:justify;text-indent:63pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">With a copy to (which shall not constitute notice hereunder)&#58;</font></div><div style="text-align:justify;text-indent:63pt"><font><br></font></div><div style="text-align:justify;text-indent:63pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Katten Muchin Rosenman LLP</font></div><div style="text-align:justify;text-indent:63pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">575 Madison Avenue</font></div><div style="text-align:justify;text-indent:63pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">New York, NY 10022</font></div><div style="text-align:justify;text-indent:63pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Attention&#58;  Evan L. Greebel, Esq.</font></div><div style="text-indent:63pt"><font><br></font></div><div style="text-indent:63pt"><font><br></font></div><div style="margin-bottom:11pt;text-indent:63pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Any such notice shall be deemed given on the date received.  A Party may add, delete, or change the person or address to whom notices should be sent at any time upon written notice delivered to the Party&#8217;s notices in accordance with this Section 15.2.</font></div><div style="margin-bottom:12pt;text-indent:63pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">15.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Force Majeure</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Neither Party shall be liable for delay or failure in the performance of any of its obligations hereunder (including, without limitation Sections 6.1.2 and 6.1.3 of this Agreement) if such delay or failure is due to causes beyond its reasonable control, including acts of God, fires, earthquakes, strikes and labor disputes, acts of war, terrorism, civil unrest or intervention of any governmental authority (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Force Majeure</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;)&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, that the affected Party promptly notifies the other Party and further provided that the affected Party shall use its commercially reasonable efforts to avoid or remove such causes of non-performance and to mitigate the effect of such occurrence and shall continue performance with the utmost dispatch whenever such causes are removed.  When such circumstances arise, the Parties shall negotiate in good faith any </font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:0pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">modifications of the terms of this Agreement that may be necessary or appropriate in order to arrive at an equitable solution.</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">15.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Assignment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;padding-left:9pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">15.4.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Ligand may, without Retrophin&#8217;s consent, assign or transfer all of its rights and obligations hereunder, in connection with any transfer of all of the Patent Rights and Know-How, to any Affiliate of Ligand or to any Third Party (including a successor in interest)&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, that such assignee or transferee agrees in writing to be bound by the terms of this Agreement.</font></div><div style="margin-bottom:12pt;padding-left:9pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">15.4.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Retrophin may assign or transfer all of its rights and obligations hereunder without consent to an Affiliate of Retrophin or to a successor in interest by reason of merger, consolidation or sale of all or substantially all of the assets of Retrophin&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">provided however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, that (i) Retrophin&#8217;s rights and obligations under this Agreement shall be assumed by its successor in interest and shall not be transferred separate from all or substantially all of its other business assets, (ii) such assignment includes all Approvals and all rights and obligations under this Agreement, (iii) such successor in interest or Affiliate shall have agreed prior to such assignment or transfer to be bound by the terms of this Agreement in writing and (iv) where this Agreement is assigned or transferred to an Affiliate, Retrophin remains responsible for the performance of this Agreement.</font></div><div style="margin-bottom:12pt;padding-left:9pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">15.4.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Subject to the foregoing, this Agreement shall inure to the benefit of and be binding on the Parties&#8217; successors and assigns.  Any assignment or transfer in violation of the foregoing shall be null and void and wholly invalid, the assignee or transferee in any such assignment or transfer shall acquire no rights whatsoever, and the non-assigning non-transferring Party shall not recognize, nor shall it be required to recognize, such assignment or transfer.</font></div><div style="margin-bottom:12pt;text-indent:63pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">15.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Further Assurances</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Each Party agrees to do and perform all such further acts and things and shall execute and deliver such other agreements, certificates, instruments and documents necessary or that the other Party may deem advisable in order to carry out the intent and accomplish the purposes of this Agreement and to evidence, perfect or otherwise confirm its rights hereunder.</font></div><div style="margin-bottom:12pt;text-indent:63pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">15.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Waivers and Modifications</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The failure of any Party to insist on the performance of any obligation hereunder shall not be deemed to be a waiver of such obligation.  Waiver of any breach of any provision hereof shall not be deemed to be a waiver of any other breach of such provision or any other provision on such occasion or any succeeding occasion.  No waiver, modification, release or amendment of any obligation under or provision of this Agreement shall be valid or effective unless in writing and signed by all Parties hereto.</font></div><div style="margin-bottom:12pt;text-indent:63pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">15.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Choice of Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  This Agreement shall be governed by, enforced, and shall be construed in accordance with the laws of the State of New York without regard to its conflicts of law provisions.</font></div><div style="margin-bottom:12pt;text-indent:63pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">15.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Publicity</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The Parties agree to issue a press release regarding the execution of this Agreement, in a form to be mutually agreed upon by the Parties.  Subject to the provisions of Sections 11.2, 11.4 and 11.5, each Party agrees not to issue any other press release or public statement disclosing the existence of this Agreement or any other information relating to this Agreement, the other Party, or the transactions contemplated </font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:0pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">hereby without the prior written consent of the other Party&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, that any disclosure which is required by applicable Laws or the rules of a securities exchange, as reasonably advised by the disclosing Party&#8217;s counsel, may be made subject to the following.  The Parties agree that any such required disclosure will not contain confidential business or technical information and, if disclosure of confidential business or technical information is required by applicable Laws, the Parties will use appropriate diligent efforts to minimize such disclosure and obtain confidential treatment for any such information which is disclosed to a governmental agency.  Each Party agrees to provide to the other Party a copy of any public announcement regarding this Agreement or the subject matter thereof as soon as reasonably practicable under the circumstances prior to its scheduled release.  Except under extraordinary circumstances, or as otherwise required under applicable Laws or the rules of a securities exchange, each Party shall provide the other with an advance copy of any such announcement at least forty eight (48) hours prior to its scheduled release.  Each Party shall have the right to expeditiously review and recommend changes to any such announcement and, except as otherwise required by applicable Laws or the rules of a securities exchange, the Party whose announcement has been reviewed shall remove any Confidential Information of the reviewing Party that the reviewing Party reasonably deems to be inappropriate for disclosure.  The contents of any announcement or similar publicity which has been reviewed and approved by the reviewing Party can be re-released by either Party without a requirement for re-approval.  Nothing in this Section 15.8 shall be construed to prohibit Retrophin or its Affiliates or Sublicensees from making a public announcement or disclosure regarding the stage of development of Licensed Products in Retrophin&#8217;s (or its Affiliates&#8217; or Sublicensees&#8217;) product pipeline or disclosing clinical trial results regarding such Licensed Products, as may be required by applicable Laws or the rules of a securities exchange, as reasonably advised by Retrophin&#8217;s (or its Affiliates&#8217; or Sublicensees&#8217;) counsel.</font></div><div style="margin-bottom:12pt;text-indent:63pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">15.9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Relationship of the Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Each Party is an independent contractor under this Agreement.  Nothing contained herein is intended or is to be construed so as to constitute Ligand and Retrophin as partners, agents or joint venturers.  Neither Party shall have any express or implied right or authority to assume or create any obligations on behalf of or in the name of the other Party or to bind the other Party to any contract, agreement or undertaking with any Third Party.</font></div><div style="margin-bottom:12pt;text-indent:63pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">15.10</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Headings</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Headings and captions are for convenience only and are not be used in the interpretation of this Agreement.</font></div><div style="margin-bottom:12pt;text-indent:63pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">15.11</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Entire Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  This Agreement (including all Appendices attached hereto, which are incorporated herein by reference) (i) sets forth all of the covenants, promises, agreements, warranties, representations, conditions and understandings between the Parties hereto, (ii) constitutes and contains the complete, final and exclusive understanding and agreement of the Parties with respect to the subject matter herein and (iii) cancels, supersedes and terminates all prior agreements and understanding between the Parties with respect to the subject matter hereof.  For the avoidance of doubt, the confidentiality agreement entered into by Ligand and Retrophin effective as of December 11, 2011 (the &#8220;Confidentiality Agreement&#8221;) shall remain in effect with respect to all Confidential Information (as that term is defined in the Confidentiality Agreement) disclosed by the Parties that does not pertain to the subject matter of this Agreement.  All Confidential Information (as that term is defined in the Confidentiality Agreement) pertaining to the subject matter of this Agreement disclosed to Ligand by Retrophin under the Confidentiality Agreement shall be considered Confidential Information (as that term is defined in this Agreement) of Retrophin disclosed under this Agreement and shall be </font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:0pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">subject to the terms and conditions of this Agreement&#59; and all Confidential Information (as that term is defined in the Confidentiality Agreement) pertaining to the subject matter of this Agreement disclosed to Retrophin by Ligand under the Confidentiality Agreement shall be considered Confidential Information (as that term is defined in this Agreement) of Ligand disclosed under this Agreement and shall be subject to the terms and conditions of this Agreement.  There are no covenants, promises, agreements, warranties, representations, conditions or understandings, whether oral or written, between the Parties other than as set forth herein.  No subsequent alteration, amendment, change or addition to this Agreement shall be binding upon the Parties hereto unless reduced to writing and signed by the respective authorized officers of the Parties.</font></div><div style="margin-bottom:12pt;text-indent:63pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">15.12</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Counterparts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  This Agreement may be executed in counter-parts with the same effect as if both Parties had signed the same document.  All such counterparts shall be deemed an original, shall be construed together and shall constitute one and the same instrument.</font></div><div style="margin-bottom:12pt;text-indent:63pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">15.13</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Exports</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Retrophin agrees not to export or re-export, directly or indirectly, any information, technical data, the direct product of such data, samples or equipment received or generated under this Agreement in violation of any applicable export control Laws.</font></div><div style="margin-bottom:12pt;text-indent:63pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">15.14</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Interpretation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-indent:81pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">15.14.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Each of the Parties acknowledges and agrees that this Agreement has been diligently reviewed by and negotiated by and between them, that in such negotiations each of them has been represented by competent counsel and that the final agreement contained herein, including the language whereby it has been expressed, represents the joint efforts of the Parties hereto and their counsel.  Accordingly, in interpreting this Agreement or any provision hereof, no presumption shall apply against any Party hereto as being responsible for the wording or drafting of this Agreement or any such provision, and ambiguities, if any, in this Agreement shall not be construed against any Party, irrespective of which Party may be deemed to have authored the ambiguous provision.</font></div><div style="margin-bottom:12pt;padding-left:9pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">15.14.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The definitions of the terms herein shall apply equally to the singular and plural forms of the terms defined.  Whenever the context may require, any pronoun shall include the corresponding masculine, feminine and neuter forms.  The words &#8220;include,&#8221; &#8220;includes&#8221; and &#8220;including&#8221; shall be deemed to be followed by the phrase &#8220;without limitation.&#8221;  The word &#8220;will&#8221; shall be construed to have the same meaning and effect as the word &#8220;shall.&#8221;  The word &#8220;any&#8221; shall mean &#8220;any and all&#8221; unless otherwise clearly indicated by context.</font></div><div style="margin-bottom:12pt;padding-left:9pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">15.14.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Unless the context requires otherwise, (a) any definition of or reference to any agreement, instrument or other document herein shall be construed as referring to such agreement, instrument or other document as from time to time amended, supplemented or otherwise modified (subject to any restrictions on such amendments, supplements or modifications set forth herein or therein), (b) any reference to any Laws herein shall be construed as referring to such Laws as from time to time enacted, repealed or amended, (c) any reference herein to any person shall be construed to include the person&#8217;s successors and assigns, (d) the words &#8220;herein&#8221;, &#8220;hereof&#8221; and &#8220;hereunder&#8221;, and words of similar import, shall be construed to refer to this Agreement in its entirety and not to any particular provision hereof, and (e) all references herein to Articles, Sections </font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:0pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">or Appendices, unless otherwise specifically provided, shall be construed to refer to Articles, Sections and Appendices of this Agreement.</font></div><div style="margin-bottom:11pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">* * *</font></div><div style="margin-bottom:11pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;signature page follows&#93;</font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:0pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:11pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">IN WITNESS WHEREOF, the Parties have caused this Agreement to be executed by their respective duly authorized officers as of the date first set forth above.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">LIGAND PHARMACEUTICALS&#160;&#160;&#160;&#160;RETROPHIN, LLC </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">INCORPORATED &#160;&#160;&#160;&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(&#8220;Ligand&#8221;)&#160;&#160;&#160;&#160;(&#8220;Retrophin&#8221;)</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">By&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">&#47;s&#47; Charles Berkman&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;By&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">&#47;s&#47; Martin Shkreli&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Name&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Charles Berkman&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Name&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Martin Shkreli&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Title&#58;&#160;&#160;&#160;&#160;   Vice President, General Counsel and&#160;&#160;&#160;&#160;Title&#58;&#160;&#160;&#160;&#160;Chief Executive Officer</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Secretary</font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:0pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Appendix 1</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Core Patent Rights</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:6.813%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.173%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.087%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.259%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.712%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.266%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.986%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.993%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.811%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #00000a;border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:1pt solid #00000a;border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:1pt solid #00000a;border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:1pt solid #00000a;border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:1pt solid #00000a;border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:1pt solid #00000a;border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:1pt solid #00000a;border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:1pt solid #00000a;border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:1pt solid #00000a;border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:0pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div><font><br></font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:0pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Appendix 2</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Active Compound</font></div><div style="margin-bottom:11pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Active Compound</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means a compound that </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:11pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:11pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:0pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Appendix 3</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Development Plan</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(attached hereto)</font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:0pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#91;***&#93;</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#91;***&#93;</font></div><div style="margin-bottom:12pt;text-align:center"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#91;***&#93;</font></div><div style="margin-bottom:12pt;text-align:center"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#91;***&#93;</font></div><div style="margin-bottom:12pt;text-align:center"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#91;***&#93;</font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#91;***&#93;</font></div><div style="margin-bottom:12pt;text-align:center"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#91;***&#93;</font></div><div style="margin-bottom:12pt;text-align:center"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#91;***&#93; &#8211; EIGHT PAGES REDACTED</font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:0pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Appendix 4</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Listed Compounds</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#91;***&#93;</font></div><div style="margin-bottom:12pt;padding-left:216pt"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font><br></font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div></div></div><div id="ic4941cc38c7541dc945d6ea6ea5eaf5a_4"></div><hr style="page-break-after:always"><div style="min-height:0pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">***Certain information (indicated by asterisks) has been</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">omitted from this document because it is not material and would</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">likely cause competitive harm to the registrant if publicly disclosed.</font></div><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">AMENDMENT TO </font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">SUBLICENSE AGREEMENT</font></div><div style="margin-bottom:12pt;text-align:center"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">THIS AMENDMENT TO SUBLICENSE AGREEMENT</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Amendment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) is made and entered into as of December 11, 2012 (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#8220;Amendment Effective Date&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">) and amends the Sublicense Agreement effective as of February 16, 2012  (the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#8220;Sublicense Agreement&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">) by and between Ligand Pharmaceuticals Incorporated, a corporation organized under the laws of Delaware and having a place of business at 11119 North Torrey Pines Road, Suite 200, La Jolla, CA, 92037 and its wholly owned subsidiary, Pharmacopeia, LLC (as successor in interest to Pharmacopeia Drug Discovery Inc.) (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#8220;PCOP&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">), a limited liability company organized under the laws of Delaware and having a place of business at 11119 North Torrey Pines Road, Suite 200, La Jolla, CA, 92037 (collectively, Ligand Pharmaceuticals Incorporated and PCOP shall be known as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#8220;Ligand&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">) and Retrophin, Inc., a corporation organized under the laws of Delaware and having a place of business at 777 Third Avenue, 22</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">nd</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> Floor, New York, NY, 10017 (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#8220;Retrophin&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">).  </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">WHEREAS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, Ligand and Retrophin have previously entered into the Sublicense Agreement&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">WHEREAS,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> Ligand and Retrophin desire to amend certain terms of the Sublicense Agreement as set forth herein.  </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">NOW THEREFORE</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, in consideration of the foregoing premises and the mutual covenants contained herein, the Parties, intending to be legally bound, agree as follows&#58;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Capitalized Terms</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The capitalized terms used herein and not otherwise defined shall have the same definitions as provided in the Sublicense Agreement.  </font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Amendments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:130%">Development Milestone Payments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">.  Table 1 of Section 8.2.1 of the Agreement is hereby amended in its entirety as follows&#58;</font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:0pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">***Certain information (indicated by asterisks) has been</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">omitted from this document because it is not material and would</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">likely cause competitive harm to the registrant if publicly disclosed.</font></div><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:216pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">&#8220;Table 1</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.177%"><tr><td style="width:1.0%"></td><td style="width:48.206%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:49.594%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:4.5pt;padding-right:4.5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Milestone Event</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:4.5pt;padding-right:4.5pt;text-align:center;text-indent:2.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Milestone Payment</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Execution of Agreement</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:9pt;text-align:justify;text-indent:2.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$1.15 million</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The earlier of (a) December 31, 2012 or (b) initiation of the first Phase 2 Trial for a Licensed Product</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;margin-top:12pt;padding-left:9pt;text-align:justify;text-indent:2.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">$1.15 million (the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:130%">&#8220;Second Milestone&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">)&#59; provided, that if the Second Milestone is received by Ligand prior to December 31, 2012, Retrophin shall make an additional $150,000 payment simultaneously with the payment of the Second Milestone (for an aggregate payment of $1.3 million) (the $150,000 additional payment, an </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:130%">&#8220;Additional Payment&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:130%;position:relative;top:-3.85pt;vertical-align:baseline">1</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:11pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:11pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:11pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:11pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:11pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:11pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:11pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:11pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:11pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:11pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div><div><font><br></font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:11pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:11pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #00000a;border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div></td><td colspan="3" style="border-bottom:1pt solid #00000a;border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:11pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div></td></tr></table></div><div style="margin-bottom:11pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1)&#160;&#160;&#160;&#160;If the Second Milestone and any Additional Payment is not received by Ligand on or before December 31, 2012, Ligand shall have the right to terminate the Agreement pursuant to Section 13.2.2 with immediate effect as of December 31, 2012 by providing written notice to Retrophin, notwithstanding (a) the cure period for the failure to make a payment when due set out in said Section 13.2.2 (Breach) or (b) the provisions of Section 13.2.4 (Disputed Breach).  In addition, and for clarity, the provisions of Section 13.4 (Effect of Termination) shall be operative, including, without limitation, the provisions of subsections (c), (k) and (m) related to amounts then due and payable. &#8220;</font></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:130%">Exit Transaction Milestone</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">. Section 8.2.2 of the Agreement is amended by replacing </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%">&#91;***&#93; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">.</font></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">(c)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:130%">Expedited Arbitration</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%">Section 14.4 of the Agreement is hereby amended in its entirety as follows&#58;</font></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">&#8220;The Parties agree that it is important to be able to clarify any disputes regarding </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%">&#91;***&#93; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">quickly. Accordingly, if&#58; (i) Ligand </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">&#59; (ii) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">&#59; (iii) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">&#59; or (iv) </font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:0pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">***Certain information (indicated by asterisks) has been</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">omitted from this document because it is not material and would</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">likely cause competitive harm to the registrant if publicly disclosed.</font></div><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%">&#91;***&#93;&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">then the Parties shall resolve such dispute in accordance with this Section 14.4. Arbitration under this Section 14.4 shall be conducted in the same manner and subject to the same terms and conditions as arbitration under Section 14.3, provided that&#58; (i) the Parties shall designate in writing a single arbitrator within fifteen (15) days of written notice of the dispute&#59; (ii) the arbitrator and the Parties shall meet, and each Party shall provide to the arbitrator a written summary of all disputed issues, such Party&#8217;s position on such disputed issues and such Party&#8217;s proposed ruling on the merits of each such issue within fifteen (15) days after the designation of the arbitrator&#59; (iii) the arbitrator shall use his or her commercially reasonable efforts to rule on each disputed issue within fifteen (15) days after completion of the hearing described in Section 14.3&#59; (iv) the arbitrator shall select one of the requested positions as his decision, and shall not have the authority to render any substantive decision other than to so select the position of either Ligand or Retrophin&#59; and (v) the Parties shall use good faith efforts to complete any expedited arbitration pursuant to this Section 14.4 promptly.&#8221;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">No Other Amendments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Except as provided herein, the Sublicense Agreement shall continue in full force and effect.</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Release</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">  </font></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">(a)&#160;&#160;&#160;&#160;As used in this Clause, &#8220;Related Persons and Entities&#8221; in connection with a Party means any and all past, present, and future parents, subsidiaries, affiliates, partners, owners, joint venturers, stockholders, predecessors, successors, officers, members, directors, administrators, employees, agents, representatives, consultants, attorneys, insurers, heirs, executors, assignors or assignees, retirement plans (and&#47;or their trustees) of that Party and any other person, firm, or corporation with whom that Party is now or may hereinafter be affiliated, and any of them.</font></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">(b)&#160;&#160;&#160;&#160;Retrophin and its Affiliates and any and all officers, directors, owners, predecessors, or successors, of that Party hereby fully and forever, knowingly, voluntarily, and irrevocably release, acquit, discharge, and promises not to sue Ligand and its Related Persons and Entities, from, without limitation, any and all claims, demands, damages, obligations, losses, causes of action, costs, expenses, attorneys&#8217; fees, judgments, liabilities, duties, debts, liens, accounts, obligations, contracts&#47;agreements, promises, representations, actions, and causes of action, other proceedings and indemnities of any nature whatsoever arising from or in any way related to&#58; (i) the quality of the medication&#59; or (ii) compliance of the medication with specifications of Governmental Authorities delivered pursuant to the Sublicense Agreement&#59; or (iii) Ligand&#8217;s conduct during diligence and negotiations leading to the Sublicense Agreement, whether accrued or contingent, secured or unsecured, negligent or intentional, known or unknown, suspected or unsuspected, and whether based on law, equity, contract, tort, statute, or other legal or equitable theory of recovery, whether mature or to mature in the future, which from the beginning of time to the date of this Amendment, Retrophin and its Affiliates and any and all officers, directors, owners, predecessors, or successors, of that Party had, now have, or claims to have against Ligand and its Related Persons and Entities, or any other person or entity described above. </font></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">(c)&#160;&#160;&#160;&#160;Retrophin acknowledges that it may later discover material facts in addition to, or different from, those which it now knows or believes to be true.  Retrophin further acknowledges that there may be future events, circumstances or occurrences materially different from those it knows or believes likely to occur.  It is the </font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:0pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">***Certain information (indicated by asterisks) has been</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">omitted from this document because it is not material and would</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">likely cause competitive harm to the registrant if publicly disclosed.</font></div><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">intention of Retrophin to fully, finally and forever settle and generally release all claims, disputes and differences described above occurring prior to the date hereof.  The releases provided in this Amendment shall remain in full effect notwithstanding the discovery or existence of any such additional or different facts or occurrence of any such future events, circumstances or conditions.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:130%"> </font></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">(d)&#160;&#160;&#160;&#160;Retrophin and its Affiliates and any and all officers, directors, owners, predecessors, or successors, of that Party hereby expressly waive the benefit of any statute or rule of law that, if applied to this Amendment would otherwise exclude from its binding effect any claims described above not known by it to exist which arose prior to the signing of this Amendment.  Retrophin acknowledges that it has read and fully understands the provisions of California Civil Code section 1542, which provides as follows&#58;</font></div><div style="margin-bottom:6pt;padding-left:76.5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">A GENERAL RELEASE DOES NOT EXTEND TO CLAIMS WHICH THE CREDITOR DOES NOT KNOW OR SUSPECT TO EXIST IN HIS FAVOR AT THE TIME OF EXECUTING THE RELEASE, WHICH, IF KNOWN BY HIM MUST HAVE MATERIALLY AFFECTED HIS SETTLEMENT WITH THE DEBTOR.</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Retrophin, being aware of said Code Section, hereby expressly waives, on behalf of itself and its Affiliates and any and all officers, directors, owners, predecessors, or successors, of that Party, any rights and benefits that they may have under section 1542 of the California Civil Code to the full extent that they may lawfully waive such rights and benefits, and shall waive any rights and benefits they may have under any other statutes or common law principles of similar effect.</font></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">(e)&#160;&#160;&#160;&#160;This Amendment and its terms, including, but not limited to, the Release set forth in this Section 4, and the execution of this Amendment, shall not be construed as an admission of liability or fault by either of the Parties.</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">5.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Governing Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">This Amendment shall be governed by, enforced, and shall be construed in accordance with the laws of the State of New York without regard to its conflicts of law provisions.</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">6.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Counterparts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  This Amendment may be executed in counter-parts with the same effect as if both Parties had signed the same document.  All such counterparts shall be deemed an original, shall be construed together and shall constitute one and the same instrument.</font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:0pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">***Certain information (indicated by asterisks) has been</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">omitted from this document because it is not material and would</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">likely cause competitive harm to the registrant if publicly disclosed.</font></div><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;IN WITNESS WHEREOF</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, the Parties have executed this Amendment to Sublicense Agreement through their duly authorized representatives to be effective as of the Amendment Effective Date.</font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">LIGAND PHARMACEUTICALS &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;RETROPHIN, INC.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">INCORPORATED</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">By&#58;  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">&#47;s&#47; Matthew Foehr&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;By&#58;  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">&#47;s&#47; Martin Shkreli&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Title&#58; Vice President, Corporate Development&#160;&#160;&#160;&#160;Title&#58; Chief Executive Officer</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Date&#58; 12&#47;20&#47;12&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Date&#58; 12&#47;19&#47;2012</font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:0pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">***Certain information (indicated by asterisks) has been</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">omitted from this document because it is not material and would</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">likely cause competitive harm to the registrant if publicly disclosed.</font></div><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">AMENDMENT NO. 2 TO </font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">SUBLICENSE AGREEMENT</font></div><div style="margin-bottom:12pt;text-align:center"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">THIS AMENDMENT NO. 2 TO SUBLICENSE AGREEMENT</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Amendment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) is made and entered into as of January 7, 2013 (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#8220;Amendment Effective Date&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">) and amends the Sublicense Agreement effective as of February 16, 2012, as amended pursuant to that certain Amendment to Sublicense Agreement dated December 11, 2012  (the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#8220;Sublicense Agreement&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">) by and between Ligand Pharmaceuticals Incorporated, a corporation organized under the laws of Delaware and having a place of business at 11119 North Torrey Pines Road, Suite 200, La Jolla, CA, 92037 and its wholly owned subsidiary, Pharmacopeia, LLC (as successor in interest to Pharmacopeia Drug Discovery Inc.) (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#8220;PCOP&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">), a limited liability company organized under the laws of Delaware and having a place of business at 11119 North Torrey Pines Road, Suite 200, La Jolla, CA, 92037 (collectively, Ligand Pharmaceuticals Incorporated and PCOP shall be known as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#8220;Ligand&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">) and Retrophin, Inc., a corporation organized under the laws of Delaware and having a place of business at 777 Third Avenue, 22</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">nd</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> Floor, New York, NY, 10017 (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#8220;Retrophin&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">).  </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">WHEREAS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, Ligand and Retrophin have previously entered into the Sublicense Agreement&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">WHEREAS,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> Ligand and Retrophin desire to amend certain terms of the Sublicense Agreement as set forth herein.  </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">NOW THEREFORE</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, in consideration of the foregoing premises and the mutual covenants contained herein, the Parties, intending to be legally bound, agree as follows&#58;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Capitalized Terms</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The capitalized terms used herein and not otherwise defined shall have the same definitions as provided in the Sublicense Agreement.  </font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Amendments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:130%">Development Milestone Payments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">.  Table 1 of Section 8.2.1 of the Agreement is hereby amended in its entirety as follows&#58;</font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:0pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">***Certain information (indicated by asterisks) has been</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">omitted from this document because it is not material and would</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">likely cause competitive harm to the registrant if publicly disclosed.</font></div><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:216pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">&#8220;Table 1</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.177%"><tr><td style="width:1.0%"></td><td style="width:48.206%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:49.594%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:4.5pt;padding-right:4.5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Milestone Event</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:4.5pt;padding-right:4.5pt;text-align:center;text-indent:2.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Milestone Payment</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Execution of Agreement</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:9pt;text-align:justify;text-indent:2.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$1.15 million</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The earlier of (a) March 31, 2013 or (b) initiation of the first Phase 2 Trial for a Licensed Product</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;margin-top:12pt;padding-left:9pt;text-align:justify;text-indent:2.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">$1.3 million (the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:130%">&#8220;Second Milestone&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">)&#59; provided, that if the Second Milestone is received by Ligand (a) prior to or on January 31, 2013, Retrophin shall make an additional $50,000 payment simultaneously with the payment of the Second Milestone (for an aggregate payment of $1.2 million), (b) after January 31, 2013 but prior to or on February 28, 2013, Retrophin shall make an additional $100,000 payment simultaneously with the payment of the Second Milestone (for an aggregate payment of $1.4 million), and (c) after February 28, 2013 but prior to or on March 31, 2013, Retrophin shall make an additional $150,000 payment simultaneously with the payment of the Second Milestone (for an aggregate payment of $1.45 million) (the additional payment, an </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:130%">&#8220;Additional Payment&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:130%;position:relative;top:-3.85pt;vertical-align:baseline">1</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:11pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:11pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:11pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:11pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:11pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:11pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:11pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:11pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:11pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:11pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:11pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:11pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #00000a;border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div></td><td colspan="3" style="border-bottom:1pt solid #00000a;border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:11pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div></td></tr></table></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1)&#160;&#160;&#160;&#160;If the Second Milestone and any Additional Payment is not received by Ligand on or before March 31, 2013, Ligand shall have the right to terminate the Agreement pursuant to Section 13.2.2 with immediate effect as of March 31, 2013 by providing written notice to Retrophin, notwithstanding (a) the cure period for the failure to make a payment when due set out in said Section 13.2.2 (Breach) or (b) the provisions of Section 13.2.4 (Disputed Breach).  In addition, and for clarity, the provisions of Section 13.4 (Effect of Termination) </font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:0pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">***Certain information (indicated by asterisks) has been</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">omitted from this document because it is not material and would</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">likely cause competitive harm to the registrant if publicly disclosed.</font></div><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">shall be operative, including, without limitation, the provisions of subsections (c), (k) and (m) related to amounts then due and payable.&#8221;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">No Other Amendments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Except as provided herein, the Sublicense Agreement shall continue in full force and effect.</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Release</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">  </font></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">(a)&#160;&#160;&#160;&#160;As used in this Clause, &#8220;Related Persons and Entities&#8221; in connection with a Party means any and all past, present, and future parents, subsidiaries, affiliates, partners, owners, joint venturers, stockholders, predecessors, successors, officers, members, directors, administrators, employees, agents, representatives, consultants, attorneys, insurers, heirs, executors, assignors or assignees, retirement plans (and&#47;or their trustees) of that Party and any other person, firm, or corporation with whom that Party is now or may hereinafter be affiliated, and any of them.</font></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">(b)&#160;&#160;&#160;&#160;Retrophin and its Affiliates and any and all officers, directors, owners, predecessors, or successors, of that Party hereby fully and forever, knowingly, voluntarily, and irrevocably release, acquit, discharge, and promises not to sue Ligand and its Related Persons and Entities, from, without limitation, any and all claims, demands, damages, obligations, losses, causes of action, costs, expenses, attorneys&#8217; fees, judgments, liabilities, duties, debts, liens, accounts, obligations, contracts&#47;agreements, promises, representations, actions, and causes of action, other proceedings and indemnities of any nature whatsoever arising from or in any way related to the Sublicense Agreement, as amended pursuant to this Amendment,  whether accrued or contingent, secured or unsecured, negligent or intentional, known or unknown, suspected or unsuspected, and whether based on law, equity, contract, tort, statute, or other legal or equitable theory of recovery, whether mature or to mature in the future, which from the beginning of time to the date of this Amendment, Retrophin and its Affiliates and any and all officers, directors, owners, predecessors, or successors, of that Party had, now have, or claims to have against Ligand and its Related Persons and Entities, or any other person or entity described above. </font></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">(c)&#160;&#160;&#160;&#160;Retrophin acknowledges that it may later discover material facts in addition to, or different from, those which it now knows or believes to be true.  Retrophin further acknowledges that there may be future events, circumstances or occurrences materially different from those it knows or believes likely to occur.  It is the intention of Retrophin to fully, finally and forever settle and generally release all claims, disputes and differences described above occurring prior to the date hereof.  The releases provided in this Amendment shall remain in full effect notwithstanding the discovery or existence of any such additional or different facts or occurrence of any such future events, circumstances or conditions.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:130%"> </font></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">(d)&#160;&#160;&#160;&#160;Retrophin and its Affiliates and any and all officers, directors, owners, predecessors, or successors, of that Party hereby expressly waive the benefit of any statute or rule of law that, if applied to this Amendment would otherwise exclude from its binding effect any claims described above not known by it to exist which arose prior to the signing of this Amendment.  Retrophin acknowledges that it has read and fully understands the provisions of California Civil Code section 1542, which provides as follows&#58;</font></div><div style="margin-bottom:6pt;padding-left:76.5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">A GENERAL RELEASE DOES NOT EXTEND TO CLAIMS WHICH THE CREDITOR DOES NOT KNOW OR SUSPECT TO EXIST IN HIS FAVOR </font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:0pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">***Certain information (indicated by asterisks) has been</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">omitted from this document because it is not material and would</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">likely cause competitive harm to the registrant if publicly disclosed.</font></div><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:6pt;padding-left:76.5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">AT THE TIME OF EXECUTING THE RELEASE, WHICH, IF KNOWN BY HIM MUST HAVE MATERIALLY AFFECTED HIS SETTLEMENT WITH THE DEBTOR.</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Retrophin, being aware of said Code Section, hereby expressly waives, on behalf of itself and its Affiliates and any and all officers, directors, owners, predecessors, or successors, of that Party, any rights and benefits that they may have under section 1542 of the California Civil Code to the full extent that they may lawfully waive such rights and benefits, and shall waive any rights and benefits they may have under any other statutes or common law principles of similar effect.</font></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">(e)&#160;&#160;&#160;&#160;This Amendment and its terms, including, but not limited to, the Release set forth in this Section 4, and the execution of this Amendment, shall not be construed as an admission of liability or fault by either of the Parties.</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">5.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Governing Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">This Amendment shall be governed by, enforced, and shall be construed in accordance with the laws of the State of New York without regard to its conflicts of law provisions.</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">6.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Counterparts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  This Amendment may be executed in counter-parts with the same effect as if both Parties had signed the same document.  All such counterparts shall be deemed an original, shall be construed together and shall constitute one and the same instrument.</font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:0pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">***Certain information (indicated by asterisks) has been</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">omitted from this document because it is not material and would</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">likely cause competitive harm to the registrant if publicly disclosed.</font></div><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;IN WITNESS WHEREOF</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, the Parties have executed this Amendment to Sublicense Agreement through their duly authorized representatives to be effective as of the Amendment Effective Date.</font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">LIGAND PHARMACEUTICALS &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;RETROPHIN, INC.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">INCORPORATED</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">By&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">&#47;s&#47; Charles Berkman&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;By&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">&#47;s&#47; Martin Shkreli&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Name&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Charles Berkman&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Name&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Martin Shkreli&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Title&#58;&#160;&#160;&#160;&#160;   Vice President, General Counsel and&#160;&#160;&#160;&#160;Title&#58;&#160;&#160;&#160;&#160;Chief Executive Officer</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Secretary</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Date&#58; January 7, 2013&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Date&#58; January 7, 2013</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:0pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">***Certain information (indicated by asterisks) has been</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">omitted from this document because it is not material and would</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">likely cause competitive harm to the registrant if publicly disclosed.</font></div><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:24pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">AMENDMENT NO. 3 TO SUBLICENSE AGREEMENT</font></div><div style="margin-bottom:18pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">THIS AMENDMENT NO. 3 TO SUBLICENSE AGREEMENT</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Amendment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) is made and entered into as of February 27, 2015 (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Amendment Effective Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) and amends the Sublicense Agreement effective as of February 16, 2012, as amended pursuant to that certain Amendment to Sublicense Agreement dated December&#160;11, 2012 and Amendment to Sublicense Agreement dated January 7, 2013 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Sublicense Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) by and between Ligand Pharmaceuticals Incorporated, a corporation organized under the laws of Delaware and having a place of business at 11119 North Torrey Pines Road, Suite 200, La Jolla, CA, 92037 and its wholly owned subsidiary, Pharmacopeia, LLC (as successor in interest to Pharmacopeia Drug Discovery Inc.) (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">PCOP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), a limited liability company organized under the laws of Delaware and having a place of business at 11119 North Torrey Pines Road, Suite 200, La Jolla, CA, 92037 (collectively, Ligand Pharmaceuticals Incorporated and PCOP shall be known as &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Ligand</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) and Retrophin, Inc., a corporation organized under the laws of Delaware and having a place of business at 777 Third Avenue, 22nd Floor, New York, NY, 10017 (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Retrophin</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">BACKGROUND</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">WHEREAS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> Ligand and Retrophin have previously entered into the Sublicense Agreement&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">WHEREAS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, Ligand and Retrophin desire to amend certain terms of the Sublicense Agreement as set forth herein.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">NOW, THEREFORE</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, in consideration of the foregoing premises and the mutual covenants contained herein, the Parties, intending to be legally bound, agree as follows&#58;</font></div><div style="margin-bottom:12pt;padding-left:40.5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Capitalized Terms</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. The capitalized terms used herein and not otherwise defined shall have the same definitions as provided in the Sublicense Agreement</font></div><div style="margin-bottom:12pt;padding-left:40.5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Amendments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. </font></div><div style="margin-bottom:12pt;padding-left:76.5pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">a)&#160;&#160;&#160;&#160;Sections 6.1.2 and 6.1.4 of the Sublicense Agreement are hereby removed.</font></div><div style="margin-bottom:12pt;padding-left:76.5pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">b)&#160;&#160;&#160;&#160;Section 6.1.3 of the Sublicense Agreement is hereby amended to read as follows&#58;</font></div><div style="margin-bottom:12pt;padding-left:76.5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;File for Approval for at least one (1) Orphan Licensed Product (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Approval Submission</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) no later than &#91;***&#93; (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Filing Deadline</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;)&#59; provided that if Retrophin exercises its Extension Option (as defined below), then the Filing Deadline shall become (a) &#91;***&#93; if the Approval Submission is filed pursuant to the Code of Federal Regulations Title 21, Subpart H (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Subpart H</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) or (b) &#91;***&#93;, if the Approval Submission is not eligible to be filed pursuant to Subpart H.  In order to exercise the Extension Option, prior to or on &#91;***&#93; (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Extension Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), Retrophin shall either (a) pay to Ligand &#91;***&#93; or (b) issue to Ligand, or ensure that Ligand receives, that number of shares of capital stock of Retrophin equal to &#91;***&#93; as determined by the average of the closing prices for such capital stock over a five (5) trading day period ending three (3) trading days before the Extension Date (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Extension Option</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">  </font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:0pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">***Certain information (indicated by asterisks) has been</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">omitted from this document because it is not material and would</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">likely cause competitive harm to the registrant if publicly disclosed.</font></div><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:76.5pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">c)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Development Milestone Events</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The third milestone event in Table 1 for $&#91;***&#93; shall be amended and restated as follows&#58; </font></div><div style="margin-bottom:12pt;padding-left:76.5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;&#91;***&#93;&#8221;</font></div><div style="margin-bottom:12pt;padding-left:40.5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">3.&#160;&#160;&#160;&#160;No Other Amendments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Except as provided herein, the Sublicense Agreement shall continue in full force and effect.</font></div><div style="margin-bottom:12pt;padding-left:40.5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">4.&#160;&#160;&#160;&#160;Governing Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">This Amendment shall be governed by, enforced, and shall be construed in accordance with the laws of the State of New York without regard to its conflicts of law provisions.</font></div><div style="margin-bottom:12pt;padding-left:40.5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">5.&#160;&#160;&#160;&#160;Counterparts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">This Amendment may be executed in counter-parts with the same effect as if both Parties had signed the same document. All such counterparts shall be deemed an original, shall be construed together and shall constitute one and the same instrument.</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> &#91;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Signature Page Follows</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#93;</font></div><div style="margin-bottom:18pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div></div></div><div id="ic4941cc38c7541dc945d6ea6ea5eaf5a_7"></div><hr style="page-break-after:always"><div style="min-height:0pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">***Text Omitted and Filed Separately with</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">the Securities and Exchange Commission.</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Confidential Treatment Requested Under</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">17 C.F.R. Sections 200.80(b)(4) and 240.24b-2.</font></div></div><div style="margin-bottom:18pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">IN WITNESS WHEREOF</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, the Parties have executed this Amendment to Sublicense Agreement through their duly authorized representatives to be effective as of the Amendment Effective Date.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">LIGAND PHARMACEUTICALS&#160;&#160;&#160;&#160;RETROPHIN, INC.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">INCORPORATED&#160;&#160;&#160;&#160;</font></div><div style="padding-left:252pt;text-align:justify;text-indent:-252pt"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">By&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">&#47;s&#47; Matthew W. Foehr&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;By&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">&#47;s&#47; Steve Aselage&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Name&#58;&#160;&#160;&#160;&#160;Matthew W. Foehr&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Name&#58;&#160;&#160;&#160;&#160;Steve Aselage</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Title&#58;&#160;&#160;&#160;&#160;President&#47;COO&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Title&#58;&#160;&#160;&#160;&#160;CEO</font></div><div style="margin-top:2pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="height:40.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:0pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">***Text Omitted and Filed Separately with</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">the Securities and Exchange Commission.</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Confidential Treatment Requested Under</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">17 C.F.R. Sections 200.80(b)(4) and 240.24b-2.</font></div></div><div style="margin-bottom:24pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">AMENDMENT NO. 4 TO SUBLICENSE AGREEMENT</font></div><div style="margin-bottom:18pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">THIS AMENDMENT NO. 4 TO SUBLICENSE AGREEMENT</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Amendment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) is made and entered into as of September 17, 2015 (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Amendment Effective Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) and amends the Sublicense Agreement effective as of February 16, 2012, as amended pursuant to that certain Amendment to Sublicense Agreement dated December 11, 2012, Amendment No. 2 to Sublicense Agreement dated January 7, 2013, and Amendment No. 3 to Sublicense Agreement dated February 27, 2015 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Sublicense Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) by and between Ligand Pharmaceuticals Incorporated, a corporation organized under the laws of Delaware and having a place of business at 11119 North Torrey Pines Road, Suite 200, La Jolla, CA, 92037 and its wholly owned subsidiary, Pharmacopeia, LLC (as successor in interest to Pharmacopeia Drug Discovery Inc.) (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">PCOP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), a limited liability company organized under the laws of Delaware and having a place of business at 11119 North Torrey Pines Road, Suite 200, La Jolla, CA, 92037 (collectively, Ligand Pharmaceuticals Incorporated and PCOP shall be known as &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Ligand</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) and Retrophin, Inc., a corporation organized under the laws of Delaware and having a place of business at 12255 El Camino Real, San Diego, CA 92130 (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Retrophin</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">BACKGROUND</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">WHEREAS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> Ligand and Retrophin have previously entered into the Sublicense Agreement pursuant to which Ligand sublicensed to Retrophin rights under the License Agreement dated March 27, 2006 between PCOP and Bristol-Myers Squib Company (the &#8220;Upstream License&#8221;)&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">WHEREAS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, Ligand and Retrophin desire to amend certain terms of the Sublicense Agreement and the Upstream Agreement as set forth herein.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">NOW, THEREFORE</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, in consideration of the foregoing premises and the mutual covenants contained herein, the Parties, intending to be legally bound, agree as follows&#58;</font></div><div style="margin-bottom:12pt;padding-left:40.5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.&#160;&#160;&#160;&#160;Capitalized Terms</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. The capitalized terms used herein and not otherwise defined shall have the same definitions as provided in the Sublicense Agreement</font></div><div style="margin-bottom:12pt;padding-left:40.5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">2.&#160;&#160;&#160;&#160;Amendments to Milestone Payments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. </font></div><div style="height:40.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:0pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">***Text Omitted and Filed Separately with</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">the Securities and Exchange Commission.</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Confidential Treatment Requested Under</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">17 C.F.R. Sections 200.80(b)(4) and 240.24b-2.</font></div></div><div style="margin-bottom:12pt;padding-left:76.5pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Development Milestone Payments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Table 1 of Section 8.2.1 of the Agreement is hereby amended in its entirety as follows&#58;</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.006%"><tr><td style="width:1.0%"></td><td style="width:48.304%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:49.496%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)   Milestone Event</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)   Milestone Payment</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)   Execution of Agreement</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d)   $1.15 million</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(e)   The earlier of (a) December 31, 2012 or (b) initiation of the first Phase 2 Trial for a Licensed Product</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(f)   $1.3 million (the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#8220;Second Milestone&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">)&#59; provided, that if the Second Milestone is received by Ligand (a) prior to or on January 31, 2012, Retrophin shall make an additional $50,000 payment simultaneously with the payment of the Second Milestone (for an aggregate payment of $1.35 million), (b) after January 31, 2013 but prior to or on February 28, 2013, Retrophin shall make an additional $100,00 payment simultaneously with the payment of the Second Milestone (for an aggregate payment of $1.4 million), and (c) after February 28, 2013 but prior to or on March 31, 2013, Retrophin shall make an additional $150,000 payment of the Second Milestone (for an aggregate payment of $1.45 million) (the additional payment, an &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Additional Payment&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">1</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:11pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:11pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:11pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:11pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:11pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:11pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:11pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:11pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:11pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:11pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:11pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:11pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:11pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #00000a;border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div></td><td colspan="3" style="border-bottom:1pt solid #00000a;border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:11pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div></td></tr></table></div><div style="margin-bottom:12pt;padding-left:76.5pt;text-align:justify"><font><br></font></div><div style="padding-left:4.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> If the Second Milestone and any Additional Payment is not received by Ligand on or before March 31, 2013, Ligand shall have the right to terminate the Agreement pursuant to Section 13.2.2 with immediate effect as of March 31, 2013 by providing written notice to Retrophin, notwithstanding (a) the cure period for </font></div><div style="height:40.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:0pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">***Text Omitted and Filed Separately with</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">the Securities and Exchange Commission.</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Confidential Treatment Requested Under</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">17 C.F.R. Sections 200.80(b)(4) and 240.24b-2.</font></div></div><div style="padding-left:4.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">the failure to make a payment when due set out in said Section 13.2.2 (Breach) or (b) the provisions of Section 13.2.4 (Disputed Breach).  In addition, and for clarity, the provisions of Section 13.4 (Effect of Termination) shall be operative, including, without limitation, the provisions of subsections (c),(k), and (m) related to amounts then due and payable.&#8221;</font></div><div style="padding-left:4.5pt"><font><br></font></div><div style="padding-left:76.5pt"><font><br></font></div><div style="margin-bottom:12pt;padding-left:76.5pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">b)&#160;&#160;&#160;&#160;Section 8.10 of the Sublicense Agreement is hereby deleted in its entirety. </font></div><div style="margin-bottom:12pt;padding-left:40.5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">3.&#160;&#160;&#160;&#160;Consideration</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Retrophin shall pay Ligand (i) $850,000 in consideration for the amendments set forth in this Amendment, and (ii) $150,000 for the efforts to amend the Upstream License Agreement in accordance with Section 4 of this Amendment, in each case such payment shall be non-refundable and shall be made within 5 days of execution of this Amendment by both parties.</font></div><div style="margin-bottom:12pt;padding-left:40.5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">4.&#160;&#160;&#160;&#160;Efforts to Amend Upstream License Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:4.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Ligand will use reasonable best efforts to obtain a waiver of Sections 3.1 and 13.2.5 by BMS for the Asia Pacific Region. &#8220;Asia Pacific Region&#8221; means Japan, China, S. Korea, Taiwan, Thailand and Vietnam.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:4.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Ligand will use reasonable best efforts to obtain BMS&#8217; agreement to the standby license provided by Section 2.2.2(v) in which event, Section 2.2.2(v) would be amended substantially in the form of the following language&#58; </font></div><div style="margin-bottom:12pt;padding-left:54pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;&#8230;provided, that, that such sublicensed rights shall not terminate if, as of the effective date of termination by BMS under Section 13.2, the Sublicensee is not in material default under its license agreement with Ligand in which case Sublicensee will assume all of Ligand&#8217;s rights and obligation under this Sublicense Agreement and be bound directly to BMS substituting Sublicensee for Ligand and subject to the payment to Ligand of all royalties and milestones under the sublicense agreement to the extent they exceed payments due to BMS under this Sublicense Agreement and payment to BMS of all royalties and milestones under this Upstream Agreement.&#8221;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;Ligand will use reasonable best efforts to obtain BMS&#8217;s agreement to the following amendments to the termination provisions of the Upstream Agreement.</font></div><div style="margin-bottom:12pt;padding-left:81pt;text-align:justify;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">i.&#160;&#160;&#160;&#160;Section 13.4 (b) of the Upstream Agreement amended to read as set forth below&#58;</font></div><div style="margin-bottom:12pt;padding-left:81pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> &#8220;&#91;***&#93;&#8221;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">ii.&#160;&#160;&#160;&#160;Section 13.4(f) amended as set forth below&#58;</font></div><div style="margin-bottom:12pt;padding-left:81pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;Ligand will &#91;***&#93;.&#8221;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-11.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">iii.&#160;&#160;&#160;&#160;Section 13.4(i) deleted.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;For the avoidance of doubt, any such efforts by Ligand made under this Sublicense Agreement shall not require Ligand to pay BMS any fee or concede and existing rights, but rather shall solely involve the use of logic and reason to seek to persuade BMS.</font></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">5.&#160;&#160;&#160;&#160;Amendments to Sublicense Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="height:40.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:0pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">***Text Omitted and Filed Separately with</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">the Securities and Exchange Commission.</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Confidential Treatment Requested Under</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">17 C.F.R. Sections 200.80(b)(4) and 240.24b-2.</font></div></div><div style="margin-bottom:12pt;padding-left:76.5pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">a)&#160;&#160;&#160;&#160;For the avoidance of doubt, none of the following amendments to the Sublicense Agreement are intended to cause a breach of the Upstream Agreement and any amendment that would otherwise cause such a breach shall be null and void ab initio.</font></div><div style="margin-bottom:12pt;padding-left:76.5pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">b)&#160;&#160;&#160;&#160;Section 1 of the Sublicense Agreement is hereby amended to include the following&#58; </font></div><div style="margin-bottom:12pt;padding-left:76.5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;1.70 &#8220;Asia Pacific Region&#8221; means Japan, China, S. Korea, Taiwan, Thailand and Vietnam.&#8221;</font></div><div style="margin-bottom:12pt;padding-left:76.5pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">c)&#160;&#160;&#160;&#160;Section 2.2.2 (vi) is hereby revised as set forth below&#58;</font></div><div style="padding-left:76.5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;&#8230;provided however, that such sublicensed rights shall not terminate if, as of the effective date of termination by Ligand under Article 13, the Sublicensee is not in material default under its license agreement with Retrophin in which case Sublicensee will assume all of Retrophin&#8217;s rights and obligation under this Sublicense Agreement and be bound directly to Ligand respectively substituting Sublicensee for Retrophin and subject to the payment to Retrophin of all royalties and milestones under the sublicense agreement to the extent they exceed payments due to Ligand under this Sublicense Agreement and payment to Ligand of all royalties and milestones under this Sublicense Agreement to the extent they exceed payments due to BMS under the Upstream Agreement.&#8221;</font></div><div style="margin-bottom:12pt;padding-left:76.5pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">d)&#160;&#160;&#160;&#160;Section 3.2 of the Sublicense Agreement is hereby amended  to include the following&#58; </font></div><div style="padding-left:76.5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;3.2.4 The provisions of Sections 3.2.1 and 3.2.2 shall not apply within the Asia Pacific Region.&#8221;</font></div><div style="padding-left:76.5pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;padding-left:76.5pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">e)&#160;&#160;&#160;&#160;Section 13.1.1 is hereby amended to add at the beginning of the first sentence &#8220;Subject to Section 13.7&#8230;&#8221;</font></div><div style="margin-bottom:12pt;padding-left:76.5pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">f)&#160;&#160;&#160;&#160;Section 13.2.6 is hereby deleted.</font></div><div style="margin-bottom:12pt;padding-left:76.5pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">g)&#160;&#160;&#160;&#160;Section 13.3 is hereby amended to add prior to the first sentence&#58;</font></div><div style="padding-left:81pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;Retrophin may terminate this Agreement for convenience upon &#91;***&#93; (&#91;***&#93;) days prior written notice to Ligand and all of the provisions of Section 13.4 will survive termination of this Agreement pursuant to this Section 13.3.&#8221;</font></div><div style="padding-left:81pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;padding-left:76.5pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">h)&#160;&#160;&#160;&#160;The following amendments will be effective (i) as between Ligand and Retrophin at a time when there is no breach claimed by BMS under the Upstream Agreement, and&#47;or (ii) at any time upon BMS&#8217;s agreement to amend or waive the applicable sections of the termination provisions in the Upstream Agreement&#59;</font></div><div style="margin-bottom:12pt;padding-left:112.5pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">a.&#160;&#160;&#160;&#160;Section 13.4(b) is hereby amended as set forth below&#58;</font></div><div style="margin-bottom:12pt;padding-left:81pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;&#91;***&#93;&#8221;</font></div><div style="margin-bottom:12pt;padding-left:112.5pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">b.&#160;&#160;&#160;&#160;Section 13.4(f) amended as set forth below&#58;</font></div><div style="height:40.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:0pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">***Text Omitted and Filed Separately with</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">the Securities and Exchange Commission.</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Confidential Treatment Requested Under</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">17 C.F.R. Sections 200.80(b)(4) and 240.24b-2.</font></div></div><div style="margin-bottom:12pt;padding-left:81pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;Retrophin will &#91;***&#93;.&#8221;</font></div><div style="margin-bottom:12pt;padding-left:112.5pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">c.&#160;&#160;&#160;&#160;Section 13.4(i) deleted.</font></div><div style="margin-bottom:12pt;padding-left:40.5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">6.&#160;&#160;&#160;&#160;Further Agreements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">a)&#160;&#160;&#160;&#160;Ligand further agrees that it will not, by act or omission, cause the termination of the Upstream Agreement provided however Ligand may terminate the Upstream Agreement for good cause with Retrophin&#8217;s prior written consent, not to be unreasonably withheld. Upon receipt by Ligand of any notice of default or any event that could likely lead to termination of the Upstream Agreement, Ligand will promptly notify Retrophin and work with Retrophin to effect cure of the default or concession with BMS.</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">b)&#160;&#160;&#160;&#160;To the extent BMS shall not agree to the amendments proposed in Section 4 above, Ligand will, to the extent it does not cause a default under the Upstream Agreement, work with Retrophin in good faith and without further consideration and without refund of payments made hereunder to achieve the objectives contemplated by this Amendment by making further efforts to seek agreement from BMS.</font></div><div style="margin-bottom:12pt;padding-left:40.5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">7.&#160;&#160;&#160;&#160;No Other Amendments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Except as provided herein, the Sublicense Agreement shall continue in full force and effect.</font></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">8.&#160;&#160;&#160;&#160;Governing Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">This Amendment shall be governed by, enforced, and shall be construed in accordance with the laws of the State of New York without regard to its conflicts of law provisions.</font></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">9.&#160;&#160;&#160;&#160;Counterparts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">This Amendment may be executed in counter-parts with the same effect as if both Parties had signed the same document. All such counterparts shall be deemed an original, shall be construed together and shall constitute one and the same instrument.</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> &#91;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Signature Page Follows</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#93;</font></div><div style="margin-bottom:18pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="height:40.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div></div></div><div id="ic4941cc38c7541dc945d6ea6ea5eaf5a_10"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">***Text Omitted and Filed Separately with</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">the Securities and Exchange Commission.</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Confidential Treatment Requested Under</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">17 C.F.R. Sections 200.80(b)(4) and 240.24b-2.</font></div></div><div style="margin-bottom:18pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">IN WITNESS WHEREOF</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, the Parties have executed this Amendment to Sublicense Agreement through their duly authorized representatives to be effective as of the Amendment Effective Date.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">LIGAND PHARMACEUTICALS&#160;&#160;&#160;&#160;RETROPHIN, INC. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">INCORPORATED&#160;&#160;&#160;&#160;</font></div><div style="padding-left:252pt;text-align:justify;text-indent:-252pt"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">By&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">&#47;s&#47; Charles Berkman&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;By&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">&#47;s&#47; Laura Clague&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Name&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Charles Berkman   &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Name&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Laura Clague&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Title&#58;&#160;&#160;&#160;&#160; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">VP, General Counsel &#38; Secretary  &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Title&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Chief Financial Officer&#160;&#160;&#160;&#160;</font></div><div style="margin-top:2pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div></div></div><div id="ic4941cc38c7541dc945d6ea6ea5eaf5a_13"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 10.2</font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">***Text Omitted and Filed Separately</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">with Securities and Exchange Commission</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Confidential Treatment Requested</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Under 17 C.F.R. Sections 200.80(b)(4) and 240.24b-2 of the </font></div><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Securities Exchange Act of 1934, as amended.</font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">AMENDMENT NO. 5 TO SUBLICENSE AGREEMENT</font></div><div style="margin-bottom:6pt;text-align:center"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">THIS AMENDMENT NO.  5 TO SUBLICENSE AGREEMENT</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Amendment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) is made and entered into as of March 20, 2018 (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Amendment Effective Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) and amends the Sublicense Agreement effective as of February 16, 2012, as amended pursuant to that certain Amendment to Sublicense Agreement dated December 11, 2012, Amendment No. 2 to Sublicense Agreement dated January 7, 2013, Amendment No. 3 to Sublicense Agreement dated February 27, 2015 and Amendment No. 4 to Sublicense Agreement dated September 17, 2015 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Sublicense Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) by and between Ligand Pharmaceuticals Incorporated, a corporation organized under the laws of Delaware and having a place of business at </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">3911 SORRENTO VALLEY BOULEVARD, SUITE 110, SAN DIEGO, CA 92121</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> and its wholly owned subsidiary, Pharmacopeia, LLC (as successor in interest to Pharmacopeia Drug Discovery Inc.) (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">PCOP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), a limited liability company organized under the laws of Delaware and having a place of business at </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">3911 SORRENTO VALLEY BOULEVARD, SUITE 110, SAN DIEGO, CA 92121</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (collectively, Ligand Pharmaceuticals Incorporated and PCOP shall be known as &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Ligand</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) and Retrophin Inc., a corporation organized under the laws of Delaware and having a place of business AT </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">3721 VALLEY CENTRE DRIVE, SUITE 200, SAN DIEGO, CA  92130</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Retrophin</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">BACKGROUND</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">WHEREAS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> Ligand and Retrophin have previously entered into the Sublicense Agreement pursuant to which Ligand sublicensed to Retrophin rights under the License Agreement dated March 27, 2006 between PCOP and Bristol-Myers Squib Company (the &#8220;Upstream License&#8221;)&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">WHEREAS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, Ligand and Retrophin desire to amend certain terms of the Sublicense Agreement as set forth herein.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">NOW, THEREFORE</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, in consideration of the foregoing premises and the mutual covenants contained herein, the parties, intending to be legally bound, agree as follows&#58;</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Capitalized Terms</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. The capitalized terms used herein and not otherwise defined shall have the same definitions as provided in the Sublicense Agreement.</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Amendments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  </font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">a)&#160;&#160;&#160;&#160;Section 6.1.3 of the Sublicense Agreement is hereby amended to read as follows&#58;</font></div><div style="padding-left:90pt;text-align:justify"><font><br></font></div><div style="padding-left:85.5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;6.1.3  File for Approval for at least one (1) Orphan Licensed Product (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Approval Submission</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) no later than </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">***</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Filing Deadline</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;)&#59;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><font><br></font></div><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">***Confidential Treatment Requested</font></div></div></div><div id="ic4941cc38c7541dc945d6ea6ea5eaf5a_16"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="padding-left:90pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font></div><div style="padding-left:90pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;.</font></div><div style="padding-left:90pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">b)&#160;&#160;&#160;&#160;Section 8.2.1 of the Sublicense Agreement is hereby amended to read as follows&#58;</font></div><div style="padding-left:108pt;text-align:justify"><font><br></font></div><div style="padding-left:90pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;8.2.1  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Development Milestone Payments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Retrophin shall make milestone payments to Ligand upon achievement of each of the milestone events in the amounts set forth below in Table 1.  The first milestone payment shall be payable by Retrophin to Ligand within thirty (30) days of execution of the Agreement.  Notwithstanding Section 15.4 or any other provision herein, the last milestone payment shall be payable by Retrophin to Ligand upon the Closing of Retrophin&#8217;s Exit Transaction.  Subject to Section 8.2.2, the remainder of the milestone payments set forth below, with the exception of the milestone payment for Initiation of the first Phase 3 Trial for the first Licensed Product, will be payable by Retrophin to Ligand within thirty (30) days of the achievement of the specified milestone event with respect to each Licensed Compound.  The milestone for Initiation of the first Phase 3 Trial for the first Licensed Product will be payable by Retrophin to Ligand within ten (10) days of the execution of Amendment No. 5 by both Parties.  The milestone payments shall not be refundable or returnable in any event, nor shall they be creditable against royalties or other payments.</font></div><div style="padding-left:108pt;text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">68</font></div><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">***Confidential Treatment Requested</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="padding-left:54pt;padding-right:54pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Table 1</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.262%"><tr><td style="width:1.0%"></td><td style="width:50.605%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.195%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #00000a;border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Milestone Event</font></div></td><td colspan="3" style="border-bottom:1pt solid #00000a;border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Milestone Payment</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Execution of Agreement</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$1.15 million</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The earlier of (a) December 31, 2012 or (b) initiation of the first Phase 2 Trial for a Licensed Product</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$1.3 million (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Second Milestone</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;)&#59; provided, that if the Second Milestone is received by Ligand (a) prior to or on January 31, 2012, Retrophin shall make an additional $50,000 payment simultaneously with the payment of the Second Milestone (for an aggregate payment of $1.35 million), (b) after January 31, 2013 but prior to or on February 28, 2013, Retrophin shall make an additional $100,000 payment simultaneously with the payment of the Second Milestone (for an aggregate payment of $1.4 million), and (c) after February 28, 2013 but prior to or on March 31, 2013, Retrophin shall make an additional $150,000 payment of the Second Milestone (for an aggregate payment of $1.45 million) (the additional payment, an &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Additional Payment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">2</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">At or prior to Initiation of the first Phase 3 Trial for the first Licensed Product</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$4.6 million</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #00000a;border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div></td><td colspan="3" style="border-bottom:1pt solid #00000a;border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">69</font></div><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">***Confidential Treatment Requested</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify"><font><br></font></div><div style="padding-left:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">If the Second Milestone and any Additional Payment is not received by Ligand on or before March 31, 2013, Ligand shall have the right to terminate the Agreement pursuant to Section 13.2.2 with immediate effect as of March 31, 2013 by providing written notice to Retrophin, notwithstanding (a) the cure period for the failure to make a payment when due set out in said Section 13.2.2 (Breach) or (b) the provisions to Section 13.2.4 (Disputed Breach). In addition, and for clarity, the provisions of Section 13.4 (Effect of Termination) shall be operative, including, without limitation, the provisions of subsections (c), (k), and (m) related to amounts then due and payable.&#8221;</font></div><div style="padding-left:54pt"><font><br></font></div><div style="margin-bottom:12pt;padding-left:54pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">In the event that a milestone event is achieved that triggers a development milestone payment as set forth above, if the preceding milestone events have not occurred such that the previous development milestone payments have not been previously paid, all such previous development milestone payments shall become due and payable upon achievement of such milestone event.  For example, if a Phase 3 Trial is initiated that triggers a development milestone payment as set forth above without a Phase 2 Trial supporting such Phase 3 Trial being previously initiated (and consequently the applicable initiation of Phase 2 Trial milestone payment has not been previously paid to Ligand), in addition to the milestone payment for the initiation of the Phase 3 Trial, Retrophin shall also pay to Ligand the applicable milestone payment for the initiation of a Phase 2 Trial.&#8221;</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">No Other Amendments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Except as provided herein, the Sublicense Agreement shall continue in full force and effect.</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Governing Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. This Amendment shall be governed by, enforced, and shall be construed in accordance with the laws of the State of New York without regard to its conflicts of law provisions.</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Counterparts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. This Amendment may be executed in counter-parts with the same effect as if both Parties had signed the same document.  All such counterparts shall be deemed an original, shall be construed together and shall constitute one and the same instrument.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">IN WITNESS WHEREOF</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, the Parties have executed this Amendment to Sublicense Agreement through their duly authorized representatives to be effective as of the Amendment Effective Date.</font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">LIGAND PHARMACEUTICALS&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;RETROPHIN, INC. </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">INCORPORATED</font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">By&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">&#47;s&#47; Charles S. Berkman&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">          &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;By&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">&#47;s&#47; Stephen Aselage&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Name&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Charles S. Berkman&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Name&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Stephen Aselage&#160;&#160;&#160;&#160;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70</font></div><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">***Confidential Treatment Requested</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Title&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Sr. VP, General Counsel &#38; Secretary</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Title&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">CEO&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">71</font></div><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">***Confidential Treatment Requested</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">72</font></div><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">***Confidential Treatment Requested</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.39
<SEQUENCE>3
<FILENAME>exhibit1039_ligandpharmace.htm
<DESCRIPTION>EX-10.39
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="ib3e782292dd84cd0ac2a381d38a8eb42_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exhibit 10.39</font></div></div><div style="margin-bottom:12pt;text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="margin-bottom:0.12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">OFFICE&#47;LABORATORY LEASE</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">BETWEEN</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">EMERY STATION OFFICE II, LLC (LANDLORD)</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">AND</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">LIGAND PHARMACEUTICALS INCORPORATED (TENANT)</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">5980 Horton Street<br>Emeryville, California</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">00056263.8 &#160;&#160;&#160;&#160;</font></div></div></div><div id="ib3e782292dd84cd0ac2a381d38a8eb42_4"></div><hr style="page-break-after:always"><div style="min-height:120.24pt;width:100%"><div style="padding-left:5.75pt;padding-right:5.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">TABLE OF CONTENTS</font></div><div style="padding-left:5.75pt;padding-right:5.75pt;text-align:center"><font><br></font></div><div style="margin-bottom:10pt;padding-left:5.75pt;padding-right:5.75pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Page</font></div><div style="text-align:justify"><font><br></font></div></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:93.300%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.500%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">Article 1 BASIC LEASE PROVISIONS</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">1</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">1.1</a><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">BASIC LEASE PROVISIONS</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">1</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">1.2</a><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">ENUMERATION OF EXHIBITS AND RIDER(S)</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">5</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">1.3</a><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">DEFINITIONS</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">5</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">Article 2 PREMISES, TERM, FAILURE TO GIVE POSSESSION, AND PARKING</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">10</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">2.1</a><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">LEASE OF PREMISES</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">10</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">2.2</a><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">TERM</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">10</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">2.3</a><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">FAILURE TO DELIVER POSSESSION</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">12</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">2.4</a><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">CONDITION OF PREMISES</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">13</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">2.5</a><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">PARKING</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">13</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">2.6</a><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">TERMINATION OF EXISTING 4TH FLOOR LEASE TO CRYSTAL BIOSCIENCE.</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">14</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">Article 3 RENT</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">14</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">Article 4 RENT ADJUSTMENTS AND PAYMENTS</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">14</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">4.1</a><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">RENT ADJUSTMENTS</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">14</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">4.2</a><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">STATEMENT OF LANDLORD</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">15</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">4.3</a><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">BOOKS AND RECORDS</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">16</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">4.4</a><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">TENANT OR LEASE SPECIFIC TAXES</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">17</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">Article 5 SECURITY</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">17</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">Article 6 SERVICES</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">18</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">6.1</a><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">LANDLORD&#8217;S GENERAL SERVICES</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">18</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">6.2</a><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">UTILITIES AND JANITORIAL SERVICES</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">19</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">6.3</a><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">ADDITIONAL AND AFTER HOUR SERVICES</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">20</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">6.4</a><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">TELEPHONE SERVICES</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">20</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">6.5</a><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">DELAYS IN FURNISHING SERVICES</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">21</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">6.6</a><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">CHOICE OF SERVICE PROVIDER</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">21</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">6.7</a><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">SIGNAGE</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">22</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">Article 7 USE OF PREMISES&#59; LANDLORD&#8217;S ACCESS RIGHTS</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">22</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">7.1</a><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">USE OF PREMISES</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">22</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">7.2</a><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">LANDLORD ACCESS TO PREMISES&#59; APPROVALS</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">31</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">7.3</a><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">QUIET ENJOYMENT</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">32</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">7.4</a><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">TRANSPORTATION DEMAND MANAGEMENT PROGRAM</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">32</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">Article 8 MAINTENANCE</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">32</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">8.1</a><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">LANDLORD&#8217;S MAINTENANCE</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">32</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">8.2</a><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">TENANT&#8217;S MAINTENANCE</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">33</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">8.3</a><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">SUDDEN WATER INTRUSION.</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">33</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">Article 9 ALTERATIONS AND IMPROVEMENTS</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">34</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">9.1</a><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">TENANT ALTERATIONS</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">34</font></div></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:1.5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.679%"><tr><td style="width:1.0%"></td><td style="width:43.433%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.832%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.435%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">00056263.8</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">-i-</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:120.24pt;width:100%"><div style="padding-left:5.75pt;padding-right:5.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">TABLE OF CONTENTS</font></div><div style="padding-left:5.75pt;padding-right:5.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(continued)</font></div><div style="margin-bottom:10pt;padding-left:5.75pt;padding-right:5.75pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Page</font></div><div style="text-align:justify"><font><br></font></div></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:93.300%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.500%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">9.2</a><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">LIENS</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">35</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">Article 10 ASSIGNMENT AND SUBLETTING</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">35</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">10.1</a><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">ASSIGNMENT AND SUBLETTING</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">35</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">10.2</a><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">RECAPTURE</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">38</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">10.3</a><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">EXCESS RENT</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">38</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">10.4</a><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">TENANT LIABILITY</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">38</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">10.5</a><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">ASSUMPTION AND ATTORNMENT</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">39</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">10.6</a></font><font style="color:#0000ff;font-family:'Times',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">PROCESSING EXPENSES</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">39</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#0000ff;font-family:'Times',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">10.7</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">EFFECT OF IMPERMISSIBLE TRANSFER</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">39</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">Article 11 DEFAULT AND REMEDIES</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">39</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">11.1</a><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">DEFAULT</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">39</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">11.2</a><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">LANDLORD&#8217;S REMEDIES</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">40</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">11.3</a><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">ATTORNEY&#8217;S FEES</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">43</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">11.4</a><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">BANKRUPTCY</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">43</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">11.5</a><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">LANDLORD&#8217;S DEFAULT</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">44</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">Article 12 SURRENDER OF PREMISES</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">44</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">12.1</a><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">IN GENERAL</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">44</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">12.2</a><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">LANDLORD&#8217;S RIGHTS</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">45</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">Article 13 HOLDING OVER</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">45</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">Article 14 DAMAGE BY FIRE OR OTHER CASUALTY</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">45</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">14.1</a><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">SUBSTANTIAL UNTENANTABILITY</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">45</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">14.2</a><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">INSUBSTANTIAL UNTENANTABILITY</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">46</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">14.3</a><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">RENT ABATEMENT</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">46</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">14.4</a><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">WAIVER OF STATUTORY REMEDIES</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">46</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">Article 15 EMINENT DOMAIN</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">46</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">15.1</a><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">TAKING OF WHOLE OR SUBSTANTIAL PART</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">46</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">15.2</a><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">TAKING OF PART</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">47</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">15.3</a><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">COMPENSATION</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">47</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">Article 16 INSURANCE</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">47</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">16.1</a><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">TENANT&#8217;S INSURANCE</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">47</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">16.2</a><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">FORM OF POLICIES</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">48</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">16.3</a><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">LANDLORD&#8217;S INSURANCE</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">48</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">16.4</a><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">WAIVER OF SUBROGATION</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">48</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">16.5</a><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">NOTICE OF CASUALTY</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">49</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">Article 17 WAIVER OF CLAIMS AND INDEMNITY</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">49</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">17.1</a><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">WAIVER OF CLAIMS</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">49</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">17.2</a><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">INDEMNITY</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">50</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">17.3</a><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">WAIVER OF CONSEQUENTIAL DAMAGES</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">50</font></div></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:1.5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.679%"><tr><td style="width:1.0%"></td><td style="width:43.433%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.832%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.435%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">00056263.8</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">-ii-</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:120.24pt;width:100%"><div style="padding-left:5.75pt;padding-right:5.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">TABLE OF CONTENTS</font></div><div style="padding-left:5.75pt;padding-right:5.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(continued)</font></div><div style="margin-bottom:10pt;padding-left:5.75pt;padding-right:5.75pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Page</font></div><div style="text-align:justify"><font><br></font></div></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:93.300%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.500%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">Article 18 RULES AND REGULATIONS</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">50</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">18.1</a><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">RULES</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">50</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">18.2</a><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">ENFORCEMENT</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">51</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">Article 19 LANDLORD&#8217;S RESERVED RIGHTS</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">51</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">Article 20 ESTOPPEL CERTIFICATE</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">51</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">20.1</a><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">IN GENERAL</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">51</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">20.2</a><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">ENFORCEMENT</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">52</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">Article 21 RELOCATION OF TENANT</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">52</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">Article 22 REAL ESTATE BROKERS</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">52</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">Article 23 MORTGAGEE PROTECTION</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">52</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">23.1</a><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">SUBORDINATION AND ATTORNMENT</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">52</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">23.2</a><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">MORTGAGEE PROTECTION</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">53</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">Article 24 NOTICES</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">53</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">Article 25 FURNITURE, FIXTURES AND EQUIPMENT</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">54</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">Article 26 MISCELLANEOUS</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">55</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">26.1</a><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">LATE CHARGES</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">55</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">26.2</a><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">NO JURY TRIAL&#59; VENUE&#59; JURISDICTION</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">55</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">26.3</a><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">NO DISCRIMINATION</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">56</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">26.4</a><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">FINANCIAL STATEMENTS</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">56</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">26.5</a><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">OPTION</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">56</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">26.6</a><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">TENANT AUTHORITY</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">56</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">26.7</a><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">ENTIRE AGREEMENT</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">56</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">26.8</a><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">MODIFICATION OF LEASE FOR BENEFIT OF MORTGAGEE</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">57</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">26.9</a><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">EXCULPATION</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">57</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">26.10</a><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">ACCORD AND SATISFACTION</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">57</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">26.11</a><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">LANDLORD&#8217;S OBLIGATIONS ON SALE OF BUILDING</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">57</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">26.12</a><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">BINDING EFFECT</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">57</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">26.13</a><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">CAPTIONS</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">57</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">26.14</a><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">TIME&#59; APPLICABLE LAW&#59; CONSTRUCTION</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">58</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">26.15</a><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">ABANDONMENT</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">58</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">26.16</a><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">LANDLORD&#8217;S RIGHT TO PERFORM TENANT&#8217;S DUTIES</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">58</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">26.17</a><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">SECURITY SYSTEM</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">58</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">26.18</a><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">NO LIGHT, AIR OR VIEW EASEMENTS</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">58</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">26.19</a><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">RECORDATION</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">59</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">26.20</a><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">SURVIVAL</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">59</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">26.21</a><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">OFAC</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">59</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:2.75pt;text-align:justify"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">26.22</a><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">INSPECTION</a><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none"> </a><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">BY A CASP IN ACCORDANCE WITH CIVIL</a><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none"> </a><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">CODE SECTION&#160;1938.</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">59</font></div></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:1.5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.679%"><tr><td style="width:1.0%"></td><td style="width:43.433%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.832%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.435%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">00056263.8</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">-iii-</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:120.24pt;width:100%"><div style="padding-left:5.75pt;padding-right:5.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">TABLE OF CONTENTS</font></div><div style="padding-left:5.75pt;padding-right:5.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(continued)</font></div><div style="margin-bottom:10pt;padding-left:5.75pt;padding-right:5.75pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Page</font></div><div style="text-align:justify"><font><br></font></div></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:93.300%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.500%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">26.23</a><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">COUNTERPARTS</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">60</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">26.24</a><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ib3e782292dd84cd0ac2a381d38a8eb42_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">EXHIBITS AND RIDERS</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">60</font></div></td></tr></table></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:1.5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.679%"><tr><td style="width:1.0%"></td><td style="width:43.433%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.832%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.435%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">00056263.8</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">-iv-</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div></div></div><div id="ib3e782292dd84cd0ac2a381d38a8eb42_7"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:36pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">OFFICE&#47;LABORATORY LEASE</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Article 1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:29.72pt;text-decoration:underline"><br>BASIC LEASE PROVISIONS</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">BASIC LEASE PROVISIONS</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">In the event of any conflict between these Basic Lease Provisions and any other Lease provision, such other Lease provision shall control.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">BUILDING AND ADDRESS&#58;</font></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5980 Horton Street</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Emeryville, California 94608</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">LANDLORD AND ADDRESS&#58;</font></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Emery Station Office II, LLC</font></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1120 Nye Street, Suite 400</font></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">San Rafael, California 94901</font></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Notices to Landlord shall be addressed&#58;</font></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Emery Station Office II, LLC</font></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">c&#47;o Wareham Property Group</font></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1120 Nye Street, Suite 400</font></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">San Rafael, California 94901</font></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">With a copy to&#58;</font></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Stewart Ward &#38; Josephson LLP</font></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1601 Response Road, Suite 360</font></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Sacramento, California  95815</font></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Attention&#58; Winnifred C. Ward, Esq.</font></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">And to&#58;</font></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Shartsis Friese LLP</font></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">One Maritime Plaza, 18th Floor</font></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">San Francisco, California 94901</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Attention&#58;  Senior Real Estate Partner</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(3)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">TENANT AND NOTICE ADDRESS&#58; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">Name and Entity&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Ligand Pharmaceuticals Incorporated, a Delaware corporation</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">Federal Tax Identification Number&#58; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;77-0160744</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">00056263.8 &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Tenant shall promptly notify Landlord of any change in the foregoing items.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">Notices to Tenant shall be addressed&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Prior to the Phase I Rent Commencement Date&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;3911 Sorrento Valley Blvd. #110<br>&#160;&#160;&#160;&#160;San Diego, CA 92121<br>&#160;&#160;&#160;&#160;Attention&#58; General Counsel</font></div><div style="margin-bottom:12pt;padding-left:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;On and after the Phase I Rent Commencement Date&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;At the Premises<br>&#160;&#160;&#160;&#160;Attention&#58; VP of Operations &#38; General Counsel</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(4)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">DATE OF LEASE&#58;  as of June 8, 2021</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(5)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">INITIAL TERM&#58;&#160;&#160;&#160;&#160;Commencing on the Phase I Commencement Date, and ending on the last day of the one hundred twentieth (120</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">) full calendar month following the Phase II Commencement Date</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(6)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">PROJECTED COMMENCEMENT DATES&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">Phase I Premises&#58;&#160;&#160;&#160;&#160;July 1, 2021</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">Phase II Premises&#58;&#160;&#160;&#160;&#160;The date that the Existing Tenant vacates the Phase II Premises and possession thereof is delivered to Tenant, which date is estimated to be April 1, 2022</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(7)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">RENT COMMENCEMENT DATES&#58;  </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">Phase I Premises&#58;&#160;&#160;&#160;&#160;Sixty (60) days after the Phase I Commencement Date.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">Phase II Premises&#58;&#160;&#160;&#160;&#160;Sixty (60) days after the Phase II Commencement Date.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(8)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">EXPIRATION DATE&#58;  The last day of the 120</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> full calendar month following the Phase II Rent Commencement Date</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">00056263.8 &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(9)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">MONTHLY BASE RENT&#58;</font></div><div style="padding-left:72pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.500%"><tr><td style="width:1.0%"></td><td style="width:50.548%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.252%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><br>MONTHS OF TERM FOLLOWING PHASE I RENT COMMENCEMENT DATE</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">MONTHLY RATE PER RENTABLE SQUARE FOOT OF PREMISES</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Months 01 &#8211; 12**</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$6.00</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Months 13 &#8211; 24**</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$6.21</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Month 25 &#8211; 36***</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$6.43</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Month 37 &#8211; 48***</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$6.66</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Month 49 &#8211; 60</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$6.89</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Month 61 &#8211; 72</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$7.13</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Month 73 &#8211; 84</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$7.38</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Month 85 &#8211; 96</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$7.64</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Month 97 &#8211; 108</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$7.91</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Month 108 &#8211; 120</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$8.19</font></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Month 121 &#8211; Month 120 following the Phase II Rent Commencement Date****</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$8.48</font></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">*Based upon Phase I Rent Commencement Date, although the Term is calculated from the Phase II Rent Commencement Date&#59; see last row of above table.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">**The Monthly Base Rent for the Phase II Premises shall commence as of the Phase II Rent Commencement Date, which shall occur during either Months 01 &#8211; 12 after the Phase I Rent Commencement Date, or during Months 13 &#8211; 24 after the Phase I Rent Commencement Date, and as of such occurrence, Tenant shall pay Monthly Base Rent for the Phase II Premises, in addition to the Monthly Base Rent payable for the Phase I Premises, at the applicable Monthly Base Rent Rate.  &#8220;Months 01 &#8211; 24&#8221; will include any partial calendar month&#58; (a) following the Phase I Rent Commencement Date, if the Phase I Rent Commencement Date is other than the first (1st) day of a calendar month, and&#47;or (b) following the Phase II Rent Commencement Date, if the Phase II Rent Commencement Date is other than the first (1st) day of a calendar month, </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">00056263.8 &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and in the event such period includes any such partial calendar months, Tenant shall pay the prorated amount of Monthly Base Rent for such partial calendar months pursuant to Article 3 in addition to the Monthly Base Rent for the subsequent full calendar months of the Term.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">***The Monthly Base Rent, but not Operating Expenses, for the Phase I Premises and the Phase II Premises shall be abated for Months 26 and 38 of the Term (the &#8220;Abated Base Rent&#8221;).  If a Default, as defined in Section 11.1 of this Lease, shall occur at any time during the Term, then the Abated Base Rent shall upon the written request of Landlord become due and payable in addition to any other remedies that Landlord may possess under this Lease.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">****If this period is longer than 12 months, then the Monthly Base Rent Rate shall increase to $8.78 per square foot of Rentable Area of the Premises.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(10)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.02pt">PREMISES&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">Phase I Premises&#58;  The space located in the Building that is highlighted in yellow on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> attached hereto.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">Phase II Premises&#58;  The space located in the Building that is unhighlighted (i.e., in white) on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit&#160;A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> attached hereto.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(11)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.02pt">RENTABLE AREA OF THE PREMISES&#58; 25,429 square feet, comprised of&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">Phase I Premises&#58; 8,816 square feet</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">Phase II Premises&#58; 16,613 square feet</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(12)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.02pt">TENANT&#8217;S SHARE&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">Phase I Premises&#58; &#160;&#160;&#160;&#160;5.55%</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">Phase II Premises&#58;&#160;&#160;&#160;&#160;10.42%</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(13)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.02pt">SECURITY DEPOSIT&#58;&#160;&#160;&#160;&#160;$152,574.00</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(14)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.02pt">SUITE NUMBER OF PREMISES&#58;&#160;&#160;&#160;&#160;600</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(15)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.02pt">TENANT&#8217;S USE OF PREMISES&#58;&#160;&#160;&#160;&#160;Research and development laboratory use, and related office use</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(16)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.02pt">PARKING&#58;&#160;&#160;&#160;&#160;Up to fifty-one (51) unreserved parking spaces within the Terraces Garage.  Upon providing not less than ten (10) days&#8217; prior written notice to Landlord (&#8220;Tenant&#8217;s Parking Adjustment Notice&#8221;), and not more often than once per month, Tenant may adjust the number of parking spaces it leases during the Term (but in any event not to exceed 51 spaces).  Any such adjustment shall take effect as of the first (1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">st</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">) day of the calendar month following Tenant&#8217;s Parking Adjustment Notice.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(17)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.02pt">BROKERS&#58;</font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Landlord&#8217;s Broker&#58;&#160;&#160;&#160;&#160;N&#47;A</font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tenant&#8217;s Broker&#58;&#160;&#160;&#160;&#160;RE&#58;Align Tenant Strategies</font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">00056263.8 &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(18)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.02pt">TENANT IMPROVEMENT ALLOWANCE&#58;&#160;&#160;&#160;&#160;$50.00 per square foot of Rentable Area of the Premises (i.e., $1,271,450.00)</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">ENUMERATION OF EXHIBITS AND RIDER(S)</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Exhibits and Rider set forth below and attached to this Lease are incorporated in this Lease by this reference&#58;</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">EXHIBIT A&#160;&#160;&#160;&#160;Outline of Premises</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">EXHIBIT B&#160;&#160;&#160;&#160;Workletter Agreement</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">EXHIBIT C-1&#160;&#160;&#160;&#160;Laboratory Rules and Regulations</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">EXHIBIT C-2&#160;&#160;&#160;&#160;Rules and Regulations</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">EXHIBIT D&#160;&#160;&#160;&#160;Crystal Bio Lease Extension Amendment</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">EXHIBIT E&#160;&#160;&#160;&#160;FF&#38;E</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">RIDER 1&#160;&#160;&#160;&#160;Commencement Date Agreement</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">DEFINITIONS</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">For purposes hereof, in addition to terms defined elsewhere in this Lease, the following terms shall have the following meanings&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">AFFILIATE&#58;  Any corporation or other business entity that is currently owned or controlled by, owns or controls, or is under common ownership or control with Tenant or Landlord, as the case may be.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">BANKRUPTCY CODE&#58;  As defined in Section 11.3.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">BUILDING&#58;  The building located at the address specified in Section 1.1.  The Building may include office, medical, laboratory, retail and other uses.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">CABLE&#58;  As defined in Section 8.2.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">CITY&#58;  The City of Emeryville, California.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">COMMON AREAS&#58;  All areas of the Project made available by Landlord from time to time for the general common use or benefit of the tenants of the Building, and their employees and invitees, or the public, as such areas currently exist and as they may be changed from time to time.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">DEFAULT&#58;  As defined in Section 11.1.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">DEFAULT RATE&#58;  Two (2) percentage points above the rate then most recently announced by Bank of America N.A. at its San Francisco main office as its base lending reference rate, from time to time announced, but in no event higher than the maximum rate permitted by Law.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">EXISTING TENANT&#58;  As defined in Section 2.3.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">EXPIRATION DATE&#58;  The date specified in Section 1.1.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">FORCE MAJEURE&#58;  Any accident, casualty, act of God, war or civil commotion, strike or labor troubles, or any cause whatsoever beyond the reasonable control of Landlord, including water shortages, energy shortages or governmental preemption in connection with an act of God, </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">00056263.8 &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a national emergency, or by reason of Law, or by reason of the conditions of supply and demand which have been or are affected by act of God, war or other emergency.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">GREEN BUILDING STANDARDS&#58; One or more of the following&#58;  the U.S. EPA&#8217;s Energy Star&#174; Portfolio Manager, the Green Building Initiative&#8217;s Green Globes&#8482; building rating system, the U.S. Green Building Council&#8217;s Leadership in Energy and Environmental Design (LEED&#174;) building rating system, the ASHRAE Building Energy Quotient (BEQ), the Global Real Estate Sustainability Benchmark (GRESB), or other standard for high performance buildings adopted by Landlord with respect to the Building or the Project, as the same may be revised from time to time.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">HAZARDOUS MATERIALS&#58;  As defined in Section 7.1(f).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">HAZARDOUS MATERIALS LAWS&#58;  As defined in Section 7.1(f).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">INDEMNITEES&#58;  Collectively, Landlord, any Mortgagee or ground lessor of the Property, the property manager and the leasing manager for the Property, and their respective partners, members, directors, officers, agents and employees.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">LAND&#58;  The parcel(s) of real estate on which the Building and Project are located.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">LANDLORD WORK&#58;  The construction or installation of improvements to the Premises to be furnished by Landlord, if any, as specifically described in the Workletter or exhibits attached hereto.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">LAWS OR LAW&#58;  All laws, ordinances, rules, regulations, other requirements, orders, rulings or decisions adopted or made by any governmental body, agency, department or judicial authority having jurisdiction over the Property, the Premises or Tenant&#8217;s activities at the Premises and any covenants, conditions or restrictions of record which affect the Property.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">LEASE&#58;  This instrument and all exhibits and riders attached hereto, as may be amended from time to time.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">LEASEHOLD IMPROVEMENTS&#58;  As defined in Section 12.1.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">MONTHLY BASE RENT&#58;  The monthly base rent specified in Section 1.1.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">MORTGAGEE&#58;  Any holder of a mortgage, deed of trust or other security instrument encumbering the Property.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">NAMED TENANT&#58;  As defined in Section 2.2(d).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">NATIONAL HOLIDAYS&#58;  New Year&#8217;s Day, Memorial Day, Independence Day, Labor Day, Thanksgiving Day and Christmas Day and other holidays recognized by Landlord and the janitorial and other unions servicing the Building in accordance with their contracts.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">OPERATING EXPENSES&#58;  All costs, expenses and disbursements which Landlord shall pay or become obligated to pay directly in connection with the ownership, management, operation, maintenance, replacement and repair of the Building and the Property, including, without limitation, property management fees&#59; costs and expenses of any capital expenditure or improvement that is Landlord&#8217;s responsibility under this Lease, and if Landlord elects to amortize such costs and expenses over a period that Landlord may determine, such costs and expenses shall be together with interest thereon at a rate reasonably determined by Landlord&#59; an equitable allocation of management office expenses (including, without limitation, office rent, </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">00056263.8 &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">6</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">supplies, equipment, salaries, wages, bonuses and other compensation relating to employees of Landlord or its agents engaged in the management, operation, repair, or maintenance of the Building)&#59; and, if applicable, the cost of operating a fitness center and&#47;or any conference centers that are available for use by Tenant, as reasonably determined by Landlord.  Operating Expenses shall not include&#58; (i) costs of alterations of the premises of tenants of the Project&#59; (ii) costs of goods or services to the extent billed directly to other tenants of the Project, including the cost incurred by Landlord in performing work to or for a tenant of space in the Project (including Tenant) at such tenant&#8217;s cost and expense&#59; (iii) depreciation charges&#59; (iv) interest and principal payments on loans except for loans for, or imputed interest on, capital expenditures or improvements which Landlord may elect to amortize as specified above)&#59; (v) ground rental payments&#59; (vi) real estate brokerage and leasing commissions&#59; (vii) advertising and marketing expenses&#59; (viii) costs to the extent Landlord has been reimbursed for the same by insurance proceeds, condemnation awards, third party warranties or other third parties (other than tenants&#8217; reimbursement of Operating Expenses)&#59; (ix) expenses incurred in negotiating leases of tenants in the Project or enforcing lease obligations of tenants in the Project&#59; (x) Landlord&#8217;s general corporate overhead&#59; and (xi) costs directly incurred in connection with a sale, financing, refinancing or transfer of all or any portion of the Project (except as provided for in the definition of Taxes, below).  If any Operating Expense, though paid in one year, relates to more than one calendar year, at the option of Landlord such expense may be proportionately allocated among such related calendar years.  Operating Expenses for the Property that are not, in Landlord&#8217;s reasonable discretion, allocable solely to either the office, laboratory or retail portion of the Building shall be equitably allocated by Landlord between&#47;amongst such uses.  The above enumeration of services and facilities shall not be deemed to impose an obligation on Landlord to make available or provide such services or facilities except to the extent if any that Landlord has specifically agreed elsewhere in this Lease to make the same available or provide the same.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">PHASE I COMMENCEMENT DATE&#58;  The date determined pursuant to Article 2, which date is anticipated to be the Projected Phase I Commencement Date specified in Section 1.1.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">PHASE II COMMENCEMENT DATE&#58;  The date determined pursuant to Article 2, which date is anticipated to be the Projected Phase II Commencement Date specified in Section 1.1.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">PHASE I PREMISES&#58;  The space defined in Section&#160;1.1.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">PHASE II PREMISES&#58;  The space defined in Section&#160;1.1.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">PHASE I RENT COMMENCEMENT DATE&#58;  The date determined pursuant to Section&#160;1.1.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">PHASE II RENT COMMENCEMENT DATE&#58;  The date determined pursuant to Section&#160;1.1.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">PHASE I TENANT WORK&#58;  As defined in the Work Letter.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">PHASE II TENANT WORK&#58;  As defined in the Work Letter.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">PREMISES&#58;  Collectively, the Phase I Premises and the Phase II Premises, at the Suite Number listed in Section&#160;1.1.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">PROJECT or PROPERTY&#58;  The Project consists of the office and laboratory&#47;research building with ground floor office and&#47;or retail spaces located at the street address specified in Section 1.1, and associated surface and garage parking as designated by Landlord from time to time, landscaping and improvements, together with the Land, any associated interests in real </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">00056263.8 &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">7</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">property, and the personal property, fixtures, machinery, equipment, systems and apparatus located in or used in conjunction with any of the foregoing.  The Project may also be referred to as the Property.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">PROJECT&#8217;S SUSTAINABILITY PRACTICES&#58; The operations and maintenance practices for the Building, whether incorporated into the Building&#8217;s Rules and Regulations, construction rules and regulations or separate written sustainability policies of Landlord with respect to the Building or the Project, as the same may be revised from time to time so long as such revisions do not materially and negatively impact Tenant&#8217;s use of the Premises, addressing, among other things&#58; energy efficiency&#59; energy measurement and reporting&#59; water usage&#59; recycling, composting, and waste management&#59; indoor air quality&#59; and chemical use.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">PROJECTED PHASE I COMMENCEMENT DATE&#58;  The date specified in Section 1.1.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">PROJECTED PHASE II COMMENCEMENT DATE&#58;  The date specified in Section 1.1.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">REAL PROPERTY&#58;  The Property excluding any personal property.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">RENT&#58;  Collectively, Monthly Base Rent, Rent Adjustments and Rent Adjustment Deposits, and all other charges, payments, late fees or other amounts required to be paid by Tenant under this Lease.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">RENT ADJUSTMENT&#58;  Any amounts owed by Tenant for payment of Operating Expenses and&#47;or Taxes.  The Rent Adjustments shall be determined and paid as provided in Article 4.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">RENT ADJUSTMENT DEPOSIT&#58;  An amount equal to Landlord&#8217;s estimate of the Rent Adjustment attributable to each month of the applicable calendar year (or partial calendar year) during the Term, as provided in Article 4.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">RENTABLE AREA OF THE PREMISES&#58;  The amount of square footage set forth in Section 1.1.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">SECURITY DEPOSIT&#58;  The funds specified in Section 1.1, if any, deposited by Tenant with Landlord as security for Tenant&#8217;s performance of its obligations under this Lease.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">STANDARD OPERATING HOURS&#58;  Monday through Friday from 8&#58;00 A.M. to 6&#58;00&#160;P.M., and Saturday from 9&#58;00 A.M. to 1&#58;00 P.M., excluding National Holidays.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">SUBSTANTIALLY COMPLETE or SUBSTANTIAL COMPLETION&#58;  The completion of the Landlord Work, the Tenant Work, the Phase I Tenant Work or the Phase II Tenant Work, as the case may be, as evidenced by receipt of a certificate of occupancy or similar certification from local, city and&#47;or state administrative bodies, except for minor insubstantial details of construction, decoration or mechanical adjustments which remain to be done.  Substantial Completion shall be deemed to have occurred notwithstanding a requirement to complete &#8220;punch-list&#8221; or similar minor corrective work.  If Landlord shall be delayed in Substantial Completion due to a Tenant Delay, the date of Substantial Completion for purposes of determining the Rent Commencement Date shall be the date when Substantial Completion would have occurred if there had been no Tenant Delay.  Tenant acknowledges that the length of any Tenant Delay is to be measured by the duration of the delay in Substantial Completion caused by the event or conduct constituting Tenant Delay, which may exceed the duration of such event or conduct due to the necessity of rescheduling work or other causes.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">00056263.8 &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">TAXES&#58;  All federal, state and local governmental taxes, assessments, license fees and charges, whether general, special, ordinary or extraordinary, which Landlord shall pay or become obligated to pay directly in connection with the ownership, leasing, management, control, sale, transfer, or operation of the Property or any of its components (including any personal property used in connection therewith) or Landlord&#8217;s business of owning and operating the Property, which may also include any rental, revenue, general gross receipts or similar taxes levied in lieu of or in addition to general real and&#47;or personal property taxes.  For purposes hereof, Taxes for any year shall be Taxes which are assessed for any period of such year, whether or not such Taxes are billed and payable in a subsequent calendar year.  There shall be included in Taxes for any year the amount of all fees, costs and expenses (including reasonable attorneys&#8217; fees) paid by Landlord during such year in seeking or obtaining any refund or reduction of Taxes.  Taxes for any year shall be reduced by the net amount of any tax refund received by Landlord attributable to such year.  If a special assessment payable in installments is levied against any part of the Property, Taxes for any year shall include only the installment of such assessment and any interest payable or paid during such year.  Taxes shall be determined without reference to any abatement or exemption from or credit against Taxes applicable to all or part of the Property.  Taxes shall not include any federal or state inheritance, general income, gift or estate taxes, except that if a change occurs in the method of taxation resulting in whole or in part in the substitution of any such taxes, or any other assessment, for any Taxes as above defined, such substituted taxes or assessments shall be included in the Taxes.  Tenant and Landlord acknowledge that Proposition 13 was adopted by the voters of the State of California in the June, 1978 election and that assessments, taxes, fees, levies and charges may be imposed by governmental agencies for such purposes as fire protection, street, sidewalk, road, utility construction and maintenance, refuse removal and for other governmental services which may formerly have been provided without charge to property owners or occupants.  It is the intention of the parties that all new and increased assessments, taxes, fees, levies and charges due to any cause whatsoever are to be included within the definition of Taxes for purposes of this Lease.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">TENANT ADDITIONS&#58;  Collectively, Landlord Work, Tenant Work and Tenant Alterations.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">TENANT ALTERATIONS&#58;  Any alterations, improvements, additions, installations or construction in or to the Premises or any Building systems serving the Premises (excluding Landlord Work or Tenant Work)&#59; and any supplementary air-conditioning systems installed by Landlord or by Tenant at Landlord&#8217;s request pursuant to Section 6.1(b).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">TENANT DELAY&#58;  Any event or occurrence that materially delays the completion of the Landlord Work, if any, which is caused by or is described as follows&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.69pt">special work, changes, alterations, additions, or any Change Orders (defined in the Workletter) requested or made by Tenant in the design or finish in any part of the Premises after approval of the plans and specifications (as described in the Workletter)&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.36pt">Tenant&#8217;s delay in submitting plans, supplying information, approving plans, specifications or estimates, giving authorizations or otherwise&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.03pt">failure to pay for those portions of Tenant Work that Tenant is obligated to pay for pursuant to the Workletter&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.69pt">the performance or completion by Tenant or any person engaged by Tenant of any work in or about the Premises&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(v)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">failure to perform or comply with any obligation or condition binding upon Tenant pursuant to the Workletter, including the failure to approve and pay for </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">00056263.8 &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">9</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">such Landlord Work or other items if and to the extent the Workletter provides they are to be approved or paid by Tenant&#59; or</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(vi)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.69pt">Any other act or omission of Tenant which delays Substantial Completion.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">TENANT PARTY OR TENANT PARTIES&#58;  As defined in Section 7.1(f)(1)(x).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">TENANT WORK&#58;  All work installed or furnished to the Premises by Tenant, if any, pursuant to the Workletter.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">TENANT&#8217;S SHARE&#58;  The percentage that represents the ratio of the Rentable Area of the Premises to the Rentable Area of the Building, as set forth in Section 1.1. Tenant&#8217;s Share shall mean only the percentage that represents the ratio of the Rentable Area of the Phase I Premises to the Rentable Area of the Building as of the Phase I Rent Commencement Date, and shall mean the percentage that represents the ratio of the Rentable Area of the entire Premises to the Rentable Area of the Building as of the Phase II Rent Commencement Date</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">TERM&#58; The initial term of this Lease commencing on the Commencement Date and expiring on the Expiration Date, and extension of the initial term, if any.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">TERMINATION DATE&#58;  The Expiration Date or such earlier date as this Lease terminates or Tenant&#8217;s right to possession of the Premises terminates.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">WORKLETTER&#58;  The Agreement regarding the manner of completion of Landlord Work and Tenant Work set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit B</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> attached hereto.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Article 2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:29.72pt;text-decoration:underline"><br>PREMISES, TERM, FAILURE TO GIVE POSSESSION, AND PARKING</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">LEASE OF PREMISES</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Landlord hereby leases to Tenant and Tenant hereby leases from Landlord the Premises for the Term and upon the terms, covenants and conditions provided in this Lease.  The parties acknowledge and agree that the Rentable Area set forth in this Lease has been conclusively determined and is deemed final for the purposes of this Lease.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">TERM</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">The &#8220;Phase I Commencement Date&#8221; shall be (i) the date on which Landlord has substantially completed the Landlord Work (if any) and tendered possession of the Phase I Premises to Tenant&#59; or (ii) any earlier date upon which Tenant, with Landlord&#8217;s written permission, takes possession of any portion of the Phase I Premises to commence construction of the Tenant Work.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">The &#8220;Phase II Commencement Date&#8221; shall be (i) the date on which Landlord has substantially completed the Landlord Work (if any) and tendered possession of the Phase II Premises to Tenant&#59; or (ii) any earlier date upon which Tenant, with Landlord&#8217;s written permission, takes possession of any portion of the Phase II Premises to commence construction of the Tenant Work.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">Within thirty (30) days following the occurrence of the Rent Commencement Date, Landlord and Tenant shall enter into an agreement (the form of which is attached hereto as Rider&#160;1) confirming the Phase I Commencement Date, the Phase II Commencement Date, the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">00056263.8 &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">10</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Phase I Rent Commencement Date, the Phase II Rent Commencement Date and the Expiration Date.  If Tenant fails to enter into such agreement, then the Phase I Commencement Date, the Phase II Commencement Date, the Phase I Rent Commencement Date, the Phase I Rent Commencement Date and the Expiration Date shall be the dates designated by Landlord in such agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Option to Extend</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Provided that at the time of exercise and at all times prior to the commencement of the subject Extended Term, Tenant shall not be in default under this Lease or otherwise failed to have timely performed all of Tenant&#8217;s obligations under this Lease, the Term of this Lease shall be subject to two (2) extension options for an additional period of 60 months each (individually, the &#8220;Extension Option&#8221;, and collectively, the &#8220;Extension Options&#8221;).  The first Extension Option shall commence as of the expiration of the Initial Term and expire on the date that is 60 full calendar months thereafter (the &#8220;First Extended Term&#8221;), and the second Extension Option shall commence as of the expiration of the First Extended Term and expire on the date that is 60 full calendar months thereafter (the &#8220;Second Extended Term&#8221;, and individually with the First Extended Term, an &#8220;Extended Term&#8221;).  The Extension Options shall be exercisable as follows&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">The Extension Option shall be upon the same material terms and conditions contained in this Lease, except that (i) the initial Monthly Base Rent for the Premises shall be equal to the Fair Market Rent (as defined in Section 2.2(d)(2) below) for the Premises as of the first month of the subject Extension Option determined in the manner set forth in Section 2.2(d)(3) below and (ii) Tenant shall accept the Premises in an &#8220;as is&#8221; condition without any obligation of Landlord to repaint, remodel, repair, improve or alter the Premises (subject, however, to the terms of Section 8.1 of this Lease).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">Tenant&#8217;s election to exercise an Extension Option must be given to Landlord in writing no less than eight (8) months prior to (i) the expiration of the initial Term (as to the first Extension Option), or (ii) the expiration of the First Extended Term (as to the second Extension Option) (the &#8220;Extension Notice&#8221;).  Within thirty (30) days of Landlord&#8217;s receipt of the Extension Notice, Landlord shall send Tenant written notice of Landlord&#8217;s determination of the Fair Market Rent for the Premises (the &#8220;Fair Market Rent Notice&#8221;).  For purposes of this Section, the term &#8220;Fair Market Rent&#8221; shall mean the base rental rate, periodic rental rate adjustment and other charges and increases, if any, for space comparable in size, location and quality to the Premises under a primary lease (and not sublease) to new or renewing tenants, for a comparable term with a tenant improvement allowance, if applicable and taking into consideration such amenities as existing improvements, view, floor on which the Premises are situated and the like, situated in buildings in Emeryville, California.  Notwithstanding anything to the contrary contained herein, the subject Extension Option shall automatically terminate and be of no further force or effect, whether or not Tenant has timely exercised such Extension Option, if an uncured Default exists at the time of exercise of such Extension Option or at the time of commencement of the subject Extended Term.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(3)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">If Tenant properly exercises an Extension Option, the Monthly Base Rent during the applicable Extended Term shall be determined in the following manner.  The Monthly Base Rent as of the commencement of such Extended Term shall be adjusted to an amount equal to the Fair Market Rent for the Premises as specified in the Fair Market Rent Notice, subject to Tenant&#8217;s right of arbitration as set forth below.  If Tenant believes that the Fair Market Rent specified in the Fair Market Rent Notice exceeds the actual Fair Market Rent for the Premises as of the date of such notice, then Tenant shall so notify Landlord within fifteen (15) days of Tenant&#8217;s receipt of the Fair Market Rent Notice.  If Tenant fails to so notify Landlord within such 15-day period, Landlord&#8217;s determination of the Fair Market Rent shall be final and binding upon the parties.  If the parties are unable to agree upon the Fair Market Rent within ten (10) days after Landlord&#8217;s receipt of Tenant&#8217;s objection to the Fair Market Rent Notice, the amount of </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">00056263.8 &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">11</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Monthly Base Rent as of the commencement of the subject Extended Term shall be determined as follows&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.69pt">Within 20 days after the 10-day period has expired and the parties have failed to agree on the Fair Market Rent, Tenant, at its sole expense, shall obtain and delivery in writing to Landlord a determination of the Fair Market Rent for the Premises for a term equal to the subject Extended Term from a broker (&#8220;Tenant&#8217;s Broker&#8221;) licensed in the State of California and engaged in the office and laboratory brokerage business in Emeryville, California or other nearby markets, for at least the immediately preceding five (5) years.  If Landlord accepts such determination, the Monthly Base Rent for such Extended Term shall be adjusted to an amount equal to the amount determined by Tenant&#8217;s Broker.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.36pt">If Landlord does not accept such determination, within 10 days after receipt of the determination of Tenant&#8217;s broker, Landlord shall designate a broker (&#8220;Landlord&#8217;s Broker&#8221;) licensed in the State of California and engaged in the office and laboratory brokerage business in Emeryville, California or other nearby markets, for at least the immediately preceding five (5) years.  Landlord&#8217;s Broker and Tenant&#8217;s Broker shall name a third broker, similarly qualified, within five (5) days after appointment of Landlord&#8217;s Broker.  Landlord&#8217;s Broker and Tenant&#8217;s Broker shall each determine the Fair Market Rent for the Premises as of the commencement of the subject Extended Term for a term equal to such Extended Term within 10 days after the appointment of the third broker.  The Monthly Base Rent payable by Tenant effective as of the commencement of such Extended Term shall be adjusted to an amount equal to the determination of Fair Market Rent made by either Landlord&#8217;s Broker or Tenant&#8217;s Broker that the third broker finds to be closer to the Fair Market Rent.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.03pt">Landlord shall pay the costs and fees of Landlord&#8217;s Broker in connection with any determination hereunder, and Tenant shall pay the costs and fees of Tenant&#8217;s Broker in connection with such determination.  The costs and fees of any third broker shall be paid one-half by Landlord and one-half by Tenant.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(4)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">If the amount of the Fair Market Rent is not known as of the commencement of the subject Extended Term, then Tenant shall continue to pay the Monthly Base Rent for the Premises in effect at the expiration of such Extended Term until the amount of the Fair Market Rent is determined.  When such determination is made, Tenant shall pay any deficiency (if any exists) to Landlord upon demand and Landlord shall credit to Tenant any surplus (if any exists).  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(5)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">In connection with the extension of the Term pursuant to Tenant&#8217;s exercise of an Extension Option, the parties acknowledge and agree that Landlord shall not be responsible for the payment to any real estate broker, salesperson or finder claiming to have represented Tenant of any commission, finder&#8217;s fee or other compensation in connection with or as a consequence of Tenant&#8217;s exercise of such Extension Option. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(6)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">Notwithstanding anything to the contrary contained herein, Tenant&#8217;s rights under this Section 2.2(d) are personal to the original Tenant executing this Lease (&#8220;Named Tenant&#8221;) and shall not be assigned or assignable, in whole or in part, to any third party.  Any assignment or other transfer of such rights by Named Tenant shall be void and of no force or effect.  Without limiting the generality of the foregoing, no sublessee of the Premises shall be permitted to exercise the rights granted to Tenant under this Section 2.2(d).</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">FAILURE TO DELIVER POSSESSION</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">If (a) the Phase I Premises are not delivered to Tenant by the Projected Phase I Commencement Date for any reason, or (b) the Phase II Premises are not delivered to Tenant by </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">00056263.8 &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">12</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the Projected Phase II Commencement Date for any reason, Landlord shall not be liable for any claims, damages or liabilities by reason thereof, nor affect the validity of this Lease or the obligations of Tenant hereunder.  Landlord and Tenant acknowledge and agree that the Phase I Premises are vacant as of the date of this Lease.  If the tenant occupying the Phase II Premises (the &#8220;Existing Tenant&#8221;) does not vacate the Phase II Premises prior to the Projected Phase II Commencement Date (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">e.g. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">April 1, 2022), Landlord shall make commercially reasonable efforts to regain legal possession of the Phase II Premises as soon as possible, including pursuing all available remedies at law or in equity to evict such tenant.  Landlord represents and warrants to Tenant that (a) pursuant to the express terms of the Existing Tenant&#8217;s lease (the &#8220;Existing Tenant Lease&#8221;), such Existing Tenant Lease is scheduled to expire on June 30, 2022 (the &#8220;Existing Tenant Lease Expiration Date&#8221;), and (b) the Existing Tenant does not have any rights to remain in or otherwise occupy the Phase II Premises beyond the Existing Tenant Lease Expiration Date.  Notwithstanding anything in this Section 2.3 to the contrary, if Landlord fails to deliver the Phase&#160;II Premises to Tenant by the Projected Phase II Commencement Date, then Landlord will credit against the first installments of Monthly Base Rent and Rent Adjustments Deposits first becoming due under this Lease an amount equal to one (1) day of Monthly Base Rent and Rent Adjustments Deposits allocable to the Phase II Premises for each day that delivery is delayed beyond the Projected Phase II Commencement Date.  The remedy set forth above shall be Tenant&#8217;s sole remedy in the event of a delay in delivering possession of the Phase&#160;II Premises to Tenant.  In no event shall Landlord be liable for special or consequential damages as a result of any such delay.  </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">CONDITION OF PREMISES</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tenant shall be conclusively deemed to have accepted&#58; (a) the Phase I Premises &#8220;AS IS&#8221; in the condition existing on the Phase I Commencement Date, and (b) the Phase II Premises &#8220;AS IS&#8221; in the condition existing on the Phase II Commencement Date, both subject to the terms and conditions of this Lease (including without limitation any repair and maintenance obligations of Landlord, and the systems serving the Premises, the Building and the Project being in good order and repair as of the subject Commencement Date).  No agreement of Landlord to alter, remodel, decorate, clean or improve the Premises or the Real Property and no representation regarding the condition of the Premises or the Real Property has been made by or on behalf of Landlord to Tenant, except as may be specifically stated in this Lease or in the Workletter.  Landlord will deliver the Phase I Premises and the Phase II Premises with all HVAC systems in good operating condition on the Phase I Commencement Date and the Phase II Commencement Date.  Should Tenant determine that there is any noncompliance with the foregoing delivery condition and provide Landlord with a written notice thereof, Landlord shall promptly after receipt of written notice from Tenant setting forth with specificity the nature and extent of such noncompliance, rectify the same at Landlord&#8217;s expense&#59; such noncompliance shall not, however, entitle Tenant to an abatement of rent or to terminate this Lease, or otherwise release Tenant from any of Tenant&#8217;s obligations under this Lease.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">PARKING</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">During the Term, Tenant may use up to the number of spaces specified in Section 1.1 for parking at the standard prevailing monthly rates being charged from time to time by Landlord or its parking operator without regard to discounts provided to any other occupants of the Building.  Tenant may adjust the number of spaces it uses upon not less than thirty (30) days prior written notice to Landlord.  In the event Tenant fails at any time to pay the full amount of such parking charges within 30 days following Landlord&#8217;s notice to Tenant of such failure to pay, Tenant&#8217;s parking rights shall be reduced to the extent of Tenant&#8217;s failure to pay for any such parking.  The locations and type of parking (including, without limitation, valet parking, if any) shall be designated by Landlord or Landlord&#8217;s parking operator from time to time.  Tenant acknowledges and agrees that the parking spaces serving the Project may include tandem or valet parking and a </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">00056263.8 &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">13</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">mixture of spaces for compact vehicles as well as full-size passenger automobiles, and that Tenant shall not use parking spaces for vehicles larger than the striped size of the parking spaces.  All vehicles utilizing Tenant&#8217;s parking spaces shall prominently display identification stickers or other markers, and&#47;or have passes or keycards for ingress and egress, as may be required and provided by Landlord or its parking operator from time to time.  Tenant shall comply with any and all parking rules and regulations from time to time established by Landlord or Landlord&#8217;s parking operator, including a requirement that Tenant pay to Landlord or Landlord&#8217;s parking operator a charge for loss and replacement of passes, keycards, identification stickers or markers, and for any and all loss or other damage caused by persons or vehicles related to use of Tenant&#8217;s parking spaces.  Tenant shall not allow any vehicles using Tenant&#8217;s parking spaces to be parked, loaded or unloaded except in accordance with this Section, including in the areas and in the manner designated by Landlord or its parking operator for such activities.  If any vehicle is using the parking or loading areas contrary to any provision of this Section, Landlord or its parking operator shall have the right, in addition to all other rights and remedies of Landlord under this Lease, to remove or tow away the vehicle without prior notice to Tenant, and the cost thereof shall be paid to Landlord within ten (10) days after notice from Landlord.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">TERMINATION OF EXISTING 4TH FLOOR LEASE TO CRYSTAL BIOSCIENCE.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tenant&#8217;s Affiliate, Crystal Bioscience, Inc. (&#8220;Crystal Bio&#8221;), currently leases space on the 4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> Floor of the Building known as Suite 405 (&#8220;Suite 405&#8221;) pursuant to the terms of that certain Lab Lease dated February 19, 2009 (as amended, the &#8220;Crystal Bio Lease&#8221;), the term of which lease expires as of August 31, 2021 (the &#8220;Original Crystal Bio Lease Expiration Date&#8221;).  It is the intent of the parties that that the Original Crystal Bio Lease is hereby revised to be the date that is thirty (30) days after Tenant has Substantially Completed the Phase II Tenant Work (the &#8220;Revised Crystal Bio Lease Expiration Date&#8221;).  Crystal Bio shall continue to have use of its parking spaces under the terms and conditions of the Crystal Bio Lease until the Revised Crystal Bio Lease Expiration Date.  Tenant shall cause Crystal Bio to&#58; (i) surrender Suite 405 to Landlord in accordance with the terms of the Crystal Bio Lease (including, without limitation, decommissioning and decontaminating Suite 405 using a reputable third-party vendor reasonably acceptable to Landlord) on or before the Revised Crystal Bio Lease Expiration Date, and (ii) enter into amendment to the Crystal Bio Lease extending the Term thereof to the Revised Crystal Bio Lease Expiration Date, in substantially the form attached as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit D</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> hereto.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Article 3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:29.72pt;text-decoration:underline"><br>RENT</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">From and after the Phase I Rent Commencement Date, Tenant shall pay to Landlord at the address specified in Section 1.1, or to such other persons, or at such other places designated by Landlord, without any prior demand therefor in immediately available funds and without any deduction or offset whatsoever, Rent, including Monthly Base Rent and Rent Adjustments in accordance with Article 4, during the Term. Monthly Base Rent shall be paid monthly in advance on or prior to the first day of each month of the Term, except that the first installment of Monthly Base Rent due for the period commencing with the Phase II Rent Commencement Date in the Monthly Base Rent table set forth in Section 1.1 shall be paid by Tenant to Landlord concurrently with Tenant&#8217;s execution of this Lease.  Monthly Base Rent shall be prorated for partial months within the Term.  Tenant&#8217;s covenant to pay Rent shall be independent of every other covenant in this Lease.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Article 4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:29.72pt;text-decoration:underline"><br>RENT ADJUSTMENTS AND PAYMENTS</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">RENT ADJUSTMENTS</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">00056263.8 &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">14</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">From and after (i) the Phase I Rent Commencement Date, as to the Phase I Premises, and (ii) the Phase II Rent Commencement Date, as to the Phase II Premises, Tenant shall pay to Landlord Rent Adjustments with respect to each calendar year (or partial calendar year in the case of the year in which the subject Rent Commencement Date and the Termination Date occur) as follows&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">The Rent Adjustment Deposit representing Tenant&#8217;s Share of Operating Expenses for the applicable calendar year (or partial calendar year), monthly during the Term with the payment of Monthly Base Rent&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">The Rent Adjustment Deposit representing Tenant&#8217;s Share of Taxes for the applicable calendar year (or partial calendar year), monthly during the Term with the payment of Monthly Base Rent&#59; and </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(3)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">Any Rent Adjustments due in excess of the Rent Adjustment Deposits in accordance with Section 4.2.  Rent Adjustments due from Tenant to Landlord for any calendar year (or partial calendar year) shall be Tenant&#8217;s Share of Operating Expenses for such calendar year (or partial calendar year) and Tenant&#8217;s Share of Taxes for such calendar year (or partial calendar year).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">On or before the beginning of each calendar year or with Landlord&#8217;s Statement (as defined in Section 4.2 below), Landlord may estimate and notify Tenant in writing of its estimate of the amount of Operating Expenses and Taxes payable by Tenant for such calendar year.  Prior to the first determination by Landlord of the amount of Operating Expenses and Taxes for the first calendar year, Landlord may estimate such amounts in the foregoing calculation.  Landlord shall have the right from time to time during any calendar year to provide a new or revised estimate of Operating Expenses and&#47;or Taxes and to notify Tenant in writing thereof, of corresponding adjustments in Tenant&#8217;s Rent Adjustment Deposit payable over the remainder of such year, and of the amount or revised amount due allocable to months preceding such change.  The last estimate by Landlord shall remain in effect as the applicable Rent Adjustment Deposit unless and until Landlord notifies Tenant in writing of a change, which notice may be given by Landlord from time to time during any calendar year throughout the Term.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">For purposes of determining Rent Adjustments, if the Building or Property is not fully occupied during all or a portion of any calendar year during the Term, Landlord shall make appropriate adjustments to the variable components of Operating Expenses for such calendar year (or partial calendar year), employing sound accounting and management principles consistently applied, to determine the amount of Operating Expenses that would have been paid or incurred by Landlord had the Building or Property been one hundred percent (100%) occupied, and the amount so determined shall be deemed to have been the amount of Operating Expenses for such calendar year (or partial calendar year).  In the event that the Property is not fully assessed for all or a portion of any calendar year (or partial calendar year) during the Term, then Taxes shall be adjusted to an amount which would have been payable in such calendar year (or partial calendar year) if the Property had been fully assessed.  In the event any other tenant in the Building provides itself with a service of a type which Landlord would supply under this Lease without an additional or separate charge to Tenant, then Operating Expenses shall be deemed to include the cost Landlord would have incurred had Landlord provided such service to such other tenant.  In addition, Landlord shall have the right, at its sole discretion, from time to time, to equitably allocate certain Operating Expenses among only certain tenants of the Project as to any expense or cost that relates to a repair, replacement or service that benefits only those tenants, and the Rent Adjustments shall reflect any such allocations.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">STATEMENT OF LANDLORD</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">00056263.8 &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">15</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">As soon as practical after the expiration of each calendar year, Landlord will furnish Tenant with a statement respecting the prior calendar year (&#8220;Landlord&#8217;s Statement&#8221;) showing the following&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">Operating Expenses and Taxes for such calendar year&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">The amount of Rent Adjustments due Landlord for the last calendar year, less credit for Rent Adjustment Deposits paid, if any&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">Any change in the Rent Adjustment Deposit due monthly in the current calendar year, including the amount or revised amount due for months preceding any such change pursuant to Landlord&#8217;s Statement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tenant shall pay to Landlord within ten (10) days after receipt of such statement any amounts for Rent Adjustments then due in accordance with Landlord&#8217;s Statement.  Any amounts due from Landlord to Tenant pursuant to this Section shall be credited to the Rent Adjustment Deposit next coming due, or refunded to Tenant if the Term has already expired, provided Tenant is not in default hereunder.  No interest or penalties shall accrue on any amounts that Landlord is obligated to credit or refund to Tenant by reason of this Section 4.2.  Landlord&#8217;s failure to deliver Landlord&#8217;s Statement or to compute the amount of the Rent Adjustments shall not constitute a waiver by Landlord of its right to deliver such items nor constitute a waiver or release of Tenant&#8217;s obligations to pay such amounts.  The Rent Adjustment Deposit shall be credited against Rent Adjustments due for the applicable calendar year (or partial calendar year).  During the last complete calendar year or during any partial calendar year in which this Lease terminates, Landlord may include in the Rent Adjustment Deposit its estimate of Rent Adjustments which might not be finally determined until after the termination of this Lease.  Tenant&#8217;s obligation to pay Rent Adjustments survives the expiration or termination of this Lease.  Notwithstanding the foregoing, in no event shall the sum of Monthly Base Rent and the Rent Adjustments be less than the Monthly Base Rent payable under this Lease.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">BOOKS AND RECORDS</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Landlord shall maintain books and records showing Operating Expenses and Taxes in accordance with sound accounting and management practices, consistently applied.  Tenant or its representative (which representative shall be a certified public accountant licensed to do business in the state in which the Property is located and whose primary business is certified public accounting and who shall not be paid on a contingency basis) shall have the right, for a period of sixty (60) days following the date upon which Landlord&#8217;s Statement is delivered to Tenant, to examine Landlord&#8217;s books and records with respect to the items in the foregoing statement of Operating Expenses and Taxes during normal business hours, upon written notice, delivered at least five (5) business days in advance.  Tenant shall pay for all costs of such examination.  If Tenant performs such examination, but does not object in writing to Landlord&#8217;s Statement within ninety (90) days after Tenant&#8217;s receipt thereof, specifying the nature of the item in dispute and the reasons therefor, then Landlord&#8217;s Statement shall be considered final and accepted by Tenant and Tenant shall be deemed to have waived its right to dispute Landlord&#8217;s Statement.  If Tenant does dispute any Landlord&#8217;s Statement, Tenant shall deliver a copy of any such audit to Landlord at the time of notification of the dispute.  If Tenant does not provide such notice of dispute and a copy of such audit to Landlord within such ninety (90) day period, it shall be deemed to have waived such right to dispute Landlord&#8217;s Statement.  Any amount due to Landlord as shown on Landlord&#8217;s Statement, whether or not disputed by Tenant as provided herein shall be paid by Tenant when due as provided above, without prejudice to any such written exception.  In no event shall Tenant be permitted to examine Landlord&#8217;s records or to dispute any statement of Operating Expenses and Taxes unless Tenant has paid and continues to pay all Rent when due. Upon resolution of any dispute with respect to Operating Expenses and Taxes, Tenant shall </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">00056263.8 &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">16</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">either pay Landlord any shortfall or Landlord shall credit Tenant with respect to any overages paid by Tenant.  The records obtained by Tenant shall be treated as confidential and neither Tenant nor any of its representatives or agents shall disclose or discuss the information set forth in the audit to or with any other person or entity (the &#8220;Confidentiality Requirement&#8221;).  Tenant shall indemnify and hold Landlord harmless for any losses or damages arising out of the breach of the Confidentiality Requirement.  </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">TENANT OR LEASE SPECIFIC TAXES</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">In addition to Monthly Base Rent, Rent Adjustments, Rent Adjustment Deposits and other charges to be paid by Tenant, Tenant shall pay to Landlord, upon demand, any and all taxes payable by Landlord (other than federal or state inheritance, general income, gift or estate taxes) whether or not now customary or within the contemplation of the parties hereto&#58; (a) upon, allocable to, or measured by the Rent payable hereunder, including any gross receipts tax or excise tax levied by any governmental or taxing body with respect to the receipt of such Rent&#59; or (b) upon or with respect to the possession, leasing, operation, management, maintenance, alteration, repair, use or occupancy by Tenant of the Premises or any portion thereof&#59; or (c) upon the measured value of Tenant&#8217;s personal property located in the Premises or in any storeroom or any other place in the Premises or the Property, or the areas used in connection with the operation of the Property, it being the intention of Landlord and Tenant that, to the extent possible, such personal property taxes shall be billed to and paid directly by Tenant&#59; (d) resulting from any Landlord Work, Tenant Work, Tenant Alterations, or any other improvements to the Premises, whether title thereto is in Landlord or Tenant&#59; or (e) upon this transaction.  Taxes or supplemental taxes paid by Tenant pursuant to this Section 4.4 shall not be included in any computation of Taxes payable pursuant to Sections 4.1 and 4.2, but standard property management fees shall apply to any such payments.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Article 5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:29.72pt;text-decoration:underline"><br>SECURITY</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">Simultaneously with Tenant&#8217;s execution and delivery of this Lease to Landlord, Tenant shall pay Landlord in immediately available funds the cash amount of the Security Deposit for the full and faithful performance by Tenant of each and every term, provision, covenant, and condition of this Lease.  If Tenant fails timely to perform any of the terms, provisions, covenants and conditions of this Lease or any other document executed by Tenant in connection with this Lease, then Landlord may use, apply, or retain the whole or any part of the Security Deposit for the payment of any Rent not paid when due, for the cost of repairing any damage, for the cost of cleaning the Premises, for the payment of any other sum which Landlord may expend or may be required to expend by reason of Tenant&#8217;s failure to perform, and otherwise for compensation of Landlord for any other loss or damage to Landlord occasioned by Tenant&#8217;s failure to perform, including, but not limited to, any loss of future Rent and any damage or deficiency in the reletting of the Premises (whether such loss, damages or deficiency accrue before or after summary proceedings or other reentry by Landlord) and the amount of the unpaid past Rent, future Rent loss, and all other losses, costs and damages, that Landlord would be entitled to recover if Landlord were to pursue recovery under Section 11.2(b) or (c) of this Lease or California Civil Code Section 1951.2 or 1951.4 (and any supplements, amendments, replacements and substitutions thereof and therefor from time to time).  If Landlord so uses, applies or retains all or part of the Security Deposit, Tenant shall within five (5) business days after demand pay or deliver to Landlord in immediately available funds the sum necessary to replace the amount used, applied or retained.  If Tenant has fully and faithfully performed and observed all of Tenant&#8217;s obligations under the terms, provisions, covenants and conditions of this Lease, the Security Deposit (except any amount retained for application by Landlord as provided herein) shall be returned to Tenant with thirty (30) days after the latest of&#58;  (i) the Expiration Date&#59; (ii) the removal of Tenant from the Premises&#59; or (iii) the surrender of the Premises by </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">00056263.8 &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">17</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tenant to Landlord in accordance with this Lease, or such longer time as may be permissible under Law&#59; provided, however, in no event shall any such return be construed as an admission by Landlord that Tenant has performed all of its obligations hereunder.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">The Security Deposit shall not be deemed an advance rent deposit or an advance payment of any kind, or a measure of Landlord&#8217;s damages with respect to Tenant&#8217;s failure to perform, nor shall any action or inaction of Landlord with respect to it or its use or application be a waiver of, or bar or defense to, enforcement of any right or remedy of Landlord.  Landlord shall not be required to keep the Security Deposit separate from its general funds and shall not have any fiduciary duties or other duties (except as set forth in this Section) concerning the Security Deposit.  Tenant shall not be entitled to any interest on the Security Deposit.  In the event of any sale, lease or transfer of Landlord&#8217;s interest in the Building, Landlord shall have the right to transfer the Security Deposit, or balance thereof, to the transferee and any such transfer shall release Landlord from all liability for the return of the Security Deposit.  Tenant thereafter shall look solely to such transferee for the return or payment of the Security Deposit.  Tenant shall not assign or encumber or attempt to assign or encumber the Security Deposit or any interest in it and Landlord shall not be bound by any such assignment, encumbrance, attempted assignment or attempted encumbrance, and regardless of one or more assignments of this Lease, Landlord may return the Security Deposit to the original Tenant without liability to any assignee.  Tenant hereby waives any and all rights of Tenant under the provisions of Section 1950.7 of the California Civil Code, and any and all rights of Tenant under all provisions of Law, now or hereafter enacted, regarding security deposits.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Article 6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:29.72pt;text-decoration:underline"><br>SERVICES</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">6.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">LANDLORD&#8217;S GENERAL SERVICES</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">Landlord shall furnish the following services the cost of which services shall be included in Operating Expenses or paid directly by Tenant to the utility or service provider&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">heat, ventilation and air-conditioning (&#8220;HVAC&#8221;) in the Premises during Standard Operating Hours as necessary in Landlord&#8217;s reasonable judgment for the comfortable occupancy of the Premises under normal business office and laboratory operations, and outside of Standard Operating Hours, HVAC shall be set to minimum safe setback levels for laboratory operations, operating 24 hours a day, 7 days a week, subject to compliance with all applicable voluntary and mandatory regulations and Laws&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">tempered and cold water for normal and customary use in the Premises and in lavatories in common with other tenants from the regular supply of the Building&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(3)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">customary cleaning and janitorial services in the Common Areas five (5) days per week, excluding National Holidays&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(4)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">washing of the outside windows in the Premises weather permitting at intervals determined by Landlord&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(5)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">automatic passenger elevator service in common with other tenants of the Building.  Freight elevator service, if any, will be subject to reasonable scheduling by Landlord.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">Landlord shall provide a security program for the Building (but not individually for Tenant or the Premises), the cost of which program shall be an Operating Expense.  Landlord shall not be liable in any manner to Tenant or any other Tenant Parties for any acts (including criminal acts) of others, or for any direct, indirect, or consequential damages, or any injury or </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">00056263.8 &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">18</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">damage to, or interference with, Tenant&#8217;s business, including, but not limited to, loss of profits, loss of rents or other revenues, loss of business opportunity, loss of goodwill or loss of use, or other loss or damage, bodily injury or death, related to any malfunction, circumvention or other failure of any security program, or for the failure of any security program to prevent bodily injury, death, or property damage, or loss, or to apprehend any person suspected of causing such injury, death, damage or loss.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">So long as this Lease is in full force and effect and Tenant has paid all Rent then due, Landlord shall furnish to the Premises replacement lamps, bulbs, ballasts and starters used in any normal Building lighting installed in the Premises, except that if the replacement or repair of such items is a result of negligence of Tenant, its employees, agents, servants, licensees, subtenants, contractors or invitees, such cost shall be paid by Tenant within ten (10) days after notice from Landlord and shall not be included as part of Operating Expenses.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">If Tenant uses heat generating machines or equipment in the Premises to an extent which adversely affects the temperature otherwise maintained by the air-cooling system or whenever the occupancy or electrical load adversely affects the temperature otherwise maintained by the air-cooling system, Landlord reserves the right to install or to require Tenant to install supplementary air-conditioning units in the Premises.  Tenant shall bear all costs and expenses related to the installation, maintenance and operation of such units.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">Tenant shall pay Landlord at rates fixed by Landlord for all tenants in the Building, charges for all water furnished to the Premises beyond that described in Section&#160;6.1(a)(2), including the expenses of installation of a water line, meter and fixtures.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.03pt">On and after the Phase I Commencement Date, Landlord agrees that in the event of an interruption of power to the Building, Tenant may connect Tenant loads (including back-up of all of Tenant&#8217;s cold storage and incubators) to the emergency generator serving the Building (the &#8220;Emergency Generator&#8221;) on the following conditions&#58; (i) Tenant loads to the Emergency Generator shall in no event exceed Tenant&#8217;s Share of the kVA capacity of the Emergency Generator Landlord elects to make available for shared use by tenants of the Building&#59; (ii) any use of the Emergency Generator, including the duration of use, shall be subject to the requirements and limitations (if any) imposed by applicable Law&#59; and (iii) in the event of an emergency causing an interruption of power to any portion of the Building, Landlord may, in its reasonable discretion, immediately shed or shut down Tenant loads (an &#8220;Emergency Shut Down&#8221;) to the extent necessary to redirect the power from the Emergency Generator (&#8220;Emergency Generator Power&#8221;) to the Building&#8217;s emergency&#47;life-safety systems (e.g., elevators, fire-life safety and emergency lighting). To the extent Landlord&#8217;s load shedding equipment accommodates shedding Tenant loads in stages, then Landlord shall use commercially reasonable good-faith efforts to shed Tenant loads in a priority which Tenant has delivered to Landlord in writing.  Notwithstanding anything to the contrary herein, Tenant acknowledges that the Emergency Generator and any transfer switch may be exercised on a periodic basis, such exercise to be conducted by Landlord or the Building Management Staff at Landlord&#8217;s reasonable discretion.  Tenant further acknowledges that annual maintenance procedures require that the Emergency Generator be taken off-line and that an annual full load test be performed on an annual basis, which test shall be conducted by Landlord or the Building Management Staff at Landlord&#8217;s reasonable discretion&#59; provided, however, Landlord shall give Tenant not less than five (5) business days&#8217; prior written notice thereof.  Landlord shall not be liable to Tenant, and Tenant shall not be entitled to any abatement of rent or other recourse in the event that Emergency Generator Power is not available for any reason.  Landlord&#8217;s actual out-of-pocket cost of maintenance, repair and testing of the Emergency Generator shall be included in Operating Expenses.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">6.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">UTILITIES AND JANITORIAL SERVICES</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">00056263.8 &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">19</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">All utility services used in the production of heating and cooling and air supply and exhaust from the central HVAC systems serving the Building and Premises, including, without limitation, electricity and gas, as well as water and sewer services, shall constitute Operating Expenses.  All utility services used by Tenant within the Premises, including, without limitation, electricity and gas, shall be paid for by Tenant either through a separate charge or as part of Operating Expenses.  Such charges shall be based upon Tenant&#8217;s usage, which usage&#58; (a) as to electricity, other than overhead lighting, shall be measured by a separate meter or sub-meter to be installed as part of the Tenant Work, and paid by Tenant within 15 days after billing as additional Rent under this Lease&#59; and (b) as to all other utilities, shall either be reasonably estimated by Landlord and paid by Tenant within 15 days after billing as additional Rent under this Lease or included in Operating Expenses.  In addition, Tenant shall provide its own janitorial services to the Premises, using a janitorial service reasonably acceptable to Landlord or shall make arrangements with Landlord for Landlord, through Landlord&#8217;s vendors, to perform such Premises cleaning services, and shall pay the costs thereof directly to Landlord.  Notwithstanding any provision of this Lease to the contrary, Tenant shall not make any alterations or additions to the electric equipment or systems, in each instance, without the prior written approval of Landlord, which approval shall not be unreasonably withheld, conditioned or delayed so long as such alterations or additions (i) do not exceed the capacity of the wiring, feeders and risers and (ii) are in compliance with the City&#8217;s building code.  Tenant&#8217;s use of electric current shall at no time exceed the capacity of the wiring, feeders and risers providing electric current to the Premises or the Building.  The consent of Landlord to the installation of electric equipment shall not relieve Tenant from the obligation to limit usage of electricity to no more than such capacity.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">6.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">ADDITIONAL AND AFTER HOUR SERVICES</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">At Tenant&#8217;s written request, Landlord shall furnish additional quantities of any of the services or utilities specified in Section 6.1, if Landlord can reasonably do so, on the terms set forth herein. For services or utilities requested by Tenant and furnished by Landlord, Tenant shall pay to Landlord as a charge therefor Landlord&#8217;s prevailing rates charged from time to time for such services and utilities, as additional Rent under this Lease.  Without limiting the generality of the foregoing, for HVAC service outside of Standard Operating Hours, Landlord&#8217;s prevailing rate as of the date of this Lease includes a one (1) hour minimum per activation.  If Tenant shall fail to make any such payment, Landlord may, upon notice to Tenant and in addition to Landlord&#8217;s other remedies under this Lease, discontinue any or all of such additional services.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">6.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">TELEPHONE SERVICES</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">All telephone and communication connections which Tenant may desire shall be subject to Landlord&#8217;s prior written approval, in Landlord&#8217;s reasonable discretion, and the location of all Cables and the work in connection therewith shall be performed by contractors approved by Landlord and shall be subject to the direction of Landlord and in compliance with Landlord&#8217;s then current Building standards for Cable installation.  Landlord reserves the right to designate and control the entity or entities providing Cable installation, removal, repair and maintenance in the Building and to restrict and control access to telephone cabinets or panels.  In the event Landlord designates a particular vendor or vendors to provide such Cable installation, removal, repair and maintenance for the Building, Tenant agrees to abide by and participate in such program.  Tenant shall be responsible for and shall pay, as additional Rent under this Lease, all costs incurred in connection with the installation of Cables in the Premises, including any hook-up, access and maintenance fees related to the installation of such Cables in the Premises and the commencement of service therein, and the maintenance thereafter of such Cables&#59; and there shall be included in Operating Expenses for the Building all installation, removal, hook-up or maintenance costs incurred by Landlord in connection with Cables serving the Building which are not allocable to any individual users of such service but are allocable to the Building </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">00056263.8 &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">20</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">generally.  If Tenant fails to maintain all Cables in the Premises and such failure affects or interferes with the operation or maintenance of any other Cables serving the Building, Landlord or any vendor hired by Landlord may enter into and upon the Premises forthwith and perform such repairs, restorations or alterations as Landlord deems necessary in order to eliminate any such interference (and Landlord may recover from Tenant all of Landlord&#8217;s costs in connection therewith).  If required by Landlord, no later than the Termination Date Tenant shall remove all Cables installed by Tenant for and during Tenant&#8217;s occupancy and surrender the installation in a condition previously approved by Landlord.  Tenant agrees that neither Landlord nor any of its agents or employees shall be liable to Tenant, or any of Tenant&#8217;s employees, agents, customers or invitees or anyone claiming through, by or under Tenant, for any damages, injuries, losses, expenses, claims or causes of action because of any interruption, diminution, delay or discontinuance at any time for any reason in the furnishing of any telephone or other communication service to the Premises and the Building.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">6.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">DELAYS IN FURNISHING SERVICES</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tenant agrees that Landlord shall not be in breach of this Lease nor be liable to Tenant for damages or otherwise, for any failure to furnish, or a delay in furnishing, or a change in the quantity or character of any service when such failure, delay or change is occasioned, in whole or in part, by repairs, improvements or mechanical breakdowns, by the act or default of Tenant or other parties or by an event of Force Majeure.  No such failure, delay or change shall be deemed to be an eviction or disturbance of Tenant&#8217;s use and possession of the Premises, or relieve Tenant from paying Rent or from performing any other obligations of Tenant under this Lease, without any deduction or offset. Failure to any extent to make available, or any slowdown, stoppage, or interruption of, the specified utility services resulting from any cause, including changes in service provider or Landlord&#8217;s compliance with any voluntary or similar governmental or business guidelines now or hereafter published or any requirements now or hereafter established by any governmental agency, board, or bureau having jurisdiction over the operation of the Property, shall not render Landlord liable in any respect for damages to either persons, property, or business, nor be construed as an eviction of Tenant or work an abatement of Rent, nor relieve Tenant of Tenant&#8217;s obligations for fulfillment of any covenant or agreement hereof. Should any equipment or machinery furnished by Landlord break down or for any cause cease to function properly, Landlord shall use reasonable diligence to repair same promptly, but Tenant shall have no claim for abatement of Rent or damages on account of any interruption of service occasioned thereby or resulting therefrom.  Tenant hereby waives any benefits of any applicable existing or future Law, including the provisions of California Civil Code section 1932(1), permitting the termination of this Lease due to such interruption, failure or inability.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">6.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">CHOICE OF SERVICE PROVIDER</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tenant acknowledges that Landlord may, at Landlord&#8217;s sole option, to the extent permitted by applicable law, elect to change, from time to time, the company or companies which provide services (including electrical service, gas service, water, telephone and technical services) to the Building, the Premises and&#47;or its occupants.  Notwithstanding anything to the contrary set forth in this Lease, Tenant acknowledges that Landlord has not and does not make any representations or warranties concerning the identity or identities of the company or companies which provide services to the Building and the Premises or its occupants, and Tenant acknowledges that the choice of service providers and matters concerning the engagement and termination thereof shall be solely that of Landlord. The foregoing provision is not intended to modify, amend, change or otherwise derogate any provision of this Lease concerning the nature or type of service to be provided or any specific information concerning the amount thereof to be provided. Tenant agrees to cooperate with Landlord and each of its service providers in connection with any change in service or provider.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">00056263.8 &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">21</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">6.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">SIGNAGE</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">Standard Signage</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Initial Building standard signage for Tenant will be installed by Landlord in the directory in the main lobby of the Building.  As of the Phase I Rent Commencement Date, Landlord also shall install signage for Tenant in the listing of tenants in the elevator lobby for the floor on which the Premises is located and at Tenant&#8217;s main entry door to the Premises, all at Tenant&#8217;s</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">sole cost and expense.  As of the Phase II Rent Commencement Date, Tenant shall have exclusive signage rights in the elevator lobby for the floor on which the Premises is located, at Tenant&#8217;s sole cost and expense.  Any change in such initial signage shall be only with Landlord&#8217;s prior written consent, shall conform to Building standard signage and shall be at Tenant&#8217;s sole cost and expense.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Exterior Sign</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  In addition to the signage identified in Section 6.7(a) above, Tenant shall be entitled to one sign panel on any available monument signage for the Building, to the extent Landlord offers such sign panel rights to any other full-floor tenants in the Building (as applicable, &#8220;Tenant&#8217;s Exterior Sign&#8221;).  Landlord shall have the right to reasonably approve the plans and specifications for the design and installation of Tenant&#8217;s Exterior Sign, the identity of any contractor or subcontractor to be employed on the work of installing Tenant&#8217;s Sign, and the time for performance of such work.  Any and all maintenance and repair relating to Tenant&#8217;s Exterior Sign shall be the sole responsibility of Tenant.  Tenant shall promptly perform such maintenance and repair obligations in a good and workmanlike manner, such that Tenant&#8217;s Sign appears and operates at all times in the manner intended at the time it was designed and installed.  All costs pertaining to the design, installation, operation, maintenance, repair and removal of Tenant&#8217;s Exterior Sign or any part thereof shall be paid by Tenant when due.  The provisions of this Lease pertaining to mechanic&#8217;s liens shall apply to Tenant&#8217;s Exterior Sign.  Notwithstanding anything to the contrary contained herein, Tenant&#8217;s rights under this Section 6.7(b) are personal to Named Tenant and shall not be assigned or assignable, in whole or in part, to any third party.  Any assignment or other transfer of such rights by Named Tenant shall be void and of no force or effect.  Without limiting the generality of the foregoing, no sublessee of the Premises shall be permitted to exercise the rights granted to Named Tenant under this Section 6.7(b).</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Article 7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:29.72pt;text-decoration:underline"><br>USE OF PREMISES&#59; LANDLORD&#8217;S ACCESS RIGHTS</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">7.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">USE OF PREMISES</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">Tenant shall occupy and use the Premises only for the uses specified in Section&#160;1.1 to conduct Tenant&#8217;s business.  Tenant shall not occupy or use the Premises (or permit the use or occupancy of the Premises) for any purpose or in any manner which&#58; (1) is unlawful or in violation of any Law or Hazardous Materials Law&#59; (2) may be dangerous to persons or property or which may increase the cost of, or invalidate, any policy of insurance carried on the Building or covering its operations&#59; (3) is contrary to or prohibited by the terms and conditions of this Lease or the rules of the Building set forth in Article 18&#59; (4) would tend to create or continue a nuisance&#59; or (5) in any manner that will cause the Building or any part thereof not to conform with the Project&#8217;s Sustainability Practices or the certification of the Building&#8217;s core and shell issued pursuant to the applicable Green Building Standards.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">Landlord shall provide Tenant access to the Premises 24 hours per day, 7 days per week and 365&#47;366 days per year through access card keys, the cost of which shall be paid by Tenant within thirty (30) days of Landlord&#8217;s demand therefor, and Tenant shall place a deposit for such cards with Landlord to cover lost cards or cards which are not returned at the end of the Term.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">00056263.8 &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">22</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">Landlord and Tenant acknowledge that the Americans With Disabilities Act of 1990 (42 U.S.C. &#167;12101 et seq.) and regulations and guidelines promulgated thereunder, as all of the same may be amended and supplemented from time to time (collectively referred to herein as the &#8220;ADA&#8221;) establish requirements for business operations, accessibility and barrier removal, and that such requirements may or may not apply to the Premises, the Building and the Project depending on, among other things&#58; (1) whether Tenant&#8217;s business is deemed a &#8220;public accommodation&#8221; or &#8220;commercial facility&#8221;, (2) whether such requirements are &#8220;readily achievable&#8221;, and (3) whether a given alteration affects a &#8220;primary function area&#8221; or triggers &#8220;path of travel&#8221; requirements.  The parties hereby agree that&#58; (a) Landlord shall be responsible for ADA Title III compliance in the Common Areas (including the restrooms), except as provided below, (b) Tenant shall be responsible for ADA Title III compliance in the Premises, including any Leasehold Improvements or other work to be performed in the Premises under or in connection with this Lease, (c)&#160;Landlord may perform, or require that Tenant perform, and Tenant shall be responsible for the cost of, ADA Title III &#8220;path of travel&#8221; requirements triggered by Tenant Additions in the Premises (but Tenant shall not be responsible for the cost of &#8220;path of travel&#8221; requirements in the Common Areas), and (d) Landlord may perform, or require Tenant to perform, and Tenant shall be responsible for the cost of, ADA Title III compliance in the Common Areas necessitated by the Building being deemed to be a &#8220;public accommodation&#8221; instead of a &#8220;commercial facility&#8221; as a result of Tenant&#8217;s use of the Premises.  Tenant shall be solely responsible for requirements under Title I of the ADA relating to Tenant&#8217;s employees.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">Landlord and Tenant agree to cooperate and use commercially reasonable efforts to participate in traffic management programs generally applicable to businesses located in or about the area and Tenant shall encourage and support van, shuttle service, and carpooling by, and staggered and flexible working hours for, its office workers and service employees to the extent reasonably permitted by the requirements of Tenant&#8217;s business.  Neither this Section or any other provision of this Lease is intended to or shall create any rights or benefits in any other person, firm, company, governmental entity or the public.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">Tenant agrees to cooperate with Landlord and to comply with any and all guidelines or controls concerning energy management and usage disclosure imposed upon Landlord by federal or state governmental organizations or by any energy conservation association to which Landlord is a party or which is applicable to the Building, including, without limitation, the requirements of California&#8217;s Nonresidential Building Energy Use Disclosure Program, as more particularly specified in California Public Resources Code Sections 25402.10 et seq. and regulations adopted pursuant thereto.  Further, Tenant hereby authorizes (and agrees that Landlord shall have the authority to authorize) any electric or gas utility company providing service to the Building to disclose from time to time so much of the data collected and maintained by it regarding Tenant&#8217;s energy consumption data as may be necessary to cause the Building to participate in the ENERGY STAR&#174; Portfolio Manager system and similar programs&#59; and Tenant further authorizes Landlord to disclose information concerning energy use by Tenant, either individually or in combination with the energy use of other tenants, as applicable as Landlord determines to be necessary to comply with applicable Laws pertaining to the Building or Landlord&#8217;s ownership thereof.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.03pt;text-decoration:underline">Hazardous Materials</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">Definitions.  The following terms shall have the following meanings for purposes of this Lease&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.69pt">&#8220;Biohazardous Materials&#8221; means any and all substances and materials defined or referred to as &#8220;medical waste,&#8221; &#8220;biological waste,&#8221; &#8220;biohazardous waste,&#8221; &#8220;biohazardous material&#8221; or any other term of similar import under any Hazardous Materials </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">00056263.8 &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">23</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Laws, including (but not limited to) California Health &#38; Safety Code Sections 25105 et seq., and any regulations promulgated thereunder, as amended from time to time.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.36pt">&#8220;Chemical Control Area Plan&#8221; means that certain plan for the use and storage of Hazardous Materials in the Building created by Landlord and approved by the City.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.03pt">&#8220;Environmental Condition&#8221; means the Release of any Hazardous Materials in, over, on, under, through, from or about the Project (including, but not limited to, the Premises).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.69pt">&#8220;Environmental Damages&#8221; means all claims, suits, judgments, damages, losses, penalties, fines, liabilities, encumbrances, liens, costs and expenses of whatever kind or nature, contingent or otherwise, matured or unmatured, foreseeable or unforeseeable, arising out of or in connection with any Environmental Condition, including, to the extent arising out of an Environmental Condition, without limitation&#58;  (A) damages for personal injury, or for injury or damage to the Project or natural resources occurring on or off the Project, including without limitation (1) any claims brought by or on behalf of any person, (2) any loss of, lost use of, damage to or diminution in value of any Project or natural resource, and (3) costs of any investigation, remediation, removal, abatement, containment, closure, restoration or monitoring work required by any federal, state or local governmental agency or political subdivision, or otherwise reasonably necessary to protect the public health or safety, whether on or off the Project&#59; (B) reasonable fees incurred for the services of attorneys, consultants, contractors, experts and laboratories in connection with the preparation of any feasibility studies, investigations or reports or the performance of any work described above&#59; (C) any liability to any third person or governmental agency to indemnify such person or agency for costs expended or liabilities incurred in connection with any items described in clause (A) or (B) above&#59; (D) any fair market or fair market rental value of the Project&#59; and (E) the amount of any penalties, damages or costs a party is required to pay or incur in excess of that which the party otherwise would reasonably have expected to pay or incur absent the existence of the applicable Environmental Condition.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(v)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">&#8220;Handling&#8221; or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Handles&#8221;, when used with reference to any substance or material, includes (but is not limited to) any receipt, storage, use, generation, Release, transportation, treatment or disposal of such substance or material.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(vi)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.69pt">&#8220;Hazardous Materials&#8221; means any and all chemical, explosive, biohazardous, radioactive or otherwise toxic or hazardous materials or hazardous wastes, including without limitation any asbestos-containing materials, PCB&#8217;s, CFCs, petroleum and derivatives thereof, Radioactive Materials, Biohazardous Materials, Hazardous Wastes, any other substances defined or listed as or meeting the characteristics of a hazardous substance, hazardous material, Hazardous Waste, toxic substance, toxic waste, biohazardous material, biohazardous waste, biological waste, medical waste, radiation, radioactive substance, radioactive waste, or other similar term, as applicable, under any law, statute, ordinance, code, rule, regulation, directive, order, condition or other written requirement enacted, promulgated or issued by any public officer or governmental or quasi-governmental authority, whether now in force or hereafter in force at any time or from time to time to protect the environment or human health, and&#47;or any mixed materials, substances or wastes containing more than one of the foregoing categories of materials, substances or wastes.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(vii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15.36pt">&#8220;Hazardous Materials Laws&#8221; means, collectively, (A) the Comprehensive Environmental Response, Compensation and Liability Act of 1980, 42 U.S.C. Sections&#160;9601-9657, (B) the Hazardous Materials Transportation Act of 1975, 49 U.S.C. Sections&#160;1801-1812, (C) the Resource Conservation and Recovery Act of 1976, 42 U.S.C. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">00056263.8 &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">24</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Sections&#160;6901-6987 (together with any amendments thereto, any regulations thereunder and any amendments to any such regulations as in effect from time to time, &#8220;RCRA&#8221;), (D) the California Carpenter-Presley-Tanner Hazardous Substance Account Act, California Health &#38; Safety Code Sections&#160;25300 et seq., (E) the Hazardous Materials Release Response Plans and Inventory Act, California Health &#38; Safety Code Sections&#160;25500 et seq., (F) the California Hazardous Waste Control Law, California Health &#38; Safety Code Sections&#160;25100 et seq. (together with any amendments thereto, any regulations thereunder and any amendments to any such regulations as in effect from time to time, the &#8220;CHWCL&#8221;), (G) California Health &#38; Safety Code Sections&#160;25015-25027.8, (H) any amendments to or successor statutes to any of the foregoing, as adopted or enacted from time to time, (I) any regulations or amendments thereto promulgated pursuant to any of the foregoing from time to time, (J) any Laws relating to Biohazardous Materials, including (but not limited to) any regulations or requirements with respect to the shipping, use, decontamination and disposal thereof, and (K) any other Law now or at any time hereafter in effect regulating, relating to or imposing liability or standards of conduct concerning any Hazardous Materials, including (but not limited to) any requirements or conditions imposed pursuant to the terms of any orders, permits, licenses, registrations or operating plans issued or approved by any governmental or quasi-governmental authority from time to time either on a Project-wide basis or in connection with any Handling of Hazardous Materials in, on or about the Premises or the Project.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(viii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12.03pt">&#8220;Hazardous Wastes&#8221; means (A) any waste listed as or meeting the identified characteristics of a &#8220;hazardous waste&#8221; or terms of similar import under RCRA, (B)&#160;any waste meeting the identified characteristics of a &#8220;hazardous waste&#8221;, &#8220;extremely hazardous waste&#8221; or &#8220;restricted hazardous waste&#8221; under the CHWCL, and&#47;or (C) any and all other substances and materials defined or referred to as a &#8220;hazardous waste&#8221; or other term of similar import under any Hazardous Materials Laws.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ix)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.69pt">&#8220;Landlord&#8217;s Contamination&#8221; means any Hazardous Materials which exist in, on, under or in the vicinity of the Project as of the date of this Lease or which migrate onto or beneath the Project after termination of this Lease.  Tenant shall not be required to pay any costs with respect to the remediation or abatement of Landlord&#8217;s Contamination.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(x)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">&#8220;Radioactive Materials&#8221; means (A) any and all substances and materials the Handling of which requires an approval, consent, permit or license from the Nuclear Regulatory Commission, (B) any and all substances and materials the Handling of which requires a Radioactive Material License or other similar approval, consent, permit or license from the State of California, and (C) any and all other substances and materials defined or referred to as &#8220;radiation,&#8221; a &#8220;radioactive material&#8221; or &#8220;radioactive waste,&#8221; or any other term of similar import under any Hazardous Materials Laws, including (but not limited to) Title 26, California Code of Regulations Section&#160;17-30100, and any statutes, regulations or other laws administered, enforced or promulgated by the Nuclear Regulatory Commission.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(xi)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.69pt">&#8220;Release&#8221; means any accidental or intentional spilling, leaking, pumping, pouring, emitting, discharging, injecting, escaping, leaching, migrating, dumping or disposing into the air, land, surface water, groundwater or the environment (including without limitation the abandonment or discarding of receptacles containing any Hazardous Materials).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(xii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15.36pt">&#8220;Tenant&#8217;s Contamination&#8221; means any Hazardous Material Release on or about the Property by Tenant and&#47;or any agents, employees, contractors, vendors, suppliers, licensees, subtenants, and invitees of Tenant (individually, a &#8220;Tenant Party&#8221; and collectively, &#8220;Tenant Parties&#8221;).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Handling of Hazardous Materials</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The parties acknowledge that Tenant wishes and intends to use all or a portion of the Premises as a bio-pharmaceutical research and </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">00056263.8 &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">25</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">development facility in conformance with the conduct by Tenant of its business in accordance with the use specified in Section&#160;1.1, that such use, as conducted or proposed to be conducted by Tenant, would customarily include the Handling of Hazardous Materials, and that Tenant shall therefore be permitted to engage in the Handling in the Premises of necessary and reasonable quantities of Hazardous Materials customarily used in or incidental to the operation of a bio-pharmaceutical research, development preparation and&#47;or dispensing facility in conformance with business operations of Tenant in the manner conducted or proposed to be conducted by Tenant hereunder (&#8220;Permitted Hazardous Materials&#8221;), provided that the Handling of such Permitted Hazardous Materials by all Tenant Parties shall at all times comply with and be subject to all provisions of this Lease and all Laws, including all Hazardous Materials Laws, and with Landlord&#8217;s Chemical Control Area Plan for the Building.  Without limiting the generality of the foregoing, Tenant shall comply at all times with all Hazardous Materials Laws applicable to any aspect of Tenant&#8217;s use of the Premises and the Project and of Tenant&#8217;s operations and activities in, on and about the Premises and the Project, and shall ensure at all times that Tenant&#8217;s Handling of Hazardous Materials in, on and about the Premises does not violate (x) the terms of any governmental licenses or permits applicable to the Building (including, but not limited to, the Building Discharge Permit as defined below) or Premises or to Tenant&#8217;s Handling of any Hazardous Materials therein, or (y) any applicable requirements or restrictions relating to the occupancy classification of the Building and the Premises.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(3)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Disposition or Emission of Hazardous Materials</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Tenant shall not Release or dispose of any Hazardous Materials, except to the extent authorized by permit, at the Premises or on the Project, but instead shall arrange for off-site disposal, under Tenant&#8217;s own name and EPA waste generator number (or other similar identifying information issued or prescribed by any other governmental authority with respect to Radioactive Materials, Biohazardous Materials or any other Hazardous Materials) and at Tenant&#8217;s sole expense, in compliance with all applicable Hazardous Materials Laws, with the Laboratory Rules and Regulations (defined below) and with all other applicable Laws and regulatory requirements.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(4)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Information Regarding Hazardous Materials</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Tenant shall maintain and make available to Landlord the following information and&#47;or documentation upon demand&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.69pt">An inventory of all Hazardous Materials that Tenant receives, uses, handles, generates, transports, stores, treats or disposes of from time to time, or at the time of preparation of such inventory proposes or expects to use, handle, generate, transport, store, treat or dispose of from time to time, in connection with its operations at the Premises.  Such inventory shall include, but shall separately identify, any Hazardous Wastes, Biohazardous Materials and Radioactive Materials covered by the foregoing description.  If such inventory includes any Biohazardous Materials, Tenant shall also disclose in writing to Landlord the Biosafety Level designation associated with the use of such materials.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.36pt">Copies of all then existing permits, licenses, registrations and other similar documents issued by any governmental or quasi-governmental authority that authorize any Handling of Hazardous Materials in, on or about the Premises or the Project by any Tenant Party.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.03pt">All Material Safety Data Sheets (&#8220;MSDSs&#8221;), if any, required to be completed with respect to operations of Tenant at the Premises from time to time in accordance with Title 26, California Code of Regulations Section&#160;8-5194 or 42 U.S.C. Section&#160;11021, or any amendments thereto, and any Hazardous Materials Inventory Sheets that detail the MSDSs.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.69pt">All hazardous waste manifests (as defined in Title 26, California Code of Regulations Section&#160;22-66481), if any, that Tenant is required to complete from time to time in connection with its operations at the Premises.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">00056263.8 &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">26</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(v)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">A copy of any &#8220;Hazardous Materials Business Plan&#8221; required from time to time with respect to Tenant&#8217;s operations at the Premises pursuant to California Health &#38; Safety Code Sections&#160;25500 et seq., and any regulations promulgated thereunder, as amended from time to time, or in connection with Tenant&#8217;s application for a business license from the City.  If applicable law does not require Tenant to prepare a Hazardous Materials Business Plan, Tenant shall furnish to Landlord at the times and in the manner set forth above the information that would customarily be contained in a Hazardous Materials Business Plan, including (but not limited to) information regarding Tenant&#8217;s Hazardous Materials inventories.  The parties acknowledge that a Hazardous Materials Business Plan would ordinarily include an emergency response plan, and that regardless of whether applicable Law requires Tenant or other tenants in the Building to prepare Hazardous Materials Business Plans, Landlord in its discretion may elect to prepare a coordinated emergency response plan for the entire Building and&#47;or for multiple Buildings on the Project (if and to the extent applicable).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(vi)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.69pt">Any &#8220;Contingency Plans and Emergency Procedures&#8221; required of Tenant from time to time, in connection with its operations at the Premises, pursuant to applicable Law, Title 26, California Code of Regulations Sections&#160;22-67140 et seq., and any amendments thereto, and any &#8220;Training Programs and Records&#8221; required under Title 26, California Code of Regulations Section&#160;22-66493, and any amendments thereto from time to time.  Landlord in its discretion may elect to prepare a Contingency Plan and Emergency Procedures for the entire Building and&#47;or for multiple buildings on the Project, in which event, if applicable law does not require Tenant to prepare a Contingency Plan and Emergency Procedures for its operations at the Premises, Tenant shall furnish to Landlord at the times and in the manner set forth above the information that would customarily be contained in a Contingency Plan and Emergency Procedures.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(vii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15.36pt">Copies of any biennial or other periodic reports furnished or required to be furnished to the California Department of Health Services from time to time, under applicable law, pursuant to Title 26, California Code of Regulations Section&#160;22-66493 and any amendments thereto, relating to any Hazardous Materials.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(viii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12.03pt">Copies of any industrial wastewater discharge permits issued to or held by Tenant from time to time in connection with its operations at the Premises (the parties presently anticipate, however, that because of the existence of the Building Discharge Permit in Landlord&#8217;s name as described above.  Tenant will not be required to maintain a separate, individual discharge permit).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ix)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.69pt">Copies of any other lists, reports, studies, or inventories of Hazardous Materials or of any subcategories of materials included in Hazardous Materials that Tenant is otherwise required to prepare and file from time to time with any governmental or quasi-governmental authority in connection with Tenant&#8217;s operations at the Premises, including (but not limited to) reports filed by Tenant with the federal Food &#38; Drug Administration or any other regulatory authorities primarily in connection with the presence (or lack thereof) of any &#8220;select agents&#8221; or other Biohazardous Materials on the Premises, together with proof of filing thereof.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(x)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">Any other information reasonably requested by Landlord in writing from time to time in connection with (A) Landlord&#8217;s monitoring (in Landlord&#8217;s reasonable discretion) and enforcement of Tenant&#8217;s obligations under this Section and of compliance with applicable Laws in connection with any Handling or Release of Hazardous Materials in the Premises or Building or on or about the Project by any Tenant Party, (B) any inspections or enforcement actions by any governmental authority pursuant to any Hazardous Materials Laws or any other Laws relating to the presence or Handling of Hazardous Materials in the Premises or Building or on or about the Project by any Tenant Party, and&#47;or (C) Landlord&#8217;s preparation (in </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">00056263.8 &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">27</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Landlord&#8217;s discretion) and enforcement of any reasonable rules and procedures relating to the presence or Handling by Tenant or any Tenant Party of Hazardous Materials in the Premises or Building or on or about the Project, including (but not limited to) any contingency plans or emergency response plans as described above.  Except as otherwise required by Law, Landlord shall keep confidential any information supplied to Landlord by Tenant pursuant to the foregoing, provided, however, that the foregoing shall not apply to any information filed with any governmental authority or available to the public at large.  Landlord may provide such information to its lenders, consultants or investors provided such entities agree to keep such information confidential.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(5)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Indemnification&#59; Notice of Release</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Tenant shall be responsible for and shall indemnify, defend and hold Landlord harmless from and against all Environmental Damages to the extent arising out of or otherwise relating to, (i) any Handling of Hazardous Materials by any Tenant Party in, on or about the Premises or the Project in violation of this Section, (ii) any breach of Tenant&#8217;s obligations under this Section or of any Hazardous Materials Laws by any Tenant Party, or (iii) the existence of any Tenant&#8217;s Contamination in, on or about the Premises or the Project to the extent caused by any Tenant Party, including without limitation any removal, cleanup or restoration work and materials necessary to return the Project or any improvements of whatever nature located on the Project to the condition existing prior to the Handling of Hazardous Materials in, on or about the Premises or the Project by any Tenant Party.  In the event of any Tenant&#8217;s Contamination in, on or about the Premises or any other portion of the Project or any adjacent lands, Tenant shall promptly remedy the problem in accordance with all applicable Hazardous Materials Laws, shall give Landlord oral notice of any such non-standard or non-customary Release promptly after Tenant becomes aware of such Release, followed by written notice to Landlord within five (5) days after Tenant becomes aware of such Release, and shall furnish Landlord with concurrent copies of any and all notices, reports and other written materials filed by any Tenant Party with any governmental authority in connection with such Release.  Tenant shall have no obligation to remedy any Hazardous Materials contamination which was not caused or released by a Tenant Party.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(6)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Governmental Notices</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Tenant shall promptly provide Landlord with copies of all notices received by Tenant relating to any actual or alleged presence or Handling by any Tenant Party of Hazardous Materials in, on or about the Premises or any other portion of the Project, including, without limitation, any notice of violation, notice of responsibility or demand for action from any federal, state or local governmental authority or official in connection with any actual or alleged presence or Handling by any Tenant Party of Hazardous Materials in or about the Premises or any other portion of the Project.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(7)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Inspection by Landlord</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  In addition to, and not in limitation of, Landlord&#8217;s rights under this Lease, upon reasonable prior request by Landlord, Tenant shall grant Landlord and its consultants, as well as any governmental authorities having jurisdiction over the Premises or over any aspect of Tenant&#8217;s use thereof, reasonable access to the Premises at reasonable times to inspect Tenant&#8217;s Handling of Hazardous Materials in, on and about the Premises, and Landlord shall not thereby incur any liability to Tenant or be deemed guilty of any disturbance of Tenant&#8217;s use or possession of the Premises by reason of such entry&#59; provided, however, that Landlord shall use reasonable efforts to minimize interference with Tenant&#8217;s use of the Premises caused by such entry.  Landlord shall comply with any security precaution reasonably imposed by Tenant during any entry onto the Premises and shall minimize to the extent reasonably possible any interference with Tenant&#8217;s use of the Premises caused by such entry.  Notwithstanding Landlord&#8217;s rights of inspection and review of documents, materials and physical conditions under this Section with respect to Tenant&#8217;s Handling of Hazardous Materials, Landlord shall have no duty or obligation to perform any such inspection or review or to monitor in any way any documents, materials, physical conditions or compliance with Laws in connection with Tenant&#8217;s Handling of Hazardous Materials, and no third Party shall be entitled </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">00056263.8 &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">28</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to rely on Landlord to conduct any such inspection, review or monitoring by reason of the provisions of this Section.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(8)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Monitoring by Landlord</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Landlord reserves the right to monitor, in Landlord&#8217;s reasonable discretion and at Landlord&#8217;s cost, the reasonable cost of which shall be recoverable as an Operating Expense (except in the case of a breach of any of Tenant&#8217;s obligations under this Section, in which event such monitoring costs may be charged back entirely to Tenant and shall be reimbursed by Tenant to Landlord within ten (10) days after written demand by Landlord from time to time, accompanied by supporting documentation reasonably evidencing the costs for which such reimbursement is claimed), at such times and from time to time as Landlord in its reasonable discretion may determine, through consultants engaged by Landlord or otherwise as Landlord in its reasonable discretion may determine&#58; (x) all aqueous and atmospheric discharges and emissions from the Premises during the Term by a Tenant Party, (y) Tenant&#8217;s compliance and the collective compliance of all tenants in the Building with requirements and restrictions relating to the occupancy classification of the Building (including, but not limited to, Hazardous Materials inventory levels of Tenant and all other tenants in the Building), and (z) Tenant&#8217;s compliance with all other requirements of this Section.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(9)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Discovery of Discharge</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  If Landlord, Tenant or any governmental or quasi-governmental authority discovers any Release from the Premises during the Term by a Tenant Party in violation of this Section that, in Landlord&#8217;s reasonable determination, jeopardizes the ability of the Building or the Project to meet applicable Laws or otherwise adversely affects the Building&#8217;s or the Project&#8217;s compliance with applicable discharge or emission standards, or if Landlord discovers any other breach of Tenant&#8217;s obligations under this Section, then upon receipt of written notice from Landlord or at such earlier time as Tenant obtains actual knowledge of the applicable discharge, emission or breach, Tenant at its sole expense shall within a reasonable time (x) in the case of a Release in violation of this Lease, cease the applicable discharge or emission and remediate any continuing effects of the discharge or emission until such time, if any, as Tenant demonstrates to Landlord&#8217;s reasonable satisfaction that the applicable discharge or emission is in compliance with all applicable Laws and any other applicable regulatory commitments and obligations to the satisfaction of the appropriate governmental agency with jurisdiction over the Release, and (y) in the case of any other breach of Tenant&#8217;s obligations under this Section, take such corrective measures as Landlord may reasonably request in writing in order to cure or eliminate the breach as promptly as practicable and to remediate any continuing effects of the breach.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(10)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.02pt;text-decoration:underline">Post-Occupancy Study</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  No later than fifteen (15) days following the Termination Date, Tenant at its sole cost and expense, shall obtain and deliver to Landlord an environmental study, performed by an expert reasonably satisfactory to Landlord, evaluating, the presence or absence of any Tenant&#8217;s Contamination in, on and about the Premises and the Project.  Such study shall be based on a reasonable and prudent level of tests and investigations of the Premises and surrounding portions of the Project (if appropriate) which tests shall be conducted no earlier than fifteen (15) days prior to the Termination Date.  Liability for any remedial actions required or recommended on the basis of such study shall be allocated in accordance with the applicable provisions of this Lease.  To the extent any such remedial actions are the responsibility of Tenant, Tenant at its sole expense shall promptly commence and diligently pursue to completion the required remedial actions.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(11)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.02pt;text-decoration:underline">Emergency Response Plans</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  If Landlord in its reasonable discretion adopts any emergency response plan and&#47;or any Contingency Plan and Emergency Procedures for the Building (or for multiple buildings on the Project if and to the extent applicable) as contemplated above, Landlord shall provide copies of any such plans and procedures to Tenant and, so long as such plans and procedures are reasonable, Tenant shall comply with all of the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">00056263.8 &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">29</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">requirements of such plans and procedures to the extent applicable to Tenant and&#47;or the Premises.  If Landlord elects to adopt or materially modify any such plans or procedures that apply to the Building during the Term, Landlord shall consult with Tenant and Tenant shall cooperate, in the preparation of such plans, procedures or modifications in efforts to accurately reflect and maintain consistency with Tenant&#8217;s operations in the Premises, but Landlord alone shall determine, in its good faith reasonable discretion, the appropriate scope of such consultation and nothing in this Section shall be construed to give Tenant any right of approval or disapproval over Landlord&#8217;s adoption or modification of any such plans or procedures.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(12)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.02pt;text-decoration:underline">Radioactive Materials</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Without limiting any other applicable provisions of this Section, if Tenant Handles or proposes to Handle any Radioactive Materials in or about the Premises, Tenant shall provide Landlord with copies of Tenant&#8217;s licenses or permits for such Radioactive Materials and with copies of all radiation protection programs and procedures required under applicable Laws or otherwise adopted by Tenant from time to time in connection with Tenant&#8217;s Handling of such Radioactive Materials.  In addition, Tenant shall comply with any and all rules and procedures issued by Landlord in its good faith discretion from time to time with respect to the Handling of Radioactive Materials on the Project (such as, by way of example but not limitation, rules implementing a label defacement program for decayed waste destined for common trash and&#47;or rules relating to transportation and storage of Radioactive Materials on the Project), provided that such rules and procedures shall be reasonable and not in conflict with any applicable Laws.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(13)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.02pt;text-decoration:underline">Deemed Holdover Occupancy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Notwithstanding any other provisions of this Lease, Tenant expressly agrees as follows&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.69pt">If Tenant Handles any Radioactive Materials in or about the Premises or the Project during the Term, then for so long as any license or permit relating to such Radioactive Materials remains open or valid following the Termination Date, and another entity handling Radioactive Materials which is a prospective tenant of Landlord is legally prohibited from occupying a portion of the Premises for a use similar to Tenant&#8217;s use, then Tenant shall be deemed to be occupying that portion of the Premises on a holdover basis without Landlord&#8217;s consent (notwithstanding such otherwise applicable termination or expiration of the Term) and shall be required to continue to pay Rent and other charges in accordance with Article&#160;13 solely for that portion of the Premises effected by the radioactive materials license, until such time as all such Radioactive Materials licenses and permits have been fully closed out in accordance with the requirements of this Lease and with all applicable Hazardous Materials Laws and other Laws.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.36pt">If Tenant Handles any Hazardous Materials in or about the Premises or the Project during the Term and, on or before the Termination Date, has failed to remove from the Premises or the Project all known Hazardous Materials Handled by a Tenant Party or has failed to complete any remediation or removal of Tenant&#8217;s Contamination and&#47;or to have fully remediated in compliance with the requirements of this Lease and with all applicable Hazardous Materials Laws and any other applicable Laws, the Tenant&#8217;s Handling and&#47;or Release (if applicable) of any such Hazardous Materials during the Term, then for so long as such circumstances continue to exist, Tenant shall be deemed to be occupying the Premises on a holdover basis without Landlord&#8217;s consent (notwithstanding such otherwise applicable termination or expiration of the Term) and shall be required to continue to pay Rent and other charges in accordance with Article&#160;13 until such time as all such circumstances have been fully resolved in accordance with the requirements of this Lease and with all applicable Hazardous Materials Laws and other Laws.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(14)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.02pt;text-decoration:underline">Survival of Obligations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Each party&#8217;s obligations under this Section shall survive the Termination Date and shall survive any conveyance by Landlord of its interest in the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">00056263.8 &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">30</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Premises.  The provisions of this Section and any exercise by either party of any of the rights and remedies contained herein shall be without prejudice to any other rights and remedies that such party may have under this Lease or under applicable Law with respect to any Environmental Conditions and&#47;or any Hazardous Materials.  Either party&#8217;s exercise or failure to exercise, at any time or from time to time, any or all of the rights granted in this Section shall not in any way impose any liability on such party or shift from the other party to such party any responsibility or obligation imposed upon the other party under this Lease or under Hazardous Materials Laws, Environmental Conditions and&#47;or compliance with Laws.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(15)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.02pt;text-decoration:underline">Laboratory Rules and Regulations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Tenant agrees for itself and for its subtenants, employees, agents, and invitees to comply with the laboratory rules and regulations (&#8220;Laboratory Rules and Regulations&#8221;) attached to this Lease as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit C-1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> and with all reasonable modifications and additions thereto which Landlord may make from time to time.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">7.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">LANDLORD ACCESS TO PREMISES&#59; APPROVALS</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">Tenant shall permit Landlord to erect, use and maintain pipes, ducts, wiring and conduits in and through the Premises, so long as Tenant&#8217;s use, layout or design of the Premises is not materially affected or altered.  Landlord or Landlord&#8217;s agents shall have the right to enter upon the Premises in the event of an emergency, or to inspect the Premises, to perform any services required hereunder, to conduct safety and other testing in the Premises and to make such repairs, alterations, improvements or additions to the Premises or the Building or other parts of the Property as Landlord may deem necessary or desirable (including all alterations, improvements and additions in connection with a change in service provider or providers).  Any entry or work by Landlord may be during Standard Operating Hours and Landlord shall use reasonable efforts to ensure that any entry or work shall not materially interfere with Tenant&#8217;s occupancy of the Premises.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">Advance notice shall not be required for entry in the event of an emergency or urgent situation, as reasonably determined by Landlord, but any other entry or work by Landlord shall be upon at least one (1) business day&#8217;s prior notice to Tenant, which notice may be delivered orally or by e-mail to Tenant&#8217;s on-site manager at the Premises. If Tenant shall not be personally present to permit an entry into the Premises when for any reason an entry therein shall be necessary or permissible, Landlord (or Landlord&#8217;s agents), after attempting to notify Tenant (unless Landlord believes an emergency situation exists), may enter the Premises without rendering Landlord or its agents liable therefor, and without relieving Tenant of any obligations under this Lease.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">Landlord may enter the Premises for the purpose of conducting such inspections, tests and studies as Landlord may deem desirable or necessary to confirm Tenant&#8217;s compliance with all Laws and Hazardous Materials Laws or for other purposes necessary in Landlord&#8217;s reasonable judgment to ensure the sound condition of the Property and the systems serving the Property.  Landlord&#8217;s rights under this Section 7.2(c) are for Landlord&#8217;s own protection only, and Landlord has not, and shall not be deemed to have assumed, any responsibility to Tenant or any other party as a result of the exercise or non-exercise of such rights, for compliance with Laws or Hazardous Materials Laws or for the accuracy or sufficiency of any item or the quality or suitability of any item for its intended use.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">Landlord may do any of the foregoing, or undertake any of the inspection or work described in the preceding paragraphs without such action constituting an actual or constructive eviction of Tenant, in whole or in part, or giving rise to an abatement of Rent by reason of loss or interruption of business of Tenant, or otherwise.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">00056263.8 &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">31</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">The review, approval or consent of Landlord with respect to any item required or permitted under this Lease is for Landlord&#8217;s own protection only, and Landlord has not, and shall not be deemed to have assumed, any responsibility to Tenant or any other party, as a result of the exercise or non-exercise of such rights, for compliance with Laws or Hazardous Materials Laws or for the accuracy or sufficiency of any item or the quality or suitability of any item for its intended use.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">7.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">QUIET ENJOYMENT</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Landlord covenants, in lieu of any implied covenant of quiet possession or quiet enjoyment, that so long as Tenant is in compliance with the covenants and conditions set forth in this Lease, Tenant shall have the right to quiet enjoyment of the Premises without hindrance or interference from Landlord or those claiming through Landlord, and subject to the covenants and conditions set forth in this Lease and to the rights of any Mortgagee or ground lessor.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">7.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">TRANSPORTATION DEMAND MANAGEMENT PROGRAM</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">Landlord may elect or may be required to develop and implement a Transportation Demand Management (&#8220;TDM&#8221;) program for the Building in order to reduce the traffic-related impacts resulting from development of the Property.  One element of any such TDM program will require tenants of the Building to adopt programs and offer incentives to their employees to reduce auto use and support the increase of alternative modes of transit.  The following are examples of such programs and incentives&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">Alternative commute subsidies and&#47;or parking cash-out, where employees are provided with a subsidy if they use transit or commute by alternative modes&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">Opportunities to purchase commuter checks which allow employees to purchase transit tickets at discounted rates from their before-tax income&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(3)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">Compressed work weeks and flex time where employees adjust their work schedules to reduce peak hour trips to&#47;from the Building.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">In order to support any such TDM program for the Building, Tenant agrees that it shall adopt programs and offer incentives to its employees in order to reduce auto use and support the increase of alternative modes of transit.  The specifics of Tenant&#8217;s programs and incentives shall be tailored to the needs of Tenant&#8217;s workforce and shall be determined by Tenant in its good faith efforts to meet the goals of the TDM program.  Upon request by Landlord from time to time, but not more often than once per calendar year, Tenant shall provide to Landlord a written report summarizing the programs and incentives being offered by Tenant to achieve the goals of the TDM program.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Article 8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:29.72pt;text-decoration:underline"><br>MAINTENANCE</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">LANDLORD&#8217;S MAINTENANCE</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Subject to the provisions of Articles 4 and 14, Landlord shall, as an Operating Expense, maintain and make necessary repairs to the foundations, roofs, exterior walls, and the structural elements of the Building, the electrical, plumbing, heating, ventilating, air-conditioning, mechanical, communication, security and the fire and life safety systems of the Building and those corridors, washrooms and lobbies which are Common Areas of the Building, except that&#58;  (a) Landlord shall not be responsible for the maintenance or repair of any floor or wall coverings in the Premises or any of such systems which are located within the Premises and are </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">00056263.8 &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">32</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">supplemental or special to the Building&#8217;s standard systems&#59; and (b) the cost of performing any of said maintenance or repairs whether to the Premises or to the Building caused by the negligence of Tenant, its employees, agents, servants, licensees, subtenants, contractors or invitees, shall be paid by Tenant, subject to the waivers set forth in Section 16.4.  Landlord shall not be liable to Tenant for any expense, injury, loss or damage resulting from work done in or upon, or in connection with the use of, any adjacent or nearby building, land, street or alley.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">TENANT&#8217;S MAINTENANCE</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tenant shall periodically inspect the Premises to identify any conditions that are dangerous or in need of maintenance, repair or replacement.  Tenant shall promptly provide Landlord with notice of any such conditions. Tenant shall, at its sole cost and expense, perform all maintenance, repair and replacement of the Premises that are not Landlord&#8217;s express responsibility under this Lease, and keep the Premises in good condition and repair, reasonable wear and tear excepted.  Tenant&#8217;s maintenance, repair and replacement obligations include, without limitation, maintenance, repairs and replacements of&#58; (a)&#160;floor covering&#59; (b) interior partitions&#59; (c) doors&#59; (d) the interior side of demising walls&#59; (e)&#160;electronic, phone and data cabling, wiring and related equipment that is installed by or for the exclusive benefit of Tenant (collectively, &#8220;Cable&#8221;)&#59; (f) supplemental air conditioning units, kitchens, including hot water heaters, plumbing, and similar facilities exclusively serving Tenant&#59; and (g)&#160;Tenant Alterations. Landlord shall allocate one hundred percent (100%) of the cost (plus any applicable administration fees) of Landlord&#8217;s maintenance, repair or replacement of any Tenant Alterations, or repairs or replacements required to areas outside of the Premises due to same, to Tenant as additional Rent under this Lease. Tenant shall reimburse Landlord for the cost of repairing damage to the Building caused by the acts of Tenant, Tenant Parties and their respective contractors and vendors. All maintenance, repairs and replacements, including, but not limited to, janitorial and cleaning services, pest control and waste management and recycling performed by or on behalf of Landlord or Tenant must comply with the Project&#8217;s Sustainability Practices and Tenant is strongly encouraged to comply with the applicable Green Building Standards.  If Tenant fails to make any repairs or replacements of the Premises for more than fifteen (15) days after notice from Landlord (although notice shall not be required in an emergency), Landlord may make the repairs or replacements, and Tenant shall pay, as additional Rent under this Lease, the reasonable cost of the repairs or replacements, together with an administrative charge in an amount equal to 15% of the cost of the repairs or replacements. Tenant hereby waives all right to make repairs or replacements at the expense of Landlord or in lieu thereof to vacate the Premises and its other similar rights as provided in California Civil Code Sections 1932(1), 1941 and 1942 or any other Laws (whether now or hereafter in effect).  In addition to the foregoing, Tenant shall be responsible for all costs in connection with maintaining, repairing and replacing all special tenant fixtures and improvements, including garbage disposals, showers, plumbing, water filtration systems and appliances.  If Tenant requests that Landlord maintain, repair and&#47;or replace any such fixtures and improvements, Tenant shall reimburse Landlord for the cost of all such maintenance, repair and replacement work, plus an administrative fee equal to fifteen percent (15%) of such cost, as additional Rent under this Lease, and Landlord&#8217;s liability for such maintenance, repair and replacement work shall be subject to and limited by the provisions of Article 17 below.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">SUDDEN WATER INTRUSION</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Notwithstanding anything in this Lease to the contrary, in the event of sudden water intrusion into the Premises, due to a leaking or bursting pipe or other water source, Landlord will have the right, but not the obligation, to undertake immediate mitigation and repairs measures (the &#8220;Water Damage Work&#8221;) of such nature as would normally be Tenant&#8217;s responsibility under Section 8.2 above and to notify Tenant promptly after the repairs have been undertaken (including notice by telephone, to the extent reasonably practicable).  Landlord shall determine, </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">00056263.8 &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">33</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">in its sole and absolute discretion, the contractors to be used for the Water Damage Work, and Tenant will reimburse Landlord for the reasonable cost of the Water Damage Work, as additional Rent under this Lease, within 30 days following Tenant&#8217;s receipt of written demand from Landlord therefor.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Article 9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:29.72pt;text-decoration:underline"><br>ALTERATIONS AND IMPROVEMENTS</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">9.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">TENANT ALTERATIONS</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">The following provisions shall apply to the completion of any Tenant Alterations&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">Tenant shall not, except as provided herein, without the prior written consent of Landlord, which consent shall not be unreasonably withheld, make or cause to be made any Tenant Alterations in or to the Premises or any Property systems serving the Premises.  Prior to making any Tenant Alterations, Tenant shall give Landlord ten (10) days prior written notice (or such earlier notice as would be necessary pursuant to applicable Law) to permit Landlord sufficient time to post appropriate notices of non-responsibility. Tenant shall furnish Landlord with the names and addresses of all contractors and subcontractors and copies of all contracts.  All Tenant Alterations shall be completed at such time and in such manner as Landlord may from time to time designate, and only by contractors or mechanics approved by Landlord, which approval shall not be unreasonably withheld&#59; provided, however, that Landlord may, in its sole discretion, specify the engineers and contractors to perform all work relating to the Building&#8217;s systems (including the mechanical, heating, plumbing, security, ventilating, air-conditioning, electrical, communication and the fire and life safety systems in the Building).  The contractors, mechanics and engineers who may be used are further limited to those whose work will not cause or threaten to cause disharmony or interference with Landlord or other tenants in the Building and their respective agents and contractors performing work in or about the Building.  Landlord may further condition its consent upon Tenant furnishing to Landlord and Landlord approving prior to the commencement of any work or delivery of materials to the Premises related to the Tenant Alterations such of the following as specified by Landlord&#58;  architectural plans and specifications, opinions from Landlord&#8217;s engineers stating that the Tenant Alterations will not in any way adversely affect the Building&#8217;s systems, necessary permits and licenses, certificates of insurance, and such other documents in such form reasonably requested by Landlord.  Landlord may, in the exercise of reasonable judgment, request that Tenant provide Landlord with appropriate evidence of Tenant&#8217;s ability to complete and pay for the completion of the Tenant Alterations such as a performance bond or letter of credit.  Upon completion of the Tenant Alterations, Tenant shall deliver to Landlord an as-built digitized set of plans and specifications for the Tenant Alterations in both protected document (&#8220;.pdf&#8221;) and computer-aided design (&#8220;CAD&#8221;) formats.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">Tenant shall pay the cost of all Tenant Alterations and the cost of decorating the Premises and any work to the Property occasioned thereby.  Upon completion of Tenant Alterations, Tenant shall furnish Landlord with contractors&#8217; affidavits and full and final waivers of lien and receipted bills covering all labor and materials expended and used in connection therewith and such other documentation reasonably requested by Landlord or Mortgagee.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(3)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">Tenant agrees to complete all Tenant Alterations (i) in accordance with all Laws, Hazardous Materials Laws, all requirements of applicable insurance companies and in accordance with Landlord&#8217;s standard construction rules and regulations, (ii) in a good and workmanlike manner with the use of good grades of materials, and (iii) in accordance with the requirements of the Project&#8217;s Sustainability Practices and Tenant is strongly encouraged to comply with the applicable Green Building Standards.  Tenant shall notify Landlord immediately </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">00056263.8 &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">34</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">if Tenant receives any notice of violation of any Law in connection with completion of any Tenant Alterations and shall immediately take such steps as are necessary to remedy such violation.  In no event shall such supervision or right to supervise by Landlord nor shall any approvals given by Landlord under this Lease constitute any warranty by Landlord to Tenant of the adequacy of the design, workmanship or quality of such work or materials for Tenant&#8217;s intended use or of compliance with the requirements of Section 9.1(a)(3)(i) and (ii) above or impose any liability upon Landlord in connection with the performance of such work.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">For any Tenant Alterations which Tenant requests Landlord to install, the forgoing provisions of this Section 9.1 shall apply&#59; provided, however, in addition to paying the cost of the Tenant Alterations, Tenant also shall pay an administrative fee equal to fifteen percent (15%) of such cost to Landlord, as additional Rent under this Lease, and Landlord&#8217;s liability for such Tenant Alterations work shall be subject to and limited by the provisions of Article 17 below.  All Tenant Additions, whether installed by Landlord or Tenant, shall without compensation or credit to Tenant, become part of the Premises and the property of Landlord at the time of their installation and shall remain in the Premises, unless pursuant to Article 12, Tenant may remove them or is required to remove them at Landlord&#8217;s request.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">Notwithstanding anything in this Section 9.1 to the contrary, Landlord&#8217;s consent shall not be required for any Tenant Alteration that satisfies all of the following criteria (a &#8220;Cosmetic Alteration&#8221;)&#58; (i) is of a cosmetic nature such as painting, wallpapering, hanging pictures and installing carpeting&#59; (ii) is not visible from the exterior of the Premises or Building&#59; (iii) will not affect the Building&#8217;s systems&#59; (iv) does not require work to be performed inside the walls or above the ceiling of the Premises&#59; (v) does not require a building permit&#59; and (f) does not exceed (in the aggregate with all other such Cosmetic Alterations) $75,000.00 in any calendar year during the Term.  Cosmetic Alterations shall be subject to all the other provisions of this Section 9.1.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">9.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">LIENS</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tenant shall not permit any lien or claim for lien of any mechanic, laborer or supplier or any other lien to be filed against the Building, the Land, the Premises, or any other part of the Property arising out of work performed, or alleged to have been performed by, or at the direction of, or on behalf of Tenant.  If any such lien or claim for lien is filed, Tenant shall within ten (10) days after receiving notice of such lien or claim (a) have such lien or claim for lien released of record or (b) deliver to Landlord a bond in form, content, amount, and issued by surety, satisfactory to Landlord, indemnifying, protecting, defending and holding harmless the Indemnitees against all costs and liabilities resulting from such lien or claim for lien and the foreclosure or attempted foreclosure thereof.  If Tenant fails to take any of the above actions, Landlord, in addition to its rights and remedies under Article 11, without investigating the validity of such lien or claim for lien, may pay or discharge the same and Tenant shall, as payment of additional Rent hereunder, reimburse Landlord upon demand for the amount so paid by Landlord, including Landlord&#8217;s expenses and attorneys&#8217; fees.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Article 10</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:23.72pt;text-decoration:underline"><br>ASSIGNMENT AND SUBLETTING</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">10.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt;text-decoration:underline">ASSIGNMENT AND SUBLETTING</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">Without the prior written consent of Landlord, which consent of Landlord shall not be unreasonably withheld, conditioned or delayed, Tenant may not sublease, assign, mortgage, pledge, hypothecate or otherwise transfer or permit the transfer of this Lease or the encumbering of Tenant&#8217;s interest therein in whole or in part, by operation of Law or otherwise or permit the use or occupancy of the Premises, or any part thereof, by anyone other than Tenant.  </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">00056263.8 &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">35</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tenant agrees that the provisions governing sublease and assignment set forth in this Article&#160;10 shall be deemed to be reasonable.  If Tenant desires to enter into any sublease of the Premises or assignment of this Lease, Tenant shall deliver written notice thereof to Landlord (&#8220;Tenant&#8217;s Notice&#8221;), together with the identity of the proposed subtenant or assignee and the proposed principal terms thereof and financial and other information sufficient for Landlord to make an informed judgment with respect to such proposed subtenant or assignee within fifteen (15) days after receiving Tenant&#8217;s Notice.  If Tenant proposes to sublease less than all of the Rentable Area of the Premises, the space proposed to be sublet and the space retained by Tenant must each be a marketable unit as reasonably determined by Landlord and otherwise in compliance with all Laws.  Landlord shall notify Tenant in writing of its approval or disapproval of the proposed sublease or assignment or its decision to exercise its rights under Section 10.2 within thirty (30) days after receipt of Tenant&#8217;s Notice (and all required information).  In no event may Tenant publicly offer or advertise all or any portion of the Premises for assignment or sublease at a rental less than that then sought by Landlord for a direct lease (non-sublease) of comparable space in the Project.  Tenant shall submit for Landlord&#8217;s approval (which approval shall not be unreasonably withheld) any advertising which Tenant or its agents intend to use with respect to the space proposed to be sublet.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">With respect to Landlord&#8217;s consent to an assignment or sublease, Landlord may take into consideration any factors that Landlord may deem relevant, and the reasons for which Landlord&#8217;s denial shall be deemed to be reasonable shall include, without limitation, the following&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.69pt">the business reputation or creditworthiness of any proposed subtenant or assignee is not acceptable to Landlord&#59; or</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.36pt">in Landlord&#8217;s reasonable judgment the proposed assignee or sublessee would diminish the value or reputation of the Project or Landlord, or would increase the expenses associated with operating, maintaining and repairing the Project&#59; or</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.03pt">any proposed assignee&#8217;s or sublessee&#8217;s use of the Premises would violate Section 7.1 of this Lease or would violate the provisions of any other leases of tenants in the Project&#59; or</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.69pt">the portion of the Premises retained by Tenant after a proposed sublease would not constitute a &#8220;marketable unit&#8221;, meaning that such space would be&#58; (A) deprived of ready access to the then-current corridor and elevator lobby without extension or reconfiguration of the corridor or creation of a connecting corridor&#59; or (B) rendered in violation of any building code requirements&#59; or (C) lacking exterior windows&#59; or</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(v)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">the proposed sublessee or assignee is a current occupant of the Project with which Landlord is actively negotiating to lease more space in the Building or a bona fide prospective tenant of Landlord in the Project as demonstrated by a written proposal dated within three (3) months prior to the date of Tenant&#8217;s request&#59; or</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(vi)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.69pt">the proposed sublessee or assignee would materially increase the estimated pedestrian and vehicular traffic to and from the Premises and the Project above that deemed typical by Landlord for office&#47;lab use in the Project&#59; or</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(vii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15.36pt">Tenant is in uncured Default under this Lease.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">Any sublease or assignment shall be expressly subject to the terms and conditions of this Lease.  Any subtenant or assignee shall execute such documents as Landlord may reasonably require to evidence such subtenant or assignee&#8217;s assumption of the obligations and </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">00056263.8 &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">36</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">liabilities of Tenant under this Lease.  Tenant shall deliver to Landlord a copy of all agreements executed by Tenant and the proposed subtenant and assignee with respect to the Premises.  Landlord&#8217;s approval of a sublease, assignment, hypothecation, transfer or third party use or occupancy shall not constitute a waiver of Tenant&#8217;s obligation to obtain Landlord&#8217;s consent to further assignments or subleases, hypothecations, transfers or third party use or occupancy.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">For purposes of this Article 10, an assignment shall be deemed to include a change in the majority control of Tenant, resulting from any transfer, sale or assignment of shares of stock of Tenant occurring by operation of Law or otherwise if Tenant is a corporation whose shares of stock are not traded publicly.  If Tenant is a partnership, any change in the partners of Tenant shall be deemed to be an assignment.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">For purposes of this Lease, a &#8220;Permitted Transferee&#8221; shall mean any Person which&#58;  (i) is an Affiliate&#59; or (ii) is the corporation or other entity (the &#8220;Successor&#8221;) resulting from a merger, consolidation or non-bankruptcy reorganization with Tenant&#59; or (iii) is otherwise a deemed assignee due to a change of control under Section 10.1(d) above&#59; or (iv) purchases substantially all the assets of Tenant as a going concern (the &#8220;Purchaser&#8221;).  Notwithstanding anything to the contrary in Sections 10.1(a) and (b), 10.2 and 10.3, provided there is no uncured Default under this Lease, Tenant shall have the right, without the prior written consent of Landlord, to assign this Lease to a Permitted Transferee or to sublease the Premises or any part thereof to a Permitted Transferee provided that&#58;  (1) Landlord receives thirty (30) days&#8217; prior written notice of an assignment or sublease (including a proposed transaction described in subparts (i), (ii), (iii) or (iv) of this Section 10.1(e))&#59; (2) with respect to an assignment of this Lease or a sublease of more than half the Premises to an entity described in subparts (ii) or (iv)&#160;of this Section 10.1(e), the Permitted Transferee&#8217;s net worth and liquidity are each not less than the greater of (A) Tenant&#8217;s net worth and liquidity as of the date of this Lease or (B) Tenant&#8217;s net worth and liquidity immediately prior to such assignment or subletting&#59; (3) with respect to an assignment of this Lease or a sublease of more than half the Premises to an entity described in subparts (i) or (iii) of this Section 10.1(e), Tenant (as the assignor or sublandlord) continues in existence with a net worth and liquidity not less than the greater of (A) Tenant&#8217;s net worth and liquidity as of the date of this Lease or (B) Tenant&#8217;s net worth and liquidity immediately prior to such assignment or subletting&#59; (4) the Permitted Transferee expressly assumes (except a Permitted Transferee which is a deemed assignee under subpart (iii) of this Section 10.1(e) or which is a sublessee in the event of a sublease under this Section 10.1(e)) in writing reasonably satisfactory to Landlord all of the obligations of Tenant under this Lease and delivers such assumption to Landlord no later than fifteen (15) days prior to the effective date of the assignment&#59; (5) Landlord receives no later than five (5) days before the effective date a fully executed copy of the applicable assignment or sublease agreement between Tenant and the Permitted Transferee&#59; (6) promptly after Landlord&#8217;s written request, Tenant and the Permitted Transferee provide such reasonable documents and information which Landlord reasonably requests for the purpose of substantiating whether or not the assignment or sublease is to a Permitted Transferee&#59; and (7) such transfer is not being entered into for the purpose of avoiding the requirement for Landlord&#8217;s prior consent or the provisions of Sections 10.2 or 10.3.  All determinations of net worth and liquidity for purposes of this Subsection shall exclude any value attributable to goodwill or going concern value.  Provided that Tenant complies with the terms of this Section 10.1(e), the excess rent provisions of Section 10.3 shall not apply to any assignment or sublease pursuant hereto.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.03pt">With respect to any sublease hereunder, Tenant hereby irrevocably assigns to Landlord, effective upon any such sublease, all rent and other payments due from subtenant under the sublease, provided however, that Tenant shall have a license to collect such rent and other payments until the occurrence of a Default by Tenant under any of the provisions of this Lease.  At any time after such Default, at Landlord&#8217;s option, Landlord shall have the right to give notice to the subtenant of such assignment.  Landlord shall credit Tenant with any rent received </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">00056263.8 &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">37</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">by Landlord under such assignment but the acceptance of any payment on account of rent from the subtenant as the result of any such default shall in no manner whatsoever serve to release Tenant from any liability under the terms, covenants, conditions, provisions or agreement under this Lease.  No such payment of rent or any other payment by the subtenant directly to Landlord and&#47;or acceptance of such payment(s) by Landlord, regardless of the circumstances or reasons therefor, shall in any manner whatsoever be deemed an attornment by the subtenant to Landlord in the absence of a specific written agreement signed by Landlord to such an effect.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">10.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt;text-decoration:underline">RECAPTURE</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Excluding any assignment or sublease contemplated in Section 10.1(e), Landlord shall have the option to exclude from the Premises covered by this Lease (&#8220;recapture&#8221;) the space proposed to be sublet or subject to the assignment, effective as of the proposed commencement date of such sublease or assignment.  If Landlord elects to recapture, Tenant shall surrender possession of the space proposed to be subleased or subject to the assignment to Landlord on the effective date of recapture of such space from the Premises, such date being the Termination Date for such space.  Effective as of the date of recapture of any portion of the Premises pursuant to this section, the Monthly Base Rent, Rentable Area of the Premises and Tenant&#8217;s Share shall be adjusted accordingly.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">10.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt;text-decoration:underline">EXCESS RENT</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tenant shall pay Landlord on the first day of each month during the term of the sublease or assignment, as additional Rent under this Lease, fifty percent (50%) of the amount by which the sum of all rent and other consideration (direct or indirect) due from the subtenant or assignee for such month exceeds&#58;  (i)&#160;that portion of the Monthly Base Rent and Rent Adjustments due under this Lease for said month which is allocable to the space sublet or assigned&#59; and (ii) the following costs and expenses for the subletting or assignment of such space&#58; (1) brokerage commissions and attorneys&#8217; fees and expenses, (2) the actual costs paid in making any improvements or substitutions in the Premises required by any sublease or assignment&#59; and (3) moving costs and other amounts actually paid with respect of such subtenant&#8217;s or assignee&#8217;s other leases or occupancy arrangements, but only to the extent same are typical, reasonable and appropriate under the prevailing market conditions.  All such costs and expenses shall be amortized over the term of the sublease or assignment pursuant to sound accounting principles.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">10.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt;text-decoration:underline">TENANT LIABILITY</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">In the event of any sublease or assignment, whether or not with Landlord&#8217;s consent, Tenant shall not be released or discharged from any liability, whether past, present or future, under this Lease, including any liability arising from the exercise of any renewal or expansion option, to the extent such exercise is expressly permitted by Landlord.  Tenant&#8217;s liability shall remain primary, and in the event of default by any subtenant, assignee or successor of Tenant in performance or observance of any of the covenants or conditions of this Lease, Landlord may proceed directly against Tenant without the necessity of exhausting remedies against said subtenant, assignee or successor.  After any assignment, Landlord may consent to subsequent assignments or subletting of this Lease, or amendments or modifications of this Lease with assignees of Tenant, without notifying Tenant, or any successor of Tenant, and without obtaining its or their consent thereto, and such action shall not relieve Tenant or any successor of Tenant of liability under this Lease.  If Landlord grants consent to such sublease or assignment, Tenant shall pay all reasonable attorneys&#8217; fees and expenses incurred by Landlord with respect to such assignment or sublease.  In addition, if Tenant has any options to extend the Term or to add other space to the Premises, such options shall not be available to any subtenant or assignee, directly or indirectly without Landlord&#8217;s express written consent, which may be withheld in Landlord&#8217;s sole discretion.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">00056263.8 &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">38</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">10.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt;text-decoration:underline">ASSUMPTION AND ATTORNMENT</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">If Tenant shall assign this Lease as permitted herein, the assignee shall expressly assume all of the obligations of Tenant hereunder in a written instrument satisfactory to Landlord and furnished to Landlord not later than fifteen (15) days prior to the effective date of the assignment.  Each sublease by Tenant hereunder shall be subject and subordinate to this Lease and to the matters to which this Lease is or shall be subordinate, and each subtenant by entering into a sublease is deemed to have agreed that in the event of termination, re-entry or dispossession by Landlord under this Lease, Landlord may, at its option, either terminate the sublease or take over all of the right, title and interest of Tenant, as sublandlord, under such sublease, and such subtenant shall, at Landlord&#8217;s option, attorn to Landlord pursuant to the then executory provisions of such sublease, except that Landlord shall not be&#58; (1) liable for any previous act or omission of Tenant under such sublease&#59; (2) subject to any counterclaim, offset or defense that such subtenant might have against Tenant&#59; (3) bound by any previous modification of such sublease or by any rent or additional rent or advance rent which such subtenant might have paid for more than the current month to Tenant, and all such rent shall remain due and owing, notwithstanding such advance payment&#59; (4) bound by any security or advance rental deposit made by such subtenant which is not delivered or paid over to Landlord and with respect to which such subtenant shall look solely to Tenant for refund or reimbursement&#59; or (5) obligated to perform any work in the subleased space or to prepare it for occupancy, and in connection with such attornment, the subtenant shall execute and deliver to Landlord any instruments Landlord may reasonably request to evidence and confirm such attornment.  Each subtenant or licensee of Tenant shall be deemed, automatically upon and as a condition of its occupying or using the Premises or any part thereof, to have agreed to be bound by the terms and conditions set forth in this Section 10.5.  The provisions of this Section 10.5 shall be self-operative, and no further instrument shall be required to give effect to this provision.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">10.6</font><font style="color:#000000;font-family:'Times',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt;text-decoration:underline">PROCESSING EXPENSES</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tenant shall pay to Landlord, as Landlord&#8217;s cost of processing each proposed assignment or subletting (whether or not the same is ultimately approved by Landlord or consummated by Tenant), an amount equal to the sum of (i) Landlord&#8217;s reasonable attorneys&#8217; and other professional fees, plus (ii) the sum of $2,500.00 for the cost of Landlord&#8217;s administrative, accounting and clerical time (collectively, &#8220;Processing Costs&#8221;).  Notwithstanding anything to the contrary herein, Landlord shall not be required to process any request for Landlord&#8217;s consent to an assignment or subletting until Tenant has paid to Landlord the amount of Landlord&#8217;s estimate of the Processing Costs.  When the actual amount of the Processing Costs is determined, it shall be reconciled with Landlord&#8217;s estimate, and any payments or refunds required as a result thereof shall promptly thereafter be made by the parties.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times',sans-serif;font-size:12pt;font-weight:400;line-height:100%">10.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt;text-decoration:underline">EFFECT OF IMPERMISSIBLE TRANSFER</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Any assignment or sublease effected without Landlord&#8217;s consent in violation of this Article 10 shall, at Landlord&#8217;s option, be a noncurable Default under Section 11.1 without the necessity of any notice and grace period.  If Landlord elects to treat such unapproved assignment or sublease as a noncurable Default, Landlord may, in addition to all other remedies provided for in Section 11.2 below, increase the Monthly Base Rent to one hundred ten percent (110%) of the Monthly Base Rent then in effect.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Article 11</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:23.72pt;text-decoration:underline"><br>DEFAULT AND REMEDIES</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">11.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt;text-decoration:underline">DEFAULT</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">00056263.8 &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">39</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The occurrence or existence of any one or more of the following shall constitute a &#8220;Default&#8221; by Tenant under this Lease&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">Tenant fails to pay any installment or other payment of Rent including Rent Adjustment Deposits or Rent Adjustments within five (5) business days after the date when due&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">Tenant vacates or abandons the Premises&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">Tenant violates the restrictions on assignments and subleases set forth in Article 10 &#8211; Assignment and Subletting&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">Tenant fails to maintain any insurance policy required hereunder, and fails to cure such default within five (5) days after written notice thereof to Tenant&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">Tenant fails to observe or perform any of the other covenants, conditions or provisions of this Lease and fails to cure such default within fifteen (15) days after written notice thereof to Tenant, unless the default involves an Environmental Condition, which shall be cured forthwith or unless the failure to perform is a Default for which this Lease specifies there is no cure or grace period&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.03pt">the interest of Tenant in this Lease is levied upon under execution or other legal process&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">a petition is filed by or against Tenant to declare Tenant bankrupt or seeking a plan of reorganization or arrangement under any Chapter of the Bankruptcy Code, or any amendment, replacement or substitution therefor, or to delay payment of, reduce or modify Tenant&#8217;s debts, which in the case of an involuntary action is not discharged within thirty (30) days&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">Tenant is declared insolvent by Law or any assignment of Tenant&#8217;s property is made for the benefit of creditors&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.69pt">a receiver is appointed for Tenant or Tenant&#8217;s property, which appointment is not discharged within thirty (30) days&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(j)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.69pt">any action taken by or against Tenant to reorganize or modify Tenant&#8217;s capital structure in a materially adverse way which in the case of an involuntary action is not discharged within thirty (30) days&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(k)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">upon the dissolution of Tenant&#59; or</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(l)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.69pt">upon the third occurrence during any 12-month period during the Term that Tenant fails to pay Rent when due or has breached a particular covenant of this Lease (whether or not such failure or breach is thereafter cured within any stated cure or grace period or statutory period).</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">11.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt;text-decoration:underline">LANDLORD&#8217;S REMEDIES</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">A Default shall constitute a breach of this Lease for which Landlord shall have the rights and remedies set forth in this Section 11.2 and all other rights and remedies set forth in this Lease or now or hereafter allowed by Law, whether legal or equitable, and all rights and remedies of Landlord shall be cumulative and none shall exclude any other right or remedy now or hereafter allowed by applicable Law.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">00056263.8 &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">40</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">With respect to a Default, at any time Landlord may terminate Tenant&#8217;s right to possession by written notice to Tenant stating such election.  Any written notice required pursuant to Section 11.1 shall constitute notice of unlawful detainer pursuant to California Code of Civil Procedure Section 1161 if, at Landlord&#8217;s sole discretion, it states Landlord&#8217;s election that Tenant&#8217;s right to possession is terminated after expiration of any period required by Law or any longer period required by Section 11.1.  Upon the expiration of the period stated in Landlord&#8217;s written notice of termination (and unless such notice provides an option to cure within such period and Tenant cures the Default within such period), Tenant&#8217;s right to possession shall terminate and this Lease shall terminate, and Tenant shall remain liable as hereinafter provided.  Upon such termination in writing of Tenant&#8217;s right to possession, Landlord shall have the right, subject to applicable Law, to re-enter the Premises and dispossess Tenant and the legal representatives of Tenant and all other occupants of the Premises by unlawful detainer or other summary proceedings, or as otherwise permitted by Law, regain possession of the Premises and remove their property (including their trade fixtures, personal property and Required Removables pursuant to Article 12), but Landlord shall not be obligated to effect such removal, and such property may, at Landlord&#8217;s option, be stored elsewhere, sold or otherwise dealt with as permitted by Law, at the risk of, expense of and for the account of Tenant, and the proceeds of any sale shall be applied pursuant to Law.  Landlord shall in no event be responsible for the value, preservation or safekeeping of any such property.  Tenant hereby waives all claims for damages that may be caused by Landlord&#8217;s removing or storing Tenant&#8217;s personal property pursuant to this Section or Section 12.1, and Tenant hereby indemnifies, and agrees to defend, protect and hold harmless, the Indemnitees from any and all loss, claims, demands, actions, expenses, liability and cost (including attorneys&#8217; fees and expenses) arising out of or in any way related to such removal or storage.  Upon such written termination of Tenant&#8217;s right to possession and this Lease, Landlord shall have the right to recover damages for Tenant&#8217;s Default as provided herein or by Law, including the following damages provided by California Civil Code Section 1951.2&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">the worth at the time of award of the unpaid Rent which had been earned at the time of termination&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">the worth at the time of award of the amount by which the unpaid Rent which would have been earned after termination until the time of award exceeds the amount of such Rent loss that Tenant proves could reasonably have been avoided&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(3)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">the worth at the time of award of the amount by which the unpaid Rent for the balance of the term of this Lease after the time of award exceeds the amount of such Rent loss that Tenant proves could be reasonably avoided&#59; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(4)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">any other amount necessary to compensate Landlord for all the detriment proximately caused by Tenant&#8217;s failure to perform its obligations under this Lease or which in the ordinary course of things would be likely to result therefrom, including, without limitation, Landlord&#8217;s unamortized costs of tenant improvements, leasing commissions and legal fees incurred in connection with entering into this Lease&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(5)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">any other amounts, in addition to or in lieu of those listed above, that may be permitted by applicable Law.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The word &#8220;rent&#8221; as used in this Section&#160;11.2 shall have the same meaning as the defined term Rent in this Lease.  The &#8220;worth at the time of award&#8221; of the amount referred to in clauses (1) and (2) above is computed by allowing interest at the Default Rate.  The worth at the time of award of the amount referred to in clause (3) above is computed by discounting such amount at the discount rate of the Federal Reserve Bank of San Francisco at the time of award plus one percent (1%).  For the purpose of determining unpaid Rent under clause (3) above, the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">00056263.8 &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">41</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">monthly Rent reserved in this Lease shall be deemed to be the sum of the Monthly Base Rent, monthly storage space rent, if any, the amounts last payable by Tenant as Rent Adjustments for the calendar year in which Landlord terminated this Lease as provided hereinabove, and any additional Rent under this Lease.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">Even if Tenant is in Default and&#47;or has abandoned the Premises, this Lease shall continue in effect for so long as Landlord does not terminate Tenant&#8217;s right to possession by written notice as provided in Section 11.2(b) above, and Landlord may enforce all its rights and remedies under this Lease, including the right to recover Rent as it becomes due under this Lease.  In such event, Landlord shall have all of the rights and remedies of a landlord under California Civil Code Section 1951.4 (lessor may continue Lease in effect after lessee&#8217;s breach and abandonment and recover Rent as it becomes due, if lessee has the right to sublet or assign, subject only to reasonable limitations), or any successor statute.  During such time as Tenant is in Default, if Landlord has not terminated this Lease by written notice and if Tenant requests Landlord&#8217;s consent to an assignment of this Lease or a sublease of the Premises, such consent shall be governed by the terms and conditions of Article 10 above.  Tenant acknowledges and agrees that the provisions of Article 10 shall be deemed to constitute reasonable limitations of Tenant&#8217;s right to assign or sublet.  Tenant acknowledges and agrees that in the absence of written notice pursuant to Section 11.2(b) above terminating Tenant&#8217;s right to possession, no other act of Landlord shall constitute a termination of Tenant&#8217;s right to possession or an acceptance of Tenant&#8217;s surrender of the Premises, including acts of maintenance or preservation or efforts to relet the Premises or the appointment of a receiver upon initiative of Landlord to protect Landlord&#8217;s interest under this Lease or the withholding of consent to a subletting or assignment, or terminating a subletting or assignment, if in accordance with other provisions of this Lease.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">In the event that Landlord seeks an injunction with respect to a breach or threatened breach by Tenant of any of the covenants, conditions or provisions of this Lease, Tenant agrees to pay the premium for any bond required in connection with such injunction.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">Tenant hereby waives any and all rights to relief from forfeiture, redemption or reinstatement granted by Law (including California Civil Code of Procedure Sections 1174 and 1179) in the event of Tenant being evicted or dispossessed for any cause or in the event of Landlord obtaining possession of the Premises by reason of Tenant&#8217;s Default or otherwise.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.03pt">Notwithstanding any other provision of this Lease, a notice to Tenant given under this Article and Article 24 of this Lease or given pursuant to California Code of Civil Procedure Section 1161, and any notice served by mail, shall be deemed served, and the requisite waiting period deemed to begin under said Code of Civil Procedure Section upon mailing (except as may be required under Code of Civil Procedure Section 1161 et seq.), without any additional waiting requirement under Code of Civil Procedure Section 1011 et seq. or by other Law.  For purposes of Code of Civil Procedure Section 1162, Tenant&#8217;s &#8220;place of residence&#8221;, &#8220;usual place of business&#8221;, &#8220;the property&#8221; and &#8220;the place where the property is situated&#8221; shall mean and be the Premises, whether or not Tenant has vacated same at the time of service.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">The voluntary or other surrender or termination of this Lease, or a mutual termination or cancellation thereof, shall not work a merger and shall terminate all or any existing assignments, subleases, subtenancies or occupancies permitted by Tenant, except if and as otherwise specified in writing by Landlord.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">No delay or omission in the exercise of any right or remedy of Landlord upon any default by Tenant, and no exercise by Landlord of its rights pursuant to Section 25.16 to perform any duty which Tenant fails timely to perform, shall impair any right or remedy or be construed as a waiver.  No provision of this Lease shall be deemed waived by Landlord unless such waiver is in writing signed by Landlord.  The waiver by Landlord of any breach of any provision of this </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">00056263.8 &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">42</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Lease shall not be deemed a waiver of any subsequent breach of the same or any other provision of this Lease.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">11.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt;text-decoration:underline">ATTORNEY&#8217;S FEES</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">In the event any party brings any suit or other proceeding with respect to the subject matter or enforcement of this Lease, the prevailing party (as determined by the court, agency or other authority before which such suit or proceeding is commenced) shall, in addition to such other relief as may be awarded, be entitled to recover attorneys&#8217; fees, expenses and costs of investigation as actually incurred, including court costs, expert witness fees, costs and expenses of investigation, and all attorneys&#8217; fees, costs and expenses in any such suit or proceeding (including in any action or participation in or in connection with any case or proceeding under the Bankruptcy Code, 11 United States Code Sections 101 et seq. (the &#8220;Bankruptcy Code&#8221;), or any successor statutes, in establishing or enforcing the right to indemnification, in appellate proceedings, or in connection with the enforcement or collection of any judgment obtained in any such suit or proceeding).</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">11.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt;text-decoration:underline">BANKRUPTCY</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The following provisions shall apply in the event of the bankruptcy or insolvency of Tenant&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">In connection with any proceeding under Chapter 7 of the Bankruptcy Code where the trustee of Tenant elects to assume this Lease for the purposes of assigning it, such election or assignment, may only be made upon compliance with the provisions of (b) and (c) below, which conditions Landlord and Tenant acknowledge to be commercially reasonable.  In the event the trustee elects to reject this Lease, then Landlord shall immediately be entitled to possession of the Premises without further obligation to Tenant or the trustee.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">Any election to assume this Lease under Chapter 11 or 13 of the Bankruptcy Code by Tenant as debtor-in-possession or by Tenant&#8217;s trustee (the &#8220;Electing Party&#8221;) must provide for&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Electing Party to cure or provide to Landlord adequate assurance that it will cure all monetary defaults under this Lease within fifteen (15) days from the date of assumption, and that it will cure all nonmonetary defaults under this Lease within thirty (30) days from the date of assumption.  Landlord and Tenant acknowledge such condition to be commercially reasonable.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">If the Electing Party has assumed this Lease or elects to assign Tenant&#8217;s interest under this Lease to any other person, such interest may be assigned only if the intended assignee has provided adequate assurance of future performance (as herein defined), of all of the obligations imposed on Tenant under this Lease.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">For the purposes hereof, &#8220;adequate assurance of future performance&#8221; means that Landlord has ascertained that each of the following conditions has been satisfied&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.69pt">The assignee has submitted a current financial statement, certified by its chief financial officer, which shows a net worth and working capital in amounts sufficient to assure the future performance by the assignee of Tenant&#8217;s obligations under this Lease&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.36pt">Landlord has obtained consents or waivers from any third parties that may be required under a lease, mortgage, financing arrangement, or other agreement by which Landlord is bound, to enable Landlord to permit such assignment. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">00056263.8 &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">43</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">Landlord&#8217;s acceptance of rent or any other payment from any trustee, receiver, assignee, person, or other entity will not be deemed to have waived, or waive, the requirement of Landlord&#8217;s consent, Landlord&#8217;s right to terminate this Lease for any transfer of Tenant&#8217;s interest under this Lease without such consent, or Landlord&#8217;s claim for any amount of Rent due from Tenant.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">11.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt;text-decoration:underline">LANDLORD&#8217;S DEFAULT</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Landlord shall be in default hereunder in the event Landlord has not commenced and pursued with reasonable diligence the cure of any failure of Landlord to meet its obligations hereunder within thirty (30) days after the receipt by Landlord of written notice from Tenant of the alleged failure to perform.  Failure to provide the requisite notice and cure period by Tenant under this paragraph shall be an absolute defense by Landlord against any claims for failure to perform any of its obligations.  In no event shall Tenant have the right to terminate or rescind this Lease as a result of Landlord&#8217;s default as to any covenant or agreement contained in this Lease. Tenant hereby waives such remedies of termination and rescission and hereby agrees that Tenant&#8217;s remedies for default hereunder and for breach of any promise or inducement shall be limited to a suit for damages and&#47;or injunction. In addition, Tenant hereby covenants that, prior to the exercise of any such remedies, it will give any Mortgagee notice and a reasonable time to cure any default by Landlord (as specified in Section 23.2 below).</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Article 12</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:23.72pt;text-decoration:underline"><br>SURRENDER OF PREMISES</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">12.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt;text-decoration:underline">IN GENERAL</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Upon the Termination Date, Tenant shall surrender and vacate the Premises immediately and deliver possession thereof to Landlord in a clean, good and tenantable condition, ordinary wear and tear excepted, and any damage from casualty and condemnation, and damage caused by Landlord, shall be governed by the provisions of this Lease dealing specifically therewith.  Tenant shall deliver to Landlord all keys to the Premises.  All improvements in and to the Premises, including any Tenant Alterations (collectively, &#8220;Leasehold Improvements&#8221;) shall remain upon the Premises at the end of the Term without compensation to Tenant.  Landlord, however, by written notice to Tenant at least 30 days prior to the Termination Date, may require Tenant, at its expense, to remove (a) any Cable, and (b) any Tenant Additions that, in Landlord&#8217;s reasonable judgment, are of a nature that would require removal and repair costs that are materially in excess of the removal and repair costs associated with standard laboratory and office improvements (collectively referred to as &#8220;Required Removables&#8221;).  Required Removables may include, without limitation, internal stairways, raised floors, personal baths and showers, vaults, rolling file systems and structural alterations and modifications. The designated Required Removables shall be removed by Tenant before the Termination Date. Tenant&#8217;s removal and disposal of items pursuant to this Section 12.1 must comply with the Project&#8217;s Sustainability Practices and Tenant is strongly encouraged to comply with the applicable Green Building Standards.  Tenant shall repair damage caused by the installation or removal of Required Removables.  If Tenant fails to perform its obligations in a timely manner, Landlord may perform such work at Tenant&#8217;s expense. In the event possession of the Premises is not delivered to Landlord when required hereunder, or if Tenant shall fail to remove those items described above, Landlord may (but shall not be obligated to), at Tenant&#8217;s expense, remove any of such property and store, sell or otherwise deal with such property, and undertake, at Tenant&#8217;s expense, such restoration work as Landlord deems necessary or advisable.  Notwithstanding anything in this Section 12.1 to the contrary, failure by Tenant to strictly comply with the provisions of this Section 12.1 with respect to any Required Removables that are required to be removed from the Premises by Tenant hereunder shall constitute a failure of Tenant to validly surrender the Premises.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">00056263.8 &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">44</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">12.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt;text-decoration:underline">LANDLORD&#8217;S RIGHTS</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">All property which may be removed from the Premises by Landlord shall be conclusively presumed to have been abandoned by Tenant and Landlord may deal with such property as provided in Section 11.2(b), including the waiver and indemnity obligations provided in that Section.  Tenant shall also reimburse Landlord for all costs and expenses incurred by Landlord in removing any Tenant Additions and in restoring the Premises to the condition required by this Lease.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Article 13</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:23.72pt;text-decoration:underline"><br>HOLDING OVER</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">In the event that Tenant holds over in possession of the Premises after the Termination Date, for each month or partial month Tenant holds over possession of the Premises, Tenant shall pay Landlord 150% of the monthly Rent payable for the month immediately preceding the holding over (including 100% of any applicable Rent Adjustments or increases to Rent Adjustments which Landlord may reasonably estimate).  Tenant shall also pay all damages, including consequential damages, sustained by Landlord by reason of such holding over.  The provisions of this Article shall not constitute a waiver by Landlord of any re-entry rights of Landlord, and Tenant&#8217;s continued occupancy of the Premises shall be as a tenancy in sufferance.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Article 14</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:23.72pt;text-decoration:underline"><br>DAMAGE BY FIRE OR OTHER CASUALTY</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">14.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt;text-decoration:underline">SUBSTANTIAL UNTENANTABILITY</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">If any fire or other casualty (whether insured or uninsured) renders all or a substantial portion of the Premises or the Building untenantable, Landlord shall, with reasonable promptness after the occurrence of such damage, estimate the length of time that will be required to substantially complete the repair and restoration and shall, by notice advise Tenant of such estimate (&#8220;Landlord&#8217;s Notice&#8221;).  If Landlord estimates that the amount of time required to substantially complete such repair and restoration will exceed three hundred sixty-five (365) days from the date such damage occurred, then Landlord, or Tenant if all or a substantial portion of the Premises is rendered untenantable, shall have the right to terminate this Lease as of the date of such damage by delivering written notice to the other at any time within twenty (20) days after delivery of Landlord&#8217;s Notice, provided that if Landlord so chooses, Landlord&#8217;s Notice may also constitute such notice of termination.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">Unless this Lease is terminated as provided in the preceding subparagraph, Landlord shall proceed with reasonable promptness to repair and restore the Premises to its condition as existed prior to such casualty, subject to reasonable delays for insurance adjustments and Force Majeure delays, and also subject to zoning Laws and building codes then in effect.  Landlord shall have no liability to Tenant, and Tenant shall not be entitled to terminate this Lease if such repairs and restoration are not in fact completed within the time period estimated by Landlord so long as Landlord shall proceed with reasonable diligence to complete such repairs and restoration.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">Tenant acknowledges that Landlord shall be entitled to the full proceeds of any insurance coverage, whether carried by Landlord or Tenant, for damages to the Premises, except for those proceeds of Tenant&#8217;s insurance for its own personal property and equipment which would be removable by Tenant at the Termination Date.  All such insurance proceeds shall be payable to Landlord whether or not the Premises are to be repaired and restored&#59; provided, however, if this Lease is not terminated and the parties proceed to repair and restore Tenant Additions at Tenant&#8217;s cost, to the extent Landlord received proceeds of Tenant&#8217;s insurance </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">00056263.8 &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">45</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">covering Tenant Additions, such proceeds shall be applied to reimburse Tenant for its cost of repairing and restoring Tenant Additions.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">Notwithstanding anything to the contrary herein set forth&#58;  (i) Landlord shall have no duty pursuant to this Section to repair or restore any portion of any Tenant Additions or to expend for any repair or restoration of the Premises or Building in amounts in excess of insurance proceeds paid to Landlord and available for repair or restoration&#59; and (ii) Tenant shall not have the right to terminate this Lease pursuant to this Section if any damage or destruction was caused by the act or neglect of Tenant, its agent or employees.  Whether or not this Lease is terminated pursuant to this Article 14, in no event shall Tenant be entitled to any compensation or damages for loss of the use of the whole or any part of the Premises or for any inconvenience or annoyance occasioned by any such damage, destruction, rebuilding or restoration of the Premises or the Building or access thereto.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">Any repair or restoration of the Premises performed by Tenant shall be in accordance with the provisions of Article 9 hereof.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">14.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt;text-decoration:underline">INSUBSTANTIAL UNTENANTABILITY</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">If the Premises or the Building is damaged by a casualty but neither is rendered substantially untenantable and Landlord estimates that the time to substantially complete the repair or restoration will not exceed three hundred sixty-five (365) days from the date such damage occurred, then Landlord shall proceed to repair and restore the Building or the Premises other than Tenant Additions, with reasonable promptness, unless such damage is to the Premises and occurs during the last six (6) months of the Term, in which event either Tenant or Landlord shall have the right to terminate this Lease as of the date of such casualty by giving written notice thereof to the other within twenty (20) days after the date of such casualty.  Notwithstanding the aforesaid, Landlord&#8217;s obligation to repair shall be limited in accordance with the provisions of Section 14.1 above.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">14.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt;text-decoration:underline">RENT ABATEMENT</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Except for the negligence or willful act of Tenant or its agents, employees, contractors or invitees, if all or any part of the Premises are rendered untenantable by fire or other casualty and this Lease is not terminated, Monthly Base Rent and Rent Adjustments shall abate for that part of the Premises which is untenantable on a per diem basis from the date of the casualty until Landlord has Substantially Completed the repair and restoration work in the Premises which it is required to perform, provided, that as a result of such casualty, Tenant does not occupy the portion of the Premises which is untenantable during such period.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">14.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt;text-decoration:underline">WAIVER OF STATUTORY REMEDIES</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The provisions of this Lease, including this Article 14, constitute an express agreement between Landlord and Tenant with respect to any and all damage to, or destruction of, the Premises or the Property or any part of either, and any Law, including Sections 1932(2), 1933(4), 1941 and 1942 of the California Civil Code, with respect to any rights or obligations concerning damage or destruction shall have no application to this Lease or to any damage to or destruction of all or any part of the Premises or the Property or any part of either, and are hereby waived.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Article 15</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:23.72pt;text-decoration:underline"><br>EMINENT DOMAIN</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">15.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt;text-decoration:underline">TAKING OF WHOLE OR SUBSTANTIAL PART</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">00056263.8 &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">46</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">In the event the whole or any substantial part of the Building or of the Premises is taken or condemned by any competent authority for any public use or purpose (including a deed given in lieu of condemnation) and is thereby rendered untenantable, this Lease shall terminate as of the date title vests in such authority, and Monthly Base Rent and Rent Adjustments shall be apportioned as of the Termination Date.  Notwithstanding anything to the contrary herein set forth, in the event the taking is temporary (for less than the remaining Term of this Lease), Landlord may elect either (i) to terminate this Lease or (ii) permit Tenant to receive the entire award attributable to the Premises in which case Tenant shall continue to pay Rent and this Lease shall not terminate.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">15.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt;text-decoration:underline">TAKING OF PART</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">In the event a part of the Building or the Premises is taken or condemned by any competent authority (or a deed is delivered in lieu of condemnation) and this Lease is not terminated, this Lease shall be amended to reduce or increase, as the case may be, the Monthly Base Rent and Tenant&#8217;s Share to reflect the Rentable Area of the Premises or Building, as the case may be, remaining after any such taking or condemnation.  Landlord, upon receipt and to the extent of the award in condemnation (or proceeds of sale) shall make necessary repairs and restorations to the Premises (exclusive of Tenant Additions) and to the Building to the extent necessary to constitute the portion of the Building not so taken or condemned as a complete architectural and economically efficient unit.  Notwithstanding the foregoing, if as a result of any taking, or a governmental order that the grade of any street or alley adjacent to the Building is to be changed and such taking or change of grade makes it necessary or desirable to substantially remodel or restore the Building or prevents the economical operation of the Building, Landlord shall have the right to terminate this Lease upon ninety (90) days prior written notice to Tenant.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">15.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt;text-decoration:underline">COMPENSATION</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Landlord shall be entitled to receive the entire award (or sale proceeds) from any such taking, condemnation or sale without any payment to Tenant, and Tenant hereby assigns to Landlord, Tenant&#8217;s interest, if any, in such award&#59; provided, however, Tenant shall have the right separately to pursue against the condemning authority a separate award in respect of the loss, if any, to Tenant Additions paid for by Tenant without any credit or allowance from Landlord so long as there is no diminution of Landlord&#8217;s award as a result.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Article 16</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:23.72pt;text-decoration:underline"><br>INSURANCE</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">16.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt;text-decoration:underline">TENANT&#8217;S INSURANCE</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tenant, at Tenant&#8217;s expense, agrees to maintain in force, with a company or companies acceptable to Landlord, during the Term&#58; (a) Commercial General Liability Insurance on a primary basis and without any right of contribution from any insurance carried by Landlord covering the Premises on an occurrence basis against all claims for personal injury, bodily injury, death and property damage, including contractual liability covering the indemnification provisions in this Lease, and such insurance shall be for such limits that are reasonably required by Landlord from time to time but not less than a combined single limit (each occurrence and in the aggregate) of Five Million and No&#47;100 Dollars ($5,000,000.00) (which limit may be achieved through use of umbrella coverage)&#59; (b) Workers&#8217; Compensation and Employers&#8217; Liability Insurance to the extent required by and in accordance with the Laws of the State of California&#59; (c) &#8220;All Risks&#8221; property insurance in an amount adequate to cover the full replacement cost of all Tenant Additions, equipment, installations, fixtures and contents of the Premises in the event of loss from water damage, earthquake sprinkler leakage, and such other risks as Landlord may designate from time to time&#59; (d) in the event a motor vehicle is to be used by Tenant in </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">00056263.8 &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">47</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">connection with its business operation from the Premises, Comprehensive Automobile Liability Insurance coverage with limits of not less than One Million and No&#47;100 Dollars ($1,000,000.00) combined single limit coverage against bodily injury liability and property damage liability arising out of the use by or on behalf of Tenant, its agents and employees in connection with this Lease, of any owned, non-owned or hired motor vehicles&#59; and (e) such other insurance or coverages as Landlord reasonably requires.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">16.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt;text-decoration:underline">FORM OF POLICIES</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Each policy referred to in Section&#160;16.1 shall satisfy the following requirements&#58; (i) the Commercial General Liability policy shall name Landlord and the Indemnitees as additional insureds, (ii) the &#8220;All-Risks&#8221; property insurance policy shall name Landlord and the Indemnitees as loss payees, (iii) each policy shall be issued by one or more responsible insurance companies licensed to do business in the State of California reasonably satisfactory to Landlord, (iv) where applicable, each policy shall provide for deductible amounts satisfactory to Landlord and not permit co-insurance, and (v) each policy of &#8220;All-Risks&#8221; property insurance shall provide that the policy shall not be invalidated should the insured waive in writing prior to a loss, any or all rights of recovery against any other party for losses covered by such policies.  Tenant shall deliver to Landlord, certificates of insurance (and at Landlord&#8217;s request, copies of all policies and renewals thereof to be maintained by Tenant hereunder), prior to Tenant&#8217;s entry into the Premises and prior to the expiration date of each policy.  Additionally, Tenant shall provide Landlord written notice of any cancellation or amendment of any such insurance within two (2) business days following Tenant&#8217;s knowledge of the same.  If Tenant fails to carry the insurance required under this Article&#160;16 or fails to provide certificates of renewal as and when required hereunder, Landlord may, but shall not be obligated to acquire such insurance on Tenant&#8217;s behalf or Tenant&#8217;s sole cost and expense.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">16.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt;text-decoration:underline">LANDLORD&#8217;S INSURANCE</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Landlord agrees to purchase and keep in full force and effect during the Term hereof, including any extensions or renewals thereof, insurance under policies issued by insurers of recognized responsibility, qualified to do business in the State of California on the Building in amounts sufficient to cover 80% of the replacement cost thereof, insuring against fire and such other risks as may be included in standard forms of all risk coverage insurance reasonably available from time to time (which requirement may be achieved through use of a single insurance policy covering multiple buildings owned by Landlord and affiliates of Landlord).  Landlord agrees to maintain in force during the Term, Commercial General Liability Insurance covering the Building on an occurrence basis against all claims for personal injury, bodily injury, death, and property damage.  Such insurance shall be for a combined single limit (each occurrence and in the aggregate) of not less than Five Million and No&#47;100 Dollars ($5,000,000.00) (which limit may be achieved through use of umbrella coverage).  Neither Landlord&#8217;s obligation to carry such insurance nor the carrying of such insurance shall be deemed to be an indemnity by Landlord with respect to any claim, liability, loss, cost or expense due, in whole or in part, to Tenant&#8217;s negligent acts or omissions or willful misconduct.  Without obligation to do so, Landlord may, in its sole discretion from time to time, carry insurance in amounts greater and&#47;or for coverage additional to the coverage and amounts set forth above.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">16.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt;text-decoration:underline">WAIVER OF SUBROGATION</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">Landlord agrees that, if obtainable at no, or minimal, additional cost, and so long as the same is permitted under the laws of the State of California, it will include in its &#8220;All Risks&#8221; policies appropriate clauses pursuant to which the insurance companies (i) waive all right of subrogation against Tenant with respect to losses payable under such policies and&#47;or (ii) agree </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">00056263.8 &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">48</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">that such policies shall not be invalidated should the insured waive in writing prior to a loss any or all right of recovery against any party for losses covered by such policies.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">Tenant agrees to include, if obtainable at no, or minimal, additional cost, and so long as the same is permitted under the laws of the State of California, in its &#8220;All Risks&#8221; insurance policy or policies on Tenant Additions, whether or not removable, and on Tenant&#8217;s furniture, furnishings, fixtures and other property removable by Tenant under the provisions of this Lease, appropriate clauses pursuant to which the insurance company or companies (i) waive the right of subrogation against Landlord and&#47;or any tenant of space in the Building with respect to losses payable under such policy or policies and&#47;or (ii) agree that such policy or policies shall not be invalidated should the insured waive in writing prior to a loss any or all right of recovery against any party for losses covered by such policy or policies.  If Tenant is unable to obtain in such policy or policies either of the clauses described in the preceding sentence, Tenant shall, if legally possible and without necessitating a change in insurance carriers, have Landlord named in such policy or policies as an additional insured.  If Landlord shall be named as an additional insured in accordance with the foregoing, Landlord agrees to endorse promptly to the order of Tenant, without recourse, any check, draft, or order for the payment of money representing the proceeds of any such policy or representing any other payment growing out of or connected with said policies, and Landlord does hereby irrevocably waive any and all rights in and to such proceeds and payments.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">Provided that Landlord&#8217;s right of full recovery under its policy or policies aforesaid is not adversely affected or prejudiced thereby, Landlord hereby waives any and all right of recovery which it might otherwise have against Tenant, its servants, agents and employees, for loss or damage occurring to the Real Property and the fixtures, appurtenances and equipment therein, to the extent the same is covered by Landlord&#8217;s insurance, notwithstanding that such loss or damage may result from the negligence or fault of Tenant, its servants, agents or employees.  Provided that Tenant&#8217;s right of full recovery under its aforesaid policy or policies is not adversely affected or prejudiced thereby, Tenant hereby waives any and all right of recovery which it might otherwise have against Landlord, its servants, and employees and against every other tenant of the Real Property who shall have executed a similar waiver as set forth in this Section 16.4(c) for loss or damage to Tenant Additions, whether or not removable, and to Tenant&#8217;s furniture, furnishings, fixtures and other property removable by Tenant under the provisions hereof to the extent the same is coverable by Tenant&#8217;s insurance required under this Lease, notwithstanding that such loss or damage may result from the negligence or fault of Landlord, its servants, agents or employees, or such other tenant and the servants, agents or employees thereof.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">Landlord and Tenant hereby agree to advise the other promptly if the clauses to be included in their respective insurance policies pursuant to subparagraphs (a) and (b) above cannot be obtained on the terms hereinbefore provided.  Landlord and Tenant hereby also agree to notify the other promptly of any cancellation or change of the terms of any such policy that would affect such clauses.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">16.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt;text-decoration:underline">NOTICE OF CASUALTY</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tenant shall give Landlord notice in case of a fire or accident in the Premises promptly after Tenant is aware of such event.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Article 17</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:23.72pt;text-decoration:underline"><br>WAIVER OF CLAIMS AND INDEMNITY</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">17.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt;text-decoration:underline">WAIVER OF CLAIMS</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">00056263.8 &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">49</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">To the extent permitted by Law, Tenant hereby releases the Indemnitees from, and waives all claims for, damage to person or property sustained by Tenant or any occupant of the Premises or the Property resulting directly or indirectly from any existing or future condition, defect, matter or thing in and about the Premises or the Property or any part of either or any equipment or appurtenance therein, or resulting from any accident in or about the Premises or the Property, or resulting directly or indirectly from any act or neglect of any tenant or occupant of the Property or of any other person, including Landlord&#8217;s agents and servants, except to the extent caused by the gross negligence or willful and wrongful act of any of the Indemnitees.  To the extent permitted by Law, Tenant hereby waives any consequential damages, compensation or claims for inconvenience or loss of business, rents, or profits as a result of such injury or damage, whether or not caused by the gross negligence or willful and wrongful act of any of the Indemnitees.  If any such damage, whether to the Premises or the Property or any part of either, or whether to Landlord or to other tenants in the Property, results from any act or neglect of Tenant, its employees, servants, agents, contractors, invitees or customers, Tenant shall be liable therefor and Landlord may, at Landlord&#8217;s option, repair such damage and Tenant shall, upon demand by Landlord, as payment of additional Rent hereunder, reimburse Landlord within ten (10) days after demand for the total cost of such repairs, in excess of amounts, if any, paid to Landlord under insurance covering such damages.  Tenant shall not be liable for any such damage caused by its acts or neglect if Landlord or a tenant has recovered the full amount of the damage from proceeds of insurance policies and the insurance company has waived its right of subrogation against Tenant.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">17.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt;text-decoration:underline">INDEMNITY</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">To the extent permitted by Law, Tenant hereby indemnifies, and agrees to protect, defend and hold the Indemnitees harmless, against any and all actions, claims, demands, liability, costs and expenses, including attorneys&#8217; fees and expenses for the defense thereof, arising from Tenant&#8217;s occupancy of the Premises, from the undertaking of any Tenant Additions or repairs to the Premises, from the conduct of Tenant&#8217;s business on the Premises, or from any breach or default on the part of Tenant in the performance of any covenant or agreement on the part of Tenant to be performed pursuant to the terms of this Lease, or from any willful act or negligence of Tenant, its agents, contractors, servants, employees, customers or invitees, in or about the Premises or the Property or any part of either.  In case of any action or proceeding brought against the Indemnitees by reason of any such claim, upon notice from Landlord, Tenant covenants to defend such action or proceeding by counsel chosen by Landlord, in Landlord&#8217;s sole discretion.  Landlord reserves the right to settle, compromise or dispose of any and all actions, claims and demands related to the foregoing indemnity.  The foregoing indemnity shall not operate to relieve Indemnitees of liability to the extent such liability is caused by the willful and wrongful act of Indemnitees.  Further, the foregoing indemnity is subject to and shall not diminish any waivers in effect in accordance with Section 16.4 by Landlord or its insurers to the extent of amounts, if any, paid to Landlord under its &#8220;All Risks&#8221; property insurance.  This Article&#160;17 shall survive the expiration or earlier termination of this Lease.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">17.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt;text-decoration:underline">WAIVER OF CONSEQUENTIAL DAMAGES</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">To the extent permitted by law, Tenant hereby waives and releases the Indemnitees from any consequential damages, compensation or claims for inconvenience or loss of business, rents or profits as a result of any injury or damage, whether or not caused by the willful and wrongful act of any of the Indemnitees.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Article 18</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:23.72pt;text-decoration:underline"><br>RULES AND REGULATIONS</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">18.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt;text-decoration:underline">RULES</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">00056263.8 &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">50</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tenant agrees for itself and for its subtenants, employees, agents, and invitees to comply with the rules and regulations listed on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit C-2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> attached hereto and with all reasonable modifications and additions thereto which Landlord may make from time to time.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">18.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt;text-decoration:underline">ENFORCEMENT</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Nothing in this Lease shall be construed to impose upon Landlord any duty or obligation to enforce the rules and regulations as set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit C-2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> or as hereafter adopted, or the terms, covenants or conditions of any other lease as against any other tenant, and Landlord shall not be liable to Tenant for violation of the same by any other tenant, its servants, employees, agents, visitors or licensees.  Landlord shall use reasonable efforts to enforce the rules and regulations of the Project in a uniform and non-discriminatory manner.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Article 19</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:23.72pt;text-decoration:underline"><br>LANDLORD&#8217;S RESERVED RIGHTS</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Landlord shall have the following rights exercisable without notice to Tenant and without liability to Tenant for damage or injury to persons, property or business and without being deemed an eviction or disturbance of Tenant&#8217;s use or possession of the Premises or giving rise to any claim for offset or abatement of Rent&#58;  (1) to change the Building&#8217;s name or street address upon thirty (30) days&#8217; prior written notice to Tenant&#59; (2) to install, affix and maintain all signs on the exterior and&#47;or interior of the Building&#59; (3) to designate and&#47;or approve prior to installation, all types of signs, window shades, blinds, drapes, awnings or other similar items, and all internal lighting that may be visible from the exterior of the Premises&#59; (4) upon reasonable notice to Tenant, to display the Premises to prospective purchasers and lenders at reasonable hours at any time during the Term and to prospective tenants at reasonable hours during the last twelve (12) months of the Term&#59; (5) to grant to any party the exclusive right to conduct any business or render any service in or to the Building, provided such exclusive right shall not operate to prohibit Tenant from using the Premises for the purpose permitted hereunder&#59; (6) to change the arrangement and&#47;or location of entrances or passageways, doors and doorways, corridors, elevators, stairs, washrooms or public portions of the Building, and to close entrances, doors, corridors, elevators or other facilities, provided that such action shall not materially and adversely interfere with Tenant&#8217;s access to the Premises or the Building&#59; (7) to have access for Landlord and other tenants of the Building to any mail chutes and boxes located in or on the Premises as required by any applicable rules of the United States Post Office&#59; and (8) to close the Building after Standard Operating Hours, except that Tenant and its employees and invitees shall be entitled to admission at all times, under such regulations as Landlord prescribes for security purposes.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Article 20</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:23.72pt;text-decoration:underline"><br>ESTOPPEL CERTIFICATE</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">20.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt;text-decoration:underline">IN GENERAL</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Within ten (10) days after request therefor by Landlord, Mortgagee or any prospective mortgagee or owner, Tenant agrees as directed in such request to execute the proposed form of estoppel certificate (an &#8220;Estoppel Certificate&#8221;) (which may require that such instrument be notarized), binding upon Tenant, certifying (i) that this Lease is unmodified and in full force and effect (or if there have been modifications, a description of such modifications and that this Lease as modified is in full force and effect)&#59; (ii) the dates to which Rent has been paid&#59; (iii)&#160;that Tenant is in the possession of the Premises if that is the case&#59; (iv) that Landlord is not in default under this Lease, or, if Tenant believes Landlord is in default, the nature thereof in detail&#59; (v) that Tenant has no offsets or defenses to the performance of its obligations under this Lease (or if Tenant believes there are any offsets or defenses, a full and complete explanation thereof)&#59; (vi) </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">00056263.8 &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">51</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">that the Premises have been completed in accordance with the terms and provisions hereof or the Workletter, that Tenant has accepted the Premises and the condition thereof and of all improvements thereto and has no claims against Landlord or any other party with respect thereto&#59; (vii) that if an assignment of rents or leases has been served upon Tenant by a Mortgagee, Tenant will acknowledge receipt thereof and agree to be bound by the provisions thereof&#59; (viii)&#160;that Tenant will give to the Mortgagee copies of all notices required or permitted to be given by Tenant to Landlord&#59; and (ix) to any other information reasonably requested.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">20.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt;text-decoration:underline">ENFORCEMENT</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">In the event that Tenant fails to timely deliver an Estoppel Certificate, then such failure shall be a Default for which there shall be no cure or grace period.  In addition to any other remedy available to Landlord, Landlord may impose a charge equal to $500.00 for each day that Tenant fails to deliver an Estoppel Certificate&#59; and (i) Tenant shall be bound to, and deemed to have irrevocably agreed to, the accuracy and truthfulness of the Estoppel Certificate delivered to Tenant, and (ii) Landlord, and any third party receiving such form of Estoppel Certificate, including a Mortgagee or purchaser, may rely upon the accuracy and truthfulness thereof.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Article 21</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:23.72pt;text-decoration:underline"><br>RELOCATION OF TENANT</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;Intentionally omitted.&#93;</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Article 22</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:23.72pt;text-decoration:underline"><br>REAL ESTATE BROKERS</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tenant represents that, except for the broker(s) listed in Section 1.1, Tenant has not dealt with any real estate broker, sales person, or finder in connection with this Lease, and no such person initiated or participated in the negotiation of this Lease, or showed the Premises to Tenant.  Tenant hereby agrees to indemnify, protect, defend and hold Landlord and the Indemnitees, harmless from and against any and all liabilities and claims for commissions and fees arising out of a breach of the foregoing representation, as well as from any claim or claims for any commission or fee by any broker or other party claiming to represent Tenant in connection with any future extensions or renewals of the Term.  Landlord agrees to pay any commission to which the brokers listed in Section 1.1 are entitled in connection with this Lease pursuant to Landlord&#8217;s written agreement with such broker.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Article 23</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:23.72pt;text-decoration:underline"><br>MORTGAGEE PROTECTION</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">23.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt;text-decoration:underline">SUBORDINATION AND ATTORNMENT</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This Lease is and shall be expressly subject and subordinate at all times to (i) any ground or underlying lease of the Real Property, now or hereafter existing, and all amendments, extensions, renewals and modifications to any such lease, and (ii) the lien of any mortgage or trust deed now or hereafter encumbering fee title to the Real Property and&#47;or the leasehold estate under any such lease, and all amendments, extensions, renewals, replacements and modifications of such mortgage or trust deed and&#47;or the obligation secured thereby, unless such ground lease or ground lessor, or mortgage, trust deed or Mortgagee, expressly provides or elects that this Lease shall be superior to such lease or mortgage or trust deed.  If any such mortgage or trust deed is foreclosed (including any sale of the Real Property pursuant to a power of sale), or if any such lease is terminated, upon request of the Mortgagee or ground lessor, as the case may be, Tenant shall attorn to the purchaser at the foreclosure sale or to the ground lessor under such lease, as the case may be, provided, however, that such purchaser or ground lessor shall not be (i) bound by </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">00056263.8 &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">52</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">any payment of Rent for more than one month in advance except payments in the nature of security for the performance by Tenant of its obligations under this Lease&#59; (ii) subject to any offset, defense or damages arising out of a default of any obligations of any preceding Landlord&#59; or (iii) bound by any amendment or modification of this Lease made without the written consent of the Mortgagee or ground lessor&#59; or (iv) liable for any security deposits not actually received in cash by such purchaser or ground lessor.  This subordination shall be self-operative and no further certificate or instrument of subordination need be required by any such Mortgagee or ground lessor.  In confirmation of such subordination, however, Tenant shall execute promptly any reasonable certificate or instrument that Landlord, Mortgagee or ground lessor may request.  Tenant hereby constitutes Landlord as Tenant&#8217;s attorney-in-fact to execute such certificate or instrument for and on behalf of Tenant upon Tenant&#8217;s failure to do so within fifteen (15) days after a request to do so.  Upon request by such successor in interest, Tenant shall execute and deliver reasonable instruments confirming the attornment provided for herein.  The terms of this paragraph shall survive any termination of this Lease by reason of foreclosure.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">23.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt;text-decoration:underline">MORTGAGEE PROTECTION</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tenant agrees to give any Mortgagee or ground lessor, by registered or certified mail, a copy of any notice of default served upon Landlord by Tenant, provided that prior to such notice Tenant has received notice (by way of service on Tenant of a copy of an assignment of rents and leases, or otherwise) of the address of such Mortgagee or ground lessor.  Tenant further agrees that if Landlord shall have failed to cure such default within the time provided for in this Lease, then the Mortgagee or ground lessor shall have an additional thirty (30) days after receipt of notice thereof within which to cure such default or if such default cannot be cured within that time, then such additional notice time as may be necessary, if, within such thirty (30) days, any Mortgagee or ground lessor has commenced and is diligently pursuing the remedies necessary to cure such default (including commencement of foreclosure proceedings or other proceedings to acquire possession of the Real Property, if necessary to effect such cure).  Such period of time shall be extended by any period within which such Mortgagee or ground lessor is prevented from commencing or pursuing such foreclosure proceedings or other proceedings to acquire possession of the Real Property by reason of Landlord&#8217;s bankruptcy.  Until the time allowed as aforesaid for Mortgagee or ground lessor to cure such defaults has expired without cure, Tenant shall have no right to, and shall not, terminate this Lease on account of default.  This Lease may not be modified or amended so as to reduce the Rent or shorten the Term, or so as to adversely affect in any other respect to any material extent the rights of Landlord, nor shall this Lease be canceled or surrendered, without the prior written consent, in each instance, of the ground lessor or the Mortgagee.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Article 24</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:23.72pt;text-decoration:underline"><br>NOTICES</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">All notices, demands or requests provided for or permitted to be given pursuant to this Lease must be in writing and shall be personally delivered, sent by Federal Express or other reputable overnight courier service, or mailed by first class, registered or certified United States mail, return receipt requested, postage prepaid.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">All notices, demands or requests to be sent pursuant to this Lease shall be deemed to have been properly given or served by delivering or sending the same in accordance with this Section, addressed to the parties hereto at their respective addresses listed in Section 1.1.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">Notices, demands or requests sent by mail or overnight courier service as described above shall be effective upon deposit in the mail or with such courier service.  However, except with respect to a notice given under Code of Civil Procedure Section 1161 et seq., the time period in which a response to any such notice, demand or request must be given </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">00056263.8 &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">53</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall commence to run from (i) in the case of delivery by mail, the date of receipt on the return receipt of the notice, demand or request by the addressee thereof, or (ii) in the case of delivery by Federal Express or other overnight courier service, the date of acceptance of delivery by an employee, officer, director or partner of Landlord or Tenant.  Rejection or other refusal to accept or the inability to deliver because of changed address of which no notice was given, as indicated by advice from Federal Express or other overnight courier service or by mail return receipt, shall be deemed to be receipt of notice, demand or request sent.  Notices may also be served by personal service upon any officer, director or partner of Landlord or Tenant, and shall be effective upon such service.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">By giving to the other party at least thirty (30) days written notice thereof, either party shall have the right from time to time during the term of this Lease to change their respective addresses for notices, statements, demands and requests, provided such new address shall be within the United States of America.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Article 25</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:23.72pt;text-decoration:underline"><br>FURNITURE, FIXTURES AND EQUIPMENT</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">During the Term, at no charge to Tenant, Tenant shall be permitted to use the existing office and laboratory furniture, fixtures and equipment located in the Phase I or Phase II Premises (as applicable) as of the Phase I or Phase II Commencement Date (as applicable), and as described in more particular detail in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit E</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> attached hereto (the &#8220;FF&#38;E&#8221;).  Tenant shall accept the FF&#38;E in its current &#8220;AS-IS&#8221; condition and &#8220;WITH ALL FAULTS&#8221;.  Landlord specifically disclaims all express or implied warranties regarding the existence or condition of, such FF&#38;E, including without limitation the implied warranties of merchantability and suitability for a particular purpose.  For purposes of documenting the current condition of the FF&#38;E, Tenant and Landlord shall, prior to the Phase I Commencement Date, as to the Phase I Premises, and prior to the Phase II Commencement Date, as to the Phase II Premises, conduct a joint walk-through of the Premises in order to inventory items of damage or disrepair in the FF&#38;E.  No item of the FF&#38;E shall be removed from the Premises without Landlord&#8217;s prior written consent&#59; provided, however, not more than once during the Term, Tenant may request in writing that Landlord remove certain portions of the original FF&#38;E, upon which removal the remaining FF&#38;E shall be considered the &#8220;FF&#38;E&#8221; under this Lease.  Landlord and Tenant may enter into a reasonable form of letter agreement or other documentation evidencing such remaining FF&#38;E.  In addition, not withstanding anything herein to the contrary, Tenant may elect, via a written notice delivered to Landlord not later than sixty (60) days following the Phase II Commencement Date, to offer to purchase all or a portion of the remaining FF&#38;E (the &#8220;Proposed Purchased FF&#38;E&#8221;), and if Landlord and Tenant agree upon the price for such Proposed Purchased FF&#38;E, then following any such purchase, any portion of the Proposed Purchased FF&#38;E that is actually purchased by Tenant shall be referred to in this Article 25 as the &#8220;Purchased FF&#38;E&#8221;, and Tenant will have no remaining obligations to Landlord to manage, repair or replace any portion of the Purchased FF&#38;E.  Upon such agreement, the parties shall enter into a commercially reasonable bill of sale for such Purchased FF&#38;E, and Landlord shall assign, transfer and convey to Tenant all of Landlord&#8217;s right, title and interest in and to the Purchased FF&#38;E on an &#8220;as is, where is&#8221; basis.  Landlord represents and warrants that it has the legal right and ownership to the FF&#38;E and has the legal ability to transfer the ownership thereof to Tenant.  Tenant shall use the FF&#38;E only for the purposes for which such FF&#38;E is intended and, subject to the terms of this Article 25 with respect to Purchased FF&#38;E, if Tenant does not elect to purchase all of the FF&#38;E pursuant to this Article 25, then Tenant shall be responsible for the proper maintenance, care and repair of the remaining unpurchased FF&#38;E (the &#8220;Unpurchased FF&#38;E&#8221;), at Tenant&#8217;s sole cost and expense.  On or about the date of expiration of the Term, provided that Tenant did not exercise its right to acquire all of the FF&#38;E, the parties shall once again conduct a walk-through of the Premises to catalog any items of damage, disrepair, misuse or loss among the Unpurchased FF&#38;E (reasonable wear and tear excepted), and Tenant shall be </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">00056263.8 &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">54</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">responsible, at Tenant&#8217;s sole cost and expense, for curing any such items (including, with respect to loss, replacing any lost item with a substantially similar new item reasonably acceptable to Landlord).  If Tenant does not elect to purchase all of the FF&#38;E pursuant to this Article 25, then Tenant shall not modify, reconfigure or relocate any of the Unpurchased FF&#38;E except with the advanced written permission of Landlord, and any work of modifying any of the Unpurchased FF&#38;E (including, without limitation, changing the configuration of, &#8220;breaking down&#8221; or reassembly of cubicles or other modular furniture, if any) shall be performed at Tenant&#8217;s sole cost using Landlord&#8217;s specified vendors or an alternate vendor approved in writing by Landlord (such approval to be granted or withheld on Landlord&#8217;s good faith discretion, based upon Landlord&#8217;s assessment of factors which include, without limitation, whether the performance by such vendor will void applicable warranties for such furniture and whether such vendor is sufficiently experienced in the design of such furniture).  If Tenant does elect to purchase any of the FF&#38;E, then Tenant shall remove the Purchased FF&#38;E upon the expiration or earlier termination of the Term in accordance with Article 12 above.  Notwithstanding anything herein to the contrary, in no event shall Tenant have any duty or obligation to replace any Unpurchased FF&#38;E that does not have a useful life extending beyond the Term.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Article 26</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:23.72pt;text-decoration:underline"><br>MISCELLANEOUS</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">26.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt;text-decoration:underline">LATE CHARGES</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">All payments required hereunder (other than the Monthly Base Rent, Rent Adjustments, and Rent Adjustment Deposits, which shall be due as hereinbefore provided) to Landlord shall be paid within ten (10) business days after Landlord&#8217;s demand therefor.  All such amounts (including Monthly Base Rent, Rent Adjustments, and Rent Adjustment Deposits) not paid when due shall bear interest from the date due until the date paid at the Default Rate in effect on the date such payment was due.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">In the event Tenant is more than five (5) business days late in paying any installment of Rent due under this Lease, Tenant shall pay Landlord a late charge equal to five percent (5%) of the delinquent installment of Rent.  The parties agree that (i) such delinquency will cause Landlord to incur costs and expenses not contemplated herein, the exact amount of which will be difficult to calculate, including the cost and expense that will be incurred by Landlord in processing each delinquent payment of rent by Tenant, (ii) the amount of such late charge represents a reasonable estimate of such costs and expenses and that such late charge shall be paid to Landlord for each delinquent payment in addition to all Rent otherwise due hereunder.  The parties further agree that the payment of late charges and the payment of interest provided for in subparagraph (a) above are distinct and separate from one another in that the payment of interest is to compensate Landlord for its inability to use the money improperly withheld by Tenant, while the payment of late charges is to compensate Landlord for its additional administrative expenses in handling and processing delinquent payments.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">Payment of interest at the Default Rate and&#47;or of late charges shall not excuse or cure any default by Tenant under this Lease, nor shall the foregoing provisions of this Article or any such payments prevent Landlord from exercising any right or remedy available to Landlord upon Tenant&#8217;s failure to pay Rent when due, including the right to terminate this Lease.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">26.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt;text-decoration:underline">NO JURY TRIAL&#59; VENUE&#59; JURISDICTION</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">To the fullest extent permitted by Laws, each party hereto (which includes any assignee, successor, heir or personal representative of a party) shall not seek a jury trial, hereby waives trial by jury, and hereby further waives any objection to venue in the County in which the Project is located, and agrees and consents to personal jurisdiction of the courts of the State of </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">00056263.8 &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">55</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">California, in any action or proceeding or counterclaim brought by any party hereto against the other on any matter whatsoever arising out of or in any way connected with this Lease, the relationship of Landlord and Tenant, Tenant&#8217;s use or occupancy of the Premises, or any claim of injury or damage, or the enforcement of any remedy under any statute, emergency or otherwise, whether any of the foregoing is based on this Lease or on tort law.  No party will seek to consolidate any such action in which a jury has been waived with any other action in which a jury trial cannot or has not been waived.  It is the intention of the parties that these provisions shall be subject to no exceptions.  The provisions of this Section shall survive the expiration or earlier termination of this Lease.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">26.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt;text-decoration:underline">NO DISCRIMINATION</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tenant agrees for Tenant and Tenant&#8217;s heirs, executors, administrators, successors and assigns and all persons claiming under or through Tenant, and this Lease is made and accepted upon and subject to the following conditions&#58;  that there shall be no discrimination against or segregation of any person or group of persons on account of race, color, creed, religion, sex, marital status, national origin or ancestry (whether in the leasing, subleasing, transferring, use, occupancy, tenure or enjoyment of the Premises or otherwise) nor shall Tenant or any person claiming under or through Tenant establish or permit any such practice or practices of discrimination or segregation with reference to the use or occupancy of the Premises by Tenant or any person claiming through or under Tenant.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">26.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt;text-decoration:underline">FINANCIAL STATEMENTS</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Within ten (10) days after written request from Landlord from time to time during the Term, Tenant shall provide Landlord with current financial statements setting forth Tenant&#8217;s financial condition and net worth for the most recent quarter, including balance sheets and statements of profits and losses.  Such statements shall be prepared by an independent accountant and certified by Tenant&#8217;s president, chief executive officer or chief financial officer.  Landlord shall keep such financial information confidential and shall only disclose such information to Landlord&#8217;s lenders, consultants, purchasers or investors, or other agents (who shall be subject to the same confidentiality obligations) on a need to know basis in connection with the administration of this Lease.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">26.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt;text-decoration:underline">OPTION</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This Lease shall not become effective as a lease or otherwise until executed and delivered by both Landlord and Tenant. The submission of this Lease to Tenant does not constitute a reservation of or option for the Premises, but when executed by Tenant and delivered to Landlord, this Lease shall constitute an irrevocable offer by Tenant in effect for fifteen (15) days to lease the Premises on the terms and conditions herein contained. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">26.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt;text-decoration:underline">TENANT AUTHORITY</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tenant represents and warrants to Landlord that it has full authority and power to enter into and perform its obligations under this Lease, that the person executing this Lease is fully empowered to do so, and that no consent or authorization is necessary from any third party.  Landlord may request that Tenant provide Landlord evidence of Tenant&#8217;s authority.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">26.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt;text-decoration:underline">ENTIRE AGREEMENT</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This Lease, the Exhibits, and Riders attached hereto contain the entire agreement between Landlord and Tenant concerning the Premises and there are no other agreements, either oral or </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">00056263.8 &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">56</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">written, and no other representations or statements, either oral or written, on which Tenant has relied.  This Lease shall not be modified except by a writing executed by Landlord and Tenant.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">26.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt;text-decoration:underline">MODIFICATION OF LEASE FOR BENEFIT OF MORTGAGEE</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">If Mortgagee of Landlord requires a modification of this Lease which shall not result in any increased cost or expense to Tenant or in any other substantial and adverse change in the rights and obligations of Tenant hereunder, then Tenant agrees that this Lease may be so modified.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">26.9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt;text-decoration:underline">EXCULPATION</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tenant agrees, on its behalf and on behalf of its successors and assigns, that any liability or obligation under this Lease shall only be enforced against Landlord&#8217;s equity interest in the Property up to a maximum of Five Million Dollars ($5,000,000.00) and in no event against any other assets of Landlord, or Landlord&#8217;s members, officers, directors or partners, and that any liability of Landlord with respect to this Lease shall be so limited and Tenant shall not be entitled to any judgment in excess of such amount.  Notwithstanding anything to the contrary contained herein, in no event shall Landlord be liable to Tenant for consequential, punitive or special damages with respect to this Lease.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">26.10</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9pt;text-decoration:underline">ACCORD AND SATISFACTION</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">No payment by Tenant or receipt by Landlord of a lesser amount than any installment or payment of Rent due shall be deemed to be other than on account of the amount due, and no endorsement or statement on any check or any letter accompanying any check or payment of Rent shall be deemed an accord and satisfaction, and Landlord may accept such check or payment without prejudice to Landlord&#8217;s right to recover the balance of such installment or payment of Rent or pursue any other remedies available to Landlord.  No receipt of money by Landlord from Tenant after the termination of this Lease or Tenant&#8217;s right of possession of the Premises shall reinstate, continue or extend the Term.  Receipt or acceptance of payment from anyone other than Tenant, including an assignee of Tenant, is not a waiver of any breach of Article 10, and Landlord may accept such payment on account of the amount due without prejudice to Landlord&#8217;s right to pursue any remedies available to Landlord.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">26.11</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9pt;text-decoration:underline">LANDLORD&#8217;S OBLIGATIONS ON SALE OF BUILDING</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">In the event of any sale or other transfer of the Building, Landlord shall be entirely freed and relieved of all agreements and obligations of Landlord hereunder accruing or to be performed after the date of such sale or transfer, and any remaining liability of Landlord with respect to this Lease shall be limited to the dollar amount specified in Section 25.9 and Tenant shall not be entitled to any judgment in excess of such amount. Landlord shall have the right to assign this Lease to an entity comprised of the principals of Landlord or any Landlord Affiliate. Upon such assignment and assumption of the obligations of Landlord hereunder, Landlord shall be entirely freed and relieved of all obligations hereunder.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">26.12</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9pt;text-decoration:underline">BINDING EFFECT</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Subject to the provisions of Article 10, this Lease shall be binding upon and inure to the benefit of Landlord and Tenant and their respective heirs, legal representatives, successors and permitted assigns.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">26.13</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9pt;text-decoration:underline">CAPTIONS</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">00056263.8 &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">57</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Article and Section captions in this Lease are inserted only as a matter of convenience and in no way define, limit, construe, or describe the scope or intent of such Articles and Sections.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">26.14</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9pt;text-decoration:underline">TIME&#59; APPLICABLE LAW&#59; CONSTRUCTION</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Time is of the essence of this Lease and each and all of its provisions.  This Lease shall be construed in accordance with the Laws of the State of California.  If more than one person signs this Lease as Tenant, the obligations hereunder imposed shall be joint and several.  If any term, covenant or condition of this Lease or the application thereof to any person or circumstance shall, to any extent, be invalid or unenforceable, the remainder of this Lease, or the application of such term, covenant or condition to persons or circumstances other than those as to which it is held invalid or unenforceable, shall not be affected thereby and each item, covenant or condition of this Lease shall be valid and be enforced to the fullest extent permitted by Law.  Wherever the term &#8220;including&#8221; or &#8220;includes&#8221; is used in this Lease, it shall have the same meaning as if followed by the phrase &#8220;but not limited to&#8221;.  The language in all parts of this Lease shall be construed according to its normal and usual meaning and not strictly for or against either Landlord or Tenant.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">26.15</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9pt;text-decoration:underline">ABANDONMENT</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">In the event Tenant vacates or abandons the Premises but is otherwise in compliance with all the terms, covenants and conditions of this Lease, Landlord shall (i) have the right to enter into the Premises in order to show the space to prospective tenants, (ii) have the right to reduce the services provided to Tenant pursuant to the terms of this Lease to such levels as Landlord reasonably determines to be adequate services for an unoccupied premises, and (iii) during the last six (6) months of the Term, have the right to prepare the Premises for occupancy by another tenant upon the end of the Term.  Tenant expressly acknowledges that in the absence of written notice pursuant to Section 11.2(b) or pursuant to California Civil Code Section 1951.3 terminating Tenant&#8217;s right to possession, none of the foregoing acts of Landlord or any other act of Landlord shall constitute a termination of Tenant&#8217;s right to possession or an acceptance of Tenant&#8217;s surrender of the Premises, and this Lease shall continue in effect.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">26.16</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9pt;text-decoration:underline">LANDLORD&#8217;S RIGHT TO PERFORM TENANT&#8217;S DUTIES</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">If Tenant fails timely to perform any of its duties under this Lease, Landlord shall have the right (but not the obligation), to perform such duty on behalf and at the expense of Tenant without prior notice to Tenant, and all sums expended or expenses incurred by Landlord in performing such duty shall be deemed to be additional Rent under this Lease and shall be due and payable upon demand by Landlord.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">26.17</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9pt;text-decoration:underline">SECURITY SYSTEM</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Landlord, in its sole and absolute discretion, shall install certain card key access and video camera systems respecting certain main entry points of the Building.  Subject to the foregoing, Landlord shall not be obligated to provide or maintain any security patrol or security system.  Landlord shall not be responsible for the quality of any such patrol or system which may be provided hereunder or for damage or injury to Tenant, its employees, invitees or others due to the failure, action or inaction of such patrol or system.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">26.18</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9pt;text-decoration:underline">NO LIGHT, AIR OR VIEW EASEMENTS</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">00056263.8 &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">58</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Any diminution or shutting off of light, air or view by any structure which may be erected on lands of or adjacent to the Project shall in no way affect this Lease or impose any liability on Landlord.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">26.19</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9pt;text-decoration:underline">RECORDATION</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Neither this Lease, nor any notice nor memorandum regarding the terms hereof, shall be recorded by Tenant.  Any such unauthorized recording shall be a Default for which there shall be no cure or grace period.  Tenant agrees to execute and acknowledge, at the request of Landlord, a memorandum of this Lease, in recordable form.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">26.20</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9pt;text-decoration:underline">SURVIVAL</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The waivers of the right of jury trial, the other waivers of claims or rights, the releases and the obligations of Tenant under this Lease to indemnify, protect, defend and hold harmless Landlord and&#47;or Indemnitees shall survive the expiration or termination of this Lease, and so shall all other obligations or agreements which by their terms survive expiration or termination of this Lease.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">26.21</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9pt;text-decoration:underline">OFAC</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">Tenant hereby represents, warrants and covenants to Landlord, either that (i) Tenant is regulated by the SEC, FINRA or the Federal Reserve (a &#8220;Regulated Entity&#8221;) or (ii) neither Tenant nor any person or entity that directly or indirectly (A) controls Tenant or (B) has an ownership interest in Tenant of twenty-five percent (25%) or more, appears on the list of Specially Designated Nationals and Blocked Persons (&#8220;OFAC List&#8221;) published by the Office of Foreign Assets Control (&#8220;OFAC&#8221;) of the U.S. Department of the Treasury.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">Tenant covenants that during the term of this Lease to provide to Landlord information reasonably requested by Landlord including without limitation, organizational structural charts and organizational documents which Landlord may deem to be necessary (&#8220;Tenant OFAC Information&#8221;) in order for Landlord to confirm Tenant&#8217;s continuing compliance with the provisions of this Article.  Tenant represents and warrants that the Tenant OFAC Information it has provided or to be provided to Landlord or Landlord&#8217;s Broker in connection with the execution of this Lease is true and complete.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">Landlord advises Tenant hereby that the purpose of this Section is to provide to Landlord information and assurances to enable Landlord to comply with the Laws relating to OFAC.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">Tenant acknowledges that the breach of any of the representations, warranties and&#47;or covenants by Tenant under this Section 25.21 shall be an immediate Default under this Lease.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">26.22</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9pt;text-decoration:underline">INSPECTION BY A CASP IN ACCORDANCE WITH CIVIL CODE SECTION&#160;1938.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Landlord discloses that to Landlord&#8217;s knowledge, neither the Building nor the Premises have undergone inspection by a Certified Access Specialist.  Furthermore, pursuant to Section 1938 of the California Civil Code, Landlord notifies Tenant of the following&#58;  &#8220;A Certified Access Specialist (CASp) can inspect the subject premises and determine whether the subject premises comply with all of the applicable construction-related accessibility standards under state law.  Although California state law does not require a CASp inspection of the subject premises, the commercial property owner or lessor may not prohibit the lessee or tenant from obtaining a CASp inspection of the subject premises for the occupancy or potential occupancy of </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">00056263.8 &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">59</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the lessee or tenant, if requested by the lessee or tenant.  The parties shall mutually agree on the arrangements for the time and manner of any such CASp inspection, the payment of the costs and fees for the CASp inspection and the cost of making any repairs necessary to correct violations of construction-related accessibility standards within the Premises.&#8221;  Tenant agrees that (a) Tenant may, at its option and at its sole cost, cause a CASp to inspect the Premises and determine whether the Premises complies with all of the applicable construction-related accessibility standards under California law, (b) the parties shall mutually coordinate and reasonably approve of the timing of any such CASp inspection so that Landlord may, at its option, have a representative present during such inspection, and (c) Tenant shall be solely responsible for the cost of any repairs necessary to correct violations of construction-related accessibility standards within the Premises and Building identified by any such CASp inspection, any and all such alterations and repairs within the Premises to be performed by Tenant shall be subject to Landlord&#8217;s consent and in accordance with this Lease.  Landlord and Tenant hereby agree that if Tenant elects to perform a CASp inspection of the Premises, Tenant will provide written notice to Landlord, and Landlord may elect, in Landlord&#8217;s sole discretion, to retain a CASp to perform the inspection.  If Landlord does not so elect, the time and manner of the CASp inspection is subject to the prior written approval of Landlord.  In either event, the payment of the fee for the CASp inspection shall be borne by Tenant.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">26.23</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9pt;text-decoration:underline">COUNTERPARTS  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This Lease may be executed in any number of counterparts, each of which shall be deemed an original, but all of which, together, shall constitute one and the same instrument.  Telecopied signatures or signatures transmitted by electronic mail in so-called &#8220;pdf&#8221; format or via DocuSign or similar electronic means, may be used in place of original signatures on this Lease.  Landlord and Tenant intend to be bound by the signatures on the telecopied or e-mailed document, are aware that the other party will rely on the telecopied or e-mailed signatures, and hereby waive any defenses to the enforcement of the terms of this Lease based on such telecopied or e-mailed signatures.  Promptly following request by either party, the other party shall provide the requesting party with original signatures on this Lease.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">26.24</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9pt;text-decoration:underline">EXHIBITS AND RIDERS</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">All exhibits, riders and&#47;or addenda referred to in this Lease as an exhibit, rider, or addenda hereto, or attached hereto, are hereby incorporated into and made a part of this Lease.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;Signatures on Following Page&#93;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">00056263.8 &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">60</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">IN WITNESS WHEREOF, this Lease has been executed as of the date set forth in Section 1.1 hereof.</font></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.302%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.302%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.302%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.060%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">TENANT&#58;</font></td><td colspan="12" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">LANDLORD&#58;</font></td></tr><tr style="height:39pt"><td colspan="3" rowspan="4" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">LIGAND PHARMACEUTICALS INCORPORATED, a Delaware corporation</font></div><div style="margin-bottom:18pt;padding-left:2.75pt;padding-right:2.75pt"><font><br></font></div><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Matthew W. Foehr&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;Matthew W. Foehr&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Its&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">President&#47;COO&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt"><font><br></font></div><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Charles Berkman&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;Charles Berkman&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Its&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">SVP, General Counsel &#38; Secretary&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></td><td colspan="12" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">EMERY STATION OFFICE II, LLC,<br>a California limited liability company</font></td></tr><tr style="height:39pt"><td colspan="3" rowspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="9" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Emery Station Associates II, LLC,<br>its Managing Member</font></td></tr><tr style="height:51pt"><td colspan="3" rowspan="2" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="6" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Wareham-NZL, LLC,<br>its Managing Member</font></td></tr><tr style="height:239pt"><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:24pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Richard K. Robbins&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><br>Richard K. Robbins<br>Its Manager</font></div></td></tr></table></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">00056263.8 &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">61</font></div></div></div><div id="ib3e782292dd84cd0ac2a381d38a8eb42_10"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">EXHIBIT A</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">OUTLINE OF PREMISES</font></div><div style="text-align:center"><img alt="image_0a.jpg" src="image_0a.jpg" style="height:787px;margin-bottom:5pt;vertical-align:text-bottom;width:556px"></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">00056263.8 &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">A-1</font></div></div></div><div id="ib3e782292dd84cd0ac2a381d38a8eb42_13"></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">EXHIBIT B</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">WORKLETTER AGREEMENT<br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(Tenant Build &#47; Allowance)</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">THIS WORK AGREEMENT (this &#8220;Work Agreement&#8221;) is attached to and made a part of that certain Lease (the &#8220;Lease&#8221;) between EMERY STATION OFFICE II, LLC (&#8220;Landlord&#8221;), and LIGAND PHARMACEUTICALS INCORPORATED (&#8220;Tenant&#8221;).  All capitalized terms used but not defined herein shall have the respective meanings given such terms in the Lease.  This Work Agreement sets forth the terms and conditions relating to the construction of Tenant Work (defined below) in the Premises.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Allowance&#59; Tenant Work.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">Allowance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Tenant shall be entitled to the Tenant Improvement Allowance specified in Section 1.1 of the Lease for the costs relating to the design, permitting and construction of Tenant&#8217;s improvements which are permanently affixed to the Premises (the &#8220;Tenant Work&#8221;).  The portion of the Tenant Work that is in the Phase I Premises is defined as the &#8220;Phase I Tenant Work&#8221;, and the portion of the Tenant Work that is in the Phase II Premises and a portion of the Phase I Premises is defined as the &#8220;Phase II Tenant Work&#8221;.  The parties contemplate that the Phase I Tenant Work shall be Substantially Completed prior to the Phase II Tenant Work.  Except in connection with the performance of Landlord Work, in no event will Landlord be obligated to make disbursements pursuant to this Work Agreement in a total amount which exceeds the Tenant Improvement Allowance.  Landlord will not charge Tenant any fees for Landlord&#8217;s review, coordination and cooperation related to the Tenant Work.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Disbursement of the Tenant Improvement Allowance.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.69pt;text-decoration:underline">Tenant Improvement Allowance Items</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Except as otherwise set forth in this Work Agreement, the Tenant Improvement Allowance shall be disbursed by Landlord only for the following items and costs (collectively the &#8220;Tenant Improvement Allowance Items&#8221;)&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(A)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:19.36pt">Payment of the fees of the Architect, Construction Manager and the Building Consultants (as those terms are defined below) and payment of fees and costs reasonably incurred by Landlord for the review of the Construction Drawings (defined below) by Landlord or by Landlord&#8217;s third party consultants&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(B)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:20.02pt">The payment of plan check, permit and license fees relating to the Tenant Work&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(C)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:20.02pt">The cost of construction of the Tenant Work, including, without limitation, after hours charges, testing and inspection costs, freight elevator usage, trash removal costs, and contractors&#8217; fees and general conditions&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(D)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:19.36pt">The cost of any changes to the Building when such changes are required by the Construction Drawings, such cost to include all direct architectural and&#47;or engineering fees and expenses incurred in connection therewith&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(E)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:20.69pt">The cost of any changes to the Construction Drawings (defined below) or Tenant Work required by applicable building codes (collectively, &#8220;Code&#8221;)&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(F)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.35pt">The Coordination Fee (defined below).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.36pt;text-decoration:underline">Disbursement of Tenant Improvement Allowance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Landlord shall disburse the Tenant Improvement Allowance to reimburse Tenant for Tenant Improvement </font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:111%">00056263.8 &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:111%">B-1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Allowance Items and shall authorize the release of funds as follows, and otherwise in accordance with Landlord&#8217;s standard disbursement process&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(A)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:19.36pt">Phase I Tenant Work.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt">Upon completion of the Phase I Tenant Work, Tenant shall deliver to Landlord an invoice from Tenant which will include&#58; (i) a copy of all pay applications from Contractor (defined below) approved by Tenant and the Architect (hereafter defined), in a commercially reasonable form to be provided or approved in advance by Landlord, including a schedule of values and showing the percentage of completion, by trade, of the Phase I Tenant Work, which details the portion of the work completed and the portion not completed&#59; (ii)&#160;invoices from all of Tenant&#8217;s Agents (defined below) for labor rendered and materials delivered to the Phase I Premises&#59; (iii)&#160;executed conditional mechanic&#8217;s lien releases from all of Tenant&#8217;s Agents who have lien rights with respect to the subject request for payment (along with unconditional mechanics&#8217; lien releases with respect to payments made pursuant to Tenant&#8217;s prior submission hereunder) in compliance with all applicable laws&#59; (iv) a copy of the check(s) which Tenant issued to pay the requested sums to Tenant&#8217;s Agents&#59; and (v) all other information reasonably requested by Landlord (collectively, the &#8220;Phase I Payment Request Supporting Documentation&#8221;).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt">Within forty (40) days after Tenant&#8217;s delivery to Landlord of all Phase I Payment Request Supporting Documentation, Landlord shall deliver to Tenant payment in an amount equal to the lesser of&#58;  (x)&#160;the amount so requested by Tenant, as set forth above, less a ten percent (10%) retention (the &#8220;Final Phase I Retention&#8221;), and (y)&#160;the balance of any remaining available portion of the Tenant Improvement Allowance allocable to Phase I (not including the Final Phase I Retention), provided that if Landlord, in good faith, disputes any item in a request for payment based on non-compliance of any work with the Approved Working Drawings (defined below) or due to any substandard work and delivers a written objection to such item setting forth with reasonable particularity Landlord&#8217;s reasons for its dispute within five (5) business days following Tenant&#8217;s submission of its Phase I Payment Request Supporting Documentation, Landlord may deduct the amount of such disputed item from the payment. Landlord and Tenant shall, in good faith, endeavor to diligently resolve any such dispute.  Landlord&#8217;s payment of such amounts shall not be deemed Landlord&#8217;s approval or acceptance of the work furnished or materials supplied as set forth in Tenant&#8217;s payment request.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt">Subject to the provisions of this Work Agreement, following the final completion of construction of the Phase I Tenant Work, Landlord shall deliver to Tenant a check made payable to Tenant, or a check or checks made payable to another party or parties as reasonably requested by Tenant, in the amount of the Final Phase I Retention, provided that (i)&#160;Tenant delivers to Landlord properly executed unconditional mechanics&#8217; lien releases from all of Tenant&#8217;s Agents in compliance with all applicable laws, as reasonably determined by Landlord&#59; (ii)&#160;Landlord has determined in good faith that no substandard work exists which adversely affects the mechanical, electrical, plumbing, heating, ventilating and air conditioning, life-safety or other systems of the Building, the curtain wall of the Building, the structure or exterior appearance of the Building&#59; (iii)&#160;Architect delivers to Landlord a certificate, in a form reasonably acceptable to Landlord, certifying that the construction of the Phase I Tenant Work has been finally completed&#59; (iv) Tenant supplies Landlord with evidence that all governmental approvals required for an occupant to legally occupy the Phase I Premises has been obtained (if required under any building permit issued for the Phase I Tenant Work)&#59; and (v)&#160;Tenant has fulfilled its Completion Obligations (defined below) relating to the Phase I Premises and has otherwise complied with Landlord&#8217;s standard &#8220;close-out&#8221; requirements regarding city approvals, closeout tasks, closeout documentation regarding the general contractor, financial close-out matters, and Tenant&#8217;s vendors.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(B)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:20.02pt">Phase II Tenant Work.</font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:111%">00056263.8 &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:111%">B-2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt">During construction of the Phase II Tenant Work, if Tenant desires payment for any portion of the Phase II Tenant Work that has then been completed, Tenant shall deliver to Landlord an invoice from Tenant which will include&#58; (i) a copy of all pay applications from Contractor approved by Tenant and the Architect, in a commercially reasonable form to be provided or approved in advance by Landlord, including a schedule of values and showing the percentage of completion, by trade, of the Phase II Tenant Work, which details the portion of the work completed and the portion not completed&#59; (ii)&#160;invoices from all of Tenant&#8217;s Agents for labor rendered and materials delivered to the Phase II Premises&#59; (iii)&#160;executed conditional mechanic&#8217;s lien releases from all of Tenant&#8217;s Agents who have lien rights with respect to the subject request for payment (along with unconditional mechanics&#8217; lien releases with respect to payments made pursuant to Tenant&#8217;s prior submission hereunder) in compliance with all applicable laws&#59; (iv) a copy of the check(s) which Tenant issued to pay the requested sums to Tenant&#8217;s Agents&#59; and (v) all other information reasonably requested by Landlord (collectively, the &#8220;Phase II Payment Request Supporting Documentation&#8221;).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt">Within forty (40) days after Tenant&#8217;s delivery to Landlord of all Phase II Payment Request Supporting Documentation, Landlord shall deliver to Tenant payment in an amount equal to the lesser of&#58;  (x)&#160;the amount so requested by Tenant, as set forth above, less (1) the applicable Phase II Over-Allowance Amount (defined in Section 3(b)(i)(B) below) and (2) a ten percent (10%) retention (the aggregate amount of such retentions to be known as the &#8220;Final Phase II Retention&#8221;), and (y)&#160;the balance of any remaining available portion of the Tenant Improvement Allowance allocable to Phase II (not including the Final Phase II Retention), provided that if Landlord, in good faith, disputes any item in a request for payment based on non-compliance of any work with the Approved Working Drawings or due to any substandard work and delivers a written objection to such item setting forth with reasonable particularity Landlord&#8217;s reasons for its dispute within five (5) business days following Tenant&#8217;s submission of its Phase II Payment Request Supporting Documentation, Landlord may deduct the amount of such disputed item from the payment. Landlord and Tenant shall, in good faith, endeavor to diligently resolve any such dispute.  Landlord&#8217;s payment of such amounts shall not be deemed Landlord&#8217;s approval or acceptance of the work furnished or materials supplied as set forth in Tenant&#8217;s payment request.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt">Subject to the provisions of this Work Agreement, following the final completion of construction of the Phase II Tenant Work, Landlord shall deliver to Tenant a check made payable to Tenant, or a check or checks made payable to another party or parties as reasonably requested by Tenant, in the amount of the Final Phase II Retention, provided that (i)&#160;Tenant delivers to Landlord properly executed unconditional mechanics&#8217; lien releases from all of Tenant&#8217;s Agents in compliance with all applicable laws, as reasonably determined by Landlord&#59; (ii)&#160;Landlord has determined in good faith that no substandard work exists which adversely affects the mechanical, electrical, plumbing, heating, ventilating and air conditioning, life-safety or other systems of the Building, the curtain wall of the Building, the structure or exterior appearance of the Building&#59; (iii)&#160;Architect delivers to Landlord a certificate, in a form reasonably acceptable to Landlord, certifying that the construction of the Phase II Tenant Work has been finally completed&#59; (iv)&#160;Tenant supplies Landlord with evidence that all governmental approvals required for an occupant to legally occupy the Phase II Premises has been obtained&#59; and (v)&#160;Tenant has fulfilled its Completion Obligations relating to the Phase II Premises and has otherwise complied with Landlord&#8217;s standard &#8220;close-out&#8221; requirements regarding city approvals, closeout tasks, closeout documentation regarding the general contractor, financial close-out matters, and Tenant&#8217;s vendors.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Construction Drawings</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">Selection of Architect&#59; Construction Drawings</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.69pt">Tenant shall retain ID Studios as architect, which architect is hereby approved by Landlord (the &#8220;Architect&#8221;), to prepare the Construction Drawings.  Tenant shall </font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:111%">00056263.8 &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:111%">B-3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">retain engineering consultants approved in writing, in advance by Landlord, such approval not to be unreasonably withheld (the &#8220;Building Consultants&#8221;) to prepare all plans and engineering working drawings and perform all work relating to mechanical, electrical and plumbing (&#8220;MEP&#8221;), HVAC&#47;Air Balancing, life-safety, structural, sprinkler and riser work.  The MEP work will be performed on a design-build basis, using a mutually acceptable subcontractor.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.36pt">The plans and drawings to be prepared by Architect and the Building Consultants hereunder (i.e., both the Space Plan and the Working Drawings, as each term is defined below) shall be known collectively as the &#8220;Construction Drawings.&#8221;  All MEP drawings will be prepared on a &#8220;design-build-assist&#8221; basis with a Landlord-approved MEP basis of design (&#8220;BOD&#8221;), as prepared by an approved MEP engineer consultant.  Landlord&#8217;s review of the Construction Drawings shall be for its sole purpose and shall not obligate Landlord to review the same, for quality, design, Code compliance or other like matters.  Accordingly, notwithstanding that any Construction Drawings are reviewed by Landlord or its space planner, architect, engineers and consultants, and notwithstanding any advice or assistance which may be rendered to Tenant by Landlord or Landlord&#8217;s space planner, architect, engineers, and consultants, Landlord shall have no liability whatsoever in connection therewith and shall not be responsible for any omissions or errors contained in the Construction Drawings.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Space Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Tenant shall supply Landlord for Landlord&#8217;s review and approval Tenant&#8217;s proposed space plan or space plans for the Premises (collectively, the &#8220;Space Plan&#8221;) before any architectural working drawings or engineering drawings have been commenced.  The Space Plan shall include a layout and designation of all laboratory facilities, offices, rooms and other partitioning, their intended use, and equipment to be contained therein.  Landlord may request clarification or more specific drawings for special use items not included in the Space Plan.  Landlord shall advise Tenant within five (5) business days after Landlord&#8217;s receipt of the Space Plan (or, if applicable, such additional information requested by Landlord pursuant to the provisions of the immediately preceding sentence) if the same is approved or is unsatisfactory or incomplete in any respect.  Upon any disapproval by Landlord, Tenant shall promptly cause the Space Plan to be revised to correct any deficiencies or other matters Landlord may reasonably require.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">Working Drawings</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  After the Space Plan has been approved by Landlord, Tenant shall supply the Architect and the Building Consultants with a complete listing of standard and non-standard equipment and specifications, including, without limitation, B.T.U. calculations, electrical requirements and special electrical receptacle requirements, to enable the Architect and the Building Consultants to complete the Working Drawings and shall cause the Architect and the Engineers to promptly complete the architectural and engineering drawings, and Architect shall compile a fully coordinated set of drawings, including but not limited to architectural, structural, mechanical, electrical, plumbing, fire sprinkler and life safety in a form which is complete to allow subcontractors to bid on the work and to obtain all applicable permits (collectively, the &#8220;Working Drawings&#8221;) and shall submit the same to Landlord for Landlord&#8217;s review and approval.  Landlord shall advise Tenant within five (5) business days after Landlord&#8217;s receipt of the Working Drawings if Landlord, in good faith, determines that the same are approved or are unsatisfactory or incomplete.  If Tenant is so advised, Tenant shall promptly revise the Working Drawings to correct any deficiencies or other matters Landlord may reasonably require.  Tenant may elect to submit the Working Drawings to the appropriate city&#47;governmental agency to start the permit process prior to receiving Landlord&#8217;s approval of the Working Drawings&#59; provided, however, the Working Drawings shall not be deemed approved by Landlord until Tenant has revised the Working Drawings to correct any deficiencies or other matters Landlord may reasonably require.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Landlord&#8217;s Approval</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Tenant acknowledges that it shall be deemed reasonable for Landlord to disapprove the Space Plan and any subsequent Working Drawings unless, at a minimum, the same are prepared on the basis that&#58; (i) the Tenant Work as specified and designed comply with the requirements of the Project&#8217;s Sustainability Practices (if any), and (ii) the </font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:111%">00056263.8 &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:111%">B-4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">sprinkler systems shall be designed in compliance with the specifications provided by FM Global.  Additionally, Landlord&#8217;s approval of any matter under this Work Agreement may be withheld if Landlord reasonably determines that the same would violate any provision of the Lease or this Work Agreement or would adversely affect the mechanical, electrical, plumbing, heating, ventilating and air conditioning, life-safety or other systems of the Building, the curtain wall of the Building, the structure or exterior appearance of the Building.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Construction of the Tenant Work</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">Tenant&#8217;s Selection of Contractors.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.69pt;text-decoration:underline">The Contractor</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Tenant shall retain WCI as general contractor, which general contractor is hereby approved by Landlord, to construct the Tenant Work (&#8220;Contractor&#8221;).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.36pt;text-decoration:underline">Tenant&#8217;s Agents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  All subcontractors, laborers, materialmen, and suppliers used by Tenant (such subcontractors, laborers, materialmen, and suppliers, and the Contractor to be known collectively as &#8220;Tenant&#8217;s Agents&#8221;) must be approved in writing by Landlord, in Landlord&#8217;s sole discretion, but not unreasonably withheld, provided that Landlord will require Tenant to retain the Building Consultants.  All of Tenant&#8217;s Agents shall be licensed in the State of California and capable of being bonded.  Notwithstanding anything herein to the contrary, in connection with Tenant&#8217;s construction of the Tenant Work, any of Tenant&#8217;s Agents that are (A) to be reimbursed to Tenant through the Tenant Improvement Allowance, and&#47;or (B) involved in principal construction trades, shall be union-affiliated and in compliance with all then existing master labor agreements.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.03pt;text-decoration:underline">Construction Manager</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Tenant shall retain a qualified construction manager (the &#8220;Construction Manager&#8221;).  The Construction Manager shall be considered one of Tenant&#8217;s Agents for all purposes under this Workletter.  The Construction Manager shall, at a minimum, attend all meetings with the Contractor (as set forth in Section 3(b)(vi) below).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Construction of Tenant Work by Tenant&#8217;s Agents.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.69pt;text-decoration:underline">Construction Contract&#59; Over-Allowance Amounts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(A)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:19.36pt">Tenant shall enter into a construction contract and general conditions with Contractor for construction of the Phase I Tenant Work (the &#8220;Phase I Contract&#8221;). Prior to the commencement of the construction of the Phase I Tenant Work, Tenant shall provide Landlord with a schedule of values consisting of a detailed breakdown, by trade, of the final costs to be incurred or which have been incurred, for all Tenant Improvement Allowance Items in connection with the design and construction of the Phase I Tenant Work, which costs form the basis for the amount of the Phase I Contract (the &#8220;Final Phase I Costs&#8221;).  Tenant shall be solely responsible for the difference between the amount of the Phase I Final Costs and the amount of the Tenant Improvement Allowance allocable to the Phase I Tenant Work.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(B)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:20.02pt">Tenant shall enter into a construction contract and general conditions with Contractor for construction of the Phase II Tenant Work (the &#8220;Phase II Contract&#8221;). Prior to the commencement of the construction of the Phase II Tenant Work, Tenant shall provide Landlord with a schedule of values consisting of a detailed breakdown, by trade, of the final costs to be incurred or which have been incurred, for all Tenant Improvement Allowance Items in connection with the design and construction of the Phase II Tenant Work, which costs form the basis for the amount of the Phase II Contract (&#8220;Final Phase II Costs&#8221;).  Prior to the commencement of construction of the Phase II Tenant Work, Landlord and Tenant shall identify the amount (the &#8220;Phase II Over-Allowance Amount&#8221;) equal to the difference between the amount of the Phase II Final Costs and the amount of the Tenant Improvement Allowance allocable to the Phase II Tenant Work (less any portion thereof already disbursed by Landlord, or in the process of being disbursed by Landlord, on or before the commencement of </font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:111%">00056263.8 &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:111%">B-5</font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">construction of the Phase II Tenant Work), and Landlord will reimburse Tenant on a periodic basis, as described in Section 1.2(b)(ii) above, for a percentage of each amount requested by the Contractor or otherwise to be disbursed under this Work Agreement, which percentage shall be equal to the Tenant Improvement Allowance allocable to the Phase II Tenant Work divided by the amount of the Final Phase II Costs (after deducting from the Final Phase II Costs any amounts expended in connection with the preparation of the Construction Drawings, and the cost of all other Tenant Improvement Allowance Items incurred prior to the commencement of construction of the Phase II Tenant Work), and Tenant shall be solely responsible for any Phase II Over-Allowance Amount.  If, after the Final Phase II Costs have been initially determined, the costs relating to the design and construction of the Phase II Tenant Work shall change, any additional costs for such design and construction in excess of the Final Phase II Costs shall be added to the Phase II Over-Allowance Amount and the Final Phase II Costs, and Landlord&#8217;s reimbursement percentage, shall be recalculated in accordance with the terms of the immediately preceding sentence.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(C)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:20.02pt">Notwithstanding anything set forth herein to the contrary, construction of the Tenant Work shall not commence until Tenant has procured and delivered to Landlord a copy of all applicable building permits for the applicable Tenant Work.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.36pt;text-decoration:underline">Construction Requirements.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(A)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:19.36pt;text-decoration:underline">Landlord&#8217;s General Conditions for Tenant&#8217;s Agents and Tenant Improvement Work</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Construction of the Tenant Work shall comply with the following&#58;  (1)&#160;the Tenant Work shall be constructed in strict accordance with the Approved Working Drawings and Landlord&#8217;s then-current published construction guidelines&#59; (2)&#160;Tenant&#8217;s Agents shall submit schedules of all work relating to the Tenant Work to Landlord and Landlord shall, within five (5) business days after receipt thereof, inform Tenant&#8217;s Agents of any changes which are necessary thereto, and Tenant&#8217;s Agents shall adhere to such corrected schedule&#59; and (3)&#160;Tenant shall abide by all rules made by Landlord&#8217;s Building Manager with respect to the use of contractor parking, materials delivery, freight, loading dock and service elevators, any required shutdown of utilities (including life-safety systems), storage of materials, coordination of work with the contractors of Landlord, and any other matter in connection with this Work Agreement, including, without limitation, the construction of the Tenant Work, such requirements will not be unreasonable or differ from industry norms.  Tenant shall pay an oversight and supervisory fee (the &#8220;Coordination Fee&#8221;) to Landlord in an amount equal to one percent (1%) of the Final Costs.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(B)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:20.02pt;text-decoration:underline">Indemnity</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Tenant&#8217;s indemnity of Landlord as set forth in the Lease shall also apply with respect to any and all costs, losses, damages, injuries and liabilities related in any way to any act or omission of Tenant or Tenant&#8217;s Agents, or anyone directly or indirectly employed by any of them, or in connection with Tenant&#8217;s non-payment of any amount arising out of the Tenant Work and&#47;or Tenant&#8217;s disapproval of all or any portion of any request for payment.  Such indemnity by Tenant, as set forth in the Lease, shall also apply with respect to any and all costs, losses, damages, injuries and liabilities related in any way to Landlord&#8217;s performance of any ministerial acts reasonably necessary (1)&#160;to permit Tenant to complete the Tenant Work, and (2) to enable Tenant to obtain any related building permit or certificate of occupancy.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(C)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:20.02pt;text-decoration:underline">Requirements of Tenant&#8217;s Agents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Contractor shall guarantee to Tenant and for the benefit of Landlord that the portion of the Tenant Work for which it is responsible shall be free from any defects in workmanship and materials for a period of not less than one (1) year from the date of completion thereof.  Contractor shall be responsible for the replacement or repair, without additional charge, of all work done or furnished in accordance with its contract that shall become defective within one (1) year after the completion of the work performed by such contractor or subcontractor.  The correction of such work shall include, without additional charge, all additional expenses and damages incurred in connection with the removal or replacement of all or any part of the Tenant Work, and&#47;or the Building and&#47;or </font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:111%">00056263.8 &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:111%">B-6</font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">common areas that are damaged or disturbed thereby.  All such warranties or guarantees as to materials or workmanship of or with respect to the Tenant Work shall be contained in the Contract or subcontract and shall be written such that such guarantees or warranties shall inure to the benefit of both Landlord and Tenant, as their respective interests may appear, and can be directly enforced by either.  Tenant covenants to give to Landlord any assignment or other assurances as may be necessary to effect such right of direct enforcement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.03pt;text-decoration:underline">Insurance Requirements.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(A)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:19.36pt;text-decoration:underline">General Coverages</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  All of Tenant&#8217;s Agents shall carry employer&#8217;s liability and worker&#8217;s compensation insurance covering all of their respective employees, and shall also carry commercial general liability insurance, including personal and bodily injury, property damage and completed operations liability, all with limits, in form and with companies as are required to be carried by Tenant as set forth in the Lease.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(B)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:20.02pt;text-decoration:underline">Special Coverages</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Tenant or Contractor shall carry &#8220;Builder&#8217;s All Risk&#8221; insurance in an amount approved by Landlord covering the construction of the Tenant Work, and such other insurance as Landlord may require, it being understood and agreed that the Tenant Work shall be insured by Tenant pursuant to the Lease immediately upon completion thereof.  Such insurance shall be in amounts and shall include such extended coverage endorsements as may be reasonably required by Landlord, and shall be in form and with companies as are required to be carried by Tenant as set forth in the Lease.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(C)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:20.02pt;text-decoration:underline">General Terms</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Certificates for all of the foregoing insurance coverage shall be delivered to Landlord before the commencement of construction of the Tenant Work and before the Contractor&#8217;s equipment is moved onto the site.  All such policies of insurance must contain a provision that the company writing said policy will endeavor to give Landlord thirty (30) days&#8217; prior written notice of any cancellation of such insurance.  In the event that the Tenant Work are damaged by any cause during the course of the construction thereof, Tenant shall immediately repair the same at Tenant&#8217;s sole cost and expense.  Tenant&#8217;s Agents shall maintain all of the foregoing insurance coverage in force until the Tenant Work are fully completed and accepted by Landlord, except for any Products and Completed Operations Coverage insurance required by Landlord, which is to be maintained for one (1) year following completion of the work and acceptance by Landlord and Tenant.  All policies carried hereunder shall insure Landlord, Wareham Property Group as Landlord&#8217;s manager, and Tenant, as their interests may appear, as well as Tenant&#8217;s Agents.  All insurance, except Workers&#8217; Compensation, maintained by Tenant&#8217;s Agents shall preclude subrogation claims by the insurer against anyone insured thereunder.  Such insurance shall provide that it is primary insurance as respects Landlord and Tenant and that any other insurance maintained by Landlord or Tenant is excess and noncontributing with the insurance required hereunder.  The requirements for the foregoing insurance shall not derogate from the provisions for indemnification of Landlord by Tenant under the Lease and&#47;or this Work Agreement. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.69pt;text-decoration:underline">Governmental Compliance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Tenant Work shall comply in all respects with the following&#58;  (A) the Code and other federal, state, city and&#47;or quasi-governmental laws, codes, ordinances and regulations, as each may apply according to the rulings of the controlling public official, agent or other person or entity&#59; (B) applicable standards of the American Insurance Association (formerly, the National Board of Fire Underwriters) and the National Electrical Code&#59; and (C) building material manufacturer&#8217;s specifications.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(v)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Inspection by Landlord</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Prior to the completion of any portion of the Tenant Work, Landlord shall have the right to inspect the same at all times (provided, however, that Landlord will provide Tenant&#8217;s Agents with Building standards prior to commencement of Tenant Work), provided however, that Landlord&#8217;s failure to inspect the Tenant Work shall in no event constitute a waiver of any of Landlord&#8217;s rights hereunder nor shall Landlord&#8217;s inspection of the Tenant Work constitute Landlord&#8217;s approval of the same.  Should Landlord disapprove </font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:111%">00056263.8 &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:111%">B-7</font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(which disapproval shall not be unreasonable) any portion of the Tenant Work, Landlord shall notify Tenant in writing of such disapproval and shall specify the items disapproved&#59; provided, however, if such Tenant Work is being performed pursuant to Working Drawings approved by Landlord, Landlord will have no right to disapprove, or Landlord will be responsible for any costs or delays related to such disapproval.  Any defects or deviations in, and&#47;or disapproval by Landlord of, the Tenant Work shall be rectified by Tenant at no expense to Landlord, provided however, that in the event Landlord determines that a defect or deviation exists or disapproves of any matter in connection with any portion of the Tenant Work and such defect, deviation or matter might adversely affect the mechanical, electrical, plumbing, heating, ventilating and air conditioning or life-safety systems of the Building, the structure or exterior appearance of the Building or any other tenant&#8217;s use of such other tenant&#8217;s leased premises, Landlord may take such action as Landlord deems necessary, at Tenant&#8217;s expense and without incurring any liability on Landlord&#8217;s part, to correct any such defect, deviation and&#47;or matter, including, without limitation, causing the cessation of performance of the construction of the Tenant Work until such time as the defect, deviation and&#47;or matter is corrected to Landlord&#8217;s satisfaction.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(vi)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.69pt;text-decoration:underline">Meetings</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Tenant shall hold periodic meetings at a reasonable time with the Architect and the Contractor regarding the progress of the preparation of the Construction Drawings and the construction of the Tenant Work, which meetings shall be held at a location designated or reasonably approved by Landlord, and Landlord and&#47;or its agents shall receive prior written notice of, and shall have the right to attend, all such meetings.  Upon Landlord&#8217;s request, certain of Tenant&#8217;s Agents shall attend such meetings.  In addition, minutes shall be taken at all such meetings, and Landlord will be included in the distribution list for such minutes.  One such meeting each month shall include the review of Contractor&#8217;s current request for payment.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">Copy of Record Set of Plans</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Within thirty (30) days following the completion of construction, (i) Tenant shall cause the Architect and Contractor (A) to update the Approved Working Drawings as necessary to reflect all changes made to the Approved Working Drawings during the course of construction, (B) to certify to the best of their knowledge that the updated drawings are true and correct, which certification shall survive the expiration or termination of the Lease, and (C) to deliver to Landlord such updated drawings, and (ii) Tenant shall deliver to Landlord a copy of all warranties, guaranties, and operating manuals and information relating to the improvements, equipment, and systems in the Premises.  Tenant&#8217;s obligations set forth in this Section are collectively referred to as the &#8220;Completion Obligations.&#8221;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Landlord Work</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Landlord shall deliver the Premises in a broom clean, decommissioned and decontaminated condition, using a reputable third-party vendor selected by Landlord for the decommissioning and decontamination work, and with all Building systems serving the Premises in good working order.  Subject to the foregoing and the terms of Section 2.4 of the Lease, Tenant shall accept the Premises in their then existing, &#8220;AS-IS&#8221; condition&#59; provided, however, that in connection with the Tenant Work (as opposed to any future Tenant Alterations), Landlord shall be responsible for ensuring that the Building and Common Areas of the 6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> floor comply with ADA requirements, which shall be at Landlord&#8217;s sole cost and expense and not included in Operating Expenses.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Miscellaneous</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">Tenant&#8217;s Representative</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Tenant has designated Sandra Clark of Space Matters as its sole representative with respect to the matters set forth in this Work Agreement, until further notice to Landlord, who shall have full authority and responsibility to act on behalf of Tenant as required in this Work Agreement.</font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:111%">00056263.8 &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:111%">B-8</font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Landlord&#8217;s Representative</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Landlord has designated Geoffrey Sears as its sole representative with respect to the matters set forth in this Work Agreement, who, until further notice to Tenant, shall have full authority and responsibility to act on behalf of Landlord as required in this Work Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">Tenant&#8217;s Default</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Notwithstanding any provision to the contrary contained in the Lease, if a Default by Tenant under the Lease (including, without limitation, this Work Agreement) has occurred at any time on or before the substantial completion of the Tenant Work, then (i)&#160;in addition to all other rights and remedies granted to Landlord pursuant to the Lease, Landlord shall have the right to withhold payment of all or any portion of the Tenant Improvement Allowance, and (ii)&#160;all other obligations of Landlord under the terms of this Work Agreement shall be forgiven until such time as such default is cured pursuant to the terms of the Lease.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:111%">00056263.8 &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:111%">B-9</font></div></div></div><div id="ib3e782292dd84cd0ac2a381d38a8eb42_16"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">EXHIBIT C-1</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">LABORATORY RULES AND REGULATIONS</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.&#160;&#160;&#160;&#160;Any laboratory equipment (glass and cage washers, sterilizers, centrifuges, etc.) being used during Standard Operating Hours must be properly insulated for noise to prevent interruption of other tenants&#8217; business.  Landlord reserves the right to request all equipment be insulated prior to occupancy.  Should other tenants complain of noise, the laboratory tenant will be responsible for abating any noise issues, at the laboratory tenant&#8217;s sole cost.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.&#160;&#160;&#160;&#160;Any damages to property due to leaks from laboratory equipment will be the sole responsibility of the laboratory tenant.  Should damage occur in other tenant spaces, any and all damages and clean-up will be the responsibility of the laboratory tenant.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3.&#160;&#160;&#160;&#160;Animal activities are a recognized and necessary process in the biotech industry.  Such activities may only be conducted by laboratory tenants pursuant to all the requirements of their respective lease (including any &#8220;Use&#8221; clause) and require specific, written approval by Landlord in advance.  Any animal activities shall be conducted pursuant to all regulations, standards and best industry practices relating to them.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4.&#160;&#160;&#160;&#160;The Project is a mixed-use facility, and laboratory tenants share space with office tenants.  To reduce the potential interaction with office tenants and their employees and visitors with any biotech animal operations, any animal testing performed, any deliveries of animals and any equipment, foods, cleaners, etc. associated with animal activities, must be coordinated through the loading dock after hours and with the cooperation of the building management and security personnel.  The laboratory tenant should make every effort to handle any deliveries relating to animal activities outside of Standard Operating Hours.  The freight elevator must be used at all times, and delivery trucks should not be visible to the other tenants in the campus area.  No cartons, containers or cardboard boxes bearing the nature of contents may be stored or left in common area spaces, including any garage&#47;freight areas.  Feed bags, animal carriers, and any and all other related containers must be disposed of properly and with discretion.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5.&#160;&#160;&#160;&#160;All exterior signage relating to laboratory operations (i.e., visible to common areas, including corridors) must be kept to the minimum required by Laws.  All signs must have Landlord&#8217;s approval prior to installation.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">00056263.8 &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">C-1-1</font></div></div></div><div id="ib3e782292dd84cd0ac2a381d38a8eb42_19"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">EXHIBIT C-2</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">RULES AND REGULATIONS</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt">No sidewalks, entrance, passages, courts, elevators, vestibules, stairways, corridors or halls shall be obstructed or encumbered by Tenant or used for any purpose other than ingress and egress to and from the Premises and if the Premises are situated on the ground floor of the Project, Tenant shall further, at Tenant&#8217;s own expense, keep the sidewalks and curb directly in front of the Premises clean and free from rubbish.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt">No awning or other projection shall be attached to the outside walls or windows of the Project without the prior written consent of Landlord.  No curtains, blinds, shades, drapes or screens shall be attached to or hung in, or used in connection with any window or door of the Premises, without the prior written consent of Landlord.  Such awnings, projections, curtains, blinds, shades, drapes, screens and other fixtures must be of a quality, type, design, color, material and general appearance approved by Landlord, and shall be attached in the manner approved by Landlord.  All lighting fixtures hung in offices or spaces along the perimeter of the Premises must be of a quality, type, design, bulb color, size and general appearance approved by Landlord.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt">No sign, advertisement, notice, lettering, decoration or other thing shall be exhibited, inscribed, painted or affixed by Tenant on any part of the outside or inside of the Premises or of the Project, without the prior written consent of Landlord.  In the event of the violation of the foregoing by Tenant, Landlord may remove same without any liability, and may charge the expense incurred by such removal to Tenant.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt">The sashes, sash doors, skylights, windows and doors that reflect or admit light or air into the halls, passageways or other public places in the Project shall not be covered or obstructed by Tenant, nor shall any bottles, parcels or other articles be placed on the window sills or in the public portions of the Project.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt">No showcases or other articles shall be put in front of or affixed to any part of the exterior of the Project, nor placed in public portions thereof without the prior written consent of Landlord.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt">The water and wash closets and other plumbing fixtures shall not be used for any purposes other than those for which they were constructed, and no sweepings, rubbish, rags or other substances shall be thrown therein.  All damages resulting from any misuse of the fixtures shall be borne by Tenant to the extent that Tenant or Tenant&#8217;s agents, servants, employees, contractors, visitors or licensees shall have caused the same.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt">Tenant shall not mark, paint, drill into or in any way deface any part of the Premises or the Project.  No boring, cutting or stringing of wires shall be permitted, except with the prior written consent of Landlord, and as Landlord may direct.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt">No animal or bird of any kind shall be brought into or kept in or about the Premises or the Project, except dogs that qualify as &#8220;service animals&#8221; under the ADA.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">9.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt">Tenant shall cooperate with Landlord&#8217;s efforts to implement the Project&#8217;s Sustainability Practices and the applicable Green Building Standards, including, but not limited to, complying with Landlord&#8217;s then-current energy saving efforts and participating in any recycling programs and occupant satisfaction and transportation surveys.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">00056263.8 &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">C-2-1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">10.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt">Prior to leaving the Premises for the day, Tenant shall draw or lower window coverings and extinguish all lights.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">11.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt">Tenant shall regularly conduct cleaning and janitorial activities, especially in bathrooms, kitchens and janitorial spaces, to remove mildew and prevent moist conditions and shall comply with the Project&#8217;s Sustainability Practices and Tenant is strongly encouraged to comply with the applicable Green Building Standards.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">12.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt">Tenant shall not make, or permit to be made, any unseemly or disturbing noises or disturb or interfere with occupants of the Project, or neighboring buildings or premises, or those having business with them.  Tenant shall not throw anything out of the doors, windows or skylights or down the passageways.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">13.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt">Neither Tenant nor any of Tenant&#8217;s agents, servants, employees, contractors, visitors or licensees shall at any time bring or keep upon the Premises any flammable, combustible or explosive fluid, chemical or substance.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">14.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt">No additional locks, bolts or mail slots of any kind shall be placed upon any of the doors or windows by Tenant, nor shall any change be made in existing locks or the mechanism thereof.  Tenant must, upon the termination of the tenancy, restore to Landlord all keys of stores, offices and toilet rooms, either furnished to, or otherwise procured by Tenant, and in the event of the loss of any keys so furnished, Tenant shall pay to Landlord the cost thereof.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">15.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt">All removals, or the carrying in or out of any safes, freight, furniture, construction material, bulky matter or heavy equipment of any description must take place during the hours which Landlord or its agent may determine from time to time.  Landlord reserves the right to prescribe the weight and position of all safes, which must be placed upon two-inch thick plank strips to distribute the weight.  The moving of safes, freight, furniture, fixtures, bulky matter or heavy equipment of any kind must be made upon previous notice to the Building Manager and in a manner and at times prescribed by the Building Manager, and the persons employed by Tenant for such work are subject to Landlord&#8217;s prior approval.  Landlord reserves the right to inspect all safes, freight or other bulky articles to be brought into the Project and to exclude from the Project all safes, freight or other bulky articles which exceed the load bearing capacity of the floors of the Building or which violate any of these Rules and Regulations or the Lease of which these Rules and Regulations are a part.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">16.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt">Tenant shall not purchase janitorial or maintenance or other like service from any company or persons not approved by Landlord.  Landlord shall approve a sufficient number of sources of such services to provide Tenant with a reasonable selection, but only in such instances and to such extent as Landlord in its judgment shall consider consistent with security and proper operation of the Project.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">17.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt">Landlord shall have the right to prohibit any advertising or business conducted by Tenant referring to the Project which, in Landlord&#8217;s opinion, tends to impair the reputation of the Project or its desirability as a first class building for offices and&#47;or commercial services and upon notice from Landlord, Tenant shall refrain from or discontinue such advertising.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">18.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt">Landlord reserves the right to exclude from the Project between the hours of 6&#58;00&#160;p.m. and 8&#58;00 a.m. Monday through Friday, after 1&#58;00 p.m. on Saturdays and at all hours Sundays and legal holidays, all persons who do not present a pass to the Project issued by Landlord.  Landlord may furnish passes to Tenant so that Tenant may validate and issue same.  Tenant shall safeguard said passes and shall be responsible for all acts of persons in or about the Project who possess a pass issued to Tenant.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">00056263.8 &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">C-2-2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">19.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt">Tenant&#8217;s vendors and contractors shall, while in the Premises or elsewhere in the Project, be subject to and under the control and direction of the Building Manager (but not as agent or servant of said Building Manager or of Landlord) and, prior to commencing any work, shall be required to maintain and provide copies of such insurance coverage as reasonably approved by Landlord with liability policies naming Landlord and the Indemnitees as additional insureds.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">20.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt">If the Premises is or becomes infested with vermin as a result of the use or any misuse or neglect of the Premises by Tenant, its agents, servants, employees, contractors, visitors or licensees, Tenant shall forthwith at Tenant&#8217;s expense cause the same to be exterminated from time to time to the satisfaction of Landlord and shall employ such licensed exterminators as shall be approved in writing in advance by Landlord.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">21.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt">The requirements of Tenant will be attended to only upon application at the office of the Project.  Project personnel shall not perform any work or do anything outside of their regular duties unless under special instructions from the office of Landlord.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">22.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt">Canvassing, soliciting and peddling in the Project are prohibited and Tenant shall cooperate to prevent the same.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">23.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt">No water cooler, air conditioning unit or system or other apparatus shall be installed or used by Tenant without the written consent of Landlord.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">24.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt">There shall not be used in any premises, or in the public halls, plaza areas, lobbies, or elsewhere in the Project, either by Tenant, Tenant&#8217;s contractors or others, in the delivery or receipt of merchandise, any hand trucks or dollies, except those equipped with rubber tires and sideguards.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">25.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt">Tenant, Tenant&#8217;s agents, servants, employees, contractors, licensees, or visitors shall not park any vehicles in any driveways, service entrances, or areas posted &#8220;No Parking&#8221; and shall comply with any other parking restrictions imposed by Landlord from time to time.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">26.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt">Tenant shall install and maintain, at Tenant&#8217;s sole cost and expense, an adequate visibly marked (at all times properly operational) fire extinguisher next to any duplicating or photocopying machine or similar heat producing equipment, which may or may not contain combustible material, in the Premises.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">27.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt">Tenant shall keep its window coverings closed during any period of the day when the sun is shining directly on the windows of the Premises.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">28.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt">Tenant shall not use the name of the Project for any purpose other than as the address of the business to be conducted by Tenant in the Premises, nor shall Tenant use any picture of the Project in its advertising, stationery or in any other manner without the prior written permission of Landlord.  Landlord expressly reserves the right at any time to change said name without in any manner being liable to Tenant therefor.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">29.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt">Tenant shall not prepare any food nor do any cooking, operate or conduct any restaurant, luncheonette or cafeteria for the sale or service of food or beverages to its employees or to others, except that food and beverage preparation by Tenant&#8217;s employees using microwave ovens or coffee makers shall be permitted provided no odors of cooking or other processes emanate from the Premises.  Tenant shall not install or permit the installation or use of any vending machine or permit the delivery of any food or beverage to the Premises except by such persons and in such manner as are approved in advance in writing by Landlord.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">00056263.8 &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">C-2-3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">30.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt">The Premises shall not be used as an employment agency, a public stenographer or typist, a labor union office, a physician&#8217;s or dentist&#8217;s office, a dance or music studio, a school, a beauty salon, or barber shop, the business of photographic reproductions or offset printing, a restaurant or bar, an establishment for the sale of confectionery, soda, beverages, sandwiches, ice cream or baked goods, an establishment for preparing, dispensing or consumption of food or beverages of any kind in any manner whatsoever, or news or cigar stand, or a radio, television or recording studio, theatre or exhibition hall, or manufacturing, or the storage or sale of merchandise, goods, services or property of any kind at wholesale, retail or auction, or for lodging, sleeping or for any immoral purposes.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">31.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt">Business machines and mechanical equipment shall be placed and maintained by Tenant at Tenant&#8217;s expense in settings sufficient in Landlord&#8217;s judgment to absorb and prevent vibration, noise and annoyance.  Tenant shall not install any machine or equipment which causes noise, heat, cold or vibration to be transmitted to the structure of the building in which the Premises are located without Landlord&#8217;s prior written consent, which consent may be conditioned on such terms as Landlord may require.  Tenant shall not place a load upon any floor of the Premises exceeding the floor load per square foot that such floor was designed to carry and which is allowed by Law.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">32.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt">Tenant shall not bring any Hazardous Materials onto the Premises except for those that are in general commercial use and are incidental to Tenant&#8217;s business office operations and only in quantities suitable for immediate use.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">33.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt">Tenant shall not store any vehicle within the parking area.  Tenant&#8217;s parking rights are limited to the use of parking spaces for short-term parking, of up to twenty-four (24) hours, of vehicles utilized in the normal and regular daily travel to and from the Project.  Tenants who wish to park a vehicle for longer than a 24-hour period shall notify the Building Manager for the Project and consent to such long-term parking may be granted for periods up to two (2) weeks.  Any motor vehicles parked without the prior written consent of the Building Manager for the Project for longer than a 24-hour period shall be deemed stored in violation of this rule and regulation and shall be towed away and stored at the owner&#8217;s expense or disposed of as provided by Law.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">34.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt">Smoking is prohibited in the Premises, the Building and all enclosed Common Areas of the Project, including all lobbies, all hallways, all elevators and all lavatories.  &#8220;Smoking&#8221;, as used herein, shall be deemed to include the use of e-cigarettes, smokeless cigarettes and other similar products.  All rules and regulations set forth in this Exhibit C applicable to smoking also apply to the use of e-cigarettes, smokeless cigarettes and other similar products.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">35.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt">Tenant shall not store any items within 18 inches of a sprinkler head.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">36.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt">Building ladders including fixed ladders and step ladders are not to be used by Tenant, Tenant&#8217;s agents, servants, employees, contractors, licensees or visitors. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">37.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt">Electrical power strips and portable &#8220;space heaters&#8221; are not permitted. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">38.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt">Tenants are not permitted to open an electrical panel.  Tenants are required to contact Landlord to reset a circuit breaker.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">39.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt">Tenant shall reimburse Landlord for the cost (plus an administrative charge at Landlord&#8217;s then prevailing rate) of Landlord providing any special services or work requested by Tenant to the extent such services or work are not specifically set forth as a Landlord obligation in the Lease.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">00056263.8 &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">C-2-4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">00056263.8 &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">C-2-5</font></div></div></div><div id="ib3e782292dd84cd0ac2a381d38a8eb42_22"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">EXHIBIT D</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">CRYSTAL BIO LEASE EXTENSION AMENDMENT</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">EIGHTH AMENDMENT<br>(5980 Horton Street, Emeryville, California)</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This Eighth Amendment (this &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Amendment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), dated as of June __, 2021, is entered into by and between EMERY STATION OFFICE II, LLC, a California limited liability company (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Landlord</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), and CRYSTAL BIOSCIENCE, INC., a California corporation (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Tenant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;). </font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Recitals</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times',sans-serif;font-size:12pt;font-weight:400;line-height:100%">A.</font><font style="color:#000000;font-family:'Times',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.34pt">Landlord and Tenant entered into that certain Lease dated February 16, 2009, as amended by that certain First Amendment to Lease dated May 21, 2010, that certain Second Amendment to Lease dated April 13, 2011, that certain Third Amendment to Lease dated June 14, 2011, that certain Fourth Amendment to Lease dated November 20, 2013, that certain Fifth Amendment to Lease dated February 2, 2014, that certain Sixth Amendment to Lease dated September 29, 2014, and that certain Seventh Amendment to Lease dated March 14, 2016 (collectively, the &#8220;</font><font style="color:#000000;font-family:'Times',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Lease</font><font style="color:#000000;font-family:'Times',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), whereby Tenant leases certain space known as Suite 405 and consisting of approximately 7,320 rentable square feet (the &#8220;</font><font style="color:#000000;font-family:'Times',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Premises</font><font style="color:#000000;font-family:'Times',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) within the building located at 5980 Horton Street, Emeryville, California (the &#8220;</font><font style="color:#000000;font-family:'Times',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Building</font><font style="color:#000000;font-family:'Times',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times',sans-serif;font-size:12pt;font-weight:400;line-height:100%">B.</font><font style="color:#000000;font-family:'Times',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:25pt">Tenant&#8217;s parent company, Ligand Pharmaceuticals Incorporated, a Delaware corporation (&#8220;</font><font style="color:#000000;font-family:'Times',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Ligand Phama</font><font style="color:#000000;font-family:'Times',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), and Landlord have entered into that certain Office&#47;Laboratory Lease dated substantially concurrently herewith for space (the &#8220;</font><font style="color:#000000;font-family:'Times',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Ligand Pharma Space</font><font style="color:#000000;font-family:'Times',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) on the 6</font><font style="color:#000000;font-family:'Times',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Times',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> Floor of the Building (the &#8220;</font><font style="color:#000000;font-family:'Times',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Ligand Pharma Lease</font><font style="color:#000000;font-family:'Times',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).  Pursuant to the terms of the Ligand Pharma Lease, Ligand Pharma intends to complete certain improvement work within the Ligand Pharma Space designated as the &#8220;Phase II Tenant Work&#8221; in the Ligand Pharma Lease.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times',sans-serif;font-size:12pt;font-weight:400;line-height:100%">C.</font><font style="color:#000000;font-family:'Times',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:25pt">The current Term of the Lease expires as of August 31, 2021 (the &#8220;</font><font style="color:#000000;font-family:'Times',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Prior Expiration Date</font><font style="color:#000000;font-family:'Times',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), and the parties now desire to extend the Term of the Lease to the date that is thirty (30) days after completion of the Phase II Tenant Work under the Ligand Pharma Lease, on the following terms and conditions.</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">NOW THEREFORE, in consideration of the foregoing and the mutual covenants contained herein, the parties agree as follows&#58;</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Agreement</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.</font><font style="color:#000000;font-family:'Times',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Definitions&#59; Recitals</font><font style="color:#000000;font-family:'Times',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Unless otherwise specified herein, all capitalized terms used in this Amendment are used as defined in the Lease.  The parties acknowledge the truthfulness of the foregoing Recitals, which are hereby incorporated into this Amendment.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.</font><font style="color:#000000;font-family:'Times',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Inconsistencies</font><font style="color:#000000;font-family:'Times',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  To the extent that there are any inconsistencies between the terms of the Lease and this Amendment, the terms of this Amendment shall control.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3.</font><font style="color:#000000;font-family:'Times',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Extension</font><font style="color:#000000;font-family:'Times',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Term of the Lease is hereby extended for a period of approximately ten (10) months and shall expire the date that is thirty (30) days after Substantial Completion of the Phase II Tenant Work under the Ligand Pharma Lease (the &#8220;</font><font style="color:#000000;font-family:'Times',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Extended Expiration Date</font><font style="color:#000000;font-family:'Times',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), unless sooner terminated in accordance with the terms of the Lease.  The Extended Expiration Date is estimated to be on or about June 30, 2022.  Tenant acknowledges and agrees that Tenant and Ligand Pharma shall confirm the actual Extended Expiration Date in a Commencement Date Memorandum to be executed in connection with the Ligand Pharma </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">00056263.8 &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">D-1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Lease.  That portion of the Term commencing the day immediately following the Prior Expiration Date (the &#8220;</font><font style="color:#000000;font-family:'Times',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Extension Date</font><font style="color:#000000;font-family:'Times',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) and ending on the Extended Termination Date shall be referred to herein as the &#8220;</font><font style="color:#000000;font-family:'Times',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Extended Term</font><font style="color:#000000;font-family:'Times',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4.</font><font style="color:#000000;font-family:'Times',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Monthly Base Rent</font><font style="color:#000000;font-family:'Times',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  As of the Extension Date, the schedule of Monthly Base Rent shall remain as set forth in the Lease.  All such Monthly Base Rent shall continue to be payable by Tenant in accordance with the terms of the Lease.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5.</font><font style="color:#000000;font-family:'Times',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Premises &#8220;As-Is&#8221;</font><font style="color:#000000;font-family:'Times',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Tenant is in possession of the Premises and accepts the same &#8220;as is&#8221; without any agreements, representations, understandings or obligations on the part of Landlord to perform any alterations, repairs or improvements, except as may be expressly provided otherwise in this Amendment.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times',sans-serif;font-size:12pt;font-weight:400;line-height:100%">6.</font><font style="color:#000000;font-family:'Times',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Miscellaneous</font><font style="color:#000000;font-family:'Times',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">This Amendment sets forth the entire agreement between the parties with respect to the matters set forth herein. There have been no additional oral or written representations or agreements. Under no circumstances shall Tenant be entitled to any Rent abatement, improvement allowance, leasehold improvements, or other work to the Premises, or any similar economic incentives that may have been provided Tenant in connection with entering into the Lease, unless specifically set forth in this Amendment.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">Except as herein modified or amended, the provisions, conditions and terms of the Lease shall remain unchanged and in full force and effect.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">In the case of any inconsistency between the provisions of the Lease and this Amendment, the provisions of this Amendment shall govern and control.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">Submission of this Amendment by Landlord is not an offer to enter into this Amendment but rather is a solicitation for such an offer by Tenant. Landlord shall not be bound by this Amendment until Landlord has executed and delivered the same to Tenant. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">The capitalized terms used in this Amendment shall have the same definitions as set forth in the Lease to the extent that such capitalized terms are defined therein and not redefined in this Amendment.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.03pt">Tenant hereby represents to Landlord that Tenant has dealt with no broker in connection with this Amendment.  Tenant agrees to indemnify and hold Landlord, its members, principals, beneficiaries, partners, officers, directors, employees, mortgagee(s) and agents, and the respective principals and members of any such agents (collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Landlord Related Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) harmless from all claims of any brokers claiming to have represented Tenant in connection with this Amendment.  Landlord hereby represents to Tenant that Landlord has dealt with no broker in connection with this Amendment.  Landlord agrees to indemnify and hold Tenant, its members, principals, beneficiaries, partners, officers, directors, employees, and agents, and the respective principals and members of any such agents (collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Tenant Related Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) harmless from all claims of any brokers claiming to have represented Landlord in connection with this Amendment.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">This Amendment may be executed in counterparts each of which counterparts when taken together shall constitute one and the same agreement. Any facsimile, PDF or other electronic signature shall constitute a valid and binding method for executing this Amendment. Executed counterparts of this Amendment exchanged by facsimile transmission, PDF email, or other electronic means shall be fully enforceable.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">00056263.8 &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">D-2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">IN WITNESS WHEREOF, the parties have executed this Amendment as of the date set forth above.</font></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.302%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.302%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.302%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.060%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">TENANT&#58;</font></td><td colspan="12" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">LANDLORD&#58;</font></td></tr><tr style="height:39pt"><td colspan="3" rowspan="4" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">CRYSTAL BIOSCIENCE, INC.,<br>a California corporation</font></div><div style="margin-bottom:18pt;padding-left:2.75pt;padding-right:2.75pt"><font><br></font></div><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Its&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt"><font><br></font></div><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Its&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></td><td colspan="12" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">EMERY STATION OFFICE II, LLC,<br>a California limited liability company</font></td></tr><tr style="height:39pt"><td colspan="3" rowspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="9" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Emery Station Associates II, LLC,<br>its Managing Member</font></td></tr><tr style="height:51pt"><td colspan="3" rowspan="2" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="6" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Wareham-NZL, LLC,<br>its Managing Member</font></td></tr><tr style="height:189pt"><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:24pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Richard K. Robbins&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><br>Richard K. Robbins<br>Its Manager</font></div></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">00056263.8 &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">D-3</font></div></div></div><div id="ib3e782292dd84cd0ac2a381d38a8eb42_25"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">EXHIBIT E</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">FF&#38;E</font></div><div style="text-align:center"><img alt="image_1a.jpg" src="image_1a.jpg" style="height:578px;margin-bottom:5pt;vertical-align:text-bottom;width:674px"></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">00056263.8 &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">E-1</font></div></div></div><div id="ib3e782292dd84cd0ac2a381d38a8eb42_28"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">RIDER 1</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">COMMENCEMENT DATE AGREEMENT</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">________________, LLC, a ___________ limited liability company (&#8220;Landlord&#8221;), and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, a</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> (&#8220;Tenant&#8221;), have entered into a certain Office&#47;Laboratory  Lease dated as of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, 20__ (the &#8220;Lease&#8221;).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">WHEREAS, Landlord and Tenant wish to confirm and memorialize the Commencement Date, the Rent Commencement Date and Expiration Date of the Lease as provided for in Section 2.2 of the Lease&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">NOW, THEREFORE, in consideration of the foregoing and the mutual covenants contained herein and in the Lease, Landlord and Tenant agree as follows&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.&#160;&#160;&#160;&#160;Unless otherwise defined herein, all capitalized terms shall have the same meaning ascribed to them in the Lease.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.&#160;&#160;&#160;&#160;The Phase I Commencement Date (as defined in the Lease) of the Lease is ___________, 20__.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3.&#160;&#160;&#160;&#160;The Phase II Commencement Date (as defined in the Lease) of the Lease is ___________, 20__.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4.&#160;&#160;&#160;&#160;The Phase I Rent Commencement Date (as defined in the Lease) of the Lease is ___________, 20__.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5.&#160;&#160;&#160;&#160;The Phase II Rent Commencement Date (as defined in the Lease) of the Lease is ___________, 20__.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">6.&#160;&#160;&#160;&#160;The Expiration Date (as defined in the Lease) of the Lease is ___________, 20__.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">7.&#160;&#160;&#160;&#160;The Extended Expiration Date under the Crystal Bio Lease (as defined in the ________ Amendment to the Crystal Bio Lease) is __________, 20__.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8.&#160;&#160;&#160;&#160;Tenant hereby confirms the following&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;That it has accepted possession of the Premises pursuant to the terms of the Lease&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;That the Landlord Work is Substantially Complete&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)&#160;&#160;&#160;&#160;That the Lease is in full force and effect.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">9.&#160;&#160;&#160;&#160;Except as expressly modified hereby, all terms and provisions of the Lease are hereby ratified and confirmed and shall remain in full force and effect and binding on the parties hereto.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">10.&#160;&#160;&#160;&#160;The Lease and this Commencement Date Agreement contain all of the terms, covenants, conditions and agreements between Landlord and Tenant relating to the subject matter herein.  No prior other agreements or understandings pertaining to such matters are valid or of any force and effect.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">00056263.8 &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Rider 1-1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:51.339%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.461%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">TENANT&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">LANDLORD&#58;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">,<br>a </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">________________ LLC, <br>a ________ limited liability company</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Print Name&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><br>Its&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Print Name&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><br>Its&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt"><font><br></font></div><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><br>&#160;&#160;&#160;&#160;Richard K. Robbins<br>&#160;&#160;&#160;&#160;Managing Member</font></div><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#91;INSERT CORRECT SIGNATURE BLOCK FOR PROPERTY&#93;</font></div></td></tr></table></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">00056263.8 &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Rider 1-2</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>4
<FILENAME>lgnd_123121xexhibit211.htm
<DESCRIPTION>EX-21.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i7cef0d3bc15a4c38a20c5278b0ba2f18_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 21.1</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">LIGAND PHARMACEUTICALS INCORPORATED</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">LIST OF SUBSIDIARIES</font></div><div><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:81.250%"><tr><td style="width:1.0%"></td><td style="width:49.984%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.239%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.477%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Jurisdiction of Incorporation</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ab Initio Biotherapeutics, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allergan Ligand Retinoid Therapeutics, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cita NeuroPharmaceuticals Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canada</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Crystal Bioscience, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">California</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CyDex Pharmaceuticals, Inc. &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Glycomed Incorporated &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">California</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Icagen, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ligand Biopharmaceuticals Incorporated</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ligand Holdings UK Limited</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">England and Wales</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ligand JVR, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ligand Pharmaceuticals (Canada) Incorporated</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canada</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ligand Pharmaceuticals International, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ligand Pharmaceuticals UK Limited</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United Kingdom</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ligand UK Development Limited</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">England and Wales</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ligand UK Group Limited</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">England and Wales</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ligand UK Limited</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">England and Wales</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ligand UK Research Limited</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">England and Wales</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Metabasis Therapeutics, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Neurogen Corporation</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">OmniAb, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">OMT I, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">OMT II, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pfenex Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharmacopeia, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Seragen Incorporated</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Seragen Technology, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Taurus Biosciences, LLC</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vernalis Therapeutics Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">xCella Biosciences, Inc.</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr></table></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>5
<FILENAME>lgnd_123121xexhibit231.htm
<DESCRIPTION>EX-23.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i9724531571574be1b51b2dfd65e500c7_1"></div><div style="min-height:40.5pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 23.1</font></div><div style="text-align:right"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consent of Independent Registered Public Accounting Firm</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consent to the incorporation by reference in the following Registration Statements&#58;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) Registration Statement (Form S-8 No. 333-252480) pertaining to the 2002 Stock Incentive Plan, as amended and restated of Ligand Pharmaceuticals Incorporated,</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2) Registration Statement (Form S-8 No. 333-233130) pertaining to the 2002 Stock Incentive Plan, as amended and restated of Ligand Pharmaceuticals Incorporated,</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3) Registration Statement (Form S-8 No. 333-212775) pertaining to the 2002 Stock Incentive Plan, as amended and restated of Ligand Pharmaceuticals Incorporated, </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4) Registration Statement (Form S-8 No. 333-182547) pertaining to the 2002 Stock Incentive Plan, as amended and restated of Ligand Pharmaceuticals Incorporated, </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5) Registration Statement (Form S-8 No. 333-160132) pertaining to the 2002 Stock Incentive Plan, as amended and restated, and Employee Stock Purchase Plan, as amended and restated of Ligand Pharmaceuticals Incorporated, and</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(6) Registration Statement (Form S-8 No. 333-131029) pertaining to the 2002 Stock Incentive Plan and 2002 Employee Stock Purchase Plan of Ligand Pharmaceuticals Incorporated&#59; </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of our reports dated February&#160;28, 2022, with respect to the consolidated financial statements of Ligand Pharmaceuticals Incorporated and the effectiveness of internal control over financial reporting of Ligand Pharmaceuticals Incorporated included in this Annual Report (Form 10-K) of Ligand Pharmaceuticals Incorporated for the year ended December&#160;31, 2021.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#47;s&#47; Ernst &#38; Young LLP</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">San Diego, California</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">February&#160;28, 2022</font></div><div><font><br></font></div><div style="height:130.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>6
<FILENAME>lgnd_123121xexhibit311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="ifc18771e930f4538ac6d90482c240e2a_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.1</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:173%">I, John L. Higgins, certify that&#58;</font></div><div style="margin-bottom:7pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.064%"><tr><td style="width:1.0%"></td><td style="width:11.711%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:86.089%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:36pt;padding-right:2pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">I have reviewed this Annual Report on Form 10-K of Ligand Pharmaceuticals Incorporated&#59;</font></div></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:10.438%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.362%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:36pt;padding-right:2pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:10.438%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.362%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:36pt;padding-right:2pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:10.438%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.362%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:36pt;padding-right:2pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:18.130%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:79.670%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:72pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a)</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:18.130%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:79.670%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:72pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">b)</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:18.130%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:79.670%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:72pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">c)</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:18.130%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:79.670%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:72pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">d)</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:10.438%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.362%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:36pt;padding-right:2pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions)&#58;</font></div></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:18.130%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:79.670%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:72pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a)</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information&#59; and</font></div></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:18.130%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:79.670%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:72pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">b)</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div></td></tr></table></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58;&#160;&#160;February&#160;28, 2022</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;padding-left:2pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; John L. Higgins</font></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;padding-left:2pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">John L. Higgins</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;padding-left:2pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;padding-left:2pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Executive Officer)</font></div></td></tr></table></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>7
<FILENAME>lgnd_123121xexhibit312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i8a12a81d0619496986f2fe889dfdf0a9_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.2</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:173%">I, Matthew Korenberg, certify that&#58;</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:10.438%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.362%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:36pt;padding-right:2pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">I have reviewed this Annual Report on Form 10-K of Ligand Pharmaceuticals Incorporated&#59;</font></div></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:10.438%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.362%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:36pt;padding-right:2pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:10.438%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.362%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:36pt;padding-right:2pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:10.438%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.362%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:36pt;padding-right:2pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:18.130%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:79.670%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:72pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a)</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:18.130%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:79.670%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:72pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">b)</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:18.130%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:79.670%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:72pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">c)</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:18.130%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:79.670%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:72pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">d)</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:10.438%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.362%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:36pt;padding-right:2pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions)&#58;</font></div></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:18.130%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:79.670%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:72pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a)</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information&#59; and</font></div></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:18.130%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:79.670%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:72pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">b)</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div></td></tr></table></div><div style="margin-top:6pt"><font><br></font></div><div style="margin-bottom:7pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58;&#160;&#160;&#160;&#160;February&#160;28, 2022</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:65.064%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;padding-left:2pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Matthew Korenberg</font></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;padding-left:2pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Matthew Korenberg</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;padding-left:2pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Executive Vice President, Finance and Chief Financial Officer</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;padding-left:2pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Financial Officer)</font></div></td></tr></table></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>8
<FILENAME>lgnd_123121xexhibit321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i295749a652e14564aeb64710292b4a3c_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:173%">Exhibit 32.1</font></div><div style="text-align:right"><font><br></font></div><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:173%">CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:173%">In connection with the Annual Report of Ligand Pharmaceuticals Incorporated (the &#8220;Company&#8221;) on Form 10-K for the year ended December&#160;31, 2021, as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I, John L. Higgins, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge&#58;</font></div><div style="margin-bottom:7pt;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.358%"><tr><td style="width:1.0%"></td><td style="width:8.577%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.223%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Report fully complies with the requirements of Section 13(a) or Section 15(d), as applicable, of the Securities Exchange Act of 1934, as amended&#59; and</font></div></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"></td><td style="width:10.456%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.334%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.866%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.944%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:2pt;padding-left:2pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 28, 2022</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:2pt;padding-right:2pt;text-indent:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; John L. Higgins</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:2pt;margin-top:2pt;padding-left:2pt;padding-right:2pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">John L. Higgins</font></div><div style="margin-bottom:2pt;margin-top:2pt;padding-left:2pt;padding-right:2pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Chief Executive Officer</font></div><div style="margin-bottom:2pt;margin-top:2pt;padding-left:2pt;padding-right:2pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(Principal Executive Officer)</font></div></td></tr></table></div><div style="margin-top:6pt"><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:173%">The foregoing certification is being furnished solely to accompany the Report pursuant to 18 U.S.C. Section 1350, and is not being filed for purposes of Section&#160;18 of the Securities Exchange Act of 1934, as amended, and is not to be incorporated by reference into any filing of the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing. A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.</font></div><div><font><br></font></div><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:173%">CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:173%">In connection with the Annual Report of Ligand Pharmaceuticals Incorporated (the &#8220;Company&#8221;) on Form 10-K for the year ended December&#160;31, 2021, as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I, Matthew Korenberg, Executive Vice President, Finance and Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge&#58;</font></div><div style="margin-bottom:7pt;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.198%"><tr><td style="width:1.0%"></td><td style="width:10.208%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.592%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Report fully complies with the requirements of Section 13(a) or Section 15(d), as applicable, of the Securities Exchange Act of 1934, as amended&#59; and</font></div></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.038%"><tr><td style="width:1.0%"></td><td style="width:10.226%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.068%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.230%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.770%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.206%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</font></td><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div></td></tr><tr style="height:13pt"><td colspan="15" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:2pt;padding-left:2pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 28, 2022</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:2pt;padding-right:2pt;text-indent:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Matthew Korenberg</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:2pt;margin-top:2pt;padding-left:2pt;padding-right:2pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Matthew Korenberg</font></div><div style="margin-bottom:2pt;margin-top:2pt;padding-left:2pt;padding-right:2pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Executive Vice President, Finance and Chief Financial Officer</font></div><div style="margin-bottom:2pt;margin-top:2pt;padding-left:2pt;padding-right:2pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(Principal Financial Officer)</font></div></td></tr></table></div><div style="margin-top:6pt"><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:173%">The foregoing certification is being furnished solely to accompany the Report pursuant to 18 U.S.C. Section 1350, and is not being filed for purposes of Section&#160;18 of the Securities Exchange Act of 1934, as amended, and is not to be incorporated by reference into any filing of the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing. A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.</font></div><div><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>9
<FILENAME>lgnd-20211231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:d46a5cfc-72eb-4b3a-bd09-c8907e0f4c5d,g:058bd086-7924-4675-b3eb-d4a9ba4991e0-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:lgnd="http://www.ligand.com/20211231" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.ligand.com/20211231">
  <xs:import namespace="http://fasb.org/srt/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2021q4" schemaLocation="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="lgnd-20211231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="lgnd-20211231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="lgnd-20211231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="lgnd-20211231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.ligand.com/role/Cover">
        <link:definition>0001001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AuditInformation" roleURI="http://www.ligand.com/role/AuditInformation">
        <link:definition>0002002 - Document - Audit Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDBALANCESHEETS" roleURI="http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS">
        <link:definition>1001003 - Statement - CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDBALANCESHEETSParenthetical" roleURI="http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETSParenthetical">
        <link:definition>1002004 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFOPERATIONS" roleURI="http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS">
        <link:definition>1003005 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS" roleURI="http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS">
        <link:definition>1004006 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY" roleURI="http://www.ligand.com/role/CONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY">
        <link:definition>1005007 - Statement - CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFCASHFLOWS" roleURI="http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS">
        <link:definition>1006008 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationandSummaryofSignificantAccountingPolicies" roleURI="http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies">
        <link:definition>2101101 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies" roleURI="http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>2202201 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationandSummaryofSignificantAccountingPoliciesTables" roleURI="http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesTables">
        <link:definition>2303301 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails" roleURI="http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails">
        <link:definition>2404401 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationandSummaryofSignificantAccountingPoliciesRevenuefromSignificantPartnersDetails" roleURI="http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRevenuefromSignificantPartnersDetails">
        <link:definition>2405402 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Revenue from Significant Partners (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationandSummaryofSignificantAccountingPoliciesCommercialLicenseRightsDetails" roleURI="http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCommercialLicenseRightsDetails">
        <link:definition>2406403 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Commercial License Rights (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationandSummaryofSignificantAccountingPoliciesRoyaltyRevenueDetails" roleURI="http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRoyaltyRevenueDetails">
        <link:definition>2407404 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Royalty Revenue (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationandSummaryofSignificantAccountingPoliciesCalculationofEarningsperShareDetails" roleURI="http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCalculationofEarningsperShareDetails">
        <link:definition>2408405 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Calculation of Earnings per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SaleofVernalisRDandPromactaLicense" roleURI="http://www.ligand.com/role/SaleofVernalisRDandPromactaLicense">
        <link:definition>2109102 - Disclosure - Sale of Vernalis R&amp;D and Promacta License</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SaleofVernalisRDandPromactaLicenseNarrativeDetails" roleURI="http://www.ligand.com/role/SaleofVernalisRDandPromactaLicenseNarrativeDetails">
        <link:definition>2410406 - Disclosure - Sale of Vernalis R&amp;D and Promacta License - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShorttermInvestmentsInvestmentinViking" roleURI="http://www.ligand.com/role/ShorttermInvestmentsInvestmentinViking">
        <link:definition>2111103 - Disclosure - Short-term Investments: Investment in Viking</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShorttermInvestmentsInvestmentinVikingNarrativeDetails" roleURI="http://www.ligand.com/role/ShorttermInvestmentsInvestmentinVikingNarrativeDetails">
        <link:definition>2412407 - Disclosure - Short-term Investments: Investment in Viking - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Acquisitions" roleURI="http://www.ligand.com/role/Acquisitions">
        <link:definition>2113104 - Disclosure - Acquisitions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsTables" roleURI="http://www.ligand.com/role/AcquisitionsTables">
        <link:definition>2314302 - Disclosure - Acquisitions (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsNarrativeDetails" roleURI="http://www.ligand.com/role/AcquisitionsNarrativeDetails">
        <link:definition>2415408 - Disclosure - Acquisitions - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails" roleURI="http://www.ligand.com/role/AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails">
        <link:definition>2416409 - Disclosure - Acquisitions - Assets Acquired and Liabilities Assumed (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsIntangiblesAcquiredandWeightedAverageUsefulLifeDetails" roleURI="http://www.ligand.com/role/AcquisitionsIntangiblesAcquiredandWeightedAverageUsefulLifeDetails">
        <link:definition>2417410 - Disclosure - Acquisitions - Intangibles Acquired and Weighted Average Useful Life (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsProFormaFinancialInformationDetails" roleURI="http://www.ligand.com/role/AcquisitionsProFormaFinancialInformationDetails">
        <link:definition>2418411 - Disclosure - Acquisitions - Pro Forma Financial Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsAllocationofConsiderationDetails" roleURI="http://www.ligand.com/role/AcquisitionsAllocationofConsiderationDetails">
        <link:definition>2419412 - Disclosure - Acquisitions - Allocation of Consideration (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurement" roleURI="http://www.ligand.com/role/FairValueMeasurement">
        <link:definition>2120105 - Disclosure - Fair Value Measurement</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementTables" roleURI="http://www.ligand.com/role/FairValueMeasurementTables">
        <link:definition>2321303 - Disclosure - Fair Value Measurement (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" roleURI="http://www.ligand.com/role/FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails">
        <link:definition>2422413 - Disclosure - Fair Value Measurement - Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementReconciliationofLevel3FinancialInstrumentsDetails" roleURI="http://www.ligand.com/role/FairValueMeasurementReconciliationofLevel3FinancialInstrumentsDetails">
        <link:definition>2423414 - Disclosure - Fair Value Measurement - Reconciliation of Level 3 Financial Instruments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsNarrativeDetails" roleURI="http://www.ligand.com/role/FairValueMeasurementsNarrativeDetails">
        <link:definition>2424415 - Disclosure - Fair Value Measurements - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Leases" roleURI="http://www.ligand.com/role/Leases">
        <link:definition>2125106 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesTables" roleURI="http://www.ligand.com/role/LeasesTables">
        <link:definition>2326304 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesNarrativeDetails" roleURI="http://www.ligand.com/role/LeasesNarrativeDetails">
        <link:definition>2427416 - Disclosure - Leases - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesOperatingandFinanceLeaseAssetsandLiabilitiesDetails" roleURI="http://www.ligand.com/role/LeasesOperatingandFinanceLeaseAssetsandLiabilitiesDetails">
        <link:definition>2428417 - Disclosure - Leases - Operating and Finance Lease Assets and Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails" roleURI="http://www.ligand.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails">
        <link:definition>2429418 - Disclosure - Leases - Maturities of Operating and Finance Lease Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails_1" roleURI="http://www.ligand.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails_1">
        <link:definition>2429418 - Disclosure - Leases - Maturities of Operating and Finance Lease Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConvertibleSeniorNotes" roleURI="http://www.ligand.com/role/ConvertibleSeniorNotes">
        <link:definition>2130107 - Disclosure - Convertible Senior Notes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConvertibleSeniorNotesTables" roleURI="http://www.ligand.com/role/ConvertibleSeniorNotesTables">
        <link:definition>2331305 - Disclosure - Convertible Senior Notes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConvertibleSeniorNotesNarrativeDetails" roleURI="http://www.ligand.com/role/ConvertibleSeniorNotesNarrativeDetails">
        <link:definition>2432419 - Disclosure - Convertible Senior Notes - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConvertibleSeniorNotesEquityandLiabilityComponentsofFinancingArrangementsDetails" roleURI="http://www.ligand.com/role/ConvertibleSeniorNotesEquityandLiabilityComponentsofFinancingArrangementsDetails">
        <link:definition>2433420 - Disclosure - Convertible Senior Notes - Equity and Liability Components of Financing Arrangements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetAccountDetails" roleURI="http://www.ligand.com/role/BalanceSheetAccountDetails">
        <link:definition>2134108 - Disclosure - Balance Sheet Account Details</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetAccountDetailsTables" roleURI="http://www.ligand.com/role/BalanceSheetAccountDetailsTables">
        <link:definition>2335306 - Disclosure - Balance Sheet Account Details (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetAccountDetailsInvestmentCategoriesDetails" roleURI="http://www.ligand.com/role/BalanceSheetAccountDetailsInvestmentCategoriesDetails">
        <link:definition>2436421 - Disclosure - Balance Sheet Account Details - Investment Categories (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetAccountDetailsNarrativeDetails" roleURI="http://www.ligand.com/role/BalanceSheetAccountDetailsNarrativeDetails">
        <link:definition>2437422 - Disclosure - Balance Sheet Account Details - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetAccountDetailsAvailableforSaleDebtSecuritiesbyContractualMaturityDetails" roleURI="http://www.ligand.com/role/BalanceSheetAccountDetailsAvailableforSaleDebtSecuritiesbyContractualMaturityDetails">
        <link:definition>2438423 - Disclosure - Balance Sheet Account Details - Available-for-Sale Debt Securities by Contractual Maturity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetAccountDetailsAvailableforSaleDebtSecuritiesinanUnrealizedLossPositionDetails" roleURI="http://www.ligand.com/role/BalanceSheetAccountDetailsAvailableforSaleDebtSecuritiesinanUnrealizedLossPositionDetails">
        <link:definition>2439424 - Disclosure - Balance Sheet Account Details - Available-for-Sale Debt Securities in an Unrealized Loss Position (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetAccountDetailsPropertyandEquipmentDetails" roleURI="http://www.ligand.com/role/BalanceSheetAccountDetailsPropertyandEquipmentDetails">
        <link:definition>2440425 - Disclosure - Balance Sheet Account Details - Property and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetAccountDetailsGoodwillandOtherIntangibleAssetsDetails" roleURI="http://www.ligand.com/role/BalanceSheetAccountDetailsGoodwillandOtherIntangibleAssetsDetails">
        <link:definition>2441426 - Disclosure - Balance Sheet Account Details - Goodwill and Other Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetAccountDetailsAccruedLiabilitiesDetails" roleURI="http://www.ligand.com/role/BalanceSheetAccountDetailsAccruedLiabilitiesDetails">
        <link:definition>2442427 - Disclosure - Balance Sheet Account Details - Accrued Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetAccountDetailsContingentLiabilitiesDetails" roleURI="http://www.ligand.com/role/BalanceSheetAccountDetailsContingentLiabilitiesDetails">
        <link:definition>2443428 - Disclosure - Balance Sheet Account Details - Contingent Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquity" roleURI="http://www.ligand.com/role/StockholdersEquity">
        <link:definition>2144109 - Disclosure - Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityTables" roleURI="http://www.ligand.com/role/StockholdersEquityTables">
        <link:definition>2345307 - Disclosure - Stockholders' Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityShareBasedCompensationDetails" roleURI="http://www.ligand.com/role/StockholdersEquityShareBasedCompensationDetails">
        <link:definition>2446429 - Disclosure - Stockholders' Equity - Share-Based Compensation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityNarrativeDetails" roleURI="http://www.ligand.com/role/StockholdersEquityNarrativeDetails">
        <link:definition>2447430 - Disclosure - Stockholders' Equity - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityStockOptionPlanActivityDetails" roleURI="http://www.ligand.com/role/StockholdersEquityStockOptionPlanActivityDetails">
        <link:definition>2448431 - Disclosure - Stockholders' Equity - Stock Option Plan Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityBreakdownofOptionsOutstandingDetails" roleURI="http://www.ligand.com/role/StockholdersEquityBreakdownofOptionsOutstandingDetails">
        <link:definition>2449432 - Disclosure - Stockholders' Equity - Breakdown of Options Outstanding (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityAssumptionsDetails" roleURI="http://www.ligand.com/role/StockholdersEquityAssumptionsDetails">
        <link:definition>2450433 - Disclosure - Stockholders' Equity - Assumptions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityRestrictedStockActivityDetails" roleURI="http://www.ligand.com/role/StockholdersEquityRestrictedStockActivityDetails">
        <link:definition>2451434 - Disclosure - Stockholders' Equity - Restricted Stock Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentandContingenciesLegalProceedings" roleURI="http://www.ligand.com/role/CommitmentandContingenciesLegalProceedings">
        <link:definition>2152110 - Disclosure - Commitment and Contingencies: Legal Proceedings</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentandContingenciesLegalProceedingsNarrativeDetails" roleURI="http://www.ligand.com/role/CommitmentandContingenciesLegalProceedingsNarrativeDetails">
        <link:definition>2453435 - Disclosure - Commitment and Contingencies: Legal Proceedings - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.ligand.com/role/IncomeTaxes">
        <link:definition>2154111 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesTables" roleURI="http://www.ligand.com/role/IncomeTaxesTables">
        <link:definition>2355308 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesNarrativeDetails" roleURI="http://www.ligand.com/role/IncomeTaxesNarrativeDetails">
        <link:definition>2456436 - Disclosure - Income Taxes - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails" roleURI="http://www.ligand.com/role/IncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails">
        <link:definition>2457437 - Disclosure - Income Taxes - Components of Income Tax Expense (Benefit) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesReconciliationofIncomeTaxExpenseBenefitDetails" roleURI="http://www.ligand.com/role/IncomeTaxesReconciliationofIncomeTaxExpenseBenefitDetails">
        <link:definition>2458438 - Disclosure - Income Taxes - Reconciliation of Income Tax Expense (Benefit) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesDeferredTaxesDetails" roleURI="http://www.ligand.com/role/IncomeTaxesDeferredTaxesDetails">
        <link:definition>2459439 - Disclosure - Income Taxes - Deferred Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesReconciliationofUnrecognizedTaxBenefitsDetails" roleURI="http://www.ligand.com/role/IncomeTaxesReconciliationofUnrecognizedTaxBenefitsDetails">
        <link:definition>2460440 - Disclosure - Income Taxes - Reconciliation of Unrecognized Tax Benefits (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="lgnd_ContingentLiabilityRollForward" abstract="true" name="ContingentLiabilityRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="lgnd_RoyaltyEvomelaMember" abstract="true" name="RoyaltyEvomelaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lgnd_SelexisAndDianomiMember" abstract="true" name="SelexisAndDianomiMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lgnd_CrystalMember" abstract="true" name="CrystalMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lgnd_LeaseLiabilityCurrent" abstract="false" name="LeaseLiabilityCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_LupinPatentInfringementMember" abstract="true" name="LupinPatentInfringementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lgnd_ExercisePriceofConvertibleBondHedge" abstract="false" name="ExercisePriceofConvertibleBondHedge" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLeaseLiabilities" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLeaseLiabilities" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_PurchaseCommitmentConsiderationPaidAllocatedToInventory" abstract="false" name="PurchaseCommitmentConsiderationPaidAllocatedToInventory" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_CommercialLicenseRights" abstract="false" name="CommercialLicenseRights" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_MilestoneMember" abstract="true" name="MilestoneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lgnd_ForecastedCashFlowsEffectiveInterestRatePercent" abstract="false" name="ForecastedCashFlowsEffectiveInterestRatePercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="lgnd_EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomeAmount" abstract="false" name="EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomeAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_ContingentValueRightForInternalResearchAndDevelopmentMember" abstract="true" name="ContingentValueRightForInternalResearchAndDevelopmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lgnd_ExercisePriceRangeThreeMember" abstract="true" name="ExercisePriceRangeThreeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lgnd_VikingTherapeuticsInc.Member" abstract="true" name="VikingTherapeuticsInc.Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lgnd_ConvertibleSeniorNotesDue2023Member" abstract="true" name="ConvertibleSeniorNotesDue2023Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lgnd_AccruedSubcontractorExpensesCurrent" abstract="false" name="AccruedSubcontractorExpensesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_RoyaltyKyprolisMember" abstract="true" name="RoyaltyKyprolisMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lgnd_PaymentsToContingentValueRightHoldersFinancingActivity" abstract="false" name="PaymentsToContingentValueRightHoldersFinancingActivity" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_DebtInstrumentConvertibleMaximumThresholdPercentageofDebtTradingPriceTrigger" abstract="false" name="DebtInstrumentConvertibleMaximumThresholdPercentageofDebtTradingPriceTrigger" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="lgnd_BusinessCombinationConsiderationTransferredHoldback" abstract="false" name="BusinessCombinationConsiderationTransferredHoldback" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_AccountsReceivableCreditLossExpenseReversalCOVID19" abstract="false" name="AccountsReceivableCreditLossExpenseReversalCOVID19" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_BusinessCombinationContingentConsiderationLiabilityPercentageOfAcquireeRevenues" abstract="false" name="BusinessCombinationContingentConsiderationLiabilityPercentageOfAcquireeRevenues" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="lgnd_DevelopmentRegulatoryCommercialMilestonesAndTieredRoyaltiesMember" abstract="true" name="DevelopmentRegulatoryCommercialMilestonesAndTieredRoyaltiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lgnd_CommercialLicenseRightsPolicyTextBlock" abstract="false" name="CommercialLicenseRightsPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="lgnd_PaymentsToUnwindWarrants" abstract="false" name="PaymentsToUnwindWarrants" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_EarnoutRightsForPartnerResearchAndDevelopmentMember" abstract="true" name="EarnoutRightsForPartnerResearchAndDevelopmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lgnd_AdjustmentsToAdditionalPaidInCapitalWarrantAndBondHedgeUnwindTransactions" abstract="false" name="AdjustmentsToAdditionalPaidInCapitalWarrantAndBondHedgeUnwindTransactions" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_DebtInstrumentConvertibleIncreaseDecreaseIfConvertedValueInExcessOfPrincipal" abstract="false" name="DebtInstrumentConvertibleIncreaseDecreaseIfConvertedValueInExcessOfPrincipal" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_AmendedESPPMember" abstract="true" name="AmendedESPPMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssets" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssets" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_BusinessCombinationCashHoldbackForPotentialIndemnificationClaims" abstract="false" name="BusinessCombinationCashHoldbackForPotentialIndemnificationClaims" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_PartnerBMember" abstract="true" name="PartnerBMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lgnd_AuditInformationAbstract" abstract="true" name="AuditInformationAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="lgnd_RestrictedStockUnitsAndPerformanceSharesMember" abstract="true" name="RestrictedStockUnitsAndPerformanceSharesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lgnd_USDistrictCourtForTheNorthernDistrictOfOhioMember" abstract="true" name="USDistrictCourtForTheNorthernDistrictOfOhioMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lgnd_ContractRevenueMember" abstract="true" name="ContractRevenueMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lgnd_SelexisMember" abstract="true" name="SelexisMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lgnd_AccruedSalesReturns" abstract="false" name="AccruedSalesReturns" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_RepaymentsOfNotesPayableInterestPortion" abstract="false" name="RepaymentsOfNotesPayableInterestPortion" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_CydexPharmaceuticalsIncMember" abstract="true" name="CydexPharmaceuticalsIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lgnd_LiabilityForContingentValueRightsCompanyCydexMember" abstract="true" name="LiabilityForContingentValueRightsCompanyCydexMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lgnd_CorporateShareRepurchaseAbstract" abstract="true" name="CorporateShareRepurchaseAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="lgnd_AdditionalRoyaltiesReceivableUnderSalesbasedMilestones" abstract="false" name="AdditionalRoyaltiesReceivableUnderSalesbasedMilestones" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_IncreaseDecreaseInOtherEconomicRights" abstract="false" name="IncreaseDecreaseInOtherEconomicRights" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_LeaseLiability" abstract="false" name="LeaseLiability" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_BusinessCombinationContingentConsiderationLiabilityAmountPerShare" abstract="false" name="BusinessCombinationContingentConsiderationLiabilityAmountPerShare" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="lgnd_LicenseFeesMilestonesAndOtherProductOtherMember" abstract="true" name="LicenseFeesMilestonesAndOtherProductOtherMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lgnd_NumberOfContingentValueRightsIssued" abstract="false" name="NumberOfContingentValueRightsIssued" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="lgnd_ExercisePriceRangeNineMember" abstract="true" name="ExercisePriceRangeNineMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lgnd_EffectiveIncomeTaxRateReconciliationProvisionToReturnAdjustmentsAmount" abstract="false" name="EffectiveIncomeTaxRateReconciliationProvisionToReturnAdjustmentsAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_PartnerAMember" abstract="true" name="PartnerAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lgnd_ProductRoyaltyPercentage" abstract="false" name="ProductRoyaltyPercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="lgnd_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateAfterYearFive" abstract="false" name="DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateAfterYearFive" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_ExercisePriceRangeFiveMember" abstract="true" name="ExercisePriceRangeFiveMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lgnd_MaterialSalesCaptisolMember" abstract="true" name="MaterialSalesCaptisolMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lgnd_PfenexMember" abstract="true" name="PfenexMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lgnd_ScheduleofContingentLiabilitiesTableTextBlock" abstract="false" name="ScheduleofContingentLiabilitiesTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="lgnd_ScheduleofCommercialLicenseRightsTableTextBlock" abstract="false" name="ScheduleofCommercialLicenseRightsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="lgnd_RoyaltyPromactaMember" abstract="true" name="RoyaltyPromactaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lgnd_Phase3ClinicalTrialMember" abstract="true" name="Phase3ClinicalTrialMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lgnd_PurchaseCommitmentConsiderationPaidToDate" abstract="false" name="PurchaseCommitmentConsiderationPaidToDate" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_OtherBalanceSheetDetailsAbstract" abstract="true" name="OtherBalanceSheetDetailsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="lgnd_LiabilityForContingentValueRightsCompanyCrystalMember" abstract="true" name="LiabilityForContingentValueRightsCompanyCrystalMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lgnd_LesseeOperatingLeaseLiabilityTenantImprovementAllowance" abstract="false" name="LesseeOperatingLeaseLiabilityTenantImprovementAllowance" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_NumberOfAssetAcquisitions" abstract="false" name="NumberOfAssetAcquisitions" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="lgnd_ExercisePriceRangeSevenMember" abstract="true" name="ExercisePriceRangeSevenMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lgnd_EffectiveIncomeTaxRateReconciliationExpiredTaxCreditsResearch" abstract="false" name="EffectiveIncomeTaxRateReconciliationExpiredTaxCreditsResearch" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_ContractualRelationshipsJazzMember" abstract="true" name="ContractualRelationshipsJazzMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lgnd_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities" abstract="false" name="FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_AccruedInventoryPurchases" abstract="false" name="AccruedInventoryPurchases" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_InvestmentInVikingCurrent" abstract="false" name="InvestmentInVikingCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_ExercisePriceRangeSixMember" abstract="true" name="ExercisePriceRangeSixMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lgnd_FinanceLeaseLiabilityTenantImprovementAllowance" abstract="false" name="FinanceLeaseLiabilityTenantImprovementAllowance" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_AccruedSupplierExpensesCurrent" abstract="false" name="AccruedSupplierExpensesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearFive" abstract="false" name="DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearFive" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_AmortizationOfCommercialLicenseAndOtherEconomicRights" abstract="false" name="AmortizationOfCommercialLicenseAndOtherEconomicRights" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_ContingentValueRightOnProductRevenuesMember" abstract="true" name="ContingentValueRightOnProductRevenuesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lgnd_ConvertibleSeniorNotesDue2019Member" abstract="true" name="ConvertibleSeniorNotesDue2019Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lgnd_ExercisePriceRangeTenMember" abstract="true" name="ExercisePriceRangeTenMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lgnd_ProceedsFromUnwindingConvertibleBondHedges" abstract="false" name="ProceedsFromUnwindingConvertibleBondHedges" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_NumberOfAcquisitions" abstract="false" name="NumberOfAcquisitions" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="lgnd_LiabilityForRestrictedInvestmentsOwedToFormerLicenseesMember" abstract="true" name="LiabilityForRestrictedInvestmentsOwedToFormerLicenseesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lgnd_PaymentsToAcquireBusinessesGrossAttributableToVestedPortionOfStockOptions" abstract="false" name="PaymentsToAcquireBusinessesGrossAttributableToVestedPortionOfStockOptions" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_MetabasisTherapeuticsMember" abstract="true" name="MetabasisTherapeuticsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lgnd_IncreaseDecreaseInDebtDiscount" abstract="false" name="IncreaseDecreaseInDebtDiscount" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions" abstract="false" name="EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_IncomeTaxReconciliationContingentValueRights" abstract="false" name="IncomeTaxReconciliationContingentValueRights" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_PalvellaTherapeuticsIncMember" abstract="true" name="PalvellaTherapeuticsIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lgnd_LicenseUpfrontPayment" abstract="false" name="LicenseUpfrontPayment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_CaliforniaAndNewJerseyResearchTaxCreditCarryforwardMember" abstract="true" name="CaliforniaAndNewJerseyResearchTaxCreditCarryforwardMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lgnd_AziyoandCorMatrixMember" abstract="true" name="AziyoandCorMatrixMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lgnd_LicenseFeesMember" abstract="true" name="LicenseFeesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lgnd_NumberOfContingentValueRightAgreements" abstract="false" name="NumberOfContingentValueRightAgreements" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="lgnd_VernalisMember" abstract="true" name="VernalisMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lgnd_ExercisePriceRangeOneMember" abstract="true" name="ExercisePriceRangeOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lgnd_BusinessCombinationContingentConsiderationLiabilityFairValueDisclosure" abstract="false" name="BusinessCombinationContingentConsiderationLiabilityFairValueDisclosure" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_ExercisePriceRangeTwoMember" abstract="true" name="ExercisePriceRangeTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lgnd_NovanMolluscumProductsMember" abstract="true" name="NovanMolluscumProductsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lgnd_AbInitioMember" abstract="true" name="AbInitioMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lgnd_CurrentPortionOfLiabilityForContingentValueRights" abstract="false" name="CurrentPortionOfLiabilityForContingentValueRights" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_NonCashChangeInEstimatedFairValueOfContingentValueRights" abstract="false" name="NonCashChangeInEstimatedFairValueOfContingentValueRights" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_LiabilityForContingentValueRightsCompanyPfenexMember" abstract="true" name="LiabilityForContingentValueRightsCompanyPfenexMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lgnd_ProceedsFromCommercialLicenseRights" abstract="false" name="ProceedsFromCommercialLicenseRights" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_ContractualRelationshipsAlvogenMember" abstract="true" name="ContractualRelationshipsAlvogenMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilitiesCurrent" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilitiesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod" abstract="false" name="BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_PartnerCMember" abstract="true" name="PartnerCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lgnd_AssetsAndLiabilitiesLesseeTableTextBlock" abstract="false" name="AssetsAndLiabilitiesLesseeTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="lgnd_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityContingentConsiderationFromAcquisition" abstract="false" name="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityContingentConsiderationFromAcquisition" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_PaymentsToContingentValueRightHolders" abstract="false" name="PaymentsToContingentValueRightHolders" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_PromactaMember" abstract="true" name="PromactaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lgnd_CashPaidDuringTheYearAbstract" abstract="true" name="CashPaidDuringTheYearAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="lgnd_MilestonePaymentsMember" abstract="true" name="MilestonePaymentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lgnd_GainLossOnShortTermInvestments" abstract="false" name="GainLossOnShortTermInvestments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_FiniteLivedIntangibleAssetsAccumulatedAmortizationResearchDevelopmentExpenseAndCreditLossAdjustments" abstract="false" name="FiniteLivedIntangibleAssetsAccumulatedAmortizationResearchDevelopmentExpenseAndCreditLossAdjustments" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_BusinessCombinationAssumptionsUsedEstimatedFutureCashFlowsDiscountRate" abstract="false" name="BusinessCombinationAssumptionsUsedEstimatedFutureCashFlowsDiscountRate" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="lgnd_ContractualRelationshipsMerckMember" abstract="true" name="ContractualRelationshipsMerckMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lgnd_PaymentsforConvertibleBondHedges" abstract="false" name="PaymentsforConvertibleBondHedges" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_ExercisePriceRangeElevenMember" abstract="true" name="ExercisePriceRangeElevenMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lgnd_ComputerEquipmentAndSoftwareMember" abstract="true" name="ComputerEquipmentAndSoftwareMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsDiscountRate" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsDiscountRate" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="lgnd_XCellaBiosciencesIncMember" abstract="true" name="XCellaBiosciencesIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lgnd_EmployeeStockPurchasePlanAbstract" abstract="true" name="EmployeeStockPurchasePlanAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="lgnd_ContractualRelationshipsArcellxMember" abstract="true" name="ContractualRelationshipsArcellxMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssets" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssets" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_DeferredTaxLiabilitiesFiniteLivedIntangibleAssets" abstract="false" name="DeferredTaxLiabilitiesFiniteLivedIntangibleAssets" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_RoyaltyAgreementExpirationPeriod" abstract="false" name="RoyaltyAgreementExpirationPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndCurrentAssetsOther" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndCurrentAssetsOther" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_CashCashEquivalentsandShorttermInvestmentsPolicyTextBlock" abstract="false" name="CashCashEquivalentsandShorttermInvestmentsPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="lgnd_AccruedAssetAcquisitionsCurrent" abstract="false" name="AccruedAssetAcquisitionsCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_FiniteLivedIntangibleAssetsCreditLossAdjustments" abstract="false" name="FiniteLivedIntangibleAssetsCreditLossAdjustments" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_LiabilityForContingentValueRightsCompanyIcagenMember" abstract="true" name="LiabilityForContingentValueRightsCompanyIcagenMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityRepurchasesContingentLiabilities" abstract="false" name="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityRepurchasesContingentLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_BusinessAcquisitionContingentConsiderationPotentialCashPaymentAdditions" abstract="false" name="BusinessAcquisitionContingentConsiderationPotentialCashPaymentAdditions" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_CorMatrixMember" abstract="true" name="CorMatrixMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lgnd_VestingPeriodOneMember" abstract="true" name="VestingPeriodOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lgnd_LiabilityForContingentValueRights" abstract="false" name="LiabilityForContingentValueRights" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_VestingPeriodTwoMember" abstract="true" name="VestingPeriodTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lgnd_NumberOfOptionsUnderConvertibleBondHedges" abstract="false" name="NumberOfOptionsUnderConvertibleBondHedges" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="lgnd_ExercisePriceRangeFourMember" abstract="true" name="ExercisePriceRangeFourMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lgnd_TaurusBiosciencesLLCMember" abstract="true" name="TaurusBiosciencesLLCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lgnd_AziyoMember" abstract="true" name="AziyoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lgnd_BasisOfPresentationTable" abstract="true" name="BasisOfPresentationTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="lgnd_ContractualRelationshipsSIIMember" abstract="true" name="ContractualRelationshipsSIIMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lgnd_LeaseRightOfUseAsset" abstract="false" name="LeaseRightOfUseAsset" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_RoyaltyOtherMember" abstract="true" name="RoyaltyOtherMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lgnd_IcagenMember" abstract="true" name="IcagenMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lgnd_ExercisePriceRangeEightMember" abstract="true" name="ExercisePriceRangeEightMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lgnd_BasisOfPresentationLineItems" abstract="true" name="BasisOfPresentationLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="lgnd_TwoThousandTwoStockIncentivePlanMember" abstract="true" name="TwoThousandTwoStockIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lgnd_NumberOfSharesSoldOfEquityMethodInvestee" abstract="false" name="NumberOfSharesSoldOfEquityMethodInvestee" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="lgnd_MaturityPeriodOfHighlyLiquidSecuritiesMaximum" abstract="false" name="MaturityPeriodOfHighlyLiquidSecuritiesMaximum" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="lgnd_LiabilityForContingentValueRightsCompanyMetabasisMember" abstract="true" name="LiabilityForContingentValueRightsCompanyMetabasisMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>10
<FILENAME>lgnd-20211231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:d46a5cfc-72eb-4b3a-bd09-c8907e0f4c5d,g:058bd086-7924-4675-b3eb-d4a9ba4991e0-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="lgnd-20211231.xsd#CONSOLIDATEDBALANCESHEETS"/>
  <link:calculationLink xlink:role="http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_52c7764f-7651-40ed-a726-c4ac340e644d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_b3ee2cb3-27eb-4a29-bd77-378324a90101" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_52c7764f-7651-40ed-a726-c4ac340e644d" xlink:to="loc_us-gaap_AccountsPayableCurrent_b3ee2cb3-27eb-4a29-bd77-378324a90101" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_003ed902-a228-4c35-a68e-b596b29062b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_52c7764f-7651-40ed-a726-c4ac340e644d" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_003ed902-a228-4c35-a68e-b596b29062b6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_CurrentPortionOfLiabilityForContingentValueRights_0b48c2a3-f889-422a-a01c-3e3fbabf9390" xlink:href="lgnd-20211231.xsd#lgnd_CurrentPortionOfLiabilityForContingentValueRights"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_52c7764f-7651-40ed-a726-c4ac340e644d" xlink:to="loc_lgnd_CurrentPortionOfLiabilityForContingentValueRights_0b48c2a3-f889-422a-a01c-3e3fbabf9390" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_12c5f817-97ba-4ead-b835-dedafe902b88" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_52c7764f-7651-40ed-a726-c4ac340e644d" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_12c5f817-97ba-4ead-b835-dedafe902b88" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_b8d31c60-8655-41ea-b34c-abd8ab102a83" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_52c7764f-7651-40ed-a726-c4ac340e644d" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_b8d31c60-8655-41ea-b34c-abd8ab102a83" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_ff334ded-7c1e-4e66-bdef-eb518beaec25" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_52c7764f-7651-40ed-a726-c4ac340e644d" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_ff334ded-7c1e-4e66-bdef-eb518beaec25" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_1b6e484a-247c-4550-94f1-98943843830f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_109997d0-431c-4f2e-bbe5-6e1472d679d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_1b6e484a-247c-4550-94f1-98943843830f" xlink:to="loc_us-gaap_LiabilitiesCurrent_109997d0-431c-4f2e-bbe5-6e1472d679d4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtNoncurrent_9665e138-b7f7-48c3-9fc0-760cc7400f6e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_1b6e484a-247c-4550-94f1-98943843830f" xlink:to="loc_us-gaap_ConvertibleDebtNoncurrent_9665e138-b7f7-48c3-9fc0-760cc7400f6e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_LiabilityForContingentValueRights_da1b9503-2fe6-40f4-82db-458f4c0b5178" xlink:href="lgnd-20211231.xsd#lgnd_LiabilityForContingentValueRights"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_1b6e484a-247c-4550-94f1-98943843830f" xlink:to="loc_lgnd_LiabilityForContingentValueRights_da1b9503-2fe6-40f4-82db-458f4c0b5178" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_fd8d5980-73f3-4e24-a4bb-fee66d170218" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_1b6e484a-247c-4550-94f1-98943843830f" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_fd8d5980-73f3-4e24-a4bb-fee66d170218" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_930b4c34-ddcf-4545-a75e-0eeea2eab2c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_1b6e484a-247c-4550-94f1-98943843830f" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_930b4c34-ddcf-4545-a75e-0eeea2eab2c0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_71c328e2-d9aa-4ea6-9db0-47674252dc16" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_1b6e484a-247c-4550-94f1-98943843830f" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_71c328e2-d9aa-4ea6-9db0-47674252dc16" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_5ad9211f-1e5e-408b-aa72-eb174be61d09" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_e06d59cf-118e-4538-b1bd-3ee823abafcd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_5ad9211f-1e5e-408b-aa72-eb174be61d09" xlink:to="loc_us-gaap_Liabilities_e06d59cf-118e-4538-b1bd-3ee823abafcd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_ed3d479c-04a2-47b9-8019-4a636947cdd2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_5ad9211f-1e5e-408b-aa72-eb174be61d09" xlink:to="loc_us-gaap_CommitmentsAndContingencies_ed3d479c-04a2-47b9-8019-4a636947cdd2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_d89330b0-e3e0-4d63-9cb0-cbf678cd5ff2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_5ad9211f-1e5e-408b-aa72-eb174be61d09" xlink:to="loc_us-gaap_StockholdersEquity_d89330b0-e3e0-4d63-9cb0-cbf678cd5ff2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_dea2f483-9cbc-4c6b-97ba-d8cdcdeda8e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_5a8b4925-0da3-4a81-b122-cf3e18193186" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_dea2f483-9cbc-4c6b-97ba-d8cdcdeda8e9" xlink:to="loc_us-gaap_AssetsCurrent_5a8b4925-0da3-4a81-b122-cf3e18193186" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_adc690de-9ca8-42c7-b9a4-a03c08df324d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_dea2f483-9cbc-4c6b-97ba-d8cdcdeda8e9" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_adc690de-9ca8-42c7-b9a4-a03c08df324d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_d394eac4-275b-41fb-b27d-b39deacacf3b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_dea2f483-9cbc-4c6b-97ba-d8cdcdeda8e9" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_d394eac4-275b-41fb-b27d-b39deacacf3b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_4a613886-ed63-4bb4-a769-0272eda82c38" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_dea2f483-9cbc-4c6b-97ba-d8cdcdeda8e9" xlink:to="loc_us-gaap_Goodwill_4a613886-ed63-4bb4-a769-0272eda82c38" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_CommercialLicenseRights_cd38f36e-13fa-492d-af8b-1e863885ffb7" xlink:href="lgnd-20211231.xsd#lgnd_CommercialLicenseRights"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_dea2f483-9cbc-4c6b-97ba-d8cdcdeda8e9" xlink:to="loc_lgnd_CommercialLicenseRights_cd38f36e-13fa-492d-af8b-1e863885ffb7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_6a8ab850-fe83-4e6c-bde6-41bffe2c7194" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_dea2f483-9cbc-4c6b-97ba-d8cdcdeda8e9" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_6a8ab850-fe83-4e6c-bde6-41bffe2c7194" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_a3d7f7c2-4450-428b-8630-4b0cb714a5ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_dea2f483-9cbc-4c6b-97ba-d8cdcdeda8e9" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_a3d7f7c2-4450-428b-8630-4b0cb714a5ef" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAsset_2b5ce6b3-dd4e-4b59-bae3-ce0045661502" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAsset"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_dea2f483-9cbc-4c6b-97ba-d8cdcdeda8e9" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAsset_2b5ce6b3-dd4e-4b59-bae3-ce0045661502" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_47f59a08-6692-4393-b6b0-c7efa9fe0a84" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_dea2f483-9cbc-4c6b-97ba-d8cdcdeda8e9" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_47f59a08-6692-4393-b6b0-c7efa9fe0a84" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_fc223a11-91bc-4684-aa59-9e185d243d9d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_f544d25b-7e63-434b-8175-a2958ff2916f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_fc223a11-91bc-4684-aa59-9e185d243d9d" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_f544d25b-7e63-434b-8175-a2958ff2916f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments_74cbe9a4-ce90-4aac-8f72-5201cdcc4d73" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermInvestments"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_fc223a11-91bc-4684-aa59-9e185d243d9d" xlink:to="loc_us-gaap_ShortTermInvestments_74cbe9a4-ce90-4aac-8f72-5201cdcc4d73" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_9dfb0eaa-4b5e-4d1a-8fab-8b75b91ddf14" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_fc223a11-91bc-4684-aa59-9e185d243d9d" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_9dfb0eaa-4b5e-4d1a-8fab-8b75b91ddf14" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_132a269f-045b-4545-8aca-555d472cec93" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_fc223a11-91bc-4684-aa59-9e185d243d9d" xlink:to="loc_us-gaap_InventoryNet_132a269f-045b-4545-8aca-555d472cec93" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesReceivable_4dec5967-1568-48a4-aeb6-56890c43bfd1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxesReceivable"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_fc223a11-91bc-4684-aa59-9e185d243d9d" xlink:to="loc_us-gaap_IncomeTaxesReceivable_4dec5967-1568-48a4-aeb6-56890c43bfd1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_25865453-ffe5-4e20-a926-fe47336e881f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_fc223a11-91bc-4684-aa59-9e185d243d9d" xlink:to="loc_us-gaap_OtherAssetsCurrent_25865453-ffe5-4e20-a926-fe47336e881f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_ac4dfd94-4101-4eda-84f0-b561aa163cfa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_d3083599-fbcd-4979-bfeb-fe430e8a50c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_ac4dfd94-4101-4eda-84f0-b561aa163cfa" xlink:to="loc_us-gaap_PreferredStockValue_d3083599-fbcd-4979-bfeb-fe430e8a50c1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_6c274c56-fed2-4864-9d0b-d670037ce23e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_ac4dfd94-4101-4eda-84f0-b561aa163cfa" xlink:to="loc_us-gaap_CommonStockValue_6c274c56-fed2-4864-9d0b-d670037ce23e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_016c8067-58d5-42a9-86aa-0b5fc441e207" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_ac4dfd94-4101-4eda-84f0-b561aa163cfa" xlink:to="loc_us-gaap_AdditionalPaidInCapital_016c8067-58d5-42a9-86aa-0b5fc441e207" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_d2c05321-0263-4af3-a7e5-126f2aa1ca67" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_ac4dfd94-4101-4eda-84f0-b561aa163cfa" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_d2c05321-0263-4af3-a7e5-126f2aa1ca67" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_791b7155-fcb8-4ec6-8487-e5f4b5bf4aea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_ac4dfd94-4101-4eda-84f0-b561aa163cfa" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_791b7155-fcb8-4ec6-8487-e5f4b5bf4aea" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="simple" xlink:href="lgnd-20211231.xsd#CONSOLIDATEDSTATEMENTSOFOPERATIONS"/>
  <link:calculationLink xlink:role="http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_bc70f75e-f65f-483e-b32e-643247091c94" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_5c781cd8-2166-42b4-b8b4-87ee41ecbcdf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_bc70f75e-f65f-483e-b32e-643247091c94" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_5c781cd8-2166-42b4-b8b4-87ee41ecbcdf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingCostsAndExpenses_aab5eb20-6974-4920-ae3f-ba536e92004d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingCostsAndExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_bc70f75e-f65f-483e-b32e-643247091c94" xlink:to="loc_us-gaap_OperatingCostsAndExpenses_aab5eb20-6974-4920-ae3f-ba536e92004d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfIntangibleAssets_8dcd0346-d372-4de9-ae7d-125f69a2974e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnDispositionOfIntangibleAssets"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_bc70f75e-f65f-483e-b32e-643247091c94" xlink:to="loc_us-gaap_GainLossOnDispositionOfIntangibleAssets_8dcd0346-d372-4de9-ae7d-125f69a2974e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_762228d4-894b-4dc7-aa41-38082849134a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_7bc19473-df33-474d-8441-11d108d95d02" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_762228d4-894b-4dc7-aa41-38082849134a" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_7bc19473-df33-474d-8441-11d108d95d02" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_e37d22e3-3b9f-4208-b311-cd3f5438d7af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_762228d4-894b-4dc7-aa41-38082849134a" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_e37d22e3-3b9f-4208-b311-cd3f5438d7af" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_0d957c26-c2af-41ac-a73d-e30d8e66a79b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnInvestments_b600a3ba-2d3a-46ba-8672-dc515e34c04c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnInvestments"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_0d957c26-c2af-41ac-a73d-e30d8e66a79b" xlink:to="loc_us-gaap_GainLossOnInvestments_b600a3ba-2d3a-46ba-8672-dc515e34c04c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_f4d75894-7855-4305-bbc7-6e37cf23974e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_0d957c26-c2af-41ac-a73d-e30d8e66a79b" xlink:to="loc_us-gaap_InvestmentIncomeInterest_f4d75894-7855-4305-bbc7-6e37cf23974e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_0bf6a9a1-5a3c-4df5-a77a-8a86e34e310c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_0d957c26-c2af-41ac-a73d-e30d8e66a79b" xlink:to="loc_us-gaap_InterestExpense_0bf6a9a1-5a3c-4df5-a77a-8a86e34e310c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_e318ae17-6445-4097-91f2-fe4474c946dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_0d957c26-c2af-41ac-a73d-e30d8e66a79b" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_e318ae17-6445-4097-91f2-fe4474c946dc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingCostsAndExpenses_89f8e42b-c66d-4838-b1bc-36f1c4918dc3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingCostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostDirectMaterial_d2c466e9-813a-429b-b3ef-0f2fbdbd5075" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostDirectMaterial"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingCostsAndExpenses_89f8e42b-c66d-4838-b1bc-36f1c4918dc3" xlink:to="loc_us-gaap_CostDirectMaterial_d2c466e9-813a-429b-b3ef-0f2fbdbd5075" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSoldAmortization_375b4b58-2aab-44ab-8ddb-2016ad426f24" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSoldAmortization"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingCostsAndExpenses_89f8e42b-c66d-4838-b1bc-36f1c4918dc3" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSoldAmortization_375b4b58-2aab-44ab-8ddb-2016ad426f24" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_11a0fbeb-1e11-41d5-9f74-4a9b15eddefc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingCostsAndExpenses_89f8e42b-c66d-4838-b1bc-36f1c4918dc3" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_11a0fbeb-1e11-41d5-9f74-4a9b15eddefc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_cd5969f4-4633-4bd6-9433-88d57f56479b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingCostsAndExpenses_89f8e42b-c66d-4838-b1bc-36f1c4918dc3" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_cd5969f4-4633-4bd6-9433-88d57f56479b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncome_6fd3aebc-0f98-41b2-b5de-b7f1af743b54" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherOperatingIncome"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingCostsAndExpenses_89f8e42b-c66d-4838-b1bc-36f1c4918dc3" xlink:to="loc_us-gaap_OtherOperatingIncome_6fd3aebc-0f98-41b2-b5de-b7f1af743b54" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_b3900377-d2cc-442e-b9f0-3b2a1a196236" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_0815840b-afe1-48a8-817a-8c4146ad6f32" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_b3900377-d2cc-442e-b9f0-3b2a1a196236" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_0815840b-afe1-48a8-817a-8c4146ad6f32" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_345ea2c9-cf3f-4d7f-924f-331542b326f4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_b3900377-d2cc-442e-b9f0-3b2a1a196236" xlink:to="loc_us-gaap_OperatingIncomeLoss_345ea2c9-cf3f-4d7f-924f-331542b326f4" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS" xlink:type="simple" xlink:href="lgnd-20211231.xsd#CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS"/>
  <link:calculationLink xlink:role="http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_74bab6c3-7ae0-4081-83da-41f69955565f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_f513b73e-f825-4b60-81d8-91b088d7a3cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_74bab6c3-7ae0-4081-83da-41f69955565f" xlink:to="loc_us-gaap_NetIncomeLoss_f513b73e-f825-4b60-81d8-91b088d7a3cb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_8a4881ea-bc59-4680-b3f0-c0e358aff0b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_74bab6c3-7ae0-4081-83da-41f69955565f" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_8a4881ea-bc59-4680-b3f0-c0e358aff0b8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_5a229ca4-8ccf-4fb0-881d-7df836dc2ab9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_74bab6c3-7ae0-4081-83da-41f69955565f" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_5a229ca4-8ccf-4fb0-881d-7df836dc2ab9" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="lgnd-20211231.xsd#CONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:calculationLink xlink:role="http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_7d53f23a-f16f-45a7-9ffd-5b30813fd3dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfIntangibleAssets_bf632cf0-889d-4e7a-8226-87e76cc2d2c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfIntangibleAssets"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_7d53f23a-f16f-45a7-9ffd-5b30813fd3dd" xlink:to="loc_us-gaap_ProceedsFromSaleOfIntangibleAssets_bf632cf0-889d-4e7a-8226-87e76cc2d2c6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_50ef52c3-6fd1-4cb7-bf56-b3585cebbe5c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_7d53f23a-f16f-45a7-9ffd-5b30813fd3dd" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_50ef52c3-6fd1-4cb7-bf56-b3585cebbe5c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_1eeb1a36-f0fb-4642-a3f7-f1351e85d28c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_7d53f23a-f16f-45a7-9ffd-5b30813fd3dd" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_1eeb1a36-f0fb-4642-a3f7-f1351e85d28c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireShortTermInvestments_7af3b6e0-94ca-4ff7-af56-1bbf2581698c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireShortTermInvestments"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_7d53f23a-f16f-45a7-9ffd-5b30813fd3dd" xlink:to="loc_us-gaap_PaymentsToAcquireShortTermInvestments_7af3b6e0-94ca-4ff7-af56-1bbf2581698c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ProceedsFromCommercialLicenseRights_6bb9f21e-4606-4068-b4fa-04be3ae027a5" xlink:href="lgnd-20211231.xsd#lgnd_ProceedsFromCommercialLicenseRights"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_7d53f23a-f16f-45a7-9ffd-5b30813fd3dd" xlink:to="loc_lgnd_ProceedsFromCommercialLicenseRights_6bb9f21e-4606-4068-b4fa-04be3ae027a5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfShortTermInvestments_8956b8fc-c163-46dd-b2fe-5984043aad91" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfShortTermInvestments"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_7d53f23a-f16f-45a7-9ffd-5b30813fd3dd" xlink:to="loc_us-gaap_ProceedsFromSaleOfShortTermInvestments_8956b8fc-c163-46dd-b2fe-5984043aad91" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments_ec717f9b-9196-4f5a-a6ee-fd7e0ce91677" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_7d53f23a-f16f-45a7-9ffd-5b30813fd3dd" xlink:to="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments_ec717f9b-9196-4f5a-a6ee-fd7e0ce91677" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_55e73428-5ee6-45d2-a262-434f4c262599" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_7d53f23a-f16f-45a7-9ffd-5b30813fd3dd" xlink:to="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_55e73428-5ee6-45d2-a262-434f4c262599" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_fd135ab5-46b8-43ae-b33e-e32c61bd0400" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromDivestitureOfBusinesses"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_7d53f23a-f16f-45a7-9ffd-5b30813fd3dd" xlink:to="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_fd135ab5-46b8-43ae-b33e-e32c61bd0400" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_de95939e-268c-4a38-a793-27ac39e0a6f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_7d53f23a-f16f-45a7-9ffd-5b30813fd3dd" xlink:to="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_de95939e-268c-4a38-a793-27ac39e0a6f6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_21c29d5a-a733-4220-9a74-d4d0a14bfd86" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_009eb335-0dfe-40ba-89bc-842e0a8afea2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_21c29d5a-a733-4220-9a74-d4d0a14bfd86" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_009eb335-0dfe-40ba-89bc-842e0a8afea2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_ffebd638-cdd0-49dc-bbb7-db5d493a7d7b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_21c29d5a-a733-4220-9a74-d4d0a14bfd86" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_ffebd638-cdd0-49dc-bbb7-db5d493a7d7b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_e4eed0c3-6dd1-4c23-a473-beaebbede25e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_21c29d5a-a733-4220-9a74-d4d0a14bfd86" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_e4eed0c3-6dd1-4c23-a473-beaebbede25e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_69aa78fe-2962-4c25-8ad9-3e3deb920b34" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_273e3ce9-1d63-45f5-a17e-2e0593158044" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_69aa78fe-2962-4c25-8ad9-3e3deb920b34" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_273e3ce9-1d63-45f5-a17e-2e0593158044" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments_6aacaf40-910c-4f7a-b972-6b36a8e280a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_69aa78fe-2962-4c25-8ad9-3e3deb920b34" xlink:to="loc_us-gaap_FinanceLeasePrincipalPayments_6aacaf40-910c-4f7a-b972-6b36a8e280a2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromHedgeFinancingActivities_d8df1c21-1692-4e11-854a-e6d5cc046b39" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromHedgeFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_69aa78fe-2962-4c25-8ad9-3e3deb920b34" xlink:to="loc_us-gaap_ProceedsFromHedgeFinancingActivities_d8df1c21-1692-4e11-854a-e6d5cc046b39" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForHedgeFinancingActivities_e4527777-45d2-4292-9ee3-5677f98d3d30" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForHedgeFinancingActivities"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_69aa78fe-2962-4c25-8ad9-3e3deb920b34" xlink:to="loc_us-gaap_PaymentsForHedgeFinancingActivities_e4527777-45d2-4292-9ee3-5677f98d3d30" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_7ea6e7f6-4ebc-44bc-81d3-dfbdb9ca58b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_69aa78fe-2962-4c25-8ad9-3e3deb920b34" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_7ea6e7f6-4ebc-44bc-81d3-dfbdb9ca58b7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_ca545d2b-0566-4387-a957-94fee48a432e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_69aa78fe-2962-4c25-8ad9-3e3deb920b34" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_ca545d2b-0566-4387-a957-94fee48a432e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_0be1eaee-2aa3-459a-b244-b348f8cb73ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_69aa78fe-2962-4c25-8ad9-3e3deb920b34" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_0be1eaee-2aa3-459a-b244-b348f8cb73ee" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfWarrants_d5c1d05b-bbb4-454e-8ef9-6c05ebf7886a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRepurchaseOfWarrants"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_69aa78fe-2962-4c25-8ad9-3e3deb920b34" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfWarrants_d5c1d05b-bbb4-454e-8ef9-6c05ebf7886a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PaymentsToContingentValueRightHoldersFinancingActivity_47fe46c5-a1b4-4c43-923d-5b5b3bdfc5dc" xlink:href="lgnd-20211231.xsd#lgnd_PaymentsToContingentValueRightHoldersFinancingActivity"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_69aa78fe-2962-4c25-8ad9-3e3deb920b34" xlink:to="loc_lgnd_PaymentsToContingentValueRightHoldersFinancingActivity_47fe46c5-a1b4-4c43-923d-5b5b3bdfc5dc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_754cb084-e914-48f1-85b7-3d45a0f2c9da" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_797ffd4b-29ce-46d3-afd6-b92e55b4829f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_754cb084-e914-48f1-85b7-3d45a0f2c9da" xlink:to="loc_us-gaap_ProfitLoss_797ffd4b-29ce-46d3-afd6-b92e55b4829f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfOtherAssets_f7f94565-2c3c-490d-bbbc-b33d8cd8a7f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnSaleOfOtherAssets"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_754cb084-e914-48f1-85b7-3d45a0f2c9da" xlink:to="loc_us-gaap_GainLossOnSaleOfOtherAssets_f7f94565-2c3c-490d-bbbc-b33d8cd8a7f8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfBusiness_2b21b8ad-770b-4c56-ad64-5e4620f9af15" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnSaleOfBusiness"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_754cb084-e914-48f1-85b7-3d45a0f2c9da" xlink:to="loc_us-gaap_GainLossOnSaleOfBusiness_2b21b8ad-770b-4c56-ad64-5e4620f9af15" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_NonCashChangeInEstimatedFairValueOfContingentValueRights_b1ce59bf-91fb-47e4-9126-495c5b1eb6be" xlink:href="lgnd-20211231.xsd#lgnd_NonCashChangeInEstimatedFairValueOfContingentValueRights"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_754cb084-e914-48f1-85b7-3d45a0f2c9da" xlink:to="loc_lgnd_NonCashChangeInEstimatedFairValueOfContingentValueRights_b1ce59bf-91fb-47e4-9126-495c5b1eb6be" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_1001b62d-f8ea-40f5-93a9-78bb911fd80b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_754cb084-e914-48f1-85b7-3d45a0f2c9da" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_1001b62d-f8ea-40f5-93a9-78bb911fd80b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_GainLossOnShortTermInvestments_6d759967-6af7-4509-9bb9-f34cd1937ddc" xlink:href="lgnd-20211231.xsd#lgnd_GainLossOnShortTermInvestments"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_754cb084-e914-48f1-85b7-3d45a0f2c9da" xlink:to="loc_lgnd_GainLossOnShortTermInvestments_6d759967-6af7-4509-9bb9-f34cd1937ddc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_93010ef0-f1c7-4d15-8cd7-0963d224ad56" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_754cb084-e914-48f1-85b7-3d45a0f2c9da" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_93010ef0-f1c7-4d15-8cd7-0963d224ad56" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_0261cc55-e6f3-4a45-a84d-469f45c1dd03" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_754cb084-e914-48f1-85b7-3d45a0f2c9da" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_0261cc55-e6f3-4a45-a84d-469f45c1dd03" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AmortizationOfCommercialLicenseAndOtherEconomicRights_528abd46-5582-4894-842f-93b6670bb2d5" xlink:href="lgnd-20211231.xsd#lgnd_AmortizationOfCommercialLicenseAndOtherEconomicRights"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_754cb084-e914-48f1-85b7-3d45a0f2c9da" xlink:to="loc_lgnd_AmortizationOfCommercialLicenseAndOtherEconomicRights_528abd46-5582-4894-842f-93b6670bb2d5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_60e4c889-a150-4b17-9446-eb46be9f3e1b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_754cb084-e914-48f1-85b7-3d45a0f2c9da" xlink:to="loc_us-gaap_ShareBasedCompensation_60e4c889-a150-4b17-9446-eb46be9f3e1b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_c1ca4640-9fb9-4e6b-af72-5b17c8f9cb5e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredIncomeTaxes"/>
    <link:calculationArc order="11" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_754cb084-e914-48f1-85b7-3d45a0f2c9da" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_c1ca4640-9fb9-4e6b-af72-5b17c8f9cb5e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement_103e61b8-3643-4c67-8847-ec1e14d0e98c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherOperatingActivitiesCashFlowStatement"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_754cb084-e914-48f1-85b7-3d45a0f2c9da" xlink:to="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement_103e61b8-3643-4c67-8847-ec1e14d0e98c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_1d582201-b93d-4ecf-be80-4f28fff466b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="13" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_754cb084-e914-48f1-85b7-3d45a0f2c9da" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_1d582201-b93d-4ecf-be80-4f28fff466b1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_ca28a9ff-fd4b-4bb4-8fd0-50e1af24a4fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:calculationArc order="14" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_754cb084-e914-48f1-85b7-3d45a0f2c9da" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_ca28a9ff-fd4b-4bb4-8fd0-50e1af24a4fa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_04fb3cec-2efa-4319-9644-17d11491f28e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:calculationArc order="15" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_754cb084-e914-48f1-85b7-3d45a0f2c9da" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_04fb3cec-2efa-4319-9644-17d11491f28e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable_cbc82b76-1892-4f3f-9d6b-088dfece61c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInIncomeTaxesReceivable"/>
    <link:calculationArc order="16" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_754cb084-e914-48f1-85b7-3d45a0f2c9da" xlink:to="loc_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable_cbc82b76-1892-4f3f-9d6b-088dfece61c7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_IncreaseDecreaseInOtherEconomicRights_48744f54-4939-4349-8b40-6776b5a5d73c" xlink:href="lgnd-20211231.xsd#lgnd_IncreaseDecreaseInOtherEconomicRights"/>
    <link:calculationArc order="17" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_754cb084-e914-48f1-85b7-3d45a0f2c9da" xlink:to="loc_lgnd_IncreaseDecreaseInOtherEconomicRights_48744f54-4939-4349-8b40-6776b5a5d73c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_a427dcb8-d9ca-4247-aee8-40d64f2421e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:calculationArc order="18" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_754cb084-e914-48f1-85b7-3d45a0f2c9da" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_a427dcb8-d9ca-4247-aee8-40d64f2421e9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_94db94f1-de77-4280-a52d-d863648eb960" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentLiabilities"/>
    <link:calculationArc order="19" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_754cb084-e914-48f1-85b7-3d45a0f2c9da" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_94db94f1-de77-4280-a52d-d863648eb960" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_c4805369-c2b6-42fb-bded-443c90431a7d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:calculationArc order="20" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_754cb084-e914-48f1-85b7-3d45a0f2c9da" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_c4805369-c2b6-42fb-bded-443c90431a7d" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCommercialLicenseRightsDetails" xlink:type="simple" xlink:href="lgnd-20211231.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesCommercialLicenseRightsDetails"/>
  <link:calculationLink xlink:role="http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCommercialLicenseRightsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_c37c8c14-ede8-45d1-bf41-b26be2d2539b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_1288b6d0-2c8e-4fc9-a214-9de40eca6f0d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_c37c8c14-ede8-45d1-bf41-b26be2d2539b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_1288b6d0-2c8e-4fc9-a214-9de40eca6f0d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_FiniteLivedIntangibleAssetsAccumulatedAmortizationResearchDevelopmentExpenseAndCreditLossAdjustments_824ed07d-4a40-4dc6-a24a-d6c26f7ccba5" xlink:href="lgnd-20211231.xsd#lgnd_FiniteLivedIntangibleAssetsAccumulatedAmortizationResearchDevelopmentExpenseAndCreditLossAdjustments"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_c37c8c14-ede8-45d1-bf41-b26be2d2539b" xlink:to="loc_lgnd_FiniteLivedIntangibleAssetsAccumulatedAmortizationResearchDevelopmentExpenseAndCreditLossAdjustments_824ed07d-4a40-4dc6-a24a-d6c26f7ccba5" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCalculationofEarningsperShareDetails" xlink:type="simple" xlink:href="lgnd-20211231.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesCalculationofEarningsperShareDetails"/>
  <link:calculationLink xlink:role="http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCalculationofEarningsperShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_7da30710-605a-4560-8712-744d6f6c7ee2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_cfe72c93-5e12-468c-952f-ed185c2ba880" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_7da30710-605a-4560-8712-744d6f6c7ee2" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_cfe72c93-5e12-468c-952f-ed185c2ba880" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_5cd170de-e55c-4f0e-ab36-ae706ebdb97f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_7da30710-605a-4560-8712-744d6f6c7ee2" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_5cd170de-e55c-4f0e-ab36-ae706ebdb97f" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails" xlink:type="simple" xlink:href="lgnd-20211231.xsd#AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails"/>
  <link:calculationLink xlink:role="http://www.ligand.com/role/AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_27444324-1b62-4e17-bca8-04317de0a94d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssets_9fc0d87d-4da1-42de-8734-4b17631de538" xlink:href="lgnd-20211231.xsd#lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssets"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_27444324-1b62-4e17-bca8-04317de0a94d" xlink:to="loc_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssets_9fc0d87d-4da1-42de-8734-4b17631de538" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash_37675968-e002-4304-b01f-5359d216cabf" xlink:href="lgnd-20211231.xsd#lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_27444324-1b62-4e17-bca8-04317de0a94d" xlink:to="loc_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash_37675968-e002-4304-b01f-5359d216cabf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_08534e72-f483-4340-9654-3fe1284f9dd2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_27444324-1b62-4e17-bca8-04317de0a94d" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_08534e72-f483-4340-9654-3fe1284f9dd2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLeaseLiabilities_7cdc4bee-11c1-497b-8de9-a37e327cebdd" xlink:href="lgnd-20211231.xsd#lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLeaseLiabilities"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_27444324-1b62-4e17-bca8-04317de0a94d" xlink:to="loc_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLeaseLiabilities_7cdc4bee-11c1-497b-8de9-a37e327cebdd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssets_918aeaf2-f3e7-42c9-b43f-7f620e9064e3" xlink:href="lgnd-20211231.xsd#lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssets"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_27444324-1b62-4e17-bca8-04317de0a94d" xlink:to="loc_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssets_918aeaf2-f3e7-42c9-b43f-7f620e9064e3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_0b4ebcad-0fe2-4003-8e19-4056fcba0bc8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_27444324-1b62-4e17-bca8-04317de0a94d" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_0b4ebcad-0fe2-4003-8e19-4056fcba0bc8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_ede66278-71ad-43f0-a0b7-c1e16986cfc7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_27444324-1b62-4e17-bca8-04317de0a94d" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_ede66278-71ad-43f0-a0b7-c1e16986cfc7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue_4498372a-ca33-4e14-90a1-4a30210847c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_27444324-1b62-4e17-bca8-04317de0a94d" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue_4498372a-ca33-4e14-90a1-4a30210847c1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_6fa1a29a-2f5d-4cc4-9969-3340cc80e2f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_27444324-1b62-4e17-bca8-04317de0a94d" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_6fa1a29a-2f5d-4cc4-9969-3340cc80e2f3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_7b7d2a51-3d7b-4f56-97fd-a1cbee3c8a23" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_27444324-1b62-4e17-bca8-04317de0a94d" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_7b7d2a51-3d7b-4f56-97fd-a1cbee3c8a23" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther_4b1915d4-cdaa-47c3-a96f-2d40090c0369" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther"/>
    <link:calculationArc order="11" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_27444324-1b62-4e17-bca8-04317de0a94d" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther_4b1915d4-cdaa-47c3-a96f-2d40090c0369" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_fb37b324-f4d1-4854-b8c4-cd1f82acd2db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_27444324-1b62-4e17-bca8-04317de0a94d" xlink:to="loc_us-gaap_Goodwill_fb37b324-f4d1-4854-b8c4-cd1f82acd2db" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilitiesCurrent_49f6b20b-af08-4003-98d3-715e30929360" xlink:href="lgnd-20211231.xsd#lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="13" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_27444324-1b62-4e17-bca8-04317de0a94d" xlink:to="loc_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilitiesCurrent_49f6b20b-af08-4003-98d3-715e30929360" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_124b0a50-b8aa-408d-a582-da32cd6da7e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets"/>
    <link:calculationArc order="14" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_27444324-1b62-4e17-bca8-04317de0a94d" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_124b0a50-b8aa-408d-a582-da32cd6da7e0" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/LeasesOperatingandFinanceLeaseAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="lgnd-20211231.xsd#LeasesOperatingandFinanceLeaseAssetsandLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.ligand.com/role/LeasesOperatingandFinanceLeaseAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_LeaseLiabilityCurrent_f984ae73-23fc-49c9-a5b2-09d4f6a632f4" xlink:href="lgnd-20211231.xsd#lgnd_LeaseLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_f01537ae-2b6b-4c33-9c02-39059177848c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_lgnd_LeaseLiabilityCurrent_f984ae73-23fc-49c9-a5b2-09d4f6a632f4" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_f01537ae-2b6b-4c33-9c02-39059177848c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_df68bb3e-0b81-4b8c-89ee-a57379fb721d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_lgnd_LeaseLiabilityCurrent_f984ae73-23fc-49c9-a5b2-09d4f6a632f4" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_df68bb3e-0b81-4b8c-89ee-a57379fb721d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_LeaseLiability_5a391d19-58a7-45a4-86a0-93b3f604833b" xlink:href="lgnd-20211231.xsd#lgnd_LeaseLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_LeaseLiabilityCurrent_18a7904b-02cf-476d-88f2-f3d23e3ff392" xlink:href="lgnd-20211231.xsd#lgnd_LeaseLiabilityCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_lgnd_LeaseLiability_5a391d19-58a7-45a4-86a0-93b3f604833b" xlink:to="loc_lgnd_LeaseLiabilityCurrent_18a7904b-02cf-476d-88f2-f3d23e3ff392" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_9ec798d4-da2e-4670-81a2-f04e30f0789b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_lgnd_LeaseLiability_5a391d19-58a7-45a4-86a0-93b3f604833b" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_9ec798d4-da2e-4670-81a2-f04e30f0789b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_bcec7ead-7fe8-4394-9e6d-f118f12eb03f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_lgnd_LeaseLiability_5a391d19-58a7-45a4-86a0-93b3f604833b" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_bcec7ead-7fe8-4394-9e6d-f118f12eb03f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_LeaseRightOfUseAsset_8d00d242-588d-4ce2-a351-ebfccf011978" xlink:href="lgnd-20211231.xsd#lgnd_LeaseRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_dcf93e34-5e64-45f7-b687-1e8d8513f94f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_lgnd_LeaseRightOfUseAsset_8d00d242-588d-4ce2-a351-ebfccf011978" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_dcf93e34-5e64-45f7-b687-1e8d8513f94f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAsset_1415c70c-ab57-4705-88ab-f02c19bd486a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAsset"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_lgnd_LeaseRightOfUseAsset_8d00d242-588d-4ce2-a351-ebfccf011978" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAsset_1415c70c-ab57-4705-88ab-f02c19bd486a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails" xlink:type="simple" xlink:href="lgnd-20211231.xsd#LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.ligand.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_efad9b77-4c12-40df-a954-8ca627e8cd5b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_FinanceLeaseLiabilityTenantImprovementAllowance_d65177ad-85a5-47bc-a3cf-a0d2cc4b1232" xlink:href="lgnd-20211231.xsd#lgnd_FinanceLeaseLiabilityTenantImprovementAllowance"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_efad9b77-4c12-40df-a954-8ca627e8cd5b" xlink:to="loc_lgnd_FinanceLeaseLiabilityTenantImprovementAllowance_d65177ad-85a5-47bc-a3cf-a0d2cc4b1232" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_1bdd9215-b3cd-4990-8ad3-70c317bca682" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_efad9b77-4c12-40df-a954-8ca627e8cd5b" xlink:to="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_1bdd9215-b3cd-4990-8ad3-70c317bca682" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability_b9b52449-089e-46aa-8d30-7e61598effe9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_efad9b77-4c12-40df-a954-8ca627e8cd5b" xlink:to="loc_us-gaap_FinanceLeaseLiability_b9b52449-089e-46aa-8d30-7e61598effe9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_8edc800f-680f-4160-accf-0e953579dd2b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_71089fdc-aec5-4097-b229-05366b1034e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_8edc800f-680f-4160-accf-0e953579dd2b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_71089fdc-aec5-4097-b229-05366b1034e8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_89344977-fa97-41ac-bfec-e0111c40676f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_8edc800f-680f-4160-accf-0e953579dd2b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_89344977-fa97-41ac-bfec-e0111c40676f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_11039f48-b1b2-43fc-8a18-69fa25e2257b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_8edc800f-680f-4160-accf-0e953579dd2b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_11039f48-b1b2-43fc-8a18-69fa25e2257b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_7152ce4a-42ab-4c69-8ef9-badf1536c940" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_8edc800f-680f-4160-accf-0e953579dd2b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_7152ce4a-42ab-4c69-8ef9-badf1536c940" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_39769372-2a61-48ab-960f-2cd069fa84d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_8edc800f-680f-4160-accf-0e953579dd2b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_39769372-2a61-48ab-960f-2cd069fa84d3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_6d4f2eaa-84fb-409a-a029-44d65dc8c4c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_8edc800f-680f-4160-accf-0e953579dd2b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_6d4f2eaa-84fb-409a-a029-44d65dc8c4c6" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails_1" xlink:type="simple" xlink:href="lgnd-20211231.xsd#LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails_1"/>
  <link:calculationLink xlink:role="http://www.ligand.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_7b7e32d0-1807-44a7-9a59-b851cd99ee4d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_6377afe5-9dae-4437-a55f-a6b47307f5d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_7b7e32d0-1807-44a7-9a59-b851cd99ee4d" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_6377afe5-9dae-4437-a55f-a6b47307f5d4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_dd1508e7-5c03-4fca-a181-ab9375452107" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_7b7e32d0-1807-44a7-9a59-b851cd99ee4d" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_dd1508e7-5c03-4fca-a181-ab9375452107" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_051f3bf2-4559-4730-9226-6dcc68482988" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_7b7e32d0-1807-44a7-9a59-b851cd99ee4d" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_051f3bf2-4559-4730-9226-6dcc68482988" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_cea738dd-52e0-4c13-b5b7-ded7a3470e87" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_7b7e32d0-1807-44a7-9a59-b851cd99ee4d" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_cea738dd-52e0-4c13-b5b7-ded7a3470e87" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_2bb27bf5-59db-43d5-b0af-112d1a58cf05" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_7b7e32d0-1807-44a7-9a59-b851cd99ee4d" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_2bb27bf5-59db-43d5-b0af-112d1a58cf05" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive_2d39cbb1-768a-4ff0-9b63-c7f5151b5d6a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_7b7e32d0-1807-44a7-9a59-b851cd99ee4d" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive_2d39cbb1-768a-4ff0-9b63-c7f5151b5d6a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_3c18e6b5-8383-4702-856d-8f796112d2dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_LesseeOperatingLeaseLiabilityTenantImprovementAllowance_ae16602e-1423-4b52-af09-b54032dab86d" xlink:href="lgnd-20211231.xsd#lgnd_LesseeOperatingLeaseLiabilityTenantImprovementAllowance"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_3c18e6b5-8383-4702-856d-8f796112d2dd" xlink:to="loc_lgnd_LesseeOperatingLeaseLiabilityTenantImprovementAllowance_ae16602e-1423-4b52-af09-b54032dab86d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_cf911157-0c3f-4ab9-945f-c62459c30a63" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_3c18e6b5-8383-4702-856d-8f796112d2dd" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_cf911157-0c3f-4ab9-945f-c62459c30a63" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_40bbfab5-06f8-4f1e-a525-21489e627e1e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_3c18e6b5-8383-4702-856d-8f796112d2dd" xlink:to="loc_us-gaap_OperatingLeaseLiability_40bbfab5-06f8-4f1e-a525-21489e627e1e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/ConvertibleSeniorNotesEquityandLiabilityComponentsofFinancingArrangementsDetails" xlink:type="simple" xlink:href="lgnd-20211231.xsd#ConvertibleSeniorNotesEquityandLiabilityComponentsofFinancingArrangementsDetails"/>
  <link:calculationLink xlink:role="http://www.ligand.com/role/ConvertibleSeniorNotesEquityandLiabilityComponentsofFinancingArrangementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermNotesPayable_27912edf-a5c9-40ea-87ea-b58f67e7ec50" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermNotesPayable"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_42fb8e32-6462-485b-80d5-491468d4828e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermNotesPayable_27912edf-a5c9-40ea-87ea-b58f67e7ec50" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_42fb8e32-6462-485b-80d5-491468d4828e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_a79780a5-dc84-4063-961b-e48e8cd7553f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermNotesPayable_27912edf-a5c9-40ea-87ea-b58f67e7ec50" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_a79780a5-dc84-4063-961b-e48e8cd7553f" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/BalanceSheetAccountDetailsInvestmentCategoriesDetails" xlink:type="simple" xlink:href="lgnd-20211231.xsd#BalanceSheetAccountDetailsInvestmentCategoriesDetails"/>
  <link:calculationLink xlink:role="http://www.ligand.com/role/BalanceSheetAccountDetailsInvestmentCategoriesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_d75db786-acba-412f-8027-5dce974cab44" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_b0410e9a-0ace-4adf-931b-26fb72a19158" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_d75db786-acba-412f-8027-5dce974cab44" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_b0410e9a-0ace-4adf-931b-26fb72a19158" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_fa5f1e66-7160-4feb-84bd-28e2a3e7cab2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_d75db786-acba-412f-8027-5dce974cab44" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_fa5f1e66-7160-4feb-84bd-28e2a3e7cab2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_a654cc3c-f05d-49d3-82a3-381ef9552c33" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_d75db786-acba-412f-8027-5dce974cab44" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_a654cc3c-f05d-49d3-82a3-381ef9552c33" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/BalanceSheetAccountDetailsAvailableforSaleDebtSecuritiesbyContractualMaturityDetails" xlink:type="simple" xlink:href="lgnd-20211231.xsd#BalanceSheetAccountDetailsAvailableforSaleDebtSecuritiesbyContractualMaturityDetails"/>
  <link:calculationLink xlink:role="http://www.ligand.com/role/BalanceSheetAccountDetailsAvailableforSaleDebtSecuritiesbyContractualMaturityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_e6e1c820-64bf-47a3-b23d-b51fee195990" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_60b69969-b63d-4d08-a1c5-754f7b999872" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_e6e1c820-64bf-47a3-b23d-b51fee195990" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_60b69969-b63d-4d08-a1c5-754f7b999872" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearFive_f840ed65-ea29-48a6-a4a5-5f1e04226ab1" xlink:href="lgnd-20211231.xsd#lgnd_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearFive"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_e6e1c820-64bf-47a3-b23d-b51fee195990" xlink:to="loc_lgnd_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearFive_f840ed65-ea29-48a6-a4a5-5f1e04226ab1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_fdc0a337-55af-44a7-8cd8-24aac8aef514" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_e6e1c820-64bf-47a3-b23d-b51fee195990" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_fdc0a337-55af-44a7-8cd8-24aac8aef514" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis_6bb4d949-4c7e-4c98-8df9-e9cb023c4622" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HeldToMaturitySecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_16caac90-370f-4fd4-a37d-3dd9e041a442" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis_6bb4d949-4c7e-4c98-8df9-e9cb023c4622" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_16caac90-370f-4fd4-a37d-3dd9e041a442" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_4a50cc4d-fb88-441e-a3e9-c74ff1975702" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis_6bb4d949-4c7e-4c98-8df9-e9cb023c4622" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_4a50cc4d-fb88-441e-a3e9-c74ff1975702" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateAfterYearFive_4372f19b-7064-47da-9b43-f4bfabe45001" xlink:href="lgnd-20211231.xsd#lgnd_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateAfterYearFive"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis_6bb4d949-4c7e-4c98-8df9-e9cb023c4622" xlink:to="loc_lgnd_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateAfterYearFive_4372f19b-7064-47da-9b43-f4bfabe45001" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/BalanceSheetAccountDetailsAvailableforSaleDebtSecuritiesinanUnrealizedLossPositionDetails" xlink:type="simple" xlink:href="lgnd-20211231.xsd#BalanceSheetAccountDetailsAvailableforSaleDebtSecuritiesinanUnrealizedLossPositionDetails"/>
  <link:calculationLink xlink:role="http://www.ligand.com/role/BalanceSheetAccountDetailsAvailableforSaleDebtSecuritiesinanUnrealizedLossPositionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionAccumulatedLoss_910e95b8-24ea-41e0-b76f-1003041ab759" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionAccumulatedLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_0374c8fd-4a13-4a97-a883-e5c4e22b7031" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionAccumulatedLoss_910e95b8-24ea-41e0-b76f-1003041ab759" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_0374c8fd-4a13-4a97-a883-e5c4e22b7031" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_c7fdf4be-6029-4e1b-b409-a17cdade890d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionAccumulatedLoss_910e95b8-24ea-41e0-b76f-1003041ab759" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_c7fdf4be-6029-4e1b-b409-a17cdade890d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_26986bd0-4c3f-4aa8-a270-c0470a725177" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_717a6ec7-744f-40e1-a022-e9395b640361" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_26986bd0-4c3f-4aa8-a270-c0470a725177" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_717a6ec7-744f-40e1-a022-e9395b640361" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_678647ec-4ad5-4a02-b94d-8b04fd41a008" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_26986bd0-4c3f-4aa8-a270-c0470a725177" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_678647ec-4ad5-4a02-b94d-8b04fd41a008" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/BalanceSheetAccountDetailsPropertyandEquipmentDetails" xlink:type="simple" xlink:href="lgnd-20211231.xsd#BalanceSheetAccountDetailsPropertyandEquipmentDetails"/>
  <link:calculationLink xlink:role="http://www.ligand.com/role/BalanceSheetAccountDetailsPropertyandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_c04138dc-de76-40c8-8617-691faddbe261" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_4862fd23-af1e-4165-93a5-72a085f4685c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_c04138dc-de76-40c8-8617-691faddbe261" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_4862fd23-af1e-4165-93a5-72a085f4685c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_e79a7627-2b7d-434d-b645-ea786065f85a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_c04138dc-de76-40c8-8617-691faddbe261" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_e79a7627-2b7d-434d-b645-ea786065f85a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/BalanceSheetAccountDetailsGoodwillandOtherIntangibleAssetsDetails" xlink:type="simple" xlink:href="lgnd-20211231.xsd#BalanceSheetAccountDetailsGoodwillandOtherIntangibleAssetsDetails"/>
  <link:calculationLink xlink:role="http://www.ligand.com/role/BalanceSheetAccountDetailsGoodwillandOtherIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill_10d38aa7-6d25-4a66-9e94-78f2a3ad58fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetIncludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_5a6bbcd1-ceea-42e7-b995-5f55b209820f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill_10d38aa7-6d25-4a66-9e94-78f2a3ad58fa" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_5a6bbcd1-ceea-42e7-b995-5f55b209820f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_70a9c8bc-ee17-44ac-858d-6447fd417951" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill_10d38aa7-6d25-4a66-9e94-78f2a3ad58fa" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_70a9c8bc-ee17-44ac-858d-6447fd417951" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/BalanceSheetAccountDetailsAccruedLiabilitiesDetails" xlink:type="simple" xlink:href="lgnd-20211231.xsd#BalanceSheetAccountDetailsAccruedLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.ligand.com/role/BalanceSheetAccountDetailsAccruedLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_164a421a-125b-40d0-9952-4709e440d4b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_7a799a0a-f2ce-4a0b-8ca1-2fa2ebefc257" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_164a421a-125b-40d0-9952-4709e440d4b7" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_7a799a0a-f2ce-4a0b-8ca1-2fa2ebefc257" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AccruedSalesReturns_2de2e1bc-00a2-415f-9275-90b16e323827" xlink:href="lgnd-20211231.xsd#lgnd_AccruedSalesReturns"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_164a421a-125b-40d0-9952-4709e440d4b7" xlink:to="loc_lgnd_AccruedSalesReturns_2de2e1bc-00a2-415f-9275-90b16e323827" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent_c7a02ba4-13fd-4e54-96cf-f204cd4357d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedRoyaltiesCurrentAndNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_164a421a-125b-40d0-9952-4709e440d4b7" xlink:to="loc_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent_c7a02ba4-13fd-4e54-96cf-f204cd4357d3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AccruedAssetAcquisitionsCurrent_f52c0d91-2e90-4b22-88b3-867c1e123462" xlink:href="lgnd-20211231.xsd#lgnd_AccruedAssetAcquisitionsCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_164a421a-125b-40d0-9952-4709e440d4b7" xlink:to="loc_lgnd_AccruedAssetAcquisitionsCurrent_f52c0d91-2e90-4b22-88b3-867c1e123462" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AccruedSubcontractorExpensesCurrent_735fa1a1-b0ee-46da-90c7-edba514dbfc2" xlink:href="lgnd-20211231.xsd#lgnd_AccruedSubcontractorExpensesCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_164a421a-125b-40d0-9952-4709e440d4b7" xlink:to="loc_lgnd_AccruedSubcontractorExpensesCurrent_735fa1a1-b0ee-46da-90c7-edba514dbfc2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_473e550c-698b-4954-a76f-dfd0c18ee09e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_164a421a-125b-40d0-9952-4709e440d4b7" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_473e550c-698b-4954-a76f-dfd0c18ee09e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AccruedSupplierExpensesCurrent_9175650c-b6f1-4d82-b2a8-46832fbfb97a" xlink:href="lgnd-20211231.xsd#lgnd_AccruedSupplierExpensesCurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_164a421a-125b-40d0-9952-4709e440d4b7" xlink:to="loc_lgnd_AccruedSupplierExpensesCurrent_9175650c-b6f1-4d82-b2a8-46832fbfb97a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedSalesCommissionCurrentAndNoncurrent_b2b9b38d-9bbd-4a53-9526-6317a3af9445" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedSalesCommissionCurrentAndNoncurrent"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_164a421a-125b-40d0-9952-4709e440d4b7" xlink:to="loc_us-gaap_AccruedSalesCommissionCurrentAndNoncurrent_b2b9b38d-9bbd-4a53-9526-6317a3af9445" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_2a6a236b-c3c5-4d68-b8ed-5e4522ba622b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_164a421a-125b-40d0-9952-4709e440d4b7" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_2a6a236b-c3c5-4d68-b8ed-5e4522ba622b" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/IncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails" xlink:type="simple" xlink:href="lgnd-20211231.xsd#IncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails"/>
  <link:calculationLink xlink:role="http://www.ligand.com/role/IncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_d4c6e66f-a548-4b12-9af0-5467ea907d99" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_9af3e050-dc02-4c16-a0f3-c5508c7a8052" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_d4c6e66f-a548-4b12-9af0-5467ea907d99" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_9af3e050-dc02-4c16-a0f3-c5508c7a8052" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_bd7fc8ea-b626-49a8-9390-922153d37d38" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_d4c6e66f-a548-4b12-9af0-5467ea907d99" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_bd7fc8ea-b626-49a8-9390-922153d37d38" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_59cfecc1-6beb-43da-83cb-c42111a9b7df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_d165aa4f-5542-4c16-be14-02f7248351ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_59cfecc1-6beb-43da-83cb-c42111a9b7df" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_d165aa4f-5542-4c16-be14-02f7248351ff" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_52e0efec-6bc2-49fc-bd73-658c5b68e4b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_59cfecc1-6beb-43da-83cb-c42111a9b7df" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_52e0efec-6bc2-49fc-bd73-658c5b68e4b6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_6641b2e2-9fb8-465f-9403-a9f02a92f8d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_1377e6e8-f080-4e2d-b4ad-10fc56654e19" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_6641b2e2-9fb8-465f-9403-a9f02a92f8d2" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_1377e6e8-f080-4e2d-b4ad-10fc56654e19" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_f08ee568-156e-49b2-87ac-a959605c94b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_6641b2e2-9fb8-465f-9403-a9f02a92f8d2" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_f08ee568-156e-49b2-87ac-a959605c94b4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit_496df975-4b08-477e-9d25-a02f0493549c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_6641b2e2-9fb8-465f-9403-a9f02a92f8d2" xlink:to="loc_us-gaap_CurrentForeignTaxExpenseBenefit_496df975-4b08-477e-9d25-a02f0493549c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/IncomeTaxesReconciliationofIncomeTaxExpenseBenefitDetails" xlink:type="simple" xlink:href="lgnd-20211231.xsd#IncomeTaxesReconciliationofIncomeTaxExpenseBenefitDetails"/>
  <link:calculationLink xlink:role="http://www.ligand.com/role/IncomeTaxesReconciliationofIncomeTaxExpenseBenefitDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_95ac6a96-0a5c-4670-8e4b-158575da13f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomeAmount_140183cd-a8b3-4f7f-96d8-b6d2f71edcc6" xlink:href="lgnd-20211231.xsd#lgnd_EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomeAmount"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_95ac6a96-0a5c-4670-8e4b-158575da13f6" xlink:to="loc_lgnd_EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomeAmount_140183cd-a8b3-4f7f-96d8-b6d2f71edcc6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_IncomeTaxReconciliationContingentValueRights_d4ed6cf2-b80f-46f9-9fae-ae63e09484d1" xlink:href="lgnd-20211231.xsd#lgnd_IncomeTaxReconciliationContingentValueRights"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_95ac6a96-0a5c-4670-8e4b-158575da13f6" xlink:to="loc_lgnd_IncomeTaxReconciliationContingentValueRights_d4ed6cf2-b80f-46f9-9fae-ae63e09484d1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_9e629ed4-d7a8-4663-9401-313a5996346c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_95ac6a96-0a5c-4670-8e4b-158575da13f6" xlink:to="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_9e629ed4-d7a8-4663-9401-313a5996346c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_bd16f00a-d297-4160-816c-fecc31155cce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_95ac6a96-0a5c-4670-8e4b-158575da13f6" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_bd16f00a-d297-4160-816c-fecc31155cce" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_2a1fe175-dbd4-40ce-b8f7-e6688e59dd0b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_95ac6a96-0a5c-4670-8e4b-158575da13f6" xlink:to="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_2a1fe175-dbd4-40ce-b8f7-e6688e59dd0b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_EffectiveIncomeTaxRateReconciliationProvisionToReturnAdjustmentsAmount_e6ea6df8-0472-4aed-9c46-cca60c07830c" xlink:href="lgnd-20211231.xsd#lgnd_EffectiveIncomeTaxRateReconciliationProvisionToReturnAdjustmentsAmount"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_95ac6a96-0a5c-4670-8e4b-158575da13f6" xlink:to="loc_lgnd_EffectiveIncomeTaxRateReconciliationProvisionToReturnAdjustmentsAmount_e6ea6df8-0472-4aed-9c46-cca60c07830c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_4043e8d5-c74a-4e2f-b3e8-7645ab252080" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_95ac6a96-0a5c-4670-8e4b-158575da13f6" xlink:to="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_4043e8d5-c74a-4e2f-b3e8-7645ab252080" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_EffectiveIncomeTaxRateReconciliationExpiredTaxCreditsResearch_56d96fbe-8955-47ec-b0d5-dcf41fc9a865" xlink:href="lgnd-20211231.xsd#lgnd_EffectiveIncomeTaxRateReconciliationExpiredTaxCreditsResearch"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_95ac6a96-0a5c-4670-8e4b-158575da13f6" xlink:to="loc_lgnd_EffectiveIncomeTaxRateReconciliationExpiredTaxCreditsResearch_56d96fbe-8955-47ec-b0d5-dcf41fc9a865" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_868da4cd-445d-4154-9200-19f1138263fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_95ac6a96-0a5c-4670-8e4b-158575da13f6" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_868da4cd-445d-4154-9200-19f1138263fb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions_c870f452-55c0-4d25-a508-c3845d120df1" xlink:href="lgnd-20211231.xsd#lgnd_EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_95ac6a96-0a5c-4670-8e4b-158575da13f6" xlink:to="loc_lgnd_EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions_c870f452-55c0-4d25-a508-c3845d120df1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_f083637d-4566-4b12-ae7e-7c9498017b5c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_95ac6a96-0a5c-4670-8e4b-158575da13f6" xlink:to="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_f083637d-4566-4b12-ae7e-7c9498017b5c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_21b32ae6-16b5-4dfe-897c-d5d0375e0df8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_95ac6a96-0a5c-4670-8e4b-158575da13f6" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_21b32ae6-16b5-4dfe-897c-d5d0375e0df8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationDispositionOfBusiness_7d773ef0-5674-4166-ace2-21c654d82876" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationDispositionOfBusiness"/>
    <link:calculationArc order="13" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_95ac6a96-0a5c-4670-8e4b-158575da13f6" xlink:to="loc_us-gaap_IncomeTaxReconciliationDispositionOfBusiness_7d773ef0-5674-4166-ace2-21c654d82876" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/IncomeTaxesDeferredTaxesDetails" xlink:type="simple" xlink:href="lgnd-20211231.xsd#IncomeTaxesDeferredTaxesDetails"/>
  <link:calculationLink xlink:role="http://www.ligand.com/role/IncomeTaxesDeferredTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities_95d6a01b-fd9b-4229-814f-b44c162494ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_ea568acb-c50a-4d07-bcf4-12202a343351" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxLiabilities_95d6a01b-fd9b-4229-814f-b44c162494ec" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_ea568acb-c50a-4d07-bcf4-12202a343351" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_f54e2b49-705d-48d5-81ab-9bcb5df47d04" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxLiabilities_95d6a01b-fd9b-4229-814f-b44c162494ec" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_f54e2b49-705d-48d5-81ab-9bcb5df47d04" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_f69dd136-858e-46eb-8f7a-f8651bdbc53b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_99484c08-36d0-49c4-af5c-aa928b847253" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_f69dd136-858e-46eb-8f7a-f8651bdbc53b" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_99484c08-36d0-49c4-af5c-aa928b847253" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_fd908632-4c1d-4120-b05d-72c6ce223b13" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_f69dd136-858e-46eb-8f7a-f8651bdbc53b" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_fd908632-4c1d-4120-b05d-72c6ce223b13" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_6a973a8a-59e9-48f8-95a7-18481066860a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_f69dd136-858e-46eb-8f7a-f8651bdbc53b" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_6a973a8a-59e9-48f8-95a7-18481066860a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_a67a2fd7-23b0-4d2a-8d4c-da0243afcf21" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_f69dd136-858e-46eb-8f7a-f8651bdbc53b" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_a67a2fd7-23b0-4d2a-8d4c-da0243afcf21" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_d0a0fe15-e82e-420b-b5d5-de8c3d2e2476" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_DeferredTaxLiabilitiesFiniteLivedIntangibleAssets_1183ef04-fa1e-407b-b285-f346c38b1825" xlink:href="lgnd-20211231.xsd#lgnd_DeferredTaxLiabilitiesFiniteLivedIntangibleAssets"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_d0a0fe15-e82e-420b-b5d5-de8c3d2e2476" xlink:to="loc_lgnd_DeferredTaxLiabilitiesFiniteLivedIntangibleAssets_1183ef04-fa1e-407b-b285-f346c38b1825" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther_36536f1d-8102-4437-81c5-f4c362a86f5a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesOther"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_d0a0fe15-e82e-420b-b5d5-de8c3d2e2476" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesOther_36536f1d-8102-4437-81c5-f4c362a86f5a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_fe80e796-ca63-4f59-a84b-f501b34e0d4e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_37faf1a4-3870-4bd4-9598-f46b5f17b3ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_fe80e796-ca63-4f59-a84b-f501b34e0d4e" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_37faf1a4-3870-4bd4-9598-f46b5f17b3ae" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_287aa164-1337-486d-836d-863e3f796bba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_fe80e796-ca63-4f59-a84b-f501b34e0d4e" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_287aa164-1337-486d-836d-863e3f796bba" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>11
<FILENAME>lgnd-20211231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:d46a5cfc-72eb-4b3a-bd09-c8907e0f4c5d,g:058bd086-7924-4675-b3eb-d4a9ba4991e0-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="simple" xlink:href="lgnd-20211231.xsd#CONSOLIDATEDSTATEMENTSOFOPERATIONS"/>
  <link:definitionLink xlink:role="http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="extended" id="ia388a6f9f6944eaca49a2289c4f21578_CONSOLIDATEDSTATEMENTSOFOPERATIONS">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_7f579b7f-60e5-43db-a5f6-4664d2597b32" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_e55e735d-d93c-4004-b6bf-3604775193c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_7f579b7f-60e5-43db-a5f6-4664d2597b32" xlink:to="loc_us-gaap_RevenuesAbstract_e55e735d-d93c-4004-b6bf-3604775193c7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_424cee43-9c0d-4e2f-9b45-9fc16278948a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_e55e735d-d93c-4004-b6bf-3604775193c7" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_424cee43-9c0d-4e2f-9b45-9fc16278948a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingCostsAndExpensesAbstract_7accd9f2-c11c-45f6-8020-1b44175b41ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingCostsAndExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_7f579b7f-60e5-43db-a5f6-4664d2597b32" xlink:to="loc_us-gaap_OperatingCostsAndExpensesAbstract_7accd9f2-c11c-45f6-8020-1b44175b41ed" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostDirectMaterial_f68e29a4-1fc1-467f-bc61-dea63151a5ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostDirectMaterial"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingCostsAndExpensesAbstract_7accd9f2-c11c-45f6-8020-1b44175b41ed" xlink:to="loc_us-gaap_CostDirectMaterial_f68e29a4-1fc1-467f-bc61-dea63151a5ba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSoldAmortization_6c0f43c6-6422-403f-95b5-7826e0af6baa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSoldAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingCostsAndExpensesAbstract_7accd9f2-c11c-45f6-8020-1b44175b41ed" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSoldAmortization_6c0f43c6-6422-403f-95b5-7826e0af6baa" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_89f8edf7-8eac-4e97-b9a2-b127c7277c3d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingCostsAndExpensesAbstract_7accd9f2-c11c-45f6-8020-1b44175b41ed" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_89f8edf7-8eac-4e97-b9a2-b127c7277c3d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_62ea7c60-7c8e-472a-8bc5-619f17efce26" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingCostsAndExpensesAbstract_7accd9f2-c11c-45f6-8020-1b44175b41ed" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_62ea7c60-7c8e-472a-8bc5-619f17efce26" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncome_56ea61f8-95c7-4d5e-b497-af8ddd0d09a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherOperatingIncome"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingCostsAndExpensesAbstract_7accd9f2-c11c-45f6-8020-1b44175b41ed" xlink:to="loc_us-gaap_OtherOperatingIncome_56ea61f8-95c7-4d5e-b497-af8ddd0d09a8" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingCostsAndExpenses_74dd02cf-149f-476a-a495-c2f07f2c111e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingCostsAndExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingCostsAndExpensesAbstract_7accd9f2-c11c-45f6-8020-1b44175b41ed" xlink:to="loc_us-gaap_OperatingCostsAndExpenses_74dd02cf-149f-476a-a495-c2f07f2c111e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfIntangibleAssets_03d58d7a-86c4-467d-aafb-845794443ea9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnDispositionOfIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_7f579b7f-60e5-43db-a5f6-4664d2597b32" xlink:to="loc_us-gaap_GainLossOnDispositionOfIntangibleAssets_03d58d7a-86c4-467d-aafb-845794443ea9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_64a09cc9-77a0-4d5b-9474-cc7f3cd928d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_7f579b7f-60e5-43db-a5f6-4664d2597b32" xlink:to="loc_us-gaap_OperatingIncomeLoss_64a09cc9-77a0-4d5b-9474-cc7f3cd928d0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_3fae6145-168e-4370-ba7d-81bc62afe266" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_7f579b7f-60e5-43db-a5f6-4664d2597b32" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_3fae6145-168e-4370-ba7d-81bc62afe266" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnInvestments_7150a71f-3c5e-4e1d-ae21-8f5c44a0984f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_3fae6145-168e-4370-ba7d-81bc62afe266" xlink:to="loc_us-gaap_GainLossOnInvestments_7150a71f-3c5e-4e1d-ae21-8f5c44a0984f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_3e61c8d4-aa0b-43dd-9cd9-aed882780cb8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_3fae6145-168e-4370-ba7d-81bc62afe266" xlink:to="loc_us-gaap_InvestmentIncomeInterest_3e61c8d4-aa0b-43dd-9cd9-aed882780cb8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_84a61da3-c506-4df1-a401-0981d9376dc3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_3fae6145-168e-4370-ba7d-81bc62afe266" xlink:to="loc_us-gaap_InterestExpense_84a61da3-c506-4df1-a401-0981d9376dc3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_3995a43c-5fbf-40a0-afde-2f534d842561" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_3fae6145-168e-4370-ba7d-81bc62afe266" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_3995a43c-5fbf-40a0-afde-2f534d842561" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_cb20164e-e55b-4dce-a725-6739e38fabb1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_3fae6145-168e-4370-ba7d-81bc62afe266" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_cb20164e-e55b-4dce-a725-6739e38fabb1" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_fbd93f7f-ba56-435e-bf47-bb1355886f24" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_7f579b7f-60e5-43db-a5f6-4664d2597b32" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_fbd93f7f-ba56-435e-bf47-bb1355886f24" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_c9e9220c-c9dc-489d-991d-20135a12f160" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_7f579b7f-60e5-43db-a5f6-4664d2597b32" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_c9e9220c-c9dc-489d-991d-20135a12f160" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_461be9aa-d70e-4b66-9151-321e57bffbc9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_7f579b7f-60e5-43db-a5f6-4664d2597b32" xlink:to="loc_us-gaap_NetIncomeLoss_461be9aa-d70e-4b66-9151-321e57bffbc9" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_514039c4-e647-436e-823f-efe472133b14" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_7f579b7f-60e5-43db-a5f6-4664d2597b32" xlink:to="loc_us-gaap_EarningsPerShareAbstract_514039c4-e647-436e-823f-efe472133b14" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_67e4f9f4-5ca3-4e5a-b258-fc8381e8b0b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareAbstract_514039c4-e647-436e-823f-efe472133b14" xlink:to="loc_us-gaap_EarningsPerShareBasic_67e4f9f4-5ca3-4e5a-b258-fc8381e8b0b0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_eea7dfd6-3698-4e5e-9f24-1eb21e93e15a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareAbstract_514039c4-e647-436e-823f-efe472133b14" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_eea7dfd6-3698-4e5e-9f24-1eb21e93e15a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_f7719d14-1c59-4106-89e9-7b61b74bca1c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareAbstract_514039c4-e647-436e-823f-efe472133b14" xlink:to="loc_us-gaap_EarningsPerShareDiluted_f7719d14-1c59-4106-89e9-7b61b74bca1c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_49141d96-8077-42fd-b992-2ec877401997" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareAbstract_514039c4-e647-436e-823f-efe472133b14" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_49141d96-8077-42fd-b992-2ec877401997" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_be4602ea-23f1-42b1-acc3-104622bf46fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_7f579b7f-60e5-43db-a5f6-4664d2597b32" xlink:to="loc_us-gaap_StatementTable_be4602ea-23f1-42b1-acc3-104622bf46fe" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_3cea458f-60c3-4900-8e3f-91a103b04b1b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_be4602ea-23f1-42b1-acc3-104622bf46fe" xlink:to="loc_srt_ProductOrServiceAxis_3cea458f-60c3-4900-8e3f-91a103b04b1b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_3cea458f-60c3-4900-8e3f-91a103b04b1b_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_3cea458f-60c3-4900-8e3f-91a103b04b1b" xlink:to="loc_srt_ProductsAndServicesDomain_3cea458f-60c3-4900-8e3f-91a103b04b1b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_4fa2ccd9-adea-4249-9a9c-3a90dcfb0b38" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_3cea458f-60c3-4900-8e3f-91a103b04b1b" xlink:to="loc_srt_ProductsAndServicesDomain_4fa2ccd9-adea-4249-9a9c-3a90dcfb0b38" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyMember_de06a141-3d68-4a0b-b579-c3225b13a75f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RoyaltyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_4fa2ccd9-adea-4249-9a9c-3a90dcfb0b38" xlink:to="loc_us-gaap_RoyaltyMember_de06a141-3d68-4a0b-b579-c3225b13a75f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_MaterialSalesCaptisolMember_4ca12813-8669-40f7-8040-5b7ae2b723cd" xlink:href="lgnd-20211231.xsd#lgnd_MaterialSalesCaptisolMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_4fa2ccd9-adea-4249-9a9c-3a90dcfb0b38" xlink:to="loc_lgnd_MaterialSalesCaptisolMember_4ca12813-8669-40f7-8040-5b7ae2b723cd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ContractRevenueMember_5338f5da-9475-45d7-8693-a9617dbe6f5f" xlink:href="lgnd-20211231.xsd#lgnd_ContractRevenueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_4fa2ccd9-adea-4249-9a9c-3a90dcfb0b38" xlink:to="loc_lgnd_ContractRevenueMember_5338f5da-9475-45d7-8693-a9617dbe6f5f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_VernalisMember_a7855eab-9dd5-413b-b564-d7a7230dedb3" xlink:href="lgnd-20211231.xsd#lgnd_VernalisMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_4fa2ccd9-adea-4249-9a9c-3a90dcfb0b38" xlink:to="loc_lgnd_VernalisMember_a7855eab-9dd5-413b-b564-d7a7230dedb3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PromactaMember_aa219b84-375a-4e3d-bf2a-6066bba0f5a7" xlink:href="lgnd-20211231.xsd#lgnd_PromactaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_4fa2ccd9-adea-4249-9a9c-3a90dcfb0b38" xlink:to="loc_lgnd_PromactaMember_aa219b84-375a-4e3d-bf2a-6066bba0f5a7" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ligand.com/role/CONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="lgnd-20211231.xsd#CONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY"/>
  <link:definitionLink xlink:role="http://www.ligand.com/role/CONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY" xlink:type="extended" id="i3a2ea0b127bf44e996a5f735b080c531_CONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_8818abb3-1a3c-4219-a6a9-f7ef3c48cd1b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9a7e1744-c9f3-4335-b964-acf9b4b89d68" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_8818abb3-1a3c-4219-a6a9-f7ef3c48cd1b" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9a7e1744-c9f3-4335-b964-acf9b4b89d68" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_6752e2d5-0697-42a9-bb9c-7432fe634a39" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9a7e1744-c9f3-4335-b964-acf9b4b89d68" xlink:to="loc_us-gaap_SharesOutstanding_6752e2d5-0697-42a9-bb9c-7432fe634a39" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_306a2706-ea8e-4c25-97ba-104c0e6007bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9a7e1744-c9f3-4335-b964-acf9b4b89d68" xlink:to="loc_us-gaap_StockholdersEquity_306a2706-ea8e-4c25-97ba-104c0e6007bd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_03362e1f-6392-4f73-ab37-c3e9e0f1cb8e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9a7e1744-c9f3-4335-b964-acf9b4b89d68" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_03362e1f-6392-4f73-ab37-c3e9e0f1cb8e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_996471c7-c252-4c09-afbd-c153ca209f03" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9a7e1744-c9f3-4335-b964-acf9b4b89d68" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_996471c7-c252-4c09-afbd-c153ca209f03" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_51566d10-b4e1-4ee4-bd1c-f697a2006bbb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9a7e1744-c9f3-4335-b964-acf9b4b89d68" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_51566d10-b4e1-4ee4-bd1c-f697a2006bbb" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares_83e6f08d-332d-465f-9c4e-3d0f3f60ea3d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9a7e1744-c9f3-4335-b964-acf9b4b89d68" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodShares_83e6f08d-332d-465f-9c4e-3d0f3f60ea3d" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue_e9fc5126-6ab3-4c5a-8c6a-6e2f650e2668" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9a7e1744-c9f3-4335-b964-acf9b4b89d68" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodValue_e9fc5126-6ab3-4c5a-8c6a-6e2f650e2668" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss_e782d2fd-b814-41e5-84e5-b136982beb98" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9a7e1744-c9f3-4335-b964-acf9b4b89d68" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss_e782d2fd-b814-41e5-84e5-b136982beb98" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_456f3388-ef90-4cc5-8e74-6691b99d2c9a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9a7e1744-c9f3-4335-b964-acf9b4b89d68" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_456f3388-ef90-4cc5-8e74-6691b99d2c9a" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_b2a135e8-058b-4f91-b8a3-620f9b16482b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9a7e1744-c9f3-4335-b964-acf9b4b89d68" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_b2a135e8-058b-4f91-b8a3-620f9b16482b" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdateExtensibleList_d47ede79-5263-4963-bac5-df0e91bf032c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingStandardsUpdateExtensibleList"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9a7e1744-c9f3-4335-b964-acf9b4b89d68" xlink:to="loc_us-gaap_AccountingStandardsUpdateExtensibleList_d47ede79-5263-4963-bac5-df0e91bf032c" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AdjustmentsToAdditionalPaidInCapitalWarrantAndBondHedgeUnwindTransactions_e336c828-071b-4658-8155-4076fecb4d75" xlink:href="lgnd-20211231.xsd#lgnd_AdjustmentsToAdditionalPaidInCapitalWarrantAndBondHedgeUnwindTransactions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9a7e1744-c9f3-4335-b964-acf9b4b89d68" xlink:to="loc_lgnd_AdjustmentsToAdditionalPaidInCapitalWarrantAndBondHedgeUnwindTransactions_e336c828-071b-4658-8155-4076fecb4d75" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther_80df4eb0-eda1-4e52-99ab-6b6c1620664b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalOther"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9a7e1744-c9f3-4335-b964-acf9b4b89d68" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther_80df4eb0-eda1-4e52-99ab-6b6c1620664b" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_3eaccbab-082b-458f-8183-27d3994d2e0a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9a7e1744-c9f3-4335-b964-acf9b4b89d68" xlink:to="loc_us-gaap_NetIncomeLoss_3eaccbab-082b-458f-8183-27d3994d2e0a" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_a1614e86-bd6a-466c-ae0b-5d7b3788eb8b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_a2395e77-a1a7-4a05-8118-43fb36fd7ada" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_8c2dd33d-929c-449f-a14f-043a5aee0c52" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_8818abb3-1a3c-4219-a6a9-f7ef3c48cd1b" xlink:to="loc_us-gaap_StatementTable_8c2dd33d-929c-449f-a14f-043a5aee0c52" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_81512786-4853-4ee0-bcd2-c8b8c548fdac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_8c2dd33d-929c-449f-a14f-043a5aee0c52" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_81512786-4853-4ee0-bcd2-c8b8c548fdac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_81512786-4853-4ee0-bcd2-c8b8c548fdac_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_81512786-4853-4ee0-bcd2-c8b8c548fdac" xlink:to="loc_us-gaap_EquityComponentDomain_81512786-4853-4ee0-bcd2-c8b8c548fdac_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_c6ac9720-ca4b-4c03-8585-644260180b14" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_81512786-4853-4ee0-bcd2-c8b8c548fdac" xlink:to="loc_us-gaap_EquityComponentDomain_c6ac9720-ca4b-4c03-8585-644260180b14" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_0ec3e438-e3e9-4af8-9f7f-6b485b48e443" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_c6ac9720-ca4b-4c03-8585-644260180b14" xlink:to="loc_us-gaap_CommonStockMember_0ec3e438-e3e9-4af8-9f7f-6b485b48e443" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_aebfca3e-8c41-4853-a228-e7712731dda3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_c6ac9720-ca4b-4c03-8585-644260180b14" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_aebfca3e-8c41-4853-a228-e7712731dda3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_bf0367a1-ac37-4545-82d3-a4b26ad90783" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_c6ac9720-ca4b-4c03-8585-644260180b14" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_bf0367a1-ac37-4545-82d3-a4b26ad90783" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_0183de0b-da31-437d-85ab-922ecd84908e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_c6ac9720-ca4b-4c03-8585-644260180b14" xlink:to="loc_us-gaap_RetainedEarningsMember_0183de0b-da31-437d-85ab-922ecd84908e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_11dd6d86-d657-482f-a7a7-af22d93ea598" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_8c2dd33d-929c-449f-a14f-043a5aee0c52" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_11dd6d86-d657-482f-a7a7-af22d93ea598" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_11dd6d86-d657-482f-a7a7-af22d93ea598_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_11dd6d86-d657-482f-a7a7-af22d93ea598" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_11dd6d86-d657-482f-a7a7-af22d93ea598_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_5d306195-77e4-4846-abd1-d1172091211a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_11dd6d86-d657-482f-a7a7-af22d93ea598" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_5d306195-77e4-4846-abd1-d1172091211a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_b18ef67e-0d4b-4f01-a1f9-aebb92a6cadb" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_5d306195-77e4-4846-abd1-d1172091211a" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_b18ef67e-0d4b-4f01-a1f9-aebb92a6cadb" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" xlink:href="lgnd-20211231.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="extended" id="i397b7e7e9e104dee96ab20f94f57842e_BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BasisOfPresentationLineItems_45561629-4d3b-4c98-8ce7-efa616027437" xlink:href="lgnd-20211231.xsd#lgnd_BasisOfPresentationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_99ece381-8465-4091-8180-fbaeeabf3b66" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lgnd_BasisOfPresentationLineItems_45561629-4d3b-4c98-8ce7-efa616027437" xlink:to="loc_us-gaap_NumberOfOperatingSegments_99ece381-8465-4091-8180-fbaeeabf3b66" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_MaturityPeriodOfHighlyLiquidSecuritiesMaximum_4e9c811d-fc80-46b6-8ce7-9be8fe6eed2b" xlink:href="lgnd-20211231.xsd#lgnd_MaturityPeriodOfHighlyLiquidSecuritiesMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lgnd_BasisOfPresentationLineItems_45561629-4d3b-4c98-8ce7-efa616027437" xlink:to="loc_lgnd_MaturityPeriodOfHighlyLiquidSecuritiesMaximum_4e9c811d-fc80-46b6-8ce7-9be8fe6eed2b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWriteDown_3b3dd016-78cd-4fd5-8d4d-4c0e8001f614" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWriteDown"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lgnd_BasisOfPresentationLineItems_45561629-4d3b-4c98-8ce7-efa616027437" xlink:to="loc_us-gaap_InventoryWriteDown_3b3dd016-78cd-4fd5-8d4d-4c0e8001f614" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_6dc4eeab-d274-4a22-8703-0a609a91ed75" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lgnd_BasisOfPresentationLineItems_45561629-4d3b-4c98-8ce7-efa616027437" xlink:to="loc_us-gaap_InventoryNet_6dc4eeab-d274-4a22-8703-0a609a91ed75" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_2f0bcd53-e009-4946-9b6e-15617909855c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lgnd_BasisOfPresentationLineItems_45561629-4d3b-4c98-8ce7-efa616027437" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_2f0bcd53-e009-4946-9b6e-15617909855c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BusinessCombinationContingentConsiderationLiabilityAmountPerShare_dc2ef763-7466-47ed-a97d-43e26cd82fc4" xlink:href="lgnd-20211231.xsd#lgnd_BusinessCombinationContingentConsiderationLiabilityAmountPerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lgnd_BasisOfPresentationLineItems_45561629-4d3b-4c98-8ce7-efa616027437" xlink:to="loc_lgnd_BusinessCombinationContingentConsiderationLiabilityAmountPerShare_dc2ef763-7466-47ed-a97d-43e26cd82fc4" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_2b0c96e6-3bc3-42a3-85a2-ae4524eb4961" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lgnd_BasisOfPresentationLineItems_45561629-4d3b-4c98-8ce7-efa616027437" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_2b0c96e6-3bc3-42a3-85a2-ae4524eb4961" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_NumberOfContingentValueRightsIssued_e9461207-afd5-4160-b8be-9790e46f2771" xlink:href="lgnd-20211231.xsd#lgnd_NumberOfContingentValueRightsIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lgnd_BasisOfPresentationLineItems_45561629-4d3b-4c98-8ce7-efa616027437" xlink:to="loc_lgnd_NumberOfContingentValueRightsIssued_e9461207-afd5-4160-b8be-9790e46f2771" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_LicenseUpfrontPayment_12a8499b-6c1b-467d-ba0c-f21ebfc97cc3" xlink:href="lgnd-20211231.xsd#lgnd_LicenseUpfrontPayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lgnd_BasisOfPresentationLineItems_45561629-4d3b-4c98-8ce7-efa616027437" xlink:to="loc_lgnd_LicenseUpfrontPayment_12a8499b-6c1b-467d-ba0c-f21ebfc97cc3" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AdditionalRoyaltiesReceivableUnderSalesbasedMilestones_ff29f341-3eb4-454a-ba54-66136ea830b3" xlink:href="lgnd-20211231.xsd#lgnd_AdditionalRoyaltiesReceivableUnderSalesbasedMilestones"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lgnd_BasisOfPresentationLineItems_45561629-4d3b-4c98-8ce7-efa616027437" xlink:to="loc_lgnd_AdditionalRoyaltiesReceivableUnderSalesbasedMilestones_ff29f341-3eb4-454a-ba54-66136ea830b3" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ProductRoyaltyPercentage_fbb4ef7d-ef16-4472-96e7-0fc8f580ca15" xlink:href="lgnd-20211231.xsd#lgnd_ProductRoyaltyPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lgnd_BasisOfPresentationLineItems_45561629-4d3b-4c98-8ce7-efa616027437" xlink:to="loc_lgnd_ProductRoyaltyPercentage_fbb4ef7d-ef16-4472-96e7-0fc8f580ca15" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_c3dcd443-6b97-44a3-ad49-f3a15a836272" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lgnd_BasisOfPresentationLineItems_45561629-4d3b-4c98-8ce7-efa616027437" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_c3dcd443-6b97-44a3-ad49-f3a15a836272" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_837af47b-2302-495f-80d3-78a6a5cb70fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lgnd_BasisOfPresentationLineItems_45561629-4d3b-4c98-8ce7-efa616027437" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_837af47b-2302-495f-80d3-78a6a5cb70fb" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromRoyaltiesReceived_821f1d21-f302-462c-801d-bd2c6db1658d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromRoyaltiesReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lgnd_BasisOfPresentationLineItems_45561629-4d3b-4c98-8ce7-efa616027437" xlink:to="loc_us-gaap_ProceedsFromRoyaltiesReceived_821f1d21-f302-462c-801d-bd2c6db1658d" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_RoyaltyAgreementExpirationPeriod_7b2f801e-b00a-41f5-87e8-eaa9a4e7c14a" xlink:href="lgnd-20211231.xsd#lgnd_RoyaltyAgreementExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lgnd_BasisOfPresentationLineItems_45561629-4d3b-4c98-8ce7-efa616027437" xlink:to="loc_lgnd_RoyaltyAgreementExpirationPeriod_7b2f801e-b00a-41f5-87e8-eaa9a4e7c14a" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ForecastedCashFlowsEffectiveInterestRatePercent_36da0e60-2e29-436c-bf54-2cdd225d6631" xlink:href="lgnd-20211231.xsd#lgnd_ForecastedCashFlowsEffectiveInterestRatePercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lgnd_BasisOfPresentationLineItems_45561629-4d3b-4c98-8ce7-efa616027437" xlink:to="loc_lgnd_ForecastedCashFlowsEffectiveInterestRatePercent_36da0e60-2e29-436c-bf54-2cdd225d6631" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_FiniteLivedIntangibleAssetsCreditLossAdjustments_2f97a989-cd2d-4610-ac09-8f8fe41e1a40" xlink:href="lgnd-20211231.xsd#lgnd_FiniteLivedIntangibleAssetsCreditLossAdjustments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lgnd_BasisOfPresentationLineItems_45561629-4d3b-4c98-8ce7-efa616027437" xlink:to="loc_lgnd_FiniteLivedIntangibleAssetsCreditLossAdjustments_2f97a989-cd2d-4610-ac09-8f8fe41e1a40" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AccountsReceivableCreditLossExpenseReversalCOVID19_60f7b51d-9b9a-4895-bc4b-8117db918cdf" xlink:href="lgnd-20211231.xsd#lgnd_AccountsReceivableCreditLossExpenseReversalCOVID19"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lgnd_BasisOfPresentationLineItems_45561629-4d3b-4c98-8ce7-efa616027437" xlink:to="loc_lgnd_AccountsReceivableCreditLossExpenseReversalCOVID19_60f7b51d-9b9a-4895-bc4b-8117db918cdf" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_9759cc5f-3815-404d-a647-d714431210b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lgnd_BasisOfPresentationLineItems_45561629-4d3b-4c98-8ce7-efa616027437" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_9759cc5f-3815-404d-a647-d714431210b0" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_acf4f770-24df-4a04-9025-60d036878ef8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lgnd_BasisOfPresentationLineItems_45561629-4d3b-4c98-8ce7-efa616027437" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_acf4f770-24df-4a04-9025-60d036878ef8" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_9c759d76-9dc2-4bc9-9afa-4efa23ae33f4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lgnd_BasisOfPresentationLineItems_45561629-4d3b-4c98-8ce7-efa616027437" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_9c759d76-9dc2-4bc9-9afa-4efa23ae33f4" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiMeasurementInput_baaa3dbe-6fc8-4c00-abd9-c15a72c86193" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNiMeasurementInput"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lgnd_BasisOfPresentationLineItems_45561629-4d3b-4c98-8ce7-efa616027437" xlink:to="loc_us-gaap_EquitySecuritiesFvNiMeasurementInput_baaa3dbe-6fc8-4c00-abd9-c15a72c86193" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareDeclared_d12eff52-2219-4971-b71f-428f56bb8833" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockDividendsPerShareDeclared"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lgnd_BasisOfPresentationLineItems_45561629-4d3b-4c98-8ce7-efa616027437" xlink:to="loc_us-gaap_CommonStockDividendsPerShareDeclared_d12eff52-2219-4971-b71f-428f56bb8833" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_b73b5694-bea2-4a7e-b0c4-42e11cb803b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lgnd_BasisOfPresentationLineItems_45561629-4d3b-4c98-8ce7-efa616027437" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_b73b5694-bea2-4a7e-b0c4-42e11cb803b2" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_e4d67a36-7bb6-4e9b-9a19-b2b97bf35588" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lgnd_BasisOfPresentationLineItems_45561629-4d3b-4c98-8ce7-efa616027437" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_e4d67a36-7bb6-4e9b-9a19-b2b97bf35588" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_ffb43a75-941b-4602-a20d-9ee188e927b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lgnd_BasisOfPresentationLineItems_45561629-4d3b-4c98-8ce7-efa616027437" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_ffb43a75-941b-4602-a20d-9ee188e927b2" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets_dcdfeaaf-3476-4262-afa1-6058bfdc3e16" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lgnd_BasisOfPresentationLineItems_45561629-4d3b-4c98-8ce7-efa616027437" xlink:to="loc_us-gaap_DerivativeAssets_dcdfeaaf-3476-4262-afa1-6058bfdc3e16" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_234513bf-3429-4767-afd2-62f497e396ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lgnd_BasisOfPresentationLineItems_45561629-4d3b-4c98-8ce7-efa616027437" xlink:to="loc_us-gaap_DerivativeLiabilities_234513bf-3429-4767-afd2-62f497e396ab" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c4f6da74-c651-4e46-97a6-432aa78ffb3f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lgnd_BasisOfPresentationLineItems_45561629-4d3b-4c98-8ce7-efa616027437" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c4f6da74-c651-4e46-97a6-432aa78ffb3f" xlink:type="arc" order="28"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BasisOfPresentationTable_445dd6ca-01ad-4024-b237-bc3f1c1722ba" xlink:href="lgnd-20211231.xsd#lgnd_BasisOfPresentationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_lgnd_BasisOfPresentationLineItems_45561629-4d3b-4c98-8ce7-efa616027437" xlink:to="loc_lgnd_BasisOfPresentationTable_445dd6ca-01ad-4024-b237-bc3f1c1722ba" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_a582a1c9-9f3e-41d5-8078-e98e64a951eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_lgnd_BasisOfPresentationTable_445dd6ca-01ad-4024-b237-bc3f1c1722ba" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_a582a1c9-9f3e-41d5-8078-e98e64a951eb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_a582a1c9-9f3e-41d5-8078-e98e64a951eb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_a582a1c9-9f3e-41d5-8078-e98e64a951eb" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_a582a1c9-9f3e-41d5-8078-e98e64a951eb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_19709d80-44b0-4ba8-8341-10f2b4127722" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_a582a1c9-9f3e-41d5-8078-e98e64a951eb" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_19709d80-44b0-4ba8-8341-10f2b4127722" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedDividendRateMember_c55bbd67-736a-4a42-b732-44fe6f1d6680" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputExpectedDividendRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_19709d80-44b0-4ba8-8341-10f2b4127722" xlink:to="loc_us-gaap_MeasurementInputExpectedDividendRateMember_c55bbd67-736a-4a42-b732-44fe6f1d6680" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_cf4792a9-1856-4344-a7ad-1914ea21558f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_lgnd_BasisOfPresentationTable_445dd6ca-01ad-4024-b237-bc3f1c1722ba" xlink:to="loc_us-gaap_DebtInstrumentAxis_cf4792a9-1856-4344-a7ad-1914ea21558f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_cf4792a9-1856-4344-a7ad-1914ea21558f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_cf4792a9-1856-4344-a7ad-1914ea21558f" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_cf4792a9-1856-4344-a7ad-1914ea21558f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_22c8915c-682f-4fa5-8679-4f2d17f8a363" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_cf4792a9-1856-4344-a7ad-1914ea21558f" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_22c8915c-682f-4fa5-8679-4f2d17f8a363" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ConvertibleSeniorNotesDue2023Member_433777cf-e053-4cdd-8b0f-ed455cade86a" xlink:href="lgnd-20211231.xsd#lgnd_ConvertibleSeniorNotesDue2023Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_22c8915c-682f-4fa5-8679-4f2d17f8a363" xlink:to="loc_lgnd_ConvertibleSeniorNotesDue2023Member_433777cf-e053-4cdd-8b0f-ed455cade86a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ConvertibleSeniorNotesDue2019Member_2ce06856-380e-4632-90de-d93cb5e61598" xlink:href="lgnd-20211231.xsd#lgnd_ConvertibleSeniorNotesDue2019Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_22c8915c-682f-4fa5-8679-4f2d17f8a363" xlink:to="loc_lgnd_ConvertibleSeniorNotesDue2019Member_2ce06856-380e-4632-90de-d93cb5e61598" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_1f56019e-1171-4f15-acef-1d482d90028b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_lgnd_BasisOfPresentationTable_445dd6ca-01ad-4024-b237-bc3f1c1722ba" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_1f56019e-1171-4f15-acef-1d482d90028b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_1f56019e-1171-4f15-acef-1d482d90028b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_1f56019e-1171-4f15-acef-1d482d90028b" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_1f56019e-1171-4f15-acef-1d482d90028b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_133d52b8-a211-408a-94bd-34a249e22f44" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_1f56019e-1171-4f15-acef-1d482d90028b" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_133d52b8-a211-408a-94bd-34a249e22f44" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_51afe914-9a69-44f6-9a5c-c9bfd4d451f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_133d52b8-a211-408a-94bd-34a249e22f44" xlink:to="loc_us-gaap_SeniorNotesMember_51afe914-9a69-44f6-9a5c-c9bfd4d451f5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleNotesPayableMember_5489c2e1-cb3d-45b3-b832-390033abc36f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleNotesPayableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_133d52b8-a211-408a-94bd-34a249e22f44" xlink:to="loc_us-gaap_ConvertibleNotesPayableMember_5489c2e1-cb3d-45b3-b832-390033abc36f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_e90e3fae-c6db-4fb5-bb69-cc9090b4e19a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_lgnd_BasisOfPresentationTable_445dd6ca-01ad-4024-b237-bc3f1c1722ba" xlink:to="loc_srt_CounterpartyNameAxis_e90e3fae-c6db-4fb5-bb69-cc9090b4e19a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e90e3fae-c6db-4fb5-bb69-cc9090b4e19a_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_e90e3fae-c6db-4fb5-bb69-cc9090b4e19a" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e90e3fae-c6db-4fb5-bb69-cc9090b4e19a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_552369a4-efa6-47f2-9590-c0c035ea710a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_e90e3fae-c6db-4fb5-bb69-cc9090b4e19a" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_552369a4-efa6-47f2-9590-c0c035ea710a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_NovanMolluscumProductsMember_ce37b981-8c26-4d93-a20d-62943baabfef" xlink:href="lgnd-20211231.xsd#lgnd_NovanMolluscumProductsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_552369a4-efa6-47f2-9590-c0c035ea710a" xlink:to="loc_lgnd_NovanMolluscumProductsMember_ce37b981-8c26-4d93-a20d-62943baabfef" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PalvellaTherapeuticsIncMember_462587ce-054f-4023-9c07-c4c387f9b6ab" xlink:href="lgnd-20211231.xsd#lgnd_PalvellaTherapeuticsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_552369a4-efa6-47f2-9590-c0c035ea710a" xlink:to="loc_lgnd_PalvellaTherapeuticsIncMember_462587ce-054f-4023-9c07-c4c387f9b6ab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AziyoMember_2e83cc2b-cc94-4ecd-82a0-895a6bf729b0" xlink:href="lgnd-20211231.xsd#lgnd_AziyoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_552369a4-efa6-47f2-9590-c0c035ea710a" xlink:to="loc_lgnd_AziyoMember_2e83cc2b-cc94-4ecd-82a0-895a6bf729b0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_CorMatrixMember_a699f8b8-ed9b-43c7-a2d8-638961d4688e" xlink:href="lgnd-20211231.xsd#lgnd_CorMatrixMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_552369a4-efa6-47f2-9590-c0c035ea710a" xlink:to="loc_lgnd_CorMatrixMember_a699f8b8-ed9b-43c7-a2d8-638961d4688e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_SelexisMember_8924c349-f088-4432-ac39-41811792ea4e" xlink:href="lgnd-20211231.xsd#lgnd_SelexisMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_552369a4-efa6-47f2-9590-c0c035ea710a" xlink:to="loc_lgnd_SelexisMember_8924c349-f088-4432-ac39-41811792ea4e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_c48122a4-5c7d-47d2-bca5-bde380c5cfe9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_lgnd_BasisOfPresentationTable_445dd6ca-01ad-4024-b237-bc3f1c1722ba" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_c48122a4-5c7d-47d2-bca5-bde380c5cfe9" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_c48122a4-5c7d-47d2-bca5-bde380c5cfe9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_c48122a4-5c7d-47d2-bca5-bde380c5cfe9" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_c48122a4-5c7d-47d2-bca5-bde380c5cfe9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_7f836396-616c-46d6-8daa-762cbc959ff8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_c48122a4-5c7d-47d2-bca5-bde380c5cfe9" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_7f836396-616c-46d6-8daa-762cbc959ff8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyAgreementsMember_82e346bd-6993-491e-bb49-af4184d2ce24" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RoyaltyAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_7f836396-616c-46d6-8daa-762cbc959ff8" xlink:to="loc_us-gaap_RoyaltyAgreementsMember_82e346bd-6993-491e-bb49-af4184d2ce24" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember_cf84d76e-67b1-4bd8-af4f-7e617da80947" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_7f836396-616c-46d6-8daa-762cbc959ff8" xlink:to="loc_us-gaap_LicensingAgreementsMember_cf84d76e-67b1-4bd8-af4f-7e617da80947" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_1c828ed9-cef7-4d27-9bb1-cf4d862888bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_lgnd_BasisOfPresentationTable_445dd6ca-01ad-4024-b237-bc3f1c1722ba" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_1c828ed9-cef7-4d27-9bb1-cf4d862888bf" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1c828ed9-cef7-4d27-9bb1-cf4d862888bf_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_1c828ed9-cef7-4d27-9bb1-cf4d862888bf" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1c828ed9-cef7-4d27-9bb1-cf4d862888bf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4691cd80-0fd2-49a1-a305-204acee9845f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_1c828ed9-cef7-4d27-9bb1-cf4d862888bf" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4691cd80-0fd2-49a1-a305-204acee9845f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PfenexMember_1e79f4ba-74b0-4ff3-b88c-6537c424e246" xlink:href="lgnd-20211231.xsd#lgnd_PfenexMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4691cd80-0fd2-49a1-a305-204acee9845f" xlink:to="loc_lgnd_PfenexMember_1e79f4ba-74b0-4ff3-b88c-6537c424e246" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_IcagenMember_865a4441-c86f-46f7-bd17-be432c45ece2" xlink:href="lgnd-20211231.xsd#lgnd_IcagenMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4691cd80-0fd2-49a1-a305-204acee9845f" xlink:to="loc_lgnd_IcagenMember_865a4441-c86f-46f7-bd17-be432c45ece2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_MetabasisTherapeuticsMember_d901eb06-6208-4689-82a2-09d8c74f6312" xlink:href="lgnd-20211231.xsd#lgnd_MetabasisTherapeuticsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4691cd80-0fd2-49a1-a305-204acee9845f" xlink:to="loc_lgnd_MetabasisTherapeuticsMember_d901eb06-6208-4689-82a2-09d8c74f6312" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_6217cb25-255f-48eb-9301-8433268fa6db" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_lgnd_BasisOfPresentationTable_445dd6ca-01ad-4024-b237-bc3f1c1722ba" xlink:to="loc_srt_RangeAxis_6217cb25-255f-48eb-9301-8433268fa6db" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_6217cb25-255f-48eb-9301-8433268fa6db_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_6217cb25-255f-48eb-9301-8433268fa6db" xlink:to="loc_srt_RangeMember_6217cb25-255f-48eb-9301-8433268fa6db_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_87a330e9-8386-476a-aa98-7737b639071a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_6217cb25-255f-48eb-9301-8433268fa6db" xlink:to="loc_srt_RangeMember_87a330e9-8386-476a-aa98-7737b639071a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_14322eae-716d-4968-bb50-f6843193a50a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_87a330e9-8386-476a-aa98-7737b639071a" xlink:to="loc_srt_MinimumMember_14322eae-716d-4968-bb50-f6843193a50a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_8c765748-1cc9-4175-a3c3-a598db0efbc9" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_87a330e9-8386-476a-aa98-7737b639071a" xlink:to="loc_srt_MaximumMember_8c765748-1cc9-4175-a3c3-a598db0efbc9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_4cdca474-e92e-49e1-93ea-d6ba41a6ef8d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_lgnd_BasisOfPresentationTable_445dd6ca-01ad-4024-b237-bc3f1c1722ba" xlink:to="loc_us-gaap_AwardTypeAxis_4cdca474-e92e-49e1-93ea-d6ba41a6ef8d" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4cdca474-e92e-49e1-93ea-d6ba41a6ef8d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_4cdca474-e92e-49e1-93ea-d6ba41a6ef8d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4cdca474-e92e-49e1-93ea-d6ba41a6ef8d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1e284b0a-90e7-49bd-bb53-620f3cc71b7c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_4cdca474-e92e-49e1-93ea-d6ba41a6ef8d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1e284b0a-90e7-49bd-bb53-620f3cc71b7c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_8af34d06-e19a-4aca-8294-be20403a4063" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1e284b0a-90e7-49bd-bb53-620f3cc71b7c" xlink:to="loc_us-gaap_EmployeeStockOptionMember_8af34d06-e19a-4aca-8294-be20403a4063" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_RestrictedStockUnitsAndPerformanceSharesMember_695d6396-a367-481f-893e-4d57f448296c" xlink:href="lgnd-20211231.xsd#lgnd_RestrictedStockUnitsAndPerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1e284b0a-90e7-49bd-bb53-620f3cc71b7c" xlink:to="loc_lgnd_RestrictedStockUnitsAndPerformanceSharesMember_695d6396-a367-481f-893e-4d57f448296c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_6d355d05-9ee7-4e4d-be21-816c2935999c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lgnd_RestrictedStockUnitsAndPerformanceSharesMember_695d6396-a367-481f-893e-4d57f448296c" xlink:to="loc_us-gaap_PerformanceSharesMember_6d355d05-9ee7-4e4d-be21-816c2935999c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_05b31ee8-979b-4b5a-aca1-a7d3378081ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_lgnd_BasisOfPresentationTable_445dd6ca-01ad-4024-b237-bc3f1c1722ba" xlink:to="loc_us-gaap_VestingAxis_05b31ee8-979b-4b5a-aca1-a7d3378081ec" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_05b31ee8-979b-4b5a-aca1-a7d3378081ec_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VestingAxis_05b31ee8-979b-4b5a-aca1-a7d3378081ec" xlink:to="loc_us-gaap_VestingDomain_05b31ee8-979b-4b5a-aca1-a7d3378081ec_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_44880f8a-96c8-47ba-8e4b-f0b4ec505965" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VestingAxis_05b31ee8-979b-4b5a-aca1-a7d3378081ec" xlink:to="loc_us-gaap_VestingDomain_44880f8a-96c8-47ba-8e4b-f0b4ec505965" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_VestingPeriodOneMember_9185233b-0405-47e9-96fc-3e5f204a2a4c" xlink:href="lgnd-20211231.xsd#lgnd_VestingPeriodOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_44880f8a-96c8-47ba-8e4b-f0b4ec505965" xlink:to="loc_lgnd_VestingPeriodOneMember_9185233b-0405-47e9-96fc-3e5f204a2a4c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_VestingPeriodTwoMember_1bea8ace-d398-45dc-a833-5617442294d9" xlink:href="lgnd-20211231.xsd#lgnd_VestingPeriodTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_44880f8a-96c8-47ba-8e4b-f0b4ec505965" xlink:to="loc_lgnd_VestingPeriodTwoMember_1bea8ace-d398-45dc-a833-5617442294d9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_29bda5ca-3975-4eba-87f6-ff6c0ab3bbf6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_lgnd_BasisOfPresentationTable_445dd6ca-01ad-4024-b237-bc3f1c1722ba" xlink:to="loc_us-gaap_PlanNameAxis_29bda5ca-3975-4eba-87f6-ff6c0ab3bbf6" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_29bda5ca-3975-4eba-87f6-ff6c0ab3bbf6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_29bda5ca-3975-4eba-87f6-ff6c0ab3bbf6" xlink:to="loc_us-gaap_PlanNameDomain_29bda5ca-3975-4eba-87f6-ff6c0ab3bbf6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_4311cde2-b966-4c41-8fb7-1f6185add88b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_29bda5ca-3975-4eba-87f6-ff6c0ab3bbf6" xlink:to="loc_us-gaap_PlanNameDomain_4311cde2-b966-4c41-8fb7-1f6185add88b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_TwoThousandTwoStockIncentivePlanMember_9f9f102b-6b57-4cfd-b8ab-c5f238be945a" xlink:href="lgnd-20211231.xsd#lgnd_TwoThousandTwoStockIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_4311cde2-b966-4c41-8fb7-1f6185add88b" xlink:to="loc_lgnd_TwoThousandTwoStockIncentivePlanMember_9f9f102b-6b57-4cfd-b8ab-c5f238be945a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_18c39c10-58dd-4d1b-a905-d9aada4ab72a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_lgnd_BasisOfPresentationTable_445dd6ca-01ad-4024-b237-bc3f1c1722ba" xlink:to="loc_srt_ProductOrServiceAxis_18c39c10-58dd-4d1b-a905-d9aada4ab72a" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_18c39c10-58dd-4d1b-a905-d9aada4ab72a_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_18c39c10-58dd-4d1b-a905-d9aada4ab72a" xlink:to="loc_srt_ProductsAndServicesDomain_18c39c10-58dd-4d1b-a905-d9aada4ab72a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_ed10acfe-7d15-4364-8c91-079132be7228" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_18c39c10-58dd-4d1b-a905-d9aada4ab72a" xlink:to="loc_srt_ProductsAndServicesDomain_ed10acfe-7d15-4364-8c91-079132be7228" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ContractRevenueMember_fd7a48d8-1572-4354-9db6-3c2ac62972fe" xlink:href="lgnd-20211231.xsd#lgnd_ContractRevenueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_ed10acfe-7d15-4364-8c91-079132be7228" xlink:to="loc_lgnd_ContractRevenueMember_fd7a48d8-1572-4354-9db6-3c2ac62972fe" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_MaterialSalesCaptisolMember_a0d9e7d3-26c7-49c7-b337-beabfe206738" xlink:href="lgnd-20211231.xsd#lgnd_MaterialSalesCaptisolMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_ed10acfe-7d15-4364-8c91-079132be7228" xlink:to="loc_lgnd_MaterialSalesCaptisolMember_a0d9e7d3-26c7-49c7-b337-beabfe206738" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_95a22866-a7f9-4a00-ba0f-9873a97c00a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_lgnd_BasisOfPresentationTable_445dd6ca-01ad-4024-b237-bc3f1c1722ba" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_95a22866-a7f9-4a00-ba0f-9873a97c00a9" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_95a22866-a7f9-4a00-ba0f-9873a97c00a9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_95a22866-a7f9-4a00-ba0f-9873a97c00a9" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_95a22866-a7f9-4a00-ba0f-9873a97c00a9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_71102116-714d-4bab-8b84-dc447625c31d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_95a22866-a7f9-4a00-ba0f-9873a97c00a9" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_71102116-714d-4bab-8b84-dc447625c31d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockCompensationPlanMember_9bcc383f-6358-4a24-8995-052d0af36e20" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockCompensationPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_71102116-714d-4bab-8b84-dc447625c31d" xlink:to="loc_us-gaap_StockCompensationPlanMember_9bcc383f-6358-4a24-8995-052d0af36e20" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_49045f0a-455c-4b45-9a07-d26b872d65dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_lgnd_BasisOfPresentationTable_445dd6ca-01ad-4024-b237-bc3f1c1722ba" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_49045f0a-455c-4b45-9a07-d26b872d65dd" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_49045f0a-455c-4b45-9a07-d26b872d65dd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_49045f0a-455c-4b45-9a07-d26b872d65dd" xlink:to="loc_us-gaap_TypeOfAdoptionMember_49045f0a-455c-4b45-9a07-d26b872d65dd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_c1ba069c-ac82-49db-aa75-f1623375f7d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_49045f0a-455c-4b45-9a07-d26b872d65dd" xlink:to="loc_us-gaap_TypeOfAdoptionMember_c1ba069c-ac82-49db-aa75-f1623375f7d6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate201613Member_46bc2462-f5d0-45bd-b68e-a54ec41ce7a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingStandardsUpdate201613Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfAdoptionMember_c1ba069c-ac82-49db-aa75-f1623375f7d6" xlink:to="loc_us-gaap_AccountingStandardsUpdate201613Member_46bc2462-f5d0-45bd-b68e-a54ec41ce7a0" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRevenuefromSignificantPartnersDetails" xlink:type="simple" xlink:href="lgnd-20211231.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesRevenuefromSignificantPartnersDetails"/>
  <link:definitionLink xlink:role="http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRevenuefromSignificantPartnersDetails" xlink:type="extended" id="i9a8bceb6c93b48e7b8f6b6dc8b7ab828_BasisofPresentationandSummaryofSignificantAccountingPoliciesRevenuefromSignificantPartnersDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_bb83286f-93b3-4938-8cad-8a32d0a69f2e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EntityWideRevenueMajorCustomerLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_47e2fdbd-2c8d-40e7-a852-9dcbf9882cff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_bb83286f-93b3-4938-8cad-8a32d0a69f2e" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_47e2fdbd-2c8d-40e7-a852-9dcbf9882cff" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_146bb70f-b313-4c35-a47a-c71078a05bad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_bb83286f-93b3-4938-8cad-8a32d0a69f2e" xlink:to="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_146bb70f-b313-4c35-a47a-c71078a05bad" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_58b78baf-9aa0-4d47-ab8e-b3752d686f26" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_146bb70f-b313-4c35-a47a-c71078a05bad" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_58b78baf-9aa0-4d47-ab8e-b3752d686f26" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_58b78baf-9aa0-4d47-ab8e-b3752d686f26_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_58b78baf-9aa0-4d47-ab8e-b3752d686f26" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_58b78baf-9aa0-4d47-ab8e-b3752d686f26_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_cd4d71a9-704c-49fa-8c09-73c5f3d3ae40" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_58b78baf-9aa0-4d47-ab8e-b3752d686f26" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_cd4d71a9-704c-49fa-8c09-73c5f3d3ae40" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_7ade5dfb-e10d-416f-8618-96f05cde8de2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_cd4d71a9-704c-49fa-8c09-73c5f3d3ae40" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_7ade5dfb-e10d-416f-8618-96f05cde8de2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_a485bd9d-97d0-40e5-b4ca-f0d1c5d66e55" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_146bb70f-b313-4c35-a47a-c71078a05bad" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_a485bd9d-97d0-40e5-b4ca-f0d1c5d66e55" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_a485bd9d-97d0-40e5-b4ca-f0d1c5d66e55_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_a485bd9d-97d0-40e5-b4ca-f0d1c5d66e55" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_a485bd9d-97d0-40e5-b4ca-f0d1c5d66e55_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_a3dd914d-f2de-4b19-865d-a373bf7c00ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_a485bd9d-97d0-40e5-b4ca-f0d1c5d66e55" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_a3dd914d-f2de-4b19-865d-a373bf7c00ed" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember_00cb6fd9-d5f5-48d4-aef5-af9c48d52bfe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_a3dd914d-f2de-4b19-865d-a373bf7c00ed" xlink:to="loc_us-gaap_SalesRevenueNetMember_00cb6fd9-d5f5-48d4-aef5-af9c48d52bfe" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_30695815-a4c7-4ffe-961d-055e052ea55d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_146bb70f-b313-4c35-a47a-c71078a05bad" xlink:to="loc_srt_MajorCustomersAxis_30695815-a4c7-4ffe-961d-055e052ea55d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_30695815-a4c7-4ffe-961d-055e052ea55d_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_30695815-a4c7-4ffe-961d-055e052ea55d" xlink:to="loc_srt_NameOfMajorCustomerDomain_30695815-a4c7-4ffe-961d-055e052ea55d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_fe75c67c-f42b-4db5-98c2-516912fee410" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_30695815-a4c7-4ffe-961d-055e052ea55d" xlink:to="loc_srt_NameOfMajorCustomerDomain_fe75c67c-f42b-4db5-98c2-516912fee410" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PartnerAMember_6de5f8ef-dbeb-4967-b63b-2a3508dcc4cd" xlink:href="lgnd-20211231.xsd#lgnd_PartnerAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_fe75c67c-f42b-4db5-98c2-516912fee410" xlink:to="loc_lgnd_PartnerAMember_6de5f8ef-dbeb-4967-b63b-2a3508dcc4cd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PartnerBMember_52fcec19-2395-4e4c-a4ae-ea7855b41880" xlink:href="lgnd-20211231.xsd#lgnd_PartnerBMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_fe75c67c-f42b-4db5-98c2-516912fee410" xlink:to="loc_lgnd_PartnerBMember_52fcec19-2395-4e4c-a4ae-ea7855b41880" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PartnerCMember_c7710676-10ec-4ff9-980c-4231715d448f" xlink:href="lgnd-20211231.xsd#lgnd_PartnerCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_fe75c67c-f42b-4db5-98c2-516912fee410" xlink:to="loc_lgnd_PartnerCMember_c7710676-10ec-4ff9-980c-4231715d448f" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCommercialLicenseRightsDetails" xlink:type="simple" xlink:href="lgnd-20211231.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesCommercialLicenseRightsDetails"/>
  <link:definitionLink xlink:role="http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCommercialLicenseRightsDetails" xlink:type="extended" id="i4c19eb67868c4d89b9bc6b84ddd0fd20_BasisofPresentationandSummaryofSignificantAccountingPoliciesCommercialLicenseRightsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_10942df7-2e8f-4a14-b70f-f66b21e02642" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_571703e1-bde0-4ec0-a602-9beeabe558b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_10942df7-2e8f-4a14-b70f-f66b21e02642" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_571703e1-bde0-4ec0-a602-9beeabe558b8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_FiniteLivedIntangibleAssetsAccumulatedAmortizationResearchDevelopmentExpenseAndCreditLossAdjustments_fe29475f-70bd-465e-ac6d-046af66f5631" xlink:href="lgnd-20211231.xsd#lgnd_FiniteLivedIntangibleAssetsAccumulatedAmortizationResearchDevelopmentExpenseAndCreditLossAdjustments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_10942df7-2e8f-4a14-b70f-f66b21e02642" xlink:to="loc_lgnd_FiniteLivedIntangibleAssetsAccumulatedAmortizationResearchDevelopmentExpenseAndCreditLossAdjustments_fe29475f-70bd-465e-ac6d-046af66f5631" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_1f74b667-e842-408d-a243-15369d8e22fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_10942df7-2e8f-4a14-b70f-f66b21e02642" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_1f74b667-e842-408d-a243-15369d8e22fe" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_f677aa3a-87cf-4244-a7d9-ea3127e0d739" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_10942df7-2e8f-4a14-b70f-f66b21e02642" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_f677aa3a-87cf-4244-a7d9-ea3127e0d739" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_FiniteLivedIntangibleAssetsCreditLossAdjustments_d183fbb7-7cf2-4d25-b367-79f6414a4d3c" xlink:href="lgnd-20211231.xsd#lgnd_FiniteLivedIntangibleAssetsCreditLossAdjustments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_10942df7-2e8f-4a14-b70f-f66b21e02642" xlink:to="loc_lgnd_FiniteLivedIntangibleAssetsCreditLossAdjustments_d183fbb7-7cf2-4d25-b367-79f6414a4d3c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_73637e86-8ddb-423b-b294-08c754fa63e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_10942df7-2e8f-4a14-b70f-f66b21e02642" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_73637e86-8ddb-423b-b294-08c754fa63e0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_2ad8977d-68e7-4042-8ae1-bd6986fbbde6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_73637e86-8ddb-423b-b294-08c754fa63e0" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_2ad8977d-68e7-4042-8ae1-bd6986fbbde6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2ad8977d-68e7-4042-8ae1-bd6986fbbde6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_2ad8977d-68e7-4042-8ae1-bd6986fbbde6" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2ad8977d-68e7-4042-8ae1-bd6986fbbde6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_dffbbc08-44f6-4cd2-bf26-57a25534c4a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_2ad8977d-68e7-4042-8ae1-bd6986fbbde6" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_dffbbc08-44f6-4cd2-bf26-57a25534c4a3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember_29b262de-ef1e-4327-a5ef-a9c7f8aa1999" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_dffbbc08-44f6-4cd2-bf26-57a25534c4a3" xlink:to="loc_us-gaap_LicensingAgreementsMember_29b262de-ef1e-4327-a5ef-a9c7f8aa1999" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_29a115f8-8f51-4e40-82bb-312e7cfa6ebe" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_73637e86-8ddb-423b-b294-08c754fa63e0" xlink:to="loc_srt_CounterpartyNameAxis_29a115f8-8f51-4e40-82bb-312e7cfa6ebe" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_29a115f8-8f51-4e40-82bb-312e7cfa6ebe_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_29a115f8-8f51-4e40-82bb-312e7cfa6ebe" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_29a115f8-8f51-4e40-82bb-312e7cfa6ebe_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_dc607d86-b008-4f46-b153-dedeced2d0ea" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_29a115f8-8f51-4e40-82bb-312e7cfa6ebe" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_dc607d86-b008-4f46-b153-dedeced2d0ea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AziyoandCorMatrixMember_2da57140-a99a-43d9-9ae1-b0536ce32907" xlink:href="lgnd-20211231.xsd#lgnd_AziyoandCorMatrixMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_dc607d86-b008-4f46-b153-dedeced2d0ea" xlink:to="loc_lgnd_AziyoandCorMatrixMember_2da57140-a99a-43d9-9ae1-b0536ce32907" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_SelexisAndDianomiMember_2d61a699-ec3f-474f-9ce4-547b6ec23eae" xlink:href="lgnd-20211231.xsd#lgnd_SelexisAndDianomiMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_dc607d86-b008-4f46-b153-dedeced2d0ea" xlink:to="loc_lgnd_SelexisAndDianomiMember_2d61a699-ec3f-474f-9ce4-547b6ec23eae" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRoyaltyRevenueDetails" xlink:type="simple" xlink:href="lgnd-20211231.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesRoyaltyRevenueDetails"/>
  <link:definitionLink xlink:role="http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRoyaltyRevenueDetails" xlink:type="extended" id="i9a60900e2d5b4d3cbde477e1d5df378e_BasisofPresentationandSummaryofSignificantAccountingPoliciesRoyaltyRevenueDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_61876364-d732-4dd3-b412-d51f8c1b271f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_09593bb9-eff6-4663-9bdf-8d82e5f21159" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_61876364-d732-4dd3-b412-d51f8c1b271f" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_09593bb9-eff6-4663-9bdf-8d82e5f21159" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_6f754a3e-7ecf-449e-bab9-fd95566a9464" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_61876364-d732-4dd3-b412-d51f8c1b271f" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_6f754a3e-7ecf-449e-bab9-fd95566a9464" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_73d286c9-40d4-4dfc-96ce-8ddaf457c655" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_6f754a3e-7ecf-449e-bab9-fd95566a9464" xlink:to="loc_srt_ProductOrServiceAxis_73d286c9-40d4-4dfc-96ce-8ddaf457c655" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_73d286c9-40d4-4dfc-96ce-8ddaf457c655_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_73d286c9-40d4-4dfc-96ce-8ddaf457c655" xlink:to="loc_srt_ProductsAndServicesDomain_73d286c9-40d4-4dfc-96ce-8ddaf457c655_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_55637727-8a43-4dea-922e-02dfff786ed2" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_73d286c9-40d4-4dfc-96ce-8ddaf457c655" xlink:to="loc_srt_ProductsAndServicesDomain_55637727-8a43-4dea-922e-02dfff786ed2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyMember_c5c5b697-8e19-4e13-839c-fc4c48cf2db6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RoyaltyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_55637727-8a43-4dea-922e-02dfff786ed2" xlink:to="loc_us-gaap_RoyaltyMember_c5c5b697-8e19-4e13-839c-fc4c48cf2db6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_RoyaltyKyprolisMember_857a5904-3105-4ad2-9d51-89c851e89f21" xlink:href="lgnd-20211231.xsd#lgnd_RoyaltyKyprolisMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RoyaltyMember_c5c5b697-8e19-4e13-839c-fc4c48cf2db6" xlink:to="loc_lgnd_RoyaltyKyprolisMember_857a5904-3105-4ad2-9d51-89c851e89f21" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_RoyaltyEvomelaMember_51b05dc9-5d35-4b88-b266-0f4622136b86" xlink:href="lgnd-20211231.xsd#lgnd_RoyaltyEvomelaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RoyaltyMember_c5c5b697-8e19-4e13-839c-fc4c48cf2db6" xlink:to="loc_lgnd_RoyaltyEvomelaMember_51b05dc9-5d35-4b88-b266-0f4622136b86" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_RoyaltyOtherMember_436b3ab7-213e-4a57-b6cf-ed8f4701852b" xlink:href="lgnd-20211231.xsd#lgnd_RoyaltyOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RoyaltyMember_c5c5b697-8e19-4e13-839c-fc4c48cf2db6" xlink:to="loc_lgnd_RoyaltyOtherMember_436b3ab7-213e-4a57-b6cf-ed8f4701852b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_RoyaltyPromactaMember_da346cd7-6a12-483f-98e3-aceefd0f3048" xlink:href="lgnd-20211231.xsd#lgnd_RoyaltyPromactaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RoyaltyMember_c5c5b697-8e19-4e13-839c-fc4c48cf2db6" xlink:to="loc_lgnd_RoyaltyPromactaMember_da346cd7-6a12-483f-98e3-aceefd0f3048" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_MaterialSalesCaptisolMember_961e9207-f7a4-4533-af26-dfe4b90111f6" xlink:href="lgnd-20211231.xsd#lgnd_MaterialSalesCaptisolMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_55637727-8a43-4dea-922e-02dfff786ed2" xlink:to="loc_lgnd_MaterialSalesCaptisolMember_961e9207-f7a4-4533-af26-dfe4b90111f6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ContractRevenueMember_4f3368a2-3c4f-45c0-ae42-460526ee7941" xlink:href="lgnd-20211231.xsd#lgnd_ContractRevenueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_55637727-8a43-4dea-922e-02dfff786ed2" xlink:to="loc_lgnd_ContractRevenueMember_4f3368a2-3c4f-45c0-ae42-460526ee7941" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember_0b61ce1a-f41b-4c75-95cd-23011169bf2c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ServiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lgnd_ContractRevenueMember_4f3368a2-3c4f-45c0-ae42-460526ee7941" xlink:to="loc_us-gaap_ServiceMember_0b61ce1a-f41b-4c75-95cd-23011169bf2c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_LicenseFeesMember_0b13eaaa-f921-40e0-b799-6ad69763a2a7" xlink:href="lgnd-20211231.xsd#lgnd_LicenseFeesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lgnd_ContractRevenueMember_4f3368a2-3c4f-45c0-ae42-460526ee7941" xlink:to="loc_lgnd_LicenseFeesMember_0b13eaaa-f921-40e0-b799-6ad69763a2a7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_MilestoneMember_30c34cf4-badf-44a4-90a1-8ba4e50e2ce3" xlink:href="lgnd-20211231.xsd#lgnd_MilestoneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lgnd_ContractRevenueMember_4f3368a2-3c4f-45c0-ae42-460526ee7941" xlink:to="loc_lgnd_MilestoneMember_30c34cf4-badf-44a4-90a1-8ba4e50e2ce3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_LicenseFeesMilestonesAndOtherProductOtherMember_c1ead832-3861-4d4a-9648-aeb950464831" xlink:href="lgnd-20211231.xsd#lgnd_LicenseFeesMilestonesAndOtherProductOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lgnd_ContractRevenueMember_4f3368a2-3c4f-45c0-ae42-460526ee7941" xlink:to="loc_lgnd_LicenseFeesMilestonesAndOtherProductOtherMember_c1ead832-3861-4d4a-9648-aeb950464831" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCalculationofEarningsperShareDetails" xlink:type="simple" xlink:href="lgnd-20211231.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesCalculationofEarningsperShareDetails"/>
  <link:definitionLink xlink:role="http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCalculationofEarningsperShareDetails" xlink:type="extended" id="i41e3a67eead649eb8ac45f9a85d2e847_BasisofPresentationandSummaryofSignificantAccountingPoliciesCalculationofEarningsperShareDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDilutedLineItems_76834600-660e-4466-9e19-655c2228bc66" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDilutedLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_cade78f4-05b1-480f-ad26-7b748f97898c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareDilutedLineItems_76834600-660e-4466-9e19-655c2228bc66" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_cade78f4-05b1-480f-ad26-7b748f97898c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_b78fd97d-3093-4185-9853-9cb641007cbd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareDilutedLineItems_76834600-660e-4466-9e19-655c2228bc66" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_b78fd97d-3093-4185-9853-9cb641007cbd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_f9d75a86-da5e-491a-bfbf-f1d02043e911" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareDilutedLineItems_76834600-660e-4466-9e19-655c2228bc66" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_f9d75a86-da5e-491a-bfbf-f1d02043e911" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_12ae774b-58fe-47d3-aaf6-8313640118a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareDilutedLineItems_76834600-660e-4466-9e19-655c2228bc66" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_12ae774b-58fe-47d3-aaf6-8313640118a1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable_24515808-d5b7-42c3-8a79-41b139e3283b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EarningsPerShareDilutedLineItems_76834600-660e-4466-9e19-655c2228bc66" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable_24515808-d5b7-42c3-8a79-41b139e3283b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_75946995-c655-481e-b269-145e0d6ecddb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable_24515808-d5b7-42c3-8a79-41b139e3283b" xlink:to="loc_us-gaap_AwardTypeAxis_75946995-c655-481e-b269-145e0d6ecddb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_75946995-c655-481e-b269-145e0d6ecddb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_75946995-c655-481e-b269-145e0d6ecddb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_75946995-c655-481e-b269-145e0d6ecddb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_15e33ac1-43c4-4998-a987-ed75d5914680" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_75946995-c655-481e-b269-145e0d6ecddb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_15e33ac1-43c4-4998-a987-ed75d5914680" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_073620d1-0c29-4406-ab39-7d49842e35e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_15e33ac1-43c4-4998-a987-ed75d5914680" xlink:to="loc_us-gaap_RestrictedStockMember_073620d1-0c29-4406-ab39-7d49842e35e3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_53f43f93-a1ea-4c72-8d4b-353b50662df1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_15e33ac1-43c4-4998-a987-ed75d5914680" xlink:to="loc_us-gaap_EmployeeStockOptionMember_53f43f93-a1ea-4c72-8d4b-353b50662df1" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ligand.com/role/SaleofVernalisRDandPromactaLicenseNarrativeDetails" xlink:type="simple" xlink:href="lgnd-20211231.xsd#SaleofVernalisRDandPromactaLicenseNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.ligand.com/role/SaleofVernalisRDandPromactaLicenseNarrativeDetails" xlink:type="extended" id="i7e2acb5e94034c5c8312bb7d78ccf509_SaleofVernalisRDandPromactaLicenseNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_9f1756bf-9e97-4c43-9e55-7cfbaa53d63d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_2020ec1f-5747-4c44-a5c6-e34d554fd167" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromDivestitureOfBusinesses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_9f1756bf-9e97-4c43-9e55-7cfbaa53d63d" xlink:to="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_2020ec1f-5747-4c44-a5c6-e34d554fd167" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_085ef362-ebe9-49d1-8e78-efee7ee16595" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_9f1756bf-9e97-4c43-9e55-7cfbaa53d63d" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_085ef362-ebe9-49d1-8e78-efee7ee16595" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit_74ebf4f8-dfe1-4d69-8ee1-d668b1e34601" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_9f1756bf-9e97-4c43-9e55-7cfbaa53d63d" xlink:to="loc_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit_74ebf4f8-dfe1-4d69-8ee1-d668b1e34601" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfIntangibleAssets_f08858c7-23ef-4c21-945e-e66d9389992d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnDispositionOfIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_9f1756bf-9e97-4c43-9e55-7cfbaa53d63d" xlink:to="loc_us-gaap_GainLossOnDispositionOfIntangibleAssets_f08858c7-23ef-4c21-945e-e66d9389992d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_d89c338c-6764-4734-a1d7-12b9b3512b0a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_9f1756bf-9e97-4c43-9e55-7cfbaa53d63d" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_d89c338c-6764-4734-a1d7-12b9b3512b0a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_98859f47-c6c4-439e-9b18-08511a4218ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_9f1756bf-9e97-4c43-9e55-7cfbaa53d63d" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_98859f47-c6c4-439e-9b18-08511a4218ce" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_76445c02-a064-463b-bdc8-eceda9fe778a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_98859f47-c6c4-439e-9b18-08511a4218ce" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_76445c02-a064-463b-bdc8-eceda9fe778a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_76445c02-a064-463b-bdc8-eceda9fe778a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_76445c02-a064-463b-bdc8-eceda9fe778a" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_76445c02-a064-463b-bdc8-eceda9fe778a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_cce12e06-aecb-46ad-b642-eb303a0272c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_76445c02-a064-463b-bdc8-eceda9fe778a" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_cce12e06-aecb-46ad-b642-eb303a0272c6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_VernalisMember_a342cf93-270a-45a5-884a-5b76611dd994" xlink:href="lgnd-20211231.xsd#lgnd_VernalisMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_cce12e06-aecb-46ad-b642-eb303a0272c6" xlink:to="loc_lgnd_VernalisMember_a342cf93-270a-45a5-884a-5b76611dd994" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PromactaMember_0d647945-b2e9-42c2-837d-54270be10584" xlink:href="lgnd-20211231.xsd#lgnd_PromactaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_cce12e06-aecb-46ad-b642-eb303a0272c6" xlink:to="loc_lgnd_PromactaMember_0d647945-b2e9-42c2-837d-54270be10584" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_568a4653-ed6e-4637-883f-a0ebd2ad3828" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_98859f47-c6c4-439e-9b18-08511a4218ce" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_568a4653-ed6e-4637-883f-a0ebd2ad3828" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_568a4653-ed6e-4637-883f-a0ebd2ad3828_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_568a4653-ed6e-4637-883f-a0ebd2ad3828" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_568a4653-ed6e-4637-883f-a0ebd2ad3828_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_b8075a56-4fff-484b-ba4d-d4a94dfde624" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_568a4653-ed6e-4637-883f-a0ebd2ad3828" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_b8075a56-4fff-484b-ba4d-d4a94dfde624" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_b974dad4-e6ad-4f88-a9f9-c23b91f9a2c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_b8075a56-4fff-484b-ba4d-d4a94dfde624" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_b974dad4-e6ad-4f88-a9f9-c23b91f9a2c0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_61dc526f-d1d8-42db-81f4-a666350cec56" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_98859f47-c6c4-439e-9b18-08511a4218ce" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_61dc526f-d1d8-42db-81f4-a666350cec56" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_61dc526f-d1d8-42db-81f4-a666350cec56_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_61dc526f-d1d8-42db-81f4-a666350cec56" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_61dc526f-d1d8-42db-81f4-a666350cec56_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_57831bc4-8a30-44dc-bbcb-be605d5d15a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_61dc526f-d1d8-42db-81f4-a666350cec56" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_57831bc4-8a30-44dc-bbcb-be605d5d15a4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember_e7731b9e-6dc1-49b1-a21d-d2a3b809d03f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_57831bc4-8a30-44dc-bbcb-be605d5d15a4" xlink:to="loc_us-gaap_DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember_e7731b9e-6dc1-49b1-a21d-d2a3b809d03f" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ligand.com/role/ShorttermInvestmentsInvestmentinVikingNarrativeDetails" xlink:type="simple" xlink:href="lgnd-20211231.xsd#ShorttermInvestmentsInvestmentinVikingNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.ligand.com/role/ShorttermInvestmentsInvestmentinVikingNarrativeDetails" xlink:type="extended" id="i12c05ec09bcf4baab9ac1e8d1883c346_ShorttermInvestmentsInvestmentinVikingNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityLineItems_c19b0140-dab6-4d7f-84a0-886cc9cf7d07" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableInterestEntityLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LimitedLiabilityCompanyLLCOrLimitedPartnershipLPMembersOrLimitedPartnersOwnershipInterest_773ae10f-beeb-4d8a-8803-23f7ee2fd7e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LimitedLiabilityCompanyLLCOrLimitedPartnershipLPMembersOrLimitedPartnersOwnershipInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_c19b0140-dab6-4d7f-84a0-886cc9cf7d07" xlink:to="loc_us-gaap_LimitedLiabilityCompanyLLCOrLimitedPartnershipLPMembersOrLimitedPartnersOwnershipInterest_773ae10f-beeb-4d8a-8803-23f7ee2fd7e1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstanding_dfdba9e5-1a4e-422c-ba23-367ac768dcf9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_c19b0140-dab6-4d7f-84a0-886cc9cf7d07" xlink:to="loc_us-gaap_WarrantsAndRightsOutstanding_dfdba9e5-1a4e-422c-ba23-367ac768dcf9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_d3811958-2988-43c3-bd3c-0fb88e542030" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_c19b0140-dab6-4d7f-84a0-886cc9cf7d07" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_d3811958-2988-43c3-bd3c-0fb88e542030" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_28ae9d1c-9cff-43a4-b283-72d456cb59fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_c19b0140-dab6-4d7f-84a0-886cc9cf7d07" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_28ae9d1c-9cff-43a4-b283-72d456cb59fd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_NumberOfSharesSoldOfEquityMethodInvestee_5915cfa9-187c-4479-addf-38c3e4e88541" xlink:href="lgnd-20211231.xsd#lgnd_NumberOfSharesSoldOfEquityMethodInvestee"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_c19b0140-dab6-4d7f-84a0-886cc9cf7d07" xlink:to="loc_lgnd_NumberOfSharesSoldOfEquityMethodInvestee_5915cfa9-187c-4479-addf-38c3e4e88541" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_InvestmentInVikingCurrent_53118682-c90d-48e0-8b35-645c55aeefd9" xlink:href="lgnd-20211231.xsd#lgnd_InvestmentInVikingCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_c19b0140-dab6-4d7f-84a0-886cc9cf7d07" xlink:to="loc_lgnd_InvestmentInVikingCurrent_53118682-c90d-48e0-8b35-645c55aeefd9" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_e5e10251-892c-446e-a677-7f04b53ac543" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_c19b0140-dab6-4d7f-84a0-886cc9cf7d07" xlink:to="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_e5e10251-892c-446e-a677-7f04b53ac543" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_b1329fa1-4db3-40a7-9c33-5541c6204cd4" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_e5e10251-892c-446e-a677-7f04b53ac543" xlink:to="loc_srt_OwnershipAxis_b1329fa1-4db3-40a7-9c33-5541c6204cd4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_b1329fa1-4db3-40a7-9c33-5541c6204cd4_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_OwnershipAxis_b1329fa1-4db3-40a7-9c33-5541c6204cd4" xlink:to="loc_srt_OwnershipDomain_b1329fa1-4db3-40a7-9c33-5541c6204cd4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_9c621c7e-93c9-4249-ad8f-370aae9b0083" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_OwnershipAxis_b1329fa1-4db3-40a7-9c33-5541c6204cd4" xlink:to="loc_srt_OwnershipDomain_9c621c7e-93c9-4249-ad8f-370aae9b0083" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_VikingTherapeuticsInc.Member_583679cf-99df-4bf5-873c-a43902c990f7" xlink:href="lgnd-20211231.xsd#lgnd_VikingTherapeuticsInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_OwnershipDomain_9c621c7e-93c9-4249-ad8f-370aae9b0083" xlink:to="loc_lgnd_VikingTherapeuticsInc.Member_583679cf-99df-4bf5-873c-a43902c990f7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_9678f2c5-3769-421c-b6bf-49e4404f5a45" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_e5e10251-892c-446e-a677-7f04b53ac543" xlink:to="loc_us-gaap_FinancialInstrumentAxis_9678f2c5-3769-421c-b6bf-49e4404f5a45" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9678f2c5-3769-421c-b6bf-49e4404f5a45_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_9678f2c5-3769-421c-b6bf-49e4404f5a45" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9678f2c5-3769-421c-b6bf-49e4404f5a45_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4c08c35f-5cb8-458f-ba60-1b37b720999a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_9678f2c5-3769-421c-b6bf-49e4404f5a45" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4c08c35f-5cb8-458f-ba60-1b37b720999a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_8ac3f846-35e4-4010-b603-8ceb6978f123" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4c08c35f-5cb8-458f-ba60-1b37b720999a" xlink:to="loc_us-gaap_WarrantMember_8ac3f846-35e4-4010-b603-8ceb6978f123" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ligand.com/role/AcquisitionsTables" xlink:type="simple" xlink:href="lgnd-20211231.xsd#AcquisitionsTables"/>
  <link:definitionLink xlink:role="http://www.ligand.com/role/AcquisitionsTables" xlink:type="extended" id="i100d9f7ea5664a7fa3ea6b66a956aa0a_AcquisitionsTables">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_bb63b1da-63b1-48e9-ba43-e5a3ff8f5d8b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_49ecfd5e-2f40-40f6-ba40-3f1a32de11cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_bb63b1da-63b1-48e9-ba43-e5a3ff8f5d8b" xlink:to="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_49ecfd5e-2f40-40f6-ba40-3f1a32de11cf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock_c093594b-205c-4d06-b764-fcedd527257d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_bb63b1da-63b1-48e9-ba43-e5a3ff8f5d8b" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock_c093594b-205c-4d06-b764-fcedd527257d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionProFormaInformationTextBlock_313ff8b6-273f-4cff-95f0-02da5e741114" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionProFormaInformationTextBlock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_bb63b1da-63b1-48e9-ba43-e5a3ff8f5d8b" xlink:to="loc_us-gaap_BusinessAcquisitionProFormaInformationTextBlock_313ff8b6-273f-4cff-95f0-02da5e741114" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_c5250113-688e-41a1-ae9b-b21aebdf585a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_bb63b1da-63b1-48e9-ba43-e5a3ff8f5d8b" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_c5250113-688e-41a1-ae9b-b21aebdf585a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_9c10c32d-c1a1-4da5-8f49-258dfb02d183" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_c5250113-688e-41a1-ae9b-b21aebdf585a" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_9c10c32d-c1a1-4da5-8f49-258dfb02d183" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9c10c32d-c1a1-4da5-8f49-258dfb02d183_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_9c10c32d-c1a1-4da5-8f49-258dfb02d183" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9c10c32d-c1a1-4da5-8f49-258dfb02d183_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9087023e-cea2-4d66-b660-ea30767e88b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_9c10c32d-c1a1-4da5-8f49-258dfb02d183" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9087023e-cea2-4d66-b660-ea30767e88b0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PfenexMember_f509be9a-3367-451b-a163-1d35826cc549" xlink:href="lgnd-20211231.xsd#lgnd_PfenexMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9087023e-cea2-4d66-b660-ea30767e88b0" xlink:to="loc_lgnd_PfenexMember_f509be9a-3367-451b-a163-1d35826cc549" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_TaurusBiosciencesLLCMember_ee74915d-1979-4c74-bb53-d5225f70cfe8" xlink:href="lgnd-20211231.xsd#lgnd_TaurusBiosciencesLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9087023e-cea2-4d66-b660-ea30767e88b0" xlink:to="loc_lgnd_TaurusBiosciencesLLCMember_ee74915d-1979-4c74-bb53-d5225f70cfe8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_XCellaBiosciencesIncMember_32faa422-daea-42b9-8df2-1eec6775f22f" xlink:href="lgnd-20211231.xsd#lgnd_XCellaBiosciencesIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9087023e-cea2-4d66-b660-ea30767e88b0" xlink:to="loc_lgnd_XCellaBiosciencesIncMember_32faa422-daea-42b9-8df2-1eec6775f22f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_IcagenMember_ad62c5b9-2bba-4577-9fa2-bfb700fe0f68" xlink:href="lgnd-20211231.xsd#lgnd_IcagenMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9087023e-cea2-4d66-b660-ea30767e88b0" xlink:to="loc_lgnd_IcagenMember_ad62c5b9-2bba-4577-9fa2-bfb700fe0f68" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AbInitioMember_b4dde99e-7017-49f5-80be-641fe6f89872" xlink:href="lgnd-20211231.xsd#lgnd_AbInitioMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9087023e-cea2-4d66-b660-ea30767e88b0" xlink:to="loc_lgnd_AbInitioMember_b4dde99e-7017-49f5-80be-641fe6f89872" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ligand.com/role/AcquisitionsNarrativeDetails" xlink:type="simple" xlink:href="lgnd-20211231.xsd#AcquisitionsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.ligand.com/role/AcquisitionsNarrativeDetails" xlink:type="extended" id="i0781d99dc83c4fc68a294b7a778d7a7f_AcquisitionsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_c5d08779-62cb-4008-b847-0f007c07745c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_NumberOfAcquisitions_51b3cdb2-5d1d-4033-a481-876a6fe5c4a0" xlink:href="lgnd-20211231.xsd#lgnd_NumberOfAcquisitions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_c5d08779-62cb-4008-b847-0f007c07745c" xlink:to="loc_lgnd_NumberOfAcquisitions_51b3cdb2-5d1d-4033-a481-876a6fe5c4a0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfBusinessesAcquired_0d1baf8e-b872-4274-a1f9-fbb6e2b6d05f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfBusinessesAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_c5d08779-62cb-4008-b847-0f007c07745c" xlink:to="loc_us-gaap_NumberOfBusinessesAcquired_0d1baf8e-b872-4274-a1f9-fbb6e2b6d05f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_NumberOfAssetAcquisitions_447ecdf8-643f-45c3-be00-f00de613cde1" xlink:href="lgnd-20211231.xsd#lgnd_NumberOfAssetAcquisitions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_c5d08779-62cb-4008-b847-0f007c07745c" xlink:to="loc_lgnd_NumberOfAssetAcquisitions_447ecdf8-643f-45c3-be00-f00de613cde1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_e1ee743d-4ead-4515-819b-95034001187d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_c5d08779-62cb-4008-b847-0f007c07745c" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_e1ee743d-4ead-4515-819b-95034001187d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_b5153cf6-0aa0-4933-ad6c-a536505fb35d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_c5d08779-62cb-4008-b847-0f007c07745c" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_b5153cf6-0aa0-4933-ad6c-a536505fb35d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_09783ace-7e4c-4712-8060-7a5ab9d2201e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_c5d08779-62cb-4008-b847-0f007c07745c" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_09783ace-7e4c-4712-8060-7a5ab9d2201e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BusinessCombinationContingentConsiderationLiabilityFairValueDisclosure_d8ebfb95-53a7-4599-a7a0-05d33020ab32" xlink:href="lgnd-20211231.xsd#lgnd_BusinessCombinationContingentConsiderationLiabilityFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_c5d08779-62cb-4008-b847-0f007c07745c" xlink:to="loc_lgnd_BusinessCombinationContingentConsiderationLiabilityFairValueDisclosure_d8ebfb95-53a7-4599-a7a0-05d33020ab32" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_092a4482-64f5-47de-be74-dfc7f0cd7986" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_c5d08779-62cb-4008-b847-0f007c07745c" xlink:to="loc_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_092a4482-64f5-47de-be74-dfc7f0cd7986" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_5cb6a0b8-4aa4-4d7c-a5e8-044b8de29bfe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_c5d08779-62cb-4008-b847-0f007c07745c" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_5cb6a0b8-4aa4-4d7c-a5e8-044b8de29bfe" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_55714393-e87e-458a-802f-3d351b6a99c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_c5d08779-62cb-4008-b847-0f007c07745c" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_55714393-e87e-458a-802f-3d351b6a99c4" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PaymentsToAcquireBusinessesGrossAttributableToVestedPortionOfStockOptions_c4570378-53f1-4129-a81e-ec3529056ec5" xlink:href="lgnd-20211231.xsd#lgnd_PaymentsToAcquireBusinessesGrossAttributableToVestedPortionOfStockOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_c5d08779-62cb-4008-b847-0f007c07745c" xlink:to="loc_lgnd_PaymentsToAcquireBusinessesGrossAttributableToVestedPortionOfStockOptions_c4570378-53f1-4129-a81e-ec3529056ec5" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards_0e8413c0-8217-4a58-ab32-2f2de6f59984" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_c5d08779-62cb-4008-b847-0f007c07745c" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards_0e8413c0-8217-4a58-ab32-2f2de6f59984" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_128e7d5d-1269-4b99-8dc7-8b7ecc1a7a44" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_c5d08779-62cb-4008-b847-0f007c07745c" xlink:to="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_128e7d5d-1269-4b99-8dc7-8b7ecc1a7a44" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsDiscountRate_52c7dc41-ff8b-4d78-81c4-26e3029fb395" xlink:href="lgnd-20211231.xsd#lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsDiscountRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_c5d08779-62cb-4008-b847-0f007c07745c" xlink:to="loc_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsDiscountRate_52c7dc41-ff8b-4d78-81c4-26e3029fb395" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual_c12d66bd-cef1-4e83-83b1-133e2f0d3fa2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_c5d08779-62cb-4008-b847-0f007c07745c" xlink:to="loc_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual_c12d66bd-cef1-4e83-83b1-133e2f0d3fa2" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual_8c618373-2845-41f9-a30f-d08e14fbc163" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_c5d08779-62cb-4008-b847-0f007c07745c" xlink:to="loc_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual_8c618373-2845-41f9-a30f-d08e14fbc163" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationIntegrationRelatedCosts_30cdd8e8-9bb7-4a39-94da-d6ef575d71e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationIntegrationRelatedCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_c5d08779-62cb-4008-b847-0f007c07745c" xlink:to="loc_us-gaap_BusinessCombinationIntegrationRelatedCosts_30cdd8e8-9bb7-4a39-94da-d6ef575d71e6" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BusinessCombinationConsiderationTransferredHoldback_cbe160a7-b42a-49d3-b087-c5cec0192f87" xlink:href="lgnd-20211231.xsd#lgnd_BusinessCombinationConsiderationTransferredHoldback"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_c5d08779-62cb-4008-b847-0f007c07745c" xlink:to="loc_lgnd_BusinessCombinationConsiderationTransferredHoldback_cbe160a7-b42a-49d3-b087-c5cec0192f87" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BusinessCombinationContingentConsiderationLiabilityPercentageOfAcquireeRevenues_e4f65ca9-c25f-4b2d-bd4d-7cf78b48241a" xlink:href="lgnd-20211231.xsd#lgnd_BusinessCombinationContingentConsiderationLiabilityPercentageOfAcquireeRevenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_c5d08779-62cb-4008-b847-0f007c07745c" xlink:to="loc_lgnd_BusinessCombinationContingentConsiderationLiabilityPercentageOfAcquireeRevenues_e4f65ca9-c25f-4b2d-bd4d-7cf78b48241a" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_12b0114a-377d-40a7-b523-09e4ba537b1b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_c5d08779-62cb-4008-b847-0f007c07745c" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_12b0114a-377d-40a7-b523-09e4ba537b1b" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_ad5b9280-c977-43ff-8d39-4c4e474ce79f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_c5d08779-62cb-4008-b847-0f007c07745c" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_ad5b9280-c977-43ff-8d39-4c4e474ce79f" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BusinessCombinationCashHoldbackForPotentialIndemnificationClaims_78a0c92b-ec3b-4e07-bdd7-61ae319deee3" xlink:href="lgnd-20211231.xsd#lgnd_BusinessCombinationCashHoldbackForPotentialIndemnificationClaims"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_c5d08779-62cb-4008-b847-0f007c07745c" xlink:to="loc_lgnd_BusinessCombinationCashHoldbackForPotentialIndemnificationClaims_78a0c92b-ec3b-4e07-bdd7-61ae319deee3" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount_5cc705e9-c05f-461e-a751-ae057ccdf75f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_c5d08779-62cb-4008-b847-0f007c07745c" xlink:to="loc_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount_5cc705e9-c05f-461e-a751-ae057ccdf75f" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BusinessCombinationAssumptionsUsedEstimatedFutureCashFlowsDiscountRate_d7db5274-72b1-491b-837e-c762283276b3" xlink:href="lgnd-20211231.xsd#lgnd_BusinessCombinationAssumptionsUsedEstimatedFutureCashFlowsDiscountRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_c5d08779-62cb-4008-b847-0f007c07745c" xlink:to="loc_lgnd_BusinessCombinationAssumptionsUsedEstimatedFutureCashFlowsDiscountRate_d7db5274-72b1-491b-837e-c762283276b3" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_ce7d3fda-d700-4ec3-a3e2-1ffb7c77aa14" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_c5d08779-62cb-4008-b847-0f007c07745c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_ce7d3fda-d700-4ec3-a3e2-1ffb7c77aa14" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_3dba7021-dacc-4db4-b9d4-e033549dbce6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_c5d08779-62cb-4008-b847-0f007c07745c" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_3dba7021-dacc-4db4-b9d4-e033549dbce6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_39277b30-6cca-491a-8b24-15ecbf20a42c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_3dba7021-dacc-4db4-b9d4-e033549dbce6" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_39277b30-6cca-491a-8b24-15ecbf20a42c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_39277b30-6cca-491a-8b24-15ecbf20a42c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_39277b30-6cca-491a-8b24-15ecbf20a42c" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_39277b30-6cca-491a-8b24-15ecbf20a42c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_51960bd7-3b8c-40e5-aed9-86caa3f450f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_39277b30-6cca-491a-8b24-15ecbf20a42c" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_51960bd7-3b8c-40e5-aed9-86caa3f450f2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PfenexMember_eeaf22ed-2c7e-422d-90b8-8fce92b4a592" xlink:href="lgnd-20211231.xsd#lgnd_PfenexMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_51960bd7-3b8c-40e5-aed9-86caa3f450f2" xlink:to="loc_lgnd_PfenexMember_eeaf22ed-2c7e-422d-90b8-8fce92b4a592" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_TaurusBiosciencesLLCMember_be38d77b-2254-4e52-87e0-cd8823dd37f0" xlink:href="lgnd-20211231.xsd#lgnd_TaurusBiosciencesLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_51960bd7-3b8c-40e5-aed9-86caa3f450f2" xlink:to="loc_lgnd_TaurusBiosciencesLLCMember_be38d77b-2254-4e52-87e0-cd8823dd37f0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_XCellaBiosciencesIncMember_13294cf4-a87c-4135-b858-f761857d771a" xlink:href="lgnd-20211231.xsd#lgnd_XCellaBiosciencesIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_51960bd7-3b8c-40e5-aed9-86caa3f450f2" xlink:to="loc_lgnd_XCellaBiosciencesIncMember_13294cf4-a87c-4135-b858-f761857d771a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_IcagenMember_0f188ef5-d047-40dd-b2ab-daba2caafdfc" xlink:href="lgnd-20211231.xsd#lgnd_IcagenMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_51960bd7-3b8c-40e5-aed9-86caa3f450f2" xlink:to="loc_lgnd_IcagenMember_0f188ef5-d047-40dd-b2ab-daba2caafdfc" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AbInitioMember_a837f279-3b3a-4333-b084-e4a0d62ec924" xlink:href="lgnd-20211231.xsd#lgnd_AbInitioMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_51960bd7-3b8c-40e5-aed9-86caa3f450f2" xlink:to="loc_lgnd_AbInitioMember_a837f279-3b3a-4333-b084-e4a0d62ec924" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_6021dce9-a119-4b88-8558-333225d48dba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_3dba7021-dacc-4db4-b9d4-e033549dbce6" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_6021dce9-a119-4b88-8558-333225d48dba" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_6021dce9-a119-4b88-8558-333225d48dba_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_6021dce9-a119-4b88-8558-333225d48dba" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_6021dce9-a119-4b88-8558-333225d48dba_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_d3fdeb2a-c669-4b53-a642-491d35236e7a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_6021dce9-a119-4b88-8558-333225d48dba" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_d3fdeb2a-c669-4b53-a642-491d35236e7a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember_b5718848-c274-430f-823f-69fc3f5a1cca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_d3fdeb2a-c669-4b53-a642-491d35236e7a" xlink:to="loc_us-gaap_CustomerRelationshipsMember_b5718848-c274-430f-823f-69fc3f5a1cca" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TechnologyBasedIntangibleAssetsMember_a89d3d8a-5b85-4b32-af49-7bcb3d8ecb8e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TechnologyBasedIntangibleAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_d3fdeb2a-c669-4b53-a642-491d35236e7a" xlink:to="loc_us-gaap_TechnologyBasedIntangibleAssetsMember_a89d3d8a-5b85-4b32-af49-7bcb3d8ecb8e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationByTypeAxis_418acbc3-70c4-46c6-bb1b-3a641e4d28bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContingentConsiderationByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_3dba7021-dacc-4db4-b9d4-e033549dbce6" xlink:to="loc_us-gaap_ContingentConsiderationByTypeAxis_418acbc3-70c4-46c6-bb1b-3a641e4d28bd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain_418acbc3-70c4-46c6-bb1b-3a641e4d28bd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContingentConsiderationTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis_418acbc3-70c4-46c6-bb1b-3a641e4d28bd" xlink:to="loc_us-gaap_ContingentConsiderationTypeDomain_418acbc3-70c4-46c6-bb1b-3a641e4d28bd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain_54e5ba0d-1219-418f-9a2b-29a9027c8daf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContingentConsiderationTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis_418acbc3-70c4-46c6-bb1b-3a641e4d28bd" xlink:to="loc_us-gaap_ContingentConsiderationTypeDomain_54e5ba0d-1219-418f-9a2b-29a9027c8daf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ContingentValueRightForInternalResearchAndDevelopmentMember_59bcbf1b-5eb3-4bc3-9306-3960aa5f5205" xlink:href="lgnd-20211231.xsd#lgnd_ContingentValueRightForInternalResearchAndDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_54e5ba0d-1219-418f-9a2b-29a9027c8daf" xlink:to="loc_lgnd_ContingentValueRightForInternalResearchAndDevelopmentMember_59bcbf1b-5eb3-4bc3-9306-3960aa5f5205" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ContingentValueRightOnProductRevenuesMember_f4595703-ad72-48f7-91e3-995e44af9d08" xlink:href="lgnd-20211231.xsd#lgnd_ContingentValueRightOnProductRevenuesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_54e5ba0d-1219-418f-9a2b-29a9027c8daf" xlink:to="loc_lgnd_ContingentValueRightOnProductRevenuesMember_f4595703-ad72-48f7-91e3-995e44af9d08" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_EarnoutRightsForPartnerResearchAndDevelopmentMember_22ebb10e-8704-4168-8223-0fdaa8a77bf3" xlink:href="lgnd-20211231.xsd#lgnd_EarnoutRightsForPartnerResearchAndDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_54e5ba0d-1219-418f-9a2b-29a9027c8daf" xlink:to="loc_lgnd_EarnoutRightsForPartnerResearchAndDevelopmentMember_22ebb10e-8704-4168-8223-0fdaa8a77bf3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_MilestonePaymentsMember_0248c79e-552a-4f67-973b-1f5d8afe17b3" xlink:href="lgnd-20211231.xsd#lgnd_MilestonePaymentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_54e5ba0d-1219-418f-9a2b-29a9027c8daf" xlink:to="loc_lgnd_MilestonePaymentsMember_0248c79e-552a-4f67-973b-1f5d8afe17b3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_97af8335-8952-4444-a507-6533fc0bfa79" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_3dba7021-dacc-4db4-b9d4-e033549dbce6" xlink:to="loc_srt_RangeAxis_97af8335-8952-4444-a507-6533fc0bfa79" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_97af8335-8952-4444-a507-6533fc0bfa79_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_97af8335-8952-4444-a507-6533fc0bfa79" xlink:to="loc_srt_RangeMember_97af8335-8952-4444-a507-6533fc0bfa79_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_d2b60a6d-1e3a-48ea-a1a0-79714032011e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_97af8335-8952-4444-a507-6533fc0bfa79" xlink:to="loc_srt_RangeMember_d2b60a6d-1e3a-48ea-a1a0-79714032011e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_5327711c-d0a5-4fbc-86f3-7a9c9e9d00be" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_d2b60a6d-1e3a-48ea-a1a0-79714032011e" xlink:to="loc_srt_MinimumMember_5327711c-d0a5-4fbc-86f3-7a9c9e9d00be" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_3596a089-df36-47fc-9163-18998485e04d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_d2b60a6d-1e3a-48ea-a1a0-79714032011e" xlink:to="loc_srt_MaximumMember_3596a089-df36-47fc-9163-18998485e04d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_55508a0b-23be-4572-8ce8-a08993e80998" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_3dba7021-dacc-4db4-b9d4-e033549dbce6" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_55508a0b-23be-4572-8ce8-a08993e80998" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_55508a0b-23be-4572-8ce8-a08993e80998_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_55508a0b-23be-4572-8ce8-a08993e80998" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_55508a0b-23be-4572-8ce8-a08993e80998_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_e035656f-1f48-4754-b11b-9679c2050d62" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_55508a0b-23be-4572-8ce8-a08993e80998" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_e035656f-1f48-4754-b11b-9679c2050d62" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_70149d3a-517c-47ce-81fd-bbe118d0cd80" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_e035656f-1f48-4754-b11b-9679c2050d62" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_70149d3a-517c-47ce-81fd-bbe118d0cd80" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ligand.com/role/AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails" xlink:type="simple" xlink:href="lgnd-20211231.xsd#AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails"/>
  <link:definitionLink xlink:role="http://www.ligand.com/role/AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails" xlink:type="extended" id="ia7622965161849d1b81cd153a65f6672_AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_679e1d50-703a-432d-9bc9-78923314bdba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_0c77a7db-7336-4e86-91e0-187c3058d722" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_679e1d50-703a-432d-9bc9-78923314bdba" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_0c77a7db-7336-4e86-91e0-187c3058d722" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash_7a3a27a9-2837-4248-9281-9287df0a2c1b" xlink:href="lgnd-20211231.xsd#lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_679e1d50-703a-432d-9bc9-78923314bdba" xlink:to="loc_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash_7a3a27a9-2837-4248-9281-9287df0a2c1b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_e9ddb1ed-c2e2-4078-ab1a-77e6551645c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_679e1d50-703a-432d-9bc9-78923314bdba" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_e9ddb1ed-c2e2-4078-ab1a-77e6551645c1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_f8891eeb-943c-49b2-9c28-27728653e49f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_679e1d50-703a-432d-9bc9-78923314bdba" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_f8891eeb-943c-49b2-9c28-27728653e49f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssets_06921ea5-ac55-465e-a235-28a1eb35e8d2" xlink:href="lgnd-20211231.xsd#lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_679e1d50-703a-432d-9bc9-78923314bdba" xlink:to="loc_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssets_06921ea5-ac55-465e-a235-28a1eb35e8d2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_79b43f65-02c9-476e-b002-22b948c94342" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_679e1d50-703a-432d-9bc9-78923314bdba" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_79b43f65-02c9-476e-b002-22b948c94342" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssets_a7e18bd5-438a-4208-a3c1-a9037e340805" xlink:href="lgnd-20211231.xsd#lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_679e1d50-703a-432d-9bc9-78923314bdba" xlink:to="loc_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssets_a7e18bd5-438a-4208-a3c1-a9037e340805" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_c130bd25-b9ef-4349-9385-91dc79716d96" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_679e1d50-703a-432d-9bc9-78923314bdba" xlink:to="loc_us-gaap_Goodwill_c130bd25-b9ef-4349-9385-91dc79716d96" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_5bf0776d-21f9-43d9-b569-b0fa8ff402e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_679e1d50-703a-432d-9bc9-78923314bdba" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_5bf0776d-21f9-43d9-b569-b0fa8ff402e5" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilitiesCurrent_a28bcbcf-f829-47ba-88e0-3b841e03b433" xlink:href="lgnd-20211231.xsd#lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_679e1d50-703a-432d-9bc9-78923314bdba" xlink:to="loc_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilitiesCurrent_a28bcbcf-f829-47ba-88e0-3b841e03b433" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue_f6bee2bb-85cb-4244-b349-7baf12cc7490" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_679e1d50-703a-432d-9bc9-78923314bdba" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue_f6bee2bb-85cb-4244-b349-7baf12cc7490" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLeaseLiabilities_0ee25c71-08c3-4254-808d-47acf4446328" xlink:href="lgnd-20211231.xsd#lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLeaseLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_679e1d50-703a-432d-9bc9-78923314bdba" xlink:to="loc_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLeaseLiabilities_0ee25c71-08c3-4254-808d-47acf4446328" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther_ae95c9a6-f829-4eaf-8833-c955058ad209" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_679e1d50-703a-432d-9bc9-78923314bdba" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther_ae95c9a6-f829-4eaf-8833-c955058ad209" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_dbc3279f-c1c9-43ca-aee1-4bb86ad9f06d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_679e1d50-703a-432d-9bc9-78923314bdba" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_dbc3279f-c1c9-43ca-aee1-4bb86ad9f06d" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_5a7b1fcb-0bf9-42be-8691-65068cf9e61a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_679e1d50-703a-432d-9bc9-78923314bdba" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_5a7b1fcb-0bf9-42be-8691-65068cf9e61a" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_4075696d-7dc1-4751-9cfd-03ed2e33b6d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_679e1d50-703a-432d-9bc9-78923314bdba" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_4075696d-7dc1-4751-9cfd-03ed2e33b6d8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_f3012c2e-4843-418a-bbf0-634b757a0cdf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_4075696d-7dc1-4751-9cfd-03ed2e33b6d8" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_f3012c2e-4843-418a-bbf0-634b757a0cdf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f3012c2e-4843-418a-bbf0-634b757a0cdf_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_f3012c2e-4843-418a-bbf0-634b757a0cdf" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f3012c2e-4843-418a-bbf0-634b757a0cdf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_08669799-d306-4839-b8e9-d21aed53a016" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_f3012c2e-4843-418a-bbf0-634b757a0cdf" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_08669799-d306-4839-b8e9-d21aed53a016" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PfenexMember_bf9c20bd-1e59-4918-ba5a-5e559a56fa85" xlink:href="lgnd-20211231.xsd#lgnd_PfenexMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_08669799-d306-4839-b8e9-d21aed53a016" xlink:to="loc_lgnd_PfenexMember_bf9c20bd-1e59-4918-ba5a-5e559a56fa85" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ligand.com/role/AcquisitionsIntangiblesAcquiredandWeightedAverageUsefulLifeDetails" xlink:type="simple" xlink:href="lgnd-20211231.xsd#AcquisitionsIntangiblesAcquiredandWeightedAverageUsefulLifeDetails"/>
  <link:definitionLink xlink:role="http://www.ligand.com/role/AcquisitionsIntangiblesAcquiredandWeightedAverageUsefulLifeDetails" xlink:type="extended" id="id2ad643185444787803678ff75647307_AcquisitionsIntangiblesAcquiredandWeightedAverageUsefulLifeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_a4d6eb01-92aa-4b5f-aa78-0f7831c6d89d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_54c50aea-261b-4e92-9a01-815948d08722" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a4d6eb01-92aa-4b5f-aa78-0f7831c6d89d" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_54c50aea-261b-4e92-9a01-815948d08722" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_ba0fc520-7238-4306-b152-31ef6f5f5566" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a4d6eb01-92aa-4b5f-aa78-0f7831c6d89d" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_ba0fc520-7238-4306-b152-31ef6f5f5566" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_6517ca8d-a104-4c4f-8926-735f57fdf47d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a4d6eb01-92aa-4b5f-aa78-0f7831c6d89d" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_6517ca8d-a104-4c4f-8926-735f57fdf47d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_bafe7e91-db9b-412b-8a79-981d5a1fd32d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_6517ca8d-a104-4c4f-8926-735f57fdf47d" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_bafe7e91-db9b-412b-8a79-981d5a1fd32d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_bafe7e91-db9b-412b-8a79-981d5a1fd32d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_bafe7e91-db9b-412b-8a79-981d5a1fd32d" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_bafe7e91-db9b-412b-8a79-981d5a1fd32d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_ec3ac34e-c0b6-40b5-8824-95cd7237767a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_bafe7e91-db9b-412b-8a79-981d5a1fd32d" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_ec3ac34e-c0b6-40b5-8824-95cd7237767a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PfenexMember_f4a41357-bd2b-440d-9c22-b01a192caaa1" xlink:href="lgnd-20211231.xsd#lgnd_PfenexMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_ec3ac34e-c0b6-40b5-8824-95cd7237767a" xlink:to="loc_lgnd_PfenexMember_f4a41357-bd2b-440d-9c22-b01a192caaa1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_947bcc5e-c409-447c-b555-5a8c95c4b733" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_6517ca8d-a104-4c4f-8926-735f57fdf47d" xlink:to="loc_srt_RangeAxis_947bcc5e-c409-447c-b555-5a8c95c4b733" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_947bcc5e-c409-447c-b555-5a8c95c4b733_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_947bcc5e-c409-447c-b555-5a8c95c4b733" xlink:to="loc_srt_RangeMember_947bcc5e-c409-447c-b555-5a8c95c4b733_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_27bb72d6-292e-40c3-8d55-af30455895ec" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_947bcc5e-c409-447c-b555-5a8c95c4b733" xlink:to="loc_srt_RangeMember_27bb72d6-292e-40c3-8d55-af30455895ec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_9d16e419-85b2-42cd-9e98-120ea541fd21" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_27bb72d6-292e-40c3-8d55-af30455895ec" xlink:to="loc_srt_MinimumMember_9d16e419-85b2-42cd-9e98-120ea541fd21" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_b1bf3dc8-5a85-4fe3-ba16-0bef59eb3f59" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_27bb72d6-292e-40c3-8d55-af30455895ec" xlink:to="loc_srt_MaximumMember_b1bf3dc8-5a85-4fe3-ba16-0bef59eb3f59" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_19dc81df-4059-46a5-a5de-2beedc570150" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_6517ca8d-a104-4c4f-8926-735f57fdf47d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_19dc81df-4059-46a5-a5de-2beedc570150" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_19dc81df-4059-46a5-a5de-2beedc570150_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_19dc81df-4059-46a5-a5de-2beedc570150" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_19dc81df-4059-46a5-a5de-2beedc570150_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_589662da-e23c-49f7-a1b0-54eec1b480f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_19dc81df-4059-46a5-a5de-2beedc570150" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_589662da-e23c-49f7-a1b0-54eec1b480f3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ContractualRelationshipsAlvogenMember_329fbed1-1777-4ea3-9eb2-d00210b750fd" xlink:href="lgnd-20211231.xsd#lgnd_ContractualRelationshipsAlvogenMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_589662da-e23c-49f7-a1b0-54eec1b480f3" xlink:to="loc_lgnd_ContractualRelationshipsAlvogenMember_329fbed1-1777-4ea3-9eb2-d00210b750fd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ContractualRelationshipsMerckMember_a077c45a-1497-4441-97e9-92d566254d30" xlink:href="lgnd-20211231.xsd#lgnd_ContractualRelationshipsMerckMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_589662da-e23c-49f7-a1b0-54eec1b480f3" xlink:to="loc_lgnd_ContractualRelationshipsMerckMember_a077c45a-1497-4441-97e9-92d566254d30" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ContractualRelationshipsJazzMember_477b6f48-5a62-4346-bfba-26b1b0fec93b" xlink:href="lgnd-20211231.xsd#lgnd_ContractualRelationshipsJazzMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_589662da-e23c-49f7-a1b0-54eec1b480f3" xlink:to="loc_lgnd_ContractualRelationshipsJazzMember_477b6f48-5a62-4346-bfba-26b1b0fec93b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ContractualRelationshipsSIIMember_78e7f93b-806a-4799-8784-319afcab9df7" xlink:href="lgnd-20211231.xsd#lgnd_ContractualRelationshipsSIIMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_589662da-e23c-49f7-a1b0-54eec1b480f3" xlink:to="loc_lgnd_ContractualRelationshipsSIIMember_78e7f93b-806a-4799-8784-319afcab9df7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ContractualRelationshipsArcellxMember_8e551b19-5a52-47a0-a379-8139d467dfdc" xlink:href="lgnd-20211231.xsd#lgnd_ContractualRelationshipsArcellxMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_589662da-e23c-49f7-a1b0-54eec1b480f3" xlink:to="loc_lgnd_ContractualRelationshipsArcellxMember_8e551b19-5a52-47a0-a379-8139d467dfdc" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TechnologyBasedIntangibleAssetsMember_11551fdd-6cc9-426f-930b-968203ec6992" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TechnologyBasedIntangibleAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_589662da-e23c-49f7-a1b0-54eec1b480f3" xlink:to="loc_us-gaap_TechnologyBasedIntangibleAssetsMember_11551fdd-6cc9-426f-930b-968203ec6992" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ligand.com/role/AcquisitionsProFormaFinancialInformationDetails" xlink:type="simple" xlink:href="lgnd-20211231.xsd#AcquisitionsProFormaFinancialInformationDetails"/>
  <link:definitionLink xlink:role="http://www.ligand.com/role/AcquisitionsProFormaFinancialInformationDetails" xlink:type="extended" id="i127cb0a75b4d43c4a8d56f0d6527b054_AcquisitionsProFormaFinancialInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_33a15522-9060-4220-803a-be7bf90c75b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaRevenue_1e6a4776-c90a-456f-9186-b12c3725dd71" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionsProFormaRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_33a15522-9060-4220-803a-be7bf90c75b3" xlink:to="loc_us-gaap_BusinessAcquisitionsProFormaRevenue_1e6a4776-c90a-456f-9186-b12c3725dd71" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_b529d7bd-638f-47bc-839b-c32544d7bb32" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_33a15522-9060-4220-803a-be7bf90c75b3" xlink:to="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_b529d7bd-638f-47bc-839b-c32544d7bb32" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareProFormaAbstract_768a840d-d0b6-4c89-af09-859e895348a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareProFormaAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_33a15522-9060-4220-803a-be7bf90c75b3" xlink:to="loc_us-gaap_EarningsPerShareProFormaAbstract_768a840d-d0b6-4c89-af09-859e895348a1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic_8e80db24-e7c4-466a-8801-e5fd54f05fab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareProFormaAbstract_768a840d-d0b6-4c89-af09-859e895348a1" xlink:to="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic_8e80db24-e7c4-466a-8801-e5fd54f05fab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted_2928931a-554f-454e-a489-c7b6b40d2244" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareProFormaAbstract_768a840d-d0b6-4c89-af09-859e895348a1" xlink:to="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted_2928931a-554f-454e-a489-c7b6b40d2244" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_8aeebff7-feb5-48f1-b40c-19f7ff9689e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_33a15522-9060-4220-803a-be7bf90c75b3" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_8aeebff7-feb5-48f1-b40c-19f7ff9689e4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_0dfcca7b-9627-4723-a1b8-66145ae4454c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_8aeebff7-feb5-48f1-b40c-19f7ff9689e4" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_0dfcca7b-9627-4723-a1b8-66145ae4454c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_0dfcca7b-9627-4723-a1b8-66145ae4454c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_0dfcca7b-9627-4723-a1b8-66145ae4454c" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_0dfcca7b-9627-4723-a1b8-66145ae4454c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1e04b3a2-a4ff-4c56-b20f-fd4f56ed8d3d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_0dfcca7b-9627-4723-a1b8-66145ae4454c" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1e04b3a2-a4ff-4c56-b20f-fd4f56ed8d3d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PfenexMember_2ce15711-5a34-4315-8a8d-9cffa3758040" xlink:href="lgnd-20211231.xsd#lgnd_PfenexMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1e04b3a2-a4ff-4c56-b20f-fd4f56ed8d3d" xlink:to="loc_lgnd_PfenexMember_2ce15711-5a34-4315-8a8d-9cffa3758040" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ligand.com/role/AcquisitionsAllocationofConsiderationDetails" xlink:type="simple" xlink:href="lgnd-20211231.xsd#AcquisitionsAllocationofConsiderationDetails"/>
  <link:definitionLink xlink:role="http://www.ligand.com/role/AcquisitionsAllocationofConsiderationDetails" xlink:type="extended" id="iec2ce38a49434eab90dc17c596a9158b_AcquisitionsAllocationofConsiderationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_78e2e383-d3bf-4eb4-b26e-0dfb0fc510f9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_130bd56a-5733-41d3-9292-976074ad5021" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_78e2e383-d3bf-4eb4-b26e-0dfb0fc510f9" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_130bd56a-5733-41d3-9292-976074ad5021" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash_f6ad7588-6319-472a-b448-b52ac0a39683" xlink:href="lgnd-20211231.xsd#lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_78e2e383-d3bf-4eb4-b26e-0dfb0fc510f9" xlink:to="loc_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash_f6ad7588-6319-472a-b448-b52ac0a39683" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_0d854eb3-6d6f-4988-98a4-d340758c9551" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_78e2e383-d3bf-4eb4-b26e-0dfb0fc510f9" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_0d854eb3-6d6f-4988-98a4-d340758c9551" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndCurrentAssetsOther_423c54ff-4118-4f07-954c-35b3b98893e8" xlink:href="lgnd-20211231.xsd#lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndCurrentAssetsOther"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_78e2e383-d3bf-4eb4-b26e-0dfb0fc510f9" xlink:to="loc_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndCurrentAssetsOther_423c54ff-4118-4f07-954c-35b3b98893e8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_2471a2c2-b018-468b-98a6-5f125b9ce7f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_78e2e383-d3bf-4eb4-b26e-0dfb0fc510f9" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_2471a2c2-b018-468b-98a6-5f125b9ce7f1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_d1451739-91ff-4c02-9d18-db7843ae1277" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_78e2e383-d3bf-4eb4-b26e-0dfb0fc510f9" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_d1451739-91ff-4c02-9d18-db7843ae1277" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities_d76209c1-4b23-453b-b447-9fd714d7d19b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_78e2e383-d3bf-4eb4-b26e-0dfb0fc510f9" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities_d76209c1-4b23-453b-b447-9fd714d7d19b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue_9d48b5fb-58b2-4852-a4b3-e72d5cadb336" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_78e2e383-d3bf-4eb4-b26e-0dfb0fc510f9" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue_9d48b5fb-58b2-4852-a4b3-e72d5cadb336" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilitiesCurrent_8c709acd-7e8f-4561-8f20-7d5bf1242069" xlink:href="lgnd-20211231.xsd#lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_78e2e383-d3bf-4eb4-b26e-0dfb0fc510f9" xlink:to="loc_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilitiesCurrent_8c709acd-7e8f-4561-8f20-7d5bf1242069" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_4c2ec7e7-2f3b-4d7d-8287-5bbeea97352f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_78e2e383-d3bf-4eb4-b26e-0dfb0fc510f9" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_4c2ec7e7-2f3b-4d7d-8287-5bbeea97352f" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_2b5f980e-b409-44e1-ac00-3eef4464d369" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_78e2e383-d3bf-4eb4-b26e-0dfb0fc510f9" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_2b5f980e-b409-44e1-ac00-3eef4464d369" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets_709b59ab-f7eb-49f3-a9ec-3652a3fb9266" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_78e2e383-d3bf-4eb4-b26e-0dfb0fc510f9" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets_709b59ab-f7eb-49f3-a9ec-3652a3fb9266" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_f72aaeec-9421-469f-8b8c-59b37fd7b138" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_78e2e383-d3bf-4eb4-b26e-0dfb0fc510f9" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_f72aaeec-9421-469f-8b8c-59b37fd7b138" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssets_34da2a39-f5a6-4ebd-bb91-7a6f43398b55" xlink:href="lgnd-20211231.xsd#lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_78e2e383-d3bf-4eb4-b26e-0dfb0fc510f9" xlink:to="loc_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssets_34da2a39-f5a6-4ebd-bb91-7a6f43398b55" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_f9af72cd-cf9a-48ec-a51a-3d25f3165e5a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_78e2e383-d3bf-4eb4-b26e-0dfb0fc510f9" xlink:to="loc_us-gaap_Goodwill_f9af72cd-cf9a-48ec-a51a-3d25f3165e5a" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_8da3b66f-6d34-47bb-b935-0c6fe439ccc3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_78e2e383-d3bf-4eb4-b26e-0dfb0fc510f9" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_8da3b66f-6d34-47bb-b935-0c6fe439ccc3" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_82568526-79fb-4664-a5c1-804a26a71f07" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_78e2e383-d3bf-4eb4-b26e-0dfb0fc510f9" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_82568526-79fb-4664-a5c1-804a26a71f07" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_60ff1ab2-da64-4f5c-b5cc-dc642e9b5a5f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_82568526-79fb-4664-a5c1-804a26a71f07" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_60ff1ab2-da64-4f5c-b5cc-dc642e9b5a5f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_60ff1ab2-da64-4f5c-b5cc-dc642e9b5a5f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_60ff1ab2-da64-4f5c-b5cc-dc642e9b5a5f" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_60ff1ab2-da64-4f5c-b5cc-dc642e9b5a5f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_0e86980b-559b-47fc-be1b-843ded912f12" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_60ff1ab2-da64-4f5c-b5cc-dc642e9b5a5f" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_0e86980b-559b-47fc-be1b-843ded912f12" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_TaurusBiosciencesLLCMember_a1b20bc8-eb0c-4242-8b7e-be1b702f20b5" xlink:href="lgnd-20211231.xsd#lgnd_TaurusBiosciencesLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_0e86980b-559b-47fc-be1b-843ded912f12" xlink:to="loc_lgnd_TaurusBiosciencesLLCMember_a1b20bc8-eb0c-4242-8b7e-be1b702f20b5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_XCellaBiosciencesIncMember_d56de1d3-b632-4af6-8de4-7683ff5a3f0e" xlink:href="lgnd-20211231.xsd#lgnd_XCellaBiosciencesIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_0e86980b-559b-47fc-be1b-843ded912f12" xlink:to="loc_lgnd_XCellaBiosciencesIncMember_d56de1d3-b632-4af6-8de4-7683ff5a3f0e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_IcagenMember_9f579d04-a1c0-4379-bbab-3621dc218604" xlink:href="lgnd-20211231.xsd#lgnd_IcagenMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_0e86980b-559b-47fc-be1b-843ded912f12" xlink:to="loc_lgnd_IcagenMember_9f579d04-a1c0-4379-bbab-3621dc218604" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AbInitioMember_a1337efc-301b-4b86-866e-e71e789fd2f8" xlink:href="lgnd-20211231.xsd#lgnd_AbInitioMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_0e86980b-559b-47fc-be1b-843ded912f12" xlink:to="loc_lgnd_AbInitioMember_a1337efc-301b-4b86-866e-e71e789fd2f8" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ligand.com/role/FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" xlink:type="simple" xlink:href="lgnd-20211231.xsd#FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"/>
  <link:definitionLink xlink:role="http://www.ligand.com/role/FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" xlink:type="extended" id="i5ef17c0c222c4431a28e9a6e07bd0665_FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_7ce13dbf-a23f-4c18-b42c-56952c95a659" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_52bceeb7-539f-4abd-bd27-cc54cfadaf5d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_7ce13dbf-a23f-4c18-b42c-56952c95a659" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_52bceeb7-539f-4abd-bd27-cc54cfadaf5d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_ae78c4f6-46a8-4c7a-add4-8ed192fb3004" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_7ce13dbf-a23f-4c18-b42c-56952c95a659" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_ae78c4f6-46a8-4c7a-add4-8ed192fb3004" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities_d8b5e7de-d3b2-49c0-b202-824c4c1a8ff8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_7ce13dbf-a23f-4c18-b42c-56952c95a659" xlink:to="loc_us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities_d8b5e7de-d3b2-49c0-b202-824c4c1a8ff8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_NumberOfContingentValueRightAgreements_215a4a3f-6826-4cb7-8a7e-f32d68777c4f" xlink:href="lgnd-20211231.xsd#lgnd_NumberOfContingentValueRightAgreements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_7ce13dbf-a23f-4c18-b42c-56952c95a659" xlink:to="loc_lgnd_NumberOfContingentValueRightAgreements_215a4a3f-6826-4cb7-8a7e-f32d68777c4f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Investments_f49a02ac-ea89-4ccf-aba1-2d6bff824b28" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Investments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_7ce13dbf-a23f-4c18-b42c-56952c95a659" xlink:to="loc_us-gaap_Investments_f49a02ac-ea89-4ccf-aba1-2d6bff824b28" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetGross_00d0b57a-61b5-4c46-9444-3371d0617ddb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerAssetGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_7ce13dbf-a23f-4c18-b42c-56952c95a659" xlink:to="loc_us-gaap_ContractWithCustomerAssetGross_00d0b57a-61b5-4c46-9444-3371d0617ddb" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_89a0b620-a1ef-4d65-b623-1fec62075764" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_7ce13dbf-a23f-4c18-b42c-56952c95a659" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_89a0b620-a1ef-4d65-b623-1fec62075764" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_96166cda-a88b-4294-be27-9670e3a0305a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_7ce13dbf-a23f-4c18-b42c-56952c95a659" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_96166cda-a88b-4294-be27-9670e3a0305a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_72416618-50c9-4ef6-9529-081c63561ace" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_96166cda-a88b-4294-be27-9670e3a0305a" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_72416618-50c9-4ef6-9529-081c63561ace" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_72416618-50c9-4ef6-9529-081c63561ace_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_72416618-50c9-4ef6-9529-081c63561ace" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_72416618-50c9-4ef6-9529-081c63561ace_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_7a47499a-a35b-4b91-aab5-62ef821707c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_72416618-50c9-4ef6-9529-081c63561ace" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_7a47499a-a35b-4b91-aab5-62ef821707c9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_6c8c17ae-4946-47ad-aeb8-d81488e4bb55" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_7a47499a-a35b-4b91-aab5-62ef821707c9" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_6c8c17ae-4946-47ad-aeb8-d81488e4bb55" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_a49a2e00-0c8f-488c-85c2-90e5ed90bc0f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_96166cda-a88b-4294-be27-9670e3a0305a" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_a49a2e00-0c8f-488c-85c2-90e5ed90bc0f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a49a2e00-0c8f-488c-85c2-90e5ed90bc0f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_a49a2e00-0c8f-488c-85c2-90e5ed90bc0f" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a49a2e00-0c8f-488c-85c2-90e5ed90bc0f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_50c529c2-e43f-4450-91c0-ad8749765940" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_a49a2e00-0c8f-488c-85c2-90e5ed90bc0f" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_50c529c2-e43f-4450-91c0-ad8749765940" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_c21fa0d6-c6c8-4459-a875-e35e813fa034" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_50c529c2-e43f-4450-91c0-ad8749765940" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_c21fa0d6-c6c8-4459-a875-e35e813fa034" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_797bc646-e64a-4d04-b8ee-7bcf911e4d6c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_50c529c2-e43f-4450-91c0-ad8749765940" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_797bc646-e64a-4d04-b8ee-7bcf911e4d6c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_de1f7af2-213f-48db-b40e-393c4d6c66a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_50c529c2-e43f-4450-91c0-ad8749765940" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_de1f7af2-213f-48db-b40e-393c4d6c66a8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_08351d3c-cb6d-46a2-b74b-71b78bd31a46" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_96166cda-a88b-4294-be27-9670e3a0305a" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_08351d3c-cb6d-46a2-b74b-71b78bd31a46" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_08351d3c-cb6d-46a2-b74b-71b78bd31a46_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_08351d3c-cb6d-46a2-b74b-71b78bd31a46" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_08351d3c-cb6d-46a2-b74b-71b78bd31a46_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_5d542108-3a9d-4bba-bf0d-66f1b6521b58" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_08351d3c-cb6d-46a2-b74b-71b78bd31a46" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_5d542108-3a9d-4bba-bf0d-66f1b6521b58" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestmentsMember_cd3a3584-acdd-4965-9be1-6b445ecd9ed5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermInvestmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_5d542108-3a9d-4bba-bf0d-66f1b6521b58" xlink:to="loc_us-gaap_ShortTermInvestmentsMember_cd3a3584-acdd-4965-9be1-6b445ecd9ed5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember_ec60ccb2-0aa7-4830-8c72-ae7596ad61cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_5d542108-3a9d-4bba-bf0d-66f1b6521b58" xlink:to="loc_us-gaap_EquitySecuritiesMember_ec60ccb2-0aa7-4830-8c72-ae7596ad61cd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_1693ca8e-4e0c-4fc7-bc2f-9b161988b0a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_5d542108-3a9d-4bba-bf0d-66f1b6521b58" xlink:to="loc_us-gaap_WarrantMember_1693ca8e-4e0c-4fc7-bc2f-9b161988b0a7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_47abba56-bd79-4959-bf67-fd6afa36e0c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_96166cda-a88b-4294-be27-9670e3a0305a" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_47abba56-bd79-4959-bf67-fd6afa36e0c7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_47abba56-bd79-4959-bf67-fd6afa36e0c7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_47abba56-bd79-4959-bf67-fd6afa36e0c7" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_47abba56-bd79-4959-bf67-fd6afa36e0c7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_63a295a5-e177-40a6-a86f-817ff974659d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_47abba56-bd79-4959-bf67-fd6afa36e0c7" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_63a295a5-e177-40a6-a86f-817ff974659d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_LiabilityForContingentValueRightsCompanyCrystalMember_b27c2590-3b5f-4924-8dce-abde16c09c39" xlink:href="lgnd-20211231.xsd#lgnd_LiabilityForContingentValueRightsCompanyCrystalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_63a295a5-e177-40a6-a86f-817ff974659d" xlink:to="loc_lgnd_LiabilityForContingentValueRightsCompanyCrystalMember_b27c2590-3b5f-4924-8dce-abde16c09c39" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_LiabilityForContingentValueRightsCompanyCydexMember_45faa090-f713-4578-aac7-1654eb5e538b" xlink:href="lgnd-20211231.xsd#lgnd_LiabilityForContingentValueRightsCompanyCydexMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_63a295a5-e177-40a6-a86f-817ff974659d" xlink:to="loc_lgnd_LiabilityForContingentValueRightsCompanyCydexMember_45faa090-f713-4578-aac7-1654eb5e538b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_LiabilityForContingentValueRightsCompanyMetabasisMember_e1ee4d7a-8187-4f64-a268-5e35c88063b4" xlink:href="lgnd-20211231.xsd#lgnd_LiabilityForContingentValueRightsCompanyMetabasisMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_63a295a5-e177-40a6-a86f-817ff974659d" xlink:to="loc_lgnd_LiabilityForContingentValueRightsCompanyMetabasisMember_e1ee4d7a-8187-4f64-a268-5e35c88063b4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_LiabilityForContingentValueRightsCompanyIcagenMember_3150e3fe-bbb9-4221-a745-359f6e177540" xlink:href="lgnd-20211231.xsd#lgnd_LiabilityForContingentValueRightsCompanyIcagenMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_63a295a5-e177-40a6-a86f-817ff974659d" xlink:to="loc_lgnd_LiabilityForContingentValueRightsCompanyIcagenMember_3150e3fe-bbb9-4221-a745-359f6e177540" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_LiabilityForContingentValueRightsCompanyPfenexMember_1f7521c5-52e8-43c0-8dba-17266c24c517" xlink:href="lgnd-20211231.xsd#lgnd_LiabilityForContingentValueRightsCompanyPfenexMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_63a295a5-e177-40a6-a86f-817ff974659d" xlink:to="loc_lgnd_LiabilityForContingentValueRightsCompanyPfenexMember_1f7521c5-52e8-43c0-8dba-17266c24c517" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_LiabilityForRestrictedInvestmentsOwedToFormerLicenseesMember_c52e9532-2827-4b22-ae9d-d494e5460284" xlink:href="lgnd-20211231.xsd#lgnd_LiabilityForRestrictedInvestmentsOwedToFormerLicenseesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_63a295a5-e177-40a6-a86f-817ff974659d" xlink:to="loc_lgnd_LiabilityForRestrictedInvestmentsOwedToFormerLicenseesMember_c52e9532-2827-4b22-ae9d-d494e5460284" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_facadfc5-eb7b-42ed-8669-efef22f7ab36" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_96166cda-a88b-4294-be27-9670e3a0305a" xlink:to="loc_srt_RangeAxis_facadfc5-eb7b-42ed-8669-efef22f7ab36" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_facadfc5-eb7b-42ed-8669-efef22f7ab36_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_facadfc5-eb7b-42ed-8669-efef22f7ab36" xlink:to="loc_srt_RangeMember_facadfc5-eb7b-42ed-8669-efef22f7ab36_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_03c6e6c8-b2c9-4784-bf4a-780eaf3d52ba" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_facadfc5-eb7b-42ed-8669-efef22f7ab36" xlink:to="loc_srt_RangeMember_03c6e6c8-b2c9-4784-bf4a-780eaf3d52ba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_f2ba99e8-d060-4e3b-8e59-6a1c5ffddf93" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_03c6e6c8-b2c9-4784-bf4a-780eaf3d52ba" xlink:to="loc_srt_MaximumMember_f2ba99e8-d060-4e3b-8e59-6a1c5ffddf93" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TimingOfTransferOfGoodOrServiceAxis_0f7e9152-3eed-4abd-8744-59a09fb76e65" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TimingOfTransferOfGoodOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_96166cda-a88b-4294-be27-9670e3a0305a" xlink:to="loc_us-gaap_TimingOfTransferOfGoodOrServiceAxis_0f7e9152-3eed-4abd-8744-59a09fb76e65" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TimingOfTransferOfGoodOrServiceDomain_0f7e9152-3eed-4abd-8744-59a09fb76e65_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TimingOfTransferOfGoodOrServiceDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TimingOfTransferOfGoodOrServiceAxis_0f7e9152-3eed-4abd-8744-59a09fb76e65" xlink:to="loc_us-gaap_TimingOfTransferOfGoodOrServiceDomain_0f7e9152-3eed-4abd-8744-59a09fb76e65_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TimingOfTransferOfGoodOrServiceDomain_fc4b9915-02d3-4994-b30c-8cfb0d31a5f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TimingOfTransferOfGoodOrServiceDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TimingOfTransferOfGoodOrServiceAxis_0f7e9152-3eed-4abd-8744-59a09fb76e65" xlink:to="loc_us-gaap_TimingOfTransferOfGoodOrServiceDomain_fc4b9915-02d3-4994-b30c-8cfb0d31a5f7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransferredOverTimeMember_fc92830b-41e0-45f1-9d44-7afdb16fa650" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransferredOverTimeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TimingOfTransferOfGoodOrServiceDomain_fc4b9915-02d3-4994-b30c-8cfb0d31a5f7" xlink:to="loc_us-gaap_TransferredOverTimeMember_fc92830b-41e0-45f1-9d44-7afdb16fa650" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_d32d4a68-feb5-4a2c-9bc5-d8fe8a2d9a9f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_96166cda-a88b-4294-be27-9670e3a0305a" xlink:to="loc_srt_ProductOrServiceAxis_d32d4a68-feb5-4a2c-9bc5-d8fe8a2d9a9f" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_d32d4a68-feb5-4a2c-9bc5-d8fe8a2d9a9f_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_d32d4a68-feb5-4a2c-9bc5-d8fe8a2d9a9f" xlink:to="loc_srt_ProductsAndServicesDomain_d32d4a68-feb5-4a2c-9bc5-d8fe8a2d9a9f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_3f53783e-5bef-482e-9a92-fce8f1a7aaad" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_d32d4a68-feb5-4a2c-9bc5-d8fe8a2d9a9f" xlink:to="loc_srt_ProductsAndServicesDomain_3f53783e-5bef-482e-9a92-fce8f1a7aaad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_DevelopmentRegulatoryCommercialMilestonesAndTieredRoyaltiesMember_b2afe4b4-1060-4038-8e84-084b45b9d19a" xlink:href="lgnd-20211231.xsd#lgnd_DevelopmentRegulatoryCommercialMilestonesAndTieredRoyaltiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_3f53783e-5bef-482e-9a92-fce8f1a7aaad" xlink:to="loc_lgnd_DevelopmentRegulatoryCommercialMilestonesAndTieredRoyaltiesMember_b2afe4b4-1060-4038-8e84-084b45b9d19a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_Phase3ClinicalTrialMember_0dacc0c5-cda8-4276-be62-30c31047e671" xlink:href="lgnd-20211231.xsd#lgnd_Phase3ClinicalTrialMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_3f53783e-5bef-482e-9a92-fce8f1a7aaad" xlink:to="loc_lgnd_Phase3ClinicalTrialMember_0dacc0c5-cda8-4276-be62-30c31047e671" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ligand.com/role/FairValueMeasurementReconciliationofLevel3FinancialInstrumentsDetails" xlink:type="simple" xlink:href="lgnd-20211231.xsd#FairValueMeasurementReconciliationofLevel3FinancialInstrumentsDetails"/>
  <link:definitionLink xlink:role="http://www.ligand.com/role/FairValueMeasurementReconciliationofLevel3FinancialInstrumentsDetails" xlink:type="extended" id="i2d26e625000d47ec8a2ae31c6dcc08d9_FairValueMeasurementReconciliationofLevel3FinancialInstrumentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_381b9e01-9cf0-4348-b4cb-f2e75b147b9c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_fc75ec10-e447-4089-a139-4b35986565d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_381b9e01-9cf0-4348-b4cb-f2e75b147b9c" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_fc75ec10-e447-4089-a139-4b35986565d3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_1ec631d8-fc6d-4902-8c73-265ca4eaf152" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_fc75ec10-e447-4089-a139-4b35986565d3" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_1ec631d8-fc6d-4902-8c73-265ca4eaf152" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PaymentsToContingentValueRightHolders_c50eedd8-bcc8-49f2-8aa6-a474f930fe6d" xlink:href="lgnd-20211231.xsd#lgnd_PaymentsToContingentValueRightHolders"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_fc75ec10-e447-4089-a139-4b35986565d3" xlink:to="loc_lgnd_PaymentsToContingentValueRightHolders_c50eedd8-bcc8-49f2-8aa6-a474f930fe6d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_1ba87578-fd1d-44a0-b610-ade04f3fd9cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_fc75ec10-e447-4089-a139-4b35986565d3" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_1ba87578-fd1d-44a0-b610-ade04f3fd9cd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityContingentConsiderationFromAcquisition_e69025dd-6aab-4908-853d-377d4cdd0bd1" xlink:href="lgnd-20211231.xsd#lgnd_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityContingentConsiderationFromAcquisition"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_fc75ec10-e447-4089-a139-4b35986565d3" xlink:to="loc_lgnd_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityContingentConsiderationFromAcquisition_e69025dd-6aab-4908-853d-377d4cdd0bd1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_98f574c1-3ae9-4cab-bffd-f10114fc797d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_d2854d7d-1588-4d9d-9823-eaa7716a9300" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_381b9e01-9cf0-4348-b4cb-f2e75b147b9c" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_d2854d7d-1588-4d9d-9823-eaa7716a9300" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_425431f8-cbdb-4775-871d-2b00549f523c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_d2854d7d-1588-4d9d-9823-eaa7716a9300" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_425431f8-cbdb-4775-871d-2b00549f523c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_425431f8-cbdb-4775-871d-2b00549f523c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_425431f8-cbdb-4775-871d-2b00549f523c" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_425431f8-cbdb-4775-871d-2b00549f523c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_ccf3164e-883f-4035-bbd9-9266f4458fbf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_425431f8-cbdb-4775-871d-2b00549f523c" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_ccf3164e-883f-4035-bbd9-9266f4458fbf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_1321f716-870d-424e-a212-0e78eeb6f58a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_ccf3164e-883f-4035-bbd9-9266f4458fbf" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_1321f716-870d-424e-a212-0e78eeb6f58a" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ligand.com/role/LeasesNarrativeDetails" xlink:type="simple" xlink:href="lgnd-20211231.xsd#LeasesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.ligand.com/role/LeasesNarrativeDetails" xlink:type="extended" id="ibb5e2a9add514c549fa88f05a0d5c470_LeasesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_cfc774c3-f88d-4a6f-addf-27f032112ca5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PurchaseCommitmentConsiderationPaidToDate_d0c19824-0ab9-4e6c-92ae-18d2dc66a44a" xlink:href="lgnd-20211231.xsd#lgnd_PurchaseCommitmentConsiderationPaidToDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_cfc774c3-f88d-4a6f-addf-27f032112ca5" xlink:to="loc_lgnd_PurchaseCommitmentConsiderationPaidToDate_d0c19824-0ab9-4e6c-92ae-18d2dc66a44a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PurchaseCommitmentConsiderationPaidAllocatedToInventory_d8657cd7-7268-46a3-959b-3a7cec764418" xlink:href="lgnd-20211231.xsd#lgnd_PurchaseCommitmentConsiderationPaidAllocatedToInventory"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_cfc774c3-f88d-4a6f-addf-27f032112ca5" xlink:to="loc_lgnd_PurchaseCommitmentConsiderationPaidAllocatedToInventory_d8657cd7-7268-46a3-959b-3a7cec764418" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability_6cfe05bf-cd9e-47d2-a5ee-51ac1a4a4c42" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_cfc774c3-f88d-4a6f-addf-27f032112ca5" xlink:to="loc_us-gaap_FinanceLeaseLiability_6cfe05bf-cd9e-47d2-a5ee-51ac1a4a4c42" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_3ab65873-555e-4f12-b862-e1bd3f097fe7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_cfc774c3-f88d-4a6f-addf-27f032112ca5" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_3ab65873-555e-4f12-b862-e1bd3f097fe7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeFinanceLeaseRemainingLeaseTerm_3d46d66a-5ad7-4022-b218-a64b5243040d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeFinanceLeaseRemainingLeaseTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_cfc774c3-f88d-4a6f-addf-27f032112ca5" xlink:to="loc_us-gaap_LesseeFinanceLeaseRemainingLeaseTerm_3d46d66a-5ad7-4022-b218-a64b5243040d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_a7870093-87be-4b2d-b3f9-04a9c3c908e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_cfc774c3-f88d-4a6f-addf-27f032112ca5" xlink:to="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_a7870093-87be-4b2d-b3f9-04a9c3c908e9" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_7d7df23f-e84e-46b3-9898-a1229dbef2bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_cfc774c3-f88d-4a6f-addf-27f032112ca5" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_7d7df23f-e84e-46b3-9898-a1229dbef2bc" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_6976b233-d0c7-47f1-9d32-198e5ff08e66" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_cfc774c3-f88d-4a6f-addf-27f032112ca5" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_6976b233-d0c7-47f1-9d32-198e5ff08e66" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_2f027ec8-cd7a-4b44-bffd-96d27827c8fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_cfc774c3-f88d-4a6f-addf-27f032112ca5" xlink:to="loc_us-gaap_OperatingLeaseLiability_2f027ec8-cd7a-4b44-bffd-96d27827c8fc" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_a415c02b-3566-4e1f-9c2e-ccb855d4612f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_cfc774c3-f88d-4a6f-addf-27f032112ca5" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_a415c02b-3566-4e1f-9c2e-ccb855d4612f" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_2af0b0ab-4a31-4523-89a8-3acc6fb613f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_cfc774c3-f88d-4a6f-addf-27f032112ca5" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_2af0b0ab-4a31-4523-89a8-3acc6fb613f5" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_d2c6fee9-393f-4046-96f9-6099e6984b2f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_cfc774c3-f88d-4a6f-addf-27f032112ca5" xlink:to="loc_us-gaap_OperatingLeasePayments_d2c6fee9-393f-4046-96f9-6099e6984b2f" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseExpense_4d3d5517-f6e2-425c-bd12-b26a178e2dc0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_cfc774c3-f88d-4a6f-addf-27f032112ca5" xlink:to="loc_us-gaap_OperatingLeaseExpense_4d3d5517-f6e2-425c-bd12-b26a178e2dc0" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubleaseIncome_28a60c66-3c71-4188-8c2e-e2cce366a477" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubleaseIncome"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_cfc774c3-f88d-4a6f-addf-27f032112ca5" xlink:to="loc_us-gaap_SubleaseIncome_28a60c66-3c71-4188-8c2e-e2cce366a477" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_83c5be6a-95a4-4641-a0cd-157889e26e72" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_cfc774c3-f88d-4a6f-addf-27f032112ca5" xlink:to="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_83c5be6a-95a4-4641-a0cd-157889e26e72" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_92ea63c4-56fa-4525-b117-2b415de1afc5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_cfc774c3-f88d-4a6f-addf-27f032112ca5" xlink:to="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_92ea63c4-56fa-4525-b117-2b415de1afc5" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestPaymentOnLiability_8e1fe9d6-abe3-4536-9eb1-de37e81ac55a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseInterestPaymentOnLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_cfc774c3-f88d-4a6f-addf-27f032112ca5" xlink:to="loc_us-gaap_FinanceLeaseInterestPaymentOnLiability_8e1fe9d6-abe3-4536-9eb1-de37e81ac55a" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestExpense_8df92bc5-0a71-4f66-9d89-768ac27170ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseInterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_cfc774c3-f88d-4a6f-addf-27f032112ca5" xlink:to="loc_us-gaap_FinanceLeaseInterestExpense_8df92bc5-0a71-4f66-9d89-768ac27170ff" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_fb4f274d-0f14-4fd1-a63d-68cb0769d2eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_cfc774c3-f88d-4a6f-addf-27f032112ca5" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_fb4f274d-0f14-4fd1-a63d-68cb0769d2eb" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_41899db4-6b03-47a1-83f5-c4353472f619" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_fb4f274d-0f14-4fd1-a63d-68cb0769d2eb" xlink:to="loc_srt_ProductOrServiceAxis_41899db4-6b03-47a1-83f5-c4353472f619" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_41899db4-6b03-47a1-83f5-c4353472f619_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_41899db4-6b03-47a1-83f5-c4353472f619" xlink:to="loc_srt_ProductsAndServicesDomain_41899db4-6b03-47a1-83f5-c4353472f619_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_1d202e19-9674-41f7-a188-591fffc33e8b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_41899db4-6b03-47a1-83f5-c4353472f619" xlink:to="loc_srt_ProductsAndServicesDomain_1d202e19-9674-41f7-a188-591fffc33e8b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_MaterialSalesCaptisolMember_8275957b-6748-41ac-8486-ca67397bba6c" xlink:href="lgnd-20211231.xsd#lgnd_MaterialSalesCaptisolMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_1d202e19-9674-41f7-a188-591fffc33e8b" xlink:to="loc_lgnd_MaterialSalesCaptisolMember_8275957b-6748-41ac-8486-ca67397bba6c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_cde755cf-a0d1-4655-8276-3c776b36441a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_fb4f274d-0f14-4fd1-a63d-68cb0769d2eb" xlink:to="loc_srt_RangeAxis_cde755cf-a0d1-4655-8276-3c776b36441a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_cde755cf-a0d1-4655-8276-3c776b36441a_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_cde755cf-a0d1-4655-8276-3c776b36441a" xlink:to="loc_srt_RangeMember_cde755cf-a0d1-4655-8276-3c776b36441a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_188e79e7-df82-42f0-8d7b-709a09e01a34" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_cde755cf-a0d1-4655-8276-3c776b36441a" xlink:to="loc_srt_RangeMember_188e79e7-df82-42f0-8d7b-709a09e01a34" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_83ad8da2-a8a2-46b8-827a-a6477d741510" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_188e79e7-df82-42f0-8d7b-709a09e01a34" xlink:to="loc_srt_MaximumMember_83ad8da2-a8a2-46b8-827a-a6477d741510" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_3a68c1e1-2c7d-4cb0-8a75-c189b5f7dfd9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_fb4f274d-0f14-4fd1-a63d-68cb0769d2eb" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_3a68c1e1-2c7d-4cb0-8a75-c189b5f7dfd9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3a68c1e1-2c7d-4cb0-8a75-c189b5f7dfd9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_3a68c1e1-2c7d-4cb0-8a75-c189b5f7dfd9" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3a68c1e1-2c7d-4cb0-8a75-c189b5f7dfd9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_61525164-163c-43bb-ac47-75d81b12d969" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_3a68c1e1-2c7d-4cb0-8a75-c189b5f7dfd9" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_61525164-163c-43bb-ac47-75d81b12d969" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingMember_18704ac3-d0e4-4507-aafd-ff2086ae8a8a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BuildingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_61525164-163c-43bb-ac47-75d81b12d969" xlink:to="loc_us-gaap_BuildingMember_18704ac3-d0e4-4507-aafd-ff2086ae8a8a" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ligand.com/role/ConvertibleSeniorNotesNarrativeDetails" xlink:type="simple" xlink:href="lgnd-20211231.xsd#ConvertibleSeniorNotesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.ligand.com/role/ConvertibleSeniorNotesNarrativeDetails" xlink:type="extended" id="i4ebd0432cb904d02ad9da404743595a4_ConvertibleSeniorNotesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_3cbdccb5-91f1-4d96-ba76-ab237a466acf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_1d8f6da1-6390-4ff3-8cbf-6d88b6b778a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3cbdccb5-91f1-4d96-ba76-ab237a466acf" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_1d8f6da1-6390-4ff3-8cbf-6d88b6b778a3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_263ddd47-6856-44b0-824a-1e592eabdeed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3cbdccb5-91f1-4d96-ba76-ab237a466acf" xlink:to="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_263ddd47-6856-44b0-824a-1e592eabdeed" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_bd1926ad-8f5e-4051-bf2d-d03f9d6ec92c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3cbdccb5-91f1-4d96-ba76-ab237a466acf" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_bd1926ad-8f5e-4051-bf2d-d03f9d6ec92c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_215d617b-a24a-48c9-9d7c-6a19aa782d83" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3cbdccb5-91f1-4d96-ba76-ab237a466acf" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_215d617b-a24a-48c9-9d7c-6a19aa782d83" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_53d9ac47-622d-4a4a-ab83-2eecfcf327d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3cbdccb5-91f1-4d96-ba76-ab237a466acf" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_53d9ac47-622d-4a4a-ab83-2eecfcf327d8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_afdbfa24-a6b5-4c01-90ab-654af923486b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3cbdccb5-91f1-4d96-ba76-ab237a466acf" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_afdbfa24-a6b5-4c01-90ab-654af923486b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_be865312-65ae-4be5-8296-e6f66f3082c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdTradingDays"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3cbdccb5-91f1-4d96-ba76-ab237a466acf" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_be865312-65ae-4be5-8296-e6f66f3082c3" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_9f6c50fe-5b70-4b37-b124-b50f0f44ca5f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3cbdccb5-91f1-4d96-ba76-ab237a466acf" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_9f6c50fe-5b70-4b37-b124-b50f0f44ca5f" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_cd2dcd1b-f35c-429a-ad59-acded6e03c19" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3cbdccb5-91f1-4d96-ba76-ab237a466acf" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_cd2dcd1b-f35c-429a-ad59-acded6e03c19" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_DebtInstrumentConvertibleMaximumThresholdPercentageofDebtTradingPriceTrigger_be0f0595-46e8-4101-bef8-c3259241712a" xlink:href="lgnd-20211231.xsd#lgnd_DebtInstrumentConvertibleMaximumThresholdPercentageofDebtTradingPriceTrigger"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3cbdccb5-91f1-4d96-ba76-ab237a466acf" xlink:to="loc_lgnd_DebtInstrumentConvertibleMaximumThresholdPercentageofDebtTradingPriceTrigger_be0f0595-46e8-4101-bef8-c3259241712a" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal_28d2abf5-68a0-4e55-ab14-cec32e3573ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3cbdccb5-91f1-4d96-ba76-ab237a466acf" xlink:to="loc_us-gaap_DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal_28d2abf5-68a0-4e55-ab14-cec32e3573ac" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_DebtInstrumentConvertibleIncreaseDecreaseIfConvertedValueInExcessOfPrincipal_89a946ed-3450-4a21-ad0e-5cd4873b3930" xlink:href="lgnd-20211231.xsd#lgnd_DebtInstrumentConvertibleIncreaseDecreaseIfConvertedValueInExcessOfPrincipal"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3cbdccb5-91f1-4d96-ba76-ab237a466acf" xlink:to="loc_lgnd_DebtInstrumentConvertibleIncreaseDecreaseIfConvertedValueInExcessOfPrincipal_89a946ed-3450-4a21-ad0e-5cd4873b3930" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_e7843c22-b768-45de-8063-4df1528d25c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3cbdccb5-91f1-4d96-ba76-ab237a466acf" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_e7843c22-b768-45de-8063-4df1528d25c9" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature_e435a8e0-38e8-4005-b289-74ad521ba857" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3cbdccb5-91f1-4d96-ba76-ab237a466acf" xlink:to="loc_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature_e435a8e0-38e8-4005-b289-74ad521ba857" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_e5416c34-0019-4fa0-8a43-082ff8f864ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3cbdccb5-91f1-4d96-ba76-ab237a466acf" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_e5416c34-0019-4fa0-8a43-082ff8f864ba" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfNotesPayable_fa65c44b-2ed5-4c67-aab9-7f00b271b0cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfNotesPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3cbdccb5-91f1-4d96-ba76-ab237a466acf" xlink:to="loc_us-gaap_RepaymentsOfNotesPayable_fa65c44b-2ed5-4c67-aab9-7f00b271b0cb" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedPremium_6946f177-8f9e-4146-a28b-79d746002494" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedPremium"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3cbdccb5-91f1-4d96-ba76-ab237a466acf" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedPremium_6946f177-8f9e-4146-a28b-79d746002494" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeGainLossOnDerivativeNet_d97cb466-6f28-4d45-8097-d6f031598385" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeGainLossOnDerivativeNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3cbdccb5-91f1-4d96-ba76-ab237a466acf" xlink:to="loc_us-gaap_DerivativeGainLossOnDerivativeNet_d97cb466-6f28-4d45-8097-d6f031598385" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeGainLossOnDerivativeNet_c6836c98-8fdd-475f-ae9b-8c68f9e7c220" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeGainLossOnDerivativeNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_ce896489-81cb-4566-a056-e03c3cb0cb77" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3cbdccb5-91f1-4d96-ba76-ab237a466acf" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_ce896489-81cb-4566-a056-e03c3cb0cb77" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ExercisePriceofConvertibleBondHedge_207a41ac-2d9f-4f06-b60e-483b1af2b73e" xlink:href="lgnd-20211231.xsd#lgnd_ExercisePriceofConvertibleBondHedge"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3cbdccb5-91f1-4d96-ba76-ab237a466acf" xlink:to="loc_lgnd_ExercisePriceofConvertibleBondHedge_207a41ac-2d9f-4f06-b60e-483b1af2b73e" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_e9a84c52-64db-4328-b383-35da1334d2df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3cbdccb5-91f1-4d96-ba76-ab237a466acf" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_e9a84c52-64db-4328-b383-35da1334d2df" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsGross_145dc2b2-c7fe-42a7-b9f0-e66fae00c828" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFinanceCostsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3cbdccb5-91f1-4d96-ba76-ab237a466acf" xlink:to="loc_us-gaap_DeferredFinanceCostsGross_145dc2b2-c7fe-42a7-b9f0-e66fae00c828" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRepurchaseAmount_eaa8820b-7b4e-4a42-a41c-dd4dc0ea1055" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRepurchaseAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3cbdccb5-91f1-4d96-ba76-ab237a466acf" xlink:to="loc_us-gaap_DebtInstrumentRepurchaseAmount_eaa8820b-7b4e-4a42-a41c-dd4dc0ea1055" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_RepaymentsOfNotesPayableInterestPortion_73864c36-9e86-4bbe-a0d1-f75f0659b005" xlink:href="lgnd-20211231.xsd#lgnd_RepaymentsOfNotesPayableInterestPortion"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3cbdccb5-91f1-4d96-ba76-ab237a466acf" xlink:to="loc_lgnd_RepaymentsOfNotesPayableInterestPortion_73864c36-9e86-4bbe-a0d1-f75f0659b005" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_IncreaseDecreaseInDebtDiscount_4d7a7f6c-b462-4f5f-ac37-caedb1bc9b16" xlink:href="lgnd-20211231.xsd#lgnd_IncreaseDecreaseInDebtDiscount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3cbdccb5-91f1-4d96-ba76-ab237a466acf" xlink:to="loc_lgnd_IncreaseDecreaseInDebtDiscount_4d7a7f6c-b462-4f5f-ac37-caedb1bc9b16" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_165bb370-c7b9-4e3b-ae6d-aa75bfc7114b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3cbdccb5-91f1-4d96-ba76-ab237a466acf" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_165bb370-c7b9-4e3b-ae6d-aa75bfc7114b" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PaymentsforConvertibleBondHedges_cfb9688b-19c2-426b-85fe-fde77e05e03f" xlink:href="lgnd-20211231.xsd#lgnd_PaymentsforConvertibleBondHedges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3cbdccb5-91f1-4d96-ba76-ab237a466acf" xlink:to="loc_lgnd_PaymentsforConvertibleBondHedges_cfb9688b-19c2-426b-85fe-fde77e05e03f" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_214d243f-5779-46cd-add8-b5d821fe45a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3cbdccb5-91f1-4d96-ba76-ab237a466acf" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_214d243f-5779-46cd-add8-b5d821fe45a6" xlink:type="arc" order="28"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PaymentsToUnwindWarrants_e017c6d2-d6a0-4d45-b526-e7af65037ab1" xlink:href="lgnd-20211231.xsd#lgnd_PaymentsToUnwindWarrants"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3cbdccb5-91f1-4d96-ba76-ab237a466acf" xlink:to="loc_lgnd_PaymentsToUnwindWarrants_e017c6d2-d6a0-4d45-b526-e7af65037ab1" xlink:type="arc" order="29"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ProceedsFromUnwindingConvertibleBondHedges_09ea9513-4cba-480d-a11c-e518dabf08c7" xlink:href="lgnd-20211231.xsd#lgnd_ProceedsFromUnwindingConvertibleBondHedges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3cbdccb5-91f1-4d96-ba76-ab237a466acf" xlink:to="loc_lgnd_ProceedsFromUnwindingConvertibleBondHedges_09ea9513-4cba-480d-a11c-e518dabf08c7" xlink:type="arc" order="30"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_NumberOfOptionsUnderConvertibleBondHedges_c7dcd601-c71a-4b06-9597-69002c2a0b32" xlink:href="lgnd-20211231.xsd#lgnd_NumberOfOptionsUnderConvertibleBondHedges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3cbdccb5-91f1-4d96-ba76-ab237a466acf" xlink:to="loc_lgnd_NumberOfOptionsUnderConvertibleBondHedges_c7dcd601-c71a-4b06-9597-69002c2a0b32" xlink:type="arc" order="31"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_31849f3b-be78-4cb2-ad35-3b6fcd0f68c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3cbdccb5-91f1-4d96-ba76-ab237a466acf" xlink:to="loc_us-gaap_DebtInstrumentTable_31849f3b-be78-4cb2-ad35-3b6fcd0f68c2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_5ec05f6a-ed21-401a-a58b-07d341363ae1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_31849f3b-be78-4cb2-ad35-3b6fcd0f68c2" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_5ec05f6a-ed21-401a-a58b-07d341363ae1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_5ec05f6a-ed21-401a-a58b-07d341363ae1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_5ec05f6a-ed21-401a-a58b-07d341363ae1" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_5ec05f6a-ed21-401a-a58b-07d341363ae1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_7d6f923e-92db-4236-82fd-a26bd2332daf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_5ec05f6a-ed21-401a-a58b-07d341363ae1" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_7d6f923e-92db-4236-82fd-a26bd2332daf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherExpenseMember_9ee0abdb-68ac-4368-b7b1-a6ab9cb2f958" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_7d6f923e-92db-4236-82fd-a26bd2332daf" xlink:to="loc_us-gaap_OtherExpenseMember_9ee0abdb-68ac-4368-b7b1-a6ab9cb2f958" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_9eaeafd3-573d-4183-b8aa-7ded150b64fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_31849f3b-be78-4cb2-ad35-3b6fcd0f68c2" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_9eaeafd3-573d-4183-b8aa-7ded150b64fb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_9eaeafd3-573d-4183-b8aa-7ded150b64fb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_9eaeafd3-573d-4183-b8aa-7ded150b64fb" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_9eaeafd3-573d-4183-b8aa-7ded150b64fb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_b3e07e26-1cd2-4e08-80e1-c6a4ef556ea5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_9eaeafd3-573d-4183-b8aa-7ded150b64fb" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_b3e07e26-1cd2-4e08-80e1-c6a4ef556ea5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleNotesPayableMember_10774392-7a5b-4880-853e-47b6173552d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleNotesPayableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_b3e07e26-1cd2-4e08-80e1-c6a4ef556ea5" xlink:to="loc_us-gaap_ConvertibleNotesPayableMember_10774392-7a5b-4880-853e-47b6173552d9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_fe5938d7-f9a2-47a6-bff6-aad39f6ea3bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_31849f3b-be78-4cb2-ad35-3b6fcd0f68c2" xlink:to="loc_us-gaap_DebtInstrumentAxis_fe5938d7-f9a2-47a6-bff6-aad39f6ea3bf" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_fe5938d7-f9a2-47a6-bff6-aad39f6ea3bf_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_fe5938d7-f9a2-47a6-bff6-aad39f6ea3bf" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_fe5938d7-f9a2-47a6-bff6-aad39f6ea3bf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_1a082805-25b6-4991-9b39-983e58db32ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_fe5938d7-f9a2-47a6-bff6-aad39f6ea3bf" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_1a082805-25b6-4991-9b39-983e58db32ba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ConvertibleSeniorNotesDue2019Member_8ce1425a-8bfb-4af2-90e9-c36eab6184a0" xlink:href="lgnd-20211231.xsd#lgnd_ConvertibleSeniorNotesDue2019Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1a082805-25b6-4991-9b39-983e58db32ba" xlink:to="loc_lgnd_ConvertibleSeniorNotesDue2019Member_8ce1425a-8bfb-4af2-90e9-c36eab6184a0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ConvertibleSeniorNotesDue2023Member_46177839-1ab1-41a6-b8fc-3f6ed0a70c3f" xlink:href="lgnd-20211231.xsd#lgnd_ConvertibleSeniorNotesDue2023Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1a082805-25b6-4991-9b39-983e58db32ba" xlink:to="loc_lgnd_ConvertibleSeniorNotesDue2023Member_46177839-1ab1-41a6-b8fc-3f6ed0a70c3f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_52d04c39-abcc-4cec-a40c-9354238889fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_31849f3b-be78-4cb2-ad35-3b6fcd0f68c2" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_52d04c39-abcc-4cec-a40c-9354238889fb" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_52d04c39-abcc-4cec-a40c-9354238889fb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_52d04c39-abcc-4cec-a40c-9354238889fb" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_52d04c39-abcc-4cec-a40c-9354238889fb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_31e5c6bf-27a2-47d9-abb9-a023a6bc7352" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_52d04c39-abcc-4cec-a40c-9354238889fb" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_31e5c6bf-27a2-47d9-abb9-a023a6bc7352" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember_7dd50121-b364-485f-b53e-f3820e3c32f4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_31e5c6bf-27a2-47d9-abb9-a023a6bc7352" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember_7dd50121-b364-485f-b53e-f3820e3c32f4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_21729284-8d82-4375-b6b6-e6a070432af6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_31e5c6bf-27a2-47d9-abb9-a023a6bc7352" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_21729284-8d82-4375-b6b6-e6a070432af6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_4b469371-aa77-4629-9fe4-4f68d0b72cff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_31849f3b-be78-4cb2-ad35-3b6fcd0f68c2" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_4b469371-aa77-4629-9fe4-4f68d0b72cff" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_4b469371-aa77-4629-9fe4-4f68d0b72cff_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_4b469371-aa77-4629-9fe4-4f68d0b72cff" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_4b469371-aa77-4629-9fe4-4f68d0b72cff_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_dab54512-62fd-4485-baaf-cde6394886f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_4b469371-aa77-4629-9fe4-4f68d0b72cff" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_dab54512-62fd-4485-baaf-cde6394886f8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_fb382041-8d9f-423d-b806-770045a7d654" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_dab54512-62fd-4485-baaf-cde6394886f8" xlink:to="loc_us-gaap_SubsequentEventMember_fb382041-8d9f-423d-b806-770045a7d654" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ligand.com/role/ConvertibleSeniorNotesEquityandLiabilityComponentsofFinancingArrangementsDetails" xlink:type="simple" xlink:href="lgnd-20211231.xsd#ConvertibleSeniorNotesEquityandLiabilityComponentsofFinancingArrangementsDetails"/>
  <link:definitionLink xlink:role="http://www.ligand.com/role/ConvertibleSeniorNotesEquityandLiabilityComponentsofFinancingArrangementsDetails" xlink:type="extended" id="i66b577241ce34d81a91809ada03bd205_ConvertibleSeniorNotesEquityandLiabilityComponentsofFinancingArrangementsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_69eed360-00d4-458b-9607-1f44e769c60f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermNotesPayableCurrentAndNoncurrentTotalAbstract_0d1e4955-7eb8-426a-9f00-bc29e7bda00d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermNotesPayableCurrentAndNoncurrentTotalAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_69eed360-00d4-458b-9607-1f44e769c60f" xlink:to="loc_us-gaap_LongtermNotesPayableCurrentAndNoncurrentTotalAbstract_0d1e4955-7eb8-426a-9f00-bc29e7bda00d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_8fefd10d-ca79-4d94-9276-e594b552e54f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermNotesPayableCurrentAndNoncurrentTotalAbstract_0d1e4955-7eb8-426a-9f00-bc29e7bda00d" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_8fefd10d-ca79-4d94-9276-e594b552e54f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_3aff9655-5d55-4376-9fae-e372c94086bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermNotesPayableCurrentAndNoncurrentTotalAbstract_0d1e4955-7eb8-426a-9f00-bc29e7bda00d" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_3aff9655-5d55-4376-9fae-e372c94086bf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermNotesPayable_24c5f927-5ffb-4457-8aed-67b80a6e55d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermNotesPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermNotesPayableCurrentAndNoncurrentTotalAbstract_0d1e4955-7eb8-426a-9f00-bc29e7bda00d" xlink:to="loc_us-gaap_LongTermNotesPayable_24c5f927-5ffb-4457-8aed-67b80a6e55d8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_49b68a9f-754f-43a0-a1bb-11b792b866e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_69eed360-00d4-458b-9607-1f44e769c60f" xlink:to="loc_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_49b68a9f-754f-43a0-a1bb-11b792b866e6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtFairValueDisclosures_88f3cc44-342f-46ee-9689-8001263ed6e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtFairValueDisclosures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_69eed360-00d4-458b-9607-1f44e769c60f" xlink:to="loc_us-gaap_ConvertibleDebtFairValueDisclosures_88f3cc44-342f-46ee-9689-8001263ed6e3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_917241e5-2bba-4cdf-b7da-60473a2a52d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_69eed360-00d4-458b-9607-1f44e769c60f" xlink:to="loc_us-gaap_DebtInstrumentTable_917241e5-2bba-4cdf-b7da-60473a2a52d7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_d1769b50-91a3-4129-a865-bc64ac5afe89" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_917241e5-2bba-4cdf-b7da-60473a2a52d7" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_d1769b50-91a3-4129-a865-bc64ac5afe89" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_d1769b50-91a3-4129-a865-bc64ac5afe89_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_d1769b50-91a3-4129-a865-bc64ac5afe89" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_d1769b50-91a3-4129-a865-bc64ac5afe89_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_91a5b5e9-100d-4c8e-865e-a21a39a0b4df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_d1769b50-91a3-4129-a865-bc64ac5afe89" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_91a5b5e9-100d-4c8e-865e-a21a39a0b4df" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleNotesPayableMember_12210cdd-2e0b-4449-adaa-601c7ded6b56" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleNotesPayableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_91a5b5e9-100d-4c8e-865e-a21a39a0b4df" xlink:to="loc_us-gaap_ConvertibleNotesPayableMember_12210cdd-2e0b-4449-adaa-601c7ded6b56" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_c663dcd1-dd1c-43f3-8701-1bf66a57e8b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_917241e5-2bba-4cdf-b7da-60473a2a52d7" xlink:to="loc_us-gaap_DebtInstrumentAxis_c663dcd1-dd1c-43f3-8701-1bf66a57e8b9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_c663dcd1-dd1c-43f3-8701-1bf66a57e8b9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_c663dcd1-dd1c-43f3-8701-1bf66a57e8b9" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_c663dcd1-dd1c-43f3-8701-1bf66a57e8b9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_7ee37a51-3761-49e4-b14b-7ac6d927678b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_c663dcd1-dd1c-43f3-8701-1bf66a57e8b9" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_7ee37a51-3761-49e4-b14b-7ac6d927678b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ConvertibleSeniorNotesDue2023Member_34a28e3a-0095-4487-976f-2cc2d30bbb45" xlink:href="lgnd-20211231.xsd#lgnd_ConvertibleSeniorNotesDue2023Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7ee37a51-3761-49e4-b14b-7ac6d927678b" xlink:to="loc_lgnd_ConvertibleSeniorNotesDue2023Member_34a28e3a-0095-4487-976f-2cc2d30bbb45" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ligand.com/role/BalanceSheetAccountDetailsInvestmentCategoriesDetails" xlink:type="simple" xlink:href="lgnd-20211231.xsd#BalanceSheetAccountDetailsInvestmentCategoriesDetails"/>
  <link:definitionLink xlink:role="http://www.ligand.com/role/BalanceSheetAccountDetailsInvestmentCategoriesDetails" xlink:type="extended" id="ib119a4b97b8b49f6be0e96b23f51eac1_BalanceSheetAccountDetailsInvestmentCategoriesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_5659e983-39df-4bd5-9733-72efefd9bb0d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_afe6b300-0255-4890-8e9c-b86bc0def127" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_5659e983-39df-4bd5-9733-72efefd9bb0d" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_afe6b300-0255-4890-8e9c-b86bc0def127" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_18c531a4-d729-44f5-81a5-f47436f74809" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_5659e983-39df-4bd5-9733-72efefd9bb0d" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_18c531a4-d729-44f5-81a5-f47436f74809" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_1b9e11d6-edfc-42d6-be3e-63909df782bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_5659e983-39df-4bd5-9733-72efefd9bb0d" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_1b9e11d6-edfc-42d6-be3e-63909df782bb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_6f7f6bc7-57a3-4b34-b417-aed94784dea0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_5659e983-39df-4bd5-9733-72efefd9bb0d" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_6f7f6bc7-57a3-4b34-b417-aed94784dea0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_9e2cfea5-636f-4367-911d-b1a969895558" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_5659e983-39df-4bd5-9733-72efefd9bb0d" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_9e2cfea5-636f-4367-911d-b1a969895558" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_4c7197d8-9f32-493c-8e68-9d39cc97bcd8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_9e2cfea5-636f-4367-911d-b1a969895558" xlink:to="loc_us-gaap_InvestmentTypeAxis_4c7197d8-9f32-493c-8e68-9d39cc97bcd8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_4c7197d8-9f32-493c-8e68-9d39cc97bcd8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InvestmentTypeAxis_4c7197d8-9f32-493c-8e68-9d39cc97bcd8" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_4c7197d8-9f32-493c-8e68-9d39cc97bcd8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_e8f5871e-aaa5-4f28-93b2-4f88abb36b6c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InvestmentTypeAxis_4c7197d8-9f32-493c-8e68-9d39cc97bcd8" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_e8f5871e-aaa5-4f28-93b2-4f88abb36b6c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestmentsMember_5c2610f5-2331-491d-b115-478b505d88fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermInvestmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_e8f5871e-aaa5-4f28-93b2-4f88abb36b6c" xlink:to="loc_us-gaap_ShortTermInvestmentsMember_5c2610f5-2331-491d-b115-478b505d88fc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MutualFundMember_6d12a0f3-8339-4a2c-94fd-c270d83322a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MutualFundMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermInvestmentsMember_5c2610f5-2331-491d-b115-478b505d88fc" xlink:to="loc_us-gaap_MutualFundMember_6d12a0f3-8339-4a2c-94fd-c270d83322a9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DemandDepositsMember_7111ee51-d8e9-46f5-acf1-cf231134f149" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DemandDepositsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermInvestmentsMember_5c2610f5-2331-491d-b115-478b505d88fc" xlink:to="loc_us-gaap_DemandDepositsMember_7111ee51-d8e9-46f5-acf1-cf231134f149" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_4b569812-646a-48e5-853a-2beb2ed49417" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermInvestmentsMember_5c2610f5-2331-491d-b115-478b505d88fc" xlink:to="loc_us-gaap_CommercialPaperMember_4b569812-646a-48e5-853a-2beb2ed49417" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_82a81814-a545-409d-a622-773d27cefeda" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermInvestmentsMember_5c2610f5-2331-491d-b115-478b505d88fc" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_82a81814-a545-409d-a622-773d27cefeda" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AgencySecuritiesMember_7bfa6c90-8a6e-45f8-b794-52db674f7c15" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AgencySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermInvestmentsMember_5c2610f5-2331-491d-b115-478b505d88fc" xlink:to="loc_us-gaap_AgencySecuritiesMember_7bfa6c90-8a6e-45f8-b794-52db674f7c15" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember_72d26381-e471-4de5-bb84-94515c8962ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermInvestmentsMember_5c2610f5-2331-491d-b115-478b505d88fc" xlink:to="loc_us-gaap_EquitySecuritiesMember_72d26381-e471-4de5-bb84-94515c8962ae" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentDebtSecuritiesMember_d6f4ee38-792f-4116-943c-738239a94bc3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermInvestmentsMember_5c2610f5-2331-491d-b115-478b505d88fc" xlink:to="loc_us-gaap_USGovernmentDebtSecuritiesMember_d6f4ee38-792f-4116-943c-738239a94bc3" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_90c2fe31-61e5-4c40-9344-c1dfb9db5681" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermInvestmentsMember_5c2610f5-2331-491d-b115-478b505d88fc" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_90c2fe31-61e5-4c40-9344-c1dfb9db5681" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_8fcf0c08-da85-40c4-a8ac-1afcc4e10108" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermInvestmentsMember_5c2610f5-2331-491d-b115-478b505d88fc" xlink:to="loc_us-gaap_WarrantMember_8fcf0c08-da85-40c4-a8ac-1afcc4e10108" xlink:type="arc" order="9"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ligand.com/role/BalanceSheetAccountDetailsNarrativeDetails" xlink:type="simple" xlink:href="lgnd-20211231.xsd#BalanceSheetAccountDetailsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.ligand.com/role/BalanceSheetAccountDetailsNarrativeDetails" xlink:type="extended" id="iedcd82b27bd142a6995efc828f217bc4_BalanceSheetAccountDetailsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentsLineItems_c1ee8fee-2106-40e8-b993-eea60f5c9dfc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfInvestmentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_bb66ad8a-fbc4-4552-a358-b5baec903c47" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_c1ee8fee-2106-40e8-b993-eea60f5c9dfc" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_bb66ad8a-fbc4-4552-a358-b5baec903c47" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_c1b166a5-1b79-49ba-864d-369c35e998aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_c1ee8fee-2106-40e8-b993-eea60f5c9dfc" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_c1b166a5-1b79-49ba-864d-369c35e998aa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_75d9d6ec-2e95-413c-8db4-1b3338fbad45" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_c1ee8fee-2106-40e8-b993-eea60f5c9dfc" xlink:to="loc_us-gaap_Depreciation_75d9d6ec-2e95-413c-8db4-1b3338fbad45" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_1625a876-0714-4a88-aa50-9dd8257dfa0b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_c1ee8fee-2106-40e8-b993-eea60f5c9dfc" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_1625a876-0714-4a88-aa50-9dd8257dfa0b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_6e62cf5a-b855-4bfe-a2ef-62adf4fe865f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_c1ee8fee-2106-40e8-b993-eea60f5c9dfc" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_6e62cf5a-b855-4bfe-a2ef-62adf4fe865f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_0cc21e0f-e1f8-4f0a-8d0c-7e986af9e764" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_c1ee8fee-2106-40e8-b993-eea60f5c9dfc" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_0cc21e0f-e1f8-4f0a-8d0c-7e986af9e764" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_b076f095-85af-4669-aa9b-adf116ea3255" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_c1ee8fee-2106-40e8-b993-eea60f5c9dfc" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_b076f095-85af-4669-aa9b-adf116ea3255" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_8bd6349f-571a-4e41-a5e6-e84e66a2ca5a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_c1ee8fee-2106-40e8-b993-eea60f5c9dfc" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_8bd6349f-571a-4e41-a5e6-e84e66a2ca5a" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_cb721dfa-263c-4eed-83a9-a31288c13f2a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_c1ee8fee-2106-40e8-b993-eea60f5c9dfc" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_cb721dfa-263c-4eed-83a9-a31288c13f2a" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_7ebd01bf-869e-4b5c-93e2-c47d801ca65e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_c1ee8fee-2106-40e8-b993-eea60f5c9dfc" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_7ebd01bf-869e-4b5c-93e2-c47d801ca65e" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_NumberOfContingentValueRightAgreements_818eb49c-75e5-4cfb-b571-b087332a8691" xlink:href="lgnd-20211231.xsd#lgnd_NumberOfContingentValueRightAgreements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_c1ee8fee-2106-40e8-b993-eea60f5c9dfc" xlink:to="loc_lgnd_NumberOfContingentValueRightAgreements_818eb49c-75e5-4cfb-b571-b087332a8691" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentsTable_4a97391f-3097-4925-9e88-1fe4a445084d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfInvestmentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_c1ee8fee-2106-40e8-b993-eea60f5c9dfc" xlink:to="loc_us-gaap_ScheduleOfInvestmentsTable_4a97391f-3097-4925-9e88-1fe4a445084d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_43638ca6-30e4-4fe5-8143-e5f0eea7f8a1" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfInvestmentsTable_4a97391f-3097-4925-9e88-1fe4a445084d" xlink:to="loc_srt_RangeAxis_43638ca6-30e4-4fe5-8143-e5f0eea7f8a1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_43638ca6-30e4-4fe5-8143-e5f0eea7f8a1_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_43638ca6-30e4-4fe5-8143-e5f0eea7f8a1" xlink:to="loc_srt_RangeMember_43638ca6-30e4-4fe5-8143-e5f0eea7f8a1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_08aa7cb9-d181-4ce2-ac29-c2f2bd283eae" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_43638ca6-30e4-4fe5-8143-e5f0eea7f8a1" xlink:to="loc_srt_RangeMember_08aa7cb9-d181-4ce2-ac29-c2f2bd283eae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_1a9622fb-8a28-4e30-b488-83771f4e5c89" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_08aa7cb9-d181-4ce2-ac29-c2f2bd283eae" xlink:to="loc_srt_MinimumMember_1a9622fb-8a28-4e30-b488-83771f4e5c89" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_70f9e66f-8b28-434b-91a2-24d13568d9c8" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_08aa7cb9-d181-4ce2-ac29-c2f2bd283eae" xlink:to="loc_srt_MaximumMember_70f9e66f-8b28-434b-91a2-24d13568d9c8" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ligand.com/role/BalanceSheetAccountDetailsAvailableforSaleDebtSecuritiesinanUnrealizedLossPositionDetails" xlink:type="simple" xlink:href="lgnd-20211231.xsd#BalanceSheetAccountDetailsAvailableforSaleDebtSecuritiesinanUnrealizedLossPositionDetails"/>
  <link:definitionLink xlink:role="http://www.ligand.com/role/BalanceSheetAccountDetailsAvailableforSaleDebtSecuritiesinanUnrealizedLossPositionDetails" xlink:type="extended" id="ie6b3332a3a6f479f933a1c0cb7978585_BalanceSheetAccountDetailsAvailableforSaleDebtSecuritiesinanUnrealizedLossPositionDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract_fd31d12c-d741-46f3-98c2-c00cd531d9fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_2bb79ede-fd57-44dd-a323-27da74449d23" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract_fd31d12c-d741-46f3-98c2-c00cd531d9fd" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_2bb79ede-fd57-44dd-a323-27da74449d23" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_904f63c6-32bf-4f15-8b42-a9a7cca83c2f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_2bb79ede-fd57-44dd-a323-27da74449d23" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_904f63c6-32bf-4f15-8b42-a9a7cca83c2f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_b0ee55d1-e9d6-4cbc-83ee-c794e33f2038" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_2bb79ede-fd57-44dd-a323-27da74449d23" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_b0ee55d1-e9d6-4cbc-83ee-c794e33f2038" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionAccumulatedLoss_4e028922-1a37-45d5-89b2-006c91e3fce7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionAccumulatedLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_2bb79ede-fd57-44dd-a323-27da74449d23" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionAccumulatedLoss_4e028922-1a37-45d5-89b2-006c91e3fce7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsAbstract_3cc6a091-918c-4f11-9455-b817837e158b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract_fd31d12c-d741-46f3-98c2-c00cd531d9fd" xlink:to="loc_us-gaap_AvailableForsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsAbstract_3cc6a091-918c-4f11-9455-b817837e158b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_8d86b493-84b5-4ecc-8d54-1cd8815906dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsAbstract_3cc6a091-918c-4f11-9455-b817837e158b" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_8d86b493-84b5-4ecc-8d54-1cd8815906dd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_eb954a07-facc-4c5b-aa78-6f6148baeab9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsAbstract_3cc6a091-918c-4f11-9455-b817837e158b" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_eb954a07-facc-4c5b-aa78-6f6148baeab9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_6df0edf2-f46a-4844-a131-af94047ca7cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsAbstract_3cc6a091-918c-4f11-9455-b817837e158b" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_6df0edf2-f46a-4844-a131-af94047ca7cb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable_c5cc5be8-c088-4854-b3b2-511108c06ee7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract_fd31d12c-d741-46f3-98c2-c00cd531d9fd" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable_c5cc5be8-c088-4854-b3b2-511108c06ee7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_33560243-62cb-4e16-ad77-80a182fd8a30" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable_c5cc5be8-c088-4854-b3b2-511108c06ee7" xlink:to="loc_us-gaap_FinancialInstrumentAxis_33560243-62cb-4e16-ad77-80a182fd8a30" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_33560243-62cb-4e16-ad77-80a182fd8a30_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_33560243-62cb-4e16-ad77-80a182fd8a30" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_33560243-62cb-4e16-ad77-80a182fd8a30_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b9de9dde-7cc0-4323-9eb4-f99f45818263" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_33560243-62cb-4e16-ad77-80a182fd8a30" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b9de9dde-7cc0-4323-9eb4-f99f45818263" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DemandDepositsMember_e62999b1-41d6-4d58-8142-cebef25e08cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DemandDepositsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b9de9dde-7cc0-4323-9eb4-f99f45818263" xlink:to="loc_us-gaap_DemandDepositsMember_e62999b1-41d6-4d58-8142-cebef25e08cb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_81faa6ee-b678-4677-94ca-53ad6853ac2d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b9de9dde-7cc0-4323-9eb4-f99f45818263" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_81faa6ee-b678-4677-94ca-53ad6853ac2d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_b69b6cc0-26b7-4f4f-aa09-f7cc74c09b20" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b9de9dde-7cc0-4323-9eb4-f99f45818263" xlink:to="loc_us-gaap_CommercialPaperMember_b69b6cc0-26b7-4f4f-aa09-f7cc74c09b20" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentDebtSecuritiesMember_f1818c25-0692-4a36-abb0-c582d42983d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b9de9dde-7cc0-4323-9eb4-f99f45818263" xlink:to="loc_us-gaap_USGovernmentDebtSecuritiesMember_f1818c25-0692-4a36-abb0-c582d42983d2" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ligand.com/role/BalanceSheetAccountDetailsPropertyandEquipmentDetails" xlink:type="simple" xlink:href="lgnd-20211231.xsd#BalanceSheetAccountDetailsPropertyandEquipmentDetails"/>
  <link:definitionLink xlink:role="http://www.ligand.com/role/BalanceSheetAccountDetailsPropertyandEquipmentDetails" xlink:type="extended" id="ie2ff6713d2774207bfda4210048efffd_BalanceSheetAccountDetailsPropertyandEquipmentDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_267ec64a-591d-47fa-8788-0e9ca58fc719" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_049fb234-4b39-456d-9ad1-1476ff5ba256" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_267ec64a-591d-47fa-8788-0e9ca58fc719" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_049fb234-4b39-456d-9ad1-1476ff5ba256" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_b193b24a-ee74-486d-8f72-f064e8fc57f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_267ec64a-591d-47fa-8788-0e9ca58fc719" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_b193b24a-ee74-486d-8f72-f064e8fc57f0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_0599b126-b534-4ad4-96c0-ab490973598b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_267ec64a-591d-47fa-8788-0e9ca58fc719" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_0599b126-b534-4ad4-96c0-ab490973598b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_11218658-29e9-4a18-93e6-9b93abc2ba53" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_267ec64a-591d-47fa-8788-0e9ca58fc719" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_11218658-29e9-4a18-93e6-9b93abc2ba53" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ee98e46b-dcfc-4a97-92ac-07fef5ff8412" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_11218658-29e9-4a18-93e6-9b93abc2ba53" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ee98e46b-dcfc-4a97-92ac-07fef5ff8412" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ee98e46b-dcfc-4a97-92ac-07fef5ff8412_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ee98e46b-dcfc-4a97-92ac-07fef5ff8412" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ee98e46b-dcfc-4a97-92ac-07fef5ff8412_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_8ff5ed49-eb1d-4a31-a368-d78a7df712ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ee98e46b-dcfc-4a97-92ac-07fef5ff8412" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_8ff5ed49-eb1d-4a31-a368-d78a7df712ee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OfficeEquipmentMember_6f022ee1-1b23-4f9e-b4ee-c467fade6b05" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OfficeEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_8ff5ed49-eb1d-4a31-a368-d78a7df712ee" xlink:to="loc_us-gaap_OfficeEquipmentMember_6f022ee1-1b23-4f9e-b4ee-c467fade6b05" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_696d0c03-70a3-4be8-884e-f942e1e11be5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_8ff5ed49-eb1d-4a31-a368-d78a7df712ee" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_696d0c03-70a3-4be8-884e-f942e1e11be5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ComputerEquipmentAndSoftwareMember_01dcfbdf-b489-4b8a-8907-5aa65c9bfcd4" xlink:href="lgnd-20211231.xsd#lgnd_ComputerEquipmentAndSoftwareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_8ff5ed49-eb1d-4a31-a368-d78a7df712ee" xlink:to="loc_lgnd_ComputerEquipmentAndSoftwareMember_01dcfbdf-b489-4b8a-8907-5aa65c9bfcd4" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ligand.com/role/BalanceSheetAccountDetailsGoodwillandOtherIntangibleAssetsDetails" xlink:type="simple" xlink:href="lgnd-20211231.xsd#BalanceSheetAccountDetailsGoodwillandOtherIntangibleAssetsDetails"/>
  <link:definitionLink xlink:role="http://www.ligand.com/role/BalanceSheetAccountDetailsGoodwillandOtherIntangibleAssetsDetails" xlink:type="extended" id="i567ca1bcfaa04bee89c0d08250d5055d_BalanceSheetAccountDetailsGoodwillandOtherIntangibleAssetsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_7e028af6-b953-42b6-8459-d308772f8dcd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_ace36be3-10b9-4ec3-b2b1-b789de303463" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_7e028af6-b953-42b6-8459-d308772f8dcd" xlink:to="loc_us-gaap_Goodwill_ace36be3-10b9-4ec3-b2b1-b789de303463" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_ad1a3a3e-f429-4bb3-9a50-2155d3988268" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_7e028af6-b953-42b6-8459-d308772f8dcd" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_ad1a3a3e-f429-4bb3-9a50-2155d3988268" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_9e4933c4-b2e3-43b0-9d96-c62ebb6d7d0d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_7e028af6-b953-42b6-8459-d308772f8dcd" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_9e4933c4-b2e3-43b0-9d96-c62ebb6d7d0d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill_5944412c-fbea-44e1-be28-384e4ed660c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetIncludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_7e028af6-b953-42b6-8459-d308772f8dcd" xlink:to="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill_5944412c-fbea-44e1-be28-384e4ed660c4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_e30b204b-a58b-496b-aa44-b85513c997ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_7e028af6-b953-42b6-8459-d308772f8dcd" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_e30b204b-a58b-496b-aa44-b85513c997ba" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_a023ad36-5521-44b7-8758-0c40f3e6ff02" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_e30b204b-a58b-496b-aa44-b85513c997ba" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_a023ad36-5521-44b7-8758-0c40f3e6ff02" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_a023ad36-5521-44b7-8758-0c40f3e6ff02_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_a023ad36-5521-44b7-8758-0c40f3e6ff02" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_a023ad36-5521-44b7-8758-0c40f3e6ff02_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_882958b5-4931-4824-bc70-b74f000e273b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_a023ad36-5521-44b7-8758-0c40f3e6ff02" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_882958b5-4931-4824-bc70-b74f000e273b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PatentedTechnologyMember_1a17c4fe-9a0a-4073-998e-2c2250da24b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PatentedTechnologyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_882958b5-4931-4824-bc70-b74f000e273b" xlink:to="loc_us-gaap_PatentedTechnologyMember_1a17c4fe-9a0a-4073-998e-2c2250da24b3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeNamesMember_e117c169-5ec7-4e7f-b623-152b74a40bbf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TradeNamesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_882958b5-4931-4824-bc70-b74f000e273b" xlink:to="loc_us-gaap_TradeNamesMember_e117c169-5ec7-4e7f-b623-152b74a40bbf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember_7e16e275-8669-4a69-90b0-23a043ef0a8f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_882958b5-4931-4824-bc70-b74f000e273b" xlink:to="loc_us-gaap_CustomerRelationshipsMember_7e16e275-8669-4a69-90b0-23a043ef0a8f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualRightsMember_ca251ec6-4ecd-42c1-8233-c7779d2fade3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractualRightsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_882958b5-4931-4824-bc70-b74f000e273b" xlink:to="loc_us-gaap_ContractualRightsMember_ca251ec6-4ecd-42c1-8233-c7779d2fade3" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ligand.com/role/BalanceSheetAccountDetailsContingentLiabilitiesDetails" xlink:type="simple" xlink:href="lgnd-20211231.xsd#BalanceSheetAccountDetailsContingentLiabilitiesDetails"/>
  <link:definitionLink xlink:role="http://www.ligand.com/role/BalanceSheetAccountDetailsContingentLiabilitiesDetails" xlink:type="extended" id="i6e1526c86f294886bcc021f6e541b7d4_BalanceSheetAccountDetailsContingentLiabilitiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_301e28e7-1513-4497-9b8d-63bedd3d42c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ContingentLiabilityRollForward_bfe88c9a-1db5-4a3d-ac6b-f091ad02f156" xlink:href="lgnd-20211231.xsd#lgnd_ContingentLiabilityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_301e28e7-1513-4497-9b8d-63bedd3d42c0" xlink:to="loc_lgnd_ContingentLiabilityRollForward_bfe88c9a-1db5-4a3d-ac6b-f091ad02f156" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod_94ae76a9-d2ee-434c-ab55-bebc27054ef1" xlink:href="lgnd-20211231.xsd#lgnd_BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lgnd_ContingentLiabilityRollForward_bfe88c9a-1db5-4a3d-ac6b-f091ad02f156" xlink:to="loc_lgnd_BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod_94ae76a9-d2ee-434c-ab55-bebc27054ef1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BusinessAcquisitionContingentConsiderationPotentialCashPaymentAdditions_7dcf8a07-14b4-4b1c-90cc-3f5a964cc899" xlink:href="lgnd-20211231.xsd#lgnd_BusinessAcquisitionContingentConsiderationPotentialCashPaymentAdditions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lgnd_ContingentLiabilityRollForward_bfe88c9a-1db5-4a3d-ac6b-f091ad02f156" xlink:to="loc_lgnd_BusinessAcquisitionContingentConsiderationPotentialCashPaymentAdditions_7dcf8a07-14b4-4b1c-90cc-3f5a964cc899" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PaymentsToContingentValueRightHolders_ed653cba-ccbf-48e3-9e7a-b811f697d481" xlink:href="lgnd-20211231.xsd#lgnd_PaymentsToContingentValueRightHolders"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lgnd_ContingentLiabilityRollForward_bfe88c9a-1db5-4a3d-ac6b-f091ad02f156" xlink:to="loc_lgnd_PaymentsToContingentValueRightHolders_ed653cba-ccbf-48e3-9e7a-b811f697d481" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities_f5e2950d-240c-4562-9852-a77847d44652" xlink:href="lgnd-20211231.xsd#lgnd_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lgnd_ContingentLiabilityRollForward_bfe88c9a-1db5-4a3d-ac6b-f091ad02f156" xlink:to="loc_lgnd_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities_f5e2950d-240c-4562-9852-a77847d44652" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityRepurchasesContingentLiabilities_4e02a059-5c67-463d-90e9-926f0b4e0142" xlink:href="lgnd-20211231.xsd#lgnd_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityRepurchasesContingentLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lgnd_ContingentLiabilityRollForward_bfe88c9a-1db5-4a3d-ac6b-f091ad02f156" xlink:to="loc_lgnd_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityRepurchasesContingentLiabilities_4e02a059-5c67-463d-90e9-926f0b4e0142" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod_958b8d88-c9a9-460d-bbe3-06f13c4f7109" xlink:href="lgnd-20211231.xsd#lgnd_BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_b83c2c54-90f4-499e-addc-bd6770884728" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_301e28e7-1513-4497-9b8d-63bedd3d42c0" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_b83c2c54-90f4-499e-addc-bd6770884728" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_9b318c3e-2690-4975-98df-d015d261a74e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_b83c2c54-90f4-499e-addc-bd6770884728" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_9b318c3e-2690-4975-98df-d015d261a74e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9b318c3e-2690-4975-98df-d015d261a74e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_9b318c3e-2690-4975-98df-d015d261a74e" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9b318c3e-2690-4975-98df-d015d261a74e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a41a4dff-f9b1-4c76-9a53-7a9cfd2bdedf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_9b318c3e-2690-4975-98df-d015d261a74e" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a41a4dff-f9b1-4c76-9a53-7a9cfd2bdedf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_CydexPharmaceuticalsIncMember_a8375cca-721f-4b61-9a32-21ca7aaf90a8" xlink:href="lgnd-20211231.xsd#lgnd_CydexPharmaceuticalsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a41a4dff-f9b1-4c76-9a53-7a9cfd2bdedf" xlink:to="loc_lgnd_CydexPharmaceuticalsIncMember_a8375cca-721f-4b61-9a32-21ca7aaf90a8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_MetabasisTherapeuticsMember_4f4bf3b2-e39c-4e95-b30d-3787fe5405af" xlink:href="lgnd-20211231.xsd#lgnd_MetabasisTherapeuticsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a41a4dff-f9b1-4c76-9a53-7a9cfd2bdedf" xlink:to="loc_lgnd_MetabasisTherapeuticsMember_4f4bf3b2-e39c-4e95-b30d-3787fe5405af" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_CrystalMember_d19fdf53-a536-4b40-a060-cc6173dac9c8" xlink:href="lgnd-20211231.xsd#lgnd_CrystalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a41a4dff-f9b1-4c76-9a53-7a9cfd2bdedf" xlink:to="loc_lgnd_CrystalMember_d19fdf53-a536-4b40-a060-cc6173dac9c8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_IcagenMember_6614b4c7-a8f5-4c15-9d4e-e91f43dc2e13" xlink:href="lgnd-20211231.xsd#lgnd_IcagenMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a41a4dff-f9b1-4c76-9a53-7a9cfd2bdedf" xlink:to="loc_lgnd_IcagenMember_6614b4c7-a8f5-4c15-9d4e-e91f43dc2e13" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PfenexMember_ee75745f-f328-420f-aacc-7ee987930df5" xlink:href="lgnd-20211231.xsd#lgnd_PfenexMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a41a4dff-f9b1-4c76-9a53-7a9cfd2bdedf" xlink:to="loc_lgnd_PfenexMember_ee75745f-f328-420f-aacc-7ee987930df5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_XCellaBiosciencesIncMember_8af87dcf-2c50-40d9-9445-2630fdb729e6" xlink:href="lgnd-20211231.xsd#lgnd_XCellaBiosciencesIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a41a4dff-f9b1-4c76-9a53-7a9cfd2bdedf" xlink:to="loc_lgnd_XCellaBiosciencesIncMember_8af87dcf-2c50-40d9-9445-2630fdb729e6" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ligand.com/role/StockholdersEquityShareBasedCompensationDetails" xlink:type="simple" xlink:href="lgnd-20211231.xsd#StockholdersEquityShareBasedCompensationDetails"/>
  <link:definitionLink xlink:role="http://www.ligand.com/role/StockholdersEquityShareBasedCompensationDetails" xlink:type="extended" id="ibd4bdff1dbab443a8d85a64c12f38238_StockholdersEquityShareBasedCompensationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b304a0fe-4313-4c79-b4d3-959e361b72ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_42dcb56d-2c72-4d94-b0b3-f48ef2308b10" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b304a0fe-4313-4c79-b4d3-959e361b72ea" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_42dcb56d-2c72-4d94-b0b3-f48ef2308b10" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c6efcff7-a707-4b34-b36d-edabd7dbc851" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b304a0fe-4313-4c79-b4d3-959e361b72ea" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c6efcff7-a707-4b34-b36d-edabd7dbc851" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_b5dcf70c-ff5d-4528-b5e6-376df37cff6c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c6efcff7-a707-4b34-b36d-edabd7dbc851" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_b5dcf70c-ff5d-4528-b5e6-376df37cff6c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_b5dcf70c-ff5d-4528-b5e6-376df37cff6c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_b5dcf70c-ff5d-4528-b5e6-376df37cff6c" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_b5dcf70c-ff5d-4528-b5e6-376df37cff6c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_0f5de99c-66db-406d-9ab4-e7ff7077916c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_b5dcf70c-ff5d-4528-b5e6-376df37cff6c" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_0f5de99c-66db-406d-9ab4-e7ff7077916c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_23b0c8e1-3859-432d-9dcc-922cfda776fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_0f5de99c-66db-406d-9ab4-e7ff7077916c" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_23b0c8e1-3859-432d-9dcc-922cfda776fd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_4eb4dad0-c398-47e5-9f02-eda0d68a6912" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_0f5de99c-66db-406d-9ab4-e7ff7077916c" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_4eb4dad0-c398-47e5-9f02-eda0d68a6912" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ligand.com/role/StockholdersEquityNarrativeDetails" xlink:type="simple" xlink:href="lgnd-20211231.xsd#StockholdersEquityNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.ligand.com/role/StockholdersEquityNarrativeDetails" xlink:type="extended" id="i407800fb56c642c5b2efc80016c75cc8_StockholdersEquityNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_da084a01-c8a9-4def-8fbb-5943bee70eef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_bdd0ea9b-9ff3-4a06-9551-494b11b84b48" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_da084a01-c8a9-4def-8fbb-5943bee70eef" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_bdd0ea9b-9ff3-4a06-9551-494b11b84b48" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_5f4f726e-3193-4c95-abba-79ebd90e866a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_da084a01-c8a9-4def-8fbb-5943bee70eef" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_5f4f726e-3193-4c95-abba-79ebd90e866a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_3ff7eb9b-a4ca-43fa-a068-170f11ff0b73" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_da084a01-c8a9-4def-8fbb-5943bee70eef" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_3ff7eb9b-a4ca-43fa-a068-170f11ff0b73" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_aac8010a-a6d5-437c-b478-0896aff66d05" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_da084a01-c8a9-4def-8fbb-5943bee70eef" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_aac8010a-a6d5-437c-b478-0896aff66d05" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_45a6081b-6f6a-4665-997e-64d445fd5fb9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_da084a01-c8a9-4def-8fbb-5943bee70eef" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_45a6081b-6f6a-4665-997e-64d445fd5fb9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_b2844709-ac6e-4d63-ae09-3d4e728d9b8b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_da084a01-c8a9-4def-8fbb-5943bee70eef" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_b2844709-ac6e-4d63-ae09-3d4e728d9b8b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_c2f2eac0-447d-41e3-87c7-87d6490133b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_da084a01-c8a9-4def-8fbb-5943bee70eef" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_c2f2eac0-447d-41e3-87c7-87d6490133b5" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_81466139-0c2c-4813-a190-e6bdc0ec9b01" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_da084a01-c8a9-4def-8fbb-5943bee70eef" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_81466139-0c2c-4813-a190-e6bdc0ec9b01" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_EmployeeStockPurchasePlanAbstract_579e5008-ce9c-4983-a494-e21438cc7cab" xlink:href="lgnd-20211231.xsd#lgnd_EmployeeStockPurchasePlanAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_da084a01-c8a9-4def-8fbb-5943bee70eef" xlink:to="loc_lgnd_EmployeeStockPurchasePlanAbstract_579e5008-ce9c-4983-a494-e21438cc7cab" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee_72a28ea9-c186-4ad3-9e82-8641735e7c05" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lgnd_EmployeeStockPurchasePlanAbstract_579e5008-ce9c-4983-a494-e21438cc7cab" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee_72a28ea9-c186-4ad3-9e82-8641735e7c05" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_3db18913-ae25-43f5-a420-96a3f98237cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lgnd_EmployeeStockPurchasePlanAbstract_579e5008-ce9c-4983-a494-e21438cc7cab" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_3db18913-ae25-43f5-a420-96a3f98237cf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_bb3337c6-aef0-4ca1-809e-762017b53bc3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lgnd_EmployeeStockPurchasePlanAbstract_579e5008-ce9c-4983-a494-e21438cc7cab" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_bb3337c6-aef0-4ca1-809e-762017b53bc3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_CorporateShareRepurchaseAbstract_d6ea3787-0a12-43e2-969c-c85f2d4823a7" xlink:href="lgnd-20211231.xsd#lgnd_CorporateShareRepurchaseAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_da084a01-c8a9-4def-8fbb-5943bee70eef" xlink:to="loc_lgnd_CorporateShareRepurchaseAbstract_d6ea3787-0a12-43e2-969c-c85f2d4823a7" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_56922688-d9b1-4c95-a9ec-79bb87a47beb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lgnd_CorporateShareRepurchaseAbstract_d6ea3787-0a12-43e2-969c-c85f2d4823a7" xlink:to="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_56922688-d9b1-4c95-a9ec-79bb87a47beb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramPeriodInForce1_c5449800-1656-476d-9807-675ee2e37525" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchaseProgramPeriodInForce1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lgnd_CorporateShareRepurchaseAbstract_d6ea3787-0a12-43e2-969c-c85f2d4823a7" xlink:to="loc_us-gaap_StockRepurchaseProgramPeriodInForce1_c5449800-1656-476d-9807-675ee2e37525" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_78fcd216-2a6a-4fd1-a298-c7c4cbb45eab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lgnd_CorporateShareRepurchaseAbstract_d6ea3787-0a12-43e2-969c-c85f2d4823a7" xlink:to="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_78fcd216-2a6a-4fd1-a298-c7c4cbb45eab" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares_73dadf94-5a56-4181-869f-166c8113c611" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lgnd_CorporateShareRepurchaseAbstract_d6ea3787-0a12-43e2-969c-c85f2d4823a7" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodShares_73dadf94-5a56-4181-869f-166c8113c611" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue_d8c8f2d9-9e60-43bf-9835-a8417396e756" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lgnd_CorporateShareRepurchaseAbstract_d6ea3787-0a12-43e2-969c-c85f2d4823a7" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodValue_d8c8f2d9-9e60-43bf-9835-a8417396e756" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1366b02c-cbf7-4fc7-830a-cc37d3dbf740" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_da084a01-c8a9-4def-8fbb-5943bee70eef" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1366b02c-cbf7-4fc7-830a-cc37d3dbf740" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_9b58ab0e-0290-4e69-a715-b367e9c265fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1366b02c-cbf7-4fc7-830a-cc37d3dbf740" xlink:to="loc_us-gaap_PlanNameAxis_9b58ab0e-0290-4e69-a715-b367e9c265fb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_9b58ab0e-0290-4e69-a715-b367e9c265fb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_9b58ab0e-0290-4e69-a715-b367e9c265fb" xlink:to="loc_us-gaap_PlanNameDomain_9b58ab0e-0290-4e69-a715-b367e9c265fb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_f4844e7f-a351-4aea-9b1a-b0da2282b235" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_9b58ab0e-0290-4e69-a715-b367e9c265fb" xlink:to="loc_us-gaap_PlanNameDomain_f4844e7f-a351-4aea-9b1a-b0da2282b235" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_TwoThousandTwoStockIncentivePlanMember_68179bf7-976e-4a4a-ab72-62ac521ba93d" xlink:href="lgnd-20211231.xsd#lgnd_TwoThousandTwoStockIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_f4844e7f-a351-4aea-9b1a-b0da2282b235" xlink:to="loc_lgnd_TwoThousandTwoStockIncentivePlanMember_68179bf7-976e-4a4a-ab72-62ac521ba93d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AmendedESPPMember_16847e96-6b24-4587-a2fb-b824f16aca51" xlink:href="lgnd-20211231.xsd#lgnd_AmendedESPPMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_f4844e7f-a351-4aea-9b1a-b0da2282b235" xlink:to="loc_lgnd_AmendedESPPMember_16847e96-6b24-4587-a2fb-b824f16aca51" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_542d7e1e-ab84-4335-a1cf-921ac26ea1fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1366b02c-cbf7-4fc7-830a-cc37d3dbf740" xlink:to="loc_us-gaap_AwardTypeAxis_542d7e1e-ab84-4335-a1cf-921ac26ea1fb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_542d7e1e-ab84-4335-a1cf-921ac26ea1fb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_542d7e1e-ab84-4335-a1cf-921ac26ea1fb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_542d7e1e-ab84-4335-a1cf-921ac26ea1fb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_71930a3a-baec-41c1-8c0d-564154deb0e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_542d7e1e-ab84-4335-a1cf-921ac26ea1fb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_71930a3a-baec-41c1-8c0d-564154deb0e7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_f383a41d-bbc9-4a1f-bdc6-c8916a62eea9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_71930a3a-baec-41c1-8c0d-564154deb0e7" xlink:to="loc_us-gaap_EmployeeStockOptionMember_f383a41d-bbc9-4a1f-bdc6-c8916a62eea9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_1cd92795-1953-4fd3-949d-228eaffd0cb1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_71930a3a-baec-41c1-8c0d-564154deb0e7" xlink:to="loc_us-gaap_RestrictedStockMember_1cd92795-1953-4fd3-949d-228eaffd0cb1" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ligand.com/role/StockholdersEquityBreakdownofOptionsOutstandingDetails" xlink:type="simple" xlink:href="lgnd-20211231.xsd#StockholdersEquityBreakdownofOptionsOutstandingDetails"/>
  <link:definitionLink xlink:role="http://www.ligand.com/role/StockholdersEquityBreakdownofOptionsOutstandingDetails" xlink:type="extended" id="i0f5c244daaf84998b1eeb975c6f19600_StockholdersEquityBreakdownofOptionsOutstandingDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cb7f60e9-1f40-446b-95b7-4c76f33581af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_a0df090c-a607-4690-a87e-2b6af6812c3f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cb7f60e9-1f40-446b-95b7-4c76f33581af" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_a0df090c-a607-4690-a87e-2b6af6812c3f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_08313f55-7025-4e9a-bb67-01dca66512fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cb7f60e9-1f40-446b-95b7-4c76f33581af" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_08313f55-7025-4e9a-bb67-01dca66512fe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_62debd97-a495-4b4e-8295-c0bf05245725" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cb7f60e9-1f40-446b-95b7-4c76f33581af" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_62debd97-a495-4b4e-8295-c0bf05245725" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_8b347fa0-8a16-4e3e-87e5-9001a6f1b34b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cb7f60e9-1f40-446b-95b7-4c76f33581af" xlink:to="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_8b347fa0-8a16-4e3e-87e5-9001a6f1b34b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_4707b869-93f9-4e8a-a65c-77a93cff005b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cb7f60e9-1f40-446b-95b7-4c76f33581af" xlink:to="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_4707b869-93f9-4e8a-a65c-77a93cff005b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_6fe1d26f-b627-4b66-8f21-012bfdff0e37" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cb7f60e9-1f40-446b-95b7-4c76f33581af" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_6fe1d26f-b627-4b66-8f21-012bfdff0e37" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_fc1856de-4189-4ee7-b78d-657f45cb3bdd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cb7f60e9-1f40-446b-95b7-4c76f33581af" xlink:to="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_fc1856de-4189-4ee7-b78d-657f45cb3bdd" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f4f001e0-3090-4d34-b419-18cfe71e3f68" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cb7f60e9-1f40-446b-95b7-4c76f33581af" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f4f001e0-3090-4d34-b419-18cfe71e3f68" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_2573533b-9b60-4e40-a7bd-a4dc8fff05cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f4f001e0-3090-4d34-b419-18cfe71e3f68" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_2573533b-9b60-4e40-a7bd-a4dc8fff05cb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_2573533b-9b60-4e40-a7bd-a4dc8fff05cb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_2573533b-9b60-4e40-a7bd-a4dc8fff05cb" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_2573533b-9b60-4e40-a7bd-a4dc8fff05cb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_b0ee9d45-caa4-4748-a8f8-6b64536df057" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_2573533b-9b60-4e40-a7bd-a4dc8fff05cb" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_b0ee9d45-caa4-4748-a8f8-6b64536df057" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ExercisePriceRangeElevenMember_f0353014-f85d-44d8-9478-3e5a385498cd" xlink:href="lgnd-20211231.xsd#lgnd_ExercisePriceRangeElevenMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_b0ee9d45-caa4-4748-a8f8-6b64536df057" xlink:to="loc_lgnd_ExercisePriceRangeElevenMember_f0353014-f85d-44d8-9478-3e5a385498cd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ExercisePriceRangeOneMember_a1fb80de-1233-41e1-bf58-5a9ee6c08588" xlink:href="lgnd-20211231.xsd#lgnd_ExercisePriceRangeOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lgnd_ExercisePriceRangeElevenMember_f0353014-f85d-44d8-9478-3e5a385498cd" xlink:to="loc_lgnd_ExercisePriceRangeOneMember_a1fb80de-1233-41e1-bf58-5a9ee6c08588" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ExercisePriceRangeTwoMember_b5dd8030-63eb-4433-bb49-a7fefc33db57" xlink:href="lgnd-20211231.xsd#lgnd_ExercisePriceRangeTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lgnd_ExercisePriceRangeElevenMember_f0353014-f85d-44d8-9478-3e5a385498cd" xlink:to="loc_lgnd_ExercisePriceRangeTwoMember_b5dd8030-63eb-4433-bb49-a7fefc33db57" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ExercisePriceRangeThreeMember_64ecb2ce-4d00-429b-8ff0-319ac8beb1d7" xlink:href="lgnd-20211231.xsd#lgnd_ExercisePriceRangeThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lgnd_ExercisePriceRangeElevenMember_f0353014-f85d-44d8-9478-3e5a385498cd" xlink:to="loc_lgnd_ExercisePriceRangeThreeMember_64ecb2ce-4d00-429b-8ff0-319ac8beb1d7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ExercisePriceRangeFourMember_66aaf301-1c6e-424b-abac-f8ade2a95044" xlink:href="lgnd-20211231.xsd#lgnd_ExercisePriceRangeFourMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lgnd_ExercisePriceRangeElevenMember_f0353014-f85d-44d8-9478-3e5a385498cd" xlink:to="loc_lgnd_ExercisePriceRangeFourMember_66aaf301-1c6e-424b-abac-f8ade2a95044" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ExercisePriceRangeFiveMember_8cab401c-0fcc-4f58-8e56-343ef72ae3ea" xlink:href="lgnd-20211231.xsd#lgnd_ExercisePriceRangeFiveMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lgnd_ExercisePriceRangeElevenMember_f0353014-f85d-44d8-9478-3e5a385498cd" xlink:to="loc_lgnd_ExercisePriceRangeFiveMember_8cab401c-0fcc-4f58-8e56-343ef72ae3ea" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ExercisePriceRangeSixMember_26362468-4345-4a15-bbef-121231317713" xlink:href="lgnd-20211231.xsd#lgnd_ExercisePriceRangeSixMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lgnd_ExercisePriceRangeElevenMember_f0353014-f85d-44d8-9478-3e5a385498cd" xlink:to="loc_lgnd_ExercisePriceRangeSixMember_26362468-4345-4a15-bbef-121231317713" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ExercisePriceRangeSevenMember_313f9bc0-463f-4a59-9cf6-76be107ba058" xlink:href="lgnd-20211231.xsd#lgnd_ExercisePriceRangeSevenMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lgnd_ExercisePriceRangeElevenMember_f0353014-f85d-44d8-9478-3e5a385498cd" xlink:to="loc_lgnd_ExercisePriceRangeSevenMember_313f9bc0-463f-4a59-9cf6-76be107ba058" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ExercisePriceRangeEightMember_2ec60fa7-9e29-4306-b85c-56b85562ca59" xlink:href="lgnd-20211231.xsd#lgnd_ExercisePriceRangeEightMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lgnd_ExercisePriceRangeElevenMember_f0353014-f85d-44d8-9478-3e5a385498cd" xlink:to="loc_lgnd_ExercisePriceRangeEightMember_2ec60fa7-9e29-4306-b85c-56b85562ca59" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ExercisePriceRangeNineMember_8064e242-cfa0-43c4-bd27-a5e7d9cdb222" xlink:href="lgnd-20211231.xsd#lgnd_ExercisePriceRangeNineMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lgnd_ExercisePriceRangeElevenMember_f0353014-f85d-44d8-9478-3e5a385498cd" xlink:to="loc_lgnd_ExercisePriceRangeNineMember_8064e242-cfa0-43c4-bd27-a5e7d9cdb222" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ExercisePriceRangeTenMember_b3e5250c-310b-4ee9-8a18-acab857aa65b" xlink:href="lgnd-20211231.xsd#lgnd_ExercisePriceRangeTenMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lgnd_ExercisePriceRangeElevenMember_f0353014-f85d-44d8-9478-3e5a385498cd" xlink:to="loc_lgnd_ExercisePriceRangeTenMember_b3e5250c-310b-4ee9-8a18-acab857aa65b" xlink:type="arc" order="10"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ligand.com/role/StockholdersEquityAssumptionsDetails" xlink:type="simple" xlink:href="lgnd-20211231.xsd#StockholdersEquityAssumptionsDetails"/>
  <link:definitionLink xlink:role="http://www.ligand.com/role/StockholdersEquityAssumptionsDetails" xlink:type="extended" id="if843db0ec6d64fa1a1715b7ccb2bafd3_StockholdersEquityAssumptionsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0574f6d7-b4c2-49eb-8d64-0937941cf599" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_52ad0be0-4343-4c87-a5d2-35d1994c37f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0574f6d7-b4c2-49eb-8d64-0937941cf599" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_52ad0be0-4343-4c87-a5d2-35d1994c37f5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_97855cb4-45df-4362-afa2-df3e7b67f3aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0574f6d7-b4c2-49eb-8d64-0937941cf599" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_97855cb4-45df-4362-afa2-df3e7b67f3aa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_0d81f167-9fb5-4039-a27b-a7afd2d0fcb6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0574f6d7-b4c2-49eb-8d64-0937941cf599" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_0d81f167-9fb5-4039-a27b-a7afd2d0fcb6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_08fbda8c-998f-430c-903a-6cfee627bb4a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0574f6d7-b4c2-49eb-8d64-0937941cf599" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_08fbda8c-998f-430c-903a-6cfee627bb4a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_4e9329a6-ef2b-4284-bd14-ef61b3358d21" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_08fbda8c-998f-430c-903a-6cfee627bb4a" xlink:to="loc_srt_RangeAxis_4e9329a6-ef2b-4284-bd14-ef61b3358d21" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_4e9329a6-ef2b-4284-bd14-ef61b3358d21_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_4e9329a6-ef2b-4284-bd14-ef61b3358d21" xlink:to="loc_srt_RangeMember_4e9329a6-ef2b-4284-bd14-ef61b3358d21_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_02a14687-6b77-4bd4-bfa9-15253e795a21" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_4e9329a6-ef2b-4284-bd14-ef61b3358d21" xlink:to="loc_srt_RangeMember_02a14687-6b77-4bd4-bfa9-15253e795a21" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_f116d8f2-a457-44e4-a296-d6447b1b1edc" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_02a14687-6b77-4bd4-bfa9-15253e795a21" xlink:to="loc_srt_MinimumMember_f116d8f2-a457-44e4-a296-d6447b1b1edc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_12791a1a-d7f9-42d2-ace4-bf7952a2c739" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_02a14687-6b77-4bd4-bfa9-15253e795a21" xlink:to="loc_srt_MaximumMember_12791a1a-d7f9-42d2-ace4-bf7952a2c739" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ligand.com/role/StockholdersEquityRestrictedStockActivityDetails" xlink:type="simple" xlink:href="lgnd-20211231.xsd#StockholdersEquityRestrictedStockActivityDetails"/>
  <link:definitionLink xlink:role="http://www.ligand.com/role/StockholdersEquityRestrictedStockActivityDetails" xlink:type="extended" id="i617546093681431b9d8176e8add70726_StockholdersEquityRestrictedStockActivityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_958e7386-d292-408c-856a-e00016c7dc19" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_b95b8415-b763-4a43-a89b-49921aa5f7d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_958e7386-d292-408c-856a-e00016c7dc19" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_b95b8415-b763-4a43-a89b-49921aa5f7d8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_49799b7d-76cc-4a0f-8bd5-cbdfaffcb60c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_b95b8415-b763-4a43-a89b-49921aa5f7d8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_49799b7d-76cc-4a0f-8bd5-cbdfaffcb60c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_9e77264a-b5d9-47b9-8467-b7a9edaadfad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_b95b8415-b763-4a43-a89b-49921aa5f7d8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_9e77264a-b5d9-47b9-8467-b7a9edaadfad" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_646e9e58-1ddf-4b60-a5bf-ab7a40f7085a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_b95b8415-b763-4a43-a89b-49921aa5f7d8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_646e9e58-1ddf-4b60-a5bf-ab7a40f7085a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_790aece2-46ad-4dd6-9879-22bf9c20baa6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_b95b8415-b763-4a43-a89b-49921aa5f7d8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_790aece2-46ad-4dd6-9879-22bf9c20baa6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_f0d21073-f3dc-4810-ac03-47f14e30f9d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_70c71caa-d428-4c26-84c7-d1df964a33fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_958e7386-d292-408c-856a-e00016c7dc19" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_70c71caa-d428-4c26-84c7-d1df964a33fb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_e028bb85-3198-4f81-9d71-3db2b5c3e9ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_70c71caa-d428-4c26-84c7-d1df964a33fb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_e028bb85-3198-4f81-9d71-3db2b5c3e9ca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_06904328-2993-4eee-8a96-012ecab3e08d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_70c71caa-d428-4c26-84c7-d1df964a33fb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_06904328-2993-4eee-8a96-012ecab3e08d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_d6e340bc-770e-485e-bcf7-f47a861538aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_70c71caa-d428-4c26-84c7-d1df964a33fb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_d6e340bc-770e-485e-bcf7-f47a861538aa" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_70ed09b9-177f-49f9-8620-d4185b4b3f8b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_70c71caa-d428-4c26-84c7-d1df964a33fb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_70ed09b9-177f-49f9-8620-d4185b4b3f8b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_644aa3a4-52ad-4d20-8e0d-ca3f07157f68" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9b08cd0d-c9d6-4817-aeb4-7846c217a5e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_958e7386-d292-408c-856a-e00016c7dc19" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9b08cd0d-c9d6-4817-aeb4-7846c217a5e9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_5b70cd2f-a098-4d2d-9089-207024d90009" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9b08cd0d-c9d6-4817-aeb4-7846c217a5e9" xlink:to="loc_us-gaap_AwardTypeAxis_5b70cd2f-a098-4d2d-9089-207024d90009" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5b70cd2f-a098-4d2d-9089-207024d90009_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_5b70cd2f-a098-4d2d-9089-207024d90009" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5b70cd2f-a098-4d2d-9089-207024d90009_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d0363292-520c-462b-8509-43805194d996" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_5b70cd2f-a098-4d2d-9089-207024d90009" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d0363292-520c-462b-8509-43805194d996" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_d2f2a51f-36d9-4ff3-921e-ee9aaf03fe88" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d0363292-520c-462b-8509-43805194d996" xlink:to="loc_us-gaap_RestrictedStockMember_d2f2a51f-36d9-4ff3-921e-ee9aaf03fe88" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ligand.com/role/CommitmentandContingenciesLegalProceedingsNarrativeDetails" xlink:type="simple" xlink:href="lgnd-20211231.xsd#CommitmentandContingenciesLegalProceedingsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.ligand.com/role/CommitmentandContingenciesLegalProceedingsNarrativeDetails" xlink:type="extended" id="i55d59077cfe84c25baf43f79193ad626_CommitmentandContingenciesLegalProceedingsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainContingenciesLineItems_5c47282e-c4a0-4ff6-bb95-388484427138" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber_b95982b2-d2e9-4a91-a072-29ba9ad43a07" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GainContingenciesLineItems_5c47282e-c4a0-4ff6-bb95-388484427138" xlink:to="loc_us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber_b95982b2-d2e9-4a91-a072-29ba9ad43a07" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNewClaimsFiledNumber_0777e04b-be8a-4493-a208-19758ce833a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyNewClaimsFiledNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GainContingenciesLineItems_5c47282e-c4a0-4ff6-bb95-388484427138" xlink:to="loc_us-gaap_LossContingencyNewClaimsFiledNumber_0777e04b-be8a-4493-a208-19758ce833a8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainContingenciesTable_00d09a06-3540-49c1-98b0-668190e34583" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainContingenciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_GainContingenciesLineItems_5c47282e-c4a0-4ff6-bb95-388484427138" xlink:to="loc_us-gaap_GainContingenciesTable_00d09a06-3540-49c1-98b0-668190e34583" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_ff122ff2-8a40-4330-ad28-971832fdfdbb" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_GainContingenciesTable_00d09a06-3540-49c1-98b0-668190e34583" xlink:to="loc_srt_LitigationCaseAxis_ff122ff2-8a40-4330-ad28-971832fdfdbb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_ff122ff2-8a40-4330-ad28-971832fdfdbb_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_LitigationCaseAxis_ff122ff2-8a40-4330-ad28-971832fdfdbb" xlink:to="loc_srt_LitigationCaseTypeDomain_ff122ff2-8a40-4330-ad28-971832fdfdbb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_9b871619-0fd8-4148-b4ff-e8fa31cb16d4" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_LitigationCaseAxis_ff122ff2-8a40-4330-ad28-971832fdfdbb" xlink:to="loc_srt_LitigationCaseTypeDomain_9b871619-0fd8-4148-b4ff-e8fa31cb16d4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_LupinPatentInfringementMember_de0e751f-7a47-4fc2-a479-2ae03cc4a88f" xlink:href="lgnd-20211231.xsd#lgnd_LupinPatentInfringementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_9b871619-0fd8-4148-b4ff-e8fa31cb16d4" xlink:to="loc_lgnd_LupinPatentInfringementMember_de0e751f-7a47-4fc2-a479-2ae03cc4a88f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_USDistrictCourtForTheNorthernDistrictOfOhioMember_019cb9af-ac27-48ef-b06f-b38c8c244f08" xlink:href="lgnd-20211231.xsd#lgnd_USDistrictCourtForTheNorthernDistrictOfOhioMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_9b871619-0fd8-4148-b4ff-e8fa31cb16d4" xlink:to="loc_lgnd_USDistrictCourtForTheNorthernDistrictOfOhioMember_019cb9af-ac27-48ef-b06f-b38c8c244f08" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ligand.com/role/IncomeTaxesNarrativeDetails" xlink:type="simple" xlink:href="lgnd-20211231.xsd#IncomeTaxesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.ligand.com/role/IncomeTaxesNarrativeDetails" xlink:type="extended" id="i37e5cd2e2b914061bd6b08393982f0be_IncomeTaxesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_07ff9066-9969-45ae-a3bd-49b1f18162d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_140662a7-974a-4bf2-9404-d91cf334c146" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_07ff9066-9969-45ae-a3bd-49b1f18162d6" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_140662a7-974a-4bf2-9404-d91cf334c146" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_5d326857-30c2-4b8b-aa49-8827155b4b05" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_07ff9066-9969-45ae-a3bd-49b1f18162d6" xlink:to="loc_us-gaap_OperatingLossCarryforwards_5d326857-30c2-4b8b-aa49-8827155b4b05" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_2cf9efdb-1af5-469e-a864-6704b2bd4fd6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_07ff9066-9969-45ae-a3bd-49b1f18162d6" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_2cf9efdb-1af5-469e-a864-6704b2bd4fd6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_c8897460-0513-4741-b6de-11d364eb4501" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_07ff9066-9969-45ae-a3bd-49b1f18162d6" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_c8897460-0513-4741-b6de-11d364eb4501" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_cbd0e1f1-e84d-4912-8406-437eed1ccce3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_07ff9066-9969-45ae-a3bd-49b1f18162d6" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable_cbd0e1f1-e84d-4912-8406-437eed1ccce3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_08b3863d-a014-4827-bc08-10772bd4163d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_cbd0e1f1-e84d-4912-8406-437eed1ccce3" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_08b3863d-a014-4827-bc08-10772bd4163d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_08b3863d-a014-4827-bc08-10772bd4163d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_08b3863d-a014-4827-bc08-10772bd4163d" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_08b3863d-a014-4827-bc08-10772bd4163d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_b49427cf-2e25-4384-8eab-9277643bf96f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_08b3863d-a014-4827-bc08-10772bd4163d" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_b49427cf-2e25-4384-8eab-9277643bf96f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InternalRevenueServiceIRSMember_ed571ef0-d127-4be9-a404-2db8a0c13cb7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InternalRevenueServiceIRSMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_b49427cf-2e25-4384-8eab-9277643bf96f" xlink:to="loc_us-gaap_InternalRevenueServiceIRSMember_ed571ef0-d127-4be9-a404-2db8a0c13cb7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_17cee323-4af2-4e52-a94c-ed7c03c4516d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_b49427cf-2e25-4384-8eab-9277643bf96f" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_17cee323-4af2-4e52-a94c-ed7c03c4516d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCountryMember_131244c7-6451-48ee-b94d-387c4cbc9d20" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCountryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_b49427cf-2e25-4384-8eab-9277643bf96f" xlink:to="loc_us-gaap_ForeignCountryMember_131244c7-6451-48ee-b94d-387c4cbc9d20" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis_79e6c013-9254-4884-904a-a69b70aaec3c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_cbd0e1f1-e84d-4912-8406-437eed1ccce3" xlink:to="loc_us-gaap_TaxCreditCarryforwardAxis_79e6c013-9254-4884-904a-a69b70aaec3c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_79e6c013-9254-4884-904a-a69b70aaec3c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_79e6c013-9254-4884-904a-a69b70aaec3c" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_79e6c013-9254-4884-904a-a69b70aaec3c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_fd421cf5-7d8c-446d-941d-a3341accc2af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_79e6c013-9254-4884-904a-a69b70aaec3c" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_fd421cf5-7d8c-446d-941d-a3341accc2af" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchMember_84e805d9-81e4-4950-86fb-cd28711394cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_fd421cf5-7d8c-446d-941d-a3341accc2af" xlink:to="loc_us-gaap_ResearchMember_84e805d9-81e4-4950-86fb-cd28711394cf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_CaliforniaAndNewJerseyResearchTaxCreditCarryforwardMember_1b762e8a-8da9-42a6-ae9b-9e5c2e08db39" xlink:href="lgnd-20211231.xsd#lgnd_CaliforniaAndNewJerseyResearchTaxCreditCarryforwardMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_fd421cf5-7d8c-446d-941d-a3341accc2af" xlink:to="loc_lgnd_CaliforniaAndNewJerseyResearchTaxCreditCarryforwardMember_1b762e8a-8da9-42a6-ae9b-9e5c2e08db39" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalLossCarryforwardMember_259fb65f-6dc8-4d75-96a1-5e1df9d7da98" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalLossCarryforwardMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_fd421cf5-7d8c-446d-941d-a3341accc2af" xlink:to="loc_us-gaap_CapitalLossCarryforwardMember_259fb65f-6dc8-4d75-96a1-5e1df9d7da98" xlink:type="arc" order="2"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>12
<FILENAME>lgnd-20211231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:d46a5cfc-72eb-4b3a-bd09-c8907e0f4c5d,g:058bd086-7924-4675-b3eb-d4a9ba4991e0-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_59098bb5-7749-497f-8697-7ae04a671647_verboseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental disclosure of cash flow information</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_497ef40a-4965-4a7d-95c9-bf8d58e5d60d_terseLabel_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_label_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NameOfMajorCustomerDomain" xlink:to="lab_srt_NameOfMajorCustomerDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_03b4c769-75dc-4f64-a42e-113583657b71_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current State and Local Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_97532c92-e341-44bb-8257-4ed7923cd92a_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_ExercisePriceRangeTenMember_2e5eb03f-4938-4421-82c5-b85264118884_terseLabel_en-US" xlink:label="lab_lgnd_ExercisePriceRangeTenMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">$177.50-$195.91</link:label>
    <link:label id="lab_lgnd_ExercisePriceRangeTenMember_label_en-US" xlink:label="lab_lgnd_ExercisePriceRangeTenMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range Ten [Member]</link:label>
    <link:label id="lab_lgnd_ExercisePriceRangeTenMember_documentation_en-US" xlink:label="lab_lgnd_ExercisePriceRangeTenMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range Ten [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ExercisePriceRangeTenMember" xlink:href="lgnd-20211231.xsd#lgnd_ExercisePriceRangeTenMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_ExercisePriceRangeTenMember" xlink:to="lab_lgnd_ExercisePriceRangeTenMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_f321c18f-0233-4bd0-8e0f-c3440a920c3c_verboseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember" xlink:to="lab_us-gaap_LeaseholdImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_b23e5454-61e5-4c18-947f-406d27616057_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit), Continuing Operations, Income Tax Reconciliation [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Amount [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic_f64a9912-380e-457a-9389-022cbeb4b7da_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic (USD per share)</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Pro Forma Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic" xlink:to="lab_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_2dddf622-3894-4e19-9aaa-67de8907094d_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock outstanding (shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts_5255fa74-5919-458d-b708-c0ba13704107_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition-related costs</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Acquisition Related Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:to="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod_77e30fb5-4b85-4bd8-b44e-1d4e468772d1_periodStartLabel_en-US" xlink:label="lab_lgnd_BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial rights at beginning of period</link:label>
    <link:label id="lab_lgnd_BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod_7a0c9183-4500-4be2-99f4-9d4bf7c66282_periodEndLabel_en-US" xlink:label="lab_lgnd_BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial rights at end of period</link:label>
    <link:label id="lab_lgnd_BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod_label_en-US" xlink:label="lab_lgnd_BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition Contingent Consideration Potential Cash Payment at End of Period</link:label>
    <link:label id="lab_lgnd_BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod_documentation_en-US" xlink:label="lab_lgnd_BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition Contingent Consideration Potential Cash Payment at End of Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod" xlink:href="lgnd-20211231.xsd#lgnd_BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod" xlink:to="lab_lgnd_BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLiabilities_0fb95aea-0def-432c-b7e6-4d34484d0792_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative liability</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilities_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilities" xlink:to="lab_us-gaap_DerivativeLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_ContractualRelationshipsAlvogenMember_b47eac94-21df-4338-a749-83027dbe2dd7_terseLabel_en-US" xlink:label="lab_lgnd_ContractualRelationshipsAlvogenMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual Relationships - Alvogen</link:label>
    <link:label id="lab_lgnd_ContractualRelationshipsAlvogenMember_label_en-US" xlink:label="lab_lgnd_ContractualRelationshipsAlvogenMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual Relationships - Alvogen [Member]</link:label>
    <link:label id="lab_lgnd_ContractualRelationshipsAlvogenMember_documentation_en-US" xlink:label="lab_lgnd_ContractualRelationshipsAlvogenMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual Relationships - Alvogen</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ContractualRelationshipsAlvogenMember" xlink:href="lgnd-20211231.xsd#lgnd_ContractualRelationshipsAlvogenMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_ContractualRelationshipsAlvogenMember" xlink:to="lab_lgnd_ContractualRelationshipsAlvogenMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_cddf3862-805a-4794-a436-3b8f01e5d479_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNi_09625452-58fa-4333-ae56-b3adeee77c09_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment in Viking common stock</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNi_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNi" xlink:to="lab_us-gaap_EquitySecuritiesFvNi" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_51137f91-36b8-4244-b152-d66f9d3e00d3_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt conversion price per share (USD per share)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Conversion Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:to="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_PromactaMember_10be0430-f87e-4256-b7c3-b5ca41941d54_terseLabel_en-US" xlink:label="lab_lgnd_PromactaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Promacta</link:label>
    <link:label id="lab_lgnd_PromactaMember_label_en-US" xlink:label="lab_lgnd_PromactaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Promacta [Member]</link:label>
    <link:label id="lab_lgnd_PromactaMember_documentation_en-US" xlink:label="lab_lgnd_PromactaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Promacta</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PromactaMember" xlink:href="lgnd-20211231.xsd#lgnd_PromactaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_PromactaMember" xlink:to="lab_lgnd_PromactaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_e1618f5b-fd30-423c-99e3-b43e383a5791_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_93bf4992-37a2-4f01-82b2-ea147d7948b6_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_ce99010b-d271-4e15-9831-1cc349c13ce1_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average remaining lease term of operating leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_NovanMolluscumProductsMember_fba854f3-e18a-4f38-a7e2-f8e70536eef5_terseLabel_en-US" xlink:label="lab_lgnd_NovanMolluscumProductsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Novan</link:label>
    <link:label id="lab_lgnd_NovanMolluscumProductsMember_label_en-US" xlink:label="lab_lgnd_NovanMolluscumProductsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Novan Molluscum Products [Member]</link:label>
    <link:label id="lab_lgnd_NovanMolluscumProductsMember_documentation_en-US" xlink:label="lab_lgnd_NovanMolluscumProductsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Novan Molluscum Products</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_NovanMolluscumProductsMember" xlink:href="lgnd-20211231.xsd#lgnd_NovanMolluscumProductsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_NovanMolluscumProductsMember" xlink:to="lab_lgnd_NovanMolluscumProductsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_1249dac4-4667-4f3b-9aae-ae98b2dc1003_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Translation</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Transactions and Translations Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c02f3009-9b00-4b27-afb0-b7cd8df01714_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativesPolicyTextBlock_321c3794-d652-4562-93ee-e344cfa19431_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives</link:label>
    <link:label id="lab_us-gaap_DerivativesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_DerivativesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativesPolicyTextBlock" xlink:to="lab_us-gaap_DerivativesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_PaymentsToAcquireBusinessesGrossAttributableToVestedPortionOfStockOptions_c3114fd0-1604-4410-835b-f175ed07d43b_terseLabel_en-US" xlink:label="lab_lgnd_PaymentsToAcquireBusinessesGrossAttributableToVestedPortionOfStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross payments to acquire business attributable to vested portion of stock options</link:label>
    <link:label id="lab_lgnd_PaymentsToAcquireBusinessesGrossAttributableToVestedPortionOfStockOptions_label_en-US" xlink:label="lab_lgnd_PaymentsToAcquireBusinessesGrossAttributableToVestedPortionOfStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Businesses, Gross, Attributable to Vested Portion of Stock Options</link:label>
    <link:label id="lab_lgnd_PaymentsToAcquireBusinessesGrossAttributableToVestedPortionOfStockOptions_documentation_en-US" xlink:label="lab_lgnd_PaymentsToAcquireBusinessesGrossAttributableToVestedPortionOfStockOptions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Businesses, Gross, Attributable to Vested Portion of Stock Options</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PaymentsToAcquireBusinessesGrossAttributableToVestedPortionOfStockOptions" xlink:href="lgnd-20211231.xsd#lgnd_PaymentsToAcquireBusinessesGrossAttributableToVestedPortionOfStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_PaymentsToAcquireBusinessesGrossAttributableToVestedPortionOfStockOptions" xlink:to="lab_lgnd_PaymentsToAcquireBusinessesGrossAttributableToVestedPortionOfStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_EffectiveIncomeTaxRateReconciliationExpiredTaxCreditsResearch_6bf2b5bc-4894-4547-b655-d6b5e1dabf78_terseLabel_en-US" xlink:label="lab_lgnd_EffectiveIncomeTaxRateReconciliationExpiredTaxCreditsResearch" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development credits</link:label>
    <link:label id="lab_lgnd_EffectiveIncomeTaxRateReconciliationExpiredTaxCreditsResearch_label_en-US" xlink:label="lab_lgnd_EffectiveIncomeTaxRateReconciliationExpiredTaxCreditsResearch" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Expired Tax Credits, Research</link:label>
    <link:label id="lab_lgnd_EffectiveIncomeTaxRateReconciliationExpiredTaxCreditsResearch_documentation_en-US" xlink:label="lab_lgnd_EffectiveIncomeTaxRateReconciliationExpiredTaxCreditsResearch" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Expired Tax Credits, Research</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_EffectiveIncomeTaxRateReconciliationExpiredTaxCreditsResearch" xlink:href="lgnd-20211231.xsd#lgnd_EffectiveIncomeTaxRateReconciliationExpiredTaxCreditsResearch"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_EffectiveIncomeTaxRateReconciliationExpiredTaxCreditsResearch" xlink:to="lab_lgnd_EffectiveIncomeTaxRateReconciliationExpiredTaxCreditsResearch" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_133a5dbb-aebc-491d-aac6-0a1b925d56e5_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares available for future option grants (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dd10fcc7-a665-43d8-b9b0-77af32ca60bb_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected volatility (as a percent)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_961801ce-c920-495d-b33f-30d18c19870b_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_84c0ba26-389f-4b43-a58b-a12046153b5e_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intrinsic value of options exercised</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_c90d69ea-7aef-4dcd-a101-e8e25616debd_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value adjustments to contingent liabilities</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_b8722100-ebff-4a54-b666-2312b3eb348f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lower range of exercise prices (USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Exercise Price Range, Lower Range Limit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_AdditionalRoyaltiesReceivableUnderSalesbasedMilestones_0b9435d1-f7c9-4a95-b236-5a80539ecefb_terseLabel_en-US" xlink:label="lab_lgnd_AdditionalRoyaltiesReceivableUnderSalesbasedMilestones" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional royalties receivable under sales-based milestones</link:label>
    <link:label id="lab_lgnd_AdditionalRoyaltiesReceivableUnderSalesbasedMilestones_label_en-US" xlink:label="lab_lgnd_AdditionalRoyaltiesReceivableUnderSalesbasedMilestones" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Royalties Receivable Under Sales-based Milestones</link:label>
    <link:label id="lab_lgnd_AdditionalRoyaltiesReceivableUnderSalesbasedMilestones_documentation_en-US" xlink:label="lab_lgnd_AdditionalRoyaltiesReceivableUnderSalesbasedMilestones" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Royalties Receivable Under Sales-based Milestones</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AdditionalRoyaltiesReceivableUnderSalesbasedMilestones" xlink:href="lgnd-20211231.xsd#lgnd_AdditionalRoyaltiesReceivableUnderSalesbasedMilestones"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_AdditionalRoyaltiesReceivableUnderSalesbasedMilestones" xlink:to="lab_lgnd_AdditionalRoyaltiesReceivableUnderSalesbasedMilestones" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_aa1c461c-8d87-4fff-958c-e6e45fe355d4_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_6643bdfb-dc18-4c2b-88f7-5f01682d0169_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_4d71be2f-52b8-4b6d-9104-691eb77f7ec4_negatedLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liabilities, net</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_c6c066b1-71c0-4880-992e-c3396cbe3038_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liabilities, net</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_BusinessCombinationContingentConsiderationLiabilityPercentageOfAcquireeRevenues_a7c11d72-61dc-4e23-b596-59e6c97019df_terseLabel_en-US" xlink:label="lab_lgnd_BusinessCombinationContingentConsiderationLiabilityPercentageOfAcquireeRevenues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proportion of milestone payments (as a percent)</link:label>
    <link:label id="lab_lgnd_BusinessCombinationContingentConsiderationLiabilityPercentageOfAcquireeRevenues_label_en-US" xlink:label="lab_lgnd_BusinessCombinationContingentConsiderationLiabilityPercentageOfAcquireeRevenues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Percentage of Acquiree Revenues</link:label>
    <link:label id="lab_lgnd_BusinessCombinationContingentConsiderationLiabilityPercentageOfAcquireeRevenues_documentation_en-US" xlink:label="lab_lgnd_BusinessCombinationContingentConsiderationLiabilityPercentageOfAcquireeRevenues" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Percentage of Acquiree Revenues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BusinessCombinationContingentConsiderationLiabilityPercentageOfAcquireeRevenues" xlink:href="lgnd-20211231.xsd#lgnd_BusinessCombinationContingentConsiderationLiabilityPercentageOfAcquireeRevenues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_BusinessCombinationContingentConsiderationLiabilityPercentageOfAcquireeRevenues" xlink:to="lab_lgnd_BusinessCombinationContingentConsiderationLiabilityPercentageOfAcquireeRevenues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_0a6f5262-b85f-42a8-b983-4959760f42d6_verboseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization expense</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_e6a6549a-252e-4e99-b33e-2004391a9710_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Approximate Fair Value</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_ff73a80f-b5c0-4711-99e1-66ddd57490a2_terseLabel_en-US" xlink:label="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average useful lives of acquired finite-lived intangible assets</link:label>
    <link:label id="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_d1d65b6a-ec75-4f7a-aff7-bb7620a6fa9f_verboseLabel_en-US" xlink:label="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated useful life (in years)</link:label>
    <link:label id="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_label_en-US" xlink:label="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired Finite-lived Intangible Assets, Weighted Average Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:to="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_f62c7ab5-6422-45e3-82e8-4f40d5840651_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock repurchase program, remaining authorized repurchase amount</link:label>
    <link:label id="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_label_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchase Program, Remaining Authorized Repurchase Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:to="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_de7914d8-fdc3-4641-a7c2-ed1b71dfbf17_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions for tax positions of prior years</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_2d6e037f-c579-4b31-bf63-a7bb95846aed_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average discount rate of operating leases (as a percent)</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_51564947-c9a6-4c52-b6f0-bdfd07b5eb26_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potentially dilutive shares excluded from calculation due to anti-dilutive effect (shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_341259cc-47f4-4183-91c7-45192ccf5b4e_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue recognized</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Revenue Recognized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_475405d0-d5f1-4572-b185-ff904eb6861c_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development expenses</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_b4b697fa-907c-42b3-ac82-11c43490efc6_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNet" xlink:to="lab_us-gaap_DeferredTaxAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination and Asset Acquisition [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:to="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_f0776dd0-39b2-4666-99ef-d30f451231b4_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis" xlink:to="lab_us-gaap_BusinessAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b5ccb52e-98ea-48ad-b4a9-205c6c61c9d3_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_314ca2d1-2458-4446-8b95-bee678e4ae03_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_ScheduleofContingentLiabilitiesTableTextBlock_3231342c-586d-496b-834d-aaea4097e493_terseLabel_en-US" xlink:label="lab_lgnd_ScheduleofContingentLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Contingent Liabilities</link:label>
    <link:label id="lab_lgnd_ScheduleofContingentLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_lgnd_ScheduleofContingentLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Contingent Liabilities [Table Text Block]</link:label>
    <link:label id="lab_lgnd_ScheduleofContingentLiabilitiesTableTextBlock_documentation_en-US" xlink:label="lab_lgnd_ScheduleofContingentLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Contingent Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ScheduleofContingentLiabilitiesTableTextBlock" xlink:href="lgnd-20211231.xsd#lgnd_ScheduleofContingentLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_ScheduleofContingentLiabilitiesTableTextBlock" xlink:to="lab_lgnd_ScheduleofContingentLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_0a4e5aff-0542-4fd4-8fa7-774cca90e6e6_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsLineItems_0f4f3fc6-803a-4db1-9203-41760f3198fe_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards [Line Items]</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsLineItems_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="lab_us-gaap_OperatingLossCarryforwardsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_da5ab060-e90f-45bc-85dd-0ab3f2f0f634_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable at end of period (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInvestmentsLineItems_8a6d1d66-e2ed-4a89-8c3a-1dbc8ddcc3d8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInvestmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Investments [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInvestmentsLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInvestmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Investments [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfInvestmentsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems" xlink:to="lab_us-gaap_ScheduleOfInvestmentsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_ExercisePriceRangeEightMember_2e465d09-e582-4f46-892d-ab5abf690748_terseLabel_en-US" xlink:label="lab_lgnd_ExercisePriceRangeEightMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">$119.08-$159.01</link:label>
    <link:label id="lab_lgnd_ExercisePriceRangeEightMember_label_en-US" xlink:label="lab_lgnd_ExercisePriceRangeEightMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range Eight [Member]</link:label>
    <link:label id="lab_lgnd_ExercisePriceRangeEightMember_documentation_en-US" xlink:label="lab_lgnd_ExercisePriceRangeEightMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range Eight [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ExercisePriceRangeEightMember" xlink:href="lgnd-20211231.xsd#lgnd_ExercisePriceRangeEightMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_ExercisePriceRangeEightMember" xlink:to="lab_lgnd_ExercisePriceRangeEightMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_3d3502ea-3eb1-452f-8100-0c4a8b599b7f_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, $0.001 par value; 5,000 shares authorized; zero issued and outstanding at December 31, 2021 and 2020</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_13b3e33b-a80e-444e-a893-cc65152caba0_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of consecutive trading days</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Threshold Consecutive Trading Days</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:to="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_fa812ff9-7c57-4e63-bd84-b663353d56e4_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_676e7f81-c3aa-468b-ae46-b6c89460ce35_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retain earnings (accumulated deficit)</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_ExercisePriceRangeTwoMember_021382a4-862e-4891-8eeb-94c29eb1f2af_terseLabel_en-US" xlink:label="lab_lgnd_ExercisePriceRangeTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">$67.53-$74.42</link:label>
    <link:label id="lab_lgnd_ExercisePriceRangeTwoMember_label_en-US" xlink:label="lab_lgnd_ExercisePriceRangeTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range Two [Member]</link:label>
    <link:label id="lab_lgnd_ExercisePriceRangeTwoMember_documentation_en-US" xlink:label="lab_lgnd_ExercisePriceRangeTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range Two [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ExercisePriceRangeTwoMember" xlink:href="lgnd-20211231.xsd#lgnd_ExercisePriceRangeTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_ExercisePriceRangeTwoMember" xlink:to="lab_lgnd_ExercisePriceRangeTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_PartnerBMember_6677db29-ad54-426a-acc7-3b85bdebefec_terseLabel_en-US" xlink:label="lab_lgnd_PartnerBMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Partner B</link:label>
    <link:label id="lab_lgnd_PartnerBMember_label_en-US" xlink:label="lab_lgnd_PartnerBMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Partner B [Member]</link:label>
    <link:label id="lab_lgnd_PartnerBMember_documentation_en-US" xlink:label="lab_lgnd_PartnerBMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Partner B [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PartnerBMember" xlink:href="lgnd-20211231.xsd#lgnd_PartnerBMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_PartnerBMember" xlink:to="lab_lgnd_PartnerBMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_959961ce-afbb-40b0-ac50-c786c9a5fcdf_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available-for-Sale Debt Securities in an Unrealized Loss Position</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Unrealized Loss Position, Fair Value [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_20f831a6-4a98-4ab7-a206-9761f4b77e62_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_1c90cdf8-a155-4e42-a991-7fab094e1bfe_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of fixed assets recorded in accounts payable</link:label>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_label_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_5325f9c3-7a11-4859-a5a2-ccf07c896993_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther_95f47eb7-41ab-4bad-b5c4-4789e81c26d1_negatedLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other liabilities</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_cda5fcc9-79cf-4ecf-a994-b32be6c228f1_terseLabel_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-Known Seasoned Issuer</link:label>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_label_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions_9c372b57-0926-4fc1-ac34-9ccfec37daa8_negatedTerseLabel_en-US" xlink:label="lab_lgnd_EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in uncertain tax positions</link:label>
    <link:label id="lab_lgnd_EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions_label_en-US" xlink:label="lab_lgnd_EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Uncertain Tax Positions</link:label>
    <link:label id="lab_lgnd_EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions_documentation_en-US" xlink:label="lab_lgnd_EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Uncertain Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions" xlink:href="lgnd-20211231.xsd#lgnd_EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions" xlink:to="lab_lgnd_EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeasePrincipalPayments_7e94cd75-8787-4d84-a08b-cd02d05db56f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments under finance lease obligations</link:label>
    <link:label id="lab_us-gaap_FinanceLeasePrincipalPayments_label_en-US" xlink:label="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Principal Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeasePrincipalPayments" xlink:to="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue_8774524c-2a2a-42c7-85e2-99b53fa9300c_negatedLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue_2c1699c3-d576-428f-84b5-c9a05a1eba5a_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Deferred Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_0a047dc9-edfe-4900-b967-1cbc753b2491_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic net income (loss) per share (USD per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseExpense_8e0bc6b9-7d0e-4500-8f7a-89ecb7b37762_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease expense</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseExpense_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseExpense" xlink:to="lab_us-gaap_OperatingLeaseExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubleaseIncome_6dd86bc5-5a3f-4906-af29-54e90dc2fc38_terseLabel_en-US" xlink:label="lab_us-gaap_SubleaseIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sublease income</link:label>
    <link:label id="lab_us-gaap_SubleaseIncome_label_en-US" xlink:label="lab_us-gaap_SubleaseIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sublease Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubleaseIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubleaseIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubleaseIncome" xlink:to="lab_us-gaap_SubleaseIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_59fc0265-cceb-4ad2-8abf-87aa46c0e365_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at beginning of period (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_be241392-0b4d-4add-a9c8-283207565297_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at end of period (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_0da87a58-b230-4f4e-a8e6-9789377938d3_periodStartLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of level 3 financial instruments at beginning of period</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_d1cfee0a-8dcc-453b-bac9-cb0bf2ad358b_periodEndLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of level 3 financial instruments at end of period</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_d39fe657-7bce-4a91-a752-0e0193ad4b1f_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">After one year through five years</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year One Through Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_LiabilityForContingentValueRightsCompanyIcagenMember_5a6fc03b-8ab8-45ce-944a-6a9fa51c9c3c_terseLabel_en-US" xlink:label="lab_lgnd_LiabilityForContingentValueRightsCompanyIcagenMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent liabilities - Icagen</link:label>
    <link:label id="lab_lgnd_LiabilityForContingentValueRightsCompanyIcagenMember_label_en-US" xlink:label="lab_lgnd_LiabilityForContingentValueRightsCompanyIcagenMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability For Contingent Value Rights Company, Icagen [Member]</link:label>
    <link:label id="lab_lgnd_LiabilityForContingentValueRightsCompanyIcagenMember_documentation_en-US" xlink:label="lab_lgnd_LiabilityForContingentValueRightsCompanyIcagenMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability For Contingent Value Rights Company, Icagen</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_LiabilityForContingentValueRightsCompanyIcagenMember" xlink:href="lgnd-20211231.xsd#lgnd_LiabilityForContingentValueRightsCompanyIcagenMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_LiabilityForContingentValueRightsCompanyIcagenMember" xlink:to="lab_lgnd_LiabilityForContingentValueRightsCompanyIcagenMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainContingenciesLineItems_bc194a9e-5b02-4a33-8ae5-8d12b19cbeb4_terseLabel_en-US" xlink:label="lab_us-gaap_GainContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain Contingencies [Line Items]</link:label>
    <link:label id="lab_us-gaap_GainContingenciesLineItems_label_en-US" xlink:label="lab_us-gaap_GainContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain Contingencies [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainContingenciesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainContingenciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainContingenciesLineItems" xlink:to="lab_us-gaap_GainContingenciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_7fcc901a-9d66-447f-934e-fad7493489b1_terseLabel_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption, Adjustment</link:label>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_label_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption, Adjustment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:to="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInvestmentsTable_a2e2ed71-26b0-459a-b4cf-13427772644e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInvestmentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Investments [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInvestmentsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInvestmentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Investments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfInvestmentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInvestmentsTable" xlink:to="lab_us-gaap_ScheduleOfInvestmentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommercialPaperMember_d749494c-6d2a-48ab-a7ad-9e45636f0e9d_terseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial paper</link:label>
    <link:label id="lab_us-gaap_CommercialPaperMember_label_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Paper [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaperMember" xlink:to="lab_us-gaap_CommercialPaperMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilities_b39ba25d-aabd-4ca1-ac2d-42c20237afaf_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income taxes, net</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilities" xlink:to="lab_us-gaap_DeferredTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_VestingPeriodOneMember_e69b3a86-b53d-4305-9910-7521f31467f2_terseLabel_en-US" xlink:label="lab_lgnd_VestingPeriodOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vest 1/8 on the six month anniversary of the date of grant</link:label>
    <link:label id="lab_lgnd_VestingPeriodOneMember_label_en-US" xlink:label="lab_lgnd_VestingPeriodOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting Period One [Member]</link:label>
    <link:label id="lab_lgnd_VestingPeriodOneMember_documentation_en-US" xlink:label="lab_lgnd_VestingPeriodOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting Period One [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_VestingPeriodOneMember" xlink:href="lgnd-20211231.xsd#lgnd_VestingPeriodOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_VestingPeriodOneMember" xlink:to="lab_lgnd_VestingPeriodOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal_12b9c174-942c-468f-b207-0dceb18374df_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">If-converted value in excess of principal</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, If-converted Value in Excess of Principal</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal" xlink:to="lab_us-gaap_DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssets_9d6c9302-2b74-4bc0-b59e-efa36f7e2685_terseLabel_en-US" xlink:label="lab_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use asset</link:label>
    <link:label id="lab_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssets_label_en-US" xlink:label="lab_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Right-of-Use Assets</link:label>
    <link:label id="lab_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssets_documentation_en-US" xlink:label="lab_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Right-of-Use Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssets" xlink:href="lgnd-20211231.xsd#lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssets" xlink:to="lab_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_7a601bdb-a974-440d-99a5-f4e915bdef88_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Groups, Including Discontinued Operations [Table]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Groups, Including Discontinued Operations [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_FinanceLeaseLiabilityTenantImprovementAllowance_e816e379-b81c-4ff7-b62e-b35798a373b1_negatedTerseLabel_en-US" xlink:label="lab_lgnd_FinanceLeaseLiabilityTenantImprovementAllowance" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less tenant improvement allowance</link:label>
    <link:label id="lab_lgnd_FinanceLeaseLiabilityTenantImprovementAllowance_label_en-US" xlink:label="lab_lgnd_FinanceLeaseLiabilityTenantImprovementAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Tenant Improvement Allowance</link:label>
    <link:label id="lab_lgnd_FinanceLeaseLiabilityTenantImprovementAllowance_documentation_en-US" xlink:label="lab_lgnd_FinanceLeaseLiabilityTenantImprovementAllowance" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Tenant Improvement Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_FinanceLeaseLiabilityTenantImprovementAllowance" xlink:href="lgnd-20211231.xsd#lgnd_FinanceLeaseLiabilityTenantImprovementAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_FinanceLeaseLiabilityTenantImprovementAllowance" xlink:to="lab_lgnd_FinanceLeaseLiabilityTenantImprovementAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_ExercisePriceRangeSixMember_b77543a8-e329-40ef-a857-9a2939149c89_terseLabel_en-US" xlink:label="lab_lgnd_ExercisePriceRangeSixMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">$101.07-$117.58</link:label>
    <link:label id="lab_lgnd_ExercisePriceRangeSixMember_label_en-US" xlink:label="lab_lgnd_ExercisePriceRangeSixMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range Six [Member]</link:label>
    <link:label id="lab_lgnd_ExercisePriceRangeSixMember_documentation_en-US" xlink:label="lab_lgnd_ExercisePriceRangeSixMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range Six [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ExercisePriceRangeSixMember" xlink:href="lgnd-20211231.xsd#lgnd_ExercisePriceRangeSixMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_ExercisePriceRangeSixMember" xlink:to="lab_lgnd_ExercisePriceRangeSixMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_20e5c587-7611-4a02-b232-c9639748c45d_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redemption Period Two</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period Two [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_SelexisAndDianomiMember_ea78ac1c-c499-4b10-b276-54ca208085d5_terseLabel_en-US" xlink:label="lab_lgnd_SelexisAndDianomiMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selexis and Dianomi</link:label>
    <link:label id="lab_lgnd_SelexisAndDianomiMember_label_en-US" xlink:label="lab_lgnd_SelexisAndDianomiMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selexis and Dianomi [Member]</link:label>
    <link:label id="lab_lgnd_SelexisAndDianomiMember_documentation_en-US" xlink:label="lab_lgnd_SelexisAndDianomiMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selexis and Dianomi</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_SelexisAndDianomiMember" xlink:href="lgnd-20211231.xsd#lgnd_SelexisAndDianomiMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_SelexisAndDianomiMember" xlink:to="lab_lgnd_SelexisAndDianomiMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityVoluntaryFilers_b0e2c794-2517-4383-8346-126191468367_terseLabel_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:label id="lab_dei_EntityVoluntaryFilers_label_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers" xlink:to="lab_dei_EntityVoluntaryFilers" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_bcd507cd-12f1-4c4d-b5a7-3e1ebda77a23_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_1e7b4ed7-6911-4c94-98ef-4a846e0ea6f0_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quoted Prices in Active Markets for Identical Assets (Level 1)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_02dce89d-0e2a-47b6-995c-77082ca1d841_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_59eef456-389d-46aa-be6e-a4e1c1d06a3c_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State, net of federal benefit</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:to="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_29580603-1587-4f56-be76-26fc873ed82d_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_1f7d630a-238b-4361-bc29-66665e90a641_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payment, Due [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_fbf752f3-86ba-4706-a13d-c5d83180174d_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions based on tax positions related to the current year</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_5cfa67f4-e282-47d3-9c75-0daddf117f22_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_DeferredTaxLiabilitiesFiniteLivedIntangibleAssets_f6157e5f-6166-4e75-8a7a-0e8cc570942f_negatedTerseLabel_en-US" xlink:label="lab_lgnd_DeferredTaxLiabilitiesFiniteLivedIntangibleAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Identified intangibles</link:label>
    <link:label id="lab_lgnd_DeferredTaxLiabilitiesFiniteLivedIntangibleAssets_label_en-US" xlink:label="lab_lgnd_DeferredTaxLiabilitiesFiniteLivedIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Finite-Lived Intangible Assets</link:label>
    <link:label id="lab_lgnd_DeferredTaxLiabilitiesFiniteLivedIntangibleAssets_documentation_en-US" xlink:label="lab_lgnd_DeferredTaxLiabilitiesFiniteLivedIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Finite-Lived Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_DeferredTaxLiabilitiesFiniteLivedIntangibleAssets" xlink:href="lgnd-20211231.xsd#lgnd_DeferredTaxLiabilitiesFiniteLivedIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_DeferredTaxLiabilitiesFiniteLivedIntangibleAssets" xlink:to="lab_lgnd_DeferredTaxLiabilitiesFiniteLivedIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_ComputerEquipmentAndSoftwareMember_52173e7f-9933-4b98-9d9c-c12810a78aec_verboseLabel_en-US" xlink:label="lab_lgnd_ComputerEquipmentAndSoftwareMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer equipment and software</link:label>
    <link:label id="lab_lgnd_ComputerEquipmentAndSoftwareMember_label_en-US" xlink:label="lab_lgnd_ComputerEquipmentAndSoftwareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer Equipment And Software [Member]</link:label>
    <link:label id="lab_lgnd_ComputerEquipmentAndSoftwareMember_documentation_en-US" xlink:label="lab_lgnd_ComputerEquipmentAndSoftwareMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer equipment and software.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ComputerEquipmentAndSoftwareMember" xlink:href="lgnd-20211231.xsd#lgnd_ComputerEquipmentAndSoftwareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_ComputerEquipmentAndSoftwareMember" xlink:to="lab_lgnd_ComputerEquipmentAndSoftwareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_d3c9e51b-dd25-46cf-a7b3-54a763ca8c64_verboseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_3ad19fca-6827-4d23-925d-14dea84ecd9b_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_f05c6eaa-0e28-4310-b05a-d74ec516c799_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized tax benefits that would impact effective tax rate</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits that Would Impact Effective Tax Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_ProceedsFromCommercialLicenseRights_1596c07d-84ab-443e-a73f-e667a5f78d81_terseLabel_en-US" xlink:label="lab_lgnd_ProceedsFromCommercialLicenseRights" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from commercial license rights</link:label>
    <link:label id="lab_lgnd_ProceedsFromCommercialLicenseRights_label_en-US" xlink:label="lab_lgnd_ProceedsFromCommercialLicenseRights" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Commercial License Rights</link:label>
    <link:label id="lab_lgnd_ProceedsFromCommercialLicenseRights_documentation_en-US" xlink:label="lab_lgnd_ProceedsFromCommercialLicenseRights" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Commercial License Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ProceedsFromCommercialLicenseRights" xlink:href="lgnd-20211231.xsd#lgnd_ProceedsFromCommercialLicenseRights"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_ProceedsFromCommercialLicenseRights" xlink:to="lab_lgnd_ProceedsFromCommercialLicenseRights" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_4dab73c4-5a52-464a-bd02-685c27f500cf_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards_9ffe5482-b12f-451b-ab23-0154aca26d15_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash to settle unvested stock options recognized as share-based compensation expense</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Cash Used to Settle Award</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_f3c9beaf-11db-4744-8abc-1d30082f5f36_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated amortization expense for 2025</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomeAmount_991d6e99-a1b5-471b-9561-d917ca2e1e3f_negatedLabel_en-US" xlink:label="lab_lgnd_EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomeAmount" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">FDII</link:label>
    <link:label id="lab_lgnd_EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomeAmount_label_en-US" xlink:label="lab_lgnd_EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomeAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Foreign Derived Intangible Income, Amount</link:label>
    <link:label id="lab_lgnd_EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomeAmount_documentation_en-US" xlink:label="lab_lgnd_EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomeAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Foreign Derived Intangible Income, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomeAmount" xlink:href="lgnd-20211231.xsd#lgnd_EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomeAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomeAmount" xlink:to="lab_lgnd_EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomeAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxesReceivable_dc5c2de8-7db8-4cdf-9aba-43f0967e490e_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income taxes receivable</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesReceivable_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes Receivable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxesReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesReceivable" xlink:to="lab_us-gaap_IncomeTaxesReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_5490db20-c247-4937-8f35-b09ee32de1d4_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reduction in contingent liability</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1_058e09e4-adc3-4034-b469-1c002a5dda97_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible debt conversion ratio</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Conversion Ratio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:to="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_FiniteLivedIntangibleAssetsAccumulatedAmortizationResearchDevelopmentExpenseAndCreditLossAdjustments_2021833c-159f-45b2-b5ea-71a3e2bade7f_negatedLabel_en-US" xlink:label="lab_lgnd_FiniteLivedIntangibleAssetsAccumulatedAmortizationResearchDevelopmentExpenseAndCreditLossAdjustments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments</link:label>
    <link:label id="lab_lgnd_FiniteLivedIntangibleAssetsAccumulatedAmortizationResearchDevelopmentExpenseAndCreditLossAdjustments_label_en-US" xlink:label="lab_lgnd_FiniteLivedIntangibleAssetsAccumulatedAmortizationResearchDevelopmentExpenseAndCreditLossAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization, Research &amp; Development Expense, and Credit Loss Adjustments</link:label>
    <link:label id="lab_lgnd_FiniteLivedIntangibleAssetsAccumulatedAmortizationResearchDevelopmentExpenseAndCreditLossAdjustments_documentation_en-US" xlink:label="lab_lgnd_FiniteLivedIntangibleAssetsAccumulatedAmortizationResearchDevelopmentExpenseAndCreditLossAdjustments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization, Research &amp; Development Expense, and Credit Loss Adjustments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_FiniteLivedIntangibleAssetsAccumulatedAmortizationResearchDevelopmentExpenseAndCreditLossAdjustments" xlink:href="lgnd-20211231.xsd#lgnd_FiniteLivedIntangibleAssetsAccumulatedAmortizationResearchDevelopmentExpenseAndCreditLossAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_FiniteLivedIntangibleAssetsAccumulatedAmortizationResearchDevelopmentExpenseAndCreditLossAdjustments" xlink:to="lab_lgnd_FiniteLivedIntangibleAssetsAccumulatedAmortizationResearchDevelopmentExpenseAndCreditLossAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssets_0a4ea4df-b450-4be1-aedf-6246ed9221db_terseLabel_en-US" xlink:label="lab_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangibles acquired</link:label>
    <link:label id="lab_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssets_9d9634cb-0158-4a3e-807f-2c0600884f68_verboseLabel_en-US" xlink:label="lab_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired intangibles</link:label>
    <link:label id="lab_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssets_label_en-US" xlink:label="lab_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets</link:label>
    <link:label id="lab_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssets_documentation_en-US" xlink:label="lab_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssets" xlink:href="lgnd-20211231.xsd#lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssets" xlink:to="lab_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_b18009e2-79e0-4c0b-8d12-758ae0173939_periodStartLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at beginning of period</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_99868f28-cdde-42a9-a0ff-67deb4e3b5a5_periodEndLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at end of period</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefits" xlink:to="lab_us-gaap_UnrecognizedTaxBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_c64947aa-efe4-44bb-ba5d-a14b08255a62_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="lab_us-gaap_DeferredTaxAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_5c1d708f-75bf-4757-9c8c-2ef3990142f4_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:to="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_7227f65f-cf9a-4cbe-8314-e0a8af9e490a_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_bd39e7e7-f470-4a1e-9195-24ccd6964edd_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross unrealized gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_XCellaBiosciencesIncMember_0e092ec0-759d-4bda-b06e-d908f3fa60db_terseLabel_en-US" xlink:label="lab_lgnd_XCellaBiosciencesIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">xCella</link:label>
    <link:label id="lab_lgnd_XCellaBiosciencesIncMember_label_en-US" xlink:label="lab_lgnd_XCellaBiosciencesIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">xCella Biosciences, Inc. [Member]</link:label>
    <link:label id="lab_lgnd_XCellaBiosciencesIncMember_documentation_en-US" xlink:label="lab_lgnd_XCellaBiosciencesIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">xCella Biosciences, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_XCellaBiosciencesIncMember" xlink:href="lgnd-20211231.xsd#lgnd_XCellaBiosciencesIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_XCellaBiosciencesIncMember" xlink:to="lab_lgnd_XCellaBiosciencesIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_63c861bb-8acb-4903-ad1a-245139762ab5_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeFinanceLeasesTextBlock_200a5d24-0c3b-48b8-9eef-acdfe9ba1101_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeFinanceLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeFinanceLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeFinanceLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Finance Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeFinanceLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeFinanceLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeFinanceLeasesTextBlock" xlink:to="lab_us-gaap_LesseeFinanceLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxAssetsNet_540dab83-ccf7-4c07-9a95-de73bc783eeb_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income taxes, net</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxAssetsNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxAssetsNet" xlink:to="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_34fe3bcb-23e4-4019-9033-5475309ff792_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_7324fa1b-d3e6-4ba1-a6c8-025d8fd680cc_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_AmortizationOfCommercialLicenseAndOtherEconomicRights_c09fa5e3-6b37-4dd0-baf9-e4e2c9b040cc_terseLabel_en-US" xlink:label="lab_lgnd_AmortizationOfCommercialLicenseAndOtherEconomicRights" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of commercial license and other economic rights</link:label>
    <link:label id="lab_lgnd_AmortizationOfCommercialLicenseAndOtherEconomicRights_label_en-US" xlink:label="lab_lgnd_AmortizationOfCommercialLicenseAndOtherEconomicRights" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Commercial License and Other Economic Rights</link:label>
    <link:label id="lab_lgnd_AmortizationOfCommercialLicenseAndOtherEconomicRights_documentation_en-US" xlink:label="lab_lgnd_AmortizationOfCommercialLicenseAndOtherEconomicRights" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Commercial License and Other Economic Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AmortizationOfCommercialLicenseAndOtherEconomicRights" xlink:href="lgnd-20211231.xsd#lgnd_AmortizationOfCommercialLicenseAndOtherEconomicRights"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_AmortizationOfCommercialLicenseAndOtherEconomicRights" xlink:to="lab_lgnd_AmortizationOfCommercialLicenseAndOtherEconomicRights" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_3f2fb275-e4ea-4d7e-b568-d977022f651a_verboseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesOutstanding_db00dbce-3d24-4c29-9e3e-841fc43619e4_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at beginning of period (shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_3db6494b-64db-4296-b3c1-96eafc46781c_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at end of period (shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_label_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding" xlink:to="lab_us-gaap_SharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_1f2f53bc-3d62-45fe-b0b1-d80b5d95b7af_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable at end of period (USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionAccumulatedLoss_4f4bf3bc-9378-4ef6-b2da-e2cd099c542f_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionAccumulatedLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionAccumulatedLoss_label_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionAccumulatedLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Held-to-maturity, Unrealized Loss Position, Accumulated Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionAccumulatedLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionAccumulatedLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionAccumulatedLoss" xlink:to="lab_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionAccumulatedLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesMember_2da44e01-3ee2-43c0-8da3-13fdb3b4108f_verboseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment in Viking common stock</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesMember_dd0f5213-9a95-407a-b534-5d9d23beff1d_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesMember_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesMember" xlink:to="lab_us-gaap_EquitySecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_c52af841-8b81-40bf-9544-4f16f6d78c68_verboseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Remaining Contractual Term in Years</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_9249d7d4-a704-481b-9f9a-33aed2246051_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_d340d455-e863-4f2e-8b91-3ee70fa5b7d0_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Federal Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_320f54ad-46e1-4700-aa7c-71c4dc9cb8d2_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_961d101c-0bf9-4af0-9c2c-9882a83a1a37_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Present value of lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_01e31fbb-430b-4306-bf93-a0bdb76f4ef2_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_425578a4-b64c-4fd5-b107-13e945adecdb_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, $0.001 par value; 60,000 shares authorized; 16,767 and 16,080 shares issued and outstanding at December&#160;31, 2021 and 2020, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_4aca1d5d-2c5c-414f-bbfb-71c7300735b8_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average discount rate of finance leases (as a percent)</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_e52f777f-3021-4759-b3d2-05fdfda0229f_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average period in which cost is expected to be recognized</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_97a840fa-743a-458d-adf3-cbcc3996704f_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at beginning of period (USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_7c6f8228-c540-4b58-9eeb-ff357efd1bb5_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at end of period (USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature_676eff2e-adb3-472f-98f8-0ccbb5b06c5e_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion value over the principal amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Beneficial Conversion Feature</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature" xlink:to="lab_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_994c4fa5-f74b-44be-9e78-fec94ddb9de8_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Concentration Risk</link:label>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerConcentrationRiskMember" xlink:to="lab_us-gaap_CustomerConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_IncreaseDecreaseInOtherEconomicRights_0c99cb72-8332-456a-b84c-9ca14f20934d_terseLabel_en-US" xlink:label="lab_lgnd_IncreaseDecreaseInOtherEconomicRights" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other economic rights</link:label>
    <link:label id="lab_lgnd_IncreaseDecreaseInOtherEconomicRights_label_en-US" xlink:label="lab_lgnd_IncreaseDecreaseInOtherEconomicRights" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Economic Rights</link:label>
    <link:label id="lab_lgnd_IncreaseDecreaseInOtherEconomicRights_documentation_en-US" xlink:label="lab_lgnd_IncreaseDecreaseInOtherEconomicRights" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Economic Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_IncreaseDecreaseInOtherEconomicRights" xlink:href="lgnd-20211231.xsd#lgnd_IncreaseDecreaseInOtherEconomicRights"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_IncreaseDecreaseInOtherEconomicRights" xlink:to="lab_lgnd_IncreaseDecreaseInOtherEconomicRights" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_dbcbf51f-6fa8-427f-842b-ee677050f3ef_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net decrease in cash, cash equivalents, and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_8f851b43-defe-453e-8f52-f35ba553fd13_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_ExercisePriceofConvertibleBondHedge_ba9d7e63-dba4-471e-bfbc-3f81105e7977_terseLabel_en-US" xlink:label="lab_lgnd_ExercisePriceofConvertibleBondHedge" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise price of convertible bond hedge (USD per share)</link:label>
    <link:label id="lab_lgnd_ExercisePriceofConvertibleBondHedge_label_en-US" xlink:label="lab_lgnd_ExercisePriceofConvertibleBondHedge" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price of Convertible Bond Hedge</link:label>
    <link:label id="lab_lgnd_ExercisePriceofConvertibleBondHedge_documentation_en-US" xlink:label="lab_lgnd_ExercisePriceofConvertibleBondHedge" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price of Convertible Bond Hedge</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ExercisePriceofConvertibleBondHedge" xlink:href="lgnd-20211231.xsd#lgnd_ExercisePriceofConvertibleBondHedge"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_ExercisePriceofConvertibleBondHedge" xlink:to="lab_lgnd_ExercisePriceofConvertibleBondHedge" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_3b3efb80-9af0-4cff-af1b-3670c7efa911_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisitions</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:to="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetGross_8494f463-bc53-476a-a36d-8d1ea4dc6e7f_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross contract asset</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetGross_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Asset, before Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerAssetGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetGross" xlink:to="lab_us-gaap_ContractWithCustomerAssetGross" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_57244117-b9c3-477e-8c99-e2a08f247f5b_terseLabel_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_label_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_IcfrAuditorAttestationFlag" xlink:to="lab_dei_IcfrAuditorAttestationFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_3e01f49e-abc2-4364-9b68-46d6983e934e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock Option Weighted-Average Assumptions</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_OwnershipAxis_a501e0b7-2bcd-43e8-9732-5440c3eb6701_terseLabel_en-US" xlink:label="lab_srt_OwnershipAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Axis]</link:label>
    <link:label id="lab_srt_OwnershipAxis_label_en-US" xlink:label="lab_srt_OwnershipAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_OwnershipAxis" xlink:to="lab_srt_OwnershipAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_3e343d6b-3838-4ff5-9fbb-cab96ffcaaf2_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_6c3f3ec7-72ea-48d2-84f6-9d178d1e9ebe_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (loss)</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Pro Forma Net Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:to="lab_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_LupinPatentInfringementMember_4231bf82-74b5-4183-b7f3-3b74b8eb20c2_terseLabel_en-US" xlink:label="lab_lgnd_LupinPatentInfringementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lupin Patent Infringement</link:label>
    <link:label id="lab_lgnd_LupinPatentInfringementMember_label_en-US" xlink:label="lab_lgnd_LupinPatentInfringementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lupin Patent Infringement [Member]</link:label>
    <link:label id="lab_lgnd_LupinPatentInfringementMember_documentation_en-US" xlink:label="lab_lgnd_LupinPatentInfringementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lupin Patent Infringement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_LupinPatentInfringementMember" xlink:href="lgnd-20211231.xsd#lgnd_LupinPatentInfringementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_LupinPatentInfringementMember" xlink:to="lab_lgnd_LupinPatentInfringementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_005b7e66-7377-412a-9f0e-558306435afc_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:to="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_AbInitioMember_8df9ba0d-09a0-4147-9d8f-13656edf08a2_terseLabel_en-US" xlink:label="lab_lgnd_AbInitioMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ab Initio</link:label>
    <link:label id="lab_lgnd_AbInitioMember_label_en-US" xlink:label="lab_lgnd_AbInitioMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ab Initio [Member]</link:label>
    <link:label id="lab_lgnd_AbInitioMember_documentation_en-US" xlink:label="lab_lgnd_AbInitioMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ab Initio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AbInitioMember" xlink:href="lgnd-20211231.xsd#lgnd_AbInitioMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_AbInitioMember" xlink:to="lab_lgnd_AbInitioMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive_b46c7434-038d-4178-b925-218ba575f36d_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid, after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockDividendsPerShareDeclared_88ef1aa4-23e9-45cb-9fdd-4205da230335_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockDividendsPerShareDeclared" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividend declared (USD per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockDividendsPerShareDeclared_label_en-US" xlink:label="lab_us-gaap_CommonStockDividendsPerShareDeclared" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Dividends, Per Share, Declared</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareDeclared" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockDividendsPerShareDeclared"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockDividendsPerShareDeclared" xlink:to="lab_us-gaap_CommonStockDividendsPerShareDeclared" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_588f6a7f-be7d-474f-b203-8f70995251cf_verboseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_5246833d-bfa4-4220-9efc-8916c960a7b2_totalLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_9d6d5ef9-6b27-4f4b-9858-db738ad46aa4_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_53734d98-0d9e-4485-b4c8-c592ea5f6ee4_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock compensation</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_LiabilityForRestrictedInvestmentsOwedToFormerLicenseesMember_bf9e6950-0474-4f06-ab3a-15d1035eccc3_terseLabel_en-US" xlink:label="lab_lgnd_LiabilityForRestrictedInvestmentsOwedToFormerLicenseesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for restricted investments owed to former licensees</link:label>
    <link:label id="lab_lgnd_LiabilityForRestrictedInvestmentsOwedToFormerLicenseesMember_label_en-US" xlink:label="lab_lgnd_LiabilityForRestrictedInvestmentsOwedToFormerLicenseesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Restricted Investments Owed to Former Licensees [Member]</link:label>
    <link:label id="lab_lgnd_LiabilityForRestrictedInvestmentsOwedToFormerLicenseesMember_documentation_en-US" xlink:label="lab_lgnd_LiabilityForRestrictedInvestmentsOwedToFormerLicenseesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Restricted Investments Owed to Former Licensees [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_LiabilityForRestrictedInvestmentsOwedToFormerLicenseesMember" xlink:href="lgnd-20211231.xsd#lgnd_LiabilityForRestrictedInvestmentsOwedToFormerLicenseesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_LiabilityForRestrictedInvestmentsOwedToFormerLicenseesMember" xlink:to="lab_lgnd_LiabilityForRestrictedInvestmentsOwedToFormerLicenseesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_838bb41c-61ab-4bd3-a91a-6bddb2dbdd7c_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_14d6412f-e8b0-4387-bc20-a6fb75dcca00_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_316a0c21-0e7f-4e6a-92e3-eae9919d7eec_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss)</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_VernalisMember_9116ab8b-9bad-47d3-b0c7-afa75de8d35d_terseLabel_en-US" xlink:label="lab_lgnd_VernalisMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vernalis</link:label>
    <link:label id="lab_lgnd_VernalisMember_label_en-US" xlink:label="lab_lgnd_VernalisMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vernalis [Member]</link:label>
    <link:label id="lab_lgnd_VernalisMember_documentation_en-US" xlink:label="lab_lgnd_VernalisMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vernalis</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_VernalisMember" xlink:href="lgnd-20211231.xsd#lgnd_VernalisMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_VernalisMember" xlink:to="lab_lgnd_VernalisMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_9cdef587-ee51-4fcc-99b7-314eadcf0e15_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeDomain" xlink:to="lab_us-gaap_MeasurementInputTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsTable_34822d78-9985-4ae1-b7b9-788dadb94f72_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards [Table]</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsTable_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable" xlink:to="lab_us-gaap_OperatingLossCarryforwardsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleNotesPayableMember_3d54cf13-af2b-4161-9340-f310a1824b58_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleNotesPayableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Notes</link:label>
    <link:label id="lab_us-gaap_ConvertibleNotesPayableMember_label_en-US" xlink:label="lab_us-gaap_ConvertibleNotesPayableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Notes Payable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleNotesPayableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleNotesPayableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleNotesPayableMember" xlink:to="lab_us-gaap_ConvertibleNotesPayableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfShortTermInvestments_b8a9a1cf-d1a8-45c9-8b87-9fe433787e82_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sale of short-term investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfShortTermInvestments_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Short-term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfShortTermInvestments" xlink:to="lab_us-gaap_ProceedsFromSaleOfShortTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_9823996a-f442-40ec-b752-c587f8993b93_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less than 12 months</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpenseAbstract_08605d48-fe12-4fdf-a0ed-81c4beece2b3_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income (expense):</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpenseAbstract_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_4f169e68-dc2a-4032-ad4b-7f3a5c163cab_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average remaining lease term of finance leases</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_RoyaltyAgreementExpirationPeriod_149593ff-3e6a-4527-af1e-77c26b95d529_terseLabel_en-US" xlink:label="lab_lgnd_RoyaltyAgreementExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expiration period of royalty agreement</link:label>
    <link:label id="lab_lgnd_RoyaltyAgreementExpirationPeriod_label_en-US" xlink:label="lab_lgnd_RoyaltyAgreementExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Agreement, Expiration Period</link:label>
    <link:label id="lab_lgnd_RoyaltyAgreementExpirationPeriod_documentation_en-US" xlink:label="lab_lgnd_RoyaltyAgreementExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Agreement, Expiration Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_RoyaltyAgreementExpirationPeriod" xlink:href="lgnd-20211231.xsd#lgnd_RoyaltyAgreementExpirationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_RoyaltyAgreementExpirationPeriod" xlink:to="lab_lgnd_RoyaltyAgreementExpirationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_RestrictedStockUnitsAndPerformanceSharesMember_07931fd4-1826-47e9-bb6d-30be78767a53_terseLabel_en-US" xlink:label="lab_lgnd_RestrictedStockUnitsAndPerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RSUs and PSUs</link:label>
    <link:label id="lab_lgnd_RestrictedStockUnitsAndPerformanceSharesMember_label_en-US" xlink:label="lab_lgnd_RestrictedStockUnitsAndPerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units and Performance Shares [Member]</link:label>
    <link:label id="lab_lgnd_RestrictedStockUnitsAndPerformanceSharesMember_documentation_en-US" xlink:label="lab_lgnd_RestrictedStockUnitsAndPerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units and Performance Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_RestrictedStockUnitsAndPerformanceSharesMember" xlink:href="lgnd-20211231.xsd#lgnd_RestrictedStockUnitsAndPerformanceSharesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_RestrictedStockUnitsAndPerformanceSharesMember" xlink:to="lab_lgnd_RestrictedStockUnitsAndPerformanceSharesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1cb1ba64-a0fd-43d3-ab1e-bb36206a6f6e_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_AuditInformationAbstract_label_en-US" xlink:label="lab_lgnd_AuditInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Audit Information [Abstract]</link:label>
    <link:label id="lab_lgnd_AuditInformationAbstract_documentation_en-US" xlink:label="lab_lgnd_AuditInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Audit Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AuditInformationAbstract" xlink:href="lgnd-20211231.xsd#lgnd_AuditInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_AuditInformationAbstract" xlink:to="lab_lgnd_AuditInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_7315ce57-7555-467a-8d69-40d971d431dc_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_TwoThousandTwoStockIncentivePlanMember_d8ccaa55-e5fd-4d33-a306-f323fd4cca6e_terseLabel_en-US" xlink:label="lab_lgnd_TwoThousandTwoStockIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2002 Stock Incentive Plan</link:label>
    <link:label id="lab_lgnd_TwoThousandTwoStockIncentivePlanMember_label_en-US" xlink:label="lab_lgnd_TwoThousandTwoStockIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two thousand Two Stock Incentive Plan [Member]</link:label>
    <link:label id="lab_lgnd_TwoThousandTwoStockIncentivePlanMember_documentation_en-US" xlink:label="lab_lgnd_TwoThousandTwoStockIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two thousand two Stock Incentive Plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_TwoThousandTwoStockIncentivePlanMember" xlink:href="lgnd-20211231.xsd#lgnd_TwoThousandTwoStockIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_TwoThousandTwoStockIncentivePlanMember" xlink:to="lab_lgnd_TwoThousandTwoStockIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_1dcd92c6-5029-46db-a729-db9ec984ed2c_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">After one year through five years</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_65d2d09d-0afb-48e4-be81-ae8f5e9351f5_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_ffb0cc78-2e67-469b-a2f9-80ef5ddbd8b9_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingCostsAndExpenses_96994a78-f28a-4efc-a957-50b384cdc4d0_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingCostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating costs and expenses</link:label>
    <link:label id="lab_us-gaap_OperatingCostsAndExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingCostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Costs and Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingCostsAndExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingCostsAndExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingCostsAndExpenses" xlink:to="lab_us-gaap_OperatingCostsAndExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_IncreaseDecreaseInDebtDiscount_80c4ad00-d5ac-47a6-914b-a0a8af5de6d8_negatedTerseLabel_en-US" xlink:label="lab_lgnd_IncreaseDecreaseInDebtDiscount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reduction in debt discount</link:label>
    <link:label id="lab_lgnd_IncreaseDecreaseInDebtDiscount_label_en-US" xlink:label="lab_lgnd_IncreaseDecreaseInDebtDiscount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Debt Discount</link:label>
    <link:label id="lab_lgnd_IncreaseDecreaseInDebtDiscount_documentation_en-US" xlink:label="lab_lgnd_IncreaseDecreaseInDebtDiscount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Debt Discount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_IncreaseDecreaseInDebtDiscount" xlink:href="lgnd-20211231.xsd#lgnd_IncreaseDecreaseInDebtDiscount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_IncreaseDecreaseInDebtDiscount" xlink:to="lab_lgnd_IncreaseDecreaseInDebtDiscount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_2afc28a8-c98e-4a3a-8ed6-27249d22c7c8_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_9972472d-3ed2-40f4-b9d0-76ecb1c206b1_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual_cc3cd8a4-02b5-4486-baa7-f8b2597e256c_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue of acquiree since acquisition date included in comprehensive income</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Pro Forma Information, Revenue of Acquiree since Acquisition Date, Actual</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual" xlink:to="lab_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_29226057-604d-4de5-8747-df9bb330ee63_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants issued in public offering (shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_BusinessCombinationContingentConsiderationLiabilityFairValueDisclosure_c76e1d65-8116-480e-b050-d5048f854d7a_terseLabel_en-US" xlink:label="lab_lgnd_BusinessCombinationContingentConsiderationLiabilityFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of contingent earn-out payment</link:label>
    <link:label id="lab_lgnd_BusinessCombinationContingentConsiderationLiabilityFairValueDisclosure_label_en-US" xlink:label="lab_lgnd_BusinessCombinationContingentConsiderationLiabilityFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Fair Value Disclosure</link:label>
    <link:label id="lab_lgnd_BusinessCombinationContingentConsiderationLiabilityFairValueDisclosure_documentation_en-US" xlink:label="lab_lgnd_BusinessCombinationContingentConsiderationLiabilityFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BusinessCombinationContingentConsiderationLiabilityFairValueDisclosure" xlink:href="lgnd-20211231.xsd#lgnd_BusinessCombinationContingentConsiderationLiabilityFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_BusinessCombinationContingentConsiderationLiabilityFairValueDisclosure" xlink:to="lab_lgnd_BusinessCombinationContingentConsiderationLiabilityFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_388811af-e2d8-48fb-befb-7a7cbe5574de_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:to="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_fc25ad95-8b67-42d2-98c5-1f406802a3f9_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other expense, net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_c25af138-f551-46f2-9769-b80736ecbfb4_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other, net</link:label>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_label_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for (Proceeds from) Other Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:to="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_CurrentPortionOfLiabilityForContingentValueRights_542634b6-12ed-4cdd-a0a7-824918770f38_terseLabel_en-US" xlink:label="lab_lgnd_CurrentPortionOfLiabilityForContingentValueRights" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current contingent liabilities</link:label>
    <link:label id="lab_lgnd_CurrentPortionOfLiabilityForContingentValueRights_label_en-US" xlink:label="lab_lgnd_CurrentPortionOfLiabilityForContingentValueRights" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Portion of Liability for Contingent Value Rights</link:label>
    <link:label id="lab_lgnd_CurrentPortionOfLiabilityForContingentValueRights_documentation_en-US" xlink:label="lab_lgnd_CurrentPortionOfLiabilityForContingentValueRights" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of liability for contingent value rights.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_CurrentPortionOfLiabilityForContingentValueRights" xlink:href="lgnd-20211231.xsd#lgnd_CurrentPortionOfLiabilityForContingentValueRights"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_CurrentPortionOfLiabilityForContingentValueRights" xlink:to="lab_lgnd_CurrentPortionOfLiabilityForContingentValueRights" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_017563e1-3cc5-4b08-ab76-2de9df13a663_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_53be0a1b-4be6-4785-b903-443cb4ad3169_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_090501ab-c505-40e1-944e-e506679e3d3a_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_030af636-8948-46a9-8d66-51b6ef0771fe_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_fa6311b9-40a8-4e1a-bc81-1ad4b35cd411_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Maturity of Operating Lease Liabilities</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_fa7543e9-9a17-420f-bf5d-d4e8727378b4_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_03c6b06c-bc39-44d9-aeab-36bbccb8f066_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at beginning of period</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_2dccd00d-344c-4b43-925b-696cb597b746_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at end of period</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_6ae25cbd-4d2c-450d-aa48-7970aa028b52_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_EffectiveIncomeTaxRateReconciliationProvisionToReturnAdjustmentsAmount_8590f158-8d8e-46ba-b302-bd84142c66b7_negatedTerseLabel_en-US" xlink:label="lab_lgnd_EffectiveIncomeTaxRateReconciliationProvisionToReturnAdjustmentsAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision to return adjustments</link:label>
    <link:label id="lab_lgnd_EffectiveIncomeTaxRateReconciliationProvisionToReturnAdjustmentsAmount_label_en-US" xlink:label="lab_lgnd_EffectiveIncomeTaxRateReconciliationProvisionToReturnAdjustmentsAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Provision to Return Adjustments, Amount</link:label>
    <link:label id="lab_lgnd_EffectiveIncomeTaxRateReconciliationProvisionToReturnAdjustmentsAmount_documentation_en-US" xlink:label="lab_lgnd_EffectiveIncomeTaxRateReconciliationProvisionToReturnAdjustmentsAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Provision to Return Adjustments, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_EffectiveIncomeTaxRateReconciliationProvisionToReturnAdjustmentsAmount" xlink:href="lgnd-20211231.xsd#lgnd_EffectiveIncomeTaxRateReconciliationProvisionToReturnAdjustmentsAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_EffectiveIncomeTaxRateReconciliationProvisionToReturnAdjustmentsAmount" xlink:to="lab_lgnd_EffectiveIncomeTaxRateReconciliationProvisionToReturnAdjustmentsAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_1561c323-5df3-4866-8714-6ecb8c4e2228_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable and accrued liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_AssetsAndLiabilitiesLesseeTableTextBlock_5cbe0466-bd16-4433-bd7a-7b913a6cf20e_terseLabel_en-US" xlink:label="lab_lgnd_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Operating and Finance Lease Assets and Liabilities</link:label>
    <link:label id="lab_lgnd_AssetsAndLiabilitiesLesseeTableTextBlock_label_en-US" xlink:label="lab_lgnd_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets and Liabilities, Lessee [Table Text Block]</link:label>
    <link:label id="lab_lgnd_AssetsAndLiabilitiesLesseeTableTextBlock_documentation_en-US" xlink:label="lab_lgnd_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets and Liabilities, Lessee</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:href="lgnd-20211231.xsd#lgnd_AssetsAndLiabilitiesLesseeTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:to="lab_lgnd_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_9f2adf53-7972-4255-882a-febabc2cfd09_verboseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable, Aggregate Intrinsic Value</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_48728e28-bfb4-4477-82f7-9ace473e8f9d_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaids and other assets</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtConversionConvertedInstrumentAmount1_d3653b2e-14e1-47f6-a2d0-0696d1571415_terseLabel_en-US" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notices for conversion</link:label>
    <link:label id="lab_us-gaap_DebtConversionConvertedInstrumentAmount1_label_en-US" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Conversion, Converted Instrument, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:to="lab_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfIntangibleAssets_d0484668-7230-4ed5-ae0f-ef89b5d859b7_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sale of Promacta license</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfIntangibleAssets" xlink:to="lab_us-gaap_ProceedsFromSaleOfIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_47dccf8b-805e-4d81-90b8-27f9a00a54aa_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share repurchases</link:label>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_label_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Repurchase of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:to="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_adfee9de-ed30-466a-ae6d-db7a4cd4a7f6_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, useful life</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_ExercisePriceRangeFourMember_bdfebb1a-4b97-40f6-8ad1-67077b5a5116_terseLabel_en-US" xlink:label="lab_lgnd_ExercisePriceRangeFourMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">$95.68</link:label>
    <link:label id="lab_lgnd_ExercisePriceRangeFourMember_label_en-US" xlink:label="lab_lgnd_ExercisePriceRangeFourMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range Four [Member]</link:label>
    <link:label id="lab_lgnd_ExercisePriceRangeFourMember_documentation_en-US" xlink:label="lab_lgnd_ExercisePriceRangeFourMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range Four [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ExercisePriceRangeFourMember" xlink:href="lgnd-20211231.xsd#lgnd_ExercisePriceRangeFourMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_ExercisePriceRangeFourMember" xlink:to="lab_lgnd_ExercisePriceRangeFourMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_014274ce-3afb-4551-8d25-afbac7c9e9fe_verboseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders&#8217; equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermNotesPayableCurrentAndNoncurrentTotalAbstract_446399c5-6cd5-4898-9230-3b4af8baaec2_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermNotesPayableCurrentAndNoncurrentTotalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Payable, Current and Noncurrent</link:label>
    <link:label id="lab_us-gaap_LongtermNotesPayableCurrentAndNoncurrentTotalAbstract_label_en-US" xlink:label="lab_us-gaap_LongtermNotesPayableCurrentAndNoncurrentTotalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Payable, Current and Noncurrent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermNotesPayableCurrentAndNoncurrentTotalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermNotesPayableCurrentAndNoncurrentTotalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermNotesPayableCurrentAndNoncurrentTotalAbstract" xlink:to="lab_us-gaap_LongtermNotesPayableCurrentAndNoncurrentTotalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_af16b7d4-b2f1-4937-a16a-087a1d6b9685_verboseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentrations of Business Risk</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_ConvertibleSeniorNotesDue2023Member_143437ed-ce4b-4076-b601-418242ac720f_terseLabel_en-US" xlink:label="lab_lgnd_ConvertibleSeniorNotesDue2023Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023 Convertible Senior Notes</link:label>
    <link:label id="lab_lgnd_ConvertibleSeniorNotesDue2023Member_label_en-US" xlink:label="lab_lgnd_ConvertibleSeniorNotesDue2023Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Senior Notes due 2023 [Member]</link:label>
    <link:label id="lab_lgnd_ConvertibleSeniorNotesDue2023Member_documentation_en-US" xlink:label="lab_lgnd_ConvertibleSeniorNotesDue2023Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Senior Notes due 2023</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ConvertibleSeniorNotesDue2023Member" xlink:href="lgnd-20211231.xsd#lgnd_ConvertibleSeniorNotesDue2023Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_ConvertibleSeniorNotesDue2023Member" xlink:to="lab_lgnd_ConvertibleSeniorNotesDue2023Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_5426aff9-4611-4c4f-a20c-e20eaa062ea1_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue_405e0300-b11c-4a8b-b8d8-8d738e0da55d_totalLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease payments</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Payment, Due</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_022674ba-6cf5-4e2e-bb0c-2c889c016798_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments for New Accounting Pronouncements [Axis]</link:label>
    <link:label id="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_label_en-US" xlink:label="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_cbf4ef75-1167-4657-bd8a-6921e70e9d43_totalLabel_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current expense (benefit)</link:label>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_aede11c4-29fc-4e2c-bce1-f87062402bbf_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal amount of 2023 Notes outstanding</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_86c9b9b4-3cc4-404e-8bbd-2f11777f9e8c_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Face amount of debt instrument</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockCompensationPlanMember_332aa7dd-12a8-4b07-a6cc-5cc82f39034f_terseLabel_en-US" xlink:label="lab_us-gaap_StockCompensationPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Awards</link:label>
    <link:label id="lab_us-gaap_StockCompensationPlanMember_label_en-US" xlink:label="lab_us-gaap_StockCompensationPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockCompensationPlanMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockCompensationPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockCompensationPlanMember" xlink:to="lab_us-gaap_StockCompensationPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_e009bf9b-4e34-444a-85b3-d33a6e21bb0c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Allocation of Consideration / Recognized Identified Assets Acquired and Liabilities Assumed</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiability_8a8c3cd6-54aa-484d-b887-cbcbad990cce_verboseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance lease liability</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiability_eca89fe6-28ef-4b84-ae8e-d570ada128ea_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Present value of lease liabilities</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiability_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiability" xlink:to="lab_us-gaap_FinanceLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_8c56c8e7-5f55-4d4d-9862-16950fa8925a_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net deferred tax liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_7d366eb6-a93d-48fb-b66d-cfb116dd5b67_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining lease term of operating leases</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:to="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_0c1e2573-b0f5-4a0f-9c7b-9588cd9e3535_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems" xlink:to="lab_us-gaap_BusinessAcquisitionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_87b2c2ec-6a08-4282-87c4-f90b9127577d_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Condensed Statement of Operations:</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_3be59db3-3a3e-43ca-a1a4-63f7b771eaea_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_32162e27-5738-43c1-a34b-269917c9b363_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value by Asset Class [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted_81760028-8faf-47d0-ab86-3db18195bff1_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted (USD per share)</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Pro Forma Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted" xlink:to="lab_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_83bd76b3-c08c-4dcf-a73d-e59f91bd363d_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts and unbilled receivables</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_13674c72-554e-43b0-a20f-92403900a0ef_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_3e5fbbf3-eb2f-44d6-ba13-90ef6fcd3ea7_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherOperatingIncome_7f7235e6-5b9f-49e4-983d-2e0936519538_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherOperatingIncome" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other operating income</link:label>
    <link:label id="lab_us-gaap_OtherOperatingIncome_label_en-US" xlink:label="lab_us-gaap_OtherOperatingIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Operating Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherOperatingIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherOperatingIncome" xlink:to="lab_us-gaap_OtherOperatingIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_2abc4baf-e10a-4c21-9ab5-4aeb5cd99a87_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average exercise price (USD per share)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:to="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments_d80390fe-4ebf-4443-b6bb-555bd9e7d229_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:to="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_ec8f1e6e-216f-45ee-abbd-05a565f4f499_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_1938d1d6-8187-4247-9ad9-35a82559f361_negatedLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax benefit (expense)</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_d3a2193f-a6f6-457d-8eca-53558e6053b8_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total income tax expense (benefit)</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_c1bf786e-a67c-40d8-ab60-38faeb9aba39_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_54874052-acbf-4f1a-bc3d-2fb69d41a638_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentTypeAxis_133884a4-adef-4ea5-869c-dc3e03914818_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Type [Axis]</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeAxis_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeAxis" xlink:to="lab_us-gaap_InvestmentTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_ContractualRelationshipsMerckMember_e41f8cc3-9b12-4fb2-899d-f9959215a418_terseLabel_en-US" xlink:label="lab_lgnd_ContractualRelationshipsMerckMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual Relationships - Merck</link:label>
    <link:label id="lab_lgnd_ContractualRelationshipsMerckMember_label_en-US" xlink:label="lab_lgnd_ContractualRelationshipsMerckMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual Relationships - Merck [Member]</link:label>
    <link:label id="lab_lgnd_ContractualRelationshipsMerckMember_documentation_en-US" xlink:label="lab_lgnd_ContractualRelationshipsMerckMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual Relationships - Merck</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ContractualRelationshipsMerckMember" xlink:href="lgnd-20211231.xsd#lgnd_ContractualRelationshipsMerckMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_ContractualRelationshipsMerckMember" xlink:to="lab_lgnd_ContractualRelationshipsMerckMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_eb477e08-06fb-47ac-ad22-1628a275444a_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_705f8019-76a9-4bff-b1fa-0d17a2ff473d_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_a76cb8b9-4b63-4e0b-afbc-24cafe0ef3d5_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock Option Plan Activity by Exercise Price Range</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Exercise Price Range [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_a7d13677-b346-4c50-b3c0-b9f7918b28dd_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_9837c1b6-4043-41b9-b81e-dea38b7c4368_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_1f0cc8d0-08e6-40bb-a83d-8cea083d03e7_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in valuation allowance</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_CashPaidDuringTheYearAbstract_a8236afa-b7ea-4ba6-857f-b56f89bfc76c_terseLabel_en-US" xlink:label="lab_lgnd_CashPaidDuringTheYearAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid during the year:</link:label>
    <link:label id="lab_lgnd_CashPaidDuringTheYearAbstract_label_en-US" xlink:label="lab_lgnd_CashPaidDuringTheYearAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Paid During the Year [Abstract]</link:label>
    <link:label id="lab_lgnd_CashPaidDuringTheYearAbstract_documentation_en-US" xlink:label="lab_lgnd_CashPaidDuringTheYearAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Paid During the Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_CashPaidDuringTheYearAbstract" xlink:href="lgnd-20211231.xsd#lgnd_CashPaidDuringTheYearAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_CashPaidDuringTheYearAbstract" xlink:to="lab_lgnd_CashPaidDuringTheYearAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransferredOverTimeMember_874c235e-5427-4813-907c-7e4a4f9a4d1e_terseLabel_en-US" xlink:label="lab_us-gaap_TransferredOverTimeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transferred over Time</link:label>
    <link:label id="lab_us-gaap_TransferredOverTimeMember_label_en-US" xlink:label="lab_us-gaap_TransferredOverTimeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transferred over Time [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransferredOverTimeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransferredOverTimeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransferredOverTimeMember" xlink:to="lab_us-gaap_TransferredOverTimeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_a6e8f317-7b2a-4661-8e1d-0273546337b5_verboseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Value of warrants issued</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Additional Paid in Capital, Warrant Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_23337801-20c2-46f0-8e27-8266a6ecd051_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodValue_bb7202bc-76e9-4291-9455-372cb3ba1b36_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodValue" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase of common stock</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodValue_cec337f7-b033-423b-85e1-2dc5833429ec_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares repurchased in period</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodValue_label_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchased During Period, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchasedDuringPeriodValue" xlink:to="lab_us-gaap_StockRepurchasedDuringPeriodValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_718f7ea6-7632-44e2-bd5a-392de1a8c935_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Fair Value, Fiscal Year Maturity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable_d6c9196f-c65e-481e-85db-dc33428b010c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Variable Interest Entities [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Variable Interest Entities [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:to="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_f8a98526-a413-42f7-9d60-de005330ad00_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Condensed Balance Sheet:</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_1094430e-174a-4480-99da-4b481caec060_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized compensation cost</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_d4deaa69-13d7-446f-80f2-cee8a04d04e9_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_PartnerCMember_1c3b334b-4168-43f6-a24b-512fd8813bf6_terseLabel_en-US" xlink:label="lab_lgnd_PartnerCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Partner C</link:label>
    <link:label id="lab_lgnd_PartnerCMember_label_en-US" xlink:label="lab_lgnd_PartnerCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Partner C [Member]</link:label>
    <link:label id="lab_lgnd_PartnerCMember_documentation_en-US" xlink:label="lab_lgnd_PartnerCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Partner C [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PartnerCMember" xlink:href="lgnd-20211231.xsd#lgnd_PartnerCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_PartnerCMember" xlink:to="lab_lgnd_PartnerCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_fffe2fa8-d835-46dc-9042-dd8cf24c833d_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized compensation cost, restricted stock</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SalesRevenueNetMember_6eb77bd5-47d3-4001-8ec6-5171227ad06a_terseLabel_en-US" xlink:label="lab_us-gaap_SalesRevenueNetMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_SalesRevenueNetMember_label_en-US" xlink:label="lab_us-gaap_SalesRevenueNetMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Benchmark [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesRevenueNetMember" xlink:to="lab_us-gaap_SalesRevenueNetMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_7e42346f-8120-4fc7-a4a3-66687afc7bd1_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average grant date fair value per share of stock options (USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_ba25f195-af07-4ee5-b172-c7f23cd03615_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_ExercisePriceRangeNineMember_d94a2f31-ac10-448b-b421-707fffa23226_terseLabel_en-US" xlink:label="lab_lgnd_ExercisePriceRangeNineMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">$159.81-$171.28</link:label>
    <link:label id="lab_lgnd_ExercisePriceRangeNineMember_label_en-US" xlink:label="lab_lgnd_ExercisePriceRangeNineMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range Nine [Member]</link:label>
    <link:label id="lab_lgnd_ExercisePriceRangeNineMember_documentation_en-US" xlink:label="lab_lgnd_ExercisePriceRangeNineMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range Nine [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ExercisePriceRangeNineMember" xlink:href="lgnd-20211231.xsd#lgnd_ExercisePriceRangeNineMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_ExercisePriceRangeNineMember" xlink:to="lab_lgnd_ExercisePriceRangeNineMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_fc089f73-5412-4450-ab14-ef223388a8f8_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_LiabilityForContingentValueRightsCompanyCrystalMember_8aa813a7-3b17-4935-b2d6-5f2cea2396c5_terseLabel_en-US" xlink:label="lab_lgnd_LiabilityForContingentValueRightsCompanyCrystalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent liabilities - Crystal</link:label>
    <link:label id="lab_lgnd_LiabilityForContingentValueRightsCompanyCrystalMember_label_en-US" xlink:label="lab_lgnd_LiabilityForContingentValueRightsCompanyCrystalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability For Contingent Value Rights Company, Crystal [Member]</link:label>
    <link:label id="lab_lgnd_LiabilityForContingentValueRightsCompanyCrystalMember_documentation_en-US" xlink:label="lab_lgnd_LiabilityForContingentValueRightsCompanyCrystalMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability For Contingent Value Rights Company, Crystal [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_LiabilityForContingentValueRightsCompanyCrystalMember" xlink:href="lgnd-20211231.xsd#lgnd_LiabilityForContingentValueRightsCompanyCrystalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_LiabilityForContingentValueRightsCompanyCrystalMember" xlink:to="lab_lgnd_LiabilityForContingentValueRightsCompanyCrystalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_VestingPeriodTwoMember_481ff573-a9b6-4202-8836-6622c6b36086_terseLabel_en-US" xlink:label="lab_lgnd_VestingPeriodTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vest 1/48 each month for forty-two months</link:label>
    <link:label id="lab_lgnd_VestingPeriodTwoMember_label_en-US" xlink:label="lab_lgnd_VestingPeriodTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting Period Two [Member]</link:label>
    <link:label id="lab_lgnd_VestingPeriodTwoMember_documentation_en-US" xlink:label="lab_lgnd_VestingPeriodTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting Period Two [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_VestingPeriodTwoMember" xlink:href="lgnd-20211231.xsd#lgnd_VestingPeriodTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_VestingPeriodTwoMember" xlink:to="lab_lgnd_VestingPeriodTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_bc15085c-3b19-40ec-884c-c31b2e92dfb0_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_label_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:to="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_NonCashChangeInEstimatedFairValueOfContingentValueRights_34d39a22-a057-4f99-bd13-605e1aa632bb_negatedLabel_en-US" xlink:label="lab_lgnd_NonCashChangeInEstimatedFairValueOfContingentValueRights" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in estimated fair value of contingent liabilities</link:label>
    <link:label id="lab_lgnd_NonCashChangeInEstimatedFairValueOfContingentValueRights_label_en-US" xlink:label="lab_lgnd_NonCashChangeInEstimatedFairValueOfContingentValueRights" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Cash Change In Estimated Fair Value Of Contingent Value Rights</link:label>
    <link:label id="lab_lgnd_NonCashChangeInEstimatedFairValueOfContingentValueRights_documentation_en-US" xlink:label="lab_lgnd_NonCashChangeInEstimatedFairValueOfContingentValueRights" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Cash Change In Estimated Fair Value Of Contingent Value Rights.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_NonCashChangeInEstimatedFairValueOfContingentValueRights" xlink:href="lgnd-20211231.xsd#lgnd_NonCashChangeInEstimatedFairValueOfContingentValueRights"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_NonCashChangeInEstimatedFairValueOfContingentValueRights" xlink:to="lab_lgnd_NonCashChangeInEstimatedFairValueOfContingentValueRights" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableInterestEntityLineItems_db3dc49a-b37f-4cf8-9172-3b1eedae7bf3_terseLabel_en-US" xlink:label="lab_us-gaap_VariableInterestEntityLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entity [Line Items]</link:label>
    <link:label id="lab_us-gaap_VariableInterestEntityLineItems_label_en-US" xlink:label="lab_us-gaap_VariableInterestEntityLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entity [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableInterestEntityLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableInterestEntityLineItems" xlink:to="lab_us-gaap_VariableInterestEntityLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_AdjustmentsToAdditionalPaidInCapitalWarrantAndBondHedgeUnwindTransactions_1aed152d-0696-49f1-9f8e-8d816286b6d9_terseLabel_en-US" xlink:label="lab_lgnd_AdjustmentsToAdditionalPaidInCapitalWarrantAndBondHedgeUnwindTransactions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant and bond hedge unwind transactions</link:label>
    <link:label id="lab_lgnd_AdjustmentsToAdditionalPaidInCapitalWarrantAndBondHedgeUnwindTransactions_label_en-US" xlink:label="lab_lgnd_AdjustmentsToAdditionalPaidInCapitalWarrantAndBondHedgeUnwindTransactions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Additional Paid in Capital, Warrant and Bond Hedge Unwind Transactions</link:label>
    <link:label id="lab_lgnd_AdjustmentsToAdditionalPaidInCapitalWarrantAndBondHedgeUnwindTransactions_documentation_en-US" xlink:label="lab_lgnd_AdjustmentsToAdditionalPaidInCapitalWarrantAndBondHedgeUnwindTransactions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Additional Paid in Capital, Warrant and Bond Hedge Unwind Transactions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AdjustmentsToAdditionalPaidInCapitalWarrantAndBondHedgeUnwindTransactions" xlink:href="lgnd-20211231.xsd#lgnd_AdjustmentsToAdditionalPaidInCapitalWarrantAndBondHedgeUnwindTransactions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_AdjustmentsToAdditionalPaidInCapitalWarrantAndBondHedgeUnwindTransactions" xlink:to="lab_lgnd_AdjustmentsToAdditionalPaidInCapitalWarrantAndBondHedgeUnwindTransactions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFinanceCostsGross_574ef106-4a99-46fe-be9b-b0b43a39a7a2_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt issuance costs</link:label>
    <link:label id="lab_us-gaap_DeferredFinanceCostsGross_label_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Issuance Costs, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFinanceCostsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFinanceCostsGross" xlink:to="lab_us-gaap_DeferredFinanceCostsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseAxis_1389e9ad-4ad8-45db-b6d6-3eefe671922c_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:label id="lab_srt_LitigationCaseAxis_label_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseAxis" xlink:to="lab_srt_LitigationCaseAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_IncomeTaxReconciliationContingentValueRights_2321b4ab-d737-4be2-a3e7-8ee8cb09a88d_terseLabel_en-US" xlink:label="lab_lgnd_IncomeTaxReconciliationContingentValueRights" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent liabilities</link:label>
    <link:label id="lab_lgnd_IncomeTaxReconciliationContingentValueRights_label_en-US" xlink:label="lab_lgnd_IncomeTaxReconciliationContingentValueRights" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Reconciliation, Contingent Value Rights</link:label>
    <link:label id="lab_lgnd_IncomeTaxReconciliationContingentValueRights_documentation_en-US" xlink:label="lab_lgnd_IncomeTaxReconciliationContingentValueRights" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Reconciliation, Contingent Value Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_IncomeTaxReconciliationContingentValueRights" xlink:href="lgnd-20211231.xsd#lgnd_IncomeTaxReconciliationContingentValueRights"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_IncomeTaxReconciliationContingentValueRights" xlink:to="lab_lgnd_IncomeTaxReconciliationContingentValueRights" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_a95d41d8-0368-4cf0-8980-53030ea76cad_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of intangible assets with finite lives</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of Intangible Assets, Finite-lived</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:to="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAbstract_e6aad60a-caee-4f66-ab7f-bf4bcdc8cf5e_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAbstract" xlink:to="lab_us-gaap_LiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermInvestmentsMember_29a7e35f-d85c-4e38-b4e3-774b5615eefd_verboseLabel_en-US" xlink:label="lab_us-gaap_ShortTermInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term investments</link:label>
    <link:label id="lab_us-gaap_ShortTermInvestmentsMember_5c131a86-2c44-4e9f-9744-037b2fc623b2_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term investments</link:label>
    <link:label id="lab_us-gaap_ShortTermInvestmentsMember_label_en-US" xlink:label="lab_us-gaap_ShortTermInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Investments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestmentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermInvestmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermInvestmentsMember" xlink:to="lab_us-gaap_ShortTermInvestmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_0410b17b-c7d2-4fc5-b12d-a3f3b696d140_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleDebtFairValueDisclosures_2686a8d7-9d21-4bb9-983c-7e3fa5f907b5_verboseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebtFairValueDisclosures" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of convertible senior notes outstanding (Level 2)</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebtFairValueDisclosures_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebtFairValueDisclosures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt, Fair Value Disclosures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtFairValueDisclosures" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtFairValueDisclosures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtFairValueDisclosures" xlink:to="lab_us-gaap_ConvertibleDebtFairValueDisclosures" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_92c68964-21c1-4855-9707-95ee5772ae09_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityCurrent_3d618e96-7e41-4758-9ebe-6aa433c1d393_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current finance lease liabilities</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityCurrent" xlink:to="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_512cc81c-c82f-4553-8490-905ce24cbf1f_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (loss) before income tax</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_3e55a8c4-0507-4b44-9f6b-45fdcd315214_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Other Observable Inputs (Level 2)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfAdoptionMember_20e698af-ff7b-421d-b691-0faee7106dce_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfAdoptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Adoption [Domain]</link:label>
    <link:label id="lab_us-gaap_TypeOfAdoptionMember_label_en-US" xlink:label="lab_us-gaap_TypeOfAdoptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfAdoptionMember" xlink:to="lab_us-gaap_TypeOfAdoptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_339dbf8e-b120-40af-bbfb-ab9549b8975b_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill and Other Identifiable Intangible Assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Intangible Assets and Goodwill [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputExpectedDividendRateMember_6f86024a-34e1-48dc-a010-10aa18ee4c80_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputExpectedDividendRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividend yield</link:label>
    <link:label id="lab_us-gaap_MeasurementInputExpectedDividendRateMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputExpectedDividendRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Expected Dividend Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedDividendRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputExpectedDividendRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputExpectedDividendRateMember" xlink:to="lab_us-gaap_MeasurementInputExpectedDividendRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorLocation_5a5588d0-93c3-4bc4-8372-74b4f8c1b4a4_terseLabel_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Location</link:label>
    <link:label id="lab_dei_AuditorLocation_label_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Location</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorLocation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorLocation" xlink:to="lab_dei_AuditorLocation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_93f40478-bcf4-4d26-bebd-eff948bf8b73_totalLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Unrealized Loss Position</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeGainLossOnDerivativeNet_d8f456c3-ce24-4493-8ef9-1705552b87e3_negatedLabel_en-US" xlink:label="lab_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net change in fair value of derivatives</link:label>
    <link:label id="lab_us-gaap_DerivativeGainLossOnDerivativeNet_ee6cb583-71e6-465e-80b2-51642fb2b899_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (loss) on derivative liabilities</link:label>
    <link:label id="lab_us-gaap_DerivativeGainLossOnDerivativeNet_label_en-US" xlink:label="lab_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Gain (Loss) on Derivative, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeGainLossOnDerivativeNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:to="lab_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_80744c76-d994-4566-8f23-403f43a6972d_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_7a38683e-1957-4e47-9903-d7700206affd_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-lived intangible asset, useful life</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseInterestExpense_466de153-d13f-4972-b63f-a1b09276c66c_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseInterestExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance lease expense</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseInterestExpense_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseInterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseInterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseInterestExpense" xlink:to="lab_us-gaap_FinanceLeaseInterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_06121d5a-7504-44e0-a9d2-e1efa3fc726c_verboseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_41170f09-f97f-4a80-9ed7-2ba77edc9732_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Computation of Basic and Diluted Net Income (Loss) per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearFive_a1e52291-a40f-41a5-b936-6677cfe741ba_terseLabel_en-US" xlink:label="lab_lgnd_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">After five years</link:label>
    <link:label id="lab_lgnd_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearFive_label_en-US" xlink:label="lab_lgnd_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year Five</link:label>
    <link:label id="lab_lgnd_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearFive_documentation_en-US" xlink:label="lab_lgnd_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearFive" xlink:href="lgnd-20211231.xsd#lgnd_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearFive" xlink:to="lab_lgnd_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AgencySecuritiesMember_db6e1406-0471-450e-b9f8-6208be4c1e7f_terseLabel_en-US" xlink:label="lab_us-gaap_AgencySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Agency bonds</link:label>
    <link:label id="lab_us-gaap_AgencySecuritiesMember_label_en-US" xlink:label="lab_us-gaap_AgencySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Agency Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AgencySecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AgencySecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AgencySecuritiesMember" xlink:to="lab_us-gaap_AgencySecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_afb45a01-c412-4d6d-b848-dd73e26bd463_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Leases</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Payment, Due [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:to="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_d33907b4-998f-432d-ba36-c2011b2db555_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_6ea09c79-3e3f-463b-bca2-cef2b5909583_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock authorized (shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_062b4415-ca79-44ca-bd4a-fd2674f46bc4_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_2a7514b5-cb14-40db-8c42-435df4cf2d37_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restricted Stock Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_5f81465a-674b-4460-a125-acbedf0a7fc8_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_01550b83-99b8-4a4b-865d-6eaec65583a9_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Account Details</link:label>
    <link:label id="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Balance Sheet Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:to="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_25c7bdab-e0c3-4360-8dc0-4c3ee1e4ccf0_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest on debt instrument (as a percent)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_e8642282-357f-439c-af43-12684d7e41cd_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Renewal term</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Renewal Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_a52a71eb-4910-4fa7-9184-15151e1de5e2_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration liability</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fed9fce3-ab1a-436f-b156-f7ac5ba47863_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_1693e4a3-9944-45bf-a817-bde441819b72_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract_8ad588b1-3674-4350-aba2-2534b2379411_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Amortized Cost, Fiscal Year Maturity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_CommercialLicenseRightsPolicyTextBlock_86c2c3a3-92f2-46e9-9cec-c5b5c7fd41e5_terseLabel_en-US" xlink:label="lab_lgnd_CommercialLicenseRightsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial license and other economic rights</link:label>
    <link:label id="lab_lgnd_CommercialLicenseRightsPolicyTextBlock_label_en-US" xlink:label="lab_lgnd_CommercialLicenseRightsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial License Rights [Policy Text Block]</link:label>
    <link:label id="lab_lgnd_CommercialLicenseRightsPolicyTextBlock_documentation_en-US" xlink:label="lab_lgnd_CommercialLicenseRightsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial License Rights [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_CommercialLicenseRightsPolicyTextBlock" xlink:href="lgnd-20211231.xsd#lgnd_CommercialLicenseRightsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_CommercialLicenseRightsPolicyTextBlock" xlink:to="lab_lgnd_CommercialLicenseRightsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_a54ef0ce-9844-4d4c-b437-00470b120191_terseLabel_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State and Local Jurisdiction</link:label>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_label_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State and Local Jurisdiction [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:to="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_a2a16027-ae72-4a63-bc27-967fada7ff38_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock price trigger to classify convertible debt as current (as a percent)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:to="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VestingDomain_09ab656c-d1ae-4300-9e42-6438609ca472_terseLabel_en-US" xlink:label="lab_us-gaap_VestingDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Domain]</link:label>
    <link:label id="lab_us-gaap_VestingDomain_label_en-US" xlink:label="lab_us-gaap_VestingDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingDomain" xlink:to="lab_us-gaap_VestingDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedSalesCommissionCurrentAndNoncurrent_fb6fcd9a-4f9a-428f-aef5-b865004d4afd_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedSalesCommissionCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amounts owed to former licensees</link:label>
    <link:label id="lab_us-gaap_AccruedSalesCommissionCurrentAndNoncurrent_label_en-US" xlink:label="lab_us-gaap_AccruedSalesCommissionCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Sales Commission</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedSalesCommissionCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedSalesCommissionCurrentAndNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedSalesCommissionCurrentAndNoncurrent" xlink:to="lab_us-gaap_AccruedSalesCommissionCurrentAndNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_ForecastedCashFlowsEffectiveInterestRatePercent_d68f1de4-60e9-489d-a18e-3e2dc5ec8494_terseLabel_en-US" xlink:label="lab_lgnd_ForecastedCashFlowsEffectiveInterestRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective interest rate of forecasted cash flows (as a percent)</link:label>
    <link:label id="lab_lgnd_ForecastedCashFlowsEffectiveInterestRatePercent_label_en-US" xlink:label="lab_lgnd_ForecastedCashFlowsEffectiveInterestRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forecasted Cash Flows, Effective Interest Rate, Percent</link:label>
    <link:label id="lab_lgnd_ForecastedCashFlowsEffectiveInterestRatePercent_documentation_en-US" xlink:label="lab_lgnd_ForecastedCashFlowsEffectiveInterestRatePercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forecasted Cash Flows, Effective Interest Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ForecastedCashFlowsEffectiveInterestRatePercent" xlink:href="lgnd-20211231.xsd#lgnd_ForecastedCashFlowsEffectiveInterestRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_ForecastedCashFlowsEffectiveInterestRatePercent" xlink:to="lab_lgnd_ForecastedCashFlowsEffectiveInterestRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_7e217fa6-786c-4462-8c10-d00e5a21e6c5_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign tax differential on income/loss of foreign subsidiaries</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:to="lab_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount_94a8ccd1-25cb-42f6-a35e-5f933f1650a8_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill acquired that is expected to be deductible for tax purposes</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Goodwill, Expected Tax Deductible Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount" xlink:to="lab_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnInvestments_fbb206b8-ec3f-4548-ad8f-62da04f98316_terseLabel_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized (loss) gain on available-for-sale investments</link:label>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnInvestments_label_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Gain (Loss) on Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrealizedGainLossOnInvestments" xlink:to="lab_us-gaap_UnrealizedGainLossOnInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_36da8f9a-1569-484b-857b-cbb9f9d76057_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_RoyaltyKyprolisMember_56858698-d24c-450c-9e2e-271f24423b5b_terseLabel_en-US" xlink:label="lab_lgnd_RoyaltyKyprolisMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Kyprolis</link:label>
    <link:label id="lab_lgnd_RoyaltyKyprolisMember_label_en-US" xlink:label="lab_lgnd_RoyaltyKyprolisMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty, Kyprolis [Member]</link:label>
    <link:label id="lab_lgnd_RoyaltyKyprolisMember_documentation_en-US" xlink:label="lab_lgnd_RoyaltyKyprolisMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty, Kyprolis</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_RoyaltyKyprolisMember" xlink:href="lgnd-20211231.xsd#lgnd_RoyaltyKyprolisMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_RoyaltyKyprolisMember" xlink:to="lab_lgnd_RoyaltyKyprolisMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_c2d6d7cf-ca52-455c-95f7-bc961755be03_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award vesting period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LimitedLiabilityCompanyLLCOrLimitedPartnershipLPMembersOrLimitedPartnersOwnershipInterest_73e597c9-9a43-4c58-9393-d6619b26d28e_terseLabel_en-US" xlink:label="lab_us-gaap_LimitedLiabilityCompanyLLCOrLimitedPartnershipLPMembersOrLimitedPartnersOwnershipInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership interest (as a percent)</link:label>
    <link:label id="lab_us-gaap_LimitedLiabilityCompanyLLCOrLimitedPartnershipLPMembersOrLimitedPartnersOwnershipInterest_label_en-US" xlink:label="lab_us-gaap_LimitedLiabilityCompanyLLCOrLimitedPartnershipLPMembersOrLimitedPartnersOwnershipInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Limited Liability Company or Limited Partnership, Members or Limited Partners, Ownership Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LimitedLiabilityCompanyLLCOrLimitedPartnershipLPMembersOrLimitedPartnersOwnershipInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LimitedLiabilityCompanyLLCOrLimitedPartnershipLPMembersOrLimitedPartnersOwnershipInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LimitedLiabilityCompanyLLCOrLimitedPartnershipLPMembersOrLimitedPartnersOwnershipInterest" xlink:to="lab_us-gaap_LimitedLiabilityCompanyLLCOrLimitedPartnershipLPMembersOrLimitedPartnersOwnershipInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_909bb36d-4533-4c2a-a97f-08737ceb6d87_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Maturity of Finance Lease Liabilities</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Fiscal Year Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_b50f5300-ffa4-4b7f-940f-133812e5aed9_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:to="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_PartnerAMember_b183a5c6-4a8d-4aed-8350-c2d83efd9a72_terseLabel_en-US" xlink:label="lab_lgnd_PartnerAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Partner A</link:label>
    <link:label id="lab_lgnd_PartnerAMember_label_en-US" xlink:label="lab_lgnd_PartnerAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Partner A [Member]</link:label>
    <link:label id="lab_lgnd_PartnerAMember_documentation_en-US" xlink:label="lab_lgnd_PartnerAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Partner A [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PartnerAMember" xlink:href="lgnd-20211231.xsd#lgnd_PartnerAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_PartnerAMember" xlink:to="lab_lgnd_PartnerAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_33ecf780-3691-4015-bfc5-840955dc1371_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated amortization expense for 2024</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCountryMember_0ee6496c-2fdf-483f-936a-39f0d6b97cff_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCountryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-US</link:label>
    <link:label id="lab_us-gaap_ForeignCountryMember_label_en-US" xlink:label="lab_us-gaap_ForeignCountryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Tax Authority [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCountryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCountryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCountryMember" xlink:to="lab_us-gaap_ForeignCountryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesAbstract_6b084973-3188-4f0a-ac56-de37aa7e3ab8_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liabilities:</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Gross [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationsPolicy_6db6178e-ef80-470c-8b25-c8f060d240f0_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisitions</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationsPolicy_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationsPolicy" xlink:to="lab_us-gaap_BusinessCombinationsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_2242dd9c-c6e4-49a2-b69d-a0f7ea35ea88_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_096598dd-f32e-44eb-879a-318a73a376d7_negatedLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable and accrued liabilities</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_TaurusBiosciencesLLCMember_32562d7b-7c9b-4b13-b4f7-ed60074fa736_terseLabel_en-US" xlink:label="lab_lgnd_TaurusBiosciencesLLCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Taurus</link:label>
    <link:label id="lab_lgnd_TaurusBiosciencesLLCMember_label_en-US" xlink:label="lab_lgnd_TaurusBiosciencesLLCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Taurus Biosciences, LLC [Member]</link:label>
    <link:label id="lab_lgnd_TaurusBiosciencesLLCMember_documentation_en-US" xlink:label="lab_lgnd_TaurusBiosciencesLLCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Taurus Biosciences, LLC</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_TaurusBiosciencesLLCMember" xlink:href="lgnd-20211231.xsd#lgnd_TaurusBiosciencesLLCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_TaurusBiosciencesLLCMember" xlink:to="lab_lgnd_TaurusBiosciencesLLCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesAbstract_d6648497-fce3-4772-abfc-b28f9328e2dc_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues:</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract" xlink:to="lab_us-gaap_RevenuesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_eb2429b8-8613-421b-bcc4-871b8333d5b8_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Intangible Assets and Other Long-Lived Assets</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_AccountsReceivableCreditLossExpenseReversalCOVID19_82a594ee-0471-4984-a8b6-d38290b2800f_negatedTerseLabel_en-US" xlink:label="lab_lgnd_AccountsReceivableCreditLossExpenseReversalCOVID19" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional reserve for credit losses due to COVID-19</link:label>
    <link:label id="lab_lgnd_AccountsReceivableCreditLossExpenseReversalCOVID19_label_en-US" xlink:label="lab_lgnd_AccountsReceivableCreditLossExpenseReversalCOVID19" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Credit Loss Expense (Reversal), COVID-19</link:label>
    <link:label id="lab_lgnd_AccountsReceivableCreditLossExpenseReversalCOVID19_documentation_en-US" xlink:label="lab_lgnd_AccountsReceivableCreditLossExpenseReversalCOVID19" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Credit Loss Expense (Reversal), COVID-19</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AccountsReceivableCreditLossExpenseReversalCOVID19" xlink:href="lgnd-20211231.xsd#lgnd_AccountsReceivableCreditLossExpenseReversalCOVID19"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_AccountsReceivableCreditLossExpenseReversalCOVID19" xlink:to="lab_lgnd_AccountsReceivableCreditLossExpenseReversalCOVID19" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_108221e1-095f-4d86-aa59-1f593467f397_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_928d7337-dd3a-402d-a70a-a7a5a4889671_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_ContractualRelationshipsSIIMember_c95fb5f2-ca8e-4703-b4a6-500970653158_terseLabel_en-US" xlink:label="lab_lgnd_ContractualRelationshipsSIIMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual Relationships - SII</link:label>
    <link:label id="lab_lgnd_ContractualRelationshipsSIIMember_label_en-US" xlink:label="lab_lgnd_ContractualRelationshipsSIIMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual Relationships - SII [Member]</link:label>
    <link:label id="lab_lgnd_ContractualRelationshipsSIIMember_documentation_en-US" xlink:label="lab_lgnd_ContractualRelationshipsSIIMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual Relationships - SII</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ContractualRelationshipsSIIMember" xlink:href="lgnd-20211231.xsd#lgnd_ContractualRelationshipsSIIMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_ContractualRelationshipsSIIMember" xlink:to="lab_lgnd_ContractualRelationshipsSIIMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_1c63ac94-a0b7-4066-b2a3-1a4b797bf528_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized net gain (loss) on available-for-sale securities, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_f25f8e03-ad85-4eee-935f-b61027320f25_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_OtherBalanceSheetDetailsAbstract_label_en-US" xlink:label="lab_lgnd_OtherBalanceSheetDetailsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Balance Sheet Details [Abstract]</link:label>
    <link:label id="lab_lgnd_OtherBalanceSheetDetailsAbstract_documentation_en-US" xlink:label="lab_lgnd_OtherBalanceSheetDetailsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Balance Sheet Details [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_OtherBalanceSheetDetailsAbstract" xlink:href="lgnd-20211231.xsd#lgnd_OtherBalanceSheetDetailsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_OtherBalanceSheetDetailsAbstract" xlink:to="lab_lgnd_OtherBalanceSheetDetailsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_5371873a-d81a-4b54-9d76-d397b5b491fa_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred State and Local Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_db6a696a-0f9e-4e6d-a8be-c2916d6a3183_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_23b28451-0da4-4987-a830-bfbe07a2a83c_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_d0d621d2-9530-43a0-bbf1-47a91033bf8d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">12 months or greater</link:label>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_label_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Held-to-maturity, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:to="lab_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_519fabfa-7b66-4281-a2d6-b6a0e1ed11d6_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Table]</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContingentConsiderationTypeDomain_15612627-f8c7-42fa-a01a-afcb0476d248_terseLabel_en-US" xlink:label="lab_us-gaap_ContingentConsiderationTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ContingentConsiderationTypeDomain_label_en-US" xlink:label="lab_us-gaap_ContingentConsiderationTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContingentConsiderationTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain" xlink:to="lab_us-gaap_ContingentConsiderationTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_3d79797b-761b-4fda-bc06-53b80b488bb4_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental schedule of non-cash investing and financing activities</link:label>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_0328fb51-de91-4cd7-b785-7854c02e3c16_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase the number of shares under the 2002 Stock Incentive Plan (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_51f0b507-f438-463e-8a94-38fece458bda_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Post-combination expense</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Transaction Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" xlink:to="lab_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_18e1f960-cb5c-490a-8f8b-6f95a4885d3b_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_47644d04-55ef-4f57-a931-399b71f3af91_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_USDistrictCourtForTheNorthernDistrictOfOhioMember_8d5f0468-402b-412b-b44e-9a057fe70329_terseLabel_en-US" xlink:label="lab_lgnd_USDistrictCourtForTheNorthernDistrictOfOhioMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US District Court for the Northern District of Ohio</link:label>
    <link:label id="lab_lgnd_USDistrictCourtForTheNorthernDistrictOfOhioMember_label_en-US" xlink:label="lab_lgnd_USDistrictCourtForTheNorthernDistrictOfOhioMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US District Court for the Northern District of Ohio [Member]</link:label>
    <link:label id="lab_lgnd_USDistrictCourtForTheNorthernDistrictOfOhioMember_documentation_en-US" xlink:label="lab_lgnd_USDistrictCourtForTheNorthernDistrictOfOhioMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US District Court for the Northern District of Ohio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_USDistrictCourtForTheNorthernDistrictOfOhioMember" xlink:href="lgnd-20211231.xsd#lgnd_USDistrictCourtForTheNorthernDistrictOfOhioMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_USDistrictCourtForTheNorthernDistrictOfOhioMember" xlink:to="lab_lgnd_USDistrictCourtForTheNorthernDistrictOfOhioMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_BusinessCombinationContingentConsiderationLiabilityAmountPerShare_561dc1bb-a2fb-40de-b90e-00ae8a02c9f7_terseLabel_en-US" xlink:label="lab_lgnd_BusinessCombinationContingentConsiderationLiabilityAmountPerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration liability per share (USD per share)</link:label>
    <link:label id="lab_lgnd_BusinessCombinationContingentConsiderationLiabilityAmountPerShare_label_en-US" xlink:label="lab_lgnd_BusinessCombinationContingentConsiderationLiabilityAmountPerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Amount per Share</link:label>
    <link:label id="lab_lgnd_BusinessCombinationContingentConsiderationLiabilityAmountPerShare_documentation_en-US" xlink:label="lab_lgnd_BusinessCombinationContingentConsiderationLiabilityAmountPerShare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Amount per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BusinessCombinationContingentConsiderationLiabilityAmountPerShare" xlink:href="lgnd-20211231.xsd#lgnd_BusinessCombinationContingentConsiderationLiabilityAmountPerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_BusinessCombinationContingentConsiderationLiabilityAmountPerShare" xlink:to="lab_lgnd_BusinessCombinationContingentConsiderationLiabilityAmountPerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostDirectMaterial_117b1420-09a8-459f-9c7c-6421bc49666f_terseLabel_en-US" xlink:label="lab_us-gaap_CostDirectMaterial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Captisol</link:label>
    <link:label id="lab_us-gaap_CostDirectMaterial_label_en-US" xlink:label="lab_us-gaap_CostDirectMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost, Direct Material</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostDirectMaterial" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostDirectMaterial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostDirectMaterial" xlink:to="lab_us-gaap_CostDirectMaterial" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_ee0b1486-ef89-42c7-ba6a-6d3b2655aec5_negatedLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayment of debt</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:to="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_1c1d2227-dfc1-4041-9b3d-d9f28791e965_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_b3ad9384-b472-48ae-ba03-8e72c0464836_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment , gross</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_ScheduleofCommercialLicenseRightsTableTextBlock_8ca428e2-da9b-4c65-a512-53a369a5feac_terseLabel_en-US" xlink:label="lab_lgnd_ScheduleofCommercialLicenseRightsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Commercial License Rights</link:label>
    <link:label id="lab_lgnd_ScheduleofCommercialLicenseRightsTableTextBlock_label_en-US" xlink:label="lab_lgnd_ScheduleofCommercialLicenseRightsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Commercial License Rights [Table Text Block]</link:label>
    <link:label id="lab_lgnd_ScheduleofCommercialLicenseRightsTableTextBlock_documentation_en-US" xlink:label="lab_lgnd_ScheduleofCommercialLicenseRightsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Commercial License Rights [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ScheduleofCommercialLicenseRightsTableTextBlock" xlink:href="lgnd-20211231.xsd#lgnd_ScheduleofCommercialLicenseRightsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_ScheduleofCommercialLicenseRightsTableTextBlock" xlink:to="lab_lgnd_ScheduleofCommercialLicenseRightsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c120712c-1dce-4a8b-8dc1-e5760a95a8f0_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at beginning of period (USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_68f3a881-a21f-4e28-ac8a-7bd72522e743_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at end of period (USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_c49bc46f-f89e-4567-9130-965b1f6fe9f9_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of positions in an unrealized loss position</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Unrealized Loss Position, Number of Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_LiabilityForContingentValueRightsCompanyMetabasisMember_35d0cf9d-52d0-4e2a-8daa-f9b99ea233ba_terseLabel_en-US" xlink:label="lab_lgnd_LiabilityForContingentValueRightsCompanyMetabasisMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent liabilities - Metabasis</link:label>
    <link:label id="lab_lgnd_LiabilityForContingentValueRightsCompanyMetabasisMember_label_en-US" xlink:label="lab_lgnd_LiabilityForContingentValueRightsCompanyMetabasisMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability For Contingent Value Rights Company, Metabasis [Member]</link:label>
    <link:label id="lab_lgnd_LiabilityForContingentValueRightsCompanyMetabasisMember_documentation_en-US" xlink:label="lab_lgnd_LiabilityForContingentValueRightsCompanyMetabasisMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability For Contingent Value Rights Company, Metabasis</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_LiabilityForContingentValueRightsCompanyMetabasisMember" xlink:href="lgnd-20211231.xsd#lgnd_LiabilityForContingentValueRightsCompanyMetabasisMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_LiabilityForContingentValueRightsCompanyMetabasisMember" xlink:to="lab_lgnd_LiabilityForContingentValueRightsCompanyMetabasisMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_c3633b54-5da3-4625-beaa-91d027409308_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_7aa37938-5358-4ff2-a6b1-8949073cec17_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-Average Grant&#160;Date Fair Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_SelexisMember_6320fe0b-8cab-479f-b31a-0b679463c0e9_terseLabel_en-US" xlink:label="lab_lgnd_SelexisMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selexis</link:label>
    <link:label id="lab_lgnd_SelexisMember_label_en-US" xlink:label="lab_lgnd_SelexisMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selexis [Member]</link:label>
    <link:label id="lab_lgnd_SelexisMember_documentation_en-US" xlink:label="lab_lgnd_SelexisMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selexis</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_SelexisMember" xlink:href="lgnd-20211231.xsd#lgnd_SelexisMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_SelexisMember" xlink:to="lab_lgnd_SelexisMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_33114035-6616-4361-bf6f-9fbc2e1c37a2_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization/accretion of premium (discount) on investments, net</link:label>
    <link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_label_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accretion (Amortization) of Discounts and Premiums, Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:to="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_49575012-f42c-4874-a660-48340c242ec7_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_CorporateShareRepurchaseAbstract_50e35e98-b7e3-44e7-b1eb-11105645a0f1_terseLabel_en-US" xlink:label="lab_lgnd_CorporateShareRepurchaseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Share Repurchase</link:label>
    <link:label id="lab_lgnd_CorporateShareRepurchaseAbstract_label_en-US" xlink:label="lab_lgnd_CorporateShareRepurchaseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Share Repurchase [Abstract]</link:label>
    <link:label id="lab_lgnd_CorporateShareRepurchaseAbstract_documentation_en-US" xlink:label="lab_lgnd_CorporateShareRepurchaseAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Share Repurchase [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_CorporateShareRepurchaseAbstract" xlink:href="lgnd-20211231.xsd#lgnd_CorporateShareRepurchaseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_CorporateShareRepurchaseAbstract" xlink:to="lab_lgnd_CorporateShareRepurchaseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardNameDomain_ebeeafd7-7881-4cf0-ac97-c5070f696c53_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardNameDomain_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="lab_us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable_914a7c01-a877-4cc2-b3da-bfdfd899e038_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Unrealized Loss Position, Fair Value [Table]</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Unrealized Loss Position, Fair Value [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_BasisOfPresentationTable_6cd3032a-d521-43df-856b-3d13e2590bb4_terseLabel_en-US" xlink:label="lab_lgnd_BasisOfPresentationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation [Table]</link:label>
    <link:label id="lab_lgnd_BasisOfPresentationTable_label_en-US" xlink:label="lab_lgnd_BasisOfPresentationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation [Table]</link:label>
    <link:label id="lab_lgnd_BasisOfPresentationTable_documentation_en-US" xlink:label="lab_lgnd_BasisOfPresentationTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BasisOfPresentationTable" xlink:href="lgnd-20211231.xsd#lgnd_BasisOfPresentationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_BasisOfPresentationTable" xlink:to="lab_lgnd_BasisOfPresentationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputDiscountRateMember_6412cc97-c90a-49c8-80a7-45b8386c82da_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discount Rate</link:label>
    <link:label id="lab_us-gaap_MeasurementInputDiscountRateMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Discount Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputDiscountRateMember" xlink:to="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableInterestEntityDisclosureTextBlock_72fb7d5e-607c-4b80-b787-d7f2327aec2e_terseLabel_en-US" xlink:label="lab_us-gaap_VariableInterestEntityDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Investments: Investment in Viking</link:label>
    <link:label id="lab_us-gaap_VariableInterestEntityDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_VariableInterestEntityDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entity Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableInterestEntityDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableInterestEntityDisclosureTextBlock" xlink:to="lab_us-gaap_VariableInterestEntityDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_f9635afc-f23b-4aa7-b6fa-d0d480fda353_terseLabel_en-US" xlink:label="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenue from Significant Partners</link:label>
    <link:label id="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_label_en-US" xlink:label="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedules of Concentration of Risk, by Risk Factor [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:to="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodOneMember_c67f31ee-9af8-4a24-aa58-a722b20a5ed5_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redemption Period One</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodOneMember_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period One [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_CommercialLicenseRights_da98af64-8a95-429f-90d2-48a75a679c42_terseLabel_en-US" xlink:label="lab_lgnd_CommercialLicenseRights" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial license and other economic rights</link:label>
    <link:label id="lab_lgnd_CommercialLicenseRights_label_en-US" xlink:label="lab_lgnd_CommercialLicenseRights" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial License Rights</link:label>
    <link:label id="lab_lgnd_CommercialLicenseRights_documentation_en-US" xlink:label="lab_lgnd_CommercialLicenseRights" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial License Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_CommercialLicenseRights" xlink:href="lgnd-20211231.xsd#lgnd_CommercialLicenseRights"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_CommercialLicenseRights" xlink:to="lab_lgnd_CommercialLicenseRights" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_7e8851ad-4f36-46d6-b121-30978e38d7a9_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupClassificationDomain_c7aee615-4b82-4af3-b11d-b75394e957c5_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Classification [Domain]</link:label>
    <link:label id="lab_us-gaap_DisposalGroupClassificationDomain_label_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Classification [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain" xlink:to="lab_us-gaap_DisposalGroupClassificationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_35586620-699b-4dd7-a766-d30d78ef9fa8_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateAfterYearFive_b291ba37-3a59-4751-b914-627c32a18625_terseLabel_en-US" xlink:label="lab_lgnd_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">After five years</link:label>
    <link:label id="lab_lgnd_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateAfterYearFive_label_en-US" xlink:label="lab_lgnd_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year Five</link:label>
    <link:label id="lab_lgnd_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateAfterYearFive_documentation_en-US" xlink:label="lab_lgnd_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateAfterYearFive" xlink:href="lgnd-20211231.xsd#lgnd_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateAfterYearFive" xlink:to="lab_lgnd_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_c5921648-ba9f-48a0-9d9c-fd45d8485e62_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_PaymentsToContingentValueRightHolders_886a7cbe-811e-4a08-b9ef-1d16eaa25702_negatedLabel_en-US" xlink:label="lab_lgnd_PaymentsToContingentValueRightHolders" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to CVR holders and other contingency payments</link:label>
    <link:label id="lab_lgnd_PaymentsToContingentValueRightHolders_5f1e7c36-0ece-4c1b-98d0-4b3c6e11e0a0_negatedTerseLabel_en-US" xlink:label="lab_lgnd_PaymentsToContingentValueRightHolders" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments</link:label>
    <link:label id="lab_lgnd_PaymentsToContingentValueRightHolders_label_en-US" xlink:label="lab_lgnd_PaymentsToContingentValueRightHolders" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Contingent Value Right Holders</link:label>
    <link:label id="lab_lgnd_PaymentsToContingentValueRightHolders_documentation_en-US" xlink:label="lab_lgnd_PaymentsToContingentValueRightHolders" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to contingent value right holders</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PaymentsToContingentValueRightHolders" xlink:href="lgnd-20211231.xsd#lgnd_PaymentsToContingentValueRightHolders"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_PaymentsToContingentValueRightHolders" xlink:to="lab_lgnd_PaymentsToContingentValueRightHolders" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_34a7c30b-fa06-43ae-9ca8-72bbf37615ab_netLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares used in diluted per share calculation (shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_63f06106-457c-4763-97e9-453f01f3064a_totalLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares used to compute diluted income per share (shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_f4b0fec2-69d2-472b-9d3f-93bd178296e3_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_302c32b9-e63c-4a80-a2a9-9344c2e1de98_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_3592b728-ed19-4d91-8c8d-0fb56d9de20c_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock Option Plan Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_ContingentLiabilityRollForward_ee573311-3b31-4c57-a23a-00807e057938_terseLabel_en-US" xlink:label="lab_lgnd_ContingentLiabilityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Liability [Roll Forward]</link:label>
    <link:label id="lab_lgnd_ContingentLiabilityRollForward_label_en-US" xlink:label="lab_lgnd_ContingentLiabilityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Liability [Roll Forward]</link:label>
    <link:label id="lab_lgnd_ContingentLiabilityRollForward_documentation_en-US" xlink:label="lab_lgnd_ContingentLiabilityRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Liability [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ContingentLiabilityRollForward" xlink:href="lgnd-20211231.xsd#lgnd_ContingentLiabilityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_ContingentLiabilityRollForward" xlink:to="lab_lgnd_ContingentLiabilityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_b4624e37-9905-4066-bcd4-d0aa254c035d_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reacquisition of equity due to 2023 debt extinguishment, net of tax</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_32e0528b-e0c5-456a-9d00-d41795360d4d_negatedLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt issuance costs related to the equity component of convertible debt</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_05737444-52ce-45f5-9058-fff00a38d6a5_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_2c8bc212-38cc-4efa-904e-b5271c81aeea_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_68924464-49b0-4686-914e-7414231c53d6_negatedLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less accumulated depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_GainLossOnShortTermInvestments_dd48dbca-82a9-4c76-8b60-1bb2890d38dc_negatedTerseLabel_en-US" xlink:label="lab_lgnd_GainLossOnShortTermInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss (gain) short-term investments</link:label>
    <link:label id="lab_lgnd_GainLossOnShortTermInvestments_label_en-US" xlink:label="lab_lgnd_GainLossOnShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Short-Term Investments</link:label>
    <link:label id="lab_lgnd_GainLossOnShortTermInvestments_documentation_en-US" xlink:label="lab_lgnd_GainLossOnShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Short-Term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_GainLossOnShortTermInvestments" xlink:href="lgnd-20211231.xsd#lgnd_GainLossOnShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_GainLossOnShortTermInvestments" xlink:to="lab_lgnd_GainLossOnShortTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_ce50b535-2579-4cdc-ac80-71eaf424af2d_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_a3165fce-a6cf-4cc7-a774-2c7cfe14e21a_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative expenses</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_1071d253-1469-4233-8709-20d420cd3125_verboseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principles of Consolidation</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_80c9dc3e-d203-47f8-9017-24d95814bcd9_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_a484bb9f-60cc-4735-a785-63f3881aeb09_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_51dbb464-bfe9-4674-8d34-7eb39f59cc6c_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_9d504e9a-8e93-4a3c-9e98-33f3ad544ba7_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Taxes paid related to net share settlement of equity awards</link:label>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment, Tax Withholding, Share-based Payment Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_b4d610b4-66f5-448b-810d-097b4068edfb_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_e9a68ee9-1c47-4830-b03a-cd26bc7f9369_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Including Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_b8054206-a4d4-4112-a9f5-c04a34be85b7_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options vested and expected to vest, Aggregate Intrinsic Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_LiabilityForContingentValueRightsCompanyPfenexMember_4c81720a-9c74-42f7-80a8-b8c366ca2feb_terseLabel_en-US" xlink:label="lab_lgnd_LiabilityForContingentValueRightsCompanyPfenexMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent liabilities - Pfenex</link:label>
    <link:label id="lab_lgnd_LiabilityForContingentValueRightsCompanyPfenexMember_label_en-US" xlink:label="lab_lgnd_LiabilityForContingentValueRightsCompanyPfenexMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability For Contingent Value Rights Company, Pfenex [Member]</link:label>
    <link:label id="lab_lgnd_LiabilityForContingentValueRightsCompanyPfenexMember_documentation_en-US" xlink:label="lab_lgnd_LiabilityForContingentValueRightsCompanyPfenexMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability For Contingent Value Rights Company, Pfenex</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_LiabilityForContingentValueRightsCompanyPfenexMember" xlink:href="lgnd-20211231.xsd#lgnd_LiabilityForContingentValueRightsCompanyPfenexMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_LiabilityForContingentValueRightsCompanyPfenexMember" xlink:to="lab_lgnd_LiabilityForContingentValueRightsCompanyPfenexMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_15c96362-f39c-4ff5-a225-d4b91b32fb37_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock_4496f1d4-7cd7-44ca-a13a-2b8980f857a4_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:to="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_DebtInstrumentConvertibleIncreaseDecreaseIfConvertedValueInExcessOfPrincipal_9e49fe2c-f471-4a8c-958a-591a66a26b41_terseLabel_en-US" xlink:label="lab_lgnd_DebtInstrumentConvertibleIncreaseDecreaseIfConvertedValueInExcessOfPrincipal" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (decrease) in if-converted value in excess of principal</link:label>
    <link:label id="lab_lgnd_DebtInstrumentConvertibleIncreaseDecreaseIfConvertedValueInExcessOfPrincipal_label_en-US" xlink:label="lab_lgnd_DebtInstrumentConvertibleIncreaseDecreaseIfConvertedValueInExcessOfPrincipal" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Increase (Decrease) If-Converted Value in Excess of Principal</link:label>
    <link:label id="lab_lgnd_DebtInstrumentConvertibleIncreaseDecreaseIfConvertedValueInExcessOfPrincipal_documentation_en-US" xlink:label="lab_lgnd_DebtInstrumentConvertibleIncreaseDecreaseIfConvertedValueInExcessOfPrincipal" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Increase (Decrease) If-Converted Value in Excess of Principal</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_DebtInstrumentConvertibleIncreaseDecreaseIfConvertedValueInExcessOfPrincipal" xlink:href="lgnd-20211231.xsd#lgnd_DebtInstrumentConvertibleIncreaseDecreaseIfConvertedValueInExcessOfPrincipal"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_DebtInstrumentConvertibleIncreaseDecreaseIfConvertedValueInExcessOfPrincipal" xlink:to="lab_lgnd_DebtInstrumentConvertibleIncreaseDecreaseIfConvertedValueInExcessOfPrincipal" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MutualFundMember_899d7693-597c-45a3-aee9-6ca9f178a022_terseLabel_en-US" xlink:label="lab_us-gaap_MutualFundMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mutual fund</link:label>
    <link:label id="lab_us-gaap_MutualFundMember_label_en-US" xlink:label="lab_us-gaap_MutualFundMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mutual Fund [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MutualFundMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MutualFundMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MutualFundMember" xlink:to="lab_us-gaap_MutualFundMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_45d82f04-dad0-4cf4-a072-2b36c625160e_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_6bb5bd7c-5530-4a0e-ab55-f1f2ed68d200_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Recently Adopted and Accounting Standards Not Yet Adopted</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_14bd65d6-3d7c-4f86-8192-fdff8ee3a8fa_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOther" xlink:to="lab_us-gaap_DeferredTaxAssetsOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain_3270c8a3-7db5-44e0-bdd5-87e3124e57d4_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyNewClaimsFiledNumber_737a0723-67ff-49f0-918e-d666a2364a55_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyNewClaimsFiledNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of civil complaints filed against entity</link:label>
    <link:label id="lab_us-gaap_LossContingencyNewClaimsFiledNumber_label_en-US" xlink:label="lab_us-gaap_LossContingencyNewClaimsFiledNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, New Claims Filed, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNewClaimsFiledNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyNewClaimsFiledNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyNewClaimsFiledNumber" xlink:to="lab_us-gaap_LossContingencyNewClaimsFiledNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_c8c861b1-ffd0-4404-947c-c0778b313fa6_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_a0565513-d02f-413e-a9d5-f754c6ebb550_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityNoncurrent_fafc1cbd-a6f0-4556-a1ad-415232be43ba_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term finance lease liabilities</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_7a9a71ea-cd6b-48b4-b146-7c2b0b97931b_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-lived intangible assets, net</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_05e3a99e-b15e-4ee0-b775-e339bf0e043f_totalLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_d105f2e0-8e0e-4101-a37a-c643f88471f0_verboseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_0cab888e-be33-4e9c-aa29-830d3220422b_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_ExercisePriceRangeElevenMember_26ad8d1d-a898-4db1-8166-9e18794c0afc_terseLabel_en-US" xlink:label="lab_lgnd_ExercisePriceRangeElevenMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">$12.53 &#8211; $195.91</link:label>
    <link:label id="lab_lgnd_ExercisePriceRangeElevenMember_label_en-US" xlink:label="lab_lgnd_ExercisePriceRangeElevenMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range Eleven [Member]</link:label>
    <link:label id="lab_lgnd_ExercisePriceRangeElevenMember_documentation_en-US" xlink:label="lab_lgnd_ExercisePriceRangeElevenMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range Eleven [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ExercisePriceRangeElevenMember" xlink:href="lgnd-20211231.xsd#lgnd_ExercisePriceRangeElevenMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_ExercisePriceRangeElevenMember" xlink:to="lab_lgnd_ExercisePriceRangeElevenMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_be0a8bae-3d0e-47ba-8bc5-4a7ad5801974_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less than 12 months</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_222d1f21-6015-47a0-a081-d55f3158b857_verboseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_LeaseLiability_442bc569-58da-47b2-b2b2-f5aaf5a7b3c9_totalLabel_en-US" xlink:label="lab_lgnd_LeaseLiability" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease liabilities</link:label>
    <link:label id="lab_lgnd_LeaseLiability_label_en-US" xlink:label="lab_lgnd_LeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Liability</link:label>
    <link:label id="lab_lgnd_LeaseLiability_documentation_en-US" xlink:label="lab_lgnd_LeaseLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_LeaseLiability" xlink:href="lgnd-20211231.xsd#lgnd_LeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_LeaseLiability" xlink:to="lab_lgnd_LeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_f7b20858-14a5-4863-a41d-690c84e06ea1_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_MilestonePaymentsMember_9cc12e55-491c-4a93-9675-6d33c6212252_terseLabel_en-US" xlink:label="lab_lgnd_MilestonePaymentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payments</link:label>
    <link:label id="lab_lgnd_MilestonePaymentsMember_label_en-US" xlink:label="lab_lgnd_MilestonePaymentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payments [Member]</link:label>
    <link:label id="lab_lgnd_MilestonePaymentsMember_documentation_en-US" xlink:label="lab_lgnd_MilestonePaymentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_MilestonePaymentsMember" xlink:href="lgnd-20211231.xsd#lgnd_MilestonePaymentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_MilestonePaymentsMember" xlink:to="lab_lgnd_MilestonePaymentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis_473e3e69-b2c9-4a46-a735-b528d8215bca_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_f13bdc0c-2cc5-490b-8b58-5e5c778c7397_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total deferred expense (benefit)</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_4469db34-b439-4f22-a4b3-5dd2a400176c_verboseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options vested and expected to vest, Weighted Average Remaining Contractual Term in Years</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets_bb6669bc-3d8b-426b-8230-68e71c0673d9_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets, net</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_15e89692-581b-4b78-8c39-289ee34b37a1_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock repurchase program, authorized amount</link:label>
    <link:label id="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_label_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchase Program, Authorized Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:to="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_25d538ab-21c8-43f1-a4cb-edff801fa340_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_ContractualRelationshipsJazzMember_1722c55e-6c93-45bf-87b8-be9f7d5e6ece_terseLabel_en-US" xlink:label="lab_lgnd_ContractualRelationshipsJazzMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual Relationships - Jazz</link:label>
    <link:label id="lab_lgnd_ContractualRelationshipsJazzMember_label_en-US" xlink:label="lab_lgnd_ContractualRelationshipsJazzMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual Relationships - Jazz [Member]</link:label>
    <link:label id="lab_lgnd_ContractualRelationshipsJazzMember_documentation_en-US" xlink:label="lab_lgnd_ContractualRelationshipsJazzMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual Relationships - Jazz</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ContractualRelationshipsJazzMember" xlink:href="lgnd-20211231.xsd#lgnd_ContractualRelationshipsJazzMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_ContractualRelationshipsJazzMember" xlink:to="lab_lgnd_ContractualRelationshipsJazzMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationIntegrationRelatedCosts_588a4575-ce9a-41c9-98a0-9902e5a61809_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationIntegrationRelatedCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Integration related costs</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationIntegrationRelatedCosts_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationIntegrationRelatedCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Integration Related Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationIntegrationRelatedCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationIntegrationRelatedCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationIntegrationRelatedCosts" xlink:to="lab_us-gaap_BusinessCombinationIntegrationRelatedCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_702cf9f1-b904-45e2-98cf-de6f435bae26_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurements, Fair Value Hierarchy [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_93a20c30-a5b8-49b6-9cb1-ee16c778b668_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss)</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_2e309add-9bc8-4a37-875d-21e989c43e4a_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss)</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_753ccfcd-6c15-4016-b2f0-2acfbeb4b97f_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_9c1844b4-6940-4442-a282-d69d8eb20158_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right of use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_269fb827-14b8-45c3-a1b1-5f1f72608085_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net operating loss carryforwards</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_a2957e6c-563a-4e34-969d-55a9261c20d8_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_80d07e45-e9bf-4d85-84ea-1a9a035cbd9b_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_MaturityPeriodOfHighlyLiquidSecuritiesMaximum_28cce70d-e838-4ffd-b0df-9d5cd530775a_terseLabel_en-US" xlink:label="lab_lgnd_MaturityPeriodOfHighlyLiquidSecuritiesMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturity period of cash and cash equivalents, maximum</link:label>
    <link:label id="lab_lgnd_MaturityPeriodOfHighlyLiquidSecuritiesMaximum_label_en-US" xlink:label="lab_lgnd_MaturityPeriodOfHighlyLiquidSecuritiesMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturity Period Of Highly Liquid Securities Maximum</link:label>
    <link:label id="lab_lgnd_MaturityPeriodOfHighlyLiquidSecuritiesMaximum_documentation_en-US" xlink:label="lab_lgnd_MaturityPeriodOfHighlyLiquidSecuritiesMaximum" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturity period of highly liquid securities maximum.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_MaturityPeriodOfHighlyLiquidSecuritiesMaximum" xlink:href="lgnd-20211231.xsd#lgnd_MaturityPeriodOfHighlyLiquidSecuritiesMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_MaturityPeriodOfHighlyLiquidSecuritiesMaximum" xlink:to="lab_lgnd_MaturityPeriodOfHighlyLiquidSecuritiesMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_483f2e82-cd4c-4cdc-b3ec-d530e86a018a_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated amortization on finite-lived intangible assets</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_3679a486-000c-4c92-bd11-06d87aa806e7_negatedLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Accumulated amortization</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_bcd43ed8-816c-41fa-9275-ec04474ca4ce_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_068c7084-5183-4ce8-a625-37134b7bd646_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee_cc2a8419-0baf-4765-9f2e-7a88159f583b_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares allowed to purchase in employee stock purchase plan per employee (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Maximum Number of Shares Per Employee</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_NumberOfAcquisitions_e28f8d80-1147-42c2-b402-58e990bb79b3_terseLabel_en-US" xlink:label="lab_lgnd_NumberOfAcquisitions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of acquisitions</link:label>
    <link:label id="lab_lgnd_NumberOfAcquisitions_label_en-US" xlink:label="lab_lgnd_NumberOfAcquisitions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Acquisitions</link:label>
    <link:label id="lab_lgnd_NumberOfAcquisitions_documentation_en-US" xlink:label="lab_lgnd_NumberOfAcquisitions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Acquisitions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_NumberOfAcquisitions" xlink:href="lgnd-20211231.xsd#lgnd_NumberOfAcquisitions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_NumberOfAcquisitions" xlink:to="lab_lgnd_NumberOfAcquisitions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_ace3a109-52b4-4606-867f-c138821c1617_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfBusinessesAcquired_93cd7799-2b7d-42e4-80a0-79ae5b6bc9fd_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfBusinessesAcquired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of business combinations</link:label>
    <link:label id="lab_us-gaap_NumberOfBusinessesAcquired_label_en-US" xlink:label="lab_us-gaap_NumberOfBusinessesAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Businesses Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfBusinessesAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfBusinessesAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfBusinessesAcquired" xlink:to="lab_us-gaap_NumberOfBusinessesAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentMember_8cbe9091-002d-4e9f-a77f-227d02f41868_terseLabel_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In Process Research and Development</link:label>
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentMember_label_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In Process Research and Development [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InProcessResearchAndDevelopmentMember" xlink:to="lab_us-gaap_InProcessResearchAndDevelopmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_680ffbf8-8961-4f55-ab69-bdef4145ee7d_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_d51c631c-81e5-46ce-aa53-217c246c1b6f_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PatentedTechnologyMember_a5fe23b8-8df4-46cb-b600-bfab1a98671e_verboseLabel_en-US" xlink:label="lab_us-gaap_PatentedTechnologyMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Complete technology</link:label>
    <link:label id="lab_us-gaap_PatentedTechnologyMember_label_en-US" xlink:label="lab_us-gaap_PatentedTechnologyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patented Technology [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PatentedTechnologyMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PatentedTechnologyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PatentedTechnologyMember" xlink:to="lab_us-gaap_PatentedTechnologyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_c3402188-e8ff-4c11-860a-84fee9219659_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available-for-Sale Debt Securities by Contractual Maturity</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_c612c1b3-87cd-4a82-933c-d39744937d1f_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Vernalis R&amp;D and Promacta License</link:label>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:to="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_b5c66361-d56f-491d-8f6c-e212083ff6f3_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_dac6e460-13f1-45e1-b9a5-2495e80e3323_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenue by Major Customers, by Reporting Segments [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenue by Major Customers, by Reporting Segments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:to="lab_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByLiabilityClassAxis_04484205-59ca-4a1f-a8ff-de0ac7ffcb10_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByLiabilityClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByLiabilityClassAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByLiabilityClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis" xlink:to="lab_us-gaap_FairValueByLiabilityClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BuildingMember_cbf720e2-93e9-42c4-b573-1e4e0e4b3ee1_terseLabel_en-US" xlink:label="lab_us-gaap_BuildingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Building</link:label>
    <link:label id="lab_us-gaap_BuildingMember_label_en-US" xlink:label="lab_us-gaap_BuildingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Building [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BuildingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BuildingMember" xlink:to="lab_us-gaap_BuildingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual_fbfed3e7-1de5-4f4c-95ff-23dcb5ea4f05_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (loss) before income taxes of acquiree since acquisition date included in comprehensive income</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Pro Forma Information, Earnings or Loss of Acquiree since Acquisition Date, Actual</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual" xlink:to="lab_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_5788a594-5d8c-4fbc-864d-93a588e315b0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_8e31de37-11d5-429f-bd30-2d22068b6be7_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_529e1e9a-bcea-4438-9ef5-c97c55d7b1bd_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range [Axis]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermNotesPayable_5b8565bc-7603-428b-b3d4-b55036515847_totalLabel_en-US" xlink:label="lab_us-gaap_LongTermNotesPayable" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total long-term portion of notes payable</link:label>
    <link:label id="lab_us-gaap_LongTermNotesPayable_label_en-US" xlink:label="lab_us-gaap_LongTermNotesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Payable, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermNotesPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermNotesPayable" xlink:to="lab_us-gaap_LongTermNotesPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_ceb52213-5cd5-4b08-9f96-cad44989a9d5_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_d004411b-a831-49ac-822e-7c5550fb71ce_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_NumberOfContingentValueRightsIssued_6fffb4e8-f9a1-4189-95a7-b5c7d4c10941_terseLabel_en-US" xlink:label="lab_lgnd_NumberOfContingentValueRightsIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of contingent value rights</link:label>
    <link:label id="lab_lgnd_NumberOfContingentValueRightsIssued_label_en-US" xlink:label="lab_lgnd_NumberOfContingentValueRightsIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Contingent Value Rights Issued</link:label>
    <link:label id="lab_lgnd_NumberOfContingentValueRightsIssued_documentation_en-US" xlink:label="lab_lgnd_NumberOfContingentValueRightsIssued" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Contingent Value Rights Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_NumberOfContingentValueRightsIssued" xlink:href="lgnd-20211231.xsd#lgnd_NumberOfContingentValueRightsIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_NumberOfContingentValueRightsIssued" xlink:to="lab_lgnd_NumberOfContingentValueRightsIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_4d1f6faa-f3b6-4ad1-863a-f14eaaf84bd2_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options vested and expected to vest at end of period (USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_ada188e9-4348-4467-ab84-13c5f6e67855_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use asset recognized</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Finance Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_LeaseRightOfUseAsset_dba9cea2-bae0-4539-af6f-e5dacfa8fa3f_totalLabel_en-US" xlink:label="lab_lgnd_LeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease assets</link:label>
    <link:label id="lab_lgnd_LeaseRightOfUseAsset_label_en-US" xlink:label="lab_lgnd_LeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Right-of-Use Asset</link:label>
    <link:label id="lab_lgnd_LeaseRightOfUseAsset_documentation_en-US" xlink:label="lab_lgnd_LeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_LeaseRightOfUseAsset" xlink:href="lgnd-20211231.xsd#lgnd_LeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_LeaseRightOfUseAsset" xlink:to="lab_lgnd_LeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_AccruedAssetAcquisitionsCurrent_b7e5fada-009e-4e98-be16-6e70a7437035_terseLabel_en-US" xlink:label="lab_lgnd_AccruedAssetAcquisitionsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition related liabilities</link:label>
    <link:label id="lab_lgnd_AccruedAssetAcquisitionsCurrent_label_en-US" xlink:label="lab_lgnd_AccruedAssetAcquisitionsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Asset Acquisitions, Current</link:label>
    <link:label id="lab_lgnd_AccruedAssetAcquisitionsCurrent_documentation_en-US" xlink:label="lab_lgnd_AccruedAssetAcquisitionsCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Asset Acquisitions, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AccruedAssetAcquisitionsCurrent" xlink:href="lgnd-20211231.xsd#lgnd_AccruedAssetAcquisitionsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_AccruedAssetAcquisitionsCurrent" xlink:to="lab_lgnd_AccruedAssetAcquisitionsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_7519eae3-906a-40a0-92ff-3e4cf3cb5eb2_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_fc318095-763b-40df-9ec3-d282ff83872b_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total revenues (as a percent)</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskPercentage1" xlink:to="lab_us-gaap_ConcentrationRiskPercentage1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_4c296c21-8c8c-4b1b-941e-fb7d3d5afe2d_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash received from options exercised</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds, Issuance of Shares, Share-based Payment Arrangement, Including Option Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_2fa39c18-0fe5-44aa-8fcf-3bdb06fb76ae_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationDispositionOfBusiness_b3642669-508c-4a19-80d1-b949a2504cc1_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationDispositionOfBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Vernalis R&amp;D</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationDispositionOfBusiness_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationDispositionOfBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Disposition of Business, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationDispositionOfBusiness" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationDispositionOfBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationDispositionOfBusiness" xlink:to="lab_us-gaap_IncomeTaxReconciliationDispositionOfBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_d3977b28-32b6-4d21-b33c-8505647b6516_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at beginning of period (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_ec74e66f-3c25-4434-8f01-42ea8fe1ad2b_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at end of period (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TimingOfTransferOfGoodOrServiceAxis_5b80ec42-60a8-471c-a7d3-370a078c2ecd_terseLabel_en-US" xlink:label="lab_us-gaap_TimingOfTransferOfGoodOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Timing of Transfer of Good or Service [Axis]</link:label>
    <link:label id="lab_us-gaap_TimingOfTransferOfGoodOrServiceAxis_label_en-US" xlink:label="lab_us-gaap_TimingOfTransferOfGoodOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Timing of Transfer of Good or Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TimingOfTransferOfGoodOrServiceAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TimingOfTransferOfGoodOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TimingOfTransferOfGoodOrServiceAxis" xlink:to="lab_us-gaap_TimingOfTransferOfGoodOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_ProceedsFromUnwindingConvertibleBondHedges_151213f2-9180-4ea7-ac4c-93f40e7d16d5_terseLabel_en-US" xlink:label="lab_lgnd_ProceedsFromUnwindingConvertibleBondHedges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from unwinding convertible bond hedges</link:label>
    <link:label id="lab_lgnd_ProceedsFromUnwindingConvertibleBondHedges_label_en-US" xlink:label="lab_lgnd_ProceedsFromUnwindingConvertibleBondHedges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Unwinding Convertible Bond Hedges</link:label>
    <link:label id="lab_lgnd_ProceedsFromUnwindingConvertibleBondHedges_documentation_en-US" xlink:label="lab_lgnd_ProceedsFromUnwindingConvertibleBondHedges" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Unwinding Convertible Bond Hedges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ProceedsFromUnwindingConvertibleBondHedges" xlink:href="lgnd-20211231.xsd#lgnd_ProceedsFromUnwindingConvertibleBondHedges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_ProceedsFromUnwindingConvertibleBondHedges" xlink:to="lab_lgnd_ProceedsFromUnwindingConvertibleBondHedges" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TradeNamesMember_2641cacf-0cdb-4142-bac7-048dba831af1_verboseLabel_en-US" xlink:label="lab_us-gaap_TradeNamesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade name</link:label>
    <link:label id="lab_us-gaap_TradeNamesMember_label_en-US" xlink:label="lab_us-gaap_TradeNamesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade Names [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeNamesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TradeNamesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TradeNamesMember" xlink:to="lab_us-gaap_TradeNamesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_LesseeOperatingLeaseLiabilityTenantImprovementAllowance_77ca700c-10e5-4ca1-b456-da21367e4190_negatedTerseLabel_en-US" xlink:label="lab_lgnd_LesseeOperatingLeaseLiabilityTenantImprovementAllowance" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less tenant improvement allowance</link:label>
    <link:label id="lab_lgnd_LesseeOperatingLeaseLiabilityTenantImprovementAllowance_label_en-US" xlink:label="lab_lgnd_LesseeOperatingLeaseLiabilityTenantImprovementAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Tenant Improvement Allowance</link:label>
    <link:label id="lab_lgnd_LesseeOperatingLeaseLiabilityTenantImprovementAllowance_documentation_en-US" xlink:label="lab_lgnd_LesseeOperatingLeaseLiabilityTenantImprovementAllowance" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Tenant Improvement Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_LesseeOperatingLeaseLiabilityTenantImprovementAllowance" xlink:href="lgnd-20211231.xsd#lgnd_LesseeOperatingLeaseLiabilityTenantImprovementAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_LesseeOperatingLeaseLiabilityTenantImprovementAllowance" xlink:to="lab_lgnd_LesseeOperatingLeaseLiabilityTenantImprovementAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_b76b28d6-2eb5-4f4e-992d-390cd087bc79_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrentAbstract_6ca4bdba-516e-4367-9c3a-39ad89ce920a_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncurrent liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Noncurrent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesNoncurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RoyaltyAgreementsMember_6534d183-c110-4471-8e3c-f8257800fe7a_terseLabel_en-US" xlink:label="lab_us-gaap_RoyaltyAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Agreements</link:label>
    <link:label id="lab_us-gaap_RoyaltyAgreementsMember_label_en-US" xlink:label="lab_us-gaap_RoyaltyAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Agreements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyAgreementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RoyaltyAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RoyaltyAgreementsMember" xlink:to="lab_us-gaap_RoyaltyAgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_6df1311f-09a2-477f-848e-e88a5246721f_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitment and Contingencies: Legal Proceedings</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsAbstract_0497b1c0-2c7a-4a4c-b167-dfe9f43fb227_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsAbstract_label_en-US" xlink:label="lab_us-gaap_AvailableForsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Number of Positions [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsAbstract" xlink:to="lab_us-gaap_AvailableForsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_31c50c81-c6bf-4af4-a2e9-68373ffb981b_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration liability, measurement input (as a percent)</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Measurement Input</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsDiscountRate_40b38ba4-a8dd-4b3d-9ddd-95045cd2c527_terseLabel_en-US" xlink:label="lab_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsDiscountRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discount rate used to value intangible assets acquired (as a percent)</link:label>
    <link:label id="lab_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsDiscountRate_label_en-US" xlink:label="lab_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsDiscountRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Discount Rate</link:label>
    <link:label id="lab_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsDiscountRate_documentation_en-US" xlink:label="lab_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsDiscountRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Discount Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsDiscountRate" xlink:href="lgnd-20211231.xsd#lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsDiscountRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsDiscountRate" xlink:to="lab_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsDiscountRate" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_AccruedSupplierExpensesCurrent_d688467a-8056-46cd-a0cd-0f74e7ee6c7b_terseLabel_en-US" xlink:label="lab_lgnd_AccruedSupplierExpensesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplier</link:label>
    <link:label id="lab_lgnd_AccruedSupplierExpensesCurrent_label_en-US" xlink:label="lab_lgnd_AccruedSupplierExpensesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Supplier Expenses, Current</link:label>
    <link:label id="lab_lgnd_AccruedSupplierExpensesCurrent_documentation_en-US" xlink:label="lab_lgnd_AccruedSupplierExpensesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Supplier Expenses, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AccruedSupplierExpensesCurrent" xlink:href="lgnd-20211231.xsd#lgnd_AccruedSupplierExpensesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_AccruedSupplierExpensesCurrent" xlink:to="lab_lgnd_AccruedSupplierExpensesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionProFormaInformationTextBlock_3191f60f-dbba-44e3-95b4-1880f127560b_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Pro Forma Information</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionProFormaInformationTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Pro Forma Information [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionProFormaInformationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:to="lab_us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_BasisOfPresentationLineItems_8a13d566-8ce7-49e8-aa07-15cd9da3f71f_terseLabel_en-US" xlink:label="lab_lgnd_BasisOfPresentationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation [Line Items]</link:label>
    <link:label id="lab_lgnd_BasisOfPresentationLineItems_label_en-US" xlink:label="lab_lgnd_BasisOfPresentationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation [Line Items]</link:label>
    <link:label id="lab_lgnd_BasisOfPresentationLineItems_documentation_en-US" xlink:label="lab_lgnd_BasisOfPresentationLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of presentation.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BasisOfPresentationLineItems" xlink:href="lgnd-20211231.xsd#lgnd_BasisOfPresentationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_BasisOfPresentationLineItems" xlink:to="lab_lgnd_BasisOfPresentationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_3b4a7422-88b4-4cd0-a5af-e8f971d50d6d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_00269a17-1367-4e4c-8cc0-a160791678bc_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award vesting right (as a percent)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_7e9f0252-03f9-4f8b-b78c-65084192d0aa_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of business segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnSaleOfBusiness_b910f80c-38ab-467f-b30e-4d156413e80f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfBusiness" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain from sale of Vernalis R&amp;D</link:label>
    <link:label id="lab_us-gaap_GainLossOnSaleOfBusiness_label_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Disposition of Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfBusiness" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnSaleOfBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnSaleOfBusiness" xlink:to="lab_us-gaap_GainLossOnSaleOfBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_2710d5ef-1ed4-40ab-baff-0b8378495851_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis_64f78a32-28b4-4074-9f82-15501df7f674_totalLabel_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Held-to-Maturity, Amortized Cost, after Allowance for Credit Loss, Maturity, Allocated and Single Maturity Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HeldToMaturitySecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis" xlink:to="lab_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_3a646c68-b9bf-48b8-8ede-f56cc0257dee_totalLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_3e7c5a04-93ee-4dbe-beab-82e5829e60d4_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_f11ce0bc-8ff0-4151-bfb0-ca63f1c4aa31_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Disaggregation of Revenue</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_67052019-d7f6-4c3d-ab34-b6e5bcb272d6_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_CorMatrixMember_49892181-c7a4-4647-b493-fd5f12e39101_terseLabel_en-US" xlink:label="lab_lgnd_CorMatrixMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CorMatrix</link:label>
    <link:label id="lab_lgnd_CorMatrixMember_label_en-US" xlink:label="lab_lgnd_CorMatrixMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CorMatrix [Member]</link:label>
    <link:label id="lab_lgnd_CorMatrixMember_documentation_en-US" xlink:label="lab_lgnd_CorMatrixMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CorMatrix [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_CorMatrixMember" xlink:href="lgnd-20211231.xsd#lgnd_CorMatrixMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_CorMatrixMember" xlink:to="lab_lgnd_CorMatrixMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_b5b63ced-fa96-43f4-9cc8-920223ff76a9_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired intangibles</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_c20af09e-ce33-499f-a25d-fc9b106c6cdd_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangibles assets with finite-life - core technology</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_6630e778-c7f7-474a-bc3b-bb2359e2d425_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research credit carryforwards</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_VikingTherapeuticsInc.Member_e11f8d35-01c3-45d3-877e-e2212652201c_terseLabel_en-US" xlink:label="lab_lgnd_VikingTherapeuticsInc.Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Viking Therapeutics, Inc.</link:label>
    <link:label id="lab_lgnd_VikingTherapeuticsInc.Member_label_en-US" xlink:label="lab_lgnd_VikingTherapeuticsInc.Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Viking Therapeutics, Inc. [Member]</link:label>
    <link:label id="lab_lgnd_VikingTherapeuticsInc.Member_documentation_en-US" xlink:label="lab_lgnd_VikingTherapeuticsInc.Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Viking Therapeutics, Inc. [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_VikingTherapeuticsInc.Member" xlink:href="lgnd-20211231.xsd#lgnd_VikingTherapeuticsInc.Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_VikingTherapeuticsInc.Member" xlink:to="lab_lgnd_VikingTherapeuticsInc.Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasePayments_9c3cd2f9-4a1e-47f0-9f15-6b1e1c2a2395_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease payments</link:label>
    <link:label id="lab_us-gaap_OperatingLeasePayments_label_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments" xlink:to="lab_us-gaap_OperatingLeasePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_cd28fda8-c1e5-4a7d-aa5b-d2c700200207_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expenses</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_1ee4b357-7859-474d-9e64-eef88f8a9660_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consideration transferred</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAsset_b90465b9-e22f-4b2c-aa1f-e613487250fb_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance lease assets</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Right-of-Use Asset, after Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseRightOfUseAsset" xlink:to="lab_us-gaap_FinanceLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_211dc57c-9fa0-4a8a-b138-95b523327562_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, fair value</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_039ea497-ccd4-4f37-a521-c68fde2669ea_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:to="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_c1e358f0-4346-4ed0-9b7d-9a74d79b6be2_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value by Liability Class [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value by Liability Class [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement_5cde13f4-4bd3-4a4b-a5da-2fbc3a8740b8_terseLabel_en-US" xlink:label="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement_label_en-US" xlink:label="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Operating Activities, Cash Flow Statement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherOperatingActivitiesCashFlowStatement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:to="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_RepaymentsOfNotesPayableInterestPortion_fd5fd4de-a0b9-46ac-b587-898b085d6672_terseLabel_en-US" xlink:label="lab_lgnd_RepaymentsOfNotesPayableInterestPortion" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued interest portion of repurchased amount of debt instrument</link:label>
    <link:label id="lab_lgnd_RepaymentsOfNotesPayableInterestPortion_label_en-US" xlink:label="lab_lgnd_RepaymentsOfNotesPayableInterestPortion" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments Of Notes Payable, Interest Portion</link:label>
    <link:label id="lab_lgnd_RepaymentsOfNotesPayableInterestPortion_documentation_en-US" xlink:label="lab_lgnd_RepaymentsOfNotesPayableInterestPortion" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments Of Notes Payable, Interest Portion</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_RepaymentsOfNotesPayableInterestPortion" xlink:href="lgnd-20211231.xsd#lgnd_RepaymentsOfNotesPayableInterestPortion"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_RepaymentsOfNotesPayableInterestPortion" xlink:to="lab_lgnd_RepaymentsOfNotesPayableInterestPortion" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_ContingentValueRightForInternalResearchAndDevelopmentMember_8de7ee6d-a48d-49db-8150-3203146a8fec_terseLabel_en-US" xlink:label="lab_lgnd_ContingentValueRightForInternalResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Value Right for Internal Research and Development</link:label>
    <link:label id="lab_lgnd_ContingentValueRightForInternalResearchAndDevelopmentMember_label_en-US" xlink:label="lab_lgnd_ContingentValueRightForInternalResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Value Right for Internal Research and Development [Member]</link:label>
    <link:label id="lab_lgnd_ContingentValueRightForInternalResearchAndDevelopmentMember_documentation_en-US" xlink:label="lab_lgnd_ContingentValueRightForInternalResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Value Right for Internal Research and Development</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ContingentValueRightForInternalResearchAndDevelopmentMember" xlink:href="lgnd-20211231.xsd#lgnd_ContingentValueRightForInternalResearchAndDevelopmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_ContingentValueRightForInternalResearchAndDevelopmentMember" xlink:to="lab_lgnd_ContingentValueRightForInternalResearchAndDevelopmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_AccruedInventoryPurchases_2282342e-3120-4c7e-92e8-e0fc335cc238_terseLabel_en-US" xlink:label="lab_lgnd_AccruedInventoryPurchases" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued inventory purchases</link:label>
    <link:label id="lab_lgnd_AccruedInventoryPurchases_label_en-US" xlink:label="lab_lgnd_AccruedInventoryPurchases" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Inventory Purchases</link:label>
    <link:label id="lab_lgnd_AccruedInventoryPurchases_documentation_en-US" xlink:label="lab_lgnd_AccruedInventoryPurchases" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Inventory Purchases</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AccruedInventoryPurchases" xlink:href="lgnd-20211231.xsd#lgnd_AccruedInventoryPurchases"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_AccruedInventoryPurchases" xlink:to="lab_lgnd_AccruedInventoryPurchases" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_69ff359d-9e47-40ee-be01-7bf90e273e6d_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_65eef106-7ab1-472e-80a9-d5518cd5f69f_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_706b714b-aaeb-4abd-8844-af3841589e5d_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_45b081df-9e71-472b-982c-1f445f47dc48_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember_917ea987-d0b5-4185-afe6-e1916373305b_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Held-for-sale or Disposed of by Sale, Not Discontinued Operations</link:label>
    <link:label id="lab_us-gaap_DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember_label_en-US" xlink:label="lab_us-gaap_DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Held-for-sale or Disposed of by Sale, Not Discontinued Operations [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember" xlink:to="lab_us-gaap_DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_4991d446-26e5-4d6d-bd10-b43ba93101fe_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ServiceMember_a11a8bec-c18c-40e6-b228-c9594ab5dce3_terseLabel_en-US" xlink:label="lab_us-gaap_ServiceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Service Revenue</link:label>
    <link:label id="lab_us-gaap_ServiceMember_label_en-US" xlink:label="lab_us-gaap_ServiceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Service [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ServiceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ServiceMember" xlink:to="lab_us-gaap_ServiceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_2237166c-8751-4d30-8865-cb1d6b69c91d_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:to="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_PalvellaTherapeuticsIncMember_6f45a3a9-c462-4cce-98eb-d744baf4f20c_terseLabel_en-US" xlink:label="lab_lgnd_PalvellaTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Palvella</link:label>
    <link:label id="lab_lgnd_PalvellaTherapeuticsIncMember_label_en-US" xlink:label="lab_lgnd_PalvellaTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Palvella Therapeutics, Inc. [Member]</link:label>
    <link:label id="lab_lgnd_PalvellaTherapeuticsIncMember_documentation_en-US" xlink:label="lab_lgnd_PalvellaTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Palvella Therapeutics, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PalvellaTherapeuticsIncMember" xlink:href="lgnd-20211231.xsd#lgnd_PalvellaTherapeuticsIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_PalvellaTherapeuticsIncMember" xlink:to="lab_lgnd_PalvellaTherapeuticsIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_5c18cfa5-7a77-4d07-bd70-623be7a7ce36_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average exercise price (USD per share)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:to="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TimingOfTransferOfGoodOrServiceDomain_0149ff1f-098f-4522-9249-a8d917f04f7a_terseLabel_en-US" xlink:label="lab_us-gaap_TimingOfTransferOfGoodOrServiceDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Timing of Transfer of Good or Service [Domain]</link:label>
    <link:label id="lab_us-gaap_TimingOfTransferOfGoodOrServiceDomain_label_en-US" xlink:label="lab_us-gaap_TimingOfTransferOfGoodOrServiceDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Timing of Transfer of Good or Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TimingOfTransferOfGoodOrServiceDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TimingOfTransferOfGoodOrServiceDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TimingOfTransferOfGoodOrServiceDomain" xlink:to="lab_us-gaap_TimingOfTransferOfGoodOrServiceDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_7eed8a90-ea01-44ca-a2df-ce802246fe85_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_6a1ecd09-d2d8-4bc5-9b97-6f7a2da2403a_netLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying value of equity component of 2023 Notes</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Carrying Amount of Equity Component</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" xlink:to="lab_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_730a7a93-4b80-46fc-9004-b5f9c1d25863_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_8100fe27-d4bc-430a-a883-c8dd2ba65380_terseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of exchange rate changes on cash</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_647317b6-558f-4548-8119-a67f82df25c9_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, fair value</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial and Nonfinancial Liabilities, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_ExercisePriceRangeFiveMember_cf71e381-125f-4716-84fb-5c4b1cfb67c8_terseLabel_en-US" xlink:label="lab_lgnd_ExercisePriceRangeFiveMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">$98.20-$100.38</link:label>
    <link:label id="lab_lgnd_ExercisePriceRangeFiveMember_label_en-US" xlink:label="lab_lgnd_ExercisePriceRangeFiveMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range Five [Member]</link:label>
    <link:label id="lab_lgnd_ExercisePriceRangeFiveMember_documentation_en-US" xlink:label="lab_lgnd_ExercisePriceRangeFiveMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range Five [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ExercisePriceRangeFiveMember" xlink:href="lgnd-20211231.xsd#lgnd_ExercisePriceRangeFiveMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_ExercisePriceRangeFiveMember" xlink:to="lab_lgnd_ExercisePriceRangeFiveMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_2f4d9305-122b-42aa-9daf-022c1e15dbf0_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock authorized (shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAxis_c0a4d734-68ef-4bf8-9a6a-130220fc9cf2_terseLabel_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Axis]</link:label>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAxis_label_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:to="lab_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_ContractRevenueMember_9c8d4aae-e2c0-4e93-abff-999dd1088a02_terseLabel_en-US" xlink:label="lab_lgnd_ContractRevenueMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract revenue</link:label>
    <link:label id="lab_lgnd_ContractRevenueMember_label_en-US" xlink:label="lab_lgnd_ContractRevenueMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract Revenue [Member]</link:label>
    <link:label id="lab_lgnd_ContractRevenueMember_documentation_en-US" xlink:label="lab_lgnd_ContractRevenueMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ContractRevenueMember" xlink:href="lgnd-20211231.xsd#lgnd_ContractRevenueMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_ContractRevenueMember" xlink:to="lab_lgnd_ContractRevenueMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_d5ea98b2-31bb-4837-ab82-a8886bb644a7_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">12 months or greater</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityContingentConsiderationFromAcquisition_b7c71565-576d-4688-b2fb-b1a8122ac673_terseLabel_en-US" xlink:label="lab_lgnd_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityContingentConsiderationFromAcquisition" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent liabilities from xCella asset acquisition</link:label>
    <link:label id="lab_lgnd_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityContingentConsiderationFromAcquisition_label_en-US" xlink:label="lab_lgnd_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityContingentConsiderationFromAcquisition" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Contingent Consideration from Acquisition</link:label>
    <link:label id="lab_lgnd_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityContingentConsiderationFromAcquisition_documentation_en-US" xlink:label="lab_lgnd_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityContingentConsiderationFromAcquisition" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Contingent Consideration from Acquisition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityContingentConsiderationFromAcquisition" xlink:href="lgnd-20211231.xsd#lgnd_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityContingentConsiderationFromAcquisition"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityContingentConsiderationFromAcquisition" xlink:to="lab_lgnd_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityContingentConsiderationFromAcquisition" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_DebtInstrumentConvertibleMaximumThresholdPercentageofDebtTradingPriceTrigger_0496287c-bfec-4eca-9156-eb360f97766d_terseLabel_en-US" xlink:label="lab_lgnd_DebtInstrumentConvertibleMaximumThresholdPercentageofDebtTradingPriceTrigger" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum threshold of debt trading price trigger (as a percent)</link:label>
    <link:label id="lab_lgnd_DebtInstrumentConvertibleMaximumThresholdPercentageofDebtTradingPriceTrigger_label_en-US" xlink:label="lab_lgnd_DebtInstrumentConvertibleMaximumThresholdPercentageofDebtTradingPriceTrigger" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Maximum Threshold Percentage of Debt Trading Price Trigger</link:label>
    <link:label id="lab_lgnd_DebtInstrumentConvertibleMaximumThresholdPercentageofDebtTradingPriceTrigger_documentation_en-US" xlink:label="lab_lgnd_DebtInstrumentConvertibleMaximumThresholdPercentageofDebtTradingPriceTrigger" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Maximum Threshold Percentage of Debt Trading Price Trigger</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_DebtInstrumentConvertibleMaximumThresholdPercentageofDebtTradingPriceTrigger" xlink:href="lgnd-20211231.xsd#lgnd_DebtInstrumentConvertibleMaximumThresholdPercentageofDebtTradingPriceTrigger"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_DebtInstrumentConvertibleMaximumThresholdPercentageofDebtTradingPriceTrigger" xlink:to="lab_lgnd_DebtInstrumentConvertibleMaximumThresholdPercentageofDebtTradingPriceTrigger" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_RoyaltyPromactaMember_5460bda7-2352-475a-8eca-c406e69689e6_terseLabel_en-US" xlink:label="lab_lgnd_RoyaltyPromactaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Promacta</link:label>
    <link:label id="lab_lgnd_RoyaltyPromactaMember_label_en-US" xlink:label="lab_lgnd_RoyaltyPromactaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty, Promacta [Member]</link:label>
    <link:label id="lab_lgnd_RoyaltyPromactaMember_documentation_en-US" xlink:label="lab_lgnd_RoyaltyPromactaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty, Promacta</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_RoyaltyPromactaMember" xlink:href="lgnd-20211231.xsd#lgnd_RoyaltyPromactaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_RoyaltyPromactaMember" xlink:to="lab_lgnd_RoyaltyPromactaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_ff308ea8-b907-41f5-95af-ec9d7b82566c_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for acquisition, net of cash and restricted cash acquired</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Businesses, Net of Cash Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_7816ec65-89e2-4cbf-9617-fadb5f5e85aa_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Senior Notes</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_AccruedSalesReturns_09642e75-55f2-4ab2-9bbf-f341dbc6ebc1_terseLabel_en-US" xlink:label="lab_lgnd_AccruedSalesReturns" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Return reserve and customer refunds</link:label>
    <link:label id="lab_lgnd_AccruedSalesReturns_label_en-US" xlink:label="lab_lgnd_AccruedSalesReturns" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Sales Returns</link:label>
    <link:label id="lab_lgnd_AccruedSalesReturns_documentation_en-US" xlink:label="lab_lgnd_AccruedSalesReturns" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Sales Returns</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AccruedSalesReturns" xlink:href="lgnd-20211231.xsd#lgnd_AccruedSalesReturns"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_AccruedSalesReturns" xlink:to="lab_lgnd_AccruedSalesReturns" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_af66daf1-ee9f-4c11-aa0e-36df33af3300_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Components of Income Tax Benefit</link:label>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_61a582e7-e2ab-4d77-9745-0741a64b186e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercisable (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Exercise Price Range, Shares Exercisable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeniorNotesMember_a3da4fd4-1c6d-4a1f-a9f8-de5a37907067_terseLabel_en-US" xlink:label="lab_us-gaap_SeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes</link:label>
    <link:label id="lab_us-gaap_SeniorNotesMember_label_en-US" xlink:label="lab_us-gaap_SeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeniorNotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeniorNotesMember" xlink:to="lab_us-gaap_SeniorNotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_7e49d842-dfc8-420c-bb76-1ddfabe48cb2_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Unobservable Inputs (Level 3)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_60c9f3bc-ddd8-4552-baf4-e8b8c034fd37_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities_03c7499d-6bfe-42dc-93a1-52c5e21b8923_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment for contingent consideration liabilities</link:label>
    <link:label id="lab_us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities_label_en-US" xlink:label="lab_us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment for Contingent Consideration Liability, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities" xlink:to="lab_us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_AmendedESPPMember_9364d7cf-3a2d-4f4e-b9b4-c18e826437ed_terseLabel_en-US" xlink:label="lab_lgnd_AmendedESPPMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended ESPP</link:label>
    <link:label id="lab_lgnd_AmendedESPPMember_label_en-US" xlink:label="lab_lgnd_AmendedESPPMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended ESPP [Member]</link:label>
    <link:label id="lab_lgnd_AmendedESPPMember_documentation_en-US" xlink:label="lab_lgnd_AmendedESPPMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended ESPP [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AmendedESPPMember" xlink:href="lgnd-20211231.xsd#lgnd_AmendedESPPMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_AmendedESPPMember" xlink:to="lab_lgnd_AmendedESPPMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_eb95bdef-c0de-41d1-9611-3a0747faf25e_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Professional fees</link:label>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Professional Fees, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:to="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLeaseLiabilities_cb17699d-573c-4fe9-b735-8e52aa347f3b_negatedTerseLabel_en-US" xlink:label="lab_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLeaseLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liabilities</link:label>
    <link:label id="lab_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLeaseLiabilities_label_en-US" xlink:label="lab_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Lease Liabilities</link:label>
    <link:label id="lab_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLeaseLiabilities_documentation_en-US" xlink:label="lab_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Lease Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLeaseLiabilities" xlink:href="lgnd-20211231.xsd#lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLeaseLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLeaseLiabilities" xlink:to="lab_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLeaseLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_9778c77f-cd17-43c3-94f1-5ae8abdfa4ac_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:to="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_28ed98f7-71e4-4b0c-a536-f1c9f8205319_totalLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total other expense, net</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_ec6591ce-1413-4554-b4e6-e2e8a6b27248_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PerformanceSharesMember_8cee0986-d9a4-4963-88cf-a9c4fc40102e_terseLabel_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PSUs</link:label>
    <link:label id="lab_us-gaap_PerformanceSharesMember_label_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Shares [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PerformanceSharesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PerformanceSharesMember" xlink:to="lab_us-gaap_PerformanceSharesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_f7bf5ce9-1964-4de4-9403-165c1eedb78e_verboseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractualRightsMember_97083d2a-dbfb-43a8-8fda-653a1bd7d431_terseLabel_en-US" xlink:label="lab_us-gaap_ContractualRightsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual relationships</link:label>
    <link:label id="lab_us-gaap_ContractualRightsMember_label_en-US" xlink:label="lab_us-gaap_ContractualRightsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual Rights [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualRightsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractualRightsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractualRightsMember" xlink:to="lab_us-gaap_ContractualRightsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_58874710-da10-487d-bb57-74977dec0e79_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_658203a0-3058-48bf-a9ea-c595f53dc2f7_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_fef37026-e44a-40e1-92ca-bd98c4a5142e_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net proceeds from debt issuance</link:label>
    <link:label id="lab_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Debt, Net of Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:to="lab_us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryWriteDown_0713193c-e065-4433-8a6c-1df8507e80bf_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWriteDown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Write-downs related to obsolete inventory</link:label>
    <link:label id="lab_us-gaap_InventoryWriteDown_label_en-US" xlink:label="lab_us-gaap_InventoryWriteDown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Write-down</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWriteDown" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWriteDown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWriteDown" xlink:to="lab_us-gaap_InventoryWriteDown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockMember_305533c0-ce93-45e0-b533-e052a0ffe537_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock</link:label>
    <link:label id="lab_us-gaap_RestrictedStockMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockMember" xlink:to="lab_us-gaap_RestrictedStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupClassificationAxis_bf365104-49d6-427c-85ba-09b8d0ce0c57_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Classification [Axis]</link:label>
    <link:label id="lab_us-gaap_DisposalGroupClassificationAxis_label_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Classification [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis" xlink:to="lab_us-gaap_DisposalGroupClassificationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingStandardsUpdate201613Member_67adf065-5e27-42d1-b393-584e2faf3b04_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate201613Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update 2016-13</link:label>
    <link:label id="lab_us-gaap_AccountingStandardsUpdate201613Member_label_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate201613Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update 2016-13 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate201613Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingStandardsUpdate201613Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingStandardsUpdate201613Member" xlink:to="lab_us-gaap_AccountingStandardsUpdate201613Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorName_39961cc6-c246-46c4-a050-3295a893a28e_terseLabel_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Name</link:label>
    <link:label id="lab_dei_AuditorName_label_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorName" xlink:to="lab_dei_AuditorName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_a098568b-7a16-4c94-a6c4-23866f055315_negatedLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less imputed interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_eab4426b-64fc-4cbc-8d5f-f9a595e4dbf3_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_a32e1af2-d355-4ce2-8600-91504af4d271_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average remaining life in years</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_50e15947-b233-47d3-8de0-14ac2191b646_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less imputed interest</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OfficeEquipmentMember_63c2eabb-cb67-4818-a9d6-f186bf95cced_verboseLabel_en-US" xlink:label="lab_us-gaap_OfficeEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lab and office equipment</link:label>
    <link:label id="lab_us-gaap_OfficeEquipmentMember_label_en-US" xlink:label="lab_us-gaap_OfficeEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OfficeEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OfficeEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OfficeEquipmentMember" xlink:to="lab_us-gaap_OfficeEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_ef4a72b6-3783-4dd3-86b4-832337ec5478_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current expense (benefit):</link:label>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_EarnoutRightsForPartnerResearchAndDevelopmentMember_690b36d5-6a97-4f15-9ce2-8297673fea1c_terseLabel_en-US" xlink:label="lab_lgnd_EarnoutRightsForPartnerResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnout Rights for Partner Research and Development</link:label>
    <link:label id="lab_lgnd_EarnoutRightsForPartnerResearchAndDevelopmentMember_label_en-US" xlink:label="lab_lgnd_EarnoutRightsForPartnerResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnout Rights for Partner Research and Development [Member]</link:label>
    <link:label id="lab_lgnd_EarnoutRightsForPartnerResearchAndDevelopmentMember_documentation_en-US" xlink:label="lab_lgnd_EarnoutRightsForPartnerResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnout Rights for Partner Research and Development</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_EarnoutRightsForPartnerResearchAndDevelopmentMember" xlink:href="lgnd-20211231.xsd#lgnd_EarnoutRightsForPartnerResearchAndDevelopmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_EarnoutRightsForPartnerResearchAndDevelopmentMember" xlink:to="lab_lgnd_EarnoutRightsForPartnerResearchAndDevelopmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingCostsAndExpensesAbstract_517d5078-e786-4e35-95fe-a3882f7c6255_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingCostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating costs and expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingCostsAndExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingCostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Costs and Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingCostsAndExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingCostsAndExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingCostsAndExpensesAbstract" xlink:to="lab_us-gaap_OperatingCostsAndExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_cdc1c002-b652-405f-bf65-7e741aa721f3_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_de14d748-509f-46a7-92f9-52699efd67b7_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_ee580cd9-b4d5-4f83-a1da-7567501f3a56_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Income, Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeInterest" xlink:to="lab_us-gaap_InvestmentIncomeInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_3d8df3d9-01fb-4338-9e2f-9d12ffca2884_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchaseProgramPeriodInForce1_357317e9-6e9a-427a-8b94-f889a06347ee_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramPeriodInForce1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock repurchase program, period in force</link:label>
    <link:label id="lab_us-gaap_StockRepurchaseProgramPeriodInForce1_label_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramPeriodInForce1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchase Program, Period in Force</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramPeriodInForce1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchaseProgramPeriodInForce1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchaseProgramPeriodInForce1" xlink:to="lab_us-gaap_StockRepurchaseProgramPeriodInForce1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_838b62fe-f403-4b6c-b975-76b98d2caecb_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_20324993-3a50-4d2c-919a-59508a02ff45_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross unrealized losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_31d0e305-0d1a-493a-b225-1d45f7a093af_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation and Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_9cd20260-1c4d-4a77-bd3c-3bd2a63eaeef_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated amortization expense for 2023</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilitiesCurrent_fb131b84-474e-446d-b6e4-2d1104dcbbc5_negatedTerseLabel_en-US" xlink:label="lab_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued liabilities</link:label>
    <link:label id="lab_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilitiesCurrent_3e05aa3c-629f-4e55-8325-64c1ffe6f9f9_negatedLabel_en-US" xlink:label="lab_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued liabilities</link:label>
    <link:label id="lab_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Accrued Liabilities, Current</link:label>
    <link:label id="lab_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilitiesCurrent_documentation_en-US" xlink:label="lab_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilitiesCurrent" xlink:href="lgnd-20211231.xsd#lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilitiesCurrent" xlink:to="lab_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_AccruedSubcontractorExpensesCurrent_a7e05b89-ac3a-41d7-8471-1a8cb92e896f_terseLabel_en-US" xlink:label="lab_lgnd_AccruedSubcontractorExpensesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subcontractor</link:label>
    <link:label id="lab_lgnd_AccruedSubcontractorExpensesCurrent_label_en-US" xlink:label="lab_lgnd_AccruedSubcontractorExpensesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Subcontractor Expenses, Current</link:label>
    <link:label id="lab_lgnd_AccruedSubcontractorExpensesCurrent_documentation_en-US" xlink:label="lab_lgnd_AccruedSubcontractorExpensesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Subcontractor Expenses, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AccruedSubcontractorExpensesCurrent" xlink:href="lgnd-20211231.xsd#lgnd_AccruedSubcontractorExpensesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_AccruedSubcontractorExpensesCurrent" xlink:to="lab_lgnd_AccruedSubcontractorExpensesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_LiabilityForContingentValueRightsCompanyCydexMember_c7446fb4-c9d6-4f02-8b2a-25a69d8f31db_verboseLabel_en-US" xlink:label="lab_lgnd_LiabilityForContingentValueRightsCompanyCydexMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent liabilities - CyDex</link:label>
    <link:label id="lab_lgnd_LiabilityForContingentValueRightsCompanyCydexMember_label_en-US" xlink:label="lab_lgnd_LiabilityForContingentValueRightsCompanyCydexMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability For Contingent Value Rights Company, Cydex [Member]</link:label>
    <link:label id="lab_lgnd_LiabilityForContingentValueRightsCompanyCydexMember_documentation_en-US" xlink:label="lab_lgnd_LiabilityForContingentValueRightsCompanyCydexMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability For Contingent Value Rights Company, Cydex</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_LiabilityForContingentValueRightsCompanyCydexMember" xlink:href="lgnd-20211231.xsd#lgnd_LiabilityForContingentValueRightsCompanyCydexMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_LiabilityForContingentValueRightsCompanyCydexMember" xlink:to="lab_lgnd_LiabilityForContingentValueRightsCompanyCydexMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_1d4257db-e26d-4a8c-ab6c-3791f669ac66_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_8afc027c-dc31-43ca-b7f9-5f80eac24b92_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Depreciation_6cf7b23f-d038-4360-a2c3-180d15835ae8_verboseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation expense</link:label>
    <link:label id="lab_us-gaap_Depreciation_label_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TechnologyBasedIntangibleAssetsMember_8fe5e0ed-b7d9-4c7f-9174-3ce0efe08115_terseLabel_en-US" xlink:label="lab_us-gaap_TechnologyBasedIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Core Technology</link:label>
    <link:label id="lab_us-gaap_TechnologyBasedIntangibleAssetsMember_16e9b20d-7b7a-497a-9338-0c83eea4f29c_verboseLabel_en-US" xlink:label="lab_us-gaap_TechnologyBasedIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired Technologies</link:label>
    <link:label id="lab_us-gaap_TechnologyBasedIntangibleAssetsMember_label_en-US" xlink:label="lab_us-gaap_TechnologyBasedIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Technology-Based Intangible Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TechnologyBasedIntangibleAssetsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TechnologyBasedIntangibleAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TechnologyBasedIntangibleAssetsMember" xlink:to="lab_us-gaap_TechnologyBasedIntangibleAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_2165cdb2-d738-442a-af6d-4dba32d1054b_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income taxes, net</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Deferred Income Taxes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:to="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_RoyaltyOtherMember_94062337-9324-4d0c-bc70-09d00d13aee1_terseLabel_en-US" xlink:label="lab_lgnd_RoyaltyOtherMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_lgnd_RoyaltyOtherMember_label_en-US" xlink:label="lab_lgnd_RoyaltyOtherMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty, Other [Member]</link:label>
    <link:label id="lab_lgnd_RoyaltyOtherMember_documentation_en-US" xlink:label="lab_lgnd_RoyaltyOtherMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_RoyaltyOtherMember" xlink:href="lgnd-20211231.xsd#lgnd_RoyaltyOtherMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_RoyaltyOtherMember" xlink:to="lab_lgnd_RoyaltyOtherMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_NumberOfAssetAcquisitions_af4110dd-cf9b-4519-aef8-8f6420d80c0e_terseLabel_en-US" xlink:label="lab_lgnd_NumberOfAssetAcquisitions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of asset acquisitions</link:label>
    <link:label id="lab_lgnd_NumberOfAssetAcquisitions_label_en-US" xlink:label="lab_lgnd_NumberOfAssetAcquisitions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Asset Acquisitions</link:label>
    <link:label id="lab_lgnd_NumberOfAssetAcquisitions_documentation_en-US" xlink:label="lab_lgnd_NumberOfAssetAcquisitions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Asset Acquisitions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_NumberOfAssetAcquisitions" xlink:href="lgnd-20211231.xsd#lgnd_NumberOfAssetAcquisitions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_NumberOfAssetAcquisitions" xlink:to="lab_lgnd_NumberOfAssetAcquisitions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_e1861e4c-9f52-47b8-a6af-95da7a914ed1_terseLabel_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_label_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Held-to-maturity, Unrealized Loss Position, Accumulated Loss [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract" xlink:to="lab_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxesPaid_61a64113-9b9b-4fc8-a1d2-7c76a6505265_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Taxes paid</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesPaid_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxesPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaid" xlink:to="lab_us-gaap_IncomeTaxesPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetImpairmentCharges_8e88b0ce-c540-49c8-94ca-81257af4da5e_terseLabel_en-US" xlink:label="lab_us-gaap_AssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset impairment charges</link:label>
    <link:label id="lab_us-gaap_AssetImpairmentCharges_label_en-US" xlink:label="lab_us-gaap_AssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Impairment Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetImpairmentCharges" xlink:to="lab_us-gaap_AssetImpairmentCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_b451dc6e-2aea-43ca-9e7b-d9031c8c3b23_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rate change for changes in federal, foreign or state law</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:to="lab_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash_142fbefc-665f-411e-8692-80ebaadc980c_terseLabel_en-US" xlink:label="lab_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash_label_en-US" xlink:label="lab_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Restricted Cash</link:label>
    <link:label id="lab_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash_documentation_en-US" xlink:label="lab_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Restricted Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash" xlink:href="lgnd-20211231.xsd#lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash" xlink:to="lab_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_ExercisePriceRangeThreeMember_325ff57c-566a-4d27-8c45-b31584a6cc52_terseLabel_en-US" xlink:label="lab_lgnd_ExercisePriceRangeThreeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">$82.90-$95.35</link:label>
    <link:label id="lab_lgnd_ExercisePriceRangeThreeMember_label_en-US" xlink:label="lab_lgnd_ExercisePriceRangeThreeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range Three [Member]</link:label>
    <link:label id="lab_lgnd_ExercisePriceRangeThreeMember_documentation_en-US" xlink:label="lab_lgnd_ExercisePriceRangeThreeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range Three [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ExercisePriceRangeThreeMember" xlink:href="lgnd-20211231.xsd#lgnd_ExercisePriceRangeThreeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_ExercisePriceRangeThreeMember" xlink:to="lab_lgnd_ExercisePriceRangeThreeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_19ba79a9-a5d9-49aa-9ee9-8e586f243b97_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContingentConsiderationByTypeAxis_8a5c48ee-449d-4287-9c45-33c21d264a8d_terseLabel_en-US" xlink:label="lab_us-gaap_ContingentConsiderationByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration by Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ContingentConsiderationByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ContingentConsiderationByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration by Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContingentConsiderationByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis" xlink:to="lab_us-gaap_ContingentConsiderationByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USGovernmentDebtSecuritiesMember_0f34f706-56b2-45d2-b73e-37a3912058d7_terseLabel_en-US" xlink:label="lab_us-gaap_USGovernmentDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. government securities</link:label>
    <link:label id="lab_us-gaap_USGovernmentDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USGovernmentDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Government Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USGovernmentDebtSecuritiesMember" xlink:to="lab_us-gaap_USGovernmentDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_DevelopmentRegulatoryCommercialMilestonesAndTieredRoyaltiesMember_69e805de-eb18-4c4a-9b73-72217e5e934e_terseLabel_en-US" xlink:label="lab_lgnd_DevelopmentRegulatoryCommercialMilestonesAndTieredRoyaltiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development, Regulatory, &amp; Commercial Milestones and Tiered Royalties</link:label>
    <link:label id="lab_lgnd_DevelopmentRegulatoryCommercialMilestonesAndTieredRoyaltiesMember_label_en-US" xlink:label="lab_lgnd_DevelopmentRegulatoryCommercialMilestonesAndTieredRoyaltiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development, Regulatory, &amp; Commercial Milestones and Tiered Royalties [Member]</link:label>
    <link:label id="lab_lgnd_DevelopmentRegulatoryCommercialMilestonesAndTieredRoyaltiesMember_documentation_en-US" xlink:label="lab_lgnd_DevelopmentRegulatoryCommercialMilestonesAndTieredRoyaltiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development, Regulatory, &amp; Commercial Milestones and Tiered Royalties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_DevelopmentRegulatoryCommercialMilestonesAndTieredRoyaltiesMember" xlink:href="lgnd-20211231.xsd#lgnd_DevelopmentRegulatoryCommercialMilestonesAndTieredRoyaltiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_DevelopmentRegulatoryCommercialMilestonesAndTieredRoyaltiesMember" xlink:to="lab_lgnd_DevelopmentRegulatoryCommercialMilestonesAndTieredRoyaltiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_3ab09dcb-8d84-4804-8129-83e9ba00ba71_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments_0eef2e46-e6a2-42a9-b5c4-b687fa560961_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from maturity of short-term investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments_label_en-US" xlink:label="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Maturities, Prepayments and Calls of Short-term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments" xlink:to="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_ca77fa79-f43d-4b8f-a2a8-d9b4cb48a175_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated amortization expense for 2022</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_23c72e10-47d7-483a-bfda-3f7b1d2277fe_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_cac5d2f1-aa07-4ded-875c-0aac1bdffe3c_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Intrinsic Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_7a8a5c49-080a-40e4-9502-1a7e5c4b62c5_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeAxis" xlink:to="lab_us-gaap_MeasurementInputTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_773ab761-e3a2-4ddb-b4b9-e8c114369e2a_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating loss carryforward</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwards" xlink:to="lab_us-gaap_OperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_d5f5fa84-f07b-4242-b4bf-b99120fa9617_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock issued (shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_2764692c-e6f3-406f-9e36-e5b3317464b9_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock issued (shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareProFormaAbstract_e14bb605-1325-461d-b95d-744d92c91ac8_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareProFormaAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss) per common share:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareProFormaAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareProFormaAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Pro Forma [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareProFormaAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareProFormaAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareProFormaAbstract" xlink:to="lab_us-gaap_EarningsPerShareProFormaAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent_c2d7c043-28e6-4d94-8a28-de9873950d75_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalties owed to third parties</link:label>
    <link:label id="lab_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent_label_en-US" xlink:label="lab_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Royalties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedRoyaltiesCurrentAndNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" xlink:to="lab_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_NumberOfSharesSoldOfEquityMethodInvestee_b46928b1-0d75-4d79-ac8a-a2e5de496da3_terseLabel_en-US" xlink:label="lab_lgnd_NumberOfSharesSoldOfEquityMethodInvestee" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock sold of equity method investee (in shares)</link:label>
    <link:label id="lab_lgnd_NumberOfSharesSoldOfEquityMethodInvestee_label_en-US" xlink:label="lab_lgnd_NumberOfSharesSoldOfEquityMethodInvestee" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Shares Sold Of Equity Method Investee</link:label>
    <link:label id="lab_lgnd_NumberOfSharesSoldOfEquityMethodInvestee_documentation_en-US" xlink:label="lab_lgnd_NumberOfSharesSoldOfEquityMethodInvestee" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Shares Sold Of Equity Method Investee</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_NumberOfSharesSoldOfEquityMethodInvestee" xlink:href="lgnd-20211231.xsd#lgnd_NumberOfSharesSoldOfEquityMethodInvestee"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_NumberOfSharesSoldOfEquityMethodInvestee" xlink:to="lab_lgnd_NumberOfSharesSoldOfEquityMethodInvestee" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfWarrants_8b2119a5-5b0a-47a7-9452-cf4ef111c6b0_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfWarrants" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase of warrants</link:label>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfWarrants_label_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfWarrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Repurchase of Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfWarrants" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRepurchaseOfWarrants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRepurchaseOfWarrants" xlink:to="lab_us-gaap_PaymentsForRepurchaseOfWarrants" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_207e1c5a-4d1f-4d5b-a942-5bdbb066b211_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_f9a7144b-c4cb-458b-bfe8-249bbcc74f97_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on debt extinguishment</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_label_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Extinguishment of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract_c4d90bf6-1133-4fa2-bf54-ec94b5e01c7e_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Unrealized Loss Position [Line Items]</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Unrealized Loss Position [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRepurchaseAmount_5f1effc5-5d6d-4340-9485-8ed2c8bfe44f_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRepurchaseAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchased amount of debt instrument</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRepurchaseAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRepurchaseAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Repurchase Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRepurchaseAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRepurchaseAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRepurchaseAmount" xlink:to="lab_us-gaap_DebtInstrumentRepurchaseAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_7c2a5913-4448-4de7-8465-126773b9685c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_84d0b163-2500-4b1a-962d-b147f4774797_negatedLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_49f3e910-24ab-4dbc-977b-7f9f8ce515ae_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LicensingAgreementsMember_0673f5cc-5d0d-4060-ae21-c2f572d07500_terseLabel_en-US" xlink:label="lab_us-gaap_LicensingAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Licensing Agreements</link:label>
    <link:label id="lab_us-gaap_LicensingAgreementsMember_label_en-US" xlink:label="lab_us-gaap_LicensingAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Licensing Agreements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LicensingAgreementsMember" xlink:to="lab_us-gaap_LicensingAgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_c8a394ba-70d2-4519-8045-e08145f9b14b_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred expense (benefit):</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_BusinessAcquisitionContingentConsiderationPotentialCashPaymentAdditions_e85d127f-6d26-4d86-ae14-6be7ad2c170a_terseLabel_en-US" xlink:label="lab_lgnd_BusinessAcquisitionContingentConsiderationPotentialCashPaymentAdditions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Contingent Liabilities</link:label>
    <link:label id="lab_lgnd_BusinessAcquisitionContingentConsiderationPotentialCashPaymentAdditions_label_en-US" xlink:label="lab_lgnd_BusinessAcquisitionContingentConsiderationPotentialCashPaymentAdditions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition Contingent Consideration Potential Cash Payment Additions</link:label>
    <link:label id="lab_lgnd_BusinessAcquisitionContingentConsiderationPotentialCashPaymentAdditions_documentation_en-US" xlink:label="lab_lgnd_BusinessAcquisitionContingentConsiderationPotentialCashPaymentAdditions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition Contingent Consideration Potential Cash Payment Additions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BusinessAcquisitionContingentConsiderationPotentialCashPaymentAdditions" xlink:href="lgnd-20211231.xsd#lgnd_BusinessAcquisitionContingentConsiderationPotentialCashPaymentAdditions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_BusinessAcquisitionContingentConsiderationPotentialCashPaymentAdditions" xlink:to="lab_lgnd_BusinessAcquisitionContingentConsiderationPotentialCashPaymentAdditions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_69d8e859-d778-451c-a003-4f769cbfdf55_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective rate (as a percent)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Effective Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_label_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operations and Disposal Groups [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:to="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_ProductRoyaltyPercentage_38d65dc3-0ba7-4bb2-963d-e8087f377745_terseLabel_en-US" xlink:label="lab_lgnd_ProductRoyaltyPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product royalty (as a percent)</link:label>
    <link:label id="lab_lgnd_ProductRoyaltyPercentage_label_en-US" xlink:label="lab_lgnd_ProductRoyaltyPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Royalty Percentage</link:label>
    <link:label id="lab_lgnd_ProductRoyaltyPercentage_documentation_en-US" xlink:label="lab_lgnd_ProductRoyaltyPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Royalty Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ProductRoyaltyPercentage" xlink:href="lgnd-20211231.xsd#lgnd_ProductRoyaltyPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_ProductRoyaltyPercentage" xlink:to="lab_lgnd_ProductRoyaltyPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_6ee7ceab-e57c-44dd-a49f-8e2857ec9f1f_verboseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseTypeDomain_aa6d4fe1-8906-4abb-8f14-f338869f4204_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:label id="lab_srt_LitigationCaseTypeDomain_label_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseTypeDomain" xlink:to="lab_srt_LitigationCaseTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_96723406-0c2e-4a8e-b91a-c38baaf0040a_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award expiration period</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_ExercisePriceRangeOneMember_f44f419d-4372-463c-abb8-b09595629383_terseLabel_en-US" xlink:label="lab_lgnd_ExercisePriceRangeOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">$12.53-$56.26</link:label>
    <link:label id="lab_lgnd_ExercisePriceRangeOneMember_label_en-US" xlink:label="lab_lgnd_ExercisePriceRangeOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range One [Member]</link:label>
    <link:label id="lab_lgnd_ExercisePriceRangeOneMember_documentation_en-US" xlink:label="lab_lgnd_ExercisePriceRangeOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range One [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ExercisePriceRangeOneMember" xlink:href="lgnd-20211231.xsd#lgnd_ExercisePriceRangeOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_ExercisePriceRangeOneMember" xlink:to="lab_lgnd_ExercisePriceRangeOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_685ce244-5096-4861-bc84-56f3659cd52e_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnInvestments_fa85b09f-6fe8-40bd-b8c8-9751fe4905c3_terseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (loss) from short-term investments</link:label>
    <link:label id="lab_us-gaap_GainLossOnInvestments_label_en-US" xlink:label="lab_us-gaap_GainLossOnInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnInvestments" xlink:to="lab_us-gaap_GainLossOnInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_a25d1489-5f9f-4a84-9c10-816499e6afae_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate (as a percent)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_0c8f2998-70a1-4ece-854d-0995742e9afb_terseLabel_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury bills</link:label>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Treasury Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USTreasurySecuritiesMember" xlink:to="lab_us-gaap_USTreasurySecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromHedgeFinancingActivities_b7d48418-0240-4615-a97f-4aba0f9ef5b3_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromHedgeFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from bond hedge settlement</link:label>
    <link:label id="lab_us-gaap_ProceedsFromHedgeFinancingActivities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromHedgeFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Hedge, Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromHedgeFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromHedgeFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromHedgeFinancingActivities" xlink:to="lab_us-gaap_ProceedsFromHedgeFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_IcagenMember_f8232ea1-9727-4d06-83b1-9884a23f33d0_terseLabel_en-US" xlink:label="lab_lgnd_IcagenMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Icagen</link:label>
    <link:label id="lab_lgnd_IcagenMember_label_en-US" xlink:label="lab_lgnd_IcagenMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Icagen [Member]</link:label>
    <link:label id="lab_lgnd_IcagenMember_documentation_en-US" xlink:label="lab_lgnd_IcagenMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Icagen</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_IcagenMember" xlink:href="lgnd-20211231.xsd#lgnd_IcagenMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_IcagenMember" xlink:to="lab_lgnd_IcagenMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_db6931e1-cc99-4614-9dcb-7afa40af8bf6_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Reconciliation of Level 3 Financial Instruments</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_8537fe51-e52e-43c3-9000-3e332c3571d7_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net proceeds from stock option exercises and ESPP</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermInvestments_91efe5e2-e5ba-42e5-837e-da801fa8161d_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term investments</link:label>
    <link:label id="lab_us-gaap_ShortTermInvestments_label_en-US" xlink:label="lab_us-gaap_ShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermInvestments" xlink:to="lab_us-gaap_ShortTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_45a5223f-c194-4267-9644-acd1e1da833a_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_0d85501f-303d-4683-8c2a-4ec2cd08ce7f_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_fbeade55-08d4-4327-a679-14d56be46b36_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_710720c9-2a51-4962-b924-7092a4f00a8e_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_df2a1a94-b291-474c-a7de-0430ba8aac8b_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_cb864f7c-2682-4b18-b0c0-d1f9a6ab3066_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable" xlink:to="lab_us-gaap_DisaggregationOfRevenueTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_863352bb-3057-4335-aab1-d3a5fa13aac7_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:to="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNet_35a6c7ab-278a-47e7-a35b-1b154e529c9b_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryNet_5c18372c-3015-4970-87e8-a0a120c81b72_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryNet_label_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_4ca153aa-c26a-484e-8c10-f896c55ad9d3_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Federal Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_7e574ee3-4265-48dc-8c40-57444598ef98_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_85ae38dd-3927-4a51-8d25-2aaac6726cf7_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityRepurchasesContingentLiabilities_4436cb4c-0f54-43e9-8054-d74ab71d9b33_negatedTerseLabel_en-US" xlink:label="lab_lgnd_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityRepurchasesContingentLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchases</link:label>
    <link:label id="lab_lgnd_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityRepurchasesContingentLiabilities_label_en-US" xlink:label="lab_lgnd_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityRepurchasesContingentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Repurchases, Contingent Liabilities</link:label>
    <link:label id="lab_lgnd_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityRepurchasesContingentLiabilities_documentation_en-US" xlink:label="lab_lgnd_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityRepurchasesContingentLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Repurchases, Contingent Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityRepurchasesContingentLiabilities" xlink:href="lgnd-20211231.xsd#lgnd_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityRepurchasesContingentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityRepurchasesContingentLiabilities" xlink:to="lab_lgnd_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityRepurchasesContingentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_7b9dbf95-aab8-436e-b493-d8a52cccddb0_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation allowance, change in amount</link:label>
    <link:label id="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_label_en-US" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_AziyoMember_163e1f3d-3268-45ec-b9d9-453b710ea323_terseLabel_en-US" xlink:label="lab_lgnd_AziyoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aziyo</link:label>
    <link:label id="lab_lgnd_AziyoMember_label_en-US" xlink:label="lab_lgnd_AziyoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aziyo [Member]</link:label>
    <link:label id="lab_lgnd_AziyoMember_documentation_en-US" xlink:label="lab_lgnd_AziyoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aziyo [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AziyoMember" xlink:href="lgnd-20211231.xsd#lgnd_AziyoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_AziyoMember" xlink:to="lab_lgnd_AziyoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_a1de6c80-1d00-4313-8d01-5c3e1ea9507c_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_8aba96e3-e661-4640-9963-bcb1a9de5359_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, par value (USD per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityPublicFloat_51865b9c-2e30-4623-abbc-8f64ddef77de_terseLabel_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:label id="lab_dei_EntityPublicFloat_label_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityPublicFloat" xlink:to="lab_dei_EntityPublicFloat" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_191e4998-6c60-4962-9e83-c8af58e38d39_terseLabel_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Documents Incorporated by Reference</link:label>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_label_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_5ff9d213-2e2a-44e7-a1ba-7238d675f332_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock under employee stock compensation plans, net (shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss_0b79f362-71fd-41b8-b369-88d23e34390d_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized net gain (loss) on available-for-sale securities, net of deferred tax</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Unrealized Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodShares_2365185f-7be5-44fc-bda1-f6e9bb6cb6f8_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodShares" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase of common stock (shares)</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodShares_0638b3f6-fda7-4a3d-bad8-e7f5d3b003e0_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares repurchased in period (shares)</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodShares_label_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchased During Period, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchasedDuringPeriodShares" xlink:to="lab_us-gaap_StockRepurchasedDuringPeriodShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_e2d049c0-4991-4caf-bf9f-7268c054db7a_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation adjustment</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_7ba531d2-b1b1-44f3-b80f-3284338aa2cb_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock issued under amended ESSP (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleDebtNoncurrent_35b062d6-7f08-42bb-b8de-baca2da4a596_verboseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023 convertible senior notes, net</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebtNoncurrent_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtNoncurrent" xlink:to="lab_us-gaap_ConvertibleDebtNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_70b5613d-fbba-4f2c-b738-08ee395f7ad6_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_PurchaseCommitmentConsiderationPaidAllocatedToInventory_19270c49-8c4a-4dc0-8757-40c2755dcd5e_terseLabel_en-US" xlink:label="lab_lgnd_PurchaseCommitmentConsiderationPaidAllocatedToInventory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Portion of consideration allocated to inventory</link:label>
    <link:label id="lab_lgnd_PurchaseCommitmentConsiderationPaidAllocatedToInventory_label_en-US" xlink:label="lab_lgnd_PurchaseCommitmentConsiderationPaidAllocatedToInventory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Commitment, Consideration Paid, Allocated to Inventory</link:label>
    <link:label id="lab_lgnd_PurchaseCommitmentConsiderationPaidAllocatedToInventory_documentation_en-US" xlink:label="lab_lgnd_PurchaseCommitmentConsiderationPaidAllocatedToInventory" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Commitment, Consideration Paid, Allocated to Inventory</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PurchaseCommitmentConsiderationPaidAllocatedToInventory" xlink:href="lgnd-20211231.xsd#lgnd_PurchaseCommitmentConsiderationPaidAllocatedToInventory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_PurchaseCommitmentConsiderationPaidAllocatedToInventory" xlink:to="lab_lgnd_PurchaseCommitmentConsiderationPaidAllocatedToInventory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_b620dfc3-6479-4129-afe9-42d3f6015f2c_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Current Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_e4be5a6a-978e-4516-9fb9-c2dd4f4328fa_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_6843ec00-141b-42cf-801e-57228a310445_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Investments_b6fe5f49-ea83-4c92-970c-7ebc61899565_terseLabel_en-US" xlink:label="lab_us-gaap_Investments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments</link:label>
    <link:label id="lab_us-gaap_Investments_label_en-US" xlink:label="lab_us-gaap_Investments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Investments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Investments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Investments" xlink:to="lab_us-gaap_Investments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_0054776a-6382-4bbc-a936-e521d5c52d86_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock under employee stock compensation plans, net</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_cd1db95d-4ea8-409c-bcf8-faf351a70ce8_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated fair value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_LiabilityForContingentValueRights_2c57461c-5555-49fe-9c3f-986111a6eae7_verboseLabel_en-US" xlink:label="lab_lgnd_LiabilityForContingentValueRights" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term contingent liabilities</link:label>
    <link:label id="lab_lgnd_LiabilityForContingentValueRights_label_en-US" xlink:label="lab_lgnd_LiabilityForContingentValueRights" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Contingent Value Rights</link:label>
    <link:label id="lab_lgnd_LiabilityForContingentValueRights_documentation_en-US" xlink:label="lab_lgnd_LiabilityForContingentValueRights" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for contingent value rights.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_LiabilityForContingentValueRights" xlink:href="lgnd-20211231.xsd#lgnd_LiabilityForContingentValueRights"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_LiabilityForContingentValueRights" xlink:to="lab_lgnd_LiabilityForContingentValueRights" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_d52272a6-68f9-4221-a2bb-14770c7e91ee_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Compensation Expense</link:label>
    <link:label id="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of Share-based Compensation Arrangements by Share-based Payment Award [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:to="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_ea2da603-5eca-4730-b02f-7970e9d14865_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proportion of fair market value of common stock at which stock is purchased under ESPP (as a percent)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy_618a67f8-ad92-4d9e-9f9e-6fdb6e2f7ae6_terseLabel_en-US" xlink:label="lab_us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable</link:label>
    <link:label id="lab_us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy_label_en-US" xlink:label="lab_us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivables, Trade and Other Accounts Receivable, Allowance for Doubtful Accounts, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy" xlink:to="lab_us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_89fcfdf5-6ec3-45da-96f1-3b777903fbb6_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_668d14a9-7445-4a03-a9bc-7abaa79ff125_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation allowance for deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_LeaseLiabilityCurrent_1865da2a-d71a-48e1-9816-59d8d6e72fbf_totalLabel_en-US" xlink:label="lab_lgnd_LeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current lease liabilities</link:label>
    <link:label id="lab_lgnd_LeaseLiabilityCurrent_label_en-US" xlink:label="lab_lgnd_LeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Liability, Current</link:label>
    <link:label id="lab_lgnd_LeaseLiabilityCurrent_documentation_en-US" xlink:label="lab_lgnd_LeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_LeaseLiabilityCurrent" xlink:href="lgnd-20211231.xsd#lgnd_LeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_LeaseLiabilityCurrent" xlink:to="lab_lgnd_LeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_CrystalMember_82c2ca8b-17ae-4729-a069-91c6d7ef638f_terseLabel_en-US" xlink:label="lab_lgnd_CrystalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Crystal</link:label>
    <link:label id="lab_lgnd_CrystalMember_label_en-US" xlink:label="lab_lgnd_CrystalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Crystal [Member]</link:label>
    <link:label id="lab_lgnd_CrystalMember_documentation_en-US" xlink:label="lab_lgnd_CrystalMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Crystal [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_CrystalMember" xlink:href="lgnd-20211231.xsd#lgnd_CrystalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_CrystalMember" xlink:to="lab_lgnd_CrystalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherExpenseMember_8bbb99c6-dcd8-410d-b521-665151fbe987_terseLabel_en-US" xlink:label="lab_us-gaap_OtherExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Expense</link:label>
    <link:label id="lab_us-gaap_OtherExpenseMember_label_en-US" xlink:label="lab_us-gaap_OtherExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherExpenseMember" xlink:to="lab_us-gaap_OtherExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MajorCustomersAxis_7adcc3f4-596b-45ee-80ad-7f74ac30498c_terseLabel_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:label id="lab_srt_MajorCustomersAxis_label_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MajorCustomersAxis" xlink:to="lab_srt_MajorCustomersAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireShortTermInvestments_37afeab7-f3a1-46a8-9f96-4bd189ff4091_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireShortTermInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of short-term investments</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireShortTermInvestments_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Short-term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireShortTermInvestments" xlink:to="lab_us-gaap_PaymentsToAcquireShortTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_719d7737-fcea-44e2-b12e-eb816f01ff43_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_af171c7d-7cab-4648-ab28-1545be71bc44_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of trading days</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Threshold Trading Days</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdTradingDays"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:to="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndCurrentAssetsOther_161d8348-69cc-4ab7-8225-497723063fef_terseLabel_en-US" xlink:label="lab_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndCurrentAssetsOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and other assets</link:label>
    <link:label id="lab_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndCurrentAssetsOther_label_en-US" xlink:label="lab_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndCurrentAssetsOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Current Assets, Other</link:label>
    <link:label id="lab_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndCurrentAssetsOther_documentation_en-US" xlink:label="lab_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndCurrentAssetsOther" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Current Assets, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndCurrentAssetsOther" xlink:href="lgnd-20211231.xsd#lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndCurrentAssetsOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndCurrentAssetsOther" xlink:to="lab_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndCurrentAssetsOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_4124d9ff-54c0-4453-890e-b059a338ccdc_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByAssetClassAxis_c3cc1cb2-381d-4577-87d4-af133efbc95c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByAssetClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByAssetClassAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByAssetClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByAssetClassAxis" xlink:to="lab_us-gaap_FairValueByAssetClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentAnnualReport_36092e32-024b-4d65-80a1-e9ce5f622d3b_terseLabel_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:label id="lab_dei_DocumentAnnualReport_label_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentAnnualReport" xlink:to="lab_dei_DocumentAnnualReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit_fde18e97-d78a-4a11-8bac-cae6c38f4d89_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill written off</link:label>
    <link:label id="lab_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit_label_en-US" xlink:label="lab_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Written off Related to Sale of Business Unit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit" xlink:to="lab_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VestingAxis_f8df591f-63ec-491d-becb-e5fbce365f2e_terseLabel_en-US" xlink:label="lab_us-gaap_VestingAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Axis]</link:label>
    <link:label id="lab_us-gaap_VestingAxis_label_en-US" xlink:label="lab_us-gaap_VestingAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingAxis" xlink:to="lab_us-gaap_VestingAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromRoyaltiesReceived_e3925c96-329a-49a3-8102-0b4526534e20_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromRoyaltiesReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from royalties received</link:label>
    <link:label id="lab_us-gaap_ProceedsFromRoyaltiesReceived_label_en-US" xlink:label="lab_us-gaap_ProceedsFromRoyaltiesReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Royalties Received</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromRoyaltiesReceived" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromRoyaltiesReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromRoyaltiesReceived" xlink:to="lab_us-gaap_ProceedsFromRoyaltiesReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities_860fc818-b175-4f25-845f-84a8bed8c1ff_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities assumed</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_2d01b4c7-ddf8-4007-99e0-4986499def21_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_ffd4ce3f-0352-48f3-bc36-db69a61fdaa6_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_Phase3ClinicalTrialMember_3cd1f8d7-0664-4013-9ee2-7dfa1d8efbc6_terseLabel_en-US" xlink:label="lab_lgnd_Phase3ClinicalTrialMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Phase 3 Clinical Trial</link:label>
    <link:label id="lab_lgnd_Phase3ClinicalTrialMember_label_en-US" xlink:label="lab_lgnd_Phase3ClinicalTrialMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Phase 3 Clinical Trial [Member]</link:label>
    <link:label id="lab_lgnd_Phase3ClinicalTrialMember_documentation_en-US" xlink:label="lab_lgnd_Phase3ClinicalTrialMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Phase 3 Clinical Trial</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_Phase3ClinicalTrialMember" xlink:href="lgnd-20211231.xsd#lgnd_Phase3ClinicalTrialMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_Phase3ClinicalTrialMember" xlink:to="lab_lgnd_Phase3ClinicalTrialMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaidNet_7997ccf1-0982-4820-b6a9-bf505d58078d_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest paid</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfNotesPayable_51e17e2b-4915-4771-84a5-c8b70b290ecc_terseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfNotesPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of notes</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfNotesPayable_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfNotesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Notes Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfNotesPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfNotesPayable" xlink:to="lab_us-gaap_RepaymentsOfNotesPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_31eccbec-d828-4157-9b9e-5138eaf54714_verboseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_InvestmentInVikingCurrent_f38d0066-1ed7-40d9-9c42-38eb7c9034a4_verboseLabel_en-US" xlink:label="lab_lgnd_InvestmentInVikingCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Value of warrants in Viking</link:label>
    <link:label id="lab_lgnd_InvestmentInVikingCurrent_label_en-US" xlink:label="lab_lgnd_InvestmentInVikingCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment in Viking, Current</link:label>
    <link:label id="lab_lgnd_InvestmentInVikingCurrent_documentation_en-US" xlink:label="lab_lgnd_InvestmentInVikingCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment in Viking, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_InvestmentInVikingCurrent" xlink:href="lgnd-20211231.xsd#lgnd_InvestmentInVikingCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_InvestmentInVikingCurrent" xlink:to="lab_lgnd_InvestmentInVikingCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionDomain_1c3b385e-3cf2-4715-9dfa-e8762e435119_terseLabel_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Domain]</link:label>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionDomain_label_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:to="lab_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_145c8509-a4a0-4993-a21e-1c15a0ea7382_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by (used in) operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAmount_8c7edc28-76a3-44a9-b509-9832ecfdd50b_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax credit carryforward</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAmount_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardAmount" xlink:to="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDilutedLineItems_0723a7de-6fcd-4ae1-b26a-fe952e37a08c_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDilutedLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Line Items]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDilutedLineItems_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDilutedLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDilutedLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDilutedLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDilutedLineItems" xlink:to="lab_us-gaap_EarningsPerShareDilutedLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber_fda452b9-d11d-45bd-9d6d-c49ad976d04c_terseLabel_en-US" xlink:label="lab_us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of patents allegedly infringed upon</link:label>
    <link:label id="lab_us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber_label_en-US" xlink:label="lab_us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain Contingency, Patents Allegedly Infringed upon, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber" xlink:to="lab_us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDebtTableTextBlock_4d3271e4-3de8-4aa0-91db-25bacca169dd_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Equity and Liability Components of the Convertible Senior Notes</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDebtTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Debt [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDebtTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDebtTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDebtTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_88953f36-9487-4c19-b529-93de9bbc015d_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_cbd476ff-6083-41c7-b0f5-fcb6a2586cb4_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAxis_d3824ad1-e58e-4a2b-8bf4-2511e99f9d54_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward [Axis]</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAxis_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis" xlink:to="lab_us-gaap_TaxCreditCarryforwardAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_20b8fb6b-26d3-4e50-929c-44204b80e253_netLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted net income (loss) per share (USD per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_d32add20-9bcd-4da7-8de5-9336986dba37_netLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares used in basic per share calculation (shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_e84f1084-fa20-4e3f-9147-e3adf5f6c815_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average common shares outstanding - basic (shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_ac02f72a-61ed-40a8-b269-8cabbc944f69_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of debt discount and issuance fees</link:label>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_label_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Debt Issuance Costs and Discounts</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:to="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_20902a5b-0d67-4cf3-a602-7f73f2858897_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dilutive potential common shares (shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number Diluted Shares Outstanding Adjustment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:to="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_LicenseFeesMilestonesAndOtherProductOtherMember_eddbb4e5-3636-44e1-b4d5-cccd262d4a8d_terseLabel_en-US" xlink:label="lab_lgnd_LicenseFeesMilestonesAndOtherProductOtherMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_lgnd_LicenseFeesMilestonesAndOtherProductOtherMember_label_en-US" xlink:label="lab_lgnd_LicenseFeesMilestonesAndOtherProductOtherMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Fees, Milestones, and Other Product, Other [Member]</link:label>
    <link:label id="lab_lgnd_LicenseFeesMilestonesAndOtherProductOtherMember_documentation_en-US" xlink:label="lab_lgnd_LicenseFeesMilestonesAndOtherProductOtherMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Fees, Milestones, and Other Product, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_LicenseFeesMilestonesAndOtherProductOtherMember" xlink:href="lgnd-20211231.xsd#lgnd_LicenseFeesMilestonesAndOtherProductOtherMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_LicenseFeesMilestonesAndOtherProductOtherMember" xlink:to="lab_lgnd_LicenseFeesMilestonesAndOtherProductOtherMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingStandardsUpdateExtensibleList_8fb472a5-c07a-4a38-9fdd-c7d133c930f8_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdateExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update [Extensible List]</link:label>
    <link:label id="lab_us-gaap_AccountingStandardsUpdateExtensibleList_label_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdateExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdateExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingStandardsUpdateExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingStandardsUpdateExtensibleList" xlink:to="lab_us-gaap_AccountingStandardsUpdateExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_MaterialSalesCaptisolMember_93994051-a759-4384-a797-7adaeda6ad56_terseLabel_en-US" xlink:label="lab_lgnd_MaterialSalesCaptisolMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Captisol</link:label>
    <link:label id="lab_lgnd_MaterialSalesCaptisolMember_label_en-US" xlink:label="lab_lgnd_MaterialSalesCaptisolMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Material Sales, Captisol [Member]</link:label>
    <link:label id="lab_lgnd_MaterialSalesCaptisolMember_documentation_en-US" xlink:label="lab_lgnd_MaterialSalesCaptisolMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Material Sales, Captisol [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_MaterialSalesCaptisolMember" xlink:href="lgnd-20211231.xsd#lgnd_MaterialSalesCaptisolMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_MaterialSalesCaptisolMember" xlink:to="lab_lgnd_MaterialSalesCaptisolMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiMeasurementInput_8c48ad64-ca75-4a5d-b581-8ecf091cd228_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement input (as a percent)</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiMeasurementInput_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Measurement Input</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiMeasurementInput" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNiMeasurementInput"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiMeasurementInput" xlink:to="lab_us-gaap_EquitySecuritiesFvNiMeasurementInput" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_6f683b62-585e-4681-8658-c0dcf6571615_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_1652fd26-01a7-4ff2-a9bb-d62d4797e26c_verboseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets, net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_130f0eca-8d6b-45b4-a8d2-ade2aa5ba433_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets, net (excluding goodwill)</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_CydexPharmaceuticalsIncMember_c5f7fa35-d6fb-4da7-a808-6615dc2d098d_verboseLabel_en-US" xlink:label="lab_lgnd_CydexPharmaceuticalsIncMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cydex</link:label>
    <link:label id="lab_lgnd_CydexPharmaceuticalsIncMember_label_en-US" xlink:label="lab_lgnd_CydexPharmaceuticalsIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cydex Pharmaceuticals, Inc [Member]</link:label>
    <link:label id="lab_lgnd_CydexPharmaceuticalsIncMember_documentation_en-US" xlink:label="lab_lgnd_CydexPharmaceuticalsIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cydex Pharmaceuticals, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_CydexPharmaceuticalsIncMember" xlink:href="lgnd-20211231.xsd#lgnd_CydexPharmaceuticalsIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_CydexPharmaceuticalsIncMember" xlink:to="lab_lgnd_CydexPharmaceuticalsIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_ContractualRelationshipsArcellxMember_54215fc0-85ae-4f26-a316-bba44531c6a8_terseLabel_en-US" xlink:label="lab_lgnd_ContractualRelationshipsArcellxMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual Relationships - Arcellx</link:label>
    <link:label id="lab_lgnd_ContractualRelationshipsArcellxMember_label_en-US" xlink:label="lab_lgnd_ContractualRelationshipsArcellxMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual Relationships - Arcellx [Member]</link:label>
    <link:label id="lab_lgnd_ContractualRelationshipsArcellxMember_documentation_en-US" xlink:label="lab_lgnd_ContractualRelationshipsArcellxMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual Relationships - Arcellx</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ContractualRelationshipsArcellxMember" xlink:href="lgnd-20211231.xsd#lgnd_ContractualRelationshipsArcellxMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_ContractualRelationshipsArcellxMember" xlink:to="lab_lgnd_ContractualRelationshipsArcellxMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_990bb314-3921-4980-a173-44b44df4e572_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income taxes, net</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_MetabasisTherapeuticsMember_91182398-2e0b-4b2c-9a60-90051c573296_terseLabel_en-US" xlink:label="lab_lgnd_MetabasisTherapeuticsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Metabasis Therapeutics</link:label>
    <link:label id="lab_lgnd_MetabasisTherapeuticsMember_ddf7c066-1155-4bcc-8cce-de632eb4e9f1_verboseLabel_en-US" xlink:label="lab_lgnd_MetabasisTherapeuticsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Metabasis</link:label>
    <link:label id="lab_lgnd_MetabasisTherapeuticsMember_label_en-US" xlink:label="lab_lgnd_MetabasisTherapeuticsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Metabasis Therapeutics [Member]</link:label>
    <link:label id="lab_lgnd_MetabasisTherapeuticsMember_documentation_en-US" xlink:label="lab_lgnd_MetabasisTherapeuticsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Metabasis Therapeutics [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_MetabasisTherapeuticsMember" xlink:href="lgnd-20211231.xsd#lgnd_MetabasisTherapeuticsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_MetabasisTherapeuticsMember" xlink:to="lab_lgnd_MetabasisTherapeuticsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_30f3a471-9a39-41da-a6d6-99217109fd4f_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_ebdb3cb2-243c-4aa7-915d-a38c13363819_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnSaleOfOtherAssets_b6705d5c-6543-413f-ba1b-286e6e1f3f89_negatedLabel_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain from sale of Promacta license</link:label>
    <link:label id="lab_us-gaap_GainLossOnSaleOfOtherAssets_label_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Disposition of Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnSaleOfOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnSaleOfOtherAssets" xlink:to="lab_us-gaap_GainLossOnSaleOfOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_09128e98-ef6d-45af-b5ee-57ea98986997_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate bonds</link:label>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:to="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_4ce8ddd0-907d-4ea7-a863-7b7cceda62d9_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_003772f5-7813-4284-9d62-98ed7b1bf406_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_f2ef61af-f743-46cc-b40d-1d8b0bda296f_verboseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation of fixed assets and amortization of intangible assets</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EntityWideRevenueMajorCustomerLineItems_67af9f3a-0ce0-4538-9f5f-73f69bd89c3f_terseLabel_en-US" xlink:label="lab_us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Major Customer</link:label>
    <link:label id="lab_us-gaap_EntityWideRevenueMajorCustomerLineItems_label_en-US" xlink:label="lab_us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Major Customer [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EntityWideRevenueMajorCustomerLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:to="lab_us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_18dd6376-068b-4870-a57b-3a4687cbeb0e_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expense, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_13f63f79-3731-44d5-b2c9-7150c398f547_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_f0301e13-e83d-47e2-beaa-9b440c98a1ef_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_456a84cd-4ae8-41c2-a6c1-0465c190ef70_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock outstanding (shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_AziyoandCorMatrixMember_c4e6c041-7bcb-48ea-891f-36bb6659255b_terseLabel_en-US" xlink:label="lab_lgnd_AziyoandCorMatrixMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aziyo and CorMatrix</link:label>
    <link:label id="lab_lgnd_AziyoandCorMatrixMember_label_en-US" xlink:label="lab_lgnd_AziyoandCorMatrixMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aziyo and CorMatrix [Member]</link:label>
    <link:label id="lab_lgnd_AziyoandCorMatrixMember_documentation_en-US" xlink:label="lab_lgnd_AziyoandCorMatrixMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aziyo and CorMatrix [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AziyoandCorMatrixMember" xlink:href="lgnd-20211231.xsd#lgnd_AziyoandCorMatrixMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_AziyoandCorMatrixMember" xlink:to="lab_lgnd_AziyoandCorMatrixMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_49e239d6-14ef-446e-ad2a-b2e5a2026411_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_EmployeeStockPurchasePlanAbstract_6ae8ea57-e75e-4d54-b633-b9454a3e6f55_terseLabel_en-US" xlink:label="lab_lgnd_EmployeeStockPurchasePlanAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Purchase Plan</link:label>
    <link:label id="lab_lgnd_EmployeeStockPurchasePlanAbstract_label_en-US" xlink:label="lab_lgnd_EmployeeStockPurchasePlanAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Purchase Plan [Abstract]</link:label>
    <link:label id="lab_lgnd_EmployeeStockPurchasePlanAbstract_documentation_en-US" xlink:label="lab_lgnd_EmployeeStockPurchasePlanAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Purchase Plan [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_EmployeeStockPurchasePlanAbstract" xlink:href="lgnd-20211231.xsd#lgnd_EmployeeStockPurchasePlanAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_EmployeeStockPurchasePlanAbstract" xlink:to="lab_lgnd_EmployeeStockPurchasePlanAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromDivestitureOfBusinesses_7de6659a-204c-47ce-a5ef-f250eff6629c_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds on sale of Vernalis R&amp;D, net</link:label>
    <link:label id="lab_us-gaap_ProceedsFromDivestitureOfBusinesses_label_en-US" xlink:label="lab_us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Divestiture of Businesses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromDivestitureOfBusinesses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:to="lab_us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_373aed3d-d1c9-4361-ba8a-2e6b8be2b8cd_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGrossAbstract_81c97d0d-99d3-4aee-8d19-09a2d0303922_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGrossAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets:</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGrossAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGrossAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Gross [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGrossAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGrossAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="lab_us-gaap_DeferredTaxAssetsGrossAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_f0b23ef4-27d5-4e34-8316-f403b255eda2_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable_f65804d7-0a8f-435e-a7d0-01212e1ea566_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_cc363425-b117-4442-bc10-15937e8bdcb2_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upper range of exercise prices (USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Exercise Price Range, Upper Range Limit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_6328f6ae-62e5-40cf-b0ea-a56632c05462_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reductions for tax positions of prior years</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_d53af6f3-ce8f-41db-a1e7-bf83ea1dee0b_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Within one year</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerRelationshipsMember_0a32d34d-343c-4fa9-bf4a-6b4529c9d246_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerRelationshipsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Relationships</link:label>
    <link:label id="lab_us-gaap_CustomerRelationshipsMember_67976109-a3d0-4909-bb68-8323946c0513_verboseLabel_en-US" xlink:label="lab_us-gaap_CustomerRelationshipsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer relationships</link:label>
    <link:label id="lab_us-gaap_CustomerRelationshipsMember_label_en-US" xlink:label="lab_us-gaap_CustomerRelationshipsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Relationships [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerRelationshipsMember" xlink:to="lab_us-gaap_CustomerRelationshipsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_ConvertibleSeniorNotesDue2019Member_e307377f-6a8e-49b1-b65e-c92d2cfddaf9_terseLabel_en-US" xlink:label="lab_lgnd_ConvertibleSeniorNotesDue2019Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2019 Convertible Senior Notes</link:label>
    <link:label id="lab_lgnd_ConvertibleSeniorNotesDue2019Member_label_en-US" xlink:label="lab_lgnd_ConvertibleSeniorNotesDue2019Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Senior Notes due 2019 [Member]</link:label>
    <link:label id="lab_lgnd_ConvertibleSeniorNotesDue2019Member_documentation_en-US" xlink:label="lab_lgnd_ConvertibleSeniorNotesDue2019Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Senior Notes due 2019 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ConvertibleSeniorNotesDue2019Member" xlink:href="lgnd-20211231.xsd#lgnd_ConvertibleSeniorNotesDue2019Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_ConvertibleSeniorNotesDue2019Member" xlink:to="lab_lgnd_ConvertibleSeniorNotesDue2019Member" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_PaymentsToContingentValueRightHoldersFinancingActivity_9847bf3c-8600-492e-b8bc-469f5ba8c787_negatedLabel_en-US" xlink:label="lab_lgnd_PaymentsToContingentValueRightHoldersFinancingActivity" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to CVR Holders</link:label>
    <link:label id="lab_lgnd_PaymentsToContingentValueRightHoldersFinancingActivity_label_en-US" xlink:label="lab_lgnd_PaymentsToContingentValueRightHoldersFinancingActivity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Contingent Value Right Holders, Financing Activity</link:label>
    <link:label id="lab_lgnd_PaymentsToContingentValueRightHoldersFinancingActivity_documentation_en-US" xlink:label="lab_lgnd_PaymentsToContingentValueRightHoldersFinancingActivity" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Contingent Value Right Holders, Financing Activity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PaymentsToContingentValueRightHoldersFinancingActivity" xlink:href="lgnd-20211231.xsd#lgnd_PaymentsToContingentValueRightHoldersFinancingActivity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_PaymentsToContingentValueRightHoldersFinancingActivity" xlink:to="lab_lgnd_PaymentsToContingentValueRightHoldersFinancingActivity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_bfea8ae8-4b78-47a1-891e-883d6f941a81_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_1a905d45-9c1a-436e-ac79-e0c88faa8d9c_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_d30af78d-bcb7-4cde-a805-feac7456705f_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_ExercisePriceRangeSevenMember_7e11dc47-fa9f-4866-9d89-fb2485892963_terseLabel_en-US" xlink:label="lab_lgnd_ExercisePriceRangeSevenMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">117.97</link:label>
    <link:label id="lab_lgnd_ExercisePriceRangeSevenMember_label_en-US" xlink:label="lab_lgnd_ExercisePriceRangeSevenMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range Seven [Member]</link:label>
    <link:label id="lab_lgnd_ExercisePriceRangeSevenMember_documentation_en-US" xlink:label="lab_lgnd_ExercisePriceRangeSevenMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range Seven [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ExercisePriceRangeSevenMember" xlink:href="lgnd-20211231.xsd#lgnd_ExercisePriceRangeSevenMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_ExercisePriceRangeSevenMember" xlink:to="lab_lgnd_ExercisePriceRangeSevenMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForwardTableTextBlock_eaccd97a-adad-4aaa-b525-adbc87328bc8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForwardTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Unrecognized Tax Benefits</link:label>
    <link:label id="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForwardTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForwardTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns Roll Forward [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForwardTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForwardTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForwardTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForwardTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeAssets_83cca4c1-18e8-4ca4-a272-dd75e950fb72_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative asset</link:label>
    <link:label id="lab_us-gaap_DerivativeAssets_label_en-US" xlink:label="lab_us-gaap_DerivativeAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeAssets" xlink:to="lab_us-gaap_DerivativeAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionsProFormaRevenue_c3c15bc6-a866-4505-9417-27839bd32e6b_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionsProFormaRevenue_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Pro Forma Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionsProFormaRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:to="lab_us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesOther_04be1833-6ffb-447d-9750-6fe6a7df7a33_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesOther" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesOther_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesOther" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_473cc3b7-3e8f-46a8-a8bd-103e98ff7e84_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise price of warrants (USD per share)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_79ea5587-13ef-4d3b-a037-281c440108fb_verboseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant exercise price (USD per share)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedPremium_d5e75e1d-2a63-4e72-854d-62d2929ec9dc_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedPremium" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt issuance costs related to the liability component of convertible debt</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedPremium_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedPremium" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Unamortized Premium</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedPremium" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedPremium"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentUnamortizedPremium" xlink:to="lab_us-gaap_DebtInstrumentUnamortizedPremium" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_BusinessCombinationAssumptionsUsedEstimatedFutureCashFlowsDiscountRate_25dc3036-8bc6-4b3f-b608-7033e0e383d7_terseLabel_en-US" xlink:label="lab_lgnd_BusinessCombinationAssumptionsUsedEstimatedFutureCashFlowsDiscountRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Projected cash flow discount rate (as a percent)</link:label>
    <link:label id="lab_lgnd_BusinessCombinationAssumptionsUsedEstimatedFutureCashFlowsDiscountRate_label_en-US" xlink:label="lab_lgnd_BusinessCombinationAssumptionsUsedEstimatedFutureCashFlowsDiscountRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Assumptions Used Estimated Future Cash Flows, Discount Rate</link:label>
    <link:label id="lab_lgnd_BusinessCombinationAssumptionsUsedEstimatedFutureCashFlowsDiscountRate_documentation_en-US" xlink:label="lab_lgnd_BusinessCombinationAssumptionsUsedEstimatedFutureCashFlowsDiscountRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Assumptions Used Estimated Future Cash Flows, Discount Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BusinessCombinationAssumptionsUsedEstimatedFutureCashFlowsDiscountRate" xlink:href="lgnd-20211231.xsd#lgnd_BusinessCombinationAssumptionsUsedEstimatedFutureCashFlowsDiscountRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_BusinessCombinationAssumptionsUsedEstimatedFutureCashFlowsDiscountRate" xlink:to="lab_lgnd_BusinessCombinationAssumptionsUsedEstimatedFutureCashFlowsDiscountRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_8acb916f-cb35-47fb-9246-5538719ee9dc_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options vested and expected to vest at end of period (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_LicenseFeesMember_a835ce03-953b-485c-9834-3587964cd7fd_terseLabel_en-US" xlink:label="lab_lgnd_LicenseFeesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Fees</link:label>
    <link:label id="lab_lgnd_LicenseFeesMember_label_en-US" xlink:label="lab_lgnd_LicenseFeesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Fees [Member]</link:label>
    <link:label id="lab_lgnd_LicenseFeesMember_documentation_en-US" xlink:label="lab_lgnd_LicenseFeesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Fees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_LicenseFeesMember" xlink:href="lgnd-20211231.xsd#lgnd_LicenseFeesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_LicenseFeesMember" xlink:to="lab_lgnd_LicenseFeesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantMember_eee71add-84d2-4a96-bc3d-dd497eb0799e_verboseLabel_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants</link:label>
    <link:label id="lab_us-gaap_WarrantMember_0c0eafd9-eefa-41c7-ab62-4f328efde34c_netLabel_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment in Viking warrants</link:label>
    <link:label id="lab_us-gaap_WarrantMember_label_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantMember" xlink:to="lab_us-gaap_WarrantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalLossCarryforwardMember_9bd3c3c2-4dde-42dd-afa1-6d4ad800b705_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalLossCarryforwardMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Loss Carryforward</link:label>
    <link:label id="lab_us-gaap_CapitalLossCarryforwardMember_label_en-US" xlink:label="lab_us-gaap_CapitalLossCarryforwardMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Loss Carryforward [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalLossCarryforwardMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalLossCarryforwardMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalLossCarryforwardMember" xlink:to="lab_us-gaap_CapitalLossCarryforwardMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnDispositionOfIntangibleAssets_88155e8e-522b-4516-8c6c-df618f456360_terseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnDispositionOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain from sale of intangible assets</link:label>
    <link:label id="lab_us-gaap_GainLossOnDispositionOfIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_GainLossOnDispositionOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Disposition of Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnDispositionOfIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnDispositionOfIntangibleAssets" xlink:to="lab_us-gaap_GainLossOnDispositionOfIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_9a22139f-25c0-4dc9-bd2a-0aa820fdba86_verboseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable, Weighted Average Remaining Contractual Term in Years</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetIncludingGoodwill_29995c1b-209c-41b9-8b6b-55ec978d0008_totalLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total goodwill and other identifiable intangible assets, net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetIncludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Including Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetIncludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchMember_bba98318-e309-4eb1-9151-9d37c6762b1f_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research Tax Credit Carryforward</link:label>
    <link:label id="lab_us-gaap_ResearchMember_label_en-US" xlink:label="lab_us-gaap_ResearchMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research Tax Credit Carryforward [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchMember" xlink:to="lab_us-gaap_ResearchMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_CaliforniaAndNewJerseyResearchTaxCreditCarryforwardMember_636c19c9-5536-4271-9671-13c4a63b7318_terseLabel_en-US" xlink:label="lab_lgnd_CaliforniaAndNewJerseyResearchTaxCreditCarryforwardMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">California and New Jersey Research Tax Credit Carryforward</link:label>
    <link:label id="lab_lgnd_CaliforniaAndNewJerseyResearchTaxCreditCarryforwardMember_label_en-US" xlink:label="lab_lgnd_CaliforniaAndNewJerseyResearchTaxCreditCarryforwardMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">California and New Jersey Research Tax Credit Carryforward [Member]</link:label>
    <link:label id="lab_lgnd_CaliforniaAndNewJerseyResearchTaxCreditCarryforwardMember_documentation_en-US" xlink:label="lab_lgnd_CaliforniaAndNewJerseyResearchTaxCreditCarryforwardMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">California and New Jersey Research Tax Credit Carryforward [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_CaliforniaAndNewJerseyResearchTaxCreditCarryforwardMember" xlink:href="lgnd-20211231.xsd#lgnd_CaliforniaAndNewJerseyResearchTaxCreditCarryforwardMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_CaliforniaAndNewJerseyResearchTaxCreditCarryforwardMember" xlink:to="lab_lgnd_CaliforniaAndNewJerseyResearchTaxCreditCarryforwardMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSoldAmortization_6a7f2d31-c013-48a1-8f3c-d92ff13d4540_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSoldAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of intangibles</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSoldAmortization_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSoldAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost, Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSoldAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSoldAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSoldAmortization" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSoldAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProfitLoss_1f12570a-acdb-4e3a-8e43-5ca99a7e50c5_terseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss)</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_label_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="lab_us-gaap_ProfitLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_ffbbe47a-adec-406f-b85e-b4108cd8b6cf_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments [Domain]</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember" xlink:to="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashCurrent_5515fb19-9972-4ccb-bf65-6b7c4601754b_verboseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash in other current assets</link:label>
    <link:label id="lab_us-gaap_RestrictedCashCurrent_label_en-US" xlink:label="lab_us-gaap_RestrictedCashCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashCurrent" xlink:to="lab_us-gaap_RestrictedCashCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_aa083afd-391c-4210-8802-09e229797b1e_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash at beginning of year</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0a7116f0-4f2c-4485-b999-7831425b4acf_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash at end of year</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_66ca9390-6c17-4a46-81cb-0b69c908179c_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (USD per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_NumberOfOptionsUnderConvertibleBondHedges_bc38d1a0-45ac-4abe-ba2a-5ae9005e5d92_terseLabel_en-US" xlink:label="lab_lgnd_NumberOfOptionsUnderConvertibleBondHedges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of options under convertible bond hedges</link:label>
    <link:label id="lab_lgnd_NumberOfOptionsUnderConvertibleBondHedges_label_en-US" xlink:label="lab_lgnd_NumberOfOptionsUnderConvertibleBondHedges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Options under Convertible Bond Hedges</link:label>
    <link:label id="lab_lgnd_NumberOfOptionsUnderConvertibleBondHedges_documentation_en-US" xlink:label="lab_lgnd_NumberOfOptionsUnderConvertibleBondHedges" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Options under Convertible Bond Hedges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_NumberOfOptionsUnderConvertibleBondHedges" xlink:href="lgnd-20211231.xsd#lgnd_NumberOfOptionsUnderConvertibleBondHedges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_NumberOfOptionsUnderConvertibleBondHedges" xlink:to="lab_lgnd_NumberOfOptionsUnderConvertibleBondHedges" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_7cb5f340-57e0-449f-98e4-948f757eddb2_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_8d6a5f0c-3596-4136-86e7-4468312729aa_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_2ef15d46-1873-415f-af3b-49ff4c2e0488_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Definite-lived intangible assets</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForHedgeFinancingActivities_d7b87e75-b0a8-400a-b7a6-a6e92188364c_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsForHedgeFinancingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to convert holders for bond conversion</link:label>
    <link:label id="lab_us-gaap_PaymentsForHedgeFinancingActivities_label_en-US" xlink:label="lab_us-gaap_PaymentsForHedgeFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Hedge, Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForHedgeFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForHedgeFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForHedgeFinancingActivities" xlink:to="lab_us-gaap_PaymentsForHedgeFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InternalRevenueServiceIRSMember_1c944ad7-bc7a-472f-9ee1-62dba2f97d79_terseLabel_en-US" xlink:label="lab_us-gaap_InternalRevenueServiceIRSMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Internal Revenue Service (IRS)</link:label>
    <link:label id="lab_us-gaap_InternalRevenueServiceIRSMember_label_en-US" xlink:label="lab_us-gaap_InternalRevenueServiceIRSMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Internal Revenue Service (IRS) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InternalRevenueServiceIRSMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InternalRevenueServiceIRSMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InternalRevenueServiceIRSMember" xlink:to="lab_us-gaap_InternalRevenueServiceIRSMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_99327c8d-0b67-4c51-b183-e839ce94fc98_negatedLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstanding_8c2fd541-8253-44f3-9577-d2aea735c7b4_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants</link:label>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstanding_label_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants and Rights Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantsAndRightsOutstanding" xlink:to="lab_us-gaap_WarrantsAndRightsOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_b5a4be7b-3158-404c-a0ee-3d3744adfd1a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_MilestoneMember_6ba56c5d-32f4-44e1-a83f-87d5c463ff96_terseLabel_en-US" xlink:label="lab_lgnd_MilestoneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone</link:label>
    <link:label id="lab_lgnd_MilestoneMember_label_en-US" xlink:label="lab_lgnd_MilestoneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone [Member]</link:label>
    <link:label id="lab_lgnd_MilestoneMember_documentation_en-US" xlink:label="lab_lgnd_MilestoneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_MilestoneMember" xlink:href="lgnd-20211231.xsd#lgnd_MilestoneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_MilestoneMember" xlink:to="lab_lgnd_MilestoneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_da75aa78-dd23-4907-ac98-046743dc7a72_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_PfenexMember_4c5d9b13-8a61-415d-b9c9-fa2eef8a2f9e_terseLabel_en-US" xlink:label="lab_lgnd_PfenexMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pfenex</link:label>
    <link:label id="lab_lgnd_PfenexMember_label_en-US" xlink:label="lab_lgnd_PfenexMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pfenex [Member]</link:label>
    <link:label id="lab_lgnd_PfenexMember_documentation_en-US" xlink:label="lab_lgnd_PfenexMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pfenex</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PfenexMember" xlink:href="lgnd-20211231.xsd#lgnd_PfenexMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_PfenexMember" xlink:to="lab_lgnd_PfenexMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_BusinessCombinationCashHoldbackForPotentialIndemnificationClaims_5085e7a0-d0b7-4443-89ba-c50edf3c876f_terseLabel_en-US" xlink:label="lab_lgnd_BusinessCombinationCashHoldbackForPotentialIndemnificationClaims" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash holdback for potential indemnification claims</link:label>
    <link:label id="lab_lgnd_BusinessCombinationCashHoldbackForPotentialIndemnificationClaims_label_en-US" xlink:label="lab_lgnd_BusinessCombinationCashHoldbackForPotentialIndemnificationClaims" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Cash Holdback for Potential Indemnification Claims</link:label>
    <link:label id="lab_lgnd_BusinessCombinationCashHoldbackForPotentialIndemnificationClaims_documentation_en-US" xlink:label="lab_lgnd_BusinessCombinationCashHoldbackForPotentialIndemnificationClaims" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Cash Holdback for Potential Indemnification Claims</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BusinessCombinationCashHoldbackForPotentialIndemnificationClaims" xlink:href="lgnd-20211231.xsd#lgnd_BusinessCombinationCashHoldbackForPotentialIndemnificationClaims"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_BusinessCombinationCashHoldbackForPotentialIndemnificationClaims" xlink:to="lab_lgnd_BusinessCombinationCashHoldbackForPotentialIndemnificationClaims" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DemandDepositsMember_6fb367c9-ba6c-4390-988f-652af97de789_terseLabel_en-US" xlink:label="lab_us-gaap_DemandDepositsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bank deposits</link:label>
    <link:label id="lab_us-gaap_DemandDepositsMember_label_en-US" xlink:label="lab_us-gaap_DemandDepositsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Demand Deposits [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DemandDepositsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DemandDepositsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DemandDepositsMember" xlink:to="lab_us-gaap_DemandDepositsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_63b998d5-df6f-4fee-82c2-0b5650d84593_verboseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities_48e1a213-4942-46c3-896f-7b22d829611c_verboseLabel_en-US" xlink:label="lab_lgnd_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Adjustment</link:label>
    <link:label id="lab_lgnd_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities_label_en-US" xlink:label="lab_lgnd_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Fair Value Adjustment, Contingent Liabilities</link:label>
    <link:label id="lab_lgnd_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities_documentation_en-US" xlink:label="lab_lgnd_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Fair Value Adjustment, Contingent Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities" xlink:href="lgnd-20211231.xsd#lgnd_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities" xlink:to="lab_lgnd_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_PaymentsToUnwindWarrants_720eab49-0916-471a-85a0-75e6deed089c_terseLabel_en-US" xlink:label="lab_lgnd_PaymentsToUnwindWarrants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to unwind warrants</link:label>
    <link:label id="lab_lgnd_PaymentsToUnwindWarrants_label_en-US" xlink:label="lab_lgnd_PaymentsToUnwindWarrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Unwind Warrants</link:label>
    <link:label id="lab_lgnd_PaymentsToUnwindWarrants_documentation_en-US" xlink:label="lab_lgnd_PaymentsToUnwindWarrants" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Unwind Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PaymentsToUnwindWarrants" xlink:href="lgnd-20211231.xsd#lgnd_PaymentsToUnwindWarrants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_PaymentsToUnwindWarrants" xlink:to="lab_lgnd_PaymentsToUnwindWarrants" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorFirmId_c5fbe6a2-a2ca-4384-9873-c480dd6f421a_terseLabel_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:label id="lab_dei_AuditorFirmId_label_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorFirmId"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorFirmId" xlink:to="lab_dei_AuditorFirmId" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_FiniteLivedIntangibleAssetsCreditLossAdjustments_b566b711-e23b-413e-b8bd-2be9a7cda725_terseLabel_en-US" xlink:label="lab_lgnd_FiniteLivedIntangibleAssetsCreditLossAdjustments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit loss adjustments on finite-lived intangible assets</link:label>
    <link:label id="lab_lgnd_FiniteLivedIntangibleAssetsCreditLossAdjustments_label_en-US" xlink:label="lab_lgnd_FiniteLivedIntangibleAssetsCreditLossAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-lived Intangible Assets, Credit Loss Adjustments</link:label>
    <link:label id="lab_lgnd_FiniteLivedIntangibleAssetsCreditLossAdjustments_documentation_en-US" xlink:label="lab_lgnd_FiniteLivedIntangibleAssetsCreditLossAdjustments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-lived Intangible Assets, Credit Loss Adjustments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_FiniteLivedIntangibleAssetsCreditLossAdjustments" xlink:href="lgnd-20211231.xsd#lgnd_FiniteLivedIntangibleAssetsCreditLossAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_FiniteLivedIntangibleAssetsCreditLossAdjustments" xlink:to="lab_lgnd_FiniteLivedIntangibleAssetsCreditLossAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments_bc46e4be-3165-4259-a429-175fbbed322d_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for equity method investment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:to="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_CashCashEquivalentsandShorttermInvestmentsPolicyTextBlock_24a6dc74-c966-446d-aed4-1861244689f7_verboseLabel_en-US" xlink:label="lab_lgnd_CashCashEquivalentsandShorttermInvestmentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Equivalents &amp; Short-term Investments</link:label>
    <link:label id="lab_lgnd_CashCashEquivalentsandShorttermInvestmentsPolicyTextBlock_label_en-US" xlink:label="lab_lgnd_CashCashEquivalentsandShorttermInvestmentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, and Short-term Investments [Policy Text Block]</link:label>
    <link:label id="lab_lgnd_CashCashEquivalentsandShorttermInvestmentsPolicyTextBlock_documentation_en-US" xlink:label="lab_lgnd_CashCashEquivalentsandShorttermInvestmentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, and Short-term Investments [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_CashCashEquivalentsandShorttermInvestmentsPolicyTextBlock" xlink:href="lgnd-20211231.xsd#lgnd_CashCashEquivalentsandShorttermInvestmentsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_CashCashEquivalentsandShorttermInvestmentsPolicyTextBlock" xlink:to="lab_lgnd_CashCashEquivalentsandShorttermInvestmentsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RoyaltyMember_7ff123d9-ac7c-422e-b6c9-366a63b81f67_terseLabel_en-US" xlink:label="lab_us-gaap_RoyaltyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalties</link:label>
    <link:label id="lab_us-gaap_RoyaltyMember_label_en-US" xlink:label="lab_us-gaap_RoyaltyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RoyaltyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RoyaltyMember" xlink:to="lab_us-gaap_RoyaltyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_0ba125b7-1b68-4d6c-b297-e89dc5152486_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_NumberOfContingentValueRightAgreements_c4e963e6-fe93-47ec-8123-7bf28921e482_terseLabel_en-US" xlink:label="lab_lgnd_NumberOfContingentValueRightAgreements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of CVR agreements</link:label>
    <link:label id="lab_lgnd_NumberOfContingentValueRightAgreements_label_en-US" xlink:label="lab_lgnd_NumberOfContingentValueRightAgreements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Contingent Value Right Agreements</link:label>
    <link:label id="lab_lgnd_NumberOfContingentValueRightAgreements_documentation_en-US" xlink:label="lab_lgnd_NumberOfContingentValueRightAgreements" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Contingent Value Right Agreements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_NumberOfContingentValueRightAgreements" xlink:href="lgnd-20211231.xsd#lgnd_NumberOfContingentValueRightAgreements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_NumberOfContingentValueRightAgreements" xlink:to="lab_lgnd_NumberOfContingentValueRightAgreements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_b9edd251-cab3-42bc-95bc-9f8a97cf48ef_verboseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities, net of acquisitions:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_68224c42-2476-447c-81fe-1b9b119fa31a_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_RoyaltyEvomelaMember_b62a1d2f-ee57-40f1-8ad1-7a6d857ed717_terseLabel_en-US" xlink:label="lab_lgnd_RoyaltyEvomelaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Evomela</link:label>
    <link:label id="lab_lgnd_RoyaltyEvomelaMember_label_en-US" xlink:label="lab_lgnd_RoyaltyEvomelaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty, Evomela [Member]</link:label>
    <link:label id="lab_lgnd_RoyaltyEvomelaMember_documentation_en-US" xlink:label="lab_lgnd_RoyaltyEvomelaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty, Evomela</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_RoyaltyEvomelaMember" xlink:href="lgnd-20211231.xsd#lgnd_RoyaltyEvomelaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_RoyaltyEvomelaMember" xlink:to="lab_lgnd_RoyaltyEvomelaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable_db15380e-58dc-419f-8420-7f0fdad62e61_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income taxes receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Income Taxes Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInIncomeTaxesReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_0fb4d206-9079-4d3d-8cd1-2d2ddb8031db_verboseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross payments to acquire business</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Businesses, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesGross" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseInterestPaymentOnLiability_88eadd24-bba1-49de-aee8-6c3570842740_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for amounts included in finance lease liabilities</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseInterestPaymentOnLiability_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Interest Payment on Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseInterestPaymentOnLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:to="lab_us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock_7870dded-363d-433a-89fe-b6484e1c0385_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangibles Acquired</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets Acquired as Part of Business Combination [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_OwnershipDomain_cfbf07e3-a270-4d7d-874d-54927225cfed_terseLabel_en-US" xlink:label="lab_srt_OwnershipDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Domain]</link:label>
    <link:label id="lab_srt_OwnershipDomain_label_en-US" xlink:label="lab_srt_OwnershipDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_OwnershipDomain" xlink:to="lab_srt_OwnershipDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_PaymentsforConvertibleBondHedges_ebe8c8ed-7435-47ed-ba6d-7a7b44113070_terseLabel_en-US" xlink:label="lab_lgnd_PaymentsforConvertibleBondHedges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for convertible bond hedges</link:label>
    <link:label id="lab_lgnd_PaymentsforConvertibleBondHedges_label_en-US" xlink:label="lab_lgnd_PaymentsforConvertibleBondHedges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Convertible Bond Hedges</link:label>
    <link:label id="lab_lgnd_PaymentsforConvertibleBondHedges_documentation_en-US" xlink:label="lab_lgnd_PaymentsforConvertibleBondHedges" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Convertible Bond Hedges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PaymentsforConvertibleBondHedges" xlink:href="lgnd-20211231.xsd#lgnd_PaymentsforConvertibleBondHedges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_PaymentsforConvertibleBondHedges" xlink:to="lab_lgnd_PaymentsforConvertibleBondHedges" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_02dc0dc9-f026-43b5-89b8-26930b9b5cc4_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_239d86ba-3565-4d3e-8731-52dd6a9cedc3_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Assets and Liabilities Measured at Fair Value</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesTextBlock_cab58224-bcdf-449a-9fb5-1ae7dd5f7b4e_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Investment Categories</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesTextBlock_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesTextBlock" xlink:to="lab_us-gaap_MarketableSecuritiesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_ContingentValueRightOnProductRevenuesMember_16111acf-d729-4f03-b089-0f39883c8c6d_terseLabel_en-US" xlink:label="lab_lgnd_ContingentValueRightOnProductRevenuesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Value Right on Product Revenues</link:label>
    <link:label id="lab_lgnd_ContingentValueRightOnProductRevenuesMember_label_en-US" xlink:label="lab_lgnd_ContingentValueRightOnProductRevenuesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Value Right on Product Revenues [Member]</link:label>
    <link:label id="lab_lgnd_ContingentValueRightOnProductRevenuesMember_documentation_en-US" xlink:label="lab_lgnd_ContingentValueRightOnProductRevenuesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Value Right on Product Revenues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ContingentValueRightOnProductRevenuesMember" xlink:href="lgnd-20211231.xsd#lgnd_ContingentValueRightOnProductRevenuesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_ContingentValueRightOnProductRevenuesMember" xlink:to="lab_lgnd_ContingentValueRightOnProductRevenuesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_29746446-e3f2-4d85-8d38-03ee356f4d98_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsCurrent" xlink:to="lab_us-gaap_OtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeFinanceLeaseRemainingLeaseTerm_c11f27b3-650e-467f-9662-5edaa37d39b0_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeFinanceLeaseRemainingLeaseTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining lease term of finance leases</link:label>
    <link:label id="lab_us-gaap_LesseeFinanceLeaseRemainingLeaseTerm_label_en-US" xlink:label="lab_us-gaap_LesseeFinanceLeaseRemainingLeaseTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Finance Lease, Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeFinanceLeaseRemainingLeaseTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeFinanceLeaseRemainingLeaseTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeFinanceLeaseRemainingLeaseTerm" xlink:to="lab_us-gaap_LesseeFinanceLeaseRemainingLeaseTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther_fd765a18-334f-46cb-afc2-5fdd0b62eb75_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other tax adjustments</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Additional Paid in Capital, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_56faf66d-c979-490d-bac5-de5cc48ad973_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax at federal statutory rate</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_11125915-7f22-44de-b1b0-523dc04e4328_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options outstanding (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Exercise Price Range, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_LicenseUpfrontPayment_4eb40396-bca5-4985-9437-ffe085595a1c_terseLabel_en-US" xlink:label="lab_lgnd_LicenseUpfrontPayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront payment for license</link:label>
    <link:label id="lab_lgnd_LicenseUpfrontPayment_label_en-US" xlink:label="lab_lgnd_LicenseUpfrontPayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Upfront Payment</link:label>
    <link:label id="lab_lgnd_LicenseUpfrontPayment_documentation_en-US" xlink:label="lab_lgnd_LicenseUpfrontPayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Upfront Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_LicenseUpfrontPayment" xlink:href="lgnd-20211231.xsd#lgnd_LicenseUpfrontPayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_LicenseUpfrontPayment" xlink:to="lab_lgnd_LicenseUpfrontPayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_5b87ba73-e7a3-4057-a629-10b037d86054_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryPolicyTextBlock" xlink:to="lab_us-gaap_InventoryPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentForeignTaxExpenseBenefit_0694bf07-fe5c-40a9-ae84-94fb77ad5e94_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign</link:label>
    <link:label id="lab_us-gaap_CurrentForeignTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Foreign Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_BusinessCombinationConsiderationTransferredHoldback_99632647-319e-4742-9ec9-9455a2311ca6_terseLabel_en-US" xlink:label="lab_lgnd_BusinessCombinationConsiderationTransferredHoldback" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Holdback from acquisition</link:label>
    <link:label id="lab_lgnd_BusinessCombinationConsiderationTransferredHoldback_label_en-US" xlink:label="lab_lgnd_BusinessCombinationConsiderationTransferredHoldback" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred, Holdback</link:label>
    <link:label id="lab_lgnd_BusinessCombinationConsiderationTransferredHoldback_documentation_en-US" xlink:label="lab_lgnd_BusinessCombinationConsiderationTransferredHoldback" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred, Holdback</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BusinessCombinationConsiderationTransferredHoldback" xlink:href="lgnd-20211231.xsd#lgnd_BusinessCombinationConsiderationTransferredHoldback"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_BusinessCombinationConsiderationTransferredHoldback" xlink:to="lab_lgnd_BusinessCombinationConsiderationTransferredHoldback" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_703110ef-0554-4a74-a71f-473b2d1b346e_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Within one year</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_PurchaseCommitmentConsiderationPaidToDate_cebf2d76-f680-4617-9403-a33c3077df27_terseLabel_en-US" xlink:label="lab_lgnd_PurchaseCommitmentConsiderationPaidToDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consideration paid to date</link:label>
    <link:label id="lab_lgnd_PurchaseCommitmentConsiderationPaidToDate_label_en-US" xlink:label="lab_lgnd_PurchaseCommitmentConsiderationPaidToDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Commitment, Consideration Paid to Date</link:label>
    <link:label id="lab_lgnd_PurchaseCommitmentConsiderationPaidToDate_documentation_en-US" xlink:label="lab_lgnd_PurchaseCommitmentConsiderationPaidToDate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Commitment, Consideration Paid to Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PurchaseCommitmentConsiderationPaidToDate" xlink:href="lgnd-20211231.xsd#lgnd_PurchaseCommitmentConsiderationPaidToDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_PurchaseCommitmentConsiderationPaidToDate" xlink:to="lab_lgnd_PurchaseCommitmentConsiderationPaidToDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainContingenciesTable_b01d3ab4-4572-4f91-ad7a-00b9a01a6bfc_terseLabel_en-US" xlink:label="lab_us-gaap_GainContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain Contingencies [Table]</link:label>
    <link:label id="lab_us-gaap_GainContingenciesTable_label_en-US" xlink:label="lab_us-gaap_GainContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain Contingencies [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainContingenciesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainContingenciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainContingenciesTable" xlink:to="lab_us-gaap_GainContingenciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_4b5a7717-3cca-4b63-a02b-1224fa1f44b3_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscount_cdc4a7ab-e7bc-4feb-8c3f-d24fa17e1a9a_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unamortized discount (including unamortized debt issuance cost)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Unamortized Discount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:to="lab_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_7b7e1ef1-ddb0-4d63-81f7-746b6647aefe_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>13
<FILENAME>lgnd-20211231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:d46a5cfc-72eb-4b3a-bd09-c8907e0f4c5d,g:058bd086-7924-4675-b3eb-d4a9ba4991e0-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.ligand.com/role/Cover" xlink:type="simple" xlink:href="lgnd-20211231.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_c3879d9b-3580-427f-b899-27f36943ac90" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_37d2a555-b022-4808-93be-c4b1c53afc1c" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c3879d9b-3580-427f-b899-27f36943ac90" xlink:to="loc_dei_DocumentType_37d2a555-b022-4808-93be-c4b1c53afc1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport_9bb75128-d8f5-4aa0-94b7-bc1e64db2d43" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c3879d9b-3580-427f-b899-27f36943ac90" xlink:to="loc_dei_DocumentAnnualReport_9bb75128-d8f5-4aa0-94b7-bc1e64db2d43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_35279ae2-21aa-424b-bad3-55d218edb0f9" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c3879d9b-3580-427f-b899-27f36943ac90" xlink:to="loc_dei_DocumentPeriodEndDate_35279ae2-21aa-424b-bad3-55d218edb0f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_9d9f6eca-9851-4e8c-880f-c1bff0aefe5e" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c3879d9b-3580-427f-b899-27f36943ac90" xlink:to="loc_dei_DocumentTransitionReport_9d9f6eca-9851-4e8c-880f-c1bff0aefe5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_16e5886b-9a48-4eb7-8a92-3e48fce177e5" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c3879d9b-3580-427f-b899-27f36943ac90" xlink:to="loc_dei_EntityFileNumber_16e5886b-9a48-4eb7-8a92-3e48fce177e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_313c2d9c-4ba9-4401-b8c4-196a2722948f" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c3879d9b-3580-427f-b899-27f36943ac90" xlink:to="loc_dei_EntityRegistrantName_313c2d9c-4ba9-4401-b8c4-196a2722948f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_f0a062b9-e72f-4693-a2f9-777cb7fff19f" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c3879d9b-3580-427f-b899-27f36943ac90" xlink:to="loc_dei_EntityIncorporationStateCountryCode_f0a062b9-e72f-4693-a2f9-777cb7fff19f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_afecf07f-2854-44c2-9cc7-f1af65a4316f" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c3879d9b-3580-427f-b899-27f36943ac90" xlink:to="loc_dei_EntityTaxIdentificationNumber_afecf07f-2854-44c2-9cc7-f1af65a4316f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_1ba76228-37e2-46d3-88fe-f800276a3aff" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c3879d9b-3580-427f-b899-27f36943ac90" xlink:to="loc_dei_EntityAddressAddressLine1_1ba76228-37e2-46d3-88fe-f800276a3aff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_84501b19-f82b-4b80-988a-2841d7b98aab" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c3879d9b-3580-427f-b899-27f36943ac90" xlink:to="loc_dei_EntityAddressCityOrTown_84501b19-f82b-4b80-988a-2841d7b98aab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_10609deb-b1b0-4ec2-9272-348e3c3c5669" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c3879d9b-3580-427f-b899-27f36943ac90" xlink:to="loc_dei_EntityAddressStateOrProvince_10609deb-b1b0-4ec2-9272-348e3c3c5669" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_fc2ff61a-5d68-4524-81c3-5ca7d9ba4d36" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c3879d9b-3580-427f-b899-27f36943ac90" xlink:to="loc_dei_EntityAddressPostalZipCode_fc2ff61a-5d68-4524-81c3-5ca7d9ba4d36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_6df88391-9066-4456-8d25-cbce05cfdfe4" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c3879d9b-3580-427f-b899-27f36943ac90" xlink:to="loc_dei_CityAreaCode_6df88391-9066-4456-8d25-cbce05cfdfe4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_1a9bb876-5780-4688-bd5f-d54f54f24731" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c3879d9b-3580-427f-b899-27f36943ac90" xlink:to="loc_dei_LocalPhoneNumber_1a9bb876-5780-4688-bd5f-d54f54f24731" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_8eb3f873-c50d-4bdc-bd78-e7c9d18700a9" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c3879d9b-3580-427f-b899-27f36943ac90" xlink:to="loc_dei_Security12bTitle_8eb3f873-c50d-4bdc-bd78-e7c9d18700a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_701bf4d7-6a0a-4cf7-a76d-c4240dfdf3a7" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c3879d9b-3580-427f-b899-27f36943ac90" xlink:to="loc_dei_TradingSymbol_701bf4d7-6a0a-4cf7-a76d-c4240dfdf3a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_fe32ce5e-c2e9-4ffc-b630-7e3fb21d783b" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c3879d9b-3580-427f-b899-27f36943ac90" xlink:to="loc_dei_SecurityExchangeName_fe32ce5e-c2e9-4ffc-b630-7e3fb21d783b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_367fbb8b-348c-49a3-ad37-8579eb496432" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c3879d9b-3580-427f-b899-27f36943ac90" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_367fbb8b-348c-49a3-ad37-8579eb496432" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers_dff0350d-ffe3-4f6b-bef0-74bbf8f11f67" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c3879d9b-3580-427f-b899-27f36943ac90" xlink:to="loc_dei_EntityVoluntaryFilers_dff0350d-ffe3-4f6b-bef0-74bbf8f11f67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_8cfe5cc8-ce32-4230-8210-6f4d6006d7d6" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c3879d9b-3580-427f-b899-27f36943ac90" xlink:to="loc_dei_EntityCurrentReportingStatus_8cfe5cc8-ce32-4230-8210-6f4d6006d7d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_c5c0fa98-4eaf-403c-8f11-52a4aad89304" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c3879d9b-3580-427f-b899-27f36943ac90" xlink:to="loc_dei_EntityInteractiveDataCurrent_c5c0fa98-4eaf-403c-8f11-52a4aad89304" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_58d182da-b41a-46fd-b08f-44641f97b71d" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c3879d9b-3580-427f-b899-27f36943ac90" xlink:to="loc_dei_EntityFilerCategory_58d182da-b41a-46fd-b08f-44641f97b71d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_1a52db7d-7ed0-4fa1-98e8-e0856ffd5ccc" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c3879d9b-3580-427f-b899-27f36943ac90" xlink:to="loc_dei_EntitySmallBusiness_1a52db7d-7ed0-4fa1-98e8-e0856ffd5ccc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_ab823c6c-e3dc-4256-8507-8c9b7b9ee11e" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c3879d9b-3580-427f-b899-27f36943ac90" xlink:to="loc_dei_EntityEmergingGrowthCompany_ab823c6c-e3dc-4256-8507-8c9b7b9ee11e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag_e29f1dd2-5b35-4545-a5b5-bd627acc91f9" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c3879d9b-3580-427f-b899-27f36943ac90" xlink:to="loc_dei_IcfrAuditorAttestationFlag_e29f1dd2-5b35-4545-a5b5-bd627acc91f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_b459fe27-b200-4d2d-9deb-93e9d038236f" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c3879d9b-3580-427f-b899-27f36943ac90" xlink:to="loc_dei_EntityShellCompany_b459fe27-b200-4d2d-9deb-93e9d038236f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat_5597c93d-c8a4-42b8-8cdb-f076e12f8d68" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c3879d9b-3580-427f-b899-27f36943ac90" xlink:to="loc_dei_EntityPublicFloat_5597c93d-c8a4-42b8-8cdb-f076e12f8d68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_16d3769a-668b-4591-8e66-ee0788bb6f9d" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c3879d9b-3580-427f-b899-27f36943ac90" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_16d3769a-668b-4591-8e66-ee0788bb6f9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock_671df86a-d6a9-4c1d-9e43-fa6450b906a3" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c3879d9b-3580-427f-b899-27f36943ac90" xlink:to="loc_dei_DocumentsIncorporatedByReferenceTextBlock_671df86a-d6a9-4c1d-9e43-fa6450b906a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_41a1163c-bc94-4cc5-96c8-02523bda07e1" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c3879d9b-3580-427f-b899-27f36943ac90" xlink:to="loc_dei_AmendmentFlag_41a1163c-bc94-4cc5-96c8-02523bda07e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_d4d93e73-6770-4ba8-a90b-c50438e39386" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c3879d9b-3580-427f-b899-27f36943ac90" xlink:to="loc_dei_DocumentFiscalYearFocus_d4d93e73-6770-4ba8-a90b-c50438e39386" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_0912a6c8-244c-45ba-9e65-bacff7e97003" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c3879d9b-3580-427f-b899-27f36943ac90" xlink:to="loc_dei_DocumentFiscalPeriodFocus_0912a6c8-244c-45ba-9e65-bacff7e97003" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_159d3294-d54f-4bd8-a46a-863f24d37473" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c3879d9b-3580-427f-b899-27f36943ac90" xlink:to="loc_dei_EntityCentralIndexKey_159d3294-d54f-4bd8-a46a-863f24d37473" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_bd0549b3-b890-4b2f-b340-231fb74ae915" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c3879d9b-3580-427f-b899-27f36943ac90" xlink:to="loc_dei_CurrentFiscalYearEndDate_bd0549b3-b890-4b2f-b340-231fb74ae915" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/AuditInformation" xlink:type="simple" xlink:href="lgnd-20211231.xsd#AuditInformation"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/AuditInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AuditInformationAbstract_ef966191-e08a-47b9-b8ed-15246ee77799" xlink:href="lgnd-20211231.xsd#lgnd_AuditInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName_109784ba-7bd8-4ed6-a10e-bd90ffc33e05" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorName"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_AuditInformationAbstract_ef966191-e08a-47b9-b8ed-15246ee77799" xlink:to="loc_dei_AuditorName_109784ba-7bd8-4ed6-a10e-bd90ffc33e05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation_316d55ba-1b1c-49ce-a392-69118ba12a03" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorLocation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_AuditInformationAbstract_ef966191-e08a-47b9-b8ed-15246ee77799" xlink:to="loc_dei_AuditorLocation_316d55ba-1b1c-49ce-a392-69118ba12a03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId_51df2017-cde8-4ed6-b87b-c0b1688fe498" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorFirmId"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_AuditInformationAbstract_ef966191-e08a-47b9-b8ed-15246ee77799" xlink:to="loc_dei_AuditorFirmId_51df2017-cde8-4ed6-b87b-c0b1688fe498" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="lgnd-20211231.xsd#CONSOLIDATEDBALANCESHEETS"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_d1c2f871-486c-4d05-874f-db6372e67712" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_581dd665-87bd-40fa-a77e-20df5e49b3c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_d1c2f871-486c-4d05-874f-db6372e67712" xlink:to="loc_us-gaap_AssetsAbstract_581dd665-87bd-40fa-a77e-20df5e49b3c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_bc2c6017-db67-4a4d-8c22-1e5dbef0b963" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_581dd665-87bd-40fa-a77e-20df5e49b3c5" xlink:to="loc_us-gaap_AssetsCurrentAbstract_bc2c6017-db67-4a4d-8c22-1e5dbef0b963" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_3ab95d8e-61a0-4072-bb58-d9ccdc70dd9f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_bc2c6017-db67-4a4d-8c22-1e5dbef0b963" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_3ab95d8e-61a0-4072-bb58-d9ccdc70dd9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments_c5abf1f3-4619-4476-aee9-fd2dfc104983" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_bc2c6017-db67-4a4d-8c22-1e5dbef0b963" xlink:to="loc_us-gaap_ShortTermInvestments_c5abf1f3-4619-4476-aee9-fd2dfc104983" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_74a1c7b9-2563-489a-bcc8-deb0847bf989" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_bc2c6017-db67-4a4d-8c22-1e5dbef0b963" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_74a1c7b9-2563-489a-bcc8-deb0847bf989" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_79df6060-96fa-4e0d-b097-7dead6b6f35f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_bc2c6017-db67-4a4d-8c22-1e5dbef0b963" xlink:to="loc_us-gaap_InventoryNet_79df6060-96fa-4e0d-b097-7dead6b6f35f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesReceivable_f0fff1c3-656a-460d-a54a-f2a0c13593cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxesReceivable"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_bc2c6017-db67-4a4d-8c22-1e5dbef0b963" xlink:to="loc_us-gaap_IncomeTaxesReceivable_f0fff1c3-656a-460d-a54a-f2a0c13593cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_959190a2-7ab5-477e-85f3-fae1b2484641" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_bc2c6017-db67-4a4d-8c22-1e5dbef0b963" xlink:to="loc_us-gaap_OtherAssetsCurrent_959190a2-7ab5-477e-85f3-fae1b2484641" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_80107296-c4a2-46de-90ba-25929bbcf4fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_bc2c6017-db67-4a4d-8c22-1e5dbef0b963" xlink:to="loc_us-gaap_AssetsCurrent_80107296-c4a2-46de-90ba-25929bbcf4fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_38d4f8b1-fec1-4b43-aecd-475b35baa26b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_581dd665-87bd-40fa-a77e-20df5e49b3c5" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_38d4f8b1-fec1-4b43-aecd-475b35baa26b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_dec77b60-7f06-41ba-a9cc-b439ab3e88fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_581dd665-87bd-40fa-a77e-20df5e49b3c5" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_dec77b60-7f06-41ba-a9cc-b439ab3e88fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_aa73a612-8a29-484b-a8f6-40910e24071b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_581dd665-87bd-40fa-a77e-20df5e49b3c5" xlink:to="loc_us-gaap_Goodwill_aa73a612-8a29-484b-a8f6-40910e24071b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_CommercialLicenseRights_b36f6e86-e97e-4a3d-b028-af51cdac260f" xlink:href="lgnd-20211231.xsd#lgnd_CommercialLicenseRights"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_581dd665-87bd-40fa-a77e-20df5e49b3c5" xlink:to="loc_lgnd_CommercialLicenseRights_b36f6e86-e97e-4a3d-b028-af51cdac260f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_2cd9549f-bffc-48b8-bc07-a850770f42c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_581dd665-87bd-40fa-a77e-20df5e49b3c5" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_2cd9549f-bffc-48b8-bc07-a850770f42c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_33812220-1683-4c0a-8515-fa449aa5c9fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_581dd665-87bd-40fa-a77e-20df5e49b3c5" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_33812220-1683-4c0a-8515-fa449aa5c9fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAsset_3c0da645-6e46-4405-b340-e7c36fa2a726" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAsset"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_581dd665-87bd-40fa-a77e-20df5e49b3c5" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAsset_3c0da645-6e46-4405-b340-e7c36fa2a726" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_c2118285-4101-4e43-ba1c-84408467c9af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_581dd665-87bd-40fa-a77e-20df5e49b3c5" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_c2118285-4101-4e43-ba1c-84408467c9af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_45e2ff9f-26be-4b99-b82d-56705e87b789" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_581dd665-87bd-40fa-a77e-20df5e49b3c5" xlink:to="loc_us-gaap_Assets_45e2ff9f-26be-4b99-b82d-56705e87b789" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a017f150-70c3-4aa5-9254-3a6ed20e12b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_d1c2f871-486c-4d05-874f-db6372e67712" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a017f150-70c3-4aa5-9254-3a6ed20e12b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_c7852881-5705-4f09-84f3-e61675e9434a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a017f150-70c3-4aa5-9254-3a6ed20e12b6" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_c7852881-5705-4f09-84f3-e61675e9434a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_d5e3295b-bb76-44cc-bce1-f46f2d822858" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_c7852881-5705-4f09-84f3-e61675e9434a" xlink:to="loc_us-gaap_AccountsPayableCurrent_d5e3295b-bb76-44cc-bce1-f46f2d822858" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_2a6a99fc-2f0a-4a69-993f-ec0a9d125359" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_c7852881-5705-4f09-84f3-e61675e9434a" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_2a6a99fc-2f0a-4a69-993f-ec0a9d125359" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_CurrentPortionOfLiabilityForContingentValueRights_9cf346a3-6a06-4f9f-8f9a-ee0d7bd7460b" xlink:href="lgnd-20211231.xsd#lgnd_CurrentPortionOfLiabilityForContingentValueRights"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_c7852881-5705-4f09-84f3-e61675e9434a" xlink:to="loc_lgnd_CurrentPortionOfLiabilityForContingentValueRights_9cf346a3-6a06-4f9f-8f9a-ee0d7bd7460b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_f3ae4a17-d2ba-4f4e-9830-1ab1556565df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_c7852881-5705-4f09-84f3-e61675e9434a" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_f3ae4a17-d2ba-4f4e-9830-1ab1556565df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_3794a1f2-36b7-449b-b2a3-b749e46581bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_c7852881-5705-4f09-84f3-e61675e9434a" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_3794a1f2-36b7-449b-b2a3-b749e46581bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_5ceddcf5-e056-48ee-b73b-6360f0c63d08" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_c7852881-5705-4f09-84f3-e61675e9434a" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_5ceddcf5-e056-48ee-b73b-6360f0c63d08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_edb84afd-8ec8-4d8e-baa5-7832225ea891" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_c7852881-5705-4f09-84f3-e61675e9434a" xlink:to="loc_us-gaap_LiabilitiesCurrent_edb84afd-8ec8-4d8e-baa5-7832225ea891" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtNoncurrent_27948da4-7625-44ec-8c33-06831650c0d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a017f150-70c3-4aa5-9254-3a6ed20e12b6" xlink:to="loc_us-gaap_ConvertibleDebtNoncurrent_27948da4-7625-44ec-8c33-06831650c0d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_LiabilityForContingentValueRights_0dc686ff-1895-4569-86dd-213f108f5444" xlink:href="lgnd-20211231.xsd#lgnd_LiabilityForContingentValueRights"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a017f150-70c3-4aa5-9254-3a6ed20e12b6" xlink:to="loc_lgnd_LiabilityForContingentValueRights_0dc686ff-1895-4569-86dd-213f108f5444" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_bde7ead5-6112-4807-aa20-688d17d7b8bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a017f150-70c3-4aa5-9254-3a6ed20e12b6" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_bde7ead5-6112-4807-aa20-688d17d7b8bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_4cadd63f-4fec-433c-b528-efac1efd2fc3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a017f150-70c3-4aa5-9254-3a6ed20e12b6" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_4cadd63f-4fec-433c-b528-efac1efd2fc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_8993d63e-8a5f-4fb6-bc32-9d917fbd0e2c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a017f150-70c3-4aa5-9254-3a6ed20e12b6" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_8993d63e-8a5f-4fb6-bc32-9d917fbd0e2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_18f30909-9b42-443f-a3b9-6b26b6fc23c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a017f150-70c3-4aa5-9254-3a6ed20e12b6" xlink:to="loc_us-gaap_Liabilities_18f30909-9b42-443f-a3b9-6b26b6fc23c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_0da8435c-3aeb-437e-a378-40901e478fd2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a017f150-70c3-4aa5-9254-3a6ed20e12b6" xlink:to="loc_us-gaap_CommitmentsAndContingencies_0da8435c-3aeb-437e-a378-40901e478fd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_b801d8d4-35b0-4a8d-86ad-5ebdba25c352" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a017f150-70c3-4aa5-9254-3a6ed20e12b6" xlink:to="loc_us-gaap_StockholdersEquityAbstract_b801d8d4-35b0-4a8d-86ad-5ebdba25c352" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_91a5357a-2fb8-4cf9-85c5-db975af88f54" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_b801d8d4-35b0-4a8d-86ad-5ebdba25c352" xlink:to="loc_us-gaap_PreferredStockValue_91a5357a-2fb8-4cf9-85c5-db975af88f54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_8d63fc33-abc7-4b7c-a6f6-bd27a79f49fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_b801d8d4-35b0-4a8d-86ad-5ebdba25c352" xlink:to="loc_us-gaap_CommonStockValue_8d63fc33-abc7-4b7c-a6f6-bd27a79f49fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_562af4ce-7cba-4e85-91e9-9765fff9adc7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_b801d8d4-35b0-4a8d-86ad-5ebdba25c352" xlink:to="loc_us-gaap_AdditionalPaidInCapital_562af4ce-7cba-4e85-91e9-9765fff9adc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_4e082fa3-daea-48b4-a79f-5fea8dc36bd4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_b801d8d4-35b0-4a8d-86ad-5ebdba25c352" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_4e082fa3-daea-48b4-a79f-5fea8dc36bd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_e1356047-6152-47c4-8884-d8c0c3c7922e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_b801d8d4-35b0-4a8d-86ad-5ebdba25c352" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_e1356047-6152-47c4-8884-d8c0c3c7922e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_96e67246-599c-45ad-9964-15c1bc476598" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_b801d8d4-35b0-4a8d-86ad-5ebdba25c352" xlink:to="loc_us-gaap_StockholdersEquity_96e67246-599c-45ad-9964-15c1bc476598" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_173e7c81-d675-442b-a648-1982a31d2f5d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a017f150-70c3-4aa5-9254-3a6ed20e12b6" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_173e7c81-d675-442b-a648-1982a31d2f5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="simple" xlink:href="lgnd-20211231.xsd#CONSOLIDATEDBALANCESHEETSParenthetical"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_415d9137-fa2b-49e5-b810-0f9521d0495e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_24f51fee-6947-42c1-b9ce-2b165d6461d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_415d9137-fa2b-49e5-b810-0f9521d0495e" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_24f51fee-6947-42c1-b9ce-2b165d6461d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_17a61640-f59a-4107-8169-6ec7af30f58a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_415d9137-fa2b-49e5-b810-0f9521d0495e" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_17a61640-f59a-4107-8169-6ec7af30f58a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_8c485237-5e72-4d5e-b53c-24cd52c3a16b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_415d9137-fa2b-49e5-b810-0f9521d0495e" xlink:to="loc_us-gaap_PreferredStockSharesIssued_8c485237-5e72-4d5e-b53c-24cd52c3a16b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_4c18c8a6-48b5-412a-babe-58c4a20d8704" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_415d9137-fa2b-49e5-b810-0f9521d0495e" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_4c18c8a6-48b5-412a-babe-58c4a20d8704" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_93c82744-eeeb-4abb-ab2b-5bf61fd05f5a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_415d9137-fa2b-49e5-b810-0f9521d0495e" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_93c82744-eeeb-4abb-ab2b-5bf61fd05f5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_50023ea4-4470-4a87-bf15-32eec3a90470" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_415d9137-fa2b-49e5-b810-0f9521d0495e" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_50023ea4-4470-4a87-bf15-32eec3a90470" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_ea7c0205-3731-4341-8391-9f0a3c072d94" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_415d9137-fa2b-49e5-b810-0f9521d0495e" xlink:to="loc_us-gaap_CommonStockSharesIssued_ea7c0205-3731-4341-8391-9f0a3c072d94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_b5987e0e-41a3-4c68-836b-b08921a72a03" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_415d9137-fa2b-49e5-b810-0f9521d0495e" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_b5987e0e-41a3-4c68-836b-b08921a72a03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="simple" xlink:href="lgnd-20211231.xsd#CONSOLIDATEDSTATEMENTSOFOPERATIONS"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_e8847ed7-3168-4c52-ad9c-007e6c8c0daf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_be4602ea-23f1-42b1-acc3-104622bf46fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_e8847ed7-3168-4c52-ad9c-007e6c8c0daf" xlink:to="loc_us-gaap_StatementTable_be4602ea-23f1-42b1-acc3-104622bf46fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_3cea458f-60c3-4900-8e3f-91a103b04b1b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_be4602ea-23f1-42b1-acc3-104622bf46fe" xlink:to="loc_srt_ProductOrServiceAxis_3cea458f-60c3-4900-8e3f-91a103b04b1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_4fa2ccd9-adea-4249-9a9c-3a90dcfb0b38" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_3cea458f-60c3-4900-8e3f-91a103b04b1b" xlink:to="loc_srt_ProductsAndServicesDomain_4fa2ccd9-adea-4249-9a9c-3a90dcfb0b38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyMember_de06a141-3d68-4a0b-b579-c3225b13a75f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RoyaltyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_4fa2ccd9-adea-4249-9a9c-3a90dcfb0b38" xlink:to="loc_us-gaap_RoyaltyMember_de06a141-3d68-4a0b-b579-c3225b13a75f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_MaterialSalesCaptisolMember_4ca12813-8669-40f7-8040-5b7ae2b723cd" xlink:href="lgnd-20211231.xsd#lgnd_MaterialSalesCaptisolMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_4fa2ccd9-adea-4249-9a9c-3a90dcfb0b38" xlink:to="loc_lgnd_MaterialSalesCaptisolMember_4ca12813-8669-40f7-8040-5b7ae2b723cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ContractRevenueMember_5338f5da-9475-45d7-8693-a9617dbe6f5f" xlink:href="lgnd-20211231.xsd#lgnd_ContractRevenueMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_4fa2ccd9-adea-4249-9a9c-3a90dcfb0b38" xlink:to="loc_lgnd_ContractRevenueMember_5338f5da-9475-45d7-8693-a9617dbe6f5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_VernalisMember_a7855eab-9dd5-413b-b564-d7a7230dedb3" xlink:href="lgnd-20211231.xsd#lgnd_VernalisMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_4fa2ccd9-adea-4249-9a9c-3a90dcfb0b38" xlink:to="loc_lgnd_VernalisMember_a7855eab-9dd5-413b-b564-d7a7230dedb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PromactaMember_aa219b84-375a-4e3d-bf2a-6066bba0f5a7" xlink:href="lgnd-20211231.xsd#lgnd_PromactaMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_4fa2ccd9-adea-4249-9a9c-3a90dcfb0b38" xlink:to="loc_lgnd_PromactaMember_aa219b84-375a-4e3d-bf2a-6066bba0f5a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_7f579b7f-60e5-43db-a5f6-4664d2597b32" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_be4602ea-23f1-42b1-acc3-104622bf46fe" xlink:to="loc_us-gaap_StatementLineItems_7f579b7f-60e5-43db-a5f6-4664d2597b32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_e55e735d-d93c-4004-b6bf-3604775193c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7f579b7f-60e5-43db-a5f6-4664d2597b32" xlink:to="loc_us-gaap_RevenuesAbstract_e55e735d-d93c-4004-b6bf-3604775193c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_424cee43-9c0d-4e2f-9b45-9fc16278948a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_e55e735d-d93c-4004-b6bf-3604775193c7" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_424cee43-9c0d-4e2f-9b45-9fc16278948a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingCostsAndExpensesAbstract_7accd9f2-c11c-45f6-8020-1b44175b41ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingCostsAndExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7f579b7f-60e5-43db-a5f6-4664d2597b32" xlink:to="loc_us-gaap_OperatingCostsAndExpensesAbstract_7accd9f2-c11c-45f6-8020-1b44175b41ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostDirectMaterial_f68e29a4-1fc1-467f-bc61-dea63151a5ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostDirectMaterial"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingCostsAndExpensesAbstract_7accd9f2-c11c-45f6-8020-1b44175b41ed" xlink:to="loc_us-gaap_CostDirectMaterial_f68e29a4-1fc1-467f-bc61-dea63151a5ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSoldAmortization_6c0f43c6-6422-403f-95b5-7826e0af6baa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSoldAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingCostsAndExpensesAbstract_7accd9f2-c11c-45f6-8020-1b44175b41ed" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSoldAmortization_6c0f43c6-6422-403f-95b5-7826e0af6baa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_89f8edf7-8eac-4e97-b9a2-b127c7277c3d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingCostsAndExpensesAbstract_7accd9f2-c11c-45f6-8020-1b44175b41ed" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_89f8edf7-8eac-4e97-b9a2-b127c7277c3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_62ea7c60-7c8e-472a-8bc5-619f17efce26" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingCostsAndExpensesAbstract_7accd9f2-c11c-45f6-8020-1b44175b41ed" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_62ea7c60-7c8e-472a-8bc5-619f17efce26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncome_56ea61f8-95c7-4d5e-b497-af8ddd0d09a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherOperatingIncome"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingCostsAndExpensesAbstract_7accd9f2-c11c-45f6-8020-1b44175b41ed" xlink:to="loc_us-gaap_OtherOperatingIncome_56ea61f8-95c7-4d5e-b497-af8ddd0d09a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingCostsAndExpenses_74dd02cf-149f-476a-a495-c2f07f2c111e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingCostsAndExpenses"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingCostsAndExpensesAbstract_7accd9f2-c11c-45f6-8020-1b44175b41ed" xlink:to="loc_us-gaap_OperatingCostsAndExpenses_74dd02cf-149f-476a-a495-c2f07f2c111e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfIntangibleAssets_03d58d7a-86c4-467d-aafb-845794443ea9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnDispositionOfIntangibleAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7f579b7f-60e5-43db-a5f6-4664d2597b32" xlink:to="loc_us-gaap_GainLossOnDispositionOfIntangibleAssets_03d58d7a-86c4-467d-aafb-845794443ea9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_64a09cc9-77a0-4d5b-9474-cc7f3cd928d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7f579b7f-60e5-43db-a5f6-4664d2597b32" xlink:to="loc_us-gaap_OperatingIncomeLoss_64a09cc9-77a0-4d5b-9474-cc7f3cd928d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_3fae6145-168e-4370-ba7d-81bc62afe266" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7f579b7f-60e5-43db-a5f6-4664d2597b32" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_3fae6145-168e-4370-ba7d-81bc62afe266" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnInvestments_7150a71f-3c5e-4e1d-ae21-8f5c44a0984f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnInvestments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_3fae6145-168e-4370-ba7d-81bc62afe266" xlink:to="loc_us-gaap_GainLossOnInvestments_7150a71f-3c5e-4e1d-ae21-8f5c44a0984f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_3e61c8d4-aa0b-43dd-9cd9-aed882780cb8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_3fae6145-168e-4370-ba7d-81bc62afe266" xlink:to="loc_us-gaap_InvestmentIncomeInterest_3e61c8d4-aa0b-43dd-9cd9-aed882780cb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_84a61da3-c506-4df1-a401-0981d9376dc3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_3fae6145-168e-4370-ba7d-81bc62afe266" xlink:to="loc_us-gaap_InterestExpense_84a61da3-c506-4df1-a401-0981d9376dc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_3995a43c-5fbf-40a0-afde-2f534d842561" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_3fae6145-168e-4370-ba7d-81bc62afe266" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_3995a43c-5fbf-40a0-afde-2f534d842561" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_cb20164e-e55b-4dce-a725-6739e38fabb1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_3fae6145-168e-4370-ba7d-81bc62afe266" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_cb20164e-e55b-4dce-a725-6739e38fabb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_fbd93f7f-ba56-435e-bf47-bb1355886f24" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7f579b7f-60e5-43db-a5f6-4664d2597b32" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_fbd93f7f-ba56-435e-bf47-bb1355886f24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_c9e9220c-c9dc-489d-991d-20135a12f160" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7f579b7f-60e5-43db-a5f6-4664d2597b32" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_c9e9220c-c9dc-489d-991d-20135a12f160" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_461be9aa-d70e-4b66-9151-321e57bffbc9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7f579b7f-60e5-43db-a5f6-4664d2597b32" xlink:to="loc_us-gaap_NetIncomeLoss_461be9aa-d70e-4b66-9151-321e57bffbc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_514039c4-e647-436e-823f-efe472133b14" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7f579b7f-60e5-43db-a5f6-4664d2597b32" xlink:to="loc_us-gaap_EarningsPerShareAbstract_514039c4-e647-436e-823f-efe472133b14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_67e4f9f4-5ca3-4e5a-b258-fc8381e8b0b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_514039c4-e647-436e-823f-efe472133b14" xlink:to="loc_us-gaap_EarningsPerShareBasic_67e4f9f4-5ca3-4e5a-b258-fc8381e8b0b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_eea7dfd6-3698-4e5e-9f24-1eb21e93e15a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_514039c4-e647-436e-823f-efe472133b14" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_eea7dfd6-3698-4e5e-9f24-1eb21e93e15a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_f7719d14-1c59-4106-89e9-7b61b74bca1c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_514039c4-e647-436e-823f-efe472133b14" xlink:to="loc_us-gaap_EarningsPerShareDiluted_f7719d14-1c59-4106-89e9-7b61b74bca1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_49141d96-8077-42fd-b992-2ec877401997" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_514039c4-e647-436e-823f-efe472133b14" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_49141d96-8077-42fd-b992-2ec877401997" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS" xlink:type="simple" xlink:href="lgnd-20211231.xsd#CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_3cbd8ac6-b3c0-4228-a234-f7512bb68e5b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_1b48728b-df26-49a0-a21b-a816e673a29d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_3cbd8ac6-b3c0-4228-a234-f7512bb68e5b" xlink:to="loc_us-gaap_NetIncomeLoss_1b48728b-df26-49a0-a21b-a816e673a29d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_f00ae1ec-fce7-46b6-8470-6b4e36a30368" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_3cbd8ac6-b3c0-4228-a234-f7512bb68e5b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_f00ae1ec-fce7-46b6-8470-6b4e36a30368" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_fc1ed51a-acfe-4dab-9d62-f5bb5e926195" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_3cbd8ac6-b3c0-4228-a234-f7512bb68e5b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_fc1ed51a-acfe-4dab-9d62-f5bb5e926195" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_91d5f645-cee1-4278-90d1-c037af4e6472" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_3cbd8ac6-b3c0-4228-a234-f7512bb68e5b" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_91d5f645-cee1-4278-90d1-c037af4e6472" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/CONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="lgnd-20211231.xsd#CONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/CONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_bd77d7b6-115a-4637-9a81-31c12f71f893" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_8c2dd33d-929c-449f-a14f-043a5aee0c52" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_bd77d7b6-115a-4637-9a81-31c12f71f893" xlink:to="loc_us-gaap_StatementTable_8c2dd33d-929c-449f-a14f-043a5aee0c52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_81512786-4853-4ee0-bcd2-c8b8c548fdac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_8c2dd33d-929c-449f-a14f-043a5aee0c52" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_81512786-4853-4ee0-bcd2-c8b8c548fdac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_c6ac9720-ca4b-4c03-8585-644260180b14" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_81512786-4853-4ee0-bcd2-c8b8c548fdac" xlink:to="loc_us-gaap_EquityComponentDomain_c6ac9720-ca4b-4c03-8585-644260180b14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_0ec3e438-e3e9-4af8-9f7f-6b485b48e443" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_c6ac9720-ca4b-4c03-8585-644260180b14" xlink:to="loc_us-gaap_CommonStockMember_0ec3e438-e3e9-4af8-9f7f-6b485b48e443" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_aebfca3e-8c41-4853-a228-e7712731dda3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_c6ac9720-ca4b-4c03-8585-644260180b14" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_aebfca3e-8c41-4853-a228-e7712731dda3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_bf0367a1-ac37-4545-82d3-a4b26ad90783" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_c6ac9720-ca4b-4c03-8585-644260180b14" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_bf0367a1-ac37-4545-82d3-a4b26ad90783" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_0183de0b-da31-437d-85ab-922ecd84908e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_c6ac9720-ca4b-4c03-8585-644260180b14" xlink:to="loc_us-gaap_RetainedEarningsMember_0183de0b-da31-437d-85ab-922ecd84908e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_11dd6d86-d657-482f-a7a7-af22d93ea598" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_8c2dd33d-929c-449f-a14f-043a5aee0c52" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_11dd6d86-d657-482f-a7a7-af22d93ea598" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_5d306195-77e4-4846-abd1-d1172091211a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_11dd6d86-d657-482f-a7a7-af22d93ea598" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_5d306195-77e4-4846-abd1-d1172091211a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_b18ef67e-0d4b-4f01-a1f9-aebb92a6cadb" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_5d306195-77e4-4846-abd1-d1172091211a" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_b18ef67e-0d4b-4f01-a1f9-aebb92a6cadb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_8818abb3-1a3c-4219-a6a9-f7ef3c48cd1b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_8c2dd33d-929c-449f-a14f-043a5aee0c52" xlink:to="loc_us-gaap_StatementLineItems_8818abb3-1a3c-4219-a6a9-f7ef3c48cd1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9a7e1744-c9f3-4335-b964-acf9b4b89d68" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8818abb3-1a3c-4219-a6a9-f7ef3c48cd1b" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9a7e1744-c9f3-4335-b964-acf9b4b89d68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_6752e2d5-0697-42a9-bb9c-7432fe634a39" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9a7e1744-c9f3-4335-b964-acf9b4b89d68" xlink:to="loc_us-gaap_SharesOutstanding_6752e2d5-0697-42a9-bb9c-7432fe634a39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_306a2706-ea8e-4c25-97ba-104c0e6007bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9a7e1744-c9f3-4335-b964-acf9b4b89d68" xlink:to="loc_us-gaap_StockholdersEquity_306a2706-ea8e-4c25-97ba-104c0e6007bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_03362e1f-6392-4f73-ab37-c3e9e0f1cb8e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9a7e1744-c9f3-4335-b964-acf9b4b89d68" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_03362e1f-6392-4f73-ab37-c3e9e0f1cb8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_996471c7-c252-4c09-afbd-c153ca209f03" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9a7e1744-c9f3-4335-b964-acf9b4b89d68" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_996471c7-c252-4c09-afbd-c153ca209f03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_51566d10-b4e1-4ee4-bd1c-f697a2006bbb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9a7e1744-c9f3-4335-b964-acf9b4b89d68" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_51566d10-b4e1-4ee4-bd1c-f697a2006bbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares_83e6f08d-332d-465f-9c4e-3d0f3f60ea3d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodShares"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9a7e1744-c9f3-4335-b964-acf9b4b89d68" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodShares_83e6f08d-332d-465f-9c4e-3d0f3f60ea3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue_e9fc5126-6ab3-4c5a-8c6a-6e2f650e2668" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodValue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9a7e1744-c9f3-4335-b964-acf9b4b89d68" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodValue_e9fc5126-6ab3-4c5a-8c6a-6e2f650e2668" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss_e782d2fd-b814-41e5-84e5-b136982beb98" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9a7e1744-c9f3-4335-b964-acf9b4b89d68" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss_e782d2fd-b814-41e5-84e5-b136982beb98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_456f3388-ef90-4cc5-8e74-6691b99d2c9a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9a7e1744-c9f3-4335-b964-acf9b4b89d68" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_456f3388-ef90-4cc5-8e74-6691b99d2c9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_b2a135e8-058b-4f91-b8a3-620f9b16482b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9a7e1744-c9f3-4335-b964-acf9b4b89d68" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_b2a135e8-058b-4f91-b8a3-620f9b16482b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdateExtensibleList_d47ede79-5263-4963-bac5-df0e91bf032c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingStandardsUpdateExtensibleList"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9a7e1744-c9f3-4335-b964-acf9b4b89d68" xlink:to="loc_us-gaap_AccountingStandardsUpdateExtensibleList_d47ede79-5263-4963-bac5-df0e91bf032c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AdjustmentsToAdditionalPaidInCapitalWarrantAndBondHedgeUnwindTransactions_e336c828-071b-4658-8155-4076fecb4d75" xlink:href="lgnd-20211231.xsd#lgnd_AdjustmentsToAdditionalPaidInCapitalWarrantAndBondHedgeUnwindTransactions"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9a7e1744-c9f3-4335-b964-acf9b4b89d68" xlink:to="loc_lgnd_AdjustmentsToAdditionalPaidInCapitalWarrantAndBondHedgeUnwindTransactions_e336c828-071b-4658-8155-4076fecb4d75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther_80df4eb0-eda1-4e52-99ab-6b6c1620664b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalOther"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9a7e1744-c9f3-4335-b964-acf9b4b89d68" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther_80df4eb0-eda1-4e52-99ab-6b6c1620664b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_3eaccbab-082b-458f-8183-27d3994d2e0a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9a7e1744-c9f3-4335-b964-acf9b4b89d68" xlink:to="loc_us-gaap_NetIncomeLoss_3eaccbab-082b-458f-8183-27d3994d2e0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_a1614e86-bd6a-466c-ae0b-5d7b3788eb8b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9a7e1744-c9f3-4335-b964-acf9b4b89d68" xlink:to="loc_us-gaap_SharesOutstanding_a1614e86-bd6a-466c-ae0b-5d7b3788eb8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_a2395e77-a1a7-4a05-8118-43fb36fd7ada" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9a7e1744-c9f3-4335-b964-acf9b4b89d68" xlink:to="loc_us-gaap_StockholdersEquity_a2395e77-a1a7-4a05-8118-43fb36fd7ada" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="lgnd-20211231.xsd#CONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_adc6445c-40c1-42e8-8a15-f803734866a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_ae7c5187-ac48-4490-9ef9-4575ff393d06" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_adc6445c-40c1-42e8-8a15-f803734866a9" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_ae7c5187-ac48-4490-9ef9-4575ff393d06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_58764637-b1ad-4cf4-8376-62667ba123bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_ae7c5187-ac48-4490-9ef9-4575ff393d06" xlink:to="loc_us-gaap_ProfitLoss_58764637-b1ad-4cf4-8376-62667ba123bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_6143198b-6054-4366-bf48-54481538de22" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_ae7c5187-ac48-4490-9ef9-4575ff393d06" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_6143198b-6054-4366-bf48-54481538de22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfOtherAssets_396bdaf8-3413-4ed1-9db4-ab97e0b7bc8f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnSaleOfOtherAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_6143198b-6054-4366-bf48-54481538de22" xlink:to="loc_us-gaap_GainLossOnSaleOfOtherAssets_396bdaf8-3413-4ed1-9db4-ab97e0b7bc8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfBusiness_bcd8e3be-4c79-4178-9688-69c01c87b9bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnSaleOfBusiness"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_6143198b-6054-4366-bf48-54481538de22" xlink:to="loc_us-gaap_GainLossOnSaleOfBusiness_bcd8e3be-4c79-4178-9688-69c01c87b9bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_NonCashChangeInEstimatedFairValueOfContingentValueRights_58461ba9-70f0-465f-a613-ff09dd71a98a" xlink:href="lgnd-20211231.xsd#lgnd_NonCashChangeInEstimatedFairValueOfContingentValueRights"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_6143198b-6054-4366-bf48-54481538de22" xlink:to="loc_lgnd_NonCashChangeInEstimatedFairValueOfContingentValueRights_58461ba9-70f0-465f-a613-ff09dd71a98a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_3d42211f-118f-4007-ad68-0d42e1e8a53a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_6143198b-6054-4366-bf48-54481538de22" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_3d42211f-118f-4007-ad68-0d42e1e8a53a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_GainLossOnShortTermInvestments_d416e0e0-004e-45ab-820a-77712f53621e" xlink:href="lgnd-20211231.xsd#lgnd_GainLossOnShortTermInvestments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_6143198b-6054-4366-bf48-54481538de22" xlink:to="loc_lgnd_GainLossOnShortTermInvestments_d416e0e0-004e-45ab-820a-77712f53621e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_4e1e3f54-38f0-456e-9e68-21f8b8e1455f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_6143198b-6054-4366-bf48-54481538de22" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_4e1e3f54-38f0-456e-9e68-21f8b8e1455f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_eabdc909-63f7-43ce-a647-401653ba1c8c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_6143198b-6054-4366-bf48-54481538de22" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_eabdc909-63f7-43ce-a647-401653ba1c8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_8154ce35-b9fe-4b2a-94f1-28c24fadc6bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_6143198b-6054-4366-bf48-54481538de22" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_8154ce35-b9fe-4b2a-94f1-28c24fadc6bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AmortizationOfCommercialLicenseAndOtherEconomicRights_540b3523-4f80-4c5a-b3b5-b359df0c6df5" xlink:href="lgnd-20211231.xsd#lgnd_AmortizationOfCommercialLicenseAndOtherEconomicRights"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_6143198b-6054-4366-bf48-54481538de22" xlink:to="loc_lgnd_AmortizationOfCommercialLicenseAndOtherEconomicRights_540b3523-4f80-4c5a-b3b5-b359df0c6df5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_231909c1-9fe4-441e-875b-e0c72a0d7e11" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_6143198b-6054-4366-bf48-54481538de22" xlink:to="loc_us-gaap_ShareBasedCompensation_231909c1-9fe4-441e-875b-e0c72a0d7e11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_d3e1550f-7b74-4bb4-ade4-fbb685ca9dd4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredIncomeTaxes"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_6143198b-6054-4366-bf48-54481538de22" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_d3e1550f-7b74-4bb4-ade4-fbb685ca9dd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement_9440422f-e6d0-4fe5-bf58-10f550aefd3c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherOperatingActivitiesCashFlowStatement"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_6143198b-6054-4366-bf48-54481538de22" xlink:to="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement_9440422f-e6d0-4fe5-bf58-10f550aefd3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_7b7147b4-0e29-4960-ae69-f82421e68ec2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_ae7c5187-ac48-4490-9ef9-4575ff393d06" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_7b7147b4-0e29-4960-ae69-f82421e68ec2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_1410128e-deb0-4bde-9a45-b8e61f2ad99f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_7b7147b4-0e29-4960-ae69-f82421e68ec2" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_1410128e-deb0-4bde-9a45-b8e61f2ad99f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_d52defde-ca28-4d64-a8f4-81dec65fdceb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_7b7147b4-0e29-4960-ae69-f82421e68ec2" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_d52defde-ca28-4d64-a8f4-81dec65fdceb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_f0f2e152-f6db-49af-b2f9-d37c71937514" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_7b7147b4-0e29-4960-ae69-f82421e68ec2" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_f0f2e152-f6db-49af-b2f9-d37c71937514" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable_1bd26256-9401-41bf-9219-f3cad540f62b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInIncomeTaxesReceivable"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_7b7147b4-0e29-4960-ae69-f82421e68ec2" xlink:to="loc_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable_1bd26256-9401-41bf-9219-f3cad540f62b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_IncreaseDecreaseInOtherEconomicRights_036452a6-3597-4ba2-8aca-6ac1b2701d58" xlink:href="lgnd-20211231.xsd#lgnd_IncreaseDecreaseInOtherEconomicRights"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_7b7147b4-0e29-4960-ae69-f82421e68ec2" xlink:to="loc_lgnd_IncreaseDecreaseInOtherEconomicRights_036452a6-3597-4ba2-8aca-6ac1b2701d58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_90be713a-1bed-4ea9-9ff0-e9010c6559b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_7b7147b4-0e29-4960-ae69-f82421e68ec2" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_90be713a-1bed-4ea9-9ff0-e9010c6559b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_4b30fce3-3a82-4926-affa-4d799ebd1d12" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentLiabilities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_7b7147b4-0e29-4960-ae69-f82421e68ec2" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_4b30fce3-3a82-4926-affa-4d799ebd1d12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_795b1182-814d-4bd6-a5b2-cd6a4265c513" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_7b7147b4-0e29-4960-ae69-f82421e68ec2" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_795b1182-814d-4bd6-a5b2-cd6a4265c513" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_9c4d6b52-7604-4190-bb83-8fd4d51c15f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_adc6445c-40c1-42e8-8a15-f803734866a9" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_9c4d6b52-7604-4190-bb83-8fd4d51c15f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfIntangibleAssets_2c168458-0243-43d6-8528-15de1ee73ef3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfIntangibleAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_9c4d6b52-7604-4190-bb83-8fd4d51c15f2" xlink:to="loc_us-gaap_ProceedsFromSaleOfIntangibleAssets_2c168458-0243-43d6-8528-15de1ee73ef3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_b41fc0dc-790d-4059-877b-758997905b71" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_9c4d6b52-7604-4190-bb83-8fd4d51c15f2" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_b41fc0dc-790d-4059-877b-758997905b71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_15a98180-0b73-4ede-a850-d1552ef70604" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_9c4d6b52-7604-4190-bb83-8fd4d51c15f2" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_15a98180-0b73-4ede-a850-d1552ef70604" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireShortTermInvestments_2a9f5ab9-a8a5-46c2-8eca-235d4d724d44" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireShortTermInvestments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_9c4d6b52-7604-4190-bb83-8fd4d51c15f2" xlink:to="loc_us-gaap_PaymentsToAcquireShortTermInvestments_2a9f5ab9-a8a5-46c2-8eca-235d4d724d44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ProceedsFromCommercialLicenseRights_5a41c30b-02b4-4d6c-a452-80c2e798ce84" xlink:href="lgnd-20211231.xsd#lgnd_ProceedsFromCommercialLicenseRights"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_9c4d6b52-7604-4190-bb83-8fd4d51c15f2" xlink:to="loc_lgnd_ProceedsFromCommercialLicenseRights_5a41c30b-02b4-4d6c-a452-80c2e798ce84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfShortTermInvestments_fd5ef123-91cc-4650-93d0-a8d33e4e1d9d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfShortTermInvestments"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_9c4d6b52-7604-4190-bb83-8fd4d51c15f2" xlink:to="loc_us-gaap_ProceedsFromSaleOfShortTermInvestments_fd5ef123-91cc-4650-93d0-a8d33e4e1d9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments_b72c3641-45fe-4482-aad1-8100a59d764a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_9c4d6b52-7604-4190-bb83-8fd4d51c15f2" xlink:to="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments_b72c3641-45fe-4482-aad1-8100a59d764a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_8501b20e-e0a1-4c62-83ff-62d7ae8d97a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_9c4d6b52-7604-4190-bb83-8fd4d51c15f2" xlink:to="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_8501b20e-e0a1-4c62-83ff-62d7ae8d97a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_ed32cbb0-4d9e-45c4-bc25-5a3a7fe954b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromDivestitureOfBusinesses"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_9c4d6b52-7604-4190-bb83-8fd4d51c15f2" xlink:to="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_ed32cbb0-4d9e-45c4-bc25-5a3a7fe954b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_121b5d1b-a49c-4bea-9ab2-7e044efeca8b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_9c4d6b52-7604-4190-bb83-8fd4d51c15f2" xlink:to="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_121b5d1b-a49c-4bea-9ab2-7e044efeca8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_8ee7c178-1b05-4bb3-b2bd-15171afa9cd0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_9c4d6b52-7604-4190-bb83-8fd4d51c15f2" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_8ee7c178-1b05-4bb3-b2bd-15171afa9cd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_09252a61-7da5-40fa-8419-e4da99dd97eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_adc6445c-40c1-42e8-8a15-f803734866a9" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_09252a61-7da5-40fa-8419-e4da99dd97eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_54dcdd16-c397-4f0e-a39f-8bab0e6d1025" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_09252a61-7da5-40fa-8419-e4da99dd97eb" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_54dcdd16-c397-4f0e-a39f-8bab0e6d1025" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments_f3eb4ca6-6ba5-4ab9-a5be-d6818c16f78e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_09252a61-7da5-40fa-8419-e4da99dd97eb" xlink:to="loc_us-gaap_FinanceLeasePrincipalPayments_f3eb4ca6-6ba5-4ab9-a5be-d6818c16f78e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromHedgeFinancingActivities_612e6b72-01c5-443f-8e5c-992cfe3f5afa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromHedgeFinancingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_09252a61-7da5-40fa-8419-e4da99dd97eb" xlink:to="loc_us-gaap_ProceedsFromHedgeFinancingActivities_612e6b72-01c5-443f-8e5c-992cfe3f5afa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForHedgeFinancingActivities_08fae7b9-712f-492f-8760-17b67f9fea8a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForHedgeFinancingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_09252a61-7da5-40fa-8419-e4da99dd97eb" xlink:to="loc_us-gaap_PaymentsForHedgeFinancingActivities_08fae7b9-712f-492f-8760-17b67f9fea8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_cf637c94-7aba-4e99-b4cf-3666226a744b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_09252a61-7da5-40fa-8419-e4da99dd97eb" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_cf637c94-7aba-4e99-b4cf-3666226a744b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_32328b8d-e2b4-4083-94be-2bcb16c0de3c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_09252a61-7da5-40fa-8419-e4da99dd97eb" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_32328b8d-e2b4-4083-94be-2bcb16c0de3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_bf049635-c061-4f74-9041-00b54426ab73" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_09252a61-7da5-40fa-8419-e4da99dd97eb" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_bf049635-c061-4f74-9041-00b54426ab73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfWarrants_8747ae61-8a2b-45f2-82b1-add1584efa5f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRepurchaseOfWarrants"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_09252a61-7da5-40fa-8419-e4da99dd97eb" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfWarrants_8747ae61-8a2b-45f2-82b1-add1584efa5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PaymentsToContingentValueRightHoldersFinancingActivity_10ddc4cf-b924-497d-b81a-e866057d9109" xlink:href="lgnd-20211231.xsd#lgnd_PaymentsToContingentValueRightHoldersFinancingActivity"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_09252a61-7da5-40fa-8419-e4da99dd97eb" xlink:to="loc_lgnd_PaymentsToContingentValueRightHoldersFinancingActivity_10ddc4cf-b924-497d-b81a-e866057d9109" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d18cd53d-769f-4933-b7fc-48edb5d21c7c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_09252a61-7da5-40fa-8419-e4da99dd97eb" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d18cd53d-769f-4933-b7fc-48edb5d21c7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_f1a45c6d-e3ec-45b3-8d67-c67b8736c91e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_adc6445c-40c1-42e8-8a15-f803734866a9" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_f1a45c6d-e3ec-45b3-8d67-c67b8736c91e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6a8b4f27-c0e5-47b3-8c9b-caca51525972" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_adc6445c-40c1-42e8-8a15-f803734866a9" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6a8b4f27-c0e5-47b3-8c9b-caca51525972" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_985f106c-fec1-485d-b966-85b131e3ec8a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_adc6445c-40c1-42e8-8a15-f803734866a9" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_985f106c-fec1-485d-b966-85b131e3ec8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_ac9b4ab5-d413-460b-a8aa-294e8b09a9eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_adc6445c-40c1-42e8-8a15-f803734866a9" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_ac9b4ab5-d413-460b-a8aa-294e8b09a9eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_3d988e52-28cd-4706-a0f0-c4f6f12e077a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_adc6445c-40c1-42e8-8a15-f803734866a9" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_3d988e52-28cd-4706-a0f0-c4f6f12e077a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_CashPaidDuringTheYearAbstract_e6ee01fa-515d-4035-a4cc-dce0cebddd4b" xlink:href="lgnd-20211231.xsd#lgnd_CashPaidDuringTheYearAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_3d988e52-28cd-4706-a0f0-c4f6f12e077a" xlink:to="loc_lgnd_CashPaidDuringTheYearAbstract_e6ee01fa-515d-4035-a4cc-dce0cebddd4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_69a69608-ace6-4a35-8d09-0cf000a8590c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPaidNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_CashPaidDuringTheYearAbstract_e6ee01fa-515d-4035-a4cc-dce0cebddd4b" xlink:to="loc_us-gaap_InterestPaidNet_69a69608-ace6-4a35-8d09-0cf000a8590c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaid_ae8d046e-323c-4611-bdc9-de1a250ff526" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxesPaid"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_CashPaidDuringTheYearAbstract_e6ee01fa-515d-4035-a4cc-dce0cebddd4b" xlink:to="loc_us-gaap_IncomeTaxesPaid_ae8d046e-323c-4611-bdc9-de1a250ff526" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent_66b32c99-db29-4eef-974c-131d0083e497" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_CashPaidDuringTheYearAbstract_e6ee01fa-515d-4035-a4cc-dce0cebddd4b" xlink:to="loc_us-gaap_RestrictedCashCurrent_66b32c99-db29-4eef-974c-131d0083e497" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_421dbd96-03d0-40db-a9bf-c625f58cadaf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_adc6445c-40c1-42e8-8a15-f803734866a9" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_421dbd96-03d0-40db-a9bf-c625f58cadaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AccruedInventoryPurchases_0bde36ad-20c2-4cd2-b254-3cc01061b288" xlink:href="lgnd-20211231.xsd#lgnd_AccruedInventoryPurchases"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_421dbd96-03d0-40db-a9bf-c625f58cadaf" xlink:to="loc_lgnd_AccruedInventoryPurchases_0bde36ad-20c2-4cd2-b254-3cc01061b288" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments_a55ddf69-67b9-4939-a571-fb4f8a5873ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_421dbd96-03d0-40db-a9bf-c625f58cadaf" xlink:to="loc_us-gaap_UnrealizedGainLossOnInvestments_a55ddf69-67b9-4939-a571-fb4f8a5873ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_6a40af8b-6131-4fd3-9376-c9648454fa76" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_421dbd96-03d0-40db-a9bf-c625f58cadaf" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_6a40af8b-6131-4fd3-9376-c9648454fa76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="lgnd-20211231.xsd#BasisofPresentationandSummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_6961a1af-1897-427c-ac3d-d396182ff2f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_2233694c-b7d9-44ed-bdb0-200d874914c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_6961a1af-1897-427c-ac3d-d396182ff2f2" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_2233694c-b7d9-44ed-bdb0-200d874914c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="lgnd-20211231.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_88f2a1e7-0599-4bf2-92ed-6996e73461d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_0684f77d-d995-400d-9fcd-90ed33061adb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_88f2a1e7-0599-4bf2-92ed-6996e73461d1" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_0684f77d-d995-400d-9fcd-90ed33061adb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_cf5ddeb2-6b6b-477b-8d86-29a098e37067" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_88f2a1e7-0599-4bf2-92ed-6996e73461d1" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_cf5ddeb2-6b6b-477b-8d86-29a098e37067" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_f7af14b5-5e08-4363-9172-39fa47b71ec4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_88f2a1e7-0599-4bf2-92ed-6996e73461d1" xlink:to="loc_us-gaap_UseOfEstimates_f7af14b5-5e08-4363-9172-39fa47b71ec4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_bf88ce3a-b5ff-4ba7-9c1e-83f55bfcc89c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_88f2a1e7-0599-4bf2-92ed-6996e73461d1" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_bf88ce3a-b5ff-4ba7-9c1e-83f55bfcc89c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_CashCashEquivalentsandShorttermInvestmentsPolicyTextBlock_d331ed39-e1d5-4ab9-bf27-480b0c1be43b" xlink:href="lgnd-20211231.xsd#lgnd_CashCashEquivalentsandShorttermInvestmentsPolicyTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_88f2a1e7-0599-4bf2-92ed-6996e73461d1" xlink:to="loc_lgnd_CashCashEquivalentsandShorttermInvestmentsPolicyTextBlock_d331ed39-e1d5-4ab9-bf27-480b0c1be43b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy_c8f9ba6f-855a-4a57-b95a-20339d3d1d46" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_88f2a1e7-0599-4bf2-92ed-6996e73461d1" xlink:to="loc_us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy_c8f9ba6f-855a-4a57-b95a-20339d3d1d46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryPolicyTextBlock_8089af1f-c525-43ec-bdaf-d9de3ba6eff7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_88f2a1e7-0599-4bf2-92ed-6996e73461d1" xlink:to="loc_us-gaap_InventoryPolicyTextBlock_8089af1f-c525-43ec-bdaf-d9de3ba6eff7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_933790f5-4623-447e-998e-22a9c3f2820a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_88f2a1e7-0599-4bf2-92ed-6996e73461d1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_933790f5-4623-447e-998e-22a9c3f2820a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsPolicy_b7333197-c955-41d6-85b1-f259d7c45cd6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationsPolicy"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_88f2a1e7-0599-4bf2-92ed-6996e73461d1" xlink:to="loc_us-gaap_BusinessCombinationsPolicy_b7333197-c955-41d6-85b1-f259d7c45cd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_fa3b3aa4-35db-4bf2-9a8f-7ea32d77cf36" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_88f2a1e7-0599-4bf2-92ed-6996e73461d1" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_fa3b3aa4-35db-4bf2-9a8f-7ea32d77cf36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_CommercialLicenseRightsPolicyTextBlock_5af233f0-81ee-43ba-a490-c1e6fdfcf8df" xlink:href="lgnd-20211231.xsd#lgnd_CommercialLicenseRightsPolicyTextBlock"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_88f2a1e7-0599-4bf2-92ed-6996e73461d1" xlink:to="loc_lgnd_CommercialLicenseRightsPolicyTextBlock_5af233f0-81ee-43ba-a490-c1e6fdfcf8df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_9feee9a5-3537-4355-b7ca-38349d5cfaad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_88f2a1e7-0599-4bf2-92ed-6996e73461d1" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_9feee9a5-3537-4355-b7ca-38349d5cfaad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_f5a880ad-3450-443c-98c3-95ea31170e42" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_88f2a1e7-0599-4bf2-92ed-6996e73461d1" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_f5a880ad-3450-443c-98c3-95ea31170e42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_5dd5861b-2c3f-4549-be1c-f98ed6b5945e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_88f2a1e7-0599-4bf2-92ed-6996e73461d1" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_5dd5861b-2c3f-4549-be1c-f98ed6b5945e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesPolicyTextBlock_a02f1dec-5793-4a7a-b758-c9e6e498b94e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativesPolicyTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_88f2a1e7-0599-4bf2-92ed-6996e73461d1" xlink:to="loc_us-gaap_DerivativesPolicyTextBlock_a02f1dec-5793-4a7a-b758-c9e6e498b94e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_1d9c45e9-cd2a-427f-9d38-0eca2b35fe58" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_88f2a1e7-0599-4bf2-92ed-6996e73461d1" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_1d9c45e9-cd2a-427f-9d38-0eca2b35fe58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_75f5fb11-f0e3-4f5c-9351-f7a7fbbdce7a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_88f2a1e7-0599-4bf2-92ed-6996e73461d1" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_75f5fb11-f0e3-4f5c-9351-f7a7fbbdce7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_95a125b6-3db8-4370-8233-461c061addde" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_88f2a1e7-0599-4bf2-92ed-6996e73461d1" xlink:to="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_95a125b6-3db8-4370-8233-461c061addde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_609b05be-c423-415f-9583-deefc2eb285d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_88f2a1e7-0599-4bf2-92ed-6996e73461d1" xlink:to="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_609b05be-c423-415f-9583-deefc2eb285d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_4a661855-53dc-41b8-8461-9aaf74685683" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_88f2a1e7-0599-4bf2-92ed-6996e73461d1" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_4a661855-53dc-41b8-8461-9aaf74685683" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="lgnd-20211231.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesTables"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_6a6012fc-df14-45b8-b96e-73f6a6e02d3a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_bb8e8ccb-d418-4d9e-8a1c-a3bd2dfed5ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_6a6012fc-df14-45b8-b96e-73f6a6e02d3a" xlink:to="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_bb8e8ccb-d418-4d9e-8a1c-a3bd2dfed5ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ScheduleofCommercialLicenseRightsTableTextBlock_d3f1de71-9dba-4502-b542-136ef349e7ed" xlink:href="lgnd-20211231.xsd#lgnd_ScheduleofCommercialLicenseRightsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_6a6012fc-df14-45b8-b96e-73f6a6e02d3a" xlink:to="loc_lgnd_ScheduleofCommercialLicenseRightsTableTextBlock_d3f1de71-9dba-4502-b542-136ef349e7ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_068d2486-61ad-49cf-887d-4f3dc025f94b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_6a6012fc-df14-45b8-b96e-73f6a6e02d3a" xlink:to="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_068d2486-61ad-49cf-887d-4f3dc025f94b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_2a413d0f-fa61-4c8b-bda8-4f19d193faf7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_6a6012fc-df14-45b8-b96e-73f6a6e02d3a" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_2a413d0f-fa61-4c8b-bda8-4f19d193faf7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" xlink:href="lgnd-20211231.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_10859251-e32d-4678-b439-4f0b5110ec1c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BasisOfPresentationTable_445dd6ca-01ad-4024-b237-bc3f1c1722ba" xlink:href="lgnd-20211231.xsd#lgnd_BasisOfPresentationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_10859251-e32d-4678-b439-4f0b5110ec1c" xlink:to="loc_lgnd_BasisOfPresentationTable_445dd6ca-01ad-4024-b237-bc3f1c1722ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_a582a1c9-9f3e-41d5-8078-e98e64a951eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_BasisOfPresentationTable_445dd6ca-01ad-4024-b237-bc3f1c1722ba" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_a582a1c9-9f3e-41d5-8078-e98e64a951eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_19709d80-44b0-4ba8-8341-10f2b4127722" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_a582a1c9-9f3e-41d5-8078-e98e64a951eb" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_19709d80-44b0-4ba8-8341-10f2b4127722" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedDividendRateMember_c55bbd67-736a-4a42-b732-44fe6f1d6680" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputExpectedDividendRateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_19709d80-44b0-4ba8-8341-10f2b4127722" xlink:to="loc_us-gaap_MeasurementInputExpectedDividendRateMember_c55bbd67-736a-4a42-b732-44fe6f1d6680" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_cf4792a9-1856-4344-a7ad-1914ea21558f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_BasisOfPresentationTable_445dd6ca-01ad-4024-b237-bc3f1c1722ba" xlink:to="loc_us-gaap_DebtInstrumentAxis_cf4792a9-1856-4344-a7ad-1914ea21558f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_22c8915c-682f-4fa5-8679-4f2d17f8a363" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_cf4792a9-1856-4344-a7ad-1914ea21558f" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_22c8915c-682f-4fa5-8679-4f2d17f8a363" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ConvertibleSeniorNotesDue2023Member_433777cf-e053-4cdd-8b0f-ed455cade86a" xlink:href="lgnd-20211231.xsd#lgnd_ConvertibleSeniorNotesDue2023Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_22c8915c-682f-4fa5-8679-4f2d17f8a363" xlink:to="loc_lgnd_ConvertibleSeniorNotesDue2023Member_433777cf-e053-4cdd-8b0f-ed455cade86a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ConvertibleSeniorNotesDue2019Member_2ce06856-380e-4632-90de-d93cb5e61598" xlink:href="lgnd-20211231.xsd#lgnd_ConvertibleSeniorNotesDue2019Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_22c8915c-682f-4fa5-8679-4f2d17f8a363" xlink:to="loc_lgnd_ConvertibleSeniorNotesDue2019Member_2ce06856-380e-4632-90de-d93cb5e61598" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_1f56019e-1171-4f15-acef-1d482d90028b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_BasisOfPresentationTable_445dd6ca-01ad-4024-b237-bc3f1c1722ba" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_1f56019e-1171-4f15-acef-1d482d90028b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_133d52b8-a211-408a-94bd-34a249e22f44" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_1f56019e-1171-4f15-acef-1d482d90028b" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_133d52b8-a211-408a-94bd-34a249e22f44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_51afe914-9a69-44f6-9a5c-c9bfd4d451f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeniorNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_133d52b8-a211-408a-94bd-34a249e22f44" xlink:to="loc_us-gaap_SeniorNotesMember_51afe914-9a69-44f6-9a5c-c9bfd4d451f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleNotesPayableMember_5489c2e1-cb3d-45b3-b832-390033abc36f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleNotesPayableMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_133d52b8-a211-408a-94bd-34a249e22f44" xlink:to="loc_us-gaap_ConvertibleNotesPayableMember_5489c2e1-cb3d-45b3-b832-390033abc36f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_e90e3fae-c6db-4fb5-bb69-cc9090b4e19a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_BasisOfPresentationTable_445dd6ca-01ad-4024-b237-bc3f1c1722ba" xlink:to="loc_srt_CounterpartyNameAxis_e90e3fae-c6db-4fb5-bb69-cc9090b4e19a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_552369a4-efa6-47f2-9590-c0c035ea710a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_e90e3fae-c6db-4fb5-bb69-cc9090b4e19a" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_552369a4-efa6-47f2-9590-c0c035ea710a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_NovanMolluscumProductsMember_ce37b981-8c26-4d93-a20d-62943baabfef" xlink:href="lgnd-20211231.xsd#lgnd_NovanMolluscumProductsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_552369a4-efa6-47f2-9590-c0c035ea710a" xlink:to="loc_lgnd_NovanMolluscumProductsMember_ce37b981-8c26-4d93-a20d-62943baabfef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PalvellaTherapeuticsIncMember_462587ce-054f-4023-9c07-c4c387f9b6ab" xlink:href="lgnd-20211231.xsd#lgnd_PalvellaTherapeuticsIncMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_552369a4-efa6-47f2-9590-c0c035ea710a" xlink:to="loc_lgnd_PalvellaTherapeuticsIncMember_462587ce-054f-4023-9c07-c4c387f9b6ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AziyoMember_2e83cc2b-cc94-4ecd-82a0-895a6bf729b0" xlink:href="lgnd-20211231.xsd#lgnd_AziyoMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_552369a4-efa6-47f2-9590-c0c035ea710a" xlink:to="loc_lgnd_AziyoMember_2e83cc2b-cc94-4ecd-82a0-895a6bf729b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_CorMatrixMember_a699f8b8-ed9b-43c7-a2d8-638961d4688e" xlink:href="lgnd-20211231.xsd#lgnd_CorMatrixMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_552369a4-efa6-47f2-9590-c0c035ea710a" xlink:to="loc_lgnd_CorMatrixMember_a699f8b8-ed9b-43c7-a2d8-638961d4688e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_SelexisMember_8924c349-f088-4432-ac39-41811792ea4e" xlink:href="lgnd-20211231.xsd#lgnd_SelexisMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_552369a4-efa6-47f2-9590-c0c035ea710a" xlink:to="loc_lgnd_SelexisMember_8924c349-f088-4432-ac39-41811792ea4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_c48122a4-5c7d-47d2-bca5-bde380c5cfe9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_BasisOfPresentationTable_445dd6ca-01ad-4024-b237-bc3f1c1722ba" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_c48122a4-5c7d-47d2-bca5-bde380c5cfe9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_7f836396-616c-46d6-8daa-762cbc959ff8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_c48122a4-5c7d-47d2-bca5-bde380c5cfe9" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_7f836396-616c-46d6-8daa-762cbc959ff8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyAgreementsMember_82e346bd-6993-491e-bb49-af4184d2ce24" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RoyaltyAgreementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_7f836396-616c-46d6-8daa-762cbc959ff8" xlink:to="loc_us-gaap_RoyaltyAgreementsMember_82e346bd-6993-491e-bb49-af4184d2ce24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember_cf84d76e-67b1-4bd8-af4f-7e617da80947" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_7f836396-616c-46d6-8daa-762cbc959ff8" xlink:to="loc_us-gaap_LicensingAgreementsMember_cf84d76e-67b1-4bd8-af4f-7e617da80947" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_1c828ed9-cef7-4d27-9bb1-cf4d862888bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_BasisOfPresentationTable_445dd6ca-01ad-4024-b237-bc3f1c1722ba" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_1c828ed9-cef7-4d27-9bb1-cf4d862888bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4691cd80-0fd2-49a1-a305-204acee9845f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_1c828ed9-cef7-4d27-9bb1-cf4d862888bf" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4691cd80-0fd2-49a1-a305-204acee9845f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PfenexMember_1e79f4ba-74b0-4ff3-b88c-6537c424e246" xlink:href="lgnd-20211231.xsd#lgnd_PfenexMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4691cd80-0fd2-49a1-a305-204acee9845f" xlink:to="loc_lgnd_PfenexMember_1e79f4ba-74b0-4ff3-b88c-6537c424e246" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_IcagenMember_865a4441-c86f-46f7-bd17-be432c45ece2" xlink:href="lgnd-20211231.xsd#lgnd_IcagenMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4691cd80-0fd2-49a1-a305-204acee9845f" xlink:to="loc_lgnd_IcagenMember_865a4441-c86f-46f7-bd17-be432c45ece2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_MetabasisTherapeuticsMember_d901eb06-6208-4689-82a2-09d8c74f6312" xlink:href="lgnd-20211231.xsd#lgnd_MetabasisTherapeuticsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4691cd80-0fd2-49a1-a305-204acee9845f" xlink:to="loc_lgnd_MetabasisTherapeuticsMember_d901eb06-6208-4689-82a2-09d8c74f6312" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_6217cb25-255f-48eb-9301-8433268fa6db" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_BasisOfPresentationTable_445dd6ca-01ad-4024-b237-bc3f1c1722ba" xlink:to="loc_srt_RangeAxis_6217cb25-255f-48eb-9301-8433268fa6db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_87a330e9-8386-476a-aa98-7737b639071a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_6217cb25-255f-48eb-9301-8433268fa6db" xlink:to="loc_srt_RangeMember_87a330e9-8386-476a-aa98-7737b639071a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_14322eae-716d-4968-bb50-f6843193a50a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_87a330e9-8386-476a-aa98-7737b639071a" xlink:to="loc_srt_MinimumMember_14322eae-716d-4968-bb50-f6843193a50a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_8c765748-1cc9-4175-a3c3-a598db0efbc9" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_87a330e9-8386-476a-aa98-7737b639071a" xlink:to="loc_srt_MaximumMember_8c765748-1cc9-4175-a3c3-a598db0efbc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_4cdca474-e92e-49e1-93ea-d6ba41a6ef8d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_BasisOfPresentationTable_445dd6ca-01ad-4024-b237-bc3f1c1722ba" xlink:to="loc_us-gaap_AwardTypeAxis_4cdca474-e92e-49e1-93ea-d6ba41a6ef8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1e284b0a-90e7-49bd-bb53-620f3cc71b7c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_4cdca474-e92e-49e1-93ea-d6ba41a6ef8d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1e284b0a-90e7-49bd-bb53-620f3cc71b7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_8af34d06-e19a-4aca-8294-be20403a4063" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1e284b0a-90e7-49bd-bb53-620f3cc71b7c" xlink:to="loc_us-gaap_EmployeeStockOptionMember_8af34d06-e19a-4aca-8294-be20403a4063" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_RestrictedStockUnitsAndPerformanceSharesMember_695d6396-a367-481f-893e-4d57f448296c" xlink:href="lgnd-20211231.xsd#lgnd_RestrictedStockUnitsAndPerformanceSharesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1e284b0a-90e7-49bd-bb53-620f3cc71b7c" xlink:to="loc_lgnd_RestrictedStockUnitsAndPerformanceSharesMember_695d6396-a367-481f-893e-4d57f448296c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_6d355d05-9ee7-4e4d-be21-816c2935999c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PerformanceSharesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_RestrictedStockUnitsAndPerformanceSharesMember_695d6396-a367-481f-893e-4d57f448296c" xlink:to="loc_us-gaap_PerformanceSharesMember_6d355d05-9ee7-4e4d-be21-816c2935999c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_05b31ee8-979b-4b5a-aca1-a7d3378081ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingAxis"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_BasisOfPresentationTable_445dd6ca-01ad-4024-b237-bc3f1c1722ba" xlink:to="loc_us-gaap_VestingAxis_05b31ee8-979b-4b5a-aca1-a7d3378081ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_44880f8a-96c8-47ba-8e4b-f0b4ec505965" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingAxis_05b31ee8-979b-4b5a-aca1-a7d3378081ec" xlink:to="loc_us-gaap_VestingDomain_44880f8a-96c8-47ba-8e4b-f0b4ec505965" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_VestingPeriodOneMember_9185233b-0405-47e9-96fc-3e5f204a2a4c" xlink:href="lgnd-20211231.xsd#lgnd_VestingPeriodOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_44880f8a-96c8-47ba-8e4b-f0b4ec505965" xlink:to="loc_lgnd_VestingPeriodOneMember_9185233b-0405-47e9-96fc-3e5f204a2a4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_VestingPeriodTwoMember_1bea8ace-d398-45dc-a833-5617442294d9" xlink:href="lgnd-20211231.xsd#lgnd_VestingPeriodTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_44880f8a-96c8-47ba-8e4b-f0b4ec505965" xlink:to="loc_lgnd_VestingPeriodTwoMember_1bea8ace-d398-45dc-a833-5617442294d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_29bda5ca-3975-4eba-87f6-ff6c0ab3bbf6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_BasisOfPresentationTable_445dd6ca-01ad-4024-b237-bc3f1c1722ba" xlink:to="loc_us-gaap_PlanNameAxis_29bda5ca-3975-4eba-87f6-ff6c0ab3bbf6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_4311cde2-b966-4c41-8fb7-1f6185add88b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_29bda5ca-3975-4eba-87f6-ff6c0ab3bbf6" xlink:to="loc_us-gaap_PlanNameDomain_4311cde2-b966-4c41-8fb7-1f6185add88b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_TwoThousandTwoStockIncentivePlanMember_9f9f102b-6b57-4cfd-b8ab-c5f238be945a" xlink:href="lgnd-20211231.xsd#lgnd_TwoThousandTwoStockIncentivePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_4311cde2-b966-4c41-8fb7-1f6185add88b" xlink:to="loc_lgnd_TwoThousandTwoStockIncentivePlanMember_9f9f102b-6b57-4cfd-b8ab-c5f238be945a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_18c39c10-58dd-4d1b-a905-d9aada4ab72a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_BasisOfPresentationTable_445dd6ca-01ad-4024-b237-bc3f1c1722ba" xlink:to="loc_srt_ProductOrServiceAxis_18c39c10-58dd-4d1b-a905-d9aada4ab72a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_ed10acfe-7d15-4364-8c91-079132be7228" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_18c39c10-58dd-4d1b-a905-d9aada4ab72a" xlink:to="loc_srt_ProductsAndServicesDomain_ed10acfe-7d15-4364-8c91-079132be7228" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ContractRevenueMember_fd7a48d8-1572-4354-9db6-3c2ac62972fe" xlink:href="lgnd-20211231.xsd#lgnd_ContractRevenueMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_ed10acfe-7d15-4364-8c91-079132be7228" xlink:to="loc_lgnd_ContractRevenueMember_fd7a48d8-1572-4354-9db6-3c2ac62972fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_MaterialSalesCaptisolMember_a0d9e7d3-26c7-49c7-b337-beabfe206738" xlink:href="lgnd-20211231.xsd#lgnd_MaterialSalesCaptisolMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_ed10acfe-7d15-4364-8c91-079132be7228" xlink:to="loc_lgnd_MaterialSalesCaptisolMember_a0d9e7d3-26c7-49c7-b337-beabfe206738" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_95a22866-a7f9-4a00-ba0f-9873a97c00a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_BasisOfPresentationTable_445dd6ca-01ad-4024-b237-bc3f1c1722ba" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_95a22866-a7f9-4a00-ba0f-9873a97c00a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_71102116-714d-4bab-8b84-dc447625c31d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_95a22866-a7f9-4a00-ba0f-9873a97c00a9" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_71102116-714d-4bab-8b84-dc447625c31d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockCompensationPlanMember_9bcc383f-6358-4a24-8995-052d0af36e20" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockCompensationPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_71102116-714d-4bab-8b84-dc447625c31d" xlink:to="loc_us-gaap_StockCompensationPlanMember_9bcc383f-6358-4a24-8995-052d0af36e20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_49045f0a-455c-4b45-9a07-d26b872d65dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_BasisOfPresentationTable_445dd6ca-01ad-4024-b237-bc3f1c1722ba" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_49045f0a-455c-4b45-9a07-d26b872d65dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_c1ba069c-ac82-49db-aa75-f1623375f7d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_49045f0a-455c-4b45-9a07-d26b872d65dd" xlink:to="loc_us-gaap_TypeOfAdoptionMember_c1ba069c-ac82-49db-aa75-f1623375f7d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate201613Member_46bc2462-f5d0-45bd-b68e-a54ec41ce7a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingStandardsUpdate201613Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfAdoptionMember_c1ba069c-ac82-49db-aa75-f1623375f7d6" xlink:to="loc_us-gaap_AccountingStandardsUpdate201613Member_46bc2462-f5d0-45bd-b68e-a54ec41ce7a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BasisOfPresentationLineItems_45561629-4d3b-4c98-8ce7-efa616027437" xlink:href="lgnd-20211231.xsd#lgnd_BasisOfPresentationLineItems"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_BasisOfPresentationTable_445dd6ca-01ad-4024-b237-bc3f1c1722ba" xlink:to="loc_lgnd_BasisOfPresentationLineItems_45561629-4d3b-4c98-8ce7-efa616027437" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_99ece381-8465-4091-8180-fbaeeabf3b66" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_BasisOfPresentationLineItems_45561629-4d3b-4c98-8ce7-efa616027437" xlink:to="loc_us-gaap_NumberOfOperatingSegments_99ece381-8465-4091-8180-fbaeeabf3b66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_MaturityPeriodOfHighlyLiquidSecuritiesMaximum_4e9c811d-fc80-46b6-8ce7-9be8fe6eed2b" xlink:href="lgnd-20211231.xsd#lgnd_MaturityPeriodOfHighlyLiquidSecuritiesMaximum"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_BasisOfPresentationLineItems_45561629-4d3b-4c98-8ce7-efa616027437" xlink:to="loc_lgnd_MaturityPeriodOfHighlyLiquidSecuritiesMaximum_4e9c811d-fc80-46b6-8ce7-9be8fe6eed2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWriteDown_3b3dd016-78cd-4fd5-8d4d-4c0e8001f614" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWriteDown"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_BasisOfPresentationLineItems_45561629-4d3b-4c98-8ce7-efa616027437" xlink:to="loc_us-gaap_InventoryWriteDown_3b3dd016-78cd-4fd5-8d4d-4c0e8001f614" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_6dc4eeab-d274-4a22-8703-0a609a91ed75" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_BasisOfPresentationLineItems_45561629-4d3b-4c98-8ce7-efa616027437" xlink:to="loc_us-gaap_InventoryNet_6dc4eeab-d274-4a22-8703-0a609a91ed75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_2f0bcd53-e009-4946-9b6e-15617909855c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_BasisOfPresentationLineItems_45561629-4d3b-4c98-8ce7-efa616027437" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_2f0bcd53-e009-4946-9b6e-15617909855c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BusinessCombinationContingentConsiderationLiabilityAmountPerShare_dc2ef763-7466-47ed-a97d-43e26cd82fc4" xlink:href="lgnd-20211231.xsd#lgnd_BusinessCombinationContingentConsiderationLiabilityAmountPerShare"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_BasisOfPresentationLineItems_45561629-4d3b-4c98-8ce7-efa616027437" xlink:to="loc_lgnd_BusinessCombinationContingentConsiderationLiabilityAmountPerShare_dc2ef763-7466-47ed-a97d-43e26cd82fc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_2b0c96e6-3bc3-42a3-85a2-ae4524eb4961" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_BasisOfPresentationLineItems_45561629-4d3b-4c98-8ce7-efa616027437" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_2b0c96e6-3bc3-42a3-85a2-ae4524eb4961" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_NumberOfContingentValueRightsIssued_e9461207-afd5-4160-b8be-9790e46f2771" xlink:href="lgnd-20211231.xsd#lgnd_NumberOfContingentValueRightsIssued"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_BasisOfPresentationLineItems_45561629-4d3b-4c98-8ce7-efa616027437" xlink:to="loc_lgnd_NumberOfContingentValueRightsIssued_e9461207-afd5-4160-b8be-9790e46f2771" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_LicenseUpfrontPayment_12a8499b-6c1b-467d-ba0c-f21ebfc97cc3" xlink:href="lgnd-20211231.xsd#lgnd_LicenseUpfrontPayment"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_BasisOfPresentationLineItems_45561629-4d3b-4c98-8ce7-efa616027437" xlink:to="loc_lgnd_LicenseUpfrontPayment_12a8499b-6c1b-467d-ba0c-f21ebfc97cc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AdditionalRoyaltiesReceivableUnderSalesbasedMilestones_ff29f341-3eb4-454a-ba54-66136ea830b3" xlink:href="lgnd-20211231.xsd#lgnd_AdditionalRoyaltiesReceivableUnderSalesbasedMilestones"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_BasisOfPresentationLineItems_45561629-4d3b-4c98-8ce7-efa616027437" xlink:to="loc_lgnd_AdditionalRoyaltiesReceivableUnderSalesbasedMilestones_ff29f341-3eb4-454a-ba54-66136ea830b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ProductRoyaltyPercentage_fbb4ef7d-ef16-4472-96e7-0fc8f580ca15" xlink:href="lgnd-20211231.xsd#lgnd_ProductRoyaltyPercentage"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_BasisOfPresentationLineItems_45561629-4d3b-4c98-8ce7-efa616027437" xlink:to="loc_lgnd_ProductRoyaltyPercentage_fbb4ef7d-ef16-4472-96e7-0fc8f580ca15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_c3dcd443-6b97-44a3-ad49-f3a15a836272" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_BasisOfPresentationLineItems_45561629-4d3b-4c98-8ce7-efa616027437" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_c3dcd443-6b97-44a3-ad49-f3a15a836272" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_837af47b-2302-495f-80d3-78a6a5cb70fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_BasisOfPresentationLineItems_45561629-4d3b-4c98-8ce7-efa616027437" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_837af47b-2302-495f-80d3-78a6a5cb70fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromRoyaltiesReceived_821f1d21-f302-462c-801d-bd2c6db1658d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromRoyaltiesReceived"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_BasisOfPresentationLineItems_45561629-4d3b-4c98-8ce7-efa616027437" xlink:to="loc_us-gaap_ProceedsFromRoyaltiesReceived_821f1d21-f302-462c-801d-bd2c6db1658d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_RoyaltyAgreementExpirationPeriod_7b2f801e-b00a-41f5-87e8-eaa9a4e7c14a" xlink:href="lgnd-20211231.xsd#lgnd_RoyaltyAgreementExpirationPeriod"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_BasisOfPresentationLineItems_45561629-4d3b-4c98-8ce7-efa616027437" xlink:to="loc_lgnd_RoyaltyAgreementExpirationPeriod_7b2f801e-b00a-41f5-87e8-eaa9a4e7c14a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ForecastedCashFlowsEffectiveInterestRatePercent_36da0e60-2e29-436c-bf54-2cdd225d6631" xlink:href="lgnd-20211231.xsd#lgnd_ForecastedCashFlowsEffectiveInterestRatePercent"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_BasisOfPresentationLineItems_45561629-4d3b-4c98-8ce7-efa616027437" xlink:to="loc_lgnd_ForecastedCashFlowsEffectiveInterestRatePercent_36da0e60-2e29-436c-bf54-2cdd225d6631" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_FiniteLivedIntangibleAssetsCreditLossAdjustments_2f97a989-cd2d-4610-ac09-8f8fe41e1a40" xlink:href="lgnd-20211231.xsd#lgnd_FiniteLivedIntangibleAssetsCreditLossAdjustments"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_BasisOfPresentationLineItems_45561629-4d3b-4c98-8ce7-efa616027437" xlink:to="loc_lgnd_FiniteLivedIntangibleAssetsCreditLossAdjustments_2f97a989-cd2d-4610-ac09-8f8fe41e1a40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AccountsReceivableCreditLossExpenseReversalCOVID19_60f7b51d-9b9a-4895-bc4b-8117db918cdf" xlink:href="lgnd-20211231.xsd#lgnd_AccountsReceivableCreditLossExpenseReversalCOVID19"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_BasisOfPresentationLineItems_45561629-4d3b-4c98-8ce7-efa616027437" xlink:to="loc_lgnd_AccountsReceivableCreditLossExpenseReversalCOVID19_60f7b51d-9b9a-4895-bc4b-8117db918cdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_9759cc5f-3815-404d-a647-d714431210b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_BasisOfPresentationLineItems_45561629-4d3b-4c98-8ce7-efa616027437" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_9759cc5f-3815-404d-a647-d714431210b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_acf4f770-24df-4a04-9025-60d036878ef8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_BasisOfPresentationLineItems_45561629-4d3b-4c98-8ce7-efa616027437" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_acf4f770-24df-4a04-9025-60d036878ef8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_9c759d76-9dc2-4bc9-9afa-4efa23ae33f4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_BasisOfPresentationLineItems_45561629-4d3b-4c98-8ce7-efa616027437" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_9c759d76-9dc2-4bc9-9afa-4efa23ae33f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiMeasurementInput_baaa3dbe-6fc8-4c00-abd9-c15a72c86193" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNiMeasurementInput"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_BasisOfPresentationLineItems_45561629-4d3b-4c98-8ce7-efa616027437" xlink:to="loc_us-gaap_EquitySecuritiesFvNiMeasurementInput_baaa3dbe-6fc8-4c00-abd9-c15a72c86193" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareDeclared_d12eff52-2219-4971-b71f-428f56bb8833" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockDividendsPerShareDeclared"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_BasisOfPresentationLineItems_45561629-4d3b-4c98-8ce7-efa616027437" xlink:to="loc_us-gaap_CommonStockDividendsPerShareDeclared_d12eff52-2219-4971-b71f-428f56bb8833" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_b73b5694-bea2-4a7e-b0c4-42e11cb803b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_BasisOfPresentationLineItems_45561629-4d3b-4c98-8ce7-efa616027437" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_b73b5694-bea2-4a7e-b0c4-42e11cb803b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_e4d67a36-7bb6-4e9b-9a19-b2b97bf35588" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_BasisOfPresentationLineItems_45561629-4d3b-4c98-8ce7-efa616027437" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_e4d67a36-7bb6-4e9b-9a19-b2b97bf35588" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_ffb43a75-941b-4602-a20d-9ee188e927b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_BasisOfPresentationLineItems_45561629-4d3b-4c98-8ce7-efa616027437" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_ffb43a75-941b-4602-a20d-9ee188e927b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets_dcdfeaaf-3476-4262-afa1-6058bfdc3e16" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeAssets"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_BasisOfPresentationLineItems_45561629-4d3b-4c98-8ce7-efa616027437" xlink:to="loc_us-gaap_DerivativeAssets_dcdfeaaf-3476-4262-afa1-6058bfdc3e16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_234513bf-3429-4767-afd2-62f497e396ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilities"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_BasisOfPresentationLineItems_45561629-4d3b-4c98-8ce7-efa616027437" xlink:to="loc_us-gaap_DerivativeLiabilities_234513bf-3429-4767-afd2-62f497e396ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c4f6da74-c651-4e46-97a6-432aa78ffb3f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_BasisOfPresentationLineItems_45561629-4d3b-4c98-8ce7-efa616027437" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c4f6da74-c651-4e46-97a6-432aa78ffb3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRevenuefromSignificantPartnersDetails" xlink:type="simple" xlink:href="lgnd-20211231.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesRevenuefromSignificantPartnersDetails"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRevenuefromSignificantPartnersDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_dbe3683d-75aa-4050-a99f-2bbfcf25fd7a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_146bb70f-b313-4c35-a47a-c71078a05bad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_dbe3683d-75aa-4050-a99f-2bbfcf25fd7a" xlink:to="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_146bb70f-b313-4c35-a47a-c71078a05bad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_58b78baf-9aa0-4d47-ab8e-b3752d686f26" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_146bb70f-b313-4c35-a47a-c71078a05bad" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_58b78baf-9aa0-4d47-ab8e-b3752d686f26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_cd4d71a9-704c-49fa-8c09-73c5f3d3ae40" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_58b78baf-9aa0-4d47-ab8e-b3752d686f26" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_cd4d71a9-704c-49fa-8c09-73c5f3d3ae40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_7ade5dfb-e10d-416f-8618-96f05cde8de2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_cd4d71a9-704c-49fa-8c09-73c5f3d3ae40" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_7ade5dfb-e10d-416f-8618-96f05cde8de2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_a485bd9d-97d0-40e5-b4ca-f0d1c5d66e55" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_146bb70f-b313-4c35-a47a-c71078a05bad" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_a485bd9d-97d0-40e5-b4ca-f0d1c5d66e55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_a3dd914d-f2de-4b19-865d-a373bf7c00ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_a485bd9d-97d0-40e5-b4ca-f0d1c5d66e55" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_a3dd914d-f2de-4b19-865d-a373bf7c00ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember_00cb6fd9-d5f5-48d4-aef5-af9c48d52bfe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_a3dd914d-f2de-4b19-865d-a373bf7c00ed" xlink:to="loc_us-gaap_SalesRevenueNetMember_00cb6fd9-d5f5-48d4-aef5-af9c48d52bfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_30695815-a4c7-4ffe-961d-055e052ea55d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_146bb70f-b313-4c35-a47a-c71078a05bad" xlink:to="loc_srt_MajorCustomersAxis_30695815-a4c7-4ffe-961d-055e052ea55d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_fe75c67c-f42b-4db5-98c2-516912fee410" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_30695815-a4c7-4ffe-961d-055e052ea55d" xlink:to="loc_srt_NameOfMajorCustomerDomain_fe75c67c-f42b-4db5-98c2-516912fee410" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PartnerAMember_6de5f8ef-dbeb-4967-b63b-2a3508dcc4cd" xlink:href="lgnd-20211231.xsd#lgnd_PartnerAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_fe75c67c-f42b-4db5-98c2-516912fee410" xlink:to="loc_lgnd_PartnerAMember_6de5f8ef-dbeb-4967-b63b-2a3508dcc4cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PartnerBMember_52fcec19-2395-4e4c-a4ae-ea7855b41880" xlink:href="lgnd-20211231.xsd#lgnd_PartnerBMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_fe75c67c-f42b-4db5-98c2-516912fee410" xlink:to="loc_lgnd_PartnerBMember_52fcec19-2395-4e4c-a4ae-ea7855b41880" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PartnerCMember_c7710676-10ec-4ff9-980c-4231715d448f" xlink:href="lgnd-20211231.xsd#lgnd_PartnerCMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_fe75c67c-f42b-4db5-98c2-516912fee410" xlink:to="loc_lgnd_PartnerCMember_c7710676-10ec-4ff9-980c-4231715d448f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_bb83286f-93b3-4938-8cad-8a32d0a69f2e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EntityWideRevenueMajorCustomerLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_146bb70f-b313-4c35-a47a-c71078a05bad" xlink:to="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_bb83286f-93b3-4938-8cad-8a32d0a69f2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_47e2fdbd-2c8d-40e7-a852-9dcbf9882cff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_bb83286f-93b3-4938-8cad-8a32d0a69f2e" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_47e2fdbd-2c8d-40e7-a852-9dcbf9882cff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCommercialLicenseRightsDetails" xlink:type="simple" xlink:href="lgnd-20211231.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesCommercialLicenseRightsDetails"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCommercialLicenseRightsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_7f4e5f78-8777-46b0-bba1-bd9fd66cc1bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_73637e86-8ddb-423b-b294-08c754fa63e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_7f4e5f78-8777-46b0-bba1-bd9fd66cc1bd" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_73637e86-8ddb-423b-b294-08c754fa63e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_2ad8977d-68e7-4042-8ae1-bd6986fbbde6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_73637e86-8ddb-423b-b294-08c754fa63e0" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_2ad8977d-68e7-4042-8ae1-bd6986fbbde6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_dffbbc08-44f6-4cd2-bf26-57a25534c4a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_2ad8977d-68e7-4042-8ae1-bd6986fbbde6" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_dffbbc08-44f6-4cd2-bf26-57a25534c4a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember_29b262de-ef1e-4327-a5ef-a9c7f8aa1999" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_dffbbc08-44f6-4cd2-bf26-57a25534c4a3" xlink:to="loc_us-gaap_LicensingAgreementsMember_29b262de-ef1e-4327-a5ef-a9c7f8aa1999" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_29a115f8-8f51-4e40-82bb-312e7cfa6ebe" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_73637e86-8ddb-423b-b294-08c754fa63e0" xlink:to="loc_srt_CounterpartyNameAxis_29a115f8-8f51-4e40-82bb-312e7cfa6ebe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_dc607d86-b008-4f46-b153-dedeced2d0ea" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_29a115f8-8f51-4e40-82bb-312e7cfa6ebe" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_dc607d86-b008-4f46-b153-dedeced2d0ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AziyoandCorMatrixMember_2da57140-a99a-43d9-9ae1-b0536ce32907" xlink:href="lgnd-20211231.xsd#lgnd_AziyoandCorMatrixMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_dc607d86-b008-4f46-b153-dedeced2d0ea" xlink:to="loc_lgnd_AziyoandCorMatrixMember_2da57140-a99a-43d9-9ae1-b0536ce32907" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_SelexisAndDianomiMember_2d61a699-ec3f-474f-9ce4-547b6ec23eae" xlink:href="lgnd-20211231.xsd#lgnd_SelexisAndDianomiMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_dc607d86-b008-4f46-b153-dedeced2d0ea" xlink:to="loc_lgnd_SelexisAndDianomiMember_2d61a699-ec3f-474f-9ce4-547b6ec23eae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_10942df7-2e8f-4a14-b70f-f66b21e02642" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_73637e86-8ddb-423b-b294-08c754fa63e0" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_10942df7-2e8f-4a14-b70f-f66b21e02642" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_571703e1-bde0-4ec0-a602-9beeabe558b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_10942df7-2e8f-4a14-b70f-f66b21e02642" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_571703e1-bde0-4ec0-a602-9beeabe558b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_FiniteLivedIntangibleAssetsAccumulatedAmortizationResearchDevelopmentExpenseAndCreditLossAdjustments_fe29475f-70bd-465e-ac6d-046af66f5631" xlink:href="lgnd-20211231.xsd#lgnd_FiniteLivedIntangibleAssetsAccumulatedAmortizationResearchDevelopmentExpenseAndCreditLossAdjustments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_10942df7-2e8f-4a14-b70f-f66b21e02642" xlink:to="loc_lgnd_FiniteLivedIntangibleAssetsAccumulatedAmortizationResearchDevelopmentExpenseAndCreditLossAdjustments_fe29475f-70bd-465e-ac6d-046af66f5631" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_1f74b667-e842-408d-a243-15369d8e22fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_10942df7-2e8f-4a14-b70f-f66b21e02642" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_1f74b667-e842-408d-a243-15369d8e22fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_f677aa3a-87cf-4244-a7d9-ea3127e0d739" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_10942df7-2e8f-4a14-b70f-f66b21e02642" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_f677aa3a-87cf-4244-a7d9-ea3127e0d739" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_FiniteLivedIntangibleAssetsCreditLossAdjustments_d183fbb7-7cf2-4d25-b367-79f6414a4d3c" xlink:href="lgnd-20211231.xsd#lgnd_FiniteLivedIntangibleAssetsCreditLossAdjustments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_10942df7-2e8f-4a14-b70f-f66b21e02642" xlink:to="loc_lgnd_FiniteLivedIntangibleAssetsCreditLossAdjustments_d183fbb7-7cf2-4d25-b367-79f6414a4d3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRoyaltyRevenueDetails" xlink:type="simple" xlink:href="lgnd-20211231.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesRoyaltyRevenueDetails"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRoyaltyRevenueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4abe62c8-3b12-4258-a3d5-68c9fdb2bdc5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_6f754a3e-7ecf-449e-bab9-fd95566a9464" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4abe62c8-3b12-4258-a3d5-68c9fdb2bdc5" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_6f754a3e-7ecf-449e-bab9-fd95566a9464" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_73d286c9-40d4-4dfc-96ce-8ddaf457c655" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_6f754a3e-7ecf-449e-bab9-fd95566a9464" xlink:to="loc_srt_ProductOrServiceAxis_73d286c9-40d4-4dfc-96ce-8ddaf457c655" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_55637727-8a43-4dea-922e-02dfff786ed2" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_73d286c9-40d4-4dfc-96ce-8ddaf457c655" xlink:to="loc_srt_ProductsAndServicesDomain_55637727-8a43-4dea-922e-02dfff786ed2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyMember_c5c5b697-8e19-4e13-839c-fc4c48cf2db6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RoyaltyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_55637727-8a43-4dea-922e-02dfff786ed2" xlink:to="loc_us-gaap_RoyaltyMember_c5c5b697-8e19-4e13-839c-fc4c48cf2db6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_RoyaltyKyprolisMember_857a5904-3105-4ad2-9d51-89c851e89f21" xlink:href="lgnd-20211231.xsd#lgnd_RoyaltyKyprolisMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RoyaltyMember_c5c5b697-8e19-4e13-839c-fc4c48cf2db6" xlink:to="loc_lgnd_RoyaltyKyprolisMember_857a5904-3105-4ad2-9d51-89c851e89f21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_RoyaltyEvomelaMember_51b05dc9-5d35-4b88-b266-0f4622136b86" xlink:href="lgnd-20211231.xsd#lgnd_RoyaltyEvomelaMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RoyaltyMember_c5c5b697-8e19-4e13-839c-fc4c48cf2db6" xlink:to="loc_lgnd_RoyaltyEvomelaMember_51b05dc9-5d35-4b88-b266-0f4622136b86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_RoyaltyOtherMember_436b3ab7-213e-4a57-b6cf-ed8f4701852b" xlink:href="lgnd-20211231.xsd#lgnd_RoyaltyOtherMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RoyaltyMember_c5c5b697-8e19-4e13-839c-fc4c48cf2db6" xlink:to="loc_lgnd_RoyaltyOtherMember_436b3ab7-213e-4a57-b6cf-ed8f4701852b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_RoyaltyPromactaMember_da346cd7-6a12-483f-98e3-aceefd0f3048" xlink:href="lgnd-20211231.xsd#lgnd_RoyaltyPromactaMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RoyaltyMember_c5c5b697-8e19-4e13-839c-fc4c48cf2db6" xlink:to="loc_lgnd_RoyaltyPromactaMember_da346cd7-6a12-483f-98e3-aceefd0f3048" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_MaterialSalesCaptisolMember_961e9207-f7a4-4533-af26-dfe4b90111f6" xlink:href="lgnd-20211231.xsd#lgnd_MaterialSalesCaptisolMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_55637727-8a43-4dea-922e-02dfff786ed2" xlink:to="loc_lgnd_MaterialSalesCaptisolMember_961e9207-f7a4-4533-af26-dfe4b90111f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ContractRevenueMember_4f3368a2-3c4f-45c0-ae42-460526ee7941" xlink:href="lgnd-20211231.xsd#lgnd_ContractRevenueMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_55637727-8a43-4dea-922e-02dfff786ed2" xlink:to="loc_lgnd_ContractRevenueMember_4f3368a2-3c4f-45c0-ae42-460526ee7941" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember_0b61ce1a-f41b-4c75-95cd-23011169bf2c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ServiceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_ContractRevenueMember_4f3368a2-3c4f-45c0-ae42-460526ee7941" xlink:to="loc_us-gaap_ServiceMember_0b61ce1a-f41b-4c75-95cd-23011169bf2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_LicenseFeesMember_0b13eaaa-f921-40e0-b799-6ad69763a2a7" xlink:href="lgnd-20211231.xsd#lgnd_LicenseFeesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_ContractRevenueMember_4f3368a2-3c4f-45c0-ae42-460526ee7941" xlink:to="loc_lgnd_LicenseFeesMember_0b13eaaa-f921-40e0-b799-6ad69763a2a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_MilestoneMember_30c34cf4-badf-44a4-90a1-8ba4e50e2ce3" xlink:href="lgnd-20211231.xsd#lgnd_MilestoneMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_ContractRevenueMember_4f3368a2-3c4f-45c0-ae42-460526ee7941" xlink:to="loc_lgnd_MilestoneMember_30c34cf4-badf-44a4-90a1-8ba4e50e2ce3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_LicenseFeesMilestonesAndOtherProductOtherMember_c1ead832-3861-4d4a-9648-aeb950464831" xlink:href="lgnd-20211231.xsd#lgnd_LicenseFeesMilestonesAndOtherProductOtherMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_ContractRevenueMember_4f3368a2-3c4f-45c0-ae42-460526ee7941" xlink:to="loc_lgnd_LicenseFeesMilestonesAndOtherProductOtherMember_c1ead832-3861-4d4a-9648-aeb950464831" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_61876364-d732-4dd3-b412-d51f8c1b271f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_6f754a3e-7ecf-449e-bab9-fd95566a9464" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_61876364-d732-4dd3-b412-d51f8c1b271f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_09593bb9-eff6-4663-9bdf-8d82e5f21159" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_61876364-d732-4dd3-b412-d51f8c1b271f" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_09593bb9-eff6-4663-9bdf-8d82e5f21159" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCalculationofEarningsperShareDetails" xlink:type="simple" xlink:href="lgnd-20211231.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesCalculationofEarningsperShareDetails"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCalculationofEarningsperShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_de1baf4b-b0d4-403e-8663-e0d6cf8041b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable_24515808-d5b7-42c3-8a79-41b139e3283b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_de1baf4b-b0d4-403e-8663-e0d6cf8041b5" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable_24515808-d5b7-42c3-8a79-41b139e3283b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_75946995-c655-481e-b269-145e0d6ecddb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable_24515808-d5b7-42c3-8a79-41b139e3283b" xlink:to="loc_us-gaap_AwardTypeAxis_75946995-c655-481e-b269-145e0d6ecddb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_15e33ac1-43c4-4998-a987-ed75d5914680" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_75946995-c655-481e-b269-145e0d6ecddb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_15e33ac1-43c4-4998-a987-ed75d5914680" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_073620d1-0c29-4406-ab39-7d49842e35e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_15e33ac1-43c4-4998-a987-ed75d5914680" xlink:to="loc_us-gaap_RestrictedStockMember_073620d1-0c29-4406-ab39-7d49842e35e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_53f43f93-a1ea-4c72-8d4b-353b50662df1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_15e33ac1-43c4-4998-a987-ed75d5914680" xlink:to="loc_us-gaap_EmployeeStockOptionMember_53f43f93-a1ea-4c72-8d4b-353b50662df1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDilutedLineItems_76834600-660e-4466-9e19-655c2228bc66" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDilutedLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable_24515808-d5b7-42c3-8a79-41b139e3283b" xlink:to="loc_us-gaap_EarningsPerShareDilutedLineItems_76834600-660e-4466-9e19-655c2228bc66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_cade78f4-05b1-480f-ad26-7b748f97898c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedLineItems_76834600-660e-4466-9e19-655c2228bc66" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_cade78f4-05b1-480f-ad26-7b748f97898c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_b78fd97d-3093-4185-9853-9cb641007cbd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedLineItems_76834600-660e-4466-9e19-655c2228bc66" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_b78fd97d-3093-4185-9853-9cb641007cbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_f9d75a86-da5e-491a-bfbf-f1d02043e911" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedLineItems_76834600-660e-4466-9e19-655c2228bc66" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_f9d75a86-da5e-491a-bfbf-f1d02043e911" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_12ae774b-58fe-47d3-aaf6-8313640118a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedLineItems_76834600-660e-4466-9e19-655c2228bc66" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_12ae774b-58fe-47d3-aaf6-8313640118a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/SaleofVernalisRDandPromactaLicense" xlink:type="simple" xlink:href="lgnd-20211231.xsd#SaleofVernalisRDandPromactaLicense"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/SaleofVernalisRDandPromactaLicense" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_d3e5914c-ae78-4517-972e-ec14ffe0d750" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_bc6123c3-b95c-4c84-99dd-39f04cf51c70" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_d3e5914c-ae78-4517-972e-ec14ffe0d750" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_bc6123c3-b95c-4c84-99dd-39f04cf51c70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/SaleofVernalisRDandPromactaLicenseNarrativeDetails" xlink:type="simple" xlink:href="lgnd-20211231.xsd#SaleofVernalisRDandPromactaLicenseNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/SaleofVernalisRDandPromactaLicenseNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_7459ac63-b2bb-4743-b8a3-0576d30c4a88" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_98859f47-c6c4-439e-9b18-08511a4218ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_7459ac63-b2bb-4743-b8a3-0576d30c4a88" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_98859f47-c6c4-439e-9b18-08511a4218ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_76445c02-a064-463b-bdc8-eceda9fe778a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_98859f47-c6c4-439e-9b18-08511a4218ce" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_76445c02-a064-463b-bdc8-eceda9fe778a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_cce12e06-aecb-46ad-b642-eb303a0272c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_76445c02-a064-463b-bdc8-eceda9fe778a" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_cce12e06-aecb-46ad-b642-eb303a0272c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_VernalisMember_a342cf93-270a-45a5-884a-5b76611dd994" xlink:href="lgnd-20211231.xsd#lgnd_VernalisMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_cce12e06-aecb-46ad-b642-eb303a0272c6" xlink:to="loc_lgnd_VernalisMember_a342cf93-270a-45a5-884a-5b76611dd994" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PromactaMember_0d647945-b2e9-42c2-837d-54270be10584" xlink:href="lgnd-20211231.xsd#lgnd_PromactaMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_cce12e06-aecb-46ad-b642-eb303a0272c6" xlink:to="loc_lgnd_PromactaMember_0d647945-b2e9-42c2-837d-54270be10584" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_568a4653-ed6e-4637-883f-a0ebd2ad3828" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_98859f47-c6c4-439e-9b18-08511a4218ce" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_568a4653-ed6e-4637-883f-a0ebd2ad3828" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_b8075a56-4fff-484b-ba4d-d4a94dfde624" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_568a4653-ed6e-4637-883f-a0ebd2ad3828" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_b8075a56-4fff-484b-ba4d-d4a94dfde624" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_b974dad4-e6ad-4f88-a9f9-c23b91f9a2c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_b8075a56-4fff-484b-ba4d-d4a94dfde624" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_b974dad4-e6ad-4f88-a9f9-c23b91f9a2c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_61dc526f-d1d8-42db-81f4-a666350cec56" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_98859f47-c6c4-439e-9b18-08511a4218ce" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_61dc526f-d1d8-42db-81f4-a666350cec56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_57831bc4-8a30-44dc-bbcb-be605d5d15a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_61dc526f-d1d8-42db-81f4-a666350cec56" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_57831bc4-8a30-44dc-bbcb-be605d5d15a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember_e7731b9e-6dc1-49b1-a21d-d2a3b809d03f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_57831bc4-8a30-44dc-bbcb-be605d5d15a4" xlink:to="loc_us-gaap_DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember_e7731b9e-6dc1-49b1-a21d-d2a3b809d03f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_9f1756bf-9e97-4c43-9e55-7cfbaa53d63d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_98859f47-c6c4-439e-9b18-08511a4218ce" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_9f1756bf-9e97-4c43-9e55-7cfbaa53d63d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_2020ec1f-5747-4c44-a5c6-e34d554fd167" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromDivestitureOfBusinesses"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_9f1756bf-9e97-4c43-9e55-7cfbaa53d63d" xlink:to="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_2020ec1f-5747-4c44-a5c6-e34d554fd167" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_085ef362-ebe9-49d1-8e78-efee7ee16595" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_9f1756bf-9e97-4c43-9e55-7cfbaa53d63d" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_085ef362-ebe9-49d1-8e78-efee7ee16595" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit_74ebf4f8-dfe1-4d69-8ee1-d668b1e34601" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_9f1756bf-9e97-4c43-9e55-7cfbaa53d63d" xlink:to="loc_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit_74ebf4f8-dfe1-4d69-8ee1-d668b1e34601" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfIntangibleAssets_f08858c7-23ef-4c21-945e-e66d9389992d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnDispositionOfIntangibleAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_9f1756bf-9e97-4c43-9e55-7cfbaa53d63d" xlink:to="loc_us-gaap_GainLossOnDispositionOfIntangibleAssets_f08858c7-23ef-4c21-945e-e66d9389992d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_d89c338c-6764-4734-a1d7-12b9b3512b0a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_9f1756bf-9e97-4c43-9e55-7cfbaa53d63d" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_d89c338c-6764-4734-a1d7-12b9b3512b0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/ShorttermInvestmentsInvestmentinViking" xlink:type="simple" xlink:href="lgnd-20211231.xsd#ShorttermInvestmentsInvestmentinViking"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/ShorttermInvestmentsInvestmentinViking" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5aee0a7d-e499-4022-8d2b-284c41cd6f91" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityDisclosureTextBlock_11c2dfeb-7da1-4d4b-8167-6041efbc9466" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableInterestEntityDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5aee0a7d-e499-4022-8d2b-284c41cd6f91" xlink:to="loc_us-gaap_VariableInterestEntityDisclosureTextBlock_11c2dfeb-7da1-4d4b-8167-6041efbc9466" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/ShorttermInvestmentsInvestmentinVikingNarrativeDetails" xlink:type="simple" xlink:href="lgnd-20211231.xsd#ShorttermInvestmentsInvestmentinVikingNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/ShorttermInvestmentsInvestmentinVikingNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_2a1ed085-e7b3-4333-a13c-2c53893a33e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_e5e10251-892c-446e-a677-7f04b53ac543" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_2a1ed085-e7b3-4333-a13c-2c53893a33e8" xlink:to="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_e5e10251-892c-446e-a677-7f04b53ac543" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_b1329fa1-4db3-40a7-9c33-5541c6204cd4" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_e5e10251-892c-446e-a677-7f04b53ac543" xlink:to="loc_srt_OwnershipAxis_b1329fa1-4db3-40a7-9c33-5541c6204cd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_9c621c7e-93c9-4249-ad8f-370aae9b0083" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipAxis_b1329fa1-4db3-40a7-9c33-5541c6204cd4" xlink:to="loc_srt_OwnershipDomain_9c621c7e-93c9-4249-ad8f-370aae9b0083" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_VikingTherapeuticsInc.Member_583679cf-99df-4bf5-873c-a43902c990f7" xlink:href="lgnd-20211231.xsd#lgnd_VikingTherapeuticsInc.Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipDomain_9c621c7e-93c9-4249-ad8f-370aae9b0083" xlink:to="loc_lgnd_VikingTherapeuticsInc.Member_583679cf-99df-4bf5-873c-a43902c990f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_9678f2c5-3769-421c-b6bf-49e4404f5a45" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_e5e10251-892c-446e-a677-7f04b53ac543" xlink:to="loc_us-gaap_FinancialInstrumentAxis_9678f2c5-3769-421c-b6bf-49e4404f5a45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4c08c35f-5cb8-458f-ba60-1b37b720999a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_9678f2c5-3769-421c-b6bf-49e4404f5a45" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4c08c35f-5cb8-458f-ba60-1b37b720999a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_8ac3f846-35e4-4010-b603-8ceb6978f123" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4c08c35f-5cb8-458f-ba60-1b37b720999a" xlink:to="loc_us-gaap_WarrantMember_8ac3f846-35e4-4010-b603-8ceb6978f123" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityLineItems_c19b0140-dab6-4d7f-84a0-886cc9cf7d07" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableInterestEntityLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_e5e10251-892c-446e-a677-7f04b53ac543" xlink:to="loc_us-gaap_VariableInterestEntityLineItems_c19b0140-dab6-4d7f-84a0-886cc9cf7d07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LimitedLiabilityCompanyLLCOrLimitedPartnershipLPMembersOrLimitedPartnersOwnershipInterest_773ae10f-beeb-4d8a-8803-23f7ee2fd7e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LimitedLiabilityCompanyLLCOrLimitedPartnershipLPMembersOrLimitedPartnersOwnershipInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_c19b0140-dab6-4d7f-84a0-886cc9cf7d07" xlink:to="loc_us-gaap_LimitedLiabilityCompanyLLCOrLimitedPartnershipLPMembersOrLimitedPartnersOwnershipInterest_773ae10f-beeb-4d8a-8803-23f7ee2fd7e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstanding_dfdba9e5-1a4e-422c-ba23-367ac768dcf9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_c19b0140-dab6-4d7f-84a0-886cc9cf7d07" xlink:to="loc_us-gaap_WarrantsAndRightsOutstanding_dfdba9e5-1a4e-422c-ba23-367ac768dcf9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_d3811958-2988-43c3-bd3c-0fb88e542030" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_c19b0140-dab6-4d7f-84a0-886cc9cf7d07" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_d3811958-2988-43c3-bd3c-0fb88e542030" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_28ae9d1c-9cff-43a4-b283-72d456cb59fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_c19b0140-dab6-4d7f-84a0-886cc9cf7d07" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_28ae9d1c-9cff-43a4-b283-72d456cb59fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_NumberOfSharesSoldOfEquityMethodInvestee_5915cfa9-187c-4479-addf-38c3e4e88541" xlink:href="lgnd-20211231.xsd#lgnd_NumberOfSharesSoldOfEquityMethodInvestee"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_c19b0140-dab6-4d7f-84a0-886cc9cf7d07" xlink:to="loc_lgnd_NumberOfSharesSoldOfEquityMethodInvestee_5915cfa9-187c-4479-addf-38c3e4e88541" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_InvestmentInVikingCurrent_53118682-c90d-48e0-8b35-645c55aeefd9" xlink:href="lgnd-20211231.xsd#lgnd_InvestmentInVikingCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_c19b0140-dab6-4d7f-84a0-886cc9cf7d07" xlink:to="loc_lgnd_InvestmentInVikingCurrent_53118682-c90d-48e0-8b35-645c55aeefd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/Acquisitions" xlink:type="simple" xlink:href="lgnd-20211231.xsd#Acquisitions"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/Acquisitions" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_f27ce442-c075-42fe-822e-7c7b46f7e583" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock_86966975-6ff5-4dc9-a463-3eecf8850089" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_f27ce442-c075-42fe-822e-7c7b46f7e583" xlink:to="loc_us-gaap_BusinessCombinationDisclosureTextBlock_86966975-6ff5-4dc9-a463-3eecf8850089" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/AcquisitionsTables" xlink:type="simple" xlink:href="lgnd-20211231.xsd#AcquisitionsTables"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/AcquisitionsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_c9d6e1d7-ab1f-47bb-9bc7-3879514980b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_c5250113-688e-41a1-ae9b-b21aebdf585a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_c9d6e1d7-ab1f-47bb-9bc7-3879514980b4" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_c5250113-688e-41a1-ae9b-b21aebdf585a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_9c10c32d-c1a1-4da5-8f49-258dfb02d183" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_c5250113-688e-41a1-ae9b-b21aebdf585a" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_9c10c32d-c1a1-4da5-8f49-258dfb02d183" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9087023e-cea2-4d66-b660-ea30767e88b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_9c10c32d-c1a1-4da5-8f49-258dfb02d183" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9087023e-cea2-4d66-b660-ea30767e88b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PfenexMember_f509be9a-3367-451b-a163-1d35826cc549" xlink:href="lgnd-20211231.xsd#lgnd_PfenexMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9087023e-cea2-4d66-b660-ea30767e88b0" xlink:to="loc_lgnd_PfenexMember_f509be9a-3367-451b-a163-1d35826cc549" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_TaurusBiosciencesLLCMember_ee74915d-1979-4c74-bb53-d5225f70cfe8" xlink:href="lgnd-20211231.xsd#lgnd_TaurusBiosciencesLLCMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9087023e-cea2-4d66-b660-ea30767e88b0" xlink:to="loc_lgnd_TaurusBiosciencesLLCMember_ee74915d-1979-4c74-bb53-d5225f70cfe8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_XCellaBiosciencesIncMember_32faa422-daea-42b9-8df2-1eec6775f22f" xlink:href="lgnd-20211231.xsd#lgnd_XCellaBiosciencesIncMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9087023e-cea2-4d66-b660-ea30767e88b0" xlink:to="loc_lgnd_XCellaBiosciencesIncMember_32faa422-daea-42b9-8df2-1eec6775f22f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_IcagenMember_ad62c5b9-2bba-4577-9fa2-bfb700fe0f68" xlink:href="lgnd-20211231.xsd#lgnd_IcagenMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9087023e-cea2-4d66-b660-ea30767e88b0" xlink:to="loc_lgnd_IcagenMember_ad62c5b9-2bba-4577-9fa2-bfb700fe0f68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AbInitioMember_b4dde99e-7017-49f5-80be-641fe6f89872" xlink:href="lgnd-20211231.xsd#lgnd_AbInitioMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9087023e-cea2-4d66-b660-ea30767e88b0" xlink:to="loc_lgnd_AbInitioMember_b4dde99e-7017-49f5-80be-641fe6f89872" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_bb63b1da-63b1-48e9-ba43-e5a3ff8f5d8b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_c5250113-688e-41a1-ae9b-b21aebdf585a" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_bb63b1da-63b1-48e9-ba43-e5a3ff8f5d8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_49ecfd5e-2f40-40f6-ba40-3f1a32de11cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_bb63b1da-63b1-48e9-ba43-e5a3ff8f5d8b" xlink:to="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_49ecfd5e-2f40-40f6-ba40-3f1a32de11cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock_c093594b-205c-4d06-b764-fcedd527257d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_bb63b1da-63b1-48e9-ba43-e5a3ff8f5d8b" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock_c093594b-205c-4d06-b764-fcedd527257d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionProFormaInformationTextBlock_313ff8b6-273f-4cff-95f0-02da5e741114" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionProFormaInformationTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_bb63b1da-63b1-48e9-ba43-e5a3ff8f5d8b" xlink:to="loc_us-gaap_BusinessAcquisitionProFormaInformationTextBlock_313ff8b6-273f-4cff-95f0-02da5e741114" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/AcquisitionsNarrativeDetails" xlink:type="simple" xlink:href="lgnd-20211231.xsd#AcquisitionsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/AcquisitionsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_f554086f-e6a9-44a5-ad0e-82e7442dd27c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_3dba7021-dacc-4db4-b9d4-e033549dbce6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_f554086f-e6a9-44a5-ad0e-82e7442dd27c" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_3dba7021-dacc-4db4-b9d4-e033549dbce6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_39277b30-6cca-491a-8b24-15ecbf20a42c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_3dba7021-dacc-4db4-b9d4-e033549dbce6" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_39277b30-6cca-491a-8b24-15ecbf20a42c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_51960bd7-3b8c-40e5-aed9-86caa3f450f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_39277b30-6cca-491a-8b24-15ecbf20a42c" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_51960bd7-3b8c-40e5-aed9-86caa3f450f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PfenexMember_eeaf22ed-2c7e-422d-90b8-8fce92b4a592" xlink:href="lgnd-20211231.xsd#lgnd_PfenexMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_51960bd7-3b8c-40e5-aed9-86caa3f450f2" xlink:to="loc_lgnd_PfenexMember_eeaf22ed-2c7e-422d-90b8-8fce92b4a592" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_TaurusBiosciencesLLCMember_be38d77b-2254-4e52-87e0-cd8823dd37f0" xlink:href="lgnd-20211231.xsd#lgnd_TaurusBiosciencesLLCMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_51960bd7-3b8c-40e5-aed9-86caa3f450f2" xlink:to="loc_lgnd_TaurusBiosciencesLLCMember_be38d77b-2254-4e52-87e0-cd8823dd37f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_XCellaBiosciencesIncMember_13294cf4-a87c-4135-b858-f761857d771a" xlink:href="lgnd-20211231.xsd#lgnd_XCellaBiosciencesIncMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_51960bd7-3b8c-40e5-aed9-86caa3f450f2" xlink:to="loc_lgnd_XCellaBiosciencesIncMember_13294cf4-a87c-4135-b858-f761857d771a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_IcagenMember_0f188ef5-d047-40dd-b2ab-daba2caafdfc" xlink:href="lgnd-20211231.xsd#lgnd_IcagenMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_51960bd7-3b8c-40e5-aed9-86caa3f450f2" xlink:to="loc_lgnd_IcagenMember_0f188ef5-d047-40dd-b2ab-daba2caafdfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AbInitioMember_a837f279-3b3a-4333-b084-e4a0d62ec924" xlink:href="lgnd-20211231.xsd#lgnd_AbInitioMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_51960bd7-3b8c-40e5-aed9-86caa3f450f2" xlink:to="loc_lgnd_AbInitioMember_a837f279-3b3a-4333-b084-e4a0d62ec924" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_6021dce9-a119-4b88-8558-333225d48dba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_3dba7021-dacc-4db4-b9d4-e033549dbce6" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_6021dce9-a119-4b88-8558-333225d48dba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_d3fdeb2a-c669-4b53-a642-491d35236e7a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_6021dce9-a119-4b88-8558-333225d48dba" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_d3fdeb2a-c669-4b53-a642-491d35236e7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember_b5718848-c274-430f-823f-69fc3f5a1cca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_d3fdeb2a-c669-4b53-a642-491d35236e7a" xlink:to="loc_us-gaap_CustomerRelationshipsMember_b5718848-c274-430f-823f-69fc3f5a1cca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TechnologyBasedIntangibleAssetsMember_a89d3d8a-5b85-4b32-af49-7bcb3d8ecb8e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TechnologyBasedIntangibleAssetsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_d3fdeb2a-c669-4b53-a642-491d35236e7a" xlink:to="loc_us-gaap_TechnologyBasedIntangibleAssetsMember_a89d3d8a-5b85-4b32-af49-7bcb3d8ecb8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationByTypeAxis_418acbc3-70c4-46c6-bb1b-3a641e4d28bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContingentConsiderationByTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_3dba7021-dacc-4db4-b9d4-e033549dbce6" xlink:to="loc_us-gaap_ContingentConsiderationByTypeAxis_418acbc3-70c4-46c6-bb1b-3a641e4d28bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain_54e5ba0d-1219-418f-9a2b-29a9027c8daf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContingentConsiderationTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis_418acbc3-70c4-46c6-bb1b-3a641e4d28bd" xlink:to="loc_us-gaap_ContingentConsiderationTypeDomain_54e5ba0d-1219-418f-9a2b-29a9027c8daf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ContingentValueRightForInternalResearchAndDevelopmentMember_59bcbf1b-5eb3-4bc3-9306-3960aa5f5205" xlink:href="lgnd-20211231.xsd#lgnd_ContingentValueRightForInternalResearchAndDevelopmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_54e5ba0d-1219-418f-9a2b-29a9027c8daf" xlink:to="loc_lgnd_ContingentValueRightForInternalResearchAndDevelopmentMember_59bcbf1b-5eb3-4bc3-9306-3960aa5f5205" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ContingentValueRightOnProductRevenuesMember_f4595703-ad72-48f7-91e3-995e44af9d08" xlink:href="lgnd-20211231.xsd#lgnd_ContingentValueRightOnProductRevenuesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_54e5ba0d-1219-418f-9a2b-29a9027c8daf" xlink:to="loc_lgnd_ContingentValueRightOnProductRevenuesMember_f4595703-ad72-48f7-91e3-995e44af9d08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_EarnoutRightsForPartnerResearchAndDevelopmentMember_22ebb10e-8704-4168-8223-0fdaa8a77bf3" xlink:href="lgnd-20211231.xsd#lgnd_EarnoutRightsForPartnerResearchAndDevelopmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_54e5ba0d-1219-418f-9a2b-29a9027c8daf" xlink:to="loc_lgnd_EarnoutRightsForPartnerResearchAndDevelopmentMember_22ebb10e-8704-4168-8223-0fdaa8a77bf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_MilestonePaymentsMember_0248c79e-552a-4f67-973b-1f5d8afe17b3" xlink:href="lgnd-20211231.xsd#lgnd_MilestonePaymentsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_54e5ba0d-1219-418f-9a2b-29a9027c8daf" xlink:to="loc_lgnd_MilestonePaymentsMember_0248c79e-552a-4f67-973b-1f5d8afe17b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_97af8335-8952-4444-a507-6533fc0bfa79" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_3dba7021-dacc-4db4-b9d4-e033549dbce6" xlink:to="loc_srt_RangeAxis_97af8335-8952-4444-a507-6533fc0bfa79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_d2b60a6d-1e3a-48ea-a1a0-79714032011e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_97af8335-8952-4444-a507-6533fc0bfa79" xlink:to="loc_srt_RangeMember_d2b60a6d-1e3a-48ea-a1a0-79714032011e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_5327711c-d0a5-4fbc-86f3-7a9c9e9d00be" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_d2b60a6d-1e3a-48ea-a1a0-79714032011e" xlink:to="loc_srt_MinimumMember_5327711c-d0a5-4fbc-86f3-7a9c9e9d00be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_3596a089-df36-47fc-9163-18998485e04d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_d2b60a6d-1e3a-48ea-a1a0-79714032011e" xlink:to="loc_srt_MaximumMember_3596a089-df36-47fc-9163-18998485e04d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_55508a0b-23be-4572-8ce8-a08993e80998" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_3dba7021-dacc-4db4-b9d4-e033549dbce6" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_55508a0b-23be-4572-8ce8-a08993e80998" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_e035656f-1f48-4754-b11b-9679c2050d62" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_55508a0b-23be-4572-8ce8-a08993e80998" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_e035656f-1f48-4754-b11b-9679c2050d62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_70149d3a-517c-47ce-81fd-bbe118d0cd80" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_e035656f-1f48-4754-b11b-9679c2050d62" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_70149d3a-517c-47ce-81fd-bbe118d0cd80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_c5d08779-62cb-4008-b847-0f007c07745c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_3dba7021-dacc-4db4-b9d4-e033549dbce6" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_c5d08779-62cb-4008-b847-0f007c07745c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_NumberOfAcquisitions_51b3cdb2-5d1d-4033-a481-876a6fe5c4a0" xlink:href="lgnd-20211231.xsd#lgnd_NumberOfAcquisitions"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_c5d08779-62cb-4008-b847-0f007c07745c" xlink:to="loc_lgnd_NumberOfAcquisitions_51b3cdb2-5d1d-4033-a481-876a6fe5c4a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfBusinessesAcquired_0d1baf8e-b872-4274-a1f9-fbb6e2b6d05f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfBusinessesAcquired"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_c5d08779-62cb-4008-b847-0f007c07745c" xlink:to="loc_us-gaap_NumberOfBusinessesAcquired_0d1baf8e-b872-4274-a1f9-fbb6e2b6d05f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_NumberOfAssetAcquisitions_447ecdf8-643f-45c3-be00-f00de613cde1" xlink:href="lgnd-20211231.xsd#lgnd_NumberOfAssetAcquisitions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_c5d08779-62cb-4008-b847-0f007c07745c" xlink:to="loc_lgnd_NumberOfAssetAcquisitions_447ecdf8-643f-45c3-be00-f00de613cde1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_e1ee743d-4ead-4515-819b-95034001187d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_c5d08779-62cb-4008-b847-0f007c07745c" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_e1ee743d-4ead-4515-819b-95034001187d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_b5153cf6-0aa0-4933-ad6c-a536505fb35d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_c5d08779-62cb-4008-b847-0f007c07745c" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_b5153cf6-0aa0-4933-ad6c-a536505fb35d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_09783ace-7e4c-4712-8060-7a5ab9d2201e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_c5d08779-62cb-4008-b847-0f007c07745c" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_09783ace-7e4c-4712-8060-7a5ab9d2201e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BusinessCombinationContingentConsiderationLiabilityFairValueDisclosure_d8ebfb95-53a7-4599-a7a0-05d33020ab32" xlink:href="lgnd-20211231.xsd#lgnd_BusinessCombinationContingentConsiderationLiabilityFairValueDisclosure"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_c5d08779-62cb-4008-b847-0f007c07745c" xlink:to="loc_lgnd_BusinessCombinationContingentConsiderationLiabilityFairValueDisclosure_d8ebfb95-53a7-4599-a7a0-05d33020ab32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_092a4482-64f5-47de-be74-dfc7f0cd7986" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_c5d08779-62cb-4008-b847-0f007c07745c" xlink:to="loc_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_092a4482-64f5-47de-be74-dfc7f0cd7986" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_5cb6a0b8-4aa4-4d7c-a5e8-044b8de29bfe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_c5d08779-62cb-4008-b847-0f007c07745c" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_5cb6a0b8-4aa4-4d7c-a5e8-044b8de29bfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_55714393-e87e-458a-802f-3d351b6a99c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_c5d08779-62cb-4008-b847-0f007c07745c" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_55714393-e87e-458a-802f-3d351b6a99c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PaymentsToAcquireBusinessesGrossAttributableToVestedPortionOfStockOptions_c4570378-53f1-4129-a81e-ec3529056ec5" xlink:href="lgnd-20211231.xsd#lgnd_PaymentsToAcquireBusinessesGrossAttributableToVestedPortionOfStockOptions"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_c5d08779-62cb-4008-b847-0f007c07745c" xlink:to="loc_lgnd_PaymentsToAcquireBusinessesGrossAttributableToVestedPortionOfStockOptions_c4570378-53f1-4129-a81e-ec3529056ec5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards_0e8413c0-8217-4a58-ab32-2f2de6f59984" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_c5d08779-62cb-4008-b847-0f007c07745c" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards_0e8413c0-8217-4a58-ab32-2f2de6f59984" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_128e7d5d-1269-4b99-8dc7-8b7ecc1a7a44" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_c5d08779-62cb-4008-b847-0f007c07745c" xlink:to="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_128e7d5d-1269-4b99-8dc7-8b7ecc1a7a44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsDiscountRate_52c7dc41-ff8b-4d78-81c4-26e3029fb395" xlink:href="lgnd-20211231.xsd#lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsDiscountRate"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_c5d08779-62cb-4008-b847-0f007c07745c" xlink:to="loc_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsDiscountRate_52c7dc41-ff8b-4d78-81c4-26e3029fb395" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual_c12d66bd-cef1-4e83-83b1-133e2f0d3fa2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_c5d08779-62cb-4008-b847-0f007c07745c" xlink:to="loc_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual_c12d66bd-cef1-4e83-83b1-133e2f0d3fa2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual_8c618373-2845-41f9-a30f-d08e14fbc163" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_c5d08779-62cb-4008-b847-0f007c07745c" xlink:to="loc_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual_8c618373-2845-41f9-a30f-d08e14fbc163" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationIntegrationRelatedCosts_30cdd8e8-9bb7-4a39-94da-d6ef575d71e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationIntegrationRelatedCosts"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_c5d08779-62cb-4008-b847-0f007c07745c" xlink:to="loc_us-gaap_BusinessCombinationIntegrationRelatedCosts_30cdd8e8-9bb7-4a39-94da-d6ef575d71e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BusinessCombinationConsiderationTransferredHoldback_cbe160a7-b42a-49d3-b087-c5cec0192f87" xlink:href="lgnd-20211231.xsd#lgnd_BusinessCombinationConsiderationTransferredHoldback"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_c5d08779-62cb-4008-b847-0f007c07745c" xlink:to="loc_lgnd_BusinessCombinationConsiderationTransferredHoldback_cbe160a7-b42a-49d3-b087-c5cec0192f87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BusinessCombinationContingentConsiderationLiabilityPercentageOfAcquireeRevenues_e4f65ca9-c25f-4b2d-bd4d-7cf78b48241a" xlink:href="lgnd-20211231.xsd#lgnd_BusinessCombinationContingentConsiderationLiabilityPercentageOfAcquireeRevenues"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_c5d08779-62cb-4008-b847-0f007c07745c" xlink:to="loc_lgnd_BusinessCombinationContingentConsiderationLiabilityPercentageOfAcquireeRevenues_e4f65ca9-c25f-4b2d-bd4d-7cf78b48241a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_12b0114a-377d-40a7-b523-09e4ba537b1b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_c5d08779-62cb-4008-b847-0f007c07745c" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_12b0114a-377d-40a7-b523-09e4ba537b1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_ad5b9280-c977-43ff-8d39-4c4e474ce79f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_c5d08779-62cb-4008-b847-0f007c07745c" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_ad5b9280-c977-43ff-8d39-4c4e474ce79f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BusinessCombinationCashHoldbackForPotentialIndemnificationClaims_78a0c92b-ec3b-4e07-bdd7-61ae319deee3" xlink:href="lgnd-20211231.xsd#lgnd_BusinessCombinationCashHoldbackForPotentialIndemnificationClaims"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_c5d08779-62cb-4008-b847-0f007c07745c" xlink:to="loc_lgnd_BusinessCombinationCashHoldbackForPotentialIndemnificationClaims_78a0c92b-ec3b-4e07-bdd7-61ae319deee3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount_5cc705e9-c05f-461e-a751-ae057ccdf75f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_c5d08779-62cb-4008-b847-0f007c07745c" xlink:to="loc_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount_5cc705e9-c05f-461e-a751-ae057ccdf75f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BusinessCombinationAssumptionsUsedEstimatedFutureCashFlowsDiscountRate_d7db5274-72b1-491b-837e-c762283276b3" xlink:href="lgnd-20211231.xsd#lgnd_BusinessCombinationAssumptionsUsedEstimatedFutureCashFlowsDiscountRate"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_c5d08779-62cb-4008-b847-0f007c07745c" xlink:to="loc_lgnd_BusinessCombinationAssumptionsUsedEstimatedFutureCashFlowsDiscountRate_d7db5274-72b1-491b-837e-c762283276b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_ce7d3fda-d700-4ec3-a3e2-1ffb7c77aa14" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_c5d08779-62cb-4008-b847-0f007c07745c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_ce7d3fda-d700-4ec3-a3e2-1ffb7c77aa14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails" xlink:type="simple" xlink:href="lgnd-20211231.xsd#AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_45b82020-7606-4f56-882f-247047645f7f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_4075696d-7dc1-4751-9cfd-03ed2e33b6d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_45b82020-7606-4f56-882f-247047645f7f" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_4075696d-7dc1-4751-9cfd-03ed2e33b6d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_f3012c2e-4843-418a-bbf0-634b757a0cdf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_4075696d-7dc1-4751-9cfd-03ed2e33b6d8" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_f3012c2e-4843-418a-bbf0-634b757a0cdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_08669799-d306-4839-b8e9-d21aed53a016" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_f3012c2e-4843-418a-bbf0-634b757a0cdf" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_08669799-d306-4839-b8e9-d21aed53a016" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PfenexMember_bf9c20bd-1e59-4918-ba5a-5e559a56fa85" xlink:href="lgnd-20211231.xsd#lgnd_PfenexMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_08669799-d306-4839-b8e9-d21aed53a016" xlink:to="loc_lgnd_PfenexMember_bf9c20bd-1e59-4918-ba5a-5e559a56fa85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_679e1d50-703a-432d-9bc9-78923314bdba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_4075696d-7dc1-4751-9cfd-03ed2e33b6d8" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_679e1d50-703a-432d-9bc9-78923314bdba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_0c77a7db-7336-4e86-91e0-187c3058d722" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_679e1d50-703a-432d-9bc9-78923314bdba" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_0c77a7db-7336-4e86-91e0-187c3058d722" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash_7a3a27a9-2837-4248-9281-9287df0a2c1b" xlink:href="lgnd-20211231.xsd#lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_679e1d50-703a-432d-9bc9-78923314bdba" xlink:to="loc_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash_7a3a27a9-2837-4248-9281-9287df0a2c1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_e9ddb1ed-c2e2-4078-ab1a-77e6551645c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_679e1d50-703a-432d-9bc9-78923314bdba" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_e9ddb1ed-c2e2-4078-ab1a-77e6551645c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_f8891eeb-943c-49b2-9c28-27728653e49f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_679e1d50-703a-432d-9bc9-78923314bdba" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_f8891eeb-943c-49b2-9c28-27728653e49f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssets_06921ea5-ac55-465e-a235-28a1eb35e8d2" xlink:href="lgnd-20211231.xsd#lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_679e1d50-703a-432d-9bc9-78923314bdba" xlink:to="loc_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssets_06921ea5-ac55-465e-a235-28a1eb35e8d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_79b43f65-02c9-476e-b002-22b948c94342" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_679e1d50-703a-432d-9bc9-78923314bdba" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_79b43f65-02c9-476e-b002-22b948c94342" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssets_a7e18bd5-438a-4208-a3c1-a9037e340805" xlink:href="lgnd-20211231.xsd#lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssets"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_679e1d50-703a-432d-9bc9-78923314bdba" xlink:to="loc_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssets_a7e18bd5-438a-4208-a3c1-a9037e340805" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_c130bd25-b9ef-4349-9385-91dc79716d96" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_679e1d50-703a-432d-9bc9-78923314bdba" xlink:to="loc_us-gaap_Goodwill_c130bd25-b9ef-4349-9385-91dc79716d96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_5bf0776d-21f9-43d9-b569-b0fa8ff402e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_679e1d50-703a-432d-9bc9-78923314bdba" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_5bf0776d-21f9-43d9-b569-b0fa8ff402e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilitiesCurrent_a28bcbcf-f829-47ba-88e0-3b841e03b433" xlink:href="lgnd-20211231.xsd#lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_679e1d50-703a-432d-9bc9-78923314bdba" xlink:to="loc_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilitiesCurrent_a28bcbcf-f829-47ba-88e0-3b841e03b433" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue_f6bee2bb-85cb-4244-b349-7baf12cc7490" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_679e1d50-703a-432d-9bc9-78923314bdba" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue_f6bee2bb-85cb-4244-b349-7baf12cc7490" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLeaseLiabilities_0ee25c71-08c3-4254-808d-47acf4446328" xlink:href="lgnd-20211231.xsd#lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLeaseLiabilities"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_679e1d50-703a-432d-9bc9-78923314bdba" xlink:to="loc_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLeaseLiabilities_0ee25c71-08c3-4254-808d-47acf4446328" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther_ae95c9a6-f829-4eaf-8833-c955058ad209" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_679e1d50-703a-432d-9bc9-78923314bdba" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther_ae95c9a6-f829-4eaf-8833-c955058ad209" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_dbc3279f-c1c9-43ca-aee1-4bb86ad9f06d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_679e1d50-703a-432d-9bc9-78923314bdba" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_dbc3279f-c1c9-43ca-aee1-4bb86ad9f06d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_5a7b1fcb-0bf9-42be-8691-65068cf9e61a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_679e1d50-703a-432d-9bc9-78923314bdba" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_5a7b1fcb-0bf9-42be-8691-65068cf9e61a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/AcquisitionsIntangiblesAcquiredandWeightedAverageUsefulLifeDetails" xlink:type="simple" xlink:href="lgnd-20211231.xsd#AcquisitionsIntangiblesAcquiredandWeightedAverageUsefulLifeDetails"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/AcquisitionsIntangiblesAcquiredandWeightedAverageUsefulLifeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_8fc052a3-7c1c-45ef-a1fa-1b353835eafd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_6517ca8d-a104-4c4f-8926-735f57fdf47d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_8fc052a3-7c1c-45ef-a1fa-1b353835eafd" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_6517ca8d-a104-4c4f-8926-735f57fdf47d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_bafe7e91-db9b-412b-8a79-981d5a1fd32d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_6517ca8d-a104-4c4f-8926-735f57fdf47d" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_bafe7e91-db9b-412b-8a79-981d5a1fd32d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_ec3ac34e-c0b6-40b5-8824-95cd7237767a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_bafe7e91-db9b-412b-8a79-981d5a1fd32d" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_ec3ac34e-c0b6-40b5-8824-95cd7237767a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PfenexMember_f4a41357-bd2b-440d-9c22-b01a192caaa1" xlink:href="lgnd-20211231.xsd#lgnd_PfenexMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_ec3ac34e-c0b6-40b5-8824-95cd7237767a" xlink:to="loc_lgnd_PfenexMember_f4a41357-bd2b-440d-9c22-b01a192caaa1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_947bcc5e-c409-447c-b555-5a8c95c4b733" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_6517ca8d-a104-4c4f-8926-735f57fdf47d" xlink:to="loc_srt_RangeAxis_947bcc5e-c409-447c-b555-5a8c95c4b733" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_27bb72d6-292e-40c3-8d55-af30455895ec" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_947bcc5e-c409-447c-b555-5a8c95c4b733" xlink:to="loc_srt_RangeMember_27bb72d6-292e-40c3-8d55-af30455895ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_9d16e419-85b2-42cd-9e98-120ea541fd21" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_27bb72d6-292e-40c3-8d55-af30455895ec" xlink:to="loc_srt_MinimumMember_9d16e419-85b2-42cd-9e98-120ea541fd21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_b1bf3dc8-5a85-4fe3-ba16-0bef59eb3f59" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_27bb72d6-292e-40c3-8d55-af30455895ec" xlink:to="loc_srt_MaximumMember_b1bf3dc8-5a85-4fe3-ba16-0bef59eb3f59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_19dc81df-4059-46a5-a5de-2beedc570150" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_6517ca8d-a104-4c4f-8926-735f57fdf47d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_19dc81df-4059-46a5-a5de-2beedc570150" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_589662da-e23c-49f7-a1b0-54eec1b480f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_19dc81df-4059-46a5-a5de-2beedc570150" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_589662da-e23c-49f7-a1b0-54eec1b480f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ContractualRelationshipsAlvogenMember_329fbed1-1777-4ea3-9eb2-d00210b750fd" xlink:href="lgnd-20211231.xsd#lgnd_ContractualRelationshipsAlvogenMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_589662da-e23c-49f7-a1b0-54eec1b480f3" xlink:to="loc_lgnd_ContractualRelationshipsAlvogenMember_329fbed1-1777-4ea3-9eb2-d00210b750fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ContractualRelationshipsMerckMember_a077c45a-1497-4441-97e9-92d566254d30" xlink:href="lgnd-20211231.xsd#lgnd_ContractualRelationshipsMerckMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_589662da-e23c-49f7-a1b0-54eec1b480f3" xlink:to="loc_lgnd_ContractualRelationshipsMerckMember_a077c45a-1497-4441-97e9-92d566254d30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ContractualRelationshipsJazzMember_477b6f48-5a62-4346-bfba-26b1b0fec93b" xlink:href="lgnd-20211231.xsd#lgnd_ContractualRelationshipsJazzMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_589662da-e23c-49f7-a1b0-54eec1b480f3" xlink:to="loc_lgnd_ContractualRelationshipsJazzMember_477b6f48-5a62-4346-bfba-26b1b0fec93b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ContractualRelationshipsSIIMember_78e7f93b-806a-4799-8784-319afcab9df7" xlink:href="lgnd-20211231.xsd#lgnd_ContractualRelationshipsSIIMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_589662da-e23c-49f7-a1b0-54eec1b480f3" xlink:to="loc_lgnd_ContractualRelationshipsSIIMember_78e7f93b-806a-4799-8784-319afcab9df7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ContractualRelationshipsArcellxMember_8e551b19-5a52-47a0-a379-8139d467dfdc" xlink:href="lgnd-20211231.xsd#lgnd_ContractualRelationshipsArcellxMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_589662da-e23c-49f7-a1b0-54eec1b480f3" xlink:to="loc_lgnd_ContractualRelationshipsArcellxMember_8e551b19-5a52-47a0-a379-8139d467dfdc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TechnologyBasedIntangibleAssetsMember_11551fdd-6cc9-426f-930b-968203ec6992" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TechnologyBasedIntangibleAssetsMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_589662da-e23c-49f7-a1b0-54eec1b480f3" xlink:to="loc_us-gaap_TechnologyBasedIntangibleAssetsMember_11551fdd-6cc9-426f-930b-968203ec6992" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_a4d6eb01-92aa-4b5f-aa78-0f7831c6d89d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_6517ca8d-a104-4c4f-8926-735f57fdf47d" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_a4d6eb01-92aa-4b5f-aa78-0f7831c6d89d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_54c50aea-261b-4e92-9a01-815948d08722" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a4d6eb01-92aa-4b5f-aa78-0f7831c6d89d" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_54c50aea-261b-4e92-9a01-815948d08722" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_ba0fc520-7238-4306-b152-31ef6f5f5566" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a4d6eb01-92aa-4b5f-aa78-0f7831c6d89d" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_ba0fc520-7238-4306-b152-31ef6f5f5566" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/AcquisitionsProFormaFinancialInformationDetails" xlink:type="simple" xlink:href="lgnd-20211231.xsd#AcquisitionsProFormaFinancialInformationDetails"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/AcquisitionsProFormaFinancialInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_33b7292e-79eb-4c6b-af85-a21ce4ca8c3a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_8aeebff7-feb5-48f1-b40c-19f7ff9689e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_33b7292e-79eb-4c6b-af85-a21ce4ca8c3a" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_8aeebff7-feb5-48f1-b40c-19f7ff9689e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_0dfcca7b-9627-4723-a1b8-66145ae4454c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_8aeebff7-feb5-48f1-b40c-19f7ff9689e4" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_0dfcca7b-9627-4723-a1b8-66145ae4454c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1e04b3a2-a4ff-4c56-b20f-fd4f56ed8d3d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_0dfcca7b-9627-4723-a1b8-66145ae4454c" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1e04b3a2-a4ff-4c56-b20f-fd4f56ed8d3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PfenexMember_2ce15711-5a34-4315-8a8d-9cffa3758040" xlink:href="lgnd-20211231.xsd#lgnd_PfenexMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1e04b3a2-a4ff-4c56-b20f-fd4f56ed8d3d" xlink:to="loc_lgnd_PfenexMember_2ce15711-5a34-4315-8a8d-9cffa3758040" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_33a15522-9060-4220-803a-be7bf90c75b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_8aeebff7-feb5-48f1-b40c-19f7ff9689e4" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_33a15522-9060-4220-803a-be7bf90c75b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaRevenue_1e6a4776-c90a-456f-9186-b12c3725dd71" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionsProFormaRevenue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_33a15522-9060-4220-803a-be7bf90c75b3" xlink:to="loc_us-gaap_BusinessAcquisitionsProFormaRevenue_1e6a4776-c90a-456f-9186-b12c3725dd71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_b529d7bd-638f-47bc-839b-c32544d7bb32" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_33a15522-9060-4220-803a-be7bf90c75b3" xlink:to="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_b529d7bd-638f-47bc-839b-c32544d7bb32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareProFormaAbstract_768a840d-d0b6-4c89-af09-859e895348a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareProFormaAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_33a15522-9060-4220-803a-be7bf90c75b3" xlink:to="loc_us-gaap_EarningsPerShareProFormaAbstract_768a840d-d0b6-4c89-af09-859e895348a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic_8e80db24-e7c4-466a-8801-e5fd54f05fab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareProFormaAbstract_768a840d-d0b6-4c89-af09-859e895348a1" xlink:to="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic_8e80db24-e7c4-466a-8801-e5fd54f05fab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted_2928931a-554f-454e-a489-c7b6b40d2244" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareProFormaAbstract_768a840d-d0b6-4c89-af09-859e895348a1" xlink:to="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted_2928931a-554f-454e-a489-c7b6b40d2244" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/AcquisitionsAllocationofConsiderationDetails" xlink:type="simple" xlink:href="lgnd-20211231.xsd#AcquisitionsAllocationofConsiderationDetails"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/AcquisitionsAllocationofConsiderationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_694605f7-0c6f-4f95-b153-75a4ed6eeb34" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_82568526-79fb-4664-a5c1-804a26a71f07" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_694605f7-0c6f-4f95-b153-75a4ed6eeb34" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_82568526-79fb-4664-a5c1-804a26a71f07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_60ff1ab2-da64-4f5c-b5cc-dc642e9b5a5f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_82568526-79fb-4664-a5c1-804a26a71f07" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_60ff1ab2-da64-4f5c-b5cc-dc642e9b5a5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_0e86980b-559b-47fc-be1b-843ded912f12" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_60ff1ab2-da64-4f5c-b5cc-dc642e9b5a5f" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_0e86980b-559b-47fc-be1b-843ded912f12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_TaurusBiosciencesLLCMember_a1b20bc8-eb0c-4242-8b7e-be1b702f20b5" xlink:href="lgnd-20211231.xsd#lgnd_TaurusBiosciencesLLCMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_0e86980b-559b-47fc-be1b-843ded912f12" xlink:to="loc_lgnd_TaurusBiosciencesLLCMember_a1b20bc8-eb0c-4242-8b7e-be1b702f20b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_XCellaBiosciencesIncMember_d56de1d3-b632-4af6-8de4-7683ff5a3f0e" xlink:href="lgnd-20211231.xsd#lgnd_XCellaBiosciencesIncMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_0e86980b-559b-47fc-be1b-843ded912f12" xlink:to="loc_lgnd_XCellaBiosciencesIncMember_d56de1d3-b632-4af6-8de4-7683ff5a3f0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_IcagenMember_9f579d04-a1c0-4379-bbab-3621dc218604" xlink:href="lgnd-20211231.xsd#lgnd_IcagenMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_0e86980b-559b-47fc-be1b-843ded912f12" xlink:to="loc_lgnd_IcagenMember_9f579d04-a1c0-4379-bbab-3621dc218604" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AbInitioMember_a1337efc-301b-4b86-866e-e71e789fd2f8" xlink:href="lgnd-20211231.xsd#lgnd_AbInitioMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_0e86980b-559b-47fc-be1b-843ded912f12" xlink:to="loc_lgnd_AbInitioMember_a1337efc-301b-4b86-866e-e71e789fd2f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_78e2e383-d3bf-4eb4-b26e-0dfb0fc510f9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_82568526-79fb-4664-a5c1-804a26a71f07" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_78e2e383-d3bf-4eb4-b26e-0dfb0fc510f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_130bd56a-5733-41d3-9292-976074ad5021" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_78e2e383-d3bf-4eb4-b26e-0dfb0fc510f9" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_130bd56a-5733-41d3-9292-976074ad5021" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash_f6ad7588-6319-472a-b448-b52ac0a39683" xlink:href="lgnd-20211231.xsd#lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_78e2e383-d3bf-4eb4-b26e-0dfb0fc510f9" xlink:to="loc_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash_f6ad7588-6319-472a-b448-b52ac0a39683" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_0d854eb3-6d6f-4988-98a4-d340758c9551" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_78e2e383-d3bf-4eb4-b26e-0dfb0fc510f9" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_0d854eb3-6d6f-4988-98a4-d340758c9551" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndCurrentAssetsOther_423c54ff-4118-4f07-954c-35b3b98893e8" xlink:href="lgnd-20211231.xsd#lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndCurrentAssetsOther"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_78e2e383-d3bf-4eb4-b26e-0dfb0fc510f9" xlink:to="loc_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndCurrentAssetsOther_423c54ff-4118-4f07-954c-35b3b98893e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_2471a2c2-b018-468b-98a6-5f125b9ce7f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_78e2e383-d3bf-4eb4-b26e-0dfb0fc510f9" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_2471a2c2-b018-468b-98a6-5f125b9ce7f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_d1451739-91ff-4c02-9d18-db7843ae1277" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_78e2e383-d3bf-4eb4-b26e-0dfb0fc510f9" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_d1451739-91ff-4c02-9d18-db7843ae1277" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities_d76209c1-4b23-453b-b447-9fd714d7d19b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_78e2e383-d3bf-4eb4-b26e-0dfb0fc510f9" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities_d76209c1-4b23-453b-b447-9fd714d7d19b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue_9d48b5fb-58b2-4852-a4b3-e72d5cadb336" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_78e2e383-d3bf-4eb4-b26e-0dfb0fc510f9" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue_9d48b5fb-58b2-4852-a4b3-e72d5cadb336" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilitiesCurrent_8c709acd-7e8f-4561-8f20-7d5bf1242069" xlink:href="lgnd-20211231.xsd#lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_78e2e383-d3bf-4eb4-b26e-0dfb0fc510f9" xlink:to="loc_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilitiesCurrent_8c709acd-7e8f-4561-8f20-7d5bf1242069" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_4c2ec7e7-2f3b-4d7d-8287-5bbeea97352f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_78e2e383-d3bf-4eb4-b26e-0dfb0fc510f9" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_4c2ec7e7-2f3b-4d7d-8287-5bbeea97352f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_2b5f980e-b409-44e1-ac00-3eef4464d369" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_78e2e383-d3bf-4eb4-b26e-0dfb0fc510f9" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_2b5f980e-b409-44e1-ac00-3eef4464d369" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets_709b59ab-f7eb-49f3-a9ec-3652a3fb9266" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_78e2e383-d3bf-4eb4-b26e-0dfb0fc510f9" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets_709b59ab-f7eb-49f3-a9ec-3652a3fb9266" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_f72aaeec-9421-469f-8b8c-59b37fd7b138" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_78e2e383-d3bf-4eb4-b26e-0dfb0fc510f9" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_f72aaeec-9421-469f-8b8c-59b37fd7b138" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssets_34da2a39-f5a6-4ebd-bb91-7a6f43398b55" xlink:href="lgnd-20211231.xsd#lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssets"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_78e2e383-d3bf-4eb4-b26e-0dfb0fc510f9" xlink:to="loc_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssets_34da2a39-f5a6-4ebd-bb91-7a6f43398b55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_f9af72cd-cf9a-48ec-a51a-3d25f3165e5a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_78e2e383-d3bf-4eb4-b26e-0dfb0fc510f9" xlink:to="loc_us-gaap_Goodwill_f9af72cd-cf9a-48ec-a51a-3d25f3165e5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_8da3b66f-6d34-47bb-b935-0c6fe439ccc3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_78e2e383-d3bf-4eb4-b26e-0dfb0fc510f9" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_8da3b66f-6d34-47bb-b935-0c6fe439ccc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/FairValueMeasurement" xlink:type="simple" xlink:href="lgnd-20211231.xsd#FairValueMeasurement"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/FairValueMeasurement" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_387621d2-2b67-4c7b-bfcb-3cb0ca4e76f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentsDisclosureTextBlock_d75d9e71-70ca-451d-abc1-87acba38cc86" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_387621d2-2b67-4c7b-bfcb-3cb0ca4e76f6" xlink:to="loc_us-gaap_FinancialInstrumentsDisclosureTextBlock_d75d9e71-70ca-451d-abc1-87acba38cc86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/FairValueMeasurementTables" xlink:type="simple" xlink:href="lgnd-20211231.xsd#FairValueMeasurementTables"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/FairValueMeasurementTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_3f925d8f-ca29-4c0a-82b8-88a26534d950" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_8972e968-9cdd-4dfa-a0a0-5fd32d06f949" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_3f925d8f-ca29-4c0a-82b8-88a26534d950" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_8972e968-9cdd-4dfa-a0a0-5fd32d06f949" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_991f6a0d-1376-4836-8570-9cec2555b8a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_3f925d8f-ca29-4c0a-82b8-88a26534d950" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_991f6a0d-1376-4836-8570-9cec2555b8a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" xlink:type="simple" xlink:href="lgnd-20211231.xsd#FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_238d56cf-d2c7-41d2-9150-12ae48b607d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_96166cda-a88b-4294-be27-9670e3a0305a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_238d56cf-d2c7-41d2-9150-12ae48b607d3" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_96166cda-a88b-4294-be27-9670e3a0305a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_72416618-50c9-4ef6-9529-081c63561ace" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_96166cda-a88b-4294-be27-9670e3a0305a" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_72416618-50c9-4ef6-9529-081c63561ace" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_7a47499a-a35b-4b91-aab5-62ef821707c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_72416618-50c9-4ef6-9529-081c63561ace" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_7a47499a-a35b-4b91-aab5-62ef821707c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_6c8c17ae-4946-47ad-aeb8-d81488e4bb55" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_7a47499a-a35b-4b91-aab5-62ef821707c9" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_6c8c17ae-4946-47ad-aeb8-d81488e4bb55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_a49a2e00-0c8f-488c-85c2-90e5ed90bc0f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_96166cda-a88b-4294-be27-9670e3a0305a" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_a49a2e00-0c8f-488c-85c2-90e5ed90bc0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_50c529c2-e43f-4450-91c0-ad8749765940" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_a49a2e00-0c8f-488c-85c2-90e5ed90bc0f" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_50c529c2-e43f-4450-91c0-ad8749765940" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_c21fa0d6-c6c8-4459-a875-e35e813fa034" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_50c529c2-e43f-4450-91c0-ad8749765940" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_c21fa0d6-c6c8-4459-a875-e35e813fa034" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_797bc646-e64a-4d04-b8ee-7bcf911e4d6c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_50c529c2-e43f-4450-91c0-ad8749765940" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_797bc646-e64a-4d04-b8ee-7bcf911e4d6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_de1f7af2-213f-48db-b40e-393c4d6c66a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_50c529c2-e43f-4450-91c0-ad8749765940" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_de1f7af2-213f-48db-b40e-393c4d6c66a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_08351d3c-cb6d-46a2-b74b-71b78bd31a46" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_96166cda-a88b-4294-be27-9670e3a0305a" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_08351d3c-cb6d-46a2-b74b-71b78bd31a46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_5d542108-3a9d-4bba-bf0d-66f1b6521b58" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_08351d3c-cb6d-46a2-b74b-71b78bd31a46" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_5d542108-3a9d-4bba-bf0d-66f1b6521b58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestmentsMember_cd3a3584-acdd-4965-9be1-6b445ecd9ed5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermInvestmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_5d542108-3a9d-4bba-bf0d-66f1b6521b58" xlink:to="loc_us-gaap_ShortTermInvestmentsMember_cd3a3584-acdd-4965-9be1-6b445ecd9ed5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember_ec60ccb2-0aa7-4830-8c72-ae7596ad61cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_5d542108-3a9d-4bba-bf0d-66f1b6521b58" xlink:to="loc_us-gaap_EquitySecuritiesMember_ec60ccb2-0aa7-4830-8c72-ae7596ad61cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_1693ca8e-4e0c-4fc7-bc2f-9b161988b0a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_5d542108-3a9d-4bba-bf0d-66f1b6521b58" xlink:to="loc_us-gaap_WarrantMember_1693ca8e-4e0c-4fc7-bc2f-9b161988b0a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_47abba56-bd79-4959-bf67-fd6afa36e0c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_96166cda-a88b-4294-be27-9670e3a0305a" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_47abba56-bd79-4959-bf67-fd6afa36e0c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_63a295a5-e177-40a6-a86f-817ff974659d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_47abba56-bd79-4959-bf67-fd6afa36e0c7" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_63a295a5-e177-40a6-a86f-817ff974659d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_LiabilityForContingentValueRightsCompanyCrystalMember_b27c2590-3b5f-4924-8dce-abde16c09c39" xlink:href="lgnd-20211231.xsd#lgnd_LiabilityForContingentValueRightsCompanyCrystalMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_63a295a5-e177-40a6-a86f-817ff974659d" xlink:to="loc_lgnd_LiabilityForContingentValueRightsCompanyCrystalMember_b27c2590-3b5f-4924-8dce-abde16c09c39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_LiabilityForContingentValueRightsCompanyCydexMember_45faa090-f713-4578-aac7-1654eb5e538b" xlink:href="lgnd-20211231.xsd#lgnd_LiabilityForContingentValueRightsCompanyCydexMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_63a295a5-e177-40a6-a86f-817ff974659d" xlink:to="loc_lgnd_LiabilityForContingentValueRightsCompanyCydexMember_45faa090-f713-4578-aac7-1654eb5e538b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_LiabilityForContingentValueRightsCompanyMetabasisMember_e1ee4d7a-8187-4f64-a268-5e35c88063b4" xlink:href="lgnd-20211231.xsd#lgnd_LiabilityForContingentValueRightsCompanyMetabasisMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_63a295a5-e177-40a6-a86f-817ff974659d" xlink:to="loc_lgnd_LiabilityForContingentValueRightsCompanyMetabasisMember_e1ee4d7a-8187-4f64-a268-5e35c88063b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_LiabilityForContingentValueRightsCompanyIcagenMember_3150e3fe-bbb9-4221-a745-359f6e177540" xlink:href="lgnd-20211231.xsd#lgnd_LiabilityForContingentValueRightsCompanyIcagenMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_63a295a5-e177-40a6-a86f-817ff974659d" xlink:to="loc_lgnd_LiabilityForContingentValueRightsCompanyIcagenMember_3150e3fe-bbb9-4221-a745-359f6e177540" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_LiabilityForContingentValueRightsCompanyPfenexMember_1f7521c5-52e8-43c0-8dba-17266c24c517" xlink:href="lgnd-20211231.xsd#lgnd_LiabilityForContingentValueRightsCompanyPfenexMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_63a295a5-e177-40a6-a86f-817ff974659d" xlink:to="loc_lgnd_LiabilityForContingentValueRightsCompanyPfenexMember_1f7521c5-52e8-43c0-8dba-17266c24c517" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_LiabilityForRestrictedInvestmentsOwedToFormerLicenseesMember_c52e9532-2827-4b22-ae9d-d494e5460284" xlink:href="lgnd-20211231.xsd#lgnd_LiabilityForRestrictedInvestmentsOwedToFormerLicenseesMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_63a295a5-e177-40a6-a86f-817ff974659d" xlink:to="loc_lgnd_LiabilityForRestrictedInvestmentsOwedToFormerLicenseesMember_c52e9532-2827-4b22-ae9d-d494e5460284" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_facadfc5-eb7b-42ed-8669-efef22f7ab36" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_96166cda-a88b-4294-be27-9670e3a0305a" xlink:to="loc_srt_RangeAxis_facadfc5-eb7b-42ed-8669-efef22f7ab36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_03c6e6c8-b2c9-4784-bf4a-780eaf3d52ba" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_facadfc5-eb7b-42ed-8669-efef22f7ab36" xlink:to="loc_srt_RangeMember_03c6e6c8-b2c9-4784-bf4a-780eaf3d52ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_f2ba99e8-d060-4e3b-8e59-6a1c5ffddf93" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_03c6e6c8-b2c9-4784-bf4a-780eaf3d52ba" xlink:to="loc_srt_MaximumMember_f2ba99e8-d060-4e3b-8e59-6a1c5ffddf93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TimingOfTransferOfGoodOrServiceAxis_0f7e9152-3eed-4abd-8744-59a09fb76e65" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TimingOfTransferOfGoodOrServiceAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_96166cda-a88b-4294-be27-9670e3a0305a" xlink:to="loc_us-gaap_TimingOfTransferOfGoodOrServiceAxis_0f7e9152-3eed-4abd-8744-59a09fb76e65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TimingOfTransferOfGoodOrServiceDomain_fc4b9915-02d3-4994-b30c-8cfb0d31a5f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TimingOfTransferOfGoodOrServiceDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TimingOfTransferOfGoodOrServiceAxis_0f7e9152-3eed-4abd-8744-59a09fb76e65" xlink:to="loc_us-gaap_TimingOfTransferOfGoodOrServiceDomain_fc4b9915-02d3-4994-b30c-8cfb0d31a5f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransferredOverTimeMember_fc92830b-41e0-45f1-9d44-7afdb16fa650" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransferredOverTimeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TimingOfTransferOfGoodOrServiceDomain_fc4b9915-02d3-4994-b30c-8cfb0d31a5f7" xlink:to="loc_us-gaap_TransferredOverTimeMember_fc92830b-41e0-45f1-9d44-7afdb16fa650" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_d32d4a68-feb5-4a2c-9bc5-d8fe8a2d9a9f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_96166cda-a88b-4294-be27-9670e3a0305a" xlink:to="loc_srt_ProductOrServiceAxis_d32d4a68-feb5-4a2c-9bc5-d8fe8a2d9a9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_3f53783e-5bef-482e-9a92-fce8f1a7aaad" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_d32d4a68-feb5-4a2c-9bc5-d8fe8a2d9a9f" xlink:to="loc_srt_ProductsAndServicesDomain_3f53783e-5bef-482e-9a92-fce8f1a7aaad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_DevelopmentRegulatoryCommercialMilestonesAndTieredRoyaltiesMember_b2afe4b4-1060-4038-8e84-084b45b9d19a" xlink:href="lgnd-20211231.xsd#lgnd_DevelopmentRegulatoryCommercialMilestonesAndTieredRoyaltiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_3f53783e-5bef-482e-9a92-fce8f1a7aaad" xlink:to="loc_lgnd_DevelopmentRegulatoryCommercialMilestonesAndTieredRoyaltiesMember_b2afe4b4-1060-4038-8e84-084b45b9d19a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_Phase3ClinicalTrialMember_0dacc0c5-cda8-4276-be62-30c31047e671" xlink:href="lgnd-20211231.xsd#lgnd_Phase3ClinicalTrialMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_3f53783e-5bef-482e-9a92-fce8f1a7aaad" xlink:to="loc_lgnd_Phase3ClinicalTrialMember_0dacc0c5-cda8-4276-be62-30c31047e671" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_7ce13dbf-a23f-4c18-b42c-56952c95a659" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_96166cda-a88b-4294-be27-9670e3a0305a" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_7ce13dbf-a23f-4c18-b42c-56952c95a659" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_52bceeb7-539f-4abd-bd27-cc54cfadaf5d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_7ce13dbf-a23f-4c18-b42c-56952c95a659" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_52bceeb7-539f-4abd-bd27-cc54cfadaf5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_ae78c4f6-46a8-4c7a-add4-8ed192fb3004" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_7ce13dbf-a23f-4c18-b42c-56952c95a659" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_ae78c4f6-46a8-4c7a-add4-8ed192fb3004" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities_d8b5e7de-d3b2-49c0-b202-824c4c1a8ff8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_7ce13dbf-a23f-4c18-b42c-56952c95a659" xlink:to="loc_us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities_d8b5e7de-d3b2-49c0-b202-824c4c1a8ff8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_NumberOfContingentValueRightAgreements_215a4a3f-6826-4cb7-8a7e-f32d68777c4f" xlink:href="lgnd-20211231.xsd#lgnd_NumberOfContingentValueRightAgreements"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_7ce13dbf-a23f-4c18-b42c-56952c95a659" xlink:to="loc_lgnd_NumberOfContingentValueRightAgreements_215a4a3f-6826-4cb7-8a7e-f32d68777c4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Investments_f49a02ac-ea89-4ccf-aba1-2d6bff824b28" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Investments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_7ce13dbf-a23f-4c18-b42c-56952c95a659" xlink:to="loc_us-gaap_Investments_f49a02ac-ea89-4ccf-aba1-2d6bff824b28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetGross_00d0b57a-61b5-4c46-9444-3371d0617ddb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerAssetGross"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_7ce13dbf-a23f-4c18-b42c-56952c95a659" xlink:to="loc_us-gaap_ContractWithCustomerAssetGross_00d0b57a-61b5-4c46-9444-3371d0617ddb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_89a0b620-a1ef-4d65-b623-1fec62075764" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_7ce13dbf-a23f-4c18-b42c-56952c95a659" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_89a0b620-a1ef-4d65-b623-1fec62075764" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/FairValueMeasurementReconciliationofLevel3FinancialInstrumentsDetails" xlink:type="simple" xlink:href="lgnd-20211231.xsd#FairValueMeasurementReconciliationofLevel3FinancialInstrumentsDetails"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/FairValueMeasurementReconciliationofLevel3FinancialInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_4cacd7f5-32c7-4682-8489-b7332555561e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_d2854d7d-1588-4d9d-9823-eaa7716a9300" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_4cacd7f5-32c7-4682-8489-b7332555561e" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_d2854d7d-1588-4d9d-9823-eaa7716a9300" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_425431f8-cbdb-4775-871d-2b00549f523c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_d2854d7d-1588-4d9d-9823-eaa7716a9300" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_425431f8-cbdb-4775-871d-2b00549f523c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_ccf3164e-883f-4035-bbd9-9266f4458fbf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_425431f8-cbdb-4775-871d-2b00549f523c" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_ccf3164e-883f-4035-bbd9-9266f4458fbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_1321f716-870d-424e-a212-0e78eeb6f58a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_ccf3164e-883f-4035-bbd9-9266f4458fbf" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_1321f716-870d-424e-a212-0e78eeb6f58a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_381b9e01-9cf0-4348-b4cb-f2e75b147b9c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_d2854d7d-1588-4d9d-9823-eaa7716a9300" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_381b9e01-9cf0-4348-b4cb-f2e75b147b9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_fc75ec10-e447-4089-a139-4b35986565d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_381b9e01-9cf0-4348-b4cb-f2e75b147b9c" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_fc75ec10-e447-4089-a139-4b35986565d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_1ec631d8-fc6d-4902-8c73-265ca4eaf152" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_fc75ec10-e447-4089-a139-4b35986565d3" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_1ec631d8-fc6d-4902-8c73-265ca4eaf152" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PaymentsToContingentValueRightHolders_c50eedd8-bcc8-49f2-8aa6-a474f930fe6d" xlink:href="lgnd-20211231.xsd#lgnd_PaymentsToContingentValueRightHolders"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_fc75ec10-e447-4089-a139-4b35986565d3" xlink:to="loc_lgnd_PaymentsToContingentValueRightHolders_c50eedd8-bcc8-49f2-8aa6-a474f930fe6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_1ba87578-fd1d-44a0-b610-ade04f3fd9cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_fc75ec10-e447-4089-a139-4b35986565d3" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_1ba87578-fd1d-44a0-b610-ade04f3fd9cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityContingentConsiderationFromAcquisition_e69025dd-6aab-4908-853d-377d4cdd0bd1" xlink:href="lgnd-20211231.xsd#lgnd_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityContingentConsiderationFromAcquisition"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_fc75ec10-e447-4089-a139-4b35986565d3" xlink:to="loc_lgnd_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityContingentConsiderationFromAcquisition_e69025dd-6aab-4908-853d-377d4cdd0bd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_98f574c1-3ae9-4cab-bffd-f10114fc797d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_fc75ec10-e447-4089-a139-4b35986565d3" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_98f574c1-3ae9-4cab-bffd-f10114fc797d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="simple" xlink:href="lgnd-20211231.xsd#FairValueMeasurementsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_d8fab9b0-98f8-4b25-b9f7-b403ccb1930c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_9167826f-3cf9-49d1-9030-662f912773da" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_d8fab9b0-98f8-4b25-b9f7-b403ccb1930c" xlink:to="loc_us-gaap_AssetImpairmentCharges_9167826f-3cf9-49d1-9030-662f912773da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/Leases" xlink:type="simple" xlink:href="lgnd-20211231.xsd#Leases"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/Leases" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_0710f35b-4ed8-421c-aaf6-73ba5b6e316f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_5d0eebaf-55d2-4a5f-b4b6-f55f1759336d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_0710f35b-4ed8-421c-aaf6-73ba5b6e316f" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_5d0eebaf-55d2-4a5f-b4b6-f55f1759336d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeFinanceLeasesTextBlock_4cd6952d-94b1-4e68-b394-42795a1279e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeFinanceLeasesTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_0710f35b-4ed8-421c-aaf6-73ba5b6e316f" xlink:to="loc_us-gaap_LesseeFinanceLeasesTextBlock_4cd6952d-94b1-4e68-b394-42795a1279e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/LeasesTables" xlink:type="simple" xlink:href="lgnd-20211231.xsd#LeasesTables"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/LeasesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_47b5c519-50a8-41e5-a2f3-98ecbfe33143" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AssetsAndLiabilitiesLesseeTableTextBlock_f68fde02-7d3a-47b2-b077-41b54822cea8" xlink:href="lgnd-20211231.xsd#lgnd_AssetsAndLiabilitiesLesseeTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_47b5c519-50a8-41e5-a2f3-98ecbfe33143" xlink:to="loc_lgnd_AssetsAndLiabilitiesLesseeTableTextBlock_f68fde02-7d3a-47b2-b077-41b54822cea8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_6eb80328-1ff4-4c90-9095-8182393c1123" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_47b5c519-50a8-41e5-a2f3-98ecbfe33143" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_6eb80328-1ff4-4c90-9095-8182393c1123" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_591b3f11-ef40-4efe-be6c-a43ef28ccd32" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_47b5c519-50a8-41e5-a2f3-98ecbfe33143" xlink:to="loc_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_591b3f11-ef40-4efe-be6c-a43ef28ccd32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/LeasesNarrativeDetails" xlink:type="simple" xlink:href="lgnd-20211231.xsd#LeasesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/LeasesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_74a15e0d-1673-49b1-9971-35d6377ca425" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_fb4f274d-0f14-4fd1-a63d-68cb0769d2eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_74a15e0d-1673-49b1-9971-35d6377ca425" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_fb4f274d-0f14-4fd1-a63d-68cb0769d2eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_41899db4-6b03-47a1-83f5-c4353472f619" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_fb4f274d-0f14-4fd1-a63d-68cb0769d2eb" xlink:to="loc_srt_ProductOrServiceAxis_41899db4-6b03-47a1-83f5-c4353472f619" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_1d202e19-9674-41f7-a188-591fffc33e8b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_41899db4-6b03-47a1-83f5-c4353472f619" xlink:to="loc_srt_ProductsAndServicesDomain_1d202e19-9674-41f7-a188-591fffc33e8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_MaterialSalesCaptisolMember_8275957b-6748-41ac-8486-ca67397bba6c" xlink:href="lgnd-20211231.xsd#lgnd_MaterialSalesCaptisolMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_1d202e19-9674-41f7-a188-591fffc33e8b" xlink:to="loc_lgnd_MaterialSalesCaptisolMember_8275957b-6748-41ac-8486-ca67397bba6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_cde755cf-a0d1-4655-8276-3c776b36441a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_fb4f274d-0f14-4fd1-a63d-68cb0769d2eb" xlink:to="loc_srt_RangeAxis_cde755cf-a0d1-4655-8276-3c776b36441a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_188e79e7-df82-42f0-8d7b-709a09e01a34" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_cde755cf-a0d1-4655-8276-3c776b36441a" xlink:to="loc_srt_RangeMember_188e79e7-df82-42f0-8d7b-709a09e01a34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_83ad8da2-a8a2-46b8-827a-a6477d741510" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_188e79e7-df82-42f0-8d7b-709a09e01a34" xlink:to="loc_srt_MaximumMember_83ad8da2-a8a2-46b8-827a-a6477d741510" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_3a68c1e1-2c7d-4cb0-8a75-c189b5f7dfd9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_fb4f274d-0f14-4fd1-a63d-68cb0769d2eb" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_3a68c1e1-2c7d-4cb0-8a75-c189b5f7dfd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_61525164-163c-43bb-ac47-75d81b12d969" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_3a68c1e1-2c7d-4cb0-8a75-c189b5f7dfd9" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_61525164-163c-43bb-ac47-75d81b12d969" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingMember_18704ac3-d0e4-4507-aafd-ff2086ae8a8a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BuildingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_61525164-163c-43bb-ac47-75d81b12d969" xlink:to="loc_us-gaap_BuildingMember_18704ac3-d0e4-4507-aafd-ff2086ae8a8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_cfc774c3-f88d-4a6f-addf-27f032112ca5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_fb4f274d-0f14-4fd1-a63d-68cb0769d2eb" xlink:to="loc_us-gaap_LesseeLeaseDescriptionLineItems_cfc774c3-f88d-4a6f-addf-27f032112ca5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PurchaseCommitmentConsiderationPaidToDate_d0c19824-0ab9-4e6c-92ae-18d2dc66a44a" xlink:href="lgnd-20211231.xsd#lgnd_PurchaseCommitmentConsiderationPaidToDate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_cfc774c3-f88d-4a6f-addf-27f032112ca5" xlink:to="loc_lgnd_PurchaseCommitmentConsiderationPaidToDate_d0c19824-0ab9-4e6c-92ae-18d2dc66a44a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PurchaseCommitmentConsiderationPaidAllocatedToInventory_d8657cd7-7268-46a3-959b-3a7cec764418" xlink:href="lgnd-20211231.xsd#lgnd_PurchaseCommitmentConsiderationPaidAllocatedToInventory"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_cfc774c3-f88d-4a6f-addf-27f032112ca5" xlink:to="loc_lgnd_PurchaseCommitmentConsiderationPaidAllocatedToInventory_d8657cd7-7268-46a3-959b-3a7cec764418" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability_6cfe05bf-cd9e-47d2-a5ee-51ac1a4a4c42" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_cfc774c3-f88d-4a6f-addf-27f032112ca5" xlink:to="loc_us-gaap_FinanceLeaseLiability_6cfe05bf-cd9e-47d2-a5ee-51ac1a4a4c42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_3ab65873-555e-4f12-b862-e1bd3f097fe7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_cfc774c3-f88d-4a6f-addf-27f032112ca5" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_3ab65873-555e-4f12-b862-e1bd3f097fe7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeFinanceLeaseRemainingLeaseTerm_3d46d66a-5ad7-4022-b218-a64b5243040d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeFinanceLeaseRemainingLeaseTerm"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_cfc774c3-f88d-4a6f-addf-27f032112ca5" xlink:to="loc_us-gaap_LesseeFinanceLeaseRemainingLeaseTerm_3d46d66a-5ad7-4022-b218-a64b5243040d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_a7870093-87be-4b2d-b3f9-04a9c3c908e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_cfc774c3-f88d-4a6f-addf-27f032112ca5" xlink:to="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_a7870093-87be-4b2d-b3f9-04a9c3c908e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_7d7df23f-e84e-46b3-9898-a1229dbef2bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_cfc774c3-f88d-4a6f-addf-27f032112ca5" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_7d7df23f-e84e-46b3-9898-a1229dbef2bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_6976b233-d0c7-47f1-9d32-198e5ff08e66" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_cfc774c3-f88d-4a6f-addf-27f032112ca5" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_6976b233-d0c7-47f1-9d32-198e5ff08e66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_2f027ec8-cd7a-4b44-bffd-96d27827c8fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_cfc774c3-f88d-4a6f-addf-27f032112ca5" xlink:to="loc_us-gaap_OperatingLeaseLiability_2f027ec8-cd7a-4b44-bffd-96d27827c8fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_a415c02b-3566-4e1f-9c2e-ccb855d4612f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_cfc774c3-f88d-4a6f-addf-27f032112ca5" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_a415c02b-3566-4e1f-9c2e-ccb855d4612f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_2af0b0ab-4a31-4523-89a8-3acc6fb613f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_cfc774c3-f88d-4a6f-addf-27f032112ca5" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_2af0b0ab-4a31-4523-89a8-3acc6fb613f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_d2c6fee9-393f-4046-96f9-6099e6984b2f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_cfc774c3-f88d-4a6f-addf-27f032112ca5" xlink:to="loc_us-gaap_OperatingLeasePayments_d2c6fee9-393f-4046-96f9-6099e6984b2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseExpense_4d3d5517-f6e2-425c-bd12-b26a178e2dc0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseExpense"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_cfc774c3-f88d-4a6f-addf-27f032112ca5" xlink:to="loc_us-gaap_OperatingLeaseExpense_4d3d5517-f6e2-425c-bd12-b26a178e2dc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubleaseIncome_28a60c66-3c71-4188-8c2e-e2cce366a477" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubleaseIncome"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_cfc774c3-f88d-4a6f-addf-27f032112ca5" xlink:to="loc_us-gaap_SubleaseIncome_28a60c66-3c71-4188-8c2e-e2cce366a477" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_83c5be6a-95a4-4641-a0cd-157889e26e72" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_cfc774c3-f88d-4a6f-addf-27f032112ca5" xlink:to="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_83c5be6a-95a4-4641-a0cd-157889e26e72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_92ea63c4-56fa-4525-b117-2b415de1afc5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_cfc774c3-f88d-4a6f-addf-27f032112ca5" xlink:to="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_92ea63c4-56fa-4525-b117-2b415de1afc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestPaymentOnLiability_8e1fe9d6-abe3-4536-9eb1-de37e81ac55a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseInterestPaymentOnLiability"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_cfc774c3-f88d-4a6f-addf-27f032112ca5" xlink:to="loc_us-gaap_FinanceLeaseInterestPaymentOnLiability_8e1fe9d6-abe3-4536-9eb1-de37e81ac55a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestExpense_8df92bc5-0a71-4f66-9d89-768ac27170ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseInterestExpense"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_cfc774c3-f88d-4a6f-addf-27f032112ca5" xlink:to="loc_us-gaap_FinanceLeaseInterestExpense_8df92bc5-0a71-4f66-9d89-768ac27170ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/LeasesOperatingandFinanceLeaseAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="lgnd-20211231.xsd#LeasesOperatingandFinanceLeaseAssetsandLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/LeasesOperatingandFinanceLeaseAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_144f9eb9-0b3d-4b51-9acf-fb9d47666f49" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_f2f7f042-c625-4d0a-bbd5-8885b3baa2ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_144f9eb9-0b3d-4b51-9acf-fb9d47666f49" xlink:to="loc_us-gaap_AssetsAbstract_f2f7f042-c625-4d0a-bbd5-8885b3baa2ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_3efa2098-4cef-4f17-9c51-f38d5f9a527b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_f2f7f042-c625-4d0a-bbd5-8885b3baa2ef" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_3efa2098-4cef-4f17-9c51-f38d5f9a527b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAsset_8bcdfad8-fa40-4af5-bcb6-3be4d05d329a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAsset"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_f2f7f042-c625-4d0a-bbd5-8885b3baa2ef" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAsset_8bcdfad8-fa40-4af5-bcb6-3be4d05d329a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_LeaseRightOfUseAsset_6c167341-655a-40b7-8bda-2c61cec90bfd" xlink:href="lgnd-20211231.xsd#lgnd_LeaseRightOfUseAsset"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_f2f7f042-c625-4d0a-bbd5-8885b3baa2ef" xlink:to="loc_lgnd_LeaseRightOfUseAsset_6c167341-655a-40b7-8bda-2c61cec90bfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAbstract_7f558bb2-ae0a-4104-a231-cc00163bee98" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_144f9eb9-0b3d-4b51-9acf-fb9d47666f49" xlink:to="loc_us-gaap_LiabilitiesAbstract_7f558bb2-ae0a-4104-a231-cc00163bee98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_d8fffbd8-0e01-4dea-ae45-fe551a303bcb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_7f558bb2-ae0a-4104-a231-cc00163bee98" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_d8fffbd8-0e01-4dea-ae45-fe551a303bcb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_9e267d7e-01ad-4ce9-becf-4a43ee0c88e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_d8fffbd8-0e01-4dea-ae45-fe551a303bcb" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_9e267d7e-01ad-4ce9-becf-4a43ee0c88e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_6279c765-6313-4c82-a2c5-8d336c52dd06" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_d8fffbd8-0e01-4dea-ae45-fe551a303bcb" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_6279c765-6313-4c82-a2c5-8d336c52dd06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_LeaseLiabilityCurrent_ba8a6e87-8e2a-43c5-bfeb-b26a6d0ee7a2" xlink:href="lgnd-20211231.xsd#lgnd_LeaseLiabilityCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_d8fffbd8-0e01-4dea-ae45-fe551a303bcb" xlink:to="loc_lgnd_LeaseLiabilityCurrent_ba8a6e87-8e2a-43c5-bfeb-b26a6d0ee7a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract_f59526f8-0102-457f-8498-b8ccbb5def65" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_7f558bb2-ae0a-4104-a231-cc00163bee98" xlink:to="loc_us-gaap_LiabilitiesNoncurrentAbstract_f59526f8-0102-457f-8498-b8ccbb5def65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_2e849332-f0b6-4f9c-8bbf-3df6121ba338" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_f59526f8-0102-457f-8498-b8ccbb5def65" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_2e849332-f0b6-4f9c-8bbf-3df6121ba338" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_40cf0b2b-66e2-41df-8657-c3e8ad0570c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_f59526f8-0102-457f-8498-b8ccbb5def65" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_40cf0b2b-66e2-41df-8657-c3e8ad0570c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_LeaseLiability_a76226fe-9d07-4a06-8cc1-0bd6977d7bb5" xlink:href="lgnd-20211231.xsd#lgnd_LeaseLiability"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_7f558bb2-ae0a-4104-a231-cc00163bee98" xlink:to="loc_lgnd_LeaseLiability_a76226fe-9d07-4a06-8cc1-0bd6977d7bb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_e8cafb6b-4b54-4367-99ab-d13adf1d7acb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_144f9eb9-0b3d-4b51-9acf-fb9d47666f49" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_e8cafb6b-4b54-4367-99ab-d13adf1d7acb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails" xlink:type="simple" xlink:href="lgnd-20211231.xsd#LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_e4ae77b7-aeea-4e5b-8b72-11e71edd4176" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_e4cc3584-86d3-433d-8892-afbf20dbce06" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_e4ae77b7-aeea-4e5b-8b72-11e71edd4176" xlink:to="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_e4cc3584-86d3-433d-8892-afbf20dbce06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_4cbbf84a-ed59-4c1c-a981-a391bb382d99" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_e4cc3584-86d3-433d-8892-afbf20dbce06" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_4cbbf84a-ed59-4c1c-a981-a391bb382d99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_43961731-2d94-44d5-be54-a50ab92359ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_e4cc3584-86d3-433d-8892-afbf20dbce06" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_43961731-2d94-44d5-be54-a50ab92359ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_7419c0ed-aa47-42b0-9ef6-d39bb753add0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_e4cc3584-86d3-433d-8892-afbf20dbce06" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_7419c0ed-aa47-42b0-9ef6-d39bb753add0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_d0a872ed-34e0-465b-898f-35c7d47b80b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_e4cc3584-86d3-433d-8892-afbf20dbce06" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_d0a872ed-34e0-465b-898f-35c7d47b80b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_953857d3-1c69-435d-b51c-11e87d0c9c81" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_e4cc3584-86d3-433d-8892-afbf20dbce06" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_953857d3-1c69-435d-b51c-11e87d0c9c81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_89b9bca0-f437-4f3d-b00e-5c8c8282301a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_e4cc3584-86d3-433d-8892-afbf20dbce06" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_89b9bca0-f437-4f3d-b00e-5c8c8282301a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_e252ed50-9100-416a-9098-5737b8964ac0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_e4cc3584-86d3-433d-8892-afbf20dbce06" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_e252ed50-9100-416a-9098-5737b8964ac0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_LesseeOperatingLeaseLiabilityTenantImprovementAllowance_232a6127-fbf5-4005-b8c5-0a68c4df89a1" xlink:href="lgnd-20211231.xsd#lgnd_LesseeOperatingLeaseLiabilityTenantImprovementAllowance"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_e4cc3584-86d3-433d-8892-afbf20dbce06" xlink:to="loc_lgnd_LesseeOperatingLeaseLiabilityTenantImprovementAllowance_232a6127-fbf5-4005-b8c5-0a68c4df89a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_30a93c25-7d6d-4b79-af1e-2812113bfe25" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_e4cc3584-86d3-433d-8892-afbf20dbce06" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_30a93c25-7d6d-4b79-af1e-2812113bfe25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_426e9388-e347-4790-8a2a-b8e03a0d514f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_e4cc3584-86d3-433d-8892-afbf20dbce06" xlink:to="loc_us-gaap_OperatingLeaseLiability_426e9388-e347-4790-8a2a-b8e03a0d514f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_ff1e78de-afec-4152-978e-768923e42820" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_e4ae77b7-aeea-4e5b-8b72-11e71edd4176" xlink:to="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_ff1e78de-afec-4152-978e-768923e42820" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_2353ece9-7c37-4b38-97f2-f69b982cc1b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_ff1e78de-afec-4152-978e-768923e42820" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_2353ece9-7c37-4b38-97f2-f69b982cc1b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_c964e4a1-f273-438b-a866-f8cba68803f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_ff1e78de-afec-4152-978e-768923e42820" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_c964e4a1-f273-438b-a866-f8cba68803f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_76b0e920-1fa8-40c2-95db-978ac75200a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_ff1e78de-afec-4152-978e-768923e42820" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_76b0e920-1fa8-40c2-95db-978ac75200a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_1210cf7b-9b14-43dd-a1bb-f979da595009" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_ff1e78de-afec-4152-978e-768923e42820" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_1210cf7b-9b14-43dd-a1bb-f979da595009" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_d0f1c5eb-7a6d-455e-83ee-f2a2b24f6c7f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_ff1e78de-afec-4152-978e-768923e42820" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_d0f1c5eb-7a6d-455e-83ee-f2a2b24f6c7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive_b449f476-a42e-497e-b203-525d70c23ea1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_ff1e78de-afec-4152-978e-768923e42820" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive_b449f476-a42e-497e-b203-525d70c23ea1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_6fd152a4-1d70-4ba8-8474-75e918f275f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_ff1e78de-afec-4152-978e-768923e42820" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_6fd152a4-1d70-4ba8-8474-75e918f275f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_FinanceLeaseLiabilityTenantImprovementAllowance_627be92a-df4a-4989-9ac9-befe8ba4ba98" xlink:href="lgnd-20211231.xsd#lgnd_FinanceLeaseLiabilityTenantImprovementAllowance"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_ff1e78de-afec-4152-978e-768923e42820" xlink:to="loc_lgnd_FinanceLeaseLiabilityTenantImprovementAllowance_627be92a-df4a-4989-9ac9-befe8ba4ba98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_f7d15fb4-74d6-4e57-9c7c-911d61aa83f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_ff1e78de-afec-4152-978e-768923e42820" xlink:to="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_f7d15fb4-74d6-4e57-9c7c-911d61aa83f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability_d3c8a743-b624-4614-9a15-aa51951e5707" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_ff1e78de-afec-4152-978e-768923e42820" xlink:to="loc_us-gaap_FinanceLeaseLiability_d3c8a743-b624-4614-9a15-aa51951e5707" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails_1" xlink:type="simple" xlink:href="lgnd-20211231.xsd#LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails_1"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.ligand.com/role/ConvertibleSeniorNotes" xlink:type="simple" xlink:href="lgnd-20211231.xsd#ConvertibleSeniorNotes"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/ConvertibleSeniorNotes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_a8a71998-5179-4351-8cab-3a88b49e03c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_2c8de28e-6f19-4632-8152-926c46686328" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_a8a71998-5179-4351-8cab-3a88b49e03c6" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_2c8de28e-6f19-4632-8152-926c46686328" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/ConvertibleSeniorNotesTables" xlink:type="simple" xlink:href="lgnd-20211231.xsd#ConvertibleSeniorNotesTables"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/ConvertibleSeniorNotesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_6992b06f-1f8b-4bca-a658-240a77ebe1af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtTableTextBlock_d77c2a9c-3703-4755-a8e1-223f39eb773c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDebtTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_6992b06f-1f8b-4bca-a658-240a77ebe1af" xlink:to="loc_us-gaap_ScheduleOfDebtTableTextBlock_d77c2a9c-3703-4755-a8e1-223f39eb773c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/ConvertibleSeniorNotesNarrativeDetails" xlink:type="simple" xlink:href="lgnd-20211231.xsd#ConvertibleSeniorNotesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/ConvertibleSeniorNotesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_dc776402-7285-4b54-8722-06ff903e0a64" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_31849f3b-be78-4cb2-ad35-3b6fcd0f68c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_dc776402-7285-4b54-8722-06ff903e0a64" xlink:to="loc_us-gaap_DebtInstrumentTable_31849f3b-be78-4cb2-ad35-3b6fcd0f68c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_5ec05f6a-ed21-401a-a58b-07d341363ae1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_31849f3b-be78-4cb2-ad35-3b6fcd0f68c2" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_5ec05f6a-ed21-401a-a58b-07d341363ae1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_7d6f923e-92db-4236-82fd-a26bd2332daf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_5ec05f6a-ed21-401a-a58b-07d341363ae1" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_7d6f923e-92db-4236-82fd-a26bd2332daf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherExpenseMember_9ee0abdb-68ac-4368-b7b1-a6ab9cb2f958" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_7d6f923e-92db-4236-82fd-a26bd2332daf" xlink:to="loc_us-gaap_OtherExpenseMember_9ee0abdb-68ac-4368-b7b1-a6ab9cb2f958" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_9eaeafd3-573d-4183-b8aa-7ded150b64fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_31849f3b-be78-4cb2-ad35-3b6fcd0f68c2" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_9eaeafd3-573d-4183-b8aa-7ded150b64fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_b3e07e26-1cd2-4e08-80e1-c6a4ef556ea5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_9eaeafd3-573d-4183-b8aa-7ded150b64fb" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_b3e07e26-1cd2-4e08-80e1-c6a4ef556ea5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleNotesPayableMember_10774392-7a5b-4880-853e-47b6173552d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleNotesPayableMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_b3e07e26-1cd2-4e08-80e1-c6a4ef556ea5" xlink:to="loc_us-gaap_ConvertibleNotesPayableMember_10774392-7a5b-4880-853e-47b6173552d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_fe5938d7-f9a2-47a6-bff6-aad39f6ea3bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_31849f3b-be78-4cb2-ad35-3b6fcd0f68c2" xlink:to="loc_us-gaap_DebtInstrumentAxis_fe5938d7-f9a2-47a6-bff6-aad39f6ea3bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_1a082805-25b6-4991-9b39-983e58db32ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_fe5938d7-f9a2-47a6-bff6-aad39f6ea3bf" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_1a082805-25b6-4991-9b39-983e58db32ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ConvertibleSeniorNotesDue2019Member_8ce1425a-8bfb-4af2-90e9-c36eab6184a0" xlink:href="lgnd-20211231.xsd#lgnd_ConvertibleSeniorNotesDue2019Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1a082805-25b6-4991-9b39-983e58db32ba" xlink:to="loc_lgnd_ConvertibleSeniorNotesDue2019Member_8ce1425a-8bfb-4af2-90e9-c36eab6184a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ConvertibleSeniorNotesDue2023Member_46177839-1ab1-41a6-b8fc-3f6ed0a70c3f" xlink:href="lgnd-20211231.xsd#lgnd_ConvertibleSeniorNotesDue2023Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1a082805-25b6-4991-9b39-983e58db32ba" xlink:to="loc_lgnd_ConvertibleSeniorNotesDue2023Member_46177839-1ab1-41a6-b8fc-3f6ed0a70c3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_52d04c39-abcc-4cec-a40c-9354238889fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_31849f3b-be78-4cb2-ad35-3b6fcd0f68c2" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_52d04c39-abcc-4cec-a40c-9354238889fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_31e5c6bf-27a2-47d9-abb9-a023a6bc7352" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_52d04c39-abcc-4cec-a40c-9354238889fb" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_31e5c6bf-27a2-47d9-abb9-a023a6bc7352" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember_7dd50121-b364-485f-b53e-f3820e3c32f4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_31e5c6bf-27a2-47d9-abb9-a023a6bc7352" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember_7dd50121-b364-485f-b53e-f3820e3c32f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_21729284-8d82-4375-b6b6-e6a070432af6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_31e5c6bf-27a2-47d9-abb9-a023a6bc7352" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_21729284-8d82-4375-b6b6-e6a070432af6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_4b469371-aa77-4629-9fe4-4f68d0b72cff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_31849f3b-be78-4cb2-ad35-3b6fcd0f68c2" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_4b469371-aa77-4629-9fe4-4f68d0b72cff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_dab54512-62fd-4485-baaf-cde6394886f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_4b469371-aa77-4629-9fe4-4f68d0b72cff" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_dab54512-62fd-4485-baaf-cde6394886f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_fb382041-8d9f-423d-b806-770045a7d654" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_dab54512-62fd-4485-baaf-cde6394886f8" xlink:to="loc_us-gaap_SubsequentEventMember_fb382041-8d9f-423d-b806-770045a7d654" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_3cbdccb5-91f1-4d96-ba76-ab237a466acf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_31849f3b-be78-4cb2-ad35-3b6fcd0f68c2" xlink:to="loc_us-gaap_DebtInstrumentLineItems_3cbdccb5-91f1-4d96-ba76-ab237a466acf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_1d8f6da1-6390-4ff3-8cbf-6d88b6b778a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3cbdccb5-91f1-4d96-ba76-ab237a466acf" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_1d8f6da1-6390-4ff3-8cbf-6d88b6b778a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_263ddd47-6856-44b0-824a-1e592eabdeed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3cbdccb5-91f1-4d96-ba76-ab237a466acf" xlink:to="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_263ddd47-6856-44b0-824a-1e592eabdeed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_bd1926ad-8f5e-4051-bf2d-d03f9d6ec92c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3cbdccb5-91f1-4d96-ba76-ab237a466acf" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_bd1926ad-8f5e-4051-bf2d-d03f9d6ec92c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_215d617b-a24a-48c9-9d7c-6a19aa782d83" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3cbdccb5-91f1-4d96-ba76-ab237a466acf" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_215d617b-a24a-48c9-9d7c-6a19aa782d83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_53d9ac47-622d-4a4a-ab83-2eecfcf327d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3cbdccb5-91f1-4d96-ba76-ab237a466acf" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_53d9ac47-622d-4a4a-ab83-2eecfcf327d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_afdbfa24-a6b5-4c01-90ab-654af923486b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3cbdccb5-91f1-4d96-ba76-ab237a466acf" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_afdbfa24-a6b5-4c01-90ab-654af923486b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_be865312-65ae-4be5-8296-e6f66f3082c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdTradingDays"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3cbdccb5-91f1-4d96-ba76-ab237a466acf" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_be865312-65ae-4be5-8296-e6f66f3082c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_9f6c50fe-5b70-4b37-b124-b50f0f44ca5f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3cbdccb5-91f1-4d96-ba76-ab237a466acf" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_9f6c50fe-5b70-4b37-b124-b50f0f44ca5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_cd2dcd1b-f35c-429a-ad59-acded6e03c19" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3cbdccb5-91f1-4d96-ba76-ab237a466acf" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_cd2dcd1b-f35c-429a-ad59-acded6e03c19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_DebtInstrumentConvertibleMaximumThresholdPercentageofDebtTradingPriceTrigger_be0f0595-46e8-4101-bef8-c3259241712a" xlink:href="lgnd-20211231.xsd#lgnd_DebtInstrumentConvertibleMaximumThresholdPercentageofDebtTradingPriceTrigger"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3cbdccb5-91f1-4d96-ba76-ab237a466acf" xlink:to="loc_lgnd_DebtInstrumentConvertibleMaximumThresholdPercentageofDebtTradingPriceTrigger_be0f0595-46e8-4101-bef8-c3259241712a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal_28d2abf5-68a0-4e55-ab14-cec32e3573ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3cbdccb5-91f1-4d96-ba76-ab237a466acf" xlink:to="loc_us-gaap_DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal_28d2abf5-68a0-4e55-ab14-cec32e3573ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_DebtInstrumentConvertibleIncreaseDecreaseIfConvertedValueInExcessOfPrincipal_89a946ed-3450-4a21-ad0e-5cd4873b3930" xlink:href="lgnd-20211231.xsd#lgnd_DebtInstrumentConvertibleIncreaseDecreaseIfConvertedValueInExcessOfPrincipal"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3cbdccb5-91f1-4d96-ba76-ab237a466acf" xlink:to="loc_lgnd_DebtInstrumentConvertibleIncreaseDecreaseIfConvertedValueInExcessOfPrincipal_89a946ed-3450-4a21-ad0e-5cd4873b3930" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_e7843c22-b768-45de-8063-4df1528d25c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3cbdccb5-91f1-4d96-ba76-ab237a466acf" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_e7843c22-b768-45de-8063-4df1528d25c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature_e435a8e0-38e8-4005-b289-74ad521ba857" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3cbdccb5-91f1-4d96-ba76-ab237a466acf" xlink:to="loc_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature_e435a8e0-38e8-4005-b289-74ad521ba857" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_e5416c34-0019-4fa0-8a43-082ff8f864ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3cbdccb5-91f1-4d96-ba76-ab237a466acf" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_e5416c34-0019-4fa0-8a43-082ff8f864ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfNotesPayable_fa65c44b-2ed5-4c67-aab9-7f00b271b0cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfNotesPayable"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3cbdccb5-91f1-4d96-ba76-ab237a466acf" xlink:to="loc_us-gaap_RepaymentsOfNotesPayable_fa65c44b-2ed5-4c67-aab9-7f00b271b0cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedPremium_6946f177-8f9e-4146-a28b-79d746002494" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedPremium"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3cbdccb5-91f1-4d96-ba76-ab237a466acf" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedPremium_6946f177-8f9e-4146-a28b-79d746002494" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeGainLossOnDerivativeNet_d97cb466-6f28-4d45-8097-d6f031598385" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeGainLossOnDerivativeNet"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3cbdccb5-91f1-4d96-ba76-ab237a466acf" xlink:to="loc_us-gaap_DerivativeGainLossOnDerivativeNet_d97cb466-6f28-4d45-8097-d6f031598385" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeGainLossOnDerivativeNet_c6836c98-8fdd-475f-ae9b-8c68f9e7c220" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeGainLossOnDerivativeNet"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3cbdccb5-91f1-4d96-ba76-ab237a466acf" xlink:to="loc_us-gaap_DerivativeGainLossOnDerivativeNet_c6836c98-8fdd-475f-ae9b-8c68f9e7c220" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_ce896489-81cb-4566-a056-e03c3cb0cb77" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3cbdccb5-91f1-4d96-ba76-ab237a466acf" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_ce896489-81cb-4566-a056-e03c3cb0cb77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ExercisePriceofConvertibleBondHedge_207a41ac-2d9f-4f06-b60e-483b1af2b73e" xlink:href="lgnd-20211231.xsd#lgnd_ExercisePriceofConvertibleBondHedge"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3cbdccb5-91f1-4d96-ba76-ab237a466acf" xlink:to="loc_lgnd_ExercisePriceofConvertibleBondHedge_207a41ac-2d9f-4f06-b60e-483b1af2b73e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_e9a84c52-64db-4328-b383-35da1334d2df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3cbdccb5-91f1-4d96-ba76-ab237a466acf" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_e9a84c52-64db-4328-b383-35da1334d2df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsGross_145dc2b2-c7fe-42a7-b9f0-e66fae00c828" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFinanceCostsGross"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3cbdccb5-91f1-4d96-ba76-ab237a466acf" xlink:to="loc_us-gaap_DeferredFinanceCostsGross_145dc2b2-c7fe-42a7-b9f0-e66fae00c828" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRepurchaseAmount_eaa8820b-7b4e-4a42-a41c-dd4dc0ea1055" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRepurchaseAmount"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3cbdccb5-91f1-4d96-ba76-ab237a466acf" xlink:to="loc_us-gaap_DebtInstrumentRepurchaseAmount_eaa8820b-7b4e-4a42-a41c-dd4dc0ea1055" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_RepaymentsOfNotesPayableInterestPortion_73864c36-9e86-4bbe-a0d1-f75f0659b005" xlink:href="lgnd-20211231.xsd#lgnd_RepaymentsOfNotesPayableInterestPortion"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3cbdccb5-91f1-4d96-ba76-ab237a466acf" xlink:to="loc_lgnd_RepaymentsOfNotesPayableInterestPortion_73864c36-9e86-4bbe-a0d1-f75f0659b005" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_IncreaseDecreaseInDebtDiscount_4d7a7f6c-b462-4f5f-ac37-caedb1bc9b16" xlink:href="lgnd-20211231.xsd#lgnd_IncreaseDecreaseInDebtDiscount"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3cbdccb5-91f1-4d96-ba76-ab237a466acf" xlink:to="loc_lgnd_IncreaseDecreaseInDebtDiscount_4d7a7f6c-b462-4f5f-ac37-caedb1bc9b16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_165bb370-c7b9-4e3b-ae6d-aa75bfc7114b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3cbdccb5-91f1-4d96-ba76-ab237a466acf" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_165bb370-c7b9-4e3b-ae6d-aa75bfc7114b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PaymentsforConvertibleBondHedges_cfb9688b-19c2-426b-85fe-fde77e05e03f" xlink:href="lgnd-20211231.xsd#lgnd_PaymentsforConvertibleBondHedges"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3cbdccb5-91f1-4d96-ba76-ab237a466acf" xlink:to="loc_lgnd_PaymentsforConvertibleBondHedges_cfb9688b-19c2-426b-85fe-fde77e05e03f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_214d243f-5779-46cd-add8-b5d821fe45a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3cbdccb5-91f1-4d96-ba76-ab237a466acf" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_214d243f-5779-46cd-add8-b5d821fe45a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PaymentsToUnwindWarrants_e017c6d2-d6a0-4d45-b526-e7af65037ab1" xlink:href="lgnd-20211231.xsd#lgnd_PaymentsToUnwindWarrants"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3cbdccb5-91f1-4d96-ba76-ab237a466acf" xlink:to="loc_lgnd_PaymentsToUnwindWarrants_e017c6d2-d6a0-4d45-b526-e7af65037ab1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ProceedsFromUnwindingConvertibleBondHedges_09ea9513-4cba-480d-a11c-e518dabf08c7" xlink:href="lgnd-20211231.xsd#lgnd_ProceedsFromUnwindingConvertibleBondHedges"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3cbdccb5-91f1-4d96-ba76-ab237a466acf" xlink:to="loc_lgnd_ProceedsFromUnwindingConvertibleBondHedges_09ea9513-4cba-480d-a11c-e518dabf08c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_NumberOfOptionsUnderConvertibleBondHedges_c7dcd601-c71a-4b06-9597-69002c2a0b32" xlink:href="lgnd-20211231.xsd#lgnd_NumberOfOptionsUnderConvertibleBondHedges"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3cbdccb5-91f1-4d96-ba76-ab237a466acf" xlink:to="loc_lgnd_NumberOfOptionsUnderConvertibleBondHedges_c7dcd601-c71a-4b06-9597-69002c2a0b32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/ConvertibleSeniorNotesEquityandLiabilityComponentsofFinancingArrangementsDetails" xlink:type="simple" xlink:href="lgnd-20211231.xsd#ConvertibleSeniorNotesEquityandLiabilityComponentsofFinancingArrangementsDetails"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/ConvertibleSeniorNotesEquityandLiabilityComponentsofFinancingArrangementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_e3d73a0e-cfc4-4f5e-9b7f-10ce34737121" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_917241e5-2bba-4cdf-b7da-60473a2a52d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_e3d73a0e-cfc4-4f5e-9b7f-10ce34737121" xlink:to="loc_us-gaap_DebtInstrumentTable_917241e5-2bba-4cdf-b7da-60473a2a52d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_d1769b50-91a3-4129-a865-bc64ac5afe89" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_917241e5-2bba-4cdf-b7da-60473a2a52d7" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_d1769b50-91a3-4129-a865-bc64ac5afe89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_91a5b5e9-100d-4c8e-865e-a21a39a0b4df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_d1769b50-91a3-4129-a865-bc64ac5afe89" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_91a5b5e9-100d-4c8e-865e-a21a39a0b4df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleNotesPayableMember_12210cdd-2e0b-4449-adaa-601c7ded6b56" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleNotesPayableMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_91a5b5e9-100d-4c8e-865e-a21a39a0b4df" xlink:to="loc_us-gaap_ConvertibleNotesPayableMember_12210cdd-2e0b-4449-adaa-601c7ded6b56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_c663dcd1-dd1c-43f3-8701-1bf66a57e8b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_917241e5-2bba-4cdf-b7da-60473a2a52d7" xlink:to="loc_us-gaap_DebtInstrumentAxis_c663dcd1-dd1c-43f3-8701-1bf66a57e8b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_7ee37a51-3761-49e4-b14b-7ac6d927678b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_c663dcd1-dd1c-43f3-8701-1bf66a57e8b9" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_7ee37a51-3761-49e4-b14b-7ac6d927678b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ConvertibleSeniorNotesDue2023Member_34a28e3a-0095-4487-976f-2cc2d30bbb45" xlink:href="lgnd-20211231.xsd#lgnd_ConvertibleSeniorNotesDue2023Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7ee37a51-3761-49e4-b14b-7ac6d927678b" xlink:to="loc_lgnd_ConvertibleSeniorNotesDue2023Member_34a28e3a-0095-4487-976f-2cc2d30bbb45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_69eed360-00d4-458b-9607-1f44e769c60f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_917241e5-2bba-4cdf-b7da-60473a2a52d7" xlink:to="loc_us-gaap_DebtInstrumentLineItems_69eed360-00d4-458b-9607-1f44e769c60f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermNotesPayableCurrentAndNoncurrentTotalAbstract_0d1e4955-7eb8-426a-9f00-bc29e7bda00d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermNotesPayableCurrentAndNoncurrentTotalAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_69eed360-00d4-458b-9607-1f44e769c60f" xlink:to="loc_us-gaap_LongtermNotesPayableCurrentAndNoncurrentTotalAbstract_0d1e4955-7eb8-426a-9f00-bc29e7bda00d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_8fefd10d-ca79-4d94-9276-e594b552e54f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermNotesPayableCurrentAndNoncurrentTotalAbstract_0d1e4955-7eb8-426a-9f00-bc29e7bda00d" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_8fefd10d-ca79-4d94-9276-e594b552e54f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_3aff9655-5d55-4376-9fae-e372c94086bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermNotesPayableCurrentAndNoncurrentTotalAbstract_0d1e4955-7eb8-426a-9f00-bc29e7bda00d" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_3aff9655-5d55-4376-9fae-e372c94086bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermNotesPayable_24c5f927-5ffb-4457-8aed-67b80a6e55d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermNotesPayable"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermNotesPayableCurrentAndNoncurrentTotalAbstract_0d1e4955-7eb8-426a-9f00-bc29e7bda00d" xlink:to="loc_us-gaap_LongTermNotesPayable_24c5f927-5ffb-4457-8aed-67b80a6e55d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_49b68a9f-754f-43a0-a1bb-11b792b866e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_69eed360-00d4-458b-9607-1f44e769c60f" xlink:to="loc_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_49b68a9f-754f-43a0-a1bb-11b792b866e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtFairValueDisclosures_88f3cc44-342f-46ee-9689-8001263ed6e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtFairValueDisclosures"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_69eed360-00d4-458b-9607-1f44e769c60f" xlink:to="loc_us-gaap_ConvertibleDebtFairValueDisclosures_88f3cc44-342f-46ee-9689-8001263ed6e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/BalanceSheetAccountDetails" xlink:type="simple" xlink:href="lgnd-20211231.xsd#BalanceSheetAccountDetails"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/BalanceSheetAccountDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_OtherBalanceSheetDetailsAbstract_271992ec-868c-434c-8dcb-10c4e417eb17" xlink:href="lgnd-20211231.xsd#lgnd_OtherBalanceSheetDetailsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_39d9da46-3a50-4322-9b9d-16eb7018ae61" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_OtherBalanceSheetDetailsAbstract_271992ec-868c-434c-8dcb-10c4e417eb17" xlink:to="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_39d9da46-3a50-4322-9b9d-16eb7018ae61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/BalanceSheetAccountDetailsTables" xlink:type="simple" xlink:href="lgnd-20211231.xsd#BalanceSheetAccountDetailsTables"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/BalanceSheetAccountDetailsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_OtherBalanceSheetDetailsAbstract_4ac3c0a4-266f-4b99-ae93-f499284b838a" xlink:href="lgnd-20211231.xsd#lgnd_OtherBalanceSheetDetailsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesTextBlock_d9485c6a-6ee9-4248-bd46-57925ef43359" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_OtherBalanceSheetDetailsAbstract_4ac3c0a4-266f-4b99-ae93-f499284b838a" xlink:to="loc_us-gaap_MarketableSecuritiesTextBlock_d9485c6a-6ee9-4248-bd46-57925ef43359" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_b2553e89-558c-4c1a-8ae5-ffe125a2f1be" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_OtherBalanceSheetDetailsAbstract_4ac3c0a4-266f-4b99-ae93-f499284b838a" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_b2553e89-558c-4c1a-8ae5-ffe125a2f1be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_2fe2168c-565b-48a5-b3b3-ac224549876b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_OtherBalanceSheetDetailsAbstract_4ac3c0a4-266f-4b99-ae93-f499284b838a" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_2fe2168c-565b-48a5-b3b3-ac224549876b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_2b541041-e48c-402b-82d8-96ec1fa4b6c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_OtherBalanceSheetDetailsAbstract_4ac3c0a4-266f-4b99-ae93-f499284b838a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_2b541041-e48c-402b-82d8-96ec1fa4b6c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_d7068098-910d-4aa4-8fcf-06d21b0fc8f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_OtherBalanceSheetDetailsAbstract_4ac3c0a4-266f-4b99-ae93-f499284b838a" xlink:to="loc_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_d7068098-910d-4aa4-8fcf-06d21b0fc8f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_6f38c694-687c-45af-aeda-70aa5118aa82" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_OtherBalanceSheetDetailsAbstract_4ac3c0a4-266f-4b99-ae93-f499284b838a" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_6f38c694-687c-45af-aeda-70aa5118aa82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ScheduleofContingentLiabilitiesTableTextBlock_1d5f883e-6dc6-4787-a751-c391b773b65a" xlink:href="lgnd-20211231.xsd#lgnd_ScheduleofContingentLiabilitiesTableTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_OtherBalanceSheetDetailsAbstract_4ac3c0a4-266f-4b99-ae93-f499284b838a" xlink:to="loc_lgnd_ScheduleofContingentLiabilitiesTableTextBlock_1d5f883e-6dc6-4787-a751-c391b773b65a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/BalanceSheetAccountDetailsInvestmentCategoriesDetails" xlink:type="simple" xlink:href="lgnd-20211231.xsd#BalanceSheetAccountDetailsInvestmentCategoriesDetails"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/BalanceSheetAccountDetailsInvestmentCategoriesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_OtherBalanceSheetDetailsAbstract_87b1d53d-30b3-4a4e-b0d6-549fe091dff8" xlink:href="lgnd-20211231.xsd#lgnd_OtherBalanceSheetDetailsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_9e2cfea5-636f-4367-911d-b1a969895558" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_OtherBalanceSheetDetailsAbstract_87b1d53d-30b3-4a4e-b0d6-549fe091dff8" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_9e2cfea5-636f-4367-911d-b1a969895558" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_4c7197d8-9f32-493c-8e68-9d39cc97bcd8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_9e2cfea5-636f-4367-911d-b1a969895558" xlink:to="loc_us-gaap_InvestmentTypeAxis_4c7197d8-9f32-493c-8e68-9d39cc97bcd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_e8f5871e-aaa5-4f28-93b2-4f88abb36b6c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeAxis_4c7197d8-9f32-493c-8e68-9d39cc97bcd8" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_e8f5871e-aaa5-4f28-93b2-4f88abb36b6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestmentsMember_5c2610f5-2331-491d-b115-478b505d88fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermInvestmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_e8f5871e-aaa5-4f28-93b2-4f88abb36b6c" xlink:to="loc_us-gaap_ShortTermInvestmentsMember_5c2610f5-2331-491d-b115-478b505d88fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MutualFundMember_6d12a0f3-8339-4a2c-94fd-c270d83322a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MutualFundMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermInvestmentsMember_5c2610f5-2331-491d-b115-478b505d88fc" xlink:to="loc_us-gaap_MutualFundMember_6d12a0f3-8339-4a2c-94fd-c270d83322a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DemandDepositsMember_7111ee51-d8e9-46f5-acf1-cf231134f149" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DemandDepositsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermInvestmentsMember_5c2610f5-2331-491d-b115-478b505d88fc" xlink:to="loc_us-gaap_DemandDepositsMember_7111ee51-d8e9-46f5-acf1-cf231134f149" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_4b569812-646a-48e5-853a-2beb2ed49417" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermInvestmentsMember_5c2610f5-2331-491d-b115-478b505d88fc" xlink:to="loc_us-gaap_CommercialPaperMember_4b569812-646a-48e5-853a-2beb2ed49417" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_82a81814-a545-409d-a622-773d27cefeda" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermInvestmentsMember_5c2610f5-2331-491d-b115-478b505d88fc" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_82a81814-a545-409d-a622-773d27cefeda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AgencySecuritiesMember_7bfa6c90-8a6e-45f8-b794-52db674f7c15" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AgencySecuritiesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermInvestmentsMember_5c2610f5-2331-491d-b115-478b505d88fc" xlink:to="loc_us-gaap_AgencySecuritiesMember_7bfa6c90-8a6e-45f8-b794-52db674f7c15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember_72d26381-e471-4de5-bb84-94515c8962ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermInvestmentsMember_5c2610f5-2331-491d-b115-478b505d88fc" xlink:to="loc_us-gaap_EquitySecuritiesMember_72d26381-e471-4de5-bb84-94515c8962ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentDebtSecuritiesMember_d6f4ee38-792f-4116-943c-738239a94bc3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentDebtSecuritiesMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermInvestmentsMember_5c2610f5-2331-491d-b115-478b505d88fc" xlink:to="loc_us-gaap_USGovernmentDebtSecuritiesMember_d6f4ee38-792f-4116-943c-738239a94bc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_90c2fe31-61e5-4c40-9344-c1dfb9db5681" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermInvestmentsMember_5c2610f5-2331-491d-b115-478b505d88fc" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_90c2fe31-61e5-4c40-9344-c1dfb9db5681" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_8fcf0c08-da85-40c4-a8ac-1afcc4e10108" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermInvestmentsMember_5c2610f5-2331-491d-b115-478b505d88fc" xlink:to="loc_us-gaap_WarrantMember_8fcf0c08-da85-40c4-a8ac-1afcc4e10108" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_5659e983-39df-4bd5-9733-72efefd9bb0d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_9e2cfea5-636f-4367-911d-b1a969895558" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_5659e983-39df-4bd5-9733-72efefd9bb0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_afe6b300-0255-4890-8e9c-b86bc0def127" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_5659e983-39df-4bd5-9733-72efefd9bb0d" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_afe6b300-0255-4890-8e9c-b86bc0def127" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_18c531a4-d729-44f5-81a5-f47436f74809" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_5659e983-39df-4bd5-9733-72efefd9bb0d" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_18c531a4-d729-44f5-81a5-f47436f74809" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_1b9e11d6-edfc-42d6-be3e-63909df782bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_5659e983-39df-4bd5-9733-72efefd9bb0d" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_1b9e11d6-edfc-42d6-be3e-63909df782bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_6f7f6bc7-57a3-4b34-b417-aed94784dea0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_5659e983-39df-4bd5-9733-72efefd9bb0d" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_6f7f6bc7-57a3-4b34-b417-aed94784dea0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/BalanceSheetAccountDetailsNarrativeDetails" xlink:type="simple" xlink:href="lgnd-20211231.xsd#BalanceSheetAccountDetailsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/BalanceSheetAccountDetailsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_OtherBalanceSheetDetailsAbstract_365cc20b-907a-4a21-9419-e2d724137263" xlink:href="lgnd-20211231.xsd#lgnd_OtherBalanceSheetDetailsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentsTable_4a97391f-3097-4925-9e88-1fe4a445084d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfInvestmentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_OtherBalanceSheetDetailsAbstract_365cc20b-907a-4a21-9419-e2d724137263" xlink:to="loc_us-gaap_ScheduleOfInvestmentsTable_4a97391f-3097-4925-9e88-1fe4a445084d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_43638ca6-30e4-4fe5-8143-e5f0eea7f8a1" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsTable_4a97391f-3097-4925-9e88-1fe4a445084d" xlink:to="loc_srt_RangeAxis_43638ca6-30e4-4fe5-8143-e5f0eea7f8a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_08aa7cb9-d181-4ce2-ac29-c2f2bd283eae" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_43638ca6-30e4-4fe5-8143-e5f0eea7f8a1" xlink:to="loc_srt_RangeMember_08aa7cb9-d181-4ce2-ac29-c2f2bd283eae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_1a9622fb-8a28-4e30-b488-83771f4e5c89" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_08aa7cb9-d181-4ce2-ac29-c2f2bd283eae" xlink:to="loc_srt_MinimumMember_1a9622fb-8a28-4e30-b488-83771f4e5c89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_70f9e66f-8b28-434b-91a2-24d13568d9c8" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_08aa7cb9-d181-4ce2-ac29-c2f2bd283eae" xlink:to="loc_srt_MaximumMember_70f9e66f-8b28-434b-91a2-24d13568d9c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentsLineItems_c1ee8fee-2106-40e8-b993-eea60f5c9dfc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfInvestmentsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsTable_4a97391f-3097-4925-9e88-1fe4a445084d" xlink:to="loc_us-gaap_ScheduleOfInvestmentsLineItems_c1ee8fee-2106-40e8-b993-eea60f5c9dfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_bb66ad8a-fbc4-4552-a358-b5baec903c47" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_c1ee8fee-2106-40e8-b993-eea60f5c9dfc" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_bb66ad8a-fbc4-4552-a358-b5baec903c47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_c1b166a5-1b79-49ba-864d-369c35e998aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_c1ee8fee-2106-40e8-b993-eea60f5c9dfc" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_c1b166a5-1b79-49ba-864d-369c35e998aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_75d9d6ec-2e95-413c-8db4-1b3338fbad45" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_c1ee8fee-2106-40e8-b993-eea60f5c9dfc" xlink:to="loc_us-gaap_Depreciation_75d9d6ec-2e95-413c-8db4-1b3338fbad45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_1625a876-0714-4a88-aa50-9dd8257dfa0b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_c1ee8fee-2106-40e8-b993-eea60f5c9dfc" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_1625a876-0714-4a88-aa50-9dd8257dfa0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_6e62cf5a-b855-4bfe-a2ef-62adf4fe865f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_c1ee8fee-2106-40e8-b993-eea60f5c9dfc" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_6e62cf5a-b855-4bfe-a2ef-62adf4fe865f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_0cc21e0f-e1f8-4f0a-8d0c-7e986af9e764" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_c1ee8fee-2106-40e8-b993-eea60f5c9dfc" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_0cc21e0f-e1f8-4f0a-8d0c-7e986af9e764" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_b076f095-85af-4669-aa9b-adf116ea3255" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_c1ee8fee-2106-40e8-b993-eea60f5c9dfc" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_b076f095-85af-4669-aa9b-adf116ea3255" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_8bd6349f-571a-4e41-a5e6-e84e66a2ca5a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_c1ee8fee-2106-40e8-b993-eea60f5c9dfc" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_8bd6349f-571a-4e41-a5e6-e84e66a2ca5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_cb721dfa-263c-4eed-83a9-a31288c13f2a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_c1ee8fee-2106-40e8-b993-eea60f5c9dfc" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_cb721dfa-263c-4eed-83a9-a31288c13f2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_7ebd01bf-869e-4b5c-93e2-c47d801ca65e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_c1ee8fee-2106-40e8-b993-eea60f5c9dfc" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_7ebd01bf-869e-4b5c-93e2-c47d801ca65e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_NumberOfContingentValueRightAgreements_818eb49c-75e5-4cfb-b571-b087332a8691" xlink:href="lgnd-20211231.xsd#lgnd_NumberOfContingentValueRightAgreements"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_c1ee8fee-2106-40e8-b993-eea60f5c9dfc" xlink:to="loc_lgnd_NumberOfContingentValueRightAgreements_818eb49c-75e5-4cfb-b571-b087332a8691" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/BalanceSheetAccountDetailsAvailableforSaleDebtSecuritiesbyContractualMaturityDetails" xlink:type="simple" xlink:href="lgnd-20211231.xsd#BalanceSheetAccountDetailsAvailableforSaleDebtSecuritiesbyContractualMaturityDetails"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/BalanceSheetAccountDetailsAvailableforSaleDebtSecuritiesbyContractualMaturityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_OtherBalanceSheetDetailsAbstract_f0c218a4-9dc9-473c-99a6-aff417e6a745" xlink:href="lgnd-20211231.xsd#lgnd_OtherBalanceSheetDetailsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract_d62714af-89d5-4410-a6dc-b39c8d626e2f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_OtherBalanceSheetDetailsAbstract_f0c218a4-9dc9-473c-99a6-aff417e6a745" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract_d62714af-89d5-4410-a6dc-b39c8d626e2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_65f130f2-716d-4880-940d-9d1bfe2a0397" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract_d62714af-89d5-4410-a6dc-b39c8d626e2f" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_65f130f2-716d-4880-940d-9d1bfe2a0397" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_884d8ff2-96c9-49d7-9bf5-308a985e0f1b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract_d62714af-89d5-4410-a6dc-b39c8d626e2f" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_884d8ff2-96c9-49d7-9bf5-308a985e0f1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateAfterYearFive_2dc96dd2-69ab-4bd9-a1f7-43f111433fef" xlink:href="lgnd-20211231.xsd#lgnd_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateAfterYearFive"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract_d62714af-89d5-4410-a6dc-b39c8d626e2f" xlink:to="loc_lgnd_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateAfterYearFive_2dc96dd2-69ab-4bd9-a1f7-43f111433fef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis_57879669-1e8f-4ec5-bf13-62759ff0180c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HeldToMaturitySecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract_d62714af-89d5-4410-a6dc-b39c8d626e2f" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis_57879669-1e8f-4ec5-bf13-62759ff0180c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_f363c94a-9020-4139-ac86-852df0cc584a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_OtherBalanceSheetDetailsAbstract_f0c218a4-9dc9-473c-99a6-aff417e6a745" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_f363c94a-9020-4139-ac86-852df0cc584a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_d1d9f70b-710a-4922-a429-abad24f57715" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_f363c94a-9020-4139-ac86-852df0cc584a" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_d1d9f70b-710a-4922-a429-abad24f57715" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_7f08b9e8-068b-4f8e-ba00-d6b1978c4602" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_f363c94a-9020-4139-ac86-852df0cc584a" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_7f08b9e8-068b-4f8e-ba00-d6b1978c4602" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearFive_46e4065b-3a2b-4e7b-b46a-f673e49ecf28" xlink:href="lgnd-20211231.xsd#lgnd_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearFive"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_f363c94a-9020-4139-ac86-852df0cc584a" xlink:to="loc_lgnd_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearFive_46e4065b-3a2b-4e7b-b46a-f673e49ecf28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_66bcf6fc-15f6-4f41-9930-6ad9f992d684" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_f363c94a-9020-4139-ac86-852df0cc584a" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_66bcf6fc-15f6-4f41-9930-6ad9f992d684" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/BalanceSheetAccountDetailsAvailableforSaleDebtSecuritiesinanUnrealizedLossPositionDetails" xlink:type="simple" xlink:href="lgnd-20211231.xsd#BalanceSheetAccountDetailsAvailableforSaleDebtSecuritiesinanUnrealizedLossPositionDetails"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/BalanceSheetAccountDetailsAvailableforSaleDebtSecuritiesinanUnrealizedLossPositionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_OtherBalanceSheetDetailsAbstract_f1eec772-aa51-4f62-835d-544a7d797ef7" xlink:href="lgnd-20211231.xsd#lgnd_OtherBalanceSheetDetailsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable_c5cc5be8-c088-4854-b3b2-511108c06ee7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_OtherBalanceSheetDetailsAbstract_f1eec772-aa51-4f62-835d-544a7d797ef7" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable_c5cc5be8-c088-4854-b3b2-511108c06ee7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_33560243-62cb-4e16-ad77-80a182fd8a30" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable_c5cc5be8-c088-4854-b3b2-511108c06ee7" xlink:to="loc_us-gaap_FinancialInstrumentAxis_33560243-62cb-4e16-ad77-80a182fd8a30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b9de9dde-7cc0-4323-9eb4-f99f45818263" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_33560243-62cb-4e16-ad77-80a182fd8a30" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b9de9dde-7cc0-4323-9eb4-f99f45818263" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DemandDepositsMember_e62999b1-41d6-4d58-8142-cebef25e08cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DemandDepositsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b9de9dde-7cc0-4323-9eb4-f99f45818263" xlink:to="loc_us-gaap_DemandDepositsMember_e62999b1-41d6-4d58-8142-cebef25e08cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_81faa6ee-b678-4677-94ca-53ad6853ac2d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b9de9dde-7cc0-4323-9eb4-f99f45818263" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_81faa6ee-b678-4677-94ca-53ad6853ac2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_b69b6cc0-26b7-4f4f-aa09-f7cc74c09b20" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b9de9dde-7cc0-4323-9eb4-f99f45818263" xlink:to="loc_us-gaap_CommercialPaperMember_b69b6cc0-26b7-4f4f-aa09-f7cc74c09b20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentDebtSecuritiesMember_f1818c25-0692-4a36-abb0-c582d42983d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentDebtSecuritiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b9de9dde-7cc0-4323-9eb4-f99f45818263" xlink:to="loc_us-gaap_USGovernmentDebtSecuritiesMember_f1818c25-0692-4a36-abb0-c582d42983d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract_fd31d12c-d741-46f3-98c2-c00cd531d9fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable_c5cc5be8-c088-4854-b3b2-511108c06ee7" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract_fd31d12c-d741-46f3-98c2-c00cd531d9fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_2bb79ede-fd57-44dd-a323-27da74449d23" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract_fd31d12c-d741-46f3-98c2-c00cd531d9fd" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_2bb79ede-fd57-44dd-a323-27da74449d23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_904f63c6-32bf-4f15-8b42-a9a7cca83c2f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_2bb79ede-fd57-44dd-a323-27da74449d23" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_904f63c6-32bf-4f15-8b42-a9a7cca83c2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_b0ee55d1-e9d6-4cbc-83ee-c794e33f2038" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_2bb79ede-fd57-44dd-a323-27da74449d23" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_b0ee55d1-e9d6-4cbc-83ee-c794e33f2038" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionAccumulatedLoss_4e028922-1a37-45d5-89b2-006c91e3fce7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionAccumulatedLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_2bb79ede-fd57-44dd-a323-27da74449d23" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionAccumulatedLoss_4e028922-1a37-45d5-89b2-006c91e3fce7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsAbstract_3cc6a091-918c-4f11-9455-b817837e158b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract_fd31d12c-d741-46f3-98c2-c00cd531d9fd" xlink:to="loc_us-gaap_AvailableForsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsAbstract_3cc6a091-918c-4f11-9455-b817837e158b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_8d86b493-84b5-4ecc-8d54-1cd8815906dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsAbstract_3cc6a091-918c-4f11-9455-b817837e158b" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_8d86b493-84b5-4ecc-8d54-1cd8815906dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_eb954a07-facc-4c5b-aa78-6f6148baeab9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsAbstract_3cc6a091-918c-4f11-9455-b817837e158b" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_eb954a07-facc-4c5b-aa78-6f6148baeab9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_6df0edf2-f46a-4844-a131-af94047ca7cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsAbstract_3cc6a091-918c-4f11-9455-b817837e158b" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_6df0edf2-f46a-4844-a131-af94047ca7cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/BalanceSheetAccountDetailsPropertyandEquipmentDetails" xlink:type="simple" xlink:href="lgnd-20211231.xsd#BalanceSheetAccountDetailsPropertyandEquipmentDetails"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/BalanceSheetAccountDetailsPropertyandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_OtherBalanceSheetDetailsAbstract_00d2d285-f722-42b4-b8e8-5d7bd620b713" xlink:href="lgnd-20211231.xsd#lgnd_OtherBalanceSheetDetailsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_11218658-29e9-4a18-93e6-9b93abc2ba53" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_OtherBalanceSheetDetailsAbstract_00d2d285-f722-42b4-b8e8-5d7bd620b713" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_11218658-29e9-4a18-93e6-9b93abc2ba53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ee98e46b-dcfc-4a97-92ac-07fef5ff8412" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_11218658-29e9-4a18-93e6-9b93abc2ba53" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ee98e46b-dcfc-4a97-92ac-07fef5ff8412" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_8ff5ed49-eb1d-4a31-a368-d78a7df712ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ee98e46b-dcfc-4a97-92ac-07fef5ff8412" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_8ff5ed49-eb1d-4a31-a368-d78a7df712ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OfficeEquipmentMember_6f022ee1-1b23-4f9e-b4ee-c467fade6b05" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OfficeEquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_8ff5ed49-eb1d-4a31-a368-d78a7df712ee" xlink:to="loc_us-gaap_OfficeEquipmentMember_6f022ee1-1b23-4f9e-b4ee-c467fade6b05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_696d0c03-70a3-4be8-884e-f942e1e11be5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_8ff5ed49-eb1d-4a31-a368-d78a7df712ee" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_696d0c03-70a3-4be8-884e-f942e1e11be5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ComputerEquipmentAndSoftwareMember_01dcfbdf-b489-4b8a-8907-5aa65c9bfcd4" xlink:href="lgnd-20211231.xsd#lgnd_ComputerEquipmentAndSoftwareMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_8ff5ed49-eb1d-4a31-a368-d78a7df712ee" xlink:to="loc_lgnd_ComputerEquipmentAndSoftwareMember_01dcfbdf-b489-4b8a-8907-5aa65c9bfcd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_267ec64a-591d-47fa-8788-0e9ca58fc719" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_11218658-29e9-4a18-93e6-9b93abc2ba53" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_267ec64a-591d-47fa-8788-0e9ca58fc719" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_049fb234-4b39-456d-9ad1-1476ff5ba256" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_267ec64a-591d-47fa-8788-0e9ca58fc719" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_049fb234-4b39-456d-9ad1-1476ff5ba256" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_b193b24a-ee74-486d-8f72-f064e8fc57f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_267ec64a-591d-47fa-8788-0e9ca58fc719" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_b193b24a-ee74-486d-8f72-f064e8fc57f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_0599b126-b534-4ad4-96c0-ab490973598b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_267ec64a-591d-47fa-8788-0e9ca58fc719" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_0599b126-b534-4ad4-96c0-ab490973598b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/BalanceSheetAccountDetailsGoodwillandOtherIntangibleAssetsDetails" xlink:type="simple" xlink:href="lgnd-20211231.xsd#BalanceSheetAccountDetailsGoodwillandOtherIntangibleAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/BalanceSheetAccountDetailsGoodwillandOtherIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_OtherBalanceSheetDetailsAbstract_7d3f0498-5d0c-4538-846c-81298bc5c0c4" xlink:href="lgnd-20211231.xsd#lgnd_OtherBalanceSheetDetailsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_e30b204b-a58b-496b-aa44-b85513c997ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_OtherBalanceSheetDetailsAbstract_7d3f0498-5d0c-4538-846c-81298bc5c0c4" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_e30b204b-a58b-496b-aa44-b85513c997ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_a023ad36-5521-44b7-8758-0c40f3e6ff02" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_e30b204b-a58b-496b-aa44-b85513c997ba" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_a023ad36-5521-44b7-8758-0c40f3e6ff02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_882958b5-4931-4824-bc70-b74f000e273b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_a023ad36-5521-44b7-8758-0c40f3e6ff02" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_882958b5-4931-4824-bc70-b74f000e273b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PatentedTechnologyMember_1a17c4fe-9a0a-4073-998e-2c2250da24b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PatentedTechnologyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_882958b5-4931-4824-bc70-b74f000e273b" xlink:to="loc_us-gaap_PatentedTechnologyMember_1a17c4fe-9a0a-4073-998e-2c2250da24b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeNamesMember_e117c169-5ec7-4e7f-b623-152b74a40bbf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TradeNamesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_882958b5-4931-4824-bc70-b74f000e273b" xlink:to="loc_us-gaap_TradeNamesMember_e117c169-5ec7-4e7f-b623-152b74a40bbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember_7e16e275-8669-4a69-90b0-23a043ef0a8f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_882958b5-4931-4824-bc70-b74f000e273b" xlink:to="loc_us-gaap_CustomerRelationshipsMember_7e16e275-8669-4a69-90b0-23a043ef0a8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualRightsMember_ca251ec6-4ecd-42c1-8233-c7779d2fade3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractualRightsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_882958b5-4931-4824-bc70-b74f000e273b" xlink:to="loc_us-gaap_ContractualRightsMember_ca251ec6-4ecd-42c1-8233-c7779d2fade3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_7e028af6-b953-42b6-8459-d308772f8dcd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_e30b204b-a58b-496b-aa44-b85513c997ba" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_7e028af6-b953-42b6-8459-d308772f8dcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_ace36be3-10b9-4ec3-b2b1-b789de303463" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_7e028af6-b953-42b6-8459-d308772f8dcd" xlink:to="loc_us-gaap_Goodwill_ace36be3-10b9-4ec3-b2b1-b789de303463" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_ad1a3a3e-f429-4bb3-9a50-2155d3988268" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_7e028af6-b953-42b6-8459-d308772f8dcd" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_ad1a3a3e-f429-4bb3-9a50-2155d3988268" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_9e4933c4-b2e3-43b0-9d96-c62ebb6d7d0d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_7e028af6-b953-42b6-8459-d308772f8dcd" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_9e4933c4-b2e3-43b0-9d96-c62ebb6d7d0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill_5944412c-fbea-44e1-be28-384e4ed660c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetIncludingGoodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_7e028af6-b953-42b6-8459-d308772f8dcd" xlink:to="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill_5944412c-fbea-44e1-be28-384e4ed660c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/BalanceSheetAccountDetailsAccruedLiabilitiesDetails" xlink:type="simple" xlink:href="lgnd-20211231.xsd#BalanceSheetAccountDetailsAccruedLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/BalanceSheetAccountDetailsAccruedLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_OtherBalanceSheetDetailsAbstract_b82b5818-b7fe-4df4-8382-d8ece10b9636" xlink:href="lgnd-20211231.xsd#lgnd_OtherBalanceSheetDetailsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_4690f9f2-d8eb-4c0c-b4f1-34aa08c1cf18" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_OtherBalanceSheetDetailsAbstract_b82b5818-b7fe-4df4-8382-d8ece10b9636" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_4690f9f2-d8eb-4c0c-b4f1-34aa08c1cf18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_cd06cf94-13c1-43ed-b6f6-1ac7550c115f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_OtherBalanceSheetDetailsAbstract_b82b5818-b7fe-4df4-8382-d8ece10b9636" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_cd06cf94-13c1-43ed-b6f6-1ac7550c115f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedSalesCommissionCurrentAndNoncurrent_d7835060-d70c-427f-ac90-4f5cd9543d74" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedSalesCommissionCurrentAndNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_OtherBalanceSheetDetailsAbstract_b82b5818-b7fe-4df4-8382-d8ece10b9636" xlink:to="loc_us-gaap_AccruedSalesCommissionCurrentAndNoncurrent_d7835060-d70c-427f-ac90-4f5cd9543d74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent_923cc86d-bb0b-457c-93ae-fc7fd963392e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedRoyaltiesCurrentAndNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_OtherBalanceSheetDetailsAbstract_b82b5818-b7fe-4df4-8382-d8ece10b9636" xlink:to="loc_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent_923cc86d-bb0b-457c-93ae-fc7fd963392e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AccruedSalesReturns_31fd50e2-e1fa-4669-9ab2-fd21c2a7911e" xlink:href="lgnd-20211231.xsd#lgnd_AccruedSalesReturns"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_OtherBalanceSheetDetailsAbstract_b82b5818-b7fe-4df4-8382-d8ece10b9636" xlink:to="loc_lgnd_AccruedSalesReturns_31fd50e2-e1fa-4669-9ab2-fd21c2a7911e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AccruedAssetAcquisitionsCurrent_c3844eba-3fdf-4e35-b253-3456a4ebc993" xlink:href="lgnd-20211231.xsd#lgnd_AccruedAssetAcquisitionsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_OtherBalanceSheetDetailsAbstract_b82b5818-b7fe-4df4-8382-d8ece10b9636" xlink:to="loc_lgnd_AccruedAssetAcquisitionsCurrent_c3844eba-3fdf-4e35-b253-3456a4ebc993" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AccruedSubcontractorExpensesCurrent_1a2c2b3f-ddd5-4216-94ed-af5248362b66" xlink:href="lgnd-20211231.xsd#lgnd_AccruedSubcontractorExpensesCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_OtherBalanceSheetDetailsAbstract_b82b5818-b7fe-4df4-8382-d8ece10b9636" xlink:to="loc_lgnd_AccruedSubcontractorExpensesCurrent_1a2c2b3f-ddd5-4216-94ed-af5248362b66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AccruedSupplierExpensesCurrent_94574be7-cf25-46be-b25b-9cac204a2de0" xlink:href="lgnd-20211231.xsd#lgnd_AccruedSupplierExpensesCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_OtherBalanceSheetDetailsAbstract_b82b5818-b7fe-4df4-8382-d8ece10b9636" xlink:to="loc_lgnd_AccruedSupplierExpensesCurrent_94574be7-cf25-46be-b25b-9cac204a2de0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_c8e57ba9-90a3-43df-a01b-c85e67fb7ad9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_OtherBalanceSheetDetailsAbstract_b82b5818-b7fe-4df4-8382-d8ece10b9636" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_c8e57ba9-90a3-43df-a01b-c85e67fb7ad9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_ff429617-8305-424e-b89d-e70f1df23c92" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_OtherBalanceSheetDetailsAbstract_b82b5818-b7fe-4df4-8382-d8ece10b9636" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_ff429617-8305-424e-b89d-e70f1df23c92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/BalanceSheetAccountDetailsContingentLiabilitiesDetails" xlink:type="simple" xlink:href="lgnd-20211231.xsd#BalanceSheetAccountDetailsContingentLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/BalanceSheetAccountDetailsContingentLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_OtherBalanceSheetDetailsAbstract_1e8e760a-4611-4465-be91-61a1a4cc5e2a" xlink:href="lgnd-20211231.xsd#lgnd_OtherBalanceSheetDetailsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_b83c2c54-90f4-499e-addc-bd6770884728" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_OtherBalanceSheetDetailsAbstract_1e8e760a-4611-4465-be91-61a1a4cc5e2a" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_b83c2c54-90f4-499e-addc-bd6770884728" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_9b318c3e-2690-4975-98df-d015d261a74e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_b83c2c54-90f4-499e-addc-bd6770884728" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_9b318c3e-2690-4975-98df-d015d261a74e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a41a4dff-f9b1-4c76-9a53-7a9cfd2bdedf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_9b318c3e-2690-4975-98df-d015d261a74e" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a41a4dff-f9b1-4c76-9a53-7a9cfd2bdedf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_CydexPharmaceuticalsIncMember_a8375cca-721f-4b61-9a32-21ca7aaf90a8" xlink:href="lgnd-20211231.xsd#lgnd_CydexPharmaceuticalsIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a41a4dff-f9b1-4c76-9a53-7a9cfd2bdedf" xlink:to="loc_lgnd_CydexPharmaceuticalsIncMember_a8375cca-721f-4b61-9a32-21ca7aaf90a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_MetabasisTherapeuticsMember_4f4bf3b2-e39c-4e95-b30d-3787fe5405af" xlink:href="lgnd-20211231.xsd#lgnd_MetabasisTherapeuticsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a41a4dff-f9b1-4c76-9a53-7a9cfd2bdedf" xlink:to="loc_lgnd_MetabasisTherapeuticsMember_4f4bf3b2-e39c-4e95-b30d-3787fe5405af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_CrystalMember_d19fdf53-a536-4b40-a060-cc6173dac9c8" xlink:href="lgnd-20211231.xsd#lgnd_CrystalMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a41a4dff-f9b1-4c76-9a53-7a9cfd2bdedf" xlink:to="loc_lgnd_CrystalMember_d19fdf53-a536-4b40-a060-cc6173dac9c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_IcagenMember_6614b4c7-a8f5-4c15-9d4e-e91f43dc2e13" xlink:href="lgnd-20211231.xsd#lgnd_IcagenMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a41a4dff-f9b1-4c76-9a53-7a9cfd2bdedf" xlink:to="loc_lgnd_IcagenMember_6614b4c7-a8f5-4c15-9d4e-e91f43dc2e13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PfenexMember_ee75745f-f328-420f-aacc-7ee987930df5" xlink:href="lgnd-20211231.xsd#lgnd_PfenexMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a41a4dff-f9b1-4c76-9a53-7a9cfd2bdedf" xlink:to="loc_lgnd_PfenexMember_ee75745f-f328-420f-aacc-7ee987930df5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_XCellaBiosciencesIncMember_8af87dcf-2c50-40d9-9445-2630fdb729e6" xlink:href="lgnd-20211231.xsd#lgnd_XCellaBiosciencesIncMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a41a4dff-f9b1-4c76-9a53-7a9cfd2bdedf" xlink:to="loc_lgnd_XCellaBiosciencesIncMember_8af87dcf-2c50-40d9-9445-2630fdb729e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_301e28e7-1513-4497-9b8d-63bedd3d42c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_b83c2c54-90f4-499e-addc-bd6770884728" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_301e28e7-1513-4497-9b8d-63bedd3d42c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ContingentLiabilityRollForward_bfe88c9a-1db5-4a3d-ac6b-f091ad02f156" xlink:href="lgnd-20211231.xsd#lgnd_ContingentLiabilityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_301e28e7-1513-4497-9b8d-63bedd3d42c0" xlink:to="loc_lgnd_ContingentLiabilityRollForward_bfe88c9a-1db5-4a3d-ac6b-f091ad02f156" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod_94ae76a9-d2ee-434c-ab55-bebc27054ef1" xlink:href="lgnd-20211231.xsd#lgnd_BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_ContingentLiabilityRollForward_bfe88c9a-1db5-4a3d-ac6b-f091ad02f156" xlink:to="loc_lgnd_BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod_94ae76a9-d2ee-434c-ab55-bebc27054ef1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BusinessAcquisitionContingentConsiderationPotentialCashPaymentAdditions_7dcf8a07-14b4-4b1c-90cc-3f5a964cc899" xlink:href="lgnd-20211231.xsd#lgnd_BusinessAcquisitionContingentConsiderationPotentialCashPaymentAdditions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_ContingentLiabilityRollForward_bfe88c9a-1db5-4a3d-ac6b-f091ad02f156" xlink:to="loc_lgnd_BusinessAcquisitionContingentConsiderationPotentialCashPaymentAdditions_7dcf8a07-14b4-4b1c-90cc-3f5a964cc899" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PaymentsToContingentValueRightHolders_ed653cba-ccbf-48e3-9e7a-b811f697d481" xlink:href="lgnd-20211231.xsd#lgnd_PaymentsToContingentValueRightHolders"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_ContingentLiabilityRollForward_bfe88c9a-1db5-4a3d-ac6b-f091ad02f156" xlink:to="loc_lgnd_PaymentsToContingentValueRightHolders_ed653cba-ccbf-48e3-9e7a-b811f697d481" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities_f5e2950d-240c-4562-9852-a77847d44652" xlink:href="lgnd-20211231.xsd#lgnd_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_ContingentLiabilityRollForward_bfe88c9a-1db5-4a3d-ac6b-f091ad02f156" xlink:to="loc_lgnd_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities_f5e2950d-240c-4562-9852-a77847d44652" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityRepurchasesContingentLiabilities_4e02a059-5c67-463d-90e9-926f0b4e0142" xlink:href="lgnd-20211231.xsd#lgnd_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityRepurchasesContingentLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_ContingentLiabilityRollForward_bfe88c9a-1db5-4a3d-ac6b-f091ad02f156" xlink:to="loc_lgnd_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityRepurchasesContingentLiabilities_4e02a059-5c67-463d-90e9-926f0b4e0142" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod_958b8d88-c9a9-460d-bbe3-06f13c4f7109" xlink:href="lgnd-20211231.xsd#lgnd_BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_ContingentLiabilityRollForward_bfe88c9a-1db5-4a3d-ac6b-f091ad02f156" xlink:to="loc_lgnd_BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod_958b8d88-c9a9-460d-bbe3-06f13c4f7109" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/StockholdersEquity" xlink:type="simple" xlink:href="lgnd-20211231.xsd#StockholdersEquity"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/StockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_a2b79bae-f573-4eec-a7d7-996d1d342cca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_b6dcd9d6-e796-49a6-92d2-aabbec8d1a1c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_a2b79bae-f573-4eec-a7d7-996d1d342cca" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_b6dcd9d6-e796-49a6-92d2-aabbec8d1a1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/StockholdersEquityTables" xlink:type="simple" xlink:href="lgnd-20211231.xsd#StockholdersEquityTables"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/StockholdersEquityTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_8fdc501c-dcfd-48b5-86f7-d185186ab6b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_1ffbd2b6-e930-4c50-8920-599b8f0f0312" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_8fdc501c-dcfd-48b5-86f7-d185186ab6b1" xlink:to="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_1ffbd2b6-e930-4c50-8920-599b8f0f0312" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_ac48dc55-5b75-438e-a7f0-d7ad3f75d26d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_8fdc501c-dcfd-48b5-86f7-d185186ab6b1" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_ac48dc55-5b75-438e-a7f0-d7ad3f75d26d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_0011e92e-e0d1-4f04-9918-a3a8b37f91c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_8fdc501c-dcfd-48b5-86f7-d185186ab6b1" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_0011e92e-e0d1-4f04-9918-a3a8b37f91c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_d5d9a117-3945-4b2a-8139-2ab892278c1e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_8fdc501c-dcfd-48b5-86f7-d185186ab6b1" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_d5d9a117-3945-4b2a-8139-2ab892278c1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_dcd25d4a-cde5-4988-8ae9-753fc50ac88b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_8fdc501c-dcfd-48b5-86f7-d185186ab6b1" xlink:to="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_dcd25d4a-cde5-4988-8ae9-753fc50ac88b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/StockholdersEquityShareBasedCompensationDetails" xlink:type="simple" xlink:href="lgnd-20211231.xsd#StockholdersEquityShareBasedCompensationDetails"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/StockholdersEquityShareBasedCompensationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_fb98de17-192d-4f1f-b72d-f51fe98d8aca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c6efcff7-a707-4b34-b36d-edabd7dbc851" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_fb98de17-192d-4f1f-b72d-f51fe98d8aca" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c6efcff7-a707-4b34-b36d-edabd7dbc851" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_b5dcf70c-ff5d-4528-b5e6-376df37cff6c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c6efcff7-a707-4b34-b36d-edabd7dbc851" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_b5dcf70c-ff5d-4528-b5e6-376df37cff6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_0f5de99c-66db-406d-9ab4-e7ff7077916c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_b5dcf70c-ff5d-4528-b5e6-376df37cff6c" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_0f5de99c-66db-406d-9ab4-e7ff7077916c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_23b0c8e1-3859-432d-9dcc-922cfda776fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_0f5de99c-66db-406d-9ab4-e7ff7077916c" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_23b0c8e1-3859-432d-9dcc-922cfda776fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_4eb4dad0-c398-47e5-9f02-eda0d68a6912" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_0f5de99c-66db-406d-9ab4-e7ff7077916c" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_4eb4dad0-c398-47e5-9f02-eda0d68a6912" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b304a0fe-4313-4c79-b4d3-959e361b72ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c6efcff7-a707-4b34-b36d-edabd7dbc851" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b304a0fe-4313-4c79-b4d3-959e361b72ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_42dcb56d-2c72-4d94-b0b3-f48ef2308b10" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b304a0fe-4313-4c79-b4d3-959e361b72ea" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_42dcb56d-2c72-4d94-b0b3-f48ef2308b10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/StockholdersEquityNarrativeDetails" xlink:type="simple" xlink:href="lgnd-20211231.xsd#StockholdersEquityNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/StockholdersEquityNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_72fb6e4d-29bd-490b-8763-54cd7440a6f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1366b02c-cbf7-4fc7-830a-cc37d3dbf740" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_72fb6e4d-29bd-490b-8763-54cd7440a6f1" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1366b02c-cbf7-4fc7-830a-cc37d3dbf740" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_9b58ab0e-0290-4e69-a715-b367e9c265fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1366b02c-cbf7-4fc7-830a-cc37d3dbf740" xlink:to="loc_us-gaap_PlanNameAxis_9b58ab0e-0290-4e69-a715-b367e9c265fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_f4844e7f-a351-4aea-9b1a-b0da2282b235" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_9b58ab0e-0290-4e69-a715-b367e9c265fb" xlink:to="loc_us-gaap_PlanNameDomain_f4844e7f-a351-4aea-9b1a-b0da2282b235" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_TwoThousandTwoStockIncentivePlanMember_68179bf7-976e-4a4a-ab72-62ac521ba93d" xlink:href="lgnd-20211231.xsd#lgnd_TwoThousandTwoStockIncentivePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_f4844e7f-a351-4aea-9b1a-b0da2282b235" xlink:to="loc_lgnd_TwoThousandTwoStockIncentivePlanMember_68179bf7-976e-4a4a-ab72-62ac521ba93d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AmendedESPPMember_16847e96-6b24-4587-a2fb-b824f16aca51" xlink:href="lgnd-20211231.xsd#lgnd_AmendedESPPMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_f4844e7f-a351-4aea-9b1a-b0da2282b235" xlink:to="loc_lgnd_AmendedESPPMember_16847e96-6b24-4587-a2fb-b824f16aca51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_542d7e1e-ab84-4335-a1cf-921ac26ea1fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1366b02c-cbf7-4fc7-830a-cc37d3dbf740" xlink:to="loc_us-gaap_AwardTypeAxis_542d7e1e-ab84-4335-a1cf-921ac26ea1fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_71930a3a-baec-41c1-8c0d-564154deb0e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_542d7e1e-ab84-4335-a1cf-921ac26ea1fb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_71930a3a-baec-41c1-8c0d-564154deb0e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_f383a41d-bbc9-4a1f-bdc6-c8916a62eea9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_71930a3a-baec-41c1-8c0d-564154deb0e7" xlink:to="loc_us-gaap_EmployeeStockOptionMember_f383a41d-bbc9-4a1f-bdc6-c8916a62eea9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_1cd92795-1953-4fd3-949d-228eaffd0cb1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_71930a3a-baec-41c1-8c0d-564154deb0e7" xlink:to="loc_us-gaap_RestrictedStockMember_1cd92795-1953-4fd3-949d-228eaffd0cb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_da084a01-c8a9-4def-8fbb-5943bee70eef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1366b02c-cbf7-4fc7-830a-cc37d3dbf740" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_da084a01-c8a9-4def-8fbb-5943bee70eef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_bdd0ea9b-9ff3-4a06-9551-494b11b84b48" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_da084a01-c8a9-4def-8fbb-5943bee70eef" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_bdd0ea9b-9ff3-4a06-9551-494b11b84b48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_5f4f726e-3193-4c95-abba-79ebd90e866a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_da084a01-c8a9-4def-8fbb-5943bee70eef" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_5f4f726e-3193-4c95-abba-79ebd90e866a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_3ff7eb9b-a4ca-43fa-a068-170f11ff0b73" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_da084a01-c8a9-4def-8fbb-5943bee70eef" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_3ff7eb9b-a4ca-43fa-a068-170f11ff0b73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_aac8010a-a6d5-437c-b478-0896aff66d05" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_da084a01-c8a9-4def-8fbb-5943bee70eef" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_aac8010a-a6d5-437c-b478-0896aff66d05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_45a6081b-6f6a-4665-997e-64d445fd5fb9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_da084a01-c8a9-4def-8fbb-5943bee70eef" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_45a6081b-6f6a-4665-997e-64d445fd5fb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_b2844709-ac6e-4d63-ae09-3d4e728d9b8b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_da084a01-c8a9-4def-8fbb-5943bee70eef" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_b2844709-ac6e-4d63-ae09-3d4e728d9b8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_c2f2eac0-447d-41e3-87c7-87d6490133b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_da084a01-c8a9-4def-8fbb-5943bee70eef" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_c2f2eac0-447d-41e3-87c7-87d6490133b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_81466139-0c2c-4813-a190-e6bdc0ec9b01" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_da084a01-c8a9-4def-8fbb-5943bee70eef" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_81466139-0c2c-4813-a190-e6bdc0ec9b01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_EmployeeStockPurchasePlanAbstract_579e5008-ce9c-4983-a494-e21438cc7cab" xlink:href="lgnd-20211231.xsd#lgnd_EmployeeStockPurchasePlanAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_da084a01-c8a9-4def-8fbb-5943bee70eef" xlink:to="loc_lgnd_EmployeeStockPurchasePlanAbstract_579e5008-ce9c-4983-a494-e21438cc7cab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee_72a28ea9-c186-4ad3-9e82-8641735e7c05" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_EmployeeStockPurchasePlanAbstract_579e5008-ce9c-4983-a494-e21438cc7cab" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee_72a28ea9-c186-4ad3-9e82-8641735e7c05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_3db18913-ae25-43f5-a420-96a3f98237cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_EmployeeStockPurchasePlanAbstract_579e5008-ce9c-4983-a494-e21438cc7cab" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_3db18913-ae25-43f5-a420-96a3f98237cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_bb3337c6-aef0-4ca1-809e-762017b53bc3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_EmployeeStockPurchasePlanAbstract_579e5008-ce9c-4983-a494-e21438cc7cab" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_bb3337c6-aef0-4ca1-809e-762017b53bc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_CorporateShareRepurchaseAbstract_d6ea3787-0a12-43e2-969c-c85f2d4823a7" xlink:href="lgnd-20211231.xsd#lgnd_CorporateShareRepurchaseAbstract"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_da084a01-c8a9-4def-8fbb-5943bee70eef" xlink:to="loc_lgnd_CorporateShareRepurchaseAbstract_d6ea3787-0a12-43e2-969c-c85f2d4823a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_56922688-d9b1-4c95-a9ec-79bb87a47beb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_CorporateShareRepurchaseAbstract_d6ea3787-0a12-43e2-969c-c85f2d4823a7" xlink:to="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_56922688-d9b1-4c95-a9ec-79bb87a47beb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramPeriodInForce1_c5449800-1656-476d-9807-675ee2e37525" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchaseProgramPeriodInForce1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_CorporateShareRepurchaseAbstract_d6ea3787-0a12-43e2-969c-c85f2d4823a7" xlink:to="loc_us-gaap_StockRepurchaseProgramPeriodInForce1_c5449800-1656-476d-9807-675ee2e37525" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_78fcd216-2a6a-4fd1-a298-c7c4cbb45eab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_CorporateShareRepurchaseAbstract_d6ea3787-0a12-43e2-969c-c85f2d4823a7" xlink:to="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_78fcd216-2a6a-4fd1-a298-c7c4cbb45eab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares_73dadf94-5a56-4181-869f-166c8113c611" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodShares"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_CorporateShareRepurchaseAbstract_d6ea3787-0a12-43e2-969c-c85f2d4823a7" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodShares_73dadf94-5a56-4181-869f-166c8113c611" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue_d8c8f2d9-9e60-43bf-9835-a8417396e756" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_CorporateShareRepurchaseAbstract_d6ea3787-0a12-43e2-969c-c85f2d4823a7" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodValue_d8c8f2d9-9e60-43bf-9835-a8417396e756" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/StockholdersEquityStockOptionPlanActivityDetails" xlink:type="simple" xlink:href="lgnd-20211231.xsd#StockholdersEquityStockOptionPlanActivityDetails"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/StockholdersEquityStockOptionPlanActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_a383806d-d95a-4cc4-adf6-022f0cf2a32c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_976b07bb-cf21-4881-b833-7d6a4f4e8933" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_a383806d-d95a-4cc4-adf6-022f0cf2a32c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_976b07bb-cf21-4881-b833-7d6a4f4e8933" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_03421353-68f3-49ce-a231-9c3a5ecacade" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_976b07bb-cf21-4881-b833-7d6a4f4e8933" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_03421353-68f3-49ce-a231-9c3a5ecacade" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_5aaa764a-e2cd-4321-95c2-ccdb08cc4aff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_976b07bb-cf21-4881-b833-7d6a4f4e8933" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_5aaa764a-e2cd-4321-95c2-ccdb08cc4aff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_a9a386b8-3f52-4473-8fd9-0aca435ab287" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_976b07bb-cf21-4881-b833-7d6a4f4e8933" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_a9a386b8-3f52-4473-8fd9-0aca435ab287" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_e08717aa-c6cb-417a-ac35-cbcc3c34ab96" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_976b07bb-cf21-4881-b833-7d6a4f4e8933" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_e08717aa-c6cb-417a-ac35-cbcc3c34ab96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_77a1abe2-cc4f-4f03-a878-a0fc048481a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_976b07bb-cf21-4881-b833-7d6a4f4e8933" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_77a1abe2-cc4f-4f03-a878-a0fc048481a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_3956544c-07f6-4810-a8e5-2096ba813eec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_a383806d-d95a-4cc4-adf6-022f0cf2a32c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_3956544c-07f6-4810-a8e5-2096ba813eec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_229daefc-4a2f-4460-9158-2fdc4eb3ee12" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_a383806d-d95a-4cc4-adf6-022f0cf2a32c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_229daefc-4a2f-4460-9158-2fdc4eb3ee12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_ee884d19-7da0-40f2-96ae-e6f9d2f7b5bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_a383806d-d95a-4cc4-adf6-022f0cf2a32c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_ee884d19-7da0-40f2-96ae-e6f9d2f7b5bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_5e1d5448-1716-4641-8e99-c639b808076e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_ee884d19-7da0-40f2-96ae-e6f9d2f7b5bf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_5e1d5448-1716-4641-8e99-c639b808076e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_2d1443a3-7ff9-4598-942f-7ebe07b88897" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_ee884d19-7da0-40f2-96ae-e6f9d2f7b5bf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_2d1443a3-7ff9-4598-942f-7ebe07b88897" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_8babe78c-2f6a-45d5-8dfb-05679343f134" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_ee884d19-7da0-40f2-96ae-e6f9d2f7b5bf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_8babe78c-2f6a-45d5-8dfb-05679343f134" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_802efc3a-835e-4246-a91b-a484860ec1b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_ee884d19-7da0-40f2-96ae-e6f9d2f7b5bf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_802efc3a-835e-4246-a91b-a484860ec1b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_12d9ee47-59c5-416a-bef3-d2efad2f530e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_ee884d19-7da0-40f2-96ae-e6f9d2f7b5bf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_12d9ee47-59c5-416a-bef3-d2efad2f530e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_e6fc0841-4293-4201-bc0c-7eaa7a84512a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_a383806d-d95a-4cc4-adf6-022f0cf2a32c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_e6fc0841-4293-4201-bc0c-7eaa7a84512a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_df4f01fe-0c1d-4654-9d99-3290014fbfd3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_a383806d-d95a-4cc4-adf6-022f0cf2a32c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_df4f01fe-0c1d-4654-9d99-3290014fbfd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_8cf55266-56ef-44dc-9726-bfe3344c7ba2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_a383806d-d95a-4cc4-adf6-022f0cf2a32c" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_8cf55266-56ef-44dc-9726-bfe3344c7ba2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_710a000b-5f45-45c2-aeda-8ad4a0f4b52f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_a383806d-d95a-4cc4-adf6-022f0cf2a32c" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_710a000b-5f45-45c2-aeda-8ad4a0f4b52f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_7d33dbf7-6fb7-405c-ad95-c6e36b5c8ea0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_a383806d-d95a-4cc4-adf6-022f0cf2a32c" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_7d33dbf7-6fb7-405c-ad95-c6e36b5c8ea0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_808a74c7-0e16-4eb7-b41c-276475bbae4d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_a383806d-d95a-4cc4-adf6-022f0cf2a32c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_808a74c7-0e16-4eb7-b41c-276475bbae4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_d899d3fb-dd08-4df3-b322-00a806c4c529" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_a383806d-d95a-4cc4-adf6-022f0cf2a32c" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_d899d3fb-dd08-4df3-b322-00a806c4c529" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_149843a5-b133-4fe5-9146-84c0f7a8e9de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_a383806d-d95a-4cc4-adf6-022f0cf2a32c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_149843a5-b133-4fe5-9146-84c0f7a8e9de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/StockholdersEquityBreakdownofOptionsOutstandingDetails" xlink:type="simple" xlink:href="lgnd-20211231.xsd#StockholdersEquityBreakdownofOptionsOutstandingDetails"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/StockholdersEquityBreakdownofOptionsOutstandingDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_2790b637-d18d-4e49-83bd-f4237c2dc9fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f4f001e0-3090-4d34-b419-18cfe71e3f68" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_2790b637-d18d-4e49-83bd-f4237c2dc9fe" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f4f001e0-3090-4d34-b419-18cfe71e3f68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_2573533b-9b60-4e40-a7bd-a4dc8fff05cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f4f001e0-3090-4d34-b419-18cfe71e3f68" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_2573533b-9b60-4e40-a7bd-a4dc8fff05cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_b0ee9d45-caa4-4748-a8f8-6b64536df057" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_2573533b-9b60-4e40-a7bd-a4dc8fff05cb" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_b0ee9d45-caa4-4748-a8f8-6b64536df057" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ExercisePriceRangeElevenMember_f0353014-f85d-44d8-9478-3e5a385498cd" xlink:href="lgnd-20211231.xsd#lgnd_ExercisePriceRangeElevenMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_b0ee9d45-caa4-4748-a8f8-6b64536df057" xlink:to="loc_lgnd_ExercisePriceRangeElevenMember_f0353014-f85d-44d8-9478-3e5a385498cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ExercisePriceRangeOneMember_a1fb80de-1233-41e1-bf58-5a9ee6c08588" xlink:href="lgnd-20211231.xsd#lgnd_ExercisePriceRangeOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_ExercisePriceRangeElevenMember_f0353014-f85d-44d8-9478-3e5a385498cd" xlink:to="loc_lgnd_ExercisePriceRangeOneMember_a1fb80de-1233-41e1-bf58-5a9ee6c08588" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ExercisePriceRangeTwoMember_b5dd8030-63eb-4433-bb49-a7fefc33db57" xlink:href="lgnd-20211231.xsd#lgnd_ExercisePriceRangeTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_ExercisePriceRangeElevenMember_f0353014-f85d-44d8-9478-3e5a385498cd" xlink:to="loc_lgnd_ExercisePriceRangeTwoMember_b5dd8030-63eb-4433-bb49-a7fefc33db57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ExercisePriceRangeThreeMember_64ecb2ce-4d00-429b-8ff0-319ac8beb1d7" xlink:href="lgnd-20211231.xsd#lgnd_ExercisePriceRangeThreeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_ExercisePriceRangeElevenMember_f0353014-f85d-44d8-9478-3e5a385498cd" xlink:to="loc_lgnd_ExercisePriceRangeThreeMember_64ecb2ce-4d00-429b-8ff0-319ac8beb1d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ExercisePriceRangeFourMember_66aaf301-1c6e-424b-abac-f8ade2a95044" xlink:href="lgnd-20211231.xsd#lgnd_ExercisePriceRangeFourMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_ExercisePriceRangeElevenMember_f0353014-f85d-44d8-9478-3e5a385498cd" xlink:to="loc_lgnd_ExercisePriceRangeFourMember_66aaf301-1c6e-424b-abac-f8ade2a95044" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ExercisePriceRangeFiveMember_8cab401c-0fcc-4f58-8e56-343ef72ae3ea" xlink:href="lgnd-20211231.xsd#lgnd_ExercisePriceRangeFiveMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_ExercisePriceRangeElevenMember_f0353014-f85d-44d8-9478-3e5a385498cd" xlink:to="loc_lgnd_ExercisePriceRangeFiveMember_8cab401c-0fcc-4f58-8e56-343ef72ae3ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ExercisePriceRangeSixMember_26362468-4345-4a15-bbef-121231317713" xlink:href="lgnd-20211231.xsd#lgnd_ExercisePriceRangeSixMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_ExercisePriceRangeElevenMember_f0353014-f85d-44d8-9478-3e5a385498cd" xlink:to="loc_lgnd_ExercisePriceRangeSixMember_26362468-4345-4a15-bbef-121231317713" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ExercisePriceRangeSevenMember_313f9bc0-463f-4a59-9cf6-76be107ba058" xlink:href="lgnd-20211231.xsd#lgnd_ExercisePriceRangeSevenMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_ExercisePriceRangeElevenMember_f0353014-f85d-44d8-9478-3e5a385498cd" xlink:to="loc_lgnd_ExercisePriceRangeSevenMember_313f9bc0-463f-4a59-9cf6-76be107ba058" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ExercisePriceRangeEightMember_2ec60fa7-9e29-4306-b85c-56b85562ca59" xlink:href="lgnd-20211231.xsd#lgnd_ExercisePriceRangeEightMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_ExercisePriceRangeElevenMember_f0353014-f85d-44d8-9478-3e5a385498cd" xlink:to="loc_lgnd_ExercisePriceRangeEightMember_2ec60fa7-9e29-4306-b85c-56b85562ca59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ExercisePriceRangeNineMember_8064e242-cfa0-43c4-bd27-a5e7d9cdb222" xlink:href="lgnd-20211231.xsd#lgnd_ExercisePriceRangeNineMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_ExercisePriceRangeElevenMember_f0353014-f85d-44d8-9478-3e5a385498cd" xlink:to="loc_lgnd_ExercisePriceRangeNineMember_8064e242-cfa0-43c4-bd27-a5e7d9cdb222" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ExercisePriceRangeTenMember_b3e5250c-310b-4ee9-8a18-acab857aa65b" xlink:href="lgnd-20211231.xsd#lgnd_ExercisePriceRangeTenMember"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_ExercisePriceRangeElevenMember_f0353014-f85d-44d8-9478-3e5a385498cd" xlink:to="loc_lgnd_ExercisePriceRangeTenMember_b3e5250c-310b-4ee9-8a18-acab857aa65b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cb7f60e9-1f40-446b-95b7-4c76f33581af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f4f001e0-3090-4d34-b419-18cfe71e3f68" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cb7f60e9-1f40-446b-95b7-4c76f33581af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_a0df090c-a607-4690-a87e-2b6af6812c3f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cb7f60e9-1f40-446b-95b7-4c76f33581af" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_a0df090c-a607-4690-a87e-2b6af6812c3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_08313f55-7025-4e9a-bb67-01dca66512fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cb7f60e9-1f40-446b-95b7-4c76f33581af" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_08313f55-7025-4e9a-bb67-01dca66512fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_62debd97-a495-4b4e-8295-c0bf05245725" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cb7f60e9-1f40-446b-95b7-4c76f33581af" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_62debd97-a495-4b4e-8295-c0bf05245725" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_8b347fa0-8a16-4e3e-87e5-9001a6f1b34b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cb7f60e9-1f40-446b-95b7-4c76f33581af" xlink:to="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_8b347fa0-8a16-4e3e-87e5-9001a6f1b34b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_4707b869-93f9-4e8a-a65c-77a93cff005b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cb7f60e9-1f40-446b-95b7-4c76f33581af" xlink:to="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_4707b869-93f9-4e8a-a65c-77a93cff005b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_6fe1d26f-b627-4b66-8f21-012bfdff0e37" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cb7f60e9-1f40-446b-95b7-4c76f33581af" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_6fe1d26f-b627-4b66-8f21-012bfdff0e37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_fc1856de-4189-4ee7-b78d-657f45cb3bdd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cb7f60e9-1f40-446b-95b7-4c76f33581af" xlink:to="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_fc1856de-4189-4ee7-b78d-657f45cb3bdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/StockholdersEquityAssumptionsDetails" xlink:type="simple" xlink:href="lgnd-20211231.xsd#StockholdersEquityAssumptionsDetails"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/StockholdersEquityAssumptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_aa26152f-6ea1-4150-87ac-2627071fcf38" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_08fbda8c-998f-430c-903a-6cfee627bb4a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_aa26152f-6ea1-4150-87ac-2627071fcf38" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_08fbda8c-998f-430c-903a-6cfee627bb4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_4e9329a6-ef2b-4284-bd14-ef61b3358d21" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_08fbda8c-998f-430c-903a-6cfee627bb4a" xlink:to="loc_srt_RangeAxis_4e9329a6-ef2b-4284-bd14-ef61b3358d21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_02a14687-6b77-4bd4-bfa9-15253e795a21" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_4e9329a6-ef2b-4284-bd14-ef61b3358d21" xlink:to="loc_srt_RangeMember_02a14687-6b77-4bd4-bfa9-15253e795a21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_f116d8f2-a457-44e4-a296-d6447b1b1edc" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_02a14687-6b77-4bd4-bfa9-15253e795a21" xlink:to="loc_srt_MinimumMember_f116d8f2-a457-44e4-a296-d6447b1b1edc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_12791a1a-d7f9-42d2-ace4-bf7952a2c739" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_02a14687-6b77-4bd4-bfa9-15253e795a21" xlink:to="loc_srt_MaximumMember_12791a1a-d7f9-42d2-ace4-bf7952a2c739" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0574f6d7-b4c2-49eb-8d64-0937941cf599" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_08fbda8c-998f-430c-903a-6cfee627bb4a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0574f6d7-b4c2-49eb-8d64-0937941cf599" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_52ad0be0-4343-4c87-a5d2-35d1994c37f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0574f6d7-b4c2-49eb-8d64-0937941cf599" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_52ad0be0-4343-4c87-a5d2-35d1994c37f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_97855cb4-45df-4362-afa2-df3e7b67f3aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0574f6d7-b4c2-49eb-8d64-0937941cf599" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_97855cb4-45df-4362-afa2-df3e7b67f3aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_0d81f167-9fb5-4039-a27b-a7afd2d0fcb6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0574f6d7-b4c2-49eb-8d64-0937941cf599" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_0d81f167-9fb5-4039-a27b-a7afd2d0fcb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/StockholdersEquityRestrictedStockActivityDetails" xlink:type="simple" xlink:href="lgnd-20211231.xsd#StockholdersEquityRestrictedStockActivityDetails"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/StockholdersEquityRestrictedStockActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_a2526076-8e66-4c54-88fb-02dfd038b49a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9b08cd0d-c9d6-4817-aeb4-7846c217a5e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_a2526076-8e66-4c54-88fb-02dfd038b49a" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9b08cd0d-c9d6-4817-aeb4-7846c217a5e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_5b70cd2f-a098-4d2d-9089-207024d90009" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9b08cd0d-c9d6-4817-aeb4-7846c217a5e9" xlink:to="loc_us-gaap_AwardTypeAxis_5b70cd2f-a098-4d2d-9089-207024d90009" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d0363292-520c-462b-8509-43805194d996" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_5b70cd2f-a098-4d2d-9089-207024d90009" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d0363292-520c-462b-8509-43805194d996" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_d2f2a51f-36d9-4ff3-921e-ee9aaf03fe88" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d0363292-520c-462b-8509-43805194d996" xlink:to="loc_us-gaap_RestrictedStockMember_d2f2a51f-36d9-4ff3-921e-ee9aaf03fe88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_958e7386-d292-408c-856a-e00016c7dc19" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9b08cd0d-c9d6-4817-aeb4-7846c217a5e9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_958e7386-d292-408c-856a-e00016c7dc19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_b95b8415-b763-4a43-a89b-49921aa5f7d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_958e7386-d292-408c-856a-e00016c7dc19" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_b95b8415-b763-4a43-a89b-49921aa5f7d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_49799b7d-76cc-4a0f-8bd5-cbdfaffcb60c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_b95b8415-b763-4a43-a89b-49921aa5f7d8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_49799b7d-76cc-4a0f-8bd5-cbdfaffcb60c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_9e77264a-b5d9-47b9-8467-b7a9edaadfad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_b95b8415-b763-4a43-a89b-49921aa5f7d8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_9e77264a-b5d9-47b9-8467-b7a9edaadfad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_646e9e58-1ddf-4b60-a5bf-ab7a40f7085a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_b95b8415-b763-4a43-a89b-49921aa5f7d8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_646e9e58-1ddf-4b60-a5bf-ab7a40f7085a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_790aece2-46ad-4dd6-9879-22bf9c20baa6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_b95b8415-b763-4a43-a89b-49921aa5f7d8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_790aece2-46ad-4dd6-9879-22bf9c20baa6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_f0d21073-f3dc-4810-ac03-47f14e30f9d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_b95b8415-b763-4a43-a89b-49921aa5f7d8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_f0d21073-f3dc-4810-ac03-47f14e30f9d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_70c71caa-d428-4c26-84c7-d1df964a33fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_958e7386-d292-408c-856a-e00016c7dc19" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_70c71caa-d428-4c26-84c7-d1df964a33fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_e028bb85-3198-4f81-9d71-3db2b5c3e9ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_70c71caa-d428-4c26-84c7-d1df964a33fb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_e028bb85-3198-4f81-9d71-3db2b5c3e9ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_06904328-2993-4eee-8a96-012ecab3e08d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_70c71caa-d428-4c26-84c7-d1df964a33fb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_06904328-2993-4eee-8a96-012ecab3e08d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_d6e340bc-770e-485e-bcf7-f47a861538aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_70c71caa-d428-4c26-84c7-d1df964a33fb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_d6e340bc-770e-485e-bcf7-f47a861538aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_70ed09b9-177f-49f9-8620-d4185b4b3f8b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_70c71caa-d428-4c26-84c7-d1df964a33fb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_70ed09b9-177f-49f9-8620-d4185b4b3f8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_644aa3a4-52ad-4d20-8e0d-ca3f07157f68" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_70c71caa-d428-4c26-84c7-d1df964a33fb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_644aa3a4-52ad-4d20-8e0d-ca3f07157f68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/CommitmentandContingenciesLegalProceedings" xlink:type="simple" xlink:href="lgnd-20211231.xsd#CommitmentandContingenciesLegalProceedings"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/CommitmentandContingenciesLegalProceedings" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_084a06e7-83b4-40a8-b17d-2540e701db89" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_6c788484-698a-4755-a1ef-7c1a59dae053" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_084a06e7-83b4-40a8-b17d-2540e701db89" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_6c788484-698a-4755-a1ef-7c1a59dae053" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/CommitmentandContingenciesLegalProceedingsNarrativeDetails" xlink:type="simple" xlink:href="lgnd-20211231.xsd#CommitmentandContingenciesLegalProceedingsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/CommitmentandContingenciesLegalProceedingsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_2ab60b70-0cb0-4d7c-809a-84a2269fc648" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainContingenciesTable_00d09a06-3540-49c1-98b0-668190e34583" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainContingenciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_2ab60b70-0cb0-4d7c-809a-84a2269fc648" xlink:to="loc_us-gaap_GainContingenciesTable_00d09a06-3540-49c1-98b0-668190e34583" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_ff122ff2-8a40-4330-ad28-971832fdfdbb" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GainContingenciesTable_00d09a06-3540-49c1-98b0-668190e34583" xlink:to="loc_srt_LitigationCaseAxis_ff122ff2-8a40-4330-ad28-971832fdfdbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_9b871619-0fd8-4148-b4ff-e8fa31cb16d4" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseAxis_ff122ff2-8a40-4330-ad28-971832fdfdbb" xlink:to="loc_srt_LitigationCaseTypeDomain_9b871619-0fd8-4148-b4ff-e8fa31cb16d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_LupinPatentInfringementMember_de0e751f-7a47-4fc2-a479-2ae03cc4a88f" xlink:href="lgnd-20211231.xsd#lgnd_LupinPatentInfringementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_9b871619-0fd8-4148-b4ff-e8fa31cb16d4" xlink:to="loc_lgnd_LupinPatentInfringementMember_de0e751f-7a47-4fc2-a479-2ae03cc4a88f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_USDistrictCourtForTheNorthernDistrictOfOhioMember_019cb9af-ac27-48ef-b06f-b38c8c244f08" xlink:href="lgnd-20211231.xsd#lgnd_USDistrictCourtForTheNorthernDistrictOfOhioMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_9b871619-0fd8-4148-b4ff-e8fa31cb16d4" xlink:to="loc_lgnd_USDistrictCourtForTheNorthernDistrictOfOhioMember_019cb9af-ac27-48ef-b06f-b38c8c244f08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainContingenciesLineItems_5c47282e-c4a0-4ff6-bb95-388484427138" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainContingenciesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GainContingenciesTable_00d09a06-3540-49c1-98b0-668190e34583" xlink:to="loc_us-gaap_GainContingenciesLineItems_5c47282e-c4a0-4ff6-bb95-388484427138" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber_b95982b2-d2e9-4a91-a072-29ba9ad43a07" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GainContingenciesLineItems_5c47282e-c4a0-4ff6-bb95-388484427138" xlink:to="loc_us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber_b95982b2-d2e9-4a91-a072-29ba9ad43a07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNewClaimsFiledNumber_0777e04b-be8a-4493-a208-19758ce833a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyNewClaimsFiledNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GainContingenciesLineItems_5c47282e-c4a0-4ff6-bb95-388484427138" xlink:to="loc_us-gaap_LossContingencyNewClaimsFiledNumber_0777e04b-be8a-4493-a208-19758ce833a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/IncomeTaxes" xlink:type="simple" xlink:href="lgnd-20211231.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_53d87cd4-9758-49b7-8509-2622e8e55536" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_2bbe48f5-4cda-400e-84d9-719cc4919662" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_53d87cd4-9758-49b7-8509-2622e8e55536" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_2bbe48f5-4cda-400e-84d9-719cc4919662" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/IncomeTaxesTables" xlink:type="simple" xlink:href="lgnd-20211231.xsd#IncomeTaxesTables"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/IncomeTaxesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_4a60fb93-0c23-448e-9550-22047592cd6e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_b4920b01-50a3-4519-8be5-12eb8f55e85a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_4a60fb93-0c23-448e-9550-22047592cd6e" xlink:to="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_b4920b01-50a3-4519-8be5-12eb8f55e85a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_ff023e4d-08d3-4c0c-82e4-34d09199d80f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_4a60fb93-0c23-448e-9550-22047592cd6e" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_ff023e4d-08d3-4c0c-82e4-34d09199d80f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_f221d3a4-32ab-4f3c-b191-ffc89146cbdd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_4a60fb93-0c23-448e-9550-22047592cd6e" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_f221d3a4-32ab-4f3c-b191-ffc89146cbdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForwardTableTextBlock_43886bba-0943-40ca-ada9-c7b448a46181" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForwardTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_4a60fb93-0c23-448e-9550-22047592cd6e" xlink:to="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForwardTableTextBlock_43886bba-0943-40ca-ada9-c7b448a46181" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/IncomeTaxesNarrativeDetails" xlink:type="simple" xlink:href="lgnd-20211231.xsd#IncomeTaxesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/IncomeTaxesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_9ecfccb8-43a1-4733-a7c5-949fd3a35a78" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_cbd0e1f1-e84d-4912-8406-437eed1ccce3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_9ecfccb8-43a1-4733-a7c5-949fd3a35a78" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable_cbd0e1f1-e84d-4912-8406-437eed1ccce3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_08b3863d-a014-4827-bc08-10772bd4163d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_cbd0e1f1-e84d-4912-8406-437eed1ccce3" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_08b3863d-a014-4827-bc08-10772bd4163d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_b49427cf-2e25-4384-8eab-9277643bf96f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_08b3863d-a014-4827-bc08-10772bd4163d" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_b49427cf-2e25-4384-8eab-9277643bf96f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InternalRevenueServiceIRSMember_ed571ef0-d127-4be9-a404-2db8a0c13cb7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InternalRevenueServiceIRSMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_b49427cf-2e25-4384-8eab-9277643bf96f" xlink:to="loc_us-gaap_InternalRevenueServiceIRSMember_ed571ef0-d127-4be9-a404-2db8a0c13cb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_17cee323-4af2-4e52-a94c-ed7c03c4516d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_b49427cf-2e25-4384-8eab-9277643bf96f" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_17cee323-4af2-4e52-a94c-ed7c03c4516d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCountryMember_131244c7-6451-48ee-b94d-387c4cbc9d20" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCountryMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_b49427cf-2e25-4384-8eab-9277643bf96f" xlink:to="loc_us-gaap_ForeignCountryMember_131244c7-6451-48ee-b94d-387c4cbc9d20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis_79e6c013-9254-4884-904a-a69b70aaec3c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_cbd0e1f1-e84d-4912-8406-437eed1ccce3" xlink:to="loc_us-gaap_TaxCreditCarryforwardAxis_79e6c013-9254-4884-904a-a69b70aaec3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_fd421cf5-7d8c-446d-941d-a3341accc2af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_79e6c013-9254-4884-904a-a69b70aaec3c" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_fd421cf5-7d8c-446d-941d-a3341accc2af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchMember_84e805d9-81e4-4950-86fb-cd28711394cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_fd421cf5-7d8c-446d-941d-a3341accc2af" xlink:to="loc_us-gaap_ResearchMember_84e805d9-81e4-4950-86fb-cd28711394cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_CaliforniaAndNewJerseyResearchTaxCreditCarryforwardMember_1b762e8a-8da9-42a6-ae9b-9e5c2e08db39" xlink:href="lgnd-20211231.xsd#lgnd_CaliforniaAndNewJerseyResearchTaxCreditCarryforwardMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_fd421cf5-7d8c-446d-941d-a3341accc2af" xlink:to="loc_lgnd_CaliforniaAndNewJerseyResearchTaxCreditCarryforwardMember_1b762e8a-8da9-42a6-ae9b-9e5c2e08db39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalLossCarryforwardMember_259fb65f-6dc8-4d75-96a1-5e1df9d7da98" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalLossCarryforwardMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_fd421cf5-7d8c-446d-941d-a3341accc2af" xlink:to="loc_us-gaap_CapitalLossCarryforwardMember_259fb65f-6dc8-4d75-96a1-5e1df9d7da98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_07ff9066-9969-45ae-a3bd-49b1f18162d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_cbd0e1f1-e84d-4912-8406-437eed1ccce3" xlink:to="loc_us-gaap_OperatingLossCarryforwardsLineItems_07ff9066-9969-45ae-a3bd-49b1f18162d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_140662a7-974a-4bf2-9404-d91cf334c146" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_07ff9066-9969-45ae-a3bd-49b1f18162d6" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_140662a7-974a-4bf2-9404-d91cf334c146" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_5d326857-30c2-4b8b-aa49-8827155b4b05" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_07ff9066-9969-45ae-a3bd-49b1f18162d6" xlink:to="loc_us-gaap_OperatingLossCarryforwards_5d326857-30c2-4b8b-aa49-8827155b4b05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_2cf9efdb-1af5-469e-a864-6704b2bd4fd6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_07ff9066-9969-45ae-a3bd-49b1f18162d6" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_2cf9efdb-1af5-469e-a864-6704b2bd4fd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_c8897460-0513-4741-b6de-11d364eb4501" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_07ff9066-9969-45ae-a3bd-49b1f18162d6" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_c8897460-0513-4741-b6de-11d364eb4501" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/IncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails" xlink:type="simple" xlink:href="lgnd-20211231.xsd#IncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/IncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_60b42a25-92f8-4f35-8dfd-3f4df14b5ef3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_b45aff8b-f9f4-4678-97ed-67890b12cc48" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_60b42a25-92f8-4f35-8dfd-3f4df14b5ef3" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_b45aff8b-f9f4-4678-97ed-67890b12cc48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_1984be0e-6e4b-4fb0-88a1-57d69f81b02b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_b45aff8b-f9f4-4678-97ed-67890b12cc48" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_1984be0e-6e4b-4fb0-88a1-57d69f81b02b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_2f08685e-7b82-4d21-8a02-598823740e30" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_b45aff8b-f9f4-4678-97ed-67890b12cc48" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_2f08685e-7b82-4d21-8a02-598823740e30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit_8c6ed444-6f0b-479d-a0ba-4aeeebe4ccdc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_b45aff8b-f9f4-4678-97ed-67890b12cc48" xlink:to="loc_us-gaap_CurrentForeignTaxExpenseBenefit_8c6ed444-6f0b-479d-a0ba-4aeeebe4ccdc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_2870535a-6053-4dfb-9778-2bd3515a15fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_b45aff8b-f9f4-4678-97ed-67890b12cc48" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_2870535a-6053-4dfb-9778-2bd3515a15fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_46cfb26c-c8ca-484b-b00f-930fb1ba4e76" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_60b42a25-92f8-4f35-8dfd-3f4df14b5ef3" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_46cfb26c-c8ca-484b-b00f-930fb1ba4e76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_f6d49fb0-7e36-480d-baaf-e16905f460be" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_46cfb26c-c8ca-484b-b00f-930fb1ba4e76" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_f6d49fb0-7e36-480d-baaf-e16905f460be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_95c2d1e6-2f55-4022-b94b-49adb96a464f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_46cfb26c-c8ca-484b-b00f-930fb1ba4e76" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_95c2d1e6-2f55-4022-b94b-49adb96a464f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_aebc6e7c-ef75-4a43-b3a7-2a6ad9c8e429" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_46cfb26c-c8ca-484b-b00f-930fb1ba4e76" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_aebc6e7c-ef75-4a43-b3a7-2a6ad9c8e429" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_a01dc29f-79fc-4b3c-a39a-5d56a532265e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_60b42a25-92f8-4f35-8dfd-3f4df14b5ef3" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_a01dc29f-79fc-4b3c-a39a-5d56a532265e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/IncomeTaxesReconciliationofIncomeTaxExpenseBenefitDetails" xlink:type="simple" xlink:href="lgnd-20211231.xsd#IncomeTaxesReconciliationofIncomeTaxExpenseBenefitDetails"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/IncomeTaxesReconciliationofIncomeTaxExpenseBenefitDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_dec8356d-02a3-4e79-94df-dfad968f2745" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_f87ff42f-3380-4c77-bb9e-bb215d8c0caf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_dec8356d-02a3-4e79-94df-dfad968f2745" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_f87ff42f-3380-4c77-bb9e-bb215d8c0caf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_988f141b-e4dd-4084-a843-9edff562f546" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_f87ff42f-3380-4c77-bb9e-bb215d8c0caf" xlink:to="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_988f141b-e4dd-4084-a843-9edff562f546" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_41323646-8713-4372-9153-39dfa39f5ebe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_f87ff42f-3380-4c77-bb9e-bb215d8c0caf" xlink:to="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_41323646-8713-4372-9153-39dfa39f5ebe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_IncomeTaxReconciliationContingentValueRights_2587fe3e-f04b-4899-a5b7-d47b7b8f473a" xlink:href="lgnd-20211231.xsd#lgnd_IncomeTaxReconciliationContingentValueRights"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_f87ff42f-3380-4c77-bb9e-bb215d8c0caf" xlink:to="loc_lgnd_IncomeTaxReconciliationContingentValueRights_2587fe3e-f04b-4899-a5b7-d47b7b8f473a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_47bfda93-5d47-42a8-8022-40f5966c285a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_f87ff42f-3380-4c77-bb9e-bb215d8c0caf" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_47bfda93-5d47-42a8-8022-40f5966c285a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomeAmount_549e73dc-a3a2-4617-a18f-e174d7d8c152" xlink:href="lgnd-20211231.xsd#lgnd_EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomeAmount"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_f87ff42f-3380-4c77-bb9e-bb215d8c0caf" xlink:to="loc_lgnd_EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomeAmount_549e73dc-a3a2-4617-a18f-e174d7d8c152" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_EffectiveIncomeTaxRateReconciliationExpiredTaxCreditsResearch_63350de3-d50d-41cd-9c31-a9fd7aac2d4b" xlink:href="lgnd-20211231.xsd#lgnd_EffectiveIncomeTaxRateReconciliationExpiredTaxCreditsResearch"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_f87ff42f-3380-4c77-bb9e-bb215d8c0caf" xlink:to="loc_lgnd_EffectiveIncomeTaxRateReconciliationExpiredTaxCreditsResearch_63350de3-d50d-41cd-9c31-a9fd7aac2d4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions_efb6ccc8-d1aa-4050-90e3-108d3a31c931" xlink:href="lgnd-20211231.xsd#lgnd_EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_f87ff42f-3380-4c77-bb9e-bb215d8c0caf" xlink:to="loc_lgnd_EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions_efb6ccc8-d1aa-4050-90e3-108d3a31c931" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_48ee37eb-baa4-41ad-9510-c97f5c49514b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_f87ff42f-3380-4c77-bb9e-bb215d8c0caf" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_48ee37eb-baa4-41ad-9510-c97f5c49514b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_EffectiveIncomeTaxRateReconciliationProvisionToReturnAdjustmentsAmount_9ee9684d-47bd-44c8-bcd7-c08f150a365a" xlink:href="lgnd-20211231.xsd#lgnd_EffectiveIncomeTaxRateReconciliationProvisionToReturnAdjustmentsAmount"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_f87ff42f-3380-4c77-bb9e-bb215d8c0caf" xlink:to="loc_lgnd_EffectiveIncomeTaxRateReconciliationProvisionToReturnAdjustmentsAmount_9ee9684d-47bd-44c8-bcd7-c08f150a365a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_cbd1f191-5015-4540-827b-d7222c620036" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_f87ff42f-3380-4c77-bb9e-bb215d8c0caf" xlink:to="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_cbd1f191-5015-4540-827b-d7222c620036" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_dd4cdd7d-2227-433d-beb6-d0e5a22c71a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_f87ff42f-3380-4c77-bb9e-bb215d8c0caf" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_dd4cdd7d-2227-433d-beb6-d0e5a22c71a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationDispositionOfBusiness_95e48ba2-9900-4737-9bcd-b88921ea32f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationDispositionOfBusiness"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_f87ff42f-3380-4c77-bb9e-bb215d8c0caf" xlink:to="loc_us-gaap_IncomeTaxReconciliationDispositionOfBusiness_95e48ba2-9900-4737-9bcd-b88921ea32f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_31f77e55-a8bd-4afe-8f5b-b90e17a6979b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_f87ff42f-3380-4c77-bb9e-bb215d8c0caf" xlink:to="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_31f77e55-a8bd-4afe-8f5b-b90e17a6979b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_7c0379de-003b-4cf1-8afb-bd909309fcca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_f87ff42f-3380-4c77-bb9e-bb215d8c0caf" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_7c0379de-003b-4cf1-8afb-bd909309fcca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/IncomeTaxesDeferredTaxesDetails" xlink:type="simple" xlink:href="lgnd-20211231.xsd#IncomeTaxesDeferredTaxesDetails"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/IncomeTaxesDeferredTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_4a821668-9b2a-4ede-bd43-bb34e2fedb0a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGrossAbstract_5e35efb3-a550-4430-b023-1bc2f6fd07d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGrossAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_4a821668-9b2a-4ede-bd43-bb34e2fedb0a" xlink:to="loc_us-gaap_DeferredTaxAssetsGrossAbstract_5e35efb3-a550-4430-b023-1bc2f6fd07d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_2f27df3d-bdc7-4d1c-9f80-ee5c7b442d99" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_5e35efb3-a550-4430-b023-1bc2f6fd07d9" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_2f27df3d-bdc7-4d1c-9f80-ee5c7b442d99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_727b517c-9d82-4fb4-813b-037abd8b543e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_5e35efb3-a550-4430-b023-1bc2f6fd07d9" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_727b517c-9d82-4fb4-813b-037abd8b543e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_24063b66-bf33-4ff2-9691-97838a61289b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_5e35efb3-a550-4430-b023-1bc2f6fd07d9" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_24063b66-bf33-4ff2-9691-97838a61289b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_bd9b7b42-916d-4681-95db-d893a411d61f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_5e35efb3-a550-4430-b023-1bc2f6fd07d9" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_bd9b7b42-916d-4681-95db-d893a411d61f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_66559647-5055-4ead-954d-502eddf02b30" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_5e35efb3-a550-4430-b023-1bc2f6fd07d9" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_66559647-5055-4ead-954d-502eddf02b30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_59e02a4c-0410-42f5-a2b1-74ef08e87e69" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_5e35efb3-a550-4430-b023-1bc2f6fd07d9" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_59e02a4c-0410-42f5-a2b1-74ef08e87e69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_752484d3-a2e9-432f-a914-f21cd64078e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_5e35efb3-a550-4430-b023-1bc2f6fd07d9" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_752484d3-a2e9-432f-a914-f21cd64078e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesAbstract_90497338-1b7b-4535-b374-527f7cb78ed6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_4a821668-9b2a-4ede-bd43-bb34e2fedb0a" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesAbstract_90497338-1b7b-4535-b374-527f7cb78ed6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_DeferredTaxLiabilitiesFiniteLivedIntangibleAssets_20cd8683-4682-4a44-9086-264d21f10eb2" xlink:href="lgnd-20211231.xsd#lgnd_DeferredTaxLiabilitiesFiniteLivedIntangibleAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_90497338-1b7b-4535-b374-527f7cb78ed6" xlink:to="loc_lgnd_DeferredTaxLiabilitiesFiniteLivedIntangibleAssets_20cd8683-4682-4a44-9086-264d21f10eb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther_e38c7d55-85f3-492e-b458-3f7bd760781a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesOther"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_90497338-1b7b-4535-b374-527f7cb78ed6" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesOther_e38c7d55-85f3-492e-b458-3f7bd760781a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_8ff17f27-bee6-417a-9ee6-b819638b0b0d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_90497338-1b7b-4535-b374-527f7cb78ed6" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_8ff17f27-bee6-417a-9ee6-b819638b0b0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities_4651fd85-8fa6-476e-8b94-b89bbae1aa2c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_90497338-1b7b-4535-b374-527f7cb78ed6" xlink:to="loc_us-gaap_DeferredTaxLiabilities_4651fd85-8fa6-476e-8b94-b89bbae1aa2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/IncomeTaxesReconciliationofUnrecognizedTaxBenefitsDetails" xlink:type="simple" xlink:href="lgnd-20211231.xsd#IncomeTaxesReconciliationofUnrecognizedTaxBenefitsDetails"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/IncomeTaxesReconciliationofUnrecognizedTaxBenefitsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_7301fbc7-290c-4325-9f41-a1a944a97661" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_6607c39c-5388-48ed-9059-a78316753da1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_7301fbc7-290c-4325-9f41-a1a944a97661" xlink:to="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_6607c39c-5388-48ed-9059-a78316753da1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_45331e02-72d3-41f1-861b-1e7ffb5093ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_6607c39c-5388-48ed-9059-a78316753da1" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_45331e02-72d3-41f1-861b-1e7ffb5093ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_0705d83c-4e03-4faf-9c38-9d48c792cdf2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_6607c39c-5388-48ed-9059-a78316753da1" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_0705d83c-4e03-4faf-9c38-9d48c792cdf2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_ad62843b-fb25-4e2f-91fc-30f41ef3619b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_6607c39c-5388-48ed-9059-a78316753da1" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_ad62843b-fb25-4e2f-91fc-30f41ef3619b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_0012c10c-400a-490f-be45-2ffff9f19b38" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_6607c39c-5388-48ed-9059-a78316753da1" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_0012c10c-400a-490f-be45-2ffff9f19b38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_e20c731e-d14e-49a2-a13f-c2e3171d42f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_6607c39c-5388-48ed-9059-a78316753da1" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_e20c731e-d14e-49a2-a13f-c2e3171d42f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>image_0a.jpg
<TEXT>
begin 644 image_0a.jpg
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M 0$! 0$!         0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M (N@#T6BO.E_:,^%$C87XG>#B?;7K7_XY0W[17PK7/\ Q<OPCQZ:[:__ !=
M'HM%><M^T=\*%Z_$WP@/^X[:_P#Q=#?M'?"=%+-\3O!P4=SKUK_\<H ]&KYK
M_:>\1?V+XN\&*)X4WQS!;>^<)!-(9[9$V9E3YU9PS-@[(][MPM>C?\--?"#<
M!_PM+P;\W(_XGUK_ /%UX7\=/$VJ^,/$&D:YX7OY/%?@]PZZ;J7AF5YK:"ZW
MQ)MNGA@E5HE=79OG5ONJNS:S4 ?4G@WQ)'XN\*:-KD,300:E:17:12<LBNBL
M!^M;U9^FV,.EV,%K C)!"BQHK,6VJ!@#)Y-:% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %?.>G>'_B/\3/$OC26Q^*VI>%['2];FTRVT^TT>
MRG1$2*)U;?)%N)_>M_WROX_1E>2? -BTWQ)RQ8KXQOA_#\OR0\?+_7GUH R&
M^#/Q1;I\>=:7CC_BG]-]?^N52+\&/B8L;C_A>WB#>W1ET33/E_."O;J* /$8
M?@O\3%8F?X[^(7&WA8]$TQ.?^_!I8_@K\1&R)OCGXH=6V_ZO2M,0CU_Y=_\
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M5?V9KG<';XP?$]V'][6X!_*WKVZB@#Q:']FN:,'S/BU\2YSG(,FMQ#'_ 'S
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MN3_PK7PX_.[]Y8(VW_=STJY%^RK\'K>%HD^&GA@HW\+:5"W\UKUBB@#S2/\
M9K^$\>W'PU\)Y7./^));?_$4O_#.7PI_Z)MX2V==O]B6NW_T"O2J* /.U_9U
M^%2_=^&?@]/]W0;4?^TZ;_PSK\+-K+_PK;PCM/;^PK7TQ_<KT:B@#@8_@5\.
M+>/RX_ 'AA(_[JZ/;@?=V_W/[H J7_A2/PYV[/\ A O#&W^[_8]O]?[E=S10
M!QG_  I?X?\ '_%#>&^/^H1;_P#Q%,_X4K\/%;</ GAH'=G/]CV_7I_<KMJ*
M .*_X4K\/%SCP'X9YZ_\2>W_ /B*/^%)_#S;@> _#*_[NCV__P 17:T4 <C_
M ,*F\$;MP\'>'U;^\NF09_\ 0*?%\+_!D+.8_"6AJTAW.RZ=#R??Y:ZNB@#F
M)/AWX3DP'\,:.><\Z?%UZ_W?:G1_#WPM;L2GAO1XRW4K8Q#/)/\ =]2?SKI:
M* .;;X>^%F4H?#6CE2FS;]AB^[Z?=Z4Z'X?^%X=WE^'-)C+?>VV,0S_X[714
M4 82^#= 5V<:)IP=L@M]E3)SU_AKR;XOPV.E>*_"T=C\-_#?B2\LS$]O=:H_
MV?[#YM[!"/(V6\O.^4.?N[=F>:]VKYM_:=TFTO/&OP]DNPL<C7+I$\MG%*FY
M7B;_ %NUY(F]&6)E_O,G% 'N/@W7CXH\(Z/K3V_V4ZC90W?D;MWE^8BOMW87
M.-W7 KH:1:6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O(_@
M'))-=?$QI!C_ (K&]4#.>%B@7^G_ .K[J^N5Y7\#V_XF7Q/3'W/&%S\W][-M
M:M_[-C\* /5**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MKGM0N-;B\3:7%:VMO+H4D<OVR=I"LT4@VF+:O\0/S _A0!T-%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %?)_[6EC)?>.O" @OK"RE:)H\7UKYC7&Z=$V(
MHNH7E;:[_)$I?!W*<[:^L*^3_P!I?PP+7XO>$+ZRLKR1]6817MPC74NW8R[?
M(1'"+(P7;\WR[F1MI.64 ^F])COH=/MEU&>"YOUB07$MM&8HWDQ\S(C,Q52V
M<*6./4UJTB_=%+0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7
MD_P/DC;5?B<4<,K>+[KG>K<K;6JMG;]WY@>&YKUBO*/@/"([CXD$RF:1_&%\
MSL6S_!#A?^ KM7_@- 'J]%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !116%X@U:;0]/-VFGW6I;98D:"S56EPTBJS@$C(127(Z[5.,M@4 ;M%%% &
M7-%>-J5O)'<Q):K&XE@:'+N^5VE7W?*!\V1@YW#E<<ZE%% !1110 4444 %%
M%-W;>M #J*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ KY^_:)\7>)?#OB7P_::1XQL?!EE<6=U-+=:MJ
M5I96\SH\05 ]Q97&7VNS;5*_*K?*V*^@:\5^.'Q+L? ^M:-I]YIEQ?C4H2NZ
M+6QI_E?Z1;QIC<Z@MYDL?S@[E7?_  [J /1? >J76N^"?#^HW:R"[NK"WGF6
M9=KJ[Q*S;AM7G)_NCZ"NEKG_  7XBC\8>$=&UV&-H8=2LX;Q(V.[8'17QGOU
MZUT% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %>4_ _"Z]\5T
M& $\82],<[K"R?M_O5ZM7D?P1DF_X2+XK+,QD;_A+Y<.% 7;]AL]H'^Z-JGW
MS0!ZY1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4QE++@''O3Z* .
M=\+Z/>Z#H-K87VJ3ZW<6^Y#?72J)9EW';YFW@MMP"P W$9VC.*Z*BB@ HHHH
M **** "BBB@ KD?'WAS4O%&FV%KIFK-H[P:I9WLTBQ!_.AAG25X>?N[PNW=V
MS^%==10 4444 %9.O7EYI^BW]SI]F=1O887>"S#A/.<+E4R>F>E:U% $<;F2
M-6*E"1G:>HJ2BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "OG#]J?PGJ^N77AJ^LSJUQ8K*MG+%IY'EH\UQ B;O^)A:?
MZW/E?Q_*[8*-RWT?7SS^UAXBN_#MOX.E&O?V!8-JC,UQ%$DL_G+#)Y>U'N(=
MZ_>^1=Y=MJ['W;2 >L?#'4EUKX=^&;Z*XEN8[G3+:59KC;YKYB7E]K,-WKAC
MSWKKJP/"-Q%=>%='FA;=%+9PNC"U-KN4H#GR6YB_W#]WI6_0 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !7E/P3C>/7OBHTDWFR-XMD^4.S!!]
MAL]HYZ?+MKU:O+?@[)YGB'XI$JR/_P )8ZG*[>FGV*KQ_N[?KUH ]2HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH ***9)(L:,SG:H[T /HIGF# .>&Z4R
M2XCAW;W5=HW-N/04 3450;5+-6*FYA! R5WCIG;_ #XJO_PDVCKG.IV:X;;\
MUPGWNF.M &O16-_PE^A+_P QG3^6V_\ 'TG7\Z9_PF&@?]!S3_\ P+3_ .*H
M W**PV\9>'U9@=<TY2O7-VG_ ,52?\)OX>_Z#NF_^!D7_P 50!NT5S[>/O#2
MR+&?$&E[VZ+]MBY_\>I__";^'O\ H.Z;_P"!D7_Q5 &[16%_PF_A[_H.Z;_X
M&1?_ !5(WCCPZJY.O:8O_;Y%_P#%4 ;U%8"^//#3,0/$&E9'_3[%_P#%4W_A
M8'ACS/+_ .$BTHR?W?ML6?\ T*@#H:*YS_A/O#/F*G_"0Z468;@OVV+[OK]Z
MDC^(GA::1HU\2:2T@7=M6^BSM]?O4 =)17+2?$OPE#M$GBC1T+'Y=U_$,\;O
M[WI2M\2O"2J[GQ-HX5'V,QOHN&_N_>Z\T =117*R?%#P='")7\5Z(D3?==M0
MAP?_ !ZH&^+W@53SXU\/+G^]JL'_ ,7[&@#L:*XQ?C-X ;;CQQX<^;I_Q-K?
M_P"+IO\ PNKX?,JL/'/AL@G&?[7M_P#XN@#M:*XMOC1\/U95_P"$X\-[F^ZO
M]KV_/_C]1-\</ARO7Q[X84[=^&UBW^[Z_?H [FBO/F_: ^&4:J7^(?A5-W3=
MK=L.^/[]5I/VDOA)"V)/BEX,0]?F\06G_P <H ]*HKS3_AI;X1,R@?%/P62W
M3'B"T_\ CE.;]I#X31PB4_$_P<(B=N_^WK3&?^_E 'I-%>9Q_M,?".9&>/XH
M>#611DM_;UK@?^/U W[3WPA5-[?%'P<J=/,_MVUVGY<\'?0!ZG17EW_#3GPA
M\MV_X6AX1^1MC+_;=ON#?[N_-13?M1?""WW^9\2O#*A#AO\ B9Q<?='][_:7
M\Z /5J*\C_X:N^#GEO)_PLOPPR)G<5U.(]\?WJ(_VKOA!(VV/XD>'I3O\K;'
M>HWS_P!WC^+@\4 >N45Y+_PU5\(OO?\ "Q-!V[MN?M:_>]/T--C_ &M/@[(N
M4^(_A]UQG*WBF@#URBO*U_:B^$[*I'CW1=K=#]HJ2/\ :6^&,S,D7C+3967;
ME8W8]?PH ]0HKR^']I3X97$<<B>,M-*NVT9D8?-_=Z?>]J>O[1WPXD8*/%EB
MSLNX+A]Q&W/3;0!Z;17F*_M#?#S[/YS>)K=5^;[T<BG<OWEP5ZKCD=J9_P -
M)?#G:K?\)*F&^[_HD_S_ "J?E_=_-]Y>GK0!ZC17E#?M0?#10K?\)&^QNC?V
M==8/3_IE[BH8_P!JSX72PI+'XF,D4BY1X]/NB&^G[J@#UVBO)9OVHOAK;L4E
MU^:(AE0A],NUVLR[E!_=<<597]I'P"RJRZG?LK)O7&B7W*_WO]3TH ]1HKR7
M_AIKX?!2[:CJ8B_YZ?V#J!3M_%Y&.K8J.X_:D^'=NS(][K6]3M*KX8U,G/<?
M\>U 'KU%>1-^T_X#C;83XEW\?+_PB.KY&[[O_+K_ !=O6G?\-,>!V:()'XJ=
MYO\ 5*O@[6-TGIM_T7GK0!ZW17 ^$_C%X9\9:\NCV$NJ0:C):M>Q6NJ:->6#
M2PJRJ[I]HB3?M9T!VYQN7UKOJ "BBB@ HHHH **** "BBB@ HHHH *^8_P!K
MBUN-)U;PEXDD\17/A?2K7S[:?586N%CMV9DEVR_9YDE99$B9/NNJ#<WRG::^
MG*\+^.?@\>(/&7A.]NOM=O#'#=V]C>:3]B2_COF1942.6X4E=Z0R* A49^_\
MO*@'JW@N;[1X3T6;^TFUE9+*%_[1*;/M64'[W;VW?>_X%6]6!X-76%\(Z-_;
MYC;6_L<7V_RON^?L&_;C_:S6_0 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !7E_P 'K5K?Q)\5B^29/%I<%CU_XEU@!_*O4*\G^"MPLWB3XM%%
MC 'C!U_=G=G;IM@#^- 'K%%%% !1110 4444 %%%% !3)$61=KC(/:GT4 %>
M.>-_!N@^.OC5HECK^E6&LV,/AZ]G%M?0^:H?[1:J'"MQ]W<,^]>QUYKJ"LOQ
M\TS)^23PS=XQV9;JW_\ BE_[YH \@\/>%_!_B#2[#7=%_9PGO;*^CCNK>=GT
MI%E1EX+*]UN_B^ZRU>C\"Z+-YCO^R]&&F7!$W]BME6'S*W^D?^.UZM^SZLJ_
M!'P()2N_^Q[7[O\ =\L;?TKT6@#YN7P;HTEP97_9>@$B[5#.FB<A?N_\M^VX
MUQ_@WP;\/-)^'WB77->^$^AZA<3>,GTR'1;C2[&::VEN+N&UB@WG,6U7E7.U
MMH7UV_-]@U\R77EK\/\ 7LKO_P"+LV/WNS?V[9T 7/\ A4/@^29'?]F3PZSX
M^63[#H[;-NW;_%_Z#_=J.\^#?A#E8/V8_"T[;3CS+'1U!]/7C)_3O7TG10!\
M@?%;X3^%;/X6>+KB+]G/PSHMU#H]U*FH166E;K5O*;]ZI1<[D^]\O]U?P\A_
M:-\7>!_A3\1=9\-:1\(_AJ4TVSM[CS=0\&6\S.[HA;<Z.BA?G1?N]>/[M?<'
MQZV?\*1\?>8VQ?[!OOF]/]'>O+/$GP7\&?$;X]:S%X@TB>XCU#PW:7-PL.J7
M,'VEUN'3YUBE4,JA(O4?=;KS0!FVWPQT6ZTFQN+7]F#P;,DD:S[9$TR-0656
MW+^Z;VZX^[3[/X7P1['/[+G@:%T7Y?*N-.;9ZK_Q[KBOI:UM8[2WC@B39%&J
MHBKV4=*LT ?,-K\-?L^Z+_AESP/%"V[<(;G3N>R\?9Q_#5J3P/=-&Z']FKP:
M45EV*U[8_=[_ /+OQTKNOC9\<%^#K:0@T1]:GOXIYMBW:6X58FB4C<_5B9EP
M/8UYY\.?VD->^(OQJT/1([.'1=%N+.]>?3IRKW8FMW>)OG7*/%YJ.JLC9/EG
MY=OS$ D7P'=36^R;]F3P5^[?]TAOK$J%[-_Q[\-[?^/4EUX%OKC:K?LQ>!IU
M;&_S=0L?_D7G[S?Y-?35% 'P_P#'C6+[X6^!X=9G^ OP_P!"DDOQ +JZ%O?H
M69'=@$2!&W-MDRQ;C_:)Q61X!UZS^*7PK\0:Q<?#OPA=:YI_C'3-)AM]/T9+
M#ST-U:[HIG=7PK;F1L_P_*RU]C_$#X=>'?B;H*Z)XGM9+RP,RRHD=W+;.)55
MMK*\3J^<,W\5>&Z+X-T7P3X%E@TJVDW3?$FU6YNKF[EN9=R:PBHSRS,S_=55
MZ\L[?WF) -1?#OB&"2$6_P"SUX-11N0,^K6J;%7E/NVC<;N?;WJ)/">O_: ?
M^&<? B#8WS-J]KNZ_*O_ !Y?6OI.B@#YT_X1?Q+]G\M?V>_ 2HS9:,ZW#M#=
M,_\ 'A3H?"?B.XMV5O@!\/8X5^[!-K41S]-NGD=J^B:*!W/G=?!.O2++"GP#
M^',4?.%;6$VD_+Z:=_LC_OE:6X\+^*+K?<'X"_#TS/%\_G:VA<^D;?\ $O\
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MU+"D21201-GAF)W7"=!T#>E %N3_ (7!)#L$7@?/=F>[*G\-M11K\:ED)<^
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MH_@.\=G5OE^5])VMC_@3?^/5[K0 4444 %%%% !1110 4444 %%%% !7R?\
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M(H9"&4_Q"OD7]B6:W\57?CNX6$7&E_V=H>CNKO;W4$DMO9&*55EA>6)UVE.
MW1N5%7_%GQ^\/?L@^*-1\&ZK8:K=^'[B%-5T%;1HREG$[,DMKF6566))4#)C
M*J)]@PJ*M 'U?17QS)_P4X^',+2K)H.O(RYV?/9?/UQ_R\<?P_\ ?52K_P %
M)/!C?.OA#Q+)'GY6C%L21_W]^M 'V#7S)^U!H.HZIX\\(SP:7J%Y9KI=[;_:
MK'2KB_\ LDK7=@^[;"C;7V1/L;Y<,OWJRF_X* >&?(N;@>&+PV]O&TADCUO2
MI68+]X*J73%F_P!D<FJ<G_!1KPI'($/@KQ1\W\16W^]Z<2T 9O[*6GSV_P :
MM2&IVTMEJL.B-OL[@-'+;^:\$SHT6]=B[IUV[XBWWOG4!4K[.KXVC_;U\!6N
MK2ZI%\/-<CU*1-DM\MO:B5U^7Y=X?<P^4=?05>N/^"C'A>#R\^#=>+2+E$\^
MU+?\""RG;^- 'M?Q;PVO?"Z-F4;_ !2OW@V<K8WC_+[_ "]^VZI?ACM?QY\6
M'+JTJ^(+>,HIZ :58%?_ $*OFOQ1^VQI/CC5/"=W8>$=3MHM%U9=2>34;NUM
M_,'V>>'8C,^W=^_5NOW=W^Z8]&_;6T_PCXD\6ZF?"=UJ">(M2BO4@L=2MYFM
M]EI:VK+)L+?>:+<K?=967'.Z@#[CHKX];_@H1!Y+R#X9Z^0I(7$R8+=A]WUH
M7_@H09!((_A;KTNP<^7*6V_[V(N* /L*BODVS_;LCN-/^V7/@BYTJ/GY-0O'
MB;KU_P"/<KMQ\V[/W?\ :^6H+K]NG4([BYA@^%7B"]>-V19;7S7CDVMMW*?L
M^<-VRM 'US2-7R-)^W)KNU_+^"_BK]US+NBN/W:C&[=_H_R\>M,_X;HU:2%G
MC^#WB>4A?,^59R NYAG_ (]_N_*?F]5;^[0!@^%VBF\3?#:8P1S,VFV%PT>W
MJTMQJ+R_-M^?YU3_ 'O[WS;J^H?@6NWX)^ !C;CP_8?+_P!NZ5\02?$+5/ =
MQHVLR^%HU_L6RA1-S7MND_E2W4R*JFSVKN6[VK\W\7WJW_"G[;WBOP/X1T7P
M]'\*[V\;2;""R\R1[M'=8HE3>R_8^/NY^]ZT ??5%?#(_P""B'B?=(H^%%VS
M("=JRW!;;\WS;?L^<?+4^F?\%"M:U#5(X&^&US CLR!KE[L;G"%]B^3:S,6V
MJ6^Y]U6/% 'J/B3389-+^++-*$\_QWH^^16QC]UHZ\;NC?3^+\J^C5^Z*^)&
M^,WB36+7Q@L/A.UMY-<U:RUO9<RZG9LGE+80O$/M&FQ!VW6ZM]X-L?=MPM?0
MZ^*/BL58-X \.JZY_P"9JE(;CY<?Z%^?]: /5:Y'XK2R6_PQ\6RQ1^;,FDW;
M)'C.YO)? KGU\6?%1=V?A]X>XS_S-;\_^258WB;4/BEXH\.ZKH[^ _#=NM_:
M2VK2MXKE=55T9=V/L'S=1^OX@#/"-JB_$#X:B.5UCB\$W:Q(^UI-OFZ;G>V,
MG[J>G>O:J^9]/U#XG:#X^\%63>"_#[ZA:^&M0M(HD\32^7+$DNFJSL[66X,K
M;?EVMG>?F^7YO08_%'Q>DL_^1"\*17&W^+Q;.REOPT_I0!ZO17EH\1?%Q89-
M_@KPBTH"X\OQ5<;?]KKI_P!:LMX@^*?F($\&^%=N5W9\47'K\W_,/H ])HKQ
M[0?'WQ*\03:RD/@SPQ$=,N38RK)XGN/FG5$<X/V#[F'7]:V9M:^*FU1'X3\)
M9\KECXFNMN__ ,%_2@#TBBO,9-:^+RQLR>%O!3-_=_X26[_^0*R/$7CGXK>&
M?"^IZW>>$O![0:?:2WLT<7B6Z+E$3>RC_0,9PK=Z /9:*AM;@75NDJ?=<9%3
M4 %%%% !7SY^T]\1+3P%JG@.?4;"&\LH[^>X=+G4K*R2Y7[-+";?=<RINW>?
MNV_=;8JD_-7T'7S9^TE\2IOACXXT2[M9=%CN]0TN;3]NO:BEI%+OFB56BWQ/
MGRF;S9=I_P!5]Y6PA4 ^A-+DCDTZV>!/*A:-2B+MP%QP/EX_*K]<9\*5*?#+
MPH$BD@0:3:;8I'WNB^2GRLV%W-[X%=G0 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !7CG[/LBR:E\5W1LJWC:['WL_,MK:JPZ_WE:O8Z\E^ ;,
M]Y\3,NSJOC&]"^F/*@H ]:HHHH **** "BBB@ HHHH **** "O/-4S_PO3P]
MSQ_PCVI\>G^DV'^?\FO0Z\ZU2-8_CMH$I*Y?PYJ2=.F+JP_^*_\ ': $_9]C
M$?P5\&JH51_9T6 JXXKT:N ^ KI)\&O!K)O_ .09#N\P8;=M^;/XYKOZ "OG
MC4%;_A"-6RI!7XF6(7DK\O\ ;5K]WUZG\S7T/7SSJ3>7X#U0G=M;XF62C=\G
M_,;M5[_>^;\Z /H:BBB@#SWX^,R_ OX@[0Y;_A'[_ C^]_Q[OTZ5\::IH>O>
M+O'4N@^'="M[^^F;6-5O)8M$TF:Z=O[=NH4:5[Q%79L7:NUMWRK\M?8/[0=K
M!??";7;>Y2.6VD-N)$E^ZR_:(L@^O^[_ !=*\ _93^%WB1OA_P"$/&/A;7=,
MT.1M)N]%FL]3TJ6]BV+J5Q,DJ*D\/S;G_+_QT V_@KX^\3^%_@;<:?%9:7_P
ME5CXO?PT\+V\-K:V[RW2JK.EHJK\JRK]S[W!SSNKI9H[BX\;:M:_$GP;X)U:
MXC\/S:Q%J5C9>?+B%U1D;SE9C\K+_P!\XYK>T/\ 9QBCT/Q#9ZMXBN9+_6O$
M">)7OM%MUL3;7:I$NZ)6:7&3%N^8M]XU:NOV=[&XT_Q&EQXH\1:K?ZQHEQH0
MN]6NEN/LT,WWF1 JKG=M//\ =H ^/?A[X?\ &=C8_#'Q1X@\/VL^A^)]5TBU
ME^U:%HC6LD5TRK\OE(TR;E;=]U/F_N_=KZ?^,C?##X5_V7:Q_#'0?$7B/57V
MV6D6>D6XEE4,H+;O+.WEE"^K-V4.Z*OP=UNXTWPCX>U+XAZ+=:-X1O\ 3]0B
MMX-%:*\9++;A'E-VP"M\N6V<9KL?B]\+].\92:1XCCUQ_"/B/09UGM-?A1&V
M)\RO#*K\/$X=E9<C[W7U /%?BMXI^%\?P%\1ZQHGA;PSX/\ $JNVFQ6?B/2K
M?3[RRN-\:NVS;N9T242KY6[=\NW-9O[/GP]\':I\6-:TO19])^(O@>WT2*Y;
M4[FQBO%2]>?:L3SN7;S52(MLRORNOR+PS>O?LT>"=,C\+W7C.[V:OXM\17MW
M/J6L7$2^>V)WC6 ?W$1$1-B\?+WZUQWQ=:7X4_$K1]$\*^,;'X9:=XS@N);N
M\N(8I;>RN+55<2Q02LL2-,'97;^+REXW?-0![=_PI?X?[=O_  @OAO;G=M_L
MFWQG_OBO!/CWX)T3PSX]\&V'AVULO"$NJ>3$+K1[&UBDCD75]+V2*K(59EW,
M5W*?XJ[S]EOXD:U\0_#OB*/6=<L_$L^DZK+81:I8PI$D\:?*&(1F&YL;_P#=
M=>OWCYW^V#8FZ^+GP>W0A_FO]K[-^T^99_,N?E4K][\.] 'J\?P@\:?:C(_Q
MN\8%2<[8]/T@8_V?FLBO_CN:M-\'O%FV7'QI\:;V_P!7NM-'PG_DAS7JL?W1
M3J /+U^$'B3O\9/'+>G[G1Q_[CZCD^#>ONRG_A<'CI3C'RKI7/W?^G#_ &?_
M !YJ]4HH \L;X.^(FD#?\+A\<@?\\Q'I 'Z6%5E^".O+Y:K\8_'ZB/[ISI3?
MGFP^;_@6?YUQOC3]IK6O"/Q*U[0DT#3+K2M)N8;>69[RZ2<JT5O*[_+:O"IV
MW'RJ\JYV-S6Y^S#X^UWQ_H?BFYU[49;^XM=:DM(E<HWD(L$&Z-62")7 <O\
M,-_WOOMV -O_ (4GX@*D?\+E\?<_]@K_ .0*KM\ ]99B?^%R_$,9&.+C3_\
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M58%M]4M],M8;R&,J5258E5P,?+C<#TKJZXKX/[F^%/@XF228G1K+][(I#O\
MN$^9LLW/_ F^IKM: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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ML4JNRNNY-NWY=U3?$KP[?1ZD-!U3P_XA\*W^N3:%:>';;5=1MV1[J*[NO/\
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MI?N%OFV^F[FNHKF/AVL4?@7P\D4VGSQKI]NJOI&W[&<1+_J=O'E_W<=L5T]
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MW.FZ[J&GQ7EPD2RRQ13LJ;_*1$W8X^51TH ]*HKYQ\1:YXNUKXM>+-*MM?\
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MUOX6^$[Z;5D\0:5+;ZI;Z/J;Q"!=0@:=EFE3R@JHK[FW?*NZOLNO,O@1\/\
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M :S!>M"L&Z5X%^V;I&M:]\(;>Q\/:?;ZIK$VLV2V]G=Q12Q3,7(VLLW[L_\
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M'\_C'4-'U&R\1ZEX:U'3!,D5UID-K*Q679O5EN(I5_Y9CH,UW-)NH \8T;X
MZCH?B75?$%M\2?$\.KZPL7]ISQVFF?Z4T2;(BRFS(7:O'R]:]"\#>$X_!/A^
M'2H[^ZU,K--<RWEYL\V:2::2:1VV*J9+R-]U172[AZT YH 6O!OCQJECI?Q
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M40D;-L_X1&X^_P#>/[FR]:]^KP#X8^8O_"ATE";U\'7&Z2/E=WDV'R_^S?\
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MOX(L#NSS_P ?UY0![-1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MK)-N69-SK_=97W+9C\9>.[']N271)/$ME+K;HGAUM:_LQ%0V_D?;57R-^/\
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M89:@#LZ^7O#Z^%M8^+'QI\/^);FSM;._M[.W=KBX6&1U9[QFVEN0R[E8,O\
M=5J^H:^2?#/PS\._%C]IKXUVGBF&XU>STV;27M+7^T)X4@=[1M[*D3J/FV+R
MW]V@#>^&?PM\*>!?%UOJ6K?%&/Q+'HI:WT+2I[^**VTU98]I/E!RIE8%\;0B
M*K;415"A='XJ_#[PI\4=6N-9TCXEKX8O;BT73]373]01[:_M5=F59DWKRNY]
MKJP^\P;>ORUT<?[)/PJBSCPP^X]6;4[LEO<_O:R_$W[-OP>\&^%]4U;4?#A@
MTS3[66ZG;^T;KA%!=L?O>O%5HQ:GBNK?%#P1I?Q4\!>!M$M[V"T\.ZF;9]7O
M)(6@N));NUN'N/-\WG>T4V6V?>8;=N>/8_BE\/\ X2_%WQ!87^L^*K2SU"W7
M[/+_ &9K45N]W&R-MBE*G=MVNV-I5L.PSM9E/DWA?0?V<]8U35;O_A!]7TFX
MT_2KC6MMWJ,S1W-K$BJ[(B7;H?E<?*P&?F_NM4NAZ]^SUXBL=<N9O!NJ:5%H
MUBVJ?Z7>']_#YNS,#173*WSN%"[@/FJ-1G=_&[4/#*^!?"B>!/$/A<3^$=3M
MKVS\/-J5JEI>Q1*T36QWN%7".S*W\+(IZXJK^S]XTATGQ)X]\1>,?$O@W0I?
M$E[;W*:?9ZU;L4EBB\EW;;,Z#<B1+\K%B49FV[@HH_"WPW\%?B[K5WHUEX(U
MC2+^UMUOC%J=U+$SH[8W#9<OGG^%NFYO[QKU=?V7/A?M(;PI#.&VY^TW,\V=
MO3[[FA>8'C7[9GC#PQX\\"Z-INA^+-&U#4[&^FU9H;.^AN'1+?3;V;<Z G",
MT03=C'S=&Z5[5'XL^+W _P"%<>&_]YO%TO\ \@5\\_MC?#+PM\'/AOI&H>$=
M!M]+OKW59;2:4/*^^*6QO$E7<9,C*L?T]*^C;'X#Z%:K)_Q/?&DIDY/F^,-4
M;:?]G_2..M,"YX5U[XA:CJ<<?B#PAH^B::R%GN;7Q"]Y,C8X7ROLJ \_[?YU
MPO[1G[2K_ 74M#M%T.'54U"-Y9)I[Y[?RU5XTPH6"7<?G+<[?N=\UZ!X?^%&
MD^%]:.J6FH>))IS_ ,LM1\2:A>0?=*_ZJ:=T_B_N]>:A^(_P7\(_%B:QF\4Z
M;-?2V".ENT=[<0; ^TM\L;J&Y1>N>E '@GP[\?\ B+6/#?P?;0]"TW4=>L+&
MZTY;>ZU5HHI(DM+5O.W^0Q&Y"C;=O!;;NKV6/Q5\9&7YOAYX35_^QMF_^0/K
M7E'PO^'NC2>#?@K81QZQ9QZGIDVHW,EOJ=W;3^<UI!N_>I*'5?E7"*=FU0-O
MW:]F_P"%%^'FC ;5?&/RC[W_  F>KK^/%U0!D2>*/C:V[R_A[X."Y^7S/%UQ
MG'O_ *!7F?QR\<?%'0?#.DZSXD\%^&+.RTG58=1']G^)9YGF:%'EV;6LE^\$
M8=?2O95^ _AM(FC_ +2\8,K]=WC/6#_[=5YE\:O@?X6M_#NAZ?-)XEU&UU/7
M]-T^X@U#Q7JES&\3W"[U82W+=5W#=][YN* +7A_6OB!#\4/B5_PAVA>']7TJ
MXUJTGN)]6UF:TDC=M*LAM1$MY5*[54[MW7=\M=NNL?&1N#X5\$IN[GQ)=G;_
M .2'-<AX<^&.B^-/B9\4WO;KQ!:FQUFUMXET?Q'J6FQE/[*LF^9+:=$<_-]Y
M@376?\,V^"VE\QY_%;OMV9D\9ZPW'XW7O0!)#JWQCD"%_"_@F+(!9?\ A(;L
MD>W_ !Y5YY;^,_%FG?M"2Z5XFT;18)=8T2&VCFTJ]FN%14_M&9-V^!.?W4JM
MT'W?[V*] M_V<?!MJ<0OXEC7=O*KXKU7!?Y?F_X^>OR]?]IO[QKE-#^$OA?P
M]\>K^>QM;I[RR\/Q7ENUYJ=U<LDLLMU$S_O96_@W+\W3<VW[S4 >A_ W_DB/
MP_\ ^Q?T_P#])X_6N\K@O@3)YWP1\ 2>6(MWA^P.Q?X?]'CXKO: "BBB@ KQ
M>U\S_AL#4N!Y1\#6OS;NI^WW';\:]HKQJV\K_AKB^)/[_P#X0F#8-G\/V^?=
MS_WS^E 'LM%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %>/
M?"[YOC-\9B R_P#$TTX'CY3_ ,2VWYW>O/W>VT?WJ]AKR?X6MN^+WQD^]\NK
M6 Z_+_R#+6@#UBBBB@ HHHH **** "BBB@ HHHH *\Z\13;/C9X,C".6;1M7
MDW*QV@"6P'S#_@0KT6O,_%#))\=_ T13YAHFL2ALCM+8#_V:@"?X#S&X^',4
MIV_/J.I'Y/N_\?\ <?=KT6O-?V?9#-\,[9FWY_M'4O\ 6=?^/^XKD_VK)]47
MPGX;ATR_O[&6YU2:-_[.N;BW>0+IM[(JEK>2.7;O2-B%<?=H ]:U'Q5H^DZI
M9:9?:M96NI7S;;:SFN$26<\_<1CEONMT]*^,_%UC=WW[0GQ4AM+B&QGN/%O@
MGR9YH'F1)T_>HSH&3>NY%7[P]FJC\*=:U/4OBY\-S<ZEJE_NU*X56U"]N[AO
M*_L^!V3][.S;5EE9MKM+MW+]WY=W3ZAY:_M)?$F6)\?\5AX.1HUV[?\ 5/\
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M2--TE;J^\K2K6S\BXEE5;6+]TNYFV13N=W3<A_BKU./]@7X1>9(\N@K<L_\
MSUAM^/IMB'_U^] %&X_9O\:>/)/$UUXV\2V-U>W_ (9F\.V$MLN[R-\J2^:^
MR*#/SQ)\C*WW?O#D-%=_LR>,/'5KXKE\?^,;75=4U+1O[%TN>"()]C"W'VC<
M3$D._P">*)L$'[K=OE,]Q_P3Z^#\D<BQ:,\3M%L5F6)U##.UL%/O+Q]=OS;N
M:\FNO^"9]S--/(WCC24B8,55?#B(I^9L?(DJHO!_A7^)J /H?X4_"/QGX?\
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MJ"))+NL+5BS_ +O:S?PYV_=5?K7?M\'_ -VZCQQXR1F;_6+JO(^7;C[F/?\
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M[2/7?$ND+\([ZX\:-XC5]"\16>FJN@6MH;B)H0\0VQ%$A5E?]RV[YE^=OFH
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MV[;OX1\V[;SN;@]8^ ?C3_A/M1U2+1]'ELY=>BU+^U6U/]_]DBU)=0\K[/\
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M'N/.MX_VBOAJSMTD1;?S%]=O^F[?T-?0T=K#'G9$JY.[IWIS6\3-DQJ3_NT
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M*^9,-]E\K-]XX7+?\!KU.U\06W@V3XU^)+BUFN8-'O?[09/E^=8M'LW94/\
MP#\Z^SPU1U:49OJC!]A=.U;2_B+\5K/Q-X7\2Z'K^CZ5H-_IMZ-+U"*ZECFN
M)[5XMRIG:-MO+]X]ONU\R>+HQ-\!Y4D?;M\)>$-^UNJ>3<?]\M][_OG_ &J]
M.\8_M6:U9^&;R*#3M'T+6=FZ*1+^/6+8OYZ0M"_ER0M&^Z56/WF55<['Q7)_
M$;P;+I_[,.AZTDOG+JV@>';+['Y6UX1;V\K;MS-\V[S?XA\JJU=)+1],^(M!
MO-:^'.EMI\:OJNGI::A:0L<>9+"R/Y6X_=\Q5:/=VWYYK3\+_$;1/%V(;"^C
M_M!!BXTV9A'>6CX'R2PGYD;KU^HRO-3_  _UBTU_P+H&HZ?*TMC<Z?;RP.R,
MFY#&N#M;##\:XC]HS28+SP'!=1+;6^LQZSH\5EJ$ENLLEL[ZG:KN3+*?0[=P
MSMH ]?HKYS\=?%CQIINDVF@X_L;QI9743:G>06@FLYK-]T4=Q 7&W;+*T2["
M=Z-O'S!=S)XZ^,OBWPSX5NM%>V^S^-],??<7WV)C97EHJ.5NXL_+ME=8XF3.
MY'EQRNUV /HVBF1L649ZT^@ KS_XQ>,M0\#>#?M^D_91J$U_96<<M]"\T$?G
M7$<3.R(RLVU68X!'.*[:\N%M;6:9B L:,Y9C@#%?&.I_M2:7XT^">GVGC.]A
MA\:2WUA?2Z?I]C<6D4T*7J.5@EEWQ%]D3K_K=N]&W;>5H [.']I#Q;8^+- T
M*_MM*U:+4-;339]2TW3;FWC2)EM?F\N67*,'N&3<Q_A5MO\ #7U(M?F^NM>#
M])U[PIK-[+-X:T:VUJUU:TG\1Z??-/<Q1+9[[B"6&W:&9F595^;^^C?+\M?4
M/A7]H8_$+XS:;I'AF>WO?!EQIRRO--IUQ;W+SG[5ED:79E%^RJORHW+-\P*[
M: /H"OE?]J7X9Q?%;XI> ]#EU*33S)9WAS';^;_'$H^;>N/O;CU^YC^*O=_&
M7Q&TOP5)96US]JOM5U!V2PTFPC\VZO&7[_EI_=7<NYV(1-R[F6O ;KQ]?^//
MVD= MKOP[<>'KW1H6M+JVN;J*5RTOD7"KNBW+N5%9OE9OE_WJ!HG_86\$W/A
M;P?XFN9+R.^M[R[M_)E5/*+?Z-&[;HMQ"\R[?O'.WM7H7P<\'Z1X@N+WXA:A
M8VM[XFU#4;S9=R0KYEB(G>T6)/E&QUBA5';[Q.Y<[0HJC^R7G_A6]W(H_=R7
M:.G^[]DM_P#97H=RXQ_#5GX/>&8M>U"]\=BYO;6UU+4KJYL=+AO9UM]F6A\^
M6+?M9W"%]N-J[_N[EWT"/.?&FH67PG_:P/BCQ/>QZ;HFIVL1M[MHI60LMN\3
M*S!,!]RK\H9OE96P,5[+X=_:(^'?BW6K31](\4V=]J=VY2&W4.K2,-QP,K_L
MFNNUSQCH7A>/S-9UG3])3&\M?720KC.,_.1WKD]/OIOB1XLTS4K6"YA\+Z,[
MW%O>3(T7]H73(T0:-3\QA1'D^8X#LRLNY5R0#TJBBB@ K/\ [/MFOEO#;QM=
MJC1+.R#S C')7/7' X]JT** /,Q\&;"\CO%UO5]8U=FUJ76K.:._FLY[$O$T
M7DQ2V[(^P([C&>=WS9KG+C]G@/XHM[F#Q5XF@T!-OFZ>_BC5999AL;=^]-UN
M1MVQMRG^'WKV^N.\;?%+PK\-U@;Q/X@L-%:=6:&*YF"R3;?O;$^\^,KT'>@#
M%N/@-X1O(=4@N[6^U6/4+9K25=7U2ZU#;&=I_=?:)7\ILJK;EP=R*>U<?IO[
M&_PZTFWN8X;/4);B9HF^V7UV;N6/8VX*GG!U4'.UL+\RJH/W17IG@KXA^'_B
M1ILNH>'=2AU2UCD\J5H\@Q/@':Z-M9=RLK#(Y5E;H176LP4<T >;^'?@'X&\
M/V+6[>&=*U-V=G-QJ&GV\LIRV[;N\L?*.PKR'X;K9Z7^V=XNT&QL8[&VL[&[
MNXEAC\I%66UT&+:B!=N%^S]?]NO;6^-GP]61D?QSX;1P2I5M6MP0PS_M_P"R
MWY5X7\+]0M?$'[<'C?5]/O;/4-.?1'2&>SE$BNNS31NW#@_,C+QG[JT >P_&
M3P/I6N^'-2UJ]ENK;4-*TRXDL[R*\>-;615WB54W!-X*#YF'3<O1FKK_  ;J
M5UK7A/1K[4(#;W]U90SSPG^!V169?P)KB_C;X*G\4>%=2NV\07UC:6-C+<?V
M8@B^QW,B?.IN 49W3Y=I3=L96;<K<8[GPOJS:_X9TK5&A-LU]:17)@)SY>]%
M;;^&: /*O#\?C'X2ZMX1\-7=SI.K>'M7UF[LTE@LYDNH0\5Y=J78RLO_ "R"
MYQ_%74?!N1I;?Q@7RNWQ+J V^WF4GQ2D*^+/A=&ICRWB5R5?KM&F7_2G?!^2
M.:'Q=+#()H'\1WRB0;OO*ZHXY_NNKK_P&@#T:BBB@#YZ^)#2?:OCZ09MJ^"K
M=59E.W_4ZB>#W^]_GK7T!;_ZE/\ =%?/?Q#S'<?M"W;-^[7PE;VN[!X=;6]?
MW[3K7T!9JT=K"DAW2*BACC'.* +-%%% 'SA\*Y/^*;^  CPL36MTH5=W"?9'
MV_>53_=ZJO\ NK]VOH^OG'X5[KCPS\!900Q:WNK@ONSO5K1_G^[_ !;U;_@5
M?1U !1110 4444 %%%% !1110 4444 %>.S6Y_X:TM)P5"GP5,A7C)_TZ/\
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M(=6O'V(K)--<*S*V\_\ +)XOFPNW8WR_WNXD^R/@/\?+E=6\ _#\:?:OIO\
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M?<R2LBIM;=7IO[37CRY\7:\-6TN^UP>'H+=8KBPO'N+6"&YBEN4=6@,13?\
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MO1?"-Q>:XMO+I5K(TMK:)_8GVAFB>)8E\UOLJM]W:I?^)J /NJBOG/\ 9/\
MV@?$WQTL]8?Q%9:3:36L%K=V_P#92N%V32W28?=*_P W^C=.&7=RM>E>(-/^
M)=QK%P^A:[X5LM+8_N8M0T6ZN)U&T?>=+M%;YMW11QMH W/B);FZ\ ^)H@=K
M/IET@;..L35\W?L,3+-X1\8E(C KZQ%*%;^ZUC:^O\/RG%>K76D_%YK&Z2[\
M2>"_L_DR^;Y7A^[=\%>@7[9_GWKQ+]B^QG\-ZQK-@+J>2RO=*TZ_,-QL9O/-
ME:N[;MH;I<*NW[JA5KQLUCS8:7R+AN>H_%+X'ZAXP\66?B3PUXGE\'ZUY7V6
M]O+6W68S1!75?E9@NX"1UW,&_A.-R)CSOXS?#70/A_X9^'OAZ=Y)--N-0N+2
M^\2WVG_VGJ*,\,]P\N[:QWRRKN9L-_$VWY=R_4^[TK)U[PWI/BJR-CK.F6>J
MVFX/Y-];I/'N'1MKJ5S7R6'Q=6GRQDO=1NXIG@?[//@?PCXN^'OCK09-*L;_
M $AM9ETR6_AL18W6HPHD4R2S,BHWFJ\[[6&TKM5A\WS'O/A[\$O"_P &M2U3
M78=4U6^GFA6(WOB"_P#M)M(0J*R)*XW*A\J+=N8_<7H!7H6BZ#IGAK3DL-'T
MZTTNPC_U=K9P+#$O^ZB@"O%_B%XL\':I\8H]#\;^)-%T[0M L;74H=)U>[BM
MTOKV5YU5W65OWJP+$C*/NJ\NYOF5<5[2K7JRC&ZB]6MV*R21E_"OQ!IOB[]J
M[Q[K6AWL&L:5)X>L($U&QE6: LCMN171=K'YO[Q_A_#Z0_\ 0:Y[P3\0/"'C
M:WFA\,^(='UPVNU7CTN]BG\H=MP1N*Z%LJM9YA3E%4YM6TVZZ=PB]SYH_;.C
M?^S])==WSZ;?VJ*JNV7EGLE7[OR_WOO?A7L_P_MX)/%'Q4BE7,4FN1-*C+\I
M#:58Y^M?/O[:UO:7EYI=S?WFR#1=!U+55L_MMQ:?:66XLEVAX94;=SN'WMNW
M.UJH?L9_$0>+/BQXA2TAU;3[6?1X;J:QU/6+V^9I/+M DK?:99&'R$['_C1E
M]A7V^7:X:!A+=GSM-KW@[3_B?8'2]1L;+2%UB5[:74'^SQ0VC+<+;[WVM*J)
MOM_E\K;M5=S+MKH/&FN6&O6MK:0/INI-,UPMKKELJNKJ]U<*[Q76W>J;F^9O
ME9_XMVWY?;?'WV?2?VRM#CLC]EMO[0TI?LMH9?*?=%*I9D7]UN^9?O?-A<KU
M:NM_:X^%=I>7FF>/'OTBGLYM/T\6.QOGWWRJ'W!_^FK<;3WKTKBN>XZAXJ'A
M?X:VFK);&\NOLMO':60<)]HN)=D<$.[HNYW1=W0;LU2TWX9OJ$5M=>+M9O\
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M9=RL[[5;=\O\%?1J_ _0_.,DFJ^+)0PQY;>*]2V;?3'G\_C38&5X-UBVT?\
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MFKA+3X:V]TZS2)!KVD2;+>-I97_XF$'RHB_,S-]T*.NZO8*\Z^.6U?"^B%B
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M(D7YO[BU^GGB)@N@ZDV/NVTIZ9_@-?)?[ J;/#_BH9WMYME\^!_S[_\ Z_\
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MMO\ OK^G'3=\WL%>-7DB?\-=:;'_ ,M/^$'N&/7I]O@_^O0![+1110 4444
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M3/\ +*ZMLB1MK?.LJK_ M?47[.JQ_P#"M5,-FFGQG6-7Q;1KA8_^)A<?*/\
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M,L6[<Z_-N7[K?2W@7X?^'_!\U_J&B2W]Y<7P2"YO-2UB[U*5A"SJL?FW$LK
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M#:+R[:T6)(XOMUZRLS^:[%V=G;:JHJHT7WJZ(T[TY3[/_(GJ?1/P/D,WP8\
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MJ/\ M?T_O5Z]7D/AUG7]J+QHGRA&\*:._P OWO\ CZU$?-0!Z]1110 4444
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M^U!XN3#L6\):0^YC\H_TO45P/^^:]:KR7P^I;]J#QF7V_+X4T8)M]/M6I=:
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MURZNT#2W44+MLE=D#;)77=M_BKZFA;S(U;!&[G:U>+_MZ*&_98\9@@-E]/\
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M;FQ?A[X)U+Q9\'7M=-MKS67L/'FJ37JP2P0W$\3)<0EAYNV+=MF1C_P+:O\
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MAS'Y?Q8^+&V/RUDU*Q=FQ]]O[/MUW?DJK_P&KOQP5I/!VFA#AO\ A(]"]?\
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M&.?]%CKV2O%?B7O7]HCX,.!N5AK4)7=C&;1&SUY^Y_X]]: /:J*** "BBB@
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MQ?O$-.G3S$BB9]N?M#;3\O7F@#TVOD+5KRWG_;F\+PQ7%N\RW=^SPJ^9%/\
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M\=S/%I^H:?X?F\<VZV-OJ0E1E9;Z]W?)*S,K*C0*V[YMRMN^9:^V* "BBB@
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M>7'K$3,R[N/]'GYXKZ3KP#]LRZBLOA7#<7$H@B6XNHMS(7RTNG7D*+CW:5:
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M&G0?P+Z5!HNGZ=;^+/$%S;7HGO[D6YN[4%?W.U"J?+U&Y?7^[3N*QA:?"O\
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M* "BBB@ HHHH *\;T-4;]K;Q@S*N\>#-(56QV^VZCN_]EKV2O']'RO[6'BL
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M(V.F>W\-7?#<NW]L#Q-$4V_\2+>K;>O_ !YJ>?\ @/\ X[6;^U];Q/9^!)9
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MV\OS,@L%X3GC<<5S>N?'SX.>&;6^FN+^Q$%BY,LEII4LD:.C8^^L6S<K9[T
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M]?KQ[XE9_P"&A_@T1_<UK_TE2@#V&BBB@ HHHH **** "BBB@ HHHH ****
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MQ_\ &OK7CW[./B";PCK>MZAJ'AKQ(EAJ>DZ7%:7%OH5U*C>3]IWY;9_MJW_
MOSPCC)5*<G4IV\GU*Y=2!?V[/$DRMY?P/UUN-RLMQ<<\_+_RYUM:#^UIX^\3
M6SW&E? C6[N.-_*EW:BR;'VJVUE>W4_==&_X%7L/_"XK'='M\->+7\P;D/\
M8%P,_+NYROR_\"QS47PAFN;P^+]5N-*NM'BU+6VN[>'4(6AG:/[+;IN=3T^=
M'7_@-<$JU!1YW22:*L^C/!]+_:*^(_@K5O$9N/@5XAGG\0ZDNJA(99I4@W6\
M%NJ;TM67.Z#=\V&^;[M6E_;"^(ZJKM\ O$2_/AE_TO=MV_\ 7GR=U?6FZF[1
M7'6S*C4ES2AS/U:'&$CXDUBW^)'Q\^,GP[\32_#'4O"-EI=W:^=<WT[,OE17
M<5PS,K(CI_JF7[OS;J^RO&/ANV\2>&=6TB\A%Q97]I+;2Q==RNC*1^M:6VD^
M[653,:=6$8\EG';78KV;74^3?^%]?&WPKX5TVWU/X3BT:&*ULKC7]4U:)XUE
M9T@\UX4V;]SNK;59?O=?EKE=-_:$\2_'*XTO1=,\0:;>S"XLM82SL?"4OFA[
M>?[0J,SZHJMM\A=WW?O?+\WW?I']HB&*X^$^J1SAFA-Q9;]LK1<?:X/XEY%>
M8?LY_ .#19/!_C3[?IL+1Z4A73])TUK=3YL3<.[SRL^WS6^;C=]XUZ>$Q5&%
M*59Q49:VM?4B47>Q!H^H?%#PW\3+CQM)X/;Q3=7>GR65P@@&D*GS6^UE3S;M
MCQ"=S;EW;E^7Y*C^*VJ?%?XK6NAP2?"^31?L%Z]VLUMK$5RS-Y4B)N5UBVCY
MAW+>B_Q+]2\5YM\:_B-J/PWTO1I].L]/GEU"_:V>74YWB@@1+6>X=V9$=ONV
M^WA3]ZIHYS6K34(Q7XC]FDKW.6F^,/QCMRJ_\*JCN .ODW\?.[[O5^-O?_>7
M[M$?QD^,4RP@?"81[CAI&OXL=0V[;OR%V[E]<\_[)X/1?C'XA\9?&#P9;RW3
MVK"]>UN[;0]29]+N$\AG5]KP*[[O-7Y6^[M5OEKZN4?+6V*S:MA^5.*NQ1IJ
M1X0OQF^-:J^_X2+)TVF.^A7;^<_S?I^-7KCXQ?%X6_[KX4+YN-O.I1'YO[VW
M</E_X%7M5<_XJ\<>'O ]K%/XAUS3M#@F?9%)J5TENLC?W5WD;C["N..=8B;M
M&";]&/V274^*X?VG-3^$OQ8\6W)\*J-?UB:%+O3+J:+;#B:0JJ2H_P S?O69
MMRC;7N__  N+XZK&2?A 'D7NMY %?G^'_2._;-<U\&_"O@GXT?&#XLZC=66G
M^*-(#Z:]E=[UEBD4^:S8V-M*[HD_[Y93_$*]UD_9[^&$RXD^'GA20;M_SZ);
M'YOF^;[G7YC7V5&<JE.,IJSLCG:['S3XB_X7/K6L:M>_\*JE@?4)KB[EVW%J
MWS/8)9,J_P"E?W$5EW+]YJB;1_C3<>;Y_P .G8O,+I_,:R+.RZ8VG[=OVWYM
MR.S?[W^S\M?3MO\  GX7VK)#%\/_  I&R?,JKHUKD?+MS]STXHD^!/POVI%)
M\/\ PGM5=B(VBVW ZX^Y_L_^.UN!\L6?AGXVZ?XVM_$X\ 327]FL2+!-/:>0
MZ+:/:JNW[?\ +N5]S?=W,BU-9Z'\=O#NDV]O%\/Q(EM# C*YLMLRPV;VBK\N
MJ+C=&^[ZKQZ5]/R?!GX8V]M([>!_"L-LN%=CI-LJ?*W3[GJ!3;CX8_"Z&9EF
M\)>$XYHT7<)--M0R)NVK_#PN>* /#-!\:?M"^%])TK1XO!.E"UMK>*UMUF@M
M [HB*N[C5_O?\!KR;7+/XO\ PC\*WFH:GKWB31M)L[A6:*WDM'7=+<;6?9%?
ML[;G<M\R_,V=WWC7VPWPY^',-P'/ACPS%-G[W]GVX;_T'Z5A:U\(_A5J#6EG
M>:'X?LWCG%ZEO D5MYS(Y;YU3;YB;SDJV5W4 >1?L8_%CQ3XVOK_ $G6=6O-
M<TI;222VN]1"&=98KC8Z[E9CMV2Q<.SMN#?-CY1];5\U_L]^$=,L?C!\2M5T
M]%A3SWB2*!5$6Z6^NFE<X7=N/E)WQCW+&OI2@#YL^.&LW,WQ^^&&E%(EM()T
MNMS;M[.]Q&O7&/E6+=_7'#=[\=CH*V_A%O%']F_V NNI]K_M?9]EV_9KG;OW
M_+][;U[[:\Z_:7\*Z5XJ^(G@6.WU&?3=8N;N+3KB^TZ\9+JVA^TP2KM7E49M
MKJ'8;AN^6I]4_99L+?3[V2#QCXTUR^",T$.H:I;JK-M 5-_V5MJ_*J[MIX]<
M5SUL12H).K*R8TKGCOCZ'X<Z#XN\5:_H&J_#=-+6UA.GV,*6M]YKLL"[5M]J
MIL_=2[F1]_SM_>6M?39OABO@7Q=:>)&\,6^KW6E(-'FU6)5?RFM6V>2RJTH3
M[WW.?O;<TH_9C\212,8_#OF8^ZT_B^%<JJ[55L:1TQT7E5^;%>&:Q\*]7M_
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MQOXG*O\ PT'\%V _>;M94?[OV1=W\EH ]DHHHH **** "BBB@ HHHH ****
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MT;["=O\ [-7LM>0?$[_DO/P6Y_Y>=6X_[<'H ]?HHHH **** "BBB@ HHHH
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MLR[OFQMKE_!'@/5/"OB3X<Z=>_"JU\)3:'KTL\OB.*ZMY5NDF6X5(4=%WO\
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M)=^Z/XBZ4B[G;:?](TMEV_W?O+_P*OH6@ HHHH **** "BBB@ HHHH ****
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MLZ^(RRG>N=8T_EMR_P#40_X%_P !ITWP]T5OD_X9PUYN_P#R&--_B/S?\O\
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M^U_BRH;X4^,U/0Z->_\ HAZX>-HY_B-\(IA^ZC?0-195W;?F9++:N._R[O\
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M_P"$JG!5>N[^R;_'X4 >PK2TBTM !1110 4444 %%%% !1110 4444 %%%%
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M%\,>-LX8_-X4OUZ?6*K'_"Y++:Q_X1SQ9O"Y\O\ X1ZZW?P\?<Q_%_Z%_=-
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M^$)R[)&BHN_;J"KGC^%5^E;S>&OBO)"ZOXY\**Q^[)%X3N%(_P"^M1:O3**
M/+I/"GQ0DAC4?$#0XRK[BZ^%WW-S]WF\X7]?]JFKX(^)TF2_Q)T]"Q_Y9^&4
MP/INN&KU.B@#RQ? ?Q+5\_\ "T+9NO#>&HO_ ([4*^ ?BA]J)/Q2M6A_AC_X
M1J'CK_TU_P XKUFB@#R[_A!?B8N[_BY]K_X347'_ )%J/_A7_P 1MJC_ (6A
M\V_+,/#]MRNW[OWO6O5:* /(6^''Q*:-5_X6W-]X'</#UI]WNO\ +_Q[VVS+
M\-?B"RQ!_BYJ65V[VCT33QO]>L38KUBB@#RV/X9^.%'S_%K6B=W\.CZ;T_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %>2_'*$2>(/A3(S,/)\7PLOE_>R;*\7_V
M;\MU>M5Y'\<#(VO?"@(C.3XPASM&[ ^Q7><C_./O?PY !ZVM+2+2T %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 5X_XN7;^TY\-CM_YE_6_F9L
M#_6V'YFO8*\E\897]I3X:_+P=$UP;A_OV- 'K5%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %>3?')0VO?"K)DW#Q?#A4^Z?]#N^M>LUY)\<F?^W/A2$4.1XOA)YQ_R
MY7G^R?\ >_X#0!ZW13?X:=0 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !7E/C61H?VA/ACAL+)IVM1GW^6U;_V7]*]6KR;QUA?CY\+CLW,;36%
M#?\ ;*#W_P \T >LT444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5Y-\>F\N\^&A!7S/
M^$PLMNYL?\LIPW_CK-7K->0?M 2&.X^&A#%6/C&Q'_CD_P#LF@#UY:6D6EH
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M\5-+N].OF>UT*_66*5EE:_54@B^>UVJZOMMXI=OFO\U^YW)OVKGV/PITV/\
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M^N@\"R*W[0WQ44)M9-/T12WK\MT?_9J]9H \(_X57\;F8%OCG:KST'@VU/\
M[5_SFI(?A;\:1Q+\;X'_ .FB^$;53V[;_P#>KW.B@#PG_A5?QL5O^2Z6S#G[
MW@ZUZ_P_\M?I3Y/A7\:&^9/CC;JWS?\ ,GVI'M_RUKW.B@#PP?"OXS_+YGQQ
MA8;ER%\(VH[C_;IG_"I?C5\@_P"%ZP_+][_BC[7GT_Y:U[M10!XBOPH^+K*
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M\9:AXNBM;;7/%VLW&JW-K92>:MG%*JA8-_\ $5^<[NGS4 >U;AVY-?)?@?\
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MNUQM:?&Q1Y^U6?EI%W-M7=7&WW[97Q-_L72;>"ZTVWO+>:_+ZG/:6B)J20M
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M5CG672[:]M['R%T_Y49H8/E:X"A6=O/9]KL2JP)M7Y\URWQ$\!W%]X-\)_\
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M^*WAO5;OP7K'A[3=+L-0AEN-3N+)U+S-;[ BPW$K;OW3_-@8'?YJ (O"F?\
MAJ+XBYBPH\/:'M?8O_/6_P#XNOX?[/TKV.O(/"]X%_::^(-OL=<>'=%;/\)_
M?7^X_P#CR_\ ?+5Z_0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MWECS8MC,4^ZDJ[5_>K\SB27=U&WVB@ HHHH \:\--_QE5X[!'/\ PC&CX_\
M B__ /BO_':]EKQGPS&)/VK/'DI$>Y/#&CH&/7#7%Z?_ &7_ -!KV:@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M\7X?=YKPZ\T.'4O ?PENIVTN>XO-'AL4@=&N-156;?OLDV-Y4J[0OFLZJO\
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M3UI+6WNXY-&O?*"6^_RW1?M7#8E;<O\ %M7YEKI(="^/RW(=_%G@%HRN"O\
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M%>(Q_"GXO*?G^.$C#=G_ )%6R'\6<?\ ?/%#?"/XM21[?^%X7"MGAE\,V7%
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M7_/ZT >UT5XNW[/NJ-A3\8?B'G &Y;RR'\6?^?7Z?Y-/;]GW6)#\WQB^(G_
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!]%%%6 RBBBH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH ?1115@)MHVTM% ";:-M+10 FVC;2T4 )MHVTM% ";:-M+10 FVC;
M2T4 )MHVTM% ";:-M+10 FVC;2T4 )MHVTM% ";:-M+10 FVC;2T4 )MHVTM
M% ";:-M+10 FVC;2T4 )MHVTM% ";:-M+10 FVC;2T4 )MHVTM% ";:-M+10
M FVC;2T4 )MHVTM% ";:-M+10 FVC;2T4 )MHVTM% ";:-M+10 FVC;2T4 )
MMHVTM% ";:-M+10 FVC;2T4 )MHVTM% ";:-M+10 FVC;2T4 )MHVTM% ";:
M-M+10 FVC;2T4 )MHVTM% ";:-M+10 FVC;2T4 )MHVTM% ";:-M+10 FVC;
M2T4 )MHVTM% ";:-M+10 FVC;2T4 )MHVTM% ";:-M+10 FVC;2T4 )MHVTM
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
<% !1110 4444 %%%% !1110 4444 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>image_1a.jpg
<TEXT>
begin 644 image_1a.jpg
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MF"/9&3':4=+;:6U6H BQ34*D%!>FR:.WC)"?WUF@ A:*VTAM0G%;S5<PBMM
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M\$(2[,_/35.?%3'PVO:+X,OUZM):]FTMM6P"!^$;XNA6/AQ\WZFCV\F3:YF
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M0KWG[AHKXX>E6XK;!O5,U,)NJ_?C'B O.9'B-D(((<3O!).X#?[:)SO+M1&
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MJUU!>>7$D3E:P(SF54[/A>(V0@@A)+0))G$;@&URPWG])#DAPK2I!SKMHU$
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M-TKM*.0O8>/\Y?ER[;@_9V*.I+=I;GINGH() K Q-MTP3#[<,4U]K6\-6^K
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MXXRQP1R"2GW&SSB_K(2'CI9T.'1(Q@1C@[%8J1UIY4O&&$;-?+\<*_ME?L%
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MFC%6L=W++KLLKN!6W"[CNMGM-D-_F-LX1A(8F(LX]XT&H@_FMJ(XT"YS&^(
M(D$QX5+M?M27YC:J5@XD<QOW.(3.H@#&Y %6 F6,M4*KYC:$T70=Y^WCOL;]
MNECAE#'/>&.?Z3Z% (D0>M999[5T+"(B(M+]:&Z3P8[FMO:AN4U$1$2D-=IE
M;LLA'XU9 !WRT$,/C:8)3#?DQM$1F?B?ZU,I,"-A6J!(*"LGH:/E_]\?YC9T
M(PQMY,*)???=-^:WZUFE"^;,F1-U%(ZQ.$F.R7,4'L5@@RZ!$0>=DO==M,2B
M1M!.<UM16V;?U?193&B8,])Y8HR@%:%K%LUM:#0GGWQRQ4F#1:Z__OJH-^6F
M,_Y^VVVWQ3Z@/>PW-T.BMZ(?H7_5"SHH&FFNVS9B;F,. .<%<TP^5M$XCCSR
MR(:,9^B1Z/2YEH7V,6'"A'B\1Q]]=(_QPOL-<P_07_C_%)7.4PHT<:ZU7(-A
MW# /@//.M8C9+=?5.2ZT,'0EQMG##S\<K]VDJW/\C)LT+LO,;96"\T=!7PQ:
MC(MV%BM$,T2S*NI-W+/0X6@WNCC:4S+ H2W1I_03]Y"I4Z?&GZ6QC0Y//Z(9
M8KJB6&.^;30Q],BB]L@[.@49*9A)WW+<LV?/CH:G>B@SMW%L'&.U.02<%\X5
M]Y7\'H[1D,*A]$6]XR>=UV0HYCBX?K@7#U1S&T6#F>M3ZUR4F=O8'G-A:LU7
M?NFEEZ*63;_GXQ\3+'TK(B+2'VANDZ&,YC81$1$9E'3:W$;RF"0VE>A848KD
M<%EE-/;)<Q&F)MIW_/''1P,,!BT,.1C!$%WRP'255[AC?[S(8! HFMM(6B(8
MU6/HH'HBR<<\$8Y(@!!6:=4YVDZ"<\&"!;'B(@("B?9J;<? 5FP[YAR2A"26
M,>PD@8,_V3\)9B9[\0R)Z,3Y(2E/DI0$9DK"D]S^^<]_'D62_!BVWW[[V#[^
MKUX8!U0PS%<E0A"@G67F-H0\$MPDOFMQW777Q41M_GT$0)*M29"J-[%,HGS^
M_/E11,F/FTETO/!V&V^]]598M&A1%,807O+CP\"%T-C,JE1L%Q'BE%-."5ML
ML46/[6((8C)<JZM=U4M_F-M(HG-,7'^8T1H-Q%:VRW65;[==YC;.!545\VUS
M[7_M:U^+)K9*M,/<QO6)N%*<0(WI\<PSSXRFLW;1E^8V^I_[#$)A47RYY99;
M&A)]*]&JN0V1"6$4 2J?P(O@QSVZ*&#15_R.XIZ?KP[*??"&&VYHZ5A$1$2D
M^]'<)H,=S6WM0W.;B(B(2&OTA;F-]S>,4V@?Z(V8S] UK[SRRC!CQHR8YUU[
M[;5[/ ^G9V)62#KPP .C)L3?\__O#W,;FE$RO6"V8U4D-)I*NF<ET+,P$J$!
MYJ8H]$R.AV=7-"AT471.-!!6C7KVV6>C;I73+G,;^BP: 3H/*S&=<,()<74Z
M--0R?99BHF@9*3^?M&Q,9D5S&WV-5K-X\>*:;4$'1Q?.5S%C'YA3T"\Q_=&>
M7+]DI3?:C8FD7M"M=MIIIZ5Z3*/F-OJ60K2<_[PM] MFFT8*(W(=''3003W.
M(WV)R8_CQ6B5F_G0NC$W80IE-</==MLM!OU"H$>G0/LC* K+F,M-<FC6Z,9<
MCX\\\DB<4\#_IWUQ7,.&#8LF4N82H">1?V'N /HUURQS$M(XJ]?<QG:9;\"^
MT9 P4C(&VP77"F:TXKOQQ(D3X_T,O8P)J3-GSERZFAR?90QQ31',#:'8;=*>
MT ,9OUR#&#"+$UTY'XS=XMR!QQY[+(ZSM H<USB%&^LU\Y69VY@?P3P05N0K
M@WV@_S,V\O'#..<^0U';>L</]R2NE?2[@'.(#LCU/E#-;1A*T4=KK9Y69FZC
MS<RGX!BJP7V">WZNG]-_W+?X;CO'OHB(2!F:VV0HH[E-1$1$!B7]96XCD47R
MG\0Q+Q*((QA0$ ](II/<*WOF(9G**F14KCO[[+.C*8RD)$ET$L08G4@XYLG+
M:NT@,4XRL)+ABM5UZA%[,!A052Y/ZI,$1X3!,)*WG>,B 8A9 1,?"3T2Y23,
M&VT[R542R+R<8?[!F)22T\4@@8MY@@0M25<JC#%1C&0PR4;^)+&;?P?1AJ3X
MBR^^6/<8(GG->231F[;#WWEP+C.W(=PQX8J*?;6HE$A'^"!)S_8;22R3I&5[
M]'O^65:\(WG;C9#<I@_IXUSLY/CHUV8-2%2G9+L8M(K;G3Y]>A0A^X/^,+<Q
M21)S4;,F- 0;Q(&^,K<A/A<%440@5F]$:*I$.\QM"!^,KZ*QCA=6!%ZN[7;1
ME^8VC@&AL7B?P*S+?:*6^%*+5LUM]#,B+>:[O-INJL3+.<XGK/.[[N"##^YQ
M+/SNI*\8*R(B(C*XT=PF@QW-;>U#<YN(B(A(:_2%N:T(>BHZ%EKAHX\^&LT?
MF,@P5I$O+YK<,!6@@Q9S_WUI;N,9'1,.AK.TVA<&$XI8-@*Y>HX1W1<=%PVW
MDOZ)GHK9B1P^QI:33CHI7'/--7'B'7H+Q]BJN8WW:(I^HMMBOD!SPLC".P7M
M(C_?B#Z+"0C385$7YQQ2-+2:$2>!MHL)*3>W$;P'89Y"*Z'?\O]#Q[WVVFMK
MFE1RT-;():![I_8W8FZC[RB B0DP;PN&*(ZU$=,D^CZ:(T51<XV7\<_[#&;.
M8E]S3GA'Y-K@SQ3\/(^TPF"E<\;U@R:?S*84O\2LA\Y7-(ZF0#O&R(5AB^^R
M ACS 6@GUR\Z<BUS&VWF,ZQZU8@QM%XX%HQ111V4<8.!+9F5&.])"^>S'#]S
M [@FT#N3X8KVLOH:&ALK-#)O)-="^7^*KZ*QYBLX<FSWWGMO["^N(^8J8#)D
M._529FY#+V;,5RO"RG?1'9ES46G\T.Y\_!3'3K7QD^9C<%\:J.8V]H$9D_MZ
M-<K,;8PGSB]CIAK\/R9E[N7Y][F&T-;;/?Y%1$0JH;E-AC*:VT1$1&10TFYS
M&\E $GZ(#:S^DX(D'X8NJE]1&0MA!K/577?=%9-W92($22_,+[R,L,I8OCI8
MLT&%0*IMD4S/?XYAX8HKKHA5SVI!,IOJ>I7,;>E8:#O;0JA"?"A+EC<2"%)4
M%R39R ,E#Z<8TC"+L7W$B51YKIB0Y;LD$S'P<>X0?Q!R\L]0O8QCJY6LS$%,
M0WQ8=]UUEVZ'MC ILYJYC2J5]?0U9C2,A/GW$3[NO//.V->-))9))&/>*YK;
MCCSRR)A [T9X$>$XN=80V])Y76.-->*XHN)@*]OE/!6WRS6*4-$?:&[[4QQ[
MB&KYMKG7S9DSIU08:8>Y+;WD(M#EJX1Q+Z0][1P#?6ENXW[([XBB^,+]#H&H
M$=&W$JV:VX"JJDP$X'=@WD9$J5P@XG?KK%FSPM9;;]WC]RKG&7&_D>JL(B(B
M,C#1W":#'<UM[4-SFXB(B$AK](>YK0BY<'+6F#?(8:/KY?O&5(9A \TQ_WE?
MFMLP2O!LB>Z9MD&^?>[<N0T?'^^O:'_L'VT/\PM%W\AQ8YSC/:"H7_(SBGE2
MB(_)=^C&//\W:VZCCYAG=^NMM\9)>WG1N6:#/#WM._;88WO\',T#4U$]?8V.
M@:Y4-+?Q\U=>>26>RZ(1!A,814\Q-=4+?<C[5>J[1LUMZ')//OEDKR)\6VZY
M9;C\\LOKTG83Z';HFQ2LS35>5I;B>"=/GMSRN:D4Z, '''# TGP*8QP#(G,3
M&-OT#3H<_<*UEFMD>3O1!9E+P01IQA-S%:KME_L)Q_O  P]$C;P5[:L2C'MT
M0PK;YN_4:*R<7\QK:*[,'4CS!9@+P/BD("]Z)M<Z!KQ4F)A5]*Z[[KI8%)65
MZ]+JC:D/,#H5"W&BFZ*W)XV2B;#<-RM-GBVCS-R&F8XQCS&R#-I*@<[B]=*.
M2-<+*VT.5',;!7,7+EP8^ZD:9>8VQ@SGAOM2-?C_\\X[KZ*YC;9I;A,1D?Y
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M! @$81HA.( ACL ,DP4P?[!25S@!(UI^^,,?6I"""?OYP&1XQ@'!L&S7"84
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MI;85F=MD;A-"""&$* 29VU145%145%145%145%145.IRN?CBB]UO?_M;=^#
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M9AYC?Q=??+&9Q3"BG7WVV78=D<7KTDLOM8Q<9&ACWX\\\HC5@2 4IBRRPA%
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M-YY!&+?!S%W\9L1$1?^FFCV0MN1SBADKV :LP\3$E2PF3\R6]XP<.=+:(&A
M16'F-M[#NH51HT;9,UJR;&:86[FF^+@OZP"6+U]N]ZA<,K<1RV;=!>:[8'S_
M_///M\\SZP<RA<V1R4;)?%A\FV#DY9XGA!!"".&1N4T49V1N$T(((421))OF
MM@T;-I@9+=Y0Q(0S 14F=,DRQDYZJ4QN\O!%D.2""RZ("1XPD>XGD-DQCDE9
M=BX+(]?,;4P,,P$<;\IB@1;!FJU;MR9M$[*A<3SMZMN!B7(6+/ W@ARI!,V
M:V 2F+YCT0(/O5'F-M_^9#-[_?77$RZP9 (= QO9V<J6+9LWH4\[,J%/,.&Q
MQQYS7;ITB2D?XR*+-S9NW!AY#00"" @01&+W.W\L8XQ%72R2(P#$!'?\6.S8
ML:,%C1+5G<EY@E/T7W!70*],S&U<%Y^1>,,?[< /;CX748$AZKQZ]6HW8,"
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M8 <&*2;#@V4V;-C0)G0338@SV<H.M?%U277B?MFR918@PA 5+(,="IE4!0+
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M&QN0A>VZBT$*0R]_#UL4SKPQ&6K"S&V8XEA\S=QB-A>4%T68]V6C.!9O1)G
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M.ZYERY9F$FO:M&E*YC:>03[YY!-WZ:67FLDJZABN ^,<!C.,@QC#,- U:-#
MG7GFF>[TTT^W^F(42V20PPQ&W<@2]]IKK[D#!PY8'0X?/NPV;=KD'GKH(=>U
M:U=[7S!KF1?7.'/F3+=CQX[(/OGAAQ_<YLV;$QK\,A'71]NW:=/&C'K9*A,C
M'H8\^H^V#/Z=S'(]>_8T8Y_/V@8RMPF1')G;A!!"""&$$*+P(G.;$.DA<YL0
M0@@A<AZ9VX000@@AA!!"B-Q YC8API&Y+3\RMPF1/F3T6K)DB678BC(2C1\_
MWFW8L"$KYUNT:)'KTZ=/J*$+,P6&L;#,8-Z@-G;L6,LR%J_Y\^=;9C-,9?''
M8OKB^IY\\LE\QV'J>N:99]S%%U^<DKF--0KSYLVS]0IA9C(O,IQU[-C139@P
MP=IW_?KU=B[N4Z^^^JJ;/GVZ&S!@@)G2N*ZH<MJU:V=9\Z@K)JV??OK)LL?Q
MW^^__]X=.G3(_MZK5Z_0K&N5*E6RQ1FK5Z^.[!/*7;=NG:M7K]Y1,;=YXUCI
MTJ43MEFZHBS:&2-;_)C!0(GQ[\B1(Y:9SB-SFQ#)D;E-""&$$$(((0HO,K<)
MD1XRMPDAA! BYY&Y30@AA!!"""&$R UD;A,B')G;\B-SFQ#I\]EGG]FBE_C,
M5T$Q7[YUZ]:LG&_9LF7NRBNO##4Y8?(BLU>800US&V:+>^ZY)[1<LL\-'3HT
M]%A>P^3U^NNOYSL.<Q_'DHDM%7,;)K41(T:XZM6K1[Z?>_.0(4/,=/;VVV_;
ML=]^^ZUE2,.01M:U#S[XP,V9,\<U:=+$%AF%&;?([C9FS!BW<^?.A,\^'W[X
MH9GE,/#%M^N))YYHV>Z>?OKIF QF03" O?'&&Y91[FB9V^B_;!K;HLK%Y(;9
M#1/DN^^^ZW[\\<>8:Y6Y38CDR-PFA!!"""&$$(47F=N$2(^LF-N8$&8"=N7*
ME9(D29(D25G7-==<$QK<'#5JU#&OFR1)DB1)DB1)DB05)_7NW3OFM_FYYYYK
M@;AC72]).M8B2U&U:M5B/A^8/C O%%>]]=9;KD:-&C*W"9$&^_;MLTQD&(*B
M#$3<6W;LV)&5\[W\\LONZJNO#C4Z84+#4!'VMUPQM_%>GD7*EBT;:D@C\QSF
M*;*S478BWGSS3=>F39M08R%&ORY=NMB]/AF8YOA>J%V[MBM1HD3H-6!^WK-G
M3^CQGW_^N7OII9?R&::C1 :VTTX[S35LV- U;=K4-6O6S$QZG-\;[,(R\P6%
M"8W%5:>>>JJ=MU&C1E96\^;-78L6+>S_SSKK+#,LD]TNS&@3II-//MEUZ-#!
MLO&1W2X>F=N$2$Z4N8V%7L?Z^5>2)$F2)$F2)$E*K-MOOSWFMQQ9[YD7.M;U
MDJ1<U8H5*VQ.,B-SF]]QJT*%"I(D29(D25D7N\.&!3=YV#_6=9,D29(D29(D
M29*DXJ233CHIYK<Y"RU9.'VLZR5)QUHL]H\W<8P;-\YMV;*EV&KQXL5FN)"Y
M38C4^:7-;9C#V%RN,)K;R+JV:-$B,[9A/HM_'\8RC%Y__>M?[;W__.<_(]OA
MYY]_-D-9E2I50DTD&*W\9GO)X#SOO/..:]NV;60_D@%NW;IUH<<?.'# /?_\
M\ZY.G3HI&<C..><<=^.--]IF V1'>__]]]V:-6LL>UR/'CVL[HFRM-&7M.%Y
MYYUGU_C((X_8(I)-FS;9./ODDT_L_\GR-W7J5->Q8T?[WDNE;C5KUG2S9LUR
MV[9M"[U6F=N$2$Z4N8W/R+%^_I4D29(D29(D29(2BXU_XN=AV&#H6-=+DG)5
MQ)S#YD'2,K=)DB1)DB1)DB1)DB1)DB1)DB1)DO1_&CMVK!D-BJO(U"-SFQ#I
M0=:NA0L7AF8/\YHT:9(92+,!)JI!@P:%FI\PC+'!7)A!+1?,;8</'W9SY\ZU
M>H9E)B-K&UGI*"\9WW[[K1GE.";*Z$?F,LQB7%<R4?^J5:N:^23L&@8/'NR6
M+U\>6A?& !GUDF5N(V-;_?KUW5UWW64&L,\^^\RNX[OOOG-??/&%V[IUJQDE
M^_;MZRI6K!A9#F6,&#'"/?WTTY9Q$R,:=2 #)UGHR+C&_^_?O]^]]]Y[;NG2
MI6;.JUNW;N3&A(@QW+5K5S/Z??WUUZ'7*G.;$,F),K=)DB1)DB1)DB1)DB05
M![&!&9MN[=Z].^$<RJ^.=44E29(D29(D29(D29(D29(D29(D*1<E<YO,;4*D
M"R8@S$/L4!MU;[GYYIO=^O7KLW*^IYYZRO7JU2O4'(:YB*R485G1<L'<MG?O
M7C=CQHS(]U'W*5.FN,V;-R=M!\Q<CS_^N#OQQ!-_D>^'WKU[FYDLC"-'CK@W
MWGC#G7GFF0G+8+?B8<.&F2$MBEV[=KDGGGC"-6C0(#)[VP477& F0=H^%7[\
M\4?WYIMONI$C1^:[QP>%^6WTZ-&6B2X*F=N$2([,;9(D29(D29(D29(D%6>U
M;]_>+5BP(.$\(_SJ6%=4DB1)DB1)DB1)DB1)DB1)DB1)DG)1,K?)W"9$NF <
M>O755UV%"A4B[RUD(R.S5S;XZU__ZMJT:1-J;B,K5^7*E5V)$B7R_2T7S&W;
MMV^W'7NCWH=!<-:L6>[CCS].V@X8Y1Y^^.'(3&O95K=NW=S\^?-#ZT*6M/_]
MW_]U]>K52UA&PX8-[3Z;:,=BLJ[MV;/'=>C0(=2DB-JU:^<>>N@A,]6ERE=?
M?>4V;MSH6K1H$6F:.^^\\]Q__==_68:]*&1N$R(Y,K=)DB1)DB1)DB1)DE2<
M==QQQ[G?_>YW2><)?W6L*RI)DB1)DB1)DB1)DB1)DB1)DB1)N2B9VV1N$R)=
M_OG/?[HU:]:8J2<JBYC/M)6-<]UZZZVN9LV:H>8V,I^1?0N36_S?<L'<MFW;
MMJ3FMCESYKA//ODD:5M@ ,/H]TN9VSIW[NQFSYX=6I<??OC!O??>>ZY1HT:1
MQC'4K%DS&RN'#AU*>&V???:998HK6[9L:#DM6[:T=DQD0HL'TQQ]T*-'#U>F
M3)G0<C%HGG/..:Y/GSYNP( !H6K;MJT[_?330X]GG)Q\\LFN2Y<N,<=,FC3)
MS)UD.12B."!SFR1)DB1)DB1)DB1)Q5W_\1__81N")>)7_LUERY1P75K_A^O5
MZ71)DB1)DJ2LZ_>UPH.N9YUQRC&OFR1)DB1)DB1)DB05)_VN6NP"YDKE3W(]
M.E8_YO62I&.M\UN>ZDJ7C,V*,W'B1,L85%SUTDLON>K5J\>TB<QM0B3G__V_
M_V>&GJCL;6><<8:;,&&"^_[[[]W//_]<H'-P[+Y]^]Q55UT5:4ZJ4J6*:]6J
ME?OW?__W?'_+!7/;KEV[+#-8U/O*ER_O9LR882:X9.S?O]^RO$49"K.MCAT[
MND<>>22T+I@.R4J'\2O,6.A%UK1-FS99%K5$8'X;.'"@JUBQ8F@YS9LW=_?>
M>V]:YC8@T]OEEU]N)L)?<B$+F0:G3Y^>U-0G1%$ARMS&,U:O7KTD29(D29(D
M29*D'!:;$P5_RQU__/&6[?Y8UTN2<E4]>_:TN>.,S&UGU_NMV_5:?^<^N$:2
M)$F2)"GK^LOH<T*#F ^,:W',ZR9)DB1)DB1)DB1)Q4G7#:H?\]O\PC;_X;[;
M./B8UTN2CK7>6];'G5$CU@""Z:(X@T'G=[_[G<QM0J3)UJU;W:A1HUR=.G5"
MY\6/.^XXUZ]?/S-X_>,?_RC0.0X>/.A>?/%%UZ%#AT@3$1G=6$P09E[*!7/;
M@0,'W,,//QSY/C*5W7[[[6[#A@U)VP.CUA-//)'0W,8U9TN)S&U )KG++KO,
M5:Y<.;(^9%PC2V8JYK8KKK@BTMS6NG5K-VW:-/?%%U\D;:<@O%_F-B&./E'F
MMO_\S_\\UE430@@AA!!"")&$__[O_X[Y+<<F4O_S/_]SK*LE1,["?/=%%UTD
M<YLD29(D2;DKF=LD29(D29(D29(D*3<D<YLDA4OFMOS(W"9$P<#8-'/F3#,O
M19FL&C=N[*9,F6(9OM+EQQ]_=.O7KS=C4K5JU2)-1 T:-' C1HQPIYYZ:DZ:
MVS!U84@[X803W*]__>M\[R/KV2677.*>??;9I&W"H@D,)!CBPNI<HD0)-VC0
M(+N'45ZF6K5JE=NY<V=D?<@D=^.--[K?__[WD>UP]MEG6UMA\HN"+' 8&;MV
M[1J9!:Y3ITYNSIPYUO:I0GM1?XZE_65N$^+H(7.;$$(((8000A1>9&X3(CUD
M;I,D29(D*><E<YLD29(D29(D29(DY89D;I.D<,G<EA^9VX0H&)B,"-3WZ=/'
M3%5A<^/ERY>WC%OSYLTSDQ$FIF3PGA]^^,$^FYC23C_]]-!,91C7R,;5N7-G
M-W[\>'M?+IK;OO_^>S-]4+^33CHIW_N./_YX5[MV;3=QXD2W:]>NA%GN:)L5
M*U:XNG7KAIK ,'"-&3/&K5V[-O6.S(##AP^;P;%]^_:1[4!FOWOOO=>]__[[
M"<M9LV:-:]Z\N67\"RNG=^_>;NG2I>Z;;[Y)J6X___RSF2H??_QQ5[]^?1L+
M,K<)<?20N4T((8000@@A"B\RMPF1'C*W29(D29*4\Y*Y39(D29(D29(D29)R
M0S*W25*X9&[+C\QM0A0,C%9D5QL[=JR9P,*RDGGSUL477VP&-[*88?;B.,Q'
ME.'%OWD=\Q*FL+_\Y2_NK+/."C6>>?-9JU:MW,B1(]U==]V5[W.<*^8V%CJ\
M\<8;KDN7+JY"A0J1[\>D1X:W??OVF;GOIY]^RC,#!MOGS3??M+(J5JR8KPRN
MM4>/'K8@R;=O0?J4/OKNN^^L#HGX]MMOS91&MK@H\Q@&QPLNN,"]\,(+UA;!
M?N?_N=8-&S:XR9,GNYHU:T:VS^#!@\VT=^3(D;SVB;]&_I_7^3M]],PSSYCQ
MKERY<K^HL4WF-E$<D;E-""&$$$(((0HO,K<)D1XRMTF2)$F2E/.2N4V2)$F2
M)$F2)$F2<D,RMTE2N&1NRX_,;4(4',Q$+'[!4(6)+6Q^'-,31BQO1)L_?[[[
M^]__[O;OWV_F*$Q4&)8^_OAC,Y+Q^>O?O[]EVRI=NG2D:8IL<60IFSU[=LZ;
MVS9OWFR9V<XXXXS(]Y.%KD6+%F[<N'%N\>+%;NO6K=8N&,TP_.W=N]>,;5PK
MV=!*E2J5KPP,AE6K5G7777>=92VC;5,%4QO7M6K5*C=W[EQW__WWNP\__##A
M,1C)/O_\<S=AP@17IDR94(,C[8_!;># @69P_.BCCRQ3&^?:O7NW>_GEE]V?
M__QG5Z]>O=!K\B);'67PG;5DR1*W?OUZMV?/GKPVHOZ4NV7+%O?BBR]:-K^.
M'3NZ4TXY)7)LRMPF1/:0N4T((8000@@A"B\RMPF1'C*W29(D29*4\Y*Y39(D
M29(D29(D29)R0S*W25*X9&[+C\QM0F3&^^^_;T:H&C5JN!-//#'2[%.R9$E7
MO7IUUZU;-S.Y39HTR=UWWWUV+.:S6V^]U0T9,L2U:]?.S%!A)@FOLF7+NF;-
MFKFGGW[:O?;::SEO;CMPX(![]=57+8L8IKRH8V@_LM7U[=O7W7SSS6[*E"GN
M@0<><%.G3G6WWWZ[U94R3C[Y9'?<<<>%EL'K39LV=7?<<8=;NG2I&>L.'CQH
M!CDRFF$"PU2(*6W7KEUNTZ9-;L6*%>[))Y^TON <O7KU<I===EG2A1B P9&,
M<ZU;M[8^CKHVQ@<+/C"RW7WWW=8GM]UVFV5]:]*DB1G0HHR,?OR<=MII9AKK
MUZ^?N_;::^UXWT;3IDVS<8#A<<"  :Y!@P;63E'ET0^8!+MW[^Y&C!B14!=>
M>*&K7;MV:#F,$S+#]>[=.^88QC9CDW87HC@@<YL00@@AA!!"%%YD;A,B/61N
MDR1)DB0IYR5SFR1)DB1)DB1)DB3EAF1NDZ1PR=R6'YG;A,B,GW_^V;)H8<C"
M?!26O2N;PKS5N'%C-WGR9,LL]NZ[[^:\N8TVPE V;-@P5Z5*E:/:/K[N& ![
M]NQIUTY=N=>1-6W'CAW69ABO,*71CI=??KEKV+"A&;[HOPH5*KC.G3M;%K=4
MV+!A@YD5R1IWM/L_&_+7B DMK'_CP;1SQ157A)9UP@DGN-___O>6C5"(XHS,
M;4(((8000@A1>)&Y38CTD+E-DB1)DJ2<E\QMDB1)DB1)DB1)DI0;DKE-DL(E
M<UM^9&X3(G/( K9RY4K7IT\?,U4=36-2S9HUW:A1H]SV[=LM*U9A,+?!3S_]
MY)8M6^8&#AQHYJI$6<I2%66$F<EX'1,@&?#(F$86,[*CD=&-C'=GGWVV98BK
M6[>N._WTT\WH5:I4J;RRTC6W??755V[UZM6N4Z=.=LYC;5Y+IM*E2[MSSSW7
M,MN152\9,K<)D1R9VX000@@AA!"B\")SFQ#I(7.;)$F2)$DY+YG;)$F2)$F2
M)$F2)"DW)'.;)(5+YK;\R-PF1.;\^../9O@B$]B  0-<Y<J5S?23;4/2F6>>
MZ:Z__GKWTDLOF5GLG__\9Z$QMU'7/7OVN'GSYKF.'3N:"2Q3@QLFM X=.MA_
MLV&6"Y:;CKF-:]N_?[^;.7.FZ]*EBSOYY),SRN#&M3!^CC_^^*R.(>I4LF1)
MU[9M6QL3NW;MLK&;#)G;A$B.S&U"""&$$$((47B1N4V(])"Y39(D29*DG)?,
M;9(D29(D29(D29*4&Y*Y39+")7-;?F1N$R)[8/K">-:S9T]7ITX=5Z9,&3.)
M%=1XA1D)@Q/9X,@V-GKT:/?VVV^;L<U36,QM'C+.S9T[U[5OW]X,;M0OG?;Q
MV=HPD&%L>^RQQ\R(]MO?_M;*RL145E!S&] GAP\?=M.F3;/L<.7*E2N0.8UC
MN#:,C+5JU7*GG'**._'$$T/[*!W1-M2I4:-&[NZ[[W:[=^]V/_SP0TK7)G.;
M$,F1N4T((8000@@A"B\RMPF1'C*W29(D29*4\Y*Y39(D29(D29(D29)R0S*W
M25*X9&[+C\QM0F0/;W#:O'FSFSY]NIG<,*85- ,7IJ;33S_=77/-->YO?_N;
M9=KZYIMO+%.8I["9V[[__GO+<K9TZ5+WQS_^T=6H42.M+'?''7><F;_(D$>;
M'#QXT"U;MLS]Z4]_<C5KUG0GG732,3&WT2?T_\Z=.]VB18M<W[Y]7;5JU=(^
M]ZFGGNHNOOABRP)(EKL;;[S1G7/..69R*^CU8/BCG?OW[^^>??99MV/'#NN7
MX#A*A,QM0B1'YC8AA!!"""&$*+S(W"9$>LC<)DF2)$E2SDOF-DF2)$F2)$F2
M)$G*#<G<)DGADKDM/S*W"9%=, S]^../;LN6+68DFC1IDALR9(CKTJ6+:]RX
ML1F>R%A6JE0I,T)@?"M1HH1E>:M8L:)]'ILW;^YZ].CA1HX<:?<H%M-\_/''
MH><K;.8V^/GGG^UOE/W  P^X8<.&N0LOO-#:AP40& (Q]F%DH_ZTS6FGG>;.
M/?=<=]EEE[F)$R>:H0TC&6"6PXCVX(,/NC_\X0^N:]>NKDF3)M;6F,(PO%&6
M+X^VYQRT-^<C2QIE7W#!!58^AK)9LV;EE9\.9$/;LV>/F??H>PQEK5JULBQL
M]'O)DB6MSQ'UXC7^QGMX[^VWW^Z>>^XY]\DGGUB?KUFSQK+3<<U^'&%VH[_)
M5N?'D<_R1YE<&]=.EC9,>I@C[[WW7FNS??OVV?A,!YG;A$A.43&W<7_^[KOO
M[+N%>P;WPOOOO]]-GCS9[D^WW7:;FS!A@ILR98I;O'BQF67CC^>^_\$''U@F
MTSESYMCWV)UWWAES//?'A0L7NC???-/N'WP7\+H799-A,MW[E<@/;<CW&<\D
MP3:FS3=LV&"F_%R%[U3&&*;Q8-W)DKIQXT;WQ1=?'.LJ"B&$$$*((H+,;4*D
MA\QMDB1)DB3EO&1NDR1)DB1)DB1)DJ3<D,QMDA0NF=OR(W.;$$</,GE]_?77
M;OWZ]9:)BT7]5UUUE67FZM"A@QFJFC5KYEJV;.DZ=>ID9K'APX>;&8V%_>^_
M_[XM2D^48>NCCSXR\P&&KK/..BM&#1LV=&>??;:9H\)XZZVWW!UWW&$FJ/AC
M>8TZAIF6R!ZW=NU:=_WUU^<[S@O3W.>??VX+TQ-!)C<6UY.%C?89.'"@+8QH
MW;JUF;AH(]IFT*!!9J9X^>67S5Q'V\9#6VW:M,D]]=139J+ 5-*M6S?7MFU;
MU[1I4RL/XV#[]NWM'+0WY^,Z*'O!@@7NM==><Q]^^*%=8]@YT@$CV<J5*^U[
M!M,=_4Y=Z'/$_V-BY&^\YXTWWK!CPCATZ) MY&<<_>4O?[%Q0F9 ^HAKHK\H
MLTV;-F84Y-HQ #S^^.-F4CERY$B!KP,3XKAQXT+[F3:]Y))+W'OOO5?@\H4H
M"AQM<QOW2HP\F&>W;=MF!FJRA')?X+['__/:]NW;W=Z]>^V]8>;B1'#/.W#@
M@'TW8(C%[,OW2.7*E<V8BT$8TS37A;EV\.#!;L6*%3''<Z]ZYYUW[%GRRBNO
MM.\@,E*6+ETZYG@,S/WZ]7/WW7>?>_CAARU+:;#=*)O%<%QW<8=G +Y+N8]C
M#,?LM77K5KOOTO=^#/!OOK\P1G_VV6?NVV^_M3ZA#;F/TQ_!-B:CY]RY<PMD
MY/ZEX!H88V1K#=:]=NW:]GT89?P70@@AA! B761N$T4=YDWYC<4&)_RV9&,M
MYA?8G";X^Y)XD?^-R6_/7;MVN8,'#]I<:1"9VR1)DB1)RGG)W"9)DB1)DB1)
MDB1)N2&9VR0I7#*WY4?F-B&.+CX+#D8#3 ,8$U@4P.)T3 @L(N"_+"YGD3:F
M!!:E8^!B07HB8QNPD(!%"92)T2U>E!^5E84%#=2)]X0=1QVI>]@U<2P+(<+.
MB;@.%M4GJS]_#[8/F7I\^P3;AM=92(%9D/.'E<MKM!D&@/BVIBQ?'O_F==J;
M<C&4439UH'S:-.H<Z<"B$19^8/*C/3B?[W=?#]_GO(?W1F4IHBU].U%77QYM
M$QQ'_MJX=MJ OJ=-N)Z"0KW(CA<UOJB'#"BBN'.TS6U\MLFD1@8U3-)D9<3\
M6[]^?=>@00,SN9)]D@R/=]]]MUN^?+E]-M.YCW&_P!R,N;AZ]>KNY)-/MNR,
MF-+(#NF-:5'F-NZ]&)#),,FS)8M!,;&153+^>)G;4@=C&_=\%M;RNX5LG)BE
MZ2>,S?7JU3,3(O_NW;NWN^FFF]S\^?/-(/_55U_)W":$$$(((40*R-PFBC+,
M#; 9#::U)4N6N.G3I[NQ8\?:[T0V!FO5JI7]KJQ;MZX[XXPS;$,K7F-#*S8%
MFS=OGAG?@O.+,K=)DB1)DI3SDKE-DB1)DB1)DB1)DG)#,K=)4KAD;LN/S&U"
M""&$$)EQ-,QMF)Q9>/;HHX^ZZZZ[SA:<D0D-(]@IIYQBV=0PCG'>4J5*V6L8
MELA4B?GIAAMN,/,2N[!C<DKE&C#.L8@30UM8S#>1N>W55U]U(T>.=!4K5@QM
MBZ!D;DL,"P8Q%I,%;\Z<.6[4J%&VJ+!%BQ:N9LV:UL9ERI1Q)4J4L#' ?_EW
ME2I5S.S6L6-'&WMD@EVZ=*E;M&B192J5N4T((8000HAP9&X3115^7[)A#IN@
M\-L*0UK+EBUMLQPVMJE0H8)E6^=WY6]^\QL3O^EYC4SN9YYYINO0H8-MIC-U
MZE3[K>ZSQ<O<)DF2)$E23DOF-DF2)$F2)$F2)$G*#<G<)DGADKDM/S*W"2&$
M$$)D1C;-;61P) O:FV^^:5G8,#1A7$MD%@L3"]3:MFWK'GC@ ??66V_9XK.P
M+(Z\AHGLQAMOC'DFQ."&80HC49,F32Q3'!GBJ,^%%UYH6>3>?OMMVP&>16UW
MW767[?+.0CB.Y[\8\#!C-6[<..;X=NW:N5MOO=6,6S*WQ4*F-C*XKEJURDV:
M-,G:BD6%P<QWJ8CQR")$=N*?,&%"OD6',K<)(8000@CQ?\C<)HHJ/_WTD\TO
M#!\^/.UYA:#85(??8K?<<HM;N7*E98(C@[S,;9(D29(DY:QD;I,D29(D29(D
M29*DW)#,;9(4+IG;\B-SFQ!"""%$9F33W(8);>W:M99I"X,:NZ?_^M>_3GOA
M&>:R$TXXP94O7][]\8]_-+-4F%GLN^^^<WOV[+',<,&,;>7*E3-#&N:S=>O6
MF9%HW[Y][M-//W4'#APP QZF-L1K&-+((N:/QY"%N8KL85S/KEV[W-Z]>^V]
M^_?OM^M\]]UW96Z+ V,;BV@Q$)*)C3Y,U]B&.(;^P*#(LWZE2I5D;A-"""&$
M$"("F=M$425;YC9^8S)G0"9QYBO8[*9UZ]8RMTF2)$F2E+N2N4V2)$F2)$F2
M)$F2<D,RMTE2N&1NRX_,;4(((800F9$M<]O!@P?=\N7+W1577&$9SWP6-+]+
M>JU:M=S%%U_LKKON.LN<=O_]][O[[KO/,GR-&C7*#&H8?S!$!1>@G7'&&6[H
MT*%F<,,\%81_L^MZ_*(TLJW=<<<=]JSXY9=?VH(XLK3%P]_(#->S9\]\!J2;
M;[[9%M%A9 L[GM<W;][LYL^?[V;,F)$G#$T8X#BFN,"U<LU_^]O?7*]>O5SE
MRI5CS(+T*8L$.W7JY(8,&>+&C1MGV?(8 U.G3K6^^M.?_N0NO?125Z]>/3.U
MT??HI)-.,I-D83.WD<40X^4KK[P2,SXPMFW=NM5]]=57Q[J*0@@AA!"BB"!S
MFRBJA)G;?);VSIT[V[P%O]WOO/-.^WU)O(PL\OR^9([!;[KBC\7@QAS#-==<
MXZI5JR9SFR1)DB1)N2N9VR1)DB1)DB1)DB0I-R1SFR2%2^:V_,C<)H000@B1
M&9F:VS!]L>#LC3?><*-'CW9ERY:-R=:&T:E-FS;N^NNO-_/3.^^\8T8X,EM]
M_?77E@V-US")L0"M18L6EO7-9_SBOV1'&SMVK!G1?OCAA[QS?_+))^[))Y]T
MYYP3&^>]Z**+;#'GH4.'$M8=<]SBQ8O-=!4\OGGSYN[YYY^W;&\B,?0__;AL
MV3(S-F)&\_V/P8VL:RU;MK3%@X\\\HA[_?77W;9MV]SGGW^>-P9H9Y[K%RU:
MY,:/'^^Z=^_NZM:M:Z;(H$FR,)G;A!!"""&$^*60N4T459AK6+-FC;OQQAO-
M>-:D21/;G.:&&VYPLV;-<J^^^JK[X(,/[+<]OR_)H,X\P(8-&]R\>?,LLWK]
M^O5=R9(E8S9?(8-;_"8J,K=)DB1)DI13DKE-DB1)DB1)DB1)DG)#,K=)4KAD
M;LN/S&U"""&$$)F1J;GMYY]_-H/2Q(D3;2%8O!FI;]^^[JFGGG+??/.-^\<_
M_I&7!2TH7N-O9/]:N'"AF9N"Y5 _3%(\YQT^?#@OB]J.'3O<S)DS7:-&C6+.
M208PGA.I5R(X'Z:ZMFW;QAS/O]>M6V?G$HFA[W;OWFW&MJI5J^:9$E&Y<N4L
MDQM]BIF-A89D-&/,!/N??U,.QD7&R7OOO>>F3)GBSCSSS)A%B#*W"2&$$$((
MD1^9VT11A=^)F,V(@Y$%G,UIMF_?;D8VYA#B?U^"GV/@/0<.''!__O.?+9-\
M< .=X(8\,K=)DB1)DI23DKE-DB1)DB1)DB1)DG)#,K=)4KAD;LN/S&U"""&$
M$)F1J;F-'=(Q+W7KULV=>.*)>0O&V F]1X\>EJV-#&NI@+F)]\Z9,\>.+5VZ
MM)7%PC/JB%&.[%X^>QL9P'CV.^NLLV+JWJ=/'[=Y\V8S2B6"K'&<JW7KUC''
MMVO7SG9Z_^*++U*J=W%FZ]:M[N&''S:#(3O@!PUH P8,L(QN]"F+"U.!A8A?
M??65]1\&-HR&9 .4N4T((8000HAP9&X3115^'S+GL&7+%LODOG?O7O?==]^E
M?"SF-[+,7W?==999/+@9B\QMDB1)DB3EM&1NDR1)DB1)DB1)DJ3<D,QMDA0N
MF=OR(W.;$$(((41F9&)N8X?T#S[XP%USS34QSV28G%JT:.'FS9M7( /21Q]]
M9!G9ZM:M:X8Y7RZ[K0\<.- RP3WSS#/NH8<>LMW;JU>O'E/WEBU;N@<??- ]
M^>23]CZOEUYZR1:V+5FRQ/X]>_9L]X<__,$RA 6/KU^_OKO__OO=@@4+8HY?
MOGRY>_OMM]V77WYI6>'(',=KP??P]T.'#EG;I *+[7@_)C&RQ:U8L<*]\,(+
MUB_4\_GGG[>%J?P-,Q_GC3**L<B/;'3OOONN6[UZM5WOTJ5+;7=[RJ.NJU:M
M,N,8QCYO$BPH7..++[YH1L133CDESXAXTDDGN4LNN<3ZZ<B1(P4NFUWV;[GE
M%M>P8<-(<QL+%KTI<OWZ]>Z55UZQ:^9ZJ=O:M6MM9W^RQJ72)Y2'J9&^I2\9
M+Y1#7_AVY-^\C@&2.M G/DN ASXZ>/"@]5O\&*2N9!$(@[&P:=.FF&,X-^,#
MTY\OFP6>9+A;N7*E]2OU>O;99^UZ]^S9D[*94 @AA!!"%'YD;A,B&G[?L>D.
M&_"4*%%"YC9)DB1)D@J'9&Z3)$F2)$F2)$F2I-R0S&V2%"Z9V_(C<YL00@@A
M1&9D8F[[QS_^828JS&'!,JI4J>*&#AUJF=/B33^I\N&''[I^_?JY4T\]-:]<
MC%._^<UO$BY&2Z3:M6N[-FW:N)(E2Q;H^)HU:[JKK[[:O?_^^U8_,I:=?OKI
M,>\9/'BP+8;#3)4*&);8@?Z>>^YQ_?OW=TV;-K5K)FL=]2Q?OKR9[?@;ACV,
M?U$9Z=C%'N/533?=Y#IUZF376ZY<.3.;L< 54QBOCQLWS@QT!36>>;C&&3-F
MN)-//MD==]QQ=OV, \R&#SSP@(V/@O8_8-9[]=57W1577!%I;L,<Z!<K7GGE
ME386,=I1IVK5JKF>/7N:"1+3'_5)A-_9G]\8CSSRB/7U>>>=YTX[[33K#]J1
M<ODWXVCX\.%FD,1TR'%!,*]A5"1[7?P8?.*))]S''W\<6@?&S@TWW!!S3*E2
MI6Q\D*V .M+_F.MNO?56UZ%#!VN/,F7*V.<#4R'9#5/-9B"$$$(((0H_,K<)
MD1@V!6$#'GX?R]PF29(D25*AD,QMDB1)DB1)DB1)DI0;DKE-DL(E<UM^9&X3
M0@@AA,B,3,QM9).:/GVZF=DPUOACNW7K9EG;,LD,1M:K^?/GFWG'E_MO__9O
MIJ)@;L.(MFS9,C,R77#!!:Y>O7JVD*YLV;*6K0ZS&*)O,"[Q-S*8=>W:U=UU
MUUWNS3??S#./[=Z]V\Q=PX8-,S,6U\FN])BB.!Y#X/'''V_77:%"!5>G3AW7
MKET[=]UUUUG6+\Q2J6::\V#F^OO?_^Y&C1IE9?M^8;$@F?Q83)MNF?'0AJ^]
M]IH;-&A0J+EMX\:-EJGLCW_\HUTW9C9,:%PS=<*,QMC$,(CQ[?777[>L>T%H
M/[*<D8&0-APY<J2[\,(+7>/&C<VDAU&.<N@+WX[\&],A]6C2I(GKTZ>/?0XP
MVWE3V=$PMY&9#H,;IK8N7;JX,\XXP_WVM[^U?J5^] 'FMJ>??EKF-B&$$$*(
M8H3,;4(DAM^-_):N7+FRS&V2)$F2)!4.R=PF29(D29(D29(D2;DAF=LD*5PR
MM^5'YC8AA!!"B,S(Q-R&>0=#%8LGO?D,D\W--]_L-F_>G)&Y"7,.!C*,4B><
M<$)&IK9<,[>1Z0LCU<"! ZW,$B5*I'1^V@!S%6:MB1,GND\__=2]]]Y[9O3J
MT:.'+<0+F@P3B3ZG[F0?\UG<TNDOK@^35O?NW?/*Y-P8PAY[[#$S>F4*Y\"0
MAC$M6'?J/6?.'/?DDT^Z\>/'FZDM41O29IC1QHX=Z]:L61-S#DQZ>_;LL?)H
MPZI5JZ;<'[Y/,!^V;]_>LM4Q-AB[V32W,5XQ-#[UU%-F<L/DB,$NK#YDJENX
M<*&=7P@AA!!"% ]D;A,B,3*W29(D29)4Z"1SFR1)DB1)DB1)DB3EAF1NDZ1P
MR=R6'YG;A!!"""$R(Q-S&P:MCAT[YAEMR&Q%YJQ''GG$LHIE"EFU[KCC#LM"
M1MG!^F% (L,9=8\W=&&PXV^8@H+"%-2Y<^>\;%?4FW+BR^;?',_?@\>37>T/
M?_B#9?DJB+F-Z\%,-6O6+,O6%M_FG)?K\>?VXM\8_#!I<:T8JIHU:^;6K5MG
M9J>V;=OFM0%_X_^#Y?AKI0S:)MA>9'+#$(4I*UFVN2"8IR9-FF29RX)]0AN_
M_?;;=IV9$F5NP\SVT$,/F?$1,QW7A?RU^G$1-$1RS60ZFSQYLIGXZ L@:QTF
MM/[]^^>UG^\'RHQO0_[-=<:W(WV#,0YC'YGTLFUNN^VVV]SUUU]OXXTZ<+[@
M-7OUZ]?//?/,,\K<)H000@A1C)"Y38AH^.WWQAMON)8M6UIF;IG;)$F2)$DJ
M%)*Y39(D29(D29(D29)R0S*W25*X9&[+C\QM0@@AA!"9D8FY[<$''W2U:M7*
M.[Y4J5+NK+/.<HL6+<HH:UN0F3-GFI'+GP-#$:8>LG"1;6O$B!&N1HT:,74G
M.]NCCS[JEBQ9XI8O7YZG5:M6F2'LE5=>L7^3^6OTZ-%F6@L>CT'KKW_]JWOV
MV6=CCE^Y<J5EI/OZZZ\+9&X[<." >_GEEUVO7KW,8!?,_H5AZIQSSK',<&0
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M*TP?RO?RLGSY\N6Q0AV?._GDD^/Q.-:O?O6K<.655X8GGG@B?/755W7!&%[
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M4<4F:A'B>OGEE^.D)<P-SK53ITYA@PTVB-<#TXLV8F!AD!&TP2PC:$:X*C_
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M*QYV[-@QQ^ @=)-6SVN,#S[X(+X,SP^N#1TZ-!H_Q<)M/.RP0MQCCSW6J &
M.;'UUEO7;<M*<9A-K/Z7I:GA-HP?@C79\!A!)-K'=2BE:A;[(,#$1+"LT45
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M=&G<;O:;6A^=^E@7]5C6Q7INN^VV,&[<N/C_B'/YPG*9/PA\[ /+H=;&]O,
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M#M)6(A1RLQ>2U1%''!%NN>66^/V*?>"]K)ME(9BM6K4J?E^CPQL_9_F>-6#
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M08T<.3**FKR6WV_XF<)\1L8YZZRSXF<G_3YN9N*S>L())T3IA^^/:<I%;DM
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M#'-57>.][!-MG7'&&>'LL\^.[7,\.3^0XFJJ'I=-;D/FXAS:$U7Q:!,Y;L"
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M7_+"C 5B'6.4EN'(.?'ZW_WN=R4Y?B(B(B(B4MXHMTE31KE-1$1$&B6UD=L
MT8-J78@]F>]E4A()!1(1B% D76ZXX8:8;" APD,$293=NW=7263P;Q(4"&9,
MXJ/RVH(%"Z(H18*#BG%,[$/:X>:,-OCY<\\]%^Z\\\XH!:63)L@\)&*0-!##
M,N4V^HH8PFJ 5*)#Z"#Y@JC"S1SR!]O.7#&0]Y$HFCAQ8A1ID(=($"&2;=Z\
M.29QZ-^6+5O"BR^^&.4EI+]TDH6$%C)+.G&&+(CL1((**8FJ7:PPR.0OVJ-?
M_(RJ7@AT3SWU5%B^?'E,Z"Q=NK1>Y#827U1LZ]"A0Y35.+Z,-T(C8XAPQ,,D
MQR%3Y.-FF=\E8A#[2%_'C1L7$VQ)DHQM( A2D0HQB_MC5IKD]8A0)*IHA^WS
M.HY/>CO%RFU4WB/IR'[2#@D\CAO]XM^(?53@N_#""\/DR9-C<HWCEE3SRB6W
MT2[G!=)>TBX_2[?;N7/GBG:7+5L6QY7VV&_$441 ?L=GAG.!<RX! 0HICL\J
MK^$SR&1!/C.%HMSV94R@<BS2;7.MXQKUP0<?U+IM*%1N Q+2$R9,B%4*TWWB
M7.1SLG7KUISOY5K+YP@Q&$$O>2_)8RI3DHSF,R8B(B(B=8MRFS1VE-M*AW*;
MB(B(2'&4H]RV<>/&F(LA7\)"H.1WR+N]^>:;\3O_)&=(D"_B>W[R'RS.QV)X
MZ45)D<_(W9&G)*>836Y+\A'TC1S<L\\^&W,MZ1P<VT:B&SIT:'Q_>E%*%L\C
M/T4NJE"YC1PBBP?VZ=,G+@J:Y//(\Y&[(/?"^\B+TA=RE>2%Z0\YP4&#!L7]
M3?I#&^1'R-%E+JHI(B(B(B*-#^4V:<HHMXF(B$BCI+9R&S=')!1NN^VV*'=D
M2_XD05(A28STZM4KKN+'*G\D+))D3'JR'L(.LAJB&1),(@A5!Q(/4MD==]P1
MA9ETE;1.G3K%!-6B18NJR&W))"KZ1;(HLSH6D+CAYHW*7>G)5R2%D+_8?\0X
M!)]=NW95>3]"#6UG$P$S Y&)2EWY['-F'TE.U8?<QO%%R"))Q^^SD4A'"(+I
M8X.$A)R3C#OC1]*)"9SI;232'^(3?<D&_4-$9)PS$V?%RFV%!&-&);>DVAKG
M9BZYK=!VJ>1&DC)IMRZI"[F-E399H1,1E0>L0H,51/GB8D_(;8PW;2"QIMMN
MT:)%F#%C1JV$P32UD=N0?9%:2?RFD\D<HQMOO#%>7W-! IQ55TEL(U4F[R4Q
MS3'-5H%01$1$1/8\RFW2V%%N*QW*;2(B(B+%48YR&_D3<B2(7=SOY<J)I2%G
M2XZ&_ HY,O)P2<Z !3ZG3Y\>%^_+);<ADPT9,B2L7KTZ9^X)P8P%&,DCDA]-
MWDN%-:0Z<KODC?.5V_@[BP9.G3HUYD.2W"%MDX?DV8!GAVS5WO@9>3=R5N1'
MD@4O:8.V9LZ<&3[\\,,\CI"(B(B(B#1DE-ND*:/<)B(B(HV2VLIMP,T1,@G)
M&1(?U8DYB0!%4@&!@V0'DY*0L4@^(,XD"0J2%8@7"%OY)&T2F/!')2,20U0?
M2K;=NG7K6#EN]NS95>0V$AWT9_SX\5$8RK8]$CFTS8J%!QYX8$5"B/>R3PA;
M"%J\)EO2AYM")F%=<<45-0I,"'148RM47*I/N8W$'\=SSIPY.>4ACBG'&(F0
M<R!Y+U7+2!(FU<:H^$8UO';MVE7:!M(?PB,B9+9$5G*<2*Z1"$-H3+^_+N4V
MS@EDO!X]>L0^\SDIA=Q&NR0=:1>AJ:Y7G:P+N8US UF,\:.:6*'!N8D,EMEN
MJ>0V9+#,R<:L!(JLRV>\&&HCMW%MX9R_]-)+X_F13B9W[=HU)J)SP;5R[MRY
M<2)DYBJK?(:*&2L1$1$1J3W*;=+846XK'<IM(B(B(L51CG(;^3CR+>3]R 'D
MRHEE0@X#66SRY,EQFXDLQN1.]N?^^^_/*K?Q.O("RY<OS[H : )Y+G[/PGKD
M1=/W\M_YSG?BPI7D8?*5VVB/'-JP8<,J<A3\27Z(Q4_):]:T[RQZ2GXF?0QY
MSA@[=FRU^1$1$1$1$6D<*+=)4T:Y341$1!HEQ<AM@%A!PN/66V^-(@9B2EJR
MJ"ZH%H04UZU;MY@,(8F1:Q6^?"!QPPT;U=M:M6I5D;@A4=._?_\XZ2E3;B/A
MT;Y]^SCYAX11==LF(8,HEZP F!9G>%BJKE^((E2Y8WMID20SD,N2OA1"?<IM
MR#T(5ZS86)V41R6HH4.'QL14\EX27*SHB.P$5)H:/'APO&%.7H-0B!3&*HLU
M"5U(D23/6&$RW<="Y#8J"EYYY951D.K7KU],/I)XN_WVV\.4*5-BHHP_.6>1
MBI"(6/DR?5PYSHP+YQL"*.."D,:_,]OEO+CKKKLJM4NBD78Y=[.U2_]8N;,N
MJ0NYK=@X[;33H@R6*4>60F[CVO";W_PF7'_]]97:YAR^\\X[8V*V&&HCMW%>
M\=")7-NR9<N*:Q[75BI*,L9<&[)!E4/.(UZ7WA_$3J[%A1Q/$1$1$2D=RFW2
MV%%N*QW*;2(B(B+%48YR6S&0+WCLL<="V[9MPW[[[1>WR9\]>_:,.:YL<MLA
MAQP2<VKD$7E_=9 W(.?(O7NZC:.//CK>ARY<N#!ON8V\(_TAKY.\CCS>Z:>?
M'G-.^3P'?_;99W&;Y!2314_)DYQWWGGA\<<?+WH\141$1$2DO%%NDZ:,<IN(
MB(@T2HJ5VX $!-+'K%FSPL477QP3$6W:M(F5E'AH0+2H3N@BF(PS>O3H.#&G
MV(I!#S[X8!2#DHE2R%'(+JQ6F"FWD51"IEJ\>'%>[7;ITJ72!"R"&\2U:]?6
M^'[D)<8CD>,8$_Z>""E)8HND&8F;39LVA8\^^BC>5-94R:T^Y3:JKR')O/;:
M:]5N8]>N77&L6,$Q>2_))LX7JDAQP\TX<O_;K%FS2GV@\EX^TB-R&F.&()86
M"?.5VQAG;M21N) D20(B16W<N#&N>)FLE/GIIY_&/B.N\5D9-&A0["=B9_I<
M/_GDD\.D29-B@HUCFK2+L,2JD;G:7;5J59RDQ[F9JUW:0>9CG^L"Y;;_"QLV
M; @WWWQSI;8YKQ 4:SK_:Z(V<EL"JYCV[=NWTK6)\P5I\G>_^UV5UW.>\P4/
MU\GDL\9UB&LUGQTJ*!8JV(J(B(A(:5!ND\:.<EOI4&X3$1$1*8[&)K<!>3P6
ME62A1+;)]_[D=<B/9I/;R*>P@%X^.1[R!N0<KK[ZZDHY*Q;1&S]^?,S!Y2NW
MD1,CMWC,,<=4O(Y%_!BSM]]^.^_])?=SZJFGQEQ-DNOHT*%#F#Y]>JW&3T1$
M1$1$&@[*;=*446X3$1&11DDIY#8@H4'B@^I<+[_\<I@Q8T:X_/++HSQ!=;;,
M:F>9P>^IBC9FS)@X.:<8D$%(W"03I9(J1@@HF7(;8@=)&*H8U<2"!0O"66>=
M5:4R'=):4GFL.A@3DC1)HHQ]WG___2LESO@9JR2R,B&K*%)!*9^*9?4IMR&K
M<;YDDVC2\'XJ7)URRBF5]I?*>8A3; .IB_,E+?Q1V8^^Y5O1#W'GWGOOC>.8
MG /YRFW 1#O.980TQH5_(Y#1+GU(@I]QPX]@AI2'Q$;"+GVN<ZZ<?_[Y,1''
M_A?:[KIUZ^*8D83,;)?C0+NT5Q<HM_W_<MM--]U416[CLUJ?<AOC3W(X?2TA
ML4REQ)___.=5]H/SB\\(XF]R7O%>/GL///! G0F3(B(B(E(5Y39I["BWE0[E
M-A$1$9'B:(QR&WFV8<.&A<,..ZSB7IO<%?N436YCX;Q''GFDQCPD)!/GIDV;
M%N_G$\&-/ F+0-Y]]]UYR6W\R7,N.4UR(<GKR!FQL&,^.=<$)M]1J>V((XZH
MR(VT:M4J"GLB(B(B(M*X46Z3IHQRFXB(B#1*2B6W)2#J[-RY,THW"!=+ERZ-
M4ACM<2-%HH+DQ'[[[5=)8"(0O1#<'G_\\5A]*VEOV[9M\6:+GR-DW'+++7'"
MWQ577!&&#Q\>$S+I0-#BABMIG\0-VT-*R93;D$DF3IP8WGCCC1KW#1D'H2@S
MT45%-ZJ2U02O8_^0[1+I[NBCCXY)GK0P1_O(3">>>&+HW;MWN.BBBZ* =]]]
M]T51C2IYF=NK3[F-*F+SYLV+U9ZJ [&(A%>G3ITJ"3B\'S&.WR/B(*6EV^_?
MOW^LH):OW 8//?10..&$$RK&NA"YK38P-E1B&S%B1$R:I?>O8\>.L;+6>^^]
M5ZMVD;(013,GK+'R).T6DN0KAKJ0VWCVH7(8D_%FSYY=<# >V=HMA=S&M6C]
M^O55'@CYK%(AC=\50S%R&P(L^X^LEKZN(I)RS4S#1%*N(:R(FDX^\P4/4C#)
M?!$1$1&I/Y3;I+&CW%8ZE-M$1$1$BJ/<Y3;R8N3_R#\L6K0HYO%8;(^<X>C1
MHV-.BFVD<Z0\0Y+;2Z0Q<@#\?<B0(5GE-G*0Y.:X3\^W3RR21RXOR6V2VR"?
MR2*0^<AM3*;;NG5K7% TO;!C\^;-8U[CXHLOCGDQ]H\@%YP$^YL$^TO.DH5%
MDW%F?Q'=;KCAAEH?-Q$1$1$1:1@HMTE31KE-1$1$&B6EEMNR@1B%C,6D&R8P
ML>H>J^BEDRMI&>CFFV^.-U>\AXI8B%/777==? ]5OA#">!C9=]]]:ZP(E[3)
MI*GKK[^^BMQ&.PA73)*J"299(5IE)KKH7SYB#V)5FS9M8K]Y'XD6!"RJ32%\
ML8IB\KO,_E-YCOO"P8,'1QF/AS,J15$ICX13?<IM'!.VL67+EFJW@5B$:,/^
M9O;QK;?>BA(C8TSR*OU[DEB%"C<(E9T[=ZY(9NUIN0TX%B0 2>"ESTN$QG'C
MQD6AJ+;M+EFR)/3ITZ=2NTQ@XWS>DRM\IJD+N8WSE\J/G,^U 8&0<^A[W_O>
M'I';N"XAA:7;YGSE>DE5MV(H1F[C\\F7,U111!).^M:B18OXL/KIIY_&UP 5
M ;E^9'Z.J=K&2J9\WD5$1$2D_E!ND\:.<EOI4&X3$1$1*8YRE=N^_/++^+T^
M>27R;^15O__][\=<8LN6+6->@G;3"]A5%]QO7WCAA7$1S:2B6Q((8U1[2W((
M^4"E-_*'24Z3!499Z)'%2?.1V\A3L$AJCQX]JN1#Z2O[A3C'GP0_(UC<+PE>
MFVW?^1F+$HX?/[ZH8R<B(B(B(N6/<ILT993;1$1$I%%2%W); C=4""*???99
M%&5(++":7KK2$$D')#8FX[SZZJLQ6</-4Y*TR)6LR"=(GHP=.[;*0PW[NG'C
MQAK[_^233X;SSS^_2J*+JF+YK&B(6(5\DB1[D%"0>Q"^F-A%U216$\S6]V2_
M&0,2.23 6$UQ^?+EL5)>?<IMK**(U$7UJ.I +")QEBFW4:&.26J(253>(NF4
MF41<MFQ9C>.;AH?7GCU[5H@^=2&W<6XSCJPFF984$1/[]NT;S^?:MLN#R*A1
MHZJTB_"V9LV:$N])=I3;_AY6K%@15PE-MXU 1E5&QJ<8BI';@,0P*Z]R34U?
M-_B\\ODB$0Z[=^^. C&?N\S/.I_C[=NW%[4?(B(B(E(<RFW2V%%N*QW*;2(B
M(B+%4:YR&_D6[G]9M)/O[O?99Y\:I:Z:8N# @>'NN^^N(K=1 8X);X7(;>0M
MR#\F^\:?)Y]\<NQO/G(;N1K^??KII]<JWUM3D&MAH4(1$1$1$6G<*+=)4T:Y
M341$1!HE=2FW);#B(*OR(6-Q(T52)BUC(+QP$X64<>RQQU:I[E;;('G"]C(?
M:MC7W_WN=S7V&[F-R5:EEMOFSIT;Y3/D&^0N*K,-&S8LKEC()"6VEQ8 DT01
M%>R8Z$B[B#7//?=<@Y?;J()7"KF-"7&]>O6J4[DMD3=OO?76F*!,DHMLES'B
M^!;3[NVWWUZI7<Y=GA56KEQ9XCW)3E.7V[ANT39MI=M&,N3G5!XLAF+E-IX9
M9\R8$<^)=/]8+77.G#EQ;/@<,_9(NNGD,MM%!B6ASD.OB(B(B-0?RFW2V%%N
M*QW*;2(B(B+%48YR&PN$KENW+BZT1_Z,JFBU7?0S'7M2;B.?48C<1K[QM==>
M"UV[=BU)_C<SE-M$1$1$1)H&RFW2E%%N$Q$1D49)?<AM"3MV[ @+%BR(B91T
M\NCPPP\/1QYY9$S8,,&)GR%W'7C@@7'23I<N76+%*BJ\(<,,&C0H#!X\.%QX
MX84Q.G?N'-^?*825J]R6GKR%?$,5N:5+E\9J4#?==%.L7H?DPGL9@V0"&,DL
M$D;L.VTL7+@PJ]SVU%-/U2BW(29-GSZ]RBJ)=2FW;=FR)8YEIMR&Z/?LL\_6
M.+YI'G_\\="M6[=X#OU#'<EM"??<<T\\KDFRD>.,$$:5O6*@PA_25G)>LV\<
M'R31NJ"IRVU\!I@XF4ZV)E44.08(N\50K-S&YW/MVK6Q F1ZDFC+EBW#\.'#
M8[)\UZY=<1SXS";75H+KZA577!$^^."#HO9!1$1$1(I'N4T:.\IMI4.Y341$
M1*0XRE%NX[Z7O"6+?^Z]]]X5[R4GQ&2S#ATZQ-Q!OW[]PH ! ZKD2%GXD;Q
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M%=MJ:@\)"PD(V2M=_:TQR&U <HE)8/0CW0?D0"J&]>_?O]+/6<V18YPM499
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MFC+*;2(B(M(HJ:W<1K(!F2Q918]$!;):GSY]PL477QQOD&Z\\<8P8<*$F'A
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M;+N(B'Q.7GGEE3JOMI5+;BNGX+-$PK?0SU-UX\[GC(0N^\VUA<IR>X)2RFU
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MY38@T?'7O_XU5O^A.A4K]+$J($((LAE)$.0*9"&"OR/(4 &)) .R%.^O+MG
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M:6X3$1$1Z0J:VVPVF\UFL]EL-IO-9K/UYS9LV+#LQS_^<?;..^]4C*'\45Q
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M:!@NT2]XA^/\E\UTQG[S7*.8'&.'>SJ)*1C=8B$VW@&)E6.Z8T8T8K\///!
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M2HB(.ZD0'6E&<QNB*::]]/,(RPC3"-658'E$VE3885U49B"1HA%B;)FYC6/
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M7_E*6"8:0+EN7GGEE:I")U].2-[+)V5H;A,1$1$1:0TTMTFKH[FM<6ANDYZ
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M/ME'JC@BTB"L(_ @=L=&@A)?P$BXP*1&%6-F7$M-9/$%EKY)#"-I8,*$"4&
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M$]DGA#OVL=;M12A$@"<A W$?\2[]3%?-;21+D,A Q5Z^9/#%.C4"EC4^PSG
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M<1M 9(C;PB%N@S\BQ&T  ' Q(6X#      !(NQ"W <0'<1L   #X'N(V
M     '] W 80&>*V<(C;X(\(<1L  %Q,B-L       #2+L1M /%!W 8   "^
MA[@-        P!\0MP%$AK@M'.(V^"-R\N1)6[]^O8T:-<HZ=^X<T=&C1[O7
MG3U[-K67"P  :1SB-@      @+0+<1M ?!"W 0  @.\A;@,       #P!\1M
M )$A;@N'N T    @,8C;        TB[$;0#Q0=P&    OH>X#0       , ?
M$+<!1(:X+1SB-@   (#$(&X#      !(NQ"W <0'<1L   #X'N(V
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M3%:^5.Y47Q=B:ENZ>"Z[_+(,(9\? P<.M&W;MJ5;Y\R98\6*%0LY)\1M
M +$3+6[3;RVO6+$B(B(B(B(B^MBDO_PM0X8,=O755Z?ZNA#]:H4*%2Q'CAR)
MQ6WZ1[NE$YO;UPOO0$1$1$QQG[RO4L2X;<##UZ?ZVA 1$1$1$1'3D_>T*1WR
MO7F=:E?:QKFWI_JZ$%/;^>.:6HD_YPSY_!@U:I3]_///Z=8U:]98R9(EB=L
M    +I!H<5N[=NWLZZ^_1D1$1$1$1!\[=NS8D._E<N;,:1,F3$CU=2'ZU<V;
M-UO=NG43B]MNJ)#?=BWI:+;E 41$1,04=]@352/&;6/ZUTKUM2$B(B(B(B*F
M)Q_K4C'D>_.F=?YLI]=W3?5U(::VF^>UM[(EK@CY_/C;W_YVD1Y[]B?_^]__
M["]_^0MQ&P   , %$BUNN^^^^U)[:0       ' >WGOOO9#OY:ZXX@K[^../
M4WM9 +Y%OSCQMMMN(VY#1$1$_TK<AHB(B(B(B.@/B=L0(TO<%@YQ&P   $!B
M$+<!      "D78C; .*#N T1$1%]+W$;(B(B(B(BHC\D;D.,+'%;.,1M
M (E!W 8      )!V(6X#B _B-D1$1/2]Q&V(B(B(B(B(_I"X#3&RQ&WA$+<!
M    ) 9Q&P      0-J%N T@/HC;$!$1T?<2MR$B(B(B(B+Z0^(VQ,@2MX5#
MW 8   "0&,1M        :1?B-H#X(&Y#1$1$WTO<AHB(B(B(B.@/B=L0(TO<
M%@YQ&P   $!B$+<!      "D78C; .*#N T1$1%]+W$;(B(B(B(BHC\D;D.,
M+'%;.,1M     (E!W 8      )!V(6X#B _B-D1$1/2]Q&V(B(B(B(B(_I"X
M#3&RQ&WA$+<!    ) 9Q&P      0-J%N T@/HC;$!$1T?<2MR$B(B(B(B+Z
M0^(VQ,@2MX5#W 8   "0&,1M        :1?B-H#X(&Y#1$1$WTO<AHB(B(B(
MB.@/B=L0(TO<%@YQ&P   $!B$+<!      "D78C; .*#N T1$1%]+W$;(B(B
M(B(BHC\D;D.,+'%;.,1M     (GQ1X_;?OSQ1]NZ=:O-FC7+WGWWW8"K5JVR
M0X<.V:^__IKP/HX=.V9???65S9@Q(V0?JU>OMA]^^,'.G3N7 D=R<3E\^+#[
M6GORY,F!XYDX<:*M7[_>CAX]FMK+@_^/4Z=.V=JU:]WGL'>-IDR98HL7+[:?
M?OHIM9<'     !<)XC: ^"!N0T1$1-]+W(:(B(B(B(CH#XG;$"-+W!8.<1L
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M'W_<"A4JY)NX;<N6+?;ZZZ^'K+--FS8V??ITV[-G3\+K20F(V_P/<1L
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MH,*ZI'&;PC:=']V[6K\>F(R&XK=;;KDE$.8IGE28-F;,F$"8EQR:WC9HT*#
M!$3B-@   (#T"W$;0'P0MR$B(J+O)6Y#1$1$1$1$](?$;8B1)6X+A[@-
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M,F7*$+<!    I&.(VP#B@[@-$1$1?2]Q&R(B(B(B(J(_)&Y#C"QQ6SC$;0
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M^\X[)T.&#+&;;KHI,'4NT;A-UU#!7=)KJ*F#FOJ6W'N3H@A0P6>)$B6(VP
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M1GJ&(-&X[:.//K)[[[W7LF3)$K(-;5.3ZZ)-X-/'=6[U>=&^?7L7>Q*W 0
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M7>P(     .D#XC: ^"!N0T1$1-]+W(:(B(B(B(CH#XG;$"-+W!8.<1L   !
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M>XD        0!\1M )$A;@N'N T1$1$Q,8G;$!$1$1$1TZ[$;8CQ2=P&
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MME]__=56KESI'CJ*]/Y8S9$CAY4O7]Y-?-NP88.=.7/&;?MB0=P&
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M]*B=.G7*31=3"*?7Z\$EA6[Z>X5OO7KU<A&9]]"2_M0TM]Z]>[MP[F) W 8
M      !^@;@-TC);MVZU"1,F6)<N76SHT*&V:-$BV[)EB^W=N]<.'SYL)T^>
MM)]__MG.GCWK?DZD/W5_*W+3ZQ2KE2]?/C#![9)++K&,&3-:V[9MW2]2\B;"
M$;?]_Q"W(2(B(B8F<1LB(B(B(F+:E;@-,3Z)VP   ,#W)!*W[=NWS]:L66/S
MYLVS;=NVN7 M%A2[Z6&FCS[ZR+IUZ^:FM^F!)>_!)4UUFSAQ8DH<WGDA;@,
M      "_0-P&:9D??OC!-F[<://GSW?AE:(U_0PH%O0+D;[XX@L;,F2("[:\
MGQ/)JE6K6N?.G2UW[MS$;4$0MR$B(B(F)G$;(B(B(B)BVI6X#3$^B=L   #
M]UQHW)82Z+=V3YHTR?+ERV>9,F4*Q&V5*E6R%U]\,>[M>;_U^]BQ8^ZW@BNX
MV[QYLYL2]]___M?6K5MG&S9LL*^^^LIV[][M]J\@;\F2)<G&;=YV]7K]_Z9-
MF]P#1-[VMF_?;@</'G0/8NFUL:Q34^T.'3KDOL[3;R?7=K2]X'7JXUJG7J<(
M+^FV]8#8\>/'W;2\M6O7!M3Z]$"9 L)@-$5/$_6TW>#7?_WUU_;CCS\&?G.Z
M7J?WZUB#SY_6I*!1:]>^M2:M3:_3.?6.00^CZ4^]3VO1W^W8L<.]5_N/="P
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MV=*M6<=0HD0)*U^^O%6K5LWJUZ]OK5JULAX]>KCW_OO?_W9?VWHA'0
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M:NO>O;L[!KU.Y]0[ADLOO=3]F2U;-LN3)X^[MEJ3XC=%< H/->5-ZP<
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MRI2$XS:9-6M6>^JIIUPPYT5JP6C],V;,L,*%"X<]:/FO?_TKXOD!      "
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MK;WWVFNQU]K[\[FN[Y7V7L^X'LNSGOOW^=V$$$(((820Y UR&R'1!;D-
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M\,(+O<O\S)DS_3D0<ELHR&V$$$(((;$%N8T00@@AA!!"DC?(;81$%^0V
M2'C.E]RFSEX:=#-\^'"7J22 !;9UP0476*-&C6S<N'%VZM0I.W/F3,3U2)K2
M>B14Y<^?/W4=39HTL4F3)MGWWW\?U7Y%DMMTPS9Y\F3;L6-'INO00*LV;=JD
M.9X*%2KX>L.)=OJ99B7?NW>O??KII[9JU2I;LF2)O?;::_;G/__97GWU51?%
M IDS9X[UZM7+SUOP(*_JU:O;E"E38I;;=.ZG3Y\>\OKT?/WUUS9JU"B[\LHK
MTYQ[B8GJZ*;9U <.'.@BWH(%"^R]]][S;G#JM/?33S]%];X       #D19#;
M("\A:4T=Z1LV;)AF(AT]5TE)2?%N;GH&I+\#R&VA(+<10@@AA,06Y#9"""&$
M$$((2=X@MQ$279#;    (.$Y'W+;V;-G;=^^?39Z]&B?B3MX.Y+<BA<O;F/&
MC/'9NC/CQQ]_](YHZ0<T2:R:.W=NU!)5)+FM:M6JJ;.#9X;DLVNOO3;-\F7+
MEK4//_S0CSV I#:)>Q+PUJ]?;\\]]YS=====W@U-@[:TC$2Q8'$L4O+ER^?=
MY23@]>C1(R:Y3=M?M&B1_SXC)"ANW[[=[KWW7BM3IHQWWM-^A-L_R6YMV[:U
MP8,'V^+%BVW7KEV^O#K 1=-9#P      ("^!W 9Y@=]__]V?Q\R>/=NNN^ZZ
M-->\Q+:B18OZ1#X;-FSPYT "N2T4Y#9"""&$D-B"W$8((8000@@AR1OD-D*B
M"W(;    )#SG0VY3]S.MKW[]^E:R9,DTVZE6K9H-&## UJQ9DSI@*2.^^^X[
M6[UZM0M<P>OIU*F3"UH2J*(ADMRF_5+7M ,'#F2ZCI=>>BED,)9$M0\^^,!E
MK@#JUB:I;<B0(=:^?7OOQ';))9=8Z=*E?>"69#&);1K(E9G<IM>4+U_>)DR8
M8-V[=X]);E/7N94K5]JQ8\<R/$Z)>GJ//OGD$[]NKKGF&BM7KES8_2M<N+"?
M YU'O>]Z?R0W;MJT*>KN>@       'D%Y#;("QP^?-@GPNG8L6/(<P4]3^C:
MM:N]_OKK=NK4J=1)@Y#;0D%N(X000@B)+<AMA!!"""&$$)*\06XC)+H@MP$
M $#"<R[EME]__=7EL.G3I[M )8$K_4V1Q"QU.#MZ]&B6UBD!2R*6.IT%K^N6
M6VZQ9<N6V>G3IZ/:QTAR6_7JU>W55U^UO__][YFN(Y+<]O[[[[O<IAG)U5%.
M4IY$/DEMZE:7F<"66;2-IY]^VFZ__?:8Y#:)=MI7B8-907+:MFW;;-:L639H
MT" _]UIGW;IUK6+%BMZ-+[V@=]%%%WG7/KW^G7?>L1]^^"%-5SL       !
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MMQ%"""&$Q!+D-D(((8000@A)WB"W$1)=D-L $ASDME"0VP#R'MF5VP
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MUE:M6F577WUUQ'7I,ZY'CQXNL$5ZC:2V2))?2DJ*=ZO;M6M7ELXM (2"W 8
M      "0&""W 80'N2T4Y#8   " V$!N P      2%Z0VP"B [D-(,&)E]RF
MCF&K5Z^V^O7K6ZE2I4+64:!  :M:M:J-'#G2OOKJ*_]PB,29,V=LX\:-UKMW
M;ZM6K5K4XEGUZM7MKKONLCU[]D3<CHYEZ]:M]N"##UJ-&C6BWD;-FC7MOOON
M\_.G_8VT#7W0W7OOO7[LD=9UVVVWV<R9,WT_PHF!F:59LV8N\QTZ="BZ-Q\
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M[MV[VUMOO973EQ% TH/<!@       ) 8(+<!A >Y+13D-@   (#80&X#
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M=X[+3&S33<B"!0OLU*E3.73U .0>D-L         $@/D-H#P(+>%@MP&
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MO?+GS^]2F*0W17_6S_3P5*_1:_5AT:%#!Y?!]NW;YY\%K[WV6H9RV[!AP^S
M@0/VRBNO6*=.G:Q<N7+>"4WKU?J#MR>IK6C1HBZH-6K4R.6YCS_^V/];ITZ=
MB-MXXHDG;._>O39GSAR[X88;,MR&CE7;J%RYLEUSS37>;>WKK[\.^WZHD]NR
M9<O\N#,2YFK6K.G=Y52\!X#806[+.T@(_N677^S$B1,N&0>B_]>-:SAA^(\_
M_O#?J5-F\#+'CQ_W=>4FR?CLV;,^:%3_'@4?JXY=0K;.1;RVH?-WKK8!
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MYYBW\<TWW]BJ5:NL9\^>:;:ASJ7;MV]GT"H     0!X'N0T@/,AMH2"W 0
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MUJQ9=M]]]UG+EBVM9LV:/AFQ)FG.GS^_77#!!7Y>BA0I8MVZ=?/[>@
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MRFW[]NVSEUYZR0<H:4#-I9=>ZMT7-:-?R9(E4V?U"UXW<EO.@-R6,<AM
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MCQYM3S[YI"U<N-!V[]Y]7O81       @(Y#;(+>S8\<.>_KIIT-J01D%N0T
M( ;TT%1M,_7@=\&"!3Z(H7CQXB$?G)K-3 ^#GWCB"1_(  #Q(QYRVZ1)DUS6
MT:Q^I4N7]J*';GAJU*AAM6O7]ID'D=MR'N2VC$%N P    " G :Y#9(=/5N8
M-V^>=>C0P3M2J%N;)C/3LZ#JU:O[Y$A5JE3QY[W(;;&!W 8    0&['(;:=/
MG[;-FS=;SYX]74P+'M>@F=-U#ZR?JTZJFI B :Y.G3I^3ZP:JNZ+54/5;.OZ
MV;OOOGO>Y#9]S]RW;Y]U[]X]S;%7J%#!VK5K9Z^]]II]]=57/O#M]]]_/R_[
M!       $ W(;9#;D=PV8<($'U,;:6RVNK@AMP$ Q $]!)4TH;:9NLGHVK6K
M?_ &9@4+3F"&,#U$U8-B (@?L<IMFIU/KVW=NK4U:M3(!R,-&## N[EI,)/$
MJ%Z]>B&W)0#(;1F#W 8      #D-<ALD.WJVH&>X&B1;KUX]E]SZ]NUK8\:,
ML3ESYMB*%2MLW+AQ+K0AM\4&<AL   ! ;,0BM^W:M<OO1R6P!7=LTY]UCW;O
MO??:"R^\X#6V;=NVV<Z=.VWKUJVV9LT:OR=^]=57;?SX\;XMU>VNN>8:^_##
M#^W4J5/GX<C-)3KM6_I!;0T:-+!9LV;9GCU[[,R9,_;''W^<E_T!      "(
M%N0VR.VH-C9ERA1KU:J577WUU5Y+&SAPH(_-GC]_OG^O[]&C!W(; $ L2 Z0
M3:P/5WW(]NG3QZZ[[CI_\!L\8V]P*E>N;-VZ=;-UZ];Q !4@SL0JMVG0TJ9-
MFWP D@8OO?WVV[9V[5K;OGV[W\,</7K4A@P9@MR6 ""W90QR&P      Y#3(
M;9#LZ'K50%\]'YH[=ZX_A_CHHX]\(*\Z0^C9A IN!0H40&Z+$>0V    @-B(
M16[3?6Z7+EV\ZUJ@8YON:U5STZSJN@?>NW>OG3AQPB6QLV?/VB^__.*U)M5.
M52^2]":A+5!C5:<TO>9\<.S8,:_SM6W;-LVQ2[)3_4[["       D,@@MT%N
MY_CQXSXV6]>ZGANL7+G2/0HY&!J;K>_VZ6O+R&T  %%R^/!A6[9L6<A@A$C1
M ^7&C1M[!R@^#P'B3ZQR6T9(1E41YM%''T5N2P"0VS(&N0T      '(:Y#;(
M[6A@KYXG(+?%#G(;    0&QD5VZ3J/;LL\]:]>K54[NV%2I4R"?L?>:99UQ2
M2_0)>U4SU&04+5JT2'/LF@U^\^;-WMD-       @D4%N@[Q,8&SV(X\\@MP&
M ! +T<IME2I5\@?(FAU,'ZP $%^0V_(.R&T9@]P&       Y#7(;Y':0V^('
M<AL   ! ;&1';OO]]]^]EJ/:I\0V=6S3,A4J5/!:FFIJO_WVVWD\BNSQS3??
MV$LOO112,VS=NK7?9W[__?<YO8L        9@MP&>1GD-@" .)%5N4T#'$J5
M*F5WW767+5^^W <^)/H,9P#)2+++;2H0J;WNA@T;O,/CI$F3;.3(D?;PPP_[
M39K^.WSX<'OBB2=LXL2)]N*++WJQZO///[<C1X[X#=N>/7M\=D+M4R"//_ZX
MKU/"EPI5/__\LVW<N-%?]^233_I-X:!!@WQ;*O[H9E#KTFO#[:-F:5R]>K4/
MO-+YT'X-'CS8QHP9X[*3UJWETW_.Z?^U_)=??ND%,6UK_/CQO@X->APX<*#O
MBXYOVK1IMG3I4C\V[6_Z?<EIN4W[(T%,G^E]^_:U&V^\,6005IDR9:Q]^_;6
MJU>O-.]'<,:.'>O_CNAX M?8%U]\X>=W]NS9?DWK/0\^/SK/&N"E;6_?OMV7
M27^NLR*WJ9BW:]<N/W;]'7GLL<=2WTM=,WI_WWGG'=NW;U_8?[/B*;?I&'0.
M/O[X8WOEE5?\N'5=Z+K4<0\;-LR>?OII>_755VWMVK5>J 0     @,0&N0UR
M.\AM\0.Y#0   " VLB.WZ7Y6XQWZ]^^?9IEJU:IY;6K+EBWG9%]5CU.MZN67
M7_;:C[:E6E"@#JH:D6I%>HUJ1^DG#=;W2M6W5-=4K>W..^_T+FT77WQQ2 U7
M$U/><\\]:6ISHT:-LOGSY_NZ@U$M3+6MG3MWVLJ5*VWFS)E>1QTZ=&AJG4[U
MJJ>>>LIFS)AA;[_]MNW>O=N[WS'V P      8@&Y#?(RR&T  '$BDMRF6<TT
MJ*%HT:)6L6)%%R<Z=>IDBQ<O=N&"AYL YX9DEMM.GCQI.W;LL-=??]T+(QKT
MI\Y?^@S19XD&1Q4I4L2%*=V Z7.G>?/FUK-G3Y>=)#I)-GKOO?>\B!.\C]6K
M5W<I2.*;/K<D3DE>DGBE E7)DB6M6+%BOBW-8JC?K5NWSHX?/YY&*I,,I8*.
MI#0)70T:-+!RY<KY?FEY[==UUUUGHT>/]N4EZNF\:1WZLP9O22[3@*W[[KO/
M"TTI*2E6MFQ9*URXL!4J5,CWI4J5*G[?J(*3Y"\5D"3$27(+?'[FM-RF0I6$
M0@EA&<G-F:5.G3K^?JM )U%MU:I5]LPSSWBAK46+%E:S9DU_SP/G1Z+TI9=>
M:HT:-;(>/7K8N''C_#T_<." G3Y].G7_,I+;='XDT.E<2)+LTJ6+U:]?WV?B
MU'M9O'AQ+P#J_5714P4Z#3+3-1K\[U>\Y#:]EY(O5:@<,&" M6W;UH];UY:N
M?1UWZ=*EK7;MVM:N73L7WE1TU+6H;823, $     (.=!;H/<#G);_$!N P
M (B-[,AM&@BF^MN]]]Z;9AG5:"1UJ6X5+U174YU)]WVJ6>K[8ILV;:Q6K5I>
M!U,M2#4AU0QKU*CAM2+);IJH<_/FS5YG#*!ZI6J=JG%FIS:GXU.=4X*<ZEZZ
MK]>DBIIP4^=1PEWOWKVM6;-FO@T-*@W4Z?1GU5V;-&GBKU%-3Q,WJB[']UT
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M<I.,=M===_DZ3IPX$5>Y3?5&B7.J56E]JG%&4Z<-3'JL.I\FLE0'N.")0P$
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M-KU'VH:DQ>#UJV"HV3=5A-4^Z=@578,3)TYT25+7<_#V)/SIG.C]!0    "
MQ &Y#7([R&WQ [D-    (#:R([<%T'U7[=JU0Y;7_ZO+F>IZSS__O->M5!?4
M?7!649U+M54):^DGB%1]2?7)C1LW>HU*DVWJS[HWUO@RU16#E]%DGJKY:L)#
MU><"M;9#APYY72W]1**JI:F^I'U.7Y\+=*,+EMM4?U)M3S57=:W3OFC=J@.J
M!J5:[<<??^S[K(DC54<+WI[J=JIOJNX*       0#<AMD)=!;@,  (!<2;+)
M;1*Z-%NA!*1@R4?=M20(Z0N*9D)4T47;5F<J1<M)^%$11447W;RI."/9Z+WW
MW@N1VS3(2@46B6&ZV?ODDT^\&*/UG#U[UM>E=3SUU%,^VV!@.8EJ*BQ)-@IT
M_)HP88+?_$ENT@VB"EC'CAUS64DS)DI."A[0=<455]CDR9-]N\.'#W=Q2LL'
M9GB4M*5C4B%)ZSMQXH3_;LV:-?YZ%;L"'<IT'!+L)DV:Y.=-G;]R6FX3DKCT
M7DDR3"^W:3";1+-(:)LZ)X,'#[;''W_<5JQ8X<<FZ4_G0N^1SH_>)UT#.BZ]
MYSI&#135-@("FHJ,>I\E#NK]C"2WZ5I3,5+;E(2F:T''H.UHH*D$-UTC*LYI
M^>#N;2KN]>G3)_5ZBU9NT_NL8QH[=JP/Y O(D!(7]3X\\\PSON^ZM@/[I.@:
MW;U[M\]XJ<*@.OL%%PMU[K4_NH8      " Q0&Z#W YR6_Q ;@,   "(C5CD
M-M6<U,U,@R>#EU4-1Q-9JD:H21HEB]UTTTW^6M44Y\Z=Z_4\"6SANKE)"OOH
MHX]\XL)2I4JEKE>U/DVJJ8DX=^[<Z750U8)4X]&?]^S98_/FS?-))76O':A3
M:5_:M&ECK[_^>JJ<)E13FC-G3DC-L'7KUGZ?*7$N$JI):A"I)F34,;WSSCNV
M=>M6']NF?=%WV. ZG6JBJE>IWJC)*E-24E*WIWJFZFB:U)+N;0      $ W(
M;9"706X#  " 7$FRR6TJBNA+B&9##%ZGNF])X,JHV!(.[9]F#$POMZGHHX)6
MCQX]O"@CN2@]@>Y8ZB(7+-IIED)U^ H<IXI,X997D49%+'7V"MYVK5JU7-IZ
MY957_*91!:#@@E,D5 1304R#(<N5*Y>F(YR*1?I"IXYCR2ZW26!3D>S==]_U
M_V;E_ 1FHU0'-140]1X%GQ^=,YV?2'*;"HBZ1E:M6A6VV!@X)KW7.M?J]A<H
M'&I;>D\EX6EFS&CE-KT'V[9M\_<@<)UIW1K4-V+$"/^="H21CEO7F?X^!\^^
MJ6/7<08ZR@$     0&* W :Y'>2V^('<!@   ! ;L<AMDM,DC*GF5K9LV;"U
MUN":C"8=U.26&D0F*4P3%VHB1]49)7\%^.*++VS:M&E>9PI>1^/&C7TR3=5!
MP]6$5+N2L*;[P3IUZEC1HD53[[6U?Z-'C_8N;X%E8Y';5%?:O'FSUT]5%],Z
MLU*GT^MTS#U[]DPCX*F.IKJHU@D      )!5D-L@+X/<!@   +F29)/;5#"1
M)!0\JY]RXXTW>A%)7<VB(9+<IJ)*^?+E[=EGG_6!A)&*,OKY/??<$S(SHXIA
M$NY>?/'%B-O6>O?MV^=%G.!E=6SJP"9I*5HDT6E&1Q6N@@MR*D:I<*49'9-=
M;HL%71\J5NH:#!82)2AJ=LEP<IN*CI(557!3X2\S9L^>[;-@!LMSVI8*BNO6
MK8M:;M.Y>/[YY^WJJZ].<WUV[-C1N]5E=LWK2XE>IV)I\#ZI8Z"..3O7&0
M    G!N0VR"W@]P6/Y#;     &(C%KE-'#ITR"?>5)<UK4<UF("PE5DD=.G^
M=MBP85[74[U2@IJ$L3ONN"--US:M<_#@P1E.=AA M5?5@U0'"]Z>UKEAPX;4
MR3ACD=MB074P3>Y9LF3)U.\$A0L7MLZ=._OW!       @*R"W 9Y&>0V
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M4:$ZL*FC6T:BFVJ2K5JU\AJGNJYI\LK _;+JC:H)+5NV+$O[HDDU=^S8X;7
MX&-3[6O,F#%VY,@1?UU.R6U"==RN7;NF3M*I[P/5JE6S\>/'G[-M @    !
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M$-RKK[YJ(T>.M#Y]^M@MM]SB]4?5KK2-X#I=_?KU7=HK5*A0JMRF]T$U-
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MGWSBG?)4+ S(:"HB]NW;-RJY39T&=1WJFHCU^-)'W?RT?Z^\\DJVWD,
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M;7/%BA5>U N\IWHO51#4/D8CM^D+Q>K5J[T+7^!Z4#ITZ& OO_QRMLX]
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M.7*D'3ER)+5NF=W.;5I.ZTH_@%0U+'6,BU2GT[*JH\V:-<O:MV\?MAZ*W 8
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M8G^-)YYXP@<&%;%I.1I@U8"A!E/U\U&C1OF@H?X>* ZL5Z^>#Z(2MP$
M! ?B-LCJ$+>E'\1M     (EQMG&;;K38O7MW?Z[&6S1VI/!,XS2ZN%+C4KMW
M[_;Q2HV3ZCGZO<9%-6:I*$[CD.$W?]2O+[WT4A\WT_(?>N@AJU"A0L0XH6[<
M6+MV;1_#U8T8-4ZH<2!]+M1R-;N;Q@C#MT5C81J'U#+#.9NX36B\ZLTWW_0Q
MR]!X6.BFG56K5O6QLH4+%]J>/7M\C%%CC_J]MDM_KC$ZC0-J7$O;0]P&
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M0-P&$!OBMFB(VP     2@[@-       @\T+<!I VB-L    @\!"W 0
M  0#XC: V!"W14/<!@   ) 8Q&T       "9%^(V@+1!W 8   "!A[@-
M    (!@0MP'$AK@M&N(V    @,0@;@,      ,B\$+<!I WB-@    @\Q&T
M        P8"X#2 VQ&W1$+<!    ) 9Q&P      0.:%N T@;1"W 0  0. A
M;@,        (!L1M +$A;HN&N T    @,8C;        ,B_$;0!I@[@-
M @]Q&P       $ P(&X#B UQ6S3$;0    ")0=P&      "0>2%N T@;Q&T
M   0>(C;         ((!<1M ;(C;HB%N P   $@,XC8      (#,"W$;0-I(
ME[BM2)$BUK-G3QL\># B(B)BNEN_?OV8<5NC1HTR?-T0$1$1$1$1LY/5JU>/
M.#<O7;JT#1@P(,/7"S&C[=Z]NUURR241?S]TPZ;]^_=G6^?,F6.E2I4B;@,
M   X2U*+VY*2DC+\\R\B(B(B(B*>WI8M6T:<R^7,F=/NN...#%\OQ* Z<.!
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M;D-$1,3 2]R&B(B(B(B(& R)VQ!C2]P6#7$;    0&(0MP$      &1>B-L
MT@9Q&R(B(@9>XC9$1$1$1$3$8$C<AAA;XK9HB-L     $H.X#0      (/-"
MW :0-HC;$!$1,? 2MR$B(B(B(B(&0^(VQ-@2MT5#W 8   "0&,1M
MF1?B-H"T0=R&B(B(@9>X#1$1$1$1$3$8$K<AQI:X+1KB-@   (#$(&X#
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MP9"X#3&VQ&W1$+<!    ) 9Q6]9!L[;I3O3WWGNOE2]?WG+FS)G0!8#$;0
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M_&(_!6TZ+O_][W_].?JO?J^+!O5G"MDT4]NQ8\?LAQ]^\)^''IL9(6X#
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MX)UWWO&9]RI4J.!!7&A[%=/=???='N3-GS_?WX_A^T-!WG///1<1UP$
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MY/3NW=O/W<-OAI+:#&[$;8B(B!@8B=L0$1$1$1$1@R%Q&V)LB=NB(6X#
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M?\V:-<LOUGWYY9?]W$?OM]!RM1TA%>Z5+U\^.3#4^N;+E\^&#!E"W 8
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M]>.M]T+MVK5]7;3O\^;-:SERY/!8+13+Q;-\/4[A8<KC0]P&     %D)XC8
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M4$V!8*M6K7RFMM!KE"A1PO[TIS_9VK5K(R*VU'CQQ1>M;MVZ$<N0FE6/N T
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M$R=.M-V[=Y_V^2=/GO38L'OW[K[.X1<VRH<??MCZ]^\?%;>-'#G29X4#
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MZPH5*ECOWKU]AG9]1W ZB-L0$1$Q\!*W(2(B(B(B(@9#XC;$V!*W14/<!@
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MRNA\7>=X^AY"LW.GO!E-+(C;$!$1,? 2MR$B(B(B(B(&0^(VQ-@2MT5#W 8
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M+_?/_>W;M_=]K,=JF>$SSLG77GO-7GGEE8CP4>M=J5(EWV9MO\+#>&?6 P
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M33?#>>&%%^+^[D'GB?K.@+@-$1$1 RMQ&R(B(B(B(F(P)&Y#C"UQ6S3$;0
M  ")\5O$;8E:N'!AN^JJJR*"M7A5N*39RP8/'NRSE<6#+E[3K&LI+Y0+J=GC
M)DZ<:+MV[3KCLC3#F8(PA6*A6>3.9AMTD9[6Z6SBMO10^U[!F&9<TTQI0G?
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M!LU\5J5*%9^M;,"  ?;WO__=-F[<F*8P+X2>LV_?/@_[)D^>;&/'CK4''GC
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M;D-$1,3 2]R&B(B(B(B(& R)VQ!C2]P6#7$;    0&(0MP$      &1>B-L
MT@9Q&R(B(@9>XC9$1$1$1$3$8$C<AAA;XK9HB-L     $H.X#0      (/-"
MW :0-HC;$!$1,? 2MR$B(B(B(B(&0^(VQ-@2MT5#W 8   "0&,1M
MF1?B-H"T0=R&B(B(@9>X#1$1$1$1$3$8$K<AQI:X+1KB-@   (#$(&X#
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MB*>W9LV:$>=R%UUTD5U__?49OEZ(0;55JU8^]IQ0W%:M6C7;OGW[.?KJ!@
M +(;3S_]=,RX[2]_^4M&KQH       ! MN+!!Q^,.#>_Y99;[.3)DQF]6@ 9
MSK___6\K5ZY<Q-^/O_[UKQF]6AG*O_[UKZ@@EK@-    ('Y2B]O^_.<_9_2J
M 0      P!GXV]_^%G$N]_O?_][^\8]_9/1J 0264Z=.6;-FS8C;    (+@0
MMP$        $ ^(V@-@0MT5#W 8   "0&,1M        F1?B-H"T0=P&
M@8>X#0       " 8$+<!Q(:X+1KB-@   (#$(&X#      #(O!"W :0-XC8
M   (/,1M         ,& N T@-L1MT1"W 0   "0&<1L      $#FA;@-(&T0
MMP$  $#@(6X#        " ;$;0"Q(6Z+AK@-    (#&(VP       #(OQ&T
M:8.X#0    (/<1L       ! ,"!N X@-<5LTQ&T     B4'<!@      D'DA
M;@-(&\1M    $'B(VP        "" 7$;0&R(VZ(A;@,   !(#.(V      "
MS MQ&T#:(&X#  " P$/<!@       ! ,B-L 8D/<%@UQ&P   $!B$+<!
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M'W[XP4-#<?SX<=NW;Y]MVK0ITZCWL-Z'>K\#$+<!      !D7HC; -(&<1L
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MLF4V9<H4>^&%%^R11Q[Q[RZ:-&GBW]>7+ETZ^3RV;MVZ/BNWQI!20MP&
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M:'[+$"KT;T&)$B7\]6(-O/]?]NX%:->J/N]_TNE,FJ2)G:1.4L=&AU0I"L'
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M>R]:AKG-?4.?G7/..>5ZL#_7BO.NXZE5DZEC];O./8*1D\&R*U2&$$(((82
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MB ?+% E5'V6:$DQO*^D*X'M7LKJ6*K_,3T1@X@Y17E)$FRRE:J( _?;MVXM
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MY[AMBJ4R&'G>=6//_M\]B&&(#M%W#3H6]PO7LX)D(?2QB+E- 3[7&)/IN.>
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MS&UALQ-SV_*(N2VL!V(>S")6Z)#D/HW!9=XF9JJ EAB>/W?6?L2&Q87$+A5
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M>-;5]][\YC<7O<%V%:&J"?T;T=SF_8LV(*8I9JY@V2QSPW'1-<S7"RZXH,2
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M7_K2E\KO<;_WEJ&W68V]+PX2<UL((8005H:=:6X3C":4"&9[GR$J$#V\"#$
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M$J:>G7?>N: B6#ZHJKF-<56Q4:HYC6 L1"&"NS#/Y7_W@Q_\("9'636QIL#
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MSK_<#(M H->\>?/J[0OCW]2I4]/++[_<[$R0]!/]WI(,D@A75(W+BW\$OA&
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M9/WD,ZJI341$1$2D-M#<)JT%<VJ"/YGKYN>@E33FG03C%E>&YUC,I9D_4]6
M=0#FVLQ1F:]>?_WUD4B&"NG,RTO-]S6WU4=SFXB(B$AE; QS6QZT*,;!2Y<N
M3;_^]:\+=%)T,L;#:&9H2FAW:);H7VA(Q1HG!JQ5JU;%^]#Z&$^C_V%28UP\
M;]Z\T&-Y7P;[NN^^^^KIJ.A#Z&?L(_\Z^B+&-D G1=_CO9P?VA+C?0QKZ(\<
M#R,<6FLI2(*)%LDUYH^Q:-&B!K=A'L$UT$?Y;3![K5V[MLDDG>A=:'RE=-]\
MXHQ2H-&Q/??JWGOOC6O.ZYF95HC&B&9+WY 0M2DX)OH>FB'/&YHGYT<_LM_\
M>6)>1"-LR/PG(B(B(B*%:&Z3C@[S9Q+G%,^36]I(:D-Q"LUM(B(B4K-L3'.;
MB(B(B(B(B)2/YC:1TFANJX_F-A$1$9'*V-CF-A$1$1$1$=EX:&X3:1X4=/CA
M#W^HN4U$1$1J%\UM(B(B(B(B(K6!YC:1TFANJX_F-A$1$9'*T-PF(B(B(B+2
M?M'<)M(\-+>)B(A(S:.Y341$1$1$1*0VT-PF4AK-;?71W"8B(B)2&9K;1$1$
M1$1$VB^:VT2:A^8V$1$1J7DTMXF(B(B(B(C4!IK;1$JCN:T^FMM$1$1$*D-S
MFXB(B(B(2/M%<YM(\]#<)B(B(C6/YC81$1$1$1&1VD!SFTAI-+?51W.;B(B(
M2&5H;A,1$1$1$6F_:&X3:1Z:VT1$1*3FT=PF(B(B(B(B4AMH;A,IC>:V^FAN
M$Q$1$:D,S6TB(B(B(B+M%\UM(LU#<YN(B(C4/)K;1$1$1$1$1&H#S6TBI='<
M5A_-;2(B(B*5H;E-1$1$1$2D_:*Y3:1Y:&X3$1&1FD=SFXB(B(B(B$AMH+E-
MI#2:V^JCN4U$1$2D,C2WB8B(B(B(M%\TMXDT#\UM(B(B4O-H;A,1$1$1$1&I
M#32WB91&<UM]-+>)B(B(5(;F-A$1$1$1D?:+YC:1YJ&Y341$1&H>S6TB(B(B
M(B(BM8'F-I'2:&ZKC^8V$1$1D<K0W"8B(B(B(M)^T=PFTCPTMXF(B$C-H[E-
M1$1$1$1$I#;0W"92&LUM]='<)B(B(E(9FMM$1$1$1$3:+YK;1)J'YC81$1&I
M>1HRM^V___[IE%-.L=EL-IO-9K/9;#:;S=9*K5>O7@5S\QUVV"$-'SZ\S<_+
M9FOKAMC6M6O7@L_'Q(D3T]JU:SMM6[QX<>K>O;OF-A$1$9$6TI"Y;;?==FOS
M\:_-9K/9;#:;S6:SV1IO P8,*)C+,;\[XH@CVOR\;+9:;2>??')HSYK;1$1$
MI&9IR-QFL]EL-IO-9K/9;#:;S6:SU6H;/WY\>OGEESMM6[!@0=IYYYT+^D1S
MFXB(B$CY-&1NL]EL-IO-9K/9;#:;S6;K#&V7779)IYYZ:GK]]=<;74/YAVP#
MS6TB(B*R,='<9K/9;#:;S6:SV6PVF\UF:V]-<YOF-A$1$9%*T-QFL]EL-IO-
M9K/9;#:;K3,WC&VOOOIJ^O+++QM=0_F'; /-;2(B(K(QT=QFL]EL-IO-9K/9
M;#:;S69K;TUSF^8V$1$1D4K0W&:SV6PVF\UFL]EL-INM,[>==MHI#1LV+ QN
MC?$/V0::VT1$1&1CHKG-9K/9;#:;S6:SV6PVF\W6WIKF-LUM(B(B(I6@N<UF
ML]EL-IO-9K/9;#9;9V___,__G/[MW_ZMT364?\C>K+E-1$1$-B8-F=LVW733
MM.666]IL-IO-9K/9;#:;S69KI;;))IL4S,V_^<UOIJY=N[;Y>=EL;=VZ=.F2
MOO[UKQ=\/JZXXHK()-E9VT,//:2Y341$1*0"&C*W\5I;CW]M-IO-9K/9;#:;
MS=9X^]:WOE4PE_O:U[Z6-M]\\S8_+YNMEAO:L^8V$1$1J5D:,K>-&3,F/?74
M4S:;S6:SV6PVF\UFL]E:J0T=.K1@;MZO7[^T<.'"-C\OFZVMV]RY<T-<RW\^
MIDR9DC[__/-.VU:N7)EVVVTWS6TB(B(B+:0A<]LQQQS3YN-?F\UFL]EL-IO-
M9K,UWJZ\\LJ"N=P66VR1IDZ=VN;G9;/5:GOBB2=2__[]-;>)B(A([=*0N>U?
M__5?V_K41$1$1$1$1#H5__(O_U(P-__O__V_I__S?_Y/6Y^62)OS^]__/GWW
MN]\M^'S\S__Y/]OZM-J4?__W?T__[;_]-\UM(B(B(BVD(7/;__@?_Z.M3TU$
M1$1$1$2:X'_]K_]5,)?[IW_ZI_2___?_;NO3$JE9_N___;_IAS_\H>8V$1$1
MJ5TTMXF(B(B(B(C4!IK;1$JCN:T^FMM$1$1$*D-SFXB(B(B(2/M%<YM(\]#<
M)B(B(C6/YC81$1$1$1&1VD!SFTAI-+?51W.;B(B(2&5H;A,1$1$1$6F_:&X3
M:1Z:VT1$1*3FT=PF(B(B(B(B4AMH;A,IC>:V^FAN$Q$1$:D,S6TB(B(B(B+M
M%\UM(LU#<YN(B(C4/)K;1$1$1$1$1&H#S6TBI='<5A_-;2(B(B*5H;E-1$1$
M1$2D_:*Y3:1Y:&X3$1&1FD=SFXB(B(B(B$AMH+E-I#2:V^JCN4U$1$2D,C2W
MB8B(B(B(M%\TMXDT#\UM(B(B4O-H;A,1$1$1$1&I#32WB91&<UM]-+>)B(B(
M5(;F-A$1$1$1D?:+YC:1YJ&Y3=HE?_[SG],[[[R37GKII?3\\\_7:V^\\49:
MOWY]6Y^F2$WR__[?_TM_^M.?TH<??IC>?//-"+H@R&#-FC4E/T_\CO=^]=57
M;7WJTHG1W"8B(B(B(B)2&VAN$RF-YK;Z:&X3$1$1J0S-;2(B(B(B(NT7S6TB
MS4-SF[1+WGWWW?33G_XT'7C@@6G777>MUX8/'Y[NO//.,/&(R-_YV]_^%E_\
MRY<O#U/0Z:>?GG[P@Q^D/GWZI!X]>J3==MNMWN=IGWWVB2",5UYYI:U/7SHQ
MFMM$1$1$1$1$:@/-;2*ET=Q6'\UM(B(B(I6AN4U$1$1$1*3]HKE-I'EH;LOQ
M^>>?AWD#8>VBBRYJ5ALW;ERZY))+TN677YXF3IR8)D^>G&;-FI5^_>M?IR5+
MEH09ZXLOOFCK2^PP_.$/?TC#A@U+.^ZX8TFSP^&''YYNNNDFS6WM"$Q7#S_\
M<+KLLLOJ/E?77GMM6KAP850-:PE\P:U;MRZM6K4J]CU[]NQTPPTWI$F3)J4K
MKK@B/K.77GIINO+**^-8,V;,2/?==U]:MFQ9?*?]Y2]_Z5#/$/U!54/,0"-'
MCDP''710ZMZ]>]IJJZW2)IMLDK[^]:^GKWWM:_4^3UMNN65\KU'9K13<'P9;
M]&ESOSM_]K.?Q??FA D3TI0I4](MM]R2'GSPP;1Z]>KTT4<?I?_ZK_]JY5Z2
M6D5SFXB(B(B(B$AMH+E-I#2:V^JCN4U$1$2D,C2WB8B(B(B(M%\TMXDT#\UM
M.?[XQS_&PM#WOO>]D@'TC35,(2PH;;'%%NG;W_YV5#_JUZ]?.O[XX]/8L6/#
MZ,:7T5MOO96^_/)+#1L5HKFM8_'7O_XU??;99VGTZ-%IL\TVJS-8[;WWWF%X
MPI!5+GRVV-?;;[^=GGWVV73;;;>%Z>KDDT^.SV3/GCW3]MMOG[ITZ1*?64Q=
MF+?XTMM___W3"2><$&953%;///-,>OWUU]-__,=_Q#FV]^<)D^WMM]^>]MUW
MW]2U:]>RO]^:,K>]_/++Z;KKKHM!5W.^-[G/__B/_Y@VWWSSM,TVVZ3==]\]
M#'<GG712& [ON>>>]/SSSZ?UZ]>G/__YSZW<6U)K=!1S&T9> OXPA?+=QN?J
M=[_[7513Y#MKZ=*ET9Y[[KGXS'[UU5<%V_,]Q."-,0M_"U]XX848L!5OOW+E
MRC#L\[OL-=I++[V4-FS8$.9=$1$1$1$1D9:@N4VD-)K;ZJ.Y341$1*0R:MW<
M1OS3VK5KTXH5*PHTR7?>>:?!!.#,']$ZT4/SVQ";\:<__2GTU#SLAY@TDA3G
MW\]K'%]$1$1$1*16T=PFTCPTM^6HQ-R6&35H&-V^^<UOQ@+3IIMN&H8WOHSZ
M]^^?QH\?GUY]]=58D)&6H[FM8T'51 P>F)KRE<,..>20M'CQXOALE@L+FY@Z
MJ 0V8," M-UVVX61#=,<GTD^F]_XQC?J/J_99Y;7,%IEGUE,JGOMM5>84ZD>
MAQFDO9M2[[[[[C1HT* PDY6JT-;:YK:&OC>Y5]RS77?=-0T>/#@]\L@CZ?WW
MWV_EWI):HZ.8VQAX(>9@-/WI3W^:CCSRR+3GGGNF77;9)8RW?/?0^/Z[YIIK
MTIMOOEFP/:8TJAHRZ<&(>\PQQZ1]]MDGJC!VZ]:M;GL"J4:,&)'Z]NU;]QIM
MR) A(?9\\LDG;=0#(B(B(B(BTM[1W"92&LUM]='<)B(B(E(9M6YN(_X)O99$
MMGE-<M*D29&(LQ3$EY'HEL2W^6U(AKQZ]>IZR3^)1Y@\>7($LN7??_WUU\?Q
M141$1$1$:A7-;2+-0W-;CDK-;4TUOI#Z].F3SCCCC+1HT:+TZ:>?MO4EMULT
MMW4L^.S-GS\_??_[WZ^[AQC-CCWVV/3>>^_56[PL!=F[$,JY[U1IP^RQU59;
MA6FJ)9]7MOO6M[Z5>O7J%8NHCS_^>%2$:X]DU>RNNNJJM,,..X21KSE]L3'-
M;8TUJNKQ&<>\,V?.G/@[4YRE33H/&]/<AF&,C()4/KOKKKM"'*%Z(.:Q,6/&
M1- >YG1$F)MOOCD,K\TUJF>?PP<>>"#]Y"<_B;]35))$>,'0B;DS;SK%\,8Q
MR5 (_#W#"/SDDT^F"RZX(!UUU%%ICSWV" ,OAE6^,_/?=^R7 1X#NGQ__> '
M/XC)$14I1386/.O\3:;ZZGGGG5?7".CCF3:+IHB(B(A(^T9SFW0$6&=D_LJ:
M(^N>K)?<=]]]:?;LV>F7O_QENN222]*H4:/JYK3\?^;,F1%LVQ":V^JCN4U$
M1$2D,BHQMWWPP0<1FX3FF==K&FK$13#?N^RRRT+CF3=O7EJR9$GZ^../0T\M
MQ4LOO13C9V(*\N?'/A@+EN+MM]].M]UV6[VQ\X]__..H %>L([WPP@OIZJNO
M#DTU_W[B'SB^B(B(B(A(K:*Y33HR65SSN^^^&\:SQQY[+-UYYYVAC5'<@[4!
MUAF(PV;-@=AG7KOVVFO3W+EST]-//QW;YOT^FMMR;&QS&XW@=2H2(8Q274I:
MAN:VC@6+EY=??GGJW;MWW3W<9IMMTEEGG97^^M>_-GH?^1WF-Q9&R<Q%M3:,
M'M7\W%)!B2]:%FW;(P07\9G!6-M0Q3:^ES#R<:T#!PX,0UG6?O2C'X7YL+B"
M5,;&,K?1.%^^-ZGJ=__]]\>U^+GNG%3;W,9SQ//$^.699YZ)P"4&403D4;61
MOR^(,)C&J.:(B6RWW79+AQUV6'R6>.89,Q"TA,F-[ZK&X#T<!Z%IVVVW;=)X
M6VQN8\#VN]_]+EUXX85Q+IQ78]MK;I.VA.J"#S_\<#KTT$,+GK^CCSXZ)B16
M#A01$1$1:=]H;I/V#NLL)#HBT!<=@21'!/,.'3HTUI=)2+3UUEL7K-^0,(S?
M__K7OVYPOYK;ZJ.Y341$1*0R*C&W,3Z=.G5JZ(;EQC,1:\'[]]Y[[S1HT* T
M=NS8=,<==Z15JU:%OEBLB6IN$Q$1$1$1:1C-;=)1(0;[/__S/V,>/VW:M'3I
MI9>FD2-'AN]@__WWKZOPGA7O8,V!HD.\AE^!6&9,;S-FS$A+ERY-Z]:M"[U9
M<UN.UC"W968-3#P$ZDO+T-S6L6#!\8033DC=NG6KNX=4.:1*4E/WD&I(5'?#
MT<N7'4$&#1FX6MK:N[EMPX8-$:A!'S=TC9AY6'3FBY\_-BP89PWS()G8&JJ:
MMC'-;5G;?OOMT^FGGQ[G9O6VSDFUS6T(+WQWS)HU*QUQQ!%AJ$488@!%X!+?
M(]EW2?9_7N<[AH'6IIMN&A4B+[[XXA!FFJKB]LX[[Z1SSSTW]>C1HZSOJ&)S
M&Y]C1""$I'*VU]PF;8GF-A$1$1&1CHWF-FGO,"^]YYY[8NV$-9Y--MFD;EV(
MM9]L;2C_G&MN:QF:VT1$1$0JHS7-;<6Z*.-CQLML?^:99X;&4ZR):FX3$1$1
M$1%I&,UMTE'!OT&A+Y+BL'; VD5F8LMK;7F]K7C-@6TH]G'000=%Q;?WWW]?
M<UN>UC*WT;IV[1I&C0\__##]^<]_;NM+;W=H;NLX8)IZ]MEGP["!(S>[A\<=
M=URZZZZ[FKR'+[[X8ABK^O;M&]65-L;GM;V;VPC6>."!!\(-W= "]9%''AD+
MOYC'^(/3'%K#W$: "=_-_"'D'*7S44US&Y\)A!%*W!YXX($AR#!0:LG?<D07
M IL(B,+ 5@H,HLN7+T_]^O4K^)XB _C!!Q^<)DR8$$$]9#WD>X_&>&3-FC7I
ML\\^BW$"?_<8L'',;'M$(K[[?O:SGT7F@]MOO[UN>TKV_NI7OXHQ6OZ<-;=)
M:Z"Y341$1$2D8Z.Y3=H[K(O,FS<OUD3+70?2W-8R-+>)B(B(5$9KF]M*Q1(0
MG+;KKKNF$T\\,3W^^..A V5H;A,1$1$1$6D8S6W24<%K0%ST3W[RDXK\ :PY
M;+755N'](4Z<6&GBG(O?I[FM@0[<99==TO'''Y^&#!F2?O2C']4U1,W!@P='
MX/EAAQT659!8O&DL6/ZHHXZ*A9E//_VTK2^]W:&YK>- ( $! =_YSG<*W+F4
MFL3TUA!4[UJ_?GV:,V=.F,^Z=.G2:. !OZ=B$N82JC0=>^RQ4<F,SRU&.@+N
M^>SNM]]^:;?==HLORJP*7'LWM]''F%T:"M;  <WW&']H6O*9*<?<QM\)^CO_
MG<GW*/>!/T+[[KMOVG;;;4LNS&<- R3FGX8,1-*QJ8:YC>>;"FB_^<UOPA"&
M")/_.XW!=H<==HCO@>]___OQ-SW[CA@X<& 8T0C&R3_K?$>0=8"_201%(>:0
M.2 /K]UWWWUIIYUVJO>Y^/G/?YY>??75& M03:X4&(%^^]O?AI&M^#.!08\!
M&Y]SML\^PYCB5J]>'<:Y_'B%GQ%YFJHT)U()FMM$1$1$1#HVFMNDO<.\E/52
MUGQ8!V;-IF?/GK%&R5HPZZC[[[]_P7JUYK:6H;E-1$1$I#(VAKF-N EB)AC?
MYG5$=-%!@P:%OD/,1'$,QC;;;)-^^M.?AFY)O 80*T:B78QI^7TQWG[WW7=+
MGI?F-A$1$1$1Z2QH;I..2BES6U;]O5>O7N'7P!^ CISY-3*?U9Y[[AD^*XQM
MV;84P2%&>_KTZ1$;K;DME6=N._/,,R,POC@ G84;*K-0B6W)DB61F:A/GSX%
M%5:*6__^_:/*RMJU:POV16 ZC7TVU++WE&M$R;^_J7T7'Z-X/TUMT]"Q&WM_
M4^\IWF]3YC8>?!YN/CC5/L=JWYN&[E,EQVCN?6IN_S=V[LW=1Y;)J]@8-7GR
MY"@OV1!4,B) G@J(#7W&LL8B)X;3BRZZ*-U[[[VQ^(E1C451/K>80GBFV-\M
MM]P2QCH^GQA="%H8,&! /7-;6]VK<OLZ_WN^V_BN*>5DIF'NX?/4G'/(4XZY
MC7*A^45H]HL!B#Y=M6I5FCU[=GQN61!O:!\LH&,$XOXUU"=^/AL_]TKVT=94
MP]S&WVZ>GPLOO# &0A@[\R8US&Z(+7P/4"60O^E\1Q#PA &-,0(!?(Q[\L%-
MF4F40=C"A0OK&7<0CJBBAHDWO\UYYYT7)MZ&3&T9#0D\?&Z?>NJI],477[2H
M3T4V%IK;1$1$1$0Z-IK;I+W#O)1U8M:660<>/GQXNO322]/,F3.C$L6++[X8
M2=7R29$TM[4,S6TB(B(BE;$QS&UHI<\__WQHQ7F(P7COO?<BT)+@-(+-BA,^
MH.<3&\![6ZHQ:VX3$1$1$9'.@N8VZ:ADYK;1HT?'V@&M6[=NX56X_/++TSWW
MW!,%.O""?/[YYQ&+35PI\:.3)DU*^^RS3[TJ\)MOOGGJWKU[^#<TMZ7*S&TL
MVG"3$/&I)L4""IF(&C*3T*@,@["952'ZRU_^DEY[[;4(C*?JV/CQX].H4:-B
M >>DDTX*@77DR)$1#(_!8\:,&>FQQQZ+A9_B*C' 0A3GBFGGF6>>B2](CL>V
MYY]_?ES+B!$CTHDGGAC!_-G^.2;'YKT//?10G!,57A!\>0@OOOCB<$^6:K?>
M>FL\?)EI@N/_[G>_B]<1A\\YYYQT\LDG1\4FWD_@\YMOOAGGAZ!))9TSSC@C
MWG/JJ:?&N4R<.#&$9@PT[!N:,K=1 8J'/G-ZYMNT:=-B,2PSOF$*X,.#^8?K
MIG_IE^P<.3;/-XM[]]]_?[KAAAMBL8]KX1SI.][/>6.*^L4O?I'FSIT;V:HP
M[G!?RX&J/<\]]UQ4]YDR94H$B63'X!YQ#.X9F;#X4'.^]%M6K2>#[%?L@_>7
MND<(\&S'8B/7_\$''T05(XP7')-G@&>!Q=!,T,=\Q'%*P?71/WQVKK_^^N@#
MSIE[2)]@*.-9Y=FAKXL72)]\\LFXKBVVV"+N'0NSW#_,4(T%Q?!L77GEE?4J
M&16;VL@ZQOWB62,H 3,IVW+]/ ,T/C^<&Y]=/H\LCF(884&5+UWZ!;-+U@>\
MEWT]^."#Z<8;;TSCQHU+YYY[;CKMM-/B>>#:"8Q@P9=%5IY_]D=?YY\'OK#Y
MO)]UUED-?J;HUZP?>&[Y//)9ON:::^+<.";WB^\)G@T6I]D&DRW/<I9=C>^;
MXD7KO*F'SU*IXU]VV65QC_[S/_^SP7O1$G,;9 8WGGV^!\CH1O\5FX:RMO/.
M.Z>Q8\?&\YB'[R9>X[/*,T@EJ[///CN=<LHI!9\=ML4@Q;DL6[:LT4I9Q?!L
M\%UV]]UWQ[5R#.Y;_AA\9G@=LR;?_RR\4STK?PR^NZ@^U]#]YC/#\T>_\*SP
MO!)0@]F3^\M]YEA<'W_\";(A0(1GNA3LAV,N6+ @OC=X)K//)^=[R267I)MO
MOCF^>[@_M6QRJ]3<QF>=SS!_ _G>P(R6/6L8T;._#YC:^![@F<^^)^A'_@YB
M=N.S3Q 3]YK G,P@Q[X8//$\\*QD?Z]@S9HUT?_%GT'^GO+YX1B-\?KKK\>Y
M\7U6/";A;Y,!A%)K:&X3$1$1$>G8:&Z3]@YK/>O6K8LU,=;Q$<-8HT%K84[+
MO!7137-;Y6AN$Q$1$:F,UC2W\3,:)W$NZ)MHU%0TSF(YT$,Y%XZ-%I[70YN#
MYC81$1$1$>DL:&Z3C@IQS\1*$S-_S#''I D3)H2VMG3ITO3**Z]$_#MQ^FC(
MQ-'S?F*RB<=GO0(/%!X(_ M9+#>Z7%:82'-;JLS<5@SB*"(HYH=\R;Q\([@>
M$Q,"*L'R&*<P<K%@<_CAAZ>>/7M&E9<N7;K$/J@RP_]9>&*1A_/DO==>>VV8
M;!!?,5( !@7NR:.//AH/"X8&A%<J4.VQQQ[Q(/ %R>(/#P(/0;9_CLFQ#SGD
MD#! 8"#"J$'?S)\_/Q:O&NH?@OWI'\P_B):8.%@8&SAP8 B8F)8H.9@]A)AO
M, =Q?EP/E9EP87(NN"\YE][_'WMG VU'5=[]^@5(@0HH@EJ^5%I$ NB+"91"
M2Q,6-GQI0!"H0$&()$ 7$1!BF_*Q%BM02$LL!(0($E";0D@J\ATD(5E0@M@4
M"@E26:" ;>5#P:I5YWU_^UW[=M^Y,W-FSCGWWG/N_?W6>E9N[CTSLV=_S9S]
M//_][+IK$)I1#@*EGWGFF9!!!\%?F;BMRA"/,%A0@3)X$*L@JD, Q'U3O]1+
M+"-"$L03B!"XYJ1)D[+MMMLNW MEI.ZX)\J-XA11'8.4>T.,@# (X0X#LJB?
ML#"(\ M!'"(IQ#WL%HN0AUVO&*2T4;S&>][SGI 5D/)2;P@A[[GGGE OB&'H
M2XA :,NB^Z>\W#.3!H(@A&>(Z/;::Z]P38ZC_C???//09G_\QW\< E:8<!!6
M17$6_U*/./\1QB&882Z@#JB76%X4M+1M/ >BD721DT5+@M^Y)N7C&%)1(OHJ
M@_[%(N5!!QU4*JBB#>GKB'<0\S45[C#&$;<0A,\XXE_&%'5VXXTW!B$DHC)2
M8)+MB7Z3]@?$,O1?4F/2_Q$CT=>YK_7KUX<Z0+!"^S'AEO77F#&.!5[$ILP1
MC&7FCZVWWCI<D[IC09F^0=^A+>@;6VVU5>/QD3?F ;*J(<PKHUUQ6TH4'K$
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M2I0EOGM01]0]0D$$7HCA:4,$7MQ7+%L4()-MCP#/E2M7AO'*/3%?(Q2D/J-
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M,F8Y/_79:I[FO8WG1CX(%*$JO^.9/IKB-D1V9,KC_:4J4QGO_'PN%=<C2";
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M+QKWGK8AH@+^3Z!\V;VRJ(: 8MVZ=;7:AD4D%MUVVVVWRHQ3J;$@1ITS@.M
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MV=8U%+>5TZZXC6=S=":DQY'-BW.6.57JPG, @0R9_=+S(^QB#F0.[P=Q&V7
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M-F%N9CRRHR/G0(1V]-%'#_H,?8S/(+ K@V<%YR![9-ZY-]+B-OK*77?=%<2
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M:9JF:9JF=6:*VS1-TS1-TS1-T_K7%+=I6C-3W"8B(B(]C^(V$1$1$1$1D=Y
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MTS1-TS1-T_K7%+=I6C-3W"8B(B(]3[OBMM_\YC?9VK5KL[_^Z[_.WOWN=X<
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M(&O&C!GAMMMN"Y===EDX]=13PV&''1:^^]WOAF]]ZULQ,+;EEEN&S3??/(K
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M5/1GSA>S@I4(^0+""FT8*2+-HBS<1M_CON,>S)^CM0J3GM46&PTR#S3\O:#
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MV[C&Z3K3IS&C:??\W!EPP+GS=R&U57HV\7>2OH#)7RW<AKB7J0FDYS:F%.W
M/<^]SW,?TXKMY:8D@Q0X!@H8_"WC][0!LY-B0G-.#)[@^<*QY\]9SI._*1P3
M?^,8Z,#]SS7@.(K]FK\!S!B9]VOZ '^O,5'S?HV!AXG("HF)LG ;(3N.@S;A
M^<4U8 91SHMS/^><<V+;Y#/:TB?9)\%!PKS<Y_0I[EL&"M '\WWP]X%VR)_%
MQ><RS_1F_XT3$1'I"<-MTND8;FL>AMM$1$1$&J,_PFW4G9E,L=H*3G@[3!A)
M[;@XP649>*U\3F8RQ]QW8/OLZ[CCCHMUZ>1;X)GAH;$?@BCY9VX\-GQ&ZJR)
MLG ;_@+U:>JO?"^EALN*:=2F\2+QN:C#Y^_C? E8X!WC=R6J!:.H%]-.U(&I
M-7-^;)-CPQ]E(DCVR3GF-6#JWQP/=66^/Z< '/7]2RZY)'I2U+_Q;M@GGY?S
M^C>^$?X&^Z#^3?")L!OGFU\OCHG:.>U+/V%_M!7_QH<C4)+7\],$B_AV3!::
M* NW<=[L$\\$/PZOC??2-[B.J49-6S,9'77OO*^FU9_PK?"1.&<F3J7=Z)=#
MAPZMJ+ES;ES/B1,G]NBIE]%HN(WQ OBB!'[R/L/_T_]2&))C8T)1O/6BWTY[
M39@P(?8O^CM^.WX)O@>#,^G?>7_G^R-!*KP+0D.I3?$G.!<\K?R:[+KKKK']
M:,?<)\!SPQMEO\5P6]%3Y9Y@V_BA'".>%=O@6/%9BJ&E6L)M^%9XE.PCGTB1
M9P\!JS0^@#[-N?*\P+?A>4-;)\\ROW;<1_0?5G/D/BRV-3_CVA;;^L(++XSW
M7W%L ^?!*H_T0R@+MW$<],UT7_.,PC?&XZ5_T/;<P_0!7D>?YSQI8^X#:@D<
M!_LAE,KY<J\G+RX_+MJ*^V[8L&'QV<!KV2[_GQ\3/A/[Q]LK\XH( >*M\LS
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MEOX68")A9M,/N9[YN?-<YA[B[P5](>\;&',,QN495A9NXST\]^FW&&(<"VU
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M,5S;?!;'%.I*[R\+MV$&4.#GFA?#+8ED]'%\>;\E!,4,F,65"OL:;B,(A'F
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M8BR%X3%CQL2!^&F@/_\FW,(J9L4@4[WA-O;!<?'ZW%!@T \#ZF?.G%G3N:7
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MOOIJQ7 ;H9^9,V>6W28/ Z7/BCYD.?\YG?M*_G,Y+X]:/.>\'LJ=0[:%%T.
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M'G1QY38\ X*@^#N-C/?APX?'4%.BV>&V:L$HJ#?<EE:S*Q?$NOKJJRMZS.7
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M$1&I'\-MTILQW"8B(B(]DF:'VX /3A36">8DPZ62> V3Z@F8M$='PVT\88S
M3?X>BID8+11!*ZVXP\\)_] /K%J3GMJ7E(?;*.AC0E# 3,$]S ^>"G;MM=?&
M[=0: " @@6%"VPA,4.Q'%+P)$^5M(&C!A'Y"$96.@P^DA)0HME+X3($/"M84
MD&E?>R&F<A!$N."""Z+1E@<Q6,6(-K(*'\&M6E<7XW6L1L:YXFEEA/;R[2(,
MAF365=IN,HDP'?-5[BC8$VXB.$=8JCN$VP@?T19,M=PHXHL$Y@J%[5H#2HP?
M3!-,MO34-\9*(^$VQNA55UT5)]'E(2(,@#///#,^%:]:V"?!&*4M&'WI_*:Q
MW!7A-O;QZ*./QA!/;G00E.'+'$9#+08105:>HLKXS0.\A)DP]PC)U=,G]#_G
MBS&=]TDM=%:XC?LLYST/7:;[^'GGG1>-R4IF[T<??11FSIP9^YEQ7#314KB-
M8Z5]F#OYTSM76665V'[&<3$H2-^P7T)B1QQQ1,G] W5&N(WS3 @2@YDQ7^D<
M<3R8>(QC5KI+[\>('SQX<#2LZ)M6#+?Q5- TKO-KG2=9$F*G5E'K9'O:@<'+
MO8UC2N.Z*\)M_']*J+W8/_Q_P>0+$1&15L)PF_1T#+<U#\-M(B(B(HW1E>$V
MH#[ZX(,/1G\Q?XA<JLFR:A5>&._G>R#[2+73O#Z[VVZ[Q1 *VV,B6RWP.KP#
MZJ&$5Y*7U9O#;81^\$^+M6F\(5:[PM,I=QZI.;.R&CX#P:,47.,<X2.,'3LV
MAI7X[M/1<!OG"]_@F&..:>,_LU(4#]WC.Q5MJ%8_3^"A$NK"%\1_JO5]B4;#
M;8!7@A>(3\1X3\=$GZ4''#(!D^VFWW%]4A>Y^NJK8WBHU@=)<OW@RQ$0Q<?(
MC[<[A=OPF6E7_A[F7@P?/CSZ\97\0_Q/Q@?7(5YA,>C%]<[UD(\MS@EC'P^;
MOJYU;@/]A3^(QY?ZNJ/A-OQBKM?BRFUX^%SOE7PX?LZ]@+D&C*&B7X2X!W#/
M+WK.FV^^>=PVQ] >^)S<BXK!L]566RW>][E>*_49?81/Q0,7\[H&]R+N^_B;
MC#'#;2(B(O5CN$UZ,X;;1$1$I$?2&>$V2"L[%0V!7!2D*0)3+*P6^NAHN(W0
M'!-[4H$VF0L\18]"(R$=BNE\<*/82A&8?1$\XLO.@0<>&-N9AU50'FZC(,V3
MOOKW[[\XF,#K>0U%:HK+?)XC1,-^4J&9_5'DY-AI P$:3"0*]'OOO7<TN"C2
M\UI"4SRUBP)_.HZT>ANKKW$<;)_7I^-@NQ1*"3U0^,\+UP1),%QFS)A15V@&
M:#.K<_%$0PJVN:'&!UV>GD:!E?-*X1S#)#]N_J2=_)S?\SK&"R'$M=9:*QX7
MYD@^T8V^Q&0@C$>!GV.C':D/.0<$) C>\+K<7*&/&(LIK-4=PFUL@_-Y\LDG
MQU4 4Q_3)QA@&#P4R6DKQY[.>QI7>?\R!OBR@D%W[+''QK'(]AL)M_'%B, /
MJVOEAASCGS#H#3?<$,,KA!:YGE+X,IU_WH\)@#F"4<08)9Q"B":%4: KPFWT
M%WU%L)*G'::^YD^N_9$C1\9^PIBBS>E>D1\+[>0:O.666TH"?QA$&$>L>,@8
MK:5/GG_^^;A/#'16.LO[I!8Z*]R&J<(QL)T\\,L3% GQ85QQ#7!\'%,:BQP7
M_8V)1K@KOS[3_P4IW 8<+X97_K13[E_<[YGLRGT]C7GZD>TSSKE>Z'_N%_G]
M W5&N"W=2PEZ$0YCC!2/G3Z;/7MV-$HYGOS_$@+!_#_$F$A/>&VU<!OOI_W\
M?Y$?/^.:X^9\8%RW-Z[I ^XG&,88?]P3N5>G<=T5X39,0=K*/O)SP/^UK/:7
M[J/U_G\H(B+2&1ANDYZ.X;;F8;A-1$1$I#&Z.MP&U"P);Q#PP;LLULNWW7;;
MZ.<0S*&63R FK]TBPBV#!@V*[>?!>[R.6FSRX5)]EN^2J3Y+'9;/X=3!\2M2
M[;0WA]MXD">A$KYGY)X'M6967\,;P+.A;]/#2/D[WAO^*KXFXR=Y0FR7<T7]
M.]6:.QINX_V<._QZ?)7D\=*'] -^'T$>O,:B=Y7[S]3N>0WG@.]/C#O&9ZW!
MI40SPFVTBS8QWO"3\VU1M^=A>]3U^5T:C_R<\T:[&6OX.Y7\=L8[UP)>#7V+
MI\RD3=Z7A^*Z4[B-^\"$"1/B-9_ZB^_2ZZRS3IP?D/HC>68HS7/ #Z3?&)?E
MYCG@/S.W(>]K?DYXDKD-M?0U<QOH:WQOZE>\+WDM'0FWX=?2ST4OD?D#3,[%
M_^2Z2/M(UR3C'&^5![#R6ORL8J /;QD/D'D,N8]+7U*+8R)O\A$K!0;Q)PFO
MTD_Y=<\VF,=!G^6^/?W&,7&\W'_Q4O-:",>)!T[;P7";B(A(_1AND]Z,X381
M$1'ID716N(TBW6677=8FG%#N0Q'!$8KNU2:O=S3<Q@<ROK007,H-)LP&S HF
MV:<@5@J94=2G[1A#K!94+/BFHF\*M]%VWL,'18J7Z344-=DGA4H*S(1QDLG$
M\5#,I-B-(<"7+5[#1'LF)F%R\+-4;.=/@E*L!I>.@W9Q' 00>'(?!@S]P';9
M!Q\X,8\HK!<G]+/2$J&92OW6'GPPQLRA/03<*'KG3] C[,'V,0%8*8?@ <$?
MS)Y4[&:_%+5I VWG]?1U>E(?V\ \2MNE@$UQF&,AA,2'[Q0VPI0C"'CBB2?&
MOL#DR(^5"7($?5)@I3N$VY+QR!,%&6>YL4!?<%T1,.+\$@SD^P+G/05),$%8
MC8S0!E]6!@X<&*\W^B\]D;.1<!MCGM]CA/'Z?,QCJF'&\-3 ZZZ[+IH:G"NN
M+ZY'#"",(\(XK/:%0<A3Z3!1,/,XAJX,MZ7CP=PB!)D;N/0WXY"Q<<899\3^
M8H4N^IBQS)CF6 @&$<3!=,Y7&\O[A&,<,6)$O%]AB-)_;"/U">8?VS_WW'-C
MJ);7<ZUS7\C[I!8Z*]R60K-<@QMMM-'B[3(FN6=QS\1D(Y!$WW!],A8YUXQ#
M^CU_&F=^/\[#;=SO6 V-:RH_%]QW6>F,^W,:\RF(S!-6>;HB?<9J:L4)!9T5
M;L.$XOQB:&*&\MKT=$5,+J[A4:-&Q?MZ<44YSC/W;=K5JN$V)@<PGC#YN8_D
MXYK^8)SR_SC]B4F?CVON,8QKCA'S'D.4,<"YX5C3N.Z*<!O7.O=*3,U\L@K&
M(?<@)@$P5@T.B(A(*V"X37HZAMN:A^$V$1$1D<98$N$VZI743GEH)@\0+-9T
M\1BH<5.;Q7_ 7Z,^C2^2UV=Y'X$M:N.$MV@/V^7[([57?#QJMM3="<OQ>9LP
M#[5XZKV&VS:-'AJA$ORL_',U;<.'PYO"S^,\X(W@6?'WJ5.GQO!)\8%V^%SX
M)SP@--'1<!O@R>#I4(-GV[E/R,,:\:X(E^$/,$[P9#CW>!SXE7BI>%*$QG;?
M??=8'\=7IQZ^),)MP'7!F"1@5/1,6)$0/X6^&3!@0(G?CN?%0P[Q]?$ZD]_.
MN<&'Y+KC.R6K'U)+X9PR+KG6NFNXC?/)?8JY!CQH,HT!/!S&-"%'K@]\KS1&
MZ0>N#3P[/) \R)6$%X2GB;>>C_U\;@/GN]Z^YMIH)-S&^)@U:U9L6W[-<+SX
MDMQ?.0\\\#*_)JDQ</YX#>W@^N8!O?F^V2;S- BEYG,)T@-VN6?A\7$=Y5Y_
M(JT.QS'2M\E/H\]H'_,&6)F-:Q9_D'-.Z(X@+*$[/$R.*;]G\'\ #XSE?@V&
MVT1$1.K'<)OT9@RWB8B(2(^DL\)M%!,IWF&VY$^[RT7@A.!)7E"N1$?#;<!3
MS0A9,3$_;PM/.6-5KWWWW3<6,BF(4\2E^$F1OV_?OK$PB=&SYIIKM@DVY.$V
MP# B3#1LV+ V@3X*FA1(*5@2!*/(S#XH"+,_BK"$G_C02&&2?:8B,\7,O&\(
MX$V>/#FNH),;.&R?4!W&%,?!$\/8!WV57IN;#;R6#[ 4HRG0=@0^Z!)BH#T\
M]8TOA_G$-$PP^HQ^Q*# C, \X;AI&_NGK_@]YS %7C!",&@X%OJ%PG-N;K ?
MQA3'1M]A<% H)C1!H3H/SM"&].1%/D\GHZ8[A-L2M)MQ0(",<9BVP?FDGS!-
M,$+H3\93ZE_, H(N'!.K0S'6Z1?&&$5^^J*1<!OPY0A3#J,NA9:2J<)8P,A@
MVX1..%>TCZ 6XP"CD,(\1E1:_8_W8<*F)V!"5X7; *,!(P8C(9F$Z7@PC#"3
M:3,F(N..ON98"*P1&L,P24_J(V3#=9:>"ICZ!#,N]0GC-O4)(1[ZA'%?[!-^
MUZQP&V.!\4C["?[4*P)^A.\(GG'<^5-E:2]C%,,+XY^^83^C1X^._<8D5,8A
MXQ_3-3?4BN$VSC\K$S*NZ<,\Y$K?<M_@=]SK&#.$Q-@^1A[7(?<#[BOYL7=&
MN(U['&9P,JTY=LYM?NQ#A@R);>/\Y_<FQB!/<<2PY)[1JN$V L@8A)CL]#<&
M7W%<,ZXP= F'%L<UX67&-:9A6AF1]^5!UJX(MP''P/F@'>DUC#WN503<.%]<
MU_F8QYC'%.7_2Q$1D:["<)MT=]+G1QYV4NY[!9/?J"/D$^SX.Y^1^=Q>[CU,
MQN6S9G'BL.$VPVTB(B(BC; DPFT)'J1W]=57QT /WF#11\*KH#Y+?9@)9M3"
M^>R7/D<G3XW/T7QOQ&.@IDJ-$_%W:K9XD_A9U$_3>\\^^VS#;9MN&KTZPB<\
MH(WMXP6E/J)&3I_MM==>L6^3A\S?>5 I=>9\92@\#[PB'L:9^XR-A-L +Y'V
MX66SC_P[%'V^S3;;1 \&'Y8:/OW,G]06\%+QI/"O&%.,&>KPM'%)A=N (-XE
MEUQ2M@\Y%KPZ?!\\_/QX\9CP,>@+_'8F<.9^._Y^\MOQG-*Y9 6W[AIN ]J$
MU\U<@[R_\'.X)^#!))^X.,^!:X9SCI>57S^,!_H:3XQQ4NQKKI6.]#5U@$;"
M;<#O. X>KIB_-SU<E>-EN^EXDT^+9X</RSV5VD+1 \3#PQ_DODV[TUCF3\86
M_B)>$]<F=8N\)L&]&"^*\!F>%K4(ML_[\CZES<EOXCJDWY@GP77*?2?U$]X:
MWB$>.]=#&G.&VT1$1.K'<)OT=/BNP0,3F,M=],[XWL[\K!UVV*&DIL!G4&H"
MY3RZ_&$B28;;1$1$I&7HK' ;$"K#-"D:.\ETP1SB"T6YIU\5:23<Q@1Z0D<4
M6YF$GX<E*BF90A2%*0!3K,Y#:\5P&V $$$2BX([A46Z%HFIBGQ@<%& )[^3F
M L5@CH-B+2N=45@N][2U2J(]G OZD.!+,Y@_?W[<%D\HXUQ06*[WF%.AG/?2
MWQ3**7ZSXA$A%3Y0%Y_>5TWT#05NBL84SW.Z4[@-&-NL<):,"(KL]?1Q6N$/
MPP"#DR)YHRNWY; :$B8")A#71;WG/YD&!+IX<ET>1NG*<!OPI#],%?J$_JJG
MKU,_$W*BGS% &,^-]@EC+>^36J@4;FM4*83&/9<"$=M/_53+,3%^"1ESO^!+
M= K$%L-M'"OGGNN$ZS\WARIMFVL>0PL3GGM]OK(<ZHQP&^>9[6*XUGJ/XG6,
M"ZX9B@^)5@ZW);@6,<@);A97R*QG7/?OWS^&))/!V57A-JYO^H/0=Z70?5$<
M)\8CDR=$1$2Z"L-MTMWANR:?M_G<WZSO(DRTY;-N\;N'X3;#;2(B(B*-L"3#
M;?R>S\[4GIF(1LVR^  (:M[4XGD=P0;JH$PX2P\TK.<S-?5XZK^\GV!1JL_V
M]G ;YP%/X++++HL^'P&W/$!42]V;]Q!XHSU%;ZW1<!LL6+ @;IL #^.M%I^[
M*-Z3'N2(#[(DPVWLF]6Y""'E#_9$A,7PMW@X("$AZOZ<KXZ,=SP=_'8>8)<?
M;W<+MWW\\<<Q#,O#!#F>_&&*E93F.7",^,N$-/.5S!@+/,P3OYB5[6A7(WV=
MYC;@-='7C83;&.\$,)DC4%SIK)+2/ -J:'CJS \H>J2$VYA_2UB4OBP^N+<]
M,2> ^Q7^*_<<QCRA.KQ([IWU]!FO)TR(W\;8R3'<)B(B4C^&VZ2GPYPQYE@5
MO:!FRW";B(B(M R=&6XC^(0A0J&\6%"ER,B3 0GXU!+::"3<QO8II#[^^./Q
M"5BKK+)*U8GM%'PIXC*QD$E9[)<)_>GWY<)M[&?1HD6QZ,@3TFA;/08(PI2@
M,(Z)0J$Z[QO^CME$.(GS0\ M!1%J*>I25.:)#'R)(SC2#-(*8!AU!),(1M4;
MOJ)M%,L)(&&"8.9@$E"\Y@,Z1F#18*BV/3Y#8[QA4%#TS^ENX3;..6UBG/-T
M>\YY+6&B?"SS!81V8"JD<]^L<!O]2SB%<Y=61ZSG_-,?F(J<+XR.?,QW=;B-
MOF;L4?Q@94%,DUJ-#5Z',809@='*..::P"RIMT_8+T8%]T^6"*\GV :='6ZC
M[PD*\2>&6-&4K72>&5N8R(2.."?I_E@,MP&&,J9O,AC;"_)R37 ]7G755=$0
MQ13NBG ;*T>P3TPR@M.UG&/">AA>C+]\Y<SN$&ZC7QC7K.#'2FR<MWK'-=<N
MUP4%D32NNRK<1M =@YCSQ5-*:PF'&VX3$9$E@>$VZ>X8;NLZ#+>)B(B(-,:2
M#+<!'@6U=B:JX4$6O4L"*(,'#XX/&>2!HM15>0 FM=QR[6Y/; N_8L*$";$^
MG>JFO3W<!IPK?!7JY'@>Q5IS)5$?IZ:.A\7#3_&7BKY3,\)M^(YXIG@R!+#P
MN6OUKE([>4@?84F^J]7JS><T,]S&OID'R1CA08AY6WDX'@^1Q:\E#$8XBN\\
M'?';^4Y*D),@57Z\W2W<QOC$WWCTT4?C_84'25;K#^X/K(S'.&.%2,)2>,7I
M]XPA5H-,<QOH[T;ZFNN&ZS'U=2/A-L8[_<7U26BTEK&>YAEPOCF'W%LJA=OP
MO[F6\+FX+]9RC'FXC6/#&W_^^>?CO9-[2ZWW8WPI5G?C/,Z>/;N-3PB&VT1$
M1.K'<)OT= RWB8B(2*^C,\-M!%-8?8O5V_)M8Y!@TA#6H1A;"XV$VQ(49PD^
M8#;QM#="=ZRRQ!,.,8PP("CF\G-"1(3OID^?'C^X\02O_$-BN7!;(BT'3'&6
MIYY1/*<XS;8Q3BC"4N1D&^R?(N:>>^X9)^?S892"*D7=8D$3*)C29X0!6-V,
MB8\4=@ERI&.AZ,SQ\(6-0!M/?#SBB"-BH1X#K%J!O5[H XJXA!!XNAOF!GW#
M$_<(?&"88-K0)MI&&RE>,P9808?@ ";9C3?>&+?QR2>?Q$(]XN^$30@H82H0
M(",<PK%1J*8?&4\$8]9??_W8UX2+KKCBBAAFY/U%NENX+3%W[MQHX&$4$;RB
M[PAH<.ST 882?4Q?$[(B1,)3'$>/'ATF39H4CPUS)!EKS0JW ><? Y1KD> (
MJ^]Q'6%"<;RTBW'/.:.]G'O&)=<ARUWS/HRQ8M]W=;@MP?<OSAW7(]<.?4*;
M&;>,7XZ%8\) XN=LG^ H]TWN4XP#]LUXYCH]X803XKF@W:E/&+M<#ZE/N+_0
M)UP/A' Q&#' JXW'<G1VN(W[.O=D]H,IC G#DQ^Y'S/^TG69^H=K"Y.,8Z)O
MF6S)_:&]<!MPS\;<Q6S'=.4:QVBBS]@^!C-F%'W/-861A&DU=NS8+@FW,8F
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MM&+<41/'9\$S3?XP_<L8H(UXTAPSX<ACCSTV7'#!!=$3)"39D1I#,\-M@-?
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MV^G[_#7T<[G7E+M>:@FWI6T6SW'Q_Y5*YY:?TV[>D[>)>TTMXX'^91_%]Z=
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M)T\.,V;,"'/GSHVKA#&!\)-//@GOO/-.F#U[=@RP'7[XX3$@1SO2-@EF'7#
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M&@-B>0BHV>$V)L81*&)UKO777[^L?]Q5X39"?M.F30MKKKEFF_VR8ALKHJ7
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MC*Q;M\XM7KS8]BPJJ/*\%>P# "][-S\'& /""]_;"@MN0X!VP&G,7Q!PY#J
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MKX8*K.;;\_/!O_E_X+C@'LW?@1093ZKH%@?<QGV#>7CJJ:=<\^;-\STK\'<
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M95F6Y9RWX#99EF59EF59EF59S@T+;I/E: MN2Y3@-JDH1.4C7S4),"7J<V.
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M9;#.G3N[F3-GN@\^^, =.7+$^@.<1Y6U/_[QCV[TZ-&N;MVZD?!9,E>H4,&
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M]3[ PG"?2%@!H$MG'N@G$-B##S[H7GCA!;=APP9;!W/GSK4881P!,I.UP5P
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M#+AMRY8M;N# @5;I*]UQR!6XC7A>OWZ][:OT*>KU[=JU<XL6+4HY#D!F@')
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M@WY^_/%'.P< 72JXC6,]:#=ERA37OGU[=]EEE[DJ5:H8J /H]/.?_]S^Y+R
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M(I4 )GPEH3ONN,/F%6B.F&8\?2PQ/\P)YV)>^+R#Y&.JH$2)1$H2V8/]H@W
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MG)NQ9Y\(PM8 AZRE<-]YQB!^@^(^MF7+%MMCPK')>J5M@%D_EW C/B9\I6@
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M.+XDUCV  F,#W M(!L 1=8])%K_T'8CBE5=>L;EES26#V_AB$/8%U@[W(P]
M1)E[!1 =:S N?CD?^R_5L]C[P\!&E-G7R&^F<BG5IX#Y"@-N([Z!_+B/<%^C
MG53SRC6RGU&="G"<^&$>_#X4!;=Q?Z$J'/E1W)]I(]UUQ'PQ#XP7XQ:$RKGG
M,W= .8"+ %P%69^L%^YG_CJ\X^ VGC.XW_/>.7P,^R>?K?'\PK%%J6R?/8CW
MX+/'R0*W\3/@2V(4@#&3N& ]<>^E*B7/7X"?C G5O'@VR@3*!^ABOP>,8Z_)
MIAHI\!F@+8 M]\AP-;U4<\V< N6%CZ,]GN>HQ FPG&P_8GWS<]8*S^'A"F[
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M8\T2GT!:Z<PK?0$2!-PAS@#M/%P=![<1VX H[#% >9GN:^Q35,.B&I0'7A#
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MA'T,,.3!*&(#* LXR5<%\W-)^R2Q^]B@;5X;C@UB@=A@W1$;K,N2%$GR[ ,
M3\$]B+\S)XPO<\):(@&?&&/,N#[FF1@"SB")G\1Y8A* *AG<%A3MT#Y5?X*O
M!RX"_.7GF8IX89VP1Q$O@%G;MFVS_2Q.S"US!"017"^,@Z]DR5[/6#$.C %F
M#R V:!\@B7T$P(AQX+H 'H+71=Q/GSX]H:ID>$R($_8@[@WLW[3+N++/'SIT
MR&++5ZJF+6 9(#NNFSW?0US 'L0F, -CSS6$X3:2]XES/BL! &'OX#R,%_LY
M>P60#.!6&(0%JJ,"E:]N2#S1)P 8P"W_.D .P!+:)T[8TP!:N&< &K$6B#6
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MCJ^Z1#?9=A@2S"5@M\_%\50@4DVK3V[;?__]2V)<K9C591*YS;&(&4\^^>1
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M:?]<'TO>']76H^0V<Z5G"5VY36R01B:ARM[:VGXFE=N,'7'5E=N(JZJA3B*
M&H.>JY+&ZC61VXA&8KY]'YVOC1AC7FOG6A$XW7=)M8Y-IM+VQI^X'U0ERCY4
MT7(?US?F09+8L&.['I5(S?&3BK+S05U[=$6N^5Q[$/MK)<_%(+>Y]VB3[O-^
M<JTQ240<%^LF]^AN5=[YVLQ5;WWK6T=*#=97[C>J4;;?[WYG+N_>*\:A3VZS
M)ABVIJE4N:W>1^HFAJK<IK\=YY133BESYWRMQ\SUCC,7N<W8UG:S$0/#_R=R
M6PB3$;DMA!!""%-/Y+800@@AA!!""&$ZB-P6PF BM\TD<EL((800PMR8+[E-
M MA11QTU([%5I2<5@"29DVXD#DM\)U)(XNV#J- 5&0@GDC0E%9.OV@(/@4*%
M,M5=4!/,NZ*0Y%E572:I%"+!7+6WMJ3C.E6@&5:Y[< ##VSNO__^>9';7"O!
M314>DL:H).<N*N<X3XFOI$'B3Y5^B Y=\8>\IMJ/\R-'S$5N(XY(OE<9I!UK
M9 ;716 @-DG(=CXV;5DW4H;C=84<<AM98"'D-I_%NG*;7,:++KIH8KG-<57H
MJON17$X86TBYK8W84"F%C%1C@P@U+#:(%)+325!]++3<UH94X;-B%;ST7:T<
M9NR2C=K7]/*7O[S(G]J_5AOK)KFN2+E-6QYZZ*'+I :?^\>MD#8,U>A(,&1$
M\[-*6.9>[4#L&]0.!"K5W\PULY';]!]9A51G?_6]CB.6M+\QK;J0_77'NWF@
M]E'[V.0V<;RBY#;C^-QSSYTAMY&4"8^3(%94UYIMY3;7HOV[<AL!:5*Y345
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MPT+);40,%<IVW777Y6*)&'3,,<>,)9U52(4D3R)7W8]^UKZ.LS+DMB[MV)"
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M@YNF;TCQ!\G92B9]&^')-P00W"P.7HHWLH6B?IN'1>OAAQ]>OM5A-F+3L(V
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M[$HWA"O2SR AJ2TXD:3<Q(A9M3J<:R%TD;WNN>>>4KFK;Q\D+-7>^@:N]B$
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MPMR(W!9"""&$$$((BY?(;2%,1N2VT,N?_O2GYO+++^^5VU00._WTTTM5I?E
M=2M5F2:15 X\\,#FYS__>9&IAD&*>NZYYXI$-F[%*1(-.8=\]+K7O6[DYH9#
MSAI7GFMOJK81E[J5K;H0[?QQO*]JU\X[[]S<=MMM ]_[_///EZI>?>?@.LF*
MCS_^^*S[L&)BN>JJJYIMMMEFHG:8!KE-'XC]DTXZJ;<O5=K[VM>^UCSRR",C
MVX+41;[IVY=X)*J-&V>O>M6K>N/L7__U7XL$UEWX_.UO?RL2J@?<H_I ^Q';
M"%_>1[@D?OFO?B6[J6IG+(W:E^IO*J39SZ#8'D=N6VVUU<HY^:_KGG1L#=JT
MW3_]TS\UKWSE*Y=59QPUAX253^2V$$(((8000@AA.HC<%L)@(K?-)');""&$
M$,+<B-P60@@AA!!""(N7R&TA3$;DMM#+7__ZUR*<J5[5)YY\Z4M?&ADHXT">
MN>"""YK--]]\(DGEBU_\8O/,,\^,K'AF_W_YRU^:[;;;;E:5U5;T=NRQQQ:I
M;%3UJ&NNN:99;[WUBEC8W0>Y[9.?_&1O-3$BT=*E2WO/@31UP@DG- \\\,"L
M^[%"9CKKK+.:33?==*)VF :Y32P]_?33I0):WWFNL\XZ1=X;5>5.?Y+!"%X+
M$4<DN=UWW[VY\<8;ESL/XI9*C"K$#7L_Z6NOO?9J;K[YYMYK<M-X[+''FH,.
M.J@(8H,DNRJ/'7KHH<V]]][;&]>CY#;]0C EH0UZ8&]3S6VKK;9J/O_YSS<G
MGWQR<\899Y2$$8*><_0[8MR@]SO/=[WK7<UQQQU7),11<FE8N41N"R&$$$((
M(800IH/(;2$,)G+;3"*WA1!"""',C<AM(8000@@AA+!XB=P6PF1$;@N]D'QN
MN.&&(CV1AKI!0GK;8X\]FIMNNFG.QR*_G'CBB47<FD3F(:6H2#:.E$+6(T6I
M;K40HM$DFRI@?_C#'T;*;6YRY"T24W<?H^0V_4G@(O<-ZD\2T6<_^]G>RF^3
MH*V/.NJHYFUO>]M$[3 M<ILJ9T<>>63O>:Z[[KKE(?+O?O>[H>V@/\V-JL M
M1!R1'C_QB4\TUUUWW7+GX9I>>.&%4NEP6&5!OSOEE%-FM%\7X^VTTTXKTMF@
M6%*-S@-V<MFUUU[;?/_[WQ^X77_]]460W7###7O[LT^@,_^\X0UO:/;<<\]2
M2>YG/_M9$?A(K)*I5&K\Z4]_VEQRR27-+KOL,B.!HF[&PY(E2TH%R/_ZK_\:
M([K#RB)R6P@AA!!"""&$,!U$;@MA,)';9A*Y+8000@AA;D1N"R&$$$(((83%
M2^2V$"8C<EL8RAUWW%'^&#M(IB*=?.A#'RKRR%P@ )%OB%4$K4ED'G+;G_[T
MI['E-O+7-,IM_L#=)W2U(6 9;[.1V_"][WVO67/--0=*7B2?CWSD(\V55UXY
M4?]UJ57R=MUUU^8UKWG-1.VPF.0VXB>!:E1;+*3<YOJVW7;;YMO?_O:,\]!V
MJIOUR6(V/S_OO/.:W__^]R/[60*"6.JKJ&;S.^=$NNO;M/T@06[4YB9%KOW1
MCWY4;F3ZS7560;3.*X2UAQYZJ-EGGWUZJ\R]XQWO:*ZXXHK<QZ:<R&TAA!!"
M""&$$,)T$+DMA,%$;IM)Y+800@@AA+D1N2V$$$(((800%B^1VT*8C,AM82@J
M'WW\XQ]O5EMMM1E!HCK3JJNN6BHOD9&()+/ASW_^<_/  P\T'_WH1XOH,HG@
M<L011S1///%$$7>&07Y[\<47FZVWWGKB8RS$=M999Q4A;!3?^M:WYB2WW7WW
MW<U66VW5K++**C/>3S!2"8L$-I?^5$F/<+3IIIL.%9\&;=,@MXD5%=F(DWWG
MN?;::Y=J822X81"L"'!?_>I7%R2.7-\VVVQ3XF30N9"#C.4^F8SH=<$%%Y0J
M@J.0@+#66FM-W,?SM;W[W>]N+KOLLC+^AU''ODISKW_]ZTN,=??UYC>_N<3'
MPP\_//*ZP\HC<EL((8000@@AA# =1&X+83"1VV82N2V$$$((86Y$;@LAA!!"
M""&$Q4ODMA F(W);&,HO?O&+YNBCCV[>^M:W]LI$VVVW77/GG7<V+[SPPL3[
M)Y[X@^]7OO*54@UK4L%EK[WV:G[RDY\T?_O;WX8>A[3T^../-YMMMEF1\L;9
M]RM>\8IF@PTV*#+8]MMO/^MMR9(ES3O?^<Y2&:WO6&>??7:I,#4*TM)[W_O>
M6<MMY!U"8/>/R>W^W'GGG9L?_O"'8\EV@_K3'ZM/..&$WF,,VZ9!;B.!.?XI
MIYQ2]C>HVM?JJZ_>''744<W]]]\_LDVTXSGGG-.[+W&Q_OKK-UMNN>6<XLRF
M[XRE'__XQP//154VQ^H3TIR?9(NGGWYZZ#5I(T(146Z0++80V_O?__[FKKON
M:O[XQS^.[ -<>.&%14H<)+>ZX1UPP '-O??>.]:^PLHA<EL((8000@@AA# =
M1&X+83"1VV82N2V$$$((86Y$;@LAA!!"""&$Q4ODMA F(W);&,HSSSQ3)M:-
M-]ZX5S(AC.RWWW[-8X\]-O'^!:"'<6]YRUL&"ENC-HD35UQQQ4@Q[+>__6US
MPPTWE%@==]^$/L+34T\]-=OF*SSZZ*.E,INJ:'W'6BBYS3C57@2G8=<M0>7)
M)Y^<^%KUIS;SQ^H^D6R0X%6W:9#;0-+3)R]_^<L'RI 6%Q_YR$=*[(["OE08
M<^Q!%=-,MI=<<LG(*G#S@6M4V:U/M-0W)YYX8O/SG_]\Y#6=?/+)S<M>]K*A
M_;DBM_F4VTAZ>^ZY9ZDX&*:7R&TAA!!"""&$$,)T$+DMA,%$;IM)Y+800@@A
MA+D1N2V$$$(((800%B^1VT*8C,AM82A__>M?FR>>>*+999==>N4S/R=$G732
M2<U/?_K34M5I%'__^]_+OJ^^^NHB9-G';"I K;GFFLUG/_O9<HZ">1!$')6L
M]MACCU)Q:]Q]K['&&LTQQQS3//#  W-JPVF2V\A;O_K5KTJUO;[^5+%.I;G3
M3CNM>?#!!\?N3_N^_/++FQUVV*%(88-$+GV\ZJJKEIOSH&-/B]SFFJ^\\LIF
MO?76&_B>?_JG?VI66665YL@CCRSQX;SZL*_KKKNNM*FV[>[KM:]];?/YSW^^
M5"!<T:A,]L4O?G'@>=2-_.;:^]!&)+!/?_K3 _MXH39)(@0["2/#T#<D797V
MQ/P@63&5VQ8'D=M"""&$$$(((83I(');"(.)W#:3R&TAA!!""',C<EL((800
M0@@A+%XBMX4P&9';PE"(.<0E$@G1IT\T(0=MM-%&12"Y^>:;2^4GU=*(,.02
MV]_^]K?FA1=>*!6JR&8JB'WB$Y\HP39;P44%*C+3N>>>6\24YYY[K@2UXTFH
M^,,?_E!^[OQ5;2)=C;OO5[WJ5<V2)4O*C85L-8[D5=%F9+7''W^\B$V''798
MD9CZCK50<IMK^)__^9\B[;WM;6_K/1_M]($/?* Y[KCCFEMNN:7\4?YWO_O=
M<OVI??_\YS\76>Z'/_QALW3ITN;C'__X4(F/*"9.WOSF-P_\_;3(;="..^^\
M<VG7ONM1T5 ;W7''':6O__2G/Y7VU?_B\,477RSBY0477- KM^G+#WWH0\VE
MEUY:Q@<9<UR\EB3ZZU__NHB(]]]_?_.7O_RE]_4D+P(BP;!/3-,W^^Z[;QFC
MJA:*2^VN;;S?S[_TI2\-K?ZW$)M^^?"'/]R<?_[YS4,//=3\_O>_+^=:Q[__
M=[[:1-6VK;;:JK?*'$G6F+"?,+U$;@LAA!!"""&$$*:#R&TA#"9RVTPBMX40
M0@@AS(W(;2&$$$(((82P>(G<%L)D1&X+8T%8VVNOO8H0TR>(5.'D_>]_?ZGB
M]KWO?:_YQ2]^4:0HTAG)1V6W2RZYI.QKM=56:U[VLI?U[DN%);+3L./9"&Z$
M'-6OB%B$',<C7=U^^^W-?OOMUZR[[KI#]S'H&([O_(XXXHCFX8<?7B9V$8JJ
MZ.:_-C_S.P-*(@?)Z3_^XS^*=*>R'*%KF%BW4');/6</0'?;;;>1_:DZ&?'J
ME%-.:6ZZZ:92A4[;V@A5Q,&++KJH^<QG/E->2Q+KVY=C$?Q4T".%#7K--,EM
MCSSR2'/ZZ:<7\:FOC?S\]:]_?;/33CN5OK[GGGN:9Y]]MHA6XI!P1OI3Y>S5
MKWYUJ?@V:!^.+TY5@7/M[3AK;S7."'1MN?#BBR]NOO"%+S2''WYX^7<?WJ_/
MWO6N=_56[K.]Z4UO*N=L4:4=B*K&\G>_^]TRSM[XQC?V5EKT<^/&_L?9O'8V
M51OKMN&&&Y9J=+?==ELYUZ>??KK$I_%'+/4[X[^O[VT23LXYYYP9<1.FB\AM
M(8000@@AA!#"=!"Y+83!1&Z;2>2V$$(((82Y$;DMA!!"""&$$!8OD=M"F(S(
M;6$LR"+?_.8WFW>\XQW-O_[KO_9*(AZJJ7BF2IJX^. '/]ALOOGF92-)D9KL
M8_755R]"#X&L;U^D(2+7H&I770F-N$)"\OK--MNL'&_333=M-MA@@V:--=88
M*O*0BPARW0>"?F[?KH6\=-999S4_^,$/2JRKR*42G:I9SS__?//88X\U/_K1
MCXH@]96O?*4\2'0>;W_[VTO%.YMC])W#0LIM(!P2HE1O&]8VVH24M<XZZY3C
M#NI/UZA:F]<.ZT_[(-2=<,()I2)>GQ@U+7*;/O[)3W[2;++))D/%*.]5"4U;
MDAA5$],^^M][];WV(;;U27+:3?RJ?$>H(VJI<$A>DQA4A4GBFG/ZSG>^TYQV
MVFE%G'0LQWC?^][7[+GGGD5 ' 8I\?CCCR^5Y/JN2:PZ9Q*<"GZN2=]K6^?I
M]WW7H@T(9>36[W__^T.WZZ^_OE2!(ZCUM4M?A;GV0H_<:JP[USK^G:_J<FNM
MM5:)\;[]N ZQ?====Y6Q'*:7R&TAA!!"""&$$,)T$+DMA,%$;IM)Y+800@@A
MA+D1N2V$$$(((800%B^1VT*8C,AM82Q4C5(5Z<033VS>_>YW#ZVX-M>-;$+4
M(D\=<, !1;)94<<BZ1#MMMQRRR(G#1)V:L4QLMS>>^_=''?<<<W7OO:U(E2<
M>>:9S:FGGEH$G7WVV:?9;KOMRG@@.]6J:"2]M[[UK4/;;*'E-OVIJM@QQQQ3
MY+05V9^U_7;????FFFNN:<X___QFJZVV&OC::9+;5#DC=6HCDM>H"H*3QOB@
M<R>&JGRHNIWC?O6K7RUQ9B.S'7744:7"VXX[[EAD-F.CQAF)<Y===BD5RX;Q
MP@LO%!%SUUUW+8ND^;HN?>?\#SWTT"+@Z:M1:.^KK[ZZV7KKK0?NDQ H-N>S
M[;N;\:DMW,/<$,/T$KDMA!!"""&$$$*8#B*WA3"8R&TSB=P60@@AA# W(K>%
M$$(((800PN(E<EL(DQ&Y+8R-!(5GGGFFR#6J-PVK1#47$8JX1213_4EU,16_
M^E[O(=YLY1?O$>C;;KMM<\455Q0Y396X496B9B//3)O<!E7G5 )3[>N-;WQC
MD9-61'^^\I6O+)6_+KWTTN:/?_QC<]555RT*N0VJ\]U___W-@0<>6"H6SD=L
MB-D5$6?CRFT@[DFJ,'>[]KGVNPIK%EPJL&E'[38.H^0V8T;\:/M!#^SGLKEF
M\28VSSGGG!E]'Z:/R&TK#W.&!:-JDBI_UDVU0S_W^S#_:%?SJ<J=[7;W[[3[
MXL*:J]V/Y/G?__[WBU*J_OO?_UX^$UC3M>.2//\___,_Y0L4_E&I8]+<U[YV
M<^,TCTG]\I>__&6Y<Q:#/GN,\V4$83HQUO1A.Q[UJW^G7U<<VMUX-^>UQ]0?
M_O"',C>:(U?4,<R[CC&M<\UB81KZ<#Z.$<(T$+DMA,%$;IM)Y+800@@AA+D1
MN6U^\$Q&'DK[[QN>J7K&_X_\MXUIP7-KS[2U>?N9F;]?S-<S;?O)WT/FGX7(
M%<C?Q4,((83PCTSDMA F(W);&)OZ8?*!!QYH3C[YY"*=O?SE+Y]7X62UU58K
MLAF)ZZZ[[FHNN>22H7*;*G)+EBR9N/(8L475-A6P;KSQQN;))Y\L#P4] "2)
MS:?D-:URF_XD]/STIS\MU>C>\I:WE#:9S_XD7'WB$Y\H0AHQTL,.,M-BD=NT
MD7,1(Y_][&=+!;JYQH8J</8EUDEA\]G6X\IMT$:2".9C')/U-MEDD]*WO_G-
M;\9^L#1*;M-?XE+%Q/766V]>8]-XE%2A\N+CCS^>!,-%0.2VE8=Y\)Y[[FD.
M/_SP9N.--UZVF<O\W(/K,/^X9ZJT>=!!!RW7[OY]WWWWE83IL#BX]MIKRY=#
MJ,ZJ#WV)PS;;;%/68(L-?TCZ_O>_7RKRMN/RV&./;1Y^^.$B\OVCX@_>/I_X
M0HSVM9L;?3[J6[^N;*P-B?SM<R;W7WGEE<T33SRQLD\OS!*?RR^[[++R126U
M7S?;;+-FK[WV*NOQL&*HST-\MFR/J9UVVJFY^>:;RQPY5\RC[O/FU?8Q5)OV
M@)L<'6;/-/2AA)H0_A&(W!;"8"*WS21R6P@AA!#"W(C<-C]X)N/ORCOOO/-R
MS\I]Z?8XN3IA;CSVV&/--[[QC?(<N_W,[**++BI?RCT?//KHH\WYYY]?<E?J
M_C_XP0^69^EY;CY[7GSQQ>8G/_E)<]AAARW7=Y_[W.>:>^^]MPAH<Z7^7?S@
M@P]>[A@'''! _BX>0@@AA$5/Y+80)B-R6YB8FJASVFFG%7%IW777+5+4;$4=
M#^)>\YK7E <,/J@2N(A0A!/5OKI_#&YO$FN)81_]Z$>;-[SA#6.=@XIS)"42
M'7E.<IB*!D\]]51Y,"CY6$R[@<R'?#2M<AM\ Y7^)"=\Y2M?:;;??OLB.\VE
M/XEBJZRR2GE(Y.&&A&X)8H0G#QP6D]Q6$8\$-P].-MA@@^95KWK51.WCO A@
M'KX0"27-20+::*.-RK[FHXK;I'*;I+Z?__SGI=_UQ^JKKSZKL>NX.^RP0TE(
M((E.DL@TCMRF&IP8.O[XXYL/?. #95P:P[-M)W(BL="#ZA-..*'$OAMAOHUM
M^IE4;C/G& ]GGGEF<_KIIS=?^]K7FC/..*,D\S_TT$,3'=L:Q]SJ_?9CL\\+
M+KB@N?ONNR?:ES^<>#![UEEG+=N7S?[=AZ81#Z1ONNFF&0M&X]//YR,)>*ZX
MC^NGZZ^_?KEV]<<*?\CP+7T+C7N9&%RZ=.ERY^0<GW[ZZ9%5NZQ/K$O,5^UV
M]V\?<(DV87%P[KGGEG5N%>2M.]R+;KOMMI5]:A-CG)E'N]*Y-:BY;66,M87B
MM[_];7/===>5]5S[VJU=?_"#'\S+'^]6!"3*(XXX8L8:ZZM?_>K8Z\8P??@,
MYPMGUE]__67]ZC.<SXH2JO]1<"_\\8]_7-9[[7OI#W_XPU)I:Z'Q6<=X]QRB
M/:;67GOM4@U^/IZ+>2[@/F]>;1_C;6][6_G,.JWKQ<5"^G#%XDMCK'.)\.TQ
MZW/3SW[VLR2A_(,1N2W\H^+YLZ0ZSTUON>66YIO?_&9SX847EN?WGC&==]YY
MY5F#.?V..^YH'GGDD?+YO%8!B-PVD\AM(8000@AS(W+;_""7P6=9N3NU#7T)
M\,<__O$B[_RC\.RSSY9G4^UG,[X SQ<^K<R_8_C[_(DGGCCC"[?ESWAN-!_<
M?__]S5%'';5<_HW<$L_2_Y&>FR\TONA63D WS\O?RWQNGH\O\_*\_X8;;F@V
MWWSSY8[QH0]]J,3SROA[P$(A=\N747[WN]]=;MQZ'B%O,O)M""&$L/B)W!:F
M@>J+R/7U^<@76/B[_K>__>V2W^IO^G*:_2U,GK3_]S-Y%/R)!Q]\L+QWG%Q[
M>0,^1_BLY[V77WYY^?N:OY?Y?'KQQ1>7X\HUE#]A3=PF<EN8%:0!'Z $W:&'
M'EHJJ D:DAJ)A\CE(8&'!A)Y;60@\I(';Q(J7_G*5Q8)RA][M]ABBQ*P_M!9
M^?6O?SU2;B,L^88? XN81="Q7P]$',LQ;<Y#(K'?K;766N5X!@9IJ8V!ZZ&*
MAQOD+-?TZE>_NLADWE_WV;TFU^KWKMMKW7S(9JNNNFKSCG>\HPA1?6*5;67)
M;143B20C"?<''GA@\\YWOK.T9?O:1_6G:]:?9$>3BDG-'_?;+%:Y#6)#19)3
M3CFE5%PA=8GW0;%1VT8<:A>O);))RK0/$Z\$"7*,;Z9ZTYO>M&SLU+;NQIEK
M\W/MW8TS J48^W_LW5VH==5U/G HO>A%FQ#2YH-(U02:4@3%BXBD*FD3[84)
M5:EHTVA$_%:D6DW$I+$5FMC$>I%BDL8V5L4&1(L0Q5:P-30U18E%*K6DDE(J
MN6A+KWK3F_/GMV"\_W'F66NOM3_/WN>,!Q;O><_9>ZVYYO=\GO',R1R*W)@*
M9A $)I,GHRJ#:+R3Y_2]DV=+)X.HMFGW>20+PG?JB6V!*>8V;14!:S UN"&O
M!$-X_MO>]K8NCZ55_O3E6=1/G_4=97'111=U1@/WE0>%W<"\YC;]A7:MOJJ[
MT<?H(_2Y\\ DS@F"K;%2F[GSSCOGJOLF5TAU=3+?2_LU8=Q&[(*YC:&&44A?
MEM-H##;>"[+=-(AD^CASI)PFI\8*RA\[Y:G,;4<'96X[&BAS6V&;<%S,;;&.
M:T^:_MSG/K>R@(=Y4,:HW4>5X7J!Z[#YA[532S+;F1O/5S@Z*'-;X:B!&(>K
M-!88*P22X:#Q"O@?N@)>%/]M<S@G<PLFOO_^^[NU'9$./U3FMH,H<UNA4"@4
M"H7"<BASVVIP',QMUC4V]Z4[Y[HB[D=@8AM'LTF4N6UW4>:V]4(<G7RT07]^
M=_J/&#YQ385"H5 H%'8;96XK'#;"V.:0"+%O#&P.+[KTTDN[0V?X/OA=Q%KC
M'ZRC^ C$-YYQQAE=S+WU''["VEK<:VSZV()138R=#2*_]*4O==\5*R%^WQI<
M_>>9X-&Q=A5#\<8;;W0:'2\+E+FML#"(M78Q%9QB-W7'Q=]^^^U[G_C$)[K*
M?/+))W=&&>1$&&)4?N*OQG#EE5=VIT8YE0F1(#@^FXNFFML$DL:.[LPO@I0$
M]7F6P$V71J%Q.-D*:8/4L/AM3TWQ3M+ ].;X=.^D 5]XX87=]PG9# D,$@*3
MO1-!V[M*I\6E!3TB\?.?_WQWY#V3UUUWW;7W[G>_>_ ]#MO<IN/2*2A/YBC!
M2-+-N.C=!3 S!2&]E*5+/LAC[\WL==555W4=D8Y/H"P"0V>8L<OF-G7#^Z@;
M.D?.X:@;.G:=>-0-';"ZHJS4!4'M3COT7<^(@0()H2[:[5?0,;)"7H=),TR3
MRCN,6=H/H\0%%URP]^E/?[HCY]R?T30Z^'G*79YJ/W;J>OSQQ[MT&!1^X1=^
MH:NSGBT=WLT[,3XZJ<VI9TQMVJXV&(/*/)C'W!:.<<2FR1Z2DT&$:? #'_A
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MV]1A\UTFS.A[]0?F5@(\W%,=DJ;HYSS+_>25,4L=CSF ]BZXP)RXW25[".;
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MUR[PP38<R_6$CB2.0WLM<UNA4"@4"D<?96XK[#+,>:W[Q5_DC2$CQK$UN]F
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ME_,<*&8.XO2YL5V[IP)Y+8A&F>>TE+GM:*+,;85=AN!9@94Q9EGW63?/LQ&
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M;^U,'=O4VI$ R?"1Q4G]*W&,^6?,O)JQ;G,;<X+VF_]F+-*W3B&UE)G=< 0
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M0E;+'V1SB#J$ "(0,CE,4.LRMYGL(I2)!@*%Y5W^'.&'V4I9">:59H(!4X5
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MH&@ 0)UH7<MVLZWMGP9]=*PJUN\VW%9[><E+7C*>N_>[W_V.&;K,[H^ZUVO
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M'#3'*]S6<KJG[9ZW9XB>,9LP>+JGG<9!U<?0O6S/#]7E>B9IW,%4:Q9N P
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MKO'-2-C?G1=%79RW5-1K<,3\S6+7O_[UQ[#VL0J*  !@\Q%N Y8CW+85X38
M (#UV,]P&P    #@^"+<!JR&<!L  -AXA-L X,2FF5&;3?6*5[SB>'V_P 4N
M,,ZNV>R8QWHK&C:/WOS46[6F0:P=SV;I;.9- ]\! #C\"+<!RQ%NVXIP&P
MP'H(MP$   # X46X#5@-X38  +#Q"+<!P(E-KQBO&'_222<-%[S@!8<?^($?
M&'[YEW]Y? /8-[_YS8->/:Q(;V<[_?33A\M<YC+#A2YTH>&44TX9GOK4IP[G
MGGOND=?0 P" PXMP&[ <X;:M"+<!  "LAW ;     !Q>A-N U1!N P  &X]P
M&P"<N/SC/_[C\*4O?6DX[;33AHM>]*+#Q2YVL?'/KWSE*P]ZU; '.IZ?^<QG
MAIO=[&;C\;S$)2XQW/[VMQ\'80  @!,#X39@.<)M6Q%N P  6 _A-@     X
MO BW :LAW 8  #8>X38 .''IH?13G_K4<).;W&3XUF_]UN&[ONN[AJ<__>G#
MAS_\X8->->R!KWWM:\.?__F?#]>][G7'X_D]W_,]X^#5CWSD(P>]:@  8)\0
M;@.6(]RV%>$V  " ]1!N P   (##BW ;L!K";0  8.,1;@. $Y=SSSUW^.,_
M_N/A>M>[WO#MW_[MPS6O><WA#6]XP_@V-QP^OOC%+P[O>,<[AJM?_>K#=WS'
M=PS7O_[UA[>][6W#E[_\Y8->-0  L$\(MP'+$6[;BG ;  # >@BW 0   ,#A
M1;@-6 WA-@  L/$(MP' B<OG/__YX:UO?>MPZUO?>GS;UT,>\A!O^3K$?/:S
MGQW#B3>[V<V&&]S@!L-99YTU?/*3GSSHU0(  /N(<!NP'.&VK0BW 0  K(=P
M&P     <7H3;@-40;@,  !N/<!L G+A\XQO?&-_>]F=_]F?#AS[TH>'C'_^X
MP=&'F*]__>O#W__]WX\#>\\YYYSA$Y_XQ/"UKWWMH%<+  #L(\)MP'*$V[8B
MW 8  + >PFT     <'@1;@-60[@-  !L/,)M      !L!L)MP'*$V[8BW 8
M + >PFT     <'@1;@-60[@-  !L/,)M      !L!L)MP'*$V[8BW 8  + >
MPFT     <'@1;@-60[@-  !L/,)M      !L!L)MP'*$V[8BW 8  + >PFT
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MP^(OWOW*PP4O\"U;:J0WN.9)![YN)$F2),F=O?_I5SKJ6>YB%[G@<-:]?O3
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MDS\99].<[Y-_]^_^W4&O%@  P*'AO_[7_SI\V[=]VY8:Z;_\E__RH%<-
M ' ,_M-_^D]'/<M]YW=^Y_#?__M_/^C5 C:6?_B'?QA^^J=_6K@-  !L+L)M
M      !L!L)MP'*$V[8BW 8  + >PFT     <'@1;@-60[@-  !L/,)M
M  !L!L)MP'*$V[8BW 8  + >PFT     <'@1;@-60[@-  !L/,)M      !L
M!L)MP'*$V[8BW 8  + >PFT     <'@1;@-60[@-  !L/,)M      !L!L)M
MP'*$V[8BW 8  + >PFT     <'@1;@-60[@-  !L/,)M      !L!L)MP'*$
MV[8BW 8  + >PFT     <'@1;@-60[@-  !L/,)M      !L!L)MP'*$V[8B
MW 8  + >PFT     <'@1;@-60[@-  !L/,)M      !L!L)MP'*$V[8BW 8
M + >PFT     <'@1;@-60[@-  !L/,)M      !L!L)MP'*$V[8BW 8  + >
MPFT     <'@1;@-60[@-  !L/,)M      !L!L)MP'*$V[8BW 8  + >PFT
M    <'@1;@-60[@-  !L/,)M      !L!L)MP'*$V[8BW 8  + >PFT
M<'@1;@-60[@-  !L/,)M      !L!L)MP'*$V[8BW 8  + >PFT     <'@1
M;@-60[@-  !L/)L8;OO4ISXUO/:UKQT>^]C''O')3W[R\.YWOWOXPA>^<&#K
MA</#G_[IGPXO><E+QO9=^WG<XQXW/.E)3QK>][[W'=?U^!__XW\,SW_^\X^T
MX\<__O'CN748[^__[N_^;OCC/_[CX5G/>M91Y^:K7O6J\9S]^M>_?M"K"
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M1_;/?>][W_$-9ST<'D:$VP   (XOPFTX[/2,T&R0-[WI37?='R3<MC>$VP
M -9C/\-MW_C&-X9SSSUW#!$]^<E/'FM#!==6K95>^M*7'OOCJR\5,*L..I]E
M_7@AW';B(-PFW 8  '"B(MR&$Y6>XQION/@<MZJ->6[BR9Z[>N%(S]*]05ZX
M#0  ;"SKA-MZ:ULAG5YUVZR"RPI ASW<UNR(-[SA#8>+7.0B8W"OM](UH.HK
M7_G*6M^[$\)MZR/<MO\(MQV;"JT/>M"#QH?"]DW7C-[T6$#L((K/^X%P&P
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M:UGM@VID?5>UQMK85)_M^%;CZ=_[N67L1[BM_=]Q;#FM<]NV7=VV?=[V @
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M[<)M%4L;V/#"%[YP/!ZUH9W.FPJWA8B[_O?V/   @+TBW(83'>&V_4.X#0
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MO?VI#N3"%77\%HRH$[J.]3CH<%O;U<QOS0I81WKK7;BDCOF=9EJLT[Y.^,4
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M9#S6,K8+MQ5,[7=:U\.=Z,UN#3B?]F'7G()N!6$!  #V@G ;3G2$V_8/X38
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M^(,URM%-_TDRMPDAA!"B;"BUN2T.A!Z,$@@A#SWTD)F[,%0PJ1P5C7B@PI3
M3@'AWVO:W,;$/N?&P($P@@D)LP)"3EJ8.,?@13F9H$<(\>:J:/)F-W80Q)B!
MB8+\,:X1S8OPP,6:VVAWOHO!9,F2)1;IB5WQ>+[$^(0(1?GR1=4C\9"+^6/F
MS)G5S&VT-0:=?-&J,+<A>D7K=?SQQUL9,0ZQP"W.I(+0E@4,6AB40K-76G,;
M!BC$E[ ,'%N(B(2PT:I5JUWG"<UM&)2X)A!)HFU->1$Z?.+_2?05GX>):R84
M"+WP@]B'B=+O(HKH@K!'7>+$6B_T$"D/DR<&2%[X&=/T'>=(8V[#"(C)B@AF
MU+'4YAX$0X0H1*\P7T1,=D)$."5OQKK_C/L#1BSN%QC@$):H*Y]QG7,-8I*B
MCHBK&-["_D"TP@05FM:XOGCI8[QZ0Q\O?UD$S21S&^=AS,<9Q\@7015A.'KO
MI-^3QDUT[,2-&R].TW;>R%=?S6T<QTM[/F-RDKF-\81)\OOOO\]Y/*(T]4'L
M#H]GL@ A5.8V(8000F1%YC91Z<C<5CID;A-"""&$*(Y"S&W,:S-_'C4CL7@,
MDPYSQJ4"#8D-*=%=PKPPSJ#CA'\K%W,;<_<??/"!;7@:'HMNR@:8N8Z-PEHY
MZAEN+H>&BQF-9V'J$.;!9IKH1\S[IP5="!TRW*@2_8@VIJQ1_1F-%?TLRSH^
M#(]$VPNU#G23X<.'V^=QYC;:&K,49JMB*96YC?,P/T'=T8<8"_0/&S;R7H).
MPY@*-]I,2GS.]]!7,*5%S6V8T1B#64#;I1^][LW&CEV[=C436QIS&YN?H@M%
MWSN];LN](JUN&ZTOWZ6],0 *(8000HC2(7.;$,XV;F<='N^5X9I'/U? >Q+O
MRJQIY)V?H O1=Q:9VX000@A1-M2&N8W%_4QX8Q+ ;/7^^^_;)/K@P8-M(C^<
MY.7?F)^(AA26IZ;-;9P'XQ@[[C'QC&B P0236198I,5N@1A6V(4.,2NN?9GL
MYN&1ERI$$@Q>B"=$D-JZ=6M)S&V8M&@#%H@A&A&1"0&,?)EXIPSYQ(6H,(?(
M022UJ)"S<N7*O&V-08H'Y6AH8\Q?+%+#Z+-@P8(J4:1(1-E:NW9MIGY8O'BQ
MZ]*EBXE<7C1(:VYC?+*+8'3\(2!F%5(PW= ^_CRAN8U^I#]#\UMX'22E-'W%
M&*:^"%_4B1<3VAAS&B\H4;-1**X@Z'!L\^;-S72%B0J1BLA_:<QMF'P0A+9M
MVY8JXF%6$)=8",DU&K8'9BN$5ZY!VCV,OH:XQCL5HBK_)1*@%RJY_C BT2>(
MA!AKP_:A/1!A.=;7A_\2Z7'<N'&[KB/:!>,NYM2T))G;Z"-VNXR[UBD'PBS7
M1:G'#0G3( NH,;5!?36WT1=<KX6:VVA?!.5\"\E9J(  '36W4>YPS @AA!!"
MI$7F-E'IR-Q6.F1N$T(((80HCD+,;<SYLG",C?+"8PXYY!";^\ZJ(^4"#8ES
M1C?[8_YZR) A5?Y6+N8VM& ^1R,-CT4'Y5DU2Y0P]!8BY!UUU%&[SH/NUZU;
M-[=ITR9[APCS0!MFDTYTOK10GBNNN*+*'#^:(.=F_C^ZZ _M:?;LV9FT(-YE
MV% O-.FAA=*'$&=N0S_&#(@&4BRE,K>QH25U(>(<[8"^AIY(GW =\8Z79.Z*
M2WR/,J&_1LUM;-B:U=B'<0RMSK]KTH9LMLM:B#3F-B(8L.8@'&^ETM^H$VU%
MGD(((800HG3(W":$LS6=K'7EG3,:B -=C2  O-_ROB]SFQ!"""'*GMHPMT5A
M$AV#"D:N08,&51..F'C& !3^K:;-;4S<SYHU:Y<9C0E]S!%,]F>%A8?D^^23
M3[I[[[W7C1@QPD0B3%TL.F*2/QHM;<\]][2'1"(F$6%K[MRYU0Q^:<UM&$9V
M[MSI'G[X8=L)$&,)YT\SN9XKT38(3U%S&\8<(F8132H7^<QM"$&8CJ+F-D1$
M^C@+O+RR&Y\7_+*8VXA4AFDI+ -E8L?-EUYZ*5,YIDZ=6L6X%)K;, 5A8,)0
M66S?1),W:/)RXB'J&,9+C(B(CXQOC%P(4/[EAN/"\S!6*2\B)%'H[K[[[FH+
MYZ()DQ'C&(,FUWFI(U<QOC%5849"K(V^C/$21MVH$Z)2HT:-W TWW&#U1W2F
M3%Q'?)_KD(D-0F\CYM(O1-(+A>(6+5J8Z!7"8DR,5Z%X?-III]GU[B.>I2')
MW$9TQ&>>><;N;U&XOR ,1W<]+56BSWOTZ%'OS6V([N11C+D-\3Z-N8WQ)G.;
M$$(((4J%S&VBTI&YK73(W":$$$((41R%F-N8EV9N&ST"_<'K*FPPB>92RH64
MZ"Q]^O3994(C+\H[=.C0:F:H<C&WH<50AJBY#>UEQHP9F:*JH1NB)T3-;>@3
MZ+>T=Y@'Z^N8[\]B;J,\;/(8ZM+HB>A<+!#DG3S,HT.'#K81)/I.6F@/]/#0
MW(;NS2:P$&=NHPRT-3I+L93"W(:ADW-@-B1"'F._%)H4FT]&S6V\*Z+3\KZ3
M!=J+=T;_KLEX17^;.'%B*G/;9Y]]YE:O7EU-+RI%\GHDUZ@00@@AA"@=,K>)
MA@SZ,>OF6-/)^W#4V,8:;.8/7GGE%5M+##*W"2&$$*+LJ0MSFX?(8@@ &(?"
M14WL]-:T:=,JY:EI<QO" 28THE5Q/(86)O2C^66%7>P01C!_8>Q"A"$B7-NV
M;4W$8/(_K#OB$Z( !C>BK85U2FMNP[R#*81(<$S.^UWCR ?3#KM',KE//CQK
MLFL=!B<$&1(3_=0_*DS4M+F-2%@+%RXL2>2V18L6N=-//[V@R&T\>R-*1L=?
M(9';$$9...&$7><)S6WL ,@+==3<1CD13C W^C[)FCIV[&@[5[)[9!Q<-[0Y
MQBK*B'!'I#MVSN1EA7'C#9B,'_X?\Q8F,<9/+H&&MB9"(-<3[<5+4:D-;I@,
MJ1]B<=A'F,TP6_7NW=O&.G5@W(9B$68CZDX;42^,GRP&O/_^^\WXQ[TG-)_2
MGHS;$%X.Y\^?7^5ECX68F!6Y_M*29&[C?O;<<\\EFMNX+R&$AL=P[^"ZY;HN
M=-R0& <(UOX^4U/F-D3A?.8VA%+&9B'FMNNOO]Z,9S*W"2&$$**^(7.;J'1D
M;BL=,K<)(8000A1'(>8V#\^BS M[4PZ:&GK0TJ5+2Z:),'>-EN$7J%%6- PB
M9T7-.EG,;5'3G$^EBMR&AH%&&1Z+_L0&@5DBMWWPP0=FR KG[WWD-G1=-OB,
M:L-H/5DCM]'?X1P_.B7G3HK<1K]DC=QVZ:67FH;CSX.F@8X 2>8VM/IB=6HH
MA;F-<86>R&+AJ*[-F*2/T'OI _1-VBG4GGF7HUVCF[]B;F,\QT5NH_VSP(:C
ME".,W$89)DV:E,K<AMZU9LV::GH1^B,&2_3T0K6W4TXYQ3;:1%L40@@AA!"E
M0^8VT5!!.^9=CO=&UG2&4:5YO^*=DG==YCW"M6LRMPDAA!"B[*E+<QN3Z40G
M8K<^S##ABT;X_W[BN";-;7R718/DS?'L7(!QP^]:4"A^!T?$'$PO3(PCQE!F
M#%286JB;+S</FDSN,\D=-6ND-;<1>>S&&V\TTU3XX(KHA*D.T]&"!0O,8/7:
M:Z_9]S&6T588U!"EV!&/Y] P_YHVMQ'Q"J-/M-[L[HC0E@4BP"$R>&$NB[D-
M,\_DR9.KB4@L,GW^^><SE6/\^/%5S&NAN8WQL&G3)A/TPKP0Y=B]<OOV[=:F
MA2;,HY@KX^"EA06%[*!)O]#VB'V8NS"P'7/,,57,C8PC#$JT:=3TR&?A.".Q
M>RCB#Z8?=CK,9V+*"H8F1+AP$1]Y<@UC[&2,42:$7DQ9F&A#B&#'N,(TQ7'T
M"V8H(M-%[ST(F-$%ENQ023AOKJ=0@./:]L)O&@HQMW%^CF-'S_ 8V@*QCS%:
M[+CA'N-?;(LQMW$OH4VCYC9VA<&@F&]<4!<BU'G3L4\RMPDAA!"BDI&Y350Z
M,K>5#IG;A!!"""&*HQAS&YLULEE<J$.A,3+?G$4G2(+Y;S1<= QO" K-.AB"
MPC)C,D+;XKDY'SR/HT/4A+F->7&,7\SMA\>RH2=FHBR1R%@KQUQ]&/$,<]N9
M9Y[IMF[=ZOKV[5LE#_1FRI?%0(?NW*]?/UO(Y\^#)D'Y^2RJ/Z.=HGMD,=!M
MV[;-WG?"C?S03= 6H#Z8VQYZZ"$S9S$6O2;(?WD?06]#UV2C4B("<#[&@->=
M2>BVM*7?E#34UN+,;>C<63<<Y;J@'_WU@M[>M6M7&W=IS&WHI1LV;+ U N%W
MV;1VUJQ9IBT6H[^AMZ$O"B&$$$*(TB%SFVBHL-YW[MRYMNZ6^8#P.N!=B/<8
MUH&R-C1$YC8AA!!"E#UU:6X#)J9YF&("W>=-Q*7HY'9-FML0B)B49P*>*$[D
MW:E3)S-^L>BJE) 7(@)FHBU;MK@E2Y:XBRZZR")08;+YV?]O@.+_HZ&"TYC;
M,%)P7@2UT#3'0RO'$]&,-D=TP;B'Z0Z#2;B+)']G7$0--S5M;L/L]>233UKD
MOM LQ6).'L:S['2)B$)_>E$RB[D-0QACC?[PY<#PA)#%CGU9P& 31CH+S6T(
M?(PQGO=]WY.(.,?NE<4:*[/@39A<+XP/S(]<E^$8XD4( U$H,)$0>3 ^T49A
M/;B.J!O&(_JWE-';&+\(E%SG85DP"F+,]$8ERDR_K5Z]NLKQF#EON>667<9"
M^IGK8\"  78/",\Y?/APZZ^PK>@;(J<Q5JDS[42^O!!F,3,58F[C_L&U1/2S
M<(=+S%6(?5EWLLQ',>8V#)I<B]'(:XB5&#OSF=N>>NHIUZM7KRH1^D@RMPDA
MA!"BDI&Y350Z,K>5#IG;A!!"""&*HQAS&_/7;$*'X<OK#.@GHT:-,@-7,7/#
MS"UCI&$N'9W#:U4L-KOBBBO,:#-Z].@J94;;F#!A@AFI\D'T*.;XHWI(*<QM
MS/NC;0P9,J2*9H0VQKP]&F9:F+]'DPPU K0GWI-9R(?^$^:!7H6)"=T@+7R7
M32?14?UY>,;&;(8^@H8;YH%)CS[.8CK#\,5.^NB4_CQ$ D.G@G(VMWG]$ ,:
MX\^/1?J!/F633Q8/4TYOWN*=C_$?ZH)H85G,;5=>>:7I_VDA/]H3K=*7$0V/
M#2S1IM.8V[CNZ"MTZ[#/N5:(")BTH:@00@@AA*@[9&X3#0W>S]A,A'<4WE7"
M=R 2Z^=8\XG>QB;]461N$T(((4394]?FMLV;-YMY(8SL0V0H#&YA>?*9VSA'
M^/VTYC8FUC%5W7[[[3:1S60U9J1++[W4'@1K$B\(L/"(B%CAQ'TT$A8IC;F-
M18_L*H?1(C2^M&G3QB+%>4-(+C"K^.A=8?XU;6[CX1EQ)32ED=JU:^>F3)F2
MRAS%=V@#=J=$^/%MD-;<!O3)[-FS[>'?+[9C;"!N80Y, T(1QL'++[^\2J2S
MT-R&T())BQ>-<'=,V@,AAXAG=0%MB/#$>&&7R["OXL9ECQX]+(H9AM"F39M6
M$SKI/\RC&,I*!>90KF],G&%^Y$_40R\0<A\AFAGWF1#&.")M>#SC&U$R7&!)
M?1E+"*@>KB%$4W:H9)R2Z#-,7%DIQ-SF[QN(=+2O%]B\2,=QI82VYOJ.MC7C
ME@FA7.8VQC=]'QH\25P71.W,9QZFCSMV[+AK<8!/,K<)(800HI*1N4U4.C*W
ME0Z9VX000@@ABJ,8<QNF&(Q>T0T;SS__?%M@6<SFF5]\\84]&[,@+=0KCCON
M.-,B*#>FHK#,&-70#:)Z2!P8FMJV;5NM[J4PMWF-:<2($69D\FV##HR&\=__
M_=^IVH!S$)V-2'6AAL8YSSWW7-,NA@X=6D5/1HO C/;22R^ESH-ZHH6%.]VC
M,4^<.-&,6I@)0T-6BQ8M3$/F63P-M*>/!A::"='.T#:@-LQMM/LUUUQ3)8\T
MYC;T*/1=-GP,=6PV-:0_6?R81K_%4,GFGM&( G'F-G2OGCU[ND<>>215_2@C
MUPSU"[5Q^HJ_L>@SC;D-/8>QC8X=CCDT]K%CQ\9J=D(((800HFZ1N4TT)'B'
M97TN[TJL+>0]RK]S\Q[%^Q;K^WAOY_TE;LV:S&U"""&$*'OJVMR&:'#FF6=6
MB=R&22&,&$5*,K<QH<[NB(A%X?<1'@BMF\_<QD,?"Z00#?S#'L<B"B&,U :4
M'R-$=$(_FC"W80C)96YC\G[9LF55S(*DWKU[V^(Q!(Q\L+/>Q1=?;()<>(Z:
M-K<A/F 4P205]C\""=&STH@CG /#$();*"9F,;<!$?58-.?%"UX&,*^D73A'
M!"]VU:2MPG*$YC;XY)-/3! *S3^,?Q;UE=(,EA7:FG'4MV_?G&.2A(B'D(J)
MB6LY_(RZT_:83WFQ*E7T-@1%=CZ-FEIY44.,]88OA%;$V.A.)!A:F<S@N@@7
M4T:-;?R-J(%AB&[N"URSO*=Y(97^HKVR4HBYS<.UU+)ERUV"'^7 H+5BQ8J2
M1LFCOD2^*\3<QAC&$'KHH8=6.19Q>?GRY;M$\CBHP\*%"^U>%HUB*7.;$$((
M(2H9F=M$I2-S6^F0N4T((800HCB*,;>QP2$;4F):"HTYS(</&S;,/B]TKAZS
M$5')#COLL"KZ!_/TF'$P?6',"<O,/#KY4J9<4":,6VP6&!J!2*&Y#8,8\^SA
MYVG,;1[RH/P^#S:"1--8LV9-JC;8N7.G;6[*\VZHLZ&%8'Q"*QTW;ISEX3]G
MTTH,@$\__72J/- WT"K0Z,(\T&/1O'AW08_ )!6V ?I06I,>&UFRX!8-(\P#
M_1##%]2&N8T\, .&>:0QMS&.T3LQLH7'8OAB+(2;0^:"=S?TT?!:(<69VV@G
MSN_-?_D@HAJ+,-&>PG/S_LCFJ0L6+$AE;@/TQ/[]^YLV[;]+Y,!^_?K5V::D
M0@@AA! B&9G;1$."=UC>=UE;&P9;(+&9"FM[[[[[;EOKE[1>3>8V(8000I0]
M=6EN8X$>I@F$B7 '-$2":*2?)',;)I7GGW^^BDG%3ZJS*"I?]#4FY1&OP@EO
M%@\N7KRXUG9@H_R8L?*9VX@4A>B3RTR",8T7M^;-FU<SDRQ=NC2ON8TZ$SV-
MZ%?A#H*DVC"W(8AA"@D79]$N"%68F1 H<L%XP&2$.2C,(ZNYC1==#),(%EXT
M9/='^HFH7;E,.8#X@? 5-2U%S6V(;T0-)')?^)T33CC!QF6^-JU)UJY=:P:?
M7&.2-&#  -MUDOZ9-FV:1=J*FI$0@3#!4>]<XS<MC!7ZFATSH]>-%P<13+D.
M&)N8X4+H/\2X(4.&Q$:C\\(6]R*$S?"Z88SR(N@753(Q@KB),)B58LQM+ ;%
MW.?KSQAGC')/+X78Z:&_N!Z(7!B6L7/GSM:VW'.2X)I?OWY]->,7 CR":=(B
M;<1UKB'J0OV\6=$GF=N$$$((4<G(W"8J'9G;2H?,;4(((800Q5&,N8VY7XPQ
M;&"(?A9J"Z>==III=?DTRCC0+N;,F6/:61@Q#&V)N6@VN61>?M:L657*C#F(
M9VHV;TR".6N,3,Q?H^-$]9'0W+9ERQ8S'86?8^R:/'FR>^VUU_+6 XT,+<";
MEGC^QWS&\VJ^C4F!N?<)$R94VX@S-+=17O+P&@)YH2?S]S3Z&@:^T:-'NR9-
MFE3)8_#@P6821!NBO"P<#-L9[6G>O'FV@64^-FW:9,:JZ,)#(HJA#T--F]L8
MJR^__'*U^08,CNBV48-7"/H:GT<WFT2'IWSYS&V,)]8\DC<:5E3O23*WT8]\
M1AOGTV093Y2%*']1_9IU"&A9:<UM+ )EW/D-+KUNR[G137-I8D(((800HO:1
MN4TT!'BG8P,8M#7>^]FH)-RLAC6^S"%,G3K5=*-<D>1E;A-"""%$V5.(N8T'
M(!Z8,!5@:,' @-DD"SQT<3PB2#B9[7=C8V>]L#Q)YC8B*KWRRBL6:2S\_K''
M'NMFS)B1<[<YP"P5&J[(__+++[=S9EE Z-L$X\O[[[]O#X)I=V1D8ATC16@F
MBS/<((81R2B7(,.N<9AEHN8VC'&(.;GZR4=.FS1I4I7=('VJ#7,;D9[NO_]^
M,TB%WVG=NK6[]]Y[W?;MVQ/-(EZ4&S%BA/5_>'Q6<QN[7B)>1 TK[-9(!#(,
M/TG]BV$28Q*[^/'@'QX?-;<Q?A%#^"XO';[?$>O889,7;H2C-&.)[] &B*6,
M7\Q?C&'&!.U+VS).TYX+@R<O1''WAS!A;D.<H]Z;-V^VJ(<8A4+#*HD%=Y@#
MV<TR:C8K% 2O</?$,'%?8=Q0MFB=&4.T_2VWW&+EC+O>,$MU[=K5HB6&<#Y,
M<=Z B_C'M<5UGY5BS&T(D>Q*RK@.RX^H^_###]NQN5Y60_@>0C#7/^,DO,8X
M#R^O/7KTJ%+&#ATZF'A+'7*=EW+2#^$" 7:RY3HES^CU3%]Q')$WV1TSKF]E
M;A-"""%$)2-SFZAT9&XK'3*WB?H&US]S8FQ,5=N)^5>NF5)LNB0J!YZQ6,3.
MG#[S7^Q\_.233]I<-W-3_)>H08Q;Q@_S9GZNEKEP3!&E'*=LLD5^?J$]&@,F
M%HPNY,^\*O/%;("'(6?%BA7V7\;W4T\]99\SK\VF4<S5YMOH+@O,$5(N\LQ7
M#]H-XPMS?T*4.\68VX!["%&AT(Y"LQ@:'9M.,O^?=A-#-#*^BP[(L1C!O%[H
MC6OH-OR>,O?,LS,ZB'^NYIFZ;=NVM@EAG$;)_U->YO7/...,V+GWT-S&O?'6
M6V^M\CD&+709YL[SP3WUM[_];;6---FTD'LM]Z@XO8HY=;1;VJ%[]^[53&&A
MN<WG$7VW8'Z>C?=RY8&&AHF0MO!Z%L=R?J+.H?GP/>[+F-W",E G-#STHZ0\
M^#NZZ,R9,VVS0+\II,\#7<.O!:P-<QOW\*A9$5T%G0D=)PFT-+39J%Z(SH-A
M#(TF"=H ,YCOR[@Q%V=N\^,>C8[?%0QN2=HFO\NT7Y\^?:ILG$N?LF"3LK-!
M9UIS&^-BU:I5MJENN%B4<]-'F!ZSZK;\+F,695P7&LU1""&$$$+$(W.;J'1X
MK^(]A?6EO$^SZ8Q_5^&]B?=AUMZR)I-UW,P)YD+F-B&$$$*4/868VS!Q86(9
M-6J43? CK/(0E18F;GE0(OH1.YV%D\,\="$"L=->6)XD<QN3PD32XN$M_#X&
M(HPKE"T7U&7HT*'V?8[#9,<D.O7)8DI 1*%-,.O-GCW;1.<TQA+: M,6SWQ>
M?*$-*$?4<(,H190OZIL$$^H(+5'##XN=,'MX0TA<.:@SPM511QT5&T6N-LQM
ME!\!/AJ)CP=S3(\(]TD[]"'*(>1CI(F*(%G-;3Z,,Q'4PO-@.B.B&R\#249!
MGMWI4P2W<&R3HN8VQA@+ Q ($<.\R9/R\L(]9LP8$U[2F$<YEQ>)N!X0E%AP
M@=#"M<KB0<9[FD4-G M!*VHRC3.!A>8V;S8:.'!@-8,D=:..4Z9,L3J5 NY3
MC+^X<G$-(+8QGI*8/GVZE3,4/GWB[XAJ45$/48O(AO0/^?)RAX!9R(+C8LQM
M7"M<#^0?EA\QFQTT,5VEC3[)]Q#_,.TQ3D(3),(EIM'HKIS''W^\W?_S]27W
M;$1+[N'A=7#FF6>:L2S:;EZX'CY\>*S)EB1SFQ!"""$J&9G;1*4C<UOID+E-
MU#>8EV*1,O,IM9W8S98Y8!\A10A@[A13&'-<+(IG_IWY*.;]6/3.?[G/8GQ@
MKHIH2,R3,;^*^8T-]THY3ID_98Z)N6+FE- 8F'?EWD[^;#[%?.U!!QUDIA?F
MV)@+9'P?<\PQIJOP+#E__GS; "W?8I8L, <V=NQ8F]_-5P_F\C$14'8ARIUB
MS6U^D1EZ)!OA1:-277KII99'&D,+Y^&[/!?SK.QU#Z\7H8=P7_#G0@O$8,1]
MP.LW:'O,3:-Q135*RLHS-7/]T6AH/H7F-J)AL>M[U!#$!J$LJLL'AAZ,7;Y\
MH?9RXXTW)IIPR1]C'?<S?\\)CP_-;>B2Y!'V(=\G#_H$?2,N#]ZQ:0LTH-"4
M2/MQ'UZT:-&N=N:W@O>.L!ST,YKI;;?=9GG$Z0#4#Z,O[47Y_/&T(3HAIBV?
M1TV;V\@'/8I-/<,\&%?H0NBA23".V$0SNADAF@Q:/GIGKLU V8R3>8VHAN-3
MDKF-A$GTW'//-3-YDM;"[S*;W?+=L(]:M&AA!D1T&HY/:VYCO/#,RO@)QY_7
MF6E#\DRC_7 NC'EL2(D)DW&==;-@(8000@B1&YG;1*7#>Q7OA:RE/>"  ZJM
MQ>2=FS5RO&^D6:LL<YL00@@ARIY"S&T(!BSZQ^1#A"Q,"DQ^8UI9NG2I3<*S
MFRB3OTP:\^#$@Q;&&T107BQXJ"(Z%X8'/S',Y'Z3)DULLAG#3%B>)',;D\>8
M/&ZXX083'?RY$%!YCD+XQ8@4)V#P_X@2F+4P(C%QSF0W!BPFE[/LGH:@Q,ZH
M%UYXH1E5^O;M:VW+@BTF[A&!*"</B)B\,*AA.F+BO%NW;E6B+R%,(U(C2H<[
M&O* BE! Y# ,&;1I=/*<<F.RPS08[F;(@RSE(BH;^5(>^H8RL?L@P@5&*LY/
M6V-PBXI;M6%N(_$]HG^Q:,V;P^@;7D!I7\J H85Q2+_2]HPY#"Y$J(M&L@I%
MA[3F-OJ)9W!,8HP)?Q[Z U&,OV,BP]A#&Y(0AC Y(<+0_J'X&)IZ0G.;CU*%
M8,E.G-31BV_4F7$P:- @$Q0W;MQH>=#OE(^Z(RAAWF+'7.K/==.^?7M;B$&;
ML(B!<Y]^^NEFR.)<B)$LON X#(&<C[& P8GZ8)A"D*,.?F=0$N.)G0G][I(^
MA>8VX#S4#W,08JYO [] @_)ATHP35[/"+J7<A^+,;=R;,$'E,E^QT(.VB3-S
M<CSC-;SG4%YV->7:Y'Y%?Q%1D6N\D)V0BS&W>2&:>VG+EBVKC'7Z";&0ZYW^
MY'[!N>AGQ@[W9NK%>$7XQ9S%(AVN<4S'X:ZNY(/9# $VO!\A1'(M(\HAY,7=
MCX QB% =1E/TPB^+<A#!^6V@;;DOL9OJR)$CS<Q*/:@;8G78/C*W"2&$$**2
MD;E-5#HRMY4.F=M$?<.;V^+FHFLZR=PF/,SCLMCCOOONLSE>YO:8MV*C+&]J
M8UZ6WR;^R[P4\_+,Z3*OR1SNZ-&C;6,PS!6E'*?,<;(X'[V%^;%^_?K9?#WS
M9.3/?#WSM<S1\3O*'!O_9;Z6N5O&.;\+[=JU,S, ICWF_\*-K J%WVX6T<29
M#Z*)N5:,=IA#A"AWBC6W<6VA:V&4O>:::TR;# UNAQYZJ%T/Z&_HI]NV;3--
MBW<\YM31:-!J,,]BIF&>GOM1J*MP#G9@1R,*-W_$L(,^PP*T\+D:?8C\F-\F
M+_)![T*+P&##W#PZ%W/:T8W_0G,;QS'_C[[HM3J^CYF6>Q21J')M],GQZ)'\
M]H<+\+C/LK$DN@'Z!28XYM+1(= M,'U=>>65ED_4+$@*S6VT(_<YVIA[8)@'
M&C&&)C0(ZL]WR8/? -H;#0!S8)@'[4+=T'P\'$>D.?K&UX-^H1S\+O!]^A\M
MQ.>!88I[(.9&[LMA'F@1F(7#C1EKVMSF^P,3&.7V_<GO!SHDOVF4AV>U:'^B
M<3 F&(-A/W(L&B#K WB/0_?&H(EVB?['QI'DAU[.&&4<TQ;1WY%<YC9^[]")
MN![1\]#[R(/?<O0D%BUSW?"[%]7Y^,WBMXOK,XNYS>NVC$,TZ6@$139^1"][
MZ*&'3!M%YZ/?O6[+-<VU0316SL\8H'QHKHPKF=N$$$(((4J+S&VBDN$]@W=>
MWI&9&PS7;/*>R098O*LQYGD73;-&3>8V(8000I0]A9K;F+!%^/4/2TQ@\]R"
MN,L$/,(I"VJ(8C9GSAP31#"*(%:P8 F!@(GC\($+$Q&"+8N3,+B%Y4DRMP$3
MS92714Y^\AN!!<$%$9=)^5FS9KFY<^?:Y+=/"#D(&$Q$DS\3^IT[=S;S6%80
M<##T8-CC7-0- 8D=7ZDSAB),)$QV(YS3[I@?:#,,?6$[8"P;,6*$+6(,#1/4
M#0,'N^.Q,QQMBK 4U@F!A<A2B F<)VQ#1#4$(X0"RD/?W'___6: X?N8S.@7
M(I^1=S1J5VV8VSP(6BPN0#0(HY\QSA#TB41VSSWW6+]BQF',<5[ZD,1XH:V\
M,)?5W :($+0I(ADO!UY\HA\04]C=$A,8_4K"W$F?4A]?#LK@#6M>[ G-;1[,
MH)BFJ /E#(5(!#D6-& $0@BAWQE'U)UQC^C#+L&((QQ+.5D$@3D*,8UQ3IZ<
MB\\1V_@^@AO'<Q[:A;[%5(@!CKX/C6T<RSD0",,(7*2HN8T7)81(KB.N]5#X
M]((1ADX^IWS%F'\V;-A@]XHX@9-KD7IA8$T"49/ZAD90GV@GKB4_KKG/8,*B
MG[UQD>L34:W02'3%F-L H9&76$187EB]X$U[(,AS7NK'_<+?CQD[1!9D['+=
M(\@B*OH^XGX0FMM\W1%;PT637 >,)^[YC)NX^Q'MB^!.7W/?B(X#QA37.?<%
M?B>X+_'_B-;<SQ'[>*&.&M=D;A-"""%$)2-SFZCO\!S,.RX+/,/W Y^8F^$9
M.GR/X]_,C_#>&W<,"T-Y;XA&J9>Y3>8V4;^0N4W4)3X2&D8+YLJ88TZ*7)0K
M,6?*9DQ$4>.WJ]1CE?,S]\Q<5:B?9$G,$3(/AQ; ;RYS[<QQ%C)/Q?P;FU\Q
M+XT),&X>-IJ8.T5+8(,SS8^)<J=8<YN'Z$P^ZAKS[>&U@O[ ?8.Y='09-"WF
MI+W&P]\PT?"=<(,YKF7FT)FK1@? -!/"QI7,JZ,#A/FA!:)[LL"-O)B[GSQY
MLN5/'LR]=^K4R3;^"_,CA>8V6+UZM=U+.*<O$_<F]!?FZ3D_FD/X[(ZA"+,6
MY:6,S/LSUQ^V,_J9KQMEHSW0*XE<B0;*HCJ^0]NA"X;1WT)SFV\'-#KJ%&Z4
MQS$\*V-$"O- ,Z8MT-%"0Q7&+;09?B?86#($'8'G;.H=WILI'P:YP8,'VWW2
MYX&YD#ZE[&$>/(]@NF*S5'Z3/+5A;@,,EABF?7MZ/9NV8QRB'3&FPO[D&!8X
MHFOSO7"S2?[-[Q5UY7/,;(QKWM/8E!;]">V*,8?^SF]OU(069V[CO/Q&TW[\
MGG%-H?>C19$'_8TNQ )/ZL.QOER,:=8;\#G]QF]0%G.;ATT=T=30"D.=E_(P
M=M!+^8U%,Z3?O6[+>RO7!NL=>$[@6+_A(YJ3S&U"""&$$*5%YC91J?@(W+P7
M\HX<?7_G/8/W)MZI^$Z<MI:DT?$>%9T'D;E-""&$$&5#*<QMQ29O+,/\@.D'
ML80)X? [N<QM@+GJDDLNL0GYN"A.<8F)9(P3WER&4,!$>"$O.3YR&V)07,2N
MM*(S[4"9V-$.$0&!AO9)>S[,49A0>!B-FDGR);Z+00H! ]&+2%_1]JHM<QN+
M73#]( JE[5.^@SB&R$&9.G3HL$MD*L3<AN"!^(;PQ@(ZC&EIR^%%,X0NZN<_
M2S*W >(GAB/*7LP8XEB$&_+@)8?=!1&."CTGXP^!CJAX"$<8(,//H^:V\)K
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ME7536?1'YG5X=_WXXX\+UD.%$$(((40\,K>)2D7F-B&$$$(T6 HQM[%K'88
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M0QA&]&6BG,453)278I(90P/EH,R<DS:A'-&VH+T03C!_A":_Z+D0X7DF1#!
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M>8_S>>_%-JLQB)QUUEG=-MMLL^)X9YQQ1M$]:!"#< X!\6Q6:]^M:3P,/S3
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M2@31$$(((82P=A!S6UCLQ-PV.V)N"R&$$$*8CFG,;70<&B$S!@--_2YMCZY
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M+2Q&[*4V'^]G#*_SBTG-;>:O_3E[O\3<%D(((80%PQMM;K-P;H';PG1['.]
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M?U?\_/;;;R_9W60WZQ]#YK>]]]Z[N^>>>TH_#<.Q_O5?_[5DK_N#/_B#E;+
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M-@5S:]>NM?;MV_OSG:S]GET&\: ".4W1RZ[E:GOGSY_?MZNFO0$D,L1M
M     (D!<1M 9(C;TD+<AHB(B!B?Q&V(B(B(B(C)*W$;8FP2M\%IS;%CQVS+
MEBW6HT</GW*EZ5?9%7 %:IF:_G7KK;?:>^^]9_OV[;,I4Z8D1=PF-+WM\\\_
M]XEH"JL41,6[333%3=/,]%JS<UM'&[<)32A3%*,)>@H;TYMJ%DLHEAW;)M)R
MM:TTT:Y+ERYVXXTW>I"F_1S/<O5Z-8&N8<.&-F_>/-_/ (D,<1L       !
M8D#<!A 9XK:T$+<A(B(BQB=Q&R(B(B(B8O)*W(88F\1M<%JCR60*W+9MVV9/
M//&$5:E2Q<XYYYQLC9.TS'ONN<?6K5OGT=B! P?LE5=>29JX31&8+DY9O'BQ
MOPZ%:?$&@$V:-+'>O7M;\>+%XX[*0HTE;A-[]NSQ*7IZ7+Y\^>)Z;@5G!0L6
MS-;WCG^0*5S8+Q#ZY)-/_.*(V;-G^_[3U^-9KEZO]D,07&H_ R0RQ&T
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MQQ.W94PPK6W<N'$><@416[#_@_= L-U"WP/ZGN#"-H5N"ATU)?/**Z\D;@,
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M/$G'7BZ\\,+_.R%=N+"?6&-R6SC$;8B(B(CQ2=R&B(B(B(B8O!*W(<8F<1L
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MJU>OGE6N7-G?=]I^)4J42%';X+SSS@L+%_7K!@T:9%O<IHOWQH\?[^])
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M9_#0][O"-DV4UW&EU,=TB-O20MR&B(B(&)_$;8B(B(B(B,DK<1MB;!*W 0
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M0^IK.K:@GY5/G#B1[C*(V])"W(:(B(@8G\1MB(B(B(B(R2MQ&V)L$K<!  !
MPI/5N$W1SYX]>VSDR)%V[KGGIMQU.V_>O!Y?S9@Q(].X+"-6K5IE=]]]MY4K
M5RYEG?0<G3MWML\__]R.'CV:%'&;MM.^??NL0X<.5JI4J;"+M]JV;>L1F"*J
M:-"R%$5I&Y0L63)E667+EK6.'3OZ:SY5'#MVS"].Z]*EB^__8%W*E"EC;=JT
ML14K5D3]NM)# 9TFIUUUU54G)6[3I+LI4Z9X=!A,PCOKK+/LYIMOMC?>>"/3
ML$ULV;+%6K5J9:5+ER9N P    " N"%N@]R$;BJCXQY//_VTU:]?W\XYYYRP
M2?2Z05+KUJW]YD:Z84]&QW&(V])"W(:(B(@8G\1MB(B(B(B(R2MQ&V)L$K<!
M  ! PI/5N$TH_IHS9X[5K%G3IU_I<;H#=XD2)?R"/%UXE)6+\!2#39@PP:=A
MG7?>>2G+5<2E"66'#Q_V<"H9XC:AB$KK5+MV[93O5U"ESWF+%R_V94;+K[_^
M:H\__GC8LK2-+KOL,ENR9(D=.G0HZF7%@[:MMH_B,5U<%L2-"MVTGW2!F;9A
M/,O?OGV[+U]QU\F(VW2!G:8 AMXU7G%;]^[=?;]DQI$C1WR;UZE3)^5]2MP&
M      #Q0-P&N04=,]"T\XD3)_HQ$QTO",(V_1RNFR/I_:T_U[&.S&Z00]R6
M%N(V1$1$Q/@D;D-$1$1$1$Q>B=L08Y.X#0   !*>>.(VH0\U??KTL0H5*H3=
M?5M1SW///>=!3BR3R4Z<.&'OO/..=>K4*6Q]\N7+9RU:M/")6@')$K<I6GK]
M]=>M9<N68=M(4^D&#!A@JU>OCGH;:6+:].G3?5N$/K\FA^E.Z)LV;8II8IZV
M^>^__^X72V9ETEZPKT+OOJ[_*N+25#3=I3W6Y>K[=6';HD6+K&'#AE:D2)&3
M$K?MWKW;+X0+PKP@;NO:M:O?-3XCM-UTD=Z++[YHQ8L73_/WA[@-      "R
M G$;Y ;T,[.FL>MGV>K5J_LQG=3'>"ZXX *;-FV:WQ H&HC;TD+<AHB(B!B?
MQ&V(B(B(B(C)*W$;8FP2MP$  $#"$V_<IL!HZ=*EUJQ9LY3I;5)!4H,&#>R%
M%U[P"Y!T85-F*#C2Q*Q;;[W5PZ_0*6>*YW0W;P5% <D2MRG8T_H\^."#?F?R
M(*;2KR^ZZ")?AZU;MV8:N.GU:#*;IHTI\,J3)T]*4*9E*:@:,V:,3R13L!8-
M6I[VW\B1(_TU1QO9!6C*GBY&JURY<MCT,@5?-]QP@\=?.W?N]&T0#8KA%'%I
M7[=JU<J*%BWJ^_]DQ&VZ@&[RY,EAD]OT:P5I>M^F]Y[5?M#4ME=>><771=N>
MN T      +(#XC9(=G1<X?#APW[#F^;-FUNA0H7"?N[6L8SZ]>O;I$F3?&)[
MI&,OD2!N2PMQ&R(B(F)\$K<A(B(B(B(FK\1MB+%)W 8    )3[QQFRY:^NFG
MGSS04LRF"Y:"X$JQFZ*W8<.&V<*%"VW+EBT>%6GZF!ZGD.G@P8,^06OY\N4>
M--UQQQUA4^#TWPLOO-"G::U?OS[LHKYDB=L426E9,V?.M*NNNBHE M-KTZ2P
M)DV:V-"A0SWL4^2F96C;!!/5%$+I@B^%3^/'C[?V[=M;HT:-/-H*@D(%<XJL
M=.'8L\\^Z_'7CAT[_+%Z;BU+@9DFHBF2T@50>C[%9SUZ]/#E:1]$&\6%[G]-
MB^O?O[_?C5VO)]@F)4N6].VB_?_66V_9YY]_;GOV[/%]KM<5O#[]7E_7!^2Y
M<^?Z>U*O0X%<Z*2[[([;%*@I&M/SZ.*Z8)]H"E[GSIWMPP\_M%V[=GETIFVG
M?:+';=RXT?=EAPX=K$R9,E:V;-FPL).X#0      L@IQ&R0S.D:@XR9SYLRQ
M=NW:^8V/@AO\Z.=M_?JRRR[S8R Z%J3C0]%"W)86XC9$1$3$^"1N0T1$1$1$
M3%Z)VQ!CD[@-    $IYXXS:A2$FAV.#!@\-"H= //RU:M+#1HT?;!Q]\X-^K
MSS?;MFWSH&K&C!G6O7MWCWA"'Z<+GPH4*. QEZ(?15"A)$O<%J"X[[GGGO/G
M"YU&IM=9JE0IO_!+VUWAEF(VO0;%;IJL-G;L6.O8L:-_G[;O%5=<X=M;X5_H
MLA27:>J=(D&%<'JL7HLN&M,$-05F"J6&#Q]NK5NW]N]5D%BP8$'?-]%.6 M%
MP9PN,E. J*!-%ZN%QHFZF$U1WY A0SSXTC[7]VN=]/KT^]FS9WL@I]>5+U\^
M?YP,C26S.V[317?:/@K0-"$N]7NV;=NV/IUM[=JU'KGI_:I(,UAFB1(E/(13
MG%B^?/B'?N(V      #("L1MD,PH5M//T)KDKN-#J8_QZ/A%GSY];,F2);9_
M_WX[<.! U"Y;MBQ-R$7<1MR&B(B(&(_$;8B(B(B(B,DK<1MB;!*W 0  0,*3
M'7&;)I-I"M;JU:L]FM*%-:$3O,XYYQPK5JR8AU@U:]:T>O7J^90WW:V[3ITZ
M5K5J58^$@HEFP45/BIP43&GJEV*@U%/%DBUN.WKTJ%]X=/_]]_MK#GV\@C5=
M^*5M5ZM6+=\VP3:J7;NV5:Y<V6,J?9_B,4T-TV0Q35T+O7.YMINVMR*XBRZZ
MR!\;+*M^_?H>96G"6L6*%7V[Z7OUF'CB-D5B>FV???:9#1PXT$.QT,!1[X5"
MA0KY1+YJU:KY/@_> _JO?J^OZT.ROD]!6_"^T>O01+J3%;=I/RNZU/LR]'OT
MW-H?VK8*U;3MM!T5FFG;*;K4YW1->.O6K9MO4^(V      "(%^(V2&9T+$8W
MB='QB- ;\80>L]#T<QVKT,_+L:AC!ZF/#Q"W$;<A(B(BQB-Q&R(B(B(B8O)*
MW(88F\1M    D/!D1]P6H,EJZ]>OM\<??]R:-6MF9<J4B7@Q4V9JTI>")$5#
M[[SSCNW=NS?B\R5;W"84,.G[%($IEE(D%<1<F:FH31=R*9Q2D+5OWSX/TK0L
M?694H*;OB65;Z_D5EMU^^^VV8<,&#[ZRBO:_)J%I?;3_-<TL]=2US SNY*X0
M4MNT4Z=.:?9/=L9MAPX=\M?=LV?/-,^3G@K?M'[]^O6SF3-G^NM5D$C<!@
M    \4+<!LF,)IXK.-/QH%B/!65%XC;B-D1$1,1X)&Y#1$1$1$1,7HG;$&.3
MN T    2GNR,VX2FJRG"F39MFD<ZNENW)F IO#KWW',]7%+,I8A)(9:F>FG*
MEZ:V:>*7+H!2?#1LV##;LF6+_?KKK^D^5S+&;0&* $>.'.G3RQ2!%2Y<V,.U
M2-M'VTT3S71W<]VI7-M&4_(T,2]8EO:C0BI]T$QO6?IUZFVMYU>DE5YP%2O:
M9MI&4Z9,L=MNN\TNN. "*UFRI*^_UDG/K]>D]=%Z:9VTGOHS?8\F^&E:FL+&
M<>/&V>S9L^VJJZXZ:7%;@*8#:DJ@GE_KH6T>NNV"==1VT_IU[][=)^?I??;8
M8X\1MP$     0+9 W ;)#'';J86X#1$1$3$^B=L0$1$1$1&35^(VQ-@D;@,
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MC;@-$1$1,1Z)VQ 1$1$1$9-7XC;$V"1N P  @(3G9,9M         ! ]Q&T
MD=%-7RZ^^&+BMA"(VQ 1$1'CD[@-$1$1$1$Q>25N0XQ-XC8   !(>(C;
M     !(#XC: R!"WI86X#1$1$3$^B=L0$1$1$1&35^(VQ-@D;@,  ("$A[@-
M        (#$@;@.(#'%;6HC;$!$1$>.3N T1$1$1$3%Y)6Y#C$WB-@   $AX
MB-L         $@/B-H#($+>EA;@-$1$1,3Z)VQ 1$1$1$9-7XC;$V"1N P
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MO6H       "0":^__GK8SW*:VJ8;1@) 9'[[[3>_H0]Q&P   "0LQ&T
M    B0%Q&T!DB-O20MP&    $!_$;0       ,D+<1M ;!"W 0  0,)#W 8
M      "0&!"W 42&N"TMQ&T     \4'<!@      D+P0MP'$!G$;    )#S$
M;0        ") 7$;0&2(V])"W 8    0'\1M        R0MQ&T!L$+<!  !
MPD/<!@       ) 8$+<!1(:X+2W$;0    #Q0=P&      "0O!"W <0&<1L
M   D/,1M         (D!<1M 9(C;TD+<!@   ! ?Q&T       #)"W$;0&P0
MMP$  $#"0]P&        D!@0MP%$AK@M+<1M     /%!W 8      )"\$+<!
MQ 9Q&P   "0\Q&T         B0%Q&T!DB-O20MP&    $!_$;0       ,D+
M<1M ;!"W 0  0,)#W 8       "0&!"W 42&N"TMQ&T     \4'<!@
MD+P0MP'$!G$;    )#S$;0        ") 7$;0&2(V])"W 8    0'\1M
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M^8\__NB3S5>N7.G',J9.G>K7)NN8PKWWWAMVSJU?OWXV8\8,GXB=&N(V
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MY*9EY12QG/L\61"W90\ZMZ_SZ(H30_=GR9(E[<477[2=.W?FV+H1MP$   !
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MG1"W0;*CR6VOOOJJW[2H6+%B/GE"QX]T0Z(F39KX>[I^_?IA=Y,D;LL:Q&T
M    \9%=<=NOO_YJ&S9LL">??-(_]X:&.CI_4Z)$"3\/>,TUUUCKUJU],MLM
MM]QBK5JU\J]=<LDE'AJ%/DXW!M6YTE&C1GE,IGCN5$+<EGL@;B-N P   ,BM
M$+=!;D<_%^FX@(XIZ-A"I4J5K&;-FM:P84.[]MIK_5Q<Y<J5B=L    @]Y"5
MN$TG$^;.G>LG:$(?HQ,PK[WVFGW__?<9/J?N,*COZ=2I4\IC"Q0H8 4+%DSY
M?>W:M3U V[5K5X;+4BAW].A1OP P"-N" _(Z0:23+"<[;HL%XC;(#HC;
M  !R)\1MD.SH(E-%:KKI3Z-&C>SVVV^W(4.&V$LOO62+%BWRR1.3)T\.N\$1
M<5O6(&X#    B(_LBML4>^F\JBXT"SU7J5_KQIS-FC6S9YYYQI8L6>+G6!7#
M'3Y\V,^WZ6N*XIHW;^XWAPA]O (WW<ASTJ1)'B#IAI^G"N*VW -Q&W$;
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M]]]_=W6.4U_[\LLO/7+3.5:=^U'4%GIQIKZFS]"*XDY5X$;<EGL@;B-N P
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MF-=0S3ES/EPS^C!A5.8LU!)X%1$1$9%B#+=)5\9PFXB(B#0EM83;&!3'I&&
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MX8;PXHLOQF B.^E1QK1ITV(8BX!;ODTPW+@FZ5K3SH3A4G_@/"B? !OF#/7
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M9 SJ8^1@,F3+9  9@ZFM,%&CAMLP+PCY$<R[Y99;PNFGGQX&#AP8#1I,IA3
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M<-XCB3V%1/.KK[ZZK8)=I=]3D0WC2#X))(4$DGGSYH5*9$5C$3,)AC!,??6
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MF> 79C_*)7/3S5L=>8LE%?N..NJH, [95L8JD]P=:6ZC#^@+Q@U]<-IIIX7
M(=N'F8FQ0N 08^2AAQX:CB6VD3% ,*(><QO]@HF0X"&&*I+]6.Y&&VT4^I*@
M*]M"@M_0H4.#N0@#$Y/M& PK38(S44\5,8(Z3- ?=-!!(7C%<MD&QCS_)1#;
MJU>OK%^_?B&PR%C"Q$>?,C;R)J=JYC:"%P0,,6,2_$A_1S_P)M'O?O>[(=C
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MF.@H><Y[QHP979_K:W,;1A),9<G0DG0AZJ->8QH[@>VYYYY=N7P"0R+745P
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MF1MQV&&'Q><C^B_/0<I>;@X#N3+:KVA*:T=S&^7F&8;VCBF4>Y#CYPMZ,G>
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M%]1;V@4L]4EVQD(\J;7#'^V*N0<A,B]+,K>1J.>Z*6LN$JZ[[KI1M,%D6!0
M^PKN$80EC&O5!CE)$+W[[KNC"(#A%"-2;A C]MMOORAH(.2T8F=$Q#/J%N$I
M%T X;_J9?]-VB!;<%SD\0[CG<H,LG\_+S41+!"GJ(1=[$4 X9A*EZ1.T(?=
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MYT9+1]/A>O*V))*YC<]1U^QH5ZQK=BF[[[[[:M8U&A$&K[RNT7$PCZ*E,]<
MLR!:;'X.%J)%\WG@@0<J[A!'&W#OGW[ZZ27US3D8JV&:8O')OC"W<0YTJC%C
MQL3G6GI.K+?>>E$[9%(K.EXMK8J_HRM?<<45W;3A5IG;Z./T0TR*^=]Y/C)_
MH)J>29_@&3IITJ1N"P,G7;VOS&UHFSS3Z(<\;^O5 FDK],CB KW4!\>B_D5$
M1*0^-+>)=(?W<=Z;F3/*&+7<8O+%T-PF(B(B;4-/S&TDU)CHSZ2[DT\^.:X@
MQ0Y&)#))1I)P))E+HI>7)9)X_)=D/T8%$LF(!&>??79)PIJ7* 0>3"0'''!
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MM'M9L2RYN2VU&?</_3^U65J)$R&$^D:4X#.8[1"5DBF)@0F&-OH;8B-UBTA
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M8*K A%2.=C2W\3,F-G2%-"9@/(!.P.*,Z%S5=E_CG-0?VB'Z95%O0[_DW&B
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M#!V3G<O0.I+67QR+Y>:V5 _HZYP;XQ%MBF9)'=">2?^AW&C#8\:,B?V&?OC
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M.^'3G_YTG%S%ZNN-&-MR@QN[NS&9C7JF/36WB8B(B(C(BH#F-NED6F%N(X]
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M.N1WJ1ZY5MHA-] Q^8[=W6A/=@ILA;DM'9=^/V'"A/_'WIM 256>^_HG'J.
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M@^6B&.6V!$1ONHD.&C0H=.O6+;1MVS;^'J)+6>;X,&[<]1QAZH033HB_1YG
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MR^(RZ':6C \B&)U!#SOLL'#!!1>$AQ]^. I."'_I?4N6Q;@A0;$L?F>EEX5
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MD5H>-1KVC]H/M6-N$IC4;UD/M2GJ-M3YJ,,@;W$\J)-FCDDNN8U_4Y>B;H6
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MHO_1AVG3?/_C>N'WT6!7=(W7TT\X9NPG")%E EI,F,H0POA^+%_^^B@J%V5
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MVIZNFML0%IF\_\8WOM&06,G.FNSDN=UVVP7#$2+HE"E3LJ5+EV8__>E/@RC
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M@P\.QK6?_.0GX9U0<UMS8& []MAC*R+-<B_CWE--.\S##OG''7=<IXBUM.F
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M.^>=/H.@!3!WS&+U=/S&H/C**Z]T1(G# ,#Y3Y@PH=-<^*Q9LX))+L(<.AI
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ME<"D0L:<6LMMI#!%G'_^^3$.(9*EO9G;,-CD33&<9\0=\Z:G<G2$N8W[!?<
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MFMND.Z.Y341$1+HDC3:W\26!%R965.6%)Z\GGWPR#@BS<AO9Q4XYY90XT$\
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M0OV*/LM]"$,/XZ2,-[,(&4'_8<.&Q47'&(>NELV,\6O&LAGG)2,-!B2RU&&
MPGQ#>93+@F)D+]MRRRW+FO=26=1W[[WWCI.ZJ1=CIZDL^ILVD9$%8R']7F08
MHMYD5V-!MFI@B" #2Z6,>4G4?>VUUXZ3]ID47FU!-C[#N<+$\5HSPQ%?8#R?
M,=EZCB&_RRY&MR*.89%6M+D-\R/C^3P?LN:(>H5A#+,:?=KH<HG5T'YB-;6
M$87,1M2GZ)P@QD1&/Y%:J,?<1ESK]MMOCW&N[+LM!B;BI,3%VKMP9;WF-NXY
M&*'X6_9907R.^-E##SU44]TP6I/Y+7]OJL7<EJ\/&>*XGW*_S=9_R) AT4!<
M[7MORE!)YC3BK_F%4C'LU7H?R<+W#)ZK/-]2>?03V>V8()B,_-S[QXT;%XW7
ME>I('!:3%R:I=$\B@R3Q= Q:V7X\\, #8Y91GI4<<[)+\@Z2?<ZP#9GON+_7
M<LQXIF^[[;8E^ZG5W)9M!WW-^4W<-WN-T->\FPP?/KQD'XTRMW'=<&Y1?O:8
M$*_FW:92_[<%S6TB(B(B70/-;=*=T=PF(B(B79)F,;<Q:,]JJ@0CTJ ] ^0$
M3 AP9@?'"?(2P*QE@A^#W 0;LG5D$)Z!=R8ZL%HG;<A.!F+50%:UFS]_?GP!
MK 8!I@LNN*!5P)D5_#!:E3.W$0@G"$,]F)#%__.!80+W!-,IA^!&(R"3'9,"
MLOLA@,#D"":397_?*',; 1-6'#SKK+.BT2S[=P)]!+7HIWK1W"8B(B(B(IT9
MS6W2U='<UC@TMTE'DB9O8Y["],-$]48:7O+B/D'Y[ N5^US6W,98)).3F3B>
MLJ>T=;^,F3)6S#AAN4Q8S2:,6F3+FC!A0AS?K@8+DC&NRSA\M3ZB#\BZ<^65
M5[;I?,$,1YVJE<]QQCR%T:FK',,5;6[CVN3Y@(&$,?%R6>]J%;$:RB!S$09"
MX@H8/1I9+O$;LNZ5R]J41W.;-))ZS&V88XAM84;*7KN8;KE>,/F0Q:L]U&MN
MHV[,,SO[[+-+/H]QAWLRUU$M=2"&6604;JNY#8@S$C_><<<=2\IB 5*>5[7V
MU>S9L^/^\QE'>>XM7+BPYOIDZT4\=XLMMBBYE_#<8F'2]/SBGD4FMV7+EE4M
MD]CB+KOL$ON-LC!I8: FYIKVP7G'@J#$?OF.Q$_.IW[]^I6TBQ@J^WWOO?<J
M[I-CSO.&F#>+IV;+:*NY+4%?4U[^^&,BSY^;C3*W44?:<N&%%Y:8 7D6]N[=
M.\: VWM=9='<)B(B(M(UT-PFW1G-;2(B(M(E:19S&\&#B1,GE@2H"68S28>7
MIVR@AD *J[>6,RIE8<+4D4<>65)'!LL)<F!\8P"<U?Q8#3>[C\TWWSQ.JJHE
MHQC!'8(OV7U@R+OBBBO"RR^_7-7<1ML)4IUSSCDM*P!F^X"  ,&F:B^0M<+
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M(.:+"9!RZ!O>>[F'L4@F]]RL@9![#@:Y]DY@Y;G)?9KW@WS=DKB/T2^U&+>
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MC]OON...,4-;=O7T6L2D-":I[;###K&<FVZZ*6:!^_SSSY=##W0=-+=U'IB
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M%U\<I;3\(-@<?/#!H7W[]E%.677556.?('D4DEGH$Z2&G7?>.><>N^^^>ZP
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M.^^\<WC\\<<;E7H:D]N \<B7VP8/'AQ%GW)"!;A==MFER7(;;9TZ=6H]N>W
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MQHA>V; AD[GXO>]]+SX3ZX+GI__+3:5R&V/)NATX<&!.!3M$,J2_FVZZ*59
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M7@]Q+PE"',\]D2=&C1H5KYM]QN'#AT?I)"L6 963N-8))YP0*R[1)B0LVHA
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MJ8.33CII\-*7OG1PP@DG++-WO_O=@W_[MW\;_/C'/QY\\8M?; ;!M[SE+8T
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MCQN4E6BWR&P+2!@1'='>>>>=-_C6M[[5!((M/.V2\<YWOK.I6PMJ._?:348
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M/&]['""+$!"[:MY_2D$[1A"%HW-^4"M] #\J^AAS@%(V^MRN3EEAJ\6!GOD
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MWS/F8Q,MBI7*)6R("$EP1L;9G_=&<:[?4^(VQEW>)>0#^W&E-NCD4([?"[9
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M?Q<$;$6_&YZ1=S[O7_I?<<SE/<NXP-YN>Y'?\L2!(PB4&9=HD]TM;L,?A;;
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MC$B3YTAVYZ*HHI2X#1#=S)T[-YQUUEFQ/,K5&^5#6^)O1-RA+(X__O@HE.3
M[CRJ66^(VU*]<HAM+HJD//#-Z"CR$OV+P]!ID[G(C_K#MD_[S*&N&!<H(\H:
M 0E],2^'2J'=(PZBW7-=?!P052(^H>T333BU?=H&_^9W^'107]0;_8YQ"7\!
M^A#1D!I9W :T>>J$=H-/ N-9_EW$33P[SYH+62HI;\J(^L(?@G&&NN3]PGJ
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MH:5-+]H9[8T-HOP>_)]GH>XJS3O7Y&_TA>*UV#AR8T1$1$1$I.^CN$T:&?8
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MG'7666'APH5-FQYZZ*&P]MIKMRH3Q6TB?9MJQ6U$#\//8,R8,6&9998I:0=
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M<YUUUHGY^-&/?A167GGE*(;C_DGTU5EQ&U'.TGT0GI5*ZZZ[;KPO]RMW'?)
M5+8[[K@CO/[ZZ^'++[\,BQ<O#J^\\DJXYIIKPC[[[!.?:ZFEENJ4N(V$D(_\
MKK[ZZK$\R#>)<EEEE56B@+"]B'#DX?;;;X^B.Q'I/12WB8B(B(B(-"Z*VT2J
M0W&;B(B(U#V*VT1$1$1$1$3J \5M(J51W-86Q6TBS4=7Q&WPU5=?A4<>>20<
M?OCA8<TUUXP"K<Z*N]H3EG56W%:KM.222X9!@P9%1PT$*D<??72<8TV:-"EL
MO?76T5FC5!GV1$)01QF==]YY,9K>__S/_W1WLQ&1=E#<)B(B(B(BTK@H;A.I
M#L5M(B(B4O<H;A,1$1$1$1&I#Q2WB91&<5M;%+>)-!]=%;<AI/KNN^]BQ+!]
M]]TW1F1;=MEE^YRXK:-$1#4BJZVPP@HQ$:FNTN\NL\PR,7)<9Z*^<1_*9^S8
ML>&AAQXR:IM(':"X341$1$1$I'%1W"92'8K;1$1$I.Y1W"8B(B(B(B)2'RAN
M$RF-XK:V*&X3:3ZZ*FX#!&Y$<%NP8$$4H17'UF80MQ'9;=UUUPTC1XZ,"<%:
MI=]=;[WU8CE3#]7>%T'=J%&CPGWWW1?+0T1Z'\5M(B(B(B(BC8OB-I'J4-PF
M(B(B=8_B-A$1$1$1$9'Z0'&;2&D4M[5%<9M(\U$+<1L@</OSG_\<GGCBB7#Q
MQ1>'\>/'1]'6\LLOWRFQ&)'0R-.0(4/"_OOO'^;,F1/>???=5O>L%W%;__[]
MHZ -N\B))YX8QHP94]5S\_G[[[\_''WTT>'O__[O8[GS_.U]9XDEE@@KK;12
MC-@V8\:,\,$''X1OO_VVNYJ)B%2!XC81$1$1$9'&17&;2'4H;A,1$9&Z1W&;
M%/GO__[O\-EGGX477WPQ//C@@RWI\<<?#XL6+:JI8R7WXGH8]'%4>_+))Z.3
MQL,//QP>>NBAEGOSN^>>>R[^S//T[+//QKS^Y2]_:7-M?O?IIY]&9Z_\._/G
MSP\???21#@1=8/'BQ>&]]]Z+)S#G94L=?O'%%[%>:X%U*"(B(B+-AN(VD=(H
M;FN+XC:1YJ-6XK8<_! 0=QQ[[+%QWC%BQ(@P>/#@&($-0=:RRRX;[Y=$7 BU
MB$"VXHHKAH$#!\8(:(B\MMMNNW#<<<>%V;-GAX4+%T9'B9R>$+>E_)'(;[]^
M_<)22RW5DE?$=SOOO',XZZRSPLLOOQQNO/'&L....X855EBAXGOLN>>><;^2
MO>OITZ>'S3??/([%JZZZ:HP 1U0X[LU/1',_^M&/P@8;;!!VW777<.VUU\;R
M_O[[[VO9+$2D"S23N.WKK[^.8U#1SO;**Z^$+[_\,@J?:W&/=]YY)SSRR".M
M[O'::Z_%>XB(B(B(B-02Q6TBU:&X341$1.H>Q6U2!,=)1$N''')(-/RGA&,#
MB\+BJ;M=@0DSU[O^^NO#D4<>&;;>>NMX2C!&?T[13??^\8]_'$\0YF>>I[WW
MWCOFE9.&BV H0R2WWW[[M?K.J%&CPCWWW!.%>M(YWGCCC7#--=>$8<.&M2K;
M8XXY)CS]]--MG%<Z2ZK#"1,FM*G#N^^^VSH4$1$1D3Z'XC:1TBAN:XOB-I'F
MHSO$;1Q2Q5X>AUF]\,(+49R&: L1%Q'.$+HAW%INN>6B8(N]N3777#,*VG;;
M;;=PRBFGQ#WCUU]_/>[1<JU2!U_UA+@-41M"-1+Y182'J(U][3WVV"-<<,$%
M\0 WGA6!V:VWWMHI<=OGGW\>OOGFFRCB>_311\-IIYT6YVP(_7"B0M2V\LHK
MA_777S_LN^^^X=>__G5X]=57XUYGK0X%$Y':T$SB-L:ARRZ[+-K@<GL+42PY
M7+(6PEN$P]B7!PT:U.H>TZ9-"\\__WQ-!'0B(B(B(B()Q6TBU:&X341$1.J>
MSHK;,$ @<)DY<V8X\, #6Q(")4[APUA=#[S]]MOAM[_];:L\3IX\.0IC,#Y+
M6W"<Y%3% PXXH%6;P&&*TVQK,3?%B$^$K]MOOSV*Z$:/'AT-:JNLLDH\X19'
M!$[:3?=&[#9NW+CX,\\3)^WB0(!#01&N3UO$R2+_#HX7=]YY9XP6)YV#4S8O
MO_SR:*#,RY:Z9*%3*W%;>W5XQQUW]-DZ)"H=SDI3ITYM-79=>>65<=RM5?F*
MB(B(2/VAN$WZ FG-3]2&IYYZ*LR=.S?<?//-X=)++PVGGWYZ/!CEH(,.:EGK
M3)HT*5QRR24QFGLY%+>U17&;2//!GCN"+/;DK[ONNE;IAAMN"$\\\427]KR_
M^NJK\-Y[[T4! GNN'! V9\Z<Z"ATTTTWQ7LPGB. 0Q#"'C)C$=]![-6><(OY
M#(><W7???6WR7JN4\D=>2>QE8QL@KSP/H@NBKB5X3['WR&<KO0?/G 1\_/SD
MDT]B>>$X15G-FC4K7H^?[$'/FS<O[J4BJ%/8)E)_5"MNX_/YGGUW)VP$C&N,
M(5TE"<^*=K:CCSXZ'EI8"W';BR^^&'[YRU]&@6]^C^.//SX*Z!2WB8B(B(A(
M+5'<)O*_L._X[;??AEMNN24<?OCAK6QP)/PLV3=6W"8B(B)U3V?%;4R(_O"'
M/X2CCCJJU?<0)W$2*2>UU@,X4?W\YS]OE4=.;/W%+WX1#3G2EIX0MWW]]==1
MO(,8BC;#R<+MG8BKN*V^4-S6O;SYYILQ,AZ1"O/G9K$Y?_[\Z"PD(B(B(GT3
MQ6W2Z+ >9-_@WGOO#1===%$XZ:23XB%#K.DWWWSS>+ -SJ[]^O5K:>?L">R^
M^^Y1@% .Q6UM4=PF(B(BTC6J%;>=<\XY%4=ZK$4:,F1(./;88TO:P*I%<9N(
MB(B(B/0U%+>)_"_XXF(S0M2V_/++MPHJ03KCC#/"*Z^\HKA-1$1$ZA_%;5*D
M)\1MG 1!E#^<VBHQX"ENJR\4MW4OBMM$1$1$FA?%;=+H$!&'O8/MM]\^"MA2
MPI"64G'-K[BM<RAN$Q$1$>D:BML4MXF(B(B(2..BN$WD?WGWW7?CGL7&&V]<
M<G]!<9N(B(@T#(K;I$AWB]L0YCSSS#-ARRVWC"=%I.OW[]\_;+KIIN'TTT\/
M5UYY99@U:U:8/7MV3#-GSHQM<H,--E#<5@<H;NM>%+>)B(B(-"^*VZ31^>23
M3^(:?MMMMZW8:5=Q6^=0W"8B(B+2-12W*6X3$1$1$9'&17&;2 A???55]/7]
MV<]^UF8]KKA-1$1$&@[%;5*DN\5M'WWT4308%J.V;;311N&DDTX*SS__?/CL
ML\_"7_[REY;O8+A;L&!!F#Y]>MAOO_U:TOGGGQ_K<?'BQ6WNH[BM^^@I<1LB
MKA=>>"%<=-%%K>J==D+?IIWT112WB8B(B#0OBMNDT2%RVTTWW11VV667,&#
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M^]G/?E9611OM/!KDF*?_\P"0MDR$S,"9?>WLGZP>EG8GG#89?O&+7Y05"5,
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M+K6F>M\2<EM__?6KXX\_?D+AMDS&^, ##Y15Z.9%O26UTH]\Y",#'S\
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M)TL5I]WIZ[K?\N\I?G46C^;'<%M>>\$%%Y2'@?J8IR_3OQ-=<6VJ>/GEETM
M+,>U#GK&A!@3>.JGP)ACG57I]MMOOQ$K$6;?\M"2/D]0]/[[[R_!K9PGF:&C
M>9[D>LOWP41FT,P#4$)GV8>)MB]AU5SK=0$Y;<LYF7:U*=R6?L@UF[YHGB=+
M+KED*;9.Y8\CPFT   #S+\)MF.D(MTT=PFT   "#T;9P6VHS"79ML,$&<X-C
MN6]^W>M>5^HDJ4\D_)89W)][[KGRK)B:4;->FII9)B)<=MEE)Q1N2RUPSIPY
MY3Y](N2S4D_+]C.A8ETG>>][WUN"=1,)MZ5>F7I.!MTUZ[ )[^4>/S5!
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MLLU\'R1(F\&=V><<CYQG.6Z=UW>"EI=??GDYK@   )B9"+=AIB/<-G4(MP$
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M4]/*_N?/KKONNE+ORFLG6O,#    ,',0;@-&DN?[C+WN'$.=,<49URC<!@
M6L]DPVT      &!J$6X#>I.)3-[VMK<)MS40;@,  !B,>1UN P    #,.X3;
M@/X0;@,  *U'N T     @'8@W ;T1KBM&^$V  " P1!N P   (#A1;@-Z _A
M-@  T'J$VP      : ?";4!OA-NZ$6X#   8#.$V     !A>A-N _A!N P
MK4>X#0    " =B#<!O1&N*T;X38  (#!$&X#    @.%%N WH#^$V  #0>H3;
M      !H!\)M0&^$V[H1;@,  !@,X38     &%Z$VX#^$&X#  "M1[@-
M (!V(-P&]$:XK1OA-@  @,$0;@,   " X46X#>@/X38  -!ZA-L      &@'
MPFU ;X3;NA%N P  & SA-@     87H3;@/X0;@,  *U'N T     @'8@W ;T
M1KBM&^$V  " P1!N P   (#A1;@-Z _A-@  T'J$VP      : ?";4!OA-NZ
M$6X#   8#.$V     !A>A-N _A!N P  K4>X#0    " =B#<!O1&N*T;X38
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MPFT      +0#X3:@-\)MW0BW 0  #(9P&P     ,+\)M0'\(MP$ @-8CW 8
M    0#L0;@-Z(]S6C7 ;  # 8 BW 0   ,#P(MP&](=P&P  :#W";0
MM /A-J WPFW="+<!   ,AG ;      POPFU ?PBW 0" UB/<!@    ! .Q!N
M WHCW-:-<!L  ,!@"+<!    P/ BW ;TAW ;  !H/<)M      "T ^$VH#?"
M;=T(MP$   R&<!L     #"_";4!_"+<! (#6(]P&     $ [$&X#>B/<UHUP
M&P  P& (MP$   # \"+<!O2'<!L  &@]PFT      +0#X3:@-\)MW0BW 0
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M&X:=7_[RE]6MM]Y:!N'FV6&##38HH;255UZY3/:39^#\+M(LX FW30[A-@
M@,$0;A-N P   #"\"+>A+3S^^.-E+.J>>^Y9;;+))F7L[^JKKUY"8UE4(V.#
M,V:U>;X*MP$  /1@T'#;4T\]59:]/>B@@TJ JSDXJ5]WW'''<J.7 %!;PFW9
M1@(I66FMWNY--]U4_>QG/QOU/4\^^619-OB  PXH-ZF#]$EN*K-,<1Z\A-LF
MAW#;U"/<-CX_^<E/RG'=<,,-Y_9/ KP//OA@"< .(\)M    \Q[A-@P[F>CC
MJJNN*L_A$_WM0[AM<@BW 0  #(9PFW ;    @.%%N UMX9_^Z9_*;P99U&*B
MS_S";0   #T8)-R6 ,LWOO&-$FQ(T*I^;\)<"1!EQH$LI[OTTDN7OX^9B2#_
MG<)&0CUY34)'>7VVDW#;M[_][>KDDT\N :#:%' NOOCBZE_^Y5]&M&%>A]LN
MNNBB:N.--YZ[VMK66V]=VC#:X,+TR8TWWEB">MG/9I^D0-9OGV2_A-L&0[AM
MZA%N&Y]''GFDVF>??:H55URQ7/]9I3'?J_G.&M8"KG ;  # O$>X#</."R^\
M4,)MVV^_?7G^SN\IKWG-:\I*]BDLYWD\_R[<-CC";0   (/1;[@M]Y_-VN5X
MIB[5N6+Q(HLL4NZ))_+^S3??O/KXQS]>5D<>%.$V     #,-X3:TA83;/OWI
M3Y>%,/([0Y[]LYC&DDLN.7>L<#UV=2K";=E6/?YXHK]1[+???M6CCSY:QC\+
MMP$ @-8RV7!;"A#?^][W2@@M-TKULKEUB&N##3:H#C_\\.H+7_A"=?WUUY<'
MA]MNNZVL>I;!2I=>>FEUYIEGEH%["7"MM]YZU?[[[U\]\<03U3///%,"77?>
M>>=<O_.=[Y1@1>>@OGD5;LO^I9#SB4]\HH3/$D+*/W.3]_.?_[SGRDOYLQ2
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M][K7E7Y9:ZVUJDLNN:2LVCC,"+<!  #,>X3;,-,1;ILZA-L    &0[A-N T
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M2NDFFVQ2SI^L8)I^?,<[WE'MO__^Y3LJGY-!NXK=  "@7X3;,-,1;ILZA-L
M   &HXWAMORFG%I":@*9R#$3NB5PE;I8:HXKK[QR^0T[-:_\-IU:2>Z34P=+
M_263LN7>.>_/O7?-6.&VU&53=\T$@:DSI(Z56D5J"77M,&W/!)^9=#3]ECI@
M9RUHT'!;ZEJI@V3"NK1CGWWVJ3;<<,-2_TM-)ON;FDAJC.F+/#]G@LO4T5(/
M'*TFELD/4^?(=A..2]TE8_%20TU]('7#'*?T9087IG::?<WQ2RTLM;W417O5
MO@    !,'\)M& :$VP   /I@LN&V%"$ZPVU9G2A%BZQ:,UG:$&[+35Q6&TOQ
M(@6-%#82>L@@J]$*+PFW)<#4&6Y+ "N%CQ1Y^F6JPFT)9B1$EM#'%EML46YV
M4Y!*""M%J0PH2T@H@9T,**N+."F.Y?T)NF4?$H:J"V'CA=L2J,E*5WEOLSB4
MS\EGI%B8SU]MM=6J/??<LZQ$E2#7:.3O4GC+>9$@3LZ'M+%N>\SV4\Q+NQ/T
M2=$K1;\$C:8RW):'@O1%KIV$Z1)N:>Y?3+M29$O!+_N8\%L",?G,B8;;<JYE
M)LZL(+CVVFN7X%E=O.L\9OFSM"''-<\/.>99A2L%NUYDA:]33CFEG./U=CO/
MA7H_ZH!6CE<*>UD5L0ZZ=0:-1@NWI:"8\.>'/O2A<FS2WN;[<FP2GDK_Y/ME
MK*!CMI4":[:3@%:]C?1S@I2CD=6VLNI8]K?YV=GWA*ZRDF O<ASR=]G7NMWI
MESI,UAEL2Y\G3)5]2C\F/)65%U-('JMP.U:X+<&N!#OS>0E4I?B<XY%CD^.?
MSTE[<IW6X;9\5E9CRS%)WZ3]>4^O\R?'-_V0<SG?$>G'M"?G^DP)M^6<3S M
MWR'IXYS+.7_JZS9]D?\G)-R6'[N:[\_UE(!AKOOT35[7_ ZJ^['^_LEUE0!B
MSCG%;@  T"_";9CI"+=-'<)M    @]'&<%OJ(\\\\TQU_?775X<??GB95"UU
MMOPFG=^TFW6!SAI1?O=><\TUR^2=V;?F9*1CA=OJE=IVV6674@-JUHSJS\CG
MUI,BICZ<B1,ST6(S4#9(N"U_ESIKMKO99IN50%M^J\_O[LW?\9MMR:1S^3T^
M$TUF8L!,4->+M"OUD]0_LG^IRW5NMZY?YL^R[]E^?N]/32G]<N.--PXTN2L
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M<@R:]<Z8?DI=(_6$FV^^N>QKZEGIT^]][WNE+I25VE)+33TAQRS]W,\DC0
M  #F/<)M& ;F1;@M$[]D'&#&2F9AA$P,DW&1&:.9VG(6#<B8ZCP?-Y_%A=L
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M-+=)6V!+F-LJ39C@"++ .D[6#C)W4"B8B>8V$1$1:1A::FX#A .$#B)DY<T
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MKLVF>(,&#2IH;F-^?\:,&6&>O1)BQ#7>YZ,VP_G/.NNL[/;;;Z_(W!:U4\8
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MY('VG^Z47\FSBK$-@Q+GQ 2$033]3#%S&W7(M3&X$:DMO1?RP#-(GC"XM=0
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M[+'&[K333FOV6<UM(B(BTC"TQ-S&PCJB&$V;-BT($@@8W;MW#Q&A,+\@HF!
MP!3""Q9F$T0(!!Q,/82^Q7B$:0-1 -$$40,S#P+&"R^\4+6Y#9&"/,V=.S><
M$T,'H@\&'\PJ"!9Y<P>_Q\!!'OD;+W.+%BT*+W+50IE@CL%,@I&!:$>Q3/;9
M9Y_P DB9<$T$D5@F&(8H$Q8C\5G*!,&*A6"8,2B3"*()(A$OF[P,\UE,9]P#
M@S/N([_0B_M'",(T,V?.G%"N1 [C7C&E4"Z\"&,(Q&1X\LDGA_PS^*.LWWOO
MO6SLV+&M:FX#C"&<DXA1U"_YQ "(Z2O> VV$ML7]77[YY<&\MF[=NF#2(Y_U
M,+<!></<PVZ4U$//GCVSSIT[!Z,;=4L]T/:I<XQ<#! F3YX<ZI,(='P^&G2*
MF=LB"'"4)\8X#%:8#JDGV@S/$_7--3D'1D:BP]'VN?])DR8%4]"&#1LVFY-H
MI^SZN7CQXFS"A DA(A8#%@1+A#_:(^5#^\0@Q Z9W!N?N>***[+ITZ<'<1(C
MZ@]^\(.*S6WQVCPCU#OEDA],D7_ND7)%<&Q)O3SRR"/A>8AB,>5+62'*(CR6
M,A=ACL- Q3VGT0%Y?HDTEH+(2CLDBB)"+Y^G+#'PE3- %:.>YK8(=8TX3SO%
MZ$BY(Y[SO/,\D&_:*\\1=<ESWKMW[Q#>G/X=HS'&TKQ@BTF0<\^<.3.TM5-/
M/37LAHHH'ON5?'\;S6W4+<__4T\]%>J%8^G_:&_DA3Z2[Q",@R-'C@QU0C]$
MN]#<)B(B(ML"FMNDK:.Y;>NAN4U$1$2D-AK1W 9H@>@PS%<SMX_V@W;!N5+]
M!HT"#>&VVVX+"SB9>\?@5HVY#=WPR2>?#->;.'%BN'>T.S0#YNNCOHN&Q/70
M$+@>QZ"GIO/>+36W1= "V!P/_0G-!9T@:@_<,_=.?:%#\#OT%#0&(LBA:Z-]
MH0NB]P"Z$=H+6ADZ'7/U:'24)YH4YXF:&/H8^@/Z)]?EG)0'FA>;"8J(B(B(
M2..AN4T:A7J;VUB/R#B8]<2,J?OW[Y]UZ]8MK(=F;B&N0V:,S+B6]:-QS=W!
M!Q\<]&4T9\;"S!.P[I8QN>8V$1$1:7A:8FX#7G98L/3SG_\\# HP.2"*\#+%
M+G_L@H? P<L01J133CDEF&X082Z[[+)LW+AQP:A$)+(T(A)PSKOOOCM$VXJ)
M8S&N81XIE2?.Q<OBK%FSLE&C1@4!!\&&%S9>\.+Y,%KLM]]^P10410O$&L25
MO+&J4C" 4":K5JT*AB06<W&?L4RX=_)2J$QXF>2SF)\P6)3* W][ZZVW0OEA
M/,.\1M0HS'0(+FFY(6JQV(LRQ2A')#A$(<2J[WSG.Z%<B(;&CHZ85#"LL3@J
M[K2(,(4)#!$G/2_BV\*%"\.]I;^G;KE&.8,@>:&.R'MZ//]'O"JV^R$1LRC?
M:"+LTZ?/YGOHV[=ON#ZF+EZV$:\X#W5!/BEOKD$[H-QK'<QB5N$]??;LV<&D
M<^ZYYX:ZI1ZH#XQ>X\>/#Z(9QB0,02^__')HEY0]><&(1]YI*\6(4;@P [%(
MC7JBS7 /U#?7Y%FCK6/T(3_482DS%,\*=8!A!W,IYBT,F3UZ] CE1/M$X$-X
MY=[XS$LOO106U<8H;+15RCRM/TQX/-.E3$"<YXX[[FAR7$R(E42KPSS8$K@?
MS$64*>=C,26#.\JD$N@[J$?N/^:)MH\Q-!*?<YZ9&+F/GYBJJ..6&IAH][15
M#'YIF5"G",*T_99 .^7<B+JT1\J8O%-&M!_:*\\1]XD@C4%P]>K598U<<<!+
MF=]___W!$#=HT*#0MA&3*?M\WT#$O]BW\'QBH.58^C_:&WGIU:M7Z"_IBWA>
MXO<#?3-]9'QV8J)M1N/BVK5KP[-$GY!^AOZ"/K,<&$&)+DB_F1[/]R']<JG(
M?T"Y\=G\\?2YY<R5(B(B(A'-;=+684,+(B[DYPMJ28PQ&#_G-[+0W*:Y341$
M1*06MK2Y#=V4=]GX7LO</.:O2N:K@3GK)4N6!/T!O09="/V">7+^SR9\:(7I
M^= Y[KSSSJ!'IN_4-]YX8UCXR1Q\^GOT6.;JXR:B;#1''M%:. >:$1'1T)"X
M'EHMF]\5 F,9>@SY3*^!;L<QE<R1H\&@7Z'SH1.,&#$B: ]H"-P[8V3NG]^A
M;;$I(Y\MI2MQ7<;5;(+WT$,/!=T%38VRH'XX+WE&VQX^?'C8-)--!]$S6JH9
MBXB(B(C(ED=SFS0*C,O9U)YUA_72QEA'Q]I@UJ.Q[F_*E"EAW2GK:QFCQS71
MC-M9/\K_67-WTTTWA:CFK+7[Z*./FN13<YN(B(@T/"TUMT$TD[%H'P,%Y@LF
M^C'5\&)$8E$3(@0_2?R.S_!97I8*B0+\#I&!XV+B6#Y?S/24/Y[\8)Z(>8GY
M(&&\(B+6K;?>&J(+L=,!NQ;P<KEFS9H6E6.$_&V),BETCWR68PK=8TS\GL]$
M@PCF#,J6Z\7KIWG@;ZE!AY_<!]?(GY?K<TSZ>_Y?B<&GV'GY?ZDZCFTNWD.\
M[U+W0%W$^TW;4TLC;*5Y(:^QK>7SPKU0]JFIA7SQV7Q>.$>Y:W&>_'W'X^/U
M.#?GJK0.^%RA_,?S%CLG]TW]<TQ:?[&ME8+S\+E\6XWU7TN$*\[-.=+R)8_E
MRC<]/G]/,4\1_HV)JFO7KJ'_8.>3PPX[+(B=M4"94L?Y9X+RSQN JR&VTV+]
M1;Z]5MH'Q7.G?4HL^T)]$7^/$=;BL>FSG/9'G"<^QY'8;O+G3NLF]OWYSW"N
M2NZIEG8=K\]G\\>[&%U$1$2J07.;M'7B^#4_7U!+XAV?C36(X*ZY[?^CN4U$
M1$2D-K:TN2T_IYUJ=I40YZRCWEE(O\G/Z1>;IXY:3W[^/,U/U"FBEI#7$0M=
M+Y_?6N;H(WGMH9"V&N\_KPF6.V>J'^<UL51G=,,Z$1$1$9'&1W.;- IQS5I^
M+%ZK-A;'[(S%&:NFZZ'3M9Z5KA_5W"8B(B(-3RWFMK8*+WSLSD?DKWB_AQQR
M2-CYL%1D.!&1=]YY)WOLL<=""&_Z#B('$,%NP8(%K9TU$1$1$6D':&X3*0P1
MZ;_^]:]K;DO0W"8B(B)2&UO:W"8B(B(B(B);#LUM(M6AN4U$1$0:GFW1W,9N
M>X\^^FC6IT^?S?=[\LDG9W/FS,DV;=K4VMD3D09FU:I5V;AQX[*.'3N&OF/'
M'7<,(;]7K%C1VED3$1$1D7: YC:1PFAN:X[F-A$1$9':T-PF(B(B(B+2=M'<
M)E(=FMM$1$2DX=D6S6V$W1T_?GQVU%%';;[?_OW[9Z^]]EH(Y2LB4HRGGWXZ
M&S!@0+;KKKN&OF/GG7?.9LR8D6W<N+&ULR8B(B(B[0#-;2*%T=S6',UM(B(B
M(K6AN4U$1$1$1*3MHKE-I#HTMXF(B$C#LRV:VS"P#1LV+-MSSSVSSWSF,]D7
MO_C%[(HKKL@^_/##[$]_^E-K9T]$&ICY\^>',=J7OO2E['.?^UR(X+9LV3*-
ML2(B(B)2%S2WB11&<UMS-+>)B(B(U(;F-A$1$1$1D;:+YC:1ZM#<)B(B(@W/
MMFANXR5MXL2)V9 A0[)^_?H%D>JAAQ[*_O*7O[1VUD2DP7G^^>>S2R^]-$1O
M(PT?/CQ;MVY=:V=+1$1$1-H)FMM$"J.YK3F:VT1$1$1J0W.;B(B(B(A(VT5S
MFTAU:&X3$1&1AF=;-+>)B(B(B(B(-"*:VT0*H[FM.9K;1$1$1&I#<YN(B(B(
MB$C;17.;2'5H;A,1$9&&1W.;B(B(B(B(2&.@N4VD,)K;FJ.Y341$1*0V-+>)
MB(B(B(BT732WB52'YC81$1%I>#2WB8B(B(B(B#0&FMM$"J.YK3F:VT1$1$1J
M0W.;B(B(B(A(VT5SFTAU:&X3$1&1AD=SFXB(B(B(B$ACH+E-I#":VYJCN4U$
M1$2D-C2WB8B(B(B(M%TTMXE4A^8V$1$1:7@TMXF(B(B(B(@T!IK;1 JCN:TY
MFMM$1$1$:D-SFXB(B(B(2-M%<YM(=6AN$Q$1D8:GF+FM9\^>V?CQXTTFD\ED
M,IE,)I/)9#)MI=2U:]<F8_-O?.,;V>VWW][J^3*96CM=<\TUV<X[[]SD^1@[
M=FSVP0<?;+-I^?+EV9Y[[JFY341$1*2%%#.W'7[XX:W^_FLRF4PFD\ED,IE,
MIM)IX,"!3<9R7_C"%[*A0X>V>KY,ID9-=]QQ1[;OOOMJ;A,1$9'&I9BYS60R
MF4PFD\ED,IE,)I/)9&K4-'+DR.RUUU[;9M/<N7.SW7??O4F9:&X3$1$1J9QB
MYC:3R60RF4PFD\ED,IE,IFTA;;?==MFAAQZ:O?SRRR7G4/XJ'J"Y341$1+8D
MFMM,)I/)9#*93":3R60RF4QM+6ENT]PF(B(B4@N:VTPFD\ED,IE,)I/)9#)M
MR^G;W_YVMF#!@FS3IDTEYU#^*AZ@N4U$1$2V))K;3":3R60RF4PFD\ED,IE,
M;2UI;M/<)B(B(E(+FMM,)I/)9#*93":3R60R;<OIH(,.RD:/'EW6K_97\0#-
M;2(B(K(ET=QF,IE,)I/)9#*93":3R61J:TESF^8V$1$1D5K0W&8RF4PFD\ED
M,IE,)I-I6T__^(__F/WG?_YGR3F4OXH?UMPF(B(B6Q+-;2:3R60RF4PFD\ED
M,IE,IK:6-+=I;A,1$1&I!<UM)I/)9#*93":3R60RF;;UI+E-1$1$&H9BYK;N
MW;MG8\:,,9E,)I/)9#*93":3R;254I<N79J,S??99Y_LYIMO;O5\F4RMG2Z_
M_/+LRU_^<I/G@]^___[[VVQZ\LDGLSWWW+-)F6AN$Q$1$:F<8N:V0P\]M-7?
M?TTFD\ED,IE,)I/)5#KU[=NWR5CN\Y__?#9X\.!6SY?)U*CIEEMN"=JSYC81
M$1%I6(J9V_[U7_^UM;,F(B(B(B(BLDWQ+__R+TW&YM_^]K>S__[O_V[M;(FT
M.C__^<^SKW_]ZTV>CW_[MW]K[6RU*O_U7_^5_=,__9/F-A$1$9$64LS<]L__
M_,^MG341$1$1$1$IP[__^[\W&<O]W=_]7?8?__$?K9TMD8;E?_[G?[+33CM-
M<YN(B(@T+IK;1$1$1$1$1!H#S6TBA='<UAS-;2(B(B*UH;E-1$1$1$2D[:*Y
M3:0Z-+>)B(A(PZ.Y341$1$1$1*0QT-PF4AC-;<W1W"8B(B)2&YK;1$1$1$1$
MVBZ:VT2J0W.;B(B(-#R:VT1$1$1$1$0: \UM(H71W-8<S6TB(B(BM:&Y341$
M1$1$I.VBN4VD.C2WB8B(2,.CN4U$1$1$1$2D,=#<)E(8S6W-T=PF(B(B4AN:
MVT1$1$1$1-HNFMM$JD-SFXB(B#0\FMM$1$1$1$1$&@/-;2*%T=S6',UM(B(B
M(K6AN4U$1$1$1*3MHKE-I#HTMXF(B$C#H[E-1$1$1$1$I#'0W"92&,UMS='<
M)B(B(E(;FMM$1$1$1$3:+IK;1*I#<YN(B(@T/)K;1$1$1$1$1!H#S6TBA='<
MUAS-;2(B(B*UH;E-1$1$1$2D[:*Y3:0Z-+>)-#!__.,?P[.U<.'"((*/&#$B
M&SQX<-:_?_^L3Y\^V3GGG-,L(0R_\LHKV:>??IJ]^NJKV4,//11,(2PZ&31H
M4-:O7[^BQY9*<^?.#8M4_O*7O[1VL8C(-HCF-A$1$1$1$9'&0'.;2&$TMS5'
M<YN(B(A(;6AN$Q$1$1$1:;MH;A.I#LUM(E7PYS__.?OXXX^S7_[RE]EKK[V6
M/??<<]F2)4NR!0L69(\\\D@V9\Z<[,<__G$V;]Z\[+'''LL>?_SQ[/GGG\]6
MK5J5_>I7OPK'5F(.XSJ8TSCVGGONR08.')AUZ=(EVV.//;(==M@A3%[^G__S
M?PH:/<X]]]SL1S_Z4?;HHX]F-]]\<]:K5Z_LP ,/S+[ZU:]FVVVW7?;7?_W7
MV6<^\YF"QY9*M]YZ:_;[W_]^FS>W42_OO/-.J/]GGGDF6[QX<39__OSLX8<?
M#O6/"9"Z7[9L6?;22R]E&S9L"/5.G=)NGGWVV6SV[-EU2[SXT-YXV:'3?O+)
M)[.E2Y>&/- &R!<&QY@W\DJ;7;Y\>?;RRR]G;[_]=O:[W_TN^].?_M3:12M2
M$LUM(B(B(B(B(HV!YC:1PFAN:X[F-A$1$9':T-PF(B(B(B+2=M'<)E(=FMM$
M*@!#%^:D3S[Y)%NS9DTP#(T:-2KKW;MW=O#!!V=[[[UW]@__\ _9YS__^6S[
M[;?/=MYYYR#8'G;882'JV4TWW10,2!S+0\>Y2IG$6 RR?OWZ[+O?_6ZVVVZ[
M565"(T\WW'!#>"YWW'''JDULFML*PWT326_=NG7!.$;]]^C1(SO@@ -"A_FE
M+WTI^\(7OI#][=_^;6@/QQ]_?';))9<$8]D;;[P1#&ZTF[/..JMN=4+"Y/CE
M+W\YF!^)S'?BB2=FAQQR2-:Q8\=@:(QF2-HF+T4=.G3(#CKHH-#Q7W;99=G]
M]]\?(OU]]-%'9=NE2&O2GLQM\3N%/N5___=_0^*[(4W\#M-IH6>RTN/CW]/?
M\SN.E?J1UD=;*^N8]T+MQ.\#$1$1$1$IAN8VD<)H;FN.YC81$1&1VM#<)M)8
MQ+5#>7W5#:5%1$1$I!":VT2J0W.;2!E8]/WNN^]FBQ8MRJZ[[KKLC#/."*:U
M3ITZ9;ONNFLP,WWQBU_<'$V-R&A_\S=_$Z*D\27$9_;99Y]PS'>^\YU@/..+
MB>A?Q7CUU5>SZZ^_/D1<PY14C=F)8S!6[;333MGG/O<YS6UU@/LF4MOX\>.S
M_OW[9X<??GBH_UUVV66SJ>VSG_ULJ'O*G+K'[+CGGGN&_I%Z'S%B1*C[4T\]
MM:[F-A)M[^___N^SW7??/1C=:)/D@;9#OF*[)&_1@/>5KWPEVVNOO8+1[913
M3LFNNNJJ;.'"A:&MBS0B[<7<QB0WD3QYWNA36!!(OT*43;Y?NG?O'M)%%UV4
M/?#  R'B8PH3Y9LV;0K?(T3VO/+**T-T3XRSZ?']^O7+;KSQQNS\\\_?_#O2
MM==>&Q85$;%1ZL.''WZ8O?CBB]DUUUS3I*QY9Z"L,0\W*K_YS6^R%UYX(1L^
M?'B3O(\>/3H8G_G^$Q$1$1$1R:.Y3:0PFMN:H[E-1$1$I#8TMXDT%JM7K\YN
MN^VV;,"  4%7/?WTT[.SSSX[FSY]>FMG341$1$0:$,UM(M6AN4VD")C:_O"'
M/V0K5Z[,)D^>',P#^^VW7S"RM=2$A!&*<S#1>-]]]P5AEX<P-8QQ328HB0B'
M":G::V!J(V(7AJ9Z&JBV17,;.RO]^M>_SI8N71I,"D1'PSS6DGIG40,F,LQD
M]3:WU9HP8V+6.^^\\\*+%-'I1!J-+6ENXUG',$:4Q6>>>29;L&!!-F?.G.R'
M/_QAB&XX8\:,;/;LV=DCCSR2/?'$$]G/?O:S;./&C54MW.,[Y=-//PU&(A8U
M,=E]Y)%'9GOLL4?H(W@.TWY[WWWWS4:.'!GR!/2]7(]K\YTT9,B0K&O7KL&D
M2I1.S*SI\?15O.#Q0I>6%^9G!D<??/!!S>767L!PB-GOS3??#"8US.QSY\[-
M9LV:E3WXX(-!B)@Y<V9H$T3N?/[YY\-G^4[$;/C>>^^%[^UCCSVV25F?<,()
MH;TT<EECM'_TT4?#]UN:=[ZOGGSRR6!^$Q$1$1$1R:.Y3=H#S+4P5\.X_>VW
MWPZ;FS%OP[P)8^4?_>A'80Z?=.^]]V;3IDW+?O*3GV1OO?56T7-J;FN.YC81
M$1&1VJC%W/;;W_XV;*R,YLD[;:V)M00;-FP(:URD=6$<PUHFM.Q8/XQ=7GKI
MI9KTO>>>>RZ,?>(XB#I_^NFG&UKOW-J@%??NW3ML=,ZS^)G/?";H_6QX+2(B
M(B*21W.;M&?BNF:\%JRI??GEE\,8<O'BQ6&]->NN68/+V)7$O_D=.ASK4]'5
M.#;UIFAN$RE %+81M8F@1N0U(E_5TU#$<T-4':+R8&B+\) B[C(!4N@X?H\)
M8OOMMP]?<I@:2/R;WS&Q6>Q8[H'(74RLI,?&Z'.E[G%;,[=A1"':SE-//94-
M&C0HE%LMAD&.)9H;Y=[:9K92J4>/'F'A!F:?;:6NI6VP)<QMT<3\_OOOAQ>J
M"1,FA.?]B"..R/;>>^_PS-+?TD=VZ- AVW___<,S0A3&>?/F96O7KLT^^>23
MBIX7KH-Q].JKKPX3W>6^4_+F-JZQ?OWZ;.S8L>$EK9"(E2;-;>6)]8_!:\6*
M%=F4*5.RBR^^.)C4*'^,XCOLL$/H_XF.R4*LHX\^.KOPP@O#9XEL1MNA7N;/
MGQ_,AFE9:VX3$1$1$9'VBN8V:>LP)T";96Z'\2\;&XT9,R8;.G1H=L899V2'
M'')(MLLNNX0YW3C7SES.=[[SG>RAAQXJ>E[-;<W1W"8B(B)2&[68VW@_O>..
M.UJT@6^AQ*:=+%##-">M"PL&T:S3ML'XY::;;@H;=[242RZY)/O<YS[7I,Z_
M^]WO!M.<_#\TMXF(B(A(-6AND_8,@258/\LZV:E3IX9 0@3:89URY\Z=P[KK
M&/R#L2;K<7?;;;?LT$,/#1&P;[_]]G L\PRLY46_T]PF4@#,"BQT'SQX<# S
M;+?==D4-8RU-/*P''GA@=NFEEX;)#QY(8.<L#'7%CB,OO7KURNZ\\\XP<<A#
MO6S9LC"I.6[<N.Q;W_I6T6,Q:UQTT45AIR6BD7$<"3/3\.'#FYD@TK2MF=LP
M&;*P@4FIW7??O>9(>&W%W+;SSCN'=H^#FN= I%&HM[D-LQ@1M]@=@(5+F)8P
M,C,)C9D-0Q,O4SR[G_WL9T-D- S$/"-[[KEGZ+_/.>><[.Z[[\[6K%E3]GDA
MTMLMM]P2C'.\J)7[3LF;V^A_60S%2U\^2ENAI+FM-+Q48]PB&MNP8</"=R=E
M3GEA^N:[EGJB[BEKV@(F</IP7KB)PHJ9#;,BWZD,0H\YYI@F9:VY341$1$1$
MVBN:VZ2M0P3W)4N6A+EY!#0T  Q8C/F94T%<RV\BI[FM96AN$Q$1$:D-S6U2
M",UMK8?F-A$1$1&I!LUMTE[!]\+X$^\*6MLWOO&-L+::H!($DV"]=;H&E[$3
M6AN_8PSUE:]\)>O8L6-8=XMO8>'"A<&[H;E-) ?F+8QM3/KLM==>P42PI8Q$
M+)3GP202SZI5J\*UGWGFF2"JES(LW'///=GKK[\>'N!H-MNT:5.(),2"]$+'
MT2FP$/_QQQ\/)HL__O&/F^^9A?=,P&"\8)%_H838CRMV6S"W43;4PV67718Z
MPWI$[6LKYC;:"28?%FE@>A!I%.II;L,H1A_*0AH,:O3UO#!5^[Q@="/*%X9D
MC$!$\2H$?343_B>>>&*VTTX[;3Z>ES<,=4Q^(PH0-2SVN=PO8A4&O+B[09\^
M?<(+7?H=@J# CN((6!S/]P?'L]#PFFNN";L?I'G6W/;_ZI_Z&#]^?"C[3ITZ
M56U@IJ]$V,$0=^:99X:RSR]>T]PF(B(B(B+M%<UMTM9AK$ZT-N9J*IT+T-S6
M,C2WB8B(B-2&YC8IA.:VUD-SFXB(B(A4@^8V::\08.2YYYX+09=JF6L@$ F;
M3PX<.##[X0]_&#PNW;IU:_8YS6VR38*+E$7O+'@_X( #"DX2IF(V#Q3N4LP&
M3%SP<!$ND7_S.Z*_\)ERB^:/.^ZX(.@2^0<3V9 A0XHNIB>*6!KI+8);E8>:
MQ?2%CB4/3+!@W-H6#&HMA7)E<<-==]T5ZK%0&XCN82+[Y.N?%.N?OV$^B:[C
M4N8V)KMH.W2^E23.3W0I\L<U^#?GQVRSRRZ[A#QPOM@F<4(S:<WG,/&4:I.8
M;:Z\\LIL]>K5K5T=(INIE[D-HQA"SJ1)DT+TK71RGF>5/IN^.]^O\USQC,6=
MN]/^@+Z A7T8F5C,E^^?,0@M6+"@610U%O9\[WO?RW[ZTY\&8QQY*P2[B?-2
MQNX&Z?%\'V#.8[#SJU_]JHGAF7[L)S_Y20C=F_8=?/[99Y_=)DU+E UE_,HK
MKV1CQHP)_65J:J1?Q-!./TE_29VG_2C_Y_<Q3'+<O9UC:"OTQ6G]M 5S&^V.
M]PX6YZ7MA-#0O&M\^.&'K9U%$1$1$1%I0#2W25N'C>)FSIR9G7SRR9OG5YGS
M84XHS@DPMZNYK78TMXF(B(C4QI8PM_'NBQ9:Z=J$F+[UK6^%S1'1+J5UT=S6
M>FAN$Q$1$9%JT-PF[95"YK8T,AN!0.(Z[+@.EW^S;I<UNHP]4R\#:[=//?74
M;-&B1=GAAQ^NN4T$6,3-Y.!99YT5S IQX7JAQ .'*8T)H^G3IX>'B6A?3.9A
M8KC__OO#Y 51?7A(2T7_XLNJ9\^>84*(+S(F(HL9Z@C9B!$B;U!C@?H##SP0
M\E3H6$P;1/W1V%8:%N+,F3,GM $F @NU 3I4ZK][]^[9Z-&CPT((ZG_Y\N7!
M-,*_J7^B.1']YFM?^UI9<QMU3MMY\<470^=;*O$9VARF&,)XTID/'3HT^_[W
MOY_=>^^]H0W1!I<M6Y8]]=13P5PQ?_[\[.Z[[PY?(A@W2T60XPL$0XP3E-)(
MU,/<QLO4FC5K0AA<GIU\/X\)E#[TVFNO#<\PS_+33S\=3&(L7,+T2C^:7Z1$
MW\QS@S&9E[6\H//FFV]F/_C!#\+YT^,PFLV=.S=\]V"Z*M8_;]BP(3S7F/'2
MXWGVZ7^(OI4:VP C,[LF$J$N[3_X/_E+HW=N*V @I_ZON.**4(?IRS'M@!?F
MPPX[+/2G+#RCSI<N71KZ=G[R_PD3)H3^^N"##PZF-H[C''Q?Y$W#;<'<1KNC
MG6!F3MO)&V^\D7WTT4?;9#L1$1$1$9'R:&Z3M@[FMA_]Z$=AGH>H[$1P8Z,7
MYO.9$^!OS.VF<_J:VUJ&YC81$1&1VM@2YK9^_?H%C;&2M0EIXMT.71/-55H7
MS6VMA^8V$1$1$:D&S6W27BED;L/01A"/\\\_/[OUUEN#K^6QQQX+_@C68A,-
MGK74%UQP0=".6,.=CFD99['N%K^%YC;9YL$4\/;;;X?%&9@>2AG16/Q^^>67
MAPF_%2M6!.,!$=]8!/Z'/_PA3.BM7[\^>^&%%X():=BP85GGSIW#A$:Q\V*
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MQH%L^DJ[I<ZH.\UM(B(B(E(IFMM$2L-8B_%>(>]&FC2WR38'T;8060M-#+*
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MDL&J5@B6$/1BLGO1L;A!TV!16EK!W$; AZ -GTTS)<6"@8156U@QA@Q7E2!
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MS9H5@JYQ-3RV91^QC>(^"=Y2?\P"!'/S#_BTT&]GSIP9@I7Y?<4VYUCQ"X/
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M;B^]]%(3SJ+UH*_\_O>_#\_.]-YF?H'/2A$1$0'-;=(;8)X@XUHT-,:X,;[
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M@B (@I .,K<)0C)8W[U\^7++M,UZX%1K/F5N$P1!$ 2A:%!H<YO?_8V)6G9
M\^7\_.<_-^& R75,+.P.R*0ZYA2$!LX?[GR(Z8<)\JCX4A9S&\81=JUC@5 X
M.=^]>W<SL&23E2H5<IE8YMII#\Q7888O=I7C^9')=PQZ7",3S!AF$-/"=N/?
M3# COH7GKX[F-MH'(204,XA!S$3T146"A:M<$^,A3 5][KGGNADS9F0EBM+'
MM"G&. 2.4%"A+3&%(M @[&&"0RCR<1+6A\]UZ- AY4L.I*U9I+AW[]Z,ZD<L
M,J;8%=+O$(+ICFM%%"DF<QOM@/%P^O3I)>*$,3=HT""K9[X@<YL@"((@"$+U
MA<QM0E6'S&WY@\QM@B (@B (N2$7<QN: )_SQAWT',JZ[;;;S&@2ZBS9 MT4
MW0N-,]2)T$U'C1IE.ENF^/SSSTWC"#4B-O<</'BPV[5KEYF'T 2C^BIF-(PF
MZ<#&B>BG4>-993&WH4G2UL.'#R_1UCQGHQ?QS)TO5+2Y#>T<?3#:)L35A1=>
MN/]W&)C0 :-F,4QP;/Q*7*.)H9W19\V;-R]1)L8C-J@-=6WT/W17WN&X7C17
M3&'TA>^S=.!S:-)GGWUVB=A!![_SSCLM*V&FH#Z\BXX8,<*RLOFRT"0Q\+$9
M+"8J^@%-F@U+X]8C//GDDQ;OF9C;B%?&*VL.,JTCY[OZZJM+F$599-J[=V][
MURL6<QMZ*_=/]-UP+07O]2PPSQ=D;A,$01 $(1UD;A.$U&"=(>MKP_7%<92Y
M31 $01"$HD&AS6T(-!B+^O;M6R+]+<8G)M;9$2V<-$X"$^Q,BA]TT$$EZE,6
M<QMU8E>PEBU;EBB/;%(<ER]C22X3RTS (P"0=2V<0$=L8=*;"?UT[<9ULL-C
M-"-7=32W<<[Y\^>;4<FW)WW/3GASY\[-Z7JS!6,+H8^=#D,Q$;&(=L-<F<F8
M  @O/I;#.$&H8<=)8C!=6<0[.PO2;JE><B!C$'$EDRQUG!<S'8L1_>Z0E$$?
ML,LGHDBQF=MH3W9=#>,$08X%QZD6868+QL'LV;-E;A,$01 $0:B&D+E-J.J0
MN2U_D+E-$ 1!$ 0A-^1B;L,$0V8KLBJ%Y@ZR/V'XRB5[FS?BL $H.I$OG\5H
MZ"?H'9D '7#CQHVFW6#B\75LVK2IE8VVQM^Y#K2.J&:W>O7JM.? [(-V%SV^
MHLUM:]:LB36W<6VIS&V^K<>,&6-MY-NZ;MVZII.2O2M?J&ASV\J5*TOI^,0[
MNG"H/_7HT<,TV*B&QB:JC 5?7XQ,;)A*YK^P3(YG$:0_GC9E$TSZE[C -$A[
M7G[YY6E-52$H!_,2ZP7"^"7+&N;,+5NV9*R7H@-3O]_\YC<EUB.P@)/8HOTS
M*>OAAQ]V'3MVS,C<1IU9_\!])ILZTD[A6#GII).L;,R"Q6)N0ZLF P1&V? >
MVJE3)ULGDB^P@:_,;8(@"((@I(+,;8*0&KS7L^XRNDXW2IG;!$$0!$$H&A3:
MW(9)@\EG)I-#\0<S#D:RS9LW9U0..\HQ$1^=3*9^HT>/+O$[)N$Q=24))DQ>
M,S'+9'PX0<]#'I/EF/'R@5PFEIG<1I1HT:)%B79C!STFM\DPE0Z(6NQ0Q\1S
M>/[J:&ZCSU]\\44SE&%<XG/$4L.&#=V4*5,R%D?R!8R7B#7AKAF\@-,G]"U]
MEPGX+)/[F-G".#G__//-I(6Y+!T0H!!+>(E)]9(#&S=N;/U(;*<#]Q"NDZR-
M8=V(/Q;TLI-AL9G;:'?BD'&'*.H%6,8&]\Q\Q0GW/3+:T6]A/3"W<=^5N4T0
M!$$0!*'J0N8VH:I#YK;\0>8V01 $01"$W)"+N0VMD$63Z")A&3R?L;D@^DLN
MV=O0&]!)T?"\T05S5[-FS<SLE0G0B-#0.";,2H919/KTZ;91(1KM P\\4,J<
M-F3($+=TZ=*T=:2<>O7JE3 ,P8HVM[%9:E0/]N:VI,U.P^O@<YB(_'N*;^O%
MBQ?G3?NI:'/;UJU;W:1)DTJ<"SV.O@[K,'#@0-LH,SKW0'W)1.B-9;0-;1J^
MRQ%7_?KU,Y.1-W32)Q@*T>A]W+5NW=K=?OOM69N1B%$V=6W0H$&)?L5@MF[=
MNEA-.0Z,1S3HKEV[EM DV=B6-0;HBYF F&6,A^,)QIG;V$2U7;MVIMMG L8K
M)LWHN@$T48QF;,9:+.8VVIVZ8G;$].C_3E8\=.)\C1G,;8Q_SA/60^8V01 $
M01 \9&X3A-1@_25S *SI3K7F4^8V01 $01"*!H4VMR'^("I@4@K+X1D(,27=
M<Q 3Y-NV;;,%@#5JU"@UF3QJU"@33,+?,6%/)BHFO9/ )#:F&[)E^>/8'?'<
M<\^U7?HR,>^D0RX3RTS6\C+&[HKAL=V[=S<#6KK,61B6F,3'-.1-.J&YJ+J9
MVP 9L?KW[V\BG!=X:!L,C8AK%6DH^OSSS]WX\>/-;.?KC5C4H4,',^&1F2\3
M[-JURSZ/(!>V <;-!0L6I+TFQ!ZNG1@-=T5,8LV:-:ULQG2Z!;B(7"Q<9 %C
M5(AA["..%)NYC?O>BA4K;*=%;SSDGH/(B;B&6)>/A<>,L7GSYI5:N,EYB7?&
MKR (@B (@E U(7.;4-4A<UO^('.;( B"4,SXYIMO3$/"6$%&I#@RU^J-*8)0
M".1B;O,;^+$I76B\04O!B,$BRTP-,U%@#$$K8_Q@%O&F, QA+-9$A\TD ];Z
M]>O=O??>:V6$U]>[=V\S;:$1H2.1?2VJ ;$!(SI%$J@?U\=8]MFYPN,KVMS&
MLW%4#^::.,<''WR0]ASSY\^W]V]O^O)M3?MA$LL'*MK<A@;_Z*./6CN$;8_^
MZ4G\8PKDGAW59]%F.=YO"AHEQ[,N "V>]SQO:$);)+[(,N@_B\Y(/*73KZ,@
M1GGO"S-W<2UD;Z-NF6Z2BSY(')QSSCDEK@'SUHP9,^Q:4X%,9<3[55==9>T1
M&N1@G+F->I+9\99;;C%=/YT1CSAC?09&P+ <,B^B]:)M%XNYC<U O8$QS )(
MK*'I,A[3:;*9@+A$)X[V&_^G3?B[( B"( C5&S*W"4(R>#<CLSR;YK#N.=6:
M3YG;!$$0!$$H&A3:W,9#%).?47,;IC(F\U.50QV8M,3TA. 0=QT853"RA;]C
MIS3$%LQ,26#2ET55F,5"089%0^PLAQ##1'8F8#*?27UV%V,'1([C=[F:V]B1
MC%T#PV,1S%C(%&?V\F#"F<G^)YYXPDQ"T3:KKN8V)OX1PJ+9\-C]#V& OO.[
M#J8#L>F-E]0]VQWJZ%_,6\1U&'^\;"!<(/IGDG4MR=R&2?/AAQ].609QPOA[
MY)%'2L59$FDW#)>(@,1)TG73CCMW[K1Q&!HT$0L10:@SXZ,8S6T;-VXT(8W=
M6,,X.?OLL]W,F3.M#MG$B1?$,"SZ]B)FN+ZH>97K0,3-5_9(01 $01 $H?@@
M<YM0U2%S6_X@<YM02#!_1W8)YG69(XXC<RC,+^4K<X,@""7!^"KF<<A<*_/M
MS&DGS2=C&F&N4_<)H5#(Q=P&T#GFS)GCNG7K9MJCUPS8'._BBR^V161H?6@!
MF<8YS\OH(SSK#1\^W'37J'$,@PT:85*Y_([W2'2&W_SF-[8QH==PJ"=Z'/<'
MSH5&@>[ >4(#%#K+E"E3[#L_>@[^CTEIT:)%I38P]*QH<QOW0O3;\.^8[M!\
MTBW0 ]PST:RBQJ4^??K8^PN;#G(_S01\CGL;FB=ZGV^_BC:W 6( \V7<0D;Z
M@WXG0V!<ED%B"),:!JWP_<V3N$0_)$Y"H-FRSJ!3IT[[XV[0H$&6Z2M3;=V#
M_F5Q\H ! ZR^OF^(:71LM&-B,5V6Q"1S&W&.B325]DW9:'C$ ?IJ7+S'F=M\
M&Z$QHF6GTB@Q\:%CHH?6K5NWQ)H&3(+$$ID4B\G<1IM@C,5X&-ZCT-FG3IUJ
M,9W-6@KZFC+9 -:;);D.-ATFXUY8#[1[M.ATID1!$ 1!$*H^9&X3A-+@69IG
M=MZ!)DZ<:/,>T0TZHI2Y31 $01"$HD&AS6U,:C*!&A4_$'XP+KWSSCN)@@^3
MZ@@B3/1&C5*>7-^T:=-*_(X'-G92Q$"3!"9-F1#E^D)!BLE_Q%@64*4R[X3@
M81%CV]RY<RT;%Y.R_"Z7B65$%*X]S.P%V:F.B>W0*!,%AB8$)\[C!:V0U=7<
M1IL2MXB0B&K^\PA9;=NVM6/HQTQ ;&)L0[Q#5&!"/IVP$H(VP+A)_"&^^?@C
M=FO5JI4V\Z '@@[MTZA1HQ)M@-GMNNNNLQA,%2<(-6W:M+&LB*E><*+Q<_[Y
MYYO@E23TT8Y+EBPQ82L4CFO7KFW'(GC07L5H;J-=J!\[)89QP@0)U\-]!4$[
M$R!6<3] Y)DU:];^.*%?Z+?H^$8TXW.IS*N"( B"( A"Y8;,;4)5A\QM^8/,
M;4(A@:%FV;)EKE^_?C:/&\>! P?:7$RZ+!6"()0-C"_&8?_^_8MR',K<)E0&
MY&IN8VRQR2#:7[UZ]?:;M_B)MH.VP4:3V1BC* _C&F:N$TXXH80AS)-- L>.
M'9M8+O7"[$+&*+0+7P;7RH(U="MO'H'H)QA20O,8_^8>@CDKNJ$?.@9ZS.#!
M@UW#A@UCQW=%F]O0BZ)Z,"8R^O+EEU].>PYTEX4+%YIV&;ZKH%M=?OGEI@ME
MFG6,^R[Z-H8GM#+?UH4PMQ%+YYUWGNGWT3ZB'NAI;'(9!^J\<N5*^TQ<]C;Z
M$TV/& ^!!GCUU5?O?U?!^,080?O*1BOU=>"X>^ZYQQUVV&$EQABQC0%T]>K5
M:>=-T./(C!8U23%N,8_1_DG?11Q+.S _@YDL+MZ3S&U>7\>0B@:==/W\C?=;
MXBV,/[Y#,5VRGH(Z%).YC3JAA?,<$MY'R=[&-<^>/=O^G@D8(ZQM(!8G3YYL
M]T'.@2:+$?>""RXHI1.CK6::N4\0!$$0A*H+F=L$H33\ABL\,^-#BVZ8$T>9
MVP1!$ 1!*!H4VMQ&.4PX#QTZU$PQOAQO(D.<89*5R4\F,)E 9D*6G078#1'A
MA!WG>,"J7[]^*9'G@0<>L$EU1*1PPAO3"!/IZ]>OM_*BP@P3V$S*<@XFNOV.
M=CSL879C1[#1HT?;KHOOO_^^3=3S><JACDRZ(LB\\LHK)J[03AA3*.NCCSXR
M82F7B66.QPB&$2L4%!!V6K=N;0^G9/>B#.I%G?@W A(+G7KUZF4F*=J.'??"
M\U=7<QL/]@A3[-"'H2L49V@3^NG..^^TOF$B'4$/T8SZ$IO4D5B@;";\$<RH
M+V(&?9"-8..S_6&(Y+S$''7!Y$9]Z&,$&_[.3H><FS[F&%Y.$!41.<C.AI&3
MO@[;P!OV$/KXG(\3A%#$ \J</GVZ[2S*F$9 31)LHD3 8.$$YV7'/D0.^H=Q
M3I_0_XP)^B4:>^W:M;-[#W5(UX>%,K<1)_0].X#2#_XSB$V(3CUZ]##AA;'/
M?9!Q[N.$OJ'.")C$,^.4W29//_UT-VK4J/UQPD]V&>4^$PI"] .+QEBT0I_[
M+)""( B"( A"U8',;4)5A\QM^8/,;4(AP5P/"\69FTN:(R)3#)_+-,-]L8*Y
M'.9YF,]DH7:4;"!%)@U!B .+KM$06/0>C1WFC4>,&&'SI66!'X?1!=\A+[SP
MPH*-0YG;A,J 7,UM?C=TO@<8UV@QX7,NQIDN7;J8.06M$CT&@PT:@]=T,(RC
MNZ'+H/E@2$-G0/-$F\0$AO809M["Y(..Q4:(G!L-U6L\E,7O."?:0YCMBG*&
M#!GBEB]?7N(Z>*[$H()F&#ZCH[6@=[# S6L=Z#>4?]MMM[GFS9M;/1GGT7:L
M:',;.EU4#Z8O6K9L:77E/*GNAV@XM .Z<_B,33W96!1MAF=M-$DV+41/Y-R4
MA_:T9<L6T\W))L7Y,$PU;=K4S9@QPSY7*',;)CMB,^Y>3'OR'H:NF01T3S1E
M8CEZ/.U[Y957VG.2!^.!MF N@X7%M!_'HCEZDU^VH&_8,),L>L2P/S^:?>/&
MC2UVT4/1 >D;8H$V]]HX;8!>R7=NU(Q)O+ A*&L&T"-Y[F,<>:V?F,"DA=&3
MZR#>^1E=')K*W,9X17=$?\3L2!TIG_.@]:'G$P-D0 LWU83$$>_/M"L9S(K)
MW.;U3,9AY\Z=][<)XX_[%5GRN)^QX2[QS::N?BT%U\[:"M9[L&DHZSFX-MJ
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MW7??V34^_OCC;M*D2?OY[+//VG?>#S_\4.@JY@TRMPF"('.;4-6Q?OUZFWO
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MIS"V&3.9@'*)E2^__-+*I7U]N=2)G[0IL<HY*9\Q1IL0(W%C"N-DGSY]S/Q
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M)=RFE%)**=6:^@)N(V&<!#- *( &H#*2I0$'2,ZFXM$::ZP1VC5DR)!.F !
MBF1RDJG/...,D'3=#-Q&>T@\)UF>2EA?^<I7 B0 U $D "1$(GB\/]>C323I
M _E$^ *(A>3O*. Q7I>3^)VVAT0Z'DN"/7 $ !T)X223TZ]X#_K&]P%< +^
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MWG@\4!AP2K["8!'<1F+UQ1=?'!)-J=Q4#_ C[N?/GU\3;N/[7"NM4D9[ #L
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M2'"GO?25Y'K&%.B#*F/\"Z0&/),")K0+, ;(AXI%J:BVPWU(X$\3XVD;R>V
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MY)%'PCS6$G$+W ,XE,(L[''$".LVK<J7%[$!F,3<IFN0JE+<'Z"(N69,B%M
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M"V7WHWIB+SKYY),K]IG--]\\5+FBHEXS<!MSROHA1IG#.): D<0&U2:+P"*
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M( [W!EH!OJ)MM2JWT7;B'A@'0(B*7SR?JF)E1?RR5H#HXG79UP!XB7% OU2
MNHS_N''C*MK%7!!C_*Q548F2JEL =O'ZQ"[0%_/4#-R&8K4_*N'%_8:QX[P
M8@2RRI]5[$$ ?#PN!;&///+([-9;;PU5S X\\, **)!]!R Y/V;U!%3)VH]
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MSZQMJB$R)Q%$Y;&,,Y7=B&/ *N(M D7$"%7'6&_$,^!0.E;L17?<<4?8OZ(
M8H#IMMYZZ[#W8*JH+5RXL'1?B!_N^<,?_C! 6K&B)7,!B,7><MUUUX6]EGLS
MGX!+[%V N/R<>\8]G+:RGHF+HHID1>)WZN]\YSL5\\O] =Z(P2CV3B E]J+T
M=W#BA,I=0$QOOOEFQ?CP_^>>>RZ<,^Q7P%^ 1@!<Q$:M_3]O[K'CCCN&==<5
MN(T*>T"'P()I/[D6L< <I/V<-FU:N%]\'&T$E 0<8#\&N$ZKW<7'M+JF^#GG
M(A7'2-!^XHDGPCG 6@>D3F&ZU.QY0) 3)DP(<<'YR'[/7AMC@/G@O1+V)JX#
M]+#__OLWM=^RMK@V>R*05:WYX_N<,U2W WYFO0)?\?RX;]:"VXA?@#2@J;("
M. 1^)*;B=5CSC$<9N(TV$:> ;.GCA@T;%O:O/.193ZQ3 /X(SQ:9-0M87+9*
M*>*U3_ZZ[!&\EF)/:Q5N(UZ \:GN2HPPAT5[/GL4,.O!!Q\< %@ 1LY2QI+S
MRJIN2O6=A-O48)9PF]9::ZT'I(7;M-9::ZVUUEKK]K!PF];%%FZKEG";4DHI
MI51KZFVXC>1GDJ!)MB3I'4 @5JW)@P( ;B1JDV 6*X=P/V >$M.[ K>1],;S
MJ9I#,AO7!8SZ\(<_')*V&0L @T9@6PJ^ %<!2^7A-N :DNX;P6T <">==%(5
MW$;_ %FHZL3/TY^1X$X%%>:@K*@$1 4X^IPFJI>!VV@'(%D>+-E[[[T#F$-5
MN+*B2A#0!DGYZ;4 9 !Y&K4E%7,];MRX  O$ZP"A %SU)=P&H$+5)N:ND6ZZ
MZ::JBGA ,4 9W*,5N(VQILH4\%Q1[)9QO?@''J/J("J"VTBL!K@@=KI+] FH
M$[ R;=_..^\<0!1BD>I@@+$1%@-\82VR]P!! ;\!1?$SQAV0B_$FSJG>E*X1
M]@2N#2"25F$$8J$2%OL?^Q6P#_=LIDH=\-?==]\=JCP2EQ$4(IXG39J4W7//
M/:$_P%?L(\0;D!+_Y_O\/DQ\4T$QMI<]DS6]=.G2[/777V_8!L8$*)"QBC'(
MO\!![+=1W)\UP[73/9O^4^4,.(BV145XB2ISP$6 9:Q-GLMZBM7IRNRU/(8^
M4MUNU*A1%3\K [<1,\"+]"FM8 B != 4QXGV X2QUE)0BJ]WV667,+?<!ZAQ
M^/#AW;ZF& _.(N*8N:8M@*'L)8#%:77/U,0H:Y%J89P-C%&LF A01K^8#R#&
M"&X#*-'W9L!D8H"Q8OT0GP"B5&>L=7[3%_8IUA- &7L!^Q'S40MN U(%).6\
M*BM@0^(RK<Q'_TXXX812<!O)[0"05%-+'T=\<,XVLW\QWB364Y&OUCQ3N9;7
M*@!I914KRP'AIW')> $HM@JWL;<1VU1D _C?88<=PFNJHKGE^ZQEUC3]9/T3
MH^P!:85=I53O2KA-#68)MVFMM=9Z0%JX36NMM=9::ZVU;@\+MVE=;.&V:@FW
M*:644DJUIMZ&VQ#)9R2 DV1VS3779&>>>68 (( 42)0F01WP(0\!<)\]]]PS
M5++A-5\>I&D$MY%T#9QQT447A41X$N_+5 UJ9*H177KII57@ 8ET)-V7@=NH
M\E8$MP$2 (+EP282]ZD,QL_*"EB A+\T.;XLW$8[>.W-8_-@"6!,,W ;0 ^)
M^(! Z;6 E:@Z1&6DLJ+_  Q4V(G785Z)W[Z&VXA10(Y&ZDFXC;$&S"A*W.P.
M RH!%Z(BN(VY8&TT$Z>-!*A#!3'ZE$)65 ,#M".6&7M@*/8V()LQ8\:$N&(L
M8^5  )=826N//?8(< ; VM%''UT!R;#O  <^]=13%>U@_YL^?7HGW,/OI0"[
MS51Y8MT '*55PA@S*DD"4*65XHI$?ZBVQ!J(>R;]82^A;51X*S.>7(,V1*"+
MZ] .*D6Q5[.'44EKT:)%88].]TT Y7///3=4ED(18&9?H+(<P%5^_73%[%L=
M'1V%>U CN(UUREJDVA008GPN<\<^Q-R2$,T^!PA$;*7K$1B)]<>^Q9P '>8K
M!W:'&5?F@*I>4:QA(-D?__C' 7ICKJFX!G#)'D",Y\\Q^O6)3WPB&S]^?  P
MF3OV$"J$QL=0Z0W(NQF(#'%^,]? HE3# [CZTI>^%.:!.8J5X?+G-VN*=<;C
M <N8CP4+%E3!;4!\2Y8L:1C[J7B]$2N.Q>NP'H%&R\!MS#UCS#F</HYKL'\U
M Y$S-KQ&28'3O+L"S1&;["_I=0$: <XY UJ%VQ![ >-.K+"'<G8"K@&Q4Z&2
M:Q=5#V1- 52R#U#!$7A1*=7[$FY3@UG";5IKK;4>D!9NTUIKK;766FNMV\/"
M;5H76[BM6L)M2BFEE%*MJ2_@ME0D4P-XD$P-Z$9E,9+,2)(GL8S$3-H7$^5)
MK";Y_]ACC\V..>:8BOLV@MNH*@)(1))V"EL $@$# *<!R)!X#CP&',!CH_D9
M[<DG=_<TW$;2?0HE8-K'/>M5J<NKE<IMM -0)E\UJ2N5VX UB)U\-3&J:P%K
M-0.WT7\ AIZJW$8%,"H&#C2X#> +((%83V.\60/8$*>H%MQVQ157E*I@UXP
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MG'!"MF3)D@KX)A7? Z)AGJF\E$]\;P9NXUKWWW]_ +E(UH^)^ER#:\^=.S=
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MYIIK @S%&!#_Q!'C#LQ&/P!B "P98Q)!F6_63008^@)NHTW$8A[HB'- !31
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M'N@AA4Z:A=L0H 9Q Q24C@5SPWV %:BJ!M0T=^[< !<PIT \9Y]]=C9V[-@
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M'*LEUC?[&K!C"@-R7FV\\<9AKP/TX3K,6SS?.CHZPOG"..^YYYYA;(@G]D5
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M4_V3?:9,_- 6'LMYLF+%BLZX[ K<QG/?>NNML/^SKW.N%[U&RL\A,4-E5]I
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M^W!]P ZJP-!FVAXKK9#LS_6 &XXXXHALYLR9X;7SF6>>65'5I:MP6Q10#O
MXPET!1#$^,3VI',)H$%5&Y+Z&3,JO# ^] ]H#SCJW'//#> !$ 3@5?XZS#$Q
M09^I\D0%OQ_\X ?9DT\^6;>=Q")Q0=6MSW[VLR&!G^O$ZCB, W 08\,U 98
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MX(J$=A*I29BF"DA,_B?!&E@ H =@CJ1\$KM)\#[[[+,K[@M$,'WZ]) XWDC
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M2R+2>NNM%SZ(V7[[[</9PE\<)#$)Z(G7-SONN&.V[;;;9EMLL47XBX3\=4(
M.>&V_JU:<!N@&K$P<N3(;,\]]^PTKZ_XWDX[[11B@<>EU5KQJ%&C0G(6"9WY
ML[]=)=RFE%)**:64ZHJ$VU1_5AYNX_.&(4.&A/=]@+!X7X#WA'@?@-^7>>^
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M7VVB^DCZEYN* +</?O"# 0RX_?;;0_)"=U6"ZD]P&PN.#[5'C1K560T('W#
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M#W!.CHW!AXQ^7$LT3.2UY99;AB" O!F("5 F+&-FI+)E@]&,+&D8-:@31?6
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M^7Y^[[WW+C__Y^?Q3([.SS;YX)/\+D*Y341$1$1$1$1$1$1$1&0\H]RFW 8
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MEN)<RJR9Z)A]T>[Q9ULR.2V%LCS6^KHIWJ6D5Q=R\W@RU2[;UWB<K+;::J4
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MW7+++=5>>^W5=/D4=Z^]]MKR/!Q-)O;5DP8;KY_UON^^^T9\78B<>)OC)$7
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MN4VY#0"@!\IM    @TNY#;JCW"8B(B(B(B(B(B(B(B(RUE%N4VX# .B!<AL
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M+V^L^=W5_^^/?_QC]=!##S7MD]_][G<3O5D   /C][__?35Y\N26]TCS00(
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M1[D- .A[RFT   #0'Y3;H#WEME;*;0  O5%N P  &%S*;= =Y38 H.\IMP$
M $!_4&Z#]I3;6BFW 0#T1KD-  !@<"FW07>4VP" OJ?<!@   /U!N0W:4VYK
MI=P& - ;Y38  (#!I=P&W5%N P#ZGG(;    ] ?E-FA/N:V5<AL 0&^4VP
M  :7<AMT1[D- .A[RFT   #0'Y3;H#WEME;*;0  O5%N P  &%S*;= =Y38
MH.\IMP$  $!_4&Z#]I3;6BFW 0#T1KD-  !@<"FW07>4VP" OJ?<!@   /U!
MN0W:4VYKI=P& - ;Y38  (#!I=P&W5%N P#ZGG(;    ] ?E-FA/N:V5<AL
M0&^4VP    :7<AMT1[D- .A[RFT   #0'Y3;H#WEME;*;0  O5%N P  &%S*
M;= =Y38 H.\IMP$  $!_4&Z#]I3;6BFW 0#T1KD-  !@<"FW07>4VP" OJ?<
M!@   /U!N0W:4VYKI=P& - ;Y38  (#!I=P&W5%N P#ZGG(;    ] ?E-FA/
MN:V5<AL 0&^4VP    :7<AMT1[D- .A[RFT   #0'Y3;H#WEME;*;0  O5%N
M P  &%S*;= =Y38 H.\IMP$  $!_4&Z#]I3;6BFW 0#T1KD-  !@<"FW07>4
MVP" OJ?<!@   /U!N0W:4VYKI=P& - ;Y38  (#!I=P&W5%N P#ZGG(;
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MW5%N P#ZGG(;    ] ?E-FA/N:V5<AL 0&^4VP    :7<AMT1[D- .A[RFT
M  #0'Y3;H#WEME;*;0  O5%N P  &%S*;= =Y38 H.\IMP$  $!_4&Z#]I3;
M6BFW 0#T1KD-  !@<"FW07>4VP" OJ?<!@   /U!N0W:4VYKI=P& - ;Y38
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MY38 H.\IMP$  $!_4&Z#]I3;6BFW 0#T1KD-  !@<"FW07>4VP" OJ?<!@
M /U!N0W:4VYKI=P& - ;Y38  (#!I=P&W5%N P#ZGG(;    ] ?E-FA/N:V5
M<AL 0&^4VP    :7<AMT1[D- .A[RFT   #0'Y3;H#WEME;*;0  O5%N P
M&%S*;= =Y38 H.\IMP$  $!_4&Z#]I3;6BFW 0#T1KD-  !@<"FW07>4VP"
MOJ?<!@   /U!N0W:4VYKI=P& - ;Y38  (#!I=P&W5%N P#ZGG(;    ] ?E
M-FA/N:V5<AL 0&^4VP    :7<AMT1[D- .A[RFT   #0'Y3;H#WEME;*;0
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MGCRY>OSQQR=\NT3Z-7G/.>\]]U1NRTGF;[SQQJ@7!@"852^^^&(ITR?Y,P
M # QGGGFF:8W$_(FW%_^\I>)WBR8<*^__GI+^?/-_GNL/_[QC]5##SW4M$]^
M][O?3?1F 0 ,C-___O?EY,?A)W7E9"\   #ZV\LOO]STLUP^#.ZUUUZ;Z,V"
MOI7WG//>LW(; -"W\GW&'_[PAQ+?<P   ,#$46Z#]I3;6BFW 0#T1KD-  !@
M<"FW07>4VP      @(XHMT%[RFVME-L  'JCW 8  #"XE-N@.\IM      !
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MYO4]?\[K?:.\2?*;W_RFY5B>,F7*!&TY    T"^4VZ ]Y;96RFT  +U1;@,
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M2^2V$,9CI9#;1+42@<2F?M&J9&@N,""0*X@K=>'1AG?_?OSQQ\NBVG18'"7
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M[+#L]Q9;B0#.ZWJD+><F=1#L1"@BT+1O,G4M(IFWD;I?4DZ-ZJ3<JLPW2MZ
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G$$(((8000@@AA!!"""&$>>?_ <WNYMX76:'D     $E%3D2N0F""

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>lgnd-20211231_g1.jpg
<TEXT>
begin 644 lgnd-20211231_g1.jpg
M_]C_X  02D9)1@ ! 0$ D "0  #_X1#R17AI9@  34T *@    @ ! $[  (
M   -   (2H=I  0    !   (6)R=  $    :   0T.H<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 $)O8F)Y+E9I
M9V%R<P    60 P "    %   $*:0!  "    %   $+J2D0 "     S$S  "2
MD@ "     S$S  #J'  '   (#   ")H     '.H    (
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "O#/BA_R/ES_P!<H_\ T$5[G7AGQ0_Y'RY_ZY1_^@B@#D*FL_\
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M0#+P/\LB?4?U&10!L5X9\4/^1\N?^N4?_H(KW.O#/BA_R/ES_P!<H_\ T$4
M<A4UG_Q_V_\ UU7^=0U-9_\ '_;_ /75?YTQGTY1112$%%%% !1110 4444
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M0!\P45[KJ?PS\.:BQ=+:2R<]6M7VC_ODY'Y"L"?X-6[-_HVLRQCTDMP_\F%
M'E-%>I)\&5##?KI*]P+3!_\ 0ZT[/X1:)"P:[N;NY(_AW!%/Y#/ZT >-HC2.
M$12S,<  9)KO/"_PPO\ 4W2YUP/8VG7RB,2R#Z?P_CS[5ZEI7AO1]$_Y!FGP
MP/C'F;=SG_@1R?UK3H$06-C;:;91VEC"L$$8PJ(.!4]%%( J.XN(K2UEN+AP
MD4*%W8]%4#)-25R/Q-OVL?!%PJ-M:ZD2 $>AY(_)2* /'_$6N3^(=<GU"XR
MYQ$A/^K0?=7_ #W)K+HHIC);:VFO+J.WM8FEFE8*B(,EC7KOACX6V%C$EQKX
M%Y=$9\G/[N/V_P!H_I[5F?"#18Y&O-9F4,T;?9X2?X3C+'ZX*C\Z]3H C@@A
MMH5BMHDBC7[J1J% _ 5)112$%%%% '.^/O\ D0]4_P"N0_\ 0A7S_7T!X^_Y
M$/5/^N0_]"%?/],85Z[\'?\ D"ZC_P!?"_\ H->15Z[\'?\ D"ZC_P!?"_\
MH- 'HM4=;_Y%_4/^O63_ -!-7JHZW_R+^H?]>LG_ *":0CYKHHHIC/0_@[_R
M,%__ ->O_LPKU^O(/@[_ ,C!?_\ 7K_[,*]?I""BBB@ HHHH *XGXL?\B6/^
MOI/Y-7;5Q/Q8_P"1+'_7TG\FH \3HHHIC/;/A/\ \B6?^OI_Y+7;5Q/PG_Y$
ML_\ 7T_\EKMJ0CE_B/"9O .H[>J>6_Y2+G],UX+7T=XFM3>^%=3MT&6>UDVC
MU.TD?K7SC3&%>E_!N?;?ZK!GEXHWQ_NEA_[-7FE=A\+[X6?CB%&.!=1/#GWQ
MN'ZJ!^- 'N5%%%(04444 %%%% !7AGQ0_P"1\N?^N4?_ *"*]SKPOXGD'QY=
M8(.(XP?;Y!0!R-36?_'_ &__ %U7^=0U-9_\?]O_ -=5_G3&?3E%%%(04444
M %%%% !1110 4444 %%%% !1110!X+\2?^2A:E_VR_\ 125R]=1\2?\ DH6I
M?]LO_125R],85]/6_P#QZQ?[@_E7S#7T];_\>L7^X/Y4 24444A!1110 444
M4 %%%% !7S[XZ_Y'G5?^NW]!7T%7S[XZ_P"1YU7_ *[?T% '/UJ>&/\ D;M'
M_P"OZ#_T8*RZU/#'_(W:/_U_0?\ HP4QGT=1112$>!?$1BWC_4RW)W(/RC6N
M:KO/BSI#VGB5-25?W-[& 6]'48(_+;^M<'3&=E\+]8@TOQ9Y=VZI'>1&%7;@
M!\@K^>,?4BO<*^7:ZO1?B/K^C0K!YT=Y O"I<J6*CT# @_GF@#W>BO*XOC-(
M$_?:(CMZI=%1^6TU:3XR6A(WZ/,!WQ,#C]*0CTJBO/$^,6E'/F:=>+Z;2I_J
M*E7XP:$5^>RU$'T$:'_V>@#OJ*XI/BMX;8X8W:<=6A_P-:=GX^\,WIQ'JT,9
M])@T?ZL * .BHID,\5Q$);>5)8VZ.C!@?Q%/H *\^^,)_P"*9LO^OP?^@-7H
M-<3\5[0W'@OS@/\ CVN$D)]CE?YL* /$Z***8SV[X4E/^$)79U^T2;_KQ_3%
M=I7E7PAUN.*6[T:9PK3'SX ?XB!AA]< '\#7JM(04444 %%%9VN:[8^'M.:\
MU*4(HX1!]Z1O[JCN: ,KXB7$,'@74%FD5#*JI&">6;<#@?@#^5>!UN>*?%-Y
MXHU+S[G]W F1#;@Y6,?U/J:PZ8PKUWX._P#(%U'_ *^%_P#0:\BKUWX._P#(
M%U'_ *^%_P#0: /1:HZW_P B_J'_ %ZR?^@FKU4=;_Y%_4/^O63_ -!-(1\U
MT444QGH?P=_Y&"__ .O7_P!F%>OUY!\'?^1@O_\ KU_]F%>OTA!1110 4444
M %<3\6/^1+'_ %])_)J[:N)^+'_(EC_KZ3^34 >)T444QGMGPG_Y$L_]?3_R
M6NVKB?A/_P B6?\ KZ?^2UVU(0$ @@C(/4&OFO6M/;2M<O;%@1]GF9!GNH/!
M_$8-?2E>/_%O13:ZW!JL2_N[Q-DA Z2*,?JN/R- 'GM3V-Y+I^H6]Y;G$MO(
MLB?4'-044QGTSIU_#JFF6]];',5Q&)%]LCI]1TJS7D7PR\8QZ=)_8NIR!+>5
MLV\C'B-SU4^Q_G]:]=I""BBB@ HHKE/&/CJS\,P-! 5N=28?)"#D1^[^GTZG
M]: )/&OC"'POIVV/;)J$P/D1'G;_ +;>P_7\Z\(N+B6[N9+BYD:6:5B[NQR6
M)ZFI=1U&ZU6_EO+^9IIY3EF/\AZ#VJM3&%36?_'_ &__ %U7^=0U-9_\?]O_
M -=5_G0!].4444A!1110 4444 %%%% !1110 4444 %%%% '@OQ)_P"2A:E_
MVR_]%)7+UU/Q*4CX@ZB2" 1$1QU_=)7+4QA77+\3O$Z(%6[APHP/W"_X5R-%
M '7_ /"T/%'_ #]P_P#?A?\ "C_A:'BC_G[A_P"_"_X5R%% '7_\+0\4?\_<
M/_?A?\*/^%H>*/\ G[A_[\+_ (5R%% '7_\ "T/%'_/W#_WX7_"C_A:'BC_G
M[A_[\+_A7(44 >@Z#\4M8_MBWBU8PSVLL@1\1A60'C((].M>PU\O#)8;<YSQ
MBOJ&D(*^??'7_(\ZK_UV_H*^@J^??'7_ "/.J_\ 7;^@H Y^M3PQ_P C=H__
M %_0?^C!676IX8_Y&[1_^OZ#_P!&"F,^CJ***0C.UW0[/Q#I,EA?KE&Y5Q]Z
M-NS#WKPOQ)X1U3PS<E;R(R6Q.([F,91OKZ'V/ZU[WJ6I6NDZ?+>ZA,L,$0RS
M'^0]2?2O"_%WC.]\47A!+06$;9AMP?\ QYO4_P NWNP.;HHJ_H^BWVO:@EGI
ML)ED;DGHJ#U8]A0,H45W)^$GB$,0)K ^XE;_ .)J(_"GQ("?EM3[^=_]:@#B
MZ*ZX_##Q0!_QZ1'V\]/\:A/PW\5@$G2CQZ7$1_\ 9J .7HK:O/!_B&P4M<Z1
M=!1U9$W@?4KFL4@@D$8(ZB@"YIVK7^DS^=IMY-;/W\ML _4=#^->E^%?BJEP
MZ6?B0+$YX6[084G_ &AV^HX]A7E%% 'U"K!E#*001D$=ZJZMIT>K:1=6$W"7
M$3(3_=R.#^!YKS;X7>+Y!.N@:C*61@?LCL?ND<E/ICD?EZ5ZI2$?,E]9SZ=?
MSV=TFR:!RCCW!_E4%>R?$7P.VM1_VKI,>;Z-<2Q#_ELHZ8_VA^H^@KQQE9&*
MNI5E."",$&F,?;W$MI<QW%M(T4T3!T=3@J1T->K^'/BO:3PI!XC4V\X&/M,:
M[D?W('(/TR/I7DE% 'T=;^)M#NEW0:O9/[>>H(_ G-%QXGT.T7,^KV2\9QYZ
MDG\ <U\XT4 >P:Y\6M.MHVCT*%KV;M+(I2,?@?F/TX^M>6ZMK-_KE\UWJ=PT
M\IX&>BCT Z 51I41I'5(U+,QPJJ,DGTH 2@@JQ##!'!![5ZGX)^&AC>/4O$D
M?S [HK-N<>A?_P")_/TK@/$__(W:Q_U_3_\ HPT 9=>N_!W_ ) NH_\ 7PO_
M *#7D5>N_!W_ ) NH_\ 7PO_ *#0!Z+5'6_^1?U#_KUD_P#035ZJ.M_\B_J'
M_7K)_P"@FD(^:Z***8ST/X._\C!?_P#7K_[,*]?KR#X._P#(P7__ %Z_^S"O
M7Z0@HHHH **** "N)^+'_(EC_KZ3^35VU<3\6/\ D2Q_U])_)J /$Z***8SV
MSX3_ /(EG_KZ?^2UVU<3\)_^1+/_ %]/_):[:D(*R?$VA1>(M N-/EPKL-T3
MG^!QT/\ 3Z$UK44 ?,=W:3V-Y+:W<;130L4=&Z@BH:]L\>^!4\0PF_TT!-2C
M7!'03@=C[^A_ ^WB\\$MM.\-Q&T4L9VNCC!4^A%,9'7;>&?B;J6BPK:ZA'_:
M%JO"[FQ(@] W<>Q_.N)HH ]NM?BKX;GC!F>YMF[K)"3C_OG-+<_%3PU!&3%)
M<W)[+'"1_P"A8KQ"B@#O]?\ BOJ5^C0:-"-/B/!E)W2D>QZ+^I]ZX)Y'ED:2
M5F=V.69CDD^I--I\,,MQ,D-O&TLKG"HBY+'T H 96Y?^%;S2_"]OJ]^/)-U,
M$BA(^;;M)W'TZ<"N^\%?#1;)H]2\1(LDXPT5KU6,^K>I]N@]^T_QA_Y%JR_Z
M^Q_Z U 'CU36?_'_ &__ %U7^=0U-9_\?]O_ -=5_G0!].4444A!1110 444
M4 %%%% !1110 4444 %%%% '%^./ (\3R)>V,RP7T:;") =DBCIG'0\]>:X7
M_A5/B3^[:_\ ?[_ZU>W44 >(_P#"JO$G]RU_[_?_ %J/^%5>)/[EK_W^_P#K
M5[=10!XC_P *J\2?W+7_ +_?_6H_X55XD_N6O_?[_P"M7MU% 'B/_"JO$G]R
MU_[_ '_UJ/\ A57B3^Y:_P#?[_ZU>W44 >(_\*J\2?W+7_O]_P#6H_X55XD_
MN6O_ '^_^M7MU% 'D.A?"O5H]:MI=6:W2UBD#N$DW,^#G:!CO7KU%% !7E'C
M?X>ZS?>(;G4M)C2ZBN"',8D"NAP ?O8!Z=C7J]% '@'_  @'BC?M_LB7/^^F
M/SS6_P"$OAQK<6OV=]JD*V<%K,LV&D5F<J<@ *3W'>O8** "BBL7QAJ;:1X1
MU&[C;;(L6R,CJ&8[0?P)S0!Y/\1/%3Z]K;6EN_\ H%FY6, \2/T+_P!![?6N
M/HHIC+ND:5<ZWJL%A8KNEF; )Z*.Y/L!7O\ X<\.67AK2TM+)07(S+,1AI6]
M3_0=JXWX0:0D>FW>K2)^]FD\F,GLB@$X^I/_ ([7I%(04444 %%%% !6#XA\
M':1XCA;[7;K'<X^6YB&'!]_[P]C6]10!\VZYHUSH&L3:?>@>9$>&'1U/1A]:
MSZ]+^,EO&M]I5P /,DCD1CWPI4C_ -"->:4QDMK<R6=Y#=0';+#(LB'T(.17
MTO9W*7MC!=1<I/&LB_1AD?SKYCKZ*\)$GP;I&3G_ $./_P!!% &Q7,^)? >D
M^)"TTBFUO"/^/B$<M_O#HW\_>NFHI"/#]5^%_B#3V)M8X[^+LT+8;'NIQ^F:
MYJYT;4[-BMWIUU"1U\R%A_2OI6B@#Y=JY:Z/J=\0+/3[J?/3RX6;^0KZ6HIC
M/$](^%>NW[*U_P"7IT)ZF0[GQ[*/ZD5Z7X=\%:/X; DM(3-=8P;F;EOP[+^%
M=#12$%>-^*OAWKTGB&]O-/MUNX+J=YE*2*"NXYP02/7M7LE% '@"?#[Q0[$#
M2) 0<<R(/YFO4_A]X9N_#.C3QZBT?GW$OF%(SD(,  $^O6NLHH *AN[<7=E/
M;,<+-&T9([ C%344 >%7OPS\36MPR0V:W48/RR12K@_@2"*JI\/_ !0YPND2
MCG'S.@_F:]_HH X/X=>#+_PY)<WFJ^6DTZ"-84;<5&<DDCCTZ5WE%% !1110
M 4444 %8/C/0)?$GAN2QMI%CF#K)&7^Z2.Q_,UO44 >!S?#OQ3"S Z6S@=TE
M1@?UHA^'?BF9E TMD![O*B@?K7OE% &!X,\/R^&_#<=C<R+),7:20I]T$]A^
M0K?HHH **** "L'Q'X-TKQ-'F]B,=R!A;F+AQ['U'L?TK>HH \3U?X6:[8,S
M6 CU&$=#&=KX]U/]":Y:YT75+)BMWIUU"0<?/"P_I7TK10!\NU=M=&U.^(%G
MIUU/GH8X68?F!7TK13&>*Z/\*M;OF#:D8].A[[R'<_11Q^9%>F^'?"&D^&H_
M]!AWW!&&N9>7;\>P]A6[12$%<OX^\-77B;08[>P=%GAF$JK(<!^"",]CS744
M4 > R?#[Q3$V&TF0\X^61&_D:T=$^&GB"?5(&OK5;.W216=Y)%)P#DX ).:]
MMHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH *XWXJ,P\#R!1D-/&&YZ#/^.*[*N=\>:<VI^"
M=0BC&9(T$R@#/W"&/Z T ?/]%%%,9[A\+)HY? \21XW13R*_USG^1%=E7@_@
M7QBWA;472X5I+"X(\U5ZH1T8?U'?\*]NT_4[+5K1;G3KF.XA;^)&SCV(['V-
M(1:HHHH **** "BC..M<+XP^)%GI,$EGHLJ75^1M\Q?FCA]R>A/M^?I0!R'Q
M6U5+[Q2EG"VY+&+8V/[[<G]-H_"N&ITDCS2O+*[/([%F9CDL3U)--IC%1&DD
M5$!9F(  [FOIC3;3[!I-I9CI;P)%_P!\J!_2O%OAMX?;6?$T=U*F;6P(E<D<
M%_X5_/G\*]RI""BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** (+NQM+^'RKZUAN8_P"[+&&'ZUS5[\-/#-X2RV;V
MS'O!*1^AR/TKK** /.YO@[I;9^SZE=Q^GF!6_D!51_@RI8^7KI5>P:TR?SWB
MO3Z* /+O^%,>NO?^2?\ ]G5N'X.:<I_?ZI=./]A%7^>:]&HH X^S^%_AFTP9
M+>:[([SS'^2X%=-8Z98Z9%Y>G6<%LG<11A<_7'6K5% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
$4 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>lgnd-20211231_g2.jpg
<TEXT>
begin 644 lgnd-20211231_g2.jpg
M_]C_X  02D9)1@ ! 0$ D "0  #_X0 Z17AI9@  34T *@    @  U$0  $
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M>/6XT.U8?^0[IJ]<^#W_  <)?LF_&&1(5^)T?AF\<X\CQ!IMSIX7W,S(8?\
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MGSX)>,/'FM07UUH_@K1;S7;Z&R17N98+:%YI%B5V52Y5" &903C) YK\X_\
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M7K&&]14N8H+J!)XUE5690X60!@K, 0<$CFNHKB::=F>C&2:N@HKY#_X*,_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "OYD/^#EC_ )2Y^._^P9I'_I!#7]-]
M?S(?\'+'_*7/QW_V#-(_]((:]S(/]Y?H_P T?.\3_P"Z+_$OR9\%445]C?\
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M^]/T1];PW_N2]6<#^U7_ ,FO?$C_ +%;4_\ TDEK^-FO[)OVJ_\ DU[XD?\
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MC5K[V6Q^9QW1_:1114.HZC;Z1I\]W=SPVMK:QM---,X2.%%&69F/ 4 $DG@
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MZOZ#*_GS_P"#N'_D^SX>?]B'#_Z<+ZO7R/\ WI>C/"XB_P!R?JC\IZZ[P?\
M!/7O'?PJ\7^+]+M6O-+\#O9'5Q&"7M8;IY(DG/\ TS$J1QD_WIX_4D<C7ZI?
M\&KWP^T7XP?&_P"-_@_Q+86^K>'?$G@7[%J-C.NZ.YA>ZC1@?P8X(Y!.1@XK
MZW%5_8TG4[?YGPV!P_MZ\:/>_P"1^5M?:G_!#G_@II<?\$Y_VL[4ZU=S_P#"
MM/'#1:9XF@W?N[3YL0WX']Z!F8MCDQO* "=N/,?^"GG[ FN?\$Y/VL]=\ ZE
M]INM$8_;_#NJ2)M&J:>Y/EOD<>8A!C<#HZ-C@J3\\T2C3Q%*V\9((2JX6O?:
M46?VOV-]#JEE#=6LT5Q;W"++%+$X=)4895E8<$$$$$<$5+7Y-_\ !L=_P4__
M .%X?"5O@'XRU#S/%G@6T\[PU/.X#:EI*X7[.,\M);$@ =3"5P,1,:_62O@\
M5AY4*KIRZ'Z9@\7#$T56AU_!]C\$_P#@[S'_ !DO\(C_ -2S=#_R:K\AZ_7O
M_@[T7'[1_P (&]?#5V/_ ":%?D)7VF4_[I#^NK/S[._]^J>J_)'ZC?\ !I1_
MRD<\:_\ 9-[[_P!.>E5_0]7\\/\ P:4?\I'/&O\ V3>^_P#3GI5?T/5\WGG^
M]/T1];PW_N2]6<#^U7_R:]\2/^Q6U/\ ])):_C9K^R;]JO\ Y->^)'_8K:G_
M .DDM?QLUZ/#OP3]4>3Q5\=/T?Z!7]1?_!NG_P H;O@[_P!QK_T^:A7\NE?O
MU_P1/_X*\?LY?LO?\$R/AGX%\>?$[3O#OBS0_P"U/MVGRZ=>RO;^;JMY/'EH
MX60[HY4;AC][G!R*Z<\ISG02@FW?IKT9Q\-UH4\3*51I+E>[MU1^M5%?'O\
MP_V_9#_Z+1I'_@IU+_Y'H_X?[?LA_P#1:-(_\%.I?_(]?*_4Z_\ (_N9]M]?
MPW_/R/WK_,^PJ*\'_9<_X*:_ O\ ;3\=WOAGX7^/[+Q9KFG6#:G<VL%A=P&*
MV62.,R%IHD7[\L8P#GYNF <>\5C.G*#Y9JS\S:G4A47-!IKRU/S;_P"#J/\
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M: *,L0,L0!W(%>:\)76K@_N9ZRQV&;LJD?O1]35Y7^W1_P F2_&+_L1]:_\
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M'/:SKE^I5.?M^/3\3^?RBBK&E:7<:[JEM8V<,ES>7DJP00QC<\KL0JJ!W))
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M /&JY_[0PW\Z^\ZO[*QG_/M_<=Q_P:0_\G]^/O\ LG]Q_P"G'3Z_H2K\F?\
M@@C_ ,$;OC+_ ,$Z/VJ_%7B_XC1>%UT?6/"<VCVYTS4_M4GGM>6DPRNQ<+MA
M?GUQZU^LU?)YO5A4Q+E!W5D?<9#1J4L(H5%9W>Y^;?\ P=1_\HP(/^QRTW_T
M5=5_-_7]('_!U'_RC @_['+3?_15U7\W]>]D/^[?-_H?+\2?[Y\D"MM;([<U
M]>#_ (+T?M<J/^2U:[_X+K#_ .,5\A@9-;$_P\\06MA)=2Z'K$=K"I9YFLI%
MC0#G);& *]:I2IS_ (B3]4>+2K5:=_92:]&U^1ZI\>O^"C_QX_:>T232_'?Q
M8\;>(-(G_P!;ILFI/#8S>F^WCVQ-CMN4XKQ.BMCX?^*K?P1XTTW5KO0M'\36
M^GS"9]+U7S_L5[CHDHADBD*YP<+(N<8.1D%QA&"M!?<3*I*I*\W?S>IW7[)O
M[%_Q*_;>^)</A7X:^%M0\0Z@S+]IGC0K9Z9&QQYMS.?DB0<\L<G&%#$@'^F#
M_@DE_P $IO"__!+_ .![Z;!+!KGC[Q$L<OB77E0A;AUSMMX 1E;>/<VW.&<D
MNV,A4\^_X(@_\%,_@K^U[\'XO!?@?PIX=^$_C#P_!]HU#P;IT$=O;S ;5>\M
M2JKYR$[=Y8&1"0'W95V^\Z^0S;,*U23HR7*ET[GW6297AZ45B(2YV^O1>GGZ
MZA1117BGT1_)?_P6)_Y2C?'7_L;KS_T.OFNOI3_@L3_RE&^.O_8W7G_H=?-=
M?HV&_@Q]%^1^3XO^//U?YA17T=_P3_\ ^"6WQ2_X*5_\);_PK6/P^_\ PA?V
M/^T?[4U#[)C[5Y_E;/E;=_Q[R9Z8X]:^C/\ B%L_:E_YX?#W_P 'Y_\ C514
MQE"$N2<TF:4LOQ-6*G3@VGUL?G+7T#_P2B_Y29? 7_L>](_]*XZ^F?\ B%L_
M:E_YX?#W_P 'Y_\ C5>K?L+?\&Z'[1O[//[9OPM\=>((/!/]A>$?%&GZMJ'V
M76_,F$$-PCN47RQN(4'C/-<];'X9TY)36SZG5A\KQ:JQ;IO==/,_?2O*_P!N
MC_DR7XQ?]B/K7_I!/7JE>5_MT?\ )DOQB_[$?6O_ $@GKXBE\:]3]&K?PY>C
M/X[Z***_2#\C/ZE?^#>K_E#S\&_^N&J_^G>^K[/KXP_X-ZO^4//P;_ZX:K_Z
M=[ZOL^OSS&?[Q/\ Q/\ ,_5,O_W6G_AC^2"BBBN8[#\>_P#@[YT^&7X#?!F[
M9E^T0Z_?PHO<H]O&6/YHGYU^#]?M)_P=^?%NVN?$OP5\"0L#>65MJ6O70S]V
M.9H8(>/<P7'Y5^+=?<9/%K"1OY_F?G&?R3QT[>7Y(L:07&K6OEC=)YR;1ZG(
MQ7]KE?QI_LS>!)?BC^TA\/\ PS!&\TWB+Q)IVF)&@RSF:ZCC '_?5?V65YG$
M3UIKU_0]GA2+M5?I^H4445\T?7!1110!^7/_  =K_P#*./P5_P!E(L?_ $V:
MK7\\-?T/?\':_P#RCC\%?]E(L?\ TV:K7\\-?:9'_NOS9^>\2?[Z_1&Y\,O%
M$/@?XD^']:N(Y)K?1]3MKV2./&]UBE5R!GC)"\9K]Z#_ ,'<WP5V_P#)-?BE
MG_=L/_DBOY^Z*[,5@:6(LZJV.#!YE7PJ:HO?R/V\^-O_  =[68T2:'X<?!VZ
M;4I%Q%>>)-6400-ZM;P*6D'L)D^M?D+^U'^U/XY_;*^,^J>/OB%K<VN>(M4(
M4R,H2&UB7.R"&,?+'$@)PJ]R2<LS$^>T4\-@:%#6E'7N+%YEB,3I6E==ME^
M5^@W_!NM_P $\KW]L/\ ;6TSQIJMI*O@/X374&MWD[1GR[Z_1@]I:*2-I/F*
M)7'/R1D'&]36+_P39_X(%_&#]NW7K/5->TW4/AK\.5*2SZWJ]D\5Q?QD_=LH
M'PTI('^L;$8Z[F/RG^C?]EW]E_P7^QS\$M%^'_@'28](\.Z)%M1>&FNI3]^>
M9\ R2N>68_0   #SLUS2%.#I4W>3_#_@GK9+D]2K45>LK16NO7_@'H-?D?\
M\'=W_)JGPI_[&R;_ -(Y*_7"OR/_ .#N[_DU3X4_]C9-_P"D<E?/Y5_O</7]
M#ZC.O]QJ>GZH_ NO8O\ @GC_ ,G_ /P-_P"R@Z!_Z<K>O':]B_X)X_\ )_\
M\#?^R@Z!_P"G*WK[BM\#]&?G.'_BQ]5^9_8%1117YN?K1_)C_P %C?\ E*1\
M=/\ L;;O_P!"%?--?2W_  6-_P"4I'QT_P"QMN__ $(5\TU^C8;^#'T7Y'Y/
MB_X\_5_F?H%_P0L_X*Y^"O\ @E>?BE_PF'AKQ1XB_P"$[_LG[)_8P@/V?[)]
MMW^9YLB?>^U)C&?NMG'%??&K_P#!W7\(8;1FL/A;\2+F?!VI<2V4"$]LLLKD
M?E7X"T5RU\KP]:HZDUJ_,[<-G6*H4E2IM67DO4_23_@HA_P<J?%/]LOP%J7@
MOP;H=K\*_!^L0M:ZC]FO6OM5U&!AM>)KG9&(XW&=RQH&()4N5)!_-NBNJ^#O
MP+\9_M"^,H?#O@7PKKWB[6[C&VSTFQDNI0/[S! =JCNS84#DD"NBC0I4(6IJ
MR.3$8FOB9\U1N3_K9',6]O)=SQQ11O)+(P1$1=S.3P !W)K^H;_@@G_P3XNO
MV!?V'[&+Q#;R6WCKQ_,NOZ]!*NV33]T86"S/O%'RP/(DED'0"OGK_@C'_P &
M[,7[*WB?1_BM\:FL-7\>6/\ I&D^&X=MQ8Z!+P5GED&5FN5YVA?W<9^8,[!6
M7]8*^;SC,HU?W-+;J^Y]=D.43H/ZQ75I=%V\WYA7\@__  4M_P"4CG[0'_92
M/$7_ *<[FOZ^*_D'_P""EO\ RD<_: _[*1XB_P#3G<T^'OXD_0GBK^%#U?Y'
MB=%%?3G[ _\ P23^+G_!2'PQXAU?X;Q^&WL_#-U%9WO]IZC]E;S)$+KM&QLC
M"GFOIZE2%./--V1\;1HSJRY*:N^R/F.BOT:_XA;/VI?^>'P]_P#!^?\ XU1_
MQ"V?M2_\\/A[_P"#\_\ QJN?^T,-_.OO.S^RL9_S[?W'B_\ P0M_Y2S_  3_
M .PU+_Z23U_5E7X7?\$Q/^#?/]H/]D_]O/X;?$3Q9%X+7P[X6U%[J^-IK)FG
MV&"5!M3RQN.YQW%?NC7S.=UJ=6K%TW=6Z>K/L.'</5HT)1JQ:=^OHCPW_@IU
M_P HWOC]_P!DZU__ --T]?R&U_7E_P %.O\ E&]\?O\ LG6O_P#INGK^0VO1
MX>_AS]3R>*OXL/1_F%?UC?\ !%__ )17? W_ +%>#_T)J_DYK^L;_@B__P H
MKO@;_P!BO!_Z$U/B#^#'U_0CA;_>)_X?U1]/4445\F?<A1110!_,O_P<Q_\
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M%!3TE1.0K/G^86YMI+*YDAFCDAFA8HZ.I5D8'!!!Y!![5]WEN-6(I7?Q+?\
MS^9^:YOE[PE?E7PO5?Y?(^@OVM_VY=1_:]_9L^"?A_Q+)<77BSX4VNHZ!+?2
M$N;_ $XFU>R=V/650)XF]5AC8DEC7SS117;3IQ@N6.W^>IYU2I*I+FGOI^"L
M?J-_P:4?\I'/&O\ V3>^_P#3GI5?T/5_/#_P:4?\I'/&O_9-[[_TYZ57]#U?
M'9Y_O3]$??<-_P"Y+U9P/[5?_)KWQ(_[%;4__226OXV:_LF_:K_Y->^)'_8K
M:G_Z22U_&S7H\._!/U1Y/%7QT_1_H%?U%_\ !NG_ ,H;O@[_ -QK_P!/FH5_
M+I7]1?\ P;I_\H;O@[_W&O\ T^:A6_$'^[K_ !+\F<_"_P#O4O\ "_S1]LT4
M45\>?>!1110!^;?_  =1_P#*,"#_ +'+3?\ T5=5_-_7]('_  =1_P#*,"#_
M +'+3?\ T5=5_-_7V60_[M\W^A^?\2?[Y\D.@_UZ?[PK^V">".Z@>.1%DCD4
MJZ,-RL#P01W!K^)^#_7I_O"O[8JX^(O^7?S_ $/0X3_Y>_\ ;OZGX?\ _!Q!
M_P $1='\#>&-4_: ^$&CVVDV%EB;QCX>LHMD$:LP']H6\:\( 6'FHH"@?O !
MB0G\6Z_M:UW0K/Q1H=YIFI6L%]I^HP/:W5M.@>*XB=2KHRG@JRD@@]0:_E/_
M ."P_P#P3OO/^"<7[9&L>%[:&X;P3KN[5_"EW(2_F63L1Y#.>LD+9C;N0$<X
M#BMLES!U%["H]5MZ?\ Y^(LL5*7UBDM'OY/O\_S]3P7X!_';Q1^S+\8O#_CS
MP7JDNC^)O#-VMY97*#(##@HZGAXW4LK(>&5F!X-?U=_\$W?V\/#O_!13]E/0
M?B'HAM[;4)E^QZ]I<<FYM'U%%7SH#GG;\RNA/WHW0\$D#^12OMK_ ((7?\%-
M9O\ @G;^UG;1:]?2I\,O';Q:9XDB9CY5B=V(=0 YYA+'=CDQ/(,$A<=6;8'V
M]+FC\4=O/R./(\R^K5N2;]R6_D^_^9_45145E?0ZG90W%O-%<6]PBR12QL&2
M1",AE(X((.01UJ6OB3]$/Y+_ /@L3_RE&^.O_8W7G_H=?-=?2G_!8G_E*-\=
M?^QNO/\ T.OFNOT;#?P8^B_(_)\7_'GZO\S]LO\ @SL_YN*_[EK_ -RU?ME7
MXF_\&=G_ #<5_P!RU_[EJ_;*OC,X_P!\G\OR1^@9!_N%/Y_^E,****\P]@*\
MK_;H_P"3)?C%_P!B/K7_ *03UZI7E?[='_)DOQB_[$?6O_2">M*7QKU,ZW\.
M7HS^.^BBBOT@_(S^I7_@WJ_Y0\_!O_KAJO\ Z=[ZOL^OC#_@WJ_Y0\_!O_KA
MJO\ Z=[ZOL36=?L?#MI]HU"]M+& =9+B98D_-B!7Y[C/]XG_ (G^9^J9?_NM
M/_#'\D6ZR/'_ (^T7X5^"-6\2>(M2M-&T'0K22^U"^NGV0VL$:EG=CZ  U\]
M_M.?\%BOV<?V3M,O'\2?%'PWJ&J6:D_V/H5RNJZB[]H_+A+"-C_TU*#N2!S7
MX7?\%<?^"[OC7_@H\\GA'P[;7G@;X3QLK-I'G!KS6W5@RR7CKP55@"L*DHI&
M27(4KT8/+*U>2TM'N_T[G+F&<4,-%ZJ4NB7Z]CPW_@J=^VW<?\% ?VW/&/Q#
M5KA=!FG&G>'K>8;6MM,@RL *_P +/\TK+SAYG&<5\\T5):VLM]=1P01R333.
M$CC12S.Q.  !R23Q@5]O3IQA%0CLC\YJU)5)NI+=NY]Z?\&W?[+\W[0W_!37
MPUK,UN\FA_#.VF\37LF/E$J#RK5<]-WGR(X'4B%_0D?TV5\,_P#! [_@FW/_
M ,$^?V/%N/$MBUI\1_B(\>K>((I%'F:=&H86UD2/^>2.S,#R))I!R *^YJ^(
MS;%*OB&X[+1'Z)D>#>'PJ4MY:O\ KT"BBBO-/8"BBB@#\N?^#M?_ )1Q^"O^
MRD6/_ILU6OYX:_H>_P"#M?\ Y1Q^"O\ LI%C_P"FS5:_GAK[3(_]U^;/SWB3
M_?7Z(WOA7X9M_&OQ/\-Z->-*MKJVJ6ME,8B%<))*J-M)! ."<9!K^@^W_P"#
M3_\ 9IA^]XA^+TW^_K5E_2S%?@#^S[_R7OP/_P!A^P_]*(Z_LUKGSS%5:3@J
M<FKW_0[.','0KQJ.M%.UM_F?G7X=_P"#7;]E?1"OVK3_ !WK&WK]K\0LN[Z^
M2D?Z5])_L^?\$J_V=_V6[VUO/!/PC\'Z=J5B0UOJ-U:G4;^!A_$EQ<F256]U
M85] T5\Y4QE>:M*;?S/JZ> PU-WA32?H@HHHKF.L*_(__@[N_P"35/A3_P!C
M9-_Z1R5^N%?D?_P=W?\ )JGPI_[&R;_TCDKT,J_WN'K^AY>=?[C4]/U1^!=>
MQ?\ !/'_ )/_ /@;_P!E!T#_ -.5O7CM>Q?\$\?^3_\ X&_]E!T#_P!.5O7W
M%;X'Z,_.</\ Q8^J_,_L"HHHK\W/UH_DQ_X+&_\ *4CXZ?\ 8VW?_H0KYIKZ
M6_X+&_\ *4CXZ?\ 8VW?_H0KYIK]&PW\&/HOR/R?%_QY^K_,_13_ (($_P#!
M)SX:_P#!4%OBO_PL/4_&.G?\(-_9'V :%>P6WF_:_MWF>;YL$N['V:/;MVXR
MV<Y&/TCT[_@U/_9DL9E:34_BI>*.J3:Y;!3_ -\6JG]:^>O^#.S_ )N*_P"Y
M:_\ <M7[95\MFF.KT\3*$)-+3\D?9Y+EV&JX.%2I!-N^OS9\,_#'_@W)_9+^
M&NJ)>2?#V]\23QXV#6M;N[B('U,2NL;?1E(]J^NOA!\"/!/[/WAG^Q? OA'P
MUX.TG(9K31=-AL8G;^\RQJH9O]HY)SUKK**\BIB*M3^))OU9[M'"T:7\*"7H
MD%%%%8G0%?R#_P#!2W_E(Y^T!_V4CQ%_Z<[FOZ^*_D'_ ."EO_*1S]H#_LI'
MB+_TYW-?0\/?Q)^A\KQ5_"AZO\CQ.OW@_P"#0;_D@_QF_P"P_8?^D\E?@_7[
MP?\ !H-_R0?XS?\ 8?L/_2>2O6SK_=)?+\SP^'_]^C\_R9^PE%%%?$'Z,%%%
M% 'AO_!3K_E&]\?O^R=:_P#^FZ>OY#:_KR_X*=?\HWOC]_V3K7__ $W3U_(;
M7U?#W\.?J?$\5?Q8>C_,*_K&_P""+_\ RBN^!O\ V*\'_H35_)S7]8W_  1?
M_P"45WP-_P"Q7@_]":GQ!_!CZ_H1PM_O$_\ #^J/IZBBBODS[D**** /YE_^
M#F/_ )2U^,?^P1I/_I''7P'7WY_P<Q_\I:_&/_8(TG_TCCKX#K]!P'^[4_1?
MD?EN9_[W4_Q/\S]1O^#2C_E(UXU_[)O??^G/2Z_H>K^>'_@TH_Y2->-?^R;W
MW_ISTNOZ'J^6SS_>GZ(^TX;_ -R7JSQW_@H=_P F ?'+_LGVO_\ IMN*_C]K
M^P+_ (*'?\F ?'+_ +)]K_\ Z;;BOX_:]+A[^'/U1X_%7\6GZ/\ ,*_L4_8@
M;=^Q9\(3Z^"=&/\ Y(PU_'77]B'[##;OV)?@Z?7P/HO_ *004<1?!#U97"O\
M2IZ(]4K\D?\ @YU_X)??\+D^%Z_M ^#=/W>)_!5H(?%4$(PVH:4F2MU@?>DM
M\_,>IA)).(E%?K=4.H:?;ZM83VMU!#=6MU&T4T,J!XY488964\$$$@@\$&OG
M<+B94*JJ1Z?BCZK&X2&)HNC/K^#[G\4-?0W_  31_;CU#]A7]HI=:,D\GA'Q
M192^'O%5DA)%QI]P-CR!1]Z6$D2IW)0KD!VKTO\ X+@_\$R[C_@G)^UE<QZ-
M:W!^&OC9I=3\,7!&4MAN!FL"?[T#,H&>3&\1))+8^+J^\C*GB*5UK&2/S.4:
MN%KV>DHO^OD_R"BBBN@Y3^OC_@FE_P HX_V?_P#LF_AW_P!-EM7ME>)_\$TO
M^4<?[/\ _P!DW\._^FRVKVROS>M_$EZL_6L/_"CZ+\C\"?\ @[M_Y.S^%?\
MV*,O_I9+7Y(U^MW_  =V_P#)V?PK_P"Q1E_]+):_)&ON,J_W2'I^I^<YU_OU
M3U_1'VS_ ,&Z?_*9'X._]QK_ -,>H5_477\NG_!NG_RF1^#O_<:_],>H5_47
M7S_$'^\+_"OS9]1PO_NLO\3_ "04445X9](%%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 5_,A_P<L?\I<_'?_8,TC_T@AK^F^OYWO\ @X-_8G^,WQH_X*B>-/$'@[X1
M_$[Q9H-UI^EI#J6C>%KZ_LYF2RA5PLL43(Q5@00#P00:]K(I*.(;D^C_ #1\
M_P 20E+"I15_>7Y,_+ROU._X-)/^4@_CO_LGEU_Z<M.KX=_X=I?M'?\ 1O\
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M,7_#+?\ P3 ^&]A<6XM]8\76S>+=3^7:S27V)(MPZAEM1;1D'D&,].@_ ?\
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M_P -,? EO@KXQU'S?'7PWM%.D3SN6EUG1PVU>3UDMB4B/3,;0D;B)&'XG_\
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M)J4Y8B+BF_=[>;/$Z_KP_P""87_*-SX _P#9.]!_]-\%?R]_\.TOVCO^C?\
MXV?^$-J?_P 8K^I/_@G3X7U/P1^P!\$=&UK3K[1]8TGP)HMG?6-[;O;W-G/'
M8PK)%)&X#(ZL"I5@"""",U.?U(RIQY7?4OABG.-6?,FM/U/9:***^7/LPK^?
M/_@[A_Y/L^'G_8AP_P#IPOJ_H,K\-/\ @Z%_9)^*W[0'[9_@75/ ?PR^(7C;
M2[/P5%:SWF@>';S4K>"87UXQC9X8V57VLIVDYPP/0BO6R62CBDWV9XG$$92P
M;45?5'XS5^JW_!H^W_&>'Q"'_4A3?^G"QKX5_P"':7[1W_1O_P ;/_"&U/\
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M0=*GU*YB@73M21I6CA5F"!I$4L1@%U&<D5^$G_#M+]H[_HW_ .-G_A#:G_\
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MR/RW%8>JZ\VHO=]'W/U&_P"#.S_FXK_N6O\ W+5^V5?D'_P:G_LT_$?]G?\
MX7S_ ,+ ^'_C;P+_ &Q_PC_V#_A(=#NM,^W>5_:GF>5YZ+OV>9'NVYV[USC(
MK]?*^0S>2>+FUY?DC[S(HN.!@I*SU_-A1117FGK!1110 5_(/_P4M_Y2.?M
M?]E(\1?^G.YK^OBOY9_^"@__  3X^/GC3]OCXX:QH_P/^+^K:1JWC_7KVQOK
M+P;J-Q;7L$FHSO'+%(L)5T=2&5E)!!!!(->_D$XQJ2YG;0^7XGIRE2ARJ^K_
M "/C.BO;/^':7[1W_1O_ ,;/_"&U/_XQ1_P[2_:._P"C?_C9_P"$-J?_ ,8K
MZGVU/^9?>?&_5ZO\K^YGB=%>V?\ #M+]H[_HW_XV?^$-J?\ \8H_X=I?M'?]
M&_\ QL_\(;4__C%'MJ?\R^\/J]7^5_<SQ.OZ</\ @VI_Y1%^ O\ L):O_P"G
M">OY^_\ AVE^T=_T;_\ &S_PAM3_ /C%?T1_\&^GPK\4?!?_ ()<^"?#_C'P
MWKWA/7K6_P!4>?3=9T^6PO(5>^F9"T4JJZAE(()'(((XKQ<]J0EATHM/5?DS
MZ#ANC..*;DFO=?3S1['_ ,%.O^4;WQ^_[)UK_P#Z;IZ_D-K^P#_@HGX8U+QM
M^P%\;M&T73K[5]8U;P'K=G8V-E;O<7-Y/)83)'%%&@+.[,0H50220 ,U_+7_
M ,.TOVCO^C?_ (V?^$-J?_QBL<@J1C3ES.VIT<3TYRJPY4WH_P SQ.BO;/\
MAVE^T=_T;_\ &S_PAM3_ /C%'_#M+]H[_HW_ .-G_A#:G_\ &*^@]M3_ )E]
MY\O]7J_RO[F>)T5[9_P[2_:._P"C?_C9_P"$-J?_ ,8H_P"':7[1W_1O_P ;
M/_"&U/\ ^,4>VI_S+[P^KU?Y7]S/)?!G_(X:3_U^0_\ H8K^U*OY%_"7_!-G
M]HNV\5:9))\ OC5'''=Q,S-X'U,*H#C))\CI7]=%?-<05(R]GRN^_P"A]=PO
M3G%5.9-;?J?S+_\ !S'_ ,I:_&/_ &"-)_\ 2..O@.OU)_X.%_V*OC)\:O\
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M'?\ 1O\ \;/_  AM3_\ C%?5>VI_S+[SXOZO5_E?W,_J,_X)I?\ *./]G_\
M[)OX=_\ 39;5[97D'_!/CPUJ7@O]@?X'Z/K&GWVDZOI/@#0;*^L;V!K>YLIX
M].@22*6-@&1T8%65@"""" 17K]?G=;^)+U9^J8?^%'T7Y'X$_P#!W;_R=G\*
M_P#L49?_ $LEK\D:_:S_ (.C_P!E'XI?M!?M._#74/ 7PU\?^-[&Q\+R6]S<
MZ!X>N]2AMY#=R,$=X8V"MM(."0<'-?E__P .TOVCO^C?_C9_X0VI_P#QBOM,
MKK06%@FU]_F?GV<T:DL;4:B]^WDCQ.BO;/\ AVE^T=_T;_\ &S_PAM3_ /C%
M'_#M+]H[_HW_ .-G_A#:G_\ &*]#VU/^9?>>9]7J_P K^YGB=%>V?\.TOVCO
M^C?_ (V?^$-J?_QBC_AVE^T=_P!&_P#QL_\ "&U/_P",4>VI_P R^\/J]7^5
M_<S[Z_X-%O\ D\?XG?\ 8F#_ -+K>OW^K\0?^#7/]D[XJ?L_?M7?$34?'OPT
M^('@G3[[PF+:VNM?\/7>FPW$OVR!O+1YHU#-M!.T'. 37[?5\9G4E+%-Q[(_
M0.'XRC@TI*VK_,****\H]H**** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *^5+W_ (+;_LPZ=>36
M\WQ-V30.8W7_ (1W5CM8'!&1:XZU]5U_,K\!/@?'^TI^V!HO@.;49-(B\5:\
MU@UXD(F:V#.WS!"5W8QTR*QJU'&UAH_;K_A^'^R[_P!%/_\ +<U;_P"1:ZKX
M9?\ !5_]G;XNZO#8:-\5/#RW5P=L::DD^EASSP#=1QC)QP,Y/&.HKXX_XAC-
M'_Z+#J?_ (3B?_)%?/G[9'_! [XC_LR?#_4O%GAW7M.^(6A:-"US?);VCV6H
M00J,O+Y!9U95 ).V0L ,[2 <3S55JT/0_<Z&=+F%9(V62.10RLIRK ]"#Z4Z
MOQ8_X(4_\%']>^&WQET?X.>*-0FU+P;XJD-KHQN'+OHUZ1F-(R<GR92-GE]
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M*O*[+<=C]7/B!_P<'?L\^"[^:&PNO&'BI8CCS=*T?;&Y_P!G[2\)_'&.*Q=
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MGX2\/7^JZA-]GT_3+>2[N9=C-Y<4:EW;"@DX4$X )/:OEO\ X?A_LN_]%/\
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MB^$O_8&_]K25]%5<7=7$%>-?M'_\%!?@[^R=(UOXX\=:1IFIJI8:9 6O+\\
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MVL1Z'X<TLQK<W;PR3;#)(L: 1Q*SL2S 852>IZ D==7Y7?\ !RI^T=]C\/\
M@7X4V-Q^\O9'\1ZK&I&1&FZ&U![X9C<$@X&8U//::DN6-P/N7]FS_@HK\'?V
MO?&=WX?^'?BZ3Q%JUA9M?W$0T:_M5BA#HA8R3P(GWG4 ;LG)P#@XZK]I/]JG
MP%^R%X&M?$OQ$U[_ (1[1;Z_33(+G[%<7>^X>.214VP1NPRD4AR1CY<9R0#\
M8?\ !NC^S7_PKK]F#7/B)?6OEZEX_O\ R;-W3YA86I9%*GJ \S39 X(C0\X%
M6?\ @Y-_Y,9\*?\ 8]VG_IOU&HYY<G,Q]3UC_A^'^R[_ -%/_P#+<U;_ .1:
M/^'X?[+O_13_ /RW-6_^1:_,?_@F!_P22L?^"AWPO\1^(KKQQ>>%7T'51IP@
MBTM;L3 Q))OW&5,?>QC!Z5]-_P#$,9H__18=3_\ "<3_ .2*B,ZK5TD/0^G?
M^'X?[+O_ $4__P MS5O_ )%KZ?\ !_BS3_'OA+2]=TFX^UZ5K5I%?V<_EM'Y
MT,J!XWVL RY5@<, 1GD U^8?_$,9H_\ T6'4_P#PG$_^2*_2WX2> E^%7PJ\
M,^%X[IKY/#>DVNE+<-'Y9G$$*1!RN3MW;<XR<9ZFM(.?VA'&?M._MJ_#+]C:
MST>X^)'B;_A&X=?>6.P;^SKN\\]H@A<8MXI"N Z_>QG/&<&O(O\ A^'^R[_T
M4_\ \MS5O_D6OF+_ (.<_P#D3?@]_P!?NJ_^@6E>$?\ !.C_ ((K:=^W9^SA
M%X\N?B%>^&Y9-2N+#['%HZW2@1;?FWF9.N[ICC%1*I/FY8CLC]%H/^"WO[+M
MQ,D:_%!0TC!06\/:JJ@GU)M< >YXKV?X&?M??##]I:-O^$%\=>'/$DT:EWM;
M6[47<:C'S- V)57GJ5 K\[]9_P"#8JS.G2?V?\9+E;M03&+CPT#&QP< [;D$
M9..><>AKX<_:[_88^*O_  30^)FDW6JSO;I)*9M$\3:)<2+#)(G.%DPKQ3 <
ME#@X.06&32=2I'62"R/Z.J*^-_\ @C1_P4/O/VX?@;?:;XIFA?Q]X*:*WU&5
M0$_M.W<'R;K;V8E'5P!@,H/&\*/LBMHR35T2%%%%4 445\'?MZ?\%U/"?[)'
MC_7O N@^%=6\3^--#<07#7++::;;R-&KK\X+228##*A5!_O5,I**NP/N+Q1X
MITWP3X>O-6UC4+/2]+T^(SW5W=S+##;H.K.[$!0/4FO"OV3?^"F'PV_;4^+G
MBKPCX#&OWDGA. 7,NIW%HD-A?1F01AH#YAE(W'^.-..?2OQ9_:4_:P^/7_!1
M?1_$7B379-2NO!'A%4O;VRTV)K?0]&#.(X]P)(>0LX"[V>0Y.. <?3'_  ;.
M_P#)PGQ(_P"Q=A_]*5K%5KR26Q5M#]DJ***Z"0HHJ*^OH=,LIKFYFBM[>W1I
M9997")$BC)9B>   22>!0!YA^TY^VQ\+_P!C>UTB;XD>*H?#:Z\\B6"FRN;N
M2X,84N0D$<C +O7D@#+ 9S4W[,O[97PW_;&T?5-0^&_B3_A([/19DM[V3^S[
MJS\EW4LHQ/'&6R 3E017X._\%3/VS9/VWOVL=:\06,DS>%=#7^R=!0]/LL;'
M,Y'8RR%GYY 9%/W17WM_P;+?\D=^*7_89L__ $0]81K<T^5;%6T/TZHHKXF_
MX+7_ /!0N^_8T^"%GX=\)W@M?'GCE98;6Y1OWFDVBX$MROI(2P2,]CN8<IBM
M9225V2>I?M4_\%3?@K^Q_JLNE>*?%2WGB*$9?1M(A-]>1>T@7Y(F[[9'4D$'
M&#FO"]&_X..?@+JFJ+;SZ/\ $O382<?:;C2;5HASCI'=._O]VOBK_@EC_P $
M@;S]O+3[KX@^/-8U32? _P!L>*$VQ#7^OSJW[UED<,$C5LAI"&+-N P06'VQ
M\3_^#=SX'^*/!<UIX;NO%7A?6UC/V?4/M_VR,R8X,L4@PR^H0H?0BL5*I)71
M6A]>?L^?M.> _P!JCP7_ ,)!X!\2Z?XCTU2$F,!9)K5B,A98G DC8\\.HSCC
M-=Y7\Y_@GQO\3O\ @C_^VS=6[,UOJ_AVY6VU6R21OL6OV+;7QR/FCD0AD8C*
M-@\,I%?T)?"WXE:3\9/AOH7BS0;C[5HOB*QAU"SEXRT<B!E# $X89P1V((ZB
MM*=3FT>XF;U%%%:""O'_ -IO]O7X3_L<:II-G\2/%?\ PCESKD4DUBG]F7EY
MYZ1E0YS!%(%P6'WL$YXKV"OR!_X.;?\ DIWPG_[!>H?^C8:SJ2<8W0(^SO\
MA^'^R[_T4_\ \MS5O_D6I+;_ (+=_LOW<ZQK\4(U9S@%_#^JHOXEK8 ?B:^
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M\03>&8_[+N-1^V168NFS$8QLV%TZ[^N>,5-2I*+2B,_93_A^'^R[_P!%/_\
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MAQ_0%^R!^TOI/[7O[.?ACX@:.H@BURVS<VN\,UC<H2DT)/\ LR*P!(&Y=K8
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MD?U945\A_P#!'/\ ;Z7]M7]FZ.RUR\67Q]X+6.PUD.^9+^/&(;SU.]05<_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %?SG_P#!.?\ Y2@?#C_L;A_Z&]?T85_-A^QU
M\4="^"O[?O@_Q9XFOO[-\/Z#XF-W?77DR3>1$KOEMD:L[?15)KGK;Q*1_2?4
M=Y%#/:2I<+&]NZ%9%D *,I'((/&,=<U\H7'_  7(_9>@MY'7XEO,R*6$:>'-
M5W.1V&;8#)Z<D#W%?)G[>W_!=ZW^-W@:_P#AS\"]#\075]XHA;3KC6;BV*7/
MER J\=I A9R[KQO;!7)PN<,-)5(I;BLSX2_8YT#_ (2/_@H?\-[/PVTD<'_"
M>V$ME*JJ[0P1WR2"3!X.V-=V#P=M?TIU^9?_  1+_P""3>O? 7Q,OQ;^)FGM
MI?B+[.\&@:+,!Y^GK(NV2YG'\$A0E%C/*AG+ $@+^FE30BU'4<C\V?\ @Y>_
MY-G^'O\ V,[_ /I++6]_P;9?\F,^*_\ L>[O_P!-^G5@_P#!R]_R;/\ #W_L
M9W_])9:WO^#;+_DQGQ7_ -CW=_\ IOTZI7\4.A^A%?.W_!67PAI_C3_@G9\5
MH-1MTN([/17U"#(&8IH&66-P>Q#*.G8D=Z^@[_4+?2K*6YNIH;:WA4O)+*X1
M(U'4DG@#W-?EM_P7!_X*H^$?$/PDO_@[\.=:M?$5]K4J)XAU.QD$MI9P1N'^
MS)(/EDD=U7<4)555E))8A=:DDHNY*/FS_@WSU&ZLO^"B=A';R2)%>:!J$5R%
MZ/&%1P#[;T0_4"OWBK\N?^#=7]BK4_!FE:Y\9_$%G+9_\)!:?V1X=BFCVM+:
MEUDFN@#_  NR1HC#J%D[,"?T&_:R\;3?#7]EGXE>(K61H;K0O"VIW\#@X*R1
M6DKICD<[E&.>M1134-1O<_!#_@HU^T;K'[>'[=>MW6F&;4K,ZBOAOPO:1Y(:
MW24Q0[ ?XII"9#_M2XZ  ?N'^P)^QCH?[#G[.ND>$=-AMY-8DC6ZU[447Y]2
MO64;W)Z[%^XB]E4=RQ/XH_\ !%OX<0?$O_@I'\.8;J/S+;1YKC6&&W.'M[:2
M2(^V)1&<U_0U4T%>\V.04445T$F/\0_A_H_Q6\#:MX;\06%OJFBZY:O9WMK,
MNY)HW&"/8]P1R" 1@BOYS?VA_AGXB_X)L?MW:EI>CWD\>I> ]9BU#1;U^MQ;
MG;-;NV#@[HV577IG>I[BOZ2J_%__ (.5/ D&C_M0>!?$$42QR:YX<:VF9?\
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M?!7_ %Y:G_Z0S5^W'[7_ /R:7\4?^Q1U;_TCEK\1_P#@@]_RDQ\%?]>6I_\
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M)HI#G'S.>,8KYU_X.4O $6L?LH^"?$FU3=:%XG%F"1R(KFVF+\Y_OV\7'?\
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M.KR?]N_QY-\,OV+?BIKEN66ZL/"VH&W8'[DK6[I&W;H[*?7BAZ:@?@W^VO\
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M#W_7[JO_ *!:5[7_ ,&]O_*/"V_[&+4/_:=8+^*RNA]Q5\G?\%O/!NG^+O\
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M"[_L4=)_](XJ*?QR!F9^WI_R8S\:/^Q$US_TWSU^0/\ P;P_\I!C_P!BQ?\
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M%KX9:EJ>I3I:VEI:^*+&:>ZF=@J1QHLI9G9B % ))( KTVM;W$?BU_P<L?\
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M"@G !)QP#1B.@1/Z/**^3_\ A^'^R[_T4_\ \MS5O_D6C_A^'^R[_P!%/_\
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M>?\ 8NZA_P"DTE?AI_P0>_Y28^"O^O+4_P#TAFK]R_VC/^3>_'G_ &+NH?\
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M@7]8V_*OV&K^?7_@M-^T=!^TY^WUKW]CS_VAI'A&*+PQI[Q ,)VA9S,5VYW
MW$DP5AG<H4], 8XA^[8J.Y^FO_! +09](_X)Q:'<3*RQZIK.HW4)*D;D$WDD
MCU^:)AD>F.U?2'[6_P ?+7]E[]FKQIX^O K+X;TR2X@C;[LUPV(X(S_OS/&O
M_ JROV$O@9+^S7^Q]\/?!-TGEWVBZ/%]N3'W+J7,TZ_A+(XSWQ7PC_P<F_M,
M?V1X+\%_"?3[G$^KRG7]7C4\B",F.V0^S2&5L>L*U5^2 MV?'7_!(3X$77[6
MW_!1#P_>:RK:C9Z#<R>+=:EE3<)FB<.F\8P=]R\0(/!!;@]*_H-K^=#X!?\
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M_@Y8_P"3M/ O_8HI_P"EES7[2U^+7_!RQ_R=IX%_[%%/_2RYK&O\!43]&_\
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M,_&C_L1-<_\ 3?/7XV_\$ ?^4CNB?]@;4?\ T37/4^.)70_>JBBBN@D^,?\
M@OE_RC:\3?\ 84TW_P!*4K\Q_P#@E?\ \$Q;/_@HY_PG?VOQA=>$_P#A#?[/
MV>3IJWGVK[5]JSG,B;=OV<>N=_;'/Z<?\%\O^4;7B;_L*:;_ .E*5\V_\&P/
M_-</^X#_ .Y*N:<4ZJ3*Z&G_ ,0QFC_]%AU/_P )Q/\ Y(H_XAC-'_Z+#J?_
M (3B?_)%?J;16OL8=A79^67_ !#&:/\ ]%AU/_PG$_\ DBO@'_@GUIW]D?\
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MUGID9VJ>G_+.TBST'*]!7]$>B:+:^&]%L].L8([6QT^!+:WA086&-%"JH]@
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MMN.G7J >= >_!(92>J.A[UZQ76G=71(4444 %%%% 'S%_P %EO\ E&=\5/\
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M?/?_  4X_;!L?V,OV2O$6O\ VQ8?$FJP/I?AZ!7VS2WLJE5D7'.(@3*3P/D
MSEAEMV5V!^%?B^X;X[?\%$-4FMHDNG\9?$65XHX0VV8W6IDA5P2V#O &"3SW
MK^EBOP+_ ."%_P"S1=?'W]NK1M=FAD?0_AV/[>OINWGC*VJ9/\1FP^.ZPOTZ
MU^^E88?9LJ1^"O\ P7^_Y2.ZW_V!M._]$U^TO[('_)I?PN_[%'2?_2.*OQ:_
MX+_?\I'=;_[ VG?^B:_:7]D#_DTOX7?]BCI/_I'%13^.0,S/V]/^3&?C1_V(
MFN?^F^>OY]?V)?V.->_;G^-)\#^'=4TG2=1_L^;4?/U(R"'9&4!7]VK-D[QC
MC'%?T%?MZ?\ )C/QH_[$37/_ $WSU^0/_!O#_P I!C_V+%__ .AP4JRO-)@M
MCL?^(:?XM?\ 0]?#K_OY>?\ QBC_ (AI_BU_T/7PZ_[^7G_QBOVEHJ_80#F9
MQ?[-OPTO/@O^SKX!\':A/;W5]X3\.:=HUS-;Y\F:6WMHX79-P!VED)&0#@C@
M5\5_\')O_)C/A3_L>[3_ --^HU^A%?GO_P ')O\ R8SX4_['NT_]-^HU532#
M)/SL_8,_X)1>-/\ @H%X"UKQ!X8\1>%]&M=#U :=-'JC3K)(YC63<OEQN,88
M#D@YKW;_ (AI_BU_T/7PZ_[^7G_QBO?_ /@VA_Y-G^(7_8SI_P"DL5?I-6=.
MC%Q3939^1_[-O_!OE\3_ (+_ +17@'QCJ'C+P'=6/A/Q'IVLW,-O)=^=-%;W
M,<SJFZ$#<50@9(&2.17ZX445M&"CL2?BU_P<L?\ )VG@7_L44_\ 2RYJ_P#L
M@?\ ! ?2_P!J+]FGPA\0)OB=J&C2^*++[6UDFAI.MN=[+M#F==WW<YP.M4/^
M#EC_ ).T\"_]BBG_ *67-?HW_P $E/\ E'%\)?\ L#?^UI*YU%2J.Y1\>?\
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MPW[R1,$8,K$.JG:P(.,$$<5_3=7\Z/PL_P"4OWAO_LL-M_Z>EKGQ'0J)V/\
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M^AK^$_\ X,]0_P#D*NB^'W_!M#\1K_5(U\5?$/P3I-EN_>/I,5UJ$NWV62.
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M?(9X5; 69<;61L!PNTE2%9?V\_9W_;.^&'[5>AV][X%\9:-K4DR[FL1,(K^
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M3^=K]O?]BCQI_P $S?VEX+C39M2M]#-]_:/A'Q% Q5B(V#HI<?=N(CM##@G
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M\\_PI^.NH?#'X6?$CPS:S216_C[2[6QGV_Q>3>PS@'ZJD@SZ,1WK^H"OQO\
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MOVAX7 ^J@\]*CT'_ ((4_M/>.-33^UO#&G:26.PW&J>(K28(O')\F25L<G@
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MJWCCX7ZQX+T33O$P%YJ=AJ]Q<VYBOB3YLD7E02@K(?G.=I#L^!@C'V_^P?\
M#7XE_!G]F[1/"7Q3U+P[K7B#PZOV&VU#2+J>X6ZLT $/FF6*(B51E#@$%44D
MY)K*BI1]UC9[)1116P@HHHH ^8O^"RW_ "C.^*G_ %Y6G_I=;5\%?\&SO_)P
MGQ(_[%V'_P!*5K],/V_OV?-:_:J_9!\:_#_P]=:79ZSXDMX(K:;49'CM4*7,
M4IWLB.P&V,@84\D?6OF7_@D%_P $KOB%^P!\4O%NN>,M8\&ZE::]I4=C;IHU
MW<S2(ZS!R7$L$0"X'8DY[5C*+]HF5T/ORBBBMB0HHHH ^"O^#C#_ ),$T_\
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MRA8 E2RD@D XQP.E94XM3;8V<E^WI_R8S\:/^Q$US_TWSU^0/_!O#_RD&/\
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M>T7_ ,#8O_BJKEEV,O;T_P"9?>;5%8O_  L?P]_T'M%_\#8O_BJ/^%C^'O\
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MC^'O^@]HO_@;%_\ %4?\+'\/?]![1?\ P-B_^*JN678R]O3_ )E]YM45B_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MZ/>^CO<_2JOCS_@NHVW_ ()YZ]CC_B:6'_HX5]AU\=_\%UO^4>6O?]A2P_\
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M/.?3BOT&HK&OG6)JTW3G:S\COROPQR3+\7#&X=2YX.ZO*ZOZ6"OSO_X.-/\
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MRV&89E*3=351B[)*]E=V;;>_16/Q=_XAY_C5_P!!SX?_ /@PN/\ Y'JY;?\
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MO)V_A4L>$7T55PH'8**YBBBOTB,5%<JV/XLJU9U9NI4=Y2;;;W;>["NXT/\
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MK1?92^S+[]'Y._0_<&BBBO@3^M HHHH ^9_^"PO_ "CC^)7_ %[VG_I;;U^
M=?OY_P %A?\ E''\2O\ KWM/_2VWK\ Z^VX:_P!VE_B_1'\P^-G_ ".:/_7I
M?^ES"BBE7EA]:^B/QT2BOMC]O3_@FM)\./V;OAY\8O!-B\GA_6O#.E2^(K.%
M=W]G74EI$3<@?\\I&/S?W7;T8;?B>L,/B(5H<\/^&9ZN<9/B<LQ'U?%*SLFG
MT:>J:\OR=T]4%>B?LL?M->)/V2/C1I/C3PS/MN[!]MQ;.Q$-_;L1YD$@'56
M_ @$<@5YW16LX1G%QDKIG!AL15P]6->C)QE%IIK=-;,_I2_9?_:5\-_M9?!K
M2?&GA>X\RRU!-L]NS S6$X WP2 =&4GZ$$$<$5Z%7X _\$S/^"@.I?L,?&59
MKI[B\\#Z^Z0ZY8(2VU1PMQ&O3S$R?]Y<KZ$?O9X0\7Z9X_\ "VGZWHM];ZEI
M.JVZ75I=0-NCGB<95@?<&OSW-,NEA:ME\+V?Z']@<!\94L^P7-*RK0LIQ_\
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M?%3^?Z']">!O\/&>L/\ V\=1117RI^^!1110 4444 %?._\ P5@_Y1Y_$_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M?X5_Z4C\>Z***_1C^-3=^%__ "4GP_\ ]A&W_P#1BU_3K#_JE^@K^8KX7_\
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M_/<ZP\J>*DVM):H_L+PUS:AC,AH4Z<ES4URR756T5UYJS1-1117DGWP4444
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M_P"D<5>C5YS^Q]_R:3\+?^Q1TG_TCBKT:ORNM_$EZL_O++?]SI?X8_DCPO\
M;^_8AT/]N3X'W7A^]$-GX@L0UQH>J,F6LKC'W6/4Q/@*Z^F".5%?@#\5_A9K
MOP3^(FK>%?$EA-INM:+<-;74$@Z,.A![JPP0PX(((X-?TY5\7_\ !77_ ()L
M0?M??#QO%WA:SCC^(WANV/E!!AM:MERQMF]9!R8R>Y*]&!'N9+FGL)>QJOW7
M^#_R/S'Q.X$_M2B\RP,?W\%JE]N*Z?XET[K3M;\.Z*DO+2;3[N2WN(I(9X7,
M<D<BE6C8'!!!Y!![&HZ^X/Y;-#PMXIU'P1XDL=8TB\N-.U33)TN;6Y@<I)!(
MA!5E/8@BOWH_X)A?\%!M/_;E^#J_;Y+>U\>>'HTBUNR3"B;LMU&O_/-\<@?=
M;(Z%2?P'KO/V:OVB_$G[*WQBTCQIX7NC!J&ER?/$2?*O(3_K(9!W1QP?3@C!
M (\O-,NCBJ5E\2V?Z'W' O&-7(<=SRNZ,[*<?+^9>:_%77FO9/\ @LE_RD6^
M(7_72U_])(:^7Z]D_;Y^/VD_M0_M1^(/'6BPW%O8^((K6;R)Q^\MY%MHDDC)
MZ':ZL,C@@ ]Z\;KLP<7&A",MTE^1X'$6(IU\UQ-:D[QE4FT^Z<FT_N"OT*_X
M-T?^3H/&?_8M'_TIAK\]:_0K_@W1_P"3H/&?_8M'_P!*8:Y<X_W.IZ?J>WX=
M_P#)1X3_ !?HS]BJ***_.3^S HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **\W\7>)IM
M3O67<RQC[J<@ =OKD<Y/K^>-]H;_ &?^^105RGL-%>/>>W^S_P!\BCSV_P!G
M_OD4!RGL-%>/>>W^S_WR*//;_9_[Y% <I[#17C_F2;-VT;?78*3SV_V?^^10
M'*>PT5X]Y[?[/_?(H\]O]G_OD4!RGL-%>/>>W^S_ -\BCSV_V?\ OD4!RGL-
M%>/>>W^S_P!\BCSV_P!G_OD4!RGL-%>/>>W^S_WR*//;_9_[Y% <I[#17CWG
MM_L_]\BCSV_V?^^10'*>PT5X]Y[?[/\ WR*//;_9_P"^10'*>PT5X]Y[?[/_
M 'R*T?#_ (DN-(OHS&S%2P!3/##TQTH#E/4**1&WHK?WAFEH)"BBB@ HHHH
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MGX':5?SVMQXW\N>VD:*1?[&OSM93@C(@QU':H?\ AZ1\"?\ H>O_ "BZA_\
M&* /H"BOG_\ X>D? G_H>O\ RBZA_P#&*O:/_P %*/@AKLJI#X^L8V8X'VBR
MNK<?G)$HH ]RHK)\(^.]#^(&G?;-!UG2=;LP<&>PNX[F//\ O(2*UJ "BBO
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M_'K>-/"-C(?AWXBN#^[C4LNAW+9)@/I$W)C)Z<KU W?89%FG,EAJKUZ/]/\
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M)C?%KQ5X/UW4_#/B31M+2:QU/3IS!<VC^?&"4<<J2"1D=C7U!7R!_P %\/\
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M2[+CYE@?Y;8 ]2&A$;_5C7Z%4%!4UA_Q_0_]=%_G4-.CW>8NW[V>* /7[?\
MX]X_]T4^OF/PK_P4$^'^OW AMO&5G#)$QC:.X\RWPP.""95QV[<5ZAX5_:"T
M_P 4S+_9^J:7JL9&<6EU'<,1Z_(:"+'IE%<M:?%&W; N+>:-O]GYL?RK5M/&
MFFW9 %RJ-Z2 KC\Z!69J44R&YCN5W1R)(OJK9I] !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MI4A<C!7G</S.H _6C_@G=^W@/VKO#EUHVOK:VGC318EDF$(V1ZE!POGHO\+
MD!U' + C .U?IBOQ7_8;^)4WPI_:P\#:I'-Y,,VJ16%R2,KY%P?)DR/97+>Q
M4'M7[44 ?@O\0?\ D?=<_P"PA/\ ^C&K'K8^(/\ R/NN?]A"?_T8U=%^S!IM
MOK/[2WP[L[RWANK2Z\3:;#/!,@DCF1KJ(,K*>&4@D$'@@T <+17[EG]FSX=$
M?\B#X*_\$=M_\17S?^WI_P $X/!&M_!_7/%'@W1;/PSX@\/VTNHM%8KY5K?1
M1J7DC,7W$(4,5* <\'((P ?FQX/\:ZO\/O$%OJNAZE?:3J5JP>*YM)FBD0_4
M=O;H:_4;_@FW^W;/^U!H-UX=\2^2OC#0X1,TR (NIV^0OF[1PKJ2H8#@[@1C
MD#\I:]L_X)T^+;KP?^V;X%FMF_X_+TV$J]GCFC:,Y^FX'ZJ* /V4J.]O8=-L
MYKBXFCM[>W0R2RR,%2-0,EF)X  &23TJ2OAG_@L1^U5-X5T&S^&.BW/EW6M0
MB\UN2-AN2VW8C@R#D;V4LP('RJO4.: /-?VY?^"INK_$/5KSPQ\-[ZXT?PW"
M6AFU:$F.[U3L3&>#%%UQC#L.25SMKXQFF>XF:21FDDD)9F8Y9B>I)IM>Z?L4
M_L-:[^U_XEFD69M'\+::X2^U1HM^7QGR8AP&D(()YPH()SD @'A=%?L%X$_X
M)C_!CP-I<4#>$UUJ>/EKK5+F2>64^I (C_!4 ]JQ_BU_P2D^$GQ$T.2+2M)F
M\):EM/DWFG3NRJW;?%(Q1ESU VD_WA0!^3NE:O=:#J4-Y8W5Q9WENP>*>"0Q
MR1,.A5EP0?<5^@__  3\_P""H5QXLUFQ\#_$J\C:\NBMOI>N. OGOT6*XQQN
M/ $G<_>Y.ZOBW]H_]G7Q#^S#\3+KPSXAA7S$'G6EU'_J;^ DA94/H<$$'D$$
M'I7! X- '] %%?./_!,G]I^X_:-^ 2V^KW!N/$GA-TT^^D8Y>YC*DP3-_M,J
MLI/4M&Q[U]'4 ?@O\0?^1]US_L(3_P#HQJQZV/B#_P C[KG_ &$)_P#T8U=!
M^S)I-KK_ .TE\/;&^M;>]L;WQ+IL%Q;SQB2*>-KJ-61U;(96!(((P0<4 </1
M7[>7G[(?PIOK62&3X:^ U60;28]"M8V'T94!'U!!KYG_ &XO^"6_A%_ACJOB
MCX>V#:#K&B6[WDVGQ2M):W\2 LX"N24D"C(VD*=N-N3D 'Y\_#GXH>(?A'XF
MAUCPSK%_HNHP$%9K64IN']UAT93W5@0>XK]5O^">W[<L?[6O@VXT_6([>S\9
MZ&@:]BB^6.]A) %Q&O\ #R0K+T!((X8 ?D77M'_!/3XBW'PU_;#\#W$+#R]4
MU!=(G0_=D2Y_<\\CHSJP]U'7I0!^S%?@7X@_Y#U]_P!?$G_H1K]]*_ OQ!_R
M'K[_ *^)/_0C0!3HKT3]D?2K77?VH?A_9WUM;WEG=:_9Q303QB2.9#,H*LIR
M&!'!!X-?L.W[-GPY=2#X!\%$'@@Z';<_^.4 ?AI6MX(\>ZU\-O$,&K>']4OM
M'U*V;='<6DQC<>V1U![@\'O7Z,?\%!?^"<O@N?X.:]XR\%Z/;^'-<\/6[ZC/
M;62^7:7L"?-*#%]V-E0,RE !\NT@Y!7\T: /UH_X)S_MS2?M7>%+S2=?6&'Q
MEH,2R7+1+LCU& G:)U4<*0V RCC+*1@-@?3%?CW_ ,$Q_%T_A+]M7P=Y6YH]
M2>>PG0-MWI) ^,_1PC8[[?QK]A* /S+_ ."V?_)Q/A?_ +%Q/_2FXKXSK[,_
MX+9_\G$^%_\ L7$_]*;BOC.@#]C/^":7_)C_ ("_Z][G_P!*YZ]TKPO_ ()I
M?\F/^ O^O>Y_]*YZ]TH _G_HHKT3]DOP9IGQ$_:5\%:'K5JM]I6J:K%;W5NS
M,HEC8\C*D$?@0: /.Z*_8S_AVE\#_P#H0K/_ ,#[O_X[1_P[2^!__0A6?_@?
M=_\ QV@#X_\ ^")G_)Q/BC_L7'_]*;>O/_\ @JU_R?!XJ_Z]['_TDBK]+O@Y
M^R5\._V?]?N=4\'^&X-%O[RW-K-*ES/*7B+*VW$CL/O*IR!GBJ'Q/_8D^%OQ
MF\9W7B'Q-X3M]4UB\5%FN7N[B,N$0(O"2!>%4#@=J /Q4HK]C/\ AVE\#_\
MH0K/_P #[O\ ^.U\E_\ !5S]EOP%^SUX/\'W'@WP[#HLVI7EQ'<LEQ-+YJJB
M%1^\=L8)/3% 'Q/117Z ?\$POV/?AO\ 'G]G2\UKQ;X7M]8U2/6Y[59WNIXR
M(EBA8+A'4<%F.<9YH _/^OL#_@BE_P G3Z__ -BI<?\ I79U]F?\.TO@?_T(
M5G_X'W?_ ,=KJ_@[^R'\.?@#XFGUCPAX9@T74KFU:REG2YGE+0LZ.5Q([#EH
MT.<9X^M 'I-%%4_$&NVOA?0;[4[Z3R;/3K>2ZN)"/N1HI9C^ !- 'YP_\%H_
MC1_PDGQ:T+P1;29M_#5K]LNP!_R\3@%0?]V(*1_UT-?%-=1\:?B9=?&7XM>(
MO%-Y\LVNW\MWLYQ$K,=B#)/"KM4<]!6Q\$/@K>?%OPYX^O+6!IE\)^'GU9B
M204FBR!QU\OS3]%:@#@[:YDL[F.:)FCEB8.C*<%2#D$5^X'[,?Q?C^/'P#\*
M^*E=7FU6P0W>  %N4^288'  D5\>V.!TK\.Z_1+_ ((G?&8ZAX:\5> [J;,F
MGR+K%BA'_+-\1S#Z!Q$?K(: /NZBBB@#X_\ ^"UO_)K&@?\ 8UV__I)>5^7]
M?J!_P6M_Y-8T#_L:[?\ ])+ROR_H **^^_\ @C5\,/#7Q \#^.)->\.Z'KDE
MM?6JPM?V$5RT0,;Y"EU.,X'3TK[!\2_LB_"WQ=IC6=]\/O"#0MWATN&"1?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M_H6HH_UFK_RK\?\ ,/\ B"64_P#/^I_Y+_\ (G\]/_#K/]H3_HE7B;_OB/\
M^+H_X=9_M"?]$J\3?]\1_P#Q=?T+44?ZS5_Y5^/^8?\ $$LI_P"?]3_R7_Y$
M^#_^"%G[-7CO]F[X<^/K3QUX9U+PU<:IJ-K+:QW84&=5CD#$8)Z$C\Z^@O\
M@H[\.];^+'[$WQ \.^'--N-6UK5+%([6T@ ,D[">-B!DCL"?PKVZBO'K8R=3
M$?66E>Z?EI_PQ^BX#ANAA,G_ +%A)N'+*-W;FM*]WM:ZOIH?ST_\.L_VA/\
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M1_PZS_:$_P"B5>)O^^(__BZ_H6HH_P!9J_\ *OQ_S%_Q!+*O^?\ 4_\ )?\
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MI/\ AUG^T)_T2KQ-_P!\1_\ Q=?T+45]!_K-7_E7X_YGY'_Q!+*?^?\ 4_\
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M 4'_ ,>H'H8VC_\ !&#X&Z;^P-_PSK+HM]=>"Y'-U)>/< :D;TG=]K67;A9
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MG#)&W&7."0?ESU !]:?\$GOA?>?#7]D'3YKZ,PS>*+^;6EC;.Y8W6.*,G/\
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M+P@/]U%KTZ@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_P#I)95^Z%?A?_P4A_Y34ZO_ -C!H/\ Z26573W)D?NA1114%!1110 4444
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ML_[#-Y_Z/>OW:K\)?C1_R6+Q9_V&;S_T>] ',TJ(TCA54LS'  ')-=+\%_\
MDL7A/_L,V?\ Z/2OW:H _"+PE\(/%GCZ_6UT/PSKVK7#G 2TL)9C[_=4XQZG
MI7U+^S/_ ,$@/%WCR_MM0^($G_"*:(&#O91R+)J-RO7'&4BSZL2P_NU^G%%
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M)MP';/3.<BO:*** "OA?_@N'_P B%X _["%W_P"BXZ^Z*^%_^"X?_(A> /\
ML(7?_HN.@#\YZ_4S_@C)_P FEW__ &,=U_Z)MZ_+.OU,_P"",G_)I=__ -C'
M=?\ HFWH ^M**** .?\ BK\1+/X2_#77?$VH?\>>A6,M[(N[:9-BDA ?5CA1
M[D5^%_B[Q1>>-_%6I:UJ4S7&H:M=2WES(>KR2,78_B2:_2;_ (+-?&G_ (1#
MX'Z3X-M9MMYXLO/.N55QD6MN58AAU^:4Q8/0^6U?F30!Z%^RK\0_#OPD^/\
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MSV94]:^2*_1C_@AY_P B%X__ .PA:?\ HN2@#[HHHHH **** "BBB@ HHHH
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M=<9WG.<]J^EOV6/V7O"O[(7P>T_P;X3M/)L[0;[FY<#S]0G( >>4]V;'3H
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M7JG_  ;C_&74M,^-GC;X?M-+)I.IZ3_;21$_)#/!+%$6 [%EF /KL7TKRO\
MX*0_\IJ=7_[&#0?_ $DLJ<5:0/8_<+Q)XDT_P=X?O=6U6\M]/TW387N;JYN'
M$<4$:C+.S'@  9K\O?VH/^#@?6M6\;R>&_@CX6AU"/S?(AU74;>2XGOWSC,%
MLA! /;<23_='2O3/^#B#XT:GX#_9?\,^%=/FDMXO&FK.+YT8J9;>V0/Y1]FD
MDC8_[E:'_!"']D#PU\._V7M-^)LUC:WWB[QF\[I>R('DL+6.5X5AC)'R;C&S
M,1RV0"< "I5DKL/(^:=3_P""B7[<GPXT]O$6N>$=8715 E;[=X,,=JB <Y94
M5E'?):OI;_@GU_P7!\/?M/\ BNQ\&^/-+MO!_BS4&$-E=0S%M.U*4\",;OFB
MD8\!6+!CP&!(4_>C#<,'D'@@]Z_&;_@O?^R5H/P ^,?A?Q]X1M8=%C\9>=]M
MM;4"*..\A*,9XU7&TN) 3C'S+GJQJE9Z!JC]?_B/\1-%^$G@35?$WB*_ATO1
M-%MVNKRZE/RQ(OZDG@ #DD@#)-?E;\8?^"[OQ2^-WQ.;PW\"O!JQP22&.S>6
MP;4M4O@/X_*7*1@]=N&QW;TJ_P#!4']KC7?BG_P2Y^ OVFXD^T>/D:XUEQQ]
MK>Q58FW>S2MYF/50>U?4G_!#;]F;0?A%^QIH_B^&SMY/$WCSS+V]OBF95@65
MDB@5NH0!-Q ZLY//&%:RNPW/G?2/^"AG[:7[-\$>O?$KX8WFO^%HL27C3Z)]
ME:*/J3YMN,1$#O(AQCD5)^TE_P ' FM:;X_T/_A5^G^';_P[JFE6US<1ZK:R
MF\L+MG=98'*R*N5PN" 00<Y(-?JI+$LT;(ZJZ."K*PR&![&OP3_X+ _LXZ#^
MS9^WA>6/AJUCT_1_$%M;:W%91*%BLWE9ED1 .B[XV8#H ^!P!3C9L'='Z'_\
M%2/VZOC'^Q%;^&_$OAG1?"^K>"M>@2":>[M)GFL+W!;8Q60#8Z\J<=5<>F?:
M?^"=_P"VII_[<O[.UCXHC6WM->LV^Q:Y8Q$[;2Z49RH))\MUPZY)X)&25-=I
M\:/@-H7[37[/.H>"/$<(FTS7M.6$N%!>VDV@QS)GHZ.%8>X]":_&_P#8U^,?
MB/\ X)&_M_ZEX3\9F2W\/W-R-(U\!2(IK<G,%]'GJ%W!P>NQG7J>$M4!^Y]S
M<QV=O)--(D4,2EW=SM5% R23V '>OS&LO^"SOQ0_:#_;1_X5S\(?#_A:^T/4
M-5-AIMY?VTTDC6\>?,NY"LB@)M5Y,8!"X'6O2_\ @N/^W-%\$/V=+?P1X;U!
M&\1?$: AIK>3)MM,(Q)(&'_/7.Q2.J^8>PK&_P"""_[#?_"G_A%-\5O$%GL\
M1^-H?+TI9%^:TTW((<=P9F ;_<5/4TDK*[#J?H1 K)"BR,'D"@,P&T,>YQVI
MU%%24%%%% !1110 4444 %%%% !103M'-8NM>-[72UQ'B>3H,'Y?_K_A0!M$
MX%9.K^,;/2E;YO.D&1A3QGTSTKY]_:8_;S\$_ #3VD\7>*+6QF92\6FVI$EU
M/_NQ@Y/XG\*_._\ :5_X+>>*O&9N-/\ AUID?ABQ8&,:C=@7-\XZ94$;$!'8
MJ2/6O0PF68C$?PXZ=WHOZ]#Y/B#C?)\F36+JWG_)'67W;+YM'Z;_ !W_ &L_
M#OP<T&74/%/B33?#MBN0%>7$LI[ #[Q)^@K\_OVC_P#@NQF6>Q^&V@?:-I(7
M5-8SMYSDI I&.>02Q!STK\\_&_C[7/B5K\NJ>(-6U#6M1F.6N+R=II/H"Q.!
M[#@5DU]/@^'J-/WJWO/\#\+X@\8LSQ=Z>715&'?>;^>R^2OYGH7QK_:K^(7[
M0U])-XN\4ZIJD4G_ "ZB3R;51V'E)A./4@GWKST# HHKWJ=.,%RP5EY'Y/BL
M77Q-1U<1-SD]VVV_O844459SA1110 4444 %%%% !1110 5^LW_!)?7[?XQ?
M\$_-0\)S;F_L6XO=*GW\[A,6G&/;;(!^%?DS7Z$?\$%_B))#XH\>>%)IE%M<
M6T.I01]VE!V.?^^%%>+G]+GP;?9I_I^I^F>$N/\ JW$5.#VJ1E'\.9?C%'B%
M[92Z;>S6\R[)K=S'(O\ =8'!%15Z/^UUX._X03]I+Q=8[?+22_>[C7^ZDQ\Q
M0/P85YQ7P)_6@4444 %%.BADN&VQQR2-Z(I8_I4W]DWG_/G>?^ [_P"% %>B
MK']DWG_/G>?^ [_X4?V3>?\ /G>?^ [_ .% %>BK']DWG_/G>?\ @._^%']D
MWG_/G>?^ [_X4 5Z*L?V3>?\^=Y_X#O_ (4?V3>?\^=Y_P" [_X4 5Z*L?V3
M>?\ /G>?^ [_ .%']DWG_/G>?^ [_P"% %>BK']DWG_/G>?^ [_X4?V3>?\
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M+='C;_:1@RGW4UYY^W1^R5:?M:_!Z338S';^)-(+76BW3\*DI W1.?\ GG(
M ?0A6YVX/C?_  3(^#WQF_9MUG4O#7C'PI):^#M5!NHKC^U;2?\ LZY4<X2.
M9FVR  '"GYE0\#<:^S: /P3\:>#-4^'?BF^T36[&XTW5--E,-S;3+M>-A_,'
MJ".""".*H65]-IEY'<6\TMO<0L'CEC<H\;#D$$<@CU%?L[^U-^Q1X*_:PT8+
MKEJUCK=NA6TUBS55NH>.%?C$D8/.QNG.TJ237P+\8?\ @D3\4OA]=32:#'I_
MC+3D!99+.98+@*/[T,A'S>R,_P#2@#F/!O\ P5 ^-/@S2%LE\5C4HH_N/J-G
M%<S#ZR,N]O\ @1)K$^+O_!0#XL_&O1Y--UCQ9=0Z;,I26UT^)+..93C(<Q@,
MX..C$CKQR:P+_P#8]^+&FS>7)\-?'+-ZQ:)<2K^:H15_PU^PW\8/%=U'#:_#
MGQ5$\S!5-Y8M9*"3CEIMBJ/<D"@#RFO5OV1_V3]>_:P^)EOI&G1S6NCV[J^J
MZGY>8[&'OUX:1NBKU)YZ D?1OP#_ ."+VO:Q>P7GQ$UJVT>Q4[GT[3'%Q=2#
M(^5I2/+3//*[_P##[[^%GPG\._!3P9;>'_"^EVVDZ5:Y*PQ Y=CC+NQRSN<#
M+,23@>@H L_#WP%I?PM\$:7X=T6W6UTO1[=;:VC'4*HZD]V)R2>Y)-;-%% '
MX+_$'_D?=<_["$__ *,:NH_9-_Y.G^&?_8UZ7_Z5Q5ZEXQ_X)C?''5?%VJ75
MOX(\R"YO)I8V_MFP&Y6<D'!GST/>M[]GK_@G!\:/ WQ]\#ZWJG@W[+I>C^(+
M"^O)O[7L7\F&*YC=VVK,6.%4G !)QP": /U0HHHH **** "OP+\0?\AZ^_Z^
M)/\ T(U^^E?D/K'_  2^^.EUJ]U+'X'W1R3.RG^V=/Y!)(_Y;T <'^QE_P G
M:?#?_L8['_T<M?MI7Y;_ +,W_!.?XR_#W]H?P3KNL>#OL>E:1K5K=W<_]K6,
MGE1)*K,VU9BQP > "?:OU(H X#]IWX!:=^TO\%]8\)ZAMC:\C\RRN"/^/2Z4
M$Q2?0-P0.2I8<9S7XH>,?".H^ /%>HZ)JUK)9ZGI-P]K<PN.8Y$)!'OTX/0C
MFOWNKXC_ ."FG_!/G7_C?XTTWQE\/])AU#6+I!::Q9BXAMC*%'[NX#2NJD@#
M8PSG 0X/)H ^#_V?/C=JW[._Q<T?Q9H[9N--E_>PDD)=0MQ)$WLRY'L<'J!7
M[7?#'XCZ3\7O &D^)M#N/M.EZS;K<0.>& /!5@"<,K JPSP5(K\G?^'6_P =
MO^A%_P#*UI__ ,?KZ^_X)C?"CXQ?LZOJGA7QMX6FL_"=YF\LKG^TK.X^PW/
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M\&Z3_;&J6OB"&^EA^U0V^V%;:Y0MNE=5.&D08!SSTP#7P?\ \.M_CM_T(O\
MY6M/_P#C] 'TQ_P0\_Y$+Q__ -A"T_\ 1<E?=%?*/_!*W]FKQM^S=X1\7VOC
M31?[%GU2\MY;5?MD%QYJJCACF)W P2.N*^KJ /@/_@L9^RJTZVOQ4T6V9F41
MV.OJBY^486&X/TXC8_\ 7/WK\^Z_>[Q?X3T_QYX6U#1=6M8[S3=4MWM;F!Q\
MLD;@@C]>O8\U^5?Q$_X)0?%_0?'6K6?A_P -_P!N:';W+K8W_P#:=E ;J'/R
M,4>8,K8QD$=0<9&#0!Z9_P $@/VMO^$;\0R?"[7+K;8ZM(UQH<DC +!<8R\&
M2>D@&Y1_?! R7K]&J_(?2O\ @F9^T!H6J6][9^#9;6\LY5F@FCUS3U>)U.58
M'S^"" <U^I7P+UOQ5K_PKT>?QMHQT+Q2L(CU&V$T,R-*O!D1HG9=KXW 9R,X
M[9(!UU?'_P#P6M_Y-8T#_L:[?_TDO*^P*^;_ /@J#\!/%G[1/P"T?1/!ND_V
MQJEKX@AOI8?M4-OMA6VN4+;I753AI$& <\], T ?D?7Z,?\ !#S_ )$+Q_\
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M?NH-3@/^" /['^K_  9^$&O?$/Q%9S:??>.O)BTRWE4JXL8\L)B#T\QVRO\
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MK#;ME;MG(%+1/0-3P_\ X(*?\H]-*_[#-_\ ^AK7OW[;W_)F_P 5/^Q3U/\
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M\!+\*?B==R:-IME<R2:+J\B,T-L)&+/;SXR4&\LROC'SD'& 3^N%?*7[6/\
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MY8O-//(9))6/4LQY)]S5>BBO</RZ4FW=[A1110(**** "BBB@ HHHH ****
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MTS6;?6(=]O(K]R/XA]15J@04444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MB/\ X(M?M":Y^RQ_P08_:A\=>&93;^(-%U+_ $"<'!MY9(K>+S >Q4.2".A
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MW_QVC_A[#X%_Z%OQ=_WQ;?\ QVO@6B@+L^^O^'L/@7_H6_%W_?%M_P#':/\
MA[#X%_Z%OQ=_WQ;?_':^!:* NS[Z_P"'L/@7_H6_%W_?%M_\=H_X>P^!?^A;
M\7?]\6W_ ,=KX%HH"[/OK_A[#X%_Z%OQ=_WQ;?\ QVC_ (>P^!?^A;\7?]\6
MW_QVO@6B@+L^^O\ A[#X%_Z%OQ=_WQ;?_':/^'L/@7_H6_%W_?%M_P#':^!:
M* NS[Z_X>P^!?^A;\7?]\6W_ ,=H_P"'L/@7_H6_%W_?%M_\=KX%HH"[/OK_
M (>P^!?^A;\7?]\6W_QVC_A[#X%_Z%OQ=_WQ;?\ QVO@6B@+L^^O^'L/@7_H
M6_%W_?%M_P#':/\ A[#X%_Z%OQ=_WQ;?_':^!:* NS[Z_P"'L/@7_H6_%W_?
M%M_\=H_X>P^!?^A;\7?]\6W_ ,=KX%HH"[/OK_A[#X%_Z%OQ=_WQ;?\ QVN,
M^-__  5'M?$_@F\TSP?HNJ:?>W\;0/>7[1JUNK#!*!&;+>F<8ZU\<44!=@[&
M1F9OF9CDD]S4UGJ%QITJR6]Q/;NIR#'(5P?PJ&B@1Z=X'_;)^)?P_"K8^*]0
MF@C^[!=MY\(_X":]@\#_ /!5SQ-IQCC\0^']+U:,\226[&W;\$P0?Q-?*-%
M7/O:W_:R^ _[0ENEOXLT>WT^ZD&U1J=CDJ?59(]P'U)%4]8_X)T_#'XM6CWG
M@?Q1):[AOQ;7*:A$#Z$!LH/U%?"O6KFB^(=0\-W23:??7=C-&<JT$I3!_"@J
MY[Y\1?\ @F=\1/!RR3:6-.\1VZ9;%K-Y<H7W63;D^RYKPOQ7X*UCP)?_ &76
MM+U#2;C. EW T);Z;@,CW%>O?#3_ (*&_$KX>M''<:I'XALUQF+44WOCT5Q]
MW\C7N_A;_@H]\/?BM8#3_'GAMM/\X8D=XA>6H_X$/WGY+0&A\+45]ZZK^Q'\
M&_V@K5KSP3K4.F7,HW*NG3K-&@][=B&'XUXE\5/^":7C[P(DMQI/V/Q-9Q\X
MMG\NX5?4H^!^"DT"L?.]%7-=T"^\+:DUGJ5E=Z?=IUAN86BD'X, :IT""BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@"YH/B"^\+:O#?Z;>7%C>V[!XIX'
M*.A'H:^S/V7/^"FPDDM='^(1\J;(2+68U.UCT'G*.0?]H9[YQ7Q/10!^XW@C
MXL6^J:;;S-<1WEG<*&ANHF$BNN/O;APPZ\BNW@N$NH5DC99(V&0RG(-?BS^S
ME^V!XJ_9UU)([2X;4M"=\SZ;<.?+([E#_ WOTXK]&?V9OVQ?#WQJTD3Z#>XN
MXUS<Z9.0EQ">^5_B'^TN>O/I05N?2%%9OA_Q3;>(81Y9\N;&6C;J/IZBM*@D
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH ***\?_:7_;D\ ?LM1_9]>U"2\UME#1Z38*)KL@C(+@D+&IXY<C(/ - '
ML%%?F?\ $_\ X+4^.->N)H_"OAW0_#]HW$<EWOOKI??.4CYZX*''3)ZUYI>?
M\%4/CI<S;D\916Z_W(]&L2O_ (]"3^M 'Z]T5^1NE?\ !5WXWZ<ZF;Q/8WX!
MY$^D6J@_]^XUKZ3_ &(/^"I'B?\ :"^-NB>!_$GAW15DUA)PFH:>\D/E-%;R
M39:-RX;=Y9'#+@MGM@@'V_1110 45X?^U#^W_P" ?V6VDL=2NY-8\2!-RZ1I
MY#S)D9'FM]V('@_-\V#D*17QC\2_^"SWQ%\2W,B>&])T#PS:;B8RT;7MR!V!
M=\(?PC% 'Z?45^0,W_!4SXZRRLR^-EC4]%71K# _. G]:ZCP-_P6$^+GAB\W
M:H_A_P 20'AH[NP$##W5H2F#]01STH _5:BOE_\ 9A_X*H^!?CS?6NCZTC>#
M?$5P0D<5Y*'L[E^/ECGP &)SA7"YX ))KZ@H ***\?\ VY_V@=:_9D_9]O?%
MF@VNEW>HV]W;P+'?QO)"5D?:<A'1LXZ?-0![!17Y?_\ #ZWXJ?\ 0 ^'_P#X
M W?_ ,DT?\/K?BI_T /A_P#^ -W_ /)- 'Z@45\S_P#!.?\ ;DU3]K[3/$EM
MXCM-%T_7-#DBDCCTY)(XYK>0$;MLCN<JZD$AL?.O [_3% !1110 45^<OQH_
MX+(^-?#'Q8\1:;X7TCP;>>'].OY;6QN+NTN7FN(T8KYA*SH/F(+#Y1@$=ZYG
M_A];\5/^@!\/_P#P!N__ ))H _4"BOSU_9M_X*R?$;XP_'CPIX7U/1?!4&GZ
M[J,=I/):V=TLR(QY*EKA@#]0?I7Z%4 %%?,W_!1[]LWQ1^Q_IGA&;PS8:#?-
MKTMTEP-3@EE""(1%=GERIC/F'.<]!TKY8_X?6_%3_H ?#_\ \ ;O_P"2: /U
M HK\O_\ A];\5/\ H ?#_P#\ ;O_ .2:=#_P6N^**RKYGA[P"R=PMG=J3^/V
MD_RH _3ZBOSY^'/_  6^N!<I'XN\#PM"Q4-<:1>%60=R(I =WM^\%?8WP _:
M@\%_M,^'FU#PGJT=XT 'VFSE7RKNT)_YZ1GD#_:&5/8F@#T"BBB@ HKFOBM\
M8/#?P0\(3:[XJU>UT?383M\R9OFE;LB(,L['GY5!/!/0&OB+XT?\%LI4O9K7
MX?\ A6%H4)"W^M.Q,@]1!&1MY]9#GT% 'Z!45^1>L?\ !5OXX:E.S0^*+/3U
M)R$M](M&4>W[R-S^M&C_ /!5SXX:9.K3>*+/45!SLN-(M%4^W[N-#^M 'ZZ4
M5\#_  /_ ."UT=]J$=K\0_#,5G#(0#J&BEF2+_>@D8MCIRKD^QK[>^'WQ&T/
MXK>%+77/#FJ6>L:3>#,5Q;ON4^JD=58=U8 @\$"@#:HHHH **_+_ /X?6_%3
M_H ?#_\ \ ;O_P"2:[;]FW_@K)\1OC#\>/"GA?4]%\%0:?KNHQVD\EK9W2S(
MC'DJ6N& /U!^E 'Z%4444 %%>;?M>?&+4_@#^SGXF\7Z/!8W.I:+%"\$5ZCO
M Q>>.,[@K*QX<]&'./I7P1_P^M^*G_0 ^'__ ( W?_R30!^H%%?'W_!._P#X
M*!>,OVMOBMK.A^)-,\,V5IIVDM?QOIMO/'(SB:),$R3.-N'/0 YQS7V#0 45
M\+?ML?\ !3CQ[^S=^T9K7A#0])\(W6FZ;%;/%+?6MQ).QD@21LE)T7JQQA1Q
MCKUKRC_A];\5/^@!\/\ _P  ;O\ ^2: /U HKYR_X)\_MT_\->^&M2M-:M]/
MTWQ=H[>9/;6:ND%Q;,<++&'9FX/RL"3@[3_%@?1M !117E_[9OQKU7]G;]FO
MQ)XRT2WT^ZU31_LODQ7T;O;MYMU#"VX(RL<+(Q&&'('4<4 >H45^7_\ P^M^
M*G_0 ^'_ /X W?\ \DU]3_\ !.']LWQ1^V!IGBZ;Q-8:#8MH,MJEN-,@EB#B
M42EM_F2OG'EC&,=3UH ^F:**^#_VS?\ @J%X_P#V=OVE/$G@W1-'\'W6EZ/]
ME\F6^M;E[AO-M89FW%)U4X:1@,*. .IYH ^\**_+_P#X?6_%3_H ?#__ , ;
MO_Y)H_X?6_%3_H ?#_\ \ ;O_P"2: /U HK\Q+3_ (+8?$U)/W_ASP)(OI':
MW:'\S<&N\\!?\%P5+1Q^*/ 9"E_GN-+U#.U>.D4B\D<_\M!GVZT ??\ 17D_
MP _;:^'/[2;+;^'->C75""3IE\OV>\&/13P__ "V*]8H ***CO+R'3[26XN)
M8X+>!#)))(P5(U R6)/  '))H DHKXX_:/\ ^"POA/X<7UQI?@?3V\8:A"2C
MWKR>3IT;<?=."\O<<!5X!#$5\S>+O^"O'QD\17TDEC?Z'H$3?=ALM,CD5.,=
M9_,)/?KU[ <4 ?K!17Y Q_\ !4KX[)(K'QPKA3DJ=&T_#>W$&:ZCP9_P6&^+
MOARZW:DWAWQ!"1ADN]/\DCGJ#"R8/;D$>U 'ZK45Y1^QG^TM)^U=\%(?%4VD
M+HL_VJ2REMTN//5GC"Y=254@'=PISCU/6O5Z "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M[K%&.T_7@^M>9U^NW_!2;XK^%-$_9)\46&H:CI]Q=ZQ"MM8VJ2K)+-+O# @
MY  4G=T'XU^1(X% !5[PSXHU+P9KEOJ6DWMQI]_:L&BG@?:RD?S^AJC10!]\
M?LB?\%(;7Q?-::'XTFATO6^(X-2^[;W9[;_^>;GU^Z?49Q7W!X3^(4>I(D=T
MRH[8V2@_*X/3G^O0U^$Y&:^C_P!D[_@H!K'P;DM]%\3-<:UX;R$20MNNK ?[
M)/WU_P!D\^]!7J?KB#FBO*_A'\>--\:>';;4M-OH-6TFZ 9)H&SLR.F.H/\
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M .@W-?GG7Z&?\$-?^0#\2/\ KXT__P!!N: /O2OQ_P#^"I'_ "?;XZ_[</\
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MU>?U^TW["NI>'-2_9,\#_P#"+M;?88=+ABN$B(S'=A1]H#CL_FER<]<YZ$4
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MH/\ , U]"?M#_P#!9CXT?M'_  QN/">I7/A_0],OD$5X^BVDEO<7B=U=WE?
M/?8%STZ<5\HT5SU,+1J352<4VMF>M@\\S#"X>>%PU:4:<]XIM)]/Q6C[@!@4
M445T'DA1110 5^E__!!KXBQWG@?QUX3FN&DN+6[AU.&%N1'"R^6V/8N:_-"O
MKC_@BU\1G\'?MC1Z/A?)\5:7<6DC$XVF)#,OYL@'XUY><T?:8.:[:_<?=>&^
M8?5.(L-)[2?(_P#MY67XM$GQN\&_\*\^,'B;1-NU=-U&:%/=0QP17+U] _\
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MDMR7RZ_2.)UY[2_E\3U^BW_!#N53X&^($>X;UOK-B.X!CEQ_(_E0!]U4444
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M&KX/?\)E^T#J7BRXA+6?A"Q(A8KQ]IN-T:_E&)CQTX_'Y)\0?\AZ^_Z^)/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M?A^Q_P""U/P-F\5MI:^&XM$T]M2.I(KV8@%_<[_-# J4QU!!&* 9^B_[,_\
MP<-?LL_M5?$FS\)Z#XRU?1=:U*5+>S3Q%I?]G17<KG"QH^]AN)XP<=:7]L3_
M (+3:/\ L@_\% ? /P#NOAWJFO7WCR2QCBUJ'68[>&S^U2^4"83$Q?;U/SKG
MM7Y&?\'"&N_LP_%'X]?#'3_V8-/\$WWB24F/59? UHD.G7 :0""(1P!8C,#N
M)(7=@C)QBNS_ ."U&M^+/AI_P6#_ &<;Y-#NO%'C?1-#\/R'2DD_?:E?QNN8
M0W]YI!C/O03<_H:HK\._&O\ P5N_;:_X)]?\% / .@_M'1^$F\&?$*>&1=#L
M+6T:UL[.681.\-U$HF\R+)^621QE>0:_0K_@HO>_'Q/$NDR?#KXV_"_X"^ X
M].:6_P!>\2:?#J-W<W98%8TBE!54"9RVWK0.Y]=45^3_ /P2F_X+$?$3QQ^W
MYXJ_9Y^*7CKP7\8X[:UNKK0/&OA>UB@347MU,K1[(0L>#$LG&W<&4#->5?LO
M_P#!5+]I[_@K#^V!XX\,_#WXU?#G]GC2_#:R'2M"U30[74KG5@DI4C,Z-(7
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M_%217XB?M%? [5/V=/C#K7A/5%;S-/F/V>8C"W=NQS%*/9EQ]#D=0: /8?\
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M_P#\%5I_C#X>O/"/P_AO-)T&]4Q7VIS_ +N[OHR,-$B@GRXVZ$D[F''R@D$
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MVR>SO8&@GA/HR, 1^-2JD7+E3U['1+"UHTE6E!J#V=G9^CV,RBBBJ.<^\/\
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MT+7#OY3?[28-?F9_P6D@D?\ X.*/V>&6.1E%QH7(4D?\?8K]TZ, _P *_7%
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M)Y-JS#!8[>6QDXQWQ7YZT4 2WU[-J5]-<W$C37%S(TLKGJ[L26)^I)-1444
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M?B#_ )#U]_U\2?\ H1K]]*^0[S_@BY\+;V[EF;7O'P:9RY OK3 ).?\ GVH
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MVN8VU;XA:G>P@_.MII26K,/9FDD _(T ?G:B-(X55+,QP !R37W'_P $^_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MCXT\$WU]>>%+R[%G=6=XWF3:<[ [&$G\:$C;SR"1VJUFF'>(^K7][\+]C"7
MN;QRG^V7!>RM??WN7^:W;\;:VL?"]%%%>B?'!1110 4444 %!Z444 ?T&?\
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M9 '(Y\M1]P#MWXS0!^5%%>Z?M]_LCQ_LC_%RWT_3[F6ZT'7(7NM-:8YEC52
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %8GC+Q3_85F8X?FNI!A?]C/?_  %7?$&NQZ!IS32<MT1?[QKX"_X*K_\
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M?Y\5^HWPI^#'PU_X)&_ V3Q=XNN(=6\:7T?EF=5!N+B4C/V:U4_=4?Q.>WX
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MW]D;]M'QS^Q3X[N-=\%WELOVZ-8;VQO(C+:WJ*25#J"IRN3@@@C->@?ME_\
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M\_X*S^"_L?C'POKT:?+>6\MI,_NA4H/R+5\AU^:G]MO<****!!1110 4444
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M_P ._P#H+^,/_ N#_P",U]./&T9PRLOU%"022+E49AZ@4!8^8_\ AU/\._\
MH+^,/_ N#_XS1_PZG^'?_07\8?\ @7!_\9KZ;*D-MP<^E*\+QC+(R_44!8^8
M_P#AU/\ #O\ Z"_C#_P+@_\ C-'_  ZG^'?_ $%_&'_@7!_\9KZ:KX5_X*:?
M\%UO"O\ P3E^*UOX$C^&_C/XC>+7L(]2GMM-;[+:V\,C.J$S>7+EB8WR-@Q@
M=<T"T/4/^'4_P[_Z"_C#_P "X/\ XS1_PZG^'?\ T%_&'_@7!_\ &:\O_P""
M6W_!>7X>_P#!3/X@ZEX'7PQK7P[\?V,4EU'HNI7*W2W<"8WLDH2/YUSRA0$
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M-]<]J!KL?KH#D45R_P /?%BZC;):R2!F"AHFW9WK]?U^E=10(**** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M9=6-HHHKZX_G<**** "BBB@ HHHH ***EL;&;5+V&VMH9+BXN'$<<:+N9V/
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M\-#O4DD_DE^3:/SA^%_[.GCKXTWPM_"WA37-:DS@FWM6*I[D] !ZU]&?#?\
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M_&7B#P7H,^C-J.N6&ERSV%D([K=(9)5&U=B\G)&!0*QX%^TYXT_:N_X(S?\
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M\5_V?/L$DL&@V7AO5&T/3('24@0RD#8 JXP74NY/WL"O>?V-/V/_ -J'0O\
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M>&XRBVK7442#4=6=0S1VT>,/*WWL+D@9)KUI+>&T58;=%BMX0(XD5=JH@X4
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M^@H(L?*=%=/\0?@MXL^%5WY/B#0-2TOG"O+"1')[JW0CWKF*!!1110 4444
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M+GJ[>BJ.237ZD?%SQUX:_P""1_['-AX;\/BUNO&6KHRP-CY[RZ*@2W<G?8G
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M%/W:^;:**]G#X>%&"ITU9(_-LVS;%9EBI8S&3YIRZ_HNR71!1116QYP4444
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M;/AU^SIX<_X1/X+^'=/U%K(&*.XB@^SZ9;'N5& TASSD J?6O@OX\?M7>/\
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M.:/N#P58?Q*1P0>H->M_&?\ X*2?%+XX^!I_#NJ:G96>EWB[+M;&V$,ERO\
M=9ASM/=>AKP6B@ HHHH LZ-K-UX=U:VO[&>2UO+.19H94.&C=3D&OT ^'?BW
M0/\ @HC^SM<Z)K7DV_B;34'G'^.WG ^2X3OM;D'\?;/Y[5U?P6^,.K? SX@V
M/B#2)&6:V;;-#GY+F(_>C8>_Z$"@:*7Q,^'&J_"7QO?^']9@:"^T^0HW'RRK
M_"ZGNI'.?PZBL&OO[]I7X6:/^VW\ K'QQX36.37;&W,D2K_K)5',EL_^TIY&
M?_9A7P')&T$K1R*T<D;%65AAE(X(([$>E AM%%% !1110!]B?L5?\%3(_P!G
M7X:0^$_%&AZAK.G:=G[!<6#1^=&I.=CAV4$#L0<UX_\ MJ?M?ZA^U]\1K?5)
MK,Z9I&EQ-!I]F6W-&K$%F<C@LV!TX&*\;HH **** +F@:]>>%];M-2T^9K>]
ML95G@D4\HRG(_P ^E?K)^QK^TA;_ !H^'6F^((V5+HC[-J4 /,<R@;OS!##Z
MX]:_(^O</V#_ -HIO@3\7H[>]F9=!\0%;6[&>(I,_NY?P)(_X%[4#1^QT4JS
M1JZG<K#(([BG5ROPU\1K>VALV=6,8W0L#D,I]#_G@UU5 @HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MW*%2VUKIQO;?=._<_0S_ (.-OB3H-WX5\ ^$X[FWF\26M_+J,L*$-);6[1%
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M#_\ AUM\+_\ GKXL_P#!FG_QJC_AUM\+_P#GKXL_\&:?_&J Y6?GA17Z'_\
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MQDG '?HO^"V/@?Q9X._X+%_LZ^&_"=_IG_":Z5HOA_3=,O;U6-I]LCD$:22
M'.S> 2,YQ02?T-/:31PB1HI%0]&*G!_&B&VDN3^[CDD_W5)K^>']JW3/VD/^
M"*7_  4@^$VO:]\?/$7Q0M_'UQ%=ZDTJR0V=S$UPL5S:M:/+)&,C.UDVD Y&
MVOO[_@LUKOP;D^*/A>W^+?[2'Q0^'5N=)W67@CX?7!@U749&8$7+LL<A(_A"
M'!.<C(H'<_1^:"2W;;)&\;>C+BG0V,UPFZ.&61?54)%?A5_P1'_;W\1>%?\
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M/GDM[:R@>66)07C@G)?=$W!4 #'-?<.AZLGB#0K'4(T:./4+:*Z1"<E%D0.
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MU)[#F@#SF*5[>59(V:.2,AE=2592.A!'(-?5O[+/_!1B[\,);^'?B!NU31W
MACU(J'FMU/&)5Z2)[\$#/WJ['XM?\$6=<\*>"9]0\,^*HO$&I6<1D>QFLOLY
MN,#)$;!V^;@X!')QR*^(KFWDL[F2&:-HYH7,<B,,,C X(/T- 'VE^T]^P+IO
MQ"TI_&7PO>UE%TAN)-/@D!@N@>2T)_A;U0_IC!^,-1TZXTB_FM;J":UNK=S'
M+%*I5XV'4$&O5?V8OVOO$7[-VKI'"S:EX=F<&YTV1^ /[T1_@8?D?3N/JGXE
M?!;P'^W]X _X2?PI=0V/B2--OG[ KAQSY5P@_1AS[GH K<_/NBMSXA_#K6?A
M5XKNM%UVRDL=0M6PRL/E<=F4_P 2GL:PZ"0HHHH **** "BBB@ HHHH ****
M );&^FTR]AN;:62WN+=Q)%(C;6C8<@@U]\_LZ_&C0OVY/@_>>"/&4<<GB"U@
MQ(>%:X &%N(_1Q_$!W&>X ^ :U_ 7CK4_AIXOL=<T>Y>UU#3Y!)$Z]_53Z@]
M"#0!N?'GX):M\ ?B->:!JBEA&=]K<A<)=PG[KC\.H['(YKC*_0O7]*\/_P#!
M1S]G".\L_L]EXHTQ3L_O6-R!S&W<Q/U'L?7-? 7B;PU?>#O$%YI>IVTEGJ%A
M*T,\+C#(P.#_ /K[T#91HHHH$%%!.!3I+>2&*.1XY$CD^XS(0K_0]_PH ;11
M10 5H>%?%%]X*\26.K:;/);7VGS+-#(AP0P_H>E9]% 'Z#>/M#TS_@H1^RI;
MZOIRPP^)],5I(U[P7*C]Y"?1'P".O!'?-?G[>6<VG7<MO<1R0SP.8Y(W&&C8
M'!!'J#Q7LW[#O[2;_L__ !4CBOIF'AW7&6WOESQ"W1)@/4=_48]*]&_X*3_L
MW+X=UR/X@:'$K:7K#*NHK$,K%,?NRC'\+C'XY/>@K<^3Z***"0HHHH ****
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MBVTCZ]7^GWGY;XD9SRPAEM-[^]+TZ+[]?DAM%%%?IQ^0A1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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ME_LD?\$K?B!^TJ;;5-2A;PCX5DP_VZ]C(FN4_P"F,9Y;//S'@&OL::]_9O\
M^"6.D^7&EMJWC2.,'^&\U:5L<$MR+=6]5 ''2OF[]K?_ (+)^+/BN;K1OA]'
M-X/T%LQF]!_XF-RO3AO^60/4;<-S@FOB^]OIM2O);BXFEN+B=S))+(Q9Y&/)
M))Y)/J:X5@\5B_>Q4N6/\J_5GT\N(LCX?_=Y#25>LMZU1:)_W(]/73YH^I?V
MI?\ @K;\1OCZ;C3M#F;P3X>D) AT^0K>3+_TTG^\#_N%0?2OE>>>2ZN))97:
M265B[NQW,['DDGN3ZTVBO7P^&I4(\M*-D?GN;9UCLSK>WQU5SEYO1>BV2\D%
M%%%;GEA1110 C*&Z@'ZBD\I?[J_E3J* NRUX=U<^%_$6GZI'&K2:;=17:#'5
MHW#C^5?L'^WO9K\7_P!C'0/%2HDD\:V6J,P^8(LL.9!_WT5'X5^.1&17Z\_L
M:ZC'^T+_ ,$L(=)>X^V7EEIEUIERQ.662*1IE4^XC,8^F*^8XFHWIPJ+H[??
M_P ,?N7@CF'+C<1@F_BBI+UB[?E+\#X8\A/[B_E1Y"?W%_*E3=M&X%6QR#U!
MI:^./Z.&^0G]Q?RH\A/[B_E3J* &^0G]Q?RH\A/[B_E3J* &^0G]Q?RH\A/[
MB_E3J* &^0G]Q?RH\A/[B_E3J* &^0G]Q?RH\A/[B_E3J* &^0G]Q?RH\A/[
MB_E3J* &^0G]Q?RH\A/[B_E3J* &^0G]Q?RH6-4^ZJK]!3J* "BBB@"WH6O7
MWAC58[[3;RZT^\A.4GMY3'(GT92#7T_\!_\ @I[KGA40Z?XVM?[>T_'EF]A
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MW/SWHKLOCK\#]:^ 'CZXT'6(_F7Y[:Y4?NKN+LZG^8['BN-H)"BBB@ HHHH
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M3+2XLYEGL-4A6>WE7HZLNY6]\C^0KT.@&%%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M?TWX3^'&CM8(HHI=32'Y5AB4 Q0>W0-QV&*^>X@KU,36AE&'=G/6;[0_X/\
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ML\*_]^[C_P"(H"S/E6BOJK_ATMXQ_P"AL\*_]^[C_P"(H_X=+>,?^AL\*_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M;9WAO51=SB&1"A9?=<AN.3MQWKS?6?\ D-7W_7S+_P"AFJ]!F?N9X?\ VC?
M?B?PFNN6?C#PZVEM'YC3/J$48B'HX9@5//0X-?FE_P %1_VJ=%_:0^+6EV7A
MN9;S1?"L,D,=Z!A;J:0J9"OJ@"( >YSVQ7S$LKI$46218VZJ&(4_ATIO2@ H
MHHH **GT[3+K6+DPV=O<7<P7<8X(S(P'K@ G%0,"DC*P*M&2K*1@J1U!'K0
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M^&O[,?[%WC#]DK_@VL^/VK>.-/O-"U3XBM_:]IIEVABGM;58UBC,B'E7?;N
M."%8 @'(KZ&_X)"E?^(8;Q1NV[?[$\6;\],>=<]:_5O6M&LO$NFRV>I65GJ5
ME<#;+;7<"3PRCT9'!5A[$57TSP=HVB: VDV.C:/8Z2P96L+:QBAM6#?>!B50
MF&R<\<YYH"Q^5?\ P:".K?L)_$/:5)7Q:F<'I^X-?K/!_KT_WA67X:\&Z+X*
MLY+?1-%T?1+>1M[PZ=8Q6D;M_>*QJH)]R,UI&1HAO5=S+R%_O'TH&?C7K/\
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M_P!#UJG_ 'XM_P#XW7DM%?/'[!<]:_X;L^+W_0]:I_WXM_\ XW1_PW9\7O\
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MF&[U%K<33QPC_D(Q <\=I4[CN,^@S\+LK(S*RLK*<$$8((Z@U]!?L(?M9R?
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M:VR6SOYZ>3OH>SF7#>5T<BCCJ4_WC2=[Z-NUU;RU\U;4^ :***^Z/SH****
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MR.*O4""BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M[Q),Z*2DD2 +G.)#@=:^OO\ AXE\(/\ H:)__!5=_P#QNC_AXE\(/^AHG_\
M!5=__&Z T/ _^"*G_!,K6/V,_P!@K7_"'Q.L[>/QM\2[R^N_%$4%S'<M"DZ>
M2L7FQDHQ";G!5B 9.N0:^)? 7_!)[]N__@E9\6?%EC^RUJ_A?Q3\/_$]R;B-
M=3N=.9;< X3S+>_8 3!<*9(P=P4<]!7ZK?\ #Q+X0?\ 0T3_ /@JN_\ XW1_
MP\2^$'_0T3_^"J[_ /C= :'R]XY_X)C_ !H_;K_X)7>)OAK^T%XTT63XL:]K
M(\1:=>6,2_8M(EB0+#:L(@$\O.\MY0*_.#ZU\;> O^"7O_!1G5/V-/%'[/\
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M_7*[C_OU\_U]]?M2:5#^U9^Q/I?C&Q43ZEI4"ZCE1EL@;+E /=E_(5\"@Y%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M93\,^++?$TEF\$[-C[J31?O.?9E44%=#X1HHHH)"BBB@ HHHH **** /:_\
M@GOXK_X1?]J?0%9MD.J+-9RG/8QLP_-E6OUU^'5UYVC.FXLT;Y.?< _SS7X@
M?"3Q$WA+XI^'-25MGV/4[>1CZ+YB[O\ QW-?M3\)=56\,FW[MQ"DZ_3M^C"@
MKH=M11102%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M_9>&'WKU/_)8_P#!7XGD]%%%?6'Q(4444 %%% &30 45[MX)_P"":WQF\?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M/V_PWX/:5I;X#]W?73?+NC[[%7(SWW>U?$(N9%M3 ))! QR8PQV$_3I3*\_
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MY=OKMG);,,_?D7F,?F37SW73?!CQFWP[^+7AO7%)!TS4(ICCN-V/ZT >E?\
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ME\ZPA;^\BG]*FK/\*NS:!;;L;E4J<'N"1_2M"@04444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !7%_%:^^SE%_NP,_P"1!_I7:5Y?\?\ 7DT;2=6NI/NV-@SGG_8<_P!1
M51BVTD*4N5.3Z'XB_&G6O^$D^,?BS4,[OMVL7=P#[-,[?UKF:=)</=R-+(=T
MDAWL?4GDTVOZ/IPY(*"Z*WW'\J5:CJ3<WU;?WA1115F84444 %%%% !7Z&?!
M!O\ A6W_  2=U75/]7+=Z;>76.Y8SF(?F%K\\9FVQ,?0$U^AW[2@_P"%:_\
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M<XKPO_@H9_P3LNOV,[VQU;2]1GUKPCJTI@BFG4"YM)0,[)-H"D$=& 'IBOU
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M\*6,MO;Q.X#74[HRI&@[DD]NP)[5_.#?WK:E?SW#*%:XD:5E'12Q)Q^M=?\
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M_P (?#?B&WQ(+"\VO(.ABD7"_P#CQKX0K\O/[J] HHHH _7[_@F#XXTOQ?\
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MSK$,(&.0@]O3\*;110 445:T71;SQ)J]MI^GVTUY>WD@B@AB4L\KGH * *M
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MY'_SS=?Y8_I74T#>X4444""BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MM?>W[$M['\<OV)M<\(WDGF-8K<Z80QRVQAYJGZ?/@?2O@VZM)=/NI+>=3'-
MQCD4_P + X(_.@ID=376I7%]%''-<331Q?<5W+!/H.U0T4$A1110!ZU^P[X^
M;X>_M,>&YV?;;ZA*;"<9QO$BE5'_ 'WL/X5Z#_P5,\ _\(Y\<M/UJ./9#KUC
M@X'WI(CAS^.]?RKYNT+6I/#>N66I0_Z[3[B.Z3']Y&##]17W%_P4DT6+Q_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MS+A7EF\3ECY)]8_9?^7Y>A]?1S_#8_#K+^(*?M:?2?VX>:>[_/O?8^9/B/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M;.Z35)#],(E>[PNN;-*'K^C/G^+96R;$?X?S:/SOHHHK]W/YQ"BBB@ HHHH
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MBOKS_@LK=E6\"V^3CRYI<=N#BOE,V][.,'#MSO\ #_@'V>2^YD6/GWY%^/\
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MU_P22\+_ !UTF3QE\(KS3M-U"\4W'V*.0-INI'N8W7(C8GMR"<Y(K\V?B/\
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M;<G&=JS8SGMRH&>^.:!'Q316EXQ\(:EX \5:AHFL6LECJFES&"Y@D^]&X_\
MK8(]016;0 4444 =)\'+\Z5\6O#5TN<V^I0N,>S"OJ3_ (*VZ=C4?!MY_P!,
MY8/U+5\E^"9_LOC+29-VSR[N,[O3YA7V/_P5O@_XISP9+M_Y>YDW?\ )Q05T
M/B2BBB@D***][_8(_8MD_;!\>7T=Y>2Z?X<T)4?4)H1F61G^Y$G8%L,<GH%/
M!H \$HK](/VC?^"/GA&W^&=]J'@6[U2QUS2[=YUAO)_/BO@@R4. "K$ X(SD
MX&!U'YPRQ/;RO'(K1R1L4=3U5@<$'Z&@!M%%% !7K7["\K1?M4^$MIV[KG:?
M<&O):]0_8MF$/[4W@G.?FU*-1CU)H ]"_P""I$"Q?M#6; <R:7&3[X.*^;:^
MGO\ @JQ$R?'30V[2:."/^_C"OF&@;W'VUO)>7$<,,<DTTS!(XT4LSL3@  <D
MD\8%=KXJ_9I^('@?PJNN:MX/U_3]*(#&XEM&"Q@]W&,H/=@*]0_X):Z?H>I?
MMD>'TUH6[;8IWLDG(V-<"-BG7@MGE1ZXQS7ZU^([6PO?#]]%JJV[Z:\#BZ%Q
MCRO*P=V[/&W&<YH$?@9FBM+QC'9P^+]573VW6*WDHMR.Z;SBLV@ HHHH ^VO
M^"44GF>!_'$1.5\R,[?JCC^E?'?CR,0^.M<0#:%U"X 'IB5J^O/^"2D@DT[Q
MU"/O?Z*?S$H_I7R5\48S%\3_ !*IZKJUV#^$ST#>QA4444""BNB^%?PG\0?&
MOQK:^'_#.FS:IJEWDI$F%"J.2S,<!5 YR37HG[07[!?Q&_9K\-0ZUX@TVWFT
MF0A9+NQF\Z.U<\!9. 5SZX(]Z /&:*** "D?E&^E+0W*F@#]</V%)OM'P5\
MN!C=8_U<5](5\V?\$])_M'[/W@=VX+::?_1S"OI.@IA11102%%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M(?Y1:_(__ F>"^/,Z3NZOX(_62#_ (.G-6^U1+-\$]/6%F_>%/%+EU'^R#:
M,?8D5] ? #_@XX^!_P 4[VWL_%4/B#X>W=P_E^9J=N)[//J9H2P1?=PM?@R<
M@FGI)@8_2L<1X=Y74ARPO%][W_,Z,/XA9M3FI5)*2[6L?UC> /BIH7Q3\,VN
ML^&]6TW7=)O%#PW=E<+-$X/3#*<9]C@UTXZ5_+?^R)^V]\1OV)?'<>M^!=>N
MK6W9E:]TJ<M+IVH#/*RQ9QG'1E^8>M?T ?\ !.G_ (*+>%O^"@WPC36M'D73
MO$.F[8=<T21P9M.E(Z@X^>)NJN.H]""*_+N(N$L1E7OKWJ??JO4_4^&^,,/F
M?[N7NU+;='Z'TA12*:6ODS[$**1NU1&1P/Y4!UL.GE,?T[\=:^$_C1_P<&?
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M/_!<G_QROPDS_G%&?\XH_P"(;Y5_>^\/^(E9M_=^X_=O_B)=^ __ $!_'_\
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MJ"5W;P<KG!XZUY)_P;1_"]?"'[)7C+QG=VZ6Y\1:VR).Q_UEO;H%))] V_\
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M):%.U>]27>]E^!_-N;>/W$N)J-X64:4>R2?XL^\O^'YNM?\ 1.;/_P ';?\
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MW]+[7_#S/Q<HJ:_L)M*OYK6X3R[BVD:*5/[CJ<$?@0:AK[4_/]@'7\:_=O\
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MO=9V_;+V\O/+^[]HG>7;]-Q.*6QT2^U.W::UL;ZZAC.&DAMWD1?J0"!54'-
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M  37+']FKP+NSC[(^WZ?:'KZHH&PHHHH$%%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M<>]U_D?J&"\,:TJ7/6J)-]+,_DI+*P^4J?Q&1]0":;7]"G_!0?\ X(R?"_\
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MF_/G%?TY1P\*,%3HJT5TZ'\.8C&5,15=:LW*4MV]6-I5*C);@*,]/_KUZ/\
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M]CE:F]YW9(AXIU(HQ2U\.??#/X_QIMW917UK-#*@:.="CJ?X@1@C\JEQ0>E
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M^V^-TVCWND_##X?:7<:5X*>]@,,NMW,^/M-\BGYO)*J%3(Y SUS7%_\ !8A
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M)71YV,PE3"UY8>LK2B[,****Z#F/HS_@EE<>1^UQ8\9\S3;E/IDQ_P"%5/\
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M*#2?V5^QYX/L?NEFM$ Z9V1)VKXN^'N@-XJ\>Z+IL>=][>Q1#'^\/\*^P/\
M@K3K\=KH7@W1(<1JL\UR4']S:$4?@5H&MCXGHHHH$%%%% !7U1_P2>M&D^-'
MB"?^&/1VC/U::(_TKY7K[&_X)%Z5YWB#QA>;>(4MH-WIO+G_ -E_2@%N?/\
M^UU>KJ/[37C69?NOJ)Q^"(/Z5YS73?&?5!K/Q<\370;<)-2GY^CE?Z5S- !1
M2HC2R*JJS,QPJ@9)/H*]7T_]A?XN:IX975H? >N-9O%YR?NP)'3&<A<YZ<T
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M86*^F1<#L'-?OG@OBI\N(P[>GNO[[K]#^3/I*9?",\)B[:N\?DK/Y[F70_\
MJF'<CBBE^^:_=9:JS/Y;HRM*[Z:_<?MG^Q#XF;Q3^R?X&OI)/-E.EQ([GJS*
M-I_E7\\?_!27XK?\+L_;Q^*6OBXCNK>77)[6TD7D/! ?+CY]E45^WG[&WQ*/
MPJ_X)3_\)5+)\V@:'J5[&7;[S1^88US[MM%?SKZCJ#:Q?W5[)\DUY,]PZ@Y
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M6OTJ>#PTJGMYPCS+JTK_ '[GY/3Q^*C2^KPJ24']E-V=_*]B)$:1U559F8X
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M)H7QN4^JL#P5(X(-?<6F?\%PU3PD%O/ <SZ]LP9(;Q19E_7!^?'MG- 'G_\
MP69\":3X6_:'T?4M/AAMKS7M+%Q?)& OFR+(Z"0@=R% )[XKX_KM/C]\>->_
M:/\ B9>^*/$4R->77R10QC$5I$/NQ(/[H'XDY)R237%T %%%.A@>ZE6*-=TD
MA"J/4GI0!]V?'%?^$3_X)>:/8MB.:;3=.B(]6\Z-F_0&OA&ON[_@I;<)X1_9
MG\)Z+"?EEOHHBH_N) S9_,"OA&@;"BBNZ_9V_9Y\0?M-_$FW\,^'8X_M#H9[
MBXESY-G"I :1_;) QU)(% CA:*^Y/'O_  10US1_!LEUH/BRVU36+>/>;2:W
M\M+@@<JC?PD]MV:^(]6TJYT'5;JQO(7M[RRF>">)QAHY%)5E/T((H JNBR##
M*K#W%*B+&,*H4>PI:* .Z_9?TW^V/VC? ]MC*S:S;AN,X&[FO>/^"M&I;_B;
MX2M ?ECTJ24CT)F8?RKRO]A'1FUO]JGPJJKN^RS-='V"#.:['_@J'JZW_P"T
M9!:@\Z?IL2$>F[#_ -:"NA\X4444$A1110 4444 %%%% !7MW_!._3?[3_:N
MT%<9\B&>?_OE0:\1KZ,_X)>:;]J_:7-S_P ^NEW ^F]<?TH H_\ !2W4OMG[
M4NH0?\^=E;)]-T2M_6O :]@_;TU+^U?VKO%4F[=Y;0PYSG[D2K_2O'Z 8444
M4 %%>B_L\?LK>-/VH=9NK3PGIJW":>H:ZNIY!%;P9Z L>-QYPO4@'TK0_:,_
M8R\>?LNQV=QXHTV-=/OF\N&]M91-!OY.QB/NM@$@'J : /*J*** /N'_ ():
MP-;?!SQM=-_J_/9>G=8<G^=?%7B*Y6\\0ZA,OW9KF5Q]"Y-?<7_!/-1X>_8X
M\77[<>9=WL@)]/LT:C]<U\'PL6A4MRQ )/K04QU%%%!(4444 %%%% !39SB%
M_P#=-.IMP"T#@#)*D >M '[%?L=V7V3X9^#X\%?+TR,X/NI/]:]XKQ[]F'3C
M9>$/#<.W'DZ3;DCTS$I_K7L- V%%%% @HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MTYDW\C]M!THH' H/2OYK/Z;#.:I>(]9M_#N@WFH74BPVMC ]Q*YZ(B*68_@
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MYG.#J=^=?AH?9Y+[^18^GVY)?=+7\#X"HHHKZH^,"BBB@ HHHH *^L/^"/\
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M=9'UN+_>\,T)_P#/NI*/WIO_ "/":***^K/BPHHHH **** "OT-_9*(^*_\
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M=DNB/[LRO*\+EV&CA,'!1A'I^K?5OJV%%%%<!Z 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4$XHK7\ ^$YO'?C;2]'MUW2ZA<I$![9R?
MT!K2C2G5J1I4U=R:27F]$9UJT*5.56H[1BFV^R6K/JO]G2V7X,?LC:EKUPGE
MS7D<VH$-U/'EH/Q501]:^/7=I6+.S,['+$GDFOK#]N_Q;!X+^&VA^#;!MBW
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M6+9M\.I:1;7"MZAHU-=:K8%?GQ_P0 _;CTWXX?LN6?P[U2] \9?#^+[+Y,S
M2WECG]U.HZL!]UO0CZ5^@T;[RP5<8K^5\TP<\+BIT:G1NWH?U5E.-ABL+"K3
M:U2OZCPV:1NM(S[>M4M9UZUT'3[B\OKB"SL[5#+-<3R"..)%&69F/  '?I7!
M9GH.26K9X5_P4T_:ZF_8B_9)\1>/-/\ [/DURU,5KI<%XI:*XN)& 4,%92V
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MG9/::7<3Q/\ 1E0@_@:M_P#"D?&W_0E>,?\ P1W7_P ;K^D7_@F!\'(O@O\
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M9K&'39RP_P"F4;1M^9%?GF>17Z%_#X?\+)_X)'7UK_K+JSTFYB!]'2Y9E_\
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M>Y4':3WQ7D=?7TZE+%4%-+FA-)ZK=/NCX>K3K8/$.FWRS@VM'LUV9] ?%?\
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M=)L;K4K^X.(X+>,R.WJ<#L.YZ"O1O$?[$/Q4\*:')J5YX/O/LL:[F\BXAN)
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M>G^)/"6KWF@Z_ILF^UO;63:Z$\$-V92!@AL@X%?HS\!O^#F_QYX0T2.S\=>
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MUZ[;S+K6]2N+Z5\?>+R,?Y5^F>&.#<L75Q/2*27S/R[Q0QBCA*>'ZMW^XPZ
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M1_\ $T?\/2OVCO\ HM'CO_P-'_Q->"T4?V1@?^?,/_ 5_D']L8__ )_2_P#
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ML/.*[N+M]ZNOQ/SMHK[8\;?\$E[696F\.^*IX5Q\D%];;U/_ &T5O_9:\?\
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M9_P52_8X\,_L]7^A^)/"=M_9>G:Y,]K/8*28HI0I<,F>0" <@D\T ?']%%%
M!7H_[(GAIO%O[2O@^RV[E:_$C^BA59L_F!7G%?1W_!+_ ,*?V[^T;)?,N8])
MTV64-_=D9D"_INH!&W_P5@\0_;?C#H&FJV[['I?V@C^Z9)''\D%?*U>R?M]^
M*O\ A*?VI_$FUMT.GM%:1'V6-2?_ !YFKQN@;W"BBB@1^@7_  1D^,_A7PUX
M3\3>%]0OK'2]<NKY;V(W$BQ?;(]BKA68@%@1C;UQS6Y_P6*^-OA'4_A%I?A6
MUU"QU3Q!-?)=(EM*LILHUSN=R.%W?= ZG/3'-?G''(T,BNC-&Z\JRG:R_0T2
MRM/*TDCO)(W5G8LQ^I/- #:*** "OJW_ ()-^&3?_%OQ#JF/^//31: ^AED5
MA_Z+-?*5?=W_  2*\.FS\%^)M6";FO;^&(9[^2KDC_Q^@<=S] ?"B;= MSMV
M^8"Y'IDDUHU#I\7D6$*?W44?I4U @HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@!&0/UICV\>,LO YYZ"I** /#_P!LW]A7P!^W1\-O[!\;
M:4)+BW#-8:E:XCOM-D/5HG]#QE3E3W&<&OQE_;!_X((_&3]G6_N[[PG8K\2?
M"T9+)<::-M_"G_32W)R2!_<+ _I7]!!C4]A2-"K=E_*OH,EXGQV6.U"7N]GJ
MCYO/.%\%F:YJRM+NM#^2#Q%X:U#P=J[:?K.G:AH]\I(:VOK=[>9<?[#@&J;!
M=JM\IW>A_P _SK^L7QU\$?"'Q.M6A\1>&=!UR-_O"^L(Y\_]] UY-<?\$IOV
M<+F9I&^"WP[#,<G;HT2@GZ 5^@87Q.I-?[51=_)H_/\ $>%]6_[BJK>:9_,F
M754)POMD]:LZ%I5UXJO1:Z3976J7C=(+.%[B1OHJ FOZ:]'_ ."7'[.V@WL=
MQ:_!CX=QW$3;DD.BPLR'U&0<?A7JGA'X,>$O $:KH?AG0=(6/A?L=C'#M^FT
M"JK>*%)+]Q1=_-H5'PMJW_>UE\DS^=_]FK_@C+\?OVEKJWFM?!\WA719B"=2
M\0G[&@7U$?\ K&_!:_5O]@+_ ((;?#7]D#5+'Q'KDK^/?'5KAX[Z\@"V>G2?
MWH("2-PY D?+8Z;:^Z! J_PK^5'D+FOB,WXRS+'KD<N2/9'VN3\%9?@'S\O/
M+NS\3_\ @O[\=/'O[1'QPL_AOX7\)>.+OP;X')DNKBTT2[DM]1OF !<,L>UD
M125')&<D=:_/3_AG;XB@8_X5]X]Q_P!BY>?_ !JOZO#&#1M/K7IY/QY4R["K
M"TJ":76^YYN<< PS'%/$U:[5^EEI^)_*(/V=_B'G_DGGCXY.,#P[>\_^0J^K
MO^".?_!.37_VA/VO=-U#QCX7U[1?"7@<IJUY_:6G36J7LX;]S"OFJ-PW L<=
MAVXK^@W;GO3?LRE@2H./:M,P\1<7B<//#QIJ"DK73U,LO\.<+AL1"O*HY<KO
M9HBLXUCVJJA(U&%51\H ]*LXIHC -.K\]U/T9*PFVC8*6B@=D0S)S^.:_GC_
M ."P_P"S'XLTK_@HS\2I]&\(^+-6T_6;N/4TN;/1[BXAD::-78*\:,O!.",Y
MXZ5_1"5S2- K'I7N</Y[5RK$O$4HIMJVI\_Q%D%/-L,L/4=K.]T?RA?\,Z?$
M1O\ FGOCT>W_  CM[_\ &J7_ (9S^(@_YI]X]_\ "<O/_C5?U>;31M/K7VO_
M !%+$_\ /A?>?%?\0LP__/\ ?_@*_P S^4N3X$_$V73(;-O ?Q :UMY'ECB_
MX1R\VHS8W$?NN^!5;_AG3XB#_FG_ (]_\)R]_P#C5?U>[3ZT;:2\4,0E98>/
MWE?\0NH/?$/[E_F?RAC]G;X@Y_Y)_P"/3W_Y%V\''?\ Y9U^H'_!M%^S5KGA
M/QU\2O&7B+P_K.CM#:VVDV(U+3Y;.1V):64J)%4E<&,9 QE>M?KYY7^<4")1
M[_6O+SCC[$YAA9865)14NJ;[IGI9+X?T,OQ<<4JKDX]&EV$CC55_SQ3Z**^#
M/T$**** "BBB@ HHHH AOCB,<D ')Q7X3_\ !?\ L?&WQJ_;UD@TKP?XNU32
M/"NC6]A;75EHUU<0RE\RR89$*G#N1P:_=R2,2C#>N:1H017K9'F\LLQ?UJ,%
M)VZL\/B#)GF>%>%<^5>2N?RB#]G3XAD?\D^\>?\ A.7O_P :H/[.?Q$S_P D
M_P#'O_A.7O\ \:K^KP*1WHVGUK[M>*6)ZT%]Y\/_ ,0LP_\ S_?_ ("O\S\A
M?^#:7]F_7/!?C#XE^+O$7AW7M#N#!;:5:?VE82VAF3F1BJR!21DXR!7ZZ1ME
M%^G-2F$-U_E2^4,5\!G&:5,QQ<\745G+ITT/OLERF&782.$INZ6M^XX=*;(<
M(WTIPH8;A7FGK'S?_P %5?&6L>#?^"?OQ+FT/3M0UC6-0TLZ=:VME;O<32&=
MEB?"1@MPC,<CTK^=%?V=_B%Y84?#WQZ>!\W_  CUY_\ &J_JZ^SKGMZ=*$@"
M'Y<?E7UG#?%E3**,J=.DI<SO=MGQW$G"$,XK1JU:CCRJUDC^43_AG/XB?]$^
M\>_^$Y>?_&JTO!W[*_Q"\6>+M)T:3X>^. FK7T%G(TF@W<:+')(JN6)C  "D
MDG/&*_JKVGUI'BW]?Y5]%4\3\5*#BJ*5U:]SYZEX7X:$U-UF[-.UO^"87PV\
M*P^!/A_HNBVR[(=+LH;1%_NA$"X_2MQH5E/S#/XTY(P@^E*%Q7YC.\G=];GZ
MA3CR*T>FQY%^UQ^Q]X#_ &R_AK+X7\<:.NH6JDO:7$9$=WI\F,>9#)C*GIGJ
M".""*_&O]L3_ (-\OBQ\"+RZU+P J_$CPPN7C6W*PZK OH\)(5\>J'IVK]\/
M)4G./TIIMHR>5!SZU[F2\28_+7^X?N]4]ON/G\YX7P.9)NO'WNZW/Y*?&?@7
M6_AKJC6?B71=6\/7:G'E:C9R6K%O0;P-P]US62)?,7Y<,#[@ ?SK^M3Q7\-/
M#_CNV:'6M$TG5H6&TI>6B3#'_ @:\CUW_@F#^SSXEOI+J]^#7P[FN)3N>0:+
M"K.?<@<U^A8?Q05O]HHN_P#=:_4_/\1X73O^XJJWFG^A_,3M/M31/&'6/>K2
M2' 7JQSTP!U^E?TVQ_\ !*+]F^-PP^"OP]..S:/$P_(C%=_X!_9(^%_PL@6/
MPY\/_!^BQI]T6FDP18_):VK^*&'Y;4J#;\Y?Y&-'PNQ'-^]K1MY)G\W7P*_X
M)\_&K]I34(X?"?PX\174,AP;RZMFLK- ?XO,EVC'TS7Z1_L3?\&W>F>';RUU
MSXV:TFO3*1(/#FE.T=GQ@A9Y\AI!V*H IZ9(XK]8(;&*WC5$C544850, #Z5
M((54]!^5?(YMQYF.,BZ</<B^V_WGUV4\ X#!S52?OM=]C)\(>"]*\$^&[71]
M(T^TTW2M/B6"UM+:%88;>,  *JK@ #V%:JP*G1<4J)LIU?$W;UEJS[B,4H\J
M6A']G3=NV]?6N;^*'PC\/?&;PA=:%XCTRWU73;Q=LD<H^Z1R&!'*L.Q!!%=1
M2;!GIUJJ525.:J4W9K9K1F=;#TJU-TJL5*+W35TS\Q/VE_\ @CGXC\(7-SJG
MP[O$U_2P3)_9MTVR[A'7:K_=D_'!]N]?(OCGX8>(_AK>R6_B'0=6T2:-@K?:
M[9HU)] WW3^!-?OD+8 =ORJGJ_A;3]?M_*OK*TO(S_#-"KK^1K]3R7Q8S/"0
M]EBDJJ[O1_>?@O$OT?\ )\?4=?+Y.A+MO'_@'\_:,L@&UE;(SP>E*K;6]ST&
M<5^XOB/]C#X4^+;GS]1^'_A2ZN#QYCZ='N_/%9H_8"^#(/\ R3?PG^.GI_A7
MV<?&G!N-IX>7I=?H?GE3Z-N:J7N8NFUYJ7^1^);2J950N-Q.,#[V?3&37H7P
MO_98^(GQBO$3P[X4UBZC8C]_-;F&W7ZN^!CW%?LSX0_9H\ > (U71?!WAO3%
M4Y'D:?&N#^5=E!I\=JJK&JQHHP%50%'X5Y&.\:*SBXX*@H^<G?\  ]_*?HUT
MHM2S'%W[J,='\WJ?GW^S=_P1I6WN;?5/B9JBW1CQ(-'L&*Q_227J?0A.#ZFO
MO#P)X%T?P%X9M]+T73;72]/M1MBM[>,1H@^@_K6N8 3]:=&GEKBORC..(LPS
M6I[3&U&UT71?+8_>.&."LHR&E[++:2CW;U;^>_R$\A0.G2OR9_X.6Y_%'CV;
MX9^#_#_AOQ-KEK9_:=7N9=-TVXNXU9B(U1C&C $!21GGFOUIIOE#)]ZYLGS#
MZABX8M04G'HSV,YRWZ_A)X3FY5+=H_E#;]GCXA,W_)/_ !]_X3E[_P#&Z#^S
MG\1,?\D_\>_^$Y>__&Z_J\\JC:?6OOH^*&)6]!?>S\__ .(6X?\ Y_O[E_F?
MRA?\,Y_$3_HGWCW_ ,)R\_\ C5'_  SG\1/^B?>/?_"<O/\ XU7]7NT^M&T^
MM7_Q%+$_\^%]_P#P!?\ $+,/_P _W_X"O\S^4+_AG/XB?]$^\>_^$Y>?_&J/
M^&<_B)_T3[Q[_P"$Y>?_ !JOZO=I]:-I]:/^(I8G_GPOO#_B%F'_ .?[_P#
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M^1<^P<JWX5ZQ_P %=_A/_P (Y\7]'\66\?\ HWB*T\B=E'RB6+H3[L&)_P"
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MQN*J8NK\4VV_GT^6R/L<KR^E@<)3P='X8145\EO\]V%%%%<)W!1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M/\:?!71_%'Q EU+4-1\16B7L-E!<&WBLXI &3)7#%]I&<G'M7YMU^EG[%O\
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M'_L]:'\4/#"1W4^F6RW$ABY::SDQN'^T8W&,=@6KX^I_PF9OS[4L1H^RFO\
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M$,!+A/\ IHC;<X]O4USYI1GEF*_M3#J].6E2*_\ 2EY]_P#@LZ\GKT\WP?\
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M#^U,9_S^E_X$_P#,YW_A3/@__H4_#/\ X+(?_B:/^%,^#_\ H4_#/_@LA_\
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M=GKL?!W[1'[36L?&K4I;+#:=H=O*0EFK9,A4XW2'^(^W0>E>75-J?_(4NO\
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M_P"#6/\ 9/M_ %I;WWAOQ=<>($TU(Y[M?$\Z1R78B :0(!@*9,G;TQQ7@O\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M.%QO@D'T!V#_ '37R7$2>%Q%#-(_8?++_#+_ "_-GVW"LEC,-B,GG]M<T/\
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MGRZ>]S'IEQ(\ D7:6"E "1Z$U\9T4?\ $7\Y_P"?=+_P&?\ \F'_ !!G)/\
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MJWTUU=327%Q<.7DED;<SL>22:AHHK\TE)MW9^HQBDK+8****0PHHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0!\P_P#!03X0CXD_ 'QEH\<:O.ELU_:H!SYD7[Y /JPQ7XVD;3@]0<&OZ OB
MCI@EMTFPI5AM9=N=V/7\":_#W]J7X3M\$OC[XE\.[2MM:W;26A/\<#DM&WXB
MOTSP_P ;I5PC_P 2_)_H?D_B9E^M'&Q7>+_-?J>?T445^D'Y.%%%% !1110
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MA_X*<>)/V/O#\GAV;2X?$WAAY6FBM7N#!+9NQRQC?:PVDY)4CJ>HJO\ MO\
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M7+1'_CTA_N9_OMU/M]:WOB#XST+]C#X2P:)HJQS:Y>(3$#C?(^,-/)[#L/\
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M%]T.BP%I #QYLA&0?=0O_CU=O^Q1X8M_AC\&]9\;:BFW[8CRH6X/D1 G /\
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MS?LF_LR7/[3_ (]N-,6_73+#381<7EQL\QPI. JKD9)/J1CK71_MD_L8O^S
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M7-O;9E3P,7I2C=_XI:_DE]YKT445^M'XV%%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M;6P&)EA:ZUC^*Z->3"BBBNT\\**** "BBO9OV1?V,M?_ &I?$@>,2:;X9LY
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M?M,88JV#SM)P#WQTKV/]K?\ X*$:?\;_ (8MX9\/Z3>6L=^RM>3W1&54<[%
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M?"R;PU_9?_"*6JP[-HE6:7S@?[V_=G/?T]J^'?V'/V@+']G[XR+>:ME=&U2
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M_#2/P_\ ^AR\/?\ @6*/^&D?A_\ ]#EX>_\  L5V_P!M9=_T$0_\#C_F</\
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MV^AZ5X&ODTW3O!WA?1&@U&54AVG4+R-I&$?W55=H4,97.!@U^\?_  TC\/\
M_H<O#W_@6*/^&D?A_P#]#EX>_P# L4?VUEW_ $$0_P# X_YA_869?] ]3_P"
M7^1^>W_!=7_@G+\3OVS?^";GPFT_P#H<^J>,/AU;V4]WH0(6[F7[%''*D:G[
MTJ2(HV9Y&[GBN+EM/VM/VNO^")WQ:^&WQ.^".I>'?&>AZ;INA^%=-LM+F@OM
M?MX1$ID9'E<,ZA.=@4<=*_3W_AI'X?\ _0Y>'O\ P+%'_#2/P_\ ^AR\/?\
M@6*/[:R[_H(A_P"!Q_S#^PLR_P"@>I_X!+_(_,?]E[_@D9XY_:"_X-]%^ _C
M;1M1^'OQ AU>YUC3K;68?):&XCN)6A\P<D1NKGGKR#[5X%X,G_X*8? K]DRY
M_9ATWX(_VGX?CMY=!MO%R:?+<36MK*Q_U5T)A"8U#$!FB)"CV%?MK_PTC\/_
M /H<O#W_ (%BC_AI'X?_ /0Y>'O_  +%']M9=_T$0_\  X_YA_869?\ 0/4_
M\ E_D?F9X(_X(V^-/V./^""WQ5^%VGZ;-XR^+7Q"C.I:A8:./M&;@J$2WA_O
MA$502/O,"0!G%>C_ /!,O]E'XD?!_P#X-_/$'PR\3>"]>T7X@7&E>)(8= NK
M?9?2O<2SF%0F>KAEQZY%?=G_  TC\/\ _H<O#W_@6*/^&D?A_P#]#EX>_P#
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M8?;7C/RSRKT0?[*_J<>E=[\?OBAI?[+OPNM?!_A?;#JMQ"40K]ZW0CYIF/\
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M!-=7. ((R,-M'=B.A[5^L\-XWA>'#]2GCXQ]O[U[J\F]>7E=M.FS5G>Y^/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M%->,/^A3\2_^"R;_ .)H_LW%_P#/J7_@+_R#^T\'_P _8_\ @2_S.;HKI/\
MA37C#_H4_$O_ (+)O_B:/^%->,/^A3\2_P#@LF_^)H_LW%_\^I?^ O\ R#^T
M\'_S]C_X$O\ ,YNBND_X4UXP_P"A3\2_^"R;_P")H_X4UXP_Z%/Q+_X+)O\
MXFC^S<7_ ,^I?^ O_(/[3P?_ #]C_P"!+_,YNBND_P"%->,/^A3\2_\ @LF_
M^)H_X4UXP_Z%/Q+_ ."R;_XFC^S<7_SZE_X"_P#(/[3P?_/V/_@2_P SFZ*Z
M3_A37C#_ *%/Q+_X+)O_ (FC_A37C#_H4_$O_@LF_P#B:/[-Q?\ SZE_X"_\
M@_M/!_\ /V/_ ($O\SFZ*Z3_ (4UXP_Z%/Q+_P""R;_XFC_A37C#_H4_$O\
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ML****HD**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MI3K?9FNBD^DO7Y]&_FJBAE*,58%64D$$8((Z@T5^;GZ:%%%% !1110 4444
M%%%% !6UX(^(>M_#C5%O-$U*YT^8=1&WRN/1EZ$5BT5I1K5*,U4I2<9+9IV:
M^:,JU"G6@Z5:*E%[IJZ?JF?4GPV_;OTWQ)8_V7X[TN()(-CW4,7F0N#U+Q]5
M_P" YK6\5?L@^!?C-ILFJ>"=4M]/E8;MMLXEM\GH&3K'^6?:OD6M+PMXQU;P
M1J2WFD:A=:?<(<AX7V_F.AK[[#<=?6::PV?4(XB"VEM47I);_@WU9^?8K@#Z
MM5>*X?KRPTWO'>F_6+V_%+HCJOB;^S5XO^%4K-?Z7)=68Z7=F#-"1ZG'*_\
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M5[-M0BTKP7X??5+B*W#!3)(=RHHR1U;- ]#Z8\QO[S?G1YC?WF_.OEG]@?\
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M%&6<GH *^K_V=/V:-.^#N@GQIXW:&&[MX_-B@GQY=@O9F]9#V';ZY T/@[\
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M$EW<22RNTDDC%G=CEF)ZDTRO!X@SROFV-EC*W71+I&*V2]/Q=V?0<.Y#0R?
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@".YMUN[>2*09212I'L:^1?^"C'[,A^-OP<U*QMT5M
M<T/.HZ<YSN<J#O3/7#KD\=2H%?7U<W\1-!%]8K=H/WEOPW'53Z_3_&NC"8JI
MAJT:]+>+NCFQF#IXK#SPU;X9*S_KR/Y]'1HG9'5HY$)5E88*D<$'W%)7TA_P
M4N_9O/P3^-TFL6-N8]"\5%KF,*N%M[@8$L?ZAO?>?2OF^OZ P&-IXO#PQ%/:
M2OZ=U\GH?S-F6 J8+%3PM7>+MZ]G\UJ%%%%=APA1110 4444 %26EW-I]W%<
M6\CPW$#K)'(APT;*<@CW! -1T4 ?I)\*/$^E?\%'_P!D*[\/:PT4?BG246*5
MS]^&X53Y-PO^RXRI_P"!>U?G?XT\':A\/O%FH:'JUNUMJ&ESM;SQL,88=Q[$
M8(]B*[;]E+]H>]_9I^,%AKT+-)ITA^SZE;@\3V[$;OQ7AA],=Z^J/^"E_P"S
MS9_%/P'8_%SPDJWBBVC;4#",FYMF^Y-Q_$A.UNO4?W:^-PO_  D9A]5?\&L[
MQ[1EU7SZ?+S/O,7_ ,+>5_6X_P"\4%:?>4.DO5=?GY'P;10#D45]D?!A1110
M 4444 %%%% 'MG[$/[6EW^R[\25:Y>2;POJS+%J=N#GR_2=1_>7/..HR.N*]
M^_X*/?LEV?CKP^OQ8\$1QW4=Q"L^J16H#+<Q$<7*X[CHP'UXP:^%:^P?^":_
M[947@R]3X=>++A6T#4F*:;/.=R6LC<&%\_\ +-_T/'?(^4SS U:%99K@E[\?
MBC_-'_-?UL?:</9C0Q-!Y+F#_=R^"7\DNGR?];L^/@<BBOIK_@H1^Q1-\!?$
MTOBCP_ TO@_5IBS*@S_9DK<[#_L-R5/3J/3/S+FO?R_'4<90CB*#NG^#[/S1
M\UF66U\!B)8;$*TE]S71KR8$X%?27[$O[ 6I?M#WT&O>($N-+\'0N"&QMFU+
M'\,>>B^KG\ :[#]AC_@G+-\0?LGC#Q[;R6N@J1-9:8_R27^.=\G]V/VZM[ <
M^W?M)_M=V_ABSD\)^!VAA^S)]GFO8% BMP./+A'3CINZ>F>M?F'B)XG8+(L-
M)1G[VUUJ[]H]WW>T?4_6_#'PFQW$&*C*I#W-[/16_FEVCV6\O3?8^.?[1^B_
ML]>&H_!G@>VLXKZSB$ $"_N--4#&/]J3^7<YR*^2M3U.XUK49KR\GENKJX8O
M++(VYG8]R:BDD::1G=F=W)9F8[F8GJ2>Y]Z;7\$\4<5XW/,2Z^)=HJ_+&^B_
MS;ZM[^2T/]%.$^$<#D&%5#"J\FES2MJ_\DNB6B\WJ"@R2!%!9FZ*!DG\* <U
M^EW[%/[-WAGP)\$-!U-M-LK_ %;7K**^N;J>)9&_>*&"+G.%4'''6O(?^"G?
M[/GA_P ,^&=-\8:/96^FWTEV+6[2!0D=PK*2&VCC<"!T[9KW\=X<8S"Y1_:L
MJB;24G&VR=NO5J^JMZ/O\]E_B;@L7G/]D1IR2<G%3NM9*_3=)VT=_5+I\7T4
M45^<GZ6%%%#-M&3P/4T !YKV#]FS]JW4/@U=1Z;J1EU#PY*WS1YS):$_Q)GM
MZK7D<UM+;QH\D4L:2?<9T*A_H3U_"HZ]+*\UQ>6XF.*PDG&:_%=FNJ?8\S-L
MIPF9X66$QD%*#_!]T^C7<^N/C;^R_HOQVT;_ (2SP/<V:WUROF/'&<07AQ_X
MY)['K[=3\HZWH=YX:U6:QU"VFL[RW8I)%*NUE/\ GN.#76?!;X\ZY\$-;\_3
M9O.L96'VFRD/[J8>W]UO<?K7TUJ>B>!_VW?!OVJTD6QUZU3&_ ^TVK?W7'_+
M1/?T].E??U<#E_%$77R^U'&;RI[1J=W%]'Y??_,?G=+,,RX4FL/F+=;!;1J6
MO*GV4UU7G]W\I\7T5U?Q7^#&O?!K6S9ZQ:LL;']S=1_-#./56_H<&N4K\VQ6
M%K8:JZ&(BXRCNFK-'Z?A<71Q5*-?#R4H2U33NF%%%%<YT!1110 444Z"%[F>
M.*-6>25@B*.K,3@ ?4T -HK[4^$/_!*JQU;P9:WOBS7-0AU*\C67[-9*$6U!
M&0K,P.YNF>!@\<]:\+_:[_9*OOV7O$EFJWG]J:+JV[[)<E-CJRXW1N,D9 (Y
M!YSVZ5]5F/!>;X'!+'XFE:&E]4VK[76Z_3K8^1RWCC)L?C7E^%JWJ:VT:3MO
M9O1V_'=7/'Z***^5/K@I8W:&59$9HY%Z,IVL/H:2B@#O_ '[3WC;X<[([+69
MKBU3_EVO!YT9_DWZU[+X6_X*$Z?J=FMOXL\.[H\?/);;9D;_ +9O@#\S7RW3
M9QF!_P#=-?497QIG. CR4*[<?Y9>\ON=[?*Q\IFO ^2YC+GKT$I?S1]V7K=6
MO\[GZ?6DRW%I#)&,1R1JZ#&, @$?I4E4O#5W'?>&M-FA8/'):Q%6'?Y!5VOZ
MYIRYH*7='\<U(\LW%]&%%%%60%?S^_\ !S+HGB7Q)_P6'^#>G^#=2AT?Q5>>
M'K&+2KV5RB6MR;^Y".2%8@ X.=I^AK^@*OE?]K3_ ((_?"O]L[]JOP?\8O%N
MH^-K;Q7X(A@@T^'3-0@AL9%AF>9/,1X'<G=(<[77(P* 9\)^#O\ @W<_:"_:
MU_:0T7QC^V-\;--\<Z9X<VK#9Z->2W<]Y&K;O)+R00)"I;.6".37DO\ P7*^
M'NA^+_\ @OC\ O"^IZ59WGAV^30["?3I$_<2VYN=IB('\.WC'I7[WN^]RW]X
MYKY6_:7_ ."0'PK_ &K/VQO!_P <?$VI>-K?QEX)>U?3X-/U""+3Y#;2>9'Y
MD;0.Y^;KM=<CTH%8_,?_ (.<_A#X9^#_ .VO^S?K'A/0M+\,WUQ'%'*VEVL=
MJLGE7@\MBJ  LH  /7 [U[_^W1_P59^)NK?\%5M-_9K^&7C'P!\%[.WT^)=5
M\=^(K96N#(;;SV2.1F144 ;55FP[8.Y>E?87[?/_  24^%__  4<\?>"O$GC
M[4/&=GJ'@,8TU=$U"&VBD_>>9^]$D,A;YO[I7BN8_;N_X(6? 7_@H?\ %S3?
M''CJS\36'B.Q@BMI[C0[^.T&J11@!$N \4F["C&5VG'>@#\L_P#@F[K%U=_\
M')ES;ZA\6(_C!-<6NK6>K>*[>UCL8-6(L9O,PL;,A12.'#'.W-=%\0OV*OVG
M/^#??7?'7Q[^"/BSP)XW^$.L2XOS=%7+V\DWR>='E5;:[A08IV))R5../TN^
M$/\ P0W^!/P%_:SL?C!X0L_$FA:QIFF/I-KHUM>0KHL,#V[6[?NO)\TL4<G<
MTI.[GVKS?4?^#:7X":Y>>7J7B[XY:EX?^U?:V\.77B]7T=COW[/)\C(3=SPP
M(]:!6/S)_P""XO[:&M?MO_L\_LC_ !,;1;3POX;UE-0:\TV>-Y-'M]1AGM@[
M-Y:Y:(J7( 4.5,@ .,GUG]JWX!_M ?\ !1#2O@KJ'C+XV?L26NE>#;RS;PU'
MX5U^YM]199&A$</DB!Y=W[M<*57:V<XZU^N_QA_X)Q?!CXY?LNZ?\&]<\#Z7
M_P (#HT21Z78VV87TID!"R0R [ED&X\G.<G(-?-/[-?_  ;-_LR_LQ_&+2?&
MVFP^//$6J:'<+=V-OKNL136L$RG<CA88(F)4X(RQ''.: LS[Z\/6%QI/AW3K
M2\<27EK:0P7#@[@\BHJN<]\L"<U\<_\ !3+]D_\ 9?\ ^"C7B#1_!_QD^)$'
MAS6?AK)-/%90>*+/1;B(W:19+BY1A(I6)"-G3GGT^U'=I'9FY9CDGUKXH_;U
M_P""!_P%_P""BGQD/C[QL?&ND^)I;=+:YN-!U2*V6[5.$,BRPRC('&5Q04?G
MW_P1/^.UW^RM_P %B?%7[-OPR\9-\1_@;-]I%K<);1_N714D,_FH 7$<CO&S
MDE6V@K@$5^[-?-_[ _\ P2A^"O\ P3<T^Z_X5KX=N$UG4(A!=ZYJEQ]JU*YC
M&2$+A555Y/"(N>^:^D* 04444 %.A_UJ_44V@2+"=S':J\DGL* /S%U(;=4N
M_P#KO)_Z$:AJ;4CG4[K_ *[R?^A&H:_AVI\3/[RA\*"BBBI*"BBB@ HHHH *
M*** "BBB@ HH)P*]0^ G[+.N?&J[CN9$DTW05;]Y>2+\TH[B->Y]^@]^E=V6
MY9BL?76&PD'*;Z+\WV7F]#S\RS3"Y?AWBL9-0@NK_)=6_):G'_#7X8:U\6/$
M<>FZ+:-<2M@R2'B*!?[SMV_F:^K_  UX1\'?L2^!VU+5)X[[7KE,&0 >=<-_
M<B7^%,_Q'_ZU0?$#XP^$?V1/"G_".^&;6&[UK;S$&W;6_P">D[CJ?11^G?Y/
M\<^/-6^)'B&;5-9O)+R[F/5ONQC^ZH["OT3VF7<*1M3M7QW?>%+T[R_'TV?Y
MO[/,N+I<U6]# =MIU?7M'\/5ZK;^-/QRUKXW^(C=ZE)Y5I"3]ELXS^ZMU_JW
MJ3^E<9117YMC,97Q5:6(Q$G*<M6W_7_#'Z=@L%0PE".&PT5&$59);+^OQ"BB
MBN8ZCWG]G[_@G[XL^._A"/7OM=CHFEW'_'JUR&:2Y']X*!]WW)Y]*XS]HO\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M/^(7\-?] _\ Y/4_^2/J7_AY';_]";/_ .#0?_&J/^'D=O\ ]";/_P"#0?\
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MGAW1)BOA^R<K-(G'VZ0<?]\#H!WZ^PZ+]KW]I>&&U?P3X5ECAL[=1#?7%O\
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MT?W[:Y"XCNH^S#^1'8@UA^&/$]]X,UZUU/3;B2UO;1P\<B''X'V/I7U_X/\
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M.C+ZJPP0>X(-8M?ND)QG%2B[IZH_G2I3E"3A-6:T:[,****HD**** "BBB@
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M?I7D/Q2_X-M_"]_;RR>"_B-KFFS=8X=8LH[R,^Q>+RR/KM/TK],J*.>061^
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MRK*>A'XUUM8%!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7Y:_P#!2/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH ",BO)/V@/@GI?Q \):GHNIVHNM&UB)HY4QS%D=0>Q4\@]OPKU
MNHKVRCU"U>&5=T<@P?:JA.4)*<79K5$SA&<7":NGHUY'X+?M-_L\:M^S3\4K
MOP_J0::V8F6PNPN$O(">&'N. 1V->>U^QG[;/[(=C^T#\.[C1;KR8=5M<SZ3
M?%>89.V>^QONL!G&3[5^0_C3P;J7P]\5W^B:Q:R66I:;*89X7'*L/Y@]B.*_
M;.&<^CF.'M/^)'==_->O7L_D?S]Q;PW+*\3>G_"G\+[?W7YKIW7S,NBBBOIC
MY(**** "GVUO)>7,<,,;RS3,$1$7<SL>@ [FK/A_P_?>*];M=-TVUGOK^\<1
MPP0H6>1CV K]$OV0/V&=#_9?\.?\)MX^DLYO$4,?F@2D-;Z2.RK_ 'Y?4COP
M,XR?#SS/L-E=!UJ[UMHKVVZOLEU9]!P[PWB\XQ*H89:75W:]K]%W;Z)'+_L0
M?\$[;;P5:6_CGXD0PK=0I]IL],N"/+LE'(EGSQN[A>W?G(&S^U#^V#+XS6X\
M.^%9FMM'_P!7<7B?(]V.A5/[J?J1Z5SW[2_[5U]\8[J32]+:6Q\-Q-]W.)+X
MC^)_1?1?S]!XZHW,J^I K^%?$SQ:Q.<UI87!3M3V<EI==H]H]WO+TW_T+\*O
M!O"9%0AB<;!.INHO6S_FGWEV6T?78KKO@O\ &75/@IXOCU+3V\R%\)=6K-B.
MY3N#Z'T/8U]J?#__ ()J> M3^$-BM\U]<:SJ%DDTFH1S_P"KD9 <H,8V@GIW
M'>O@GQ%HY\/>(+ZP:2.9K*=X#(ARK[3C(^M?G69</YIP]*AC:C492UBXN[35
MG9_?YIGZ9E7$64\21Q&!IQ<HQTDI*R:=U=?=Y-:,^OOBG\,=!_;"^',/B3PW
M+"FN0IA&/RLQ Y@E]#Z'I^'-?'NL:1=:!JEQ8WL$EM=6KF.6*1=K(1[5U_P)
M^.6I_ [Q:M[:LTVGSD+>VA;Y9T]O1AU!KZ/^,/P=T/\ :S\#V_BKPK<0KK"Q
M_*>%^T<<Q2C^%QV)_P#KCZ7%X6AQ5AGC<'%1QL%[\%HJB7VH^?=?)]&_F,'B
MJ_".*6 QLG+ S?[N;U=-O[,O+L_FNJ7QS15G6-'NO#VJ3V-];RVMW;.4EBD7
M:R$56K\OE%Q;C)6:/U:,E**E%W3"O4/@O^V+X\^ NBOIN@ZC;/IS,66VO8//
MCA)ZE!D;<UY?173@L?B<'5]MA9N$NZ=F<N.R_#8VE[#%TU./:237XG3?%CXP
M^(?C;XI;6/$E\U]>%?+0 ;8X4R3M1?X1DD_C7,T45C7KU*U1U:TG*3U;;NWZ
MLVP^'I4*:HT8J,8Z))627D@HHHK(V"BBB@#TCX!?M+ZU\#M16-6;4-$E;,]D
M[=/]J,_PL/R/3BOH3QI\*_!?[8OA<:YH%Y#9ZVJ?-,J@.K=DG3KU_B'X9KXS
MK8\#>/M7^&^O1ZEHM[+9749ZJ?ED'HPZ$&OMLAXN^KT/[-S.'ML,_LO>/G!]
M/2Z\FCX7B#@WZQB/[3RJ?L,4OM+X9^4UUOWL_-/0M?$OX5ZY\)=>;3]:LWMW
MR?*E',5P/5&Z'Z=1Z5SM?87PW_:)\(_M,^'U\-^,K.UM=2F7:%D.V*=O[T3_
M ,#>Q]NM>3?M ?L<:M\+3-J6B^=K&AYW':N;BU'^TH^\/]H?B!6N<<'KV']I
M9+/VV'ZV^.'E);Z=[>JMJ8Y+QI+ZPLLSR'L,3TO\$_.+VU[7\D[Z+Q:B@'-%
M?"'Z %%%% !1136GC1MK.H/H30 ZBC-% !5K0M(E\0Z[8Z?!M$^H7$=M&6Z!
MG8*,_B156IM,U&;1]2MKRW;R[BSE2>)L?==6#*?P(%53Y>9<^W4FIS<KY-^G
MJ?I9\-?^"??PW\(^#K>SU3P_9Z[J#1#[1=WB[G9\<[?[HSTQ7QS^W/\ LW6/
M[.GQ0MX='D<Z+K,!N+:*0Y:W8'#IGNHX(/OCM7TM\-?^"HG@N_\ !MNWB*'5
M-.UB"(+<1QPB:.9@.J-D=<?Q 8)_&OE/]KW]I1_VF/B6NI0VLEEI.GQ?9K&&
M0CS-N22[XX#-QP"< "OV7C;%\,5,FA'+>3VEUR\JM)+KS==N_4_$>!,'Q53S
MN<\T<_96ES<SO%OIRZVW_ETM<\IHHHK\8/W **** "BBB@ ILPW0L/4$4ZB@
M#]*_ NN6_B7P5I-]:NLEO<6D;(RG(.% _I6K7Y__  J_:;\7?!W3&L=)O+>2
MQ8[EM[N+SHXCW*C(QFNM_P"&_P#Q_P#W/#O_ ( -_P#%U_1N7^+.4O#P^M1G
M&=E=))J_D[K0_FC,/!_-UB9_590E3N[-R:=NEU9ZGVG17Q9_PW_X_P#[GAW_
M , &_P#BZ/\ AO\ \?\ ]SP[_P" #?\ Q==G_$6,B_O_ /@*_P#DCB_XA#G_
M /T[_P# G_\ (GVG7E?Q9_8<^#WQY^*FD^./&GPX\,>)O&&@I''IVKWT#-=6
M:QNTB!"& PKLS#(/)-> ?\-_^/\ ^YX=_P# !O\ XNC_ (;_ /'_ /<\._\
M@ W_ ,71_P 18R+^_P#^ K_Y(/\ B$.?_P#3O_P)_P#R)]ILVYLGJ>37E?Q+
M_8>^#_QE^,.D_$+Q7\.?#/B#QQH+0MIVMW<+-=V9A;?$4(8#Y&Y&0<&O /\
MAO\ \?\ ]SP[_P" #?\ Q='_  W_ ./_ .YX=_\  !O_ (NC_B+&1?W_ /P%
M?_)!_P 0AS__ *=_^!/_ .1/H/X]_L4_"/\ :G\0:+JWQ(^'GAKQIJ7AT;=+
MN=3A:22Q&[?A"&'\7/.>:C^/'[#OP=_:BU_2M5^(WPU\)^,M2T,!;"ZU.U,D
MMJ 00 01D @<'(XKP#_AO_Q__<\._P#@ W_Q='_#?_C_ /N>'?\ P ;_ .+H
M_P"(L9%_?_\  5_\D'_$(<__ .G?_@3_ /D3Z!T_]A_X/Z1\<5^)EI\-_"MK
M\0(X#;+KT5L4NTB,9B*##;0#&2G"]#7#VO\ P2(_9=LO%RZ]%\!_ATFL+<?:
MQ=?8&W>=G=OQOVYSSTZUYM_PW_X__N>'?_ !O_BZ/^&__'_]SP[_ . #?_%T
M?\18R+^__P" K_Y(/^(0Y_\ ].__  )__(GUUXK^'/A_QUX*G\-ZUH>EZIX?
MNH?L\NFW%LKVS1XQMV8P!],8KR7X._\ !,C]GC]GOQO#XE\$?!KP)X9\06^?
M)O[.Q/G19Z[=S,%_ 5X__P -_P#C_P#N>'?_   ;_P"+H_X;_P#'_P#<\._^
M #?_ !='_$6,B_O_ /@*_P#D@_XA#G__ $[_ / G_P#(GVGGFO _BO\ \$K_
M -F_X[?$+4_%GC+X+^!O$GB;6I%EO]2O;:1KB[=55 SD. 2%51TZ 5Y1_P -
M_P#C_P#N>'?_   ;_P"+H_X;_P#'_P#<\._^ #?_ !='_$6,B_O_ /@*_P#D
M@_XA#G__ $[_ / G_P#(GKOP=_X)?_L[?L]?$&Q\6>!O@WX)\+>)M,)-IJ5A
M;2+/;DC!VDN1R/:O=J^+/^&__'_]SP[_ . #?_%T?\-_^/\ ^YX=_P# !O\
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M48Q5VWHD@^%OPOU7XN^+8-(TF$R22'=+*?\ 5VR=W8]@/S/05]7>*O%'AO\
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MJAX5\00^+/#&FZI;G=;ZE:Q7<1'=9$##]#5^N<L**** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ;+$LT3(RAE<%6![@U
M^&_[</\ P1?^*7P>^+FJW'@/PSJ'C+P7J-R\^G2:8GG7%FC-D02Q#Y\IG&X
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M&%?]62?^/A .V>&';KQ@U\/YS7[KE6:4<?AU7H_-=4^S/YTSK)Z^6XIX:O\
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MUUUT2TTT6FVIY?#/!T<GQ6(Q,:TJGMG>SZ:M]]7KOH%%>O\ P[_88^(GQ/\
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M(QZ>P4?D!6!#"]Q,L<:M))(0JJHRS$] !7V[^QS^RXWPXTN/5-0MUD\3:H@
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M&.ER1JNW?+>W;R'_ (&9=V?QI<T5L%F?C#\)/^"EWQT^"U_#-H_Q*\3W$43
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MA6[K<1<8XB2I_P -/:[5./KW?WOY'/&CPSP3AHRJ?Q6M[*527>W\J^Z/FV?
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@#C_B-X'CU.TFGCACE212MQ"R[ED4C#9'<$=1W%?FS\>/^"5.IZO\
M'JW/@^2&S\(ZT[3W3RG/]D'(+*H_B#9^4?7G%?JL1D5POCGP;]@8W=LO[EC\
MX'_+//\ 3->IE><8G+YN>'>ZLT]5Y.W==#R<WR/"9G3C3Q2ORNZ:T?FK]GU_
MS/E^:Z\#?\$__A1%HVAVL=QJUPN5B)!N=0EQ_K9FZA!Z=!G  ))KY1^(7Q%U
M?XH^)9M5UFZ:YN9"=J](X5_NHO8?Y->A?M>_!C7/A_X_N-7O+FZU73=6D)AO
M93N:,]?*?L,<XQ@8_7R.-/-D5=RKN8+N/1<\9-?R?XC<49KF.8U,-CDX1B_A
M;W[2;ZM].B6W5O\ L'PRX3RC*\LIXG+VIRE'XDK676*7V4NO5O5]$FYI]O<R
M6=Q'-#))#-$P9'1BK(1T((Y!K]$?!O\ P3U^&UY\$;.&YT^2XU.\L$N7U7[2
MZRB5DW;E .S:,X VXQUR>:_/?Q#I8T+Q!?V*R"9;*YEMQ(.D@1RN[\<9KY_B
M#A/&Y-"C5Q3C:HKKE=[-6T>BUUZ77F?1<.\88'.YUJ6$4KTW9\RM=.ZNM7IH
M][/R+GBKXA:]XY6%=:UK5-56W&(ENKEY5C]2 QQGWZUGZ5JEQH>J6][9S/;W
M5I(LL,J'#1L#D$5](?\ !/C]E'PY\?GUG5O$PDO+'2I5MX[%)6B\QBNXLY4A
ML8( P1R#6#^WS^S;H?[/'Q TU?#S31Z;K%N9A:R/O-LP8@A2>2IQWR<YYJJW
M#69?V6L^J-.#?\SYM[)^E]-[^1-'BC*_[6?#]--5$OY5R;7:];:[6\R3XB_\
M%&O'GQ(^&L_ANXATBS6^A-O=WEM$RS3QD88<L57<."0.YQBO&/ &K6.@^/-%
MOM3M_M6FV=]#/=0XSYL2N"ZX]P"*R,T,K)C<K+N&1D8R*\G&YUC<96A7Q=1U
M)1M;FUVU_P"'[]3U\#D> P-&>'P=-4XSO?ETO?3_ (;MT/TP^/?[4/PWO?V>
M=<8:UI>J0ZIIDD%I9QD,\TCH0@"]L,0<]L9ZBOS/_3V]*M>'] N/$^OV6FV,
M0EOM2G2V@3IOD=@JC/N2*^D/B;_P3(\2?#[X5W'B"'6K+4KS3K<W-Y8I 8]J
M*-S;7W')4 GISBOK,XQN;<5OZW3PZY:$;/E^_J[OR2O8^0R7 Y/P@OJ=7$OF
MKRNN;RT6RLM]6[7?H?,M=#\,_B?K'PE\31ZIH]RT,RD"6,\QW"_W7'?^8KG@
M<BBOA</B*M"I&M1DXRB[IK1IGW^(P]+$4I4:\5*,E9IZIKS/M"RU+P=^W#X
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M=ZZ,'.E"O"==<T$TVNZOJOFCFQD*L\/.%!\LVFHOL[:/Y,_4D?L>?#9?!_\
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ME5X+JTD$BAT*LC Y&0:^Q?\ @E#J/A>U@\2+=-91^*//5H6FP)/LNQ1A"?\
M;W9Q7!?\%.KSPW=_'2R_L,V;7ZV6-5:VQM,N[Y=V.-^W'/\ 6O$Q'#')D<<]
M>(3E*7P]=VM[W<NK5MM;GN87BKGSZ?#ZP[48Q^+I:R>UK*.MD[[Z6.\\0?\
M!5Q-2^&,UK;>&Y8?$EQ;& R&?_1HG*X\P#&2,\A<_C7QHS;W9CU8DG\:3- ;
M->1G7$>89LX/'3YN166B7J].KMJ>UD?#.79/&<<OI\O.[O5O;;=O17=D?2'_
M  3T_:@\/_ #6M<T_P 2;K6RUPQR)>JF[R70$;6]%().?4"JW_!03]IOP_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M9@<ASO&J-;EJ5L.]E)WCJMTGJKK9W5]!?"'A2^\<>)]/T?38O.OM2G6WA3.
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M>?\ 0F^)/_ %_P#"C_AGOQY_T)OB3_P!?_"MO['Q_P#SXG_X#+_(Q_MK+_\
MG_#_ ,#C_F<?178?\,]^//\ H3?$G_@"_P#A1_PSWX\_Z$WQ)_X O_A1_8^/
M_P"?$_\ P&7^0?VUE_\ S_A_X''_ #./HKL/^&>_'G_0F^)/_ %_\*/^&>_'
MG_0F^)/_  !?_"C^Q\?_ ,^)_P#@,O\ (/[:R_\ Y_P_\#C_ )G'T5V'_#/?
MCS_H3?$G_@"_^%'_  SWX\_Z$WQ)_P" +_X4?V/C_P#GQ/\ \!E_D']M9?\
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M92ZR?Z)=%^K9_.O%W%F*SS&.O5T@M(QZ17ZM]7^B04445],?*!1110 4444
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MMX*TWQ%X=U*UU?1=7@6XM+NW?=',A_D1T(."""" 0143C9C3-FBBBH&%%%%
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MW2-+^SMX!9B69O#FGDD]S]FCK^9,_P#'S_P+^M?TU?LU_P#)N?@#_L6]._\
M26.MJQ,3MJ_$?_@X9_Y/OT__ +%2R_\ 1]S7[<5^(_\ P<,_\GWZ?_V*EE_Z
M/N:FGN.6QZQ_P;3_ /(R?%K_ *]=,_\ 0[FOU@K\G_\ @VG_ .1D^+7_ %ZZ
M9_Z'<U^L%*I\01V"BBJ'BGQ-9^#/#6H:OJ4RV]AIEN]U<2MT1$4LQ_(5E*2C
M%RD[)%PA*<E"*NWHD?'7_!7/X^_V5X>TOX?6$W[[42NH:F%/2)21%&?]Y@6_
MX OK7P&!N.*Z[X[_ !9O/CA\6M<\3WQ82:I<L\<9.?(B'RQQC_=0*/?&:[+]
MAOX!M^T#^T!I.G7$)DT?3C_:&I$CY3#&1\A_WV*I_P ")[5_).?8^OQ'GK=#
M7GDH07:-[+T_F?:[/[*X?R^APSP^E7T]G%SF^\FKOUZ17>R/LK]BC]A?PEIG
MP!TF]\8>&=,UC7-<']H.;V#S&MHW \N,9Z?( Q'JQ]*]:_X8S^%7_0@^&?\
MP#6O2T01H%4!548  X I:_IG+^&<MPN&AAE1A+E25W%-NW5NV[W/Y5S'BO-,
M7BJF)=><>=MV4I)*_1)/9;(\S_X8S^%7_0@^&?\ P#6C_AC/X5?]"#X9_P#
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M\)W\)[OP;?3;M2\+-OMMQ^:2TD)QC_<?(]@Z"OA?"//_ &&+GE=5^[4]Z/\
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MC%QIQB^B1_,M:2E4E);-L****T,PHHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ J.ZM8[VW:&55DCD&&4CK4E%
M'C?QS^!FG>,_#UQI>J6_VK3;KF.3'SP/V(/9AV/>OSU^.7P-U3X'^*FL;U6G
ML9R6L[P+\EPGOZ,.X_'H17ZU75K'>V[12JKQR## ]Z\C^-OP,T_QCH%QINJ6
MHO-,NONMCYX&[$'LP[$=:^%XTX+H9W1]I3M&O%>[+O\ W9>79[K[T?H' W'5
M?(J_LZEY4)/WH]O[T?/NMFO.S7PEX)_;8^(WP]\ +X;TS7%CTZ-#'"9(%DFM
MT/55<C('IZ=JY;X*>$+?XK?&KP_HVJW<D<&M:C'%<S,_[Q]S?-S_ 'CZ^M:7
MQ]_9\U3X%^(/+F#76DW#'[)>A?ED']UO1QW']*X&">2UG22-FCDC8,K*<,I'
M0@U_.>85L?A\5#"YKS2]BTN23=DE;1>375=+=#^F,OHY?B,)/%Y1RQ]LF^>*
M5VVGJ]M4]T];WZGZ"?M8?L8_#OP_^SYKFI:7I-KHE_H%D]U;7,3%6F9!G8YS
M\Y;&.<G)K\^:[;QU^T=XX^)?AN+1]=\2ZGJ.G1D$PR2G;*1T+_WB.N37,>&_
M"NJ>,M46QT?3;[5;Q@66"T@::0@=]J@FN_BS-L#FF,A/+,/[-<J5DDFWZ1T\
MN[/.X0R?'Y3@IT\TQ'M7S-W;;459=9:^?9'US^RC_P %#?#7PN^#%GX=\26M
M_'>:+&8K=[>+S$ND'W1Q]UO4GBOF7XZ_%.3XU?%?6/$KVZVBZE-NCA'6-!PH
M)[GWKG=>\/:AX5U22QU2QO--O8?]9;W4+12I]58 BOHC]C?]@^U_:+\#7'B3
M6-7N=/L/M#VMM%:JI=V3ABQ/09QC'6NNGC<\X@A2R.*4O9K1647[JM>3?9:?
MYLY*F!R'AR=;/I-Q]J]7=R7O.]HI=WK\NB/FNBO0OVGO@/+^SE\6+KPZUY_:
M%OY275M<$;6>)\XW#LPP<XXKOO@O_P $[?%WQE^&L?B2.^TW2X;U#)8P7.XR
M7"CHQP/E!P0,\_A7@T.'<RK8R> HTG*I"_,E;2VCUV]-=>A]!B.)<LH8*GF%
M:LHTJEN5N^M]5I:_KIIU/G]C@5^BG[&/[-?P_P!;_9LT>\N="TC6[K7(&>]N
MKF%9I"VYEV@G)0+@<#'//>OS[\6>%K[P1XFOM'U*!K;4-.F:">-OX6'^/!^A
MK1\*_%OQ5X%TJXL=%\1ZUI-C=$F:"TNFBCE)&#D X/'%>EPIG6&R?&SJXZA[
M16<;.UT[]GZ6?7\CR^+LCQ.=8&%+ 8CV3YE*ZO:2MW3OUNNFGS6A^T#X1TOP
M%\:?$FCZ+-YVEZ?>M% V_=M'!*Y[[22O_ :XZE=VD=F9F9F.22<DFON/_@E+
MH'AFZ\$Z[>^393>)X[WRY#( TT5OL7;MSR%+%N1WR*QR/)UGF:_5:4E24W)K
MK9;V2TO;9:HWS[.GD&4?6JL76<%&+Z-O17;UM?=Z/4^0?A=\7]>^$&N+?:+>
M/#N/[ZW;F&X'HR]/QZBOJ?PS\1_ O[97AA=(UJVBL=<C4[(';;-$W]Z%^I'?
M&>G6O+O^"C^C>&]#_:*DB\/):PR-9H^IQ6X 6.Y)/4#@,5VD^Y->#VMU+8W,
M<T,CPS1,&1T.UE(Z$&O7PN>XKA[%ULJK-5Z";C*#UB_.-[\K_"^]]SQL5D.$
MXCP='-Z*EA\0XJ49K22[*5K<R[;.VUD['I7QX_9;UWX*7,ER%;4]#9OW=[&O
M^K'82#^$]L]">E>8U]*? S]M\+9+H?CN/[;:2+Y(U#9YC%3QB5>K<=QD^M:W
MQ=_8NTGQ_IO_  D'P_NK5?M(\Q;1) ;6X_ZYMT4^W %=.,X2PN94GCN&Y<ZW
ME2?QQ]/YEV_!LY<#QAB\KJK <3PY&](UE_#GZ_ROO^*1\JT5>\2>&=0\'ZQ-
MI^J6<]C>0'#Q2H58>_N/>J-?G=2G*$G":LUHT]T?I5.I&<5.#NGJFM4PHHHJ
M2@HHHH **** "BBB@ HHHH **** -_P/\4O$/PVNO-T35KRPYW-&CGRY/]Y.
MC?C7N/@'_@H;J-B(X?$FC0W\8X:>T(CD;W*GY?RKYOHKZ#*>*,TRS3!UG%?R
M[Q^YW1\[G'"F4YIKC:"E+^;:7_@2L_O/L8>(?@K^T0,72:?8ZE-U,H^PW!;T
M#\;_ ,,UROCK_@GBSHUQX7UY9$8;U@O5ZCL%=>/Q-?,==-X'^,OBCX<.O]CZ
MU?6D8.?)\PM"WU0\&OIO]<,KS#3.L%%R_GI^[+[NOS?R/EEP7FN7:Y'CI**^
MQ5]^/HGT^2OYFKXS_9G\<>!-S7OA^\EA3DS6H^T1@>I9<@?C7"NC1N5965E.
M"".AKZ#\%_\ !0KQ!IFV/7=*L=5C_BEA_<R?@H^7\Z[J']HKX0_&A1'XBTN"
MSNI. ;^T!9?I*H(7\34_ZN</X[7+<=[.7\M56_\ )E9?F5_K-Q'@-,SP'M(_
MS47?Y\KN_OL?(-%?75[^Q9\//B-$UQX7UZ2WW?,/LERMX@_,G _E7">*_P#@
MGMXFTS<VE:IINII_#&Q,,GXEL+^M<>+\.\\HQYZ=-5(]X24K^BT?X';@_$G(
M:\N2I5=*7:I%Q:]7JOQ/ *;(^R-F_NC-=QXJ_9S\<>#2WVWPWJ3(OWI+>/[1
M&OU9,BN)U"%[598Y4:.15.5888?A7R.*P.(PTN7$4Y0?:2:_,^RP>.PV*7/A
MJD9KO%I_D?HI\$_AO8?"_P"'&FZ=90QQNT"2W$@'S3R, 2S'OUKK*K:+_P @
M2Q_Z]HO_ $ 59K^T,%AZ=##PHTE:,4DDNUC^'\=B:N(Q$Z]9WE)MMONV%%%%
M=1RA1D#JRCZG%%?@#_P<P?#A?C/_ ,%A/@WX.GU*\TNT\3>'K'3Y;BW^9X5D
MO[E2RJ2 2,]Z /W^R#T93]#FO/\ QU^UE\+?A?\ $O3?!?B7XC>"?#_C#63&
MMAH>H:Q!;ZA>F0[8Q'"S!VW-P,#DU_/O_P %'/V)/&W_  ;N_'KX<^*_A#\:
M/$6I6WB:<DQ7*_9IW>!QN2XA1C%+ X8#!)SALCI7H'_!8SXS:7%_P6N_9I^(
M&OW%KHFDMI?A[7+^:9]L5E$95E<LQ[*">?:@FY_0117YQ?L[_P#!S_\ L]?M
M%?M.:;\-;/3O&&AQZY>KIVE^(=2AC73[V=V"Q*4!\V(.Q #2* /XL5]"_ML_
M\%,=._8V\=Z3X5L?A7\6?BWXGU6R.I?V;X(T1[^2UMPP7S)& *J,D=\T%'TQ
M17R7^P#_ ,%B_AO^W]\1/$G@>QT/Q=\//B)X51Y=1\+^*[3[+?0QHP1VX^7*
MLPRA.X Y( !KRSQK_P '%?PW?XVZ]X(^%_PK^,7QVN/#*L=3O_ ^D?;+>V*M
ML?@C<55N-X&PDC!- 7/T'HKYM^)__!5'X6? S]B?0?CIXZN-3\(^'O$MN'T_
M2;V#.K3W#;]MJ(5R?-^1L]E )) !->+_ +/G_!PK\,_B_P#&3PIX+\7?#KXI
M_!JZ\>HK^&;_ ,9:<+:RUS<<+Y4B\;6R '/RDLHSD@4 ??5%*RE&*G@C@U^>
M?_!:[X6_M:?%B1[;X+^.K/X=_"G2/#,^I^(-4CO!:WT]S&9&:!6BS<%6C"#
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M([NTDR8+V+.2CC^1'(/0]:_2[]G/]N?P-^T/I\$=OJ$.BZ\P DTN^E"2%O\
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M9Z)1117]('\OA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M\/PCC\WJK%\3SNEK&C%VA'_$_M/Y_-K0W/$_BW7OBOXG6XU"XO-7U*[<1Q(
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M_H;HK2-1H7*?RPWNGW&FW4D-Q#-!-$=KQR(59#Z$'I40=AW-?T^^.?@MX/\
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MX6_'KQ2NN>,O OA[Q)JT<"VJW5];>9((E+%4SZ LQ_$U,96=RF?G7_P;3_\
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M]GZD"?E$,A'SG_<8*_T4CO7ZW*P=01R#R".]>5#]A_X3@_\ (BZ+_P!\O_\
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M2%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M)&,CK7&?&?X-ZU\"/'=QX?UZ*..\A42QO$VZ.>-L[74D X.".1U!KVK]BO\
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M9A/^@67_ ($O\C\WO,7^\OYT>8O]Y?SK](?^%1^$_P#H5O#?_@L@_P#B:/\
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M%_O+^='F+_>7\Z_2'_A4?A/_ *%;PW_X+(/_ (FC_A4?A/\ Z%;PW_X*X/\
MXFC_ (@WB_\ H)C_ . O_,/^(V83_H%E_P"!+_(_-[S%_O+^='F+_>7\Z_2)
MOA#X40_-X5\.#ZZ7!_\ $TG_  J/PG_T*WAO_P %D'_Q-'_$&\7_ -!,?_ 7
M_F'_ !&S"?\ 0++_ ,"7^1^;WF+_ 'E_.CS%_O+^=?I#_P *C\)_]"MX;_\
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M$"H\RXQAI"/Y>E:M%%??'YV%%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MZ!?#AURY.DJ/[-B? M=_E?>);[O4DU^T%?A3X=X_X.]=3_Z^$_\ 37#7[K4
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M7X5S/K9/==-=3YK*,IR7!^VXBP"<O:Q<FTV]/B:BM+7:V?730XNBOT8_;=^
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M)H/$VO:O>6?]K*S6$-JH^1!P)&)/.3GY>.G6OE!G"#YB!]:]P^ '[?\ XH^
M/@AO#]K!IFJZ?$Q:U%T6W6Q/49!Y7OCCOS7=PGB,GHXWFSJ/-3Y7;=ZZ6NEK
MM?YGG\88?.JV Y<CFHU>97V3Y=;I-Z+6WRN>>?'+X377P/\ BCJOAF[F2Z?3
MY $G48$R, 5;';KT]179?L._%?0?@U^T!9:MXBQ'ITEK+:?:"FX6CN4*R$#G
M VD9 )^:O.?B+\2=0^*?C74/$&L74<^HZE)YDK+\JC@ !1V    K$^T1_P#/
M1/SKSZ>94\)F7US KW83YH*6NB=TG\O/YGI5,MJ8S*_J68/WIPY9N.FK5FU\
M]M/D?;?_  4<_:2\$_$#X1V?A[1-2M=:U2:]CN@T )6UC4')+$=6SC ]#G'%
M?%=CITFK:A!;PQ^;<7$BQQJ!RS$X%5Q/&O1HQ^(JQI>M-H^I6]W;S+'/:R++
M&V>C Y%='$'$%3.<=]=Q*4=$K1[+UW9S\-\.4LDP'U'"R<M6[RZM^FRVV/IS
MQ1_P2X\4>'?AI-K$>M6-WJUK;FXFTQ(SC@9*+)_$P]P 3WKYU\&^/-:^'NJ?
M;M"U2\TJ[*[3+;OM)'H>Q_&OJ+Q7_P %7KO7/AA-IMKX?AM?$%U;F"2\^UAH
M8V(P9%3;GGD[<\>IKY#%Q&!_K$_[ZKT^*I9'1K49\/SEM[SO)6>EK-V=][VT
MVL>5PC'/JU&M#B.$=96BK1=UUNE=6VM?7>_0Z:#_ (23XZ?$&VMWFO-=U_5Y
M5@C:5]SR,>!ST 'X 5Z!\;?V&?'7P'\'+KVK1Z9>Z:I43O83-(UH6( WAE7N
M0,KD5Q/P'^+W_"DOBUHWB:...[&FRYDA+ >9&W#@'L=N<'L:^E?VL/\ @HQX
M7^*_P<O/#?AFSU+[5K"HEQ+>HD:VZ9#,  S;F.,=L9SS3RC"Y+B,MQ.)S*NU
MB%?E5]W:Z[\S;T>NBUTW%G.*SW#9IA<-EE!/#.RF[;*]GU7*E'5::O378^6O
MAGX<M?%WQ&T'2KZ;[+9:EJ-O:W$H.TQQO(JL<]N">37Z ?M"?L9_#72O@!KD
MEKHMEH]QHVG27-M?1G;()(UW*"2<'>0%/^]Q7YPK=(A!6159>00V"*ZKQ)\?
MO%WC#PS'HVJ>*-2OM+C"@6TDPV8'3..3CW)J>&^(,NP&$Q%#%X=595%:+TTT
M:ZZI7UNM?P+XFX=S+,,9AJ^#Q+I1IN\DKZZI]-&[*UGI^)RJOB+<W'&3[5](
M?#__ ()H>,O'?PR@U_\ M#3=/NKR'[1;6$Q?S&7JNY@,*Q'3&1TY]/FUYHW0
MJ9$PPQ]ZOL+X;?\ !56/PE\*K/2]0\/M?:YIUL+>*=+D+!-M&$9AC*X&,@9S
MCJ,\9\(T\BJ5JBSR;C'E]VU]^NR;OVZ;E\95<_IT*;R&"E+F]Z]MNF[2M?=[
MK3S/G'Q;\6_&\NBR^$]8\0:O+I^FRM;O8R391&0E2O3) ([G%.^ WP2U7]H'
MXC6OAS26AAFE1IIIY<^7;Q+C<QQUZC@=<UR_B7Q._BKQ%?ZG=21?:-0N)+F3
M:?E#.Q8@>PSBNN_9Q^/]U^SI\3[?Q%9PPWJK$UM<6SR;1-$Q!(!YP<J"#@UY
M.%Q&'K8^G_:$Y2HJ23;;;Y+_ #>W1?(]C%X?$T<OJ?V=3C&LXMI))+G:^2WZ
MOYG>?M2_L,:Q^S3X;M=:.J6^M:3-,+>658O*D@D;[H*Y.0?4'L?:LC]D?]JV
MZ_9>\47T_P#9ZZII>JHJ7-N)/+=2N=KJ<'GGD$<^U=+^UW^WNW[2?A.U\/V.
MDKH^E1S+<W!EG$LL\B_= P %49/KGVKYZ^T1_P#/1/\ OJO8SC,,#E^<+$\.
M3:A&S3U>MM;<VK7KY]+'BY+E^/S')7A>)H)SDVFM%[MTU?ET3OV\NMSV?]K[
M]KFZ_:BUK3U33O[+TC2=QMX6D\R1W;@NQP ..,#TZUQ'P4^"VN?'OQU#H&@Q
MQ-=2*9))9FVQ0(.K,<$X^@)-<?\ :(_^>B?]]5ZA^R3^TE'^S5\4_P"VIK;[
M?I]Y#]EO(HW"R;,Y#*3QD'G'?ID=:\^CCZ>99K'$9S4?+.2YY+>VW1:+9:+1
M'I5LOJ97E$\-DE-<T(ODB]F]];O5O5ZO5EO]I#]CSQ1^S1;6-UJTMCJ&G7[^
M4ES9LS+')C.U@P!' X/(/UXKRF.-II%1%9W<A551N9B>@ [FOHS]M;]NK2_V
MCO#=CH6@V-U9Z;!/]IGFO-JRRL 0JA5) '.<YKQ'X1>,;7P+\4/#VMW</VNS
MTG4(+J:)0&+HCAC@="<#C/>MN(,/E4<T='+*EZ/N^\];7WMU:1AP[BLWGE*K
MYK3M7][W5I>WPWW2;-?QE^S;XZ^'OA2'7-:\,ZC8:3, 5N'V,%!Z;@K%ESG^
M("N(K]#?VE/VW?AOK?P!UJTTW5X=:OM<LGMK>RCB;>C.,;GW  ;"<_4#'K7Y
MX#]W&-Q^Z.371Q=DN7Y;B84LNK^UBXW;NG9^L=-=[;KJ<W!N>9EFF%G5S+#^
MQDI62LU=>DM=-K[/H;OPUUC3_#_Q#T.^U6'SM-L[Z&:Y3&<QJX)X[XZX[XK]
M%_VCOVC/AU+^SMJSOK&DZK;ZI8F*SLH)%>61V'R#8.5VG!^;&,5^9:2K)]UE
M;Z&A8E5MP50?4"GP[Q=7RG"U\-2IQDJJM=]-&OFK/9AQ)P;A\XQ6'Q5:I*+H
MN]EUU3^3TW01 K&H;D@ &G4Z.-II%1%+.Y"JHZL3P!7O%S_P3G^(EM\,CXD:
M+3698/M1TX3-]J$>,]-NW=CG;N_'/%>%E^4XS&J7U2FY\BN[*]E_7S/>S#.,
M%@7!8RK&'.[*[M=_UUV/!:^BOV%_V--+_:5M-7U;7[V\ATG3)Q:+!:.(YI9=
M@<DL0<* P['//2OG4'->D?L\_M2^)_V:]0O)-#:TGM=0Q]HM+M"\3,.CC!!#
M=LYKLX;Q&7T<PIU,TASTE>ZWZ:775)]#BXGP^95\MJ4LIGR5G:SVZZV?1M;,
MW/VU?V8[7]F7XAV=GIMY->:3JUN;BW$Y!F@PVTJQ_BZ9S@5P?P7^*^H?!'XE
MZ7XFTU(Y;K37.8I#A9D8;70GME21GMFK'QM^.7B#X_\ C(ZWX@GCDN%3RH88
M5*0VR==J DGKSR3S7*Z=IUQK%QY-G;W%W,>-D,9D;\@*698RA_:DL3E,7""E
M>"ZJUK6WZZI=-BLLP>(_LF&%SB2J3<;3?1WT=]NFC?7<^COVH/\ @H==?'OX
M=/X9T[0_['L[UD:]EDN/-DD"L&"*-HP-P&3W'&*^:Z]4\ _L<>.?'1CD;3ET
MFU?GS[Y]F1[*,G/L0*]V^&__  3NT+2FCDURXO=<N!AC"J^1"?JO+,/<$5]7
M_JWQ/Q'76*Q4'LES32@DO)63MUT3/D?]9N%>&<.\)A)K=OE@W-MO>[NU?2VL
MEL?'VCZ+>>(KP6]A:7-]/G&R"(R,/K@<?C7KWP[_ &&?&7C(QRZ@D&@VCX.;
MAM\Q'JJ+G\B17W/X#_9_M?"=K'#INFZ?I%NG \N/YR/K]X_B:[G3/A_96(_>
M;[AB.=QVJ?P']:^\RCPAPE*T\QJNH^T?=C]^[_ _/LY\9L95O#+:2IK^:7O2
M^[X5\^8^:_A%^PEX9\'RQR/82Z]J,?/G7G^K1AZ(/NGZDU[[X>^%:V<*K.88
M8UZ10H !_0?@*[*&!+=-L:*B^BC%.K]2R[*<'@*?LL'34%Y+?U>[^9^39GG.
M.S"I[7&U93?F]O1;+Y)%/3="M=*7]S"H;NYY8_C5RBBO0/,"BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@"K?:-:ZC_KH(W.<[L8;\QS6#J?PSAFW-:W$D
M+')PXW _CP?YUU%% 'B?C[]EO1?&4++JV@:;?<$M(L6QO^^DPQ/UKPOQS_P3
MET6_+/HNHZAI,S L(Y5%Q&O_  $;6'XDU]P5#=Z=;WZXFACD_P!Y<UX.9\+Y
M5F'^]T(R?>UG]ZL_Q/HLKXLS?+O]TQ$HKM>\?_ 7=?@?F#XV_8A\=>$]TEK9
MV^M0KT-G)^\QZE6QC\S7!Z==>+/@YK;7-JVM>'[V,;6D0/%D>A/W6'US7ZP:
MC\.;&\.Z-I;=AT"MN4?@:Y_7O@TNK0"*X6TU"'G<EQ$KC\%;(KX''>$>#<O:
MY?7E3DMK^\EZ/1K[V?HF \9,8H>RS&A"K%[V]UOU3YD_N1^4^N^([[Q7JLM]
MJ5[<:A>3'+SSR&1V_$_RKZ'_ ."8^H^%K#XR:E_;[6<>HR6:C2WNL; P8^9@
MMP&QMQWZU[SX]_8>\'^(A))<^'ULIF.!+:%HF^H RGZ5Y#XO_P"";MN9F;1/
M$%Q#Y?(CNX1,<]OF0J!]<5\OA_#_ #W*<PAF%&$,1R.]N:S?KS6UUNM7KKJ?
M58CQ$R#.,NJ9=6G/#<ZM?ENEMMRWTZ-65U=:&O\ \%5K_P *W8\,#3Y-/E\0
M!Y#,;8JSB# V[ROOG&>:^<OV;/#>B^+_ (Z^&=-\1.JZ/=WJ).&;:LG/",>P
M/0FNM\4_L,>/M&>26&&RU9?6"XS*_P#P$C^M>>>)?A-XH\&/_P 3/0=4LF4]
M6A)Q_P!\YKYGB3^TJF;/-,9@G!7BW%Q;BU&VC=K.]M6?4\+_ -F4\G658+'*
MH[22DI+F3E?51O=6OHC[V_;M^#O@6P_9OU2\;2](TF\TV,-ILUO"D,C2\!4&
MT#=NZ<YZY]Z_.>M/7O&.M:]!';:MJVL7T<',<-[=RRK'V^57) _"LRO.XMX@
MHYOC%B*%%4DHI6ZNW5V2]/0]/@[AVODV">&KUW5;DW=WLD[:*[?KZL]$^'?[
M*7C[XJ^$9=<T/P_<7>FID1R%E0W!'41@GYOT%>?7EO)I\\L,\;PS0,5D1QM9
M".H(K[T_9?\ V\OA_P"%/@'HVEZU>-I.I>'[)+62V\LL;G8,;H_7=C.#W-?%
MGQQ\=0_$[XI>)?$-M;_9+?6+R6YCB/5%/3/O6_$&3Y5A,OPV(P.(]I4FO>C=
M::7V6L;/2SU?R9S\-YUF^,S'$X?'X;V=*#]R5FKZVW>DKK6ZT7S1]=?LZ_LN
M>'_!'@BQO-2T^WU/6KV-9YI+E-ZPYY"*IXP/<5Z9_P (%H/_ $ =#_\ !?#_
M /$U=T4_\22Q_P"O:+_T 59K^G,KR7!8/#0H4*<4DET5WYM]6S^5\TSS'8W%
M3Q%>K)MM]79>271+L9/_  @6@_\ 0!T/_P %\/\ \31_P@6@_P#0!T/_ ,%\
M/_Q-:U?-O_!7OXZ^+/V:/^"<'Q4\=>!]8DT'Q7X=TQ+C3K^.&.9K9S-&I(21
M60_*2/F4]:]#ZK0_D7W(\_ZY7_G?WL]\_P"$"T'_ * .A_\ @OA_^)H_X0+0
M?^@#H?\ X+X?_B:_"K]C/XE_\%3/V[?V=%^*'P^^-.A7WA]KB:WCM;R'2H+Z
M>2(@,JQ?8CG/0?,,^U?0W_!'_P#X+N?$/XP?M6W/[.O[2'A^QT'XB0S/8Z?J
M,,!LY;B[C^];7,18KYC=5:/:I';N3ZK0_D7W(/KE?^>7WL_5+_A7>A^5YG_"
M/Z-Y?3=_9T6/SVTS_A M!_Z .A_^"^'_ .)K\Q_#5IXS/_!Q3?W!_:;\-WWA
MWR?*?X?#5KG[="/LD9^Q_8-GD9QA_.#;L-G&:^Z?V@_^"B/P*_9/\36^B_$G
MXK>#_!VL74?G1V5]<L9BGJ5C5BO_  +%'U6A_(ON0?7*_P#._O9Z?_P@6@_]
M '0__!?#_P#$T?\ "!:#_P! '0__  7P_P#Q-97PJ^.O@SXY?#.W\:>#_%&C
M^(/"-TKO%K%K./L;JA(<[VP %(.2<8Q7E6D_\%6?V;->^*5MX)L?C5X%N_%E
MY>+IT&F174C2S7+-M6)6V;"Q8@#YNIH^JT/Y%]R#ZY7_ )W][/:O^$"T'_H
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M_P %.OB9\<OBM\ [/X^?"OQ)JE[=+J.J6PU"UBMKB1FBP\BO'%-'&53$D;!
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MY7X[_9^@^)7@K5O#VLPS76DZW:O9WD*N(VEB<88!E<,N1W!!KPG]C3_@B?\
M K]@#Q1?ZY\*_ 4>A:WJ47V>74+N\EU&ZCC/5(Y)Y7:-6_B"$!N^:^RJ* YC
M@/\ A6EWZO\ ]\I_\71_PK2[]7_[Y3_XNN_HH#F. _X5I=^K_P#?*?\ Q=6=
M)^&DWVY3<';"I#')&6]L G\\UVU% <P*-HP.U%%%!(4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
'!1110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>lgnd-20211231_g3.jpg
<TEXT>
begin 644 lgnd-20211231_g3.jpg
M_]C_X  02D9)1@ ! 0$ D "0  #_X0!:17AI9@  34T *@    @ !0,!  4
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M 0$! 0$!         0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<
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M_LL_]&T_L_\ _AO-(_\ D>C_ (=._LL_]&T_L_\ _AO-(_\ D>OH"B@#Y_\
M^'3O[+/_ $;3^S__ .&\TC_Y'H_X=._LL_\ 1M/[/_\ X;S2/_D>OH"B@#Y_
M_P"'3O[+/_1M/[/_ /X;S2/_ )'H_P"'3O[+/_1M/[/_ /X;S2/_ )'KZ HH
M ^?_ /AT[^RS_P!&T_L__P#AO-(_^1Z/^'3O[+/_ $;3^S__ .&\TC_Y'KZ
MHH ^?_\ AT[^RS_T;3^S_P#^&\TC_P"1Z/\ AT[^RS_T;3^S_P#^&\TC_P"1
MZ^@** /G_P#X=._LL_\ 1M/[/_\ X;S2/_D>C_AT[^RS_P!&T_L__P#AO-(_
M^1Z^@** /G__ (=._LL_]&T_L_\ _AO-(_\ D>C_ (=._LL_]&T_L_\ _AO-
M(_\ D>OH"B@#Y_\ ^'3O[+/_ $;3^S__ .&\TC_Y'H_X=._LL_\ 1M/[/_\
MX;S2/_D>OH"B@#Y__P"'3O[+/_1M/[/_ /X;S2/_ )'H_P"'3O[+/_1M/[/_
M /X;S2/_ )'KZ HH ^?_ /AT[^RS_P!&T_L__P#AO-(_^1Z/^'3O[+/_ $;3
M^S__ .&\TC_Y'KZ HH ^?_\ AT[^RS_T;3^S_P#^&\TC_P"1Z/\ AT[^RS_T
M;3^S_P#^&\TC_P"1Z^@** /G_P#X=._LL_\ 1M/[/_\ X;S2/_D>C_AT[^RS
M_P!&T_L__P#AO-(_^1Z^@** /G__ (=._LL_]&T_L_\ _AO-(_\ D>C_ (=.
M_LL_]&T_L_\ _AO-(_\ D>OH"B@#Y_\ ^'3O[+/_ $;3^S__ .&\TC_Y'H_X
M=._LL_\ 1M/[/_\ X;S2/_D>OH"B@#Y__P"'3O[+/_1M/[/_ /X;S2/_ )'H
M_P"'3O[+/_1M/[/_ /X;S2/_ )'KZ HH ^?_ /AT[^RS_P!&T_L__P#AO-(_
M^1Z/^'3O[+/_ $;3^S__ .&\TC_Y'KZ HH ^?_\ AT[^RS_T;3^S_P#^&\TC
M_P"1Z/\ AT[^RS_T;3^S_P#^&\TC_P"1Z^@** /G_P#X=._LL_\ 1M/[/_\
MX;S2/_D>C_AT[^RS_P!&T_L__P#AO-(_^1Z^@** /G__ (=._LL_]&T_L_\
M_AO-(_\ D>C_ (=._LL_]&T_L_\ _AO-(_\ D>OH"B@#Y_\ ^'3O[+/_ $;3
M^S__ .&\TC_Y'H_X=._LL_\ 1M/[/_\ X;S2/_D>OH"B@#Y__P"'3O[+/_1M
M/[/_ /X;S2/_ )'H_P"'3O[+/_1M/[/_ /X;S2/_ )'KZ HH ^?_ /AT[^RS
M_P!&T_L__P#AO-(_^1Z/^'3O[+/_ $;3^S__ .&\TC_Y'KZ HH ^?_\ AT[^
MRS_T;3^S_P#^&\TC_P"1Z/\ AT[^RS_T;3^S_P#^&\TC_P"1Z^@** /G_P#X
M=._LL_\ 1M/[/_\ X;S2/_D>C_AT[^RS_P!&T_L__P#AO-(_^1Z^@** /G__
M (=._LL_]&T_L_\ _AO-(_\ D>C_ (=._LL_]&T_L_\ _AO-(_\ D>OH"B@#
MY_\ ^'3O[+/_ $;3^S__ .&\TC_Y'H_X=._LL_\ 1M/[/_\ X;S2/_D>OH"B
M@#Y__P"'3O[+/_1M/[/_ /X;S2/_ )'H_P"'3O[+/_1M/[/_ /X;S2/_ )'K
MZ HH ^?_ /AT[^RS_P!&T_L__P#AO-(_^1Z/^'3O[+/_ $;3^S__ .&\TC_Y
M'KZ HH ^?_\ AT[^RS_T;3^S_P#^&\TC_P"1Z/\ AT[^RS_T;3^S_P#^&\TC
M_P"1Z^@** /G_P#X=._LL_\ 1M/[/_\ X;S2/_D>C_AT[^RS_P!&T_L__P#A
MO-(_^1Z^@** /G__ (=._LL_]&T_L_\ _AO-(_\ D>C_ (=._LL_]&T_L_\
M_AO-(_\ D>OH"B@#Y_\ ^'3O[+/_ $;3^S__ .&\TC_Y'H_X=._LL_\ 1M/[
M/_\ X;S2/_D>OH"B@#Y__P"'3O[+/_1M/[/_ /X;S2/_ )'H_P"'3O[+/_1M
M/[/_ /X;S2/_ )'KZ HH ^?_ /AT[^RS_P!&T_L__P#AO-(_^1Z/^'3O[+/_
M $;3^S__ .&\TC_Y'KZ HH ^?_\ AT[^RS_T;3^S_P#^&\TC_P"1Z/\ AT[^
MRS_T;3^S_P#^&\TC_P"1Z^@** /G_P#X=._LL_\ 1M/[/_\ X;S2/_D>C_AT
M[^RS_P!&T_L__P#AO-(_^1Z^@** /G__ (=._LL_]&T_L_\ _AO-(_\ D>C_
M (=._LL_]&T_L_\ _AO-(_\ D>OH"B@#Y_\ ^'3O[+/_ $;3^S__ .&\TC_Y
M'H_X=._LL_\ 1M/[/_\ X;S2/_D>OH"B@#Y__P"'3O[+/_1M/[/_ /X;S2/_
M )'H_P"'3O[+/_1M/[/_ /X;S2/_ )'KZ HH ^?_ /AT[^RS_P!&T_L__P#A
MO-(_^1Z/^'3O[+/_ $;3^S__ .&\TC_Y'KZ HH ^?_\ AT[^RS_T;3^S_P#^
M&\TC_P"1Z/\ AT[^RS_T;3^S_P#^&\TC_P"1Z^@** /G_P#X=._LL_\ 1M/[
M/_\ X;S2/_D>C_AT[^RS_P!&T_L__P#AO-(_^1Z^@** /G__ (=._LL_]&T_
ML_\ _AO-(_\ D>C_ (=._LL_]&T_L_\ _AO-(_\ D>OH"B@#Y_\ ^'3O[+/_
M $;3^S__ .&\TC_Y'H_X=._LL_\ 1M/[/_\ X;S2/_D>OH"B@#Y__P"'3O[+
M/_1M/[/_ /X;S2/_ )'H_P"'3O[+/_1M/[/_ /X;S2/_ )'KZ HH ^?_ /AT
M[^RS_P!&T_L__P#AO-(_^1Z/^'3O[+/_ $;3^S__ .&\TC_Y'KZ HH ^?_\
MAT[^RS_T;3^S_P#^&\TC_P"1Z/\ AT[^RS_T;3^S_P#^&\TC_P"1Z^@** /G
M_P#X=._LL_\ 1M/[/_\ X;S2/_D>C_AT[^RS_P!&T_L__P#AO-(_^1Z^@**
M/G__ (=._LL_]&T_L_\ _AO-(_\ D>C_ (=._LL_]&T_L_\ _AO-(_\ D>OH
M"B@#Y_\ ^'3O[+/_ $;3^S__ .&\TC_Y'H_X=._LL_\ 1M/[/_\ X;S2/_D>
MOH"B@#Y__P"'3O[+/_1M/[/_ /X;S2/_ )'H_P"'3O[+/_1M/[/_ /X;S2/_
M )'KZ HH ^?_ /AT[^RS_P!&T_L__P#AO-(_^1Z/^'3O[+/_ $;3^S__ .&\
MTC_Y'KZ HH ^?_\ AT[^RS_T;3^S_P#^&\TC_P"1Z/\ AT[^RS_T;3^S_P#^
M&\TC_P"1Z^@** /G_P#X=._LL_\ 1M/[/_\ X;S2/_D>C_AT[^RS_P!&T_L_
M_P#AO-(_^1Z^@** /G__ (=._LL_]&T_L_\ _AO-(_\ D>C_ (=._LL_]&T_
ML_\ _AO-(_\ D>OH"B@#Y_\ ^'3O[+/_ $;3^S__ .&\TC_Y'H_X=._LL_\
M1M/[/_\ X;S2/_D>OH"B@#Y__P"'3O[+/_1M/[/_ /X;S2/_ )'H_P"'3O[+
M/_1M/[/_ /X;S2/_ )'KZ HH ^?_ /AT[^RS_P!&T_L__P#AO-(_^1Z/^'3O
M[+/_ $;3^S__ .&\TC_Y'KZ HH ^?_\ AT[^RS_T;3^S_P#^&\TC_P"1Z/\
MAT[^RS_T;3^S_P#^&\TC_P"1Z^@** /G_P#X=._LL_\ 1M/[/_\ X;S2/_D>
MC_AT[^RS_P!&T_L__P#AO-(_^1Z^@** /G__ (=._LL_]&T_L_\ _AO-(_\
MD>C_ (=._LL_]&T_L_\ _AO-(_\ D>OH"B@#Y_\ ^'3O[+/_ $;3^S__ .&\
MTC_Y'H_X=._LL_\ 1M/[/_\ X;S2/_D>OH"B@#Y__P"'3O[+/_1M/[/_ /X;
MS2/_ )'H_P"'3O[+/_1M/[/_ /X;S2/_ )'KZ HH ^?_ /AT[^RS_P!&T_L_
M_P#AO-(_^1Z/^'3O[+/_ $;3^S__ .&\TC_Y'KZ HH ^?_\ AT[^RS_T;3^S
M_P#^&\TC_P"1Z/\ AT[^RS_T;3^S_P#^&\TC_P"1Z^@** /G_P#X=._LL_\
M1M/[/_\ X;S2/_D>C_AT[^RS_P!&T_L__P#AO-(_^1Z^@** /G__ (=._LL_
M]&T_L_\ _AO-(_\ D>C_ (=._LL_]&T_L_\ _AO-(_\ D>OH"B@#Y_\ ^'3O
M[+/_ $;3^S__ .&\TC_Y'H_X=._LL_\ 1M/[/_\ X;S2/_D>OH"B@#Y__P"'
M3O[+/_1M/[/_ /X;S2/_ )'H_P"'3O[+/_1M/[/_ /X;S2/_ )'KZ HH ^?_
M /AT[^RS_P!&T_L__P#AO-(_^1Z/^'3O[+/_ $;3^S__ .&\TC_Y'KZ HH ^
M?_\ AT[^RS_T;3^S_P#^&\TC_P"1Z/\ AT[^RS_T;3^S_P#^&\TC_P"1Z^@*
M* /G_P#X=._LL_\ 1M/[/_\ X;S2/_D>C_AT[^RS_P!&T_L__P#AO-(_^1Z^
M@** /G__ (=._LL_]&T_L_\ _AO-(_\ D>C_ (=._LL_]&T_L_\ _AO-(_\
MD>OH"B@#Y_\ ^'3O[+/_ $;3^S__ .&\TC_Y'H_X=._LL_\ 1M/[/_\ X;S2
M/_D>OH"B@#Y__P"'3O[+/_1M/[/_ /X;S2/_ )'H_P"'3O[+/_1M/[/_ /X;
MS2/_ )'KZ HH ^?_ /AT[^RS_P!&T_L__P#AO-(_^1Z/^'3O[+/_ $;3^S__
M .&\TC_Y'KZ HH ^?_\ AT[^RS_T;3^S_P#^&\TC_P"1Z/\ AT[^RS_T;3^S
M_P#^&\TC_P"1Z^@** /G_P#X=._LL_\ 1M/[/_\ X;S2/_D>C_AT[^RS_P!&
MT_L__P#AO-(_^1Z^@** /G__ (=._LL_]&T_L_\ _AO-(_\ D>C_ (=._LL_
M]&T_L_\ _AO-(_\ D>OH"B@#Y_\ ^'3O[+/_ $;3^S__ .&\TC_Y'H_X=._L
ML_\ 1M/[/_\ X;S2/_D>OH"B@#Y__P"'3O[+/_1M/[/_ /X;S2/_ )'H_P"'
M3O[+/_1M/[/_ /X;S2/_ )'KZ HH ^?_ /AT[^RS_P!&T_L__P#AO-(_^1Z/
M^'3O[+/_ $;3^S__ .&\TC_Y'KZ HH ^?_\ AT[^RS_T;3^S_P#^&\TC_P"1
MZ\3_ ."EO_!-+]G'X;?\$X_V@/$7AW]G_P"">@>(- ^&_B+4M,U/3? VEVMY
MIUU#I=S)#/#-' 'CEC=5974AE90000#7W97S_P#\%8O^467[2W_9*O%'_IHN
MJ #_ ()._P#*++]FG_LE7A?_ --%K7T!7S__ ,$G?^467[-/_9*O"_\ Z:+6
MOH"@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "OG__ (*Q?\HLOVEO^R5>*/\ TT75?0%?/_\ P5B_Y19?
MM+?]DJ\4?^FBZH /^"3O_*++]FG_ +)5X7_]-%K7T!7S_P#\$G?^467[-/\
MV2KPO_Z:+6OH"@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M#;?3[:*#PNATFUU"2]+R:[+.'#_V<T2I;K<-D"59$5!EF/7_ +/?_!1?X9_
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ".N]"/4
M8KPC_@FY^Q+_ ,.]_P!E;3_AG_PDW_"7?8-5U/4_[2_L[^S]_P!LO9KK9Y7F
MRXV>;LSO.[;G S@>\44 %%?%O_!9WXC>-M?\#?#7X"_"WQ5JW@OXE?M >)1I
M%IK^E7<EK?>']+LHS>ZC?1O&0X*QQQQ?*R_\?/7L>D_X)>_MR+\<O^":NB_$
M+XC:BND>(OA[97NB?$.XOV"G3M2T@O#?RS8R!GR3/_NR#@=* /JZBOA?X2?\
M' 'PI^*?Q(\*Z7=?#C]H/P7X2\>7\&F>%_'_ (G\!3Z?X3\0SW+*MHMO=[V;
M%P6'EL\:*1RQ6NN_:V_X+(^!?V6?CAJ7PWTOX;_'/XT>,_#]I!?>(=.^&7@Y
M]?;PS%<*7MS>OYD:1&5 650S':,D $9 /KJBOFFY_P""K_PHG_99^'_Q@TAO
M$?B#P?\ $CQ38>#M.^QZ>(;RTU"ZO&L]ES#</$T0AG5UDZL-I*JX(SZ%\2_V
MO/#?PL_:F^&GPBU"QUR;Q)\5+/5K[2;FWAB:QMTTZ*.6<3NTBNK,LJA-B."0
M<E>I /5**_/71?\ @Y6^ NLZ=H6K_P#"*_&>U\'WVLMH&N>+9?"RGP[X(O/M
M9M4CU6^6=H8&D.R51&TC"*:-F"%MH]1_9N_X+0_"S]IK]JNU^$NF^'/BIX:U
M/7["XU3PGK?B?PM)I.B^.K6 !I9]+FD;S)XPAWAFC0%1D9XR ?7-%?$OQG_X
M+Q?"OX4?$_Q%H.D^ /CQ\3-#\%7DNG^*?&7@?P/-K/ACPQ<0@&XCNKQ77YH1
MS)Y2R;<$=017H7[2?_!6+X3_ +.WP=^'OC"T/BKXG-\6T\WP/H/@/1WUK6O%
M:"$3R/:VRE<K'$P9R[)LS@X;B@#Z8HKY[_84_P""D_@G]O:3Q/INC^'?B+\/
M_&7@IH/[>\(>._#TFB:[I<=QO-O*\)9T,<HC<J4=N!\P4D \'_P7F^)GB3X/
M_P#!*[XE>(O"/B#7/"WB"QN-%6VU/2+Z6QO+<2:S8QN$EB977=&[H<$95F!X
M)% 'V!17R?\ MK?\%?OAU^P;\:/"WPW\2^%_BCXL\:>--!FUK0-+\'^'O[:N
MM::*01FSAC202&X(WR#<JQ[(G)D4X4\CJ'_!4[X5_MC_ /!.CX^>,+6?XU?#
MF/X9Z7J%CXSTJVM4T#X@>$9([=G8PI)(4ANMH8Q.7*AT()!5@ #[>HK\P_VE
M/^"JOB3X$_\ !0[]D_P!X=\(_M">*_ /B#PK/J&III_AN+4IO%9N+*!+2=IP
MX:9[/>\UYM8)'YBN0YVX^AOAI^UY\,_A!\2?VMO$VN>-OB;#I7PJUBRG\6GQ
M7>)=:)H'_$K@E6/188BTB0.C*S1E=[SNVT'<,@'UM17P/X?_ .#AGX7R?$+P
MKI?BSX1_M+?#'PUXVU*WTG1/&OC+X?2:7X:O[FX&;=%N#*S_ +W^$^7C +,5
M4%AVG[)?Q.\2>)/^"P/[7/AG4?$.N7_AOPWH_@F72-)N;^66QTI[BSO6G:WA
M9BD1E9%+E "Y4$YP* /L2BOCO_@KY\3O$GPTG_9@_P"$;\0ZYX?_ .$@^/'A
MO1]4_LV_EM/[2LI8[PRVLWEL/,A?:NZ-\JVT9!P*@_:C_P""W?PY_9>_:>\1
M?!D_#WXX?$3XE>']-LM770_ OA+^W+G4K2X4LTT(2486 !/-,WEX\U-GF?-M
M /LNBODGP;_P6B^#OC[X#?"WXE:7'XMF\(_%#QA'X$^UR:?%"WA35I"Z+!JJ
M/*IMQYBA-R>8-TD9^ZX8^P?'#]L'PO\  ?XX?"OX=ZA:ZSJGBKXOZE=6&C6F
MFQ12&VCM;9KBYO+C?(A2WC15#,@=MTB *<D@ ]6HKXE^,_\ P7B^%?PH^)_B
M+0=)\ ?'CXF:'X*O)=/\4^,O _@>;6?#'ABXA -Q'=7BNOS0CF3REDVX(Z@B
MO0OVD_\ @K%\)_V=O@[\/?&%H?%7Q.;XMIYO@?0? >COK6M>*T$(GD>UME*Y
M6.)@SEV39G!PW% 'TQ17R-\(/^"P'@WX_P#P-^*>O:#\/?C;I/CCX3Z<+[6_
MAUK'@][/QE$LJR&V:*R9RDWFB-R@64\+\VW(!^;?^"=O_!=_3O"G_!*OP+\4
M/C]H_P 6[6XG\36_A;5/%FK:!!:V.L7%]<W,BW]LWFHLMC B;)&B3,9C*)$V
M * /U+HKX-T7_@X6^$>IWOBC1;OX;_M#:+\0-#$$VD> M1\ S1>*_&EO-YNR
MYTNP#EY8-L,C,\IB" #=MR!7J7PH_P""OWP5^)_[#VL_'^ZU36/!_@OPS>3Z
M7KEEXAT\VNL:/J,,BQ-I\MJA<FZ+O&JQ1ERQD4#)R  ?4%%?(/[,?_!9_P"'
M_P"T3\;])^'NM?#OXY?!GQ'XI\W_ (1A?B9X,E\/V_BLQ)YDBV,I=UD81_/L
M<HQ!& 3Q7%?&+_@X4^%/PG^+'Q(\$V?PS_:"\>>(/A+JTNG>*XO"/@O^U8=&
MMXXQ(=1FF6<1QV9^=0SLLF89"8PH#$ ^\Z*_,G_@IK_P6?D\!^$?V3_%WP>T
MCXM>,_!/Q8\7:?JUY>>#O#2WXU_2T$IDT52[*ZZA+(%(MAL9A;S*6 #*?TF\
M)^(/^$L\*Z9JGV'4--_M*TBNOL=_#Y-U:^8@;RY4R=DBYPRY.""* -"BOA+X
MN?\ !PE\&?AI\0_%.E:/X+^.7Q(\-^ ;V73O%WC;P9X)FU3POX5N(C^_2[O-
MZ8\H?,S1HZXY!:O&?^"[?_!36\F_9A^!=G\&;[XXW/AGXZ^)-,E?QM\+-):6
M[N-(;>9-/L;@LCPZK.=ABA*JY$,P;&UE(!^J=%>%_LRZ9JWPM_X)\^'I/#[?
M%;Q3KUMX4?5-.A^)]QY_BZYN987N(K74V^7%RKNL+KQMV[<\9K\<OV/=/\=?
MMV_M ^&?&'A/]M;QQ;_M03?#[4-5O=%U?4(].T;0==AU.V1_#MUHIAWK9#<Z
MNH1BS0K.H8(%(!_0#17@G[5WQ#^/WAGX,^&]+^%/@/PKX@^)WB:-;34=4O\
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MWXP^)GC;XO\ A&\\#V_Q#\#Z]XPE6]UZQA6\-E>V5U>A5^TXE:.1&9055L8
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %?/_ /P5B_Y19?M+?]DJ\4?^FBZK
MZ KY_P#^"L7_ "BR_:6_[)5XH_\ 31=4 '_!)W_E%E^S3_V2KPO_ .FBUKZ
MKY__ ."3O_*++]FG_LE7A?\ ]-%K7T!0 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 5^67[1G_!.'X,?\%'?^"]?Q T3XS>#?^$RTOPW\'M!O
MM.A_M:^T[[/,^IWZ,VZTFB9LKQAB1[9K]3:_,W]I;]H[Q)^PO_P6H\:?$*;X
M _M%_%;PGXL^%>BZ%:W_ ,./ \NNPP7<.H7LTB2R%XXU(1U. Q8;AD $&@#-
M^)'[%OA__@A_^TG\!O&/[/\ J'B+PI\+/B1X[LOAWXW\ W6M7>JZ3=_VF&2U
MU&W%U)*\-Q%.B[F5LNK@95=X?W#X\?\ !4[XC'X]>+/ ?[//[-WB+]H.;X;W
M4>G^,M67Q98>%],TB\>-9?L<$MV#]KN$C9&=(P F]06R2!YC-XR^*'_!8[]I
M;X.-)\$/BA\$?@3\(?%$7CO6;WXCZ;%H^N^)-6LT8:?96]@))'6!99&EDE;Y
M6"##(RJ'^2_VI_\ @FA\,?@9^WC\;=?^/G[&/QP_:2\/_$[Q/+XJ\(>+_AE-
MJ>J7%I'<HC3Z=>V=M?6X@\F82%)6SO$F!\J@* ?HMK?_  67\ Z+^P/-\;G\
M,^-!J4>N'P;_ ,(')9!/$0\3?:/LW]C-%D@3>;_%DCR_G )PM-_8R_X*>>,/
MC%^TC)\'?C=\"M:_9]^)&I:(_B7PW8W/B.U\167B+3HW$<[1W=LBHEQ$S*7@
M8%@K!B1G%?+MW_P3TU[P/_P3 \#:Y\%?V;KOX3^(/AS\6;#XO67PLO?&=QK>
MI:W!:$PE99[AF%K>3VI$GV5'<1LBJ2TC,E?3G[(?_!0+XP?MN_M)VEKI_P"S
M[\1O@Y\']#T>XD\1ZG\4- ?1];U+4W*+;6VFPK.085'F/),R."%"@1L06 .1
M\3?\%B/B?XY\4^(=3^!O[*/CCXV?"/PAJ=UI.J>-+7Q1I^D/>S6CE+O^S-/G
M!GU!8W5T5D*^8Z%5SP3K?'W_ (+::#X \+?LYZ[\/?A[XC^*VF_M)"^BT"WT
MZY6SU*"Y@M1)%;M#(A3<TY$,K/+&EN$DD9F5"*_,K0/^"6GP@_9*U[Q5X#^.
MW[ O[07QS\;1Z_J$WA[QU\/KO5M0T;Q383W$DEF]Y)#J$,=A*JND3AHR0$WM
MDDEON7PS^QOJOPD^-'_!._3O#_P5U/X<^&_ EYXLOM<\/6&K7?BRQ\"O>:3.
MZ0W.J2*<DSRE0S$)YA*1LRJI(!H^%/\ @N)\7O'+>./ FC_L=>-M0_:'^&]X
MC>)? 47C*P_LW2=-D@CG@O6UHQB"1YE<B.WAC>1S&^.!FO%_VRO^"D6G?M$>
M.O\ @G;^T)X*\"^+/$S>(-:\3-9>$=/5)-4FU#^SVLVLMQ(10ER&5IFPJ1JT
MC  $5]@?LJ?##Q+X=_X*\?M?>)M0\.ZY8^'/$VB>"XM'U6XL)8K'57@LKU9U
MMYF4)*8V=0X0DJ6 .,BOSR_9A^$/QV_9H_9E_P""?GB#2?@3\1/$WB'X6^)/
MB!J'B+PY+I-QI]Y96=R]Z/WAF15@FE@D9K=9BBSR>6@;YP: /T3_ &._^"I^
ML?%GXO>,OAE\</A%JG[/'Q.\&^'1XRETF_\ $-IKUAJ&A[S&][!?6P5'$<@V
MR+M^0D<L0P7RX_\ !<+XCW?A)OBQI_[(WQ(U#]F&.%M0_P"%B)XBT]=4DTQ2
M=VI)H)_THVVT>:&+@^5\Y  Q7+^ OAM\0?\ @KK^UWXX^*FN_"CQ_P# GX;Z
M?\)-8^&'AM/'5@-)\2ZO?ZHX-S=O:([20V\,:!5W,=S/N1B2X3X5^$/_  39
M^#_PN^'&E?#7XB?\$R_V@?'7[0&DPKI5QK&BZ_JL/@?Q+=IA5O6UI=06WM(Y
M@/,?$!6(L5QQ@ 'ZM?M@_P#!5_5O@?\ &KX<^ /A;\(M2^.7B3XM^$KGQ1X4
MBTS7H=+AOO)EMCMEFGB,5O ;::2;[1(X ,:1A&:4%?JKX5Z_X@\5_#'P_J?B
MGP_%X1\3:AIT%SJFB)J"ZBND7+QAI+;[0BJLWEL2OF*H5MN1P17QIIO[-^L?
M#7_@JE^S*VC>"=5TGP/X%^#&L^')IK1[O5-+T*42Z<L%DVH2H#(VV)@C3;9)
M5C+%<YQ]SWETME:2S,LC+"A<B-#(Y &>%4$L?0 $F@#\M/VJ_P#@B3^SW\)O
MV=?B'\;?VE/B+XN\3?%+3XK[6IOBI)K^H:/<Z'.\CO:1:;91W;0QB)FBBA@/
MFEGPJ_>"CGO%.L_%W]JW]E7]@7]G_P"*OB+Q7X?U?X\17>H_$:ZM;M]/UG5=
M(TNP-T+2>1?G1[E)+43X82%BX/5L>6V/[9GB#]I']JV;XI?M)_LE_MT^-+'P
M?K3W'PY\ :-\)YW\*^'(HV(@U"Y66>-K[4F7YB\J;(2Q"*0%*_6W[:.M?$+X
M_P#A+]FO]K/X8_!_XE2:]\(=>U&\U7X<>(=.31_%ESHU]!)87JK;,S?Z0H2.
M:.'?^\7:>NT  Y;X=?LG>&?^".__  59^!G@SX)KX@\/_"/]H;3->TC6O"$^
MMW6I:;8:IIUJM]!J,(NI))4E=!)$^'P0!P.^+^U7_P $2?V>_A-^SK\0_C;^
MTI\1?%WB;XI:?%?:U-\5)-?U#1[G0YWD=[2+3;*.[:&,1,T44,!\TL^%7[P4
M=E\(_%_Q _X*<?\ !2/X7_&+4?@O\6O@S\)/V>M&UF>Q7Q_I7]D:YXCUK48%
MM66/3U:1_(AMPY$F3N9]H&>#\M6/[9GB#]I']JV;XI?M)_LE_MT^-+'P?K3W
M'PY\ :-\)YW\*^'(HV(@U"Y66>-K[4F7YB\J;(2Q"*0%*@'WQ^R=K7[3WC?_
M () _".:TF\-6_QZUS0+%=0U3QNL_EZ? ^?]-N(8@9)KP6WE,8F*;IF.]E 8
M5P?_  ;]>$?$'@#PY^U%H?BKQAJGC[Q)I'QRU>SU+Q%J*".XU>=-/TU6F**2
ML:DCY8U.V-0J#A17V9^S1\<_^&E/@CH?C;_A#O'?@'^W$D?^P?&6D_V5KFG[
M)7CQ<6V]_++;-RC<<JRGOBOG7_@DM\,O$GPX\9_M72^(O#VN:#'XB^.FMZOI
M+ZC82VJZI926E@L=U 9%'FPLR.!(F5)5@#P: /L2BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ KY__P""L7_*++]I;_LE7BC_ --%U7T!7S__ ,%8O^467[2W
M_9*O%'_IHNJ #_@D[_RBR_9I_P"R5>%__31:U] 5\_\ _!)W_E%E^S3_ -DJ
M\+_^FBUKZ H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ KY_\ ^"L7_*++]I;_ +)5XH_]-%U7T!7S_P#\
M%8O^467[2W_9*O%'_IHNJ #_ ()._P#*++]FG_LE7A?_ --%K7T!7S__ ,$G
M?^467[-/_9*O"_\ Z:+6OH"@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "OG__ (*Q?\HLOVEO^R5>*/\
MTT75?0%?/_\ P5B_Y19?M+?]DJ\4?^FBZH /^"3O_*++]FG_ +)5X7_]-%K7
MT!7S_P#\$G?^467[-/\ V2KPO_Z:+6OH"@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M7[I__P 10![_ $5X!_PT/\=O^C=?_+]T_P#^(H_X:'^.W_1NO_E^Z?\ _$4
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M_CM_T;K_ .7[I_\ \10![_17@'_#0_QV_P"C=?\ R_=/_P#B*/\ AH?X[?\
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MU_\ +]T__P"(H_X:'^.W_1NO_E^Z?_\ $4 >_P!%> ?\-#_';_HW7_R_=/\
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M )?NG_\ Q% 'O]%> ?\ #0_QV_Z-U_\ +]T__P"(H_X:'^.W_1NO_E^Z?_\
M$4 >_P!%> ?\-#_';_HW7_R_=/\ _B*/^&A_CM_T;K_Y?NG_ /Q% 'O]%> ?
M\-#_ !V_Z-U_\OW3_P#XBC_AH?X[?]&Z_P#E^Z?_ /$4 >_T5X!_PT/\=O\
MHW7_ ,OW3_\ XBC_ (:'^.W_ $;K_P"7[I__ ,10![_17@'_  T/\=O^C=?_
M "_=/_\ B*/^&A_CM_T;K_Y?NG__ !% 'O\ 17@'_#0_QV_Z-U_\OW3_ /XB
MC_AH?X[?]&Z_^7[I_P#\10![_17@'_#0_P =O^C=?_+]T_\ ^(H_X:'^.W_1
MNO\ Y?NG_P#Q% 'O]%> ?\-#_';_ *-U_P#+]T__ .(H_P"&A_CM_P!&Z_\
ME^Z?_P#$4 >_T5X!_P -#_';_HW7_P OW3__ (BC_AH?X[?]&Z_^7[I__P 1
M0![_ $5X!_PT/\=O^C=?_+]T_P#^(H_X:'^.W_1NO_E^Z?\ _$4 >_T5X!_P
MT/\ ';_HW7_R_=/_ /B*/^&A_CM_T;K_ .7[I_\ \10![_17@'_#0_QV_P"C
M=?\ R_=/_P#B*/\ AH?X[?\ 1NO_ )?NG_\ Q% 'O]%> ?\ #0_QV_Z-U_\
M+]T__P"(H_X:'^.W_1NO_E^Z?_\ $4 >_P!%> ?\-#_';_HW7_R_=/\ _B*/
M^&A_CM_T;K_Y?NG_ /Q% 'O]%> ?\-#_ !V_Z-U_\OW3_P#XBC_AH?X[?]&Z
M_P#E^Z?_ /$4 >_T5X!_PT/\=O\ HW7_ ,OW3_\ XBC_ (:'^.W_ $;K_P"7
M[I__ ,10![_17@'_  T/\=O^C=?_ "_=/_\ B*/^&A_CM_T;K_Y?NG__ !%
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M?X[?]&Z_^7[I_P#\10![_17@'_#0_P =O^C=?_+]T_\ ^(H_X:'^.W_1NO\
MY?NG_P#Q% 'O]%> ?\-#_';_ *-U_P#+]T__ .(H_P"&A_CM_P!&Z_\ E^Z?
M_P#$4 >_T5X!_P -#_';_HW7_P OW3__ (BC_AH?X[?]&Z_^7[I__P 10![_
M $5X!_PT/\=O^C=?_+]T_P#^(H_X:'^.W_1NO_E^Z?\ _$4 >_T5X!_PT/\
M';_HW7_R_=/_ /B*/^&A_CM_T;K_ .7[I_\ \10![_17@'_#0_QV_P"C=?\
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M5]?U\@?\$(_^49_A?_L:_&?_ *EFL4 ?7]%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 5X!^T/\ \GU_LZ_]S+_Z;XZ]_KP#]H?_ )/K_9U_[F7_ --\
M= 'O]?/_ /P5B_Y19?M+?]DJ\4?^FBZKZ KY_P#^"L7_ "BR_:6_[)5XH_\
M31=4 '_!)W_E%E^S3_V2KPO_ .FBUKZ KY__ ."3O_*++]FG_LE7A?\ ]-%K
M7T!0 4444 %%%% !1110 4444 %?('_!"/\ Y1G^%_\ L:_&?_J6:Q7U_7R!
M_P $(_\ E&?X7_[&OQG_ .I9K% 'U_1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 5X!^T/_P GU_LZ_P#<R_\ IOCKW^O /VA_^3Z_V=?^YE_]-\= 'O\
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M:/!WP#\&S>(O'7BSPSX+\/V[K%+JFO:I!IMG&['"JTTS*@)/ !.35[P%\0M
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MX>D?_)%?0%% 'S__ ,/8OV6?^CEOV?\ _P .'I'_ ,D4?\/8OV6?^CEOV?\
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MX>D?_)%?0%% 'S__ ,/8OV6?^CEOV?\ _P .'I'_ ,D4?\/8OV6?^CEOV?\
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MX>D?_)%?0%% 'S__ ,/8OV6?^CEOV?\ _P .'I'_ ,D4?\/8OV6?^CEOV?\
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MX>D?_)%?0%% 'S__ ,/8OV6?^CEOV?\ _P .'I'_ ,D4?\/8OV6?^CEOV?\
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M]B_99_Z.6_9__P##AZ1_\D4?\/8OV6?^CEOV?_\ PX>D?_)%?0%% 'S_ /\
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M_J6:Q7U_7R!_P0C_ .49_A?_ +&OQG_ZEFL4 ?7]%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MT'9DM%4$\=&6(YXYKZ&^!G_!"_P7X5\FZ\>>(-2\5W2X9[*RS867NI8$RO\
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MLUB@#Z_HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M45Y?^T5^V1\._P!EK2S-XN\06UK>LF^'3+?]_?W'IMB7D _WFVK_ +0K\_\
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M6:Q0!]?T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M5\3/B!XLAEO--\&_#WP\VNZ]-9Q$"6[: .BI K$+N9P6.=H;:VW2_P""3O\
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M_@C_ .:&C_ALCXB_]&G?M ?^#?P1_P#-#0!] 45\_P#_  V1\1?^C3OV@/\
MP;^"/_FAH_X;(^(O_1IW[0'_ (-_!'_S0T ?0%%?/_\ PV1\1?\ HT[]H#_P
M;^"/_FAH_P"&R/B+_P!&G?M ?^#?P1_\T- 'T!17S_\ \-D?$7_HT[]H#_P;
M^"/_ )H:/^&R/B+_ -&G?M ?^#?P1_\ -#0!] 45\_\ _#9'Q%_Z-._: _\
M!OX(_P#FAH_X;(^(O_1IW[0'_@W\$?\ S0T ?0%%?/\ _P -D?$7_HT[]H#_
M ,&_@C_YH:/^&R/B+_T:=^T!_P"#?P1_\T- 'T!17S__ ,-D?$7_ *-._: _
M\&_@C_YH:/\ ALCXB_\ 1IW[0'_@W\$?_-#0!] 45\__ /#9'Q%_Z-._: _\
M&_@C_P":&C_ALCXB_P#1IW[0'_@W\$?_ #0T ?0%%?/_ /PV1\1?^C3OV@/_
M  ;^"/\ YH:/^&R/B+_T:=^T!_X-_!'_ ,T- 'T!17S_ /\ #9'Q%_Z-._:
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MC3OV@/\ P;^"/_FAH_X;(^(O_1IW[0'_ (-_!'_S0T ?0%%?/_\ PV1\1?\
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M1\1?^C3OV@/_  ;^"/\ YH:/^&R/B+_T:=^T!_X-_!'_ ,T- 'T!17S_ /\
M#9'Q%_Z-._: _P#!OX(_^:&C_ALCXB_]&G?M ?\ @W\$?_-#0!] 45\__P##
M9'Q%_P"C3OV@/_!OX(_^:&C_ (;(^(O_ $:=^T!_X-_!'_S0T ?0%%?/_P#P
MV1\1?^C3OV@/_!OX(_\ FAH_X;(^(O\ T:=^T!_X-_!'_P T- 'T!17S_P#\
M-D?$7_HT[]H#_P &_@C_ .:&C_ALCXB_]&G?M ?^#?P1_P#-#0!] 45\_P#_
M  V1\1?^C3OV@/\ P;^"/_FAH_X;(^(O_1IW[0'_ (-_!'_S0T ?0%%?/_\
MPV1\1?\ HT[]H#_P;^"/_FAH_P"&R/B+_P!&G?M ?^#?P1_\T- 'T!17S_\
M\-D?$7_HT[]H#_P;^"/_ )H:/^&R/B+_ -&G?M ?^#?P1_\ -#0!] 45\_\
M_#9'Q%_Z-._: _\ !OX(_P#FAH_X;(^(O_1IW[0'_@W\$?\ S0T ?0%%?/\
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M^(O_ $:=^T!_X-_!'_S0T?\ #9'Q%_Z-._: _P#!OX(_^:&NP^;/H"BOG_\
MX;(^(O\ T:=^T!_X-_!'_P T-'_#9'Q%_P"C3OV@/_!OX(_^:&@#Z HKY_\
M^&R/B+_T:=^T!_X-_!'_ ,T-'_#9'Q%_Z-._: _\&_@C_P":&@#Z HKY_P#^
M&R/B+_T:=^T!_P"#?P1_\T-'_#9'Q%_Z-._: _\ !OX(_P#FAH ^@**^?_\
MALCXB_\ 1IW[0'_@W\$?_-#1_P -D?$7_HT[]H#_ ,&_@C_YH: /H"BOG_\
MX;(^(O\ T:=^T!_X-_!'_P T-'_#9'Q%_P"C3OV@/_!OX(_^:&@#Z HKY_\
M^&R/B+_T:=^T!_X-_!'_ ,T-'_#9'Q%_Z-._: _\&_@C_P":&@#Z HKY_P#^
M&R/B+_T:=^T!_P"#?P1_\T-'_#9'Q%_Z-._: _\ !OX(_P#FAH ^@**^?_\
MALCXB_\ 1IW[0'_@W\$?_-#1_P -D?$7_HT[]H#_ ,&_@C_YH: /H"BOG_\
MX;(^(O\ T:=^T!_X-_!'_P T-'_#9'Q%_P"C3OV@/_!OX(_^:&@#Z HKY_\
M^&R/B+_T:=^T!_X-_!'_ ,T-'_#9'Q%_Z-._: _\&_@C_P":&@#Z HKY_P#^
M&R/B+_T:=^T!_P"#?P1_\T-'_#9'Q%_Z-._: _\ !OX(_P#FAH ^@**^?_\
MALCXB_\ 1IW[0'_@W\$?_-#1_P -D?$7_HT[]H#_ ,&_@C_YH: /H"BOG_\
MX;(^(O\ T:=^T!_X-_!'_P T-'_#9'Q%_P"C3OV@/_!OX(_^:&@#Z HKY_\
M^&R/B+_T:=^T!_X-_!'_ ,T-'_#9'Q%_Z-._: _\&_@C_P":&@#Z HKY_P#^
M&R/B+_T:=^T!_P"#?P1_\T-'_#9'Q%_Z-._: _\ !OX(_P#FAH ^@**^?_\
MALCXB_\ 1IW[0'_@W\$?_-#1_P -D?$7_HT[]H#_ ,&_@C_YH: /H"BOG_\
MX;(^(O\ T:=^T!_X-_!'_P T-'_#9'Q%_P"C3OV@/_!OX(_^:&@#Z HKY_\
M^&R/B+_T:=^T!_X-_!'_ ,T-'_#9'Q%_Z-._: _\&_@C_P":&@#Z HKY_P#^
M&R/B+_T:=^T!_P"#?P1_\T-'_#9'Q%_Z-._: _\ !OX(_P#FAH ^@**^?_\
MALCXB_\ 1IW[0'_@W\$?_-#1_P -D?$7_HT[]H#_ ,&_@C_YH: /H"BOG_\
MX;(^(O\ T:=^T!_X-_!'_P T-'_#9'Q%_P"C3OV@/_!OX(_^:&@#Z HKY_\
M^&R/B+_T:=^T!_X-_!'_ ,T-'_#9'Q%_Z-._: _\&_@C_P":&@#Z HKY_P#^
M&R/B+_T:=^T!_P"#?P1_\T-'_#9'Q%_Z-._: _\ !OX(_P#FAH ^@**^?_\
MALCXB_\ 1IW[0'_@W\$?_-#1_P -D?$7_HT[]H#_ ,&_@C_YH: /H"BOG_\
MX;(^(O\ T:=^T!_X-_!'_P T-'_#9'Q%_P"C3OV@/_!OX(_^:&@#Z HKY_\
M^&R/B+_T:=^T!_X-_!'_ ,T-'_#9'Q%_Z-._: _\&_@C_P":&@#Z HKY_P#^
M&R/B+_T:=^T!_P"#?P1_\T-'_#9'Q%_Z-._: _\ !OX(_P#FAH ^@*\ _:'_
M .3Z_P!G7_N9?_3?'2?\-D?$7_HT[]H#_P &_@C_ .:&N!U/XR>(OBW^W7\"
M?[?^$_Q ^%_]G_V_Y'_"3WFAW']I[]/&[R?[,U&\QY>Q=WF^7GS4V[\/M /K
MZOG_ /X*Q?\ *++]I;_LE7BC_P!-%U7T!7S_ /\ !6+_ )19?M+?]DJ\4?\
MIHNJ #_@D[_RBR_9I_[)5X7_ /31:UXS_P %!_\ @E/\6OVO/VSO _QB\!?M
M(6_PHNOAWHTNFZ#IMU\.++Q5'IUS.Y:YO8C=W C2>5!#'O$6]5BP'PQ%>S?\
M$G?^467[-/\ V2KPO_Z:+6OH"@#Y/^%?_!/SXF>,_P!GGXH?#3]IKX]2?M$^
M'OB-IXTR+R_ ]AX2DT:$I(LI0VCOYCLS1NK/_JVA!&<FO.OV<_\ @C)XR\'_
M !O^'7B+XR?M)^,_CKX7^"DIN/AYX:U'0;72HM(N!$8(KF^N(79]2N(HL!)9
M0K*VYNCLI^]:* /CO]LO_@EYXO\ B_\ M*K\9?@?\=M>_9\^)FI:+'X<\17U
MMX>M?$6G^(K")V>$2V5RZ1K<1%B$G!+*I*@#.:ZCX*_\$[-0_9+_ &%)OA+\
M'OB;K'A/QA=WS:Q=_$#5]+@\0:CJ.HSW:7%]=W$$Y$<LDZAXOF/R*RD%F3)^
MG** /EO]OG_@G#JG[5WC_P #_$CX=_%37/@G\9_AY#<V.D^+=/TJ#5H9[&YV
M_:+.[L9F6*YB)4.H9@$?YL$UC? '_@C_ .$_ G[+?Q:\ _$CQ5KWQ<\1_'V6
M:Z^(?BW4HTLKS6YWA$2&"*,E+6*!0/(B4L(CT)  'U[10!\%?LY_\$9/&7@_
MXW_#KQ%\9/VD_&?QU\+_  4E-Q\//#6HZ#:Z5%I%P(C!%<WUQ"[/J5Q%%@)+
M*%96W-T=E/WK110 5\@?\$(_^49_A?\ [&OQG_ZEFL5]?U\@?\$(_P#E&?X7
M_P"QK\9_^I9K% 'U_1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%>2_M(_MO?#?]E>Q?_A*M?A_M39NBTFRQ<:A-Z?NP?D![-(54^M? ?QD_P""
MJGQ>_:S\2MX3^$^AZCX?M[PE(X]+1KK5[A.A9I5&(5Z$E I7G+D5Y^*S*C0?
M*W>79:L^KR/@W,LS7M81Y*76<_=C;NNK^6G=H^_/VDOVWOAO^RM8O_PE6O0C
M5-F^+2++%QJ$W<?NP?D![-(54^M? /QG_P""K?Q<_:L\3?\ "*_"C1=0\.V]
MX2D46EQM=:Q<KT+&51^Z'0DQ@%><N174_LX_\$2->\9:@FO?%[7Y+ 7#>?-I
M=A.+B^G8G)\ZX.44D]=F\G/WE-??OP7_ &??!G[/'AH:3X-\.Z?H5J0/-:%,
MS7)'1I96R\A]V8UQ\N-Q7Q?NX=NK_KY>A]']8X:R+^ OKE==7I33\EJG_P"3
M?XD? /[-_P#P1,\0>.-07Q!\8->FT_[4_GRZ793BXOYV/)\^X.Y%)/7;O)!^
M\IK[^^"_[/O@S]GCPT-)\&^'=/T*U('FM"F9KDCHTLK9>0^[,:[*BO0PN7T,
M/_#6O=[GRF><5YEFKMBJGN=(K2*^77U=WYA11178?.!1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %> ?M#_ /)]?[.O_<R_^F^.O?Z\ _:'_P"3Z_V=?^YE
M_P#3?'0![_7S_P#\%8O^467[2W_9*O%'_IHNJ^@*^?\ _@K%_P HLOVEO^R5
M>*/_ $T75 !_P2=_Y19?LT_]DJ\+_P#IHM:^@*^?_P#@D[_RBR_9I_[)5X7_
M /31:U] 4 %%%% !1110 4444 %%%% !7R!_P0C_ .49_A?_ +&OQG_ZEFL5
M]?U\@?\ !"/_ )1G^%_^QK\9_P#J6:Q0!]?T444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 45X_^TG^W5\-?V5[:1/$^OQ2:NJ;H]'L,7%_)W&4!Q&#V:0JI]:^!
M?C#_ ,%2OC%^UYXF;PG\*=%U'P_:WF42'24:YU:=.A9Y@/W*]"2@7;SER*\_
M%9E0HOE;O+LM6?69'P9F691]M"/)2W<Y^[&W==7\M.[1]^?M*?MS?#?]E6SD
M7Q1KT3:MLW1Z/8XN+^7N/W8.$![-(54^M? /QD_X*G_&#]KCQ*WA/X5Z+J/A
MZUO"4CATE&NM6N$Z%FF4?NEZ$F,+MYRY%=E^S;_P1$U?Q3=)KGQ>UZ:S:X?S
MI-)TZ<37<K$Y/GW)RH)/4)O)S]\&OOOX-_ /P=^S[X:72?!OA_3M!L\#S/(C
M_>W!'1I)&R\C>[DFN/DQN*^/]W#LM_Z^[T/HOK/#>1?[O'ZY77VGI33\EK?\
M?*2/@+]FO_@B/K7BR\CU[XO:Y+8_:'\^32=/G$]Y,QY/GW!RJDGJ$WDY^\IK
M[]^#?P#\'?L^^&ETGP;X?T[0;/ \SR(_WMP1T:21LO(WNY)KKZ*]#"Y?1PZ_
M=K7N]SY//.*LRS:7^UU/=Z16D5\NOJ[OS"BBBNP^="BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBN'_:)^+T?P1^%&I:Y^[:\5?(L8WZ
M2W#Y"#'<#EB/136&*Q%/#TI5ZKM&*;?HA2DDKL[BBN!_9I^,R_'+X46.L/Y:
MZC&3;7\:# 2=<9('8,"K =@V.U=]2PN*IXFC&O2=XR2:^8HR4E=!111704%%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%8GQ'\=V?PR\"ZIKU^V+73(&F*YP9&Z*@]V8A1[D5Y]^R%^T3+\?O!-X^
MI?9X]<TN<I<QPKM5HWR8W R<#&5^J$]ZX:F98>GBH8*4O?FFTO)?T[>C)=1*
M7+U/7****[B@HHHH **** "BBB@ HHHH **** "O /VA_P#D^O\ 9U_[F7_T
MWQU[_7@'[0__ "?7^SK_ -S+_P"F^.@#W^OG_P#X*Q?\HLOVEO\ LE7BC_TT
M75?0%?/_ /P5B_Y19?M+?]DJ\4?^FBZH /\ @D[_ ,HLOV:?^R5>%_\ TT6M
M?0%?/_\ P2=_Y19?LT_]DJ\+_P#IHM:^@* "BBB@ HHHH **** "BBB@ KY
M_P""$?\ RC/\+_\ 8U^,_P#U+-8KZ_KY _X(1_\ *,_PO_V-?C/_ -2S6* /
MK^BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M=;V?;3L>JMM0HHHK0 HHHH **** "BBB@ HHHH *\ _:'_Y/K_9U_P"YE_\
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MBB@ HHHH **** "BBB@ HHHH *\ _:'_ .3Z_P!G7_N9?_3?'7O]> ?M#_\
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MH"BOG_\ X=._LL_]&T_L_P#_ (;S2/\ Y'H_X=._LL_]&T_L_P#_ (;S2/\
MY'H ^@**^?\ _AT[^RS_ -&T_L__ /AO-(_^1Z/^'3O[+/\ T;3^S_\ ^&\T
MC_Y'H ^@**^?_P#AT[^RS_T;3^S_ /\ AO-(_P#D>C_AT[^RS_T;3^S_ /\
MAO-(_P#D>@#Z HKY_P#^'3O[+/\ T;3^S_\ ^&\TC_Y'H_X=._LL_P#1M/[/
M_P#X;S2/_D>@#Z HKY__ .'3O[+/_1M/[/\ _P"&\TC_ .1Z/^'3O[+/_1M/
M[/\ _P"&\TC_ .1Z /H"BOG_ /X=._LL_P#1M/[/_P#X;S2/_D>C_AT[^RS_
M -&T_L__ /AO-(_^1Z /H"BOG_\ X=._LL_]&T_L_P#_ (;S2/\ Y'H_X=._
MLL_]&T_L_P#_ (;S2/\ Y'H ^@**^?\ _AT[^RS_ -&T_L__ /AO-(_^1Z/^
M'3O[+/\ T;3^S_\ ^&\TC_Y'H ^@**^?_P#AT[^RS_T;3^S_ /\ AO-(_P#D
M>C_AT[^RS_T;3^S_ /\ AO-(_P#D>@#Z HKY_P#^'3O[+/\ T;3^S_\ ^&\T
MC_Y'H_X=._LL_P#1M/[/_P#X;S2/_D>@#Z HKY__ .'3O[+/_1M/[/\ _P"&
M\TC_ .1Z/^'3O[+/_1M/[/\ _P"&\TC_ .1Z /H"BOG_ /X=._LL_P#1M/[/
M_P#X;S2/_D>C_AT[^RS_ -&T_L__ /AO-(_^1Z /H"BOG_\ X=._LL_]&T_L
M_P#_ (;S2/\ Y'H_X=._LL_]&T_L_P#_ (;S2/\ Y'H ^@**^?\ _AT[^RS_
M -&T_L__ /AO-(_^1Z/^'3O[+/\ T;3^S_\ ^&\TC_Y'H ^@**^?_P#AT[^R
MS_T;3^S_ /\ AO-(_P#D>C_AT[^RS_T;3^S_ /\ AO-(_P#D>@#Z HKY_P#^
M'3O[+/\ T;3^S_\ ^&\TC_Y'H_X=._LL_P#1M/[/_P#X;S2/_D>@#Z HKY__
M .'3O[+/_1M/[/\ _P"&\TC_ .1Z/^'3O[+/_1M/[/\ _P"&\TC_ .1Z /H"
MBOG_ /X=._LL_P#1M/[/_P#X;S2/_D>C_AT[^RS_ -&T_L__ /AO-(_^1Z /
MH"BOG_\ X=._LL_]&T_L_P#_ (;S2/\ Y'H_X=._LL_]&T_L_P#_ (;S2/\
MY'H ^@**^?\ _AT[^RS_ -&T_L__ /AO-(_^1Z/^'3O[+/\ T;3^S_\ ^&\T
MC_Y'H ^@**^?_P#AT[^RS_T;3^S_ /\ AO-(_P#D>C_AT[^RS_T;3^S_ /\
MAO-(_P#D>@#Z HKY_P#^'3O[+/\ T;3^S_\ ^&\TC_Y'H_X=._LL_P#1M/[/
M_P#X;S2/_D>@#Z HKY__ .'3O[+/_1M/[/\ _P"&\TC_ .1Z/^'3O[+/_1M/
M[/\ _P"&\TC_ .1Z /H"BOG_ /X=._LL_P#1M/[/_P#X;S2/_D>C_AT[^RS_
M -&T_L__ /AO-(_^1Z /H"BOG_\ X=._LL_]&T_L_P#_ (;S2/\ Y'H_X=._
MLL_]&T_L_P#_ (;S2/\ Y'H ^@**^?\ _AT[^RS_ -&T_L__ /AO-(_^1Z/^
M'3O[+/\ T;3^S_\ ^&\TC_Y'H ^@**^?_P#AT[^RS_T;3^S_ /\ AO-(_P#D
M>C_AT[^RS_T;3^S_ /\ AO-(_P#D>@#Z HKY_P#^'3O[+/\ T;3^S_\ ^&\T
MC_Y'H_X=._LL_P#1M/[/_P#X;S2/_D>@#Z HKY__ .'3O[+/_1M/[/\ _P"&
M\TC_ .1Z/^'3O[+/_1M/[/\ _P"&\TC_ .1Z /H"BOG_ /X=._LL_P#1M/[/
M_P#X;S2/_D>C_AT[^RS_ -&T_L__ /AO-(_^1Z /H"BOG_\ X=._LL_]&T_L
M_P#_ (;S2/\ Y'KS?XP?LO?L%_ 43+XJ^#W[,>F74.=]F/ >D7%X/^V$=NTG
M_CM3.I&"O-V7F=&'PM;$3]G0@Y2[)-O[D?9%%?D9\8OCW^Q7H)EM_!'['OP6
M\0S+\JW6H^ =&L;?/JJBW>1A[$(:\$OO@=#^V->26?@O]E_X*V5F[%6C\+?"
MG2XDB[?/=-;LZ=>OF*,GZ5Y=7.</%\L+R?9(^TP/ASF]:'M<2HT8=ZDDOP5V
MOG8_=#Q_\5/#/PITDWWB;Q!HWA^SP2)=0O([=6QV7<1N/L,DU\Q?&'_@M+\(
M?AV98-!;6/&EZN0/L%MY%J&'9I9MIQ[HKBODSX!?\$'?'U_IMK#K=QX8^'FD
MKTL[9%N[B$>T4.(?REKZV^#W_!%[X0?#GRI]<CUCQI>I@DZA<F&V#?[,4.WC
MV=GK/ZQCZW\."@N[W^[_ (!W?V3PIEW^^8F6(DOLTU:/WWL_E)>A\O\ CW_@
MLQ\8OC1JW]D_#WPW8Z#)<9\F.QLWU;4C]"RE#VZ0UDZ?^P+^T_\ MA7L=]XV
MO-3L;.1@RR>*=49%B]=EJNYX^O3RU&3]:_0+Q+_P33_9S\:SQS:W\ _@OK4\
M*A%FU'P3IMW* ./OR0LQ_$UE_P##IW]EG_HVG]G_ /\ #>:1_P#(]']DSJ:X
MJHY>2T7]?<+_ %^P^#7+DF"A2_O2]Z7WZ?BV>'_![_@A)X-\/^7<>-O%6L>(
MYUPQM=/C6PML]U8G?(P]P4-?57P?_9%^&?P%6)O"?@O0M+N81A;S[/YUY_W_
M )-TG_CU<+_PZ=_99_Z-I_9__P##>:1_\CT?\.G?V6?^C:?V?_\ PWFD?_(]
M=]# X>C_  XK]?O/E<SXHS7,+K%UY23Z7M'_ ,!5E^!] 45\_P#_  Z=_99_
MZ-I_9_\ _#>:1_\ (]'_  Z=_99_Z-I_9_\ _#>:1_\ (]=9X!] 45\__P##
MIW]EG_HVG]G_ /\ #>:1_P#(]'_#IW]EG_HVG]G_ /\ #>:1_P#(] 'T!17S
M_P#\.G?V6?\ HVG]G_\ \-YI'_R/1_PZ=_99_P"C:?V?_P#PWFD?_(] 'T!1
M7S__ ,.G?V6?^C:?V?\ _P -YI'_ ,CT?\.G?V6?^C:?V?\ _P -YI'_ ,CT
M ?0%%?/_ /PZ=_99_P"C:?V?_P#PWFD?_(]'_#IW]EG_ *-I_9__ /#>:1_\
MCT ?0%%?/_\ PZ=_99_Z-I_9_P#_  WFD?\ R/1_PZ=_99_Z-I_9_P#_  WF
MD?\ R/0!] 45\]W7_!*C]E.QMVFF_9M_9[AAC&6=_A]HZJH]R;>N!\8?LE_L
M+^"-ZWGP1_9NFE3@Q6?P^TF[;/I^[MF /U(KGQ&,H8>/-7FHKS:7YDRDEN?8
M5%?G3XP\&?L<:?N70_V2?@GJ;C@/=> -%M8S[C%N[$?4#\*\YU+X#_"?XE7;
M6OAO]E?]GBT=N%33OA;I=W<8/KNMW'Y**^9Q7'&4TGRPFZDNT4W^+LOQ,98J
MFMM3]7*Y#Q?\?O!?@/<NJ^)M'MI$^]"MP)9A_P!LTRWZ5^>GPH_X)+-9:^-6
M\/\ PA^'_@>ZD(/VNVT*PTAE_P" 01JXQ[+7T)X/_P""9$C;7U_Q1&O]Z'3[
M8MGZ2.1_Z!7+_K%F^)TP.":7>;Y5]VGX,GVU27P1^\[/QA_P4=\%Z(&32;/6
M-:D'W6$0MX3_ ,"<[O\ QRO,/$G_  49\9>)[G[-X?T/3=.:4X0;7O+C\/NJ
M?^^*]Q\(?L)_#GPGM:32;C6)EZ2:A<M)GZHNU#^*TOCW_@GO\ _BK>+<>*/@
M?\(?$MQ']V;5O!VG7L@[?>EA8T?V9Q%BO]YQ,:2[05W][L_Q8>SK2^*5O0^>
MQX?_ &@/C>/W[>)H+6;EA-(-+A(]T^3</HIK<\)?\$TM>U-Q+K_B/3['<=SI
M:Q/=2'ZEM@!]^?QKTC_AT[^RS_T;3^S_ /\ AO-(_P#D>C_AT[^RS_T;3^S_
M /\ AO-(_P#D>KI\"X*4N?&3G6E_>D_TU_$%A8[RNRWX/_X)Y^ /#H5M075-
M=E')^TW/EQY]EC"G'L2:]3\(?"7POX!5?[&T#2=.9?\ EI#;(LA^KXW'\37D
M/_#IW]EG_HVG]G__ ,-YI'_R/1_PZ=_99_Z-I_9__P##>:1_\CU]'@\FP.%_
MW>E&+[I*_P!^_P")M&G".R/H"BOG_P#X=._LL_\ 1M/[/_\ X;S2/_D>C_AT
M[^RS_P!&T_L__P#AO-(_^1Z](T/H"BOG_P#X=._LL_\ 1M/[/_\ X;S2/_D>
MC_AT[^RS_P!&T_L__P#AO-(_^1Z /H"BOG__ (=._LL_]&T_L_\ _AO-(_\
MD>C_ (=._LL_]&T_L_\ _AO-(_\ D>@#Z HKY_\ ^'3O[+/_ $;3^S__ .&\
MTC_Y'H_X=._LL_\ 1M/[/_\ X;S2/_D>@#Z HKY__P"'3O[+/_1M/[/_ /X;
MS2/_ )'H_P"'3O[+/_1M/[/_ /X;S2/_ )'H ^@**^?_ /AT[^RS_P!&T_L_
M_P#AO-(_^1Z/^'3O[+/_ $;3^S__ .&\TC_Y'H ^@**^?_\ AT[^RS_T;3^S
M_P#^&\TC_P"1Z/\ AT[^RS_T;3^S_P#^&\TC_P"1Z /H"BOG_P#X=._LL_\
M1M/[/_\ X;S2/_D>C_AT[^RS_P!&T_L__P#AO-(_^1Z /H"BOG__ (=._LL_
M]&T_L_\ _AO-(_\ D>C_ (=._LL_]&T_L_\ _AO-(_\ D>@#Z HKY_\ ^'3O
M[+/_ $;3^S__ .&\TC_Y'H_X=._LL_\ 1M/[/_\ X;S2/_D>@#Z HKY__P"'
M3O[+/_1M/[/_ /X;S2/_ )'H_P"'3O[+/_1M/[/_ /X;S2/_ )'H ^@**^?_
M /AT[^RS_P!&T_L__P#AO-(_^1Z/^'3O[+/_ $;3^S__ .&\TC_Y'H ^@**^
M?_\ AT[^RS_T;3^S_P#^&\TC_P"1Z/\ AT[^RS_T;3^S_P#^&\TC_P"1Z /H
M"BOG_P#X=._LL_\ 1M/[/_\ X;S2/_D>C_AT[^RS_P!&T_L__P#AO-(_^1Z
M/H"BOG__ (=._LL_]&T_L_\ _AO-(_\ D>C_ (=._LL_]&T_L_\ _AO-(_\
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M1110 5\@?\$(_P#E&?X7_P"QK\9_^I9K%?7]?('_  0C_P"49_A?_L:_&?\
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M&I_*_N/H"BO!?^'GGP'_ .BB:;_X"77_ ,:H_P"'GGP'_P"BB:;_ . EU_\
M&J/[/Q7_ #[E_P" O_(/8U/Y7]Q[U17@R_\ !3OX$.P'_"Q-,Y..;2Z'_M*M
M#_AXI\$?^BD>'/\ OX__ ,34O XE;TY?<_\ (/93[/[CVFBO%O\ AXI\$?\
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M]$E^1M&,8[(****ZB@HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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ME_\ 3?'0![_7S_\ \%8O^467[2W_ &2KQ1_Z:+JOH"OG_P#X*Q?\HLOVEO\
MLE7BC_TT75 !_P $G?\ E%E^S3_V2KPO_P"FBUKZ KY__P""3O\ RBR_9I_[
M)5X7_P#31:U] 4 %%%% !1110 4444 %%%% !7R!_P $(_\ E&?X7_[&OQG_
M .I9K%?7]?('_!"/_E&?X7_[&OQG_P"I9K% 'U_1110 4444 %%%% !1110
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M>#M/3([=O>OK7QO_ ,%?_C1KO@S5](UK0_"J:?KME-ILK2:3<PLBRH48HWG
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M4O%UM#_>2VL6ES]&9U_E6E/%9A/_ '7+;><Y?H['AXSQ XBQ6DJTHK^[:/\
MZ2D_Q.C\/>+_ -FCX)#_ (D.B^$H+F/D26.A&:=L=/WQC)/XOW^M7M=_X*4>
M#;'<MCI/B"^8="T<<,9_$N3_ ..T[0O^";'@VQ*M?:KX@OV'55DCAC/X!"?_
M !ZNRT/]B7X9Z$%(\.+=2#^.YNII<_\  2VW]*[HT^**BM%4J2^;?_MR/F*^
M(QN(ESUI7?=MM_C<\9UW_@IW?2[ETSPE:P>C75\TN?\ @*HO\ZXOQE^V9\0/
MBUX;U"QET/0KK1YXF%W -&^V6[QCD^8LWF(5 &3N&.]?9FA?![PGX8*G3_#.
M@V;*<AXK")6S_O;<U3^-WPOG^+GPSO/#=KJS:&M]L62=+?SOW:L"4V[EX. .
M"...1Q6>)R'/9TI2J8UN5G:,8J-WT5[QM?N8^SKKWE/5;6T/S-G,,ES))#9:
M9IZRMN,-A8PV4 . ,K%"JHN<<X49Z]:Z#X3>'=8NO&$=YX3\/Z7>>(K#_2X[
MF'1;6XOXB"!YBR-&9,@D#(.0".@KZ0_X=>?]3Q_Y1O\ [?73?!S]@BX^#_Q(
MTOQ#;^-)+AM/D+/ NE^5]H0@JR%O.; (/H?SKXC!<'YXL5&I5A**;]Z2G'FL
MWJ[\UWW\S.F\6JCJ<TDY;OFU=][N^IY<?CM^T)H.5NK'Q$RCY 9O#B[<CT80
MC/YFE_X;B^+.B-_IFDV;<]+C294Z=1PRU]N45]__ *JXZ/\ #Q]3YZ_J:?5Y
M])L^*K#_ (*7^+H\?:M"\.3<\^4LT>1^,C?G6Q8?\%/;Z/;]J\'VDW7=Y6HM
M'GTQF-J^M;W2K74ABXMK>X!&W$D8;CTYK'O_ (3^%=5#?:O#/A^YW#!\W3H7
MR/Q6C^P\]A_#Q]_6"_X(>RJK:?X'SW8?\%.]-D ^U>$;Z'CGRK]9.?3E%_.M
MBR_X*7>#9!_I&B^)HC@?ZN."3GOUD%>J7_[,_P /]1+>9X.\/KN.3Y5FD7_H
M(%8]]^Q=\,=0/[SPK;K\V[]U=7$7/_ 9!Q[=*/J/$\?AQ%.7K&WY1#EK]T<[
M9?\ !0SX=W1_>2:U;<@9DLL_C\K&MBP_;E^&%\0/^$D:!F. );"Y7]?+Q^M9
M][^P#\-;K_5Z=J%MU_U=_(<_]]$]*Q[[_@FWX%N1^YU#Q-;MC VW,++GU(,1
M/ZBCGXJA]FC+_P "_P T'^T+L>@6'[5WPYU(+Y?B[2%W9QYKF+IZ[@,?C6Q8
M_'/P5J8_T?Q=X9E.W=M74X=P'N-V1^->'W__  3)T&0-]E\3:Q#TQYL$<F/R
MVUC7_P#P3 8%FM?&@Z\++I?0?[PE_I1_:7$L/BPD)>DTOSD'/7_E1]167C#2
M=2_X]]4TZXZ']W<HW7IT-:-?&E[_ ,$RO$,9_P!'\2Z-*-W_ "TBDCX]> W/
MM6</^">OQ(T(AK+5M!Z[A]GOYXR".G6,<T?ZQ9S#^)E[^4T_T8>VJ=8'VY17
MQ&/V7_CKX?\ ^/'4M2.T%A]E\0>7SZ#+KS1_PAG[1WAP?Z[Q7)Y8_P"@I'=9
MS_VT;/\ 2C_6[$Q_BX&JO1-_H@^L2ZP9]N45\1'Q_P#M'>'AC[/XKDVX3_D#
M1W7_ +2;/UI?^&K/CAH9Q>:;>L<[?])T$QX(ZCA5_&C_ %ZPL?XM"K'UBO\
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MFOBM>]Y/LCNJ*\$\2_\ !1;P%HX9;&/6M7?^$PVPBC/U,C*1_P!\FN \2_\
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M_KY__P""L7_*++]I;_LE7BC_ --%U7T!7S__ ,%8O^467[2W_9*O%'_IHNJ
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M'PO_ &4/@1'\,?A]X)T/PWX$6.6.32(XC-%>"5=DIN&E+/.SJ K/*SLP !)
MH ^1?^"LOQH\*?&SPW^QMI'A36M'\07WQ&^,_A3Q%X>2SN1,;[3;-FN[F]C"
MDEH8XMNY\%5\U0<$@C]!J^9_V5/^".G[,_[$?QBU#X@?"_X2Z#X5\7ZDLB-J
M*7-U=M:K)NWK;)/+(EJK!BI$"Q@J=OW<"OIB@#S/XV^*OC'H.OVD?PX\!_#/
MQ7I;V^ZYN/$GCN^\/W$,VXC8D4&D7RNFW:=YD0Y)&S W'XE_X(O>.?VB-/\
M^">OAV+PQ\+?@OK&C+XE\6&.ZU3XHZGIMT\A\3:J9E,,?A^X5524R(K"4ET5
M7*QEC&OZ35\@?\$(_P#E&?X7_P"QK\9_^I9K% '?_P#"Q_VIO^B-_L__ /AY
M-7_^9BC_ (6/^U-_T1O]G_\ \/)J_P#\S%?0%% 'S_\ \+'_ &IO^B-_L_\
M_AY-7_\ F8H_X6/^U-_T1O\ 9_\ _#R:O_\ ,Q7T!10!\_\ _"Q_VIO^B-_L
M_P#_ (>35_\ YF*/^%C_ +4W_1&_V?\ _P /)J__ ,S%?0%% 'S_ /\ "Q_V
MIO\ HC?[/_\ X>35_P#YF*/^%C_M3?\ 1&_V?_\ P\FK_P#S,5] 44 ?/_\
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M6/\ M3?]$;_9_P#_  \FK_\ S,4?\+'_ &IO^B-_L_\ _AY-7_\ F8KZ HH
M^?\ _A8_[4W_ $1O]G__ ,/)J_\ \S%'_"Q_VIO^B-_L_P#_ (>35_\ YF*^
M@** /G__ (6/^U-_T1O]G_\ \/)J_P#\S%'_  L?]J;_ *(W^S__ .'DU?\
M^9BOH"B@#Y__ .%C_M3?]$;_ &?_ /P\FK__ #,4?\+'_:F_Z(W^S_\ ^'DU
M?_YF*^@** /G_P#X6/\ M3?]$;_9_P#_  \FK_\ S,4?\+'_ &IO^B-_L_\
M_AY-7_\ F8KZ HH ^?\ _A8_[4W_ $1O]G__ ,/)J_\ \S%'_"Q_VIO^B-_L
M_P#_ (>35_\ YF*^@** /G__ (6/^U-_T1O]G_\ \/)J_P#\S%'_  L?]J;_
M *(W^S__ .'DU?\ ^9BOH"B@#Y__ .%C_M3?]$;_ &?_ /P\FK__ #,4?\+'
M_:F_Z(W^S_\ ^'DU?_YF*^@** /G_P#X6/\ M3?]$;_9_P#_  \FK_\ S,4?
M\+'_ &IO^B-_L_\ _AY-7_\ F8KZ HH ^?\ _A8_[4W_ $1O]G__ ,/)J_\
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M HH ^?\ _A8_[4W_ $1O]G__ ,/)J_\ \S%'_"Q_VIO^B-_L_P#_ (>35_\
MYF*^@** /G__ (6/^U-_T1O]G_\ \/)J_P#\S%'_  L?]J;_ *(W^S__ .'D
MU?\ ^9BOH"B@#Y__ .%C_M3?]$;_ &?_ /P\FK__ #,4?\+'_:F_Z(W^S_\
M^'DU?_YF*^@** /G_P#X6/\ M3?]$;_9_P#_  \FK_\ S,4?\+'_ &IO^B-_
ML_\ _AY-7_\ F8KZ HH ^?\ _A8_[4W_ $1O]G__ ,/)J_\ \S%'_"Q_VIO^
MB-_L_P#_ (>35_\ YF*^@** /G__ (6/^U-_T1O]G_\ \/)J_P#\S%'_  L?
M]J;_ *(W^S__ .'DU?\ ^9BOH"B@#Y__ .%C_M3?]$;_ &?_ /P\FK__ #,4
M?\+'_:F_Z(W^S_\ ^'DU?_YF*^@** /G_P#X6/\ M3?]$;_9_P#_  \FK_\
MS,4?\+'_ &IO^B-_L_\ _AY-7_\ F8KZ HH ^?\ _A8_[4W_ $1O]G__ ,/)
MJ_\ \S%'_"Q_VIO^B-_L_P#_ (>35_\ YF*^@** /G__ (6/^U-_T1O]G_\
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M ,KZH_\ $07XF_Z(?H?_ (7TO_RKK[<?]A'X,NA4_#+P7AACC2XP?SQ6<?\
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M  1M^,_A+Q#+-XB\&?!_QI8QR9@B3XK:IHRRKZ2JOAV=O^^)1]:^KOA'\/\
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M% 'S_P#\+'_:F_Z(W^S_ /\ AY-7_P#F8H_X6/\ M3?]$;_9_P#_  \FK_\
MS,5] 44 ?/\ _P +'_:F_P"B-_L__P#AY-7_ /F8H_X6/^U-_P!$;_9__P##
MR:O_ /,Q7T!10!\__P#"Q_VIO^B-_L__ /AY-7_^9BC_ (6/^U-_T1O]G_\
M\/)J_P#\S%?0%% 'S_\ \+'_ &IO^B-_L_\ _AY-7_\ F8H_X6/^U-_T1O\
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M^OG_ /X*Q?\ *++]I;_LE7BC_P!-%U7T!7S_ /\ !6+_ )19?M+?]DJ\4?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M._\ *++]FG_LE7A?_P!-%K7T!7S_ /\ !)W_ )19?LT_]DJ\+_\ IHM:^@*
M"BBB@ HHHH **** "BBB@ KY _X(1_\ *,_PO_V-?C/_ -2S6*^OZ^0/^"$?
M_*,_PO\ ]C7XS_\ 4LUB@#Z_HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "O /VA_P#D^O\ 9U_[F7_TWQU[_7@'[0__ "?7^SK_ -S+_P"F^.@#W^OG
M_P#X*Q?\HLOVEO\ LE7BC_TT75?0%?/_ /P5B_Y19?M+?]DJ\4?^FBZH /\
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MG=1QS>)M5GA<QR3!@LD4D<BDC#(ZL,@@D _2:BOG_P#X>Q?LL_\ 1RW[/_\
MX</2/_DBC_A[%^RS_P!'+?L__P#AP](_^2* /H"BOG__ (>Q?LL_]'+?L_\
M_AP](_\ DBC_ (>Q?LL_]'+?L_\ _AP](_\ DB@#Z HKY_\ ^'L7[+/_ $<M
M^S__ .'#TC_Y(H_X>Q?LL_\ 1RW[/_\ X</2/_DB@#Z HKY__P"'L7[+/_1R
MW[/_ /X</2/_ )(H_P"'L7[+/_1RW[/_ /X</2/_ )(H ^@**^?_ /A[%^RS
M_P!'+?L__P#AP](_^2*/^'L7[+/_ $<M^S__ .'#TC_Y(H ^@**^?_\ A[%^
MRS_T<M^S_P#^'#TC_P"2*/\ A[%^RS_T<M^S_P#^'#TC_P"2* /H"BOG_P#X
M>Q?LL_\ 1RW[/_\ X</2/_DBC_A[%^RS_P!'+?L__P#AP](_^2* /H"BOG__
M (>Q?LL_]'+?L_\ _AP](_\ DBC_ (>Q?LL_]'+?L_\ _AP](_\ DB@#Z HK
MY_\ ^'L7[+/_ $<M^S__ .'#TC_Y(H_X>Q?LL_\ 1RW[/_\ X</2/_DB@#Z
MHKY__P"'L7[+/_1RW[/_ /X</2/_ )(H_P"'L7[+/_1RW[/_ /X</2/_ )(H
M ^@**^?_ /A[%^RS_P!'+?L__P#AP](_^2*/^'L7[+/_ $<M^S__ .'#TC_Y
M(H ^@**^?_\ A[%^RS_T<M^S_P#^'#TC_P"2*/\ A[%^RS_T<M^S_P#^'#TC
M_P"2* /H"BOG_P#X>Q?LL_\ 1RW[/_\ X</2/_DBC_A[%^RS_P!'+?L__P#A
MP](_^2* /H"BOG__ (>Q?LL_]'+?L_\ _AP](_\ DBC_ (>Q?LL_]'+?L_\
M_AP](_\ DB@#Z HKY_\ ^'L7[+/_ $<M^S__ .'#TC_Y(H_X>Q?LL_\ 1RW[
M/_\ X</2/_DB@#Z HKY__P"'L7[+/_1RW[/_ /X</2/_ )(H_P"'L7[+/_1R
MW[/_ /X</2/_ )(H ^@**^?_ /A[%^RS_P!'+?L__P#AP](_^2*/^'L7[+/_
M $<M^S__ .'#TC_Y(H ^@**^?_\ A[%^RS_T<M^S_P#^'#TC_P"2*/\ A[%^
MRS_T<M^S_P#^'#TC_P"2* /H"BOG_P#X>Q?LL_\ 1RW[/_\ X</2/_DBC_A[
M%^RS_P!'+?L__P#AP](_^2* /H"BOG__ (>Q?LL_]'+?L_\ _AP](_\ DBC_
M (>Q?LL_]'+?L_\ _AP](_\ DB@#Z HKY_\ ^'L7[+/_ $<M^S__ .'#TC_Y
M(H_X>Q?LL_\ 1RW[/_\ X</2/_DB@#Z HKY__P"'L7[+/_1RW[/_ /X</2/_
M )(H_P"'L7[+/_1RW[/_ /X</2/_ )(H ^@**^?_ /A[%^RS_P!'+?L__P#A
MP](_^2*/^'L7[+/_ $<M^S__ .'#TC_Y(H ^@**^?_\ A[%^RS_T<M^S_P#^
M'#TC_P"2*/\ A[%^RS_T<M^S_P#^'#TC_P"2* /H"BOG_P#X>Q?LL_\ 1RW[
M/_\ X</2/_DBC_A[%^RS_P!'+?L__P#AP](_^2* /H"BOG__ (>Q?LL_]'+?
ML_\ _AP](_\ DBC_ (>Q?LL_]'+?L_\ _AP](_\ DB@#Z HKY_\ ^'L7[+/_
M $<M^S__ .'#TC_Y(H_X>Q?LL_\ 1RW[/_\ X</2/_DB@#Z HKY__P"'L7[+
M/_1RW[/_ /X</2/_ )(H_P"'L7[+/_1RW[/_ /X</2/_ )(H ^@**^?_ /A[
M%^RS_P!'+?L__P#AP](_^2*/^'L7[+/_ $<M^S__ .'#TC_Y(H ^@**^?_\
MA[%^RS_T<M^S_P#^'#TC_P"2*/\ A[%^RS_T<M^S_P#^'#TC_P"2* /H"BOG
M_P#X>Q?LL_\ 1RW[/_\ X</2/_DBC_A[%^RS_P!'+?L__P#AP](_^2* /H"B
MOG__ (>Q?LL_]'+?L_\ _AP](_\ DBC_ (>Q?LL_]'+?L_\ _AP](_\ DB@#
MZ HKY_\ ^'L7[+/_ $<M^S__ .'#TC_Y(H_X>Q?LL_\ 1RW[/_\ X</2/_DB
M@#Z HKY__P"'L7[+/_1RW[/_ /X</2/_ )(H_P"'L7[+/_1RW[/_ /X</2/_
M )(H ^@**^?_ /A[%^RS_P!'+?L__P#AP](_^2*/^'L7[+/_ $<M^S__ .'#
MTC_Y(H ^@**^?_\ A[%^RS_T<M^S_P#^'#TC_P"2*/\ A[%^RS_T<M^S_P#^
M'#TC_P"2* /H"BOG_P#X>Q?LL_\ 1RW[/_\ X</2/_DBC_A[%^RS_P!'+?L_
M_P#AP](_^2* /H"BOG__ (>Q?LL_]'+?L_\ _AP](_\ DBC_ (>Q?LL_]'+?
ML_\ _AP](_\ DB@#Z HKY_\ ^'L7[+/_ $<M^S__ .'#TC_Y(H_X>Q?LL_\
M1RW[/_\ X</2/_DB@#Z HKY__P"'L7[+/_1RW[/_ /X</2/_ )(H_P"'L7[+
M/_1RW[/_ /X</2/_ )(H ^@**^?_ /A[%^RS_P!'+?L__P#AP](_^2*/^'L7
M[+/_ $<M^S__ .'#TC_Y(H ^@**^?_\ A[%^RS_T<M^S_P#^'#TC_P"2*/\
MA[%^RS_T<M^S_P#^'#TC_P"2* /H"BOG_P#X>Q?LL_\ 1RW[/_\ X</2/_DB
MC_A[%^RS_P!'+?L__P#AP](_^2* /H"BOG__ (>Q?LL_]'+?L_\ _AP](_\
MDBC_ (>Q?LL_]'+?L_\ _AP](_\ DB@#Z HKY_\ ^'L7[+/_ $<M^S__ .'#
MTC_Y(H_X>Q?LL_\ 1RW[/_\ X</2/_DB@#Z HKY__P"'L7[+/_1RW[/_ /X<
M/2/_ )(H_P"'L7[+/_1RW[/_ /X</2/_ )(H ^@**^?_ /A[%^RS_P!'+?L_
M_P#AP](_^2*/^'L7[+/_ $<M^S__ .'#TC_Y(H ^@**^?_\ A[%^RS_T<M^S
M_P#^'#TC_P"2*/\ A[%^RS_T<M^S_P#^'#TC_P"2* /H"BOG_P#X>Q?LL_\
M1RW[/_\ X</2/_DBC_A[%^RS_P!'+?L__P#AP](_^2* /H"BOG__ (>Q?LL_
M]'+?L_\ _AP](_\ DBC_ (>Q?LL_]'+?L_\ _AP](_\ DB@#Z HKY_\ ^'L7
M[+/_ $<M^S__ .'#TC_Y(H_X>Q?LL_\ 1RW[/_\ X</2/_DB@#Z HKY__P"'
ML7[+/_1RW[/_ /X</2/_ )(H_P"'L7[+/_1RW[/_ /X</2/_ )(H ^@**^?_
M /A[%^RS_P!'+?L__P#AP](_^2*/^'L7[+/_ $<M^S__ .'#TC_Y(H ^@**^
M?_\ A[%^RS_T<M^S_P#^'#TC_P"2*/\ A[%^RS_T<M^S_P#^'#TC_P"2* /H
M"BOG_P#X>Q?LL_\ 1RW[/_\ X</2/_DBC_A[%^RS_P!'+?L__P#AP](_^2*
M/H"BOG__ (>Q?LL_]'+?L_\ _AP](_\ DBC_ (>Q?LL_]'+?L_\ _AP](_\
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M?LL_]'+?L_\ _AP](_\ DBC_ (>Q?LL_]'+?L_\ _AP](_\ DB@#Z HKY_\
M^'L7[+/_ $<M^S__ .'#TC_Y(H_X>Q?LL_\ 1RW[/_\ X</2/_DB@#Z HKY_
M_P"'L7[+/_1RW[/_ /X</2/_ )(H_P"'L7[+/_1RW[/_ /X</2/_ )(H ^@*
M*^?_ /A[%^RS_P!'+?L__P#AP](_^2*/^'L7[+/_ $<M^S__ .'#TC_Y(H ^
M@**^?_\ A[%^RS_T<M^S_P#^'#TC_P"2*/\ A[%^RS_T<M^S_P#^'#TC_P"2
M* /H"BOG_P#X>Q?LL_\ 1RW[/_\ X</2/_DBC_A[%^RS_P!'+?L__P#AP](_
M^2* /H"BOG__ (>Q?LL_]'+?L_\ _AP](_\ DBC_ (>Q?LL_]'+?L_\ _AP]
M(_\ DB@#Z HKY_\ ^'L7[+/_ $<M^S__ .'#TC_Y(H_X>Q?LL_\ 1RW[/_\
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M\(QXAM-7_L_S=/'E>=]GD?R]_E2;=V-WEOC.TX /KZOG_P#X*Q?\HLOVEO\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH *\ _:'_ .3Z_P!G7_N9?_3?'7O]> ?M#_\ )]?[.O\ W,O_ *;XZ /?
MZ^?_ /@K%_RBR_:6_P"R5>*/_31=5] 5\_\ _!6+_E%E^TM_V2KQ1_Z:+J@
M_P""3O\ RBR_9I_[)5X7_P#31:U] 5\__P#!)W_E%E^S3_V2KPO_ .FBUKZ
MH **** "BBB@ HHHH **** "OD#_ ((1_P#*,_PO_P!C7XS_ /4LUBOK^OD#
M_@A'_P HS_"__8U^,_\ U+-8H ^OZ*** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M/0__ )4T?\.H?$7_ $>%^U__ .%'H?\ \J: /K^BOD#_ (=0^(O^CPOVO_\
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M%^U__P"%'H?_ ,J: /K^BOD#_AU#XB_Z/"_:_P#_  H]#_\ E31_PZA\1?\
M1X7[7_\ X4>A_P#RIH ^OZ*^0/\ AU#XB_Z/"_:__P#"CT/_ .5-'_#J'Q%_
MT>%^U_\ ^%'H?_RIH ^OZ*^0/^'4/B+_ */"_:__ /"CT/\ ^5-'_#J'Q%_T
M>%^U_P#^%'H?_P J: /K^BOD#_AU#XB_Z/"_:_\ _"CT/_Y4T?\ #J'Q%_T>
M%^U__P"%'H?_ ,J: /K^BOD#_AU#XB_Z/"_:_P#_  H]#_\ E31_PZA\1?\
M1X7[7_\ X4>A_P#RIH ^OZ*^0/\ AU#XB_Z/"_:__P#"CT/_ .5-'_#J'Q%_
MT>%^U_\ ^%'H?_RIH ^OZ*^0/^'4/B+_ */"_:__ /"CT/\ ^5-'_#J'Q%_T
M>%^U_P#^%'H?_P J: /K^BOD#_AU#XB_Z/"_:_\ _"CT/_Y4T?\ #J'Q%_T>
M%^U__P"%'H?_ ,J: /K^BOD#_AU#XB_Z/"_:_P#_  H]#_\ E31_PZA\1?\
M1X7[7_\ X4>A_P#RIH ^OZ*^0/\ AU#XB_Z/"_:__P#"CT/_ .5-'_#J'Q%_
MT>%^U_\ ^%'H?_RIH ^OZ*^0/^'4/B+_ */"_:__ /"CT/\ ^5-'_#J'Q%_T
M>%^U_P#^%'H?_P J: /K^BOD#_AU#XB_Z/"_:_\ _"CT/_Y4T?\ #J'Q%_T>
M%^U__P"%'H?_ ,J: /I7XQ?&'1_@;X2L]:US[5]BOM<TCP_']GB\Q_M6IZE;
M:;:Y&1\OVB[BW'^%=QP<8/55\4>./^",5U\2M%AT[7OVLOVM]4L;?4++58H9
MO$6B%4NK.ZBO+64?\2G[T5Q!#(O^U&*V/^'4/B+_ */"_:__ /"CT/\ ^5-
M'U_17R!_PZA\1?\ 1X7[7_\ X4>A_P#RIH_X=0^(O^CPOVO_ /PH]#_^5- '
MU_17R!_PZA\1?]'A?M?_ /A1Z'_\J:/^'4/B+_H\+]K_ /\ "CT/_P"5- 'U
M_17R!_PZA\1?]'A?M?\ _A1Z'_\ *FC_ (=0^(O^CPOVO_\ PH]#_P#E30!]
M?T5\@?\ #J'Q%_T>%^U__P"%'H?_ ,J:/^'4/B+_ */"_:__ /"CT/\ ^5-
M'U_17R!_PZA\1?\ 1X7[7_\ X4>A_P#RIH_X=0^(O^CPOVO_ /PH]#_^5- '
MU_17R!_PZA\1?]'A?M?_ /A1Z'_\J:/^'4/B+_H\+]K_ /\ "CT/_P"5- 'U
M_17R!_PZA\1?]'A?M?\ _A1Z'_\ *FC_ (=0^(O^CPOVO_\ PH]#_P#E30!]
M?T5\@?\ #J'Q%_T>%^U__P"%'H?_ ,J:/^'4/B+_ */"_:__ /"CT/\ ^5-
M'U_17R!_PZA\1?\ 1X7[7_\ X4>A_P#RIH_X=0^(O^CPOVO_ /PH]#_^5- '
MU_17R!_PZA\1?]'A?M?_ /A1Z'_\J:/^'4/B+_H\+]K_ /\ "CT/_P"5- 'U
M_17R!_PZA\1?]'A?M?\ _A1Z'_\ *FC_ (=0^(O^CPOVO_\ PH]#_P#E30!]
M?T5\@?\ #J'Q%_T>%^U__P"%'H?_ ,J:/^'4/B+_ */"_:__ /"CT/\ ^5-
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MV/\ AU#XB_Z/"_:__P#"CT/_ .5- 'U_17R!_P .H?$7_1X7[7__ (4>A_\
MRIH_X=0^(O\ H\+]K_\ \*/0_P#Y4T ?7]%?('_#J'Q%_P!'A?M?_P#A1Z'_
M /*FC_AU#XB_Z/"_:_\ _"CT/_Y4T ?7]%?('_#J'Q%_T>%^U_\ ^%'H?_RI
MH_X=0^(O^CPOVO\ _P */0__ )4T ?7]%?('_#J'Q%_T>%^U_P#^%'H?_P J
M:/\ AU#XB_Z/"_:__P#"CT/_ .5- 'U_17R!_P .H?$7_1X7[7__ (4>A_\
MRIH_X=0^(O\ H\+]K_\ \*/0_P#Y4T ?7]%?('_#J'Q%_P!'A?M?_P#A1Z'_
M /*FC_AU#XB_Z/"_:_\ _"CT/_Y4T ?7]%?('_#J'Q%_T>%^U_\ ^%'H?_RI
MH_X=0^(O^CPOVO\ _P */0__ )4T ?7]%?('_#J'Q%_T>%^U_P#^%'H?_P J
M:/\ AU#XB_Z/"_:__P#"CT/_ .5- 'U_17R!_P .H?$7_1X7[7__ (4>A_\
MRIH_X=0^(O\ H\+]K_\ \*/0_P#Y4T ?7]%?('_#J'Q%_P!'A?M?_P#A1Z'_
M /*FC_AU#XB_Z/"_:_\ _"CT/_Y4T ?7]%?('_#J'Q%_T>%^U_\ ^%'H?_RI
MH_X=0^(O^CPOVO\ _P */0__ )4T ?7]%?('_#J'Q%_T>%^U_P#^%'H?_P J
M:/\ AU#XB_Z/"_:__P#"CT/_ .5- 'U_17R!_P .H?$7_1X7[7__ (4>A_\
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M3^#M/\-RZE86;RQ3ZF(;09$5S-E8TD9F"6P?Y?-V@ ^]**** "BBB@ HHHH
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M#5+&)-(LK?4+^",6.GB;/VRYD1RLCJA2W1OO>8RE #[_ **^0?\ @J'^T?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MA^_F)DWR.68!W8)M0*H /M"BBB@ HHHH **** "BBB@ HHHH **** "OG_\
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MC?\ 9UA^.GPU^!?PB\&W1T7XC>+-7\9:?I?B#Q3-@?:-&TB&:56BA&3%<7K
M\EXXP=K%OU(KPOQ%_P $O_V:?%_B"^U;5OV=_@7JFJZI<27=Y>7?@/2I[B[F
MD8O)+)(T!9W9B6+,22223F@#Y#_;0^*'PG_9F^.?["?QE\+:MX5C_9Q\#WVN
M>"/^$@T*XBOM"T2'4-.2TLI#<Q%XT@6:T,32[L*=Q9A@YZ?]G7X\>%/VW/\
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MLS*JJQ*DD* <@4WX*?LT?#C]FO3;ZS^'/P_\$^ +/4YA<7D'AO0K72H[N0#
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M):7. "!7B7_!*O\ Y/(_;A_[*Q;_ /IEL:^KO@S\ ? G[./A230?A[X)\(^
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !7S_\ \%8O^467[2W_ &2KQ1_Z
M:+JOH"OG_P#X*Q?\HLOVEO\ LE7BC_TT75 !_P $G?\ E%E^S3_V2KPO_P"F
MBUKZ KY__P""3O\ RBR_9I_[)5X7_P#31:U] 4 %%%% !1110 4444 %%%%
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MMJ/^':?PZ_Z&/]H#_P /MXW_ /EM7T!10!\__P##M/X=?]#'^T!_X?;QO_\
M+:C_ (=I_#K_ *&/]H#_ ,/MXW_^6U?0%% 'S_\ \.T_AU_T,?[0'_A]O&__
M ,MJ/^':?PZ_Z&/]H#_P^WC?_P"6U?0%% 'S_P#\.T_AU_T,?[0'_A]O&_\
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MM ?^'V\;_P#RVH_X=I_#K_H8_P!H#_P^WC?_ .6U?0%% 'S_ /\ #M/X=?\
M0Q_M ?\ A]O&_P#\MJ/^':?PZ_Z&/]H#_P /MXW_ /EM7T!10!\__P##M/X=
M?]#'^T!_X?;QO_\ +:C_ (=I_#K_ *&/]H#_ ,/MXW_^6U?0%% 'S_\ \.T_
MAU_T,?[0'_A]O&__ ,MJ/^':?PZ_Z&/]H#_P^WC?_P"6U?0%% 'S_P#\.T_A
MU_T,?[0'_A]O&_\ \MJ/^':?PZ_Z&/\ : _\/MXW_P#EM7T!10!\_P#_  [3
M^'7_ $,?[0'_ (?;QO\ _+:C_AVG\.O^AC_: _\ #[>-_P#Y;5] 44 ?/_\
MP[3^'7_0Q_M ?^'V\;__ "VH_P"':?PZ_P"AC_: _P##[>-__EM7T!10!\__
M /#M/X=?]#'^T!_X?;QO_P#+:C_AVG\.O^AC_: _\/MXW_\ EM7T!10!\_\
M_#M/X=?]#'^T!_X?;QO_ /+:C_AVG\.O^AC_ &@/_#[>-_\ Y;5] 44 ?/\
M_P .T_AU_P!#'^T!_P"'V\;_ /RVH_X=I_#K_H8_V@/_  ^WC?\ ^6U?0%%
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MJ/\ AVG\.O\ H8_V@/\ P^WC?_Y;5] 44 ?/_P#P[3^'7_0Q_M ?^'V\;_\
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M (?;QO\ _+:C_AVG\.O^AC_: _\ #[>-_P#Y;5] 44 ?/_\ P[3^'7_0Q_M
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MM/X=?]#'^T!_X?;QO_\ +:C_ (=I_#K_ *&/]H#_ ,/MXW_^6U?0%% 'S_\
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M\_\ _#M/X=?]#'^T!_X?;QO_ /+:C_AVG\.O^AC_ &@/_#[>-_\ Y;5] 44
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M_P#EM7T!10!\_P#_  [3^'7_ $,?[0'_ (?;QO\ _+:C_AVG\.O^AC_: _\
M#[>-_P#Y;5] 44 ?/_\ P[3^'7_0Q_M ?^'V\;__ "VH_P"':?PZ_P"AC_:
M_P##[>-__EM7T!10!\__ /#M/X=?]#'^T!_X?;QO_P#+:C_AVG\.O^AC_: _
M\/MXW_\ EM7T!10!\_\ _#M/X=?]#'^T!_X?;QO_ /+:C_AVG\.O^AC_ &@/
M_#[>-_\ Y;5] 44 ?/\ _P .T_AU_P!#'^T!_P"'V\;_ /RVKS/]J[]E'0?V
M8_ GA/QAX/\ %GQLM=<M?B1X'TX'4?B]XKUBTFMKWQ7I-C=0RVMYJ,MO,DEM
M<31E9(V&'R,$ C[,KY__ ."EG_)NOAS_ +*K\./_ %-]"H ^@**** "BBB@
MKY__ ."L7_*++]I;_LE7BC_TT75?0%?/_P#P5B_Y19?M+?\ 9*O%'_IHNJ #
M_@D[_P HLOV:?^R5>%__ $T6M?0%?/\ _P $G?\ E%E^S3_V2KPO_P"FBUKZ
M H **** "BBB@ HHHH **** "BBB@ HHHH ^?_\ @D[_ ,HLOV:?^R5>%_\
MTT6M?0%?/_\ P2=_Y19?LT_]DJ\+_P#IHM:^@* "BBB@ HHHH **** /-_CQ
M^US\.?V99;*/QQXGM=#GU%3);P^1-<S2*#@MLA1V"YXR0!D'T->=_P##V?\
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M4."%7;EOO9 QN]FG3R;ZI)7>^[^+RMI^ENYT16&]F_Z9]:?\/9_V??\ H?\
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M'\:-+^/?P9_;D^,R7_B&:/X>:1\.-5N+/X;3Z+M'V%+F6UEA%M.W2>20R,"
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M /C%=65YOQ-B\.JE*E3LM/>4D[KJUS+?RT*IU*\E=)'IGP[_ &E? _Q6UO\
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MZ^ND\97]KI<6F0:C9HL>^Z@DECCG=XA@*SD[ "!VGP<_X-4?V9;S]DC1-/\
MB!X"FU3XQWWAQ1KGBA?$^KJW]LRPDRW*PK=+ 0DS$A3'M8(-RG)SZ9H?4O\
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M9N7DM9'8?*)+720MLR8RID['(K]#O^"C/A?4_''_  3Z^.>BZ+IU]K&L:MX
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MP_X<:\U#X;1W,GG:3/"L$/GF&"-$CO0W.\AV\QU#  _7ZBBB@ HHHH ****
M"OG_ /X*6?\ )NOAS_LJOPX_]3?0J^@*^?\ _@I9_P FZ^'/^RJ_#C_U-]"H
M ^@**** "BBB@ KY_P#^"L7_ "BR_:6_[)5XH_\ 31=5] 5\_P#_  5B_P"4
M67[2W_9*O%'_ *:+J@ _X)._\HLOV:?^R5>%_P#TT6M?0%?/_P#P2=_Y19?L
MT_\ 9*O"_P#Z:+6OH"@ HHHH **** "BBB@ HHHH **** "BBB@#Y_\ ^"3O
M_*++]FG_ +)5X7_]-%K7T!7Q#_P3Y_;8\,? K]@CX'^"/%7@WX_:7XG\&^ -
M!T/6+,?!#QG<"TO+;3H(9XO,BTMHWVR(R[D9E.,@D$&O7O\ AY9\.O\ H7/V
M@/\ PQ/C?_Y4T ?0%%?/_P#P\L^'7_0N?M ?^&)\;_\ RIH_X>6?#K_H7/V@
M/_#$^-__ )4T ?0%%?/_ /P\L^'7_0N?M ?^&)\;_P#RIH_X>6?#K_H7/V@/
M_#$^-_\ Y4T ?0%%?/\ _P /+/AU_P!"Y^T!_P"&)\;_ /RIH_X>6?#K_H7/
MV@/_  Q/C?\ ^5- 'T!17S__ ,/+/AU_T+G[0'_AB?&__P J:/\ AY9\.O\
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M.O\ H7/V@/\ PQ/C?_Y4T?\ #RSX=?\ 0N?M ?\ AB?&_P#\J: /H"BOG_\
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M /AY9\.O^A<_: _\,3XW_P#E31_P\L^'7_0N?M ?^&)\;_\ RIH ^@**^?\
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M_P#E30!] 45\_P#_  \L^'7_ $+G[0'_ (8GQO\ _*FC_AY9\.O^A<_: _\
M#$^-_P#Y4T ?0%%?/_\ P\L^'7_0N?M ?^&)\;__ "IH_P"'EGPZ_P"A<_:
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MC_AY9\.O^A<_: _\,3XW_P#E30!] 45\_P#_  \L^'7_ $+G[0'_ (8GQO\
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M (8GQO\ _*FC_AY9\.O^A<_: _\ #$^-_P#Y4T ?0%%?/_\ P\L^'7_0N?M
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M^'7_ $+G[0'_ (8GQO\ _*FC_AY9\.O^A<_: _\ #$^-_P#Y4T ?0%%?/_\
MP\L^'7_0N?M ?^&)\;__ "IH_P"'EGPZ_P"A<_: _P##$^-__E30!] 45\__
M /#RSX=?]"Y^T!_X8GQO_P#*FC_AY9\.O^A<_: _\,3XW_\ E30!] 45\_\
M_#RSX=?]"Y^T!_X8GQO_ /*FC_AY9\.O^A<_: _\,3XW_P#E30!] 45\_P#_
M  \L^'7_ $+G[0'_ (8GQO\ _*FC_AY9\.O^A<_: _\ #$^-_P#Y4T ?0%%?
M/_\ P\L^'7_0N?M ?^&)\;__ "IH_P"'EGPZ_P"A<_: _P##$^-__E30!S/[
M;G_!)?P/^VQ\7=&^(G_"<?&#X2_$31]+;0O^$H^&_BEM!U.]TXR&7[',^R17
MB$A+@!0<GDD  :WPI_X)>^ _@5^RAXP^%?@OQ)\2O#,_CR66]UWQQ9^))?\
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MG_LE7A?_ --%K7T!0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M%?P!T4 ?W^45_ '10!_?Y17\ =% ']_E%?P!T4 ?W^45_ '10!_?Y17\ =%
M']_E%?P!T4 ?W^45_ '10!_?Y17\ =% ']_E%?P!T4 ?W^45_ '10!_?Y17\
M =% ']_E%?P!T4 ?W^45_ '10!_?Y17\ =% ']_E%?P!T4 ?W^45_ '10!_?
MY17\ =% ']_E%?P!T4 ?W^45_ '10!_?Y17\ =% ']_E%?P!T4 ?W^45_ '1
M0!_?Y17\ =% ']_E%?P!T4 ?W^45_ '10!_?Y17\ =% ']_E%?P!T4 ?W^45
M_ '10!_?Y17\ =% ']_E%?P!T4 ?W^45_ '10!_?Y17\ =% ']_E%?P!T4 ?
MW^45_ '10!_?Y17\ =% ']_E%?P!T4 ?W^45_ '10!_?Y17\ =% ']_E%?P!
MT4 ?W^45_ '10!_?Y17\ =% ']_E%?P!T4 ?W^45_ '10!_?Y17\ =% ']_E
M%?P!T4 ?W^45_ '10!_?Y17\ =% ']_E%?P!T4 ?W^45_ '10!_?Y17\ =%
M']_E%?P!T4 ?W^45_ '10!_?Y17\ =% ']_E%?P!T4 ?W^5\_P#_  5B_P"4
?67[2W_9*O%'_ *:+JOX@ZL:3_P A6U_ZZI_,4 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140091802667400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - USD ($)<br> $ in Billions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Feb. 23, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-33093<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">LIGAND PHARMACEUTICALS INC<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">77-0160744<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">5980 Horton Street, Suite 405<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Emeryville<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94608<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">858<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">550-7500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $.001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">LGND<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-Known Seasoned Issuer</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,852,650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text">Portions of the Proxy Statement for the Registrant&#8217;s 2021 Annual Meeting of Stockholders to be filed with the Commission within 120 days of December&#160;31, 2021 are incorporated by reference in Part&#160;III of this Annual Report on Form&#160;10-K.&#160;With the exception of those portions that are specifically incorporated by reference in this Annual Report on Form&#160;10-K, such Proxy Statement shall not be deemed filed as part of this Report or incorporated by reference herein.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000886163<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140091808423464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Audit Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_AuditInformationAbstract', window );"><strong>Audit Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">Ernst&#160;& Young&#160;LLP<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">San Diego, California<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">42<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_AuditInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Audit Information [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_AuditInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140091802894680">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 19,522<span></span>
</td>
<td class="nump">$ 47,619<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term investments</a></td>
<td class="nump">321,586<span></span>
</td>
<td class="nump">363,567<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">85,453<span></span>
</td>
<td class="nump">56,847<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory</a></td>
<td class="nump">27,326<span></span>
</td>
<td class="nump">26,487<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesReceivable', window );">Income taxes receivable</a></td>
<td class="nump">6,193<span></span>
</td>
<td class="nump">2,217<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">4,671<span></span>
</td>
<td class="nump">3,822<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">464,751<span></span>
</td>
<td class="nump">500,559<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxAssetsNet', window );">Deferred income taxes, net</a></td>
<td class="nump">34,482<span></span>
</td>
<td class="nump">24,320<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">551,040<span></span>
</td>
<td class="nump">595,330<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">181,206<span></span>
</td>
<td class="nump">189,662<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_CommercialLicenseRights', window );">Commercial license and other economic rights</a></td>
<td class="nump">10,110<span></span>
</td>
<td class="nump">10,979<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">20,511<span></span>
</td>
<td class="nump">14,434<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease assets</a></td>
<td class="nump">16,542<span></span>
</td>
<td class="nump">6,892<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAsset', window );">Finance lease assets</a></td>
<td class="nump">16,207<span></span>
</td>
<td class="nump">15,842<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">2,741<span></span>
</td>
<td class="nump">4,267<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">1,297,590<span></span>
</td>
<td class="nump">1,362,285<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">8,403<span></span>
</td>
<td class="nump">3,784<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued liabilities</a></td>
<td class="nump">17,579<span></span>
</td>
<td class="nump">18,530<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_CurrentPortionOfLiabilityForContingentValueRights', window );">Current contingent liabilities</a></td>
<td class="nump">2,588<span></span>
</td>
<td class="nump">39,884<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue</a></td>
<td class="nump">10,996<span></span>
</td>
<td class="nump">29,435<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current operating lease liabilities</a></td>
<td class="nump">2,053<span></span>
</td>
<td class="nump">1,885<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Current finance lease liabilities</a></td>
<td class="nump">46<span></span>
</td>
<td class="nump">6,593<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">41,665<span></span>
</td>
<td class="nump">100,111<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebtNoncurrent', window );">2023 convertible senior notes, net</a></td>
<td class="nump">320,717<span></span>
</td>
<td class="nump">442,293<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_LiabilityForContingentValueRights', window );">Long-term contingent liabilities</a></td>
<td class="nump">8,483<span></span>
</td>
<td class="nump">9,249<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred income taxes, net</a></td>
<td class="nump">59,095<span></span>
</td>
<td class="nump">64,598<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long-term operating lease liabilities</a></td>
<td class="nump">15,494<span></span>
</td>
<td class="nump">5,643<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="nump">30,977<span></span>
</td>
<td class="nump">30,866<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">476,431<span></span>
</td>
<td class="nump">652,760<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.001 par value; 5,000 shares authorized; zero issued and outstanding at December 31, 2021 and 2020</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value; 60,000 shares authorized; 16,767 and 16,080 shares issued and outstanding at December&#160;31, 2021 and 2020, respectively</a></td>
<td class="nump">17<span></span>
</td>
<td class="nump">16<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">372,969<span></span>
</td>
<td class="nump">318,358<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(917)<span></span>
</td>
<td class="num">(801)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained earnings</a></td>
<td class="nump">449,090<span></span>
</td>
<td class="nump">391,952<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">821,159<span></span>
</td>
<td class="nump">709,525<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 1,297,590<span></span>
</td>
<td class="nump">$ 1,362,285<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_CommercialLicenseRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commercial License Rights</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_CommercialLicenseRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_CurrentPortionOfLiabilityForContingentValueRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Current portion of liability for contingent value rights.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_CurrentPortionOfLiabilityForContingentValueRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_LiabilityForContingentValueRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Liability for contingent value rights.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_LiabilityForContingentValueRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of long-term convertible debt as of the balance sheet date, net of the amount due in the next twelve months or greater than the normal operating cycle, if longer. The debt is convertible into another form of financial instrument, typically the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount due within one year of the balance sheet date (or one operating cycle, if longer) from tax authorities as of the balance sheet date representing refunds of overpayments or recoveries based on agreed-upon resolutions of disputes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.5(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.10)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.3(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(g))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140091802038344">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares<br> shares in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (USD per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock authorized (shares)</a></td>
<td class="nump">5,000<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock issued (shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock outstanding (shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (USD per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock authorized (shares)</a></td>
<td class="nump">60,000<span></span>
</td>
<td class="nump">60,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock issued (shares)</a></td>
<td class="nump">16,767<span></span>
</td>
<td class="nump">16,080<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock outstanding (shares)</a></td>
<td class="nump">16,767<span></span>
</td>
<td class="nump">16,080<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140091802747032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 277,133<span></span>
</td>
<td class="nump">$ 186,419<span></span>
</td>
<td class="nump">$ 120,282<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingCostsAndExpensesAbstract', window );"><strong>Operating costs and expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostDirectMaterial', window );">Cost of Captisol</a></td>
<td class="nump">62,176<span></span>
</td>
<td class="nump">30,419<span></span>
</td>
<td class="nump">11,347<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSoldAmortization', window );">Amortization of intangibles</a></td>
<td class="nump">47,167<span></span>
</td>
<td class="nump">23,442<span></span>
</td>
<td class="nump">16,864<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">69,012<span></span>
</td>
<td class="nump">59,392<span></span>
</td>
<td class="nump">55,908<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">57,483<span></span>
</td>
<td class="nump">64,435<span></span>
</td>
<td class="nump">41,884<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherOperatingIncome', window );">Other operating income</a></td>
<td class="num">(37,600)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingCostsAndExpenses', window );">Total operating costs and expenses</a></td>
<td class="nump">198,238<span></span>
</td>
<td class="nump">177,688<span></span>
</td>
<td class="nump">126,003<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Income from operations</a></td>
<td class="nump">78,895<span></span>
</td>
<td class="nump">25,845<span></span>
</td>
<td class="nump">807,076<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnInvestments', window );">Gain (loss) from short-term investments</a></td>
<td class="num">(3,997)<span></span>
</td>
<td class="num">(16,933)<span></span>
</td>
<td class="nump">1,049<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">886<span></span>
</td>
<td class="nump">8,078<span></span>
</td>
<td class="nump">28,430<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(19,626)<span></span>
</td>
<td class="num">(27,420)<span></span>
</td>
<td class="num">(35,745)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other expense, net</a></td>
<td class="num">(8,860)<span></span>
</td>
<td class="num">(108)<span></span>
</td>
<td class="num">(4,171)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other expense, net</a></td>
<td class="num">(31,597)<span></span>
</td>
<td class="num">(36,383)<span></span>
</td>
<td class="num">(10,437)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income (loss) before income tax</a></td>
<td class="nump">47,298<span></span>
</td>
<td class="num">(10,538)<span></span>
</td>
<td class="nump">796,639<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax benefit (expense)</a></td>
<td class="nump">9,840<span></span>
</td>
<td class="nump">7,553<span></span>
</td>
<td class="num">(167,337)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="nump">$ 57,138<span></span>
</td>
<td class="num">$ (2,985)<span></span>
</td>
<td class="nump">$ 629,302<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic net income (loss) per share (USD per share)</a></td>
<td class="nump">$ 3.44<span></span>
</td>
<td class="num">$ (0.18)<span></span>
</td>
<td class="nump">$ 33.13<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Shares used in basic per share calculation (shares)</a></td>
<td class="nump">16,630<span></span>
</td>
<td class="nump">16,185<span></span>
</td>
<td class="nump">18,995<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted net income (loss) per share (USD per share)</a></td>
<td class="nump">$ 3.31<span></span>
</td>
<td class="num">$ (0.18)<span></span>
</td>
<td class="nump">$ 31.85<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Shares used in diluted per share calculation (shares)</a></td>
<td class="nump">17,246<span></span>
</td>
<td class="nump">16,185<span></span>
</td>
<td class="nump">19,757<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember', window );">Royalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 48,927<span></span>
</td>
<td class="nump">$ 33,796<span></span>
</td>
<td class="nump">$ 46,976<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lgnd_MaterialSalesCaptisolMember', window );">Captisol</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">164,250<span></span>
</td>
<td class="nump">109,959<span></span>
</td>
<td class="nump">31,489<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lgnd_ContractRevenueMember', window );">Contract revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">63,956<span></span>
</td>
<td class="nump">42,664<span></span>
</td>
<td class="nump">41,817<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lgnd_VernalisMember', window );">Vernalis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingCostsAndExpensesAbstract', window );"><strong>Operating costs and expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfIntangibleAssets', window );">Gain from sale of intangible assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">17,114<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lgnd_PromactaMember', window );">Promacta</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingCostsAndExpensesAbstract', window );"><strong>Operating costs and expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfIntangibleAssets', window );">Gain from sale of intangible assets</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 812,797<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostDirectMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cost of material used for good produced and service rendered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostDirectMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSoldAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for allocation of cost of intangible asset over its useful life directly used in production of good and rendering of service.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSoldAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDispositionOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDispositionOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of realized and unrealized gain (loss) on investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27405-111563<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(c),9(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123384075&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingCostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Excludes Selling, General and Administrative Expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingCostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingCostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingCostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherOperatingIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of other operating income, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherOperatingIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_RoyaltyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lgnd_MaterialSalesCaptisolMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lgnd_MaterialSalesCaptisolMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lgnd_ContractRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lgnd_ContractRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lgnd_VernalisMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lgnd_VernalisMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lgnd_PromactaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lgnd_PromactaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140091802116168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="nump">$ 57,138<span></span>
</td>
<td class="num">$ (2,985)<span></span>
</td>
<td class="nump">$ 629,302<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Unrealized net gain (loss) on available-for-sale securities, net of tax</a></td>
<td class="num">(116)<span></span>
</td>
<td class="num">(162)<span></span>
</td>
<td class="nump">200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustment</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(423)<span></span>
</td>
<td class="nump">608<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive income (loss)</a></td>
<td class="nump">$ 57,022<span></span>
</td>
<td class="num">$ (3,570)<span></span>
</td>
<td class="nump">$ 630,110<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140091805337944">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Cumulative Effect, Period of Adoption, Adjustment</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional paid-in capital</div></th>
<th class="th"><div>Accumulated other comprehensive income (loss)</div></th>
<th class="th"><div>Retain earnings (accumulated deficit)</div></th>
<th class="th">
<div>Retain earnings (accumulated deficit) </div>
<div>Cumulative Effect, Period of Adoption, Adjustment</div>
</th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance at beginning of period (shares) at Dec. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,766,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at beginning of period at Dec. 31, 2018</a></td>
<td class="nump">$ 560,914<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21<span></span>
</td>
<td class="nump">$ 791,114<span></span>
</td>
<td class="num">$ (1,024)<span></span>
</td>
<td class="num">$ (229,197)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of common stock under employee stock compensation plans, net (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">180,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of common stock under employee stock compensation plans, net</a></td>
<td class="num">(1,421)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,421)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="nump">$ 24,515<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,515<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Repurchase of common stock (shares)</a></td>
<td class="num">(4,122,133)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,122,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Repurchase of common stock</a></td>
<td class="num">$ (448,433)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (4)<span></span>
</td>
<td class="num">(448,429)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss', window );">Unrealized net gain (loss) on available-for-sale securities, net of deferred tax</a></td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustment</a></td>
<td class="nump">$ 608<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">608<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingStandardsUpdateExtensibleList', window );">Accounting Standards Update [Extensible List]</a></td>
<td class="text">Accounting Standards Update 2016-13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther', window );">Other tax adjustments</a></td>
<td class="nump">$ 1,547<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,547<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="nump">629,302<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">629,302<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance at end of period (shares) at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,824,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at end of period at Dec. 31, 2019</a></td>
<td class="nump">767,232<span></span>
</td>
<td class="num">$ (5,168)<span></span>
</td>
<td class="nump">$ 17<span></span>
</td>
<td class="nump">367,326<span></span>
</td>
<td class="num">(216)<span></span>
</td>
<td class="nump">400,105<span></span>
</td>
<td class="num">$ (5,168)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of common stock under employee stock compensation plans, net (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">190,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of common stock under employee stock compensation plans, net</a></td>
<td class="nump">1,535<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,535<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="nump">$ 30,727<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,727<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Repurchase of common stock (shares)</a></td>
<td class="num">(934,079)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(934,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Repurchase of common stock</a></td>
<td class="num">$ (77,998)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1)<span></span>
</td>
<td class="num">(77,997)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss', window );">Unrealized net gain (loss) on available-for-sale securities, net of deferred tax</a></td>
<td class="num">(162)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(162)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustment</a></td>
<td class="num">(423)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(423)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt', window );">Reacquisition of equity due to 2023 debt extinguishment, net of tax</a></td>
<td class="num">(3,236)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,236)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther', window );">Other tax adjustments</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="num">(2,985)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,985)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance at end of period (shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,080,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at end of period at Dec. 31, 2020</a></td>
<td class="nump">709,525<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16<span></span>
</td>
<td class="nump">318,358<span></span>
</td>
<td class="num">(801)<span></span>
</td>
<td class="nump">391,952<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of common stock under employee stock compensation plans, net (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">687,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of common stock under employee stock compensation plans, net</a></td>
<td class="nump">27,745<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">27,744<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="nump">38,783<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38,783<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Repurchase of common stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss', window );">Unrealized net gain (loss) on available-for-sale securities, net of deferred tax</a></td>
<td class="num">(116)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(116)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustment</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt', window );">Reacquisition of equity due to 2023 debt extinguishment, net of tax</a></td>
<td class="num">(12,407)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(12,407)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_AdjustmentsToAdditionalPaidInCapitalWarrantAndBondHedgeUnwindTransactions', window );">Warrant and bond hedge unwind transactions</a></td>
<td class="nump">491<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">491<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="nump">57,138<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">57,138<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance at end of period (shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,767,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at end of period at Dec. 31, 2021</a></td>
<td class="nump">$ 821,159<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17<span></span>
</td>
<td class="nump">$ 372,969<span></span>
</td>
<td class="num">$ (917)<span></span>
</td>
<td class="nump">$ 449,090<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_AdjustmentsToAdditionalPaidInCapitalWarrantAndBondHedgeUnwindTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments to Additional Paid in Capital, Warrant and Bond Hedge Unwind Transactions</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_AdjustmentsToAdditionalPaidInCapitalWarrantAndBondHedgeUnwindTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingStandardsUpdateExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates amendment to accounting standards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL121967933-165497<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL121967933-165497<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL122642865-165497<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL121967933-165497<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL121967933-165497<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL120254526-165497<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=122150657&amp;loc=SL122150809-237846<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL122642865-165497<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S65<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124359872&amp;loc=SL124427846-239511<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124402435&amp;loc=SL124402458-218513<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124402435&amp;loc=SL124402458-218513<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL120254526-165497<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 45: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 49: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 50: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 51: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 52: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 53: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 54: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 55: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 56: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 57: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 58: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 59: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 60: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 61: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -Subparagraph (a)<br><br>Reference 62: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -Subparagraph (a)(1)<br><br>Reference 63: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -Subparagraph (a)(2)<br><br>Reference 64: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -Subparagraph (a)(3)(iii)(01)<br><br>Reference 65: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -Subparagraph (a)(3)(iii)(03)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingStandardsUpdateExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustment to additional paid in capital resulting from the recognition of convertible debt instruments as two separate components - a debt component and an equity component. This bifurcation may result in a basis difference associated with the liability component that represents a temporary difference for purposes of applying accounting for income taxes. The initial recognition of deferred taxes for the tax effect of that temporary difference is as an adjustment to additional paid in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 25<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123466103&amp;loc=SL6014347-161799<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of other increase (decrease) in additional paid in capital (APIC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123468992&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140091805816648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="nump">$ 57,138<span></span>
</td>
<td class="num">$ (2,985)<span></span>
</td>
<td class="nump">$ 629,302<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfOtherAssets', window );">Gain from sale of Promacta license</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(812,797)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfBusiness', window );">Gain from sale of Vernalis R&amp;D</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(17,114)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_NonCashChangeInEstimatedFairValueOfContingentValueRights', window );">Change in estimated fair value of contingent liabilities</a></td>
<td class="num">(36,962)<span></span>
</td>
<td class="nump">963<span></span>
</td>
<td class="num">(30)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation of fixed assets and amortization of intangible assets</a></td>
<td class="nump">51,071<span></span>
</td>
<td class="nump">25,691<span></span>
</td>
<td class="nump">18,361<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_GainLossOnShortTermInvestments', window );">Loss (gain) short-term investments</a></td>
<td class="nump">3,997<span></span>
</td>
<td class="nump">16,933<span></span>
</td>
<td class="num">(1,049)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments', window );">Amortization/accretion of premium (discount) on investments, net</a></td>
<td class="nump">111<span></span>
</td>
<td class="nump">1,479<span></span>
</td>
<td class="num">(10,274)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Amortization of debt discount and issuance fees</a></td>
<td class="nump">16,692<span></span>
</td>
<td class="nump">23,077<span></span>
</td>
<td class="nump">29,988<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on debt extinguishment</a></td>
<td class="nump">7,303<span></span>
</td>
<td class="nump">2,466<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_AmortizationOfCommercialLicenseAndOtherEconomicRights', window );">Amortization of commercial license and other economic rights</a></td>
<td class="num">(125)<span></span>
</td>
<td class="nump">2,275<span></span>
</td>
<td class="nump">25,370<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">38,783<span></span>
</td>
<td class="nump">30,727<span></span>
</td>
<td class="nump">24,515<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes', window );">Deferred income taxes, net</a></td>
<td class="num">(8,618)<span></span>
</td>
<td class="num">(19,053)<span></span>
</td>
<td class="nump">74,829<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherOperatingActivitiesCashFlowStatement', window );">Other</a></td>
<td class="nump">1,572<span></span>
</td>
<td class="nump">191<span></span>
</td>
<td class="num">(3,498)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities, net of acquisitions:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable, net</a></td>
<td class="num">(28,616)<span></span>
</td>
<td class="num">(26,061)<span></span>
</td>
<td class="nump">25,463<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventory</a></td>
<td class="num">(427)<span></span>
</td>
<td class="num">(17,799)<span></span>
</td>
<td class="num">(2,061)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued liabilities</a></td>
<td class="nump">2,810<span></span>
</td>
<td class="num">(1,245)<span></span>
</td>
<td class="num">(6,664)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable', window );">Income taxes receivable</a></td>
<td class="num">(3,976)<span></span>
</td>
<td class="nump">9,144<span></span>
</td>
<td class="num">(11,219)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_IncreaseDecreaseInOtherEconomicRights', window );">Other economic rights</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(12,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="num">(17,870)<span></span>
</td>
<td class="nump">29,236<span></span>
</td>
<td class="num">(1,147)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities', window );">Other</a></td>
<td class="num">(4,085)<span></span>
</td>
<td class="num">(3,339)<span></span>
</td>
<td class="nump">3,575<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by (used in) operating activities</a></td>
<td class="nump">78,798<span></span>
</td>
<td class="nump">54,586<span></span>
</td>
<td class="num">(29,336)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfIntangibleAssets', window );">Proceeds from sale of Promacta license</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">812,797<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Cash paid for acquisition, net of cash and restricted cash acquired</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(404,884)<span></span>
</td>
<td class="num">(11,840)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(8,761)<span></span>
</td>
<td class="num">(4,458)<span></span>
</td>
<td class="num">(2,553)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireShortTermInvestments', window );">Purchases of short-term investments</a></td>
<td class="num">(181,325)<span></span>
</td>
<td class="num">(422,523)<span></span>
</td>
<td class="num">(2,356,545)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_ProceedsFromCommercialLicenseRights', window );">Proceeds from commercial license rights</a></td>
<td class="nump">494<span></span>
</td>
<td class="nump">1,358<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfShortTermInvestments', window );">Proceeds from sale of short-term investments</a></td>
<td class="nump">154,230<span></span>
</td>
<td class="nump">394,539<span></span>
</td>
<td class="nump">535,877<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments', window );">Proceeds from maturity of short-term investments</a></td>
<td class="nump">67,105<span></span>
</td>
<td class="nump">644,155<span></span>
</td>
<td class="nump">1,494,851<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireEquityMethodInvestments', window );">Cash paid for equity method investment</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(500)<span></span>
</td>
<td class="num">(1,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromDivestitureOfBusinesses', window );">Proceeds on sale of Vernalis R&amp;D, net</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">22,061<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities', window );">Other, net</a></td>
<td class="num">(1,220)<span></span>
</td>
<td class="nump">1,900<span></span>
</td>
<td class="num">(4,669)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by investing activities</a></td>
<td class="nump">30,523<span></span>
</td>
<td class="nump">231,648<span></span>
</td>
<td class="nump">466,918<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayment of debt</a></td>
<td class="num">(155,760)<span></span>
</td>
<td class="num">(222,209)<span></span>
</td>
<td class="num">(27,323)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeasePrincipalPayments', window );">Payments under finance lease obligations</a></td>
<td class="num">(9,188)<span></span>
</td>
<td class="num">(9,549)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromHedgeFinancingActivities', window );">Proceeds from bond hedge settlement</a></td>
<td class="nump">18,938<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">12,401<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForHedgeFinancingActivities', window );">Payments to convert holders for bond conversion</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(12,401)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Net proceeds from stock option exercises and ESPP</a></td>
<td class="nump">33,763<span></span>
</td>
<td class="nump">3,017<span></span>
</td>
<td class="nump">2,997<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Taxes paid related to net share settlement of equity awards</a></td>
<td class="num">(6,018)<span></span>
</td>
<td class="num">(1,481)<span></span>
</td>
<td class="num">(4,418)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Share repurchases</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(77,998)<span></span>
</td>
<td class="num">(453,048)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfWarrants', window );">Repurchase of warrants</a></td>
<td class="num">(18,446)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(380)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_PaymentsToContingentValueRightHoldersFinancingActivity', window );">Payments to CVR Holders</a></td>
<td class="num">(1,050)<span></span>
</td>
<td class="num">(2,325)<span></span>
</td>
<td class="num">(3,000)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash used in financing activities</a></td>
<td class="num">(137,761)<span></span>
</td>
<td class="num">(310,545)<span></span>
</td>
<td class="num">(485,172)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect', window );">Net decrease in cash, cash equivalents, and restricted cash</a></td>
<td class="num">(28,440)<span></span>
</td>
<td class="num">(24,311)<span></span>
</td>
<td class="num">(47,590)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of exchange rate changes on cash</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">83<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash at beginning of year</a></td>
<td class="nump">47,962<span></span>
</td>
<td class="nump">72,273<span></span>
</td>
<td class="nump">119,780<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash at end of year</a></td>
<td class="nump">19,522<span></span>
</td>
<td class="nump">47,962<span></span>
</td>
<td class="nump">72,273<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_CashPaidDuringTheYearAbstract', window );"><strong>Cash paid during the year:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest paid</a></td>
<td class="nump">3,028<span></span>
</td>
<td class="nump">4,463<span></span>
</td>
<td class="nump">5,827<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaid', window );">Taxes paid</a></td>
<td class="nump">3,722<span></span>
</td>
<td class="nump">2,130<span></span>
</td>
<td class="nump">103,817<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrent', window );">Restricted cash in other current assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">343<span></span>
</td>
<td class="nump">730<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental schedule of non-cash investing and financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_AccruedInventoryPurchases', window );">Accrued inventory purchases</a></td>
<td class="nump">1,974<span></span>
</td>
<td class="nump">1,562<span></span>
</td>
<td class="nump">170<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnInvestments', window );">Unrealized (loss) gain on available-for-sale investments</a></td>
<td class="num">(221)<span></span>
</td>
<td class="num">(212)<span></span>
</td>
<td class="nump">256<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Purchase of fixed assets recorded in accounts payable</a></td>
<td class="nump">$ 1,567<span></span>
</td>
<td class="nump">$ 249<span></span>
</td>
<td class="nump">$ 495<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_AccruedInventoryPurchases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Inventory Purchases</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_AccruedInventoryPurchases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_AmortizationOfCommercialLicenseAndOtherEconomicRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortization of Commercial License and Other Economic Rights</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_AmortizationOfCommercialLicenseAndOtherEconomicRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_CashPaidDuringTheYearAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash Paid During the Year</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_CashPaidDuringTheYearAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_GainLossOnShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gain (Loss) on Short-Term Investments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_GainLossOnShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_IncreaseDecreaseInOtherEconomicRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) in Other Economic Rights</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_IncreaseDecreaseInOtherEconomicRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_NonCashChangeInEstimatedFairValueOfContingentValueRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Non-Cash Change In Estimated Fair Value Of Contingent Value Rights.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_NonCashChangeInEstimatedFairValueOfContingentValueRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_PaymentsToContingentValueRightHoldersFinancingActivity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments to Contingent Value Right Holders, Financing Activity</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_PaymentsToContingentValueRightHoldersFinancingActivity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_ProceedsFromCommercialLicenseRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from Commercial License Rights</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_ProceedsFromCommercialLicenseRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69F<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495745-112612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCostsAndDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeasePrincipalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for principal payment on finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeasePrincipalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from sale and disposal of integrated set of activities and assets capable of being conducted and managed for purpose of providing return in form of dividend, lower cost, or other economic benefit to investor, owner, member and participant.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4582445-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of other assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4297-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 310<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123371682&amp;loc=d3e55415-109406<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the account that represents the temporary difference that results from Income or Loss that is recognized for accounting purposes but not for tax purposes and vice versa.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in income taxes receivable, which represents the amount due from tax authorities for refunds of overpayments or recoveries of income taxes paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInIncomeTaxesReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in current liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherOperatingActivitiesCashFlowStatement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other cash or noncash adjustments to reconcile net income to cash provided by (used in) operating activities that are not separately disclosed in the statement of cash flows (for example,  cash received or cash paid during the current period for miscellaneous operating activities, net change during the reporting period in other assets or other liabilities).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherOperatingActivitiesCashFlowStatement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForHedgeFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a financial contract that meets the hedge criteria as either cash flow hedge, fair value hedge or hedge of net investment in foreign operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 27<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3581-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForHedgeFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash (inflow) outflow from investing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForProceedsFromOtherInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount paid by the entity to reacquire the right to purchase equity shares at a predetermined price, usually issued together with corporate debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of or advances to an equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromDivestitureOfBusinesses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from the sale of a portion of the company's business, for example a segment, division, branch or other business, during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromDivestitureOfBusinesses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromHedgeFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a financial contract that meets the hedge criteria as either cash flow hedge, fair value hedge or hedge of net investment in foreign operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 27<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3581-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromHedgeFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from maturities, prepayments, calls and collections of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from disposal of asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from sales of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140091803822648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock', window );">Basis of Presentation and Summary of Significant Accounting Policies</a></td>
<td class="text">Basis of Presentation and Summary of Significant Accounting Policies<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Business</span></div><div style="text-indent:24pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a biopharmaceutical company focused on developing or acquiring technologies that help pharmaceutical companies discover and develop medicines. We operate in one business segment: development and licensing of biopharmaceutical assets.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Principles of Consolidation</span></div><div style="text-indent:24pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying consolidated financial statements include Ligand and its wholly-owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our consolidated financial statements have been prepared in accordance with U.S. GAAP and include the accounts of our parent company and its wholly-owned subsidiaries. All intercompany transactions and balances have been eliminated in consolidation.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="text-indent:24pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of consolidated financial statements in conformity with U.S. GAAP requires the use of estimates and assumptions that affect the amounts reported in the consolidated financial statements and the accompanying notes. Actual results may differ from those estimates.</span></div><div style="text-indent:24pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentrations of Business Risk</span></div><div style="text-indent:24pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject us to significant concentrations of credit risk consist primarily of cash equivalents and investments. We invest excess cash principally in United States government debt securities, investment grade corporate debt securities, mutual funds and certificates of deposit. We maintain some cash and cash equivalents balances with financial institutions that are in excess of the Federal Deposit Insurance Corporation insurance limits. We have established guidelines relative to diversification and maturities that maintain safety and liquidity. These guidelines are periodically reviewed and modified to take advantage of trends in yields and interest rates.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue from significant partners, which is defined as 10% or more of our total revenue, was as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.578%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.524%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year-ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Partner A</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Partner B</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Partner C</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&lt;10%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&lt;10%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13%</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We obtain Captisol primarily from two sites related to a single supplier, Hovione.&#160;If this supplier were not able to supply the requested amounts of Captisol from each site, and if our safety stocks of material were depleted, we would be unable to continue to derive revenues from the sale of Captisol until we obtained material from an alternative source, which could take a considerable length of time.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Equivalents </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Cash equivalents consist of highly liquid investments with maturities of three months or less from the date of acquisition. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Short-term Investments</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Short-term investments primarily consist of investments in debt and equity securities. We classify our short-term investments as &#8220;available-for-sale&#8221;. Such investments are carried at fair value, with unrealized gains and losses on debt securities included in the statement of comprehensive income (loss), net of tax, and unrealized gains and losses on equity securities included the consolidated statement of operations. We determine the cost of investments based on the specific identification method. We determine the realized gains or losses on the sale of available-for-sale securities using the specific identification method and includes net realized gains and losses as a component of other income or expense within the consolidated statements of operations.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Debt securities consist of certificates of deposit, corporate debt securities, and securities of government-sponsored entities have effective maturities greater than&#160;three&#160;months and less than twelve months from the date of acquisition. Debt securities securities available-for-sale in an unrealized loss position are assessed for the current expected credit losses methodology. We start by assessing whether we intend to sell the security, or whether it is more likely than not that we will be required to sell the security before recovery of its amortized cost basis. If either of the criteria regarding intent or requirement to sell is met, the security&#8217;s amortized cost basis is written down to fair value through earnings. For debt securities available-for-sale that do not meet the aforementioned criteria, we evaluate whether the decline in fair value has resulted from credit losses or other factors. In making this assessment, we consider the extent to which fair value is less than amortized cost, any changes in interest rates, and any changes to the rating of the security by a rating agency, among other factors. If this assessment indicates that a credit loss exists, the present value of cash flows expected to be collected from the security is compared to the amortized cost basis of the security. If the present value of cash flows expected to be collected is less than the amortized cost basis, a credit loss exists and an allowance for credit losses is recorded, limited by the amount that the fair value is less than the amortized cost basis. Any impairment that has not been recorded through an allowance for credit losses is recognized in other comprehensive income or loss, as applicable.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Equity securities are mutual funds, investments in privately held companies (non-marketable equity securities), and companies that have completed initial public offerings (marketable equity securities). Mutual funds are valued at their publicly quoted net asset value (NAV) price on the last day of the period. Our non-marketable equity securities without readily determinable market values are initially measured at cost and adjusted to fair value for observable transactions for identical or similar investments of the same issuer or impairment. Our marketable equity securities are measured at fair value. Equity investments are classified as short-term investments, or non-current other assets, based on the nature of the securities and their availability for use in current operations. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Accounts Receivable </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our accounts receivable arise primarily from sales on credit to customers. We establish an allowance for credit losses to present the net amount of accounts receivable expected to be collected. The allowance is determined by using the loss-rate method, which requires an estimation of loss rates based upon historical loss experience adjusted for factors that are relevant to determining the expected collectability of accounts receivable. Some of these factors include macroeconomic conditions that correlate with historical loss experience, delinquency trends, aging behavior of receivables and credit and liquidity quality indicators for industry groups, customer classes or individual customers. </span></div><div style="margin-top:14pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inventory</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Inventory, which consists of finished goods, is stated at the lower of cost or net realizable value. We determine cost using the first-in, first-out method or the specific identification method. We analyze our inventory levels periodically and write down inventory to net realizable value if it has become obsolete, has a cost basis in excess of its expected net realizable value or is in excess of expected requirements. There were no write downs related to obsolete inventory recorded for the years ended December&#160;31, 2021, 2020 and 2019.  As of December 31, 2021 and 2020, inventory consist of Captisol prepayments of $24.6&#160;million and $26.1&#160;million, respectively. </span></div><div style="margin-top:14pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment are stated at cost, subject to review for impairment, and depreciated over the estimated useful lives of the assets, which generally range from <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RleHRyZWdpb246MDE1MzU3NWExNzUxNDlhMGJlMjM2NzA3MzMyMzJiNjlfNjcyNw_c91288e2-cf87-4740-a1f7-845dfc930514">three</span> to ten years, using the straight-line method. Amortization of leasehold improvements is recorded over the shorter of the lease term or estimated useful life of the related asset. Maintenance and repairs are charged to operations as incurred. When assets are sold, or otherwise disposed of, the cost and related accumulated depreciation are removed from the accounts and any gain or loss is included in operating income or expense.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Acquisitions</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We first determine whether a set of assets acquired constitute a business and should be accounted for as a business combination. If the assets acquired are not a business, we account for the transaction as an asset acquisition. Business combinations are accounted for by using the acquisition method of accounting which requires us to use significant estimates and assumptions, especially with respect to intangible assets. We record the excess consideration over the aggregate fair value of tangible and intangible assets, net of liabilities assumed, as goodwill.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the acquisition method of accounting, we recognize separately from goodwill the identifiable assets acquired, the liabilities assumed, including contingent consideration and all contractual contingencies, generally at the acquisition date fair value. Contingent purchase consideration to be settled in cash are remeasured to estimated fair value at each reporting period with the change in fair value recorded in statement of operations. Costs that we incur to complete the business combination such as investment banking, legal and other professional fees are not considered part of consideration and we charge them to general and administrative expense as they are incurred. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Should the initial accounting for a business combination be incomplete by the end of a reporting period that falls within the measurement period, we report provisional amounts in our financial statements. During the measurement period, we adjust the provisional amounts recognized at the acquisition date to reflect new information obtained about facts and circumstances that existed as of the acquisition date that, if known, would have affected the measurement of the amounts recognized as of that date and we record those adjustments to our financial statements in the period of change, if any.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the acquisition method of accounting for business combinations, if we identify changes to acquired deferred tax asset valuation allowances or liabilities related to uncertain tax positions during the measurement period and they relate to new information obtained about facts and circumstances that existed as of the acquisition date, those changes are considered a measurement period adjustment and we record the offset to goodwill. We record all other changes to deferred tax asset valuation allowances and liabilities related to uncertain tax positions in current period income tax expense. </span></div><div style="margin-top:14pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingent Liabilities</span></div><div style="text-indent:24pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the acquisition of Pfenex in October 2020, we entered into a CVR agreement pursuant to which former equity holders of Pfenex received one nontransferable contractual right entitling such holder to receive $2.00 per share (or approximately $77.8&#160;million total) in the event that Pfenex&#8217;s teriparatide injection product received notice from the FDA that such product is therapeutically equivalent with respect to FORTEO&#174; (teriparatide injection) on or before December 31, 2021. The FDA did not provide notice of such event prior to the CVR expiration date and as a result, the Pfenex CVRs expired without payment.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the acquisition of Icagen in April 2020, Icagen selling shareholders will be entitled to receive up to an additional $25&#160;million of cash payments based on certain revenue achievements.</span></div><div style="text-indent:24pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the acquisition of CyDex in January 2011, we recorded a contingent liability for amounts potentially due to holders of the CyDex CVRs and former license holders. The liability is periodically assessed based on events and circumstances related to the underlying milestones, royalties and material sales. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the acquisition of Metabasis in January 2010, we issued Metabasis stockholders four tradable CVRs for each Metabasis share. The fair values of the CVRs are remeasured at each reporting date through the term of the related agreement. </span></div><div style="text-indent:24pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any change in fair value is recorded in our consolidated statement of operations. For additional information, see &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note (5), Fair Value Measurement and Note (8), Balance Sheet Account Details</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.&#8221;   </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill, Intangible Assets and Other Long-Lived Assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill, which has an indefinite useful life, represents the excess of cost over fair value of net assets acquired. Goodwill is reviewed for impairment at least annually during the fourth quarter, or more frequently if an event occurs indicating the potential for impairment. During the goodwill impairment review, we assess qualitative factors to determine whether it is more likely than not that the fair value of our reporting unit is less than the carrying amount, including goodwill. We operate in one reporting unit. The qualitative factors include, but are not limited to, macroeconomic conditions, industry and market considerations, and the overall financial performance. If, after assessing the totality of these qualitative factors, we determine that it is not more likely than not that the fair value of our reporting unit is less than the carrying amount, then no additional assessment is deemed necessary. Otherwise, we proceed to perform the quantitative assessment. We will then evaluate goodwill for impairment by comparing the estimated fair value of the reporting unit to its carrying value, including the associated goodwill. To determine the fair value, we generally use a combination of market approach based on Ligand and comparable publicly traded companies in similar lines of businesses and the income approach based on estimated discounted future cash flows. Our cash flow assumptions consider historical and forecasted revenue, operating costs and other relevant factors. We may also elect to bypass the qualitative assessment in a period and elect to proceed to perform the quantitative assessment for the goodwill impairment test. We performed the annual assessment for goodwill impairment during the fourth quarter of 2021, noting no impairment. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our identifiable intangible assets are typically composed of acquired core technologies, licensed technologies, contractual relationships, customer relationships and trade names. The cost of identifiable intangible assets with finite lives is generally amortized on a straight-line basis over the assets&#8217; respective estimated useful lives. We regularly perform reviews to determine if any event has occurred that may indicate that intangible assets with finite useful lives and other long-lived assets are potentially impaired. If indicators of impairment exist, an impairment test is performed to assess the recoverability of the affected assets by determining whether the carrying amount of such assets exceeds the undiscounted expected future cash flows. If the affected assets are not recoverable, we estimate the fair value of the assets and record an impairment loss if the carrying value of the assets exceeds the fair value. Factors that may indicate potential impairment include market conditions, industry and economic trends, changes in regulations, clinical success, historical and forecasted financial results, market capitalization, significant changes in the ability of a particular asset to generate positive cash flows, and the pattern of utilization of a particular asset. We did not identify indicators of impairment for the finite-lived intangibles at December&#160;31, 2021.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Commercial license and other economic rights</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021 and 2020, commercial license and other economic rights consist of the following (in thousands):</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:24.338%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.607%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Adjustments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Adjustments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Aziyo and CorMatrix</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17,696&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(9,461)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,235&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17,696&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(9,588)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,108&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Selexis and Dianomi</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,602&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(8,727)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,875&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,602&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(7,731)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,871&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28,298&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(18,188)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,110&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28,298&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(17,319)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,979&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%">(1) Amounts represent accumulated amortization to principal of $11.7 million and credit loss adjustments of $6.5 million as of December 31, 2021. </span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%">(2) Amounts represent accumulated amortization to principal of $11.3 million and credit loss adjustments of $6.0 million as of December 31, 2020. </span></div><div style="padding-left:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commercial license and other economic rights as of December&#160;31, 2021 represent a portfolio of future milestone and royalty payment rights acquired from Selexis in April 2013 and April 2015, CorMatrix in May 2016, and Dianomi in January 2019. Commercial license rights acquired are accounted for as financial assets, and other economic rights are accounted for as funded research and developments as further discussed below. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2019, we entered into a development funding and royalties agreement with Novan, pursuant to which we would receive certain payments at specified milestones, as well as royalties on any future net sales of SB206, a product candidate being developed to treat molluscum contagiosum, and any other Novan products used for the treatment of molluscum (&#8220;Novan Molluscum Products&#8221;). We paid Novan an upfront payment of $12.0 million, which Novan is required to use to fund the development of SB206. We are not obligated to provide additional funding to Novan for the development or commercialization </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of SB206. Pursuant to the agreement, we would receive up to $20.0 million of milestone payments upon the achievement by Novan of certain regulatory milestones for SB206 or any other Novan Molluscum Product and commercial milestones. In addition to the milestone payments, Novan will pay us tiered royalties from 7.0% to 10.0% based on aggregate annual net sales of SB206 or any other Novan Molluscum Product in North America. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2018, we entered into a development funding and royalties agreement with Palvella. Pursuant to the agreement, we will receive up to $8.0 million of milestone payments upon the achievement by Palvella of certain corporate, financing and regulatory milestones for PTX-022, a product candidate being developed to treat pachyonychia congenita. In addition to the milestone payments, Palvella will pay us tiered royalties from 5.0% to 9.8% based on aggregate annual worldwide net sales of any PTX-022 products, if approved, subject to Palvella&#8217;s right to reduce the royalty rates by making payments in certain circumstances. We made an upfront payment of $10.0 million, which Palvella is required to use to fund the development of PTX-022. We are not obligated to provide additional funding to Palvella for development or commercialization of PTX-022. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determined the economic rights related to Novan and Palvella should be characterized as a funded research and development arrangement, thus we account for them in accordance with ASC 730-20, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Arrangement, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and reduce our asset as the funds are expended by Novan and Palvella. As of December 31, 2019, Novan had used up the $12.0 million upfront payment provided by us. As such, our other economic rights related to Novan had been fully amortized as of December 31, 2019. As of December 31, 2020, the fund has been fully expended by Palvella and our cost basis for the asset has been reduced to zero, and therefore we will recognize milestones and royalties as revenue when earned. During 2020, we recorded a $3.0 million milestone from Palvella under contract revenue, which has been included in our consolidated statement of operations for the year ended December&#160;31, 2020.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2017, we entered into a royalty agreement with Aziyo pursuant to which we will receive royalties from certain marketed products that Aziyo acquired from CorMatrix. Pursuant to the agreement, we received $10.0 million in 2017 from Aziyo to buydown the royalty rates on the products CorMatrix sold to Aziyo. The agreement closed on May 31, 2017, in connection with the closing of the asset sale from CorMatrix to Aziyo (the &#8220;CorMatrix Asset Sale&#8221;). Per the agreement, we will receive a 5% royalty on the products Aziyo acquired in the CorMatrix Asset Sale, reduced from the original 20% royalty from CorMatrix pursuant to the previously disclosed interest purchase agreement, dated May 3, 2016 (the &#8220;Original Interest Purchase Agreement&#8221;) between CorMatrix and us. In addition, Aziyo has agreed to pay us up to $10.0 million of additional milestones tied to cumulative net sales of the products Aziyo acquired in the CorMatrix Asset Sale and to extend the term on these royalties by one year. The royalty agreement will terminate on May 31, 2027. In addition, in May 2017, we entered into an amended and restated interest purchase agreement (the &#8220;Amended Interest Purchase Agreement&#8221;) with CorMatrix, which supersedes in its entirety the Original Interest Purchase Agreement. Other than removing the commercial products sold to Aziyo in the CorMatrix Sale, the terms of the Amended Interest Purchase Agreement remain unchanged with respect to the CorMatrix developmental pipeline products, including the royalty rate of 5% on such pipeline products. The Amended Interest Purchase Agreement will terminate 10 years from the date of the first commercial sale of such products. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for the Aziyo commercial license right as a financial asset in accordance with ASC 310, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Receivables</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and amortize the commercial license right using the effective interest method whereby we forecast expected cash flows over the term of the arrangement to arrive at an annualized effective interest. The annual effective interest associated with the forecasted cash flows from the royalty agreement with Aziyo as of December&#160;31, 2021 is 21.6%. Revenue is calculated by multiplying the carrying value of the commercial license right by the effective interest. The payments received in 2021 were accordingly allocated between revenue and the amortization of the commercial license rights.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to 2020, we accounted for commercial license rights related to developmental pipeline products such as Selexis and Dianomi on a non-accrual basis. These developmental pipeline products are non-commercialized, non-approved products that require FDA or other regulatory approval, and thus have uncertain cash flows. The developmental pipeline products are on a non-accrual basis as we are not yet able to forecast future cash flows given their pre-commercial stages of development. We will prospectively update the yield model under the effective interest method once the underlying products are commercialized and we can reliably forecast expected cash flows. Income will be calculated by multiplying the carrying value of the commercial license right by the effective interest rate. We regularly perform reviews to determine if any event has occurred that may indicate the carrying value of these commercial license rights are potentially impaired. If the affected commercial license rights are not recoverable, we estimate the fair value of the assets and record an impairment loss if the carrying value of the assets exceeds the fair value. During 2020, given the expected cash flow from the Selexis program, we started to account for the Selexis commercial license right as a financial asset in accordance with ASC 310, and amortize the commercial license right using the effective interest method whereby we forecast expected cash flows over the term of the arrangement to arrive at an annualized effective interest. The annual effective interest associated with the forecasted cash flows from the royalty agreement with Selexis as of December&#160;31, 2021 is 21%. Revenue is calculated by multiplying the carrying value of the commercial license right by the effective interest. The payments received in the year ended December&#160;31, 2021 and 2020 were allocated </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">accordingly between revenue and the amortization of the commercial license rights. We still accounted for commercial license rights related to Dianomi on a non-accrual basis as of December&#160;31, 2021.</span></div><div><span><br/></span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For commercial license rights, we have elected a prospective approach to account for changes in estimated cash flows and selected a method for determining when an impairment would be recognized and how to measure that impairment. In circumstances where our new estimate of expected cash flows is greater than previously expected, we will update our yield prospectively. In circumstances where our new estimate of expected cash flows is less than previously expected and below our original estimated yield we record an impairment. Impairment is recognized by reducing the financial asset to an amount that represents the present value of our most recent estimate of expected cash flows discounted by the original effective interest rate.&#160;In circumstances where our new estimate of expected cash flows is less than previously expected, but not below our original estimated yield, we update our yield prospectively.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As a result of adopting ASU 2016-13, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Financial Instruments &#8211; Credit Losses: Measurement of Credit losses on Financial Instruments (Topic 326)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, we now recognize an allowance for current expected credit losses on the commercial license rights subject to credit risk. We recorded a $5.5 million pre-tax reserve for credit losses upon adoption of the standard on January 1, 2020. We estimated the credit losses at the individual asset level by considering the performance against the programs, the company operating performance and the macroeconomic forecast. In addition, we have judgmentally applied credit loss risk factors to the future expected payments with consideration given to the timing of the payment. Given the higher inherent credit risk associated with longer term receivables, we applied a lower risk factor to the earlier years and progressively higher risk factors to the later years. During the twelve months ended December&#160;31, 2021 and 2020, we further considered the current and expected future economic and market conditions surrounding novel coronavirus (COVID-19) pandemic, along with other factors, and recorded an additional $0.5&#160;million each year, for credit losses in other expense, net, in our consolidated statements of operations.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our revenue is generated primarily from royalties on sales of products commercialized by our partners, Captisol material sales, and contract revenue for services, license fees and development, regulatory and sales based milestone payments.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We apply the following five-step model in accordance with ASC 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in order to determine the revenue: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations, including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation.</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Royalties</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We receive royalty revenue on sales by our partners of products covered by patents that we or our partners own under contractual agreements. We do not have future performance obligations under these license arrangements. We generally satisfy our obligation to grant intellectual property rights on the effective date of the contract. However, we apply the royalty recognition constraint required under the guidance for sales-based royalties which requires a royalty to be recorded no sooner than the underlying sale occurs. Therefore, royalties on sales of products commercialized by our partners are recognized in the quarter the product is sold. Our partners generally report sales information to us on a one quarter lag. Thus, we estimate the expected royalty proceeds based on an analysis of historical experience and interim data provided by our partners including their publicly announced sales. Differences between actual and estimated royalty revenues, which have not been material, are adjusted in the period in which they become known, typically the following quarter. </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Captisol Sales</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue from Captisol sales is recognized when control of Captisol material or intellectual property license rights is transferred to our customers in an amount that reflects the consideration we expect to receive from our customers in exchange for those products. A performance obligation is considered distinct from other obligations in a contract when it provides a benefit to the customer either on its own or together with other resources that are readily available to the customer and is separately identified in the contract. For Captisol material, we consider our performance obligation is satisfied at a point in time, once we have transferred control of the product, meaning the customer has the ability to use and obtain the benefit of the Captisol material or intellectual property license right. We recognize revenue for satisfied performance obligations only when we determine there are no uncertainties regarding payment terms or transfer of control. Sales tax and other taxes we collect concurrent with revenue-producing activities are excluded from revenue. We have elected to recognize the cost of freight and shipping when control over Captisol material has transferred to the customer as an expense in Cost of Captisol. We expense incremental costs of obtaining a contract when incurred if the expected amortization period of the asset that we would have recognized is one year or less or the amount is immaterial. We did not incur any incremental costs of obtaining a contract during the periods reported.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Contract Revenue</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our contracts with customers often will include variable consideration in the form of contingent milestone-based payments. We include contingent milestone based payments in the estimated transaction price when it is probable a significant reversal in the amount of cumulative revenue recognized will not occur. These estimates are based on historical experience, anticipated results and our best judgment at the time. If the contingent milestone based payment is sales-based, we apply the royalty recognition constraint and record revenue when the underlying sale has taken place. Significant judgments must be made in determining the transaction price for our sales of intellectual property. Because of the risk that products in development with our partners will not reach development based milestones or receive regulatory approval, we generally recognize any contingent payments that would be due to us upon the development milestone or regulatory approval. Depending on the terms of the arrangement, we may also defer a portion of the consideration received if we have to satisfy a future obligation, which typically occurs with our contracts for R&amp;D services.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For R&amp;D services we recognize revenue over time and we measure our progress using an input method. The input methods we use are based on the effort we expend or costs we incur toward the satisfaction of our performance obligation. We estimate the amount of effort we expend, including the time it will take us to complete the activities, or the costs we may incur in a given period, relative to the estimated total effort or costs to satisfy the performance obligation. This results in a percentage that we multiply by the transaction price to determine the amount of revenue we recognize each period. This approach requires us to make numerous estimates and use significant judgement. If our estimates or judgements change over the course of the collaboration, they may affect the timing and amount of revenue that we recognize in the current and future periods.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We occasionally have sub-license obligations related to arrangements for which we receive license fees, milestones and royalties. We evaluate the determination of gross as a principal versus net as an agent reporting based on each individual agreement.</span></div><div><span><br/></span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Deferred Revenue</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Depending on the terms of the arrangement, we may also defer a portion of the consideration received if we have to satisfy a future obligation.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The timing of revenue recognition, billings and cash collections results in billed accounts receivable, unbilled receivables (contract assets), and customer advances and deposits (contract liabilities) on the consolidated balance sheet. Except for royalty revenue, we generally receive payment at the point we satisfy our obligation or soon after. Therefore, we do not generally carry a contract asset balance. Any fees billed in advance of being earned are recorded as deferred revenue. During the twelve months ended December&#160;31, 2021, the amount recognized as revenue that was previously deferred at December 31, 2020 was $30.1 million. During the twelve months ended December&#160;31, 2020, the amount recognized as revenue that was previously deferred at December 31, 2019 was $0.9 million.</span></div><div><span><br/></span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Disaggregation of Revenue </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Royalty revenue for 2021, 2020 and 2019 are reported as below (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:61.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.601%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kyprolis</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,472&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,164&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,046&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Evomela</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,079&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,377&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,171&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,376&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,255&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,566&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Promacta</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,193&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,927&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,796&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,976&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table represents disaggregation of Captisol and Contract Revenue (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:61.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.601%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Captisol</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">164,250&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109,959&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,489&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:5pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Service Revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,712&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,803&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,776&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;License Fees</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,084&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,378&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,199&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Milestone</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,748&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,516&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,173&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,412&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,967&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,669&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,956&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,664&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,817&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expense consists of labor, material, equipment, and allocated facilities costs of our scientific staff who are working pursuant to our collaborative agreements and other research and development projects. Also included in research and development expenses are third-party costs incurred for our research programs including in-licensing costs, CRO costs and costs incurred by other research and development service vendors. We expense these costs as they are incurred. When we make payments for research and development services prior to the services being rendered, we record those amounts as prepaid assets on our consolidated balance sheet and we expense them as the services are provided. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share-Based Compensation</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We incur share-based compensation expense related to restricted stock, ESPP, and stock options.</span></div><div style="text-indent:45pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted stock unit (RSU) and performance stock unit (PSU) are all considered restricted stock. The fair value of restricted stock is determined by the closing market price of our common stock on the date of grant. We recognize share-based compensation expense based on the fair value on a straight-line basis over the requisite service periods of the awards, taking into consideration of forfeitures as they occur. PSU generally represents a right to receive a certain number of shares of common stock based on the achievement of corporate performance goals and continued employment during the vesting period. At each reporting period, we reassess the probability of the achievement of such corporate performance goals and any expense change resulting from an adjustment in the estimated shares to be released are treated as a cumulative catch-up in the period of adjustment. A limited amount of PSUs contain a market condition dependent upon the Company&#8217;s relative and absolute total stockholder return over a three-year period, with a range of 0% to 200% of the target amount granted to be issued under the award. Share-based compensation expense for these PSUs is measured using the Monte-Carlo simulation valuation model and is not adjusted for the achievement, or lack thereof, of the market conditions.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Black-Scholes-Merton option-pricing model is used to estimate the fair value of stock purchases under our ESPP and stock options granted. The model assumptions include expected volatility, term, dividends, and the risk-free interest rate. We look to historical and implied volatilities of our stock to determine the expected volatility. The expected term of an award is based on historical forfeiture experience, exercise activity, and on the terms and conditions of the stock awards. The expected dividend yield is determined to be 0% given that except for 2007, during which we declared a cash dividend on our common stock of $2.50 per share, we have not paid any dividends on our common stock in the past and currently do not expect to pay cash dividends or make any other distributions on common stock in the future. The risk-free interest rate is based upon U.S. Treasury securities with remaining terms similar to the expected term of the share-based awards.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We grant options, RSUs and PSUs to employees and non-employee directors. Non-employee directors are accounted for as employees. Options and RSUs granted to certain non-employee directors typically vest one year from the date of grant. Options granted to employees typically vest 1/8 on the six month anniversary of the date of grant, and 1/48 each month thereafter for forty-two months. RSUs and PSUs granted to employees vest over three years. All option awards generally expire ten years from the date of grant.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Share-based compensation expense for awards to employees and non-employee directors is recognized on a straight-line basis over the vesting period until the last tranche vests. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Derivatives</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2018, we issued $750.0 million aggregate principal amount of 2023 Notes, bearing cash interest at a rate of 0.75% per year, payable semi-annually, as further described in &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note (7), Convertible Senior Notes.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; Concurrently with the issuance of the notes, we entered into a series of convertible note hedge and warrant transactions which in combination are designed to reduce the potential dilution to our stockholders and/or offset the cash payments we are required to make in excess of the principal amount upon conversion of the notes. The conversion option associated with the 2023 Notes temporarily met the criteria for an embedded derivative liability which required bifurcation and separate accounting. In addition, the note hedge and warrants were also temporarily classified as a derivative asset and liability, respectively, on our consolidated balance sheet. As a result of shareholder approval to increase the number of authorized shares of our common stock on June 19, 2018, as discussed in &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note (7), Convertible Senior Notes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,&#8221; the derivative asset and liabilities were reclassified to additional paid-in capital. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with our 2019 Notes, which we issued in August 2014 for $245.0 million aggregate principal amount, on May 22, 2018, we amended it making an irrevocable election to settle the entire note in cash. As a result, we reclassified from equity to derivative liability the fair value of the conversion premium as of May 22, 2018. Amounts paid in excess of the principal amount would be offset by an equal receipt of cash under the corresponding convertible bond hedge. As a result, we reclassified from equity to derivative asset the fair value of the bond hedge as of May 22, 2018. Changes in the fair value of these derivatives are reflected in other expense, net, in our consolidated statements of operations.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the payoff of the 2019 Notes in August 15, 2019, the bond hedge was settled and accordingly, the derivative asset and derivative liability were settled to zero. See detail in &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note (7), Convertible Senior Notes.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The provision for income taxes is computed using the asset and liability method, under which deferred tax assets and liabilities are recognized for the expected future tax consequences of temporary differences between the financial reporting and tax bases of assets and liabilities, and for the expected future tax benefit to be derived from tax loss and credit carryforwards. Deferred tax assets and liabilities are determined using the enacted tax rates in effect for the years in which those tax assets are expected to be realized. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in the provision for income taxes in the period that includes the enactment date. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred tax assets are regularly assessed to determine the likelihood they will be recovered from future taxable income. A valuation allowance is established when we believe it is more likely than not the future realization of all or some of a deferred tax asset will not be achieved. In evaluating the ability to recover deferred tax assets within the jurisdiction which they arise we consider all available positive and negative evidence. Factors reviewed include the cumulative pre-tax book income for the past three years, scheduled reversals of deferred tax liabilities, history of earnings and reliable forecasting, projections of pre-tax book income over the foreseeable future, and the impact of any feasible and prudent tax planning strategies.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize the impact of a tax position in our financial statements only if that position is more likely than not of being sustained upon examination by taxing authorities, based on the technical merits of the position. Tax authorities regularly examine our returns in the jurisdictions in which we do business and we regularly assess the tax risk of our return filing positions. Due to the complexity of some of the uncertainties, the ultimate resolution may result in payments that are materially different from our current estimate of the tax liability. These differences, as well as any interest and penalties, will be reflected in the provision for income taxes in the period in which they are determined.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income (Loss) Per Share</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic income (loss) per share is calculated by dividing net income (loss) by the weighted-average number of common shares outstanding during the period. Diluted income per share is computed based on the sum of the weighted average number of common shares and potentially dilutive common shares outstanding during the period. Diluted loss per share is computed based on the sum of the weighted average number of common shares outstanding during the period.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Potentially dilutive common shares consist of shares issuable under 2023 convertible senior notes, stock options and restricted stock. 2023 convertible senior notes have a dilutive impact when the average market price of the Company&#8217;s common stock exceeds the applicable conversion price of the respective notes. It is our intent and policy to settle conversions through combination settlement, which essentially involves payment in cash equal to the principal portion and delivery of shares of common stock for the excess of the conversion value over the principal portion. Potentially dilutive common shares from stock options and restricted stock are determined using the average share price for each period under the treasury stock method. In addition, the following amounts are assumed to be used to repurchase shares: proceeds from exercise of stock options and the average amount of unrecognized compensation expense for stock options and restricted stock. In loss periods, basic net loss per </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">share and diluted net loss per share are identical since the effect of otherwise dilutive potential common shares is anti-dilutive and therefore excluded.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">For the twelve months ended December 31, 2020, all of the 0.6&#160;million weighted average shares of outstanding equity awards as of December 31, 2020 were anti-dilutive due to the net loss for the period.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the calculation of weighted average shares used to calculate basic and diluted income (loss) per share (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:62.189%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.649%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares outstanding:</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,630&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,185&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,995&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dilutive potential common shares:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Restricted stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Stock options</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">520&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">719&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares used to compute diluted income (loss) per share</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,246&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,185&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,757&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Potentially dilutive shares excluded from calculation due to anti-dilutive effect</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,793&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,458&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,926&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comprehensive Income (Loss)</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Comprehensive income (loss) represents net income (loss) adjusted for the change during the periods presented in unrealized gains and losses on available-for-sale debt securities, foreign currency translation adjustments, and reclassification adjustments for realized gains or losses included in net income (loss). The unrealized gains or losses are reported on the Consolidated Statements of Comprehensive Income (Loss).</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Translation</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The British Pound Sterling was the functional currency of our subsidiary, Vernalis, which was sold in fourth quarter of the year ended December 31, 2020. For the years ended December 31, 2020 and 2019 the corresponding financial statements have been translated into U.S. Dollars in accordance with ASC 830-30, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Translation of Financial Statements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">. Assets and liabilities are translated at end-of-period rates while revenues and expenses are translated at average rates in effect during the period in which the activity took place. Equity is translated at historical rates and the resulting cumulative translation adjustments are included as a component of accumulated other comprehensive income (loss).</span></div><div style="text-indent:24pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impact of COVID-19 Pandemic</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, we have not experienced material disruptions in our business operations or financial impacts as a result of the COVID-19 pandemic. While it is not possible at this time to estimate the impact that COVID-19 could have on our business in the future, the continued spread of COVID-19 and variants of the virus, the rate of vaccinations regionally and globally and the measures taken by the government authorities, and any future epidemic disease outbreaks, could: disrupt the supply chain and the manufacture or shipment of products and supplies for use by us in our discovery activities and by our partners for their discovery and development activities; delay, limit or prevent us or our partners&#8217; from continuing research and development activities; impede our negotiations with partners and potential partners; impede testing, monitoring, data collection and analysis and other related activities, by us and our partners; interrupt or delay the operations of the FDA or other regulatory authorities, which may impact review and approval timelines for initiation of clinical trials or marketing; impede the launch or commercialization of any approved products; any of which could delay our partnership programs, increase our operating costs, and have a material adverse effect on our business, financial condition and results of operations. In addition, if COVID-19 infects our genetically modified animals, which form the basis of our platform, or if there is an outbreak among our employees who maintain and care for these animals, we and our partners may be unable to produce antibodies for development.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some of our partners are working to develop drugs to treat COVID-19. For example, we are supplying Captisol to partners, including Gilead for Veklury (remdesivir), the first FDA-approved treatment for COVID-19 for the treatment of patients with COVID-19 requiring hospitalization and, as a result, we have extended our Captisol supply agreement with Gilead until September 2030 and worked to increase our manufacturing of Captisol to meet this increased demand. In addition, certain of our OmniAb and other license partners have initiated antibody discovery programs for the potential treatment of COVID-19.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The full extent to which the COVID-19 pandemic will directly or indirectly impact our business, the businesses of our partners, our results of operations and our financial condition will depend on future developments that are highly uncertain and cannot be </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">accurately predicted, including new information that may emerge concerning COVID-19, the actions taken to contain it or treat its impact, including the timing and extent of governments reopening or further restricting activities, and the economic impact on local, regional, national and international markets.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Accounting Standards Not Yet Adopted</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In August 2020, the FASB issued ASU 2020-06, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Debt &#8211; Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging &#8211; Contracts in Entity&#8217;s Own Equity (Subtopic 815 &#8211; 40)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, which simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts on an entity&#8217;s own equity. This guidance is part of the FASB&#8217;s simplification initiative, which aims to reduce unnecessary complexity in U.S. GAAP. The ASU is effective for public entities for fiscal years beginning after December 15, 2021, and interim periods within those fiscal years. Effective January 1, 2022, we will adopt ASU 2020-06. We are finalizing our analysis of certain assumptions that will be utilized at the transition and expects the effect of adopting ASU 2020-06 will result in an increase to retained earnings, a decrease to additional paid-in capital, and an increase to the convertible senior notes. We expect that interest expense recognized in future periods will be reduced as a result of accounting for the convertible debt instrument as a single liability measured at its amortized cost. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We do not believe that any other recently issued, but not yet effective accounting pronouncements, if adopted, would have a material impact on our consolidated financial statements or disclosures.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows.  Describes procedure if disclosures are provided in more than one note to the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140091803843480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Sale of Vernalis R&amp;D and Promacta License<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract', window );"><strong>Discontinued Operations and Disposal Groups [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock', window );">Sale of Vernalis R&amp;D and Promacta License</a></td>
<td class="text">Sale of Vernalis R&amp;D and Promacta License<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Vernalis R&amp;D</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On October 11, 2020, we entered into an Agreement for the Sale and Purchase of the Entire Issued Share Capital of Vernalis (R&amp;D) Limited (the &#8220;Purchase and Sale Agreement&#8221;) with HitGen UK Ltd (&#8220;Buyer&#8221;). Under the terms of the Purchase and Sale Agreement, we transferred certain intellectual property on completed collaboration licenses to Ligand UK Limited, which is a subsidiary of the Company, which we retain rights and interest to and are entitled to receive future milestones and royalties. Under the Purchase and Sale Agreement, we are also entitled to a share of the economic rights on current research collaboration contracts. In addition, Vernalis will continue to support certain existing Ligand partnerships. On December 2, 2020, we completed the sale. Pursuant to the terms of the Purchase and Sale Agreement, at the closing of the transaction, Buyer paid $26.7&#160;million in cash, following adjustment for debt, cash and net working capital. As Vernalis R&amp;D has the input, process and output elements defined in ASC 805, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Business Combinations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, we concluded the sale qualifies as a sale of business. Net assets sold, net of working capital adjustment, was $6.1&#160;million, goodwill allocated to the selling business that was written off was $3.5&#160;million, resulting in a $17.1 million gain from sale of Vernalis R&amp;D recorded to income from operations.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Promacta License</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On March 5, 2019, we entered into an Asset Purchase Agreement (the &#8220;Asset Purchase Agreement&#8221;) with RPI Finance Trust (&#8220;RPI&#8221;), doing business as &#8220;Royalty Pharma&#8221;, who is not an affiliate. Under the Asset Purchase Agreement, we sold, transferred, assigned and conveyed to RPI, and RPI purchased, acquired and accepted from us, all of our rights, title and interest in and to the Purchased Assets, which include among other things the intellectual property and related know-how generated by us in connection with the license agreement (collectively, the &#8220;Purchased Assets&#8221;), dated December 29, 1994, by and between Novartis (as successor in interest to SmithKline Beecham Corporation) and Ligand, which allowed us to receive a royalty on net sales of Promacta. We concluded the sale does not qualify as a sale of a business, but as a sale of a non-financial asset. At the closing on March 6, 2019, RPI paid us $827.0&#160;million in cash and we do not have any remaining performance obligations related to Novartis or RPI for Promacta. The carrying value of our Promacta asset as of March 6, 2019 was zero. Of the total cash proceeds from the sale, $14.2&#160;million was recorded to revenue related to the Promacta royalty for the period between January 1, 2019 and March 6, 2019, and the remaining $812.8&#160;million was recorded to income from operations in accordance with ASC 610-20,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"> Other Income - Gains and Losses from the Derecognition of Nonfinancial Assets.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=2122178<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140091803868856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Short-term Investments: Investment in Viking<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityDisclosureTextBlock', window );">Short-term Investments: Investment in Viking</a></td>
<td class="text">Short-term Investments: Investment in Viking<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ownership in Viking was approximately 8.6% as of December&#160;31, 2021, and we account for it as an investment in available-for-sale equity securities, which is measured at fair value, with changes in fair value recognized in net income. Viking is considered a related party as we maintain a seat on Viking's board of directors and we do not exert significant influence over Viking. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, we have zero Viking warrants outstanding. As of December&#160;31, 2021 and December&#160;31, 2020, we recorded our common stock in Viking in &#8220;short-term investments&#8221; at fair value of $30.9 million and $32.8 million, respectively. </span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2020, we owned warrants to purchase up to 1.5 million shares of Viking's common stock at an exercise price of  $1.50 per share, and during the year ended December&#160;31, 2021 we exercised all outstanding Viking warrants. As of December&#160;31, 2021, we have zero Viking warrants outstanding. During the year ended December&#160;31, 2021, we also sold 0.6&#160;million Viking shares. We recorded the warrants in &#8220;Short-term investments&#8221; in our consolidated balance sheet at fair value of $6.3 million at December&#160;31, 2020. See further discussion in &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note (5), Fair Value Measurement.</span>&#8221;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableInterestEntityDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a variable interest entity (VIE), including but not limited to, judgments and assumptions in determining whether to consolidate and in identifying the primary beneficiary, gain (loss) recognized on the initial consolidation of the VIE, terms of arrangements, amounts and classification of the VIE's assets and liabilities, and the entity's maximum exposure to loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableInterestEntityDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140091804008760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract', window );"><strong>Business Combination and Asset Acquisition [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationDisclosureTextBlock', window );">Acquisitions</a></td>
<td class="text">Acquisitions<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As set forth below, we completed five acquisitions from January 1, 2019 through December 31, 2021, of which three (Pfenex, Icagen and Ab Initio) were accounted for as business combinations and two (Taurus and xCella) were accounted for as asset acquisitions. For business combinations, we applied the acquisition method of accounting. Accordingly, we recorded the tangible and intangible assets acquired and liabilities assumed at their estimated fair values as of the applicable date of acquisition. Except for the Pfenex acquisition, for all other acquisitions, we did not incur any material acquisition related costs.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Pfenex Acquisition </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 1, 2020, we acquired Pfenex, which develops next-generation and novel protein therapeutics to improve existing therapies and create new therapies for biological targets linked to critical, unmet diseases using a protein expression technology platform.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The purchase price of $465.1 million included $429.6 million cash consideration paid upon acquisition, and a contingent CVR payment of up to $77.8 million in cash based on a certain specified milestone with an estimated initial fair value of $37.0 million. The CVR will only be paid in full if the milestone is achieved by December 31, 2021. The amount of the CVR included in purchase price was reduced by $1.5&#160;million which was determined to be post-combination expense. The fair value of the CVR liability was determined using a probability adjusted income approach. These cash flows were then discounted to present value using a discount rate based on market participants' cost of debt reflective of the Company, which was 7.1%. The liability is periodically assessed based on events and circumstances related to the underlying milestone, and any change in fair value is recorded in our consolidated statements of operations. During the year ended December&#160;31, 2021, we wrote off the entire CVR liability of $37.6&#160;million to other operation income, primarily due to not achieving the specific development and regulatory milestone by December 31, 2021 as defined by Pfenex CVR.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In connection with the acquisition, a portion of Pfenex's equity awards that were outstanding and unvested prior to the acquisition became fully vested per the terms of the merger agreement. The acceleration of vesting required us to allocate the fair value of the equity attributable to pre-combination service to the purchase price and the remaining amount was considered our post-combination expense. We paid $17.3 million in cash for equity compensation, which is attributable to pre-combination services and is reflected as a component of the total purchase price paid of $429.6 million. In addition, the fair value of equity compensation attributable to the post-combination service period was $8.7 million. These amounts were associated with the accelerated vesting of stock options previously granted to Pfenex employees and were fully paid in cash, which was recognized as general and administrative expenses during the fourth quarter of 2020. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recorded $20.7 million of acquisition-related costs for legal, severance and other costs in connection with the acquisition within operating expenses in our consolidated statement of operations for 2020. The following table sets forth an allocation of the purchase price to the identifiable tangible and intangible assets acquired and liabilities assumed, with the excess recorded to goodwill (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.449%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.351%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash </span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,407&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts and unbilled receivables</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,359&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,823&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use asset</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,070&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,338&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangibles acquired</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">385,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,303&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,814)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,606)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,908)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,070)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,382)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(42,622)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 61pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total consideration</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">465,098&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%">(1) Goodwill represents the excess of the purchase price over the preliminary fair value of the underlying assets acquired and liabilities assumed. Goodwill is attributable to the assembled workforce of experienced personnel at Pfenex and expected synergies. None of the goodwill is deductible for tax purposes. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The intangibles acquired and their weighted average useful life are as follows (in thousands, except useful lives):</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.707%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.497%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Approximate<br/>Fair Value</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Estimated useful life<br/>(in years)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contractual Relationships:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Alvogen</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Merck</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jazz</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SII</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Arcellx</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired Technologies</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-19</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">385,000&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of the contractual relationships were based on the discounted cash flow method that estimated the present value of the potential royalties, milestones and collaboration revenue streams derived from the licensing of the related technologies over the estimated contractual relationship period. The fair values of the acquired technologies were based on the discounted cash flow method that estimated the present value of the potential royalties, milestones, collaboration and product revenue streams derived from the licensing of the related technologies over the estimated useful lives. These projected cash flows were discounted to present value using discount rate, which varies from 12% to 15%. The intangible assets acquired are being amortized on a straight-line basis over the estimated useful life. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Approximately $2.0 million of revenue and $19.3 million of loss before income taxes of Pfenex were included in the consolidated statement of operations for the year ended December 31, 2020. The following summary presents our unaudited pro forma consolidated results of operations for the years ended December 31, 2020 and December 31, 2019 as if the Pfenex acquisition had occurred on January 1, 2019, which gives effect to certain transaction accounting adjustments, including amortization of acquired intangibles and stock based compensation expense for retained Pfenex employees. The transaction accounting adjustments do not include non-recurring adjustments related to Pfenex's executive salary, board of director compensation, and salary of Pfenex employees involved in the reduction of force as part of the acquisition, estimated to be $7.1 million in 2020 and $4.8&#160;million in 2019. The pro forma financial information is not necessarily indicative of the operating results that would have occurred had the acquisition been consummated as if the date indicated, nor is it necessarily indicative of future operating results (in thousands, except per share amounts):</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.707%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.497%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Unaudited)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">189,203&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">170,608&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net Income (loss)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(60,059)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">594,941&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net income (loss) per common share:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Basic</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.71)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.32&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Diluted</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.71)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Taurus Acquisition</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 9, 2020, we acquired Taurus, which discovers and develops novel antibodies from immunized cows and cow-derived libraries. These antibodies feature some of the longest CDR3s of any species, with unique genetic and structural diversity that can enable binding to challenging antigens with application in therapeutics, diagnostics and research.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The purchase price of  $5.1 million included $4.6 million in cash, and a $0.5 million holdback to satisfy indemnification obligations which will be settled by September 2021. We also issued nontransferable CVRs for up to $4.5 million tied to partnered and internal research and development and for up to $25.0 million as a 25% share of post-clinical Taurus product revenues (including milestone payments) received by us. We accounted for this transaction as an asset acquisition as we concluded that substantially all of the fair value of the gross assets acquired was concentrated in the acquired core technology. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The allocation of the consideration was allocated to the acquisition date fair values of acquired assets as follows (in thousands)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.303%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.497%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangibles assets with finite-life - core technologies</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,005&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,052&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The core technology is being amortized on a straight-line basis over the estimated useful life of 10 years. We account for the CVRs in accordance with ASC 450, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contingencies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, when the contingency is resolved and the liability becomes payable. None of the CVRs are recognized as of the acquisition date.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">xCella Acquisition</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 8, 2020, we acquired xCella, an antibody discovery company. xCella's xPloration platform is a proprietary microcapillary platform that can screen single B cells for specificity and bioactivity and will increase Ligand&#8217;s antibody discovery throughput and efficiency. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We paid $7.1 million in cash (including a $0.5 million holdback to satisfy indemnification obligations which will be settled by September 2021), and issued earnout rights for up to $5.0 million tied to our use of the xCella technology for partnered research and development and for up to $25.75 million as a 25% share of any future milestone payments we received under a certain existing xCella partner arrangement. We evaluated this acquisition in accordance with ASC 805, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Business Combinations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, to discern whether the assets and operations of xCella met the definition of a business. We accounted for this transaction as an asset acquisition as we concluded that substantially all of the fair value of the gross assets acquired was concentrated in the acquired core technology.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The allocation of the consideration was allocated to the acquisition date fair values of acquired assets and assumed liabilities as follows (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.303%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.497%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and other assets</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">240&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(142)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(604)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangibles assets with finite-life - core technology</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,582&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,076&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The core technology is being amortized on a straight-line basis over the estimated useful life of 15 years. We account for the earnout rights in accordance with ASC 450, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contingencies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, when the contingency is resolved and the liability becomes payable. None of the earnout rights are recognized as of the acquisition date.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Icagen Acquisition</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 1, 2020, we acquired the core assets, including its partnered programs and ion channel technology from Icagen and certain of its affiliates. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The purchase price of $19.9&#160;million included $15.1 million cash consideration paid upon acquisition, and a CVR of up to $25.0 million of cash payments based on certain revenue milestones with an estimated fair value of $4.8 million. The fair value of the earn-out liability was determined using a probability weighted income approach incorporating the estimated future cash flows from expected future milestones. These cash flows were then discounted to present value using a discount rate based on the market participants' cost of debt reflective of the Company, which was 5.5%. The liability is periodically assessed based on events and circumstances related to the underlying milestones, and any change in fair value is recorded in our consolidated statements of operations. The carrying amount of the liability may fluctuate significantly and actual amount paid may be materially different than the carrying amount of the liability. As the acquisition is not considered significant, pro forma information has not been provided. The results of Icagen have been included in our results of operations since the date of acquisition.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The allocation of the consideration was allocated to the acquisition date fair values of acquired assets and assumed liabilities as follows (in thousands):</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.303%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.497%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,173&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaids and other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">588&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities assumed</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(812)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,685)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">861&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired intangibles</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,800&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,015&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,940&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%">(1) Goodwill represents the excess of the purchase price over the preliminary fair value of the underlying assets acquired and liabilities assumed. Goodwill is attributable to the assembled workforce of experienced personnel at Icagen and expected synergies.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The majority of the goodwill is deductible for tax purposes. Acquired intangibles include $11.1 million of customer relationships and $1.7 million of core technology. The fair values of the customer relationships were based on a discounted cash flow analysis incorporating the estimated future cash flows from these relationships during the contractual term. These cash flows were then discounted to present value using a discount rate of 17%. The fair value of the customer relationships is being amortized on a straight-line basis over the weighted average estimated useful life of 9.6 years. The fair value of the core technology was based on the discounted cash flow method that estimated the present value of the potential royalties, milestones, and collaboration revenue streams derived from the licensing of the related technologies. These projected cash flows were discounted to present value using a discount rate of 17%. The fair value of the core technology is being amortized on a straight-line basis over the estimated useful life of 10 years. The total acquired intangibles are being amortized on a straight-line basis over the estimated useful life of 9.7 years.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Ab Initio Acquisition</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 23, 2019, we acquired privately-held Ab Initio, an antigen-discovery company located in South San Francisco, California. Ab Initio has a patented antigen technology that is synergistic with the OmniAb</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">therapeutic antibody discovery platform, providing our current and potential new partners enhanced capabilities for the discovery of therapeutic antibodies against difficult-to-access cellular targets. Ab Initio has a collaboration agreement with Pfizer to discover novel therapeutic antibodies against an undisclosed target in the GPCR superfamily.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The purchase price of $12.0 million included $11.9 million cash consideration paid upon acquisition, net of cash acquired, and $0.15 million cash holdback for potential indemnification claims. As the acquisition is not considered significant, pro forma information has not been provided.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The final purchase consideration was allocated to the acquisition date fair values of acquired assets and assumed liabilities as follows (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.303%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.497%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and other assets</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and accrued liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(83)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(146)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangibles assets with finite-life - core technologies</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,400&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,812&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,011&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%">(1) Goodwill represents the excess of the purchase price over the fair value of the underlying assets acquired and liabilities assumed. Goodwill is attributable to the assembled workforce of experienced personnel at Ab Initio and expected synergies.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None of the goodwill is deductible for tax purposes. The fair value of the core technologies was determined based on the discounted cash flow method that estimated the present value of the hypothetical royalty/ milestone streams from the licensing of the antigen-discovery technology and collaboration agreement. These projected cash flows were discounted to present value using a discount rate of 12.0%. The fair value of the core technologies is being amortized on a straight-line basis over the weighted average estimated useful life of approximately 20 years.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAndAssetAcquisitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -URI http://asc.fasb.org/topic&amp;trid=2303972<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140091804277336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurement<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsDisclosureTextBlock', window );">Fair Value Measurement</a></td>
<td class="text">Fair Value Measurement<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We measure certain financial assets and liabilities at fair value on a recurring basis. Fair value is a market-based measurement that should be determined using assumptions that market participants would use in pricing an asset or liability. We establish a three-level hierarchy to prioritize the inputs used in measuring fair value. The levels are described in the below with level 1 having the highest priority and level 3 having the lowest:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1 - Observable inputs such as quoted prices in active markets </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2 - Inputs other than the quoted prices in active markets that are observable either directly or indirectly </span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 3 - Unobservable inputs in which there is little or no market data, which require the Company to develop its own assumptions</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a summary of the assets and liabilities that are measured at fair value on a recurring basis as of December&#160;31, 2021 and 2020 (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.829%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr><td colspan="24" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements at Reporting Date Using</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted Prices in</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Active Markets</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">for Identical</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Assets</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Observable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Inputs</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unobservable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Inputs</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level&#160;1)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level&#160;2)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level&#160;3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">290,697&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,735&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">280,553&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">409&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in Viking common stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,889&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,889&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">321,586&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,624&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">280,553&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">409&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent liabilities - Cydex</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">349&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">349&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent liabilities - Metabasis </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,358&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,358&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent liabilities - Icagen </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,364&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,364&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liability for amounts owed to a former licensor</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,157&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,358&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,713&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.268%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.473%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.473%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.473%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.623%"/><td style="width:0.1%"/></tr><tr><td colspan="24" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements at Reporting Date Using</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted Prices in</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Active Markets</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">for Identical</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Assets</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Observable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Inputs</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unobservable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Inputs</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level&#160;1)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level&#160;2)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level&#160;3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">324,478&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,438&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">320,647&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">393&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in Viking common stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,763&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,763&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in Viking warrants </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,326&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,326&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">363,567&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,527&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">320,647&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">393&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent liabilities - Crystal </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">800&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">800&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent liabilities - Cydex</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">508&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">508&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent liabilities - Metabasis </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,821&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,821&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent liabilities - Icagen </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,404&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,404&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent liabilities - Pfenex </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(6)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,600&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,600&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liability for amounts owed to a former licensor</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,193&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,821&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,312&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">(1) Excluding our investment in Viking, our short-term investments in marketable debt and equity securities are classified as available-for-sale securities based on management's intentions and are at level 2 of the fair value hierarchy, as these investment securities are valued based upon quoted prices for identical or similar instruments in markets that are not active, and model-based valuation techniques for which all significant assumptions are observable in the market. Short-term investments in mutual funds are valued at their net asset value (NAV) on the last day of the period. We have classified marketable securities with original maturities of greater than one year as short-term investments based upon our ability and intent to use any and all of those marketable securities to satisfy the liquidity needs of our current operations. In addition, we have investment in warrants resulting from Seelos Therapeutics Inc. milestone payments that were settled in shares during the first quarter of 2019 and are at level 3 of the fair value hierarchy, based on Black Scholes value estimated by management on the last day of the period.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2) Investment in Viking warrants, which we received as a result of Viking&#8217;s partial repayment of the Viking note receivable and our purchase of Viking common stock and warrants in April 2016, is classified as level 1 as the fair value is determined using quoted market prices in active markets for the same securities. The change of the fair value is recorded in &#8220;gain (loss) from short-term investments&#8221; in our consolidated statement of operations. See further discussion in &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note (3), Short-term Investments: Investment in Viking.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221;  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3) The fair value of Crystal contingent liabilities was determined using a probability weighted income approach. Most of the contingent payments are based on development or regulatory milestones as defined in the merger agreement with Crystal. The fair value is subjective and is affected by changes in inputs to the valuation model including management&#8217;s estimates regarding the timing and probability of achievement of certain developmental and regulatory milestones. During the twelve months ended December&#160;31, 2020, we paid $1.8 million contingent liability on development milestones to former Crystal shareholders. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(4) In connection with our acquisition of Metabasis in January 2010, we issued Metabasis stockholders four tradable CVRs, one CVR from each of four respective series of CVR, for each Metabasis share. The CVRs entitle Metabasis stockholders to cash payments as frequently as every six months as cash is received by us from proceeds from the sale or partnering of any of the Metabasis drug development programs, among other triggering events. The liability for the CVRs is determined using quoted prices in a market that is not active for the underlying CVR. The carrying amount of the liability may fluctuate significantly based upon quoted market prices and actual amounts paid under the agreements may be materially differ than the carrying amount of the liability. Several of the Metabasis drug development programs have been outlicensed to Viking, including VK2809. VK2809 is a novel selective TR-&#946; agonist with potential in multiple indications, including hypercholesterolemia, dyslipidemia, NASH, and X-ALD. Under the terms of the agreement with Viking, we may be entitled to up to $375.0 million of development, regulatory and commercial milestones and tiered royalties on potential future sales including a $10.0 million payment upon initiation of a Phase 3 clinical trial.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(5) The fair value of Icagen contingent liabilities was determined using a probability weighted income approach. Most of the contingent payments are based on certain revenue milestones as defined in the asset purchase agreement with Icagen. The fair value is subjective and is affected by changes in inputs to the valuation model including management&#8217;s estimates regarding the timing and probability of achievement of certain developmental and regulatory milestones. Changes in these estimates may materially affect the fair value. During the year-end December 31, 2021, we paid a $1.1 million contingent liability based on revenue milestones to Icagen.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(6) The fair value of the Pfenex contingent liability was determined using a probability adjusted income approach. These cash flows were then discounted to present value using a discount rate based on the market participants' cost of debt reflective of the Company. During the year-end December 31, 2021, we reduced the contingent liability by $37.6&#160;million primarily due to the lower probability of achieving the specific development and regulatory milestone by December 31, 2021 as defined by the Pfenex CVR. See further detail on Pfenex CVR in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 4, Acquisitions</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the level 3 financial instruments as of December&#160;31, 2021 is as follows (in thousands):</span></div><div style="text-align:center;text-indent:45pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.303%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.497%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of level 3 financial instruments as of December 31, 2020</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,312&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments to CVR holders and other contingency payments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,770)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value adjustments to contingent liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(36,549)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent liabilities from xCella asset acquisition</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">720&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of level 3 financial instruments as of December&#160;31, 2021</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,713&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Assets Measured on a Non-Recurring Basis</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We apply fair value techniques on a non-recurring basis associated with valuing potential impairment losses related to our goodwill, indefinite-lived intangible assets, and long-lived assets.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We evaluate goodwill and indefinite-lived intangible assets annually for impairment and whenever circumstances occur indicating that goodwill might be impaired. We determine the fair value of our reporting unit based on a combination of inputs, including the market capitalization of Ligand, as well as Level 3 inputs such as discounted cash flows, which are not observable from the market, directly or indirectly. We determine the fair value of our indefinite-lived intangible assets using the income approach based on Level 3 inputs.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There was no impairment of our goodwill, indefinite-lived assets, or long-lived assets recorded during the twelve months ended December&#160;31, 2021.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value of Financial Instruments</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2014 and May 2018, we issued the 2019 Notes and 2023 Notes, respectively. We use quoted market rates in an inactive market, which are classified as a Level 2 input, to estimate the fair value of our 2019 and 2023 Notes. The carrying value of the notes does not reflect the market rate. See &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note (7), Convertible Senior Notes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; for additional information related to the fair value.</span></div>In addition, our accounts receivable, accounts payable, accrued liabilities, current deferred revenue, current operating lease liabilities, current financing lease liabilities are financial instruments and are recorded at cost in the consolidated balance sheets. The estimated fair value of these financial instruments approximates their carrying value due to their short-term nature.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for financial instruments. This disclosure includes, but is not limited to, fair value measurements of short and long term marketable securities, international currencies forward contracts, and auction rate securities. Financial instruments may include hedging and non-hedging currency exchange instruments, derivatives, securitizations and securities available for sale at fair value. Also included are investment results, realized and unrealized gains and losses as well as impairments and risk management disclosures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140091885917368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text">Leases<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Finance lease</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In May 2020 and January 2021, we entered into an agreement and the first amendment with Hovione, our third-party manufacturer, to increase our manufacturing of Captisol, respectively. The agreements are considered to include an embedded finance lease under ASC 842, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Leases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, as it provides the Company the right to use the underlying equipment to exclusively </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">manufacture Captisol. As of December&#160;31, 2021, we have fully paid consideration of $69.1&#160;million for prepaid inventory and capacity ramp-up fee. We allocated consideration in the agreements between lease and non-lease components using relative standalone prices. Since the inception of the agreements, we have allocated $50.2&#160;million of the consideration paid to the non-lease component which is accounted for as prepaid inventory and being amortized to cost of Captisol based on the usage.  As of December&#160;31, 2021 the Hovione finance lease has no remaining lease liability and the right of use asset balance is $16.1&#160;million. The right of use asset is to be amortized straight-line over the remaining seven year lease term. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Operating lease </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We lease certain office facilities and equipment primarily under various operating leases. Our operating leases have remaining contractual terms up to ten years, some of which include options to extend the leases for up to ten years. Our lease agreements do not contain any material residual value guarantees, material restrictive covenants, or material termination options. Our operating lease costs are primarily related to facility leases for administration offices and research and development facilities.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease assets and lease liabilities are recognized at the commencement of an arrangement where it is determined at inception that a lease exists. Lease assets represent the right to use an underlying asset for the lease term, and lease liabilities represent the obligation to make lease payments arising from the lease. These assets and liabilities are initially recognized based on the present value of lease payments over the lease term calculated using our incremental borrowing rate generally applicable to the location of the lease asset, unless the implicit rate is readily determinable. Lease assets also include any upfront lease payments made and lease incentives. Lease terms include options to extend or terminate the lease when it is reasonably certain that those options will be exercised.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to base rent, certain of our operating leases require variable payments, such as insurance and common area maintenance. These variable lease costs, other than those dependent upon an index or rate, are expensed when the obligation for those payments is incurred. Leases with an initial term of 12 months or less are not recorded on the balance sheet, and the expense for these short-term leases and for operating leases is recognized on a straight-line basis over the lease term.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The depreciable life of lease assets and leasehold improvements is limited by the expected lease term, unless there is a transfer of title or purchase option reasonably certain of exercise.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2021, we entered into several new lease agreements including our Emeryville headquarter and animal facility expansion and a new Icagen office lease, which resulted in an increase in operating lease right of use assets of $12.7&#160;million  and lease liabilities of $13.2&#160;million as of December&#160;31, 2021 for the portion of the lease with a starting accounting lease commencement date during the period. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Operating and Finance Lease Assets and Liabilities (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.683%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.498%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating lease assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16,542&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,892&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Finance lease assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16,207&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15,842&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total lease assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32,749&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22,734&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current operating lease liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,053&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,885&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current finance lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">46&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,593&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,099&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,478&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Long-term operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15,494&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,643&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDAvZnJhZzpmNDRmMTQwOTY3NGU0MzVkYWNmMjkzYWVjOTgxYmE2NS90YWJsZToyNmY5ZDQ2ZjdiYTI0Y2E3OWY3YzM1YWYzY2NhMjdkMC90YWJsZXJhbmdlOjI2ZjlkNDZmN2JhMjRjYTc5ZjdjMzVhZjNjY2EyN2QwXzExLTAtMS0xLTQxMjk0_189a0b16-c5f6-426a-9fe4-540e7d6227de"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDAvZnJhZzpmNDRmMTQwOTY3NGU0MzVkYWNmMjkzYWVjOTgxYmE2NS90YWJsZToyNmY5ZDQ2ZjdiYTI0Y2E3OWY3YzM1YWYzY2NhMjdkMC90YWJsZXJhbmdlOjI2ZjlkNDZmN2JhMjRjYTc5ZjdjMzVhZjNjY2EyN2QwXzExLTAtMS0xLTQxMjk0_2ee456c7-520d-4723-b00d-a8a6a8da65cf">Long-term finance lease liabilities</span></span></span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">112&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total lease liabilities   </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17,651&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,233&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Maturity of Operating and Finance Lease Liabilities as of December&#160;31, 2021</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.391%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.499%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Maturity Dates</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating Leases</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Finance Leases</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,653&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">56&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,414&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">49&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,716&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,614&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,670&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,832&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25,899&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">109&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less tenant improvement allowance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4,327)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less imputed interest</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4,025)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Present value of lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17,547&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">104&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, our operating leases have a weighted-average remaining lease term of 8.1 years and a weighted-average discount rate of 4.1%. As of December&#160;31, 2020, our operating leases have a weighted-average remaining lease term of 4.4 years and a weighted-average discount rate of 5.7%. Cash paid for amounts included in the measurement of operating lease liabilities was $2.6 million and $2.4&#160;million for the twelve months ended December&#160;31, 2021 and 2020, respectively. Operating lease expense was $2.6 million (net of sublease income of $0.4 million) and $2.1 million (net of sublease income of $0.3 million) for the twelve months ended December&#160;31, 2021 and 2020, respectively.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, our finance leases have a weighted-average remaining lease term of 7.0 years and a weighted-average discount rate of 3.0%. As of December&#160;31, 2020, our finance leases have a weighted-average remaining lease term of 7.9 years and a weighted-average discount rate of 3.5%. Cash paid for amounts included in the measurement of these finance lease liabilities was $9.3&#160;million and $9.7&#160;million for the twelve months ended December&#160;31, 2021 and 2020, respectively. Finance lease expense was $2.3 million and 0.2&#160;million for the twelve months ended December&#160;31, 2021 and 2020, respectively.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeFinanceLeasesTextBlock', window );">Leases</a></td>
<td class="text">Leases<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Finance lease</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In May 2020 and January 2021, we entered into an agreement and the first amendment with Hovione, our third-party manufacturer, to increase our manufacturing of Captisol, respectively. The agreements are considered to include an embedded finance lease under ASC 842, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Leases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, as it provides the Company the right to use the underlying equipment to exclusively </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">manufacture Captisol. As of December&#160;31, 2021, we have fully paid consideration of $69.1&#160;million for prepaid inventory and capacity ramp-up fee. We allocated consideration in the agreements between lease and non-lease components using relative standalone prices. Since the inception of the agreements, we have allocated $50.2&#160;million of the consideration paid to the non-lease component which is accounted for as prepaid inventory and being amortized to cost of Captisol based on the usage.  As of December&#160;31, 2021 the Hovione finance lease has no remaining lease liability and the right of use asset balance is $16.1&#160;million. The right of use asset is to be amortized straight-line over the remaining seven year lease term. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Operating lease </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We lease certain office facilities and equipment primarily under various operating leases. Our operating leases have remaining contractual terms up to ten years, some of which include options to extend the leases for up to ten years. Our lease agreements do not contain any material residual value guarantees, material restrictive covenants, or material termination options. Our operating lease costs are primarily related to facility leases for administration offices and research and development facilities.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease assets and lease liabilities are recognized at the commencement of an arrangement where it is determined at inception that a lease exists. Lease assets represent the right to use an underlying asset for the lease term, and lease liabilities represent the obligation to make lease payments arising from the lease. These assets and liabilities are initially recognized based on the present value of lease payments over the lease term calculated using our incremental borrowing rate generally applicable to the location of the lease asset, unless the implicit rate is readily determinable. Lease assets also include any upfront lease payments made and lease incentives. Lease terms include options to extend or terminate the lease when it is reasonably certain that those options will be exercised.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to base rent, certain of our operating leases require variable payments, such as insurance and common area maintenance. These variable lease costs, other than those dependent upon an index or rate, are expensed when the obligation for those payments is incurred. Leases with an initial term of 12 months or less are not recorded on the balance sheet, and the expense for these short-term leases and for operating leases is recognized on a straight-line basis over the lease term.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The depreciable life of lease assets and leasehold improvements is limited by the expected lease term, unless there is a transfer of title or purchase option reasonably certain of exercise.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2021, we entered into several new lease agreements including our Emeryville headquarter and animal facility expansion and a new Icagen office lease, which resulted in an increase in operating lease right of use assets of $12.7&#160;million  and lease liabilities of $13.2&#160;million as of December&#160;31, 2021 for the portion of the lease with a starting accounting lease commencement date during the period. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Operating and Finance Lease Assets and Liabilities (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.683%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.498%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating lease assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16,542&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,892&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Finance lease assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16,207&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15,842&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total lease assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32,749&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22,734&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current operating lease liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,053&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,885&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current finance lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">46&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,593&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,099&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,478&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Long-term operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15,494&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,643&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDAvZnJhZzpmNDRmMTQwOTY3NGU0MzVkYWNmMjkzYWVjOTgxYmE2NS90YWJsZToyNmY5ZDQ2ZjdiYTI0Y2E3OWY3YzM1YWYzY2NhMjdkMC90YWJsZXJhbmdlOjI2ZjlkNDZmN2JhMjRjYTc5ZjdjMzVhZjNjY2EyN2QwXzExLTAtMS0xLTQxMjk0_189a0b16-c5f6-426a-9fe4-540e7d6227de"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDAvZnJhZzpmNDRmMTQwOTY3NGU0MzVkYWNmMjkzYWVjOTgxYmE2NS90YWJsZToyNmY5ZDQ2ZjdiYTI0Y2E3OWY3YzM1YWYzY2NhMjdkMC90YWJsZXJhbmdlOjI2ZjlkNDZmN2JhMjRjYTc5ZjdjMzVhZjNjY2EyN2QwXzExLTAtMS0xLTQxMjk0_2ee456c7-520d-4723-b00d-a8a6a8da65cf">Long-term finance lease liabilities</span></span></span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">112&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total lease liabilities   </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17,651&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,233&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Maturity of Operating and Finance Lease Liabilities as of December&#160;31, 2021</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.391%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.499%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Maturity Dates</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating Leases</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Finance Leases</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,653&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">56&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,414&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">49&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,716&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,614&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,670&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,832&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25,899&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">109&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less tenant improvement allowance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4,327)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less imputed interest</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4,025)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Present value of lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17,547&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">104&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, our operating leases have a weighted-average remaining lease term of 8.1 years and a weighted-average discount rate of 4.1%. As of December&#160;31, 2020, our operating leases have a weighted-average remaining lease term of 4.4 years and a weighted-average discount rate of 5.7%. Cash paid for amounts included in the measurement of operating lease liabilities was $2.6 million and $2.4&#160;million for the twelve months ended December&#160;31, 2021 and 2020, respectively. Operating lease expense was $2.6 million (net of sublease income of $0.4 million) and $2.1 million (net of sublease income of $0.3 million) for the twelve months ended December&#160;31, 2021 and 2020, respectively.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, our finance leases have a weighted-average remaining lease term of 7.0 years and a weighted-average discount rate of 3.0%. As of December&#160;31, 2020, our finance leases have a weighted-average remaining lease term of 7.9 years and a weighted-average discount rate of 3.5%. Cash paid for amounts included in the measurement of these finance lease liabilities was $9.3&#160;million and $9.7&#160;million for the twelve months ended December&#160;31, 2021 and 2020, respectively. Finance lease expense was $2.3 million and 0.2&#160;million for the twelve months ended December&#160;31, 2021 and 2020, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeFinanceLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for finance leases of lessee. Includes, but is not limited to, description of lessee's finance lease and maturity analysis of finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeFinanceLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140091803965608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Senior Notes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Convertible Senior Notes</a></td>
<td class="text">Convertible Senior Notes<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">0.75% Convertible Senior Notes due 2019</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2014, we issued $245.0 million aggregate principal amount of 2019 Notes, resulting in net proceeds of $239.3 million. The implied estimated effective rate of the liability component of the 2019 Notes was 5.83%. The 2019 Notes are convertible into common stock at an initial conversion rate of 13.3251 shares per $1,000 principal amount of convertible notes, subject to adjustment upon certain events, which is equivalent to an initial conversion price of approximately $75.05 per share of common stock. The notes bear cash interest at a rate of 0.75% per year, payable semi-annually. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Holders of the 2019 Notes may convert the notes at any time prior to the close of business on the business day immediately preceding May 15, 2019, under any of the following circumstances: </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) during any fiscal quarter (and only during such fiscal quarter) commencing after December&#160;31, 2014, if,</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for at least 20 trading days (whether or not consecutive) during the 30 consecutive trading day period ending on the last trading day of the immediately preceding fiscal quarter, the last reported sale price of our common stock on such trading day is greater than 130% of the conversion price on such trading day; </span></div><div style="padding-left:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2) during the five business day period immediately following any 10 consecutive trading day period, in which the trading price per $1,000 principal amount of notes was less than 98% of the product of the last reported sale price of our common stock on such trading day and the conversion rate on each such trading day; or </span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3) upon the occurrence of certain specified corporate events as specified in the indenture governing the notes. </span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 22, 2018, we entered into a supplemental indenture whereby we made an irrevocable election to settle the entire 2019 Notes in cash. As such, we would have been required to deliver cash to settle the principal and any premium due upon conversion. As a result of the requirement to deliver cash to settle any premium due upon conversion, on May 22, 2018, we reclassified from equity to liability the conversion option (a derivative) fair value of $341.6 million. In accordance with ASC 815, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivatives and Hedging</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the derivative was adjusted to its fair value as of December 31, 2018 to $23.4 million with the resulting $118.7 million increase, net of payments made, reflected in other expense, net, in our consolidated statements of operations for the year ended December 31, 2018.  </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">   </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">                                                                                                                               </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March and April 2018, we received notices for conversion of $21.8 million of principal amount of the 2019 Notes which were settled in May and June 2018. We paid the noteholders the conversion value of the notes in cash, up to the principal amount of the 2019 Notes. The excess of the conversion value over the principal amount, totaling $31.6 million, was paid in shares of common stock. In July and August 2018, we received notices for conversion of $195.9 million of principal amount of the 2019 Notes which were settled in October and November 2018. We paid the noteholders the $195.9 million principal amount and the excess of conversion value over the principal amount, totaling $439.6 million, in cash. The equity dilution and cash conversion premium payment upon conversion of the 2019 Notes was offset by the reacquisition of the shares and cash under the convertible bond hedge transactions entered into in connection with the offering of the 2019 Notes. As a result of the conversions, we recorded a $3.2 million loss on extinguishment of debt calculated as the difference between the estimated fair value of the debt and the carrying value of the 2019 Notes as of the settlement dates. To measure the fair value of the converted 2019 Notes as of the settlement dates, the applicable interest rates were estimated using Level 2 observable inputs and applied to the converted notes using the same methodology as in the issuance date valuation.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2019, we received notices for conversion of $1.0 million of principal amount of the 2019 Notes, which were settled in cash upon the 2019 Notes' maturity date in August 2019. As a result, we paid the noteholders (1) the $1.0 million principal amount, and (2) the excess of conversion value over the principal portion in an amount of $0.5 million in cash.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 15, 2019, the 2019 Notes maturity date, we paid the noteholders the remaining $26.3 million principal amount and $11.9 million bond premium, which was classified as a derivative liability, in cash. We recorded the decrease in fair value of the derivative liability of $11.0 million in other expense, net, in our consolidated statements of operations for the twelve months ended December 31, 2019.                                                             </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Convertible Bond Hedge and Warrant Transactions</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2014, we entered into convertible bond hedges and sold warrants covering 3,264,643 shares of our common stock to minimize the impact of potential dilution to our common stock and/or offset the cash payments we were required to make in excess of the principal amount upon conversion of the 2019 Notes. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The convertible bond hedges had an exercise price of $75.05 per share and are exercisable when and if the 2019 Notes were converted. If upon conversion of the 2019 Notes, the price of our common stock was above the exercise price of the convertible bond hedges, the counterparties would have delivered shares of common stock and/or cash with an aggregate value approximately equal to the difference between the price of common stock at the conversion date and the exercise price, multiplied by the number of shares of common stock related to the convertible bond hedge transaction being exercised. The convertible bond hedges and warrants described below were separate transactions entered into by us and were not part of the terms of the 2019 Notes. Holders of the 2019 Notes and warrants did not have any rights with respect to the convertible bond hedges.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of the irrevocable cash election, conversion notices received relating to the 2019 Notes after May 22, 2018 must be fully settled in cash and amounts paid in excess of the principal amount would be offset by an equal receipt of cash under the convertible bond hedge. Upon the 2019 Notes payoff on August 15, 2019, the bond hedge was settled, with the remaining $10.2 million fair value decrease reflected in other expense, net, in our consolidated statement of operations for the twelve months ended December 31, 2019.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Concurrently with the convertible bond hedge transactions, we entered into warrant transactions whereby we sold warrants to acquire 3,264,643 shares of common stock with an exercise price of $125.08 per share, subject to certain adjustments. The warrants had expired between November 13, 2019 and April 22, 2020. The warrants have a dilutive effect to the extent the market price per share of common stock exceeds the applicable exercise price of the warrants, as measured under the terms of the warrant transactions. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">0.75% Convertible Senior Notes due 2023</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2018, we issued $750 million aggregate principal amount of 2023 Notes, bearing cash interest at a rate of 0.75% per year, payable semi-annually. The net proceeds from the offering, after deducting the initial purchasers' discount and offering expenses, were approximately $733.1 million. The 2023 Notes will be convertible into cash, shares of common stock, or a combination of cash and shares of common stock, at our election, based on an initial conversion rate, subject to adjustment, of 4.0244 shares per $1,000 principal amount of the 2023 Notes which represents an initial conversion price of approximately $248.48 per share.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Holders of the 2023 Notes may convert the notes at any time prior to the close of business on the business day immediately preceding November 15, 2022, under any of the following circumstances:</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) during any fiscal quarter (and only during such fiscal quarter) commencing after September 30, 2018, if, for at least 20 trading days (whether or not consecutive) during the 30 consecutive trading day period ending on the last trading day of the immediately preceding fiscal quarter, the last reported sale price of our common stock on such trading day is greater than 130% of the conversion price on such trading day;</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2) during the five business day period immediately following any 10 consecutive trading day period, in which the trading price per $1,000 principal amount of notes was less than 98% of the product of the last reported sale price of our common stock on such trading day and the conversion rate on each such trading day; or</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3) upon the occurrence of certain specified corporate events as specified in the indenture governing the notes.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The notes will have a dilutive effect to the extent the average market price per share of common stock for a given reporting period exceeds the conversion price of $248.48. As of December&#160;31, 2021, the &#8220;if-converted value&#8221; did not exceed the principal amount of the 2023 Notes.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the issuance of the 2023 Notes, we incurred $16.9 million of issuance costs, which primarily consisted of underwriting, legal and other professional fees. The portion of these costs allocated to the liability component totaling $13.7 million is amortized to interest expense using the effective interest method over the five year expected life of the 2023 Notes.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is our intent and policy to settle conversions through combination settlement, which essentially involves payment in cash equal to the principal portion and delivery of shares of common stock for the excess of the conversion value over the principal portion.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">During 2020, we repurchased $254.7 million in principal of the 2023 Notes for $222.8 million in cash, including accrued interest of $0.6 million. We accounted for the repurchase as a debt extinguishment, which resulted (1) a loss of $2.5 million reflected in other expense, net, in our consolidated statement of operations for the year ended December&#160;31, 2020; (2) a $35.0 million reduction in debt discount, and (3) a $3.2 million reduction to additional paid-in-capital, net of tax, related to the reacquisition of the equity component in our condensed consolidated balance sheet as of December&#160;31, 2020. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2021, we repurchased $152.0&#160;million in principal of the 2023 Notes for $156.0&#160;million in cash, including accrued interest of $0.3&#160;million. We accounted for the repurchase as a debt extinguishment, which resulted in (1) a loss of $7.3&#160;million reflected in other expense, net, in our condensed consolidated statement of operations for the year ended December&#160;31, 2021, (2) a $13.7&#160;million reduction in debt discount, and (3) a $10.2&#160;million reduction to additional paid in capital, net of tax, related to the reacquisition of the equity component in our condensed consolidated balance sheet as of December&#160;31, 2021. After the repurchases, approximately $343.3 million in principal amount of the 2023 Notes remain outstanding. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During February 2022, we repurchased $125.5&#160;million in principal of the 2023 Notes for $123.9&#160;million in cash, including accrued interest of $0.3&#160;million. </span></div><div style="text-indent:27pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Convertible Bond Hedge and Warrant Transactions</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In conjunction with the 2023 Notes, in May 2018, we entered into convertible bond hedges and sold warrants covering 3,018,327 shares of our common stock to minimize the impact of potential dilution to our common stock and/or offset the cash payments we are required to make in excess of the principal amount upon conversion of the 2023 Notes. The convertible bond hedges have an exercise price of $248.48 per share and are exercisable when and if the 2023 Notes are converted. We paid $140.3 million for these convertible bond hedges. If upon conversion of the 2023 Notes, the price of our common stock is above the exercise price of the convertible bond hedges, the counterparties will deliver shares of common stock and/or cash with an aggregate value approximately equal to the difference between the price of common stock at the conversion date and the exercise price, multiplied by the number of shares of common stock related to the convertible bond hedge transaction being exercised. The convertible bond hedges and warrants described below are separate transactions entered into by us and are not part of the terms of the 2023 Notes. Holders of the 2023 Notes and warrants will not have any rights with respect to the convertible bond hedges.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Concurrently with the convertible bond hedge transactions, we entered into warrant transactions whereby we sold warrants covering 3,018,327 shares of common stock with an exercise price of $315.38 per share, subject to certain adjustments. We received $90.0 million for these warrants. The warrants have various expiration dates ranging from August 15, 2023 to </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">February 6, 2024. The warrants will have a dilutive effect to the extent the market price per share of common stock exceeds the applicable exercise price of the warrants, as measured under the terms of the warrant transactions. The common stock issuable upon exercise of the warrants will be in unregistered shares, and we do not have the obligation and do not intend to file any registration statement with the SEC registering the issuance of the shares under the warrants.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2020, in connection with the repurchases of $234.4&#160;million in principal of the 2023 Notes for $203.8&#160;million in cash, including accrued interest of $0.6&#160;million, during the quarter ended March 31, 2020, we entered into amendments with Barclays Bank PLC, Deutsche Bank AG, London Branch, and Goldman Sachs &amp; Co. LLC to the convertible note hedges transactions we initially entered into in connection with the issuance of the 2023 Notes. The amendments provide that the options under the convertible note hedges corresponding to such repurchased 2023 Notes will remain outstanding notwithstanding such repurchase.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In January 2021, in connection with the repurchases of approximately $20.3&#160;million in principal of the 2023 Notes for approximately $19.1&#160;million in cash, including accrued interest of $0.1&#160;million, during the quarter ended December 31, 2020, we entered into amendments with Barclays Bank PLC, Deutsche Bank AG, London Branch, and Goldman Sachs &amp; Co. LLC to the convertible note hedges transactions we initially entered into in connection with the issuance of the 2023 Notes. The amendments provide that the options under the convertible note hedges corresponding to such repurchased 2023 Notes will remain outstanding notwithstanding such repurchase.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2021, in connection with the repurchases of $152.0&#160;million in principal of the 2023 Notes for $156.0&#160;million in cash, including accrued interest of $0.3&#160;million, we entered into Warrant Early Unwind Agreements and Bond Hedge Unwind Agreements with Barclays Bank PLC, Deutsche Bank AG, and Goldman Sachs &amp; Co. LLC to unwind a portion of the convertible note hedges transactions we initially entered into in connection with the issuance of the 2023 Notes. We paid $18.4&#160;million as part of the Warrant Early Unwind Agreements reducing the number of shares covered by the warrants from 3,018,327 to 2,559,254. We received $18.9&#160;million as part of the Bond Hedge Early Unwind Agreements reducing the number of options under the convertible bond hedges to 598,021. These unwind transactions resulted in a $0.5&#160;million net increase in additional paid-in-capital in our condensed consolidated balance sheet as of December&#160;31, 2021.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes information about the equity and liability components of the 2023 Notes (in thousands).</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.683%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.499%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Principal amount of 2023 Notes outstanding</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">343,301&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">495,280&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized discount (including unamortized debt issuance cost)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22,584)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(52,987)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total long-term portion of notes payable</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">320,717&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">442,293&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying value of equity component of 2023 Notes</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,627&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,397&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of convertible senior notes outstanding (Level 2)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">341,801&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">466,053&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, there were no events of default or violation of any covenants under our financing obligations.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140091803821224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Account Details<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_OtherBalanceSheetDetailsAbstract', window );"><strong>Other Balance Sheet Details [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock', window );">Balance Sheet Account Details</a></td>
<td class="text">Balance Sheet Account DetailsShort-term Investments<div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Excluding our investments in Viking, the following table summarizes the various investment categories at December&#160;31, 2021 and 2020 (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.321%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.501%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross unrealized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">gains</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross unrealized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">losses</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">fair value</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mutual Fund</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">152,136&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(249)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">151,887&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bank deposits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,389&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,381&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,008&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,998&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,308&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(38)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,287&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,807&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">402&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,027)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,182&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,577&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,554&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">408&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">408&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">292,225&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">842&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,370)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">290,697&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Mutual fund</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">151,512&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">386&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">151,898&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Bank deposits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,120&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,154&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Commercial paper  </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,459&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,485&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Corporate bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,512&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,610&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Agency bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,499&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,501&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Corporate equity securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,466&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">360&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,388)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,438&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Treasury bills</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,999&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,999&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Warrants</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">393&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">393&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">324,567&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,302&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,391)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">324,478&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Gain (loss) from short-term investments on our consolidated statements of operations includes both realized and unrealized gain (loss) from our short-term investments in public equity and warrant securities, and realized gain (loss) from available-for-sale debt securities. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our available-for-sale debt securities by contractual maturity (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.976%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.498%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Within one year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111,334&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111,315&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">After one year through five years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,952&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,909&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">After five years</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136,286&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136,224&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our available-for-sale debt securities in an unrealized loss position (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:18.783%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.765%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.765%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.765%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.765%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.765%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.772%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Less than 12 months</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12 months or greater</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Estimated<br/>Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Estimated<br/>Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Estimated<br/>Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bank deposits</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,008&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,008&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,252&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,996&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,248&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,689&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,125&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(38)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,814&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Government Securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,553&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,553&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(34)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,949&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(60)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,674&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(94)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72,623&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">December 31, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bank deposits</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,013&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,013&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,526&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,526&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,693&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,693&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,232&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,232&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our investment policy is capital preservation and we only invested in U.S.-dollar denominated investments. We held a total of 55 positions which were in an unrealized loss position as of December&#160;31, 2021. We believe that we will collect the principal and interest due on our debt securities that have an amortized cost in excess of fair value. The unrealized losses are largely due to changes in interest rates and not to unfavorable changes in the credit quality associated with these securities that impacted our assessment on collectability of principal and interest. We do not intend to sell these securities nor do we believe that we will be required to sell these securities before the recovery of the amortized cost basis. Accordingly, no credit losses were recognized for the twelve months ended December&#160;31, 2021.</span></div><div><span><br/></span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and equipment are stated at cost and consists of the following (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.976%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.498%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lab and office equipment</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,183&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,666&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,983&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,519&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment and software</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,056&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1056&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,222&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,241&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,711)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,807)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,511&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,434&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation of equipment is computed using the straight-line method over the estimated useful lives of the assets which ranges from <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90ZXh0cmVnaW9uOjhkMWM4MjU1M2QwNzQ1ODVhMDJmY2U3NDA0ZGE4ZTE5XzIwODU_49dc7d90-487d-4145-93b5-5005d27536fa">three</span> to ten years. Leasehold improvements are amortized using the straight-line method over their estimated useful lives or their related lease term, whichever is shorter. Depreciation expense of $3.9 million, $1.8 million, and $1.5 million was recognized for the twelve months ended December&#160;31, 2021, 2020, and 2019, respectively, and was included in operating expenses.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill and identifiable intangible assets consist of the following (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.976%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.498%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indefinite-lived intangible assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Goodwill</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">181,206&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">189,662&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Definite-lived intangible assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Complete technology</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">280,617&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">277,740&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Less: Accumulated amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(78,991)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(63,600)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Trade name</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,642&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,642&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Less: Accumulated amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,444)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,312)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Customer relationships</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,700&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,700&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Less: Accumulated amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18,267)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,597)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Contractual relationships</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">362,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">362,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Accumulated amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(36,217)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,243)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total goodwill and other identifiable intangible assets, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">732,246&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">784,992&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-indent:24pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization of finite-lived intangible assets is computed using the straight-line method over the estimated useful life of the asset of up to 20 years. Amortization expense of $47.2 million, $23.4 million, and $16.9 million was recognized for the years ended December&#160;31, 2021, 2020, and 2019, respectively. Estimated amortization expense for the years ending December&#160;31, 2022 through 2026 is $47.0 million per year. For each of the years ended December&#160;31, 2021, 2021, and 2019, there was no material impairment of intangible assets with finite lives.</span></div><div style="text-indent:24pt"><span><br/></span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accrued liabilities consist of the following (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.976%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.498%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Compensation</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,532&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,810&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Professional fees</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,046&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">977&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts owed to former licensees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">630&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">421&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalties owed to third parties</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">149&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">693&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Return reserve and customer refunds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,420&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">687&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition related liabilities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,500&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Subcontractor</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,759&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">733&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Supplier</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">848&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">604&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,195&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,105&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,579&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,530&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingent liabilities:</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the acquisition of Crystal in October 2017, we entered into contingent liabilities based on achievement of certain research and business milestones as well as certain revenue goal.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the acquisition of CyDex in January 2011, we issued a series of CVRs and also assumed certain contingent liabilities. We may be required to make additional payments upon achievement of certain clinical and regulatory milestones to the CyDex shareholders and former license holders.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the acquisition of Metabasis in January 2010, we entered into four CVR agreements with Metabasis shareholders. The CVRs entitle the holders to cash payments as frequently as every six months as proceeds are received by us upon the sale or licensing of any of the Metabasis drug development programs and upon the achievement of specified milestones.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For CVRs associated with the Pfenex and Icagen acquisitions, see &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note (4), Acquisitions</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; for more information.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes roll-forward of contingent liabilities as of December 2021 and 2020 (in thousands):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:6.356%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.110%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.964%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.110%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.110%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.110%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:7.525%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.110%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.115%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2019</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Additional Contingent Liabilities</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Payments</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair Value Adjustment</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Repurchases</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Payments</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair Value Adjustment</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Repurchases</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cydex</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">348&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">160&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">508&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(50)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(108)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">350&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Metabasis</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,935&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,867)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(247)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,821&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(464)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,357&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Crystal</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,659&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,800)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(59)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">800&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(800)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Icagen</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,800&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(525)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,129&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,404&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,050)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,010&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,364&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pfenex</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">37,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">600&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">37,600&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(37,600)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">xCella</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(720)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">720&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">8,942</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">41,800</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(2,325)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">963</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(247)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">49,133</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(1,820)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(36,242)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">11,071</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_OtherBalanceSheetDetailsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other Balance Sheet Details [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_OtherBalanceSheetDetailsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -URI http://asc.fasb.org/topic&amp;trid=2122208<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalBalanceSheetDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140091803793464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity</a></td>
<td class="text">Stockholders&#8217; Equity<div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share-based Compensation Expense</span></div><div><span><br/></span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes non-cash share-based compensation expense (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:64.002%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.043%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.043%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.046%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation expense as a component of:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expenses</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,436&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,497&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,641&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,347&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,230&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,874&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,783&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,727&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,515&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Plans</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2020, our 2002 Stock Incentive Plan was amended to increase the number of shares available for issuance by 1.1 million shares. As of December&#160;31, 2021, there were 0.7 million shares available for future option grants or direct issuance under the Amended 2002 Plan.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following is a summary of our stock option plan activity and related information:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"/><td style="width:49.120%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.976%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.976%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.976%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.244%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exercise</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Price</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Remaining</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contractual</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Term in</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Intrinsic</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Value</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at January&#160;1, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,736,304&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66.71&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.47</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125,858&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">338,617&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116.69&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(112,011)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.65&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,531)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139.37&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,956,379&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77.54&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.45</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72,002&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at December&#160;31, 2019</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,454,726&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61.82&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.42</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,345&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options vested and expected to vest as of December&#160;31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,956,379&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77.54&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.45</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72,002&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">806,300&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92.93&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(156,845)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.26&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(44,012)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91.30&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,561,822&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85.59&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.09</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,033&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at December&#160;31, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,611,830&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76.05&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.54</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,286&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options vested and expected to vest as of December&#160;31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,561,822&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85.59&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.09</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,033&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">393,589&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159.12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(619,731)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54.28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(136,082)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110.83&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2021 </span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,199,598&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.34</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113,302&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at December&#160;31, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,391,952&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98.16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.12</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,849&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options vested and expected to vest as of December&#160;31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,199,598&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.34</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113,302&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-indent:24pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average grant-date fair value of all stock options granted during 2021, 2020 and 2019 was $80.08, $41.39 and $48.65 per share, respectively. The total intrinsic value of all options exercised during 2021, 2020 and 2019 was approximately $77.3 million, $11.9 million and $10.4 million, respectively. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash received from options exercised, net of fees paid, in 2021, 2020 and 2019 was $33.0 million, $2.5 million and $2.6 million, respectively. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following is a further breakdown of the options outstanding as of December&#160;31, 2021:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:30.040%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.057%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.057%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.057%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.057%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.212%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Range of exercise prices</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Options</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">outstanding</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">remaining&#160; life</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">in&#160;years</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted&#160;average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">exercise price</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Options</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">exercisable</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted&#160;average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">exercise&#160;price</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$12.53-$56.26</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">253,824&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.94</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37.55&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">239,824&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38.90&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$67.53-$74.42</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">278,281&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.04</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72.10&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">217,587&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73.17&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$82.90-$95.35</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159,988&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.06</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86.11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132,963&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86.24&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$95.68</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">266,263&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.12</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95.68&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109,154&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95.68&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$98.20-$100.38</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">294,772&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.33</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">160,120&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.79&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$101.07-$117.58</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159,204&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.45</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111.26&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99,488&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111.18&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$117.97</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">237,292&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.12</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117.97&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">158,958&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117.97&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$119.08-$159.01</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">299,585&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.00</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">149.40&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">205,098&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">152.50&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$159.81-$171.28</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,881&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.51</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">166.28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,828&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">165.62&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$177.50-$195.91</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">243,508&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.91</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178.62&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,932&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">181.84&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,199,598&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.34</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,391,952&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98.16&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The assumptions used for the specified reporting periods and the resulting estimates of weighted-average grant date fair value per share of options granted:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.538%"><tr><td style="width:1.0%"/><td style="width:52.609%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.440%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.986%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.440%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.541%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.440%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="18" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4%-1.2%</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2%-1.4%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4%-2.6%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47%-63%</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47%-71%</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40%-49%</span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.7 to 6.3 years</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.7 to 5.1 years</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.6 to 5.9 years</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-indent:27pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, there was $40.7 million of total unrecognized compensation cost related to non-vested stock options.  That cost is expected to be recognized over a weighted average period of 2.4 years.</span></div><div style="margin-top:14pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock Activity</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of our restricted stock activity and related information:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:69.929%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.458%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.578%"/><td style="width:0.1%"/></tr><tr style="height:15pt"><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Grant&#160;Date Fair</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Value</span></div></td></tr><tr style="height:12pt"><td colspan="12" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at January 1, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132,273&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130.63&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118,498&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115.90&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(102,846)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121.55&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(666)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">134.36&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December&#160;31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">147,259&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125.11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111,306&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89.73&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(52,363)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121.69&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December&#160;31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">206,202&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106.88&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">167,292&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">169.63&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(98,501)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125.59&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,850)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">141.85&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December&#160;31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">264,143&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">138.21&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, unrecognized compensation cost related to non-vested stock awards amounted to $20.6&#160;million. That cost is expected to be recognized over a weighted average period of 1.6 years.</span></div><div style="text-indent:24pt"><span><br/></span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Employee Stock Purchase Plan</span></div><div style="text-indent:24pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, 44,360 shares of our common stock are available for future issuance under the Amended Employee Stock Purchase Plan, or ESPP. The ESPP permits eligible employees to purchase up to 1,250 shares of Ligand common stock per calendar year at a discount through payroll deductions. The price at which stock is purchased under the ESPP is equal to 85% of the fair market value of the common stock on the first of a six month offering period or purchase date, whichever is lower. There were 8,448, 6,455 and 4,745 shares issued under the ESPP in 2021, 2020 and 2019, respectively. </span></div><div style="text-indent:24pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share Repurchases </span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 11, 2019, our Board of Directors approved a stock repurchase program authorizing the repurchase of up to $500.0 million of our common stock from time to time over the next three years. We expect to acquire shares primarily through open-market transactions and have entered into a Rule 10b5-1 trading plan, and may enter into additional Rule 10b5-1 trading plans in the future, to facilitate open-market repurchases. The timing and amount of repurchase transactions will be determined by management based on our evaluation of market conditions, share price, legal requirements and other factors. Our prior $350.0 million stock repurchase program was terminated in connection with the approval of the new stock repurchase program. Authorization to repurchase $248.8 million of our common stock remained available as of December&#160;31, 2021.</span></div>During the twelve months ended December&#160;31, 2021, we did not repurchase any common stock. During the twelve months ended December&#160;31, 2020 and 2019, we repurchased 934,079 shares for $78.0 million, and 4,122,133 shares for $448.4 million, respectively.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140091803826472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitment and Contingencies: Legal Proceedings<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitment and Contingencies: Legal Proceedings</a></td>
<td class="text">Commitment and Contingencies: Legal Proceedings<div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record an estimate of a loss when the loss is considered probable and estimable. Where a liability is probable and there is a range of estimated loss and no amount in the range is more likely than any other number in the range, we record the minimum estimated liability related to the claim in accordance with </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASC 450,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Contingencies</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. As additional information becomes available, we assess the potential liability related to our pending litigation and revises our estimates. Revisions in our estimates of potential liability could materially impact our results of operations.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 9, 2019, CyDex, our wholly-owned subsidiary, received a Paragraph IV certification Notice Letter from Alembic Global Holdings SA (&#8220;Alembic&#8221;) stating that Alembic had submitted an ANDA to the FDA, seeking approval to manufacture, offer to sell, and sell a generic version of EVOMELA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> prior to the expiration of any of the &#8217;077 patent; the &#8217;088 patent, the &#8217;582 patent, or U.S. Patent No. 10,040,872 (&#8220;the &#8217;872 patent&#8221;), and alleging that these patents, each of which relates to Captisol, are invalid, unenforceable, and/or would not be infringed by Alembic&#8217;s ANDA product. On May 23, 2019, CyDex filed a complaint against Alembic, Alembic Pharmaceuticals, Ltd., and Alembic Pharmaceuticals, Inc. in the U.S. District Court for the District of Delaware, asserting that the filing of Alembic&#8217;s ANDA constitutes infringement of each of the &#8217;088 patent and the &#8217;582 patent. The parties entered into a settlement agreement on June 1, 2021 and the lawsuit has been dismissed.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 16, 2019, CyDex received a Paragraph IV certification Notice Letter from Lupin Ltd. (&#8220;Lupin&#8221;) stating that Lupin had submitted an ANDA to the FDA, seeking approval to manufacture, offer to sell, and sell a generic version of EVOMELA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> prior to the expiration of any of the &#8217;077 patent; the &#8217;088 patent, the &#8217;582 patent, or the &#8217;872 patent, and alleging that these patents, each of which relates to Captisol, are invalid, unenforceable, and/or would not be infringed by Lupin&#8217;s ANDA product. CyDex filed a complaint on October 29, 2019, alleging patent infringement against Lupin. Lupin filed an answer on December 11, 2019 and counterclaimed for declaratory judgments of invalidity and non-infringement as to all four patents and CyDex filed its answer to Lupin&#8217;s counterclaims on January 2, 2020. The parties entered into a settlement agreement on April 26, 2021 and the lawsuit has been dismissed.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 31, 2019, we received three civil complaints filed in the U.S. District Court for the Northern District of Ohio on behalf of several Indian tribes. The Northern District of Ohio is the Court that the Judicial Panel on Multi-District Litigation (&#8220;JPML&#8221;) has assigned more than one thousand civil cases which have been designated as a Multi-District Litigation (&#8220;MDL&#8221;) and captioned In Re: National Prescription Opiate Litigation. The allegations in these complaints focus on the activities of defendants other than the company and no individualized factual allegations have been advanced against us in any of the three complaints. We reject all claims raised in the complaints and intend to vigorously defend these matters.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 12, 2021, Abvivo submitted a JAMS arbitration demand naming the Company as respondent. Abvivo claimed that the Company was in violation of the assignment provision of that certain Commercial Platform License and Services Agreement (&#8220;CPLSA&#8221;), dated October 9, 2019, by and among OMT and Crystal, on the one hand, and Abvivo, on the other hand because the Company allegedly withheld its consent to a proposed assignment required for Abvivo to negotiate a discovery and development alliance with certain third parties. On January 26, 2021, we submitted a response to the demand, denying all claims and alleging counterclaims against Abvivo and Brian Lundstrom, a Company employee and the sole owner of Abvivo. We alleged that Mr. Lundstrom breached his fiduciary duty of loyalty to the Company and that Abvivo and Mr. Lundstrom fraudulently induced the Company, OMT and Crystal into certain business transactions and contracts. Abvivo and Mr. Lundstrom&#8217;s response to these counterclaims was due on February 9, 2021, but they did not submit a response. Under JAMS rules, the counterclaims were deemed denied. On February 22, 2021, Abvivo submitted documents to JAMS which indicated that it sought to dismiss its claim without prejudice. On February 25, 2021, we submitted additional counterclaims against Abvivo and Mr. Lundstrom.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These counterclaims alleged that Abvivo and Mr. Lundstrom made false promises regarding the CPLSA, Abvivo&#8217;s breach of and failure to perform under the CPLSA, and Abvivo&#8217;s infringement of certain Ligand trademarks.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 11, 2021, Abvivo and Mr. Lundstrom submitted an answer to our amended counterclaims denying all of the claims and asserting various affirmative defenses. On June 21, 2021, the parties executed a confidential settlement agreement that settled all claims in this arbitration.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 29, 2021, the parties jointly submitted to JAMS a dismissal with prejudice of all claims by all parties in the arbitration.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CyDex and Baxter Healthcare Corp. (&#8220;Baxter&#8221;) are parties to a license agreement relating to Ligand&#8217;s Captisol</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">technology and, more specifically, relating to Captisol-enabled Nexterone (amiodarone HCl premixed injection). Baxter contends that it has </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">overpaid royalties for several years, and seeks both refunds of those overpayment and a reduced royalty going forward. CyDex contends that Baxter has not paid the royalties due to CyDex under the terms of the license agreement. On April 6, 2021, Baxter initiated an arbitration with the American Arbitration Association pursuant to the arbitration provision of the license agreement. On April 21, 2021, CyDex filed an Answering Statement and Counterdemand. On May 5, 2021, Baxter filed an Answering Statement in response to CyDex&#8217;s Counterdemand. On June 30, 2021, the parties held a Preliminary Hearing before the arbitrator. The parties have completed fact discovery and have exchanged expert witness statements; depositions of the expert witnesses will be completed by the end of March 2022. The arbitration hearing is currently scheduled for May 2022.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we may also become subject to other legal proceedings or claims arising in the ordinary course of our business. We currently believe that none of the claims or actions pending against us is likely to have, individually or in the aggregate, a material adverse effect on our business, financial condition or results of operations. Given the unpredictability inherent in litigation, however, we cannot predict the outcome of these matters.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140091803872488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">Income Taxes<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of the income tax expense (benefit) for continuing operations are as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"/><td style="width:66.403%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.092%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.833%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.092%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.686%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.094%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current expense (benefit):</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,190)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,889&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89,471&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">589&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,103&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(66)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,222)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,501&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92,508&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred expense (benefit):</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,355)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,672)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74,627&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,263)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,382)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">202&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,618)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19,054)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74,829&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total income tax expense (benefit)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,840)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,553)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">167,337&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-indent:24pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of income tax expense (benefit) from continuing operations to the amount computed by applying the statutory federal income tax rate to the net income (loss) from continuing operations is summarized as follows (in thousands):</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:66.841%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.047%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.047%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.682%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.048%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax at federal statutory rate</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,932&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,213)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">167,294&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State, net of federal benefit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(408)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,456)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,466&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,161)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(278)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,919)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(362)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(819)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">FDII</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(637)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,652)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(402)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,692)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(699)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(879)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in uncertain tax positions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">586&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(650)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">441&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rate change for changes in federal, foreign or state law</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,963)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(173)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(210)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision to return adjustments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(617)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,803)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(184)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign tax differential on income/loss of foreign subsidiaries</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(114)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,839)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,410&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(121,876)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,193)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sale of Vernalis R&amp;D</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127,372&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">743&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,076&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">748&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,840)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,553)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">167,337&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We remeasured certain deferred tax assets and liabilities based on the rates at which they are expected to reverse in the future, which is generally 21%. Significant components of our deferred tax assets and liabilities as of December&#160;31, 2021 and 2020 are shown below. We assess the positive and negative evidence to determine if sufficient future taxable income will be generated to </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">use the existing deferred tax assets. Our evaluation of evidence resulted in management concluding that the majority of our deferred tax assets will be realized. However, we maintain a valuation allowance to offset certain net deferred tax assets as management believes realization of such assets are uncertain as of December&#160;31, 2021, 2020 and 2019. The valuation allowance increased $11.4 million in 2021, decreased $116.5 million in 2020 and increased $136.9 million in 2019.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We offset all deferred tax assets and liabilities by jurisdiction, as well as any related valuation allowance, and present them on our consolidated balance sheet as a non-current deferred income tax asset or liability (as applicable). Deferred tax assets (liabilities) are comprised of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.807%"><tr><td style="width:1.0%"/><td style="width:76.478%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.662%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.547%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.813%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating loss carryforwards</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,352&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,147&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research credit carryforwards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,797&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,623&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,374&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,994&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,668&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,120&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123,191&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108,884&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance for deferred tax assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(36,283)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24,858)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86,908&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,026&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:13pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Identified intangibles</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(102,221)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(119,381)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,300)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,923)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax liabilities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(111,521)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(124,304)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:13pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income taxes, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24,613)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40,278)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, we had federal net operating loss carryforwards set to expire through 2037 of $119.6 million and $176.3 million of state net operating loss carryforwards that begin to expire in 2032. We also have $9.8 million of federal research and development credit carryforwards, which expire through 2041. We have $29.7 million of California research and development credit carryforwards that have no expiration date. In addition, we have approximately $101.6 million of non-U.S. net operating loss carryovers and approximately $17.5 million of non-U.S. capital loss carryovers that have no expiration date. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December 31, 2020 we had approximately $110.1&#160;million of non-U.S. net operating loss carryovers and approximately $17.6&#160;million of non-U.S. capital loss carryovers. We have a full valuation allowance against these non-U.S. tax attributes. The year over year decrease in non-U.S. deferred tax assets was attributable to the sale of Vernalis in December 2020. The remaining non-U.S. deferred tax assets as of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2021 were</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> attributable to the portion of the Vernalis business that we did not sell. We have a full valuation allowance against these non-U.S. tax attributes. See detail in &#8220;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note (2), Sale of Vernalis R&amp;D and Promacta License</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">  &#160;&#160; </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to Section 382 and 383 of the Internal Revenue Code of 1986, as amended, utilization of our net operating losses and credits may be subject to annual limitations in the event of any significant future changes in its ownership structure. These annual limitations may result in the expiration of net operating losses and credits prior to utilization. The deferred tax assets as of December&#160;31, 2021 are net of any previous limitations due to Section 382 and 383.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for income taxes by evaluating a probability threshold that a tax position must meet before a financial statement benefit is recognized. The minimum threshold is a tax position that is more likely than not to be sustained upon examination by the applicable taxing authority, including resolution of any related appeals or litigation processes, based on the technical merits of the position. Our remaining liabilities for uncertain tax positions are presented net of the deferred tax asset balances on the accompanying consolidated balance sheet.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the amount of unrecognized tax benefits at December&#160;31, 2021, 2020 and 2019 is as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.807%"><tr><td style="width:1.0%"/><td style="width:66.613%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.064%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.547%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.064%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.547%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.365%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at beginning of year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,871&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,736&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,289&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Additions based on tax positions related to the current year</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">252&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,911&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">543&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Additions for tax positions of prior years</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">945&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">179&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Reductions for tax positions of prior years</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,072)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(955)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,096)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at end of year</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,996&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,871&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,736&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-indent:24pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Included in the balance of unrecognized tax benefits at December&#160;31, 2021 is $28.1 million of tax benefits that, if recognized would impact the effective rate. There are no positions for which it is reasonably possible that the uncertain tax benefit will significantly increase or decrease within twelve months.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize interest and penalties related to uncertain tax positions in income tax expense. As of December&#160;31, 2021 and December&#160;31, 2020, we recognized an immaterial amount of interest and penalties. We file income tax returns in the United States, various state jurisdictions, United Kingdom, and Canada with varying statutes of limitations. The federal statute of limitation remains open for the 2018 tax year to the present.&#160;The state income tax returns generally remain open for the 2017 tax year through the present.&#160;Net operating loss and research credit carryforwards arising prior to these years are also open to examination if and when utilized. No tax returns are currently under examination by any tax authorities. We believe our reserve for unrecognized tax benefits and contingent tax issues is adequate with respect to all open years.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140091801798312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Principles of Consolidation</span></div><div style="text-indent:24pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying consolidated financial statements include Ligand and its wholly-owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our consolidated financial statements have been prepared in accordance with U.S. GAAP and include the accounts of our parent company and its wholly-owned subsidiaries. All intercompany transactions and balances have been eliminated in consolidation.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="text-indent:24pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of consolidated financial statements in conformity with U.S. GAAP requires the use of estimates and assumptions that affect the amounts reported in the consolidated financial statements and the accompanying notes. Actual results may differ from those estimates.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentrations of Business Risk</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentrations of Business Risk</span></div><div style="text-indent:24pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject us to significant concentrations of credit risk consist primarily of cash equivalents and investments. We invest excess cash principally in United States government debt securities, investment grade corporate debt securities, mutual funds and certificates of deposit. We maintain some cash and cash equivalents balances with financial institutions that are in excess of the Federal Deposit Insurance Corporation insurance limits. We have established guidelines relative to diversification and maturities that maintain safety and liquidity. These guidelines are periodically reviewed and modified to take advantage of trends in yields and interest rates.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_CashCashEquivalentsandShorttermInvestmentsPolicyTextBlock', window );">Cash Equivalents &amp; Short-term Investments</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Equivalents </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Cash equivalents consist of highly liquid investments with maturities of three months or less from the date of acquisition. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Short-term Investments</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Short-term investments primarily consist of investments in debt and equity securities. We classify our short-term investments as &#8220;available-for-sale&#8221;. Such investments are carried at fair value, with unrealized gains and losses on debt securities included in the statement of comprehensive income (loss), net of tax, and unrealized gains and losses on equity securities included the consolidated statement of operations. We determine the cost of investments based on the specific identification method. We determine the realized gains or losses on the sale of available-for-sale securities using the specific identification method and includes net realized gains and losses as a component of other income or expense within the consolidated statements of operations.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Debt securities consist of certificates of deposit, corporate debt securities, and securities of government-sponsored entities have effective maturities greater than&#160;three&#160;months and less than twelve months from the date of acquisition. Debt securities securities available-for-sale in an unrealized loss position are assessed for the current expected credit losses methodology. We start by assessing whether we intend to sell the security, or whether it is more likely than not that we will be required to sell the security before recovery of its amortized cost basis. If either of the criteria regarding intent or requirement to sell is met, the security&#8217;s amortized cost basis is written down to fair value through earnings. For debt securities available-for-sale that do not meet the aforementioned criteria, we evaluate whether the decline in fair value has resulted from credit losses or other factors. In making this assessment, we consider the extent to which fair value is less than amortized cost, any changes in interest rates, and any changes to the rating of the security by a rating agency, among other factors. If this assessment indicates that a credit loss exists, the present value of cash flows expected to be collected from the security is compared to the amortized cost basis of the security. If the present value of cash flows expected to be collected is less than the amortized cost basis, a credit loss exists and an allowance for credit losses is recorded, limited by the amount that the fair value is less than the amortized cost basis. Any impairment that has not been recorded through an allowance for credit losses is recognized in other comprehensive income or loss, as applicable.</span></div>Equity securities are mutual funds, investments in privately held companies (non-marketable equity securities), and companies that have completed initial public offerings (marketable equity securities). Mutual funds are valued at their publicly quoted net asset value (NAV) price on the last day of the period. Our non-marketable equity securities without readily determinable market values are initially measured at cost and adjusted to fair value for observable transactions for identical or similar investments of the same issuer or impairment. Our marketable equity securities are measured at fair value. Equity investments are classified as short-term investments, or non-current other assets, based on the nature of the securities and their availability for use in current operations.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy', window );">Accounts Receivable</a></td>
<td class="text">Accounts Receivable Our accounts receivable arise primarily from sales on credit to customers. We establish an allowance for credit losses to present the net amount of accounts receivable expected to be collected. The allowance is determined by using the loss-rate method, which requires an estimation of loss rates based upon historical loss experience adjusted for factors that are relevant to determining the expected collectability of accounts receivable. Some of these factors include macroeconomic conditions that correlate with historical loss experience, delinquency trends, aging behavior of receivables and credit and liquidity quality indicators for industry groups, customer classes or individual customers.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventory</a></td>
<td class="text">InventoryInventory, which consists of finished goods, is stated at the lower of cost or net realizable value. We determine cost using the first-in, first-out method or the specific identification method. We analyze our inventory levels periodically and write down inventory to net realizable value if it has become obsolete, has a cost basis in excess of its expected net realizable value or is in excess of expected requirements.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text"><div style="margin-top:14pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment are stated at cost, subject to review for impairment, and depreciated over the estimated useful lives of the assets, which generally range from <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RleHRyZWdpb246MDE1MzU3NWExNzUxNDlhMGJlMjM2NzA3MzMyMzJiNjlfNjcyNw_c91288e2-cf87-4740-a1f7-845dfc930514">three</span> to ten years, using the straight-line method. Amortization of leasehold improvements is recorded over the shorter of the lease term or estimated useful life of the related asset. Maintenance and repairs are charged to operations as incurred. When assets are sold, or otherwise disposed of, the cost and related accumulated depreciation are removed from the accounts and any gain or loss is included in operating income or expense.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsPolicy', window );">Acquisitions</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Acquisitions</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We first determine whether a set of assets acquired constitute a business and should be accounted for as a business combination. If the assets acquired are not a business, we account for the transaction as an asset acquisition. Business combinations are accounted for by using the acquisition method of accounting which requires us to use significant estimates and assumptions, especially with respect to intangible assets. We record the excess consideration over the aggregate fair value of tangible and intangible assets, net of liabilities assumed, as goodwill.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the acquisition method of accounting, we recognize separately from goodwill the identifiable assets acquired, the liabilities assumed, including contingent consideration and all contractual contingencies, generally at the acquisition date fair value. Contingent purchase consideration to be settled in cash are remeasured to estimated fair value at each reporting period with the change in fair value recorded in statement of operations. Costs that we incur to complete the business combination such as investment banking, legal and other professional fees are not considered part of consideration and we charge them to general and administrative expense as they are incurred. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Should the initial accounting for a business combination be incomplete by the end of a reporting period that falls within the measurement period, we report provisional amounts in our financial statements. During the measurement period, we adjust the provisional amounts recognized at the acquisition date to reflect new information obtained about facts and circumstances that existed as of the acquisition date that, if known, would have affected the measurement of the amounts recognized as of that date and we record those adjustments to our financial statements in the period of change, if any.</span></div>Under the acquisition method of accounting for business combinations, if we identify changes to acquired deferred tax asset valuation allowances or liabilities related to uncertain tax positions during the measurement period and they relate to new information obtained about facts and circumstances that existed as of the acquisition date, those changes are considered a measurement period adjustment and we record the offset to goodwill. We record all other changes to deferred tax asset valuation allowances and liabilities related to uncertain tax positions in current period income tax expense.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy', window );">Goodwill, Intangible Assets and Other Long-Lived Assets</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill, Intangible Assets and Other Long-Lived Assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill, which has an indefinite useful life, represents the excess of cost over fair value of net assets acquired. Goodwill is reviewed for impairment at least annually during the fourth quarter, or more frequently if an event occurs indicating the potential for impairment. During the goodwill impairment review, we assess qualitative factors to determine whether it is more likely than not that the fair value of our reporting unit is less than the carrying amount, including goodwill. We operate in one reporting unit. The qualitative factors include, but are not limited to, macroeconomic conditions, industry and market considerations, and the overall financial performance. If, after assessing the totality of these qualitative factors, we determine that it is not more likely than not that the fair value of our reporting unit is less than the carrying amount, then no additional assessment is deemed necessary. Otherwise, we proceed to perform the quantitative assessment. We will then evaluate goodwill for impairment by comparing the estimated fair value of the reporting unit to its carrying value, including the associated goodwill. To determine the fair value, we generally use a combination of market approach based on Ligand and comparable publicly traded companies in similar lines of businesses and the income approach based on estimated discounted future cash flows. Our cash flow assumptions consider historical and forecasted revenue, operating costs and other relevant factors. We may also elect to bypass the qualitative assessment in a period and elect to proceed to perform the quantitative assessment for the goodwill impairment test. We performed the annual assessment for goodwill impairment during the fourth quarter of 2021, noting no impairment. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our identifiable intangible assets are typically composed of acquired core technologies, licensed technologies, contractual relationships, customer relationships and trade names. The cost of identifiable intangible assets with finite lives is generally amortized on a straight-line basis over the assets&#8217; respective estimated useful lives. We regularly perform reviews to determine if any event has occurred that may indicate that intangible assets with finite useful lives and other long-lived assets are potentially impaired. If indicators of impairment exist, an impairment test is performed to assess the recoverability of the affected assets by determining whether the carrying amount of such assets exceeds the undiscounted expected future cash flows. If the affected assets are not recoverable, we estimate the fair value of the assets and record an impairment loss if the carrying value of the assets exceeds the fair value. Factors that may indicate potential impairment include market conditions, industry and economic trends, changes in regulations, clinical success, historical and forecasted financial results, market capitalization, significant changes in the ability of a particular asset to generate positive cash flows, and the pattern of utilization of a particular asset. We did not identify indicators of impairment for the finite-lived intangibles at December&#160;31, 2021.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_CommercialLicenseRightsPolicyTextBlock', window );">Commercial license and other economic rights</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Commercial license and other economic rights</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021 and 2020, commercial license and other economic rights consist of the following (in thousands):</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:24.338%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.607%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Adjustments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Adjustments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Aziyo and CorMatrix</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17,696&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(9,461)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,235&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17,696&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(9,588)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,108&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Selexis and Dianomi</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,602&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(8,727)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,875&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,602&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(7,731)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,871&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28,298&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(18,188)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,110&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28,298&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(17,319)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,979&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%">(1) Amounts represent accumulated amortization to principal of $11.7 million and credit loss adjustments of $6.5 million as of December 31, 2021. </span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%">(2) Amounts represent accumulated amortization to principal of $11.3 million and credit loss adjustments of $6.0 million as of December 31, 2020. </span></div><div style="padding-left:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commercial license and other economic rights as of December&#160;31, 2021 represent a portfolio of future milestone and royalty payment rights acquired from Selexis in April 2013 and April 2015, CorMatrix in May 2016, and Dianomi in January 2019. Commercial license rights acquired are accounted for as financial assets, and other economic rights are accounted for as funded research and developments as further discussed below. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2019, we entered into a development funding and royalties agreement with Novan, pursuant to which we would receive certain payments at specified milestones, as well as royalties on any future net sales of SB206, a product candidate being developed to treat molluscum contagiosum, and any other Novan products used for the treatment of molluscum (&#8220;Novan Molluscum Products&#8221;). We paid Novan an upfront payment of $12.0 million, which Novan is required to use to fund the development of SB206. We are not obligated to provide additional funding to Novan for the development or commercialization </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of SB206. Pursuant to the agreement, we would receive up to $20.0 million of milestone payments upon the achievement by Novan of certain regulatory milestones for SB206 or any other Novan Molluscum Product and commercial milestones. In addition to the milestone payments, Novan will pay us tiered royalties from 7.0% to 10.0% based on aggregate annual net sales of SB206 or any other Novan Molluscum Product in North America. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2018, we entered into a development funding and royalties agreement with Palvella. Pursuant to the agreement, we will receive up to $8.0 million of milestone payments upon the achievement by Palvella of certain corporate, financing and regulatory milestones for PTX-022, a product candidate being developed to treat pachyonychia congenita. In addition to the milestone payments, Palvella will pay us tiered royalties from 5.0% to 9.8% based on aggregate annual worldwide net sales of any PTX-022 products, if approved, subject to Palvella&#8217;s right to reduce the royalty rates by making payments in certain circumstances. We made an upfront payment of $10.0 million, which Palvella is required to use to fund the development of PTX-022. We are not obligated to provide additional funding to Palvella for development or commercialization of PTX-022. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determined the economic rights related to Novan and Palvella should be characterized as a funded research and development arrangement, thus we account for them in accordance with ASC 730-20, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Arrangement, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and reduce our asset as the funds are expended by Novan and Palvella. As of December 31, 2019, Novan had used up the $12.0 million upfront payment provided by us. As such, our other economic rights related to Novan had been fully amortized as of December 31, 2019. As of December 31, 2020, the fund has been fully expended by Palvella and our cost basis for the asset has been reduced to zero, and therefore we will recognize milestones and royalties as revenue when earned. During 2020, we recorded a $3.0 million milestone from Palvella under contract revenue, which has been included in our consolidated statement of operations for the year ended December&#160;31, 2020.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2017, we entered into a royalty agreement with Aziyo pursuant to which we will receive royalties from certain marketed products that Aziyo acquired from CorMatrix. Pursuant to the agreement, we received $10.0 million in 2017 from Aziyo to buydown the royalty rates on the products CorMatrix sold to Aziyo. The agreement closed on May 31, 2017, in connection with the closing of the asset sale from CorMatrix to Aziyo (the &#8220;CorMatrix Asset Sale&#8221;). Per the agreement, we will receive a 5% royalty on the products Aziyo acquired in the CorMatrix Asset Sale, reduced from the original 20% royalty from CorMatrix pursuant to the previously disclosed interest purchase agreement, dated May 3, 2016 (the &#8220;Original Interest Purchase Agreement&#8221;) between CorMatrix and us. In addition, Aziyo has agreed to pay us up to $10.0 million of additional milestones tied to cumulative net sales of the products Aziyo acquired in the CorMatrix Asset Sale and to extend the term on these royalties by one year. The royalty agreement will terminate on May 31, 2027. In addition, in May 2017, we entered into an amended and restated interest purchase agreement (the &#8220;Amended Interest Purchase Agreement&#8221;) with CorMatrix, which supersedes in its entirety the Original Interest Purchase Agreement. Other than removing the commercial products sold to Aziyo in the CorMatrix Sale, the terms of the Amended Interest Purchase Agreement remain unchanged with respect to the CorMatrix developmental pipeline products, including the royalty rate of 5% on such pipeline products. The Amended Interest Purchase Agreement will terminate 10 years from the date of the first commercial sale of such products. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for the Aziyo commercial license right as a financial asset in accordance with ASC 310, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Receivables</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and amortize the commercial license right using the effective interest method whereby we forecast expected cash flows over the term of the arrangement to arrive at an annualized effective interest. The annual effective interest associated with the forecasted cash flows from the royalty agreement with Aziyo as of December&#160;31, 2021 is 21.6%. Revenue is calculated by multiplying the carrying value of the commercial license right by the effective interest. The payments received in 2021 were accordingly allocated between revenue and the amortization of the commercial license rights.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to 2020, we accounted for commercial license rights related to developmental pipeline products such as Selexis and Dianomi on a non-accrual basis. These developmental pipeline products are non-commercialized, non-approved products that require FDA or other regulatory approval, and thus have uncertain cash flows. The developmental pipeline products are on a non-accrual basis as we are not yet able to forecast future cash flows given their pre-commercial stages of development. We will prospectively update the yield model under the effective interest method once the underlying products are commercialized and we can reliably forecast expected cash flows. Income will be calculated by multiplying the carrying value of the commercial license right by the effective interest rate. We regularly perform reviews to determine if any event has occurred that may indicate the carrying value of these commercial license rights are potentially impaired. If the affected commercial license rights are not recoverable, we estimate the fair value of the assets and record an impairment loss if the carrying value of the assets exceeds the fair value. During 2020, given the expected cash flow from the Selexis program, we started to account for the Selexis commercial license right as a financial asset in accordance with ASC 310, and amortize the commercial license right using the effective interest method whereby we forecast expected cash flows over the term of the arrangement to arrive at an annualized effective interest. The annual effective interest associated with the forecasted cash flows from the royalty agreement with Selexis as of December&#160;31, 2021 is 21%. Revenue is calculated by multiplying the carrying value of the commercial license right by the effective interest. The payments received in the year ended December&#160;31, 2021 and 2020 were allocated </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">accordingly between revenue and the amortization of the commercial license rights. We still accounted for commercial license rights related to Dianomi on a non-accrual basis as of December&#160;31, 2021.</span></div><div><span><br/></span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For commercial license rights, we have elected a prospective approach to account for changes in estimated cash flows and selected a method for determining when an impairment would be recognized and how to measure that impairment. In circumstances where our new estimate of expected cash flows is greater than previously expected, we will update our yield prospectively. In circumstances where our new estimate of expected cash flows is less than previously expected and below our original estimated yield we record an impairment. Impairment is recognized by reducing the financial asset to an amount that represents the present value of our most recent estimate of expected cash flows discounted by the original effective interest rate.&#160;In circumstances where our new estimate of expected cash flows is less than previously expected, but not below our original estimated yield, we update our yield prospectively.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As a result of adopting ASU 2016-13, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Financial Instruments &#8211; Credit Losses: Measurement of Credit losses on Financial Instruments (Topic 326)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, we now recognize an allowance for current expected credit losses on the commercial license rights subject to credit risk. We recorded a $5.5 million pre-tax reserve for credit losses upon adoption of the standard on January 1, 2020. We estimated the credit losses at the individual asset level by considering the performance against the programs, the company operating performance and the macroeconomic forecast. In addition, we have judgmentally applied credit loss risk factors to the future expected payments with consideration given to the timing of the payment. Given the higher inherent credit risk associated with longer term receivables, we applied a lower risk factor to the earlier years and progressively higher risk factors to the later years. During the twelve months ended December&#160;31, 2021 and 2020, we further considered the current and expected future economic and market conditions surrounding novel coronavirus (COVID-19) pandemic, along with other factors, and recorded an additional $0.5&#160;million each year, for credit losses in other expense, net, in our consolidated statements of operations.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our revenue is generated primarily from royalties on sales of products commercialized by our partners, Captisol material sales, and contract revenue for services, license fees and development, regulatory and sales based milestone payments.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We apply the following five-step model in accordance with ASC 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in order to determine the revenue: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations, including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation.</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Royalties</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We receive royalty revenue on sales by our partners of products covered by patents that we or our partners own under contractual agreements. We do not have future performance obligations under these license arrangements. We generally satisfy our obligation to grant intellectual property rights on the effective date of the contract. However, we apply the royalty recognition constraint required under the guidance for sales-based royalties which requires a royalty to be recorded no sooner than the underlying sale occurs. Therefore, royalties on sales of products commercialized by our partners are recognized in the quarter the product is sold. Our partners generally report sales information to us on a one quarter lag. Thus, we estimate the expected royalty proceeds based on an analysis of historical experience and interim data provided by our partners including their publicly announced sales. Differences between actual and estimated royalty revenues, which have not been material, are adjusted in the period in which they become known, typically the following quarter. </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Captisol Sales</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue from Captisol sales is recognized when control of Captisol material or intellectual property license rights is transferred to our customers in an amount that reflects the consideration we expect to receive from our customers in exchange for those products. A performance obligation is considered distinct from other obligations in a contract when it provides a benefit to the customer either on its own or together with other resources that are readily available to the customer and is separately identified in the contract. For Captisol material, we consider our performance obligation is satisfied at a point in time, once we have transferred control of the product, meaning the customer has the ability to use and obtain the benefit of the Captisol material or intellectual property license right. We recognize revenue for satisfied performance obligations only when we determine there are no uncertainties regarding payment terms or transfer of control. Sales tax and other taxes we collect concurrent with revenue-producing activities are excluded from revenue. We have elected to recognize the cost of freight and shipping when control over Captisol material has transferred to the customer as an expense in Cost of Captisol. We expense incremental costs of obtaining a contract when incurred if the expected amortization period of the asset that we would have recognized is one year or less or the amount is immaterial. We did not incur any incremental costs of obtaining a contract during the periods reported.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Contract Revenue</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our contracts with customers often will include variable consideration in the form of contingent milestone-based payments. We include contingent milestone based payments in the estimated transaction price when it is probable a significant reversal in the amount of cumulative revenue recognized will not occur. These estimates are based on historical experience, anticipated results and our best judgment at the time. If the contingent milestone based payment is sales-based, we apply the royalty recognition constraint and record revenue when the underlying sale has taken place. Significant judgments must be made in determining the transaction price for our sales of intellectual property. Because of the risk that products in development with our partners will not reach development based milestones or receive regulatory approval, we generally recognize any contingent payments that would be due to us upon the development milestone or regulatory approval. Depending on the terms of the arrangement, we may also defer a portion of the consideration received if we have to satisfy a future obligation, which typically occurs with our contracts for R&amp;D services.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For R&amp;D services we recognize revenue over time and we measure our progress using an input method. The input methods we use are based on the effort we expend or costs we incur toward the satisfaction of our performance obligation. We estimate the amount of effort we expend, including the time it will take us to complete the activities, or the costs we may incur in a given period, relative to the estimated total effort or costs to satisfy the performance obligation. This results in a percentage that we multiply by the transaction price to determine the amount of revenue we recognize each period. This approach requires us to make numerous estimates and use significant judgement. If our estimates or judgements change over the course of the collaboration, they may affect the timing and amount of revenue that we recognize in the current and future periods.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We occasionally have sub-license obligations related to arrangements for which we receive license fees, milestones and royalties. We evaluate the determination of gross as a principal versus net as an agent reporting based on each individual agreement.</span></div><div><span><br/></span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Deferred Revenue</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Depending on the terms of the arrangement, we may also defer a portion of the consideration received if we have to satisfy a future obligation.</span></div>The timing of revenue recognition, billings and cash collections results in billed accounts receivable, unbilled receivables (contract assets), and customer advances and deposits (contract liabilities) on the consolidated balance sheet. Except for royalty revenue, we generally receive payment at the point we satisfy our obligation or soon after. Therefore, we do not generally carry a contract asset balance. Any fees billed in advance of being earned are recorded as deferred revenue.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expenses</a></td>
<td class="text">Research and Development ExpensesResearch and development expense consists of labor, material, equipment, and allocated facilities costs of our scientific staff who are working pursuant to our collaborative agreements and other research and development projects. Also included in research and development expenses are third-party costs incurred for our research programs including in-licensing costs, CRO costs and costs incurred by other research and development service vendors. We expense these costs as they are incurred. When we make payments for research and development services prior to the services being rendered, we record those amounts as prepaid assets on our consolidated balance sheet and we expense them as the services are provided.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Share-Based Compensation</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share-Based Compensation</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We incur share-based compensation expense related to restricted stock, ESPP, and stock options.</span></div><div style="text-indent:45pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted stock unit (RSU) and performance stock unit (PSU) are all considered restricted stock. The fair value of restricted stock is determined by the closing market price of our common stock on the date of grant. We recognize share-based compensation expense based on the fair value on a straight-line basis over the requisite service periods of the awards, taking into consideration of forfeitures as they occur. PSU generally represents a right to receive a certain number of shares of common stock based on the achievement of corporate performance goals and continued employment during the vesting period. At each reporting period, we reassess the probability of the achievement of such corporate performance goals and any expense change resulting from an adjustment in the estimated shares to be released are treated as a cumulative catch-up in the period of adjustment. A limited amount of PSUs contain a market condition dependent upon the Company&#8217;s relative and absolute total stockholder return over a three-year period, with a range of 0% to 200% of the target amount granted to be issued under the award. Share-based compensation expense for these PSUs is measured using the Monte-Carlo simulation valuation model and is not adjusted for the achievement, or lack thereof, of the market conditions.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Black-Scholes-Merton option-pricing model is used to estimate the fair value of stock purchases under our ESPP and stock options granted. The model assumptions include expected volatility, term, dividends, and the risk-free interest rate. We look to historical and implied volatilities of our stock to determine the expected volatility. The expected term of an award is based on historical forfeiture experience, exercise activity, and on the terms and conditions of the stock awards. The expected dividend yield is determined to be 0% given that except for 2007, during which we declared a cash dividend on our common stock of $2.50 per share, we have not paid any dividends on our common stock in the past and currently do not expect to pay cash dividends or make any other distributions on common stock in the future. The risk-free interest rate is based upon U.S. Treasury securities with remaining terms similar to the expected term of the share-based awards.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We grant options, RSUs and PSUs to employees and non-employee directors. Non-employee directors are accounted for as employees. Options and RSUs granted to certain non-employee directors typically vest one year from the date of grant. Options granted to employees typically vest 1/8 on the six month anniversary of the date of grant, and 1/48 each month thereafter for forty-two months. RSUs and PSUs granted to employees vest over three years. All option awards generally expire ten years from the date of grant.</span></div>Share-based compensation expense for awards to employees and non-employee directors is recognized on a straight-line basis over the vesting period until the last tranche vests.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesPolicyTextBlock', window );">Derivatives</a></td>
<td class="text">Derivatives<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2018, we issued $750.0 million aggregate principal amount of 2023 Notes, bearing cash interest at a rate of 0.75% per year, payable semi-annually, as further described in &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note (7), Convertible Senior Notes.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; Concurrently with the issuance of the notes, we entered into a series of convertible note hedge and warrant transactions which in combination are designed to reduce the potential dilution to our stockholders and/or offset the cash payments we are required to make in excess of the principal amount upon conversion of the notes. The conversion option associated with the 2023 Notes temporarily met the criteria for an embedded derivative liability which required bifurcation and separate accounting. In addition, the note hedge and warrants were also temporarily classified as a derivative asset and liability, respectively, on our consolidated balance sheet. As a result of shareholder approval to increase the number of authorized shares of our common stock on June 19, 2018, as discussed in &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note (7), Convertible Senior Notes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,&#8221; the derivative asset and liabilities were reclassified to additional paid-in capital. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with our 2019 Notes, which we issued in August 2014 for $245.0 million aggregate principal amount, on May 22, 2018, we amended it making an irrevocable election to settle the entire note in cash. As a result, we reclassified from equity to derivative liability the fair value of the conversion premium as of May 22, 2018. Amounts paid in excess of the principal amount would be offset by an equal receipt of cash under the corresponding convertible bond hedge. As a result, we reclassified from equity to derivative asset the fair value of the bond hedge as of May 22, 2018. Changes in the fair value of these derivatives are reflected in other expense, net, in our consolidated statements of operations.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The provision for income taxes is computed using the asset and liability method, under which deferred tax assets and liabilities are recognized for the expected future tax consequences of temporary differences between the financial reporting and tax bases of assets and liabilities, and for the expected future tax benefit to be derived from tax loss and credit carryforwards. Deferred tax assets and liabilities are determined using the enacted tax rates in effect for the years in which those tax assets are expected to be realized. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in the provision for income taxes in the period that includes the enactment date. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred tax assets are regularly assessed to determine the likelihood they will be recovered from future taxable income. A valuation allowance is established when we believe it is more likely than not the future realization of all or some of a deferred tax asset will not be achieved. In evaluating the ability to recover deferred tax assets within the jurisdiction which they arise we consider all available positive and negative evidence. Factors reviewed include the cumulative pre-tax book income for the past three years, scheduled reversals of deferred tax liabilities, history of earnings and reliable forecasting, projections of pre-tax book income over the foreseeable future, and the impact of any feasible and prudent tax planning strategies.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize the impact of a tax position in our financial statements only if that position is more likely than not of being sustained upon examination by taxing authorities, based on the technical merits of the position. Tax authorities regularly examine our returns in the jurisdictions in which we do business and we regularly assess the tax risk of our return filing positions. Due to the complexity of some of the uncertainties, the ultimate resolution may result in payments that are materially different from our current estimate of the tax liability. These differences, as well as any interest and penalties, will be reflected in the provision for income taxes in the period in which they are determined.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Income (Loss) Per Share</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income (Loss) Per Share</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic income (loss) per share is calculated by dividing net income (loss) by the weighted-average number of common shares outstanding during the period. Diluted income per share is computed based on the sum of the weighted average number of common shares and potentially dilutive common shares outstanding during the period. Diluted loss per share is computed based on the sum of the weighted average number of common shares outstanding during the period.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Potentially dilutive common shares consist of shares issuable under 2023 convertible senior notes, stock options and restricted stock. 2023 convertible senior notes have a dilutive impact when the average market price of the Company&#8217;s common stock exceeds the applicable conversion price of the respective notes. It is our intent and policy to settle conversions through combination settlement, which essentially involves payment in cash equal to the principal portion and delivery of shares of common stock for the excess of the conversion value over the principal portion. Potentially dilutive common shares from stock options and restricted stock are determined using the average share price for each period under the treasury stock method. In addition, the following amounts are assumed to be used to repurchase shares: proceeds from exercise of stock options and the average amount of unrecognized compensation expense for stock options and restricted stock. In loss periods, basic net loss per </span></div>share and diluted net loss per share are identical since the effect of otherwise dilutive potential common shares is anti-dilutive and therefore excluded.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive Income (Loss)</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comprehensive Income (Loss)</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Comprehensive income (loss) represents net income (loss) adjusted for the change during the periods presented in unrealized gains and losses on available-for-sale debt securities, foreign currency translation adjustments, and reclassification adjustments for realized gains or losses included in net income (loss). The unrealized gains or losses are reported on the Consolidated Statements of Comprehensive Income (Loss).</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Foreign Currency Translation</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Translation</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The British Pound Sterling was the functional currency of our subsidiary, Vernalis, which was sold in fourth quarter of the year ended December 31, 2020. For the years ended December 31, 2020 and 2019 the corresponding financial statements have been translated into U.S. Dollars in accordance with ASC 830-30, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Translation of Financial Statements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">. Assets and liabilities are translated at end-of-period rates while revenues and expenses are translated at average rates in effect during the period in which the activity took place. Equity is translated at historical rates and the resulting cumulative translation adjustments are included as a component of accumulated other comprehensive income (loss).</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Accounting Standards Recently Adopted and Accounting Standards Not Yet Adopted</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Accounting Standards Not Yet Adopted</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In August 2020, the FASB issued ASU 2020-06, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Debt &#8211; Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging &#8211; Contracts in Entity&#8217;s Own Equity (Subtopic 815 &#8211; 40)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, which simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts on an entity&#8217;s own equity. This guidance is part of the FASB&#8217;s simplification initiative, which aims to reduce unnecessary complexity in U.S. GAAP. The ASU is effective for public entities for fiscal years beginning after December 15, 2021, and interim periods within those fiscal years. Effective January 1, 2022, we will adopt ASU 2020-06. We are finalizing our analysis of certain assumptions that will be utilized at the transition and expects the effect of adopting ASU 2020-06 will result in an increase to retained earnings, a decrease to additional paid-in capital, and an increase to the convertible senior notes. We expect that interest expense recognized in future periods will be reduced as a result of accounting for the convertible debt instrument as a single liability measured at its amortized cost. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We do not believe that any other recently issued, but not yet effective accounting pronouncements, if adopted, would have a material impact on our consolidated financial statements or disclosures.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_CashCashEquivalentsandShorttermInvestmentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash, Cash Equivalents, and Short-term Investments [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_CashCashEquivalentsandShorttermInvestmentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_CommercialLicenseRightsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commercial License Rights [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_CommercialLicenseRightsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -Subparagraph (a)-(d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6909625&amp;loc=d3e227-128457<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123345438&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for its derivative instruments and hedging activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41620-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41638-113959<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41675-113959<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(n))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579240-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -URI http://asc.fasb.org/topic&amp;trid=2175825<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32847-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL116659661-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32280-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4556-108314<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 330<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6471895&amp;loc=d3e55923-109411<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4492-108314<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124437754&amp;loc=d3e543-108305<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI http://asc.fasb.org/topic&amp;trid=2126998<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the allowance for doubtful accounts for trade and other accounts receivable balances, and when impairments, charge-offs or recoveries are recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5144-111524<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130561-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130563-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130563-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130564-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140091802138392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock', window );">Schedule of Revenue from Significant Partners</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue from significant partners, which is defined as 10% or more of our total revenue, was as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.578%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.524%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year-ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Partner A</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Partner B</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Partner C</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&lt;10%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&lt;10%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13%</span></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_ScheduleofCommercialLicenseRightsTableTextBlock', window );">Schedule of Commercial License Rights</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021 and 2020, commercial license and other economic rights consist of the following (in thousands):</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:24.338%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.607%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Adjustments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Adjustments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Aziyo and CorMatrix</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17,696&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(9,461)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,235&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17,696&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(9,588)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,108&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Selexis and Dianomi</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,602&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(8,727)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,875&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,602&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(7,731)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,871&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28,298&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(18,188)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,110&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28,298&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(17,319)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,979&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%">(1) Amounts represent accumulated amortization to principal of $11.7 million and credit loss adjustments of $6.5 million as of December 31, 2021. </span></div>(2) Amounts represent accumulated amortization to principal of $11.3 million and credit loss adjustments of $6.0 million as of December 31, 2020.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Schedule of Disaggregation of Revenue</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Royalty revenue for 2021, 2020 and 2019 are reported as below (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:61.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.601%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kyprolis</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,472&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,164&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,046&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Evomela</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,079&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,377&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,171&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,376&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,255&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,566&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Promacta</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,193&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,927&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,796&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,976&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table represents disaggregation of Captisol and Contract Revenue (in thousands):</span></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:61.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.601%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Captisol</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">164,250&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109,959&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,489&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:5pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Service Revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,712&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,803&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,776&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;License Fees</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,084&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,378&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,199&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Milestone</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,748&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,516&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,173&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,412&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,967&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,669&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,956&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,664&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,817&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Computation of Basic and Diluted Net Income (Loss) per Share</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the calculation of weighted average shares used to calculate basic and diluted income (loss) per share (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:62.189%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.649%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares outstanding:</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,630&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,185&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,995&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dilutive potential common shares:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Restricted stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Stock options</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">520&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">719&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares used to compute diluted income (loss) per share</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,246&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,185&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,757&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Potentially dilutive shares excluded from calculation due to anti-dilutive effect</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,793&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,458&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,926&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_ScheduleofCommercialLicenseRightsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of Commercial License Rights [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_ScheduleofCommercialLicenseRightsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13537-108611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13531-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6327-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6442-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140091802752520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=lgnd_PfenexMember', window );">Pfenex</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock', window );">Schedule of Allocation of Consideration / Recognized Identified Assets Acquired and Liabilities Assumed</a></td>
<td class="text">The following table sets forth an allocation of the purchase price to the identifiable tangible and intangible assets acquired and liabilities assumed, with the excess recorded to goodwill (in thousands):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.449%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.351%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash </span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,407&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts and unbilled receivables</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,359&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,823&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use asset</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,070&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,338&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangibles acquired</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">385,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,303&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,814)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,606)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,908)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,070)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,382)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(42,622)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 61pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total consideration</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">465,098&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table>(1) Goodwill represents the excess of the purchase price over the preliminary fair value of the underlying assets acquired and liabilities assumed. Goodwill is attributable to the assembled workforce of experienced personnel at Pfenex and expected synergies. None of the goodwill is deductible for tax purposes.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock', window );">Schedule of Finite-Lived Intangibles Acquired</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The intangibles acquired and their weighted average useful life are as follows (in thousands, except useful lives):</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.707%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.497%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Approximate<br/>Fair Value</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Estimated useful life<br/>(in years)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contractual Relationships:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Alvogen</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Merck</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jazz</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SII</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Arcellx</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired Technologies</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-19</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">385,000&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionProFormaInformationTextBlock', window );">Schedule of Pro Forma Information</a></td>
<td class="text">The pro forma financial information is not necessarily indicative of the operating results that would have occurred had the acquisition been consummated as if the date indicated, nor is it necessarily indicative of future operating results (in thousands, except per share amounts):<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.707%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.497%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Unaudited)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">189,203&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">170,608&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net Income (loss)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(60,059)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">594,941&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net income (loss) per common share:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Basic</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.71)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.32&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Diluted</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.71)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=lgnd_TaurusBiosciencesLLCMember', window );">Taurus</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock', window );">Schedule of Allocation of Consideration / Recognized Identified Assets Acquired and Liabilities Assumed</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The allocation of the consideration was allocated to the acquisition date fair values of acquired assets as follows (in thousands)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.303%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.497%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangibles assets with finite-life - core technologies</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,005&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,052&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=lgnd_XCellaBiosciencesIncMember', window );">xCella</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock', window );">Schedule of Allocation of Consideration / Recognized Identified Assets Acquired and Liabilities Assumed</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The allocation of the consideration was allocated to the acquisition date fair values of acquired assets and assumed liabilities as follows (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.303%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.497%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and other assets</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">240&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(142)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(604)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangibles assets with finite-life - core technology</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,582&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,076&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=lgnd_IcagenMember', window );">Icagen</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock', window );">Schedule of Allocation of Consideration / Recognized Identified Assets Acquired and Liabilities Assumed</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The allocation of the consideration was allocated to the acquisition date fair values of acquired assets and assumed liabilities as follows (in thousands):</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.303%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.497%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,173&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaids and other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">588&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities assumed</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(812)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,685)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">861&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired intangibles</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,800&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,015&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,940&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%">(1) Goodwill represents the excess of the purchase price over the preliminary fair value of the underlying assets acquired and liabilities assumed. Goodwill is attributable to the assembled workforce of experienced personnel at Icagen and expected synergies.</span></div><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=lgnd_AbInitioMember', window );">Ab Initio</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock', window );">Schedule of Allocation of Consideration / Recognized Identified Assets Acquired and Liabilities Assumed</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The final purchase consideration was allocated to the acquisition date fair values of acquired assets and assumed liabilities as follows (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.303%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.497%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and other assets</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and accrued liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(83)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(146)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangibles assets with finite-life - core technologies</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,400&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,812&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,011&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%">(1) Goodwill represents the excess of the purchase price over the fair value of the underlying assets acquired and liabilities assumed. Goodwill is attributable to the assembled workforce of experienced personnel at Ab Initio and expected synergies.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionProFormaInformationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of pro forma results of operations for a material business acquisition or series of individually immaterial business acquisitions that are material in the aggregate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionProFormaInformationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of finite-lived intangible assets acquired as part of a business combination or through an asset purchase, by major class and in total, including the value of the asset acquired, any significant residual value (the expected value of the asset at the end of its useful life) and the weighted-average amortization period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=lgnd_PfenexMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=lgnd_PfenexMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=lgnd_TaurusBiosciencesLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=lgnd_TaurusBiosciencesLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=lgnd_XCellaBiosciencesIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=lgnd_XCellaBiosciencesIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=lgnd_IcagenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=lgnd_IcagenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=lgnd_AbInitioMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=lgnd_AbInitioMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140091802860360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurement (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock', window );">Schedule of Assets and Liabilities Measured at Fair Value</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a summary of the assets and liabilities that are measured at fair value on a recurring basis as of December&#160;31, 2021 and 2020 (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.829%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr><td colspan="24" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements at Reporting Date Using</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted Prices in</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Active Markets</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">for Identical</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Assets</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Observable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Inputs</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unobservable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Inputs</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level&#160;1)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level&#160;2)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level&#160;3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">290,697&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,735&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">280,553&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">409&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in Viking common stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,889&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,889&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">321,586&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,624&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">280,553&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">409&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent liabilities - Cydex</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">349&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">349&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent liabilities - Metabasis </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,358&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,358&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent liabilities - Icagen </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,364&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,364&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liability for amounts owed to a former licensor</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,157&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,358&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,713&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.268%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.473%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.473%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.473%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.623%"/><td style="width:0.1%"/></tr><tr><td colspan="24" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements at Reporting Date Using</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted Prices in</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Active Markets</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">for Identical</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Assets</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Observable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Inputs</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unobservable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Inputs</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level&#160;1)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level&#160;2)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level&#160;3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">324,478&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,438&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">320,647&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">393&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in Viking common stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,763&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,763&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in Viking warrants </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,326&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,326&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">363,567&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,527&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">320,647&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">393&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent liabilities - Crystal </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">800&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">800&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent liabilities - Cydex</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">508&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">508&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent liabilities - Metabasis </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,821&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,821&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent liabilities - Icagen </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,404&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,404&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent liabilities - Pfenex </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(6)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,600&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,600&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liability for amounts owed to a former licensor</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,193&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,821&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,312&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">(1) Excluding our investment in Viking, our short-term investments in marketable debt and equity securities are classified as available-for-sale securities based on management's intentions and are at level 2 of the fair value hierarchy, as these investment securities are valued based upon quoted prices for identical or similar instruments in markets that are not active, and model-based valuation techniques for which all significant assumptions are observable in the market. Short-term investments in mutual funds are valued at their net asset value (NAV) on the last day of the period. We have classified marketable securities with original maturities of greater than one year as short-term investments based upon our ability and intent to use any and all of those marketable securities to satisfy the liquidity needs of our current operations. In addition, we have investment in warrants resulting from Seelos Therapeutics Inc. milestone payments that were settled in shares during the first quarter of 2019 and are at level 3 of the fair value hierarchy, based on Black Scholes value estimated by management on the last day of the period.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2) Investment in Viking warrants, which we received as a result of Viking&#8217;s partial repayment of the Viking note receivable and our purchase of Viking common stock and warrants in April 2016, is classified as level 1 as the fair value is determined using quoted market prices in active markets for the same securities. The change of the fair value is recorded in &#8220;gain (loss) from short-term investments&#8221; in our consolidated statement of operations. See further discussion in &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note (3), Short-term Investments: Investment in Viking.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221;  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3) The fair value of Crystal contingent liabilities was determined using a probability weighted income approach. Most of the contingent payments are based on development or regulatory milestones as defined in the merger agreement with Crystal. The fair value is subjective and is affected by changes in inputs to the valuation model including management&#8217;s estimates regarding the timing and probability of achievement of certain developmental and regulatory milestones. During the twelve months ended December&#160;31, 2020, we paid $1.8 million contingent liability on development milestones to former Crystal shareholders. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(4) In connection with our acquisition of Metabasis in January 2010, we issued Metabasis stockholders four tradable CVRs, one CVR from each of four respective series of CVR, for each Metabasis share. The CVRs entitle Metabasis stockholders to cash payments as frequently as every six months as cash is received by us from proceeds from the sale or partnering of any of the Metabasis drug development programs, among other triggering events. The liability for the CVRs is determined using quoted prices in a market that is not active for the underlying CVR. The carrying amount of the liability may fluctuate significantly based upon quoted market prices and actual amounts paid under the agreements may be materially differ than the carrying amount of the liability. Several of the Metabasis drug development programs have been outlicensed to Viking, including VK2809. VK2809 is a novel selective TR-&#946; agonist with potential in multiple indications, including hypercholesterolemia, dyslipidemia, NASH, and X-ALD. Under the terms of the agreement with Viking, we may be entitled to up to $375.0 million of development, regulatory and commercial milestones and tiered royalties on potential future sales including a $10.0 million payment upon initiation of a Phase 3 clinical trial.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(5) The fair value of Icagen contingent liabilities was determined using a probability weighted income approach. Most of the contingent payments are based on certain revenue milestones as defined in the asset purchase agreement with Icagen. The fair value is subjective and is affected by changes in inputs to the valuation model including management&#8217;s estimates regarding the timing and probability of achievement of certain developmental and regulatory milestones. Changes in these estimates may materially affect the fair value. During the year-end December 31, 2021, we paid a $1.1 million contingent liability based on revenue milestones to Icagen.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(6) The fair value of the Pfenex contingent liability was determined using a probability adjusted income approach. These cash flows were then discounted to present value using a discount rate based on the market participants' cost of debt reflective of the Company. During the year-end December 31, 2021, we reduced the contingent liability by $37.6&#160;million primarily due to the lower probability of achieving the specific development and regulatory milestone by December 31, 2021 as defined by the Pfenex CVR. See further detail on Pfenex CVR in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 4, Acquisitions</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Schedule of Reconciliation of Level 3 Financial Instruments</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the level 3 financial instruments as of December&#160;31, 2021 is as follows (in thousands):</span></div><div style="text-align:center;text-indent:45pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.303%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.497%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of level 3 financial instruments as of December 31, 2020</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,312&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments to CVR holders and other contingency payments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,770)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value adjustments to contingent liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(36,549)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent liabilities from xCella asset acquisition</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">720&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of level 3 financial instruments as of December&#160;31, 2021</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,713&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19279-110258<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2C<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=SL7498348-110258<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19279-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140091808340648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_AssetsAndLiabilitiesLesseeTableTextBlock', window );">Schedule of Operating and Finance Lease Assets and Liabilities</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Operating and Finance Lease Assets and Liabilities (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.683%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.498%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating lease assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16,542&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,892&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Finance lease assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16,207&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15,842&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total lease assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32,749&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22,734&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current operating lease liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,053&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,885&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current finance lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">46&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,593&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,099&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,478&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Long-term operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15,494&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,643&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDAvZnJhZzpmNDRmMTQwOTY3NGU0MzVkYWNmMjkzYWVjOTgxYmE2NS90YWJsZToyNmY5ZDQ2ZjdiYTI0Y2E3OWY3YzM1YWYzY2NhMjdkMC90YWJsZXJhbmdlOjI2ZjlkNDZmN2JhMjRjYTc5ZjdjMzVhZjNjY2EyN2QwXzExLTAtMS0xLTQxMjk0_189a0b16-c5f6-426a-9fe4-540e7d6227de"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDAvZnJhZzpmNDRmMTQwOTY3NGU0MzVkYWNmMjkzYWVjOTgxYmE2NS90YWJsZToyNmY5ZDQ2ZjdiYTI0Y2E3OWY3YzM1YWYzY2NhMjdkMC90YWJsZXJhbmdlOjI2ZjlkNDZmN2JhMjRjYTc5ZjdjMzVhZjNjY2EyN2QwXzExLTAtMS0xLTQxMjk0_2ee456c7-520d-4723-b00d-a8a6a8da65cf">Long-term finance lease liabilities</span></span></span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">112&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total lease liabilities   </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17,651&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,233&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Maturity of Operating Lease Liabilities</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Maturity of Operating and Finance Lease Liabilities as of December&#160;31, 2021</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.391%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.499%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Maturity Dates</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating Leases</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Finance Leases</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,653&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">56&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,414&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">49&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,716&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,614&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,670&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,832&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25,899&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">109&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less tenant improvement allowance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4,327)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less imputed interest</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4,025)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Present value of lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17,547&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">104&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Maturity of Finance Lease Liabilities</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Maturity of Operating and Finance Lease Liabilities as of December&#160;31, 2021</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.391%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.499%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Maturity Dates</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating Leases</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Finance Leases</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,653&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">56&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,414&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">49&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,716&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,614&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,670&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,832&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25,899&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">109&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less tenant improvement allowance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4,327)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less imputed interest</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4,025)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Present value of lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17,547&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">104&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_AssetsAndLiabilitiesLesseeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Assets and Liabilities, Lessee</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_AssetsAndLiabilitiesLesseeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of finance lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to finance lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140091803789592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Senior Notes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtTableTextBlock', window );">Schedule of Equity and Liability Components of the Convertible Senior Notes</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes information about the equity and liability components of the 2023 Notes (in thousands).</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.683%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.499%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Principal amount of 2023 Notes outstanding</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">343,301&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">495,280&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized discount (including unamortized debt issuance cost)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22,584)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(52,987)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total long-term portion of notes payable</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">320,717&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">442,293&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying value of equity component of 2023 Notes</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,627&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,397&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of convertible senior notes outstanding (Level 2)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">341,801&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">466,053&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140091805743384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Account Details (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_OtherBalanceSheetDetailsAbstract', window );"><strong>Other Balance Sheet Details [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesTextBlock', window );">Schedule of Investment Categories</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Excluding our investments in Viking, the following table summarizes the various investment categories at December&#160;31, 2021 and 2020 (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.321%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.501%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross unrealized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">gains</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross unrealized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">losses</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">fair value</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mutual Fund</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">152,136&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(249)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">151,887&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bank deposits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,389&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,381&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,008&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,998&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,308&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(38)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,287&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,807&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">402&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,027)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,182&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,577&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,554&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">408&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">408&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">292,225&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">842&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,370)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">290,697&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Mutual fund</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">151,512&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">386&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">151,898&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Bank deposits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,120&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,154&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Commercial paper  </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,459&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,485&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Corporate bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,512&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,610&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Agency bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,499&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,501&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Corporate equity securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,466&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">360&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,388)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,438&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Treasury bills</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,999&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,999&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Warrants</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">393&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">393&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">324,567&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,302&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,391)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">324,478&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock', window );">Schedule of Available-for-Sale Debt Securities by Contractual Maturity</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our available-for-sale debt securities by contractual maturity (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.976%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.498%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Within one year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111,334&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111,315&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">After one year through five years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,952&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,909&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">After five years</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136,286&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136,224&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock', window );">Schedule of Available-for-Sale Debt Securities in an Unrealized Loss Position</a></td>
<td class="text">The following table summarizes our available-for-sale debt securities in an unrealized loss position (in thousands):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:18.783%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.765%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.765%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.765%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.765%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.765%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.772%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Less than 12 months</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12 months or greater</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Estimated<br/>Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Estimated<br/>Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Estimated<br/>Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bank deposits</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,008&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,008&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,252&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,996&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,248&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,689&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,125&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(38)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,814&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Government Securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,553&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,553&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(34)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,949&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(60)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,674&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(94)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72,623&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">December 31, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bank deposits</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,013&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,013&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,526&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,526&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,693&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,693&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,232&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,232&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property and Equipment</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and equipment are stated at cost and consists of the following (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.976%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.498%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lab and office equipment</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,183&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,666&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,983&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,519&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment and software</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,056&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1056&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,222&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,241&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,711)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,807)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,511&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,434&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock', window );">Schedule of Goodwill and Other Identifiable Intangible Assets</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill and identifiable intangible assets consist of the following (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.976%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.498%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indefinite-lived intangible assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Goodwill</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">181,206&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">189,662&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Definite-lived intangible assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Complete technology</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">280,617&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">277,740&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Less: Accumulated amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(78,991)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(63,600)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Trade name</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,642&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,642&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Less: Accumulated amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,444)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,312)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Customer relationships</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,700&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,700&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Less: Accumulated amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18,267)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,597)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Contractual relationships</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">362,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">362,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Accumulated amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(36,217)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,243)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total goodwill and other identifiable intangible assets, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">732,246&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">784,992&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Liabilities</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accrued liabilities consist of the following (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.976%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.498%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Compensation</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,532&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,810&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Professional fees</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,046&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">977&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts owed to former licensees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">630&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">421&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalties owed to third parties</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">149&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">693&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Return reserve and customer refunds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,420&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">687&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition related liabilities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,500&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Subcontractor</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,759&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">733&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Supplier</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">848&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">604&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,195&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,105&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,579&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,530&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_ScheduleofContingentLiabilitiesTableTextBlock', window );">Schedule of Contingent Liabilities</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes roll-forward of contingent liabilities as of December 2021 and 2020 (in thousands):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:6.356%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.110%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.964%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.110%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.110%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.110%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:7.525%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.110%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.115%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2019</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Additional Contingent Liabilities</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Payments</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair Value Adjustment</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Repurchases</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Payments</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair Value Adjustment</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Repurchases</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cydex</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">348&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">160&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">508&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(50)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(108)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">350&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Metabasis</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,935&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,867)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(247)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,821&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(464)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,357&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Crystal</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,659&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,800)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(59)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">800&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(800)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Icagen</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,800&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(525)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,129&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,404&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,050)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,010&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,364&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pfenex</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">37,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">600&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">37,600&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(37,600)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">xCella</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(720)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">720&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">8,942</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">41,800</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(2,325)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">963</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(247)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">49,133</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(1,820)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(36,242)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">11,071</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_OtherBalanceSheetDetailsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other Balance Sheet Details [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_OtherBalanceSheetDetailsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_ScheduleofContingentLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of Contingent Liabilities [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_ScheduleofContingentLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI http://asc.fasb.org/topic&amp;trid=2196928<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121590138&amp;loc=SL82922954-210456<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27290-111563<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922888-210455<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of marketable securities. This may consist of investments in certain debt and equity securities, short-term investments and other assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill and intangible assets, which may be broken down by segment or major class.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140091799625496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock', window );">Schedule of Share-Based Compensation Expense</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes non-cash share-based compensation expense (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:64.002%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.043%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.043%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.046%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation expense as a component of:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expenses</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,436&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,497&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,641&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,347&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,230&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,874&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,783&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,727&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,515&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Stock Option Plan Activity</a></td>
<td class="text"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following is a summary of our stock option plan activity and related information:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"/><td style="width:49.120%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.976%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.976%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.976%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.244%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exercise</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Price</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Remaining</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contractual</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Term in</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Intrinsic</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Value</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at January&#160;1, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,736,304&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66.71&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.47</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125,858&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">338,617&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116.69&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(112,011)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.65&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,531)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139.37&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,956,379&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77.54&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.45</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72,002&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at December&#160;31, 2019</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,454,726&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61.82&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.42</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,345&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options vested and expected to vest as of December&#160;31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,956,379&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77.54&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.45</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72,002&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">806,300&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92.93&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(156,845)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.26&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(44,012)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91.30&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,561,822&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85.59&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.09</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,033&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at December&#160;31, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,611,830&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76.05&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.54</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,286&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options vested and expected to vest as of December&#160;31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,561,822&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85.59&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.09</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,033&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">393,589&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159.12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(619,731)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54.28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(136,082)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110.83&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2021 </span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,199,598&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.34</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113,302&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at December&#160;31, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,391,952&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98.16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.12</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,849&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options vested and expected to vest as of December&#160;31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,199,598&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.34</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113,302&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock', window );">Schedule of Stock Option Plan Activity by Exercise Price Range</a></td>
<td class="text"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following is a further breakdown of the options outstanding as of December&#160;31, 2021:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:30.040%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.057%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.057%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.057%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.057%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.212%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Range of exercise prices</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Options</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">outstanding</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">remaining&#160; life</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">in&#160;years</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted&#160;average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">exercise price</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Options</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">exercisable</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted&#160;average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">exercise&#160;price</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$12.53-$56.26</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">253,824&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.94</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37.55&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">239,824&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38.90&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$67.53-$74.42</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">278,281&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.04</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72.10&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">217,587&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73.17&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$82.90-$95.35</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159,988&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.06</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86.11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132,963&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86.24&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$95.68</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">266,263&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.12</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95.68&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109,154&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95.68&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$98.20-$100.38</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">294,772&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.33</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">160,120&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.79&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$101.07-$117.58</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159,204&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.45</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111.26&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99,488&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111.18&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$117.97</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">237,292&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.12</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117.97&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">158,958&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117.97&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$119.08-$159.01</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">299,585&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.00</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">149.40&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">205,098&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">152.50&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$159.81-$171.28</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,881&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.51</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">166.28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,828&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">165.62&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$177.50-$195.91</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">243,508&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.91</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178.62&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,932&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">181.84&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,199,598&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.34</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,391,952&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98.16&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Stock Option Weighted-Average Assumptions</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The assumptions used for the specified reporting periods and the resulting estimates of weighted-average grant date fair value per share of options granted:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.538%"><tr><td style="width:1.0%"/><td style="width:52.609%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.440%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.986%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.440%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.541%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.440%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="18" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4%-1.2%</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2%-1.4%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4%-2.6%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47%-63%</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47%-71%</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40%-49%</span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.7 to 6.3 years</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.7 to 5.1 years</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.6 to 5.9 years</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock', window );">Schedule of Restricted Stock Activity</a></td>
<td class="text"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of our restricted stock activity and related information:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:69.929%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.458%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.578%"/><td style="width:0.1%"/></tr><tr style="height:15pt"><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Grant&#160;Date Fair</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Value</span></div></td></tr><tr style="height:12pt"><td colspan="12" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at January 1, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132,273&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130.63&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118,498&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115.90&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(102,846)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121.55&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(666)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">134.36&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December&#160;31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">147,259&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125.11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111,306&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89.73&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(52,363)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121.69&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December&#160;31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">206,202&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106.88&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">167,292&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">169.63&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(98,501)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125.59&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,850)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">141.85&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December&#160;31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">264,143&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">138.21&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested restricted stock units.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140091802498584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Schedule of Components of Income Tax Benefit</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of the income tax expense (benefit) for continuing operations are as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"/><td style="width:66.403%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.092%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.833%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.092%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.686%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.094%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current expense (benefit):</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,190)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,889&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89,471&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">589&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,103&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(66)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,222)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,501&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92,508&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred expense (benefit):</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,355)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,672)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74,627&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,263)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,382)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">202&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,618)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19,054)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74,829&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total income tax expense (benefit)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,840)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,553)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">167,337&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Effective Income Tax Rate Reconciliation</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of income tax expense (benefit) from continuing operations to the amount computed by applying the statutory federal income tax rate to the net income (loss) from continuing operations is summarized as follows (in thousands):</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:66.841%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.047%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.047%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.682%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.048%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax at federal statutory rate</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,932&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,213)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">167,294&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State, net of federal benefit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(408)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,456)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,466&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,161)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(278)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,919)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(362)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(819)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">FDII</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(637)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,652)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(402)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,692)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(699)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(879)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in uncertain tax positions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">586&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(650)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">441&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rate change for changes in federal, foreign or state law</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,963)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(173)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(210)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision to return adjustments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(617)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,803)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(184)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign tax differential on income/loss of foreign subsidiaries</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(114)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,839)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,410&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(121,876)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,193)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sale of Vernalis R&amp;D</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127,372&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">743&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,076&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">748&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,840)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,553)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">167,337&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Deferred Tax Assets and Liabilities</a></td>
<td class="text">Deferred tax assets (liabilities) are comprised of the following:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.807%"><tr><td style="width:1.0%"/><td style="width:76.478%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.662%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.547%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.813%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating loss carryforwards</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,352&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,147&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research credit carryforwards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,797&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,623&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,374&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,994&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,668&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,120&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123,191&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108,884&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance for deferred tax assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(36,283)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24,858)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86,908&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,026&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:13pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Identified intangibles</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(102,221)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(119,381)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,300)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,923)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax liabilities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(111,521)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(124,304)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:13pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income taxes, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24,613)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40,278)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForwardTableTextBlock', window );">Schedule of Unrecognized Tax Benefits</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the amount of unrecognized tax benefits at December&#160;31, 2021, 2020 and 2019 is as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.807%"><tr><td style="width:1.0%"/><td style="width:66.613%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.064%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.547%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.064%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.547%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.365%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at beginning of year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,871&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,736&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,289&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Additions based on tax positions related to the current year</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">252&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,911&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">543&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Additions for tax positions of prior years</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">945&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">179&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Reductions for tax positions of prior years</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,072)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(955)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,096)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at end of year</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,996&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,871&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,736&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in unrecognized tax benefits, excluding amounts pertaining to examined tax returns.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140091790130776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies - Narrative (Details)<br> $ / shares in Units, shares in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="4">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>May 31, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>segment </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2007 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Oct. 01, 2020 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Apr. 01, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 01, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 15, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 22, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 31, 2014 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 31, 2010 </div>
<div>right</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_BasisOfPresentationLineItems', window );"><strong>Basis of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of business segments | segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_MaturityPeriodOfHighlyLiquidSecuritiesMaximum', window );">Maturity period of cash and cash equivalents, maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWriteDown', window );">Write-downs related to obsolete inventory</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,326,000<span></span>
</td>
<td class="nump">26,487,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">277,133,000<span></span>
</td>
<td class="nump">186,419,000<span></span>
</td>
<td class="nump">120,282,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_AccountsReceivableCreditLossExpenseReversalCOVID19', window );">Additional reserve for credit losses due to COVID-19</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (500,000)<span></span>
</td>
<td class="num">(500,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,100,000<span></span>
</td>
<td class="nump">$ 900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockDividendsPerShareDeclared', window );">Dividend declared (USD per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive shares excluded from calculation due to anti-dilutive effect (shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,793<span></span>
</td>
<td class="nump">8,458<span></span>
</td>
<td class="nump">8,926<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockCompensationPlanMember', window );">Equity Awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_BasisOfPresentationLineItems', window );"><strong>Basis of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive shares excluded from calculation due to anti-dilutive effect (shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lgnd_ContractRevenueMember', window );">Contract revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_BasisOfPresentationLineItems', window );"><strong>Basis of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 63,956,000<span></span>
</td>
<td class="nump">$ 42,664,000<span></span>
</td>
<td class="nump">$ 41,817,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lgnd_MaterialSalesCaptisolMember', window );">Captisol</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_BasisOfPresentationLineItems', window );"><strong>Basis of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,600,000<span></span>
</td>
<td class="nump">26,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 164,250,000<span></span>
</td>
<td class="nump">109,959,000<span></span>
</td>
<td class="nump">$ 31,489,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options | 2002 Stock Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_BasisOfPresentationLineItems', window );"><strong>Basis of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Award expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options | Vest 1/8 on the six month anniversary of the date of grant | 2002 Stock Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_BasisOfPresentationLineItems', window );"><strong>Basis of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Award vesting right (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options | Vest 1/48 each month for forty-two months | 2002 Stock Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_BasisOfPresentationLineItems', window );"><strong>Basis of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">42 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Award vesting right (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.08%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=lgnd_RestrictedStockUnitsAndPerformanceSharesMember', window );">RSUs and PSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_BasisOfPresentationLineItems', window );"><strong>Basis of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">PSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_BasisOfPresentationLineItems', window );"><strong>Basis of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_BasisOfPresentationLineItems', window );"><strong>Basis of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment, useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | PSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_BasisOfPresentationLineItems', window );"><strong>Basis of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Award vesting right (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_BasisOfPresentationLineItems', window );"><strong>Basis of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment, useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | PSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_BasisOfPresentationLineItems', window );"><strong>Basis of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Award vesting right (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=lgnd_PfenexMember', window );">Pfenex</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_BasisOfPresentationLineItems', window );"><strong>Basis of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_BusinessCombinationContingentConsiderationLiabilityAmountPerShare', window );">Contingent consideration liability per share (USD per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 77,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=lgnd_IcagenMember', window );">Icagen</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_BasisOfPresentationLineItems', window );"><strong>Basis of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=lgnd_MetabasisTherapeuticsMember', window );">Metabasis Therapeutics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_BasisOfPresentationLineItems', window );"><strong>Basis of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_NumberOfContingentValueRightsIssued', window );">Number of contingent value rights | right</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_RoyaltyAgreementsMember', window );">Royalty Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_BasisOfPresentationLineItems', window );"><strong>Basis of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_ProductRoyaltyPercentage', window );">Product royalty (as a percent)</a></td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember', window );">Licensing Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_BasisOfPresentationLineItems', window );"><strong>Basis of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Finite-lived intangible assets, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,110,000<span></span>
</td>
<td class="nump">10,979,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_FiniteLivedIntangibleAssetsCreditLossAdjustments', window );">Credit loss adjustments on finite-lived intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,500,000<span></span>
</td>
<td class="nump">6,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember', window );">Licensing Agreements | Accounting Standards Update 2016-13</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_BasisOfPresentationLineItems', window );"><strong>Basis of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_FiniteLivedIntangibleAssetsCreditLossAdjustments', window );">Credit loss adjustments on finite-lived intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=lgnd_NovanMolluscumProductsMember', window );">Novan | Royalty Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_BasisOfPresentationLineItems', window );"><strong>Basis of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_AdditionalRoyaltiesReceivableUnderSalesbasedMilestones', window );">Additional royalties receivable under sales-based milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=lgnd_NovanMolluscumProductsMember', window );">Novan | Royalty Agreements | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_BasisOfPresentationLineItems', window );"><strong>Basis of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_ProductRoyaltyPercentage', window );">Product royalty (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=lgnd_NovanMolluscumProductsMember', window );">Novan | Royalty Agreements | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_BasisOfPresentationLineItems', window );"><strong>Basis of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_ProductRoyaltyPercentage', window );">Product royalty (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=lgnd_NovanMolluscumProductsMember', window );">Novan | Licensing Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_BasisOfPresentationLineItems', window );"><strong>Basis of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_LicenseUpfrontPayment', window );">Upfront payment for license</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=lgnd_PalvellaTherapeuticsIncMember', window );">Palvella | Contract revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_BasisOfPresentationLineItems', window );"><strong>Basis of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=lgnd_PalvellaTherapeuticsIncMember', window );">Palvella | Royalty Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_BasisOfPresentationLineItems', window );"><strong>Basis of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_AdditionalRoyaltiesReceivableUnderSalesbasedMilestones', window );">Additional royalties receivable under sales-based milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=lgnd_PalvellaTherapeuticsIncMember', window );">Palvella | Royalty Agreements | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_BasisOfPresentationLineItems', window );"><strong>Basis of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_ProductRoyaltyPercentage', window );">Product royalty (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=lgnd_PalvellaTherapeuticsIncMember', window );">Palvella | Royalty Agreements | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_BasisOfPresentationLineItems', window );"><strong>Basis of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_ProductRoyaltyPercentage', window );">Product royalty (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=lgnd_PalvellaTherapeuticsIncMember', window );">Palvella | Licensing Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_BasisOfPresentationLineItems', window );"><strong>Basis of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_LicenseUpfrontPayment', window );">Upfront payment for license</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Finite-lived intangible assets, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=lgnd_AziyoMember', window );">Aziyo | Royalty Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_BasisOfPresentationLineItems', window );"><strong>Basis of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_ProductRoyaltyPercentage', window );">Product royalty (as a percent)</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromRoyaltiesReceived', window );">Proceeds from royalties received</a></td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_ForecastedCashFlowsEffectiveInterestRatePercent', window );">Effective interest rate of forecasted cash flows (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=lgnd_AziyoMember', window );">Aziyo | Royalty Agreements | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_BasisOfPresentationLineItems', window );"><strong>Basis of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_AdditionalRoyaltiesReceivableUnderSalesbasedMilestones', window );">Additional royalties receivable under sales-based milestones</a></td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=lgnd_CorMatrixMember', window );">CorMatrix | Royalty Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_BasisOfPresentationLineItems', window );"><strong>Basis of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_ProductRoyaltyPercentage', window );">Product royalty (as a percent)</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_RoyaltyAgreementExpirationPeriod', window );">Expiration period of royalty agreement</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=lgnd_SelexisMember', window );">Selexis | Royalty Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_BasisOfPresentationLineItems', window );"><strong>Basis of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_ForecastedCashFlowsEffectiveInterestRatePercent', window );">Effective interest rate of forecasted cash flows (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=lgnd_ConvertibleSeniorNotesDue2023Member', window );">2023 Convertible Senior Notes | Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_BasisOfPresentationLineItems', window );"><strong>Basis of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount of 2023 Notes outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 750,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest on debt instrument (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=lgnd_ConvertibleSeniorNotesDue2023Member', window );">2023 Convertible Senior Notes | Convertible Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_BasisOfPresentationLineItems', window );"><strong>Basis of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount of 2023 Notes outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 343,301,000<span></span>
</td>
<td class="nump">$ 495,280,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 750,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest on debt instrument (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=lgnd_ConvertibleSeniorNotesDue2019Member', window );">2019 Convertible Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_BasisOfPresentationLineItems', window );"><strong>Basis of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=lgnd_ConvertibleSeniorNotesDue2019Member', window );">2019 Convertible Senior Notes | Convertible Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_BasisOfPresentationLineItems', window );"><strong>Basis of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount of 2023 Notes outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 245,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest on debt instrument (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember', window );">Dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_BasisOfPresentationLineItems', window );"><strong>Basis of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiMeasurementInput', window );">Measurement input (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_AccountsReceivableCreditLossExpenseReversalCOVID19">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accounts Receivable, Credit Loss Expense (Reversal), COVID-19</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_AccountsReceivableCreditLossExpenseReversalCOVID19</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_AdditionalRoyaltiesReceivableUnderSalesbasedMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional Royalties Receivable Under Sales-based Milestones</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_AdditionalRoyaltiesReceivableUnderSalesbasedMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_BasisOfPresentationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Basis of presentation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_BasisOfPresentationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_BusinessCombinationContingentConsiderationLiabilityAmountPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Contingent Consideration, Liability, Amount per Share</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_BusinessCombinationContingentConsiderationLiabilityAmountPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_FiniteLivedIntangibleAssetsCreditLossAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Finite-lived Intangible Assets, Credit Loss Adjustments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_FiniteLivedIntangibleAssetsCreditLossAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_ForecastedCashFlowsEffectiveInterestRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Forecasted Cash Flows, Effective Interest Rate, Percent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_ForecastedCashFlowsEffectiveInterestRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_LicenseUpfrontPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License Upfront Payment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_LicenseUpfrontPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_MaturityPeriodOfHighlyLiquidSecuritiesMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maturity period of highly liquid securities maximum.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_MaturityPeriodOfHighlyLiquidSecuritiesMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_NumberOfContingentValueRightsIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of Contingent Value Rights Issued</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_NumberOfContingentValueRightsIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_ProductRoyaltyPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Product Royalty Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_ProductRoyaltyPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_RoyaltyAgreementExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Royalty Agreement, Expiration Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_RoyaltyAgreementExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockDividendsPerShareDeclared">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate dividends declared during the period for each share of common stock outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockDividendsPerShareDeclared</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226008-175313<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226052-175313<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13433-108611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226008-175313<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13433-108611<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226052-175313<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWriteDown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4542-108314<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWriteDown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromRoyaltiesReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received for royalties during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a),(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromRoyaltiesReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockCompensationPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockCompensationPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lgnd_ContractRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lgnd_ContractRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lgnd_MaterialSalesCaptisolMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lgnd_MaterialSalesCaptisolMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=lgnd_TwoThousandTwoStockIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=lgnd_TwoThousandTwoStockIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=lgnd_VestingPeriodOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=lgnd_VestingPeriodOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=lgnd_VestingPeriodTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=lgnd_VestingPeriodTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=lgnd_RestrictedStockUnitsAndPerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=lgnd_RestrictedStockUnitsAndPerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=lgnd_PfenexMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=lgnd_PfenexMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=lgnd_IcagenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=lgnd_IcagenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=lgnd_MetabasisTherapeuticsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=lgnd_MetabasisTherapeuticsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_RoyaltyAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_RoyaltyAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201613Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201613Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=lgnd_NovanMolluscumProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=lgnd_NovanMolluscumProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=lgnd_PalvellaTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=lgnd_PalvellaTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=lgnd_AziyoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=lgnd_AziyoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=lgnd_CorMatrixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=lgnd_CorMatrixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=lgnd_SelexisMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=lgnd_SelexisMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=lgnd_ConvertibleSeniorNotesDue2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=lgnd_ConvertibleSeniorNotesDue2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=lgnd_ConvertibleSeniorNotesDue2019Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=lgnd_ConvertibleSeniorNotesDue2019Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140091808105816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies - Revenue from Significant Partners (Details) - Customer Concentration Risk - Revenue<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Partner A</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideRevenueMajorCustomerLineItems', window );"><strong>Revenue, Major Customer</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Total revenues (as a percent)</a></td>
<td class="nump">41.00%<span></span>
</td>
<td class="nump">45.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Partner B</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideRevenueMajorCustomerLineItems', window );"><strong>Revenue, Major Customer</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Total revenues (as a percent)</a></td>
<td class="nump">14.00%<span></span>
</td>
<td class="nump">17.00%<span></span>
</td>
<td class="nump">27.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Partner C</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideRevenueMajorCustomerLineItems', window );"><strong>Revenue, Major Customer</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Total revenues (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EntityWideRevenueMajorCustomerLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EntityWideRevenueMajorCustomerLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=lgnd_PartnerAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=lgnd_PartnerAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=lgnd_PartnerBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=lgnd_PartnerBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=lgnd_PartnerCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=lgnd_PartnerCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140091802097288">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies - Commercial License Rights (Details) - Licensing Agreements - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross</a></td>
<td class="nump">$ 28,298<span></span>
</td>
<td class="nump">$ 28,298<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_FiniteLivedIntangibleAssetsAccumulatedAmortizationResearchDevelopmentExpenseAndCreditLossAdjustments', window );">Adjustments</a></td>
<td class="num">(18,188)<span></span>
</td>
<td class="num">(17,319)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net</a></td>
<td class="nump">10,110<span></span>
</td>
<td class="nump">10,979<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated amortization on finite-lived intangible assets</a></td>
<td class="nump">11,700<span></span>
</td>
<td class="nump">11,300<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_FiniteLivedIntangibleAssetsCreditLossAdjustments', window );">Credit loss adjustments on finite-lived intangible assets</a></td>
<td class="nump">6,500<span></span>
</td>
<td class="nump">6,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember', window );">Aziyo and CorMatrix</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross</a></td>
<td class="nump">17,696<span></span>
</td>
<td class="nump">17,696<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_FiniteLivedIntangibleAssetsAccumulatedAmortizationResearchDevelopmentExpenseAndCreditLossAdjustments', window );">Adjustments</a></td>
<td class="num">(9,461)<span></span>
</td>
<td class="num">(9,588)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net</a></td>
<td class="nump">8,235<span></span>
</td>
<td class="nump">8,108<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember', window );">Selexis and Dianomi</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross</a></td>
<td class="nump">10,602<span></span>
</td>
<td class="nump">10,602<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_FiniteLivedIntangibleAssetsAccumulatedAmortizationResearchDevelopmentExpenseAndCreditLossAdjustments', window );">Adjustments</a></td>
<td class="num">(8,727)<span></span>
</td>
<td class="num">(7,731)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net</a></td>
<td class="nump">$ 1,875<span></span>
</td>
<td class="nump">$ 2,871<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_FiniteLivedIntangibleAssetsAccumulatedAmortizationResearchDevelopmentExpenseAndCreditLossAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Finite-Lived Intangible Assets, Accumulated Amortization, Research &amp; Development Expense, and Credit Loss Adjustments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_FiniteLivedIntangibleAssetsAccumulatedAmortizationResearchDevelopmentExpenseAndCreditLossAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_FiniteLivedIntangibleAssetsCreditLossAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Finite-lived Intangible Assets, Credit Loss Adjustments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_FiniteLivedIntangibleAssetsCreditLossAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 340<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6473545&amp;loc=d3e61844-108004<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=lgnd_AziyoandCorMatrixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=lgnd_AziyoandCorMatrixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=lgnd_SelexisAndDianomiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=lgnd_SelexisAndDianomiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140091801988120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies - Royalty Revenue (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 277,133<span></span>
</td>
<td class="nump">$ 186,419<span></span>
</td>
<td class="nump">$ 120,282<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember', window );">Royalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">48,927<span></span>
</td>
<td class="nump">33,796<span></span>
</td>
<td class="nump">46,976<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lgnd_RoyaltyKyprolisMember', window );">Kyprolis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">27,472<span></span>
</td>
<td class="nump">25,164<span></span>
</td>
<td class="nump">25,046<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lgnd_RoyaltyEvomelaMember', window );">Evomela</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">10,079<span></span>
</td>
<td class="nump">6,377<span></span>
</td>
<td class="nump">5,171<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lgnd_RoyaltyOtherMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">11,376<span></span>
</td>
<td class="nump">2,255<span></span>
</td>
<td class="nump">2,566<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lgnd_RoyaltyPromactaMember', window );">Promacta</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,193<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lgnd_MaterialSalesCaptisolMember', window );">Captisol</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">164,250<span></span>
</td>
<td class="nump">109,959<span></span>
</td>
<td class="nump">31,489<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lgnd_ContractRevenueMember', window );">Contract revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">63,956<span></span>
</td>
<td class="nump">42,664<span></span>
</td>
<td class="nump">41,817<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember', window );">Service Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">23,712<span></span>
</td>
<td class="nump">21,803<span></span>
</td>
<td class="nump">16,776<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lgnd_LicenseFeesMember', window );">License Fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">5,084<span></span>
</td>
<td class="nump">4,378<span></span>
</td>
<td class="nump">6,199<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lgnd_MilestoneMember', window );">Milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">28,748<span></span>
</td>
<td class="nump">11,516<span></span>
</td>
<td class="nump">17,173<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lgnd_LicenseFeesMilestonesAndOtherProductOtherMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 6,412<span></span>
</td>
<td class="nump">$ 4,967<span></span>
</td>
<td class="nump">$ 1,669<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_RoyaltyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lgnd_RoyaltyKyprolisMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lgnd_RoyaltyKyprolisMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lgnd_RoyaltyEvomelaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lgnd_RoyaltyEvomelaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lgnd_RoyaltyOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lgnd_RoyaltyOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lgnd_RoyaltyPromactaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lgnd_RoyaltyPromactaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lgnd_MaterialSalesCaptisolMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lgnd_MaterialSalesCaptisolMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lgnd_ContractRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lgnd_ContractRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lgnd_LicenseFeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lgnd_LicenseFeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lgnd_MilestoneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lgnd_MilestoneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lgnd_LicenseFeesMilestonesAndOtherProductOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lgnd_LicenseFeesMilestonesAndOtherProductOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140091805847720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies - Calculation of Earnings per Share (Details) - shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDilutedLineItems', window );"><strong>Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average common shares outstanding - basic (shares)</a></td>
<td class="nump">16,630,000<span></span>
</td>
<td class="nump">16,185,000<span></span>
</td>
<td class="nump">18,995,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Shares used to compute diluted income per share (shares)</a></td>
<td class="nump">17,246,000<span></span>
</td>
<td class="nump">16,185,000<span></span>
</td>
<td class="nump">19,757,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive shares excluded from calculation due to anti-dilutive effect (shares)</a></td>
<td class="nump">4,793,000<span></span>
</td>
<td class="nump">8,458,000<span></span>
</td>
<td class="nump">8,926,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDilutedLineItems', window );"><strong>Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment', window );">Dilutive potential common shares (shares)</a></td>
<td class="nump">96,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">43,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDilutedLineItems', window );"><strong>Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment', window );">Dilutive potential common shares (shares)</a></td>
<td class="nump">520,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">719,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDilutedLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDilutedLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140091805719480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Sale of Vernalis R&amp;D and Promacta License - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">2 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 02, 2020</div></th>
<th class="th"><div>Mar. 06, 2019</div></th>
<th class="th"><div>Mar. 06, 2019</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 01, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromDivestitureOfBusinesses', window );">Proceeds on sale of Vernalis R&amp;D, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 22,061<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net (excluding goodwill)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">551,040<span></span>
</td>
<td class="nump">$ 595,330<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=lgnd_VernalisMember', window );">Vernalis | Disposal Group, Held-for-sale or Disposed of by Sale, Not Discontinued Operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromDivestitureOfBusinesses', window );">Proceeds on sale of Vernalis R&amp;D, net</a></td>
<td class="nump">$ 26,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit', window );">Goodwill written off</a></td>
<td class="nump">$ 3,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfIntangibleAssets', window );">Gain from sale of intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=lgnd_VernalisMember', window );">Vernalis | In Process Research and Development | Disposal Group, Held-for-sale or Disposed of by Sale, Not Discontinued Operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net (excluding goodwill)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,100<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=lgnd_PromactaMember', window );">Promacta | Disposal Group, Held-for-sale or Disposed of by Sale, Not Discontinued Operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromDivestitureOfBusinesses', window );">Proceeds on sale of Vernalis R&amp;D, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 827,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfIntangibleAssets', window );">Gain from sale of intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 812,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=lgnd_PromactaMember', window );">Promacta | In Process Research and Development | Disposal Group, Held-for-sale or Disposed of by Sale, Not Discontinued Operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net (excluding goodwill)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDispositionOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDispositionOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of divestiture of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromDivestitureOfBusinesses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from the sale of a portion of the company's business, for example a segment, division, branch or other business, during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromDivestitureOfBusinesses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=lgnd_VernalisMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=lgnd_VernalisMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=lgnd_PromactaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=lgnd_PromactaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140091805847992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Short-term Investments: Investment in Viking - Narrative (Details) - USD ($)<br> $ / shares in Units, shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Aug. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Variable Interest Entity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Warrants</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 1.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Investment in Viking common stock</a></td>
<td class="nump">$ 30.9<span></span>
</td>
<td class="nump">$ 32.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants (USD per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.50<span></span>
</td>
<td class="nump">$ 125.08<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_WarrantMember', window );">Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Variable Interest Entity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_InvestmentInVikingCurrent', window );">Value of warrants in Viking</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_OwnershipAxis=lgnd_VikingTherapeuticsInc.Member', window );">Viking Therapeutics, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Variable Interest Entity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LimitedLiabilityCompanyLLCOrLimitedPartnershipLPMembersOrLimitedPartnersOwnershipInterest', window );">Ownership interest (as a percent)</a></td>
<td class="nump">8.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_NumberOfSharesSoldOfEquityMethodInvestee', window );">Stock sold of equity method investee (in shares)</a></td>
<td class="nump">0.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_InvestmentInVikingCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Investment in Viking, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_InvestmentInVikingCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_NumberOfSharesSoldOfEquityMethodInvestee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number Of Shares Sold Of Equity Method Investee</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_NumberOfSharesSoldOfEquityMethodInvestee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=123594786&amp;loc=SL75136599-209740<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LimitedLiabilityCompanyLLCOrLimitedPartnershipLPMembersOrLimitedPartnersOwnershipInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage investment held by members or limited partners of limited liability company (LLC) or limited partnership (LP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 272<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6373374&amp;loc=d3e70478-108055<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LimitedLiabilityCompanyLLCOrLimitedPartnershipLPMembersOrLimitedPartnersOwnershipInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableInterestEntityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableInterestEntityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=lgnd_VikingTherapeuticsInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=lgnd_VikingTherapeuticsInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140091795542648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1">36 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Oct. 01, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 09, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 08, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 01, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 23, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>acquisition</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_NumberOfAcquisitions', window );">Number of acquisitions | acquisition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfBusinessesAcquired', window );">Number of business combinations | acquisition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_NumberOfAssetAcquisitions', window );">Number of asset acquisitions | acquisition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Finite-lived intangible asset, useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">20 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=lgnd_PfenexMember', window );">Pfenex</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Consideration transferred</a></td>
<td class="nump">$ 465,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Gross payments to acquire business</a></td>
<td class="nump">429,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration liability</a></td>
<td class="nump">77,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_BusinessCombinationContingentConsiderationLiabilityFairValueDisclosure', window );">Fair value of contingent earn-out payment</a></td>
<td class="nump">37,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts', window );">Post-combination expense</a></td>
<td class="nump">1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Reduction in contingent liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 37,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_PaymentsToAcquireBusinessesGrossAttributableToVestedPortionOfStockOptions', window );">Gross payments to acquire business attributable to vested portion of stock options</a></td>
<td class="nump">17,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards', window );">Cash to settle unvested stock options recognized as share-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationAcquisitionRelatedCosts', window );">Acquisition-related costs</a></td>
<td class="nump">$ 20,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual', window );">Revenue of acquiree since acquisition date included in comprehensive income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual', window );">Income (loss) before income taxes of acquiree since acquisition date included in comprehensive income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(19,300,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationIntegrationRelatedCosts', window );">Integration related costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,100,000<span></span>
</td>
<td class="nump">$ 4,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=lgnd_PfenexMember', window );">Pfenex | Discount Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Contingent consideration liability, measurement input (as a percent)</a></td>
<td class="nump">0.071<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=lgnd_PfenexMember', window );">Pfenex | Customer Relationships | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsDiscountRate', window );">Discount rate used to value intangible assets acquired (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=lgnd_PfenexMember', window );">Pfenex | Customer Relationships | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsDiscountRate', window );">Discount rate used to value intangible assets acquired (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=lgnd_PfenexMember', window );">Pfenex | Core Technology | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Weighted-average useful lives of acquired finite-lived intangible assets</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=lgnd_PfenexMember', window );">Pfenex | Core Technology | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Weighted-average useful lives of acquired finite-lived intangible assets</a></td>
<td class="text">19 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=lgnd_TaurusBiosciencesLLCMember', window );">Taurus</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Consideration transferred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Gross payments to acquire business</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_BusinessCombinationConsiderationTransferredHoldback', window );">Holdback from acquisition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Acquired intangibles</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,005,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=lgnd_TaurusBiosciencesLLCMember', window );">Taurus | Contingent Value Right for Internal Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=lgnd_TaurusBiosciencesLLCMember', window );">Taurus | Contingent Value Right on Product Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_BusinessCombinationContingentConsiderationLiabilityPercentageOfAcquireeRevenues', window );">Proportion of milestone payments (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=lgnd_TaurusBiosciencesLLCMember', window );">Taurus | Core Technology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Weighted-average useful lives of acquired finite-lived intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=lgnd_XCellaBiosciencesIncMember', window );">xCella</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Consideration transferred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_BusinessCombinationConsiderationTransferredHoldback', window );">Holdback from acquisition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Acquired intangibles</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,582,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=lgnd_XCellaBiosciencesIncMember', window );">xCella | Earnout Rights for Partner Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=lgnd_XCellaBiosciencesIncMember', window );">xCella | Milestone Payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_BusinessCombinationContingentConsiderationLiabilityPercentageOfAcquireeRevenues', window );">Proportion of milestone payments (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=lgnd_XCellaBiosciencesIncMember', window );">xCella | Core Technology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Weighted-average useful lives of acquired finite-lived intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=lgnd_IcagenMember', window );">Icagen</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Consideration transferred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Gross payments to acquire business</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_BusinessCombinationContingentConsiderationLiabilityFairValueDisclosure', window );">Fair value of contingent earn-out payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Weighted-average useful lives of acquired finite-lived intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">9 years 8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=lgnd_IcagenMember', window );">Icagen | Discount Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Contingent consideration liability, measurement input (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.055<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=lgnd_IcagenMember', window );">Icagen | Customer Relationships</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsDiscountRate', window );">Discount rate used to value intangible assets acquired (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Weighted-average useful lives of acquired finite-lived intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">9 years 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Acquired intangibles</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=lgnd_IcagenMember', window );">Icagen | Core Technology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Weighted-average useful lives of acquired finite-lived intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Acquired intangibles</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=lgnd_AbInitioMember', window );">Ab Initio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Consideration transferred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Gross payments to acquire business</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Acquired intangibles</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_BusinessCombinationCashHoldbackForPotentialIndemnificationClaims', window );">Cash holdback for potential indemnification claims</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount', window );">Goodwill acquired that is expected to be deductible for tax purposes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_BusinessCombinationAssumptionsUsedEstimatedFutureCashFlowsDiscountRate', window );">Projected cash flow discount rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=lgnd_AbInitioMember', window );">Ab Initio | Core Technology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Finite-lived intangible asset, useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">20 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_BusinessCombinationAssumptionsUsedEstimatedFutureCashFlowsDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Assumptions Used Estimated Future Cash Flows, Discount Rate</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_BusinessCombinationAssumptionsUsedEstimatedFutureCashFlowsDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_BusinessCombinationCashHoldbackForPotentialIndemnificationClaims">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Cash Holdback for Potential Indemnification Claims</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_BusinessCombinationCashHoldbackForPotentialIndemnificationClaims</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_BusinessCombinationConsiderationTransferredHoldback">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Consideration Transferred, Holdback</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_BusinessCombinationConsiderationTransferredHoldback</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_BusinessCombinationContingentConsiderationLiabilityFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Contingent Consideration, Liability, Fair Value Disclosure</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_BusinessCombinationContingentConsiderationLiabilityFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_BusinessCombinationContingentConsiderationLiabilityPercentageOfAcquireeRevenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Contingent Consideration, Liability, Percentage of Acquiree Revenues</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_BusinessCombinationContingentConsiderationLiabilityPercentageOfAcquireeRevenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Discount Rate</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_NumberOfAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of Acquisitions</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_NumberOfAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_NumberOfAssetAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number Of Asset Acquisitions</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_NumberOfAssetAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_PaymentsToAcquireBusinessesGrossAttributableToVestedPortionOfStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments to Acquire Businesses, Gross, Attributable to Vested Portion of Stock Options</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_PaymentsToAcquireBusinessesGrossAttributableToVestedPortionOfStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of direct costs of the business combination including legal, accounting, and other costs incurred to consummate the business acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of goodwill arising from a business combination that is expected to be deductible for tax purposes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAcquisitionRelatedCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 25<br> -Paragraph 23<br> -URI http://asc.fasb.org/extlink&amp;oid=123586518&amp;loc=d3e1043-128460<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAcquisitionRelatedCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferred1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6613-128477<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6578-128477<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferred1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e7008-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure contingent consideration liability from business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationIntegrationRelatedCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Costs incurred to effect a business combination which have been expensed during the period. Such costs could include business integration costs, systems integration and conversion costs, and severance and other employee-related costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationIntegrationRelatedCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the amount of earnings or loss of the acquiree since the acquisition date included in the consolidated income statement for the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the amount of revenue of the acquiree since the acquisition date included in the consolidated income statement for the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of identifiable intangible assets recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI http://asc.fasb.org/extlink&amp;oid=123455525&amp;loc=d3e2207-128464<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate cash paid by the entity during the period to settle equity instruments granted under equity-based payment arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (k)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfBusinessesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of businesses acquired by the entity during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfBusinessesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=lgnd_PfenexMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=lgnd_PfenexMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TechnologyBasedIntangibleAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TechnologyBasedIntangibleAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=lgnd_TaurusBiosciencesLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=lgnd_TaurusBiosciencesLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=lgnd_ContingentValueRightForInternalResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=lgnd_ContingentValueRightForInternalResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=lgnd_ContingentValueRightOnProductRevenuesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=lgnd_ContingentValueRightOnProductRevenuesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=lgnd_XCellaBiosciencesIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=lgnd_XCellaBiosciencesIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=lgnd_EarnoutRightsForPartnerResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=lgnd_EarnoutRightsForPartnerResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=lgnd_MilestonePaymentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=lgnd_MilestonePaymentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=lgnd_IcagenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=lgnd_IcagenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=lgnd_AbInitioMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=lgnd_AbInitioMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140091805704264">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Acquisitions - Assets Acquired and Liabilities Assumed (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Oct. 01, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">$ 181,206<span></span>
</td>
<td class="nump">$ 189,662<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=lgnd_PfenexMember', window );">Pfenex</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents', window );">Cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 51,407<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash', window );">Restricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables', window );">Accounts and unbilled receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,359<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment', window );">Property and equipment, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,823<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssets', window );">Right-of-use asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,070<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets', window );">Other assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,338<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssets', window );">Intangibles acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">385,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">82,303<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable', window );">Accounts payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,814)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilitiesCurrent', window );">Accrued liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(9,606)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,908)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLeaseLiabilities', window );">Lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,070)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther', window );">Other liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,382)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities', window );">Deferred tax liabilities, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(42,622)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet', window );">Total consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 465,098<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Accrued Liabilities, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Lease Liabilities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Restricted Cash</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Right-of-Use Assets</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount due from customers or clients for goods or services, including trade receivables, that have been delivered or sold in the normal course of business, and amounts due from others, including related parties expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred for goods and services received that are used in an entity's business and related party payables, assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred revenue expected to be recognized as such within one year or the normal operating cycle, if longer, assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI http://asc.fasb.org/extlink&amp;oid=123455525&amp;loc=d3e2207-128464<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of other liabilities due after one year or the normal operating cycle, if longer, assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of other assets expected to be realized or consumed after one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of property, plant, and equipment recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI http://asc.fasb.org/extlink&amp;oid=123455525&amp;loc=d3e2207-128464<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=lgnd_PfenexMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=lgnd_PfenexMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140091805664504">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Acquisitions - Intangibles Acquired and Weighted Average Useful Life (Details) - Pfenex<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Oct. 01, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Approximate Fair Value</a></td>
<td class="nump">$ 385,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=lgnd_PfenexMember', window );">Contractual Relationships - Alvogen</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Approximate Fair Value</a></td>
<td class="nump">$ 114,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Estimated useful life (in years)</a></td>
<td class="text">12 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=lgnd_PfenexMember', window );">Contractual Relationships - Merck</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Approximate Fair Value</a></td>
<td class="nump">$ 117,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Estimated useful life (in years)</a></td>
<td class="text">12 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=lgnd_PfenexMember', window );">Contractual Relationships - Jazz</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Approximate Fair Value</a></td>
<td class="nump">$ 80,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Estimated useful life (in years)</a></td>
<td class="text">17 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=lgnd_PfenexMember', window );">Contractual Relationships - SII</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Approximate Fair Value</a></td>
<td class="nump">$ 49,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Estimated useful life (in years)</a></td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=lgnd_PfenexMember', window );">Contractual Relationships - Arcellx</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Approximate Fair Value</a></td>
<td class="nump">$ 2,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Estimated useful life (in years)</a></td>
<td class="text">17 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=lgnd_PfenexMember', window );">Acquired Technologies</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Approximate Fair Value</a></td>
<td class="nump">$ 23,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=lgnd_PfenexMember', window );">Minimum | Acquired Technologies</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Estimated useful life (in years)</a></td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=lgnd_PfenexMember', window );">Maximum | Acquired Technologies</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Estimated useful life (in years)</a></td>
<td class="text">19 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of intangible assets, excluding goodwill, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=lgnd_PfenexMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=lgnd_PfenexMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=lgnd_ContractualRelationshipsAlvogenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=lgnd_ContractualRelationshipsAlvogenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=lgnd_ContractualRelationshipsMerckMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=lgnd_ContractualRelationshipsMerckMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=lgnd_ContractualRelationshipsJazzMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=lgnd_ContractualRelationshipsJazzMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=lgnd_ContractualRelationshipsSIIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=lgnd_ContractualRelationshipsSIIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=lgnd_ContractualRelationshipsArcellxMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=lgnd_ContractualRelationshipsArcellxMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TechnologyBasedIntangibleAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TechnologyBasedIntangibleAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140091808477000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions - Pro Forma Financial Information (Details) - Pfenex - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionsProFormaRevenue', window );">Revenue</a></td>
<td class="nump">$ 189,203<span></span>
</td>
<td class="nump">$ 170,608<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss', window );">Net Income (loss)</a></td>
<td class="num">$ (60,059)<span></span>
</td>
<td class="nump">$ 594,941<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareProFormaAbstract', window );"><strong>Net income (loss) per common share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic', window );">Basic (USD per share)</a></td>
<td class="num">$ (3.71)<span></span>
</td>
<td class="nump">$ 31.32<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted', window );">Diluted (USD per share)</a></td>
<td class="num">$ (3.71)<span></span>
</td>
<td class="nump">$ 30.11<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The pro forma basic net income per share for a period as if the business combination or combinations had been completed at the beginning of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The pro forma diluted net income per share for a period as if the business combination or combinations had been completed at the beginning of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The pro forma net Income or Loss for the period as if the business combination or combinations had been completed at the beginning of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionsProFormaRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The pro forma revenue for a period as if the business combination or combinations had been completed at the beginning of the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionsProFormaRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareProFormaAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareProFormaAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=lgnd_PfenexMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=lgnd_PfenexMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140091805887048">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Acquisitions - Allocation of Consideration (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Sep. 09, 2020</div></th>
<th class="th"><div>Sep. 08, 2020</div></th>
<th class="th"><div>Apr. 01, 2020</div></th>
<th class="th"><div>Jul. 23, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">$ 181,206<span></span>
</td>
<td class="nump">$ 189,662<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=lgnd_TaurusBiosciencesLLCMember', window );">Taurus</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents', window );">Cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 47<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Intangibles assets with finite-life - core technology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,005<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet', window );">Total consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,052<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=lgnd_XCellaBiosciencesIncMember', window );">xCella</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndCurrentAssetsOther', window );">Cash and other assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 240<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilitiesCurrent', window );">Accrued liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(142)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities', window );">Deferred tax liabilities, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(604)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Intangibles assets with finite-life - core technology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,582<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet', window );">Total consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,076<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=lgnd_IcagenMember', window );">Icagen</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment', window );">Property and equipment, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,173<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets', window );">Prepaids and other assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">588<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities', window );">Liabilities assumed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(812)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,685)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets', window );">Deferred tax assets, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">861<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssets', window );">Acquired intangibles</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,015<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet', window );">Total consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19,940<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=lgnd_AbInitioMember', window );">Ab Initio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndCurrentAssetsOther', window );">Cash and other assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable', window );">Accounts payable and accrued liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(83)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities', window );">Deferred tax liabilities, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(146)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Intangibles assets with finite-life - core technology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,400<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,812<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet', window );">Total consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,011<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Accrued Liabilities, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndCurrentAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Current Assets, Other</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndCurrentAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities due within one year or within the normal operating cycle, if longer, assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred for goods and services received that are used in an entity's business and related party payables, assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred revenue expected to be recognized as such within one year or the normal operating cycle, if longer, assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax asset attributable to deductible temporary differences and carryforwards acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of identifiable intangible assets recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI http://asc.fasb.org/extlink&amp;oid=123455525&amp;loc=d3e2207-128464<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI http://asc.fasb.org/extlink&amp;oid=123455525&amp;loc=d3e2207-128464<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of property, plant, and equipment recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI http://asc.fasb.org/extlink&amp;oid=123455525&amp;loc=d3e2207-128464<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=lgnd_TaurusBiosciencesLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=lgnd_TaurusBiosciencesLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=lgnd_XCellaBiosciencesIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=lgnd_XCellaBiosciencesIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=lgnd_IcagenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=lgnd_IcagenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=lgnd_AbInitioMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=lgnd_AbInitioMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140091797155864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurement - Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>agreement</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 31, 2010 </div>
<div>agreement</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_NumberOfContingentValueRightAgreements', window );">Number of CVR agreements | agreement</a></td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TimingOfTransferOfGoodOrServiceAxis=us-gaap_TransferredOverTimeMember', window );">Transferred over Time | Phase 3 Clinical Trial</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetGross', window );">Gross contract asset</a></td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Transferred over Time | Development, Regulatory, &amp; Commercial Milestones and Tiered Royalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Investments', window );">Investments</a></td>
<td class="nump">375,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=lgnd_LiabilityForContingentValueRightsCompanyCrystalMember', window );">Contingent liabilities - Crystal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities', window );">Payment for contingent consideration liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=lgnd_LiabilityForContingentValueRightsCompanyIcagenMember', window );">Contingent liabilities - Icagen</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities', window );">Payment for contingent consideration liabilities</a></td>
<td class="nump">1,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=lgnd_LiabilityForContingentValueRightsCompanyPfenexMember', window );">Contingent liabilities - Pfenex</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Reduction in contingent liability</a></td>
<td class="nump">37,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value</a></td>
<td class="nump">321,586,000<span></span>
</td>
<td class="nump">363,567,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities, fair value</a></td>
<td class="nump">11,157,000<span></span>
</td>
<td class="nump">49,193,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Contingent liabilities - Crystal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Contingent liabilities - CyDex</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities, fair value</a></td>
<td class="nump">349,000<span></span>
</td>
<td class="nump">508,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Contingent liabilities - Metabasis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities, fair value</a></td>
<td class="nump">3,358,000<span></span>
</td>
<td class="nump">3,821,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Contingent liabilities - Icagen</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities, fair value</a></td>
<td class="nump">7,364,000<span></span>
</td>
<td class="nump">6,404,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Contingent liabilities - Pfenex</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Liability for restricted investments owed to former licensees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities, fair value</a></td>
<td class="nump">86,000<span></span>
</td>
<td class="nump">60,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Short-term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value</a></td>
<td class="nump">290,697,000<span></span>
</td>
<td class="nump">324,478,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Investment in Viking common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value</a></td>
<td class="nump">30,889,000<span></span>
</td>
<td class="nump">32,763,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Investment in Viking warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,326,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Quoted Prices in Active Markets for Identical Assets (Level 1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value</a></td>
<td class="nump">40,624,000<span></span>
</td>
<td class="nump">42,527,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities, fair value</a></td>
<td class="nump">86,000<span></span>
</td>
<td class="nump">60,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Quoted Prices in Active Markets for Identical Assets (Level 1) | Contingent liabilities - Crystal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Quoted Prices in Active Markets for Identical Assets (Level 1) | Contingent liabilities - CyDex</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities, fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Quoted Prices in Active Markets for Identical Assets (Level 1) | Contingent liabilities - Metabasis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities, fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Quoted Prices in Active Markets for Identical Assets (Level 1) | Contingent liabilities - Icagen</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities, fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Quoted Prices in Active Markets for Identical Assets (Level 1) | Contingent liabilities - Pfenex</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Quoted Prices in Active Markets for Identical Assets (Level 1) | Liability for restricted investments owed to former licensees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities, fair value</a></td>
<td class="nump">86,000<span></span>
</td>
<td class="nump">60,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Quoted Prices in Active Markets for Identical Assets (Level 1) | Short-term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value</a></td>
<td class="nump">9,735,000<span></span>
</td>
<td class="nump">3,438,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Quoted Prices in Active Markets for Identical Assets (Level 1) | Investment in Viking common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value</a></td>
<td class="nump">30,889,000<span></span>
</td>
<td class="nump">32,763,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Quoted Prices in Active Markets for Identical Assets (Level 1) | Investment in Viking warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,326,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Significant Other Observable Inputs (Level 2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value</a></td>
<td class="nump">280,553,000<span></span>
</td>
<td class="nump">320,647,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities, fair value</a></td>
<td class="nump">3,358,000<span></span>
</td>
<td class="nump">3,821,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Significant Other Observable Inputs (Level 2) | Contingent liabilities - Crystal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Significant Other Observable Inputs (Level 2) | Contingent liabilities - CyDex</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities, fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Significant Other Observable Inputs (Level 2) | Contingent liabilities - Metabasis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities, fair value</a></td>
<td class="nump">3,358,000<span></span>
</td>
<td class="nump">3,821,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Significant Other Observable Inputs (Level 2) | Contingent liabilities - Icagen</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities, fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Significant Other Observable Inputs (Level 2) | Contingent liabilities - Pfenex</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Significant Other Observable Inputs (Level 2) | Liability for restricted investments owed to former licensees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities, fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Significant Other Observable Inputs (Level 2) | Short-term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value</a></td>
<td class="nump">280,553,000<span></span>
</td>
<td class="nump">320,647,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Significant Other Observable Inputs (Level 2) | Investment in Viking common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Significant Other Observable Inputs (Level 2) | Investment in Viking warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Significant Unobservable Inputs (Level 3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value</a></td>
<td class="nump">409,000<span></span>
</td>
<td class="nump">393,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities, fair value</a></td>
<td class="nump">7,713,000<span></span>
</td>
<td class="nump">45,312,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Significant Unobservable Inputs (Level 3) | Contingent liabilities - Crystal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Significant Unobservable Inputs (Level 3) | Contingent liabilities - CyDex</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities, fair value</a></td>
<td class="nump">349,000<span></span>
</td>
<td class="nump">508,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Significant Unobservable Inputs (Level 3) | Contingent liabilities - Metabasis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities, fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Significant Unobservable Inputs (Level 3) | Contingent liabilities - Icagen</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities, fair value</a></td>
<td class="nump">7,364,000<span></span>
</td>
<td class="nump">6,404,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Significant Unobservable Inputs (Level 3) | Contingent liabilities - Pfenex</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Significant Unobservable Inputs (Level 3) | Liability for restricted investments owed to former licensees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities, fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Significant Unobservable Inputs (Level 3) | Short-term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value</a></td>
<td class="nump">409,000<span></span>
</td>
<td class="nump">393,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Significant Unobservable Inputs (Level 3) | Investment in Viking common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Significant Unobservable Inputs (Level 3) | Investment in Viking warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_NumberOfContingentValueRightAgreements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number Of Contingent Value Right Agreements</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_NumberOfContingentValueRightAgreements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e7008-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allowance for credit loss, of right to consideration in exchange for good or service transferred to customer, when right is conditioned on something other than passage of time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7A<br> -URI http://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=SL6953401-111524<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919253-210447<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130533-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Investments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.1(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Investments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial and nonfinancial obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability exceeding amount recognized at acquisition date. Includes, but is not limited to, measurement period adjustment and less amount paid soon after acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (ee)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3367-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TimingOfTransferOfGoodOrServiceAxis=us-gaap_TransferredOverTimeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TimingOfTransferOfGoodOrServiceAxis=us-gaap_TransferredOverTimeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lgnd_Phase3ClinicalTrialMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lgnd_Phase3ClinicalTrialMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lgnd_DevelopmentRegulatoryCommercialMilestonesAndTieredRoyaltiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lgnd_DevelopmentRegulatoryCommercialMilestonesAndTieredRoyaltiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=lgnd_LiabilityForContingentValueRightsCompanyCrystalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=lgnd_LiabilityForContingentValueRightsCompanyCrystalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=lgnd_LiabilityForContingentValueRightsCompanyIcagenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=lgnd_LiabilityForContingentValueRightsCompanyIcagenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=lgnd_LiabilityForContingentValueRightsCompanyPfenexMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=lgnd_LiabilityForContingentValueRightsCompanyPfenexMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=lgnd_LiabilityForContingentValueRightsCompanyCydexMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=lgnd_LiabilityForContingentValueRightsCompanyCydexMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=lgnd_LiabilityForContingentValueRightsCompanyMetabasisMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=lgnd_LiabilityForContingentValueRightsCompanyMetabasisMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=lgnd_LiabilityForRestrictedInvestmentsOwedToFormerLicenseesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=lgnd_LiabilityForRestrictedInvestmentsOwedToFormerLicenseesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_ShortTermInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_ShortTermInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_EquitySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_EquitySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140091802042648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurement - Reconciliation of Level 3 Financial Instruments (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_PaymentsToContingentValueRightHolders', window );">Payments to CVR holders and other contingency payments</a></td>
<td class="num">$ (1,820)<span></span>
</td>
<td class="num">$ (2,325)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Fair value of level 3 financial instruments at beginning of period</a></td>
<td class="nump">45,312<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_PaymentsToContingentValueRightHolders', window );">Payments to CVR holders and other contingency payments</a></td>
<td class="num">(1,770)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Fair value adjustments to contingent liabilities</a></td>
<td class="num">(36,549)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityContingentConsiderationFromAcquisition', window );">Contingent liabilities from xCella asset acquisition</a></td>
<td class="nump">720<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Fair value of level 3 financial instruments at end of period</a></td>
<td class="nump">$ 7,713<span></span>
</td>
<td class="nump">$ 45,312<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityContingentConsiderationFromAcquisition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Contingent Consideration from Acquisition</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityContingentConsiderationFromAcquisition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_PaymentsToContingentValueRightHolders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments to contingent value right holders</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_PaymentsToContingentValueRightHolders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140091803995688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Asset impairment charges</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123351718&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140091795433064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiability', window );">Finance lease liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 104,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeFinanceLeaseRemainingLeaseTerm', window );">Remaining lease term of finance leases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right of use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,542,000<span></span>
</td>
<td class="nump">$ 6,892,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,547,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted-average remaining lease term of operating leases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">8 years 1 month 6 days<span></span>
</td>
<td class="text">4 years 4 months 24 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted-average discount rate of operating leases (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.10%<span></span>
</td>
<td class="nump">5.70%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating lease payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,600,000<span></span>
</td>
<td class="nump">$ 2,400,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Operating lease expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,600,000<span></span>
</td>
<td class="nump">2,100,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubleaseIncome', window );">Sublease income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted-average remaining lease term of finance leases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">7 years 10 months 24 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent', window );">Weighted-average discount rate of finance leases (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="nump">3.50%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseInterestPaymentOnLiability', window );">Cash paid for amounts included in finance lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,300,000<span></span>
</td>
<td class="nump">$ 9,700,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseInterestExpense', window );">Finance lease expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,300,000<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember', window );">Building</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right of use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm', window );">Remaining lease term of operating leases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Renewal term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lgnd_MaterialSalesCaptisolMember', window );">Captisol</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_PurchaseCommitmentConsiderationPaidToDate', window );">Consideration paid to date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 69,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_PurchaseCommitmentConsiderationPaidAllocatedToInventory', window );">Portion of consideration allocated to inventory</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiability', window );">Finance lease liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability', window );">Right-of-use asset recognized</a></td>
<td class="nump">$ 16,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_PurchaseCommitmentConsiderationPaidAllocatedToInventory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchase Commitment, Consideration Paid, Allocated to Inventory</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_PurchaseCommitmentConsiderationPaidAllocatedToInventory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_PurchaseCommitmentConsiderationPaidToDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchase Commitment, Consideration Paid to Date</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_PurchaseCommitmentConsiderationPaidToDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense on finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918638-209977<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseInterestPaymentOnLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest paid on finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseInterestPaymentOnLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for finance lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeFinanceLeaseRemainingLeaseTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Remaining lease term of finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeFinanceLeaseRemainingLeaseTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRemainingLeaseTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918638-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubleaseIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of sublease income excluding finance and operating lease expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubleaseIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lgnd_MaterialSalesCaptisolMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lgnd_MaterialSalesCaptisolMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140091805800024">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Operating and Finance Lease Assets and Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease assets</a></td>
<td class="nump">$ 16,542<span></span>
</td>
<td class="nump">$ 6,892<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAsset', window );">Finance lease assets</a></td>
<td class="nump">16,207<span></span>
</td>
<td class="nump">15,842<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_LeaseRightOfUseAsset', window );">Total lease assets</a></td>
<td class="nump">32,749<span></span>
</td>
<td class="nump">22,734<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current operating lease liabilities</a></td>
<td class="nump">2,053<span></span>
</td>
<td class="nump">1,885<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Current finance lease liabilities</a></td>
<td class="nump">46<span></span>
</td>
<td class="nump">6,593<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_LeaseLiabilityCurrent', window );">Current lease liabilities</a></td>
<td class="nump">2,099<span></span>
</td>
<td class="nump">8,478<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>Noncurrent liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long-term operating lease liabilities</a></td>
<td class="nump">15,494<span></span>
</td>
<td class="nump">5,643<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrent', window );">Long-term finance lease liabilities</a></td>
<td class="nump">58<span></span>
</td>
<td class="nump">112<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_LeaseLiability', window );">Total lease liabilities</a></td>
<td class="nump">$ 17,651<span></span>
</td>
<td class="nump">$ 14,233<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList', window );">Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">Other Liabilities, Noncurrent<span></span>
</td>
<td class="text">Other Liabilities, Noncurrent<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_LeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lease, Liability</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_LeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_LeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lease, Liability, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_LeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_LeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lease, Right-of-Use Asset</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_LeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes noncurrent finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140091799584424">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Maturities of Operating and Finance Lease Liabilities (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Operating Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2022</a></td>
<td class="nump">$ 3,653<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2023</a></td>
<td class="nump">3,414<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2024</a></td>
<td class="nump">2,716<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2025</a></td>
<td class="nump">2,614<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2026</a></td>
<td class="nump">2,670<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="nump">10,832<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">25,899<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_LesseeOperatingLeaseLiabilityTenantImprovementAllowance', window );">Less tenant improvement allowance</a></td>
<td class="num">(4,327)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less imputed interest</a></td>
<td class="num">(4,025)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of lease liabilities</a></td>
<td class="nump">17,547<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Finance Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2022</a></td>
<td class="nump">56<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo', window );">2023</a></td>
<td class="nump">49<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree', window );">2024</a></td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour', window );">2025</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive', window );">2026</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">109<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_FinanceLeaseLiabilityTenantImprovementAllowance', window );">Less tenant improvement allowance</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount', window );">Less imputed interest</a></td>
<td class="num">(5)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiability', window );">Present value of lease liabilities</a></td>
<td class="nump">$ 104<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_FinanceLeaseLiabilityTenantImprovementAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Finance Lease, Liability, Tenant Improvement Allowance</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_FinanceLeaseLiabilityTenantImprovementAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_LesseeOperatingLeaseLiabilityTenantImprovementAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Liability, Tenant Improvement Allowance</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_LesseeOperatingLeaseLiabilityTenantImprovementAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140091794651544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Senior Notes - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="6">1 Months Ended</th>
<th class="th" colspan="3">2 Months Ended</th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Aug. 15, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 22, 2018 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Feb. 28, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 31, 2018 </div>
<div>USD ($) </div>
<div>trading_day </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 31, 2014 </div>
<div>USD ($) </div>
<div>trading_day </div>
<div>day </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Nov. 30, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 30, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>option </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on debt extinguishment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,303,000<span></span>
</td>
<td class="nump">$ 2,466,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants issued in public offering (shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,264,643<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_ExercisePriceofConvertibleBondHedge', window );">Exercise price of convertible bond hedge (USD per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75.05<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price (USD per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 125.08<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt', window );">Debt issuance costs related to the equity component of convertible debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,407,000<span></span>
</td>
<td class="nump">$ 3,236,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Value of warrants issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_PaymentsToUnwindWarrants', window );">Payments to unwind warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_ProceedsFromUnwindingConvertibleBondHedges', window );">Proceeds from unwinding convertible bond hedges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_NumberOfOptionsUnderConvertibleBondHedges', window );">Number of options under convertible bond hedges | option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">598,021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember', window );">Convertible Notes | 2019 Convertible Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount of debt instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 245,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromDebtNetOfIssuanceCosts', window );">Net proceeds from debt issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 239,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.83%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionRatio1', window );">Convertible debt conversion ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0133251<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Debt conversion price per share (USD per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75.05<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest on debt instrument (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal', window );">If-converted value in excess of principal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23,400,000<span></span>
</td>
<td class="nump">$ 341,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_DebtInstrumentConvertibleIncreaseDecreaseIfConvertedValueInExcessOfPrincipal', window );">Increase (decrease) in if-converted value in excess of principal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 118,700,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Notices for conversion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 195,900,000<span></span>
</td>
<td class="nump">$ 21,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature', window );">Conversion value over the principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 439,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 31,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on debt extinguishment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfNotesPayable', window );">Repayments of notes</a></td>
<td class="nump">$ 26,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedPremium', window );">Debt issuance costs related to the liability component of convertible debt</a></td>
<td class="nump">$ 11,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">Net change in fair value of derivatives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">Gain (loss) on derivative liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(11,000,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember', window );">Convertible Notes | 2019 Convertible Senior Notes | Redemption Period One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdTradingDays', window );">Number of trading days | trading_day</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1', window );">Number of consecutive trading days | trading_day</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger', window );">Stock price trigger to classify convertible debt as current (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">130.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember', window );">Convertible Notes | 2019 Convertible Senior Notes | Redemption Period Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdTradingDays', window );">Number of trading days | day</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1', window );">Number of consecutive trading days | trading_day</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_DebtInstrumentConvertibleMaximumThresholdPercentageofDebtTradingPriceTrigger', window );">Maximum threshold of debt trading price trigger (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">98.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember', window );">Convertible Notes | 2023 Convertible Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount of debt instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 750,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 343,301,000<span></span>
</td>
<td class="nump">495,280,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromDebtNetOfIssuanceCosts', window );">Net proceeds from debt issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 733,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionRatio1', window );">Convertible debt conversion ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0040244<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Debt conversion price per share (USD per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 248.48<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest on debt instrument (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on debt extinguishment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,300,000<span></span>
</td>
<td class="nump">2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfNotesPayable', window );">Repayments of notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19,100,000<span></span>
</td>
<td class="nump">$ 203,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">156,000,000<span></span>
</td>
<td class="nump">222,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedPremium', window );">Debt issuance costs related to the liability component of convertible debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants issued in public offering (shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,018,327<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,018,327<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,559,254<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price (USD per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 315.38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsGross', window );">Debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentRepurchaseAmount', window );">Repurchased amount of debt instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,300,000<span></span>
</td>
<td class="nump">234,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">152,000,000<span></span>
</td>
<td class="nump">254,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_RepaymentsOfNotesPayableInterestPortion', window );">Accrued interest portion of repurchased amount of debt instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="nump">$ 600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="nump">600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_IncreaseDecreaseInDebtDiscount', window );">Reduction in debt discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,700,000<span></span>
</td>
<td class="nump">35,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt', window );">Debt issuance costs related to the equity component of convertible debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,200,000<span></span>
</td>
<td class="nump">$ 3,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_PaymentsforConvertibleBondHedges', window );">Payments for convertible bond hedges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 140,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Value of warrants issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 90,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember', window );">Convertible Notes | 2023 Convertible Senior Notes | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfNotesPayable', window );">Repayments of notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 123,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentRepurchaseAmount', window );">Repurchased amount of debt instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">125,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_RepaymentsOfNotesPayableInterestPortion', window );">Accrued interest portion of repurchased amount of debt instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember', window );">Convertible Notes | 2023 Convertible Senior Notes | Redemption Period One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdTradingDays', window );">Number of trading days | trading_day</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1', window );">Number of consecutive trading days | trading_day</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger', window );">Stock price trigger to classify convertible debt as current (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">130.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember', window );">Convertible Notes | 2023 Convertible Senior Notes | Redemption Period Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdTradingDays', window );">Number of trading days | trading_day</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1', window );">Number of consecutive trading days | trading_day</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_DebtInstrumentConvertibleMaximumThresholdPercentageofDebtTradingPriceTrigger', window );">Maximum threshold of debt trading price trigger (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">98.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OtherExpenseMember', window );">Other Expense | Convertible Notes | 2019 Convertible Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">Net change in fair value of derivatives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">Gain (loss) on derivative liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (10,200,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_DebtInstrumentConvertibleIncreaseDecreaseIfConvertedValueInExcessOfPrincipal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Convertible, Increase (Decrease) If-Converted Value in Excess of Principal</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_DebtInstrumentConvertibleIncreaseDecreaseIfConvertedValueInExcessOfPrincipal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_DebtInstrumentConvertibleMaximumThresholdPercentageofDebtTradingPriceTrigger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Convertible, Maximum Threshold Percentage of Debt Trading Price Trigger</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_DebtInstrumentConvertibleMaximumThresholdPercentageofDebtTradingPriceTrigger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_ExercisePriceofConvertibleBondHedge">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise Price of Convertible Bond Hedge</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_ExercisePriceofConvertibleBondHedge</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_IncreaseDecreaseInDebtDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) in Debt Discount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_IncreaseDecreaseInDebtDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_NumberOfOptionsUnderConvertibleBondHedges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of Options under Convertible Bond Hedges</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_NumberOfOptionsUnderConvertibleBondHedges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_PaymentsToUnwindWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments to Unwind Warrants</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_PaymentsToUnwindWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_PaymentsforConvertibleBondHedges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments for Convertible Bond Hedges</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_PaymentsforConvertibleBondHedges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_ProceedsFromUnwindingConvertibleBondHedges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from Unwinding Convertible Bond Hedges</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_ProceedsFromUnwindingConvertibleBondHedges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_RepaymentsOfNotesPayableInterestPortion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Repayments Of Notes Payable, Interest Portion</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_RepaymentsOfNotesPayableInterestPortion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustment to additional paid in capital resulting from the recognition of convertible debt instruments as two separate components - a debt component and an equity component. This bifurcation may result in a basis difference associated with the liability component that represents a temporary difference for purposes of applying accounting for income taxes. The initial recognition of deferred taxes for the tax effect of that temporary difference is as an adjustment to additional paid in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 25<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123466103&amp;loc=SL6014347-161799<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123466302&amp;loc=d3e4724-112606<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of a favorable spread to a debt holder between the amount of debt being converted and the value of the securities received upon conversion. This is an embedded conversion feature of convertible debt issued that is in-the-money at the commitment date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21538-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031898-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of debt instrument into equity with equity shares divided by debt principal amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21521-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21506-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount by which the convertible debt's if-converted value exceeds its principle amount at the balance sheet date, regardless of whether the instrument is currently convertible. This element applies to public companies only.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031898-161870<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Threshold period of specified consecutive trading days within which common stock price to conversion price of convertible debt instrument must exceed threshold percentage for specified number of trading days to trigger conversion feature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum percentage of common stock price to conversion price of convertible debt instruments to determine eligibility of conversion.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleThresholdTradingDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Threshold number of specified trading days that common stock price to conversion price of convertible debt instruments must exceed threshold percentage within a specified consecutive trading period to trigger conversion feature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleThresholdTradingDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateEffectivePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRepurchaseAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value amount of debt instrument that was repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRepurchaseAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt premium.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeGainLossOnDerivativeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5618551-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeGainLossOnDerivativeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromDebtNetOfIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from additional borrowings, net of cash paid to third parties in connection with debt origination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromDebtNetOfIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=lgnd_ConvertibleSeniorNotesDue2019Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=lgnd_ConvertibleSeniorNotesDue2019Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=lgnd_ConvertibleSeniorNotesDue2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=lgnd_ConvertibleSeniorNotesDue2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OtherExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_OtherExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140091799658504">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Convertible Senior Notes - Equity and Liability Components of Financing Arrangements (Details) - Convertible Notes - 2023 Convertible Senior Notes - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>May 22, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermNotesPayableCurrentAndNoncurrentTotalAbstract', window );"><strong>Notes Payable, Current and Noncurrent</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount of 2023 Notes outstanding</a></td>
<td class="nump">$ 343,301,000<span></span>
</td>
<td class="nump">$ 495,280,000<span></span>
</td>
<td class="nump">$ 750,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Unamortized discount (including unamortized debt issuance cost)</a></td>
<td class="num">(22,584,000)<span></span>
</td>
<td class="num">(52,987,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermNotesPayable', window );">Total long-term portion of notes payable</a></td>
<td class="nump">320,717,000<span></span>
</td>
<td class="nump">442,293,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent', window );">Carrying value of equity component of 2023 Notes</a></td>
<td class="nump">20,627,000<span></span>
</td>
<td class="nump">48,397,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebtFairValueDisclosures', window );">Fair value of convertible senior notes outstanding (Level 2)</a></td>
<td class="nump">$ 341,801,000<span></span>
</td>
<td class="nump">$ 466,053,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtFairValueDisclosures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtFairValueDisclosures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying amount of the equity component of convertible debt which may be settled in cash upon conversion.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermNotesPayableCurrentAndNoncurrentTotalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermNotesPayableCurrentAndNoncurrentTotalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=lgnd_ConvertibleSeniorNotesDue2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=lgnd_ConvertibleSeniorNotesDue2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140091805344856">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Account Details - Investment Categories (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_ShortTermInvestmentsMember', window );">Short-term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Cost</a></td>
<td class="nump">$ 292,225<span></span>
</td>
<td class="nump">$ 324,567<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="nump">842<span></span>
</td>
<td class="nump">1,302<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="num">(2,370)<span></span>
</td>
<td class="num">(1,391)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated fair value</a></td>
<td class="nump">290,697<span></span>
</td>
<td class="nump">324,478<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_MutualFundMember', window );">Mutual fund</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Cost</a></td>
<td class="nump">152,136<span></span>
</td>
<td class="nump">151,512<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">386<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="num">(249)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated fair value</a></td>
<td class="nump">151,887<span></span>
</td>
<td class="nump">151,898<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_DemandDepositsMember', window );">Bank deposits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Cost</a></td>
<td class="nump">63,389<span></span>
</td>
<td class="nump">84,120<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="nump">13<span></span>
</td>
<td class="nump">35<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="num">(21)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated fair value</a></td>
<td class="nump">63,381<span></span>
</td>
<td class="nump">84,154<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Cost</a></td>
<td class="nump">36,008<span></span>
</td>
<td class="nump">45,459<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">27<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="num">(12)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated fair value</a></td>
<td class="nump">35,998<span></span>
</td>
<td class="nump">45,485<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Cost</a></td>
<td class="nump">29,308<span></span>
</td>
<td class="nump">30,512<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="nump">17<span></span>
</td>
<td class="nump">99<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="num">(38)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated fair value</a></td>
<td class="nump">29,287<span></span>
</td>
<td class="nump">30,610<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_AgencySecuritiesMember', window );">Agency bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,499<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,501<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_EquitySecuritiesMember', window );">Corporate equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Cost</a></td>
<td class="nump">5,807<span></span>
</td>
<td class="nump">4,466<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="nump">402<span></span>
</td>
<td class="nump">360<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="num">(2,027)<span></span>
</td>
<td class="num">(1,388)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated fair value</a></td>
<td class="nump">4,182<span></span>
</td>
<td class="nump">3,438<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_USGovernmentDebtSecuritiesMember', window );">U.S. government securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Cost</a></td>
<td class="nump">5,577<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="num">(23)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated fair value</a></td>
<td class="nump">5,554<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_USTreasurySecuritiesMember', window );">Treasury bills</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,999<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,999<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_WarrantMember', window );">Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Cost</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="nump">408<span></span>
</td>
<td class="nump">393<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated fair value</a></td>
<td class="nump">$ 408<span></span>
</td>
<td class="nump">$ 393<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_ShortTermInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_ShortTermInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_MutualFundMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_MutualFundMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_DemandDepositsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_DemandDepositsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_AgencySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_AgencySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_EquitySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_EquitySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_USGovernmentDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_USGovernmentDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140091807818648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Account Details - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>position </div>
<div>agreement</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 31, 2010 </div>
<div>agreement</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentsLineItems', window );"><strong>Schedule of Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions', window );">Number of positions in an unrealized loss position | position</a></td>
<td class="nump">55<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">$ 3,900,000<span></span>
</td>
<td class="nump">$ 1,800,000<span></span>
</td>
<td class="nump">$ 1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Finite-lived intangible asset, useful life</a></td>
<td class="text">20 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization expense</a></td>
<td class="nump">$ 47,200,000<span></span>
</td>
<td class="nump">23,400,000<span></span>
</td>
<td class="nump">16,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">Estimated amortization expense for 2022</a></td>
<td class="nump">47,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">Estimated amortization expense for 2023</a></td>
<td class="nump">47,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">Estimated amortization expense for 2024</a></td>
<td class="nump">47,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">Estimated amortization expense for 2025</a></td>
<td class="nump">47,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived', window );">Impairment of intangible assets with finite lives</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_NumberOfContingentValueRightAgreements', window );">Number of CVR agreements | agreement</a></td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentsLineItems', window );"><strong>Schedule of Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment, useful life</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentsLineItems', window );"><strong>Schedule of Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment, useful life</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_NumberOfContingentValueRightAgreements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number Of Contingent Value Right Agreements</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_NumberOfContingentValueRightAgreements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27290-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922888-210455<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsFinitelived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInvestmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInvestmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140091790096584">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Account Details - Available-for-Sale Debt Securities by Contractual Maturity (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract', window );"><strong>Amortized Cost</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost', window );">Within one year</a></td>
<td class="nump">$ 111,334<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost', window );">After one year through five years</a></td>
<td class="nump">24,952<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateAfterYearFive', window );">After five years</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis', window );">Total</a></td>
<td class="nump">136,286<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract', window );"><strong>Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue', window );">Within one year</a></td>
<td class="nump">111,315<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue', window );">After one year through five years</a></td>
<td class="nump">24,909<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearFive', window );">After five years</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate', window );">Total</a></td>
<td class="nump">$ 136,224<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year Five</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year Five</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27198-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27198-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123599081&amp;loc=SL120269850-112803<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=123599081&amp;loc=SL120269850-112803<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27198-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27198-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123599081&amp;loc=SL120269850-112803<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27198-111563<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of investment in debt security measured at amortized cost (held-to-maturity) with single maturity date and allocated without single maturity date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123599081&amp;loc=d3e62586-112803<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27232-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140091794601336">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Account Details - Available-for-Sale Debt Securities in an Unrealized Loss Position (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract', window );"><strong>Gross Unrealized Losses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Less than 12 months</a></td>
<td class="num">$ (34)<span></span>
</td>
<td class="num">$ (3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">12 months or greater</a></td>
<td class="num">(60)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionAccumulatedLoss', window );">Total</a></td>
<td class="num">(94)<span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsAbstract', window );"><strong>Estimated Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Less than 12 months</a></td>
<td class="nump">53,949<span></span>
</td>
<td class="nump">26,232<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">12 months or greater</a></td>
<td class="nump">18,674<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Total</a></td>
<td class="nump">72,623<span></span>
</td>
<td class="nump">26,232<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_DemandDepositsMember', window );">Bank deposits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract', window );"><strong>Gross Unrealized Losses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Less than 12 months</a></td>
<td class="num">(13)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">12 months or greater</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionAccumulatedLoss', window );">Total</a></td>
<td class="num">(13)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsAbstract', window );"><strong>Estimated Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Less than 12 months</a></td>
<td class="nump">20,008<span></span>
</td>
<td class="nump">14,013<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">12 months or greater</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Total</a></td>
<td class="nump">20,008<span></span>
</td>
<td class="nump">14,013<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract', window );"><strong>Gross Unrealized Losses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Less than 12 months</a></td>
<td class="num">(15)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">12 months or greater</a></td>
<td class="num">(5)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionAccumulatedLoss', window );">Total</a></td>
<td class="num">(20)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsAbstract', window );"><strong>Estimated Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Less than 12 months</a></td>
<td class="nump">27,252<span></span>
</td>
<td class="nump">4,526<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">12 months or greater</a></td>
<td class="nump">2,996<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Total</a></td>
<td class="nump">30,248<span></span>
</td>
<td class="nump">4,526<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract', window );"><strong>Gross Unrealized Losses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Less than 12 months</a></td>
<td class="num">(6)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">12 months or greater</a></td>
<td class="num">(32)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionAccumulatedLoss', window );">Total</a></td>
<td class="num">(38)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsAbstract', window );"><strong>Estimated Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Less than 12 months</a></td>
<td class="nump">6,689<span></span>
</td>
<td class="nump">7,693<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">12 months or greater</a></td>
<td class="nump">10,125<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Total</a></td>
<td class="nump">16,814<span></span>
</td>
<td class="nump">$ 7,693<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentDebtSecuritiesMember', window );">U.S. government securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract', window );"><strong>Gross Unrealized Losses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Less than 12 months</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">12 months or greater</a></td>
<td class="num">(23)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionAccumulatedLoss', window );">Total</a></td>
<td class="num">(23)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsAbstract', window );"><strong>Estimated Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Less than 12 months</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">12 months or greater</a></td>
<td class="nump">5,553<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Total</a></td>
<td class="nump">$ 5,553<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for more than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922890-210455<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27337-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121590138&amp;loc=SL82922954-210456<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27337-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922890-210455<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121590138&amp;loc=SL82922954-210456<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922890-210455<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27337-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27290-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922888-210455<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121590138&amp;loc=SL82922954-210456<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrealized loss on investment in debt security measured at amortized cost (held-to-maturity), in continuous loss position for 12 months or longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27337-111563<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27290-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionAccumulatedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrealized loss on investment in debt security measured at amortized cost (held-to-maturity), in unrealized loss position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27290-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionAccumulatedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_DemandDepositsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_DemandDepositsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140091801802760">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Account Details - Property and Equipment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment , gross</a></td>
<td class="nump">$ 29,222<span></span>
</td>
<td class="nump">$ 19,241<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less accumulated depreciation and amortization</a></td>
<td class="num">(8,711)<span></span>
</td>
<td class="num">(4,807)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">20,511<span></span>
</td>
<td class="nump">14,434<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember', window );">Lab and office equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment , gross</a></td>
<td class="nump">20,183<span></span>
</td>
<td class="nump">14,666<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment , gross</a></td>
<td class="nump">7,983<span></span>
</td>
<td class="nump">3,519<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=lgnd_ComputerEquipmentAndSoftwareMember', window );">Computer equipment and software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment , gross</a></td>
<td class="nump">$ 1,056<span></span>
</td>
<td class="nump">$ 1,056<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=lgnd_ComputerEquipmentAndSoftwareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=lgnd_ComputerEquipmentAndSoftwareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140091801979944">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Account Details - Goodwill and Other Intangible Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">$ 181,206<span></span>
</td>
<td class="nump">$ 189,662<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetIncludingGoodwill', window );">Total goodwill and other identifiable intangible assets, net</a></td>
<td class="nump">732,246<span></span>
</td>
<td class="nump">784,992<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentedTechnologyMember', window );">Complete technology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Definite-lived intangible assets</a></td>
<td class="nump">280,617<span></span>
</td>
<td class="nump">277,740<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Less: Accumulated amortization</a></td>
<td class="num">(78,991)<span></span>
</td>
<td class="num">(63,600)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember', window );">Trade name</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Definite-lived intangible assets</a></td>
<td class="nump">2,642<span></span>
</td>
<td class="nump">2,642<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Less: Accumulated amortization</a></td>
<td class="num">(1,444)<span></span>
</td>
<td class="num">(1,312)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember', window );">Customer relationships</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Definite-lived intangible assets</a></td>
<td class="nump">40,700<span></span>
</td>
<td class="nump">40,700<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Less: Accumulated amortization</a></td>
<td class="num">(18,267)<span></span>
</td>
<td class="num">(15,597)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ContractualRightsMember', window );">Contractual relationships</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Definite-lived intangible assets</a></td>
<td class="nump">362,000<span></span>
</td>
<td class="nump">362,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Less: Accumulated amortization</a></td>
<td class="num">$ (36,217)<span></span>
</td>
<td class="num">$ (7,243)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 340<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6473545&amp;loc=d3e61844-108004<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetIncludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of finite-lived intangible assets, indefinite-lived intangible assets and goodwill. Goodwill is an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized. Intangible assets are assets, not including financial assets, lacking physical substance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetIncludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentedTechnologyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentedTechnologyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ContractualRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ContractualRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140091799573384">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Account Details - Accrued Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_OtherBalanceSheetDetailsAbstract', window );"><strong>Other Balance Sheet Details [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Compensation</a></td>
<td class="nump">$ 6,532<span></span>
</td>
<td class="nump">$ 8,810<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Professional fees</a></td>
<td class="nump">2,046<span></span>
</td>
<td class="nump">977<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedSalesCommissionCurrentAndNoncurrent', window );">Amounts owed to former licensees</a></td>
<td class="nump">630<span></span>
</td>
<td class="nump">421<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent', window );">Royalties owed to third parties</a></td>
<td class="nump">149<span></span>
</td>
<td class="nump">693<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_AccruedSalesReturns', window );">Return reserve and customer refunds</a></td>
<td class="nump">2,420<span></span>
</td>
<td class="nump">687<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_AccruedAssetAcquisitionsCurrent', window );">Acquisition related liabilities</a></td>
<td class="nump">1,000<span></span>
</td>
<td class="nump">1,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_AccruedSubcontractorExpensesCurrent', window );">Subcontractor</a></td>
<td class="nump">1,759<span></span>
</td>
<td class="nump">733<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_AccruedSupplierExpensesCurrent', window );">Supplier</a></td>
<td class="nump">848<span></span>
</td>
<td class="nump">604<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">2,195<span></span>
</td>
<td class="nump">4,105<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued liabilities</a></td>
<td class="nump">$ 17,579<span></span>
</td>
<td class="nump">$ 18,530<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_AccruedAssetAcquisitionsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Asset Acquisitions, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_AccruedAssetAcquisitionsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_AccruedSalesReturns">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Sales Returns</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_AccruedSalesReturns</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_AccruedSubcontractorExpensesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Subcontractor Expenses, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_AccruedSubcontractorExpensesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_AccruedSupplierExpensesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Supplier Expenses, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_AccruedSupplierExpensesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_OtherBalanceSheetDetailsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other Balance Sheet Details [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_OtherBalanceSheetDetailsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.15(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedRoyaltiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedSalesCommissionCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for sales commissions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedSalesCommissionCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140091805392616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Account Details - Contingent Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_ContingentLiabilityRollForward', window );"><strong>Contingent Liability [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod', window );">Commercial rights at beginning of period</a></td>
<td class="nump">$ 49,133<span></span>
</td>
<td class="nump">$ 8,942<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_BusinessAcquisitionContingentConsiderationPotentialCashPaymentAdditions', window );">Additional Contingent Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41,800<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_PaymentsToContingentValueRightHolders', window );">Payments</a></td>
<td class="num">(1,820)<span></span>
</td>
<td class="num">(2,325)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities', window );">Fair Value Adjustment</a></td>
<td class="num">(36,242)<span></span>
</td>
<td class="nump">963<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityRepurchasesContingentLiabilities', window );">Repurchases</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(247)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod', window );">Commercial rights at end of period</a></td>
<td class="nump">11,071<span></span>
</td>
<td class="nump">49,133<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=lgnd_CydexPharmaceuticalsIncMember', window );">Cydex</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_ContingentLiabilityRollForward', window );"><strong>Contingent Liability [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod', window );">Commercial rights at beginning of period</a></td>
<td class="nump">508<span></span>
</td>
<td class="nump">348<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_BusinessAcquisitionContingentConsiderationPotentialCashPaymentAdditions', window );">Additional Contingent Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_PaymentsToContingentValueRightHolders', window );">Payments</a></td>
<td class="num">(50)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities', window );">Fair Value Adjustment</a></td>
<td class="num">(108)<span></span>
</td>
<td class="nump">160<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityRepurchasesContingentLiabilities', window );">Repurchases</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod', window );">Commercial rights at end of period</a></td>
<td class="nump">350<span></span>
</td>
<td class="nump">508<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=lgnd_MetabasisTherapeuticsMember', window );">Metabasis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_ContingentLiabilityRollForward', window );"><strong>Contingent Liability [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod', window );">Commercial rights at beginning of period</a></td>
<td class="nump">3,821<span></span>
</td>
<td class="nump">5,935<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_BusinessAcquisitionContingentConsiderationPotentialCashPaymentAdditions', window );">Additional Contingent Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_PaymentsToContingentValueRightHolders', window );">Payments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities', window );">Fair Value Adjustment</a></td>
<td class="num">(464)<span></span>
</td>
<td class="num">(1,867)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityRepurchasesContingentLiabilities', window );">Repurchases</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(247)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod', window );">Commercial rights at end of period</a></td>
<td class="nump">3,357<span></span>
</td>
<td class="nump">3,821<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=lgnd_CrystalMember', window );">Crystal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_ContingentLiabilityRollForward', window );"><strong>Contingent Liability [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod', window );">Commercial rights at beginning of period</a></td>
<td class="nump">800<span></span>
</td>
<td class="nump">2,659<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_BusinessAcquisitionContingentConsiderationPotentialCashPaymentAdditions', window );">Additional Contingent Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_PaymentsToContingentValueRightHolders', window );">Payments</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,800)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities', window );">Fair Value Adjustment</a></td>
<td class="num">(800)<span></span>
</td>
<td class="num">(59)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityRepurchasesContingentLiabilities', window );">Repurchases</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod', window );">Commercial rights at end of period</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">800<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=lgnd_IcagenMember', window );">Icagen</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_ContingentLiabilityRollForward', window );"><strong>Contingent Liability [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod', window );">Commercial rights at beginning of period</a></td>
<td class="nump">6,404<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_BusinessAcquisitionContingentConsiderationPotentialCashPaymentAdditions', window );">Additional Contingent Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,800<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_PaymentsToContingentValueRightHolders', window );">Payments</a></td>
<td class="num">(1,050)<span></span>
</td>
<td class="num">(525)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities', window );">Fair Value Adjustment</a></td>
<td class="nump">2,010<span></span>
</td>
<td class="nump">2,129<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityRepurchasesContingentLiabilities', window );">Repurchases</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod', window );">Commercial rights at end of period</a></td>
<td class="nump">7,364<span></span>
</td>
<td class="nump">6,404<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=lgnd_PfenexMember', window );">Pfenex</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_ContingentLiabilityRollForward', window );"><strong>Contingent Liability [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod', window );">Commercial rights at beginning of period</a></td>
<td class="nump">37,600<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_BusinessAcquisitionContingentConsiderationPotentialCashPaymentAdditions', window );">Additional Contingent Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_PaymentsToContingentValueRightHolders', window );">Payments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities', window );">Fair Value Adjustment</a></td>
<td class="num">(37,600)<span></span>
</td>
<td class="nump">600<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityRepurchasesContingentLiabilities', window );">Repurchases</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod', window );">Commercial rights at end of period</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">37,600<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=lgnd_XCellaBiosciencesIncMember', window );">xCella</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_ContingentLiabilityRollForward', window );"><strong>Contingent Liability [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod', window );">Commercial rights at beginning of period</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_BusinessAcquisitionContingentConsiderationPotentialCashPaymentAdditions', window );">Additional Contingent Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_PaymentsToContingentValueRightHolders', window );">Payments</a></td>
<td class="num">(720)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities', window );">Fair Value Adjustment</a></td>
<td class="nump">720<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityRepurchasesContingentLiabilities', window );">Repurchases</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod', window );">Commercial rights at end of period</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_BusinessAcquisitionContingentConsiderationPotentialCashPaymentAdditions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Acquisition Contingent Consideration Potential Cash Payment Additions</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_BusinessAcquisitionContingentConsiderationPotentialCashPaymentAdditions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Acquisition Contingent Consideration Potential Cash Payment at End of Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_ContingentLiabilityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contingent Liability [Roll Forward]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_ContingentLiabilityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityRepurchasesContingentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Repurchases, Contingent Liabilities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityRepurchasesContingentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Fair Value Adjustment, Contingent Liabilities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_PaymentsToContingentValueRightHolders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments to contingent value right holders</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_PaymentsToContingentValueRightHolders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=lgnd_CydexPharmaceuticalsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=lgnd_CydexPharmaceuticalsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=lgnd_MetabasisTherapeuticsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=lgnd_MetabasisTherapeuticsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=lgnd_CrystalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=lgnd_CrystalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=lgnd_IcagenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=lgnd_IcagenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=lgnd_PfenexMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=lgnd_PfenexMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=lgnd_XCellaBiosciencesIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=lgnd_XCellaBiosciencesIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140091808480344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Share-Based Compensation (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax', window );">Share-based compensation expense</a></td>
<td class="nump">$ 38,783<span></span>
</td>
<td class="nump">$ 30,727<span></span>
</td>
<td class="nump">$ 24,515<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax', window );">Share-based compensation expense</a></td>
<td class="nump">17,436<span></span>
</td>
<td class="nump">13,497<span></span>
</td>
<td class="nump">9,641<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax', window );">Share-based compensation expense</a></td>
<td class="nump">$ 21,347<span></span>
</td>
<td class="nump">$ 17,230<span></span>
</td>
<td class="nump">$ 14,874<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of expense for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140091805761000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 11, 2019</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Jan. 23, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_CorporateShareRepurchaseAbstract', window );"><strong>Corporate Share Repurchase</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1', window );">Stock repurchase program, authorized amount</a></td>
<td class="nump">$ 500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 350,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramPeriodInForce1', window );">Stock repurchase program, period in force</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1', window );">Stock repurchase program, remaining authorized repurchase amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 248,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Shares repurchased in period (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">934,079<span></span>
</td>
<td class="nump">4,122,133<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Shares repurchased in period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 77,998,000<span></span>
</td>
<td class="nump">$ 448,433,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant date fair value per share of stock options (USD per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 80.08<span></span>
</td>
<td class="nump">$ 41.39<span></span>
</td>
<td class="nump">$ 48.65<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Intrinsic value of options exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 77,300,000<span></span>
</td>
<td class="nump">$ 11,900,000<span></span>
</td>
<td class="nump">$ 10,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions', window );">Cash received from options exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,000,000<span></span>
</td>
<td class="nump">$ 2,500,000<span></span>
</td>
<td class="nump">$ 2,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized compensation cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted-average period in which cost is expected to be recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 4 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted-average period in which cost is expected to be recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Unrecognized compensation cost, restricted stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=lgnd_TwoThousandTwoStockIncentivePlanMember', window );">2002 Stock Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Increase the number of shares under the 2002 Stock Incentive Plan (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=lgnd_TwoThousandTwoStockIncentivePlanMember', window );">2002 Stock Incentive Plan | Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for future option grants (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=lgnd_AmendedESPPMember', window );">Amended ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for future option grants (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44,360<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_EmployeeStockPurchasePlanAbstract', window );"><strong>Employee Stock Purchase Plan</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee', window );">Shares allowed to purchase in employee stock purchase plan per employee (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Proportion of fair market value of common stock at which stock is purchased under ESPP (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod', window );">Common stock issued under amended ESSP (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,448<span></span>
</td>
<td class="nump">6,455<span></span>
</td>
<td class="nump">4,745<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_CorporateShareRepurchaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Corporate Share Repurchase [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_CorporateShareRepurchaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_EmployeeStockPurchasePlanAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Employee Stock Purchase Plan [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_EmployeeStockPurchasePlanAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The highest quantity of shares an employee can purchase under the plan per period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchase price of common stock expressed as a percentage of its fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stock repurchase plan authorized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramAuthorizedAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramPeriodInForce1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period which shares may be purchased under a stock repurchase plan authorized by an entity's Board of Directors, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramPeriodInForce1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount remaining of a stock repurchase plan authorized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=lgnd_TwoThousandTwoStockIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=lgnd_TwoThousandTwoStockIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=lgnd_AmendedESPPMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=lgnd_AmendedESPPMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140091797052408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Stock Option Plan Activity (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Balance at beginning of period (shares)</a></td>
<td class="nump">2,561,822<span></span>
</td>
<td class="nump">1,956,379<span></span>
</td>
<td class="nump">1,736,304<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (shares)</a></td>
<td class="nump">393,589<span></span>
</td>
<td class="nump">806,300<span></span>
</td>
<td class="nump">338,617<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (shares)</a></td>
<td class="num">(619,731)<span></span>
</td>
<td class="num">(156,845)<span></span>
</td>
<td class="num">(112,011)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Forfeited (shares)</a></td>
<td class="num">(136,082)<span></span>
</td>
<td class="num">(44,012)<span></span>
</td>
<td class="num">(6,531)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Balance at end of period (shares)</a></td>
<td class="nump">2,199,598<span></span>
</td>
<td class="nump">2,561,822<span></span>
</td>
<td class="nump">1,956,379<span></span>
</td>
<td class="nump">1,736,304<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable at end of period (shares)</a></td>
<td class="nump">1,391,952<span></span>
</td>
<td class="nump">1,611,830<span></span>
</td>
<td class="nump">1,454,726<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Options vested and expected to vest at end of period (shares)</a></td>
<td class="nump">2,199,598<span></span>
</td>
<td class="nump">2,561,822<span></span>
</td>
<td class="nump">1,956,379<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Balance at beginning of period (USD per share)</a></td>
<td class="nump">$ 85.59<span></span>
</td>
<td class="nump">$ 77.54<span></span>
</td>
<td class="nump">$ 66.71<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (USD per share)</a></td>
<td class="nump">159.12<span></span>
</td>
<td class="nump">92.93<span></span>
</td>
<td class="nump">116.69<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (USD per share)</a></td>
<td class="nump">54.28<span></span>
</td>
<td class="nump">21.26<span></span>
</td>
<td class="nump">23.65<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Forfeited (USD per share)</a></td>
<td class="nump">110.83<span></span>
</td>
<td class="nump">91.30<span></span>
</td>
<td class="nump">139.37<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Balance at end of period (USD per share)</a></td>
<td class="nump">106.00<span></span>
</td>
<td class="nump">85.59<span></span>
</td>
<td class="nump">77.54<span></span>
</td>
<td class="nump">$ 66.71<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable at end of period (USD per share)</a></td>
<td class="nump">98.16<span></span>
</td>
<td class="nump">76.05<span></span>
</td>
<td class="nump">61.82<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Options vested and expected to vest at end of period (USD per share)</a></td>
<td class="nump">$ 106.00<span></span>
</td>
<td class="nump">$ 85.59<span></span>
</td>
<td class="nump">$ 77.54<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Term in Years</a></td>
<td class="text">6 years 4 months 2 days<span></span>
</td>
<td class="text">6 years 1 month 2 days<span></span>
</td>
<td class="text">5 years 5 months 12 days<span></span>
</td>
<td class="text">5 years 5 months 19 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Exercisable, Weighted Average Remaining Contractual Term in Years</a></td>
<td class="text">5 years 1 month 13 days<span></span>
</td>
<td class="text">4 years 6 months 14 days<span></span>
</td>
<td class="text">4 years 5 months 1 day<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Options vested and expected to vest, Weighted Average Remaining Contractual Term in Years</a></td>
<td class="text">6 years 4 months 2 days<span></span>
</td>
<td class="text">6 years 1 month 2 days<span></span>
</td>
<td class="text">5 years 5 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value</a></td>
<td class="nump">$ 113,302<span></span>
</td>
<td class="nump">$ 59,033<span></span>
</td>
<td class="nump">$ 72,002<span></span>
</td>
<td class="nump">$ 125,858<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Exercisable, Aggregate Intrinsic Value</a></td>
<td class="nump">80,849<span></span>
</td>
<td class="nump">53,286<span></span>
</td>
<td class="nump">70,345<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Options vested and expected to vest, Aggregate Intrinsic Value</a></td>
<td class="nump">$ 113,302<span></span>
</td>
<td class="nump">$ 59,033<span></span>
</td>
<td class="nump">$ 72,002<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140091805540904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Breakdown of Options Outstanding (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2021 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=lgnd_ExercisePriceRangeElevenMember', window );">$12.53 &#8211; $195.91</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options outstanding (shares) | shares</a></td>
<td class="nump">2,199,598<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining life in years</a></td>
<td class="text">6 years 4 months 2 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Weighted average exercise price (USD per share)</a></td>
<td class="nump">$ 106.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options exercisable (shares) | shares</a></td>
<td class="nump">1,391,952<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Weighted average exercise price (USD per share)</a></td>
<td class="nump">$ 98.16<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=lgnd_ExercisePriceRangeOneMember', window );">$12.53-$56.26</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Lower range of exercise prices (USD per share)</a></td>
<td class="nump">12.53<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Upper range of exercise prices (USD per share)</a></td>
<td class="nump">$ 56.26<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options outstanding (shares) | shares</a></td>
<td class="nump">253,824<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining life in years</a></td>
<td class="text">1 year 11 months 8 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Weighted average exercise price (USD per share)</a></td>
<td class="nump">$ 37.55<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options exercisable (shares) | shares</a></td>
<td class="nump">239,824<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Weighted average exercise price (USD per share)</a></td>
<td class="nump">$ 38.90<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=lgnd_ExercisePriceRangeTwoMember', window );">$67.53-$74.42</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Lower range of exercise prices (USD per share)</a></td>
<td class="nump">67.53<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Upper range of exercise prices (USD per share)</a></td>
<td class="nump">$ 74.42<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options outstanding (shares) | shares</a></td>
<td class="nump">278,281<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining life in years</a></td>
<td class="text">4 years 14 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Weighted average exercise price (USD per share)</a></td>
<td class="nump">$ 72.10<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options exercisable (shares) | shares</a></td>
<td class="nump">217,587<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Weighted average exercise price (USD per share)</a></td>
<td class="nump">$ 73.17<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=lgnd_ExercisePriceRangeThreeMember', window );">$82.90-$95.35</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Lower range of exercise prices (USD per share)</a></td>
<td class="nump">82.90<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Upper range of exercise prices (USD per share)</a></td>
<td class="nump">$ 95.35<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options outstanding (shares) | shares</a></td>
<td class="nump">159,988<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining life in years</a></td>
<td class="text">5 years 21 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Weighted average exercise price (USD per share)</a></td>
<td class="nump">$ 86.11<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options exercisable (shares) | shares</a></td>
<td class="nump">132,963<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Weighted average exercise price (USD per share)</a></td>
<td class="nump">$ 86.24<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=lgnd_ExercisePriceRangeFourMember', window );">$95.68</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Lower range of exercise prices (USD per share)</a></td>
<td class="nump">$ 95.68<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options outstanding (shares) | shares</a></td>
<td class="nump">266,263<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining life in years</a></td>
<td class="text">8 years 1 month 13 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Weighted average exercise price (USD per share)</a></td>
<td class="nump">$ 95.68<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options exercisable (shares) | shares</a></td>
<td class="nump">109,154<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Weighted average exercise price (USD per share)</a></td>
<td class="nump">$ 95.68<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=lgnd_ExercisePriceRangeFiveMember', window );">$98.20-$100.38</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Lower range of exercise prices (USD per share)</a></td>
<td class="nump">98.20<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Upper range of exercise prices (USD per share)</a></td>
<td class="nump">$ 100.38<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options outstanding (shares) | shares</a></td>
<td class="nump">294,772<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining life in years</a></td>
<td class="text">7 years 3 months 29 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Weighted average exercise price (USD per share)</a></td>
<td class="nump">$ 99.10<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options exercisable (shares) | shares</a></td>
<td class="nump">160,120<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Weighted average exercise price (USD per share)</a></td>
<td class="nump">$ 99.79<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=lgnd_ExercisePriceRangeSixMember', window );">$101.07-$117.58</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Lower range of exercise prices (USD per share)</a></td>
<td class="nump">101.07<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Upper range of exercise prices (USD per share)</a></td>
<td class="nump">$ 117.58<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options outstanding (shares) | shares</a></td>
<td class="nump">159,204<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining life in years</a></td>
<td class="text">7 years 5 months 12 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Weighted average exercise price (USD per share)</a></td>
<td class="nump">$ 111.26<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options exercisable (shares) | shares</a></td>
<td class="nump">99,488<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Weighted average exercise price (USD per share)</a></td>
<td class="nump">$ 111.18<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=lgnd_ExercisePriceRangeSevenMember', window );">117.97</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Lower range of exercise prices (USD per share)</a></td>
<td class="nump">117.97<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Upper range of exercise prices (USD per share)</a></td>
<td class="nump">$ 117.97<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options outstanding (shares) | shares</a></td>
<td class="nump">237,292<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining life in years</a></td>
<td class="text">7 years 1 month 13 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Weighted average exercise price (USD per share)</a></td>
<td class="nump">$ 117.97<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options exercisable (shares) | shares</a></td>
<td class="nump">158,958<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Weighted average exercise price (USD per share)</a></td>
<td class="nump">$ 117.97<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=lgnd_ExercisePriceRangeEightMember', window );">$119.08-$159.01</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Lower range of exercise prices (USD per share)</a></td>
<td class="nump">119.08<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Upper range of exercise prices (USD per share)</a></td>
<td class="nump">$ 159.01<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options outstanding (shares) | shares</a></td>
<td class="nump">299,585<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining life in years</a></td>
<td class="text">7 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Weighted average exercise price (USD per share)</a></td>
<td class="nump">$ 149.40<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options exercisable (shares) | shares</a></td>
<td class="nump">205,098<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Weighted average exercise price (USD per share)</a></td>
<td class="nump">$ 152.50<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=lgnd_ExercisePriceRangeNineMember', window );">$159.81-$171.28</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Lower range of exercise prices (USD per share)</a></td>
<td class="nump">159.81<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Upper range of exercise prices (USD per share)</a></td>
<td class="nump">$ 171.28<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options outstanding (shares) | shares</a></td>
<td class="nump">6,881<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining life in years</a></td>
<td class="text">6 years 6 months 3 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Weighted average exercise price (USD per share)</a></td>
<td class="nump">$ 166.28<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options exercisable (shares) | shares</a></td>
<td class="nump">5,828<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Weighted average exercise price (USD per share)</a></td>
<td class="nump">$ 165.62<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=lgnd_ExercisePriceRangeTenMember', window );">$177.50-$195.91</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Lower range of exercise prices (USD per share)</a></td>
<td class="nump">177.50<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Upper range of exercise prices (USD per share)</a></td>
<td class="nump">$ 195.91<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options outstanding (shares) | shares</a></td>
<td class="nump">243,508<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining life in years</a></td>
<td class="text">8 years 10 months 28 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Weighted average exercise price (USD per share)</a></td>
<td class="nump">$ 178.62<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options exercisable (shares) | shares</a></td>
<td class="nump">62,932<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Weighted average exercise price (USD per share)</a></td>
<td class="nump">$ 181.84<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares reserved for issuance pertaining to the outstanding exercisable stock options as of the balance sheet date in the customized range of exercise prices for which the market and performance vesting condition has been satisfied.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average exercise price as of the balance sheet date for those equity-based payment arrangements exercisable and outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average price as of the balance sheet date at which grantees could acquire the underlying shares with respect to all outstanding stock options which are in the customized range of exercise prices.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term of outstanding stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=lgnd_ExercisePriceRangeElevenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=lgnd_ExercisePriceRangeElevenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=lgnd_ExercisePriceRangeOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=lgnd_ExercisePriceRangeOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=lgnd_ExercisePriceRangeTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=lgnd_ExercisePriceRangeTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=lgnd_ExercisePriceRangeThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=lgnd_ExercisePriceRangeThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=lgnd_ExercisePriceRangeFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=lgnd_ExercisePriceRangeFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=lgnd_ExercisePriceRangeFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=lgnd_ExercisePriceRangeFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=lgnd_ExercisePriceRangeSixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=lgnd_ExercisePriceRangeSixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=lgnd_ExercisePriceRangeSevenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=lgnd_ExercisePriceRangeSevenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=lgnd_ExercisePriceRangeEightMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=lgnd_ExercisePriceRangeEightMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=lgnd_ExercisePriceRangeNineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=lgnd_ExercisePriceRangeNineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=lgnd_ExercisePriceRangeTenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=lgnd_ExercisePriceRangeTenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140091802043160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Assumptions (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate (as a percent)</a></td>
<td class="nump">0.40%<span></span>
</td>
<td class="nump">0.20%<span></span>
</td>
<td class="nump">1.40%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility (as a percent)</a></td>
<td class="nump">47.00%<span></span>
</td>
<td class="nump">47.00%<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">4 years 8 months 12 days<span></span>
</td>
<td class="text">4 years 8 months 12 days<span></span>
</td>
<td class="text">4 years 7 months 6 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate (as a percent)</a></td>
<td class="nump">1.20%<span></span>
</td>
<td class="nump">1.40%<span></span>
</td>
<td class="nump">2.60%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility (as a percent)</a></td>
<td class="nump">63.00%<span></span>
</td>
<td class="nump">71.00%<span></span>
</td>
<td class="nump">49.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">6 years 3 months 18 days<span></span>
</td>
<td class="text">5 years 1 month 6 days<span></span>
</td>
<td class="text">5 years 10 months 24 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140091790022056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Restricted Stock Activity (Details) - Restricted Stock - $ / shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding at beginning of period (shares)</a></td>
<td class="nump">206,202<span></span>
</td>
<td class="nump">147,259<span></span>
</td>
<td class="nump">132,273<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (shares)</a></td>
<td class="nump">167,292<span></span>
</td>
<td class="nump">111,306<span></span>
</td>
<td class="nump">118,498<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (shares)</a></td>
<td class="num">(98,501)<span></span>
</td>
<td class="num">(52,363)<span></span>
</td>
<td class="num">(102,846)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited (shares)</a></td>
<td class="num">(10,850)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(666)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding at end of period (shares)</a></td>
<td class="nump">264,143<span></span>
</td>
<td class="nump">206,202<span></span>
</td>
<td class="nump">147,259<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted-Average Grant&#160;Date Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Outstanding at beginning of period (USD per share)</a></td>
<td class="nump">$ 106.88<span></span>
</td>
<td class="nump">$ 125.11<span></span>
</td>
<td class="nump">$ 130.63<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (USD per share)</a></td>
<td class="nump">169.63<span></span>
</td>
<td class="nump">89.73<span></span>
</td>
<td class="nump">115.90<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested (USD per share)</a></td>
<td class="nump">125.59<span></span>
</td>
<td class="nump">121.69<span></span>
</td>
<td class="nump">121.55<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited (USD per share)</a></td>
<td class="nump">141.85<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">134.36<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Outstanding at end of period (USD per share)</a></td>
<td class="nump">$ 138.21<span></span>
</td>
<td class="nump">$ 106.88<span></span>
</td>
<td class="nump">$ 125.11<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140091900049640">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitment and Contingencies: Legal Proceedings - Narrative (Details)<br></strong></div></th>
<th class="th">
<div>Oct. 31, 2019 </div>
<div>civil_complaint</div>
</th>
<th class="th">
<div>Oct. 29, 2019 </div>
<div>patent</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=lgnd_LupinPatentInfringementMember', window );">Lupin Patent Infringement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainContingenciesLineItems', window );"><strong>Gain Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber', window );">Number of patents allegedly infringed upon | patent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=lgnd_USDistrictCourtForTheNorthernDistrictOfOhioMember', window );">US District Court for the Northern District of Ohio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainContingenciesLineItems', window );"><strong>Gain Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyNewClaimsFiledNumber', window );">Number of civil complaints filed against entity | civil_complaint</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of entity's patents that another entity has allegedly infringed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyNewClaimsFiledNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total number of new claims filed pertaining to a loss contingency during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14435-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyNewClaimsFiledNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=lgnd_LupinPatentInfringementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=lgnd_LupinPatentInfringementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=lgnd_USDistrictCourtForTheNorthernDistrictOfOhioMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=lgnd_USDistrictCourtForTheNorthernDistrictOfOhioMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140091795430584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Valuation allowance, change in amount</a></td>
<td class="nump">$ 11.4<span></span>
</td>
<td class="num">$ (116.5)<span></span>
</td>
<td class="nump">$ 136.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate', window );">Unrecognized tax benefits that would impact effective tax rate</a></td>
<td class="nump">28.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember', window );">Research Tax Credit Carryforward</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforward</a></td>
<td class="nump">9.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_InternalRevenueServiceIRSMember', window );">Internal Revenue Service (IRS)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforward</a></td>
<td class="nump">119.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State and Local Jurisdiction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforward</a></td>
<td class="nump">176.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State and Local Jurisdiction | California and New Jersey Research Tax Credit Carryforward</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforward</a></td>
<td class="nump">29.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember', window );">Non-US</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforward</a></td>
<td class="nump">101.6<span></span>
</td>
<td class="nump">110.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember', window );">Non-US | Capital Loss Carryforward</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforward</a></td>
<td class="nump">$ 17.5<span></span>
</td>
<td class="nump">$ 17.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_InternalRevenueServiceIRSMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_InternalRevenueServiceIRSMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=lgnd_CaliforniaAndNewJerseyResearchTaxCreditCarryforwardMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=lgnd_CaliforniaAndNewJerseyResearchTaxCreditCarryforwardMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_CapitalLossCarryforwardMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=us-gaap_CapitalLossCarryforwardMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140091802959128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Components of Income Tax Expense (Benefit) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Current expense (benefit):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentFederalTaxExpenseBenefit', window );">Federal</a></td>
<td class="num">$ (1,190)<span></span>
</td>
<td class="nump">$ 10,889<span></span>
</td>
<td class="nump">$ 89,471<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">State</a></td>
<td class="num">(32)<span></span>
</td>
<td class="nump">589<span></span>
</td>
<td class="nump">3,103<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentForeignTaxExpenseBenefit', window );">Foreign</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">23<span></span>
</td>
<td class="num">(66)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Total current expense (benefit)</a></td>
<td class="num">(1,222)<span></span>
</td>
<td class="nump">11,501<span></span>
</td>
<td class="nump">92,508<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Deferred expense (benefit):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit', window );">Federal</a></td>
<td class="num">(7,355)<span></span>
</td>
<td class="num">(15,672)<span></span>
</td>
<td class="nump">74,627<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit', window );">State</a></td>
<td class="num">(1,263)<span></span>
</td>
<td class="num">(3,382)<span></span>
</td>
<td class="nump">202<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Total deferred expense (benefit)</a></td>
<td class="num">(8,618)<span></span>
</td>
<td class="num">(19,054)<span></span>
</td>
<td class="nump">74,829<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Total income tax expense (benefit)</a></td>
<td class="num">$ (9,840)<span></span>
</td>
<td class="num">$ (7,553)<span></span>
</td>
<td class="nump">$ 167,337<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentForeignTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentForeignTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred state and local tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140091795485512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Reconciliation of Income Tax Expense (Benefit) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract', window );"><strong>Income Tax Expense (Benefit), Continuing Operations, Income Tax Reconciliation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">Tax at federal statutory rate</a></td>
<td class="nump">$ 9,932<span></span>
</td>
<td class="num">$ (2,213)<span></span>
</td>
<td class="nump">$ 167,294<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes', window );">State, net of federal benefit</a></td>
<td class="num">(408)<span></span>
</td>
<td class="num">(1,456)<span></span>
</td>
<td class="nump">2,466<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_IncomeTaxReconciliationContingentValueRights', window );">Contingent liabilities</a></td>
<td class="num">(8,161)<span></span>
</td>
<td class="num">(278)<span></span>
</td>
<td class="nump">18<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost', window );">Share-based compensation</a></td>
<td class="num">(11,919)<span></span>
</td>
<td class="num">(362)<span></span>
</td>
<td class="num">(819)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomeAmount', window );">FDII</a></td>
<td class="num">(637)<span></span>
</td>
<td class="num">(1,652)<span></span>
</td>
<td class="num">(402)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_EffectiveIncomeTaxRateReconciliationExpiredTaxCreditsResearch', window );">Research and development credits</a></td>
<td class="num">(2,692)<span></span>
</td>
<td class="num">(699)<span></span>
</td>
<td class="num">(879)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions', window );">Change in uncertain tax positions</a></td>
<td class="nump">586<span></span>
</td>
<td class="num">(650)<span></span>
</td>
<td class="nump">441<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate', window );">Rate change for changes in federal, foreign or state law</a></td>
<td class="num">(7,963)<span></span>
</td>
<td class="num">(173)<span></span>
</td>
<td class="num">(210)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_EffectiveIncomeTaxRateReconciliationProvisionToReturnAdjustmentsAmount', window );">Provision to return adjustments</a></td>
<td class="num">(617)<span></span>
</td>
<td class="num">(4,803)<span></span>
</td>
<td class="num">(184)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential', window );">Foreign tax differential on income/loss of foreign subsidiaries</a></td>
<td class="num">(114)<span></span>
</td>
<td class="num">(3,839)<span></span>
</td>
<td class="nump">57<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="nump">11,410<span></span>
</td>
<td class="num">(121,876)<span></span>
</td>
<td class="num">(1,193)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationDispositionOfBusiness', window );">Sale of Vernalis R&amp;D</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">127,372<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationOtherAdjustments', window );">Other</a></td>
<td class="nump">743<span></span>
</td>
<td class="nump">3,076<span></span>
</td>
<td class="nump">748<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Total income tax expense (benefit)</a></td>
<td class="num">$ (9,840)<span></span>
</td>
<td class="num">$ (7,553)<span></span>
</td>
<td class="nump">$ 167,337<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Change in Uncertain Tax Positions</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_EffectiveIncomeTaxRateReconciliationExpiredTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Expired Tax Credits, Research</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_EffectiveIncomeTaxRateReconciliationExpiredTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomeAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Foreign Derived Intangible Income, Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomeAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_EffectiveIncomeTaxRateReconciliationProvisionToReturnAdjustmentsAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Provision to Return Adjustments, Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_EffectiveIncomeTaxRateReconciliationProvisionToReturnAdjustmentsAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_IncomeTaxReconciliationContingentValueRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Income Tax Reconciliation, Contingent Value Rights</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_IncomeTaxReconciliationContingentValueRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, attributable to increase (decrease) in the income tax rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32059-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationDispositionOfBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to the disposition of a business not qualifying as a discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationDispositionOfBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for award under share-based payment arrangement. Includes, but is not limited to, expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140091807756536">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Deferred Taxes (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGrossAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 64,352<span></span>
</td>
<td class="nump">$ 64,147<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards', window );">Research credit carryforwards</a></td>
<td class="nump">27,797<span></span>
</td>
<td class="nump">19,623<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock compensation</a></td>
<td class="nump">11,374<span></span>
</td>
<td class="nump">11,994<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
<td class="nump">19,668<span></span>
</td>
<td class="nump">13,120<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Deferred tax assets</a></td>
<td class="nump">123,191<span></span>
</td>
<td class="nump">108,884<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance for deferred tax assets</a></td>
<td class="num">(36,283)<span></span>
</td>
<td class="num">(24,858)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Net deferred tax assets</a></td>
<td class="nump">86,908<span></span>
</td>
<td class="nump">84,026<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesAbstract', window );"><strong>Deferred tax liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_DeferredTaxLiabilitiesFiniteLivedIntangibleAssets', window );">Identified intangibles</a></td>
<td class="num">(102,221)<span></span>
</td>
<td class="num">(119,381)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesOther', window );">Other</a></td>
<td class="num">(9,300)<span></span>
</td>
<td class="num">(4,923)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Net deferred tax liabilities</a></td>
<td class="num">(111,521)<span></span>
</td>
<td class="num">(124,304)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilities', window );">Deferred income taxes, net</a></td>
<td class="num">$ (24,613)<span></span>
</td>
<td class="num">$ (40,278)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_DeferredTaxLiabilitiesFiniteLivedIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Liabilities, Finite-Lived Intangible Assets</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_DeferredTaxLiabilitiesFiniteLivedIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(15)(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGrossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGrossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140091805722456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Reconciliation of Unrecognized Tax Benefits (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward', window );"><strong>Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Balance at beginning of period</a></td>
<td class="nump">$ 31,871<span></span>
</td>
<td class="nump">$ 28,736<span></span>
</td>
<td class="nump">$ 30,289<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions', window );">Additions based on tax positions related to the current year</a></td>
<td class="nump">252<span></span>
</td>
<td class="nump">3,911<span></span>
</td>
<td class="nump">543<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions', window );">Additions for tax positions of prior years</a></td>
<td class="nump">945<span></span>
</td>
<td class="nump">179<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions', window );">Reductions for tax positions of prior years</a></td>
<td class="num">(3,072)<span></span>
</td>
<td class="num">(955)<span></span>
</td>
<td class="num">(2,096)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Balance at end of period</a></td>
<td class="nump">$ 29,996<span></span>
</td>
<td class="nump">$ 31,871<span></span>
</td>
<td class="nump">$ 28,736<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>lgnd-20211231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2021q4"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:lgnd="http://www.ligand.com/20211231"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2021-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="lgnd-20211231.xsd" xlink:type="simple"/>
    <context id="i8de36dd6935847019123fffb990b7008_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i46357a7c22b94af48beacbd35008717a_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i3ed4f52b1ed24e778aa7185aa1e8bb90_I20220223">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
        </entity>
        <period>
            <instant>2022-02-23</instant>
        </period>
    </context>
    <context id="i9217b15ab4cb456c8c63180298ed612e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7462d0db8f4248fcb9fd8f1deae439f3_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id759bc1766674b9fb61441df044bc82f_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="if3c33038f43443e48bceca35aafc84c2_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i3bced838db93465eb75b31bbd5690a49_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i1477966cad0140da81a9947fe9bab347_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:MaterialSalesCaptisolMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ia7b5c3c10a34465088f2fa15825a2c42_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:MaterialSalesCaptisolMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i75309306f08c443f8965a9846c0fb0fc_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:MaterialSalesCaptisolMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i11e3d543e376468e8dda481609ac67e8_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:ContractRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="if06efbad02a54e9d92b23a3ff376910e_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:ContractRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="idea9b96f20cf4c28aea8b365b1b2069c_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:ContractRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ib3597315a63d441f8f128abd7ed8840e_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ie6c3b69702e9429aaeed46bdb9bbb9c1_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i85c760e4f98147f79ecf9fc666a45595_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:VernalisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ibb5d6e3d481646168203ad91e5a3ab1c_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:VernalisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="id75620cd2ae8495a9c4aff23e56271fa_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:VernalisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="id5ccedf4402b42a79d8bd7ff8d46fd9a_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:PromactaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ic02ae2c8af73463a961944407c02e1da_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:PromactaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i21165c6e7ed34bec9a1abbd4497ce88b_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:PromactaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="id0ff3295defe46b8bccc6c795953b0dd_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ie8198f30811b402385fed871033fac83_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i24530d11bf3d4226b1bfc80e52009811_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i2157f3f9f915470d94164dbf83569db0_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="if1aac4d81ad94163b33117197afe0895_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="iba40247e0e614545939d340c24ba1378_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ia8c2096f420a462b813274a320529a34_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i11614604a0e24aa78e71eb02f9b1c21d_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="id787fbb79cf94df2b867ff01039dd7ee_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i91bf098d468945ce94255ad9187b03e5_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ib5f40ec88b5f46f8a400c8577e872e35_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i32ab127ed5c44358939fcb7eab76b6a6_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="iaa27b23fe5ac43dab25e6b1f5344211e_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ida3ec05a32644c2db1bb9f71f76c567f_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ibb59da98705b4964a37154673c8ed2be_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i7e24f17963584a8a8d751afa02b1b0c9_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia7e3cc749ec443c7b6a42c35ebdbd292_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ibd8ac2d6daad403e8a1f73426f5256a2_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="if67a2cd7a5e7447e8e1765371f5225b9_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i3a721e0ae7354a8da5ec3fc43557bc99_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i00775ac58cda4124ad52707038f57ba7_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i98685891da6a4235a4c08510b2fafca9_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ibd8887ddedbb409e8ee0b01a14c47927_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie12d7c9cbefd4947bbe0a3c6cb0e902e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3fe3de32a504463798a10b16d8710835_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i86f3192c999a48e18bfbb2d3da1eee99_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ib1ca68e3b91b44f0a9d75354b9a561c3_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i2a0bf241e5df45f3b9a295da0a033225_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i4893aa820b6e400e86aa2f8639ddb077_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i460189e17625434e8a5a65a7ad36197f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i35055051f1cc48e3880e5291e4e63132_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if714890c34114ccca202fde217c2acc5_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8b1b6cbf7db84387abc05c19c397f3e1_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">lgnd:PartnerAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i779fbae243e046e6a31b9eaa2c179124_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">lgnd:PartnerAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i32323a9d8b2a49eca1eebf5fa5da97be_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">lgnd:PartnerBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ib29fdd94f38f445bbfcbf8d17a9b0d2c_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">lgnd:PartnerBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i19caa64fec87477596a2cd5d23955ee8_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">lgnd:PartnerBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i6a70ae97ec4641b88ce641ff76d8edd7_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">lgnd:PartnerCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i874c2ad63f1a4f0295a0ad715157a00e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:MaterialSalesCaptisolMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6a5b82872f4b4205b4cb36e3a7e65b00_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:MaterialSalesCaptisolMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5258348dd679493ba1253e4703ac77de_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i55156c07b9684b9185860bad3331609a_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ia9a9eb80fb244862b401f0cf7734c9d9_I20201001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:PfenexMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-01</instant>
        </period>
    </context>
    <context id="i66fd5bb596fe4dc0a209f580f37be1bd_I20200401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:IcagenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-01</instant>
        </period>
    </context>
    <context id="i2c4e300f1b0640468a246731197ac061_I20100131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:MetabasisTherapeuticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2010-01-31</instant>
        </period>
    </context>
    <context id="i24643322fd3648c280f9180082f606c7_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:AziyoandCorMatrixMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ieddf490290904ecbb766659c22b6325c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:AziyoandCorMatrixMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib6ab5af36644400fb3b934151581597a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:SelexisAndDianomiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8dab692d024a4e0f97bf65fe83fb703b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:SelexisAndDianomiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia8308d0606a54c10ac4769b1a226d54c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i302f4f37e71b4505a330b599087d6bee_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="icc93824bf0be4b7495cbbfa00019602d_D20190501-20190531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:NovanMolluscumProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-05-01</startDate>
            <endDate>2019-05-31</endDate>
        </period>
    </context>
    <context id="i4984262bb27142918e72ba7426eaa00b_I20190531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:NovanMolluscumProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:RoyaltyAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-05-31</instant>
        </period>
    </context>
    <context id="i76ec8fc1e4724884824d0d65bebbf615_I20190531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:NovanMolluscumProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:RoyaltyAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-05-31</instant>
        </period>
    </context>
    <context id="iac16870509044b14afde2112b0270ad8_I20190531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:NovanMolluscumProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:RoyaltyAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-05-31</instant>
        </period>
    </context>
    <context id="ifc86d31013124f84b716699c6235c139_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:PalvellaTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:RoyaltyAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i00496d61e75e4c03bdeb6272892386e7_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:PalvellaTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:RoyaltyAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i059cb8a459af48f6b7c8f8245f0a8818_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:PalvellaTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:RoyaltyAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i8efe50fcb86a4eaf887009631ddd44d0_D20181201-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:PalvellaTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="id85f4282e429462997cf6658ec77093b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:PalvellaTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id5f878ad057d4dbcba2c34a61c1d4b07_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:PalvellaTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:ContractRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iabc0130cdf4e432a836d766b1ae349c3_D20170531-20170531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:AziyoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:RoyaltyAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-05-31</startDate>
            <endDate>2017-05-31</endDate>
        </period>
    </context>
    <context id="ib3ba73729c164d36b827967a2afe6719_I20170531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:AziyoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:RoyaltyAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-05-31</instant>
        </period>
    </context>
    <context id="idfd3cb0e5e65402da94f6b645760f254_I20170531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:RoyaltyAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-05-31</instant>
        </period>
    </context>
    <context id="iceabba67d48a469eb549559806d7e623_I20170531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:AziyoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:RoyaltyAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-05-31</instant>
        </period>
    </context>
    <context id="if1c8698b58b240d19cf54dff3bafb373_I20170531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:CorMatrixMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:RoyaltyAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-05-31</instant>
        </period>
    </context>
    <context id="i1345b3a472be45ab8492e940ed55ac1a_D20170531-20170531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:CorMatrixMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:RoyaltyAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-05-31</startDate>
            <endDate>2017-05-31</endDate>
        </period>
    </context>
    <context id="ie0f36a67ac4b474f8a329695884951fa_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:AziyoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:RoyaltyAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i10f57c9a0a354a7c81c9266418797f1c_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:SelexisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:RoyaltyAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i744b30e425414018a238f9fbbb17b855_I20200101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201613Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-01</instant>
        </period>
    </context>
    <context id="id39ac2bcc6964f1cbe6799ea3c6e4480_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:RoyaltyKyprolisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i3f42318fa27c4162a9de72f632806f73_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:RoyaltyKyprolisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ie833d3fbd7ae41c78acdb6743a4958e5_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:RoyaltyKyprolisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i6ec735166d6041df97f7f723bd52feac_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:RoyaltyEvomelaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ice15212256394a4a8bc6d0cdb5b93616_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:RoyaltyEvomelaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="id98579a29cc3406ea0d48ffd0c8920f0_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:RoyaltyEvomelaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="id6a4e064f17b4a32bbb585543d61d513_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:RoyaltyOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i70fab51ef90247fbb75a99fde6e756cd_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:RoyaltyOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="icd3e128d210744fda465cb5dacddcdc6_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:RoyaltyOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="if954ceb872c04e719899033296d6f686_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:RoyaltyPromactaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ice7144c706244526b337a36e827284e4_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ia59aec17df534655ac72afe661d88b8c_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i946a606b7d2e4c08bc42b0378e0181dd_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ied5134c8bab44b978f6b885c1c70cbed_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:LicenseFeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i4f517a8e06cc46728b8724172527ebda_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:LicenseFeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i11ba1ec739d34b82ba4433ba722bc361_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:LicenseFeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="if4e90d7c48b94ff3a4921a0579c9e4e9_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:MilestoneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i757afef6fc544b019aa6e8d1c80f94f9_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:MilestoneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ie9a1b09dbf574bec9cc40c8f1897cdc6_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:MilestoneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i8436481b04714386944e45524f22e5a1_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:LicenseFeesMilestonesAndOtherProductOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i76d02ee85f37479bbbf7ef17aae36e40_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:LicenseFeesMilestonesAndOtherProductOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i46edba4f2dc546d19c17b95467b928d8_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:LicenseFeesMilestonesAndOtherProductOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i03b53fe74b3e44e5aed9677e0c396b22_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i63ea5dae35714601b3840baed12e6429_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="iefe3140ed86e45ff99888b95c61cc3e7_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ib017566aacfb4b59a18b47770cb8359c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ibf4833a4427a446eaf4af9794277325c_D20070101-20071231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
        </entity>
        <period>
            <startDate>2007-01-01</startDate>
            <endDate>2007-12-31</endDate>
        </period>
    </context>
    <context id="i011775edbe77465dad2b4242ab130485_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lgnd:TwoThousandTwoStockIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">lgnd:VestingPeriodOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i05cb34ed326948caae6c1e7e7cb67165_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lgnd:TwoThousandTwoStockIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">lgnd:VestingPeriodTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i995925b4edc84004834a7204d8ca1593_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">lgnd:RestrictedStockUnitsAndPerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i7c39587d4c0e42b7ba5b9574b3926bff_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lgnd:TwoThousandTwoStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ia70ff35785434b4585314e733c4b42c1_I20180531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lgnd:ConvertibleSeniorNotesDue2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-05-31</instant>
        </period>
    </context>
    <context id="i1e8f1b6ddb0a48e7b819cababb4487da_I20140831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lgnd:ConvertibleSeniorNotesDue2019Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2014-08-31</instant>
        </period>
    </context>
    <context id="i0a30e5369c8e4124bba63c2b980273be_I20190815">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lgnd:ConvertibleSeniorNotesDue2019Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-08-15</instant>
        </period>
    </context>
    <context id="i6a0717c8be2147b0b92f9327bf1814fd_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ifcdd30f034184cecb366b0b9b1bd9c55_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i6a0c3b111e7c4e828d7eda58eb7efe37_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i58f6278b54d04be0bf0b9577c087f56c_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i0b2d2a0659724a0394359a72b0ded635_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i97af3b7b1f564d4d911c3d6134e64410_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i891b87647a30477eb27e9edd4fc735ea_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="iad8d570ea6b24d73b93cc3ae9b3901e3_D20201202-20201202">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">lgnd:VernalisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-02</startDate>
            <endDate>2020-12-02</endDate>
        </period>
    </context>
    <context id="ie32796c2a612452280599ec9bc39e8e9_I20201201">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">lgnd:VernalisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-01</instant>
        </period>
    </context>
    <context id="if68046f8a22f4e8cb3ae551bf1b6614f_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">lgnd:VernalisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ie5330d9159b84212968447e2b2771f1b_D20190306-20190306">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">lgnd:PromactaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-03-06</startDate>
            <endDate>2019-03-06</endDate>
        </period>
    </context>
    <context id="i46cec39d09204b19b6661eeb7995f45f_I20190306">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">lgnd:PromactaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-06</instant>
        </period>
    </context>
    <context id="i13ee716c8db44abb8505546f32fd4579_D20190101-20190306">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">lgnd:PromactaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-06</endDate>
        </period>
    </context>
    <context id="ic9f4e1d55a994ce397ebaba69b0e0499_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">lgnd:VikingTherapeuticsInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ie623d2726f914332a2f5295e06936e94_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i0ccc7acfbbaf4714aeb414b4d316cace_D20190101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i05ca320ae7ad4dcaa5874e31460a42ed_D20201001-20201001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:PfenexMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-10-01</endDate>
        </period>
    </context>
    <context id="ic9ff8c1b8ef04c2a949db89fa926c247_I20201001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:PfenexMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-01</instant>
        </period>
    </context>
    <context id="i88f2f47e22764022b5dec2243aa219c7_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:PfenexMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i66bc35f78f7042ebafa5e4807cf87b90_D20201001-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:PfenexMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i95cf6d8d9303402492315ef907402a1a_I20201001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:PfenexMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">lgnd:ContractualRelationshipsAlvogenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-01</instant>
        </period>
    </context>
    <context id="i3639b90349a0416597ac3b2345fcfd8b_D20201001-20201001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:PfenexMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">lgnd:ContractualRelationshipsAlvogenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-10-01</endDate>
        </period>
    </context>
    <context id="i6618eb064ffd4735b65d23c002f29a3d_I20201001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:PfenexMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">lgnd:ContractualRelationshipsMerckMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-01</instant>
        </period>
    </context>
    <context id="ia025b98444b84bf38bee7c4b59d60941_D20201001-20201001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:PfenexMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">lgnd:ContractualRelationshipsMerckMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-10-01</endDate>
        </period>
    </context>
    <context id="i9687ebeaf03c4246885f9a884dc564ee_I20201001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:PfenexMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">lgnd:ContractualRelationshipsJazzMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-01</instant>
        </period>
    </context>
    <context id="i74a5e3f1fdec4b96b148fb5871cc991f_D20201001-20201001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:PfenexMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">lgnd:ContractualRelationshipsJazzMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-10-01</endDate>
        </period>
    </context>
    <context id="i8d2ed9e3e4254c8aa989182cdea6b83e_I20201001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:PfenexMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">lgnd:ContractualRelationshipsSIIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-01</instant>
        </period>
    </context>
    <context id="i5263ecacba2e40a0bef60af7f8f3323f_D20201001-20201001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:PfenexMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">lgnd:ContractualRelationshipsSIIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-10-01</endDate>
        </period>
    </context>
    <context id="i77b01aad4684478a851c8f13a0d12891_I20201001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:PfenexMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">lgnd:ContractualRelationshipsArcellxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-01</instant>
        </period>
    </context>
    <context id="id59883d6b9fe4a63b608829d498699ce_D20201001-20201001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:PfenexMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">lgnd:ContractualRelationshipsArcellxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-10-01</endDate>
        </period>
    </context>
    <context id="i65ac1d8a3b63426baa11a41236151bd8_I20201001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:PfenexMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TechnologyBasedIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-01</instant>
        </period>
    </context>
    <context id="id301d12eff0d4b76a98f1b19b7aa97fd_D20201001-20201001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:PfenexMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TechnologyBasedIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-10-01</endDate>
        </period>
    </context>
    <context id="ib687713e39394d8883330adccb1296e4_D20201001-20201001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:PfenexMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TechnologyBasedIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-10-01</endDate>
        </period>
    </context>
    <context id="i4c77fc6eecd341e48bc7b99f95972ddf_D20200401-20200401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:PfenexMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-04-01</endDate>
        </period>
    </context>
    <context id="if97f9e0769b54e6a845f9f9fc59f0a1a_D20200401-20200401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:PfenexMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-04-01</endDate>
        </period>
    </context>
    <context id="i81ce7b0c06a94e61a7d245d6544346aa_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:PfenexMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i981dcf3e258143ef926ca153a290587b_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:PfenexMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i77d1ae0e9cea4bc5be7e9ef1c1f3a41d_D20200909-20200909">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:TaurusBiosciencesLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-09-09</startDate>
            <endDate>2020-09-09</endDate>
        </period>
    </context>
    <context id="i4dba26cb1a1841e88daa2e5a24a15dd4_I20200909">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:TaurusBiosciencesLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">lgnd:ContingentValueRightForInternalResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-09</instant>
        </period>
    </context>
    <context id="i473bb8ab24bf433bb5e1980d2a87164e_I20200909">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:TaurusBiosciencesLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">lgnd:ContingentValueRightOnProductRevenuesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-09</instant>
        </period>
    </context>
    <context id="i27ca37b8f6ed451391cf76d3832dccdb_D20200909-20200909">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:TaurusBiosciencesLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">lgnd:ContingentValueRightOnProductRevenuesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-09-09</startDate>
            <endDate>2020-09-09</endDate>
        </period>
    </context>
    <context id="i36eaffe97d9f4ad9b8c509ecec687717_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:TaurusBiosciencesLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i37f8f2fb62fb45eda8a94c6014fb06c3_I20200909">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:TaurusBiosciencesLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-09</instant>
        </period>
    </context>
    <context id="i1decdab2b3ad4d5f9e9970051e074f04_D20200909-20200909">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:TaurusBiosciencesLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TechnologyBasedIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-09-09</startDate>
            <endDate>2020-09-09</endDate>
        </period>
    </context>
    <context id="ieb689a5898414155944b7e894ecf5662_D20200908-20200908">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:XCellaBiosciencesIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-09-08</startDate>
            <endDate>2020-09-08</endDate>
        </period>
    </context>
    <context id="i37beeb694dea43279d1ea72ec2fb6fa3_I20200908">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:XCellaBiosciencesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">lgnd:EarnoutRightsForPartnerResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-08</instant>
        </period>
    </context>
    <context id="i48c587ca12364b2ebe41d4a23afdf0a5_I20200908">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:XCellaBiosciencesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">lgnd:MilestonePaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-08</instant>
        </period>
    </context>
    <context id="i00b4cfcf8fab454fa5cb35a4499bd18e_D20200908-20200908">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:XCellaBiosciencesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">lgnd:MilestonePaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-09-08</startDate>
            <endDate>2020-09-08</endDate>
        </period>
    </context>
    <context id="ic3f66dd3dd704775a2c678c7d07ce665_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:XCellaBiosciencesIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ib2d89a76397d4f8fa55ad5491b92151e_I20200908">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:XCellaBiosciencesIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-08</instant>
        </period>
    </context>
    <context id="i27406e0d0a0147c28467e0891905560f_D20200908-20200908">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:XCellaBiosciencesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TechnologyBasedIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-09-08</startDate>
            <endDate>2020-09-08</endDate>
        </period>
    </context>
    <context id="ied333fd0de2c4cf4a2b4948199619825_D20200401-20200401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:IcagenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-04-01</endDate>
        </period>
    </context>
    <context id="i8b9c129486844e46be95446917936d16_I20200401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:IcagenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-01</instant>
        </period>
    </context>
    <context id="i187c5df306a349e38267335b0f796d41_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:IcagenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i2c2f23bb705c43f999e98dd9cfeedb0a_I20200401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:IcagenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-01</instant>
        </period>
    </context>
    <context id="i50397a39865e428d8b5ec1d1e3e72da9_I20200401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:IcagenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TechnologyBasedIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-01</instant>
        </period>
    </context>
    <context id="if2f9b634b34f4572ac8de5159f8e63fb_D20200401-20200401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:IcagenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-04-01</endDate>
        </period>
    </context>
    <context id="i797a1a3c49bb44aba3b71fee73a5a78f_D20200401-20200401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:IcagenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TechnologyBasedIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-04-01</endDate>
        </period>
    </context>
    <context id="i559e6316ff5f46eeae72eb8202827fdd_D20190723-20190723">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:AbInitioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-23</startDate>
            <endDate>2019-07-23</endDate>
        </period>
    </context>
    <context id="i2391e1562f894a61a00bffbaac6457ea_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:AbInitioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ib84e53f0d01a493a86dc0aed964fe45a_I20190723">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:AbInitioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-07-23</instant>
        </period>
    </context>
    <context id="i609b4c3a45a041b1856484ca0935a9fc_D20190723-20190723">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:AbInitioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TechnologyBasedIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-23</startDate>
            <endDate>2019-07-23</endDate>
        </period>
    </context>
    <context id="i06eb91dd76a2457bac33ba1c3af251f5_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ieccd194c6cad463fa107525565469c36_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i03010ea07e48483686f97632e65cacf7_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iae4bca14f93e4328aa90c2fce8fbaae3_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4367fea4a9a64e5a983f1e1a7761535c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6d6fdee1dc984b5fa799d65fefdb8a09_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i640373e7d8124d24b670e247208e7234_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i01a1659f9184445ca7e9d321e7b29f6d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i83d2c94c6e0b4e79aceeeff3efa78c20_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2a0bee3568b44a9bb12563aeaa8528f5_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7d8c9f4eb5724240a7b9559155e19d8f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i33b5cd64b00744faaf121a59ccec8a90_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i84a81b7b22eb417e910d5485bba6df55_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lgnd:LiabilityForContingentValueRightsCompanyCydexMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie6401005419049dc9000250436aca434_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lgnd:LiabilityForContingentValueRightsCompanyCydexMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0f8a682fcdf94c3d884f17cb17ab868c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lgnd:LiabilityForContingentValueRightsCompanyCydexMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5346db50523e458fa6677b7418028935_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lgnd:LiabilityForContingentValueRightsCompanyCydexMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i761befb7871948fea7097d919ba453c9_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lgnd:LiabilityForContingentValueRightsCompanyMetabasisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ief7b3a15b9ee435cbec80f843a28571c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lgnd:LiabilityForContingentValueRightsCompanyMetabasisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iaae0909eafc24451b37ac98a3e7c4186_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lgnd:LiabilityForContingentValueRightsCompanyMetabasisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0c03158e62e14e9d93bc8351b82e61d2_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lgnd:LiabilityForContingentValueRightsCompanyMetabasisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i05df3e58efe24ec7831e64257f22be53_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lgnd:LiabilityForContingentValueRightsCompanyIcagenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i518bc06c25204d4482b4301cdd1766e5_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lgnd:LiabilityForContingentValueRightsCompanyIcagenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iaac590afaaf54948a1215ada11b67e6c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lgnd:LiabilityForContingentValueRightsCompanyIcagenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5a59fb8107e140aaad7a5aeb9e7c180b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lgnd:LiabilityForContingentValueRightsCompanyIcagenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i36dc23d032314fa8a07bbd180231487a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lgnd:LiabilityForRestrictedInvestmentsOwedToFormerLicenseesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i01b8d0c82ed84b4ca4d821ca4a42eeba_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lgnd:LiabilityForRestrictedInvestmentsOwedToFormerLicenseesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic60c56fc16f0480485730f8ab7210dd9_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lgnd:LiabilityForRestrictedInvestmentsOwedToFormerLicenseesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iffa6d45b279f45088e9ebcb1bda002cc_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lgnd:LiabilityForRestrictedInvestmentsOwedToFormerLicenseesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ibc51353676e643b3841a0d97b6e09df4_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i2e29fab916b04659a0092e93e4ce0c0f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="icb7f607e997042d6b7cb2a76b14c89ff_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ieef2fe5db0a5418095a2663aac7e9433_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i4d9e2c86e31846918735fb68e1980c7b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i4633e33cdaf74da5bab73b86a73c762b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5465f391d98d450686c03b0526a9298e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i64e87aeff0584255b5155e1fb7330377_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9fde372ecc73482ea79fc251841260be_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iad3afe93dc254f3a87134b83bff3a320_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if82c17ea55e64548ab7c37f50afc7954_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5ec6e8e1b38040ff9f9c4e67b129466c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if603e492b3b54ca58c52c72f0db1a614_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i04c0a503b677413e90c282c029cef0df_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i90e770e8ee9247f492c911fccc5f09ee_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8c5d55bf4e3a4a18a904ad6c106afe1b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i89bb63fa9a9347e5b89eddf911a574ec_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lgnd:LiabilityForContingentValueRightsCompanyCrystalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic8dbef5f05d649cfa20404b188f90797_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lgnd:LiabilityForContingentValueRightsCompanyCrystalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i4b774db056ca4e6fbb86b328cdf6ec7e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lgnd:LiabilityForContingentValueRightsCompanyCrystalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i49c492d399144f8f95065abe6a77d858_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lgnd:LiabilityForContingentValueRightsCompanyCrystalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i09e78cdf01344954a110ff4100c16b89_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lgnd:LiabilityForContingentValueRightsCompanyCydexMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i641dc2acfdc24382ac77f797d0b878dc_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lgnd:LiabilityForContingentValueRightsCompanyCydexMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i94796a987fa04da6b4328a1f6396c729_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lgnd:LiabilityForContingentValueRightsCompanyCydexMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5ab1ef46b3dc4b3687c20938c246e8e1_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lgnd:LiabilityForContingentValueRightsCompanyCydexMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i64ddda8f7dd340a6a66150fe9da6ac8f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lgnd:LiabilityForContingentValueRightsCompanyMetabasisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3a14312c0d7a4b6ab188c0d69af3db1b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lgnd:LiabilityForContingentValueRightsCompanyMetabasisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i4994043653b246e6825b1757a960c104_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lgnd:LiabilityForContingentValueRightsCompanyMetabasisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i11062dc1f4334dbda82a1482afce4add_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lgnd:LiabilityForContingentValueRightsCompanyMetabasisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5a6efdc157074e8abf3dbebb0b3ad1b2_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lgnd:LiabilityForContingentValueRightsCompanyIcagenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i766d5476b4ed450888509671880dd88e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lgnd:LiabilityForContingentValueRightsCompanyIcagenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i32ce3f371084478bae9051b730d767d9_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lgnd:LiabilityForContingentValueRightsCompanyIcagenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3c716beea168465687c12c65fb1f22bc_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lgnd:LiabilityForContingentValueRightsCompanyIcagenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i795fda855e164fe998d1404c211cfeff_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lgnd:LiabilityForContingentValueRightsCompanyPfenexMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9ea2d72079aa4831af7d9061421a7429_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lgnd:LiabilityForContingentValueRightsCompanyPfenexMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ice7abf01eb9f42f5b54f5a4e479520a1_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lgnd:LiabilityForContingentValueRightsCompanyPfenexMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie0fd39b8e1ac4faebf9a08fe57ba3937_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lgnd:LiabilityForContingentValueRightsCompanyPfenexMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if2d95711871a49dda3f26e3f6251690b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lgnd:LiabilityForRestrictedInvestmentsOwedToFormerLicenseesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id1294f5d7b1847e0a6d5e6dbe332860f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lgnd:LiabilityForRestrictedInvestmentsOwedToFormerLicenseesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib3682c8c511e421faf31bc8dcde15b42_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lgnd:LiabilityForRestrictedInvestmentsOwedToFormerLicenseesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="idcc241ac9ac54103a54cc0d5e60c4f58_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lgnd:LiabilityForRestrictedInvestmentsOwedToFormerLicenseesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i417532a79d3e4320bfa35df66295546e_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lgnd:LiabilityForContingentValueRightsCompanyCrystalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iedd254aeb5ed46a0bbbbaec3521899ab_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:DevelopmentRegulatoryCommercialMilestonesAndTieredRoyaltiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5b1dfac6d5ae4926a0e3356f1fb10e83_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:Phase3ClinicalTrialMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib43ce77d810a40fc9387e9ee784e9e68_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lgnd:LiabilityForContingentValueRightsCompanyIcagenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i8c54435dabbb4bf1accc9ff53169d37a_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lgnd:LiabilityForContingentValueRightsCompanyPfenexMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="iac18f57f540e4a9a8a4f9d6ca432b9ee_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i34b45bfb1f924acb8a8e2d99bc22a5fc_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i5044d29e95d74c3fb4dfe5dd2471e761_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3573e853130f4f1fbcdabc617380abaf_D20201001-20201031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:MaterialSalesCaptisolMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-10-31</endDate>
        </period>
    </context>
    <context id="ia2b01f0961da4bb18dfb8e25a49046e9_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3280169138e848a0ba04a73dbb57193a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ied7021ca8f6e4678a12f1acdf2315468_D20140801-20140831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lgnd:ConvertibleSeniorNotesDue2019Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2014-08-01</startDate>
            <endDate>2014-08-31</endDate>
        </period>
    </context>
    <context id="i1183d582f8ce4971a5581dbc8a1e1af3_D20140801-20140831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lgnd:ConvertibleSeniorNotesDue2019Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2014-08-01</startDate>
            <endDate>2014-08-31</endDate>
        </period>
    </context>
    <context id="i6ba1b63d92a042cf85e08ce77d22918b_D20140801-20140831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lgnd:ConvertibleSeniorNotesDue2019Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2014-08-01</startDate>
            <endDate>2014-08-31</endDate>
        </period>
    </context>
    <context id="iebcfeb3afbe54bc3ae6cb6224e5b1f1a_D20180522-20180522">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lgnd:ConvertibleSeniorNotesDue2019Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-05-22</startDate>
            <endDate>2018-05-22</endDate>
        </period>
    </context>
    <context id="i64f0f378c0fc4cf4ae62d78c8b6e22d1_D20181231-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lgnd:ConvertibleSeniorNotesDue2019Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ie12f8a2703764c3c9b2157933d860bf3_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lgnd:ConvertibleSeniorNotesDue2019Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i0b01059b43af404594129aa6cbdd9a86_D20180301-20180430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lgnd:ConvertibleSeniorNotesDue2019Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-03-01</startDate>
            <endDate>2018-04-30</endDate>
        </period>
    </context>
    <context id="id614d6af476c4bf9847c470856137006_D20180701-20180831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lgnd:ConvertibleSeniorNotesDue2019Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-08-31</endDate>
        </period>
    </context>
    <context id="i4f364a39025b407697747d1d13afd5d0_D20181001-20181130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lgnd:ConvertibleSeniorNotesDue2019Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-01</startDate>
            <endDate>2018-11-30</endDate>
        </period>
    </context>
    <context id="iea9bdffff69d41b2bab859af4b604cca_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lgnd:ConvertibleSeniorNotesDue2019Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="icc1c18173ae448ee9cc6a4cfa0f63d46_D20190601-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lgnd:ConvertibleSeniorNotesDue2019Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-06-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i299d7fb1915643c9bd662d97a56f9224_D20190815-20190815">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lgnd:ConvertibleSeniorNotesDue2019Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-08-15</startDate>
            <endDate>2019-08-15</endDate>
        </period>
    </context>
    <context id="ie2cb0a952fa043858638ccca94aafee7_I20190815">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lgnd:ConvertibleSeniorNotesDue2019Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-08-15</instant>
        </period>
    </context>
    <context id="ic3fce11822d74ffb9e96e89bebb23277_I20140831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
        </entity>
        <period>
            <instant>2014-08-31</instant>
        </period>
    </context>
    <context id="if35894c7763245fd8dfbcdb677a1a22e_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lgnd:ConvertibleSeniorNotesDue2019Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i9807ff46d0594f389be4314eae9d0d00_I20180522">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lgnd:ConvertibleSeniorNotesDue2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-05-22</instant>
        </period>
    </context>
    <context id="i6cacda44cb2c4af291db0ef24394bf54_D20180501-20180531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lgnd:ConvertibleSeniorNotesDue2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-05-01</startDate>
            <endDate>2018-05-31</endDate>
        </period>
    </context>
    <context id="i2b189f2223d941889569bd209d33b64c_D20180501-20180531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lgnd:ConvertibleSeniorNotesDue2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-05-01</startDate>
            <endDate>2018-05-31</endDate>
        </period>
    </context>
    <context id="i6dd7d2a8849547b0b84667b449a38485_D20180501-20180531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lgnd:ConvertibleSeniorNotesDue2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-05-01</startDate>
            <endDate>2018-05-31</endDate>
        </period>
    </context>
    <context id="i75c40fa8303240178bae96b5323104b2_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lgnd:ConvertibleSeniorNotesDue2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iad6270f46e2a419fb81396b4dde75fb8_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lgnd:ConvertibleSeniorNotesDue2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic40084c55a8f45ed806b36e3520df3db_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lgnd:ConvertibleSeniorNotesDue2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i9d6e6be3ae854425ba0e34565fd2b9c3_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lgnd:ConvertibleSeniorNotesDue2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ie28d293ededa44009f8568af6cd22fe9_I20220228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lgnd:ConvertibleSeniorNotesDue2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-02-28</instant>
        </period>
    </context>
    <context id="i106a64ab6c044b39a19f90f252c7361a_D20220201-20220228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lgnd:ConvertibleSeniorNotesDue2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-01</startDate>
            <endDate>2022-02-28</endDate>
        </period>
    </context>
    <context id="i4bff4ceb2aad46e4b1484d0f72c5d0dc_D20180522-20180522">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lgnd:ConvertibleSeniorNotesDue2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-05-22</startDate>
            <endDate>2018-05-22</endDate>
        </period>
    </context>
    <context id="i304fdd56fb5543218317f467b86ae411_I20180531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lgnd:ConvertibleSeniorNotesDue2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-05-31</instant>
        </period>
    </context>
    <context id="ieab8e7c78f9745d2b71d10dcba9ea01a_I20200430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lgnd:ConvertibleSeniorNotesDue2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-30</instant>
        </period>
    </context>
    <context id="i1c98a85d32c34724861a5ba3589972ee_D20200401-20200430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lgnd:ConvertibleSeniorNotesDue2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-04-30</endDate>
        </period>
    </context>
    <context id="i71ea8f3e306b4086bfbeaaedfe295b98_I20210131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lgnd:ConvertibleSeniorNotesDue2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-31</instant>
        </period>
    </context>
    <context id="if357845be5954c78ac67d659d089ca0c_D20210101-20210131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lgnd:ConvertibleSeniorNotesDue2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-01-31</endDate>
        </period>
    </context>
    <context id="i00a18868ce4d4197a8afb1f39a028208_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MutualFundMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4ee078f3c41f42a0b0e253d5572cce12_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:DemandDepositsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iaf06af7ed8174cf3bef274cca762d884_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8cbd4d6b4d6042bca716c614bfd4632a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7e8a90585c134dbb98e6aecf3894a4ee_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ibba9764388ba4ab5b3742c104cad8606_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie389523012a64039b933f60b96d0b103_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ibe91b170813b4c308d6df67cdcda5ea8_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib7bfc8139cbb425fb7edf200713433a4_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MutualFundMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i201f7376cfcf403b9594a167f61024eb_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:DemandDepositsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i1751a1fa85af462cabdcd01341cd31d6_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if6d8d88efb7d45d5b666348e93e722c9_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iec0af917487f48e3b637625d1c5d4563_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:AgencySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i05f7d42438c243028010745501c74c06_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6a5d7b087f09490db4f5fa4e098ee683_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6243ca7a24ef40909c79d484e6b2cf6a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i17e3d08da23d4db99c73bbe97ce55cbd_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i20c406b0b22b496398fdf16c484061b8_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DemandDepositsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id5e251d71959460ba39674664cd46959_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i057c89a152c14f40b506b184456d7b2b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6fbb980b9e7c4be4bd3c3376bc2bfda4_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib7f6e9d91bc84543b6ae3503d8d78f6b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DemandDepositsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i24d8d13bc1ac4681b103e921e023e7ba_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i1a14cdb03cd74fd3800f47006e6564e8_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9f0a5635602742c38606929f85d0bc8e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2ef3fe1366ce4c63b1d61301c2c7cbb5_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9733272dc36042e6ba12faba3f716e92_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i95f33c3ebaeb4778a9c2db6a6f6bf294_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i4c5205ea5f084dac8c4dea9fdfadee02_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">lgnd:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4a16585689be4389b9863317f3aa3977_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">lgnd:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8dc42c0d5a094b05bae7e120852bb210_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentedTechnologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6b8810ae90624e1cbd1c4a5c1b42b223_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentedTechnologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ida5c64ee227a46869554690587da8f25_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5e9a6867858343a7a292fb11a532ee7e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i89bdb805a8644de089fac518b7ea8048_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i427cd915d4f24352b4c76d892b21bbe5_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iea59787485c24e82bc3497c81a2ced53_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ContractualRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0aba44ce07e94134b8623377b4bd1f1b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ContractualRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i96479b1570dc4ab694a9ba99ff1921f3_I20100131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
        </entity>
        <period>
            <instant>2010-01-31</instant>
        </period>
    </context>
    <context id="i03ae11f17dbd4fa8abcc1e76cf940016_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:CydexPharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i995ed554220d4c41bec3af6e81ce0850_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:CydexPharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i0526771434af45b0b8fabceb89eea2cc_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:CydexPharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9a7cf59bd85847db8f5d973e93d748f7_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:CydexPharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i460273d884cd42ba9f38e5fa9863bd88_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:CydexPharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="icaf2965868e840808ef1852e02d910af_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:MetabasisTherapeuticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i9bc6c029e12c43b59b76212780726386_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:MetabasisTherapeuticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i2e4b849ac2f8499fb341e31d46f606a1_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:MetabasisTherapeuticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i1d4b5cb9bf0848cd952b53016008c4d8_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:MetabasisTherapeuticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i83cae13058624959a293b420f9d495a2_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:MetabasisTherapeuticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9e883877c50c4dd5bae0f1a39a6a0e41_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:CrystalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i9b2336871c004529976d951e9de999e1_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:CrystalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i99bcc19c12eb4a95abbe38b2a1c1ee09_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:CrystalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i46955c33e54e4edc9a5157b092d74d96_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:CrystalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="iaad967943e174bfb992a030f8843e4a9_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:CrystalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if61e02a9d9f3443a954dd4ff1b746645_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:IcagenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="idcfaeb9f6dcd4e36923251345eeb6ca6_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:IcagenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i3fbebdcfd15e4645b3afda1206ded002_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:IcagenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i7fb9df0f2e264716b9f5ee2e301fba56_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:IcagenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9c2bd0e95a2b4600bd5178475b6ab429_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:PfenexMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i2e80589fd36648dfa6f6d8fa79c9c970_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:PfenexMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ida7de17e10b54528aa29a691195fafa4_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:PfenexMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i017d8efa6ba94abf99a9dc5f29b93ac6_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:XCellaBiosciencesIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="id1b889a729444f17b1b5cebb42dc2471_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:XCellaBiosciencesIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="if9bfbbb794834d7fba1e6252029a297d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:XCellaBiosciencesIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9eeb792ea9ad40c3915226866d3115db_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:XCellaBiosciencesIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i448245714de441abb40ff86cd51987ac_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="iacfc069f04d74d5284905aeca908935c_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i25d150502e6343c683387b66fba49489_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="iee6a37781cce4dbf871fcd529222b482_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i5795881ca2b5425d88c92353925e817c_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i0cf2334cbb0c4ac8b2c4b765ea0668aa_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i67c3913252f44310913216625ca1c514_D20201201-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lgnd:TwoThousandTwoStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ib571bf67523d458e92549c7f222ea20c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lgnd:TwoThousandTwoStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if81036550c4349c78f4732ee0154191c_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ibb76fff21d1145a2aa988019605605d7_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">lgnd:ExercisePriceRangeOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i2d5b9274891c4530b4756d9f6d78384d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">lgnd:ExercisePriceRangeOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i42d7e1e14d514ee5ac131e49d67d3ae9_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">lgnd:ExercisePriceRangeTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="if56255ad310d4a3bbccede5e1c84b2ec_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">lgnd:ExercisePriceRangeTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1583b4003fe544649fbe7acf591bc7c2_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">lgnd:ExercisePriceRangeThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i3186ef0fac614fe4a3a83b4e3df1fac4_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">lgnd:ExercisePriceRangeThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9203228b9f3a4a258d1dd418f1ff9fab_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">lgnd:ExercisePriceRangeFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i65a6d24f5a314cbba76284b24732fb3c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">lgnd:ExercisePriceRangeFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i708cf622e450455095803a651785b9f8_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">lgnd:ExercisePriceRangeFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i1cf30bd35d974a5688e936ed32ee1917_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">lgnd:ExercisePriceRangeFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i193ec162b3f648aaaca6368e35169ea0_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">lgnd:ExercisePriceRangeSixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i80a561831894449e862692a33049b0b5_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">lgnd:ExercisePriceRangeSixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i08eb127d3b5c4ecd8f5f19d8b095a195_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">lgnd:ExercisePriceRangeSevenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i546fb8a918cb476380308420e935eec1_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">lgnd:ExercisePriceRangeSevenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i39fc20505d3849c9ae3fc61f12edf580_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">lgnd:ExercisePriceRangeEightMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i1d0ce9ddb0d9422b8e6592ab0500d1ab_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">lgnd:ExercisePriceRangeEightMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9d3219f8f79f4fb685decb79b150bd06_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">lgnd:ExercisePriceRangeNineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="id7afd511815d4bc394f6e2368abd4dca_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">lgnd:ExercisePriceRangeNineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i828b95c8a1d249729b55e04082a16fbe_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">lgnd:ExercisePriceRangeTenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ie43fa1c2f29449588c86ec647c987e14_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">lgnd:ExercisePriceRangeTenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i331ce2c9b57a41af9de97ff9994cb5b5_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">lgnd:ExercisePriceRangeElevenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6d7b08b9d22043d5932cf089d69eba52_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">lgnd:ExercisePriceRangeElevenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i8c53cef7494647d29b8ef30c6695cfb2_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i0addec58007345efb57ddbad8ce96022_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="id82d912299e647bab45143f83254b4e2_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i9d152e0e9dfd4aad8d4279f7424f28d5_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i0f9a89ad3d5346e3b8b17b7dfbcb9f78_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i45bcdaf84c91401486b1d0398942843d_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i5adbf2e3e4984848b67e5715f6848f1d_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ice6ab2e1895644b3904facb98212b670_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ibc879451c38048cb9a8e8aa28472a4b5_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i22382abe9f7a467bbc034256835a449a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lgnd:AmendedESPPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0776b86882ee4f22a11770402d0e2885_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lgnd:AmendedESPPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i535be16f293842b4b59ed978a4dea350_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lgnd:AmendedESPPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ie6271140c911499083fbafdeb97da802_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lgnd:AmendedESPPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i66cf645fedeb4e3f9127e1557bedf870_I20190911">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
        </entity>
        <period>
            <instant>2019-09-11</instant>
        </period>
    </context>
    <context id="i4f38082a14de4b7eb626c9119b5258a9_D20190911-20190911">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
        </entity>
        <period>
            <startDate>2019-09-11</startDate>
            <endDate>2019-09-11</endDate>
        </period>
    </context>
    <context id="i4cf8373f29714ddb8d2a41d990b0fb42_I20190123">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
        </entity>
        <period>
            <instant>2019-01-23</instant>
        </period>
    </context>
    <context id="i93652c87888744bc90a296c0d62c6b8e_D20191029-20191029">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">lgnd:LupinPatentInfringementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-29</startDate>
            <endDate>2019-10-29</endDate>
        </period>
    </context>
    <context id="idcb9c868c1be4dc8bc733f81708def2c_D20191031-20191031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">lgnd:USDistrictCourtForTheNorthernDistrictOfOhioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-31</startDate>
            <endDate>2019-10-31</endDate>
        </period>
    </context>
    <context id="ia4b200a8f2e64db69b4c7fc8145284e5_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i961668aace3a442bba4c79a8ec70d54a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if699be6e6c984e4f92ca3d8242313e6d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5ec01ca4f07749ee939ef64e906c8950_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">lgnd:CaliforniaAndNewJerseyResearchTaxCreditCarryforwardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1d36cbe0fb424f31b1fc285dc4c6570b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0c31a24c4fde4de983ed94eb8e6c8a18_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:CapitalLossCarryforwardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="icb55a00b3ea6419c93f1e2c6128879a1_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i451ae05e4ee04e718c1da5b566a1bbc5_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:CapitalLossCarryforwardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="segment">
        <measure>lgnd:segment</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="right">
        <measure>lgnd:right</measure>
    </unit>
    <unit id="acquisition">
        <measure>lgnd:acquisition</measure>
    </unit>
    <unit id="agreement">
        <measure>lgnd:agreement</measure>
    </unit>
    <unit id="trading_day">
        <measure>lgnd:trading_day</measure>
    </unit>
    <unit id="day">
        <measure>lgnd:day</measure>
    </unit>
    <unit id="option">
        <measure>lgnd:option</measure>
    </unit>
    <unit id="position">
        <measure>lgnd:position</measure>
    </unit>
    <unit id="patent">
        <measure>lgnd:patent</measure>
    </unit>
    <unit id="civil_complaint">
        <measure>lgnd:civil_complaint</measure>
    </unit>
    <dei:AmendmentFlag
      contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY180L2ZyYWc6ODEzYTY0YmJkNjgyNGQ0MmI0M2UwYzUyMTA0MTA0ODQvdGFibGU6ZjY0NGM3OTc0MzdjNDlmN2I0YzU2YmI5MTVlNzRjNjcvdGFibGVyYW5nZTpmNjQ0Yzc5NzQzN2M0OWY3YjRjNTZiYjkxNWU3NGM2N18xLTEtMS0xLTQxMjk0_5fb31aee-39d1-4c52-945a-0980472c4286">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus
      contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY180L2ZyYWc6ODEzYTY0YmJkNjgyNGQ0MmI0M2UwYzUyMTA0MTA0ODQvdGFibGU6ZjY0NGM3OTc0MzdjNDlmN2I0YzU2YmI5MTVlNzRjNjcvdGFibGVyYW5nZTpmNjQ0Yzc5NzQzN2M0OWY3YjRjNTZiYjkxNWU3NGM2N18yLTEtMS0xLTQxMjk0_c454efb4-3b22-4e1f-adcd-8427640e8592">2021</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY180L2ZyYWc6ODEzYTY0YmJkNjgyNGQ0MmI0M2UwYzUyMTA0MTA0ODQvdGFibGU6ZjY0NGM3OTc0MzdjNDlmN2I0YzU2YmI5MTVlNzRjNjcvdGFibGVyYW5nZTpmNjQ0Yzc5NzQzN2M0OWY3YjRjNTZiYjkxNWU3NGM2N18zLTEtMS0xLTQxMjk0_775d2eb4-2871-45db-b874-b57de26ef190">FY</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey
      contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY180L2ZyYWc6ODEzYTY0YmJkNjgyNGQ0MmI0M2UwYzUyMTA0MTA0ODQvdGFibGU6ZjY0NGM3OTc0MzdjNDlmN2I0YzU2YmI5MTVlNzRjNjcvdGFibGVyYW5nZTpmNjQ0Yzc5NzQzN2M0OWY3YjRjNTZiYjkxNWU3NGM2N180LTEtMS0xLTQxMzky_a0ef9304-b618-4c0e-9879-2a7a8fe1e4a7">0000886163</dei:EntityCentralIndexKey>
    <us-gaap:AccountingStandardsUpdateExtensibleList
      contextRef="ie6c3b69702e9429aaeed46bdb9bbb9c1_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183My9mcmFnOmQzNzc2MmZiMDI0ZDRjNWE5MjMxODNkNmUxMTdjM2Q1L3RhYmxlOjU2ZjRlNzRkOTUxZDRhM2NiNDRhMzVjOGM0OWFmN2M0L3RhYmxlcmFuZ2U6NTZmNGU3NGQ5NTFkNGEzY2I0NGEzNWM4YzQ5YWY3YzRfMTctMC0xLTEtNDg2MjE_f0956f56-e3b9-4151-8fc0-a01564d4dcdb">http://fasb.org/us-gaap/2021-01-31#AccountingStandardsUpdate201613Member</us-gaap:AccountingStandardsUpdateExtensibleList>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i5258348dd679493ba1253e4703ac77de_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RleHRyZWdpb246MDE1MzU3NWExNzUxNDlhMGJlMjM2NzA3MzMyMzJiNjlfNjcyNw_c91288e2-cf87-4740-a1f7-845dfc930514">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="i011775edbe77465dad2b4242ab130485_D20210101-20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184NS9mcmFnOjgwZjdhYjc0MmVmMTQ4ZWJhYWQ2NWMxNGI4MTIzNTU1L3RhYmxlOjJkZmU4Y2E0Y2M2MzRjZDc5Y2M4OTM1ZDAyNTM4Njk1L3RhYmxlcmFuZ2U6MmRmZThjYTRjYzYzNGNkNzljYzg5MzVkMDI1Mzg2OTVfMS0xLTEtMS00MTI5NA_e761052f-75df-4244-b2fe-c04036514efd"
      unitRef="number">0.1250</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="i05cb34ed326948caae6c1e7e7cb67165_D20210101-20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184NS9mcmFnOjgwZjdhYjc0MmVmMTQ4ZWJhYWQ2NWMxNGI4MTIzNTU1L3RhYmxlOjJkZmU4Y2E0Y2M2MzRjZDc5Y2M4OTM1ZDAyNTM4Njk1L3RhYmxlcmFuZ2U6MmRmZThjYTRjYzYzNGNkNzljYzg5MzVkMDI1Mzg2OTVfMi0xLTEtMS00MTI5NA_f3790e7f-8a4a-4d7a-b6f3-401e66ad3a52"
      unitRef="number">0.0208</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
      contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDAvZnJhZzpmNDRmMTQwOTY3NGU0MzVkYWNmMjkzYWVjOTgxYmE2NS90YWJsZToyNmY5ZDQ2ZjdiYTI0Y2E3OWY3YzM1YWYzY2NhMjdkMC90YWJsZXJhbmdlOjI2ZjlkNDZmN2JhMjRjYTc5ZjdjMzVhZjNjY2EyN2QwXzExLTAtMS0xLTQxMjk0_189a0b16-c5f6-426a-9fe4-540e7d6227de">http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesNoncurrent</us-gaap:FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
      contextRef="i7462d0db8f4248fcb9fd8f1deae439f3_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDAvZnJhZzpmNDRmMTQwOTY3NGU0MzVkYWNmMjkzYWVjOTgxYmE2NS90YWJsZToyNmY5ZDQ2ZjdiYTI0Y2E3OWY3YzM1YWYzY2NhMjdkMC90YWJsZXJhbmdlOjI2ZjlkNDZmN2JhMjRjYTc5ZjdjMzVhZjNjY2EyN2QwXzExLTAtMS0xLTQxMjk0_2ee456c7-520d-4723-b00d-a8a6a8da65cf">http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesNoncurrent</us-gaap:FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:DebtInstrumentConvertibleConversionRatio1
      contextRef="ied7021ca8f6e4678a12f1acdf2315468_D20140801-20140831"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDYvZnJhZzo5M2Q5YTVhN2Q1NWM0ODI3ODk1ZGQ3MGJiM2M0ZjI2NC90YWJsZTo5Mzc2ZjJmNmU0MTI0MDk5OTQzMWUwNWI3ZDAwMDQyNy90YWJsZXJhbmdlOjkzNzZmMmY2ZTQxMjQwOTk5NDMxZTA1YjdkMDAwNDI3XzItMS0xLTEtNDEyOTQ_4f6acaa5-a28a-4dc6-af4a-6831b864d395"
      unitRef="number">0.0133251</us-gaap:DebtInstrumentConvertibleConversionRatio1>
    <us-gaap:DebtInstrumentConvertibleConversionRatio1
      contextRef="i6cacda44cb2c4af291db0ef24394bf54_D20180501-20180531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDYvZnJhZzo5M2Q5YTVhN2Q1NWM0ODI3ODk1ZGQ3MGJiM2M0ZjI2NC90YWJsZTo5Mzc2ZjJmNmU0MTI0MDk5OTQzMWUwNWI3ZDAwMDQyNy90YWJsZXJhbmdlOjkzNzZmMmY2ZTQxMjQwOTk5NDMxZTA1YjdkMDAwNDI3XzItMi0xLTEtNDEyOTQ_bd6a68ce-2e79-4014-84ee-930202b29b77"
      unitRef="number">0.0040244</us-gaap:DebtInstrumentConvertibleConversionRatio1>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i5258348dd679493ba1253e4703ac77de_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90ZXh0cmVnaW9uOjhkMWM4MjU1M2QwNzQ1ODVhMDJmY2U3NDA0ZGE4ZTE5XzIwODU_49dc7d90-487d-4145-93b5-5005d27536fa">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <dei:DocumentType
      contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xL2ZyYWc6MmY2MWRiOTUwNGNkNDliM2E4MWMxYTQyZmUyNTZkZjUvdGV4dHJlZ2lvbjoyZjYxZGI5NTA0Y2Q0OWIzYTgxYzFhNDJmZTI1NmRmNV80MDQ4_6b09f94d-2133-4c42-9b01-d71a43ab7c60">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xL2ZyYWc6MmY2MWRiOTUwNGNkNDliM2E4MWMxYTQyZmUyNTZkZjUvdGFibGU6ZGQ5MzNjYTdkMGNlNGIxYWJkZDU4ZTlkODQxZGRhOGMvdGFibGVyYW5nZTpkZDkzM2NhN2QwY2U0YjFhYmRkNThlOWQ4NDFkZGE4Y18wLTAtMS0xLTQxMjk0_301e6b1b-95e1-47fb-bd7e-c94ecb81729d">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xL2ZyYWc6MmY2MWRiOTUwNGNkNDliM2E4MWMxYTQyZmUyNTZkZjUvdGV4dHJlZ2lvbjoyZjYxZGI5NTA0Y2Q0OWIzYTgxYzFhNDJmZTI1NmRmNV8zMDQ_75c5e435-e0fa-4d50-9327-9faedcf8efde">2021-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate
      contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xL2ZyYWc6MmY2MWRiOTUwNGNkNDliM2E4MWMxYTQyZmUyNTZkZjUvdGV4dHJlZ2lvbjoyZjYxZGI5NTA0Y2Q0OWIzYTgxYzFhNDJmZTI1NmRmNV8zMDQ_6a5332b3-fa87-4a28-803c-69fc3b2111ac">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentTransitionReport
      contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xL2ZyYWc6MmY2MWRiOTUwNGNkNDliM2E4MWMxYTQyZmUyNTZkZjUvdGFibGU6MDBiOWVjYzU5ZjAyNGVjYmI4NTYxZDgxYWYxZGZmOTcvdGFibGVyYW5nZTowMGI5ZWNjNTlmMDI0ZWNiYjg1NjFkODFhZjFkZmY5N18wLTAtMS0xLTQxMjk0_511a4697-798e-4e3d-9f45-5f158387f9c0">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xL2ZyYWc6MmY2MWRiOTUwNGNkNDliM2E4MWMxYTQyZmUyNTZkZjUvdGV4dHJlZ2lvbjoyZjYxZGI5NTA0Y2Q0OWIzYTgxYzFhNDJmZTI1NmRmNV80MDQz_6fe61333-dd8c-4cce-bef2-7ac3373c94fb">001-33093</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xL2ZyYWc6MmY2MWRiOTUwNGNkNDliM2E4MWMxYTQyZmUyNTZkZjUvdGV4dHJlZ2lvbjoyZjYxZGI5NTA0Y2Q0OWIzYTgxYzFhNDJmZTI1NmRmNV80MDUw_19ce0d23-1eb3-4493-b882-1f2be53da81c">LIGAND PHARMACEUTICALS INC</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xL2ZyYWc6MmY2MWRiOTUwNGNkNDliM2E4MWMxYTQyZmUyNTZkZjUvdGFibGU6YzY1NWE1NWRmM2ZiNGZhYTg0N2ZhN2NiMTM0M2MyNDEvdGFibGVyYW5nZTpjNjU1YTU1ZGYzZmI0ZmFhODQ3ZmE3Y2IxMzQzYzI0MV8wLTAtMS0xLTQxMjk0_682bfd82-3bad-4e76-b63d-572771868fee">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xL2ZyYWc6MmY2MWRiOTUwNGNkNDliM2E4MWMxYTQyZmUyNTZkZjUvdGFibGU6YzY1NWE1NWRmM2ZiNGZhYTg0N2ZhN2NiMTM0M2MyNDEvdGFibGVyYW5nZTpjNjU1YTU1ZGYzZmI0ZmFhODQ3ZmE3Y2IxMzQzYzI0MV8wLTItMS0xLTQxMjk0_b17bf0dc-1219-472e-919f-9dd30bf1da40">77-0160744</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xL2ZyYWc6MmY2MWRiOTUwNGNkNDliM2E4MWMxYTQyZmUyNTZkZjUvdGFibGU6YzY1NWE1NWRmM2ZiNGZhYTg0N2ZhN2NiMTM0M2MyNDEvdGFibGVyYW5nZTpjNjU1YTU1ZGYzZmI0ZmFhODQ3ZmE3Y2IxMzQzYzI0MV8zLTAtMS0xLTQxMjk0_2d12d7be-fcaa-465e-bb21-17eb105bd9a0">5980 Horton Street, Suite 405</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xL2ZyYWc6MmY2MWRiOTUwNGNkNDliM2E4MWMxYTQyZmUyNTZkZjUvdGFibGU6YzY1NWE1NWRmM2ZiNGZhYTg0N2ZhN2NiMTM0M2MyNDEvdGFibGVyYW5nZTpjNjU1YTU1ZGYzZmI0ZmFhODQ3ZmE3Y2IxMzQzYzI0MV80LTAtMS0xLTQxMjk0_fdfa573f-5f7b-450c-ade4-f94b62cea63b">Emeryville</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xL2ZyYWc6MmY2MWRiOTUwNGNkNDliM2E4MWMxYTQyZmUyNTZkZjUvdGFibGU6YzY1NWE1NWRmM2ZiNGZhYTg0N2ZhN2NiMTM0M2MyNDEvdGFibGVyYW5nZTpjNjU1YTU1ZGYzZmI0ZmFhODQ3ZmE3Y2IxMzQzYzI0MV81LTAtMS0xLTQxMjk0_7922b15b-96ab-43c4-8b03-0ce35216c527">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xL2ZyYWc6MmY2MWRiOTUwNGNkNDliM2E4MWMxYTQyZmUyNTZkZjUvdGFibGU6YzY1NWE1NWRmM2ZiNGZhYTg0N2ZhN2NiMTM0M2MyNDEvdGFibGVyYW5nZTpjNjU1YTU1ZGYzZmI0ZmFhODQ3ZmE3Y2IxMzQzYzI0MV81LTItMS0xLTQxMjk0_622d6bf2-d1a5-4d31-90a0-48e6412b6762">94608</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xL2ZyYWc6MmY2MWRiOTUwNGNkNDliM2E4MWMxYTQyZmUyNTZkZjUvdGV4dHJlZ2lvbjoyZjYxZGI5NTA0Y2Q0OWIzYTgxYzFhNDJmZTI1NmRmNV80MDUx_8e30ed5d-a210-496c-be7d-42115b51f37d">858</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xL2ZyYWc6MmY2MWRiOTUwNGNkNDliM2E4MWMxYTQyZmUyNTZkZjUvdGV4dHJlZ2lvbjoyZjYxZGI5NTA0Y2Q0OWIzYTgxYzFhNDJmZTI1NmRmNV80MDQ0_c98be2e5-6ac6-4b7b-a506-b14e1a0c2174">550-7500</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xL2ZyYWc6MmY2MWRiOTUwNGNkNDliM2E4MWMxYTQyZmUyNTZkZjUvdGFibGU6MzRhNTAyODExMmIxNDI4Njg0NGY5OTc4ZmM1MjA0Y2EvdGFibGVyYW5nZTozNGE1MDI4MTEyYjE0Mjg2ODQ0Zjk5NzhmYzUyMDRjYV8xLTAtMS0xLTQxMjk0_fdd2bdd6-ed32-4118-9037-bfc2f847d281">Common Stock, par value $.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xL2ZyYWc6MmY2MWRiOTUwNGNkNDliM2E4MWMxYTQyZmUyNTZkZjUvdGFibGU6MzRhNTAyODExMmIxNDI4Njg0NGY5OTc4ZmM1MjA0Y2EvdGFibGVyYW5nZTozNGE1MDI4MTEyYjE0Mjg2ODQ0Zjk5NzhmYzUyMDRjYV8xLTEtMS0xLTQxMjk0_81aed8d0-19b7-41a1-af8c-e4cdbc511f1d">LGND</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xL2ZyYWc6MmY2MWRiOTUwNGNkNDliM2E4MWMxYTQyZmUyNTZkZjUvdGFibGU6MzRhNTAyODExMmIxNDI4Njg0NGY5OTc4ZmM1MjA0Y2EvdGFibGVyYW5nZTozNGE1MDI4MTEyYjE0Mjg2ODQ0Zjk5NzhmYzUyMDRjYV8xLTItMS0xLTQxMjk0_9a16dceb-bd85-457b-a2b3-a3664abc2f66">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xL2ZyYWc6MmY2MWRiOTUwNGNkNDliM2E4MWMxYTQyZmUyNTZkZjUvdGV4dHJlZ2lvbjoyZjYxZGI5NTA0Y2Q0OWIzYTgxYzFhNDJmZTI1NmRmNV80MDUy_4ad23e08-f6eb-45b0-8bf3-c4f50f526377">Yes</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xL2ZyYWc6MmY2MWRiOTUwNGNkNDliM2E4MWMxYTQyZmUyNTZkZjUvdGV4dHJlZ2lvbjoyZjYxZGI5NTA0Y2Q0OWIzYTgxYzFhNDJmZTI1NmRmNV80MDUz_b9c80773-a2dc-49e8-aac0-f6722753021a">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xL2ZyYWc6MmY2MWRiOTUwNGNkNDliM2E4MWMxYTQyZmUyNTZkZjUvdGV4dHJlZ2lvbjoyZjYxZGI5NTA0Y2Q0OWIzYTgxYzFhNDJmZTI1NmRmNV80MDQ1_8038b135-0287-49da-be3a-a401df23c453">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xL2ZyYWc6MmY2MWRiOTUwNGNkNDliM2E4MWMxYTQyZmUyNTZkZjUvdGV4dHJlZ2lvbjoyZjYxZGI5NTA0Y2Q0OWIzYTgxYzFhNDJmZTI1NmRmNV80MDQ2_682ccc4a-6ef6-47a9-992f-60a880616efc">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xL2ZyYWc6MmY2MWRiOTUwNGNkNDliM2E4MWMxYTQyZmUyNTZkZjUvdGFibGU6MzM3ZmE2YWU2NjdhNDYwMGI3MjlhNzc2NDc3NTZiYzMvdGFibGVyYW5nZTozMzdmYTZhZTY2N2E0NjAwYjcyOWE3NzY0Nzc1NmJjM18wLTAtMS0xLTQxMjk0_e1ab3bb8-c644-4a5c-ab66-0493794962c5">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xL2ZyYWc6MmY2MWRiOTUwNGNkNDliM2E4MWMxYTQyZmUyNTZkZjUvdGFibGU6MzM3ZmE2YWU2NjdhNDYwMGI3MjlhNzc2NDc3NTZiYzMvdGFibGVyYW5nZTozMzdmYTZhZTY2N2E0NjAwYjcyOWE3NzY0Nzc1NmJjM18wLTgtMS0xLTQxMjk0_5ccf1690-cc67-41c9-86b1-c35af6eeb8d3">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xL2ZyYWc6MmY2MWRiOTUwNGNkNDliM2E4MWMxYTQyZmUyNTZkZjUvdGFibGU6MzM3ZmE2YWU2NjdhNDYwMGI3MjlhNzc2NDc3NTZiYzMvdGFibGVyYW5nZTozMzdmYTZhZTY2N2E0NjAwYjcyOWE3NzY0Nzc1NmJjM18wLTEwLTEtMS00MTI5NA_48d5da0a-37aa-49e4-bafb-4366e3494fd2">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag
      contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xL2ZyYWc6MmY2MWRiOTUwNGNkNDliM2E4MWMxYTQyZmUyNTZkZjUvdGV4dHJlZ2lvbjoyZjYxZGI5NTA0Y2Q0OWIzYTgxYzFhNDJmZTI1NmRmNV80MDQ3_06437992-cc61-4954-bfd8-829219f060bf">true</dei:IcfrAuditorAttestationFlag>
    <dei:EntityShellCompany
      contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xL2ZyYWc6MmY2MWRiOTUwNGNkNDliM2E4MWMxYTQyZmUyNTZkZjUvdGV4dHJlZ2lvbjoyZjYxZGI5NTA0Y2Q0OWIzYTgxYzFhNDJmZTI1NmRmNV80MDU0_5add4c3a-861f-43a1-8514-e11d483c3339">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="i46357a7c22b94af48beacbd35008717a_I20210630"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xL2ZyYWc6MmY2MWRiOTUwNGNkNDliM2E4MWMxYTQyZmUyNTZkZjUvdGV4dHJlZ2lvbjoyZjYxZGI5NTA0Y2Q0OWIzYTgxYzFhNDJmZTI1NmRmNV8yOTA0_a1b53a64-9db5-4bac-912f-f4e9670ce0e2"
      unitRef="usd">1800000000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i3ed4f52b1ed24e778aa7185aa1e8bb90_I20220223"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xL2ZyYWc6MmY2MWRiOTUwNGNkNDliM2E4MWMxYTQyZmUyNTZkZjUvdGV4dHJlZ2lvbjoyZjYxZGI5NTA0Y2Q0OWIzYTgxYzFhNDJmZTI1NmRmNV8zNTE3_60bb6b06-3165-47da-8bdd-2ea850e5d721"
      unitRef="shares">16852650</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock
      contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xL2ZyYWc6MmY2MWRiOTUwNGNkNDliM2E4MWMxYTQyZmUyNTZkZjUvdGV4dHJlZ2lvbjoyZjYxZGI5NTA0Y2Q0OWIzYTgxYzFhNDJmZTI1NmRmNV8zODQ4MjkwNzAxMjgy_1af2f84e-af20-4736-90b1-df87c2a30770">Portions of the Proxy Statement for the Registrant&#x2019;s 2021 Annual Meeting of Stockholders to be filed with the Commission within 120 days of December&#160;31, 2021 are incorporated by reference in Part&#160;III of this Annual Report on Form&#160;10-K.&#160;With the exception of those portions that are specifically incorporated by reference in this Annual Report on Form&#160;10-K, such Proxy Statement shall not be deemed filed as part of this Report or incorporated by reference herein.</dei:DocumentsIncorporatedByReferenceTextBlock>
    <dei:AuditorFirmId
      contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY181OC9mcmFnOmJiYzNjNDJjNzM0MDQxMWZiY2RhYmJlNTQzNjgyNmJiL3RhYmxlOmU2OThlYjM2NmU5MDQ4ZWJiMGJjNjA0MjQyNmU0NzE3L3RhYmxlcmFuZ2U6ZTY5OGViMzY2ZTkwNDhlYmIwYmM2MDQyNDI2ZTQ3MTdfMS0wLTEtMS01MDE5NS90ZXh0cmVnaW9uOmM3YmY1NjY2N2U2ZjRlYTBiOTljZTY2N2IxN2Q2YTc4XzEzNzQzODk1MzQ3Mjgx_c5e81bce-0aed-4294-8987-98f7e0f49ed1">42</dei:AuditorFirmId>
    <dei:AuditorName
      contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182MS9mcmFnOjkyMGRjNjIxMDIwMzQ4MWFhOGY3ZWMxYWM1YWIwZDg3L3RleHRyZWdpb246OTIwZGM2MjEwMjAzNDgxYWE4ZjdlYzFhYzVhYjBkODdfMjE5OTAyMzI1OTUxMg_9175fa12-8ccf-4fae-9739-8be00cd67b54">Ernst&#160;&amp; Young&#160;LLP</dei:AuditorName>
    <dei:AuditorLocation
      contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182MS9mcmFnOjkyMGRjNjIxMDIwMzQ4MWFhOGY3ZWMxYWM1YWIwZDg3L3RleHRyZWdpb246OTIwZGM2MjEwMjAzNDgxYWE4ZjdlYzFhYzVhYjBkODdfMjE5OTAyMzI1OTUxNA_3d6c490a-3fdf-42a7-aa3e-4292046cc588">San Diego, California</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182NC9mcmFnOjE5MmJkY2FiNmJhNTRhMWI5ZTYxNzY3OWU4Nzk0YzQ1L3RhYmxlOjJiN2M5MDcyMTc5MTQzYjA4ZjRiZTdlMzgxZTZmY2FkL3RhYmxlcmFuZ2U6MmI3YzkwNzIxNzkxNDNiMDhmNGJlN2UzODFlNmZjYWRfNC0xLTEtMS00MTI5NA_d818a256-5a78-4d08-907d-2b129bc39e6f"
      unitRef="usd">19522000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i7462d0db8f4248fcb9fd8f1deae439f3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182NC9mcmFnOjE5MmJkY2FiNmJhNTRhMWI5ZTYxNzY3OWU4Nzk0YzQ1L3RhYmxlOjJiN2M5MDcyMTc5MTQzYjA4ZjRiZTdlMzgxZTZmY2FkL3RhYmxlcmFuZ2U6MmI3YzkwNzIxNzkxNDNiMDhmNGJlN2UzODFlNmZjYWRfNC0zLTEtMS00MTI5NA_b88a699d-c9a3-46b4-a46c-0c555d4713ad"
      unitRef="usd">47619000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:ShortTermInvestments
      contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182NC9mcmFnOjE5MmJkY2FiNmJhNTRhMWI5ZTYxNzY3OWU4Nzk0YzQ1L3RhYmxlOjJiN2M5MDcyMTc5MTQzYjA4ZjRiZTdlMzgxZTZmY2FkL3RhYmxlcmFuZ2U6MmI3YzkwNzIxNzkxNDNiMDhmNGJlN2UzODFlNmZjYWRfNS0xLTEtMS00MTI5NA_4acccf20-e366-48fb-b4a0-044a4783f5e3"
      unitRef="usd">321586000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="i7462d0db8f4248fcb9fd8f1deae439f3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182NC9mcmFnOjE5MmJkY2FiNmJhNTRhMWI5ZTYxNzY3OWU4Nzk0YzQ1L3RhYmxlOjJiN2M5MDcyMTc5MTQzYjA4ZjRiZTdlMzgxZTZmY2FkL3RhYmxlcmFuZ2U6MmI3YzkwNzIxNzkxNDNiMDhmNGJlN2UzODFlNmZjYWRfNS0zLTEtMS00MTI5NA_a4ad6365-01b6-45e6-854e-405f38205dab"
      unitRef="usd">363567000</us-gaap:ShortTermInvestments>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182NC9mcmFnOjE5MmJkY2FiNmJhNTRhMWI5ZTYxNzY3OWU4Nzk0YzQ1L3RhYmxlOjJiN2M5MDcyMTc5MTQzYjA4ZjRiZTdlMzgxZTZmY2FkL3RhYmxlcmFuZ2U6MmI3YzkwNzIxNzkxNDNiMDhmNGJlN2UzODFlNmZjYWRfNi0xLTEtMS00MTI5NA_a15a59b7-cd0c-450a-9dd8-6cd53a787869"
      unitRef="usd">85453000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i7462d0db8f4248fcb9fd8f1deae439f3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182NC9mcmFnOjE5MmJkY2FiNmJhNTRhMWI5ZTYxNzY3OWU4Nzk0YzQ1L3RhYmxlOjJiN2M5MDcyMTc5MTQzYjA4ZjRiZTdlMzgxZTZmY2FkL3RhYmxlcmFuZ2U6MmI3YzkwNzIxNzkxNDNiMDhmNGJlN2UzODFlNmZjYWRfNi0zLTEtMS00MTI5NA_8855f18e-1fee-4438-add1-cc99a31cdea8"
      unitRef="usd">56847000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet
      contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182NC9mcmFnOjE5MmJkY2FiNmJhNTRhMWI5ZTYxNzY3OWU4Nzk0YzQ1L3RhYmxlOjJiN2M5MDcyMTc5MTQzYjA4ZjRiZTdlMzgxZTZmY2FkL3RhYmxlcmFuZ2U6MmI3YzkwNzIxNzkxNDNiMDhmNGJlN2UzODFlNmZjYWRfNy0xLTEtMS00MTI5NA_4c934f86-705c-4139-9117-85c758dd5985"
      unitRef="usd">27326000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="i7462d0db8f4248fcb9fd8f1deae439f3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182NC9mcmFnOjE5MmJkY2FiNmJhNTRhMWI5ZTYxNzY3OWU4Nzk0YzQ1L3RhYmxlOjJiN2M5MDcyMTc5MTQzYjA4ZjRiZTdlMzgxZTZmY2FkL3RhYmxlcmFuZ2U6MmI3YzkwNzIxNzkxNDNiMDhmNGJlN2UzODFlNmZjYWRfNy0zLTEtMS00MTI5NA_7c802c7b-0c26-46d9-889d-3ceb37695751"
      unitRef="usd">26487000</us-gaap:InventoryNet>
    <us-gaap:IncomeTaxesReceivable
      contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182NC9mcmFnOjE5MmJkY2FiNmJhNTRhMWI5ZTYxNzY3OWU4Nzk0YzQ1L3RhYmxlOjJiN2M5MDcyMTc5MTQzYjA4ZjRiZTdlMzgxZTZmY2FkL3RhYmxlcmFuZ2U6MmI3YzkwNzIxNzkxNDNiMDhmNGJlN2UzODFlNmZjYWRfOC0xLTEtMS00MTI5NA_8d797c17-621f-43fb-a03a-1cbefce6f30f"
      unitRef="usd">6193000</us-gaap:IncomeTaxesReceivable>
    <us-gaap:IncomeTaxesReceivable
      contextRef="i7462d0db8f4248fcb9fd8f1deae439f3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182NC9mcmFnOjE5MmJkY2FiNmJhNTRhMWI5ZTYxNzY3OWU4Nzk0YzQ1L3RhYmxlOjJiN2M5MDcyMTc5MTQzYjA4ZjRiZTdlMzgxZTZmY2FkL3RhYmxlcmFuZ2U6MmI3YzkwNzIxNzkxNDNiMDhmNGJlN2UzODFlNmZjYWRfOC0zLTEtMS00MTI5NA_e1a3babf-963c-4012-a943-4b20f5b92222"
      unitRef="usd">2217000</us-gaap:IncomeTaxesReceivable>
    <us-gaap:OtherAssetsCurrent
      contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182NC9mcmFnOjE5MmJkY2FiNmJhNTRhMWI5ZTYxNzY3OWU4Nzk0YzQ1L3RhYmxlOjJiN2M5MDcyMTc5MTQzYjA4ZjRiZTdlMzgxZTZmY2FkL3RhYmxlcmFuZ2U6MmI3YzkwNzIxNzkxNDNiMDhmNGJlN2UzODFlNmZjYWRfOS0xLTEtMS00MTI5NA_3cbc4712-2b70-4d01-bfd3-a71e3b3a49a9"
      unitRef="usd">4671000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="i7462d0db8f4248fcb9fd8f1deae439f3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182NC9mcmFnOjE5MmJkY2FiNmJhNTRhMWI5ZTYxNzY3OWU4Nzk0YzQ1L3RhYmxlOjJiN2M5MDcyMTc5MTQzYjA4ZjRiZTdlMzgxZTZmY2FkL3RhYmxlcmFuZ2U6MmI3YzkwNzIxNzkxNDNiMDhmNGJlN2UzODFlNmZjYWRfOS0zLTEtMS00MTI5NA_bec9da79-8dbf-45af-975e-2be036c3aaac"
      unitRef="usd">3822000</us-gaap:OtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182NC9mcmFnOjE5MmJkY2FiNmJhNTRhMWI5ZTYxNzY3OWU4Nzk0YzQ1L3RhYmxlOjJiN2M5MDcyMTc5MTQzYjA4ZjRiZTdlMzgxZTZmY2FkL3RhYmxlcmFuZ2U6MmI3YzkwNzIxNzkxNDNiMDhmNGJlN2UzODFlNmZjYWRfMTAtMS0xLTEtNDEyOTQ_231586fc-d6be-40d8-ae7c-d65755e4470d"
      unitRef="usd">464751000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i7462d0db8f4248fcb9fd8f1deae439f3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182NC9mcmFnOjE5MmJkY2FiNmJhNTRhMWI5ZTYxNzY3OWU4Nzk0YzQ1L3RhYmxlOjJiN2M5MDcyMTc5MTQzYjA4ZjRiZTdlMzgxZTZmY2FkL3RhYmxlcmFuZ2U6MmI3YzkwNzIxNzkxNDNiMDhmNGJlN2UzODFlNmZjYWRfMTAtMy0xLTEtNDEyOTQ_636353fa-33c1-42db-bbe4-88ea5d5dba08"
      unitRef="usd">500559000</us-gaap:AssetsCurrent>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182NC9mcmFnOjE5MmJkY2FiNmJhNTRhMWI5ZTYxNzY3OWU4Nzk0YzQ1L3RhYmxlOjJiN2M5MDcyMTc5MTQzYjA4ZjRiZTdlMzgxZTZmY2FkL3RhYmxlcmFuZ2U6MmI3YzkwNzIxNzkxNDNiMDhmNGJlN2UzODFlNmZjYWRfMTEtMS0xLTEtNDEyOTQ_0d39d47e-ccab-46bf-8de0-db8f34239700"
      unitRef="usd">34482000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="i7462d0db8f4248fcb9fd8f1deae439f3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182NC9mcmFnOjE5MmJkY2FiNmJhNTRhMWI5ZTYxNzY3OWU4Nzk0YzQ1L3RhYmxlOjJiN2M5MDcyMTc5MTQzYjA4ZjRiZTdlMzgxZTZmY2FkL3RhYmxlcmFuZ2U6MmI3YzkwNzIxNzkxNDNiMDhmNGJlN2UzODFlNmZjYWRfMTEtMy0xLTEtNDEyOTQ_02853767-1a5e-43fa-98a6-faee8350498d"
      unitRef="usd">24320000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182NC9mcmFnOjE5MmJkY2FiNmJhNTRhMWI5ZTYxNzY3OWU4Nzk0YzQ1L3RhYmxlOjJiN2M5MDcyMTc5MTQzYjA4ZjRiZTdlMzgxZTZmY2FkL3RhYmxlcmFuZ2U6MmI3YzkwNzIxNzkxNDNiMDhmNGJlN2UzODFlNmZjYWRfMTItMS0xLTEtNDEyOTQ_adbdc74f-4154-4a8e-ad18-ba95b6ee4a60"
      unitRef="usd">551040000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i7462d0db8f4248fcb9fd8f1deae439f3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182NC9mcmFnOjE5MmJkY2FiNmJhNTRhMWI5ZTYxNzY3OWU4Nzk0YzQ1L3RhYmxlOjJiN2M5MDcyMTc5MTQzYjA4ZjRiZTdlMzgxZTZmY2FkL3RhYmxlcmFuZ2U6MmI3YzkwNzIxNzkxNDNiMDhmNGJlN2UzODFlNmZjYWRfMTItMy0xLTEtNDEyOTQ_cad66721-bdf8-49cc-aa63-d9559674cbea"
      unitRef="usd">595330000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:Goodwill
      contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182NC9mcmFnOjE5MmJkY2FiNmJhNTRhMWI5ZTYxNzY3OWU4Nzk0YzQ1L3RhYmxlOjJiN2M5MDcyMTc5MTQzYjA4ZjRiZTdlMzgxZTZmY2FkL3RhYmxlcmFuZ2U6MmI3YzkwNzIxNzkxNDNiMDhmNGJlN2UzODFlNmZjYWRfMTMtMS0xLTEtNDEyOTQ_9db52d62-e0c9-482a-b86d-4a8025b2ad8f"
      unitRef="usd">181206000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i7462d0db8f4248fcb9fd8f1deae439f3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182NC9mcmFnOjE5MmJkY2FiNmJhNTRhMWI5ZTYxNzY3OWU4Nzk0YzQ1L3RhYmxlOjJiN2M5MDcyMTc5MTQzYjA4ZjRiZTdlMzgxZTZmY2FkL3RhYmxlcmFuZ2U6MmI3YzkwNzIxNzkxNDNiMDhmNGJlN2UzODFlNmZjYWRfMTMtMy0xLTEtNDEyOTQ_9ab94e3a-3703-4086-ad9c-fbf8d7861984"
      unitRef="usd">189662000</us-gaap:Goodwill>
    <lgnd:CommercialLicenseRights
      contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182NC9mcmFnOjE5MmJkY2FiNmJhNTRhMWI5ZTYxNzY3OWU4Nzk0YzQ1L3RhYmxlOjJiN2M5MDcyMTc5MTQzYjA4ZjRiZTdlMzgxZTZmY2FkL3RhYmxlcmFuZ2U6MmI3YzkwNzIxNzkxNDNiMDhmNGJlN2UzODFlNmZjYWRfMTQtMS0xLTEtNDEyOTQ_3f35bf58-fa01-42bd-8c9f-79cc4a92a5ed"
      unitRef="usd">10110000</lgnd:CommercialLicenseRights>
    <lgnd:CommercialLicenseRights
      contextRef="i7462d0db8f4248fcb9fd8f1deae439f3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182NC9mcmFnOjE5MmJkY2FiNmJhNTRhMWI5ZTYxNzY3OWU4Nzk0YzQ1L3RhYmxlOjJiN2M5MDcyMTc5MTQzYjA4ZjRiZTdlMzgxZTZmY2FkL3RhYmxlcmFuZ2U6MmI3YzkwNzIxNzkxNDNiMDhmNGJlN2UzODFlNmZjYWRfMTQtMy0xLTEtNDEyOTQ_188a84da-5ada-4ebd-84e2-60593ea7a28e"
      unitRef="usd">10979000</lgnd:CommercialLicenseRights>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182NC9mcmFnOjE5MmJkY2FiNmJhNTRhMWI5ZTYxNzY3OWU4Nzk0YzQ1L3RhYmxlOjJiN2M5MDcyMTc5MTQzYjA4ZjRiZTdlMzgxZTZmY2FkL3RhYmxlcmFuZ2U6MmI3YzkwNzIxNzkxNDNiMDhmNGJlN2UzODFlNmZjYWRfMTUtMS0xLTEtNDEyOTQ_09ab660f-be3f-413d-8559-8a6c0df7b0e4"
      unitRef="usd">20511000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i7462d0db8f4248fcb9fd8f1deae439f3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182NC9mcmFnOjE5MmJkY2FiNmJhNTRhMWI5ZTYxNzY3OWU4Nzk0YzQ1L3RhYmxlOjJiN2M5MDcyMTc5MTQzYjA4ZjRiZTdlMzgxZTZmY2FkL3RhYmxlcmFuZ2U6MmI3YzkwNzIxNzkxNDNiMDhmNGJlN2UzODFlNmZjYWRfMTUtMy0xLTEtNDEyOTQ_e7b949ff-2f43-45bf-9b3d-401f0f4ae455"
      unitRef="usd">14434000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182NC9mcmFnOjE5MmJkY2FiNmJhNTRhMWI5ZTYxNzY3OWU4Nzk0YzQ1L3RhYmxlOjJiN2M5MDcyMTc5MTQzYjA4ZjRiZTdlMzgxZTZmY2FkL3RhYmxlcmFuZ2U6MmI3YzkwNzIxNzkxNDNiMDhmNGJlN2UzODFlNmZjYWRfMTYtMS0xLTEtNDEyOTQ_6d1ab5af-49db-4349-a362-0144c3fd7f0a"
      unitRef="usd">16542000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i7462d0db8f4248fcb9fd8f1deae439f3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182NC9mcmFnOjE5MmJkY2FiNmJhNTRhMWI5ZTYxNzY3OWU4Nzk0YzQ1L3RhYmxlOjJiN2M5MDcyMTc5MTQzYjA4ZjRiZTdlMzgxZTZmY2FkL3RhYmxlcmFuZ2U6MmI3YzkwNzIxNzkxNDNiMDhmNGJlN2UzODFlNmZjYWRfMTYtMy0xLTEtNDEyOTQ_6dffdc3d-9003-4813-9f87-8a890595c6ae"
      unitRef="usd">6892000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:FinanceLeaseRightOfUseAsset
      contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182NC9mcmFnOjE5MmJkY2FiNmJhNTRhMWI5ZTYxNzY3OWU4Nzk0YzQ1L3RhYmxlOjJiN2M5MDcyMTc5MTQzYjA4ZjRiZTdlMzgxZTZmY2FkL3RhYmxlcmFuZ2U6MmI3YzkwNzIxNzkxNDNiMDhmNGJlN2UzODFlNmZjYWRfMTctMS0xLTEtNDEyOTQ_b89739f6-175a-4794-8493-5a45267295e3"
      unitRef="usd">16207000</us-gaap:FinanceLeaseRightOfUseAsset>
    <us-gaap:FinanceLeaseRightOfUseAsset
      contextRef="i7462d0db8f4248fcb9fd8f1deae439f3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182NC9mcmFnOjE5MmJkY2FiNmJhNTRhMWI5ZTYxNzY3OWU4Nzk0YzQ1L3RhYmxlOjJiN2M5MDcyMTc5MTQzYjA4ZjRiZTdlMzgxZTZmY2FkL3RhYmxlcmFuZ2U6MmI3YzkwNzIxNzkxNDNiMDhmNGJlN2UzODFlNmZjYWRfMTctMy0xLTEtNDEyOTQ_da6cb585-870e-4126-9489-5123a469640c"
      unitRef="usd">15842000</us-gaap:FinanceLeaseRightOfUseAsset>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182NC9mcmFnOjE5MmJkY2FiNmJhNTRhMWI5ZTYxNzY3OWU4Nzk0YzQ1L3RhYmxlOjJiN2M5MDcyMTc5MTQzYjA4ZjRiZTdlMzgxZTZmY2FkL3RhYmxlcmFuZ2U6MmI3YzkwNzIxNzkxNDNiMDhmNGJlN2UzODFlNmZjYWRfMTgtMS0xLTEtNDEyOTQ_06be126d-3094-42ab-afea-88bbb06d6178"
      unitRef="usd">2741000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i7462d0db8f4248fcb9fd8f1deae439f3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182NC9mcmFnOjE5MmJkY2FiNmJhNTRhMWI5ZTYxNzY3OWU4Nzk0YzQ1L3RhYmxlOjJiN2M5MDcyMTc5MTQzYjA4ZjRiZTdlMzgxZTZmY2FkL3RhYmxlcmFuZ2U6MmI3YzkwNzIxNzkxNDNiMDhmNGJlN2UzODFlNmZjYWRfMTgtMy0xLTEtNDEyOTQ_38d3f331-35a4-46fd-8fd0-e62938605f66"
      unitRef="usd">4267000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182NC9mcmFnOjE5MmJkY2FiNmJhNTRhMWI5ZTYxNzY3OWU4Nzk0YzQ1L3RhYmxlOjJiN2M5MDcyMTc5MTQzYjA4ZjRiZTdlMzgxZTZmY2FkL3RhYmxlcmFuZ2U6MmI3YzkwNzIxNzkxNDNiMDhmNGJlN2UzODFlNmZjYWRfMTktMS0xLTEtNDEyOTQ_dc98a5e0-d9ba-4356-9419-99c731d0d3f9"
      unitRef="usd">1297590000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i7462d0db8f4248fcb9fd8f1deae439f3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182NC9mcmFnOjE5MmJkY2FiNmJhNTRhMWI5ZTYxNzY3OWU4Nzk0YzQ1L3RhYmxlOjJiN2M5MDcyMTc5MTQzYjA4ZjRiZTdlMzgxZTZmY2FkL3RhYmxlcmFuZ2U6MmI3YzkwNzIxNzkxNDNiMDhmNGJlN2UzODFlNmZjYWRfMTktMy0xLTEtNDEyOTQ_d0004785-b765-4a01-80c6-b327cab01a67"
      unitRef="usd">1362285000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182NC9mcmFnOjE5MmJkY2FiNmJhNTRhMWI5ZTYxNzY3OWU4Nzk0YzQ1L3RhYmxlOjJiN2M5MDcyMTc5MTQzYjA4ZjRiZTdlMzgxZTZmY2FkL3RhYmxlcmFuZ2U6MmI3YzkwNzIxNzkxNDNiMDhmNGJlN2UzODFlNmZjYWRfMjItMS0xLTEtNDEyOTQ_dacfeeee-b628-45f6-875e-51fefb34c63d"
      unitRef="usd">8403000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i7462d0db8f4248fcb9fd8f1deae439f3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182NC9mcmFnOjE5MmJkY2FiNmJhNTRhMWI5ZTYxNzY3OWU4Nzk0YzQ1L3RhYmxlOjJiN2M5MDcyMTc5MTQzYjA4ZjRiZTdlMzgxZTZmY2FkL3RhYmxlcmFuZ2U6MmI3YzkwNzIxNzkxNDNiMDhmNGJlN2UzODFlNmZjYWRfMjItMy0xLTEtNDEyOTQ_e40c0cd4-1d8c-4a05-ab8d-eb404b6475f8"
      unitRef="usd">3784000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182NC9mcmFnOjE5MmJkY2FiNmJhNTRhMWI5ZTYxNzY3OWU4Nzk0YzQ1L3RhYmxlOjJiN2M5MDcyMTc5MTQzYjA4ZjRiZTdlMzgxZTZmY2FkL3RhYmxlcmFuZ2U6MmI3YzkwNzIxNzkxNDNiMDhmNGJlN2UzODFlNmZjYWRfMjMtMS0xLTEtNDEyOTQ_acc5d97a-bd2f-4231-bbb7-4fcbece4e306"
      unitRef="usd">17579000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i7462d0db8f4248fcb9fd8f1deae439f3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182NC9mcmFnOjE5MmJkY2FiNmJhNTRhMWI5ZTYxNzY3OWU4Nzk0YzQ1L3RhYmxlOjJiN2M5MDcyMTc5MTQzYjA4ZjRiZTdlMzgxZTZmY2FkL3RhYmxlcmFuZ2U6MmI3YzkwNzIxNzkxNDNiMDhmNGJlN2UzODFlNmZjYWRfMjMtMy0xLTEtNDEyOTQ_9a8aac4c-5dfe-4c13-a510-840cc590612d"
      unitRef="usd">18530000</us-gaap:AccruedLiabilitiesCurrent>
    <lgnd:CurrentPortionOfLiabilityForContingentValueRights
      contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182NC9mcmFnOjE5MmJkY2FiNmJhNTRhMWI5ZTYxNzY3OWU4Nzk0YzQ1L3RhYmxlOjJiN2M5MDcyMTc5MTQzYjA4ZjRiZTdlMzgxZTZmY2FkL3RhYmxlcmFuZ2U6MmI3YzkwNzIxNzkxNDNiMDhmNGJlN2UzODFlNmZjYWRfMjQtMS0xLTEtNDEyOTQ_f9cc95b7-04b0-4c1c-985b-116a6adc6c73"
      unitRef="usd">2588000</lgnd:CurrentPortionOfLiabilityForContingentValueRights>
    <lgnd:CurrentPortionOfLiabilityForContingentValueRights
      contextRef="i7462d0db8f4248fcb9fd8f1deae439f3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182NC9mcmFnOjE5MmJkY2FiNmJhNTRhMWI5ZTYxNzY3OWU4Nzk0YzQ1L3RhYmxlOjJiN2M5MDcyMTc5MTQzYjA4ZjRiZTdlMzgxZTZmY2FkL3RhYmxlcmFuZ2U6MmI3YzkwNzIxNzkxNDNiMDhmNGJlN2UzODFlNmZjYWRfMjQtMy0xLTEtNDEyOTQ_bb59de50-a669-45ca-b7f3-de427548c338"
      unitRef="usd">39884000</lgnd:CurrentPortionOfLiabilityForContingentValueRights>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182NC9mcmFnOjE5MmJkY2FiNmJhNTRhMWI5ZTYxNzY3OWU4Nzk0YzQ1L3RhYmxlOjJiN2M5MDcyMTc5MTQzYjA4ZjRiZTdlMzgxZTZmY2FkL3RhYmxlcmFuZ2U6MmI3YzkwNzIxNzkxNDNiMDhmNGJlN2UzODFlNmZjYWRfMjUtMS0xLTEtNDEyOTQ_d05c1f6a-9e78-494e-aef1-f4748a7c4ebe"
      unitRef="usd">10996000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i7462d0db8f4248fcb9fd8f1deae439f3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182NC9mcmFnOjE5MmJkY2FiNmJhNTRhMWI5ZTYxNzY3OWU4Nzk0YzQ1L3RhYmxlOjJiN2M5MDcyMTc5MTQzYjA4ZjRiZTdlMzgxZTZmY2FkL3RhYmxlcmFuZ2U6MmI3YzkwNzIxNzkxNDNiMDhmNGJlN2UzODFlNmZjYWRfMjUtMy0xLTEtNDEyOTQ_827fdf2d-6cc7-47d6-bee5-201ac1cc5e36"
      unitRef="usd">29435000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182NC9mcmFnOjE5MmJkY2FiNmJhNTRhMWI5ZTYxNzY3OWU4Nzk0YzQ1L3RhYmxlOjJiN2M5MDcyMTc5MTQzYjA4ZjRiZTdlMzgxZTZmY2FkL3RhYmxlcmFuZ2U6MmI3YzkwNzIxNzkxNDNiMDhmNGJlN2UzODFlNmZjYWRfMjYtMS0xLTEtNDEyOTQ_b9ad93d0-279c-4918-b5a4-0bec26fb128c"
      unitRef="usd">2053000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i7462d0db8f4248fcb9fd8f1deae439f3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182NC9mcmFnOjE5MmJkY2FiNmJhNTRhMWI5ZTYxNzY3OWU4Nzk0YzQ1L3RhYmxlOjJiN2M5MDcyMTc5MTQzYjA4ZjRiZTdlMzgxZTZmY2FkL3RhYmxlcmFuZ2U6MmI3YzkwNzIxNzkxNDNiMDhmNGJlN2UzODFlNmZjYWRfMjYtMy0xLTEtNDEyOTQ_471b6efb-a48a-4459-a052-3be0a704db5a"
      unitRef="usd">1885000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182NC9mcmFnOjE5MmJkY2FiNmJhNTRhMWI5ZTYxNzY3OWU4Nzk0YzQ1L3RhYmxlOjJiN2M5MDcyMTc5MTQzYjA4ZjRiZTdlMzgxZTZmY2FkL3RhYmxlcmFuZ2U6MmI3YzkwNzIxNzkxNDNiMDhmNGJlN2UzODFlNmZjYWRfMjctMS0xLTEtNDEyOTQ_7f5a81c9-21c3-48cd-a989-19ec627e8729"
      unitRef="usd">46000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="i7462d0db8f4248fcb9fd8f1deae439f3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182NC9mcmFnOjE5MmJkY2FiNmJhNTRhMWI5ZTYxNzY3OWU4Nzk0YzQ1L3RhYmxlOjJiN2M5MDcyMTc5MTQzYjA4ZjRiZTdlMzgxZTZmY2FkL3RhYmxlcmFuZ2U6MmI3YzkwNzIxNzkxNDNiMDhmNGJlN2UzODFlNmZjYWRfMjctMy0xLTEtNDEyOTQ_c1516387-94c1-4be8-bbb1-5892179eb9c8"
      unitRef="usd">6593000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182NC9mcmFnOjE5MmJkY2FiNmJhNTRhMWI5ZTYxNzY3OWU4Nzk0YzQ1L3RhYmxlOjJiN2M5MDcyMTc5MTQzYjA4ZjRiZTdlMzgxZTZmY2FkL3RhYmxlcmFuZ2U6MmI3YzkwNzIxNzkxNDNiMDhmNGJlN2UzODFlNmZjYWRfMjgtMS0xLTEtNDEyOTQ_cb13249e-3307-40a0-a946-439bb92dd8a7"
      unitRef="usd">41665000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i7462d0db8f4248fcb9fd8f1deae439f3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182NC9mcmFnOjE5MmJkY2FiNmJhNTRhMWI5ZTYxNzY3OWU4Nzk0YzQ1L3RhYmxlOjJiN2M5MDcyMTc5MTQzYjA4ZjRiZTdlMzgxZTZmY2FkL3RhYmxlcmFuZ2U6MmI3YzkwNzIxNzkxNDNiMDhmNGJlN2UzODFlNmZjYWRfMjgtMy0xLTEtNDEyOTQ_f915535d-dab3-441a-9c32-8c0e1d94c5fb"
      unitRef="usd">100111000</us-gaap:LiabilitiesCurrent>
    <us-gaap:ConvertibleDebtNoncurrent
      contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182NC9mcmFnOjE5MmJkY2FiNmJhNTRhMWI5ZTYxNzY3OWU4Nzk0YzQ1L3RhYmxlOjJiN2M5MDcyMTc5MTQzYjA4ZjRiZTdlMzgxZTZmY2FkL3RhYmxlcmFuZ2U6MmI3YzkwNzIxNzkxNDNiMDhmNGJlN2UzODFlNmZjYWRfMjktMS0xLTEtNDEyOTQ_a2312bb3-92cf-4285-b0a6-e54e27555d34"
      unitRef="usd">320717000</us-gaap:ConvertibleDebtNoncurrent>
    <us-gaap:ConvertibleDebtNoncurrent
      contextRef="i7462d0db8f4248fcb9fd8f1deae439f3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182NC9mcmFnOjE5MmJkY2FiNmJhNTRhMWI5ZTYxNzY3OWU4Nzk0YzQ1L3RhYmxlOjJiN2M5MDcyMTc5MTQzYjA4ZjRiZTdlMzgxZTZmY2FkL3RhYmxlcmFuZ2U6MmI3YzkwNzIxNzkxNDNiMDhmNGJlN2UzODFlNmZjYWRfMjktMy0xLTEtNDEyOTQ_31b39473-de69-4c0d-84d1-6cd1e81d60d1"
      unitRef="usd">442293000</us-gaap:ConvertibleDebtNoncurrent>
    <lgnd:LiabilityForContingentValueRights
      contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182NC9mcmFnOjE5MmJkY2FiNmJhNTRhMWI5ZTYxNzY3OWU4Nzk0YzQ1L3RhYmxlOjJiN2M5MDcyMTc5MTQzYjA4ZjRiZTdlMzgxZTZmY2FkL3RhYmxlcmFuZ2U6MmI3YzkwNzIxNzkxNDNiMDhmNGJlN2UzODFlNmZjYWRfMzAtMS0xLTEtNDEyOTQ_fae8b3ae-5705-4645-a92d-54c76ecb20cf"
      unitRef="usd">8483000</lgnd:LiabilityForContingentValueRights>
    <lgnd:LiabilityForContingentValueRights
      contextRef="i7462d0db8f4248fcb9fd8f1deae439f3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182NC9mcmFnOjE5MmJkY2FiNmJhNTRhMWI5ZTYxNzY3OWU4Nzk0YzQ1L3RhYmxlOjJiN2M5MDcyMTc5MTQzYjA4ZjRiZTdlMzgxZTZmY2FkL3RhYmxlcmFuZ2U6MmI3YzkwNzIxNzkxNDNiMDhmNGJlN2UzODFlNmZjYWRfMzAtMy0xLTEtNDEyOTQ_925351b0-3f0d-4fa8-be36-119f1ef5ea2b"
      unitRef="usd">9249000</lgnd:LiabilityForContingentValueRights>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182NC9mcmFnOjE5MmJkY2FiNmJhNTRhMWI5ZTYxNzY3OWU4Nzk0YzQ1L3RhYmxlOjJiN2M5MDcyMTc5MTQzYjA4ZjRiZTdlMzgxZTZmY2FkL3RhYmxlcmFuZ2U6MmI3YzkwNzIxNzkxNDNiMDhmNGJlN2UzODFlNmZjYWRfMzEtMS0xLTEtNDEyOTQ_78ffbf8e-2e27-4ff5-bc07-065463cabac2"
      unitRef="usd">59095000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="i7462d0db8f4248fcb9fd8f1deae439f3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182NC9mcmFnOjE5MmJkY2FiNmJhNTRhMWI5ZTYxNzY3OWU4Nzk0YzQ1L3RhYmxlOjJiN2M5MDcyMTc5MTQzYjA4ZjRiZTdlMzgxZTZmY2FkL3RhYmxlcmFuZ2U6MmI3YzkwNzIxNzkxNDNiMDhmNGJlN2UzODFlNmZjYWRfMzEtMy0xLTEtNDEyOTQ_7f35dd89-c8e8-4610-939e-151ec1b4c8e3"
      unitRef="usd">64598000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182NC9mcmFnOjE5MmJkY2FiNmJhNTRhMWI5ZTYxNzY3OWU4Nzk0YzQ1L3RhYmxlOjJiN2M5MDcyMTc5MTQzYjA4ZjRiZTdlMzgxZTZmY2FkL3RhYmxlcmFuZ2U6MmI3YzkwNzIxNzkxNDNiMDhmNGJlN2UzODFlNmZjYWRfMzItMS0xLTEtNDEyOTQ_20380017-28cd-4446-9882-553a67242f34"
      unitRef="usd">15494000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i7462d0db8f4248fcb9fd8f1deae439f3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182NC9mcmFnOjE5MmJkY2FiNmJhNTRhMWI5ZTYxNzY3OWU4Nzk0YzQ1L3RhYmxlOjJiN2M5MDcyMTc5MTQzYjA4ZjRiZTdlMzgxZTZmY2FkL3RhYmxlcmFuZ2U6MmI3YzkwNzIxNzkxNDNiMDhmNGJlN2UzODFlNmZjYWRfMzItMy0xLTEtNDEyOTQ_e8875dbd-bcdb-4178-8a86-36e1615bd76f"
      unitRef="usd">5643000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182NC9mcmFnOjE5MmJkY2FiNmJhNTRhMWI5ZTYxNzY3OWU4Nzk0YzQ1L3RhYmxlOjJiN2M5MDcyMTc5MTQzYjA4ZjRiZTdlMzgxZTZmY2FkL3RhYmxlcmFuZ2U6MmI3YzkwNzIxNzkxNDNiMDhmNGJlN2UzODFlNmZjYWRfMzMtMS0xLTEtNDEyOTQ_52f6e280-a268-4e69-abb7-8c0cdf761c91"
      unitRef="usd">30977000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i7462d0db8f4248fcb9fd8f1deae439f3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182NC9mcmFnOjE5MmJkY2FiNmJhNTRhMWI5ZTYxNzY3OWU4Nzk0YzQ1L3RhYmxlOjJiN2M5MDcyMTc5MTQzYjA4ZjRiZTdlMzgxZTZmY2FkL3RhYmxlcmFuZ2U6MmI3YzkwNzIxNzkxNDNiMDhmNGJlN2UzODFlNmZjYWRfMzMtMy0xLTEtNDEyOTQ_895f3b32-9404-4894-8055-5a43274fb689"
      unitRef="usd">30866000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182NC9mcmFnOjE5MmJkY2FiNmJhNTRhMWI5ZTYxNzY3OWU4Nzk0YzQ1L3RhYmxlOjJiN2M5MDcyMTc5MTQzYjA4ZjRiZTdlMzgxZTZmY2FkL3RhYmxlcmFuZ2U6MmI3YzkwNzIxNzkxNDNiMDhmNGJlN2UzODFlNmZjYWRfMzQtMS0xLTEtNDEyOTQ_cec2a48f-8dc2-4917-b047-f79168cbc027"
      unitRef="usd">476431000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i7462d0db8f4248fcb9fd8f1deae439f3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182NC9mcmFnOjE5MmJkY2FiNmJhNTRhMWI5ZTYxNzY3OWU4Nzk0YzQ1L3RhYmxlOjJiN2M5MDcyMTc5MTQzYjA4ZjRiZTdlMzgxZTZmY2FkL3RhYmxlcmFuZ2U6MmI3YzkwNzIxNzkxNDNiMDhmNGJlN2UzODFlNmZjYWRfMzQtMy0xLTEtNDEyOTQ_bb85b27f-e5b4-4f46-8fb7-40f7da48862d"
      unitRef="usd">652760000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182NC9mcmFnOjE5MmJkY2FiNmJhNTRhMWI5ZTYxNzY3OWU4Nzk0YzQ1L3RhYmxlOjJiN2M5MDcyMTc5MTQzYjA4ZjRiZTdlMzgxZTZmY2FkL3RhYmxlcmFuZ2U6MmI3YzkwNzIxNzkxNDNiMDhmNGJlN2UzODFlNmZjYWRfMzUtMS0xLTEtNDEyOTQ_94087f28-3c39-4087-ba8f-6f20029a71b6"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i7462d0db8f4248fcb9fd8f1deae439f3_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182NC9mcmFnOjE5MmJkY2FiNmJhNTRhMWI5ZTYxNzY3OWU4Nzk0YzQ1L3RhYmxlOjJiN2M5MDcyMTc5MTQzYjA4ZjRiZTdlMzgxZTZmY2FkL3RhYmxlcmFuZ2U6MmI3YzkwNzIxNzkxNDNiMDhmNGJlN2UzODFlNmZjYWRfMzUtMy0xLTEtNDEyOTQ_fe7f019a-08fe-4126-afa6-3b926be9ce9e"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182NC9mcmFnOjE5MmJkY2FiNmJhNTRhMWI5ZTYxNzY3OWU4Nzk0YzQ1L3RhYmxlOjJiN2M5MDcyMTc5MTQzYjA4ZjRiZTdlMzgxZTZmY2FkL3RhYmxlcmFuZ2U6MmI3YzkwNzIxNzkxNDNiMDhmNGJlN2UzODFlNmZjYWRfMzctMC0xLTEtNDEyOTQvdGV4dHJlZ2lvbjoyZDM0NGNhMTlkYjE0MjE3YTdhM2U1MGFhZjdhM2E1MV8yNw_58ae8625-e36e-4fd0-8893-5b3fecf1139c"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i7462d0db8f4248fcb9fd8f1deae439f3_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182NC9mcmFnOjE5MmJkY2FiNmJhNTRhMWI5ZTYxNzY3OWU4Nzk0YzQ1L3RhYmxlOjJiN2M5MDcyMTc5MTQzYjA4ZjRiZTdlMzgxZTZmY2FkL3RhYmxlcmFuZ2U6MmI3YzkwNzIxNzkxNDNiMDhmNGJlN2UzODFlNmZjYWRfMzctMC0xLTEtNDEyOTQvdGV4dHJlZ2lvbjoyZDM0NGNhMTlkYjE0MjE3YTdhM2U1MGFhZjdhM2E1MV8yNw_bfa2ba8b-e70c-4c83-851c-7dc3c4bd98bf"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i7462d0db8f4248fcb9fd8f1deae439f3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182NC9mcmFnOjE5MmJkY2FiNmJhNTRhMWI5ZTYxNzY3OWU4Nzk0YzQ1L3RhYmxlOjJiN2M5MDcyMTc5MTQzYjA4ZjRiZTdlMzgxZTZmY2FkL3RhYmxlcmFuZ2U6MmI3YzkwNzIxNzkxNDNiMDhmNGJlN2UzODFlNmZjYWRfMzctMC0xLTEtNDEyOTQvdGV4dHJlZ2lvbjoyZDM0NGNhMTlkYjE0MjE3YTdhM2U1MGFhZjdhM2E1MV80MQ_338574f8-51b8-4784-8aa7-8c11c1ef0a3e"
      unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182NC9mcmFnOjE5MmJkY2FiNmJhNTRhMWI5ZTYxNzY3OWU4Nzk0YzQ1L3RhYmxlOjJiN2M5MDcyMTc5MTQzYjA4ZjRiZTdlMzgxZTZmY2FkL3RhYmxlcmFuZ2U6MmI3YzkwNzIxNzkxNDNiMDhmNGJlN2UzODFlNmZjYWRfMzctMC0xLTEtNDEyOTQvdGV4dHJlZ2lvbjoyZDM0NGNhMTlkYjE0MjE3YTdhM2U1MGFhZjdhM2E1MV80MQ_40a32e19-bd69-4a7c-8b41-a1a9697a4ab8"
      unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i7462d0db8f4248fcb9fd8f1deae439f3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182NC9mcmFnOjE5MmJkY2FiNmJhNTRhMWI5ZTYxNzY3OWU4Nzk0YzQ1L3RhYmxlOjJiN2M5MDcyMTc5MTQzYjA4ZjRiZTdlMzgxZTZmY2FkL3RhYmxlcmFuZ2U6MmI3YzkwNzIxNzkxNDNiMDhmNGJlN2UzODFlNmZjYWRfMzctMC0xLTEtNDEyOTQvdGV4dHJlZ2lvbjoyZDM0NGNhMTlkYjE0MjE3YTdhM2U1MGFhZjdhM2E1MV82Mw_6cbfdd67-7fd5-42f0-8942-c6998246b94a"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182NC9mcmFnOjE5MmJkY2FiNmJhNTRhMWI5ZTYxNzY3OWU4Nzk0YzQ1L3RhYmxlOjJiN2M5MDcyMTc5MTQzYjA4ZjRiZTdlMzgxZTZmY2FkL3RhYmxlcmFuZ2U6MmI3YzkwNzIxNzkxNDNiMDhmNGJlN2UzODFlNmZjYWRfMzctMC0xLTEtNDEyOTQvdGV4dHJlZ2lvbjoyZDM0NGNhMTlkYjE0MjE3YTdhM2U1MGFhZjdhM2E1MV82Mw_8b453d1c-62bf-4e02-a393-774c94f16305"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182NC9mcmFnOjE5MmJkY2FiNmJhNTRhMWI5ZTYxNzY3OWU4Nzk0YzQ1L3RhYmxlOjJiN2M5MDcyMTc5MTQzYjA4ZjRiZTdlMzgxZTZmY2FkL3RhYmxlcmFuZ2U6MmI3YzkwNzIxNzkxNDNiMDhmNGJlN2UzODFlNmZjYWRfMzctMC0xLTEtNDEyOTQvdGV4dHJlZ2lvbjoyZDM0NGNhMTlkYjE0MjE3YTdhM2U1MGFhZjdhM2E1MV82Mw_924cae15-73fe-49d8-b008-dcd209b734ed"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i7462d0db8f4248fcb9fd8f1deae439f3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182NC9mcmFnOjE5MmJkY2FiNmJhNTRhMWI5ZTYxNzY3OWU4Nzk0YzQ1L3RhYmxlOjJiN2M5MDcyMTc5MTQzYjA4ZjRiZTdlMzgxZTZmY2FkL3RhYmxlcmFuZ2U6MmI3YzkwNzIxNzkxNDNiMDhmNGJlN2UzODFlNmZjYWRfMzctMC0xLTEtNDEyOTQvdGV4dHJlZ2lvbjoyZDM0NGNhMTlkYjE0MjE3YTdhM2U1MGFhZjdhM2E1MV82Mw_c8320e88-7ae0-4d13-b198-5a55af220c6c"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue
      contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182NC9mcmFnOjE5MmJkY2FiNmJhNTRhMWI5ZTYxNzY3OWU4Nzk0YzQ1L3RhYmxlOjJiN2M5MDcyMTc5MTQzYjA4ZjRiZTdlMzgxZTZmY2FkL3RhYmxlcmFuZ2U6MmI3YzkwNzIxNzkxNDNiMDhmNGJlN2UzODFlNmZjYWRfMzctMS0xLTEtNDEyOTQ_abb50155-30f9-4716-9445-1cd998f2173c"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="i7462d0db8f4248fcb9fd8f1deae439f3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182NC9mcmFnOjE5MmJkY2FiNmJhNTRhMWI5ZTYxNzY3OWU4Nzk0YzQ1L3RhYmxlOjJiN2M5MDcyMTc5MTQzYjA4ZjRiZTdlMzgxZTZmY2FkL3RhYmxlcmFuZ2U6MmI3YzkwNzIxNzkxNDNiMDhmNGJlN2UzODFlNmZjYWRfMzctMy0xLTEtNDEyOTQ_cc25d293-8f2a-4f29-8559-b578412f0678"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i7462d0db8f4248fcb9fd8f1deae439f3_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182NC9mcmFnOjE5MmJkY2FiNmJhNTRhMWI5ZTYxNzY3OWU4Nzk0YzQ1L3RhYmxlOjJiN2M5MDcyMTc5MTQzYjA4ZjRiZTdlMzgxZTZmY2FkL3RhYmxlcmFuZ2U6MmI3YzkwNzIxNzkxNDNiMDhmNGJlN2UzODFlNmZjYWRfMzgtMC0xLTEtNDEyOTQvdGV4dHJlZ2lvbjpmYzZjMmE2NmIwYTU0YmMwOWJlNTliYWMxOGFjZGQyZF8xOQ_273c7d2c-f26f-4495-8029-3810b9722339"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182NC9mcmFnOjE5MmJkY2FiNmJhNTRhMWI5ZTYxNzY3OWU4Nzk0YzQ1L3RhYmxlOjJiN2M5MDcyMTc5MTQzYjA4ZjRiZTdlMzgxZTZmY2FkL3RhYmxlcmFuZ2U6MmI3YzkwNzIxNzkxNDNiMDhmNGJlN2UzODFlNmZjYWRfMzgtMC0xLTEtNDEyOTQvdGV4dHJlZ2lvbjpmYzZjMmE2NmIwYTU0YmMwOWJlNTliYWMxOGFjZGQyZF8xOQ_a9c89ef7-0ba6-49e4-8e0f-04d4defc7d37"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182NC9mcmFnOjE5MmJkY2FiNmJhNTRhMWI5ZTYxNzY3OWU4Nzk0YzQ1L3RhYmxlOjJiN2M5MDcyMTc5MTQzYjA4ZjRiZTdlMzgxZTZmY2FkL3RhYmxlcmFuZ2U6MmI3YzkwNzIxNzkxNDNiMDhmNGJlN2UzODFlNmZjYWRfMzgtMC0xLTEtNDEyOTQvdGV4dHJlZ2lvbjpmYzZjMmE2NmIwYTU0YmMwOWJlNTliYWMxOGFjZGQyZF8zMw_1fbecc58-3aeb-45ab-8dde-fdd7772b1e9c"
      unitRef="shares">60000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i7462d0db8f4248fcb9fd8f1deae439f3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182NC9mcmFnOjE5MmJkY2FiNmJhNTRhMWI5ZTYxNzY3OWU4Nzk0YzQ1L3RhYmxlOjJiN2M5MDcyMTc5MTQzYjA4ZjRiZTdlMzgxZTZmY2FkL3RhYmxlcmFuZ2U6MmI3YzkwNzIxNzkxNDNiMDhmNGJlN2UzODFlNmZjYWRfMzgtMC0xLTEtNDEyOTQvdGV4dHJlZ2lvbjpmYzZjMmE2NmIwYTU0YmMwOWJlNTliYWMxOGFjZGQyZF8zMw_83cf6256-3452-4a1a-9387-49a45db79334"
      unitRef="shares">60000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182NC9mcmFnOjE5MmJkY2FiNmJhNTRhMWI5ZTYxNzY3OWU4Nzk0YzQ1L3RhYmxlOjJiN2M5MDcyMTc5MTQzYjA4ZjRiZTdlMzgxZTZmY2FkL3RhYmxlcmFuZ2U6MmI3YzkwNzIxNzkxNDNiMDhmNGJlN2UzODFlNmZjYWRfMzgtMC0xLTEtNDEyOTQvdGV4dHJlZ2lvbjpmYzZjMmE2NmIwYTU0YmMwOWJlNTliYWMxOGFjZGQyZF81NQ_2edf7342-7552-464a-ba7d-2eab7d3c1f52"
      unitRef="shares">16767000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182NC9mcmFnOjE5MmJkY2FiNmJhNTRhMWI5ZTYxNzY3OWU4Nzk0YzQ1L3RhYmxlOjJiN2M5MDcyMTc5MTQzYjA4ZjRiZTdlMzgxZTZmY2FkL3RhYmxlcmFuZ2U6MmI3YzkwNzIxNzkxNDNiMDhmNGJlN2UzODFlNmZjYWRfMzgtMC0xLTEtNDEyOTQvdGV4dHJlZ2lvbjpmYzZjMmE2NmIwYTU0YmMwOWJlNTliYWMxOGFjZGQyZF81NQ_c1be99da-ac79-4f7d-9271-d140a4f929ee"
      unitRef="shares">16767000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="i7462d0db8f4248fcb9fd8f1deae439f3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182NC9mcmFnOjE5MmJkY2FiNmJhNTRhMWI5ZTYxNzY3OWU4Nzk0YzQ1L3RhYmxlOjJiN2M5MDcyMTc5MTQzYjA4ZjRiZTdlMzgxZTZmY2FkL3RhYmxlcmFuZ2U6MmI3YzkwNzIxNzkxNDNiMDhmNGJlN2UzODFlNmZjYWRfMzgtMC0xLTEtNDEyOTQvdGV4dHJlZ2lvbjpmYzZjMmE2NmIwYTU0YmMwOWJlNTliYWMxOGFjZGQyZF82Mg_659ec51d-fb4f-4677-990f-0aef0afb0ddb"
      unitRef="shares">16080000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i7462d0db8f4248fcb9fd8f1deae439f3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182NC9mcmFnOjE5MmJkY2FiNmJhNTRhMWI5ZTYxNzY3OWU4Nzk0YzQ1L3RhYmxlOjJiN2M5MDcyMTc5MTQzYjA4ZjRiZTdlMzgxZTZmY2FkL3RhYmxlcmFuZ2U6MmI3YzkwNzIxNzkxNDNiMDhmNGJlN2UzODFlNmZjYWRfMzgtMC0xLTEtNDEyOTQvdGV4dHJlZ2lvbjpmYzZjMmE2NmIwYTU0YmMwOWJlNTliYWMxOGFjZGQyZF82Mg_debe66dc-4946-48e8-8ecd-1a91b2d3fb58"
      unitRef="shares">16080000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182NC9mcmFnOjE5MmJkY2FiNmJhNTRhMWI5ZTYxNzY3OWU4Nzk0YzQ1L3RhYmxlOjJiN2M5MDcyMTc5MTQzYjA4ZjRiZTdlMzgxZTZmY2FkL3RhYmxlcmFuZ2U6MmI3YzkwNzIxNzkxNDNiMDhmNGJlN2UzODFlNmZjYWRfMzgtMS0xLTEtNDEyOTQ_ea3032e5-2572-4ae0-b7b0-ec72a4bea21b"
      unitRef="usd">17000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i7462d0db8f4248fcb9fd8f1deae439f3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182NC9mcmFnOjE5MmJkY2FiNmJhNTRhMWI5ZTYxNzY3OWU4Nzk0YzQ1L3RhYmxlOjJiN2M5MDcyMTc5MTQzYjA4ZjRiZTdlMzgxZTZmY2FkL3RhYmxlcmFuZ2U6MmI3YzkwNzIxNzkxNDNiMDhmNGJlN2UzODFlNmZjYWRfMzgtMy0xLTEtNDEyOTQ_9574ed40-2bf4-401e-a4af-503a3ec12a74"
      unitRef="usd">16000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182NC9mcmFnOjE5MmJkY2FiNmJhNTRhMWI5ZTYxNzY3OWU4Nzk0YzQ1L3RhYmxlOjJiN2M5MDcyMTc5MTQzYjA4ZjRiZTdlMzgxZTZmY2FkL3RhYmxlcmFuZ2U6MmI3YzkwNzIxNzkxNDNiMDhmNGJlN2UzODFlNmZjYWRfMzktMS0xLTEtNDEyOTQ_649bdc95-0a02-45f0-bf3d-a55c33672434"
      unitRef="usd">372969000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i7462d0db8f4248fcb9fd8f1deae439f3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182NC9mcmFnOjE5MmJkY2FiNmJhNTRhMWI5ZTYxNzY3OWU4Nzk0YzQ1L3RhYmxlOjJiN2M5MDcyMTc5MTQzYjA4ZjRiZTdlMzgxZTZmY2FkL3RhYmxlcmFuZ2U6MmI3YzkwNzIxNzkxNDNiMDhmNGJlN2UzODFlNmZjYWRfMzktMy0xLTEtNDEyOTQ_32367c97-3ed0-4cd7-9ff5-3e55943a6261"
      unitRef="usd">318358000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182NC9mcmFnOjE5MmJkY2FiNmJhNTRhMWI5ZTYxNzY3OWU4Nzk0YzQ1L3RhYmxlOjJiN2M5MDcyMTc5MTQzYjA4ZjRiZTdlMzgxZTZmY2FkL3RhYmxlcmFuZ2U6MmI3YzkwNzIxNzkxNDNiMDhmNGJlN2UzODFlNmZjYWRfNDAtMS0xLTEtNDEyOTQ_b0249463-fca7-4c09-b689-dd8efe4771ad"
      unitRef="usd">-917000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i7462d0db8f4248fcb9fd8f1deae439f3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182NC9mcmFnOjE5MmJkY2FiNmJhNTRhMWI5ZTYxNzY3OWU4Nzk0YzQ1L3RhYmxlOjJiN2M5MDcyMTc5MTQzYjA4ZjRiZTdlMzgxZTZmY2FkL3RhYmxlcmFuZ2U6MmI3YzkwNzIxNzkxNDNiMDhmNGJlN2UzODFlNmZjYWRfNDAtMy0xLTEtNDEyOTQ_80f23b2f-c988-40f6-b28c-10262fe3c8ed"
      unitRef="usd">-801000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182NC9mcmFnOjE5MmJkY2FiNmJhNTRhMWI5ZTYxNzY3OWU4Nzk0YzQ1L3RhYmxlOjJiN2M5MDcyMTc5MTQzYjA4ZjRiZTdlMzgxZTZmY2FkL3RhYmxlcmFuZ2U6MmI3YzkwNzIxNzkxNDNiMDhmNGJlN2UzODFlNmZjYWRfNDEtMS0xLTEtNDEyOTQ_30898963-0f6f-4229-989e-4c52005d0f3a"
      unitRef="usd">449090000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i7462d0db8f4248fcb9fd8f1deae439f3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182NC9mcmFnOjE5MmJkY2FiNmJhNTRhMWI5ZTYxNzY3OWU4Nzk0YzQ1L3RhYmxlOjJiN2M5MDcyMTc5MTQzYjA4ZjRiZTdlMzgxZTZmY2FkL3RhYmxlcmFuZ2U6MmI3YzkwNzIxNzkxNDNiMDhmNGJlN2UzODFlNmZjYWRfNDEtMy0xLTEtNDEyOTQ_7abea5d5-75a9-4869-a38c-d6fc4c016180"
      unitRef="usd">391952000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182NC9mcmFnOjE5MmJkY2FiNmJhNTRhMWI5ZTYxNzY3OWU4Nzk0YzQ1L3RhYmxlOjJiN2M5MDcyMTc5MTQzYjA4ZjRiZTdlMzgxZTZmY2FkL3RhYmxlcmFuZ2U6MmI3YzkwNzIxNzkxNDNiMDhmNGJlN2UzODFlNmZjYWRfNDItMS0xLTEtNDEyOTQ_9a81b84c-d5d3-4ba8-8175-228a185a584f"
      unitRef="usd">821159000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i7462d0db8f4248fcb9fd8f1deae439f3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182NC9mcmFnOjE5MmJkY2FiNmJhNTRhMWI5ZTYxNzY3OWU4Nzk0YzQ1L3RhYmxlOjJiN2M5MDcyMTc5MTQzYjA4ZjRiZTdlMzgxZTZmY2FkL3RhYmxlcmFuZ2U6MmI3YzkwNzIxNzkxNDNiMDhmNGJlN2UzODFlNmZjYWRfNDItMy0xLTEtNDEyOTQ_07daf109-583a-4351-9de3-d6a1f6a52d10"
      unitRef="usd">709525000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182NC9mcmFnOjE5MmJkY2FiNmJhNTRhMWI5ZTYxNzY3OWU4Nzk0YzQ1L3RhYmxlOjJiN2M5MDcyMTc5MTQzYjA4ZjRiZTdlMzgxZTZmY2FkL3RhYmxlcmFuZ2U6MmI3YzkwNzIxNzkxNDNiMDhmNGJlN2UzODFlNmZjYWRfNDMtMS0xLTEtNDEyOTQ_4e58d3cb-693a-4232-a6da-331c6bda96fd"
      unitRef="usd">1297590000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i7462d0db8f4248fcb9fd8f1deae439f3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182NC9mcmFnOjE5MmJkY2FiNmJhNTRhMWI5ZTYxNzY3OWU4Nzk0YzQ1L3RhYmxlOjJiN2M5MDcyMTc5MTQzYjA4ZjRiZTdlMzgxZTZmY2FkL3RhYmxlcmFuZ2U6MmI3YzkwNzIxNzkxNDNiMDhmNGJlN2UzODFlNmZjYWRfNDMtMy0xLTEtNDEyOTQ_e68a7afd-0f0d-4e41-a151-e9bf7ba45742"
      unitRef="usd">1362285000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id759bc1766674b9fb61441df044bc82f_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182Ny9mcmFnOmYzZTY4ZDllY2E0ODQ3ZDBhMTEzNmVlNGZlMzY4NGJlL3RhYmxlOjgzMDA4NWQwN2ZjZDQ1NGE5YzZiNDA1MjZiNGYwYzUzL3RhYmxlcmFuZ2U6ODMwMDg1ZDA3ZmNkNDU0YTljNmI0MDUyNmI0ZjBjNTNfMy0xLTEtMS00MTI5NA_d2306939-5160-4c94-87b8-3530a661cf10"
      unitRef="usd">48927000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if3c33038f43443e48bceca35aafc84c2_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182Ny9mcmFnOmYzZTY4ZDllY2E0ODQ3ZDBhMTEzNmVlNGZlMzY4NGJlL3RhYmxlOjgzMDA4NWQwN2ZjZDQ1NGE5YzZiNDA1MjZiNGYwYzUzL3RhYmxlcmFuZ2U6ODMwMDg1ZDA3ZmNkNDU0YTljNmI0MDUyNmI0ZjBjNTNfMy0zLTEtMS00MTI5NA_5250d258-6cb3-421f-9232-d63ae0a32303"
      unitRef="usd">33796000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3bced838db93465eb75b31bbd5690a49_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182Ny9mcmFnOmYzZTY4ZDllY2E0ODQ3ZDBhMTEzNmVlNGZlMzY4NGJlL3RhYmxlOjgzMDA4NWQwN2ZjZDQ1NGE5YzZiNDA1MjZiNGYwYzUzL3RhYmxlcmFuZ2U6ODMwMDg1ZDA3ZmNkNDU0YTljNmI0MDUyNmI0ZjBjNTNfMy01LTEtMS00MTI5NA_a7b4bf93-64c1-473a-a797-9733b7fe16a0"
      unitRef="usd">46976000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1477966cad0140da81a9947fe9bab347_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182Ny9mcmFnOmYzZTY4ZDllY2E0ODQ3ZDBhMTEzNmVlNGZlMzY4NGJlL3RhYmxlOjgzMDA4NWQwN2ZjZDQ1NGE5YzZiNDA1MjZiNGYwYzUzL3RhYmxlcmFuZ2U6ODMwMDg1ZDA3ZmNkNDU0YTljNmI0MDUyNmI0ZjBjNTNfNC0xLTEtMS00MTI5NA_d5cde1ac-6f81-44be-9250-5b7608954f3a"
      unitRef="usd">164250000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia7b5c3c10a34465088f2fa15825a2c42_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182Ny9mcmFnOmYzZTY4ZDllY2E0ODQ3ZDBhMTEzNmVlNGZlMzY4NGJlL3RhYmxlOjgzMDA4NWQwN2ZjZDQ1NGE5YzZiNDA1MjZiNGYwYzUzL3RhYmxlcmFuZ2U6ODMwMDg1ZDA3ZmNkNDU0YTljNmI0MDUyNmI0ZjBjNTNfNC0zLTEtMS00MTI5NA_08708d36-6ca2-48ff-a617-b56dfa47e8e8"
      unitRef="usd">109959000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i75309306f08c443f8965a9846c0fb0fc_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182Ny9mcmFnOmYzZTY4ZDllY2E0ODQ3ZDBhMTEzNmVlNGZlMzY4NGJlL3RhYmxlOjgzMDA4NWQwN2ZjZDQ1NGE5YzZiNDA1MjZiNGYwYzUzL3RhYmxlcmFuZ2U6ODMwMDg1ZDA3ZmNkNDU0YTljNmI0MDUyNmI0ZjBjNTNfNC01LTEtMS00MTI5NA_4b62efb1-0b21-4695-bca7-b53753ab83bb"
      unitRef="usd">31489000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i11e3d543e376468e8dda481609ac67e8_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182Ny9mcmFnOmYzZTY4ZDllY2E0ODQ3ZDBhMTEzNmVlNGZlMzY4NGJlL3RhYmxlOjgzMDA4NWQwN2ZjZDQ1NGE5YzZiNDA1MjZiNGYwYzUzL3RhYmxlcmFuZ2U6ODMwMDg1ZDA3ZmNkNDU0YTljNmI0MDUyNmI0ZjBjNTNfNS0xLTEtMS00MTI5NA_7adfc46e-c3e1-4418-9614-d18883ca4a67"
      unitRef="usd">63956000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if06efbad02a54e9d92b23a3ff376910e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182Ny9mcmFnOmYzZTY4ZDllY2E0ODQ3ZDBhMTEzNmVlNGZlMzY4NGJlL3RhYmxlOjgzMDA4NWQwN2ZjZDQ1NGE5YzZiNDA1MjZiNGYwYzUzL3RhYmxlcmFuZ2U6ODMwMDg1ZDA3ZmNkNDU0YTljNmI0MDUyNmI0ZjBjNTNfNS0zLTEtMS00MTI5NA_fe2d193c-db4f-42c9-ba41-3fc3ac3c3a4b"
      unitRef="usd">42664000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idea9b96f20cf4c28aea8b365b1b2069c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182Ny9mcmFnOmYzZTY4ZDllY2E0ODQ3ZDBhMTEzNmVlNGZlMzY4NGJlL3RhYmxlOjgzMDA4NWQwN2ZjZDQ1NGE5YzZiNDA1MjZiNGYwYzUzL3RhYmxlcmFuZ2U6ODMwMDg1ZDA3ZmNkNDU0YTljNmI0MDUyNmI0ZjBjNTNfNS01LTEtMS00MTI5NA_0240bf7b-a97f-4f60-beae-efa111985b79"
      unitRef="usd">41817000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182Ny9mcmFnOmYzZTY4ZDllY2E0ODQ3ZDBhMTEzNmVlNGZlMzY4NGJlL3RhYmxlOjgzMDA4NWQwN2ZjZDQ1NGE5YzZiNDA1MjZiNGYwYzUzL3RhYmxlcmFuZ2U6ODMwMDg1ZDA3ZmNkNDU0YTljNmI0MDUyNmI0ZjBjNTNfNi0xLTEtMS00MTI5NA_022bf06f-a0f7-40d4-b7b2-00273590d30e"
      unitRef="usd">277133000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib3597315a63d441f8f128abd7ed8840e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182Ny9mcmFnOmYzZTY4ZDllY2E0ODQ3ZDBhMTEzNmVlNGZlMzY4NGJlL3RhYmxlOjgzMDA4NWQwN2ZjZDQ1NGE5YzZiNDA1MjZiNGYwYzUzL3RhYmxlcmFuZ2U6ODMwMDg1ZDA3ZmNkNDU0YTljNmI0MDUyNmI0ZjBjNTNfNi0zLTEtMS00MTI5NA_51aa782e-4c4a-4c84-9dcf-eba714833480"
      unitRef="usd">186419000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie6c3b69702e9429aaeed46bdb9bbb9c1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182Ny9mcmFnOmYzZTY4ZDllY2E0ODQ3ZDBhMTEzNmVlNGZlMzY4NGJlL3RhYmxlOjgzMDA4NWQwN2ZjZDQ1NGE5YzZiNDA1MjZiNGYwYzUzL3RhYmxlcmFuZ2U6ODMwMDg1ZDA3ZmNkNDU0YTljNmI0MDUyNmI0ZjBjNTNfNi01LTEtMS00MTI5NA_de24d407-24e1-444b-9a47-af90eecebc6d"
      unitRef="usd">120282000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostDirectMaterial
      contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182Ny9mcmFnOmYzZTY4ZDllY2E0ODQ3ZDBhMTEzNmVlNGZlMzY4NGJlL3RhYmxlOjgzMDA4NWQwN2ZjZDQ1NGE5YzZiNDA1MjZiNGYwYzUzL3RhYmxlcmFuZ2U6ODMwMDg1ZDA3ZmNkNDU0YTljNmI0MDUyNmI0ZjBjNTNfOC0xLTEtMS00MTI5NA_34a4e2c4-9713-46b7-9322-be83910e6220"
      unitRef="usd">62176000</us-gaap:CostDirectMaterial>
    <us-gaap:CostDirectMaterial
      contextRef="ib3597315a63d441f8f128abd7ed8840e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182Ny9mcmFnOmYzZTY4ZDllY2E0ODQ3ZDBhMTEzNmVlNGZlMzY4NGJlL3RhYmxlOjgzMDA4NWQwN2ZjZDQ1NGE5YzZiNDA1MjZiNGYwYzUzL3RhYmxlcmFuZ2U6ODMwMDg1ZDA3ZmNkNDU0YTljNmI0MDUyNmI0ZjBjNTNfOC0zLTEtMS00MTI5NA_ee19bcb3-9b02-4d6a-a749-5ae3c47764a8"
      unitRef="usd">30419000</us-gaap:CostDirectMaterial>
    <us-gaap:CostDirectMaterial
      contextRef="ie6c3b69702e9429aaeed46bdb9bbb9c1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182Ny9mcmFnOmYzZTY4ZDllY2E0ODQ3ZDBhMTEzNmVlNGZlMzY4NGJlL3RhYmxlOjgzMDA4NWQwN2ZjZDQ1NGE5YzZiNDA1MjZiNGYwYzUzL3RhYmxlcmFuZ2U6ODMwMDg1ZDA3ZmNkNDU0YTljNmI0MDUyNmI0ZjBjNTNfOC01LTEtMS00MTI5NA_c8fe7538-77ee-4155-950d-6c3d61a05dd4"
      unitRef="usd">11347000</us-gaap:CostDirectMaterial>
    <us-gaap:CostOfGoodsAndServicesSoldAmortization
      contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182Ny9mcmFnOmYzZTY4ZDllY2E0ODQ3ZDBhMTEzNmVlNGZlMzY4NGJlL3RhYmxlOjgzMDA4NWQwN2ZjZDQ1NGE5YzZiNDA1MjZiNGYwYzUzL3RhYmxlcmFuZ2U6ODMwMDg1ZDA3ZmNkNDU0YTljNmI0MDUyNmI0ZjBjNTNfOS0xLTEtMS00MTI5NA_20b874c4-38ff-41cd-a9da-af5d2379d2ec"
      unitRef="usd">47167000</us-gaap:CostOfGoodsAndServicesSoldAmortization>
    <us-gaap:CostOfGoodsAndServicesSoldAmortization
      contextRef="ib3597315a63d441f8f128abd7ed8840e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182Ny9mcmFnOmYzZTY4ZDllY2E0ODQ3ZDBhMTEzNmVlNGZlMzY4NGJlL3RhYmxlOjgzMDA4NWQwN2ZjZDQ1NGE5YzZiNDA1MjZiNGYwYzUzL3RhYmxlcmFuZ2U6ODMwMDg1ZDA3ZmNkNDU0YTljNmI0MDUyNmI0ZjBjNTNfOS0zLTEtMS00MTI5NA_dd233803-3c89-4f6a-8bce-87be6d88f01a"
      unitRef="usd">23442000</us-gaap:CostOfGoodsAndServicesSoldAmortization>
    <us-gaap:CostOfGoodsAndServicesSoldAmortization
      contextRef="ie6c3b69702e9429aaeed46bdb9bbb9c1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182Ny9mcmFnOmYzZTY4ZDllY2E0ODQ3ZDBhMTEzNmVlNGZlMzY4NGJlL3RhYmxlOjgzMDA4NWQwN2ZjZDQ1NGE5YzZiNDA1MjZiNGYwYzUzL3RhYmxlcmFuZ2U6ODMwMDg1ZDA3ZmNkNDU0YTljNmI0MDUyNmI0ZjBjNTNfOS01LTEtMS00MTI5NA_d5d54818-316f-4554-8adc-4794aa766c09"
      unitRef="usd">16864000</us-gaap:CostOfGoodsAndServicesSoldAmortization>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182Ny9mcmFnOmYzZTY4ZDllY2E0ODQ3ZDBhMTEzNmVlNGZlMzY4NGJlL3RhYmxlOjgzMDA4NWQwN2ZjZDQ1NGE5YzZiNDA1MjZiNGYwYzUzL3RhYmxlcmFuZ2U6ODMwMDg1ZDA3ZmNkNDU0YTljNmI0MDUyNmI0ZjBjNTNfMTAtMS0xLTEtNDEyOTQ_98779b9c-864b-490d-a560-f09b597ba950"
      unitRef="usd">69012000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="ib3597315a63d441f8f128abd7ed8840e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182Ny9mcmFnOmYzZTY4ZDllY2E0ODQ3ZDBhMTEzNmVlNGZlMzY4NGJlL3RhYmxlOjgzMDA4NWQwN2ZjZDQ1NGE5YzZiNDA1MjZiNGYwYzUzL3RhYmxlcmFuZ2U6ODMwMDg1ZDA3ZmNkNDU0YTljNmI0MDUyNmI0ZjBjNTNfMTAtMy0xLTEtNDEyOTQ_f05d5eaa-2e43-4ed6-8393-fef2be5bcd05"
      unitRef="usd">59392000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="ie6c3b69702e9429aaeed46bdb9bbb9c1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182Ny9mcmFnOmYzZTY4ZDllY2E0ODQ3ZDBhMTEzNmVlNGZlMzY4NGJlL3RhYmxlOjgzMDA4NWQwN2ZjZDQ1NGE5YzZiNDA1MjZiNGYwYzUzL3RhYmxlcmFuZ2U6ODMwMDg1ZDA3ZmNkNDU0YTljNmI0MDUyNmI0ZjBjNTNfMTAtNS0xLTEtNDEyOTQ_753dae27-2394-49dd-85e6-6769c4541a2b"
      unitRef="usd">55908000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182Ny9mcmFnOmYzZTY4ZDllY2E0ODQ3ZDBhMTEzNmVlNGZlMzY4NGJlL3RhYmxlOjgzMDA4NWQwN2ZjZDQ1NGE5YzZiNDA1MjZiNGYwYzUzL3RhYmxlcmFuZ2U6ODMwMDg1ZDA3ZmNkNDU0YTljNmI0MDUyNmI0ZjBjNTNfMTEtMS0xLTEtNDEyOTQ_b811ecf8-3083-4d45-baaa-7533d31f7ea4"
      unitRef="usd">57483000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="ib3597315a63d441f8f128abd7ed8840e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182Ny9mcmFnOmYzZTY4ZDllY2E0ODQ3ZDBhMTEzNmVlNGZlMzY4NGJlL3RhYmxlOjgzMDA4NWQwN2ZjZDQ1NGE5YzZiNDA1MjZiNGYwYzUzL3RhYmxlcmFuZ2U6ODMwMDg1ZDA3ZmNkNDU0YTljNmI0MDUyNmI0ZjBjNTNfMTEtMy0xLTEtNDEyOTQ_4b4be6f7-5076-4880-aa45-7eb5771d8a81"
      unitRef="usd">64435000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="ie6c3b69702e9429aaeed46bdb9bbb9c1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182Ny9mcmFnOmYzZTY4ZDllY2E0ODQ3ZDBhMTEzNmVlNGZlMzY4NGJlL3RhYmxlOjgzMDA4NWQwN2ZjZDQ1NGE5YzZiNDA1MjZiNGYwYzUzL3RhYmxlcmFuZ2U6ODMwMDg1ZDA3ZmNkNDU0YTljNmI0MDUyNmI0ZjBjNTNfMTEtNS0xLTEtNDEyOTQ_b4651e93-7cf7-4471-8a9a-b4f4f6fb2b18"
      unitRef="usd">41884000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OtherOperatingIncome
      contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182Ny9mcmFnOmYzZTY4ZDllY2E0ODQ3ZDBhMTEzNmVlNGZlMzY4NGJlL3RhYmxlOjgzMDA4NWQwN2ZjZDQ1NGE5YzZiNDA1MjZiNGYwYzUzL3RhYmxlcmFuZ2U6ODMwMDg1ZDA3ZmNkNDU0YTljNmI0MDUyNmI0ZjBjNTNfMTItMS0xLTEtNTE3NDM_9e362b0b-c3a1-4d7a-a8b8-5a6a44bad7ae"
      unitRef="usd">37600000</us-gaap:OtherOperatingIncome>
    <us-gaap:OtherOperatingIncome
      contextRef="ib3597315a63d441f8f128abd7ed8840e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182Ny9mcmFnOmYzZTY4ZDllY2E0ODQ3ZDBhMTEzNmVlNGZlMzY4NGJlL3RhYmxlOjgzMDA4NWQwN2ZjZDQ1NGE5YzZiNDA1MjZiNGYwYzUzL3RhYmxlcmFuZ2U6ODMwMDg1ZDA3ZmNkNDU0YTljNmI0MDUyNmI0ZjBjNTNfMTItMy0xLTEtNTE3NjA_df31161f-a649-4410-842f-332e6f923457"
      unitRef="usd">0</us-gaap:OtherOperatingIncome>
    <us-gaap:OtherOperatingIncome
      contextRef="ie6c3b69702e9429aaeed46bdb9bbb9c1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182Ny9mcmFnOmYzZTY4ZDllY2E0ODQ3ZDBhMTEzNmVlNGZlMzY4NGJlL3RhYmxlOjgzMDA4NWQwN2ZjZDQ1NGE5YzZiNDA1MjZiNGYwYzUzL3RhYmxlcmFuZ2U6ODMwMDg1ZDA3ZmNkNDU0YTljNmI0MDUyNmI0ZjBjNTNfMTItNS0xLTEtNTIwNjg_debd8e36-d50f-4bcf-9c4f-0f77eef0eb1e"
      unitRef="usd">0</us-gaap:OtherOperatingIncome>
    <us-gaap:OperatingCostsAndExpenses
      contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182Ny9mcmFnOmYzZTY4ZDllY2E0ODQ3ZDBhMTEzNmVlNGZlMzY4NGJlL3RhYmxlOjgzMDA4NWQwN2ZjZDQ1NGE5YzZiNDA1MjZiNGYwYzUzL3RhYmxlcmFuZ2U6ODMwMDg1ZDA3ZmNkNDU0YTljNmI0MDUyNmI0ZjBjNTNfMTItMS0xLTEtNDEyOTQ_13d189b2-fd15-437b-a13c-f1c100ff8031"
      unitRef="usd">198238000</us-gaap:OperatingCostsAndExpenses>
    <us-gaap:OperatingCostsAndExpenses
      contextRef="ib3597315a63d441f8f128abd7ed8840e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182Ny9mcmFnOmYzZTY4ZDllY2E0ODQ3ZDBhMTEzNmVlNGZlMzY4NGJlL3RhYmxlOjgzMDA4NWQwN2ZjZDQ1NGE5YzZiNDA1MjZiNGYwYzUzL3RhYmxlcmFuZ2U6ODMwMDg1ZDA3ZmNkNDU0YTljNmI0MDUyNmI0ZjBjNTNfMTItMy0xLTEtNDEyOTQ_cc5e3b80-f9e4-441e-a306-dd7528efb915"
      unitRef="usd">177688000</us-gaap:OperatingCostsAndExpenses>
    <us-gaap:OperatingCostsAndExpenses
      contextRef="ie6c3b69702e9429aaeed46bdb9bbb9c1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182Ny9mcmFnOmYzZTY4ZDllY2E0ODQ3ZDBhMTEzNmVlNGZlMzY4NGJlL3RhYmxlOjgzMDA4NWQwN2ZjZDQ1NGE5YzZiNDA1MjZiNGYwYzUzL3RhYmxlcmFuZ2U6ODMwMDg1ZDA3ZmNkNDU0YTljNmI0MDUyNmI0ZjBjNTNfMTItNS0xLTEtNDEyOTQ_6757d12b-fada-4bb7-8b31-8f5e483ce71e"
      unitRef="usd">126003000</us-gaap:OperatingCostsAndExpenses>
    <us-gaap:GainLossOnDispositionOfIntangibleAssets
      contextRef="i85c760e4f98147f79ecf9fc666a45595_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182Ny9mcmFnOmYzZTY4ZDllY2E0ODQ3ZDBhMTEzNmVlNGZlMzY4NGJlL3RhYmxlOjgzMDA4NWQwN2ZjZDQ1NGE5YzZiNDA1MjZiNGYwYzUzL3RhYmxlcmFuZ2U6ODMwMDg1ZDA3ZmNkNDU0YTljNmI0MDUyNmI0ZjBjNTNfMTMtMS0xLTEtNDEyOTQ_56bcb15d-d776-4440-8c3a-6a424011cc2f"
      unitRef="usd">0</us-gaap:GainLossOnDispositionOfIntangibleAssets>
    <us-gaap:GainLossOnDispositionOfIntangibleAssets
      contextRef="ibb5d6e3d481646168203ad91e5a3ab1c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182Ny9mcmFnOmYzZTY4ZDllY2E0ODQ3ZDBhMTEzNmVlNGZlMzY4NGJlL3RhYmxlOjgzMDA4NWQwN2ZjZDQ1NGE5YzZiNDA1MjZiNGYwYzUzL3RhYmxlcmFuZ2U6ODMwMDg1ZDA3ZmNkNDU0YTljNmI0MDUyNmI0ZjBjNTNfMTMtMy0xLTEtNDEyOTQ_dac6b3e0-2b4c-47c3-b86e-b6bff531bfc6"
      unitRef="usd">17114000</us-gaap:GainLossOnDispositionOfIntangibleAssets>
    <us-gaap:GainLossOnDispositionOfIntangibleAssets
      contextRef="id75620cd2ae8495a9c4aff23e56271fa_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182Ny9mcmFnOmYzZTY4ZDllY2E0ODQ3ZDBhMTEzNmVlNGZlMzY4NGJlL3RhYmxlOjgzMDA4NWQwN2ZjZDQ1NGE5YzZiNDA1MjZiNGYwYzUzL3RhYmxlcmFuZ2U6ODMwMDg1ZDA3ZmNkNDU0YTljNmI0MDUyNmI0ZjBjNTNfMTMtNS0xLTEtNDEyOTQ_8144c2b9-6ed3-4294-a15f-8f7913c85631"
      unitRef="usd">0</us-gaap:GainLossOnDispositionOfIntangibleAssets>
    <us-gaap:GainLossOnDispositionOfIntangibleAssets
      contextRef="id5ccedf4402b42a79d8bd7ff8d46fd9a_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182Ny9mcmFnOmYzZTY4ZDllY2E0ODQ3ZDBhMTEzNmVlNGZlMzY4NGJlL3RhYmxlOjgzMDA4NWQwN2ZjZDQ1NGE5YzZiNDA1MjZiNGYwYzUzL3RhYmxlcmFuZ2U6ODMwMDg1ZDA3ZmNkNDU0YTljNmI0MDUyNmI0ZjBjNTNfMTQtMS0xLTEtNDEyOTQ_125124a7-3538-4327-ac93-cb3c072898c9"
      unitRef="usd">0</us-gaap:GainLossOnDispositionOfIntangibleAssets>
    <us-gaap:GainLossOnDispositionOfIntangibleAssets
      contextRef="ic02ae2c8af73463a961944407c02e1da_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182Ny9mcmFnOmYzZTY4ZDllY2E0ODQ3ZDBhMTEzNmVlNGZlMzY4NGJlL3RhYmxlOjgzMDA4NWQwN2ZjZDQ1NGE5YzZiNDA1MjZiNGYwYzUzL3RhYmxlcmFuZ2U6ODMwMDg1ZDA3ZmNkNDU0YTljNmI0MDUyNmI0ZjBjNTNfMTQtMy0xLTEtNDEyOTQ_bf47a9b5-76c5-4baf-8f0e-55d1a1e993da"
      unitRef="usd">0</us-gaap:GainLossOnDispositionOfIntangibleAssets>
    <us-gaap:GainLossOnDispositionOfIntangibleAssets
      contextRef="i21165c6e7ed34bec9a1abbd4497ce88b_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182Ny9mcmFnOmYzZTY4ZDllY2E0ODQ3ZDBhMTEzNmVlNGZlMzY4NGJlL3RhYmxlOjgzMDA4NWQwN2ZjZDQ1NGE5YzZiNDA1MjZiNGYwYzUzL3RhYmxlcmFuZ2U6ODMwMDg1ZDA3ZmNkNDU0YTljNmI0MDUyNmI0ZjBjNTNfMTQtNS0xLTEtNDEyOTQ_e034f610-d7e4-4c1c-9b84-31da075f56b3"
      unitRef="usd">812797000</us-gaap:GainLossOnDispositionOfIntangibleAssets>
    <us-gaap:OperatingIncomeLoss
      contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182Ny9mcmFnOmYzZTY4ZDllY2E0ODQ3ZDBhMTEzNmVlNGZlMzY4NGJlL3RhYmxlOjgzMDA4NWQwN2ZjZDQ1NGE5YzZiNDA1MjZiNGYwYzUzL3RhYmxlcmFuZ2U6ODMwMDg1ZDA3ZmNkNDU0YTljNmI0MDUyNmI0ZjBjNTNfMTUtMS0xLTEtNDEyOTQ_0a47b190-6b77-4544-9f99-6e6861582026"
      unitRef="usd">78895000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ib3597315a63d441f8f128abd7ed8840e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182Ny9mcmFnOmYzZTY4ZDllY2E0ODQ3ZDBhMTEzNmVlNGZlMzY4NGJlL3RhYmxlOjgzMDA4NWQwN2ZjZDQ1NGE5YzZiNDA1MjZiNGYwYzUzL3RhYmxlcmFuZ2U6ODMwMDg1ZDA3ZmNkNDU0YTljNmI0MDUyNmI0ZjBjNTNfMTUtMy0xLTEtNDEyOTQ_ef623ce1-9e53-4334-891a-6f740be970d2"
      unitRef="usd">25845000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ie6c3b69702e9429aaeed46bdb9bbb9c1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182Ny9mcmFnOmYzZTY4ZDllY2E0ODQ3ZDBhMTEzNmVlNGZlMzY4NGJlL3RhYmxlOjgzMDA4NWQwN2ZjZDQ1NGE5YzZiNDA1MjZiNGYwYzUzL3RhYmxlcmFuZ2U6ODMwMDg1ZDA3ZmNkNDU0YTljNmI0MDUyNmI0ZjBjNTNfMTUtNS0xLTEtNDEyOTQ_a1ce7e3f-45ea-4c5b-bb09-b5b7b48f5bfc"
      unitRef="usd">807076000</us-gaap:OperatingIncomeLoss>
    <us-gaap:GainLossOnInvestments
      contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182Ny9mcmFnOmYzZTY4ZDllY2E0ODQ3ZDBhMTEzNmVlNGZlMzY4NGJlL3RhYmxlOjgzMDA4NWQwN2ZjZDQ1NGE5YzZiNDA1MjZiNGYwYzUzL3RhYmxlcmFuZ2U6ODMwMDg1ZDA3ZmNkNDU0YTljNmI0MDUyNmI0ZjBjNTNfMTctMS0xLTEtNDEyOTQ_45e43b27-5cf2-41ed-9229-0b0ff4f3604b"
      unitRef="usd">-3997000</us-gaap:GainLossOnInvestments>
    <us-gaap:GainLossOnInvestments
      contextRef="ib3597315a63d441f8f128abd7ed8840e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182Ny9mcmFnOmYzZTY4ZDllY2E0ODQ3ZDBhMTEzNmVlNGZlMzY4NGJlL3RhYmxlOjgzMDA4NWQwN2ZjZDQ1NGE5YzZiNDA1MjZiNGYwYzUzL3RhYmxlcmFuZ2U6ODMwMDg1ZDA3ZmNkNDU0YTljNmI0MDUyNmI0ZjBjNTNfMTctMy0xLTEtNDEyOTQ_ad50c358-77dc-4b46-a1af-95e9d3350c60"
      unitRef="usd">-16933000</us-gaap:GainLossOnInvestments>
    <us-gaap:GainLossOnInvestments
      contextRef="ie6c3b69702e9429aaeed46bdb9bbb9c1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182Ny9mcmFnOmYzZTY4ZDllY2E0ODQ3ZDBhMTEzNmVlNGZlMzY4NGJlL3RhYmxlOjgzMDA4NWQwN2ZjZDQ1NGE5YzZiNDA1MjZiNGYwYzUzL3RhYmxlcmFuZ2U6ODMwMDg1ZDA3ZmNkNDU0YTljNmI0MDUyNmI0ZjBjNTNfMTctNS0xLTEtNDEyOTQ_3c40ec36-59f4-454a-8dbe-942e32db5c7c"
      unitRef="usd">1049000</us-gaap:GainLossOnInvestments>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182Ny9mcmFnOmYzZTY4ZDllY2E0ODQ3ZDBhMTEzNmVlNGZlMzY4NGJlL3RhYmxlOjgzMDA4NWQwN2ZjZDQ1NGE5YzZiNDA1MjZiNGYwYzUzL3RhYmxlcmFuZ2U6ODMwMDg1ZDA3ZmNkNDU0YTljNmI0MDUyNmI0ZjBjNTNfMTgtMS0xLTEtNDEyOTQ_c068756a-d52d-4bda-a0fd-73ebdab6d01e"
      unitRef="usd">886000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="ib3597315a63d441f8f128abd7ed8840e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182Ny9mcmFnOmYzZTY4ZDllY2E0ODQ3ZDBhMTEzNmVlNGZlMzY4NGJlL3RhYmxlOjgzMDA4NWQwN2ZjZDQ1NGE5YzZiNDA1MjZiNGYwYzUzL3RhYmxlcmFuZ2U6ODMwMDg1ZDA3ZmNkNDU0YTljNmI0MDUyNmI0ZjBjNTNfMTgtMy0xLTEtNDEyOTQ_90b440e0-f722-4f86-bb00-adcab81e2de1"
      unitRef="usd">8078000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="ie6c3b69702e9429aaeed46bdb9bbb9c1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182Ny9mcmFnOmYzZTY4ZDllY2E0ODQ3ZDBhMTEzNmVlNGZlMzY4NGJlL3RhYmxlOjgzMDA4NWQwN2ZjZDQ1NGE5YzZiNDA1MjZiNGYwYzUzL3RhYmxlcmFuZ2U6ODMwMDg1ZDA3ZmNkNDU0YTljNmI0MDUyNmI0ZjBjNTNfMTgtNS0xLTEtNDEyOTQ_d1bae809-7bdb-42a7-a653-d091b82eeaa2"
      unitRef="usd">28430000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InterestExpense
      contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182Ny9mcmFnOmYzZTY4ZDllY2E0ODQ3ZDBhMTEzNmVlNGZlMzY4NGJlL3RhYmxlOjgzMDA4NWQwN2ZjZDQ1NGE5YzZiNDA1MjZiNGYwYzUzL3RhYmxlcmFuZ2U6ODMwMDg1ZDA3ZmNkNDU0YTljNmI0MDUyNmI0ZjBjNTNfMTktMS0xLTEtNDEyOTQ_7686c270-6820-48a3-b4fc-187932ff78e8"
      unitRef="usd">19626000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="ib3597315a63d441f8f128abd7ed8840e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182Ny9mcmFnOmYzZTY4ZDllY2E0ODQ3ZDBhMTEzNmVlNGZlMzY4NGJlL3RhYmxlOjgzMDA4NWQwN2ZjZDQ1NGE5YzZiNDA1MjZiNGYwYzUzL3RhYmxlcmFuZ2U6ODMwMDg1ZDA3ZmNkNDU0YTljNmI0MDUyNmI0ZjBjNTNfMTktMy0xLTEtNDEyOTQ_657a50e6-4641-4c93-b62d-e1f21d75113b"
      unitRef="usd">27420000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="ie6c3b69702e9429aaeed46bdb9bbb9c1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182Ny9mcmFnOmYzZTY4ZDllY2E0ODQ3ZDBhMTEzNmVlNGZlMzY4NGJlL3RhYmxlOjgzMDA4NWQwN2ZjZDQ1NGE5YzZiNDA1MjZiNGYwYzUzL3RhYmxlcmFuZ2U6ODMwMDg1ZDA3ZmNkNDU0YTljNmI0MDUyNmI0ZjBjNTNfMTktNS0xLTEtNDEyOTQ_0f08cdcd-6537-4250-8c2b-461b4843c48e"
      unitRef="usd">35745000</us-gaap:InterestExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182Ny9mcmFnOmYzZTY4ZDllY2E0ODQ3ZDBhMTEzNmVlNGZlMzY4NGJlL3RhYmxlOjgzMDA4NWQwN2ZjZDQ1NGE5YzZiNDA1MjZiNGYwYzUzL3RhYmxlcmFuZ2U6ODMwMDg1ZDA3ZmNkNDU0YTljNmI0MDUyNmI0ZjBjNTNfMjAtMS0xLTEtNDEyOTQ_9aea6a7b-0d96-4389-b709-db1e30792f80"
      unitRef="usd">-8860000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="ib3597315a63d441f8f128abd7ed8840e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182Ny9mcmFnOmYzZTY4ZDllY2E0ODQ3ZDBhMTEzNmVlNGZlMzY4NGJlL3RhYmxlOjgzMDA4NWQwN2ZjZDQ1NGE5YzZiNDA1MjZiNGYwYzUzL3RhYmxlcmFuZ2U6ODMwMDg1ZDA3ZmNkNDU0YTljNmI0MDUyNmI0ZjBjNTNfMjAtMy0xLTEtNDEyOTQ_e416b288-86ad-439a-bccc-68eeec820a24"
      unitRef="usd">-108000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="ie6c3b69702e9429aaeed46bdb9bbb9c1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182Ny9mcmFnOmYzZTY4ZDllY2E0ODQ3ZDBhMTEzNmVlNGZlMzY4NGJlL3RhYmxlOjgzMDA4NWQwN2ZjZDQ1NGE5YzZiNDA1MjZiNGYwYzUzL3RhYmxlcmFuZ2U6ODMwMDg1ZDA3ZmNkNDU0YTljNmI0MDUyNmI0ZjBjNTNfMjAtNS0xLTEtNDEyOTQ_41307f59-40bc-4917-acb7-1da2cd644185"
      unitRef="usd">-4171000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182Ny9mcmFnOmYzZTY4ZDllY2E0ODQ3ZDBhMTEzNmVlNGZlMzY4NGJlL3RhYmxlOjgzMDA4NWQwN2ZjZDQ1NGE5YzZiNDA1MjZiNGYwYzUzL3RhYmxlcmFuZ2U6ODMwMDg1ZDA3ZmNkNDU0YTljNmI0MDUyNmI0ZjBjNTNfMjEtMS0xLTEtNDEyOTQ_3dfc84ad-28ea-4dc1-907a-c0dd4105b25b"
      unitRef="usd">-31597000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="ib3597315a63d441f8f128abd7ed8840e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182Ny9mcmFnOmYzZTY4ZDllY2E0ODQ3ZDBhMTEzNmVlNGZlMzY4NGJlL3RhYmxlOjgzMDA4NWQwN2ZjZDQ1NGE5YzZiNDA1MjZiNGYwYzUzL3RhYmxlcmFuZ2U6ODMwMDg1ZDA3ZmNkNDU0YTljNmI0MDUyNmI0ZjBjNTNfMjEtMy0xLTEtNDEyOTQ_c9ef2262-b861-45a9-9b96-69467bf9330e"
      unitRef="usd">-36383000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="ie6c3b69702e9429aaeed46bdb9bbb9c1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182Ny9mcmFnOmYzZTY4ZDllY2E0ODQ3ZDBhMTEzNmVlNGZlMzY4NGJlL3RhYmxlOjgzMDA4NWQwN2ZjZDQ1NGE5YzZiNDA1MjZiNGYwYzUzL3RhYmxlcmFuZ2U6ODMwMDg1ZDA3ZmNkNDU0YTljNmI0MDUyNmI0ZjBjNTNfMjEtNS0xLTEtNDEyOTQ_60931e5e-a826-445c-b543-03ac591cdf70"
      unitRef="usd">-10437000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182Ny9mcmFnOmYzZTY4ZDllY2E0ODQ3ZDBhMTEzNmVlNGZlMzY4NGJlL3RhYmxlOjgzMDA4NWQwN2ZjZDQ1NGE5YzZiNDA1MjZiNGYwYzUzL3RhYmxlcmFuZ2U6ODMwMDg1ZDA3ZmNkNDU0YTljNmI0MDUyNmI0ZjBjNTNfMjItMS0xLTEtNDEyOTQ_ae00a327-f274-49f6-9107-f4372e837c25"
      unitRef="usd">47298000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="ib3597315a63d441f8f128abd7ed8840e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182Ny9mcmFnOmYzZTY4ZDllY2E0ODQ3ZDBhMTEzNmVlNGZlMzY4NGJlL3RhYmxlOjgzMDA4NWQwN2ZjZDQ1NGE5YzZiNDA1MjZiNGYwYzUzL3RhYmxlcmFuZ2U6ODMwMDg1ZDA3ZmNkNDU0YTljNmI0MDUyNmI0ZjBjNTNfMjItMy0xLTEtNDEyOTQ_a6e43256-897c-436b-8bed-b2fffccfc7ec"
      unitRef="usd">-10538000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="ie6c3b69702e9429aaeed46bdb9bbb9c1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182Ny9mcmFnOmYzZTY4ZDllY2E0ODQ3ZDBhMTEzNmVlNGZlMzY4NGJlL3RhYmxlOjgzMDA4NWQwN2ZjZDQ1NGE5YzZiNDA1MjZiNGYwYzUzL3RhYmxlcmFuZ2U6ODMwMDg1ZDA3ZmNkNDU0YTljNmI0MDUyNmI0ZjBjNTNfMjItNS0xLTEtNDEyOTQ_b06bda6b-7b9f-438b-8d55-de11f63e28f8"
      unitRef="usd">796639000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182Ny9mcmFnOmYzZTY4ZDllY2E0ODQ3ZDBhMTEzNmVlNGZlMzY4NGJlL3RhYmxlOjgzMDA4NWQwN2ZjZDQ1NGE5YzZiNDA1MjZiNGYwYzUzL3RhYmxlcmFuZ2U6ODMwMDg1ZDA3ZmNkNDU0YTljNmI0MDUyNmI0ZjBjNTNfMjMtMS0xLTEtNDEyOTQ_06c71c78-cab8-4f92-9695-925b8fe52094"
      unitRef="usd">-9840000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ib3597315a63d441f8f128abd7ed8840e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182Ny9mcmFnOmYzZTY4ZDllY2E0ODQ3ZDBhMTEzNmVlNGZlMzY4NGJlL3RhYmxlOjgzMDA4NWQwN2ZjZDQ1NGE5YzZiNDA1MjZiNGYwYzUzL3RhYmxlcmFuZ2U6ODMwMDg1ZDA3ZmNkNDU0YTljNmI0MDUyNmI0ZjBjNTNfMjMtMy0xLTEtNDEyOTQ_f26a49ad-4279-4706-8cc4-cc18f35b443b"
      unitRef="usd">-7553000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ie6c3b69702e9429aaeed46bdb9bbb9c1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182Ny9mcmFnOmYzZTY4ZDllY2E0ODQ3ZDBhMTEzNmVlNGZlMzY4NGJlL3RhYmxlOjgzMDA4NWQwN2ZjZDQ1NGE5YzZiNDA1MjZiNGYwYzUzL3RhYmxlcmFuZ2U6ODMwMDg1ZDA3ZmNkNDU0YTljNmI0MDUyNmI0ZjBjNTNfMjMtNS0xLTEtNDEyOTQ_c8fb2ac4-c049-4273-961e-b98a8fbdb5ae"
      unitRef="usd">167337000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182Ny9mcmFnOmYzZTY4ZDllY2E0ODQ3ZDBhMTEzNmVlNGZlMzY4NGJlL3RhYmxlOjgzMDA4NWQwN2ZjZDQ1NGE5YzZiNDA1MjZiNGYwYzUzL3RhYmxlcmFuZ2U6ODMwMDg1ZDA3ZmNkNDU0YTljNmI0MDUyNmI0ZjBjNTNfMjQtMS0xLTEtNDEyOTQ_4dc9fd1c-f6f2-4901-aeed-d03d6cfefb7b"
      unitRef="usd">57138000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ib3597315a63d441f8f128abd7ed8840e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182Ny9mcmFnOmYzZTY4ZDllY2E0ODQ3ZDBhMTEzNmVlNGZlMzY4NGJlL3RhYmxlOjgzMDA4NWQwN2ZjZDQ1NGE5YzZiNDA1MjZiNGYwYzUzL3RhYmxlcmFuZ2U6ODMwMDg1ZDA3ZmNkNDU0YTljNmI0MDUyNmI0ZjBjNTNfMjQtMy0xLTEtNDEyOTQ_10609f4a-ffdc-4113-b3a1-c1fefa42faed"
      unitRef="usd">-2985000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ie6c3b69702e9429aaeed46bdb9bbb9c1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182Ny9mcmFnOmYzZTY4ZDllY2E0ODQ3ZDBhMTEzNmVlNGZlMzY4NGJlL3RhYmxlOjgzMDA4NWQwN2ZjZDQ1NGE5YzZiNDA1MjZiNGYwYzUzL3RhYmxlcmFuZ2U6ODMwMDg1ZDA3ZmNkNDU0YTljNmI0MDUyNmI0ZjBjNTNfMjQtNS0xLTEtNDEyOTQ_1db6dbde-71aa-46e8-ac4d-fe0df760e843"
      unitRef="usd">629302000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182Ny9mcmFnOmYzZTY4ZDllY2E0ODQ3ZDBhMTEzNmVlNGZlMzY4NGJlL3RhYmxlOjgzMDA4NWQwN2ZjZDQ1NGE5YzZiNDA1MjZiNGYwYzUzL3RhYmxlcmFuZ2U6ODMwMDg1ZDA3ZmNkNDU0YTljNmI0MDUyNmI0ZjBjNTNfMjYtMS0xLTEtNDEyOTQ_a2617f02-b232-434f-b5fe-6a9f146eda4a"
      unitRef="usdPerShare">3.44</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="ib3597315a63d441f8f128abd7ed8840e_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182Ny9mcmFnOmYzZTY4ZDllY2E0ODQ3ZDBhMTEzNmVlNGZlMzY4NGJlL3RhYmxlOjgzMDA4NWQwN2ZjZDQ1NGE5YzZiNDA1MjZiNGYwYzUzL3RhYmxlcmFuZ2U6ODMwMDg1ZDA3ZmNkNDU0YTljNmI0MDUyNmI0ZjBjNTNfMjYtMy0xLTEtNDEyOTQ_7d2062b4-2762-46d1-9277-b631811b4b4c"
      unitRef="usdPerShare">-0.18</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="ie6c3b69702e9429aaeed46bdb9bbb9c1_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182Ny9mcmFnOmYzZTY4ZDllY2E0ODQ3ZDBhMTEzNmVlNGZlMzY4NGJlL3RhYmxlOjgzMDA4NWQwN2ZjZDQ1NGE5YzZiNDA1MjZiNGYwYzUzL3RhYmxlcmFuZ2U6ODMwMDg1ZDA3ZmNkNDU0YTljNmI0MDUyNmI0ZjBjNTNfMjYtNS0xLTEtNDEyOTQ_2c8dad24-c197-4ad1-be37-8c33e18c1070"
      unitRef="usdPerShare">33.13</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182Ny9mcmFnOmYzZTY4ZDllY2E0ODQ3ZDBhMTEzNmVlNGZlMzY4NGJlL3RhYmxlOjgzMDA4NWQwN2ZjZDQ1NGE5YzZiNDA1MjZiNGYwYzUzL3RhYmxlcmFuZ2U6ODMwMDg1ZDA3ZmNkNDU0YTljNmI0MDUyNmI0ZjBjNTNfMjctMS0xLTEtNDEyOTQ_caca7f72-8b5f-427b-a7ca-71787b5450c4"
      unitRef="shares">16630000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ib3597315a63d441f8f128abd7ed8840e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182Ny9mcmFnOmYzZTY4ZDllY2E0ODQ3ZDBhMTEzNmVlNGZlMzY4NGJlL3RhYmxlOjgzMDA4NWQwN2ZjZDQ1NGE5YzZiNDA1MjZiNGYwYzUzL3RhYmxlcmFuZ2U6ODMwMDg1ZDA3ZmNkNDU0YTljNmI0MDUyNmI0ZjBjNTNfMjctMy0xLTEtNDEyOTQ_22998466-7045-474a-bc30-74cf35d65c97"
      unitRef="shares">16185000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ie6c3b69702e9429aaeed46bdb9bbb9c1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182Ny9mcmFnOmYzZTY4ZDllY2E0ODQ3ZDBhMTEzNmVlNGZlMzY4NGJlL3RhYmxlOjgzMDA4NWQwN2ZjZDQ1NGE5YzZiNDA1MjZiNGYwYzUzL3RhYmxlcmFuZ2U6ODMwMDg1ZDA3ZmNkNDU0YTljNmI0MDUyNmI0ZjBjNTNfMjctNS0xLTEtNDEyOTQ_22659a1c-fcfd-43f6-bc9a-a948de365031"
      unitRef="shares">18995000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182Ny9mcmFnOmYzZTY4ZDllY2E0ODQ3ZDBhMTEzNmVlNGZlMzY4NGJlL3RhYmxlOjgzMDA4NWQwN2ZjZDQ1NGE5YzZiNDA1MjZiNGYwYzUzL3RhYmxlcmFuZ2U6ODMwMDg1ZDA3ZmNkNDU0YTljNmI0MDUyNmI0ZjBjNTNfMjktMS0xLTEtNDEyOTQ_e3b7f96b-fd73-477e-a2c9-9a8126a277b4"
      unitRef="usdPerShare">3.31</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ib3597315a63d441f8f128abd7ed8840e_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182Ny9mcmFnOmYzZTY4ZDllY2E0ODQ3ZDBhMTEzNmVlNGZlMzY4NGJlL3RhYmxlOjgzMDA4NWQwN2ZjZDQ1NGE5YzZiNDA1MjZiNGYwYzUzL3RhYmxlcmFuZ2U6ODMwMDg1ZDA3ZmNkNDU0YTljNmI0MDUyNmI0ZjBjNTNfMjktMy0xLTEtNDEyOTQ_6bc05ca2-6601-471e-8903-189ce16cd038"
      unitRef="usdPerShare">-0.18</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ie6c3b69702e9429aaeed46bdb9bbb9c1_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182Ny9mcmFnOmYzZTY4ZDllY2E0ODQ3ZDBhMTEzNmVlNGZlMzY4NGJlL3RhYmxlOjgzMDA4NWQwN2ZjZDQ1NGE5YzZiNDA1MjZiNGYwYzUzL3RhYmxlcmFuZ2U6ODMwMDg1ZDA3ZmNkNDU0YTljNmI0MDUyNmI0ZjBjNTNfMjktNS0xLTEtNDEyOTQ_d3d6fffa-6207-4a11-a378-4bdd4933c5b4"
      unitRef="usdPerShare">31.85</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182Ny9mcmFnOmYzZTY4ZDllY2E0ODQ3ZDBhMTEzNmVlNGZlMzY4NGJlL3RhYmxlOjgzMDA4NWQwN2ZjZDQ1NGE5YzZiNDA1MjZiNGYwYzUzL3RhYmxlcmFuZ2U6ODMwMDg1ZDA3ZmNkNDU0YTljNmI0MDUyNmI0ZjBjNTNfMzAtMS0xLTEtNDEyOTQ_e73a0511-dd4e-4146-8b1f-923c97c95577"
      unitRef="shares">17246000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ib3597315a63d441f8f128abd7ed8840e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182Ny9mcmFnOmYzZTY4ZDllY2E0ODQ3ZDBhMTEzNmVlNGZlMzY4NGJlL3RhYmxlOjgzMDA4NWQwN2ZjZDQ1NGE5YzZiNDA1MjZiNGYwYzUzL3RhYmxlcmFuZ2U6ODMwMDg1ZDA3ZmNkNDU0YTljNmI0MDUyNmI0ZjBjNTNfMzAtMy0xLTEtNDEyOTQ_d71ac87d-0d11-4161-8e79-4ac651f096c2"
      unitRef="shares">16185000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ie6c3b69702e9429aaeed46bdb9bbb9c1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY182Ny9mcmFnOmYzZTY4ZDllY2E0ODQ3ZDBhMTEzNmVlNGZlMzY4NGJlL3RhYmxlOjgzMDA4NWQwN2ZjZDQ1NGE5YzZiNDA1MjZiNGYwYzUzL3RhYmxlcmFuZ2U6ODMwMDg1ZDA3ZmNkNDU0YTljNmI0MDUyNmI0ZjBjNTNfMzAtNS0xLTEtNDEyOTQ_53dbaebd-61d7-4e41-9e26-a5d546898a50"
      unitRef="shares">19757000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:NetIncomeLoss
      contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183MC9mcmFnOmE0MzI4NjZjNWM2MTRhMTc4NGQxY2RlZDAzNTdiNzc1L3RhYmxlOmEyZGRiMjFlMzQyZDRmN2JiZjYxNDZjYWY0ODY5YzExL3RhYmxlcmFuZ2U6YTJkZGIyMWUzNDJkNGY3YmJmNjE0NmNhZjQ4NjljMTFfMi0xLTEtMS00MTI5NA_1ae7905c-6172-4df9-8a26-620635358555"
      unitRef="usd">57138000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ib3597315a63d441f8f128abd7ed8840e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183MC9mcmFnOmE0MzI4NjZjNWM2MTRhMTc4NGQxY2RlZDAzNTdiNzc1L3RhYmxlOmEyZGRiMjFlMzQyZDRmN2JiZjYxNDZjYWY0ODY5YzExL3RhYmxlcmFuZ2U6YTJkZGIyMWUzNDJkNGY3YmJmNjE0NmNhZjQ4NjljMTFfMi0zLTEtMS00MTI5NA_03a602b2-6f37-4e22-b06a-30d94de11bb8"
      unitRef="usd">-2985000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ie6c3b69702e9429aaeed46bdb9bbb9c1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183MC9mcmFnOmE0MzI4NjZjNWM2MTRhMTc4NGQxY2RlZDAzNTdiNzc1L3RhYmxlOmEyZGRiMjFlMzQyZDRmN2JiZjYxNDZjYWY0ODY5YzExL3RhYmxlcmFuZ2U6YTJkZGIyMWUzNDJkNGY3YmJmNjE0NmNhZjQ4NjljMTFfMi01LTEtMS00MTI5NA_393f8fd2-9373-4162-9f31-d342ad1e7c0d"
      unitRef="usd">629302000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183MC9mcmFnOmE0MzI4NjZjNWM2MTRhMTc4NGQxY2RlZDAzNTdiNzc1L3RhYmxlOmEyZGRiMjFlMzQyZDRmN2JiZjYxNDZjYWY0ODY5YzExL3RhYmxlcmFuZ2U6YTJkZGIyMWUzNDJkNGY3YmJmNjE0NmNhZjQ4NjljMTFfMy0xLTEtMS00MTI5NA_4213fae2-a915-434f-8d4a-4d276721a775"
      unitRef="usd">-116000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="ib3597315a63d441f8f128abd7ed8840e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183MC9mcmFnOmE0MzI4NjZjNWM2MTRhMTc4NGQxY2RlZDAzNTdiNzc1L3RhYmxlOmEyZGRiMjFlMzQyZDRmN2JiZjYxNDZjYWY0ODY5YzExL3RhYmxlcmFuZ2U6YTJkZGIyMWUzNDJkNGY3YmJmNjE0NmNhZjQ4NjljMTFfMy0zLTEtMS00MTI5NA_554f4880-a1e0-49e9-a713-90829a0fa1a7"
      unitRef="usd">-162000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="ie6c3b69702e9429aaeed46bdb9bbb9c1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183MC9mcmFnOmE0MzI4NjZjNWM2MTRhMTc4NGQxY2RlZDAzNTdiNzc1L3RhYmxlOmEyZGRiMjFlMzQyZDRmN2JiZjYxNDZjYWY0ODY5YzExL3RhYmxlcmFuZ2U6YTJkZGIyMWUzNDJkNGY3YmJmNjE0NmNhZjQ4NjljMTFfMy01LTEtMS00MTI5NA_a4ede031-ec83-483d-afbc-9397862dd7d5"
      unitRef="usd">200000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183MC9mcmFnOmE0MzI4NjZjNWM2MTRhMTc4NGQxY2RlZDAzNTdiNzc1L3RhYmxlOmEyZGRiMjFlMzQyZDRmN2JiZjYxNDZjYWY0ODY5YzExL3RhYmxlcmFuZ2U6YTJkZGIyMWUzNDJkNGY3YmJmNjE0NmNhZjQ4NjljMTFfNC0xLTEtMS00MTI5NA_446d64a0-cf54-41c6-948c-800e43a8496d"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="ib3597315a63d441f8f128abd7ed8840e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183MC9mcmFnOmE0MzI4NjZjNWM2MTRhMTc4NGQxY2RlZDAzNTdiNzc1L3RhYmxlOmEyZGRiMjFlMzQyZDRmN2JiZjYxNDZjYWY0ODY5YzExL3RhYmxlcmFuZ2U6YTJkZGIyMWUzNDJkNGY3YmJmNjE0NmNhZjQ4NjljMTFfNC0zLTEtMS00MTI5NA_1930c930-4757-450c-9927-4552c5456aba"
      unitRef="usd">-423000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="ie6c3b69702e9429aaeed46bdb9bbb9c1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183MC9mcmFnOmE0MzI4NjZjNWM2MTRhMTc4NGQxY2RlZDAzNTdiNzc1L3RhYmxlOmEyZGRiMjFlMzQyZDRmN2JiZjYxNDZjYWY0ODY5YzExL3RhYmxlcmFuZ2U6YTJkZGIyMWUzNDJkNGY3YmJmNjE0NmNhZjQ4NjljMTFfNC01LTEtMS00MTI5NA_509a4a0d-d7cd-440a-8294-c8c7e92895fe"
      unitRef="usd">608000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183MC9mcmFnOmE0MzI4NjZjNWM2MTRhMTc4NGQxY2RlZDAzNTdiNzc1L3RhYmxlOmEyZGRiMjFlMzQyZDRmN2JiZjYxNDZjYWY0ODY5YzExL3RhYmxlcmFuZ2U6YTJkZGIyMWUzNDJkNGY3YmJmNjE0NmNhZjQ4NjljMTFfNS0xLTEtMS00MTI5NA_d5dc3e4c-8177-45bf-9a88-f297f5d4ece7"
      unitRef="usd">57022000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="ib3597315a63d441f8f128abd7ed8840e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183MC9mcmFnOmE0MzI4NjZjNWM2MTRhMTc4NGQxY2RlZDAzNTdiNzc1L3RhYmxlOmEyZGRiMjFlMzQyZDRmN2JiZjYxNDZjYWY0ODY5YzExL3RhYmxlcmFuZ2U6YTJkZGIyMWUzNDJkNGY3YmJmNjE0NmNhZjQ4NjljMTFfNS0zLTEtMS00MTI5NA_adae0b15-6dd4-446d-8e0c-048d64ef5c83"
      unitRef="usd">-3570000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="ie6c3b69702e9429aaeed46bdb9bbb9c1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183MC9mcmFnOmE0MzI4NjZjNWM2MTRhMTc4NGQxY2RlZDAzNTdiNzc1L3RhYmxlOmEyZGRiMjFlMzQyZDRmN2JiZjYxNDZjYWY0ODY5YzExL3RhYmxlcmFuZ2U6YTJkZGIyMWUzNDJkNGY3YmJmNjE0NmNhZjQ4NjljMTFfNS01LTEtMS00MTI5NA_20bf0a3e-274f-453e-89ab-eba6072e2d7e"
      unitRef="usd">630110000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="id0ff3295defe46b8bccc6c795953b0dd_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183My9mcmFnOmQzNzc2MmZiMDI0ZDRjNWE5MjMxODNkNmUxMTdjM2Q1L3RhYmxlOjU2ZjRlNzRkOTUxZDRhM2NiNDRhMzVjOGM0OWFmN2M0L3RhYmxlcmFuZ2U6NTZmNGU3NGQ5NTFkNGEzY2I0NGEzNWM4YzQ5YWY3YzRfMi0xLTEtMS00MTI5NA_a36e5dd9-e5a1-46f1-bf58-6a779971e0ad"
      unitRef="shares">20766000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="id0ff3295defe46b8bccc6c795953b0dd_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183My9mcmFnOmQzNzc2MmZiMDI0ZDRjNWE5MjMxODNkNmUxMTdjM2Q1L3RhYmxlOjU2ZjRlNzRkOTUxZDRhM2NiNDRhMzVjOGM0OWFmN2M0L3RhYmxlcmFuZ2U6NTZmNGU3NGQ5NTFkNGEzY2I0NGEzNWM4YzQ5YWY3YzRfMi0zLTEtMS00MTI5NA_8064504c-65e6-4f92-bd2e-399b13ad8a51"
      unitRef="usd">21000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ie8198f30811b402385fed871033fac83_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183My9mcmFnOmQzNzc2MmZiMDI0ZDRjNWE5MjMxODNkNmUxMTdjM2Q1L3RhYmxlOjU2ZjRlNzRkOTUxZDRhM2NiNDRhMzVjOGM0OWFmN2M0L3RhYmxlcmFuZ2U6NTZmNGU3NGQ5NTFkNGEzY2I0NGEzNWM4YzQ5YWY3YzRfMi01LTEtMS00MTI5NA_e1ff62db-c90c-4c92-a5b5-685167ad407b"
      unitRef="usd">791114000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i24530d11bf3d4226b1bfc80e52009811_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183My9mcmFnOmQzNzc2MmZiMDI0ZDRjNWE5MjMxODNkNmUxMTdjM2Q1L3RhYmxlOjU2ZjRlNzRkOTUxZDRhM2NiNDRhMzVjOGM0OWFmN2M0L3RhYmxlcmFuZ2U6NTZmNGU3NGQ5NTFkNGEzY2I0NGEzNWM4YzQ5YWY3YzRfMi03LTEtMS00MTI5NA_013f39f5-40bf-4ce6-b1a0-d06d9f0c597a"
      unitRef="usd">-1024000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i2157f3f9f915470d94164dbf83569db0_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183My9mcmFnOmQzNzc2MmZiMDI0ZDRjNWE5MjMxODNkNmUxMTdjM2Q1L3RhYmxlOjU2ZjRlNzRkOTUxZDRhM2NiNDRhMzVjOGM0OWFmN2M0L3RhYmxlcmFuZ2U6NTZmNGU3NGQ5NTFkNGEzY2I0NGEzNWM4YzQ5YWY3YzRfMi05LTEtMS00MTI5NA_be278b9c-4bb2-423c-9119-f53c4a6bb76c"
      unitRef="usd">-229197000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="if1aac4d81ad94163b33117197afe0895_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183My9mcmFnOmQzNzc2MmZiMDI0ZDRjNWE5MjMxODNkNmUxMTdjM2Q1L3RhYmxlOjU2ZjRlNzRkOTUxZDRhM2NiNDRhMzVjOGM0OWFmN2M0L3RhYmxlcmFuZ2U6NTZmNGU3NGQ5NTFkNGEzY2I0NGEzNWM4YzQ5YWY3YzRfMi0xMi0xLTEtNDEyOTQ_6283ab08-cddc-4e3c-b7f3-0d0265aea8fc"
      unitRef="usd">560914000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="iba40247e0e614545939d340c24ba1378_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183My9mcmFnOmQzNzc2MmZiMDI0ZDRjNWE5MjMxODNkNmUxMTdjM2Q1L3RhYmxlOjU2ZjRlNzRkOTUxZDRhM2NiNDRhMzVjOGM0OWFmN2M0L3RhYmxlcmFuZ2U6NTZmNGU3NGQ5NTFkNGEzY2I0NGEzNWM4YzQ5YWY3YzRfMy0xLTEtMS00MTI5NA_adc821ab-695b-467d-920d-bd73cc96c970"
      unitRef="shares">180000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ia8c2096f420a462b813274a320529a34_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183My9mcmFnOmQzNzc2MmZiMDI0ZDRjNWE5MjMxODNkNmUxMTdjM2Q1L3RhYmxlOjU2ZjRlNzRkOTUxZDRhM2NiNDRhMzVjOGM0OWFmN2M0L3RhYmxlcmFuZ2U6NTZmNGU3NGQ5NTFkNGEzY2I0NGEzNWM4YzQ5YWY3YzRfMy01LTEtMS00MTI5NA_52e8cb9a-dc82-4815-9825-9f4d1f7356db"
      unitRef="usd">-1421000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ie6c3b69702e9429aaeed46bdb9bbb9c1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183My9mcmFnOmQzNzc2MmZiMDI0ZDRjNWE5MjMxODNkNmUxMTdjM2Q1L3RhYmxlOjU2ZjRlNzRkOTUxZDRhM2NiNDRhMzVjOGM0OWFmN2M0L3RhYmxlcmFuZ2U6NTZmNGU3NGQ5NTFkNGEzY2I0NGEzNWM4YzQ5YWY3YzRfMy0xMi0xLTEtNDEyOTQ_1baefca0-5011-4579-a039-45c79bd53118"
      unitRef="usd">-1421000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ia8c2096f420a462b813274a320529a34_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183My9mcmFnOmQzNzc2MmZiMDI0ZDRjNWE5MjMxODNkNmUxMTdjM2Q1L3RhYmxlOjU2ZjRlNzRkOTUxZDRhM2NiNDRhMzVjOGM0OWFmN2M0L3RhYmxlcmFuZ2U6NTZmNGU3NGQ5NTFkNGEzY2I0NGEzNWM4YzQ5YWY3YzRfNC01LTEtMS00MTI5NA_d9d4db7f-d4cc-4ea5-a965-6e158ca5552f"
      unitRef="usd">24515000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ie6c3b69702e9429aaeed46bdb9bbb9c1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183My9mcmFnOmQzNzc2MmZiMDI0ZDRjNWE5MjMxODNkNmUxMTdjM2Q1L3RhYmxlOjU2ZjRlNzRkOTUxZDRhM2NiNDRhMzVjOGM0OWFmN2M0L3RhYmxlcmFuZ2U6NTZmNGU3NGQ5NTFkNGEzY2I0NGEzNWM4YzQ5YWY3YzRfNC0xMi0xLTEtNDEyOTQ_26f94dc0-57bf-411d-9641-a64a706db672"
      unitRef="usd">24515000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="iba40247e0e614545939d340c24ba1378_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183My9mcmFnOmQzNzc2MmZiMDI0ZDRjNWE5MjMxODNkNmUxMTdjM2Q1L3RhYmxlOjU2ZjRlNzRkOTUxZDRhM2NiNDRhMzVjOGM0OWFmN2M0L3RhYmxlcmFuZ2U6NTZmNGU3NGQ5NTFkNGEzY2I0NGEzNWM4YzQ5YWY3YzRfNS0xLTEtMS00ODEzMg_937dad95-d39b-466a-8f24-165affd88fec"
      unitRef="shares">4122000</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="iba40247e0e614545939d340c24ba1378_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183My9mcmFnOmQzNzc2MmZiMDI0ZDRjNWE5MjMxODNkNmUxMTdjM2Q1L3RhYmxlOjU2ZjRlNzRkOTUxZDRhM2NiNDRhMzVjOGM0OWFmN2M0L3RhYmxlcmFuZ2U6NTZmNGU3NGQ5NTFkNGEzY2I0NGEzNWM4YzQ5YWY3YzRfNS0zLTEtMS00ODEzMg_b6cdc7a7-191b-4734-8754-a6ef398ba93f"
      unitRef="usd">4000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="ia8c2096f420a462b813274a320529a34_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183My9mcmFnOmQzNzc2MmZiMDI0ZDRjNWE5MjMxODNkNmUxMTdjM2Q1L3RhYmxlOjU2ZjRlNzRkOTUxZDRhM2NiNDRhMzVjOGM0OWFmN2M0L3RhYmxlcmFuZ2U6NTZmNGU3NGQ5NTFkNGEzY2I0NGEzNWM4YzQ5YWY3YzRfNS01LTEtMS00MTI5NA_d0bb7969-9722-46f9-b1ec-039ca0f96b28"
      unitRef="usd">448429000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="ie6c3b69702e9429aaeed46bdb9bbb9c1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183My9mcmFnOmQzNzc2MmZiMDI0ZDRjNWE5MjMxODNkNmUxMTdjM2Q1L3RhYmxlOjU2ZjRlNzRkOTUxZDRhM2NiNDRhMzVjOGM0OWFmN2M0L3RhYmxlcmFuZ2U6NTZmNGU3NGQ5NTFkNGEzY2I0NGEzNWM4YzQ5YWY3YzRfNS0xMi0xLTEtNDEyOTQ_f0e97b6f-e29a-479e-b17c-67094c95f46a"
      unitRef="usd">448433000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss
      contextRef="i11614604a0e24aa78e71eb02f9b1c21d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183My9mcmFnOmQzNzc2MmZiMDI0ZDRjNWE5MjMxODNkNmUxMTdjM2Q1L3RhYmxlOjU2ZjRlNzRkOTUxZDRhM2NiNDRhMzVjOGM0OWFmN2M0L3RhYmxlcmFuZ2U6NTZmNGU3NGQ5NTFkNGEzY2I0NGEzNWM4YzQ5YWY3YzRfNi03LTEtMS00ODEzMg_779bbc30-0171-4f98-90a6-a5ca7e5cd90c"
      unitRef="usd">200000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss
      contextRef="ie6c3b69702e9429aaeed46bdb9bbb9c1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183My9mcmFnOmQzNzc2MmZiMDI0ZDRjNWE5MjMxODNkNmUxMTdjM2Q1L3RhYmxlOjU2ZjRlNzRkOTUxZDRhM2NiNDRhMzVjOGM0OWFmN2M0L3RhYmxlcmFuZ2U6NTZmNGU3NGQ5NTFkNGEzY2I0NGEzNWM4YzQ5YWY3YzRfNi0xMi0xLTEtNDEyOTQ_5fe83389-2136-4951-a219-032f07c2b368"
      unitRef="usd">200000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i11614604a0e24aa78e71eb02f9b1c21d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183My9mcmFnOmQzNzc2MmZiMDI0ZDRjNWE5MjMxODNkNmUxMTdjM2Q1L3RhYmxlOjU2ZjRlNzRkOTUxZDRhM2NiNDRhMzVjOGM0OWFmN2M0L3RhYmxlcmFuZ2U6NTZmNGU3NGQ5NTFkNGEzY2I0NGEzNWM4YzQ5YWY3YzRfNy03LTEtMS00MTI5NA_9a4ae3e3-2925-40ec-9223-19a1e128b9c7"
      unitRef="usd">608000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="ie6c3b69702e9429aaeed46bdb9bbb9c1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183My9mcmFnOmQzNzc2MmZiMDI0ZDRjNWE5MjMxODNkNmUxMTdjM2Q1L3RhYmxlOjU2ZjRlNzRkOTUxZDRhM2NiNDRhMzVjOGM0OWFmN2M0L3RhYmxlcmFuZ2U6NTZmNGU3NGQ5NTFkNGEzY2I0NGEzNWM4YzQ5YWY3YzRfNy0xMi0xLTEtNDEyOTQ_6bcb7a85-9f86-4a5d-8d66-660053b7fd7b"
      unitRef="usd">608000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther
      contextRef="ia8c2096f420a462b813274a320529a34_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183My9mcmFnOmQzNzc2MmZiMDI0ZDRjNWE5MjMxODNkNmUxMTdjM2Q1L3RhYmxlOjU2ZjRlNzRkOTUxZDRhM2NiNDRhMzVjOGM0OWFmN2M0L3RhYmxlcmFuZ2U6NTZmNGU3NGQ5NTFkNGEzY2I0NGEzNWM4YzQ5YWY3YzRfOC01LTEtMS00ODEzMg_e1b2096f-d6fb-4ed9-a243-6fd3a32a8311"
      unitRef="usd">1547000</us-gaap:AdjustmentsToAdditionalPaidInCapitalOther>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther
      contextRef="ie6c3b69702e9429aaeed46bdb9bbb9c1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183My9mcmFnOmQzNzc2MmZiMDI0ZDRjNWE5MjMxODNkNmUxMTdjM2Q1L3RhYmxlOjU2ZjRlNzRkOTUxZDRhM2NiNDRhMzVjOGM0OWFmN2M0L3RhYmxlcmFuZ2U6NTZmNGU3NGQ5NTFkNGEzY2I0NGEzNWM4YzQ5YWY3YzRfOC0xMi0xLTEtNDEyOTQ_9b40a5bd-ed61-4100-af4b-1309ad9f026b"
      unitRef="usd">1547000</us-gaap:AdjustmentsToAdditionalPaidInCapitalOther>
    <us-gaap:NetIncomeLoss
      contextRef="id787fbb79cf94df2b867ff01039dd7ee_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183My9mcmFnOmQzNzc2MmZiMDI0ZDRjNWE5MjMxODNkNmUxMTdjM2Q1L3RhYmxlOjU2ZjRlNzRkOTUxZDRhM2NiNDRhMzVjOGM0OWFmN2M0L3RhYmxlcmFuZ2U6NTZmNGU3NGQ5NTFkNGEzY2I0NGEzNWM4YzQ5YWY3YzRfOS05LTEtMS00MTI5NA_32fdc158-ac16-4430-b842-f404bb7ccc0c"
      unitRef="usd">629302000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ie6c3b69702e9429aaeed46bdb9bbb9c1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183My9mcmFnOmQzNzc2MmZiMDI0ZDRjNWE5MjMxODNkNmUxMTdjM2Q1L3RhYmxlOjU2ZjRlNzRkOTUxZDRhM2NiNDRhMzVjOGM0OWFmN2M0L3RhYmxlcmFuZ2U6NTZmNGU3NGQ5NTFkNGEzY2I0NGEzNWM4YzQ5YWY3YzRfOS0xMi0xLTEtNDEyOTQ_5dcb07af-5580-46df-8b38-c40992506477"
      unitRef="usd">629302000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="i91bf098d468945ce94255ad9187b03e5_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183My9mcmFnOmQzNzc2MmZiMDI0ZDRjNWE5MjMxODNkNmUxMTdjM2Q1L3RhYmxlOjU2ZjRlNzRkOTUxZDRhM2NiNDRhMzVjOGM0OWFmN2M0L3RhYmxlcmFuZ2U6NTZmNGU3NGQ5NTFkNGEzY2I0NGEzNWM4YzQ5YWY3YzRfMTAtMS0xLTEtNDg1NzA_e77103f8-d0fb-45a3-8465-2349d90636d5"
      unitRef="shares">16824000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i91bf098d468945ce94255ad9187b03e5_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183My9mcmFnOmQzNzc2MmZiMDI0ZDRjNWE5MjMxODNkNmUxMTdjM2Q1L3RhYmxlOjU2ZjRlNzRkOTUxZDRhM2NiNDRhMzVjOGM0OWFmN2M0L3RhYmxlcmFuZ2U6NTZmNGU3NGQ5NTFkNGEzY2I0NGEzNWM4YzQ5YWY3YzRfMTAtMy0xLTEtNDg1NzA_72b5f036-60a5-4913-8e20-b368ea5a4d80"
      unitRef="usd">17000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ib5f40ec88b5f46f8a400c8577e872e35_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183My9mcmFnOmQzNzc2MmZiMDI0ZDRjNWE5MjMxODNkNmUxMTdjM2Q1L3RhYmxlOjU2ZjRlNzRkOTUxZDRhM2NiNDRhMzVjOGM0OWFmN2M0L3RhYmxlcmFuZ2U6NTZmNGU3NGQ5NTFkNGEzY2I0NGEzNWM4YzQ5YWY3YzRfMTAtNS0xLTEtNDEyOTQ_7e5b10b0-5800-4e2a-bf1f-68195ab6a88f"
      unitRef="usd">367326000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i32ab127ed5c44358939fcb7eab76b6a6_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183My9mcmFnOmQzNzc2MmZiMDI0ZDRjNWE5MjMxODNkNmUxMTdjM2Q1L3RhYmxlOjU2ZjRlNzRkOTUxZDRhM2NiNDRhMzVjOGM0OWFmN2M0L3RhYmxlcmFuZ2U6NTZmNGU3NGQ5NTFkNGEzY2I0NGEzNWM4YzQ5YWY3YzRfMTAtNy0xLTEtNDg1NzA_7b8904a8-e501-41f6-9206-43d01f2d46de"
      unitRef="usd">-216000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="iaa27b23fe5ac43dab25e6b1f5344211e_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183My9mcmFnOmQzNzc2MmZiMDI0ZDRjNWE5MjMxODNkNmUxMTdjM2Q1L3RhYmxlOjU2ZjRlNzRkOTUxZDRhM2NiNDRhMzVjOGM0OWFmN2M0L3RhYmxlcmFuZ2U6NTZmNGU3NGQ5NTFkNGEzY2I0NGEzNWM4YzQ5YWY3YzRfMTAtOS0xLTEtNDgxNzQ_08549454-4d54-4653-83ba-920a13ea26e5"
      unitRef="usd">400105000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ida3ec05a32644c2db1bb9f71f76c567f_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183My9mcmFnOmQzNzc2MmZiMDI0ZDRjNWE5MjMxODNkNmUxMTdjM2Q1L3RhYmxlOjU2ZjRlNzRkOTUxZDRhM2NiNDRhMzVjOGM0OWFmN2M0L3RhYmxlcmFuZ2U6NTZmNGU3NGQ5NTFkNGEzY2I0NGEzNWM4YzQ5YWY3YzRfMTAtMTItMS0xLTQxMjk0_d71ee157-f882-4bf1-9dfc-5e948aaa157c"
      unitRef="usd">767232000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="ibb59da98705b4964a37154673c8ed2be_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183My9mcmFnOmQzNzc2MmZiMDI0ZDRjNWE5MjMxODNkNmUxMTdjM2Q1L3RhYmxlOjU2ZjRlNzRkOTUxZDRhM2NiNDRhMzVjOGM0OWFmN2M0L3RhYmxlcmFuZ2U6NTZmNGU3NGQ5NTFkNGEzY2I0NGEzNWM4YzQ5YWY3YzRfMTEtMS0xLTEtNDg1Nzk_87c37481-61e8-4b98-a4ba-7025528e8371"
      unitRef="shares">190000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i7e24f17963584a8a8d751afa02b1b0c9_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183My9mcmFnOmQzNzc2MmZiMDI0ZDRjNWE5MjMxODNkNmUxMTdjM2Q1L3RhYmxlOjU2ZjRlNzRkOTUxZDRhM2NiNDRhMzVjOGM0OWFmN2M0L3RhYmxlcmFuZ2U6NTZmNGU3NGQ5NTFkNGEzY2I0NGEzNWM4YzQ5YWY3YzRfMTEtNS0xLTEtNDEyOTQ_722ef89a-f932-4aa6-84c8-d1e0a371dac1"
      unitRef="usd">1535000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ib3597315a63d441f8f128abd7ed8840e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183My9mcmFnOmQzNzc2MmZiMDI0ZDRjNWE5MjMxODNkNmUxMTdjM2Q1L3RhYmxlOjU2ZjRlNzRkOTUxZDRhM2NiNDRhMzVjOGM0OWFmN2M0L3RhYmxlcmFuZ2U6NTZmNGU3NGQ5NTFkNGEzY2I0NGEzNWM4YzQ5YWY3YzRfMTEtMTItMS0xLTQxMjk0_7894d72a-00f6-41dd-b694-c260f0a85aad"
      unitRef="usd">1535000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i7e24f17963584a8a8d751afa02b1b0c9_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183My9mcmFnOmQzNzc2MmZiMDI0ZDRjNWE5MjMxODNkNmUxMTdjM2Q1L3RhYmxlOjU2ZjRlNzRkOTUxZDRhM2NiNDRhMzVjOGM0OWFmN2M0L3RhYmxlcmFuZ2U6NTZmNGU3NGQ5NTFkNGEzY2I0NGEzNWM4YzQ5YWY3YzRfMTItNS0xLTEtNDEyOTQ_36cd7be2-9867-4c64-8767-966263952851"
      unitRef="usd">30727000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ib3597315a63d441f8f128abd7ed8840e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183My9mcmFnOmQzNzc2MmZiMDI0ZDRjNWE5MjMxODNkNmUxMTdjM2Q1L3RhYmxlOjU2ZjRlNzRkOTUxZDRhM2NiNDRhMzVjOGM0OWFmN2M0L3RhYmxlcmFuZ2U6NTZmNGU3NGQ5NTFkNGEzY2I0NGEzNWM4YzQ5YWY3YzRfMTItMTItMS0xLTQxMjk0_ee6468fc-b807-4d7f-bc99-41462dcc5d8a"
      unitRef="usd">30727000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="ibb59da98705b4964a37154673c8ed2be_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183My9mcmFnOmQzNzc2MmZiMDI0ZDRjNWE5MjMxODNkNmUxMTdjM2Q1L3RhYmxlOjU2ZjRlNzRkOTUxZDRhM2NiNDRhMzVjOGM0OWFmN2M0L3RhYmxlcmFuZ2U6NTZmNGU3NGQ5NTFkNGEzY2I0NGEzNWM4YzQ5YWY3YzRfMTMtMS0xLTEtNDg1OTk_f561c9b6-73ec-47d0-9865-e0471f4169fe"
      unitRef="shares">934000</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="ibb59da98705b4964a37154673c8ed2be_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183My9mcmFnOmQzNzc2MmZiMDI0ZDRjNWE5MjMxODNkNmUxMTdjM2Q1L3RhYmxlOjU2ZjRlNzRkOTUxZDRhM2NiNDRhMzVjOGM0OWFmN2M0L3RhYmxlcmFuZ2U6NTZmNGU3NGQ5NTFkNGEzY2I0NGEzNWM4YzQ5YWY3YzRfMTMtMy0xLTEtNDg2MDI_5562435d-9d49-4e14-9a55-51b5c8c6957f"
      unitRef="usd">1000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="i7e24f17963584a8a8d751afa02b1b0c9_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183My9mcmFnOmQzNzc2MmZiMDI0ZDRjNWE5MjMxODNkNmUxMTdjM2Q1L3RhYmxlOjU2ZjRlNzRkOTUxZDRhM2NiNDRhMzVjOGM0OWFmN2M0L3RhYmxlcmFuZ2U6NTZmNGU3NGQ5NTFkNGEzY2I0NGEzNWM4YzQ5YWY3YzRfMTMtNS0xLTEtNDEyOTQ_68b018b5-6fd1-4eaa-b3ba-e519138e5f65"
      unitRef="usd">77997000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="ib3597315a63d441f8f128abd7ed8840e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183My9mcmFnOmQzNzc2MmZiMDI0ZDRjNWE5MjMxODNkNmUxMTdjM2Q1L3RhYmxlOjU2ZjRlNzRkOTUxZDRhM2NiNDRhMzVjOGM0OWFmN2M0L3RhYmxlcmFuZ2U6NTZmNGU3NGQ5NTFkNGEzY2I0NGEzNWM4YzQ5YWY3YzRfMTMtMTItMS0xLTQxMjk0_12a9493e-9c3c-44a9-8420-220f254543ed"
      unitRef="usd">77998000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss
      contextRef="ia7e3cc749ec443c7b6a42c35ebdbd292_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183My9mcmFnOmQzNzc2MmZiMDI0ZDRjNWE5MjMxODNkNmUxMTdjM2Q1L3RhYmxlOjU2ZjRlNzRkOTUxZDRhM2NiNDRhMzVjOGM0OWFmN2M0L3RhYmxlcmFuZ2U6NTZmNGU3NGQ5NTFkNGEzY2I0NGEzNWM4YzQ5YWY3YzRfMTQtNy0xLTEtNDg2MTA_56e115f9-8182-430b-bb86-17f5324b0d5b"
      unitRef="usd">-162000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss
      contextRef="ib3597315a63d441f8f128abd7ed8840e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183My9mcmFnOmQzNzc2MmZiMDI0ZDRjNWE5MjMxODNkNmUxMTdjM2Q1L3RhYmxlOjU2ZjRlNzRkOTUxZDRhM2NiNDRhMzVjOGM0OWFmN2M0L3RhYmxlcmFuZ2U6NTZmNGU3NGQ5NTFkNGEzY2I0NGEzNWM4YzQ5YWY3YzRfMTQtMTItMS0xLTQxMjk0_2ebd443f-56e2-437c-a3bf-2529e6257092"
      unitRef="usd">-162000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="ia7e3cc749ec443c7b6a42c35ebdbd292_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183My9mcmFnOmQzNzc2MmZiMDI0ZDRjNWE5MjMxODNkNmUxMTdjM2Q1L3RhYmxlOjU2ZjRlNzRkOTUxZDRhM2NiNDRhMzVjOGM0OWFmN2M0L3RhYmxlcmFuZ2U6NTZmNGU3NGQ5NTFkNGEzY2I0NGEzNWM4YzQ5YWY3YzRfMTUtNy0xLTEtNDg2MTM_629022e9-a6ea-42e7-b37e-6a9e8fee4bb4"
      unitRef="usd">-423000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="ib3597315a63d441f8f128abd7ed8840e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183My9mcmFnOmQzNzc2MmZiMDI0ZDRjNWE5MjMxODNkNmUxMTdjM2Q1L3RhYmxlOjU2ZjRlNzRkOTUxZDRhM2NiNDRhMzVjOGM0OWFmN2M0L3RhYmxlcmFuZ2U6NTZmNGU3NGQ5NTFkNGEzY2I0NGEzNWM4YzQ5YWY3YzRfMTUtMTItMS0xLTQxMjk0_a0eca2c4-faaa-409a-8daf-3c534ebdc108"
      unitRef="usd">-423000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt
      contextRef="i7e24f17963584a8a8d751afa02b1b0c9_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183My9mcmFnOmQzNzc2MmZiMDI0ZDRjNWE5MjMxODNkNmUxMTdjM2Q1L3RhYmxlOjU2ZjRlNzRkOTUxZDRhM2NiNDRhMzVjOGM0OWFmN2M0L3RhYmxlcmFuZ2U6NTZmNGU3NGQ5NTFkNGEzY2I0NGEzNWM4YzQ5YWY3YzRfMTYtNS0xLTEtNDEyOTQ_3192bc6e-b397-4dcf-8129-ba71604c84bc"
      unitRef="usd">-3236000</us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt
      contextRef="ib3597315a63d441f8f128abd7ed8840e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183My9mcmFnOmQzNzc2MmZiMDI0ZDRjNWE5MjMxODNkNmUxMTdjM2Q1L3RhYmxlOjU2ZjRlNzRkOTUxZDRhM2NiNDRhMzVjOGM0OWFmN2M0L3RhYmxlcmFuZ2U6NTZmNGU3NGQ5NTFkNGEzY2I0NGEzNWM4YzQ5YWY3YzRfMTYtMTItMS0xLTQxMjk0_652d61c3-9a15-4f74-b873-e3baa148c2e0"
      unitRef="usd">-3236000</us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt>
    <us-gaap:StockholdersEquity
      contextRef="ibd8ac2d6daad403e8a1f73426f5256a2_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183My9mcmFnOmQzNzc2MmZiMDI0ZDRjNWE5MjMxODNkNmUxMTdjM2Q1L3RhYmxlOjU2ZjRlNzRkOTUxZDRhM2NiNDRhMzVjOGM0OWFmN2M0L3RhYmxlcmFuZ2U6NTZmNGU3NGQ5NTFkNGEzY2I0NGEzNWM4YzQ5YWY3YzRfMTctOS0xLTEtNDg2MjY_bad4e6e3-1ffa-4f32-a2ed-457ceb9a1cff"
      unitRef="usd">-5168000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="if67a2cd7a5e7447e8e1765371f5225b9_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183My9mcmFnOmQzNzc2MmZiMDI0ZDRjNWE5MjMxODNkNmUxMTdjM2Q1L3RhYmxlOjU2ZjRlNzRkOTUxZDRhM2NiNDRhMzVjOGM0OWFmN2M0L3RhYmxlcmFuZ2U6NTZmNGU3NGQ5NTFkNGEzY2I0NGEzNWM4YzQ5YWY3YzRfMTctMTItMS0xLTQxMjk0_f37460d3-5c48-40a5-b100-30c22952b6c3"
      unitRef="usd">-5168000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther
      contextRef="i7e24f17963584a8a8d751afa02b1b0c9_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183My9mcmFnOmQzNzc2MmZiMDI0ZDRjNWE5MjMxODNkNmUxMTdjM2Q1L3RhYmxlOjU2ZjRlNzRkOTUxZDRhM2NiNDRhMzVjOGM0OWFmN2M0L3RhYmxlcmFuZ2U6NTZmNGU3NGQ5NTFkNGEzY2I0NGEzNWM4YzQ5YWY3YzRfMTgtNS0xLTEtNDEyOTQ_fce102dd-6a57-4b96-96bd-2e6240171a6c"
      unitRef="usd">3000</us-gaap:AdjustmentsToAdditionalPaidInCapitalOther>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther
      contextRef="ib3597315a63d441f8f128abd7ed8840e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183My9mcmFnOmQzNzc2MmZiMDI0ZDRjNWE5MjMxODNkNmUxMTdjM2Q1L3RhYmxlOjU2ZjRlNzRkOTUxZDRhM2NiNDRhMzVjOGM0OWFmN2M0L3RhYmxlcmFuZ2U6NTZmNGU3NGQ5NTFkNGEzY2I0NGEzNWM4YzQ5YWY3YzRfMTgtMTItMS0xLTQxMjk0_4a22946b-f2c1-4e57-a5fb-f6e07294a4a2"
      unitRef="usd">3000</us-gaap:AdjustmentsToAdditionalPaidInCapitalOther>
    <us-gaap:NetIncomeLoss
      contextRef="i3a721e0ae7354a8da5ec3fc43557bc99_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183My9mcmFnOmQzNzc2MmZiMDI0ZDRjNWE5MjMxODNkNmUxMTdjM2Q1L3RhYmxlOjU2ZjRlNzRkOTUxZDRhM2NiNDRhMzVjOGM0OWFmN2M0L3RhYmxlcmFuZ2U6NTZmNGU3NGQ5NTFkNGEzY2I0NGEzNWM4YzQ5YWY3YzRfMTktOS0xLTEtNDEyOTQ_493458c4-7a45-43b1-b65e-2439efa86a9a"
      unitRef="usd">-2985000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ib3597315a63d441f8f128abd7ed8840e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183My9mcmFnOmQzNzc2MmZiMDI0ZDRjNWE5MjMxODNkNmUxMTdjM2Q1L3RhYmxlOjU2ZjRlNzRkOTUxZDRhM2NiNDRhMzVjOGM0OWFmN2M0L3RhYmxlcmFuZ2U6NTZmNGU3NGQ5NTFkNGEzY2I0NGEzNWM4YzQ5YWY3YzRfMTktMTItMS0xLTQxMjk0_adf2b939-b963-4b6a-9c32-928f3035f9b1"
      unitRef="usd">-2985000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="i00775ac58cda4124ad52707038f57ba7_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183My9mcmFnOmQzNzc2MmZiMDI0ZDRjNWE5MjMxODNkNmUxMTdjM2Q1L3RhYmxlOjU2ZjRlNzRkOTUxZDRhM2NiNDRhMzVjOGM0OWFmN2M0L3RhYmxlcmFuZ2U6NTZmNGU3NGQ5NTFkNGEzY2I0NGEzNWM4YzQ5YWY3YzRfMjAtMS0xLTEtNDg1NzM_1c1ae2f4-1864-413c-979e-804489069061"
      unitRef="shares">16080000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i00775ac58cda4124ad52707038f57ba7_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183My9mcmFnOmQzNzc2MmZiMDI0ZDRjNWE5MjMxODNkNmUxMTdjM2Q1L3RhYmxlOjU2ZjRlNzRkOTUxZDRhM2NiNDRhMzVjOGM0OWFmN2M0L3RhYmxlcmFuZ2U6NTZmNGU3NGQ5NTFkNGEzY2I0NGEzNWM4YzQ5YWY3YzRfMjAtMy0xLTEtNDg1NzM_80ec26a8-a12c-4bbb-9fc6-56fd294e4cb0"
      unitRef="usd">16000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i98685891da6a4235a4c08510b2fafca9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183My9mcmFnOmQzNzc2MmZiMDI0ZDRjNWE5MjMxODNkNmUxMTdjM2Q1L3RhYmxlOjU2ZjRlNzRkOTUxZDRhM2NiNDRhMzVjOGM0OWFmN2M0L3RhYmxlcmFuZ2U6NTZmNGU3NGQ5NTFkNGEzY2I0NGEzNWM4YzQ5YWY3YzRfMjAtNS0xLTEtNDg1NzM_f5592c7a-1579-4f64-927e-5155c7e49861"
      unitRef="usd">318358000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ibd8887ddedbb409e8ee0b01a14c47927_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183My9mcmFnOmQzNzc2MmZiMDI0ZDRjNWE5MjMxODNkNmUxMTdjM2Q1L3RhYmxlOjU2ZjRlNzRkOTUxZDRhM2NiNDRhMzVjOGM0OWFmN2M0L3RhYmxlcmFuZ2U6NTZmNGU3NGQ5NTFkNGEzY2I0NGEzNWM4YzQ5YWY3YzRfMjAtNy0xLTEtNDg1NzM_6217f3ce-b594-4659-bf83-aa24e360a591"
      unitRef="usd">-801000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ie12d7c9cbefd4947bbe0a3c6cb0e902e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183My9mcmFnOmQzNzc2MmZiMDI0ZDRjNWE5MjMxODNkNmUxMTdjM2Q1L3RhYmxlOjU2ZjRlNzRkOTUxZDRhM2NiNDRhMzVjOGM0OWFmN2M0L3RhYmxlcmFuZ2U6NTZmNGU3NGQ5NTFkNGEzY2I0NGEzNWM4YzQ5YWY3YzRfMjAtOS0xLTEtNDEyOTQ_d9360eb9-9d43-4469-9363-220a92f04bbe"
      unitRef="usd">391952000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i7462d0db8f4248fcb9fd8f1deae439f3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183My9mcmFnOmQzNzc2MmZiMDI0ZDRjNWE5MjMxODNkNmUxMTdjM2Q1L3RhYmxlOjU2ZjRlNzRkOTUxZDRhM2NiNDRhMzVjOGM0OWFmN2M0L3RhYmxlcmFuZ2U6NTZmNGU3NGQ5NTFkNGEzY2I0NGEzNWM4YzQ5YWY3YzRfMjAtMTItMS0xLTQxMjk0_cba70cfd-c3af-4e40-8213-1bb9ef8eb348"
      unitRef="usd">709525000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i3fe3de32a504463798a10b16d8710835_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183My9mcmFnOmQzNzc2MmZiMDI0ZDRjNWE5MjMxODNkNmUxMTdjM2Q1L3RhYmxlOjU2ZjRlNzRkOTUxZDRhM2NiNDRhMzVjOGM0OWFmN2M0L3RhYmxlcmFuZ2U6NTZmNGU3NGQ5NTFkNGEzY2I0NGEzNWM4YzQ5YWY3YzRfMjEtMS0xLTEtNDEyOTQ_0b2780db-5718-4a0b-9728-8d2cda0b0fef"
      unitRef="shares">687000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i3fe3de32a504463798a10b16d8710835_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183My9mcmFnOmQzNzc2MmZiMDI0ZDRjNWE5MjMxODNkNmUxMTdjM2Q1L3RhYmxlOjU2ZjRlNzRkOTUxZDRhM2NiNDRhMzVjOGM0OWFmN2M0L3RhYmxlcmFuZ2U6NTZmNGU3NGQ5NTFkNGEzY2I0NGEzNWM4YzQ5YWY3YzRfMjEtMy0xLTEtNDEyOTQ_373e2591-f04d-4298-b2bf-6ebd6a5a9a5c"
      unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i86f3192c999a48e18bfbb2d3da1eee99_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183My9mcmFnOmQzNzc2MmZiMDI0ZDRjNWE5MjMxODNkNmUxMTdjM2Q1L3RhYmxlOjU2ZjRlNzRkOTUxZDRhM2NiNDRhMzVjOGM0OWFmN2M0L3RhYmxlcmFuZ2U6NTZmNGU3NGQ5NTFkNGEzY2I0NGEzNWM4YzQ5YWY3YzRfMjEtNS0xLTEtNDEyOTQ_3445fde8-b53f-4151-bb19-c4467d5f0c20"
      unitRef="usd">27744000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183My9mcmFnOmQzNzc2MmZiMDI0ZDRjNWE5MjMxODNkNmUxMTdjM2Q1L3RhYmxlOjU2ZjRlNzRkOTUxZDRhM2NiNDRhMzVjOGM0OWFmN2M0L3RhYmxlcmFuZ2U6NTZmNGU3NGQ5NTFkNGEzY2I0NGEzNWM4YzQ5YWY3YzRfMjEtMTItMS0xLTQxMjk0_55cf86c1-af27-4de8-ae93-1ad99f1a73bd"
      unitRef="usd">27745000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i86f3192c999a48e18bfbb2d3da1eee99_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183My9mcmFnOmQzNzc2MmZiMDI0ZDRjNWE5MjMxODNkNmUxMTdjM2Q1L3RhYmxlOjU2ZjRlNzRkOTUxZDRhM2NiNDRhMzVjOGM0OWFmN2M0L3RhYmxlcmFuZ2U6NTZmNGU3NGQ5NTFkNGEzY2I0NGEzNWM4YzQ5YWY3YzRfMjItNS0xLTEtNDEyOTQ_08ce7802-7422-41ba-bbaf-d72501a52f7d"
      unitRef="usd">38783000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183My9mcmFnOmQzNzc2MmZiMDI0ZDRjNWE5MjMxODNkNmUxMTdjM2Q1L3RhYmxlOjU2ZjRlNzRkOTUxZDRhM2NiNDRhMzVjOGM0OWFmN2M0L3RhYmxlcmFuZ2U6NTZmNGU3NGQ5NTFkNGEzY2I0NGEzNWM4YzQ5YWY3YzRfMjItMTItMS0xLTQxMjk0_6f4b6115-5374-4c66-b80d-a6543201f0fb"
      unitRef="usd">38783000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss
      contextRef="ib1ca68e3b91b44f0a9d75354b9a561c3_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183My9mcmFnOmQzNzc2MmZiMDI0ZDRjNWE5MjMxODNkNmUxMTdjM2Q1L3RhYmxlOjU2ZjRlNzRkOTUxZDRhM2NiNDRhMzVjOGM0OWFmN2M0L3RhYmxlcmFuZ2U6NTZmNGU3NGQ5NTFkNGEzY2I0NGEzNWM4YzQ5YWY3YzRfMjQtNy0xLTEtNDgyNDM_ae8170dd-a22f-4f04-9435-40a365607578"
      unitRef="usd">-116000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss
      contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183My9mcmFnOmQzNzc2MmZiMDI0ZDRjNWE5MjMxODNkNmUxMTdjM2Q1L3RhYmxlOjU2ZjRlNzRkOTUxZDRhM2NiNDRhMzVjOGM0OWFmN2M0L3RhYmxlcmFuZ2U6NTZmNGU3NGQ5NTFkNGEzY2I0NGEzNWM4YzQ5YWY3YzRfMjQtMTItMS0xLTQxMjk0_6b7a9a2e-eba7-4357-867d-5eac9bd23bbd"
      unitRef="usd">-116000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt
      contextRef="i86f3192c999a48e18bfbb2d3da1eee99_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183My9mcmFnOmQzNzc2MmZiMDI0ZDRjNWE5MjMxODNkNmUxMTdjM2Q1L3RhYmxlOjU2ZjRlNzRkOTUxZDRhM2NiNDRhMzVjOGM0OWFmN2M0L3RhYmxlcmFuZ2U6NTZmNGU3NGQ5NTFkNGEzY2I0NGEzNWM4YzQ5YWY3YzRfMjYtNS0xLTEtNDgyNDM_13f52c8c-fdc6-441c-921c-9cc301e885de"
      unitRef="usd">-12407000</us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt
      contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183My9mcmFnOmQzNzc2MmZiMDI0ZDRjNWE5MjMxODNkNmUxMTdjM2Q1L3RhYmxlOjU2ZjRlNzRkOTUxZDRhM2NiNDRhMzVjOGM0OWFmN2M0L3RhYmxlcmFuZ2U6NTZmNGU3NGQ5NTFkNGEzY2I0NGEzNWM4YzQ5YWY3YzRfMjYtMTItMS0xLTQxMjk0_7d2fbb83-7e6f-40be-9cba-baca576486be"
      unitRef="usd">-12407000</us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt>
    <lgnd:AdjustmentsToAdditionalPaidInCapitalWarrantAndBondHedgeUnwindTransactions
      contextRef="i86f3192c999a48e18bfbb2d3da1eee99_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183My9mcmFnOmQzNzc2MmZiMDI0ZDRjNWE5MjMxODNkNmUxMTdjM2Q1L3RhYmxlOjU2ZjRlNzRkOTUxZDRhM2NiNDRhMzVjOGM0OWFmN2M0L3RhYmxlcmFuZ2U6NTZmNGU3NGQ5NTFkNGEzY2I0NGEzNWM4YzQ5YWY3YzRfMjYtNS0xLTEtNTE4OTE_82612c94-c050-4983-a53f-20cb4c77d981"
      unitRef="usd">491000</lgnd:AdjustmentsToAdditionalPaidInCapitalWarrantAndBondHedgeUnwindTransactions>
    <lgnd:AdjustmentsToAdditionalPaidInCapitalWarrantAndBondHedgeUnwindTransactions
      contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183My9mcmFnOmQzNzc2MmZiMDI0ZDRjNWE5MjMxODNkNmUxMTdjM2Q1L3RhYmxlOjU2ZjRlNzRkOTUxZDRhM2NiNDRhMzVjOGM0OWFmN2M0L3RhYmxlcmFuZ2U6NTZmNGU3NGQ5NTFkNGEzY2I0NGEzNWM4YzQ5YWY3YzRfMjYtMTItMS0xLTUyMDg1_40b8e752-4c9d-42f1-b695-5dce03d6a985"
      unitRef="usd">491000</lgnd:AdjustmentsToAdditionalPaidInCapitalWarrantAndBondHedgeUnwindTransactions>
    <us-gaap:NetIncomeLoss
      contextRef="i2a0bf241e5df45f3b9a295da0a033225_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183My9mcmFnOmQzNzc2MmZiMDI0ZDRjNWE5MjMxODNkNmUxMTdjM2Q1L3RhYmxlOjU2ZjRlNzRkOTUxZDRhM2NiNDRhMzVjOGM0OWFmN2M0L3RhYmxlcmFuZ2U6NTZmNGU3NGQ5NTFkNGEzY2I0NGEzNWM4YzQ5YWY3YzRfMjktOS0xLTEtNDEyOTQ_d1466784-d42d-49af-8f77-727e09206649"
      unitRef="usd">57138000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183My9mcmFnOmQzNzc2MmZiMDI0ZDRjNWE5MjMxODNkNmUxMTdjM2Q1L3RhYmxlOjU2ZjRlNzRkOTUxZDRhM2NiNDRhMzVjOGM0OWFmN2M0L3RhYmxlcmFuZ2U6NTZmNGU3NGQ5NTFkNGEzY2I0NGEzNWM4YzQ5YWY3YzRfMjktMTItMS0xLTQxMjk0_2495f044-dff9-472c-a53c-65aad0347386"
      unitRef="usd">57138000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="i4893aa820b6e400e86aa2f8639ddb077_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183My9mcmFnOmQzNzc2MmZiMDI0ZDRjNWE5MjMxODNkNmUxMTdjM2Q1L3RhYmxlOjU2ZjRlNzRkOTUxZDRhM2NiNDRhMzVjOGM0OWFmN2M0L3RhYmxlcmFuZ2U6NTZmNGU3NGQ5NTFkNGEzY2I0NGEzNWM4YzQ5YWY3YzRfMzAtMS0xLTEtNDEyOTQ_173d3b11-6d5f-47c3-884f-66934749d29d"
      unitRef="shares">16767000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i4893aa820b6e400e86aa2f8639ddb077_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183My9mcmFnOmQzNzc2MmZiMDI0ZDRjNWE5MjMxODNkNmUxMTdjM2Q1L3RhYmxlOjU2ZjRlNzRkOTUxZDRhM2NiNDRhMzVjOGM0OWFmN2M0L3RhYmxlcmFuZ2U6NTZmNGU3NGQ5NTFkNGEzY2I0NGEzNWM4YzQ5YWY3YzRfMjgtMy0xLTEtNDg1NzU_e2402210-09f3-4d43-a0f9-44c53f7fad42"
      unitRef="usd">17000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i460189e17625434e8a5a65a7ad36197f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183My9mcmFnOmQzNzc2MmZiMDI0ZDRjNWE5MjMxODNkNmUxMTdjM2Q1L3RhYmxlOjU2ZjRlNzRkOTUxZDRhM2NiNDRhMzVjOGM0OWFmN2M0L3RhYmxlcmFuZ2U6NTZmNGU3NGQ5NTFkNGEzY2I0NGEzNWM4YzQ5YWY3YzRfMzAtNS0xLTEtNDEyOTQ_0745f314-d1f0-47e7-aef4-27d5c67f5451"
      unitRef="usd">372969000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i35055051f1cc48e3880e5291e4e63132_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183My9mcmFnOmQzNzc2MmZiMDI0ZDRjNWE5MjMxODNkNmUxMTdjM2Q1L3RhYmxlOjU2ZjRlNzRkOTUxZDRhM2NiNDRhMzVjOGM0OWFmN2M0L3RhYmxlcmFuZ2U6NTZmNGU3NGQ5NTFkNGEzY2I0NGEzNWM4YzQ5YWY3YzRfMjgtNy0xLTEtNDg1NzU_a109c75d-2ec5-4776-9538-dfd686d4b75d"
      unitRef="usd">-917000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="if714890c34114ccca202fde217c2acc5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183My9mcmFnOmQzNzc2MmZiMDI0ZDRjNWE5MjMxODNkNmUxMTdjM2Q1L3RhYmxlOjU2ZjRlNzRkOTUxZDRhM2NiNDRhMzVjOGM0OWFmN2M0L3RhYmxlcmFuZ2U6NTZmNGU3NGQ5NTFkNGEzY2I0NGEzNWM4YzQ5YWY3YzRfMjgtOS0xLTEtNDg1NzU_6ee7ea45-7d91-4da8-af3a-78c073a88ac9"
      unitRef="usd">449090000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183My9mcmFnOmQzNzc2MmZiMDI0ZDRjNWE5MjMxODNkNmUxMTdjM2Q1L3RhYmxlOjU2ZjRlNzRkOTUxZDRhM2NiNDRhMzVjOGM0OWFmN2M0L3RhYmxlcmFuZ2U6NTZmNGU3NGQ5NTFkNGEzY2I0NGEzNWM4YzQ5YWY3YzRfMzAtMTItMS0xLTQxMjk0_bf14a331-8ee6-4d5f-91f9-e941bca01915"
      unitRef="usd">821159000</us-gaap:StockholdersEquity>
    <us-gaap:ProfitLoss
      contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfMy0xLTEtMS00MTI5NA_35f2f2d3-e43f-4dbf-aac8-de344b664036"
      unitRef="usd">57138000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="ib3597315a63d441f8f128abd7ed8840e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfMy0zLTEtMS00MTI5NA_652f0dad-31f7-4e43-b831-40363e028d45"
      unitRef="usd">-2985000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="ie6c3b69702e9429aaeed46bdb9bbb9c1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfMy01LTEtMS00MTI5NA_50676c0d-60c9-4f5e-8cd8-27663e44fda4"
      unitRef="usd">629302000</us-gaap:ProfitLoss>
    <us-gaap:GainLossOnSaleOfOtherAssets
      contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfNS0xLTEtMS00MTI5NA_18d694f7-9bc3-40bc-97ac-c936ff27b5a3"
      unitRef="usd">0</us-gaap:GainLossOnSaleOfOtherAssets>
    <us-gaap:GainLossOnSaleOfOtherAssets
      contextRef="ib3597315a63d441f8f128abd7ed8840e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfNS0zLTEtMS00MTI5NA_3b727d2f-ea2f-4519-b1fb-137ab07df2e1"
      unitRef="usd">0</us-gaap:GainLossOnSaleOfOtherAssets>
    <us-gaap:GainLossOnSaleOfOtherAssets
      contextRef="ie6c3b69702e9429aaeed46bdb9bbb9c1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfNS01LTEtMS00MTI5NA_4c837d03-5dbd-4117-814c-e06885dc1c4b"
      unitRef="usd">812797000</us-gaap:GainLossOnSaleOfOtherAssets>
    <us-gaap:GainLossOnSaleOfBusiness
      contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfNi0xLTEtMS00MTI5NA_a517d332-23d0-4b6a-ae88-1a0f25de64c5"
      unitRef="usd">0</us-gaap:GainLossOnSaleOfBusiness>
    <us-gaap:GainLossOnSaleOfBusiness
      contextRef="ib3597315a63d441f8f128abd7ed8840e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfNi0zLTEtMS00MTI5NA_65e068fb-7d28-44da-995d-9c4626fa62f5"
      unitRef="usd">17114000</us-gaap:GainLossOnSaleOfBusiness>
    <us-gaap:GainLossOnSaleOfBusiness
      contextRef="ie6c3b69702e9429aaeed46bdb9bbb9c1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfNi01LTEtMS00MTI5NA_b1067c03-c800-4239-a568-9713caa98b55"
      unitRef="usd">0</us-gaap:GainLossOnSaleOfBusiness>
    <lgnd:NonCashChangeInEstimatedFairValueOfContingentValueRights
      contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfNy0xLTEtMS00MTI5NA_4be66006-1e66-4f3a-b859-812a099adec8"
      unitRef="usd">36962000</lgnd:NonCashChangeInEstimatedFairValueOfContingentValueRights>
    <lgnd:NonCashChangeInEstimatedFairValueOfContingentValueRights
      contextRef="ib3597315a63d441f8f128abd7ed8840e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfNy0zLTEtMS00MTI5NA_89720b0b-6202-46db-bfa5-39432800f986"
      unitRef="usd">-963000</lgnd:NonCashChangeInEstimatedFairValueOfContingentValueRights>
    <lgnd:NonCashChangeInEstimatedFairValueOfContingentValueRights
      contextRef="ie6c3b69702e9429aaeed46bdb9bbb9c1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfNy01LTEtMS00MTI5NA_e79414af-b074-471d-8e7e-df8cfd2601da"
      unitRef="usd">30000</lgnd:NonCashChangeInEstimatedFairValueOfContingentValueRights>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfOC0xLTEtMS00MTI5NA_0403765d-542c-4ab5-8232-b540dd30d91b"
      unitRef="usd">51071000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="ib3597315a63d441f8f128abd7ed8840e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfOC0zLTEtMS00MTI5NA_7a455c60-ef07-4ad1-b26b-6602a7a41574"
      unitRef="usd">25691000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="ie6c3b69702e9429aaeed46bdb9bbb9c1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfOC01LTEtMS00MTI5NA_9eea8c43-3a6f-44d7-a49b-9717ee60a731"
      unitRef="usd">18361000</us-gaap:DepreciationDepletionAndAmortization>
    <lgnd:GainLossOnShortTermInvestments
      contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfOS0xLTEtMS00MTI5NA_64003b9a-b67d-4d75-a902-82830b750f1e"
      unitRef="usd">-3997000</lgnd:GainLossOnShortTermInvestments>
    <lgnd:GainLossOnShortTermInvestments
      contextRef="ib3597315a63d441f8f128abd7ed8840e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfOS0zLTEtMS00MTI5NA_a056e48b-f2dc-4eb6-b6a2-8b91e59048c2"
      unitRef="usd">-16933000</lgnd:GainLossOnShortTermInvestments>
    <lgnd:GainLossOnShortTermInvestments
      contextRef="ie6c3b69702e9429aaeed46bdb9bbb9c1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfOS01LTEtMS00MTI5NA_3d616d8d-6b03-47b7-aec9-9378cda474b7"
      unitRef="usd">1049000</lgnd:GainLossOnShortTermInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfMTAtMS0xLTEtNDEyOTQ_a8869553-d903-4f6c-9498-94192913cca6"
      unitRef="usd">-111000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="ib3597315a63d441f8f128abd7ed8840e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfMTAtMy0xLTEtNDEyOTQ_1458d4f6-108a-490a-a13a-4c40307e7e3c"
      unitRef="usd">-1479000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="ie6c3b69702e9429aaeed46bdb9bbb9c1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfMTAtNS0xLTEtNDEyOTQ_c053fcf0-5180-4382-b395-b28e63c87d6a"
      unitRef="usd">10274000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfMTEtMS0xLTEtNDEyOTQ_4e09074e-d2f7-461c-ae9e-735e03044d94"
      unitRef="usd">16692000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="ib3597315a63d441f8f128abd7ed8840e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfMTEtMy0xLTEtNDEyOTQ_592ae330-124d-4c73-bc3a-190e1214231e"
      unitRef="usd">23077000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="ie6c3b69702e9429aaeed46bdb9bbb9c1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfMTEtNS0xLTEtNDEyOTQ_65717d09-cfa6-4a4b-9d4a-6040b29464f4"
      unitRef="usd">29988000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfMTItMS0xLTEtNTIwOTM_28e2bd19-cdf4-4b1c-b40d-ecb41ae44b21"
      unitRef="usd">-7303000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="ib3597315a63d441f8f128abd7ed8840e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfMTItMy0xLTEtNTIwOTM_ab256681-4a15-455c-ba5c-bcada6f87ce4"
      unitRef="usd">-2466000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="ie6c3b69702e9429aaeed46bdb9bbb9c1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfMTItNS0xLTEtNTIwOTM_fdbcba83-c595-4164-85dd-df95dae78bb0"
      unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <lgnd:AmortizationOfCommercialLicenseAndOtherEconomicRights
      contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfMTItMS0xLTEtNDEyOTQ_bc1b3358-b1fc-4f96-84c9-d500a5952687"
      unitRef="usd">-125000</lgnd:AmortizationOfCommercialLicenseAndOtherEconomicRights>
    <lgnd:AmortizationOfCommercialLicenseAndOtherEconomicRights
      contextRef="ib3597315a63d441f8f128abd7ed8840e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfMTItMy0xLTEtNDEyOTQ_eae9f70e-86c4-4408-a9b7-763099ea3f89"
      unitRef="usd">2275000</lgnd:AmortizationOfCommercialLicenseAndOtherEconomicRights>
    <lgnd:AmortizationOfCommercialLicenseAndOtherEconomicRights
      contextRef="ie6c3b69702e9429aaeed46bdb9bbb9c1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfMTItNS0xLTEtNDEyOTQ_baf83880-87b0-405d-a219-a2cdced0afac"
      unitRef="usd">25370000</lgnd:AmortizationOfCommercialLicenseAndOtherEconomicRights>
    <us-gaap:ShareBasedCompensation
      contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfMTMtMS0xLTEtNDEyOTQ_f2b16ca2-89bb-41a7-8892-f75fa063e111"
      unitRef="usd">38783000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="ib3597315a63d441f8f128abd7ed8840e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfMTMtMy0xLTEtNDEyOTQ_18fa8c7d-9592-45f0-96dc-9e3dd8ac53e2"
      unitRef="usd">30727000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="ie6c3b69702e9429aaeed46bdb9bbb9c1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfMTMtNS0xLTEtNDEyOTQ_cd846fd4-7bb8-4a7b-a6a6-6cf531c95014"
      unitRef="usd">24515000</us-gaap:ShareBasedCompensation>
    <us-gaap:IncreaseDecreaseInDeferredIncomeTaxes
      contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfMTQtMS0xLTEtNDEyOTQ_c21ae106-ace6-4c4c-9c5b-67c7c5520a03"
      unitRef="usd">8618000</us-gaap:IncreaseDecreaseInDeferredIncomeTaxes>
    <us-gaap:IncreaseDecreaseInDeferredIncomeTaxes
      contextRef="ib3597315a63d441f8f128abd7ed8840e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfMTQtMy0xLTEtNDEyOTQ_e6ad7ced-a012-46df-988e-2c2c997aa283"
      unitRef="usd">19053000</us-gaap:IncreaseDecreaseInDeferredIncomeTaxes>
    <us-gaap:IncreaseDecreaseInDeferredIncomeTaxes
      contextRef="ie6c3b69702e9429aaeed46bdb9bbb9c1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfMTQtNS0xLTEtNDEyOTQ_f6d5d9bf-99cc-4fff-9b0e-09cc80e652a0"
      unitRef="usd">-74829000</us-gaap:IncreaseDecreaseInDeferredIncomeTaxes>
    <us-gaap:OtherOperatingActivitiesCashFlowStatement
      contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfMTYtMS0xLTEtNDEyOTQ_3b5cd8ef-607c-4262-bf99-b2048be84b0c"
      unitRef="usd">1572000</us-gaap:OtherOperatingActivitiesCashFlowStatement>
    <us-gaap:OtherOperatingActivitiesCashFlowStatement
      contextRef="ib3597315a63d441f8f128abd7ed8840e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfMTYtMy0xLTEtNDEyOTQ_d2584167-ca75-41eb-9a45-175bacaf6d57"
      unitRef="usd">191000</us-gaap:OtherOperatingActivitiesCashFlowStatement>
    <us-gaap:OtherOperatingActivitiesCashFlowStatement
      contextRef="ie6c3b69702e9429aaeed46bdb9bbb9c1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfMTYtNS0xLTEtNDEyOTQ_c63a2290-ce0a-43d2-b6de-f0d2a139280c"
      unitRef="usd">-3498000</us-gaap:OtherOperatingActivitiesCashFlowStatement>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfMTgtMS0xLTEtNDEyOTQ_c53c25d4-8f0c-4053-9399-3cb0e090ea43"
      unitRef="usd">28616000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="ib3597315a63d441f8f128abd7ed8840e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfMTgtMy0xLTEtNDEyOTQ_389b9092-d63d-427d-80e1-1c56ac556dc6"
      unitRef="usd">26061000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="ie6c3b69702e9429aaeed46bdb9bbb9c1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfMTgtNS0xLTEtNDEyOTQ_54278125-eb27-4b9d-a051-f41dae1196f2"
      unitRef="usd">-25463000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfMTktMS0xLTEtNDEyOTQ_f2166b74-cc2b-4bd5-93d4-cf8b371f7721"
      unitRef="usd">427000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="ib3597315a63d441f8f128abd7ed8840e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfMTktMy0xLTEtNDEyOTQ_043558e9-84b0-4129-820b-5c1e7486b2ad"
      unitRef="usd">17799000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="ie6c3b69702e9429aaeed46bdb9bbb9c1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfMTktNS0xLTEtNDEyOTQ_eafa911e-4b47-44da-95ce-745a23e4baf8"
      unitRef="usd">2061000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfMjAtMS0xLTEtNDEyOTQ_af2235a5-5c02-4dd7-b28f-b806b35be916"
      unitRef="usd">2810000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="ib3597315a63d441f8f128abd7ed8840e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfMjAtMy0xLTEtNDEyOTQ_bf97fd7d-f8f6-4cb0-abdb-9a20dba220ce"
      unitRef="usd">-1245000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="ie6c3b69702e9429aaeed46bdb9bbb9c1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfMjAtNS0xLTEtNDEyOTQ_1f967744-de89-48c6-8b28-7d5cbb13e2cc"
      unitRef="usd">-6664000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInIncomeTaxesReceivable
      contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfMjEtMS0xLTEtNDEyOTQ_ca9b9fbe-8dd8-4537-91a7-0c15ab858d82"
      unitRef="usd">3976000</us-gaap:IncreaseDecreaseInIncomeTaxesReceivable>
    <us-gaap:IncreaseDecreaseInIncomeTaxesReceivable
      contextRef="ib3597315a63d441f8f128abd7ed8840e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfMjEtMy0xLTEtNDEyOTQ_a414c32c-2e75-4757-aacd-0c0292bb4e0d"
      unitRef="usd">-9144000</us-gaap:IncreaseDecreaseInIncomeTaxesReceivable>
    <us-gaap:IncreaseDecreaseInIncomeTaxesReceivable
      contextRef="ie6c3b69702e9429aaeed46bdb9bbb9c1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfMjEtNS0xLTEtNDEyOTQ_e67cb11a-71dd-4104-af78-02e9170119a8"
      unitRef="usd">11219000</us-gaap:IncreaseDecreaseInIncomeTaxesReceivable>
    <lgnd:IncreaseDecreaseInOtherEconomicRights
      contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfMjItMS0xLTEtNDEyOTQ_5678caf8-5422-4eb8-8739-b12434fb3346"
      unitRef="usd">0</lgnd:IncreaseDecreaseInOtherEconomicRights>
    <lgnd:IncreaseDecreaseInOtherEconomicRights
      contextRef="ib3597315a63d441f8f128abd7ed8840e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfMjItMy0xLTEtNDEyOTQ_f53b67ef-8827-49d4-bef7-92e7e9b7ded6"
      unitRef="usd">0</lgnd:IncreaseDecreaseInOtherEconomicRights>
    <lgnd:IncreaseDecreaseInOtherEconomicRights
      contextRef="ie6c3b69702e9429aaeed46bdb9bbb9c1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfMjItNS0xLTEtNDEyOTQ_4c2b9e75-0f66-43df-8c28-def9a4742de4"
      unitRef="usd">-12000000</lgnd:IncreaseDecreaseInOtherEconomicRights>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfMjMtMS0xLTEtNDEyOTQ_bacb6bd9-1027-4eef-a649-928c28d3ae81"
      unitRef="usd">-17870000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="ib3597315a63d441f8f128abd7ed8840e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfMjMtMy0xLTEtNDEyOTQ_b3b38284-3450-4ca7-b402-f39762d73b09"
      unitRef="usd">29236000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="ie6c3b69702e9429aaeed46bdb9bbb9c1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfMjMtNS0xLTEtNDEyOTQ_c7ae1aed-f050-4ee1-9e59-a89ca093ba09"
      unitRef="usd">-1147000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInOtherCurrentLiabilities
      contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfMjQtMS0xLTEtNDEyOTQ_2e523a40-d687-493b-8695-70349cdb8c38"
      unitRef="usd">-4085000</us-gaap:IncreaseDecreaseInOtherCurrentLiabilities>
    <us-gaap:IncreaseDecreaseInOtherCurrentLiabilities
      contextRef="ib3597315a63d441f8f128abd7ed8840e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfMjQtMy0xLTEtNDEyOTQ_b40c0e7c-05b3-4ade-910a-a3191b36b08f"
      unitRef="usd">-3339000</us-gaap:IncreaseDecreaseInOtherCurrentLiabilities>
    <us-gaap:IncreaseDecreaseInOtherCurrentLiabilities
      contextRef="ie6c3b69702e9429aaeed46bdb9bbb9c1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfMjQtNS0xLTEtNDEyOTQ_2959d17e-0589-41ec-a094-8c6793b0f15f"
      unitRef="usd">3575000</us-gaap:IncreaseDecreaseInOtherCurrentLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfMjUtMS0xLTEtNDEyOTQ_e9901377-11c6-4d67-8559-d709d1af4fcd"
      unitRef="usd">78798000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="ib3597315a63d441f8f128abd7ed8840e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfMjUtMy0xLTEtNDEyOTQ_ce7d2fc2-b2b7-4d04-b731-15edc57b834c"
      unitRef="usd">54586000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="ie6c3b69702e9429aaeed46bdb9bbb9c1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfMjUtNS0xLTEtNDEyOTQ_e2a50c01-89a2-4298-9ddf-c001abeaba94"
      unitRef="usd">-29336000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:ProceedsFromSaleOfIntangibleAssets
      contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfMjctMS0xLTEtNDEyOTQ_0c592d84-9dd5-450d-8229-252a43cdb535"
      unitRef="usd">0</us-gaap:ProceedsFromSaleOfIntangibleAssets>
    <us-gaap:ProceedsFromSaleOfIntangibleAssets
      contextRef="ib3597315a63d441f8f128abd7ed8840e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfMjctMy0xLTEtNDEyOTQ_9429ebac-50f9-482e-968a-ce3e9bba5503"
      unitRef="usd">0</us-gaap:ProceedsFromSaleOfIntangibleAssets>
    <us-gaap:ProceedsFromSaleOfIntangibleAssets
      contextRef="ie6c3b69702e9429aaeed46bdb9bbb9c1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfMjctNS0xLTEtNDEyOTQ_8d2cb7fe-570d-4207-bc48-d9450c0b89ff"
      unitRef="usd">812797000</us-gaap:ProceedsFromSaleOfIntangibleAssets>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfMjktMS0xLTEtNDEyOTQ_202071c4-3eb3-485a-8348-abf3cc584da4"
      unitRef="usd">0</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="ib3597315a63d441f8f128abd7ed8840e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfMjktMy0xLTEtNDEyOTQ_569a38c7-de2a-4a86-b052-cfe6696dce54"
      unitRef="usd">404884000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="ie6c3b69702e9429aaeed46bdb9bbb9c1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfMjktNS0xLTEtNDEyOTQ_294d4e7d-e7c4-4816-b2ab-417192a76ef4"
      unitRef="usd">11840000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfMzAtMS0xLTEtNDEyOTQ_85214034-dd7f-4878-8e49-a1e003411ebd"
      unitRef="usd">8761000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="ib3597315a63d441f8f128abd7ed8840e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfMzAtMy0xLTEtNDEyOTQ_5fc0e4ab-53ee-4d30-9fa4-97eac75cbaa8"
      unitRef="usd">4458000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="ie6c3b69702e9429aaeed46bdb9bbb9c1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfMzAtNS0xLTEtNDEyOTQ_da97840d-1ec4-424e-815e-b2de04c2aa90"
      unitRef="usd">2553000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireShortTermInvestments
      contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfMzEtMS0xLTEtNDEyOTQ_dd59c61c-5ced-4ba7-a95c-d2d7e3c77803"
      unitRef="usd">181325000</us-gaap:PaymentsToAcquireShortTermInvestments>
    <us-gaap:PaymentsToAcquireShortTermInvestments
      contextRef="ib3597315a63d441f8f128abd7ed8840e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfMzEtMy0xLTEtNDEyOTQ_676d39d9-a175-400c-a207-243a27081c84"
      unitRef="usd">422523000</us-gaap:PaymentsToAcquireShortTermInvestments>
    <us-gaap:PaymentsToAcquireShortTermInvestments
      contextRef="ie6c3b69702e9429aaeed46bdb9bbb9c1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfMzEtNS0xLTEtNDEyOTQ_eb466472-e890-4f2a-be87-cc18967d101e"
      unitRef="usd">2356545000</us-gaap:PaymentsToAcquireShortTermInvestments>
    <lgnd:ProceedsFromCommercialLicenseRights
      contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfMzItMS0xLTEtNDEyOTQ_89a087d0-b94a-4648-b20c-65fb3c9a057f"
      unitRef="usd">494000</lgnd:ProceedsFromCommercialLicenseRights>
    <lgnd:ProceedsFromCommercialLicenseRights
      contextRef="ib3597315a63d441f8f128abd7ed8840e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfMzItMy0xLTEtNDEyOTQ_5a83c2eb-91c8-47ec-bfae-e0bbc87e50ef"
      unitRef="usd">1358000</lgnd:ProceedsFromCommercialLicenseRights>
    <lgnd:ProceedsFromCommercialLicenseRights
      contextRef="ie6c3b69702e9429aaeed46bdb9bbb9c1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfMzItNS0xLTEtNDEyOTQ_d0cff412-6e96-4345-be2b-ab6fd369887a"
      unitRef="usd">0</lgnd:ProceedsFromCommercialLicenseRights>
    <us-gaap:ProceedsFromSaleOfShortTermInvestments
      contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfMzMtMS0xLTEtNDEyOTQ_4da00c23-c4e3-4eac-b980-46154f0b541d"
      unitRef="usd">154230000</us-gaap:ProceedsFromSaleOfShortTermInvestments>
    <us-gaap:ProceedsFromSaleOfShortTermInvestments
      contextRef="ib3597315a63d441f8f128abd7ed8840e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfMzMtMy0xLTEtNDEyOTQ_f7c13605-1085-4fbb-84fd-de168c6cd669"
      unitRef="usd">394539000</us-gaap:ProceedsFromSaleOfShortTermInvestments>
    <us-gaap:ProceedsFromSaleOfShortTermInvestments
      contextRef="ie6c3b69702e9429aaeed46bdb9bbb9c1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfMzMtNS0xLTEtNDEyOTQ_fd0f7db2-14f7-41d9-8514-406992f5e76f"
      unitRef="usd">535877000</us-gaap:ProceedsFromSaleOfShortTermInvestments>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments
      contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfMzQtMS0xLTEtNDEyOTQ_77095e3e-2fed-4ea3-b28e-b99099ff05b8"
      unitRef="usd">67105000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments
      contextRef="ib3597315a63d441f8f128abd7ed8840e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfMzQtMy0xLTEtNDEyOTQ_cdf9955d-3cd6-424a-b7c3-db1ccc5735b6"
      unitRef="usd">644155000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments
      contextRef="ie6c3b69702e9429aaeed46bdb9bbb9c1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfMzQtNS0xLTEtNDEyOTQ_109eeb8b-40be-4ba6-9d15-07c611e93d44"
      unitRef="usd">1494851000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments>
    <us-gaap:PaymentsToAcquireEquityMethodInvestments
      contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfMzYtMS0xLTEtNDEyOTQ_f682dcc6-15f7-4caf-b3e7-d85e4b20fbb5"
      unitRef="usd">0</us-gaap:PaymentsToAcquireEquityMethodInvestments>
    <us-gaap:PaymentsToAcquireEquityMethodInvestments
      contextRef="ib3597315a63d441f8f128abd7ed8840e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfMzYtMy0xLTEtNDEyOTQ_25732127-80d2-4c43-8279-663779e0c411"
      unitRef="usd">500000</us-gaap:PaymentsToAcquireEquityMethodInvestments>
    <us-gaap:PaymentsToAcquireEquityMethodInvestments
      contextRef="ie6c3b69702e9429aaeed46bdb9bbb9c1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfMzYtNS0xLTEtNDEyOTQ_ee769173-aeba-49dd-b289-9c750ee2c898"
      unitRef="usd">1000000</us-gaap:PaymentsToAcquireEquityMethodInvestments>
    <us-gaap:ProceedsFromDivestitureOfBusinesses
      contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfMzctMS0xLTEtNDEyOTQ_0dcec7d6-3cff-4781-bfe6-8170020cf9ef"
      unitRef="usd">0</us-gaap:ProceedsFromDivestitureOfBusinesses>
    <us-gaap:ProceedsFromDivestitureOfBusinesses
      contextRef="ib3597315a63d441f8f128abd7ed8840e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfMzctMy0xLTEtNDEyOTQ_490c4391-b487-4e06-908f-717fb1d5fed7"
      unitRef="usd">22061000</us-gaap:ProceedsFromDivestitureOfBusinesses>
    <us-gaap:ProceedsFromDivestitureOfBusinesses
      contextRef="ie6c3b69702e9429aaeed46bdb9bbb9c1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfMzctNS0xLTEtNDEyOTQ_63225a70-bccd-4618-a746-e7d9351bd47e"
      unitRef="usd">0</us-gaap:ProceedsFromDivestitureOfBusinesses>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities
      contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfMzgtMS0xLTEtNDEyOTQ_69578339-c62a-4ca1-887d-0e0879a6360f"
      unitRef="usd">1220000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities
      contextRef="ib3597315a63d441f8f128abd7ed8840e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfMzgtMy0xLTEtNDEyOTQ_e8874b60-4dbf-489d-ac8c-9f156ea04971"
      unitRef="usd">-1900000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities
      contextRef="ie6c3b69702e9429aaeed46bdb9bbb9c1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfMzgtNS0xLTEtNDEyOTQ_eb03b588-38e6-4e7d-9fc6-02ace6d40f39"
      unitRef="usd">4669000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfMzktMS0xLTEtNDEyOTQ_d69e041e-d0e6-46ac-9cdc-721f2428bc69"
      unitRef="usd">30523000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="ib3597315a63d441f8f128abd7ed8840e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfMzktMy0xLTEtNDEyOTQ_a723d417-6038-4193-b99f-6d99d34c8ca7"
      unitRef="usd">231648000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="ie6c3b69702e9429aaeed46bdb9bbb9c1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfMzktNS0xLTEtNDEyOTQ_7c5f4ad6-1e59-4db4-a536-72454d57704c"
      unitRef="usd">466918000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfNDEtMS0xLTEtNDEyOTQ_27ef7d33-ef0d-46a1-adc2-de08d5093305"
      unitRef="usd">155760000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="ib3597315a63d441f8f128abd7ed8840e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfNDEtMy0xLTEtNDEyOTQ_b62b9497-c6ea-4d5d-8879-a39d1f5b30b3"
      unitRef="usd">222209000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="ie6c3b69702e9429aaeed46bdb9bbb9c1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfNDEtNS0xLTEtNDEyOTQ_b59145ed-64ab-4aa0-8b3c-2397b8b6ffc6"
      unitRef="usd">27323000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfNDItMS0xLTEtNDEyOTQ_53ba774d-6539-4ba5-828e-14eca681ed20"
      unitRef="usd">9188000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="ib3597315a63d441f8f128abd7ed8840e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfNDItMy0xLTEtNDEyOTQ_c3e2ebce-ab58-47d2-80d5-9c24e2a28357"
      unitRef="usd">9549000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="ie6c3b69702e9429aaeed46bdb9bbb9c1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfNDItNS0xLTEtNDEyOTQ_1bba6442-c125-4ee7-a575-09daae504f16"
      unitRef="usd">0</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:ProceedsFromHedgeFinancingActivities
      contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfNDctMS0xLTEtNDEyOTQ_36bb19cb-4590-4bf4-8e5f-0d12256292d8"
      unitRef="usd">18938000</us-gaap:ProceedsFromHedgeFinancingActivities>
    <us-gaap:ProceedsFromHedgeFinancingActivities
      contextRef="ib3597315a63d441f8f128abd7ed8840e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfNDctMy0xLTEtNDEyOTQ_889e7ad5-f528-4c0d-a6e5-9d39eb05ef49"
      unitRef="usd">0</us-gaap:ProceedsFromHedgeFinancingActivities>
    <us-gaap:ProceedsFromHedgeFinancingActivities
      contextRef="ie6c3b69702e9429aaeed46bdb9bbb9c1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfNDctNS0xLTEtNDEyOTQ_d8ada786-f8c0-4f26-a636-a56e759b4c5c"
      unitRef="usd">12401000</us-gaap:ProceedsFromHedgeFinancingActivities>
    <us-gaap:PaymentsForHedgeFinancingActivities
      contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfNDgtMS0xLTEtNDEyOTQ_279feb81-4637-4780-a732-cec408932af1"
      unitRef="usd">0</us-gaap:PaymentsForHedgeFinancingActivities>
    <us-gaap:PaymentsForHedgeFinancingActivities
      contextRef="ib3597315a63d441f8f128abd7ed8840e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfNDgtMy0xLTEtNDEyOTQ_64570f53-8b45-474b-be55-8d925b04276b"
      unitRef="usd">0</us-gaap:PaymentsForHedgeFinancingActivities>
    <us-gaap:PaymentsForHedgeFinancingActivities
      contextRef="ie6c3b69702e9429aaeed46bdb9bbb9c1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfNDgtNS0xLTEtNDEyOTQ_27767f85-b6b3-48c0-8135-551ee480fecb"
      unitRef="usd">12401000</us-gaap:PaymentsForHedgeFinancingActivities>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfNDktMS0xLTEtNDEyOTQ_f21b6cfb-0e46-437c-b625-38cb0356843b"
      unitRef="usd">33763000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="ib3597315a63d441f8f128abd7ed8840e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfNDktMy0xLTEtNDEyOTQ_1a25ef45-32a1-4ad0-92c6-fc46f81f4743"
      unitRef="usd">3017000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="ie6c3b69702e9429aaeed46bdb9bbb9c1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfNDktNS0xLTEtNDEyOTQ_f26b7c6b-32bd-4c71-8580-a4ead498f810"
      unitRef="usd">2997000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfNTAtMS0xLTEtNDEyOTQ_e1364d8e-f835-4030-a1a2-4e2581e46af6"
      unitRef="usd">6018000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="ib3597315a63d441f8f128abd7ed8840e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfNTAtMy0xLTEtNDEyOTQ_0cfd8882-b519-4645-9326-bc45f0fe251e"
      unitRef="usd">1481000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="ie6c3b69702e9429aaeed46bdb9bbb9c1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfNTAtNS0xLTEtNDEyOTQ_2bbad079-f9f6-4d97-9a42-4cb79d83f02c"
      unitRef="usd">4418000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfNTEtMS0xLTEtNDEyOTQ_e06a4702-530b-419e-94ca-743fb75e1b1c"
      unitRef="usd">0</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="ib3597315a63d441f8f128abd7ed8840e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfNTEtMy0xLTEtNDEyOTQ_8bf7f455-7471-4e31-80b5-3eca7bba23a2"
      unitRef="usd">77998000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="ie6c3b69702e9429aaeed46bdb9bbb9c1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfNTEtNS0xLTEtNDEyOTQ_1cdd4e79-3534-474a-a109-c40838ff4731"
      unitRef="usd">453048000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfWarrants
      contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfNTItMS0xLTEtNDEyOTQ_7e88c1b5-bf7c-4727-8ab4-0b78172d464c"
      unitRef="usd">18446000</us-gaap:PaymentsForRepurchaseOfWarrants>
    <us-gaap:PaymentsForRepurchaseOfWarrants
      contextRef="ib3597315a63d441f8f128abd7ed8840e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfNTItMy0xLTEtNDEyOTQ_38b5fde6-3834-4df4-854b-1999cdde7e22"
      unitRef="usd">0</us-gaap:PaymentsForRepurchaseOfWarrants>
    <us-gaap:PaymentsForRepurchaseOfWarrants
      contextRef="ie6c3b69702e9429aaeed46bdb9bbb9c1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfNTItNS0xLTEtNDEyOTQ_fc194f9f-31f2-4b5c-8d8e-706ce1ba6f47"
      unitRef="usd">380000</us-gaap:PaymentsForRepurchaseOfWarrants>
    <lgnd:PaymentsToContingentValueRightHoldersFinancingActivity
      contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfNTMtMS0xLTEtNDEyOTQ_8e565403-19a7-4d48-b782-3e620d005950"
      unitRef="usd">1050000</lgnd:PaymentsToContingentValueRightHoldersFinancingActivity>
    <lgnd:PaymentsToContingentValueRightHoldersFinancingActivity
      contextRef="ib3597315a63d441f8f128abd7ed8840e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfNTMtMy0xLTEtNDEyOTQ_e894d6f2-d641-4a4a-b735-731db3ff7f41"
      unitRef="usd">2325000</lgnd:PaymentsToContingentValueRightHoldersFinancingActivity>
    <lgnd:PaymentsToContingentValueRightHoldersFinancingActivity
      contextRef="ie6c3b69702e9429aaeed46bdb9bbb9c1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfNTMtNS0xLTEtNDEyOTQ_a9562ac2-114a-4268-a450-dff7cf608039"
      unitRef="usd">3000000</lgnd:PaymentsToContingentValueRightHoldersFinancingActivity>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfNTQtMS0xLTEtNDEyOTQ_330cdbef-37d2-4961-bf2d-8ec0395cb594"
      unitRef="usd">-137761000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="ib3597315a63d441f8f128abd7ed8840e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfNTQtMy0xLTEtNDEyOTQ_1c5dbaea-414e-4c06-99bd-654947271002"
      unitRef="usd">-310545000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="ie6c3b69702e9429aaeed46bdb9bbb9c1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfNTQtNS0xLTEtNDEyOTQ_044ed183-1c80-4469-bdfa-82c4bd469b36"
      unitRef="usd">-485172000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfNTUtMS0xLTEtNDEyOTQ_23f44388-6b21-4e42-98a6-a5d679f92291"
      unitRef="usd">-28440000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="ib3597315a63d441f8f128abd7ed8840e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfNTUtMy0xLTEtNDEyOTQ_32ef6a78-e783-40fd-b2f4-9d2361ee49ab"
      unitRef="usd">-24311000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="ie6c3b69702e9429aaeed46bdb9bbb9c1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfNTUtNS0xLTEtNDEyOTQ_1e14cc32-80cb-4593-b78d-49aa0941ab3c"
      unitRef="usd">-47590000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfNTYtMS0xLTEtNDEyOTQ_c999c4a5-e5d8-4418-a1b0-beb08b00b84d"
      unitRef="usd">0</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ib3597315a63d441f8f128abd7ed8840e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfNTYtMy0xLTEtNDEyOTQ_e93b82b3-f881-4536-95c6-863985eab1e4"
      unitRef="usd">0</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ie6c3b69702e9429aaeed46bdb9bbb9c1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfNTYtNS0xLTEtNDEyOTQ_ff1320bd-7a67-46eb-9bd9-597ac711c08b"
      unitRef="usd">83000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i7462d0db8f4248fcb9fd8f1deae439f3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfNTctMS0xLTEtNDEyOTQ_c4ddae35-cab3-452a-8916-49d50884fd78"
      unitRef="usd">47962000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ida3ec05a32644c2db1bb9f71f76c567f_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfNTctMy0xLTEtNDEyOTQ_4d7da5a8-d029-4a66-bc3a-690fe3a8ad54"
      unitRef="usd">72273000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="if1aac4d81ad94163b33117197afe0895_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfNTctNS0xLTEtNDEyOTQ_f8acda0a-1a8f-4131-9a1e-a5612ba97f01"
      unitRef="usd">119780000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfNTgtMS0xLTEtNDEyOTQ_76656a83-eb6b-4486-9428-c85996b1dac1"
      unitRef="usd">19522000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i7462d0db8f4248fcb9fd8f1deae439f3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfNTgtMy0xLTEtNDEyOTQ_35224601-25ae-4cb6-87c6-4281153d66c2"
      unitRef="usd">47962000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ida3ec05a32644c2db1bb9f71f76c567f_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfNTgtNS0xLTEtNDEyOTQ_09abb43d-05e7-42c5-9a31-4f6589247978"
      unitRef="usd">72273000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:InterestPaidNet
      contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfNjEtMS0xLTEtNDEyOTQ_52e217a6-3b1e-4885-b3b1-99c9100000f9"
      unitRef="usd">3028000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="ib3597315a63d441f8f128abd7ed8840e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfNjEtMy0xLTEtNDEyOTQ_5cc48da1-2702-4cc1-af34-5fa8135f3cbb"
      unitRef="usd">4463000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="ie6c3b69702e9429aaeed46bdb9bbb9c1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfNjEtNS0xLTEtNDEyOTQ_ca51ed85-085d-4a61-8025-5d80a75aa240"
      unitRef="usd">5827000</us-gaap:InterestPaidNet>
    <us-gaap:IncomeTaxesPaid
      contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfNjItMS0xLTEtNDEyOTQ_7e8030ca-b0ec-4272-9603-5fd3dec77851"
      unitRef="usd">3722000</us-gaap:IncomeTaxesPaid>
    <us-gaap:IncomeTaxesPaid
      contextRef="ib3597315a63d441f8f128abd7ed8840e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfNjItMy0xLTEtNDEyOTQ_4ea374a8-c97b-4e29-b3af-49ec623166b5"
      unitRef="usd">2130000</us-gaap:IncomeTaxesPaid>
    <us-gaap:IncomeTaxesPaid
      contextRef="ie6c3b69702e9429aaeed46bdb9bbb9c1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfNjItNS0xLTEtNDEyOTQ_ed121337-0b8d-4f57-a772-5c5736559fda"
      unitRef="usd">103817000</us-gaap:IncomeTaxesPaid>
    <us-gaap:RestrictedCashCurrent
      contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfNjMtMS0xLTEtNDEyOTQ_98d88674-b33f-4023-85c2-4f9fa3b017c9"
      unitRef="usd">0</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashCurrent
      contextRef="i7462d0db8f4248fcb9fd8f1deae439f3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfNjMtMy0xLTEtNDEyOTQ_5c318041-5548-4ce6-b407-68d665a20ef6"
      unitRef="usd">343000</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashCurrent
      contextRef="ida3ec05a32644c2db1bb9f71f76c567f_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfNjMtNS0xLTEtNDEyOTQ_8e1949e7-9d1b-47e8-8224-0ed92c4be265"
      unitRef="usd">730000</us-gaap:RestrictedCashCurrent>
    <lgnd:AccruedInventoryPurchases
      contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfNjUtMS0xLTEtNDEyOTQ_6fbffa6d-a39a-4495-97fd-b03e7c58718d"
      unitRef="usd">1974000</lgnd:AccruedInventoryPurchases>
    <lgnd:AccruedInventoryPurchases
      contextRef="ib3597315a63d441f8f128abd7ed8840e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfNjUtMy0xLTEtNDEyOTQ_ade6b3d5-5897-46c9-a367-ee1ce81b6193"
      unitRef="usd">1562000</lgnd:AccruedInventoryPurchases>
    <lgnd:AccruedInventoryPurchases
      contextRef="ie6c3b69702e9429aaeed46bdb9bbb9c1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfNjUtNS0xLTEtNDEyOTQ_20f6431e-4f3c-4252-bf74-10a19d9f3eea"
      unitRef="usd">170000</lgnd:AccruedInventoryPurchases>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfNjYtMS0xLTEtNDEyOTQ_ca67ad37-e770-421a-b21b-60fed24c157c"
      unitRef="usd">-221000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="ib3597315a63d441f8f128abd7ed8840e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfNjYtMy0xLTEtNDEyOTQ_7bc27552-b922-468f-99c1-dffc80772f1b"
      unitRef="usd">-212000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="ie6c3b69702e9429aaeed46bdb9bbb9c1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfNjYtNS0xLTEtNDEyOTQ_9f78ee55-d1aa-40ed-a2af-77c3b22a5ca3"
      unitRef="usd">256000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfNjctMS0xLTEtNDEyOTQ_2cb1cf84-2eae-45ba-a636-921865b1e844"
      unitRef="usd">1567000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="ib3597315a63d441f8f128abd7ed8840e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfNjctMy0xLTEtNDEyOTQ_c2feaac4-66a2-423a-98d0-37d1fc01b236"
      unitRef="usd">249000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="ie6c3b69702e9429aaeed46bdb9bbb9c1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY183Ni9mcmFnOjgxMmUwNjcyNGE5NjQ2MGE4OTUwMTA5MmZmNzZlMzFiL3RhYmxlOjQ4Y2FkODI1MGMzZDQ2YTU5Mjk4NjJmMzU1YmYxN2I0L3RhYmxlcmFuZ2U6NDhjYWQ4MjUwYzNkNDZhNTkyOTg2MmYzNTViZjE3YjRfNjctNS0xLTEtNDEyOTQ_94c972b3-8587-489c-ba59-624176ca8d27"
      unitRef="usd">495000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock
      contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RleHRyZWdpb246MDE1MzU3NWExNzUxNDlhMGJlMjM2NzA3MzMyMzJiNjlfNTM2OTc_d6c94466-beba-4cd7-b3e6-a27ece948cd0">Basis of Presentation and Summary of Significant Accounting Policies&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Business&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are a biopharmaceutical company focused on developing or acquiring technologies that help pharmaceutical companies discover and develop medicines. We operate in one business segment: development and licensing of biopharmaceutical assets.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Principles of Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying consolidated financial statements include Ligand and its wholly-owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our consolidated financial statements have been prepared in accordance with U.S. GAAP and include the accounts of our parent company and its wholly-owned subsidiaries. All intercompany transactions and balances have been eliminated in consolidation.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of consolidated financial statements in conformity with U.S. GAAP requires the use of estimates and assumptions that affect the amounts reported in the consolidated financial statements and the accompanying notes. Actual results may differ from those estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Concentrations of Business Risk&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial instruments that potentially subject us to significant concentrations of credit risk consist primarily of cash equivalents and investments. We invest excess cash principally in United States government debt securities, investment grade corporate debt securities, mutual funds and certificates of deposit. We maintain some cash and cash equivalents balances with financial institutions that are in excess of the Federal Deposit Insurance Corporation insurance limits. We have established guidelines relative to diversification and maturities that maintain safety and liquidity. These guidelines are periodically reviewed and modified to take advantage of trends in yields and interest rates.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue from significant partners, which is defined as 10% or more of our total revenue, was as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.578%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Year-ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Partner A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Partner B&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Partner C&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&amp;lt;10%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&amp;lt;10%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;  &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We obtain Captisol primarily from two sites related to a single supplier, Hovione.&#160;If this supplier were not able to supply the requested amounts of Captisol from each site, and if our safety stocks of material were depleted, we would be unable to continue to derive revenues from the sale of Captisol until we obtained material from an alternative source, which could take a considerable length of time.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash Equivalents &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Cash equivalents consist of highly liquid investments with maturities of three months or less from the date of acquisition. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Short-term Investments&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Short-term investments primarily consist of investments in debt and equity securities. We classify our short-term investments as &#x201c;available-for-sale&#x201d;. Such investments are carried at fair value, with unrealized gains and losses on debt securities included in the statement of comprehensive income (loss), net of tax, and unrealized gains and losses on equity securities included the consolidated statement of operations. We determine the cost of investments based on the specific identification method. We determine the realized gains or losses on the sale of available-for-sale securities using the specific identification method and includes net realized gains and losses as a component of other income or expense within the consolidated statements of operations.  &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Debt securities consist of certificates of deposit, corporate debt securities, and securities of government-sponsored entities have effective maturities greater than&#160;three&#160;months and less than twelve months from the date of acquisition. Debt securities securities available-for-sale in an unrealized loss position are assessed for the current expected credit losses methodology. We start by assessing whether we intend to sell the security, or whether it is more likely than not that we will be required to sell the security before recovery of its amortized cost basis. If either of the criteria regarding intent or requirement to sell is met, the security&#x2019;s amortized cost basis is written down to fair value through earnings. For debt securities available-for-sale that do not meet the aforementioned criteria, we evaluate whether the decline in fair value has resulted from credit losses or other factors. In making this assessment, we consider the extent to which fair value is less than amortized cost, any changes in interest rates, and any changes to the rating of the security by a rating agency, among other factors. If this assessment indicates that a credit loss exists, the present value of cash flows expected to be collected from the security is compared to the amortized cost basis of the security. If the present value of cash flows expected to be collected is less than the amortized cost basis, a credit loss exists and an allowance for credit losses is recorded, limited by the amount that the fair value is less than the amortized cost basis. Any impairment that has not been recorded through an allowance for credit losses is recognized in other comprehensive income or loss, as applicable.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Equity securities are mutual funds, investments in privately held companies (non-marketable equity securities), and companies that have completed initial public offerings (marketable equity securities). Mutual funds are valued at their publicly quoted net asset value (NAV) price on the last day of the period. Our non-marketable equity securities without readily determinable market values are initially measured at cost and adjusted to fair value for observable transactions for identical or similar investments of the same issuer or impairment. Our marketable equity securities are measured at fair value. Equity investments are classified as short-term investments, or non-current other assets, based on the nature of the securities and their availability for use in current operations. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Accounts Receivable &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our accounts receivable arise primarily from sales on credit to customers. We establish an allowance for credit losses to present the net amount of accounts receivable expected to be collected. The allowance is determined by using the loss-rate method, which requires an estimation of loss rates based upon historical loss experience adjusted for factors that are relevant to determining the expected collectability of accounts receivable. Some of these factors include macroeconomic conditions that correlate with historical loss experience, delinquency trends, aging behavior of receivables and credit and liquidity quality indicators for industry groups, customer classes or individual customers. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:14pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Inventory&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Inventory, which consists of finished goods, is stated at the lower of cost or net realizable value. We determine cost using the first-in, first-out method or the specific identification method. We analyze our inventory levels periodically and write down inventory to net realizable value if it has become obsolete, has a cost basis in excess of its expected net realizable value or is in excess of expected requirements. There were no write downs related to obsolete inventory recorded for the years ended December&#160;31, 2021, 2020 and 2019.  As of December 31, 2021 and 2020, inventory consist of Captisol prepayments of $24.6&#160;million and $26.1&#160;million, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:14pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Property and Equipment&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment are stated at cost, subject to review for impairment, and depreciated over the estimated useful lives of the assets, which generally range from &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RleHRyZWdpb246MDE1MzU3NWExNzUxNDlhMGJlMjM2NzA3MzMyMzJiNjlfNjcyNw_c91288e2-cf87-4740-a1f7-845dfc930514"&gt;three&lt;/span&gt; to ten years, using the straight-line method. Amortization of leasehold improvements is recorded over the shorter of the lease term or estimated useful life of the related asset. Maintenance and repairs are charged to operations as incurred. When assets are sold, or otherwise disposed of, the cost and related accumulated depreciation are removed from the accounts and any gain or loss is included in operating income or expense.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Acquisitions&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;We first determine whether a set of assets acquired constitute a business and should be accounted for as a business combination. If the assets acquired are not a business, we account for the transaction as an asset acquisition. Business combinations are accounted for by using the acquisition method of accounting which requires us to use significant estimates and assumptions, especially with respect to intangible assets. We record the excess consideration over the aggregate fair value of tangible and intangible assets, net of liabilities assumed, as goodwill.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the acquisition method of accounting, we recognize separately from goodwill the identifiable assets acquired, the liabilities assumed, including contingent consideration and all contractual contingencies, generally at the acquisition date fair value. Contingent purchase consideration to be settled in cash are remeasured to estimated fair value at each reporting period with the change in fair value recorded in statement of operations. Costs that we incur to complete the business combination such as investment banking, legal and other professional fees are not considered part of consideration and we charge them to general and administrative expense as they are incurred. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Should the initial accounting for a business combination be incomplete by the end of a reporting period that falls within the measurement period, we report provisional amounts in our financial statements. During the measurement period, we adjust the provisional amounts recognized at the acquisition date to reflect new information obtained about facts and circumstances that existed as of the acquisition date that, if known, would have affected the measurement of the amounts recognized as of that date and we record those adjustments to our financial statements in the period of change, if any.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the acquisition method of accounting for business combinations, if we identify changes to acquired deferred tax asset valuation allowances or liabilities related to uncertain tax positions during the measurement period and they relate to new information obtained about facts and circumstances that existed as of the acquisition date, those changes are considered a measurement period adjustment and we record the offset to goodwill. We record all other changes to deferred tax asset valuation allowances and liabilities related to uncertain tax positions in current period income tax expense. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:14pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Contingent Liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the acquisition of Pfenex in October 2020, we entered into a CVR agreement pursuant to which former equity holders of Pfenex received one nontransferable contractual right entitling such holder to receive $2.00 per share (or approximately $77.8&#160;million total) in the event that Pfenex&#x2019;s teriparatide injection product received notice from the FDA that such product is therapeutically equivalent with respect to FORTEO&#xae; (teriparatide injection) on or before December 31, 2021. The FDA did not provide notice of such event prior to the CVR expiration date and as a result, the Pfenex CVRs expired without payment.  &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the acquisition of Icagen in April 2020, Icagen selling shareholders will be entitled to receive up to an additional $25&#160;million of cash payments based on certain revenue achievements.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the acquisition of CyDex in January 2011, we recorded a contingent liability for amounts potentially due to holders of the CyDex CVRs and former license holders. The liability is periodically assessed based on events and circumstances related to the underlying milestones, royalties and material sales. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the acquisition of Metabasis in January 2010, we issued Metabasis stockholders four tradable CVRs for each Metabasis share. The fair values of the CVRs are remeasured at each reporting date through the term of the related agreement. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Any change in fair value is recorded in our consolidated statement of operations. For additional information, see &#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note (5), Fair Value Measurement and Note (8), Balance Sheet Account Details&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&#x201d;   &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Goodwill, Intangible Assets and Other Long-Lived Assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Goodwill, which has an indefinite useful life, represents the excess of cost over fair value of net assets acquired. Goodwill is reviewed for impairment at least annually during the fourth quarter, or more frequently if an event occurs indicating the potential for impairment. During the goodwill impairment review, we assess qualitative factors to determine whether it is more likely than not that the fair value of our reporting unit is less than the carrying amount, including goodwill. We operate in one reporting unit. The qualitative factors include, but are not limited to, macroeconomic conditions, industry and market considerations, and the overall financial performance. If, after assessing the totality of these qualitative factors, we determine that it is not more likely than not that the fair value of our reporting unit is less than the carrying amount, then no additional assessment is deemed necessary. Otherwise, we proceed to perform the quantitative assessment. We will then evaluate goodwill for impairment by comparing the estimated fair value of the reporting unit to its carrying value, including the associated goodwill. To determine the fair value, we generally use a combination of market approach based on Ligand and comparable publicly traded companies in similar lines of businesses and the income approach based on estimated discounted future cash flows. Our cash flow assumptions consider historical and forecasted revenue, operating costs and other relevant factors. We may also elect to bypass the qualitative assessment in a period and elect to proceed to perform the quantitative assessment for the goodwill impairment test. We performed the annual assessment for goodwill impairment during the fourth quarter of 2021, noting no impairment. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Our identifiable intangible assets are typically composed of acquired core technologies, licensed technologies, contractual relationships, customer relationships and trade names. The cost of identifiable intangible assets with finite lives is generally amortized on a straight-line basis over the assets&#x2019; respective estimated useful lives. We regularly perform reviews to determine if any event has occurred that may indicate that intangible assets with finite useful lives and other long-lived assets are potentially impaired. If indicators of impairment exist, an impairment test is performed to assess the recoverability of the affected assets by determining whether the carrying amount of such assets exceeds the undiscounted expected future cash flows. If the affected assets are not recoverable, we estimate the fair value of the assets and record an impairment loss if the carrying value of the assets exceeds the fair value. Factors that may indicate potential impairment include market conditions, industry and economic trends, changes in regulations, clinical success, historical and forecasted financial results, market capitalization, significant changes in the ability of a particular asset to generate positive cash flows, and the pattern of utilization of a particular asset. We did not identify indicators of impairment for the finite-lived intangibles at December&#160;31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Commercial license and other economic rights&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2021 and 2020, commercial license and other economic rights consist of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.338%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.607%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Adjustments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Adjustments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Aziyo and CorMatrix&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;17,696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(9,461)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8,235&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;17,696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(9,588)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8,108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Selexis and Dianomi&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10,602&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(8,727)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,875&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10,602&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(7,731)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,871&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;28,298&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(18,188)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10,110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;28,298&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(17,319)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10,979&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%"&gt;(1) Amounts represent accumulated amortization to principal of $11.7 million and credit loss adjustments of $6.5 million as of December 31, 2021. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%"&gt;(2) Amounts represent accumulated amortization to principal of $11.3 million and credit loss adjustments of $6.0 million as of December 31, 2020. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Commercial license and other economic rights as of December&#160;31, 2021 represent a portfolio of future milestone and royalty payment rights acquired from Selexis in April 2013 and April 2015, CorMatrix in May 2016, and Dianomi in January 2019. Commercial license rights acquired are accounted for as financial assets, and other economic rights are accounted for as funded research and developments as further discussed below. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2019, we entered into a development funding and royalties agreement with Novan, pursuant to which we would receive certain payments at specified milestones, as well as royalties on any future net sales of SB206, a product candidate being developed to treat molluscum contagiosum, and any other Novan products used for the treatment of molluscum (&#x201c;Novan Molluscum Products&#x201d;). We paid Novan an upfront payment of $12.0 million, which Novan is required to use to fund the development of SB206. We are not obligated to provide additional funding to Novan for the development or commercialization &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;of SB206. Pursuant to the agreement, we would receive up to $20.0 million of milestone payments upon the achievement by Novan of certain regulatory milestones for SB206 or any other Novan Molluscum Product and commercial milestones. In addition to the milestone payments, Novan will pay us tiered royalties from 7.0% to 10.0% based on aggregate annual net sales of SB206 or any other Novan Molluscum Product in North America. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2018, we entered into a development funding and royalties agreement with Palvella. Pursuant to the agreement, we will receive up to $8.0 million of milestone payments upon the achievement by Palvella of certain corporate, financing and regulatory milestones for PTX-022, a product candidate being developed to treat pachyonychia congenita. In addition to the milestone payments, Palvella will pay us tiered royalties from 5.0% to 9.8% based on aggregate annual worldwide net sales of any PTX-022 products, if approved, subject to Palvella&#x2019;s right to reduce the royalty rates by making payments in certain circumstances. We made an upfront payment of $10.0 million, which Palvella is required to use to fund the development of PTX-022. We are not obligated to provide additional funding to Palvella for development or commercialization of PTX-022. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We determined the economic rights related to Novan and Palvella should be characterized as a funded research and development arrangement, thus we account for them in accordance with ASC 730-20, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Research and Development Arrangement, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;and reduce our asset as the funds are expended by Novan and Palvella. As of December 31, 2019, Novan had used up the $12.0 million upfront payment provided by us. As such, our other economic rights related to Novan had been fully amortized as of December 31, 2019. As of December 31, 2020, the fund has been fully expended by Palvella and our cost basis for the asset has been reduced to zero, and therefore we will recognize milestones and royalties as revenue when earned. During 2020, we recorded a $3.0 million milestone from Palvella under contract revenue, which has been included in our consolidated statement of operations for the year ended December&#160;31, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2017, we entered into a royalty agreement with Aziyo pursuant to which we will receive royalties from certain marketed products that Aziyo acquired from CorMatrix. Pursuant to the agreement, we received $10.0 million in 2017 from Aziyo to buydown the royalty rates on the products CorMatrix sold to Aziyo. The agreement closed on May 31, 2017, in connection with the closing of the asset sale from CorMatrix to Aziyo (the &#x201c;CorMatrix Asset Sale&#x201d;). Per the agreement, we will receive a 5% royalty on the products Aziyo acquired in the CorMatrix Asset Sale, reduced from the original 20% royalty from CorMatrix pursuant to the previously disclosed interest purchase agreement, dated May 3, 2016 (the &#x201c;Original Interest Purchase Agreement&#x201d;) between CorMatrix and us. In addition, Aziyo has agreed to pay us up to $10.0 million of additional milestones tied to cumulative net sales of the products Aziyo acquired in the CorMatrix Asset Sale and to extend the term on these royalties by one year. The royalty agreement will terminate on May 31, 2027. In addition, in May 2017, we entered into an amended and restated interest purchase agreement (the &#x201c;Amended Interest Purchase Agreement&#x201d;) with CorMatrix, which supersedes in its entirety the Original Interest Purchase Agreement. Other than removing the commercial products sold to Aziyo in the CorMatrix Sale, the terms of the Amended Interest Purchase Agreement remain unchanged with respect to the CorMatrix developmental pipeline products, including the royalty rate of 5% on such pipeline products. The Amended Interest Purchase Agreement will terminate 10 years from the date of the first commercial sale of such products. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We account for the Aziyo commercial license right as a financial asset in accordance with ASC 310, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Receivables&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, and amortize the commercial license right using the effective interest method whereby we forecast expected cash flows over the term of the arrangement to arrive at an annualized effective interest. The annual effective interest associated with the forecasted cash flows from the royalty agreement with Aziyo as of December&#160;31, 2021 is 21.6%. Revenue is calculated by multiplying the carrying value of the commercial license right by the effective interest. The payments received in 2021 were accordingly allocated between revenue and the amortization of the commercial license rights.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prior to 2020, we accounted for commercial license rights related to developmental pipeline products such as Selexis and Dianomi on a non-accrual basis. These developmental pipeline products are non-commercialized, non-approved products that require FDA or other regulatory approval, and thus have uncertain cash flows. The developmental pipeline products are on a non-accrual basis as we are not yet able to forecast future cash flows given their pre-commercial stages of development. We will prospectively update the yield model under the effective interest method once the underlying products are commercialized and we can reliably forecast expected cash flows. Income will be calculated by multiplying the carrying value of the commercial license right by the effective interest rate. We regularly perform reviews to determine if any event has occurred that may indicate the carrying value of these commercial license rights are potentially impaired. If the affected commercial license rights are not recoverable, we estimate the fair value of the assets and record an impairment loss if the carrying value of the assets exceeds the fair value. During 2020, given the expected cash flow from the Selexis program, we started to account for the Selexis commercial license right as a financial asset in accordance with ASC 310, and amortize the commercial license right using the effective interest method whereby we forecast expected cash flows over the term of the arrangement to arrive at an annualized effective interest. The annual effective interest associated with the forecasted cash flows from the royalty agreement with Selexis as of December&#160;31, 2021 is 21%. Revenue is calculated by multiplying the carrying value of the commercial license right by the effective interest. The payments received in the year ended December&#160;31, 2021 and 2020 were allocated &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;accordingly between revenue and the amortization of the commercial license rights. We still accounted for commercial license rights related to Dianomi on a non-accrual basis as of December&#160;31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For commercial license rights, we have elected a prospective approach to account for changes in estimated cash flows and selected a method for determining when an impairment would be recognized and how to measure that impairment. In circumstances where our new estimate of expected cash flows is greater than previously expected, we will update our yield prospectively. In circumstances where our new estimate of expected cash flows is less than previously expected and below our original estimated yield we record an impairment. Impairment is recognized by reducing the financial asset to an amount that represents the present value of our most recent estimate of expected cash flows discounted by the original effective interest rate.&#160;In circumstances where our new estimate of expected cash flows is less than previously expected, but not below our original estimated yield, we update our yield prospectively.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;As a result of adopting ASU 2016-13, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Financial Instruments &#x2013; Credit Losses: Measurement of Credit losses on Financial Instruments (Topic 326)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;, we now recognize an allowance for current expected credit losses on the commercial license rights subject to credit risk. We recorded a $5.5 million pre-tax reserve for credit losses upon adoption of the standard on January 1, 2020. We estimated the credit losses at the individual asset level by considering the performance against the programs, the company operating performance and the macroeconomic forecast. In addition, we have judgmentally applied credit loss risk factors to the future expected payments with consideration given to the timing of the payment. Given the higher inherent credit risk associated with longer term receivables, we applied a lower risk factor to the earlier years and progressively higher risk factors to the later years. During the twelve months ended December&#160;31, 2021 and 2020, we further considered the current and expected future economic and market conditions surrounding novel coronavirus (COVID-19) pandemic, along with other factors, and recorded an additional $0.5&#160;million each year, for credit losses in other expense, net, in our consolidated statements of operations.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our revenue is generated primarily from royalties on sales of products commercialized by our partners, Captisol material sales, and contract revenue for services, license fees and development, regulatory and sales based milestone payments.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We apply the following five-step model in accordance with ASC 606, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customers, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;in order to determine the revenue: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations, including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Royalties&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We receive royalty revenue on sales by our partners of products covered by patents that we or our partners own under contractual agreements. We do not have future performance obligations under these license arrangements. We generally satisfy our obligation to grant intellectual property rights on the effective date of the contract. However, we apply the royalty recognition constraint required under the guidance for sales-based royalties which requires a royalty to be recorded no sooner than the underlying sale occurs. Therefore, royalties on sales of products commercialized by our partners are recognized in the quarter the product is sold. Our partners generally report sales information to us on a one quarter lag. Thus, we estimate the expected royalty proceeds based on an analysis of historical experience and interim data provided by our partners including their publicly announced sales. Differences between actual and estimated royalty revenues, which have not been material, are adjusted in the period in which they become known, typically the following quarter. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt;Captisol Sales&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue from Captisol sales is recognized when control of Captisol material or intellectual property license rights is transferred to our customers in an amount that reflects the consideration we expect to receive from our customers in exchange for those products. A performance obligation is considered distinct from other obligations in a contract when it provides a benefit to the customer either on its own or together with other resources that are readily available to the customer and is separately identified in the contract. For Captisol material, we consider our performance obligation is satisfied at a point in time, once we have transferred control of the product, meaning the customer has the ability to use and obtain the benefit of the Captisol material or intellectual property license right. We recognize revenue for satisfied performance obligations only when we determine there are no uncertainties regarding payment terms or transfer of control. Sales tax and other taxes we collect concurrent with revenue-producing activities are excluded from revenue. We have elected to recognize the cost of freight and shipping when control over Captisol material has transferred to the customer as an expense in Cost of Captisol. We expense incremental costs of obtaining a contract when incurred if the expected amortization period of the asset that we would have recognized is one year or less or the amount is immaterial. We did not incur any incremental costs of obtaining a contract during the periods reported.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt;Contract Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our contracts with customers often will include variable consideration in the form of contingent milestone-based payments. We include contingent milestone based payments in the estimated transaction price when it is probable a significant reversal in the amount of cumulative revenue recognized will not occur. These estimates are based on historical experience, anticipated results and our best judgment at the time. If the contingent milestone based payment is sales-based, we apply the royalty recognition constraint and record revenue when the underlying sale has taken place. Significant judgments must be made in determining the transaction price for our sales of intellectual property. Because of the risk that products in development with our partners will not reach development based milestones or receive regulatory approval, we generally recognize any contingent payments that would be due to us upon the development milestone or regulatory approval. Depending on the terms of the arrangement, we may also defer a portion of the consideration received if we have to satisfy a future obligation, which typically occurs with our contracts for R&amp;amp;D services.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For R&amp;amp;D services we recognize revenue over time and we measure our progress using an input method. The input methods we use are based on the effort we expend or costs we incur toward the satisfaction of our performance obligation. We estimate the amount of effort we expend, including the time it will take us to complete the activities, or the costs we may incur in a given period, relative to the estimated total effort or costs to satisfy the performance obligation. This results in a percentage that we multiply by the transaction price to determine the amount of revenue we recognize each period. This approach requires us to make numerous estimates and use significant judgement. If our estimates or judgements change over the course of the collaboration, they may affect the timing and amount of revenue that we recognize in the current and future periods.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;We occasionally have sub-license obligations related to arrangements for which we receive license fees, milestones and royalties. We evaluate the determination of gross as a principal versus net as an agent reporting based on each individual agreement.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Deferred Revenue&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Depending on the terms of the arrangement, we may also defer a portion of the consideration received if we have to satisfy a future obligation.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The timing of revenue recognition, billings and cash collections results in billed accounts receivable, unbilled receivables (contract assets), and customer advances and deposits (contract liabilities) on the consolidated balance sheet. Except for royalty revenue, we generally receive payment at the point we satisfy our obligation or soon after. Therefore, we do not generally carry a contract asset balance. Any fees billed in advance of being earned are recorded as deferred revenue. During the twelve months ended December&#160;31, 2021, the amount recognized as revenue that was previously deferred at December 31, 2020 was $30.1 million. During the twelve months ended December&#160;31, 2020, the amount recognized as revenue that was previously deferred at December 31, 2019 was $0.9 million.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Disaggregation of Revenue &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Royalty revenue for 2021, 2020 and 2019 are reported as below (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:61.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Kyprolis&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,472&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,164&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,046&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Evomela&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,079&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,377&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,171&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,376&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,255&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,566&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Promacta&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,193&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,927&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,796&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,976&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table represents disaggregation of Captisol and Contract Revenue (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:61.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Captisol&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;164,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;109,959&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,489&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contract&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Service Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,712&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,803&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,776&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;License Fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,084&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Milestone&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,748&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,516&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,173&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,412&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,967&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,669&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63,956&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42,664&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,817&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Research and Development Expenses&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development expense consists of labor, material, equipment, and allocated facilities costs of our scientific staff who are working pursuant to our collaborative agreements and other research and development projects. Also included in research and development expenses are third-party costs incurred for our research programs including in-licensing costs, CRO costs and costs incurred by other research and development service vendors. We expense these costs as they are incurred. When we make payments for research and development services prior to the services being rendered, we record those amounts as prepaid assets on our consolidated balance sheet and we expense them as the services are provided. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Share-Based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We incur share-based compensation expense related to restricted stock, ESPP, and stock options.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:45pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restricted stock unit (RSU) and performance stock unit (PSU) are all considered restricted stock. The fair value of restricted stock is determined by the closing market price of our common stock on the date of grant. We recognize share-based compensation expense based on the fair value on a straight-line basis over the requisite service periods of the awards, taking into consideration of forfeitures as they occur. PSU generally represents a right to receive a certain number of shares of common stock based on the achievement of corporate performance goals and continued employment during the vesting period. At each reporting period, we reassess the probability of the achievement of such corporate performance goals and any expense change resulting from an adjustment in the estimated shares to be released are treated as a cumulative catch-up in the period of adjustment. A limited amount of PSUs contain a market condition dependent upon the Company&#x2019;s relative and absolute total stockholder return over a three-year period, with a range of 0% to 200% of the target amount granted to be issued under the award. Share-based compensation expense for these PSUs is measured using the Monte-Carlo simulation valuation model and is not adjusted for the achievement, or lack thereof, of the market conditions.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Black-Scholes-Merton option-pricing model is used to estimate the fair value of stock purchases under our ESPP and stock options granted. The model assumptions include expected volatility, term, dividends, and the risk-free interest rate. We look to historical and implied volatilities of our stock to determine the expected volatility. The expected term of an award is based on historical forfeiture experience, exercise activity, and on the terms and conditions of the stock awards. The expected dividend yield is determined to be 0% given that except for 2007, during which we declared a cash dividend on our common stock of $2.50 per share, we have not paid any dividends on our common stock in the past and currently do not expect to pay cash dividends or make any other distributions on common stock in the future. The risk-free interest rate is based upon U.S. Treasury securities with remaining terms similar to the expected term of the share-based awards.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We grant options, RSUs and PSUs to employees and non-employee directors. Non-employee directors are accounted for as employees. Options and RSUs granted to certain non-employee directors typically vest one year from the date of grant. Options granted to employees typically vest 1/8 on the six month anniversary of the date of grant, and 1/48 each month thereafter for forty-two months. RSUs and PSUs granted to employees vest over three years. All option awards generally expire ten years from the date of grant.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Share-based compensation expense for awards to employees and non-employee directors is recognized on a straight-line basis over the vesting period until the last tranche vests. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Derivatives&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2018, we issued $750.0 million aggregate principal amount of 2023 Notes, bearing cash interest at a rate of 0.75% per year, payable semi-annually, as further described in &#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note (7), Convertible Senior Notes.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x201d; Concurrently with the issuance of the notes, we entered into a series of convertible note hedge and warrant transactions which in combination are designed to reduce the potential dilution to our stockholders and/or offset the cash payments we are required to make in excess of the principal amount upon conversion of the notes. The conversion option associated with the 2023 Notes temporarily met the criteria for an embedded derivative liability which required bifurcation and separate accounting. In addition, the note hedge and warrants were also temporarily classified as a derivative asset and liability, respectively, on our consolidated balance sheet. As a result of shareholder approval to increase the number of authorized shares of our common stock on June 19, 2018, as discussed in &#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note (7), Convertible Senior Notes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;,&#x201d; the derivative asset and liabilities were reclassified to additional paid-in capital. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with our 2019 Notes, which we issued in August 2014 for $245.0 million aggregate principal amount, on May 22, 2018, we amended it making an irrevocable election to settle the entire note in cash. As a result, we reclassified from equity to derivative liability the fair value of the conversion premium as of May 22, 2018. Amounts paid in excess of the principal amount would be offset by an equal receipt of cash under the corresponding convertible bond hedge. As a result, we reclassified from equity to derivative asset the fair value of the bond hedge as of May 22, 2018. Changes in the fair value of these derivatives are reflected in other expense, net, in our consolidated statements of operations.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the payoff of the 2019 Notes in August 15, 2019, the bond hedge was settled and accordingly, the derivative asset and derivative liability were settled to zero. See detail in &#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note (7), Convertible Senior Notes.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x201d;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The provision for income taxes is computed using the asset and liability method, under which deferred tax assets and liabilities are recognized for the expected future tax consequences of temporary differences between the financial reporting and tax bases of assets and liabilities, and for the expected future tax benefit to be derived from tax loss and credit carryforwards. Deferred tax assets and liabilities are determined using the enacted tax rates in effect for the years in which those tax assets are expected to be realized. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in the provision for income taxes in the period that includes the enactment date. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred tax assets are regularly assessed to determine the likelihood they will be recovered from future taxable income. A valuation allowance is established when we believe it is more likely than not the future realization of all or some of a deferred tax asset will not be achieved. In evaluating the ability to recover deferred tax assets within the jurisdiction which they arise we consider all available positive and negative evidence. Factors reviewed include the cumulative pre-tax book income for the past three years, scheduled reversals of deferred tax liabilities, history of earnings and reliable forecasting, projections of pre-tax book income over the foreseeable future, and the impact of any feasible and prudent tax planning strategies.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognize the impact of a tax position in our financial statements only if that position is more likely than not of being sustained upon examination by taxing authorities, based on the technical merits of the position. Tax authorities regularly examine our returns in the jurisdictions in which we do business and we regularly assess the tax risk of our return filing positions. Due to the complexity of some of the uncertainties, the ultimate resolution may result in payments that are materially different from our current estimate of the tax liability. These differences, as well as any interest and penalties, will be reflected in the provision for income taxes in the period in which they are determined.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Income (Loss) Per Share&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic income (loss) per share is calculated by dividing net income (loss) by the weighted-average number of common shares outstanding during the period. Diluted income per share is computed based on the sum of the weighted average number of common shares and potentially dilutive common shares outstanding during the period. Diluted loss per share is computed based on the sum of the weighted average number of common shares outstanding during the period.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Potentially dilutive common shares consist of shares issuable under 2023 convertible senior notes, stock options and restricted stock. 2023 convertible senior notes have a dilutive impact when the average market price of the Company&#x2019;s common stock exceeds the applicable conversion price of the respective notes. It is our intent and policy to settle conversions through combination settlement, which essentially involves payment in cash equal to the principal portion and delivery of shares of common stock for the excess of the conversion value over the principal portion. Potentially dilutive common shares from stock options and restricted stock are determined using the average share price for each period under the treasury stock method. In addition, the following amounts are assumed to be used to repurchase shares: proceeds from exercise of stock options and the average amount of unrecognized compensation expense for stock options and restricted stock. In loss periods, basic net loss per &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;share and diluted net loss per share are identical since the effect of otherwise dilutive potential common shares is anti-dilutive and therefore excluded.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;For the twelve months ended December 31, 2020, all of the 0.6&#160;million weighted average shares of outstanding equity awards as of December 31, 2020 were anti-dilutive due to the net loss for the period.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the calculation of weighted average shares used to calculate basic and diluted income (loss) per share (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.189%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.649%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average shares outstanding:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,630&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,995&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dilutive potential common shares:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Restricted stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;520&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;719&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares used to compute diluted income (loss) per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,757&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Potentially dilutive shares excluded from calculation due to anti-dilutive effect&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,793&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,458&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,926&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Comprehensive Income (Loss)&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Comprehensive income (loss) represents net income (loss) adjusted for the change during the periods presented in unrealized gains and losses on available-for-sale debt securities, foreign currency translation adjustments, and reclassification adjustments for realized gains or losses included in net income (loss). The unrealized gains or losses are reported on the Consolidated Statements of Comprehensive Income (Loss).&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Foreign Currency Translation&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The British Pound Sterling was the functional currency of our subsidiary, Vernalis, which was sold in fourth quarter of the year ended December 31, 2020. For the years ended December 31, 2020 and 2019 the corresponding financial statements have been translated into U.S. Dollars in accordance with ASC 830-30, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt;Translation of Financial Statements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;. Assets and liabilities are translated at end-of-period rates while revenues and expenses are translated at average rates in effect during the period in which the activity took place. Equity is translated at historical rates and the resulting cumulative translation adjustments are included as a component of accumulated other comprehensive income (loss).&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Impact of COVID-19 Pandemic&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;To date, we have not experienced material disruptions in our business operations or financial impacts as a result of the COVID-19 pandemic. While it is not possible at this time to estimate the impact that COVID-19 could have on our business in the future, the continued spread of COVID-19 and variants of the virus, the rate of vaccinations regionally and globally and the measures taken by the government authorities, and any future epidemic disease outbreaks, could: disrupt the supply chain and the manufacture or shipment of products and supplies for use by us in our discovery activities and by our partners for their discovery and development activities; delay, limit or prevent us or our partners&#x2019; from continuing research and development activities; impede our negotiations with partners and potential partners; impede testing, monitoring, data collection and analysis and other related activities, by us and our partners; interrupt or delay the operations of the FDA or other regulatory authorities, which may impact review and approval timelines for initiation of clinical trials or marketing; impede the launch or commercialization of any approved products; any of which could delay our partnership programs, increase our operating costs, and have a material adverse effect on our business, financial condition and results of operations. In addition, if COVID-19 infects our genetically modified animals, which form the basis of our platform, or if there is an outbreak among our employees who maintain and care for these animals, we and our partners may be unable to produce antibodies for development.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Some of our partners are working to develop drugs to treat COVID-19. For example, we are supplying Captisol to partners, including Gilead for Veklury (remdesivir), the first FDA-approved treatment for COVID-19 for the treatment of patients with COVID-19 requiring hospitalization and, as a result, we have extended our Captisol supply agreement with Gilead until September 2030 and worked to increase our manufacturing of Captisol to meet this increased demand. In addition, certain of our OmniAb and other license partners have initiated antibody discovery programs for the potential treatment of COVID-19.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The full extent to which the COVID-19 pandemic will directly or indirectly impact our business, the businesses of our partners, our results of operations and our financial condition will depend on future developments that are highly uncertain and cannot be &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;accurately predicted, including new information that may emerge concerning COVID-19, the actions taken to contain it or treat its impact, including the timing and extent of governments reopening or further restricting activities, and the economic impact on local, regional, national and international markets.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Accounting Standards Not Yet Adopted&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In August 2020, the FASB issued ASU 2020-06, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Debt &#x2013; Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging &#x2013; Contracts in Entity&#x2019;s Own Equity (Subtopic 815 &#x2013; 40)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;, which simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts on an entity&#x2019;s own equity. This guidance is part of the FASB&#x2019;s simplification initiative, which aims to reduce unnecessary complexity in U.S. GAAP. The ASU is effective for public entities for fiscal years beginning after December 15, 2021, and interim periods within those fiscal years. Effective January 1, 2022, we will adopt ASU 2020-06. We are finalizing our analysis of certain assumptions that will be utilized at the transition and expects the effect of adopting ASU 2020-06 will result in an increase to retained earnings, a decrease to additional paid-in capital, and an increase to the convertible senior notes. We expect that interest expense recognized in future periods will be reduced as a result of accounting for the convertible debt instrument as a single liability measured at its amortized cost. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;We do not believe that any other recently issued, but not yet effective accounting pronouncements, if adopted, would have a material impact on our consolidated financial statements or disclosures.&lt;/span&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RleHRyZWdpb246MDE1MzU3NWExNzUxNDlhMGJlMjM2NzA3MzMyMzJiNjlfMjE5OTAyMzMyOTU4OA_bcff7911-ad9f-43f6-82eb-b1b3f6449dea"
      unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:ConsolidationPolicyTextBlock
      contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RleHRyZWdpb246MDE1MzU3NWExNzUxNDlhMGJlMjM2NzA3MzMyMzJiNjlfNTM2NzM_06489cdd-abff-454e-935f-d17e54a4b27c">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Principles of Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying consolidated financial statements include Ligand and its wholly-owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RleHRyZWdpb246MDE1MzU3NWExNzUxNDlhMGJlMjM2NzA3MzMyMzJiNjlfNTM3MDI_ef10855a-1f69-4f41-94fb-c01698100673">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our consolidated financial statements have been prepared in accordance with U.S. GAAP and include the accounts of our parent company and its wholly-owned subsidiaries. All intercompany transactions and balances have been eliminated in consolidation.&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RleHRyZWdpb246MDE1MzU3NWExNzUxNDlhMGJlMjM2NzA3MzMyMzJiNjlfNTM3MDM_d1b74458-9de9-4b83-8f59-f65794ea21af">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of consolidated financial statements in conformity with U.S. GAAP requires the use of estimates and assumptions that affect the amounts reported in the consolidated financial statements and the accompanying notes. Actual results may differ from those estimates.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RleHRyZWdpb246MDE1MzU3NWExNzUxNDlhMGJlMjM2NzA3MzMyMzJiNjlfNTM2OTA_1a307767-2b26-4ae2-9682-2be786643961">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Concentrations of Business Risk&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial instruments that potentially subject us to significant concentrations of credit risk consist primarily of cash equivalents and investments. We invest excess cash principally in United States government debt securities, investment grade corporate debt securities, mutual funds and certificates of deposit. We maintain some cash and cash equivalents balances with financial institutions that are in excess of the Federal Deposit Insurance Corporation insurance limits. We have established guidelines relative to diversification and maturities that maintain safety and liquidity. These guidelines are periodically reviewed and modified to take advantage of trends in yields and interest rates.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock
      contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RleHRyZWdpb246MDE1MzU3NWExNzUxNDlhMGJlMjM2NzA3MzMyMzJiNjlfNTM2OTE_46c3a373-10b6-415b-aa28-946d8eb03728">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue from significant partners, which is defined as 10% or more of our total revenue, was as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.578%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Year-ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Partner A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Partner B&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Partner C&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&amp;lt;10%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&amp;lt;10%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i8b1b6cbf7db84387abc05c19c397f3e1_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RhYmxlOmVjNDE2ZDEwOWQ0MDQzZWQ5ZmJjM2FlNTYxNmJlOTk2L3RhYmxlcmFuZ2U6ZWM0MTZkMTA5ZDQwNDNlZDlmYmMzYWU1NjE2YmU5OTZfMi0xLTEtMS00MTI5NA_43c48750-9f72-48a7-93d4-e864347342b9"
      unitRef="number">0.41</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i779fbae243e046e6a31b9eaa2c179124_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RhYmxlOmVjNDE2ZDEwOWQ0MDQzZWQ5ZmJjM2FlNTYxNmJlOTk2L3RhYmxlcmFuZ2U6ZWM0MTZkMTA5ZDQwNDNlZDlmYmMzYWU1NjE2YmU5OTZfMi0zLTEtMS00MTI5NA_b533c274-0dd3-45c7-93b4-2e0ade574ed6"
      unitRef="number">0.45</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i32323a9d8b2a49eca1eebf5fa5da97be_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RhYmxlOmVjNDE2ZDEwOWQ0MDQzZWQ5ZmJjM2FlNTYxNmJlOTk2L3RhYmxlcmFuZ2U6ZWM0MTZkMTA5ZDQwNDNlZDlmYmMzYWU1NjE2YmU5OTZfMy0xLTEtMS00MTI5NA_3e773a2e-af71-4274-8f49-23bfcb76f340"
      unitRef="number">0.14</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ib29fdd94f38f445bbfcbf8d17a9b0d2c_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RhYmxlOmVjNDE2ZDEwOWQ0MDQzZWQ5ZmJjM2FlNTYxNmJlOTk2L3RhYmxlcmFuZ2U6ZWM0MTZkMTA5ZDQwNDNlZDlmYmMzYWU1NjE2YmU5OTZfMy0zLTEtMS00MTI5NA_f7c2ef70-711a-4dda-b31f-a038b14f4d62"
      unitRef="number">0.17</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i19caa64fec87477596a2cd5d23955ee8_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RhYmxlOmVjNDE2ZDEwOWQ0MDQzZWQ5ZmJjM2FlNTYxNmJlOTk2L3RhYmxlcmFuZ2U6ZWM0MTZkMTA5ZDQwNDNlZDlmYmMzYWU1NjE2YmU5OTZfMy01LTEtMS00MTI5NA_ad5c838a-67aa-48ed-9d1c-0696b0f6fce7"
      unitRef="number">0.27</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i6a70ae97ec4641b88ce641ff76d8edd7_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RhYmxlOmVjNDE2ZDEwOWQ0MDQzZWQ5ZmJjM2FlNTYxNmJlOTk2L3RhYmxlcmFuZ2U6ZWM0MTZkMTA5ZDQwNDNlZDlmYmMzYWU1NjE2YmU5OTZfNC01LTEtMS01NzExMw_2709ec50-4d4b-4e72-887d-04beb6f00ad8"
      unitRef="number">0.13</us-gaap:ConcentrationRiskPercentage1>
    <lgnd:CashCashEquivalentsandShorttermInvestmentsPolicyTextBlock
      contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RleHRyZWdpb246MDE1MzU3NWExNzUxNDlhMGJlMjM2NzA3MzMyMzJiNjlfNTM2ODM_766266e1-3e5e-48e0-b7a6-c6f258fb4fd3">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash Equivalents &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Cash equivalents consist of highly liquid investments with maturities of three months or less from the date of acquisition. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Short-term Investments&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Short-term investments primarily consist of investments in debt and equity securities. We classify our short-term investments as &#x201c;available-for-sale&#x201d;. Such investments are carried at fair value, with unrealized gains and losses on debt securities included in the statement of comprehensive income (loss), net of tax, and unrealized gains and losses on equity securities included the consolidated statement of operations. We determine the cost of investments based on the specific identification method. We determine the realized gains or losses on the sale of available-for-sale securities using the specific identification method and includes net realized gains and losses as a component of other income or expense within the consolidated statements of operations.  &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Debt securities consist of certificates of deposit, corporate debt securities, and securities of government-sponsored entities have effective maturities greater than&#160;three&#160;months and less than twelve months from the date of acquisition. Debt securities securities available-for-sale in an unrealized loss position are assessed for the current expected credit losses methodology. We start by assessing whether we intend to sell the security, or whether it is more likely than not that we will be required to sell the security before recovery of its amortized cost basis. If either of the criteria regarding intent or requirement to sell is met, the security&#x2019;s amortized cost basis is written down to fair value through earnings. For debt securities available-for-sale that do not meet the aforementioned criteria, we evaluate whether the decline in fair value has resulted from credit losses or other factors. In making this assessment, we consider the extent to which fair value is less than amortized cost, any changes in interest rates, and any changes to the rating of the security by a rating agency, among other factors. If this assessment indicates that a credit loss exists, the present value of cash flows expected to be collected from the security is compared to the amortized cost basis of the security. If the present value of cash flows expected to be collected is less than the amortized cost basis, a credit loss exists and an allowance for credit losses is recorded, limited by the amount that the fair value is less than the amortized cost basis. Any impairment that has not been recorded through an allowance for credit losses is recognized in other comprehensive income or loss, as applicable.&lt;/span&gt;&lt;/div&gt;Equity securities are mutual funds, investments in privately held companies (non-marketable equity securities), and companies that have completed initial public offerings (marketable equity securities). Mutual funds are valued at their publicly quoted net asset value (NAV) price on the last day of the period. Our non-marketable equity securities without readily determinable market values are initially measured at cost and adjusted to fair value for observable transactions for identical or similar investments of the same issuer or impairment. Our marketable equity securities are measured at fair value. Equity investments are classified as short-term investments, or non-current other assets, based on the nature of the securities and their availability for use in current operations.</lgnd:CashCashEquivalentsandShorttermInvestmentsPolicyTextBlock>
    <lgnd:MaturityPeriodOfHighlyLiquidSecuritiesMaximum
      contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RleHRyZWdpb246MDE1MzU3NWExNzUxNDlhMGJlMjM2NzA3MzMyMzJiNjlfMzU4OA_e6af90ce-05e7-49ba-b584-1a1b8cea5b71">P3M</lgnd:MaturityPeriodOfHighlyLiquidSecuritiesMaximum>
    <us-gaap:ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy
      contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RleHRyZWdpb246MDE1MzU3NWExNzUxNDlhMGJlMjM2NzA3MzMyMzJiNjlfNTM3MDc_f412bad7-1f36-4591-907c-184dafa87332">Accounts Receivable Our accounts receivable arise primarily from sales on credit to customers. We establish an allowance for credit losses to present the net amount of accounts receivable expected to be collected. The allowance is determined by using the loss-rate method, which requires an estimation of loss rates based upon historical loss experience adjusted for factors that are relevant to determining the expected collectability of accounts receivable. Some of these factors include macroeconomic conditions that correlate with historical loss experience, delinquency trends, aging behavior of receivables and credit and liquidity quality indicators for industry groups, customer classes or individual customers.</us-gaap:ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy>
    <us-gaap:InventoryPolicyTextBlock
      contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RleHRyZWdpb246MDE1MzU3NWExNzUxNDlhMGJlMjM2NzA3MzMyMzJiNjlfNTM2OTg_a9d0aa77-cc42-4917-98ce-4d1397367a8b">InventoryInventory, which consists of finished goods, is stated at the lower of cost or net realizable value. We determine cost using the first-in, first-out method or the specific identification method. We analyze our inventory levels periodically and write down inventory to net realizable value if it has become obsolete, has a cost basis in excess of its expected net realizable value or is in excess of expected requirements.</us-gaap:InventoryPolicyTextBlock>
    <us-gaap:InventoryWriteDown
      contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RleHRyZWdpb246MDE1MzU3NWExNzUxNDlhMGJlMjM2NzA3MzMyMzJiNjlfNjQ0NQ_3bc47895-feb5-4903-a4b2-ece830500940"
      unitRef="usd">0</us-gaap:InventoryWriteDown>
    <us-gaap:InventoryWriteDown
      contextRef="ie6c3b69702e9429aaeed46bdb9bbb9c1_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RleHRyZWdpb246MDE1MzU3NWExNzUxNDlhMGJlMjM2NzA3MzMyMzJiNjlfNjQ0NQ_4a8a0e16-cfb3-4634-ab45-cca57fb220e1"
      unitRef="usd">0</us-gaap:InventoryWriteDown>
    <us-gaap:InventoryWriteDown
      contextRef="ib3597315a63d441f8f128abd7ed8840e_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RleHRyZWdpb246MDE1MzU3NWExNzUxNDlhMGJlMjM2NzA3MzMyMzJiNjlfNjQ0NQ_b493f9b2-04c4-46ef-ab24-eb72ebf2ffd5"
      unitRef="usd">0</us-gaap:InventoryWriteDown>
    <us-gaap:InventoryNet
      contextRef="i874c2ad63f1a4f0295a0ad715157a00e_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RleHRyZWdpb246MDE1MzU3NWExNzUxNDlhMGJlMjM2NzA3MzMyMzJiNjlfNzY5NjU4MTUwNTk4MQ_e852efd8-126d-4ccd-b3cc-8e2200da35b9"
      unitRef="usd">24600000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="i6a5b82872f4b4205b4cb36e3a7e65b00_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RleHRyZWdpb246MDE1MzU3NWExNzUxNDlhMGJlMjM2NzA3MzMyMzJiNjlfNzY5NjU4MTUwNTk5Ng_18b6013b-abe1-4b5b-ac02-755af44ec9f2"
      unitRef="usd">26100000</us-gaap:InventoryNet>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RleHRyZWdpb246MDE1MzU3NWExNzUxNDlhMGJlMjM2NzA3MzMyMzJiNjlfNTM3MDg_f5f612be-7dae-4dfb-b1b2-09126d6ec5f2">&lt;div style="margin-top:14pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Property and Equipment&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment are stated at cost, subject to review for impairment, and depreciated over the estimated useful lives of the assets, which generally range from &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RleHRyZWdpb246MDE1MzU3NWExNzUxNDlhMGJlMjM2NzA3MzMyMzJiNjlfNjcyNw_c91288e2-cf87-4740-a1f7-845dfc930514"&gt;three&lt;/span&gt; to ten years, using the straight-line method. Amortization of leasehold improvements is recorded over the shorter of the lease term or estimated useful life of the related asset. Maintenance and repairs are charged to operations as incurred. When assets are sold, or otherwise disposed of, the cost and related accumulated depreciation are removed from the accounts and any gain or loss is included in operating income or expense.&lt;/span&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i55156c07b9684b9185860bad3331609a_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RleHRyZWdpb246MDE1MzU3NWExNzUxNDlhMGJlMjM2NzA3MzMyMzJiNjlfMzg0ODI5MDc1MDkzNg_a3b2d52b-5dc1-46c7-ab7f-54eb66493826">P10Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:BusinessCombinationsPolicy
      contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RleHRyZWdpb246MDE1MzU3NWExNzUxNDlhMGJlMjM2NzA3MzMyMzJiNjlfNTM2OTk_13a4bf73-4b31-40e6-becb-8bc4bc8d47a5">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Acquisitions&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;We first determine whether a set of assets acquired constitute a business and should be accounted for as a business combination. If the assets acquired are not a business, we account for the transaction as an asset acquisition. Business combinations are accounted for by using the acquisition method of accounting which requires us to use significant estimates and assumptions, especially with respect to intangible assets. We record the excess consideration over the aggregate fair value of tangible and intangible assets, net of liabilities assumed, as goodwill.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the acquisition method of accounting, we recognize separately from goodwill the identifiable assets acquired, the liabilities assumed, including contingent consideration and all contractual contingencies, generally at the acquisition date fair value. Contingent purchase consideration to be settled in cash are remeasured to estimated fair value at each reporting period with the change in fair value recorded in statement of operations. Costs that we incur to complete the business combination such as investment banking, legal and other professional fees are not considered part of consideration and we charge them to general and administrative expense as they are incurred. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Should the initial accounting for a business combination be incomplete by the end of a reporting period that falls within the measurement period, we report provisional amounts in our financial statements. During the measurement period, we adjust the provisional amounts recognized at the acquisition date to reflect new information obtained about facts and circumstances that existed as of the acquisition date that, if known, would have affected the measurement of the amounts recognized as of that date and we record those adjustments to our financial statements in the period of change, if any.&lt;/span&gt;&lt;/div&gt;Under the acquisition method of accounting for business combinations, if we identify changes to acquired deferred tax asset valuation allowances or liabilities related to uncertain tax positions during the measurement period and they relate to new information obtained about facts and circumstances that existed as of the acquisition date, those changes are considered a measurement period adjustment and we record the offset to goodwill. We record all other changes to deferred tax asset valuation allowances and liabilities related to uncertain tax positions in current period income tax expense.</us-gaap:BusinessCombinationsPolicy>
    <lgnd:BusinessCombinationContingentConsiderationLiabilityAmountPerShare
      contextRef="ia9a9eb80fb244862b401f0cf7734c9d9_I20201001"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RleHRyZWdpb246MDE1MzU3NWExNzUxNDlhMGJlMjM2NzA3MzMyMzJiNjlfMzg0ODI5MDc3MTIwNA_99d6a5cd-1b17-4e64-ac0e-6efde13a5f70"
      unitRef="usdPerShare">2.00</lgnd:BusinessCombinationContingentConsiderationLiabilityAmountPerShare>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="ia9a9eb80fb244862b401f0cf7734c9d9_I20201001"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RleHRyZWdpb246MDE1MzU3NWExNzUxNDlhMGJlMjM2NzA3MzMyMzJiNjlfMzg0ODI5MDc3MTIxMQ_a5ea1096-3c67-481d-a795-b8fc1c067745"
      unitRef="usd">77800000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i66fd5bb596fe4dc0a209f580f37be1bd_I20200401"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RleHRyZWdpb246MDE1MzU3NWExNzUxNDlhMGJlMjM2NzA3MzMyMzJiNjlfMTA4NjM_5a2066c9-512f-421c-a40a-ffacb7e114b1"
      unitRef="usd">25000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <lgnd:NumberOfContingentValueRightsIssued
      contextRef="i2c4e300f1b0640468a246731197ac061_I20100131"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RleHRyZWdpb246MDE1MzU3NWExNzUxNDlhMGJlMjM2NzA3MzMyMzJiNjlfMTE1NjA_488bad91-a2af-4d8d-b69c-719c281c38b7"
      unitRef="right">4</lgnd:NumberOfContingentValueRightsIssued>
    <us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy
      contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RleHRyZWdpb246MDE1MzU3NWExNzUxNDlhMGJlMjM2NzA3MzMyMzJiNjlfNTM2Nzc_da10ef7a-61a3-4a26-bb47-d8f6f03e3c39">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Goodwill, Intangible Assets and Other Long-Lived Assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Goodwill, which has an indefinite useful life, represents the excess of cost over fair value of net assets acquired. Goodwill is reviewed for impairment at least annually during the fourth quarter, or more frequently if an event occurs indicating the potential for impairment. During the goodwill impairment review, we assess qualitative factors to determine whether it is more likely than not that the fair value of our reporting unit is less than the carrying amount, including goodwill. We operate in one reporting unit. The qualitative factors include, but are not limited to, macroeconomic conditions, industry and market considerations, and the overall financial performance. If, after assessing the totality of these qualitative factors, we determine that it is not more likely than not that the fair value of our reporting unit is less than the carrying amount, then no additional assessment is deemed necessary. Otherwise, we proceed to perform the quantitative assessment. We will then evaluate goodwill for impairment by comparing the estimated fair value of the reporting unit to its carrying value, including the associated goodwill. To determine the fair value, we generally use a combination of market approach based on Ligand and comparable publicly traded companies in similar lines of businesses and the income approach based on estimated discounted future cash flows. Our cash flow assumptions consider historical and forecasted revenue, operating costs and other relevant factors. We may also elect to bypass the qualitative assessment in a period and elect to proceed to perform the quantitative assessment for the goodwill impairment test. We performed the annual assessment for goodwill impairment during the fourth quarter of 2021, noting no impairment. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Our identifiable intangible assets are typically composed of acquired core technologies, licensed technologies, contractual relationships, customer relationships and trade names. The cost of identifiable intangible assets with finite lives is generally amortized on a straight-line basis over the assets&#x2019; respective estimated useful lives. We regularly perform reviews to determine if any event has occurred that may indicate that intangible assets with finite useful lives and other long-lived assets are potentially impaired. If indicators of impairment exist, an impairment test is performed to assess the recoverability of the affected assets by determining whether the carrying amount of such assets exceeds the undiscounted expected future cash flows. If the affected assets are not recoverable, we estimate the fair value of the assets and record an impairment loss if the carrying value of the assets exceeds the fair value. Factors that may indicate potential impairment include market conditions, industry and economic trends, changes in regulations, clinical success, historical and forecasted financial results, market capitalization, significant changes in the ability of a particular asset to generate positive cash flows, and the pattern of utilization of a particular asset. We did not identify indicators of impairment for the finite-lived intangibles at December&#160;31, 2021.&lt;/span&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy>
    <lgnd:CommercialLicenseRightsPolicyTextBlock
      contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RleHRyZWdpb246MDE1MzU3NWExNzUxNDlhMGJlMjM2NzA3MzMyMzJiNjlfNTM3MDk_e1eddc71-771e-4bf7-a429-2b85588003ae">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Commercial license and other economic rights&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2021 and 2020, commercial license and other economic rights consist of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.338%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.607%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Adjustments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Adjustments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Aziyo and CorMatrix&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;17,696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(9,461)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8,235&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;17,696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(9,588)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8,108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Selexis and Dianomi&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10,602&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(8,727)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,875&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10,602&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(7,731)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,871&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;28,298&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(18,188)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10,110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;28,298&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(17,319)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10,979&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%"&gt;(1) Amounts represent accumulated amortization to principal of $11.7 million and credit loss adjustments of $6.5 million as of December 31, 2021. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%"&gt;(2) Amounts represent accumulated amortization to principal of $11.3 million and credit loss adjustments of $6.0 million as of December 31, 2020. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Commercial license and other economic rights as of December&#160;31, 2021 represent a portfolio of future milestone and royalty payment rights acquired from Selexis in April 2013 and April 2015, CorMatrix in May 2016, and Dianomi in January 2019. Commercial license rights acquired are accounted for as financial assets, and other economic rights are accounted for as funded research and developments as further discussed below. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2019, we entered into a development funding and royalties agreement with Novan, pursuant to which we would receive certain payments at specified milestones, as well as royalties on any future net sales of SB206, a product candidate being developed to treat molluscum contagiosum, and any other Novan products used for the treatment of molluscum (&#x201c;Novan Molluscum Products&#x201d;). We paid Novan an upfront payment of $12.0 million, which Novan is required to use to fund the development of SB206. We are not obligated to provide additional funding to Novan for the development or commercialization &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;of SB206. Pursuant to the agreement, we would receive up to $20.0 million of milestone payments upon the achievement by Novan of certain regulatory milestones for SB206 or any other Novan Molluscum Product and commercial milestones. In addition to the milestone payments, Novan will pay us tiered royalties from 7.0% to 10.0% based on aggregate annual net sales of SB206 or any other Novan Molluscum Product in North America. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2018, we entered into a development funding and royalties agreement with Palvella. Pursuant to the agreement, we will receive up to $8.0 million of milestone payments upon the achievement by Palvella of certain corporate, financing and regulatory milestones for PTX-022, a product candidate being developed to treat pachyonychia congenita. In addition to the milestone payments, Palvella will pay us tiered royalties from 5.0% to 9.8% based on aggregate annual worldwide net sales of any PTX-022 products, if approved, subject to Palvella&#x2019;s right to reduce the royalty rates by making payments in certain circumstances. We made an upfront payment of $10.0 million, which Palvella is required to use to fund the development of PTX-022. We are not obligated to provide additional funding to Palvella for development or commercialization of PTX-022. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We determined the economic rights related to Novan and Palvella should be characterized as a funded research and development arrangement, thus we account for them in accordance with ASC 730-20, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Research and Development Arrangement, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;and reduce our asset as the funds are expended by Novan and Palvella. As of December 31, 2019, Novan had used up the $12.0 million upfront payment provided by us. As such, our other economic rights related to Novan had been fully amortized as of December 31, 2019. As of December 31, 2020, the fund has been fully expended by Palvella and our cost basis for the asset has been reduced to zero, and therefore we will recognize milestones and royalties as revenue when earned. During 2020, we recorded a $3.0 million milestone from Palvella under contract revenue, which has been included in our consolidated statement of operations for the year ended December&#160;31, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2017, we entered into a royalty agreement with Aziyo pursuant to which we will receive royalties from certain marketed products that Aziyo acquired from CorMatrix. Pursuant to the agreement, we received $10.0 million in 2017 from Aziyo to buydown the royalty rates on the products CorMatrix sold to Aziyo. The agreement closed on May 31, 2017, in connection with the closing of the asset sale from CorMatrix to Aziyo (the &#x201c;CorMatrix Asset Sale&#x201d;). Per the agreement, we will receive a 5% royalty on the products Aziyo acquired in the CorMatrix Asset Sale, reduced from the original 20% royalty from CorMatrix pursuant to the previously disclosed interest purchase agreement, dated May 3, 2016 (the &#x201c;Original Interest Purchase Agreement&#x201d;) between CorMatrix and us. In addition, Aziyo has agreed to pay us up to $10.0 million of additional milestones tied to cumulative net sales of the products Aziyo acquired in the CorMatrix Asset Sale and to extend the term on these royalties by one year. The royalty agreement will terminate on May 31, 2027. In addition, in May 2017, we entered into an amended and restated interest purchase agreement (the &#x201c;Amended Interest Purchase Agreement&#x201d;) with CorMatrix, which supersedes in its entirety the Original Interest Purchase Agreement. Other than removing the commercial products sold to Aziyo in the CorMatrix Sale, the terms of the Amended Interest Purchase Agreement remain unchanged with respect to the CorMatrix developmental pipeline products, including the royalty rate of 5% on such pipeline products. The Amended Interest Purchase Agreement will terminate 10 years from the date of the first commercial sale of such products. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We account for the Aziyo commercial license right as a financial asset in accordance with ASC 310, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Receivables&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, and amortize the commercial license right using the effective interest method whereby we forecast expected cash flows over the term of the arrangement to arrive at an annualized effective interest. The annual effective interest associated with the forecasted cash flows from the royalty agreement with Aziyo as of December&#160;31, 2021 is 21.6%. Revenue is calculated by multiplying the carrying value of the commercial license right by the effective interest. The payments received in 2021 were accordingly allocated between revenue and the amortization of the commercial license rights.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prior to 2020, we accounted for commercial license rights related to developmental pipeline products such as Selexis and Dianomi on a non-accrual basis. These developmental pipeline products are non-commercialized, non-approved products that require FDA or other regulatory approval, and thus have uncertain cash flows. The developmental pipeline products are on a non-accrual basis as we are not yet able to forecast future cash flows given their pre-commercial stages of development. We will prospectively update the yield model under the effective interest method once the underlying products are commercialized and we can reliably forecast expected cash flows. Income will be calculated by multiplying the carrying value of the commercial license right by the effective interest rate. We regularly perform reviews to determine if any event has occurred that may indicate the carrying value of these commercial license rights are potentially impaired. If the affected commercial license rights are not recoverable, we estimate the fair value of the assets and record an impairment loss if the carrying value of the assets exceeds the fair value. During 2020, given the expected cash flow from the Selexis program, we started to account for the Selexis commercial license right as a financial asset in accordance with ASC 310, and amortize the commercial license right using the effective interest method whereby we forecast expected cash flows over the term of the arrangement to arrive at an annualized effective interest. The annual effective interest associated with the forecasted cash flows from the royalty agreement with Selexis as of December&#160;31, 2021 is 21%. Revenue is calculated by multiplying the carrying value of the commercial license right by the effective interest. The payments received in the year ended December&#160;31, 2021 and 2020 were allocated &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;accordingly between revenue and the amortization of the commercial license rights. We still accounted for commercial license rights related to Dianomi on a non-accrual basis as of December&#160;31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For commercial license rights, we have elected a prospective approach to account for changes in estimated cash flows and selected a method for determining when an impairment would be recognized and how to measure that impairment. In circumstances where our new estimate of expected cash flows is greater than previously expected, we will update our yield prospectively. In circumstances where our new estimate of expected cash flows is less than previously expected and below our original estimated yield we record an impairment. Impairment is recognized by reducing the financial asset to an amount that represents the present value of our most recent estimate of expected cash flows discounted by the original effective interest rate.&#160;In circumstances where our new estimate of expected cash flows is less than previously expected, but not below our original estimated yield, we update our yield prospectively.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;As a result of adopting ASU 2016-13, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Financial Instruments &#x2013; Credit Losses: Measurement of Credit losses on Financial Instruments (Topic 326)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;, we now recognize an allowance for current expected credit losses on the commercial license rights subject to credit risk. We recorded a $5.5 million pre-tax reserve for credit losses upon adoption of the standard on January 1, 2020. We estimated the credit losses at the individual asset level by considering the performance against the programs, the company operating performance and the macroeconomic forecast. In addition, we have judgmentally applied credit loss risk factors to the future expected payments with consideration given to the timing of the payment. Given the higher inherent credit risk associated with longer term receivables, we applied a lower risk factor to the earlier years and progressively higher risk factors to the later years. During the twelve months ended December&#160;31, 2021 and 2020, we further considered the current and expected future economic and market conditions surrounding novel coronavirus (COVID-19) pandemic, along with other factors, and recorded an additional $0.5&#160;million each year, for credit losses in other expense, net, in our consolidated statements of operations.&lt;/span&gt;&lt;/div&gt;</lgnd:CommercialLicenseRightsPolicyTextBlock>
    <lgnd:ScheduleofCommercialLicenseRightsTableTextBlock
      contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RleHRyZWdpb246MDE1MzU3NWExNzUxNDlhMGJlMjM2NzA3MzMyMzJiNjlfNTM2NzU_fc9dac32-3e26-46a1-b9d0-2103bc5b640d">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2021 and 2020, commercial license and other economic rights consist of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.338%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.607%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Adjustments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Adjustments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Aziyo and CorMatrix&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;17,696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(9,461)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8,235&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;17,696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(9,588)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8,108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Selexis and Dianomi&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10,602&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(8,727)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,875&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10,602&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(7,731)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,871&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;28,298&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(18,188)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10,110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;28,298&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(17,319)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10,979&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%"&gt;(1) Amounts represent accumulated amortization to principal of $11.7 million and credit loss adjustments of $6.5 million as of December 31, 2021. &lt;/span&gt;&lt;/div&gt;(2) Amounts represent accumulated amortization to principal of $11.3 million and credit loss adjustments of $6.0 million as of December 31, 2020.</lgnd:ScheduleofCommercialLicenseRightsTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i24643322fd3648c280f9180082f606c7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RhYmxlOjZjMjM5MjZkZjU4ZTQwZTVhMTY3OGJhZDc0YzA3ZTM4L3RhYmxlcmFuZ2U6NmMyMzkyNmRmNThlNDBlNWExNjc4YmFkNzRjMDdlMzhfMi0yLTEtMS00MTI5NA_ff522116-2eac-4294-8ce2-bc62fb336408"
      unitRef="usd">17696000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <lgnd:FiniteLivedIntangibleAssetsAccumulatedAmortizationResearchDevelopmentExpenseAndCreditLossAdjustments
      contextRef="i24643322fd3648c280f9180082f606c7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RhYmxlOjZjMjM5MjZkZjU4ZTQwZTVhMTY3OGJhZDc0YzA3ZTM4L3RhYmxlcmFuZ2U6NmMyMzkyNmRmNThlNDBlNWExNjc4YmFkNzRjMDdlMzhfMi00LTEtMS00MTI5NA_31ed32fc-e3c7-4fd4-960e-07899a0d5f4a"
      unitRef="usd">9461000</lgnd:FiniteLivedIntangibleAssetsAccumulatedAmortizationResearchDevelopmentExpenseAndCreditLossAdjustments>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i24643322fd3648c280f9180082f606c7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RhYmxlOjZjMjM5MjZkZjU4ZTQwZTVhMTY3OGJhZDc0YzA3ZTM4L3RhYmxlcmFuZ2U6NmMyMzkyNmRmNThlNDBlNWExNjc4YmFkNzRjMDdlMzhfMi02LTEtMS00MTI5NA_1efc52c2-5a95-490e-a376-671fe2148e45"
      unitRef="usd">8235000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="ieddf490290904ecbb766659c22b6325c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RhYmxlOjZjMjM5MjZkZjU4ZTQwZTVhMTY3OGJhZDc0YzA3ZTM4L3RhYmxlcmFuZ2U6NmMyMzkyNmRmNThlNDBlNWExNjc4YmFkNzRjMDdlMzhfMi04LTEtMS00MTI5NA_3f893847-7db0-41c1-adac-386833525369"
      unitRef="usd">17696000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <lgnd:FiniteLivedIntangibleAssetsAccumulatedAmortizationResearchDevelopmentExpenseAndCreditLossAdjustments
      contextRef="ieddf490290904ecbb766659c22b6325c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RhYmxlOjZjMjM5MjZkZjU4ZTQwZTVhMTY3OGJhZDc0YzA3ZTM4L3RhYmxlcmFuZ2U6NmMyMzkyNmRmNThlNDBlNWExNjc4YmFkNzRjMDdlMzhfMi0xMC0xLTEtNDEyOTQ_d54b1893-3783-49b2-9480-a8a476594222"
      unitRef="usd">9588000</lgnd:FiniteLivedIntangibleAssetsAccumulatedAmortizationResearchDevelopmentExpenseAndCreditLossAdjustments>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="ieddf490290904ecbb766659c22b6325c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RhYmxlOjZjMjM5MjZkZjU4ZTQwZTVhMTY3OGJhZDc0YzA3ZTM4L3RhYmxlcmFuZ2U6NmMyMzkyNmRmNThlNDBlNWExNjc4YmFkNzRjMDdlMzhfMi0xMi0xLTEtNDEyOTQ_4a8b4e9c-7338-4685-8447-4354127e5388"
      unitRef="usd">8108000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="ib6ab5af36644400fb3b934151581597a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RhYmxlOjZjMjM5MjZkZjU4ZTQwZTVhMTY3OGJhZDc0YzA3ZTM4L3RhYmxlcmFuZ2U6NmMyMzkyNmRmNThlNDBlNWExNjc4YmFkNzRjMDdlMzhfNC0yLTEtMS00MTI5NA_b5b37599-d048-4d01-91e2-4b72afea3536"
      unitRef="usd">10602000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <lgnd:FiniteLivedIntangibleAssetsAccumulatedAmortizationResearchDevelopmentExpenseAndCreditLossAdjustments
      contextRef="ib6ab5af36644400fb3b934151581597a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RhYmxlOjZjMjM5MjZkZjU4ZTQwZTVhMTY3OGJhZDc0YzA3ZTM4L3RhYmxlcmFuZ2U6NmMyMzkyNmRmNThlNDBlNWExNjc4YmFkNzRjMDdlMzhfNC00LTEtMS00MTI5NA_6c84c62d-d3ea-4988-8684-a6a3082b943c"
      unitRef="usd">8727000</lgnd:FiniteLivedIntangibleAssetsAccumulatedAmortizationResearchDevelopmentExpenseAndCreditLossAdjustments>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="ib6ab5af36644400fb3b934151581597a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RhYmxlOjZjMjM5MjZkZjU4ZTQwZTVhMTY3OGJhZDc0YzA3ZTM4L3RhYmxlcmFuZ2U6NmMyMzkyNmRmNThlNDBlNWExNjc4YmFkNzRjMDdlMzhfNC02LTEtMS00MTI5NA_d419bd45-32f0-4f11-b9da-af8c817a833d"
      unitRef="usd">1875000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i8dab692d024a4e0f97bf65fe83fb703b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RhYmxlOjZjMjM5MjZkZjU4ZTQwZTVhMTY3OGJhZDc0YzA3ZTM4L3RhYmxlcmFuZ2U6NmMyMzkyNmRmNThlNDBlNWExNjc4YmFkNzRjMDdlMzhfNC04LTEtMS00MTI5NA_f0e1c28a-11ff-4a92-a116-8c134b6fec3a"
      unitRef="usd">10602000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <lgnd:FiniteLivedIntangibleAssetsAccumulatedAmortizationResearchDevelopmentExpenseAndCreditLossAdjustments
      contextRef="i8dab692d024a4e0f97bf65fe83fb703b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RhYmxlOjZjMjM5MjZkZjU4ZTQwZTVhMTY3OGJhZDc0YzA3ZTM4L3RhYmxlcmFuZ2U6NmMyMzkyNmRmNThlNDBlNWExNjc4YmFkNzRjMDdlMzhfNC0xMC0xLTEtNDEyOTQ_2247cf6b-69a2-4b8b-847e-6b73b207a2c4"
      unitRef="usd">7731000</lgnd:FiniteLivedIntangibleAssetsAccumulatedAmortizationResearchDevelopmentExpenseAndCreditLossAdjustments>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i8dab692d024a4e0f97bf65fe83fb703b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RhYmxlOjZjMjM5MjZkZjU4ZTQwZTVhMTY3OGJhZDc0YzA3ZTM4L3RhYmxlcmFuZ2U6NmMyMzkyNmRmNThlNDBlNWExNjc4YmFkNzRjMDdlMzhfNC0xMi0xLTEtNDEyOTQ_f0609774-730e-4f97-bc41-21fbff7e0e71"
      unitRef="usd">2871000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="ia8308d0606a54c10ac4769b1a226d54c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RhYmxlOjZjMjM5MjZkZjU4ZTQwZTVhMTY3OGJhZDc0YzA3ZTM4L3RhYmxlcmFuZ2U6NmMyMzkyNmRmNThlNDBlNWExNjc4YmFkNzRjMDdlMzhfNS0yLTEtMS00MTI5NA_1487b668-6eff-4db9-893d-f48d22f0c15a"
      unitRef="usd">28298000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <lgnd:FiniteLivedIntangibleAssetsAccumulatedAmortizationResearchDevelopmentExpenseAndCreditLossAdjustments
      contextRef="ia8308d0606a54c10ac4769b1a226d54c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RhYmxlOjZjMjM5MjZkZjU4ZTQwZTVhMTY3OGJhZDc0YzA3ZTM4L3RhYmxlcmFuZ2U6NmMyMzkyNmRmNThlNDBlNWExNjc4YmFkNzRjMDdlMzhfNS00LTEtMS00MTI5NA_0582eb2b-daed-4b3a-ace5-f2fd0498332f"
      unitRef="usd">18188000</lgnd:FiniteLivedIntangibleAssetsAccumulatedAmortizationResearchDevelopmentExpenseAndCreditLossAdjustments>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="ia8308d0606a54c10ac4769b1a226d54c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RhYmxlOjZjMjM5MjZkZjU4ZTQwZTVhMTY3OGJhZDc0YzA3ZTM4L3RhYmxlcmFuZ2U6NmMyMzkyNmRmNThlNDBlNWExNjc4YmFkNzRjMDdlMzhfNS02LTEtMS00MTI5NA_b13f087d-692c-441e-abd9-4df172f6377c"
      unitRef="usd">10110000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i302f4f37e71b4505a330b599087d6bee_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RhYmxlOjZjMjM5MjZkZjU4ZTQwZTVhMTY3OGJhZDc0YzA3ZTM4L3RhYmxlcmFuZ2U6NmMyMzkyNmRmNThlNDBlNWExNjc4YmFkNzRjMDdlMzhfNS04LTEtMS00MTI5NA_1b9c44bf-833f-4495-96f0-673a2427fa15"
      unitRef="usd">28298000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <lgnd:FiniteLivedIntangibleAssetsAccumulatedAmortizationResearchDevelopmentExpenseAndCreditLossAdjustments
      contextRef="i302f4f37e71b4505a330b599087d6bee_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RhYmxlOjZjMjM5MjZkZjU4ZTQwZTVhMTY3OGJhZDc0YzA3ZTM4L3RhYmxlcmFuZ2U6NmMyMzkyNmRmNThlNDBlNWExNjc4YmFkNzRjMDdlMzhfNS0xMC0xLTEtNDEyOTQ_b2b19bec-6e5a-4248-a69a-2bad446e1cff"
      unitRef="usd">17319000</lgnd:FiniteLivedIntangibleAssetsAccumulatedAmortizationResearchDevelopmentExpenseAndCreditLossAdjustments>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i302f4f37e71b4505a330b599087d6bee_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RhYmxlOjZjMjM5MjZkZjU4ZTQwZTVhMTY3OGJhZDc0YzA3ZTM4L3RhYmxlcmFuZ2U6NmMyMzkyNmRmNThlNDBlNWExNjc4YmFkNzRjMDdlMzhfNS0xMi0xLTEtNDEyOTQ_a38ea748-74ca-4b70-a4b4-224aa4583e78"
      unitRef="usd">10979000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="ia8308d0606a54c10ac4769b1a226d54c_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RleHRyZWdpb246MDE1MzU3NWExNzUxNDlhMGJlMjM2NzA3MzMyMzJiNjlfMTA5OTUxMTcwNjA5OQ_2bb39a44-783f-47a4-9320-095596400196"
      unitRef="usd">11700000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <lgnd:FiniteLivedIntangibleAssetsCreditLossAdjustments
      contextRef="ia8308d0606a54c10ac4769b1a226d54c_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RleHRyZWdpb246MDE1MzU3NWExNzUxNDlhMGJlMjM2NzA3MzMyMzJiNjlfMTA5OTUxMTcwNjEwNw_ad732201-3bec-4bfc-a08a-9ccc7209ba31"
      unitRef="usd">6500000</lgnd:FiniteLivedIntangibleAssetsCreditLossAdjustments>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i302f4f37e71b4505a330b599087d6bee_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RleHRyZWdpb246MDE1MzU3NWExNzUxNDlhMGJlMjM2NzA3MzMyMzJiNjlfMzI5ODUzNDkzNzg2MQ_82c98087-bfb5-40c1-8d66-f42ec6157e8c"
      unitRef="usd">11300000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <lgnd:FiniteLivedIntangibleAssetsCreditLossAdjustments
      contextRef="i302f4f37e71b4505a330b599087d6bee_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RleHRyZWdpb246MDE1MzU3NWExNzUxNDlhMGJlMjM2NzA3MzMyMzJiNjlfMzI5ODUzNDkzNzg3Mw_cee54688-5ee2-44c3-89ed-360cab836e67"
      unitRef="usd">6000000</lgnd:FiniteLivedIntangibleAssetsCreditLossAdjustments>
    <lgnd:LicenseUpfrontPayment
      contextRef="icc93824bf0be4b7495cbbfa00019602d_D20190501-20190531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RleHRyZWdpb246MDE1MzU3NWExNzUxNDlhMGJlMjM2NzA3MzMyMzJiNjlfMTY1NTI_9e77a7d7-fb59-4d9e-bcc9-9fe5db7ca4e7"
      unitRef="usd">12000000</lgnd:LicenseUpfrontPayment>
    <lgnd:AdditionalRoyaltiesReceivableUnderSalesbasedMilestones
      contextRef="i4984262bb27142918e72ba7426eaa00b_I20190531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RleHRyZWdpb246MDE1MzU3NWExNzUxNDlhMGJlMjM2NzA3MzMyMzJiNjlfMTY3ODI_ac9c88f7-f582-4e5a-b42d-362e10c1fd67"
      unitRef="usd">20000000</lgnd:AdditionalRoyaltiesReceivableUnderSalesbasedMilestones>
    <lgnd:ProductRoyaltyPercentage
      contextRef="i76ec8fc1e4724884824d0d65bebbf615_I20190531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RleHRyZWdpb246MDE1MzU3NWExNzUxNDlhMGJlMjM2NzA3MzMyMzJiNjlfMTcwMjM_a86a0846-1bba-4c66-a9b6-75d536f00b80"
      unitRef="number">0.070</lgnd:ProductRoyaltyPercentage>
    <lgnd:ProductRoyaltyPercentage
      contextRef="iac16870509044b14afde2112b0270ad8_I20190531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RleHRyZWdpb246MDE1MzU3NWExNzUxNDlhMGJlMjM2NzA3MzMyMzJiNjlfMTcwMjk_de1e5ff2-a15e-416a-abff-02044782e69e"
      unitRef="number">0.100</lgnd:ProductRoyaltyPercentage>
    <lgnd:AdditionalRoyaltiesReceivableUnderSalesbasedMilestones
      contextRef="ifc86d31013124f84b716699c6235c139_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RleHRyZWdpb246MDE1MzU3NWExNzUxNDlhMGJlMjM2NzA3MzMyMzJiNjlfMTc3MzU_21b9db70-9ea5-4e2b-9808-8a73855c9a81"
      unitRef="usd">8000000</lgnd:AdditionalRoyaltiesReceivableUnderSalesbasedMilestones>
    <lgnd:ProductRoyaltyPercentage
      contextRef="i00496d61e75e4c03bdeb6272892386e7_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RleHRyZWdpb246MDE1MzU3NWExNzUxNDlhMGJlMjM2NzA3MzMyMzJiNjlfMTgwMTU_a1e6a60b-815b-4e83-83b2-559619e7ecff"
      unitRef="number">0.050</lgnd:ProductRoyaltyPercentage>
    <lgnd:ProductRoyaltyPercentage
      contextRef="i059cb8a459af48f6b7c8f8245f0a8818_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RleHRyZWdpb246MDE1MzU3NWExNzUxNDlhMGJlMjM2NzA3MzMyMzJiNjlfMTgwMjE_01370727-1bf0-490e-9cdf-9beb8fb3211c"
      unitRef="number">0.098</lgnd:ProductRoyaltyPercentage>
    <lgnd:LicenseUpfrontPayment
      contextRef="i8efe50fcb86a4eaf887009631ddd44d0_D20181201-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RleHRyZWdpb246MDE1MzU3NWExNzUxNDlhMGJlMjM2NzA3MzMyMzJiNjlfMTgyMzk_74fba7b8-6c4e-44ea-9425-490017d9b7a4"
      unitRef="usd">10000000</lgnd:LicenseUpfrontPayment>
    <lgnd:LicenseUpfrontPayment
      contextRef="icc93824bf0be4b7495cbbfa00019602d_D20190501-20190531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RleHRyZWdpb246MDE1MzU3NWExNzUxNDlhMGJlMjM2NzA3MzMyMzJiNjlfMTA5OTUxMTc0NjAzMg_9e77a7d7-fb59-4d9e-bcc9-9fe5db7ca4e7"
      unitRef="usd">12000000</lgnd:LicenseUpfrontPayment>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="id85f4282e429462997cf6658ec77093b_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RleHRyZWdpb246MDE1MzU3NWExNzUxNDlhMGJlMjM2NzA3MzMyMzJiNjlfMTg3NzU_aa423d34-7ffd-4f73-96f0-d4eeca4426ed"
      unitRef="usd">0</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id5f878ad057d4dbcba2c34a61c1d4b07_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RleHRyZWdpb246MDE1MzU3NWExNzUxNDlhMGJlMjM2NzA3MzMyMzJiNjlfMTg4ODc_4071ed1b-7b51-4d7e-9203-48cbf98f47e1"
      unitRef="usd">3000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ProceedsFromRoyaltiesReceived
      contextRef="iabc0130cdf4e432a836d766b1ae349c3_D20170531-20170531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RleHRyZWdpb246MDE1MzU3NWExNzUxNDlhMGJlMjM2NzA3MzMyMzJiNjlfMTkyNDA_4b26a860-0853-4635-a012-7165206ee5a2"
      unitRef="usd">10000000</us-gaap:ProceedsFromRoyaltiesReceived>
    <lgnd:ProductRoyaltyPercentage
      contextRef="ib3ba73729c164d36b827967a2afe6719_I20170531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RleHRyZWdpb246MDE1MzU3NWExNzUxNDlhMGJlMjM2NzA3MzMyMzJiNjlfMTk1MTA_9e3290b3-fab0-4db2-9e41-9ea584934354"
      unitRef="number">0.05</lgnd:ProductRoyaltyPercentage>
    <lgnd:ProductRoyaltyPercentage
      contextRef="idfd3cb0e5e65402da94f6b645760f254_I20170531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RleHRyZWdpb246MDE1MzU3NWExNzUxNDlhMGJlMjM2NzA3MzMyMzJiNjlfMTk2MDc_1d96b78f-0db3-471a-bfe4-4e88966c53f6"
      unitRef="number">0.20</lgnd:ProductRoyaltyPercentage>
    <lgnd:AdditionalRoyaltiesReceivableUnderSalesbasedMilestones
      contextRef="iceabba67d48a469eb549559806d7e623_I20170531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RleHRyZWdpb246MDE1MzU3NWExNzUxNDlhMGJlMjM2NzA3MzMyMzJiNjlfMTk4MzQ_78012e41-24f8-4c0e-a2be-eb78b2ce7eb5"
      unitRef="usd">10000000</lgnd:AdditionalRoyaltiesReceivableUnderSalesbasedMilestones>
    <lgnd:ProductRoyaltyPercentage
      contextRef="if1c8698b58b240d19cf54dff3bafb373_I20170531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RleHRyZWdpb246MDE1MzU3NWExNzUxNDlhMGJlMjM2NzA3MzMyMzJiNjlfMjA1MzI_0b0738b4-4e68-4aa9-ac51-69da05c59236"
      unitRef="number">0.05</lgnd:ProductRoyaltyPercentage>
    <lgnd:RoyaltyAgreementExpirationPeriod
      contextRef="i1345b3a472be45ab8492e940ed55ac1a_D20170531-20170531"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RleHRyZWdpb246MDE1MzU3NWExNzUxNDlhMGJlMjM2NzA3MzMyMzJiNjlfMjA2MTc_cee71fe6-1c81-48e1-a194-137f6d50be4f">P10Y</lgnd:RoyaltyAgreementExpirationPeriod>
    <lgnd:ForecastedCashFlowsEffectiveInterestRatePercent
      contextRef="ie0f36a67ac4b474f8a329695884951fa_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RleHRyZWdpb246MDE1MzU3NWExNzUxNDlhMGJlMjM2NzA3MzMyMzJiNjlfMjExMTU_840eeb1c-143d-4da4-9326-32637b660cca"
      unitRef="number">0.216</lgnd:ForecastedCashFlowsEffectiveInterestRatePercent>
    <lgnd:ForecastedCashFlowsEffectiveInterestRatePercent
      contextRef="i10f57c9a0a354a7c81c9266418797f1c_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RleHRyZWdpb246MDE1MzU3NWExNzUxNDlhMGJlMjM2NzA3MzMyMzJiNjlfMjMwMTQ_d4031d04-87b9-47ab-9201-5a1e986ab747"
      unitRef="number">0.21</lgnd:ForecastedCashFlowsEffectiveInterestRatePercent>
    <lgnd:FiniteLivedIntangibleAssetsCreditLossAdjustments
      contextRef="i744b30e425414018a238f9fbbb17b855_I20200101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RleHRyZWdpb246MDE1MzU3NWExNzUxNDlhMGJlMjM2NzA3MzMyMzJiNjlfMjQ0NTA_31014a41-634b-4872-8347-d716a4396ab0"
      unitRef="usd">5500000</lgnd:FiniteLivedIntangibleAssetsCreditLossAdjustments>
    <lgnd:AccountsReceivableCreditLossExpenseReversalCOVID19
      contextRef="ib3597315a63d441f8f128abd7ed8840e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RleHRyZWdpb246MDE1MzU3NWExNzUxNDlhMGJlMjM2NzA3MzMyMzJiNjlfMzI5ODUzNDkzNzkyMg_0f664376-c911-4c0f-9059-ca3d46800568"
      unitRef="usd">500000</lgnd:AccountsReceivableCreditLossExpenseReversalCOVID19>
    <lgnd:AccountsReceivableCreditLossExpenseReversalCOVID19
      contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RleHRyZWdpb246MDE1MzU3NWExNzUxNDlhMGJlMjM2NzA3MzMyMzJiNjlfMzI5ODUzNDkzNzkyMg_5fd562d6-7472-43ba-882e-645984323c83"
      unitRef="usd">500000</lgnd:AccountsReceivableCreditLossExpenseReversalCOVID19>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock
      contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RleHRyZWdpb246MDE1MzU3NWExNzUxNDlhMGJlMjM2NzA3MzMyMzJiNjlfNTM2OTM_bd0427e5-dff4-4b9f-8a1d-be886a210603">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our revenue is generated primarily from royalties on sales of products commercialized by our partners, Captisol material sales, and contract revenue for services, license fees and development, regulatory and sales based milestone payments.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We apply the following five-step model in accordance with ASC 606, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customers, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;in order to determine the revenue: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations, including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Royalties&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We receive royalty revenue on sales by our partners of products covered by patents that we or our partners own under contractual agreements. We do not have future performance obligations under these license arrangements. We generally satisfy our obligation to grant intellectual property rights on the effective date of the contract. However, we apply the royalty recognition constraint required under the guidance for sales-based royalties which requires a royalty to be recorded no sooner than the underlying sale occurs. Therefore, royalties on sales of products commercialized by our partners are recognized in the quarter the product is sold. Our partners generally report sales information to us on a one quarter lag. Thus, we estimate the expected royalty proceeds based on an analysis of historical experience and interim data provided by our partners including their publicly announced sales. Differences between actual and estimated royalty revenues, which have not been material, are adjusted in the period in which they become known, typically the following quarter. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt;Captisol Sales&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue from Captisol sales is recognized when control of Captisol material or intellectual property license rights is transferred to our customers in an amount that reflects the consideration we expect to receive from our customers in exchange for those products. A performance obligation is considered distinct from other obligations in a contract when it provides a benefit to the customer either on its own or together with other resources that are readily available to the customer and is separately identified in the contract. For Captisol material, we consider our performance obligation is satisfied at a point in time, once we have transferred control of the product, meaning the customer has the ability to use and obtain the benefit of the Captisol material or intellectual property license right. We recognize revenue for satisfied performance obligations only when we determine there are no uncertainties regarding payment terms or transfer of control. Sales tax and other taxes we collect concurrent with revenue-producing activities are excluded from revenue. We have elected to recognize the cost of freight and shipping when control over Captisol material has transferred to the customer as an expense in Cost of Captisol. We expense incremental costs of obtaining a contract when incurred if the expected amortization period of the asset that we would have recognized is one year or less or the amount is immaterial. We did not incur any incremental costs of obtaining a contract during the periods reported.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt;Contract Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our contracts with customers often will include variable consideration in the form of contingent milestone-based payments. We include contingent milestone based payments in the estimated transaction price when it is probable a significant reversal in the amount of cumulative revenue recognized will not occur. These estimates are based on historical experience, anticipated results and our best judgment at the time. If the contingent milestone based payment is sales-based, we apply the royalty recognition constraint and record revenue when the underlying sale has taken place. Significant judgments must be made in determining the transaction price for our sales of intellectual property. Because of the risk that products in development with our partners will not reach development based milestones or receive regulatory approval, we generally recognize any contingent payments that would be due to us upon the development milestone or regulatory approval. Depending on the terms of the arrangement, we may also defer a portion of the consideration received if we have to satisfy a future obligation, which typically occurs with our contracts for R&amp;amp;D services.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For R&amp;amp;D services we recognize revenue over time and we measure our progress using an input method. The input methods we use are based on the effort we expend or costs we incur toward the satisfaction of our performance obligation. We estimate the amount of effort we expend, including the time it will take us to complete the activities, or the costs we may incur in a given period, relative to the estimated total effort or costs to satisfy the performance obligation. This results in a percentage that we multiply by the transaction price to determine the amount of revenue we recognize each period. This approach requires us to make numerous estimates and use significant judgement. If our estimates or judgements change over the course of the collaboration, they may affect the timing and amount of revenue that we recognize in the current and future periods.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;We occasionally have sub-license obligations related to arrangements for which we receive license fees, milestones and royalties. We evaluate the determination of gross as a principal versus net as an agent reporting based on each individual agreement.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Deferred Revenue&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Depending on the terms of the arrangement, we may also defer a portion of the consideration received if we have to satisfy a future obligation.&lt;/span&gt;&lt;/div&gt;The timing of revenue recognition, billings and cash collections results in billed accounts receivable, unbilled receivables (contract assets), and customer advances and deposits (contract liabilities) on the consolidated balance sheet. Except for royalty revenue, we generally receive payment at the point we satisfy our obligation or soon after. Therefore, we do not generally carry a contract asset balance. Any fees billed in advance of being earned are recorded as deferred revenue.</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="ib3597315a63d441f8f128abd7ed8840e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RleHRyZWdpb246MDE1MzU3NWExNzUxNDlhMGJlMjM2NzA3MzMyMzJiNjlfMzI5ODUzNDkzNzkzOA_cb002dcf-2b31-4102-a015-d4d978618e1d"
      unitRef="usd">30100000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="ie6c3b69702e9429aaeed46bdb9bbb9c1_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RleHRyZWdpb246MDE1MzU3NWExNzUxNDlhMGJlMjM2NzA3MzMyMzJiNjlfMzI5ODUzNDkzNzk0Nw_df30daa2-18be-482b-ae3c-faf30b92985c"
      unitRef="usd">900000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:DisaggregationOfRevenueTableTextBlock
      contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RleHRyZWdpb246MDE1MzU3NWExNzUxNDlhMGJlMjM2NzA3MzMyMzJiNjlfNTM3MDA_44e51e3f-417a-454e-87c0-3b324fb8a587">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Royalty revenue for 2021, 2020 and 2019 are reported as below (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:61.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Kyprolis&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,472&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,164&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,046&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Evomela&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,079&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,377&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,171&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,376&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,255&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,566&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Promacta&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,193&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,927&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,796&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,976&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table represents disaggregation of Captisol and Contract Revenue (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:61.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Captisol&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;164,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;109,959&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,489&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contract&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Service Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,712&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,803&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,776&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;License Fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,084&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Milestone&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,748&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,516&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,173&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,412&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,967&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,669&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63,956&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42,664&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,817&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id39ac2bcc6964f1cbe6799ea3c6e4480_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RhYmxlOjE1MWVhZDVmNjFlMjQzZTY4M2ViMGFmZmZmZTZjMGZjL3RhYmxlcmFuZ2U6MTUxZWFkNWY2MWUyNDNlNjgzZWIwYWZmZmZlNmMwZmNfMy0yLTEtMS00MTI5NA_fab0d062-d565-4965-92f9-3f7f25a009e4"
      unitRef="usd">27472000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3f42318fa27c4162a9de72f632806f73_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RhYmxlOjE1MWVhZDVmNjFlMjQzZTY4M2ViMGFmZmZmZTZjMGZjL3RhYmxlcmFuZ2U6MTUxZWFkNWY2MWUyNDNlNjgzZWIwYWZmZmZlNmMwZmNfMy00LTEtMS00MTI5NA_a0db6465-f973-4c9b-beeb-d2721912205e"
      unitRef="usd">25164000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie833d3fbd7ae41c78acdb6743a4958e5_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RhYmxlOjE1MWVhZDVmNjFlMjQzZTY4M2ViMGFmZmZmZTZjMGZjL3RhYmxlcmFuZ2U6MTUxZWFkNWY2MWUyNDNlNjgzZWIwYWZmZmZlNmMwZmNfMy02LTEtMS00MTI5NA_4961b6c1-ce5c-4ae0-b541-a60697ec2311"
      unitRef="usd">25046000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6ec735166d6041df97f7f723bd52feac_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RhYmxlOjE1MWVhZDVmNjFlMjQzZTY4M2ViMGFmZmZmZTZjMGZjL3RhYmxlcmFuZ2U6MTUxZWFkNWY2MWUyNDNlNjgzZWIwYWZmZmZlNmMwZmNfNC0yLTEtMS00MTI5NA_72c3f84f-018d-49c6-bbf4-8b0cd76b32c0"
      unitRef="usd">10079000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ice15212256394a4a8bc6d0cdb5b93616_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RhYmxlOjE1MWVhZDVmNjFlMjQzZTY4M2ViMGFmZmZmZTZjMGZjL3RhYmxlcmFuZ2U6MTUxZWFkNWY2MWUyNDNlNjgzZWIwYWZmZmZlNmMwZmNfNC00LTEtMS00MTI5NA_60e38e42-980f-4551-8cad-3990eaf141c9"
      unitRef="usd">6377000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id98579a29cc3406ea0d48ffd0c8920f0_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RhYmxlOjE1MWVhZDVmNjFlMjQzZTY4M2ViMGFmZmZmZTZjMGZjL3RhYmxlcmFuZ2U6MTUxZWFkNWY2MWUyNDNlNjgzZWIwYWZmZmZlNmMwZmNfNC02LTEtMS00MTI5NA_687a651f-39e4-402c-97db-2c9537404cf8"
      unitRef="usd">5171000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id6a4e064f17b4a32bbb585543d61d513_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RhYmxlOjE1MWVhZDVmNjFlMjQzZTY4M2ViMGFmZmZmZTZjMGZjL3RhYmxlcmFuZ2U6MTUxZWFkNWY2MWUyNDNlNjgzZWIwYWZmZmZlNmMwZmNfNS0yLTEtMS00MTI5NA_57a482b3-81b5-4943-ac7d-b99cca998f1e"
      unitRef="usd">11376000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i70fab51ef90247fbb75a99fde6e756cd_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RhYmxlOjE1MWVhZDVmNjFlMjQzZTY4M2ViMGFmZmZmZTZjMGZjL3RhYmxlcmFuZ2U6MTUxZWFkNWY2MWUyNDNlNjgzZWIwYWZmZmZlNmMwZmNfNS00LTEtMS00MTI5NA_90270b68-3985-4b09-b98f-63d48e48fb20"
      unitRef="usd">2255000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="icd3e128d210744fda465cb5dacddcdc6_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RhYmxlOjE1MWVhZDVmNjFlMjQzZTY4M2ViMGFmZmZmZTZjMGZjL3RhYmxlcmFuZ2U6MTUxZWFkNWY2MWUyNDNlNjgzZWIwYWZmZmZlNmMwZmNfNS02LTEtMS00MTI5NA_9151bf7a-d38c-4dfc-958e-af7d508e082f"
      unitRef="usd">2566000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if954ceb872c04e719899033296d6f686_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RhYmxlOjE1MWVhZDVmNjFlMjQzZTY4M2ViMGFmZmZmZTZjMGZjL3RhYmxlcmFuZ2U6MTUxZWFkNWY2MWUyNDNlNjgzZWIwYWZmZmZlNmMwZmNfNi02LTEtMS00MTI5NA_9ca4af67-9bc4-4b93-abca-59eed5502be2"
      unitRef="usd">14193000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id759bc1766674b9fb61441df044bc82f_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RhYmxlOjE1MWVhZDVmNjFlMjQzZTY4M2ViMGFmZmZmZTZjMGZjL3RhYmxlcmFuZ2U6MTUxZWFkNWY2MWUyNDNlNjgzZWIwYWZmZmZlNmMwZmNfNy0yLTEtMS00MTI5NA_6a6169f2-3457-4354-a044-f5fd2530cbf8"
      unitRef="usd">48927000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if3c33038f43443e48bceca35aafc84c2_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RhYmxlOjE1MWVhZDVmNjFlMjQzZTY4M2ViMGFmZmZmZTZjMGZjL3RhYmxlcmFuZ2U6MTUxZWFkNWY2MWUyNDNlNjgzZWIwYWZmZmZlNmMwZmNfNy00LTEtMS00MTI5NA_8031607c-437c-4d3d-acfe-0d6d2cb2a92a"
      unitRef="usd">33796000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3bced838db93465eb75b31bbd5690a49_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RhYmxlOjE1MWVhZDVmNjFlMjQzZTY4M2ViMGFmZmZmZTZjMGZjL3RhYmxlcmFuZ2U6MTUxZWFkNWY2MWUyNDNlNjgzZWIwYWZmZmZlNmMwZmNfNy02LTEtMS00MTI5NA_8f58f9ce-188a-48f7-89f4-42253ea900ae"
      unitRef="usd">46976000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1477966cad0140da81a9947fe9bab347_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RhYmxlOjA4ZGQ2ZjM4NzQxYjRmN2FhODY0MjZiMDRlNjBhZDVkL3RhYmxlcmFuZ2U6MDhkZDZmMzg3NDFiNGY3YWE4NjQyNmIwNGU2MGFkNWRfMi0yLTEtMS00MTI5NA_d5cde1ac-6f81-44be-9250-5b7608954f3a"
      unitRef="usd">164250000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia7b5c3c10a34465088f2fa15825a2c42_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RhYmxlOjA4ZGQ2ZjM4NzQxYjRmN2FhODY0MjZiMDRlNjBhZDVkL3RhYmxlcmFuZ2U6MDhkZDZmMzg3NDFiNGY3YWE4NjQyNmIwNGU2MGFkNWRfMi00LTEtMS00MTI5NA_eb2f4d43-aaea-4b2d-85d8-4dccbcaab427"
      unitRef="usd">109959000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i75309306f08c443f8965a9846c0fb0fc_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RhYmxlOjA4ZGQ2ZjM4NzQxYjRmN2FhODY0MjZiMDRlNjBhZDVkL3RhYmxlcmFuZ2U6MDhkZDZmMzg3NDFiNGY3YWE4NjQyNmIwNGU2MGFkNWRfMi02LTEtMS00MTI5NA_5b9b04e3-3735-4f98-803b-98e41d90e1cb"
      unitRef="usd">31489000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ice7144c706244526b337a36e827284e4_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RhYmxlOjA4ZGQ2ZjM4NzQxYjRmN2FhODY0MjZiMDRlNjBhZDVkL3RhYmxlcmFuZ2U6MDhkZDZmMzg3NDFiNGY3YWE4NjQyNmIwNGU2MGFkNWRfNS0yLTEtMS00MTI5NA_63e567da-573a-4127-ae68-efa030e2e5e5"
      unitRef="usd">23712000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia59aec17df534655ac72afe661d88b8c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RhYmxlOjA4ZGQ2ZjM4NzQxYjRmN2FhODY0MjZiMDRlNjBhZDVkL3RhYmxlcmFuZ2U6MDhkZDZmMzg3NDFiNGY3YWE4NjQyNmIwNGU2MGFkNWRfNS00LTEtMS00MTI5NA_15a1ce22-a3f0-4ff3-a224-ef916b6aea6e"
      unitRef="usd">21803000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i946a606b7d2e4c08bc42b0378e0181dd_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RhYmxlOjA4ZGQ2ZjM4NzQxYjRmN2FhODY0MjZiMDRlNjBhZDVkL3RhYmxlcmFuZ2U6MDhkZDZmMzg3NDFiNGY3YWE4NjQyNmIwNGU2MGFkNWRfNS02LTEtMS00MTI5NA_823ea13c-6017-4853-a0d1-a19689319848"
      unitRef="usd">16776000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ied5134c8bab44b978f6b885c1c70cbed_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RhYmxlOjA4ZGQ2ZjM4NzQxYjRmN2FhODY0MjZiMDRlNjBhZDVkL3RhYmxlcmFuZ2U6MDhkZDZmMzg3NDFiNGY3YWE4NjQyNmIwNGU2MGFkNWRfNi0yLTEtMS00MTI5NA_7bada92c-bbb3-442a-929f-dd915205b01b"
      unitRef="usd">5084000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4f517a8e06cc46728b8724172527ebda_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RhYmxlOjA4ZGQ2ZjM4NzQxYjRmN2FhODY0MjZiMDRlNjBhZDVkL3RhYmxlcmFuZ2U6MDhkZDZmMzg3NDFiNGY3YWE4NjQyNmIwNGU2MGFkNWRfNi00LTEtMS00MTI5NA_ce99ce0d-5fec-414e-b48a-4e9bfbf51fcb"
      unitRef="usd">4378000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i11ba1ec739d34b82ba4433ba722bc361_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RhYmxlOjA4ZGQ2ZjM4NzQxYjRmN2FhODY0MjZiMDRlNjBhZDVkL3RhYmxlcmFuZ2U6MDhkZDZmMzg3NDFiNGY3YWE4NjQyNmIwNGU2MGFkNWRfNi02LTEtMS00MTI5NA_4ea55270-fb70-48fd-b040-2303dd9d937c"
      unitRef="usd">6199000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if4e90d7c48b94ff3a4921a0579c9e4e9_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RhYmxlOjA4ZGQ2ZjM4NzQxYjRmN2FhODY0MjZiMDRlNjBhZDVkL3RhYmxlcmFuZ2U6MDhkZDZmMzg3NDFiNGY3YWE4NjQyNmIwNGU2MGFkNWRfNy0yLTEtMS00MTI5NA_836d6b6e-fb0b-4404-a6f9-9a3f9b405e90"
      unitRef="usd">28748000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i757afef6fc544b019aa6e8d1c80f94f9_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RhYmxlOjA4ZGQ2ZjM4NzQxYjRmN2FhODY0MjZiMDRlNjBhZDVkL3RhYmxlcmFuZ2U6MDhkZDZmMzg3NDFiNGY3YWE4NjQyNmIwNGU2MGFkNWRfNy00LTEtMS00MTI5NA_35674b8b-03c8-44d5-8475-5ee3f7187905"
      unitRef="usd">11516000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie9a1b09dbf574bec9cc40c8f1897cdc6_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RhYmxlOjA4ZGQ2ZjM4NzQxYjRmN2FhODY0MjZiMDRlNjBhZDVkL3RhYmxlcmFuZ2U6MDhkZDZmMzg3NDFiNGY3YWE4NjQyNmIwNGU2MGFkNWRfNy02LTEtMS00MTI5NA_83bbb733-c1a0-4ad6-9120-fc69c8b52560"
      unitRef="usd">17173000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8436481b04714386944e45524f22e5a1_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RhYmxlOjA4ZGQ2ZjM4NzQxYjRmN2FhODY0MjZiMDRlNjBhZDVkL3RhYmxlcmFuZ2U6MDhkZDZmMzg3NDFiNGY3YWE4NjQyNmIwNGU2MGFkNWRfOC0yLTEtMS00MTI5NA_0ffb9f05-0376-4c36-aaf6-d054061e6105"
      unitRef="usd">6412000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i76d02ee85f37479bbbf7ef17aae36e40_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RhYmxlOjA4ZGQ2ZjM4NzQxYjRmN2FhODY0MjZiMDRlNjBhZDVkL3RhYmxlcmFuZ2U6MDhkZDZmMzg3NDFiNGY3YWE4NjQyNmIwNGU2MGFkNWRfOC00LTEtMS00MTI5NA_4f1800d1-048f-40ec-bed8-f8ce1357e583"
      unitRef="usd">4967000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i46edba4f2dc546d19c17b95467b928d8_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RhYmxlOjA4ZGQ2ZjM4NzQxYjRmN2FhODY0MjZiMDRlNjBhZDVkL3RhYmxlcmFuZ2U6MDhkZDZmMzg3NDFiNGY3YWE4NjQyNmIwNGU2MGFkNWRfOC02LTEtMS00MTI5NA_aba08317-ce8f-44ea-a492-0d1657b94ed4"
      unitRef="usd">1669000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i11e3d543e376468e8dda481609ac67e8_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RhYmxlOjA4ZGQ2ZjM4NzQxYjRmN2FhODY0MjZiMDRlNjBhZDVkL3RhYmxlcmFuZ2U6MDhkZDZmMzg3NDFiNGY3YWE4NjQyNmIwNGU2MGFkNWRfOS0yLTEtMS00MTI5NA_fe10e957-c357-48e0-9fc2-955bd1c064bf"
      unitRef="usd">63956000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if06efbad02a54e9d92b23a3ff376910e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RhYmxlOjA4ZGQ2ZjM4NzQxYjRmN2FhODY0MjZiMDRlNjBhZDVkL3RhYmxlcmFuZ2U6MDhkZDZmMzg3NDFiNGY3YWE4NjQyNmIwNGU2MGFkNWRfOS00LTEtMS00MTI5NA_08dc3af5-ac64-4161-abfb-c0c8b69f78e9"
      unitRef="usd">42664000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idea9b96f20cf4c28aea8b365b1b2069c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RhYmxlOjA4ZGQ2ZjM4NzQxYjRmN2FhODY0MjZiMDRlNjBhZDVkL3RhYmxlcmFuZ2U6MDhkZDZmMzg3NDFiNGY3YWE4NjQyNmIwNGU2MGFkNWRfOS02LTEtMS00MTI5NA_1d2f5a7b-fcb7-4d45-9485-4cffa595d5d8"
      unitRef="usd">41817000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RleHRyZWdpb246MDE1MzU3NWExNzUxNDlhMGJlMjM2NzA3MzMyMzJiNjlfNTM3MDU_449f2086-d919-49c9-a52f-4200eb5e2e87">Research and Development ExpensesResearch and development expense consists of labor, material, equipment, and allocated facilities costs of our scientific staff who are working pursuant to our collaborative agreements and other research and development projects. Also included in research and development expenses are third-party costs incurred for our research programs including in-licensing costs, CRO costs and costs incurred by other research and development service vendors. We expense these costs as they are incurred. When we make payments for research and development services prior to the services being rendered, we record those amounts as prepaid assets on our consolidated balance sheet and we expense them as the services are provided.</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RleHRyZWdpb246MDE1MzU3NWExNzUxNDlhMGJlMjM2NzA3MzMyMzJiNjlfNTM2ODc_75bde28a-26a3-4934-a180-3e299361e987">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Share-Based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We incur share-based compensation expense related to restricted stock, ESPP, and stock options.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:45pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restricted stock unit (RSU) and performance stock unit (PSU) are all considered restricted stock. The fair value of restricted stock is determined by the closing market price of our common stock on the date of grant. We recognize share-based compensation expense based on the fair value on a straight-line basis over the requisite service periods of the awards, taking into consideration of forfeitures as they occur. PSU generally represents a right to receive a certain number of shares of common stock based on the achievement of corporate performance goals and continued employment during the vesting period. At each reporting period, we reassess the probability of the achievement of such corporate performance goals and any expense change resulting from an adjustment in the estimated shares to be released are treated as a cumulative catch-up in the period of adjustment. A limited amount of PSUs contain a market condition dependent upon the Company&#x2019;s relative and absolute total stockholder return over a three-year period, with a range of 0% to 200% of the target amount granted to be issued under the award. Share-based compensation expense for these PSUs is measured using the Monte-Carlo simulation valuation model and is not adjusted for the achievement, or lack thereof, of the market conditions.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Black-Scholes-Merton option-pricing model is used to estimate the fair value of stock purchases under our ESPP and stock options granted. The model assumptions include expected volatility, term, dividends, and the risk-free interest rate. We look to historical and implied volatilities of our stock to determine the expected volatility. The expected term of an award is based on historical forfeiture experience, exercise activity, and on the terms and conditions of the stock awards. The expected dividend yield is determined to be 0% given that except for 2007, during which we declared a cash dividend on our common stock of $2.50 per share, we have not paid any dividends on our common stock in the past and currently do not expect to pay cash dividends or make any other distributions on common stock in the future. The risk-free interest rate is based upon U.S. Treasury securities with remaining terms similar to the expected term of the share-based awards.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We grant options, RSUs and PSUs to employees and non-employee directors. Non-employee directors are accounted for as employees. Options and RSUs granted to certain non-employee directors typically vest one year from the date of grant. Options granted to employees typically vest 1/8 on the six month anniversary of the date of grant, and 1/48 each month thereafter for forty-two months. RSUs and PSUs granted to employees vest over three years. All option awards generally expire ten years from the date of grant.&lt;/span&gt;&lt;/div&gt;Share-based compensation expense for awards to employees and non-employee directors is recognized on a straight-line basis over the vesting period until the last tranche vests.</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i03b53fe74b3e44e5aed9677e0c396b22_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RleHRyZWdpb246MDE1MzU3NWExNzUxNDlhMGJlMjM2NzA3MzMyMzJiNjlfMjE5OTAyMzM4MTQ4MA_48a530b9-6443-416b-b68e-ca3abd07e4a4">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="i63ea5dae35714601b3840baed12e6429_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RleHRyZWdpb246MDE1MzU3NWExNzUxNDlhMGJlMjM2NzA3MzMyMzJiNjlfMjE5OTAyMzM4MTQ1Ng_4d7d0693-e377-44f3-aa3b-7c6d7a123204"
      unitRef="number">0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="iefe3140ed86e45ff99888b95c61cc3e7_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RleHRyZWdpb246MDE1MzU3NWExNzUxNDlhMGJlMjM2NzA3MzMyMzJiNjlfMjE5OTAyMzM4MTQ2MA_f43bca56-6a1b-4a72-b5e4-114eb6245313"
      unitRef="number">2</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:EquitySecuritiesFvNiMeasurementInput
      contextRef="ib017566aacfb4b59a18b47770cb8359c_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RleHRyZWdpb246MDE1MzU3NWExNzUxNDlhMGJlMjM2NzA3MzMyMzJiNjlfMzU3NDU_bea44ccc-3b1a-4d21-b09e-0054904e84e2"
      unitRef="number">0</us-gaap:EquitySecuritiesFvNiMeasurementInput>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="ibf4833a4427a446eaf4af9794277325c_D20070101-20071231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RleHRyZWdpb246MDE1MzU3NWExNzUxNDlhMGJlMjM2NzA3MzMyMzJiNjlfMzU4NDA_eaf9292f-53fd-43d0-8362-0dba74dfc5d7"
      unitRef="usdPerShare">2.50</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i011775edbe77465dad2b4242ab130485_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RleHRyZWdpb246MDE1MzU3NWExNzUxNDlhMGJlMjM2NzA3MzMyMzJiNjlfMzg0ODI5MDc1MDkzNw_2d162961-650a-45dc-95d3-c0f5243736a8">P6M</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i05cb34ed326948caae6c1e7e7cb67165_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RleHRyZWdpb246MDE1MzU3NWExNzUxNDlhMGJlMjM2NzA3MzMyMzJiNjlfMzg0ODI5MDc1MDkzOA_cdd060f8-8655-43b5-a630-2ef8a4ce8066">P42M</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i995925b4edc84004834a7204d8ca1593_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RleHRyZWdpb246MDE1MzU3NWExNzUxNDlhMGJlMjM2NzA3MzMyMzJiNjlfMzY1OTk_07caa280-cfdd-40a8-a8c2-7476d2e4c434">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="i7c39587d4c0e42b7ba5b9574b3926bff_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RleHRyZWdpb246MDE1MzU3NWExNzUxNDlhMGJlMjM2NzA3MzMyMzJiNjlfMzY2Mzg_fd236d44-443e-4f63-913b-4585003a25f0">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:DerivativesPolicyTextBlock
      contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RleHRyZWdpb246MDE1MzU3NWExNzUxNDlhMGJlMjM2NzA3MzMyMzJiNjlfNTM2OTY_4a544fdd-9204-4b73-b9a3-8c0a2623055c">Derivatives&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2018, we issued $750.0 million aggregate principal amount of 2023 Notes, bearing cash interest at a rate of 0.75% per year, payable semi-annually, as further described in &#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note (7), Convertible Senior Notes.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x201d; Concurrently with the issuance of the notes, we entered into a series of convertible note hedge and warrant transactions which in combination are designed to reduce the potential dilution to our stockholders and/or offset the cash payments we are required to make in excess of the principal amount upon conversion of the notes. The conversion option associated with the 2023 Notes temporarily met the criteria for an embedded derivative liability which required bifurcation and separate accounting. In addition, the note hedge and warrants were also temporarily classified as a derivative asset and liability, respectively, on our consolidated balance sheet. As a result of shareholder approval to increase the number of authorized shares of our common stock on June 19, 2018, as discussed in &#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note (7), Convertible Senior Notes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;,&#x201d; the derivative asset and liabilities were reclassified to additional paid-in capital. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with our 2019 Notes, which we issued in August 2014 for $245.0 million aggregate principal amount, on May 22, 2018, we amended it making an irrevocable election to settle the entire note in cash. As a result, we reclassified from equity to derivative liability the fair value of the conversion premium as of May 22, 2018. Amounts paid in excess of the principal amount would be offset by an equal receipt of cash under the corresponding convertible bond hedge. As a result, we reclassified from equity to derivative asset the fair value of the bond hedge as of May 22, 2018. Changes in the fair value of these derivatives are reflected in other expense, net, in our consolidated statements of operations.&lt;/span&gt;&lt;/div&gt;</us-gaap:DerivativesPolicyTextBlock>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="ia70ff35785434b4585314e733c4b42c1_I20180531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RleHRyZWdpb246MDE1MzU3NWExNzUxNDlhMGJlMjM2NzA3MzMyMzJiNjlfMzY4ODE_e1377021-785a-4149-a79f-8d6d51794c37"
      unitRef="usd">750000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ia70ff35785434b4585314e733c4b42c1_I20180531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RleHRyZWdpb246MDE1MzU3NWExNzUxNDlhMGJlMjM2NzA3MzMyMzJiNjlfMzY5NjE_d7046b3d-fdf0-404b-b406-7350777fde83"
      unitRef="number">0.0075</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i1e8f1b6ddb0a48e7b819cababb4487da_I20140831"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RleHRyZWdpb246MDE1MzU3NWExNzUxNDlhMGJlMjM2NzA3MzMyMzJiNjlfMzgyMjg_9fc680f6-5cb8-410d-911a-25e3db4f1d70"
      unitRef="usd">245000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DerivativeLiabilities
      contextRef="i0a30e5369c8e4124bba63c2b980273be_I20190815"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RleHRyZWdpb246MDE1MzU3NWExNzUxNDlhMGJlMjM2NzA3MzMyMzJiNjlfMzkwNDA_35180363-9d98-48e3-a2e2-64e22cf4e647"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeAssets
      contextRef="i0a30e5369c8e4124bba63c2b980273be_I20190815"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RleHRyZWdpb246MDE1MzU3NWExNzUxNDlhMGJlMjM2NzA3MzMyMzJiNjlfMzkwNDA_ba1f859b-5d38-463f-91ca-9609f6240f4d"
      unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RleHRyZWdpb246MDE1MzU3NWExNzUxNDlhMGJlMjM2NzA3MzMyMzJiNjlfNTM2ODA_7365240b-25f9-4c16-90ea-3251f30589b5">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The provision for income taxes is computed using the asset and liability method, under which deferred tax assets and liabilities are recognized for the expected future tax consequences of temporary differences between the financial reporting and tax bases of assets and liabilities, and for the expected future tax benefit to be derived from tax loss and credit carryforwards. Deferred tax assets and liabilities are determined using the enacted tax rates in effect for the years in which those tax assets are expected to be realized. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in the provision for income taxes in the period that includes the enactment date. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred tax assets are regularly assessed to determine the likelihood they will be recovered from future taxable income. A valuation allowance is established when we believe it is more likely than not the future realization of all or some of a deferred tax asset will not be achieved. In evaluating the ability to recover deferred tax assets within the jurisdiction which they arise we consider all available positive and negative evidence. Factors reviewed include the cumulative pre-tax book income for the past three years, scheduled reversals of deferred tax liabilities, history of earnings and reliable forecasting, projections of pre-tax book income over the foreseeable future, and the impact of any feasible and prudent tax planning strategies.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognize the impact of a tax position in our financial statements only if that position is more likely than not of being sustained upon examination by taxing authorities, based on the technical merits of the position. Tax authorities regularly examine our returns in the jurisdictions in which we do business and we regularly assess the tax risk of our return filing positions. Due to the complexity of some of the uncertainties, the ultimate resolution may result in payments that are materially different from our current estimate of the tax liability. These differences, as well as any interest and penalties, will be reflected in the provision for income taxes in the period in which they are determined.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RleHRyZWdpb246MDE1MzU3NWExNzUxNDlhMGJlMjM2NzA3MzMyMzJiNjlfNTM2ODk_003b3096-910a-40e3-8c90-45590401ec8e">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Income (Loss) Per Share&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic income (loss) per share is calculated by dividing net income (loss) by the weighted-average number of common shares outstanding during the period. Diluted income per share is computed based on the sum of the weighted average number of common shares and potentially dilutive common shares outstanding during the period. Diluted loss per share is computed based on the sum of the weighted average number of common shares outstanding during the period.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Potentially dilutive common shares consist of shares issuable under 2023 convertible senior notes, stock options and restricted stock. 2023 convertible senior notes have a dilutive impact when the average market price of the Company&#x2019;s common stock exceeds the applicable conversion price of the respective notes. It is our intent and policy to settle conversions through combination settlement, which essentially involves payment in cash equal to the principal portion and delivery of shares of common stock for the excess of the conversion value over the principal portion. Potentially dilutive common shares from stock options and restricted stock are determined using the average share price for each period under the treasury stock method. In addition, the following amounts are assumed to be used to repurchase shares: proceeds from exercise of stock options and the average amount of unrecognized compensation expense for stock options and restricted stock. In loss periods, basic net loss per &lt;/span&gt;&lt;/div&gt;share and diluted net loss per share are identical since the effect of otherwise dilutive potential common shares is anti-dilutive and therefore excluded.</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i6a0717c8be2147b0b92f9327bf1814fd_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RleHRyZWdpb246MDE1MzU3NWExNzUxNDlhMGJlMjM2NzA3MzMyMzJiNjlfNzY5NjU4MTUxMjIwNQ_1a88a4af-7f0c-406e-9d44-3c2204609cde"
      unitRef="shares">600000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RleHRyZWdpb246MDE1MzU3NWExNzUxNDlhMGJlMjM2NzA3MzMyMzJiNjlfNTM2OTQ_74cf877f-2892-4216-9db9-d7158aaa5945">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the calculation of weighted average shares used to calculate basic and diluted income (loss) per share (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.189%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.649%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average shares outstanding:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,630&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,995&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dilutive potential common shares:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Restricted stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;520&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;719&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares used to compute diluted income (loss) per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,757&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Potentially dilutive shares excluded from calculation due to anti-dilutive effect&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,793&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,458&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,926&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RhYmxlOjFmNmQxMTIzY2M1ZTQwODFiYTcwMDNlODhjZTFmZjc5L3RhYmxlcmFuZ2U6MWY2ZDExMjNjYzVlNDA4MWJhNzAwM2U4OGNlMWZmNzlfMi0xLTEtMS00MTI5NA_caca7f72-8b5f-427b-a7ca-71787b5450c4"
      unitRef="shares">16630000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ib3597315a63d441f8f128abd7ed8840e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RhYmxlOjFmNmQxMTIzY2M1ZTQwODFiYTcwMDNlODhjZTFmZjc5L3RhYmxlcmFuZ2U6MWY2ZDExMjNjYzVlNDA4MWJhNzAwM2U4OGNlMWZmNzlfMi0zLTEtMS00MTI5NA_22998466-7045-474a-bc30-74cf35d65c97"
      unitRef="shares">16185000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ie6c3b69702e9429aaeed46bdb9bbb9c1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RhYmxlOjFmNmQxMTIzY2M1ZTQwODFiYTcwMDNlODhjZTFmZjc5L3RhYmxlcmFuZ2U6MWY2ZDExMjNjYzVlNDA4MWJhNzAwM2U4OGNlMWZmNzlfMi01LTEtMS00MTI5NA_85b87757-a14e-4a74-9724-250720e61aba"
      unitRef="shares">18995000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="ifcdd30f034184cecb366b0b9b1bd9c55_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RhYmxlOjFmNmQxMTIzY2M1ZTQwODFiYTcwMDNlODhjZTFmZjc5L3RhYmxlcmFuZ2U6MWY2ZDExMjNjYzVlNDA4MWJhNzAwM2U4OGNlMWZmNzlfNC0xLTEtMS00MTI5NA_fc842e03-cb86-4d96-a65b-16e3fdc376a5"
      unitRef="shares">96000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="i6a0c3b111e7c4e828d7eda58eb7efe37_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RhYmxlOjFmNmQxMTIzY2M1ZTQwODFiYTcwMDNlODhjZTFmZjc5L3RhYmxlcmFuZ2U6MWY2ZDExMjNjYzVlNDA4MWJhNzAwM2U4OGNlMWZmNzlfNC0zLTEtMS00MTI5NA_9131d3df-082a-4297-9683-06e1f67e15c4"
      unitRef="shares">0</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="i58f6278b54d04be0bf0b9577c087f56c_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RhYmxlOjFmNmQxMTIzY2M1ZTQwODFiYTcwMDNlODhjZTFmZjc5L3RhYmxlcmFuZ2U6MWY2ZDExMjNjYzVlNDA4MWJhNzAwM2U4OGNlMWZmNzlfNC01LTEtMS00MTI5NA_42bf1bac-2e79-4a4b-b325-2612e3c33ee2"
      unitRef="shares">43000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="i0b2d2a0659724a0394359a72b0ded635_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RhYmxlOjFmNmQxMTIzY2M1ZTQwODFiYTcwMDNlODhjZTFmZjc5L3RhYmxlcmFuZ2U6MWY2ZDExMjNjYzVlNDA4MWJhNzAwM2U4OGNlMWZmNzlfNS0xLTEtMS00MTI5NA_1f5cbc5b-36d1-4b6a-95e0-462a36f321a5"
      unitRef="shares">520000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="i97af3b7b1f564d4d911c3d6134e64410_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RhYmxlOjFmNmQxMTIzY2M1ZTQwODFiYTcwMDNlODhjZTFmZjc5L3RhYmxlcmFuZ2U6MWY2ZDExMjNjYzVlNDA4MWJhNzAwM2U4OGNlMWZmNzlfNS0zLTEtMS00MTI5NA_496786e3-409d-4521-b2e1-795a93eb0cc9"
      unitRef="shares">0</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="i891b87647a30477eb27e9edd4fc735ea_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RhYmxlOjFmNmQxMTIzY2M1ZTQwODFiYTcwMDNlODhjZTFmZjc5L3RhYmxlcmFuZ2U6MWY2ZDExMjNjYzVlNDA4MWJhNzAwM2U4OGNlMWZmNzlfNS01LTEtMS00MTI5NA_929b814c-016b-498c-a5ca-7deff1e2a831"
      unitRef="shares">719000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RhYmxlOjFmNmQxMTIzY2M1ZTQwODFiYTcwMDNlODhjZTFmZjc5L3RhYmxlcmFuZ2U6MWY2ZDExMjNjYzVlNDA4MWJhNzAwM2U4OGNlMWZmNzlfOC0xLTEtMS00MTI5NA_7f3817fb-a397-4b29-81b7-5e9f31838ff1"
      unitRef="shares">17246000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ib3597315a63d441f8f128abd7ed8840e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RhYmxlOjFmNmQxMTIzY2M1ZTQwODFiYTcwMDNlODhjZTFmZjc5L3RhYmxlcmFuZ2U6MWY2ZDExMjNjYzVlNDA4MWJhNzAwM2U4OGNlMWZmNzlfOC0zLTEtMS00MTI5NA_ae96b10b-6ea9-43f3-b2aa-6ac6b29c81e9"
      unitRef="shares">16185000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ie6c3b69702e9429aaeed46bdb9bbb9c1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RhYmxlOjFmNmQxMTIzY2M1ZTQwODFiYTcwMDNlODhjZTFmZjc5L3RhYmxlcmFuZ2U6MWY2ZDExMjNjYzVlNDA4MWJhNzAwM2U4OGNlMWZmNzlfOC01LTEtMS00MTI5NA_5c6f2990-b519-4a85-a0d9-b43f30413832"
      unitRef="shares">19757000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RhYmxlOjFmNmQxMTIzY2M1ZTQwODFiYTcwMDNlODhjZTFmZjc5L3RhYmxlcmFuZ2U6MWY2ZDExMjNjYzVlNDA4MWJhNzAwM2U4OGNlMWZmNzlfOS0xLTEtMS00MTI5NA_9b1e5121-736f-46c9-bdc6-4b0bf5112803"
      unitRef="shares">4793000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ib3597315a63d441f8f128abd7ed8840e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RhYmxlOjFmNmQxMTIzY2M1ZTQwODFiYTcwMDNlODhjZTFmZjc5L3RhYmxlcmFuZ2U6MWY2ZDExMjNjYzVlNDA4MWJhNzAwM2U4OGNlMWZmNzlfOS0zLTEtMS00MTI5NA_8d0a9f53-5c00-4a07-a0c9-2782868a5b7f"
      unitRef="shares">8458000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ie6c3b69702e9429aaeed46bdb9bbb9c1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RhYmxlOjFmNmQxMTIzY2M1ZTQwODFiYTcwMDNlODhjZTFmZjc5L3RhYmxlcmFuZ2U6MWY2ZDExMjNjYzVlNDA4MWJhNzAwM2U4OGNlMWZmNzlfOS01LTEtMS00MTI5NA_98fd9378-6e49-49e3-9c3c-53fd4ab11ca7"
      unitRef="shares">8926000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock
      contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RleHRyZWdpb246MDE1MzU3NWExNzUxNDlhMGJlMjM2NzA3MzMyMzJiNjlfNTM2Nzg_a4d8fd80-df8d-4c10-8feb-5fca266f50a4">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Comprehensive Income (Loss)&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Comprehensive income (loss) represents net income (loss) adjusted for the change during the periods presented in unrealized gains and losses on available-for-sale debt securities, foreign currency translation adjustments, and reclassification adjustments for realized gains or losses included in net income (loss). The unrealized gains or losses are reported on the Consolidated Statements of Comprehensive Income (Loss).&lt;/span&gt;&lt;/div&gt;</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock
      contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RleHRyZWdpb246MDE1MzU3NWExNzUxNDlhMGJlMjM2NzA3MzMyMzJiNjlfNTM2OTU_75d36755-48f1-4dc9-b3e4-f484ab39438c">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Foreign Currency Translation&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The British Pound Sterling was the functional currency of our subsidiary, Vernalis, which was sold in fourth quarter of the year ended December 31, 2020. For the years ended December 31, 2020 and 2019 the corresponding financial statements have been translated into U.S. Dollars in accordance with ASC 830-30, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt;Translation of Financial Statements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;. Assets and liabilities are translated at end-of-period rates while revenues and expenses are translated at average rates in effect during the period in which the activity took place. Equity is translated at historical rates and the resulting cumulative translation adjustments are included as a component of accumulated other comprehensive income (loss).&lt;/span&gt;&lt;/div&gt;</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184Mi9mcmFnOjAxNTM1NzVhMTc1MTQ5YTBiZTIzNjcwNzMzMjMyYjY5L3RleHRyZWdpb246MDE1MzU3NWExNzUxNDlhMGJlMjM2NzA3MzMyMzJiNjlfNTM3MDY_1ed234ad-5a75-4d97-9af8-6c86f415b75d">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Accounting Standards Not Yet Adopted&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In August 2020, the FASB issued ASU 2020-06, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Debt &#x2013; Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging &#x2013; Contracts in Entity&#x2019;s Own Equity (Subtopic 815 &#x2013; 40)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;, which simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts on an entity&#x2019;s own equity. This guidance is part of the FASB&#x2019;s simplification initiative, which aims to reduce unnecessary complexity in U.S. GAAP. The ASU is effective for public entities for fiscal years beginning after December 15, 2021, and interim periods within those fiscal years. Effective January 1, 2022, we will adopt ASU 2020-06. We are finalizing our analysis of certain assumptions that will be utilized at the transition and expects the effect of adopting ASU 2020-06 will result in an increase to retained earnings, a decrease to additional paid-in capital, and an increase to the convertible senior notes. We expect that interest expense recognized in future periods will be reduced as a result of accounting for the convertible debt instrument as a single liability measured at its amortized cost. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;We do not believe that any other recently issued, but not yet effective accounting pronouncements, if adopted, would have a material impact on our consolidated financial statements or disclosures.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock
      contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184OC9mcmFnOmZjMWQ4ZmMzMDZiODQ5ZDE4YTlkZjE1OTljZmQ2MjUzL3RleHRyZWdpb246ZmMxZDhmYzMwNmI4NDlkMThhOWRmMTU5OWNmZDYyNTNfMjgxNA_c8aa8b42-f8ea-4485-b421-58e18085fa0b">Sale of Vernalis R&amp;amp;D and Promacta License&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Vernalis R&amp;amp;D&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;On October 11, 2020, we entered into an Agreement for the Sale and Purchase of the Entire Issued Share Capital of Vernalis (R&amp;amp;D) Limited (the &#x201c;Purchase and Sale Agreement&#x201d;) with HitGen UK Ltd (&#x201c;Buyer&#x201d;). Under the terms of the Purchase and Sale Agreement, we transferred certain intellectual property on completed collaboration licenses to Ligand UK Limited, which is a subsidiary of the Company, which we retain rights and interest to and are entitled to receive future milestones and royalties. Under the Purchase and Sale Agreement, we are also entitled to a share of the economic rights on current research collaboration contracts. In addition, Vernalis will continue to support certain existing Ligand partnerships. On December 2, 2020, we completed the sale. Pursuant to the terms of the Purchase and Sale Agreement, at the closing of the transaction, Buyer paid $26.7&#160;million in cash, following adjustment for debt, cash and net working capital. As Vernalis R&amp;amp;D has the input, process and output elements defined in ASC 805, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Business Combinations&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;, we concluded the sale qualifies as a sale of business. Net assets sold, net of working capital adjustment, was $6.1&#160;million, goodwill allocated to the selling business that was written off was $3.5&#160;million, resulting in a $17.1 million gain from sale of Vernalis R&amp;amp;D recorded to income from operations.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Promacta License&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;On March 5, 2019, we entered into an Asset Purchase Agreement (the &#x201c;Asset Purchase Agreement&#x201d;) with RPI Finance Trust (&#x201c;RPI&#x201d;), doing business as &#x201c;Royalty Pharma&#x201d;, who is not an affiliate. Under the Asset Purchase Agreement, we sold, transferred, assigned and conveyed to RPI, and RPI purchased, acquired and accepted from us, all of our rights, title and interest in and to the Purchased Assets, which include among other things the intellectual property and related know-how generated by us in connection with the license agreement (collectively, the &#x201c;Purchased Assets&#x201d;), dated December 29, 1994, by and between Novartis (as successor in interest to SmithKline Beecham Corporation) and Ligand, which allowed us to receive a royalty on net sales of Promacta. We concluded the sale does not qualify as a sale of a business, but as a sale of a non-financial asset. At the closing on March 6, 2019, RPI paid us $827.0&#160;million in cash and we do not have any remaining performance obligations related to Novartis or RPI for Promacta. The carrying value of our Promacta asset as of March 6, 2019 was zero. Of the total cash proceeds from the sale, $14.2&#160;million was recorded to revenue related to the Promacta royalty for the period between January 1, 2019 and March 6, 2019, and the remaining $812.8&#160;million was recorded to income from operations in accordance with ASC 610-20,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt; Other Income - Gains and Losses from the Derecognition of Nonfinancial Assets.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock>
    <us-gaap:ProceedsFromDivestitureOfBusinesses
      contextRef="iad8d570ea6b24d73b93cc3ae9b3901e3_D20201202-20201202"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184OC9mcmFnOmZjMWQ4ZmMzMDZiODQ5ZDE4YTlkZjE1OTljZmQ2MjUzL3RleHRyZWdpb246ZmMxZDhmYzMwNmI4NDlkMThhOWRmMTU5OWNmZDYyNTNfOTM0_a4a0d28c-8503-4b3a-a2c1-2b3fa5526cc7"
      unitRef="usd">26700000</us-gaap:ProceedsFromDivestitureOfBusinesses>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="ie32796c2a612452280599ec9bc39e8e9_I20201201"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184OC9mcmFnOmZjMWQ4ZmMzMDZiODQ5ZDE4YTlkZjE1OTljZmQ2MjUzL3RleHRyZWdpb246ZmMxZDhmYzMwNmI4NDlkMThhOWRmMTU5OWNmZDYyNTNfMTIyMA_0abb4e62-04a8-4811-8461-e57b144fb070"
      unitRef="usd">6100000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit
      contextRef="iad8d570ea6b24d73b93cc3ae9b3901e3_D20201202-20201202"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184OC9mcmFnOmZjMWQ4ZmMzMDZiODQ5ZDE4YTlkZjE1OTljZmQ2MjUzL3RleHRyZWdpb246ZmMxZDhmYzMwNmI4NDlkMThhOWRmMTU5OWNmZDYyNTNfMTI5Mg_cb98f3a0-552d-4b12-831d-da9d5bf25292"
      unitRef="usd">3500000</us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit>
    <us-gaap:GainLossOnDispositionOfIntangibleAssets
      contextRef="if68046f8a22f4e8cb3ae551bf1b6614f_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184OC9mcmFnOmZjMWQ4ZmMzMDZiODQ5ZDE4YTlkZjE1OTljZmQ2MjUzL3RleHRyZWdpb246ZmMxZDhmYzMwNmI4NDlkMThhOWRmMTU5OWNmZDYyNTNfMTMxMQ_812a606f-a4b3-4da2-a5c2-0f41ef3c9b5c"
      unitRef="usd">17100000</us-gaap:GainLossOnDispositionOfIntangibleAssets>
    <us-gaap:ProceedsFromDivestitureOfBusinesses
      contextRef="ie5330d9159b84212968447e2b2771f1b_D20190306-20190306"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184OC9mcmFnOmZjMWQ4ZmMzMDZiODQ5ZDE4YTlkZjE1OTljZmQ2MjUzL3RleHRyZWdpb246ZmMxZDhmYzMwNmI4NDlkMThhOWRmMTU5OWNmZDYyNTNfMjMwOA_bb0838d4-6c9e-4037-ac15-77059c9f4fd4"
      unitRef="usd">827000000</us-gaap:ProceedsFromDivestitureOfBusinesses>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i46cec39d09204b19b6661eeb7995f45f_I20190306"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184OC9mcmFnOmZjMWQ4ZmMzMDZiODQ5ZDE4YTlkZjE1OTljZmQ2MjUzL3RleHRyZWdpb246ZmMxZDhmYzMwNmI4NDlkMThhOWRmMTU5OWNmZDYyNTNfMjQ4Mg_74a1a2db-2e69-4640-92c3-57c209ee0ed7"
      unitRef="usd">0</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i13ee716c8db44abb8505546f32fd4579_D20190101-20190306"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184OC9mcmFnOmZjMWQ4ZmMzMDZiODQ5ZDE4YTlkZjE1OTljZmQ2MjUzL3RleHRyZWdpb246ZmMxZDhmYzMwNmI4NDlkMThhOWRmMTU5OWNmZDYyNTNfMjUyOA_af3a3528-781a-4b3d-8264-50be5fd24232"
      unitRef="usd">14200000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:GainLossOnDispositionOfIntangibleAssets
      contextRef="i13ee716c8db44abb8505546f32fd4579_D20190101-20190306"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY184OC9mcmFnOmZjMWQ4ZmMzMDZiODQ5ZDE4YTlkZjE1OTljZmQ2MjUzL3RleHRyZWdpb246ZmMxZDhmYzMwNmI4NDlkMThhOWRmMTU5OWNmZDYyNTNfMjY2Mw_608a1486-3eb6-4641-8b83-5d3d4ed80bbe"
      unitRef="usd">812800000</us-gaap:GainLossOnDispositionOfIntangibleAssets>
    <us-gaap:VariableInterestEntityDisclosureTextBlock
      contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185MS9mcmFnOjBiNmQwN2Q2OWI2ZTQxYjY4MTA5MThiY2ZiYmU1ZjQ5L3RleHRyZWdpb246MGI2ZDA3ZDY5YjZlNDFiNjgxMDkxOGJjZmJiZTVmNDlfODc2_248bd201-eb63-468f-b7b9-2acd44cc912b">Short-term Investments: Investment in Viking&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our ownership in Viking was approximately 8.6% as of December&#160;31, 2021, and we account for it as an investment in available-for-sale equity securities, which is measured at fair value, with changes in fair value recognized in net income. Viking is considered a related party as we maintain a seat on Viking's board of directors and we do not exert significant influence over Viking. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2021, we have zero Viking warrants outstanding. As of December&#160;31, 2021 and December&#160;31, 2020, we recorded our common stock in Viking in &#x201c;short-term investments&#x201d; at fair value of $30.9 million and $32.8 million, respectively. &lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At December&#160;31, 2020, we owned warrants to purchase up to 1.5 million shares of Viking's common stock at an exercise price of  $1.50 per share, and during the year ended December&#160;31, 2021 we exercised all outstanding Viking warrants. As of December&#160;31, 2021, we have zero Viking warrants outstanding. During the year ended December&#160;31, 2021, we also sold 0.6&#160;million Viking shares. We recorded the warrants in &#x201c;Short-term investments&#x201d; in our consolidated balance sheet at fair value of $6.3 million at December&#160;31, 2020. See further discussion in &#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note (5), Fair Value Measurement.&lt;/span&gt;&#x201d;</us-gaap:VariableInterestEntityDisclosureTextBlock>
    <us-gaap:LimitedLiabilityCompanyLLCOrLimitedPartnershipLPMembersOrLimitedPartnersOwnershipInterest
      contextRef="ic9f4e1d55a994ce397ebaba69b0e0499_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185MS9mcmFnOjBiNmQwN2Q2OWI2ZTQxYjY4MTA5MThiY2ZiYmU1ZjQ5L3RleHRyZWdpb246MGI2ZDA3ZDY5YjZlNDFiNjgxMDkxOGJjZmJiZTVmNDlfOTc_bacace52-996d-4bb4-a6b8-724361ab0207"
      unitRef="number">0.086</us-gaap:LimitedLiabilityCompanyLLCOrLimitedPartnershipLPMembersOrLimitedPartnersOwnershipInterest>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185MS9mcmFnOjBiNmQwN2Q2OWI2ZTQxYjY4MTA5MThiY2ZiYmU1ZjQ5L3RleHRyZWdpb246MGI2ZDA3ZDY5YjZlNDFiNjgxMDkxOGJjZmJiZTVmNDlfMjYzODgyNzkwNjg5MDE_0da76c06-65af-4e7e-bd7f-150df650db5c"
      unitRef="usd">0</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185MS9mcmFnOjBiNmQwN2Q2OWI2ZTQxYjY4MTA5MThiY2ZiYmU1ZjQ5L3RleHRyZWdpb246MGI2ZDA3ZDY5YjZlNDFiNjgxMDkxOGJjZmJiZTVmNDlfNTE2_35572fe7-d5a0-4dea-ae42-0fcafedec1f1"
      unitRef="usd">30900000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i7462d0db8f4248fcb9fd8f1deae439f3_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185MS9mcmFnOjBiNmQwN2Q2OWI2ZTQxYjY4MTA5MThiY2ZiYmU1ZjQ5L3RleHRyZWdpb246MGI2ZDA3ZDY5YjZlNDFiNjgxMDkxOGJjZmJiZTVmNDlfNTIz_d38e9449-d2c0-4593-ab1d-267753fc9a7d"
      unitRef="usd">32800000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="i7462d0db8f4248fcb9fd8f1deae439f3_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185MS9mcmFnOjBiNmQwN2Q2OWI2ZTQxYjY4MTA5MThiY2ZiYmU1ZjQ5L3RleHRyZWdpb246MGI2ZDA3ZDY5YjZlNDFiNjgxMDkxOGJjZmJiZTVmNDlfNzY5NjU4MTM5NTYxOQ_f4d9a3ca-3e77-4ead-b723-db558474d827"
      unitRef="usd">1500000</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i7462d0db8f4248fcb9fd8f1deae439f3_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185MS9mcmFnOjBiNmQwN2Q2OWI2ZTQxYjY4MTA5MThiY2ZiYmU1ZjQ5L3RleHRyZWdpb246MGI2ZDA3ZDY5YjZlNDFiNjgxMDkxOGJjZmJiZTVmNDlfNzY5NjU4MTM5NTY4MA_1b2126fa-e671-4b6a-8295-973717b31036"
      unitRef="usdPerShare">1.50</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185MS9mcmFnOjBiNmQwN2Q2OWI2ZTQxYjY4MTA5MThiY2ZiYmU1ZjQ5L3RleHRyZWdpb246MGI2ZDA3ZDY5YjZlNDFiNjgxMDkxOGJjZmJiZTVmNDlfMjE5OTAyMzI1NzA2OQ_aa27c701-53db-4efd-851d-c4f3dc44233b"
      unitRef="usd">0</us-gaap:WarrantsAndRightsOutstanding>
    <lgnd:NumberOfSharesSoldOfEquityMethodInvestee
      contextRef="ic9f4e1d55a994ce397ebaba69b0e0499_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185MS9mcmFnOjBiNmQwN2Q2OWI2ZTQxYjY4MTA5MThiY2ZiYmU1ZjQ5L3RleHRyZWdpb246MGI2ZDA3ZDY5YjZlNDFiNjgxMDkxOGJjZmJiZTVmNDlfMzg0ODI5MDY5OTQ3OQ_37c45f9e-0738-4365-8c03-5930eb73b428"
      unitRef="shares">600000</lgnd:NumberOfSharesSoldOfEquityMethodInvestee>
    <lgnd:InvestmentInVikingCurrent
      contextRef="ie623d2726f914332a2f5295e06936e94_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185MS9mcmFnOjBiNmQwN2Q2OWI2ZTQxYjY4MTA5MThiY2ZiYmU1ZjQ5L3RleHRyZWdpb246MGI2ZDA3ZDY5YjZlNDFiNjgxMDkxOGJjZmJiZTVmNDlfNzY5NjU4MTM5NTkyNw_ca6f9456-1bd2-45f6-b48e-d55af3a2bbc1"
      unitRef="usd">6300000</lgnd:InvestmentInVikingCurrent>
    <us-gaap:BusinessCombinationDisclosureTextBlock
      contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185NC9mcmFnOmMzY2U4MjkwNTcxZTRkZWE4ZDI5ZjIzMWE1NzA2YjhlL3RleHRyZWdpb246YzNjZTgyOTA1NzFlNGRlYThkMjlmMjMxYTU3MDZiOGVfMTQ5Njc_0747a6a8-74a4-4b5e-b5fd-28c0a4110eb8">Acquisitions&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As set forth below, we completed five acquisitions from January 1, 2019 through December 31, 2021, of which three (Pfenex, Icagen and Ab Initio) were accounted for as business combinations and two (Taurus and xCella) were accounted for as asset acquisitions. For business combinations, we applied the acquisition method of accounting. Accordingly, we recorded the tangible and intangible assets acquired and liabilities assumed at their estimated fair values as of the applicable date of acquisition. Except for the Pfenex acquisition, for all other acquisitions, we did not incur any material acquisition related costs.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Pfenex Acquisition &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On October 1, 2020, we acquired Pfenex, which develops next-generation and novel protein therapeutics to improve existing therapies and create new therapies for biological targets linked to critical, unmet diseases using a protein expression technology platform.  &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The purchase price of $465.1 million included $429.6 million cash consideration paid upon acquisition, and a contingent CVR payment of up to $77.8 million in cash based on a certain specified milestone with an estimated initial fair value of $37.0 million. The CVR will only be paid in full if the milestone is achieved by December 31, 2021. The amount of the CVR included in purchase price was reduced by $1.5&#160;million which was determined to be post-combination expense. The fair value of the CVR liability was determined using a probability adjusted income approach. These cash flows were then discounted to present value using a discount rate based on market participants' cost of debt reflective of the Company, which was 7.1%. The liability is periodically assessed based on events and circumstances related to the underlying milestone, and any change in fair value is recorded in our consolidated statements of operations. During the year ended December&#160;31, 2021, we wrote off the entire CVR liability of $37.6&#160;million to other operation income, primarily due to not achieving the specific development and regulatory milestone by December 31, 2021 as defined by Pfenex CVR.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In connection with the acquisition, a portion of Pfenex's equity awards that were outstanding and unvested prior to the acquisition became fully vested per the terms of the merger agreement. The acceleration of vesting required us to allocate the fair value of the equity attributable to pre-combination service to the purchase price and the remaining amount was considered our post-combination expense. We paid $17.3 million in cash for equity compensation, which is attributable to pre-combination services and is reflected as a component of the total purchase price paid of $429.6 million. In addition, the fair value of equity compensation attributable to the post-combination service period was $8.7 million. These amounts were associated with the accelerated vesting of stock options previously granted to Pfenex employees and were fully paid in cash, which was recognized as general and administrative expenses during the fourth quarter of 2020. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recorded $20.7 million of acquisition-related costs for legal, severance and other costs in connection with the acquisition within operating expenses in our consolidated statement of operations for 2020. The following table sets forth an allocation of the purchase price to the identifiable tangible and intangible assets acquired and liabilities assumed, with the excess recorded to goodwill (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:85.449%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.351%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51,407&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts and unbilled receivables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,359&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,823&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right-of-use asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,070&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,338&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangibles acquired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;385,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82,303&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,814)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,606)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,908)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,070)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,382)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(42,622)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 61pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total consideration&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;465,098&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%"&gt;(1) Goodwill represents the excess of the purchase price over the preliminary fair value of the underlying assets acquired and liabilities assumed. Goodwill is attributable to the assembled workforce of experienced personnel at Pfenex and expected synergies. None of the goodwill is deductible for tax purposes. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The intangibles acquired and their weighted average useful life are as follows (in thousands, except useful lives):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.707%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.497%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Approximate&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Estimated useful life&lt;br/&gt;(in years)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contractual Relationships:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Alvogen&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;114,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Merck&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Jazz&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;SII&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Arcellx&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquired Technologies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10-19&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;385,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair values of the contractual relationships were based on the discounted cash flow method that estimated the present value of the potential royalties, milestones and collaboration revenue streams derived from the licensing of the related technologies over the estimated contractual relationship period. The fair values of the acquired technologies were based on the discounted cash flow method that estimated the present value of the potential royalties, milestones, collaboration and product revenue streams derived from the licensing of the related technologies over the estimated useful lives. These projected cash flows were discounted to present value using discount rate, which varies from 12% to 15%. The intangible assets acquired are being amortized on a straight-line basis over the estimated useful life. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Approximately $2.0 million of revenue and $19.3 million of loss before income taxes of Pfenex were included in the consolidated statement of operations for the year ended December 31, 2020. The following summary presents our unaudited pro forma consolidated results of operations for the years ended December 31, 2020 and December 31, 2019 as if the Pfenex acquisition had occurred on January 1, 2019, which gives effect to certain transaction accounting adjustments, including amortization of acquired intangibles and stock based compensation expense for retained Pfenex employees. The transaction accounting adjustments do not include non-recurring adjustments related to Pfenex's executive salary, board of director compensation, and salary of Pfenex employees involved in the reduction of force as part of the acquisition, estimated to be $7.1 million in 2020 and $4.8&#160;million in 2019. The pro forma financial information is not necessarily indicative of the operating results that would have occurred had the acquisition been consummated as if the date indicated, nor is it necessarily indicative of future operating results (in thousands, except per share amounts):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.707%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.497%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(Unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;189,203&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;170,608&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net Income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(60,059)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;594,941&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net income (loss) per common share:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Basic&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.71)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31.32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.71)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30.11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Taurus Acquisition&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On September 9, 2020, we acquired Taurus, which discovers and develops novel antibodies from immunized cows and cow-derived libraries. These antibodies feature some of the longest CDR3s of any species, with unique genetic and structural diversity that can enable binding to challenging antigens with application in therapeutics, diagnostics and research.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The purchase price of  $5.1 million included $4.6 million in cash, and a $0.5 million holdback to satisfy indemnification obligations which will be settled by September 2021. We also issued nontransferable CVRs for up to $4.5 million tied to partnered and internal research and development and for up to $25.0 million as a 25% share of post-clinical Taurus product revenues (including milestone payments) received by us. We accounted for this transaction as an asset acquisition as we concluded that substantially all of the fair value of the gross assets acquired was concentrated in the acquired core technology. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The allocation of the consideration was allocated to the acquisition date fair values of acquired assets as follows (in thousands)&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:85.303%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.497%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangibles assets with finite-life - core technologies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,005&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,052&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The core technology is being amortized on a straight-line basis over the estimated useful life of 10 years. We account for the CVRs in accordance with ASC 450, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Contingencies&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, when the contingency is resolved and the liability becomes payable. None of the CVRs are recognized as of the acquisition date.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;xCella Acquisition&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On September 8, 2020, we acquired xCella, an antibody discovery company. xCella's xPloration platform is a proprietary microcapillary platform that can screen single B cells for specificity and bioactivity and will increase Ligand&#x2019;s antibody discovery throughput and efficiency. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;We paid $7.1 million in cash (including a $0.5 million holdback to satisfy indemnification obligations which will be settled by September 2021), and issued earnout rights for up to $5.0 million tied to our use of the xCella technology for partnered research and development and for up to $25.75 million as a 25% share of any future milestone payments we received under a certain existing xCella partner arrangement. We evaluated this acquisition in accordance with ASC 805, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Business Combinations&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;, to discern whether the assets and operations of xCella met the definition of a business. We accounted for this transaction as an asset acquisition as we concluded that substantially all of the fair value of the gross assets acquired was concentrated in the acquired core technology.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The allocation of the consideration was allocated to the acquisition date fair values of acquired assets and assumed liabilities as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:85.303%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.497%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and other assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(142)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(604)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangibles assets with finite-life - core technology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,582&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,076&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The core technology is being amortized on a straight-line basis over the estimated useful life of 15 years. We account for the earnout rights in accordance with ASC 450, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Contingencies&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, when the contingency is resolved and the liability becomes payable. None of the earnout rights are recognized as of the acquisition date.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Icagen Acquisition&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On April 1, 2020, we acquired the core assets, including its partnered programs and ion channel technology from Icagen and certain of its affiliates. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The purchase price of $19.9&#160;million included $15.1 million cash consideration paid upon acquisition, and a CVR of up to $25.0 million of cash payments based on certain revenue milestones with an estimated fair value of $4.8 million. The fair value of the earn-out liability was determined using a probability weighted income approach incorporating the estimated future cash flows from expected future milestones. These cash flows were then discounted to present value using a discount rate based on the market participants' cost of debt reflective of the Company, which was 5.5%. The liability is periodically assessed based on events and circumstances related to the underlying milestones, and any change in fair value is recorded in our consolidated statements of operations. The carrying amount of the liability may fluctuate significantly and actual amount paid may be materially different than the carrying amount of the liability. As the acquisition is not considered significant, pro forma information has not been provided. The results of Icagen have been included in our results of operations since the date of acquisition.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The allocation of the consideration was allocated to the acquisition date fair values of acquired assets and assumed liabilities as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:85.303%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.497%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,173&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaids and other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;588&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liabilities assumed&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(812)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,685)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax assets, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;861&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquired intangibles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,015&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,940&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%"&gt;(1) Goodwill represents the excess of the purchase price over the preliminary fair value of the underlying assets acquired and liabilities assumed. Goodwill is attributable to the assembled workforce of experienced personnel at Icagen and expected synergies.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The majority of the goodwill is deductible for tax purposes. Acquired intangibles include $11.1 million of customer relationships and $1.7 million of core technology. The fair values of the customer relationships were based on a discounted cash flow analysis incorporating the estimated future cash flows from these relationships during the contractual term. These cash flows were then discounted to present value using a discount rate of 17%. The fair value of the customer relationships is being amortized on a straight-line basis over the weighted average estimated useful life of 9.6 years. The fair value of the core technology was based on the discounted cash flow method that estimated the present value of the potential royalties, milestones, and collaboration revenue streams derived from the licensing of the related technologies. These projected cash flows were discounted to present value using a discount rate of 17%. The fair value of the core technology is being amortized on a straight-line basis over the estimated useful life of 10 years. The total acquired intangibles are being amortized on a straight-line basis over the estimated useful life of 9.7 years.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Ab Initio Acquisition&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July 23, 2019, we acquired privately-held Ab Initio, an antigen-discovery company located in South San Francisco, California. Ab Initio has a patented antigen technology that is synergistic with the OmniAb&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;therapeutic antibody discovery platform, providing our current and potential new partners enhanced capabilities for the discovery of therapeutic antibodies against difficult-to-access cellular targets. Ab Initio has a collaboration agreement with Pfizer to discover novel therapeutic antibodies against an undisclosed target in the GPCR superfamily.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The purchase price of $12.0 million included $11.9 million cash consideration paid upon acquisition, net of cash acquired, and $0.15 million cash holdback for potential indemnification claims. As the acquisition is not considered significant, pro forma information has not been provided.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The final purchase consideration was allocated to the acquisition date fair values of acquired assets and assumed liabilities as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:85.303%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.497%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and other assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts payable and accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(83)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(146)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangibles assets with finite-life - core technologies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,812&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,011&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%"&gt;(1) Goodwill represents the excess of the purchase price over the fair value of the underlying assets acquired and liabilities assumed. Goodwill is attributable to the assembled workforce of experienced personnel at Ab Initio and expected synergies.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;None of the goodwill is deductible for tax purposes. The fair value of the core technologies was determined based on the discounted cash flow method that estimated the present value of the hypothetical royalty/ milestone streams from the licensing of the antigen-discovery technology and collaboration agreement. These projected cash flows were discounted to present value using a discount rate of 12.0%. The fair value of the core technologies is being amortized on a straight-line basis over the weighted average estimated useful life of approximately 20 years.&lt;/span&gt;&lt;/div&gt;</us-gaap:BusinessCombinationDisclosureTextBlock>
    <lgnd:NumberOfAcquisitions
      contextRef="i0ccc7acfbbaf4714aeb414b4d316cace_D20190101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185NC9mcmFnOmMzY2U4MjkwNTcxZTRkZWE4ZDI5ZjIzMWE1NzA2YjhlL3RleHRyZWdpb246YzNjZTgyOTA1NzFlNGRlYThkMjlmMjMxYTU3MDZiOGVfNTY_851f4fa7-1686-47fb-8eb1-f249602801b7"
      unitRef="acquisition">5</lgnd:NumberOfAcquisitions>
    <us-gaap:NumberOfBusinessesAcquired
      contextRef="i0ccc7acfbbaf4714aeb414b4d316cace_D20190101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185NC9mcmFnOmMzY2U4MjkwNTcxZTRkZWE4ZDI5ZjIzMWE1NzA2YjhlL3RleHRyZWdpb246YzNjZTgyOTA1NzFlNGRlYThkMjlmMjMxYTU3MDZiOGVfMTA5OTUxMTY0NjE1MA_069763a5-a6c7-4a3a-ac4e-b685a97188fd"
      unitRef="acquisition">3</us-gaap:NumberOfBusinessesAcquired>
    <lgnd:NumberOfAssetAcquisitions
      contextRef="i0ccc7acfbbaf4714aeb414b4d316cace_D20190101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185NC9mcmFnOmMzY2U4MjkwNTcxZTRkZWE4ZDI5ZjIzMWE1NzA2YjhlL3RleHRyZWdpb246YzNjZTgyOTA1NzFlNGRlYThkMjlmMjMxYTU3MDZiOGVfMjE5OTAyMzI3MzIwOQ_27095709-c495-465c-add8-98a87f30706e"
      unitRef="acquisition">2</lgnd:NumberOfAssetAcquisitions>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="i05ca320ae7ad4dcaa5874e31460a42ed_D20201001-20201001"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185NC9mcmFnOmMzY2U4MjkwNTcxZTRkZWE4ZDI5ZjIzMWE1NzA2YjhlL3RleHRyZWdpb246YzNjZTgyOTA1NzFlNGRlYThkMjlmMjMxYTU3MDZiOGVfOTcz_af032b42-6928-49f2-a4fb-36d915c26ac9"
      unitRef="usd">465100000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="i05ca320ae7ad4dcaa5874e31460a42ed_D20201001-20201001"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185NC9mcmFnOmMzY2U4MjkwNTcxZTRkZWE4ZDI5ZjIzMWE1NzA2YjhlL3RleHRyZWdpb246YzNjZTgyOTA1NzFlNGRlYThkMjlmMjMxYTU3MDZiOGVfOTg1_59d7e938-8e3d-4b70-83a2-60018f23a94c"
      unitRef="usd">429600000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="ia9a9eb80fb244862b401f0cf7734c9d9_I20201001"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185NC9mcmFnOmMzY2U4MjkwNTcxZTRkZWE4ZDI5ZjIzMWE1NzA2YjhlL3RleHRyZWdpb246YzNjZTgyOTA1NzFlNGRlYThkMjlmMjMxYTU3MDZiOGVfMTA2OA_3885344b-4c7b-468c-a928-b880b3153371"
      unitRef="usd">77800000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <lgnd:BusinessCombinationContingentConsiderationLiabilityFairValueDisclosure
      contextRef="ia9a9eb80fb244862b401f0cf7734c9d9_I20201001"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185NC9mcmFnOmMzY2U4MjkwNTcxZTRkZWE4ZDI5ZjIzMWE1NzA2YjhlL3RleHRyZWdpb246YzNjZTgyOTA1NzFlNGRlYThkMjlmMjMxYTU3MDZiOGVfMTE1OA_25892dc7-ab3c-44ed-86a8-4e886cf21727"
      unitRef="usd">37000000</lgnd:BusinessCombinationContingentConsiderationLiabilityFairValueDisclosure>
    <us-gaap:BusinessAcquisitionCostOfAcquiredEntityTransactionCosts
      contextRef="ia9a9eb80fb244862b401f0cf7734c9d9_I20201001"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185NC9mcmFnOmMzY2U4MjkwNTcxZTRkZWE4ZDI5ZjIzMWE1NzA2YjhlL3RleHRyZWdpb246YzNjZTgyOTA1NzFlNGRlYThkMjlmMjMxYTU3MDZiOGVfMTMxMQ_f40ac4ad-1c2b-4477-b8ac-a38369d548e7"
      unitRef="usd">1500000</us-gaap:BusinessAcquisitionCostOfAcquiredEntityTransactionCosts>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="ic9ff8c1b8ef04c2a949db89fa926c247_I20201001"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185NC9mcmFnOmMzY2U4MjkwNTcxZTRkZWE4ZDI5ZjIzMWE1NzA2YjhlL3RleHRyZWdpb246YzNjZTgyOTA1NzFlNGRlYThkMjlmMjMxYTU3MDZiOGVfMTYyMQ_bf31a5ef-4885-4a11-9c50-05d3fb6fe56d"
      unitRef="number">0.071</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="i88f2f47e22764022b5dec2243aa219c7_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185NC9mcmFnOmMzY2U4MjkwNTcxZTRkZWE4ZDI5ZjIzMWE1NzA2YjhlL3RleHRyZWdpb246YzNjZTgyOTA1NzFlNGRlYThkMjlmMjMxYTU3MDZiOGVfNzY5NjU4MTQxMzM5Ng_009827ae-6b27-403d-b863-232e0fab0ab5"
      unitRef="usd">-37600000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <lgnd:PaymentsToAcquireBusinessesGrossAttributableToVestedPortionOfStockOptions
      contextRef="i05ca320ae7ad4dcaa5874e31460a42ed_D20201001-20201001"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185NC9mcmFnOmMzY2U4MjkwNTcxZTRkZWE4ZDI5ZjIzMWE1NzA2YjhlL3RleHRyZWdpb246YzNjZTgyOTA1NzFlNGRlYThkMjlmMjMxYTU3MDZiOGVfMjIzNg_52613896-6f1c-4460-a56b-a0cdb238c39e"
      unitRef="usd">17300000</lgnd:PaymentsToAcquireBusinessesGrossAttributableToVestedPortionOfStockOptions>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="i05ca320ae7ad4dcaa5874e31460a42ed_D20201001-20201001"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185NC9mcmFnOmMzY2U4MjkwNTcxZTRkZWE4ZDI5ZjIzMWE1NzA2YjhlL3RleHRyZWdpb246YzNjZTgyOTA1NzFlNGRlYThkMjlmMjMxYTU3MDZiOGVfMjM5MA_59d7e938-8e3d-4b70-83a2-60018f23a94c"
      unitRef="usd">429600000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards
      contextRef="i66bc35f78f7042ebafa5e4807cf87b90_D20201001-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185NC9mcmFnOmMzY2U4MjkwNTcxZTRkZWE4ZDI5ZjIzMWE1NzA2YjhlL3RleHRyZWdpb246YzNjZTgyOTA1NzFlNGRlYThkMjlmMjMxYTU3MDZiOGVfMjUwMQ_a69a7aaf-9efb-48d7-b9a1-b383e25802fd"
      unitRef="usd">8700000</us-gaap:EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards>
    <us-gaap:BusinessCombinationAcquisitionRelatedCosts
      contextRef="i05ca320ae7ad4dcaa5874e31460a42ed_D20201001-20201001"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185NC9mcmFnOmMzY2U4MjkwNTcxZTRkZWE4ZDI5ZjIzMWE1NzA2YjhlL3RleHRyZWdpb246YzNjZTgyOTA1NzFlNGRlYThkMjlmMjMxYTU3MDZiOGVfMjc1Nw_a5850e12-6c40-49ff-a4e7-a8f1a0db59a5"
      unitRef="usd">20700000</us-gaap:BusinessCombinationAcquisitionRelatedCosts>
    <us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock
      contextRef="i88f2f47e22764022b5dec2243aa219c7_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185NC9mcmFnOmMzY2U4MjkwNTcxZTRkZWE4ZDI5ZjIzMWE1NzA2YjhlL3RleHRyZWdpb246YzNjZTgyOTA1NzFlNGRlYThkMjlmMjMxYTU3MDZiOGVfMTQ5NjE_cf2733d1-03a4-410f-aa7e-1b6d28e52496">The following table sets forth an allocation of the purchase price to the identifiable tangible and intangible assets acquired and liabilities assumed, with the excess recorded to goodwill (in thousands):&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:85.449%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.351%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51,407&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts and unbilled receivables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,359&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,823&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right-of-use asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,070&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,338&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangibles acquired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;385,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82,303&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,814)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,606)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,908)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,070)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,382)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(42,622)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 61pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total consideration&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;465,098&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;(1) Goodwill represents the excess of the purchase price over the preliminary fair value of the underlying assets acquired and liabilities assumed. Goodwill is attributable to the assembled workforce of experienced personnel at Pfenex and expected synergies. None of the goodwill is deductible for tax purposes.</us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents
      contextRef="ia9a9eb80fb244862b401f0cf7734c9d9_I20201001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185NC9mcmFnOmMzY2U4MjkwNTcxZTRkZWE4ZDI5ZjIzMWE1NzA2YjhlL3RhYmxlOjAzNzhiODQzYjM0YjQxZjA4MTUzMzQwMGRlY2VkYzQ3L3RhYmxlcmFuZ2U6MDM3OGI4NDNiMzRiNDFmMDgxNTMzNDAwZGVjZWRjNDdfMC0xLTEtMS00MTI5NA_32212071-04c2-4522-af36-19d05f49a392"
      unitRef="usd">51407000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents>
    <lgnd:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash
      contextRef="ia9a9eb80fb244862b401f0cf7734c9d9_I20201001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185NC9mcmFnOmMzY2U4MjkwNTcxZTRkZWE4ZDI5ZjIzMWE1NzA2YjhlL3RhYmxlOjAzNzhiODQzYjM0YjQxZjA4MTUzMzQwMGRlY2VkYzQ3L3RhYmxlcmFuZ2U6MDM3OGI4NDNiMzRiNDFmMDgxNTMzNDAwZGVjZWRjNDdfMS0xLTEtMS00MTI5NA_2c70c81a-1fd9-4d67-a4e4-d1a71e618a81"
      unitRef="usd">200000</lgnd:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables
      contextRef="ia9a9eb80fb244862b401f0cf7734c9d9_I20201001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185NC9mcmFnOmMzY2U4MjkwNTcxZTRkZWE4ZDI5ZjIzMWE1NzA2YjhlL3RhYmxlOjAzNzhiODQzYjM0YjQxZjA4MTUzMzQwMGRlY2VkYzQ3L3RhYmxlcmFuZ2U6MDM3OGI4NDNiMzRiNDFmMDgxNTMzNDAwZGVjZWRjNDdfMi0xLTEtMS00MTI5NA_eb65500c-1271-4b0e-bfb0-24312b15615e"
      unitRef="usd">1359000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment
      contextRef="ia9a9eb80fb244862b401f0cf7734c9d9_I20201001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185NC9mcmFnOmMzY2U4MjkwNTcxZTRkZWE4ZDI5ZjIzMWE1NzA2YjhlL3RhYmxlOjAzNzhiODQzYjM0YjQxZjA4MTUzMzQwMGRlY2VkYzQ3L3RhYmxlcmFuZ2U6MDM3OGI4NDNiMzRiNDFmMDgxNTMzNDAwZGVjZWRjNDdfMy0xLTEtMS00MTI5NA_c8fc10f5-d7d4-4deb-9e64-f16f0d0ea0d8"
      unitRef="usd">7823000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment>
    <lgnd:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssets
      contextRef="ia9a9eb80fb244862b401f0cf7734c9d9_I20201001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185NC9mcmFnOmMzY2U4MjkwNTcxZTRkZWE4ZDI5ZjIzMWE1NzA2YjhlL3RhYmxlOjAzNzhiODQzYjM0YjQxZjA4MTUzMzQwMGRlY2VkYzQ3L3RhYmxlcmFuZ2U6MDM3OGI4NDNiMzRiNDFmMDgxNTMzNDAwZGVjZWRjNDdfNC0xLTEtMS00MTI5NA_7c5add1d-f429-40b5-885a-094aa054a2d3"
      unitRef="usd">3070000</lgnd:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets
      contextRef="ia9a9eb80fb244862b401f0cf7734c9d9_I20201001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185NC9mcmFnOmMzY2U4MjkwNTcxZTRkZWE4ZDI5ZjIzMWE1NzA2YjhlL3RhYmxlOjAzNzhiODQzYjM0YjQxZjA4MTUzMzQwMGRlY2VkYzQ3L3RhYmxlcmFuZ2U6MDM3OGI4NDNiMzRiNDFmMDgxNTMzNDAwZGVjZWRjNDdfNS0xLTEtMS00MTI5NA_8bc7a9e0-29eb-4154-8dd9-ed689e65cf41"
      unitRef="usd">1338000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets>
    <lgnd:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssets
      contextRef="ia9a9eb80fb244862b401f0cf7734c9d9_I20201001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185NC9mcmFnOmMzY2U4MjkwNTcxZTRkZWE4ZDI5ZjIzMWE1NzA2YjhlL3RhYmxlOjAzNzhiODQzYjM0YjQxZjA4MTUzMzQwMGRlY2VkYzQ3L3RhYmxlcmFuZ2U6MDM3OGI4NDNiMzRiNDFmMDgxNTMzNDAwZGVjZWRjNDdfNi0xLTEtMS00MTI5NA_4659f685-9a21-4d2f-a62a-2d0dd6705365"
      unitRef="usd">385000000</lgnd:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssets>
    <us-gaap:Goodwill
      contextRef="ia9a9eb80fb244862b401f0cf7734c9d9_I20201001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185NC9mcmFnOmMzY2U4MjkwNTcxZTRkZWE4ZDI5ZjIzMWE1NzA2YjhlL3RhYmxlOjAzNzhiODQzYjM0YjQxZjA4MTUzMzQwMGRlY2VkYzQ3L3RhYmxlcmFuZ2U6MDM3OGI4NDNiMzRiNDFmMDgxNTMzNDAwZGVjZWRjNDdfNy0xLTEtMS00MTI5NA_d1023425-22d5-4b50-a60e-301c97452ca1"
      unitRef="usd">82303000</us-gaap:Goodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable
      contextRef="ia9a9eb80fb244862b401f0cf7734c9d9_I20201001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185NC9mcmFnOmMzY2U4MjkwNTcxZTRkZWE4ZDI5ZjIzMWE1NzA2YjhlL3RhYmxlOjAzNzhiODQzYjM0YjQxZjA4MTUzMzQwMGRlY2VkYzQ3L3RhYmxlcmFuZ2U6MDM3OGI4NDNiMzRiNDFmMDgxNTMzNDAwZGVjZWRjNDdfOC0xLTEtMS00MTI5NA_a3b82e74-4e2c-4945-95ce-c4283d436591"
      unitRef="usd">6814000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable>
    <lgnd:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilitiesCurrent
      contextRef="ia9a9eb80fb244862b401f0cf7734c9d9_I20201001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185NC9mcmFnOmMzY2U4MjkwNTcxZTRkZWE4ZDI5ZjIzMWE1NzA2YjhlL3RhYmxlOjAzNzhiODQzYjM0YjQxZjA4MTUzMzQwMGRlY2VkYzQ3L3RhYmxlcmFuZ2U6MDM3OGI4NDNiMzRiNDFmMDgxNTMzNDAwZGVjZWRjNDdfOS0xLTEtMS00MTI5NA_93553fe9-d92b-4bb1-a434-aba9c514dae4"
      unitRef="usd">9606000</lgnd:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilitiesCurrent>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue
      contextRef="ia9a9eb80fb244862b401f0cf7734c9d9_I20201001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185NC9mcmFnOmMzY2U4MjkwNTcxZTRkZWE4ZDI5ZjIzMWE1NzA2YjhlL3RhYmxlOjAzNzhiODQzYjM0YjQxZjA4MTUzMzQwMGRlY2VkYzQ3L3RhYmxlcmFuZ2U6MDM3OGI4NDNiMzRiNDFmMDgxNTMzNDAwZGVjZWRjNDdfMTAtMS0xLTEtNDEyOTQ_9a1f3910-a2a9-4a5d-9bb2-6c709fca0637"
      unitRef="usd">3908000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue>
    <lgnd:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLeaseLiabilities
      contextRef="ia9a9eb80fb244862b401f0cf7734c9d9_I20201001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185NC9mcmFnOmMzY2U4MjkwNTcxZTRkZWE4ZDI5ZjIzMWE1NzA2YjhlL3RhYmxlOjAzNzhiODQzYjM0YjQxZjA4MTUzMzQwMGRlY2VkYzQ3L3RhYmxlcmFuZ2U6MDM3OGI4NDNiMzRiNDFmMDgxNTMzNDAwZGVjZWRjNDdfMTEtMS0xLTEtNDEyOTQ_6d8f74cc-0ef9-4ff7-81c2-24578a3ac5f9"
      unitRef="usd">3070000</lgnd:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLeaseLiabilities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther
      contextRef="ia9a9eb80fb244862b401f0cf7734c9d9_I20201001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185NC9mcmFnOmMzY2U4MjkwNTcxZTRkZWE4ZDI5ZjIzMWE1NzA2YjhlL3RhYmxlOjAzNzhiODQzYjM0YjQxZjA4MTUzMzQwMGRlY2VkYzQ3L3RhYmxlcmFuZ2U6MDM3OGI4NDNiMzRiNDFmMDgxNTMzNDAwZGVjZWRjNDdfMTItMS0xLTEtNDEyOTQ_f0b33175-22b1-4df7-abb3-b6a9e5a46385"
      unitRef="usd">1382000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities
      contextRef="ia9a9eb80fb244862b401f0cf7734c9d9_I20201001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185NC9mcmFnOmMzY2U4MjkwNTcxZTRkZWE4ZDI5ZjIzMWE1NzA2YjhlL3RhYmxlOjAzNzhiODQzYjM0YjQxZjA4MTUzMzQwMGRlY2VkYzQ3L3RhYmxlcmFuZ2U6MDM3OGI4NDNiMzRiNDFmMDgxNTMzNDAwZGVjZWRjNDdfMTMtMS0xLTEtNDEyOTQ_808ef26b-d30a-4fcc-b262-1786773f66c1"
      unitRef="usd">42622000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet
      contextRef="ia9a9eb80fb244862b401f0cf7734c9d9_I20201001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185NC9mcmFnOmMzY2U4MjkwNTcxZTRkZWE4ZDI5ZjIzMWE1NzA2YjhlL3RhYmxlOjAzNzhiODQzYjM0YjQxZjA4MTUzMzQwMGRlY2VkYzQ3L3RhYmxlcmFuZ2U6MDM3OGI4NDNiMzRiNDFmMDgxNTMzNDAwZGVjZWRjNDdfMTQtMS0xLTEtNDEyOTQ_abf4ebaa-48d0-490d-bda3-6e94644f0b45"
      unitRef="usd">465098000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet>
    <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock
      contextRef="i88f2f47e22764022b5dec2243aa219c7_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185NC9mcmFnOmMzY2U4MjkwNTcxZTRkZWE4ZDI5ZjIzMWE1NzA2YjhlL3RleHRyZWdpb246YzNjZTgyOTA1NzFlNGRlYThkMjlmMjMxYTU3MDZiOGVfMTQ5NjI_138fa0f7-dd69-40c6-869d-f50c947d6335">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The intangibles acquired and their weighted average useful life are as follows (in thousands, except useful lives):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.707%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.497%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Approximate&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Estimated useful life&lt;br/&gt;(in years)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contractual Relationships:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Alvogen&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;114,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Merck&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Jazz&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;SII&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Arcellx&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquired Technologies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10-19&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;385,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
      contextRef="i95cf6d8d9303402492315ef907402a1a_I20201001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185NC9mcmFnOmMzY2U4MjkwNTcxZTRkZWE4ZDI5ZjIzMWE1NzA2YjhlL3RhYmxlOmYyN2QxODFlYTFkNzQyMTRiNjgxOGJhOWYzMzI2YWNiL3RhYmxlcmFuZ2U6ZjI3ZDE4MWVhMWQ3NDIxNGI2ODE4YmE5ZjMzMjZhY2JfMi0xLTEtMS00MTI5NA_deb5ebb8-7c4a-4d6f-9d48-b5c35cbbfe4e"
      unitRef="usd">114000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="i3639b90349a0416597ac3b2345fcfd8b_D20201001-20201001"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185NC9mcmFnOmMzY2U4MjkwNTcxZTRkZWE4ZDI5ZjIzMWE1NzA2YjhlL3RhYmxlOmYyN2QxODFlYTFkNzQyMTRiNjgxOGJhOWYzMzI2YWNiL3RhYmxlcmFuZ2U6ZjI3ZDE4MWVhMWQ3NDIxNGI2ODE4YmE5ZjMzMjZhY2JfMi0yLTEtMS00MTI5NA_7d924aa0-1c95-4276-926d-3f807305b561">P12Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
      contextRef="i6618eb064ffd4735b65d23c002f29a3d_I20201001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185NC9mcmFnOmMzY2U4MjkwNTcxZTRkZWE4ZDI5ZjIzMWE1NzA2YjhlL3RhYmxlOmYyN2QxODFlYTFkNzQyMTRiNjgxOGJhOWYzMzI2YWNiL3RhYmxlcmFuZ2U6ZjI3ZDE4MWVhMWQ3NDIxNGI2ODE4YmE5ZjMzMjZhY2JfMy0xLTEtMS00MTI5NA_c3585f4c-efda-4fb7-b22d-c27ff40f95a2"
      unitRef="usd">117000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="ia025b98444b84bf38bee7c4b59d60941_D20201001-20201001"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185NC9mcmFnOmMzY2U4MjkwNTcxZTRkZWE4ZDI5ZjIzMWE1NzA2YjhlL3RhYmxlOmYyN2QxODFlYTFkNzQyMTRiNjgxOGJhOWYzMzI2YWNiL3RhYmxlcmFuZ2U6ZjI3ZDE4MWVhMWQ3NDIxNGI2ODE4YmE5ZjMzMjZhY2JfMy0yLTEtMS00MTI5NA_cf6045e6-7acf-4636-8364-edd27256644a">P12Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
      contextRef="i9687ebeaf03c4246885f9a884dc564ee_I20201001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185NC9mcmFnOmMzY2U4MjkwNTcxZTRkZWE4ZDI5ZjIzMWE1NzA2YjhlL3RhYmxlOmYyN2QxODFlYTFkNzQyMTRiNjgxOGJhOWYzMzI2YWNiL3RhYmxlcmFuZ2U6ZjI3ZDE4MWVhMWQ3NDIxNGI2ODE4YmE5ZjMzMjZhY2JfNC0xLTEtMS00MTI5NA_9217bcf6-fb34-47ea-a4bb-fee88e89766c"
      unitRef="usd">80000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="i74a5e3f1fdec4b96b148fb5871cc991f_D20201001-20201001"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185NC9mcmFnOmMzY2U4MjkwNTcxZTRkZWE4ZDI5ZjIzMWE1NzA2YjhlL3RhYmxlOmYyN2QxODFlYTFkNzQyMTRiNjgxOGJhOWYzMzI2YWNiL3RhYmxlcmFuZ2U6ZjI3ZDE4MWVhMWQ3NDIxNGI2ODE4YmE5ZjMzMjZhY2JfNC0yLTEtMS00MTI5NA_4c98e215-b669-4ca3-a85c-88aed3e2489e">P17Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
      contextRef="i8d2ed9e3e4254c8aa989182cdea6b83e_I20201001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185NC9mcmFnOmMzY2U4MjkwNTcxZTRkZWE4ZDI5ZjIzMWE1NzA2YjhlL3RhYmxlOmYyN2QxODFlYTFkNzQyMTRiNjgxOGJhOWYzMzI2YWNiL3RhYmxlcmFuZ2U6ZjI3ZDE4MWVhMWQ3NDIxNGI2ODE4YmE5ZjMzMjZhY2JfNS0xLTEtMS00MTI5NA_017c8f9c-16bd-4fb8-8c68-818724599722"
      unitRef="usd">49000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="i5263ecacba2e40a0bef60af7f8f3323f_D20201001-20201001"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185NC9mcmFnOmMzY2U4MjkwNTcxZTRkZWE4ZDI5ZjIzMWE1NzA2YjhlL3RhYmxlOmYyN2QxODFlYTFkNzQyMTRiNjgxOGJhOWYzMzI2YWNiL3RhYmxlcmFuZ2U6ZjI3ZDE4MWVhMWQ3NDIxNGI2ODE4YmE5ZjMzMjZhY2JfNS0yLTEtMS00MTI5NA_ec87116d-120b-44d3-b387-4b6a6cd81746">P10Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
      contextRef="i77b01aad4684478a851c8f13a0d12891_I20201001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185NC9mcmFnOmMzY2U4MjkwNTcxZTRkZWE4ZDI5ZjIzMWE1NzA2YjhlL3RhYmxlOmYyN2QxODFlYTFkNzQyMTRiNjgxOGJhOWYzMzI2YWNiL3RhYmxlcmFuZ2U6ZjI3ZDE4MWVhMWQ3NDIxNGI2ODE4YmE5ZjMzMjZhY2JfNi0xLTEtMS00MTI5NA_6a5af3f8-8d64-4c68-a699-5fd8f81b0738"
      unitRef="usd">2000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="id59883d6b9fe4a63b608829d498699ce_D20201001-20201001"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185NC9mcmFnOmMzY2U4MjkwNTcxZTRkZWE4ZDI5ZjIzMWE1NzA2YjhlL3RhYmxlOmYyN2QxODFlYTFkNzQyMTRiNjgxOGJhOWYzMzI2YWNiL3RhYmxlcmFuZ2U6ZjI3ZDE4MWVhMWQ3NDIxNGI2ODE4YmE5ZjMzMjZhY2JfNi0yLTEtMS00MTI5NA_cc149041-d23d-4f8e-b521-9361edce1538">P17Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
      contextRef="i65ac1d8a3b63426baa11a41236151bd8_I20201001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185NC9mcmFnOmMzY2U4MjkwNTcxZTRkZWE4ZDI5ZjIzMWE1NzA2YjhlL3RhYmxlOmYyN2QxODFlYTFkNzQyMTRiNjgxOGJhOWYzMzI2YWNiL3RhYmxlcmFuZ2U6ZjI3ZDE4MWVhMWQ3NDIxNGI2ODE4YmE5ZjMzMjZhY2JfNy0xLTEtMS00MTI5NA_501f726c-1c1b-41cd-8b08-b596cef613b6"
      unitRef="usd">23000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="id301d12eff0d4b76a98f1b19b7aa97fd_D20201001-20201001"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185NC9mcmFnOmMzY2U4MjkwNTcxZTRkZWE4ZDI5ZjIzMWE1NzA2YjhlL3RhYmxlOmYyN2QxODFlYTFkNzQyMTRiNjgxOGJhOWYzMzI2YWNiL3RhYmxlcmFuZ2U6ZjI3ZDE4MWVhMWQ3NDIxNGI2ODE4YmE5ZjMzMjZhY2JfNy0yLTEtMS00MTI5NC90ZXh0cmVnaW9uOjhmN2Q5NDM4ZjUzODQ3MTNiZDAzODA4NWRiYjE3MjFmXzQ_6c6cdf7e-b6e7-4af5-804a-3849ab07cd48">P10Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="ib687713e39394d8883330adccb1296e4_D20201001-20201001"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185NC9mcmFnOmMzY2U4MjkwNTcxZTRkZWE4ZDI5ZjIzMWE1NzA2YjhlL3RhYmxlOmYyN2QxODFlYTFkNzQyMTRiNjgxOGJhOWYzMzI2YWNiL3RhYmxlcmFuZ2U6ZjI3ZDE4MWVhMWQ3NDIxNGI2ODE4YmE5ZjMzMjZhY2JfNy0yLTEtMS00MTI5NC90ZXh0cmVnaW9uOjhmN2Q5NDM4ZjUzODQ3MTNiZDAzODA4NWRiYjE3MjFmXzc_13315e8e-bd8b-4e7e-9567-991a6079cd17">P19Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
      contextRef="ia9a9eb80fb244862b401f0cf7734c9d9_I20201001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185NC9mcmFnOmMzY2U4MjkwNTcxZTRkZWE4ZDI5ZjIzMWE1NzA2YjhlL3RhYmxlOmYyN2QxODFlYTFkNzQyMTRiNjgxOGJhOWYzMzI2YWNiL3RhYmxlcmFuZ2U6ZjI3ZDE4MWVhMWQ3NDIxNGI2ODE4YmE5ZjMzMjZhY2JfOC0xLTEtMS00MTI5NA_e531122f-c866-42bc-baf0-ee7089b63349"
      unitRef="usd">385000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <lgnd:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsDiscountRate
      contextRef="i4c77fc6eecd341e48bc7b99f95972ddf_D20200401-20200401"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185NC9mcmFnOmMzY2U4MjkwNTcxZTRkZWE4ZDI5ZjIzMWE1NzA2YjhlL3RleHRyZWdpb246YzNjZTgyOTA1NzFlNGRlYThkMjlmMjMxYTU3MDZiOGVfNDMwOQ_0a7af5b9-5aad-4e09-9455-418ada80d9eb"
      unitRef="number">0.12</lgnd:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsDiscountRate>
    <lgnd:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsDiscountRate
      contextRef="if97f9e0769b54e6a845f9f9fc59f0a1a_D20200401-20200401"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185NC9mcmFnOmMzY2U4MjkwNTcxZTRkZWE4ZDI5ZjIzMWE1NzA2YjhlL3RleHRyZWdpb246YzNjZTgyOTA1NzFlNGRlYThkMjlmMjMxYTU3MDZiOGVfNDMxNQ_3ff8e6d8-a635-49b9-9df0-a6ac72915957"
      unitRef="number">0.15</lgnd:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsDiscountRate>
    <us-gaap:BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual
      contextRef="i81ce7b0c06a94e61a7d245d6544346aa_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185NC9mcmFnOmMzY2U4MjkwNTcxZTRkZWE4ZDI5ZjIzMWE1NzA2YjhlL3RleHRyZWdpb246YzNjZTgyOTA1NzFlNGRlYThkMjlmMjMxYTU3MDZiOGVfNDgzNQ_cb5532bf-8001-4f92-9dd5-e2a13eee7c62"
      unitRef="usd">2000000</us-gaap:BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual>
    <us-gaap:BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual
      contextRef="i81ce7b0c06a94e61a7d245d6544346aa_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185NC9mcmFnOmMzY2U4MjkwNTcxZTRkZWE4ZDI5ZjIzMWE1NzA2YjhlL3RleHRyZWdpb246YzNjZTgyOTA1NzFlNGRlYThkMjlmMjMxYTU3MDZiOGVfNDg1Mw_3a7c2b1c-7952-4f94-99ca-2e1c6875d9d0"
      unitRef="usd">-19300000</us-gaap:BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual>
    <us-gaap:BusinessCombinationIntegrationRelatedCosts
      contextRef="i81ce7b0c06a94e61a7d245d6544346aa_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185NC9mcmFnOmMzY2U4MjkwNTcxZTRkZWE4ZDI5ZjIzMWE1NzA2YjhlL3RleHRyZWdpb246YzNjZTgyOTA1NzFlNGRlYThkMjlmMjMxYTU3MDZiOGVfNTU5OA_df1553b4-ed80-4ced-a652-0d7886dc9a59"
      unitRef="usd">7100000</us-gaap:BusinessCombinationIntegrationRelatedCosts>
    <us-gaap:BusinessCombinationIntegrationRelatedCosts
      contextRef="i981dcf3e258143ef926ca153a290587b_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185NC9mcmFnOmMzY2U4MjkwNTcxZTRkZWE4ZDI5ZjIzMWE1NzA2YjhlL3RleHRyZWdpb246YzNjZTgyOTA1NzFlNGRlYThkMjlmMjMxYTU3MDZiOGVfNTYxMw_7d23bbaf-786f-4809-87da-e88a6332f2a8"
      unitRef="usd">4800000</us-gaap:BusinessCombinationIntegrationRelatedCosts>
    <us-gaap:BusinessAcquisitionProFormaInformationTextBlock
      contextRef="i88f2f47e22764022b5dec2243aa219c7_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185NC9mcmFnOmMzY2U4MjkwNTcxZTRkZWE4ZDI5ZjIzMWE1NzA2YjhlL3RleHRyZWdpb246YzNjZTgyOTA1NzFlNGRlYThkMjlmMjMxYTU3MDZiOGVfMTQ5NjA_6bf770d2-dec1-46fc-9877-ed33108a24cf">The pro forma financial information is not necessarily indicative of the operating results that would have occurred had the acquisition been consummated as if the date indicated, nor is it necessarily indicative of future operating results (in thousands, except per share amounts):&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.707%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.497%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(Unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;189,203&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;170,608&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net Income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(60,059)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;594,941&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net income (loss) per common share:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Basic&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.71)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31.32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.71)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30.11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:BusinessAcquisitionProFormaInformationTextBlock>
    <us-gaap:BusinessAcquisitionsProFormaRevenue
      contextRef="i88f2f47e22764022b5dec2243aa219c7_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185NC9mcmFnOmMzY2U4MjkwNTcxZTRkZWE4ZDI5ZjIzMWE1NzA2YjhlL3RhYmxlOjhhMWEyNTY5MjNhMTRjY2ViMjZiM2ZlY2RlMDI4MDZjL3RhYmxlcmFuZ2U6OGExYTI1NjkyM2ExNGNjZWIyNmIzZmVjZGUwMjgwNmNfMi0xLTEtMS00MTI5NA_d2e37e6c-1377-4333-b35f-4ea50ef95f37"
      unitRef="usd">189203000</us-gaap:BusinessAcquisitionsProFormaRevenue>
    <us-gaap:BusinessAcquisitionsProFormaRevenue
      contextRef="i81ce7b0c06a94e61a7d245d6544346aa_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185NC9mcmFnOmMzY2U4MjkwNTcxZTRkZWE4ZDI5ZjIzMWE1NzA2YjhlL3RhYmxlOjhhMWEyNTY5MjNhMTRjY2ViMjZiM2ZlY2RlMDI4MDZjL3RhYmxlcmFuZ2U6OGExYTI1NjkyM2ExNGNjZWIyNmIzZmVjZGUwMjgwNmNfMi0yLTEtMS00MTI5NA_cf5cca03-95c0-49af-a50b-b577dc4df3cc"
      unitRef="usd">170608000</us-gaap:BusinessAcquisitionsProFormaRevenue>
    <us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss
      contextRef="i88f2f47e22764022b5dec2243aa219c7_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185NC9mcmFnOmMzY2U4MjkwNTcxZTRkZWE4ZDI5ZjIzMWE1NzA2YjhlL3RhYmxlOjhhMWEyNTY5MjNhMTRjY2ViMjZiM2ZlY2RlMDI4MDZjL3RhYmxlcmFuZ2U6OGExYTI1NjkyM2ExNGNjZWIyNmIzZmVjZGUwMjgwNmNfMy0xLTEtMS00MTI5NA_9c6f1a28-f7d2-4fe4-8a53-feb8125f654e"
      unitRef="usd">-60059000</us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss>
    <us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss
      contextRef="i81ce7b0c06a94e61a7d245d6544346aa_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185NC9mcmFnOmMzY2U4MjkwNTcxZTRkZWE4ZDI5ZjIzMWE1NzA2YjhlL3RhYmxlOjhhMWEyNTY5MjNhMTRjY2ViMjZiM2ZlY2RlMDI4MDZjL3RhYmxlcmFuZ2U6OGExYTI1NjkyM2ExNGNjZWIyNmIzZmVjZGUwMjgwNmNfMy0yLTEtMS00MTI5NA_4d2587cc-10eb-46f7-96e1-5e83fb57a5e3"
      unitRef="usd">594941000</us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss>
    <us-gaap:BusinessAcquisitionProFormaEarningsPerShareBasic
      contextRef="i88f2f47e22764022b5dec2243aa219c7_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185NC9mcmFnOmMzY2U4MjkwNTcxZTRkZWE4ZDI5ZjIzMWE1NzA2YjhlL3RhYmxlOjhhMWEyNTY5MjNhMTRjY2ViMjZiM2ZlY2RlMDI4MDZjL3RhYmxlcmFuZ2U6OGExYTI1NjkyM2ExNGNjZWIyNmIzZmVjZGUwMjgwNmNfNS0xLTEtMS00MTI5NA_8ef1aba0-40ab-4a52-ac55-10206585e3d2"
      unitRef="usdPerShare">-3.71</us-gaap:BusinessAcquisitionProFormaEarningsPerShareBasic>
    <us-gaap:BusinessAcquisitionProFormaEarningsPerShareBasic
      contextRef="i81ce7b0c06a94e61a7d245d6544346aa_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185NC9mcmFnOmMzY2U4MjkwNTcxZTRkZWE4ZDI5ZjIzMWE1NzA2YjhlL3RhYmxlOjhhMWEyNTY5MjNhMTRjY2ViMjZiM2ZlY2RlMDI4MDZjL3RhYmxlcmFuZ2U6OGExYTI1NjkyM2ExNGNjZWIyNmIzZmVjZGUwMjgwNmNfNS0yLTEtMS00MTI5NA_32cd0c04-5c98-4f98-8ad6-70690149de65"
      unitRef="usdPerShare">31.32</us-gaap:BusinessAcquisitionProFormaEarningsPerShareBasic>
    <us-gaap:BusinessAcquisitionProFormaEarningsPerShareDiluted
      contextRef="i88f2f47e22764022b5dec2243aa219c7_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185NC9mcmFnOmMzY2U4MjkwNTcxZTRkZWE4ZDI5ZjIzMWE1NzA2YjhlL3RhYmxlOjhhMWEyNTY5MjNhMTRjY2ViMjZiM2ZlY2RlMDI4MDZjL3RhYmxlcmFuZ2U6OGExYTI1NjkyM2ExNGNjZWIyNmIzZmVjZGUwMjgwNmNfNi0xLTEtMS00MTI5NA_70cb6f28-c254-4d6c-ad87-bd02fa70c7d0"
      unitRef="usdPerShare">-3.71</us-gaap:BusinessAcquisitionProFormaEarningsPerShareDiluted>
    <us-gaap:BusinessAcquisitionProFormaEarningsPerShareDiluted
      contextRef="i81ce7b0c06a94e61a7d245d6544346aa_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185NC9mcmFnOmMzY2U4MjkwNTcxZTRkZWE4ZDI5ZjIzMWE1NzA2YjhlL3RhYmxlOjhhMWEyNTY5MjNhMTRjY2ViMjZiM2ZlY2RlMDI4MDZjL3RhYmxlcmFuZ2U6OGExYTI1NjkyM2ExNGNjZWIyNmIzZmVjZGUwMjgwNmNfNi0yLTEtMS00MTI5NA_2625508e-fa06-40a6-a1ae-f702d70354b6"
      unitRef="usdPerShare">30.11</us-gaap:BusinessAcquisitionProFormaEarningsPerShareDiluted>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="i77d1ae0e9cea4bc5be7e9ef1c1f3a41d_D20200909-20200909"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185NC9mcmFnOmMzY2U4MjkwNTcxZTRkZWE4ZDI5ZjIzMWE1NzA2YjhlL3RleHRyZWdpb246YzNjZTgyOTA1NzFlNGRlYThkMjlmMjMxYTU3MDZiOGVfNjMxMQ_a2d408be-6b03-4b98-82da-99cb9e6b5981"
      unitRef="usd">5100000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="i77d1ae0e9cea4bc5be7e9ef1c1f3a41d_D20200909-20200909"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185NC9mcmFnOmMzY2U4MjkwNTcxZTRkZWE4ZDI5ZjIzMWE1NzA2YjhlL3RleHRyZWdpb246YzNjZTgyOTA1NzFlNGRlYThkMjlmMjMxYTU3MDZiOGVfNjMyMw_8be3d7d3-10ff-4adb-8ec7-766a824cbf31"
      unitRef="usd">4600000</us-gaap:PaymentsToAcquireBusinessesGross>
    <lgnd:BusinessCombinationConsiderationTransferredHoldback
      contextRef="i77d1ae0e9cea4bc5be7e9ef1c1f3a41d_D20200909-20200909"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185NC9mcmFnOmMzY2U4MjkwNTcxZTRkZWE4ZDI5ZjIzMWE1NzA2YjhlL3RleHRyZWdpb246YzNjZTgyOTA1NzFlNGRlYThkMjlmMjMxYTU3MDZiOGVfNjM0MQ_19a75eed-f00f-4c47-995c-cf2577537ed1"
      unitRef="usd">500000</lgnd:BusinessCombinationConsiderationTransferredHoldback>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i4dba26cb1a1841e88daa2e5a24a15dd4_I20200909"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185NC9mcmFnOmMzY2U4MjkwNTcxZTRkZWE4ZDI5ZjIzMWE1NzA2YjhlL3RleHRyZWdpb246YzNjZTgyOTA1NzFlNGRlYThkMjlmMjMxYTU3MDZiOGVfNjQ3OQ_6099147d-8f0f-45d5-a92f-110ec1cf277c"
      unitRef="usd">4500000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i473bb8ab24bf433bb5e1980d2a87164e_I20200909"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185NC9mcmFnOmMzY2U4MjkwNTcxZTRkZWE4ZDI5ZjIzMWE1NzA2YjhlL3RleHRyZWdpb246YzNjZTgyOTA1NzFlNGRlYThkMjlmMjMxYTU3MDZiOGVfNjU1Mg_e520db15-b3de-4479-a6e7-97c6a83a5d69"
      unitRef="usd">25000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <lgnd:BusinessCombinationContingentConsiderationLiabilityPercentageOfAcquireeRevenues
      contextRef="i27ca37b8f6ed451391cf76d3832dccdb_D20200909-20200909"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185NC9mcmFnOmMzY2U4MjkwNTcxZTRkZWE4ZDI5ZjIzMWE1NzA2YjhlL3RleHRyZWdpb246YzNjZTgyOTA1NzFlNGRlYThkMjlmMjMxYTU3MDZiOGVfNjU2MA_9d49d563-12d7-48c3-844a-2ad9175a6e13"
      unitRef="number">0.25</lgnd:BusinessCombinationContingentConsiderationLiabilityPercentageOfAcquireeRevenues>
    <us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock
      contextRef="i36eaffe97d9f4ad9b8c509ecec687717_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185NC9mcmFnOmMzY2U4MjkwNTcxZTRkZWE4ZDI5ZjIzMWE1NzA2YjhlL3RleHRyZWdpb246YzNjZTgyOTA1NzFlNGRlYThkMjlmMjMxYTU3MDZiOGVfMTQ5NjM_274715ee-7e7d-4913-bbd1-82fbf6b02823">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The allocation of the consideration was allocated to the acquisition date fair values of acquired assets as follows (in thousands)&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:85.303%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.497%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangibles assets with finite-life - core technologies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,005&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,052&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents
      contextRef="i37f8f2fb62fb45eda8a94c6014fb06c3_I20200909"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185NC9mcmFnOmMzY2U4MjkwNTcxZTRkZWE4ZDI5ZjIzMWE1NzA2YjhlL3RhYmxlOjNmOTEzYTFiZTQ5ODQ2ZWVhZGUxMjJhY2MyMDkzYmRkL3RhYmxlcmFuZ2U6M2Y5MTNhMWJlNDk4NDZlZWFkZTEyMmFjYzIwOTNiZGRfMC0xLTEtMS00MTI5NA_6363f2a2-88a2-464d-a2a5-21db8bb2fc4e"
      unitRef="usd">47000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
      contextRef="i37f8f2fb62fb45eda8a94c6014fb06c3_I20200909"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185NC9mcmFnOmMzY2U4MjkwNTcxZTRkZWE4ZDI5ZjIzMWE1NzA2YjhlL3RhYmxlOjNmOTEzYTFiZTQ5ODQ2ZWVhZGUxMjJhY2MyMDkzYmRkL3RhYmxlcmFuZ2U6M2Y5MTNhMWJlNDk4NDZlZWFkZTEyMmFjYzIwOTNiZGRfMS0xLTEtMS00MTI5NA_ce2b9a70-2bf5-45ae-b236-b7f66876026d"
      unitRef="usd">5005000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet
      contextRef="i37f8f2fb62fb45eda8a94c6014fb06c3_I20200909"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185NC9mcmFnOmMzY2U4MjkwNTcxZTRkZWE4ZDI5ZjIzMWE1NzA2YjhlL3RhYmxlOjNmOTEzYTFiZTQ5ODQ2ZWVhZGUxMjJhY2MyMDkzYmRkL3RhYmxlcmFuZ2U6M2Y5MTNhMWJlNDk4NDZlZWFkZTEyMmFjYzIwOTNiZGRfMi0xLTEtMS00MTI5NA_ae42990e-f633-4dca-85e6-1e0247a01715"
      unitRef="usd">5052000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="i1decdab2b3ad4d5f9e9970051e074f04_D20200909-20200909"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185NC9mcmFnOmMzY2U4MjkwNTcxZTRkZWE4ZDI5ZjIzMWE1NzA2YjhlL3RleHRyZWdpb246YzNjZTgyOTA1NzFlNGRlYThkMjlmMjMxYTU3MDZiOGVfNzA4Ng_fe455325-22d3-440b-a395-9593af6f6e13">P10Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i37f8f2fb62fb45eda8a94c6014fb06c3_I20200909"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185NC9mcmFnOmMzY2U4MjkwNTcxZTRkZWE4ZDI5ZjIzMWE1NzA2YjhlL3RleHRyZWdpb246YzNjZTgyOTA1NzFlNGRlYThkMjlmMjMxYTU3MDZiOGVfNzIyNQ_89b5e0d0-2a70-4731-9aca-1a1999ee0425"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="ieb689a5898414155944b7e894ecf5662_D20200908-20200908"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185NC9mcmFnOmMzY2U4MjkwNTcxZTRkZWE4ZDI5ZjIzMWE1NzA2YjhlL3RleHRyZWdpb246YzNjZTgyOTA1NzFlNGRlYThkMjlmMjMxYTU3MDZiOGVfNzU5NA_99147251-365a-444b-8dca-946feb604b5e"
      unitRef="usd">7100000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <lgnd:BusinessCombinationConsiderationTransferredHoldback
      contextRef="ieb689a5898414155944b7e894ecf5662_D20200908-20200908"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185NC9mcmFnOmMzY2U4MjkwNTcxZTRkZWE4ZDI5ZjIzMWE1NzA2YjhlL3RleHRyZWdpb246YzNjZTgyOTA1NzFlNGRlYThkMjlmMjMxYTU3MDZiOGVfNzYxOA_5429013f-90ec-4a94-a9c1-a48a31bb412f"
      unitRef="usd">500000</lgnd:BusinessCombinationConsiderationTransferredHoldback>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i37beeb694dea43279d1ea72ec2fb6fa3_I20200908"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185NC9mcmFnOmMzY2U4MjkwNTcxZTRkZWE4ZDI5ZjIzMWE1NzA2YjhlL3RleHRyZWdpb246YzNjZTgyOTA1NzFlNGRlYThkMjlmMjMxYTU3MDZiOGVfNzc0Nw_f2a738e6-2282-412e-b31a-da42bf5430ec"
      unitRef="usd">5000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i48c587ca12364b2ebe41d4a23afdf0a5_I20200908"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185NC9mcmFnOmMzY2U4MjkwNTcxZTRkZWE4ZDI5ZjIzMWE1NzA2YjhlL3RleHRyZWdpb246YzNjZTgyOTA1NzFlNGRlYThkMjlmMjMxYTU3MDZiOGVfNzg0NA_f1c41085-b6f8-4cae-a44b-25f1096c84ae"
      unitRef="usd">25750000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <lgnd:BusinessCombinationContingentConsiderationLiabilityPercentageOfAcquireeRevenues
      contextRef="i00b4cfcf8fab454fa5cb35a4499bd18e_D20200908-20200908"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185NC9mcmFnOmMzY2U4MjkwNTcxZTRkZWE4ZDI5ZjIzMWE1NzA2YjhlL3RleHRyZWdpb246YzNjZTgyOTA1NzFlNGRlYThkMjlmMjMxYTU3MDZiOGVfNzg1Mg_1a844297-c6f5-4264-aa6c-0685fa129799"
      unitRef="number">0.25</lgnd:BusinessCombinationContingentConsiderationLiabilityPercentageOfAcquireeRevenues>
    <us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock
      contextRef="ic3f66dd3dd704775a2c678c7d07ce665_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185NC9mcmFnOmMzY2U4MjkwNTcxZTRkZWE4ZDI5ZjIzMWE1NzA2YjhlL3RleHRyZWdpb246YzNjZTgyOTA1NzFlNGRlYThkMjlmMjMxYTU3MDZiOGVfMTQ5Njg_4732174c-eb2e-42e1-b540-e3ec76677106">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The allocation of the consideration was allocated to the acquisition date fair values of acquired assets and assumed liabilities as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:85.303%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.497%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and other assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(142)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(604)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangibles assets with finite-life - core technology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,582&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,076&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock>
    <lgnd:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndCurrentAssetsOther
      contextRef="ib2d89a76397d4f8fa55ad5491b92151e_I20200908"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185NC9mcmFnOmMzY2U4MjkwNTcxZTRkZWE4ZDI5ZjIzMWE1NzA2YjhlL3RhYmxlOjU4ZWFmYjAzMDg0MjRiMGZiNWRjNWMwODkyMmQ5ZjU3L3RhYmxlcmFuZ2U6NThlYWZiMDMwODQyNGIwZmI1ZGM1YzA4OTIyZDlmNTdfMC0xLTEtMS00MTI5NA_fa09e0be-ce35-4577-bdfd-24f8a01e3497"
      unitRef="usd">240000</lgnd:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndCurrentAssetsOther>
    <lgnd:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilitiesCurrent
      contextRef="ib2d89a76397d4f8fa55ad5491b92151e_I20200908"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185NC9mcmFnOmMzY2U4MjkwNTcxZTRkZWE4ZDI5ZjIzMWE1NzA2YjhlL3RhYmxlOjU4ZWFmYjAzMDg0MjRiMGZiNWRjNWMwODkyMmQ5ZjU3L3RhYmxlcmFuZ2U6NThlYWZiMDMwODQyNGIwZmI1ZGM1YzA4OTIyZDlmNTdfMS0xLTEtMS00MTI5NA_439dba71-85b9-4c32-8540-44ffc60dc3d5"
      unitRef="usd">142000</lgnd:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilitiesCurrent>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities
      contextRef="ib2d89a76397d4f8fa55ad5491b92151e_I20200908"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185NC9mcmFnOmMzY2U4MjkwNTcxZTRkZWE4ZDI5ZjIzMWE1NzA2YjhlL3RhYmxlOjU4ZWFmYjAzMDg0MjRiMGZiNWRjNWMwODkyMmQ5ZjU3L3RhYmxlcmFuZ2U6NThlYWZiMDMwODQyNGIwZmI1ZGM1YzA4OTIyZDlmNTdfMi0xLTEtMS00MTI5NA_b1dbc6d0-8c86-4a9b-a23d-b03676b898d8"
      unitRef="usd">604000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
      contextRef="ib2d89a76397d4f8fa55ad5491b92151e_I20200908"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185NC9mcmFnOmMzY2U4MjkwNTcxZTRkZWE4ZDI5ZjIzMWE1NzA2YjhlL3RhYmxlOjU4ZWFmYjAzMDg0MjRiMGZiNWRjNWMwODkyMmQ5ZjU3L3RhYmxlcmFuZ2U6NThlYWZiMDMwODQyNGIwZmI1ZGM1YzA4OTIyZDlmNTdfMy0xLTEtMS00MTI5NA_31ed57df-b807-4057-8445-9f18f8d66b3d"
      unitRef="usd">7582000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet
      contextRef="ib2d89a76397d4f8fa55ad5491b92151e_I20200908"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185NC9mcmFnOmMzY2U4MjkwNTcxZTRkZWE4ZDI5ZjIzMWE1NzA2YjhlL3RhYmxlOjU4ZWFmYjAzMDg0MjRiMGZiNWRjNWMwODkyMmQ5ZjU3L3RhYmxlcmFuZ2U6NThlYWZiMDMwODQyNGIwZmI1ZGM1YzA4OTIyZDlmNTdfNC0xLTEtMS00MTI5NA_93248104-8e33-4c2c-aba0-5ef48f8a6efd"
      unitRef="usd">7076000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="i27406e0d0a0147c28467e0891905560f_D20200908-20200908"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185NC9mcmFnOmMzY2U4MjkwNTcxZTRkZWE4ZDI5ZjIzMWE1NzA2YjhlL3RleHRyZWdpb246YzNjZTgyOTA1NzFlNGRlYThkMjlmMjMxYTU3MDZiOGVfODU4Mg_7a1a691e-7c6a-4fbe-a0de-d911b7d51ad9">P15Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="ib2d89a76397d4f8fa55ad5491b92151e_I20200908"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185NC9mcmFnOmMzY2U4MjkwNTcxZTRkZWE4ZDI5ZjIzMWE1NzA2YjhlL3RleHRyZWdpb246YzNjZTgyOTA1NzFlNGRlYThkMjlmMjMxYTU3MDZiOGVfODczMQ_4be45083-fb32-4ff8-b71e-07f289ed5b25"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="ied333fd0de2c4cf4a2b4948199619825_D20200401-20200401"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185NC9mcmFnOmMzY2U4MjkwNTcxZTRkZWE4ZDI5ZjIzMWE1NzA2YjhlL3RleHRyZWdpb246YzNjZTgyOTA1NzFlNGRlYThkMjlmMjMxYTU3MDZiOGVfODk5NQ_f8315397-dccb-4ea4-a478-25c76fd67b7c"
      unitRef="usd">19900000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="ied333fd0de2c4cf4a2b4948199619825_D20200401-20200401"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185NC9mcmFnOmMzY2U4MjkwNTcxZTRkZWE4ZDI5ZjIzMWE1NzA2YjhlL3RleHRyZWdpb246YzNjZTgyOTA1NzFlNGRlYThkMjlmMjMxYTU3MDZiOGVfOTAwNw_7b69d995-c0f4-44ba-8db2-240832757db0"
      unitRef="usd">15100000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i66fd5bb596fe4dc0a209f580f37be1bd_I20200401"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185NC9mcmFnOmMzY2U4MjkwNTcxZTRkZWE4ZDI5ZjIzMWE1NzA2YjhlL3RleHRyZWdpb246YzNjZTgyOTA1NzFlNGRlYThkMjlmMjMxYTU3MDZiOGVfOTA3MQ_97aef128-4b99-4a1d-8d3d-b27fbbe3e79d"
      unitRef="usd">25000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <lgnd:BusinessCombinationContingentConsiderationLiabilityFairValueDisclosure
      contextRef="i66fd5bb596fe4dc0a209f580f37be1bd_I20200401"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185NC9mcmFnOmMzY2U4MjkwNTcxZTRkZWE4ZDI5ZjIzMWE1NzA2YjhlL3RleHRyZWdpb246YzNjZTgyOTA1NzFlNGRlYThkMjlmMjMxYTU3MDZiOGVfOTE1OQ_9fd14f6a-7473-4ed4-b485-2817f6cf7bc4"
      unitRef="usd">4800000</lgnd:BusinessCombinationContingentConsiderationLiabilityFairValueDisclosure>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="i8b9c129486844e46be95446917936d16_I20200401"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185NC9mcmFnOmMzY2U4MjkwNTcxZTRkZWE4ZDI5ZjIzMWE1NzA2YjhlL3RleHRyZWdpb246YzNjZTgyOTA1NzFlNGRlYThkMjlmMjMxYTU3MDZiOGVfOTUwNA_5489e7eb-200b-46c1-9003-aa859ae3d1d4"
      unitRef="number">0.055</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock
      contextRef="i187c5df306a349e38267335b0f796d41_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185NC9mcmFnOmMzY2U4MjkwNTcxZTRkZWE4ZDI5ZjIzMWE1NzA2YjhlL3RleHRyZWdpb246YzNjZTgyOTA1NzFlNGRlYThkMjlmMjMxYTU3MDZiOGVfMTQ5NjU_6eee9bcc-4b80-45ea-943d-540e843ca199">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The allocation of the consideration was allocated to the acquisition date fair values of acquired assets and assumed liabilities as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:85.303%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.497%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,173&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaids and other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;588&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liabilities assumed&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(812)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,685)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax assets, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;861&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquired intangibles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,015&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,940&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%"&gt;(1) Goodwill represents the excess of the purchase price over the preliminary fair value of the underlying assets acquired and liabilities assumed. Goodwill is attributable to the assembled workforce of experienced personnel at Icagen and expected synergies.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment
      contextRef="i66fd5bb596fe4dc0a209f580f37be1bd_I20200401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185NC9mcmFnOmMzY2U4MjkwNTcxZTRkZWE4ZDI5ZjIzMWE1NzA2YjhlL3RhYmxlOjE5MzJmYTRkZmQ4MDRmNjU4NjIxNmMxMjRiZmIxNTQwL3RhYmxlcmFuZ2U6MTkzMmZhNGRmZDgwNGY2NTg2MjE2YzEyNGJmYjE1NDBfMC0xLTEtMS00MTI5NA_de7e04b5-957a-4e92-a20f-e7c506ae1cff"
      unitRef="usd">1173000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets
      contextRef="i66fd5bb596fe4dc0a209f580f37be1bd_I20200401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185NC9mcmFnOmMzY2U4MjkwNTcxZTRkZWE4ZDI5ZjIzMWE1NzA2YjhlL3RhYmxlOjE5MzJmYTRkZmQ4MDRmNjU4NjIxNmMxMjRiZmIxNTQwL3RhYmxlcmFuZ2U6MTkzMmZhNGRmZDgwNGY2NTg2MjE2YzEyNGJmYjE1NDBfMS0xLTEtMS00MTI5NA_8ace71c9-c8fe-4f3a-a10c-ecd2ea510b4d"
      unitRef="usd">588000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities
      contextRef="i66fd5bb596fe4dc0a209f580f37be1bd_I20200401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185NC9mcmFnOmMzY2U4MjkwNTcxZTRkZWE4ZDI5ZjIzMWE1NzA2YjhlL3RhYmxlOjE5MzJmYTRkZmQ4MDRmNjU4NjIxNmMxMjRiZmIxNTQwL3RhYmxlcmFuZ2U6MTkzMmZhNGRmZDgwNGY2NTg2MjE2YzEyNGJmYjE1NDBfMi0xLTEtMS00MTI5NA_b8a3c752-203d-4964-a861-f5adea84a50a"
      unitRef="usd">812000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue
      contextRef="i66fd5bb596fe4dc0a209f580f37be1bd_I20200401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185NC9mcmFnOmMzY2U4MjkwNTcxZTRkZWE4ZDI5ZjIzMWE1NzA2YjhlL3RhYmxlOjE5MzJmYTRkZmQ4MDRmNjU4NjIxNmMxMjRiZmIxNTQwL3RhYmxlcmFuZ2U6MTkzMmZhNGRmZDgwNGY2NTg2MjE2YzEyNGJmYjE1NDBfMy0xLTEtMS00MTI5NA_eb85a3f8-ec68-4ba7-a96b-e3e9fba30743"
      unitRef="usd">3685000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets
      contextRef="i66fd5bb596fe4dc0a209f580f37be1bd_I20200401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185NC9mcmFnOmMzY2U4MjkwNTcxZTRkZWE4ZDI5ZjIzMWE1NzA2YjhlL3RhYmxlOjE5MzJmYTRkZmQ4MDRmNjU4NjIxNmMxMjRiZmIxNTQwL3RhYmxlcmFuZ2U6MTkzMmZhNGRmZDgwNGY2NTg2MjE2YzEyNGJmYjE1NDBfNC0xLTEtMS00MTI5NA_8ca5b4d9-b9b3-49fd-b5a4-c952b522ac97"
      unitRef="usd">861000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets>
    <lgnd:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssets
      contextRef="i66fd5bb596fe4dc0a209f580f37be1bd_I20200401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185NC9mcmFnOmMzY2U4MjkwNTcxZTRkZWE4ZDI5ZjIzMWE1NzA2YjhlL3RhYmxlOjE5MzJmYTRkZmQ4MDRmNjU4NjIxNmMxMjRiZmIxNTQwL3RhYmxlcmFuZ2U6MTkzMmZhNGRmZDgwNGY2NTg2MjE2YzEyNGJmYjE1NDBfNS0xLTEtMS00MTI5NA_0fcb8c64-ab33-4d46-8d9f-fa62d9bae02b"
      unitRef="usd">12800000</lgnd:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssets>
    <us-gaap:Goodwill
      contextRef="i66fd5bb596fe4dc0a209f580f37be1bd_I20200401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185NC9mcmFnOmMzY2U4MjkwNTcxZTRkZWE4ZDI5ZjIzMWE1NzA2YjhlL3RhYmxlOjE5MzJmYTRkZmQ4MDRmNjU4NjIxNmMxMjRiZmIxNTQwL3RhYmxlcmFuZ2U6MTkzMmZhNGRmZDgwNGY2NTg2MjE2YzEyNGJmYjE1NDBfNi0xLTEtMS00MTI5NA_17beb110-532e-4e85-b560-b35dd147f060"
      unitRef="usd">9015000</us-gaap:Goodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet
      contextRef="i66fd5bb596fe4dc0a209f580f37be1bd_I20200401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185NC9mcmFnOmMzY2U4MjkwNTcxZTRkZWE4ZDI5ZjIzMWE1NzA2YjhlL3RhYmxlOjE5MzJmYTRkZmQ4MDRmNjU4NjIxNmMxMjRiZmIxNTQwL3RhYmxlcmFuZ2U6MTkzMmZhNGRmZDgwNGY2NTg2MjE2YzEyNGJmYjE1NDBfNy0xLTEtMS00MTI5NA_47c6a305-1b2d-47b8-99c3-cb3c5bbbd1ec"
      unitRef="usd">19940000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
      contextRef="i2c2f23bb705c43f999e98dd9cfeedb0a_I20200401"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185NC9mcmFnOmMzY2U4MjkwNTcxZTRkZWE4ZDI5ZjIzMWE1NzA2YjhlL3RleHRyZWdpb246YzNjZTgyOTA1NzFlNGRlYThkMjlmMjMxYTU3MDZiOGVfMTA1ODQ_7c1b6ccd-c75d-4eed-8154-a253139fc30c"
      unitRef="usd">11100000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
      contextRef="i50397a39865e428d8b5ec1d1e3e72da9_I20200401"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185NC9mcmFnOmMzY2U4MjkwNTcxZTRkZWE4ZDI5ZjIzMWE1NzA2YjhlL3RleHRyZWdpb246YzNjZTgyOTA1NzFlNGRlYThkMjlmMjMxYTU3MDZiOGVfMTA2MTc_ce3589c5-ebc5-4129-adc8-4251e129e03f"
      unitRef="usd">1700000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <lgnd:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsDiscountRate
      contextRef="if2f9b634b34f4572ac8de5159f8e63fb_D20200401-20200401"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185NC9mcmFnOmMzY2U4MjkwNTcxZTRkZWE4ZDI5ZjIzMWE1NzA2YjhlL3RleHRyZWdpb246YzNjZTgyOTA1NzFlNGRlYThkMjlmMjMxYTU3MDZiOGVfMTA5MTI_a082ba72-bdae-44a9-b824-58bbc8152cfa"
      unitRef="number">0.17</lgnd:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsDiscountRate>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="if2f9b634b34f4572ac8de5159f8e63fb_D20200401-20200401"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185NC9mcmFnOmMzY2U4MjkwNTcxZTRkZWE4ZDI5ZjIzMWE1NzA2YjhlL3RleHRyZWdpb246YzNjZTgyOTA1NzFlNGRlYThkMjlmMjMxYTU3MDZiOGVfMTEwNTY_6baa15ba-f0b5-4aa7-842a-b6f63d42cc53">P9Y7M6D</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <lgnd:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsDiscountRate
      contextRef="if2f9b634b34f4572ac8de5159f8e63fb_D20200401-20200401"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185NC9mcmFnOmMzY2U4MjkwNTcxZTRkZWE4ZDI5ZjIzMWE1NzA2YjhlL3RleHRyZWdpb246YzNjZTgyOTA1NzFlNGRlYThkMjlmMjMxYTU3MDZiOGVfMTEzOTE_a082ba72-bdae-44a9-b824-58bbc8152cfa"
      unitRef="number">0.17</lgnd:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsDiscountRate>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="i797a1a3c49bb44aba3b71fee73a5a78f_D20200401-20200401"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185NC9mcmFnOmMzY2U4MjkwNTcxZTRkZWE4ZDI5ZjIzMWE1NzA2YjhlL3RleHRyZWdpb246YzNjZTgyOTA1NzFlNGRlYThkMjlmMjMxYTU3MDZiOGVfMTE1MTE_90ba4a9a-9ead-41b8-be46-6787a0f63268">P10Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="ied333fd0de2c4cf4a2b4948199619825_D20200401-20200401"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185NC9mcmFnOmMzY2U4MjkwNTcxZTRkZWE4ZDI5ZjIzMWE1NzA2YjhlL3RleHRyZWdpb246YzNjZTgyOTA1NzFlNGRlYThkMjlmMjMxYTU3MDZiOGVfMTE2MjU_9cb45c43-4a73-41a6-8508-3ff80756e7c3">P9Y8M12D</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="i559e6316ff5f46eeae72eb8202827fdd_D20190723-20190723"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185NC9mcmFnOmMzY2U4MjkwNTcxZTRkZWE4ZDI5ZjIzMWE1NzA2YjhlL3RleHRyZWdpb246YzNjZTgyOTA1NzFlNGRlYThkMjlmMjMxYTU3MDZiOGVfMTI2Mjg_3876e55e-51de-436b-890e-5aa2e6dc832f"
      unitRef="usd">12000000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="i559e6316ff5f46eeae72eb8202827fdd_D20190723-20190723"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185NC9mcmFnOmMzY2U4MjkwNTcxZTRkZWE4ZDI5ZjIzMWE1NzA2YjhlL3RleHRyZWdpb246YzNjZTgyOTA1NzFlNGRlYThkMjlmMjMxYTU3MDZiOGVfMTI2NDA_5fec832c-1a08-4ccb-ba43-e28f443e4189"
      unitRef="usd">11900000</us-gaap:PaymentsToAcquireBusinessesGross>
    <lgnd:BusinessCombinationCashHoldbackForPotentialIndemnificationClaims
      contextRef="i559e6316ff5f46eeae72eb8202827fdd_D20190723-20190723"
      decimals="-4"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185NC9mcmFnOmMzY2U4MjkwNTcxZTRkZWE4ZDI5ZjIzMWE1NzA2YjhlL3RleHRyZWdpb246YzNjZTgyOTA1NzFlNGRlYThkMjlmMjMxYTU3MDZiOGVfMTI3MTE_30515022-9672-4fb7-ace6-c9bc80375442"
      unitRef="usd">150000</lgnd:BusinessCombinationCashHoldbackForPotentialIndemnificationClaims>
    <us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock
      contextRef="i2391e1562f894a61a00bffbaac6457ea_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185NC9mcmFnOmMzY2U4MjkwNTcxZTRkZWE4ZDI5ZjIzMWE1NzA2YjhlL3RleHRyZWdpb246YzNjZTgyOTA1NzFlNGRlYThkMjlmMjMxYTU3MDZiOGVfMTQ5NjY_a39219bf-52c2-4aae-ac0b-5a9f231fbaea">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The final purchase consideration was allocated to the acquisition date fair values of acquired assets and assumed liabilities as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:85.303%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.497%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and other assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts payable and accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(83)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(146)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangibles assets with finite-life - core technologies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,812&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,011&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%"&gt;(1) Goodwill represents the excess of the purchase price over the fair value of the underlying assets acquired and liabilities assumed. Goodwill is attributable to the assembled workforce of experienced personnel at Ab Initio and expected synergies.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock>
    <lgnd:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndCurrentAssetsOther
      contextRef="ib84e53f0d01a493a86dc0aed964fe45a_I20190723"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185NC9mcmFnOmMzY2U4MjkwNTcxZTRkZWE4ZDI5ZjIzMWE1NzA2YjhlL3RhYmxlOjYxYjEyY2Q3MmY5MTRmZDdhOTg0NjAyZjBjYTM1OWFiL3RhYmxlcmFuZ2U6NjFiMTJjZDcyZjkxNGZkN2E5ODQ2MDJmMGNhMzU5YWJfMC0xLTEtMS00MTI5NA_e1ce2416-468c-495e-86f2-e7db15240178"
      unitRef="usd">28000</lgnd:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndCurrentAssetsOther>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable
      contextRef="ib84e53f0d01a493a86dc0aed964fe45a_I20190723"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185NC9mcmFnOmMzY2U4MjkwNTcxZTRkZWE4ZDI5ZjIzMWE1NzA2YjhlL3RhYmxlOjYxYjEyY2Q3MmY5MTRmZDdhOTg0NjAyZjBjYTM1OWFiL3RhYmxlcmFuZ2U6NjFiMTJjZDcyZjkxNGZkN2E5ODQ2MDJmMGNhMzU5YWJfMS0xLTEtMS00MTI5NA_d39499b6-3b02-40ae-be29-79bfe4ee5dde"
      unitRef="usd">83000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities
      contextRef="ib84e53f0d01a493a86dc0aed964fe45a_I20190723"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185NC9mcmFnOmMzY2U4MjkwNTcxZTRkZWE4ZDI5ZjIzMWE1NzA2YjhlL3RhYmxlOjYxYjEyY2Q3MmY5MTRmZDdhOTg0NjAyZjBjYTM1OWFiL3RhYmxlcmFuZ2U6NjFiMTJjZDcyZjkxNGZkN2E5ODQ2MDJmMGNhMzU5YWJfMi0xLTEtMS00MTI5NA_9569ecaf-f051-47e4-95c6-da1af7b3cc47"
      unitRef="usd">146000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
      contextRef="ib84e53f0d01a493a86dc0aed964fe45a_I20190723"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185NC9mcmFnOmMzY2U4MjkwNTcxZTRkZWE4ZDI5ZjIzMWE1NzA2YjhlL3RhYmxlOjYxYjEyY2Q3MmY5MTRmZDdhOTg0NjAyZjBjYTM1OWFiL3RhYmxlcmFuZ2U6NjFiMTJjZDcyZjkxNGZkN2E5ODQ2MDJmMGNhMzU5YWJfMy0xLTEtMS00MTI5NA_a6a6c68e-3f6b-41eb-a660-289dba953c81"
      unitRef="usd">7400000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:Goodwill
      contextRef="ib84e53f0d01a493a86dc0aed964fe45a_I20190723"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185NC9mcmFnOmMzY2U4MjkwNTcxZTRkZWE4ZDI5ZjIzMWE1NzA2YjhlL3RhYmxlOjYxYjEyY2Q3MmY5MTRmZDdhOTg0NjAyZjBjYTM1OWFiL3RhYmxlcmFuZ2U6NjFiMTJjZDcyZjkxNGZkN2E5ODQ2MDJmMGNhMzU5YWJfNC0xLTEtMS00MTI5NA_c4e7ac81-9509-4cae-9e0f-08b8f176aaac"
      unitRef="usd">4812000</us-gaap:Goodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet
      contextRef="ib84e53f0d01a493a86dc0aed964fe45a_I20190723"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185NC9mcmFnOmMzY2U4MjkwNTcxZTRkZWE4ZDI5ZjIzMWE1NzA2YjhlL3RhYmxlOjYxYjEyY2Q3MmY5MTRmZDdhOTg0NjAyZjBjYTM1OWFiL3RhYmxlcmFuZ2U6NjFiMTJjZDcyZjkxNGZkN2E5ODQ2MDJmMGNhMzU5YWJfNS0xLTEtMS00MTI5NA_85070a85-1c4a-4e2e-bab6-c49eb1651851"
      unitRef="usd">12011000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet>
    <us-gaap:BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount
      contextRef="ib84e53f0d01a493a86dc0aed964fe45a_I20190723"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185NC9mcmFnOmMzY2U4MjkwNTcxZTRkZWE4ZDI5ZjIzMWE1NzA2YjhlL3RleHRyZWdpb246YzNjZTgyOTA1NzFlNGRlYThkMjlmMjMxYTU3MDZiOGVfMjE5OTAyMzI3MzkxMA_bf135955-bcaf-4f28-bf66-c7f8d9d423f5"
      unitRef="usd">0</us-gaap:BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount>
    <lgnd:BusinessCombinationAssumptionsUsedEstimatedFutureCashFlowsDiscountRate
      contextRef="ib84e53f0d01a493a86dc0aed964fe45a_I20190723"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185NC9mcmFnOmMzY2U4MjkwNTcxZTRkZWE4ZDI5ZjIzMWE1NzA2YjhlL3RleHRyZWdpb246YzNjZTgyOTA1NzFlNGRlYThkMjlmMjMxYTU3MDZiOGVfMTM2Njc_f57b0378-ccd5-4fd5-bfa2-72052031bd20"
      unitRef="number">0.120</lgnd:BusinessCombinationAssumptionsUsedEstimatedFutureCashFlowsDiscountRate>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i609b4c3a45a041b1856484ca0935a9fc_D20190723-20190723"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185NC9mcmFnOmMzY2U4MjkwNTcxZTRkZWE4ZDI5ZjIzMWE1NzA2YjhlL3RleHRyZWdpb246YzNjZTgyOTA1NzFlNGRlYThkMjlmMjMxYTU3MDZiOGVfMTM4MjA_e09c9d5d-4bdf-4059-a84a-2cef999845da">P20Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FinancialInstrumentsDisclosureTextBlock
      contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185Ny9mcmFnOmRmZjk3MmRkZDM3NDQ5NzNiY2U4YjMwMmJlMzhjNjdhL3RleHRyZWdpb246ZGZmOTcyZGRkMzc0NDk3M2JjZThiMzAyYmUzOGM2N2FfNjkyOQ_ed07af8c-c792-4267-be63-636044b1d9b4">Fair Value Measurement&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We measure certain financial assets and liabilities at fair value on a recurring basis. Fair value is a market-based measurement that should be determined using assumptions that market participants would use in pricing an asset or liability. We establish a three-level hierarchy to prioritize the inputs used in measuring fair value. The levels are described in the below with level 1 having the highest priority and level 3 having the lowest:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 1 - Observable inputs such as quoted prices in active markets &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 2 - Inputs other than the quoted prices in active markets that are observable either directly or indirectly &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 3 - Unobservable inputs in which there is little or no market data, which require the Company to develop its own assumptions&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides a summary of the assets and liabilities that are measured at fair value on a recurring basis as of December&#160;31, 2021 and 2020 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.829%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.624%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="24" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements at Reporting Date Using&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted Prices in&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Active Markets&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;for Identical&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Other&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Observable&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Inputs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unobservable&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Inputs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Level&#160;1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Level&#160;2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Level&#160;3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term investments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; (1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;290,697&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,735&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;280,553&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;409&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investment in Viking common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,889&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,889&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;321,586&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,624&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;280,553&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;409&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent liabilities - Cydex&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;349&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;349&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent liabilities - Metabasis &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,358&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,358&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent liabilities - Icagen &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(5)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,364&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,364&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liability for amounts owed to a former licensor&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Total liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,358&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,713&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.268%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.473%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.473%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.473%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.623%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="24" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements at Reporting Date Using&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted Prices in&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Active Markets&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;for Identical&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Other&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Observable&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Inputs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unobservable&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Inputs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Level&#160;1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Level&#160;2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Level&#160;3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term investments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; (1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;324,478&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,438&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;320,647&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;393&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investment in Viking common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,763&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,763&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investment in Viking warrants &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;363,567&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42,527&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;320,647&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;393&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent liabilities - Crystal &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent liabilities - Cydex&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;508&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;508&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent liabilities - Metabasis &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,821&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,821&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent liabilities - Icagen &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(5)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,404&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,404&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent liabilities - Pfenex &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(6)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liability for amounts owed to a former licensor&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Total liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,193&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,821&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,312&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;(1) Excluding our investment in Viking, our short-term investments in marketable debt and equity securities are classified as available-for-sale securities based on management's intentions and are at level 2 of the fair value hierarchy, as these investment securities are valued based upon quoted prices for identical or similar instruments in markets that are not active, and model-based valuation techniques for which all significant assumptions are observable in the market. Short-term investments in mutual funds are valued at their net asset value (NAV) on the last day of the period. We have classified marketable securities with original maturities of greater than one year as short-term investments based upon our ability and intent to use any and all of those marketable securities to satisfy the liquidity needs of our current operations. In addition, we have investment in warrants resulting from Seelos Therapeutics Inc. milestone payments that were settled in shares during the first quarter of 2019 and are at level 3 of the fair value hierarchy, based on Black Scholes value estimated by management on the last day of the period.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(2) Investment in Viking warrants, which we received as a result of Viking&#x2019;s partial repayment of the Viking note receivable and our purchase of Viking common stock and warrants in April 2016, is classified as level 1 as the fair value is determined using quoted market prices in active markets for the same securities. The change of the fair value is recorded in &#x201c;gain (loss) from short-term investments&#x201d; in our consolidated statement of operations. See further discussion in &#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note (3), Short-term Investments: Investment in Viking.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x201d;  &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(3) The fair value of Crystal contingent liabilities was determined using a probability weighted income approach. Most of the contingent payments are based on development or regulatory milestones as defined in the merger agreement with Crystal. The fair value is subjective and is affected by changes in inputs to the valuation model including management&#x2019;s estimates regarding the timing and probability of achievement of certain developmental and regulatory milestones. During the twelve months ended December&#160;31, 2020, we paid $1.8 million contingent liability on development milestones to former Crystal shareholders. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(4) In connection with our acquisition of Metabasis in January 2010, we issued Metabasis stockholders four tradable CVRs, one CVR from each of four respective series of CVR, for each Metabasis share. The CVRs entitle Metabasis stockholders to cash payments as frequently as every six months as cash is received by us from proceeds from the sale or partnering of any of the Metabasis drug development programs, among other triggering events. The liability for the CVRs is determined using quoted prices in a market that is not active for the underlying CVR. The carrying amount of the liability may fluctuate significantly based upon quoted market prices and actual amounts paid under the agreements may be materially differ than the carrying amount of the liability. Several of the Metabasis drug development programs have been outlicensed to Viking, including VK2809. VK2809 is a novel selective TR-&#x3b2; agonist with potential in multiple indications, including hypercholesterolemia, dyslipidemia, NASH, and X-ALD. Under the terms of the agreement with Viking, we may be entitled to up to $375.0 million of development, regulatory and commercial milestones and tiered royalties on potential future sales including a $10.0 million payment upon initiation of a Phase 3 clinical trial.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(5) The fair value of Icagen contingent liabilities was determined using a probability weighted income approach. Most of the contingent payments are based on certain revenue milestones as defined in the asset purchase agreement with Icagen. The fair value is subjective and is affected by changes in inputs to the valuation model including management&#x2019;s estimates regarding the timing and probability of achievement of certain developmental and regulatory milestones. Changes in these estimates may materially affect the fair value. During the year-end December 31, 2021, we paid a $1.1 million contingent liability based on revenue milestones to Icagen.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(6) The fair value of the Pfenex contingent liability was determined using a probability adjusted income approach. These cash flows were then discounted to present value using a discount rate based on the market participants' cost of debt reflective of the Company. During the year-end December 31, 2021, we reduced the contingent liability by $37.6&#160;million primarily due to the lower probability of achieving the specific development and regulatory milestone by December 31, 2021 as defined by the Pfenex CVR. See further detail on Pfenex CVR in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 4, Acquisitions&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation of the level 3 financial instruments as of December&#160;31, 2021 is as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;text-indent:45pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:85.303%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.497%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of level 3 financial instruments as of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,312&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payments to CVR holders and other contingency payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,770)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value adjustments to contingent liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(36,549)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent liabilities from xCella asset acquisition&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;720&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of level 3 financial instruments as of December&#160;31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,713&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Assets Measured on a Non-Recurring Basis&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We apply fair value techniques on a non-recurring basis associated with valuing potential impairment losses related to our goodwill, indefinite-lived intangible assets, and long-lived assets.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We evaluate goodwill and indefinite-lived intangible assets annually for impairment and whenever circumstances occur indicating that goodwill might be impaired. We determine the fair value of our reporting unit based on a combination of inputs, including the market capitalization of Ligand, as well as Level 3 inputs such as discounted cash flows, which are not observable from the market, directly or indirectly. We determine the fair value of our indefinite-lived intangible assets using the income approach based on Level 3 inputs.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There was no impairment of our goodwill, indefinite-lived assets, or long-lived assets recorded during the twelve months ended December&#160;31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2014 and May 2018, we issued the 2019 Notes and 2023 Notes, respectively. We use quoted market rates in an inactive market, which are classified as a Level 2 input, to estimate the fair value of our 2019 and 2023 Notes. The carrying value of the notes does not reflect the market rate. See &#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note (7), Convertible Senior Notes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x201d; for additional information related to the fair value.&lt;/span&gt;&lt;/div&gt;In addition, our accounts receivable, accounts payable, accrued liabilities, current deferred revenue, current operating lease liabilities, current financing lease liabilities are financial instruments and are recorded at cost in the consolidated balance sheets. The estimated fair value of these financial instruments approximates their carrying value due to their short-term nature.</us-gaap:FinancialInstrumentsDisclosureTextBlock>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock
      contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185Ny9mcmFnOmRmZjk3MmRkZDM3NDQ5NzNiY2U4YjMwMmJlMzhjNjdhL3RleHRyZWdpb246ZGZmOTcyZGRkMzc0NDk3M2JjZThiMzAyYmUzOGM2N2FfNjkyNQ_9e9cb1c9-a48d-471f-a7d0-89cae37abcf8">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides a summary of the assets and liabilities that are measured at fair value on a recurring basis as of December&#160;31, 2021 and 2020 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.829%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.624%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="24" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements at Reporting Date Using&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted Prices in&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Active Markets&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;for Identical&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Other&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Observable&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Inputs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unobservable&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Inputs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Level&#160;1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Level&#160;2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Level&#160;3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term investments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; (1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;290,697&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,735&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;280,553&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;409&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investment in Viking common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,889&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,889&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;321,586&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,624&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;280,553&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;409&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent liabilities - Cydex&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;349&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;349&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent liabilities - Metabasis &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,358&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,358&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent liabilities - Icagen &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(5)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,364&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,364&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liability for amounts owed to a former licensor&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Total liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,358&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,713&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.268%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.473%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.473%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.473%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.623%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="24" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements at Reporting Date Using&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted Prices in&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Active Markets&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;for Identical&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Other&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Observable&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Inputs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unobservable&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Inputs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Level&#160;1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Level&#160;2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Level&#160;3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term investments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; (1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;324,478&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,438&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;320,647&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;393&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investment in Viking common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,763&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,763&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investment in Viking warrants &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;363,567&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42,527&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;320,647&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;393&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent liabilities - Crystal &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent liabilities - Cydex&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;508&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;508&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent liabilities - Metabasis &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,821&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,821&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent liabilities - Icagen &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(5)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,404&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,404&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent liabilities - Pfenex &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(6)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liability for amounts owed to a former licensor&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Total liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,193&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,821&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,312&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;(1) Excluding our investment in Viking, our short-term investments in marketable debt and equity securities are classified as available-for-sale securities based on management's intentions and are at level 2 of the fair value hierarchy, as these investment securities are valued based upon quoted prices for identical or similar instruments in markets that are not active, and model-based valuation techniques for which all significant assumptions are observable in the market. Short-term investments in mutual funds are valued at their net asset value (NAV) on the last day of the period. We have classified marketable securities with original maturities of greater than one year as short-term investments based upon our ability and intent to use any and all of those marketable securities to satisfy the liquidity needs of our current operations. In addition, we have investment in warrants resulting from Seelos Therapeutics Inc. milestone payments that were settled in shares during the first quarter of 2019 and are at level 3 of the fair value hierarchy, based on Black Scholes value estimated by management on the last day of the period.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(2) Investment in Viking warrants, which we received as a result of Viking&#x2019;s partial repayment of the Viking note receivable and our purchase of Viking common stock and warrants in April 2016, is classified as level 1 as the fair value is determined using quoted market prices in active markets for the same securities. The change of the fair value is recorded in &#x201c;gain (loss) from short-term investments&#x201d; in our consolidated statement of operations. See further discussion in &#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note (3), Short-term Investments: Investment in Viking.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x201d;  &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(3) The fair value of Crystal contingent liabilities was determined using a probability weighted income approach. Most of the contingent payments are based on development or regulatory milestones as defined in the merger agreement with Crystal. The fair value is subjective and is affected by changes in inputs to the valuation model including management&#x2019;s estimates regarding the timing and probability of achievement of certain developmental and regulatory milestones. During the twelve months ended December&#160;31, 2020, we paid $1.8 million contingent liability on development milestones to former Crystal shareholders. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(4) In connection with our acquisition of Metabasis in January 2010, we issued Metabasis stockholders four tradable CVRs, one CVR from each of four respective series of CVR, for each Metabasis share. The CVRs entitle Metabasis stockholders to cash payments as frequently as every six months as cash is received by us from proceeds from the sale or partnering of any of the Metabasis drug development programs, among other triggering events. The liability for the CVRs is determined using quoted prices in a market that is not active for the underlying CVR. The carrying amount of the liability may fluctuate significantly based upon quoted market prices and actual amounts paid under the agreements may be materially differ than the carrying amount of the liability. Several of the Metabasis drug development programs have been outlicensed to Viking, including VK2809. VK2809 is a novel selective TR-&#x3b2; agonist with potential in multiple indications, including hypercholesterolemia, dyslipidemia, NASH, and X-ALD. Under the terms of the agreement with Viking, we may be entitled to up to $375.0 million of development, regulatory and commercial milestones and tiered royalties on potential future sales including a $10.0 million payment upon initiation of a Phase 3 clinical trial.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(5) The fair value of Icagen contingent liabilities was determined using a probability weighted income approach. Most of the contingent payments are based on certain revenue milestones as defined in the asset purchase agreement with Icagen. The fair value is subjective and is affected by changes in inputs to the valuation model including management&#x2019;s estimates regarding the timing and probability of achievement of certain developmental and regulatory milestones. Changes in these estimates may materially affect the fair value. During the year-end December 31, 2021, we paid a $1.1 million contingent liability based on revenue milestones to Icagen.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(6) The fair value of the Pfenex contingent liability was determined using a probability adjusted income approach. These cash flows were then discounted to present value using a discount rate based on the market participants' cost of debt reflective of the Company. During the year-end December 31, 2021, we reduced the contingent liability by $37.6&#160;million primarily due to the lower probability of achieving the specific development and regulatory milestone by December 31, 2021 as defined by the Pfenex CVR. See further detail on Pfenex CVR in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 4, Acquisitions&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i06eb91dd76a2457bac33ba1c3af251f5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185Ny9mcmFnOmRmZjk3MmRkZDM3NDQ5NzNiY2U4YjMwMmJlMzhjNjdhL3RhYmxlOjlmOTRjMTMwZTY4ZDQwYWM4ZGU2NjRlNjk0OTg1ZjZkL3RhYmxlcmFuZ2U6OWY5NGMxMzBlNjhkNDBhYzhkZTY2NGU2OTQ5ODVmNmRfNC0xLTEtMS00NjIwNw_f8651290-9199-4ef8-ba0d-3bf2501f482d"
      unitRef="usd">290697000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ieccd194c6cad463fa107525565469c36_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185Ny9mcmFnOmRmZjk3MmRkZDM3NDQ5NzNiY2U4YjMwMmJlMzhjNjdhL3RhYmxlOjlmOTRjMTMwZTY4ZDQwYWM4ZGU2NjRlNjk0OTg1ZjZkL3RhYmxlcmFuZ2U6OWY5NGMxMzBlNjhkNDBhYzhkZTY2NGU2OTQ5ODVmNmRfNC0zLTEtMS00NDc1Mw_12cc6baf-5bbe-40f6-9efa-fbc0e2e3d3b7"
      unitRef="usd">9735000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i03010ea07e48483686f97632e65cacf7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185Ny9mcmFnOmRmZjk3MmRkZDM3NDQ5NzNiY2U4YjMwMmJlMzhjNjdhL3RhYmxlOjlmOTRjMTMwZTY4ZDQwYWM4ZGU2NjRlNjk0OTg1ZjZkL3RhYmxlcmFuZ2U6OWY5NGMxMzBlNjhkNDBhYzhkZTY2NGU2OTQ5ODVmNmRfNC01LTEtMS00NDc2MA_ecb5866c-db38-4021-b2bd-c7781772257e"
      unitRef="usd">280553000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="iae4bca14f93e4328aa90c2fce8fbaae3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185Ny9mcmFnOmRmZjk3MmRkZDM3NDQ5NzNiY2U4YjMwMmJlMzhjNjdhL3RhYmxlOjlmOTRjMTMwZTY4ZDQwYWM4ZGU2NjRlNjk0OTg1ZjZkL3RhYmxlcmFuZ2U6OWY5NGMxMzBlNjhkNDBhYzhkZTY2NGU2OTQ5ODVmNmRfNC03LTEtMS00NDc2Ng_e70a7c7c-ad90-40d9-8f71-b11a225df184"
      unitRef="usd">409000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i4367fea4a9a64e5a983f1e1a7761535c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185Ny9mcmFnOmRmZjk3MmRkZDM3NDQ5NzNiY2U4YjMwMmJlMzhjNjdhL3RhYmxlOjlmOTRjMTMwZTY4ZDQwYWM4ZGU2NjRlNjk0OTg1ZjZkL3RhYmxlcmFuZ2U6OWY5NGMxMzBlNjhkNDBhYzhkZTY2NGU2OTQ5ODVmNmRfNS0xLTEtMS00NjIwNw_50a9bd40-9d64-41cb-8d5a-7c014d7d452f"
      unitRef="usd">30889000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i6d6fdee1dc984b5fa799d65fefdb8a09_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185Ny9mcmFnOmRmZjk3MmRkZDM3NDQ5NzNiY2U4YjMwMmJlMzhjNjdhL3RhYmxlOjlmOTRjMTMwZTY4ZDQwYWM4ZGU2NjRlNjk0OTg1ZjZkL3RhYmxlcmFuZ2U6OWY5NGMxMzBlNjhkNDBhYzhkZTY2NGU2OTQ5ODVmNmRfNS0zLTEtMS00NDc3NQ_888bd4d1-7268-4476-91a2-2d2e52831e1f"
      unitRef="usd">30889000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i640373e7d8124d24b670e247208e7234_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185Ny9mcmFnOmRmZjk3MmRkZDM3NDQ5NzNiY2U4YjMwMmJlMzhjNjdhL3RhYmxlOjlmOTRjMTMwZTY4ZDQwYWM4ZGU2NjRlNjk0OTg1ZjZkL3RhYmxlcmFuZ2U6OWY5NGMxMzBlNjhkNDBhYzhkZTY2NGU2OTQ5ODVmNmRfNS01LTEtMS00NjIwNw_334b72c6-eaed-40f6-abdd-3f905da65be2"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i01a1659f9184445ca7e9d321e7b29f6d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185Ny9mcmFnOmRmZjk3MmRkZDM3NDQ5NzNiY2U4YjMwMmJlMzhjNjdhL3RhYmxlOjlmOTRjMTMwZTY4ZDQwYWM4ZGU2NjRlNjk0OTg1ZjZkL3RhYmxlcmFuZ2U6OWY5NGMxMzBlNjhkNDBhYzhkZTY2NGU2OTQ5ODVmNmRfNS03LTEtMS00NjIwNw_f4945c3c-7b10-4ff2-8552-ed4a1710e33d"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i83d2c94c6e0b4e79aceeeff3efa78c20_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185Ny9mcmFnOmRmZjk3MmRkZDM3NDQ5NzNiY2U4YjMwMmJlMzhjNjdhL3RhYmxlOjlmOTRjMTMwZTY4ZDQwYWM4ZGU2NjRlNjk0OTg1ZjZkL3RhYmxlcmFuZ2U6OWY5NGMxMzBlNjhkNDBhYzhkZTY2NGU2OTQ5ODVmNmRfNi0xLTEtMS00NjIxMA_6259482b-373a-458d-a9f7-027456d4998f"
      unitRef="usd">321586000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i2a0bee3568b44a9bb12563aeaa8528f5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185Ny9mcmFnOmRmZjk3MmRkZDM3NDQ5NzNiY2U4YjMwMmJlMzhjNjdhL3RhYmxlOjlmOTRjMTMwZTY4ZDQwYWM4ZGU2NjRlNjk0OTg1ZjZkL3RhYmxlcmFuZ2U6OWY5NGMxMzBlNjhkNDBhYzhkZTY2NGU2OTQ5ODVmNmRfNi0zLTEtMS00NjIxMA_e4d4b2e2-92b1-4290-af33-268608ddc8b4"
      unitRef="usd">40624000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i7d8c9f4eb5724240a7b9559155e19d8f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185Ny9mcmFnOmRmZjk3MmRkZDM3NDQ5NzNiY2U4YjMwMmJlMzhjNjdhL3RhYmxlOjlmOTRjMTMwZTY4ZDQwYWM4ZGU2NjRlNjk0OTg1ZjZkL3RhYmxlcmFuZ2U6OWY5NGMxMzBlNjhkNDBhYzhkZTY2NGU2OTQ5ODVmNmRfNi01LTEtMS00NjIxMA_3f4f9de8-1a6f-404c-9b6f-df857bd58f8d"
      unitRef="usd">280553000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i33b5cd64b00744faaf121a59ccec8a90_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185Ny9mcmFnOmRmZjk3MmRkZDM3NDQ5NzNiY2U4YjMwMmJlMzhjNjdhL3RhYmxlOjlmOTRjMTMwZTY4ZDQwYWM4ZGU2NjRlNjk0OTg1ZjZkL3RhYmxlcmFuZ2U6OWY5NGMxMzBlNjhkNDBhYzhkZTY2NGU2OTQ5ODVmNmRfNi03LTEtMS00NjIxMA_c812132a-3e1c-4b03-aa3c-6bd90229d42a"
      unitRef="usd">409000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i84a81b7b22eb417e910d5485bba6df55_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185Ny9mcmFnOmRmZjk3MmRkZDM3NDQ5NzNiY2U4YjMwMmJlMzhjNjdhL3RhYmxlOjlmOTRjMTMwZTY4ZDQwYWM4ZGU2NjRlNjk0OTg1ZjZkL3RhYmxlcmFuZ2U6OWY5NGMxMzBlNjhkNDBhYzhkZTY2NGU2OTQ5ODVmNmRfOS0xLTEtMS00NjIxMg_70713e7d-97fd-4e19-b3a0-ae37ca21c223"
      unitRef="usd">349000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="ie6401005419049dc9000250436aca434_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185Ny9mcmFnOmRmZjk3MmRkZDM3NDQ5NzNiY2U4YjMwMmJlMzhjNjdhL3RhYmxlOjlmOTRjMTMwZTY4ZDQwYWM4ZGU2NjRlNjk0OTg1ZjZkL3RhYmxlcmFuZ2U6OWY5NGMxMzBlNjhkNDBhYzhkZTY2NGU2OTQ5ODVmNmRfOS0zLTEtMS00NjIxMg_3f7456dd-13e6-4254-99a8-679cdc712f78"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i0f8a682fcdf94c3d884f17cb17ab868c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185Ny9mcmFnOmRmZjk3MmRkZDM3NDQ5NzNiY2U4YjMwMmJlMzhjNjdhL3RhYmxlOjlmOTRjMTMwZTY4ZDQwYWM4ZGU2NjRlNjk0OTg1ZjZkL3RhYmxlcmFuZ2U6OWY5NGMxMzBlNjhkNDBhYzhkZTY2NGU2OTQ5ODVmNmRfOS01LTEtMS00NjIxMg_589efa19-14e9-4cbc-a94a-c24fb893c68e"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i5346db50523e458fa6677b7418028935_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185Ny9mcmFnOmRmZjk3MmRkZDM3NDQ5NzNiY2U4YjMwMmJlMzhjNjdhL3RhYmxlOjlmOTRjMTMwZTY4ZDQwYWM4ZGU2NjRlNjk0OTg1ZjZkL3RhYmxlcmFuZ2U6OWY5NGMxMzBlNjhkNDBhYzhkZTY2NGU2OTQ5ODVmNmRfOS03LTEtMS00NDgwOA_2fc9af41-8c98-40a2-98db-a73a55f82ddd"
      unitRef="usd">349000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i761befb7871948fea7097d919ba453c9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185Ny9mcmFnOmRmZjk3MmRkZDM3NDQ5NzNiY2U4YjMwMmJlMzhjNjdhL3RhYmxlOjlmOTRjMTMwZTY4ZDQwYWM4ZGU2NjRlNjk0OTg1ZjZkL3RhYmxlcmFuZ2U6OWY5NGMxMzBlNjhkNDBhYzhkZTY2NGU2OTQ5ODVmNmRfMTAtMS0xLTEtNDYyMTI_0ddef795-ceee-4475-96ef-33d771f9395f"
      unitRef="usd">3358000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="ief7b3a15b9ee435cbec80f843a28571c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185Ny9mcmFnOmRmZjk3MmRkZDM3NDQ5NzNiY2U4YjMwMmJlMzhjNjdhL3RhYmxlOjlmOTRjMTMwZTY4ZDQwYWM4ZGU2NjRlNjk0OTg1ZjZkL3RhYmxlcmFuZ2U6OWY5NGMxMzBlNjhkNDBhYzhkZTY2NGU2OTQ5ODVmNmRfMTAtMy0xLTEtNDYyMTI_054a038b-e010-4630-a61b-fabad197f239"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="iaae0909eafc24451b37ac98a3e7c4186_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185Ny9mcmFnOmRmZjk3MmRkZDM3NDQ5NzNiY2U4YjMwMmJlMzhjNjdhL3RhYmxlOjlmOTRjMTMwZTY4ZDQwYWM4ZGU2NjRlNjk0OTg1ZjZkL3RhYmxlcmFuZ2U6OWY5NGMxMzBlNjhkNDBhYzhkZTY2NGU2OTQ5ODVmNmRfMTAtNS0xLTEtNDQ3ODg_4e8cf975-8d78-4e4c-ab7f-4cb4a99ace40"
      unitRef="usd">3358000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i0c03158e62e14e9d93bc8351b82e61d2_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185Ny9mcmFnOmRmZjk3MmRkZDM3NDQ5NzNiY2U4YjMwMmJlMzhjNjdhL3RhYmxlOjlmOTRjMTMwZTY4ZDQwYWM4ZGU2NjRlNjk0OTg1ZjZkL3RhYmxlcmFuZ2U6OWY5NGMxMzBlNjhkNDBhYzhkZTY2NGU2OTQ5ODVmNmRfMTAtNy0xLTEtNDYyMTI_d1dba684-51b9-445f-9804-48ce49aef8ac"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i05df3e58efe24ec7831e64257f22be53_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185Ny9mcmFnOmRmZjk3MmRkZDM3NDQ5NzNiY2U4YjMwMmJlMzhjNjdhL3RhYmxlOjlmOTRjMTMwZTY4ZDQwYWM4ZGU2NjRlNjk0OTg1ZjZkL3RhYmxlcmFuZ2U6OWY5NGMxMzBlNjhkNDBhYzhkZTY2NGU2OTQ5ODVmNmRfMTEtMS0xLTEtNDYyMTI_da07fea8-4bb7-4706-b880-e4b6a818e03f"
      unitRef="usd">7364000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i518bc06c25204d4482b4301cdd1766e5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185Ny9mcmFnOmRmZjk3MmRkZDM3NDQ5NzNiY2U4YjMwMmJlMzhjNjdhL3RhYmxlOjlmOTRjMTMwZTY4ZDQwYWM4ZGU2NjRlNjk0OTg1ZjZkL3RhYmxlcmFuZ2U6OWY5NGMxMzBlNjhkNDBhYzhkZTY2NGU2OTQ5ODVmNmRfMTEtMy0xLTEtNDYyMTI_e9d3f728-6b70-4936-a360-340fed74e883"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="iaac590afaaf54948a1215ada11b67e6c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185Ny9mcmFnOmRmZjk3MmRkZDM3NDQ5NzNiY2U4YjMwMmJlMzhjNjdhL3RhYmxlOjlmOTRjMTMwZTY4ZDQwYWM4ZGU2NjRlNjk0OTg1ZjZkL3RhYmxlcmFuZ2U6OWY5NGMxMzBlNjhkNDBhYzhkZTY2NGU2OTQ5ODVmNmRfMTEtNS0xLTEtNDYyMTI_19d539d1-1f46-40c1-b0e6-be1189a2cf2c"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i5a59fb8107e140aaad7a5aeb9e7c180b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185Ny9mcmFnOmRmZjk3MmRkZDM3NDQ5NzNiY2U4YjMwMmJlMzhjNjdhL3RhYmxlOjlmOTRjMTMwZTY4ZDQwYWM4ZGU2NjRlNjk0OTg1ZjZkL3RhYmxlcmFuZ2U6OWY5NGMxMzBlNjhkNDBhYzhkZTY2NGU2OTQ5ODVmNmRfMTEtNy0xLTEtNDQ3OTc_84a247a5-f377-468b-9c73-2c114905d031"
      unitRef="usd">7364000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i36dc23d032314fa8a07bbd180231487a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185Ny9mcmFnOmRmZjk3MmRkZDM3NDQ5NzNiY2U4YjMwMmJlMzhjNjdhL3RhYmxlOjlmOTRjMTMwZTY4ZDQwYWM4ZGU2NjRlNjk0OTg1ZjZkL3RhYmxlcmFuZ2U6OWY5NGMxMzBlNjhkNDBhYzhkZTY2NGU2OTQ5ODVmNmRfMTMtMS0xLTEtNDYyMTU_fbbb3ff2-2d26-4d1b-adad-497856a7f856"
      unitRef="usd">86000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i01b8d0c82ed84b4ca4d821ca4a42eeba_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185Ny9mcmFnOmRmZjk3MmRkZDM3NDQ5NzNiY2U4YjMwMmJlMzhjNjdhL3RhYmxlOjlmOTRjMTMwZTY4ZDQwYWM4ZGU2NjRlNjk0OTg1ZjZkL3RhYmxlcmFuZ2U6OWY5NGMxMzBlNjhkNDBhYzhkZTY2NGU2OTQ5ODVmNmRfMTMtMy0xLTEtNDQ4MjA_e1bea77c-b5b9-43f1-8792-094ad5ebad96"
      unitRef="usd">86000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="ic60c56fc16f0480485730f8ab7210dd9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185Ny9mcmFnOmRmZjk3MmRkZDM3NDQ5NzNiY2U4YjMwMmJlMzhjNjdhL3RhYmxlOjlmOTRjMTMwZTY4ZDQwYWM4ZGU2NjRlNjk0OTg1ZjZkL3RhYmxlcmFuZ2U6OWY5NGMxMzBlNjhkNDBhYzhkZTY2NGU2OTQ5ODVmNmRfMTMtNS0xLTEtNDYyMTU_9f662105-ea17-43ba-a934-80c607a036f2"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="iffa6d45b279f45088e9ebcb1bda002cc_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185Ny9mcmFnOmRmZjk3MmRkZDM3NDQ5NzNiY2U4YjMwMmJlMzhjNjdhL3RhYmxlOjlmOTRjMTMwZTY4ZDQwYWM4ZGU2NjRlNjk0OTg1ZjZkL3RhYmxlcmFuZ2U6OWY5NGMxMzBlNjhkNDBhYzhkZTY2NGU2OTQ5ODVmNmRfMTMtNy0xLTEtNDYyMTU_c83656aa-c732-4f76-a69d-2d8276dbc936"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i83d2c94c6e0b4e79aceeeff3efa78c20_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185Ny9mcmFnOmRmZjk3MmRkZDM3NDQ5NzNiY2U4YjMwMmJlMzhjNjdhL3RhYmxlOjlmOTRjMTMwZTY4ZDQwYWM4ZGU2NjRlNjk0OTg1ZjZkL3RhYmxlcmFuZ2U6OWY5NGMxMzBlNjhkNDBhYzhkZTY2NGU2OTQ5ODVmNmRfMTQtMS0xLTEtNDYyMTU_5c642bc7-74b8-4988-b95f-46d2045063a1"
      unitRef="usd">11157000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i2a0bee3568b44a9bb12563aeaa8528f5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185Ny9mcmFnOmRmZjk3MmRkZDM3NDQ5NzNiY2U4YjMwMmJlMzhjNjdhL3RhYmxlOjlmOTRjMTMwZTY4ZDQwYWM4ZGU2NjRlNjk0OTg1ZjZkL3RhYmxlcmFuZ2U6OWY5NGMxMzBlNjhkNDBhYzhkZTY2NGU2OTQ5ODVmNmRfMTQtMy0xLTEtNDYyMTU_9e5b4a53-e7ca-457f-9f0f-2b942c38c22f"
      unitRef="usd">86000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i7d8c9f4eb5724240a7b9559155e19d8f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185Ny9mcmFnOmRmZjk3MmRkZDM3NDQ5NzNiY2U4YjMwMmJlMzhjNjdhL3RhYmxlOjlmOTRjMTMwZTY4ZDQwYWM4ZGU2NjRlNjk0OTg1ZjZkL3RhYmxlcmFuZ2U6OWY5NGMxMzBlNjhkNDBhYzhkZTY2NGU2OTQ5ODVmNmRfMTQtNS0xLTEtNDYyMTU_34435a7a-7916-4cfc-a1e2-1395c854e5fa"
      unitRef="usd">3358000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i33b5cd64b00744faaf121a59ccec8a90_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185Ny9mcmFnOmRmZjk3MmRkZDM3NDQ5NzNiY2U4YjMwMmJlMzhjNjdhL3RhYmxlOjlmOTRjMTMwZTY4ZDQwYWM4ZGU2NjRlNjk0OTg1ZjZkL3RhYmxlcmFuZ2U6OWY5NGMxMzBlNjhkNDBhYzhkZTY2NGU2OTQ5ODVmNmRfMTQtNy0xLTEtNDYyMTU_7d767b0a-5647-400a-87f8-de87a0a7e8fe"
      unitRef="usd">7713000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ibc51353676e643b3841a0d97b6e09df4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185Ny9mcmFnOmRmZjk3MmRkZDM3NDQ5NzNiY2U4YjMwMmJlMzhjNjdhL3RhYmxlOmEzZGEzNzRmZGQyZjQ2YWQ4YzYyZjVjZDFmNTM5YmM5L3RhYmxlcmFuZ2U6YTNkYTM3NGZkZDJmNDZhZDhjNjJmNWNkMWY1MzliYzlfNC0xLTEtMS00MTI5NA_80a06898-be18-46f2-8c53-06a89e079826"
      unitRef="usd">324478000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i2e29fab916b04659a0092e93e4ce0c0f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185Ny9mcmFnOmRmZjk3MmRkZDM3NDQ5NzNiY2U4YjMwMmJlMzhjNjdhL3RhYmxlOmEzZGEzNzRmZGQyZjQ2YWQ4YzYyZjVjZDFmNTM5YmM5L3RhYmxlcmFuZ2U6YTNkYTM3NGZkZDJmNDZhZDhjNjJmNWNkMWY1MzliYzlfNC0zLTEtMS00MTI5NA_fc3113f8-0a8e-4ba2-95a6-28163704ec81"
      unitRef="usd">3438000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="icb7f607e997042d6b7cb2a76b14c89ff_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185Ny9mcmFnOmRmZjk3MmRkZDM3NDQ5NzNiY2U4YjMwMmJlMzhjNjdhL3RhYmxlOmEzZGEzNzRmZGQyZjQ2YWQ4YzYyZjVjZDFmNTM5YmM5L3RhYmxlcmFuZ2U6YTNkYTM3NGZkZDJmNDZhZDhjNjJmNWNkMWY1MzliYzlfNC01LTEtMS00MTI5NA_ab117a60-2b3a-4c98-908e-7d5155bb1d41"
      unitRef="usd">320647000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ieef2fe5db0a5418095a2663aac7e9433_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185Ny9mcmFnOmRmZjk3MmRkZDM3NDQ5NzNiY2U4YjMwMmJlMzhjNjdhL3RhYmxlOmEzZGEzNzRmZGQyZjQ2YWQ4YzYyZjVjZDFmNTM5YmM5L3RhYmxlcmFuZ2U6YTNkYTM3NGZkZDJmNDZhZDhjNjJmNWNkMWY1MzliYzlfNC03LTEtMS00MTI5NA_5eee8ae1-e838-48eb-b559-47da95b56bc9"
      unitRef="usd">393000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i4d9e2c86e31846918735fb68e1980c7b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185Ny9mcmFnOmRmZjk3MmRkZDM3NDQ5NzNiY2U4YjMwMmJlMzhjNjdhL3RhYmxlOmEzZGEzNzRmZGQyZjQ2YWQ4YzYyZjVjZDFmNTM5YmM5L3RhYmxlcmFuZ2U6YTNkYTM3NGZkZDJmNDZhZDhjNjJmNWNkMWY1MzliYzlfNS0xLTEtMS00MTI5NA_04fd4e95-e5c4-47fd-a61b-34e457aa2ff3"
      unitRef="usd">32763000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i4633e33cdaf74da5bab73b86a73c762b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185Ny9mcmFnOmRmZjk3MmRkZDM3NDQ5NzNiY2U4YjMwMmJlMzhjNjdhL3RhYmxlOmEzZGEzNzRmZGQyZjQ2YWQ4YzYyZjVjZDFmNTM5YmM5L3RhYmxlcmFuZ2U6YTNkYTM3NGZkZDJmNDZhZDhjNjJmNWNkMWY1MzliYzlfNS0zLTEtMS00MTI5NA_4b884e6c-d0cd-442b-897f-5fb556d3a426"
      unitRef="usd">32763000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i5465f391d98d450686c03b0526a9298e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185Ny9mcmFnOmRmZjk3MmRkZDM3NDQ5NzNiY2U4YjMwMmJlMzhjNjdhL3RhYmxlOmEzZGEzNzRmZGQyZjQ2YWQ4YzYyZjVjZDFmNTM5YmM5L3RhYmxlcmFuZ2U6YTNkYTM3NGZkZDJmNDZhZDhjNjJmNWNkMWY1MzliYzlfNS01LTEtMS00MTI5NA_ffc63f23-19d3-4f3a-9f67-4ed4c9758511"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i64e87aeff0584255b5155e1fb7330377_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185Ny9mcmFnOmRmZjk3MmRkZDM3NDQ5NzNiY2U4YjMwMmJlMzhjNjdhL3RhYmxlOmEzZGEzNzRmZGQyZjQ2YWQ4YzYyZjVjZDFmNTM5YmM5L3RhYmxlcmFuZ2U6YTNkYTM3NGZkZDJmNDZhZDhjNjJmNWNkMWY1MzliYzlfNS03LTEtMS00MTI5NA_141b599d-6188-44e1-8a53-1e6869a45b18"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i9fde372ecc73482ea79fc251841260be_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185Ny9mcmFnOmRmZjk3MmRkZDM3NDQ5NzNiY2U4YjMwMmJlMzhjNjdhL3RhYmxlOmEzZGEzNzRmZGQyZjQ2YWQ4YzYyZjVjZDFmNTM5YmM5L3RhYmxlcmFuZ2U6YTNkYTM3NGZkZDJmNDZhZDhjNjJmNWNkMWY1MzliYzlfNi0xLTEtMS00MTI5NA_4a36c28b-1960-463b-aa28-95bf20d1d60f"
      unitRef="usd">6326000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="iad3afe93dc254f3a87134b83bff3a320_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185Ny9mcmFnOmRmZjk3MmRkZDM3NDQ5NzNiY2U4YjMwMmJlMzhjNjdhL3RhYmxlOmEzZGEzNzRmZGQyZjQ2YWQ4YzYyZjVjZDFmNTM5YmM5L3RhYmxlcmFuZ2U6YTNkYTM3NGZkZDJmNDZhZDhjNjJmNWNkMWY1MzliYzlfNi0zLTEtMS00MTI5NA_313d0c61-b5c5-4183-9511-99e89f473482"
      unitRef="usd">6326000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="if82c17ea55e64548ab7c37f50afc7954_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185Ny9mcmFnOmRmZjk3MmRkZDM3NDQ5NzNiY2U4YjMwMmJlMzhjNjdhL3RhYmxlOmEzZGEzNzRmZGQyZjQ2YWQ4YzYyZjVjZDFmNTM5YmM5L3RhYmxlcmFuZ2U6YTNkYTM3NGZkZDJmNDZhZDhjNjJmNWNkMWY1MzliYzlfNi01LTEtMS00MTI5NA_1dc7d050-b234-429a-84eb-840f67ca5812"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i5ec6e8e1b38040ff9f9c4e67b129466c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185Ny9mcmFnOmRmZjk3MmRkZDM3NDQ5NzNiY2U4YjMwMmJlMzhjNjdhL3RhYmxlOmEzZGEzNzRmZGQyZjQ2YWQ4YzYyZjVjZDFmNTM5YmM5L3RhYmxlcmFuZ2U6YTNkYTM3NGZkZDJmNDZhZDhjNjJmNWNkMWY1MzliYzlfNi03LTEtMS00MTI5NA_c6e4f421-f622-41dd-b0d0-b55080e3d6b5"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="if603e492b3b54ca58c52c72f0db1a614_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185Ny9mcmFnOmRmZjk3MmRkZDM3NDQ5NzNiY2U4YjMwMmJlMzhjNjdhL3RhYmxlOmEzZGEzNzRmZGQyZjQ2YWQ4YzYyZjVjZDFmNTM5YmM5L3RhYmxlcmFuZ2U6YTNkYTM3NGZkZDJmNDZhZDhjNjJmNWNkMWY1MzliYzlfNy0xLTEtMS00MTI5NA_55143552-302b-42d2-a442-3d5e20d1b216"
      unitRef="usd">363567000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i04c0a503b677413e90c282c029cef0df_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185Ny9mcmFnOmRmZjk3MmRkZDM3NDQ5NzNiY2U4YjMwMmJlMzhjNjdhL3RhYmxlOmEzZGEzNzRmZGQyZjQ2YWQ4YzYyZjVjZDFmNTM5YmM5L3RhYmxlcmFuZ2U6YTNkYTM3NGZkZDJmNDZhZDhjNjJmNWNkMWY1MzliYzlfNy0zLTEtMS00MTI5NA_258db80e-90a4-4cfe-a027-ef090fc428cb"
      unitRef="usd">42527000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i90e770e8ee9247f492c911fccc5f09ee_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185Ny9mcmFnOmRmZjk3MmRkZDM3NDQ5NzNiY2U4YjMwMmJlMzhjNjdhL3RhYmxlOmEzZGEzNzRmZGQyZjQ2YWQ4YzYyZjVjZDFmNTM5YmM5L3RhYmxlcmFuZ2U6YTNkYTM3NGZkZDJmNDZhZDhjNjJmNWNkMWY1MzliYzlfNy01LTEtMS00MTI5NA_ed72575a-474f-4443-b3b0-48c9caa1fd10"
      unitRef="usd">320647000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i8c5d55bf4e3a4a18a904ad6c106afe1b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185Ny9mcmFnOmRmZjk3MmRkZDM3NDQ5NzNiY2U4YjMwMmJlMzhjNjdhL3RhYmxlOmEzZGEzNzRmZGQyZjQ2YWQ4YzYyZjVjZDFmNTM5YmM5L3RhYmxlcmFuZ2U6YTNkYTM3NGZkZDJmNDZhZDhjNjJmNWNkMWY1MzliYzlfNy03LTEtMS00MTI5NA_622d2bf0-f2c5-43d3-9357-8554796cbff4"
      unitRef="usd">393000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i89bb63fa9a9347e5b89eddf911a574ec_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185Ny9mcmFnOmRmZjk3MmRkZDM3NDQ5NzNiY2U4YjMwMmJlMzhjNjdhL3RhYmxlOmEzZGEzNzRmZGQyZjQ2YWQ4YzYyZjVjZDFmNTM5YmM5L3RhYmxlcmFuZ2U6YTNkYTM3NGZkZDJmNDZhZDhjNjJmNWNkMWY1MzliYzlfOS0xLTEtMS00MTI5NA_25d44c91-adef-4f16-8ff7-c6b6195addf7"
      unitRef="usd">800000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="ic8dbef5f05d649cfa20404b188f90797_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185Ny9mcmFnOmRmZjk3MmRkZDM3NDQ5NzNiY2U4YjMwMmJlMzhjNjdhL3RhYmxlOmEzZGEzNzRmZGQyZjQ2YWQ4YzYyZjVjZDFmNTM5YmM5L3RhYmxlcmFuZ2U6YTNkYTM3NGZkZDJmNDZhZDhjNjJmNWNkMWY1MzliYzlfOS0zLTEtMS00MTI5NA_0940da18-7918-4236-bc62-c73b46715366"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i4b774db056ca4e6fbb86b328cdf6ec7e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185Ny9mcmFnOmRmZjk3MmRkZDM3NDQ5NzNiY2U4YjMwMmJlMzhjNjdhL3RhYmxlOmEzZGEzNzRmZGQyZjQ2YWQ4YzYyZjVjZDFmNTM5YmM5L3RhYmxlcmFuZ2U6YTNkYTM3NGZkZDJmNDZhZDhjNjJmNWNkMWY1MzliYzlfOS01LTEtMS00MTI5NA_b958df0d-3f64-40bf-a7d6-95e4c4ed89b6"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i49c492d399144f8f95065abe6a77d858_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185Ny9mcmFnOmRmZjk3MmRkZDM3NDQ5NzNiY2U4YjMwMmJlMzhjNjdhL3RhYmxlOmEzZGEzNzRmZGQyZjQ2YWQ4YzYyZjVjZDFmNTM5YmM5L3RhYmxlcmFuZ2U6YTNkYTM3NGZkZDJmNDZhZDhjNjJmNWNkMWY1MzliYzlfOS03LTEtMS00MTI5NA_93263cdd-97bf-473e-b5f9-261bec899818"
      unitRef="usd">800000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i09e78cdf01344954a110ff4100c16b89_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185Ny9mcmFnOmRmZjk3MmRkZDM3NDQ5NzNiY2U4YjMwMmJlMzhjNjdhL3RhYmxlOmEzZGEzNzRmZGQyZjQ2YWQ4YzYyZjVjZDFmNTM5YmM5L3RhYmxlcmFuZ2U6YTNkYTM3NGZkZDJmNDZhZDhjNjJmNWNkMWY1MzliYzlfMTAtMS0xLTEtNDEyOTQ_70f7333e-0fbd-40c1-be6d-1ed056b01ce7"
      unitRef="usd">508000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i641dc2acfdc24382ac77f797d0b878dc_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185Ny9mcmFnOmRmZjk3MmRkZDM3NDQ5NzNiY2U4YjMwMmJlMzhjNjdhL3RhYmxlOmEzZGEzNzRmZGQyZjQ2YWQ4YzYyZjVjZDFmNTM5YmM5L3RhYmxlcmFuZ2U6YTNkYTM3NGZkZDJmNDZhZDhjNjJmNWNkMWY1MzliYzlfMTAtMy0xLTEtNDEyOTQ_0ab1eff0-4764-46ac-a57b-615bdae67116"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i94796a987fa04da6b4328a1f6396c729_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185Ny9mcmFnOmRmZjk3MmRkZDM3NDQ5NzNiY2U4YjMwMmJlMzhjNjdhL3RhYmxlOmEzZGEzNzRmZGQyZjQ2YWQ4YzYyZjVjZDFmNTM5YmM5L3RhYmxlcmFuZ2U6YTNkYTM3NGZkZDJmNDZhZDhjNjJmNWNkMWY1MzliYzlfMTAtNS0xLTEtNDEyOTQ_024a3e02-8725-48fd-9d9c-db56e6ec2a2b"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i5ab1ef46b3dc4b3687c20938c246e8e1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185Ny9mcmFnOmRmZjk3MmRkZDM3NDQ5NzNiY2U4YjMwMmJlMzhjNjdhL3RhYmxlOmEzZGEzNzRmZGQyZjQ2YWQ4YzYyZjVjZDFmNTM5YmM5L3RhYmxlcmFuZ2U6YTNkYTM3NGZkZDJmNDZhZDhjNjJmNWNkMWY1MzliYzlfMTAtNy0xLTEtNDEyOTQ_7dca6394-183f-4962-b8ce-fa84bad5d643"
      unitRef="usd">508000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i64ddda8f7dd340a6a66150fe9da6ac8f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185Ny9mcmFnOmRmZjk3MmRkZDM3NDQ5NzNiY2U4YjMwMmJlMzhjNjdhL3RhYmxlOmEzZGEzNzRmZGQyZjQ2YWQ4YzYyZjVjZDFmNTM5YmM5L3RhYmxlcmFuZ2U6YTNkYTM3NGZkZDJmNDZhZDhjNjJmNWNkMWY1MzliYzlfMTEtMS0xLTEtNDEyOTQ_9a2422e3-8fff-4e5b-aaa4-156903e065a2"
      unitRef="usd">3821000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i3a14312c0d7a4b6ab188c0d69af3db1b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185Ny9mcmFnOmRmZjk3MmRkZDM3NDQ5NzNiY2U4YjMwMmJlMzhjNjdhL3RhYmxlOmEzZGEzNzRmZGQyZjQ2YWQ4YzYyZjVjZDFmNTM5YmM5L3RhYmxlcmFuZ2U6YTNkYTM3NGZkZDJmNDZhZDhjNjJmNWNkMWY1MzliYzlfMTEtMy0xLTEtNDEyOTQ_d50fdc3a-2fdd-4df5-9abd-52e366441f5f"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i4994043653b246e6825b1757a960c104_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185Ny9mcmFnOmRmZjk3MmRkZDM3NDQ5NzNiY2U4YjMwMmJlMzhjNjdhL3RhYmxlOmEzZGEzNzRmZGQyZjQ2YWQ4YzYyZjVjZDFmNTM5YmM5L3RhYmxlcmFuZ2U6YTNkYTM3NGZkZDJmNDZhZDhjNjJmNWNkMWY1MzliYzlfMTEtNS0xLTEtNDEyOTQ_484b01d2-060d-4f42-90b5-0306dd31c7d5"
      unitRef="usd">3821000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i11062dc1f4334dbda82a1482afce4add_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185Ny9mcmFnOmRmZjk3MmRkZDM3NDQ5NzNiY2U4YjMwMmJlMzhjNjdhL3RhYmxlOmEzZGEzNzRmZGQyZjQ2YWQ4YzYyZjVjZDFmNTM5YmM5L3RhYmxlcmFuZ2U6YTNkYTM3NGZkZDJmNDZhZDhjNjJmNWNkMWY1MzliYzlfMTEtNy0xLTEtNDEyOTQ_2f8c7248-fc94-4198-981d-ba98364a88d1"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i5a6efdc157074e8abf3dbebb0b3ad1b2_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185Ny9mcmFnOmRmZjk3MmRkZDM3NDQ5NzNiY2U4YjMwMmJlMzhjNjdhL3RhYmxlOmEzZGEzNzRmZGQyZjQ2YWQ4YzYyZjVjZDFmNTM5YmM5L3RhYmxlcmFuZ2U6YTNkYTM3NGZkZDJmNDZhZDhjNjJmNWNkMWY1MzliYzlfMTItMS0xLTEtNDQ3MDU_98aeca10-49f3-41ff-9c88-dab1065666ef"
      unitRef="usd">6404000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i766d5476b4ed450888509671880dd88e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185Ny9mcmFnOmRmZjk3MmRkZDM3NDQ5NzNiY2U4YjMwMmJlMzhjNjdhL3RhYmxlOmEzZGEzNzRmZGQyZjQ2YWQ4YzYyZjVjZDFmNTM5YmM5L3RhYmxlcmFuZ2U6YTNkYTM3NGZkZDJmNDZhZDhjNjJmNWNkMWY1MzliYzlfMTItMy0xLTEtNDYyMDU_6947df1f-383b-41cd-bdfc-0df71033c65d"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i32ce3f371084478bae9051b730d767d9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185Ny9mcmFnOmRmZjk3MmRkZDM3NDQ5NzNiY2U4YjMwMmJlMzhjNjdhL3RhYmxlOmEzZGEzNzRmZGQyZjQ2YWQ4YzYyZjVjZDFmNTM5YmM5L3RhYmxlcmFuZ2U6YTNkYTM3NGZkZDJmNDZhZDhjNjJmNWNkMWY1MzliYzlfMTItNS0xLTEtNDYyMDU_efcb7ecd-5e3c-4aa0-989f-9f5cb1fb667d"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i3c716beea168465687c12c65fb1f22bc_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185Ny9mcmFnOmRmZjk3MmRkZDM3NDQ5NzNiY2U4YjMwMmJlMzhjNjdhL3RhYmxlOmEzZGEzNzRmZGQyZjQ2YWQ4YzYyZjVjZDFmNTM5YmM5L3RhYmxlcmFuZ2U6YTNkYTM3NGZkZDJmNDZhZDhjNjJmNWNkMWY1MzliYzlfMTItNy0xLTEtNDQ2ODk_acb1b34d-e343-45dc-9a0e-cc2ad7493ec7"
      unitRef="usd">6404000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i795fda855e164fe998d1404c211cfeff_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185Ny9mcmFnOmRmZjk3MmRkZDM3NDQ5NzNiY2U4YjMwMmJlMzhjNjdhL3RhYmxlOmEzZGEzNzRmZGQyZjQ2YWQ4YzYyZjVjZDFmNTM5YmM5L3RhYmxlcmFuZ2U6YTNkYTM3NGZkZDJmNDZhZDhjNjJmNWNkMWY1MzliYzlfMTMtMS0xLTEtNDQ3MDY_a0ea8656-fd3e-42da-8b79-4a4904fd4973"
      unitRef="usd">37600000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i9ea2d72079aa4831af7d9061421a7429_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185Ny9mcmFnOmRmZjk3MmRkZDM3NDQ5NzNiY2U4YjMwMmJlMzhjNjdhL3RhYmxlOmEzZGEzNzRmZGQyZjQ2YWQ4YzYyZjVjZDFmNTM5YmM5L3RhYmxlcmFuZ2U6YTNkYTM3NGZkZDJmNDZhZDhjNjJmNWNkMWY1MzliYzlfMTMtMy0xLTEtNDYyMDU_ea40fb10-fa02-4fbc-8cb4-3a293772f8b7"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="ice7abf01eb9f42f5b54f5a4e479520a1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185Ny9mcmFnOmRmZjk3MmRkZDM3NDQ5NzNiY2U4YjMwMmJlMzhjNjdhL3RhYmxlOmEzZGEzNzRmZGQyZjQ2YWQ4YzYyZjVjZDFmNTM5YmM5L3RhYmxlcmFuZ2U6YTNkYTM3NGZkZDJmNDZhZDhjNjJmNWNkMWY1MzliYzlfMTMtNS0xLTEtNDYyMDU_3fee455e-0e4c-4a91-8ab9-0c031f0e04e8"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="ie0fd39b8e1ac4faebf9a08fe57ba3937_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185Ny9mcmFnOmRmZjk3MmRkZDM3NDQ5NzNiY2U4YjMwMmJlMzhjNjdhL3RhYmxlOmEzZGEzNzRmZGQyZjQ2YWQ4YzYyZjVjZDFmNTM5YmM5L3RhYmxlcmFuZ2U6YTNkYTM3NGZkZDJmNDZhZDhjNjJmNWNkMWY1MzliYzlfMTMtNy0xLTEtNDQ2ODk_e517fbb9-961a-4cf4-8a0c-d7ecca4c3e3e"
      unitRef="usd">37600000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="if2d95711871a49dda3f26e3f6251690b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185Ny9mcmFnOmRmZjk3MmRkZDM3NDQ5NzNiY2U4YjMwMmJlMzhjNjdhL3RhYmxlOmEzZGEzNzRmZGQyZjQ2YWQ4YzYyZjVjZDFmNTM5YmM5L3RhYmxlcmFuZ2U6YTNkYTM3NGZkZDJmNDZhZDhjNjJmNWNkMWY1MzliYzlfMTItMS0xLTEtNDEyOTQ_1ff137c0-c7bb-48c4-80fc-8ae1a72bb185"
      unitRef="usd">60000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="id1294f5d7b1847e0a6d5e6dbe332860f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185Ny9mcmFnOmRmZjk3MmRkZDM3NDQ5NzNiY2U4YjMwMmJlMzhjNjdhL3RhYmxlOmEzZGEzNzRmZGQyZjQ2YWQ4YzYyZjVjZDFmNTM5YmM5L3RhYmxlcmFuZ2U6YTNkYTM3NGZkZDJmNDZhZDhjNjJmNWNkMWY1MzliYzlfMTItMy0xLTEtNDEyOTQ_b997e78c-767a-45f1-92ea-c80ee8bdc7a4"
      unitRef="usd">60000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="ib3682c8c511e421faf31bc8dcde15b42_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185Ny9mcmFnOmRmZjk3MmRkZDM3NDQ5NzNiY2U4YjMwMmJlMzhjNjdhL3RhYmxlOmEzZGEzNzRmZGQyZjQ2YWQ4YzYyZjVjZDFmNTM5YmM5L3RhYmxlcmFuZ2U6YTNkYTM3NGZkZDJmNDZhZDhjNjJmNWNkMWY1MzliYzlfMTItNS0xLTEtNDEyOTQ_a768df4e-ba34-4c3d-9b44-c5860732a223"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="idcc241ac9ac54103a54cc0d5e60c4f58_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185Ny9mcmFnOmRmZjk3MmRkZDM3NDQ5NzNiY2U4YjMwMmJlMzhjNjdhL3RhYmxlOmEzZGEzNzRmZGQyZjQ2YWQ4YzYyZjVjZDFmNTM5YmM5L3RhYmxlcmFuZ2U6YTNkYTM3NGZkZDJmNDZhZDhjNjJmNWNkMWY1MzliYzlfMTItNy0xLTEtNDEyOTQ_ac3f2a42-6d9c-433c-be82-ea0773e9fd71"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="if603e492b3b54ca58c52c72f0db1a614_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185Ny9mcmFnOmRmZjk3MmRkZDM3NDQ5NzNiY2U4YjMwMmJlMzhjNjdhL3RhYmxlOmEzZGEzNzRmZGQyZjQ2YWQ4YzYyZjVjZDFmNTM5YmM5L3RhYmxlcmFuZ2U6YTNkYTM3NGZkZDJmNDZhZDhjNjJmNWNkMWY1MzliYzlfMTMtMS0xLTEtNDEyOTQ_6656574f-a6f7-4c69-a87e-c6564e13a3e8"
      unitRef="usd">49193000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i04c0a503b677413e90c282c029cef0df_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185Ny9mcmFnOmRmZjk3MmRkZDM3NDQ5NzNiY2U4YjMwMmJlMzhjNjdhL3RhYmxlOmEzZGEzNzRmZGQyZjQ2YWQ4YzYyZjVjZDFmNTM5YmM5L3RhYmxlcmFuZ2U6YTNkYTM3NGZkZDJmNDZhZDhjNjJmNWNkMWY1MzliYzlfMTMtMy0xLTEtNDEyOTQ_e7429cdb-aa7a-40e3-9352-9df4c72a141d"
      unitRef="usd">60000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i90e770e8ee9247f492c911fccc5f09ee_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185Ny9mcmFnOmRmZjk3MmRkZDM3NDQ5NzNiY2U4YjMwMmJlMzhjNjdhL3RhYmxlOmEzZGEzNzRmZGQyZjQ2YWQ4YzYyZjVjZDFmNTM5YmM5L3RhYmxlcmFuZ2U6YTNkYTM3NGZkZDJmNDZhZDhjNjJmNWNkMWY1MzliYzlfMTMtNS0xLTEtNDEyOTQ_791158db-ac8f-4255-9db0-32f7c2730480"
      unitRef="usd">3821000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i8c5d55bf4e3a4a18a904ad6c106afe1b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185Ny9mcmFnOmRmZjk3MmRkZDM3NDQ5NzNiY2U4YjMwMmJlMzhjNjdhL3RhYmxlOmEzZGEzNzRmZGQyZjQ2YWQ4YzYyZjVjZDFmNTM5YmM5L3RhYmxlcmFuZ2U6YTNkYTM3NGZkZDJmNDZhZDhjNjJmNWNkMWY1MzliYzlfMTMtNy0xLTEtNDEyOTQ_b03da12b-67b1-42d8-a435-07d8f24ab1f4"
      unitRef="usd">45312000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:PaymentForContingentConsiderationLiabilityOperatingActivities
      contextRef="i417532a79d3e4320bfa35df66295546e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185Ny9mcmFnOmRmZjk3MmRkZDM3NDQ5NzNiY2U4YjMwMmJlMzhjNjdhL3RleHRyZWdpb246ZGZmOTcyZGRkMzc0NDk3M2JjZThiMzAyYmUzOGM2N2FfMzEzNQ_795b4bbf-080d-41e3-9325-02775e06db13"
      unitRef="usd">1800000</us-gaap:PaymentForContingentConsiderationLiabilityOperatingActivities>
    <lgnd:NumberOfContingentValueRightAgreements
      contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185Ny9mcmFnOmRmZjk3MmRkZDM3NDQ5NzNiY2U4YjMwMmJlMzhjNjdhL3RleHRyZWdpb246ZGZmOTcyZGRkMzc0NDk3M2JjZThiMzAyYmUzOGM2N2FfMjE5OTAyMzI3Mjk5OA_3829b469-449a-4b0e-9a69-35b9ce44b0d8"
      unitRef="agreement">4</lgnd:NumberOfContingentValueRightAgreements>
    <us-gaap:Investments
      contextRef="iedd254aeb5ed46a0bbbbaec3521899ab_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185Ny9mcmFnOmRmZjk3MmRkZDM3NDQ5NzNiY2U4YjMwMmJlMzhjNjdhL3RleHRyZWdpb246ZGZmOTcyZGRkMzc0NDk3M2JjZThiMzAyYmUzOGM2N2FfNDMwNg_2d65c14f-8d6d-4cd3-bebf-ac18f4f5ed82"
      unitRef="usd">375000000</us-gaap:Investments>
    <us-gaap:ContractWithCustomerAssetGross
      contextRef="i5b1dfac6d5ae4926a0e3356f1fb10e83_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185Ny9mcmFnOmRmZjk3MmRkZDM3NDQ5NzNiY2U4YjMwMmJlMzhjNjdhL3RleHRyZWdpb246ZGZmOTcyZGRkMzc0NDk3M2JjZThiMzAyYmUzOGM2N2FfNDQyMQ_5911e281-3856-42be-a8dc-009a904a0b80"
      unitRef="usd">10000000</us-gaap:ContractWithCustomerAssetGross>
    <us-gaap:PaymentForContingentConsiderationLiabilityOperatingActivities
      contextRef="ib43ce77d810a40fc9387e9ee784e9e68_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185Ny9mcmFnOmRmZjk3MmRkZDM3NDQ5NzNiY2U4YjMwMmJlMzhjNjdhL3RleHRyZWdpb246ZGZmOTcyZGRkMzc0NDk3M2JjZThiMzAyYmUzOGM2N2FfNTA1NA_46a947c1-15e8-4988-81da-b33b039d055e"
      unitRef="usd">1100000</us-gaap:PaymentForContingentConsiderationLiabilityOperatingActivities>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="i8c54435dabbb4bf1accc9ff53169d37a_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185Ny9mcmFnOmRmZjk3MmRkZDM3NDQ5NzNiY2U4YjMwMmJlMzhjNjdhL3RleHRyZWdpb246ZGZmOTcyZGRkMzc0NDk3M2JjZThiMzAyYmUzOGM2N2FfNzY5NjU4MTQxMTY4NA_e75465f0-0234-4214-892f-a60b597a4887"
      unitRef="usd">-37600000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock
      contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185Ny9mcmFnOmRmZjk3MmRkZDM3NDQ5NzNiY2U4YjMwMmJlMzhjNjdhL3RleHRyZWdpb246ZGZmOTcyZGRkMzc0NDk3M2JjZThiMzAyYmUzOGM2N2FfNjkyNA_d52b0cab-45cb-44f5-a288-1b82d3c81742">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation of the level 3 financial instruments as of December&#160;31, 2021 is as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;text-indent:45pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:85.303%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.497%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of level 3 financial instruments as of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,312&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payments to CVR holders and other contingency payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,770)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value adjustments to contingent liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(36,549)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent liabilities from xCella asset acquisition&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;720&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of level 3 financial instruments as of December&#160;31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,713&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="iac18f57f540e4a9a8a4f9d6ca432b9ee_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185Ny9mcmFnOmRmZjk3MmRkZDM3NDQ5NzNiY2U4YjMwMmJlMzhjNjdhL3RhYmxlOjNlODZjOWQ4ZjZhMDQ2Y2M5NDEwM2YzZDk3MGRhNDk3L3RhYmxlcmFuZ2U6M2U4NmM5ZDhmNmEwNDZjYzk0MTAzZjNkOTcwZGE0OTdfMS0xLTEtMS00MTI5NA_14294040-7362-4616-850a-05159b8ee263"
      unitRef="usd">45312000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <lgnd:PaymentsToContingentValueRightHolders
      contextRef="i34b45bfb1f924acb8a8e2d99bc22a5fc_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185Ny9mcmFnOmRmZjk3MmRkZDM3NDQ5NzNiY2U4YjMwMmJlMzhjNjdhL3RhYmxlOjNlODZjOWQ4ZjZhMDQ2Y2M5NDEwM2YzZDk3MGRhNDk3L3RhYmxlcmFuZ2U6M2U4NmM5ZDhmNmEwNDZjYzk0MTAzZjNkOTcwZGE0OTdfMi0xLTEtMS00MTI5NA_ec99fe76-065b-4c38-a94c-7df62322805f"
      unitRef="usd">1770000</lgnd:PaymentsToContingentValueRightHolders>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="i34b45bfb1f924acb8a8e2d99bc22a5fc_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185Ny9mcmFnOmRmZjk3MmRkZDM3NDQ5NzNiY2U4YjMwMmJlMzhjNjdhL3RhYmxlOjNlODZjOWQ4ZjZhMDQ2Y2M5NDEwM2YzZDk3MGRhNDk3L3RhYmxlcmFuZ2U6M2U4NmM5ZDhmNmEwNDZjYzk0MTAzZjNkOTcwZGE0OTdfMy0xLTEtMS00MTI5NA_57a64f1b-549b-4164-8f40-7b217c493a76"
      unitRef="usd">-36549000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <lgnd:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityContingentConsiderationFromAcquisition
      contextRef="i34b45bfb1f924acb8a8e2d99bc22a5fc_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185Ny9mcmFnOmRmZjk3MmRkZDM3NDQ5NzNiY2U4YjMwMmJlMzhjNjdhL3RhYmxlOjNlODZjOWQ4ZjZhMDQ2Y2M5NDEwM2YzZDk3MGRhNDk3L3RhYmxlcmFuZ2U6M2U4NmM5ZDhmNmEwNDZjYzk0MTAzZjNkOTcwZGE0OTdfNC0xLTEtMS00MTI5NA_811678c0-b981-4163-8bfa-1f991a0b5805"
      unitRef="usd">720000</lgnd:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityContingentConsiderationFromAcquisition>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i5044d29e95d74c3fb4dfe5dd2471e761_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185Ny9mcmFnOmRmZjk3MmRkZDM3NDQ5NzNiY2U4YjMwMmJlMzhjNjdhL3RhYmxlOjNlODZjOWQ4ZjZhMDQ2Y2M5NDEwM2YzZDk3MGRhNDk3L3RhYmxlcmFuZ2U6M2U4NmM5ZDhmNmEwNDZjYzk0MTAzZjNkOTcwZGE0OTdfNS0xLTEtMS00MTI5NA_cc3b32bc-a8ab-46f3-86ae-75bfca07be87"
      unitRef="usd">7713000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:AssetImpairmentCharges
      contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY185Ny9mcmFnOmRmZjk3MmRkZDM3NDQ5NzNiY2U4YjMwMmJlMzhjNjdhL3RleHRyZWdpb246ZGZmOTcyZGRkMzc0NDk3M2JjZThiMzAyYmUzOGM2N2FfNjM5Mw_7fcb692a-662d-40f2-a240-501a608d9e4c"
      unitRef="usd">0</us-gaap:AssetImpairmentCharges>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDAvZnJhZzpmNDRmMTQwOTY3NGU0MzVkYWNmMjkzYWVjOTgxYmE2NS90ZXh0cmVnaW9uOmY0NGYxNDA5Njc0ZTQzNWRhY2YyOTNhZWM5ODFiYTY1XzM4NDc_74e4f42a-c3f5-4584-816c-2247cbd92046">Leases&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Finance lease&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In May 2020 and January 2021, we entered into an agreement and the first amendment with Hovione, our third-party manufacturer, to increase our manufacturing of Captisol, respectively. The agreements are considered to include an embedded finance lease under ASC 842, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt;Leases&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;, as it provides the Company the right to use the underlying equipment to exclusively &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;manufacture Captisol. As of December&#160;31, 2021, we have fully paid consideration of $69.1&#160;million for prepaid inventory and capacity ramp-up fee. We allocated consideration in the agreements between lease and non-lease components using relative standalone prices. Since the inception of the agreements, we have allocated $50.2&#160;million of the consideration paid to the non-lease component which is accounted for as prepaid inventory and being amortized to cost of Captisol based on the usage.  As of December&#160;31, 2021 the Hovione finance lease has no remaining lease liability and the right of use asset balance is $16.1&#160;million. The right of use asset is to be amortized straight-line over the remaining seven year lease term. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Operating lease &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We lease certain office facilities and equipment primarily under various operating leases. Our operating leases have remaining contractual terms up to ten years, some of which include options to extend the leases for up to ten years. Our lease agreements do not contain any material residual value guarantees, material restrictive covenants, or material termination options. Our operating lease costs are primarily related to facility leases for administration offices and research and development facilities.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Lease assets and lease liabilities are recognized at the commencement of an arrangement where it is determined at inception that a lease exists. Lease assets represent the right to use an underlying asset for the lease term, and lease liabilities represent the obligation to make lease payments arising from the lease. These assets and liabilities are initially recognized based on the present value of lease payments over the lease term calculated using our incremental borrowing rate generally applicable to the location of the lease asset, unless the implicit rate is readily determinable. Lease assets also include any upfront lease payments made and lease incentives. Lease terms include options to extend or terminate the lease when it is reasonably certain that those options will be exercised.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition to base rent, certain of our operating leases require variable payments, such as insurance and common area maintenance. These variable lease costs, other than those dependent upon an index or rate, are expensed when the obligation for those payments is incurred. Leases with an initial term of 12 months or less are not recorded on the balance sheet, and the expense for these short-term leases and for operating leases is recognized on a straight-line basis over the lease term.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The depreciable life of lease assets and leasehold improvements is limited by the expected lease term, unless there is a transfer of title or purchase option reasonably certain of exercise.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the year ended December 31, 2021, we entered into several new lease agreements including our Emeryville headquarter and animal facility expansion and a new Icagen office lease, which resulted in an increase in operating lease right of use assets of $12.7&#160;million  and lease liabilities of $13.2&#160;million as of December&#160;31, 2021 for the portion of the lease with a starting accounting lease commencement date during the period. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Operating and Finance Lease Assets and Liabilities (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.683%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.498%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating lease assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;16,542&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,892&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Finance lease assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;16,207&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15,842&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total lease assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;32,749&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;22,734&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Current operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,053&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,885&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Current finance lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,593&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,099&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8,478&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Long-term operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15,494&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,643&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDAvZnJhZzpmNDRmMTQwOTY3NGU0MzVkYWNmMjkzYWVjOTgxYmE2NS90YWJsZToyNmY5ZDQ2ZjdiYTI0Y2E3OWY3YzM1YWYzY2NhMjdkMC90YWJsZXJhbmdlOjI2ZjlkNDZmN2JhMjRjYTc5ZjdjMzVhZjNjY2EyN2QwXzExLTAtMS0xLTQxMjk0_189a0b16-c5f6-426a-9fe4-540e7d6227de"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDAvZnJhZzpmNDRmMTQwOTY3NGU0MzVkYWNmMjkzYWVjOTgxYmE2NS90YWJsZToyNmY5ZDQ2ZjdiYTI0Y2E3OWY3YzM1YWYzY2NhMjdkMC90YWJsZXJhbmdlOjI2ZjlkNDZmN2JhMjRjYTc5ZjdjMzVhZjNjY2EyN2QwXzExLTAtMS0xLTQxMjk0_2ee456c7-520d-4723-b00d-a8a6a8da65cf"&gt;Long-term finance lease liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total lease liabilities   &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;17,651&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14,233&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Maturity of Operating and Finance Lease Liabilities as of December&#160;31, 2021&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.391%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.499%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Maturity Dates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Operating Leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Finance Leases&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,653&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,414&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,716&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,614&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,670&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10,832&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;25,899&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;109&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Less tenant improvement allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4,327)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Less imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4,025)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Present value of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;17,547&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;104&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2021, our operating leases have a weighted-average remaining lease term of 8.1 years and a weighted-average discount rate of 4.1%. As of December&#160;31, 2020, our operating leases have a weighted-average remaining lease term of 4.4 years and a weighted-average discount rate of 5.7%. Cash paid for amounts included in the measurement of operating lease liabilities was $2.6 million and $2.4&#160;million for the twelve months ended December&#160;31, 2021 and 2020, respectively. Operating lease expense was $2.6 million (net of sublease income of $0.4 million) and $2.1 million (net of sublease income of $0.3 million) for the twelve months ended December&#160;31, 2021 and 2020, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2021, our finance leases have a weighted-average remaining lease term of 7.0 years and a weighted-average discount rate of 3.0%. As of December&#160;31, 2020, our finance leases have a weighted-average remaining lease term of 7.9 years and a weighted-average discount rate of 3.5%. Cash paid for amounts included in the measurement of these finance lease liabilities was $9.3&#160;million and $9.7&#160;million for the twelve months ended December&#160;31, 2021 and 2020, respectively. Finance lease expense was $2.3 million and 0.2&#160;million for the twelve months ended December&#160;31, 2021 and 2020, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:LesseeFinanceLeasesTextBlock
      contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDAvZnJhZzpmNDRmMTQwOTY3NGU0MzVkYWNmMjkzYWVjOTgxYmE2NS90ZXh0cmVnaW9uOmY0NGYxNDA5Njc0ZTQzNWRhY2YyOTNhZWM5ODFiYTY1XzM4NDc_ae8456e1-a1e4-4ae1-bc31-da9ebb9cdd0e">Leases&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Finance lease&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In May 2020 and January 2021, we entered into an agreement and the first amendment with Hovione, our third-party manufacturer, to increase our manufacturing of Captisol, respectively. The agreements are considered to include an embedded finance lease under ASC 842, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt;Leases&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;, as it provides the Company the right to use the underlying equipment to exclusively &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;manufacture Captisol. As of December&#160;31, 2021, we have fully paid consideration of $69.1&#160;million for prepaid inventory and capacity ramp-up fee. We allocated consideration in the agreements between lease and non-lease components using relative standalone prices. Since the inception of the agreements, we have allocated $50.2&#160;million of the consideration paid to the non-lease component which is accounted for as prepaid inventory and being amortized to cost of Captisol based on the usage.  As of December&#160;31, 2021 the Hovione finance lease has no remaining lease liability and the right of use asset balance is $16.1&#160;million. The right of use asset is to be amortized straight-line over the remaining seven year lease term. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Operating lease &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We lease certain office facilities and equipment primarily under various operating leases. Our operating leases have remaining contractual terms up to ten years, some of which include options to extend the leases for up to ten years. Our lease agreements do not contain any material residual value guarantees, material restrictive covenants, or material termination options. Our operating lease costs are primarily related to facility leases for administration offices and research and development facilities.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Lease assets and lease liabilities are recognized at the commencement of an arrangement where it is determined at inception that a lease exists. Lease assets represent the right to use an underlying asset for the lease term, and lease liabilities represent the obligation to make lease payments arising from the lease. These assets and liabilities are initially recognized based on the present value of lease payments over the lease term calculated using our incremental borrowing rate generally applicable to the location of the lease asset, unless the implicit rate is readily determinable. Lease assets also include any upfront lease payments made and lease incentives. Lease terms include options to extend or terminate the lease when it is reasonably certain that those options will be exercised.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition to base rent, certain of our operating leases require variable payments, such as insurance and common area maintenance. These variable lease costs, other than those dependent upon an index or rate, are expensed when the obligation for those payments is incurred. Leases with an initial term of 12 months or less are not recorded on the balance sheet, and the expense for these short-term leases and for operating leases is recognized on a straight-line basis over the lease term.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The depreciable life of lease assets and leasehold improvements is limited by the expected lease term, unless there is a transfer of title or purchase option reasonably certain of exercise.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the year ended December 31, 2021, we entered into several new lease agreements including our Emeryville headquarter and animal facility expansion and a new Icagen office lease, which resulted in an increase in operating lease right of use assets of $12.7&#160;million  and lease liabilities of $13.2&#160;million as of December&#160;31, 2021 for the portion of the lease with a starting accounting lease commencement date during the period. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Operating and Finance Lease Assets and Liabilities (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.683%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.498%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating lease assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;16,542&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,892&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Finance lease assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;16,207&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15,842&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total lease assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;32,749&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;22,734&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Current operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,053&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,885&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Current finance lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,593&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,099&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8,478&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Long-term operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15,494&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,643&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDAvZnJhZzpmNDRmMTQwOTY3NGU0MzVkYWNmMjkzYWVjOTgxYmE2NS90YWJsZToyNmY5ZDQ2ZjdiYTI0Y2E3OWY3YzM1YWYzY2NhMjdkMC90YWJsZXJhbmdlOjI2ZjlkNDZmN2JhMjRjYTc5ZjdjMzVhZjNjY2EyN2QwXzExLTAtMS0xLTQxMjk0_189a0b16-c5f6-426a-9fe4-540e7d6227de"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDAvZnJhZzpmNDRmMTQwOTY3NGU0MzVkYWNmMjkzYWVjOTgxYmE2NS90YWJsZToyNmY5ZDQ2ZjdiYTI0Y2E3OWY3YzM1YWYzY2NhMjdkMC90YWJsZXJhbmdlOjI2ZjlkNDZmN2JhMjRjYTc5ZjdjMzVhZjNjY2EyN2QwXzExLTAtMS0xLTQxMjk0_2ee456c7-520d-4723-b00d-a8a6a8da65cf"&gt;Long-term finance lease liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total lease liabilities   &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;17,651&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14,233&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Maturity of Operating and Finance Lease Liabilities as of December&#160;31, 2021&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.391%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.499%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Maturity Dates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Operating Leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Finance Leases&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,653&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,414&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,716&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,614&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,670&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10,832&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;25,899&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;109&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Less tenant improvement allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4,327)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Less imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4,025)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Present value of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;17,547&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;104&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2021, our operating leases have a weighted-average remaining lease term of 8.1 years and a weighted-average discount rate of 4.1%. As of December&#160;31, 2020, our operating leases have a weighted-average remaining lease term of 4.4 years and a weighted-average discount rate of 5.7%. Cash paid for amounts included in the measurement of operating lease liabilities was $2.6 million and $2.4&#160;million for the twelve months ended December&#160;31, 2021 and 2020, respectively. Operating lease expense was $2.6 million (net of sublease income of $0.4 million) and $2.1 million (net of sublease income of $0.3 million) for the twelve months ended December&#160;31, 2021 and 2020, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2021, our finance leases have a weighted-average remaining lease term of 7.0 years and a weighted-average discount rate of 3.0%. As of December&#160;31, 2020, our finance leases have a weighted-average remaining lease term of 7.9 years and a weighted-average discount rate of 3.5%. Cash paid for amounts included in the measurement of these finance lease liabilities was $9.3&#160;million and $9.7&#160;million for the twelve months ended December&#160;31, 2021 and 2020, respectively. Finance lease expense was $2.3 million and 0.2&#160;million for the twelve months ended December&#160;31, 2021 and 2020, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeFinanceLeasesTextBlock>
    <lgnd:PurchaseCommitmentConsiderationPaidToDate
      contextRef="i874c2ad63f1a4f0295a0ad715157a00e_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDAvZnJhZzpmNDRmMTQwOTY3NGU0MzVkYWNmMjkzYWVjOTgxYmE2NS90ZXh0cmVnaW9uOmY0NGYxNDA5Njc0ZTQzNWRhY2YyOTNhZWM5ODFiYTY1Xzc2OTY1ODE0MDIyODA_b6d39685-eeba-4a20-ae7c-7a8809718e83"
      unitRef="usd">69100000</lgnd:PurchaseCommitmentConsiderationPaidToDate>
    <lgnd:PurchaseCommitmentConsiderationPaidAllocatedToInventory
      contextRef="i874c2ad63f1a4f0295a0ad715157a00e_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDAvZnJhZzpmNDRmMTQwOTY3NGU0MzVkYWNmMjkzYWVjOTgxYmE2NS90ZXh0cmVnaW9uOmY0NGYxNDA5Njc0ZTQzNWRhY2YyOTNhZWM5ODFiYTY1Xzk4OTU2MDQ2NjE4NTE_917c057c-347c-465e-8d03-c008428870a4"
      unitRef="usd">50200000</lgnd:PurchaseCommitmentConsiderationPaidAllocatedToInventory>
    <us-gaap:FinanceLeaseLiability
      contextRef="i874c2ad63f1a4f0295a0ad715157a00e_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDAvZnJhZzpmNDRmMTQwOTY3NGU0MzVkYWNmMjkzYWVjOTgxYmE2NS90ZXh0cmVnaW9uOmY0NGYxNDA5Njc0ZTQzNWRhY2YyOTNhZWM5ODFiYTY1Xzc2OTY1ODE0MDIyOTc_f0c5d3ee-748a-4dae-a175-4c41a0520a98"
      unitRef="usd">0</us-gaap:FinanceLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
      contextRef="i3573e853130f4f1fbcdabc617380abaf_D20201001-20201031"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDAvZnJhZzpmNDRmMTQwOTY3NGU0MzVkYWNmMjkzYWVjOTgxYmE2NS90ZXh0cmVnaW9uOmY0NGYxNDA5Njc0ZTQzNWRhY2YyOTNhZWM5ODFiYTY1Xzc2OTY1ODE0MDUwNjk_e6a96e6e-f025-461b-b0af-0057cb12b89a"
      unitRef="usd">16100000</us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability>
    <us-gaap:LesseeFinanceLeaseRemainingLeaseTerm
      contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDAvZnJhZzpmNDRmMTQwOTY3NGU0MzVkYWNmMjkzYWVjOTgxYmE2NS90ZXh0cmVnaW9uOmY0NGYxNDA5Njc0ZTQzNWRhY2YyOTNhZWM5ODFiYTY1XzM4NDgyOTA3MDc5ODQ_4cab26ac-7796-4d50-9b2f-ae1fa8225e75">P7Y</us-gaap:LesseeFinanceLeaseRemainingLeaseTerm>
    <us-gaap:LesseeOperatingLeaseRemainingLeaseTerm
      contextRef="ia2b01f0961da4bb18dfb8e25a49046e9_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDAvZnJhZzpmNDRmMTQwOTY3NGU0MzVkYWNmMjkzYWVjOTgxYmE2NS90ZXh0cmVnaW9uOmY0NGYxNDA5Njc0ZTQzNWRhY2YyOTNhZWM5ODFiYTY1XzE5MA_e4991621-bdc7-44d9-b794-e0df62167137">P10Y</us-gaap:LesseeOperatingLeaseRemainingLeaseTerm>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="ia2b01f0961da4bb18dfb8e25a49046e9_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDAvZnJhZzpmNDRmMTQwOTY3NGU0MzVkYWNmMjkzYWVjOTgxYmE2NS90ZXh0cmVnaW9uOmY0NGYxNDA5Njc0ZTQzNWRhY2YyOTNhZWM5ODFiYTY1XzI1NQ_f523503f-03b3-4cd5-9420-58b8d740a29c">P10Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i3280169138e848a0ba04a73dbb57193a_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDAvZnJhZzpmNDRmMTQwOTY3NGU0MzVkYWNmMjkzYWVjOTgxYmE2NS90ZXh0cmVnaW9uOmY0NGYxNDA5Njc0ZTQzNWRhY2YyOTNhZWM5ODFiYTY1Xzc2OTY1ODE0MDYzMjY_4ccdfe46-7a8b-476f-9a8e-1fbedd52ac15"
      unitRef="usd">12700000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiability
      contextRef="i3280169138e848a0ba04a73dbb57193a_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDAvZnJhZzpmNDRmMTQwOTY3NGU0MzVkYWNmMjkzYWVjOTgxYmE2NS90ZXh0cmVnaW9uOmY0NGYxNDA5Njc0ZTQzNWRhY2YyOTNhZWM5ODFiYTY1XzM4NDgyOTA3MDE1NDQ_532e3d7c-0df5-48b1-8d52-588eff975435"
      unitRef="usd">13200000</us-gaap:OperatingLeaseLiability>
    <lgnd:AssetsAndLiabilitiesLesseeTableTextBlock
      contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDAvZnJhZzpmNDRmMTQwOTY3NGU0MzVkYWNmMjkzYWVjOTgxYmE2NS90ZXh0cmVnaW9uOmY0NGYxNDA5Njc0ZTQzNWRhY2YyOTNhZWM5ODFiYTY1XzM4NDk_349c323e-9bbd-46fd-9f63-d5dd9a48c94a">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Operating and Finance Lease Assets and Liabilities (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.683%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.498%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating lease assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;16,542&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,892&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Finance lease assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;16,207&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15,842&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total lease assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;32,749&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;22,734&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Current operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,053&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,885&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Current finance lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,593&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,099&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8,478&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Long-term operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15,494&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,643&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDAvZnJhZzpmNDRmMTQwOTY3NGU0MzVkYWNmMjkzYWVjOTgxYmE2NS90YWJsZToyNmY5ZDQ2ZjdiYTI0Y2E3OWY3YzM1YWYzY2NhMjdkMC90YWJsZXJhbmdlOjI2ZjlkNDZmN2JhMjRjYTc5ZjdjMzVhZjNjY2EyN2QwXzExLTAtMS0xLTQxMjk0_189a0b16-c5f6-426a-9fe4-540e7d6227de"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDAvZnJhZzpmNDRmMTQwOTY3NGU0MzVkYWNmMjkzYWVjOTgxYmE2NS90YWJsZToyNmY5ZDQ2ZjdiYTI0Y2E3OWY3YzM1YWYzY2NhMjdkMC90YWJsZXJhbmdlOjI2ZjlkNDZmN2JhMjRjYTc5ZjdjMzVhZjNjY2EyN2QwXzExLTAtMS0xLTQxMjk0_2ee456c7-520d-4723-b00d-a8a6a8da65cf"&gt;Long-term finance lease liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total lease liabilities   &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;17,651&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14,233&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</lgnd:AssetsAndLiabilitiesLesseeTableTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDAvZnJhZzpmNDRmMTQwOTY3NGU0MzVkYWNmMjkzYWVjOTgxYmE2NS90YWJsZToyNmY5ZDQ2ZjdiYTI0Y2E3OWY3YzM1YWYzY2NhMjdkMC90YWJsZXJhbmdlOjI2ZjlkNDZmN2JhMjRjYTc5ZjdjMzVhZjNjY2EyN2QwXzItMS0xLTEtNDEyOTQ_6d1ab5af-49db-4349-a362-0144c3fd7f0a"
      unitRef="usd">16542000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i7462d0db8f4248fcb9fd8f1deae439f3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDAvZnJhZzpmNDRmMTQwOTY3NGU0MzVkYWNmMjkzYWVjOTgxYmE2NS90YWJsZToyNmY5ZDQ2ZjdiYTI0Y2E3OWY3YzM1YWYzY2NhMjdkMC90YWJsZXJhbmdlOjI2ZjlkNDZmN2JhMjRjYTc5ZjdjMzVhZjNjY2EyN2QwXzItMy0xLTEtNDEyOTQ_6dffdc3d-9003-4813-9f87-8a890595c6ae"
      unitRef="usd">6892000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:FinanceLeaseRightOfUseAsset
      contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDAvZnJhZzpmNDRmMTQwOTY3NGU0MzVkYWNmMjkzYWVjOTgxYmE2NS90YWJsZToyNmY5ZDQ2ZjdiYTI0Y2E3OWY3YzM1YWYzY2NhMjdkMC90YWJsZXJhbmdlOjI2ZjlkNDZmN2JhMjRjYTc5ZjdjMzVhZjNjY2EyN2QwXzMtMS0xLTEtNDEyOTQ_fab60e52-3d40-4736-a4f7-28ef55eda14a"
      unitRef="usd">16207000</us-gaap:FinanceLeaseRightOfUseAsset>
    <us-gaap:FinanceLeaseRightOfUseAsset
      contextRef="i7462d0db8f4248fcb9fd8f1deae439f3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDAvZnJhZzpmNDRmMTQwOTY3NGU0MzVkYWNmMjkzYWVjOTgxYmE2NS90YWJsZToyNmY5ZDQ2ZjdiYTI0Y2E3OWY3YzM1YWYzY2NhMjdkMC90YWJsZXJhbmdlOjI2ZjlkNDZmN2JhMjRjYTc5ZjdjMzVhZjNjY2EyN2QwXzMtMy0xLTEtNDEyOTQ_178c3372-1198-4d8e-8c99-5b8ac9aa2af6"
      unitRef="usd">15842000</us-gaap:FinanceLeaseRightOfUseAsset>
    <lgnd:LeaseRightOfUseAsset
      contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDAvZnJhZzpmNDRmMTQwOTY3NGU0MzVkYWNmMjkzYWVjOTgxYmE2NS90YWJsZToyNmY5ZDQ2ZjdiYTI0Y2E3OWY3YzM1YWYzY2NhMjdkMC90YWJsZXJhbmdlOjI2ZjlkNDZmN2JhMjRjYTc5ZjdjMzVhZjNjY2EyN2QwXzQtMS0xLTEtNDEyOTQ_327d9a6b-9984-47c8-8e47-5065a823f48a"
      unitRef="usd">32749000</lgnd:LeaseRightOfUseAsset>
    <lgnd:LeaseRightOfUseAsset
      contextRef="i7462d0db8f4248fcb9fd8f1deae439f3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDAvZnJhZzpmNDRmMTQwOTY3NGU0MzVkYWNmMjkzYWVjOTgxYmE2NS90YWJsZToyNmY5ZDQ2ZjdiYTI0Y2E3OWY3YzM1YWYzY2NhMjdkMC90YWJsZXJhbmdlOjI2ZjlkNDZmN2JhMjRjYTc5ZjdjMzVhZjNjY2EyN2QwXzQtMy0xLTEtNDEyOTQ_50f397f7-8a4b-4858-97ad-32a2ff39e430"
      unitRef="usd">22734000</lgnd:LeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDAvZnJhZzpmNDRmMTQwOTY3NGU0MzVkYWNmMjkzYWVjOTgxYmE2NS90YWJsZToyNmY5ZDQ2ZjdiYTI0Y2E3OWY3YzM1YWYzY2NhMjdkMC90YWJsZXJhbmdlOjI2ZjlkNDZmN2JhMjRjYTc5ZjdjMzVhZjNjY2EyN2QwXzctMS0xLTEtNDEyOTQ_b9ad93d0-279c-4918-b5a4-0bec26fb128c"
      unitRef="usd">2053000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i7462d0db8f4248fcb9fd8f1deae439f3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDAvZnJhZzpmNDRmMTQwOTY3NGU0MzVkYWNmMjkzYWVjOTgxYmE2NS90YWJsZToyNmY5ZDQ2ZjdiYTI0Y2E3OWY3YzM1YWYzY2NhMjdkMC90YWJsZXJhbmdlOjI2ZjlkNDZmN2JhMjRjYTc5ZjdjMzVhZjNjY2EyN2QwXzctMy0xLTEtNDEyOTQ_471b6efb-a48a-4459-a052-3be0a704db5a"
      unitRef="usd">1885000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDAvZnJhZzpmNDRmMTQwOTY3NGU0MzVkYWNmMjkzYWVjOTgxYmE2NS90YWJsZToyNmY5ZDQ2ZjdiYTI0Y2E3OWY3YzM1YWYzY2NhMjdkMC90YWJsZXJhbmdlOjI2ZjlkNDZmN2JhMjRjYTc5ZjdjMzVhZjNjY2EyN2QwXzgtMS0xLTEtNDEyOTQ_7f5a81c9-21c3-48cd-a989-19ec627e8729"
      unitRef="usd">46000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="i7462d0db8f4248fcb9fd8f1deae439f3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDAvZnJhZzpmNDRmMTQwOTY3NGU0MzVkYWNmMjkzYWVjOTgxYmE2NS90YWJsZToyNmY5ZDQ2ZjdiYTI0Y2E3OWY3YzM1YWYzY2NhMjdkMC90YWJsZXJhbmdlOjI2ZjlkNDZmN2JhMjRjYTc5ZjdjMzVhZjNjY2EyN2QwXzgtMy0xLTEtNDEyOTQ_c1516387-94c1-4be8-bbb1-5892179eb9c8"
      unitRef="usd">6593000</us-gaap:FinanceLeaseLiabilityCurrent>
    <lgnd:LeaseLiabilityCurrent
      contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDAvZnJhZzpmNDRmMTQwOTY3NGU0MzVkYWNmMjkzYWVjOTgxYmE2NS90YWJsZToyNmY5ZDQ2ZjdiYTI0Y2E3OWY3YzM1YWYzY2NhMjdkMC90YWJsZXJhbmdlOjI2ZjlkNDZmN2JhMjRjYTc5ZjdjMzVhZjNjY2EyN2QwXzktMS0xLTEtNDEyOTQ_8a6bbaa9-5727-4b24-935c-964a1d1d79f6"
      unitRef="usd">2099000</lgnd:LeaseLiabilityCurrent>
    <lgnd:LeaseLiabilityCurrent
      contextRef="i7462d0db8f4248fcb9fd8f1deae439f3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDAvZnJhZzpmNDRmMTQwOTY3NGU0MzVkYWNmMjkzYWVjOTgxYmE2NS90YWJsZToyNmY5ZDQ2ZjdiYTI0Y2E3OWY3YzM1YWYzY2NhMjdkMC90YWJsZXJhbmdlOjI2ZjlkNDZmN2JhMjRjYTc5ZjdjMzVhZjNjY2EyN2QwXzktMy0xLTEtNDEyOTQ_852f4c04-224f-447b-86c8-774c3d4f7168"
      unitRef="usd">8478000</lgnd:LeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDAvZnJhZzpmNDRmMTQwOTY3NGU0MzVkYWNmMjkzYWVjOTgxYmE2NS90YWJsZToyNmY5ZDQ2ZjdiYTI0Y2E3OWY3YzM1YWYzY2NhMjdkMC90YWJsZXJhbmdlOjI2ZjlkNDZmN2JhMjRjYTc5ZjdjMzVhZjNjY2EyN2QwXzEwLTEtMS0xLTQxMjk0_20380017-28cd-4446-9882-553a67242f34"
      unitRef="usd">15494000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i7462d0db8f4248fcb9fd8f1deae439f3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDAvZnJhZzpmNDRmMTQwOTY3NGU0MzVkYWNmMjkzYWVjOTgxYmE2NS90YWJsZToyNmY5ZDQ2ZjdiYTI0Y2E3OWY3YzM1YWYzY2NhMjdkMC90YWJsZXJhbmdlOjI2ZjlkNDZmN2JhMjRjYTc5ZjdjMzVhZjNjY2EyN2QwXzEwLTMtMS0xLTQxMjk0_e8875dbd-bcdb-4178-8a86-36e1615bd76f"
      unitRef="usd">5643000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDAvZnJhZzpmNDRmMTQwOTY3NGU0MzVkYWNmMjkzYWVjOTgxYmE2NS90YWJsZToyNmY5ZDQ2ZjdiYTI0Y2E3OWY3YzM1YWYzY2NhMjdkMC90YWJsZXJhbmdlOjI2ZjlkNDZmN2JhMjRjYTc5ZjdjMzVhZjNjY2EyN2QwXzExLTEtMS0xLTQxMjk0_35382d81-d04d-4911-92d9-5cd178a4adfa"
      unitRef="usd">58000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="i7462d0db8f4248fcb9fd8f1deae439f3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDAvZnJhZzpmNDRmMTQwOTY3NGU0MzVkYWNmMjkzYWVjOTgxYmE2NS90YWJsZToyNmY5ZDQ2ZjdiYTI0Y2E3OWY3YzM1YWYzY2NhMjdkMC90YWJsZXJhbmdlOjI2ZjlkNDZmN2JhMjRjYTc5ZjdjMzVhZjNjY2EyN2QwXzExLTMtMS0xLTQxMjk0_5a321e64-34ae-4326-9662-5724e5e0c9c3"
      unitRef="usd">112000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <lgnd:LeaseLiability
      contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDAvZnJhZzpmNDRmMTQwOTY3NGU0MzVkYWNmMjkzYWVjOTgxYmE2NS90YWJsZToyNmY5ZDQ2ZjdiYTI0Y2E3OWY3YzM1YWYzY2NhMjdkMC90YWJsZXJhbmdlOjI2ZjlkNDZmN2JhMjRjYTc5ZjdjMzVhZjNjY2EyN2QwXzEyLTEtMS0xLTQxMjk0_997b0332-3da7-46c8-ac58-87a57880c5da"
      unitRef="usd">17651000</lgnd:LeaseLiability>
    <lgnd:LeaseLiability
      contextRef="i7462d0db8f4248fcb9fd8f1deae439f3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDAvZnJhZzpmNDRmMTQwOTY3NGU0MzVkYWNmMjkzYWVjOTgxYmE2NS90YWJsZToyNmY5ZDQ2ZjdiYTI0Y2E3OWY3YzM1YWYzY2NhMjdkMC90YWJsZXJhbmdlOjI2ZjlkNDZmN2JhMjRjYTc5ZjdjMzVhZjNjY2EyN2QwXzEyLTMtMS0xLTQxMjk0_f0985c1d-ffa8-41af-91bf-5021c8222b61"
      unitRef="usd">14233000</lgnd:LeaseLiability>
    <us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock
      contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDAvZnJhZzpmNDRmMTQwOTY3NGU0MzVkYWNmMjkzYWVjOTgxYmE2NS90ZXh0cmVnaW9uOmY0NGYxNDA5Njc0ZTQzNWRhY2YyOTNhZWM5ODFiYTY1XzM4NDY_416e6819-bd6a-4d00-87de-032fdbcdd1ef">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Maturity of Operating and Finance Lease Liabilities as of December&#160;31, 2021&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.391%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.499%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Maturity Dates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Operating Leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Finance Leases&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,653&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,414&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,716&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,614&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,670&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10,832&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;25,899&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;109&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Less tenant improvement allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4,327)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Less imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4,025)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Present value of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;17,547&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;104&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDAvZnJhZzpmNDRmMTQwOTY3NGU0MzVkYWNmMjkzYWVjOTgxYmE2NS90ZXh0cmVnaW9uOmY0NGYxNDA5Njc0ZTQzNWRhY2YyOTNhZWM5ODFiYTY1XzM4NDY_a7656ee5-dd8c-40c7-a8e8-e474d245d5f7">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Maturity of Operating and Finance Lease Liabilities as of December&#160;31, 2021&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.391%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.499%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Maturity Dates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Operating Leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Finance Leases&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,653&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,414&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,716&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,614&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,670&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10,832&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;25,899&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;109&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Less tenant improvement allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4,327)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Less imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4,025)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Present value of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;17,547&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;104&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDAvZnJhZzpmNDRmMTQwOTY3NGU0MzVkYWNmMjkzYWVjOTgxYmE2NS90YWJsZTpjNDViMGUzNzU3OGM0OTgzYmY0ODkwMTA3NjVmMDMzMS90YWJsZXJhbmdlOmM0NWIwZTM3NTc4YzQ5ODNiZjQ4OTAxMDc2NWYwMzMxXzEtMi0xLTEtNDEyOTQ_66fe697c-3b05-49d1-b00f-66a467203f60"
      unitRef="usd">3653000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDAvZnJhZzpmNDRmMTQwOTY3NGU0MzVkYWNmMjkzYWVjOTgxYmE2NS90YWJsZTpjNDViMGUzNzU3OGM0OTgzYmY0ODkwMTA3NjVmMDMzMS90YWJsZXJhbmdlOmM0NWIwZTM3NTc4YzQ5ODNiZjQ4OTAxMDc2NWYwMzMxXzEtNC0xLTEtNDEyOTQ_3a563c08-5b2f-4137-b1a8-c3a96757de03"
      unitRef="usd">56000</us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDAvZnJhZzpmNDRmMTQwOTY3NGU0MzVkYWNmMjkzYWVjOTgxYmE2NS90YWJsZTpjNDViMGUzNzU3OGM0OTgzYmY0ODkwMTA3NjVmMDMzMS90YWJsZXJhbmdlOmM0NWIwZTM3NTc4YzQ5ODNiZjQ4OTAxMDc2NWYwMzMxXzItMi0xLTEtNDEyOTQ_7ac93833-56d5-4c56-ae57-4367f9ab52c2"
      unitRef="usd">3414000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo
      contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDAvZnJhZzpmNDRmMTQwOTY3NGU0MzVkYWNmMjkzYWVjOTgxYmE2NS90YWJsZTpjNDViMGUzNzU3OGM0OTgzYmY0ODkwMTA3NjVmMDMzMS90YWJsZXJhbmdlOmM0NWIwZTM3NTc4YzQ5ODNiZjQ4OTAxMDc2NWYwMzMxXzItNC0xLTEtNDEyOTQ_e92292f6-0ad6-4894-adc8-d3a4161f8396"
      unitRef="usd">49000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDAvZnJhZzpmNDRmMTQwOTY3NGU0MzVkYWNmMjkzYWVjOTgxYmE2NS90YWJsZTpjNDViMGUzNzU3OGM0OTgzYmY0ODkwMTA3NjVmMDMzMS90YWJsZXJhbmdlOmM0NWIwZTM3NTc4YzQ5ODNiZjQ4OTAxMDc2NWYwMzMxXzMtMi0xLTEtNDEyOTQ_faabf3a6-1fec-4709-9567-11f8f9f159f9"
      unitRef="usd">2716000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree
      contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDAvZnJhZzpmNDRmMTQwOTY3NGU0MzVkYWNmMjkzYWVjOTgxYmE2NS90YWJsZTpjNDViMGUzNzU3OGM0OTgzYmY0ODkwMTA3NjVmMDMzMS90YWJsZXJhbmdlOmM0NWIwZTM3NTc4YzQ5ODNiZjQ4OTAxMDc2NWYwMzMxXzMtNC0xLTEtNDEyOTQ_9f290136-2644-456e-813e-5fdfcfe3c135"
      unitRef="usd">4000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDAvZnJhZzpmNDRmMTQwOTY3NGU0MzVkYWNmMjkzYWVjOTgxYmE2NS90YWJsZTpjNDViMGUzNzU3OGM0OTgzYmY0ODkwMTA3NjVmMDMzMS90YWJsZXJhbmdlOmM0NWIwZTM3NTc4YzQ5ODNiZjQ4OTAxMDc2NWYwMzMxXzQtMi0xLTEtNDEyOTQ_a89243c9-67d5-4c72-8da2-1162eb09b4ee"
      unitRef="usd">2614000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearFour
      contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDAvZnJhZzpmNDRmMTQwOTY3NGU0MzVkYWNmMjkzYWVjOTgxYmE2NS90YWJsZTpjNDViMGUzNzU3OGM0OTgzYmY0ODkwMTA3NjVmMDMzMS90YWJsZXJhbmdlOmM0NWIwZTM3NTc4YzQ5ODNiZjQ4OTAxMDc2NWYwMzMxXzQtNC0xLTEtNDEyOTQ_276cd143-88fc-4815-9970-7af2ee476bfb"
      unitRef="usd">0</us-gaap:FinanceLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive
      contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDAvZnJhZzpmNDRmMTQwOTY3NGU0MzVkYWNmMjkzYWVjOTgxYmE2NS90YWJsZTpjNDViMGUzNzU3OGM0OTgzYmY0ODkwMTA3NjVmMDMzMS90YWJsZXJhbmdlOmM0NWIwZTM3NTc4YzQ5ODNiZjQ4OTAxMDc2NWYwMzMxXzUtMi0xLTEtNDEyOTQ_c8b8ec9e-3cfd-4b94-b0d7-62d0d15f256b"
      unitRef="usd">2670000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearFive
      contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDAvZnJhZzpmNDRmMTQwOTY3NGU0MzVkYWNmMjkzYWVjOTgxYmE2NS90YWJsZTpjNDViMGUzNzU3OGM0OTgzYmY0ODkwMTA3NjVmMDMzMS90YWJsZXJhbmdlOmM0NWIwZTM3NTc4YzQ5ODNiZjQ4OTAxMDc2NWYwMzMxXzUtNC0xLTEtNDEyOTQ_36d3540a-f8e6-4f01-9873-d49a60f01618"
      unitRef="usd">0</us-gaap:FinanceLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDAvZnJhZzpmNDRmMTQwOTY3NGU0MzVkYWNmMjkzYWVjOTgxYmE2NS90YWJsZTpjNDViMGUzNzU3OGM0OTgzYmY0ODkwMTA3NjVmMDMzMS90YWJsZXJhbmdlOmM0NWIwZTM3NTc4YzQ5ODNiZjQ4OTAxMDc2NWYwMzMxXzYtMi0xLTEtNDEyOTQ_84db26d6-4b1b-41c0-b630-455048c1b19e"
      unitRef="usd">10832000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDAvZnJhZzpmNDRmMTQwOTY3NGU0MzVkYWNmMjkzYWVjOTgxYmE2NS90YWJsZTpjNDViMGUzNzU3OGM0OTgzYmY0ODkwMTA3NjVmMDMzMS90YWJsZXJhbmdlOmM0NWIwZTM3NTc4YzQ5ODNiZjQ4OTAxMDc2NWYwMzMxXzYtNC0xLTEtNDEyOTQ_c2a68d2e-1e70-43eb-8462-9823d116993b"
      unitRef="usd">0</us-gaap:FinanceLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDAvZnJhZzpmNDRmMTQwOTY3NGU0MzVkYWNmMjkzYWVjOTgxYmE2NS90YWJsZTpjNDViMGUzNzU3OGM0OTgzYmY0ODkwMTA3NjVmMDMzMS90YWJsZXJhbmdlOmM0NWIwZTM3NTc4YzQ5ODNiZjQ4OTAxMDc2NWYwMzMxXzctMi0xLTEtNDEyOTQ_94fa87b8-6c50-4993-831d-12723bd3d705"
      unitRef="usd">25899000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:FinanceLeaseLiabilityPaymentsDue
      contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDAvZnJhZzpmNDRmMTQwOTY3NGU0MzVkYWNmMjkzYWVjOTgxYmE2NS90YWJsZTpjNDViMGUzNzU3OGM0OTgzYmY0ODkwMTA3NjVmMDMzMS90YWJsZXJhbmdlOmM0NWIwZTM3NTc4YzQ5ODNiZjQ4OTAxMDc2NWYwMzMxXzctNC0xLTEtNDEyOTQ_df0bd807-eb30-49de-8cb4-94d62fabda36"
      unitRef="usd">109000</us-gaap:FinanceLeaseLiabilityPaymentsDue>
    <lgnd:LesseeOperatingLeaseLiabilityTenantImprovementAllowance
      contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDAvZnJhZzpmNDRmMTQwOTY3NGU0MzVkYWNmMjkzYWVjOTgxYmE2NS90YWJsZTpjNDViMGUzNzU3OGM0OTgzYmY0ODkwMTA3NjVmMDMzMS90YWJsZXJhbmdlOmM0NWIwZTM3NTc4YzQ5ODNiZjQ4OTAxMDc2NWYwMzMxXzgtMi0xLTEtNTIzOTU_1f60bae6-5cd9-47f7-840b-d8577834fed9"
      unitRef="usd">4327000</lgnd:LesseeOperatingLeaseLiabilityTenantImprovementAllowance>
    <lgnd:FinanceLeaseLiabilityTenantImprovementAllowance
      contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDAvZnJhZzpmNDRmMTQwOTY3NGU0MzVkYWNmMjkzYWVjOTgxYmE2NS90YWJsZTpjNDViMGUzNzU3OGM0OTgzYmY0ODkwMTA3NjVmMDMzMS90YWJsZXJhbmdlOmM0NWIwZTM3NTc4YzQ5ODNiZjQ4OTAxMDc2NWYwMzMxXzgtNC0xLTEtNTM3OTI_c6b00381-7ff7-4b85-8dcc-ddc09d7722c6"
      unitRef="usd">0</lgnd:FinanceLeaseLiabilityTenantImprovementAllowance>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDAvZnJhZzpmNDRmMTQwOTY3NGU0MzVkYWNmMjkzYWVjOTgxYmE2NS90YWJsZTpjNDViMGUzNzU3OGM0OTgzYmY0ODkwMTA3NjVmMDMzMS90YWJsZXJhbmdlOmM0NWIwZTM3NTc4YzQ5ODNiZjQ4OTAxMDc2NWYwMzMxXzgtMi0xLTEtNDEyOTQ_a7db336d-581f-4075-9f57-3621a01872b5"
      unitRef="usd">4025000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount
      contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDAvZnJhZzpmNDRmMTQwOTY3NGU0MzVkYWNmMjkzYWVjOTgxYmE2NS90YWJsZTpjNDViMGUzNzU3OGM0OTgzYmY0ODkwMTA3NjVmMDMzMS90YWJsZXJhbmdlOmM0NWIwZTM3NTc4YzQ5ODNiZjQ4OTAxMDc2NWYwMzMxXzgtNC0xLTEtNDEyOTQ_30224bde-0dd2-4fe0-bdff-2fe866629f84"
      unitRef="usd">5000</us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDAvZnJhZzpmNDRmMTQwOTY3NGU0MzVkYWNmMjkzYWVjOTgxYmE2NS90YWJsZTpjNDViMGUzNzU3OGM0OTgzYmY0ODkwMTA3NjVmMDMzMS90YWJsZXJhbmdlOmM0NWIwZTM3NTc4YzQ5ODNiZjQ4OTAxMDc2NWYwMzMxXzktMi0xLTEtNDEyOTQ_6895c019-2aff-4db3-974e-085612f6c055"
      unitRef="usd">17547000</us-gaap:OperatingLeaseLiability>
    <us-gaap:FinanceLeaseLiability
      contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDAvZnJhZzpmNDRmMTQwOTY3NGU0MzVkYWNmMjkzYWVjOTgxYmE2NS90YWJsZTpjNDViMGUzNzU3OGM0OTgzYmY0ODkwMTA3NjVmMDMzMS90YWJsZXJhbmdlOmM0NWIwZTM3NTc4YzQ5ODNiZjQ4OTAxMDc2NWYwMzMxXzktNC0xLTEtNDEyOTQ_1d862fc2-5894-4a85-af8d-b2e2f8821263"
      unitRef="usd">104000</us-gaap:FinanceLeaseLiability>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDAvZnJhZzpmNDRmMTQwOTY3NGU0MzVkYWNmMjkzYWVjOTgxYmE2NS90ZXh0cmVnaW9uOmY0NGYxNDA5Njc0ZTQzNWRhY2YyOTNhZWM5ODFiYTY1XzMyNDk_4e990f24-5c15-4468-b562-306242489d43">P8Y1M6D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDAvZnJhZzpmNDRmMTQwOTY3NGU0MzVkYWNmMjkzYWVjOTgxYmE2NS90ZXh0cmVnaW9uOmY0NGYxNDA5Njc0ZTQzNWRhY2YyOTNhZWM5ODFiYTY1XzMyOTI_49f447b3-2623-4da3-a24a-f9b02944aba6"
      unitRef="number">0.041</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="i7462d0db8f4248fcb9fd8f1deae439f3_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDAvZnJhZzpmNDRmMTQwOTY3NGU0MzVkYWNmMjkzYWVjOTgxYmE2NS90ZXh0cmVnaW9uOmY0NGYxNDA5Njc0ZTQzNWRhY2YyOTNhZWM5ODFiYTY1Xzc2OTY1ODE0MDc1ODY_4cc21896-3091-4c10-a05e-254f3af04c49">P4Y4M24D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="i7462d0db8f4248fcb9fd8f1deae439f3_I20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDAvZnJhZzpmNDRmMTQwOTY3NGU0MzVkYWNmMjkzYWVjOTgxYmE2NS90ZXh0cmVnaW9uOmY0NGYxNDA5Njc0ZTQzNWRhY2YyOTNhZWM5ODFiYTY1Xzc2OTY1ODE0MDc2MDI_23f11824-1422-4a19-a772-6d907be1945f"
      unitRef="number">0.057</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeasePayments
      contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDAvZnJhZzpmNDRmMTQwOTY3NGU0MzVkYWNmMjkzYWVjOTgxYmE2NS90ZXh0cmVnaW9uOmY0NGYxNDA5Njc0ZTQzNWRhY2YyOTNhZWM5ODFiYTY1XzMzODE_ad14d694-f026-4bbb-8b03-2c9fa7e15d6a"
      unitRef="usd">2600000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="ib3597315a63d441f8f128abd7ed8840e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDAvZnJhZzpmNDRmMTQwOTY3NGU0MzVkYWNmMjkzYWVjOTgxYmE2NS90ZXh0cmVnaW9uOmY0NGYxNDA5Njc0ZTQzNWRhY2YyOTNhZWM5ODFiYTY1XzgyNDYzMzcyMjI2MDE_b119c0fe-b662-48bc-9b84-683cb87bd340"
      unitRef="usd">2400000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeaseExpense
      contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDAvZnJhZzpmNDRmMTQwOTY3NGU0MzVkYWNmMjkzYWVjOTgxYmE2NS90ZXh0cmVnaW9uOmY0NGYxNDA5Njc0ZTQzNWRhY2YyOTNhZWM5ODFiYTY1XzM0Mjc_8cf60a1c-fdcc-494a-b391-0addb9b69753"
      unitRef="usd">2600000</us-gaap:OperatingLeaseExpense>
    <us-gaap:SubleaseIncome
      contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDAvZnJhZzpmNDRmMTQwOTY3NGU0MzVkYWNmMjkzYWVjOTgxYmE2NS90ZXh0cmVnaW9uOmY0NGYxNDA5Njc0ZTQzNWRhY2YyOTNhZWM5ODFiYTY1XzM0NTc_c9d0256b-8196-45d6-9007-5aa2cdceb469"
      unitRef="usd">400000</us-gaap:SubleaseIncome>
    <us-gaap:OperatingLeaseExpense
      contextRef="ib3597315a63d441f8f128abd7ed8840e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDAvZnJhZzpmNDRmMTQwOTY3NGU0MzVkYWNmMjkzYWVjOTgxYmE2NS90ZXh0cmVnaW9uOmY0NGYxNDA5Njc0ZTQzNWRhY2YyOTNhZWM5ODFiYTY1XzM0NjU_6f07b3c9-0e7c-4414-a103-06f4e33bff47"
      unitRef="usd">2100000</us-gaap:OperatingLeaseExpense>
    <us-gaap:SubleaseIncome
      contextRef="ib3597315a63d441f8f128abd7ed8840e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDAvZnJhZzpmNDRmMTQwOTY3NGU0MzVkYWNmMjkzYWVjOTgxYmE2NS90ZXh0cmVnaW9uOmY0NGYxNDA5Njc0ZTQzNWRhY2YyOTNhZWM5ODFiYTY1XzM0OTU_0f835546-c039-434d-bf94-ecc624943dae"
      unitRef="usd">300000</us-gaap:SubleaseIncome>
    <us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDAvZnJhZzpmNDRmMTQwOTY3NGU0MzVkYWNmMjkzYWVjOTgxYmE2NS90ZXh0cmVnaW9uOmY0NGYxNDA5Njc0ZTQzNWRhY2YyOTNhZWM5ODFiYTY1XzM2MTU_522a2a0e-6afc-4a55-a146-7563de54ecbb">P7Y</us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent
      contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDAvZnJhZzpmNDRmMTQwOTY3NGU0MzVkYWNmMjkzYWVjOTgxYmE2NS90ZXh0cmVnaW9uOmY0NGYxNDA5Njc0ZTQzNWRhY2YyOTNhZWM5ODFiYTY1XzM2NTg_3cce65b0-5f81-4f71-bf87-1be07a16dc17"
      unitRef="number">0.030</us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="i7462d0db8f4248fcb9fd8f1deae439f3_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDAvZnJhZzpmNDRmMTQwOTY3NGU0MzVkYWNmMjkzYWVjOTgxYmE2NS90ZXh0cmVnaW9uOmY0NGYxNDA5Njc0ZTQzNWRhY2YyOTNhZWM5ODFiYTY1XzEwOTk1MTE2NDI2NzE_6f99cc42-0c37-4f59-a6cc-906b138b9b09">P7Y10M24D</us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent
      contextRef="i7462d0db8f4248fcb9fd8f1deae439f3_I20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDAvZnJhZzpmNDRmMTQwOTY3NGU0MzVkYWNmMjkzYWVjOTgxYmE2NS90ZXh0cmVnaW9uOmY0NGYxNDA5Njc0ZTQzNWRhY2YyOTNhZWM5ODFiYTY1Xzc2OTY1ODE0MDc4NTk_c40c4c55-abb3-456b-bcc6-525489e20e1a"
      unitRef="number">0.035</us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:FinanceLeaseInterestPaymentOnLiability
      contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDAvZnJhZzpmNDRmMTQwOTY3NGU0MzVkYWNmMjkzYWVjOTgxYmE2NS90ZXh0cmVnaW9uOmY0NGYxNDA5Njc0ZTQzNWRhY2YyOTNhZWM5ODFiYTY1XzM3NDU_037df526-92fc-4f88-b290-9cf14cfb6273"
      unitRef="usd">9300000</us-gaap:FinanceLeaseInterestPaymentOnLiability>
    <us-gaap:FinanceLeaseInterestPaymentOnLiability
      contextRef="ib3597315a63d441f8f128abd7ed8840e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDAvZnJhZzpmNDRmMTQwOTY3NGU0MzVkYWNmMjkzYWVjOTgxYmE2NS90ZXh0cmVnaW9uOmY0NGYxNDA5Njc0ZTQzNWRhY2YyOTNhZWM5ODFiYTY1XzgyNDYzMzcyMjI3NTQ_5a7542eb-5a6c-4b31-9dfb-20a7a1975e72"
      unitRef="usd">9700000</us-gaap:FinanceLeaseInterestPaymentOnLiability>
    <us-gaap:FinanceLeaseInterestExpense
      contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDAvZnJhZzpmNDRmMTQwOTY3NGU0MzVkYWNmMjkzYWVjOTgxYmE2NS90ZXh0cmVnaW9uOmY0NGYxNDA5Njc0ZTQzNWRhY2YyOTNhZWM5ODFiYTY1XzM4MzA_2f676760-b0ed-4339-bbc1-53f93da1bd0a"
      unitRef="usd">2300000</us-gaap:FinanceLeaseInterestExpense>
    <us-gaap:FinanceLeaseInterestExpense
      contextRef="ib3597315a63d441f8f128abd7ed8840e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDAvZnJhZzpmNDRmMTQwOTY3NGU0MzVkYWNmMjkzYWVjOTgxYmE2NS90ZXh0cmVnaW9uOmY0NGYxNDA5Njc0ZTQzNWRhY2YyOTNhZWM5ODFiYTY1XzgyNDYzMzcyMjI5NTA_a5851b02-b084-4eb3-b6f5-e22adf60af33"
      unitRef="usd">200000</us-gaap:FinanceLeaseInterestExpense>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDMvZnJhZzpkZjUxYWY2NmMyMWY0YjkxODdjMWU4ODA5OWNlN2IyYS90ZXh0cmVnaW9uOmRmNTFhZjY2YzIxZjRiOTE4N2MxZTg4MDk5Y2U3YjJhXzE3NDEx_f219bb7c-1cf8-41d6-8af1-73296dd04669">Convertible Senior Notes&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;0.75% Convertible Senior Notes due 2019&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2014, we issued $245.0 million aggregate principal amount of 2019 Notes, resulting in net proceeds of $239.3 million. The implied estimated effective rate of the liability component of the 2019 Notes was 5.83%. The 2019 Notes are convertible into common stock at an initial conversion rate of 13.3251 shares per $1,000 principal amount of convertible notes, subject to adjustment upon certain events, which is equivalent to an initial conversion price of approximately $75.05 per share of common stock. The notes bear cash interest at a rate of 0.75% per year, payable semi-annually. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Holders of the 2019 Notes may convert the notes at any time prior to the close of business on the business day immediately preceding May 15, 2019, under any of the following circumstances: &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1) during any fiscal quarter (and only during such fiscal quarter) commencing after December&#160;31, 2014, if,&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;for at least 20 trading days (whether or not consecutive) during the 30 consecutive trading day period ending on the last trading day of the immediately preceding fiscal quarter, the last reported sale price of our common stock on such trading day is greater than 130% of the conversion price on such trading day; &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2) during the five business day period immediately following any 10 consecutive trading day period, in which the trading price per $1,000 principal amount of notes was less than 98% of the product of the last reported sale price of our common stock on such trading day and the conversion rate on each such trading day; or &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(3) upon the occurrence of certain specified corporate events as specified in the indenture governing the notes. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On May 22, 2018, we entered into a supplemental indenture whereby we made an irrevocable election to settle the entire 2019 Notes in cash. As such, we would have been required to deliver cash to settle the principal and any premium due upon conversion. As a result of the requirement to deliver cash to settle any premium due upon conversion, on May 22, 2018, we reclassified from equity to liability the conversion option (a derivative) fair value of $341.6 million. In accordance with ASC 815, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Derivatives and Hedging&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, the derivative was adjusted to its fair value as of December 31, 2018 to $23.4 million with the resulting $118.7 million increase, net of payments made, reflected in other expense, net, in our consolidated statements of operations for the year ended December 31, 2018.  &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;   &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;                                                                                                                               &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March and April 2018, we received notices for conversion of $21.8 million of principal amount of the 2019 Notes which were settled in May and June 2018. We paid the noteholders the conversion value of the notes in cash, up to the principal amount of the 2019 Notes. The excess of the conversion value over the principal amount, totaling $31.6 million, was paid in shares of common stock. In July and August 2018, we received notices for conversion of $195.9 million of principal amount of the 2019 Notes which were settled in October and November 2018. We paid the noteholders the $195.9 million principal amount and the excess of conversion value over the principal amount, totaling $439.6 million, in cash. The equity dilution and cash conversion premium payment upon conversion of the 2019 Notes was offset by the reacquisition of the shares and cash under the convertible bond hedge transactions entered into in connection with the offering of the 2019 Notes. As a result of the conversions, we recorded a $3.2 million loss on extinguishment of debt calculated as the difference between the estimated fair value of the debt and the carrying value of the 2019 Notes as of the settlement dates. To measure the fair value of the converted 2019 Notes as of the settlement dates, the applicable interest rates were estimated using Level 2 observable inputs and applied to the converted notes using the same methodology as in the issuance date valuation.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2019, we received notices for conversion of $1.0 million of principal amount of the 2019 Notes, which were settled in cash upon the 2019 Notes' maturity date in August 2019. As a result, we paid the noteholders (1) the $1.0 million principal amount, and (2) the excess of conversion value over the principal portion in an amount of $0.5 million in cash.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On August 15, 2019, the 2019 Notes maturity date, we paid the noteholders the remaining $26.3 million principal amount and $11.9 million bond premium, which was classified as a derivative liability, in cash. We recorded the decrease in fair value of the derivative liability of $11.0 million in other expense, net, in our consolidated statements of operations for the twelve months ended December 31, 2019.                                                             &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Convertible Bond Hedge and Warrant Transactions&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2014, we entered into convertible bond hedges and sold warrants covering 3,264,643 shares of our common stock to minimize the impact of potential dilution to our common stock and/or offset the cash payments we were required to make in excess of the principal amount upon conversion of the 2019 Notes. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The convertible bond hedges had an exercise price of $75.05 per share and are exercisable when and if the 2019 Notes were converted. If upon conversion of the 2019 Notes, the price of our common stock was above the exercise price of the convertible bond hedges, the counterparties would have delivered shares of common stock and/or cash with an aggregate value approximately equal to the difference between the price of common stock at the conversion date and the exercise price, multiplied by the number of shares of common stock related to the convertible bond hedge transaction being exercised. The convertible bond hedges and warrants described below were separate transactions entered into by us and were not part of the terms of the 2019 Notes. Holders of the 2019 Notes and warrants did not have any rights with respect to the convertible bond hedges.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As a result of the irrevocable cash election, conversion notices received relating to the 2019 Notes after May 22, 2018 must be fully settled in cash and amounts paid in excess of the principal amount would be offset by an equal receipt of cash under the convertible bond hedge. Upon the 2019 Notes payoff on August 15, 2019, the bond hedge was settled, with the remaining $10.2 million fair value decrease reflected in other expense, net, in our consolidated statement of operations for the twelve months ended December 31, 2019.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Concurrently with the convertible bond hedge transactions, we entered into warrant transactions whereby we sold warrants to acquire 3,264,643 shares of common stock with an exercise price of $125.08 per share, subject to certain adjustments. The warrants had expired between November 13, 2019 and April 22, 2020. The warrants have a dilutive effect to the extent the market price per share of common stock exceeds the applicable exercise price of the warrants, as measured under the terms of the warrant transactions. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;0.75% Convertible Senior Notes due 2023&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2018, we issued $750 million aggregate principal amount of 2023 Notes, bearing cash interest at a rate of 0.75% per year, payable semi-annually. The net proceeds from the offering, after deducting the initial purchasers' discount and offering expenses, were approximately $733.1 million. The 2023 Notes will be convertible into cash, shares of common stock, or a combination of cash and shares of common stock, at our election, based on an initial conversion rate, subject to adjustment, of 4.0244 shares per $1,000 principal amount of the 2023 Notes which represents an initial conversion price of approximately $248.48 per share.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Holders of the 2023 Notes may convert the notes at any time prior to the close of business on the business day immediately preceding November 15, 2022, under any of the following circumstances:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1) during any fiscal quarter (and only during such fiscal quarter) commencing after September 30, 2018, if, for at least 20 trading days (whether or not consecutive) during the 30 consecutive trading day period ending on the last trading day of the immediately preceding fiscal quarter, the last reported sale price of our common stock on such trading day is greater than 130% of the conversion price on such trading day;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2) during the five business day period immediately following any 10 consecutive trading day period, in which the trading price per $1,000 principal amount of notes was less than 98% of the product of the last reported sale price of our common stock on such trading day and the conversion rate on each such trading day; or&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(3) upon the occurrence of certain specified corporate events as specified in the indenture governing the notes.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The notes will have a dilutive effect to the extent the average market price per share of common stock for a given reporting period exceeds the conversion price of $248.48. As of December&#160;31, 2021, the &#x201c;if-converted value&#x201d; did not exceed the principal amount of the 2023 Notes.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the issuance of the 2023 Notes, we incurred $16.9 million of issuance costs, which primarily consisted of underwriting, legal and other professional fees. The portion of these costs allocated to the liability component totaling $13.7 million is amortized to interest expense using the effective interest method over the five year expected life of the 2023 Notes.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;It is our intent and policy to settle conversions through combination settlement, which essentially involves payment in cash equal to the principal portion and delivery of shares of common stock for the excess of the conversion value over the principal portion.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;During 2020, we repurchased $254.7 million in principal of the 2023 Notes for $222.8 million in cash, including accrued interest of $0.6 million. We accounted for the repurchase as a debt extinguishment, which resulted (1) a loss of $2.5 million reflected in other expense, net, in our consolidated statement of operations for the year ended December&#160;31, 2020; (2) a $35.0 million reduction in debt discount, and (3) a $3.2 million reduction to additional paid-in-capital, net of tax, related to the reacquisition of the equity component in our condensed consolidated balance sheet as of December&#160;31, 2020. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During 2021, we repurchased $152.0&#160;million in principal of the 2023 Notes for $156.0&#160;million in cash, including accrued interest of $0.3&#160;million. We accounted for the repurchase as a debt extinguishment, which resulted in (1) a loss of $7.3&#160;million reflected in other expense, net, in our condensed consolidated statement of operations for the year ended December&#160;31, 2021, (2) a $13.7&#160;million reduction in debt discount, and (3) a $10.2&#160;million reduction to additional paid in capital, net of tax, related to the reacquisition of the equity component in our condensed consolidated balance sheet as of December&#160;31, 2021. After the repurchases, approximately $343.3 million in principal amount of the 2023 Notes remain outstanding. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During February 2022, we repurchased $125.5&#160;million in principal of the 2023 Notes for $123.9&#160;million in cash, including accrued interest of $0.3&#160;million. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Convertible Bond Hedge and Warrant Transactions&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In conjunction with the 2023 Notes, in May 2018, we entered into convertible bond hedges and sold warrants covering 3,018,327 shares of our common stock to minimize the impact of potential dilution to our common stock and/or offset the cash payments we are required to make in excess of the principal amount upon conversion of the 2023 Notes. The convertible bond hedges have an exercise price of $248.48 per share and are exercisable when and if the 2023 Notes are converted. We paid $140.3 million for these convertible bond hedges. If upon conversion of the 2023 Notes, the price of our common stock is above the exercise price of the convertible bond hedges, the counterparties will deliver shares of common stock and/or cash with an aggregate value approximately equal to the difference between the price of common stock at the conversion date and the exercise price, multiplied by the number of shares of common stock related to the convertible bond hedge transaction being exercised. The convertible bond hedges and warrants described below are separate transactions entered into by us and are not part of the terms of the 2023 Notes. Holders of the 2023 Notes and warrants will not have any rights with respect to the convertible bond hedges.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Concurrently with the convertible bond hedge transactions, we entered into warrant transactions whereby we sold warrants covering 3,018,327 shares of common stock with an exercise price of $315.38 per share, subject to certain adjustments. We received $90.0 million for these warrants. The warrants have various expiration dates ranging from August 15, 2023 to &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;February 6, 2024. The warrants will have a dilutive effect to the extent the market price per share of common stock exceeds the applicable exercise price of the warrants, as measured under the terms of the warrant transactions. The common stock issuable upon exercise of the warrants will be in unregistered shares, and we do not have the obligation and do not intend to file any registration statement with the SEC registering the issuance of the shares under the warrants.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In April 2020, in connection with the repurchases of $234.4&#160;million in principal of the 2023 Notes for $203.8&#160;million in cash, including accrued interest of $0.6&#160;million, during the quarter ended March 31, 2020, we entered into amendments with Barclays Bank PLC, Deutsche Bank AG, London Branch, and Goldman Sachs &amp;amp; Co. LLC to the convertible note hedges transactions we initially entered into in connection with the issuance of the 2023 Notes. The amendments provide that the options under the convertible note hedges corresponding to such repurchased 2023 Notes will remain outstanding notwithstanding such repurchase.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In January 2021, in connection with the repurchases of approximately $20.3&#160;million in principal of the 2023 Notes for approximately $19.1&#160;million in cash, including accrued interest of $0.1&#160;million, during the quarter ended December 31, 2020, we entered into amendments with Barclays Bank PLC, Deutsche Bank AG, London Branch, and Goldman Sachs &amp;amp; Co. LLC to the convertible note hedges transactions we initially entered into in connection with the issuance of the 2023 Notes. The amendments provide that the options under the convertible note hedges corresponding to such repurchased 2023 Notes will remain outstanding notwithstanding such repurchase.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the year ended December 31, 2021, in connection with the repurchases of $152.0&#160;million in principal of the 2023 Notes for $156.0&#160;million in cash, including accrued interest of $0.3&#160;million, we entered into Warrant Early Unwind Agreements and Bond Hedge Unwind Agreements with Barclays Bank PLC, Deutsche Bank AG, and Goldman Sachs &amp;amp; Co. LLC to unwind a portion of the convertible note hedges transactions we initially entered into in connection with the issuance of the 2023 Notes. We paid $18.4&#160;million as part of the Warrant Early Unwind Agreements reducing the number of shares covered by the warrants from 3,018,327 to 2,559,254. We received $18.9&#160;million as part of the Bond Hedge Early Unwind Agreements reducing the number of options under the convertible bond hedges to 598,021. These unwind transactions resulted in a $0.5&#160;million net increase in additional paid-in-capital in our condensed consolidated balance sheet as of December&#160;31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes information about the equity and liability components of the 2023 Notes (in thousands).&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.683%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.499%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Principal amount of 2023 Notes outstanding&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;343,301&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;495,280&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unamortized discount (including unamortized debt issuance cost)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22,584)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(52,987)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total long-term portion of notes payable&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;320,717&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;442,293&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Carrying value of equity component of 2023 Notes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,627&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,397&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of convertible senior notes outstanding (Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;341,801&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;466,053&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2021, there were no events of default or violation of any covenants under our financing obligations.&lt;/span&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i1e8f1b6ddb0a48e7b819cababb4487da_I20140831"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDMvZnJhZzpkZjUxYWY2NmMyMWY0YjkxODdjMWU4ODA5OWNlN2IyYS90ZXh0cmVnaW9uOmRmNTFhZjY2YzIxZjRiOTE4N2MxZTg4MDk5Y2U3YjJhXzEwMQ_9fc680f6-5cb8-410d-911a-25e3db4f1d70"
      unitRef="usd">245000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:ProceedsFromDebtNetOfIssuanceCosts
      contextRef="ied7021ca8f6e4678a12f1acdf2315468_D20140801-20140831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDMvZnJhZzpkZjUxYWY2NmMyMWY0YjkxODdjMWU4ODA5OWNlN2IyYS90ZXh0cmVnaW9uOmRmNTFhZjY2YzIxZjRiOTE4N2MxZTg4MDk5Y2U3YjJhXzE3NQ_a87f41fd-9a74-4d12-ba43-7a2f6341daf9"
      unitRef="usd">239300000</us-gaap:ProceedsFromDebtNetOfIssuanceCosts>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="i1e8f1b6ddb0a48e7b819cababb4487da_I20140831"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDMvZnJhZzpkZjUxYWY2NmMyMWY0YjkxODdjMWU4ODA5OWNlN2IyYS90ZXh0cmVnaW9uOmRmNTFhZjY2YzIxZjRiOTE4N2MxZTg4MDk5Y2U3YjJhXzI2NQ_dc1d81ed-86e7-463c-b2c1-9f4c75b02523"
      unitRef="number">0.0583</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="i1e8f1b6ddb0a48e7b819cababb4487da_I20140831"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDMvZnJhZzpkZjUxYWY2NmMyMWY0YjkxODdjMWU4ODA5OWNlN2IyYS90ZXh0cmVnaW9uOmRmNTFhZjY2YzIxZjRiOTE4N2MxZTg4MDk5Y2U3YjJhXzUxOA_43bd388b-1d4f-4f5f-bcb7-d1ea408df0f3"
      unitRef="usdPerShare">75.05</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i1e8f1b6ddb0a48e7b819cababb4487da_I20140831"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDMvZnJhZzpkZjUxYWY2NmMyMWY0YjkxODdjMWU4ODA5OWNlN2IyYS90ZXh0cmVnaW9uOmRmNTFhZjY2YzIxZjRiOTE4N2MxZTg4MDk5Y2U3YjJhXzU5MA_6d66e71f-bb7a-4a9c-a686-2f2254f8e99f"
      unitRef="number">0.0075</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentConvertibleThresholdTradingDays
      contextRef="i1183d582f8ce4971a5581dbc8a1e1af3_D20140801-20140831"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDMvZnJhZzpkZjUxYWY2NmMyMWY0YjkxODdjMWU4ODA5OWNlN2IyYS90ZXh0cmVnaW9uOmRmNTFhZjY2YzIxZjRiOTE4N2MxZTg4MDk5Y2U3YjJhXzk0MA_adfaee5f-c0db-4372-872e-3c92dfd4c7a7"
      unitRef="trading_day">20</us-gaap:DebtInstrumentConvertibleThresholdTradingDays>
    <us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1
      contextRef="i1183d582f8ce4971a5581dbc8a1e1af3_D20140801-20140831"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDMvZnJhZzpkZjUxYWY2NmMyMWY0YjkxODdjMWU4ODA5OWNlN2IyYS90ZXh0cmVnaW9uOmRmNTFhZjY2YzIxZjRiOTE4N2MxZTg4MDk5Y2U3YjJhXzk5Ng_130972fd-c27a-4f24-a18a-7a846a40728d"
      unitRef="trading_day">30</us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1>
    <us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger
      contextRef="i1183d582f8ce4971a5581dbc8a1e1af3_D20140801-20140831"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDMvZnJhZzpkZjUxYWY2NmMyMWY0YjkxODdjMWU4ODA5OWNlN2IyYS90ZXh0cmVnaW9uOmRmNTFhZjY2YzIxZjRiOTE4N2MxZTg4MDk5Y2U3YjJhXzExOTE_7600e139-0dd0-4155-8bb4-ae5548616533"
      unitRef="number">1.30</us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger>
    <us-gaap:DebtInstrumentConvertibleThresholdTradingDays
      contextRef="i6ba1b63d92a042cf85e08ce77d22918b_D20140801-20140831"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDMvZnJhZzpkZjUxYWY2NmMyMWY0YjkxODdjMWU4ODA5OWNlN2IyYS90ZXh0cmVnaW9uOmRmNTFhZjY2YzIxZjRiOTE4N2MxZTg4MDk5Y2U3YjJhXzEyNTY_f78599ad-75c4-4c7f-a49e-250a4cd6d2ba"
      unitRef="day">5</us-gaap:DebtInstrumentConvertibleThresholdTradingDays>
    <us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1
      contextRef="i6ba1b63d92a042cf85e08ce77d22918b_D20140801-20140831"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDMvZnJhZzpkZjUxYWY2NmMyMWY0YjkxODdjMWU4ODA5OWNlN2IyYS90ZXh0cmVnaW9uOmRmNTFhZjY2YzIxZjRiOTE4N2MxZTg4MDk5Y2U3YjJhXzEzMDU_1e4e58ed-3d6d-4239-9a1a-3a531f6f4a66"
      unitRef="trading_day">10</us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1>
    <lgnd:DebtInstrumentConvertibleMaximumThresholdPercentageofDebtTradingPriceTrigger
      contextRef="i6ba1b63d92a042cf85e08ce77d22918b_D20140801-20140831"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDMvZnJhZzpkZjUxYWY2NmMyMWY0YjkxODdjMWU4ODA5OWNlN2IyYS90ZXh0cmVnaW9uOmRmNTFhZjY2YzIxZjRiOTE4N2MxZTg4MDk5Y2U3YjJhXzE0MTg_e01149e9-4925-495b-963a-74f1ea8036a1"
      unitRef="number">0.98</lgnd:DebtInstrumentConvertibleMaximumThresholdPercentageofDebtTradingPriceTrigger>
    <us-gaap:DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal
      contextRef="iebcfeb3afbe54bc3ae6cb6224e5b1f1a_D20180522-20180522"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDMvZnJhZzpkZjUxYWY2NmMyMWY0YjkxODdjMWU4ODA5OWNlN2IyYS90ZXh0cmVnaW9uOmRmNTFhZjY2YzIxZjRiOTE4N2MxZTg4MDk5Y2U3YjJhXzIxMzA_46673c64-e986-4444-b723-410e23235da2"
      unitRef="usd">341600000</us-gaap:DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal>
    <us-gaap:DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal
      contextRef="i64f0f378c0fc4cf4ae62d78c8b6e22d1_D20181231-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDMvZnJhZzpkZjUxYWY2NmMyMWY0YjkxODdjMWU4ODA5OWNlN2IyYS90ZXh0cmVnaW9uOmRmNTFhZjY2YzIxZjRiOTE4N2MxZTg4MDk5Y2U3YjJhXzIyNjA_fc7c2366-2296-4b61-be21-fd0c948a4711"
      unitRef="usd">23400000</us-gaap:DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal>
    <lgnd:DebtInstrumentConvertibleIncreaseDecreaseIfConvertedValueInExcessOfPrincipal
      contextRef="ie12f8a2703764c3c9b2157933d860bf3_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDMvZnJhZzpkZjUxYWY2NmMyMWY0YjkxODdjMWU4ODA5OWNlN2IyYS90ZXh0cmVnaW9uOmRmNTFhZjY2YzIxZjRiOTE4N2MxZTg4MDk5Y2U3YjJhXzIyODI_911baf28-91c9-4a4b-a789-b86438b62db4"
      unitRef="usd">118700000</lgnd:DebtInstrumentConvertibleIncreaseDecreaseIfConvertedValueInExcessOfPrincipal>
    <us-gaap:DebtConversionConvertedInstrumentAmount1
      contextRef="i0b01059b43af404594129aa6cbdd9a86_D20180301-20180430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDMvZnJhZzpkZjUxYWY2NmMyMWY0YjkxODdjMWU4ODA5OWNlN2IyYS90ZXh0cmVnaW9uOmRmNTFhZjY2YzIxZjRiOTE4N2MxZTg4MDk5Y2U3YjJhXzI2Mjk_e81ab9ba-f026-4952-8d62-145171feb202"
      unitRef="usd">21800000</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature
      contextRef="i0b01059b43af404594129aa6cbdd9a86_D20180301-20180430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDMvZnJhZzpkZjUxYWY2NmMyMWY0YjkxODdjMWU4ODA5OWNlN2IyYS90ZXh0cmVnaW9uOmRmNTFhZjY2YzIxZjRiOTE4N2MxZTg4MDk5Y2U3YjJhXzI4OTU_d024d573-2f56-40e8-b24c-ef4b81158c5b"
      unitRef="usd">31600000</us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature>
    <us-gaap:DebtConversionConvertedInstrumentAmount1
      contextRef="id614d6af476c4bf9847c470856137006_D20180701-20180831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDMvZnJhZzpkZjUxYWY2NmMyMWY0YjkxODdjMWU4ODA5OWNlN2IyYS90ZXh0cmVnaW9uOmRmNTFhZjY2YzIxZjRiOTE4N2MxZTg4MDk5Y2U3YjJhXzI5OTg_80e856d7-f53a-4880-9357-e27dfb14fcff"
      unitRef="usd">195900000</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:DebtConversionConvertedInstrumentAmount1
      contextRef="id614d6af476c4bf9847c470856137006_D20180701-20180831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDMvZnJhZzpkZjUxYWY2NmMyMWY0YjkxODdjMWU4ODA5OWNlN2IyYS90ZXh0cmVnaW9uOmRmNTFhZjY2YzIxZjRiOTE4N2MxZTg4MDk5Y2U3YjJhXzMxMTY_8c3acbe9-e88d-4714-96a8-4b0bac027e66"
      unitRef="usd">195900000</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature
      contextRef="i4f364a39025b407697747d1d13afd5d0_D20181001-20181130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDMvZnJhZzpkZjUxYWY2NmMyMWY0YjkxODdjMWU4ODA5OWNlN2IyYS90ZXh0cmVnaW9uOmRmNTFhZjY2YzIxZjRiOTE4N2MxZTg4MDk5Y2U3YjJhXzMyMDc_7b9bfe11-1385-443d-923f-87779cbefaef"
      unitRef="usd">439600000</us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="iea9bdffff69d41b2bab859af4b604cca_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDMvZnJhZzpkZjUxYWY2NmMyMWY0YjkxODdjMWU4ODA5OWNlN2IyYS90ZXh0cmVnaW9uOmRmNTFhZjY2YzIxZjRiOTE4N2MxZTg4MDk5Y2U3YjJhXzM1MjE_391d897f-f340-4f3e-ba42-ea975d65ed2a"
      unitRef="usd">-3200000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:DebtConversionConvertedInstrumentAmount1
      contextRef="icc1c18173ae448ee9cc6a4cfa0f63d46_D20190601-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDMvZnJhZzpkZjUxYWY2NmMyMWY0YjkxODdjMWU4ODA5OWNlN2IyYS90ZXh0cmVnaW9uOmRmNTFhZjY2YzIxZjRiOTE4N2MxZTg4MDk5Y2U3YjJhXzQwMDc_eacb1a0c-88c5-4cc6-ad93-4399e83fa610"
      unitRef="usd">1000000</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:DebtConversionConvertedInstrumentAmount1
      contextRef="icc1c18173ae448ee9cc6a4cfa0f63d46_D20190601-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDMvZnJhZzpkZjUxYWY2NmMyMWY0YjkxODdjMWU4ODA5OWNlN2IyYS90ZXh0cmVnaW9uOmRmNTFhZjY2YzIxZjRiOTE4N2MxZTg4MDk5Y2U3YjJhXzQxNzI_92829ab4-fb00-4ebf-ac99-444874e24fcb"
      unitRef="usd">1000000</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature
      contextRef="icc1c18173ae448ee9cc6a4cfa0f63d46_D20190601-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDMvZnJhZzpkZjUxYWY2NmMyMWY0YjkxODdjMWU4ODA5OWNlN2IyYS90ZXh0cmVnaW9uOmRmNTFhZjY2YzIxZjRiOTE4N2MxZTg4MDk5Y2U3YjJhXzQyNzU_358f8fb2-b397-4544-a24c-e9c03e6ab735"
      unitRef="usd">500000</us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature>
    <us-gaap:RepaymentsOfNotesPayable
      contextRef="i299d7fb1915643c9bd662d97a56f9224_D20190815-20190815"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDMvZnJhZzpkZjUxYWY2NmMyMWY0YjkxODdjMWU4ODA5OWNlN2IyYS90ZXh0cmVnaW9uOmRmNTFhZjY2YzIxZjRiOTE4N2MxZTg4MDk5Y2U3YjJhXzQzNzY_12beddee-a49f-4a09-87d7-d5ab0c9c525e"
      unitRef="usd">26300000</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:DebtInstrumentUnamortizedPremium
      contextRef="ie2cb0a952fa043858638ccca94aafee7_I20190815"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDMvZnJhZzpkZjUxYWY2NmMyMWY0YjkxODdjMWU4ODA5OWNlN2IyYS90ZXh0cmVnaW9uOmRmNTFhZjY2YzIxZjRiOTE4N2MxZTg4MDk5Y2U3YjJhXzQ0MDA_52045f7e-55df-4ba5-b3ec-46ed3d7664cd"
      unitRef="usd">11900000</us-gaap:DebtInstrumentUnamortizedPremium>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="iea9bdffff69d41b2bab859af4b604cca_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDMvZnJhZzpkZjUxYWY2NmMyMWY0YjkxODdjMWU4ODA5OWNlN2IyYS90ZXh0cmVnaW9uOmRmNTFhZjY2YzIxZjRiOTE4N2MxZTg4MDk5Y2U3YjJhXzQ1NDQ_bc1b63fb-7d65-4ca5-8bb7-e67a92be0606"
      unitRef="usd">-11000000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="ic3fce11822d74ffb9e96e89bebb23277_I20140831"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDMvZnJhZzpkZjUxYWY2NmMyMWY0YjkxODdjMWU4ODA5OWNlN2IyYS90ZXh0cmVnaW9uOmRmNTFhZjY2YzIxZjRiOTE4N2MxZTg4MDk5Y2U3YjJhXzU1MzE_c138a23d-4a56-4faf-b077-6cbcb293384a"
      unitRef="shares">3264643</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <lgnd:ExercisePriceofConvertibleBondHedge
      contextRef="ic3fce11822d74ffb9e96e89bebb23277_I20140831"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDMvZnJhZzpkZjUxYWY2NmMyMWY0YjkxODdjMWU4ODA5OWNlN2IyYS90ZXh0cmVnaW9uOmRmNTFhZjY2YzIxZjRiOTE4N2MxZTg4MDk5Y2U3YjJhXzU4MDc_afbc95ba-2832-454d-b456-7fbe78ba72f5"
      unitRef="usdPerShare">75.05</lgnd:ExercisePriceofConvertibleBondHedge>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="if35894c7763245fd8dfbcdb677a1a22e_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDMvZnJhZzpkZjUxYWY2NmMyMWY0YjkxODdjMWU4ODA5OWNlN2IyYS90ZXh0cmVnaW9uOmRmNTFhZjY2YzIxZjRiOTE4N2MxZTg4MDk5Y2U3YjJhXzc1MzQ_8baf607e-bf77-4042-8ce1-09df962c63ba"
      unitRef="usd">-10200000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="ic3fce11822d74ffb9e96e89bebb23277_I20140831"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDMvZnJhZzpkZjUxYWY2NmMyMWY0YjkxODdjMWU4ODA5OWNlN2IyYS90ZXh0cmVnaW9uOmRmNTFhZjY2YzIxZjRiOTE4N2MxZTg4MDk5Y2U3YjJhXzc3ODI_b2f69558-37bb-4a79-8663-373cdc6a8900"
      unitRef="shares">3264643</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="ic3fce11822d74ffb9e96e89bebb23277_I20140831"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDMvZnJhZzpkZjUxYWY2NmMyMWY0YjkxODdjMWU4ODA5OWNlN2IyYS90ZXh0cmVnaW9uOmRmNTFhZjY2YzIxZjRiOTE4N2MxZTg4MDk5Y2U3YjJhXzc4MzQ_bc55c5aa-506c-4c4f-8088-3d7ee421e032"
      unitRef="usdPerShare">125.08</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i9807ff46d0594f389be4314eae9d0d00_I20180522"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDMvZnJhZzpkZjUxYWY2NmMyMWY0YjkxODdjMWU4ODA5OWNlN2IyYS90ZXh0cmVnaW9uOmRmNTFhZjY2YzIxZjRiOTE4N2MxZTg4MDk5Y2U3YjJhXzkwNDc_63b79035-bb94-4021-b963-852097dfe215"
      unitRef="usd">750000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i9807ff46d0594f389be4314eae9d0d00_I20180522"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDMvZnJhZzpkZjUxYWY2NmMyMWY0YjkxODdjMWU4ODA5OWNlN2IyYS90ZXh0cmVnaW9uOmRmNTFhZjY2YzIxZjRiOTE4N2MxZTg4MDk5Y2U3YjJhXzkxMjc_30645648-7fc0-4226-93c4-963c49bec63a"
      unitRef="number">0.0075</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:ProceedsFromDebtNetOfIssuanceCosts
      contextRef="i6cacda44cb2c4af291db0ef24394bf54_D20180501-20180531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDMvZnJhZzpkZjUxYWY2NmMyMWY0YjkxODdjMWU4ODA5OWNlN2IyYS90ZXh0cmVnaW9uOmRmNTFhZjY2YzIxZjRiOTE4N2MxZTg4MDk5Y2U3YjJhXzkyOTA_94fad20b-bb67-4ddc-9629-ec1992a820c8"
      unitRef="usd">733100000</us-gaap:ProceedsFromDebtNetOfIssuanceCosts>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="i9807ff46d0594f389be4314eae9d0d00_I20180522"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDMvZnJhZzpkZjUxYWY2NmMyMWY0YjkxODdjMWU4ODA5OWNlN2IyYS90ZXh0cmVnaW9uOmRmNTFhZjY2YzIxZjRiOTE4N2MxZTg4MDk5Y2U3YjJhXzk2MTE_e1be444e-1229-4b56-8c35-de40bbc8e6bd"
      unitRef="usdPerShare">248.48</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DebtInstrumentConvertibleThresholdTradingDays
      contextRef="i2b189f2223d941889569bd209d33b64c_D20180501-20180531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDMvZnJhZzpkZjUxYWY2NmMyMWY0YjkxODdjMWU4ODA5OWNlN2IyYS90ZXh0cmVnaW9uOmRmNTFhZjY2YzIxZjRiOTE4N2MxZTg4MDk5Y2U3YjJhXzk5NDM_956078c3-674f-4017-9119-5104bd7c66aa"
      unitRef="trading_day">20</us-gaap:DebtInstrumentConvertibleThresholdTradingDays>
    <us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1
      contextRef="i2b189f2223d941889569bd209d33b64c_D20180501-20180531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDMvZnJhZzpkZjUxYWY2NmMyMWY0YjkxODdjMWU4ODA5OWNlN2IyYS90ZXh0cmVnaW9uOmRmNTFhZjY2YzIxZjRiOTE4N2MxZTg4MDk5Y2U3YjJhXzk5OTk_e79c660e-60bc-49ee-8132-0a5fe750cb06"
      unitRef="trading_day">30</us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1>
    <us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger
      contextRef="i2b189f2223d941889569bd209d33b64c_D20180501-20180531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDMvZnJhZzpkZjUxYWY2NmMyMWY0YjkxODdjMWU4ODA5OWNlN2IyYS90ZXh0cmVnaW9uOmRmNTFhZjY2YzIxZjRiOTE4N2MxZTg4MDk5Y2U3YjJhXzEwMTk0_7e5fc95b-ed0e-4f4e-bfb3-ae2ec187c58e"
      unitRef="number">1.30</us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger>
    <us-gaap:DebtInstrumentConvertibleThresholdTradingDays
      contextRef="i6dd7d2a8849547b0b84667b449a38485_D20180501-20180531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDMvZnJhZzpkZjUxYWY2NmMyMWY0YjkxODdjMWU4ODA5OWNlN2IyYS90ZXh0cmVnaW9uOmRmNTFhZjY2YzIxZjRiOTE4N2MxZTg4MDk5Y2U3YjJhXzEwMjU4_a7edcebd-d9f1-4c2d-9f42-66c7b837c1cc"
      unitRef="trading_day">5</us-gaap:DebtInstrumentConvertibleThresholdTradingDays>
    <us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1
      contextRef="i6dd7d2a8849547b0b84667b449a38485_D20180501-20180531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDMvZnJhZzpkZjUxYWY2NmMyMWY0YjkxODdjMWU4ODA5OWNlN2IyYS90ZXh0cmVnaW9uOmRmNTFhZjY2YzIxZjRiOTE4N2MxZTg4MDk5Y2U3YjJhXzEwMzA3_21b4cf19-8199-49a9-9319-d6cc1fe31418"
      unitRef="trading_day">10</us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1>
    <lgnd:DebtInstrumentConvertibleMaximumThresholdPercentageofDebtTradingPriceTrigger
      contextRef="i6dd7d2a8849547b0b84667b449a38485_D20180501-20180531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDMvZnJhZzpkZjUxYWY2NmMyMWY0YjkxODdjMWU4ODA5OWNlN2IyYS90ZXh0cmVnaW9uOmRmNTFhZjY2YzIxZjRiOTE4N2MxZTg4MDk5Y2U3YjJhXzEwNDIw_faa48df0-70a2-42aa-af5a-8f4012dc10ce"
      unitRef="number">0.98</lgnd:DebtInstrumentConvertibleMaximumThresholdPercentageofDebtTradingPriceTrigger>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="i9807ff46d0594f389be4314eae9d0d00_I20180522"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDMvZnJhZzpkZjUxYWY2NmMyMWY0YjkxODdjMWU4ODA5OWNlN2IyYS90ZXh0cmVnaW9uOmRmNTFhZjY2YzIxZjRiOTE4N2MxZTg4MDk5Y2U3YjJhXzExOTU2_88d3e361-1cf5-4834-af29-c3027ccf3d07"
      unitRef="usdPerShare">248.48</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DeferredFinanceCostsGross
      contextRef="i75c40fa8303240178bae96b5323104b2_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDMvZnJhZzpkZjUxYWY2NmMyMWY0YjkxODdjMWU4ODA5OWNlN2IyYS90ZXh0cmVnaW9uOmRmNTFhZjY2YzIxZjRiOTE4N2MxZTg4MDk5Y2U3YjJhXzEyMTE0_4a24fbec-4fdd-4abf-a705-dc8d89f2e023"
      unitRef="usd">16900000</us-gaap:DeferredFinanceCostsGross>
    <us-gaap:DebtInstrumentUnamortizedPremium
      contextRef="i75c40fa8303240178bae96b5323104b2_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDMvZnJhZzpkZjUxYWY2NmMyMWY0YjkxODdjMWU4ODA5OWNlN2IyYS90ZXh0cmVnaW9uOmRmNTFhZjY2YzIxZjRiOTE4N2MxZTg4MDk5Y2U3YjJhXzEyNDA5_97bd6e4c-3838-4cda-bf91-c1271e4fe722"
      unitRef="usd">13700000</us-gaap:DebtInstrumentUnamortizedPremium>
    <us-gaap:DebtInstrumentRepurchaseAmount
      contextRef="iad6270f46e2a419fb81396b4dde75fb8_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDMvZnJhZzpkZjUxYWY2NmMyMWY0YjkxODdjMWU4ODA5OWNlN2IyYS90ZXh0cmVnaW9uOmRmNTFhZjY2YzIxZjRiOTE4N2MxZTg4MDk5Y2U3YjJhXzEyODI1_32400df6-0cee-4792-aae8-2a3e486c1fc1"
      unitRef="usd">254700000</us-gaap:DebtInstrumentRepurchaseAmount>
    <us-gaap:RepaymentsOfNotesPayable
      contextRef="ic40084c55a8f45ed806b36e3520df3db_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDMvZnJhZzpkZjUxYWY2NmMyMWY0YjkxODdjMWU4ODA5OWNlN2IyYS90ZXh0cmVnaW9uOmRmNTFhZjY2YzIxZjRiOTE4N2MxZTg4MDk5Y2U3YjJhXzEyODYz_6ca4c78d-28c0-472f-82ae-2412fd7a1f18"
      unitRef="usd">222800000</us-gaap:RepaymentsOfNotesPayable>
    <lgnd:RepaymentsOfNotesPayableInterestPortion
      contextRef="ic40084c55a8f45ed806b36e3520df3db_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDMvZnJhZzpkZjUxYWY2NmMyMWY0YjkxODdjMWU4ODA5OWNlN2IyYS90ZXh0cmVnaW9uOmRmNTFhZjY2YzIxZjRiOTE4N2MxZTg4MDk5Y2U3YjJhXzEyOTA1_cfd92c7a-bf05-4cd0-9e87-606575e08199"
      unitRef="usd">600000</lgnd:RepaymentsOfNotesPayableInterestPortion>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="ic40084c55a8f45ed806b36e3520df3db_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDMvZnJhZzpkZjUxYWY2NmMyMWY0YjkxODdjMWU4ODA5OWNlN2IyYS90ZXh0cmVnaW9uOmRmNTFhZjY2YzIxZjRiOTE4N2MxZTg4MDk5Y2U3YjJhXzEyOTk2_192b0a3d-eef1-400e-87ab-c73fc2205b77"
      unitRef="usd">-2500000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <lgnd:IncreaseDecreaseInDebtDiscount
      contextRef="ic40084c55a8f45ed806b36e3520df3db_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDMvZnJhZzpkZjUxYWY2NmMyMWY0YjkxODdjMWU4ODA5OWNlN2IyYS90ZXh0cmVnaW9uOmRmNTFhZjY2YzIxZjRiOTE4N2MxZTg4MDk5Y2U3YjJhXzEzMTA2_56d86f96-53d8-4bf1-9cc1-abb7f909d544"
      unitRef="usd">-35000000</lgnd:IncreaseDecreaseInDebtDiscount>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt
      contextRef="ic40084c55a8f45ed806b36e3520df3db_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDMvZnJhZzpkZjUxYWY2NmMyMWY0YjkxODdjMWU4ODA5OWNlN2IyYS90ZXh0cmVnaW9uOmRmNTFhZjY2YzIxZjRiOTE4N2MxZTg4MDk5Y2U3YjJhXzEzMTQ3_290d56f6-2f0d-4060-a3c7-9f9a668e5d19"
      unitRef="usd">-3200000</us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt>
    <us-gaap:DebtInstrumentRepurchaseAmount
      contextRef="i75c40fa8303240178bae96b5323104b2_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDMvZnJhZzpkZjUxYWY2NmMyMWY0YjkxODdjMWU4ODA5OWNlN2IyYS90ZXh0cmVnaW9uOmRmNTFhZjY2YzIxZjRiOTE4N2MxZTg4MDk5Y2U3YjJhXzc2OTY1ODE0MTI1NjQ_56419352-7739-46db-b131-b94590ebb92b"
      unitRef="usd">152000000</us-gaap:DebtInstrumentRepurchaseAmount>
    <us-gaap:RepaymentsOfNotesPayable
      contextRef="i9d6e6be3ae854425ba0e34565fd2b9c3_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDMvZnJhZzpkZjUxYWY2NmMyMWY0YjkxODdjMWU4ODA5OWNlN2IyYS90ZXh0cmVnaW9uOmRmNTFhZjY2YzIxZjRiOTE4N2MxZTg4MDk5Y2U3YjJhXzc2OTY1ODE0MTI1ODA_e6821cea-76cb-47a9-a867-f688a0472199"
      unitRef="usd">156000000</us-gaap:RepaymentsOfNotesPayable>
    <lgnd:RepaymentsOfNotesPayableInterestPortion
      contextRef="i9d6e6be3ae854425ba0e34565fd2b9c3_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDMvZnJhZzpkZjUxYWY2NmMyMWY0YjkxODdjMWU4ODA5OWNlN2IyYS90ZXh0cmVnaW9uOmRmNTFhZjY2YzIxZjRiOTE4N2MxZTg4MDk5Y2U3YjJhXzc2OTY1ODE0MTI1OTY_2883fe16-3e24-439c-8079-f5fe784c5e04"
      unitRef="usd">300000</lgnd:RepaymentsOfNotesPayableInterestPortion>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i9d6e6be3ae854425ba0e34565fd2b9c3_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDMvZnJhZzpkZjUxYWY2NmMyMWY0YjkxODdjMWU4ODA5OWNlN2IyYS90ZXh0cmVnaW9uOmRmNTFhZjY2YzIxZjRiOTE4N2MxZTg4MDk5Y2U3YjJhXzc2OTY1ODE0MTI2MTA_3c95e2f3-b38d-4d97-a10d-9fcad669bfad"
      unitRef="usd">-7300000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <lgnd:IncreaseDecreaseInDebtDiscount
      contextRef="i9d6e6be3ae854425ba0e34565fd2b9c3_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDMvZnJhZzpkZjUxYWY2NmMyMWY0YjkxODdjMWU4ODA5OWNlN2IyYS90ZXh0cmVnaW9uOmRmNTFhZjY2YzIxZjRiOTE4N2MxZTg4MDk5Y2U3YjJhXzc2OTY1ODE0MTI3MzQ_e5f324c7-40e8-40e1-a11c-55f7cf28d6fc"
      unitRef="usd">-13700000</lgnd:IncreaseDecreaseInDebtDiscount>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt
      contextRef="i9d6e6be3ae854425ba0e34565fd2b9c3_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDMvZnJhZzpkZjUxYWY2NmMyMWY0YjkxODdjMWU4ODA5OWNlN2IyYS90ZXh0cmVnaW9uOmRmNTFhZjY2YzIxZjRiOTE4N2MxZTg4MDk5Y2U3YjJhXzc2OTY1ODE0MTI3NDk_60418113-8f31-4d6d-8b82-442e5460dbe4"
      unitRef="usd">-10200000</us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i75c40fa8303240178bae96b5323104b2_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDMvZnJhZzpkZjUxYWY2NmMyMWY0YjkxODdjMWU4ODA5OWNlN2IyYS90ZXh0cmVnaW9uOmRmNTFhZjY2YzIxZjRiOTE4N2MxZTg4MDk5Y2U3YjJhXzc2OTY1ODE0MTI4OTk_965d83a3-186a-4bfe-a278-b394b41f2adf"
      unitRef="usd">343300000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentRepurchaseAmount
      contextRef="ie28d293ededa44009f8568af6cd22fe9_I20220228"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDMvZnJhZzpkZjUxYWY2NmMyMWY0YjkxODdjMWU4ODA5OWNlN2IyYS90ZXh0cmVnaW9uOmRmNTFhZjY2YzIxZjRiOTE4N2MxZTg4MDk5Y2U3YjJhXzc2OTY1ODE0MjA4NTU_6854cef5-7847-4941-abce-529ebace3a45"
      unitRef="usd">125500000</us-gaap:DebtInstrumentRepurchaseAmount>
    <us-gaap:RepaymentsOfNotesPayable
      contextRef="i106a64ab6c044b39a19f90f252c7361a_D20220201-20220228"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDMvZnJhZzpkZjUxYWY2NmMyMWY0YjkxODdjMWU4ODA5OWNlN2IyYS90ZXh0cmVnaW9uOmRmNTFhZjY2YzIxZjRiOTE4N2MxZTg4MDk5Y2U3YjJhXzc2OTY1ODE0MjA4NzE_34e2c65b-4559-4380-ba85-ec348aeb96b1"
      unitRef="usd">123900000</us-gaap:RepaymentsOfNotesPayable>
    <lgnd:RepaymentsOfNotesPayableInterestPortion
      contextRef="i106a64ab6c044b39a19f90f252c7361a_D20220201-20220228"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDMvZnJhZzpkZjUxYWY2NmMyMWY0YjkxODdjMWU4ODA5OWNlN2IyYS90ZXh0cmVnaW9uOmRmNTFhZjY2YzIxZjRiOTE4N2MxZTg4MDk5Y2U3YjJhXzc2OTY1ODE0MjA4ODc_a5dce733-843a-44b2-bb2b-2ddaef298722"
      unitRef="usd">300000</lgnd:RepaymentsOfNotesPayableInterestPortion>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="i9807ff46d0594f389be4314eae9d0d00_I20180522"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDMvZnJhZzpkZjUxYWY2NmMyMWY0YjkxODdjMWU4ODA5OWNlN2IyYS90ZXh0cmVnaW9uOmRmNTFhZjY2YzIxZjRiOTE4N2MxZTg4MDk5Y2U3YjJhXzEzNTc1_0ce9214c-646d-49b3-b903-3f6855d88986"
      unitRef="shares">3018327</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="i9807ff46d0594f389be4314eae9d0d00_I20180522"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDMvZnJhZzpkZjUxYWY2NmMyMWY0YjkxODdjMWU4ODA5OWNlN2IyYS90ZXh0cmVnaW9uOmRmNTFhZjY2YzIxZjRiOTE4N2MxZTg4MDk5Y2U3YjJhXzEzODQ5_e1521810-1d3c-45be-add0-18d4b65574d4"
      unitRef="usdPerShare">248.48</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <lgnd:PaymentsforConvertibleBondHedges
      contextRef="i4bff4ceb2aad46e4b1484d0f72c5d0dc_D20180522-20180522"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDMvZnJhZzpkZjUxYWY2NmMyMWY0YjkxODdjMWU4ODA5OWNlN2IyYS90ZXh0cmVnaW9uOmRmNTFhZjY2YzIxZjRiOTE4N2MxZTg4MDk5Y2U3YjJhXzEzOTMy_a929e2dc-a993-4b8b-86a5-f847ae8ae092"
      unitRef="usd">140300000</lgnd:PaymentsforConvertibleBondHedges>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="i304fdd56fb5543218317f467b86ae411_I20180531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDMvZnJhZzpkZjUxYWY2NmMyMWY0YjkxODdjMWU4ODA5OWNlN2IyYS90ZXh0cmVnaW9uOmRmNTFhZjY2YzIxZjRiOTE4N2MxZTg4MDk5Y2U3YjJhXzE0ODE3_8d6cd83e-c422-4f04-993c-b19f7a6a8ce9"
      unitRef="shares">3018327</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i9807ff46d0594f389be4314eae9d0d00_I20180522"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDMvZnJhZzpkZjUxYWY2NmMyMWY0YjkxODdjMWU4ODA5OWNlN2IyYS90ZXh0cmVnaW9uOmRmNTFhZjY2YzIxZjRiOTE4N2MxZTg4MDk5Y2U3YjJhXzE0ODY5_6f00e43a-60b6-4547-b275-a0d84897d37d"
      unitRef="usdPerShare">315.38</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="i4bff4ceb2aad46e4b1484d0f72c5d0dc_D20180522-20180522"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDMvZnJhZzpkZjUxYWY2NmMyMWY0YjkxODdjMWU4ODA5OWNlN2IyYS90ZXh0cmVnaW9uOmRmNTFhZjY2YzIxZjRiOTE4N2MxZTg4MDk5Y2U3YjJhXzE0OTI3_6edfb751-fc3f-4cdf-a903-0a22677fbcff"
      unitRef="usd">90000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:DebtInstrumentRepurchaseAmount
      contextRef="ieab8e7c78f9745d2b71d10dcba9ea01a_I20200430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDMvZnJhZzpkZjUxYWY2NmMyMWY0YjkxODdjMWU4ODA5OWNlN2IyYS90ZXh0cmVnaW9uOmRmNTFhZjY2YzIxZjRiOTE4N2MxZTg4MDk5Y2U3YjJhXzE2MDI2_d586f411-1096-412a-80d1-f68d38c59298"
      unitRef="usd">234400000</us-gaap:DebtInstrumentRepurchaseAmount>
    <us-gaap:RepaymentsOfNotesPayable
      contextRef="i1c98a85d32c34724861a5ba3589972ee_D20200401-20200430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDMvZnJhZzpkZjUxYWY2NmMyMWY0YjkxODdjMWU4ODA5OWNlN2IyYS90ZXh0cmVnaW9uOmRmNTFhZjY2YzIxZjRiOTE4N2MxZTg4MDk5Y2U3YjJhXzE2MDY0_b3cab196-aa84-4212-a4b1-ea86a444b9a8"
      unitRef="usd">203800000</us-gaap:RepaymentsOfNotesPayable>
    <lgnd:RepaymentsOfNotesPayableInterestPortion
      contextRef="i1c98a85d32c34724861a5ba3589972ee_D20200401-20200430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDMvZnJhZzpkZjUxYWY2NmMyMWY0YjkxODdjMWU4ODA5OWNlN2IyYS90ZXh0cmVnaW9uOmRmNTFhZjY2YzIxZjRiOTE4N2MxZTg4MDk5Y2U3YjJhXzE2MTA2_1781d5dd-f20d-4aef-bb18-2b186a8a8eb9"
      unitRef="usd">600000</lgnd:RepaymentsOfNotesPayableInterestPortion>
    <us-gaap:DebtInstrumentRepurchaseAmount
      contextRef="i71ea8f3e306b4086bfbeaaedfe295b98_I20210131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDMvZnJhZzpkZjUxYWY2NmMyMWY0YjkxODdjMWU4ODA5OWNlN2IyYS90ZXh0cmVnaW9uOmRmNTFhZjY2YzIxZjRiOTE4N2MxZTg4MDk5Y2U3YjJhXzE2NjM0_0e69e88c-df5c-47b6-81ee-9ec4031a6fa5"
      unitRef="usd">20300000</us-gaap:DebtInstrumentRepurchaseAmount>
    <us-gaap:RepaymentsOfNotesPayable
      contextRef="if357845be5954c78ac67d659d089ca0c_D20210101-20210131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDMvZnJhZzpkZjUxYWY2NmMyMWY0YjkxODdjMWU4ODA5OWNlN2IyYS90ZXh0cmVnaW9uOmRmNTFhZjY2YzIxZjRiOTE4N2MxZTg4MDk5Y2U3YjJhXzE2Njg2_573cf8e1-8e03-4882-9edb-dde21b31ed9a"
      unitRef="usd">19100000</us-gaap:RepaymentsOfNotesPayable>
    <lgnd:RepaymentsOfNotesPayableInterestPortion
      contextRef="if357845be5954c78ac67d659d089ca0c_D20210101-20210131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDMvZnJhZzpkZjUxYWY2NmMyMWY0YjkxODdjMWU4ODA5OWNlN2IyYS90ZXh0cmVnaW9uOmRmNTFhZjY2YzIxZjRiOTE4N2MxZTg4MDk5Y2U3YjJhXzE2NzI4_b7f15874-d61d-4b61-9ac8-48017d19f2b8"
      unitRef="usd">100000</lgnd:RepaymentsOfNotesPayableInterestPortion>
    <us-gaap:DebtInstrumentRepurchaseAmount
      contextRef="i75c40fa8303240178bae96b5323104b2_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDMvZnJhZzpkZjUxYWY2NmMyMWY0YjkxODdjMWU4ODA5OWNlN2IyYS90ZXh0cmVnaW9uOmRmNTFhZjY2YzIxZjRiOTE4N2MxZTg4MDk5Y2U3YjJhXzc2OTY1ODE0MTQwMjk_56419352-7739-46db-b131-b94590ebb92b"
      unitRef="usd">152000000</us-gaap:DebtInstrumentRepurchaseAmount>
    <us-gaap:RepaymentsOfNotesPayable
      contextRef="i9d6e6be3ae854425ba0e34565fd2b9c3_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDMvZnJhZzpkZjUxYWY2NmMyMWY0YjkxODdjMWU4ODA5OWNlN2IyYS90ZXh0cmVnaW9uOmRmNTFhZjY2YzIxZjRiOTE4N2MxZTg4MDk5Y2U3YjJhXzc2OTY1ODE0MTQwNDY_e6821cea-76cb-47a9-a867-f688a0472199"
      unitRef="usd">156000000</us-gaap:RepaymentsOfNotesPayable>
    <lgnd:RepaymentsOfNotesPayableInterestPortion
      contextRef="i9d6e6be3ae854425ba0e34565fd2b9c3_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDMvZnJhZzpkZjUxYWY2NmMyMWY0YjkxODdjMWU4ODA5OWNlN2IyYS90ZXh0cmVnaW9uOmRmNTFhZjY2YzIxZjRiOTE4N2MxZTg4MDk5Y2U3YjJhXzc2OTY1ODE0MTQwNjE_2883fe16-3e24-439c-8079-f5fe784c5e04"
      unitRef="usd">300000</lgnd:RepaymentsOfNotesPayableInterestPortion>
    <lgnd:PaymentsToUnwindWarrants
      contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDMvZnJhZzpkZjUxYWY2NmMyMWY0YjkxODdjMWU4ODA5OWNlN2IyYS90ZXh0cmVnaW9uOmRmNTFhZjY2YzIxZjRiOTE4N2MxZTg4MDk5Y2U3YjJhXzc2OTY1ODE0MTQwNjQ_4910dc73-6bb0-4447-9226-4d5102a85c93"
      unitRef="usd">18400000</lgnd:PaymentsToUnwindWarrants>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="i304fdd56fb5543218317f467b86ae411_I20180531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDMvZnJhZzpkZjUxYWY2NmMyMWY0YjkxODdjMWU4ODA5OWNlN2IyYS90ZXh0cmVnaW9uOmRmNTFhZjY2YzIxZjRiOTE4N2MxZTg4MDk5Y2U3YjJhXzc2OTY1ODE0MTQwODg_8d6cd83e-c422-4f04-993c-b19f7a6a8ce9"
      unitRef="shares">3018327</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="i75c40fa8303240178bae96b5323104b2_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDMvZnJhZzpkZjUxYWY2NmMyMWY0YjkxODdjMWU4ODA5OWNlN2IyYS90ZXh0cmVnaW9uOmRmNTFhZjY2YzIxZjRiOTE4N2MxZTg4MDk5Y2U3YjJhXzc2OTY1ODE0MTQwOTE_f2709235-3ccf-4783-b4cf-3c3a3512a302"
      unitRef="shares">2559254</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <lgnd:ProceedsFromUnwindingConvertibleBondHedges
      contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDMvZnJhZzpkZjUxYWY2NmMyMWY0YjkxODdjMWU4ODA5OWNlN2IyYS90ZXh0cmVnaW9uOmRmNTFhZjY2YzIxZjRiOTE4N2MxZTg4MDk5Y2U3YjJhXzc2OTY1ODE0MTQxMDI_685c4d87-64bb-493b-87a8-e25397539a65"
      unitRef="usd">18900000</lgnd:ProceedsFromUnwindingConvertibleBondHedges>
    <lgnd:NumberOfOptionsUnderConvertibleBondHedges
      contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDMvZnJhZzpkZjUxYWY2NmMyMWY0YjkxODdjMWU4ODA5OWNlN2IyYS90ZXh0cmVnaW9uOmRmNTFhZjY2YzIxZjRiOTE4N2MxZTg4MDk5Y2U3YjJhXzc2OTY1ODE0MTQxMTc_4d1cd857-6dd4-4392-99fe-c54252ef5ba8"
      unitRef="option">598021</lgnd:NumberOfOptionsUnderConvertibleBondHedges>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDMvZnJhZzpkZjUxYWY2NmMyMWY0YjkxODdjMWU4ODA5OWNlN2IyYS90ZXh0cmVnaW9uOmRmNTFhZjY2YzIxZjRiOTE4N2MxZTg4MDk5Y2U3YjJhXzc2OTY1ODE0MTQxMjY_f378cabd-e915-478e-a60e-04f9d664f984"
      unitRef="usd">500000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:ScheduleOfDebtTableTextBlock
      contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDMvZnJhZzpkZjUxYWY2NmMyMWY0YjkxODdjMWU4ODA5OWNlN2IyYS90ZXh0cmVnaW9uOmRmNTFhZjY2YzIxZjRiOTE4N2MxZTg4MDk5Y2U3YjJhXzE3NDE0_e059c29e-f1b3-40c5-9429-c47c7e7eef12">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes information about the equity and liability components of the 2023 Notes (in thousands).&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.683%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.499%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Principal amount of 2023 Notes outstanding&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;343,301&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;495,280&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unamortized discount (including unamortized debt issuance cost)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22,584)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(52,987)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total long-term portion of notes payable&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;320,717&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;442,293&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Carrying value of equity component of 2023 Notes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,627&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,397&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of convertible senior notes outstanding (Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;341,801&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;466,053&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfDebtTableTextBlock>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i75c40fa8303240178bae96b5323104b2_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDMvZnJhZzpkZjUxYWY2NmMyMWY0YjkxODdjMWU4ODA5OWNlN2IyYS90YWJsZTpjZDZmN2U3ZGVhYTk0NjdjYmM1NjEwYzBmMmQ5MTdiYS90YWJsZXJhbmdlOmNkNmY3ZTdkZWFhOTQ2N2NiYzU2MTBjMGYyZDkxN2JhXzEtMS0xLTEtNDEyOTQ_b4f90c08-3428-48f8-b108-00192f0fa2db"
      unitRef="usd">343301000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="iad6270f46e2a419fb81396b4dde75fb8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDMvZnJhZzpkZjUxYWY2NmMyMWY0YjkxODdjMWU4ODA5OWNlN2IyYS90YWJsZTpjZDZmN2U3ZGVhYTk0NjdjYmM1NjEwYzBmMmQ5MTdiYS90YWJsZXJhbmdlOmNkNmY3ZTdkZWFhOTQ2N2NiYzU2MTBjMGYyZDkxN2JhXzEtMy0xLTEtNDEyOTQ_1fc66aa8-1234-4bb4-a40f-25d1519104ca"
      unitRef="usd">495280000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="i75c40fa8303240178bae96b5323104b2_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDMvZnJhZzpkZjUxYWY2NmMyMWY0YjkxODdjMWU4ODA5OWNlN2IyYS90YWJsZTpjZDZmN2U3ZGVhYTk0NjdjYmM1NjEwYzBmMmQ5MTdiYS90YWJsZXJhbmdlOmNkNmY3ZTdkZWFhOTQ2N2NiYzU2MTBjMGYyZDkxN2JhXzItMS0xLTEtNDEyOTQ_ce36571b-f233-4011-83d0-5b838549dafa"
      unitRef="usd">22584000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="iad6270f46e2a419fb81396b4dde75fb8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDMvZnJhZzpkZjUxYWY2NmMyMWY0YjkxODdjMWU4ODA5OWNlN2IyYS90YWJsZTpjZDZmN2U3ZGVhYTk0NjdjYmM1NjEwYzBmMmQ5MTdiYS90YWJsZXJhbmdlOmNkNmY3ZTdkZWFhOTQ2N2NiYzU2MTBjMGYyZDkxN2JhXzItMy0xLTEtNDEyOTQ_47815b0a-76e9-496f-b47b-7ed6a4eff274"
      unitRef="usd">52987000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:LongTermNotesPayable
      contextRef="i75c40fa8303240178bae96b5323104b2_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDMvZnJhZzpkZjUxYWY2NmMyMWY0YjkxODdjMWU4ODA5OWNlN2IyYS90YWJsZTpjZDZmN2U3ZGVhYTk0NjdjYmM1NjEwYzBmMmQ5MTdiYS90YWJsZXJhbmdlOmNkNmY3ZTdkZWFhOTQ2N2NiYzU2MTBjMGYyZDkxN2JhXzMtMS0xLTEtNDEyOTQ_646704af-742e-4b50-ad43-9e65a0d2b814"
      unitRef="usd">320717000</us-gaap:LongTermNotesPayable>
    <us-gaap:LongTermNotesPayable
      contextRef="iad6270f46e2a419fb81396b4dde75fb8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDMvZnJhZzpkZjUxYWY2NmMyMWY0YjkxODdjMWU4ODA5OWNlN2IyYS90YWJsZTpjZDZmN2U3ZGVhYTk0NjdjYmM1NjEwYzBmMmQ5MTdiYS90YWJsZXJhbmdlOmNkNmY3ZTdkZWFhOTQ2N2NiYzU2MTBjMGYyZDkxN2JhXzMtMy0xLTEtNDEyOTQ_96b28825-5eca-452f-9f7b-ea30ba8007d0"
      unitRef="usd">442293000</us-gaap:LongTermNotesPayable>
    <us-gaap:DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent
      contextRef="i75c40fa8303240178bae96b5323104b2_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDMvZnJhZzpkZjUxYWY2NmMyMWY0YjkxODdjMWU4ODA5OWNlN2IyYS90YWJsZTpjZDZmN2U3ZGVhYTk0NjdjYmM1NjEwYzBmMmQ5MTdiYS90YWJsZXJhbmdlOmNkNmY3ZTdkZWFhOTQ2N2NiYzU2MTBjMGYyZDkxN2JhXzQtMS0xLTEtNDEyOTQ_79ee1f4e-f319-4d98-a9f3-a88ae3cb7cce"
      unitRef="usd">20627000</us-gaap:DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent>
    <us-gaap:DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent
      contextRef="iad6270f46e2a419fb81396b4dde75fb8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDMvZnJhZzpkZjUxYWY2NmMyMWY0YjkxODdjMWU4ODA5OWNlN2IyYS90YWJsZTpjZDZmN2U3ZGVhYTk0NjdjYmM1NjEwYzBmMmQ5MTdiYS90YWJsZXJhbmdlOmNkNmY3ZTdkZWFhOTQ2N2NiYzU2MTBjMGYyZDkxN2JhXzQtMy0xLTEtNDEyOTQ_bbb40511-aa67-479d-a28d-7c18bea2b5b5"
      unitRef="usd">48397000</us-gaap:DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent>
    <us-gaap:ConvertibleDebtFairValueDisclosures
      contextRef="i75c40fa8303240178bae96b5323104b2_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDMvZnJhZzpkZjUxYWY2NmMyMWY0YjkxODdjMWU4ODA5OWNlN2IyYS90YWJsZTpjZDZmN2U3ZGVhYTk0NjdjYmM1NjEwYzBmMmQ5MTdiYS90YWJsZXJhbmdlOmNkNmY3ZTdkZWFhOTQ2N2NiYzU2MTBjMGYyZDkxN2JhXzUtMS0xLTEtNDEyOTQ_4fd9a197-7ba2-4ff8-a3ba-7c81c9df2771"
      unitRef="usd">341801000</us-gaap:ConvertibleDebtFairValueDisclosures>
    <us-gaap:ConvertibleDebtFairValueDisclosures
      contextRef="iad6270f46e2a419fb81396b4dde75fb8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDMvZnJhZzpkZjUxYWY2NmMyMWY0YjkxODdjMWU4ODA5OWNlN2IyYS90YWJsZTpjZDZmN2U3ZGVhYTk0NjdjYmM1NjEwYzBmMmQ5MTdiYS90YWJsZXJhbmdlOmNkNmY3ZTdkZWFhOTQ2N2NiYzU2MTBjMGYyZDkxN2JhXzUtMy0xLTEtNDEyOTQ_643e6582-af1b-4c8d-bafc-0cd1c0b0e84c"
      unitRef="usd">466053000</us-gaap:ConvertibleDebtFairValueDisclosures>
    <us-gaap:SupplementalBalanceSheetDisclosuresTextBlock
      contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90ZXh0cmVnaW9uOjhkMWM4MjU1M2QwNzQ1ODVhMDJmY2U3NDA0ZGE4ZTE5XzQxMzU_c39d931e-127a-478f-b726-8d58d6cbc87b">Balance Sheet Account DetailsShort-term Investments&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Excluding our investments in Viking, the following table summarizes the various investment categories at December&#160;31, 2021 and 2020 (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.321%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.501%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;gains&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;fair value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Mutual Fund&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;152,136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(249)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;151,887&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Bank deposits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63,389&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63,381&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,008&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,998&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,308&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(38)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,807&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;402&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,027)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,577&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(23)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,554&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;408&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;408&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;292,225&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;842&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,370)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;290,697&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Mutual fund&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;151,512&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;386&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;151,898&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Bank deposits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84,120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84,154&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Commercial paper  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,459&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,485&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,512&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,610&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Agency bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,499&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,501&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Corporate equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,466&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;360&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,388)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,438&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Treasury bills&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,999&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,999&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;393&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;393&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;324,567&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,302&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,391)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;324,478&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Gain (loss) from short-term investments on our consolidated statements of operations includes both realized and unrealized gain (loss) from our short-term investments in public equity and warrant securities, and realized gain (loss) from available-for-sale debt securities. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our available-for-sale debt securities by contractual maturity (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.498%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Within one year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;111,334&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;111,315&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;After one year through five years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,952&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,909&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;After five years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;136,286&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;136,224&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our available-for-sale debt securities in an unrealized loss position (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.783%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.765%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.765%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.765%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.765%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.765%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Less than 12 months&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;12 months or greater&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Estimated&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Estimated&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Estimated&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Bank deposits&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,008&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,008&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,996&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,248&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,689&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(32)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(38)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,814&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Government Securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(23)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,553&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(23)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,553&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(34)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53,949&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(60)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,674&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(94)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72,623&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Bank deposits&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,013&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,013&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,526&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,526&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,693&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,693&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our investment policy is capital preservation and we only invested in U.S.-dollar denominated investments. We held a total of 55 positions which were in an unrealized loss position as of December&#160;31, 2021. We believe that we will collect the principal and interest due on our debt securities that have an amortized cost in excess of fair value. The unrealized losses are largely due to changes in interest rates and not to unfavorable changes in the credit quality associated with these securities that impacted our assessment on collectability of principal and interest. We do not intend to sell these securities nor do we believe that we will be required to sell these securities before the recovery of the amortized cost basis. Accordingly, no credit losses were recognized for the twelve months ended December&#160;31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Property and equipment are stated at cost and consists of the following (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.498%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lab and office equipment&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,183&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,666&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,983&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,519&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer equipment and software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,056&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1056&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,222&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less accumulated depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,711)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,807)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,511&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,434&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depreciation of equipment is computed using the straight-line method over the estimated useful lives of the assets which ranges from &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90ZXh0cmVnaW9uOjhkMWM4MjU1M2QwNzQ1ODVhMDJmY2U3NDA0ZGE4ZTE5XzIwODU_49dc7d90-487d-4145-93b5-5005d27536fa"&gt;three&lt;/span&gt; to ten years. Leasehold improvements are amortized using the straight-line method over their estimated useful lives or their related lease term, whichever is shorter. Depreciation expense of $3.9 million, $1.8 million, and $1.5 million was recognized for the twelve months ended December&#160;31, 2021, 2020, and 2019, respectively, and was included in operating expenses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Goodwill and identifiable intangible assets consist of the following (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.498%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Indefinite-lived intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;181,206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;189,662&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Definite-lived intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Complete technology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;280,617&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;277,740&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Less: Accumulated amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(78,991)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(63,600)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Trade name&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,642&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,642&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Less: Accumulated amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,444)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,312)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Customer relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Less: Accumulated amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(18,267)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15,597)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Contractual relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;362,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;362,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Accumulated amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(36,217)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,243)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total goodwill and other identifiable intangible assets, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;732,246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;784,992&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:24pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amortization of finite-lived intangible assets is computed using the straight-line method over the estimated useful life of the asset of up to 20 years. Amortization expense of $47.2 million, $23.4 million, and $16.9 million was recognized for the years ended December&#160;31, 2021, 2020, and 2019, respectively. Estimated amortization expense for the years ending December&#160;31, 2022 through 2026 is $47.0 million per year. For each of the years ended December&#160;31, 2021, 2021, and 2019, there was no material impairment of intangible assets with finite lives.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accrued liabilities consist of the following (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.498%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Compensation&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,532&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,810&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Professional fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,046&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;977&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amounts owed to former licensees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;630&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;421&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Royalties owed to third parties&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;149&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;693&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Return reserve and customer refunds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,420&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;687&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquisition related liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Subcontractor&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,759&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;733&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Supplier&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;848&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;604&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,579&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,530&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Contingent liabilities:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the acquisition of Crystal in October 2017, we entered into contingent liabilities based on achievement of certain research and business milestones as well as certain revenue goal.  &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the acquisition of CyDex in January 2011, we issued a series of CVRs and also assumed certain contingent liabilities. We may be required to make additional payments upon achievement of certain clinical and regulatory milestones to the CyDex shareholders and former license holders.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the acquisition of Metabasis in January 2010, we entered into four CVR agreements with Metabasis shareholders. The CVRs entitle the holders to cash payments as frequently as every six months as proceeds are received by us upon the sale or licensing of any of the Metabasis drug development programs and upon the achievement of specified milestones.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For CVRs associated with the Pfenex and Icagen acquisitions, see &#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note (4), Acquisitions&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x201d; for more information.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes roll-forward of contingent liabilities as of December 2021 and 2020 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.356%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.110%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.964%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.110%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.110%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.110%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.525%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.110%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.115%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Additional Contingent Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Fair Value Adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Repurchases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Fair Value Adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Repurchases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cydex&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;348&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;508&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(50)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(108)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;350&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Metabasis&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,935&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,867)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(247)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,821&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(464)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,357&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Crystal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,659&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,800)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(59)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(800)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Icagen&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(525)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,404&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,050)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,010&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,364&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Pfenex&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;37,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;37,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(37,600)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;xCella&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(720)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;720&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;8,942&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;41,800&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(2,325)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;963&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(247)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;49,133&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(1,820)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(36,242)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;11,071&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:SupplementalBalanceSheetDisclosuresTextBlock>
    <us-gaap:MarketableSecuritiesTextBlock
      contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90ZXh0cmVnaW9uOjhkMWM4MjU1M2QwNzQ1ODVhMDJmY2U3NDA0ZGE4ZTE5XzQxNDE_01f0832a-d513-498a-bb4f-310c4b2d63d3">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Excluding our investments in Viking, the following table summarizes the various investment categories at December&#160;31, 2021 and 2020 (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.321%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.501%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;gains&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;fair value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Mutual Fund&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;152,136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(249)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;151,887&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Bank deposits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63,389&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63,381&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,008&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,998&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,308&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(38)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,807&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;402&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,027)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,577&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(23)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,554&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;408&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;408&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;292,225&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;842&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,370)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;290,697&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Mutual fund&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;151,512&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;386&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;151,898&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Bank deposits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84,120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84,154&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Commercial paper  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,459&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,485&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,512&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,610&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Agency bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,499&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,501&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Corporate equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,466&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;360&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,388)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,438&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Treasury bills&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,999&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,999&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;393&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;393&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;324,567&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,302&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,391)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;324,478&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:MarketableSecuritiesTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i00a18868ce4d4197a8afb1f39a028208_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpjY2RiMDBhM2MyZjc0MDYzODcyMGY4Y2M4ZGQ0MTEwZS90YWJsZXJhbmdlOmNjZGIwMGEzYzJmNzQwNjM4NzIwZjhjYzhkZDQxMTBlXzMtMS0xLTEtNDEyOTQ_2e347f5b-00b5-4a56-9efe-3815b962db17"
      unitRef="usd">152136000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i00a18868ce4d4197a8afb1f39a028208_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpjY2RiMDBhM2MyZjc0MDYzODcyMGY4Y2M4ZGQ0MTEwZS90YWJsZXJhbmdlOmNjZGIwMGEzYzJmNzQwNjM4NzIwZjhjYzhkZDQxMTBlXzMtMy0xLTEtNDEyOTQ_a769710a-8f04-484b-9dce-3902ba7ebcc9"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i00a18868ce4d4197a8afb1f39a028208_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpjY2RiMDBhM2MyZjc0MDYzODcyMGY4Y2M4ZGQ0MTEwZS90YWJsZXJhbmdlOmNjZGIwMGEzYzJmNzQwNjM4NzIwZjhjYzhkZDQxMTBlXzMtNS0xLTEtNDEyOTQ_ba950145-50d0-451f-ad3f-69f553d4869b"
      unitRef="usd">249000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i00a18868ce4d4197a8afb1f39a028208_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpjY2RiMDBhM2MyZjc0MDYzODcyMGY4Y2M4ZGQ0MTEwZS90YWJsZXJhbmdlOmNjZGIwMGEzYzJmNzQwNjM4NzIwZjhjYzhkZDQxMTBlXzMtNy0xLTEtNDEyOTQ_2a8d3086-8fbf-4689-96ac-ee77b8ac3255"
      unitRef="usd">151887000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i4ee078f3c41f42a0b0e253d5572cce12_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpjY2RiMDBhM2MyZjc0MDYzODcyMGY4Y2M4ZGQ0MTEwZS90YWJsZXJhbmdlOmNjZGIwMGEzYzJmNzQwNjM4NzIwZjhjYzhkZDQxMTBlXzQtMS0xLTEtNDEyOTQ_e40467f3-bc36-4a44-a5b9-6620e2e470b6"
      unitRef="usd">63389000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i4ee078f3c41f42a0b0e253d5572cce12_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpjY2RiMDBhM2MyZjc0MDYzODcyMGY4Y2M4ZGQ0MTEwZS90YWJsZXJhbmdlOmNjZGIwMGEzYzJmNzQwNjM4NzIwZjhjYzhkZDQxMTBlXzQtMy0xLTEtNDEyOTQ_31acdb7e-faaf-40c8-a2bb-9982c6a1e3f6"
      unitRef="usd">13000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i4ee078f3c41f42a0b0e253d5572cce12_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpjY2RiMDBhM2MyZjc0MDYzODcyMGY4Y2M4ZGQ0MTEwZS90YWJsZXJhbmdlOmNjZGIwMGEzYzJmNzQwNjM4NzIwZjhjYzhkZDQxMTBlXzQtNS0xLTEtNDEyOTQ_f86aaa1e-1be8-403f-b9f0-d9687a54958d"
      unitRef="usd">21000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i4ee078f3c41f42a0b0e253d5572cce12_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpjY2RiMDBhM2MyZjc0MDYzODcyMGY4Y2M4ZGQ0MTEwZS90YWJsZXJhbmdlOmNjZGIwMGEzYzJmNzQwNjM4NzIwZjhjYzhkZDQxMTBlXzQtNy0xLTEtNDEyOTQ_c9bb8c2f-7af5-4836-91a9-b9c0c09ab524"
      unitRef="usd">63381000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="iaf06af7ed8174cf3bef274cca762d884_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpjY2RiMDBhM2MyZjc0MDYzODcyMGY4Y2M4ZGQ0MTEwZS90YWJsZXJhbmdlOmNjZGIwMGEzYzJmNzQwNjM4NzIwZjhjYzhkZDQxMTBlXzUtMS0xLTEtNDEyOTQ_8659cf15-e9b9-4cae-9fa4-0f2bdf71b244"
      unitRef="usd">36008000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="iaf06af7ed8174cf3bef274cca762d884_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpjY2RiMDBhM2MyZjc0MDYzODcyMGY4Y2M4ZGQ0MTEwZS90YWJsZXJhbmdlOmNjZGIwMGEzYzJmNzQwNjM4NzIwZjhjYzhkZDQxMTBlXzUtMy0xLTEtNDEyOTQ_05a54db2-1032-4878-b219-3d9804f25abb"
      unitRef="usd">2000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="iaf06af7ed8174cf3bef274cca762d884_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpjY2RiMDBhM2MyZjc0MDYzODcyMGY4Y2M4ZGQ0MTEwZS90YWJsZXJhbmdlOmNjZGIwMGEzYzJmNzQwNjM4NzIwZjhjYzhkZDQxMTBlXzUtNS0xLTEtNDEyOTQ_ab8cb2eb-603b-4c76-b8f2-1b6ae2e2f74a"
      unitRef="usd">12000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iaf06af7ed8174cf3bef274cca762d884_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpjY2RiMDBhM2MyZjc0MDYzODcyMGY4Y2M4ZGQ0MTEwZS90YWJsZXJhbmdlOmNjZGIwMGEzYzJmNzQwNjM4NzIwZjhjYzhkZDQxMTBlXzUtNy0xLTEtNDEyOTQ_163a4814-45f2-4395-b792-282cdc73d944"
      unitRef="usd">35998000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i8cbd4d6b4d6042bca716c614bfd4632a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpjY2RiMDBhM2MyZjc0MDYzODcyMGY4Y2M4ZGQ0MTEwZS90YWJsZXJhbmdlOmNjZGIwMGEzYzJmNzQwNjM4NzIwZjhjYzhkZDQxMTBlXzYtMS0xLTEtNDEyOTQ_e7626039-9593-45e0-888f-03aaea65eca7"
      unitRef="usd">29308000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i8cbd4d6b4d6042bca716c614bfd4632a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpjY2RiMDBhM2MyZjc0MDYzODcyMGY4Y2M4ZGQ0MTEwZS90YWJsZXJhbmdlOmNjZGIwMGEzYzJmNzQwNjM4NzIwZjhjYzhkZDQxMTBlXzYtMy0xLTEtNDEyOTQ_5d2dc6f5-d191-4ae5-960b-0a4cc1af5d10"
      unitRef="usd">17000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i8cbd4d6b4d6042bca716c614bfd4632a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpjY2RiMDBhM2MyZjc0MDYzODcyMGY4Y2M4ZGQ0MTEwZS90YWJsZXJhbmdlOmNjZGIwMGEzYzJmNzQwNjM4NzIwZjhjYzhkZDQxMTBlXzYtNS0xLTEtNDEyOTQ_f61dbe77-1c5b-44d0-a77a-84850ecb4bf7"
      unitRef="usd">38000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i8cbd4d6b4d6042bca716c614bfd4632a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpjY2RiMDBhM2MyZjc0MDYzODcyMGY4Y2M4ZGQ0MTEwZS90YWJsZXJhbmdlOmNjZGIwMGEzYzJmNzQwNjM4NzIwZjhjYzhkZDQxMTBlXzYtNy0xLTEtNDEyOTQ_034e4d92-d7eb-4237-a04d-336d65710afc"
      unitRef="usd">29287000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i7e8a90585c134dbb98e6aecf3894a4ee_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpjY2RiMDBhM2MyZjc0MDYzODcyMGY4Y2M4ZGQ0MTEwZS90YWJsZXJhbmdlOmNjZGIwMGEzYzJmNzQwNjM4NzIwZjhjYzhkZDQxMTBlXzctMS0xLTEtNDEyOTQ_0cdf0373-fabe-42df-89c9-8081480ff28c"
      unitRef="usd">5807000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i7e8a90585c134dbb98e6aecf3894a4ee_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpjY2RiMDBhM2MyZjc0MDYzODcyMGY4Y2M4ZGQ0MTEwZS90YWJsZXJhbmdlOmNjZGIwMGEzYzJmNzQwNjM4NzIwZjhjYzhkZDQxMTBlXzctMy0xLTEtNDEyOTQ_3ad868b8-8939-4632-b274-4ae15cea8847"
      unitRef="usd">402000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i7e8a90585c134dbb98e6aecf3894a4ee_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpjY2RiMDBhM2MyZjc0MDYzODcyMGY4Y2M4ZGQ0MTEwZS90YWJsZXJhbmdlOmNjZGIwMGEzYzJmNzQwNjM4NzIwZjhjYzhkZDQxMTBlXzctNS0xLTEtNDEyOTQ_3cf85b8f-83d5-4ca3-bac4-6895dc6f93b5"
      unitRef="usd">2027000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i7e8a90585c134dbb98e6aecf3894a4ee_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpjY2RiMDBhM2MyZjc0MDYzODcyMGY4Y2M4ZGQ0MTEwZS90YWJsZXJhbmdlOmNjZGIwMGEzYzJmNzQwNjM4NzIwZjhjYzhkZDQxMTBlXzctNy0xLTEtNDEyOTQ_c47e89ac-7285-4ed8-8fcb-423286759c8e"
      unitRef="usd">4182000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ibba9764388ba4ab5b3742c104cad8606_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpjY2RiMDBhM2MyZjc0MDYzODcyMGY4Y2M4ZGQ0MTEwZS90YWJsZXJhbmdlOmNjZGIwMGEzYzJmNzQwNjM4NzIwZjhjYzhkZDQxMTBlXzgtMS0xLTEtNDEyOTQ_336cd6e4-bff5-4758-b313-5d17eaa9059c"
      unitRef="usd">5577000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ibba9764388ba4ab5b3742c104cad8606_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpjY2RiMDBhM2MyZjc0MDYzODcyMGY4Y2M4ZGQ0MTEwZS90YWJsZXJhbmdlOmNjZGIwMGEzYzJmNzQwNjM4NzIwZjhjYzhkZDQxMTBlXzgtMy0xLTEtNDEyOTQ_2de09b41-a0cc-4e2b-8c1b-37628061b423"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ibba9764388ba4ab5b3742c104cad8606_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpjY2RiMDBhM2MyZjc0MDYzODcyMGY4Y2M4ZGQ0MTEwZS90YWJsZXJhbmdlOmNjZGIwMGEzYzJmNzQwNjM4NzIwZjhjYzhkZDQxMTBlXzgtNS0xLTEtNDEyOTQ_07a284b9-40db-4b77-8fb9-c2d9db6a1c2e"
      unitRef="usd">23000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ibba9764388ba4ab5b3742c104cad8606_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpjY2RiMDBhM2MyZjc0MDYzODcyMGY4Y2M4ZGQ0MTEwZS90YWJsZXJhbmdlOmNjZGIwMGEzYzJmNzQwNjM4NzIwZjhjYzhkZDQxMTBlXzgtNy0xLTEtNDEyOTQ_7a88eb0b-1185-4b52-bd4a-6295eff1855c"
      unitRef="usd">5554000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ie389523012a64039b933f60b96d0b103_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpjY2RiMDBhM2MyZjc0MDYzODcyMGY4Y2M4ZGQ0MTEwZS90YWJsZXJhbmdlOmNjZGIwMGEzYzJmNzQwNjM4NzIwZjhjYzhkZDQxMTBlXzktMS0xLTEtNTgwODI_e5e75056-04de-4292-a0d2-c83865d4ab2b"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ie389523012a64039b933f60b96d0b103_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpjY2RiMDBhM2MyZjc0MDYzODcyMGY4Y2M4ZGQ0MTEwZS90YWJsZXJhbmdlOmNjZGIwMGEzYzJmNzQwNjM4NzIwZjhjYzhkZDQxMTBlXzktMy0xLTEtNTc5NDQ_2c10a35b-cc18-4fe5-8af8-dd3d87606817"
      unitRef="usd">408000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ie389523012a64039b933f60b96d0b103_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpjY2RiMDBhM2MyZjc0MDYzODcyMGY4Y2M4ZGQ0MTEwZS90YWJsZXJhbmdlOmNjZGIwMGEzYzJmNzQwNjM4NzIwZjhjYzhkZDQxMTBlXzktNS0xLTEtNTgwODI_6d768da9-9ce2-4b80-a551-9a36b3ea95fa"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ie389523012a64039b933f60b96d0b103_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpjY2RiMDBhM2MyZjc0MDYzODcyMGY4Y2M4ZGQ0MTEwZS90YWJsZXJhbmdlOmNjZGIwMGEzYzJmNzQwNjM4NzIwZjhjYzhkZDQxMTBlXzktNy0xLTEtNTgwODI_e9845b6f-19db-4c63-ac19-86b77226c134"
      unitRef="usd">408000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ibe91b170813b4c308d6df67cdcda5ea8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpjY2RiMDBhM2MyZjc0MDYzODcyMGY4Y2M4ZGQ0MTEwZS90YWJsZXJhbmdlOmNjZGIwMGEzYzJmNzQwNjM4NzIwZjhjYzhkZDQxMTBlXzExLTEtMS0xLTQxMjk0_8e0c78b1-b323-46c7-bb0a-c3b54077dd67"
      unitRef="usd">292225000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ibe91b170813b4c308d6df67cdcda5ea8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpjY2RiMDBhM2MyZjc0MDYzODcyMGY4Y2M4ZGQ0MTEwZS90YWJsZXJhbmdlOmNjZGIwMGEzYzJmNzQwNjM4NzIwZjhjYzhkZDQxMTBlXzExLTMtMS0xLTQxMjk0_96dbe76d-9a91-473d-b070-36342bf5077e"
      unitRef="usd">842000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ibe91b170813b4c308d6df67cdcda5ea8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpjY2RiMDBhM2MyZjc0MDYzODcyMGY4Y2M4ZGQ0MTEwZS90YWJsZXJhbmdlOmNjZGIwMGEzYzJmNzQwNjM4NzIwZjhjYzhkZDQxMTBlXzExLTUtMS0xLTQxMjk0_af914e11-6087-4216-b01c-666d8e421667"
      unitRef="usd">2370000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ibe91b170813b4c308d6df67cdcda5ea8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpjY2RiMDBhM2MyZjc0MDYzODcyMGY4Y2M4ZGQ0MTEwZS90YWJsZXJhbmdlOmNjZGIwMGEzYzJmNzQwNjM4NzIwZjhjYzhkZDQxMTBlXzExLTctMS0xLTQxMjk0_4b3176a2-28af-4398-b3aa-a5268d19ea3e"
      unitRef="usd">290697000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ib7bfc8139cbb425fb7edf200713433a4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpjY2RiMDBhM2MyZjc0MDYzODcyMGY4Y2M4ZGQ0MTEwZS90YWJsZXJhbmdlOmNjZGIwMGEzYzJmNzQwNjM4NzIwZjhjYzhkZDQxMTBlXzE0LTEtMS0xLTQ1ODQ5_741cdef6-abb2-498e-8bb5-cef5931abb8a"
      unitRef="usd">151512000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ib7bfc8139cbb425fb7edf200713433a4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpjY2RiMDBhM2MyZjc0MDYzODcyMGY4Y2M4ZGQ0MTEwZS90YWJsZXJhbmdlOmNjZGIwMGEzYzJmNzQwNjM4NzIwZjhjYzhkZDQxMTBlXzE0LTMtMS0xLTQ1ODQ5_7a7c23a0-474a-4cd4-bc44-28d64df3affc"
      unitRef="usd">386000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ib7bfc8139cbb425fb7edf200713433a4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpjY2RiMDBhM2MyZjc0MDYzODcyMGY4Y2M4ZGQ0MTEwZS90YWJsZXJhbmdlOmNjZGIwMGEzYzJmNzQwNjM4NzIwZjhjYzhkZDQxMTBlXzE0LTUtMS0xLTQ1ODQ5_b491eb9b-5874-48af-b0cd-00f0cb84efcf"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ib7bfc8139cbb425fb7edf200713433a4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpjY2RiMDBhM2MyZjc0MDYzODcyMGY4Y2M4ZGQ0MTEwZS90YWJsZXJhbmdlOmNjZGIwMGEzYzJmNzQwNjM4NzIwZjhjYzhkZDQxMTBlXzE0LTctMS0xLTQ1ODQ5_b5b0df07-64ae-4616-8c89-c12db968d021"
      unitRef="usd">151898000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i201f7376cfcf403b9594a167f61024eb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpjY2RiMDBhM2MyZjc0MDYzODcyMGY4Y2M4ZGQ0MTEwZS90YWJsZXJhbmdlOmNjZGIwMGEzYzJmNzQwNjM4NzIwZjhjYzhkZDQxMTBlXzE0LTEtMS0xLTQ1ODI3_fab653c0-ebfb-407b-81f9-44d86e8d74be"
      unitRef="usd">84120000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i201f7376cfcf403b9594a167f61024eb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpjY2RiMDBhM2MyZjc0MDYzODcyMGY4Y2M4ZGQ0MTEwZS90YWJsZXJhbmdlOmNjZGIwMGEzYzJmNzQwNjM4NzIwZjhjYzhkZDQxMTBlXzE0LTMtMS0xLTQ1ODI3_db64ef67-3f2c-427c-841e-b2cfe170cfa6"
      unitRef="usd">35000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i201f7376cfcf403b9594a167f61024eb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpjY2RiMDBhM2MyZjc0MDYzODcyMGY4Y2M4ZGQ0MTEwZS90YWJsZXJhbmdlOmNjZGIwMGEzYzJmNzQwNjM4NzIwZjhjYzhkZDQxMTBlXzE0LTUtMS0xLTQ1ODI3_11592962-6ca5-4ca1-a2f8-de6e26d0a65f"
      unitRef="usd">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i201f7376cfcf403b9594a167f61024eb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpjY2RiMDBhM2MyZjc0MDYzODcyMGY4Y2M4ZGQ0MTEwZS90YWJsZXJhbmdlOmNjZGIwMGEzYzJmNzQwNjM4NzIwZjhjYzhkZDQxMTBlXzE0LTctMS0xLTQ1ODI3_66e611b9-6cb5-4523-bf25-84f6751e87e3"
      unitRef="usd">84154000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i1751a1fa85af462cabdcd01341cd31d6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpjY2RiMDBhM2MyZjc0MDYzODcyMGY4Y2M4ZGQ0MTEwZS90YWJsZXJhbmdlOmNjZGIwMGEzYzJmNzQwNjM4NzIwZjhjYzhkZDQxMTBlXzE0LTEtMS0xLTQxMjk0_16c64670-447d-4364-8314-569093bb22a5"
      unitRef="usd">45459000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i1751a1fa85af462cabdcd01341cd31d6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpjY2RiMDBhM2MyZjc0MDYzODcyMGY4Y2M4ZGQ0MTEwZS90YWJsZXJhbmdlOmNjZGIwMGEzYzJmNzQwNjM4NzIwZjhjYzhkZDQxMTBlXzE0LTMtMS0xLTQxMjk0_95a27784-1a96-4df4-abab-2f92cd625e48"
      unitRef="usd">27000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i1751a1fa85af462cabdcd01341cd31d6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpjY2RiMDBhM2MyZjc0MDYzODcyMGY4Y2M4ZGQ0MTEwZS90YWJsZXJhbmdlOmNjZGIwMGEzYzJmNzQwNjM4NzIwZjhjYzhkZDQxMTBlXzE0LTUtMS0xLTQxMjk0_4f0f9d61-b8c3-4b6f-bf14-10188f4d09e1"
      unitRef="usd">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i1751a1fa85af462cabdcd01341cd31d6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpjY2RiMDBhM2MyZjc0MDYzODcyMGY4Y2M4ZGQ0MTEwZS90YWJsZXJhbmdlOmNjZGIwMGEzYzJmNzQwNjM4NzIwZjhjYzhkZDQxMTBlXzE0LTctMS0xLTQxMjk0_25ddae09-27ba-40a3-8d27-21d06cbbf300"
      unitRef="usd">45485000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="if6d8d88efb7d45d5b666348e93e722c9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpjY2RiMDBhM2MyZjc0MDYzODcyMGY4Y2M4ZGQ0MTEwZS90YWJsZXJhbmdlOmNjZGIwMGEzYzJmNzQwNjM4NzIwZjhjYzhkZDQxMTBlXzE1LTEtMS0xLTQxMjk0_c9a00fa3-1baa-4ac4-997f-360ac074e572"
      unitRef="usd">30512000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="if6d8d88efb7d45d5b666348e93e722c9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpjY2RiMDBhM2MyZjc0MDYzODcyMGY4Y2M4ZGQ0MTEwZS90YWJsZXJhbmdlOmNjZGIwMGEzYzJmNzQwNjM4NzIwZjhjYzhkZDQxMTBlXzE1LTMtMS0xLTQxMjk0_88c2eb8b-b065-41d1-bb9d-a0c4e4fd90ae"
      unitRef="usd">99000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="if6d8d88efb7d45d5b666348e93e722c9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpjY2RiMDBhM2MyZjc0MDYzODcyMGY4Y2M4ZGQ0MTEwZS90YWJsZXJhbmdlOmNjZGIwMGEzYzJmNzQwNjM4NzIwZjhjYzhkZDQxMTBlXzE1LTUtMS0xLTQxMjk0_206b5f4f-9c15-498f-b1a2-50208c5716e1"
      unitRef="usd">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="if6d8d88efb7d45d5b666348e93e722c9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpjY2RiMDBhM2MyZjc0MDYzODcyMGY4Y2M4ZGQ0MTEwZS90YWJsZXJhbmdlOmNjZGIwMGEzYzJmNzQwNjM4NzIwZjhjYzhkZDQxMTBlXzE1LTctMS0xLTQxMjk0_1474ca45-6fea-4378-9b3c-7fe3a9e71e9d"
      unitRef="usd">30610000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="iec0af917487f48e3b637625d1c5d4563_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpjY2RiMDBhM2MyZjc0MDYzODcyMGY4Y2M4ZGQ0MTEwZS90YWJsZXJhbmdlOmNjZGIwMGEzYzJmNzQwNjM4NzIwZjhjYzhkZDQxMTBlXzE2LTEtMS0xLTQxMjk0_2bb41202-afb7-4ca5-8b29-911bc9bd6bc9"
      unitRef="usd">4499000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="iec0af917487f48e3b637625d1c5d4563_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpjY2RiMDBhM2MyZjc0MDYzODcyMGY4Y2M4ZGQ0MTEwZS90YWJsZXJhbmdlOmNjZGIwMGEzYzJmNzQwNjM4NzIwZjhjYzhkZDQxMTBlXzE2LTMtMS0xLTQxMjk0_41ace6f5-3a2e-4188-873e-1251931b138f"
      unitRef="usd">2000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="iec0af917487f48e3b637625d1c5d4563_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpjY2RiMDBhM2MyZjc0MDYzODcyMGY4Y2M4ZGQ0MTEwZS90YWJsZXJhbmdlOmNjZGIwMGEzYzJmNzQwNjM4NzIwZjhjYzhkZDQxMTBlXzE2LTUtMS0xLTQxMjk0_c6606e7e-3bd9-4f40-80c0-548d388fe550"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iec0af917487f48e3b637625d1c5d4563_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpjY2RiMDBhM2MyZjc0MDYzODcyMGY4Y2M4ZGQ0MTEwZS90YWJsZXJhbmdlOmNjZGIwMGEzYzJmNzQwNjM4NzIwZjhjYzhkZDQxMTBlXzE2LTctMS0xLTQxMjk0_0b8fdc69-d80f-44f0-98dd-0bf73cd1ea38"
      unitRef="usd">4501000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i05f7d42438c243028010745501c74c06_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpjY2RiMDBhM2MyZjc0MDYzODcyMGY4Y2M4ZGQ0MTEwZS90YWJsZXJhbmdlOmNjZGIwMGEzYzJmNzQwNjM4NzIwZjhjYzhkZDQxMTBlXzE5LTEtMS0xLTQ1ODg5_197c366b-b341-448d-8eef-91913906cd0b"
      unitRef="usd">4466000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i05f7d42438c243028010745501c74c06_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpjY2RiMDBhM2MyZjc0MDYzODcyMGY4Y2M4ZGQ0MTEwZS90YWJsZXJhbmdlOmNjZGIwMGEzYzJmNzQwNjM4NzIwZjhjYzhkZDQxMTBlXzE5LTMtMS0xLTQ1OTI3_4da71c6e-020c-4e5b-ad64-dfc59f9bb2fc"
      unitRef="usd">360000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i05f7d42438c243028010745501c74c06_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpjY2RiMDBhM2MyZjc0MDYzODcyMGY4Y2M4ZGQ0MTEwZS90YWJsZXJhbmdlOmNjZGIwMGEzYzJmNzQwNjM4NzIwZjhjYzhkZDQxMTBlXzE5LTUtMS0xLTQ1OTMx_36d4b082-70d2-4db9-adab-cf7e3e6f681a"
      unitRef="usd">1388000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i05f7d42438c243028010745501c74c06_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpjY2RiMDBhM2MyZjc0MDYzODcyMGY4Y2M4ZGQ0MTEwZS90YWJsZXJhbmdlOmNjZGIwMGEzYzJmNzQwNjM4NzIwZjhjYzhkZDQxMTBlXzE3LTctMS0xLTQ2MjE5_914ed3c8-36f1-496e-b7bd-d58876d268e6"
      unitRef="usd">3438000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i6a5d7b087f09490db4f5fa4e098ee683_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpjY2RiMDBhM2MyZjc0MDYzODcyMGY4Y2M4ZGQ0MTEwZS90YWJsZXJhbmdlOmNjZGIwMGEzYzJmNzQwNjM4NzIwZjhjYzhkZDQxMTBlXzE3LTEtMS0xLTQxMjk0_8d02b6fd-36c8-4271-bd6c-4617f465ac53"
      unitRef="usd">3999000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i6a5d7b087f09490db4f5fa4e098ee683_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpjY2RiMDBhM2MyZjc0MDYzODcyMGY4Y2M4ZGQ0MTEwZS90YWJsZXJhbmdlOmNjZGIwMGEzYzJmNzQwNjM4NzIwZjhjYzhkZDQxMTBlXzE3LTMtMS0xLTQxMjk0_a0c6ba36-b90e-4290-83b5-501a4db0b4fb"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i6a5d7b087f09490db4f5fa4e098ee683_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpjY2RiMDBhM2MyZjc0MDYzODcyMGY4Y2M4ZGQ0MTEwZS90YWJsZXJhbmdlOmNjZGIwMGEzYzJmNzQwNjM4NzIwZjhjYzhkZDQxMTBlXzE3LTUtMS0xLTQxMjk0_9e6b4280-b52a-4e5d-b414-103242ccd8e3"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i6a5d7b087f09490db4f5fa4e098ee683_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpjY2RiMDBhM2MyZjc0MDYzODcyMGY4Y2M4ZGQ0MTEwZS90YWJsZXJhbmdlOmNjZGIwMGEzYzJmNzQwNjM4NzIwZjhjYzhkZDQxMTBlXzE3LTctMS0xLTQxMjk0_c234845b-e3b9-4846-a2db-8104e567fee2"
      unitRef="usd">3999000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i6243ca7a24ef40909c79d484e6b2cf6a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpjY2RiMDBhM2MyZjc0MDYzODcyMGY4Y2M4ZGQ0MTEwZS90YWJsZXJhbmdlOmNjZGIwMGEzYzJmNzQwNjM4NzIwZjhjYzhkZDQxMTBlXzE4LTEtMS0xLTQxMjk0_077fe98a-479c-4267-9cd8-6842994d390e"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i6243ca7a24ef40909c79d484e6b2cf6a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpjY2RiMDBhM2MyZjc0MDYzODcyMGY4Y2M4ZGQ0MTEwZS90YWJsZXJhbmdlOmNjZGIwMGEzYzJmNzQwNjM4NzIwZjhjYzhkZDQxMTBlXzE4LTMtMS0xLTQxMjk0_8320af96-9ce9-4267-8d69-dc31a531c49e"
      unitRef="usd">393000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i6243ca7a24ef40909c79d484e6b2cf6a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpjY2RiMDBhM2MyZjc0MDYzODcyMGY4Y2M4ZGQ0MTEwZS90YWJsZXJhbmdlOmNjZGIwMGEzYzJmNzQwNjM4NzIwZjhjYzhkZDQxMTBlXzE4LTUtMS0xLTQxMjk0_0a0e5fe0-127d-4b55-8685-2853d4e96707"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i6243ca7a24ef40909c79d484e6b2cf6a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpjY2RiMDBhM2MyZjc0MDYzODcyMGY4Y2M4ZGQ0MTEwZS90YWJsZXJhbmdlOmNjZGIwMGEzYzJmNzQwNjM4NzIwZjhjYzhkZDQxMTBlXzE4LTctMS0xLTQxMjk0_6fb3886b-e01b-4673-b440-3edf507354fc"
      unitRef="usd">393000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i17e3d08da23d4db99c73bbe97ce55cbd_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpjY2RiMDBhM2MyZjc0MDYzODcyMGY4Y2M4ZGQ0MTEwZS90YWJsZXJhbmdlOmNjZGIwMGEzYzJmNzQwNjM4NzIwZjhjYzhkZDQxMTBlXzIwLTEtMS0xLTQxMjk0_1af5101b-7ca2-41dd-91a6-390c86110c0d"
      unitRef="usd">324567000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i17e3d08da23d4db99c73bbe97ce55cbd_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpjY2RiMDBhM2MyZjc0MDYzODcyMGY4Y2M4ZGQ0MTEwZS90YWJsZXJhbmdlOmNjZGIwMGEzYzJmNzQwNjM4NzIwZjhjYzhkZDQxMTBlXzIwLTMtMS0xLTQxMjk0_b6dc0b59-fc79-400b-bfcd-9675116e9997"
      unitRef="usd">1302000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i17e3d08da23d4db99c73bbe97ce55cbd_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpjY2RiMDBhM2MyZjc0MDYzODcyMGY4Y2M4ZGQ0MTEwZS90YWJsZXJhbmdlOmNjZGIwMGEzYzJmNzQwNjM4NzIwZjhjYzhkZDQxMTBlXzIwLTUtMS0xLTQxMjk0_6c83d304-dd79-4c51-a5b6-213b6f2acf8d"
      unitRef="usd">1391000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i17e3d08da23d4db99c73bbe97ce55cbd_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpjY2RiMDBhM2MyZjc0MDYzODcyMGY4Y2M4ZGQ0MTEwZS90YWJsZXJhbmdlOmNjZGIwMGEzYzJmNzQwNjM4NzIwZjhjYzhkZDQxMTBlXzIwLTctMS0xLTQxMjk0_ee1f0a2d-011b-466f-b465-510ae28340a6"
      unitRef="usd">324478000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock
      contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90ZXh0cmVnaW9uOjhkMWM4MjU1M2QwNzQ1ODVhMDJmY2U3NDA0ZGE4ZTE5XzQxMzM_05009a6a-9547-4ead-b6da-ede2d3f2368c">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our available-for-sale debt securities by contractual maturity (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.498%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Within one year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;111,334&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;111,315&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;After one year through five years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,952&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,909&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;After five years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;136,286&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;136,224&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
      contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTozOGY3NWViNjZlODE0ZmY4YmQ1MWRjZDlhMGEwN2FjZC90YWJsZXJhbmdlOjM4Zjc1ZWI2NmU4MTRmZjhiZDUxZGNkOWEwYTA3YWNkXzItMS0xLTEtNDEyOTQ_193ae2b3-26d6-4bc7-8ded-b2cef03d51b8"
      unitRef="usd">111334000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTozOGY3NWViNjZlODE0ZmY4YmQ1MWRjZDlhMGEwN2FjZC90YWJsZXJhbmdlOjM4Zjc1ZWI2NmU4MTRmZjhiZDUxZGNkOWEwYTA3YWNkXzItMy0xLTEtNDEyOTQ_ca26aac2-f367-4f27-b2e9-195fde341826"
      unitRef="usd">111315000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost
      contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTozOGY3NWViNjZlODE0ZmY4YmQ1MWRjZDlhMGEwN2FjZC90YWJsZXJhbmdlOjM4Zjc1ZWI2NmU4MTRmZjhiZDUxZGNkOWEwYTA3YWNkXzMtMS0xLTEtNDEyOTQ_98c0a4a4-a654-4e91-b25c-18a7af0e0d20"
      unitRef="usd">24952000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
      contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTozOGY3NWViNjZlODE0ZmY4YmQ1MWRjZDlhMGEwN2FjZC90YWJsZXJhbmdlOjM4Zjc1ZWI2NmU4MTRmZjhiZDUxZGNkOWEwYTA3YWNkXzMtMy0xLTEtNDEyOTQ_edeae0ef-2494-45e1-9c43-74e64ee9cf6b"
      unitRef="usd">24909000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue>
    <lgnd:DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateAfterYearFive
      contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTozOGY3NWViNjZlODE0ZmY4YmQ1MWRjZDlhMGEwN2FjZC90YWJsZXJhbmdlOjM4Zjc1ZWI2NmU4MTRmZjhiZDUxZGNkOWEwYTA3YWNkXzQtMS0xLTEtNDEyOTQ_e711a1a0-3bea-4f7b-889e-71ee7b7541bc"
      unitRef="usd">0</lgnd:DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateAfterYearFive>
    <lgnd:DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearFive
      contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTozOGY3NWViNjZlODE0ZmY4YmQ1MWRjZDlhMGEwN2FjZC90YWJsZXJhbmdlOjM4Zjc1ZWI2NmU4MTRmZjhiZDUxZGNkOWEwYTA3YWNkXzQtMy0xLTEtNDEyOTQ_45d9b04b-c3f2-4967-82a7-95b2348d6c26"
      unitRef="usd">0</lgnd:DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearFive>
    <us-gaap:HeldToMaturitySecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis
      contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTozOGY3NWViNjZlODE0ZmY4YmQ1MWRjZDlhMGEwN2FjZC90YWJsZXJhbmdlOjM4Zjc1ZWI2NmU4MTRmZjhiZDUxZGNkOWEwYTA3YWNkXzUtMS0xLTEtNDEyOTQ_ae99d070-bf0c-47d9-9eb9-8752e4e47abc"
      unitRef="usd">136286000</us-gaap:HeldToMaturitySecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate
      contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTozOGY3NWViNjZlODE0ZmY4YmQ1MWRjZDlhMGEwN2FjZC90YWJsZXJhbmdlOjM4Zjc1ZWI2NmU4MTRmZjhiZDUxZGNkOWEwYTA3YWNkXzUtMy0xLTEtNDEyOTQ_78b5ba66-af4c-466c-a9bb-c17b5fa35626"
      unitRef="usd">136224000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock
      contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90ZXh0cmVnaW9uOjhkMWM4MjU1M2QwNzQ1ODVhMDJmY2U3NDA0ZGE4ZTE5XzQxMzE_ce62bdbd-4547-46dd-9fb3-141d6ee1e992">The following table summarizes our available-for-sale debt securities in an unrealized loss position (in thousands):&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.783%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.765%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.765%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.765%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.765%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.765%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Less than 12 months&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;12 months or greater&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Estimated&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Estimated&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Estimated&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Bank deposits&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,008&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,008&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,996&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,248&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,689&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(32)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(38)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,814&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Government Securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(23)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,553&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(23)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,553&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(34)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53,949&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(60)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,674&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(94)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72,623&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Bank deposits&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,013&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,013&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,526&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,526&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,693&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,693&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="i20c406b0b22b496398fdf16c484061b8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpiMGRjNDIzMzM2YzE0NWYwOWQ4MDQ2NDFhOWViOTNjZC90YWJsZXJhbmdlOmIwZGM0MjMzMzZjMTQ1ZjA5ZDgwNDY0MWE5ZWI5M2NkXzMtMS0xLTEtNDEyOTQ_e7edd020-5dec-4f13-9e62-2656cff801ae"
      unitRef="usd">13000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="i20c406b0b22b496398fdf16c484061b8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpiMGRjNDIzMzM2YzE0NWYwOWQ4MDQ2NDFhOWViOTNjZC90YWJsZXJhbmdlOmIwZGM0MjMzMzZjMTQ1ZjA5ZDgwNDY0MWE5ZWI5M2NkXzMtMy0xLTEtNDEyOTQ_6882a4ec-04f2-4cb3-a065-acc027d62dae"
      unitRef="usd">20008000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="i20c406b0b22b496398fdf16c484061b8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpiMGRjNDIzMzM2YzE0NWYwOWQ4MDQ2NDFhOWViOTNjZC90YWJsZXJhbmdlOmIwZGM0MjMzMzZjMTQ1ZjA5ZDgwNDY0MWE5ZWI5M2NkXzMtNS0xLTEtNDEyOTQ_b28b1f08-f1a6-4124-978c-feb0968195d5"
      unitRef="usd">0</us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="i20c406b0b22b496398fdf16c484061b8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpiMGRjNDIzMzM2YzE0NWYwOWQ4MDQ2NDFhOWViOTNjZC90YWJsZXJhbmdlOmIwZGM0MjMzMzZjMTQ1ZjA5ZDgwNDY0MWE5ZWI5M2NkXzMtNy0xLTEtNDEyOTQ_13c3afcd-cbf6-4a40-a395-8b38303be8f3"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionAccumulatedLoss
      contextRef="i20c406b0b22b496398fdf16c484061b8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpiMGRjNDIzMzM2YzE0NWYwOWQ4MDQ2NDFhOWViOTNjZC90YWJsZXJhbmdlOmIwZGM0MjMzMzZjMTQ1ZjA5ZDgwNDY0MWE5ZWI5M2NkXzMtOS0xLTEtNDEyOTQ_40ddb92e-a1a3-4c4e-a1fe-c84c12f9fb90"
      unitRef="usd">13000</us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="i20c406b0b22b496398fdf16c484061b8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpiMGRjNDIzMzM2YzE0NWYwOWQ4MDQ2NDFhOWViOTNjZC90YWJsZXJhbmdlOmIwZGM0MjMzMzZjMTQ1ZjA5ZDgwNDY0MWE5ZWI5M2NkXzMtMTEtMS0xLTQxMjk0_51e70be7-9dc4-43fc-b7c5-30145cfcee74"
      unitRef="usd">20008000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="id5e251d71959460ba39674664cd46959_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpiMGRjNDIzMzM2YzE0NWYwOWQ4MDQ2NDFhOWViOTNjZC90YWJsZXJhbmdlOmIwZGM0MjMzMzZjMTQ1ZjA5ZDgwNDY0MWE5ZWI5M2NkXzQtMS0xLTEtNDEyOTQ_80d91769-9520-45fa-8c9f-2b57d1f8c6ba"
      unitRef="usd">15000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="id5e251d71959460ba39674664cd46959_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpiMGRjNDIzMzM2YzE0NWYwOWQ4MDQ2NDFhOWViOTNjZC90YWJsZXJhbmdlOmIwZGM0MjMzMzZjMTQ1ZjA5ZDgwNDY0MWE5ZWI5M2NkXzQtMy0xLTEtNDEyOTQ_68dfe41e-0365-4359-bfd3-d2c60bb7176c"
      unitRef="usd">27252000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="id5e251d71959460ba39674664cd46959_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpiMGRjNDIzMzM2YzE0NWYwOWQ4MDQ2NDFhOWViOTNjZC90YWJsZXJhbmdlOmIwZGM0MjMzMzZjMTQ1ZjA5ZDgwNDY0MWE5ZWI5M2NkXzQtNS0xLTEtNDEyOTQ_34bab588-f68a-49e9-ae5a-62ab29ab924a"
      unitRef="usd">5000</us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="id5e251d71959460ba39674664cd46959_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpiMGRjNDIzMzM2YzE0NWYwOWQ4MDQ2NDFhOWViOTNjZC90YWJsZXJhbmdlOmIwZGM0MjMzMzZjMTQ1ZjA5ZDgwNDY0MWE5ZWI5M2NkXzQtNy0xLTEtNDEyOTQ_d730134b-567e-459e-9738-026c3ef2bd4b"
      unitRef="usd">2996000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionAccumulatedLoss
      contextRef="id5e251d71959460ba39674664cd46959_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpiMGRjNDIzMzM2YzE0NWYwOWQ4MDQ2NDFhOWViOTNjZC90YWJsZXJhbmdlOmIwZGM0MjMzMzZjMTQ1ZjA5ZDgwNDY0MWE5ZWI5M2NkXzQtOS0xLTEtNDEyOTQ_c2b2de09-5708-4dbf-8ea9-da8cbca72c8e"
      unitRef="usd">20000</us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="id5e251d71959460ba39674664cd46959_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpiMGRjNDIzMzM2YzE0NWYwOWQ4MDQ2NDFhOWViOTNjZC90YWJsZXJhbmdlOmIwZGM0MjMzMzZjMTQ1ZjA5ZDgwNDY0MWE5ZWI5M2NkXzQtMTEtMS0xLTQxMjk0_b10f5320-ec3a-4f6c-8f51-e2a8c18aa6a6"
      unitRef="usd">30248000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="i057c89a152c14f40b506b184456d7b2b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpiMGRjNDIzMzM2YzE0NWYwOWQ4MDQ2NDFhOWViOTNjZC90YWJsZXJhbmdlOmIwZGM0MjMzMzZjMTQ1ZjA5ZDgwNDY0MWE5ZWI5M2NkXzUtMS0xLTEtNDEyOTQ_28681560-fd6c-4773-9eba-ddd266bf97e1"
      unitRef="usd">6000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="i057c89a152c14f40b506b184456d7b2b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpiMGRjNDIzMzM2YzE0NWYwOWQ4MDQ2NDFhOWViOTNjZC90YWJsZXJhbmdlOmIwZGM0MjMzMzZjMTQ1ZjA5ZDgwNDY0MWE5ZWI5M2NkXzUtMy0xLTEtNDEyOTQ_2a6cbb67-1d5c-4434-a4fc-67dda2cbff10"
      unitRef="usd">6689000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="i057c89a152c14f40b506b184456d7b2b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpiMGRjNDIzMzM2YzE0NWYwOWQ4MDQ2NDFhOWViOTNjZC90YWJsZXJhbmdlOmIwZGM0MjMzMzZjMTQ1ZjA5ZDgwNDY0MWE5ZWI5M2NkXzUtNS0xLTEtNDEyOTQ_7ea67341-694d-4da9-a741-a1288d785a26"
      unitRef="usd">32000</us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="i057c89a152c14f40b506b184456d7b2b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpiMGRjNDIzMzM2YzE0NWYwOWQ4MDQ2NDFhOWViOTNjZC90YWJsZXJhbmdlOmIwZGM0MjMzMzZjMTQ1ZjA5ZDgwNDY0MWE5ZWI5M2NkXzUtNy0xLTEtNDEyOTQ_a59f2d1e-f0ed-4168-a45a-5f85a9749813"
      unitRef="usd">10125000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionAccumulatedLoss
      contextRef="i057c89a152c14f40b506b184456d7b2b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpiMGRjNDIzMzM2YzE0NWYwOWQ4MDQ2NDFhOWViOTNjZC90YWJsZXJhbmdlOmIwZGM0MjMzMzZjMTQ1ZjA5ZDgwNDY0MWE5ZWI5M2NkXzUtOS0xLTEtNDEyOTQ_1ae0887c-9c1d-4f51-9e25-53343f9a2f8d"
      unitRef="usd">38000</us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="i057c89a152c14f40b506b184456d7b2b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpiMGRjNDIzMzM2YzE0NWYwOWQ4MDQ2NDFhOWViOTNjZC90YWJsZXJhbmdlOmIwZGM0MjMzMzZjMTQ1ZjA5ZDgwNDY0MWE5ZWI5M2NkXzUtMTEtMS0xLTQxMjk0_eeca4ed8-09b8-4209-aac1-c3dfa7e309ec"
      unitRef="usd">16814000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="i6fbb980b9e7c4be4bd3c3376bc2bfda4_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpiMGRjNDIzMzM2YzE0NWYwOWQ4MDQ2NDFhOWViOTNjZC90YWJsZXJhbmdlOmIwZGM0MjMzMzZjMTQ1ZjA5ZDgwNDY0MWE5ZWI5M2NkXzYtMS0xLTEtNDQzNzU_7eafee7f-b861-4fe5-a984-0c2492f5ce45"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="i6fbb980b9e7c4be4bd3c3376bc2bfda4_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpiMGRjNDIzMzM2YzE0NWYwOWQ4MDQ2NDFhOWViOTNjZC90YWJsZXJhbmdlOmIwZGM0MjMzMzZjMTQ1ZjA5ZDgwNDY0MWE5ZWI5M2NkXzYtMy0xLTEtNDQzODc_48d57b29-dabd-403e-89db-5220e0db4078"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="i6fbb980b9e7c4be4bd3c3376bc2bfda4_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpiMGRjNDIzMzM2YzE0NWYwOWQ4MDQ2NDFhOWViOTNjZC90YWJsZXJhbmdlOmIwZGM0MjMzMzZjMTQ1ZjA5ZDgwNDY0MWE5ZWI5M2NkXzYtNS0xLTEtNDQ0NjM_4b11ae10-7cdd-46b5-aee2-b057c7a46c6b"
      unitRef="usd">23000</us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="i6fbb980b9e7c4be4bd3c3376bc2bfda4_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpiMGRjNDIzMzM2YzE0NWYwOWQ4MDQ2NDFhOWViOTNjZC90YWJsZXJhbmdlOmIwZGM0MjMzMzZjMTQ1ZjA5ZDgwNDY0MWE5ZWI5M2NkXzYtNy0xLTEtNDQ0ODA_49331253-3d04-4a2e-ae34-beff872eee9b"
      unitRef="usd">5553000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionAccumulatedLoss
      contextRef="i6fbb980b9e7c4be4bd3c3376bc2bfda4_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpiMGRjNDIzMzM2YzE0NWYwOWQ4MDQ2NDFhOWViOTNjZC90YWJsZXJhbmdlOmIwZGM0MjMzMzZjMTQ1ZjA5ZDgwNDY0MWE5ZWI5M2NkXzYtOS0xLTEtNDQ0NzA_53435d57-8971-40dc-8eca-0222bc35e1f5"
      unitRef="usd">23000</us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="i6fbb980b9e7c4be4bd3c3376bc2bfda4_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpiMGRjNDIzMzM2YzE0NWYwOWQ4MDQ2NDFhOWViOTNjZC90YWJsZXJhbmdlOmIwZGM0MjMzMzZjMTQ1ZjA5ZDgwNDY0MWE5ZWI5M2NkXzYtMTEtMS0xLTQ2MjU0_9613a37d-6cd4-40f0-bc6b-6bb37dd3a51c"
      unitRef="usd">5553000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpiMGRjNDIzMzM2YzE0NWYwOWQ4MDQ2NDFhOWViOTNjZC90YWJsZXJhbmdlOmIwZGM0MjMzMzZjMTQ1ZjA5ZDgwNDY0MWE5ZWI5M2NkXzYtMS0xLTEtNDEyOTQ_dffa3987-f89e-4591-a3d5-3d8a0864bdf5"
      unitRef="usd">34000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpiMGRjNDIzMzM2YzE0NWYwOWQ4MDQ2NDFhOWViOTNjZC90YWJsZXJhbmdlOmIwZGM0MjMzMzZjMTQ1ZjA5ZDgwNDY0MWE5ZWI5M2NkXzYtMy0xLTEtNDEyOTQ_2c9820db-270b-4278-add8-9a7ed3e676ad"
      unitRef="usd">53949000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpiMGRjNDIzMzM2YzE0NWYwOWQ4MDQ2NDFhOWViOTNjZC90YWJsZXJhbmdlOmIwZGM0MjMzMzZjMTQ1ZjA5ZDgwNDY0MWE5ZWI5M2NkXzYtNS0xLTEtNDEyOTQ_2b8f6ca0-2ac5-4f77-aa3f-43a74bb8cc80"
      unitRef="usd">60000</us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpiMGRjNDIzMzM2YzE0NWYwOWQ4MDQ2NDFhOWViOTNjZC90YWJsZXJhbmdlOmIwZGM0MjMzMzZjMTQ1ZjA5ZDgwNDY0MWE5ZWI5M2NkXzYtNy0xLTEtNDEyOTQ_020b3833-06ee-43a5-8b6e-eb962174137a"
      unitRef="usd">18674000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionAccumulatedLoss
      contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpiMGRjNDIzMzM2YzE0NWYwOWQ4MDQ2NDFhOWViOTNjZC90YWJsZXJhbmdlOmIwZGM0MjMzMzZjMTQ1ZjA5ZDgwNDY0MWE5ZWI5M2NkXzYtOS0xLTEtNDEyOTQ_41ce7745-1530-4bab-b1a0-df3881510de4"
      unitRef="usd">94000</us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpiMGRjNDIzMzM2YzE0NWYwOWQ4MDQ2NDFhOWViOTNjZC90YWJsZXJhbmdlOmIwZGM0MjMzMzZjMTQ1ZjA5ZDgwNDY0MWE5ZWI5M2NkXzYtMTEtMS0xLTQxMjk0_8308087f-3244-46f1-99e8-74eb9e6bbae4"
      unitRef="usd">72623000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="ib7f6e9d91bc84543b6ae3503d8d78f6b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpiMGRjNDIzMzM2YzE0NWYwOWQ4MDQ2NDFhOWViOTNjZC90YWJsZXJhbmdlOmIwZGM0MjMzMzZjMTQ1ZjA5ZDgwNDY0MWE5ZWI5M2NkXzktMS0xLTEtNDEyOTQ_c2c1448f-fc04-4ba0-9d88-aa20a94d0c25"
      unitRef="usd">1000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="ib7f6e9d91bc84543b6ae3503d8d78f6b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpiMGRjNDIzMzM2YzE0NWYwOWQ4MDQ2NDFhOWViOTNjZC90YWJsZXJhbmdlOmIwZGM0MjMzMzZjMTQ1ZjA5ZDgwNDY0MWE5ZWI5M2NkXzktMy0xLTEtNDEyOTQ_5d016907-c66e-4c48-b302-33b229565bc2"
      unitRef="usd">14013000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="ib7f6e9d91bc84543b6ae3503d8d78f6b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpiMGRjNDIzMzM2YzE0NWYwOWQ4MDQ2NDFhOWViOTNjZC90YWJsZXJhbmdlOmIwZGM0MjMzMzZjMTQ1ZjA5ZDgwNDY0MWE5ZWI5M2NkXzktNS0xLTEtNDEyOTQ_7aa69574-89fe-480b-a24c-56272730a442"
      unitRef="usd">0</us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="ib7f6e9d91bc84543b6ae3503d8d78f6b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpiMGRjNDIzMzM2YzE0NWYwOWQ4MDQ2NDFhOWViOTNjZC90YWJsZXJhbmdlOmIwZGM0MjMzMzZjMTQ1ZjA5ZDgwNDY0MWE5ZWI5M2NkXzktNy0xLTEtNDEyOTQ_17429276-b4e0-4983-b7b5-5cb83b246b0a"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionAccumulatedLoss
      contextRef="ib7f6e9d91bc84543b6ae3503d8d78f6b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpiMGRjNDIzMzM2YzE0NWYwOWQ4MDQ2NDFhOWViOTNjZC90YWJsZXJhbmdlOmIwZGM0MjMzMzZjMTQ1ZjA5ZDgwNDY0MWE5ZWI5M2NkXzktOS0xLTEtNDEyOTQ_cb54dfea-f1f2-42f9-8325-5db14ed7accb"
      unitRef="usd">1000</us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="ib7f6e9d91bc84543b6ae3503d8d78f6b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpiMGRjNDIzMzM2YzE0NWYwOWQ4MDQ2NDFhOWViOTNjZC90YWJsZXJhbmdlOmIwZGM0MjMzMzZjMTQ1ZjA5ZDgwNDY0MWE5ZWI5M2NkXzktMTEtMS0xLTQxMjk0_9826c5cf-cc0d-402f-b199-b44b360d4008"
      unitRef="usd">14013000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="i24d8d13bc1ac4681b103e921e023e7ba_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpiMGRjNDIzMzM2YzE0NWYwOWQ4MDQ2NDFhOWViOTNjZC90YWJsZXJhbmdlOmIwZGM0MjMzMzZjMTQ1ZjA5ZDgwNDY0MWE5ZWI5M2NkXzEwLTEtMS0xLTQ0MzI3_91699d05-20b6-4b53-837e-91073e6d1638"
      unitRef="usd">1000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="i24d8d13bc1ac4681b103e921e023e7ba_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpiMGRjNDIzMzM2YzE0NWYwOWQ4MDQ2NDFhOWViOTNjZC90YWJsZXJhbmdlOmIwZGM0MjMzMzZjMTQ1ZjA5ZDgwNDY0MWE5ZWI5M2NkXzEwLTMtMS0xLTQ0MzM0_66779be7-735d-4ad0-a7a5-57d4ad3aead8"
      unitRef="usd">4526000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="i24d8d13bc1ac4681b103e921e023e7ba_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpiMGRjNDIzMzM2YzE0NWYwOWQ4MDQ2NDFhOWViOTNjZC90YWJsZXJhbmdlOmIwZGM0MjMzMzZjMTQ1ZjA5ZDgwNDY0MWE5ZWI5M2NkXzExLTUtMS0xLTQ2MjUx_d87ba30d-b841-4cb5-a9d4-0df358af9572"
      unitRef="usd">0</us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="i24d8d13bc1ac4681b103e921e023e7ba_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpiMGRjNDIzMzM2YzE0NWYwOWQ4MDQ2NDFhOWViOTNjZC90YWJsZXJhbmdlOmIwZGM0MjMzMzZjMTQ1ZjA5ZDgwNDY0MWE5ZWI5M2NkXzExLTctMS0xLTQ2MjUx_4599cc99-8faf-4bc9-8392-88752cdd895c"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionAccumulatedLoss
      contextRef="i24d8d13bc1ac4681b103e921e023e7ba_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpiMGRjNDIzMzM2YzE0NWYwOWQ4MDQ2NDFhOWViOTNjZC90YWJsZXJhbmdlOmIwZGM0MjMzMzZjMTQ1ZjA5ZDgwNDY0MWE5ZWI5M2NkXzExLTktMS0xLTQ2MjUx_1e5ec187-636a-4ffc-9b87-4e890d98d62d"
      unitRef="usd">1000</us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="i24d8d13bc1ac4681b103e921e023e7ba_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpiMGRjNDIzMzM2YzE0NWYwOWQ4MDQ2NDFhOWViOTNjZC90YWJsZXJhbmdlOmIwZGM0MjMzMzZjMTQ1ZjA5ZDgwNDY0MWE5ZWI5M2NkXzExLTExLTEtMS00NjI1MQ_f37a79e6-58ad-4d88-82c7-362827b3e7e5"
      unitRef="usd">4526000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="i1a14cdb03cd74fd3800f47006e6564e8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpiMGRjNDIzMzM2YzE0NWYwOWQ4MDQ2NDFhOWViOTNjZC90YWJsZXJhbmdlOmIwZGM0MjMzMzZjMTQ1ZjA5ZDgwNDY0MWE5ZWI5M2NkXzEwLTEtMS0xLTQxMjk0_e0b3a938-02f1-4f10-86cf-3aeec4d1229d"
      unitRef="usd">1000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="i1a14cdb03cd74fd3800f47006e6564e8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpiMGRjNDIzMzM2YzE0NWYwOWQ4MDQ2NDFhOWViOTNjZC90YWJsZXJhbmdlOmIwZGM0MjMzMzZjMTQ1ZjA5ZDgwNDY0MWE5ZWI5M2NkXzEwLTMtMS0xLTQxMjk0_19151b1c-5c66-4348-b0dc-6c980d433f9a"
      unitRef="usd">7693000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="i1a14cdb03cd74fd3800f47006e6564e8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpiMGRjNDIzMzM2YzE0NWYwOWQ4MDQ2NDFhOWViOTNjZC90YWJsZXJhbmdlOmIwZGM0MjMzMzZjMTQ1ZjA5ZDgwNDY0MWE5ZWI5M2NkXzEwLTUtMS0xLTQxMjk0_b8d16f70-68ad-4165-94c6-574957262403"
      unitRef="usd">0</us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="i1a14cdb03cd74fd3800f47006e6564e8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpiMGRjNDIzMzM2YzE0NWYwOWQ4MDQ2NDFhOWViOTNjZC90YWJsZXJhbmdlOmIwZGM0MjMzMzZjMTQ1ZjA5ZDgwNDY0MWE5ZWI5M2NkXzEwLTctMS0xLTQxMjk0_f4526c52-32c4-467d-af7c-9a25c41b20ea"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionAccumulatedLoss
      contextRef="i1a14cdb03cd74fd3800f47006e6564e8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpiMGRjNDIzMzM2YzE0NWYwOWQ4MDQ2NDFhOWViOTNjZC90YWJsZXJhbmdlOmIwZGM0MjMzMzZjMTQ1ZjA5ZDgwNDY0MWE5ZWI5M2NkXzEwLTktMS0xLTQxMjk0_6586c2c3-bd4c-475b-81a7-24ddaf70f1d4"
      unitRef="usd">1000</us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="i1a14cdb03cd74fd3800f47006e6564e8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpiMGRjNDIzMzM2YzE0NWYwOWQ4MDQ2NDFhOWViOTNjZC90YWJsZXJhbmdlOmIwZGM0MjMzMzZjMTQ1ZjA5ZDgwNDY0MWE5ZWI5M2NkXzEwLTExLTEtMS00MTI5NA_e4b8ac0b-d467-4d4c-b2eb-eb9864a3b228"
      unitRef="usd">7693000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="i7462d0db8f4248fcb9fd8f1deae439f3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpiMGRjNDIzMzM2YzE0NWYwOWQ4MDQ2NDFhOWViOTNjZC90YWJsZXJhbmdlOmIwZGM0MjMzMzZjMTQ1ZjA5ZDgwNDY0MWE5ZWI5M2NkXzExLTEtMS0xLTQxMjk0_c2af9784-97c2-40fe-b860-b2bb60b96ae1"
      unitRef="usd">3000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="i7462d0db8f4248fcb9fd8f1deae439f3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpiMGRjNDIzMzM2YzE0NWYwOWQ4MDQ2NDFhOWViOTNjZC90YWJsZXJhbmdlOmIwZGM0MjMzMzZjMTQ1ZjA5ZDgwNDY0MWE5ZWI5M2NkXzExLTMtMS0xLTQxMjk0_b627c0e4-4beb-4a50-a9ac-f9515dade750"
      unitRef="usd">26232000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="i7462d0db8f4248fcb9fd8f1deae439f3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpiMGRjNDIzMzM2YzE0NWYwOWQ4MDQ2NDFhOWViOTNjZC90YWJsZXJhbmdlOmIwZGM0MjMzMzZjMTQ1ZjA5ZDgwNDY0MWE5ZWI5M2NkXzExLTUtMS0xLTQxMjk0_e8f5aa3d-b68c-4096-a6fd-81c18753d59b"
      unitRef="usd">0</us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="i7462d0db8f4248fcb9fd8f1deae439f3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpiMGRjNDIzMzM2YzE0NWYwOWQ4MDQ2NDFhOWViOTNjZC90YWJsZXJhbmdlOmIwZGM0MjMzMzZjMTQ1ZjA5ZDgwNDY0MWE5ZWI5M2NkXzExLTctMS0xLTQxMjk0_7367b806-4c67-4f75-9cb2-ce9b053f38c6"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionAccumulatedLoss
      contextRef="i7462d0db8f4248fcb9fd8f1deae439f3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpiMGRjNDIzMzM2YzE0NWYwOWQ4MDQ2NDFhOWViOTNjZC90YWJsZXJhbmdlOmIwZGM0MjMzMzZjMTQ1ZjA5ZDgwNDY0MWE5ZWI5M2NkXzExLTktMS0xLTQxMjk0_9c8cb7e4-1555-4ac2-8246-40500512a077"
      unitRef="usd">3000</us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="i7462d0db8f4248fcb9fd8f1deae439f3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpiMGRjNDIzMzM2YzE0NWYwOWQ4MDQ2NDFhOWViOTNjZC90YWJsZXJhbmdlOmIwZGM0MjMzMzZjMTQ1ZjA5ZDgwNDY0MWE5ZWI5M2NkXzExLTExLTEtMS00MTI5NA_8ef2c925-6254-47c5-8f08-5bfac86b3eb6"
      unitRef="usd">26232000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
      contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90ZXh0cmVnaW9uOjhkMWM4MjU1M2QwNzQ1ODVhMDJmY2U3NDA0ZGE4ZTE5XzEyMTA_b8eb71ce-19bf-4259-970d-11e2551ac250"
      unitRef="position">55</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90ZXh0cmVnaW9uOjhkMWM4MjU1M2QwNzQ1ODVhMDJmY2U3NDA0ZGE4ZTE5XzQxMzY_1b9de7a2-0672-4f13-b866-0b2b90c9f4a2">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Property and equipment are stated at cost and consists of the following (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.498%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lab and office equipment&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,183&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,666&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,983&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,519&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer equipment and software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,056&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1056&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,222&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less accumulated depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,711)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,807)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,511&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,434&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i9f0a5635602742c38606929f85d0bc8e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTphMDcwMTU2YTMyNDA0MjliOTRmNTFhZDFjM2Y4N2U5Mi90YWJsZXJhbmdlOmEwNzAxNTZhMzI0MDQyOWI5NGY1MWFkMWMzZjg3ZTkyXzItMS0xLTEtNDEyOTQ_c61fa836-6b8f-43da-a312-2901c07fba6a"
      unitRef="usd">20183000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i2ef3fe1366ce4c63b1d61301c2c7cbb5_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTphMDcwMTU2YTMyNDA0MjliOTRmNTFhZDFjM2Y4N2U5Mi90YWJsZXJhbmdlOmEwNzAxNTZhMzI0MDQyOWI5NGY1MWFkMWMzZjg3ZTkyXzItMy0xLTEtNDEyOTQ_6c6026fb-a4ed-4eb8-bf18-3018bd46e0aa"
      unitRef="usd">14666000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i9733272dc36042e6ba12faba3f716e92_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTphMDcwMTU2YTMyNDA0MjliOTRmNTFhZDFjM2Y4N2U5Mi90YWJsZXJhbmdlOmEwNzAxNTZhMzI0MDQyOWI5NGY1MWFkMWMzZjg3ZTkyXzMtMS0xLTEtNDEyOTQ_27d77309-0bf8-422f-b3de-ef9970fbd2c6"
      unitRef="usd">7983000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i95f33c3ebaeb4778a9c2db6a6f6bf294_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTphMDcwMTU2YTMyNDA0MjliOTRmNTFhZDFjM2Y4N2U5Mi90YWJsZXJhbmdlOmEwNzAxNTZhMzI0MDQyOWI5NGY1MWFkMWMzZjg3ZTkyXzMtMy0xLTEtNDEyOTQ_168fac8a-0471-4b66-80aa-618b2e8b69fe"
      unitRef="usd">3519000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i4c5205ea5f084dac8c4dea9fdfadee02_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTphMDcwMTU2YTMyNDA0MjliOTRmNTFhZDFjM2Y4N2U5Mi90YWJsZXJhbmdlOmEwNzAxNTZhMzI0MDQyOWI5NGY1MWFkMWMzZjg3ZTkyXzQtMS0xLTEtNDEyOTQ_76616ea2-8b3d-4402-8d87-d638e89cf83c"
      unitRef="usd">1056000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i4a16585689be4389b9863317f3aa3977_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTphMDcwMTU2YTMyNDA0MjliOTRmNTFhZDFjM2Y4N2U5Mi90YWJsZXJhbmdlOmEwNzAxNTZhMzI0MDQyOWI5NGY1MWFkMWMzZjg3ZTkyXzQtMy0xLTEtNDEyOTQ_03268a94-7a4e-4b28-8ec7-c9ac484c8bbc"
      unitRef="usd">1056000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTphMDcwMTU2YTMyNDA0MjliOTRmNTFhZDFjM2Y4N2U5Mi90YWJsZXJhbmdlOmEwNzAxNTZhMzI0MDQyOWI5NGY1MWFkMWMzZjg3ZTkyXzUtMS0xLTEtNDEyOTQ_b593e001-c61e-4d8c-81df-52219d6f5363"
      unitRef="usd">29222000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i7462d0db8f4248fcb9fd8f1deae439f3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTphMDcwMTU2YTMyNDA0MjliOTRmNTFhZDFjM2Y4N2U5Mi90YWJsZXJhbmdlOmEwNzAxNTZhMzI0MDQyOWI5NGY1MWFkMWMzZjg3ZTkyXzUtMy0xLTEtNDEyOTQ_fe6ec001-f314-4157-bec9-de5737f3e4c5"
      unitRef="usd">19241000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTphMDcwMTU2YTMyNDA0MjliOTRmNTFhZDFjM2Y4N2U5Mi90YWJsZXJhbmdlOmEwNzAxNTZhMzI0MDQyOWI5NGY1MWFkMWMzZjg3ZTkyXzYtMS0xLTEtNDEyOTQ_4b5bf506-b684-400e-9ee2-086bca38fd50"
      unitRef="usd">8711000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i7462d0db8f4248fcb9fd8f1deae439f3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTphMDcwMTU2YTMyNDA0MjliOTRmNTFhZDFjM2Y4N2U5Mi90YWJsZXJhbmdlOmEwNzAxNTZhMzI0MDQyOWI5NGY1MWFkMWMzZjg3ZTkyXzYtMy0xLTEtNDEyOTQ_47a2dc4a-7325-46f2-8dbe-231e12560415"
      unitRef="usd">4807000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTphMDcwMTU2YTMyNDA0MjliOTRmNTFhZDFjM2Y4N2U5Mi90YWJsZXJhbmdlOmEwNzAxNTZhMzI0MDQyOWI5NGY1MWFkMWMzZjg3ZTkyXzctMS0xLTEtNDEyOTQ_a91d576b-05e7-4b42-85e8-d4c85a83ebc8"
      unitRef="usd">20511000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i7462d0db8f4248fcb9fd8f1deae439f3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTphMDcwMTU2YTMyNDA0MjliOTRmNTFhZDFjM2Y4N2U5Mi90YWJsZXJhbmdlOmEwNzAxNTZhMzI0MDQyOWI5NGY1MWFkMWMzZjg3ZTkyXzctMy0xLTEtNDEyOTQ_e69b09bf-3497-492b-952f-4db7c590a50f"
      unitRef="usd">14434000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i55156c07b9684b9185860bad3331609a_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90ZXh0cmVnaW9uOjhkMWM4MjU1M2QwNzQ1ODVhMDJmY2U3NDA0ZGE4ZTE5XzIwOTE_ed3dbd98-5770-4859-9d8a-6d49a318c8e3">P10Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:Depreciation
      contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90ZXh0cmVnaW9uOjhkMWM4MjU1M2QwNzQ1ODVhMDJmY2U3NDA0ZGE4ZTE5XzIyNzM_3c0c38da-98c7-4c12-85ea-2473da7da6d8"
      unitRef="usd">3900000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="ib3597315a63d441f8f128abd7ed8840e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90ZXh0cmVnaW9uOjhkMWM4MjU1M2QwNzQ1ODVhMDJmY2U3NDA0ZGE4ZTE5XzIyNzc_70037f7a-ed58-4e36-a151-2c122936b416"
      unitRef="usd">1800000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="ie6c3b69702e9429aaeed46bdb9bbb9c1_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90ZXh0cmVnaW9uOjhkMWM4MjU1M2QwNzQ1ODVhMDJmY2U3NDA0ZGE4ZTE5XzIyODU_d6a6b581-373a-4fb0-8fd1-48b587f55c72"
      unitRef="usd">1500000</us-gaap:Depreciation>
    <us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock
      contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90ZXh0cmVnaW9uOjhkMWM4MjU1M2QwNzQ1ODVhMDJmY2U3NDA0ZGE4ZTE5XzQxNDM_4e29fcf9-5d59-46d1-8fc3-1b86a770ea41">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Goodwill and identifiable intangible assets consist of the following (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.498%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Indefinite-lived intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;181,206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;189,662&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Definite-lived intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Complete technology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;280,617&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;277,740&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Less: Accumulated amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(78,991)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(63,600)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Trade name&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,642&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,642&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Less: Accumulated amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,444)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,312)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Customer relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Less: Accumulated amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(18,267)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15,597)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Contractual relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;362,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;362,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Accumulated amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(36,217)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,243)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total goodwill and other identifiable intangible assets, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;732,246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;784,992&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock>
    <us-gaap:Goodwill
      contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZToyZTNmODAyYWEyM2E0MzlhOGRlZGI4NzExOWE2YWM1ZC90YWJsZXJhbmdlOjJlM2Y4MDJhYTIzYTQzOWE4ZGVkYjg3MTE5YTZhYzVkXzMtMS0xLTEtNDEyOTQ_f9412273-bf18-4595-82c5-0fbcc97b9d22"
      unitRef="usd">181206000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i7462d0db8f4248fcb9fd8f1deae439f3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZToyZTNmODAyYWEyM2E0MzlhOGRlZGI4NzExOWE2YWM1ZC90YWJsZXJhbmdlOjJlM2Y4MDJhYTIzYTQzOWE4ZGVkYjg3MTE5YTZhYzVkXzMtMy0xLTEtNDEyOTQ_8cc641ed-92b1-4e15-a0a8-5ba7da8d23f3"
      unitRef="usd">189662000</us-gaap:Goodwill>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i8dc42c0d5a094b05bae7e120852bb210_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZToyZTNmODAyYWEyM2E0MzlhOGRlZGI4NzExOWE2YWM1ZC90YWJsZXJhbmdlOjJlM2Y4MDJhYTIzYTQzOWE4ZGVkYjg3MTE5YTZhYzVkXzUtMS0xLTEtNDEyOTQ_20403af0-b857-4625-8c27-f50a518f8ef6"
      unitRef="usd">280617000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i6b8810ae90624e1cbd1c4a5c1b42b223_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZToyZTNmODAyYWEyM2E0MzlhOGRlZGI4NzExOWE2YWM1ZC90YWJsZXJhbmdlOjJlM2Y4MDJhYTIzYTQzOWE4ZGVkYjg3MTE5YTZhYzVkXzUtMy0xLTEtNDEyOTQ_e56b3af3-3488-49f8-a6a3-befa05947a3f"
      unitRef="usd">277740000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i8dc42c0d5a094b05bae7e120852bb210_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZToyZTNmODAyYWEyM2E0MzlhOGRlZGI4NzExOWE2YWM1ZC90YWJsZXJhbmdlOjJlM2Y4MDJhYTIzYTQzOWE4ZGVkYjg3MTE5YTZhYzVkXzYtMS0xLTEtNDEyOTQ_07f796c5-ce5a-4e69-a03e-95a90688e51d"
      unitRef="usd">78991000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i6b8810ae90624e1cbd1c4a5c1b42b223_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZToyZTNmODAyYWEyM2E0MzlhOGRlZGI4NzExOWE2YWM1ZC90YWJsZXJhbmdlOjJlM2Y4MDJhYTIzYTQzOWE4ZGVkYjg3MTE5YTZhYzVkXzYtMy0xLTEtNDEyOTQ_435320af-8c50-42e5-a2da-4327055c2fd5"
      unitRef="usd">63600000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="ida5c64ee227a46869554690587da8f25_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZToyZTNmODAyYWEyM2E0MzlhOGRlZGI4NzExOWE2YWM1ZC90YWJsZXJhbmdlOjJlM2Y4MDJhYTIzYTQzOWE4ZGVkYjg3MTE5YTZhYzVkXzctMS0xLTEtNDEyOTQ_824235af-0665-4d19-b999-ec8e6078050b"
      unitRef="usd">2642000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i5e9a6867858343a7a292fb11a532ee7e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZToyZTNmODAyYWEyM2E0MzlhOGRlZGI4NzExOWE2YWM1ZC90YWJsZXJhbmdlOjJlM2Y4MDJhYTIzYTQzOWE4ZGVkYjg3MTE5YTZhYzVkXzctMy0xLTEtNDEyOTQ_8f0ac400-cfad-4bff-ba29-9a9fba896dc8"
      unitRef="usd">2642000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="ida5c64ee227a46869554690587da8f25_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZToyZTNmODAyYWEyM2E0MzlhOGRlZGI4NzExOWE2YWM1ZC90YWJsZXJhbmdlOjJlM2Y4MDJhYTIzYTQzOWE4ZGVkYjg3MTE5YTZhYzVkXzgtMS0xLTEtNDEyOTQ_5305daab-6f34-4f89-93f4-f4501225b142"
      unitRef="usd">1444000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i5e9a6867858343a7a292fb11a532ee7e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZToyZTNmODAyYWEyM2E0MzlhOGRlZGI4NzExOWE2YWM1ZC90YWJsZXJhbmdlOjJlM2Y4MDJhYTIzYTQzOWE4ZGVkYjg3MTE5YTZhYzVkXzgtMy0xLTEtNDEyOTQ_b4581bd0-7c25-411c-989e-4732ab877f13"
      unitRef="usd">1312000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i89bdb805a8644de089fac518b7ea8048_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZToyZTNmODAyYWEyM2E0MzlhOGRlZGI4NzExOWE2YWM1ZC90YWJsZXJhbmdlOjJlM2Y4MDJhYTIzYTQzOWE4ZGVkYjg3MTE5YTZhYzVkXzktMS0xLTEtNDEyOTQ_d454f3ab-0dd9-4a5f-ac3a-0e2318fef8bc"
      unitRef="usd">40700000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i427cd915d4f24352b4c76d892b21bbe5_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZToyZTNmODAyYWEyM2E0MzlhOGRlZGI4NzExOWE2YWM1ZC90YWJsZXJhbmdlOjJlM2Y4MDJhYTIzYTQzOWE4ZGVkYjg3MTE5YTZhYzVkXzktMy0xLTEtNDEyOTQ_f269b578-9c89-4da8-92b1-0632c88da7b0"
      unitRef="usd">40700000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i89bdb805a8644de089fac518b7ea8048_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZToyZTNmODAyYWEyM2E0MzlhOGRlZGI4NzExOWE2YWM1ZC90YWJsZXJhbmdlOjJlM2Y4MDJhYTIzYTQzOWE4ZGVkYjg3MTE5YTZhYzVkXzEwLTEtMS0xLTQxMjk0_a55d4067-b68e-4f88-a068-3391ab3d12c9"
      unitRef="usd">18267000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i427cd915d4f24352b4c76d892b21bbe5_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZToyZTNmODAyYWEyM2E0MzlhOGRlZGI4NzExOWE2YWM1ZC90YWJsZXJhbmdlOjJlM2Y4MDJhYTIzYTQzOWE4ZGVkYjg3MTE5YTZhYzVkXzEwLTMtMS0xLTQxMjk0_61b41ac7-83ba-4b9e-8c8b-7b5f09ab5880"
      unitRef="usd">15597000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="iea59787485c24e82bc3497c81a2ced53_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZToyZTNmODAyYWEyM2E0MzlhOGRlZGI4NzExOWE2YWM1ZC90YWJsZXJhbmdlOjJlM2Y4MDJhYTIzYTQzOWE4ZGVkYjg3MTE5YTZhYzVkXzExLTEtMS0xLTQxMjk0_6713beee-57bb-4233-808b-f1413028e040"
      unitRef="usd">362000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i0aba44ce07e94134b8623377b4bd1f1b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZToyZTNmODAyYWEyM2E0MzlhOGRlZGI4NzExOWE2YWM1ZC90YWJsZXJhbmdlOjJlM2Y4MDJhYTIzYTQzOWE4ZGVkYjg3MTE5YTZhYzVkXzExLTMtMS0xLTQxMjk0_8a9b6c77-b9d1-4901-b6f2-d9615531bd98"
      unitRef="usd">362000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="iea59787485c24e82bc3497c81a2ced53_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZToyZTNmODAyYWEyM2E0MzlhOGRlZGI4NzExOWE2YWM1ZC90YWJsZXJhbmdlOjJlM2Y4MDJhYTIzYTQzOWE4ZGVkYjg3MTE5YTZhYzVkXzEyLTEtMS0xLTQxMjk0_be14784b-ab68-4358-adec-f2f7976ce9ea"
      unitRef="usd">36217000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i0aba44ce07e94134b8623377b4bd1f1b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZToyZTNmODAyYWEyM2E0MzlhOGRlZGI4NzExOWE2YWM1ZC90YWJsZXJhbmdlOjJlM2Y4MDJhYTIzYTQzOWE4ZGVkYjg3MTE5YTZhYzVkXzEyLTMtMS0xLTQxMjk0_c5f8cf43-4729-4980-b489-d921792fdddd"
      unitRef="usd">7243000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetIncludingGoodwill
      contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZToyZTNmODAyYWEyM2E0MzlhOGRlZGI4NzExOWE2YWM1ZC90YWJsZXJhbmdlOjJlM2Y4MDJhYTIzYTQzOWE4ZGVkYjg3MTE5YTZhYzVkXzEzLTEtMS0xLTQxMjk0_a9bc85c5-1d66-4390-be13-3fb98eb12684"
      unitRef="usd">732246000</us-gaap:IntangibleAssetsNetIncludingGoodwill>
    <us-gaap:IntangibleAssetsNetIncludingGoodwill
      contextRef="i7462d0db8f4248fcb9fd8f1deae439f3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZToyZTNmODAyYWEyM2E0MzlhOGRlZGI4NzExOWE2YWM1ZC90YWJsZXJhbmdlOjJlM2Y4MDJhYTIzYTQzOWE4ZGVkYjg3MTE5YTZhYzVkXzEzLTMtMS0xLTQxMjk0_07923f33-7ee9-4cd7-96e7-95499611502d"
      unitRef="usd">784992000</us-gaap:IntangibleAssetsNetIncludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90ZXh0cmVnaW9uOjhkMWM4MjU1M2QwNzQ1ODVhMDJmY2U3NDA0ZGE4ZTE5XzI2MTA_5517544f-6824-403b-8063-977bdbb162d1">P20Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90ZXh0cmVnaW9uOjhkMWM4MjU1M2QwNzQ1ODVhMDJmY2U3NDA0ZGE4ZTE5XzI2Mzg_a020c458-a642-461a-ae2a-01fa25425b2c"
      unitRef="usd">47200000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="ib3597315a63d441f8f128abd7ed8840e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90ZXh0cmVnaW9uOjhkMWM4MjU1M2QwNzQ1ODVhMDJmY2U3NDA0ZGE4ZTE5XzI2NDI_456ec17e-5225-4892-853d-6f796507b8e4"
      unitRef="usd">23400000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="ie6c3b69702e9429aaeed46bdb9bbb9c1_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90ZXh0cmVnaW9uOjhkMWM4MjU1M2QwNzQ1ODVhMDJmY2U3NDA0ZGE4ZTE5XzI2NTA_14ee68ae-35fa-4a6e-88da-adf2d0cf8bea"
      unitRef="usd">16900000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
      contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90ZXh0cmVnaW9uOjhkMWM4MjU1M2QwNzQ1ODVhMDJmY2U3NDA0ZGE4ZTE5XzI4MDc_03c3d4a3-5e0c-422f-8f79-ef48a85e3897"
      unitRef="usd">47000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
      contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90ZXh0cmVnaW9uOjhkMWM4MjU1M2QwNzQ1ODVhMDJmY2U3NDA0ZGE4ZTE5XzI4MDc_4e387351-b417-45aa-892d-c7e9967b61c1"
      unitRef="usd">47000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
      contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90ZXh0cmVnaW9uOjhkMWM4MjU1M2QwNzQ1ODVhMDJmY2U3NDA0ZGE4ZTE5XzI4MDc_8e429b1f-8e04-44cc-b0ad-2728d3f809f3"
      unitRef="usd">47000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
      contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90ZXh0cmVnaW9uOjhkMWM4MjU1M2QwNzQ1ODVhMDJmY2U3NDA0ZGE4ZTE5XzI4MDc_c882f072-4681-43ea-8528-f4525e96111e"
      unitRef="usd">47000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived
      contextRef="ib3597315a63d441f8f128abd7ed8840e_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90ZXh0cmVnaW9uOjhkMWM4MjU1M2QwNzQ1ODVhMDJmY2U3NDA0ZGE4ZTE5XzI4NzQ_2a0077be-1a1f-493d-bc09-19672fea6768"
      unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived
      contextRef="ie6c3b69702e9429aaeed46bdb9bbb9c1_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90ZXh0cmVnaW9uOjhkMWM4MjU1M2QwNzQ1ODVhMDJmY2U3NDA0ZGE4ZTE5XzI4NzQ_7a044a15-9261-48c6-b17f-2b511bf9e5f3"
      unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived
      contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90ZXh0cmVnaW9uOjhkMWM4MjU1M2QwNzQ1ODVhMDJmY2U3NDA0ZGE4ZTE5XzI4NzQ_ae04c644-2e3f-40c7-b440-281c20f7c4bc"
      unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90ZXh0cmVnaW9uOjhkMWM4MjU1M2QwNzQ1ODVhMDJmY2U3NDA0ZGE4ZTE5XzQxMzI_5852e9d0-bc46-4c52-aec3-cfad29f041b7">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accrued liabilities consist of the following (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.498%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Compensation&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,532&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,810&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Professional fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,046&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;977&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amounts owed to former licensees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;630&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;421&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Royalties owed to third parties&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;149&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;693&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Return reserve and customer refunds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,420&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;687&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquisition related liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Subcontractor&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,759&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;733&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Supplier&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;848&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;604&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,579&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,530&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpkMDg3Yjg2OGEzOWM0YzczOGQ4NjgwNTk2MDdiMDQzZS90YWJsZXJhbmdlOmQwODdiODY4YTM5YzRjNzM4ZDg2ODA1OTYwN2IwNDNlXzItMS0xLTEtNDEyOTQ_451aad17-987c-4d2f-b9e1-eb55a62afc19"
      unitRef="usd">6532000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i7462d0db8f4248fcb9fd8f1deae439f3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpkMDg3Yjg2OGEzOWM0YzczOGQ4NjgwNTk2MDdiMDQzZS90YWJsZXJhbmdlOmQwODdiODY4YTM5YzRjNzM4ZDg2ODA1OTYwN2IwNDNlXzItMy0xLTEtNDEyOTQ_b5d5ee79-5d86-4368-9289-4c707a340ed4"
      unitRef="usd">8810000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpkMDg3Yjg2OGEzOWM0YzczOGQ4NjgwNTk2MDdiMDQzZS90YWJsZXJhbmdlOmQwODdiODY4YTM5YzRjNzM4ZDg2ODA1OTYwN2IwNDNlXzMtMS0xLTEtNDEyOTQ_7e733da7-4b92-439d-9640-57d2d030a3f0"
      unitRef="usd">2046000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="i7462d0db8f4248fcb9fd8f1deae439f3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpkMDg3Yjg2OGEzOWM0YzczOGQ4NjgwNTk2MDdiMDQzZS90YWJsZXJhbmdlOmQwODdiODY4YTM5YzRjNzM4ZDg2ODA1OTYwN2IwNDNlXzMtMy0xLTEtNDEyOTQ_134a957d-b2fb-46a2-bc36-420ba3504458"
      unitRef="usd">977000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedSalesCommissionCurrentAndNoncurrent
      contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpkMDg3Yjg2OGEzOWM0YzczOGQ4NjgwNTk2MDdiMDQzZS90YWJsZXJhbmdlOmQwODdiODY4YTM5YzRjNzM4ZDg2ODA1OTYwN2IwNDNlXzQtMS0xLTEtNDEyOTQ_edc69c43-9d1a-4ad9-8d3c-304dbf668543"
      unitRef="usd">630000</us-gaap:AccruedSalesCommissionCurrentAndNoncurrent>
    <us-gaap:AccruedSalesCommissionCurrentAndNoncurrent
      contextRef="i7462d0db8f4248fcb9fd8f1deae439f3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpkMDg3Yjg2OGEzOWM0YzczOGQ4NjgwNTk2MDdiMDQzZS90YWJsZXJhbmdlOmQwODdiODY4YTM5YzRjNzM4ZDg2ODA1OTYwN2IwNDNlXzQtMy0xLTEtNDEyOTQ_535c5c12-2d34-465f-9958-48162fb04b29"
      unitRef="usd">421000</us-gaap:AccruedSalesCommissionCurrentAndNoncurrent>
    <us-gaap:AccruedRoyaltiesCurrentAndNoncurrent
      contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpkMDg3Yjg2OGEzOWM0YzczOGQ4NjgwNTk2MDdiMDQzZS90YWJsZXJhbmdlOmQwODdiODY4YTM5YzRjNzM4ZDg2ODA1OTYwN2IwNDNlXzUtMS0xLTEtNDEyOTQ_9b18f611-2b09-4a68-8582-02abcc4bb974"
      unitRef="usd">149000</us-gaap:AccruedRoyaltiesCurrentAndNoncurrent>
    <us-gaap:AccruedRoyaltiesCurrentAndNoncurrent
      contextRef="i7462d0db8f4248fcb9fd8f1deae439f3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpkMDg3Yjg2OGEzOWM0YzczOGQ4NjgwNTk2MDdiMDQzZS90YWJsZXJhbmdlOmQwODdiODY4YTM5YzRjNzM4ZDg2ODA1OTYwN2IwNDNlXzUtMy0xLTEtNDEyOTQ_d06080b8-be96-4714-9b02-29c8ab44f1d4"
      unitRef="usd">693000</us-gaap:AccruedRoyaltiesCurrentAndNoncurrent>
    <lgnd:AccruedSalesReturns
      contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpkMDg3Yjg2OGEzOWM0YzczOGQ4NjgwNTk2MDdiMDQzZS90YWJsZXJhbmdlOmQwODdiODY4YTM5YzRjNzM4ZDg2ODA1OTYwN2IwNDNlXzYtMS0xLTEtNDEyOTQ_0c5289fe-c2e1-44cd-8c6f-a07ec05b0749"
      unitRef="usd">2420000</lgnd:AccruedSalesReturns>
    <lgnd:AccruedSalesReturns
      contextRef="i7462d0db8f4248fcb9fd8f1deae439f3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpkMDg3Yjg2OGEzOWM0YzczOGQ4NjgwNTk2MDdiMDQzZS90YWJsZXJhbmdlOmQwODdiODY4YTM5YzRjNzM4ZDg2ODA1OTYwN2IwNDNlXzYtMy0xLTEtNDEyOTQ_64eb83b1-c22e-45ad-a7b9-6f227f8e0f53"
      unitRef="usd">687000</lgnd:AccruedSalesReturns>
    <lgnd:AccruedAssetAcquisitionsCurrent
      contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpkMDg3Yjg2OGEzOWM0YzczOGQ4NjgwNTk2MDdiMDQzZS90YWJsZXJhbmdlOmQwODdiODY4YTM5YzRjNzM4ZDg2ODA1OTYwN2IwNDNlXzctMS0xLTEtNDEyOTQ_87489421-4cce-4a6e-b68a-16d3e882fcde"
      unitRef="usd">1000000</lgnd:AccruedAssetAcquisitionsCurrent>
    <lgnd:AccruedAssetAcquisitionsCurrent
      contextRef="i7462d0db8f4248fcb9fd8f1deae439f3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpkMDg3Yjg2OGEzOWM0YzczOGQ4NjgwNTk2MDdiMDQzZS90YWJsZXJhbmdlOmQwODdiODY4YTM5YzRjNzM4ZDg2ODA1OTYwN2IwNDNlXzctMy0xLTEtNDEyOTQ_341dc107-5259-45c7-8cfe-98b2b54cbdb3"
      unitRef="usd">1500000</lgnd:AccruedAssetAcquisitionsCurrent>
    <lgnd:AccruedSubcontractorExpensesCurrent
      contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpkMDg3Yjg2OGEzOWM0YzczOGQ4NjgwNTk2MDdiMDQzZS90YWJsZXJhbmdlOmQwODdiODY4YTM5YzRjNzM4ZDg2ODA1OTYwN2IwNDNlXzgtMS0xLTEtNDEyOTQ_e72db46b-28ca-4919-a860-a9bfc8aefc7c"
      unitRef="usd">1759000</lgnd:AccruedSubcontractorExpensesCurrent>
    <lgnd:AccruedSubcontractorExpensesCurrent
      contextRef="i7462d0db8f4248fcb9fd8f1deae439f3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpkMDg3Yjg2OGEzOWM0YzczOGQ4NjgwNTk2MDdiMDQzZS90YWJsZXJhbmdlOmQwODdiODY4YTM5YzRjNzM4ZDg2ODA1OTYwN2IwNDNlXzgtMy0xLTEtNDEyOTQ_72262c87-618c-41ad-a36d-65f9b0f71708"
      unitRef="usd">733000</lgnd:AccruedSubcontractorExpensesCurrent>
    <lgnd:AccruedSupplierExpensesCurrent
      contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpkMDg3Yjg2OGEzOWM0YzczOGQ4NjgwNTk2MDdiMDQzZS90YWJsZXJhbmdlOmQwODdiODY4YTM5YzRjNzM4ZDg2ODA1OTYwN2IwNDNlXzktMS0xLTEtNDEyOTQ_fe4f0cd3-2945-4dc2-a373-ce4c187e05d2"
      unitRef="usd">848000</lgnd:AccruedSupplierExpensesCurrent>
    <lgnd:AccruedSupplierExpensesCurrent
      contextRef="i7462d0db8f4248fcb9fd8f1deae439f3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpkMDg3Yjg2OGEzOWM0YzczOGQ4NjgwNTk2MDdiMDQzZS90YWJsZXJhbmdlOmQwODdiODY4YTM5YzRjNzM4ZDg2ODA1OTYwN2IwNDNlXzktMy0xLTEtNDEyOTQ_70b5fdf8-026f-43e5-8b1a-2a0888c29fe9"
      unitRef="usd">604000</lgnd:AccruedSupplierExpensesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpkMDg3Yjg2OGEzOWM0YzczOGQ4NjgwNTk2MDdiMDQzZS90YWJsZXJhbmdlOmQwODdiODY4YTM5YzRjNzM4ZDg2ODA1OTYwN2IwNDNlXzEwLTEtMS0xLTQxMjk0_84f21be8-91d3-482c-af65-9789199f5cfc"
      unitRef="usd">2195000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="i7462d0db8f4248fcb9fd8f1deae439f3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpkMDg3Yjg2OGEzOWM0YzczOGQ4NjgwNTk2MDdiMDQzZS90YWJsZXJhbmdlOmQwODdiODY4YTM5YzRjNzM4ZDg2ODA1OTYwN2IwNDNlXzEwLTMtMS0xLTQxMjk0_132f1df1-afca-4ccc-b6e7-ab8e60913044"
      unitRef="usd">4105000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpkMDg3Yjg2OGEzOWM0YzczOGQ4NjgwNTk2MDdiMDQzZS90YWJsZXJhbmdlOmQwODdiODY4YTM5YzRjNzM4ZDg2ODA1OTYwN2IwNDNlXzExLTEtMS0xLTQxMjk0_cead6e29-acf6-40f7-bd52-a5fc33deb0f8"
      unitRef="usd">17579000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i7462d0db8f4248fcb9fd8f1deae439f3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZTpkMDg3Yjg2OGEzOWM0YzczOGQ4NjgwNTk2MDdiMDQzZS90YWJsZXJhbmdlOmQwODdiODY4YTM5YzRjNzM4ZDg2ODA1OTYwN2IwNDNlXzExLTMtMS0xLTQxMjk0_d05df960-0b0e-4b34-a3d5-e02a6da76d00"
      unitRef="usd">18530000</us-gaap:AccruedLiabilitiesCurrent>
    <lgnd:NumberOfContingentValueRightAgreements
      contextRef="i96479b1570dc4ab694a9ba99ff1921f3_I20100131"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90ZXh0cmVnaW9uOjhkMWM4MjU1M2QwNzQ1ODVhMDJmY2U3NDA0ZGE4ZTE5XzIxOTkwMjMyNjA4MDA_aa5f0290-8b86-4b20-b153-001c3a02d27e"
      unitRef="agreement">4</lgnd:NumberOfContingentValueRightAgreements>
    <lgnd:ScheduleofContingentLiabilitiesTableTextBlock
      contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90ZXh0cmVnaW9uOjhkMWM4MjU1M2QwNzQ1ODVhMDJmY2U3NDA0ZGE4ZTE5XzQxMzk_05d8c352-c277-4f9a-b8a3-07bbc7fd4d1e">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes roll-forward of contingent liabilities as of December 2021 and 2020 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.356%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.110%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.964%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.110%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.110%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.110%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.525%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.110%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.115%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Additional Contingent Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Fair Value Adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Repurchases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Fair Value Adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Repurchases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cydex&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;348&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;508&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(50)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(108)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;350&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Metabasis&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,935&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,867)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(247)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,821&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(464)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,357&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Crystal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,659&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,800)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(59)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(800)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Icagen&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(525)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,404&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,050)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,010&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,364&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Pfenex&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;37,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;37,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(37,600)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;xCella&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(720)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;720&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;8,942&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;41,800&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(2,325)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;963&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(247)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;49,133&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(1,820)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(36,242)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;11,071&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</lgnd:ScheduleofContingentLiabilitiesTableTextBlock>
    <lgnd:BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod
      contextRef="i03ae11f17dbd4fa8abcc1e76cf940016_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZToyMTA1OTJhYWFmMGY0OTkyYjkyM2UyNzEzYThlOWRlNy90YWJsZXJhbmdlOjIxMDU5MmFhYWYwZjQ5OTJiOTIzZTI3MTNhOGU5ZGU3XzEtMS0xLTEtNDEyOTQ_cc2165ce-6b4f-4dff-8ed9-73a6c68ac3be"
      unitRef="usd">348000</lgnd:BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod>
    <lgnd:BusinessAcquisitionContingentConsiderationPotentialCashPaymentAdditions
      contextRef="i995ed554220d4c41bec3af6e81ce0850_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZToyMTA1OTJhYWFmMGY0OTkyYjkyM2UyNzEzYThlOWRlNy90YWJsZXJhbmdlOjIxMDU5MmFhYWYwZjQ5OTJiOTIzZTI3MTNhOGU5ZGU3XzEtMi0xLTEtNDEyOTQ_294e6ad3-8613-4fca-99ec-ccd39283d90e"
      unitRef="usd">0</lgnd:BusinessAcquisitionContingentConsiderationPotentialCashPaymentAdditions>
    <lgnd:PaymentsToContingentValueRightHolders
      contextRef="i995ed554220d4c41bec3af6e81ce0850_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZToyMTA1OTJhYWFmMGY0OTkyYjkyM2UyNzEzYThlOWRlNy90YWJsZXJhbmdlOjIxMDU5MmFhYWYwZjQ5OTJiOTIzZTI3MTNhOGU5ZGU3XzEtMy0xLTEtNDEyOTQ_ecab0643-143b-42b3-9cf7-67ebfb1f94aa"
      unitRef="usd">0</lgnd:PaymentsToContingentValueRightHolders>
    <lgnd:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities
      contextRef="i995ed554220d4c41bec3af6e81ce0850_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZToyMTA1OTJhYWFmMGY0OTkyYjkyM2UyNzEzYThlOWRlNy90YWJsZXJhbmdlOjIxMDU5MmFhYWYwZjQ5OTJiOTIzZTI3MTNhOGU5ZGU3XzEtNC0xLTEtNDc2NzI_fb9b549c-787d-45c0-bf34-1b0985502ac7"
      unitRef="usd">160000</lgnd:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities>
    <lgnd:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityRepurchasesContingentLiabilities
      contextRef="i995ed554220d4c41bec3af6e81ce0850_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZToyMTA1OTJhYWFmMGY0OTkyYjkyM2UyNzEzYThlOWRlNy90YWJsZXJhbmdlOjIxMDU5MmFhYWYwZjQ5OTJiOTIzZTI3MTNhOGU5ZGU3XzEtNS0xLTEtNDEyOTQ_b7c93671-4252-4a3b-b351-73eae253322c"
      unitRef="usd">0</lgnd:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityRepurchasesContingentLiabilities>
    <lgnd:BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod
      contextRef="i0526771434af45b0b8fabceb89eea2cc_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZToyMTA1OTJhYWFmMGY0OTkyYjkyM2UyNzEzYThlOWRlNy90YWJsZXJhbmdlOjIxMDU5MmFhYWYwZjQ5OTJiOTIzZTI3MTNhOGU5ZGU3XzEtNi0xLTEtNDEyOTQ_99dde1c3-b43e-4185-8650-ad5dd8693aaf"
      unitRef="usd">508000</lgnd:BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod>
    <lgnd:PaymentsToContingentValueRightHolders
      contextRef="i9a7cf59bd85847db8f5d973e93d748f7_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZToyMTA1OTJhYWFmMGY0OTkyYjkyM2UyNzEzYThlOWRlNy90YWJsZXJhbmdlOjIxMDU5MmFhYWYwZjQ5OTJiOTIzZTI3MTNhOGU5ZGU3XzEtOS0xLTEtNDEyOTQ_e2b77820-6c11-4f25-b6fd-7b5fa4a7cd88"
      unitRef="usd">50000</lgnd:PaymentsToContingentValueRightHolders>
    <lgnd:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities
      contextRef="i9a7cf59bd85847db8f5d973e93d748f7_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZToyMTA1OTJhYWFmMGY0OTkyYjkyM2UyNzEzYThlOWRlNy90YWJsZXJhbmdlOjIxMDU5MmFhYWYwZjQ5OTJiOTIzZTI3MTNhOGU5ZGU3XzEtMTAtMS0xLTQxMjk0_e5a34b2d-3e11-4897-8dc7-93a0229a1355"
      unitRef="usd">-108000</lgnd:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities>
    <lgnd:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityRepurchasesContingentLiabilities
      contextRef="i9a7cf59bd85847db8f5d973e93d748f7_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZToyMTA1OTJhYWFmMGY0OTkyYjkyM2UyNzEzYThlOWRlNy90YWJsZXJhbmdlOjIxMDU5MmFhYWYwZjQ5OTJiOTIzZTI3MTNhOGU5ZGU3XzEtMTEtMS0xLTQxMjk0_41fa0019-364b-492d-8633-4defed73e838"
      unitRef="usd">0</lgnd:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityRepurchasesContingentLiabilities>
    <lgnd:BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod
      contextRef="i460273d884cd42ba9f38e5fa9863bd88_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZToyMTA1OTJhYWFmMGY0OTkyYjkyM2UyNzEzYThlOWRlNy90YWJsZXJhbmdlOjIxMDU5MmFhYWYwZjQ5OTJiOTIzZTI3MTNhOGU5ZGU3XzEtMTItMS0xLTQxMjk0_f0c8c138-d8e0-4134-83f8-379257ea8901"
      unitRef="usd">350000</lgnd:BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod>
    <lgnd:BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod
      contextRef="icaf2965868e840808ef1852e02d910af_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZToyMTA1OTJhYWFmMGY0OTkyYjkyM2UyNzEzYThlOWRlNy90YWJsZXJhbmdlOjIxMDU5MmFhYWYwZjQ5OTJiOTIzZTI3MTNhOGU5ZGU3XzItMS0xLTEtNDEyOTQ_5d705a12-fef5-463e-913b-f2154bff697a"
      unitRef="usd">5935000</lgnd:BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod>
    <lgnd:BusinessAcquisitionContingentConsiderationPotentialCashPaymentAdditions
      contextRef="i9bc6c029e12c43b59b76212780726386_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZToyMTA1OTJhYWFmMGY0OTkyYjkyM2UyNzEzYThlOWRlNy90YWJsZXJhbmdlOjIxMDU5MmFhYWYwZjQ5OTJiOTIzZTI3MTNhOGU5ZGU3XzItMi0xLTEtNDEyOTQ_37af44d3-21c4-4938-9b36-5a03156fe712"
      unitRef="usd">0</lgnd:BusinessAcquisitionContingentConsiderationPotentialCashPaymentAdditions>
    <lgnd:PaymentsToContingentValueRightHolders
      contextRef="i9bc6c029e12c43b59b76212780726386_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZToyMTA1OTJhYWFmMGY0OTkyYjkyM2UyNzEzYThlOWRlNy90YWJsZXJhbmdlOjIxMDU5MmFhYWYwZjQ5OTJiOTIzZTI3MTNhOGU5ZGU3XzItMy0xLTEtNDEyOTQ_dbba6854-8793-48e8-8c4d-308cd751e1fe"
      unitRef="usd">0</lgnd:PaymentsToContingentValueRightHolders>
    <lgnd:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities
      contextRef="i9bc6c029e12c43b59b76212780726386_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZToyMTA1OTJhYWFmMGY0OTkyYjkyM2UyNzEzYThlOWRlNy90YWJsZXJhbmdlOjIxMDU5MmFhYWYwZjQ5OTJiOTIzZTI3MTNhOGU5ZGU3XzItNC0xLTEtNDc2NzI_d8a9bbbe-c9d9-4275-b1c8-844c94df5c6a"
      unitRef="usd">-1867000</lgnd:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities>
    <lgnd:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityRepurchasesContingentLiabilities
      contextRef="i9bc6c029e12c43b59b76212780726386_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZToyMTA1OTJhYWFmMGY0OTkyYjkyM2UyNzEzYThlOWRlNy90YWJsZXJhbmdlOjIxMDU5MmFhYWYwZjQ5OTJiOTIzZTI3MTNhOGU5ZGU3XzItNS0xLTEtNDEyOTQ_cafb045f-56ba-4f9e-99c3-cc4f4a3cce47"
      unitRef="usd">247000</lgnd:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityRepurchasesContingentLiabilities>
    <lgnd:BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod
      contextRef="i2e4b849ac2f8499fb341e31d46f606a1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZToyMTA1OTJhYWFmMGY0OTkyYjkyM2UyNzEzYThlOWRlNy90YWJsZXJhbmdlOjIxMDU5MmFhYWYwZjQ5OTJiOTIzZTI3MTNhOGU5ZGU3XzItNi0xLTEtNDEyOTQ_08f59ab8-689e-42b8-bc01-343bed21766b"
      unitRef="usd">3821000</lgnd:BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod>
    <lgnd:PaymentsToContingentValueRightHolders
      contextRef="i1d4b5cb9bf0848cd952b53016008c4d8_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZToyMTA1OTJhYWFmMGY0OTkyYjkyM2UyNzEzYThlOWRlNy90YWJsZXJhbmdlOjIxMDU5MmFhYWYwZjQ5OTJiOTIzZTI3MTNhOGU5ZGU3XzItOS0xLTEtNDEyOTQ_087f98df-e371-494e-90f6-598d6612597d"
      unitRef="usd">0</lgnd:PaymentsToContingentValueRightHolders>
    <lgnd:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities
      contextRef="i1d4b5cb9bf0848cd952b53016008c4d8_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZToyMTA1OTJhYWFmMGY0OTkyYjkyM2UyNzEzYThlOWRlNy90YWJsZXJhbmdlOjIxMDU5MmFhYWYwZjQ5OTJiOTIzZTI3MTNhOGU5ZGU3XzItMTAtMS0xLTQxMjk0_c141bbf0-6904-4bcc-b710-8d4f23082ba1"
      unitRef="usd">-464000</lgnd:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities>
    <lgnd:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityRepurchasesContingentLiabilities
      contextRef="i1d4b5cb9bf0848cd952b53016008c4d8_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZToyMTA1OTJhYWFmMGY0OTkyYjkyM2UyNzEzYThlOWRlNy90YWJsZXJhbmdlOjIxMDU5MmFhYWYwZjQ5OTJiOTIzZTI3MTNhOGU5ZGU3XzItMTEtMS0xLTQxMjk0_aeda575b-6ff9-45ff-84ba-762ba29775dc"
      unitRef="usd">0</lgnd:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityRepurchasesContingentLiabilities>
    <lgnd:BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod
      contextRef="i83cae13058624959a293b420f9d495a2_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZToyMTA1OTJhYWFmMGY0OTkyYjkyM2UyNzEzYThlOWRlNy90YWJsZXJhbmdlOjIxMDU5MmFhYWYwZjQ5OTJiOTIzZTI3MTNhOGU5ZGU3XzItMTItMS0xLTQxMjk0_aed24ea7-e20b-406b-bd7b-b02620a84b01"
      unitRef="usd">3357000</lgnd:BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod>
    <lgnd:BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod
      contextRef="i9e883877c50c4dd5bae0f1a39a6a0e41_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZToyMTA1OTJhYWFmMGY0OTkyYjkyM2UyNzEzYThlOWRlNy90YWJsZXJhbmdlOjIxMDU5MmFhYWYwZjQ5OTJiOTIzZTI3MTNhOGU5ZGU3XzMtMS0xLTEtNDEyOTQ_02e6aaf3-aabd-4ac6-b27f-4873172e2a7c"
      unitRef="usd">2659000</lgnd:BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod>
    <lgnd:BusinessAcquisitionContingentConsiderationPotentialCashPaymentAdditions
      contextRef="i9b2336871c004529976d951e9de999e1_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZToyMTA1OTJhYWFmMGY0OTkyYjkyM2UyNzEzYThlOWRlNy90YWJsZXJhbmdlOjIxMDU5MmFhYWYwZjQ5OTJiOTIzZTI3MTNhOGU5ZGU3XzMtMi0xLTEtNDEyOTQ_0c00374f-cacc-437e-a6af-6af7fe9715f5"
      unitRef="usd">0</lgnd:BusinessAcquisitionContingentConsiderationPotentialCashPaymentAdditions>
    <lgnd:PaymentsToContingentValueRightHolders
      contextRef="i9b2336871c004529976d951e9de999e1_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZToyMTA1OTJhYWFmMGY0OTkyYjkyM2UyNzEzYThlOWRlNy90YWJsZXJhbmdlOjIxMDU5MmFhYWYwZjQ5OTJiOTIzZTI3MTNhOGU5ZGU3XzMtMy0xLTEtNDEyOTQ_0973edba-34e6-4706-8e34-a14e386cc497"
      unitRef="usd">1800000</lgnd:PaymentsToContingentValueRightHolders>
    <lgnd:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities
      contextRef="i9b2336871c004529976d951e9de999e1_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZToyMTA1OTJhYWFmMGY0OTkyYjkyM2UyNzEzYThlOWRlNy90YWJsZXJhbmdlOjIxMDU5MmFhYWYwZjQ5OTJiOTIzZTI3MTNhOGU5ZGU3XzMtNC0xLTEtNDc2NzI_c986a8f6-9ae3-448b-89fc-f7241ab1ffcc"
      unitRef="usd">-59000</lgnd:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities>
    <lgnd:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityRepurchasesContingentLiabilities
      contextRef="i9b2336871c004529976d951e9de999e1_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZToyMTA1OTJhYWFmMGY0OTkyYjkyM2UyNzEzYThlOWRlNy90YWJsZXJhbmdlOjIxMDU5MmFhYWYwZjQ5OTJiOTIzZTI3MTNhOGU5ZGU3XzMtNS0xLTEtNDEyOTQ_db9ea173-5f34-4c4b-ad4d-e2089671a8b2"
      unitRef="usd">0</lgnd:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityRepurchasesContingentLiabilities>
    <lgnd:BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod
      contextRef="i99bcc19c12eb4a95abbe38b2a1c1ee09_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZToyMTA1OTJhYWFmMGY0OTkyYjkyM2UyNzEzYThlOWRlNy90YWJsZXJhbmdlOjIxMDU5MmFhYWYwZjQ5OTJiOTIzZTI3MTNhOGU5ZGU3XzMtNi0xLTEtNDEyOTQ_e8bbce1b-214b-4290-935d-9c91c50b4805"
      unitRef="usd">800000</lgnd:BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod>
    <lgnd:PaymentsToContingentValueRightHolders
      contextRef="i46955c33e54e4edc9a5157b092d74d96_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZToyMTA1OTJhYWFmMGY0OTkyYjkyM2UyNzEzYThlOWRlNy90YWJsZXJhbmdlOjIxMDU5MmFhYWYwZjQ5OTJiOTIzZTI3MTNhOGU5ZGU3XzMtOS0xLTEtNDEyOTQ_bdd0be41-4704-4f6f-9a02-2857639af993"
      unitRef="usd">0</lgnd:PaymentsToContingentValueRightHolders>
    <lgnd:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities
      contextRef="i46955c33e54e4edc9a5157b092d74d96_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZToyMTA1OTJhYWFmMGY0OTkyYjkyM2UyNzEzYThlOWRlNy90YWJsZXJhbmdlOjIxMDU5MmFhYWYwZjQ5OTJiOTIzZTI3MTNhOGU5ZGU3XzMtMTAtMS0xLTQxMjk0_4454a136-c101-4141-ab9a-e04c00abfcb3"
      unitRef="usd">-800000</lgnd:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities>
    <lgnd:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityRepurchasesContingentLiabilities
      contextRef="i46955c33e54e4edc9a5157b092d74d96_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZToyMTA1OTJhYWFmMGY0OTkyYjkyM2UyNzEzYThlOWRlNy90YWJsZXJhbmdlOjIxMDU5MmFhYWYwZjQ5OTJiOTIzZTI3MTNhOGU5ZGU3XzMtMTEtMS0xLTQxMjk0_d8bacca5-dc3d-435f-bdc7-c57619f04e15"
      unitRef="usd">0</lgnd:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityRepurchasesContingentLiabilities>
    <lgnd:BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod
      contextRef="iaad967943e174bfb992a030f8843e4a9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZToyMTA1OTJhYWFmMGY0OTkyYjkyM2UyNzEzYThlOWRlNy90YWJsZXJhbmdlOjIxMDU5MmFhYWYwZjQ5OTJiOTIzZTI3MTNhOGU5ZGU3XzMtMTItMS0xLTQxMjk0_dc247685-6a60-4028-9407-0c6929a0e26d"
      unitRef="usd">0</lgnd:BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod>
    <lgnd:BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod
      contextRef="if61e02a9d9f3443a954dd4ff1b746645_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZToyMTA1OTJhYWFmMGY0OTkyYjkyM2UyNzEzYThlOWRlNy90YWJsZXJhbmdlOjIxMDU5MmFhYWYwZjQ5OTJiOTIzZTI3MTNhOGU5ZGU3XzQtMS0xLTEtNDEyOTQ_4e9d0c0d-f0dc-4121-9b21-1c3f3c6cb395"
      unitRef="usd">0</lgnd:BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod>
    <lgnd:BusinessAcquisitionContingentConsiderationPotentialCashPaymentAdditions
      contextRef="idcfaeb9f6dcd4e36923251345eeb6ca6_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZToyMTA1OTJhYWFmMGY0OTkyYjkyM2UyNzEzYThlOWRlNy90YWJsZXJhbmdlOjIxMDU5MmFhYWYwZjQ5OTJiOTIzZTI3MTNhOGU5ZGU3XzQtMi0xLTEtNDEyOTQ_ae1e4a1a-77d5-4d3f-ae77-f39dcc4a8462"
      unitRef="usd">4800000</lgnd:BusinessAcquisitionContingentConsiderationPotentialCashPaymentAdditions>
    <lgnd:PaymentsToContingentValueRightHolders
      contextRef="idcfaeb9f6dcd4e36923251345eeb6ca6_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZToyMTA1OTJhYWFmMGY0OTkyYjkyM2UyNzEzYThlOWRlNy90YWJsZXJhbmdlOjIxMDU5MmFhYWYwZjQ5OTJiOTIzZTI3MTNhOGU5ZGU3XzQtMy0xLTEtNDEyOTQ_c098db18-9469-4c81-b199-3cd504a39b1c"
      unitRef="usd">525000</lgnd:PaymentsToContingentValueRightHolders>
    <lgnd:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities
      contextRef="idcfaeb9f6dcd4e36923251345eeb6ca6_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZToyMTA1OTJhYWFmMGY0OTkyYjkyM2UyNzEzYThlOWRlNy90YWJsZXJhbmdlOjIxMDU5MmFhYWYwZjQ5OTJiOTIzZTI3MTNhOGU5ZGU3XzQtNC0xLTEtNDc2NzI_1ad824be-12d4-4dd1-82cc-a4a63697f378"
      unitRef="usd">2129000</lgnd:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities>
    <lgnd:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityRepurchasesContingentLiabilities
      contextRef="idcfaeb9f6dcd4e36923251345eeb6ca6_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZToyMTA1OTJhYWFmMGY0OTkyYjkyM2UyNzEzYThlOWRlNy90YWJsZXJhbmdlOjIxMDU5MmFhYWYwZjQ5OTJiOTIzZTI3MTNhOGU5ZGU3XzQtNS0xLTEtNDc2ODY_ab387270-5c51-4500-8693-c8e8e5fe6c64"
      unitRef="usd">0</lgnd:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityRepurchasesContingentLiabilities>
    <lgnd:BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod
      contextRef="i3fbebdcfd15e4645b3afda1206ded002_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZToyMTA1OTJhYWFmMGY0OTkyYjkyM2UyNzEzYThlOWRlNy90YWJsZXJhbmdlOjIxMDU5MmFhYWYwZjQ5OTJiOTIzZTI3MTNhOGU5ZGU3XzQtNi0xLTEtNDEyOTQ_caee7659-8bce-4f50-9162-e82f3c869510"
      unitRef="usd">6404000</lgnd:BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod>
    <lgnd:PaymentsToContingentValueRightHolders
      contextRef="i187c5df306a349e38267335b0f796d41_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZToyMTA1OTJhYWFmMGY0OTkyYjkyM2UyNzEzYThlOWRlNy90YWJsZXJhbmdlOjIxMDU5MmFhYWYwZjQ5OTJiOTIzZTI3MTNhOGU5ZGU3XzQtOS0xLTEtNDEyOTQ_3e3505d7-eb6f-4f3a-b1b3-b4e4c179161a"
      unitRef="usd">1050000</lgnd:PaymentsToContingentValueRightHolders>
    <lgnd:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities
      contextRef="i187c5df306a349e38267335b0f796d41_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZToyMTA1OTJhYWFmMGY0OTkyYjkyM2UyNzEzYThlOWRlNy90YWJsZXJhbmdlOjIxMDU5MmFhYWYwZjQ5OTJiOTIzZTI3MTNhOGU5ZGU3XzQtMTAtMS0xLTQxMjk0_52bc5387-cc13-4ca0-8ebb-2f8e54f49946"
      unitRef="usd">2010000</lgnd:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities>
    <lgnd:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityRepurchasesContingentLiabilities
      contextRef="i187c5df306a349e38267335b0f796d41_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZToyMTA1OTJhYWFmMGY0OTkyYjkyM2UyNzEzYThlOWRlNy90YWJsZXJhbmdlOjIxMDU5MmFhYWYwZjQ5OTJiOTIzZTI3MTNhOGU5ZGU3XzQtMTEtMS0xLTQxMjk0_258ca4f9-3acc-45ca-847a-1e3b822a7b2c"
      unitRef="usd">0</lgnd:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityRepurchasesContingentLiabilities>
    <lgnd:BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod
      contextRef="i7fb9df0f2e264716b9f5ee2e301fba56_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZToyMTA1OTJhYWFmMGY0OTkyYjkyM2UyNzEzYThlOWRlNy90YWJsZXJhbmdlOjIxMDU5MmFhYWYwZjQ5OTJiOTIzZTI3MTNhOGU5ZGU3XzQtMTItMS0xLTQxMjk0_b1c88dd2-8701-4d9b-94a1-3b968540c61d"
      unitRef="usd">7364000</lgnd:BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod>
    <lgnd:BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod
      contextRef="i9c2bd0e95a2b4600bd5178475b6ab429_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZToyMTA1OTJhYWFmMGY0OTkyYjkyM2UyNzEzYThlOWRlNy90YWJsZXJhbmdlOjIxMDU5MmFhYWYwZjQ5OTJiOTIzZTI3MTNhOGU5ZGU3XzUtMS0xLTEtNDEyOTQ_6718cd01-4d5e-469e-8630-962f98f01176"
      unitRef="usd">0</lgnd:BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod>
    <lgnd:BusinessAcquisitionContingentConsiderationPotentialCashPaymentAdditions
      contextRef="i81ce7b0c06a94e61a7d245d6544346aa_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZToyMTA1OTJhYWFmMGY0OTkyYjkyM2UyNzEzYThlOWRlNy90YWJsZXJhbmdlOjIxMDU5MmFhYWYwZjQ5OTJiOTIzZTI3MTNhOGU5ZGU3XzUtMi0xLTEtNDEyOTQ_83d7205f-8b18-40e7-9db7-cba6d767bd40"
      unitRef="usd">37000000</lgnd:BusinessAcquisitionContingentConsiderationPotentialCashPaymentAdditions>
    <lgnd:PaymentsToContingentValueRightHolders
      contextRef="i81ce7b0c06a94e61a7d245d6544346aa_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZToyMTA1OTJhYWFmMGY0OTkyYjkyM2UyNzEzYThlOWRlNy90YWJsZXJhbmdlOjIxMDU5MmFhYWYwZjQ5OTJiOTIzZTI3MTNhOGU5ZGU3XzUtMy0xLTEtNDEyOTQ_0789fa4c-3a71-429b-b7de-c1275324595d"
      unitRef="usd">0</lgnd:PaymentsToContingentValueRightHolders>
    <lgnd:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities
      contextRef="i81ce7b0c06a94e61a7d245d6544346aa_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZToyMTA1OTJhYWFmMGY0OTkyYjkyM2UyNzEzYThlOWRlNy90YWJsZXJhbmdlOjIxMDU5MmFhYWYwZjQ5OTJiOTIzZTI3MTNhOGU5ZGU3XzUtNC0xLTEtNDc2NzI_3409bdc1-4a0d-4b30-a201-ea78f81d6052"
      unitRef="usd">600000</lgnd:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities>
    <lgnd:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityRepurchasesContingentLiabilities
      contextRef="i81ce7b0c06a94e61a7d245d6544346aa_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZToyMTA1OTJhYWFmMGY0OTkyYjkyM2UyNzEzYThlOWRlNy90YWJsZXJhbmdlOjIxMDU5MmFhYWYwZjQ5OTJiOTIzZTI3MTNhOGU5ZGU3XzUtNS0xLTEtNDc2ODY_985a9f10-2912-4341-a476-3322c6390951"
      unitRef="usd">0</lgnd:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityRepurchasesContingentLiabilities>
    <lgnd:BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod
      contextRef="i2e80589fd36648dfa6f6d8fa79c9c970_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZToyMTA1OTJhYWFmMGY0OTkyYjkyM2UyNzEzYThlOWRlNy90YWJsZXJhbmdlOjIxMDU5MmFhYWYwZjQ5OTJiOTIzZTI3MTNhOGU5ZGU3XzUtNi0xLTEtNDEyOTQ_a07096eb-bdc5-4ae7-853e-809f216dac83"
      unitRef="usd">37600000</lgnd:BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod>
    <lgnd:PaymentsToContingentValueRightHolders
      contextRef="i88f2f47e22764022b5dec2243aa219c7_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZToyMTA1OTJhYWFmMGY0OTkyYjkyM2UyNzEzYThlOWRlNy90YWJsZXJhbmdlOjIxMDU5MmFhYWYwZjQ5OTJiOTIzZTI3MTNhOGU5ZGU3XzUtOS0xLTEtNDEyOTQ_98d9be17-0361-4dee-982d-68703c782d62"
      unitRef="usd">0</lgnd:PaymentsToContingentValueRightHolders>
    <lgnd:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities
      contextRef="i88f2f47e22764022b5dec2243aa219c7_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZToyMTA1OTJhYWFmMGY0OTkyYjkyM2UyNzEzYThlOWRlNy90YWJsZXJhbmdlOjIxMDU5MmFhYWYwZjQ5OTJiOTIzZTI3MTNhOGU5ZGU3XzUtMTAtMS0xLTQxMjk0_4293a07d-1063-4d23-923b-7eb887769129"
      unitRef="usd">-37600000</lgnd:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities>
    <lgnd:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityRepurchasesContingentLiabilities
      contextRef="i88f2f47e22764022b5dec2243aa219c7_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZToyMTA1OTJhYWFmMGY0OTkyYjkyM2UyNzEzYThlOWRlNy90YWJsZXJhbmdlOjIxMDU5MmFhYWYwZjQ5OTJiOTIzZTI3MTNhOGU5ZGU3XzUtMTEtMS0xLTQxMjk0_00c7dff7-2405-452e-978f-ec696bc32f71"
      unitRef="usd">0</lgnd:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityRepurchasesContingentLiabilities>
    <lgnd:BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod
      contextRef="ida7de17e10b54528aa29a691195fafa4_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZToyMTA1OTJhYWFmMGY0OTkyYjkyM2UyNzEzYThlOWRlNy90YWJsZXJhbmdlOjIxMDU5MmFhYWYwZjQ5OTJiOTIzZTI3MTNhOGU5ZGU3XzUtMTItMS0xLTQxMjk0_4ce5a35a-a643-4ee9-86ad-a70e85e9ab29"
      unitRef="usd">0</lgnd:BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod>
    <lgnd:BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod
      contextRef="i017d8efa6ba94abf99a9dc5f29b93ac6_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZToyMTA1OTJhYWFmMGY0OTkyYjkyM2UyNzEzYThlOWRlNy90YWJsZXJhbmdlOjIxMDU5MmFhYWYwZjQ5OTJiOTIzZTI3MTNhOGU5ZGU3XzYtMS0xLTEtNTM3OTk_c18ae7cd-c4d2-4b98-8eb7-a6b1007dd4e1"
      unitRef="usd">0</lgnd:BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod>
    <lgnd:BusinessAcquisitionContingentConsiderationPotentialCashPaymentAdditions
      contextRef="id1b889a729444f17b1b5cebb42dc2471_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZToyMTA1OTJhYWFmMGY0OTkyYjkyM2UyNzEzYThlOWRlNy90YWJsZXJhbmdlOjIxMDU5MmFhYWYwZjQ5OTJiOTIzZTI3MTNhOGU5ZGU3XzYtMi0xLTEtNTM3OTk_21600bb3-9f51-4539-b600-434b93716218"
      unitRef="usd">0</lgnd:BusinessAcquisitionContingentConsiderationPotentialCashPaymentAdditions>
    <lgnd:PaymentsToContingentValueRightHolders
      contextRef="id1b889a729444f17b1b5cebb42dc2471_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZToyMTA1OTJhYWFmMGY0OTkyYjkyM2UyNzEzYThlOWRlNy90YWJsZXJhbmdlOjIxMDU5MmFhYWYwZjQ5OTJiOTIzZTI3MTNhOGU5ZGU3XzYtMy0xLTEtNTM3OTk_fe685cb3-e876-451e-8a61-ef61a261b7a0"
      unitRef="usd">0</lgnd:PaymentsToContingentValueRightHolders>
    <lgnd:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities
      contextRef="id1b889a729444f17b1b5cebb42dc2471_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZToyMTA1OTJhYWFmMGY0OTkyYjkyM2UyNzEzYThlOWRlNy90YWJsZXJhbmdlOjIxMDU5MmFhYWYwZjQ5OTJiOTIzZTI3MTNhOGU5ZGU3XzYtNC0xLTEtNTM3OTk_8d6321c2-b026-4be0-9fd4-9d05818837ac"
      unitRef="usd">0</lgnd:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities>
    <lgnd:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityRepurchasesContingentLiabilities
      contextRef="id1b889a729444f17b1b5cebb42dc2471_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZToyMTA1OTJhYWFmMGY0OTkyYjkyM2UyNzEzYThlOWRlNy90YWJsZXJhbmdlOjIxMDU5MmFhYWYwZjQ5OTJiOTIzZTI3MTNhOGU5ZGU3XzYtNS0xLTEtNTM3OTk_4183e629-3436-4f80-9ef0-32883b9299cb"
      unitRef="usd">0</lgnd:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityRepurchasesContingentLiabilities>
    <lgnd:BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod
      contextRef="if9bfbbb794834d7fba1e6252029a297d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZToyMTA1OTJhYWFmMGY0OTkyYjkyM2UyNzEzYThlOWRlNy90YWJsZXJhbmdlOjIxMDU5MmFhYWYwZjQ5OTJiOTIzZTI3MTNhOGU5ZGU3XzYtNi0xLTEtNTM3OTk_2e7712fb-a67f-41bf-839e-62fe00ec0010"
      unitRef="usd">0</lgnd:BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod>
    <lgnd:PaymentsToContingentValueRightHolders
      contextRef="ic3f66dd3dd704775a2c678c7d07ce665_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZToyMTA1OTJhYWFmMGY0OTkyYjkyM2UyNzEzYThlOWRlNy90YWJsZXJhbmdlOjIxMDU5MmFhYWYwZjQ5OTJiOTIzZTI3MTNhOGU5ZGU3XzYtOS0xLTEtNTM1NTY_bca42596-7211-4d04-851f-7f1564b44e07"
      unitRef="usd">720000</lgnd:PaymentsToContingentValueRightHolders>
    <lgnd:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities
      contextRef="ic3f66dd3dd704775a2c678c7d07ce665_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZToyMTA1OTJhYWFmMGY0OTkyYjkyM2UyNzEzYThlOWRlNy90YWJsZXJhbmdlOjIxMDU5MmFhYWYwZjQ5OTJiOTIzZTI3MTNhOGU5ZGU3XzYtMTAtMS0xLTUzNTYy_52dada59-c243-4622-9bbc-570bf022b44d"
      unitRef="usd">720000</lgnd:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities>
    <lgnd:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityRepurchasesContingentLiabilities
      contextRef="ic3f66dd3dd704775a2c678c7d07ce665_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZToyMTA1OTJhYWFmMGY0OTkyYjkyM2UyNzEzYThlOWRlNy90YWJsZXJhbmdlOjIxMDU5MmFhYWYwZjQ5OTJiOTIzZTI3MTNhOGU5ZGU3XzYtMTEtMS0xLTUzNzk5_bab32006-408e-4985-8d83-543d70b19c60"
      unitRef="usd">0</lgnd:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityRepurchasesContingentLiabilities>
    <lgnd:BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod
      contextRef="i9eeb792ea9ad40c3915226866d3115db_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZToyMTA1OTJhYWFmMGY0OTkyYjkyM2UyNzEzYThlOWRlNy90YWJsZXJhbmdlOjIxMDU5MmFhYWYwZjQ5OTJiOTIzZTI3MTNhOGU5ZGU3XzYtMTItMS0xLTUzNzk5_fac26523-a228-4886-a281-459788d21c57"
      unitRef="usd">0</lgnd:BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod>
    <lgnd:BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod
      contextRef="ida3ec05a32644c2db1bb9f71f76c567f_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZToyMTA1OTJhYWFmMGY0OTkyYjkyM2UyNzEzYThlOWRlNy90YWJsZXJhbmdlOjIxMDU5MmFhYWYwZjQ5OTJiOTIzZTI3MTNhOGU5ZGU3XzYtMS0xLTEtNDEyOTQ_382f9b54-523d-4573-b288-a1a373431b70"
      unitRef="usd">8942000</lgnd:BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod>
    <lgnd:BusinessAcquisitionContingentConsiderationPotentialCashPaymentAdditions
      contextRef="ib3597315a63d441f8f128abd7ed8840e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZToyMTA1OTJhYWFmMGY0OTkyYjkyM2UyNzEzYThlOWRlNy90YWJsZXJhbmdlOjIxMDU5MmFhYWYwZjQ5OTJiOTIzZTI3MTNhOGU5ZGU3XzYtMi0xLTEtNDEyOTQ_3357505a-c8a3-4078-bc03-c20395d5c7cb"
      unitRef="usd">41800000</lgnd:BusinessAcquisitionContingentConsiderationPotentialCashPaymentAdditions>
    <lgnd:PaymentsToContingentValueRightHolders
      contextRef="ib3597315a63d441f8f128abd7ed8840e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZToyMTA1OTJhYWFmMGY0OTkyYjkyM2UyNzEzYThlOWRlNy90YWJsZXJhbmdlOjIxMDU5MmFhYWYwZjQ5OTJiOTIzZTI3MTNhOGU5ZGU3XzYtMy0xLTEtNDEyOTQ_e0a98de8-7b3b-4cab-99c1-01a782c04566"
      unitRef="usd">2325000</lgnd:PaymentsToContingentValueRightHolders>
    <lgnd:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities
      contextRef="ib3597315a63d441f8f128abd7ed8840e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZToyMTA1OTJhYWFmMGY0OTkyYjkyM2UyNzEzYThlOWRlNy90YWJsZXJhbmdlOjIxMDU5MmFhYWYwZjQ5OTJiOTIzZTI3MTNhOGU5ZGU3XzYtNC0xLTEtNDg2NjI_797857aa-869f-45ff-a8bb-0d10298087fa"
      unitRef="usd">963000</lgnd:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities>
    <lgnd:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityRepurchasesContingentLiabilities
      contextRef="ib3597315a63d441f8f128abd7ed8840e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZToyMTA1OTJhYWFmMGY0OTkyYjkyM2UyNzEzYThlOWRlNy90YWJsZXJhbmdlOjIxMDU5MmFhYWYwZjQ5OTJiOTIzZTI3MTNhOGU5ZGU3XzYtNS0xLTEtNDEyOTQ_34848523-faee-4406-9ab4-efd6ad47a08c"
      unitRef="usd">247000</lgnd:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityRepurchasesContingentLiabilities>
    <lgnd:BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod
      contextRef="i7462d0db8f4248fcb9fd8f1deae439f3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZToyMTA1OTJhYWFmMGY0OTkyYjkyM2UyNzEzYThlOWRlNy90YWJsZXJhbmdlOjIxMDU5MmFhYWYwZjQ5OTJiOTIzZTI3MTNhOGU5ZGU3XzYtNi0xLTEtNDEyOTQ_91ac623a-778a-4527-9406-0b9b54b73b68"
      unitRef="usd">49133000</lgnd:BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod>
    <lgnd:PaymentsToContingentValueRightHolders
      contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZToyMTA1OTJhYWFmMGY0OTkyYjkyM2UyNzEzYThlOWRlNy90YWJsZXJhbmdlOjIxMDU5MmFhYWYwZjQ5OTJiOTIzZTI3MTNhOGU5ZGU3XzYtOS0xLTEtNDEyOTQ_0f113caf-13d3-4652-9bcc-eba20194e435"
      unitRef="usd">1820000</lgnd:PaymentsToContingentValueRightHolders>
    <lgnd:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities
      contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZToyMTA1OTJhYWFmMGY0OTkyYjkyM2UyNzEzYThlOWRlNy90YWJsZXJhbmdlOjIxMDU5MmFhYWYwZjQ5OTJiOTIzZTI3MTNhOGU5ZGU3XzYtMTAtMS0xLTQxMjk0_8eb53edd-b395-4f0d-ae84-9046a92a6ab2"
      unitRef="usd">-36242000</lgnd:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities>
    <lgnd:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityRepurchasesContingentLiabilities
      contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZToyMTA1OTJhYWFmMGY0OTkyYjkyM2UyNzEzYThlOWRlNy90YWJsZXJhbmdlOjIxMDU5MmFhYWYwZjQ5OTJiOTIzZTI3MTNhOGU5ZGU3XzYtMTEtMS0xLTQxMjk0_a62dbb14-22ed-4280-8d46-2b4b3a0432cb"
      unitRef="usd">0</lgnd:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityRepurchasesContingentLiabilities>
    <lgnd:BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod
      contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMDkvZnJhZzo4ZDFjODI1NTNkMDc0NTg1YTAyZmNlNzQwNGRhOGUxOS90YWJsZToyMTA1OTJhYWFmMGY0OTkyYjkyM2UyNzEzYThlOWRlNy90YWJsZXJhbmdlOjIxMDU5MmFhYWYwZjQ5OTJiOTIzZTI3MTNhOGU5ZGU3XzYtMTItMS0xLTQxMjk0_65065cd3-47f9-4acd-8130-374e9de1a4ce"
      unitRef="usd">11071000</lgnd:BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90ZXh0cmVnaW9uOjk1MzhkNjI5YTc4YTQ4ZmY4NmJhMjZmMzlkMjRiMWI5XzM2MTI_7d6f550d-c30f-4d31-b23e-876d25facbc5">Stockholders&#x2019; Equity&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Share-based Compensation Expense&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes non-cash share-based compensation expense (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.002%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.043%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.043%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.046%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Share-based compensation expense as a component of:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,436&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,497&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,641&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,347&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,230&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,874&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38,783&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,727&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,515&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock Plans&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2020, our 2002 Stock Incentive Plan was amended to increase the number of shares available for issuance by 1.1 million shares. As of December&#160;31, 2021, there were 0.7 million shares available for future option grants or direct issuance under the Amended 2002 Plan.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Following is a summary of our stock option plan activity and related information:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.120%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.244%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Exercise&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Price&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Remaining&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Contractual&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Term in&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Intrinsic&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Value&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at January&#160;1, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,736,304&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66.71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.47&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;125,858&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;338,617&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;116.69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(112,011)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23.65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,531)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;139.37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,956,379&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77.54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.45&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72,002&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable at December&#160;31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,454,726&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61.82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.42&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70,345&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options vested and expected to vest as of December&#160;31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,956,379&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77.54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.45&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72,002&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;806,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92.93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(156,845)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(44,012)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91.30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,561,822&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85.59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.09&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59,033&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable at December&#160;31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,611,830&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76.05&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.54&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53,286&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options vested and expected to vest as of December&#160;31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,561,822&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85.59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.09&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59,033&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;393,589&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;159.12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(619,731)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54.28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(136,082)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110.83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2021 &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,199,598&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;106.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.34&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;113,302&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable at December&#160;31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,391,952&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;98.16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.12&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80,849&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options vested and expected to vest as of December&#160;31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,199,598&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;106.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.34&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;113,302&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:24pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted-average grant-date fair value of all stock options granted during 2021, 2020 and 2019 was $80.08, $41.39 and $48.65 per share, respectively. The total intrinsic value of all options exercised during 2021, 2020 and 2019 was approximately $77.3 million, $11.9 million and $10.4 million, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash received from options exercised, net of fees paid, in 2021, 2020 and 2019 was $33.0 million, $2.5 million and $2.6 million, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Following is a further breakdown of the options outstanding as of December&#160;31, 2021:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:30.040%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.057%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.057%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.057%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.057%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.212%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Range of exercise prices&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Options&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;outstanding&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;remaining&#160; life&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;in&#160;years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted&#160;average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;exercise price&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Options&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;exercisable&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted&#160;average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;exercise&#160;price&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$12.53-$56.26&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;253,824&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.94&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37.55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;239,824&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38.90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$67.53-$74.42&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;278,281&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.04&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;217,587&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73.17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$82.90-$95.35&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;159,988&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.06&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;86.11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;132,963&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;86.24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$95.68&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;266,263&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.12&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;95.68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;109,154&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;95.68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$98.20-$100.38&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;294,772&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.33&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;99.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;160,120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;99.79&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$101.07-$117.58&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;159,204&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.45&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;111.26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;99,488&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;111.18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$117.97&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;237,292&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.12&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117.97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;158,958&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117.97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$119.08-$159.01&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;299,585&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.00&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;149.40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;205,098&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;152.50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$159.81-$171.28&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,881&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.51&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;166.28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,828&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;165.62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$177.50-$195.91&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;243,508&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.91&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;178.62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62,932&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;181.84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,199,598&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.34&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;106.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,391,952&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;98.16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The assumptions used for the specified reporting periods and the resulting estimates of weighted-average grant date fair value per share of options granted:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.538%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:52.609%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.440%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.986%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.440%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.541%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.440%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="18" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.4%-1.2%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2%-1.4%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.4%-2.6%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47%-63%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47%-71%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40%-49%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.7 to 6.3 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.7 to 5.1 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.6 to 5.9 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2021, there was $40.7 million of total unrecognized compensation cost related to non-vested stock options.  That cost is expected to be recognized over a weighted average period of 2.4 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:14pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Restricted Stock Activity&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a summary of our restricted stock activity and related information:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:69.929%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.458%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.578%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" rowspan="2" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Grant&#160;Date Fair&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="12" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at January 1, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;132,273&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;130.63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;118,498&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;115.90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(102,846)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;121.55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(666)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;134.36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December&#160;31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;147,259&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;125.11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;111,306&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89.73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(52,363)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;121.69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December&#160;31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;206,202&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;106.88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;167,292&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;169.63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(98,501)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;125.59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,850)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;141.85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December&#160;31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;264,143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;138.21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2021, unrecognized compensation cost related to non-vested stock awards amounted to $20.6&#160;million. That cost is expected to be recognized over a weighted average period of 1.6 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Employee Stock Purchase Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2021, 44,360 shares of our common stock are available for future issuance under the Amended Employee Stock Purchase Plan, or ESPP. The ESPP permits eligible employees to purchase up to 1,250 shares of Ligand common stock per calendar year at a discount through payroll deductions. The price at which stock is purchased under the ESPP is equal to 85% of the fair market value of the common stock on the first of a six month offering period or purchase date, whichever is lower. There were 8,448, 6,455 and 4,745 shares issued under the ESPP in 2021, 2020 and 2019, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Share Repurchases &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On September 11, 2019, our Board of Directors approved a stock repurchase program authorizing the repurchase of up to $500.0 million of our common stock from time to time over the next three years. We expect to acquire shares primarily through open-market transactions and have entered into a Rule 10b5-1 trading plan, and may enter into additional Rule 10b5-1 trading plans in the future, to facilitate open-market repurchases. The timing and amount of repurchase transactions will be determined by management based on our evaluation of market conditions, share price, legal requirements and other factors. Our prior $350.0 million stock repurchase program was terminated in connection with the approval of the new stock repurchase program. Authorization to repurchase $248.8 million of our common stock remained available as of December&#160;31, 2021.&lt;/span&gt;&lt;/div&gt;During the twelve months ended December&#160;31, 2021, we did not repurchase any common stock. During the twelve months ended December&#160;31, 2020 and 2019, we repurchased 934,079 shares for $78.0 million, and 4,122,133 shares for $448.4 million, respectively.</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock
      contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90ZXh0cmVnaW9uOjk1MzhkNjI5YTc4YTQ4ZmY4NmJhMjZmMzlkMjRiMWI5XzM2MTQ_20dd43d6-eed9-4258-812f-057c0af9e639">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes non-cash share-based compensation expense (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.002%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.043%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.043%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.046%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Share-based compensation expense as a component of:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,436&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,497&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,641&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,347&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,230&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,874&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38,783&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,727&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,515&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax
      contextRef="i448245714de441abb40ff86cd51987ac_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTpjZGUwOTNlYmFkOTQ0Y2UwYTljYzllNjc3ZWFmZDBhZS90YWJsZXJhbmdlOmNkZTA5M2ViYWQ5NDRjZTBhOWNjOWU2NzdlYWZkMGFlXzMtMS0xLTEtNDEyOTQ_337dae03-ca47-478a-a210-973ac2fa32c4"
      unitRef="usd">17436000</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
    <us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax
      contextRef="iacfc069f04d74d5284905aeca908935c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTpjZGUwOTNlYmFkOTQ0Y2UwYTljYzllNjc3ZWFmZDBhZS90YWJsZXJhbmdlOmNkZTA5M2ViYWQ5NDRjZTBhOWNjOWU2NzdlYWZkMGFlXzMtMy0xLTEtNDEyOTQ_09453c9d-49b8-414d-9f4e-9837ed1dab44"
      unitRef="usd">13497000</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
    <us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax
      contextRef="i25d150502e6343c683387b66fba49489_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTpjZGUwOTNlYmFkOTQ0Y2UwYTljYzllNjc3ZWFmZDBhZS90YWJsZXJhbmdlOmNkZTA5M2ViYWQ5NDRjZTBhOWNjOWU2NzdlYWZkMGFlXzMtNS0xLTEtNDEyOTQ_a6b1439f-1ad8-4c7f-9acd-12132d5c560a"
      unitRef="usd">9641000</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
    <us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax
      contextRef="iee6a37781cce4dbf871fcd529222b482_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTpjZGUwOTNlYmFkOTQ0Y2UwYTljYzllNjc3ZWFmZDBhZS90YWJsZXJhbmdlOmNkZTA5M2ViYWQ5NDRjZTBhOWNjOWU2NzdlYWZkMGFlXzQtMS0xLTEtNDEyOTQ_f2b616a9-2dd9-473a-bc35-d097cf9d6bfc"
      unitRef="usd">21347000</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
    <us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax
      contextRef="i5795881ca2b5425d88c92353925e817c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTpjZGUwOTNlYmFkOTQ0Y2UwYTljYzllNjc3ZWFmZDBhZS90YWJsZXJhbmdlOmNkZTA5M2ViYWQ5NDRjZTBhOWNjOWU2NzdlYWZkMGFlXzQtMy0xLTEtNDEyOTQ_e195d30f-51f9-4a87-9c93-ad43cb03f000"
      unitRef="usd">17230000</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
    <us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax
      contextRef="i0cf2334cbb0c4ac8b2c4b765ea0668aa_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTpjZGUwOTNlYmFkOTQ0Y2UwYTljYzllNjc3ZWFmZDBhZS90YWJsZXJhbmdlOmNkZTA5M2ViYWQ5NDRjZTBhOWNjOWU2NzdlYWZkMGFlXzQtNS0xLTEtNDEyOTQ_22f10a44-25ec-4047-a6ba-ceb8374eab79"
      unitRef="usd">14874000</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
    <us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax
      contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTpjZGUwOTNlYmFkOTQ0Y2UwYTljYzllNjc3ZWFmZDBhZS90YWJsZXJhbmdlOmNkZTA5M2ViYWQ5NDRjZTBhOWNjOWU2NzdlYWZkMGFlXzUtMS0xLTEtNDEyOTQ_95a1253e-b57f-4a92-8f73-ed625817fb95"
      unitRef="usd">38783000</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
    <us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax
      contextRef="ib3597315a63d441f8f128abd7ed8840e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTpjZGUwOTNlYmFkOTQ0Y2UwYTljYzllNjc3ZWFmZDBhZS90YWJsZXJhbmdlOmNkZTA5M2ViYWQ5NDRjZTBhOWNjOWU2NzdlYWZkMGFlXzUtMy0xLTEtNDEyOTQ_a586b2df-6ee8-46ef-8409-ed6680969f79"
      unitRef="usd">30727000</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
    <us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax
      contextRef="ie6c3b69702e9429aaeed46bdb9bbb9c1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTpjZGUwOTNlYmFkOTQ0Y2UwYTljYzllNjc3ZWFmZDBhZS90YWJsZXJhbmdlOmNkZTA5M2ViYWQ5NDRjZTBhOWNjOWU2NzdlYWZkMGFlXzUtNS0xLTEtNDEyOTQ_adbc914f-9b3f-4599-bcc9-fbf0f554c9a1"
      unitRef="usd">24515000</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="i67c3913252f44310913216625ca1c514_D20201201-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90ZXh0cmVnaW9uOjk1MzhkNjI5YTc4YTQ4ZmY4NmJhMjZmMzlkMjRiMWI5XzI4OQ_6855e063-d3af-4553-aa49-d0cf60a83020"
      unitRef="shares">1100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="ib571bf67523d458e92549c7f222ea20c_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90ZXh0cmVnaW9uOjk1MzhkNjI5YTc4YTQ4ZmY4NmJhMjZmMzlkMjRiMWI5XzMyMQ_1d3513c7-5525-4758-807a-897c72f16eed"
      unitRef="shares">700000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90ZXh0cmVnaW9uOjk1MzhkNjI5YTc4YTQ4ZmY4NmJhMjZmMzlkMjRiMWI5XzM2MTU_94e06f8e-620e-4743-b290-20a36be337f8">&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Following is a summary of our stock option plan activity and related information:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.120%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.244%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Exercise&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Price&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Remaining&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Contractual&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Term in&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Intrinsic&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Value&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at January&#160;1, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,736,304&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66.71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.47&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;125,858&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;338,617&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;116.69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(112,011)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23.65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,531)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;139.37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,956,379&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77.54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.45&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72,002&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable at December&#160;31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,454,726&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61.82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.42&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70,345&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options vested and expected to vest as of December&#160;31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,956,379&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77.54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.45&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72,002&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;806,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92.93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(156,845)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(44,012)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91.30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,561,822&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85.59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.09&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59,033&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable at December&#160;31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,611,830&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76.05&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.54&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53,286&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options vested and expected to vest as of December&#160;31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,561,822&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85.59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.09&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59,033&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;393,589&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;159.12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(619,731)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54.28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(136,082)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110.83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2021 &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,199,598&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;106.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.34&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;113,302&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable at December&#160;31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,391,952&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;98.16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.12&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80,849&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options vested and expected to vest as of December&#160;31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,199,598&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;106.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.34&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;113,302&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="if1aac4d81ad94163b33117197afe0895_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTo1ZGMzZjk5MDYyYjk0OWUzYmU0YjljZDViNGZkOWJhYS90YWJsZXJhbmdlOjVkYzNmOTkwNjJiOTQ5ZTNiZTRiOWNkNWI0ZmQ5YmFhXzUtMS0xLTEtNDQyNDc_22732226-e3f5-4ad1-b696-301cee3492cf"
      unitRef="shares">1736304</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="if1aac4d81ad94163b33117197afe0895_I20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTo1ZGMzZjk5MDYyYjk0OWUzYmU0YjljZDViNGZkOWJhYS90YWJsZXJhbmdlOjVkYzNmOTkwNjJiOTQ5ZTNiZTRiOWNkNWI0ZmQ5YmFhXzUtMy0xLTEtNDEyOTQ_796a9a1a-a3ef-41fe-848a-d15239a237d2"
      unitRef="usdPerShare">66.71</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="if81036550c4349c78f4732ee0154191c_D20180101-20181231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTo1ZGMzZjk5MDYyYjk0OWUzYmU0YjljZDViNGZkOWJhYS90YWJsZXJhbmdlOjVkYzNmOTkwNjJiOTQ5ZTNiZTRiOWNkNWI0ZmQ5YmFhXzUtNS0xLTEtNDEyOTQ_55d156b0-0707-46a8-b4a7-48b7d8c0d775">P5Y5M19D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="if1aac4d81ad94163b33117197afe0895_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTo1ZGMzZjk5MDYyYjk0OWUzYmU0YjljZDViNGZkOWJhYS90YWJsZXJhbmdlOjVkYzNmOTkwNjJiOTQ5ZTNiZTRiOWNkNWI0ZmQ5YmFhXzUtNy0xLTEtNDEyOTQ_f11a695d-bcce-4a50-b925-4f967738c625"
      unitRef="usd">125858000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="ie6c3b69702e9429aaeed46bdb9bbb9c1_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTo1ZGMzZjk5MDYyYjk0OWUzYmU0YjljZDViNGZkOWJhYS90YWJsZXJhbmdlOjVkYzNmOTkwNjJiOTQ5ZTNiZTRiOWNkNWI0ZmQ5YmFhXzgtMS0xLTEtNDEyOTQ_39fbf4e2-3f30-47cd-81cc-04dffa33615e"
      unitRef="shares">338617</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="ie6c3b69702e9429aaeed46bdb9bbb9c1_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTo1ZGMzZjk5MDYyYjk0OWUzYmU0YjljZDViNGZkOWJhYS90YWJsZXJhbmdlOjVkYzNmOTkwNjJiOTQ5ZTNiZTRiOWNkNWI0ZmQ5YmFhXzgtMy0xLTEtNDEyOTQ_8fe872cf-1b0f-4f37-bc7a-71333ad42f85"
      unitRef="usdPerShare">116.69</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="ie6c3b69702e9429aaeed46bdb9bbb9c1_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTo1ZGMzZjk5MDYyYjk0OWUzYmU0YjljZDViNGZkOWJhYS90YWJsZXJhbmdlOjVkYzNmOTkwNjJiOTQ5ZTNiZTRiOWNkNWI0ZmQ5YmFhXzktMS0xLTEtNDEyOTQ_98e02232-8f31-42f6-a8dd-c6f6205d573b"
      unitRef="shares">112011</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="ie6c3b69702e9429aaeed46bdb9bbb9c1_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTo1ZGMzZjk5MDYyYjk0OWUzYmU0YjljZDViNGZkOWJhYS90YWJsZXJhbmdlOjVkYzNmOTkwNjJiOTQ5ZTNiZTRiOWNkNWI0ZmQ5YmFhXzktMy0xLTEtNDEyOTQ_311b8263-f94c-41f2-83a9-d9820974c167"
      unitRef="usdPerShare">23.65</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="ie6c3b69702e9429aaeed46bdb9bbb9c1_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTo1ZGMzZjk5MDYyYjk0OWUzYmU0YjljZDViNGZkOWJhYS90YWJsZXJhbmdlOjVkYzNmOTkwNjJiOTQ5ZTNiZTRiOWNkNWI0ZmQ5YmFhXzEwLTEtMS0xLTQxMjk0_78bc581c-5e67-4781-bfe9-5d055145d748"
      unitRef="shares">6531</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="ie6c3b69702e9429aaeed46bdb9bbb9c1_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTo1ZGMzZjk5MDYyYjk0OWUzYmU0YjljZDViNGZkOWJhYS90YWJsZXJhbmdlOjVkYzNmOTkwNjJiOTQ5ZTNiZTRiOWNkNWI0ZmQ5YmFhXzEwLTMtMS0xLTQxMjk0_763b1d52-1a2a-451e-8482-65903b4c0672"
      unitRef="usdPerShare">139.37</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="ida3ec05a32644c2db1bb9f71f76c567f_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTo1ZGMzZjk5MDYyYjk0OWUzYmU0YjljZDViNGZkOWJhYS90YWJsZXJhbmdlOjVkYzNmOTkwNjJiOTQ5ZTNiZTRiOWNkNWI0ZmQ5YmFhXzExLTEtMS0xLTQxMjk0_e39c7ae3-3bb5-46f7-a937-1eb2258e1779"
      unitRef="shares">1956379</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="ida3ec05a32644c2db1bb9f71f76c567f_I20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTo1ZGMzZjk5MDYyYjk0OWUzYmU0YjljZDViNGZkOWJhYS90YWJsZXJhbmdlOjVkYzNmOTkwNjJiOTQ5ZTNiZTRiOWNkNWI0ZmQ5YmFhXzExLTMtMS0xLTQxMjk0_168ae4ff-2a06-4f9c-b35f-844e2171f813"
      unitRef="usdPerShare">77.54</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="ie6c3b69702e9429aaeed46bdb9bbb9c1_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTo1ZGMzZjk5MDYyYjk0OWUzYmU0YjljZDViNGZkOWJhYS90YWJsZXJhbmdlOjVkYzNmOTkwNjJiOTQ5ZTNiZTRiOWNkNWI0ZmQ5YmFhXzExLTUtMS0xLTQxMjk0_e1daa995-726a-44ab-ab7d-235afdeee09f">P5Y5M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="ida3ec05a32644c2db1bb9f71f76c567f_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTo1ZGMzZjk5MDYyYjk0OWUzYmU0YjljZDViNGZkOWJhYS90YWJsZXJhbmdlOjVkYzNmOTkwNjJiOTQ5ZTNiZTRiOWNkNWI0ZmQ5YmFhXzExLTctMS0xLTQxMjk0_e60e7882-98c7-4d1f-8655-39222fb54b24"
      unitRef="usd">72002000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="ida3ec05a32644c2db1bb9f71f76c567f_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTo1ZGMzZjk5MDYyYjk0OWUzYmU0YjljZDViNGZkOWJhYS90YWJsZXJhbmdlOjVkYzNmOTkwNjJiOTQ5ZTNiZTRiOWNkNWI0ZmQ5YmFhXzEyLTEtMS0xLTQxMjk0_e2b057cd-85b5-4166-976e-75cf317cf57c"
      unitRef="shares">1454726</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="ida3ec05a32644c2db1bb9f71f76c567f_I20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTo1ZGMzZjk5MDYyYjk0OWUzYmU0YjljZDViNGZkOWJhYS90YWJsZXJhbmdlOjVkYzNmOTkwNjJiOTQ5ZTNiZTRiOWNkNWI0ZmQ5YmFhXzEyLTMtMS0xLTQxMjk0_fe9d2b19-940d-4feb-838d-5de8815ac58f"
      unitRef="usdPerShare">61.82</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="ie6c3b69702e9429aaeed46bdb9bbb9c1_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTo1ZGMzZjk5MDYyYjk0OWUzYmU0YjljZDViNGZkOWJhYS90YWJsZXJhbmdlOjVkYzNmOTkwNjJiOTQ5ZTNiZTRiOWNkNWI0ZmQ5YmFhXzEyLTUtMS0xLTQxMjk0_45d2a823-3f07-42a7-be8f-aa016eb57dee">P4Y5M1D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="ida3ec05a32644c2db1bb9f71f76c567f_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTo1ZGMzZjk5MDYyYjk0OWUzYmU0YjljZDViNGZkOWJhYS90YWJsZXJhbmdlOjVkYzNmOTkwNjJiOTQ5ZTNiZTRiOWNkNWI0ZmQ5YmFhXzEyLTctMS0xLTQxMjk0_6b4ed437-0cd0-421f-ab46-e4f664e6cf10"
      unitRef="usd">70345000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="ida3ec05a32644c2db1bb9f71f76c567f_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTo1ZGMzZjk5MDYyYjk0OWUzYmU0YjljZDViNGZkOWJhYS90YWJsZXJhbmdlOjVkYzNmOTkwNjJiOTQ5ZTNiZTRiOWNkNWI0ZmQ5YmFhXzEzLTEtMS0xLTQxMjk0_9a0fd8e6-8379-4e8e-ae83-fce2ed1b65c4"
      unitRef="shares">1956379</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="ida3ec05a32644c2db1bb9f71f76c567f_I20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTo1ZGMzZjk5MDYyYjk0OWUzYmU0YjljZDViNGZkOWJhYS90YWJsZXJhbmdlOjVkYzNmOTkwNjJiOTQ5ZTNiZTRiOWNkNWI0ZmQ5YmFhXzEzLTMtMS0xLTQxMjk0_6dc1cc40-0807-48d0-be5c-7079b2e5f0d8"
      unitRef="usdPerShare">77.54</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
      contextRef="ie6c3b69702e9429aaeed46bdb9bbb9c1_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTo1ZGMzZjk5MDYyYjk0OWUzYmU0YjljZDViNGZkOWJhYS90YWJsZXJhbmdlOjVkYzNmOTkwNjJiOTQ5ZTNiZTRiOWNkNWI0ZmQ5YmFhXzEzLTUtMS0xLTQxMjk0_7958fba8-129d-4459-b73f-aca50aa6bb16">P5Y5M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
      contextRef="ida3ec05a32644c2db1bb9f71f76c567f_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTo1ZGMzZjk5MDYyYjk0OWUzYmU0YjljZDViNGZkOWJhYS90YWJsZXJhbmdlOjVkYzNmOTkwNjJiOTQ5ZTNiZTRiOWNkNWI0ZmQ5YmFhXzEzLTctMS0xLTQxMjk0_6332c9fa-ba83-4c1e-b090-b0a7090da0d7"
      unitRef="usd">72002000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="ib3597315a63d441f8f128abd7ed8840e_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTo1ZGMzZjk5MDYyYjk0OWUzYmU0YjljZDViNGZkOWJhYS90YWJsZXJhbmdlOjVkYzNmOTkwNjJiOTQ5ZTNiZTRiOWNkNWI0ZmQ5YmFhXzE0LTEtMS0xLTQxMjk0_0e6a6896-c3de-45c0-90c7-84c5383c11e7"
      unitRef="shares">806300</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="ib3597315a63d441f8f128abd7ed8840e_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTo1ZGMzZjk5MDYyYjk0OWUzYmU0YjljZDViNGZkOWJhYS90YWJsZXJhbmdlOjVkYzNmOTkwNjJiOTQ5ZTNiZTRiOWNkNWI0ZmQ5YmFhXzE0LTMtMS0xLTQxMjk0_cd72b213-9de4-4bc5-953c-97db187f7349"
      unitRef="usdPerShare">92.93</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="ib3597315a63d441f8f128abd7ed8840e_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTo1ZGMzZjk5MDYyYjk0OWUzYmU0YjljZDViNGZkOWJhYS90YWJsZXJhbmdlOjVkYzNmOTkwNjJiOTQ5ZTNiZTRiOWNkNWI0ZmQ5YmFhXzE1LTEtMS0xLTQxMjk0_a1b3b6f7-cb3c-44a2-a2f2-c9dc27539b30"
      unitRef="shares">156845</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="ib3597315a63d441f8f128abd7ed8840e_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTo1ZGMzZjk5MDYyYjk0OWUzYmU0YjljZDViNGZkOWJhYS90YWJsZXJhbmdlOjVkYzNmOTkwNjJiOTQ5ZTNiZTRiOWNkNWI0ZmQ5YmFhXzE1LTMtMS0xLTQxMjk0_487ae073-b9c5-486c-8d79-3a0dcdde2b93"
      unitRef="usdPerShare">21.26</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="ib3597315a63d441f8f128abd7ed8840e_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTo1ZGMzZjk5MDYyYjk0OWUzYmU0YjljZDViNGZkOWJhYS90YWJsZXJhbmdlOjVkYzNmOTkwNjJiOTQ5ZTNiZTRiOWNkNWI0ZmQ5YmFhXzE2LTEtMS0xLTQxMjk0_0bd4d5cc-c33f-4f72-91be-958ae65ad345"
      unitRef="shares">44012</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="ib3597315a63d441f8f128abd7ed8840e_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTo1ZGMzZjk5MDYyYjk0OWUzYmU0YjljZDViNGZkOWJhYS90YWJsZXJhbmdlOjVkYzNmOTkwNjJiOTQ5ZTNiZTRiOWNkNWI0ZmQ5YmFhXzE2LTMtMS0xLTQxMjk0_3dd6504f-cad2-48ef-afec-d9380e09c33a"
      unitRef="usdPerShare">91.30</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i7462d0db8f4248fcb9fd8f1deae439f3_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTo1ZGMzZjk5MDYyYjk0OWUzYmU0YjljZDViNGZkOWJhYS90YWJsZXJhbmdlOjVkYzNmOTkwNjJiOTQ5ZTNiZTRiOWNkNWI0ZmQ5YmFhXzE3LTEtMS0xLTQxMjk0_325dc830-b8d9-4b59-91b9-684db763cfbe"
      unitRef="shares">2561822</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i7462d0db8f4248fcb9fd8f1deae439f3_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTo1ZGMzZjk5MDYyYjk0OWUzYmU0YjljZDViNGZkOWJhYS90YWJsZXJhbmdlOjVkYzNmOTkwNjJiOTQ5ZTNiZTRiOWNkNWI0ZmQ5YmFhXzE3LTMtMS0xLTQxMjk0_5cdcad0e-e7b2-44e8-bb6f-fe39687bff4a"
      unitRef="usdPerShare">85.59</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="ib3597315a63d441f8f128abd7ed8840e_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTo1ZGMzZjk5MDYyYjk0OWUzYmU0YjljZDViNGZkOWJhYS90YWJsZXJhbmdlOjVkYzNmOTkwNjJiOTQ5ZTNiZTRiOWNkNWI0ZmQ5YmFhXzE3LTUtMS0xLTQxMjk0_27801756-da47-402c-88f6-7366eda1db60">P6Y1M2D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i7462d0db8f4248fcb9fd8f1deae439f3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTo1ZGMzZjk5MDYyYjk0OWUzYmU0YjljZDViNGZkOWJhYS90YWJsZXJhbmdlOjVkYzNmOTkwNjJiOTQ5ZTNiZTRiOWNkNWI0ZmQ5YmFhXzE3LTctMS0xLTQxMjk0_c2836375-417a-4d2d-8fa8-755df205acb5"
      unitRef="usd">59033000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="i7462d0db8f4248fcb9fd8f1deae439f3_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTo1ZGMzZjk5MDYyYjk0OWUzYmU0YjljZDViNGZkOWJhYS90YWJsZXJhbmdlOjVkYzNmOTkwNjJiOTQ5ZTNiZTRiOWNkNWI0ZmQ5YmFhXzE4LTEtMS0xLTQxMjk0_c439067d-59b5-4f22-9eb7-4dad18a60c37"
      unitRef="shares">1611830</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="i7462d0db8f4248fcb9fd8f1deae439f3_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTo1ZGMzZjk5MDYyYjk0OWUzYmU0YjljZDViNGZkOWJhYS90YWJsZXJhbmdlOjVkYzNmOTkwNjJiOTQ5ZTNiZTRiOWNkNWI0ZmQ5YmFhXzE4LTMtMS0xLTQxMjk0_0e6b6eae-92af-4df7-8004-c452e06cb8cc"
      unitRef="usdPerShare">76.05</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="ib3597315a63d441f8f128abd7ed8840e_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTo1ZGMzZjk5MDYyYjk0OWUzYmU0YjljZDViNGZkOWJhYS90YWJsZXJhbmdlOjVkYzNmOTkwNjJiOTQ5ZTNiZTRiOWNkNWI0ZmQ5YmFhXzE4LTUtMS0xLTQxMjk0_79b8d938-5f4e-49e6-9e88-e51083b59b5e">P4Y6M14D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="i7462d0db8f4248fcb9fd8f1deae439f3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTo1ZGMzZjk5MDYyYjk0OWUzYmU0YjljZDViNGZkOWJhYS90YWJsZXJhbmdlOjVkYzNmOTkwNjJiOTQ5ZTNiZTRiOWNkNWI0ZmQ5YmFhXzE4LTctMS0xLTQxMjk0_c0a55fc9-6318-48fa-b55e-7c807cc3a2e6"
      unitRef="usd">53286000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="i7462d0db8f4248fcb9fd8f1deae439f3_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTo1ZGMzZjk5MDYyYjk0OWUzYmU0YjljZDViNGZkOWJhYS90YWJsZXJhbmdlOjVkYzNmOTkwNjJiOTQ5ZTNiZTRiOWNkNWI0ZmQ5YmFhXzE5LTEtMS0xLTQxMjk0_d780c8c8-f4b4-45f5-bd3c-1cf3309436ff"
      unitRef="shares">2561822</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="i7462d0db8f4248fcb9fd8f1deae439f3_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTo1ZGMzZjk5MDYyYjk0OWUzYmU0YjljZDViNGZkOWJhYS90YWJsZXJhbmdlOjVkYzNmOTkwNjJiOTQ5ZTNiZTRiOWNkNWI0ZmQ5YmFhXzE5LTMtMS0xLTQxMjk0_a10c8057-077f-4976-8321-d7755ccd7bb7"
      unitRef="usdPerShare">85.59</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
      contextRef="ib3597315a63d441f8f128abd7ed8840e_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTo1ZGMzZjk5MDYyYjk0OWUzYmU0YjljZDViNGZkOWJhYS90YWJsZXJhbmdlOjVkYzNmOTkwNjJiOTQ5ZTNiZTRiOWNkNWI0ZmQ5YmFhXzE5LTUtMS0xLTQxMjk0_ce67ed0f-4476-4d4f-ba5a-e383c3ac2ea5">P6Y1M2D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
      contextRef="i7462d0db8f4248fcb9fd8f1deae439f3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTo1ZGMzZjk5MDYyYjk0OWUzYmU0YjljZDViNGZkOWJhYS90YWJsZXJhbmdlOjVkYzNmOTkwNjJiOTQ5ZTNiZTRiOWNkNWI0ZmQ5YmFhXzE5LTctMS0xLTQxMjk0_000b1b6e-1bcf-4e6f-a671-8662a19ca9c1"
      unitRef="usd">59033000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTo1ZGMzZjk5MDYyYjk0OWUzYmU0YjljZDViNGZkOWJhYS90YWJsZXJhbmdlOjVkYzNmOTkwNjJiOTQ5ZTNiZTRiOWNkNWI0ZmQ5YmFhXzIwLTEtMS0xLTQ1MDYw_f1ce0cfe-92d6-4bdc-a029-8eb65c9c024e"
      unitRef="shares">393589</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTo1ZGMzZjk5MDYyYjk0OWUzYmU0YjljZDViNGZkOWJhYS90YWJsZXJhbmdlOjVkYzNmOTkwNjJiOTQ5ZTNiZTRiOWNkNWI0ZmQ5YmFhXzIwLTMtMS0xLTQ1MTI2_24dd30df-0090-4dc1-82d7-21bf0338d79c"
      unitRef="usdPerShare">159.12</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTo1ZGMzZjk5MDYyYjk0OWUzYmU0YjljZDViNGZkOWJhYS90YWJsZXJhbmdlOjVkYzNmOTkwNjJiOTQ5ZTNiZTRiOWNkNWI0ZmQ5YmFhXzIxLTEtMS0xLTQ1MDYw_31f0126e-f7bc-443a-a948-63718041e4a0"
      unitRef="shares">619731</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTo1ZGMzZjk5MDYyYjk0OWUzYmU0YjljZDViNGZkOWJhYS90YWJsZXJhbmdlOjVkYzNmOTkwNjJiOTQ5ZTNiZTRiOWNkNWI0ZmQ5YmFhXzIxLTMtMS0xLTQ1MTI2_e79e1e2b-155e-4037-b550-96f898b4258c"
      unitRef="usdPerShare">54.28</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTo1ZGMzZjk5MDYyYjk0OWUzYmU0YjljZDViNGZkOWJhYS90YWJsZXJhbmdlOjVkYzNmOTkwNjJiOTQ5ZTNiZTRiOWNkNWI0ZmQ5YmFhXzIyLTEtMS0xLTQ1MDYw_9ddc510b-f339-4a69-abaf-cfceb01d9325"
      unitRef="shares">136082</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTo1ZGMzZjk5MDYyYjk0OWUzYmU0YjljZDViNGZkOWJhYS90YWJsZXJhbmdlOjVkYzNmOTkwNjJiOTQ5ZTNiZTRiOWNkNWI0ZmQ5YmFhXzIyLTMtMS0xLTQ1MTI2_e436c9aa-1c19-4360-ad3d-b7089b305b6f"
      unitRef="usdPerShare">110.83</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTo1ZGMzZjk5MDYyYjk0OWUzYmU0YjljZDViNGZkOWJhYS90YWJsZXJhbmdlOjVkYzNmOTkwNjJiOTQ5ZTNiZTRiOWNkNWI0ZmQ5YmFhXzE3LTEtMS0xLTQ2MjU4_31ce14a9-5e3c-496e-a137-e07f216ea58e"
      unitRef="shares">2199598</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTo1ZGMzZjk5MDYyYjk0OWUzYmU0YjljZDViNGZkOWJhYS90YWJsZXJhbmdlOjVkYzNmOTkwNjJiOTQ5ZTNiZTRiOWNkNWI0ZmQ5YmFhXzIzLTMtMS0xLTQ1MTI2_32bd5375-89dc-4b4b-a35e-f91fe815da72"
      unitRef="usdPerShare">106.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTo1ZGMzZjk5MDYyYjk0OWUzYmU0YjljZDViNGZkOWJhYS90YWJsZXJhbmdlOjVkYzNmOTkwNjJiOTQ5ZTNiZTRiOWNkNWI0ZmQ5YmFhXzIzLTUtMS0xLTQ1MTYz_10067209-ee16-4555-a4f8-f1e65f63e81e">P6Y4M2D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTo1ZGMzZjk5MDYyYjk0OWUzYmU0YjljZDViNGZkOWJhYS90YWJsZXJhbmdlOjVkYzNmOTkwNjJiOTQ5ZTNiZTRiOWNkNWI0ZmQ5YmFhXzIzLTctMS0xLTQ1MTc5_66617241-ba61-4145-b60f-bc1a87705d1e"
      unitRef="usd">113302000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTo1ZGMzZjk5MDYyYjk0OWUzYmU0YjljZDViNGZkOWJhYS90YWJsZXJhbmdlOjVkYzNmOTkwNjJiOTQ5ZTNiZTRiOWNkNWI0ZmQ5YmFhXzI0LTEtMS0xLTQ1MTEz_797ac795-c91a-479b-b2b0-166d8c4c2232"
      unitRef="shares">1391952</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTo1ZGMzZjk5MDYyYjk0OWUzYmU0YjljZDViNGZkOWJhYS90YWJsZXJhbmdlOjVkYzNmOTkwNjJiOTQ5ZTNiZTRiOWNkNWI0ZmQ5YmFhXzI0LTMtMS0xLTQ1MTU1_7d8e685f-16f8-4ebb-a211-9b7d58a58e54"
      unitRef="usdPerShare">98.16</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTo1ZGMzZjk5MDYyYjk0OWUzYmU0YjljZDViNGZkOWJhYS90YWJsZXJhbmdlOjVkYzNmOTkwNjJiOTQ5ZTNiZTRiOWNkNWI0ZmQ5YmFhXzI0LTUtMS0xLTQ1MTYz_c6db42c5-5370-4be8-870d-f14d6f7a7dcc">P5Y1M13D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTo1ZGMzZjk5MDYyYjk0OWUzYmU0YjljZDViNGZkOWJhYS90YWJsZXJhbmdlOjVkYzNmOTkwNjJiOTQ5ZTNiZTRiOWNkNWI0ZmQ5YmFhXzI0LTctMS0xLTQ1MTc5_c8e8651a-6c57-41cd-a11b-54039071374c"
      unitRef="usd">80849000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTo1ZGMzZjk5MDYyYjk0OWUzYmU0YjljZDViNGZkOWJhYS90YWJsZXJhbmdlOjVkYzNmOTkwNjJiOTQ5ZTNiZTRiOWNkNWI0ZmQ5YmFhXzE5LTEtMS0xLTQ2MjU4_b5dee570-a1c2-4c8b-886b-005a0d24e98b"
      unitRef="shares">2199598</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTo1ZGMzZjk5MDYyYjk0OWUzYmU0YjljZDViNGZkOWJhYS90YWJsZXJhbmdlOjVkYzNmOTkwNjJiOTQ5ZTNiZTRiOWNkNWI0ZmQ5YmFhXzE5LTMtMS0xLTQ2MjU4_bec630f4-8227-4939-84a4-12cfa874a475"
      unitRef="usdPerShare">106.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
      contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTo1ZGMzZjk5MDYyYjk0OWUzYmU0YjljZDViNGZkOWJhYS90YWJsZXJhbmdlOjVkYzNmOTkwNjJiOTQ5ZTNiZTRiOWNkNWI0ZmQ5YmFhXzE5LTUtMS0xLTQ2MjU4_efedec4e-0bb1-4592-98b9-d4b5216d40bb">P6Y4M2D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
      contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTo1ZGMzZjk5MDYyYjk0OWUzYmU0YjljZDViNGZkOWJhYS90YWJsZXJhbmdlOjVkYzNmOTkwNjJiOTQ5ZTNiZTRiOWNkNWI0ZmQ5YmFhXzE5LTctMS0xLTQ2MjU4_94efc78c-e1d8-4f6a-b521-d19bced9d2fb"
      unitRef="usd">113302000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i0b2d2a0659724a0394359a72b0ded635_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90ZXh0cmVnaW9uOjk1MzhkNjI5YTc4YTQ4ZmY4NmJhMjZmMzlkMjRiMWI5XzU5OA_f56d98ea-d067-4993-98fb-78a90ee08d78"
      unitRef="usdPerShare">80.08</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i97af3b7b1f564d4d911c3d6134e64410_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90ZXh0cmVnaW9uOjk1MzhkNjI5YTc4YTQ4ZmY4NmJhMjZmMzlkMjRiMWI5XzYwMg_e89889a2-e4cd-4286-8652-ce72cdf4842f"
      unitRef="usdPerShare">41.39</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i891b87647a30477eb27e9edd4fc735ea_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90ZXh0cmVnaW9uOjk1MzhkNjI5YTc4YTQ4ZmY4NmJhMjZmMzlkMjRiMWI5XzYwOQ_a1c6e422-40c0-438a-8562-056ade6c5915"
      unitRef="usdPerShare">48.65</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="i0b2d2a0659724a0394359a72b0ded635_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90ZXh0cmVnaW9uOjk1MzhkNjI5YTc4YTQ4ZmY4NmJhMjZmMzlkMjRiMWI5XzcyNw_de363ffd-5559-4b50-b592-a1807b9b433f"
      unitRef="usd">77300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="i97af3b7b1f564d4d911c3d6134e64410_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90ZXh0cmVnaW9uOjk1MzhkNjI5YTc4YTQ4ZmY4NmJhMjZmMzlkMjRiMWI5XzczMQ_2fc90504-2d1d-46ec-a186-981fb005f1b6"
      unitRef="usd">11900000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="i891b87647a30477eb27e9edd4fc735ea_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90ZXh0cmVnaW9uOjk1MzhkNjI5YTc4YTQ4ZmY4NmJhMjZmMzlkMjRiMWI5XzczOA_7a961725-444c-4d55-959e-8b2e632c34e7"
      unitRef="usd">10400000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
      contextRef="i0b2d2a0659724a0394359a72b0ded635_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90ZXh0cmVnaW9uOjk1MzhkNjI5YTc4YTQ4ZmY4NmJhMjZmMzlkMjRiMWI5XzgzNA_ece4eb13-c050-48e3-ba23-017e87ade1d7"
      unitRef="usd">33000000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
      contextRef="i97af3b7b1f564d4d911c3d6134e64410_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90ZXh0cmVnaW9uOjk1MzhkNjI5YTc4YTQ4ZmY4NmJhMjZmMzlkMjRiMWI5XzgzOA_62683e17-18b7-4bbb-8388-04cdf3c322a6"
      unitRef="usd">2500000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
      contextRef="i891b87647a30477eb27e9edd4fc735ea_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90ZXh0cmVnaW9uOjk1MzhkNjI5YTc4YTQ4ZmY4NmJhMjZmMzlkMjRiMWI5Xzg0NQ_4da2dda6-e2d3-4258-ad6f-23c0aa451af5"
      unitRef="usd">2600000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock
      contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90ZXh0cmVnaW9uOjk1MzhkNjI5YTc4YTQ4ZmY4NmJhMjZmMzlkMjRiMWI5XzM2MTk_80df4952-9c43-4e3c-9d88-fbfe9aff975d">&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Following is a further breakdown of the options outstanding as of December&#160;31, 2021:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:30.040%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.057%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.057%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.057%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.057%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.212%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Range of exercise prices&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Options&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;outstanding&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;remaining&#160; life&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;in&#160;years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted&#160;average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;exercise price&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Options&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;exercisable&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted&#160;average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;exercise&#160;price&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$12.53-$56.26&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;253,824&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.94&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37.55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;239,824&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38.90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$67.53-$74.42&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;278,281&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.04&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;217,587&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73.17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$82.90-$95.35&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;159,988&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.06&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;86.11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;132,963&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;86.24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$95.68&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;266,263&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.12&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;95.68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;109,154&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;95.68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$98.20-$100.38&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;294,772&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.33&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;99.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;160,120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;99.79&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$101.07-$117.58&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;159,204&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.45&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;111.26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;99,488&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;111.18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$117.97&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;237,292&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.12&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117.97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;158,958&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117.97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$119.08-$159.01&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;299,585&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.00&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;149.40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;205,098&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;152.50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$159.81-$171.28&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,881&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.51&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;166.28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,828&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;165.62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$177.50-$195.91&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;243,508&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.91&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;178.62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62,932&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;181.84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,199,598&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.34&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;106.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,391,952&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;98.16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="ibb76fff21d1145a2aa988019605605d7_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTo2NmRhZGMxYWRhOTE0NjZlODY0NWYwNDc0OTE2MjJhYy90YWJsZXJhbmdlOjY2ZGFkYzFhZGE5MTQ2NmU4NjQ1ZjA0NzQ5MTYyMmFjXzEtMC0xLTEtNDEyOTQvdGV4dHJlZ2lvbjo4MDU2NzRlNTIzZjE0ZGE4YTQ0NzVjNmQzYTY0MzVmMF80_4fd955c0-5acf-4bd6-aa73-7f9365e273a1"
      unitRef="usdPerShare">12.53</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="ibb76fff21d1145a2aa988019605605d7_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTo2NmRhZGMxYWRhOTE0NjZlODY0NWYwNDc0OTE2MjJhYy90YWJsZXJhbmdlOjY2ZGFkYzFhZGE5MTQ2NmU4NjQ1ZjA0NzQ5MTYyMmFjXzEtMC0xLTEtNDEyOTQvdGV4dHJlZ2lvbjo4MDU2NzRlNTIzZjE0ZGE4YTQ0NzVjNmQzYTY0MzVmMF83_d00aae65-ec3f-4017-8247-bf2a3c0826b1"
      unitRef="usdPerShare">56.26</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="i2d5b9274891c4530b4756d9f6d78384d_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTo2NmRhZGMxYWRhOTE0NjZlODY0NWYwNDc0OTE2MjJhYy90YWJsZXJhbmdlOjY2ZGFkYzFhZGE5MTQ2NmU4NjQ1ZjA0NzQ5MTYyMmFjXzEtMS0xLTEtNDEyOTQ_5fbcf927-bd38-4f97-b742-92281aa5991f"
      unitRef="shares">253824</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="ibb76fff21d1145a2aa988019605605d7_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTo2NmRhZGMxYWRhOTE0NjZlODY0NWYwNDc0OTE2MjJhYy90YWJsZXJhbmdlOjY2ZGFkYzFhZGE5MTQ2NmU4NjQ1ZjA0NzQ5MTYyMmFjXzEtMy0xLTEtNDEyOTQ_59f0ff0c-a181-4c68-8409-f20e10e05fff">P1Y11M8D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="i2d5b9274891c4530b4756d9f6d78384d_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTo2NmRhZGMxYWRhOTE0NjZlODY0NWYwNDc0OTE2MjJhYy90YWJsZXJhbmdlOjY2ZGFkYzFhZGE5MTQ2NmU4NjQ1ZjA0NzQ5MTYyMmFjXzEtNS0xLTEtNDEyOTQ_94082e22-20aa-45e9-b2e6-56d13a789a17"
      unitRef="usdPerShare">37.55</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="i2d5b9274891c4530b4756d9f6d78384d_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTo2NmRhZGMxYWRhOTE0NjZlODY0NWYwNDc0OTE2MjJhYy90YWJsZXJhbmdlOjY2ZGFkYzFhZGE5MTQ2NmU4NjQ1ZjA0NzQ5MTYyMmFjXzEtNy0xLTEtNDEyOTQ_fa613ea5-0bb6-4e57-a379-7092a14ac6d9"
      unitRef="shares">239824</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="i2d5b9274891c4530b4756d9f6d78384d_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTo2NmRhZGMxYWRhOTE0NjZlODY0NWYwNDc0OTE2MjJhYy90YWJsZXJhbmdlOjY2ZGFkYzFhZGE5MTQ2NmU4NjQ1ZjA0NzQ5MTYyMmFjXzEtOS0xLTEtNDEyOTQ_fe9ef5d0-b064-466e-aa5c-103dfd582005"
      unitRef="usdPerShare">38.90</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="i42d7e1e14d514ee5ac131e49d67d3ae9_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTo2NmRhZGMxYWRhOTE0NjZlODY0NWYwNDc0OTE2MjJhYy90YWJsZXJhbmdlOjY2ZGFkYzFhZGE5MTQ2NmU4NjQ1ZjA0NzQ5MTYyMmFjXzItMC0xLTEtNDEyOTQvdGV4dHJlZ2lvbjpiOTgxYzBhM2E2NDQ0MDU1OWUwNjU5NjczNzE2MDJmYV80_a606560a-39a5-44f9-9977-3998bc123b41"
      unitRef="usdPerShare">67.53</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="i42d7e1e14d514ee5ac131e49d67d3ae9_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTo2NmRhZGMxYWRhOTE0NjZlODY0NWYwNDc0OTE2MjJhYy90YWJsZXJhbmdlOjY2ZGFkYzFhZGE5MTQ2NmU4NjQ1ZjA0NzQ5MTYyMmFjXzItMC0xLTEtNDEyOTQvdGV4dHJlZ2lvbjpiOTgxYzBhM2E2NDQ0MDU1OWUwNjU5NjczNzE2MDJmYV83_56c99941-4ef3-43bd-9edf-38c2f75b5c35"
      unitRef="usdPerShare">74.42</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="if56255ad310d4a3bbccede5e1c84b2ec_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTo2NmRhZGMxYWRhOTE0NjZlODY0NWYwNDc0OTE2MjJhYy90YWJsZXJhbmdlOjY2ZGFkYzFhZGE5MTQ2NmU4NjQ1ZjA0NzQ5MTYyMmFjXzItMS0xLTEtNDEyOTQ_8ecb0fa9-7e32-425b-92de-f46d39b45b5a"
      unitRef="shares">278281</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="i42d7e1e14d514ee5ac131e49d67d3ae9_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTo2NmRhZGMxYWRhOTE0NjZlODY0NWYwNDc0OTE2MjJhYy90YWJsZXJhbmdlOjY2ZGFkYzFhZGE5MTQ2NmU4NjQ1ZjA0NzQ5MTYyMmFjXzItMy0xLTEtNDEyOTQ_e5554e6e-2807-4bd4-b76d-e7395b405570">P4Y14D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="if56255ad310d4a3bbccede5e1c84b2ec_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTo2NmRhZGMxYWRhOTE0NjZlODY0NWYwNDc0OTE2MjJhYy90YWJsZXJhbmdlOjY2ZGFkYzFhZGE5MTQ2NmU4NjQ1ZjA0NzQ5MTYyMmFjXzItNS0xLTEtNDEyOTQ_2f69d105-a752-46f0-9f68-a2bb3e575572"
      unitRef="usdPerShare">72.10</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="if56255ad310d4a3bbccede5e1c84b2ec_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTo2NmRhZGMxYWRhOTE0NjZlODY0NWYwNDc0OTE2MjJhYy90YWJsZXJhbmdlOjY2ZGFkYzFhZGE5MTQ2NmU4NjQ1ZjA0NzQ5MTYyMmFjXzItNy0xLTEtNDEyOTQ_4796b6ab-b201-4a80-b44f-5911f4744158"
      unitRef="shares">217587</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="if56255ad310d4a3bbccede5e1c84b2ec_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTo2NmRhZGMxYWRhOTE0NjZlODY0NWYwNDc0OTE2MjJhYy90YWJsZXJhbmdlOjY2ZGFkYzFhZGE5MTQ2NmU4NjQ1ZjA0NzQ5MTYyMmFjXzItOS0xLTEtNDEyOTQ_a256e17d-2c0d-429a-920d-842f7f459861"
      unitRef="usdPerShare">73.17</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="i1583b4003fe544649fbe7acf591bc7c2_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTo2NmRhZGMxYWRhOTE0NjZlODY0NWYwNDc0OTE2MjJhYy90YWJsZXJhbmdlOjY2ZGFkYzFhZGE5MTQ2NmU4NjQ1ZjA0NzQ5MTYyMmFjXzMtMC0xLTEtNDEyOTQvdGV4dHJlZ2lvbjpjMWRiZjA4NDljODE0YjZmYjJmOTUyZDJmZDk2NjU5MF80_3e14eb0e-a9f5-4a4c-b1ec-c2e9d7bb8267"
      unitRef="usdPerShare">82.90</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="i1583b4003fe544649fbe7acf591bc7c2_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTo2NmRhZGMxYWRhOTE0NjZlODY0NWYwNDc0OTE2MjJhYy90YWJsZXJhbmdlOjY2ZGFkYzFhZGE5MTQ2NmU4NjQ1ZjA0NzQ5MTYyMmFjXzMtMC0xLTEtNDEyOTQvdGV4dHJlZ2lvbjpjMWRiZjA4NDljODE0YjZmYjJmOTUyZDJmZDk2NjU5MF83_f63359af-ddd1-4317-b694-0f635226bea5"
      unitRef="usdPerShare">95.35</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="i3186ef0fac614fe4a3a83b4e3df1fac4_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTo2NmRhZGMxYWRhOTE0NjZlODY0NWYwNDc0OTE2MjJhYy90YWJsZXJhbmdlOjY2ZGFkYzFhZGE5MTQ2NmU4NjQ1ZjA0NzQ5MTYyMmFjXzMtMS0xLTEtNDEyOTQ_9abbcc94-4cb6-4128-a57f-c90e2cd03926"
      unitRef="shares">159988</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="i1583b4003fe544649fbe7acf591bc7c2_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTo2NmRhZGMxYWRhOTE0NjZlODY0NWYwNDc0OTE2MjJhYy90YWJsZXJhbmdlOjY2ZGFkYzFhZGE5MTQ2NmU4NjQ1ZjA0NzQ5MTYyMmFjXzMtMy0xLTEtNDEyOTQ_cde5e65a-1c28-48d3-9336-a3b8e78795cb">P5Y21D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="i3186ef0fac614fe4a3a83b4e3df1fac4_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTo2NmRhZGMxYWRhOTE0NjZlODY0NWYwNDc0OTE2MjJhYy90YWJsZXJhbmdlOjY2ZGFkYzFhZGE5MTQ2NmU4NjQ1ZjA0NzQ5MTYyMmFjXzMtNS0xLTEtNDEyOTQ_f1d7d3cc-5338-4750-8567-9fd0e0eeeb7b"
      unitRef="usdPerShare">86.11</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="i3186ef0fac614fe4a3a83b4e3df1fac4_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTo2NmRhZGMxYWRhOTE0NjZlODY0NWYwNDc0OTE2MjJhYy90YWJsZXJhbmdlOjY2ZGFkYzFhZGE5MTQ2NmU4NjQ1ZjA0NzQ5MTYyMmFjXzMtNy0xLTEtNDEyOTQ_c979066a-2257-4054-848b-96c8eaa21de5"
      unitRef="shares">132963</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="i3186ef0fac614fe4a3a83b4e3df1fac4_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTo2NmRhZGMxYWRhOTE0NjZlODY0NWYwNDc0OTE2MjJhYy90YWJsZXJhbmdlOjY2ZGFkYzFhZGE5MTQ2NmU4NjQ1ZjA0NzQ5MTYyMmFjXzMtOS0xLTEtNDEyOTQ_25365ce9-7a1f-49fc-830d-a3bd17532c2a"
      unitRef="usdPerShare">86.24</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="i9203228b9f3a4a258d1dd418f1ff9fab_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTo2NmRhZGMxYWRhOTE0NjZlODY0NWYwNDc0OTE2MjJhYy90YWJsZXJhbmdlOjY2ZGFkYzFhZGE5MTQ2NmU4NjQ1ZjA0NzQ5MTYyMmFjXzQtMC0xLTEtNDEyOTQvdGV4dHJlZ2lvbjo5MGM5YzExOTYzOWY0YjI4OWRiMjhkZWM0MzAzOTM5MF80_8e9b7b97-d0d8-42b9-b716-134d625e4745"
      unitRef="usdPerShare">95.68</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="i65a6d24f5a314cbba76284b24732fb3c_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTo2NmRhZGMxYWRhOTE0NjZlODY0NWYwNDc0OTE2MjJhYy90YWJsZXJhbmdlOjY2ZGFkYzFhZGE5MTQ2NmU4NjQ1ZjA0NzQ5MTYyMmFjXzQtMS0xLTEtNDEyOTQ_e14d3c8b-c65b-474d-8a1a-2f19d95fca91"
      unitRef="shares">266263</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="i9203228b9f3a4a258d1dd418f1ff9fab_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTo2NmRhZGMxYWRhOTE0NjZlODY0NWYwNDc0OTE2MjJhYy90YWJsZXJhbmdlOjY2ZGFkYzFhZGE5MTQ2NmU4NjQ1ZjA0NzQ5MTYyMmFjXzQtMy0xLTEtNDEyOTQ_f14e1de9-887c-4716-a037-dcf2f68e8885">P8Y1M13D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="i65a6d24f5a314cbba76284b24732fb3c_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTo2NmRhZGMxYWRhOTE0NjZlODY0NWYwNDc0OTE2MjJhYy90YWJsZXJhbmdlOjY2ZGFkYzFhZGE5MTQ2NmU4NjQ1ZjA0NzQ5MTYyMmFjXzQtNS0xLTEtNDEyOTQ_dca2e172-bca5-4ce8-bdc1-295362e77a34"
      unitRef="usdPerShare">95.68</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="i65a6d24f5a314cbba76284b24732fb3c_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTo2NmRhZGMxYWRhOTE0NjZlODY0NWYwNDc0OTE2MjJhYy90YWJsZXJhbmdlOjY2ZGFkYzFhZGE5MTQ2NmU4NjQ1ZjA0NzQ5MTYyMmFjXzQtNy0xLTEtNDEyOTQ_83d96965-0f26-41c3-b24b-c8cf5abcc41e"
      unitRef="shares">109154</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="i65a6d24f5a314cbba76284b24732fb3c_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTo2NmRhZGMxYWRhOTE0NjZlODY0NWYwNDc0OTE2MjJhYy90YWJsZXJhbmdlOjY2ZGFkYzFhZGE5MTQ2NmU4NjQ1ZjA0NzQ5MTYyMmFjXzQtOS0xLTEtNDEyOTQ_91a0f409-899b-41c5-a2fc-caf3ea8d8577"
      unitRef="usdPerShare">95.68</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="i708cf622e450455095803a651785b9f8_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTo2NmRhZGMxYWRhOTE0NjZlODY0NWYwNDc0OTE2MjJhYy90YWJsZXJhbmdlOjY2ZGFkYzFhZGE5MTQ2NmU4NjQ1ZjA0NzQ5MTYyMmFjXzUtMC0xLTEtNDEyOTQvdGV4dHJlZ2lvbjoxZGE5MDNhOGNjZTE0MmNiYTM3NmRjOGU0NjgyNDRmNF83Njk2NTgxMzk0NDcw_162b10a2-23a8-4f68-917f-b54d9f6c508b"
      unitRef="usdPerShare">98.20</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="i708cf622e450455095803a651785b9f8_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTo2NmRhZGMxYWRhOTE0NjZlODY0NWYwNDc0OTE2MjJhYy90YWJsZXJhbmdlOjY2ZGFkYzFhZGE5MTQ2NmU4NjQ1ZjA0NzQ5MTYyMmFjXzUtMC0xLTEtNDEyOTQvdGV4dHJlZ2lvbjoxZGE5MDNhOGNjZTE0MmNiYTM3NmRjOGU0NjgyNDRmNF83Njk2NTgxMzk0NDc0_1cf163f7-57af-4979-ae37-12c5fbe48a15"
      unitRef="usdPerShare">100.38</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="i1cf30bd35d974a5688e936ed32ee1917_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTo2NmRhZGMxYWRhOTE0NjZlODY0NWYwNDc0OTE2MjJhYy90YWJsZXJhbmdlOjY2ZGFkYzFhZGE5MTQ2NmU4NjQ1ZjA0NzQ5MTYyMmFjXzUtMS0xLTEtNDEyOTQ_3609ae54-57ad-4e64-b791-1917a0cb7eac"
      unitRef="shares">294772</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="i708cf622e450455095803a651785b9f8_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTo2NmRhZGMxYWRhOTE0NjZlODY0NWYwNDc0OTE2MjJhYy90YWJsZXJhbmdlOjY2ZGFkYzFhZGE5MTQ2NmU4NjQ1ZjA0NzQ5MTYyMmFjXzUtMy0xLTEtNDEyOTQ_e064ab3a-a88f-4504-a23f-2453d83b21d1">P7Y3M29D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="i1cf30bd35d974a5688e936ed32ee1917_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTo2NmRhZGMxYWRhOTE0NjZlODY0NWYwNDc0OTE2MjJhYy90YWJsZXJhbmdlOjY2ZGFkYzFhZGE5MTQ2NmU4NjQ1ZjA0NzQ5MTYyMmFjXzUtNS0xLTEtNDEyOTQ_6aa21bf2-bdfe-462c-97b9-55f73cd05b57"
      unitRef="usdPerShare">99.10</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="i1cf30bd35d974a5688e936ed32ee1917_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTo2NmRhZGMxYWRhOTE0NjZlODY0NWYwNDc0OTE2MjJhYy90YWJsZXJhbmdlOjY2ZGFkYzFhZGE5MTQ2NmU4NjQ1ZjA0NzQ5MTYyMmFjXzUtNy0xLTEtNDEyOTQ_4a11d1ca-13c2-4d7a-9c6d-54d5b522c91b"
      unitRef="shares">160120</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="i1cf30bd35d974a5688e936ed32ee1917_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTo2NmRhZGMxYWRhOTE0NjZlODY0NWYwNDc0OTE2MjJhYy90YWJsZXJhbmdlOjY2ZGFkYzFhZGE5MTQ2NmU4NjQ1ZjA0NzQ5MTYyMmFjXzUtOS0xLTEtNDEyOTQ_e2dd18e8-a54e-44bb-ac95-7f16aca684f8"
      unitRef="usdPerShare">99.79</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="i193ec162b3f648aaaca6368e35169ea0_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTo2NmRhZGMxYWRhOTE0NjZlODY0NWYwNDc0OTE2MjJhYy90YWJsZXJhbmdlOjY2ZGFkYzFhZGE5MTQ2NmU4NjQ1ZjA0NzQ5MTYyMmFjXzYtMC0xLTEtNDEyOTQvdGV4dHJlZ2lvbjoyYTZhOWNiOGVmNjE0ODFkYjQ0Y2ZmMWQxMjAyYTllN183Njk2NTgxMzk0NDcy_df76dc0e-fceb-4389-9e2b-a5408d2d8f5b"
      unitRef="usdPerShare">101.07</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="i193ec162b3f648aaaca6368e35169ea0_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTo2NmRhZGMxYWRhOTE0NjZlODY0NWYwNDc0OTE2MjJhYy90YWJsZXJhbmdlOjY2ZGFkYzFhZGE5MTQ2NmU4NjQ1ZjA0NzQ5MTYyMmFjXzYtMC0xLTEtNDEyOTQvdGV4dHJlZ2lvbjoyYTZhOWNiOGVmNjE0ODFkYjQ0Y2ZmMWQxMjAyYTllN183Njk2NTgxMzk0NDc2_f68c4a5c-97b0-411d-8e27-d23ac1565a35"
      unitRef="usdPerShare">117.58</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="i80a561831894449e862692a33049b0b5_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTo2NmRhZGMxYWRhOTE0NjZlODY0NWYwNDc0OTE2MjJhYy90YWJsZXJhbmdlOjY2ZGFkYzFhZGE5MTQ2NmU4NjQ1ZjA0NzQ5MTYyMmFjXzYtMS0xLTEtNDEyOTQ_7cee17a7-213b-4855-af6e-ecc48cd99c23"
      unitRef="shares">159204</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="i193ec162b3f648aaaca6368e35169ea0_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTo2NmRhZGMxYWRhOTE0NjZlODY0NWYwNDc0OTE2MjJhYy90YWJsZXJhbmdlOjY2ZGFkYzFhZGE5MTQ2NmU4NjQ1ZjA0NzQ5MTYyMmFjXzYtMy0xLTEtNDEyOTQ_154c359a-8d6c-4734-816e-e1b0199b06b4">P7Y5M12D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="i80a561831894449e862692a33049b0b5_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTo2NmRhZGMxYWRhOTE0NjZlODY0NWYwNDc0OTE2MjJhYy90YWJsZXJhbmdlOjY2ZGFkYzFhZGE5MTQ2NmU4NjQ1ZjA0NzQ5MTYyMmFjXzYtNS0xLTEtNDEyOTQ_09a594c7-8594-40a6-837d-4186d0ebac8b"
      unitRef="usdPerShare">111.26</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="i80a561831894449e862692a33049b0b5_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTo2NmRhZGMxYWRhOTE0NjZlODY0NWYwNDc0OTE2MjJhYy90YWJsZXJhbmdlOjY2ZGFkYzFhZGE5MTQ2NmU4NjQ1ZjA0NzQ5MTYyMmFjXzYtNy0xLTEtNDEyOTQ_c7b7aac4-288c-4546-a340-6db1583cbe06"
      unitRef="shares">99488</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="i80a561831894449e862692a33049b0b5_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTo2NmRhZGMxYWRhOTE0NjZlODY0NWYwNDc0OTE2MjJhYy90YWJsZXJhbmdlOjY2ZGFkYzFhZGE5MTQ2NmU4NjQ1ZjA0NzQ5MTYyMmFjXzYtOS0xLTEtNDEyOTQ_8a415eb0-ead6-4676-a525-e1850e585d41"
      unitRef="usdPerShare">111.18</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="i08eb127d3b5c4ecd8f5f19d8b095a195_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTo2NmRhZGMxYWRhOTE0NjZlODY0NWYwNDc0OTE2MjJhYy90YWJsZXJhbmdlOjY2ZGFkYzFhZGE5MTQ2NmU4NjQ1ZjA0NzQ5MTYyMmFjXzctMC0xLTEtNDEyOTQ_13b2fd94-9002-498d-9f79-044d1b6f741f"
      unitRef="usdPerShare">117.97</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="i08eb127d3b5c4ecd8f5f19d8b095a195_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTo2NmRhZGMxYWRhOTE0NjZlODY0NWYwNDc0OTE2MjJhYy90YWJsZXJhbmdlOjY2ZGFkYzFhZGE5MTQ2NmU4NjQ1ZjA0NzQ5MTYyMmFjXzctMC0xLTEtNDEyOTQ_e3543ffe-1334-4515-933a-7f0ed8a56fbb"
      unitRef="usdPerShare">117.97</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="i546fb8a918cb476380308420e935eec1_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTo2NmRhZGMxYWRhOTE0NjZlODY0NWYwNDc0OTE2MjJhYy90YWJsZXJhbmdlOjY2ZGFkYzFhZGE5MTQ2NmU4NjQ1ZjA0NzQ5MTYyMmFjXzctMS0xLTEtNDEyOTQ_4a605df4-f25b-4a8b-8c33-10385288799d"
      unitRef="shares">237292</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="i08eb127d3b5c4ecd8f5f19d8b095a195_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTo2NmRhZGMxYWRhOTE0NjZlODY0NWYwNDc0OTE2MjJhYy90YWJsZXJhbmdlOjY2ZGFkYzFhZGE5MTQ2NmU4NjQ1ZjA0NzQ5MTYyMmFjXzctMy0xLTEtNDEyOTQ_4b9b7b29-c93f-4435-b4f2-f9dd2a5c227b">P7Y1M13D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="i546fb8a918cb476380308420e935eec1_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTo2NmRhZGMxYWRhOTE0NjZlODY0NWYwNDc0OTE2MjJhYy90YWJsZXJhbmdlOjY2ZGFkYzFhZGE5MTQ2NmU4NjQ1ZjA0NzQ5MTYyMmFjXzctNS0xLTEtNDEyOTQ_4c7c0267-013d-44a5-bdb3-3b2edfa8c909"
      unitRef="usdPerShare">117.97</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="i546fb8a918cb476380308420e935eec1_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTo2NmRhZGMxYWRhOTE0NjZlODY0NWYwNDc0OTE2MjJhYy90YWJsZXJhbmdlOjY2ZGFkYzFhZGE5MTQ2NmU4NjQ1ZjA0NzQ5MTYyMmFjXzctNy0xLTEtNDEyOTQ_956f3793-96ab-4b8f-9847-3a0198c489ed"
      unitRef="shares">158958</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="i546fb8a918cb476380308420e935eec1_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTo2NmRhZGMxYWRhOTE0NjZlODY0NWYwNDc0OTE2MjJhYy90YWJsZXJhbmdlOjY2ZGFkYzFhZGE5MTQ2NmU4NjQ1ZjA0NzQ5MTYyMmFjXzctOS0xLTEtNDEyOTQ_c7b81e06-fabb-4865-a6b3-f4c172414749"
      unitRef="usdPerShare">117.97</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="i39fc20505d3849c9ae3fc61f12edf580_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTo2NmRhZGMxYWRhOTE0NjZlODY0NWYwNDc0OTE2MjJhYy90YWJsZXJhbmdlOjY2ZGFkYzFhZGE5MTQ2NmU4NjQ1ZjA0NzQ5MTYyMmFjXzgtMC0xLTEtNDEyOTQvdGV4dHJlZ2lvbjoxMGUxNDZhNDM1M2Y0ZWNlYTkwYjgwOWJmOGQwZjQ4Ml80_cf7dc826-7f46-40a3-9799-5ece63ea999e"
      unitRef="usdPerShare">119.08</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="i39fc20505d3849c9ae3fc61f12edf580_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTo2NmRhZGMxYWRhOTE0NjZlODY0NWYwNDc0OTE2MjJhYy90YWJsZXJhbmdlOjY2ZGFkYzFhZGE5MTQ2NmU4NjQ1ZjA0NzQ5MTYyMmFjXzgtMC0xLTEtNDEyOTQvdGV4dHJlZ2lvbjoxMGUxNDZhNDM1M2Y0ZWNlYTkwYjgwOWJmOGQwZjQ4Ml83_24278ead-6a39-438c-adbd-64bdede89c19"
      unitRef="usdPerShare">159.01</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="i1d0ce9ddb0d9422b8e6592ab0500d1ab_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTo2NmRhZGMxYWRhOTE0NjZlODY0NWYwNDc0OTE2MjJhYy90YWJsZXJhbmdlOjY2ZGFkYzFhZGE5MTQ2NmU4NjQ1ZjA0NzQ5MTYyMmFjXzgtMS0xLTEtNDEyOTQ_9f1b2564-5f94-40c8-b991-124ed57ed819"
      unitRef="shares">299585</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="i39fc20505d3849c9ae3fc61f12edf580_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTo2NmRhZGMxYWRhOTE0NjZlODY0NWYwNDc0OTE2MjJhYy90YWJsZXJhbmdlOjY2ZGFkYzFhZGE5MTQ2NmU4NjQ1ZjA0NzQ5MTYyMmFjXzgtMy0xLTEtNDEyOTQ_2419443b-a3b7-43e2-847d-34782876256f">P7Y</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="i1d0ce9ddb0d9422b8e6592ab0500d1ab_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTo2NmRhZGMxYWRhOTE0NjZlODY0NWYwNDc0OTE2MjJhYy90YWJsZXJhbmdlOjY2ZGFkYzFhZGE5MTQ2NmU4NjQ1ZjA0NzQ5MTYyMmFjXzgtNS0xLTEtNDEyOTQ_87a0168b-388b-4cd1-9216-284141a40f9a"
      unitRef="usdPerShare">149.40</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="i1d0ce9ddb0d9422b8e6592ab0500d1ab_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTo2NmRhZGMxYWRhOTE0NjZlODY0NWYwNDc0OTE2MjJhYy90YWJsZXJhbmdlOjY2ZGFkYzFhZGE5MTQ2NmU4NjQ1ZjA0NzQ5MTYyMmFjXzgtNy0xLTEtNDEyOTQ_fe202c11-0e30-46a0-94c9-16f379393f9c"
      unitRef="shares">205098</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="i1d0ce9ddb0d9422b8e6592ab0500d1ab_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTo2NmRhZGMxYWRhOTE0NjZlODY0NWYwNDc0OTE2MjJhYy90YWJsZXJhbmdlOjY2ZGFkYzFhZGE5MTQ2NmU4NjQ1ZjA0NzQ5MTYyMmFjXzgtOS0xLTEtNDEyOTQ_9a7a0dfa-197a-42f6-ac46-937700c3e279"
      unitRef="usdPerShare">152.50</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="i9d3219f8f79f4fb685decb79b150bd06_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTo2NmRhZGMxYWRhOTE0NjZlODY0NWYwNDc0OTE2MjJhYy90YWJsZXJhbmdlOjY2ZGFkYzFhZGE5MTQ2NmU4NjQ1ZjA0NzQ5MTYyMmFjXzktMC0xLTEtNDEyOTQvdGV4dHJlZ2lvbjo4NjQ2ODk4NDU1MGM0NjQ3YWRlYjJiMzVmMzMzMjA0NF83Njk2NTgxMzk0NDU4_32ea0568-4a51-41e7-90c2-bbd33ebd7f3f"
      unitRef="usdPerShare">159.81</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="i9d3219f8f79f4fb685decb79b150bd06_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTo2NmRhZGMxYWRhOTE0NjZlODY0NWYwNDc0OTE2MjJhYy90YWJsZXJhbmdlOjY2ZGFkYzFhZGE5MTQ2NmU4NjQ1ZjA0NzQ5MTYyMmFjXzktMC0xLTEtNDEyOTQvdGV4dHJlZ2lvbjo4NjQ2ODk4NDU1MGM0NjQ3YWRlYjJiMzVmMzMzMjA0NF83Njk2NTgxMzk0NDYy_9f3c2cbd-5d1a-4217-8da9-25ac756d2150"
      unitRef="usdPerShare">171.28</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="id7afd511815d4bc394f6e2368abd4dca_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTo2NmRhZGMxYWRhOTE0NjZlODY0NWYwNDc0OTE2MjJhYy90YWJsZXJhbmdlOjY2ZGFkYzFhZGE5MTQ2NmU4NjQ1ZjA0NzQ5MTYyMmFjXzktMS0xLTEtNDEyOTQ_c6d8ea3a-5e12-4d42-b66b-59c43617d992"
      unitRef="shares">6881</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="i9d3219f8f79f4fb685decb79b150bd06_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTo2NmRhZGMxYWRhOTE0NjZlODY0NWYwNDc0OTE2MjJhYy90YWJsZXJhbmdlOjY2ZGFkYzFhZGE5MTQ2NmU4NjQ1ZjA0NzQ5MTYyMmFjXzktMy0xLTEtNDEyOTQ_2ce372ca-6346-4cea-a349-78ad4e5a46b3">P6Y6M3D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="id7afd511815d4bc394f6e2368abd4dca_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTo2NmRhZGMxYWRhOTE0NjZlODY0NWYwNDc0OTE2MjJhYy90YWJsZXJhbmdlOjY2ZGFkYzFhZGE5MTQ2NmU4NjQ1ZjA0NzQ5MTYyMmFjXzktNS0xLTEtNDEyOTQ_ab920968-fee2-48f9-bb39-a4dd7155515c"
      unitRef="usdPerShare">166.28</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="id7afd511815d4bc394f6e2368abd4dca_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTo2NmRhZGMxYWRhOTE0NjZlODY0NWYwNDc0OTE2MjJhYy90YWJsZXJhbmdlOjY2ZGFkYzFhZGE5MTQ2NmU4NjQ1ZjA0NzQ5MTYyMmFjXzktNy0xLTEtNDEyOTQ_54bbf658-8528-4ba2-8051-affdfcd8eb10"
      unitRef="shares">5828</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="id7afd511815d4bc394f6e2368abd4dca_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTo2NmRhZGMxYWRhOTE0NjZlODY0NWYwNDc0OTE2MjJhYy90YWJsZXJhbmdlOjY2ZGFkYzFhZGE5MTQ2NmU4NjQ1ZjA0NzQ5MTYyMmFjXzktOS0xLTEtNDEyOTQ_f44ccb3e-219b-4af4-b735-73be82a216ec"
      unitRef="usdPerShare">165.62</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="i828b95c8a1d249729b55e04082a16fbe_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTo2NmRhZGMxYWRhOTE0NjZlODY0NWYwNDc0OTE2MjJhYy90YWJsZXJhbmdlOjY2ZGFkYzFhZGE5MTQ2NmU4NjQ1ZjA0NzQ5MTYyMmFjXzEwLTAtMS0xLTQxMjk0L3RleHRyZWdpb246NzFhNGJkMTNjNDk3NDc3N2JmMWRjZmY0MzRlMGVkNGZfNA_72ca4646-adff-4a37-9c5f-81af877e5a1e"
      unitRef="usdPerShare">177.50</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="i828b95c8a1d249729b55e04082a16fbe_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTo2NmRhZGMxYWRhOTE0NjZlODY0NWYwNDc0OTE2MjJhYy90YWJsZXJhbmdlOjY2ZGFkYzFhZGE5MTQ2NmU4NjQ1ZjA0NzQ5MTYyMmFjXzEwLTAtMS0xLTQxMjk0L3RleHRyZWdpb246NzFhNGJkMTNjNDk3NDc3N2JmMWRjZmY0MzRlMGVkNGZfNw_7bda48b2-7ed4-411e-b7b6-ad813a375ea9"
      unitRef="usdPerShare">195.91</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="ie43fa1c2f29449588c86ec647c987e14_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTo2NmRhZGMxYWRhOTE0NjZlODY0NWYwNDc0OTE2MjJhYy90YWJsZXJhbmdlOjY2ZGFkYzFhZGE5MTQ2NmU4NjQ1ZjA0NzQ5MTYyMmFjXzEwLTEtMS0xLTQxMjk0_901de54b-bcd4-4d52-b967-21ca99fea15a"
      unitRef="shares">243508</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="i828b95c8a1d249729b55e04082a16fbe_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTo2NmRhZGMxYWRhOTE0NjZlODY0NWYwNDc0OTE2MjJhYy90YWJsZXJhbmdlOjY2ZGFkYzFhZGE5MTQ2NmU4NjQ1ZjA0NzQ5MTYyMmFjXzEwLTMtMS0xLTQxMjk0_6dbb385b-c81c-4330-871c-c13dc4513439">P8Y10M28D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="ie43fa1c2f29449588c86ec647c987e14_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTo2NmRhZGMxYWRhOTE0NjZlODY0NWYwNDc0OTE2MjJhYy90YWJsZXJhbmdlOjY2ZGFkYzFhZGE5MTQ2NmU4NjQ1ZjA0NzQ5MTYyMmFjXzEwLTUtMS0xLTQxMjk0_bafa13f0-c1c0-41b2-9c4a-03562f452553"
      unitRef="usdPerShare">178.62</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="ie43fa1c2f29449588c86ec647c987e14_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTo2NmRhZGMxYWRhOTE0NjZlODY0NWYwNDc0OTE2MjJhYy90YWJsZXJhbmdlOjY2ZGFkYzFhZGE5MTQ2NmU4NjQ1ZjA0NzQ5MTYyMmFjXzEwLTctMS0xLTQxMjk0_e62a5b20-33fc-4c46-b6e7-56835086910d"
      unitRef="shares">62932</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="ie43fa1c2f29449588c86ec647c987e14_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTo2NmRhZGMxYWRhOTE0NjZlODY0NWYwNDc0OTE2MjJhYy90YWJsZXJhbmdlOjY2ZGFkYzFhZGE5MTQ2NmU4NjQ1ZjA0NzQ5MTYyMmFjXzEwLTktMS0xLTQxMjk0_fcfa4f3c-c439-48b9-a5e2-fe7350286528"
      unitRef="usdPerShare">181.84</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="i331ce2c9b57a41af9de97ff9994cb5b5_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTo2NmRhZGMxYWRhOTE0NjZlODY0NWYwNDc0OTE2MjJhYy90YWJsZXJhbmdlOjY2ZGFkYzFhZGE5MTQ2NmU4NjQ1ZjA0NzQ5MTYyMmFjXzExLTEtMS0xLTQxMjk0_8c6e41c6-6ec7-46a3-8aa6-5eabe68b5098"
      unitRef="shares">2199598</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="i6d7b08b9d22043d5932cf089d69eba52_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTo2NmRhZGMxYWRhOTE0NjZlODY0NWYwNDc0OTE2MjJhYy90YWJsZXJhbmdlOjY2ZGFkYzFhZGE5MTQ2NmU4NjQ1ZjA0NzQ5MTYyMmFjXzExLTMtMS0xLTQxMjk0_a82229b7-bfa1-41bd-90bf-2c7b8eef6025">P6Y4M2D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="i331ce2c9b57a41af9de97ff9994cb5b5_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTo2NmRhZGMxYWRhOTE0NjZlODY0NWYwNDc0OTE2MjJhYy90YWJsZXJhbmdlOjY2ZGFkYzFhZGE5MTQ2NmU4NjQ1ZjA0NzQ5MTYyMmFjXzExLTUtMS0xLTQxMjk0_15e750f2-a35c-4c41-b964-8d56e3ee9a2d"
      unitRef="usdPerShare">106.00</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="i331ce2c9b57a41af9de97ff9994cb5b5_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTo2NmRhZGMxYWRhOTE0NjZlODY0NWYwNDc0OTE2MjJhYy90YWJsZXJhbmdlOjY2ZGFkYzFhZGE5MTQ2NmU4NjQ1ZjA0NzQ5MTYyMmFjXzExLTctMS0xLTQxMjk0_dd6b5e48-8531-4421-bcb0-1526a025eb93"
      unitRef="shares">1391952</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="i331ce2c9b57a41af9de97ff9994cb5b5_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTo2NmRhZGMxYWRhOTE0NjZlODY0NWYwNDc0OTE2MjJhYy90YWJsZXJhbmdlOjY2ZGFkYzFhZGE5MTQ2NmU4NjQ1ZjA0NzQ5MTYyMmFjXzExLTktMS0xLTQxMjk0_0c1a86a7-02cb-4f70-a4a1-2c693bc3a684"
      unitRef="usdPerShare">98.16</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90ZXh0cmVnaW9uOjk1MzhkNjI5YTc4YTQ4ZmY4NmJhMjZmMzlkMjRiMWI5XzM2MTY_7e0a75bb-6bd2-40c2-b3f1-a5006380ad6e">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The assumptions used for the specified reporting periods and the resulting estimates of weighted-average grant date fair value per share of options granted:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.538%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:52.609%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.440%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.986%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.440%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.541%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.440%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="18" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.4%-1.2%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2%-1.4%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.4%-2.6%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47%-63%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47%-71%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40%-49%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.7 to 6.3 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.7 to 5.1 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.6 to 5.9 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i5258348dd679493ba1253e4703ac77de_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTozMjJjMTIwZjEyNGM0ZWQyOTczNzAxYjQyNzhlYjk3My90YWJsZXJhbmdlOjMyMmMxMjBmMTI0YzRlZDI5NzM3MDFiNDI3OGViOTczXzItMS0xLTEtNDEyOTQvdGV4dHJlZ2lvbjoxNWZlZmRiZjc0NzE0NThjYTc3NTYwYjBmZTEwZmFlN180_17a26447-5f78-4f94-a0e0-861dadaf5687"
      unitRef="number">0.004</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i55156c07b9684b9185860bad3331609a_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTozMjJjMTIwZjEyNGM0ZWQyOTczNzAxYjQyNzhlYjk3My90YWJsZXJhbmdlOjMyMmMxMjBmMTI0YzRlZDI5NzM3MDFiNDI3OGViOTczXzItMS0xLTEtNDEyOTQvdGV4dHJlZ2lvbjoxNWZlZmRiZjc0NzE0NThjYTc3NTYwYjBmZTEwZmFlN183_2036c923-7605-4259-b5b2-64966166176e"
      unitRef="number">0.012</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i8c53cef7494647d29b8ef30c6695cfb2_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTozMjJjMTIwZjEyNGM0ZWQyOTczNzAxYjQyNzhlYjk3My90YWJsZXJhbmdlOjMyMmMxMjBmMTI0YzRlZDI5NzM3MDFiNDI3OGViOTczXzItMy0xLTEtNDEyOTQvdGV4dHJlZ2lvbjo4ZGFhNGFhY2YwY2E0MDhjYjk0OWM5MjNiOGQ0Y2JlZl80_c90da793-3be5-49dd-a4b5-5763bfd7f5c1"
      unitRef="number">0.002</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i0addec58007345efb57ddbad8ce96022_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTozMjJjMTIwZjEyNGM0ZWQyOTczNzAxYjQyNzhlYjk3My90YWJsZXJhbmdlOjMyMmMxMjBmMTI0YzRlZDI5NzM3MDFiNDI3OGViOTczXzItMy0xLTEtNDEyOTQvdGV4dHJlZ2lvbjo4ZGFhNGFhY2YwY2E0MDhjYjk0OWM5MjNiOGQ0Y2JlZl83_77724b1f-12eb-4830-9437-4005e2fa57c6"
      unitRef="number">0.014</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="id82d912299e647bab45143f83254b4e2_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTozMjJjMTIwZjEyNGM0ZWQyOTczNzAxYjQyNzhlYjk3My90YWJsZXJhbmdlOjMyMmMxMjBmMTI0YzRlZDI5NzM3MDFiNDI3OGViOTczXzItNS0xLTEtNDEyOTQvdGV4dHJlZ2lvbjo5Y2E2ZTVjZDRlMDA0ODJkYjYyODViYzUyYzgyMmJkZl80_baa39e95-a66e-40bf-86dc-2aa0d3e4a1c1"
      unitRef="number">0.014</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i9d152e0e9dfd4aad8d4279f7424f28d5_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTozMjJjMTIwZjEyNGM0ZWQyOTczNzAxYjQyNzhlYjk3My90YWJsZXJhbmdlOjMyMmMxMjBmMTI0YzRlZDI5NzM3MDFiNDI3OGViOTczXzItNS0xLTEtNDEyOTQvdGV4dHJlZ2lvbjo5Y2E2ZTVjZDRlMDA0ODJkYjYyODViYzUyYzgyMmJkZl83_3645d263-a716-4267-998e-46dcc6042aee"
      unitRef="number">0.026</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i5258348dd679493ba1253e4703ac77de_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTozMjJjMTIwZjEyNGM0ZWQyOTczNzAxYjQyNzhlYjk3My90YWJsZXJhbmdlOjMyMmMxMjBmMTI0YzRlZDI5NzM3MDFiNDI3OGViOTczXzMtMS0xLTEtNDEyOTQvdGV4dHJlZ2lvbjo3MTE4OGU1MmY0YTk0ODdiOGIwNDU3MWI0ZWViZGFkOV80_089c02e1-9098-4530-b3f3-c0071599fdf3"
      unitRef="number">0.47</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i55156c07b9684b9185860bad3331609a_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTozMjJjMTIwZjEyNGM0ZWQyOTczNzAxYjQyNzhlYjk3My90YWJsZXJhbmdlOjMyMmMxMjBmMTI0YzRlZDI5NzM3MDFiNDI3OGViOTczXzMtMS0xLTEtNDEyOTQvdGV4dHJlZ2lvbjo3MTE4OGU1MmY0YTk0ODdiOGIwNDU3MWI0ZWViZGFkOV83_2b71a5ae-d6e3-4fb2-801f-198c112b36f2"
      unitRef="number">0.63</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i8c53cef7494647d29b8ef30c6695cfb2_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTozMjJjMTIwZjEyNGM0ZWQyOTczNzAxYjQyNzhlYjk3My90YWJsZXJhbmdlOjMyMmMxMjBmMTI0YzRlZDI5NzM3MDFiNDI3OGViOTczXzMtMy0xLTEtNDEyOTQvdGV4dHJlZ2lvbjo3YTczMTJhOTcwNWQ0NDJhOTRmY2JiMjI2NDRkZjU2Ml80_4d1fc16e-df47-4edd-862b-7b91ca3e002a"
      unitRef="number">0.47</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i0addec58007345efb57ddbad8ce96022_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTozMjJjMTIwZjEyNGM0ZWQyOTczNzAxYjQyNzhlYjk3My90YWJsZXJhbmdlOjMyMmMxMjBmMTI0YzRlZDI5NzM3MDFiNDI3OGViOTczXzMtMy0xLTEtNDEyOTQvdGV4dHJlZ2lvbjo3YTczMTJhOTcwNWQ0NDJhOTRmY2JiMjI2NDRkZjU2Ml83_b9d40fe6-adbe-40fb-8312-fe5f2892c689"
      unitRef="number">0.71</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="id82d912299e647bab45143f83254b4e2_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTozMjJjMTIwZjEyNGM0ZWQyOTczNzAxYjQyNzhlYjk3My90YWJsZXJhbmdlOjMyMmMxMjBmMTI0YzRlZDI5NzM3MDFiNDI3OGViOTczXzMtNS0xLTEtNDEyOTQvdGV4dHJlZ2lvbjo2NTg4OWFhN2IzYmE0MGQxYjhhZjhhODAzNDQ3YzJiYl80_a354e227-47a7-49d5-93b9-55fe47faeb4e"
      unitRef="number">0.40</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i9d152e0e9dfd4aad8d4279f7424f28d5_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTozMjJjMTIwZjEyNGM0ZWQyOTczNzAxYjQyNzhlYjk3My90YWJsZXJhbmdlOjMyMmMxMjBmMTI0YzRlZDI5NzM3MDFiNDI3OGViOTczXzMtNS0xLTEtNDEyOTQvdGV4dHJlZ2lvbjo2NTg4OWFhN2IzYmE0MGQxYjhhZjhhODAzNDQ3YzJiYl83_07c2a8fe-8a21-44f4-96fc-dc6f9fbc5caf"
      unitRef="number">0.49</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i5258348dd679493ba1253e4703ac77de_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTozMjJjMTIwZjEyNGM0ZWQyOTczNzAxYjQyNzhlYjk3My90YWJsZXJhbmdlOjMyMmMxMjBmMTI0YzRlZDI5NzM3MDFiNDI3OGViOTczXzQtMS0xLTEtNDEyOTQvdGV4dHJlZ2lvbjpkMDQyMjRhMDljZGI0ZDQ1YmE4ZTQzYmVjNWRkOGZkOV80_03d55ac4-83a4-4d1f-b17e-a499a0e071d0">P4Y8M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i55156c07b9684b9185860bad3331609a_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTozMjJjMTIwZjEyNGM0ZWQyOTczNzAxYjQyNzhlYjk3My90YWJsZXJhbmdlOjMyMmMxMjBmMTI0YzRlZDI5NzM3MDFiNDI3OGViOTczXzQtMS0xLTEtNDEyOTQvdGV4dHJlZ2lvbjpkMDQyMjRhMDljZGI0ZDQ1YmE4ZTQzYmVjNWRkOGZkOV8xMA_3063dceb-1bc4-4cb9-827d-38b31692b86b">P6Y3M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i8c53cef7494647d29b8ef30c6695cfb2_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTozMjJjMTIwZjEyNGM0ZWQyOTczNzAxYjQyNzhlYjk3My90YWJsZXJhbmdlOjMyMmMxMjBmMTI0YzRlZDI5NzM3MDFiNDI3OGViOTczXzQtMy0xLTEtNDEyOTQvdGV4dHJlZ2lvbjo5OWIxNTc0YWY4Y2E0YTczYmUxYTI0YWE1OTM0ZTE0ZF80_5400b9d7-4640-44e9-b224-334e8b8d0bb6">P4Y8M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i0addec58007345efb57ddbad8ce96022_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTozMjJjMTIwZjEyNGM0ZWQyOTczNzAxYjQyNzhlYjk3My90YWJsZXJhbmdlOjMyMmMxMjBmMTI0YzRlZDI5NzM3MDFiNDI3OGViOTczXzQtMy0xLTEtNDEyOTQvdGV4dHJlZ2lvbjo5OWIxNTc0YWY4Y2E0YTczYmUxYTI0YWE1OTM0ZTE0ZF8xMA_eeecbc45-4b25-43d5-8291-7151614ed278">P5Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="id82d912299e647bab45143f83254b4e2_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTozMjJjMTIwZjEyNGM0ZWQyOTczNzAxYjQyNzhlYjk3My90YWJsZXJhbmdlOjMyMmMxMjBmMTI0YzRlZDI5NzM3MDFiNDI3OGViOTczXzQtNS0xLTEtNDEyOTQvdGV4dHJlZ2lvbjoyNGIxMzFhOTU2ZjY0YmE5OWYyYjRmMTgwZTI2YjdhY180_89c3e5c1-c16e-4f4a-aabc-5a1e7dd82aec">P4Y7M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i9d152e0e9dfd4aad8d4279f7424f28d5_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZTozMjJjMTIwZjEyNGM0ZWQyOTczNzAxYjQyNzhlYjk3My90YWJsZXJhbmdlOjMyMmMxMjBmMTI0YzRlZDI5NzM3MDFiNDI3OGViOTczXzQtNS0xLTEtNDEyOTQvdGV4dHJlZ2lvbjoyNGIxMzFhOTU2ZjY0YmE5OWYyYjRmMTgwZTI2YjdhY18xMA_375c4d39-cd66-4bad-ae5a-de106f979d65">P5Y10M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="i0f9a89ad3d5346e3b8b17b7dfbcb9f78_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90ZXh0cmVnaW9uOjk1MzhkNjI5YTc4YTQ4ZmY4NmJhMjZmMzlkMjRiMWI5XzExMjA_42882426-c5b1-4184-bbb0-fff7bcbada01"
      unitRef="usd">40700000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i0b2d2a0659724a0394359a72b0ded635_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90ZXh0cmVnaW9uOjk1MzhkNjI5YTc4YTQ4ZmY4NmJhMjZmMzlkMjRiMWI5XzEyNzQ_0b694ac3-042b-4e1f-ab94-c9239b7ef221">P2Y4M24D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock
      contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90ZXh0cmVnaW9uOjk1MzhkNjI5YTc4YTQ4ZmY4NmJhMjZmMzlkMjRiMWI5XzM2MjE_6aef95ae-e721-4c1a-8e9d-f18aba36d613">&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a summary of our restricted stock activity and related information:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:69.929%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.458%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.578%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" rowspan="2" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Grant&#160;Date Fair&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="12" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at January 1, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;132,273&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;130.63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;118,498&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;115.90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(102,846)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;121.55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(666)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;134.36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December&#160;31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;147,259&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;125.11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;111,306&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89.73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(52,363)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;121.69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December&#160;31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;206,202&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;106.88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;167,292&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;169.63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(98,501)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;125.59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,850)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;141.85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December&#160;31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;264,143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;138.21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i45bcdaf84c91401486b1d0398942843d_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZToxM2ZlNjM5MjgyMjk0M2QwYWNmM2I4N2FmNjJiYmU2Mi90YWJsZXJhbmdlOjEzZmU2MzkyODIyOTQzZDBhY2YzYjg3YWY2MmJiZTYyXzItMS0xLTEtNDEyOTQ_757e8986-f79d-4984-b32e-a3e74cd5aa48"
      unitRef="shares">132273</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i45bcdaf84c91401486b1d0398942843d_I20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZToxM2ZlNjM5MjgyMjk0M2QwYWNmM2I4N2FmNjJiYmU2Mi90YWJsZXJhbmdlOjEzZmU2MzkyODIyOTQzZDBhY2YzYjg3YWY2MmJiZTYyXzItMy0xLTEtNDEyOTQ_382d1026-7edb-4866-9064-0324d1d410c8"
      unitRef="usdPerShare">130.63</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i58f6278b54d04be0bf0b9577c087f56c_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZToxM2ZlNjM5MjgyMjk0M2QwYWNmM2I4N2FmNjJiYmU2Mi90YWJsZXJhbmdlOjEzZmU2MzkyODIyOTQzZDBhY2YzYjg3YWY2MmJiZTYyXzMtMS0xLTEtNDEyOTQ_11ba626e-7710-4f16-b6e2-585d3d2f2995"
      unitRef="shares">118498</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i58f6278b54d04be0bf0b9577c087f56c_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZToxM2ZlNjM5MjgyMjk0M2QwYWNmM2I4N2FmNjJiYmU2Mi90YWJsZXJhbmdlOjEzZmU2MzkyODIyOTQzZDBhY2YzYjg3YWY2MmJiZTYyXzMtMy0xLTEtNDEyOTQ_c22a1f01-868f-40f6-8516-7e659d500b02"
      unitRef="usdPerShare">115.90</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="i58f6278b54d04be0bf0b9577c087f56c_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZToxM2ZlNjM5MjgyMjk0M2QwYWNmM2I4N2FmNjJiYmU2Mi90YWJsZXJhbmdlOjEzZmU2MzkyODIyOTQzZDBhY2YzYjg3YWY2MmJiZTYyXzQtMS0xLTEtNDEyOTQ_7d21fd66-0098-47c0-ae73-f0017c181868"
      unitRef="shares">102846</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="i58f6278b54d04be0bf0b9577c087f56c_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZToxM2ZlNjM5MjgyMjk0M2QwYWNmM2I4N2FmNjJiYmU2Mi90YWJsZXJhbmdlOjEzZmU2MzkyODIyOTQzZDBhY2YzYjg3YWY2MmJiZTYyXzQtMy0xLTEtNDEyOTQ_3e5089e2-5523-4003-9792-a792096303d7"
      unitRef="usdPerShare">121.55</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="i58f6278b54d04be0bf0b9577c087f56c_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZToxM2ZlNjM5MjgyMjk0M2QwYWNmM2I4N2FmNjJiYmU2Mi90YWJsZXJhbmdlOjEzZmU2MzkyODIyOTQzZDBhY2YzYjg3YWY2MmJiZTYyXzUtMS0xLTEtNDEyOTQ_3f2213c6-35ea-4290-82fd-83ce0f2af1c8"
      unitRef="shares">666</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="i58f6278b54d04be0bf0b9577c087f56c_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZToxM2ZlNjM5MjgyMjk0M2QwYWNmM2I4N2FmNjJiYmU2Mi90YWJsZXJhbmdlOjEzZmU2MzkyODIyOTQzZDBhY2YzYjg3YWY2MmJiZTYyXzUtMy0xLTEtNDEyOTQ_5f1cffd1-3492-4e83-9cc2-67559bce6a59"
      unitRef="usdPerShare">134.36</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i5adbf2e3e4984848b67e5715f6848f1d_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZToxM2ZlNjM5MjgyMjk0M2QwYWNmM2I4N2FmNjJiYmU2Mi90YWJsZXJhbmdlOjEzZmU2MzkyODIyOTQzZDBhY2YzYjg3YWY2MmJiZTYyXzYtMS0xLTEtNDQyNTA_1797c792-3285-421e-b116-dbe16c6e5cdd"
      unitRef="shares">147259</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i5adbf2e3e4984848b67e5715f6848f1d_I20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZToxM2ZlNjM5MjgyMjk0M2QwYWNmM2I4N2FmNjJiYmU2Mi90YWJsZXJhbmdlOjEzZmU2MzkyODIyOTQzZDBhY2YzYjg3YWY2MmJiZTYyXzYtMy0xLTEtNDEyOTQ_2b07e6cc-0772-481f-9c1c-667aa348c066"
      unitRef="usdPerShare">125.11</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i6a0c3b111e7c4e828d7eda58eb7efe37_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZToxM2ZlNjM5MjgyMjk0M2QwYWNmM2I4N2FmNjJiYmU2Mi90YWJsZXJhbmdlOjEzZmU2MzkyODIyOTQzZDBhY2YzYjg3YWY2MmJiZTYyXzctMS0xLTEtNDEyOTQ_917b574e-d102-4815-ade7-692162a7b094"
      unitRef="shares">111306</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i6a0c3b111e7c4e828d7eda58eb7efe37_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZToxM2ZlNjM5MjgyMjk0M2QwYWNmM2I4N2FmNjJiYmU2Mi90YWJsZXJhbmdlOjEzZmU2MzkyODIyOTQzZDBhY2YzYjg3YWY2MmJiZTYyXzctMy0xLTEtNDEyOTQ_44e844c6-8ff0-4494-9f5d-a1d025d668db"
      unitRef="usdPerShare">89.73</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="i6a0c3b111e7c4e828d7eda58eb7efe37_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZToxM2ZlNjM5MjgyMjk0M2QwYWNmM2I4N2FmNjJiYmU2Mi90YWJsZXJhbmdlOjEzZmU2MzkyODIyOTQzZDBhY2YzYjg3YWY2MmJiZTYyXzgtMS0xLTEtNDEyOTQ_b722cafe-d262-4a3e-97f2-60f0bd7b20cb"
      unitRef="shares">52363</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="i6a0c3b111e7c4e828d7eda58eb7efe37_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZToxM2ZlNjM5MjgyMjk0M2QwYWNmM2I4N2FmNjJiYmU2Mi90YWJsZXJhbmdlOjEzZmU2MzkyODIyOTQzZDBhY2YzYjg3YWY2MmJiZTYyXzgtMy0xLTEtNDEyOTQ_2eff9bb0-6758-4e37-91c7-ae8f4c12b385"
      unitRef="usdPerShare">121.69</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="i6a0c3b111e7c4e828d7eda58eb7efe37_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZToxM2ZlNjM5MjgyMjk0M2QwYWNmM2I4N2FmNjJiYmU2Mi90YWJsZXJhbmdlOjEzZmU2MzkyODIyOTQzZDBhY2YzYjg3YWY2MmJiZTYyXzktMS0xLTEtNDEyOTQ_e1e724f8-b039-4606-8d38-ad8016c82658"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="i6a0c3b111e7c4e828d7eda58eb7efe37_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZToxM2ZlNjM5MjgyMjk0M2QwYWNmM2I4N2FmNjJiYmU2Mi90YWJsZXJhbmdlOjEzZmU2MzkyODIyOTQzZDBhY2YzYjg3YWY2MmJiZTYyXzktMy0xLTEtNDEyOTQ_d463bdaa-3d64-4931-ab77-7e8d841884fc"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="ice6ab2e1895644b3904facb98212b670_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZToxM2ZlNjM5MjgyMjk0M2QwYWNmM2I4N2FmNjJiYmU2Mi90YWJsZXJhbmdlOjEzZmU2MzkyODIyOTQzZDBhY2YzYjg3YWY2MmJiZTYyXzEwLTEtMS0xLTQ0MjUy_f7f0420f-0bcc-462a-9de4-96b014c8436a"
      unitRef="shares">206202</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="ice6ab2e1895644b3904facb98212b670_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZToxM2ZlNjM5MjgyMjk0M2QwYWNmM2I4N2FmNjJiYmU2Mi90YWJsZXJhbmdlOjEzZmU2MzkyODIyOTQzZDBhY2YzYjg3YWY2MmJiZTYyXzEwLTMtMS0xLTQxMjk0_8501bac5-0e88-44e9-a440-e788daf56c62"
      unitRef="usdPerShare">106.88</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="ifcdd30f034184cecb366b0b9b1bd9c55_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZToxM2ZlNjM5MjgyMjk0M2QwYWNmM2I4N2FmNjJiYmU2Mi90YWJsZXJhbmdlOjEzZmU2MzkyODIyOTQzZDBhY2YzYjg3YWY2MmJiZTYyXzExLTEtMS0xLTQxMjk0_fd890faf-df60-4c7b-8068-39bd687cbefa"
      unitRef="shares">167292</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="ifcdd30f034184cecb366b0b9b1bd9c55_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZToxM2ZlNjM5MjgyMjk0M2QwYWNmM2I4N2FmNjJiYmU2Mi90YWJsZXJhbmdlOjEzZmU2MzkyODIyOTQzZDBhY2YzYjg3YWY2MmJiZTYyXzExLTMtMS0xLTQxMjk0_e6c998e6-9779-479c-ad56-6efd758f7fab"
      unitRef="usdPerShare">169.63</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="ifcdd30f034184cecb366b0b9b1bd9c55_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZToxM2ZlNjM5MjgyMjk0M2QwYWNmM2I4N2FmNjJiYmU2Mi90YWJsZXJhbmdlOjEzZmU2MzkyODIyOTQzZDBhY2YzYjg3YWY2MmJiZTYyXzEyLTEtMS0xLTQxMjk0_46fdeef3-a373-47b6-884a-bde719b59e8a"
      unitRef="shares">98501</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="ifcdd30f034184cecb366b0b9b1bd9c55_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZToxM2ZlNjM5MjgyMjk0M2QwYWNmM2I4N2FmNjJiYmU2Mi90YWJsZXJhbmdlOjEzZmU2MzkyODIyOTQzZDBhY2YzYjg3YWY2MmJiZTYyXzEyLTMtMS0xLTQxMjk0_f89253f3-8855-46b1-b8e0-66549182be3e"
      unitRef="usdPerShare">125.59</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="ifcdd30f034184cecb366b0b9b1bd9c55_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZToxM2ZlNjM5MjgyMjk0M2QwYWNmM2I4N2FmNjJiYmU2Mi90YWJsZXJhbmdlOjEzZmU2MzkyODIyOTQzZDBhY2YzYjg3YWY2MmJiZTYyXzEzLTEtMS0xLTQxMjk0_f696c10d-f0a0-479a-866a-f0a4f3fbfd1f"
      unitRef="shares">10850</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="ifcdd30f034184cecb366b0b9b1bd9c55_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZToxM2ZlNjM5MjgyMjk0M2QwYWNmM2I4N2FmNjJiYmU2Mi90YWJsZXJhbmdlOjEzZmU2MzkyODIyOTQzZDBhY2YzYjg3YWY2MmJiZTYyXzEzLTMtMS0xLTQxMjk0_26dc45e4-78a9-4540-8635-d703c8bda000"
      unitRef="usdPerShare">141.85</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="ibc879451c38048cb9a8e8aa28472a4b5_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZToxM2ZlNjM5MjgyMjk0M2QwYWNmM2I4N2FmNjJiYmU2Mi90YWJsZXJhbmdlOjEzZmU2MzkyODIyOTQzZDBhY2YzYjg3YWY2MmJiZTYyXzE0LTEtMS0xLTQ0MjU0_b5392dd4-0a36-4132-89d3-51c5ea10c910"
      unitRef="shares">264143</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="ibc879451c38048cb9a8e8aa28472a4b5_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90YWJsZToxM2ZlNjM5MjgyMjk0M2QwYWNmM2I4N2FmNjJiYmU2Mi90YWJsZXJhbmdlOjEzZmU2MzkyODIyOTQzZDBhY2YzYjg3YWY2MmJiZTYyXzE0LTMtMS0xLTQxMjk0_e406bd58-75db-4c15-94e2-340246f89ced"
      unitRef="usdPerShare">138.21</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="ibc879451c38048cb9a8e8aa28472a4b5_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90ZXh0cmVnaW9uOjk1MzhkNjI5YTc4YTQ4ZmY4NmJhMjZmMzlkMjRiMWI5XzE0ODA_b2f92086-621c-44cc-9130-16949e98969f"
      unitRef="usd">20600000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="ifcdd30f034184cecb366b0b9b1bd9c55_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90ZXh0cmVnaW9uOjk1MzhkNjI5YTc4YTQ4ZmY4NmJhMjZmMzlkMjRiMWI5XzE1NTc_ef2c532b-4f3a-4106-a489-3194e51fca0a">P1Y7M6D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i22382abe9f7a467bbc034256835a449a_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90ZXh0cmVnaW9uOjk1MzhkNjI5YTc4YTQ4ZmY4NmJhMjZmMzlkMjRiMWI5XzE2MDI_ca7c3880-a776-412f-8501-07cfbdb630be"
      unitRef="shares">44360</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee
      contextRef="i0776b86882ee4f22a11770402d0e2885_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90ZXh0cmVnaW9uOjk1MzhkNjI5YTc4YTQ4ZmY4NmJhMjZmMzlkMjRiMWI5XzE3Nzc_8184b00a-57c6-40b8-9ea7-5443940c432d"
      unitRef="shares">1250</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="i0776b86882ee4f22a11770402d0e2885_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90ZXh0cmVnaW9uOjk1MzhkNjI5YTc4YTQ4ZmY4NmJhMjZmMzlkMjRiMWI5XzE5MzU_61c76c8a-b8c7-4677-bfbf-e901d0c212b8"
      unitRef="number">0.85</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
      contextRef="i0776b86882ee4f22a11770402d0e2885_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90ZXh0cmVnaW9uOjk1MzhkNjI5YTc4YTQ4ZmY4NmJhMjZmMzlkMjRiMWI5XzIwNzY_2b20f346-f342-4637-8850-3b648f6eb5b8"
      unitRef="shares">8448</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
      contextRef="i535be16f293842b4b59ed978a4dea350_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90ZXh0cmVnaW9uOjk1MzhkNjI5YTc4YTQ4ZmY4NmJhMjZmMzlkMjRiMWI5XzIwODA_547f1936-460d-4a72-a813-c9c54af71e20"
      unitRef="shares">6455</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
      contextRef="ie6271140c911499083fbafdeb97da802_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90ZXh0cmVnaW9uOjk1MzhkNjI5YTc4YTQ4ZmY4NmJhMjZmMzlkMjRiMWI5XzIwODc_f2d72be6-bd88-47a0-937d-ca8947cb3911"
      unitRef="shares">4745</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <us-gaap:StockRepurchaseProgramAuthorizedAmount1
      contextRef="i66cf645fedeb4e3f9127e1557bedf870_I20190911"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90ZXh0cmVnaW9uOjk1MzhkNjI5YTc4YTQ4ZmY4NmJhMjZmMzlkMjRiMWI5XzI4MDg_bc3d0a93-480e-448d-9967-e17426f6836a"
      unitRef="usd">500000000</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:StockRepurchaseProgramPeriodInForce1
      contextRef="i4f38082a14de4b7eb626c9119b5258a9_D20190911-20190911"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90ZXh0cmVnaW9uOjk1MzhkNjI5YTc4YTQ4ZmY4NmJhMjZmMzlkMjRiMWI5XzI4NjM_250e5d2a-e2ef-4986-98ec-ec9bb1986c3b">P3Y</us-gaap:StockRepurchaseProgramPeriodInForce1>
    <us-gaap:StockRepurchaseProgramAuthorizedAmount1
      contextRef="i4cf8373f29714ddb8d2a41d990b0fb42_I20190123"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90ZXh0cmVnaW9uOjk1MzhkNjI5YTc4YTQ4ZmY4NmJhMjZmMzlkMjRiMWI5XzMyODc_40aa2f53-5909-49ac-b514-1a7cd6b014ac"
      unitRef="usd">350000000</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1
      contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90ZXh0cmVnaW9uOjk1MzhkNjI5YTc4YTQ4ZmY4NmJhMjZmMzlkMjRiMWI5XzM0NDM_fe145922-dae5-42fe-af64-10bd03b16818"
      unitRef="usd">248800000</us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90ZXh0cmVnaW9uOjk1MzhkNjI5YTc4YTQ4ZmY4NmJhMjZmMzlkMjRiMWI5XzIxOTkwMjMyNTk4MTc_6cdc2055-ec5d-457a-8fac-d12eea400434"
      unitRef="usd">0</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="ib3597315a63d441f8f128abd7ed8840e_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90ZXh0cmVnaW9uOjk1MzhkNjI5YTc4YTQ4ZmY4NmJhMjZmMzlkMjRiMWI5XzM1NTg_710283a0-9a41-4679-9c5f-44c1e9bce94f"
      unitRef="shares">934079</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="ib3597315a63d441f8f128abd7ed8840e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90ZXh0cmVnaW9uOjk1MzhkNjI5YTc4YTQ4ZmY4NmJhMjZmMzlkMjRiMWI5XzM1NzI_c8569fbc-26e3-4b1a-9c0d-20b32e20589f"
      unitRef="usd">78000000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="ie6c3b69702e9429aaeed46bdb9bbb9c1_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90ZXh0cmVnaW9uOjk1MzhkNjI5YTc4YTQ4ZmY4NmJhMjZmMzlkMjRiMWI5XzM1ODA_f7e382db-b94c-4326-9f61-0dd406488f7c"
      unitRef="shares">4122133</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="ie6c3b69702e9429aaeed46bdb9bbb9c1_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTIvZnJhZzo5NTM4ZDYyOWE3OGE0OGZmODZiYTI2ZjM5ZDI0YjFiOS90ZXh0cmVnaW9uOjk1MzhkNjI5YTc4YTQ4ZmY4NmJhMjZmMzlkMjRiMWI5XzM1OTQ_b100d521-1327-462a-b0a6-036a2bba5953"
      unitRef="usd">448400000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTUvZnJhZzo1MjlkZGUzNDYzMzY0NTAzODBhMzY5YWM3M2E5YWE0Mi90ZXh0cmVnaW9uOjUyOWRkZTM0NjMzNjQ1MDM4MGEzNjlhYzczYTlhYTQyXzY3OTg_ef8def16-04a4-4bc4-9b16-b55e9cecda56">Commitment and Contingencies: Legal Proceedings&lt;div&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We record an estimate of a loss when the loss is considered probable and estimable. Where a liability is probable and there is a range of estimated loss and no amount in the range is more likely than any other number in the range, we record the minimum estimated liability related to the claim in accordance with &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ASC 450,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; Contingencies&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. As additional information becomes available, we assess the potential liability related to our pending litigation and revises our estimates. Revisions in our estimates of potential liability could materially impact our results of operations.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On April 9, 2019, CyDex, our wholly-owned subsidiary, received a Paragraph IV certification Notice Letter from Alembic Global Holdings SA (&#x201c;Alembic&#x201d;) stating that Alembic had submitted an ANDA to the FDA, seeking approval to manufacture, offer to sell, and sell a generic version of EVOMELA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; prior to the expiration of any of the &#x2019;077 patent; the &#x2019;088 patent, the &#x2019;582 patent, or U.S. Patent No. 10,040,872 (&#x201c;the &#x2019;872 patent&#x201d;), and alleging that these patents, each of which relates to Captisol, are invalid, unenforceable, and/or would not be infringed by Alembic&#x2019;s ANDA product. On May 23, 2019, CyDex filed a complaint against Alembic, Alembic Pharmaceuticals, Ltd., and Alembic Pharmaceuticals, Inc. in the U.S. District Court for the District of Delaware, asserting that the filing of Alembic&#x2019;s ANDA constitutes infringement of each of the &#x2019;088 patent and the &#x2019;582 patent. The parties entered into a settlement agreement on June 1, 2021 and the lawsuit has been dismissed.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On September 16, 2019, CyDex received a Paragraph IV certification Notice Letter from Lupin Ltd. (&#x201c;Lupin&#x201d;) stating that Lupin had submitted an ANDA to the FDA, seeking approval to manufacture, offer to sell, and sell a generic version of EVOMELA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; prior to the expiration of any of the &#x2019;077 patent; the &#x2019;088 patent, the &#x2019;582 patent, or the &#x2019;872 patent, and alleging that these patents, each of which relates to Captisol, are invalid, unenforceable, and/or would not be infringed by Lupin&#x2019;s ANDA product. CyDex filed a complaint on October 29, 2019, alleging patent infringement against Lupin. Lupin filed an answer on December 11, 2019 and counterclaimed for declaratory judgments of invalidity and non-infringement as to all four patents and CyDex filed its answer to Lupin&#x2019;s counterclaims on January 2, 2020. The parties entered into a settlement agreement on April 26, 2021 and the lawsuit has been dismissed.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On October 31, 2019, we received three civil complaints filed in the U.S. District Court for the Northern District of Ohio on behalf of several Indian tribes. The Northern District of Ohio is the Court that the Judicial Panel on Multi-District Litigation (&#x201c;JPML&#x201d;) has assigned more than one thousand civil cases which have been designated as a Multi-District Litigation (&#x201c;MDL&#x201d;) and captioned In Re: National Prescription Opiate Litigation. The allegations in these complaints focus on the activities of defendants other than the company and no individualized factual allegations have been advanced against us in any of the three complaints. We reject all claims raised in the complaints and intend to vigorously defend these matters.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 12, 2021, Abvivo submitted a JAMS arbitration demand naming the Company as respondent. Abvivo claimed that the Company was in violation of the assignment provision of that certain Commercial Platform License and Services Agreement (&#x201c;CPLSA&#x201d;), dated October 9, 2019, by and among OMT and Crystal, on the one hand, and Abvivo, on the other hand because the Company allegedly withheld its consent to a proposed assignment required for Abvivo to negotiate a discovery and development alliance with certain third parties. On January 26, 2021, we submitted a response to the demand, denying all claims and alleging counterclaims against Abvivo and Brian Lundstrom, a Company employee and the sole owner of Abvivo. We alleged that Mr. Lundstrom breached his fiduciary duty of loyalty to the Company and that Abvivo and Mr. Lundstrom fraudulently induced the Company, OMT and Crystal into certain business transactions and contracts. Abvivo and Mr. Lundstrom&#x2019;s response to these counterclaims was due on February 9, 2021, but they did not submit a response. Under JAMS rules, the counterclaims were deemed denied. On February 22, 2021, Abvivo submitted documents to JAMS which indicated that it sought to dismiss its claim without prejudice. On February 25, 2021, we submitted additional counterclaims against Abvivo and Mr. Lundstrom.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;These counterclaims alleged that Abvivo and Mr. Lundstrom made false promises regarding the CPLSA, Abvivo&#x2019;s breach of and failure to perform under the CPLSA, and Abvivo&#x2019;s infringement of certain Ligand trademarks.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March 11, 2021, Abvivo and Mr. Lundstrom submitted an answer to our amended counterclaims denying all of the claims and asserting various affirmative defenses. On June 21, 2021, the parties executed a confidential settlement agreement that settled all claims in this arbitration.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June 29, 2021, the parties jointly submitted to JAMS a dismissal with prejudice of all claims by all parties in the arbitration.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;CyDex and Baxter Healthcare Corp. (&#x201c;Baxter&#x201d;) are parties to a license agreement relating to Ligand&#x2019;s Captisol&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;technology and, more specifically, relating to Captisol-enabled Nexterone (amiodarone HCl premixed injection). Baxter contends that it has &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;overpaid royalties for several years, and seeks both refunds of those overpayment and a reduced royalty going forward. CyDex contends that Baxter has not paid the royalties due to CyDex under the terms of the license agreement. On April 6, 2021, Baxter initiated an arbitration with the American Arbitration Association pursuant to the arbitration provision of the license agreement. On April 21, 2021, CyDex filed an Answering Statement and Counterdemand. On May 5, 2021, Baxter filed an Answering Statement in response to CyDex&#x2019;s Counterdemand. On June 30, 2021, the parties held a Preliminary Hearing before the arbitrator. The parties have completed fact discovery and have exchanged expert witness statements; depositions of the expert witnesses will be completed by the end of March 2022. The arbitration hearing is currently scheduled for May 2022.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, we may also become subject to other legal proceedings or claims arising in the ordinary course of our business. We currently believe that none of the claims or actions pending against us is likely to have, individually or in the aggregate, a material adverse effect on our business, financial condition or results of operations. Given the unpredictability inherent in litigation, however, we cannot predict the outcome of these matters.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:GainContingencyPatentsAllegedlyInfringedUponNumber
      contextRef="i93652c87888744bc90a296c0d62c6b8e_D20191029-20191029"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTUvZnJhZzo1MjlkZGUzNDYzMzY0NTAzODBhMzY5YWM3M2E5YWE0Mi90ZXh0cmVnaW9uOjUyOWRkZTM0NjMzNjQ1MDM4MGEzNjlhYzczYTlhYTQyXzM4NDgyOTA3MTY4NzM_9d0d6d52-b1e3-45aa-8fb7-4658aa4a42b4"
      unitRef="patent">4</us-gaap:GainContingencyPatentsAllegedlyInfringedUponNumber>
    <us-gaap:LossContingencyNewClaimsFiledNumber
      contextRef="idcb9c868c1be4dc8bc733f81708def2c_D20191031-20191031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTUvZnJhZzo1MjlkZGUzNDYzMzY0NTAzODBhMzY5YWM3M2E5YWE0Mi90ZXh0cmVnaW9uOjUyOWRkZTM0NjMzNjQ1MDM4MGEzNjlhYzczYTlhYTQyXzM4NDgyOTA3MTY4NTE_97bf168b-bd04-4b19-92c4-5c31b4c2b1ac"
      unitRef="civil_complaint">3</us-gaap:LossContingencyNewClaimsFiledNumber>
    <us-gaap:LossContingencyNewClaimsFiledNumber
      contextRef="idcb9c868c1be4dc8bc733f81708def2c_D20191031-20191031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTUvZnJhZzo1MjlkZGUzNDYzMzY0NTAzODBhMzY5YWM3M2E5YWE0Mi90ZXh0cmVnaW9uOjUyOWRkZTM0NjMzNjQ1MDM4MGEzNjlhYzczYTlhYTQyXzM4NDgyOTA3MTY4NjI_11b5ae51-b267-4f92-9929-1fc202cee592"
      unitRef="civil_complaint">3</us-gaap:LossContingencyNewClaimsFiledNumber>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTgvZnJhZzphNDZjN2FlZGZkZjU0ZGY3YmYzZmFlNmNlNDFjZGNlNy90ZXh0cmVnaW9uOmE0NmM3YWVkZmRmNTRkZjdiZjNmYWU2Y2U0MWNkY2U3XzUyNzM_174a3899-41b7-4921-b49f-e6b856ccd83e">Income Taxes&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of the income tax expense (benefit) for continuing operations are as follows (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.403%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.092%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.833%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.092%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.686%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.094%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current expense (benefit):&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,190)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,889&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89,471&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(32)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;589&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(66)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,222)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,501&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92,508&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred expense (benefit):&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,355)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15,672)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74,627&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,263)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,382)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;202&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,618)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19,054)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74,829&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total income tax expense (benefit)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,840)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,553)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;167,337&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:24pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation of income tax expense (benefit) from continuing operations to the amount computed by applying the statutory federal income tax rate to the net income (loss) from continuing operations is summarized as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.047%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.047%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.682%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.048%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax at federal statutory rate&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,932&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,213)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;167,294&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State, net of federal benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(408)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,456)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,466&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,161)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(278)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Share-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11,919)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(362)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(819)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;FDII&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(637)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,652)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(402)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,692)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(699)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(879)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in uncertain tax positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;586&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(650)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;441&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Rate change for changes in federal, foreign or state law&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,963)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(173)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(210)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Provision to return adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(617)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,803)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(184)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign tax differential on income/loss of foreign subsidiaries&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(114)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,839)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,410&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(121,876)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,193)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sale of Vernalis R&amp;amp;D&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;127,372&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;743&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,076&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;748&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,840)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,553)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;167,337&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We remeasured certain deferred tax assets and liabilities based on the rates at which they are expected to reverse in the future, which is generally 21%. Significant components of our deferred tax assets and liabilities as of December&#160;31, 2021 and 2020 are shown below. We assess the positive and negative evidence to determine if sufficient future taxable income will be generated to &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;use the existing deferred tax assets. Our evaluation of evidence resulted in management concluding that the majority of our deferred tax assets will be realized. However, we maintain a valuation allowance to offset certain net deferred tax assets as management believes realization of such assets are uncertain as of December&#160;31, 2021, 2020 and 2019. The valuation allowance increased $11.4 million in 2021, decreased $116.5 million in 2020 and increased $136.9 million in 2019.  &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We offset all deferred tax assets and liabilities by jurisdiction, as well as any related valuation allowance, and present them on our consolidated balance sheet as a non-current deferred income tax asset or liability (as applicable). Deferred tax assets (liabilities) are comprised of the following:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.807%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:76.478%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.662%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.547%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.813%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64,352&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64,147&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research credit carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,797&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,623&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,374&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,994&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,668&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;123,191&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;108,884&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Valuation allowance for deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(36,283)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(24,858)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;86,908&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84,026&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:13pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Identified intangibles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(102,221)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(119,381)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,300)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,923)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(111,521)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(124,304)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:13pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred income taxes, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(24,613)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(40,278)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2021, we had federal net operating loss carryforwards set to expire through 2037 of $119.6 million and $176.3 million of state net operating loss carryforwards that begin to expire in 2032. We also have $9.8 million of federal research and development credit carryforwards, which expire through 2041. We have $29.7 million of California research and development credit carryforwards that have no expiration date. In addition, we have approximately $101.6 million of non-U.S. net operating loss carryovers and approximately $17.5 million of non-U.S. capital loss carryovers that have no expiration date. &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At December 31, 2020 we had approximately $110.1&#160;million of non-U.S. net operating loss carryovers and approximately $17.6&#160;million of non-U.S. capital loss carryovers. We have a full valuation allowance against these non-U.S. tax attributes. The year over year decrease in non-U.S. deferred tax assets was attributable to the sale of Vernalis in December 2020. The remaining non-U.S. deferred tax assets as of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December&#160;31, 2021 were&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; attributable to the portion of the Vernalis business that we did not sell. We have a full valuation allowance against these non-U.S. tax attributes. See detail in &#x201c;&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note (2), Sale of Vernalis R&amp;amp;D and Promacta License&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x201d;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;  &#160;&#160; &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pursuant to Section 382 and 383 of the Internal Revenue Code of 1986, as amended, utilization of our net operating losses and credits may be subject to annual limitations in the event of any significant future changes in its ownership structure. These annual limitations may result in the expiration of net operating losses and credits prior to utilization. The deferred tax assets as of December&#160;31, 2021 are net of any previous limitations due to Section 382 and 383.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We account for income taxes by evaluating a probability threshold that a tax position must meet before a financial statement benefit is recognized. The minimum threshold is a tax position that is more likely than not to be sustained upon examination by the applicable taxing authority, including resolution of any related appeals or litigation processes, based on the technical merits of the position. Our remaining liabilities for uncertain tax positions are presented net of the deferred tax asset balances on the accompanying consolidated balance sheet.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation of the amount of unrecognized tax benefits at December&#160;31, 2021, 2020 and 2019 is as follows (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.807%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.064%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.547%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.064%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.547%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.365%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at beginning of year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,871&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,736&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,289&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Additions based on tax positions related to the current year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,911&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;543&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Additions for tax positions of prior years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;945&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;179&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Reductions for tax positions of prior years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,072)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(955)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,096)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at end of year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,996&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,871&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,736&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:24pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Included in the balance of unrecognized tax benefits at December&#160;31, 2021 is $28.1 million of tax benefits that, if recognized would impact the effective rate. There are no positions for which it is reasonably possible that the uncertain tax benefit will significantly increase or decrease within twelve months.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognize interest and penalties related to uncertain tax positions in income tax expense. As of December&#160;31, 2021 and December&#160;31, 2020, we recognized an immaterial amount of interest and penalties. We file income tax returns in the United States, various state jurisdictions, United Kingdom, and Canada with varying statutes of limitations. The federal statute of limitation remains open for the 2018 tax year to the present.&#160;The state income tax returns generally remain open for the 2017 tax year through the present.&#160;Net operating loss and research credit carryforwards arising prior to these years are also open to examination if and when utilized. No tax returns are currently under examination by any tax authorities. We believe our reserve for unrecognized tax benefits and contingent tax issues is adequate with respect to all open years.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock
      contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTgvZnJhZzphNDZjN2FlZGZkZjU0ZGY3YmYzZmFlNmNlNDFjZGNlNy90ZXh0cmVnaW9uOmE0NmM3YWVkZmRmNTRkZjdiZjNmYWU2Y2U0MWNkY2U3XzUyNzg_1f77636c-cfa1-4bf2-af62-2091eb2927c9">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of the income tax expense (benefit) for continuing operations are as follows (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.403%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.092%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.833%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.092%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.686%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.094%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current expense (benefit):&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,190)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,889&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89,471&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(32)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;589&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(66)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,222)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,501&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92,508&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred expense (benefit):&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,355)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15,672)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74,627&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,263)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,382)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;202&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,618)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19,054)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74,829&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total income tax expense (benefit)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,840)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,553)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;167,337&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTgvZnJhZzphNDZjN2FlZGZkZjU0ZGY3YmYzZmFlNmNlNDFjZGNlNy90YWJsZTpmZDUyYmM5YzRhZGY0ZmU1YWE1MDg4MzM3ZjIyZjc3YS90YWJsZXJhbmdlOmZkNTJiYzljNGFkZjRmZTVhYTUwODgzMzdmMjJmNzdhXzMtMS0xLTEtNDEyOTQ_cdb6710f-f6d7-4230-902b-7a1d6a06e4c8"
      unitRef="usd">-1190000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="ib3597315a63d441f8f128abd7ed8840e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTgvZnJhZzphNDZjN2FlZGZkZjU0ZGY3YmYzZmFlNmNlNDFjZGNlNy90YWJsZTpmZDUyYmM5YzRhZGY0ZmU1YWE1MDg4MzM3ZjIyZjc3YS90YWJsZXJhbmdlOmZkNTJiYzljNGFkZjRmZTVhYTUwODgzMzdmMjJmNzdhXzMtMy0xLTEtNDEyOTQ_b0cc2780-0568-4f3c-b923-a55514f10854"
      unitRef="usd">10889000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="ie6c3b69702e9429aaeed46bdb9bbb9c1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTgvZnJhZzphNDZjN2FlZGZkZjU0ZGY3YmYzZmFlNmNlNDFjZGNlNy90YWJsZTpmZDUyYmM5YzRhZGY0ZmU1YWE1MDg4MzM3ZjIyZjc3YS90YWJsZXJhbmdlOmZkNTJiYzljNGFkZjRmZTVhYTUwODgzMzdmMjJmNzdhXzMtNS0xLTEtNDEyOTQ_da6a7863-fcd3-484a-b510-c4b93a2382e3"
      unitRef="usd">89471000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTgvZnJhZzphNDZjN2FlZGZkZjU0ZGY3YmYzZmFlNmNlNDFjZGNlNy90YWJsZTpmZDUyYmM5YzRhZGY0ZmU1YWE1MDg4MzM3ZjIyZjc3YS90YWJsZXJhbmdlOmZkNTJiYzljNGFkZjRmZTVhYTUwODgzMzdmMjJmNzdhXzQtMS0xLTEtNDEyOTQ_9cde9c60-877a-4c3a-8257-8600d4f13d55"
      unitRef="usd">-32000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="ib3597315a63d441f8f128abd7ed8840e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTgvZnJhZzphNDZjN2FlZGZkZjU0ZGY3YmYzZmFlNmNlNDFjZGNlNy90YWJsZTpmZDUyYmM5YzRhZGY0ZmU1YWE1MDg4MzM3ZjIyZjc3YS90YWJsZXJhbmdlOmZkNTJiYzljNGFkZjRmZTVhYTUwODgzMzdmMjJmNzdhXzQtMy0xLTEtNDEyOTQ_a63f8bde-c09e-4822-8e37-78e2e609892c"
      unitRef="usd">589000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="ie6c3b69702e9429aaeed46bdb9bbb9c1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTgvZnJhZzphNDZjN2FlZGZkZjU0ZGY3YmYzZmFlNmNlNDFjZGNlNy90YWJsZTpmZDUyYmM5YzRhZGY0ZmU1YWE1MDg4MzM3ZjIyZjc3YS90YWJsZXJhbmdlOmZkNTJiYzljNGFkZjRmZTVhYTUwODgzMzdmMjJmNzdhXzQtNS0xLTEtNDEyOTQ_0c553981-52a9-4967-bea4-bf99a4007215"
      unitRef="usd">3103000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTgvZnJhZzphNDZjN2FlZGZkZjU0ZGY3YmYzZmFlNmNlNDFjZGNlNy90YWJsZTpmZDUyYmM5YzRhZGY0ZmU1YWE1MDg4MzM3ZjIyZjc3YS90YWJsZXJhbmdlOmZkNTJiYzljNGFkZjRmZTVhYTUwODgzMzdmMjJmNzdhXzUtMS0xLTEtNDEyOTQ_314aeb8a-a9d5-48ed-b5b8-ac0e285928fd"
      unitRef="usd">0</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="ib3597315a63d441f8f128abd7ed8840e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTgvZnJhZzphNDZjN2FlZGZkZjU0ZGY3YmYzZmFlNmNlNDFjZGNlNy90YWJsZTpmZDUyYmM5YzRhZGY0ZmU1YWE1MDg4MzM3ZjIyZjc3YS90YWJsZXJhbmdlOmZkNTJiYzljNGFkZjRmZTVhYTUwODgzMzdmMjJmNzdhXzUtMy0xLTEtNDEyOTQ_db0da602-5e7a-4b6e-aadb-9a885fd9e71a"
      unitRef="usd">23000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="ie6c3b69702e9429aaeed46bdb9bbb9c1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTgvZnJhZzphNDZjN2FlZGZkZjU0ZGY3YmYzZmFlNmNlNDFjZGNlNy90YWJsZTpmZDUyYmM5YzRhZGY0ZmU1YWE1MDg4MzM3ZjIyZjc3YS90YWJsZXJhbmdlOmZkNTJiYzljNGFkZjRmZTVhYTUwODgzMzdmMjJmNzdhXzUtNS0xLTEtNDEyOTQ_6301f3b1-c0bb-44c7-b438-2c753764d9f3"
      unitRef="usd">-66000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTgvZnJhZzphNDZjN2FlZGZkZjU0ZGY3YmYzZmFlNmNlNDFjZGNlNy90YWJsZTpmZDUyYmM5YzRhZGY0ZmU1YWE1MDg4MzM3ZjIyZjc3YS90YWJsZXJhbmdlOmZkNTJiYzljNGFkZjRmZTVhYTUwODgzMzdmMjJmNzdhXzYtMS0xLTEtNDEyOTQ_2ab81707-8378-47a6-acf9-b094d4fbe472"
      unitRef="usd">-1222000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="ib3597315a63d441f8f128abd7ed8840e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTgvZnJhZzphNDZjN2FlZGZkZjU0ZGY3YmYzZmFlNmNlNDFjZGNlNy90YWJsZTpmZDUyYmM5YzRhZGY0ZmU1YWE1MDg4MzM3ZjIyZjc3YS90YWJsZXJhbmdlOmZkNTJiYzljNGFkZjRmZTVhYTUwODgzMzdmMjJmNzdhXzYtMy0xLTEtNDEyOTQ_7afa51a0-6231-46d0-b9b8-9f2260e217a5"
      unitRef="usd">11501000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="ie6c3b69702e9429aaeed46bdb9bbb9c1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTgvZnJhZzphNDZjN2FlZGZkZjU0ZGY3YmYzZmFlNmNlNDFjZGNlNy90YWJsZTpmZDUyYmM5YzRhZGY0ZmU1YWE1MDg4MzM3ZjIyZjc3YS90YWJsZXJhbmdlOmZkNTJiYzljNGFkZjRmZTVhYTUwODgzMzdmMjJmNzdhXzYtNS0xLTEtNDEyOTQ_ce962fb9-3885-4e9f-9cbe-55dcc442aa19"
      unitRef="usd">92508000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTgvZnJhZzphNDZjN2FlZGZkZjU0ZGY3YmYzZmFlNmNlNDFjZGNlNy90YWJsZTpmZDUyYmM5YzRhZGY0ZmU1YWE1MDg4MzM3ZjIyZjc3YS90YWJsZXJhbmdlOmZkNTJiYzljNGFkZjRmZTVhYTUwODgzMzdmMjJmNzdhXzgtMS0xLTEtNDEyOTQ_04b3a83e-1e07-43e5-a1df-37c8ee672947"
      unitRef="usd">-7355000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="ib3597315a63d441f8f128abd7ed8840e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTgvZnJhZzphNDZjN2FlZGZkZjU0ZGY3YmYzZmFlNmNlNDFjZGNlNy90YWJsZTpmZDUyYmM5YzRhZGY0ZmU1YWE1MDg4MzM3ZjIyZjc3YS90YWJsZXJhbmdlOmZkNTJiYzljNGFkZjRmZTVhYTUwODgzMzdmMjJmNzdhXzgtMy0xLTEtNDEyOTQ_3ef5de03-1413-4306-a532-89a629cecfcf"
      unitRef="usd">-15672000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="ie6c3b69702e9429aaeed46bdb9bbb9c1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTgvZnJhZzphNDZjN2FlZGZkZjU0ZGY3YmYzZmFlNmNlNDFjZGNlNy90YWJsZTpmZDUyYmM5YzRhZGY0ZmU1YWE1MDg4MzM3ZjIyZjc3YS90YWJsZXJhbmdlOmZkNTJiYzljNGFkZjRmZTVhYTUwODgzMzdmMjJmNzdhXzgtNS0xLTEtNDEyOTQ_a39d880a-5908-44d8-86b7-8ae7eb58b150"
      unitRef="usd">74627000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTgvZnJhZzphNDZjN2FlZGZkZjU0ZGY3YmYzZmFlNmNlNDFjZGNlNy90YWJsZTpmZDUyYmM5YzRhZGY0ZmU1YWE1MDg4MzM3ZjIyZjc3YS90YWJsZXJhbmdlOmZkNTJiYzljNGFkZjRmZTVhYTUwODgzMzdmMjJmNzdhXzktMS0xLTEtNDEyOTQ_64840095-3f51-4261-9da3-e11a607ac74f"
      unitRef="usd">-1263000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="ib3597315a63d441f8f128abd7ed8840e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTgvZnJhZzphNDZjN2FlZGZkZjU0ZGY3YmYzZmFlNmNlNDFjZGNlNy90YWJsZTpmZDUyYmM5YzRhZGY0ZmU1YWE1MDg4MzM3ZjIyZjc3YS90YWJsZXJhbmdlOmZkNTJiYzljNGFkZjRmZTVhYTUwODgzMzdmMjJmNzdhXzktMy0xLTEtNDEyOTQ_59d3d4bf-ecde-47b4-8f50-a4821e3bdd4f"
      unitRef="usd">-3382000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="ie6c3b69702e9429aaeed46bdb9bbb9c1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTgvZnJhZzphNDZjN2FlZGZkZjU0ZGY3YmYzZmFlNmNlNDFjZGNlNy90YWJsZTpmZDUyYmM5YzRhZGY0ZmU1YWE1MDg4MzM3ZjIyZjc3YS90YWJsZXJhbmdlOmZkNTJiYzljNGFkZjRmZTVhYTUwODgzMzdmMjJmNzdhXzktNS0xLTEtNDEyOTQ_b3a6eb38-4d84-48d9-ab21-3d7a4ec2f9a1"
      unitRef="usd">202000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTgvZnJhZzphNDZjN2FlZGZkZjU0ZGY3YmYzZmFlNmNlNDFjZGNlNy90YWJsZTpmZDUyYmM5YzRhZGY0ZmU1YWE1MDg4MzM3ZjIyZjc3YS90YWJsZXJhbmdlOmZkNTJiYzljNGFkZjRmZTVhYTUwODgzMzdmMjJmNzdhXzEwLTEtMS0xLTU4MDg1_2fd21a5f-b2f4-4884-8e61-b3b5c2b40f30"
      unitRef="usd">-8618000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="ib3597315a63d441f8f128abd7ed8840e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTgvZnJhZzphNDZjN2FlZGZkZjU0ZGY3YmYzZmFlNmNlNDFjZGNlNy90YWJsZTpmZDUyYmM5YzRhZGY0ZmU1YWE1MDg4MzM3ZjIyZjc3YS90YWJsZXJhbmdlOmZkNTJiYzljNGFkZjRmZTVhYTUwODgzMzdmMjJmNzdhXzEwLTMtMS0xLTU4MDg1_8f8ca5e0-e8b2-4f5f-93d4-f62acfea7b6e"
      unitRef="usd">-19054000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="ie6c3b69702e9429aaeed46bdb9bbb9c1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTgvZnJhZzphNDZjN2FlZGZkZjU0ZGY3YmYzZmFlNmNlNDFjZGNlNy90YWJsZTpmZDUyYmM5YzRhZGY0ZmU1YWE1MDg4MzM3ZjIyZjc3YS90YWJsZXJhbmdlOmZkNTJiYzljNGFkZjRmZTVhYTUwODgzMzdmMjJmNzdhXzEwLTUtMS0xLTU4MDg1_072ed68f-c915-42b5-af26-e58e1b8c18f4"
      unitRef="usd">74829000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTgvZnJhZzphNDZjN2FlZGZkZjU0ZGY3YmYzZmFlNmNlNDFjZGNlNy90YWJsZTpmZDUyYmM5YzRhZGY0ZmU1YWE1MDg4MzM3ZjIyZjc3YS90YWJsZXJhbmdlOmZkNTJiYzljNGFkZjRmZTVhYTUwODgzMzdmMjJmNzdhXzEwLTEtMS0xLTQxMjk0_a911ede9-fec3-4c8b-a8bd-17069cc34500"
      unitRef="usd">-9840000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ib3597315a63d441f8f128abd7ed8840e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTgvZnJhZzphNDZjN2FlZGZkZjU0ZGY3YmYzZmFlNmNlNDFjZGNlNy90YWJsZTpmZDUyYmM5YzRhZGY0ZmU1YWE1MDg4MzM3ZjIyZjc3YS90YWJsZXJhbmdlOmZkNTJiYzljNGFkZjRmZTVhYTUwODgzMzdmMjJmNzdhXzEwLTMtMS0xLTQxMjk0_b6bff959-e178-4c7a-8712-a99f1a835600"
      unitRef="usd">-7553000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ie6c3b69702e9429aaeed46bdb9bbb9c1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTgvZnJhZzphNDZjN2FlZGZkZjU0ZGY3YmYzZmFlNmNlNDFjZGNlNy90YWJsZTpmZDUyYmM5YzRhZGY0ZmU1YWE1MDg4MzM3ZjIyZjc3YS90YWJsZXJhbmdlOmZkNTJiYzljNGFkZjRmZTVhYTUwODgzMzdmMjJmNzdhXzEwLTUtMS0xLTQxMjk0_a7e8ed15-18d2-40a6-bda9-b51a5fea967b"
      unitRef="usd">167337000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTgvZnJhZzphNDZjN2FlZGZkZjU0ZGY3YmYzZmFlNmNlNDFjZGNlNy90ZXh0cmVnaW9uOmE0NmM3YWVkZmRmNTRkZjdiZjNmYWU2Y2U0MWNkY2U3XzUyNzk_1e33aca3-3439-4257-b53d-6de19575c2c5">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation of income tax expense (benefit) from continuing operations to the amount computed by applying the statutory federal income tax rate to the net income (loss) from continuing operations is summarized as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.047%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.047%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.682%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.048%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax at federal statutory rate&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,932&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,213)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;167,294&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State, net of federal benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(408)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,456)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,466&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,161)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(278)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Share-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11,919)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(362)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(819)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;FDII&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(637)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,652)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(402)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,692)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(699)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(879)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in uncertain tax positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;586&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(650)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;441&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Rate change for changes in federal, foreign or state law&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,963)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(173)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(210)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Provision to return adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(617)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,803)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(184)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign tax differential on income/loss of foreign subsidiaries&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(114)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,839)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,410&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(121,876)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,193)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sale of Vernalis R&amp;amp;D&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;127,372&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;743&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,076&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;748&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,840)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,553)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;167,337&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTgvZnJhZzphNDZjN2FlZGZkZjU0ZGY3YmYzZmFlNmNlNDFjZGNlNy90YWJsZToyNGIxMGZmMTc3YmE0ZDRlOTM1MGU3NGUwMmRiYjBlNi90YWJsZXJhbmdlOjI0YjEwZmYxNzdiYTRkNGU5MzUwZTc0ZTAyZGJiMGU2XzItMS0xLTEtNDEyOTQ_b95c3814-2dba-405b-bbbf-ebfd6a091330"
      unitRef="usd">9932000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="ib3597315a63d441f8f128abd7ed8840e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTgvZnJhZzphNDZjN2FlZGZkZjU0ZGY3YmYzZmFlNmNlNDFjZGNlNy90YWJsZToyNGIxMGZmMTc3YmE0ZDRlOTM1MGU3NGUwMmRiYjBlNi90YWJsZXJhbmdlOjI0YjEwZmYxNzdiYTRkNGU5MzUwZTc0ZTAyZGJiMGU2XzItMy0xLTEtNDEyOTQ_5770b6c0-ab5e-4447-b864-2e42be65d4a8"
      unitRef="usd">-2213000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="ie6c3b69702e9429aaeed46bdb9bbb9c1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTgvZnJhZzphNDZjN2FlZGZkZjU0ZGY3YmYzZmFlNmNlNDFjZGNlNy90YWJsZToyNGIxMGZmMTc3YmE0ZDRlOTM1MGU3NGUwMmRiYjBlNi90YWJsZXJhbmdlOjI0YjEwZmYxNzdiYTRkNGU5MzUwZTc0ZTAyZGJiMGU2XzItNS0xLTEtNDEyOTQ_2c3345ce-b95e-4ebe-8adc-6797b3848f25"
      unitRef="usd">167294000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTgvZnJhZzphNDZjN2FlZGZkZjU0ZGY3YmYzZmFlNmNlNDFjZGNlNy90YWJsZToyNGIxMGZmMTc3YmE0ZDRlOTM1MGU3NGUwMmRiYjBlNi90YWJsZXJhbmdlOjI0YjEwZmYxNzdiYTRkNGU5MzUwZTc0ZTAyZGJiMGU2XzMtMS0xLTEtNDEyOTQ_b327b89c-7c99-4265-82ed-929a6ef90f1e"
      unitRef="usd">-408000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="ib3597315a63d441f8f128abd7ed8840e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTgvZnJhZzphNDZjN2FlZGZkZjU0ZGY3YmYzZmFlNmNlNDFjZGNlNy90YWJsZToyNGIxMGZmMTc3YmE0ZDRlOTM1MGU3NGUwMmRiYjBlNi90YWJsZXJhbmdlOjI0YjEwZmYxNzdiYTRkNGU5MzUwZTc0ZTAyZGJiMGU2XzMtMy0xLTEtNDEyOTQ_75f543d6-5a8b-4aae-a2e3-d2f22abbec3d"
      unitRef="usd">-1456000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="ie6c3b69702e9429aaeed46bdb9bbb9c1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTgvZnJhZzphNDZjN2FlZGZkZjU0ZGY3YmYzZmFlNmNlNDFjZGNlNy90YWJsZToyNGIxMGZmMTc3YmE0ZDRlOTM1MGU3NGUwMmRiYjBlNi90YWJsZXJhbmdlOjI0YjEwZmYxNzdiYTRkNGU5MzUwZTc0ZTAyZGJiMGU2XzMtNS0xLTEtNDEyOTQ_6c0a7284-9f7c-4b4a-b1a7-b6e08f91178c"
      unitRef="usd">2466000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <lgnd:IncomeTaxReconciliationContingentValueRights
      contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTgvZnJhZzphNDZjN2FlZGZkZjU0ZGY3YmYzZmFlNmNlNDFjZGNlNy90YWJsZToyNGIxMGZmMTc3YmE0ZDRlOTM1MGU3NGUwMmRiYjBlNi90YWJsZXJhbmdlOjI0YjEwZmYxNzdiYTRkNGU5MzUwZTc0ZTAyZGJiMGU2XzQtMS0xLTEtNDEyOTQ_c4800103-c6db-4c05-a80b-128348bcbdc1"
      unitRef="usd">-8161000</lgnd:IncomeTaxReconciliationContingentValueRights>
    <lgnd:IncomeTaxReconciliationContingentValueRights
      contextRef="ib3597315a63d441f8f128abd7ed8840e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTgvZnJhZzphNDZjN2FlZGZkZjU0ZGY3YmYzZmFlNmNlNDFjZGNlNy90YWJsZToyNGIxMGZmMTc3YmE0ZDRlOTM1MGU3NGUwMmRiYjBlNi90YWJsZXJhbmdlOjI0YjEwZmYxNzdiYTRkNGU5MzUwZTc0ZTAyZGJiMGU2XzQtMy0xLTEtNDEyOTQ_c87ebb66-3096-48d2-8058-925370404fcc"
      unitRef="usd">-278000</lgnd:IncomeTaxReconciliationContingentValueRights>
    <lgnd:IncomeTaxReconciliationContingentValueRights
      contextRef="ie6c3b69702e9429aaeed46bdb9bbb9c1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTgvZnJhZzphNDZjN2FlZGZkZjU0ZGY3YmYzZmFlNmNlNDFjZGNlNy90YWJsZToyNGIxMGZmMTc3YmE0ZDRlOTM1MGU3NGUwMmRiYjBlNi90YWJsZXJhbmdlOjI0YjEwZmYxNzdiYTRkNGU5MzUwZTc0ZTAyZGJiMGU2XzQtNS0xLTEtNDEyOTQ_6005dace-06a8-4dfe-bc1f-73be59a2386b"
      unitRef="usd">18000</lgnd:IncomeTaxReconciliationContingentValueRights>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTgvZnJhZzphNDZjN2FlZGZkZjU0ZGY3YmYzZmFlNmNlNDFjZGNlNy90YWJsZToyNGIxMGZmMTc3YmE0ZDRlOTM1MGU3NGUwMmRiYjBlNi90YWJsZXJhbmdlOjI0YjEwZmYxNzdiYTRkNGU5MzUwZTc0ZTAyZGJiMGU2XzUtMS0xLTEtNDEyOTQ_f4251b21-18c9-4c89-b05c-87bfc5b67b79"
      unitRef="usd">-11919000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="ib3597315a63d441f8f128abd7ed8840e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTgvZnJhZzphNDZjN2FlZGZkZjU0ZGY3YmYzZmFlNmNlNDFjZGNlNy90YWJsZToyNGIxMGZmMTc3YmE0ZDRlOTM1MGU3NGUwMmRiYjBlNi90YWJsZXJhbmdlOjI0YjEwZmYxNzdiYTRkNGU5MzUwZTc0ZTAyZGJiMGU2XzUtMy0xLTEtNDEyOTQ_68f97ef6-aef6-40c1-b98d-1d4ff7875323"
      unitRef="usd">-362000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="ie6c3b69702e9429aaeed46bdb9bbb9c1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTgvZnJhZzphNDZjN2FlZGZkZjU0ZGY3YmYzZmFlNmNlNDFjZGNlNy90YWJsZToyNGIxMGZmMTc3YmE0ZDRlOTM1MGU3NGUwMmRiYjBlNi90YWJsZXJhbmdlOjI0YjEwZmYxNzdiYTRkNGU5MzUwZTc0ZTAyZGJiMGU2XzUtNS0xLTEtNDEyOTQ_1509564f-fef2-4951-adb7-179eb0a528c3"
      unitRef="usd">-819000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <lgnd:EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomeAmount
      contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTgvZnJhZzphNDZjN2FlZGZkZjU0ZGY3YmYzZmFlNmNlNDFjZGNlNy90YWJsZToyNGIxMGZmMTc3YmE0ZDRlOTM1MGU3NGUwMmRiYjBlNi90YWJsZXJhbmdlOjI0YjEwZmYxNzdiYTRkNGU5MzUwZTc0ZTAyZGJiMGU2XzYtMS0xLTEtNDEyOTQ_dd72b6cc-ee8a-41a9-a50d-80182737806e"
      unitRef="usd">637000</lgnd:EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomeAmount>
    <lgnd:EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomeAmount
      contextRef="ib3597315a63d441f8f128abd7ed8840e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTgvZnJhZzphNDZjN2FlZGZkZjU0ZGY3YmYzZmFlNmNlNDFjZGNlNy90YWJsZToyNGIxMGZmMTc3YmE0ZDRlOTM1MGU3NGUwMmRiYjBlNi90YWJsZXJhbmdlOjI0YjEwZmYxNzdiYTRkNGU5MzUwZTc0ZTAyZGJiMGU2XzYtMy0xLTEtNDEyOTQ_3d9d156a-ca70-4ad7-8456-a389e43e30f0"
      unitRef="usd">1652000</lgnd:EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomeAmount>
    <lgnd:EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomeAmount
      contextRef="ie6c3b69702e9429aaeed46bdb9bbb9c1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTgvZnJhZzphNDZjN2FlZGZkZjU0ZGY3YmYzZmFlNmNlNDFjZGNlNy90YWJsZToyNGIxMGZmMTc3YmE0ZDRlOTM1MGU3NGUwMmRiYjBlNi90YWJsZXJhbmdlOjI0YjEwZmYxNzdiYTRkNGU5MzUwZTc0ZTAyZGJiMGU2XzYtNS0xLTEtNDEyOTQ_84727ea7-30c6-4df6-a0ee-25378162af82"
      unitRef="usd">402000</lgnd:EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomeAmount>
    <lgnd:EffectiveIncomeTaxRateReconciliationExpiredTaxCreditsResearch
      contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTgvZnJhZzphNDZjN2FlZGZkZjU0ZGY3YmYzZmFlNmNlNDFjZGNlNy90YWJsZToyNGIxMGZmMTc3YmE0ZDRlOTM1MGU3NGUwMmRiYjBlNi90YWJsZXJhbmdlOjI0YjEwZmYxNzdiYTRkNGU5MzUwZTc0ZTAyZGJiMGU2XzctMS0xLTEtNDEyOTQ_c2de86b8-7c96-49a7-b54e-456749550674"
      unitRef="usd">-2692000</lgnd:EffectiveIncomeTaxRateReconciliationExpiredTaxCreditsResearch>
    <lgnd:EffectiveIncomeTaxRateReconciliationExpiredTaxCreditsResearch
      contextRef="ib3597315a63d441f8f128abd7ed8840e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTgvZnJhZzphNDZjN2FlZGZkZjU0ZGY3YmYzZmFlNmNlNDFjZGNlNy90YWJsZToyNGIxMGZmMTc3YmE0ZDRlOTM1MGU3NGUwMmRiYjBlNi90YWJsZXJhbmdlOjI0YjEwZmYxNzdiYTRkNGU5MzUwZTc0ZTAyZGJiMGU2XzctMy0xLTEtNDEyOTQ_d3f56378-4534-47d8-a64b-4fad29895cdf"
      unitRef="usd">-699000</lgnd:EffectiveIncomeTaxRateReconciliationExpiredTaxCreditsResearch>
    <lgnd:EffectiveIncomeTaxRateReconciliationExpiredTaxCreditsResearch
      contextRef="ie6c3b69702e9429aaeed46bdb9bbb9c1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTgvZnJhZzphNDZjN2FlZGZkZjU0ZGY3YmYzZmFlNmNlNDFjZGNlNy90YWJsZToyNGIxMGZmMTc3YmE0ZDRlOTM1MGU3NGUwMmRiYjBlNi90YWJsZXJhbmdlOjI0YjEwZmYxNzdiYTRkNGU5MzUwZTc0ZTAyZGJiMGU2XzctNS0xLTEtNDEyOTQ_798c43fe-0c4a-4e07-adab-9c2a7cdc225b"
      unitRef="usd">-879000</lgnd:EffectiveIncomeTaxRateReconciliationExpiredTaxCreditsResearch>
    <lgnd:EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions
      contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTgvZnJhZzphNDZjN2FlZGZkZjU0ZGY3YmYzZmFlNmNlNDFjZGNlNy90YWJsZToyNGIxMGZmMTc3YmE0ZDRlOTM1MGU3NGUwMmRiYjBlNi90YWJsZXJhbmdlOjI0YjEwZmYxNzdiYTRkNGU5MzUwZTc0ZTAyZGJiMGU2XzgtMS0xLTEtNDEyOTQ_12b451bf-7031-4c27-bbd1-de22d66d9bae"
      unitRef="usd">-586000</lgnd:EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions>
    <lgnd:EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions
      contextRef="ib3597315a63d441f8f128abd7ed8840e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTgvZnJhZzphNDZjN2FlZGZkZjU0ZGY3YmYzZmFlNmNlNDFjZGNlNy90YWJsZToyNGIxMGZmMTc3YmE0ZDRlOTM1MGU3NGUwMmRiYjBlNi90YWJsZXJhbmdlOjI0YjEwZmYxNzdiYTRkNGU5MzUwZTc0ZTAyZGJiMGU2XzgtMy0xLTEtNDEyOTQ_81f953e6-1827-482b-9a07-255c5e46a6ab"
      unitRef="usd">650000</lgnd:EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions>
    <lgnd:EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions
      contextRef="ie6c3b69702e9429aaeed46bdb9bbb9c1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTgvZnJhZzphNDZjN2FlZGZkZjU0ZGY3YmYzZmFlNmNlNDFjZGNlNy90YWJsZToyNGIxMGZmMTc3YmE0ZDRlOTM1MGU3NGUwMmRiYjBlNi90YWJsZXJhbmdlOjI0YjEwZmYxNzdiYTRkNGU5MzUwZTc0ZTAyZGJiMGU2XzgtNS0xLTEtNDEyOTQ_ab17493e-6d68-4d18-8434-9651ae1394bf"
      unitRef="usd">-441000</lgnd:EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions>
    <us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate
      contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTgvZnJhZzphNDZjN2FlZGZkZjU0ZGY3YmYzZmFlNmNlNDFjZGNlNy90YWJsZToyNGIxMGZmMTc3YmE0ZDRlOTM1MGU3NGUwMmRiYjBlNi90YWJsZXJhbmdlOjI0YjEwZmYxNzdiYTRkNGU5MzUwZTc0ZTAyZGJiMGU2XzktMS0xLTEtNDEyOTQ_e35ed29b-16a3-4480-919d-a9ee25750537"
      unitRef="usd">-7963000</us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate>
    <us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate
      contextRef="ib3597315a63d441f8f128abd7ed8840e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTgvZnJhZzphNDZjN2FlZGZkZjU0ZGY3YmYzZmFlNmNlNDFjZGNlNy90YWJsZToyNGIxMGZmMTc3YmE0ZDRlOTM1MGU3NGUwMmRiYjBlNi90YWJsZXJhbmdlOjI0YjEwZmYxNzdiYTRkNGU5MzUwZTc0ZTAyZGJiMGU2XzktMy0xLTEtNDEyOTQ_f4a289be-d502-4464-b675-783199f8dd21"
      unitRef="usd">-173000</us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate>
    <us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate
      contextRef="ie6c3b69702e9429aaeed46bdb9bbb9c1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTgvZnJhZzphNDZjN2FlZGZkZjU0ZGY3YmYzZmFlNmNlNDFjZGNlNy90YWJsZToyNGIxMGZmMTc3YmE0ZDRlOTM1MGU3NGUwMmRiYjBlNi90YWJsZXJhbmdlOjI0YjEwZmYxNzdiYTRkNGU5MzUwZTc0ZTAyZGJiMGU2XzktNS0xLTEtNDEyOTQ_45e839fb-78dd-49e6-bda7-92fdba2a0273"
      unitRef="usd">-210000</us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate>
    <lgnd:EffectiveIncomeTaxRateReconciliationProvisionToReturnAdjustmentsAmount
      contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTgvZnJhZzphNDZjN2FlZGZkZjU0ZGY3YmYzZmFlNmNlNDFjZGNlNy90YWJsZToyNGIxMGZmMTc3YmE0ZDRlOTM1MGU3NGUwMmRiYjBlNi90YWJsZXJhbmdlOjI0YjEwZmYxNzdiYTRkNGU5MzUwZTc0ZTAyZGJiMGU2XzEwLTEtMS0xLTQxMjk0_087dd8c8-f34a-445e-aeac-99738a746a6c"
      unitRef="usd">617000</lgnd:EffectiveIncomeTaxRateReconciliationProvisionToReturnAdjustmentsAmount>
    <lgnd:EffectiveIncomeTaxRateReconciliationProvisionToReturnAdjustmentsAmount
      contextRef="ib3597315a63d441f8f128abd7ed8840e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTgvZnJhZzphNDZjN2FlZGZkZjU0ZGY3YmYzZmFlNmNlNDFjZGNlNy90YWJsZToyNGIxMGZmMTc3YmE0ZDRlOTM1MGU3NGUwMmRiYjBlNi90YWJsZXJhbmdlOjI0YjEwZmYxNzdiYTRkNGU5MzUwZTc0ZTAyZGJiMGU2XzEwLTMtMS0xLTQxMjk0_8518da68-0250-4432-a1ba-27c604fcdb5a"
      unitRef="usd">4803000</lgnd:EffectiveIncomeTaxRateReconciliationProvisionToReturnAdjustmentsAmount>
    <lgnd:EffectiveIncomeTaxRateReconciliationProvisionToReturnAdjustmentsAmount
      contextRef="ie6c3b69702e9429aaeed46bdb9bbb9c1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTgvZnJhZzphNDZjN2FlZGZkZjU0ZGY3YmYzZmFlNmNlNDFjZGNlNy90YWJsZToyNGIxMGZmMTc3YmE0ZDRlOTM1MGU3NGUwMmRiYjBlNi90YWJsZXJhbmdlOjI0YjEwZmYxNzdiYTRkNGU5MzUwZTc0ZTAyZGJiMGU2XzEwLTUtMS0xLTQxMjk0_1e6a3537-7842-4d54-9c82-3642ba4c2e55"
      unitRef="usd">184000</lgnd:EffectiveIncomeTaxRateReconciliationProvisionToReturnAdjustmentsAmount>
    <us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential
      contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTgvZnJhZzphNDZjN2FlZGZkZjU0ZGY3YmYzZmFlNmNlNDFjZGNlNy90YWJsZToyNGIxMGZmMTc3YmE0ZDRlOTM1MGU3NGUwMmRiYjBlNi90YWJsZXJhbmdlOjI0YjEwZmYxNzdiYTRkNGU5MzUwZTc0ZTAyZGJiMGU2XzExLTEtMS0xLTQxMjk0_ffb81df4-adf8-42a2-beab-20a1df018ea3"
      unitRef="usd">-114000</us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential
      contextRef="ib3597315a63d441f8f128abd7ed8840e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTgvZnJhZzphNDZjN2FlZGZkZjU0ZGY3YmYzZmFlNmNlNDFjZGNlNy90YWJsZToyNGIxMGZmMTc3YmE0ZDRlOTM1MGU3NGUwMmRiYjBlNi90YWJsZXJhbmdlOjI0YjEwZmYxNzdiYTRkNGU5MzUwZTc0ZTAyZGJiMGU2XzExLTMtMS0xLTQxMjk0_5d32a482-1314-41cb-93bb-4d59b78428cb"
      unitRef="usd">-3839000</us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential
      contextRef="ie6c3b69702e9429aaeed46bdb9bbb9c1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTgvZnJhZzphNDZjN2FlZGZkZjU0ZGY3YmYzZmFlNmNlNDFjZGNlNy90YWJsZToyNGIxMGZmMTc3YmE0ZDRlOTM1MGU3NGUwMmRiYjBlNi90YWJsZXJhbmdlOjI0YjEwZmYxNzdiYTRkNGU5MzUwZTc0ZTAyZGJiMGU2XzExLTUtMS0xLTQxMjk0_98c8d2c0-9248-49ab-9052-63b3020199ed"
      unitRef="usd">57000</us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTgvZnJhZzphNDZjN2FlZGZkZjU0ZGY3YmYzZmFlNmNlNDFjZGNlNy90YWJsZToyNGIxMGZmMTc3YmE0ZDRlOTM1MGU3NGUwMmRiYjBlNi90YWJsZXJhbmdlOjI0YjEwZmYxNzdiYTRkNGU5MzUwZTc0ZTAyZGJiMGU2XzEyLTEtMS0xLTQxMjk0_74021590-2fea-442c-914c-1437142b6add"
      unitRef="usd">11410000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="ib3597315a63d441f8f128abd7ed8840e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTgvZnJhZzphNDZjN2FlZGZkZjU0ZGY3YmYzZmFlNmNlNDFjZGNlNy90YWJsZToyNGIxMGZmMTc3YmE0ZDRlOTM1MGU3NGUwMmRiYjBlNi90YWJsZXJhbmdlOjI0YjEwZmYxNzdiYTRkNGU5MzUwZTc0ZTAyZGJiMGU2XzEyLTMtMS0xLTQxMjk0_a2993026-6b16-4fc2-93d1-fcb6d8d1c171"
      unitRef="usd">-121876000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="ie6c3b69702e9429aaeed46bdb9bbb9c1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTgvZnJhZzphNDZjN2FlZGZkZjU0ZGY3YmYzZmFlNmNlNDFjZGNlNy90YWJsZToyNGIxMGZmMTc3YmE0ZDRlOTM1MGU3NGUwMmRiYjBlNi90YWJsZXJhbmdlOjI0YjEwZmYxNzdiYTRkNGU5MzUwZTc0ZTAyZGJiMGU2XzEyLTUtMS0xLTQxMjk0_ed485356-93f2-4548-b0f8-be23d5492e3e"
      unitRef="usd">-1193000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationDispositionOfBusiness
      contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTgvZnJhZzphNDZjN2FlZGZkZjU0ZGY3YmYzZmFlNmNlNDFjZGNlNy90YWJsZToyNGIxMGZmMTc3YmE0ZDRlOTM1MGU3NGUwMmRiYjBlNi90YWJsZXJhbmdlOjI0YjEwZmYxNzdiYTRkNGU5MzUwZTc0ZTAyZGJiMGU2XzEzLTEtMS0xLTQxMjk0_211eba12-db96-43b3-9725-ce474ef669ad"
      unitRef="usd">0</us-gaap:IncomeTaxReconciliationDispositionOfBusiness>
    <us-gaap:IncomeTaxReconciliationDispositionOfBusiness
      contextRef="ib3597315a63d441f8f128abd7ed8840e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTgvZnJhZzphNDZjN2FlZGZkZjU0ZGY3YmYzZmFlNmNlNDFjZGNlNy90YWJsZToyNGIxMGZmMTc3YmE0ZDRlOTM1MGU3NGUwMmRiYjBlNi90YWJsZXJhbmdlOjI0YjEwZmYxNzdiYTRkNGU5MzUwZTc0ZTAyZGJiMGU2XzEzLTMtMS0xLTQxMjk0_42f74155-0656-408d-9115-579824cb2c86"
      unitRef="usd">127372000</us-gaap:IncomeTaxReconciliationDispositionOfBusiness>
    <us-gaap:IncomeTaxReconciliationDispositionOfBusiness
      contextRef="ie6c3b69702e9429aaeed46bdb9bbb9c1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTgvZnJhZzphNDZjN2FlZGZkZjU0ZGY3YmYzZmFlNmNlNDFjZGNlNy90YWJsZToyNGIxMGZmMTc3YmE0ZDRlOTM1MGU3NGUwMmRiYjBlNi90YWJsZXJhbmdlOjI0YjEwZmYxNzdiYTRkNGU5MzUwZTc0ZTAyZGJiMGU2XzEzLTUtMS0xLTQxMjk0_6be3f919-c1dd-4da7-a49e-d24543009a2c"
      unitRef="usd">0</us-gaap:IncomeTaxReconciliationDispositionOfBusiness>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTgvZnJhZzphNDZjN2FlZGZkZjU0ZGY3YmYzZmFlNmNlNDFjZGNlNy90YWJsZToyNGIxMGZmMTc3YmE0ZDRlOTM1MGU3NGUwMmRiYjBlNi90YWJsZXJhbmdlOjI0YjEwZmYxNzdiYTRkNGU5MzUwZTc0ZTAyZGJiMGU2XzE2LTEtMS0xLTQxMjk0_3141a0a8-1daf-4855-b684-9de8c46694eb"
      unitRef="usd">743000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="ib3597315a63d441f8f128abd7ed8840e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTgvZnJhZzphNDZjN2FlZGZkZjU0ZGY3YmYzZmFlNmNlNDFjZGNlNy90YWJsZToyNGIxMGZmMTc3YmE0ZDRlOTM1MGU3NGUwMmRiYjBlNi90YWJsZXJhbmdlOjI0YjEwZmYxNzdiYTRkNGU5MzUwZTc0ZTAyZGJiMGU2XzE2LTMtMS0xLTQxMjk0_20e9ebe9-4727-4273-940f-d630d64aecf8"
      unitRef="usd">3076000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="ie6c3b69702e9429aaeed46bdb9bbb9c1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTgvZnJhZzphNDZjN2FlZGZkZjU0ZGY3YmYzZmFlNmNlNDFjZGNlNy90YWJsZToyNGIxMGZmMTc3YmE0ZDRlOTM1MGU3NGUwMmRiYjBlNi90YWJsZXJhbmdlOjI0YjEwZmYxNzdiYTRkNGU5MzUwZTc0ZTAyZGJiMGU2XzE2LTUtMS0xLTQxMjk0_e565e85c-2540-4fea-a9ba-9847447189b8"
      unitRef="usd">748000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTgvZnJhZzphNDZjN2FlZGZkZjU0ZGY3YmYzZmFlNmNlNDFjZGNlNy90YWJsZToyNGIxMGZmMTc3YmE0ZDRlOTM1MGU3NGUwMmRiYjBlNi90YWJsZXJhbmdlOjI0YjEwZmYxNzdiYTRkNGU5MzUwZTc0ZTAyZGJiMGU2XzE3LTEtMS0xLTQxMjk0_35363e1c-46d4-47ac-ad09-28f1e4ab7ddc"
      unitRef="usd">-9840000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ib3597315a63d441f8f128abd7ed8840e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTgvZnJhZzphNDZjN2FlZGZkZjU0ZGY3YmYzZmFlNmNlNDFjZGNlNy90YWJsZToyNGIxMGZmMTc3YmE0ZDRlOTM1MGU3NGUwMmRiYjBlNi90YWJsZXJhbmdlOjI0YjEwZmYxNzdiYTRkNGU5MzUwZTc0ZTAyZGJiMGU2XzE3LTMtMS0xLTQxMjk0_bc7c0e84-54c1-46c9-9f1e-ad409494dd55"
      unitRef="usd">-7553000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ie6c3b69702e9429aaeed46bdb9bbb9c1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTgvZnJhZzphNDZjN2FlZGZkZjU0ZGY3YmYzZmFlNmNlNDFjZGNlNy90YWJsZToyNGIxMGZmMTc3YmE0ZDRlOTM1MGU3NGUwMmRiYjBlNi90YWJsZXJhbmdlOjI0YjEwZmYxNzdiYTRkNGU5MzUwZTc0ZTAyZGJiMGU2XzE3LTUtMS0xLTQxMjk0_eba0561a-7379-433b-922d-7b6f99632109"
      unitRef="usd">167337000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTgvZnJhZzphNDZjN2FlZGZkZjU0ZGY3YmYzZmFlNmNlNDFjZGNlNy90ZXh0cmVnaW9uOmE0NmM3YWVkZmRmNTRkZjdiZjNmYWU2Y2U0MWNkY2U3Xzc2OTY1ODEzOTk4MzI_0843ad59-6c97-49ca-8ff3-ad47900fe2aa"
      unitRef="usd">11400000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="ib3597315a63d441f8f128abd7ed8840e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTgvZnJhZzphNDZjN2FlZGZkZjU0ZGY3YmYzZmFlNmNlNDFjZGNlNy90ZXh0cmVnaW9uOmE0NmM3YWVkZmRmNTRkZjdiZjNmYWU2Y2U0MWNkY2U3XzExMzg_bbba3b48-0638-45a6-a247-ce9a75bf8e67"
      unitRef="usd">-116500000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="ie6c3b69702e9429aaeed46bdb9bbb9c1_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTgvZnJhZzphNDZjN2FlZGZkZjU0ZGY3YmYzZmFlNmNlNDFjZGNlNy90ZXh0cmVnaW9uOmE0NmM3YWVkZmRmNTRkZjdiZjNmYWU2Y2U0MWNkY2U3XzExNjM_2f297999-a8d1-4b79-8f06-72968bdcc6b1"
      unitRef="usd">136900000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTgvZnJhZzphNDZjN2FlZGZkZjU0ZGY3YmYzZmFlNmNlNDFjZGNlNy90ZXh0cmVnaW9uOmE0NmM3YWVkZmRmNTRkZjdiZjNmYWU2Y2U0MWNkY2U3XzUyNzY_2e877d5c-2ec0-4068-b7ec-bd588e63e928">Deferred tax assets (liabilities) are comprised of the following:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.807%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:76.478%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.662%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.547%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.813%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64,352&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64,147&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research credit carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,797&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,623&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,374&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,994&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,668&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;123,191&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;108,884&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Valuation allowance for deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(36,283)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(24,858)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;86,908&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84,026&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:13pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Identified intangibles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(102,221)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(119,381)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,300)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,923)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(111,521)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(124,304)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:13pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred income taxes, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(24,613)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(40,278)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTgvZnJhZzphNDZjN2FlZGZkZjU0ZGY3YmYzZmFlNmNlNDFjZGNlNy90YWJsZTpjZGMwODFhYmY2MzA0YTRiYjRmMmRlMWJmMjU3MjVkZS90YWJsZXJhbmdlOmNkYzA4MWFiZjYzMDRhNGJiNGYyZGUxYmYyNTcyNWRlXzQtMS0xLTEtNDEyOTQ_2a54301c-cd50-48da-b4a8-234f4e9dd0e3"
      unitRef="usd">64352000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="i7462d0db8f4248fcb9fd8f1deae439f3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTgvZnJhZzphNDZjN2FlZGZkZjU0ZGY3YmYzZmFlNmNlNDFjZGNlNy90YWJsZTpjZGMwODFhYmY2MzA0YTRiYjRmMmRlMWJmMjU3MjVkZS90YWJsZXJhbmdlOmNkYzA4MWFiZjYzMDRhNGJiNGYyZGUxYmYyNTcyNWRlXzQtMy0xLTEtNDEyOTQ_b9d04466-e9d0-42a6-9331-19bd1986fb93"
      unitRef="usd">64147000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards
      contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTgvZnJhZzphNDZjN2FlZGZkZjU0ZGY3YmYzZmFlNmNlNDFjZGNlNy90YWJsZTpjZGMwODFhYmY2MzA0YTRiYjRmMmRlMWJmMjU3MjVkZS90YWJsZXJhbmdlOmNkYzA4MWFiZjYzMDRhNGJiNGYyZGUxYmYyNTcyNWRlXzUtMS0xLTEtNDEyOTQ_9dd25f87-972d-4f5b-80c7-faa0d487911c"
      unitRef="usd">27797000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards
      contextRef="i7462d0db8f4248fcb9fd8f1deae439f3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTgvZnJhZzphNDZjN2FlZGZkZjU0ZGY3YmYzZmFlNmNlNDFjZGNlNy90YWJsZTpjZGMwODFhYmY2MzA0YTRiYjRmMmRlMWJmMjU3MjVkZS90YWJsZXJhbmdlOmNkYzA4MWFiZjYzMDRhNGJiNGYyZGUxYmYyNTcyNWRlXzUtMy0xLTEtNDEyOTQ_b51e432a-6c8b-41da-88fe-e22dbc3d220b"
      unitRef="usd">19623000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTgvZnJhZzphNDZjN2FlZGZkZjU0ZGY3YmYzZmFlNmNlNDFjZGNlNy90YWJsZTpjZGMwODFhYmY2MzA0YTRiYjRmMmRlMWJmMjU3MjVkZS90YWJsZXJhbmdlOmNkYzA4MWFiZjYzMDRhNGJiNGYyZGUxYmYyNTcyNWRlXzYtMS0xLTEtNDEyOTQ_a258201a-a3f2-4d6d-96fc-1c086fed4269"
      unitRef="usd">11374000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="i7462d0db8f4248fcb9fd8f1deae439f3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTgvZnJhZzphNDZjN2FlZGZkZjU0ZGY3YmYzZmFlNmNlNDFjZGNlNy90YWJsZTpjZGMwODFhYmY2MzA0YTRiYjRmMmRlMWJmMjU3MjVkZS90YWJsZXJhbmdlOmNkYzA4MWFiZjYzMDRhNGJiNGYyZGUxYmYyNTcyNWRlXzYtMy0xLTEtNDEyOTQ_b6caa78e-b25c-49fb-b6c5-4f2b46991b81"
      unitRef="usd">11994000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTgvZnJhZzphNDZjN2FlZGZkZjU0ZGY3YmYzZmFlNmNlNDFjZGNlNy90YWJsZTpjZGMwODFhYmY2MzA0YTRiYjRmMmRlMWJmMjU3MjVkZS90YWJsZXJhbmdlOmNkYzA4MWFiZjYzMDRhNGJiNGYyZGUxYmYyNTcyNWRlXzctMS0xLTEtNDEyOTQ_b62e17cd-e307-40e6-b182-e5892246e380"
      unitRef="usd">19668000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="i7462d0db8f4248fcb9fd8f1deae439f3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTgvZnJhZzphNDZjN2FlZGZkZjU0ZGY3YmYzZmFlNmNlNDFjZGNlNy90YWJsZTpjZGMwODFhYmY2MzA0YTRiYjRmMmRlMWJmMjU3MjVkZS90YWJsZXJhbmdlOmNkYzA4MWFiZjYzMDRhNGJiNGYyZGUxYmYyNTcyNWRlXzctMy0xLTEtNDEyOTQ_9f1c38eb-fc7a-4449-83c0-658d331f206c"
      unitRef="usd">13120000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTgvZnJhZzphNDZjN2FlZGZkZjU0ZGY3YmYzZmFlNmNlNDFjZGNlNy90YWJsZTpjZGMwODFhYmY2MzA0YTRiYjRmMmRlMWJmMjU3MjVkZS90YWJsZXJhbmdlOmNkYzA4MWFiZjYzMDRhNGJiNGYyZGUxYmYyNTcyNWRlXzgtMS0xLTEtNDEyOTQ_58584d42-1637-470f-9bfd-7053787e7212"
      unitRef="usd">123191000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="i7462d0db8f4248fcb9fd8f1deae439f3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTgvZnJhZzphNDZjN2FlZGZkZjU0ZGY3YmYzZmFlNmNlNDFjZGNlNy90YWJsZTpjZGMwODFhYmY2MzA0YTRiYjRmMmRlMWJmMjU3MjVkZS90YWJsZXJhbmdlOmNkYzA4MWFiZjYzMDRhNGJiNGYyZGUxYmYyNTcyNWRlXzgtMy0xLTEtNDEyOTQ_f0e68f95-1e9a-4e34-a8fe-a28b1ccb95fe"
      unitRef="usd">108884000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTgvZnJhZzphNDZjN2FlZGZkZjU0ZGY3YmYzZmFlNmNlNDFjZGNlNy90YWJsZTpjZGMwODFhYmY2MzA0YTRiYjRmMmRlMWJmMjU3MjVkZS90YWJsZXJhbmdlOmNkYzA4MWFiZjYzMDRhNGJiNGYyZGUxYmYyNTcyNWRlXzktMS0xLTEtNDEyOTQ_c04e0eec-1101-4d55-b594-f01cdd534b5c"
      unitRef="usd">36283000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="i7462d0db8f4248fcb9fd8f1deae439f3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTgvZnJhZzphNDZjN2FlZGZkZjU0ZGY3YmYzZmFlNmNlNDFjZGNlNy90YWJsZTpjZGMwODFhYmY2MzA0YTRiYjRmMmRlMWJmMjU3MjVkZS90YWJsZXJhbmdlOmNkYzA4MWFiZjYzMDRhNGJiNGYyZGUxYmYyNTcyNWRlXzktMy0xLTEtNDEyOTQ_b47285bd-e8f3-41bb-93f1-a20f88d286c6"
      unitRef="usd">24858000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTgvZnJhZzphNDZjN2FlZGZkZjU0ZGY3YmYzZmFlNmNlNDFjZGNlNy90YWJsZTpjZGMwODFhYmY2MzA0YTRiYjRmMmRlMWJmMjU3MjVkZS90YWJsZXJhbmdlOmNkYzA4MWFiZjYzMDRhNGJiNGYyZGUxYmYyNTcyNWRlXzEwLTEtMS0xLTQxMjk0_24e95324-3aa7-4c5a-a74e-6202aed5f2b5"
      unitRef="usd">86908000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="i7462d0db8f4248fcb9fd8f1deae439f3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTgvZnJhZzphNDZjN2FlZGZkZjU0ZGY3YmYzZmFlNmNlNDFjZGNlNy90YWJsZTpjZGMwODFhYmY2MzA0YTRiYjRmMmRlMWJmMjU3MjVkZS90YWJsZXJhbmdlOmNkYzA4MWFiZjYzMDRhNGJiNGYyZGUxYmYyNTcyNWRlXzEwLTMtMS0xLTQxMjk0_723214cc-0f6a-41e4-9842-1f7e5346c1fe"
      unitRef="usd">84026000</us-gaap:DeferredTaxAssetsNet>
    <lgnd:DeferredTaxLiabilitiesFiniteLivedIntangibleAssets
      contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTgvZnJhZzphNDZjN2FlZGZkZjU0ZGY3YmYzZmFlNmNlNDFjZGNlNy90YWJsZTpjZGMwODFhYmY2MzA0YTRiYjRmMmRlMWJmMjU3MjVkZS90YWJsZXJhbmdlOmNkYzA4MWFiZjYzMDRhNGJiNGYyZGUxYmYyNTcyNWRlXzEzLTEtMS0xLTQxMjk0_7318350c-cb31-4f1c-b370-782c0855a1d9"
      unitRef="usd">102221000</lgnd:DeferredTaxLiabilitiesFiniteLivedIntangibleAssets>
    <lgnd:DeferredTaxLiabilitiesFiniteLivedIntangibleAssets
      contextRef="i7462d0db8f4248fcb9fd8f1deae439f3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTgvZnJhZzphNDZjN2FlZGZkZjU0ZGY3YmYzZmFlNmNlNDFjZGNlNy90YWJsZTpjZGMwODFhYmY2MzA0YTRiYjRmMmRlMWJmMjU3MjVkZS90YWJsZXJhbmdlOmNkYzA4MWFiZjYzMDRhNGJiNGYyZGUxYmYyNTcyNWRlXzEzLTMtMS0xLTQxMjk0_38eb1e2a-59e4-495a-ac8d-66f80e908322"
      unitRef="usd">119381000</lgnd:DeferredTaxLiabilitiesFiniteLivedIntangibleAssets>
    <us-gaap:DeferredTaxLiabilitiesOther
      contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTgvZnJhZzphNDZjN2FlZGZkZjU0ZGY3YmYzZmFlNmNlNDFjZGNlNy90YWJsZTpjZGMwODFhYmY2MzA0YTRiYjRmMmRlMWJmMjU3MjVkZS90YWJsZXJhbmdlOmNkYzA4MWFiZjYzMDRhNGJiNGYyZGUxYmYyNTcyNWRlXzE0LTEtMS0xLTQxMjk0_4726ee9c-8765-4d99-8863-c74754d123b3"
      unitRef="usd">9300000</us-gaap:DeferredTaxLiabilitiesOther>
    <us-gaap:DeferredTaxLiabilitiesOther
      contextRef="i7462d0db8f4248fcb9fd8f1deae439f3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTgvZnJhZzphNDZjN2FlZGZkZjU0ZGY3YmYzZmFlNmNlNDFjZGNlNy90YWJsZTpjZGMwODFhYmY2MzA0YTRiYjRmMmRlMWJmMjU3MjVkZS90YWJsZXJhbmdlOmNkYzA4MWFiZjYzMDRhNGJiNGYyZGUxYmYyNTcyNWRlXzE0LTMtMS0xLTQxMjk0_78264c2b-6d6f-486a-9707-2b1d650f6b91"
      unitRef="usd">4923000</us-gaap:DeferredTaxLiabilitiesOther>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTgvZnJhZzphNDZjN2FlZGZkZjU0ZGY3YmYzZmFlNmNlNDFjZGNlNy90YWJsZTpjZGMwODFhYmY2MzA0YTRiYjRmMmRlMWJmMjU3MjVkZS90YWJsZXJhbmdlOmNkYzA4MWFiZjYzMDRhNGJiNGYyZGUxYmYyNTcyNWRlXzE1LTEtMS0xLTQxMjk0_b2e8dde2-9c05-4f8f-98ba-c244863554d9"
      unitRef="usd">111521000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="i7462d0db8f4248fcb9fd8f1deae439f3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTgvZnJhZzphNDZjN2FlZGZkZjU0ZGY3YmYzZmFlNmNlNDFjZGNlNy90YWJsZTpjZGMwODFhYmY2MzA0YTRiYjRmMmRlMWJmMjU3MjVkZS90YWJsZXJhbmdlOmNkYzA4MWFiZjYzMDRhNGJiNGYyZGUxYmYyNTcyNWRlXzE1LTMtMS0xLTQxMjk0_cb8b5543-cba6-43ae-a0a6-d35c070876d5"
      unitRef="usd">124304000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredTaxLiabilities
      contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTgvZnJhZzphNDZjN2FlZGZkZjU0ZGY3YmYzZmFlNmNlNDFjZGNlNy90YWJsZTpjZGMwODFhYmY2MzA0YTRiYjRmMmRlMWJmMjU3MjVkZS90YWJsZXJhbmdlOmNkYzA4MWFiZjYzMDRhNGJiNGYyZGUxYmYyNTcyNWRlXzE3LTEtMS0xLTQxMjk0_689447c2-ddaa-4d74-8700-bca79bbf7c6d"
      unitRef="usd">24613000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:DeferredTaxLiabilities
      contextRef="i7462d0db8f4248fcb9fd8f1deae439f3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTgvZnJhZzphNDZjN2FlZGZkZjU0ZGY3YmYzZmFlNmNlNDFjZGNlNy90YWJsZTpjZGMwODFhYmY2MzA0YTRiYjRmMmRlMWJmMjU3MjVkZS90YWJsZXJhbmdlOmNkYzA4MWFiZjYzMDRhNGJiNGYyZGUxYmYyNTcyNWRlXzE3LTMtMS0xLTQxMjk0_4757adaa-827c-4980-859e-334284736333"
      unitRef="usd">40278000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:OperatingLossCarryforwards
      contextRef="ia4b200a8f2e64db69b4c7fc8145284e5_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTgvZnJhZzphNDZjN2FlZGZkZjU0ZGY3YmYzZmFlNmNlNDFjZGNlNy90ZXh0cmVnaW9uOmE0NmM3YWVkZmRmNTRkZjdiZjNmYWU2Y2U0MWNkY2U3XzE1Njg_493b5ce9-4991-4dca-a495-fefb4d6a27ab"
      unitRef="usd">119600000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i961668aace3a442bba4c79a8ec70d54a_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTgvZnJhZzphNDZjN2FlZGZkZjU0ZGY3YmYzZmFlNmNlNDFjZGNlNy90ZXh0cmVnaW9uOmE0NmM3YWVkZmRmNTRkZjdiZjNmYWU2Y2U0MWNkY2U3XzE1NzU_6389dcee-74ee-4f04-8abc-8bbbea804757"
      unitRef="usd">176300000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="if699be6e6c984e4f92ca3d8242313e6d_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTgvZnJhZzphNDZjN2FlZGZkZjU0ZGY3YmYzZmFlNmNlNDFjZGNlNy90ZXh0cmVnaW9uOmE0NmM3YWVkZmRmNTRkZjdiZjNmYWU2Y2U0MWNkY2U3XzE2NjE_e8a344e8-489f-41dc-8fa9-583e65f4811e"
      unitRef="usd">9800000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="i5ec01ca4f07749ee939ef64e906c8950_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTgvZnJhZzphNDZjN2FlZGZkZjU0ZGY3YmYzZmFlNmNlNDFjZGNlNy90ZXh0cmVnaW9uOmE0NmM3YWVkZmRmNTRkZjdiZjNmYWU2Y2U0MWNkY2U3XzE3NTU_3fa174e3-227f-4be3-b3c7-e4a502383762"
      unitRef="usd">29700000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i1d36cbe0fb424f31b1fc285dc4c6570b_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTgvZnJhZzphNDZjN2FlZGZkZjU0ZGY3YmYzZmFlNmNlNDFjZGNlNy90ZXh0cmVnaW9uOmE0NmM3YWVkZmRmNTRkZjdiZjNmYWU2Y2U0MWNkY2U3XzE4ODM_7a82c24d-5ba0-421b-880c-bf16ec2bd5ee"
      unitRef="usd">101600000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="i0c31a24c4fde4de983ed94eb8e6c8a18_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTgvZnJhZzphNDZjN2FlZGZkZjU0ZGY3YmYzZmFlNmNlNDFjZGNlNy90ZXh0cmVnaW9uOmE0NmM3YWVkZmRmNTRkZjdiZjNmYWU2Y2U0MWNkY2U3XzE5NDY_903ab8ea-2d91-4736-abac-26c38b4caa89"
      unitRef="usd">17500000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:OperatingLossCarryforwards
      contextRef="icb55a00b3ea6419c93f1e2c6128879a1_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTgvZnJhZzphNDZjN2FlZGZkZjU0ZGY3YmYzZmFlNmNlNDFjZGNlNy90ZXh0cmVnaW9uOmE0NmM3YWVkZmRmNTRkZjdiZjNmYWU2Y2U0MWNkY2U3XzIwNTg_0ea24c0d-8fe9-4109-adfe-0d1413a5cc5c"
      unitRef="usd">110100000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="i451ae05e4ee04e718c1da5b566a1bbc5_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTgvZnJhZzphNDZjN2FlZGZkZjU0ZGY3YmYzZmFlNmNlNDFjZGNlNy90ZXh0cmVnaW9uOmE0NmM3YWVkZmRmNTRkZjdiZjNmYWU2Y2U0MWNkY2U3XzIxMjE_62ecc4e0-7d91-4b94-bfad-7f5655ad4def"
      unitRef="usd">17600000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:ScheduleOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForwardTableTextBlock
      contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTgvZnJhZzphNDZjN2FlZGZkZjU0ZGY3YmYzZmFlNmNlNDFjZGNlNy90ZXh0cmVnaW9uOmE0NmM3YWVkZmRmNTRkZjdiZjNmYWU2Y2U0MWNkY2U3XzUyNzc_fe774ad9-5326-4dfe-bb5c-8758d624e61b">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation of the amount of unrecognized tax benefits at December&#160;31, 2021, 2020 and 2019 is as follows (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.807%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.064%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.547%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.064%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.547%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.365%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at beginning of year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,871&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,736&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,289&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Additions based on tax positions related to the current year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,911&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;543&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Additions for tax positions of prior years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;945&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;179&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Reductions for tax positions of prior years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,072)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(955)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,096)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at end of year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,996&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,871&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,736&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForwardTableTextBlock>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i7462d0db8f4248fcb9fd8f1deae439f3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTgvZnJhZzphNDZjN2FlZGZkZjU0ZGY3YmYzZmFlNmNlNDFjZGNlNy90YWJsZTpmNDhmMzcxZGE0NzI0Yzg3OTg2ODg5MmNjYWQ1MGIxOS90YWJsZXJhbmdlOmY0OGYzNzFkYTQ3MjRjODc5ODY4ODkyY2NhZDUwYjE5XzItMS0xLTEtNDEyOTQ_666b9256-68ea-4a00-8a6e-2ec1c4637b77"
      unitRef="usd">31871000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="ida3ec05a32644c2db1bb9f71f76c567f_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTgvZnJhZzphNDZjN2FlZGZkZjU0ZGY3YmYzZmFlNmNlNDFjZGNlNy90YWJsZTpmNDhmMzcxZGE0NzI0Yzg3OTg2ODg5MmNjYWQ1MGIxOS90YWJsZXJhbmdlOmY0OGYzNzFkYTQ3MjRjODc5ODY4ODkyY2NhZDUwYjE5XzItMy0xLTEtNDEyOTQ_0d5acb3e-b599-4064-94a0-3a3c87ff2c1c"
      unitRef="usd">28736000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="if1aac4d81ad94163b33117197afe0895_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTgvZnJhZzphNDZjN2FlZGZkZjU0ZGY3YmYzZmFlNmNlNDFjZGNlNy90YWJsZTpmNDhmMzcxZGE0NzI0Yzg3OTg2ODg5MmNjYWQ1MGIxOS90YWJsZXJhbmdlOmY0OGYzNzFkYTQ3MjRjODc5ODY4ODkyY2NhZDUwYjE5XzItNS0xLTEtNDEyOTQ_da6d1721-411f-49b3-8f34-d3db25398c28"
      unitRef="usd">30289000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTgvZnJhZzphNDZjN2FlZGZkZjU0ZGY3YmYzZmFlNmNlNDFjZGNlNy90YWJsZTpmNDhmMzcxZGE0NzI0Yzg3OTg2ODg5MmNjYWQ1MGIxOS90YWJsZXJhbmdlOmY0OGYzNzFkYTQ3MjRjODc5ODY4ODkyY2NhZDUwYjE5XzMtMS0xLTEtNDEyOTQ_9406076c-a789-4059-a96a-ff30ae06bda0"
      unitRef="usd">252000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="ib3597315a63d441f8f128abd7ed8840e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTgvZnJhZzphNDZjN2FlZGZkZjU0ZGY3YmYzZmFlNmNlNDFjZGNlNy90YWJsZTpmNDhmMzcxZGE0NzI0Yzg3OTg2ODg5MmNjYWQ1MGIxOS90YWJsZXJhbmdlOmY0OGYzNzFkYTQ3MjRjODc5ODY4ODkyY2NhZDUwYjE5XzMtMy0xLTEtNDEyOTQ_1779930e-8fc1-4aaf-939a-91cab9d89ca1"
      unitRef="usd">3911000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="ie6c3b69702e9429aaeed46bdb9bbb9c1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTgvZnJhZzphNDZjN2FlZGZkZjU0ZGY3YmYzZmFlNmNlNDFjZGNlNy90YWJsZTpmNDhmMzcxZGE0NzI0Yzg3OTg2ODg5MmNjYWQ1MGIxOS90YWJsZXJhbmdlOmY0OGYzNzFkYTQ3MjRjODc5ODY4ODkyY2NhZDUwYjE5XzMtNS0xLTEtNDEyOTQ_8d945ae5-8b17-4389-9263-09b1ec6ea749"
      unitRef="usd">543000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTgvZnJhZzphNDZjN2FlZGZkZjU0ZGY3YmYzZmFlNmNlNDFjZGNlNy90YWJsZTpmNDhmMzcxZGE0NzI0Yzg3OTg2ODg5MmNjYWQ1MGIxOS90YWJsZXJhbmdlOmY0OGYzNzFkYTQ3MjRjODc5ODY4ODkyY2NhZDUwYjE5XzQtMS0xLTEtNDEyOTQ_ace095d2-5421-48bf-93b5-2f81d32abc2b"
      unitRef="usd">945000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="ib3597315a63d441f8f128abd7ed8840e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTgvZnJhZzphNDZjN2FlZGZkZjU0ZGY3YmYzZmFlNmNlNDFjZGNlNy90YWJsZTpmNDhmMzcxZGE0NzI0Yzg3OTg2ODg5MmNjYWQ1MGIxOS90YWJsZXJhbmdlOmY0OGYzNzFkYTQ3MjRjODc5ODY4ODkyY2NhZDUwYjE5XzQtMy0xLTEtNDEyOTQ_4f97cdfc-cec8-49c0-a7c6-b66c8d851d5f"
      unitRef="usd">179000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="ie6c3b69702e9429aaeed46bdb9bbb9c1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTgvZnJhZzphNDZjN2FlZGZkZjU0ZGY3YmYzZmFlNmNlNDFjZGNlNy90YWJsZTpmNDhmMzcxZGE0NzI0Yzg3OTg2ODg5MmNjYWQ1MGIxOS90YWJsZXJhbmdlOmY0OGYzNzFkYTQ3MjRjODc5ODY4ODkyY2NhZDUwYjE5XzQtNS0xLTEtNDEyOTQ_92c3b11d-68c9-454d-a8ac-98d85e9a0f36"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
      contextRef="i8de36dd6935847019123fffb990b7008_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTgvZnJhZzphNDZjN2FlZGZkZjU0ZGY3YmYzZmFlNmNlNDFjZGNlNy90YWJsZTpmNDhmMzcxZGE0NzI0Yzg3OTg2ODg5MmNjYWQ1MGIxOS90YWJsZXJhbmdlOmY0OGYzNzFkYTQ3MjRjODc5ODY4ODkyY2NhZDUwYjE5XzUtMS0xLTEtNDEyOTQ_03182cf8-9561-492b-8216-44cab5a24525"
      unitRef="usd">3072000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
      contextRef="ib3597315a63d441f8f128abd7ed8840e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTgvZnJhZzphNDZjN2FlZGZkZjU0ZGY3YmYzZmFlNmNlNDFjZGNlNy90YWJsZTpmNDhmMzcxZGE0NzI0Yzg3OTg2ODg5MmNjYWQ1MGIxOS90YWJsZXJhbmdlOmY0OGYzNzFkYTQ3MjRjODc5ODY4ODkyY2NhZDUwYjE5XzUtMy0xLTEtNDEyOTQ_fefaaae8-2021-4dae-a1ed-ee74574f7c55"
      unitRef="usd">955000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
      contextRef="ie6c3b69702e9429aaeed46bdb9bbb9c1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTgvZnJhZzphNDZjN2FlZGZkZjU0ZGY3YmYzZmFlNmNlNDFjZGNlNy90YWJsZTpmNDhmMzcxZGE0NzI0Yzg3OTg2ODg5MmNjYWQ1MGIxOS90YWJsZXJhbmdlOmY0OGYzNzFkYTQ3MjRjODc5ODY4ODkyY2NhZDUwYjE5XzUtNS0xLTEtNDEyOTQ_c1af920d-c9f7-481c-9e1b-cc70c6d6e348"
      unitRef="usd">2096000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTgvZnJhZzphNDZjN2FlZGZkZjU0ZGY3YmYzZmFlNmNlNDFjZGNlNy90YWJsZTpmNDhmMzcxZGE0NzI0Yzg3OTg2ODg5MmNjYWQ1MGIxOS90YWJsZXJhbmdlOmY0OGYzNzFkYTQ3MjRjODc5ODY4ODkyY2NhZDUwYjE5XzYtMS0xLTEtNDEyOTQ_38872b56-3607-494c-9834-ab3e523f936c"
      unitRef="usd">29996000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i7462d0db8f4248fcb9fd8f1deae439f3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTgvZnJhZzphNDZjN2FlZGZkZjU0ZGY3YmYzZmFlNmNlNDFjZGNlNy90YWJsZTpmNDhmMzcxZGE0NzI0Yzg3OTg2ODg5MmNjYWQ1MGIxOS90YWJsZXJhbmdlOmY0OGYzNzFkYTQ3MjRjODc5ODY4ODkyY2NhZDUwYjE5XzYtMy0xLTEtNDEyOTQ_666b9256-68ea-4a00-8a6e-2ec1c4637b77"
      unitRef="usd">31871000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="ida3ec05a32644c2db1bb9f71f76c567f_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTgvZnJhZzphNDZjN2FlZGZkZjU0ZGY3YmYzZmFlNmNlNDFjZGNlNy90YWJsZTpmNDhmMzcxZGE0NzI0Yzg3OTg2ODg5MmNjYWQ1MGIxOS90YWJsZXJhbmdlOmY0OGYzNzFkYTQ3MjRjODc5ODY4ODkyY2NhZDUwYjE5XzYtNS0xLTEtNDEyOTQ_0d5acb3e-b599-4064-94a0-3a3c87ff2c1c"
      unitRef="usd">28736000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
      contextRef="i9217b15ab4cb456c8c63180298ed612e_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmYTZmOTA2ZmIyZTRlMzBiYzVlODczZDJiYjZhODJjL3NlYzowZmE2ZjkwNmZiMmU0ZTMwYmM1ZTg3M2QyYmI2YTgyY18xMTgvZnJhZzphNDZjN2FlZGZkZjU0ZGY3YmYzZmFlNmNlNDFjZGNlNy90ZXh0cmVnaW9uOmE0NmM3YWVkZmRmNTRkZjdiZjNmYWU2Y2U0MWNkY2U3XzM3NDc_04872d25-cdd0-4735-8cac-4a9cee00bbdf"
      unitRef="usd">28100000</us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>88
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( &^+7%0'04UB@0   +$    0    9&]C4')O<',O87!P+GAM
M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG
M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGD<Z,STA)8*O4'J@)I9GF
M3?X.CD:?<@X>K7A.YNJQ<&4GPZ4A!0W_<FW>J=0U[R;UEA_6\#MI7E!+ P04
M    " !OBUQ4MN_B$.X    K @  $0   &1O8U!R;W!S+V-O<F4N>&ULS9++
M:L,P$$5_I6AOCZU '\+1IJ6K%@H-M'0GI$DB8CV0IMCY^]IJXE#:#^A2,U=G
MSL!T.@H=$KZD$#&1Q7PUNMYGH>.:[8FB ,AZCT[E>DKXJ;D-R2F:GFD'4>F#
MVB'PIKD&AZ2,(@4SL(H+D<G.:*$3*@KIA#=ZP<?/U!>8T8 ].O24H:U;8'*>
M&(]CW\$%,,,(D\O?!30+L53_Q)8.L%-RS'9)#<-0#ZN2FW9HX?WYZ;6L6UF?
M27F-TZ]L!1TCKMEY\MOJ_F'SR"1O.*\:7O';#>>"WXCF[F-V_>%W$7;!V*W]
MQ\9G0=G!K[N07U!+ P04    " !OBUQ4F5R<(Q &  "<)P  $P   'AL+W1H
M96UE+W1H96UE,2YX;6SM6EMSVC@4?N^OT'AG]FT+QC:!MK03<VEVV[29A.U.
M'X416(UL>621A'^_1S80RY8-[9)-NIL\!"SI^\Y%1^?H.'GS[BYBZ(:(E/)X
M8-DOV]:[MR_>X%<R)!%!,!FGK_# "J5,7K5::0##.'W)$Q+#W(*+"$MX%,O6
M7.!;&B\CUNJTV]U6A&ELH1A'9&!]7BQH0-!445IO7R"TY1\S^!7+5(UEHP$3
M5T$FN8BT\OELQ?S:WCYES^DZ'3*!;C ;6"!_SF^GY$Y:B.%4PL3 :F<_5FO'
MT=)(@(+)?90%NDGVH],5"#(-.SJ=6,YV?/;$[9^,RMIT-&T:X./Q>#BVR]*+
M<!P$X%&[GL*=]&R_I$$)M*-IT&38]MJND::JC5-/T_=]W^N;:)P*C5M/TVMW
MW=..B<:MT'@-OO%/A\.NB<:KT'3K:28G_:YKI.D6:$)&X^MZ$A6UY4#3( !8
M<';6S-(#EEXI^G64&MD=N]U!7/!8[CF)$?[&Q036:=(9EC1&<IV0!0X -\31
M3%!\KT&VBN#"DM)<D-;/*;50&@B:R('U1X(AQ=RO_?67N\FD,WJ=?3K.:Y1_
M::L!I^V[F\^3_'/HY)^GD]=-0LYPO"P)\?LC6V&')VX[$W(Z'&="?,_V]I&E
M)3+/[_D*ZTX\9Q]6EK!=S\_DGHQR([O=]EA]]D]';B/7J<"S(M>41B1%G\@M
MNN01.+5)#3(3/PB=AIAJ4!P"I DQEJ&&^+3&K!'@$WVWO@C(WXV(]ZMOFCU7
MH5A)VH3X$$8:XIQSYG/1;/L'I4;1]E6\W*.76!4!EQC?-*HU+,76>)7 \:V<
M/!T3$LV4"P9!AI<D)A*I.7Y-2!/^*Z7:_IS30/"4+R3Z2I&/:;,CIW0FS>@S
M&L%&KQMUAVC2/'K^!?F<-0H<D1L= F<;LT8AA&F[\!ZO)(Z:K<(1*T(^8ADV
M&G*U%H&V<:F$8%H2QM%X3M*T$?Q9K#63/F#([,V1=<[6D0X1DEXW0CYBSHN0
M$;\>ACA*FNVB<5@$_9Y>PTG!Z(++9OVX?H;5,VPLCO='U!=*Y \FIS_I,C0'
MHYI9";V$5FJ?JH<T/J@>,@H%\;D>/N5Z> HWEL:\4*Z">P'_T=HWPJOX@L Y
M?RY]SZ7ON?0]H=*W-R-]9\'3BUO>1FY;Q/NN,=K7-"XH8U=RS<C'5*^3*=@Y
MG\#L_6@^GO'M^MDDA*^:62TC%I!+@;-!)+C\B\KP*L0)Z&1;)0G+5--E-XH2
MGD(;;NE3]4J5U^6ON2BX/%ODZ:^A=#XLS_D\7^>TS0LS0[=R2^JVE+ZU)CA*
M]+',<$X>RPP[9SR2';9WH!TU^_9==N0CI3!3ET.X&D*^ VVZG=PZ.)Z8D;D*
MTU*0;\/YZ<5X&N(YV02Y?9A7;>?8T='[Y\%1L*/O/)8=QXCRHB'NH8:8S\-#
MAWE[7YAGE<90-!1M;*PD+$:W8+C7\2P4X&1@+: '@Z]1 O)256 Q6\8#*Y"B
M?$R,1>APYY=<7^/1DN/;IF6U;J\I=QEM(E(YPFF8$V>KRMYEL<%5'<]56_*P
MOFH]M!5.S_Y9K<B?#!%.%@L22&.4%Z9*HO,94[[G*TG$53B_13.V$I<8O./F
MQW%.4[@2=K8/ C*YNSFI>F4Q9Z;RWRT,"2Q;B%D2XDU=[=7GFYRN>B)V^I=W
MP6#R_7#)1P_E.^=?]%U#KG[VW>/Z;I,[2$R<><41 71% B.5' 86%S+D4.Z2
MD 83 <V4R43P H)DIAR F/H+O?(,N2D5SJT^.7]%+(.&3E[2)1(4BK ,!2$7
M<N/O[Y-J=XS7^BR!;814,F35%\I#B<$],W)#V%0E\Z[:)@N%V^)4S;L:OB9@
M2\-Z;ITM)__;7M0]M!<]1O.CF> >LX=SFWJXPD6L_UC6'ODRWSEPVSK> U[F
M$RQ#I'[!?8J*@!&K8KZZKT_Y)9P[M'OQ@2";_-;;I/;=X Q\U*M:I60K$3]+
M!WP?D@9CC%OT-%^/%&*MIK&MQMHQ#'F 6/,,H68XWX=%FAHSU8NL.8T*;T'5
M0.4_V]0-:/8--!R1!5XQF;8VH^1."CS<_N\-L,+$CN'MB[\!4$L#!!0    (
M &^+7%2QO)6@O@8  +D:   8    >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL
MI5G;<MLV$'U.OP*C9#K)C&7QHIL3VS.T9"5J;$>UG&323A\@$A(Q(0$5 "WK
M[[L *5%V*9"=^L'B;0\/=H&SB^7YAHN?,B9$H:<T8?*B%2NU?M_IR# F*9:G
M?$T8W%ERD6(%IV+5D6M!<&2,TJ3C.4Z_DV+*6I?GYMI,7)[S3"64D9E ,DM3
M++97).&;BY;;VEVXIZM8Z0N=R_,U7I$Y45_7,P%GG3U*1%/").4,";*\: 7N
M^[$_T ;FB6^4;.3!,=)#67#^4Y],HXN6HQF1A(1*0V#X>20CDB0:"7C\78"V
M]N_4AH?'._2)&3P,9H$E&?'D.XU4?-$:ME!$ECA+U#W??"+%@'H:+^2)-/_1
M)G^VVVVA,).*IX4Q,$@IRW_Q4^&( X.A<\3 *PR\%P;NL3?XA8'?U*!;&'2-
M9_*A&#^,L<*7YX)OD-!/ YH^,,XTUC!\RG3<YTK 70IVZG+$'XE ;?1U/D9O
MW[Q#;Q!EZ(HF"01%GG<4O$(_V D+N*L<SCL"YWKHEC,52W3-(A(]!^@ MSU!
M;T?PRK,BCDEXBGSW!'F.YU80&MG-)V1QBCS?F'L5YF.[^6\9@[<[56]_-AI_
M[V[?X/E6=_\9+*02,.7_LD!V]Y!= ]D]YB >9K 0%7K8KDE5Q.SFKM/^;&'1
MV[/H-6,1,);A!-V3-1>JBHX=1XF,6.CT]W3ZS>C,B* \TK,1P?JH]$\-4C'_
M?GGUJF8.#/;<!@T#)C#HIY&_X^ZR8RUQ(FW^&NXY#:TXUTQ1M443FA!TEZ4+
M(JJXV#$<QVW[OG/F6_B<[?F<->%S3U94KQ1PUAU.*Z-GQ[F9?@SNQFCV*;B_
M#4;77Q^FH^!FCJ9W(PM)URG%TVE"<\I"+B" 6,?R!,T5S#3$!1KQC"FQA=^H
MDGL-^OC:1O) X=TF)!_P$YI&,._HDH:&J272-9"#0=MQ^\Z@V[4Q]$J&7A.&
M010)(N7)[@#=P'/H"ZOVG1VR=S9TT"=84S!,N [I$>*248A+U^G92)=*[OK_
MB?1(GT'0'_B&51*N@4N)V#Y"XK4M9[=,"JY=UE^RV\_)F>"/E(75/K5CC@(;
MM3)3N':)?TEMQJ6"C/$'71]?*';$LV[?&=JXE6G#M:N]"6( !?1Q*G: 8<]*
MI,P1KEW8;W@(/IG%G-D$N0:DUW/:@Y[CV!B5&<*UR_L#59 <^!*YWMO%.S0G
M82; 6Y6T[$@CGJ9F6?+PYPE:8X$><9(1].844@A:0X$D8RRLZZ#,(ZX] 4".
MC2A;H?DV7?"DDFQ-!OEX-[:5L66N\.QJOG,8NGX*8\Q6Y&A*JP&Z"^;CX'<;
MIS(U>(U2PW?8=K4_,Q N""N6,.<B-)4RJYYT-9@_B+1Q*Y."UR@I?.,))%'8
MDIKB1%3N26J0[KB-4"GX7B/!'V5"Z.HM+]G,W )MS:J)V1%K7%6*O==([*=,
M$9%OI'6QBW=4*YG9$6N8E5KO-=)Z$SHT@A2TXJ)2,FIP;K" !1.$(0$@@(ER
M2!O'4O,]NV07'.<I3A)TE4FX+:NC:<>IJ\6]4OP]NVX7C'1)L-(3[",@J!A2
M4KK&K-I]_V^;X)59P+-K]W0TN4=!%E$%M42@%('<;6K)28)7E<SL>#7[/:\4
M>J_1CF$>@Y99/66'J?.47^J]WVAO,,L6"0W!/1Q7+<1Q@=(S*+I+]WCIGD(-
M\5CU\E+8_4;"_CS3SG56E>A+IB!H3*?%JGY*@=P_)-0?]KQ^SSG"JI1TWR[$
MNYVO/-@QP5)>Z(W>DH!459>E-:@S+<.<25V;J)CH"O=IFQ>\9IN]A)FJKY>;
MR5]?#SUW\$&:KLZN8W$+>P2]V #%^"OF203Y!BF.%@0M06XBM*&P##66=BR5
MIOFIKU$&59&#(KPU+,8D)+ID^_4U;)(^[)I7"+R/Z(N!B]W ==]MAH7*;:;3
M:3X<*I]W5)!>:ERD^6.Z>7.:'W[?42-/(5F;)6D N"1HO?.0BK$R-.2:A&8?
MF"1;.Z<F%$Z0S,+X7XZ'*@[6(N-*.S B<#$J_(BE+OO4?H@[8&'A$L,O9:>V
MM7G0A;,GW@#X18;C,=FJ :B5B3)W^PW;=Q,J=<G_@T ]/(&+E2FH!JRN2UGF
M;;]A.Z]@5;31CO.RPTU^V%B5F=IOE*E'0$P J2F+R!/Z3"IUO@;*@;_AL._V
M;=TJO\S8OCW![HK"PR#:>HXU<.VVZ[7]RE!V#GK]NCXPWTPD"G6K*6_[[Z_N
MO\L$YFM$IWP\_ZASBW5Y(5%"EF#JG X@B"+_3I*?*+XV7PX67"F>FL.88%!%
M_0#<7W*N=B?Z!?NO59?_ %!+ P04    " !OBUQ4N_^T,28"  !Z!0  &
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M;QNEVDEO#2,K/UU[:>RL^F5I'T=0+L#N'Z0T1\,=T#^WZ5]02P,$%     @
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MPRZF*(D]#,8[IW&']T?%^FQK?2JW#;?<ISC87W.6?JH6+.<7HX7DBLL5'TV
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M"DQ2SI" >=?I>]<##QN!M?A&824WQLBD,N7\U4R^S+H.-D200*2,"Z(?2QA
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M!%FEQX'#JBJ' V2T:D._;+?SN6/R"93,*7#0EMBQ2HM50QTP&%AY<: (C.$
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M]UQ*7C1?UXPN654#U/]7G,N7A_H'^DO>T_\!4$L#!!0    ( &^+7%3I@9]
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M1)'QJH;N]=<ZEU_0[U>B*!!PW@.KLC\<%15L!P^<JW51U^MFN6"%TDW;J-7
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M>B1&G2ZV_@+'#<9E:=)OKZVXK!Z$,@[A0>%K_82H49&ZW0KATB3U>A9R&.S
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MS#:AE18%U#K/7%\R@V!,30:''00CG ?L"[7:3^/:?T3NY;4/"@EZCJFWLH*
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M!(1:-AG)RB999[> !6/*Q!06Q Z!!,A9A#L8)</4\6-7/V O?@G0)EL@"UH
M0:IS>-J (&S7R<^C3Z/D[]?7'WBSLO]64$? P_(5K(A3P 9U;P_#382/" 4X
MP3PK$)0'X^/GQB XWS6M!84!X_",>7LJ*1YRRO@0*ES;[OMHJ VR 1&^23I>
MS^AZ1!4-:-@M;X*X(ULN00<RTC:,,P"IJF4/^/G]0!&)]"FVK%I"Y*+MX&F
M"G1A ^II#SP'B];)LJXV,*P".!7($?(!<$_+.*$#5 GQT3:? V%J2Q"@'4-
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MY8!Y"@/3 HI!ZU1= 8(?9&OI0 !Y ?9,QR0)XVZ-.Y3&"3C8''!5! \:0;B
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MP]-!9YCL=-K/UBQ0T"5 J&7K1?;&@/;/!V;L;0+I2_<0\M/AF85[Z\@$OQ^
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M+X87Q1$[> HF37)PH' F+P>12JIN!;HFJTM8'6!\"ROW!=_ 21.6\HHPML'
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M".085.!* QU8P)BMF7<IN@4TC;Q"\0>WMK+?P\ %-^1WMCZ82@9-#E'"*:E
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MRU1^0@DIGIR8_@]P.+,R*_:_&XH-6-U;@9F<)HX!(F;1TC5LY_J'@;*&@,?
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MA ]9 2.*[-[C1X3T3O_R#Q^^6S4\?[WZE3JAZV _2A@??OJ_)^/I]"N%R1:
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M)IAKT\GHXHGO9H4W^;-B(;%9])(Z$%5;+EP[GB8Z>@:NG/\("M3Y4HN!; 0
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MW?MOIGGO"5'X!+^H9U7)H:+^D]0S]?%"$?@'M/+=&O9XMOKM70L0PW%G->E
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M%ADWAL5(.S)VT\U/G/$;FK'A>Q2#8 VQKY;S.P$91EO3HQ<EF/1=9R&6>;T
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M;"]W;W)K<VAE971S+W-H965T,3 N>&ULM5C;;MPV$/T58FL$";#>FR]Q$MN
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M<KM416)-H<C$,V-@\L'RQ7\_6YI*PTS^YSWS3IMYISSO]#/U^O&](:D@4>&
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MZ>"B3\T#;.-BU6#>*2FV%C*8=JM^M,^N,MF8Y K\ID@)!55A#^VXL6%](1L
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M0\VC%,2EP1+$C)R.#<U),H_D^>8(FX]#DO^I-W?H$D%[3:?#BO&81VNPMJF
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MB(4,"BQ;8L:E5D_]#@(RI8@%=RP7?IGHB86\(2CT=@%W!VDUYHT7/*\;Q.L
M \L>B[<!Q*GX=>J4O0%/#9VN2L&=$U\K4P(_R02:TW7,"E)T 48?,-[XC088
M+$G:4WS??E8)\6I:$I1F&)F&593YAN2OB^;N;6#H5'PJS [=P+!>:-!.(-AV
MH+42[P&D,+7R,\2E)"RTZFL%V$SM2[.$0;#Z,D)C5D(33^MBRXY(33.30XXL
M4L:_LN9&9V3==3819L9 #WA!PWFPYNP!?D$: 53$(;6<0D1U+&+@N.B*8[84
M4SD\<2>/Q7ZW91_\H%8&/@#8"--*?&)WV07]#Z_!]XT&+[T&KX(&D87%FPQ
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MXUXRF71/8EJ\O3? #H3SX\$X&0TO3@Y-.[FZ^T:?1<@08^/Z> +2_SK[O>9
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ME$0NHP5X/S/@,=P0@N8[P^?_ 5!+ P04    " !OBUQ4T_"9=+T)  !V,0
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MCG7##O(=A&4P3I<PV?Z/,IVEG D.4()DBS?Z(J55%)>D45%9+@5<]!%3=-P
M5D'YL51<<!J:M7)ZV0*9!NH20616ZQ(K'+MBHE25DS3J#6+U0#8BUWG,2_6
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MG<.7,O[$RBZAS=Q55B+C8NP?S>LH%&J;%^2I)>RR,[Z\+OH.12](1NZ.L&A
MB23)5!M8LQ].OVC8&%KTD,!7XBSHR6!%)^\9A3VZ>ZA.Y:18_RZQ>01>Q@-I
MBV:!8>H.M\]:'$J((3[DU:(](_PSKJ,6NCY:GF24.[(S+@LHD5@[E!]LZBQ\
M8%"'GLRCJ"X*V*S!!XM#Y59%>D7 '.4%V".:!IL$CM9]JPT1#2?+*HJ5ZQQ\
M9(UV6!H3\6/&3AD$[ (+CC2*<28V0"S!Z':;* )$B+,C!T\HU/*6'DAEK!@
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M_3+H$FJRD6-/H&U9WVT=[B2LC,1=WN4>W!,IE2@F3MFL)JO9TT!WSVD*9=*
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MS[0 WZ]RR-&^H0W:W]9X\E]02P,$%     @ ;XM<5,&K;G!J#   32   !D
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M*\LF]D_:B 4$T9:LWK8^[*O!4^U3=QRB#*50P-CF,G:/<6E4'0[&'$/+Q(N
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MGP'B[*/#A&-T;RCQ@_$U[I=B9<WV(1Y/U)H2M%AI4/.N*/$$I'K21F'H!Q-
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MX.POY7"LUXLG_UX6]VXXF?=NB&U53.!0@8$H]!:4L_=\K^&?X^0'ZZA_,R/
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MCO,3MM"QQXG^'CA[*GY%;KN("0[*^DE"H1$3^@)24M)1[!F=:FQFN'@8;DK
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M#;;AGPA#P!]MP/NUM:%_( ;Y3O_5/P%02P,$%     @ ;XM<5%SE%!(2#
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M!6T_UI5R1Z 04\XGR$"RR*IJ*4IUB6CMYF@'[$D GE\)K=@1BN]0\6B<(]*
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M:@?4H/JBFK#,Q?F-\9,5.JTK8M]X*RH94::6@46/I[5[D]0>-XTZL@7@&!B
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M[0.W]  GA5E/6G]J5L7BC,O^,\/K&HC32IV6Q()9.Q#>@/YN=(3S7D2OE@@
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MC++-T6,T5ZO]$RS>)LM% H=48+Z$V:9IXCI#5JAOCD_V*LI;NK:"+/BEN5?
MWSVEGB*.(WL/IE84+M#M([BB6$[> V.,39)F"6#O"I?YK"MIQF'V&-$Y.W'(
ME-2[[B4OJ>"<,ZWIH_OW)""GGIJQM7D7/+[8.,>#T,$&_Q86]PIU89-FT.7\
M?9&[NB.O*HZ[*]#:Q10HO(3/K7-_PX=-@32#\5N5W/YVXHX[SA/-Y2*W\,81
MY(2Q.5#6@&+%=].13> ^I3Y^C@&2]!,Q6=9#&<"11Y]N92&/&?;4;8/F4>D=
MHA\0"</[AI!Y+B=!2_08>W9A<=1PO3T5BD07I^Z'K$'\QY\XI:M:F0D = 7%
M!61Y5($8$IXI[^63! 6:<.EUG&#+A@9Z^<GEBBG58L1A5%^4?=OHVZ=::YBZ
M"#*NM>GF4MUKRJ5U*UXR^SX^049&#<,YS5,-<HJLE9PN,3'\T"A!G\6_\Q['
ML +ME#8T#U=DS\]=<TV3/\;"ZB?4Z)"\^F.*T>F1DD_;XIL&",E]_V@GU<N/
MC@V?O :"7>K.'Q?TJ_>'#IMHD..2:D2IN8E]2\**>\I>=MDTQ?XP:VO5J?$F
M%EW74K$TM5;N9]UBB4C1\4G1)/&:5)>+2++IO&M2%Y&<6P0ABNF)PVZ)>_=E
M:R5=Z4]:Z9DEW)[?A+D61+XA#Q&R:]9VR:EAK9R&#61Q',71$NUY& >C3PXA
M-W6&]0F_]ZFR"H-^2'HL)!=Y FQ;("KB7FJ6=; ES5CF]BGQ_+PC=8;O9&\U
M[VL'AM#R8&SA,!Y.55?=>A-YOO@QR74B=H$*F^^W5-Y7!=IC/N-8&H"Q&>H[
MAJKIJIE1G >"=^.P=#\2< XZOK6$#0C$0E2I/ICH04A$3/L\)AS7^?6,F41"
MYK+),S06>.L#%C2JII\.O%^A9,NGN=1.;WP6LT!CAF!#:3-'WM0WH32.S74-
M=ODHHMVJW41P$G>EL0Z.QF ?0D*P-^4CF.9 >@>P:&2XGK^<DCBS('%FYZXH
M OFPP:0H..9(0(Q*G2\>+8E_B\6&2;@8RI1!@%D,N)$J#1F%93N>AM1J4EL,
MMN9\LQ"OVT]AW"EEY6=NT9JH&#4D -9<BG*R/+#C6V+BYJ8<W^U ?#[+P1.2
MU16M!V/CVN8@I,(- , 6[& WX6VV$+D^1:7+C77AW$4NG!.'=%*+F0><FI_$
M@K<"M1N%VH< M5&D^O+A.&D CPM8Z"WVKH#-NIK4W'UH0;\4CZP_1XVD=PLP
M]O*T/DR2?[@:'LF##S:57K=X6_K@.DCU2AQO//XV\ET<>4PZ>LQ>C;@:1PT=
MDIY4[ZJHJ"$<BNV^P?1,J0,=Z9[P\MGE]-GE)((@;";TYS&8<F'O>NY[<LSD
M&)(OLVFUF@KC9H\* +'P=0:-[T82<CFC$927]AU  QJ/E'"?B  <'4Q6*:7Y
MD1VM6BKKYS )#K7/21=-0+*6C*%^A-(U@Y/)E?.3\#+/4C*G["U<[&%='N=[
M)\DMW @^/WU/]W6XF/Y.&@\UU-^7(H'7V)O(<=.NT2=_!H/X?^-];?S@*(%^
MP0)ZPZ)$\X$,O1+A[?7=:PUT</>I^>44&WR\04:LS:;H@S2_]GH,;H>[5FL(
M_O%=MVBIH]375WA[Q1/)L38N</C\-Y>M<:&^DY4OI0'$^A'OG W:Y2_[4I$I
M#/YR]MR__/4E=:[B/MR4L4-=*!@S/4RHJXVD'02:SDTG+*X9]'=\@ 6\Y/QN
M2W5(0+086\ABM6P[HFWJ(K=G40#'[ [KI'E *>GP_1>P]B^M?>$OGI)_2[>Y
MU*)%6!V!5^&0YMO&!'R[TE] ;3T,N>2B_/7Z^E::;</YH[O1-YM L''S %YY
M+I?TK/(&29C9ZL+!:7+Y)F5#> :+][KQE;VV=8'J"=XAB'YD.R!P#[^ N'/7
M//3?HW9?%F']U3)XO""CJ0Z"JDY#7P7% )M-QH4GXI?@:S695;'6"PPH]\H_
MN[?%;1R\V7'S-EJ-7H6@GABJV]((*QZ,N+S403@A'VQXX'@$4V](B\8+!L;0
MV//Y\,M6O=_BG D)U=:='A?9&)<-W\*0]CK7Q3367PAI<X$H^&TT00H7Q7HD
M!Y*N;V_,-2^8N6_;LZC7FQU:9:@-$$[+C"RTZ\/VRP&=S6+!T.!6&*([YG*.
ME+ ?"J#34-6M/M&1\-RX.[36FR8PV7E4S#RE&/V;M$U_^&[KZK6[<46!%C4L
M\OM':#_X;]%EAI&\;Z[GCY["F^'Q'[[;@=3^*:W7J)$6;@6O8NK+(\Z:U@_
M.7'(9%&U;;6E/S<N!?,.'X#?5Q4@BWS ";#XA);WPW\#4$L#!!0    ( &^+
M7%2?/D[N 08  $T.   9    >&PO=V]R:W-H965T<R]S:&5E=#(Q+GAM;)U7
M:V_;-A3]*Q=>,R2 %HMZ*TL".&F[%5O;H.XV#,,^,#)M<Y5$C:3SV*_?(24K
M2>NZW8#$DO@XO(]S#\G36Z4_F+40ENZ:NC5GD[6UW<ET:JJU:+@Y5IUHT;-4
MNN$6GWHU-9T6?.$G-?4T"L-LVG#93LY/?=N5/C]5&UO+5EQI,INFX?K^0M3J
M]FS")MN&=W*UMJYA>G[:\968"_M+=Z7Q-1U1%K(1K9&J)2V69Y,9.[G(W7@_
MX%<I;LVC=W*>7"OUP7V\6IQ-0F>0J$5E'0+'XT9<BKIV0##C[P%S,B[I)CY^
MWZ*_]+[#EVMNQ*6J?Y,+NSZ;%!-:B"7?U/:=NOU1#/ZD#J]2M?&_=#N,#2=4
M;8Q5S3 9%C2R[9_\;HC#UTR(A@F1M[M?R%OYG%M^?JK5+6DW&FCNQ;OJ9\,X
MV;JDS*U&K\0\>W[!C32DEG2EA1&MY7VLV@7-^S2YOKE<M7(I*]Y:FE65VK16
MMBNZ4K6LI#!T^)Y?U\(<G4XM3'+ TVI8_J)?/OK,\BRBUZJU:T,OVH58/ 68
MPI?1H6CKT$6T%_&YJ(XI9@%%8<3VX,5C@&*/%W\&[ZU>\5;^X^,2T*5J#;Q>
M/(3I2=P0JY>RY6TE>4US- KPUQKZ8W9MK 8#_]QC43):E'B+DL]8-$=A+C:U
M<*N]$S>BW0A::M4\2=,5U[85VNQ*R7[X)Y#F$60W0 9TNY;5FL ;T!^S%\0-
ML?" E*9&:6^8VFBRRB(,NL?#+(S"WU+54 )S0K\+KK\3+NV$I(GF6N@Q<>XG
MQ \KMY[0C!)V0$EZ0&^FL['U@EAR0"P_H C_V]9+^K:VWSN3MD\6'^P)?3J&
M/OWJT%^JIA':9_IG64&F!'E)VQGRO;!.>$],QRMQ-ND<G?2-F)S/?%E^&AE'
M.A>=@*H'"^K! M>I[!KC1:5:U4@L[XW"8 BIL0X3_4,67!4?RA8M:F,PUQR=
M[%CQXY:0?M#*&)HM_H) ]0P_9$?T!GO(CIZH[YG](^^5-_!2Z=?<:GE'SY"Y
M("LSO!R609(!Y!D5012G'W6E1=%WL;"@.33]#NQS6,\E=VZ"?D$61G18!'F4
M'Q$+BCP=&_,@CP$=H9'1>\_*9Q1AG;)P\ RP/3XF,!8^[<R#F)5#9YF7WM-9
MXS30@-M=7_[87:I-LZE1\:@&%($=) -%0)V64(0.JR+XSQ@[SJ'D=;U5D$J+
MA;14N\#Q1X%S@[/C]&'L;D(<TQYB9R.QLZ\F]G-I^&JEQ6K4M$$2=A%[+^QN
M8K]3][RV]UMA !6U=V3@5L]O%#Z'DB# B&6O,-?N!/$)79V*T)=5Y*?[3D.X
MC<MM'B1YY%[2@&5)_Q(F&;VX48VHN4MTB$1G09SGA#$@S5M?4XRA*0./HC3%
M;YIED'_50->Y%R7WSY* E3% DR(HHQPO<1SDGL=)!@)E]/Y)^5FW=3X0"9KZ
M2?@O>6<EMIVA>%J_DXS2_S\#,H*"V%D"CT)/\3(HT](9S8*D*!]6FR-WT)AQ
MU0A.8?-&UHHP!D*0P[.M#KX4.!0@ID5""2)6()2L+.FUQ"'!JE:X\LJ3PL4S
M99DK=);'0XRS( %N$I19CBK.,F=,%L,J'\$(+2YC"=9E^3[FYR/S\_\BZ=WF
M82MW9Z-J4)EZXUCH=.Q5"]U%V']&O1Y1!Y/G:U!U5W'L77EW<>PBQT@-)]P5
MKRNG,X.-M_[8Z0KD1FB<HLDX8PQM#-J@/=OAPIU=!V\6@S=R\*0>/?&3=S/J
MQ1<9]=MG3,%5P%A P:$3QY0L#MV#%1!HU$B9]N'%X9PZ9>&HV]#<W@8/>X@3
MT [G)UDY=#"H^D HJ&^_*2(6?4])C*.6:U.=BPJ8!XNVG3D,FW\4$I]E\<4P
M@)815&%K:AGD:8XS[V!A?=\#.+,'1\5=56]<E/S1Z7&B%J@8ZS8_*[\;9XGE
M$E<34#V'7A1!DA;D)"/;R>KIHR,^-OV5O\BX71W[4'_:'UO'N]*LOR(\#.\O
M6J^Y7DF$J19+3 V/<QQ.=']YZ3^LZOR%X5I97#_\ZQKW/:'= /0O%8(P?+@%
MQAOD^;]02P,$%     @ ;XM<5-ZL7Y8/!P  !1D  !D   !X;"]W;W)K<VAE
M971S+W-H965T,C(N>&ULS5G;;N,X$OT5PNB'&%!B4?)%#I( 2?=<LNB9"=*9
M70P6^T!+M$VT1'I(RG;ZZ_>0DB4[;6LRL^B=O"3B[52QZE2Q2%]ME/YLEIQ;
MLBUR::Y[2VM7EX.!29>\8.9"K;C$R%SI@EDT]6)@5IJSS"\J\D$4AN-!P83L
MW5SYO@=]<Z5*FPO)'S0Q95$P_7S'<[6Y[M'>KN-1+);6=0QNKE9LP3]Q^^OJ
M0:,U:% R47!IA))$\_EU[Y9>WM&I6^!G_%/PC=G[)FXK,Z4^N\9]=MT+G48\
MYZEU$ S_UOP]SW.'!#U^KT%[C4RW</][A_Z]WSPV,V.&OU?YOT1FE]>]I$<R
M/F=E;A_5YD=>;VCD\%*5&_^7;.JY88^DI;&JJ!=#@T+(ZC_;UH9XS8*H7A!Y
MO2M!7LL/S+*;*ZTV1+O90',??JM^-903TGGED]48%5AG;V[3WTMAA+.0(6=/
M;)9ST[\:6$"["8.TAKFK8*(3,#0B/REIEX9\)S.>'0(,H%.C6+13["[J1/S
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MO2(W*MP?+*&D?@8(XE'()O@TA_>^Z<+:AJL"*1/K!G#"6#R>C>@P9O'9;#J
M.^V(C-1J\]:AJ:#V[E08XJ4"I9H_A (2'9;&T^'4TQFQF)UEL.+&//BX.RZ;
M\ "Z*O9U^R^_-R3$$Q8P9G%V-H7W7)@G]^+@8=CV8:AGA3FYQAU*8(-0HF$\
M:TLTF<3I.(.77G1RL"\J-)NP%2V$\K6KH]?VB_>BW3=/YNW6_L3-1B@+$M?D
MFIY.QQ&8=A.V@M-UV#ZY=K3+PG%+'P\TWH#NUYH2Z@0?H/\<+?\"4$L#!!0
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MFUIVMY/ = T!U0X92=F?I*69]3$ .WGN<0#[<AJ;"-7D'H\-\5@0C\T>C_F
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MX$B\.927VQYZ/@^>%-=@R:&T**A&(CZ\1S]S*"],)0B(P=%-W<SNPDY7<-5
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M("._NV>/&9NSF&0<O8_CO,HXRQ[179ZRF-$2':-;4A1$L@&]N:2<L+3\$?V
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MA!^9HFR'UCRC"06);M"2YSF(A)(,/=!$[S(@VQ$2O5V!(C23[W14,66@BYT
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MFQED/*_^)S]K(4X"(!D(0'4 :@<$ P&X#L!O#0CJ@*!4IDJEU&&:Z&0REN(
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M,5$8!_U]Q;DZ;$R Z@Z>_ -02P,$%     @ ;XM<5*/E#UBI!   /Q0  !D
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M=('6F9"SC@0KU"?61>J )K;$PGYB_=\3P0H/L M&CCT/6W9A/[M>ZT2PPGW
M)9%K=6/+-^SGFV=UKW"?9Y$3Y[CSAN@'VGFK>X4'W@/UB_"_>1ITOHR83VN_
M$[%CI00YW6I=>)EH2(C3UZK3C>*'^F/)FBO%B_IR3XG.Q'30OV\Y5\\WYOM+
M^\UP]@]02P,$%     @ ;XM<5$NJZBBL"@  ;UH  !D   !X;"]W;W)K<VAE
M971S+W-H965T-#$N>&ULS5QM;]O($?XK"Z,H<D 2<7?YFCH&(KG7IHCO7.>E
M'XI^H*6U380O+DG9,7 _ODM*U*S,Y7 5T<7>AXLD#X?#>;3/LYS1\/2Q*+]7
M=T+4Y$>6YM7[D[NZOG\WFU7+.Y'%U=OB7N3R+S=%F<6U?%O>SJK[4L2K]J L
MG3''\6=9G.0G9Z?M9Y?EV6FQKM,D%Y<EJ=99%I=/<Y$6C^]/Z$GWP55R>U<W
M'\S.3N_C6_%9U%_O+TOY;K;SLDHRD5=)D9-2W+P_^4#?G5.7-T>T)M\2\5@I
MKTES+==%\;UY\W'U_L1I0A*I6-:-CUC^\R 6(DT;5S*0_VZ]GNQ.VARHONZ\
M_]I>O;R:Z[@2BR+]5[*J[]Z?A"=D)6[B=5I?%8]_%]LK\AI_RR*MVO^3QZVM
M<T*6ZZHNLNW!,H(LR3?_QC^VF5 .X$,'L.T![-D!C X<P+<'\.<'\($#W.T!
M;IN9S:6T>3B/Z_CLM"P>2=E82V_-BS:9[='R\I.\ ?YS7<J_)O*X^NS7."G)
MMSA="W(AXFI="HEJ3=Z0#U4EZHK$^8I\2N+K)$WJ1%2=T8K$-5&.E0A>B>6Z
M+)/\ELSC*JG(JW-1QTE:_7(ZJV6@S>EFRVU0\TU0;" HRLA%D==W%?EKOA*K
M?0<S>86[RV3=9<X9ZO%<+-\23E\3YC#Z]?,Y>?6G7^+;4K17JPEP8>[.V;K3
M>#G'O?PCSCLOU!F(9N]J^0Y4WCKFHZ"^'L5Q#[G&ZK<B+Y]!^>]/\@3D8RVR
MZC](>.XN/+<-SQT([[=U=BU*4MR0Q;<KLKOPBOQ!,$SF&Z]^Z[4AM(<S]W3V
MH.8;L]@+U=N%ZJ&A?BGCO+H199NI!QGT%\EZ,L[+.\DUA).%/"!9QBGY4B9Q
MBN3&WYW0MQ&Z8!=>@.;C;V51560I%V<I&9O$380ZJ#9> @4(ZFS^T^,1[LX?
MHN>_B'\DV3J3" PA<RX>I)K=-]^AUS(]M^LTKHORZ37Y<YS=_X4LBBP3Y5*"
M12Z25$A^S<4FQ5\2T?BZ*I[BM,DSDJUH%VUD(YC4 ?)WT'1^S!]D"MK%IV5I
MI[>>>.!A.%)%=RAZZH7\#LDK:\0F5?+QABS*IZI&UQ)E<!)F)0! U)2C6;B,
MGUJ]E3NX=E5M,R)?5LE*E'&[-U+RHY.J[2GV%EN(800\37&B'L3HXU)N"G,L
M T"PU+,2(B!DZK\T1//M*=2%1"D&$? QQ0EY$*++&Y&+'U@&@'-I:"5$0+,T
M0I-P)5;KS6U$DJL8=1EYTF(2:<C-1T!A0*L,I]5=!K"=*S EHS:FGP'+,H9>
M[B:HU^2F"?2A"527[ZV3O7PSZH6^FO#MYEMCZG//#X:Q <9E..,J:1N-F&M6
M+?4"3<!]2S>B$1^.%SB8X1P,</Y!CM!,!H3,K"1D!H3,<$(V1W#!^KR+*2,#
MVF4X[9JA\G2.,C #!F96,C #!F8X Q^RJC2\ZT::-=6W\YQP$#L.[,P-V1G#
M[D+4\763*^QV'"B<6TGA'"B<XQ1^ 'Y<0\[<"_L Z@Q#1H<15,H;.(<;(3BZ
M1^7 P=RU$C[@;(Z7*0Z!S^NA$G#?U<#7-Y1F[C!\0. <)W C^$;WKQS(F@=6
MP@?TSO&JQ@&*MO5DOFOEP.%\;!<-L'01/;6W/:6HZC)9UC(_"50,2/$H/ZB+
MQB03I<1O*?)*H)43%UC:=6P$S05.=_$"Q@%K;NMI;QNBV?9JS/QA8%T@=Q<G
M=Q78SW=%6;^I19FI4&() 59V[:PZ*V5G?"MM=I_B]HO(+'+\2+/MUYARYKK!
M\"[%!4IW<4I708,R77.#^RWYWGR\++),IK&JB^5W+#U RZZ5I6<7>-S%-]V&
M^ 5]4)PPU.PP=98L\(?OVEQ@=!=G]%'T'N.RC$=6'C"W:V6=V0,R]_ MMQ%R
M"Z]?;O8Y\P?A\("K/9RK53C^N2X:(;N4@B;S(A'YT+:>R45<?F\RUPC>QY5$
MJ^WK;-/YZE/35B#T%RP=0,B>E65I#ZC<PS?89BO-TU0]')]I]I(Z2^:QX7J.
M!Z3NX:1^@ Q[?;K6R;#&#)%A3VDEFC/Z<5_"XTI!'BB"9Z4B>* ('JX(!VR<
MO3[9#R$*+.^9L_P+(CI21O) )SPK=<('G?!QG3A@,?M]L7B^D%&3_0A!2?S_
MEY(<6WWR06Y\*^7&![GQ)ZO)^WTEZ<&.F>Q'""KCFU?A7P[VT9*5#V+C6UG%
M]Y7?N4Q5Q9_[_2I^#W/,9#]"$!??O,;_<IB/UKE\D"/?RBZ!#_KC3]4E6/C]
MZO\ H &H2V!>^#\:T)>JD 4@18&5384 =">8K*D0]'L%NJVYQ@S9F@<@0(%Y
M0^'H;\;!);8 9"BPLA$1@.P$^#V.V8UCT&\M1 'W-'CW#;G+A\MK <A/8-Z#
M.!KQ8^IS@?+32RO;& 'H3X#?#AF"K^E@Z.MS.DNT/A> $@7FO8Z7@=^@P!>"
M<H56-D-"T*(0ORTR*_"%F@8'5N +06K" UH<R6V>W$BP)!Z_UW=2=W^_KD3Y
M$%^G\IKS^S7 Q[!Z7@CR$5K9^0A!-\(I.A^AIO,1.I['^TM38\J9X[O#%;T0
M-"2<K)D=:O1!^UL$G2'V6X00A"0T%Y*#OGG'%?%"D(W02MD(E9_T3];]#ON*
M, 0@2$%H+@73 3A2LXN ^B,KJ3\"ZH\FZX-'??Y_OE!1D_T(01RB%Q*'8TMT
M$2A(9*6"1* @T61MEDBC#5I2UAEBI!R!A$3FK9;)$!^MSD4@&I&5C94(1".:
MJK$RC[#&RA9HX]Y+!*H1F?=>)H-XM!@7*:-?5O9:Y.K91=B\GDAX.U<&$%)'
MF0%SS+LIAX+X4@4XZBCC98Z5G17J* -FSF2]E<X5MI1QFV=1*H-FCGE_Y= O
MPL'U-NHHTVF.E7T4ZBCS:0Y^!V)V<]=Y,;F[T]F.W-Y11QE9<\P;*X>"?4RI
MC3K*R)MC92^%.LK0FX/?N)CBCG52.KR-NRU4'2X>F2Z>'&>#FAK=FT"VLH%"
MU?EE.L%HW:+S8H2?(ATCP\E#^'W-BR'L.%90H^KD,;6RTT'5P64Z1:^C\[+_
M*SE-M5MGR)$10JJ.,(_,,!^R"=#,*@<!U:F$QM+U.&5(R(I(C PV_]27[[B:
M&E5'HBV=B5:'HD>FH@_9WFN&H=%'""BST-1T&'HR($=J:U09K:9VSE939;B:
MCDQ7'[)V=8/3NME*G2$V7$F5^6HZ,F ].=XFE3:J#%139J>T*"/8E$W6 NE<
MH?L[U.99E(JJC QB3X[T^&-%E EMRJSL>U!EJINRJ3H?\\[5^-RFSA(=W*3*
MF#<=F?.>'/+QQY0H@]V46]DKH<H@..53=4L6G2OS64^J#'S3D8GOGT7RQ<IN
M7'UHDI7=$JI,C%,^6;^D<X4R.&KS+$I%9T;FQG_V2W!XR4V9#J?<RN8(50;*
M*9]B$K'S,G[KIS%$;_V4T7(Z,EO^LQ ?56A3ALXIM[-/HDRB4W>"Z<5YYR7
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M#;4SH/654G8_<!NTO=_T'U!+ P04    " !OBUQ4ET!EH10"  !?!   &0
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M1/*U/4I_?8&YZ+-FN?K;LU)4KQ39E:(#*WWB!2T2AC*S$LHX?>09UR^N")9
M(PMD!.=IBH,H",#?)P>!84U@Z"5PSXQ^\6)94=!,YD@LT*)-3+GX^'%'Z(51
MJ3PABFN&L1?IZYJ9LU,SE$9L#,4-O%!(E';2B_?#%0\CT@Y8N;7V)\;C2W(P
ML*.:]N@DVJ^YY>YHCO;ICH;1Z""-<4UC[*7QW6HS2R_H$_!90O@.)%SL\G62
M]"\U+E..,,J-N* 8I?3%A3/WXT053E3B*$0B!]).-"[K:%R>%HV4JT1L"HW
M=^8* SJC"E$$HPDKM$NK9_XEHSX.?G4%P6\V[(_>FNUXC(.F!@4G;<0U?8'6
MPGUH*JCV-B1Q$.P?&M?$:'?B+MU6R<0GT67/T(4IYF1;(L7=;!T3L8\M:=@2
M+]N'S6-)DQ>)R-TLR5ZH(B?)_7FACV-3S'#X_TA M^9WK.04_<J[HRP1#HX_
M]+@ILMA?9;N/_:[K1QSZCA7#?N ^]9UV0_^Q;^HZ]A?@&54K..L\1?#]@FAN
MW%5FFV8;:/G@8=?GKOI4K=;>G9>A<QL[)HY\^[CI ["_$=CME7RZ$.\?=S?7
M_=I/?%2;VH_]Q?]FP[,4#I@ODTT%Q^-W[D9Q4Q^QO^S\QV:K0FU''!-?UDE3
MOLAIY:MCGY+]PH1#7U))4YF(OS+=TF>>;W+?UU)3-PAYYYR21O^)7UL/M?C'
M='P=T"#776T^:52:^+7OGA5L2S/+S\G%;WX,ET8]29=Z0C*4R'Q@C7"1^+V3
MW2@/\2O/3!2*IS:Q &_U7PNHI-JIE&3_LR.^]'5&I%$MXN_B[X2T%&"C)3N<
M:):)!/A88KQX@@HKI/.+MUJAK2K#P'N6&YTC?IT[X;N[0FK'Z,#R82-JH5_4
M[ W@A5A<U+(*35DBE@7_Z;S/N0D=LA8[$S5H75?E3"[MM9]"MMTI[W/JT?IJ
M\:.]4'LS/L-7\_*"L($I[RMOJ5SR0D'P%@ 9]$=PEF1Y!5B^:+&VEV*/0FN1
MV\<5H[ #S 3X?2&$?GTQ"]07L=-_ 5!+ P04    " !OBUQ4U P).%(#  #'
M"P  &0   'AL+W=O<FMS:&5E=',O<VAE970T-2YX;6RMEM]OVC 0Q_\5*]I#
M*[5-G-]4@-1"JTWJ5E3:[6':@P$#5A.;V::T__UL)X20A$"EO4 <WWW]N?/%
MONZ&\5>QQ%B"]S2AHF<MI5Q=V[:8+G&*Q!5;8:IFYHRG2*HA7]ABQ3&:&:<T
ML5W'">T4$6KUN^;=B/>[;"T30O&( [%.4\0_;G'"-CT+6ML73V2QE/J%W>^N
MT */L7Q9C;@:V87*C*28"L(HX'C>LV[@]0#ZVL%8_"1X(TK/0(<R8>Q5#[[-
M>I:CB7""IU)+(/7WA@<X2;22XOB;BUK%FMJQ_+Q5OS?!JV F2. !2WZ1F5SV
MK-@",SQ'ZT0^L<U7G <4:+TI2X3Y!9O<UK' ="TD2W-G19 2FOVC]SP1)0?O
MD(.;.[BG.GBY@V<"S<A,6$,D4;_+V09P;:W4](/)C?%6T1"JMW$LN9HERD_V
M'[#*@0"7X'&%.9*$+@"B,W!/**)3#,PTN!$"2V$F'@B:D(1(HIS.AE@BDHAS
MY?XR'H*S+^?@"R 4/"_96BAKT;6E8M0KV=.<YS;C<0_P#/'T"GCP KB."QO<
M!Z>[._ONMLI,D1ZW2(]K]+P#>EGD+4)>(>09(?^ T"Z]B4DI:A#.\I/I1$9'
M?X1O?1@&OMNUW\IIJ%N%<6=GM,?H%XQ^*^-VTX\19BKA'J'K1!7"!JL@]@\@
M!@5BT(KXS"1*C@(&M:4]-_([%<"ZE>M&GM\,&!: 86O!#-:<8RI!LOM.KEO*
M)RIDH]:XM[*L4D:E99H2$=5#= *ODH>Z$8SCH#D-<<$;G\0[WRNI([1Q#<0/
M*ZQUDS#H>,VLG8*U<Q+K28R=AHQVJI55-XK]*&ZFA,[NI'9:2^L'H]//51<L
MW0*P-0</C"XN)>;I9RLLU]W_S/V.7\E(@UD0^@<V#NY.9^B>B/VI0LM5]VCB
M*G'=!L(#IQ?<W0*P_1HHGU_'(!LN@B@,8)6SP<QWO4.IW=T%\+3+P'0 %\6]
M_W$!=G5X <8229R:DVF>-PU$!3AB@I@N[??=N]0]WR3!X(ZN4U-;C/YI#+@=
MZ%$N,2_W'V62QD[AO^EE*;1+799N<;\COB!4J-V<JP6<JTA=*#SK&K.!9"O3
M>$V85&V<>5RJ3AMS;:#FYXS)[4#W<D7OWO\'4$L#!!0    ( &^+7%3;_&<<
M: ,   L-   9    >&PO=V]R:W-H965T<R]S:&5E=#0V+GAM;)V7W6[;.!"%
M7X40>M$"FTBD_NS"-K!I4.P"*39HDO::L<<V44K4DK3=OOV2E".Y%2FE>V.3
M$F?.&8G\,%J<A/RF]@ :?:]XK9;17NOF?1RK]1XJJJY% [6YLQ6RHMI,Y2Y6
MC02Z<4$5CTF2%'%%61VM%N[:O5PMQ$%S5L.]1.I0553^N $N3LL(1R\7/K/=
M7ML+\6K1T!T\@'YJ[J69Q5V6#:N@5DS42,)V&?V)W]^0U :X%5\8G-3%&-E2
MGH7X9B=_;Y918AT!A[6V*:CY.\('X-QF,C[^/2>-.DT;>#E^R?[1%6^*>:8*
M/@C^E6WT?AG-(K2!+3UP_5F<_H)S0;G-MQ9<N5]T.J]-(K0^*"VJ<[!Q4+&Z
M_:??SP_B(H#@0  Y!Q#GNQ5R+F^IIJN%%"<D[6J3S0Y<J2[:F&.U?2L/6IJ[
MS,3IU1V8DA2Z0I^H/DBFF9F(+?JG 4DUJW>(UAOTD=6T7@-RB]$=H\^,MTO?
MWH*FC*MWZ UB-7K<BX,R$6H1:V/.2L3KLY&;U@@)&+F%]35*\1^() 0_/=RB
MMV_>_9PE-J5U]9&N/N+2IH&T?2%MI2,ITRYEZE)F@93&(/'5UT:5+LH>AN,J
M+?)T$1\]6EFGE4UII3ZM-JJXU,IPYM?*.ZU\2BOS:>4#+5+BPJ]5=%K%E%;N
MTRJ&6D6HKK+3*J>T"I]6Z=$J$[_6K-.:C6H][L&P<:M!^A1G T6<S%+BEYQW
MDO-Q2:$I1]P=S8;^,,34WN,W'Y:;S^9SOSA.>GXDH_)WH!328 "A$:L:*8Y@
M+2#*#? M-;PH2 9FKK*4E $S%S##TV:,BX.&C>&1>0V@M-< ]AAP>])KH*<-
M)J,&[HV@K?Y(^0$L2-OWPGMD>MV0X<8H\RST.'I0X704?C]Q>PQ]N.<1G@22
M%WYX2*0\P C< PE/$LE+/SQ$4A;:R#V1\"22O/C#0R8%@(1[(N%))'GQAX=,
M"@ )]T3"XT@*X0\/:132ZE&$)U@TBC\\1%! D?3X(>/X>2W]R) X. GL&=+S
MAKR"-[\+/S)D3^@Q7'0YX]QY-?C($#57 >J1GC-DO"/Z?]0CPX8))[\>K?BB
MM;6?"9^HW+%:&86MB4JN2X,"V7;>[42+QG6[ST*;WMD-]^9K!:1=8.YOA= O
M$]M =]\_J_\ 4$L#!!0    ( &^+7%0?$(\D,PH  /<X   9    >&PO=V]R
M:W-H965T<R]S:&5E=#0W+GAM;+5;:V_;N!+]*X2Q%TB!6UM\2?8B#=#&2=?9
MQDF;N[L?%HL+6:9CH;+DU2,/8'_\4@^+LDF-93<&BC2.R>$A.7/.S,@^?X[B
M[\E2B!2]K((P^=!;INGZY\$@\99BY2;]:"U"^<XBBE=N*E_&CX-D'0MW7DQ:
M!0-B6?9@Y?IA[^*\^-M]?'$>96G@A^(^1DFV6KGQZR<11,\?>KBW^<,W_W&9
MYG\87)ROW4?Q(-+?UO>Q?#6HK<S]E0@3/PI1+!8?>A_QSU\=.Y]0C/C=%\])
MXW>4;V461=_S%Y/YAYZ5(Q*!\-+<A"O_>Q*7(@AR2Q+'WY717KUF/K'Y^\;Z
M=;%YN9F9FXC+*/C#GZ?+#[UA#\W%PLV"]%OT_(NH-L1S>UX4),5/]%R.=7@/
M>5F21JMJLD2P\L/R?_>E.HC&!();)I!J NDZ@583Z,X$:K=,8-4$UG4%7DW@
M72?8U02[ZP2GFN!TG3"L)@QW-^VT3!A5$T8[$WC;"MC:W)S5%12N+[OS;>/-
M=>/.]XTW%XZU&Z=M4S97CG?OG+:NLKETW/G6\>;:<>=[QYN+Q\7-#\JX*H)R
M[*;NQ7D</:,X'R_MY;\4D5W,E['HASD)/:2Q?->7\]*+RRA\$G'JSP*!'D3H
M1S&:1JE(T'LT=>/8S2D"G8U%ZOI!\NY\D,HU\YD#K[+_J;1/6NQ_S![["//_
M(F+AT6\/8W3VD\G*)6QE++P^HKBP,FRW,H:MW+JOB) M(S^A 4J6;BR2\J?!
MZ!5L]%K,^H@,<ZN$M$.[AJW<N.%F@P2W6_F\Y[#7L;1B%5:L=BN_[,&2A1LK
MT)5-]A_VSHVEL3OWP\?_S]W7UM.^Z>!.E5FFFY7_.MSHK_ :T^BIWC_@;%^Z
M(P6LW':^4<C*M'/XU-X5K?,DH/6,[KI;M+18,MB[[Q[@@,]]_5&:&$AZK#F2
MU!Q)"K.TU>PL19,P2>-,IE\I^O.+'( FJ5@E?P'F:6V>%N99B_DO49(@F8_-
M\V7$2RI].?.39;Z4Z:I+8TYA+$\QGRX<:E'+LLX'3\T+U,<19MO:N'M]G!JQ
MM1]6[X>!^_DCUXTP39"?))F8(S]$ZVP6^!Z*%@L1R^VAL])/WJ%_VCWFIES%
M;@"CQ&8VHV9XO(;'07A7+R+V_$2@=>Q[0F)"7D,#9U$X1TLQ?Y2JEWO06L0E
MQ!PKZ.$WY;*CYL7POL7-:.T:K=WE,*5?;*$^%)NM8<-$@AON^(QA6+]E TZ]
M 0?<0!$\N2>XH<3M18ETC%@$;BH](XU0NA1(_)WYZ:M\;[6.PCS =NXD#PQ3
M)#B:@V#"+$</!4=S<4KH5BAL;6U8;VT(;NUW-\@*!WK>]G@3UJ&&E5M6*X)1
MC6 $(KAW7W.:2/*3S,)G7_KN!HL)Q$@_L"$#8&!+99$6#"2./"'F"5K$T:J"
MD@>Z.;2,X*H5G"UT(PA=(\?%(+IIMIK)6)$W5:F>1#B7?VA!)Z.I'&>$B?6;
M' VEKK: 5"*#"0BRF8F7*?@_A1JBMA0=D!ZLM ?34V@;5F* 836X=F78NZLH
M*^.Z$#F_7L^8 3*#<I71TN8)BOLQ3/Y3D4H&;?KJO,E/1CA<AT-'%(*CR!W#
M['XE!;'HPB!9:4E6=Q/DYK3NR:,QY3\W>^SQ_I#^![HVQ=H8INW+'?ZM8J7L
M/<FJ,#*B*VUBTDPF^A:FE/"V^%!DBV&V'>^@*(6PUL"#);%:KJ->8T7)&.;D
M29@*N61:IW3*V[M<,&S<ZCL<NF"B&)O C#U9O*_H3PKQ4Z%D,E$3+Y[(L]%%
M?KRAYZ_=P%2M$YVK"=U1DK(B-XRD#-M ]!!%ZP2F]4GHQ<*5.='97)2_O<OW
MX/_ SKY62VZI$!XZ$-Y&&0$SO&1MZ;*2=Z*XX<BF KTRM(7",ASO%]/ $1\9
MAMX:AA(\A#:F1(3 %<REBLKRO"/YLDCMZK.N),"X6;T"X88-_&H8Q^C(-NY5
M'TIAIU-Z1F ].ZQ:NR>F*@8"HJ2,P%+V3:PWV9]TZE#/",KV'#'(EPVI%U'J
M16"UZ9#:![X[\X-CLOM/U>+;D0CE@T2)&X'%+<\"O*4;/A;,L'#]>..W>8(2
M^T]%V]/8QB"&HF,W-+=1*8$CL,!]=B68LT#ZU[O2P39 ZE/T6S#IQ<7[/:"4
MFA%8< [.2N7[W\1<K(H$&MW+341S=!<*J%&B1(M:)^G$*$FA72N%JJN(\F:E
MW%.CR6B2;:I7!:3E[*G2"[I'+VHP,EX2X66%,QP(C.C\TP:LT;""^?XAC;SO
M50*6QO[C8\[V$?("-TG\Q:L6WDBF/5X6Q]U2H#V+8RI32@M*@J@B<PJ3^=MX
M]_^>(PB-8G3*3^+=BK I3-BMWMWF/+9>Z[;XCN)>NH=[W\*I#23<YM2*?BE,
MO[?NB[_*5E*V9/:^C()Y7:YNP&T[? ='AA<<#??YL6)I>@Q+$WI,[X I-F8G
M86.FV)C!;'QP[V#,]/3=J5H'.SGBU#"4,DHMK/</F<[N;,3)L%U@F2)YMH?D
M#^Y(3)B>R3N48D#OF:)VUB65/ZSNGU0V=^M^BUF$L19$C:<),$>_<=T_KI9K
MUOV$#?MLV )4T3>#$_(?*OS'>XSO*_R9$@$&B\"!CYN8K@$.-<33G6$@@7K<
M3$D&@R6C6Z5SS?0V/QYA ]3/AI'$HD,C2QBDAMLF0KDS#"6$0!4V4^+$.C2_
M3E5J3:O%MTZ.0CT/II2)P<KT1@\#QTQ_=B&I>DB)LWT+DZX#IX:!A/,1X2V,
MQ94N<KBU]C;/[,;5*DVBHICW:0M1<26K')95@S.9O((;6F$V5(!S)7H<%CT9
MT5DL*_!$>L0A^G[-]7*&6"8Z^FP:29FI1SDU#,6<&&/<9)4S*%2XDEX.2^]'
MSXO+$*ET9!W%19DACR8^^L#T3IB1$@WC3)VU:35N.[Q,!Z6/@_IO7*4#'$X'
M9/F5E9]?]2L-F_N)U]);G'*]_:8Q6P78T*@#'SKQQ@<.8.T^X2-PKG?WL$6,
M^]-'@HU(KA(*#B<4]4-HU=?N\L!WS T-/K8;S-N85,K X93A@$?S8ZYG Z/=
MDF$;AI)M#LOVP769?/\AFR72'7(GN'K2HGH;B))A/CI%J68KS;-AS>N6HUW9
MAH?\A$*B8BM9LV%9.U94KFR]O,,R%8! *:6S8:4[!:E?V7H!"(6-K23([E[]
M=?770[N]MJ)ZFYW$:14QVWL^#7!<MW=2F>W2[;4;'_3JVIP[NC$VL?4:K*W;
M:RLNM6$N/6FW=[)G\?W=7ENQL?WV;'QHM]=6E&R?A)(=1<D.3,G'>G=EMD/7
MUU'<['1]KG*\<SL&FFYQ;D?QLP/S\YMW?2=[%MS;]7446SLP6]_)S#%&5R]K
M(8]4GM];?H+,42SMG(2E'<72SO[/;!WYM-;1B5I+C[=1*;IV8+H^^FFMHZ>]
M[UM #1K?Z\F_$GCKQH\R,T"!6,BY>4NPA^+R6W;EBS1:%U_UF45I&JV*7Y?"
ME=CR ?+]122OO7J1?WNH_J[CQ;]02P,$%     @ ;XM<5$OSZ>,O P  N @
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M=7-/-H95E;\Y-LKB/>2'!_RT .T<<'ZGD%1KN,NH^UA9_ 902P,$%     @
M;XM<5$;5:2H2!@  R"(  !D   !X;"]W;W)K<VAE971S+W-H965T-#DN>&UL
MO9I;;]I(%,>_R@CUH96:X+D9NR)(B;.72%NI*NWV8;4/$YB 55_H>"#M?OH=
M&\<#GDM"9*%*#89SCO]S.3_.&3Q]+,7W:LVY!#_SK*BN1FLI-Q_&XVJQYCFK
M+LL-+]0G#Z7(F5278C6N-H*S9>.49V,4!.$X9VDQFDV;]SZ)V;3<RBPM^"<!
MJFV>,_'KAF?EX]4(CI[>^)RNUK)^8SR;;MB*S[G\NODDU-6XB[),<UY4:5D
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M>?-RS=F2B]I ??Y0EO+IHGZ8H7MX9?8_4$L#!!0    ( &^+7%2H7-J&\0,
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M:'? [B^5PK>)Z^_U]3SZ#5!+ P04    " !OBUQ4'#,<$/8$   5&@  &0
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MY=3+/%3 DFR8_B2V?T-=T,CFRP53[A=MZ]C 0_E&:5'58,.@HGSW3W[40G0
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MD#; /%\*H1\']EC0' -GOP%02P,$%     @ ;XM<5#,.TE]" P  /PH  !D
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MK@/4\SEC<C?1&U0WL?Y_4$L#!!0    ( &^+7%2VS;84R04  #P8   9
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MQK\:GE8N;P$J<E5".-"<SYZY\V[F7CH+NVP#KG,_U\N%I81O3@![^86TJ'!
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M^LP KA>H^RO&Y&&@-Z@^7&:_ 5!+ P04    " !OBUQ44044_, #  "]#0
M&0   'AL+W=O<FMS:&5E=',O<VAE970V,BYX;6RE5UUSFS@4_2L:=J?;SFP
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M&" PB5?9DZ?LKT@KX@QB'T7X R(AP0T)35_O'C:XSU[MCH<MU415+R*'%YW
M^[H!2SY?HR]"*30UO7@T;_:>RD2A/[X8:S37D*L_6V)UJE@=%ZMS(M9WFFUI
M\>9EYMVG/(8/*$XI7X-M,LW%ENNF%A>P70=K164WP=COC(+=(>TOC2XQ[OG=
M8[-9 U;4\X>5U5%EW:JR;FME=UQ"+-:<_80$:?J [H'#BFF%=$JUD:%MEB"6
M;XSB(%BMP F/,S3D0U/)13P<'N1)!CYN3K-7I=EK37,!"JB,4_OJH:F$A.FC
MCK?TN%^%Z)]]/PVJ6(/6<FP5<5%%?+**@L[!2SJ'_B \_)S@=E@E,VQ-9LXU
M2$XSM( =\"V@)<@=BXVHS1?+BY9J<5C+9GAV;O&!2./6@NIHF8WV;PR7:$<4
M8SST>\VT8E+G05KS6&KSBB#*$U-U;/C]O)5,)<S]A;<56BL@/K\$XEH#<;L(
M_E=:.PVT]GM^=(+66K%PNV2UT8K^-BQDS*3%&74V-^8P]1FD@D?T/T0$UT*%
M>^?O2:U9N/]60E(B'0OST.^?:$<M9;A=RVX$O[Q;ME53"Q$>GIT[4HL2"=]R
M/Y=HQ_LYQ <R41ZBFNQP>.H?D-2R1MIEK2#:[? -TV;COR"IC99:M0@Y?Q-J
M"2/16VW@$NGH -1_?DJ:-EL]U_+@8 ;(0:[=+&7V@#W'%0?J:K6:USZY*>79
M^I69XXJIJX8IAL!K*M>,*Y3!RD"&?M^D)(NYJKC18N,FC7NAS=SB+E,SBX*T
M!N;Y2@C]=&,#5-/MY!]02P,$%     @ ;XM<5"'N&C!9 P  A L  !D   !X
M;"]W;W)K<VAE971S+W-H965T-C4N>&ULG59-;]LX$/TKA-!# FPBD?H.; .U
MU6)[*! TZ>Z9L<:V4(GTDG2<_?=+4K+B4)+A[<46J?=&[PW)X<R.7/R2.P"%
MWIJ:R;FW4VK_X/MRO8.&RGN^!Z;?;+AHJ-)#L?7E7@ M+:FI?1($B=_0BGF+
MF9U[%(L9/ZBZ8O HD#PT#17_+J'FQ[F'O=/$CVJ[4V;"7\SV= M/H'[N'X4>
M^7V4LFJ R8HS)& S]S[CAP(30["(ORHXRK-G9*R\</[+#+Z5<R\PBJ"&M3(A
MJ/Y[A174M8FD=?S3!?7Z;QKB^?,I^E=K7IMYH1)6O/Z[*M5N[F4>*F%##[7Z
MP8]_0F<H-O'6O);V%QT[;."A]4$JWG1DK:"I6/M/W[I$G!%P,D$@'8&XA&B"
M$':$\%I"U!$BFYG6BLU#015=S 0_(F'0.IIYL,FT;&V_8F;=GY30;RO-4XMO
M;,T;0,_T#22Z0RO>[#D#IB3B&_3^$GUYTSM- KI9 H--I6[130&*5K6\U;2?
M3P6Z^72+/J&*H><=/TC*2CGSE59HON.O.S7+5@V94(,)^LZ9VDGTA950?@S@
M:VN]/W+RMR07(Q:POD<A_@.1@. 10:OKZ<$(O;B:CO,+;L)^M4(;+YR(MSH(
MH1<'P6DU7KK5>+@0/.J#1S9X-!'\*Y0@:#VV:BTQM41325X7=QCG.B&OYZD<
MHG"09?E'5#%$97F4XA[U07O<:X\O:G]25,&8\I:6G"L/B:-[B(D'JH>8$ ?A
MN.BD%YU<3C@7NBRQ,=G)X'-NLH<($CJ:AY"[)!F7G/:2TXN2G[FBM:Y+$]MP
MS$HZ5($)<==@B,(X#K#C:(C*21QDXYZRWE-V\5 5L 'MI_Q_IRKOH^>_>ZKR
M86;2,(Z=S(R@<)RD3@*+(2R-$I*.IP8'[]=#\'L'J^,YZYHX>W U!@O#S%4_
M M,5=T+\V=V&K]BMY>3ZCOK"0\%9@C/7UPA,5\0X<HT-<6F4D7S"&GFW1JZP
M5K47M-(7]'7FR+"0YUGDUI8Q6!K';GT9@>$D#4-WT_EG[4D#8FO;/(G6_,!4
M>Y/WLWTK^=DV4,[\TK28MNUY#]/VI]^IV%9,HAHV.F1PG^IZ+=J6KQTHOK=-
MT M7NJ6RCSO=)H,P /U^P[DZ#<P'^L9[\1]02P,$%     @ ;XM<5*&!(#S=
M!   RQ   !D   !X;"]W;W)K<VAE971S+W-H965T-C8N>&ULC5A;<YLX%/XK
M&D]G)YE) @+,I>MX)HG;:1XZS21I]V%G'V20C;: O))LI_]^CP3&-@B:EQC$
M=X[.IW-59GLN?LJ<4H7>RJ*2MY-<J<U'QY%I3DLB;_B&5O!EQ45)%+R*M2,W
M@I+,")6%X[ENZ)2$59/YS*P]B?F,;U7!*OHDD-R6)1&_[FG!][<3/#DL/+-U
MKO2",Y]MR)J^4/5]\R3@S6FU9*RDE62\0H*N;B=W^.,"1UK ('XPNI<GSTA3
M67+^4[\\9K<35UM$"YHJK8+ SXX^T*+0FL"._QJEDW9/+7CZ?-#^V9 ',DLB
MZ0,O_F*9RF\G\01E=$6VA7KF^R^T(335^E)>2/,7[1NL.T'I5BI>-L)@0<FJ
M^I>\-0=Q(H## 0&O$?"Z L& @-\(^.\5"!J!P)Q,3<6<PX(H,I\)OD="HT&;
M?C"'::2!/JNTWU^4@*\,Y-3\L4IY2=$K>:,27:-GFO(J904CQBM\A8X ].D-
MHDU2='%/*[IBZA)=+*@BK)"7(/K]98$N/ERB#XA5Z#7G6TFJ3,X<!5;JO9RT
ML>B^ML@;L A[Z"NO5"[1IRJCV;D"!^BU'+T#QWMO5.."IC?(QU?(<SUL,>CA
M_>*N17SQ;G&<C+#Q6X_Y1I__6X_U'7*%'N#H6+5EU1I]VU!AW"BO3KW8<?'?
M=TNI!*3?/R.V!:UM@;$M&+!-ZR<*K6@&6Q=(*J*VBHM?" RAME"HU45&G2Y1
MNWF2^-[,V9VZIP^Z]CSLGZ,6?10.(R\)6M@9HVG+:#K*Z 4HT"M4006&9#@0
M6];G;6-4JPM/C0W<N,/( L+!-.PPZJ.\( SM?,*63SC*IXZ/-:T4@@A80A@H
M1JU9&O9MC'&(.TPL*"_JT%WT03BVTXA:&M&X6W(BZ+4N^!F"R-9I8,+91B2R
M'#9.="Z>,;' _+ 3B@L+*#[1=,8E;KG$HUP^+QX?;7;'_;U"/^I8;0'A<-HU
MVX(*7,]N=M*:G8R:_4PE)2+-$91YZ+0[&"$VI8ZK5-",*6M,)99H"9-NOEM0
M8=)QU\("BJ,!3V#WV W=\?3("22'[F#;*J4"FEN%%!2U#9?,E%)K/W-[MDSC
M3C(_6$#7X=3ML+*@@@ /L#KI\7C<55##4%I3@U&Q>92:9E/1KO0ZS$C0\H4I
MVQ059&\EB_L\HB3TNW0M,!QU:[8-Y6%W@*]WY.N-\GT2?,?,9*HX#*=J*V#
MS/Z%:4H'J-V'GL4]N)MM-E00NSU:%AB.!SH1/C9^[(\7BL9%.B SMEI1 6P8
MM",@RDR#=PHNI6E4#51NEY)EC(B!(M_LV"F.09>V!>7'?C<E+;!I-$#Z.%'@
M\9'BF)$[4FSKF844<%TAD*!62D&_V^  NUU.?=@U]G <=;NP%8@3?X#8<;#
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M'J *-G3/S;T\_ E]0#.G5TJNVU]TZ&S368#*O3:RZ9TM0<-$]T^?^T0<.=A
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M':AW_*3>=?C:EWKM^5[C\W^2ZN%\;[D^_K+\/HD2+BXXI]N*^O074$L#!!0
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M;64O=&AE;64Q+GAM;%!+ 0(4 Q0    ( &^+7%2QO)6@O@8  +D:   8
M          " @0T(  !X;"]W;W)K<VAE971S+W-H965T,2YX;6Q02P$"% ,4
M    " !OBUQ4N_^T,28"  !Z!0  &               @($!#P  >&PO=V]R
M:W-H965T<R]S:&5E=#(N>&UL4$L! A0#%     @ ;XM<5'L (%,5!P  0AX
M !@              ("!71$  'AL+W=O<FMS:&5E=',O<VAE970S+GAM;%!+
M 0(4 Q0    ( &^+7%1&;55$V (  &4)   8              " @:@8  !X
M;"]W;W)K<VAE971S+W-H965T-"YX;6Q02P$"% ,4    " !OBUQ4J.U*B- &
M  #P'0  &               @(&V&P  >&PO=V]R:W-H965T<R]S:&5E=#4N
M>&UL4$L! A0#%     @ ;XM<5.F!GT A P  90@  !@              ("!
MO"(  'AL+W=O<FMS:&5E=',O<VAE970V+GAM;%!+ 0(4 Q0    ( &^+7%3V
MSD+NG0<  ,<D   8              " @1,F  !X;"]W;W)K<VAE971S+W-H
M965T-RYX;6Q02P$"% ,4    " !OBUQ4'66W@V@+  !+-   &
M    @('F+0  >&PO=V]R:W-H965T<R]S:&5E=#@N>&UL4$L! A0#%     @
M;XM<5"ETZRN7*   484  !@              ("!A#D  'AL+W=O<FMS:&5E
M=',O<VAE970Y+GAM;%!+ 0(4 Q0    ( &^+7%3OD1B1QP8  "\0   9
M          " @5%B  !X;"]W;W)K<VAE971S+W-H965T,3 N>&UL4$L! A0#
M%     @ ;XM<5*GJPTG_ P  K0D  !D              ("!3VD  'AL+W=O
M<FMS:&5E=',O<VAE970Q,2YX;6Q02P$"% ,4    " !OBUQ4+ ;JMK82   (
M/P  &0              @(&%;0  >&PO=V]R:W-H965T<R]S:&5E=#$R+GAM
M;%!+ 0(4 Q0    ( &^+7%2_DU7!S T  ',H   9              " @7*
M  !X;"]W;W)K<VAE971S+W-H965T,3,N>&UL4$L! A0#%     @ ;XM<5-/P
MF72]"0  =C$  !D              ("!=8X  'AL+W=O<FMS:&5E=',O<VAE
M970Q-"YX;6Q02P$"% ,4    " !OBUQ4PS!UPQ(1  !G0P  &0
M    @(%IF   >&PO=V]R:W-H965T<R]S:&5E=#$U+GAM;%!+ 0(4 Q0    (
M &^+7%3!JVYP:@P  $T@   9              " @;*I  !X;"]W;W)K<VAE
M971S+W-H965T,38N>&UL4$L! A0#%     @ ;XM<5'Q*UKD>"P  :AL  !D
M             ("!4[8  'AL+W=O<FMS:&5E=',O<VAE970Q-RYX;6Q02P$"
M% ,4    " !OBUQ4ZN/1;@\,  #?'P  &0              @(&HP0  >&PO
M=V]R:W-H965T<R]S:&5E=#$X+GAM;%!+ 0(4 Q0    ( &^+7%1<Y102$@P
M ,L?   9              " @>[-  !X;"]W;W)K<VAE971S+W-H965T,3DN
M>&UL4$L! A0#%     @ ;XM<5(ANGSKC,   ::@  !D              ("!
M-]H  'AL+W=O<FMS:&5E=',O<VAE970R,"YX;6Q02P$"% ,4    " !OBUQ4
MGSY.[@$&  !-#@  &0              @(%1"P$ >&PO=V]R:W-H965T<R]S
M:&5E=#(Q+GAM;%!+ 0(4 Q0    ( &^+7%3>K%^6#P<   49   9
M      " @8D1 0!X;"]W;W)K<VAE971S+W-H965T,C(N>&UL4$L! A0#%
M  @ ;XM<5(1UAPMB"P  #"$  !D              ("!SQ@! 'AL+W=O<FMS
M:&5E=',O<VAE970R,RYX;6Q02P$"% ,4    " !OBUQ4]O@V29,#   &"P
M&0              @(%H) $ >&PO=V]R:W-H965T<R]S:&5E=#(T+GAM;%!+
M 0(4 Q0    ( &^+7%36XD5/&0,  )H&   9              " @3(H 0!X
M;"]W;W)K<VAE971S+W-H965T,C4N>&UL4$L! A0#%     @ ;XM<5"!I^ITI
M"0  GAD  !D              ("!@BL! 'AL+W=O<FMS:&5E=',O<VAE970R
M-BYX;6Q02P$"% ,4    " !OBUQ43V@V]L0'  #"$P  &0
M@('B- $ >&PO=V]R:W-H965T<R]S:&5E=#(W+GAM;%!+ 0(4 Q0    ( &^+
M7%35\5O1C@8  "<0   9              " @=T\ 0!X;"]W;W)K<VAE971S
M+W-H965T,C@N>&UL4$L! A0#%     @ ;XM<5 7%K3"6#   ATP  !D
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M=#,S+GAM;%!+ 0(4 Q0    ( &^+7%1='9#7%@0  &82   9
M  " @?1? 0!X;"]W;W)K<VAE971S+W-H965T,S0N>&UL4$L! A0#%     @
M;XM<5/[1@6)? P  0PH  !D              ("!060! 'AL+W=O<FMS:&5E
M=',O<VAE970S-2YX;6Q02P$"% ,4    " !OBUQ4:EEWG:L)   Q.@  &0
M            @('79P$ >&PO=V]R:W-H965T<R]S:&5E=#,V+GAM;%!+ 0(4
M Q0    ( &^+7%0%N8G+P@,  /0,   9              " @;EQ 0!X;"]W
M;W)K<VAE971S+W-H965T,S<N>&UL4$L! A0#%     @ ;XM<5.*M =2J P
MOQ$  !D              ("!LG4! 'AL+W=O<FMS:&5E=',O<VAE970S."YX
M;6Q02P$"% ,4    " !OBUQ4B4#G>]@"  "/!P  &0              @(&3
M>0$ >&PO=V]R:W-H965T<R]S:&5E=#,Y+GAM;%!+ 0(4 Q0    ( &^+7%2C
MY0]8J00  #\4   9              " @:)\ 0!X;"]W;W)K<VAE971S+W-H
M965T-# N>&UL4$L! A0#%     @ ;XM<5$NJZBBL"@  ;UH  !D
M     ("!@H$! 'AL+W=O<FMS:&5E=',O<VAE970T,2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( &^+7%3;_&<<: ,   L-   9              "
M@>B: 0!X;"]W;W)K<VAE971S+W-H965T-#8N>&UL4$L! A0#%     @ ;XM<
M5!\0CR0S"@  ]S@  !D              ("!AYX! 'AL+W=O<FMS:&5E=',O
M<VAE970T-RYX;6Q02P$"% ,4    " !OBUQ42_/IXR\#  "X"   &0
M        @('QJ $ >&PO=V]R:W-H965T<R]S:&5E=#0X+GAM;%!+ 0(4 Q0
M   ( &^+7%1&U6DJ$@8  ,@B   9              " @5>L 0!X;"]W;W)K
M<VAE971S+W-H965T-#DN>&UL4$L! A0#%     @ ;XM<5*A<VH;Q P  ]@X
M !D              ("!H+(! 'AL+W=O<FMS:&5E=',O<VAE970U,"YX;6Q0
M2P$"% ,4    " !OBUQ45 S$AZ$"  "J!P  &0              @('(M@$
M>&PO=V]R:W-H965T<R]S:&5E=#4Q+GAM;%!+ 0(4 Q0    ( &^+7%0<,QP0
M]@0  !4:   9              " @:"Y 0!X;"]W;W)K<VAE971S+W-H965T
M-3(N>&UL4$L! A0#%     @ ;XM<5.8@"-@1 P  =@H  !D
M ("!S;X! 'AL+W=O<FMS:&5E=',O<VAE970U,RYX;6Q02P$"% ,4    " !O
MBUQ4YYJ]^Z,#   2#@  &0              @($5P@$ >&PO=V]R:W-H965T
M<R]S:&5E=#4T+GAM;%!+ 0(4 Q0    ( &^+7%0S#M)?0@,  #\*   9
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M970U.2YX;6Q02P$"% ,4    " !OBUQ4=@E/LFL(  #P.@  &0
M    @(&3W@$ >&PO=V]R:W-H965T<R]S:&5E=#8P+GAM;%!+ 0(4 Q0    (
M &^+7%3;&9;+0@,  ,0,   9              " @37G 0!X;"]W;W)K<VAE
M971S+W-H965T-C$N>&UL4$L! A0#%     @ ;XM<5%$%%/S  P  O0T  !D
M             ("!KNH! 'AL+W=O<FMS:&5E=',O<VAE970V,BYX;6Q02P$"
M% ,4    " !OBUQ4<&@H%HP"  !;!@  &0              @(&E[@$ >&PO
M=V]R:W-H965T<R]S:&5E=#8S+GAM;%!+ 0(4 Q0    ( &^+7%3R?.,4\ ,
M .D.   9              " @6CQ 0!X;"]W;W)K<VAE971S+W-H965T-C0N
M>&UL4$L! A0#%     @ ;XM<5"'N&C!9 P  A L  !D              ("!
MC_4! 'AL+W=O<FMS:&5E=',O<VAE970V-2YX;6Q02P$"% ,4    " !OBUQ4
MH8$@/-T$  #+$   &0              @($?^0$ >&PO=V]R:W-H965T<R]S
M:&5E=#8V+GAM;%!+ 0(4 Q0    ( &^+7%2H!K8Z90,  & +   9
M      " @3/^ 0!X;"]W;W)K<VAE971S+W-H965T-C<N>&UL4$L! A0#%
M  @ ;XM<5 W#F4)" P  E D  !D              ("!SP$" 'AL+W=O<FMS
M:&5E=',O<VAE970V."YX;6Q02P$"% ,4    " !OBUQ4Y\1>440#  #8%
M#0              @ %(!0( >&PO<W1Y;&5S+GAM;%!+ 0(4 Q0    ( &^+
M7%27BKL<P    !,"   +              "  ;<( @!?<F5L<R\N<F5L<U!+
M 0(4 Q0    ( &^+7%0B6#9G0P4  #@M   /              "  : ) @!X
M;"]W;W)K8F]O:RYX;6Q02P$"% ,4    " !OBUQ4%MUK%"8"  !C*   &@
M            @ $0#P( >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"
M% ,4    " !OBUQ4X>Q>$?0!  "B)P  $P              @ %N$0( 6T-O
F;G1E;G1?5'EP97-=+GAM;%!+!08     3 !, ,L4  "3$P(    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>420</ContextCount>
  <ElementCount>616</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>137</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>14</UnitCount>
  <MyReports>
    <Report instance="lgnd-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="lgnd-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0002002 - Document - Audit Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/AuditInformation</Role>
      <ShortName>Audit Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="lgnd-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1001003 - Statement - CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="lgnd-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1002004 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETSParenthetical</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="lgnd-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1003005 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF OPERATIONS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="lgnd-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1004006 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="lgnd-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1005007 - Statement - CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/CONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY</Role>
      <ShortName>CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="lgnd-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>1006008 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="lgnd-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2101101 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="lgnd-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2109102 - Disclosure - Sale of Vernalis R&amp;D and Promacta License</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/SaleofVernalisRDandPromactaLicense</Role>
      <ShortName>Sale of Vernalis R&amp;D and Promacta License</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="lgnd-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2111103 - Disclosure - Short-term Investments: Investment in Viking</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/ShorttermInvestmentsInvestmentinViking</Role>
      <ShortName>Short-term Investments: Investment in Viking</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="lgnd-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2113104 - Disclosure - Acquisitions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/Acquisitions</Role>
      <ShortName>Acquisitions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="lgnd-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2120105 - Disclosure - Fair Value Measurement</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/FairValueMeasurement</Role>
      <ShortName>Fair Value Measurement</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="lgnd-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2125106 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="lgnd-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2130107 - Disclosure - Convertible Senior Notes</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.ligand.com/role/ConvertibleSeniorNotes</Role>
      <ShortName>Convertible Senior Notes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="lgnd-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2134108 - Disclosure - Balance Sheet Account Details</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/BalanceSheetAccountDetails</Role>
      <ShortName>Balance Sheet Account Details</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="lgnd-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2144109 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/StockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="lgnd-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2152110 - Disclosure - Commitment and Contingencies: Legal Proceedings</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/CommitmentandContingenciesLegalProceedings</Role>
      <ShortName>Commitment and Contingencies: Legal Proceedings</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="lgnd-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2154111 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="lgnd-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2202201 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="lgnd-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2303301 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesTables</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="lgnd-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2314302 - Disclosure - Acquisitions (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/AcquisitionsTables</Role>
      <ShortName>Acquisitions (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.ligand.com/role/Acquisitions</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="lgnd-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2321303 - Disclosure - Fair Value Measurement (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/FairValueMeasurementTables</Role>
      <ShortName>Fair Value Measurement (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.ligand.com/role/FairValueMeasurement</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="lgnd-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2326304 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.ligand.com/role/Leases</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="lgnd-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2331305 - Disclosure - Convertible Senior Notes (Tables)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.ligand.com/role/ConvertibleSeniorNotesTables</Role>
      <ShortName>Convertible Senior Notes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.ligand.com/role/ConvertibleSeniorNotes</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="lgnd-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2335306 - Disclosure - Balance Sheet Account Details (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/BalanceSheetAccountDetailsTables</Role>
      <ShortName>Balance Sheet Account Details (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.ligand.com/role/BalanceSheetAccountDetails</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="lgnd-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2345307 - Disclosure - Stockholders' Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/StockholdersEquityTables</Role>
      <ShortName>Stockholders' Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.ligand.com/role/StockholdersEquity</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="lgnd-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2355308 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.ligand.com/role/IncomeTaxes</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="lgnd-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2404401 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesTables</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="lgnd-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2405402 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Revenue from Significant Partners (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRevenuefromSignificantPartnersDetails</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies - Revenue from Significant Partners (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="lgnd-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2406403 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Commercial License Rights (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCommercialLicenseRightsDetails</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies - Commercial License Rights (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="lgnd-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2407404 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Royalty Revenue (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRoyaltyRevenueDetails</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies - Royalty Revenue (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="lgnd-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2408405 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Calculation of Earnings per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCalculationofEarningsperShareDetails</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies - Calculation of Earnings per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="lgnd-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2410406 - Disclosure - Sale of Vernalis R&amp;D and Promacta License - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/SaleofVernalisRDandPromactaLicenseNarrativeDetails</Role>
      <ShortName>Sale of Vernalis R&amp;D and Promacta License - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="lgnd-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2412407 - Disclosure - Short-term Investments: Investment in Viking - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/ShorttermInvestmentsInvestmentinVikingNarrativeDetails</Role>
      <ShortName>Short-term Investments: Investment in Viking - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="lgnd-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2415408 - Disclosure - Acquisitions - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/AcquisitionsNarrativeDetails</Role>
      <ShortName>Acquisitions - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="lgnd-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2416409 - Disclosure - Acquisitions - Assets Acquired and Liabilities Assumed (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails</Role>
      <ShortName>Acquisitions - Assets Acquired and Liabilities Assumed (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="lgnd-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2417410 - Disclosure - Acquisitions - Intangibles Acquired and Weighted Average Useful Life (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/AcquisitionsIntangiblesAcquiredandWeightedAverageUsefulLifeDetails</Role>
      <ShortName>Acquisitions - Intangibles Acquired and Weighted Average Useful Life (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="lgnd-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2418411 - Disclosure - Acquisitions - Pro Forma Financial Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/AcquisitionsProFormaFinancialInformationDetails</Role>
      <ShortName>Acquisitions - Pro Forma Financial Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="lgnd-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2419412 - Disclosure - Acquisitions - Allocation of Consideration (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/AcquisitionsAllocationofConsiderationDetails</Role>
      <ShortName>Acquisitions - Allocation of Consideration (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="lgnd-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2422413 - Disclosure - Fair Value Measurement - Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails</Role>
      <ShortName>Fair Value Measurement - Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="lgnd-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2423414 - Disclosure - Fair Value Measurement - Reconciliation of Level 3 Financial Instruments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/FairValueMeasurementReconciliationofLevel3FinancialInstrumentsDetails</Role>
      <ShortName>Fair Value Measurement - Reconciliation of Level 3 Financial Instruments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="lgnd-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2424415 - Disclosure - Fair Value Measurements - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/FairValueMeasurementsNarrativeDetails</Role>
      <ShortName>Fair Value Measurements - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="lgnd-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2427416 - Disclosure - Leases - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/LeasesNarrativeDetails</Role>
      <ShortName>Leases - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="lgnd-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>2428417 - Disclosure - Leases - Operating and Finance Lease Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/LeasesOperatingandFinanceLeaseAssetsandLiabilitiesDetails</Role>
      <ShortName>Leases - Operating and Finance Lease Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="lgnd-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>2429418 - Disclosure - Leases - Maturities of Operating and Finance Lease Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails</Role>
      <ShortName>Leases - Maturities of Operating and Finance Lease Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="lgnd-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>2432419 - Disclosure - Convertible Senior Notes - Narrative (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.ligand.com/role/ConvertibleSeniorNotesNarrativeDetails</Role>
      <ShortName>Convertible Senior Notes - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="lgnd-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>2433420 - Disclosure - Convertible Senior Notes - Equity and Liability Components of Financing Arrangements (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.ligand.com/role/ConvertibleSeniorNotesEquityandLiabilityComponentsofFinancingArrangementsDetails</Role>
      <ShortName>Convertible Senior Notes - Equity and Liability Components of Financing Arrangements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="lgnd-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>2436421 - Disclosure - Balance Sheet Account Details - Investment Categories (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/BalanceSheetAccountDetailsInvestmentCategoriesDetails</Role>
      <ShortName>Balance Sheet Account Details - Investment Categories (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="lgnd-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>2437422 - Disclosure - Balance Sheet Account Details - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/BalanceSheetAccountDetailsNarrativeDetails</Role>
      <ShortName>Balance Sheet Account Details - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="lgnd-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>2438423 - Disclosure - Balance Sheet Account Details - Available-for-Sale Debt Securities by Contractual Maturity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/BalanceSheetAccountDetailsAvailableforSaleDebtSecuritiesbyContractualMaturityDetails</Role>
      <ShortName>Balance Sheet Account Details - Available-for-Sale Debt Securities by Contractual Maturity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="lgnd-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>2439424 - Disclosure - Balance Sheet Account Details - Available-for-Sale Debt Securities in an Unrealized Loss Position (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/BalanceSheetAccountDetailsAvailableforSaleDebtSecuritiesinanUnrealizedLossPositionDetails</Role>
      <ShortName>Balance Sheet Account Details - Available-for-Sale Debt Securities in an Unrealized Loss Position (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="lgnd-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>2440425 - Disclosure - Balance Sheet Account Details - Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/BalanceSheetAccountDetailsPropertyandEquipmentDetails</Role>
      <ShortName>Balance Sheet Account Details - Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="lgnd-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>2441426 - Disclosure - Balance Sheet Account Details - Goodwill and Other Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/BalanceSheetAccountDetailsGoodwillandOtherIntangibleAssetsDetails</Role>
      <ShortName>Balance Sheet Account Details - Goodwill and Other Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="lgnd-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>2442427 - Disclosure - Balance Sheet Account Details - Accrued Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/BalanceSheetAccountDetailsAccruedLiabilitiesDetails</Role>
      <ShortName>Balance Sheet Account Details - Accrued Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="lgnd-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>2443428 - Disclosure - Balance Sheet Account Details - Contingent Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/BalanceSheetAccountDetailsContingentLiabilitiesDetails</Role>
      <ShortName>Balance Sheet Account Details - Contingent Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="lgnd-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>2446429 - Disclosure - Stockholders' Equity - Share-Based Compensation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/StockholdersEquityShareBasedCompensationDetails</Role>
      <ShortName>Stockholders' Equity - Share-Based Compensation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="lgnd-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>2447430 - Disclosure - Stockholders' Equity - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/StockholdersEquityNarrativeDetails</Role>
      <ShortName>Stockholders' Equity - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="lgnd-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>2448431 - Disclosure - Stockholders' Equity - Stock Option Plan Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/StockholdersEquityStockOptionPlanActivityDetails</Role>
      <ShortName>Stockholders' Equity - Stock Option Plan Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="lgnd-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>2449432 - Disclosure - Stockholders' Equity - Breakdown of Options Outstanding (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/StockholdersEquityBreakdownofOptionsOutstandingDetails</Role>
      <ShortName>Stockholders' Equity - Breakdown of Options Outstanding (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="lgnd-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>2450433 - Disclosure - Stockholders' Equity - Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/StockholdersEquityAssumptionsDetails</Role>
      <ShortName>Stockholders' Equity - Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="lgnd-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>2451434 - Disclosure - Stockholders' Equity - Restricted Stock Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/StockholdersEquityRestrictedStockActivityDetails</Role>
      <ShortName>Stockholders' Equity - Restricted Stock Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="lgnd-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>2453435 - Disclosure - Commitment and Contingencies: Legal Proceedings - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/CommitmentandContingenciesLegalProceedingsNarrativeDetails</Role>
      <ShortName>Commitment and Contingencies: Legal Proceedings - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="lgnd-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>2456436 - Disclosure - Income Taxes - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/IncomeTaxesNarrativeDetails</Role>
      <ShortName>Income Taxes - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="lgnd-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>2457437 - Disclosure - Income Taxes - Components of Income Tax Expense (Benefit) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/IncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails</Role>
      <ShortName>Income Taxes - Components of Income Tax Expense (Benefit) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="lgnd-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>2458438 - Disclosure - Income Taxes - Reconciliation of Income Tax Expense (Benefit) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/IncomeTaxesReconciliationofIncomeTaxExpenseBenefitDetails</Role>
      <ShortName>Income Taxes - Reconciliation of Income Tax Expense (Benefit) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="lgnd-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>2459439 - Disclosure - Income Taxes - Deferred Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/IncomeTaxesDeferredTaxesDetails</Role>
      <ShortName>Income Taxes - Deferred Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="lgnd-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>2460440 - Disclosure - Income Taxes - Reconciliation of Unrecognized Tax Benefits (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/IncomeTaxesReconciliationofUnrecognizedTaxBenefitsDetails</Role>
      <ShortName>Income Taxes - Reconciliation of Unrecognized Tax Benefits (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" original="lgnd-20211231.htm">lgnd-20211231.htm</File>
    <File>exhibit1039_ligandpharmace.htm</File>
    <File>lgnd-20211231.xsd</File>
    <File>lgnd-20211231_cal.xml</File>
    <File>lgnd-20211231_def.xml</File>
    <File>lgnd-20211231_lab.xml</File>
    <File>lgnd-20211231_pre.xml</File>
    <File>lgnd_123121xexhibit1037.htm</File>
    <File>lgnd_123121xexhibit211.htm</File>
    <File>lgnd_123121xexhibit231.htm</File>
    <File>lgnd_123121xexhibit311.htm</File>
    <File>lgnd_123121xexhibit312.htm</File>
    <File>lgnd_123121xexhibit321.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>lgnd-20211231_g1.jpg</File>
    <File>lgnd-20211231_g2.jpg</File>
    <File>lgnd-20211231_g3.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="1366">http://fasb.org/us-gaap/2021-01-31</BaseTaxonomy>
    <BaseTaxonomy items="37">http://xbrl.sec.gov/dei/2021q4</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>94
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "lgnd-20211231.htm": {
   "axisCustom": 0,
   "axisStandard": 37,
   "contextCount": 420,
   "dts": {
    "calculationLink": {
     "local": [
      "lgnd-20211231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "lgnd-20211231_def.xml"
     ]
    },
    "inline": {
     "local": [
      "lgnd-20211231.htm"
     ]
    },
    "labelLink": {
     "local": [
      "lgnd-20211231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "lgnd-20211231_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "lgnd-20211231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd"
     ]
    }
   },
   "elementCount": 829,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2021-01-31": 9,
    "http://xbrl.sec.gov/dei/2021q4": 4,
    "total": 13
   },
   "keyCustom": 79,
   "keyStandard": 537,
   "memberCustom": 69,
   "memberStandard": 58,
   "nsprefix": "lgnd",
   "nsuri": "http://www.ligand.com/20211231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20211231.htm",
      "contextRef": "i8de36dd6935847019123fffb990b7008_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover",
     "role": "http://www.ligand.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20211231.htm",
      "contextRef": "i8de36dd6935847019123fffb990b7008_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20211231.htm",
      "contextRef": "i8de36dd6935847019123fffb990b7008_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2109102 - Disclosure - Sale of Vernalis R&D and Promacta License",
     "role": "http://www.ligand.com/role/SaleofVernalisRDandPromactaLicense",
     "shortName": "Sale of Vernalis R&D and Promacta License",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20211231.htm",
      "contextRef": "i8de36dd6935847019123fffb990b7008_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20211231.htm",
      "contextRef": "i8de36dd6935847019123fffb990b7008_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:VariableInterestEntityDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2111103 - Disclosure - Short-term Investments: Investment in Viking",
     "role": "http://www.ligand.com/role/ShorttermInvestmentsInvestmentinViking",
     "shortName": "Short-term Investments: Investment in Viking",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20211231.htm",
      "contextRef": "i8de36dd6935847019123fffb990b7008_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:VariableInterestEntityDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20211231.htm",
      "contextRef": "i8de36dd6935847019123fffb990b7008_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2113104 - Disclosure - Acquisitions",
     "role": "http://www.ligand.com/role/Acquisitions",
     "shortName": "Acquisitions",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20211231.htm",
      "contextRef": "i8de36dd6935847019123fffb990b7008_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20211231.htm",
      "contextRef": "i8de36dd6935847019123fffb990b7008_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FinancialInstrumentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2120105 - Disclosure - Fair Value Measurement",
     "role": "http://www.ligand.com/role/FairValueMeasurement",
     "shortName": "Fair Value Measurement",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20211231.htm",
      "contextRef": "i8de36dd6935847019123fffb990b7008_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FinancialInstrumentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20211231.htm",
      "contextRef": "i8de36dd6935847019123fffb990b7008_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2125106 - Disclosure - Leases",
     "role": "http://www.ligand.com/role/Leases",
     "shortName": "Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20211231.htm",
      "contextRef": "i8de36dd6935847019123fffb990b7008_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20211231.htm",
      "contextRef": "i8de36dd6935847019123fffb990b7008_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2130107 - Disclosure - Convertible Senior Notes",
     "role": "http://www.ligand.com/role/ConvertibleSeniorNotes",
     "shortName": "Convertible Senior Notes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20211231.htm",
      "contextRef": "i8de36dd6935847019123fffb990b7008_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20211231.htm",
      "contextRef": "i8de36dd6935847019123fffb990b7008_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2134108 - Disclosure - Balance Sheet Account Details",
     "role": "http://www.ligand.com/role/BalanceSheetAccountDetails",
     "shortName": "Balance Sheet Account Details",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20211231.htm",
      "contextRef": "i8de36dd6935847019123fffb990b7008_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20211231.htm",
      "contextRef": "i8de36dd6935847019123fffb990b7008_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2144109 - Disclosure - Stockholders' Equity",
     "role": "http://www.ligand.com/role/StockholdersEquity",
     "shortName": "Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20211231.htm",
      "contextRef": "i8de36dd6935847019123fffb990b7008_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20211231.htm",
      "contextRef": "i8de36dd6935847019123fffb990b7008_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2152110 - Disclosure - Commitment and Contingencies: Legal Proceedings",
     "role": "http://www.ligand.com/role/CommitmentandContingenciesLegalProceedings",
     "shortName": "Commitment and Contingencies: Legal Proceedings",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20211231.htm",
      "contextRef": "i8de36dd6935847019123fffb990b7008_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20211231.htm",
      "contextRef": "i8de36dd6935847019123fffb990b7008_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2154111 - Disclosure - Income Taxes",
     "role": "http://www.ligand.com/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20211231.htm",
      "contextRef": "i8de36dd6935847019123fffb990b7008_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20211231.htm",
      "contextRef": "i8de36dd6935847019123fffb990b7008_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:AuditorName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "false",
     "longName": "0002002 - Document - Audit Information",
     "role": "http://www.ligand.com/role/AuditInformation",
     "shortName": "Audit Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20211231.htm",
      "contextRef": "i8de36dd6935847019123fffb990b7008_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:AuditorName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20211231.htm",
      "contextRef": "i8de36dd6935847019123fffb990b7008_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2202201 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies)",
     "role": "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies",
     "shortName": "Basis of Presentation and Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20211231.htm",
      "contextRef": "i8de36dd6935847019123fffb990b7008_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20211231.htm",
      "contextRef": "i8de36dd6935847019123fffb990b7008_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2303301 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Tables)",
     "role": "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesTables",
     "shortName": "Basis of Presentation and Summary of Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20211231.htm",
      "contextRef": "i8de36dd6935847019123fffb990b7008_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20211231.htm",
      "contextRef": "i88f2f47e22764022b5dec2243aa219c7_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2314302 - Disclosure - Acquisitions (Tables)",
     "role": "http://www.ligand.com/role/AcquisitionsTables",
     "shortName": "Acquisitions (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20211231.htm",
      "contextRef": "i88f2f47e22764022b5dec2243aa219c7_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20211231.htm",
      "contextRef": "i8de36dd6935847019123fffb990b7008_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2321303 - Disclosure - Fair Value Measurement (Tables)",
     "role": "http://www.ligand.com/role/FairValueMeasurementTables",
     "shortName": "Fair Value Measurement (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20211231.htm",
      "contextRef": "i8de36dd6935847019123fffb990b7008_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20211231.htm",
      "contextRef": "i8de36dd6935847019123fffb990b7008_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "lgnd:AssetsAndLiabilitiesLesseeTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2326304 - Disclosure - Leases (Tables)",
     "role": "http://www.ligand.com/role/LeasesTables",
     "shortName": "Leases (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20211231.htm",
      "contextRef": "i8de36dd6935847019123fffb990b7008_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "lgnd:AssetsAndLiabilitiesLesseeTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20211231.htm",
      "contextRef": "i8de36dd6935847019123fffb990b7008_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2331305 - Disclosure - Convertible Senior Notes (Tables)",
     "role": "http://www.ligand.com/role/ConvertibleSeniorNotesTables",
     "shortName": "Convertible Senior Notes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20211231.htm",
      "contextRef": "i8de36dd6935847019123fffb990b7008_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20211231.htm",
      "contextRef": "i8de36dd6935847019123fffb990b7008_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:MarketableSecuritiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2335306 - Disclosure - Balance Sheet Account Details (Tables)",
     "role": "http://www.ligand.com/role/BalanceSheetAccountDetailsTables",
     "shortName": "Balance Sheet Account Details (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20211231.htm",
      "contextRef": "i8de36dd6935847019123fffb990b7008_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:MarketableSecuritiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20211231.htm",
      "contextRef": "i8de36dd6935847019123fffb990b7008_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2345307 - Disclosure - Stockholders' Equity (Tables)",
     "role": "http://www.ligand.com/role/StockholdersEquityTables",
     "shortName": "Stockholders' Equity (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20211231.htm",
      "contextRef": "i8de36dd6935847019123fffb990b7008_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20211231.htm",
      "contextRef": "i8de36dd6935847019123fffb990b7008_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2355308 - Disclosure - Income Taxes (Tables)",
     "role": "http://www.ligand.com/role/IncomeTaxesTables",
     "shortName": "Income Taxes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20211231.htm",
      "contextRef": "i8de36dd6935847019123fffb990b7008_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20211231.htm",
      "contextRef": "i8de36dd6935847019123fffb990b7008_D20210101-20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2404401 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Narrative (Details)",
     "role": "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails",
     "shortName": "Basis of Presentation and Summary of Significant Accounting Policies - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20211231.htm",
      "contextRef": "i8de36dd6935847019123fffb990b7008_D20210101-20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20211231.htm",
      "contextRef": "i9217b15ab4cb456c8c63180298ed612e_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001003 - Statement - CONSOLIDATED BALANCE SHEETS",
     "role": "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS",
     "shortName": "CONSOLIDATED BALANCE SHEETS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20211231.htm",
      "contextRef": "i9217b15ab4cb456c8c63180298ed612e_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20211231.htm",
      "contextRef": "i8b1b6cbf7db84387abc05c19c397f3e1_D20210101-20211231",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2405402 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Revenue from Significant Partners (Details)",
     "role": "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRevenuefromSignificantPartnersDetails",
     "shortName": "Basis of Presentation and Summary of Significant Accounting Policies - Revenue from Significant Partners (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20211231.htm",
      "contextRef": "i8b1b6cbf7db84387abc05c19c397f3e1_D20210101-20211231",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "lgnd:ScheduleofCommercialLicenseRightsTableTextBlock",
       "lgnd:CommercialLicenseRightsPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20211231.htm",
      "contextRef": "ia8308d0606a54c10ac4769b1a226d54c_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2406403 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Commercial License Rights (Details)",
     "role": "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCommercialLicenseRightsDetails",
     "shortName": "Basis of Presentation and Summary of Significant Accounting Policies - Commercial License Rights (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "lgnd:ScheduleofCommercialLicenseRightsTableTextBlock",
       "lgnd:CommercialLicenseRightsPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20211231.htm",
      "contextRef": "ia8308d0606a54c10ac4769b1a226d54c_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20211231.htm",
      "contextRef": "i8de36dd6935847019123fffb990b7008_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2407404 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Royalty Revenue (Details)",
     "role": "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRoyaltyRevenueDetails",
     "shortName": "Basis of Presentation and Summary of Significant Accounting Policies - Royalty Revenue (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20211231.htm",
      "contextRef": "id39ac2bcc6964f1cbe6799ea3c6e4480_D20210101-20211231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20211231.htm",
      "contextRef": "i8de36dd6935847019123fffb990b7008_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:WeightedAverageNumberOfSharesOutstandingBasic",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2408405 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Calculation of Earnings per Share (Details)",
     "role": "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCalculationofEarningsperShareDetails",
     "shortName": "Basis of Presentation and Summary of Significant Accounting Policies - Calculation of Earnings per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20211231.htm",
      "contextRef": "ifcdd30f034184cecb366b0b9b1bd9c55_D20210101-20211231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20211231.htm",
      "contextRef": "i8de36dd6935847019123fffb990b7008_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProceedsFromDivestitureOfBusinesses",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2410406 - Disclosure - Sale of Vernalis R&D and Promacta License - Narrative (Details)",
     "role": "http://www.ligand.com/role/SaleofVernalisRDandPromactaLicenseNarrativeDetails",
     "shortName": "Sale of Vernalis R&D and Promacta License - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20211231.htm",
      "contextRef": "iad8d570ea6b24d73b93cc3ae9b3901e3_D20201202-20201202",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:ProceedsFromDivestitureOfBusinesses",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20211231.htm",
      "contextRef": "i9217b15ab4cb456c8c63180298ed612e_I20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:WarrantsAndRightsOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2412407 - Disclosure - Short-term Investments: Investment in Viking - Narrative (Details)",
     "role": "http://www.ligand.com/role/ShorttermInvestmentsInvestmentinVikingNarrativeDetails",
     "shortName": "Short-term Investments: Investment in Viking - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20211231.htm",
      "contextRef": "i9217b15ab4cb456c8c63180298ed612e_I20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:WarrantsAndRightsOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20211231.htm",
      "contextRef": "i0ccc7acfbbaf4714aeb414b4d316cace_D20190101-20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "lgnd:NumberOfAcquisitions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "acquisition",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2415408 - Disclosure - Acquisitions - Narrative (Details)",
     "role": "http://www.ligand.com/role/AcquisitionsNarrativeDetails",
     "shortName": "Acquisitions - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20211231.htm",
      "contextRef": "i0ccc7acfbbaf4714aeb414b4d316cace_D20190101-20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "lgnd:NumberOfAcquisitions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "acquisition",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20211231.htm",
      "contextRef": "i9217b15ab4cb456c8c63180298ed612e_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Goodwill",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2416409 - Disclosure - Acquisitions - Assets Acquired and Liabilities Assumed (Details)",
     "role": "http://www.ligand.com/role/AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails",
     "shortName": "Acquisitions - Assets Acquired and Liabilities Assumed (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20211231.htm",
      "contextRef": "ia9a9eb80fb244862b401f0cf7734c9d9_I20201001",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20211231.htm",
      "contextRef": "ia9a9eb80fb244862b401f0cf7734c9d9_I20201001",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2417410 - Disclosure - Acquisitions - Intangibles Acquired and Weighted Average Useful Life (Details)",
     "role": "http://www.ligand.com/role/AcquisitionsIntangiblesAcquiredandWeightedAverageUsefulLifeDetails",
     "shortName": "Acquisitions - Intangibles Acquired and Weighted Average Useful Life (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20211231.htm",
      "contextRef": "ia9a9eb80fb244862b401f0cf7734c9d9_I20201001",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20211231.htm",
      "contextRef": "i88f2f47e22764022b5dec2243aa219c7_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessAcquisitionsProFormaRevenue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2418411 - Disclosure - Acquisitions - Pro Forma Financial Information (Details)",
     "role": "http://www.ligand.com/role/AcquisitionsProFormaFinancialInformationDetails",
     "shortName": "Acquisitions - Pro Forma Financial Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20211231.htm",
      "contextRef": "i88f2f47e22764022b5dec2243aa219c7_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessAcquisitionsProFormaRevenue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20211231.htm",
      "contextRef": "i9217b15ab4cb456c8c63180298ed612e_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002004 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "role": "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
     "shortName": "CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20211231.htm",
      "contextRef": "i9217b15ab4cb456c8c63180298ed612e_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20211231.htm",
      "contextRef": "i9217b15ab4cb456c8c63180298ed612e_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Goodwill",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2419412 - Disclosure - Acquisitions - Allocation of Consideration (Details)",
     "role": "http://www.ligand.com/role/AcquisitionsAllocationofConsiderationDetails",
     "shortName": "Acquisitions - Allocation of Consideration (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20211231.htm",
      "contextRef": "i37f8f2fb62fb45eda8a94c6014fb06c3_I20200909",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20211231.htm",
      "contextRef": "i9217b15ab4cb456c8c63180298ed612e_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "lgnd:NumberOfContingentValueRightAgreements",
      "reportCount": 1,
      "unitRef": "agreement",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2422413 - Disclosure - Fair Value Measurement - Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)",
     "role": "http://www.ligand.com/role/FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
     "shortName": "Fair Value Measurement - Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20211231.htm",
      "contextRef": "i5b1dfac6d5ae4926a0e3356f1fb10e83_I20211231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerAssetGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "lgnd:ScheduleofContingentLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20211231.htm",
      "contextRef": "i8de36dd6935847019123fffb990b7008_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "lgnd:PaymentsToContingentValueRightHolders",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2423414 - Disclosure - Fair Value Measurement - Reconciliation of Level 3 Financial Instruments (Details)",
     "role": "http://www.ligand.com/role/FairValueMeasurementReconciliationofLevel3FinancialInstrumentsDetails",
     "shortName": "Fair Value Measurement - Reconciliation of Level 3 Financial Instruments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20211231.htm",
      "contextRef": "i34b45bfb1f924acb8a8e2d99bc22a5fc_D20210101-20211231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "lgnd:PaymentsToContingentValueRightHolders",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20211231.htm",
      "contextRef": "i8de36dd6935847019123fffb990b7008_D20210101-20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AssetImpairmentCharges",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2424415 - Disclosure - Fair Value Measurements - Narrative (Details)",
     "role": "http://www.ligand.com/role/FairValueMeasurementsNarrativeDetails",
     "shortName": "Fair Value Measurements - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20211231.htm",
      "contextRef": "i8de36dd6935847019123fffb990b7008_D20210101-20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AssetImpairmentCharges",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20211231.htm",
      "contextRef": "i9217b15ab4cb456c8c63180298ed612e_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FinanceLeaseLiability",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2427416 - Disclosure - Leases - Narrative (Details)",
     "role": "http://www.ligand.com/role/LeasesNarrativeDetails",
     "shortName": "Leases - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20211231.htm",
      "contextRef": "i9217b15ab4cb456c8c63180298ed612e_I20211231",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:LesseeFinanceLeaseRemainingLeaseTerm",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "lgnd:AssetsAndLiabilitiesLesseeTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20211231.htm",
      "contextRef": "i9217b15ab4cb456c8c63180298ed612e_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2428417 - Disclosure - Leases - Operating and Finance Lease Assets and Liabilities (Details)",
     "role": "http://www.ligand.com/role/LeasesOperatingandFinanceLeaseAssetsandLiabilitiesDetails",
     "shortName": "Leases - Operating and Finance Lease Assets and Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "lgnd:AssetsAndLiabilitiesLesseeTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20211231.htm",
      "contextRef": "i9217b15ab4cb456c8c63180298ed612e_I20211231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "lgnd:LeaseRightOfUseAsset",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20211231.htm",
      "contextRef": "i9217b15ab4cb456c8c63180298ed612e_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2429418 - Disclosure - Leases - Maturities of Operating and Finance Lease Liabilities (Details)",
     "role": "http://www.ligand.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails",
     "shortName": "Leases - Maturities of Operating and Finance Lease Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20211231.htm",
      "contextRef": "i9217b15ab4cb456c8c63180298ed612e_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20211231.htm",
      "contextRef": "i8de36dd6935847019123fffb990b7008_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GainsLossesOnExtinguishmentOfDebt",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2432419 - Disclosure - Convertible Senior Notes - Narrative (Details)",
     "role": "http://www.ligand.com/role/ConvertibleSeniorNotesNarrativeDetails",
     "shortName": "Convertible Senior Notes - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20211231.htm",
      "contextRef": "ic3fce11822d74ffb9e96e89bebb23277_I20140831",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDebtTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20211231.htm",
      "contextRef": "i75c40fa8303240178bae96b5323104b2_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentFaceAmount",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2433420 - Disclosure - Convertible Senior Notes - Equity and Liability Components of Financing Arrangements (Details)",
     "role": "http://www.ligand.com/role/ConvertibleSeniorNotesEquityandLiabilityComponentsofFinancingArrangementsDetails",
     "shortName": "Convertible Senior Notes - Equity and Liability Components of Financing Arrangements (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDebtTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20211231.htm",
      "contextRef": "i75c40fa8303240178bae96b5323104b2_I20211231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentUnamortizedDiscount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:MarketableSecuritiesTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20211231.htm",
      "contextRef": "ibe91b170813b4c308d6df67cdcda5ea8_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2436421 - Disclosure - Balance Sheet Account Details - Investment Categories (Details)",
     "role": "http://www.ligand.com/role/BalanceSheetAccountDetailsInvestmentCategoriesDetails",
     "shortName": "Balance Sheet Account Details - Investment Categories (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:MarketableSecuritiesTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20211231.htm",
      "contextRef": "ibe91b170813b4c308d6df67cdcda5ea8_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20211231.htm",
      "contextRef": "i8de36dd6935847019123fffb990b7008_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003005 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS",
     "role": "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
     "shortName": "CONSOLIDATED STATEMENTS OF OPERATIONS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20211231.htm",
      "contextRef": "i8de36dd6935847019123fffb990b7008_D20210101-20211231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:CostDirectMaterial",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20211231.htm",
      "contextRef": "i9217b15ab4cb456c8c63180298ed612e_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "position",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2437422 - Disclosure - Balance Sheet Account Details - Narrative (Details)",
     "role": "http://www.ligand.com/role/BalanceSheetAccountDetailsNarrativeDetails",
     "shortName": "Balance Sheet Account Details - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20211231.htm",
      "contextRef": "i9217b15ab4cb456c8c63180298ed612e_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "position",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20211231.htm",
      "contextRef": "i9217b15ab4cb456c8c63180298ed612e_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2438423 - Disclosure - Balance Sheet Account Details - Available-for-Sale Debt Securities by Contractual Maturity (Details)",
     "role": "http://www.ligand.com/role/BalanceSheetAccountDetailsAvailableforSaleDebtSecuritiesbyContractualMaturityDetails",
     "shortName": "Balance Sheet Account Details - Available-for-Sale Debt Securities by Contractual Maturity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20211231.htm",
      "contextRef": "i9217b15ab4cb456c8c63180298ed612e_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20211231.htm",
      "contextRef": "i9217b15ab4cb456c8c63180298ed612e_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2439424 - Disclosure - Balance Sheet Account Details - Available-for-Sale Debt Securities in an Unrealized Loss Position (Details)",
     "role": "http://www.ligand.com/role/BalanceSheetAccountDetailsAvailableforSaleDebtSecuritiesinanUnrealizedLossPositionDetails",
     "shortName": "Balance Sheet Account Details - Available-for-Sale Debt Securities in an Unrealized Loss Position (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20211231.htm",
      "contextRef": "i9217b15ab4cb456c8c63180298ed612e_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20211231.htm",
      "contextRef": "i9217b15ab4cb456c8c63180298ed612e_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2440425 - Disclosure - Balance Sheet Account Details - Property and Equipment (Details)",
     "role": "http://www.ligand.com/role/BalanceSheetAccountDetailsPropertyandEquipmentDetails",
     "shortName": "Balance Sheet Account Details - Property and Equipment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20211231.htm",
      "contextRef": "i9217b15ab4cb456c8c63180298ed612e_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20211231.htm",
      "contextRef": "i9217b15ab4cb456c8c63180298ed612e_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Goodwill",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2441426 - Disclosure - Balance Sheet Account Details - Goodwill and Other Intangible Assets (Details)",
     "role": "http://www.ligand.com/role/BalanceSheetAccountDetailsGoodwillandOtherIntangibleAssetsDetails",
     "shortName": "Balance Sheet Account Details - Goodwill and Other Intangible Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20211231.htm",
      "contextRef": "i9217b15ab4cb456c8c63180298ed612e_I20211231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:IntangibleAssetsNetIncludingGoodwill",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20211231.htm",
      "contextRef": "i9217b15ab4cb456c8c63180298ed612e_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2442427 - Disclosure - Balance Sheet Account Details - Accrued Liabilities (Details)",
     "role": "http://www.ligand.com/role/BalanceSheetAccountDetailsAccruedLiabilitiesDetails",
     "shortName": "Balance Sheet Account Details - Accrued Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20211231.htm",
      "contextRef": "i9217b15ab4cb456c8c63180298ed612e_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "lgnd:ScheduleofContingentLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20211231.htm",
      "contextRef": "i7462d0db8f4248fcb9fd8f1deae439f3_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "lgnd:BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2443428 - Disclosure - Balance Sheet Account Details - Contingent Liabilities (Details)",
     "role": "http://www.ligand.com/role/BalanceSheetAccountDetailsContingentLiabilitiesDetails",
     "shortName": "Balance Sheet Account Details - Contingent Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "lgnd:ScheduleofContingentLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20211231.htm",
      "contextRef": "ida3ec05a32644c2db1bb9f71f76c567f_I20191231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "lgnd:BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20211231.htm",
      "contextRef": "i8de36dd6935847019123fffb990b7008_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2446429 - Disclosure - Stockholders' Equity - Share-Based Compensation (Details)",
     "role": "http://www.ligand.com/role/StockholdersEquityShareBasedCompensationDetails",
     "shortName": "Stockholders' Equity - Share-Based Compensation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20211231.htm",
      "contextRef": "i8de36dd6935847019123fffb990b7008_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20211231.htm",
      "contextRef": "i66cf645fedeb4e3f9127e1557bedf870_I20190911",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockRepurchaseProgramAuthorizedAmount1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2447430 - Disclosure - Stockholders' Equity - Narrative (Details)",
     "role": "http://www.ligand.com/role/StockholdersEquityNarrativeDetails",
     "shortName": "Stockholders' Equity - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20211231.htm",
      "contextRef": "i66cf645fedeb4e3f9127e1557bedf870_I20190911",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockRepurchaseProgramAuthorizedAmount1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20211231.htm",
      "contextRef": "i7462d0db8f4248fcb9fd8f1deae439f3_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2448431 - Disclosure - Stockholders' Equity - Stock Option Plan Activity (Details)",
     "role": "http://www.ligand.com/role/StockholdersEquityStockOptionPlanActivityDetails",
     "shortName": "Stockholders' Equity - Stock Option Plan Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20211231.htm",
      "contextRef": "i8de36dd6935847019123fffb990b7008_D20210101-20211231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20211231.htm",
      "contextRef": "i8de36dd6935847019123fffb990b7008_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004006 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)",
     "role": "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS",
     "shortName": "CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20211231.htm",
      "contextRef": "i8de36dd6935847019123fffb990b7008_D20210101-20211231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20211231.htm",
      "contextRef": "i331ce2c9b57a41af9de97ff9994cb5b5_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2449432 - Disclosure - Stockholders' Equity - Breakdown of Options Outstanding (Details)",
     "role": "http://www.ligand.com/role/StockholdersEquityBreakdownofOptionsOutstandingDetails",
     "shortName": "Stockholders' Equity - Breakdown of Options Outstanding (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20211231.htm",
      "contextRef": "i331ce2c9b57a41af9de97ff9994cb5b5_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20211231.htm",
      "contextRef": "i5258348dd679493ba1253e4703ac77de_D20210101-20211231",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2450433 - Disclosure - Stockholders' Equity - Assumptions (Details)",
     "role": "http://www.ligand.com/role/StockholdersEquityAssumptionsDetails",
     "shortName": "Stockholders' Equity - Assumptions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20211231.htm",
      "contextRef": "i5258348dd679493ba1253e4703ac77de_D20210101-20211231",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20211231.htm",
      "contextRef": "ice6ab2e1895644b3904facb98212b670_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2451434 - Disclosure - Stockholders' Equity - Restricted Stock Activity (Details)",
     "role": "http://www.ligand.com/role/StockholdersEquityRestrictedStockActivityDetails",
     "shortName": "Stockholders' Equity - Restricted Stock Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20211231.htm",
      "contextRef": "i45bcdaf84c91401486b1d0398942843d_I20181231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20211231.htm",
      "contextRef": "i93652c87888744bc90a296c0d62c6b8e_D20191029-20191029",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GainContingencyPatentsAllegedlyInfringedUponNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "patent",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2453435 - Disclosure - Commitment and Contingencies: Legal Proceedings - Narrative (Details)",
     "role": "http://www.ligand.com/role/CommitmentandContingenciesLegalProceedingsNarrativeDetails",
     "shortName": "Commitment and Contingencies: Legal Proceedings - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20211231.htm",
      "contextRef": "i93652c87888744bc90a296c0d62c6b8e_D20191029-20191029",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GainContingencyPatentsAllegedlyInfringedUponNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "patent",
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20211231.htm",
      "contextRef": "i8de36dd6935847019123fffb990b7008_D20210101-20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2456436 - Disclosure - Income Taxes - Narrative (Details)",
     "role": "http://www.ligand.com/role/IncomeTaxesNarrativeDetails",
     "shortName": "Income Taxes - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20211231.htm",
      "contextRef": "i8de36dd6935847019123fffb990b7008_D20210101-20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R65": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20211231.htm",
      "contextRef": "i8de36dd6935847019123fffb990b7008_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2457437 - Disclosure - Income Taxes - Components of Income Tax Expense (Benefit) (Details)",
     "role": "http://www.ligand.com/role/IncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails",
     "shortName": "Income Taxes - Components of Income Tax Expense (Benefit) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20211231.htm",
      "contextRef": "i8de36dd6935847019123fffb990b7008_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R66": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20211231.htm",
      "contextRef": "i8de36dd6935847019123fffb990b7008_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2458438 - Disclosure - Income Taxes - Reconciliation of Income Tax Expense (Benefit) (Details)",
     "role": "http://www.ligand.com/role/IncomeTaxesReconciliationofIncomeTaxExpenseBenefitDetails",
     "shortName": "Income Taxes - Reconciliation of Income Tax Expense (Benefit) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20211231.htm",
      "contextRef": "i8de36dd6935847019123fffb990b7008_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R67": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20211231.htm",
      "contextRef": "i9217b15ab4cb456c8c63180298ed612e_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2459439 - Disclosure - Income Taxes - Deferred Taxes (Details)",
     "role": "http://www.ligand.com/role/IncomeTaxesDeferredTaxesDetails",
     "shortName": "Income Taxes - Deferred Taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20211231.htm",
      "contextRef": "i9217b15ab4cb456c8c63180298ed612e_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R68": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForwardTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20211231.htm",
      "contextRef": "i7462d0db8f4248fcb9fd8f1deae439f3_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2460440 - Disclosure - Income Taxes - Reconciliation of Unrecognized Tax Benefits (Details)",
     "role": "http://www.ligand.com/role/IncomeTaxesReconciliationofUnrecognizedTaxBenefitsDetails",
     "shortName": "Income Taxes - Reconciliation of Unrecognized Tax Benefits (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForwardTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20211231.htm",
      "contextRef": "if1aac4d81ad94163b33117197afe0895_I20181231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20211231.htm",
      "contextRef": "id0ff3295defe46b8bccc6c795953b0dd_I20181231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005007 - Statement - CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY",
     "role": "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY",
     "shortName": "CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20211231.htm",
      "contextRef": "id0ff3295defe46b8bccc6c795953b0dd_I20181231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20211231.htm",
      "contextRef": "i8de36dd6935847019123fffb990b7008_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1006008 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "role": "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
     "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20211231.htm",
      "contextRef": "i8de36dd6935847019123fffb990b7008_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20211231.htm",
      "contextRef": "i8de36dd6935847019123fffb990b7008_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101101 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies",
     "role": "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies",
     "shortName": "Basis of Presentation and Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20211231.htm",
      "contextRef": "i8de36dd6935847019123fffb990b7008_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 137,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.ligand.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditorFirmId": {
     "auth_ref": [
      "r778",
      "r779",
      "r780"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PCAOB issued Audit Firm Identifier",
        "label": "Auditor Firm ID",
        "terseLabel": "Auditor Firm ID"
       }
      }
     },
     "localname": "AuditorFirmId",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.ligand.com/role/AuditInformation"
     ],
     "xbrltype": "nonemptySequenceNumberItemType"
    },
    "dei_AuditorLocation": {
     "auth_ref": [
      "r778",
      "r779",
      "r780"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location",
        "terseLabel": "Auditor Location"
       }
      }
     },
     "localname": "AuditorLocation",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.ligand.com/role/AuditInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_AuditorName": {
     "auth_ref": [
      "r778",
      "r779",
      "r780"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name",
        "terseLabel": "Auditor Name"
       }
      }
     },
     "localname": "AuditorName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.ligand.com/role/AuditInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.ligand.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.ligand.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r778",
      "r779",
      "r780"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report",
        "terseLabel": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.ligand.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.ligand.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.ligand.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.ligand.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r781"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.ligand.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.ligand.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r776"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]",
        "terseLabel": "Documents Incorporated by Reference"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.ligand.com/role/Cover"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.ligand.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.ligand.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.ligand.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.ligand.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r775"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.ligand.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.ligand.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.ligand.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r775"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.ligand.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.ligand.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r775"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.ligand.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.ligand.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r789"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.ligand.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float",
        "terseLabel": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.ligand.com/role/Cover"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r775"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.ligand.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r775"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.ligand.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r775"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.ligand.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r775"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.ligand.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers",
        "terseLabel": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.ligand.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r790"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer",
        "terseLabel": "Entity Well-Known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.ligand.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_IcfrAuditorAttestationFlag": {
     "auth_ref": [
      "r778",
      "r779",
      "r780"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag",
        "terseLabel": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "localname": "IcfrAuditorAttestationFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.ligand.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.ligand.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r774"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.ligand.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r777"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.ligand.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.ligand.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "lgnd_AbInitioMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ab Initio",
        "label": "Ab Initio [Member]",
        "terseLabel": "Ab Initio"
       }
      }
     },
     "localname": "AbInitioMember",
     "nsuri": "http://www.ligand.com/20211231",
     "presentation": [
      "http://www.ligand.com/role/AcquisitionsAllocationofConsiderationDetails",
      "http://www.ligand.com/role/AcquisitionsNarrativeDetails",
      "http://www.ligand.com/role/AcquisitionsTables"
     ],
     "xbrltype": "domainItemType"
    },
    "lgnd_AccountsReceivableCreditLossExpenseReversalCOVID19": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounts Receivable, Credit Loss Expense (Reversal), COVID-19",
        "label": "Accounts Receivable, Credit Loss Expense (Reversal), COVID-19",
        "negatedTerseLabel": "Additional reserve for credit losses due to COVID-19"
       }
      }
     },
     "localname": "AccountsReceivableCreditLossExpenseReversalCOVID19",
     "nsuri": "http://www.ligand.com/20211231",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lgnd_AccruedAssetAcquisitionsCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.ligand.com/role/BalanceSheetAccountDetailsAccruedLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Asset Acquisitions, Current",
        "label": "Accrued Asset Acquisitions, Current",
        "terseLabel": "Acquisition related liabilities"
       }
      }
     },
     "localname": "AccruedAssetAcquisitionsCurrent",
     "nsuri": "http://www.ligand.com/20211231",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lgnd_AccruedInventoryPurchases": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Inventory Purchases",
        "label": "Accrued Inventory Purchases",
        "terseLabel": "Accrued inventory purchases"
       }
      }
     },
     "localname": "AccruedInventoryPurchases",
     "nsuri": "http://www.ligand.com/20211231",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lgnd_AccruedSalesReturns": {
     "auth_ref": [],
     "calculation": {
      "http://www.ligand.com/role/BalanceSheetAccountDetailsAccruedLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Sales Returns",
        "label": "Accrued Sales Returns",
        "terseLabel": "Return reserve and customer refunds"
       }
      }
     },
     "localname": "AccruedSalesReturns",
     "nsuri": "http://www.ligand.com/20211231",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lgnd_AccruedSubcontractorExpensesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.ligand.com/role/BalanceSheetAccountDetailsAccruedLiabilitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Subcontractor Expenses, Current",
        "label": "Accrued Subcontractor Expenses, Current",
        "terseLabel": "Subcontractor"
       }
      }
     },
     "localname": "AccruedSubcontractorExpensesCurrent",
     "nsuri": "http://www.ligand.com/20211231",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lgnd_AccruedSupplierExpensesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.ligand.com/role/BalanceSheetAccountDetailsAccruedLiabilitiesDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Supplier Expenses, Current",
        "label": "Accrued Supplier Expenses, Current",
        "terseLabel": "Supplier"
       }
      }
     },
     "localname": "AccruedSupplierExpensesCurrent",
     "nsuri": "http://www.ligand.com/20211231",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lgnd_AdditionalRoyaltiesReceivableUnderSalesbasedMilestones": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional Royalties Receivable Under Sales-based Milestones",
        "label": "Additional Royalties Receivable Under Sales-based Milestones",
        "terseLabel": "Additional royalties receivable under sales-based milestones"
       }
      }
     },
     "localname": "AdditionalRoyaltiesReceivableUnderSalesbasedMilestones",
     "nsuri": "http://www.ligand.com/20211231",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lgnd_AdjustmentsToAdditionalPaidInCapitalWarrantAndBondHedgeUnwindTransactions": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adjustments to Additional Paid in Capital, Warrant and Bond Hedge Unwind Transactions",
        "label": "Adjustments to Additional Paid in Capital, Warrant and Bond Hedge Unwind Transactions",
        "terseLabel": "Warrant and bond hedge unwind transactions"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantAndBondHedgeUnwindTransactions",
     "nsuri": "http://www.ligand.com/20211231",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lgnd_AmendedESPPMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amended ESPP [Member]",
        "label": "Amended ESPP [Member]",
        "terseLabel": "Amended ESPP"
       }
      }
     },
     "localname": "AmendedESPPMember",
     "nsuri": "http://www.ligand.com/20211231",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lgnd_AmortizationOfCommercialLicenseAndOtherEconomicRights": {
     "auth_ref": [],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortization of Commercial License and Other Economic Rights",
        "label": "Amortization of Commercial License and Other Economic Rights",
        "terseLabel": "Amortization of commercial license and other economic rights"
       }
      }
     },
     "localname": "AmortizationOfCommercialLicenseAndOtherEconomicRights",
     "nsuri": "http://www.ligand.com/20211231",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lgnd_AssetsAndLiabilitiesLesseeTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Assets and Liabilities, Lessee",
        "label": "Assets and Liabilities, Lessee [Table Text Block]",
        "terseLabel": "Schedule of Operating and Finance Lease Assets and Liabilities"
       }
      }
     },
     "localname": "AssetsAndLiabilitiesLesseeTableTextBlock",
     "nsuri": "http://www.ligand.com/20211231",
     "presentation": [
      "http://www.ligand.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "lgnd_AuditInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Audit Information [Abstract]",
        "label": "Audit Information [Abstract]"
       }
      }
     },
     "localname": "AuditInformationAbstract",
     "nsuri": "http://www.ligand.com/20211231",
     "xbrltype": "stringItemType"
    },
    "lgnd_AziyoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aziyo [Member]",
        "label": "Aziyo [Member]",
        "terseLabel": "Aziyo"
       }
      }
     },
     "localname": "AziyoMember",
     "nsuri": "http://www.ligand.com/20211231",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lgnd_AziyoandCorMatrixMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aziyo and CorMatrix [Member]",
        "label": "Aziyo and CorMatrix [Member]",
        "terseLabel": "Aziyo and CorMatrix"
       }
      }
     },
     "localname": "AziyoandCorMatrixMember",
     "nsuri": "http://www.ligand.com/20211231",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCommercialLicenseRightsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lgnd_BasisOfPresentationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Basis of presentation.",
        "label": "Basis of Presentation [Line Items]",
        "terseLabel": "Basis of Presentation [Line Items]"
       }
      }
     },
     "localname": "BasisOfPresentationLineItems",
     "nsuri": "http://www.ligand.com/20211231",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "lgnd_BasisOfPresentationTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Basis of Presentation.",
        "label": "Basis of Presentation [Table]",
        "terseLabel": "Basis of Presentation [Table]"
       }
      }
     },
     "localname": "BasisOfPresentationTable",
     "nsuri": "http://www.ligand.com/20211231",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "lgnd_BusinessAcquisitionContingentConsiderationPotentialCashPaymentAdditions": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Acquisition Contingent Consideration Potential Cash Payment Additions",
        "label": "Business Acquisition Contingent Consideration Potential Cash Payment Additions",
        "terseLabel": "Additional Contingent Liabilities"
       }
      }
     },
     "localname": "BusinessAcquisitionContingentConsiderationPotentialCashPaymentAdditions",
     "nsuri": "http://www.ligand.com/20211231",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsContingentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lgnd_BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Acquisition Contingent Consideration Potential Cash Payment at End of Period",
        "label": "Business Acquisition Contingent Consideration Potential Cash Payment at End of Period",
        "periodEndLabel": "Commercial rights at end of period",
        "periodStartLabel": "Commercial rights at beginning of period"
       }
      }
     },
     "localname": "BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod",
     "nsuri": "http://www.ligand.com/20211231",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsContingentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lgnd_BusinessCombinationAssumptionsUsedEstimatedFutureCashFlowsDiscountRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Assumptions Used Estimated Future Cash Flows, Discount Rate",
        "label": "Business Combination, Assumptions Used Estimated Future Cash Flows, Discount Rate",
        "terseLabel": "Projected cash flow discount rate (as a percent)"
       }
      }
     },
     "localname": "BusinessCombinationAssumptionsUsedEstimatedFutureCashFlowsDiscountRate",
     "nsuri": "http://www.ligand.com/20211231",
     "presentation": [
      "http://www.ligand.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "lgnd_BusinessCombinationCashHoldbackForPotentialIndemnificationClaims": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Cash Holdback for Potential Indemnification Claims",
        "label": "Business Combination, Cash Holdback for Potential Indemnification Claims",
        "terseLabel": "Cash holdback for potential indemnification claims"
       }
      }
     },
     "localname": "BusinessCombinationCashHoldbackForPotentialIndemnificationClaims",
     "nsuri": "http://www.ligand.com/20211231",
     "presentation": [
      "http://www.ligand.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lgnd_BusinessCombinationConsiderationTransferredHoldback": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Consideration Transferred, Holdback",
        "label": "Business Combination, Consideration Transferred, Holdback",
        "terseLabel": "Holdback from acquisition"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferredHoldback",
     "nsuri": "http://www.ligand.com/20211231",
     "presentation": [
      "http://www.ligand.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lgnd_BusinessCombinationContingentConsiderationLiabilityAmountPerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Contingent Consideration, Liability, Amount per Share",
        "label": "Business Combination, Contingent Consideration, Liability, Amount per Share",
        "terseLabel": "Contingent consideration liability per share (USD per share)"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiabilityAmountPerShare",
     "nsuri": "http://www.ligand.com/20211231",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "lgnd_BusinessCombinationContingentConsiderationLiabilityFairValueDisclosure": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Contingent Consideration, Liability, Fair Value Disclosure",
        "label": "Business Combination, Contingent Consideration, Liability, Fair Value Disclosure",
        "terseLabel": "Fair value of contingent earn-out payment"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiabilityFairValueDisclosure",
     "nsuri": "http://www.ligand.com/20211231",
     "presentation": [
      "http://www.ligand.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lgnd_BusinessCombinationContingentConsiderationLiabilityPercentageOfAcquireeRevenues": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Contingent Consideration, Liability, Percentage of Acquiree Revenues",
        "label": "Business Combination, Contingent Consideration, Liability, Percentage of Acquiree Revenues",
        "terseLabel": "Proportion of milestone payments (as a percent)"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiabilityPercentageOfAcquireeRevenues",
     "nsuri": "http://www.ligand.com/20211231",
     "presentation": [
      "http://www.ligand.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilitiesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.ligand.com/role/AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 13.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Accrued Liabilities, Current",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Accrued Liabilities, Current",
        "negatedLabel": "Accrued liabilities",
        "negatedTerseLabel": "Accrued liabilities"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilitiesCurrent",
     "nsuri": "http://www.ligand.com/20211231",
     "presentation": [
      "http://www.ligand.com/role/AcquisitionsAllocationofConsiderationDetails",
      "http://www.ligand.com/role/AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndCurrentAssetsOther": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Current Assets, Other",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Current Assets, Other",
        "terseLabel": "Cash and other assets"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndCurrentAssetsOther",
     "nsuri": "http://www.ligand.com/20211231",
     "presentation": [
      "http://www.ligand.com/role/AcquisitionsAllocationofConsiderationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.ligand.com/role/AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets",
        "terseLabel": "Intangibles acquired",
        "verboseLabel": "Acquired intangibles"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssets",
     "nsuri": "http://www.ligand.com/20211231",
     "presentation": [
      "http://www.ligand.com/role/AcquisitionsAllocationofConsiderationDetails",
      "http://www.ligand.com/role/AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsDiscountRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Discount Rate",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Discount Rate",
        "terseLabel": "Discount rate used to value intangible assets acquired (as a percent)"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsDiscountRate",
     "nsuri": "http://www.ligand.com/20211231",
     "presentation": [
      "http://www.ligand.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLeaseLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.ligand.com/role/AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Lease Liabilities",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Lease Liabilities",
        "negatedTerseLabel": "Lease liabilities"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLeaseLiabilities",
     "nsuri": "http://www.ligand.com/20211231",
     "presentation": [
      "http://www.ligand.com/role/AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash": {
     "auth_ref": [],
     "calculation": {
      "http://www.ligand.com/role/AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Restricted Cash",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Restricted Cash",
        "terseLabel": "Restricted cash"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash",
     "nsuri": "http://www.ligand.com/20211231",
     "presentation": [
      "http://www.ligand.com/role/AcquisitionsAllocationofConsiderationDetails",
      "http://www.ligand.com/role/AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.ligand.com/role/AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Right-of-Use Assets",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Right-of-Use Assets",
        "terseLabel": "Right-of-use asset"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssets",
     "nsuri": "http://www.ligand.com/20211231",
     "presentation": [
      "http://www.ligand.com/role/AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lgnd_CaliforniaAndNewJerseyResearchTaxCreditCarryforwardMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "California and New Jersey Research Tax Credit Carryforward [Member]",
        "label": "California and New Jersey Research Tax Credit Carryforward [Member]",
        "terseLabel": "California and New Jersey Research Tax Credit Carryforward"
       }
      }
     },
     "localname": "CaliforniaAndNewJerseyResearchTaxCreditCarryforwardMember",
     "nsuri": "http://www.ligand.com/20211231",
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lgnd_CashCashEquivalentsandShorttermInvestmentsPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash, Cash Equivalents, and Short-term Investments [Policy Text Block]",
        "label": "Cash, Cash Equivalents, and Short-term Investments [Policy Text Block]",
        "verboseLabel": "Cash Equivalents &amp; Short-term Investments"
       }
      }
     },
     "localname": "CashCashEquivalentsandShorttermInvestmentsPolicyTextBlock",
     "nsuri": "http://www.ligand.com/20211231",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "lgnd_CashPaidDuringTheYearAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash Paid During the Year",
        "label": "Cash Paid During the Year [Abstract]",
        "terseLabel": "Cash paid during the year:"
       }
      }
     },
     "localname": "CashPaidDuringTheYearAbstract",
     "nsuri": "http://www.ligand.com/20211231",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "lgnd_CommercialLicenseRights": {
     "auth_ref": [],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commercial License Rights",
        "label": "Commercial License Rights",
        "terseLabel": "Commercial license and other economic rights"
       }
      }
     },
     "localname": "CommercialLicenseRights",
     "nsuri": "http://www.ligand.com/20211231",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lgnd_CommercialLicenseRightsPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commercial License Rights [Policy Text Block]",
        "label": "Commercial License Rights [Policy Text Block]",
        "terseLabel": "Commercial license and other economic rights"
       }
      }
     },
     "localname": "CommercialLicenseRightsPolicyTextBlock",
     "nsuri": "http://www.ligand.com/20211231",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "lgnd_ComputerEquipmentAndSoftwareMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Computer equipment and software.",
        "label": "Computer Equipment And Software [Member]",
        "verboseLabel": "Computer equipment and software"
       }
      }
     },
     "localname": "ComputerEquipmentAndSoftwareMember",
     "nsuri": "http://www.ligand.com/20211231",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lgnd_ContingentLiabilityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contingent Liability [Roll Forward]",
        "label": "Contingent Liability [Roll Forward]",
        "terseLabel": "Contingent Liability [Roll Forward]"
       }
      }
     },
     "localname": "ContingentLiabilityRollForward",
     "nsuri": "http://www.ligand.com/20211231",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsContingentLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "lgnd_ContingentValueRightForInternalResearchAndDevelopmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contingent Value Right for Internal Research and Development",
        "label": "Contingent Value Right for Internal Research and Development [Member]",
        "terseLabel": "Contingent Value Right for Internal Research and Development"
       }
      }
     },
     "localname": "ContingentValueRightForInternalResearchAndDevelopmentMember",
     "nsuri": "http://www.ligand.com/20211231",
     "presentation": [
      "http://www.ligand.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lgnd_ContingentValueRightOnProductRevenuesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contingent Value Right on Product Revenues",
        "label": "Contingent Value Right on Product Revenues [Member]",
        "terseLabel": "Contingent Value Right on Product Revenues"
       }
      }
     },
     "localname": "ContingentValueRightOnProductRevenuesMember",
     "nsuri": "http://www.ligand.com/20211231",
     "presentation": [
      "http://www.ligand.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lgnd_ContractRevenueMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract Revenue",
        "label": "Contract Revenue [Member]",
        "terseLabel": "Contract revenue"
       }
      }
     },
     "localname": "ContractRevenueMember",
     "nsuri": "http://www.ligand.com/20211231",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRoyaltyRevenueDetails",
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "domainItemType"
    },
    "lgnd_ContractualRelationshipsAlvogenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual Relationships - Alvogen",
        "label": "Contractual Relationships - Alvogen [Member]",
        "terseLabel": "Contractual Relationships - Alvogen"
       }
      }
     },
     "localname": "ContractualRelationshipsAlvogenMember",
     "nsuri": "http://www.ligand.com/20211231",
     "presentation": [
      "http://www.ligand.com/role/AcquisitionsIntangiblesAcquiredandWeightedAverageUsefulLifeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lgnd_ContractualRelationshipsArcellxMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual Relationships - Arcellx",
        "label": "Contractual Relationships - Arcellx [Member]",
        "terseLabel": "Contractual Relationships - Arcellx"
       }
      }
     },
     "localname": "ContractualRelationshipsArcellxMember",
     "nsuri": "http://www.ligand.com/20211231",
     "presentation": [
      "http://www.ligand.com/role/AcquisitionsIntangiblesAcquiredandWeightedAverageUsefulLifeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lgnd_ContractualRelationshipsJazzMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual Relationships - Jazz",
        "label": "Contractual Relationships - Jazz [Member]",
        "terseLabel": "Contractual Relationships - Jazz"
       }
      }
     },
     "localname": "ContractualRelationshipsJazzMember",
     "nsuri": "http://www.ligand.com/20211231",
     "presentation": [
      "http://www.ligand.com/role/AcquisitionsIntangiblesAcquiredandWeightedAverageUsefulLifeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lgnd_ContractualRelationshipsMerckMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual Relationships - Merck",
        "label": "Contractual Relationships - Merck [Member]",
        "terseLabel": "Contractual Relationships - Merck"
       }
      }
     },
     "localname": "ContractualRelationshipsMerckMember",
     "nsuri": "http://www.ligand.com/20211231",
     "presentation": [
      "http://www.ligand.com/role/AcquisitionsIntangiblesAcquiredandWeightedAverageUsefulLifeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lgnd_ContractualRelationshipsSIIMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual Relationships - SII",
        "label": "Contractual Relationships - SII [Member]",
        "terseLabel": "Contractual Relationships - SII"
       }
      }
     },
     "localname": "ContractualRelationshipsSIIMember",
     "nsuri": "http://www.ligand.com/20211231",
     "presentation": [
      "http://www.ligand.com/role/AcquisitionsIntangiblesAcquiredandWeightedAverageUsefulLifeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lgnd_ConvertibleSeniorNotesDue2019Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Convertible Senior Notes due 2019 [Member]",
        "label": "Convertible Senior Notes due 2019 [Member]",
        "terseLabel": "2019 Convertible Senior Notes"
       }
      }
     },
     "localname": "ConvertibleSeniorNotesDue2019Member",
     "nsuri": "http://www.ligand.com/20211231",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.ligand.com/role/ConvertibleSeniorNotesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lgnd_ConvertibleSeniorNotesDue2023Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Convertible Senior Notes due 2023",
        "label": "Convertible Senior Notes due 2023 [Member]",
        "terseLabel": "2023 Convertible Senior Notes"
       }
      }
     },
     "localname": "ConvertibleSeniorNotesDue2023Member",
     "nsuri": "http://www.ligand.com/20211231",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.ligand.com/role/ConvertibleSeniorNotesEquityandLiabilityComponentsofFinancingArrangementsDetails",
      "http://www.ligand.com/role/ConvertibleSeniorNotesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lgnd_CorMatrixMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "CorMatrix [Member]",
        "label": "CorMatrix [Member]",
        "terseLabel": "CorMatrix"
       }
      }
     },
     "localname": "CorMatrixMember",
     "nsuri": "http://www.ligand.com/20211231",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lgnd_CorporateShareRepurchaseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Corporate Share Repurchase [Abstract]",
        "label": "Corporate Share Repurchase [Abstract]",
        "terseLabel": "Corporate Share Repurchase"
       }
      }
     },
     "localname": "CorporateShareRepurchaseAbstract",
     "nsuri": "http://www.ligand.com/20211231",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "lgnd_CrystalMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Crystal [Member]",
        "label": "Crystal [Member]",
        "terseLabel": "Crystal"
       }
      }
     },
     "localname": "CrystalMember",
     "nsuri": "http://www.ligand.com/20211231",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsContingentLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lgnd_CurrentPortionOfLiabilityForContingentValueRights": {
     "auth_ref": [],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Current portion of liability for contingent value rights.",
        "label": "Current Portion of Liability for Contingent Value Rights",
        "terseLabel": "Current contingent liabilities"
       }
      }
     },
     "localname": "CurrentPortionOfLiabilityForContingentValueRights",
     "nsuri": "http://www.ligand.com/20211231",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lgnd_CydexPharmaceuticalsIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cydex Pharmaceuticals, Inc.",
        "label": "Cydex Pharmaceuticals, Inc [Member]",
        "verboseLabel": "Cydex"
       }
      }
     },
     "localname": "CydexPharmaceuticalsIncMember",
     "nsuri": "http://www.ligand.com/20211231",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsContingentLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lgnd_DebtInstrumentConvertibleIncreaseDecreaseIfConvertedValueInExcessOfPrincipal": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Convertible, Increase (Decrease) If-Converted Value in Excess of Principal",
        "label": "Debt Instrument, Convertible, Increase (Decrease) If-Converted Value in Excess of Principal",
        "terseLabel": "Increase (decrease) in if-converted value in excess of principal"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleIncreaseDecreaseIfConvertedValueInExcessOfPrincipal",
     "nsuri": "http://www.ligand.com/20211231",
     "presentation": [
      "http://www.ligand.com/role/ConvertibleSeniorNotesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lgnd_DebtInstrumentConvertibleMaximumThresholdPercentageofDebtTradingPriceTrigger": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Convertible, Maximum Threshold Percentage of Debt Trading Price Trigger",
        "label": "Debt Instrument, Convertible, Maximum Threshold Percentage of Debt Trading Price Trigger",
        "terseLabel": "Maximum threshold of debt trading price trigger (as a percent)"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleMaximumThresholdPercentageofDebtTradingPriceTrigger",
     "nsuri": "http://www.ligand.com/20211231",
     "presentation": [
      "http://www.ligand.com/role/ConvertibleSeniorNotesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "lgnd_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateAfterYearFive": {
     "auth_ref": [],
     "calculation": {
      "http://www.ligand.com/role/BalanceSheetAccountDetailsAvailableforSaleDebtSecuritiesbyContractualMaturityDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_HeldToMaturitySecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year Five",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year Five",
        "terseLabel": "After five years"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateAfterYearFive",
     "nsuri": "http://www.ligand.com/20211231",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsAvailableforSaleDebtSecuritiesbyContractualMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lgnd_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearFive": {
     "auth_ref": [],
     "calculation": {
      "http://www.ligand.com/role/BalanceSheetAccountDetailsAvailableforSaleDebtSecuritiesbyContractualMaturityDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year Five",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year Five",
        "terseLabel": "After five years"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearFive",
     "nsuri": "http://www.ligand.com/20211231",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsAvailableforSaleDebtSecuritiesbyContractualMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lgnd_DeferredTaxLiabilitiesFiniteLivedIntangibleAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.ligand.com/role/IncomeTaxesDeferredTaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Liabilities, Finite-Lived Intangible Assets",
        "label": "Deferred Tax Liabilities, Finite-Lived Intangible Assets",
        "negatedTerseLabel": "Identified intangibles"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesFiniteLivedIntangibleAssets",
     "nsuri": "http://www.ligand.com/20211231",
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesDeferredTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lgnd_DevelopmentRegulatoryCommercialMilestonesAndTieredRoyaltiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Development, Regulatory, &amp; Commercial Milestones and Tiered Royalties",
        "label": "Development, Regulatory, &amp; Commercial Milestones and Tiered Royalties [Member]",
        "terseLabel": "Development, Regulatory, &amp; Commercial Milestones and Tiered Royalties"
       }
      }
     },
     "localname": "DevelopmentRegulatoryCommercialMilestonesAndTieredRoyaltiesMember",
     "nsuri": "http://www.ligand.com/20211231",
     "presentation": [
      "http://www.ligand.com/role/FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lgnd_EarnoutRightsForPartnerResearchAndDevelopmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Earnout Rights for Partner Research and Development",
        "label": "Earnout Rights for Partner Research and Development [Member]",
        "terseLabel": "Earnout Rights for Partner Research and Development"
       }
      }
     },
     "localname": "EarnoutRightsForPartnerResearchAndDevelopmentMember",
     "nsuri": "http://www.ligand.com/20211231",
     "presentation": [
      "http://www.ligand.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lgnd_EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions": {
     "auth_ref": [],
     "calculation": {
      "http://www.ligand.com/role/IncomeTaxesReconciliationofIncomeTaxExpenseBenefitDetails": {
       "order": 10.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective Income Tax Rate Reconciliation, Change in Uncertain Tax Positions",
        "label": "Effective Income Tax Rate Reconciliation, Change in Uncertain Tax Positions",
        "negatedTerseLabel": "Change in uncertain tax positions"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions",
     "nsuri": "http://www.ligand.com/20211231",
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesReconciliationofIncomeTaxExpenseBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lgnd_EffectiveIncomeTaxRateReconciliationExpiredTaxCreditsResearch": {
     "auth_ref": [],
     "calculation": {
      "http://www.ligand.com/role/IncomeTaxesReconciliationofIncomeTaxExpenseBenefitDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective Income Tax Rate Reconciliation, Expired Tax Credits, Research",
        "label": "Effective Income Tax Rate Reconciliation, Expired Tax Credits, Research",
        "terseLabel": "Research and development credits"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationExpiredTaxCreditsResearch",
     "nsuri": "http://www.ligand.com/20211231",
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesReconciliationofIncomeTaxExpenseBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lgnd_EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomeAmount": {
     "auth_ref": [],
     "calculation": {
      "http://www.ligand.com/role/IncomeTaxesReconciliationofIncomeTaxExpenseBenefitDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective Income Tax Rate Reconciliation, Foreign Derived Intangible Income, Amount",
        "label": "Effective Income Tax Rate Reconciliation, Foreign Derived Intangible Income, Amount",
        "negatedLabel": "FDII"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomeAmount",
     "nsuri": "http://www.ligand.com/20211231",
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesReconciliationofIncomeTaxExpenseBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lgnd_EffectiveIncomeTaxRateReconciliationProvisionToReturnAdjustmentsAmount": {
     "auth_ref": [],
     "calculation": {
      "http://www.ligand.com/role/IncomeTaxesReconciliationofIncomeTaxExpenseBenefitDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective Income Tax Rate Reconciliation, Provision to Return Adjustments, Amount",
        "label": "Effective Income Tax Rate Reconciliation, Provision to Return Adjustments, Amount",
        "negatedTerseLabel": "Provision to return adjustments"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationProvisionToReturnAdjustmentsAmount",
     "nsuri": "http://www.ligand.com/20211231",
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesReconciliationofIncomeTaxExpenseBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lgnd_EmployeeStockPurchasePlanAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee Stock Purchase Plan [Abstract]",
        "label": "Employee Stock Purchase Plan [Abstract]",
        "terseLabel": "Employee Stock Purchase Plan"
       }
      }
     },
     "localname": "EmployeeStockPurchasePlanAbstract",
     "nsuri": "http://www.ligand.com/20211231",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "lgnd_ExercisePriceRangeEightMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise Price Range Eight [Member]",
        "label": "Exercise Price Range Eight [Member]",
        "terseLabel": "$119.08-$159.01"
       }
      }
     },
     "localname": "ExercisePriceRangeEightMember",
     "nsuri": "http://www.ligand.com/20211231",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityBreakdownofOptionsOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lgnd_ExercisePriceRangeElevenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise Price Range Eleven [Member]",
        "label": "Exercise Price Range Eleven [Member]",
        "terseLabel": "$12.53 \u2013 $195.91"
       }
      }
     },
     "localname": "ExercisePriceRangeElevenMember",
     "nsuri": "http://www.ligand.com/20211231",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityBreakdownofOptionsOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lgnd_ExercisePriceRangeFiveMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise Price Range Five [Member]",
        "label": "Exercise Price Range Five [Member]",
        "terseLabel": "$98.20-$100.38"
       }
      }
     },
     "localname": "ExercisePriceRangeFiveMember",
     "nsuri": "http://www.ligand.com/20211231",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityBreakdownofOptionsOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lgnd_ExercisePriceRangeFourMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise Price Range Four [Member]",
        "label": "Exercise Price Range Four [Member]",
        "terseLabel": "$95.68"
       }
      }
     },
     "localname": "ExercisePriceRangeFourMember",
     "nsuri": "http://www.ligand.com/20211231",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityBreakdownofOptionsOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lgnd_ExercisePriceRangeNineMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise Price Range Nine [Member]",
        "label": "Exercise Price Range Nine [Member]",
        "terseLabel": "$159.81-$171.28"
       }
      }
     },
     "localname": "ExercisePriceRangeNineMember",
     "nsuri": "http://www.ligand.com/20211231",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityBreakdownofOptionsOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lgnd_ExercisePriceRangeOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise Price Range One [Member]",
        "label": "Exercise Price Range One [Member]",
        "terseLabel": "$12.53-$56.26"
       }
      }
     },
     "localname": "ExercisePriceRangeOneMember",
     "nsuri": "http://www.ligand.com/20211231",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityBreakdownofOptionsOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lgnd_ExercisePriceRangeSevenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise Price Range Seven [Member]",
        "label": "Exercise Price Range Seven [Member]",
        "terseLabel": "117.97"
       }
      }
     },
     "localname": "ExercisePriceRangeSevenMember",
     "nsuri": "http://www.ligand.com/20211231",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityBreakdownofOptionsOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lgnd_ExercisePriceRangeSixMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise Price Range Six [Member]",
        "label": "Exercise Price Range Six [Member]",
        "terseLabel": "$101.07-$117.58"
       }
      }
     },
     "localname": "ExercisePriceRangeSixMember",
     "nsuri": "http://www.ligand.com/20211231",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityBreakdownofOptionsOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lgnd_ExercisePriceRangeTenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise Price Range Ten [Member]",
        "label": "Exercise Price Range Ten [Member]",
        "terseLabel": "$177.50-$195.91"
       }
      }
     },
     "localname": "ExercisePriceRangeTenMember",
     "nsuri": "http://www.ligand.com/20211231",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityBreakdownofOptionsOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lgnd_ExercisePriceRangeThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise Price Range Three [Member]",
        "label": "Exercise Price Range Three [Member]",
        "terseLabel": "$82.90-$95.35"
       }
      }
     },
     "localname": "ExercisePriceRangeThreeMember",
     "nsuri": "http://www.ligand.com/20211231",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityBreakdownofOptionsOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lgnd_ExercisePriceRangeTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise Price Range Two [Member]",
        "label": "Exercise Price Range Two [Member]",
        "terseLabel": "$67.53-$74.42"
       }
      }
     },
     "localname": "ExercisePriceRangeTwoMember",
     "nsuri": "http://www.ligand.com/20211231",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityBreakdownofOptionsOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lgnd_ExercisePriceofConvertibleBondHedge": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise Price of Convertible Bond Hedge",
        "label": "Exercise Price of Convertible Bond Hedge",
        "terseLabel": "Exercise price of convertible bond hedge (USD per share)"
       }
      }
     },
     "localname": "ExercisePriceofConvertibleBondHedge",
     "nsuri": "http://www.ligand.com/20211231",
     "presentation": [
      "http://www.ligand.com/role/ConvertibleSeniorNotesNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "lgnd_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityContingentConsiderationFromAcquisition": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Contingent Consideration from Acquisition",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Contingent Consideration from Acquisition",
        "terseLabel": "Contingent liabilities from xCella asset acquisition"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityContingentConsiderationFromAcquisition",
     "nsuri": "http://www.ligand.com/20211231",
     "presentation": [
      "http://www.ligand.com/role/FairValueMeasurementReconciliationofLevel3FinancialInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lgnd_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityRepurchasesContingentLiabilities": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Repurchases, Contingent Liabilities",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Repurchases, Contingent Liabilities",
        "negatedTerseLabel": "Repurchases"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityRepurchasesContingentLiabilities",
     "nsuri": "http://www.ligand.com/20211231",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsContingentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lgnd_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Fair Value Adjustment, Contingent Liabilities",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Fair Value Adjustment, Contingent Liabilities",
        "verboseLabel": "Fair Value Adjustment"
       }
      }
     },
     "localname": "FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities",
     "nsuri": "http://www.ligand.com/20211231",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsContingentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lgnd_FinanceLeaseLiabilityTenantImprovementAllowance": {
     "auth_ref": [],
     "calculation": {
      "http://www.ligand.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Finance Lease, Liability, Tenant Improvement Allowance",
        "label": "Finance Lease, Liability, Tenant Improvement Allowance",
        "negatedTerseLabel": "Less tenant improvement allowance"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityTenantImprovementAllowance",
     "nsuri": "http://www.ligand.com/20211231",
     "presentation": [
      "http://www.ligand.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lgnd_FiniteLivedIntangibleAssetsAccumulatedAmortizationResearchDevelopmentExpenseAndCreditLossAdjustments": {
     "auth_ref": [],
     "calculation": {
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCommercialLicenseRightsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Finite-Lived Intangible Assets, Accumulated Amortization, Research &amp; Development Expense, and Credit Loss Adjustments",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization, Research &amp; Development Expense, and Credit Loss Adjustments",
        "negatedLabel": "Adjustments"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortizationResearchDevelopmentExpenseAndCreditLossAdjustments",
     "nsuri": "http://www.ligand.com/20211231",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCommercialLicenseRightsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lgnd_FiniteLivedIntangibleAssetsCreditLossAdjustments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Finite-lived Intangible Assets, Credit Loss Adjustments",
        "label": "Finite-lived Intangible Assets, Credit Loss Adjustments",
        "terseLabel": "Credit loss adjustments on finite-lived intangible assets"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsCreditLossAdjustments",
     "nsuri": "http://www.ligand.com/20211231",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCommercialLicenseRightsDetails",
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lgnd_ForecastedCashFlowsEffectiveInterestRatePercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Forecasted Cash Flows, Effective Interest Rate, Percent",
        "label": "Forecasted Cash Flows, Effective Interest Rate, Percent",
        "terseLabel": "Effective interest rate of forecasted cash flows (as a percent)"
       }
      }
     },
     "localname": "ForecastedCashFlowsEffectiveInterestRatePercent",
     "nsuri": "http://www.ligand.com/20211231",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "lgnd_GainLossOnShortTermInvestments": {
     "auth_ref": [],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gain (Loss) on Short-Term Investments",
        "label": "Gain (Loss) on Short-Term Investments",
        "negatedTerseLabel": "Loss (gain) short-term investments"
       }
      }
     },
     "localname": "GainLossOnShortTermInvestments",
     "nsuri": "http://www.ligand.com/20211231",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lgnd_IcagenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Icagen",
        "label": "Icagen [Member]",
        "terseLabel": "Icagen"
       }
      }
     },
     "localname": "IcagenMember",
     "nsuri": "http://www.ligand.com/20211231",
     "presentation": [
      "http://www.ligand.com/role/AcquisitionsAllocationofConsiderationDetails",
      "http://www.ligand.com/role/AcquisitionsNarrativeDetails",
      "http://www.ligand.com/role/AcquisitionsTables",
      "http://www.ligand.com/role/BalanceSheetAccountDetailsContingentLiabilitiesDetails",
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lgnd_IncomeTaxReconciliationContingentValueRights": {
     "auth_ref": [],
     "calculation": {
      "http://www.ligand.com/role/IncomeTaxesReconciliationofIncomeTaxExpenseBenefitDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income Tax Reconciliation, Contingent Value Rights",
        "label": "Income Tax Reconciliation, Contingent Value Rights",
        "terseLabel": "Contingent liabilities"
       }
      }
     },
     "localname": "IncomeTaxReconciliationContingentValueRights",
     "nsuri": "http://www.ligand.com/20211231",
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesReconciliationofIncomeTaxExpenseBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lgnd_IncreaseDecreaseInDebtDiscount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) in Debt Discount",
        "label": "Increase (Decrease) in Debt Discount",
        "negatedTerseLabel": "Reduction in debt discount"
       }
      }
     },
     "localname": "IncreaseDecreaseInDebtDiscount",
     "nsuri": "http://www.ligand.com/20211231",
     "presentation": [
      "http://www.ligand.com/role/ConvertibleSeniorNotesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lgnd_IncreaseDecreaseInOtherEconomicRights": {
     "auth_ref": [],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 17.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) in Other Economic Rights",
        "label": "Increase (Decrease) in Other Economic Rights",
        "terseLabel": "Other economic rights"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherEconomicRights",
     "nsuri": "http://www.ligand.com/20211231",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lgnd_InvestmentInVikingCurrent": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investment in Viking, Current",
        "label": "Investment in Viking, Current",
        "verboseLabel": "Value of warrants in Viking"
       }
      }
     },
     "localname": "InvestmentInVikingCurrent",
     "nsuri": "http://www.ligand.com/20211231",
     "presentation": [
      "http://www.ligand.com/role/ShorttermInvestmentsInvestmentinVikingNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lgnd_LeaseLiability": {
     "auth_ref": [],
     "calculation": {
      "http://www.ligand.com/role/LeasesOperatingandFinanceLeaseAssetsandLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease, Liability",
        "label": "Lease, Liability",
        "totalLabel": "Total lease liabilities"
       }
      }
     },
     "localname": "LeaseLiability",
     "nsuri": "http://www.ligand.com/20211231",
     "presentation": [
      "http://www.ligand.com/role/LeasesOperatingandFinanceLeaseAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lgnd_LeaseLiabilityCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.ligand.com/role/LeasesOperatingandFinanceLeaseAssetsandLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "lgnd_LeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease, Liability, Current",
        "label": "Lease, Liability, Current",
        "totalLabel": "Current lease liabilities"
       }
      }
     },
     "localname": "LeaseLiabilityCurrent",
     "nsuri": "http://www.ligand.com/20211231",
     "presentation": [
      "http://www.ligand.com/role/LeasesOperatingandFinanceLeaseAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lgnd_LeaseRightOfUseAsset": {
     "auth_ref": [],
     "calculation": {
      "http://www.ligand.com/role/LeasesOperatingandFinanceLeaseAssetsandLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease, Right-of-Use Asset",
        "label": "Lease, Right-of-Use Asset",
        "totalLabel": "Total lease assets"
       }
      }
     },
     "localname": "LeaseRightOfUseAsset",
     "nsuri": "http://www.ligand.com/20211231",
     "presentation": [
      "http://www.ligand.com/role/LeasesOperatingandFinanceLeaseAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lgnd_LesseeOperatingLeaseLiabilityTenantImprovementAllowance": {
     "auth_ref": [],
     "calculation": {
      "http://www.ligand.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Liability, Tenant Improvement Allowance",
        "label": "Lessee, Operating Lease, Liability, Tenant Improvement Allowance",
        "negatedTerseLabel": "Less tenant improvement allowance"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityTenantImprovementAllowance",
     "nsuri": "http://www.ligand.com/20211231",
     "presentation": [
      "http://www.ligand.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lgnd_LiabilityForContingentValueRights": {
     "auth_ref": [],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Liability for contingent value rights.",
        "label": "Liability for Contingent Value Rights",
        "verboseLabel": "Long-term contingent liabilities"
       }
      }
     },
     "localname": "LiabilityForContingentValueRights",
     "nsuri": "http://www.ligand.com/20211231",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lgnd_LiabilityForContingentValueRightsCompanyCrystalMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Liability For Contingent Value Rights Company, Crystal [Member]",
        "label": "Liability For Contingent Value Rights Company, Crystal [Member]",
        "terseLabel": "Contingent liabilities - Crystal"
       }
      }
     },
     "localname": "LiabilityForContingentValueRightsCompanyCrystalMember",
     "nsuri": "http://www.ligand.com/20211231",
     "presentation": [
      "http://www.ligand.com/role/FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lgnd_LiabilityForContingentValueRightsCompanyCydexMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Liability For Contingent Value Rights Company, Cydex",
        "label": "Liability For Contingent Value Rights Company, Cydex [Member]",
        "verboseLabel": "Contingent liabilities - CyDex"
       }
      }
     },
     "localname": "LiabilityForContingentValueRightsCompanyCydexMember",
     "nsuri": "http://www.ligand.com/20211231",
     "presentation": [
      "http://www.ligand.com/role/FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lgnd_LiabilityForContingentValueRightsCompanyIcagenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Liability For Contingent Value Rights Company, Icagen",
        "label": "Liability For Contingent Value Rights Company, Icagen [Member]",
        "terseLabel": "Contingent liabilities - Icagen"
       }
      }
     },
     "localname": "LiabilityForContingentValueRightsCompanyIcagenMember",
     "nsuri": "http://www.ligand.com/20211231",
     "presentation": [
      "http://www.ligand.com/role/FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lgnd_LiabilityForContingentValueRightsCompanyMetabasisMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Liability For Contingent Value Rights Company, Metabasis",
        "label": "Liability For Contingent Value Rights Company, Metabasis [Member]",
        "terseLabel": "Contingent liabilities - Metabasis"
       }
      }
     },
     "localname": "LiabilityForContingentValueRightsCompanyMetabasisMember",
     "nsuri": "http://www.ligand.com/20211231",
     "presentation": [
      "http://www.ligand.com/role/FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lgnd_LiabilityForContingentValueRightsCompanyPfenexMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Liability For Contingent Value Rights Company, Pfenex",
        "label": "Liability For Contingent Value Rights Company, Pfenex [Member]",
        "terseLabel": "Contingent liabilities - Pfenex"
       }
      }
     },
     "localname": "LiabilityForContingentValueRightsCompanyPfenexMember",
     "nsuri": "http://www.ligand.com/20211231",
     "presentation": [
      "http://www.ligand.com/role/FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lgnd_LiabilityForRestrictedInvestmentsOwedToFormerLicenseesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Liability for Restricted Investments Owed to Former Licensees [Member]",
        "label": "Liability for Restricted Investments Owed to Former Licensees [Member]",
        "terseLabel": "Liability for restricted investments owed to former licensees"
       }
      }
     },
     "localname": "LiabilityForRestrictedInvestmentsOwedToFormerLicenseesMember",
     "nsuri": "http://www.ligand.com/20211231",
     "presentation": [
      "http://www.ligand.com/role/FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lgnd_LicenseFeesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License Fees",
        "label": "License Fees [Member]",
        "terseLabel": "License Fees"
       }
      }
     },
     "localname": "LicenseFeesMember",
     "nsuri": "http://www.ligand.com/20211231",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRoyaltyRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lgnd_LicenseFeesMilestonesAndOtherProductOtherMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License Fees, Milestones, and Other Product, Other",
        "label": "License Fees, Milestones, and Other Product, Other [Member]",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "LicenseFeesMilestonesAndOtherProductOtherMember",
     "nsuri": "http://www.ligand.com/20211231",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRoyaltyRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lgnd_LicenseUpfrontPayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License Upfront Payment",
        "label": "License Upfront Payment",
        "terseLabel": "Upfront payment for license"
       }
      }
     },
     "localname": "LicenseUpfrontPayment",
     "nsuri": "http://www.ligand.com/20211231",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lgnd_LupinPatentInfringementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lupin Patent Infringement",
        "label": "Lupin Patent Infringement [Member]",
        "terseLabel": "Lupin Patent Infringement"
       }
      }
     },
     "localname": "LupinPatentInfringementMember",
     "nsuri": "http://www.ligand.com/20211231",
     "presentation": [
      "http://www.ligand.com/role/CommitmentandContingenciesLegalProceedingsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lgnd_MaterialSalesCaptisolMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Material Sales, Captisol [Member]",
        "label": "Material Sales, Captisol [Member]",
        "terseLabel": "Captisol"
       }
      }
     },
     "localname": "MaterialSalesCaptisolMember",
     "nsuri": "http://www.ligand.com/20211231",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRoyaltyRevenueDetails",
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.ligand.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lgnd_MaturityPeriodOfHighlyLiquidSecuritiesMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maturity period of highly liquid securities maximum.",
        "label": "Maturity Period Of Highly Liquid Securities Maximum",
        "terseLabel": "Maturity period of cash and cash equivalents, maximum"
       }
      }
     },
     "localname": "MaturityPeriodOfHighlyLiquidSecuritiesMaximum",
     "nsuri": "http://www.ligand.com/20211231",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "lgnd_MetabasisTherapeuticsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Metabasis Therapeutics [Member]",
        "label": "Metabasis Therapeutics [Member]",
        "terseLabel": "Metabasis Therapeutics",
        "verboseLabel": "Metabasis"
       }
      }
     },
     "localname": "MetabasisTherapeuticsMember",
     "nsuri": "http://www.ligand.com/20211231",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsContingentLiabilitiesDetails",
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lgnd_MilestoneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone",
        "label": "Milestone [Member]",
        "terseLabel": "Milestone"
       }
      }
     },
     "localname": "MilestoneMember",
     "nsuri": "http://www.ligand.com/20211231",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRoyaltyRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lgnd_MilestonePaymentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone Payments",
        "label": "Milestone Payments [Member]",
        "terseLabel": "Milestone Payments"
       }
      }
     },
     "localname": "MilestonePaymentsMember",
     "nsuri": "http://www.ligand.com/20211231",
     "presentation": [
      "http://www.ligand.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lgnd_NonCashChangeInEstimatedFairValueOfContingentValueRights": {
     "auth_ref": [],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non-Cash Change In Estimated Fair Value Of Contingent Value Rights.",
        "label": "Non-Cash Change In Estimated Fair Value Of Contingent Value Rights",
        "negatedLabel": "Change in estimated fair value of contingent liabilities"
       }
      }
     },
     "localname": "NonCashChangeInEstimatedFairValueOfContingentValueRights",
     "nsuri": "http://www.ligand.com/20211231",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lgnd_NovanMolluscumProductsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Novan Molluscum Products",
        "label": "Novan Molluscum Products [Member]",
        "terseLabel": "Novan"
       }
      }
     },
     "localname": "NovanMolluscumProductsMember",
     "nsuri": "http://www.ligand.com/20211231",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lgnd_NumberOfAcquisitions": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of Acquisitions",
        "label": "Number of Acquisitions",
        "terseLabel": "Number of acquisitions"
       }
      }
     },
     "localname": "NumberOfAcquisitions",
     "nsuri": "http://www.ligand.com/20211231",
     "presentation": [
      "http://www.ligand.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "lgnd_NumberOfAssetAcquisitions": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number Of Asset Acquisitions",
        "label": "Number Of Asset Acquisitions",
        "terseLabel": "Number of asset acquisitions"
       }
      }
     },
     "localname": "NumberOfAssetAcquisitions",
     "nsuri": "http://www.ligand.com/20211231",
     "presentation": [
      "http://www.ligand.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "lgnd_NumberOfContingentValueRightAgreements": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number Of Contingent Value Right Agreements",
        "label": "Number Of Contingent Value Right Agreements",
        "terseLabel": "Number of CVR agreements"
       }
      }
     },
     "localname": "NumberOfContingentValueRightAgreements",
     "nsuri": "http://www.ligand.com/20211231",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsNarrativeDetails",
      "http://www.ligand.com/role/FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "lgnd_NumberOfContingentValueRightsIssued": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of Contingent Value Rights Issued",
        "label": "Number of Contingent Value Rights Issued",
        "terseLabel": "Number of contingent value rights"
       }
      }
     },
     "localname": "NumberOfContingentValueRightsIssued",
     "nsuri": "http://www.ligand.com/20211231",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "lgnd_NumberOfOptionsUnderConvertibleBondHedges": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of Options under Convertible Bond Hedges",
        "label": "Number of Options under Convertible Bond Hedges",
        "terseLabel": "Number of options under convertible bond hedges"
       }
      }
     },
     "localname": "NumberOfOptionsUnderConvertibleBondHedges",
     "nsuri": "http://www.ligand.com/20211231",
     "presentation": [
      "http://www.ligand.com/role/ConvertibleSeniorNotesNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "lgnd_NumberOfSharesSoldOfEquityMethodInvestee": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number Of Shares Sold Of Equity Method Investee",
        "label": "Number Of Shares Sold Of Equity Method Investee",
        "terseLabel": "Stock sold of equity method investee (in shares)"
       }
      }
     },
     "localname": "NumberOfSharesSoldOfEquityMethodInvestee",
     "nsuri": "http://www.ligand.com/20211231",
     "presentation": [
      "http://www.ligand.com/role/ShorttermInvestmentsInvestmentinVikingNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "lgnd_OtherBalanceSheetDetailsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Balance Sheet Details [Abstract]",
        "label": "Other Balance Sheet Details [Abstract]"
       }
      }
     },
     "localname": "OtherBalanceSheetDetailsAbstract",
     "nsuri": "http://www.ligand.com/20211231",
     "xbrltype": "stringItemType"
    },
    "lgnd_PalvellaTherapeuticsIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Palvella Therapeutics, Inc.",
        "label": "Palvella Therapeutics, Inc. [Member]",
        "terseLabel": "Palvella"
       }
      }
     },
     "localname": "PalvellaTherapeuticsIncMember",
     "nsuri": "http://www.ligand.com/20211231",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lgnd_PartnerAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Partner A [Member]",
        "label": "Partner A [Member]",
        "terseLabel": "Partner A"
       }
      }
     },
     "localname": "PartnerAMember",
     "nsuri": "http://www.ligand.com/20211231",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRevenuefromSignificantPartnersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lgnd_PartnerBMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Partner B [Member]",
        "label": "Partner B [Member]",
        "terseLabel": "Partner B"
       }
      }
     },
     "localname": "PartnerBMember",
     "nsuri": "http://www.ligand.com/20211231",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRevenuefromSignificantPartnersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lgnd_PartnerCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Partner C [Member]",
        "label": "Partner C [Member]",
        "terseLabel": "Partner C"
       }
      }
     },
     "localname": "PartnerCMember",
     "nsuri": "http://www.ligand.com/20211231",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRevenuefromSignificantPartnersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lgnd_PaymentsToAcquireBusinessesGrossAttributableToVestedPortionOfStockOptions": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments to Acquire Businesses, Gross, Attributable to Vested Portion of Stock Options",
        "label": "Payments to Acquire Businesses, Gross, Attributable to Vested Portion of Stock Options",
        "terseLabel": "Gross payments to acquire business attributable to vested portion of stock options"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessesGrossAttributableToVestedPortionOfStockOptions",
     "nsuri": "http://www.ligand.com/20211231",
     "presentation": [
      "http://www.ligand.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lgnd_PaymentsToContingentValueRightHolders": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments to contingent value right holders",
        "label": "Payments to Contingent Value Right Holders",
        "negatedLabel": "Payments to CVR holders and other contingency payments",
        "negatedTerseLabel": "Payments"
       }
      }
     },
     "localname": "PaymentsToContingentValueRightHolders",
     "nsuri": "http://www.ligand.com/20211231",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsContingentLiabilitiesDetails",
      "http://www.ligand.com/role/FairValueMeasurementReconciliationofLevel3FinancialInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lgnd_PaymentsToContingentValueRightHoldersFinancingActivity": {
     "auth_ref": [],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments to Contingent Value Right Holders, Financing Activity",
        "label": "Payments to Contingent Value Right Holders, Financing Activity",
        "negatedLabel": "Payments to CVR Holders"
       }
      }
     },
     "localname": "PaymentsToContingentValueRightHoldersFinancingActivity",
     "nsuri": "http://www.ligand.com/20211231",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lgnd_PaymentsToUnwindWarrants": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments to Unwind Warrants",
        "label": "Payments to Unwind Warrants",
        "terseLabel": "Payments to unwind warrants"
       }
      }
     },
     "localname": "PaymentsToUnwindWarrants",
     "nsuri": "http://www.ligand.com/20211231",
     "presentation": [
      "http://www.ligand.com/role/ConvertibleSeniorNotesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lgnd_PaymentsforConvertibleBondHedges": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments for Convertible Bond Hedges",
        "label": "Payments for Convertible Bond Hedges",
        "terseLabel": "Payments for convertible bond hedges"
       }
      }
     },
     "localname": "PaymentsforConvertibleBondHedges",
     "nsuri": "http://www.ligand.com/20211231",
     "presentation": [
      "http://www.ligand.com/role/ConvertibleSeniorNotesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lgnd_PfenexMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pfenex",
        "label": "Pfenex [Member]",
        "terseLabel": "Pfenex"
       }
      }
     },
     "localname": "PfenexMember",
     "nsuri": "http://www.ligand.com/20211231",
     "presentation": [
      "http://www.ligand.com/role/AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.ligand.com/role/AcquisitionsIntangiblesAcquiredandWeightedAverageUsefulLifeDetails",
      "http://www.ligand.com/role/AcquisitionsNarrativeDetails",
      "http://www.ligand.com/role/AcquisitionsProFormaFinancialInformationDetails",
      "http://www.ligand.com/role/AcquisitionsTables",
      "http://www.ligand.com/role/BalanceSheetAccountDetailsContingentLiabilitiesDetails",
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lgnd_Phase3ClinicalTrialMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Phase 3 Clinical Trial",
        "label": "Phase 3 Clinical Trial [Member]",
        "terseLabel": "Phase 3 Clinical Trial"
       }
      }
     },
     "localname": "Phase3ClinicalTrialMember",
     "nsuri": "http://www.ligand.com/20211231",
     "presentation": [
      "http://www.ligand.com/role/FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lgnd_ProceedsFromCommercialLicenseRights": {
     "auth_ref": [],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from Commercial License Rights",
        "label": "Proceeds from Commercial License Rights",
        "terseLabel": "Proceeds from commercial license rights"
       }
      }
     },
     "localname": "ProceedsFromCommercialLicenseRights",
     "nsuri": "http://www.ligand.com/20211231",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lgnd_ProceedsFromUnwindingConvertibleBondHedges": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from Unwinding Convertible Bond Hedges",
        "label": "Proceeds from Unwinding Convertible Bond Hedges",
        "terseLabel": "Proceeds from unwinding convertible bond hedges"
       }
      }
     },
     "localname": "ProceedsFromUnwindingConvertibleBondHedges",
     "nsuri": "http://www.ligand.com/20211231",
     "presentation": [
      "http://www.ligand.com/role/ConvertibleSeniorNotesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lgnd_ProductRoyaltyPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Product Royalty Percentage",
        "label": "Product Royalty Percentage",
        "terseLabel": "Product royalty (as a percent)"
       }
      }
     },
     "localname": "ProductRoyaltyPercentage",
     "nsuri": "http://www.ligand.com/20211231",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "lgnd_PromactaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Promacta",
        "label": "Promacta [Member]",
        "terseLabel": "Promacta"
       }
      }
     },
     "localname": "PromactaMember",
     "nsuri": "http://www.ligand.com/20211231",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.ligand.com/role/SaleofVernalisRDandPromactaLicenseNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lgnd_PurchaseCommitmentConsiderationPaidAllocatedToInventory": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase Commitment, Consideration Paid, Allocated to Inventory",
        "label": "Purchase Commitment, Consideration Paid, Allocated to Inventory",
        "terseLabel": "Portion of consideration allocated to inventory"
       }
      }
     },
     "localname": "PurchaseCommitmentConsiderationPaidAllocatedToInventory",
     "nsuri": "http://www.ligand.com/20211231",
     "presentation": [
      "http://www.ligand.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lgnd_PurchaseCommitmentConsiderationPaidToDate": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase Commitment, Consideration Paid to Date",
        "label": "Purchase Commitment, Consideration Paid to Date",
        "terseLabel": "Consideration paid to date"
       }
      }
     },
     "localname": "PurchaseCommitmentConsiderationPaidToDate",
     "nsuri": "http://www.ligand.com/20211231",
     "presentation": [
      "http://www.ligand.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lgnd_RepaymentsOfNotesPayableInterestPortion": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Repayments Of Notes Payable, Interest Portion",
        "label": "Repayments Of Notes Payable, Interest Portion",
        "terseLabel": "Accrued interest portion of repurchased amount of debt instrument"
       }
      }
     },
     "localname": "RepaymentsOfNotesPayableInterestPortion",
     "nsuri": "http://www.ligand.com/20211231",
     "presentation": [
      "http://www.ligand.com/role/ConvertibleSeniorNotesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lgnd_RestrictedStockUnitsAndPerformanceSharesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restricted Stock Units and Performance Shares",
        "label": "Restricted Stock Units and Performance Shares [Member]",
        "terseLabel": "RSUs and PSUs"
       }
      }
     },
     "localname": "RestrictedStockUnitsAndPerformanceSharesMember",
     "nsuri": "http://www.ligand.com/20211231",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lgnd_RoyaltyAgreementExpirationPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty Agreement, Expiration Period",
        "label": "Royalty Agreement, Expiration Period",
        "terseLabel": "Expiration period of royalty agreement"
       }
      }
     },
     "localname": "RoyaltyAgreementExpirationPeriod",
     "nsuri": "http://www.ligand.com/20211231",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "lgnd_RoyaltyEvomelaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty, Evomela",
        "label": "Royalty, Evomela [Member]",
        "terseLabel": "Evomela"
       }
      }
     },
     "localname": "RoyaltyEvomelaMember",
     "nsuri": "http://www.ligand.com/20211231",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRoyaltyRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lgnd_RoyaltyKyprolisMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty, Kyprolis",
        "label": "Royalty, Kyprolis [Member]",
        "terseLabel": "Kyprolis"
       }
      }
     },
     "localname": "RoyaltyKyprolisMember",
     "nsuri": "http://www.ligand.com/20211231",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRoyaltyRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lgnd_RoyaltyOtherMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty, Other",
        "label": "Royalty, Other [Member]",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "RoyaltyOtherMember",
     "nsuri": "http://www.ligand.com/20211231",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRoyaltyRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lgnd_RoyaltyPromactaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty, Promacta",
        "label": "Royalty, Promacta [Member]",
        "terseLabel": "Promacta"
       }
      }
     },
     "localname": "RoyaltyPromactaMember",
     "nsuri": "http://www.ligand.com/20211231",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRoyaltyRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lgnd_ScheduleofCommercialLicenseRightsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of Commercial License Rights [Table Text Block]",
        "label": "Schedule of Commercial License Rights [Table Text Block]",
        "terseLabel": "Schedule of Commercial License Rights"
       }
      }
     },
     "localname": "ScheduleofCommercialLicenseRightsTableTextBlock",
     "nsuri": "http://www.ligand.com/20211231",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "lgnd_ScheduleofContingentLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of Contingent Liabilities [Table Text Block]",
        "label": "Schedule of Contingent Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Contingent Liabilities"
       }
      }
     },
     "localname": "ScheduleofContingentLiabilitiesTableTextBlock",
     "nsuri": "http://www.ligand.com/20211231",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "lgnd_SelexisAndDianomiMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Selexis and Dianomi",
        "label": "Selexis and Dianomi [Member]",
        "terseLabel": "Selexis and Dianomi"
       }
      }
     },
     "localname": "SelexisAndDianomiMember",
     "nsuri": "http://www.ligand.com/20211231",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCommercialLicenseRightsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lgnd_SelexisMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Selexis",
        "label": "Selexis [Member]",
        "terseLabel": "Selexis"
       }
      }
     },
     "localname": "SelexisMember",
     "nsuri": "http://www.ligand.com/20211231",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lgnd_TaurusBiosciencesLLCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Taurus Biosciences, LLC",
        "label": "Taurus Biosciences, LLC [Member]",
        "terseLabel": "Taurus"
       }
      }
     },
     "localname": "TaurusBiosciencesLLCMember",
     "nsuri": "http://www.ligand.com/20211231",
     "presentation": [
      "http://www.ligand.com/role/AcquisitionsAllocationofConsiderationDetails",
      "http://www.ligand.com/role/AcquisitionsNarrativeDetails",
      "http://www.ligand.com/role/AcquisitionsTables"
     ],
     "xbrltype": "domainItemType"
    },
    "lgnd_TwoThousandTwoStockIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand two Stock Incentive Plan.",
        "label": "Two thousand Two Stock Incentive Plan [Member]",
        "terseLabel": "2002 Stock Incentive Plan"
       }
      }
     },
     "localname": "TwoThousandTwoStockIncentivePlanMember",
     "nsuri": "http://www.ligand.com/20211231",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.ligand.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lgnd_USDistrictCourtForTheNorthernDistrictOfOhioMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "US District Court for the Northern District of Ohio",
        "label": "US District Court for the Northern District of Ohio [Member]",
        "terseLabel": "US District Court for the Northern District of Ohio"
       }
      }
     },
     "localname": "USDistrictCourtForTheNorthernDistrictOfOhioMember",
     "nsuri": "http://www.ligand.com/20211231",
     "presentation": [
      "http://www.ligand.com/role/CommitmentandContingenciesLegalProceedingsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lgnd_VernalisMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vernalis",
        "label": "Vernalis [Member]",
        "terseLabel": "Vernalis"
       }
      }
     },
     "localname": "VernalisMember",
     "nsuri": "http://www.ligand.com/20211231",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.ligand.com/role/SaleofVernalisRDandPromactaLicenseNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lgnd_VestingPeriodOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vesting Period One [Member]",
        "label": "Vesting Period One [Member]",
        "terseLabel": "Vest 1/8 on the six month anniversary of the date of grant"
       }
      }
     },
     "localname": "VestingPeriodOneMember",
     "nsuri": "http://www.ligand.com/20211231",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lgnd_VestingPeriodTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vesting Period Two [Member]",
        "label": "Vesting Period Two [Member]",
        "terseLabel": "Vest 1/48 each month for forty-two months"
       }
      }
     },
     "localname": "VestingPeriodTwoMember",
     "nsuri": "http://www.ligand.com/20211231",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lgnd_VikingTherapeuticsInc.Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Viking Therapeutics, Inc. [Member]",
        "label": "Viking Therapeutics, Inc. [Member]",
        "terseLabel": "Viking Therapeutics, Inc."
       }
      }
     },
     "localname": "VikingTherapeuticsInc.Member",
     "nsuri": "http://www.ligand.com/20211231",
     "presentation": [
      "http://www.ligand.com/role/ShorttermInvestmentsInvestmentinVikingNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lgnd_XCellaBiosciencesIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "xCella Biosciences, Inc.",
        "label": "xCella Biosciences, Inc. [Member]",
        "terseLabel": "xCella"
       }
      }
     },
     "localname": "XCellaBiosciencesIncMember",
     "nsuri": "http://www.ligand.com/20211231",
     "presentation": [
      "http://www.ligand.com/role/AcquisitionsAllocationofConsiderationDetails",
      "http://www.ligand.com/role/AcquisitionsNarrativeDetails",
      "http://www.ligand.com/role/AcquisitionsTables",
      "http://www.ligand.com/role/BalanceSheetAccountDetailsContingentLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r71",
      "r73",
      "r145",
      "r146",
      "r327",
      "r365"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCommercialLicenseRightsDetails",
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember": {
     "auth_ref": [
      "r2",
      "r153",
      "r160",
      "r166",
      "r251",
      "r462",
      "r463",
      "r464",
      "r502",
      "r503",
      "r569",
      "r572",
      "r574",
      "r575",
      "r793"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cumulative Effect, Period of Adoption, Adjustment [Member]",
        "terseLabel": "Cumulative Effect, Period of Adoption, Adjustment"
       }
      }
     },
     "localname": "CumulativeEffectPeriodOfAdoptionAdjustmentMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CumulativeEffectPeriodOfAdoptionAxis": {
     "auth_ref": [
      "r2",
      "r153",
      "r160",
      "r166",
      "r251",
      "r462",
      "r463",
      "r464",
      "r502",
      "r503",
      "r569",
      "r572",
      "r574",
      "r575",
      "r793"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cumulative Effect, Period of Adoption [Axis]",
        "terseLabel": "Cumulative Effect, Period of Adoption [Axis]"
       }
      }
     },
     "localname": "CumulativeEffectPeriodOfAdoptionAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_CumulativeEffectPeriodOfAdoptionDomain": {
     "auth_ref": [
      "r2",
      "r153",
      "r160",
      "r166",
      "r251",
      "r462",
      "r463",
      "r464",
      "r502",
      "r503",
      "r569",
      "r572",
      "r574",
      "r575",
      "r793"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cumulative Effect, Period of Adoption [Domain]",
        "terseLabel": "Cumulative Effect, Period of Adoption [Domain]"
       }
      }
     },
     "localname": "CumulativeEffectPeriodOfAdoptionDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_LitigationCaseAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Litigation Case [Axis]",
        "terseLabel": "Litigation Case [Axis]"
       }
      }
     },
     "localname": "LitigationCaseAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/CommitmentandContingenciesLegalProceedingsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_LitigationCaseTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Litigation Case [Domain]",
        "terseLabel": "Litigation Case [Domain]"
       }
      }
     },
     "localname": "LitigationCaseTypeDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/CommitmentandContingenciesLegalProceedingsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MajorCustomersAxis": {
     "auth_ref": [
      "r216",
      "r398",
      "r403",
      "r734"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Axis]",
        "terseLabel": "Customer [Axis]"
       }
      }
     },
     "localname": "MajorCustomersAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRevenuefromSignificantPartnersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r326",
      "r364",
      "r419",
      "r421",
      "r649",
      "r650",
      "r651",
      "r652",
      "r653",
      "r654",
      "r673",
      "r732",
      "r735",
      "r771",
      "r772"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/AcquisitionsIntangiblesAcquiredandWeightedAverageUsefulLifeDetails",
      "http://www.ligand.com/role/AcquisitionsNarrativeDetails",
      "http://www.ligand.com/role/BalanceSheetAccountDetailsNarrativeDetails",
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.ligand.com/role/FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
      "http://www.ligand.com/role/LeasesNarrativeDetails",
      "http://www.ligand.com/role/StockholdersEquityAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r326",
      "r364",
      "r419",
      "r421",
      "r649",
      "r650",
      "r651",
      "r652",
      "r653",
      "r654",
      "r673",
      "r732",
      "r735",
      "r771",
      "r772"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/AcquisitionsIntangiblesAcquiredandWeightedAverageUsefulLifeDetails",
      "http://www.ligand.com/role/AcquisitionsNarrativeDetails",
      "http://www.ligand.com/role/BalanceSheetAccountDetailsNarrativeDetails",
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.ligand.com/role/StockholdersEquityAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_NameOfMajorCustomerDomain": {
     "auth_ref": [
      "r216",
      "r398",
      "r403",
      "r734"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Domain]",
        "terseLabel": "Customer [Domain]"
       }
      }
     },
     "localname": "NameOfMajorCustomerDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRevenuefromSignificantPartnersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_OwnershipAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership [Axis]",
        "terseLabel": "Ownership [Axis]"
       }
      }
     },
     "localname": "OwnershipAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/ShorttermInvestmentsInvestmentinVikingNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_OwnershipDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership [Domain]",
        "terseLabel": "Ownership [Domain]"
       }
      }
     },
     "localname": "OwnershipDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/ShorttermInvestmentsInvestmentinVikingNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r214",
      "r398",
      "r401",
      "r677",
      "r731",
      "r733"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRoyaltyRevenueDetails",
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.ligand.com/role/FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
      "http://www.ligand.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r214",
      "r398",
      "r401",
      "r677",
      "r731",
      "r733"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRoyaltyRevenueDetails",
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.ligand.com/role/FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
      "http://www.ligand.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r326",
      "r364",
      "r409",
      "r419",
      "r421",
      "r649",
      "r650",
      "r651",
      "r652",
      "r653",
      "r654",
      "r673",
      "r732",
      "r735",
      "r771",
      "r772"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/AcquisitionsIntangiblesAcquiredandWeightedAverageUsefulLifeDetails",
      "http://www.ligand.com/role/AcquisitionsNarrativeDetails",
      "http://www.ligand.com/role/BalanceSheetAccountDetailsNarrativeDetails",
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.ligand.com/role/FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
      "http://www.ligand.com/role/LeasesNarrativeDetails",
      "http://www.ligand.com/role/StockholdersEquityAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r326",
      "r364",
      "r409",
      "r419",
      "r421",
      "r649",
      "r650",
      "r651",
      "r652",
      "r653",
      "r654",
      "r673",
      "r732",
      "r735",
      "r771",
      "r772"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/AcquisitionsIntangiblesAcquiredandWeightedAverageUsefulLifeDetails",
      "http://www.ligand.com/role/AcquisitionsNarrativeDetails",
      "http://www.ligand.com/role/BalanceSheetAccountDetailsNarrativeDetails",
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.ligand.com/role/FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
      "http://www.ligand.com/role/LeasesNarrativeDetails",
      "http://www.ligand.com/role/StockholdersEquityAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [
      "r72",
      "r73",
      "r145",
      "r146",
      "r327",
      "r365"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCommercialLicenseRightsDetails",
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingStandardsUpdate201613Member": {
     "auth_ref": [
      "r247"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounting Standards Update 2016-13 Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments.",
        "label": "Accounting Standards Update 2016-13 [Member]",
        "terseLabel": "Accounting Standards Update 2016-13"
       }
      }
     },
     "localname": "AccountingStandardsUpdate201613Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingStandardsUpdateExtensibleList": {
     "auth_ref": [
      "r0",
      "r1",
      "r2",
      "r3",
      "r4",
      "r154",
      "r155",
      "r156",
      "r157",
      "r222",
      "r223",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r309",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r502",
      "r503",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r602",
      "r638",
      "r736",
      "r737",
      "r738",
      "r739",
      "r740",
      "r741",
      "r742",
      "r743",
      "r744",
      "r745",
      "r746",
      "r747",
      "r791",
      "r792",
      "r793",
      "r794",
      "r795"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates amendment to accounting standards.",
        "label": "Accounting Standards Update [Extensible Enumeration]",
        "terseLabel": "Accounting Standards Update [Extensible List]"
       }
      }
     },
     "localname": "AccountingStandardsUpdateExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r54",
      "r641"
     ],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "verboseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r21",
      "r41",
      "r217",
      "r218"
     ],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Accounts receivable, net"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": {
     "auth_ref": [
      "r127"
     ],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Accretion (Amortization) of Discounts and Premiums, Investments",
        "negatedTerseLabel": "Amortization/accretion of premium (discount) on investments, net"
       }
      }
     },
     "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r56"
     ],
     "calculation": {
      "http://www.ligand.com/role/BalanceSheetAccountDetailsAccruedLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "totalLabel": "Accrued liabilities",
        "verboseLabel": "Accrued liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsAccruedLiabilitiesDetails",
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "auth_ref": [
      "r24",
      "r25",
      "r56"
     ],
     "calculation": {
      "http://www.ligand.com/role/BalanceSheetAccountDetailsAccruedLiabilitiesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Professional Fees, Current",
        "terseLabel": "Professional fees"
       }
      }
     },
     "localname": "AccruedProfessionalFeesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedRoyaltiesCurrentAndNoncurrent": {
     "auth_ref": [
      "r695",
      "r724"
     ],
     "calculation": {
      "http://www.ligand.com/role/BalanceSheetAccountDetailsAccruedLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties.",
        "label": "Accrued Royalties",
        "terseLabel": "Royalties owed to third parties"
       }
      }
     },
     "localname": "AccruedRoyaltiesCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedSalesCommissionCurrentAndNoncurrent": {
     "auth_ref": [
      "r34",
      "r36",
      "r688",
      "r717"
     ],
     "calculation": {
      "http://www.ligand.com/role/BalanceSheetAccountDetailsAccruedLiabilitiesDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for sales commissions.",
        "label": "Accrued Sales Commission",
        "terseLabel": "Amounts owed to former licensees"
       }
      }
     },
     "localname": "AccruedSalesCommissionCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r52",
      "r293"
     ],
     "calculation": {
      "http://www.ligand.com/role/BalanceSheetAccountDetailsPropertyandEquipmentDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Less accumulated depreciation and amortization"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsPropertyandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r44",
      "r79",
      "r80",
      "r81",
      "r718",
      "r743",
      "r747"
     ],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r78",
      "r81",
      "r88",
      "r89",
      "r90",
      "r150",
      "r151",
      "r152",
      "r546",
      "r738",
      "r739",
      "r795"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated other comprehensive income (loss)"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife": {
     "auth_ref": [
      "r279"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Acquired Finite-lived Intangible Assets, Weighted Average Useful Life",
        "terseLabel": "Weighted-average useful lives of acquired finite-lived intangible assets",
        "verboseLabel": "Estimated useful life (in years)"
       }
      }
     },
     "localname": "AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/AcquisitionsIntangiblesAcquiredandWeightedAverageUsefulLifeDetails",
      "http://www.ligand.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r42",
      "r465",
      "r641"
     ],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional Paid in Capital",
        "verboseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r150",
      "r151",
      "r152",
      "r462",
      "r463",
      "r464",
      "r574"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": {
     "auth_ref": [
      "r0",
      "r1",
      "r2",
      "r3",
      "r4",
      "r154",
      "r155",
      "r156",
      "r157",
      "r166",
      "r222",
      "r223",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r309",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r500",
      "r501",
      "r502",
      "r503",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r602",
      "r638",
      "r679",
      "r680",
      "r681",
      "r736",
      "r737",
      "r738",
      "r739",
      "r740",
      "r741",
      "r742",
      "r743",
      "r744",
      "r745",
      "r746",
      "r747",
      "r791",
      "r792",
      "r793",
      "r794",
      "r795"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by amendment to accounting standards.",
        "label": "Accounting Standards Update [Axis]",
        "terseLabel": "Adjustments for New Accounting Pronouncements [Axis]"
       }
      }
     },
     "localname": "AdjustmentsForNewAccountingPronouncementsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt": {
     "auth_ref": [
      "r322"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adjustment to additional paid in capital resulting from the recognition of convertible debt instruments as two separate components - a debt component and an equity component. This bifurcation may result in a basis difference associated with the liability component that represents a temporary difference for purposes of applying accounting for income taxes. The initial recognition of deferred taxes for the tax effect of that temporary difference is as an adjustment to additional paid in capital.",
        "label": "Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt",
        "negatedLabel": "Debt issuance costs related to the equity component of convertible debt",
        "terseLabel": "Reacquisition of equity due to 2023 debt extinguishment, net of tax"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY",
      "http://www.ligand.com/role/ConvertibleSeniorNotesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalOther": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of other increase (decrease) in additional paid in capital (APIC).",
        "label": "Adjustments to Additional Paid in Capital, Other",
        "terseLabel": "Other tax adjustments"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalOther",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r422",
      "r424",
      "r467",
      "r468"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued": {
     "auth_ref": [
      "r321",
      "r378",
      "r384"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.",
        "label": "Adjustments to Additional Paid in Capital, Warrant Issued",
        "verboseLabel": "Value of warrants issued"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/ConvertibleSeniorNotesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "verboseLabel": "Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AgencySecuritiesMember": {
     "auth_ref": [
      "r242"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities issued by government sponsored entities.",
        "label": "Agency Securities [Member]",
        "terseLabel": "Agency bonds"
       }
      }
     },
     "localname": "AgencySecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsInvestmentCategoriesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax, of expense for award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Expense, after Tax",
        "terseLabel": "Share-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpenseNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityShareBasedCompensationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfFinancingCostsAndDiscounts": {
     "auth_ref": [
      "r126",
      "r346",
      "r357",
      "r358",
      "r615"
     ],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.",
        "label": "Amortization of Debt Issuance Costs and Discounts",
        "terseLabel": "Amortization of debt discount and issuance fees"
       }
      }
     },
     "localname": "AmortizationOfFinancingCostsAndDiscounts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "auth_ref": [
      "r126",
      "r277",
      "r284"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Amortization of Intangible Assets",
        "verboseLabel": "Amortization expense"
       }
      }
     },
     "localname": "AmortizationOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r175"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Potentially dilutive shares excluded from calculation due to anti-dilutive effect (shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCalculationofEarningsperShareDetails",
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r175"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r175"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetImpairmentCharges": {
     "auth_ref": [
      "r126",
      "r289"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.",
        "label": "Asset Impairment Charges",
        "terseLabel": "Asset impairment charges"
       }
      }
     },
     "localname": "AssetImpairmentCharges",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r140",
      "r203",
      "r206",
      "r212",
      "r246",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r541",
      "r548",
      "r594",
      "r639",
      "r641",
      "r685",
      "r716"
     ],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets",
        "verboseLabel": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.ligand.com/role/LeasesOperatingandFinanceLeaseAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r22",
      "r23",
      "r68",
      "r140",
      "r246",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r541",
      "r548",
      "r594",
      "r639",
      "r641"
     ],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "verboseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r577"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "verboseLabel": "Assets, fair value"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r228"
     ],
     "calculation": {
      "http://www.ligand.com/role/BalanceSheetAccountDetailsInvestmentCategoriesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Gross unrealized gains"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsInvestmentCategoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r229"
     ],
     "calculation": {
      "http://www.ligand.com/role/BalanceSheetAccountDetailsInvestmentCategoriesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedTerseLabel": "Gross unrealized losses"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsInvestmentCategoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r226",
      "r259"
     ],
     "calculation": {
      "http://www.ligand.com/role/BalanceSheetAccountDetailsInvestmentCategoriesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Amortized Cost",
        "totalLabel": "Cost"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsInvestmentCategoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-sale, Unrealized Loss Position [Line Items]",
        "terseLabel": "Debt Securities, Available-for-sale, Unrealized Loss Position [Line Items]"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsAvailableforSaleDebtSecuritiesinanUnrealizedLossPositionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost": {
     "auth_ref": [
      "r232"
     ],
     "calculation": {
      "http://www.ligand.com/role/BalanceSheetAccountDetailsAvailableforSaleDebtSecuritiesbyContractualMaturityDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_HeldToMaturitySecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year One Through Five",
        "terseLabel": "After one year through five years"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsAvailableforSaleDebtSecuritiesbyContractualMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue": {
     "auth_ref": [
      "r230",
      "r232",
      "r706"
     ],
     "calculation": {
      "http://www.ligand.com/role/BalanceSheetAccountDetailsAvailableforSaleDebtSecuritiesbyContractualMaturityDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five",
        "terseLabel": "After one year through five years"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsAvailableforSaleDebtSecuritiesbyContractualMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-sale, Amortized Cost, Fiscal Year Maturity [Abstract]",
        "terseLabel": "Amortized Cost"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsAvailableforSaleDebtSecuritiesbyContractualMaturityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-sale, Fair Value, Fiscal Year Maturity [Abstract]",
        "terseLabel": "Fair Value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsAvailableforSaleDebtSecuritiesbyContractualMaturityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate": {
     "auth_ref": [
      "r230",
      "r233",
      "r707"
     ],
     "calculation": {
      "http://www.ligand.com/role/BalanceSheetAccountDetailsAvailableforSaleDebtSecuritiesbyContractualMaturityDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date.",
        "label": "Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Fair Value",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsAvailableforSaleDebtSecuritiesbyContractualMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost": {
     "auth_ref": [
      "r231"
     ],
     "calculation": {
      "http://www.ligand.com/role/BalanceSheetAccountDetailsAvailableforSaleDebtSecuritiesbyContractualMaturityDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_HeldToMaturitySecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One",
        "terseLabel": "Within one year"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsAvailableforSaleDebtSecuritiesbyContractualMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue": {
     "auth_ref": [
      "r230",
      "r231",
      "r705"
     ],
     "calculation": {
      "http://www.ligand.com/role/BalanceSheetAccountDetailsAvailableforSaleDebtSecuritiesbyContractualMaturityDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One",
        "terseLabel": "Within one year"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsAvailableforSaleDebtSecuritiesbyContractualMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r224",
      "r227",
      "r259",
      "r693"
     ],
     "calculation": {
      "http://www.ligand.com/role/BalanceSheetAccountDetailsInvestmentCategoriesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale",
        "terseLabel": "Estimated fair value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsInvestmentCategoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Number of Positions [Abstract]",
        "terseLabel": "Estimated Fair Value"
       }
      }
     },
     "localname": "AvailableForsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsAvailableforSaleDebtSecuritiesinanUnrealizedLossPositionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r426",
      "r456"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCalculationofEarningsperShareDetails",
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.ligand.com/role/StockholdersEquityNarrativeDetails",
      "http://www.ligand.com/role/StockholdersEquityRestrictedStockActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BuildingMember": {
     "auth_ref": [
      "r292"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities.",
        "label": "Building [Member]",
        "terseLabel": "Building"
       }
      }
     },
     "localname": "BuildingMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "auth_ref": [
      "r418",
      "r420"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.",
        "label": "Business Acquisition, Acquiree [Domain]",
        "terseLabel": "Business Acquisition, Acquiree [Domain]"
       }
      }
     },
     "localname": "BusinessAcquisitionAcquireeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/AcquisitionsAllocationofConsiderationDetails",
      "http://www.ligand.com/role/AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.ligand.com/role/AcquisitionsIntangiblesAcquiredandWeightedAverageUsefulLifeDetails",
      "http://www.ligand.com/role/AcquisitionsNarrativeDetails",
      "http://www.ligand.com/role/AcquisitionsProFormaFinancialInformationDetails",
      "http://www.ligand.com/role/AcquisitionsTables",
      "http://www.ligand.com/role/BalanceSheetAccountDetailsContingentLiabilitiesDetails",
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "auth_ref": [
      "r418",
      "r420",
      "r519",
      "r520"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business combination or series of individually immaterial business combinations.",
        "label": "Business Acquisition [Axis]",
        "terseLabel": "Business Acquisition [Axis]"
       }
      }
     },
     "localname": "BusinessAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/AcquisitionsAllocationofConsiderationDetails",
      "http://www.ligand.com/role/AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.ligand.com/role/AcquisitionsIntangiblesAcquiredandWeightedAverageUsefulLifeDetails",
      "http://www.ligand.com/role/AcquisitionsNarrativeDetails",
      "http://www.ligand.com/role/AcquisitionsProFormaFinancialInformationDetails",
      "http://www.ligand.com/role/AcquisitionsTables",
      "http://www.ligand.com/role/BalanceSheetAccountDetailsContingentLiabilitiesDetails",
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of direct costs of the business combination including legal, accounting, and other costs incurred to consummate the business acquisition.",
        "label": "Business Acquisition, Transaction Costs",
        "terseLabel": "Post-combination expense"
       }
      }
     },
     "localname": "BusinessAcquisitionCostOfAcquiredEntityTransactionCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessAcquisitionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Business Acquisition [Line Items]",
        "terseLabel": "Business Acquisition [Line Items]"
       }
      }
     },
     "localname": "BusinessAcquisitionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/AcquisitionsAllocationofConsiderationDetails",
      "http://www.ligand.com/role/AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.ligand.com/role/AcquisitionsIntangiblesAcquiredandWeightedAverageUsefulLifeDetails",
      "http://www.ligand.com/role/AcquisitionsNarrativeDetails",
      "http://www.ligand.com/role/AcquisitionsProFormaFinancialInformationDetails",
      "http://www.ligand.com/role/AcquisitionsTables",
      "http://www.ligand.com/role/BalanceSheetAccountDetailsContingentLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic": {
     "auth_ref": [
      "r517",
      "r518"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The pro forma basic net income per share for a period as if the business combination or combinations had been completed at the beginning of a period.",
        "label": "Business Acquisition, Pro Forma Earnings Per Share, Basic",
        "terseLabel": "Basic (USD per share)"
       }
      }
     },
     "localname": "BusinessAcquisitionProFormaEarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/AcquisitionsProFormaFinancialInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted": {
     "auth_ref": [
      "r517",
      "r518"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The pro forma diluted net income per share for a period as if the business combination or combinations had been completed at the beginning of a period.",
        "label": "Business Acquisition, Pro Forma Earnings Per Share, Diluted",
        "terseLabel": "Diluted (USD per share)"
       }
      }
     },
     "localname": "BusinessAcquisitionProFormaEarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/AcquisitionsProFormaFinancialInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_BusinessAcquisitionProFormaInformationTextBlock": {
     "auth_ref": [
      "r517",
      "r518"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of pro forma results of operations for a material business acquisition or series of individually immaterial business acquisitions that are material in the aggregate.",
        "label": "Business Acquisition, Pro Forma Information [Table Text Block]",
        "terseLabel": "Schedule of Pro Forma Information"
       }
      }
     },
     "localname": "BusinessAcquisitionProFormaInformationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/AcquisitionsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount": {
     "auth_ref": [
      "r537"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of goodwill arising from a business combination that is expected to be deductible for tax purposes.",
        "label": "Business Acquisition, Goodwill, Expected Tax Deductible Amount",
        "terseLabel": "Goodwill acquired that is expected to be deductible for tax purposes"
       }
      }
     },
     "localname": "BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss": {
     "auth_ref": [
      "r517",
      "r518"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The pro forma net Income or Loss for the period as if the business combination or combinations had been completed at the beginning of a period.",
        "label": "Business Acquisition, Pro Forma Net Income (Loss)",
        "terseLabel": "Net Income (loss)"
       }
      }
     },
     "localname": "BusinessAcquisitionsProFormaNetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/AcquisitionsProFormaFinancialInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessAcquisitionsProFormaRevenue": {
     "auth_ref": [
      "r517",
      "r518"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The pro forma revenue for a period as if the business combination or combinations had been completed at the beginning of the period.",
        "label": "Business Acquisition, Pro Forma Revenue",
        "terseLabel": "Revenue"
       }
      }
     },
     "localname": "BusinessAcquisitionsProFormaRevenue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/AcquisitionsProFormaFinancialInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationAcquisitionRelatedCosts": {
     "auth_ref": [
      "r515"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities.",
        "label": "Business Combination, Acquisition Related Costs",
        "terseLabel": "Acquisition-related costs"
       }
      }
     },
     "localname": "BusinessCombinationAcquisitionRelatedCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationAndAssetAcquisitionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination and Asset Acquisition [Abstract]"
       }
      }
     },
     "localname": "BusinessCombinationAndAssetAcquisitionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationConsiderationTransferred1": {
     "auth_ref": [
      "r531",
      "r532",
      "r534"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.",
        "label": "Business Combination, Consideration Transferred",
        "terseLabel": "Consideration transferred"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferred1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": {
     "auth_ref": [
      "r125",
      "r538"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.",
        "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability",
        "negatedTerseLabel": "Reduction in contingent liability"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/AcquisitionsNarrativeDetails",
      "http://www.ligand.com/role/FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiability": {
     "auth_ref": [
      "r530",
      "r533",
      "r536"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination.",
        "label": "Business Combination, Contingent Consideration, Liability",
        "terseLabel": "Contingent consideration liability"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/AcquisitionsNarrativeDetails",
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput": {
     "auth_ref": [
      "r582"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of input used to measure contingent consideration liability from business combination.",
        "label": "Business Combination, Contingent Consideration, Liability, Measurement Input",
        "terseLabel": "Contingent consideration liability, measurement input (as a percent)"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiabilityMeasurementInput",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "us-gaap_BusinessCombinationDisclosureTextBlock": {
     "auth_ref": [
      "r539"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).",
        "label": "Business Combination Disclosure [Text Block]",
        "terseLabel": "Acquisitions"
       }
      }
     },
     "localname": "BusinessCombinationDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/Acquisitions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessCombinationIntegrationRelatedCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Costs incurred to effect a business combination which have been expensed during the period. Such costs could include business integration costs, systems integration and conversion costs, and severance and other employee-related costs.",
        "label": "Business Combination, Integration Related Costs",
        "terseLabel": "Integration related costs"
       }
      }
     },
     "localname": "BusinessCombinationIntegrationRelatedCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual": {
     "auth_ref": [
      "r516"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents the amount of earnings or loss of the acquiree since the acquisition date included in the consolidated income statement for the reporting period.",
        "label": "Business Combination, Pro Forma Information, Earnings or Loss of Acquiree since Acquisition Date, Actual",
        "terseLabel": "Income (loss) before income taxes of acquiree since acquisition date included in comprehensive income"
       }
      }
     },
     "localname": "BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual": {
     "auth_ref": [
      "r516"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents the amount of revenue of the acquiree since the acquisition date included in the consolidated income statement for the reporting period.",
        "label": "Business Combination, Pro Forma Information, Revenue of Acquiree since Acquisition Date, Actual",
        "terseLabel": "Revenue of acquiree since acquisition date included in comprehensive income"
       }
      }
     },
     "localname": "BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents": {
     "auth_ref": [
      "r522"
     ],
     "calculation": {
      "http://www.ligand.com/role/AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents",
        "verboseLabel": "Cash"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/AcquisitionsAllocationofConsiderationDetails",
      "http://www.ligand.com/role/AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets": {
     "auth_ref": [
      "r522"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets",
        "verboseLabel": "Prepaids and other assets"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/AcquisitionsAllocationofConsiderationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables": {
     "auth_ref": [
      "r522"
     ],
     "calculation": {
      "http://www.ligand.com/role/AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 10.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount due from customers or clients for goods or services, including trade receivables, that have been delivered or sold in the normal course of business, and amounts due from others, including related parties expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables",
        "terseLabel": "Accounts and unbilled receivables"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities": {
     "auth_ref": [
      "r522"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities due within one year or within the normal operating cycle, if longer, assumed at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities",
        "negatedTerseLabel": "Liabilities assumed"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/AcquisitionsAllocationofConsiderationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable": {
     "auth_ref": [
      "r522"
     ],
     "calculation": {
      "http://www.ligand.com/role/AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities incurred for goods and services received that are used in an entity's business and related party payables, assumed at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable",
        "negatedLabel": "Accounts payable and accrued liabilities",
        "negatedTerseLabel": "Accounts payable"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/AcquisitionsAllocationofConsiderationDetails",
      "http://www.ligand.com/role/AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue": {
     "auth_ref": [
      "r522"
     ],
     "calculation": {
      "http://www.ligand.com/role/AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred revenue expected to be recognized as such within one year or the normal operating cycle, if longer, assumed at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Deferred Revenue",
        "negatedLabel": "Deferred revenue",
        "negatedTerseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/AcquisitionsAllocationofConsiderationDetails",
      "http://www.ligand.com/role/AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets": {
     "auth_ref": [
      "r522"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax asset attributable to deductible temporary differences and carryforwards acquired at the acquisition date.",
        "label": "Business Combination Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Assets",
        "terseLabel": "Deferred tax assets, net"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/AcquisitionsAllocationofConsiderationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities": {
     "auth_ref": [
      "r522"
     ],
     "calculation": {
      "http://www.ligand.com/role/AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 9.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities",
        "negatedLabel": "Deferred tax liabilities, net",
        "negatedTerseLabel": "Deferred tax liabilities, net"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/AcquisitionsAllocationofConsiderationDetails",
      "http://www.ligand.com/role/AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill": {
     "auth_ref": [
      "r522"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of intangible assets, excluding goodwill, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill",
        "terseLabel": "Approximate Fair Value"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/AcquisitionsIntangiblesAcquiredandWeightedAverageUsefulLifeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles": {
     "auth_ref": [
      "r521",
      "r522"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of identifiable intangible assets recognized as of the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles",
        "terseLabel": "Intangibles assets with finite-life - core technology",
        "verboseLabel": "Acquired intangibles"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/AcquisitionsAllocationofConsiderationDetails",
      "http://www.ligand.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet": {
     "auth_ref": [
      "r521",
      "r522"
     ],
     "calculation": {
      "http://www.ligand.com/role/AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net",
        "terseLabel": "Total consideration",
        "totalLabel": "Total consideration"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/AcquisitionsAllocationofConsiderationDetails",
      "http://www.ligand.com/role/AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther": {
     "auth_ref": [
      "r522"
     ],
     "calculation": {
      "http://www.ligand.com/role/AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 11.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of other liabilities due after one year or the normal operating cycle, if longer, assumed at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Other",
        "negatedLabel": "Other liabilities"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets": {
     "auth_ref": [
      "r522"
     ],
     "calculation": {
      "http://www.ligand.com/role/AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 14.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of other assets expected to be realized or consumed after one year or the normal operating cycle, if longer, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/AcquisitionsAllocationofConsiderationDetails",
      "http://www.ligand.com/role/AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment": {
     "auth_ref": [
      "r521",
      "r522"
     ],
     "calculation": {
      "http://www.ligand.com/role/AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of property, plant, and equipment recognized as of the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment",
        "terseLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/AcquisitionsAllocationofConsiderationDetails",
      "http://www.ligand.com/role/AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationsPolicy": {
     "auth_ref": [
      "r514"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.",
        "label": "Business Combinations Policy [Policy Text Block]",
        "terseLabel": "Acquisitions"
       }
      }
     },
     "localname": "BusinessCombinationsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "auth_ref": [
      "r130",
      "r131",
      "r132"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "terseLabel": "Purchase of fixed assets recorded in accounts payable"
       }
      }
     },
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CapitalLossCarryforwardMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deductions derived from capital losses that cannot be utilized on the tax return during a period that have been carried forward to reduce taxable income or taxes payable in a future year.",
        "label": "Capital Loss Carryforward [Member]",
        "terseLabel": "Capital Loss Carryforward"
       }
      }
     },
     "localname": "CapitalLossCarryforwardMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r19",
      "r49",
      "r128"
     ],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "verboseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r119",
      "r128",
      "r133"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, cash equivalents and restricted cash at end of year",
        "periodStartLabel": "Cash, cash equivalents and restricted cash at beginning of year"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": {
     "auth_ref": [
      "r119",
      "r603"
     ],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect",
        "totalLabel": "Net decrease in cash, cash equivalents, and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]",
        "terseLabel": "Supplemental schedule of non-cash investing and financing activities"
       }
      }
     },
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "auth_ref": [
      "r379"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "terseLabel": "Exercise price of warrants (USD per share)",
        "verboseLabel": "Warrant exercise price (USD per share)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/ConvertibleSeniorNotesNarrativeDetails",
      "http://www.ligand.com/role/ShorttermInvestmentsInvestmentinVikingNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "auth_ref": [
      "r379"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.",
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights",
        "terseLabel": "Warrants issued in public offering (shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/ConvertibleSeniorNotesNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommercialPaperMember": {
     "auth_ref": [
      "r307"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.",
        "label": "Commercial Paper [Member]",
        "terseLabel": "Commercial paper"
       }
      }
     },
     "localname": "CommercialPaperMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsAvailableforSaleDebtSecuritiesinanUnrealizedLossPositionDetails",
      "http://www.ligand.com/role/BalanceSheetAccountDetailsInvestmentCategoriesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r62",
      "r303",
      "r696",
      "r722"
     ],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "verboseLabel": "Commitments and contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r300",
      "r301",
      "r302",
      "r306",
      "r768"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitment and Contingencies: Legal Proceedings"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/CommitmentandContingenciesLegalProceedings"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockDividendsPerShareDeclared": {
     "auth_ref": [
      "r384"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate dividends declared during the period for each share of common stock outstanding.",
        "label": "Common Stock, Dividends, Per Share, Declared",
        "terseLabel": "Dividend declared (USD per share)"
       }
      }
     },
     "localname": "CommonStockDividendsPerShareDeclared",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r150",
      "r151",
      "r574"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r40"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "verboseLabel": "Common stock, par value (USD per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r40"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "verboseLabel": "Common stock authorized (shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r40"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "verboseLabel": "Common stock issued (shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r40",
      "r378"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock outstanding (shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r40",
      "r641"
     ],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "verboseLabel": "Common stock, $0.001 par value; 60,000 shares authorized; 16,767 and 16,080 shares issued and outstanding at December\u00a031, 2021 and 2020, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r83",
      "r85",
      "r86",
      "r94",
      "r699",
      "r727"
     ],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive income (loss)"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for comprehensive income.",
        "label": "Comprehensive Income, Policy [Policy Text Block]",
        "terseLabel": "Comprehensive Income (Loss)"
       }
      }
     },
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "auth_ref": [
      "r189",
      "r190",
      "r216",
      "r591",
      "r592",
      "r767"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.",
        "label": "Concentration Risk Benchmark [Domain]",
        "terseLabel": "Concentration Risk Benchmark [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskBenchmarkDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRevenuefromSignificantPartnersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "auth_ref": [
      "r189",
      "r190",
      "r216",
      "r591",
      "r592",
      "r749",
      "r767"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by benchmark of concentration risk.",
        "label": "Concentration Risk Benchmark [Axis]",
        "terseLabel": "Concentration Risk Benchmark [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRevenuefromSignificantPartnersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "auth_ref": [
      "r189",
      "r190",
      "r216",
      "r591",
      "r592",
      "r749",
      "r767"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.",
        "label": "Concentration Risk Type [Axis]",
        "terseLabel": "Concentration Risk Type [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRevenuefromSignificantPartnersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r184",
      "r711"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "verboseLabel": "Concentrations of Business Risk"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "auth_ref": [
      "r189",
      "r190",
      "r216",
      "r591",
      "r592"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.",
        "label": "Concentration Risk, Percentage",
        "terseLabel": "Total revenues (as a percent)"
       }
      }
     },
     "localname": "ConcentrationRiskPercentage1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRevenuefromSignificantPartnersDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "auth_ref": [
      "r189",
      "r190",
      "r216",
      "r591",
      "r592",
      "r767"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.",
        "label": "Concentration Risk Type [Domain]",
        "terseLabel": "Concentration Risk Type [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRevenuefromSignificantPartnersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r134",
      "r543"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Consolidation, Policy [Policy Text Block]",
        "verboseLabel": "Principles of Consolidation"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ContingentConsiderationByTypeAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of contingent consideration.",
        "label": "Contingent Consideration by Type [Axis]",
        "terseLabel": "Contingent Consideration by Type [Axis]"
       }
      }
     },
     "localname": "ContingentConsiderationByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ContingentConsiderationTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of contingent payment arrangement.",
        "label": "Contingent Consideration Type [Domain]",
        "terseLabel": "Contingent Consideration Type [Domain]"
       }
      }
     },
     "localname": "ContingentConsiderationTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ContractWithCustomerAssetGross": {
     "auth_ref": [
      "r219",
      "r256",
      "r386",
      "r388"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allowance for credit loss, of right to consideration in exchange for good or service transferred to customer, when right is conditioned on something other than passage of time.",
        "label": "Contract with Customer, Asset, before Allowance for Credit Loss",
        "terseLabel": "Gross contract asset"
       }
      }
     },
     "localname": "ContractWithCustomerAssetGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "auth_ref": [
      "r386",
      "r387",
      "r399"
     ],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Contract with Customer, Liability, Current",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": {
     "auth_ref": [
      "r400"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.",
        "label": "Contract with Customer, Liability, Revenue Recognized",
        "terseLabel": "Revenue recognized"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityRevenueRecognized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractualRightsMember": {
     "auth_ref": [
      "r528"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rights that arise from a contractual arrangement with a third party (not including franchise rights and license agreements).",
        "label": "Contractual Rights [Member]",
        "terseLabel": "Contractual relationships"
       }
      }
     },
     "localname": "ContractualRightsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsGoodwillandOtherIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConvertibleDebtFairValueDisclosures": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.",
        "label": "Convertible Debt, Fair Value Disclosures",
        "verboseLabel": "Fair value of convertible senior notes outstanding (Level 2)"
       }
      }
     },
     "localname": "ConvertibleDebtFairValueDisclosures",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/ConvertibleSeniorNotesEquityandLiabilityComponentsofFinancingArrangementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConvertibleDebtNoncurrent": {
     "auth_ref": [
      "r60"
     ],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount of long-term convertible debt as of the balance sheet date, net of the amount due in the next twelve months or greater than the normal operating cycle, if longer. The debt is convertible into another form of financial instrument, typically the entity's common stock.",
        "label": "Convertible Debt, Noncurrent",
        "verboseLabel": "2023 convertible senior notes, net"
       }
      }
     },
     "localname": "ConvertibleDebtNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConvertibleNotesPayableMember": {
     "auth_ref": [
      "r32",
      "r686",
      "r713",
      "r750"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Written promise to pay a note which can be exchanged for a specified quantity of securities (typically common stock), at the option of the issuer or the holder.",
        "label": "Convertible Notes Payable [Member]",
        "terseLabel": "Convertible Notes"
       }
      }
     },
     "localname": "ConvertibleNotesPayableMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.ligand.com/role/ConvertibleSeniorNotesEquityandLiabilityComponentsofFinancingArrangementsDetails",
      "http://www.ligand.com/role/ConvertibleSeniorNotesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "auth_ref": [
      "r410",
      "r417",
      "r748"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.",
        "label": "Corporate Debt Securities [Member]",
        "terseLabel": "Corporate bonds"
       }
      }
     },
     "localname": "CorporateDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsAvailableforSaleDebtSecuritiesinanUnrealizedLossPositionDetails",
      "http://www.ligand.com/role/BalanceSheetAccountDetailsInvestmentCategoriesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostDirectMaterial": {
     "auth_ref": [
      "r97"
     ],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingCostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cost of material used for good produced and service rendered.",
        "label": "Cost, Direct Material",
        "terseLabel": "Cost of Captisol"
       }
      }
     },
     "localname": "CostDirectMaterial",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSoldAmortization": {
     "auth_ref": [
      "r97"
     ],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingCostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for allocation of cost of intangible asset over its useful life directly used in production of good and rendering of service.",
        "label": "Cost, Amortization",
        "terseLabel": "Amortization of intangibles"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSoldAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentFederalTaxExpenseBenefit": {
     "auth_ref": [
      "r141",
      "r497",
      "r506"
     ],
     "calculation": {
      "http://www.ligand.com/role/IncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current federal tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Current Federal Tax Expense (Benefit)",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "CurrentFederalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentForeignTaxExpenseBenefit": {
     "auth_ref": [
      "r141",
      "r497"
     ],
     "calculation": {
      "http://www.ligand.com/role/IncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Current Foreign Tax Expense (Benefit)",
        "terseLabel": "Foreign"
       }
      }
     },
     "localname": "CurrentForeignTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r141",
      "r497",
      "r506",
      "r508"
     ],
     "calculation": {
      "http://www.ligand.com/role/IncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.",
        "label": "Current Income Tax Expense (Benefit)",
        "totalLabel": "Total current expense (benefit)"
       }
      }
     },
     "localname": "CurrentIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Income Tax Expense (Benefit), Continuing Operations [Abstract]",
        "terseLabel": "Current expense (benefit):"
       }
      }
     },
     "localname": "CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": {
     "auth_ref": [
      "r141",
      "r497",
      "r506"
     ],
     "calculation": {
      "http://www.ligand.com/role/IncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current state and local tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Current State and Local Tax Expense (Benefit)",
        "terseLabel": "State"
       }
      }
     },
     "localname": "CurrentStateAndLocalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "auth_ref": [
      "r188",
      "r216"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.",
        "label": "Customer Concentration Risk [Member]",
        "terseLabel": "Customer Concentration Risk"
       }
      }
     },
     "localname": "CustomerConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRevenuefromSignificantPartnersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CustomerRelationshipsMember": {
     "auth_ref": [
      "r526"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Customer relationship that exists between an entity and its customer, for example, but not limited to, tenant relationships.",
        "label": "Customer Relationships [Member]",
        "terseLabel": "Customer Relationships",
        "verboseLabel": "Customer relationships"
       }
      }
     },
     "localname": "CustomerRelationshipsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/AcquisitionsNarrativeDetails",
      "http://www.ligand.com/role/BalanceSheetAccountDetailsGoodwillandOtherIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtConversionConvertedInstrumentAmount1": {
     "auth_ref": [
      "r130",
      "r132"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Debt Conversion, Converted Instrument, Amount",
        "terseLabel": "Notices for conversion"
       }
      }
     },
     "localname": "DebtConversionConvertedInstrumentAmount1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/ConvertibleSeniorNotesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r137",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r340",
      "r347",
      "r348",
      "r350",
      "r361"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "Convertible Senior Notes"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/ConvertibleSeniorNotes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r32",
      "r34",
      "r35",
      "r139",
      "r148",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r330",
      "r336",
      "r337",
      "r338",
      "r339",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r355",
      "r356",
      "r357",
      "r358",
      "r616",
      "r686",
      "r689",
      "r713"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.ligand.com/role/ConvertibleSeniorNotesEquityandLiabilityComponentsofFinancingArrangementsDetails",
      "http://www.ligand.com/role/ConvertibleSeniorNotesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature": {
     "auth_ref": [
      "r383"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of a favorable spread to a debt holder between the amount of debt being converted and the value of the securities received upon conversion. This is an embedded conversion feature of convertible debt issued that is in-the-money at the commitment date.",
        "label": "Debt Instrument, Convertible, Beneficial Conversion Feature",
        "terseLabel": "Conversion value over the principal amount"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleBeneficialConversionFeature",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/ConvertibleSeniorNotesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent": {
     "auth_ref": [
      "r351"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The carrying amount of the equity component of convertible debt which may be settled in cash upon conversion.",
        "label": "Debt Instrument, Convertible, Carrying Amount of Equity Component",
        "netLabel": "Carrying value of equity component of 2023 Notes"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/ConvertibleSeniorNotesEquityandLiabilityComponentsofFinancingArrangementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentConvertibleConversionPrice1": {
     "auth_ref": [
      "r325",
      "r352"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The price per share of the conversion feature embedded in the debt instrument.",
        "label": "Debt Instrument, Convertible, Conversion Price",
        "terseLabel": "Debt conversion price per share (USD per share)"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleConversionPrice1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/ConvertibleSeniorNotesNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_DebtInstrumentConvertibleConversionRatio1": {
     "auth_ref": [
      "r59",
      "r325",
      "r379",
      "r380",
      "r382"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ratio applied to the conversion of debt instrument into equity with equity shares divided by debt principal amount.",
        "label": "Debt Instrument, Convertible, Conversion Ratio",
        "terseLabel": "Convertible debt conversion ratio"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleConversionRatio1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/ConvertibleSeniorNotesNarrativeDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "us-gaap_DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal": {
     "auth_ref": [
      "r353"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount by which the convertible debt's if-converted value exceeds its principle amount at the balance sheet date, regardless of whether the instrument is currently convertible. This element applies to public companies only.",
        "label": "Debt Instrument, Convertible, If-converted Value in Excess of Principal",
        "terseLabel": "If-converted value in excess of principal"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/ConvertibleSeniorNotesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Threshold period of specified consecutive trading days within which common stock price to conversion price of convertible debt instrument must exceed threshold percentage for specified number of trading days to trigger conversion feature.",
        "label": "Debt Instrument, Convertible, Threshold Consecutive Trading Days",
        "terseLabel": "Number of consecutive trading days"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleThresholdConsecutiveTradingDays1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/ConvertibleSeniorNotesNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum percentage of common stock price to conversion price of convertible debt instruments to determine eligibility of conversion.",
        "label": "Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger",
        "terseLabel": "Stock price trigger to classify convertible debt as current (as a percent)"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/ConvertibleSeniorNotesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentConvertibleThresholdTradingDays": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Threshold number of specified trading days that common stock price to conversion price of convertible debt instruments must exceed threshold percentage within a specified consecutive trading period to trigger conversion feature.",
        "label": "Debt Instrument, Convertible, Threshold Trading Days",
        "terseLabel": "Number of trading days"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleThresholdTradingDays",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/ConvertibleSeniorNotesNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r323",
      "r355",
      "r356",
      "r614",
      "r616",
      "r617"
     ],
     "calculation": {
      "http://www.ligand.com/role/ConvertibleSeniorNotesEquityandLiabilityComponentsofFinancingArrangementsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LongTermNotesPayable",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instrument, Face Amount",
        "terseLabel": "Principal amount of 2023 Notes outstanding",
        "verboseLabel": "Face amount of debt instrument"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.ligand.com/role/ConvertibleSeniorNotesEquityandLiabilityComponentsofFinancingArrangementsDetails",
      "http://www.ligand.com/role/ConvertibleSeniorNotesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateEffectivePercentage": {
     "auth_ref": [
      "r58",
      "r354",
      "r614",
      "r616"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.",
        "label": "Debt Instrument, Interest Rate, Effective Percentage",
        "terseLabel": "Effective rate (as a percent)"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateEffectivePercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/ConvertibleSeniorNotesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r58",
      "r324"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Interest on debt instrument (as a percent)"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.ligand.com/role/ConvertibleSeniorNotesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/ConvertibleSeniorNotesEquityandLiabilityComponentsofFinancingArrangementsDetails",
      "http://www.ligand.com/role/ConvertibleSeniorNotesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r60",
      "r139",
      "r148",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r330",
      "r336",
      "r337",
      "r338",
      "r339",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r355",
      "r356",
      "r357",
      "r358",
      "r616"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.ligand.com/role/ConvertibleSeniorNotesEquityandLiabilityComponentsofFinancingArrangementsDetails",
      "http://www.ligand.com/role/ConvertibleSeniorNotesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodAxis": {
     "auth_ref": [
      "r709"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information about timing of debt redemption features under terms of the debt agreement.",
        "label": "Debt Instrument, Redemption, Period [Axis]",
        "terseLabel": "Debt Instrument, Redemption, Period [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/ConvertibleSeniorNotesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodDomain": {
     "auth_ref": [
      "r709"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period as defined under terms of the debt agreement for debt redemption features.",
        "label": "Debt Instrument, Redemption, Period [Domain]",
        "terseLabel": "Debt Instrument, Redemption, Period [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/ConvertibleSeniorNotesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodOneMember": {
     "auth_ref": [
      "r709"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period one representing most current period of debt redemption features under terms of the debt agreement.",
        "label": "Debt Instrument, Redemption, Period One [Member]",
        "terseLabel": "Redemption Period One"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodOneMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/ConvertibleSeniorNotesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodTwoMember": {
     "auth_ref": [
      "r709"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period two representing second most current period of debt redemption features under terms of the debt agreement.",
        "label": "Debt Instrument, Redemption, Period Two [Member]",
        "terseLabel": "Redemption Period Two"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodTwoMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/ConvertibleSeniorNotesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentRepurchaseAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value amount of debt instrument that was repurchased.",
        "label": "Debt Instrument, Repurchase Amount",
        "terseLabel": "Repurchased amount of debt instrument"
       }
      }
     },
     "localname": "DebtInstrumentRepurchaseAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/ConvertibleSeniorNotesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r60",
      "r139",
      "r148",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r330",
      "r336",
      "r337",
      "r338",
      "r339",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r349",
      "r355",
      "r356",
      "r357",
      "r358",
      "r379",
      "r381",
      "r382",
      "r383",
      "r613",
      "r614",
      "r616",
      "r617",
      "r710"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-term Debt Instruments [Table]",
        "terseLabel": "Schedule of Long-term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/ConvertibleSeniorNotesEquityandLiabilityComponentsofFinancingArrangementsDetails",
      "http://www.ligand.com/role/ConvertibleSeniorNotesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentUnamortizedDiscount": {
     "auth_ref": [
      "r336",
      "r613",
      "r617"
     ],
     "calculation": {
      "http://www.ligand.com/role/ConvertibleSeniorNotesEquityandLiabilityComponentsofFinancingArrangementsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LongTermNotesPayable",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of debt discount.",
        "label": "Debt Instrument, Unamortized Discount",
        "negatedTerseLabel": "Unamortized discount (including unamortized debt issuance cost)"
       }
      }
     },
     "localname": "DebtInstrumentUnamortizedDiscount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/ConvertibleSeniorNotesEquityandLiabilityComponentsofFinancingArrangementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentUnamortizedPremium": {
     "auth_ref": [
      "r336",
      "r613",
      "r617"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of debt premium.",
        "label": "Debt Instrument, Unamortized Premium",
        "terseLabel": "Debt issuance costs related to the liability component of convertible debt"
       }
      }
     },
     "localname": "DebtInstrumentUnamortizedPremium",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/ConvertibleSeniorNotesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger": {
     "auth_ref": [
      "r241",
      "r264",
      "r267"
     ],
     "calculation": {
      "http://www.ligand.com/role/BalanceSheetAccountDetailsAvailableforSaleDebtSecuritiesinanUnrealizedLossPositionDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for more than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer",
        "terseLabel": "12 months or greater"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsAvailableforSaleDebtSecuritiesinanUnrealizedLossPositionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months": {
     "auth_ref": [
      "r241",
      "r264",
      "r267"
     ],
     "calculation": {
      "http://www.ligand.com/role/BalanceSheetAccountDetailsAvailableforSaleDebtSecuritiesinanUnrealizedLossPositionDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months",
        "terseLabel": "Less than 12 months"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsAvailableforSaleDebtSecuritiesinanUnrealizedLossPositionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss": {
     "auth_ref": [
      "r241",
      "r264"
     ],
     "calculation": {
      "http://www.ligand.com/role/BalanceSheetAccountDetailsAvailableforSaleDebtSecuritiesinanUnrealizedLossPositionDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionAccumulatedLoss",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss",
        "negatedTerseLabel": "Less than 12 months"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsAvailableforSaleDebtSecuritiesinanUnrealizedLossPositionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTable": {
     "auth_ref": [
      "r242"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale [Table]",
        "terseLabel": "Debt Securities, Available-for-sale [Table]"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsInvestmentCategoriesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": {
     "auth_ref": [
      "r242"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale [Table Text Block]",
        "terseLabel": "Schedule of Available-for-Sale Debt Securities by Contractual Maturity"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Unrealized Gain (Loss)",
        "terseLabel": "Unrealized net gain (loss) on available-for-sale securities, net of deferred tax"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition": {
     "auth_ref": [
      "r238",
      "r261",
      "r267"
     ],
     "calculation": {
      "http://www.ligand.com/role/BalanceSheetAccountDetailsAvailableforSaleDebtSecuritiesinanUnrealizedLossPositionDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss.",
        "label": "Debt Securities, Available-for-sale, Unrealized Loss Position",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPosition",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsAvailableforSaleDebtSecuritiesinanUnrealizedLossPositionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable": {
     "auth_ref": [
      "r260",
      "r267"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-sale, Unrealized Loss Position, Fair Value [Table]",
        "terseLabel": "Debt Securities, Available-for-sale, Unrealized Loss Position, Fair Value [Table]"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsAvailableforSaleDebtSecuritiesinanUnrealizedLossPositionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock": {
     "auth_ref": [
      "r237",
      "r263",
      "r267"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-sale, Unrealized Loss Position, Fair Value [Table Text Block]",
        "terseLabel": "Schedule of Available-for-Sale Debt Securities in an Unrealized Loss Position"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions": {
     "auth_ref": [
      "r240",
      "r262"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-sale, Unrealized Loss Position, Number of Positions",
        "terseLabel": "Number of positions in an unrealized loss position"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r141",
      "r498",
      "r506"
     ],
     "calculation": {
      "http://www.ligand.com/role/IncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Federal Income Tax Expense (Benefit)",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "DeferredFederalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredFinanceCostsGross": {
     "auth_ref": [
      "r615"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.",
        "label": "Debt Issuance Costs, Gross",
        "terseLabel": "Debt issuance costs"
       }
      }
     },
     "localname": "DeferredFinanceCostsGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/ConvertibleSeniorNotesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxAssetsNet": {
     "auth_ref": [
      "r474",
      "r475"
     ],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.",
        "label": "Deferred Income Tax Assets, Net",
        "terseLabel": "Deferred income taxes, net"
       }
      }
     },
     "localname": "DeferredIncomeTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r126",
      "r141",
      "r498",
      "r506",
      "r507",
      "r508"
     ],
     "calculation": {
      "http://www.ligand.com/role/IncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Income Tax Expense (Benefit)",
        "totalLabel": "Total deferred expense (benefit)"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]",
        "terseLabel": "Deferred expense (benefit):"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "auth_ref": [
      "r37",
      "r38",
      "r487",
      "r687",
      "r712"
     ],
     "calculation": {
      "http://www.ligand.com/role/IncomeTaxesDeferredTaxesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences.",
        "label": "Deferred Tax Liabilities, Gross",
        "negatedTotalLabel": "Net deferred tax liabilities"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesDeferredTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilitiesNet": {
     "auth_ref": [
      "r474",
      "r475"
     ],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.",
        "label": "Deferred Income Tax Liabilities, Net",
        "terseLabel": "Deferred income taxes, net"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r141",
      "r498",
      "r506"
     ],
     "calculation": {
      "http://www.ligand.com/role/IncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred state and local tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred State and Local Income Tax Expense (Benefit)",
        "terseLabel": "State"
       }
      }
     },
     "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r488"
     ],
     "calculation": {
      "http://www.ligand.com/role/IncomeTaxesDeferredTaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesDeferredTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGrossAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Gross [Abstract]",
        "terseLabel": "Deferred tax assets:"
       }
      }
     },
     "localname": "DeferredTaxAssetsGrossAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesDeferredTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "auth_ref": [
      "r490"
     ],
     "calculation": {
      "http://www.ligand.com/role/IncomeTaxesDeferredTaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "totalLabel": "Net deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesDeferredTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "auth_ref": [
      "r495",
      "r496"
     ],
     "calculation": {
      "http://www.ligand.com/role/IncomeTaxesDeferredTaxesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesDeferredTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "auth_ref": [
      "r495",
      "r496"
     ],
     "calculation": {
      "http://www.ligand.com/role/IncomeTaxesDeferredTaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.",
        "label": "Deferred Tax Assets, Other",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "DeferredTaxAssetsOther",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesDeferredTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwards": {
     "auth_ref": [
      "r493",
      "r495",
      "r496"
     ],
     "calculation": {
      "http://www.ligand.com/role/IncomeTaxesDeferredTaxesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards",
        "terseLabel": "Research credit carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxCreditCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesDeferredTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "auth_ref": [
      "r495",
      "r496"
     ],
     "calculation": {
      "http://www.ligand.com/role/IncomeTaxesDeferredTaxesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost",
        "terseLabel": "Stock compensation"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesDeferredTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r489"
     ],
     "calculation": {
      "http://www.ligand.com/role/IncomeTaxesDeferredTaxesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedTerseLabel": "Valuation allowance for deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesDeferredTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilities": {
     "auth_ref": [
      "r475",
      "r490"
     ],
     "calculation": {
      "http://www.ligand.com/role/IncomeTaxesDeferredTaxesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.",
        "label": "Deferred Tax Liabilities, Net",
        "negatedTotalLabel": "Deferred income taxes, net"
       }
      }
     },
     "localname": "DeferredTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesDeferredTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities, Gross [Abstract]",
        "terseLabel": "Deferred tax liabilities:"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesDeferredTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesOther": {
     "auth_ref": [
      "r495",
      "r496"
     ],
     "calculation": {
      "http://www.ligand.com/role/IncomeTaxesDeferredTaxesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences classified as other.",
        "label": "Deferred Tax Liabilities, Other",
        "negatedLabel": "Other"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesOther",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesDeferredTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DemandDepositsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounts that may or may not bear interest and that depositor is entitled to withdraw at anytime without prior notice. Checking and negotiable order of withdrawal (NOW) accounts are the most common forms of demand deposits.",
        "label": "Demand Deposits [Member]",
        "terseLabel": "Bank deposits"
       }
      }
     },
     "localname": "DemandDepositsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsAvailableforSaleDebtSecuritiesinanUnrealizedLossPositionDetails",
      "http://www.ligand.com/role/BalanceSheetAccountDetailsInvestmentCategoriesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r126",
      "r291"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "verboseLabel": "Depreciation expense"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r126",
      "r201"
     ],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "verboseLabel": "Depreciation of fixed assets and amortization of intangible assets"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeAssets": {
     "auth_ref": [
      "r69",
      "r70",
      "r73",
      "r590"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset.",
        "label": "Derivative Asset",
        "terseLabel": "Derivative asset"
       }
      }
     },
     "localname": "DerivativeAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeGainLossOnDerivativeNet": {
     "auth_ref": [
      "r562"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.",
        "label": "Derivative, Gain (Loss) on Derivative, Net",
        "negatedLabel": "Net change in fair value of derivatives",
        "terseLabel": "Gain (loss) on derivative liabilities"
       }
      }
     },
     "localname": "DerivativeGainLossOnDerivativeNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/ConvertibleSeniorNotesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeLiabilities": {
     "auth_ref": [
      "r69",
      "r70",
      "r73",
      "r590"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.",
        "label": "Derivative Liability",
        "terseLabel": "Derivative liability"
       }
      }
     },
     "localname": "DerivativeLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativesPolicyTextBlock": {
     "auth_ref": [
      "r147",
      "r558",
      "r559",
      "r560",
      "r561",
      "r564"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities.",
        "label": "Derivatives, Policy [Policy Text Block]",
        "terseLabel": "Derivatives"
       }
      }
     },
     "localname": "DerivativesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Disaggregation of Revenue [Line Items]",
        "terseLabel": "Disaggregation of Revenue [Line Items]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRoyaltyRevenueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "auth_ref": [
      "r398",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table]",
        "terseLabel": "Disaggregation of Revenue [Table]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRoyaltyRevenueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "auth_ref": [
      "r398"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table Text Block]",
        "terseLabel": "Schedule of Disaggregation of Revenue"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock": {
     "auth_ref": [
      "r426",
      "r456"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of share-based payment arrangement.",
        "label": "Disclosure of Share-based Compensation Arrangements by Share-based Payment Award [Table Text Block]",
        "terseLabel": "Schedule of Share-Based Compensation Expense"
       }
      }
     },
     "localname": "DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Discontinued Operations and Disposal Groups [Abstract]"
       }
      }
     },
     "localname": "DiscontinuedOperationsAndDisposalGroupsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisposalGroupClassificationAxis": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by disposal group classification.",
        "label": "Disposal Group Classification [Axis]",
        "terseLabel": "Disposal Group Classification [Axis]"
       }
      }
     },
     "localname": "DisposalGroupClassificationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/SaleofVernalisRDandPromactaLicenseNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisposalGroupClassificationDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Component or group of components disposed of, including but not limited to, disposal group held-for-sale or disposed of by sale, disposed of by means other than sale, and discontinued operations.",
        "label": "Disposal Group Classification [Domain]",
        "terseLabel": "Disposal Group Classification [Domain]"
       }
      }
     },
     "localname": "DisposalGroupClassificationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/SaleofVernalisRDandPromactaLicenseNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember": {
     "auth_ref": [
      "r288",
      "r290",
      "r296"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disposal group that either has been sold or is classified as held-for-sale. Excludes disposals classified as discontinued operations.",
        "label": "Disposal Group, Held-for-sale or Disposed of by Sale, Not Discontinued Operations [Member]",
        "terseLabel": "Disposal Group, Held-for-sale or Disposed of by Sale, Not Discontinued Operations"
       }
      }
     },
     "localname": "DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/SaleofVernalisRDandPromactaLicenseNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock": {
     "auth_ref": [
      "r17",
      "r298"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.",
        "label": "Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]",
        "terseLabel": "Sale of Vernalis R&amp;D and Promacta License"
       }
      }
     },
     "localname": "DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/SaleofVernalisRDandPromactaLicense"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain": {
     "auth_ref": [
      "r418",
      "r420"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of disposal group.",
        "label": "Disposal Group Name [Domain]",
        "terseLabel": "Disposal Group Name [Domain]"
       }
      }
     },
     "localname": "DisposalGroupsIncludingDiscontinuedOperationsNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/SaleofVernalisRDandPromactaLicenseNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r95",
      "r158",
      "r159",
      "r160",
      "r161",
      "r162",
      "r167",
      "r169",
      "r172",
      "r173",
      "r174",
      "r177",
      "r178",
      "r575",
      "r576",
      "r700",
      "r728"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "verboseLabel": "Basic net income (loss) per share (USD per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r95",
      "r158",
      "r159",
      "r160",
      "r161",
      "r162",
      "r169",
      "r172",
      "r173",
      "r174",
      "r177",
      "r178",
      "r575",
      "r576",
      "r700",
      "r728"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "netLabel": "Diluted net income (loss) per share (USD per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDilutedLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Line Items]",
        "terseLabel": "Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Line Items]"
       }
      }
     },
     "localname": "EarningsPerShareDilutedLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCalculationofEarningsperShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r175",
      "r176"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "verboseLabel": "Income (Loss) Per Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EarningsPerShareProFormaAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Pro Forma [Abstract]",
        "terseLabel": "Net income (loss) per common share:"
       }
      }
     },
     "localname": "EarningsPerShareProFormaAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/AcquisitionsProFormaFinancialInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r603"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "terseLabel": "Effect of exchange rate changes on cash"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r56"
     ],
     "calculation": {
      "http://www.ligand.com/role/BalanceSheetAccountDetailsAccruedLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Compensation"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards": {
     "auth_ref": [
      "r455"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate cash paid by the entity during the period to settle equity instruments granted under equity-based payment arrangements.",
        "label": "Share-based Payment Arrangement, Cash Used to Settle Award",
        "terseLabel": "Cash to settle unvested stock options recognized as share-based compensation expense"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r454"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "verboseLabel": "Weighted-average period in which cost is expected to be recognized"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": {
     "auth_ref": [
      "r454"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount",
        "verboseLabel": "Unrecognized compensation cost, restricted stock"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "auth_ref": [
      "r454"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "verboseLabel": "Unrecognized compensation cost"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r453"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-based Payment Arrangement, Option [Member]",
        "terseLabel": "Stock Options"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCalculationofEarningsperShareDetails",
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.ligand.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EntityWideRevenueMajorCustomerLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Revenue, Major Customer [Line Items]",
        "terseLabel": "Revenue, Major Customer"
       }
      }
     },
     "localname": "EntityWideRevenueMajorCustomerLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRevenuefromSignificantPartnersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r2",
      "r88",
      "r89",
      "r90",
      "r150",
      "r151",
      "r152",
      "r155",
      "r163",
      "r165",
      "r180",
      "r251",
      "r378",
      "r384",
      "r462",
      "r463",
      "r464",
      "r502",
      "r503",
      "r574",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r738",
      "r739",
      "r740",
      "r795"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquitySecuritiesFvNi": {
     "auth_ref": [
      "r589"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current.",
        "label": "Equity Securities, FV-NI, Current",
        "terseLabel": "Investment in Viking common stock"
       }
      }
     },
     "localname": "EquitySecuritiesFvNi",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/ShorttermInvestmentsInvestmentinVikingNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesFvNiMeasurementInput": {
     "auth_ref": [
      "r582"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of input used to measure investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Equity Securities, FV-NI, Measurement Input",
        "terseLabel": "Measurement input (as a percent)"
       }
      }
     },
     "localname": "EquitySecuritiesFvNiMeasurementInput",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "us-gaap_EquitySecuritiesMember": {
     "auth_ref": [
      "r29",
      "r33",
      "r242",
      "r714",
      "r764",
      "r765",
      "r766"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ownership interest or right to acquire or dispose of ownership interest in corporations and other legal entities for which ownership interest is represented by shares of common or preferred stock, convertible securities, stock rights, or stock warrants.",
        "label": "Equity Securities [Member]",
        "terseLabel": "Corporate equity securities",
        "verboseLabel": "Investment in Viking common stock"
       }
      }
     },
     "localname": "EquitySecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsInvestmentCategoriesDetails",
      "http://www.ligand.com/role/FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
      "http://www.ligand.com/role/FairValueMeasurementReconciliationofLevel3FinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r577",
      "r578",
      "r579",
      "r587"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value Measurements, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
      "http://www.ligand.com/role/FairValueMeasurementReconciliationofLevel3FinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock": {
     "auth_ref": [
      "r577",
      "r578",
      "r579",
      "r586",
      "r587"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.",
        "label": "Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]",
        "terseLabel": "Schedule of Assets and Liabilities Measured at Fair Value"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/FairValueMeasurementTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": {
     "auth_ref": [
      "r583"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of asset.",
        "label": "Asset Class [Domain]",
        "terseLabel": "Fair Value by Asset Class [Domain]"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueByAssetClassAxis": {
     "auth_ref": [
      "r577",
      "r587"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by class of asset.",
        "label": "Asset Class [Axis]",
        "terseLabel": "Asset Class [Axis]"
       }
      }
     },
     "localname": "FairValueByAssetClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r338",
      "r355",
      "r356",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r578",
      "r646",
      "r647",
      "r648"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
      "http://www.ligand.com/role/FairValueMeasurementReconciliationofLevel3FinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByLiabilityClassAxis": {
     "auth_ref": [
      "r585",
      "r587"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by class of liability.",
        "label": "Liability Class [Axis]",
        "terseLabel": "Liability Class [Axis]"
       }
      }
     },
     "localname": "FairValueByLiabilityClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r577",
      "r578",
      "r581",
      "r582",
      "r588"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r338",
      "r410",
      "r411",
      "r416",
      "r417",
      "r578",
      "r646"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "verboseLabel": "Quoted Prices in Active Markets for Identical Assets (Level 1)"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r338",
      "r355",
      "r356",
      "r410",
      "r411",
      "r416",
      "r417",
      "r578",
      "r647"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "verboseLabel": "Significant Other Observable Inputs (Level 2)"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r338",
      "r355",
      "r356",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r578",
      "r648"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Level 3",
        "verboseLabel": "Significant Unobservable Inputs (Level 3)"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
      "http://www.ligand.com/role/FairValueMeasurementReconciliationofLevel3FinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain": {
     "auth_ref": [
      "r583"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents classes of liabilities measured and disclosed at fair value.",
        "label": "Fair Value by Liability Class [Domain]",
        "terseLabel": "Fair Value by Liability Class [Domain]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]",
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/FairValueMeasurementReconciliationofLevel3FinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
     "auth_ref": [
      "r583",
      "r587"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of Reconciliation of Level 3 Financial Instruments"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/FairValueMeasurementTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Fair Value, Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": {
     "auth_ref": [
      "r584"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings",
        "terseLabel": "Fair value adjustments to contingent liabilities"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/FairValueMeasurementReconciliationofLevel3FinancialInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": {
     "auth_ref": [
      "r583"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value",
        "periodEndLabel": "Fair value of level 3 financial instruments at end of period",
        "periodStartLabel": "Fair value of level 3 financial instruments at beginning of period"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/FairValueMeasurementReconciliationofLevel3FinancialInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r338",
      "r355",
      "r356",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r646",
      "r647",
      "r648"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value, Measurements, Fair Value Hierarchy [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
      "http://www.ligand.com/role/FairValueMeasurementReconciliationofLevel3FinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r585",
      "r588"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "verboseLabel": "Recurring"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinanceLeaseInterestExpense": {
     "auth_ref": [
      "r621",
      "r629",
      "r636"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of interest expense on finance lease liability.",
        "label": "Finance Lease, Interest Expense",
        "terseLabel": "Finance lease expense"
       }
      }
     },
     "localname": "FinanceLeaseInterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseInterestPaymentOnLiability": {
     "auth_ref": [
      "r624",
      "r631"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of interest paid on finance lease liability.",
        "label": "Finance Lease, Interest Payment on Liability",
        "terseLabel": "Cash paid for amounts included in finance lease liabilities"
       }
      }
     },
     "localname": "FinanceLeaseInterestPaymentOnLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Liability, Payment, Due [Abstract]",
        "terseLabel": "Finance Leases"
       }
      }
     },
     "localname": "FinanceLeaseLiabilitiesPaymentsDueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FinanceLeaseLiability": {
     "auth_ref": [
      "r619",
      "r635"
     ],
     "calculation": {
      "http://www.ligand.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease.",
        "label": "Finance Lease, Liability",
        "terseLabel": "Present value of lease liabilities",
        "verboseLabel": "Finance lease liability"
       }
      }
     },
     "localname": "FinanceLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails",
      "http://www.ligand.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityCurrent": {
     "auth_ref": [
      "r619"
     ],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 6.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      },
      "http://www.ligand.com/role/LeasesOperatingandFinanceLeaseAssetsandLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "lgnd_LeaseLiabilityCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.",
        "label": "Finance Lease, Liability, Current",
        "terseLabel": "Current finance lease liabilities"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.ligand.com/role/LeasesOperatingandFinanceLeaseAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r635"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of finance lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to finance lease liability recognized in statement of financial position.",
        "label": "Finance Lease, Liability, Fiscal Year Maturity [Table Text Block]",
        "terseLabel": "Schedule of Maturity of Finance Lease Liabilities"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FinanceLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r619"
     ],
     "calculation": {
      "http://www.ligand.com/role/LeasesOperatingandFinanceLeaseAssetsandLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "lgnd_LeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.",
        "label": "Finance Lease, Liability, Noncurrent",
        "terseLabel": "Long-term finance lease liabilities"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/LeasesOperatingandFinanceLeaseAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r620"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes noncurrent finance lease liability.",
        "label": "Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]",
        "terseLabel": "Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/LeasesOperatingandFinanceLeaseAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r635"
     ],
     "calculation": {
      "http://www.ligand.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.ligand.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease.",
        "label": "Finance Lease, Liability, Payment, Due",
        "totalLabel": "Total lease payments"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive": {
     "auth_ref": [
      "r635"
     ],
     "calculation": {
      "http://www.ligand.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails_1": {
       "order": 6.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finance Lease, Liability, to be Paid, after Year Five",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r635"
     ],
     "calculation": {
      "http://www.ligand.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finance Lease, Liability, to be Paid, Year One",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive": {
     "auth_ref": [
      "r635"
     ],
     "calculation": {
      "http://www.ligand.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails_1": {
       "order": 5.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finance Lease, Liability, to be Paid, Year Five",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueYearFive",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r635"
     ],
     "calculation": {
      "http://www.ligand.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails_1": {
       "order": 4.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finance Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r635"
     ],
     "calculation": {
      "http://www.ligand.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails_1": {
       "order": 3.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finance Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r635"
     ],
     "calculation": {
      "http://www.ligand.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finance Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r635"
     ],
     "calculation": {
      "http://www.ligand.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease.",
        "label": "Finance Lease, Liability, Undiscounted Excess Amount",
        "negatedTerseLabel": "Less imputed interest"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeasePrincipalPayments": {
     "auth_ref": [
      "r623",
      "r631"
     ],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for principal payment on finance lease.",
        "label": "Finance Lease, Principal Payments",
        "negatedTerseLabel": "Payments under finance lease obligations"
       }
      }
     },
     "localname": "FinanceLeasePrincipalPayments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseRightOfUseAsset": {
     "auth_ref": [
      "r618"
     ],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 8.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.ligand.com/role/LeasesOperatingandFinanceLeaseAssetsandLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "lgnd_LeaseRightOfUseAsset",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of right-of-use asset from finance lease.",
        "label": "Finance Lease, Right-of-Use Asset, after Accumulated Amortization",
        "terseLabel": "Finance lease assets"
       }
      }
     },
     "localname": "FinanceLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.ligand.com/role/LeasesOperatingandFinanceLeaseAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r634",
      "r636"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for finance lease calculated at point in time.",
        "label": "Finance Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted-average discount rate of finance leases (as a percent)"
       }
      }
     },
     "localname": "FinanceLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r633",
      "r636"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Finance Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted-average remaining lease term of finance leases"
       }
      }
     },
     "localname": "FinanceLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r235",
      "r236",
      "r243",
      "r244",
      "r245",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r263",
      "r265",
      "r266",
      "r267",
      "r349",
      "r376",
      "r565",
      "r643",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r649",
      "r650",
      "r651",
      "r652",
      "r653",
      "r654",
      "r655",
      "r656",
      "r657",
      "r658",
      "r659",
      "r660",
      "r661",
      "r662",
      "r663",
      "r664",
      "r665",
      "r666",
      "r667",
      "r668",
      "r669",
      "r670",
      "r671",
      "r672",
      "r782",
      "r783",
      "r784",
      "r785",
      "r786",
      "r787",
      "r788"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsAvailableforSaleDebtSecuritiesinanUnrealizedLossPositionDetails",
      "http://www.ligand.com/role/ShorttermInvestmentsInvestmentinVikingNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FinancialInstrumentsDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for financial instruments. This disclosure includes, but is not limited to, fair value measurements of short and long term marketable securities, international currencies forward contracts, and auction rate securities. Financial instruments may include hedging and non-hedging currency exchange instruments, derivatives, securitizations and securities available for sale at fair value. Also included are investment results, realized and unrealized gains and losses as well as impairments and risk management disclosures.",
        "label": "Financial Instruments Disclosure [Text Block]",
        "terseLabel": "Fair Value Measurement"
       }
      }
     },
     "localname": "FinancialInstrumentsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/FairValueMeasurement"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Finite-Lived Intangible Asset, Useful Life",
        "verboseLabel": "Finite-lived intangible asset, useful life"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/AcquisitionsNarrativeDetails",
      "http://www.ligand.com/role/BalanceSheetAccountDetailsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "auth_ref": [
      "r283"
     ],
     "calculation": {
      "http://www.ligand.com/role/BalanceSheetAccountDetailsGoodwillandOtherIntangibleAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IntangibleAssetsNetIncludingGoodwill",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "negatedLabel": "Less: Accumulated amortization",
        "terseLabel": "Accumulated amortization on finite-lived intangible assets"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsGoodwillandOtherIntangibleAssetsDetails",
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCommercialLicenseRightsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "auth_ref": [
      "r285"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One",
        "verboseLabel": "Estimated amortization expense for 2022"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "auth_ref": [
      "r285"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four",
        "terseLabel": "Estimated amortization expense for 2025"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "auth_ref": [
      "r285"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three",
        "terseLabel": "Estimated amortization expense for 2024"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "auth_ref": [
      "r285"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two",
        "terseLabel": "Estimated amortization expense for 2023"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r278",
      "r280",
      "r283",
      "r286",
      "r678",
      "r682"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/AcquisitionsIntangiblesAcquiredandWeightedAverageUsefulLifeDetails",
      "http://www.ligand.com/role/AcquisitionsNarrativeDetails",
      "http://www.ligand.com/role/BalanceSheetAccountDetailsGoodwillandOtherIntangibleAssetsDetails",
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCommercialLicenseRightsDetails",
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.ligand.com/role/SaleofVernalisRDandPromactaLicenseNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "auth_ref": [
      "r283",
      "r682"
     ],
     "calculation": {
      "http://www.ligand.com/role/BalanceSheetAccountDetailsGoodwillandOtherIntangibleAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IntangibleAssetsNetIncludingGoodwill",
       "weight": 1.0
      },
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCommercialLicenseRightsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Gross",
        "terseLabel": "Definite-lived intangible assets",
        "verboseLabel": "Gross"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsGoodwillandOtherIntangibleAssetsDetails",
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCommercialLicenseRightsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Finite-Lived Intangible Assets [Line Items]",
        "terseLabel": "Finite-Lived Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsGoodwillandOtherIntangibleAssetsDetails",
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCommercialLicenseRightsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r278",
      "r282"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/AcquisitionsIntangiblesAcquiredandWeightedAverageUsefulLifeDetails",
      "http://www.ligand.com/role/AcquisitionsNarrativeDetails",
      "http://www.ligand.com/role/BalanceSheetAccountDetailsGoodwillandOtherIntangibleAssetsDetails",
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCommercialLicenseRightsDetails",
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.ligand.com/role/SaleofVernalisRDandPromactaLicenseNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "auth_ref": [
      "r283",
      "r678"
     ],
     "calculation": {
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCommercialLicenseRightsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Net",
        "terseLabel": "Finite-lived intangible assets, net",
        "totalLabel": "Net"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCommercialLicenseRightsDetails",
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax departments of governments entitled to levy and collect income taxes from the entity outside the entity's country of domicile.",
        "label": "Foreign Tax Authority [Member]",
        "terseLabel": "Non-US"
       }
      }
     },
     "localname": "ForeignCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "auth_ref": [
      "r611"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.",
        "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]",
        "terseLabel": "Foreign Currency Translation"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GainContingenciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Gain Contingencies [Line Items]",
        "terseLabel": "Gain Contingencies [Line Items]"
       }
      }
     },
     "localname": "GainContingenciesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/CommitmentandContingenciesLegalProceedingsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GainContingenciesTable": {
     "auth_ref": [
      "r305"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sets forth the existing conditions, situations, or sets of circumstances involving uncertainties as of the balance sheet date (or before issuance of the financial statements) that might result in a gain, typically reflecting care to avoid misleading implications as to the likelihood of realization, and previously disclosed contingent gains that were recognized as income in the period.",
        "label": "Gain Contingencies [Table]",
        "terseLabel": "Gain Contingencies [Table]"
       }
      }
     },
     "localname": "GainContingenciesTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/CommitmentandContingenciesLegalProceedingsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of entity's patents that another entity has allegedly infringed.",
        "label": "Gain Contingency, Patents Allegedly Infringed upon, Number",
        "terseLabel": "Number of patents allegedly infringed upon"
       }
      }
     },
     "localname": "GainContingencyPatentsAllegedlyInfringedUponNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/CommitmentandContingenciesLegalProceedingsNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_GainLossOnDispositionOfIntangibleAssets": {
     "auth_ref": [
      "r126"
     ],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 3.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) on sale or disposal of intangible assets.",
        "label": "Gain (Loss) on Disposition of Intangible Assets",
        "terseLabel": "Gain from sale of intangible assets"
       }
      }
     },
     "localname": "GainLossOnDispositionOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.ligand.com/role/SaleofVernalisRDandPromactaLicenseNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainLossOnInvestments": {
     "auth_ref": [
      "r101",
      "r126",
      "r225"
     ],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of realized and unrealized gain (loss) on investment.",
        "label": "Gain (Loss) on Investments",
        "terseLabel": "Gain (loss) from short-term investments"
       }
      }
     },
     "localname": "GainLossOnInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainLossOnSaleOfBusiness": {
     "auth_ref": [
      "r126",
      "r547"
     ],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) from sale and disposal of integrated set of activities and assets capable of being conducted and managed for purpose of providing return in form of dividend, lower cost, or other economic benefit to investor, owner, member and participant.",
        "label": "Gain (Loss) on Disposition of Business",
        "negatedTerseLabel": "Gain from sale of Vernalis R&amp;D"
       }
      }
     },
     "localname": "GainLossOnSaleOfBusiness",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainLossOnSaleOfOtherAssets": {
     "auth_ref": [
      "r126"
     ],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) on sale or disposal of other assets.",
        "label": "Gain (Loss) on Disposition of Other Assets",
        "negatedLabel": "Gain from sale of Promacta license"
       }
      }
     },
     "localname": "GainLossOnSaleOfOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainsLossesOnExtinguishmentOfDebt": {
     "auth_ref": [
      "r126",
      "r359",
      "r360"
     ],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 20.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.",
        "label": "Gain (Loss) on Extinguishment of Debt",
        "negatedTerseLabel": "Loss on debt extinguishment"
       }
      }
     },
     "localname": "GainsLossesOnExtinguishmentOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.ligand.com/role/ConvertibleSeniorNotesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r99"
     ],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 4.0,
       "parentTag": "us-gaap_OperatingCostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "verboseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r96"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "General and administrative expenses"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityShareBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r272",
      "r273",
      "r641",
      "r684"
     ],
     "calculation": {
      "http://www.ligand.com/role/AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 12.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0
      },
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "terseLabel": "Goodwill",
        "verboseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/AcquisitionsAllocationofConsiderationDetails",
      "http://www.ligand.com/role/AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.ligand.com/role/BalanceSheetAccountDetailsGoodwillandOtherIntangibleAssetsDetails",
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy": {
     "auth_ref": [
      "r275"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.",
        "label": "Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]",
        "terseLabel": "Goodwill, Intangible Assets and Other Long-Lived Assets"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsGoodwillPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit": {
     "auth_ref": [
      "r274"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of divestiture of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Written off Related to Sale of Business Unit",
        "terseLabel": "Goodwill written off"
       }
      }
     },
     "localname": "GoodwillWrittenOffRelatedToSaleOfBusinessUnit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/SaleofVernalisRDandPromactaLicenseNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss": {
     "auth_ref": [
      "r239",
      "r241"
     ],
     "calculation": {
      "http://www.ligand.com/role/BalanceSheetAccountDetailsAvailableforSaleDebtSecuritiesinanUnrealizedLossPositionDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionAccumulatedLoss",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at amortized cost (held-to-maturity), in continuous loss position for 12 months or longer.",
        "label": "Debt Securities, Held-to-maturity, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss",
        "negatedTerseLabel": "12 months or greater"
       }
      }
     },
     "localname": "HeldToMaturitySecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsAvailableforSaleDebtSecuritiesinanUnrealizedLossPositionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionAccumulatedLoss": {
     "auth_ref": [
      "r239"
     ],
     "calculation": {
      "http://www.ligand.com/role/BalanceSheetAccountDetailsAvailableforSaleDebtSecuritiesinanUnrealizedLossPositionDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at amortized cost (held-to-maturity), in unrealized loss position.",
        "label": "Debt Securities, Held-to-maturity, Unrealized Loss Position, Accumulated Loss",
        "negatedTotalLabel": "Total"
       }
      }
     },
     "localname": "HeldToMaturitySecuritiesContinuousUnrealizedLossPositionAccumulatedLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsAvailableforSaleDebtSecuritiesinanUnrealizedLossPositionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Held-to-maturity, Unrealized Loss Position, Accumulated Loss [Abstract]",
        "terseLabel": "Gross Unrealized Losses"
       }
      }
     },
     "localname": "HeldToMaturitySecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsAvailableforSaleDebtSecuritiesinanUnrealizedLossPositionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_HeldToMaturitySecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis": {
     "auth_ref": [
      "r234",
      "r704"
     ],
     "calculation": {
      "http://www.ligand.com/role/BalanceSheetAccountDetailsAvailableforSaleDebtSecuritiesbyContractualMaturityDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of investment in debt security measured at amortized cost (held-to-maturity) with single maturity date and allocated without single maturity date.",
        "label": "Debt Securities, Held-to-Maturity, Amortized Cost, after Allowance for Credit Loss, Maturity, Allocated and Single Maturity Date",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "HeldToMaturitySecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsAvailableforSaleDebtSecuritiesbyContractualMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOfIntangibleAssetsFinitelived": {
     "auth_ref": [
      "r126",
      "r287"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value.",
        "label": "Impairment of Intangible Assets, Finite-lived",
        "terseLabel": "Impairment of intangible assets with finite lives"
       }
      }
     },
     "localname": "ImpairmentOfIntangibleAssetsFinitelived",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InProcessResearchAndDevelopmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "In process investigation of new knowledge useful in developing new product or service or new process or technique or improvement to existing product or process, and translation of knowledge into plan or design for new product or process or for improvement to existing product or process.",
        "label": "In Process Research and Development [Member]",
        "terseLabel": "In Process Research and Development"
       }
      }
     },
     "localname": "InProcessResearchAndDevelopmentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/SaleofVernalisRDandPromactaLicenseNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r92",
      "r203",
      "r205",
      "r208",
      "r211",
      "r213",
      "r683",
      "r697",
      "r702",
      "r729"
     ],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Income (loss) before income tax"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Condensed Statement of Operations:"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis": {
     "auth_ref": [
      "r418",
      "r420"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name of disposal group.",
        "label": "Disposal Group Name [Axis]",
        "terseLabel": "Disposal Group Name [Axis]"
       }
      }
     },
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/SaleofVernalisRDandPromactaLicenseNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]",
        "terseLabel": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]"
       }
      }
     },
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/SaleofVernalisRDandPromactaLicenseNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable": {
     "auth_ref": [
      "r5",
      "r6",
      "r7",
      "r8",
      "r9",
      "r10",
      "r11",
      "r12",
      "r14",
      "r15",
      "r16",
      "r296",
      "r297"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.",
        "label": "Disposal Groups, Including Discontinued Operations [Table]",
        "terseLabel": "Disposal Groups, Including Discontinued Operations [Table]"
       }
      }
     },
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/SaleofVernalisRDandPromactaLicenseNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r295",
      "r299"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/ConvertibleSeniorNotesNarrativeDetails",
      "http://www.ligand.com/role/StockholdersEquityShareBasedCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r299"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/ConvertibleSeniorNotesNarrativeDetails",
      "http://www.ligand.com/role/StockholdersEquityShareBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "auth_ref": [
      "r479"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by tax jurisdiction.",
        "label": "Income Tax Authority [Axis]",
        "terseLabel": "Income Tax Authority [Axis]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority [Domain]",
        "terseLabel": "Income Tax Authority [Domain]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r142",
      "r478",
      "r485",
      "r492",
      "r504",
      "r509",
      "r511",
      "r512",
      "r513"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r143",
      "r164",
      "r165",
      "r202",
      "r476",
      "r505",
      "r510",
      "r730"
     ],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      },
      "http://www.ligand.com/role/IncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.ligand.com/role/IncomeTaxesReconciliationofIncomeTaxExpenseBenefitDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "negatedLabel": "Income tax benefit (expense)",
        "totalLabel": "Total income tax expense (benefit)"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.ligand.com/role/IncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails",
      "http://www.ligand.com/role/IncomeTaxesReconciliationofIncomeTaxExpenseBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Amount [Abstract]",
        "terseLabel": "Income Tax Expense (Benefit), Continuing Operations, Income Tax Reconciliation [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesReconciliationofIncomeTaxExpenseBenefitDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r87",
      "r472",
      "r473",
      "r485",
      "r486",
      "r491",
      "r499"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "verboseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r477"
     ],
     "calculation": {
      "http://www.ligand.com/role/IncomeTaxesReconciliationofIncomeTaxExpenseBenefitDetails": {
       "order": 9.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount",
        "terseLabel": "Change in valuation allowance"
       }
      }
     },
     "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesReconciliationofIncomeTaxExpenseBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate": {
     "auth_ref": [
      "r471",
      "r477"
     ],
     "calculation": {
      "http://www.ligand.com/role/IncomeTaxesReconciliationofIncomeTaxExpenseBenefitDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, attributable to increase (decrease) in the income tax rates.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Amount",
        "terseLabel": "Rate change for changes in federal, foreign or state law"
       }
      }
     },
     "localname": "IncomeTaxReconciliationChangeInEnactedTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesReconciliationofIncomeTaxExpenseBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationDispositionOfBusiness": {
     "auth_ref": [
      "r477"
     ],
     "calculation": {
      "http://www.ligand.com/role/IncomeTaxesReconciliationofIncomeTaxExpenseBenefitDetails": {
       "order": 13.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to the disposition of a business not qualifying as a discontinued operation.",
        "label": "Effective Income Tax Rate Reconciliation, Disposition of Business, Amount",
        "terseLabel": "Sale of Vernalis R&amp;D"
       }
      }
     },
     "localname": "IncomeTaxReconciliationDispositionOfBusiness",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesReconciliationofIncomeTaxExpenseBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential": {
     "auth_ref": [
      "r477"
     ],
     "calculation": {
      "http://www.ligand.com/role/IncomeTaxesReconciliationofIncomeTaxExpenseBenefitDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign income tax expense (benefit).",
        "label": "Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Amount",
        "terseLabel": "Foreign tax differential on income/loss of foreign subsidiaries"
       }
      }
     },
     "localname": "IncomeTaxReconciliationForeignIncomeTaxRateDifferential",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesReconciliationofIncomeTaxExpenseBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r477"
     ],
     "calculation": {
      "http://www.ligand.com/role/IncomeTaxesReconciliationofIncomeTaxExpenseBenefitDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount",
        "terseLabel": "Tax at federal statutory rate"
       }
      }
     },
     "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesReconciliationofIncomeTaxExpenseBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost": {
     "auth_ref": [
      "r477"
     ],
     "calculation": {
      "http://www.ligand.com/role/IncomeTaxesReconciliationofIncomeTaxExpenseBenefitDetails": {
       "order": 12.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for award under share-based payment arrangement. Includes, but is not limited to, expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount",
        "terseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesReconciliationofIncomeTaxExpenseBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationOtherAdjustments": {
     "auth_ref": [
      "r477"
     ],
     "calculation": {
      "http://www.ligand.com/role/IncomeTaxesReconciliationofIncomeTaxExpenseBenefitDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.",
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Amount",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "IncomeTaxReconciliationOtherAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesReconciliationofIncomeTaxExpenseBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes": {
     "auth_ref": [
      "r477"
     ],
     "calculation": {
      "http://www.ligand.com/role/IncomeTaxesReconciliationofIncomeTaxExpenseBenefitDetails": {
       "order": 11.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount",
        "terseLabel": "State, net of federal benefit"
       }
      }
     },
     "localname": "IncomeTaxReconciliationStateAndLocalIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesReconciliationofIncomeTaxExpenseBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxesPaid": {
     "auth_ref": [
      "r122",
      "r129"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.",
        "label": "Income Taxes Paid",
        "terseLabel": "Taxes paid"
       }
      }
     },
     "localname": "IncomeTaxesPaid",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxesReceivable": {
     "auth_ref": [
      "r64",
      "r694",
      "r725"
     ],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount due within one year of the balance sheet date (or one operating cycle, if longer) from tax authorities as of the balance sheet date representing refunds of overpayments or recoveries based on agreed-upon resolutions of disputes.",
        "label": "Income Taxes Receivable, Current",
        "terseLabel": "Income taxes receivable"
       }
      }
     },
     "localname": "IncomeTaxesReceivable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "auth_ref": [
      "r125"
     ],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.",
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "terseLabel": "Accounts payable and accrued liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r125"
     ],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Accounts receivable, net"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "auth_ref": [
      "r125",
      "r674"
     ],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 18.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInDeferredIncomeTaxes": {
     "auth_ref": [
      "r125"
     ],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the account that represents the temporary difference that results from Income or Loss that is recognized for accounting purposes but not for tax purposes and vice versa.",
        "label": "Increase (Decrease) in Deferred Income Taxes",
        "negatedLabel": "Deferred income taxes, net"
       }
      }
     },
     "localname": "IncreaseDecreaseInDeferredIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInIncomeTaxesReceivable": {
     "auth_ref": [
      "r125"
     ],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 16.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in income taxes receivable, which represents the amount due from tax authorities for refunds of overpayments or recoveries of income taxes paid.",
        "label": "Increase (Decrease) in Income Taxes Receivable",
        "negatedLabel": "Income taxes receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInIncomeTaxesReceivable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r125"
     ],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedLabel": "Inventory"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "verboseLabel": "Changes in operating assets and liabilities, net of acquisitions:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherCurrentLiabilities": {
     "auth_ref": [
      "r125"
     ],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 19.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in current liabilities classified as other.",
        "label": "Increase (Decrease) in Other Current Liabilities",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherCurrentLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "auth_ref": [
      "r276",
      "r281"
     ],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "terseLabel": "Intangible assets, net (excluding goodwill)",
        "verboseLabel": "Intangible assets, net"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.ligand.com/role/SaleofVernalisRDandPromactaLicenseNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntangibleAssetsNetIncludingGoodwill": {
     "auth_ref": [],
     "calculation": {
      "http://www.ligand.com/role/BalanceSheetAccountDetailsGoodwillandOtherIntangibleAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount of finite-lived intangible assets, indefinite-lived intangible assets and goodwill. Goodwill is an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized. Intangible assets are assets, not including financial assets, lacking physical substance.",
        "label": "Intangible Assets, Net (Including Goodwill)",
        "totalLabel": "Total goodwill and other identifiable intangible assets, net"
       }
      }
     },
     "localname": "IntangibleAssetsNetIncludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsGoodwillandOtherIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r91",
      "r200",
      "r612",
      "r615",
      "r701"
     ],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 3.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r116",
      "r121",
      "r129"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "terseLabel": "Interest paid"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InternalRevenueServiceIRSMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the United States of America government entitled to levy and collect income taxes from the entity.",
        "label": "Internal Revenue Service (IRS) [Member]",
        "terseLabel": "Internal Revenue Service (IRS)"
       }
      }
     },
     "localname": "InternalRevenueServiceIRSMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r20",
      "r65",
      "r641"
     ],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "terseLabel": "Inventory",
        "verboseLabel": "Inventory"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryPolicyTextBlock": {
     "auth_ref": [
      "r27",
      "r66",
      "r135",
      "r179",
      "r268",
      "r270",
      "r271",
      "r675"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.",
        "label": "Inventory, Policy [Policy Text Block]",
        "verboseLabel": "Inventory"
       }
      }
     },
     "localname": "InventoryPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryWriteDown": {
     "auth_ref": [
      "r269"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.",
        "label": "Inventory Write-down",
        "terseLabel": "Write-downs related to obsolete inventory"
       }
      }
     },
     "localname": "InventoryWriteDown",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeInterest": {
     "auth_ref": [
      "r100",
      "r199"
     ],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.",
        "label": "Investment Income, Interest",
        "terseLabel": "Interest income"
       }
      }
     },
     "localname": "InvestmentIncomeInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentTypeAxis": {
     "auth_ref": [
      "r752",
      "r753",
      "r754",
      "r755",
      "r756",
      "r757",
      "r758",
      "r759",
      "r760",
      "r761",
      "r762",
      "r763",
      "r764",
      "r765",
      "r766"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of investments.",
        "label": "Investment Type [Axis]",
        "terseLabel": "Investment Type [Axis]"
       }
      }
     },
     "localname": "InvestmentTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsInvestmentCategoriesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentTypeCategorizationMember": {
     "auth_ref": [
      "r752",
      "r753",
      "r754",
      "r755",
      "r756",
      "r757",
      "r758",
      "r759",
      "r760",
      "r761",
      "r762",
      "r763",
      "r764",
      "r765",
      "r766"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset obtained to generate income or appreciate in value.",
        "label": "Investments [Domain]",
        "terseLabel": "Investments [Domain]"
       }
      }
     },
     "localname": "InvestmentTypeCategorizationMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsInvestmentCategoriesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Investments": {
     "auth_ref": [
      "r723"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all investments.",
        "label": "Investments",
        "terseLabel": "Investments"
       }
      }
     },
     "localname": "Investments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r292"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]",
        "verboseLabel": "Leasehold improvements"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeFinanceLeaseRemainingLeaseTerm": {
     "auth_ref": [
      "r626"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Remaining lease term of finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Finance Lease, Remaining Lease Term",
        "terseLabel": "Remaining lease term of finance leases"
       }
      }
     },
     "localname": "LesseeFinanceLeaseRemainingLeaseTerm",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeFinanceLeasesTextBlock": {
     "auth_ref": [
      "r637"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for finance leases of lessee. Includes, but is not limited to, description of lessee's finance lease and maturity analysis of finance lease liability.",
        "label": "Lessee, Finance Leases [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeFinanceLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Lessee, Lease, Description [Line Items]",
        "terseLabel": "Lessee, Lease, Description [Line Items]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "auth_ref": [
      "r628"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about lessee's leases.",
        "label": "Lessee, Lease, Description [Table]",
        "terseLabel": "Lessee, Lease, Description [Table]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r635"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Schedule of Maturity of Operating Lease Liabilities"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r635"
     ],
     "calculation": {
      "http://www.ligand.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.ligand.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "auth_ref": [
      "r635"
     ],
     "calculation": {
      "http://www.ligand.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r635"
     ],
     "calculation": {
      "http://www.ligand.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "auth_ref": [
      "r635"
     ],
     "calculation": {
      "http://www.ligand.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r635"
     ],
     "calculation": {
      "http://www.ligand.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r635"
     ],
     "calculation": {
      "http://www.ligand.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r635"
     ],
     "calculation": {
      "http://www.ligand.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r635"
     ],
     "calculation": {
      "http://www.ligand.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedLabel": "Less imputed interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseRemainingLeaseTerm": {
     "auth_ref": [
      "r626"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Remaining Lease Term",
        "terseLabel": "Remaining lease term of operating leases"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRemainingLeaseTerm",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "auth_ref": [
      "r627"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Renewal Term",
        "terseLabel": "Renewal term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r637"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r55",
      "r140",
      "r207",
      "r246",
      "r310",
      "r311",
      "r312",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r542",
      "r548",
      "r549",
      "r594",
      "r639",
      "r640"
     ],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities [Abstract]",
        "verboseLabel": "Liabilities"
       }
      }
     },
     "localname": "LiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/LeasesOperatingandFinanceLeaseAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r47",
      "r140",
      "r246",
      "r594",
      "r641",
      "r690",
      "r720"
     ],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "verboseLabel": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r57",
      "r140",
      "r246",
      "r310",
      "r311",
      "r312",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r542",
      "r548",
      "r549",
      "r594",
      "r639",
      "r640",
      "r641"
     ],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:",
        "verboseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.ligand.com/role/LeasesOperatingandFinanceLeaseAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesFairValueDisclosure": {
     "auth_ref": [
      "r577"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial and nonfinancial obligations.",
        "label": "Financial and Nonfinancial Liabilities, Fair Value Disclosure",
        "verboseLabel": "Liabilities, fair value"
       }
      }
     },
     "localname": "LiabilitiesFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Noncurrent [Abstract]",
        "terseLabel": "Noncurrent liabilities:"
       }
      }
     },
     "localname": "LiabilitiesNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/LeasesOperatingandFinanceLeaseAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LicensingAgreementsMember": {
     "auth_ref": [
      "r527"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rights, generally of limited duration, under a license arrangement (for example, to sell or otherwise utilize specified products or processes in a specified territory).",
        "label": "Licensing Agreements [Member]",
        "terseLabel": "Licensing Agreements"
       }
      }
     },
     "localname": "LicensingAgreementsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCommercialLicenseRightsDetails",
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LimitedLiabilityCompanyLLCOrLimitedPartnershipLPMembersOrLimitedPartnersOwnershipInterest": {
     "auth_ref": [
      "r181"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage investment held by members or limited partners of limited liability company (LLC) or limited partnership (LP).",
        "label": "Limited Liability Company or Limited Partnership, Members or Limited Partners, Ownership Interest",
        "terseLabel": "Ownership interest (as a percent)"
       }
      }
     },
     "localname": "LimitedLiabilityCompanyLLCOrLimitedPartnershipLPMembersOrLimitedPartnersOwnershipInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/ShorttermInvestmentsInvestmentinVikingNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_LongTermNotesPayable": {
     "auth_ref": [
      "r60"
     ],
     "calculation": {
      "http://www.ligand.com/role/ConvertibleSeniorNotesEquityandLiabilityComponentsofFinancingArrangementsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.",
        "label": "Notes Payable, Noncurrent",
        "totalLabel": "Total long-term portion of notes payable"
       }
      }
     },
     "localname": "LongTermNotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/ConvertibleSeniorNotesEquityandLiabilityComponentsofFinancingArrangementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r60"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-term Debt, Type [Axis]",
        "terseLabel": "Long-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.ligand.com/role/ConvertibleSeniorNotesEquityandLiabilityComponentsofFinancingArrangementsDetails",
      "http://www.ligand.com/role/ConvertibleSeniorNotesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r60",
      "r308"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Long-term Debt, Type [Domain]",
        "terseLabel": "Long-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.ligand.com/role/ConvertibleSeniorNotesEquityandLiabilityComponentsofFinancingArrangementsDetails",
      "http://www.ligand.com/role/ConvertibleSeniorNotesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongtermNotesPayableCurrentAndNoncurrentTotalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Notes Payable, Current and Noncurrent [Abstract]",
        "terseLabel": "Notes Payable, Current and Noncurrent"
       }
      }
     },
     "localname": "LongtermNotesPayableCurrentAndNoncurrentTotalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/ConvertibleSeniorNotesEquityandLiabilityComponentsofFinancingArrangementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingencyNewClaimsFiledNumber": {
     "auth_ref": [
      "r304"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total number of new claims filed pertaining to a loss contingency during the period.",
        "label": "Loss Contingency, New Claims Filed, Number",
        "terseLabel": "Number of civil complaints filed against entity"
       }
      }
     },
     "localname": "LossContingencyNewClaimsFiledNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/CommitmentandContingenciesLegalProceedingsNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_MarketableSecuritiesTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of marketable securities. This may consist of investments in certain debt and equity securities, short-term investments and other assets.",
        "label": "Marketable Securities [Table Text Block]",
        "terseLabel": "Schedule of Investment Categories"
       }
      }
     },
     "localname": "MarketableSecuritiesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_MeasurementInputDiscountRateMember": {
     "auth_ref": [
      "r580"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using interest rate to determine present value of future cash flows.",
        "label": "Measurement Input, Discount Rate [Member]",
        "terseLabel": "Discount Rate"
       }
      }
     },
     "localname": "MeasurementInputDiscountRateMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputExpectedDividendRateMember": {
     "auth_ref": [
      "r580"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using expected dividend rate to be paid to holder of share per year.",
        "label": "Measurement Input, Expected Dividend Rate [Member]",
        "terseLabel": "Dividend yield"
       }
      }
     },
     "localname": "MeasurementInputExpectedDividendRateMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "auth_ref": [
      "r580"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Axis]",
        "terseLabel": "Measurement Input Type [Axis]"
       }
      }
     },
     "localname": "MeasurementInputTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/AcquisitionsNarrativeDetails",
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Domain]",
        "terseLabel": "Measurement Input Type [Domain]"
       }
      }
     },
     "localname": "MeasurementInputTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/AcquisitionsNarrativeDetails",
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MutualFundMember": {
     "auth_ref": [
      "r410"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Regulated investment instrument that pools funds from multiple investors to invest principally in a portfolio of securities and money market instruments to match the investment objective.",
        "label": "Mutual Fund [Member]",
        "terseLabel": "Mutual fund"
       }
      }
     },
     "localname": "MutualFundMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsInvestmentCategoriesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r119"
     ],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash used in financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "verboseLabel": "Financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r119"
     ],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash provided by investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "verboseLabel": "Investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r119",
      "r123",
      "r127"
     ],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash provided by (used in) operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "verboseLabel": "Operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r16",
      "r82",
      "r84",
      "r90",
      "r93",
      "r127",
      "r140",
      "r154",
      "r158",
      "r159",
      "r160",
      "r161",
      "r164",
      "r165",
      "r171",
      "r203",
      "r205",
      "r208",
      "r211",
      "r213",
      "r246",
      "r310",
      "r311",
      "r312",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r576",
      "r594",
      "r698",
      "r726"
     ],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      },
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net income (loss)",
        "totalLabel": "Net income (loss)"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY",
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS",
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Accounting Standards Recently Adopted and Accounting Standards Not Yet Adopted"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r102"
     ],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "totalLabel": "Total other expense, net"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NumberOfBusinessesAcquired": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of businesses acquired by the entity during the period.",
        "label": "Number of Businesses Acquired",
        "terseLabel": "Number of business combinations"
       }
      }
     },
     "localname": "NumberOfBusinessesAcquired",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [
      "r196"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of Operating Segments",
        "terseLabel": "Number of business segments"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OfficeEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property used in an office setting. Examples include, but are not limited to, computers, copiers and fax machine.",
        "label": "Office Equipment [Member]",
        "verboseLabel": "Lab and office equipment"
       }
      }
     },
     "localname": "OfficeEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OperatingCostsAndExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Excludes Selling, General and Administrative Expense.",
        "label": "Operating Costs and Expenses",
        "totalLabel": "Total operating costs and expenses"
       }
      }
     },
     "localname": "OperatingCostsAndExpenses",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingCostsAndExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Costs and Expenses [Abstract]",
        "verboseLabel": "Operating costs and expenses:"
       }
      }
     },
     "localname": "OperatingCostsAndExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r203",
      "r205",
      "r208",
      "r211",
      "r213"
     ],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Income from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseExpense": {
     "auth_ref": [
      "r622"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating lease expense. Excludes sublease income.",
        "label": "Operating Lease, Expense",
        "terseLabel": "Operating lease expense"
       }
      }
     },
     "localname": "OperatingLeaseExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, Payment, Due [Abstract]",
        "terseLabel": "Operating Leases"
       }
      }
     },
     "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r619"
     ],
     "calculation": {
      "http://www.ligand.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails_1": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "terseLabel": "Operating lease liabilities",
        "verboseLabel": "Present value of lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails",
      "http://www.ligand.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r619"
     ],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      },
      "http://www.ligand.com/role/LeasesOperatingandFinanceLeaseAssetsandLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "lgnd_LeaseLiabilityCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Current operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.ligand.com/role/LeasesOperatingandFinanceLeaseAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r619"
     ],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      },
      "http://www.ligand.com/role/LeasesOperatingandFinanceLeaseAssetsandLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "lgnd_LeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Long-term operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.ligand.com/role/LeasesOperatingandFinanceLeaseAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r625",
      "r631"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments",
        "terseLabel": "Operating lease payments"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r618"
     ],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 7.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.ligand.com/role/LeasesOperatingandFinanceLeaseAssetsandLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "lgnd_LeaseRightOfUseAsset",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease assets",
        "verboseLabel": "Operating lease right of use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.ligand.com/role/LeasesNarrativeDetails",
      "http://www.ligand.com/role/LeasesOperatingandFinanceLeaseAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r634",
      "r636"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted-average discount rate of operating leases (as a percent)"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r633",
      "r636"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted-average remaining lease term of operating leases"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OperatingLossCarryforwards": {
     "auth_ref": [
      "r493"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Operating Loss Carryforwards",
        "terseLabel": "Operating loss carryforward"
       }
      }
     },
     "localname": "OperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLossCarryforwardsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Operating Loss Carryforwards [Line Items]",
        "terseLabel": "Operating Loss Carryforwards [Line Items]"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLossCarryforwardsTable": {
     "auth_ref": [
      "r494"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization.",
        "label": "Operating Loss Carryforwards [Table]",
        "terseLabel": "Operating Loss Carryforwards [Table]"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r18",
      "r149",
      "r195",
      "r557"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows.  Describes procedure if disclosures are provided in more than one note to the financial statements.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]",
        "terseLabel": "Basis of Presentation and Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r24",
      "r25",
      "r26",
      "r56"
     ],
     "calculation": {
      "http://www.ligand.com/role/BalanceSheetAccountDetailsAccruedLiabilitiesDetails": {
       "order": 9.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsCurrent": {
     "auth_ref": [
      "r67",
      "r641"
     ],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 6.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current assets classified as other.",
        "label": "Other Assets, Current",
        "verboseLabel": "Other current assets"
       }
      }
     },
     "localname": "OtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r53"
     ],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 9.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "verboseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax": {
     "auth_ref": [
      "r76",
      "r77",
      "r79"
     ],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS": {
       "order": 3.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax",
        "terseLabel": "Unrealized net gain (loss) on available-for-sale securities, net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": {
     "auth_ref": [
      "r75"
     ],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax",
        "terseLabel": "Foreign currency translation adjustment"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY",
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherExpenseMember": {
     "auth_ref": [
      "r563"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other expense.",
        "label": "Other Expense [Member]",
        "terseLabel": "Other Expense"
       }
      }
     },
     "localname": "OtherExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/ConvertibleSeniorNotesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r61"
     ],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 6.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "verboseLabel": "Other long-term liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r103"
     ],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 4.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "verboseLabel": "Other expense, net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Nonoperating Income (Expense) [Abstract]",
        "verboseLabel": "Other income (expense):"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherOperatingActivitiesCashFlowStatement": {
     "auth_ref": [],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other cash or noncash adjustments to reconcile net income to cash provided by (used in) operating activities that are not separately disclosed in the statement of cash flows (for example,  cash received or cash paid during the current period for miscellaneous operating activities, net change during the reporting period in other assets or other liabilities).",
        "label": "Other Operating Activities, Cash Flow Statement",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherOperatingActivitiesCashFlowStatement",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherOperatingIncome": {
     "auth_ref": [
      "r98"
     ],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 5.0,
       "parentTag": "us-gaap_OperatingCostsAndExpenses",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount of other operating income, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operation.",
        "label": "Other Operating Income",
        "negatedTerseLabel": "Other operating income"
       }
      }
     },
     "localname": "OtherOperatingIncome",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PatentedTechnologyMember": {
     "auth_ref": [
      "r529"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exclusive legal right granted by the government to the owner of the patented technology to exploit the technology for a period of time specified by law.",
        "label": "Patented Technology [Member]",
        "verboseLabel": "Complete technology"
       }
      }
     },
     "localname": "PatentedTechnologyMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsGoodwillandOtherIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities": {
     "auth_ref": [
      "r117"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability exceeding amount recognized at acquisition date. Includes, but is not limited to, measurement period adjustment and less amount paid soon after acquisition date.",
        "label": "Payment for Contingent Consideration Liability, Operating Activities",
        "terseLabel": "Payment for contingent consideration liabilities"
       }
      }
     },
     "localname": "PaymentForContingentConsiderationLiabilityOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForHedgeFinancingActivities": {
     "auth_ref": [
      "r115",
      "r124"
     ],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for a financial contract that meets the hedge criteria as either cash flow hedge, fair value hedge or hedge of net investment in foreign operations.",
        "label": "Payments for Hedge, Financing Activities",
        "negatedLabel": "Payments to convert holders for bond conversion"
       }
      }
     },
     "localname": "PaymentsForHedgeFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForProceedsFromOtherInvestingActivities": {
     "auth_ref": [
      "r106",
      "r109"
     ],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash (inflow) outflow from investing activities classified as other.",
        "label": "Payments for (Proceeds from) Other Investing Activities",
        "negatedLabel": "Other, net"
       }
      }
     },
     "localname": "PaymentsForProceedsFromOtherInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForRepurchaseOfCommonStock": {
     "auth_ref": [
      "r113"
     ],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to reacquire common stock during the period.",
        "label": "Payments for Repurchase of Common Stock",
        "negatedLabel": "Share repurchases"
       }
      }
     },
     "localname": "PaymentsForRepurchaseOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForRepurchaseOfWarrants": {
     "auth_ref": [
      "r113"
     ],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount paid by the entity to reacquire the right to purchase equity shares at a predetermined price, usually issued together with corporate debt.",
        "label": "Payments for Repurchase of Warrants",
        "negatedLabel": "Repurchase of warrants"
       }
      }
     },
     "localname": "PaymentsForRepurchaseOfWarrants",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [
      "r113"
     ],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Payment, Tax Withholding, Share-based Payment Arrangement",
        "negatedTerseLabel": "Taxes paid related to net share settlement of equity awards"
       }
      }
     },
     "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessesGross": {
     "auth_ref": [
      "r107",
      "r535"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.",
        "label": "Payments to Acquire Businesses, Gross",
        "verboseLabel": "Gross payments to acquire business"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessesGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": {
     "auth_ref": [
      "r107"
     ],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.",
        "label": "Payments to Acquire Businesses, Net of Cash Acquired",
        "negatedTerseLabel": "Cash paid for acquisition, net of cash and restricted cash acquired"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireEquityMethodInvestments": {
     "auth_ref": [
      "r107"
     ],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the purchase of or advances to an equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence.",
        "label": "Payments to Acquire Equity Method Investments",
        "negatedLabel": "Cash paid for equity method investment"
       }
      }
     },
     "localname": "PaymentsToAcquireEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r108"
     ],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireShortTermInvestments": {
     "auth_ref": [
      "r109"
     ],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.",
        "label": "Payments to Acquire Short-term Investments",
        "negatedTerseLabel": "Purchases of short-term investments"
       }
      }
     },
     "localname": "PaymentsToAcquireShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PerformanceSharesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement awarded for meeting performance target.",
        "label": "Performance Shares [Member]",
        "terseLabel": "PSUs"
       }
      }
     },
     "localname": "PerformanceSharesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r426",
      "r456"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.ligand.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.ligand.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r39",
      "r362"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value (USD per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r39"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock authorized (shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r39",
      "r362"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock issued (shares)"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r39"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock outstanding (shares)"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r39",
      "r641"
     ],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock, $0.001 par value; 5,000 shares authorized; zero issued and outstanding at December 31, 2021 and 2020"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromDebtNetOfIssuanceCosts": {
     "auth_ref": [
      "r111"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from additional borrowings, net of cash paid to third parties in connection with debt origination.",
        "label": "Proceeds from Debt, Net of Issuance Costs",
        "terseLabel": "Net proceeds from debt issuance"
       }
      }
     },
     "localname": "ProceedsFromDebtNetOfIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/ConvertibleSeniorNotesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromDivestitureOfBusinesses": {
     "auth_ref": [
      "r104"
     ],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from the sale of a portion of the company's business, for example a segment, division, branch or other business, during the period.",
        "label": "Proceeds from Divestiture of Businesses",
        "terseLabel": "Proceeds on sale of Vernalis R&amp;D, net"
       }
      }
     },
     "localname": "ProceedsFromDivestitureOfBusinesses",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.ligand.com/role/SaleofVernalisRDandPromactaLicenseNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromHedgeFinancingActivities": {
     "auth_ref": [
      "r112",
      "r124"
     ],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from a financial contract that meets the hedge criteria as either cash flow hedge, fair value hedge or hedge of net investment in foreign operations.",
        "label": "Proceeds from Hedge, Financing Activities",
        "terseLabel": "Proceeds from bond hedge settlement"
       }
      }
     },
     "localname": "ProceedsFromHedgeFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions": {
     "auth_ref": [
      "r110",
      "r457"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised.",
        "label": "Proceeds, Issuance of Shares, Share-based Payment Arrangement, Including Option Exercised",
        "verboseLabel": "Cash received from options exercised"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments": {
     "auth_ref": [
      "r106",
      "r109"
     ],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from maturities, prepayments, calls and collections of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.",
        "label": "Proceeds from Maturities, Prepayments and Calls of Short-term Investments",
        "terseLabel": "Proceeds from maturity of short-term investments"
       }
      }
     },
     "localname": "ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromRoyaltiesReceived": {
     "auth_ref": [
      "r120"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash received for royalties during the current period.",
        "label": "Proceeds from Royalties Received",
        "terseLabel": "Proceeds from royalties received"
       }
      }
     },
     "localname": "ProceedsFromRoyaltiesReceived",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfIntangibleAssets": {
     "auth_ref": [
      "r105"
     ],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from disposal of asset without physical form usually arising from contractual or other legal rights, excluding goodwill.",
        "label": "Proceeds from Sale of Intangible Assets",
        "terseLabel": "Proceeds from sale of Promacta license"
       }
      }
     },
     "localname": "ProceedsFromSaleOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfShortTermInvestments": {
     "auth_ref": [
      "r106"
     ],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from sales of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.",
        "label": "Proceeds from Sale of Short-term Investments",
        "verboseLabel": "Proceeds from sale of short-term investments"
       }
      }
     },
     "localname": "ProceedsFromSaleOfShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r110",
      "r457"
     ],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Net proceeds from stock option exercises and ESPP"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r16",
      "r82",
      "r84",
      "r90",
      "r118",
      "r140",
      "r154",
      "r164",
      "r165",
      "r203",
      "r205",
      "r208",
      "r211",
      "r213",
      "r246",
      "r310",
      "r311",
      "r312",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r540",
      "r544",
      "r545",
      "r555",
      "r556",
      "r576",
      "r594",
      "r702"
     ],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net income (loss)"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r52",
      "r294"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]",
        "terseLabel": "Long-Lived Tangible Asset [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsPropertyandEquipmentDetails",
      "http://www.ligand.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r51",
      "r292"
     ],
     "calculation": {
      "http://www.ligand.com/role/BalanceSheetAccountDetailsPropertyandEquipmentDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "verboseLabel": "Property and equipment , gross"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsPropertyandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsPropertyandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r30",
      "r31",
      "r294",
      "r641",
      "r708",
      "r721"
     ],
     "calculation": {
      "http://www.ligand.com/role/BalanceSheetAccountDetailsPropertyandEquipmentDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "totalLabel": "Property and equipment, net",
        "verboseLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsPropertyandEquipmentDetails",
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r50",
      "r294",
      "r769",
      "r770"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r30",
      "r294"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Schedule of Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r30",
      "r292"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Long-Lived Tangible Asset [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsPropertyandEquipmentDetails",
      "http://www.ligand.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Property and equipment, useful life"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsNarrativeDetails",
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy": {
     "auth_ref": [
      "r48",
      "r220"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for determining the allowance for doubtful accounts for trade and other accounts receivable balances, and when impairments, charge-offs or recoveries are recognized.",
        "label": "Receivables, Trade and Other Accounts Receivable, Allowance for Doubtful Accounts, Policy [Policy Text Block]",
        "terseLabel": "Accounts Receivable"
       }
      }
     },
     "localname": "ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]",
        "terseLabel": "Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]"
       }
      }
     },
     "localname": "ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesReconciliationofUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RepaymentsOfLongTermDebt": {
     "auth_ref": [
      "r114"
     ],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.",
        "label": "Repayments of Long-term Debt",
        "negatedLabel": "Repayment of debt"
       }
      }
     },
     "localname": "RepaymentsOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepaymentsOfNotesPayable": {
     "auth_ref": [
      "r114"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for a borrowing supported by a written promise to pay an obligation.",
        "label": "Repayments of Notes Payable",
        "terseLabel": "Repayments of notes"
       }
      }
     },
     "localname": "RepaymentsOfNotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/ConvertibleSeniorNotesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r469",
      "r676",
      "r773"
     ],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 3.0,
       "parentTag": "us-gaap_OperatingCostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "verboseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityShareBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r469"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development Expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchMember": {
     "auth_ref": [
      "r494"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research tax credit carryforwards arising from certain qualifying expenditures incurred to develop new products and processes.",
        "label": "Research Tax Credit Carryforward [Member]",
        "terseLabel": "Research Tax Credit Carryforward"
       }
      }
     },
     "localname": "ResearchMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedCashCurrent": {
     "auth_ref": [
      "r19",
      "r28",
      "r133"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash, Current",
        "verboseLabel": "Restricted cash in other current assets"
       }
      }
     },
     "localname": "RestrictedCashCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockMember": {
     "auth_ref": [
      "r175"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.",
        "label": "Restricted Stock [Member]",
        "terseLabel": "Restricted Stock"
       }
      }
     },
     "localname": "RestrictedStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCalculationofEarningsperShareDetails",
      "http://www.ligand.com/role/StockholdersEquityNarrativeDetails",
      "http://www.ligand.com/role/StockholdersEquityRestrictedStockActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r43",
      "r384",
      "r465",
      "r641",
      "r719",
      "r742",
      "r747"
     ],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "verboseLabel": "Retained earnings"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r2",
      "r150",
      "r151",
      "r152",
      "r155",
      "r163",
      "r165",
      "r251",
      "r462",
      "r463",
      "r464",
      "r502",
      "r503",
      "r574",
      "r738",
      "r740"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Retain earnings (accumulated deficit)"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r197",
      "r198",
      "r204",
      "r209",
      "r210",
      "r214",
      "r215",
      "r216",
      "r397",
      "r398",
      "r677"
     ],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Total revenues"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRoyaltyRevenueDetails",
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax": {
     "auth_ref": [
      "r197",
      "r198",
      "r204",
      "r209",
      "r210",
      "r214",
      "r215",
      "r216",
      "r397",
      "r398",
      "r677"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.",
        "label": "Revenue from Contract with Customer, Including Assessed Tax",
        "terseLabel": "Total revenues"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerIncludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/SaleofVernalisRDandPromactaLicenseNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "auth_ref": [
      "r136",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r408"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue from contract with customer.",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "verboseLabel": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues [Abstract]",
        "verboseLabel": "Revenues:"
       }
      }
     },
     "localname": "RevenuesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability": {
     "auth_ref": [
      "r632",
      "r636"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for finance lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Finance Lease Liability",
        "terseLabel": "Right-of-use asset recognized"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RoyaltyAgreementsMember": {
     "auth_ref": [
      "r527"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual arrangement, generally for a defined period of time, entitling the entity to use the rights and property of another party. Examples include, but not limited to, licensing the use of copyrighted materials and leasing the extraction of natural resources.",
        "label": "Royalty Agreements [Member]",
        "terseLabel": "Royalty Agreements"
       }
      }
     },
     "localname": "RoyaltyAgreementsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RoyaltyMember": {
     "auth_ref": [
      "r401"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Money for usage-based right to asset.",
        "label": "Royalty [Member]",
        "terseLabel": "Royalties"
       }
      }
     },
     "localname": "RoyaltyMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRoyaltyRevenueDetails",
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SalesRevenueNetMember": {
     "auth_ref": [
      "r189",
      "r216"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation.",
        "label": "Revenue Benchmark [Member]",
        "terseLabel": "Revenue"
       }
      }
     },
     "localname": "SalesRevenueNetMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRevenuefromSignificantPartnersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Accrued Liabilities"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Securities, Available-for-sale [Line Items]",
        "terseLabel": "Debt Securities, Available-for-sale [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsInvestmentCategoriesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": {
     "auth_ref": [
      "r519",
      "r520"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table]",
        "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/AcquisitionsAllocationofConsiderationDetails",
      "http://www.ligand.com/role/AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.ligand.com/role/AcquisitionsIntangiblesAcquiredandWeightedAverageUsefulLifeDetails",
      "http://www.ligand.com/role/AcquisitionsNarrativeDetails",
      "http://www.ligand.com/role/AcquisitionsProFormaFinancialInformationDetails",
      "http://www.ligand.com/role/AcquisitionsTables",
      "http://www.ligand.com/role/BalanceSheetAccountDetailsContingentLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "auth_ref": [
      "r499"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.",
        "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]",
        "terseLabel": "Schedule of Components of Income Tax Benefit"
       }
      }
     },
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDebtTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.",
        "label": "Schedule of Debt [Table Text Block]",
        "terseLabel": "Schedule of Equity and Liability Components of the Convertible Senior Notes"
       }
      }
     },
     "localname": "ScheduleOfDebtTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/ConvertibleSeniorNotesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r490"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Deferred Tax Assets and Liabilities"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r174"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "verboseLabel": "Schedule of Computation of Basic and Diluted Net Income (Loss) per Share"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable": {
     "auth_ref": [
      "r169",
      "r170",
      "r172",
      "r174",
      "r178"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Complete disclosure pertaining to an entity's diluted earnings per share.",
        "label": "Schedule of Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Table]",
        "terseLabel": "Schedule of Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Table]"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareDilutedByCommonClassTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCalculationofEarningsperShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r477"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of Effective Income Tax Rate Reconciliation"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable": {
     "auth_ref": [
      "r216"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure about the extent of the entity's reliance on its major customers.",
        "label": "Schedule of Revenue by Major Customers, by Reporting Segments [Table]",
        "terseLabel": "Schedule of Revenue by Major Customers, by Reporting Segments [Table]"
       }
      }
     },
     "localname": "ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRevenuefromSignificantPartnersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock": {
     "auth_ref": [
      "r278"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of finite-lived intangible assets acquired as part of a business combination or through an asset purchase, by major class and in total, including the value of the asset acquired, any significant residual value (the expected value of the asset at the end of its useful life) and the weighted-average amortization period.",
        "label": "Schedule of Finite-Lived Intangible Assets Acquired as Part of Business Combination [Table Text Block]",
        "terseLabel": "Schedule of Finite-Lived Intangibles Acquired"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/AcquisitionsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "auth_ref": [
      "r278",
      "r282",
      "r678"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table]",
        "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsGoodwillandOtherIntangibleAssetsDetails",
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCommercialLicenseRightsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock": {
     "auth_ref": [
      "r275"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of goodwill and intangible assets, which may be broken down by segment or major class.",
        "label": "Schedule of Intangible Assets and Goodwill [Table Text Block]",
        "verboseLabel": "Schedule of Goodwill and Other Identifiable Intangible Assets"
       }
      }
     },
     "localname": "ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfInvestmentsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Schedule of Investments [Line Items]",
        "terseLabel": "Schedule of Investments [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfInvestmentsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfInvestmentsTable": {
     "auth_ref": [
      "r751"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A container table for all schedule of investment items. It ties in the \"Legal Entity [Axis]\" to all of its contained line items.",
        "label": "Schedule of Investments [Table]",
        "terseLabel": "Schedule of Investments [Table]"
       }
      }
     },
     "localname": "ScheduleOfInvestmentsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock": {
     "auth_ref": [
      "r437"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock units.",
        "label": "Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]",
        "verboseLabel": "Schedule of Restricted Stock Activity"
       }
      }
     },
     "localname": "ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r52",
      "r294"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]",
        "verboseLabel": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsPropertyandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": {
     "auth_ref": [
      "r523"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.",
        "label": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]",
        "terseLabel": "Schedule of Allocation of Consideration / Recognized Identified Assets Acquired and Liabilities Assumed"
       }
      }
     },
     "localname": "ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/AcquisitionsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r426",
      "r456"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityAssumptionsDetails",
      "http://www.ligand.com/role/StockholdersEquityBreakdownofOptionsOutstandingDetails",
      "http://www.ligand.com/role/StockholdersEquityNarrativeDetails",
      "http://www.ligand.com/role/StockholdersEquityRestrictedStockActivityDetails",
      "http://www.ligand.com/role/StockholdersEquityShareBasedCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock": {
     "auth_ref": [
      "r456"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms.",
        "label": "Share-based Payment Arrangement, Option, Exercise Price Range [Table Text Block]",
        "terseLabel": "Schedule of Stock Option Plan Activity by Exercise Price Range"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r431",
      "r443",
      "r446"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]",
        "verboseLabel": "Schedule of Stock Option Plan Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r449"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of Stock Option Weighted-Average Assumptions"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForwardTableTextBlock": {
     "auth_ref": [
      "r484"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the change in unrecognized tax benefits, excluding amounts pertaining to examined tax returns.",
        "label": "Schedule of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns Roll Forward [Table Text Block]",
        "terseLabel": "Schedule of Unrecognized Tax Benefits"
       }
      }
     },
     "localname": "ScheduleOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForwardTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfVariableInterestEntitiesTable": {
     "auth_ref": [
      "r541",
      "r542",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of qualitative and quantitative information related to variable interests the entity holds, whether or not such variable interest entity (VIE) is included in the reporting entity's consolidated financial statements. Includes, but is not limited to, description of the significant judgments and assumptions made in determining whether a variable interest (as defined) held by the entity requires the variable interest entity (VIE) (as defined) to be consolidated and (or) disclose information about its involvement with the VIE, individually or in aggregate (as applicable); the nature of restrictions, if any, on the consolidated VIE's assets and on the settlement of its liabilities reported by an entity in its statement of financial position, including the carrying amounts of such assets and liabilities; the nature of, and changes in, the risks associated with involvement in the VIE; how involvement with the VIE affects the entity's financial position, financial performance, and cash flows; the lack of recourse if creditors (or beneficial interest holders) of the consolidated VIE have no recourse to the general credit of the primary beneficiary (if applicable); the terms of arrangements, giving consideration to both explicit arrangements and implicit variable interests, if any, that could require the entity to provide financial support to the VIE, including events or circumstances that could expose the entity to a loss; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; the significant factors considered and judgments made in determining that the power to direct the activities of a VIE that most significantly impact the VIE's economic performance are shared (as defined); the carrying amounts and classification of assets and liabilities of the VIE included in the statement of financial position; the entity's maximum exposure to loss, if any, as a result of its involvement with the VIE, including how the maximum exposure is determined and significant sources of the entity's exposure to the VIE; a tabular comparison of the carrying amounts of the assets and liabilities and the entity's maximum exposure to loss; information about any liquidity arrangements, guarantees, and (or) other commitments by third parties that may affect the fair value or risk of the entity's variable interest in the VIE; whether or not the entity has provided financial support or other support (explicitly or implicitly) to the VIE that it was not previously contractually required to provide or whether the entity intends to provide that support, including the type and amount of the support and the primary reasons for providing the support; and supplemental information the entity determines necessary to provide.",
        "label": "Schedule of Variable Interest Entities [Table]",
        "terseLabel": "Schedule of Variable Interest Entities [Table]"
       }
      }
     },
     "localname": "ScheduleOfVariableInterestEntitiesTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/ShorttermInvestmentsInvestmentinVikingNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock": {
     "auth_ref": [
      "r187",
      "r189",
      "r190",
      "r191",
      "r591",
      "r593"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.",
        "label": "Schedules of Concentration of Risk, by Risk Factor [Table Text Block]",
        "terseLabel": "Schedule of Revenue from Significant Partners"
       }
      }
     },
     "localname": "SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SeniorNotesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bond that takes priority over other debt securities sold by the issuer. In the event the issuer goes bankrupt, senior debt holders receive priority for (must receive) repayment prior to (relative to) junior and unsecured (general) creditors.",
        "label": "Senior Notes [Member]",
        "terseLabel": "Senior Notes"
       }
      }
     },
     "localname": "SeniorNotesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ServiceMember": {
     "auth_ref": [
      "r401"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Assistance, including, but not limited to, technology, license and maintenance, license and service, maintenance, oil and gas, and financial service.",
        "label": "Service [Member]",
        "terseLabel": "Service Revenue"
       }
      }
     },
     "localname": "ServiceMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRoyaltyRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r125"
     ],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "verboseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r427"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period",
        "terseLabel": "Award vesting period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r436"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedLabel": "Forfeited (shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityRestrictedStockActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r441"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "verboseLabel": "Forfeited (USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityRestrictedStockActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r439"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "verboseLabel": "Granted (shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityRestrictedStockActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r439"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Granted (USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityRestrictedStockActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r438"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Outstanding at end of period (shares)",
        "periodStartLabel": "Outstanding at beginning of period (shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityRestrictedStockActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "verboseLabel": "Shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityRestrictedStockActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r438"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Outstanding at end of period (USD per share)",
        "periodStartLabel": "Outstanding at beginning of period (USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityRestrictedStockActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]",
        "terseLabel": "Weighted-Average Grant\u00a0Date Fair Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityRestrictedStockActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r440"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedLabel": "Vested (shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityRestrictedStockActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r440"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "verboseLabel": "Vested (USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityRestrictedStockActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r451"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Expected volatility (as a percent)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r452"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "verboseLabel": "Risk-free interest rate (as a percent)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityAssumptionsDetails",
      "http://www.ligand.com/role/StockholdersEquityBreakdownofOptionsOutstandingDetails",
      "http://www.ligand.com/role/StockholdersEquityNarrativeDetails",
      "http://www.ligand.com/role/StockholdersEquityRestrictedStockActivityDetails",
      "http://www.ligand.com/role/StockholdersEquityShareBasedCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee": {
     "auth_ref": [
      "r456"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The highest quantity of shares an employee can purchase under the plan per period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Maximum Number of Shares Per Employee",
        "verboseLabel": "Shares allowed to purchase in employee stock purchase plan per employee (shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized",
        "terseLabel": "Increase the number of shares under the 2002 Stock Incentive Plan (shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r456"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant",
        "verboseLabel": "Shares available for future option grants (shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r434"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number",
        "verboseLabel": "Exercisable at end of period (shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityStockOptionPlanActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r434"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "verboseLabel": "Exercisable at end of period (USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityStockOptionPlanActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r445"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "verboseLabel": "Intrinsic value of options exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r436"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period",
        "negatedLabel": "Forfeited (shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityStockOptionPlanActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
        "verboseLabel": "Granted (shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityStockOptionPlanActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r444"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "verboseLabel": "Weighted-average grant date fair value per share of stock options (USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r456"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value",
        "verboseLabel": "Aggregate Intrinsic Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityStockOptionPlanActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r433",
      "r456"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Balance at end of period (shares)",
        "periodStartLabel": "Balance at beginning of period (shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityStockOptionPlanActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]",
        "verboseLabel": "Shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityStockOptionPlanActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r432"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Balance at end of period (USD per share)",
        "periodStartLabel": "Balance at beginning of period (USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityStockOptionPlanActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityStockOptionPlanActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
     "auth_ref": [
      "r446"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value",
        "verboseLabel": "Options vested and expected to vest, Aggregate Intrinsic Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityStockOptionPlanActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "auth_ref": [
      "r447"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "verboseLabel": "Options vested and expected to vest at end of period (shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityStockOptionPlanActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r447"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "verboseLabel": "Options vested and expected to vest at end of period (USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityStockOptionPlanActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod": {
     "auth_ref": [
      "r456"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period",
        "verboseLabel": "Common stock issued under amended ESSP (shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r423",
      "r429"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCalculationofEarningsperShareDetails",
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.ligand.com/role/StockholdersEquityNarrativeDetails",
      "http://www.ligand.com/role/StockholdersEquityRestrictedStockActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "verboseLabel": "Exercised (USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityStockOptionPlanActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "verboseLabel": "Forfeited (USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityStockOptionPlanActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "verboseLabel": "Granted (USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityStockOptionPlanActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r426",
      "r430"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-based Payment Arrangement [Policy Text Block]",
        "verboseLabel": "Share-Based Compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis": {
     "auth_ref": [
      "r448"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by range of option prices pertaining to options granted.",
        "label": "Exercise Price Range [Axis]",
        "terseLabel": "Exercise Price Range [Axis]"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityBreakdownofOptionsOutstandingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain": {
     "auth_ref": [
      "r453"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices.",
        "label": "Exercise Price Range [Domain]",
        "terseLabel": "Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityBreakdownofOptionsOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit": {
     "auth_ref": [
      "r453"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.",
        "label": "Share-based Payment Arrangement, Option, Exercise Price Range, Lower Range Limit",
        "terseLabel": "Lower range of exercise prices (USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityBreakdownofOptionsOutstandingDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions": {
     "auth_ref": [
      "r442"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares reserved for issuance pertaining to the outstanding exercisable stock options as of the balance sheet date in the customized range of exercise prices for which the market and performance vesting condition has been satisfied.",
        "label": "Share-based Payment Arrangement, Option, Exercise Price Range, Shares Exercisable",
        "terseLabel": "Options exercisable (shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityBreakdownofOptionsOutstandingDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions": {
     "auth_ref": [
      "r433"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices.",
        "label": "Share-based Payment Arrangement, Option, Exercise Price Range, Shares Outstanding",
        "terseLabel": "Options outstanding (shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityBreakdownofOptionsOutstandingDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit": {
     "auth_ref": [
      "r453"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.",
        "label": "Share-based Payment Arrangement, Option, Exercise Price Range, Upper Range Limit",
        "terseLabel": "Upper range of exercise prices (USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityBreakdownofOptionsOutstandingDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": {
     "auth_ref": [
      "r427"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of vesting of award under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage",
        "terseLabel": "Award vesting right (as a percent)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r428"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period",
        "terseLabel": "Award expiration period"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r450",
      "r466"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityAssumptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r456"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value",
        "verboseLabel": "Exercisable, Aggregate Intrinsic Value"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityStockOptionPlanActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r456"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "verboseLabel": "Exercisable, Weighted Average Remaining Contractual Term in Years"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityStockOptionPlanActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r447"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "verboseLabel": "Weighted Average Remaining Contractual Term in Years"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityStockOptionPlanActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r447"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term",
        "verboseLabel": "Options vested and expected to vest, Weighted Average Remaining Contractual Term in Years"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityStockOptionPlanActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase price of common stock expressed as a percentage of its fair value.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent",
        "terseLabel": "Proportion of fair market value of common stock at which stock is purchased under ESPP (as a percent)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1": {
     "auth_ref": [
      "r434"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average exercise price as of the balance sheet date for those equity-based payment arrangements exercisable and outstanding.",
        "label": "Share-based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Weighted average exercise price (USD per share)"
       }
      }
     },
     "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityBreakdownofOptionsOutstandingDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1": {
     "auth_ref": [
      "r433"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average price as of the balance sheet date at which grantees could acquire the underlying shares with respect to all outstanding stock options which are in the customized range of exercise prices.",
        "label": "Share-based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Exercise Price",
        "terseLabel": "Weighted average exercise price (USD per share)"
       }
      }
     },
     "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityBreakdownofOptionsOutstandingDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r447"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term of outstanding stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted average remaining life in years"
       }
      }
     },
     "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityBreakdownofOptionsOutstandingDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Balance at end of period (shares)",
        "periodStartLabel": "Balance at beginning of period (shares)"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShortTermInvestments": {
     "auth_ref": [
      "r33",
      "r691",
      "r692",
      "r715"
     ],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.",
        "label": "Short-term Investments",
        "terseLabel": "Short-term investments"
       }
      }
     },
     "localname": "ShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShortTermInvestmentsMember": {
     "auth_ref": [
      "r763",
      "r764",
      "r765",
      "r766"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investments which are not otherwise included in another category or item that the entity has the intent to sell or dispose of within one year from the date of the balance sheet.",
        "label": "Short-term Investments [Member]",
        "terseLabel": "Short-term investments",
        "verboseLabel": "Short-term investments"
       }
      }
     },
     "localname": "ShortTermInvestmentsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsInvestmentCategoriesDetails",
      "http://www.ligand.com/role/FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.",
        "label": "State and Local Jurisdiction [Member]",
        "terseLabel": "State and Local Jurisdiction"
       }
      }
     },
     "localname": "StateAndLocalJurisdictionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r2",
      "r63",
      "r88",
      "r89",
      "r90",
      "r150",
      "r151",
      "r152",
      "r155",
      "r163",
      "r165",
      "r180",
      "r251",
      "r378",
      "r384",
      "r462",
      "r463",
      "r464",
      "r502",
      "r503",
      "r574",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r738",
      "r739",
      "r740",
      "r795"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY",
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Condensed Balance Sheet:"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r150",
      "r151",
      "r152",
      "r180",
      "r677"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY",
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockCompensationPlanMember": {
     "auth_ref": [
      "r175"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement in which award of equity shares are granted. Arrangement includes, but is not limited to, grantor incurring liability for product and service based on price of its shares.",
        "label": "Share-based Payment Arrangement [Member]",
        "terseLabel": "Equity Awards"
       }
      }
     },
     "localname": "StockCompensationPlanMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "auth_ref": [
      "r39",
      "r40",
      "r378",
      "r384"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture",
        "terseLabel": "Issuance of common stock under employee stock compensation plans, net (shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r39",
      "r40",
      "r378",
      "r384",
      "r435"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Exercised (shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityStockOptionPlanActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "auth_ref": [
      "r39",
      "r40",
      "r384",
      "r425",
      "r444"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture",
        "terseLabel": "Issuance of common stock under employee stock compensation plans, net"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchaseProgramAuthorizedAmount1": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of stock repurchase plan authorized.",
        "label": "Stock Repurchase Program, Authorized Amount",
        "terseLabel": "Stock repurchase program, authorized amount"
       }
      }
     },
     "localname": "StockRepurchaseProgramAuthorizedAmount1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchaseProgramPeriodInForce1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period which shares may be purchased under a stock repurchase plan authorized by an entity's Board of Directors, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Stock Repurchase Program, Period in Force",
        "terseLabel": "Stock repurchase program, period in force"
       }
      }
     },
     "localname": "StockRepurchaseProgramPeriodInForce1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount remaining of a stock repurchase plan authorized.",
        "label": "Stock Repurchase Program, Remaining Authorized Repurchase Amount",
        "terseLabel": "Stock repurchase program, remaining authorized repurchase amount"
       }
      }
     },
     "localname": "StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchasedDuringPeriodShares": {
     "auth_ref": [
      "r39",
      "r40",
      "r378",
      "r384"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.",
        "label": "Stock Repurchased During Period, Shares",
        "negatedTerseLabel": "Repurchase of common stock (shares)",
        "terseLabel": "Shares repurchased in period (shares)"
       }
      }
     },
     "localname": "StockRepurchasedDuringPeriodShares",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY",
      "http://www.ligand.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockRepurchasedDuringPeriodValue": {
     "auth_ref": [
      "r39",
      "r40",
      "r378",
      "r384"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.",
        "label": "Stock Repurchased During Period, Value",
        "negatedTerseLabel": "Repurchase of common stock",
        "terseLabel": "Shares repurchased in period"
       }
      }
     },
     "localname": "StockRepurchasedDuringPeriodValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY",
      "http://www.ligand.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r40",
      "r45",
      "r46",
      "r140",
      "r221",
      "r246",
      "r594",
      "r641"
     ],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Balance at end of period",
        "periodStartLabel": "Balance at beginning of period",
        "totalLabel": "Total stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "verboseLabel": "Stockholders\u2019 equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r138",
      "r363",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r377",
      "r384",
      "r385"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "verboseLabel": "Stockholders' Equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubleaseIncome": {
     "auth_ref": [
      "r630",
      "r636"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of sublease income excluding finance and operating lease expense.",
        "label": "Sublease Income",
        "terseLabel": "Sublease income"
       }
      }
     },
     "localname": "SubleaseIncome",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r610",
      "r642"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/ConvertibleSeniorNotesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r610",
      "r642"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/ConvertibleSeniorNotesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r610",
      "r642"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/ConvertibleSeniorNotesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": {
     "auth_ref": [
      "r74"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.",
        "label": "Supplemental Balance Sheet Disclosures [Text Block]",
        "terseLabel": "Balance Sheet Account Details"
       }
      }
     },
     "localname": "SupplementalBalanceSheetDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetails"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "verboseLabel": "Supplemental disclosure of cash flow information"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "auth_ref": [
      "r493"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Tax Credit Carryforward, Amount",
        "terseLabel": "Tax credit carryforward"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TaxCreditCarryforwardAxis": {
     "auth_ref": [
      "r494"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by specific tax credit related to an unused tax credit.",
        "label": "Tax Credit Carryforward [Axis]",
        "terseLabel": "Tax Credit Carryforward [Axis]"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardNameDomain": {
     "auth_ref": [
      "r494"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name of the tax credit carryforward.",
        "label": "Tax Credit Carryforward, Name [Domain]",
        "terseLabel": "Tax Credit Carryforward, Name [Domain]"
       }
      }
     },
     "localname": "TaxCreditCarryforwardNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TechnologyBasedIntangibleAssetsMember": {
     "auth_ref": [
      "r524"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Technology-based intangible assets, including, but not limited to, patented technology, unpatented technology, and developed technology rights.",
        "label": "Technology-Based Intangible Assets [Member]",
        "terseLabel": "Core Technology",
        "verboseLabel": "Acquired Technologies"
       }
      }
     },
     "localname": "TechnologyBasedIntangibleAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/AcquisitionsIntangiblesAcquiredandWeightedAverageUsefulLifeDetails",
      "http://www.ligand.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TimingOfTransferOfGoodOrServiceAxis": {
     "auth_ref": [
      "r398",
      "r406"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by timing of transfer of good or service to customer.",
        "label": "Timing of Transfer of Good or Service [Axis]",
        "terseLabel": "Timing of Transfer of Good or Service [Axis]"
       }
      }
     },
     "localname": "TimingOfTransferOfGoodOrServiceAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TimingOfTransferOfGoodOrServiceDomain": {
     "auth_ref": [
      "r398",
      "r406"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Timing of transfer of good or service to customer. Includes, but is not limited to, at point in time or over time.",
        "label": "Timing of Transfer of Good or Service [Domain]",
        "terseLabel": "Timing of Transfer of Good or Service [Domain]"
       }
      }
     },
     "localname": "TimingOfTransferOfGoodOrServiceDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TradeNamesMember": {
     "auth_ref": [
      "r525"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rights acquired through registration of a business name to gain or protect exclusive use thereof.",
        "label": "Trade Names [Member]",
        "verboseLabel": "Trade name"
       }
      }
     },
     "localname": "TradeNamesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsGoodwillandOtherIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TransferredOverTimeMember": {
     "auth_ref": [
      "r406"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract with customer in which good or service is transferred over time.",
        "label": "Transferred over Time [Member]",
        "terseLabel": "Transferred over Time"
       }
      }
     },
     "localname": "TransferredOverTimeMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r235",
      "r236",
      "r243",
      "r244",
      "r245",
      "r349",
      "r376",
      "r565",
      "r643",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r649",
      "r650",
      "r651",
      "r652",
      "r653",
      "r654",
      "r655",
      "r656",
      "r657",
      "r658",
      "r659",
      "r660",
      "r661",
      "r662",
      "r663",
      "r664",
      "r665",
      "r666",
      "r667",
      "r668",
      "r669",
      "r670",
      "r671",
      "r672",
      "r782",
      "r783",
      "r784",
      "r785",
      "r786",
      "r787",
      "r788"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsAvailableforSaleDebtSecuritiesinanUnrealizedLossPositionDetails",
      "http://www.ligand.com/role/ShorttermInvestmentsInvestmentinVikingNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfAdoptionMember": {
     "auth_ref": [
      "r0",
      "r1",
      "r2",
      "r3",
      "r4",
      "r154",
      "r155",
      "r156",
      "r157",
      "r166",
      "r222",
      "r223",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r309",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r500",
      "r501",
      "r502",
      "r503",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r602",
      "r638",
      "r679",
      "r680",
      "r681",
      "r736",
      "r737",
      "r738",
      "r739",
      "r740",
      "r741",
      "r742",
      "r743",
      "r744",
      "r745",
      "r746",
      "r747",
      "r791",
      "r792",
      "r793",
      "r794",
      "r795"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amendment to accounting standards.",
        "label": "Accounting Standards Update [Domain]",
        "terseLabel": "Type of Adoption [Domain]"
       }
      }
     },
     "localname": "TypeOfAdoptionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_USGovernmentDebtSecuritiesMember": {
     "auth_ref": [
      "r703"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt securities issued by the United States government.",
        "label": "US Government Debt Securities [Member]",
        "terseLabel": "U.S. government securities"
       }
      }
     },
     "localname": "USGovernmentDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsAvailableforSaleDebtSecuritiesinanUnrealizedLossPositionDetails",
      "http://www.ligand.com/role/BalanceSheetAccountDetailsInvestmentCategoriesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_USTreasurySecuritiesMember": {
     "auth_ref": [
      "r144",
      "r410",
      "r417",
      "r703"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years).",
        "label": "US Treasury Securities [Member]",
        "terseLabel": "Treasury bills"
       }
      }
     },
     "localname": "USTreasurySecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsInvestmentCategoriesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnrealizedGainLossOnInvestments": {
     "auth_ref": [
      "r126"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized gain (loss) on investment.",
        "label": "Unrealized Gain (Loss) on Investments",
        "terseLabel": "Unrealized (loss) gain on available-for-sale investments"
       }
      }
     },
     "localname": "UnrealizedGainLossOnInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "auth_ref": [
      "r470",
      "r480"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrecognized tax benefits.",
        "label": "Unrecognized Tax Benefits",
        "periodEndLabel": "Balance at end of period",
        "periodStartLabel": "Balance at beginning of period"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefits",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesReconciliationofUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions": {
     "auth_ref": [
      "r481"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.",
        "label": "Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions",
        "negatedTerseLabel": "Reductions for tax positions of prior years"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesReconciliationofUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": {
     "auth_ref": [
      "r482"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions",
        "terseLabel": "Additions based on tax positions related to the current year"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesReconciliationofUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions": {
     "auth_ref": [
      "r481"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions",
        "terseLabel": "Additions for tax positions of prior years"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesReconciliationofUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate": {
     "auth_ref": [
      "r483"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.",
        "label": "Unrecognized Tax Benefits that Would Impact Effective Tax Rate",
        "terseLabel": "Unrecognized tax benefits that would impact effective tax rate"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r182",
      "r183",
      "r185",
      "r186",
      "r192",
      "r193",
      "r194"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "verboseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "auth_ref": [
      "r490"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.",
        "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount",
        "terseLabel": "Valuation allowance, change in amount"
       }
      }
     },
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_VariableInterestEntityDisclosureTextBlock": {
     "auth_ref": [
      "r557"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for a variable interest entity (VIE), including but not limited to, judgments and assumptions in determining whether to consolidate and in identifying the primary beneficiary, gain (loss) recognized on the initial consolidation of the VIE, terms of arrangements, amounts and classification of the VIE's assets and liabilities, and the entity's maximum exposure to loss.",
        "label": "Variable Interest Entity Disclosure [Text Block]",
        "terseLabel": "Short-term Investments: Investment in Viking"
       }
      }
     },
     "localname": "VariableInterestEntityDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/ShorttermInvestmentsInvestmentinViking"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_VariableInterestEntityLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Variable Interest Entity [Line Items]",
        "terseLabel": "Variable Interest Entity [Line Items]"
       }
      }
     },
     "localname": "VariableInterestEntityLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/ShorttermInvestmentsInvestmentinVikingNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VestingAxis": {
     "auth_ref": [
      "r456"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Axis]",
        "terseLabel": "Vesting [Axis]"
       }
      }
     },
     "localname": "VestingAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VestingDomain": {
     "auth_ref": [
      "r456"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Domain]",
        "terseLabel": "Vesting [Domain]"
       }
      }
     },
     "localname": "VestingDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.",
        "label": "Warrant [Member]",
        "netLabel": "Investment in Viking warrants",
        "verboseLabel": "Warrants"
       }
      }
     },
     "localname": "WarrantMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsInvestmentCategoriesDetails",
      "http://www.ligand.com/role/FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
      "http://www.ligand.com/role/ShorttermInvestmentsInvestmentinVikingNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantsAndRightsOutstanding": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.",
        "label": "Warrants and Rights Outstanding",
        "terseLabel": "Warrants"
       }
      }
     },
     "localname": "WarrantsAndRightsOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/ShorttermInvestmentsInvestmentinVikingNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment": {
     "auth_ref": [
      "r174"
     ],
     "calculation": {
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCalculationofEarningsperShareDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.",
        "label": "Weighted Average Number Diluted Shares Outstanding Adjustment",
        "terseLabel": "Dilutive potential common shares (shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCalculationofEarningsperShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r168",
      "r174"
     ],
     "calculation": {
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCalculationofEarningsperShareDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "netLabel": "Shares used in diluted per share calculation (shares)",
        "totalLabel": "Shares used to compute diluted income per share (shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCalculationofEarningsperShareDetails",
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r167",
      "r174"
     ],
     "calculation": {
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCalculationofEarningsperShareDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "netLabel": "Shares used in basic per share calculation (shares)",
        "terseLabel": "Weighted-average common shares outstanding - basic (shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCalculationofEarningsperShareDetails",
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 14
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721665-107760"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(b))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(c),9(a))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721671-107760"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3367-108585"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(ee)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3367-108585"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3000-108585"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a),(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "27",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3581-108585"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4297-108586"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(2)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4304-108586"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4313-108586"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4332-108586"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(c))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(n))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721677-107760"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21728-107793"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(4)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1505-109256"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/subtopic&trid=2122178"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1278-109256"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e3842-109258"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e4984-109258"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "270",
   "URI": "http://asc.fasb.org/extlink&oid=124437754&loc=d3e543-108305"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "http://asc.fasb.org/topic&trid=2122149"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6327-108592"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6442-108592"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "http://asc.fasb.org/topic&trid=2134479"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8672-108599"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=SL6953401-111524"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e5144-111524"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27405-111563"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27198-111563"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27198-111563"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27198-111563"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27232-111563"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27232-111563"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=SL120269820-111563"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27290-111563"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27290-111563"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27290-111563"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6911-107765"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27290-111563"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27337-111563"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "http://asc.fasb.org/topic&trid=2196928"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL82887624-210437"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(4)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e7018-107765"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(3)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922890-210455"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4542-108314"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4556-108314"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "http://asc.fasb.org/topic&trid=2126998"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=120320667&loc=SL49117168-202975"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "((a)(1),(b))",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=123351718&loc=d3e2599-110228"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=123351718&loc=d3e2420-110228"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(12))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=123351718&loc=d3e2443-110228"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=SL51724579-110230"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "http://asc.fasb.org/topic&trid=2155823"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=6397426&loc=d3e17499-108355"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S65",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359872&loc=SL124427846-239511"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466302&loc=d3e4724-112606"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466103&loc=SL6014347-161799"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(2))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031898-161870"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031898-161870"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123467658&loc=d3e12317-112629"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(24))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123467658&loc=d3e12355-112629"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "http://asc.fasb.org/topic&trid=2208564"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21521-112644"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21538-112644"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130531-203044"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130532-203044"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130533-203044"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130561-203045"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130563-203045"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130563-203045"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130564-203045"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130549-203045"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130549-203045"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "http://asc.fasb.org/topic&trid=49130388"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=d3e4534-113899"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(f)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(k)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11149-113907"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11178-113907"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=SL37586934-109318"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32059-109318"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e31917-109318"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721533-107759"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Subparagraph": "(a)-(d)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=6909625&loc=d3e227-128457"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123586518&loc=d3e1043-128460"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(3)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "37",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123455525&loc=d3e2207-128464"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123413009&loc=d3e4845-128472"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123413009&loc=d3e4845-128472"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5227-128473"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5263-128473"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5333-128473"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5419-128473"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5419-128473"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "38",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5504-128473"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6578-128477"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6613-128477"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e7008-128479"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "805",
   "URI": "http://asc.fasb.org/topic&trid=2303972"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569616-111683"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4582445-111684"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5728-111685"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=SL6759159-111685"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5747-111685"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=SL6228884-111685"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "http://asc.fasb.org/topic&trid=2197479"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5579240-113959"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41638-113959"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41675-113959"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123477628&loc=d3e90205-114008"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r575": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r576": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r577": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r578": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r579": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r580": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r581": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r582": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r583": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r584": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r585": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r586": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=SL7498348-110258"
  },
  "r587": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19279-110258"
  },
  "r588": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=SL6742756-110258"
  },
  "r589": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594786&loc=SL75136599-209740"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(5))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r590": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13433-108611"
  },
  "r591": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611"
  },
  "r592": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611"
  },
  "r593": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611"
  },
  "r594": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r595": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL120254526-165497"
  },
  "r596": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL120254526-165497"
  },
  "r597": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r598": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r599": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r600": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r601": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL122642865-165497"
  },
  "r602": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL122642865-165497"
  },
  "r603": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r604": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r605": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r606": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r607": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r608": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r609": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r610": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901"
  },
  "r611": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "830",
   "URI": "http://asc.fasb.org/topic&trid=2175825"
  },
  "r612": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r613": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399"
  },
  "r614": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399"
  },
  "r615": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399"
  },
  "r616": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629"
  },
  "r617": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r618": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r619": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r620": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918631-209977"
  },
  "r621": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977"
  },
  "r622": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977"
  },
  "r623": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977"
  },
  "r624": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977"
  },
  "r625": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977"
  },
  "r626": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980"
  },
  "r627": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980"
  },
  "r628": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980"
  },
  "r629": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r630": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r631": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r632": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r633": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r634": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r635": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918701-209980"
  },
  "r636": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971"
  },
  "r637": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/subtopic&trid=77888251"
  },
  "r638": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "848",
   "URI": "http://asc.fasb.org/extlink&oid=122150657&loc=SL122150809-237846"
  },
  "r639": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.3(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r640": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r641": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r642": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r643": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r644": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r645": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r646": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r647": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r648": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r649": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r650": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r651": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r652": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r653": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r654": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r655": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r656": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728"
  },
  "r657": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729"
  },
  "r658": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r659": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r660": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r661": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r662": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r663": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r664": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r665": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r666": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r667": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r668": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r669": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r670": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r671": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r672": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r673": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733"
  },
  "r674": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=123371682&loc=d3e55415-109406"
  },
  "r675": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "330",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=6471895&loc=d3e55923-109411"
  },
  "r676": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433"
  },
  "r677": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r678": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959"
  },
  "r679": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r680": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r681": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r682": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004"
  },
  "r683": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "http://asc.fasb.org/extlink&oid=123384075&loc=d3e41242-110953"
  },
  "r684": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r685": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r686": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r687": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r688": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(5))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r689": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312"
  },
  "r690": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r691": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(4))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r692": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(5))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r693": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r694": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.10)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r695": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.15(5))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r696": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r697": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r698": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r699": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1474-107760"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226008-175313"
  },
  "r700": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r701": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r702": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r703": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=d3e62557-112803"
  },
  "r704": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=d3e62586-112803"
  },
  "r705": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(a)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=SL120269850-112803"
  },
  "r706": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=SL120269850-112803"
  },
  "r707": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=SL120269850-112803"
  },
  "r708": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630"
  },
  "r709": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Subparagraph": "e",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313"
  },
  "r710": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823"
  },
  "r711": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123345438&loc=d3e61044-112788"
  },
  "r712": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(15)(b)(2))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r713": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r714": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(1)(b))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r715": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(1)(g))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r716": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r717": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(15)(a))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r718": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r719": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313"
  },
  "r720": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r721": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r722": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r723": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.1(h))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r724": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.15(a))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r725": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.5(c))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r726": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r727": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r728": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r729": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313"
  },
  "r730": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r731": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r732": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
  },
  "r733": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r734": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r735": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441"
  },
  "r736": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r737": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r738": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r739": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "210",
   "URI": "http://asc.fasb.org/topic&trid=2122208"
  },
  "r740": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r741": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r742": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r743": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r744": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r745": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iv)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r746": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r747": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r748": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124508989&loc=d3e19393-158473"
  },
  "r749": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r750": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(13))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401414&loc=d3e603758-122996"
  },
  "r751": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12)",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611133-123010"
  },
  "r752": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r753": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r754": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r755": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r756": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r757": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r758": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r759": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r760": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r761": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column B)(Footnote 2))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010"
  },
  "r762": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column C)(Footnote 2))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010"
  },
  "r763": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r764": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r765": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r766": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r767": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=123364037&loc=d3e3115-115594"
  },
  "r768": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629"
  },
  "r769": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r770": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916"
  },
  "r771": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
  },
  "r772": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691"
  },
  "r773": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r774": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r775": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r776": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r777": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r778": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310"
  },
  "r779": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r780": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f"
  },
  "r781": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r782": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402"
  },
  "r783": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(1)"
  },
  "r784": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)"
  },
  "r785": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(3)"
  },
  "r786": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(i)"
  },
  "r787": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(ii)"
  },
  "r788": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(iii)"
  },
  "r789": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e637-108580"
  },
  "r790": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r791": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "848"
  },
  "r792": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "848"
  },
  "r793": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "848"
  },
  "r794": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Topic": "848"
  },
  "r795": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721659-107760"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e681-108580"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669686-108580"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e557-108580"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721663-107760"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(b)(2))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.1)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>95
<FILENAME>0000886163-22-000030-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000886163-22-000030-xbrl.zip
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M/KD]=]#J6EYD>=$[Y44V]E.)Z11C/YU/GRV0^%.,R<).;"=C4L;#@?.YW[V
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M59=O)J?/D*W>PK?ED3BHGD>"4!?1']'KCSIM-^.6<+:#T':\*BW\":Q#CRL
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M?EF&S#FM.<W]YDNZE%YS_8^JM_Z=7F?4:76=D3NXPN5?=6X$$P&-* HS/*;
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M.(G 1\7 ^(QGGACE+<+X*KQ;[*$(*=,%*ZR0; +F7CA-P TE'#BFYZF6"\C
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ML=ALAL(I!_\CP^+ (\C@DDQ1=%;-#T(0&Z>3"2+A70C;#E<^66EB2MB8PIR
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M]/-2:SGWOZ'6I]GO3/2<A)YI]^P.^CV@+^:! 5M,D#WB)_@92;B]<@O6%4
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M>59X.QT]_ );RF<9F[U:H,HN9O18008B%T"<'\KC0;4 5D3DU)4I0UQ= !@
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M<%+F=FK_Y\730"#' < 'UC9!+W#UBH**GG%'B%4MG:N@E4CVNS&T;&IX(DE
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MP!V)8>NI;DEQ6,X\P^B!&Y:WDFFO(@"9RZA3<OD' 2>9"B/8-U@ .'&("$J
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MT\ M0NM%>3M5HJ9F CH*A?B4(H]'@XFH:@9CY.56FRX$*\)(F89<K:@#TP*
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MH&B2"C!=3U3PZ:)^T4-,5/)3]!^RFF6&\R460%YY?S ^<(Q"/C&5DI;+!$7
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M0O.*VC6E L925\&#]%HGNP"!$/0" 110UF9M_JM LKY6!%5CA=<8#9 +YMS
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MW1Y G7BLA0P*<"C'TM:#A"W<S^>6.W*=QP'T(B8$80R8F@]KPNR$ >3">)<
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M#<31>H$$@;FV&4EM]MW^Q.E[YYF+:ZG3R'$=2\<-N4O\>]D@U%=6$$5SA8.
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M$_![8PR*E4?JW_+OBOJO9@T^!!/U#W+;(VQ?R)<E8["Y<\YS=N;"D$*\LE@
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M!S!?N\X8Q ?2KQQ+KI= Q#!(U31PX0+Y:JMLBI[';KL U]OD([[FJ,-UTI5
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MC.+;4%H6)6DI6ZO@::M[Q*=!7C73YZF#$+C1#W1%R F88CX365F:$&G'MU\
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M-2-3*!2,  ;.WYE7)ZZ+W\QD7O,9^6L"3@H K,:C06.&T<H W&HUO9A^P$J
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M04V>I*0J6+$D7V<JJ:)EVH=/;,F/),^9>;^D0 (4<0P"'%PD,[_^[7WKW@V
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M8&$D32+B@VD^!KT"UREVZ&6]G',!+2U2/A<!!*M1I#K .@<T8U)J5D8PI\
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MS3G7Q[CJSF19C9#.57W;J*VF8V7N/D+:HH4VEZ .NIK;B''MV=.@M12\-N'
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M]>5H\(&0*'\=GG\>TC_-1Z.KMZ-]XA>A= \H,\$&YFYOAWE$!^$.^!LCW#
M/Q:LFY?AJXCM"HO:T$E@.7W" .'%U*%*&'?-?7Q+[0ETZ4-E$JHD^0+P)A13
MAE;T4*B1[J(4):>P/]W\-WR%(A+^@AS1_$7B\9(>!3-RL]>;1/)]9^"S+%TK
M%:,F2,7<BFURWIK5X*A2SY3=A7LP,Y*TBD6[><J>6%,ZA4\$.\-_/);FMJHT
M]_RQ-/>SYO+,#,(<Q7D:A4(Q$=GV($<,0@#2!EP'XCD?8U6]MBPFVM8(-;MK
MI.#N&!,[0,KCSCB]59&@RHK/Z$>>-1:<HJ4PB3.U1]#BX@EHFYF=#6"3HA?!
M%;8/=_9;BLFD6400"[9@ :&X',SF/A6%>,M"&$IS5)*CQJ&X5<0XA[Z&XMDU
M!J2!>,]\8)PHO*%B0')%%56*<(Y16G$EI]!$1"(C7)2 N+LCL*>H=$&F"$PQ
MB6,;FY+&4A_4 LNJ%16?SJIRH1&.';,\O;X5OR*;SIQ#3/)#9"CV2E"&L0J,
MJ4ATR*-*E"914.7)=2D>7HOK@>(&UC+A&Q+K=?U':<CU">&^H4JS\S[<UK#-
MW\.'>SNZ.KL<?636\SUQU3PJN*EM]U/&R1HE<+F0=!M($U$Y7873I-0N_EG%
M[2#@N%66NIM<FLII1Y %0D-%Z"?=:^BKR"*5*5Y(A :YF3%NX^D<FM5B\BOC
M:;_Z2V W<$OI"VO2J=U9<BX@!<0-M"K(AF,BK(IV)3 'H467Y_*)F$ V###U
M&;BK$]#1 F"$6018IJZ2KR!&5:8U]&>"_37S1P.(,H:)DY$W,UH;*W8@-IA=
M3.CU0]2">7S[;X$XEOA?#>JAR!D"[%$Y(S*2_(_"1MH>WLQGOG.QL!#IE7H2
M-KU(9'0?9VDU<V0R*E(NP6!3UX?\F[!M_OMHO0=&TIBGE.YK>(!-)Z:F_>U_
M!HO $Z9O1H/NJFG=&O*G3:;UG;&HYV<F- Y0C@G: ^];I7RQU<9UC;"X )JD
MGP1S0WZF:%7;K=>3PC4+ROFZ"^ >D=:D:0K(W)3M#.LB5$F-&!]C\NM9)[=D
M?^$WAN5)#1"K>F8!P',H"4#'NKG//QKC)T%/C4L^C:,,@2/5+$DX Z_& *:S
M+*:ID&\BD9\0$^JQVHP\0%TM73/J-2T2?,UB>.7H<CQ/=M^K!J$$NF=0O7R6
M)E,^T2AK@'WQ&$;@1VXF^".O_0W']25)%@SKL5_6RJ@(&H/;P0>NB1Y!Y-@S
M!U*0++WN?M4G/90AX1TU:E5-!@\+_='"IDW-=ODM:,.7BL34'&@XC>8$*7J]
MU5H(CO10(5NOFB8.\70CXFSS$U"Y)4!_OY92XJ7:]\9=W9H^[$TV]>+3'OFH
M;68O"MXFQ5SS4$ _LE,^<64W*O\STW>LJ;[).)@YF/7%Y$<8M)E=H@"G/M-!
M&U;KV-6).BDI;^W:AR%A-&@MIPOEQPUG[NT@G:_B#]=3E.T0GNG[YTK&->%.
M-7=5!W6 T72YU@&?3$_IN8:YZE?A="7[UP+T@_*S<9XAH-[5+;XU2+I-6YRD
M48/!Y^O?+BY'UW_?D\W>D:_T6\-TZYYJ$X-:0Q U]:PHI<&;M(> ^UBUW<'?
M"12\4?HC5%5O"A783T _3,>F</,E$![!'6F;HC2!Q+',"B&:&Z4,]'_(/*2:
M0=KJ-"H59.USZ"9DW:;4<0&Y%3=Q @P.6RWSM+/G\,M=V:0FEAE=#H/!^\OA
M'JFT7[=2W,R;(1 ^:$VO.C06?#9P4KK&KCG;3SY.ZCLX@_K:FR?0-5?FMBM;
MSB,+/T0PB]EAXNWR12O+<%24F%-YK(]M5WWLQ6-][&?-)><3K)JRI4Y6>L 8
M'VJ^K=;NL->P?!2>W ;PJOBL\IYDG>65YR8N"-%M)Y'V;/M\[5T]AU[MRCGT
M\>+MZ-WHC/1:+]X%'X:#JV'P[N(R>#,\'[X;7<,?K>+-?IQ2HZD6:IAJW@$$
MYT/ N$8\38/K88V;'P!TC N_:3X!Q&D2$RH6<NH"BBU4HMF30U#MG%3*(/$$
MH<SCLY$5$9#HP!>*4V)>^&K]+C M,5/[T@^0[BGL#MW9W?9Z5W;;\&]GGS]\
MVM<R(1X0$#VQPEO4UGN#S_I+@1Q38;-S*IA@O\NO'8;I=.G8PAEB6Z7K9$EA
M<R/VRG&7"&D-ZL$T"R+.GD=?TWF#X(EWD$#ZF&89#.!MD661&?;!_WD>FEF%
M_SMZ^O20"5%<WZ(,0.$/JBII:YD4/:TS\P24DBO+C%LY'M9*$;%6*GYLS=BT
ME>I7C>6]"L$%M<@FGE_M'=_@D=>L/P4W^Z.);P38#B>ZTKTB1/ZZML]6OZ=+
M"]F6A&X#J%,$2T1GTEG2*1'#50D"L1&WMVCRE'+V)74Y&Z,J IRKYV1G;=_Q
MTVTQ?J_7V[[!V=G%Y5MD^[PR%O#JW6"/D*T(8:+"N5=/%LYF[=XB A5DA< R
M4!,+=C!U>I/*C@:N;F[SR:%5#Z&/-E"M,@@ YSB FOXM9YOU_@7J9@+TR1>I
MB O+VP2Z*<P?!*1NO]0>9WN,D72+4YW+K(UJ&HDVAF:K0KYJHJJD!IWV':2S
MW\0OQA*EDZ2W(&9Q[4 X<<M-_U)S%'.U8:X+UB%+E"&WRFZ]<'R"LBF:;NID
MT>\>LWAR:$YK'MEJE4^+NVD]&E1(._)F-@$B??_XA#6"38"8LB&(!S:ZN_9V
MH%3G$9<MYG:9$LD]0O./6F@"RM$2\!:4[?S2$!.9!3$:(04[(V8@>)\@LY&E
M#GBZ83W8E[1FC7_K&E%O></[W=DS8FL:TC><$1_,Z?#!G!+\DJZ"BS<?1N_1
M7S;_/C<'QX<A!*1O/H\^O!V=O]^/P\/K;>6]@2Q_ME!O&>IXL;]ITHRH:;J=
MVY1"!2(Z@)8QX5J6)H"+A8M#/<1F0ONB27M)UZ)N]EK9,(R:SAM%/F/-F-"H
M$>D_/X ,W7'Q.,*W[W=<Q6MEAS)&UUQL@..V49)))\^/7O],)[=/J=5KJ2)#
MV"H-@_X%W&N)C8EE6M%+(<H\8T?3193Y+X&/8/O? Q,:F'FKDR/-+NED:SFH
M:N8+C53>^(J_<R7IZ[H>UIVUDUO3.;;!3KX9G8/Y"X;OW@W/]J1V=.7CCGQ4
MO'80^NS!.*5(TV)_TYQ[(-'S2_)DFM8KFBRD7N3+4C"HF2E&O1ZR+J#9M;!Q
M/F-WM\#6 .\W;(&S 2*95@-"'TMW#U&Z>[F'I;MML9" .Q-#"%9'7)M)1/U$
MON [%K]-!)B4R,0':5*$PG$3&] . O]SCH1T*HD)G6NQ,9>YB1O1S2)8:5TV
MU#LF0AZ$#IT4BX3J&76BV#AXF)4>YPX;Q:V!S&\PBM>CC]P\/OCTZ</H;/#&
MQ$L?!K_3W\Z,N;R^_+Q':3>X&&07V,N%G!JG+O0^ 'H72#1(NQ%7(IR'T5>]
M9C4%6/9QO\!K@LWJG5YKUY%*'(Y:1,(BQJC_20^RLMF2MK_NPK!T3O3Z=H0D
MQT$L+;<@0$>W1)@8=@- ]DMRD2TE$IUCP@0*T5V*8HI0G_NM39.TG#1S4DH7
MK1+^$G7SA\3X<VLF(::.&2[,1$B>6UO"[UBB68<8ZAF(V)-U3V-[XJOV"*O
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M\(S4-X #A7\+L3CX@B4HVJ6Y(X^3&C/VW;>(5/C\[M@0#I/97-"&DP:T@N7
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M5UB(XHB)&NY GBPR-U^0_#G0X$765288"%[FS(;9'9>;"84U/ZVD$6VZ,3B
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M]*>O;$-N<^T]5CRWK>)YNI<5SP>R$+P!-9V"XM/QBE^0D$*/?54AC%(@DM6
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MU*$R%[S->O":N*F]$,0A3<WQ^.YC\#XKQNBL#6P2 _S%M><V&!@Z_9A(H$^
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MV.S$7^CW6] \V6JQVYVVB:P=4OD]8I9&KW\$]F[3*,VX&J4?JFM%4XA6./3
MF"&M&R!V#NXB"/UD6M69[IJ?8-JT5&ANLU6=[Z9N*?6$A>K&&Y4IX+V JS9#
M%FD[]8I[_['NOFUU]Y>/=?>?>(90]*D!E9[>BD9S'WZK383,Q=3Z[(H05/(6
M^K8NETF'-0=<V!WK]F.\4CLFY6MJ4Y!6G"YVP"*=\NVVC_1R_OH66815K9UW
M@PNUG*M5#^YKMZ7^5( U&'.Q=/!/Z:E0$P-1KT*>X6]N4TXRI+D''EHA\!=
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MLGIIZ+V.3&V+CEH@6$?>%6.S4J::A+9L/-!R*+7#DV44>R[%_Z RCE($ (I
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M6;.M-]T6?'!UY_5W^7H%Q_%TG;ULUJ*6P?1.M]DR3:O1U4R7 J_J&+H!1U.
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MLBB<$'IB[+;F-,T"6/T_.R'1CK#G.]B-T/LS"7GD %$7QZ?OMKI=B[48*'-
M,J;;-6S:<#J&"6?28*T"M$6"L]D-F</C71J&,S<(T6VVNG=O0<ZDR6Q-MZGI
M:NVVV66LV^@R,#]85VO9G6Y3>_UG\EQ4\Q1((0<<4H_#MSZGL(H!N_J3A1&;
MI7BR\NZ"((_N-%JVQ81Q 4:;;NFN;72:CFW:K69;*T ]QL^0!_0HQD<^Z%1^
M',X*<BR:W="I8=JF"_:SP[J=!G.Z)L-R&<R\+D X^P%\=I=.>4R]XR"*?H%R
MRHT8MM5L4DVS&HRV3+UK=QNNSL RU@VPE[M4?_UAPU=T+$\XI;FI4Z8UF<F8
M9K*V#D:J0YM6L]6BNF79S==_+!6]/AXQWO'K]R&+P'JW620_CAEUQ'H<?OGA
M/_!/FJY$6RXH:*YE ,XT-$ 1UFDW'+!Y6K1CV-\13^;W1/', XR8<+\V9E@3
M^-XTZNWF-/[CBCOQ^+VN:?_/EKCTPW^B*?4__,<*W\$#Y-_R.;>?1L,1/# .
MIN\;\"3<0@WTG)'_'MLLLW!+/BN]W Z\('S_+TW\[P\7]EQSZ81[L_?_>PZ'
M&1'0B\A9,*'^_VY'U(]J$4#)E1=&_(:]UPUXB_AX)??0AN=XW&?IGG0#=_%I
M<'2^OT>&Y[WS_>'B%G*+?_[5F@]:[7!_]]/9T?G1_I#T!GMD_Y_=C[W!X3[9
M/>GWCX;#HY/!RVVA^Z =?*'1F/NC./"WR5Y]MTX,K6EV7V[5K0>M^OMS_N_.
MS>=(QGA%)'-P<M8G_P%NXP?^()G 0VRBF-(9<S'#WV&-EN.TNHUFQVS+>*'K
MXB!ZS8)'KNR>17R*4LAA_/U>8"?(1C&[9$LY8QN?9]9><'ELG%U^;?03Y\?^
MY;?#[H^3'SN3K^??)B?G/>/;Y&CV[?S,Z]_L\*\WG[V3/?OFV]Z?_.N/;^.3
MO3]_'#<&WM>;X.K;9-_X]N/B:C#YQON33]JW\_[5UTE?_W8^:O2-OV=?)T?&
MU_/1[*O>N3XVOLV^?K%;_<E7H__EC)^<?[H:' XN!GL>[QO[9O]+__KK^=^S
M;Y-/L\'YMXMO/SY=.H>?3>?CG]XWP[NT?@2S;S^^7G\[/&H.SGO:5^-O[>3+
MT0T\__KKS<%XL/?GY-OYD3Z8G$T&GSM:?^]O\WO+TKINUW1JAMYHU$ K-VI=
M"V#EM'5J-JC5MEO:U@==J_TE>/[\%#Y49/1S,H*=Q]3R6/JK%80@,FL  8].
M(_8^_>,/AT=3C\Y '(N-B)O^4,^R@C@.)N]1)%ZR,.8V]11X!:3ESTI:=KOU
M9DM'@1F#9(Z=],5*EM:%+'T7.[=_ Z&KM^_\5:OK=_YVWU.[S;K6:3SHL>_$
MBN6J 2X(W__;:FRE-TRIXP O!ZA>$WV107G,O0V:8/IPM/L"#\:'1W?Q*GT)
MX\QEC)-*RO.SJ9[O)^@$GP9AO$5 2YW0&)Y^';]W^35S:G&8%).-'7#K\%/K
MV^'?S?[-X,?7<^>B?SCP!H='UU^__'GQ;>^3^>W<NSC9^QO8V]GXY+"O[OD,
M[VKZW\ZG<,W%3=\8C ?&WU=?C4_:UQ\'XZ^3LXO!^=@[^?*W.=@[N/AVN&_"
M&J^.SWMQ?ZA='Y__?=W_<:%];V@Z:UFZ5>LVF5XSVZY5LYPVJ]E=D]E61V\;
M76?KP__\J]LV6W_<R0D5BO]F['V@O'T8#O<&@T^]8W*V?WIR=DY./YT-/_4&
MY^3\A( Z> XZ']$;Y.2,Z,TWSEMR<D#./^Z3G*:8:8F]W7/\6>\VS 7X"#)_
M)QA<CGT^LWIX:Z]2MPA"$H\9.> 1@)Y\930D^YB\\SL4CE-A:.W+H.(B*3OP
M36T"[QSC;36'SFHS6%N-^84D[;4UE!O04+ZWFV _FHUFC8%A63.=IE;K-HQV
MK>M2YMANA[D.>U;6NYN$(9R71!+$D8>>62F/JT6;C89A-8!@.^V:28U.K:,U
M[%JKZ]H-"Z"K4WOKPQZSI:\$'1&+S'2;X"$\6-G\W6;+PSC+R5FZX-^L_K7J
M6M-83_WK-)]!_3/K7;-2_Y[.2@UA?6+X]=TJH$N]J,@Z8']OAY]\^?SCZ\VG
MYK<?O=G@$/Z>')F#<^!$>\!YOB!'PK7;2SI@<-4'3O7MR^#'X-R;]/>.-/@;
M]C'2!S\.0'<\&'^#_WZ;?&T.5NF 3>!-9JO;KK6['5;#"0H@9,QFK>GBS(U.
MV^W:FM(!S8W6 <_/>H/AD5#V2J4'QAEU$>D&)VX83,C__$MO:7\\_E\2!T_V
MK/IC!>(J-_JK%ZN[P63"(PRM@,X.8G40U"4XGI'U[HNP"KX.G@XJ2R$YZZ.<
MA#??6RYKZ8U&H^8X';MFVC:K6<PU:FUJ-QKM!AC)KH7!.[W6:&C=QE,J;WPR
M(E%H_]\6)JMD!_1]I-=_3$=;A'KQ73^I=\PYV_1Z'97*:,*-6^]> 8T\,&SS
M[+1PQD9BF+ ?8^E+Z>CAT]5WO6LSS3$:-9V!I6.:W4;-ZG2,FNX:%FLV'-K1
MP<@Y/CK$N-GIQ]Y9O[>[_^G\:+=W/"1'@]UE CDY RG;.]_?>SF?>N=!N/5F
M_YK:L< ($K@DS#"!T(A$4V9CI-XAW"<\CH@]IB$L]>W+V$(=K=YL-M>QA5K-
M>J?57<L8NO^WMO;T)E8#?C3,9S:Q),[]!@WUIW'=Y[:T)(O#?(T0#"S9<PU3
M-%5JQF[@+#I^8 <V5A'$;!H&E_B<@KI]I/'U]>:K/OBR#_]W-ND;W_C@\-L8
MGJL-C&_C@3'@_?.^UC?ZL\'>_K(#_L?@QR?]Z_DG_=OAUQO8E_9M<@![^+L!
M:V]\-8ZN^S=_WWR].=+ZGU<87ZV.8;D.\-"&11TPOMJMFM4""ZS9-MIMO=/J
MN(RAW\BC5S1DC["^-,3MK74-M;(1PCF]/E(96+8@A@(KP;\;PX\6,1R;-KF:
M8]=T0^_6S+;!:EV]Z]:ZCM/0+%=WJ*EM?6BW:QI8-&W3O!?'G]9;)N7FUBO3
M. 2&OQ'<EX"%'F"Q&/F12Y$'%>05*TQB^3PO2,0NPA'U^8WX_'8IB^VYF5?1
MCO[H;$A4C[#PM1_T(I=$S\2JTU5DNV2;-F2BR%.=_+J7;@!/>252L^<X(8LB
M]9]C6(!>2<R?2<R;6SJAX>B&T[98S;4IK9FM)JM9%A8<M)FE:TW+Z5*0F,UN
M1R,?@S &LAO&(6/Q-ADF'(2&J37O=T6]2F):K6)FY+3!]+(+?YZ$Y\%594']
ME%JT6]3B.BYMMAMNK>FVK9K9U.P:=9A9<[NFU3)L1EL-:^O#/ISA[))[WF^R
MH2JB>"11"/WW)#P-@TM0)HOI;OVME*'?HHQVUS LO6G5NBT*E-&PS5K'TAHU
MS6:-IJ&W[*;1WOJPVWME7H4R8/=I$,74^\:GTK%6X?9/<7O)J] R#*=EN4;-
MT6FS9CH-O=;5J%8S.ZQEBG:K+6/K0]=L:9UG<BC\-I?8 ZU&A5D8GS@-@67R
M*?7(_C6SDYA?,G+B@I'&HK>;YS)\('R V A2V]L'I&.\EG2 U=&H>2#R?_[5
M,?3V'Q&)F<>FX\!GQ!>.RFT"&. E>#:$AHS"V3GL/7GSG/FBR-W@587E:(\*
MCEY_[["&QIRF4Z, I)K9;=DUB[6=F@F@:EI-W6VTG:T/G>8M?O3VV7,Y1).-
M4T2/ KNQ'Y7+H7VWNQV+&:Q9:U&[53,ML!5H4VO5+-UD.M5LH",3C.JF5FLW
M-:TP>;AWE+ "UP]YS.&!,E;-0N:0:1)&"0:MXX# %>BPDZBG&V^LMR@X,!NL
M9\?O'[/=WYSYVZR;K?8ZT>Y&JV[JZT6[[WNL;M:[[:=_K-FL-S3C1<+=SZ./
M+TOM.U(R>>R)E(M]:H_)KD>CZ'$9IZ]PBR$58GHXFUB!MVF[&ZB4&7%^^]?V
M&,?7D, G7\8<OCG+N-.O:.6*JR 7 @"0*/"X0W K?[P&??3%+4W%_6=@!@GZ
M*:2X5TGQ-V=C$/&SD[W]Z_[DZ'JP=V0.?H!]>?BU>7)NF]_@G?T?J (LVY?!
MS>!P7^_#]?WS_=G7'_M:_\?( /M2@W4W!S?CR=>;3[/^WMF/KY]AC;>]BHYA
MP1'4F-,P:J:N=\"^;+1KEFL;;@='ZG5TF9@KW.^!?;%-IC0DE]1+&/EW7=-T
M3*8FT7B]M(T*Q>]%<<4T)<^L\/L!^+V_B-\=G3*GXV@UO6NU ;^I7J-NQZXQ
MTW8LNZGKK@[6RO'A8.]ED7=#G8$IBTXEHLPH7LZO8_!KX5/K?A^*+[D(NU1O
M.3;#BO9.LV8VT>+#"DW::+5,:@$?;[5 _0*39T CA_Z7''J!13W2I^$%BQ_B
M-5S.M7]-"0T%\VG]NL4Z>IC%^DKV-PA\=FN-O[N82&;L^ YFZS!BS8@]9O8%
M 8RX(%S",I?:SB-"R17SO-J%'US!,AF-8!<._! EZ&*D$7&8RWV9^7Z6>"+U
M(#V5W(G" =7OJNAZ]HC+%]C!7[B!H5K_D5A^(3GJHUR4L^\F=8P&TSHUM\4P
M5&YIM8[E-FJVZ38UMVFT&NWVUH>O+%IF?HO')IJ!W'6>@^#6Q69ZU(7#?S^(
MX9O_)AR9$? @%ZOO0E&"'-W#G!J8\;CXE2@7O4T9F44,)((_8[GHG:0"!W,G
M;%^ L#X'7N+'-!1%@F%4/H*Z^8[3*[1V&W0*P[%K9I=U:I3:&M!7VS#:S0;
MCB+O?P ]/3=Q/,Q=<Y0NXP4(<S5=7HV92(!>),[WY(VNXB9C$$-(EPZAGI<1
M9YYJ+:8N@">O(-1?H4WB)#C?15PZ#9G-A.M.-XAH@1*1-_ \T.))E-ACL/T#
MK -+BZKC,8V7><P5C6XS&'&SVLA;$+.^0]X8N=U:8!# 1=8/V O>)*Z'.W$I
MZF'8-"$2*Q$KI5%,NAIQZ"QZ.4&L&LK(#@YHO,<T3LK'-O[6OW>T1L?2&\V:
M9F"SF*Y#:Q9KT!HU-=UQC89M-AL_E<._2*F]D%/OK@I;[4$$NL2I7H!%/$SI
M>"'(F*];P5G-2 DR%. E$Q['P(*8!SPE#'STP'@SPBY9."-B!@VU11K)'HVI
M;$*PQ&'GS\CK17FCX(R-$D^6"0QKY^0-'E;[#V(TC'IF-G!1/3O%ZMGG9K5R
MP1GS9-';EV.-.0@C@!6G+!]K-+ >TK9MD]9:S&W5S#;MUKI=PZVU--KI:"T=
MOK8KUK@!K'&U.^IE^JO\&L<4?A$/ELT(M6W@F"%%MH<\!)TB_LIOP93T:RM_
MB"; :N$M8:H7$9R'1OT9ZJ;P--#E$$(C,@J#JWB<_EH'596)I0D?#%>%@013
MP@S8Y!WK$S_K?Z27W7U!>L6=RTLO1/7T6?#^YPAF2 03ZWP9TA,KN..$7APH
M^DL")7,)ZH95,U+S*F]3U3.T^>V]HCO-QCHI0WJSKC?7:X+QLQZ$#VL6^&N_
M-1L/2QCZ)1#H=;W;>44@N'>QC7JW<_?/KVRQ[;HF^[8\\6)-O4"+?6@WSA=L
MF_F4_K;?TL MW 7Y/@K"62$-BC2*W,?"$./KET_&X(<#QL-7['K9Z/_PQH,;
MVQCLV0VX!]:ZW"$]N.G?.+BO\;?SK\; V-<&/WI77W_8LY,O^XW!S5<-[@<C
MY,\?_57=,9E.K89E=6IVRS1K)FW:-6JU6C7-[#;:7;/;,NSFUH=CH6[U<MJ4
M /SS=\M\XG+SIS>%7DF/AQ>A[AP^2/-+( 7Y9="\_'Y_Q09]<1OSQ7=>H(-]
M8!;OHO&:0^;";KS"Z%)C]%"Z->0N,]^&_+ADOQ=H[Z\;J9]=V16'NI-$\.8H
MVL@>\;]-"QXM]8BW;5=O=;6:;;<P7=CNUCHM2Z_9C29U6XQ9':?QTQ[Q+X[J
MST;)+\# ]N]W.E;LZO6SJ_0(#\4)[LH#K-C68]C6_I6J=-#ZYT?-0>^[V7&:
M#M5HK='&7EI=9M8LZF(WE%:+-<RNZ3I&H1C7':GGQNM(/<]?JC=?>@6/RI,7
M;)'[V-_PO=YY@="D3.9P[XD!8I>'!R:S8IJ'2.Y@CLAJC0.21#)^"/MD8OK;
MBCD@02C>Y<WPY5<<7HV!21^V%F!(\))'(G#H4]\&?HOQ1NP7C1?C>&V'ADY$
ML$$T=U9G\Q.]\8:^71T=^M6HXF\/5O]Q!XK\9,;(BR.6WEPK2T@E6:I(,-;P
M8NB7QC'#/N!XF'"NV/\>ED9'(@4QZT]"HPA4<OPJ/6OFNDPDO/BJ:0W>R=%;
MZ0,BH; - X\$H(SD\&L>A$X ?EF.-3$U,]?!8$A#B\)C:R?7'IN)],TW>I-\
MJ@]Q%G;;:&&[@[>X\?DN5;F)Y8&DSV&QR\.)S"::PKLI7@2(+PH@'+%BFC@\
M5NNJ_UZ,%<?XC$K*D>V&/=Q>$/;FAWS@T=%&36!]5,)2X[O6,AOM;M= RT@'
M!:,)"H;K=&H=HVOH75=K:9;[\PFJ#^01/^$L"C-,H][&2/@TD-S\?<@P[^Z2
MJ0"X4F]S-ZKPN3:_A5I1X"7QW;?\RH"E_+_C<"Z31ZQFA8Q>U*@+#WA/O2LZ
MBW#F3)[E K]=VM?RDG[VXM?$>]?(T!3Y1M&8>5Z6&?1FL?1J(5/]_J2+NY,<
MEZI+-M#>&B(,-]+,>E09B_:]"=JQ:3=HK=/273"-J%[K-'6SQG3=,3L-N]%H
M=%^OD?1*<QY7E/0\J1KYL(?\YJPOK*:FHQ%P+V1O$U%)K7IB*&:THGG=92!T
M+=0F,4M2?8RPJ08!DA5U.R)]TL4B%WAP))*YZ10LBVL.1,R\&?FW8A\'(H\:
M=,+$YY)Y))&SM<A-S%:CV:9MVS"LKDE=LV,Q:EM.HPF<I*VWZ?<CP4U:#6T+
MV*P-K_"B_]NJ=6ZSE%.A,1YX 5V:2>HGDYH3Q#5U.QBB-L5SZ):+O\Q@']IW
MJEO-!FV9M:YC-6NF1>T:,'"WYIJLVVIK-M.8L?5!KV>M\=)#_$ L[GEXFA9%
M2Q-M#, A#^N9(H G&I?<O@^W\AU:TMM7E?NGCU"_R>O53\?'NWCKGXG/)$=I
M:'):<YW@"$TP:T%M8M&\@H%ZMJITV)8-8,1O"TM)\=KA(=@P01AMPR78H3.,
M!"'HVO\C*6 <> Y^*6NPP<):W"A89I=,5H0Y#&RNM!P#+I8%;WFB$2V7HG&0
M>-() -<!742HNHO[,F^"L'A0T1#5$5-X/_H$ F'$P8-$249PA?G+<OW"*/+E
MW]OXI/G7-DW]#/([E::,7\SM1+QP&@ E\12,"WL496PT7E@-PED:B:JR#RZ2
M1J$MX9R:D,)KL?C 7YLBNAF<N2< >\"L,*'A3.*QT1!X;&S?1BJ'W,E/)48O
ML=0&<TRW:5@Z<PR3M=L=2MMZITFISCJ6U=4$2\7_W\BSU*/!P8HZ07%^@DR&
MXE4G22R\22 5'L9DM7(QV9O!^7[C.QB:5LO26K6&W@(FVW9 G;,<IV8PVFEJ
MK.FT#1V8;&N[TS2V6TWM-J^]@U4%<_#_/L)IOI[6)'LGNY_Z^X-S,<(R&UE)
M=KZ2L_V#_;/]P>[^8W=T!UQ>A%'\AG'NT7S.('-V9O!L%C+?9N?PHAT/<*YD
M]'NR][?9Q[7=]*[[/T:S[SIUL<L< Y77T("6&ZT:0%BO.6X'M%;:T-IMX'$,
MV-T4G1KH>OMPBIY1D.:I_#P%Y7A&Q!@%(6+38O 52A*>%>GY?H+J$&-"_8:G
M#//Z1[Z./A.IN<'4^!WW">"0*#/'^_>8S;#=L%*:=*DT83]JPG,(@,([3%$
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MLCEFG#^)M55 M!_NEH7 Y[T>AS'U'1HZ.#7)X6Y9!?MP]Z0LQ#Z!VVQX[3
M:H]GHJ@.+A,"_L3'58QF)23]\[+0?A+C$0? \8>8)+?+/$^6(DT]ZL<E)?]/
M9:'^59S_TQ2[EY/2$7T2!A;WG=*H]>E^R:DPZ\AQ[)2.TF_XK 0.]?E>29\Y
M9?.IB]WOT.N8A24A;;E9L-IB; J%(IQZY0R9[3 0:F?7FT_B^=V*OF!ELM?5
MYJ^CP$>_Q80YN*;-)_;5^RX=I4N>=[Q>&.:1.[VOPN!93YVCV<;MB'C<9G[$
M"%T1B'EP)5?!"4%@P.XP#GQ6$JJ7FU6J>QJ1B<B;87(S#I*W( +JVZC1UQ]I
MQQ6/$>SVAF4)R^%6EU&@=,YZ20Y'M=Y?ZQU[ 3<+5X0T$I4@B<T<0NTD9N2"
M.SZ;$>[_2,)'NFP+2 J!PX3O.D"8Q&5A (N[%AU:]N,QJ@6G 6@#I?/<[P;]
MS6<":J>3M/@-,4#V,2P?U4_@I;.24/LQ'XE)6$LZ'\C[M ^XLPWLW_82,4DB
M2JR(.YR&G#TR8:.(U#$O(L!*BY(PA:&LE\CO_C0,)CR*@G!V&Q!EX! GIWLE
M80^[XS#PN4T"*XK#1&7L)=XD\''(L,,C1J/RA?5VQ22OD*_G R[P?LDN3A0*
M+FED)QX-I5U8/F] $%XF9:FSDYLMO4= ,?[A>CE<!=QJ,)EP4/^%*3B<X@3Z
M$!7 DQ#T17XC^PWC;_&8D?.04>>*SHBX*XI*F-^S>U:6[#[I*;)C<L9 ^H?V
M> $G2L<2PED4ER$NF-]M+I&[=(%!Z2U-)HE7!A4@O]LL=5<&@4I'Z9_/RD+E
M@4C?Q,ZLE]1+&!&]:DI$XQ(*LSU6@B2?^5XK'5]T+:*<VV-.AM2_6#./L^B;
M)LH%_A1\OGBTL,>I'TSXYE.^D.UJMX_LE+ 1-- _* NU8XU]GT:8SWO O=+Y
M[_>'AYM/W7*G_B4/ Q^;[&,.)];C85\LWUD8[ELN.M_G$5V/NQ=TKV6ST.7.
M/4Z.N>>5)8Z?[5<-\;Z=PU &TMXM2Z;._C7Z8)GG81B.K A&EH'$3U\D._^E
MQ3AF7\1,S'0DO1'SRY>0MS\\/2T+G4^F7C!C3,X7)J=):(\QX^+4H_XVH1&A
M$YSAZ0BN'[((1RJMJ+B]L^5^U2U_Y8NK;OF_L5O^AO'JLO1YV$_"8,K@M9_\
M$L9]]Z^9QZ_YF@V\BKO?TL5[Q>X/>L.=DI#U?#[CRD8N.P'\IVS$?E":=JR?
MZL,Z.0@"J5#*9JP.*%0\BL-2]FTZ&!X.RT+Y ?9GB]A(V9DC+YBP,/&"R/98
M"&I^Z2H^#GN]LAB:A\QG(17^0UC\-!85H!G_5S,U/'@=]T7*)RA]>(V8X5NF
MUJTB: K HJ.'#7O:G-TNA(A);Z=TS&!W6)8 \6%(?>#[]BQF8A/^#!; )PGZ
MA( ;N-2.@S+5A4HRX"-Z^* A"QNTV]*E@JC->XPZFT_LN<V2X1,VYBX@NI_N
MKI?=6\"MUJ880 (]#M0[4.DP;H :WV,Y>J$P7XJYL[*8]8=>8@L=+CUJ@GV8
MX0NPZTM7OOF1^CUOO8J=HFX6"W;DH)5Y$Z^R4?M'&EI!4H)VK8++J]WBP??1
M3A]3?S2F_*F.OX"$L/.Y+"3/IF"GQ3PB.^0S#Y,RN>TD[O.+25DF'8J]WFK?
M<_K89MP%Q/K@DJ_;JK-0NY7'+G=+#N#<=]%PXW2;#.N]TDGU(]!KUW3*%'6S
MI;/0Y=Y/S_Z'3J9_E*7STI%?.PT#FT71O-&"B,FR2^8%TTD))R0>G:T7BBW@
M3N64!0^._I+Y"2-#%E[RQ];J%) (RJ*S'V%/%3CJH%3:NMSZ9)+XP27UUVNP
M6^0-9TYW<CBQ/I:.N ?ED>67+(KY2(W-R09=EXW4_Z0W-R4A<MSJ<S34*![R
M'XL.PR6A]..JG?*#075>EMRZ8PZ+(3$-1TQETP7.H[E_ 6D#5F\Q^Z(LK$!M
ME_3>#<M&VWW@:/ZZT^V+N]U*WB,P&'P7KQ=_*>QNJ_Y) (EP3=Y>T+T2X8^6
M$?5R$GI,+;I<%E*"_9:;V$7\L<\]C_D^3R:;3_%+&ZZD/!+#H#?\6!*Z'P0^
MK,(.QCC]#-[-:!R,TQR;$A&^!$9I2F%3)RWIK1B"6Q8J/SDNBW0?L)B<3%DH
M2YR.@R@JE4M."+D!1J4VG[SG>RVI[(:MA\NR:_.W2WJ'I2/HQ Y";!17%J).
M]UOIZ "-D_YY24@<!+=/^H$?V)X(L)\S>^P'<E9)R<QS"0^_+),+8*=+Q%[*
M$A?!_4ZF\9B5P/&>VRPYYA.^LN7EAA-X2/T1(SM!4!:7^VEBI58XX=A^D[LS
MM-0PDBXBZHD=1X1.X<]+YA!K)MK4'.SUB$4C^ )NBZC+8MD@&S;/Q#1;GT5E
M:E^CD(>/.(I)D6;,HGC>5[8W"AF[E5N^D: 07.0>"&P3!]-U2)_.2&.;&)K>
MVB86BZ\8DRV05)-UU7 ][-\](;=LW.F4>I?,\TI0@[>PW2>/"Q6*GA0HUBNP
M+N1.EQ3/DM*Z"S*T+(/0Y6;O..>JR7K59+UJLOZ;Z!"N+8VD$9LMJ70Y*$')
MI[!$3L, +(\H BY?<T.<^)&$E_QR:;1X&6A;*E7!E/$2^+)N;;FD=#X.F _6
M\SF/HF2])AY%WS0Y8U/*R]1650+AM"Q5H*=!%-? ;(R3"=EC4\7L2T?IP_4&
MY!1PIRQT ^#KOHV&"X[O2GS^R*8=Q</ZTG1M$5I<U:I%G7K 2]310>TVU\ZA
MOU.Z=@YGPT_KI1D5<*LLBD-N8W3HJ1A[\9!^V#O<+PE]#^F(5<$=./&S]>8K
M%W"KS)/Y :3G.V$P8CZ89ZIU=C]P<!)&^?JE#_=WRT+PS$Y"'G-X("IR^]?V
M6.3;[ :3"7\"LZV(!.$$97&XB[VN3B'>)O#+V<G>_K"<?KHA XMFO<*!HFZV
M$OQ"&EZ7IEY$[7:;#'OE(^]P$OB\+.D<Z79O\_KC\C50'QX=E8; PV0"C#R*
M>9S$C 0N?'"6HHV;3>W"63G\&_:-G4AOE3:79,\EE>:)'XWA6W),+YAB?66A
M_!5;+^]$I', @E.6)&VYV5N=.=,D_B>I(RH400AV>$X]-BF!VSZWV84QQH_6
M\PI%" H*R?),J$W?+$Y!B]+87 E5^W-Z37IV"6JZY&['C.".=Y-8NF__#*SH
MUOXWF](E(-AE::0[;/66;/\T[*5>VQ6_H\V78!P7>0)H?P)5 $OH)9<.@-(-
M1CW'$21A"4:HY7=;2C?^^5EMAZW9H[> NQW/PH [9!R@NX_-AR!;RS#8;"(7
M&M%GZE'?XNOU!RGN=LO=LU60P>>]L@Q<^"R&I_&([+$(UD)./1IC*FZ):%W!
MP8_YV7K1G,+N]CEZ?Q67!,I&\5//+A^5AX%?%@^^W&SJNG_T:1<0T_D%K+0L
M9"TVNZ"[E8VZOR3_\)+0-FX57;5>,$+?_!'VQ_"=IPG-% _W!30>UX^K>)M&
MWVVJK</!V\Q?W9(+2ZP,V96KN8W-WA!1TN9<QW(('_X? G&;T(A0N-\I57Q/
MP/,?_K_PSG^X'P=K"HV"[YGTF<-M#/FGI7EEXR/_U'K'ZY5?%G&O\-T%< CJ
MA,P//)9<!,XLBL-@.IZ5B/:%Z^MZ5S2ER\4^-Y\!W+'Q<OH OLV<)"*[U.&E
M:<68WS+YR*@7CVT:,I'?]0L=VQ;[D=W30@WOX<[_;7'-I2VWJ[5<RV F:VB6
MW62==L,Q+*M%.X;]7=>V5KSH5]JUO=AM5?^ZE2]^P*J?#/MU;0G]V\OH;XB6
M$[VS<W*T-HHV\BAZ+VH\V_;$$]_S&(!IWT_OL&')B1QFXV1M1"_@72S$J[8^
M[-($OZ+AC R"&-6_$7;F!8WP( BOX,_:<1 ([\(P!J,"S8M,/KZ&O6U]>$_N
MI,@<?VJF##GME]C.&-;+;^%KD)!H'"2>0X @'=$VV0T\+[A"P(=L&H0QB8,1
M@Q]"<L7CL;AD$H2,."RFW -=CONBC8KH_!UFIQ@D(0@QD;RYG7Z88)-O49"/
MMA]^Z7*?^C:G'GR?GK+XT0><B.#5\+X@8@N_3J<,Y_F."/,B=C7&' &.'9]Y
M1)S 3O"J^MU'<\=9/(0SO\83/,=MJX.RX6K*_0B.4%*0IR@H![UX3&, UV7@
M73)"B9],+#C9P"4ACRXDZ!/0R$)\$-;7UDD/9'20C,;RO.Y^<LA<K,D6"#(*
M H>X%/'E1^*,\ )\!SX!8  "0'H+X-+%L[4!I('OS8C%YFWA76HKI,"_@A N
M2T(P'V*X[L(/KGST+R2PTMW C]A_$_%+^O![%DP%XB#^B$=%B?5#K#^X"Q;;
MXBM80P+X&K(H\=2Z@B0&[(9CGM 9<;CK,MPGB!E ;'BR&P:3U=<[/+*3*!)$
MI(COKN76RX+1!W>?&*('8(8:+\#G8P222%0)+4/O*@B=" X6^_U$Y'_^U3$,
M[0^+>9Q=PFF*S_H?Z??L>@K'?^MK.-+EKZZXYRU_-_6HO_P=8 WSG=LOBF*.
MV''KARMDQ,M?(E%S/V'+WT>,7=QZPC0,B&#&V0]!F/Y&X3DVGRZ\&'X-!&N/
M.)PM#17$WG#?]A+!QN%7'@KX*@SU@<.C4OE6E%I;LQ2'@?M'X@R2. '"@@T"
M_L^!+]FXT$CAV(#&!#>1UZ:D@1Q"3OC#9PF"S\1#JJ%NDS"8@=F0EO[#L@&>
M@0\?A7)!/.64I*E3$LAVETYC#HIM1I0DHA[2LYI+ ;(LZP0EB3S] >29["4!
M5,P!5T?RK7*,A0A>XT>$"YRI@E?( E?X-*_ S,7_*A O,6%D/R#E"#!P>#[:
M9W62D\> Y_0*KQ$7XQL"6_(]6^ Z%D7 ?_ '6#P^=<Y,)"3P)QMW#CQ4X< 9
M,#9R(+EHB@.V>%UZK,"NJ)B](0[H(2<#".J(HYF#(J0"=Z:P*Y;R?2'W2\/$
MS@7L,PTW=_83ZLSU%26XI22*A0<<:0//7@XUQ:;:\ 6(D8QV[I%H0AFZE$<_
M$\)(*DM+[ZN3+\ RPQ$C,\ WQ$%X!3 P."S G$20*1=M\0+_IV)T&][*@<8C
M>-&%%-XT2C$3PP'R[]S+]Z\QO0^O"D%:\U"R<8]>P:-@XU$$*ARLB@06&&Q2
MK83U)5/YL'N5D&U!"X2[@,]7"XJIQ:3$I9>@M JPIA)7\* Z$8J4.C+"U3G-
M"0EGTY Q#2U@>DC[/&-X0VQ$$_C_\R^]I?UAZ/OIWG,]2K+^)#U;Z$%ZMV'F
MHQ[%)8M[B>",N2R411UP@(H%J>#/<B[XD0]&XA3M1'9+!,I;LF\1N.H751UV
M2Y#>DI: -NDW^';U;9(Q02GP&'G ZC+;Y6H,EM*L!@HH]AE+K(@[G&*Z^NWC
M?!E;_2Y7A.QG3</8!^0^FA/)KRW[]2";FA2TR@J=RETR)S>"2HKW44@G$9%,
M02CH>6XQ%<.L@)4!)V3"#@$.A6>NGB>?HE2-@ASX.4AE-J'A1538<S9P.!:<
M0IQM95O^37PZ40HA//82U0[Q,QJED@4Y!&4C\/Q%2@>NW3;_V"8-,@3M7]AX
M>AK73G_K*9\HH,/)Q.?4 J9A=@S\Q;D$Y)AF%_J@U\NI71Z(+GQM=NG._FD8
MS#^I)(H[KP;9PN-9^N!4?\T^S_;8=?KAR 9[VD\_'9^?YO[,#=K,GCV@(/"$
M77HR1:7U!F#S,8%S@?7'W H<@$+Z"-QOS\I_V@5A?S%_G?@*Z"#_>2\'(?&9
MS4&$GP^6KN\'R1S8^,49C?,?L48P>^ I0[7(!Y&:-FA>M4>\:O>L/_\LY\+\
MY"9N!^GVU5?G8]'I/T6-$ZQ,7T2.V[&L])=_3CWE]I3?".S\YTR@@;Q"*DZH
M_ $_BIGH5RDUCISVQP5^,.ET@.M #8^%MJ0LD5#J1.DOZ*_QE,7Q<#*9VWM_
MS>!)'L]VL7\)'-*CZ<?/[,)+P@PQC_DEH/%E]O.WQ$, 9SL\FWGT9H[6GWO_
M#/8_?>X-=O?G4/=9,@'C+D/N/O=]9LVAM$.OG=P*=FD(1\DOLP?L!KX5\IOL
M@@'P*4Q"S(YH$%Q3-WV^;/R;T$N6_2Z-+#8'KE3@N#!_IJK-($KY,*J38> A
M(P!1@88/*)OBT+=_E26%4M%?L@-R&COZ6H,D5LJ.7*C:,MK=PSZ)9A,K0 O4
M@LN$F1W.]:W4N,Q;%<"[<4 C+);[PGR\HL)-!N8EZ-WHU!"W@ (.4-B6OE?4
MCSVTL E"U8]OXZ?0VX6MB$PZPL7A;>)3J@KG+Q?D@Q<%<M$/!ER=?$(O3TC4
M$"'I]1/FI<!V%,V2=@V]_<>*YSJ(FD3J[U(5 ,@O PE?ZP1,_3"9HCDC32_4
M]\=\*DY&^#[@'C"CF71N@H$[#7!CXAIT ,#:E'<J6XH 3GXM$JG6T1XV_\?7
M%-U\@)+30[_2NK%Q82[I18J>_MYY7]UNO:VUUQGW!3<VGW[:5Z=3UQ[XV)_D
ML?QB[D8<3']_Z%K@S%',)M+'H2\FZA1\7SM)Q%</&;XS^V3--(U%O,?EO5 6
MPLDERE5V]<"5MGYK!/M>%OF%"<V&$HL'T\5N 2K6#)J9G:C H?+JBV@TZ"PV
M.AN%CS[5_=$W)_2?,?.F9.4#N8K2!>A6%<J!?"B9J+S52'A3&6@* ;H+U'B)
MA5>D,1 J[:M9]L#9PG6@E\&BT5/H,V_5-:"MO:X,B-.()4XP"7S8G.LE 6P?
MM;MG7N2]2Y*F%"BX;&[KY0&(/IY$:G-$66S*ER/\YH#X+);>HIJ87+Z(*P%J
MQSR*<\@AW<A<A,XNX KT3(/BBKY?$0(!D(1<!F'$ T4BO#+_YW$D@43SL/88
M[)/,UP0*Y8*_*1?:DBD9 C=U4UO&8/6J^?;GRZX39 ($8#CWA<DH!+FD(0>+
M'+WJ(R;T:\S<8"$&>\#,DD&X7, ,:2O,CU7!YZ#5 +28"+5:^<Z$5F IF_@N
M3QK"0>P>XYXA!]N&83((O&WQ)0OG@M98-ED^(TP5.0-=*<;(L8TS&H,H9@'8
M6J 1 KW!^D8 )^Z[TH>OG(-PT52.@7*R,5!@)DXP75W8&@B^!VY('67F;\R.
M&"!M _J*@\I#4Z(@XDZZYHCQFP1S)!U.+8;A6_@I/\0<>05Z*;?))(EL4,NN
M:(1/V%98G?V,*[O@CL]FN>\6MI5"7Z+4=@OP0PP_ ZC06&)<$'H.J#GL[J#%
M*Q8?4H,16T0[=V)A A,BIX=@)VB%NX'' QG)1O>^PN'L!!D7UB9&K,09I[E.
MF(>"'H20LQA#?H+8\P>;/F%[Z<9I6DZS4F9DH6M <>F-$\&Z%-<0\S$XGZ9F
M\7!A$?-W+@A ;)\<WW*/R_T)7[BTJ'/<XF 5+%(/UA63K@?)'[,$A7& [@"?
MC (Z3Y>0SI9 AA35_0N.]2GZ0-"%I2*(.0@B^M[B1?!-%.,*,9<A"84QC[7&
M^54R,F+P<.'TQ$0-L5#G4H0XQ3D!J3D<XXO(-$*1[02L!G8LF.#MLT3O3TJ\
M\)[ K<'_!XXE YLR# [8S=C%?&/PSC27X]:NI@$2EXRF+^VO@&2&O-%2:C69
M! [P;ANY,+P!9%TBCU[D XP#ST'86#,95!4N2 K,"=A/)#-\%DA223,)LT5A
M-\_8N&0(X@@9_R27:Q$E4WR6E$< %.:Z'!4 >0)><$6R&)_ *7P"/% $AW%'
MB,;H,<+<%9'AQ?U+3#T1')\$XN$X9VB6$JC*MDD#S;# "8]8BMCI5KCL<B4$
M L6+7"[LCNT%**@E@I&-N6D9=(4K3TA*X/@"JTD\FPIXI,]7>K'<P]*IP&ZR
M+#LG$!E3RAOH8!)"%+]7J)_JHMOWDL5V[A#R>I8X+4D&\ XA9-1'I;](_]U=
MZC=LR\.L!GSEE4J&F:4K)&\P*R)=4'XMN=2=><[A:A[R5B08>#(M"WB$Y!8J
MVT AE%BVRAV32"4L#<'%_9RVCB^XEW< S_/P23Z#D\;;)<?-\<#4A?ESWH<Y
M:X!HD7+? B-/;+;(!O$2T$14M !3>]$S"?N50E *OC"7"+K,$*=J\+$X!\R?
MRFF&RYLK*+-*>8:-8;<H5NDK&/H!23I!0<H\J7"_SZ6?B7/+GTDNRKPM,\SP
M0;>2S[;582+5YAB6>)S2&[?G>6TRW4!FD"EW.(A(F1)*CH"X')5]!<>38J'@
MHG-;]3X518K'*!VGA (R"7':K= 6I-]4'+TEG@KL!C-K4'?"34[YE"%(TSRX
M96.)B\1614YB56JU(J,OE7GXQ"6V_=09,:_&]W($7$TF >V>?#[:J^E=<@J@
M8Q-N%X]V3D5R!.HY&"I9WM=4[0O0$&U@2V8YHQ^1=&2R-HAU63!^D&43SHL]
M2$W4A>C;J4+YNGP?.Q18!>[W%.U2/YZ+NF$R$3P#<\/XR <!;N/PR9YM!XDO
MJ. 4-HX1Y9=TE"B%7"K..;+,I\'(]+_,(R#3XL$\ECK4K8,&?B 10M22O*[C
M$FBG]^HDGP+[HHXJE8CB+"=G/IX-_!(O;+T8*SS/28OB\;Z>( NFT@7F+K;4
MG%>6!_-%H"S5'^9*4Z8P8D0[I^A)5\!8U+](!B-4PSL=$PMF=GW>G&-!%@>A
MB/Z#@859)$+N9RN0Q)SVY @7DO0IB/T :)F)%%M\]^IT%%55)! ZRCN/4J^1
M<B*MXSQZ@9SN.\(FTOU2;+3%Q'2UD<SQE!KG(N4"/H &JHQ/-H]93(/ DY=@
MG9WHVRAQ!-1$^P(=FK(J!Q :T\J$^SE-)Q,&_TH+9]DX J,<,#UU1(;"5A7&
M,]J^B']W9,[E7%%6PCV1TQ%DB5&IP@L*MQ_!]>AY%[EZRN%+11*ZM$7AEC'
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M%>U@&AR^CM%+E8ZO=I+9:M(=FO*#A>U@DPP^$2:7['Z(>?S4%N;L.[3W)'?
MNC79NE5M1G@E90-1(9V44RXE-;@3\U 7V)@ @*@?6RBDBE07"OFW","+76#0
M!#@MINWPB86#367[0YN'=J+XT]SO*'RP@>?-NYB*E]S#.(0;RDD94(8K[P2>
MI"Y9Q4]%\O*R1^H6+%5XW%WP1!63="0G6)&()7TJ/JPT2T0._-N4(L+@<$1
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M9HR&$AE&JE$8.COJ^1ME?$-OUBY%^CV9BGDK=F C<JL*JEQ]R.Y97^^VLQ]
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M-GNW2T.'BZA8)3CF0-JAU^L6[Q50= P8[C;P*T-#:%%($)<TLA./5KZK/%&
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MQ^-.Z(EAX"FL,F-($E#?]G2M6#P,S%1BI"D=(RX684J'JJ>P]Q]VXDG3WI8
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MSF"I*31!F2G>R-)8TUNJ<:"KG5N&5*=N++^ *454<K"J.F&X"Z2I<"&HX=7
M7Z\IB1FJ?TH[X+-FX)_;667&3/<D&Z#28C\\M0(!LK3M7!4X1_X>VC?\:LS1
M;^>_U??V=_9;[4[GA>U1Z]GMT:OU,HU^,2*5TXIY@I-:1$57!ZVV0ZHM57M/
M56WS?5H6X5.M,QC,"*%'#)3<?+R)Y<+;--%: AV0W_TJ>F^X_GTP 0>'S78J
M+NO'H&:+6#)98JB-4O_AK,H9JV+T!/:#.H9LK')+F[@DSE@D_+\PP(]EBK?S
MLLQN*+FRS'ZPT]S;V3U8@ME7A+7UAN:P]F(/]./G;OU#[<49OI7=QQ:9FX9:
MH;O*]1?@.M&PR!=F84VQS7&*SO;:[1T- V]]^B"Z*ZCA"Q%:MI-%R:XB\\'I
M$QTR)^7Z],/I=:G:G\?]M9+L5J:?07>[ 7=U3C%VXB/:BLTM)LSEI?$#_ TT
M?#^)(,!Q^V+)P0;3LE)RDUQ[V UUFJ6?E9%7P-/4)G'5O3RCHN+==JLUV\V3
M6^_J-/;L-G;W]IZ_ ^>@L=/I//]CVXW]P_D?+]'8TWZFQIYI#57>Z?,C>GET
M.T.)Z6:^35MX:ID,NMBP$>&&ZK8KHL@B3B\XAC@7;BS#=%[54(WJ!L>[0=^/
M= $-0UL3( <C_F+_9LARC] ?#D]:(.V#G1*(0!4I5($(^%27_3YU=^-M)C;(
M*"<WZ-EEU"/3>I0^C*\LTU1.\7*A9B2VT!0_MR6^QI.9^:J0*Y@0-5P7I;G8
M+T^ZVP-"/6MW3#O7R_FX[IB(*RGP&FWY)IFYA:W/T)2RL.S^V2M?7[*#@]1K
MN0%8HIJZW:P:.:I&CME"ZO92M?B+N:?JY-C03HZ#9V&?JI5C@ULY#LM9: 5[
M.3X(7]P)FN5'X^>P<S=9@&'\XU,,LY? >M&<7\BR"N4E,SH7,#-B;H"$" PA
M9G('N8M4]("3R)(C\"!'B+$*[JQ> C6*9"TA92.$%[P80XP/W:/N"\W*Z.PO
M0=HYPS):C<ZB61DOL^0E>:%TZ%JN%)5F4Y2G*I<L-UIF\.1+5 Y]-XCG!RJ-
M[L77+YV=/6NK.XKE^$%C>HH[>I492][4@[*5FB HP%-9_/KQNU:;[U<73"RG
M^@4PA859Y8@76N?:=?K<F6#:BV::1Q.,X#T&(6+$((TOFOB>C-/1+KZ4&C29
M[A'PTH#J^5.D3BM*["$&OND.J) #*U7S60Y:\G)E)KJ#B)"LLQ\, WPF@D,;
M%$=XIDA+F7-S[R?+Y@;,,;U@]\^"W.H*6/:3\U:S T+Z0?IGHK?J]PBP"ZKF
MHEQ\?HX 3Q)7P3G64\]OC;L-BA5+Q%::1E-RFUVZ7;RK?VX1HW3JK:,CJB_R
M B,_$XL0S MW SF[4RXN;_(E6=F%1%7XV-I]K86/KV62)#:'11Y"P='=L9M0
M"PL5)6R=7QU_/MY&AO3H +'>H'A3NYQ6-6)6HE53/_K)#96KJT[W29UZ*ZE.
M>>%E-QQZ;]EUZ]'^QP[Y+"4U";6T\ "]8+H3(+]X4?5!]NK%'M6;=E9^4''O
M<XYNF'BF5Y[^N&-MP?^."%;@S94,QVHEIW07/(1T0]:6L/])Z&JL-[',[N8[
M]%.%Q3C*YO_.4G+A'W?8JT36H[X98KX)8Y^)/O>6LF-K #N+QG^ZUN!-H<H
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M+N3F#A%&IM'@Y0'>ZB\/Z_\<B&BO9C0\YI<NKO\$GP#K<;<NA LVP,VNZRK
MJ-<)&-4Z6 @8M?OD2? _IM489PTTWS[NOWGK1EGQ6<L&G%Y'/B?M:'@=]4"&
M ]Z$$T^_IT=&$2B5,6TF,D-#02,D%%VH4#-I!"K&'V B#.) ;V*KF<DQN3R\
M/9P$_@2T)XZB\'$"%*CPK0NT:-8%FS2C'&M@3<+ UYA0CJ3XD1U&5_7AX60A
M]1@I>#F&*FCTTI%\G,S1=SA('Z,*&P^=S'4,?-(+U1,[RG_4/#!Z>W;PA4PG
M39'1MO%K]Z+[^Y6VC O"^?S5N6&:K?^]_G)Y>F[M- [_E6,$X0\G3HB6#KR@
M=-YB,9!P:.P'G=;%\7>8S9[[>!U@L!89L@?KTDT#P:HPL*;&4</_/)EYUA\#
MBR"P6@^#4%M_"*S]QNXS<,]Z, FA7#V00]:&$0X;!\_&" MT:A-)\=,R-%WV
M(06\K=<1IWX64= /[G"\FK2VKF2(HR3O5C%C7=B)=O0-=JR$((*:;&=1E_BV
M)XIE, K"(((?9NXC>J-<U6Q&E1>P[&.('Y(!YZM,8\94951/QK=8W*RKK_"!
MB+Q5; '61.?*LT4CV>E^%Y-Z;GZOYHO3.;7"?;B9?ZGD$GWIY85 >GX0)[T[
MA:1WEH!> KLVN_S-8=@NF\_.J#4OT&A;)Y^[I^<G*=01=Z#1'- 9VF%Z#&N!
M\<;0PUPHSC/O)RY.\L1VGO(\U\GE__,&N\7JU/D0Q>;^?G;^@&^=7%VV:"XR
M%?E;,UR:E1I@8*2XT$#O8%&1P8FKK,^*^K.!SL<!7G)B<\;QNT\=^J<]^)F^
M\*#)C=\@C@VX=M#:$CWI"5O9$'=":'RMTZ&<\ QE-B01MP^B/C0KRL9892,*
M\X/M%\P37K>A!Q=8,=(/QBJTMOY4_X$E_0EL%.0Q@E=&=Z(^PEI*4&)&_\B:
M5=B5=8;P7,@EET;5;67]'-B20XDBKFK3M9EC*IC)#9Z.MJ>'WHU2*O+,.Y)0
M;#^K9X!&V"F%M45:37T\^FJ].^_2.'!0+B#S;_#:#//<*+.1':I1+ C.2/._
ME;W#R'.F8@J2C<].;SP:5NZ,:7Q>V@[+!;^?U0 D+2W;_"A'[ZC7K  C<NJ#
MSAK%:2KL\'["SEY8F.FEE&034V/LJ)DLVR(.M,/5#8(@2Z;4YA5,-*RN;I,+
M>&3T/FCV04T;-3,L&_X=2<Y72FX@=&O:"'2[].FR% >V!KDO$/*$34UL^,J/
M1[([J "C?FWMKTQ!Y8\"C,*J,>1YZJH+:>HT8>_=(F@@.%0Q^2Y8$B3]@(43
MG+* KAW18_ $?7WK^MW[;=UQU^[ K^4->SI9FO8+S6AT<W>,.(@ KU?-8 *4
M>I?[U^&%\$26'\(OQ,_\0-=G@EJ);L#?C*GK_0X$&D7K/D&_#UM(UU&45N%0
MT2;>F^::;3U!=W=T0=B7<IW!@<Z.FONMG9W5M[W3=G<9IIG&;]#$J%'X@/ZY
M <"JY8Q2SHS:$["N8 #@L7C%,1H&T6@(0G.O?1Q*<' #+%PE3[E8D$Q>-'T#
M2Y*'@2O\@0K2[S3,,HMLGP%'I#TGWY_?7YLONKA )O&H7 "K"RC$E1@ Y,+.
MZ#5LX:%0=5>?BIMX[84_IX4;SG:3@F;R)RB&0XZU,N "9RHQ,(T!![N'7[@T
M-7C ^!")K_Y).!8+8\7PG%PX[H'_!J&JJ4,EYSK*(8"2&^S!TN!_J0<[A@!3
MUXH. O88XR$%T/DU*;K/14L8JWZA?"USI7FN3TZ_8(FJ&:Q#??=48:)7* R(
M+Y:>R+%NZO9E$J)S3%>_)K.R9%9"9R&HMC@9@3N,C0YZ<C'\X.?]1E8PSE1/
M7">;?9QK$%AJXH[I.<N5[L%;] R?UFZGD:9!4IU%NKDL<3)3#0N..BX.XG;N
MG4CKBZ9S2(4%28=>=0NOQ8_*NOD\\7<0ZF+H42@S%$'&TL%W\Q9<"8YZ,(J5
M9S;*8^(PXN?@AANG@3MS:T(.R_&)#5^A8^=RS]/S=UR*F>4TX'#Q$098(6L%
MQ%<S>$ F*1/S9,Z%I'Q'F"9S-MUG#)%EF@?[&;US"\^],I_5*QP$A7)YD6^5
MB;SNV,O]$O9)KS.9PXGI&^6.!A"'VR6EB [^/@EH?3\!:'?VGT4 %K*_'K2I
MZ6I(-RL4#_7\. +\.XF0B1^9C)K_I!]O4"\#&\BVPB:U=? DD\K[SWJ<9AA;
M3EM3JCZ".,^7;G8_$)6G@*=M&%T$1=H-UG6\[:8E/)PKQ[53RZP<]2K5Y\I,
ME1C9!^L=98@J^+T@' 44ZZ*[D&LY3S%M" \IMZLI/43Z/30(2=PBET+GYG_'
M2\ I(=A.%W&2FD@PIPMMRG#S68P$CBHEOUQ@ZLCX!CT1<:WQM#HC3%(M\,9H
M&("-],*EG_AXTS:+,T0!!(@F60D@;'XV@%%)\PU&V7U%3O/M=W*5S=DJLP!D
MDOU,]8V*(Y=K:5/N!5'\>/NM04^8]&(T<B<$QR4C8!9;1HM,./QK.&&!PX+A
M%,M'%O"(P=!;LX:>9CM0UL4<^R)/Y4&&F^)2S?Y9L?<\0SQC103ZO&%J0K(@
M\[EYI, =9+Y4] 0.>:_['E/)OZU8YE$L\])74Z_9&SB>$)KF>]7C2^[W6"K$
M9%K.17BU^;/3M&V&_84<N@K(_"T"1^="ME;63FS<S06D80<=& CQFN!O=I(?
M_9[:46:T7"1>#@QB\XOZYD5;Q^^WN9^&,+]];!I%!\'<%D?8D#'];^;N=7K5
MUX68_YASR908NS2^O;6%5U7MYMOC]]>7],?6VVT*/?3]DGDVB*TG*%V6 ZC3
MF(682L!1/O ]MMJ.;O@(O4SJ0C@ !C#$;O<^M<U2T(%O;E@7!;+$Y-<4-DC:
MR Y&>HXP?$.%]%M:;3Y[2.WR?J#IKZ1N1F+RX\(8O8@4&9$Z>Y[./.AV=>6E
M61&CJCD?@M7=>"7 RYRZW^=4B][\N)"0X860)@/9N9$.YCH]JA77"_@G$:9E
M&2O.B9;X!Y0BO2IB7U7 V=0-.H.0"4R]TW5L@)KV[A (4M&RTCN^\P"[<KJ@
M)[&+:(:'@&OZH(IUL]47.PX*R:WT6I*P'W3$;&L7%C7P4" 0&#P\%VPSS U=
MK!2];; /2$>BDO2'Q*IXQ/6+ZV/B!A^S1L(Q\3B5AC-8Z11#&78HGWD/.L</
M!N[$#O!FYWEROR_;:G1/6*>CY^HNM76P&G>IR"VOQ5K^H?%74TBL#,.,HC@3
MI)+H<.V;3;5%J6JEGQOPVFRD@W!16">ZEFG:AYV""J58D42Y!S[<;0Y#F0$/
MJ"$'"SEZ:,:M>,)M0FE#M,%)[O927UJ$H(D''$7CI6UP6\<W><JIYW%XL^P3
M:]BLA(77 SJ. 6,T(H0PT0#J+NU0HHIU XZ",[L'+E024R1>LJ3HEV4U2[.L
M_/:'ZIJ)=8VD^3'=BX>=1OOPX#'-B^V#!G@XS]YE"(\]W-]_]L?NP&.;\W]:
MTKQ8K$D^+*UP;RV895S^&<U-?6)Q.!]@.<_NP/\='KY@OY*^MOC,>BRR_D!%
M=LV9YUG;.9>>Y1T#ST&SLEZ"111[Q@ZO\G+Z"[8 R[<0K/A^-6O(A_9,K.7A
M&Q5_"='$@Z1BF2ZLEZ/+B_>8')_4S\ UN8/U+"49\\BQ2GN^DDX0/ENOV0H?
M_@$8:JMNM9J-\CZCY0G3I_];&Z'(X20^BD\T.59JSX1-^)3=KHM4G$V'4ICK
MAS KQ@8G'?-4)B2CU[L/W>MZ:U.,QU=U TNMK,=/O^ZP]=BOC$=1'!(Q7L[I
M7@>SP0V?E=GXZ==F8Q?%H0W_4UF'C"PG?H1-H'&(1?A;EQ>?=W<[VQMC+&08
M^*(R%C_]^CFX79"F?J(_M5X&Y/W1!0W<3;LZM[Y^:NZUVH^3FA6T*4]PL=;,
MINRS33FL;$J!+)\FHQ!6_KAH=07-2-<;R.<#1UKA@V^Q/.Q4(4?1N.; -C;%
M2!A\E,I,_/3KWK/E<=?+3G#I1/V#]''FSZ98BV?8[KH(1H<%8Z^R%Z5RH0;B
MPR,=BQ6T&,^PW761BYDKCNI:8YZ0J#,9BQYLP=X4^_$\.UX744&(X[W*>LP*
MQB<5/BZSN8*FXZE[71=A>-$L[EJ:#QYXM2FFX^F[72=)J2XZ[A$1Q% \N?BR
M*5:DNM?(XG+*XQY4]QK3,TAP"LRF6 LS9Z6R%S0RA&_Z#JI8(Y_E[UZ>X?WW
M;KO5JNZ_-\Y.[#?:^@*\75F*@ES@',M-L1,\K;.R$B@/5<-&:=QY:1U)G(#X
M]5/[H'E(?=-?/S7;K4>6&E9&8X6988>#B_TJN)ABD+$2?OSF./![B%RR*=;C
M"17J:V8]GJU"?;V,QU=!<W(WQ5"<)W80/G;8XIJ9BHZ)NI^W;LI@G)0VTF^R
MN"Q#IE6BQ964;O!RI%@S,9L3MIA!D>5PE;S\%!ZH0N5YW:@\:P"B\U[=51@Z
M%89.A:'S(S%TO@O%7M[PU5M'1\_@'JPX&?X:*O=&^ /K8^ /)NJE8O'U(%95
M.7(_C;I'K4=>DZ]@P-X-[0J8Y^4D8[VRO$?BSI%/*ZE8I>V>2?BWN*H@ 5)4
M:=T99,/W..Y3^I,X4!O3Y?1X<,,ULQ:M5G7]E^>+9" ]6(<G>IMB'(ZO<&11
M91M^^G6GL@PY:IR, ^^Q/M(*6H2NC=-L[.&;X^[5:649P%.J4!(*%WJM5F=3
M3,*9#.V;RB)46::E+CM\F7A!I-Q-L117,DP\Z]2/8A4G\9.@A"HYV1P#<G;4
MW&_M[&R*#?E3_0=>^B?. *V H E^JHHN\M)P4M_I/,ZA6D&3<79R:ET,1>A5
M^ B5M5BRA$0XLA^,U9-JLE=IQY7!F"+(864P\F4U<A0&=\(5HTTQ&EW7D9-0
MT$!T,TRZ,A^5^5@J1AV)$.>6BHW!\[P.!2RGNL>H#,=F-RY]@->H*LSX3G9B
MK7N8_DK<4$914#4Q$<;*AY.JA>D1-^@/:ESB'_?"-[_.G9"N7]AI-_:Q.VD4
M1#1(_I=0NB)68ZF;DGA!^1]JTC>SGX@>T#F)Y__D":/7NZ"%W3G4/+R/F#1O
MO758I$'^O\,P:R4:R'HOE.*F+OJPPE^$>RLFT4]OBF/EE5^?(MSTGN<3/SV"
MA>?S8X;2GRE71EC 8EV(B0=G%,U9V ]:=?G1?DE":\1-0I$%ND*&ELL]--8M
M-E<%^+D(8U^&D>6)B360\$<12\M+]SO2^T6HT22R5+_X*^ (>VC9H!R$\BU'
MCJ4;C/ '-?AHD("L!.&$($#LP/-D: .[9D^/&AAV6OW =8-;T#X6=Q2&$(3+
MB-\*'WOB3GF)9XV%FT@KX!7,K- :J1$6H$JK-\DO!(@.O%NSL.K"!\(/>#EZ
M!]86+#L>@N<&_QAM_V).[KNW-K9VVX]I;6QU&IWV\_<@/N&QBS_;W=][38O]
M 32 5W:>OQ?UI6APV&AWEGMLJ8N[]S*]J(_7G-,VL;P5]3K5%?^]A#-FMM;$
MC?U4\M45I<(5*LY-)L %VXC_?LY0[K4VQ-WK+.: M+][$R5%+*^)#O\>Q&^M
MGUNUO6:S!B]ZCNSG7.'9%-ZZ"*4-_XJKJ1A,,UC%7<]%T&<;%;_BC 5*:[=$
M:3TV>[]"'' !T:']R)NJ^W?[Z@X:-<C/[<[C-<C4GA^E05:/2XZ?8H)6E$VL
MGW=W*CYY&-TN WOX4O-=7QV3_+S;V7FZR7A-U_U+*@,QBA48^A>J;GAUY\S*
MH-U^%6[G"O')99KJWBQ.:=4.7T< O$*\\N'JTZ8PR<\[>_N;&&E\OKYX\U&.
MK'<JE':\*4Z"-AX'E2?Y0"<CO1C=+$X!X[%;\<K#*/<;_#1ZL2GAKXY1?FXW
M#S8Q[C@_/GGS)1X^;5+"*AVTMAVU5N5./O1&;O/8Y FYJLWDD7.9A"J63\+:
M6"4V^;G=V=O$N.,ZB)_F1*['%1?=?'1JG2?8DLWT+BO^J?CG:=')MV\;$YJT
M2H+7IX8FS^&/5,_82!_OZ=./5DOZ=@Z?W<-[#BU=/6,C+=]3VL)7T?CM5[9O
M4YZQ M*W<3FPGUNU5LD]6V4 U_,9*R""5>K@OM3!XB[U8M-HJTT\\S(;H ?^
MHN"\E+UX2]1$_-]=U^6^W,B2=[:;.-(2/C;1^HEP+0$J-(JLOH2/N<W7=04<
MIL#6=RN48^DGV.$;%GIR;X/PIO'C>[OW.S2,P0/J3["Q^$JZTHZE8YUB*YH/
MVWN76_2%::6>"QI0/,4]PZS*=^#WO[3WG_]4E^P$_T-:0_!0+6'YB=>3(6Y6
MF3WF#P;.*?%U;S30(>T>[P=V$L$_P)D*ZU8YLAX*?T#=V*,@AE]B7S?L$^00
M#S["!SDJDB*2C16D%W:EF^+/NO21^QUKZ_ADNWX:#.5=X!K*6+<"Q")"^5#1
M$+ZD?.LW 9(!#-5NM@ZP;5[3%XF/N]--]B@>-BPD%%%LB0$2GZ1$B8$?1*#0
M+.6) 3;%4Z^^ %ER$AO>$*KH!ND>2CR\.+A3MHHG#>M8/PS)1U\4=A)+ZT8Y
MOIS NOY.8$U;QZ?U[J?3;4MQ;SU_1WDCH4)F //@?N+;M,BL.U_A"\8BLA-7
MA)9P/.6K*-9[@1_".:D =+5 $2KNK4;*(;#M!*$&8']6/Y3_)/").\F]P0["
MP!>$&#!02.#1<%*S1C*$90I?!DF4?87X=XRLATSI9V^$ QL*WZ8U>*,$%P/L
ME3Y-1B.)U3;P8N$%\-(1;(# !D0\15Q-M"BQX0"08(&!3A#.F%]!V )P:#T9
M2^+ZH03IL?I"N4D(O'^<A"'OT@^0:>!H\$TAD'X$?QW3XN #5)0D?G$H81U\
M3!:!$\!113*.@3Y,1?1V)? *+$5:/>DJ29(=@?%3?6QQ@>>,1D$8)SXP!BAM
M.*2(F N^)/H@_?!G#PM6];D5CTJ#,@P") #_[O@DY7M8+' ++MQ*1H%/3.0J
M#\R)EOL^OY!/L_!<6CP+$ZRDG\1 H!2' 9X[0 @)3PH??MM/7 NTPXT$5V H
MD)"G(%B)2U)U6,.=@P$"/P+/@)%68$7@/=0) B*44>+BIL/ @W==#$$/62W+
M]!<"D5%?Y;8%2\6380$^%KYP!).!ORGL(5*9: ^'I<A@2-\9!<"%##@!K,2R
M@!Q%(+QV< -K04GNJ0"878V%*V'!2*/<JX')I)TR,<HY'!%];_8;6U_.SD\O
MNO_[^\F__^N@<]!^NVT1'(MU^G5:'F$?P(IN/ 0V=Y 8C?*7H@*[E6CC Y?
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M<&^D'RH'SONBB!>H![2D^\F@,EP7C1V!Z;!YQ9<!X8?2)2-=6#>C<NX3KGD
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MH7GH_@-YT'G\60]Q!)&;!(A-A&:]CHE!Q*Y,U6@_/0.>9,:^);+4B-#R[3
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M!!NI?.=RU'+3_7N;*=V_9]\UR;W)^57[]> /0%(_7!%_3\<J!IM 4HLX#9M
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M=N.OXU"LI9.YO2@W&U1S%ZZ)@+90U1'0!1BIJ<&KVF(9J&>(GP-_.B>$#6<
MFQ10XC7*]:QK6A0@IXDL1WILFOI2VM7'.DJ4IB8M'BR7/^&0&*Z7^/ME4:[(
MME +#AU,\R#P!,?V<_V]K%"KX&\K7Q-<B1I3,L39Q:XMYR6PX(3U*AEO0 V*
M;+"7V2QDUHQZ./NF*3XXU>*;,..>XB;$P2=D#UHP.V8H:F+HOBPN:ZYN!\VK
M- QX,T"W/"6=E!DKU)S<CC8Q)7E>"WES;K<)/Q?KS8J;TQ&YX6!'AP[S63"Z
M0LF3>+A^B*['GOT\N0.:@WJU8(PA_?3=\Z=8JV))[DJ^%KU$7"/'!9%[QJHO
M^GPFW@Z--HG%C_QW5X4)XTT>8@"9I*N1'(A!P,IFWJVY0"(]88&4M>D6(Z/D
M'QQCJ^[):J> &>JTIY^6RR"X#-W,5X'A8I(MU\O M%*6N:VG8AP)*ZU\+$:/
M8QPB37(AS%B/4K7(5A>ZEPT[$-/H-6W_?=0M@@2E9;N/Q46ZM3X@F8LT(WT@
MLJN^^[>'U6YR"V*%3P9=WG/<L'#-%S 2)'/2M[4G2$O0S5_BF7VR/M9K<S5N
M-AJNO>@RC<G@C)M.OBX)5VN'OOQ($1CY/-V:#@>)H,@@[W?T)(HRI^A6GH^C
MMOI5?LQM_);>/0_39_F@?L2D0TU !ZI7A,CVIPTF+TUW7#1A37P4ER4[!A21
M4RZ[I*_"6;##+,X 56D(+0_7JIA4'3"<U-S'0&BW@/\R*9>Z7-L.27A.50@F
ML^6KZS1A8.-9OZ7>0^Y[R^'.[CFQ6!=UT-2Y@L0=!1MY1S19*XJC[;>E(-K=
MI9_08[IKQR.&AJ:AA <G(^@>1&R"PYL>C$Z9N([,N<Z:^YY]_X^7SX].OWB"
M/WT5_1I*S2"U A>^?DO(2IIO64+YN^%Q_"@P@KOD[PO46_A;-HRDSZ*J>JN'
MO3Z4;"9Y+ 0H=,9:J9W&PK&&S@*X-'B.N,R7\;NDOQ T6?KGA8/NR41&A)([
M?C H/215P=QT+*C&3R5$K!RYT[P01AIB>@H-*J\>C<SV8!;>Y6@15C-S8&4U
MHNNLJJ(?/2=?:E4P2YZ\&8,:+@KRLQ9U*STHZ[$E.++"<([AV<7<^E7,[2'<
MP*/V$;N3-KS$K'%.Z^51_+^X"6G?1]/8+7:R)I%,(Z+9PSHA0>/Y<IGL5NIT
M<$TZOMO#6357X T<TLT+9B_;1;_=(B:9?&$@X:IO-,4TA&) G FD0R M(WJA
MNFM7P)FL:=6\E+J;WA&'(@(@-9&SQ)_44B!G%^\J+ B::F9U%$HO_?0BK./9
MO6W,IZ4'S1Z>B?@J9Z+UXMI:._X<BSHN]ZZA+3DUX\,O2=AJ\$QBH<>@;TV\
MDBD9Z[.WW'6$@Y"@-Y)8KALS6-[>Q(DK> D+ S&11O+P$@.GG'/SN!HH $B_
M6^X_P]!X=Z5S0_/+ET5VA7V411R:G?,EY))ZC:- .()^5QAXP#9;WL=\,KHA
M9H1#"M#%$GU(;^>@MK""P 0[8<L=<_^W^C*NG,"-5EMDILFCW?GCO2$GK(RO
M5I)]WDH^QD'LB4*')J1B9_<5F?MSQT#Y4>*SC\F6$8V0#&RR?'"_) ,ZHR.-
M";IV I^9\O:.X?7.'4FHITA.I%@C?40F1(P"$B&+0'LT[/TZ]XCJII1O+MCZ
MA;=]SZV-ZV >\DUDGDF\-OJ="BLCP8 1.2*S,P EB=T>=]I\.\A]SKNX?Z)?
MD& S,09HX?R">/U2/+'"67Q^)W+5FZ;;&$@'^+S0K D*LF#K3)N=J2T7TBLN
MDV#(C82>G4[^-SK]Y9+Z=-A9IG9<'8G MRT1UQ'2'-B3+=I+@/J@*S'R/)6Z
M,%:+.*PUQH%:@)!<*2J- V:@%FR1$%WB3ZO<\^<LF0M_Z$/]EWCWQDL-6<3]
M$"].=' EG1;M-FR8I+:%[286*-!)95%;O"SX-O;0K57G=,?]1O#W@TUY<# L
M$9_0.6009":0JSD[VW>4F%]B23:)O.88TX75$ES[4SZ#"*:<.L!@G @\0\X8
M84MJM*"C\>MZ%D EB8LV^RJ9ZU A61^:E+30Y]:2O#W^U+J,JX)I9..#%"TW
M65.3F;,P!EFT)P/O-AL/A#C)CGN;UPYABL+6Q:V&>MPP<QEZDS,[8AO=>]-L
M-W96<XEAH;N.&+&2 C"$R'A+S20LTB7YX0>Y<AHCIIC;[3F<?#7N>/+/"P*&
M7J4.O2NW5HI%/+A !#^V:+CU/FRS;)E<>5*%L) 2G[ 1@+X,P]3V PQ[*<UF
MM]V2&/<" V1Q$RX_]J^/1LGH(Z\3KUU3_\2A<R\K%@,)GB$+!&+T1!VQ-B-C
M*T#&V4?.-N3NO!UXMB,=]30&]#K2 NS"">TEU03)^"CM65OZ0KL2F7ZI?='R
MY!MA%95+'<!>8FM98,2I8L1-IQ0>%GM43@[!T'GP"U4T%"-.G X5=\ [S9%$
M\!L_*1E+;@I&E-H+NN@;:?4;KX86#Y,>BK#_K@#.YH9QZWS-\OE48BHKCFVS
M"Q1<VH&%S+Z%BJ:D&RUMOB<XG,+(8--S&.+B5$NG.1J%_=^G1MUVN9,H9 B'
M%AV%]/Q,]4T)W8NZ9A^\B]$].O@UR<O9&[HQ?.IRJ2YF5VF,'M=O_">!TRGW
MRQ.D/=$IELT<6]YL2^M!<*&FLE#$NPHMS-58:BPEPS@[0&?(-#.,OFP@@.A6
MB+/QY+-BA6(H#X/52<41;PG^/X]G[6C:)B.(YH?7<Q0IKFJ;^!_CJ1"-"-*'
M:(](RTZ$D#210>8-)90MRIB& TJ/A"4_9Q.[T^0LGYHC;XAUZ> =:Q OIJOI
MB;X(R\*]0'[IWDJ2P"D'WHVF#"CC>3%91J/5IJS42#;S\ R8Y:-X6X%Y7H8X
MI>J[K=96IBY&1:+&D%Y71N1NARHG63A#3;_BX/CJ(E1285^%2]3!N%C.3#]"
M!12'^FA^$<<@L8ZUVCL1B)N;UEFT)OS[FPBW\$03F /$+1")NO:RTYM<]^P+
M<SGBKMU<"+'5^[CRPU%OEI$ W-Q02KC._3YZ4Z]Z8W/(%R>7F0 %2HYT>K+?
M8^8/X"&P*A);?EP/;2E,ZMGW[/!0R.G^PIN-0.YY;1K.#B3TB*;V\X16-.CR
MA@HWH2=>6OT(%8KL&$O'0G8$[CE$LO6ON0W.;$J)+<LY?A+D/+<$"2B#R44H
M+DL.+W)*S>R0RQ0&XO-1[U$EQ!5]S37=$/GE;"98N,@=:.@E98HJ&(<XQB62
MU_$G+"1:&-2_QL>*IXR1[NCI6)"333]"DV&-D_IX^G4.)'1LE4BMF2+[^85V
MQYHTG>@+IA6DZ7P#!>9CI1B+93!XAD@*N>R;?%O\9S.Q!WBZ?(]<.JV9<TX^
MR;"K1Y7JATQ+L_8 SM'Z$W.R(0?$5@QT.GZ=Y2*![N3JTPT1T:T^B*UA]I/"
MP"BD"G;FP</0M6/^..K0^S?!K=8_"-BV[]X&TGNM (;LUNTH> "AKVZ+J33Q
M:279><7(D6"P957VQMS'.EFE-I]C'I*N2CAPXG+;'N+2'D3;:41JB;5T%%+1
M*I283^*:#.P645B(-:2TC12H>"G,W:87<<7?[G!ZNKTDY];DCFO*Z'U$HM+Z
MJKJ;E?"2P^]R/CWL)),9#6'50EF6"L=^LWH$!*Z2PJ<DRMG;'7))@\8,W<H4
M8TLWC@<1I3LD]'M8+I4#8/]VI BH=L&,L#OYI2MG(CLO%H/NM3W'DZ_U:M,L
M7[7''@#^BY.1X1E$9#KBJ_2VM 3M##6F1Q+M")K#'".;1T]['D(.N3M+C\F8
ML=40E2JK+-EISR:KXS(55SO05/YN-\L@+E<E'8D2^3MRM/X+.X:X[#3/"MX,
M?2JKEDCHJOG.  <.P($;> -J$]HW_1S)H)[-D8R]5@S7GY?MIMLR\L=!?6GO
M"YR;7LQR/[F%N*.C("5I_IA+(J<Z;7S?NWE+&,C3B-451+#DH3DQW%&_>YJH
M;/$6DDNBH4R(H?%'/9Z\@;[M^-M>DQ=.C]1+CH^?[P)X=/<:O14F8YJRIH/%
M-O!CF6]PFI,-]HZF 6MG0FHE^TT&<DL'HWR(>,/X_?K3 ,J1T6E [W]N>=TK
M@I-D5DK*A;'M"12=^Y^MPUI:5H+R^01-:KNU&L(<HG'-?.WOS/OTPYGO]YLU
MVH_2>\%&Q5Q2ZSJ:=VW*$;U[F>BATD?ANA.2T2URG"DX6(Q6KT?)??0WEEUZ
M>>UQ\X[#S9T2DERDB2BSE$$<>T 96M5-<W/G,<;!.P=UDV&1]\_&-%7\>Z"*
M>)N:B2VL7=8_R;[+ 8M!B>4](T*[?Q87BQ([CZZEU2I)9 S"37.<+#K!X0K/
M@B *BF.33=]O7<[0F-J#<KW3\!D@</;P8  "'\D.I&J6R7D*%;>QQK/O:\Z5
MF80*G*O8&JZAU+(D^D%?>A0@59*!55U$PD1KZZQH7(GNV5-%_UQI(ZN6;N1J
M5=@Z,+TM?G/:&%C$\',SYG:S\6<9C$K2A&40DM">#8%(66J+<^L:U/-PV".X
M@%"=60WJEZ7P_.[9V'"P@NJ[ZW.S4V&O8Z\X\AJ'>&#YJ'ZF#9':'Y=Y!B6-
M$$T3:K_F$L+P0N%WR70/(^+)$Z+#H_(;EVO/P;>DW$>&Q>V[(1H'9X74@6\R
M4L#5RAQ_?5])MO#G:EKJ>]Z@CGXNTJ-Q.5AQ3V_)5=$]8.RNY4X_=^Z0=G58
MW4;#^)-R.X>13/+X1A(CO0;U*;.(9 G!P<S;E%UTS8+2&IN&Z LI(\B7$5__
MSUF>Q?L(#,E&Z9U++%;;GG*F1%1#4T5/+V<);/$M#G!;?QFH"D<KLI?&4IP"
M#@QM&8M&D;QT2+8++L/E3H;92^X%&W4>UZ1#0XU*MKWC\-L.I\X193L7L77!
MW\-F(QDS"$/)\*"[":&=]CRQ< #/6/:"[/D-SRX?=' OQ."UUO4E%]F(&AMQ
MJT%=BJNBE")YLB:B[#'Y*C7WMRR=L].'_U.KW0?9T\,([%FG8_:*A6]D/&X:
MU+)VZ$CR!Q>P#@A (A0]2X,-IK[PLXR2F'EZ3>\K<SF( 0/(UH[/LM1L![=3
M0ZDKK\3)$$C1/+LT3"VW&JV(<?*HG9,D8.]RH =T!]F^N_E6E^(F4Z3BU #G
M%"8NS$^8IJF+SE0C0@Y/W=*S/C2I 78DG!&R_@WM=VV9HA!*%L/9J:$ 2-%4
M?PVFML]%#,N)OX_H7<O6 SJ(=TEX!72\?I!N'$O=&8[%@>9Z#\',EV,W1^Y;
M9>WC9"!]YJ[DIF'009/G;_@@<6P961$SI4I1VN:K\E;X*=0;DES]5S#7<$^^
MRR;^ .TZ35N["62RMJGURC"@5OO'#MYRA.R42/S.[,\N%QK T;#FPG*_?Y:1
M&+2/5J:]*?B8A(>5\\6 K=)QH-DF5]9!S\B6_>V"1<K@BH6JB?XY4RN_&OR.
MB<N,!S->=<_3\L9%"4[N+-?:U!MI?YSJ$_U,[[,3U;12BWK)H)5;10*%&'*7
M\K9SDJV,@^?:;G-*WG24+9KNW+M$W-/*TT%Y=3H#6J;J&;SPGH*44E>XO35>
MVFH%H4!Z;[GT#?;>*) V.TQ35AO1:;UZ]Z%B)VV&?4QY]ST%,9:$*^1%IIKS
MS?*:J5KBY4$1CK:K^HK[4TJP=)0PMQ75<JIJ0.DPF7P;OT0AWA0E$X+3#$R>
M**309EI,Q_RIZ+ZL5G; %, WTTN3<67Y4X"AQ@YU/*3 T>4)92%=\V4Y:G:]
M&T.*TBY]@)9M-*ZP('PWQ0FV(TVV\U[2LW ">TWPW<UI=6!S\ 'G6;I&$.)8
MY6(]_=D3E\OW([MO!)3P7FXW12W-@DW>Q=OZ+[;^4Y''NU[J3B<'6TS^$P?T
MW90KPJ'!D<K3_?++' <OGJ$<&ZE-ZPG[2W99!S?A+C3T4,!@3-T2SJ@NN&3-
MK?+HN]\*_PB![V?:#R9M%L0IGF][UUTA22SF2%Y(:OB=NELRN@1V5;#70L+[
MQ'0H3B#ZB>GX8.[FZ2B<&HUR*140.'MN4^Q6@,CP ",TVRJ<NCKGS!_ES?D0
MH=N2^'4BW[:/*@S'?5=C"J:TMM9>[O;EJGAZ!!HI]=U<_Z0,M>NZ4+['P>NF
M:'*-'"/XG!(%6.K4%-?/WX?1L:DW><G(W&RFQA(^O7IJ.[6@E7E+&ZT8H/<W
MR8[2'RQ\1=-+C"=$]J"2L8[[='N0X,;OKTLU4[ZE5:C$G(E.^YZ2[E@9MR0=
MJ18X70Y>N]73YVS-TFZ53%#9>)X8 E6$*ZG."ES+)5X%XDYVX0#/KG\&:[UP
M6>'MF.YO;0/JD\I+U@@8+/\,*#FR$WJ@SZ'W9-,*?%"]N:"AG^?;2)^-(G\*
M8N>)$\KY]7KN9(8U+0YG4C'_5#%<E9=!(! I)G5OG1QE<H_MB[1J5HR[9;?U
MRJ!'[=;4!^2VK>CI"6="4YAQ\R*F_5SML:5L@"^XOE9A T35"2:C0OLSN6 %
MZUXZ-\6?QIYH8N"R% K]D&!7W0:K;/9=#>672PS,J9Q#N3"*XC,5P%XNGVXZ
M*VNW+%-Z FJ"Y5OR1#DN2Y2A*Z+DJEI6".2&DZ ,%J%IZL::4+LV]!>5MS)E
M;[W1>[?92HD'7/Q@]'_2&NAA5&SEP6UFXJ&YO@8(@*R)1>G_XA(YKVLP]/G$
M4CKN>:97X;R8[Q()4<9XY,!#.'.S4M5Y5T 'WI>J]!U1@D)WI70=6N\?@LT;
M3Y#V\?+IFQQ%Q!#SBSCGJ6<KM?-JJT!&UY5/3]X+E'JZ:+L;:Y=E^7KN0.KR
M^D4HCM]/O?S1P=3+/Y4CU=JTE'3>ITPSN"Z<]9SU"]X@;0 .@=27.9(]C]1H
MO6"0)+!,7&!?$R&.EI <+%G/]&]KLG!CIHTV]S^B>9^_7*\[%,?C)_D ?AIM
M6_%M,<M_MZIW_ NKF_U]AY^/24?:P5;Y16M-Q9P#C^>:+Z=LG,Q^\!L[; ZE
M/(C2M9YH;_:,6M&A-$/.^&9C !\ZGS(,D6L"=1VE _]2.MC\P_)19DF>O9YI
M3?LV;!E+BZQBGV:-] (,!CA27'0YI<&)#2ROY-0Y"ZZN9^Z^(FT2S6AH-0&3
MQ2!+N*X 46E"*7UCFG6RA)4(R\FBP,W)2V@-E:!'='9.0%'[(&&(E)'>.[UZ
M+/29G>$3)GZN<<)+7;JN"!=O,"^I[6_:+Q,CPA8M M?QJKLK*=U)\/US6&^,
M <\R<BG5$1^2+0$'0^4ZU2^REU$B>+S(= R,FH 2()\A7ZFT/\*1V](5#S/L
M\8NY!X;)G(7&3Z-;"%I(8.5T/_NSG69"IY,7WSZ=3IQNMN9%7=TM.6YN4;!7
M?SSY6PPAD.;-,!A*XJH=/GN6J3Q:#59OZE+H/5FZLWO"1;P215J<BQ9/$BLO
MVH)HN$,?>IA2).[^@73E=:E<%M$/H6NG06IEYZBU$?,H/C.==ENAD E57$(!
M@0V+=+=KSOLG/S\Q],D-$*'QPK]"O2U>D%Z+3R)P<D,CC%^,MN<*5.P)"\)T
M?TRIU0J;#'TFY=7(@T9:@.XC8: 1_UI)TLJ,&#'9N9PV:!;<+CGSAP;RZ71J
MB2A@W0P, !V]8YW PVGQ;XM[=)5&T-:T)*-&]4>9BHRO$*\AK:*):%QB;-HV
MSZ*I>1MMB+!]\8G,LQGD2"_IQO7YJIYU<2>V^2"#56A!I*X+,"K2"/)P[QDZ
M;4:V?!Q ^;2ZI5@6./#3 -='_6X_Z?VY^8O!C(DZ+ G8>?-L@V8A1DL\+S6>
M?1-'5;3G+^MR(4-IXX>IO/[%3+T'[6:\JQ@_,-S?UUVISTVA>6;A'S/HHW*U
MLK4C6$&>/9=\^2Z;6M9"E$9+Z9-"D-K/O$-V,FZY._.OOWU%/3%BJXS#,1!.
M,ODM*V+.)F?)!#R-Q8::[>)%QA^OE/0#PS'*;2&UXP"5 ?1!@GY44G239[F8
M(P;2VZ5^I?_ZDW&JW>Q7OBLJ#1&Y?F[C9!M*U#06SBR/=BGDILK;1C%;9NQ\
MD]8>PYP7*[CD^%,,!<3XZ'*.A^M<R; L5B"$:5,*?Y+@2#T-;3HVX\T+-NYH
M=XNN-;$>K."[4V].>5ERCHEUB:/[$JHD:_-39S<WKO%0_HM6R]05<&54Z"MK
MI/UGA?]*//M([9)[W01+STH,Y38W;5/%C'D0WLU@^*.)!TX/#EB?#M!%OC8W
M+XGC%N=[C  Y3<]X"5V1TBD+?37!AU/*4>LGT<EQF+#4 Z$+MG.U>YJ&C)LZ
MS:9GQ7&]9MYE<BY=O"]EK^1DV'2<UCI +_;[$=?5)L5F(,O;+^QL3KECY&#G
M1.*]M7*?"PBUS97$U=S,ZG2BD9-G5*<!B0TPCPII'4YY:8U;\(8T9CXFKE\7
MBV D?=FJ 3_U(A1T]-:(J6%)G<,H3S35W/)E20NR6[L3PC@,D;A ?D+\EBF?
M/W5K8!M;IY:Q9;_S7[)\[CQ[_7U[5WT](7UB4AG-BC1X_%5=]4:7%:KI2!B0
ME4JJGZX]0/^+'*Z0WF/I6PH^.E26'Y5IR%LD[!$)JM=M[+E2N4Q&SV]+##?T
M8F9-39H##%WLT]VEO3:VSXJT"-%@/GD;=B;%NZ]2EQ"Y UN<R,O';?+^;.^(
MC3[ [6Z)17$!+#12K\0Q@NO FP81MS2R506\\QTFE1I\$=D(A.J\J;N-+WSE
MFX(S G$4RT7']Z49B\=]]$FE-K\%R02N*0_ZNV6C=B7'V8Y=87BTE$D,YV7K
M) Y<7H&#OA;12<%#/L/> 1\E1V]M\/7,!&2O:<C]] &2<3SY(0.((.^7OFZM
MRSKY34Y!<E.DBL9[6I-=0E!DB/T$YB+TP0^#E%PR.QPD2\>_4GNT7IF/":#T
M3NFT3Q<3F8(#=<Z4-[0-E+\!&RN=N5?$+,"P6%1M38&,RLS"&L+U!NI02-&!
M>G)\VF>1CLUD1I(J^$(NYLWK9I$'RL:9QL%FW;A$Z,(JH8Z.(KL#EP>#I$%%
MTWT6C=^R5(E(')5E1=FFO-!"UYY*%*?5@*HX%WV]K<0.HYY_%<XU.'(LKDG7
M=[_//WH"'>!)\[*:?!</!_0"G)V<G3*_NZF\9$$I5E\,<+>3;\IS/@9D!>J:
MO&[Y65/F,A02UV]36GY,8SG^^B5U9G"<+=L9):1M>0Y&)EH&T\G+.>4KC:,=
M>_Z"H*J>G74Z^?G52KLIB6_P2$QFO/"$F)Y"E=5<=IX?@#H6XDQ;?,0G;M<*
MA\Z(=Z/?%;$@>V4>.7O6C!4J6%9T7GN*L6E6VX]C7&ZPF22>TE[<Z&G6<:5N
ME3&$;O\J4#ZBXF,!M24^@@AWFB&E+APE<.K-,>\R7N+EJ^\93D']/QT3;6?=
M^C(Z;32S7)N058)?L&YE"Y$6Y(!"P2J#7. 0)4E5-N!MMF67F?>W,,A8H<_2
M<O#Z!)8DJBN(2KP18+<GOES#0+^$P_2&1U8QEW7X."TTL]YN2KPD%;#=RPH^
M$CU5_BUI_.7U!43+5&HC*U[N0.!=[\R[@A)!DXAA#,Z??Z!$19X:C6M5+]>U
M5V\LD4W_7!, C.N5F,V*4G.3Y2JNQ(2C$F[J^,K<;^UWY=L0-OHJ]@[;^ARD
M: B!/F,ISAX?#);B(YT[L@,5A5B#+36N[J_((IV>) OVYL4SQ7\S.IE$X-Q.
ME?K(LFQ:TF%=+6EWQI/LC-O'TB<!A6:F/DB4*,5\*J3!M$1C6W!7(8&M5KE-
M$H=@E8JQ F[\LD8SYG+R'+NS]D2$PH=<-,-49'* &+(G# B)?S8.^3(&R=YO
M.I[\6'G7RGGBV>E).  JFFUWW)7'XZ E?\88BR<C, R)U?OVB7,\C$I+ ?W(
M!:;"YV-@=(/ 7)(4\&79U)452/@N=A!*4L0)37LO3.'L' !P46UF>A"-;\53
ML'><1*+8XTESA:Z$G?,EE7D\CQI&8-"AP 1Y?&4DEC0WYI>3YYNB JUYBKR0
MLA40%R8I]2C (\P[FPI_R7@XBD2"2I];XRUGQ_K'5.T6#F#MP*+;V6CRA D4
M@L"SS?#O!ZXA^R(;3J+TXKI&&B;?.]H.8@=V#S1.&'4>!'@?+5"]"Z&7LH(?
M5'"WU]I#O;9%RQVSJ4"0MSYK6-<Z$M'>#%OK*Y?T)%Z1=!A*,SDAL&'!W,,F
M3@.OK&2OE3':32W+H,7K/+_F.#(LL_Z.>.E&X,SCR0OI;NL-0)D:11<9>T4\
M-P%F[_53*,F,FD=A%2OGTW1O@:&E9]5(,]FZ] 14;"<I]6L6V%2MW:RDVJFA
MP10E1L11:'"1WU'(I('2T2!0<E$WM:<RSKTQ5!TCCE0"T>XE2+QTKZN43T5:
M\*)8[-T@=@(UAYL?L?,JSW-(?L/WJ47_=1'6Y5SSX&T2$>)CCAS&),)*BC[T
M<:^.Q-D"Z0E.12]UP4>2"0=H6']P>JPV&E=ULUI<,?\_CPL&1/ ,M*Q<+R$O
M<B(S7VTY;QCB,-7T)7<D(I70"A9;K:39+[839L*T]WFJ,!?+5HT4)G"B7H$J
MA.?VQ^,WQ_@P850(8H?'V?7,@1S@A#W*4%'Q0[A @@+2;QV^BYJ:=65$GZ-D
MY:"T+EC!;V[&M5#20D20*Q"24.]\0V)43@@XZU!H.1*\C ZEI)+7,*WD2YV=
M/(F#OSLJMD<7T2[B5Z=/&('4*AY12OOQN\G'TSJ\R0B027'"=W0U8+'(0XN?
M8R4P32*B13N&Z);5<7M&T"AZ6V00CT@JK&9MOM:X^<0O(L>+7-<@C/^]IDNW
M, AC4K<4(\=5*:03ZYH.)R/-QKV-"8 HPXSW(@[4<JF5Q+W);2-<S9N!4L'Q
MXRIM?M3BAL]7B'X Y817Y9)&6U5+-'0P/,E5 (V,B <K#@66-*DVJ8#XRM(S
M X-,1B/>EM,B5C%4V]M';UQ9;;;7"S-Z;2E=MW'EK(J&DUX2-0(M-M#\<CIW
M#'_Z1-;%X1PW;W)BRQZ]0R#<#_:PJ>"ZD7?X1[6_+A*VH''O+L](EZ@QN81)
M1\ZN3[= L1X%3UC;Y)1QFZA0<A!E.9Y&$[-B=V+TVVE3KY(HY<;>/B5,\  %
MBBIA_@Q(Y]9SJ-E=E@GKH@ 0'#C6EF:2]LQSX1\TASPSG0>7>."Z]EZ<^4"D
MQY+!;)U%[JF],R<Y$ECY]9-J<0W/'N(:PX.A^UYH9% #<OJV(A"A_*IY"C7K
M,QQCH.'2]>*G#O0N&8@HH1HEEV%/MMQG,"0VH4@Z'A9D"'THY8 N8'#=4W.:
M,@M+3XB6LNBL2AC=)LK[5G5EL],KOP[807IOK9V:B>:/D8-NXYC9HW3DD,;]
M+WMMRX8FOCH_6H7E]B_W^K;EZ/3Q;8S+=6G8&YI!^#\/GWR\,_))-B*G]XXQ
M F*0I%D'23KQ'GD+9@:%@,GYE#[Y//X?:OPS-B7AA9/D\3"Q*M^)\6+3E<IA
M+<04V<$A%U-POV:'\[_#'?T\M;]V:DNTP/#)QW'GG+E#-,M=1*.6\CS&&#"@
M5>JW3N97KEM4]:@4T; 'VO8/:1!R<;^C?%I"#K=$KG^$SZOA5ZX&K^%+XTNP
MQ-XLI=,S98%&)C)&,Q5UC8(02&K1""O5^ZH(\1 =2HMG .%$NP^#68AZ>!$$
M!]NBHI#R"-3CRW%M)F%EG5GN'?H/)ZFNR[(MI>9 ;$H[;A-<,)+>8:;9Y5"<
MS7DC="IZF46Q+7K&"5>++[&IXS<^K\GWNR8;%YT +^+ ZTM/LS;H&W1YIY$)
M%B1$UCAJ=!2?Y_#]VI5I/H_,,<K488Y8,BFWZFQJB%./L,HIZY="U/.(((?D
MBCW"Z0+*QK@PT,\]]>!YRB\NZBL.%0FCNRDT^]JK^0C7R6[2[F)DM&['I8CG
M5"]=K=)J=2^X$./5!*;ORMNFE$LEB6B#7_#SLGP_?FW?CVW3BA0\FRQ*!B"(
MWC1XX+3SCSV2L5 R6_H$$.)$.E4?-\:1C:HE(_91[VKBBS)=V^#\LOM_GOWW
M:)2P"'R20$EUQ52X;+QR6H1%5IQUF>]=Z@_U'314*8!/O6 G>!Y4Y;ZY9C)_
M/QBP+SY5#-CG_72C_=1S[[7NE//6;*7.GAH:9Z)<E@1M7( WMB4] =LP])P%
M1OZ0CU[.WU8B5):J8-Q475))*@Y,Z>EAVI+)X]*'K6<=C6;S+>-%0%JOK1]$
M^17JS2I\-LCO[3A.YV\2=X%F0#V'2-F84\\X7"2@@J+"/B<(WO,4*6"1F"7\
M7&A7H_8P%E;WIFE)8 CG%C,-B+0QFZXA4NAT>4&,C5)W2T%EW,WN*H.#HN-I
M.JCTA-%J3;%24/;G5?+>-G+2H(&WI5 .MJ+Y9J:4SC;.9RL"B5O%LG#LQT0&
MX$,7LIVLG8-RQ"-IIG+T'&+Z&'+$EEVS0OF+J'42894= )^7PJ]<"A30ML7*
M)V>$#78CR3,.VX<U8Z6:G)P'JC5O+G!4"]IF0/'S9'\!__-,_9H\FR-)V UA
M -)9);3QGZ?@UQ9C7*5L5735_$*J9)XENDSJWR/%9E.43%BQ12T=%HE'&NYQ
M#? >P;&9:-Y@$NV(B-W^>.D0L#(9QJ),0,$X? (,[YJ,/VA=+UB!/K&E@;\#
M?-_4R56T9;\#Q!'P-H+,CNX*(35!"(BH=5*LZP%BDZ E1D;!/7!-4 $:].@*
M$<48*$/@"(F^?TAC@DNY?6LT6-,]^$E 5 D K2TW'I39AV-(QFK!*ZADP@WI
M:AP#6B<(L+8AC@$\'$MY4U"<.**S43NM%9D0Z_HYO#7ZPRAF3T>^->[ P)U:
M2DR@G)89RL95-G*T3#(7]/M?@9T9ZK'MH1,9,5$.M70=T@:%&D(P<;L^?5R8
MTO(>+GY_VC+4ISR0,144XRRH%ITV_";N==X'BRYQD^>@7"E59JA,)M_OF] Q
M^D'?V%1WT5_%\"7*RE5M=&^NR355&+3A.%>QHRA+'H5@TM6-;^UY<W!IPKM)
MR9Y9<FYG_#\T8G.\A>$U^A1>4Q:4D_"$/4=/.+6 O&HH-[O=#:%7O^P<^V0Z
M-WZPYB,.J>R--_+&V/H*F!S"#=G=EOUCU,I]=<[HSS$+T3@4;O^-::/IS1VA
M-[N'1"@Q_E7"Z(=KI 0GB6.0D_$P@X=IXAT5]Y1)71I@-@WR.9@,G4/6NHT.
MPY^R/XU\@=G>EF30@Y@R'!;"6$1W EZ")#:7AIW@3E#^:)M,Y$J:'^:KHE1!
MV*'PCWQ;GE%@H'4;['J2A1$M*7HE$14<TV38H3%^1'A9OZ0D7W8_Z8[8;/F3
MU-R9-0%/GD)0L-_WFE]DCWAK)]O&6 6V?3;QZQ2-!M-S@ OW:Y#L0\(,\E-,
M==0_G;W?UF<VZ@.:_5PF@0M;+2[Q,VHQ9"6K#DQA\D0CPRT:;RKT56J?9.XF
M"%5.4LKE?G9F#U,V_O_M")-(9R[=F1T/_EST?*,'L%E)GTU7B95:'/_G_SE]
M>/)$VS5'U 87=6_O";)*Q\)(?T1^D_76MU8M3H10=/&KBFD<T<>#=:V/<( ]
M#M$(;(B >#M8/*NRU5_R* E@_#)H?6?6%$"2F544!^G[!LGF+^OZ+6NGN8Y>
M\)BO&1@V^8Z11$_IOZPM#ZT):H0DOUDA*+AQ$U8";XW!W"J(7"6GPTVO3]VN
ML#"Q'WXC:QO36XV^ 7NI_F&Q_S#5C(72)G=:U^5RIUA\9-WB4TX3:@J=_NSH
MPOFS:T[=>=%BE%.#@QNYO@*3O4'OF;$9XM:*9G%!% #"[%M :X^VD'8(@;R,
M3RRC_;WNJ.P-A=U_;(I(O]D/&P^/$GYSTS\HR_6A4]^2'J+NU8]D4&RSUD++
MF6W:[+VI*;M JTA!CU @GSEY^0^U2MD#85'V9]J6Y;N_[V9]2N]5;R4FYXE]
MU[<A]DY,'Q)=TK>P$ZZJ8(96?DHBO&D+,A6>]1/?[*;ZD,S[*:]^E,^LWXYE
M*Z>],$HM2S0!)+IHFO)5<4545+"?\=<5KS&N$"Y4]4K>1U^!XL$M9WYDT?.C
M<<PMMV&]:7X/72'2_,AW)-\I?OW^@\D"P'EMZIN'<B-U;9V4FTQHT1$?BJ:F
MQ"MI;6O#-^%"J3HGN@O\F!'9](H#2=$-5UKXGS=EBGR+R;V3HW4T5!=D>LMZ
M,1WYD!LR^3,XQ?'U-FRWJR!^$=%4$7C7H$Y^L-T>H:?T&XX$!^+\S,O6D=9D
M8STO6FE5*GOJE+9BY<6%99P:$I5I'H@_EN85!65^5^U[CHY@PPL'KR#GQ'53
M'A^"GU_7EZR![87SD^\_.%I0>.;&]5TKW1O(WK:R>:(6YL^*7'^]=_*I(H@^
M6?]*>TC3*BQ5"\0(!T3[P^5?,P84S@_KAW/W >Z891FN]Q2RY.3?=_&WJY+C
M@!>7]3JNU9Q%)A7\V3+ BA1:O'*.AH4?(\0G<0L$TG(RLXL0UV+/(5NWR$WP
MF0PO5.5',I3R/ 1ZC4')Y94W]9F-[VN4]+[(%"O)KH)L@$W9FJAXFNGDA_@F
M1M/%3K,<<ZH8:*>":\R1L?T@E;"'QP]N5 H;&*1MO?G+T3U\^Y(&*9Y[8E1F
MT>C3!:B$=_KH_D>LX/WAK^,)USBL_TUJ<:=38E5["/T1.6Z%M%%BSGG9S+LU
M4Y2S *524@VF.ZZ9(/]J@H/.:0*;PEUJY261Z@+G$'F:LYHD.IZNST%FT\H%
MU6_U2[=)653;>" "3I>79V-A$#$:1H$TZ^)&W"9&;2,U'72A,Q\(ES8G$(-?
M<HZ&93V_C"[2VU UY2+ZVJ\R(4U+/CK-$%W/F=L>5[\P>Z \M& J,G83+L)J
MP?*R[LWB7,29>@3?H([;*NXE3FG <%6I)9L)?S!=2A1R>!%U5@E-' ^@W0^3
M7=V)%Y^,I)?"2P:3.OXG%-Z69&C7+I0BRE(*?TGX**[:A=.M(>C'1+A,R"*_
M98[BW!;31?GR&CXPN\".YU)YHLA4PTN_9"*R(S8?G"*^+GOM4TRR%V1-*3>"
M+.-E'7<L7#^.[.R5P4)+YQ7Z3]+A$Y*/Z+*']CL<)TI'PT[[1-?9\$&,DJ6?
M+AI1KLE"Q7C?([H+^*81-[9J[=,KR-#FMNN5/$2\[P_$LD4'Q^1[<,LDOC$=
MOD7M&,]7DL,WQEOZ9!8/<V8&!"#CB8/K4]K3$:?#T)Z]4WBC)\J446=@\J,B
M7QP8.F#+2@8X?FY[=$[<)M+_-?W0]#![JSWCFQ6/CW<.[4<]ZG1XJCC5*2X%
MJJ I+R5*G6N/"T=/5,X,2PB%RYXPEJ+&&!.\LZ1.I :QV%70L.D[<_'[\WK#
M0 .WR,8!H:[^P?Z=$'-41=/45]S1D;;P8BH<@LPNY=<<"UA9EC^,K.9D9'0U
M*Q<K4;$J<S$?HR,\_U/\I>[((=VM)0$S+.+UA%6'=>NM<+1L$T7V=1;199"3
M#LYV# 7TR1]OW[S#(2<0!2\F7KU( %U;8H#+%0/%:@((G%8'"-Q:<&92##+^
M/*Q=)GTT_B3ZXCEUG5@SS0KV>#49/-,$A^!02(Y'/*?TAU)'.OJ4I-X]#J])
M[#I^L4LWI>H#&T_F/K-]C *;BJ6(_JEMT'?%2?V8CJ(;DC^B5[?%SP<);UYX
M<BYWU,LL^TBQKU[>?__L%&-.M9"3VP@G)N^.<0V$V^D>)+'%<X)S8-=VE<!3
M]-'*ZH(I:%%6U?'S3IM\ 6R7CJ,K&WY&D'&0*#(3.YF =-'CR6L(7:X$6'+!
MS'KNBZAI)2Y3+6Y->Q^3K3 'R]RH/J"ROSI'+6V#7Z)M=,"$D9DOSDG!&,V@
M%AHJN&]+$-+&51"NJ <&/\6Y!XG^4@'RRBK(LYJ1+>(S=:^LVN3^KD9- LZR
M*,U?6L5Y\Y/<4QHRV\%$ZV]$:A>0,NF=/09B&'''_]Q[-"1BF"B/&ZM14UN1
M<CQ@('%1+:2#9,,Y_C;8(,%W!JI0%HIBQ]75EF'47LS!1>):)-&,CE3#+/>U
MD@+934=(^USZ6JF%(U94Y@D2?E_4\PYSU\0;Q:<P1R 5Q)WK=(GT>(])LA](
MJ  V1I-!IR+W0P?&JK@B,OBU+[G'+RQ9]4)D\J*UW=! LWZG*'L2V7*T)7-F
MA$4<A!W*V85BT\).P1QT#1?U]&50)U@A_ \P\+.=%U\:T\QI.I36,Z5=J2V)
MUO'DIS@*[8+Q>;F>;<.ZM3$JZ%)C")L:0C>FN:$'3J=0,8LO*ASLY''AG7(G
MJVY&1EP9G 40B$=D'A-CY5_5;&ES8$X_%,[?2 -18D'%B7T5!,M"F0D.1W\?
MAI-<#84FM4G[8 _*26GD$H\Y3C" I+G80_FLI(GL$$OL9/<<!@%KT%*-,QS]
MAJ''?3S)T[ETA1<=>9:%F0B7=7MZ?KZ*YW532#USG?-#4$;%1-45INOB7.=*
M)16>)OR4>__]^WL3X9[E;W'T)J\Z)%RR)^@V<+K(L=G$ZQ"F*CO R!BH7K1+
M!Z41]1ZUNFZY)\L"U?X2>GIH!M0QMLM)DA(C"5C^+I</I2F68Z*ROUXIW06V
M4FCP^02)[AE>@@:)<B/QW)@WJEKPMJJOCN TU0;-R6!- H(W=0>=.=Q'SX@>
M#3W\IA6UO,4?[-CT;$?DO-*9X].9P%ZYT;I@]Y+<LG,V+V63<>!K,(H4=#8(
MZLU1L6Q^H74@1RDO?)",2J+S.%BW 2T&_EY_F?BAJ!O-Y)@BVRJI0K'<G1_L
M S154DK"6B+&D*Q-.7/KG><;!WW$=?;"VRZ,9:GI35.&+313Q/H)W#+IMP=)
MFK#7PJF59"3_)%]D2"ATP7&LT-'NRN'+TG(("=:9&"YT5]+$NNC,OJG4HE@Y
M">^#3'U:%']J[6'ZC3LB2M=?1+@>2>*,IW1'*S7:85R4ZQZ&+@E(<'99XIR;
M9TM'6IS93X'( FN::)[ IRC[J8HT?4R3*X3[-#:22Y?,LE 8>/SL 29OJ :6
MJBPLUKI3AXL<[/-:VM2B [AN;[99WG4LI,@]I8U799RZA<)8;ZE=^/O!6YP>
M#-[B$^K?\'GM9)"'< 5:^B/8UM&&J1):AZD0:JQH%H$9F(,Q<B[3=X!G*KG6
M^LZ"/_M2?YR\0@OBL]1\@O%]656UU"F>,K7,V<G)%]/)EZ^>O7PZ52(F EVL
M [%1E.V:(:XN$3FH!D1_["T0>(DRL/:@510J2$TC/JQ&[<I0R907B&0%C@$#
M U#,I"H(:R*OE$'9GZ<D#;/0T+@YP;>?9?6,?'G*E>]U? '1G5Y3E7==K\*<
M@FLZZ-V#*@Y4BNG26B=_U?JW/$H3W $FI?CH5,I7J\3'3IVU*6Q2E2U*E,S"
M]DK5N+=7M578:<-@DB:+.K2B9,0'Z_"NH!RI'4#<8)W0#O'X9>0B]8H,/*)Q
M3%C+'%Y'8YK-=+<1MB+I/_704,$$'J>'GU)*E=,1N*F^0H%H#Y,4CER27%(V
MXJ/(X[4"Q!2VE'J9U=YU +-)-.@C0[C<D)G-D#$3C(2_DV)AYQ:*]?!2'(R0
MDZ^[PBP2NG&76.P.+"E]%F+_CB=/EUM)%_JW@O/I7FV:YM6@O.9"%WW0[;T3
M!MW>%-^K=S;8]>CP944"I\6#%I>V#4U"A&N5T=(QUT'5F NS"8 &]8H8-P:L
M\24L:P576Q9C55='?@J.)V]N4H_Y'9;)4JJG?[S^HEJ9="-Y4,. LG1?H^U'
M[Z7].E'AO#:")PSI-VAV>I66RF^NP_9;04MR,V$UYR7*JAKBEHG>Y<*==JD/
M+D\SRB$A$*C4&L=9D_F.U:LE_\C!1KF>Q;";#:;PKAM$G#+H2H<O^\EX<F:[
M)(^-7GSNE<](W<%?$4]@-)P?H.?W1J>!<6&RN:ZLU4U+BB0/SG2<.$U]AA!F
M5*7"N49$9',AFT0JN<*]T@ZN[0CCPC7S1LAE0[UA$AV[%"CN1>+-:75QHT?B
MJ-X 6:,3F)4%<SIC=[T2\M2Y7J5; +QZXAG@)#V]+"L#V] $H8Z=?RMJY.C:
MGE) \DW_UK^11W1_2Z7J@LX!<+CUH#[@#0$"J#F7EIXUON":FK$-N5@7;_9U
M/IY[7E5RS?,8?I*>(47^\>18;[3\K#P([HL@C:/-A ,!747UMC?9<+^I_Y>=
MHFS'CCQZ L\59C+*-IF1U+8TY1GD6I3>T;=!ZZ*:CBPZ/%'2IZDT,SOE-]7*
M++]@=%J(O,+(,'BV6>YIZIN;IX(?-W(0UX!G_74OE_T%OF]"1*A, JZ4/;YF
M,\E[:5K9NB'7HY8:K>$P$Y8>$DJD [1W7_4[$*;4;ERV*Q-[+<G/6DMA@LH5
M5! @"DT6\'03 )\K^MTP_9,O=T2U"+93+5+%;WT+M:^SD],3#JM?L:H.'?B*
M):,Q?DHBC L8MV=TZ:<T'=2RD,0;Z-ML$/@C:.2(T\ /_IJ$)(DCV4+R*9='
MX5\"7<,/\/19W!-4?8J6SW,^2J"RZ!?2M2*>Q#&Q3C,H.94;8G!+%7:S3U,E
M9MJ*Q&]T;1AJ055Y\J(7 <3P,.B"JJ"E1FXH^89,XVVA/T.@P5G8LB._W6U"
M"O'A/(1VWI3<M$OMJDH8#FO%S<1L-4O:$3-N+[CBX76W:EKI+* WM2\\I_[7
MU_@6S1ZIM9'=IUU"?:083M[>7!]/BG _Q0&A?.C4"4S2@SV+X],H+""+@6K#
MR!>L3JSV(<[>\>1[[8AXA):(4P>@>--MJ&H4+TWUA479$E99!. @ARC:LOI(
MZ:YZ0,4[Q $E"L<M#8NV)K22XA<T)3T5SCM@V+N5(/O9&E;19=IV#.^0[(D]
M^RN/0\^>UD(1;5*<Q@^'%O'EY$OZ#PBT@(I>H&2?U#K1%>GK0 4_(0FL0M"*
MR?6X(Q'>PU=AUG14W3E]P(,8'PAO/7G:G5.BQGX/S;JN(4T5SEB;[KMW$?(#
M1J^E \J&%4 ;Y9K*GQT%DGBA;</*=CK]N="K\G3"+)F\!HF\5#1.VN5N3NNF
MCEZ<$GLRW@/;BB.SQ&>7;)IW,-S^!62*D=[)]2B)V&--L]U8CN6GH([%50&%
M!=,U]-D0J*5JRD8XIX"3U>?E*!)ZTW$K)L[36=$T949V@0?MO<AU,V*/+@4>
M6I2'=XI]SW!#/;BXN1"F(UD=D]GFZ*A&:S?KH^JRS(X!-_'GT2R=<P5:M#NP
M\M7C5-11*]5Y9MQ'"O@_:)--EF5+I\(N^CYZO-"MR$^,$4134MJS:S=\M&$[
M\C')+5XG:;+PVWO\ZS/UT)B-T3^#&BD[$=*3ZM,=3[ZMFU [_!(5_]@:$MD=
M!,HQQ('8)+)]%P^5N%>I<*8>WYK(L)N$><H/CS9LU?].U!-L K+NS*3FS=D3
MD3Z4E\E/A[*BS:)[V>8V!L"K%D3KYQ7\E?%C=P:("^?<(8514,YRE\@-^8%Q
M;(MED>180C5H.E0^*!%S>F\5#+0MK_.%$-DYL_+WGD^Z#O%D62"%JOR*CG "
MA>NX,\M%EPZCT2(T0RC(G$IK:1ZLS%GELTIN7@G5YD2Z[0:3R9#K5=_=&8Q9
MVCO"UYA&(W_+.9O+$B8/L(P._\R(\%R+G)%^L(GC,=?@@>(.7(3Y[H1[SDVO
MYB4P$W!'X3@)P-"_:/QX/(/)4 HMM$L%;G.R.[K+K%N]I4,Q6AT:6(!N>A#J
MJPM0?RLR>L14*4Q6;).B$>"W$O0'T#S[,->;4Y79ZU2-HL5O8=8_F5392T]G
M-"3 <AUK"-0\$4^A1@EGYV59KW@[I'"%TOJ>;,SUN\WCSF(X95,24FQ%;72<
MT/E<EO_KO;.#*<M_*@[*/Q.O[K[,8<YJH]*$+!^8LG1NY28CNVR*3OR:6=<B
M=;,MC]Z6\[>S8OYV.EE&^Q^,7F]SL6LIV*E2#Y@WDBCU8OW'@Y,17VGQ"X2/
M'L!1P(X?LLD&12^UD/*0P"OM&8B*K$!M.$\"!8OD,R7P,6?#(#P$$O/:RTWP
MR0ODD(:6,L.673,WZ-6EF4'F2PR*,MKX)\#89&TPOJ'<^U'NE)UF=F[T(896
MRJ;%KP6>.DSBP';%,ZY8LPS=DJI84QJ?IFP9@4[A>+Q*:R>=\U'R="S/AT0,
M\XZ.YI5BV'%R=R:+YQ%-4QVHVS1/\==[_5*ZEWXCQ]RS)'J"3<P%T!J<02@=
M+)184GM$-]KCZ=86Q Z0TY\3\B<&U(T6@URG)MN.;.D11<2B:!:YX 4>8;:2
M*BZOO]')2B51+U>6<37'WZ/8'H.M XPNG?&^9C>*Q9ZRN69G7WMV8!/8^T^.
M-1P3WF/9W$D=@J>/TR/>7727(8&B5?PY1I<;)KKPEY!KVLR/$'T;F%_B/X1]
M:+31&(&EL]#A=<VEF5[7=T>/K ^K*6H"TD"VVAO#=0/&5K(+#YB-6 -@=0<!
M#K6,1[<0'5*#,W-TW&7(.3?'Z6!*KN'@3-'#M+]Q(,-%Q!*(/AUV)-E>OBD&
MAZ'IH&$S? MOO7TG>X:UT<'FKV I#;[&> ;.*?G=?3QY0;>VUDP,0MGZM7H9
M3W7N'8J.68Q05,UFMF,D-@^:+[A(JFW*62B.MAB X2:0EP$.6B<NNL=<C<[-
M54A%E;&3C@D:J[E8+G?L#0X[X4*ES@F.=:6KAB)IGF4ZR#6&IF9;0>[@Z4;F
M1 @UD$(+"\W+#T(-X6F32NN_N/T_T27%(?[;RU=/G[HN2;I?6J\':B ;R3((
M&%^2#6X.FV)3+J@!FBP/N/I[1D1.)F[#ZZV+LC);ZEO6^J16M*>M"^E',) *
ML?#D.=W-59D<[.3.U\]?O;XKR[U-_$EF'/+.1<H\<)K57$VF]D6^0TT$ZW;/
MJ#B05IGE:.PA7\1=7),,P].XKR9W7KQX>O=X\M1YTWE6F+Y+3ZN#0\:<G/>E
M)!SSV_?H_/!%_)NP18ZNGY8M\D1<!%9F&I?.3&54-V'<VGZ1W]1ORH&Q)F;W
MR7]W<1507I-?ATLS\=G_NVL]D6AO'N\\^^\7/]ZU+C5*B.0@!0%9%5<,H=-A
MZ0V)X%WBY7_\<QSL<9J:V<Z!Z.0]7HE%?G-14I-:OPH"2\HM91"LT#E!P8T$
MZ'&6BAQ)/[N%[GR1E!1?+'/#8N36T7WNO'GVK+W++H$-SS,2,V,"'JD%4<:2
MDJ'T::,+NZ]E'8ACT=Q;4X>Q8,K(TTA;)65-%5=S >-*D-*KW;^_L;ZLX^/S
M,V8/HG!?"'$N$2D(U) ZY# Y:=@P36^(?A6EUS.I[#U)M9QK!RH+./7&Z_*\
M4?S9UCV=?BF^V/,PSVYXQN]!#XAW*"!;4E<K8SZV93;8?-H-KLLY+C8@K^NM
M7W%_C^^RJ-=/^'=_MZ+?2W?PI!EVM!C2!\1,9\S["U(TZ^ICIZ5",7;1%,NM
MO7!OK V/#NLDY3ZL%7K>%16'Z!J<8R]6RKGSBDCG"B%54(#'CW_G@3*%1#[_
M [=",M[3H0"HB"'=ZMNK^H@*)),X2?,@M4D,/TL<(5/KH41% QNE>=6Q&97>
M!%MQA'.UFD@^"E/7YTW.2KKJ3B\#!FX6B2$?(A]$:O2LJR.:93@&9%='S&^T
M[?3[#:&,VKZ^*!-<J9$X[TKN3B=W,%M9Y!U3MYS-6Q[_.]8_>H^&ZUN8EJ14
M0V,R54J$^&EB["K>T@4$ELMNWSPQ@G"+<T> ^DPJB24PX>0ACZ\7=3$*-;FU
M6XLD.3\M:7CZ*'MJ.?5@DIO:8\D-CDX1,P[,/"<?[Y\WXE.&A9,)KI/=B:+W
M\TI75BYC20)!AO&I99J!5/\@H4F%.K>!BX6NM]@,G9),P)W(TB(W;" 35/$A
M\B8]Z_-3C"<NLN#W6I=0H>^^!Y)TBFB_,*U/Q6&A3V)8IS2?&<B$^ N$ZAQ%
MGTH89GQT$WZFZD,;7'FJGZP2EY&YY(6,AB,-=HV8M-\7G1S#SQZBKY%<6)D*
M8CUO.(_\4%UCF+!YW0B[Q**].R*\-I8SB10W2VGC6UH3O;EDTUT\V;,(8@>&
MIB=E*J\IR20D:]YUH*P4?# :B.J:G9926;>C6SKLG..RXVX.]0?1AF01ST@6
M0%E RBJ!;-PRO2@;35-AC;Z-9^@J% 0[H,*Y"Z9@T*NPFEJ3"&R_-D$XQ80<
MG<O^(1-U"9*4X^R,/F_!P;GT3[%YS]O@QZFV+&$EXY%^SB5F#C!2)V_6M8#J
M;.< *H$-Y\,O)L,W Q3@)@I\J25K)'M7Q*V<6;<X#UOI&N#5QJ#;Z;L6CJT1
M28U#UY<;KHSJ)UK;QM$R 45.CL?4.2$.4;73*GKTQ@0.I2 /C+4P"=/ <-O_
MBNH9A>!1!#%(OFI&O]VC$G OKV^L5 BC6PJFB3YI(&D^0)P(E$\X#+Q+>C-#
M8\QAPP3(VAK1&W41KJ);B2L[.KC5-5GYWT]5^][GJO8MK<ESKR&Y'3D[;'4;
M0TG+K*?<U>K4V^GL01[ 8,K6?RU%5]ZBC-\3'C=K;DC7&<U9BS__[G/_G1:_
M1[ID7'3$+:Y -5@&AT'V951B2;_HMI,%J6@93(^M3I5@KBYV2F_!U%RFRC)E
MXT088 JM56=^WH@9H)E("L!L%^M-^GNR)BH^TM20*LD2__2T>%CE:K'(*6]#
M<U*]X^>+G,+NF-$69 Z1[(43H73[J]@:3>2H7(OQC4]BZ9/!<<<2\MF1!X+Q
M5;%3=I9TI6O<]4R]7-Y0BH5RL6PYINY1_6O<I]$U)EH >$%=T,(9OW8<0P+?
M#9 ,RT.F6WL32*-HBZ8,+'_T8QL&?R!:G+62:"*934]54Y*(4U;H9]-4-7%Q
M;VA8@?LO*S02Z-AI<2&7*H[_HJ5<JF-1ZTU/'T][-_987KU3G-V:@+(4:#67
MH5RMN$J6WWH1HT%*?.^]-W4QS-H8IN($GXZDT.D!:"&M'5*^KN(,;&]_MYSV
M/0:7;X]($V.A)/F*O>-<!N='Z?[Q1=GG1G.]^QXUK[<M&Q-\!U>.&[R59<\,
M1.AKOI!\#J>M2J;Z;XME?&2!GRK.E!^%DIGZ0NY%^WR:U  4O[.R)H8T;-H^
MD=)M2I"9$D'ZV07::6:RN#8K(I)T3Q4C[*YBAJRPKK="O"0(VQ -3)?VJL[2
MB#ZVFPH<"2J";6XA36N;0Z[\8GD*7DMI/T2J2MXLO;221]&PXE1YQP.G+"(/
M@W!&B=.JWT[?$-M&X<*&F<,H..?E0-D9*5<06UFK*%WJ=41QQQ(/M-EVO>F*
M^VD%>4/2[B+8$2W,.!'@1:&895M?45&@X!00&D':K;:6"J6%KA,R^;TLG-M;
MI\.]936'/=?(-EAO'J]8%800&#(WQMV''6/=GG8Y.NOCSZX*$A^*<?L&U)^Z
M2,6N+Z(\=47495J!$J47Q0]3<Q LI'L1%U\@%<8(#*)UBSN0#W1T=F5.A>'G
MZ(/,\UIN77FRP,_%HMALK>G7DE$#PWZL==E^;ERK*<-B'>.2ZA@5*JE&7EXS
M]@D._10#?J-SYE:>$2>RSU?U+(ZEX >H"9&+RC(U'.8B;^(4/&QY-U;U'1T%
MX8& O9'"9*D?;KP%U+:%=CI^39OI7^C0O>M!/XK#]\')+GY!KNWT </8N3A2
M+I>M-)]H)X/!FY1F)FZ9\X):WT9U&?;(M935'*K),^1[:;#TNF5(P*N>HC:W
MO>W5E>Z34%BKS0U)1FY+T/&I.*-/X?G3L+#8"(U%:NC-AAZ&/7!V&[ Y(=0G
M]T?ZA7N3/"*[9B?\-G!I6X/.P4@C\6^?ICTA0$NY/W1QSM$FV/ S+(<Y4:>G
ML*+FU?,++;Y1:9"Y$<D %$F$;F2M.E[15+TC5\IW5(#.=\6 *J'6U$N-T=70
M-U6^?<X5W++ZJ6MVHO;$H!1?(J3]PB6D+MM4,I+3W+7R&/.:A7[[N@1QH$H\
M'.PR(+"L=#!U+R^<2#GYSR(PJ!%-H(+]S-XX3>-4%Y#?6[7C\E$24] 4\8!,
M=2B$?X3YU7D"T#>%X\7V;V^53 5;F2BK_ 1ZLV&8_^(*B.!MW;M6XAD5<E9I
M["(*8:$<E[@U,Q?180'+5(/:T:(I(#>@8!PE6A"$?UEE-36OB.-&-(V3C%%B
M\Q\NV-0"FZ@.^23J;ZANPZ'/'T]/CD]8USP:F147@*A;G^TFB[Y?3Z9!U7)J
MX*VVB2!#N+;\!D]/J2S9S%[%Y30:56?#L4EQI2XQ5HQ\7I8/%^RUC*>;U+XH
MBPJ[#9FT<<.S;\72)80%*+5Q,DFO;18<Y>%GHG-BON4:O=OQ(<?HEC^!(ULA
MC;"J#9BK''MY])\72L1W4?PK;A*J,:N/XD4.AIACAE=<EDUMK;3PK']K)^CW
M>6ZJU]JDP&%.28(X+FZ0;%RFXC]/-?08*T?23MR+JP>ECB"B()5ADZ.U8H_*
MQ$XAKLU$2\?[VX=$X]KC;>@!5='1/]X11<M?<'[[E@YC2RH9NZFT9ED'JJ1Q
M54P@!I7;D!_DK&826!%CO@H%FZ>$>WP58\62KL%L%8(^2<=^HS 9$9<P]WN@
M,)(0''31493&-$^O&[:[GX6GG HLE%&SJVV'E8GS(&ZK7<KDL/<_H,S.V'-9
M+P%;+W-:-C&2ZX('9(HD2M>0&\%$C3-%5_$S4MNNJ;",#GC&:Z]0"H&C<U>O
M?NUX\D(!CJ-KV^HHLX1V ^3"<!OD@4DM9>\5!)R=:YUTB+Z"F*YM4Q?"DR.N
M"<>62IQ3,%N[A&A:1]\3FEV#G)B\9*8J\'T03K8MY7G""CB/;3!-DQ4C3]6Y
M+N9S0/9!:N*-*CBWDL!#XUPGM^FQ!#*YDVG6?B!^JYZ4TCG'K\[O<@,5L'?G
MY'\_]=7[GUI]]>-Q87HJ3#IFWK#^6SRK?B![+]BGWQSS):GJ$"4SP6Q3/JNU
MEX>5Y\7<7K>KXNDU?\O4$E-W6*F%>1\XK4_%E5)UCWE2^2HJT<1FTQ*RO(PQ
MSEK&E^Q7=\[_[!P94LJ;_3-G !3[2R<* /,P?\,#.",LKAL#)XY_FA2_$*NC
MC8^OS+W>5+V_6HU]QTSQ=62^[G+1V ?BC<.T$U$PX*"%3VR26]8Q:(C)[ECL
M+?\,,Y*@4@%BX 9<9;:,I DO0^7&D9UKP09/S0@J1BZ@%&'K'MD%>Z$X6Q4C
MC8'%X7H:J(E;EXI+!,5_\M3$A; 1HG3,C6UN<X'#A*P\XY;FA*+B%@V#;TKL
MENT[<5-X@-=\_@Y)IA<&_;!Z>,7B&1Y+$;UAK<#,N4]JK-FX7F4\R0Z4-]X2
M[@LGQEOKN7DR=B.5$Q)IG#BUA,U- ';"7+5&L:0A0V-QPB+,>,[^ET41>=HI
MFX2L%#2IT]7:BP($,VBS$0IV4BI*F]4E>L;EA!?EJN.&PUI,W46]6HBX)J='
MO(()V:A9/$L.M/3_M!4*7%Y%NH'=^(W8O'&V:Y$D"DE[2_4,T][>NO-5_#VN
MWB;H[PH,U/D6)^G*."_E>?#110Q&&38BK:,[8Z^04BB13&ETPID$[A1,Y/#N
M>8XGST.[*87K0 8"S^AT426S2JE/-;] N;9249;<IGL 2CAQD1</ .8CEX6>
M4E_4Q59T#SC)QHMLRWQD\02. P??5Q+6V3/G^'!_!>L!FL5X=DF%#>Z@O=[8
ME#XN _41A1CI S9RFQC[IHBEEU?O*L?#CQ>?VH%&6\L;RFE6C I;XDR!()IA
MR3'?$B*C>Z5NJ.\Z+X3R6D,@T0M[I^/>2&^))9SY-5&R)?)D;XREZJZ$:3I3
M!%O349A(-.-@*FZ/6E3'TQ4>RB1M/@"[E6]C;'91UPM.]A)#A2,-0RE0(56)
MLP4)7E@TM(P.JTB<;W%/AGC<':-TF#0-VBM\W(7<I;1OC"U#2FRS+)9;B=8B
MX>W! 5K/#'*L$X\)XJ1P4\)@>0O(%-A<XB^0DVS'W(/,!BD3&:-==*OZG<S(
M2#^:*6'FS!=GKVTOJ[JS/I.4,L&):>K#EMQFM0]J'&%,>5&]92;R."M-%7;T
M3VYM+4R*F(W# MUV[WK/Q*+M3R).^:FQ-7\"AS LJ1Y?A7_]O*JB[X=RG+#3
MC;-D:]9#'*M%QR)S86 W<G2).<\O7[W^SV*]>?)<[XDT1R@Q#M1S-!UQ(?))
MN";P&K=CZ(5.*KG_V\5_AX:C BF9<#OG(>ZP?R:P31KE5\MH2'[&[%^1_%+\
M[P]%UW0\&3\_B[\KWAU7\; /XIZ0QU:TJ"_*<-D[5,^;^FI[88DY0?CNJM"<
MXTRS#R8I G=*">M ZP,W&&;W$"YDTVG[L/F2\0F8?)B;_P+[RLE"[[ZPC@PB
M(:XEBH_ V,!^F^?5Z'H8[75A;!"U.X5AQ)['.G'[K5;@.!D^8%*I88!(5]FR
MT+Y=V?06E 9E7V5B.=&=606U2#A2,\-_D'M:I'=U8QML6&);$SZ.;_P/(G98
ME>WDCIC6NY-OF(4BV^+J<]@(BPN;>[]T?;M@=EYX.K]Z+<LB+%1X1.-ESPV7
MMC'.@-P%IF%>5XE]2% +B<G='N,5$Y>&R5-5YITHWQ45%"H#%8C[F$&+1E0>
M[,+70+,^^35RZ[C&67,U#S2*-AAN57VX\.!V&>./DP!GLFY(0OWF,MRN\NT2
MTBC[:1-ACK-,*:"W@?$H&OD.KI(RB*P3!EKAE''D.*@>?0"$1F 7IO8K7L")
MC($25 9_UT(H,Q\<H,-&4Y!<4$Z1P@?]%?-2;MWHD[LKDLLR"==-FU*FZGW,
M;P!L&(DEP(W&6FG7&5\F*O.)5,9X#.I5)C,RZSB9HTQ)VWJXRU*U;4%?.EJ%
MY?8O]_J3>'3Z^#:S>%V)\-V^'H"RT.1\^.0C>7SQ$9YD(W)Z[Q@C@*JSN=%V
MCIMDV]]WA! OXXR]N*S7T3G+"<.X+M/6JX2P$@#ID_T'X^>IN?'42+1T/8FO
M]N?%/6N(OZR_1GEMGWR>DE\_):E5\EFQV98M:0:(E]F* 0W[T,P)\&F;Y_,^
M>8^3PF/<;J$-"XHO;3URR;6RFEK'64^M;5^>=]A(X-!S'+)RXQ,#ZL&7M^KW
MRXI21JJ+B6KOLJ]3]GF;_LH5X=7:,L0YIPI< 0X"O0S+=Y7.D?H;< AQGJ%P
ML@WSBTKT2Y[0GV[A2GZ>PAM-H97OD?26!@C.9##U(:6;$\\/RNCNLZ(N=4UT
M_OL!ISWXU,!IGW*<A3WQ [C_U]W*(S]=94VBF %ZA&5OLW"H1T>C'1M8L#<,
MY1CSQ7P)%'*5+2(JKX@\N$/_R1#&%>5*^W-#V+J$3VKQU6:P7&BGB$9QUVX%
M]T('*;V]=0$)G^5+I03D%IEZ+%IWH?K8[<=O%'_@KP#74U._3;MM>^&\-KIR
M.59;5E%O]]\8_33BSUL^%1>;1 -*O7/TU3&$CV=@ 8\\^(H9P<2@(U]XL)]]
MDK_'$32:WL <H.CW-5J)=NBN+>NN)4H&P'I(9VV+7*4;?RN"WC@%\@DDF[ #
ME<*-*+?KA65ZF=,MK<MD\0U[E9,TUVWP'2XZ-L3^>UY)PI+!WL([<D-PY6$W
ML8PHXZ+[^>F;+[6>6JR(3R0._T]UB3H"5Y3QMXR<FA@*ZV@JS^$F$38_.[/C
M9)0;4Z/TS<^5-3TK/UUUS0SD[$2E$BB<WI_R8R>MT)%%(9S,@[D_>IH^^\;
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MCPD"C:%\OF9CA'_1/O(RGQ;Q-<?<UJ)#'4RT-SSFPX@7XK+.-GLU4!J%1<?
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M$N(S[<6'UP<GOVB';W[2_CO[_M,H'QUCTT&8*8:3@#@?D0A9D'#;2Q(OM-W
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MV#R25;',$!1RG@ ASM6EU$1V*Q,,@+LV$4Q!3(A'-XMG+PSK/6OH\)LM6K+
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M[Y]A[C#FUUD4\J/AH?WI!\SQQR&,__7[\9OC[.C-Q?#XUW\/CJW??YR\>3>
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MRC!1I*]BL$)I=5>Y&U58;^>L%".QP\3QN1['+,+2M!1\*6[H>.K8CF6'OF&
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M_[=JZE7P;WPTY9JV_,+ZJ;M*FPIXH(;"U_V932Y>3TM8.B\J#=9Y31M76/-
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M/2/<IDSV+HBQ719&)\N/(<M7L]E:MILD0:C' 0_ 63 -/;1#KINNR6,3U'2
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M\;V>8^],NGI7J+*#EDDG\O<E\G-XHX$;67ZJ<S<"4R1U/#U(L76!D?H)Z(+
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M4$$))."3%""H5V"%\6 (B8*C$5:%K4QEAE'V4XMZ!#SQ^?2/1:$L0P@5^(L
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M!D%X-$B3YH+E,())A:R1Z;E5US07\]V8M)ECOE>O7;9;5)$#30FSK.$,D,4
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MN>!;DE[4<?.61\RNP<Q=-=(W\_%:FSACM."<$4M90;CWDNA"%B0K'1QID?%
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MG7N;%3IG@G/+G*&@L 1)@Q2V$#(@IU]%8>DX?7LX?<5(X4XZ76A%7,9*PK7
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MGU4?",N"X#G6MX4<<PX+1DR0G-!,T]*5(?<>X^GR$?I [M/\_#":>%C%5[!
M?QJ.I].?>X<:0^JCGOZL!T-L3T) +),I$'_E$4&?R=5MT^W+8;I]A-VB+*:K
MOMQVS!]?4-\_@>I^!_I[/7JU(+(.=*\%NAL&SFDAM<M!RY,R ]"EFAA&#1%9
M\(YQ2PMIGSQC["8S>[M\RBZ?\J&/*N]PZ)9Q:,7XE,8R6:#*5S(&QJ<*V-R
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M V-#D"6E1+LR$)X'013SAAAJX&?.2X=IDN.17U/]>Z;BLEYUV$]K>CF.;7&
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M?-9'(JV_"O<'FRX6&@P'GWPTWV#E:-;%\BTTLP9P ^/KPN#--X4O!+P)CF^
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M4! ML22'[JSGX/> 6H=( 7%>:E3ITE \O5#JOC?%7*:MWD#S?-S$\O)T__1
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MNYX0K!(NIQG-*>-!@>E'A2A+*UA>6)J7D<'4JK.STQ/NE#7A]P\'C)K28=I
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M-0-R+F:>U3*AJHAO(>\AD'$TP@83]#*1MEZ#MD6$W-:B8I9:2KN>C*-I!3<
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M=__^3Q_N9WM?MCD\>;'[Y3^]O8_] -_@NSMO#X50(//*G#B5*2*4541+%H@
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MEHH4]\8+WTA]U6+I\?29N@] ZB85F[+/FKQ=HHI3#?-:GV(OJ)@<-!SXU$$
MR"^] W5E;(QN+P<FU^O#>M/;?7*8N+<^.;>4LB^:'FM/]_]]L4. WU_"HON3
MGEUS(9N*!0]CV\DN]C^+ @B;NB$1CWK8$\PUK<8ZKC<>34^;1FHH8YL&:K-&
M]XBI9M(MM4T9)QJJ&IK575+JU3JM5FNK\RZR4VK6B,,X!?I)#?JPW2#2>N\D
MQE.:QF:M)G>Q-UKS4CN<@GB/$QHNC+5J1%;W!JQ:CZ36!9TQD+%V<[N)'/19
MPQ(,9EWI/O=&TZI]VZAJL/89N*+JKA)[TT6MA*WDX/&C_M TO^!#)[%7"#8
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M7Z *RITLS7KKA >N$O;\)JYRA_+_U9+\UR8(;[3&@JE8CI$Z8ISF)/=*Y$(
M^!4R-MWK4O7-*=)WR';?I#W^B)6_5M6G^U[%3LMK&ZJNKKR_NH#:]071?LM^
M[]3)9)V1KWK<C-OE_597%AQ^KFKJPR/]W@GP[^AB12'\5LN1&]87W)J-9T6=
M\5A\$UYT8K#"PMEP] F8/K7VQ+*;HYX?V%3P?XQE._O8W[=NQ8N'EN&>6$]F
M?#'PHR/X[%9G#WLQ5,,]:GW:82>K22R-&)OZ@MT :W Z''OLNKM($;>ID?NC
M"GP^QRYR_I_>Y^7LZT:8CE_JT636L;TEBW_M$I\O#C->!DW!BG<NQQ-N-B=E
MKAP)DEHE"I=S+A=+=MY?^6,L%MI;<4*B[B(!C)F>QS]AM=LC[&'EP[0/3!B
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M8CTML79.![02&9(*BGGQ9"WYFW8CF%,-5E$)$)2AOHZ:#8W2&PT.=7C/G#<
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M27OE+%O;5-?G$X_*)SPH1?P!YU5F_EYO5'QC3")I\*I_XQ/99T@%YSMG^T@
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MR50Q(DV2Q*F@200&V7@1@C1KFTS.]W%OZOG]($9]/1U453M9JN/C7(4JD2I
MBLR$]3T_;>R1H]FMDX@:?+L!OLTG#H,&';1-1&3MB63)$]":$FY=]."4"):M
M;9IUV92;:<K--.5F5A)WGU.YF?L!R@7%!8-,!A ,4?VCCLB QJM+-!-JO<W,
M:  (:YMR?5%IY\?KCKMCN9G1:9/ 4<?>:7&1C1FOJ4>SM 5J<+ I6/-(X'1!
M3P]%#06K" NR="?BB7CPF@3IDF=:X<Q85>>0LN\NU[ITUFLJVBRL:+.:56PN
M0M"?4"&;'XZN4QFNL_ ZE<[SQX@2_BB$L#5IJCG>PI>CQ=Z#+]N3RCI;56/;
MR^":VU]2)%]3OS?!5?HX<?7N,51'B)U[6^<[7U^+G:^?O^QL[?O,A')*$5\<
MD#)S2WS6B)$FV^BBY"*KM<W=7C?-!W#>MKC137)C"YO.-$%?>EKZX?E)"6JI
M,'24F7[^CXN\]$GN^=4YY_-I4%,92_-)[9,<E)7(2[\;LWXSM*-2:DZJ$A;O
M<<->CO?AMZID2XG?^*U,LTDUKZ,9=_CN4=C/RG@JC"4A1(7LAS]\!DX,IXI3
MP7SD](H\C1LFFQ>&^L'51. $Z?E+]5WG_-JD84V=ET$ 4AF5S./":VG1SJ5.
ME/C-L#"T_[*$N#I9N$D.7D!E^(ZM_41=<+&4$O,109XJ1TJ;*,)#*I7AK%01
MUC;Y55GG-PB'OX'Z<L67]8[0##H[JK/G229!?5#)&A&Y]QHL#_NEJ\+]*42+
MLXW5QK7$;6,2.D:-M&RE0?)E*#QS]LY1CP^T-P@11^(N";,E%05Y\[1*?-JN
MDPX10U<F]/M\3,9HRAU]1K,.R7=[1^QNOU6[7W?;A;0_'NV<[1S_CN\]/-H]
MBH>S9/SI51D?FG6OWGW>^1KH[C8^AZ.IMW?8WOFZA>][__7-*P1)_EO>/?I\
M_N;M?HK40+8!=1/'B>3:$)^T(%IH*J5G$;&E%G5(FFAR#ZLEDH'Y+),5#''&
M(MBD",)IYDW(C,]&BO]6T/2O"DUW$I1%+WLPI[#?G,(7IB)\>U279X%8:'".
ME!MM9,[!@G8Z6:H3US1F_Y 1[A\2JE_52K4"VJ70[E8![Q453\>G7[+#AI?$
M5A%%_50RBXN,JL301NNWBPN*D=8ZAO[G-"2U,GA\L3>UUC<X[)UV4%5,TXKC
M2%^ZT$OJ:^LG5?G*[=#&)2N'N]7M*-=*2F\Q.:L[N_4$6JC)CH=_OM'Z4(E"
M-!?;)4(:GXG*'>FDDD1\V$91B>;*>:V\M4L14%S+2IZVNR>G^*;309TD7T^A
MO.9B*6J)7CVJKN41D3K1.*WO* _QJ>B[U5%T_4;6.H2_QW7N#G%?<&CC-]>J
M:'V=F+X.GX&7S2<!3/)SYN+Y1W\I;@LU=I>6W*SN\!>A*^_M0]#>OT9+0%IO
M/#[B[\J$'ZWSX#0<E@2(?Y_VAG55@U"54FT5]>GO-**"P7S!AL>Y"!P7X74]
M\SI@'TF])IEO+4#%$X78>A=KF-K5,V(;V7*(.ATR $YT_-O=EVSDX"+%Q_[P
M:R9PS=YW>W.D@VMT=M@.58F)?@4_R/A#_+Y7B@6,\2/"$-9'%_93Y7&JUOO%
MJ"!&*3%07M,[:;7+KIQUIZ&H23%<D&(H5RK%<*'H_J8HGA'=FCMAN%621B>#
MY(ZAABBS#I9YSRV]/NMP&2HE2I=*H1D=2%PZB!CI./%-.<2HY2]>L-OK3L3Q
M/XLT7JW$PP?0/G??[KOD@B\-PD':4OV>90(F4F)=@"0,^)#M[.8+<$8(;@(S
M3@)+N.<T^A1BUEYHR"N6IUBE"E8Z0H6&HW3HHGPA;!W#I&3+56K=1)*,U+-X
M T6OB&A\ZG8*J;BJZE,7P4IA(LZJ-Y3J84\I?5&J#<O=\M,7V89F=WOL]=\I
M<?5+F\&NXF"YO'L6*Y=K%X+VRD"V6C>XGU@ ^RW?3,6&BPWWRM1\ETZ*UQ,1
M9[OXR]\7J_#2N>XW EA6,VYY\3*,<;0UAM K(Y+GYS<;A[.<2^\0!KD$9729
MI/6V-J#^&!M05YH_*S+>K=J^VZGMNU4?;3DFK.-FD!A6?;!;E[/@%\></G-V
M^?.BZLZJ;V>50+[R@YSX)U9]I+7_J>&.)\(=TZZQ51_KE:1W0]WN^VAP]=3A
MO5(C_,?H?H]B_C]5'M[:F\#FLB2?Z4+P9B%&_J6?;V/_/;(L_.LTUU]N0 !7
M3O=&H<LW()MOKN?W/*,9Y,,-\KX3PQ\L8_+/PUY_2$J<0:O=_3L-AI6OZ?'E
M3[:N3*#\[F3UQY]%]33SH*A.OIQ!&@U<*H.S%\(#"P(R5RRKJIGGZ"#QNCRH
M6IY,#A<O@M0>24;3W0X11QE-'1S7NZ,=?/ZGO8_RT_;;LX\?=N2G5^_Y[M&[
MSN[19_IF[X!].OKT>3:CZ<V'CVKWU<X7G M>=_AY=_N?AQ^_'G[&Y_!=O/_-
MWEOU9ONOX]WC=Y<21'>/7I_MGNUGJQ7CCA+'G",R94L\T$B$Q]VC+$O+X]HF
M7K"NW7Q[JH?+I;^GS- &E59I;K= I11"9$X&'2!*+3(P:A172BNI71"Z0:55
M0J6O$U3:#FSG;)_Q$+2'3)3WB4B:-7$I \D^T,23B,*;M4VW;L1\%?@&DQI,
M6DU,HH(RFH":)*VT0EN=G=&")ZT"A&P:3%HE3&)3F,1WMO93\,IJ'4CTPB(F
M<48\]TBYQEAF#.?*I%+6EJXK-5\,LD&E!I56$Y4@21^ R>Q$DH); $<#SR'9
MTHPBB26@4@,\MP$>,0T\NP?[R5 PP00"$>VT$O9+;#:(/HP!HD[,S,JU34GG
M&RX]GU)G#\%CKR>.NA+?_U?[<PD("[WCXUX92B]\?F:E:&^!.5)HDU/5MUC+
MI,!9D5EB8(QF2JC0:$*K TA_SOF,% 7GHZ3$12V)9,$3&Q40$RB3T42I2BM
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M7"2I; :MC?%&,DLYTD&C.#\(NT[E"1Z<O=G:1YAUD"4C-KB2H R<.!L] 2-
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M+,D+BG#TWP/@^'48ANZ.PM UN;!;G7ZWTWA_=735O\QZ +Q8:IJV$ ?0X^(
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M8<,#(A9;S0G1G $1U$P91DW0%.B[9#,/>ST&C0R>>YZ4<]O0D?%)([=-X!E
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MT0443"*(>QKRO'.*I/3*::8\\?[EAE>]@.74#&".I7Q_SUJ4..X3,$1-LGJ
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M;"@3B'F?@"=JAO)81/B1628(M0S3C7=T4PBS2<4L=CV\PF_%"UBO6Q3)_ K
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MN>A2]D:CLD9E]T%E=Q9HUDK#+(7.YJI0AV"\ML"<+T1GCD<6)"2FC;32*AX
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MI#5PB-)O;$$],>L,;E?A]/6&X/I]>!H&D\"0<RWA>+\_RKVC,*JO-DM_N9K
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MS9N[%(? 69 HQ@#&F0H-QIDFA(7RV"83)9O0SF<&_@EK7,GLUEX$FM;M]L[
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MEF!9]%A81B7GG@9' /:3(DE)+Z1*5:G32W#:TLCRG+#_<X+11F:\LI$AYIQ
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M$52 $Z(%CD*+P,F03)!E;_A:E(P2UM$1J@)SPO/H<Q8@C__1#AMAB1$EH[3
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MC?T#TKS8.VCMKXOVEN?MK4V^<]CFK<//>\W]G</F1?>@N?^ET]Q>%_^Y:%*
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MH;^BN(N@N/>$6/(6T7QC^^->BZY?M \_X.:G3?C^O;T=^/_&VON+UMHF:U_
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MW*&2.-0+'>I& 9QW7=R6+G#3-FD;FTWY&ZV!-#S@R7C C#(B7,X!J00DB)R
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M#>^'118P\WYD_,O7:'Q4^7F_$QL1(O1J#OJYMA99W1&(AJY2: &'QVI)DO9
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M-03[X 2K NE% 0]M5W'J<B&4BBDPV(A'4<2E@P3K\()@[V'S:$3HP]+DK&K
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MLIR[79:S = ;"J"+-$C'=@/*J?L\!@1=)D"V'R?_H<8 ^J1_442$A;KF3,W
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M450;473WXH2VZT_2P7B2]D1G+)3X;@FEHR(X0QOS5"\WM7,K@8B7/97EY^G
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MP4*[C85\_=G7 L_(NZIZC[&KNV3]674UO#KWV[[M8M0<"RTJYK<,#$W[MTR
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M/7BO:;K$Q'4A68V<)TA='L&F\9_(^8*^,2U6D;W5<$G7*?M?UJH4B%L<LY9
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MVQ:_&1%-4-$B,LGD[H/G;-^V@VM2V!JPW\B$9#>VEF*4\_2"^1!ENCRBP(,
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MP=4<DJ*QY+?=^PA,E[3X7_32Q"N G JCF+(G+XCV'?,: 0>OD'P@A<U5&,N
M;*@+;/D(MAJIT._4S>G-P"-$E-.+^V\!FT8#*&A=/A#D\ ,!-WPU][-6/IX8
M;.M";JU%LF(&JPO(ILK@/*8O)L!E#T>.Q=>6:"!G4@F0"DP;OO!O25$X(<B
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MZB5!JDJQC=D0G;+;$+^;&1<63JS+._""5MZ*ZU+*DWP""P0LF/_&@68$\.P
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M94/)<!WX7V-+Q/F9.P:$:>B?;T[8TA S6S#8RO#*;FR#C0E?)DSCK8 ASG(
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M;98G8L@@5)"@X6IMXPV$(B$NO!\T88JGS!ZN /BC;>+"T")CMVV7Q*$K JO
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M^P.&%-G;0X+-YK#9(GT[GWW&^?+;VTF8+LG>KD;QY^HWU1W&!!>BTPP*NAJ
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M*;ZD-7);C9J+7+GJ1-+_N6H_G:SC*3L0W!C:5:."Z.B+LXBTIR8RN_NX[3N
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MU>U$D&;":..L7,4QTD%ZGKD'[4+M>1(4.!-8+>,NBV'*21EWT'8-(9Y/%2>
MGJD(3*1"CK_)X-PJTR8+B;(4Z44KO3P8#?4@^5SQ-/:?Q':ULV]7D=]-L9''
M9,E#461UB=J'TC)P/! LILAA*<RZ3A5%[H4V4,6T$R_ZR*/OKG4)5$R$"FLO
MP5*K-4BOP",1N'#N"A<8F>QSN_4>8$-(GV]-D9:R:+AO7;M3-7*9L2R4H"&Z
M>OJ( H+4'#"6E,CTXMYN=]/NMD]OJ_:N0\^I>-*XM16FJ9W-"WG%QEG@Z++3
M7!:O^K#Y3EC#V@;W$??=2F\?:711>-<!<<5ULBQ!B)H6KV6:-NH020.+Q'W,
MZE+C^V[*;@=R'&XO;$F.5I+H'B#Z-2Q/YZNHR*QLBJ&TC!'M^+Q68:(6PVU7
M$^_FCO@V?%O5:GI^BB,L(?M8"WNF6BF$Y0+!:]IS4S#"HDM9=ZN*=R>R?0N<
MW?SP#T@O+E^=?)[/OJR:ICR=3&9_U/>-LM'<6C(,G Z:5DND=2/)U0BT-E-2
MD?BUG9?VP </8>/J0I7K=<>Z2:.O'?_[-)^U(<3\XFO"Q>+I2?UIQ&/.7G -
M4292V]Z3JQ'J615+DA/@8%R?J[4/@CF$K:\KO?H+KR^_1M%'+93RP)RO+FL(
MX+)D8-%P[1V6TJD.^ZUPAN 3'H\O#Q)&,UZ\)EXB;@AN7!ZOPYP<8P6,HR^*
M&P:!3$1@Z+74MEZX[K-3;XOP4#/Q&]E&'_[ R1?\=39=?EJ,+">!E4R[!";:
M+Y@G-T@($J.6M4L5DPK[7/7;%?&0MOTN_+N^W@XBVH,OR?^'8?[AC]G(>4E:
M@S11"81/\9 @%DR Y+[QI)BQID]0Y(% AV0.#(IVNPCR.&PC^N"($^]]40XB
MC[5D34EDOW 'QI<@- JA[7%W@@NH0S(HAL>X!POS*)Q[.3N=DQ[6(J&J[65"
M30@P'L@>\A!#+IQT<?*J3Q+;0Y$^L$;*_R[&/5B4QR'<^ N.I+?&2RM !%/S
MH0FJ-S0Y(F56EX93N<\]IH<B'5*UDN$1[J&B/#CAGI8ESB^@FJR*P.KWJ1*K
MN1D@,#(W:W5<35.6:+D<E757X ZI%LB@J+>[4 =Z%#*Z=GF[_V$(/?&XQR'7
MAWRH Q$;:V6OS( [1CZ "A9\T+0].LU3]AZQ4Z'A7@<BVW[^#=_;2&M#00T^
M!ZQMNBP$K0L$$Y65S!:=U5%F8LCAE*;\VBILV4J$?2/=MWC;.7/-'%K0B<G:
M]XCT,G<<0B1K02LM..M3<&A+@$,*EQR55KL([+!L6GG23/,B8R$G6M/ *[_!
M"V' Y)2,4TYXUR<,O#7$(85#CL^H!POMH)Q:^<H)@Y4N9] "63UHDA!K1TRR
M0VR0RC)TQU-10PMW')U1#Q;980E5?1$1H["Q:- ^DR\BLX;(0@$RVC,/VJ7"
M]/$(-;!PQO$)]5"1'8Q05SU<D:5/,7*PQ@7:F LIT6@D)#+PN.91YP.D73ZJ
M<,51J;6[\ Z?=2 3=VBB!B=KG7?+!#A=[]\4ZTU= N)Z8?1'DG5PEI)[QT/N
MR% +R(UA H$K0;,2M:A%"X@=6C%B38C.;%<N?D< 0_)XNU#IVJ6P_E(ZS,K:
MF)*6BN><:PLLR0**/"KPBASU9(32/DD6S!&..QY#7F%7^AU.J+VO+8X4B[$$
M&CXSQ=$VP^MU7:%!<.4\UHPYCET8M@'0D'SA@W"HA6 Z'D\\FTV_X'Q9NP*\
MQ^EX-O]MML1%K8&^_':ILL6W9[.3S[-IG9!961LZM=OC?!ZF'W$]3[O?WFB.
M8?\CC+[3TNA0X_5L^O$#SD]6V,Y+; OKN<":%:M3+52/ 9RE+U&[8BQ:3+I3
MRL8M:/;5:L\Q+E]-%\OY:9W,WZ=AW:0<\_,SU3M2HD1')CL85>OU.!W!,?+5
ME.?*N*R<<'WTV[W0'FBL]:TIMC=5KJNUMI)IM@U>A?4R)#S;E(/UUK&@(2>G
M:*SD:9'JCH#*U9QQJW6G^]B;$ W*F.K+CAW%T''7^R5,JJOP_A/B>4?[,T7]
MBO3^NH'QL[#$C[/Y?A<3=WO0_OM7@P$VVJ2>?J&/KH1Z.9N_#Q.LU'B/Z2PU
MX.FYVG@V6RQK$_/%B$B0HW4&0HH!%!>%](:PH'-";U4*4?4Y?WXHTGUUU3W/
M2^GTI$H>\]_GL\7B]^D<PZ0"^'L83W_!,IOCA_!U%)GB#'T 1JN,O U:L%[2
MBA*F%N0)M?YLG^.O)O 'M4EVI>IU%7EXZ3?;9'>%_II^^@Z]!$U.CS%@:S*8
M*DCV@8JD/QV*(-'2[/6Y2]D$_I"V[T?!V]V%WXVWWV%?'<0H&*U2D@D*JWTB
M?);@"!9(Q[%XK462?<)RVR(<4A3EJ.QK(L*C&)H7(RFW35O\]FPV7<Y#6IZ&
MR5DFY;<N=N@>.'J:J:VFIY,5>Y5WWU-=WX^G'R=X@8CTX @-\N0$(S\XUBIV
M1,(H9"8_BA=$[K7W?0(RNV/NJVB_/WEU(OIFBA\^S6>G'S_5<]%Z/KIX&<;S
M?P^34QP9%LVJ14\T-&4J,U?[CFBP6A4;O??.'L9(V'D(0SJS.Q"+'Z:T>]&A
M326W:[O9M9%<(#N?JWH*F:KU\W2:;\[BU0R XA3#;#1@J-<27* =404-U3)B
M2@@3(K]/KW?&.&0KMS-YAR3] UG W^?PG^/EI_&4EN(*[L7R*SFQ("69:CJ4
M=7:,2]F!4"$D%[!H?IC0S,-P#]E:'I@*;B#X9F3]!T[RA]GY%&P_4;>X'"9&
ME;VB=98LTA?OP.7B 7V*3,BDC.AC1K0;PU&6_A48(VX2B=LSD+;>X2M909 V
M@\S9D\[B0:GC&F.;L0_)"CL2KYNHA-T)<? ];),U>74(M.6RE%2&$ITCS5;3
M,"1Z2%:5PKW5E@W3P7@PO0]EISTR>K>GR2$<CROH=C$_E;2"@$>PK-80MCF
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M^\2:;L?3?)2K*//(UY231%ZP-+4-A$\*0B&C(00O7'3*"MVGGM?M>(:4H=^
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ML^6YV-GK]4LD*_=O?_K_4$L#!!0    ( &^+7%07 0K!,)\  )?[!@ 5
M;&=N9"TR,#(Q,3(S,5]D968N>&UL[+U9=ULYDB[ZWK\B;_;K127FH597GR4/
M6>5[G+:/[:SL\\2%(2"SDR+5).6TZM??P":I@2*E37*#I.CL5:V41'GO#Q$?
M@ @@AO_X7]\N!C]\A?&D/QK^[4?V%_KC#S",H]0?GO_MQU\__TSLC__K/__M
MW_[C_R'DOUY\?/O#JU&\NH#A](>78_!32#_\T9]^^>&W!)/??\CCT<4/OXW&
MO_>_>D+^L_E'+T>7U^/^^9?I#YQROOSI^*]):J]BCL1P"$0&X4E(U)%H'35
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MZ^#K<>)I?*?(DXZU\I [?'=;90+XP"\(\17NBX/195DXYX+H69<MI&R(18\
MMSUG2$"W@ 3&333<F"CJ["J/PCHUIG2G@X<$$;L2Y.\PQ+$/$-M9ND!!E_%.
M^U]A 4]S\"9J2DRT0*3AGM@0%=',968@1^"Z"D6> '9J).E2#P]I(G>V4*=?
M8'PC@3?#B*9T3VG< %FVN*)%0V120()$_OIL4THT4>=M':-T!9I3(\3.$G_(
M E7-3^D9B:_G,1,F749Z:D^\=(I$GJG)',?/5IS[U?1/3HX/G<C^(2GTSCL(
MRN;M:#)Y/WS5GUR.)HV4W^<WPZD?GO?# (JC/9WTJ$C*)H/KEH[-Y5(BWN=
MK$3?34HIP+LZ.TD[@,_>D:VAB HFZ=*:5A#WM/34Q>B(,9Z6=2T0)XTD,9HL
M<,IPFVC=Y>,6S+/GP:X"KF!E-IO9N]%P=!_:? F[61]%]J"95(3I8N0(0TGP
M2$_+T-_F/J.-4\?8;(?O^3.C>S54L#5OU[$WPZ\PF9;QX[B9HMZP3$1$JT<"
MPU4+4)DVJR@+NZW,E;>/.W .8%U4T-W:#61;P5<X_;J%,ALP;F<PQM_T!(XS
MVB1Q\Z*A3(1$'*YD""Y9RXVE,=3Q/M8A.DE.="+^"E;$ L?-,8I$QRAY0:*B
MN!BFS- (1MTA/5ERPN@4124VW -RHB387MA[MR9ZPCGEI8A$Y8#^$$6#Q^<$
MA&<E9+*2*\T.8$6<)#,Z5$4%2V(]L!@X95H" 86FL$P1B#=<$6V$ V&S#Z$.
M1[XO>G2C@ HG6;>NT2).H#^\0I!SWVDTG+R /!K#[.\^^V\P>?T-Y8'O[P_]
M^+JQQ7%TL408C :#9GSSG3$'7 -SN23T"E='40[ILC0$1R24LE9G+BMM1=4&
M]>Q=GV-1>#4N(^3YW'H!0]3/M!<=.,YI)-&E2*1U:*$Y5D(7$99G/#-=YU!E
M#: 3X=!N@JYP /L.IG=.>J1F 9SW)!F*RW70FCBF4$><@3(AYQ#K'+/>@_'L
M=;V]4!]JV.RJX==^/,0%9_(!QI^^^/'MWJR8I,)%24#C>B.%!F*YR 0R2,.9
M$('5V6K6(7KV>N]$U \I8+NFP L_Z<>>-B"SRY*HB-Z8!.5)X,J2'*VP#&R@
MH<X2OQ+._I7?C;:>H,#FHJYP#/8;E/0N2&=?T5XYAW=713#O<P-P\OYJ6G*?
M2E3K#"P 6N@Y:2*TLP4L$(=&"&$0<,5R IBJ$PNV$<P3X4L]U50X-UN6P*O^
MX JQ][(QS"6&.*)R1#*JB46SAIB 6Y^1(7H6][*2S &="#>Z$'>%$[0UE)VC
M>\#<GG1,LN1*N()!$?"<2'".$P[1&B,I<ZY.,LN&0$^$-3754^&8[<8$^^S#
M 'H!I*8</,'A,D03&/$Q"L*HU)RC9ZQSG5B@^S@ZY,*=Q-OJ!N@.PEQE=OPP
M2Z/\:QR,)I#^]N-T? 6WOQP-I_!M^GK0O/!O/T[@O'RS+1\FXVGOPWB4KN+T
M_7@>$7WVK3_IB0A>*EOD@="EHY18*)'0S#,J I6!A3:,P!?<80/^M,R$=0@Z
MY,(C"<^/<&,+98XZ%&J'!ND=/'<#WU\URV4K4+VEK.NN-/X03I?;P;J<\5NE
M=Z.IAVKO2,Q[XX#,GL?F*C@AU267CCCO(A'>T10S.DJBU<7\,>K^7O[]052_
MB70K^*$?1]=^,+W^I3&+D&)4>[0]B$@:G9D2"1!PZR-1<*X"$]ZH.D$Y]V#L
MS^KK4#7+22);R[7##.=2V:"W2'O[Y <P>>DOI_W):##')=$OX98)8K5&MX66
MM!4J*5'!>.#!<!&7$H8>%DMXZB7/69N="K##V=O@6F1#SQ.DYXB4$#:KY$L\
M*-JJ*B$B[03Q3C.3 NB\/(77J'3EXY^],G<76H>'. VB?\)XZ ?]R1R*-U8I
M\(&XE! *$V6IT)(DXY%--$$*HI7^[C_WV2MN!S%U>.#20,'172"%_ **Y\P%
M*XDP"H<$ KWUS#V:"%J'X&E6WK32V/WG/GN-[2"FM8<:__'3DC302?^]P])!
M[W_^]/G]R__]C_=O7[W^^.GU__GUS>?_>Q_4#A6$5CZ\3B&AI\>Q5$](>/1C
M:4E21;=5@G/:JVR$"M32J 1;74]HY6LZ+RMD+;,^!/2K?:D>@C0B7GM'LH$L
MHK0QM3MNV/X ZFU7987>#.,8_ 1>P>R_;X:?IJ/X^Y?1 %D^>?T_5_WI]<?1
M8/#S:/R''Z>>\P:8D9)$E]'?$$*1X'"9\S&[((-U:$_6BOG8!.A1W!-OPI,5
ML2#5%%.A9M'#,V-M% >.>R'5KIP9X[A#P&7:2,$S:"&]J!,G<@2']E65MWR>
MNY/D*WCP#X?:$^AM<D,U 5]"/"-7Q)G@R[EDI* I-:%.'8B'6$Z<#+O)OL)]
M<(/HS61R!>G5U1CI^0%]U]'\CFD1_@#IY>BBA+S-:II0(30'EHD6CA.)VS[Q
M01@2!3B@F<5@:UWP; SV.^!31>U5N'I> _F??G %:Q"C<2D-BPB1*T0<*>[3
M.202F1+1<^HRK9/;LSG6[Y)N7>FNPM7T6?KOJWDBX^?164J-,OS@@^^G-\.7
M_K(_]8,&>5A&_A%0=)/^%.;N[6RH'R&.SF<J;4;=4TQIG1@E00)#+Q4D"8E%
MDG%OQ^%1=%7K^!JU1W;:3#XJ7E3("6@D]Q$NK\;Q2QG!P]VA9P7H3&TB0O!$
MI%:9N"B!B$2SR)J"KU3\ZVELI\V]CG53(:/@,80S>H/+43&NB4;; 9=UY8F-
MVA,-/&M%2TY8G7.&)Z%]O]S97#,54A5>09A^@HBPIGV8G'WU_4$)?<&QE^NP
M7X<HH4'_7Y 6M09Z8"Q/3<2:99)(!HI8B5\"*P&R/$!P=9BT*=+3)E95O57(
MAVB25\N^/(8O)3CC*]S)\!N-H7\^?'DU'L,P7G\>>]R[8Z.K86I^&C1;^:T1
M\ ZF[W-3"%KI+(2U!+*C.'LBC@J,)%H[%IQ+/+HZ@?-UQG/:G#T"#CQDMMN'
MRS*38QGZ:(A_^#Z_' V_PGA:JGR5F=P+W#.AP)+2T@>=?,=PGGI!-*<H5Z8E
MSM"#N25/H3]MUNY=ORO.D'>^3SB+<715<JC//Y5C;93)Y-?+Y*?PNEP33@K.
MM_W)M)>D@03&$<5UB7_#+\'CA$J9 LXF=/YYG;22E@!/G&H5M+2"3;N%);69
M#[_Y,2[94URZ7XR&Z1^0SM$D^:,_7\EGZSJ:)$+H:#E."L-"\9HLL4PI(JG1
M&6*0R:A6@16=03I->AU0;2O8M_,52)N1-*9&S]*4)01*(/ERJ*,X<<X'HH,N
M?4*HUO)PNVH#\30)5U=3*SBU\RW'_?(! GR, 5]/<5LF33RX9580;I)P3B8.
MM(Y7<>":#/ODQO827Z'_W5/B'MSZ>Z:9!*M)2-J73+!(/-! 5#)!&&LAV$I!
M28_'6W020."Y< J,(9YY4^+5T65BS*(*<Q Z)^-3'8(_%4"P0SS9+&7+1IZ2
M$(DX[B*1I<*V9S(3*H57'H!&5;E%W:&3&7>)DMI!F(=.9GPPA"6?;-+D]Z"A
MPKC!62VM*E4A@)(0$R?1!AN5M#GY.O[-H[".)-UQ(W6O8\[.8J\00K6$:1[X
MW ;4)KF/&W-B):S]YD!64-]R187.9+\W8D3MHS.<DNAE*#$0@EAE%=%2<DV9
MI=6J-.V/$&L2(P_%ATU$7J5EV\7%:&;LSK,9*$0!4E@" AQ:2*6'2RD9J ..
M&?\?I*P3P_0 R@%J9.RNH@?-UW:1;X7XZC7.Z"*5!4*.7@"Q4;(9R4OS98(6
M,_)>L)1\'>4_"NL4B-"=W"NL F<Q7EU<#7#E2^NNJN9 RQ&K-KZ4@Q#H/RF)
M_A-/B%8&KGURU-A*!&D+\23(4D4?5;HV3G&LD!;%A19K'+,BE3,#I"TKE9@3
MCKVD-'(.,5GI:*6XZ]5X3H$2'4BZPQCIDECY<D;1TOHO9XC366S/^WR61I>-
M=(O!Q'#IT@D-IJ05\M-R]*R,+WW@.$].@%?M@F9:E=AH@^@9>YQ5A-[AHM &
MWWPFM$'8>?6==MCV7XJG>YUN0)@=%-)QG9Z62%425#.GB#$@$:G4Q(?$2&(,
MEU;'.&.M3G"/GC*/5/ Y!L9LHH<],^7V]FUA)3$+61L@-)6--Z.2/<NE!5 (
MCGL=?>JNK-NFZ/9;#J&&=C?9GW91S5IWN,/B":7V[624/XQA@B";R#O\_-/5
MQ84?7X_RI_[YL)_[L00+W,2L?!@-^K$/DW<EBJ",_54QU@:3^[C;U5?H]/T[
MEV"H)XWE*@W.! ,&'# J$X#3/I0(,9F5L9)#KU,D.P0!-3C>W\-Q>P,EE=),
M<T=D$L7 =Q8=>C $]TW\/>4&#?16<3V/O67G&_]YD=:;[IN?9O=/DYYS$$%8
M1G"ZEZ@6Q\I=-"4YH$7J0Q:A4E?+M9#VMS9VJ]P'=_Z=R+Q" ;421G^]6*3_
MT3__,KA^VT?G-=V&V/_BO_4OKBYZ$ERT:%240O*42!WT;/PN@,V@ =)RI.[Z
MDFKM7_O<&5!9T)7Z6 [Q3ZY_0UCP:O3'L">"2(DR38R-"3?II(A-,I4C#+"4
MLJPKW0L]Q/+<^="1E*LTJIPC>@?3GDY1EO6')!P%D9YS8@T5A'I-G7<,'D2H
M=JUQ1'%RNMY4LA6J&GP8ESYWN!0-9O&NY:3RLFQ%OTX@7PW>]C/T>*8A)B4(
M4(H#=FC\NZ"!,!2!<=19I>K$BK0 =RJ<Z%H/'98DF W\:H+CG$Q>CBY"?]@,
M?-:+[APQXG>3?IKWHWO;]Z$_P-WM[*+8W8O^ KT4.62C!3%2:U("]XEW!I<S
M 5S'9'F.LITQO"N4Y\Z9 RBD0J;_%@/H\4"CTZ")"*4J-??EQL1SXD$J+B%(
M5ZE#[A9@GSO+]J6G#LL -()8^%:W()O\\H^E,\ED5@.F![AV,D[+X6=35%53
M$FP XG 9!:DS-X:U6HM:O.RY\Z"*4#M,X&_PO>W'TMCRUTN4!BYQ_KILG3W&
MO97.!:)CDZ"#BUOP-)+,60FP<"8N]U9?H^:5CS\)Q>XNN YSY.?Y68O(F%EI
M>?2$/T*$_M=R4?KK$-_0U"=OZMO\TL?OIB-<GGHY<Y=%J3R/RTN)?/"EJVU)
M?F9"@[>"MBPGO=W[3X(,>Q!]AWGGB]K+I9SSO L!VC:QR.,<>CD$B>9-PE&C
M"RVEX01W)$-HCC8K2Z-G[7(JU[WA)#3>B?AJY&G_7*0);_M?(;U!1,/SDO-[
M-IG =%*\YBA23%(*HD,I12K1P/!).I(%XD+&:6[J9+<\CNNY<Z*"]+M,N[X-
M?FIZ&BP:HI<V![_UIU]>7N&"= 'CU]_BX*HDC!7$^+]4BF-887R6)A N*$?G
M665B:4+GQWKM50R&YCII;%N /14:U=93C:1J7!$C0)H4T$N[(-JXEK/,$NHY
M-^@TCXB.H764>-0I,*ULG=ISC\(Z%;YT)_LN4Z.;,<]WR+/S,<S20;Y=]F=>
M[^P2IV<"SP@'2*#4H_>3%;$&+ 'OG9=@(I.^E;WQU)N>N[*[%V>7>= -NE*#
M*?K)%-)+/_GR\V#TQV06OM*$6T\!93']Z*<PMY=Z0B=?2EX3#D460D<2,AK
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M$CJ"X(Z:5B>&:UZPW["72KH8=2S(KB]=/\$ D,)GP_2J[X>CB_X-)LV\=HY
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MNT(%SZ:W6_>J?:K%VR8BWEMWKS:@OKL.;QMIJE6;KVW$O#<.()6%,=P0ZZ5
M<.")XQP(Y2GG;*Q&9^:YZG[3#F_=JWX3Z5:X"II;^(M\&A55T [! ,,Q A/$
M"A=)CC)*&S-/H4Y\Q#T8Q](Q;"/5+!N/6\NUZW.9.9+_?7V)$NDOKI>L,EXY
M*E$15!'I4ZD^JABQ+EK%P#JT55N=RJQ\_/X]@1WD/>I46%V?F<X1O?Z*/L?
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M>\?XT_ F) )M6?P,)U1JY/X9-?<"'_M[#U?FF),"PK.D.!FR+D*B1&3F!4_
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M_#C![S#,?_SS'4=3I+^?;_'%-96%-L*IP(*8AWTXN0F9V,_1>:T A73NY/=
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M9:&6ER*@]F(%8D,74\=5I,1RLEHB^4Q@VH8_GVU9Z#8@Z%@6NHTRCE+?UX7
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MSC"[^1?S*,K59#(<?:W-V*9[E.\WH&+O(O_6DEEI!6"P")=XDE(FK94 Z3&
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M4=C$0U+=YEKMM/P1C<_3P,#XH KLNPE:9XI_9OQG0:\V!8 3O<6).C;1>09
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M2'N1$C+_K(' 9)7(9,FGVBP@U.%7R2DFK4F@$8HP;<;3-V'G62?_] &[#FT
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M>Y_YNP<-C:8#]R65E3G"UD;CG-0BH=+9"PC"\P 9N(I9<K,A>KL'-6TF#MN
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M0%Z<L^@A9\>=M&O>!)Y8[>CO \%X=,K3R2$#N12<C#QO+##DG N;7$[BU_O
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MQRJN5=,9FUA/,,9'>N_-6[F=I[P0"U9.;F(&"3!]AU@ZA]+E<"$J$:X1ZZS
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M(PEX*HI WX%T]9D<S9AVH;-[>&IRRFY2MY9'B.CO].BEQW%-W\4E &6"!3&
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M"."'\',5GFPF=U58-\V=3@L+NXS40?,B1*YFOG=^L 3&;R2>(!"$AH,UJYV
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MQIZ%=_XE,_JE_W,52OKROP!02P,$%     @ ;XM<5'*"JL3@U 8 [],' !0
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M3E Q[>&_FG(U.)R&IEFB-X/5B'J8)NC0)Q)&H^R,NTO*B_=>^^[^IOSCI?'
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MRC@S,IFODL&/%U<PKY,4\U7Y742@T/H^>^()X_=#]@8>^\_R;O81]'QF>"=
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M*6:;E&LJ9M'FYX/9<Y/4YP$%4?[@ ND/B[A C0IY72OZOW84_2LK]+/XT5Q
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M3"-I/#\.R:JMX%(\>2\7^"&+Y+T.S=EA+0X_#SQOT8X4,A^)K $+.J:58XB
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MB'8HMIX9@MUO\&ZH:+*,'?#Y/7,7[OL:>S>1X8A(9H8H])I&WV<7I7^Y_6"
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MNO$PCMV"L,I?%W]9R[ PHCY?E$"-<+6$!1S3B..A3FFBUEP)$4L8E5:$4V?
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MQ:ET:[<?K[5X:M1?H8^['M(:TR!>N(\5Z8HQL=+,-(<KU.=\=GTS_&@)$:
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M^G>J4 :9L&O*B[";"<^[U%L6W8^W9)AUW[I=1'%.?ADZYI[\77275-Q)TQ>
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M$W(0BP$X7L2<-C03UX1[9L>!!8..%&$^X"O"%&M"G)EDBIXCT=ZB^4)8E[_
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M95;+A>?76(/^-9U/#D^YU<KV$*^[ZNV4'O_+]_R+;?!!PB<T\\ ><@B3OV%
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M&6K?/9*@AD8)BO.^8[;,^@V/-MBPWL'F1H[S&K99^"@$Y6 KG!V^#W*!3RG
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M)9VT+D^  I,\#G^"HP9CN]A"M)["O?%5*AVM13\>/UCUNK\_)N#JF8N[@-*
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M)<C8-N2)6DK[7 3\PI#1VV,OS.Q*3Y^1SM@2N0X-%&Z>AYOO0MK.I,.81R7
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M9SK3RB>42"TX-7I3EI-#$\\//_TW^AD$72 /H3M18;:S":X%GUP!U;ZY\N>
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M%:WK"I."0)QBI3+S4 03H&W=W_X'0L6:EO+D7 'Y49>+Y)CG:^^^!&6I$1#
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M3%TW#F"^]YBOWI8N(W513D*A@4 SI2=@Y/&1H)QM<%2S'7??>G)6X; []<W
M/;Y;'\N-D1OPC&1[>Y-W)P)?"M(;>Y2*4%RN@Z%)T<WF@2JD-YWE9.5?F2HW
MVY?O1[X^$KY"6@$YI4B!+V:P8[]__D%%G_A"9HF6J1"Y] $9XBM957DXG/;N
M)"+&8Y.A(,TQRX[G@JQ519-[W$Z_SU T_51>F?#L!6_G&"4:EQ(B6ONTDN1!
MY3#(+;/(8[^7T2Y"1 ]R^)O/K&A3] SD;9]D0@6RB=IU).P<:6*^]-7(,KS
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MTV;@IK0A8*==L"1H8UCKZ=7OE:PPC#@C);=^26!RG U\B'3&1WXFE&74PUD
MOI\H303[TDT+ <+"[%6C>;T]&%-X9PJEJ)-@#WEL?!-R6$O'?\9+TTNW.>AN
MW$8 _5IQ95GRXO-]]BG(Q@B7I):X@W4/"@L,V\R_O-@I^[LZ=?*_5)!:P\P9
M;9I38-;F\A8<D)Y:Y2;"QZ@S+-%AR.D)@Z90K_G88N5<]145[B;NUCO!I+=2
M;TY]:HJ$M85""#M2%VRVDZ9'(IWI/@W@V7Z-B^_=0S/B70;M,W1RW%Y9V T.
M'BEV2E">JF(1/R!V(&1Y7SO]35/NEFPP/XTGBR);1O]*<%IS:*P^D=)LAB2?
M(]''9C!=H1%KQA.IVA+*:S$3 SH7*0D#147G$%TN-*X52E\_83H'65$T!CSQ
M7JTY5W3C'HK70I^M(DTLG3N]]>ICO6HQ@3..=J^/TEE&)K7>C;3<]9'Q'_L9
M>>U-4I1X@H[6_@O'DR_S[C"*YJ$H$BGB,541M'9H4A-P*00,M+)L(D0"^RQR
M9IE3EX*YF^_$V&1<]V&6_Y'UR>!EN"D4>2: $V0#BA<]:S6,G:QE2FJM]I]I
MHRHGA>=/=&EZ^BIKR6<Q7U5T.?/:N]U+V*O#24]?/GWUEN9IZ%';T.Y5JH#S
MH#O(3?6[GAEINM[O9\>D[TU(?.L_@SZ3;.T.2W7(RU,^*SST&-L@!EG;IR=@
M>^95!"=&0FEM(:+YX5+F:_V^KE?/5%U'#EJN?5=MC/RF5W_;%^GIJ)TN8&F:
M'G-(['@";9O^F2%(T;6?%CRXH:%'&C).F9FL#9ZWW"3ZS+L.<:).B=DH?=5(
M*_.[MX\_3?_>:(;B?KH 9;O1)WF2'=AXI5L8K-(BB(CW?//H&@)5HY? 1-]B
M\1-M/LLL>JC3([BC+1/15,)G:- L.)CV:HGLMVV5-![XL6!@/!J1C>$-K@8/
MR5,- !9+G]5P%FTR2VJS;M#K%0KIH(@"P=75QC$TPOUS$C23\O1W&E[O=>DE
M,]8B9W_I4I)0S8'^9^31.PXR)<DH*#KRU!9#85XFW(EQ%@3-WYJK6E!4A3Q3
MV)'^+)/! &8/CRF>J]%>Q6+'8ZV-ZP5.761^Y773[TW6@3 A\-!=1I<0@?Y*
M4VZ89D9V>O08X&]4N;)PPY)(M.T_^NG!96IW<Y-_Y97E]UU=E8O($6Z0HYUQ
MS>A68KC#[!XL7HSL./CSDT1\?FP4RN\L]O[Y!S*%(3NF#HL*U\3-E\QC:I0*
M )5+9;WE64*&YZ_WS5K(EGC96^16)@6S%;Z"L;S*4YR3[#R[*:?W?U.MP5X@
M?%YHH1M0:(P@MS*TRT>% )5>P)=R!.=5U:G]56/6,'XD-O9"EX**%1V@%]/@
M1'@\H<SG48W*M/J:M"'9CO#V>X'%Q/)Y/8[:RJRX7W[DU\G%I8K1U[3^1"_U
M8S#8!C7L=+2F&OWY'LQ#GA/XT[8[%+'EA6@R4.JL^) >%*#1%>APFOVH;(T[
M+SO_S]48[>D_"27\$JG,F"0:*V!00#L(G)OQ.;#D7N0PDR0W=>-1X=H?C7*V
MG]A1YP/QZQ:9*U)YG\6E?UN#G"CZB^C/;Z9QB5;A7\?N"355-17Z"@09N"^(
MM.\LZX&S;'0W_"EZ%=+Y M93?L2\513F4AY)M2B?>CL^'C4W.MG<>$TD[D!Z
M6 M;RV5U@7J6"^>,-7H^BOWJ E30%,CK1K^@RGL@.+?8\>=-@/OA=3TB8.#'
MK[(G;XM>TWM8O\4F>JZ-=QU!LO39T0EJ0>W^9IQEK[COX$%6"-PS)P 35!:P
M_YG=V?X:/=(ZM<D\\-9256<.[KU=13.I:OU* B4A^IEC?)VS\$$! 3SD'GTV
M1OY8T0L)C@A!&I*T-9CA4@RD3AXJ>=OO&+QV\\T/X^S5N-6#P]^.W?J.L(J;
M2OT1CNI  "HNLQDQ&+ZP(" Z8!9[U%53N+*J^TZ"0( !4-QKSL\66'2MGCO9
M5[4%4V% M0\3BY0( @I(<T?W.3N391^SL1BC7J"?$/Z.,,A9(?ED[*82C9$G
MR<G=@WTS?7GJ0I%%*")_ZAAR^B.AK+*AFCU>3E/<3?-XU<.P9SD(CD(]U4WS
MN&.Q&"MM4=HCT(I1&H2<+@45Z-5B/LR P8T:$CYB?=[B)TYHIRJY:BRF05V2
MM-YPY*W.JN-7]A1WP&4/=O!'<,**D1DYHX6#K[4GQ'732]GZ_:F%5R'7[UQ8
M4+?N$UF!H.\?D-6<=)\BDRFBU53%D]D63SP&3@YF>^,=O@G\KC,2OKB3Q!LG
MSG>R<$ RO^=@[$\L21L%B,]MK,Z4S>*;LY&KH')-1%O>TGGY#44IFR._V]5M
MU+)SL7.9?"SS]MR;W@G2KBW:EO]UM>G_(.+:P+@M''I!7LQI< 19L1V'.1Z,
M1@-8AWSW0<I=+<[WX4&\O<^]\N,K90)[Y=A/B!T.;KN1GN1:*70R#Q.#^5OH
M%3N#C/;68"55-EF)$)M.32:]L1K^04KM*6MAR^<5WV^2?N$;BTCT/=[2$Q!<
M84D'1Q&?/B=2G<&?.<=)G.5A3]YKSP_;/GC6M\$]'W-GM:0)/JL3\.VG!PG9
M*"H!O($L,IM>JK%4_*M7X];,B^OF9O[/E$-;\G-,TL5^1)K"8E@B]QUS(NY>
MQ?/2R["W?6*1E:@HA[XPCS<?^V728[*+1X[RY19P]XL]UCJA\=2W'77AYZ'6
M-YI>9L3K1"AZ=P'2\M",C%*;* 0G,F]*=-C-;YI]KSS,3_O<%2(=BA]C55O(
MU:H63K=+WQS 2-$@,!1U%R,=K'+S2U9]W7'24)+B1.>OEKNG^WQ*?^XS/RC6
M>C"L)VV8[3<9&K@)O:@=(BL0BF<_6]J5L0<3NY'URZO+EN#V<Q(8P[GCW)3R
MXU93AE)&"2!;/,F'HMWM[3A(,R]8$5QUO2[(EZ)FA[Y.3T^_,7P9W'RC:^-(
M1B=@!>O.,A14(JLQ0X,>7@5ZX<7N7101;MW/DJNC%U_9CU<ZW33X+NV@D0,S
M15P)8_OO\7;<K,QJLX/&&[DYT;&@[7.Z'U_:>LED_XE6G;"^J.$$^A7Z(^0T
MCB$'=0?%^OW.=*WLV*VZ2U4Q%6&-7EHWVRZXP Y<TKGJRNMW/M)/KT-U(X_C
M:"Z5$_R>B5HUHBHO:C+U3GB__:3E_W[R0=0[N^]1BL.K"OO?:3R\*DQ46GEJ
M9,NN[:CW5S:/D+=,RR>A:4?*9J=BD=YKDK,/P9. W^B!V)0[Y.O/EK#!/AR%
M[OM_O;KESMTY?"YR)@C+IXH?:&]]9'6#> <=/46R10_K$9R1HR*0%0?^& /4
M9WF;QNUYQT2SWH?OY!VCYMUPNKP'LX7-2&_KU'10&NC/[Z''V"DA9/Z(BOK2
MMJ)+AF\&)SKOW'O9I+8'JP*^$?V>V3T<,(E5]#Q$2@'$5-8V"9]=5J=$TS[8
MQFN$3UO,E@X$$3:4#OE>Y0]>MSAMOO(G5X/%"&UO/B>_"D5:9C=Z'L'>9U17
MBSR8-DN(KN3[_"D\R_23K1D=6UYLDZ(FZOGQ6(2 'O5#7$BK])9[@M?8)+?&
M"H6P!TLS8(B@VR>7[,%>^PW-(O_J;NP%R-/670D(IAJGF6Q-@V"?&NU<M-NS
M7IMS%L:6)9.*<B9</.?W7V,F:HBF[XQ 8V$D@\_0;M&3"!X;\+!+9!T"":3J
M]'IMG,P4D=M=MWY[WEJ/:\U2-M_FH.\-B[LYM6?<M;]*)%@C"OJ-M#WU?F/_
MI07["#L](K]S>HH/N<I?L =;'"G:_$<.7MF#4+&QZD:4C\4(5O5Z!N"/T!-7
M^Y;]OHL4AJ@,;G/4YNO>>1H?T9AS;5%!EY'VT"4 I_9@*81I'.8<N367*(MN
MV'VI>:JLHK+"EF]YWCDI+T0@<>?C5=B)UK,H3/JC/'J>TSW-];P$:?LK=0P\
MV(-M4%U'>B&CE.M.DM[@<&1X@^N:"]M'LX$2H?G4H9P/A^"B*-L56@C"P^B6
MU'OILT@<$I! T7CP:.C3?C14OV*M!ZI?"<F\/"1J5YDOW.9_1RTL)MCT(Y]3
MZZ!.O6^UGC%O!N4/)8A>5G<,,Q J4KOQ(,PIW\/X>G5F\_63A(@'J:(3Y)/$
M_@^<G*S"0['@%)*D@XO9@WUNS0V8E;84)Z&2%VR^%UE<PA]\-3P]<;G^,?2W
M8GS?J8C]!%60$9KJ$.7PB"T]Y PBMA%4J#2V$BBG6\HZ'G=,ZO"?B_9FV?=\
MO^[%E4-_F@Q[K,YO:YD.K-V35;/N6"FZKW[MX))$SF7ANRG&G1%(02"6PA"3
MFPY3I;_4D'ZWN >#;]FJM.5H/A$4NFL_2[S>9T.>-U3(3JD$0UKUQ.\D!.!_
MOL-.QZ,KT G>7"*Z#9CK^G[BM61-G(PKBGE&3IA*4H,WUL737R"GQV2M%DP_
M$X"O1&DAZP--=6DSC;U=\JCT]5.7WH^+O -_J/51TI[%6RAJFM.CL0X$(6R#
M,<&]NA-E]Z5?KMR, /:38^/$B7.!XSUB#C[9DF<2#O(XE5:<0W<'Q89==)J1
MAP\OJ7F5FX5Z9_B(O"FIT6)E-GIW55OTP26F)882!_)!'3<]6U-D&+C5$"J2
M$;LIHH%9'YW 4(6]GPS/O7[R46'50'2^JKTW6]-$(AA:X W0Z \9"[8D$NC[
M"5(0*)@DQ(N* &BJ"Y!UDZQ<FP<$MOH<L+5N\W\_I>W&WNY3?.QXR+']+:;)
M^W[RY+02[)&>Z*C,@C56JBSPIT%0AJ)<59F@&+))M?2Q[9U4%?%E_R1]%FW,
M@W.G/=F#Q7G609N^>XC$$,0(C=V#G3 +,/F:=LW#8:L+%&*:D:?S(F+1@#%$
MI\GMR/_ J+]U 3$=1!R= \M0!W)YA_W-B_@;TF!ZL>V"B++) \"3F:D$P:N9
ML3$!:_S-9F=_>/WZVB>?5QU]:I]%;O!P1(/E#=:?QT1G"2+(Z;F4'774?H;2
M+&[7TA_]"D&Z!OV0V(+]J+LZ50(@6P5C8RMD4<9DF=T?QHM]G8KL[*.CC;R/
M2G7&MB_]BGA]&W_Q$GD*D";0N+"S\FO;Y+8FC 0IL&*Z5KE-MSOC>N9%Y_5Y
M@4RCNXHOC'AK7GT8X7%\[ <76>JOR9UG]Y_"3J?B?B?+/R10#D+AM=>\%BAH
M$L0FU9Q[[UI541PT:H?WD$V?*\?YS0H<R<^_KU#*LF)WE\H9QCY <,:.J-2#
M3$,?%,=JT4UJV!'OMQ^?_/K\I*;-,U]-[&B,B(EYD=F3D9.H!0_*-CU!PPWR
M=9WT-]-?^IS[2S;/A]/S9Q!'+[58Q VKG;Z[[7U278N3M?ZV\D=\GSP@64GC
M%ZM'EJM$;TZPS-J]*0 0;3V%#>)#NM]ZMYRG0YZT8RQ>5+>=8)*<D^T.CR=W
M3:L\Q+HA8_GKN,F?XUWPKD'#\LPK?ZX2U1V36@55^24Y7Q]-^\F*[T"-HD&.
MLJ%RNO$\=4;E43G=X(:]W47YYE,EZWD"U$0-5V-4D0SVUF#IKZ<B,Z76ZYBO
M;H(MN#C%81\9N9*-XG7^>[?&VL63C9:+7T=JIB\0REG6XDEM%-L>;WF- *(A
M_+(KMV]9ZK1>N(K ?O5[/SY<$UM_OPS?3^!VA/:^)&:@3B#'(!S9("\NOJY@
M">3?2%:Y>#[FB];8EP\%,RXTH1[RGS:U/'P<=H:7Y%0P^<QCXKJ=OFYXO+?X
MX:D-A62X9D$Y[EITL@/(!EGQ :TAPG2>J-HG4E>,9X6(R@R8%5A@T-ON73.P
M?L/(Y<7-EU_'3<6, ]<U4H/I9Z#GGV74O'HC[7&1*H(+";)FB#@[98LY0MQ,
MEGZ%G7U%U_9O [VHI!;S[(CLE.'SX*$54A]%K+9R:*J37)#L8%1IV6]OFMQ2
MG65Q\.K5/5A((B$?=@UI8WKK[4:G;,LBA&8]CS-Z-%J@'0$!^OU#E!1Z D8L
MV-#ACX^\8HAWL8G<O$H@\"4"?OT[UP==YXNAYG^Z2 7$#[FDMAF7YI3#HYWB
M9J!F[YJGRQC-SG#U? 2F,/7P[CF1E=T(?.L>+&F*Y(UN07"%V9-OO(%LAZ92
M1JK++1R?<#/;'MHN'1\;TRCN:3MNH&O;_EK^\.56CYQRH:!XHXL^(,=[0(0>
M1?)I(QSYX-78.2NK+RO:KH-02?/,^B4-=NA=8)E$N-.5\&+TATCG CH4!!RG
M#H8AOZ2V$HVZ5X>7N4?6SW8%R"3)_'B3;IEQ_[' 4ZY7OFIPFY+WK3W7TKYA
M?7"16%(/NA37C&4I=O8HN74UTT"1O3J\_T+.N -8K2V"54>S8U2G:(J )5FH
MD=)K(()/V>RP%J $G;5K\#V_R/8Z2@R7)<**7^8D"&-4L0U5")X:4S*N);3@
M(4V/-#G4I)93XA_T9FP*;==VU\=+O)C<NOSL46[Z-71ZW&QIR<'561/4+0A$
MNM4=PCJ$20%19+;Y\9#,]7S.>"<Q^'-M[QS':NR(RXM]V[&CA!LK;83;V)%4
MU/ V19\4U$1][^FM),LW,F7TI4RF>]S60+I36EJA2"'&K]#R\FA1?2O+Q\%R
MHNOK:__#J3WF)MB.(%TA).+V$SQ36&E: S1MTCQ1NSN@Y_WX91=LZ#:*;_Z"
MMH>I\?BF#$NMML7G@9B4@66(:1_]WYQ@K>'6SI,&J425U2DR4\.NS>"S75RB
MAM*[Q<'4B?,R1SOO>HA+]?*:W7[PDNM*ZD%?N#[ #;(R:F$<@5PJ#SAH%92B
M88H/9KG9*[-)K3:/U:^M?O:KO'3-F,_ =0BVM4-0:WUMG>D:#N\[PQ@2.87&
MWP$:5<SZ4-G<"+O&Z7]\:$(0E5)J J>1U%3\%^3TVSW8)UP<P0LQ(F9!@D=O
M*%IS.-RL+?^2[&7F9O_9-,$I\$!^LLYWID>G%WIK4OZY:HQYF#Q$X^X#^51H
M$IF5#[=0C)Z;,LTV>GS 795TBD_%QA^-X9.MF.[G8]47/(F/9F?_05/C_Z I
M0M;4, HTMB1U_5.A),U+/V'^JW)U"/I:(:"6Y$^I(6%3ME#0CL#IDO9@\;<'
MO4]4],M;+<WH-4<;6?68U*GMKW<AA+866[NW7*6[_?.E"5*OX-_1@#R6QNUP
M,ZTY""U<P_WV>X"'/Q3]&JW=/%]X!&JS53;HJNM'B+==R>V:]+N !<1C:7R1
M8Q1/TAJN"9V0:F<X/18T]MKC6HI&U<F<C^U1,B2F]M4#:4]BCK%3D7=]1.9J
M'G<*&O 4&O4,^57E'#J^Q=)+4(<@(:!2W8 5J.CH.A(F/Y +8(MLOS[S.F-Q
MN$KC4>C.'<S]L!S?ZL?W3(QL?A><DG/EQ2Q,(MA!14"7Z!PE^GX&SNV*.57Z
MA.^R7/9]D?J;$RH'Q-]O'=['<CS"?3NI[F0P=N9M\FA*O%(GHFDW=+_5BG%M
M<B]OFTW-(Y85=/0_J4I.L,]N_Z"C(#*V//S^=_OXH-= S"CO8S\%@FNP#;PP
MJDL_!2(DD3Q@W^2%_CZJ=9-@8*K%JHI@05R)Q*$:O[ 7ISS]@F$Y<!&%^Q!J
MD++8]0?9TB"7W-.SA3BXC(:#AY85IFS<KPU6X1*XE).E3MR)3>[S/?QSY'A'
M!(_CVUDM/,0S&U@)TUE!>S!^34F+, =RP,-GX!%2;7W6E81[8E3['7C'F:C!
M8Q8N05K';YZOJ-].&=Z#@1P]I*ZF3KLA*^#K["&:4XCG[-6>>RW!BIWU4=01
M(:X?A-4'Q[;&%:0WTW1Z/&FJK\?<=L/?E$0GO?3@J*VH,> YJY//%I< 8_33
MUO]W"N^?E@*]&33)&#?2@'5/&2YJL^-)YLTRI3*YJZ$ZOD;/$3;RV!=MWC]Z
M,JJ#;Y0?4:%\[B<X0QQ>0-%:]6UTW8G@FXNEA<H395G/T[ #7F]J8%L'HK'Z
MIL >C I9>4,UCDLC"&+:+;L+#VB722LH4DY9H6'XVU%W_J%2&ZLV:9]S"F^*
M$_:7*3Q2;8\(_<49VNWU_NIK%2A2T[.0E>"IX*[9DJTO'C[PL206@T!AH1<1
MJ8&WZ+_B3M+E.# -YG&,N$9PQ /VV!'U)@S3EV>M*Y85?[RW[A<IK'$,C'^P
M'#$X8%]8+<9<F%KZ_KCP4*794V*'$%<CX>)_U!^>PP/2L:O:LX2Q*8I/CP9B
MFJ[5-.I=\!9XQN%L&?!B/N9@M*QW[IFW4J^]J 57]MT\*Y03417_I3QBQQKD
MF "FI@G1N++*%-DPU.P>C!WP6UYH]I YNYQ9S.>GCW-^Y&WZY('8\4?)Y]&Y
M2-(P@A6[^(X&T=K&5(AT)9O_<J%I.9&[P!@"XT:.\_W(';:4O]"G@X"AM$4)
M? @)>,(?$C9-,"+8&3V7/5B;=#D)]T@1)PI@ILRZ*PS5K7H_;(?P/^,_[>^C
M/"@UYGC%]&-[NV_P\>0\ M]_2,'MID,N98Z>I30UPDY1)/DT$;@FW%1&AV+K
MQB@O-K\[I@[05E82HX=[3YYKU'\UIWM\ZYBDA;[A\L,P:+>P0"#[6Q;I/D@(
M0-/W]];B08XU*%0$6V.'6]YAU]081+<9VZ#VCR(62[<&B\=TYZW&*L<<_B^U
MSU97S,\W?F)]!JO6>.?T7=3:Y<*R&F53'CB%6XV:10_'4LQBZT&9NNXM#JN+
M9LM Q^M.F4'JJ9%R[]0+8[ZC_K^)X_WO"&Z^B^$B:'F&". >[,[S/1CTI!'O
MW2Y4I3FY(/IJ9D'L:_"T.#MUS.?UMUQ=KQ4!#2;T32.K]M-%YQ /"! U'&OU
M&2ZB/-,4(<LV/\MA(;_^7K#\7=/$+>C26LPO/&G-WNA/RI-XI"\;_3>^HPN0
MRJ =L6YFW-0E6Q1,G,&43M=RWR"?Y<_,CL'?]?>VKQ/?^:0]=UE*^L3.S\#'
MJ\ Q,80/V+ 'X\"<H@G0L\I1K&&W^FO42X*CFHHH0EY:UZIR9KR+N_?!,YT2
M3IXR>GJ!F5=;_%=F>\+3\$'E^Z=XC*P/,4JT=A)!=EG(Z_P$WN_![,QPN[9>
MZ /8?XL>7$?^O\KX[F2 K P5B@] -!469DSV_DJ4=6BH2G];^T;7P3M3:>)'
MKUAQP_>[,D=A7T3B5=<LVN5')<RU-MH9"7/&J !ID!-"F&G,?7NP5>_2/5CO
M_<(_>$#9&KRVT2)//3RR!UN,Q4.4MFBJ-",!Z8T?21AJP!PE=-];,^8(G+KE
M%A R%S/>(GQ+#&:?H#/Q@I_)^RQ<C !Y:^9PR'+"@OM 5NJTO* ;1J&?)O]^
M/#CQ9F759R^^V9 G?!=&KOG+G#OBIW.6PZ&=_J:MF\I%$,1.$^5'U/XTHH7N
M^216!;S^Y#HI\SGE^L!;T_:QJ?HL>YF[]:D';G[M.JOR$3_B/J^I0!,F+:SM
M(W68D[")BM\"?. KCW?XS7KO/GEL^C39="#"Z4[[IT@UT_X414_Q,&B2F:V@
M<26Z(LLS5JFYP2QV R4EF). <L\]HL?=DVT2>+<C[(>A<!P6UYC_X-EX=,IA
MZ34D7W"U/HD_9D,IR=^XM&<S6^V\TL#<KQ5FOD6ULNHC//?3T$G(\BZ:T%>R
M^LQ&XMLZP*AP"3S7HS&ET,M>U-RW97W#+_<%I7$.6_?A]9/L1!N[;&@<SO0/
M=6=M1Y<PIRN>-=U(2N?RNM_2/6EMG7+S<<=YF$*P2=<;QT)#:46SV'/0UI.D
M%RC!@=/;:WT%2QBFSU4#BEDA8J2%Z))&7H_>7J[M ]?:XT7B.QP\7:-+HU+&
M$2/FTZ=25FNI:L'(>K7[,A\!%\/D0;VGMVUN^/TQ2!Z;<T.(5)H_8)S](:>?
M@#ST!S-IZ+J:E!;<$;S];\<!.[B<B+*"IFO)S5\?UI-.J#^_&\W\?O?WAY>"
MVV^JN=FD\BJ.F/^"TX3'&/5%_Q=[[QW5Y+:UBT=14% C2&]1 4&JA:((1#<B
M("H" E*C( (B(")*S:LHHJ%$1& #2J2)-",= 8ETD28U%&FA]X020LJ;WXO[
MW//=L_?^?M^^9]P[;AE[#.8?Y&UKK3G7G,^SRERC2%;P&IPEMAM-L*Q&DJ\:
M_V,(ZFW24;).\L@@JHI^0T>TH*RDS.[6[*1@5+IOWWF_R^=W;-ES5]^CZ(U+
MB=B!W"84^1RV7W=T^"$47E&[5]\\:*CD:?>Q,5Y ZK2R83;%Q:6A]S-]Y\HT
M[C3%.%V/^KI_56WU70G#,U"$/!'V8SC0BN;NR;WU[I!,0=,U9^YM\8Z/OF\U
MOHYZ^6<SY8G&$.IVJU0SO+N=&*XC6 ._CZ&#YQ#D?2ZI:SECA]/=X+H+QOW&
M(,\H&3G2$^&#"/%<TI%R^Q;ZM;CS@._M&NJ*\HW+R4%C5O BM!53GY9(205Y
M]C$N6PTTN"KC,YOKE4Y=*.34UCA=I+1R5/; WCOVEDWJ7*@8MT658 39?4_(
M.WM='\H^DGIR]KD,E>O)5DH))>(<6NF-(G//NL:2)?2G+><I#!5?+JHIV9+*
M]3#P> ;M@?'=W),A1L:^LT<D7:_&13UL4[QTO'Z[>#2N+F4W;RVD21WD]18X
ME9O&X3:JK6ZPMMN!4K?X*6L'M3CYWA6.2)(TQZW#6KN2<FH9Z?P6,U96?/_U
M!H/-7>G!$'NH$M&10_</%\6FCK5QSPUMZ5P-:]'IZ#[0[>E!^K2;/^!J3&2_
M7I6VCN<WPAF0@R:X,@I\6>*D.5]^.>2VM&?:0M.I.7;>6BA6[%[$-T%8C&):
M\.D3#1SI3I>4+A:KW_U]'L,72+(GG)DFS(;UY@%L6'(5JH -*VRKL5D*'RX
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M!&(5>';IR9Y_UT9>T19_K%WG)-SK^!$[%#F7%G>5($OS*-)?D]NC]S,@;+.
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MKFA,A8,&U%KGZ,B6%1EE#P#'])Z[YUX]%+3E/I(LA7( :HITMD+4_S 9 +<
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MDQ0H1>(/^U[;%['R0VC\3)Y3W+#913?I$W_R?_K4%"=D%1/K)'WEH-NRHG:
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M'?LKPO"NR47TJ\7;-WV/E1>:> HR^)45-4F<PUWU786QJBM>D4.CV H$7<2
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M7U/]>O%NDT$I.<&;)ZZFW#OOMG45-6AU32!):C7RW5D)B^+5%(#N!-I3C.U
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MB&T@^G4YB0,2A)_8+D$(NT,O43(GV-\P]=$/F"!17EXW,4E[ICWW49C+TJ.
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M$<HV8PCAE@2_EUMZ6;J&+<M+K;O[K+\85MX>N'7=B@2=! D<TBV411[Q:X"
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M))7D B,_A>SA)5_RB243D^:2'X)CIQ[[3_+VJ7WZ4=XJ*20,8:/UH.M,.@8
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M.F39)-/MD O0)<1!Z\;TC)X5 __6QZ*[3N;9BDFTY7@X+W61E3HLGWK/0)Z
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M/: T5]WZ;&$+P>[QA=\1 =;P:03! LQ(FS4X,QBH++CN=*8"U4;:F79(U/'
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MKV(7Z3[L,5,2ZO=EX<RS>I_]*LAS%!OM'O.MG]*\27X-Z+>C<G7^!,P)J&)
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M[5U@K3V3 Q\Z7#]*N4*]M<@ >$JO;90:/\%9#72S/-XQ9%L7IOR%NI%$>UR
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M_VGN/]6<:S0%SQ2\?AD)$N*AV,.Z6/T%'8@4UMY)7!,JJ_[>(,6=++OTV;X
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M"*[P-4*,I/'CMY&T:+E*3G#]JZ<$D\PC&H=;@B%W5A8.EEGKTSXFQF+7&AG
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MC$5()N3SE#SBLU'7F,"&@"8SLV4AZYJ'UIVPP1WGLS)?U>%-WM"RO^ZR=C
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M" @H"$&*B)1([X1J1*3WWJ5#0@F!%+[X[/?L,?;[[G&^[\=WSGE_',98/S*
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MGVKYH/8;-V0KFM$VLIB.R$(VN[R.(#[NJV^8T(F2BGD/;B5:-F+Q4A6'_AI
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M6JP<L:4YY:SZ04L%H.:O/3/WF]8,C S$=G05"[0 W"0H^1[LC$'8#+#>8>Z
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M@?AO("6;57G]O,P:E>!?!51TGC]U%YBL35Q"\L]]=^3ZUE=_$'2Y#I063C(
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MDW+QWBTS FIJ/ECN%0M$C5W'W9IH*4;E3NT%5H$7MXQ8X54$3MI9S"SPG%7
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M"H7* )]N R'$"LF$/F8!),@LM-J]HF,?PV.EK2MK_4MJTS(.[,_+BK/BN7C
MN[[/$Z&FF$=2O5,YH) FH*_TL,Q FMG2//F*K4VUR2/ 8B*N"*#4 N(:H##/
MN8&U^HNRRP9\"GPJ*L,8.@6=/QDC[F ">^G#2(FFSTX1L@,/*Z U;"#W$JX=
M=F.MP<XR)''P2ZP+,"HU(GJ_R[)]N#8Y)UZLQ'S*$O=7Y(+YR(E9OY7L6W;=
M@3[%,C3!7#R&%GH,. ?&JPP< ^*_G-SXXX=O-(I3E/L1TB0&4WQWC0>Q2-*\
M"AKT6O &P]N?07+?6-B?98[,5VT"\:(FU#3$#==ISJ'PP^OV4QXOSES8F:J)
MHP]$0&#<+U[?,UC/@A](5]1H2C.V8MQ%:EY[Z+J'@M<\<Y?<O:QJYXE"=QLE
ME@\"+W$,RJ(2%X'1%4=\]#%4I)L8]C;4$8G>I3V!U$WP?[6SB<3'U)AZ&3)P
M'/J"Y'@,L&FT#I@+"LWOX<IET6S9V)E_X/3K5G<@V[L3ZTFD?ZJV;/Y#M:5Q
M'/M4\O<Q (7$Z\T :'W@"[X>?-! 7(R4K[Y=QVY626VEGN_.IWMFSC"^<%-%
MB>L!$IGT122Z@AED)WFEM&"/V"D:QX"F=0.:=O:_&<,=6A3UWC?Z],C )<I2
M?%(Q<>XIHDO)M$EVBM^4P;I--K[J[U)X<X*]DR[3K /;,IF+UJ[/1_J=R*-O
MWQFI<AO2IW>:^@XYB[91IN;MJUKFEJ5IXK.5Y==YXKG-'GHOBC1_J!9%O1,N
M5.Y9JVI"OP()4=-!0D](T%;39^/=D^[)ILVI.T9G5NT]YNU0F0#Z#UL[QS,M
MDT=?Z9;\Y6DI #>IDSXF]$%-["71^VXK<@S(2L Z%OR@J2!:(2Q(YZ :#%QS
MKIK'[#WK>'ITFF66CI_#_)TX,*P(U_OT)"&DF^BFLN18E6HN'K-D<_/:S^#(
MWY5YI*+YZ )P6<>\/D(/?GHG[='[SPR:L:.87AEN9/.Y>LF@P*XLT@QDH&@T
MI&3:0@O6B0/+O:\C^^RO6QT#*,KU[L> A"R_Y3R**)(ZI %$;[2/EITW_Y@0
M-+3-3+(T(E1%2OFD7_J^;C2(R>&PG+#4MD]P5 ><3*7RXOTI',#F([?18/_O
M-B)#69!#)Q</[F2#&H\;"ZNAVQ ]"BLUB7*:?.M).8(#OYF1[GGI[._Z9XYU
M']FW[R]6,BX[BWCW,@'FD+,9V%).6@?ZK&.$L7,.02<R7;KB,:?[O9LAHJ\L
MLY^SC(F&=(^*/1UI_&]0]_R_;[MS0TL,SR"6,0A 76J+^77[:TQ"D%D"HA<-
M5 "'VS -*G9!C5#ZO3[O?PW\PFT?G:#^5G^'C).&>Y"&<F' EO'P_*^NYU9K
MV1(Y,G;63,?K=':7 6R%]XB8-@CIBLSF=@%B-$/E9J6;>D2(SP=SE^$GU]P-
M#$"&U'F5DP<Z-8JK#C7/";Y2Y:;;1VMPB(#G9V $_N-6?Y%,"+A@DYNT45]Z
M#'#OF0BUHI8BQ!3;8A4CPGRJG/?2%63'H]'[Q:H_)NTS0D]6P/2YS%84G%O>
M<:NX=@!_W$IV>(.;=XIN[_CIY>]&IS272ZW/&6IQY[><FGTDH'A4<@PXLP\'
MX#WH9'$>(SAC/N::<:UL\#N:N8?W[6I?@&NKLSI?Z<.YB:CA8T!H*.TD2:5S
MMB>"XLD:&Y<VGS/8W^P8=D%I4,3^F=WSX,WJ279#U'W"M"=[$=4LB8A%?SI2
M@*L6DX+(R FIFAHIHH='%/G0<ME[1SOJ"N8I9?$?UV9"7EP!8&RH"<AGV[RT
M46$9\H574**;^% 3=FB+JZCH_9HV\@VA>ZACT=.FCGSJ&-!\W7=[_*$>A!-6
MXPX'S[ZX&Q]NE&+Q;3UR<*<$O?W1J3( 1T<U%7D4+N]F=$E5*';.@L)?TO][
MJ)S45=?C_JFP/'G[Q_R3LHZU$Q)BY[1@I,*?#Y%F+=(N^\$\^4<W[S27VX8_
MP9WKZF^EOJ?69AA:YI")XYTFP]:N8/K;9]^BV=0B37R1_) F1L.*??V[1#J=
M4GO6H_&BP;,+X4\;.@94]L1BH3/GJ7EM2FB'_HM>PQ9:91Q09Q"Z;90FVH&1
M)T3$5$ BA2_7#RLVW%XW'I)9E)NTFKQGHVN^+Y;:570CX+DS%FJXJ[\UL_*"
M("%@]NMJX1FV:^$75!_'I>PFKAT1L?Y?#"&9$/Q])$D,%$VVH"A[1 J#&QI1
MK?X\YRU=QH-C&A^DV%AR!0AK_GS9])+!RK$$.5OPIU"IE!)1%K^)BE7C# X.
MF-/K+''R=8)-VX][?U/EU:4XWYOHN1@_7N3XWC_RJ(*ZW4*-N=Q44^^%WDPY
MO5$43-V"_*[R^#X^CFO9,]0*E,#],Z&9(9?K$</>'T^8VT>1ST$T@]EZPH9G
M-@Y47+O@A!V;O<7)+5"6]4+&^W8X?1TR"#LC^*OJ2?Y?[E;FSZ^'JCT^#="[
M_)8!JN1UZN-?T-GML6, <8"43I9Y,F5!$FU/34;9!4[;#T=-;(X18LGL)TJ^
M:WDA+]#D8-D+F%AI-:UYJA?=HPY+ TQKZM[5G1:\AM(Z^?(TG B4R#?@);!9
M6&/5@]"891O1IX1Z)<$,+O[\3MZ&&C.I"I1EG9L#M %BXQA%-!@;(+*0TL@/
M]5D:@7AJ>R-*G'$(@QO;:$'/F[K; _=_R6*J07S(9LE&=MK/#""J;8:G7M>V
M4/_LKEK=JE;E1UY?$VW5O!X'48G^!A93E]NA2^X[&Q5.'?96S&F.\41\1%EN
MW4?JZ$1C+3;!:1G;;#"6@D.7:^<2/1A(3D;#W.:BDV)!4K8@E+PM#^%2XQ")
MDSZ@RI:26D.-5V&?!2QA9EVIK0\\DKA\S_\:96)0^Z181NBD,=^9 X<'2L*0
ML]OAMK5Z#CNVC=559*EW%WUDVV.[4#H LS:PX#'@N<$;8+G;A%(4Q?"+C<76
M9++AK?!^4=HOUQ>2J+0;;9OD:NH.K7%A)1A]=C%5O][-86(J!UU,IQWB#ZBL
M6.I7))V+CE[XK@<^[3+N7E.L'2[GXV-9]R8XIPXLTKQAJ0Y=9H]%XRUFWF2
MY2U)-B/Z>-_HI3MM:.=:APW_JDF/ ^B"A63@K9O",AFYR]([@[OR,N?E _%'
MC:PX=KT<%VD(#ED['7Z HETA)<X7EX^CWOA.F5DU(LIL)LN[4 \-#%R;LZ+V
M1;FY[>%"%@/Y$BJQE0<>IG3C;?C^SWWD/23E?.B\#$5R9@+9TNC6,[:Q_PF4
MIJQ^6>[N_.5C +9.<LV ="TO%%R"4%I5:2D>&BZ??1VWR<A\2!DZ',)7?>_"
M#\Q[1,"UO_0K1>RKNMV]M(\4-TD$QHU3G>BX* OF!G^,5VI%B(7Y*Z9/.DSZ
M19EW' -Z?XY\]U04,(U]N#;C3[E%O3H;9[LI1]%FI;[)A^<4';:1"IJ1G/6Z
M^&D7>SRMH< YX2$@OK#8XCQIO]T'@A]"<F)7,F%U=#-LA(Q]H6#6!:P4.J H
M0MJVCZX(TXE[\SOT@LY_^FS%RG5B!MEJ0GE(1T"OYK<I?+HTA?_T6;&I3^/_
M/N@__6/$ CAZ6I*$\A"TN4@0KRC28G:_6U_GDL3^Y=0P*"+;"H:R*!O86-B5
MWOZL!WNL/+UQ^TO/X,B:1PN$)(9I!3+#F*9'VBZ8"5\<=GH=7$SX;7_BQW*G
MX0%@<R:FEV%)BWL+736S@0)NH A>,P8#6PZUO;X_;-;U7>(<8HU?$DJVRTMW
M9Q3G?/[6?C$SP6\O1$0W<DXRJJG/L^KI6VTY9[\_E$/6I[,O6!5QG=C/:T&3
MKGVNRJWWH\GUN55$(U#>]A?XL-MQYT9R=7,0/70W\VCJY*A+[3[..F*#)U:$
MJ+SKN1D/ ?1GE[O5/$F*N,UV-M,?E$W"THU(%4$G+*8*Q#DH1=%RK;DT_4QJ
MZR7E1<0*&Y1.*GA@DF9XMF]'B(K/TZO^\?M1OR_$1N[S":(\VP-UFH\!$_[S
M/,VM+#=K6]=2GYL#GV&I>Z[9I9P_@[6"9>?8)X+F/#8E<L3?+%#Y1_2JW]OQ
M]+UQTSO*:3 3QD0Q?,);<Q-3VM$D<;8/\_IJZT VWQ_U'\))1=(.NYEOD25R
MRZ"QI@-,4J,$A8M@T%RDM]$HUN>A,#Q5<=EGZE0>]<,9$^Q)S9NW7/\E[MKM
M_,]<'?9 :C(=&FV?@Y])9I4QEH=F\/R E-4Y0F77.85;R0V2*Y H=)G_2[ [
M.P,V6HT#Z>2$D5OZ'./V! )<VQ)=*Z+U\2WT-P**,;/'@._H<Q06PG,+7,2V
MS;C#H>/KCZT^Z7TCU>!/OU]-YA* <QDU^)1V,WZ9R.OB ]M%/5.>.S\:T@6R
MK^YSAT(^@<Z3PO#;-";16?8-:_=A*=6V84*"R.3IKCH[JCTKQ65-A= M)[\C
ML2E"O@9+)+J/W'3E2)L2]F\OSF6BK4&T/+; )>O=\AK"=C:Q^&5B#2D>G]+B
MY8P $OR*\ESTT]^*X=P: \3!6_:[N,#=U"L<=L9#[A5=]X,Z.]\4;VWER'4I
M%%OH6GW\D]$2T&7VSWO)#7>(MZD?ML&NVS&5TSQ5]=:@,1%HYWI17>I9KI?W
M,7[7?P(.,MEELAJ/ =0OX-FWM>PA(/89:"/SD*+XD(*J:6UU53U25L;PC%4H
MY13@(<,9++B/TF8JQ&O_Z*^1 >2W[<U6I1;)3B0S[/.\;KV\_&9ES;,GY=\E
M\C#)!H:CNY,CO]X]8MAR:NV)O+%F:DKH\!3L?1 U?, TES08DS_5&R)+IW/#
MQ?W8*\BGVQ,V!F%'2=C7<$.?GKF)E#$G;Y&. 2MTK0%E5XS&(-& 2(4Q?(]W
M]7L[T7'#_ZE:7O>=N%%U-IT[QX!U$1LG$RVN1_?^5T@L_M_VO[>9G2!XS+NA
M(A3T.HIE1,H&?$CCT,X/ L^=H^3:T)J;@P0+&H@0LII<:GGG4N%KX,W;+T2M
M['=[/0>)&!R0=*V'PF78J A- ;/#!0);6P+A_P][;QX.]?_O#T])BE#9LDY%
MR)J0")/Z( E1V9E*B+%DW\:,R+Z%$&)(]F6R[\8N27;#6,:^+S.6,9G%/;[?
M[SF_<[[?^_>[SW7_<5_GOJ[SQ]-US9CWZ_W:G\_':WD\&CSN_4@#8H9ODB*/
M 4^>'P.PFOR E0;IEGX.H_A['OYQ>\HFG7<=0D_C/0X2ABYMB%"UBU8;,9H,
MQP!Z?IK[_[ .K,J+ C\<?)/:W>+[I'MS( 2#^104JZJ_AK8GG,D@0QO4.8Z$
M@:R,[*-*D+_@?+;<S>*RG?W<4<ER2X<W!J5ZW-74V0V[/Y^ 35^%S6F2,7&/
MH(TWQW2_]^BI3(O\=FFJK7?9;%ITD>%A^\O] I"='F:CFP9C:L(=#_3X(</V
M\28%VL8<T :_I[Z;4>]DIPZ0\E_+">Q_*$BQY9V1;>I(E[_1NN68Y<_#I88E
M5&[K/U2Q[;P?MO'DQ3;JV&:_K>8RS2C(?WRMNKI&9^AQ]W=@@4B HO)3S./-
M_ ?/XC]P3 [>&,F&0"0/1MX]Y$O0D?T0(V?0)\@6 ."+]Z>'1<+:@#CM:.DY
M=.CPO%%73F5%8-<U/^=O,W>-'09<;]2+1,_$463[.29@/:COW8&H602699&8
MCG<]U$OH,"SSR2]__<B]7/-2!VIWS&WXZDNWR=0_7(3]D_TS[U!"*QJA4T'2
MB)SU4]2J'AZE^I7?O?Q;\UE,Y( MROETJ5CI'=T8#@R_]9'@ 91%*V N]=*O
MBO'"S^'BPUF3E87PY&7"@?0DELHXZ(^_?0]UEGPKW@+8]I.YJ2L_<LG<GFG8
MP:K8!?;7T04WW,2-S_':,HI"7Q(>APTI%1;86%4]OY"D&O#\*#?!ZZL%)8,P
MMOQ[@;>Q8/XM5J#V)8OX:-N<W:NYS37I/=M6VPDJZ&Z'LN4=7;VO)!F+^%44
MU]@F\F]<"(AL+$[+F2CN_ %NXQQ4@MN9OSYCO(9Q[*A1LLES/)7N^6-I1I$#
MYK!M%7CJRH8Q F<$)XHA0^ 0/3H[&K*&\Q]TA?)C9M:5$G\)7W+O28_KBMYS
M9 Z1:.'+O[(#1GPR2BW_HM3A;VNVLP1;F=2+W;.S!HZ7:D],)A$.ZXPFFK:<
MTBPQYK0I?S\VG'$+QDC];:E$^7J0XD[S_T2P(9ZCL_:L<WDGJ=;MBW/<]\@O
M?$Z"=^4[C;8UR1?SJ)=<2.?7LM5(($+>Y(K2\I RMA(?.(W_+B7;S<"_\;M/
M9JAMD!!GY%5&,&=N9Z^8ZEWW*'155^^9](*\1>8<[ UG$5%XV]F:2-4SQ()]
MO2O>\&<X0G[VNY#=RQFOCP$^O-OUI(+K=;Z4#\> H(A,W 3EB[+@C<$J 0F>
M60ME/I\^R%(-1@;[UED$#S(E^Q7UNL2RJ;V(KU D]H>^BK=):!E&*!OHJ-87
M34PBEXO; M^)-Q+/DV2):$(R_O8:C'5@NTIXNAKRQ:&JBO]7//"3E6*W$.$L
MZD$S([Q53I6=VJ7*$=D%OW+0)VTXXJB9RKE6;4?85NQPH?P9]PU@)<G?_?4S
M!CCMV_O5M$*7?[:Q6T&W1"Y+'?I"9+M5JKZ)"KX'9*7V ;\;=<1B4G>%!]Q-
M)/8]KS8C\^GH4Y&%\0I:QP  ,]C#FXEZGH*3)K#@-@6$B06EQAN^E=K+79B/
M'?="0;75YHT?!*+.>B\R[L$Q5E0FZ^L8[4RRX*#5T.;"+TCA3%MABSOE%U/;
M48B(:A'X//D!,66>-5+@>IHA7JHL'V(:W>[DLYTCY;:IQ-K".$>X.V59!:X(
MM6XX@*.S#H 8/MGVHY>O#GX](+D9YG$M":!B/\76@][N$"6G%^-TLLFB Z^&
M'*P$3.U]/VBC^$%>IW'9 _'G]I&AS<)02[QFE][%WD)BGL5(5>]:C*E9023U
M8299_,O7)@FITR'\L'6EPXU#!'>&BXU=VD\BIJ3[FV&<99PI=*;YA GDU=[[
M?SI!#-!0A[5Y*Q@< T*B:$/<P.[P\I.:F@%O?YYE-71_U75-\KO/G3 5]'HH
M^9)(Y\")&N4+O&:0$_L?7]5O:\+P:*G!\.[A5\!HZ#'@TM!R^\UC@#AY'V2)
M ]\B*([@^NV_0U: ?KMUNY?3?]Z$:'>9LC=SX3T+\IXTFU<;N?[5NQ9RER)C
M4H5;.;CX7W XIR!J8Z7*\J4FZW><EZ:-=9,OEG%C5A_>)'?"\LDGUWFKH*)X
MA?>23HV:13ISZ7:O3\^W:2NN_&E9L>J*RM%:BV?-Y_BCI0[P0Y/9>0FU-902
MF"1FQLYSSVR5YP(K).]/RWGA&36?<_P*'.8LF8PXTW\Z<!Y3J7^?/Z\-CN'J
M IY!DG=8-HP,R\KHM]*CDG9)MP6R=Y%%JAPT:*-)%L=KZ_"P=C2Q8/J<C'[Z
MQ0$Q$DO]AVC>!-66]QM@UA,=<*_Y;C(;O!W$YEZ-IG)O&'INO&/**?ND8WUM
MXT.<ZS/*E/\C9#Q5E,R)UVR--BDF:V5/KY4TV#_NK>>&3W^TUAO@&T&=IRH1
MBV9COM=D\(V62M0[OX\A^81FBSSQEP&;0T5.!+V)F@NJJ<W\Q,3LB?&JH3\Z
M]_+2K654&YVB$ [OIR(8!Q$7!L$V4"_:3]]B(-7,2*@,*A#B%V!MH:05U'GU
M&)![.P8T*P+P1?]HEL#!"F9U7!T53(:W*R=7=05X/XAA]<=C7>+4A!W]:LAL
MW03'H1,5)\QI21%+6T<NG6K(Y.>G6Y O%SED)[1^0]H@]90O5! $7*'9:0;D
M>/M:T4GRQ=?4&0-H0[X9[\<C6[J,D5-'B?A(ZOE!W,D5&Q:I_09I)KM4^JFG
M915-99&]21,M"XAY[BZU#?!'TXQTX;@"<U.=FM]5B5_]FQ1NMG8O@=^1P;2R
M#,P0D7.C8VES",;FV&+[BU<L"7YEUS%O7D79LSNIO--5<0$S57 YE$ETQVOU
MR/VC>PE6CXH,/*6/OO>D?G2;A_>>7V3!"R_V$%G!4QL!Y[N;[GL+>3T+5&&&
M=<%:4*<;I7%H@CUN"F.1F-XW5F:3G)S<=[DRV>#6XDH&PWT&CEU;,B=DMC\4
MRK2@QTB,?%15/7S >O%&A]= 6Q:GVZ58AS3-AWL?]6"B= O,O*:-N.4B>@+"
M33Y]J2@TXFT:I*N]5I[0O3E!<EV%\[F#B ]@(NVOT49%!/>&=,T)Y%X+*Z5'
MY8AM2D!\#B,;1/7.9,T&.8#&'Y-FOPU#J-PQ_MIMY?Q#5WF7A]TH.SN:J^UY
M4!?$E]8?R"*4%7823[YY1N R?C_:/^M'LWISEMB?:/N\Z/C8^=AJW]B'IL"J
MG4U6X'@N'M'^>6Q/KQ9<.657O<E'K_SGXZ7#3P<8Q?W^^ZP#?\Y&&!K$_&PI
MNMEZYF70JIWHWT:P43[L![BR"KN9AT]%=W(2$!C./B93L)D39OA^QV5VPLL'
MWS<?+T3L'HG2[=,13@Y0HMZJWB&JYZ_"F :KP@YT7"=*A&M'+M]=J(Q&0V;%
M96RN?E1B<<N0 2-^9)B*Q43<NOEW5$E7XA]WLI5,J69)D<Q[#S7QJ>8+VT]_
M8'L,,%JC*UL%U4_7\UG)XYL8.Z_<CB_.NQJ3.<"PPQ"D;"H?QCDSAQKZ9(58
MZ#XH#40I'P-F$8CJ!>\V)KVSQ*2]7G3)<^$T'T%X]R[R+ZMC@ I@%NZW[@+V
M]7[8*3[/>PL97!<%W:#LN-RG,$>(?GU/_R_L2O]C_[^QU]Z]G:!Q0YN[,$C!
M62Y*U.$QX)015*VT.].N3^Y+S5_@'1XB$Y4124,8IYTG^EM9YR@L:V;=ED+A
M'QSR1+0#<,.7)L+F&&J59X.J@:Q*!QQB?A6_?LM"[Q@%9=SCW#J'3/._O.<G
M^ ,U6X+ Z5=\Z_;'H5IY0K8>O+-"'X@"51]D5 ]^IPI3A3=OGW6+^Y-G8#'=
M"_>2[-C5DMM3C-?BKY$M6XSW2]!'KX[SL=^J;/JBZMP BJ[-#B\S658R_J5=
MCI%9N[*O?>!OK*_.,0X=_\\>TP-\%G;!.W+AL$,<>($(UDMX.BJ-?4L7-F>Y
M^PC;%J$HLMO34O#IDY%<I4:EZ/,2?8,<KIM:$S>*'/?5P<$H)OF=: '%,MQ*
MR/Z?*DFSI^_B.J_,:7I9D<64XN$(CJ-H7-YL=SN8*.3<,J%L,;\1YN', ]9<
M2AE5JZW]%$5)'=6;UB?K^L$ ?7.L9Z'RM+&N NLOA_!4?M\0N#-Z?7Q7BGZL
MX,[M:Q_<EMKRXOW/ZNK2PR"P86 E-@)DCPQ7$!#$RP_:O#88^GT'9/L]LEP#
M]>M !$?7\JG01G8IY%/23C%J%E@RG/UA]I=2B858RH?1!?X%=55D(RHG%^E,
M:*140$U(K[S7JB1=K2#?,&4\GHE,B J,2 %U+^-V-Z[3AYG=J.'QIYNM#QA[
M@(E69<0H1Y_7+L]<OZ1/VJZAR;QHDB)1LVML1@[?56&5MWZTG.PAD&;-/ *1
M'K>ZV93#Z-V;U/5HH7>AR5^-UCT^4%*5N?%L!#$\/$RZLDEUV SG'[GNZ[BO
M+_3L/!>P7D(F$?99D89\L1.\A$%\_^:SA89HKU:OI%["ZACO).^/J.J:_&^)
M+)D%/Q=G \_U^3)L)=.2-2:FD^R(AD#6#<><MS#^Z([R<3L798CG0E9BRN?O
M_ $M!WW>5Z(JV)1=D=Q^-6!I<6#)(MDE_E6MJ<D+>\G1RL3B$N')RKK&RCW#
MX:P]%79]L ;L-NUO&;@<0;[H-U>":K40WID7(725S9<8CDHYGU%XP.O'Z?$C
MYA9[0LU="3V1+RR)[3&_;KYZG6-4.J::%G)7&Y@QEBYQV7*^P7%"? MKA)R"
M*0V"'\%;]4"OWAX#7DG'/EVMM][ZG367[CN!K$QQ*B-\4'^)Y(T+Z-2B>T>G
MN"J^?+26;2IO5_AQ(D/5-FG^-ODYSCO'KG4"N9$]3>^)I0?9 05@OTV;.@_?
M-SXK\K997_-\,A9SYR<(HT&O-Q*%9DL]E*;5(@"_LN55J"F<;...8,[>JAM#
M7@QCP\AO"/J>>M^Z:-#Q/(?1<:Q&.J5:+[A[7L8E+ZE J4G1*76O?K)O\QW\
M8K,8D43(QU-*NL.J'-VZ+*_7=3;5)AR6UY!$(P#  ($#@NUF LW'O+5SSR<_
MP\<?DKAT@]6["<INQ0X7W=+"8WNO' .LW3["<,I&%69VJ-.@V;@91A,1ZS&R
ML[+)A0=]A9:WJ*ND[YH)!ZU4,>(SP@GC<83W(:%Z1*BZL=Z1J9VQNV=P\]OU
M.P+EJ+,:Y.38!DL)R+P,).%<'2V:5?@CN!^18OBL??>H_Z+>QMT:9+GN&NC(
M1PK9BX,\V\#&@G$OP*'P<FS(9"N"WIU?6K^VXMFYVA!!SC1[36XJ>9/%=]97
M!MD/CX8#R6#20V*ICE4G9GH9Z;XB&C,><FI"GX&10<^<1:M4[@*C^%#KTLB[
MHTY+"[-1!'^'N76*+6M\8YV==,@7]\"M/' Z.3!"M'1AZ7][&;-YGE8X3NA?
M"7]1,J%:<W52G/<LW#1E.\]OW.@PN';&7W"/%JH0G(DB>1TOB&8D6S)H5&C*
M*L& Q^_4,4!/;&P6\=*: 5?*]S.VJEU7 )R4-_S.YM6!Q!Y3F%./CLB:B"U1
M=HUU$MN*P 7#1IJ%7NA)J>@GZ-]7.G55!;23BL<<[5$9^V=19<3NMJ-]N]T9
MLUX[65*60="N)/@:>CF/,#GU7Z$Z_U=[])NK@&[C/I,Z]S^6M<_]^!H!V$<$
M' .J;*- MKT'U.X1G@4=FU_U'H.WS7KVM_,&8E2B_=WFP#''@//' ">+TRI<
MG89W,):-O1\BUCI<Q>&^W$? ;"OD0S"B4IS=P]K&\%GBRW?/CX+N;_M?.M%B
M;%4F:^'<=0J]X;_QP%#T\CTVBM0H?%+M,)2DW;//L5?':QS4?K.5(5\U<3]V
M<_B$0 O/T!9W-F'^O4)8)4<'1%#AR.(K28:TL3E%RZ;E,!Y(,":ZD&R(CF3]
M697'_3IC0KP9VNX=KJJJFP,X_08G2R7*.MT D3-B0U4:>@FOT(*]="=M7N>.
MMN)YU>?MRX&+<!]@K6HH Z9.Z=_KT.\8L+GR-[GI<)*"MSQ4):\YK>@M#MY=
MR?/AR98=]>?M[W]\<6Z6'J3[U$%+44JN\CN/'?;I;I6?(HEG;HDDTQ?[_!XQ
M_^(7KR7?-OAW;^RWLAE*>F>/J* LFJI^'U[/8(O[_OKW6K';:':__GH>KM.;
MG_W4(7#+B,2W>@P0:!1%783QRA>CD_7]<\T@T'-5\EU:X.V?2B\71(*"P"<Z
MBE9N0K*:0K(/.H5BU,5^M.=?W3VW+[\)*M?;\B^D]C5?-_/YA0D-W@$J&)K5
M?4#\L>/*]A+,(BBC!^%5#)O96=01*HM>&)!5N#K-N#;L";[C07=!J6P@*.35
MSLC!069)?]!J016_TL(C5.K8.K?D=LE4MX2!%#HZ],REIP/_O,9]2C)Q$^.X
M:,2YV\/<P2(4\Y=C<93B&1Z*."4([A!+M,BX$O/S:.XZWC,B:.N<KNI44*RB
M)@U77^1G_=X'LQU#MV.!ZP@FLI55Z2I:$I)OMWM>T&6PZ46HAV"@BBC=(>3!
M6#9:@O,MU9!Z0^7YZ,\_[00M2H'<,2 :=JX*+4>XU"]P;<1!>ZGDVS9H^O<C
MT )8?6*Z&^Z0H#$9UZ66Z7 BY:KV?^*C^A_[[VGZTQ::UDZ[/R:MHMXD&-@T
M5BQT=UF(M&2PC\H[FAZ)\S.I!^?5U[KM!F0+D?9;^/ODTCS_^NGRP7QY,ZFD
M*5ZYE[!(*:]$3"#F=+/FH_7'M";O'.FF-S#[J:H^/Y@D/_$[M4X/XR0;$?-*
MH/;$X$+O[ Z%>+ ]IK++[IM5V\K7_,WL3+KWEN&D=S TIF8K&!^S8%J[)^DN
M?OGEX"83M'I@90=HY%3L[_O2Q5(6#$]8*F+62X7S8GM_4+7PO-$Y&58J,?S'
M@(IAV#K5=DP/G6>]3 MC.3:!:?^9C<]('9<WI]N$K^BNAX= Y?-Z"^PQGP+O
M?E5KB]GN)K[0%"*<SC70-Q\:'XKF'DW-T5+4:A"J<FR*EX2R$<7G@1BF>57$
MG/.%"?GEO'S5P1'-TW#V> 7<UZAX_R;( >,8=JZ&?*F?X+5W8_< R0N1V6VA
MKQ_-H]N.R;WG :) O[S$U013@?!66E9M"CQTM+Z.*5L77S7A?U?#D]-U^UIL
M_?V\!/3[A(0(<B>1@B=U("H1'458=N^O^%)DZ>>P;,OKE;$@"1>D-3!E!PS:
M67XA4?D5M6M+!8^18'57YHC23'WB>C+YE6:%,O!066HE\1LE$_X6S$8=!EXJ
M;=293UNN;_R<&,(QSWMWK\,%^1(D.U/K2Q*DGB^@A2B)(R G9Q9+;Z0I6@BW
M$[3E9/I;I"9,RP,N1L&E-3]GBNMA4.Q\2)NLQ4]XR=;!WW-C7\T[BI@F=,!8
M1Z2"$[25']PKXHY(4O=OO/6R9 \@4W-EN4G,>U-"K%C"(G4(FX6O+>7J%Y^U
M1A@%)2KZ_=;)Q<#MT4V-6RME^"UV?<OWN]?^G;6N%%$>2N;J;;D#IJ^<!LV_
MR&BRGO?GZ7N9"N%]41MJ,)[I#$[QK+#:SF H@:D/FGO_HI=X_MQ^?_Q(EV?^
M5_OU(K%:SJ8EF]1ZS\GE>J :O%63YD/]D),-"ZF0GM='EN^S6QPJ([6NR!5P
M7ZVHH]M1!"Q4B[>ZIPMO6([,EI?5I.[NKG6\:V?DBM=0 ="5>"(JT)N3\UB,
M7_>[50&VX3>-Z=_17,R[DQ.Y[RPU5QG6(?L5+: S5&::VQ6&\7;/ZW& 'Q81
M?WKCD@VN^C6$R_SR+(/WTL +I%0V7I.C%\RMR4 ?^@TI%0<NV+8VO_?91>!Z
M+B0VOV"P:<705/I1B=214*6IU(]=Z?%NZOE3+.EY#Q?THB^WYZT1U@C?!GF<
M)5_<_[V1<OL6:-Q2CR\C9&<KG-8LGL-0YF^H]]3S9A.39A-Y$VDF,?3&DB/O
M#,<DK$!;U7[X#,AR_R2(RBB[H(?9,TCJ^>9(UW:I;E<NTHYU1],F_>C'S)3H
M?K_\WJB5IF2!J7VUXO1^K#H5/K:2E>*2Q":9)5$1/#_']:T0-:\W2$F<M)V0
MJFG4GO?7[C)=ZLHK EO8FP9/<J7.+S\3BF=;U]M=%8MF-ZI-3(S[$Y5S4^NG
M[E;P/\@*&?1P-;,UD; [&WIY1,WV^IHP9T&+'?Y/] 16MP&8\%=B,BZV$WBV
M\;X[DF-5*2_TX(+3Q9D'5C8"F?N@]_(D'UI??8H#AI!ODAB\;9\.9-?$[YG;
M.7F8?=)?UG['%Z*I M.K/[4JSD!EZIG58]G ?D\J*+%_BHEV4T-5. K8 +2;
MM<,6$MD/KG8,R>AW_V2U_S.^$KV@BNS-V5H9IT3D!7^/9:&U%0D^X^JG;>**
MF1IK/JRQ/#(K(,+5V8T&@3'_PH5M.E"U@6"">/KFI/WQ2G58\Z"#>SX:OXUH
M>?_"K@)>Z)R5M5[\\\.7-ZE3E"EB-@ZD3D$VLWJ;R)LU]!K?F5Q_ +$H$D\X
M;VC^_2I=;49ZL ^6K(28PU+HR:^. >_?P?&I1UPM27%KU#,#<\%GWG7GF07K
MC_L\AABB;B:6;L)A3QORN"0WD8? V\> ]@(J;789 '<!B5P,QP#N;"J_'FZ'
M&DB]=0QHJ041^_SEU;6J8E/@<R/' %HQ5Z476,E,0<> J$':Y[R3&ZIJ\"OP
M67,@V:8Y%=F/((IUD[F&M6ECWAPV4"_2OM$?K-0=LUW5)Z!B>:](Q4/BP4ZJ
M\8<'LL[7K#Y7?(EMBG*Y7ZE2\<]O!>+6X:'P?2Y\*)6^]1C0!5D$3FQ069J(
M5GBV^3'$'#P,>X%L@DN2-#">"S5H1IFM7I>:?/BX^<F3N*#1D$V640P5>PS
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MH30\)1>"5@;9(KV#GE;&S%/7-RL_>SWMDN-FY-!JN=O3+8RZT<[Q\J=G^9?
M>SP4%LIGT.QW 6[<2MNTK ;^(*:,I2![\L;7&>-)2I;SB[.C-MST9F^Y%Q<7
M\4,!RGE4QFP2']&+X(J6 UWR-F#=I(ATN#955O/V?F,KW)'XL,L>TY'A-N "
M%D0/@&O06RB1+?A\DZHXTTUW[(55Z]3?W+K6J1I7[,#?A=X!5E4@*YC_I#P@
MGDETQ&N#B>KS=P^<6=:->!P7W[ MU6PO"<3DA0#US2DT9%/3NH.9;*%!MF-
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M7Z=22B_+^USL.B?@'I7MZ=()\#4B<QI1&6\N($_T&3>]<$9S7 $PH=*J!9
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MH*W #KSAZ$ 529(.OJUW>(3D,O&/\%53_6T!TQL%NDJED&CS2ZM2,A=SSH:
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M3-\?H\4<6#"\]4RSH*;U/%: :*AUI<_?T;&PE9M4^+U"\YI BJSF0:=W'44
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MQ]@L3Y53F#L:PJ0JAC,)"J?]'E6]4K$P24K5O[L,G*_ZPA&/O8U[?9<24':
MLP(WN4:K5C7VABMI7!P0LTL9K^QAA^E]0DS'A&%6[GQUS";(8]L+\,GM^S3@
MR'-'V?(#5F6@5 %%)K<V[C></?,'9&MKP@1KCR"[4(Z7$#K>CZ@H3@IZB#W
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M 51;F F-599!ZMB&X! D+SHFH]/MQ:RP#'C7D>/780+BP/7J+FTM/3BAL_$
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MF%*U%9F.KH+GHY <R(539(&1ZKG- 1G0Y"W$\4_K2P$_'&O4(,M2[0,AWG3
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MB/IS[5&=@IFJO?X;ZU +;=I7\"PW.\5I](%NL<WEJ,O3=S+] '^^BA%52)O
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M%\N+W@5T]3D)"%[X"O&0OX!L"I 6((V7T %=SF1:LST=\+,/4A:_B&YU]5]
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M'YH-;D6@\<#=J5]  M@*CJO;4&!G>([BPFZLG=@EY:ZGWX\\U3XXJ.SVTMZ
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M&T/L#.'L7!^ZE(3O)8=W1$FNXA OLXCF47+D;QO-[(BM7_LK.HFEF344X'<
MRX$FF&9,_%/'G!S_3QG2<GT<>,MO?F1P4G+2+7W"[NI+7BG.J,XC]:7#DEW\
M)]S#M/FY"6+[K<F>GQUY)<D^G#&R,0:MO_,9O5M?,C:&*<'XR-_478B:&SZV
M!% K3_K-M$OR5QE2>*,O,61[&D4?"E^MT%0,&Z$"SJ.?AP0^Q47%E!Q"H=Z\
MDJ/*V_.LJK*)BF:2.[K/Z?M$'(-XW[F9VYL&L^+T:=B/(QGB"F_2A+MDP 77
MO$DR.-^8P/+; RY(SX"S'Z./B\<S<_SLR*$,, MSA02K3:T1M]VBE939O3\Z
MZ;R/,-E/O)F^LC\D(T%.1,1$]P)LU*LHY;E5C/QZ:G)[<U \8O?*XGKX;,-W
M])T&X>(U--9(>B(V]-8C66M"MN&C:Y?9\&.7865(XH4 07F$%N04H;QY;)8)
M)XE/+K@S>C3IVWMZ('G@W6*2P[#0?.R9GA,B)X5Y[&\7XB'X\]VS^HO2EVSL
M1,/QD:_;?T^T.AUDM92CF%DN<3?/+PE!%^O(?R/;P91Q%/< A:,%NPL9+CJP
M-;E?FVYPIM:+#Z*GD'"%I2,!\R520^8YAP&^G_9KHT#G9BK@;"68"Z9YJRYT
M)>K%F,EZ68]3Y(8(/^*IQT?]EV"1\*%3: WH83=^@UQ.XL=FSR=%*TR%.H"'
M27K%C[N<'1T\9)*;WK/$")R+KOT3<H#L'/2&6_V3Q"HQCK:73O*&L1#&G/9[
MNK]MOJBR6 /_I@>F@']4J6SQ%G8\%_9L X3:TL"3.N$"2A 7FI9846.Z?C)_
M?K9">\GRUV\0B0U^P!Y\K(NBD#_"C%R(]I3.R;1POX*+;M8&X5MR\D#$JXP@
MGZFW%HF_0Z$8('>@TWY3V#7TH,?B\UV%B=E91V&@W&?GM> D>W%^^;7_5I6,
M>Q-1RMY&8WJ3N0K1)!\%E-V70N#69E.F4J?NT.$Y'H2/G=[]% 4I)#]7,I/C
MTY%[2\#FEYK9_R007*$"WE@O?(F*+<YN0T9GR=K()6H.7*2SAT_>>0FO@R[7
MD0%C7\%3TOC3L0LR9=!TVY]OS^5*N;4SB9'S_RP><A]3SNG=T4AR/=-U<^!:
M0\0SY80<,Y^UG'C*>V(V5KZ%3SH<Q4[P &.W'NEE:^?=<8N_S?#^/GW#8J%2
M .=T"A3[HS$5([U]C+.81[P>:SEAC\FD&:P2'H*]%1:BP\'"]W)>K<F_&G\D
M/(B>_TFYU ]3(QI9=F=W>+#MY.86_RD6N,P*;HAPHL^6<W.87M787.8;PB7%
M'T*B-44;1OWJB5_ IFBX7,BGZ?+.L,:7:X!Y&FIT^@<0,A1S6M5@5RJ=\R>K
MIHHU?6LC&@4OR5&^6LQ JH7B&#OFQJD ;5Q5)LIWTE4;WN#=+B9D$TXAWH#/
M*V)M0\?^:8RC +I(!3B#+P2R/_)++H)U\L"5(S&7I!B_R:UNZ##<)9@HF*?%
MPV1!KQLL"YX?,0WT?I]NK*<?8_%D7Y"!\_7^UW9]ZF,; 21.]$(6KN,7A&56
M7Y18+*WJU\VYSPG\_9BL19;8:T>UTVAF0-(GBE8O@,_V_.Z6TRN8*O0]OB0L
M?K+;A[F]$/:%/EG'"+N].E41:%-6+C[>ZMNY@/Q?)]7_'P;R!OD;"<[X2EVQ
M&,H#P6U^'>_RN])G=E>JY1#X/KA F1L'(G'K+<!)5ZF <JF&TGLZ'=$E']IE
M$8W\H%U&,K&D!WWV\+.9*K!7!"T(IX^2;P^U8+2X0.FQ/IX"MY+*Q@X+DRY
MJ],CAB,-"M=G@VRH $Y9D?0"'6[RN93[G12[=QD!3W6X3/XCV&L6@;V' +1@
MD%$4&5SO0I&=3YQR3MAK\;00F8/CCP4G%DU/#=[^D.OQ9"Q #G@ RRC=<*Q!
MMYL&:."0S>'A/2:*8OJ^'&BA'K<=>VQWL^ Z!O,ZJLW\/DABAA(UX6FFW,)M
M C3!9#,;K$*EAPFW%GE:52@W8<9C#7J>/=:/41^6M:B #\][[DL/6-!C2]QC
M)=;7A^(O9PFFE!T#A8US?A@.9Q;7H\T5DR&[-ZJ'35Y.*O^UWO]UG[Q5\2>/
M&,<@V'O(-P8+B+B3ZMB=;#8/3/U3[MJG'8CK()DC,S IK &)/R:@J(!+<)?&
M,(SC_DW?(%!9T2_UJW?OP?^ 92B*AWE;NZ?A92 29\8CW+4>J%#>#ZO> BYW
MWIRT(R,:[GIYX^=).FFMIO8#?D'_NW^*R\>&Q.!ZSA3P\%CG$A6P'?1=6(!R
MB;(#DMPF^VG.J5,!]EW86F]"'K$+1N$GH:^\,]()]<+]8X):S9Y. J=UJ-[8
MY(>765'H0E-?+07%K< 7:XO2;SPK*3)U=/I$/D\PG_S3UZ(*LPK6$XSW'XCS
MBW]Z-T1WVJ%*%O(1@;6%LIV;6D2\^5YVOJ31*[>+G%<!:Y?97+I(6B85-O_M
MY=*DAY*#\6"?:0+[83;=N5,EG5<;*F*WO]K]3KA\S33XG$07*11';T7(7>CN
M#6CE>S]:7 A1.MYQ%RA'?\73_UR3P'@+<;8^\9JS+%!80$+M=LA4@,9LWMJT
M?OM'FPZIQ_=-)U,K=Z$2_N5C5=W:0J\]Q4L6\9X$D ]N;O%A.";#ST/J9%ZQ
M>_MWVZF]K=D91A*3Q;1Y,8OIC&6]^/>Y;R"-EH$OKLG9AG;&+M+FH84T04K!
M7DO:ZB)>AZ(O'(Z3XHJ-&1NF%U<,GN^52H$F0SNF99"O45<"-X@+'HF*D/.N
M#P?M-HZD?:0>^N^HL&B\>ZKWDQM?3>*&+Y"KPQNX,7.1?!(WSW_,KJV/.:=>
M']B1=AH6C"EC_XI\ UT)=(K?O/'IB^.N67"0SO.TPPF@==M(EM;@;W&0=^S8
M'P]S*J!D2T*[.?/"B'K  K^MF,[0KJ*A\7&K/[ZJE/?:IZ3;/U1'0T.7:9L6
M[C^P[HO3E$/5G$?5.^>U5[W"U2E_BO:'^/0O5H:H5($V'NLO&*-O3*TZ_.KR
MGD,NNF $:H,RJ0 )\LESV#Z.G<(\@8O#P%]#6E6KP]W;,UCM?%=F6O>L1>6L
M[MJ9THUI2+2>6!S8K95E2X@[/GW--!]+ND NJG"CV9,5JTDW8:!EMHMCUK6)
M_7=]^+[ZO,SKMWC53-*WD'NW/AK[\,:1166]:^BM2Y[% C^X-OHS7 T+U>SP
MC2/%>4M!VUQ&D"<P<=,/56406YW3LA5##S8%GF??W.H L'O?XQ8,M:2=KYK\
MJ:-U-\8[L,^\FBV+8-LQT1I'K,\H4]YL8JH5ZW^GV/+)87W^YV#K\*3$;BA/
M;V:BR8>1C@5,1&X#8KH.G:(QA^&)4$ 0Q(!;42$+DFX.'ERN T7E8OPK-8Z:
MAF7$R]T<&U8UX(D\"DNNQ\+52<8V:VN(Z$$9F_$EQK=F,>1IG ._IU<-0$:E
M2W&1"L :]4VZH-1(SAD&0SM\X',$V_31:?J]:3!BMOOX9?;0TT/DE\T5&8%;
M8)[(][ VNV*+WM#/(=?6ZF!U0,@G+]L'%Z647Q1/)G!WNPU3 9]01R&@]&FB
M ;Z!IE'O!,(79M/$XC7/V3Y^/&,G-@DO&WSD2\0&G3FSSJNR?A3\A(6$P<V]
M5$1&"EVO&U#7^F[GPE<<MY4^N2+/GW4BU)&OT1:J3U0,FQ"2(7\\U.$S')NJ
MT!=0;/_KUELZE""W:Q:^#NP-+< C7\]A3>%TY"C3\D@@AU6K?\<5#M=TE\VZ
M6Y>DA1X&_L[40O)S1[0O@X_&"@R./VR.P.T:V=EE,"_RHE.+WT^QQV[^>QW"
MG;S%4.Z#@+\5H4X/XZJW,GR\"K0%,D6PGO8F9E5)HA,AS,.A+92Q&;%<V*+M
M.UFN3>W,C#J00*_<9SO;Z$ ;MUO,)4G[8*=_Z]'WF<O(V'*B-W^FQ<.#*W7:
M1K6#RZC .?GCO#A]BOYENMLB4V4W ^$M1[,28Y(*,TJCT.T[)V:O9YG2?'YO
M>0*X3]X392B_9VE&Z^MG)+[4!4AK=YRENLU31A_ ]K,M36NHX^[UI8L"B2'T
MIO"G'N/[+>B?SLUJR#@$5^;L6*N^RZJ(SQ,JP*&U);H_(//!JPYA94$KU!5R
M-?S%M@^^D_!U\OU$2E_+B=?SB@2%6UUNO.JU@DLO3H%_"A:N;@QG:F9GZT^F
M$Q#P:V1X$]E'NNDIP8!1H$\F]H/<M\8;'EO2JRF[$QY#(96WMDN)/H$9^"Y<
M]9? 01<4;ZD/.2-'EPJH?P/OTZ,<1 T?K,E(M*P5L[,%ZIGA,K/PAD!#U(A4
MU8<]MR<N$'H4%Q^^P#A/E^6\^3U2MV!2FY/R)WLO.9\"L<+-O;VM#]%]WXI<
M@VU'8_(-H4$>&KDC]5P?>-]FM_\M/\-F45RM;.4RD1AK_MHL1>D9#8D[*M_0
MN\,6\OUON*4283^;P$/A&-<4#7SK0E0O%>Y%;5M,SH>+GT0N-(C&_LGE\]-4
M0/Q0Q09%2IP-B"P0]WE^;&UAYR\V?*CV!6I4T]!0D[ZSMZ%]<ZAG>>E35Y>3
M0Y?(D:*5QZ'A@<+&(#;MM5]2=!T9E?1UO3H=50#SUX)".5+TP3^YW7)*_@1[
M?='/;U.:.G1#] >\.0<3S(:/:TY1 3K7GIM)LT[I.V(2I'A-<WY.:/$7;!25
MY@MCKY:,+4O[$/?2?C6>?\02OB]S5Z!<*%8M]> ;RIWV"FHHH\)XJ;_."M(]
M7(6\WKFB.A^7]$>PL+V-1=E\(8Q!->E,<M9Q+TZ-<NX'SN(UW-T0W*0$.D<"
M!F'1!CA+[/ZF![YOFS%!A,/@\E/Q.,_0'LT';AT"*VB7KXW5C96)"[//5RH_
MG2Y]4*1T[XWC8Z&/E\/3*0XD>FS]_)]*&D_0X_S:D3@'S D,.MQ@3)&K&BA1
M'#]381]WL7VL4W(E*,5-;I'W<CBD$(XUA$Q64_CZ*$S<0?DVTT$G8V]($B&8
M+P_<ISOQI>_B-%?8KZ'YF/76/@Y+I@M?KJN4+6CRDMMFW/QL&J/@K;-R,[G"
M^>W&+^3J(#H#0;B"(%T(,:4=_"NE$W+^@.RST!=#XL'NZN#HKF<]7XM/3\S#
MW[/NJV%KT17>&S[W-?)J8S:%B1[7UY')-H!V]9A8;;43R6C-Y"7 O\Y5I:'\
MT_EY,2D&09I]-2EO:PR;>.A%/C]+9_0Y<O$[ZQR38UUHGO#P;,R['PB??[;3
MMB*2W "?,V=%?UQ 9P )5]A)%^II6NTU(NP/B%/!T&$!'4-BQ\[='\UR.7#C
MYD@LR/](IR_&OE<!!=(]#%HM#DDC\>-P<1T()I1XV""BW+U^P:7!$ -B" PQ
M206;J!EX./IX7(E(G_/2M#&^;F_DR=RDOG_;ACS.][X@ ;%M'L$U__.+4OC:
M0R]C R\!CMV4Q]G@7;4(2,_8OAJ-+!JTK9AL0+"F?4PD"RRE&B?<*L1*<,[:
M\!_C"?9/N:"OJ/$@1CTJ&;@LFV/_L&$IWJ(F;(B//0D]7PK"6DJ"\5;U.'PI
M!OX&=-8A%9PRV]L<U#_1&NO^P.9F>4,$8.[MU\]/_M;=6F08OJ4MT\OZRT^V
M$PA,SHG%,R]=%VQK2)$VU3?[&'I;!;F*;I\[J^Y !9Q9@S>9:G(2G#%CK7".
MP%3,7*M:H5GCD.)%C@[?E#]O#59O(^JE,NW+E/G+F/[(VT5\)]@!":))),'K
M]OU(//PU149'I/0G@T/B).[L^\4"SJD"X2H<[4K^$)]=A4OTA?^A C+#['>I
M )1/NFCCZXG7W5X>9X5>ZYLQDWK#N"F_K'Y3AN!82^1D'#X;79Y"U"8H.H1Z
MY8D4[)%+E">93N';IUST.USD9U%F!'[B(TH?%5 -CJ%(P+3)%9I78+<;<=^_
MB43].@G[PG: /SG?HGJI!U1_UUS\FYSL7OEY ]IUD+7H:YX]C;(_YV,G1I,U
M%PECQ;#3Y'"4=.!8TTEN<5)L@Q@FH]C L.8Z=]]$7H*6N:RRXXM@F:MH;I"3
M-.&F=)M')!I[9S?.2&_!T-H(QQ@!,W##P-D(L1L6;G?^_,89.(<\VTV"OA#;
MB6)1-C(CT=$HK8MCJ"9= +5!*J;G^-0MOI-NX_0BW"L;31[NM[B<H+Y<N3EZ
M9,*Y<F]/=##@0JT('X// 9+"-D^N"1,-FX.4NM<OLL>F'VA>Q3&DQ8@,86KC
M'E:7,@-B'DMU<IS? XLXH0Z0W4""@C/%J&D!3A00I0(&KD,*AKFXUD!C><3F
MC(?AY&!X@S@]+N^_5CXS5T0<LT'@8SWH$]X?![Q_O]73K:#>_O7XN<<APV^=
M#_1HNV 8BM%_V+D,4DAW#]5P.+2;*>V%S<4'4TP?,8[/52&VK!U*UN1@VH0@
M@5L7JSGB"J<DP.DJ;^./L:^VNXS&D#9C'8H'45O21"=0TQ=ST%E"BG-:<UI?
MU77^%4JOOWHR%?"@2SW)&.QCR[B]3.33PR#5.E#G(D3[=Z@ >+[55$*WJS5"
M198*N#FEHKS>]^*1Q:>]4"ZC_Q))Q/@MC'8@H1(JP!D1B[<:=D2 /\:%ZK+B
M%$3VP@J'A:9/Q@8A6"/(RU'$>1C0&0=NH7-/W5J;#+\+6ER8CL^A LPN,8Z+
M;T.XQB;FL(;@1"PA57=8DW=S\":V 2R5?FU)W8U2)10X_Z5E)BF7WC8I_KGP
MU49.?"Z!%[1%QH4;#;!4XWWCW7W7P:2*:H>]^".)WP@_Q55?)NX[B6<TW_V[
M?\JI\8C"O$F\.DD9A?-(N?G%.$>UI NB)ST:/DR)++TM./_T]TZ7BN"IS,.C
MOD3X_ <J@ EF-K_N.P5BIR$"6R;\U)SU XHO./[,"P1B6LGG-O SO-2Y?95P
M!3=F6/?A3IW=C^9FLD][AS T5-LA\U?Z(9APXU:37S_,XSMALEE1*7@C-!.7
M#93.#%_VAD_= 5 !WBA/0AX6OX^YU9H ;;'HI7SZ9MM87D<%7%0Q)YD6X'M#
MV[ I%."4"5ZHKA_Y[ (TV$:T]R-Y*9.[1XYNYXU4R.=^XZTPN)&)*Q_LQ)#<
MECOLQ)]AR<?[]E#/V"QJ7HN;[73$?RLL!+2&-]V@B,>Q\VQFLM4]&:TK KI5
MZQ+KAY;?AEI:PAF0%\@E83Q40',V^6N#3JZ>4+>^%-M,P=9 ]SYNZU+9W]!7
MSGGI5GT4%\D!N]-XE@///RS'BNV<DW">8@1%A&K3V-J<$' Q+Y?@T''Q1MF=
M;CSS,OVN[ES#&XI:YJL#S;]F\[\L__1)@M?\$2$*QZZ%)?F<#5+LO7.6X5U\
M=$_9C3,D^70R#)M$XIS# ",:F(4B9YD'%-EGF)8;ZZLMD2(OO&==CH<1^'MM
M@#"%L3IXDQKE&B)JKB(1X2&2<9.DQ;F^_XSTX]YLU&8M[9I?F0.W*[$7AO O
MR-F*R+/K>_JBZ3&"RQ^3J]6]#%+RP=XR04A%[%CT-2PB^H!L+#CKG^$C./AD
M/B6>'Y@H>UN()C$9) D^M <!V>:1RN4*<2/IO4AS?/E+7LJL8_Y4F-_^2.@0
M[3? ?@<"@J@2:-'^(<,)*I8P\8M8"A:RH9R+E<#\]4MNK0Q[7*VN3M3/^]+J
MU1[NHR8$H*]5W!:BB<+7 20[++RE"J=S%/',5E69-'%5/WSVSA?]0+V>FMUU
M&_16\N(7( :Y+3G?&V WJ1!ZR\A2RC;-,^%^6:3P^%LH7KL=>(DD@4%&6@B)
MH<84*K''52XZ<Y/<W[YX!II\5@I^\D@86R00*V'2/EE<4K^H87_2SNGA$!2J
MCL=QA'-Y",N5:+Q[9>G[+W],/J5=4\V#=I_5$1[J?5+\A<B?O]64/U[Z!<**
M,F*14@5%BM<K0@C2DE-N;3EQ"GH#[R*!^5QTQ +L(+&W+)W]7= SN5=S\9S'
M2:-UKGN0B9;VGX3JEA/1W+,7X\R'!H975=2T*$_1JH<_&"6;_TLTZ?^._QN#
M 73>-C15M\:SR?HI"_A!)D.8#170](QR6>&D([Q!*NE]Y'5%_=L:O#'Q] 0
M]*![07(U.;LH)"#HS>I4//UQ,B1N#FL$$KJ5!(>".65"^UVDTE] /V_)BNN1
MQCDA3YN4(=!/-Y*>BU)"I'L(\/->F1W7?4</1=*Z7*D X5;Q;['DMR2!_]SU
M;0?DU!?9B_-9[(AHT.1.5R,26EOAIUV]>T(C&4(-::P61TC,,\(FA6]_<DB<
MO36\<G>-GI/O^LF+3J'#OX58+Z. 4FA<MQ7N=/*.(?U#CBSAA/V4AI $1'$0
M>'L31X>Z2AE!2=9=\(ALWR2J7IE0C^"0 6*OB>&0J064$42[H'@S%8 _0,\K
M'@'=#,A)D7F*.'O1-'(]D' =^6GQP$@G]"GN7THPE(U(%_;K)&J[>"%4/W<8
M<A<[&_73;E8D9"EY2LT^7HCY\@7]>;K-5W8%1$]XT]4IO _!S&=1FGES+'T%
MD>NFFI [?,4I5JX)UBIQ]%+DF;_ P1_UV(D=E@_7GZR"0J<, T(DMOU#W@4&
MR!2'!Y[X[AK:SF[@K2NJ78 7QHRP)IBEN8N:4H$!+1_65_0+(7K,-GZW T 4
MU6*;&A5D(7H^&<%*!6 D"$<%@:_O'4T1W#M<!4(G5EY<H:% (RI =>I6>Z@)
M@PD'J6!JS)$POMJ)!=EV#+;XOGM/O@5_[9P-;[()NZ*%D8Z:Y2"$Y.E7\2K-
M&%Q2+Y+)3V3_15JDT$,8QLHI<U0 )QKC$C9,$:E)!,OU&23[3KG[5-H#9:@
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M$-.Q<'[20&['G%3(?@ <"?/[,$=6OLJ6[\R[)*V$26Q//Z<I1O( 7QPI@O>
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M3'0?NEJ'5PS?<V/K\:!56"HYSL_Q.D[(<$3/VU<T*!Z/7^9$.+%>=X%ZS+E
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MD$8-_@@#2#&SQ;;.4,U@D8U^I"WCS3AA4/C(1Z@=:6XV)F;J-LRKU2('FT
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MII(@NM8PZ]@E(-X4%SW7TJ#^E\+\XC8$Q/ZMIIZU;T)FQHQV(B=8'3+7.43
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M70_#TPH[38BGL0Q,%T.:XA5#Y-F,=89G(K]<6GPA7]G\QNSD*=Z53WX8K3O
MKQ6FH>%UTK!IU,55/HW<T]6#<AU3V%E9RJU\9OPFN[NV0]_Q&)2[_4N$2]4.
M^>,W B/&XE@&?>V5,E@D-^9KDUY)=\A]Z1WM*[==OG'MX\:"])\8@8@AP0<_
M*.SR9&VR'+PMG8V:2@,^6ZFJT4$BOA_<P:TJWKY9;M6IV_/AQ7:>WYG;MT]Y
M>D)BJ+7HES&L%#>2>B%N=$7!PBU<+O#9K777C1?F%O;:8IWQCLT2MKS*(I4
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M][1SE!O#<FQBQN5#=<^*+=5338>W3S-]OU]KH<<RS9;S5F5^9'X[4@J%+@;
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MZ603"^_!51J]1S@!0]]8]"85/&OWZY<:+TJ_4S;6$_/U07RJ@Y)Z&WO [!&
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M8A@[@EJ"F([3N$1:R49'-IR?=*JQR0Q .EFRO *.U23Z=]_SX "^EK*1!:>
M+M!XCZE[G:5/!BE)KZY_#Z+04K4O_?G%LDY P;KNJ884:O(1@.X9>.#=%C55
M,3[$>CY=*:^<B5*(4_E@$(5M8-%*2+HOF>P\T (\A9C^AF9/TAU^/1O2<HG
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M0CY6S J3'E?XM40#>!T"ZFT,/4SVI.I#HH"5J!>0R@W[=3W__$4AZ]6]XVC
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M=87+HPJTO/RFBWM_(D!Y(7UK&05P%]B0SO'WE2/T\2H;=?JYR;%R>-.#'09
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M[J'1\Y!I'J))VGWZ+]47"B1QFWX@ #0SBXA@ '@VO=:H5EPQ.J)3DZ"T!8]
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M8EI8$[[8P0"T&O9D9C)?_R[P.XK*P]X,9\K@I<JGL"9,8)U+_E(5_'%BA69
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MX1I*Z$A_Y$E4L_$.8GR65$%<7*LI-/*=H7F;2(=%<?BY7#WEY6VX7,,%#[A
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M4HDB!"JP<=B@BE[TUVX109<BDA]Y@MF00*J&Y#M9N.-X_IC\6QFY.*'N@4/
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M[,=1,1AD0)"#X=:T$MDE2E?"T(75A.,IM6-B:CP9MAO6Q=/)JV#%>H&PD4/
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M05J16H@./##O;('>O63Y:UD;NV:E(3:485;4C9%+,"\Q+7'HNK@PVQ(+L@.
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MC[I>;[O2I5,<.5@#[?^\G^ >^+3N8A I&N\Y?VWU67@?G^8HK)GP4T-@Y7/
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M*O0+)IZICPO,-G);9!\DA=?DSO]0&+DQ1UUB?@<:+&/'B+7R/9KC2LYY9X?
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M>G);RH_$.1:)S#T?98DNNU^G;:BXM16$)JN+$^($-&2)?V$S?VD K",-$%D
M'5XXL%2CG]C[?!H@"G$VKP%5>0>TOPHBTBFO4 G)CK^V3)I\(>>0!F#1H^2C
M_E;[TQD@@PX-P*;S;\!X&B!O> E%9@*2#?PEV6&O7L#6^D$X#NI]2D4"#0 ?
MH0%^P8_A ?]2#E&NP(2%ZH3M*=Q16V!A)X)_P4F1J\SKQWV1WX[?0X6ES*@V
M9A5TS+_[VZ!]!,4$6YRB <*!N%3H!%(*_RJ&A+CX5]PM-[TT7<;C_N$E'O+F
MT2U=<@FN7(UP=T" ]ZJQL?[#4NCFKZO%>YWFU5E9F;-)T;<0<1K+XAG$5+>1
M=5SC@<E,2Y?L/P*K_XRJ%/Y]".@^/PL2^@33O"<YV$[W]/!V%"Z&.J&A4#M3
M-X!4]*<!RGM%!I<:FW.0R71M+/7W(P$)Y?7-,]7.)R'-BTN[;^YS47L@"N #
M9GVKZ<5;_SJ(.L-DU@Y"XNUMX$Y].RWH179CK4"'I/_]L?)?4.V9_H:$;F %
M/%:.Q\K+:FZN@VV8=UX!,E '7BL+J:"_=\%;%D:1G;X^GK+J<PGZG R:DZH$
M_BX+[N8:?=LG*M_\W/Y(GNJ ]E"WYY]G7ZD>RS\JI.ITREKT%#Z>V)>:*IOL
M6AI.#SN)=O4#5M>%\[6"JEEBJT>:S 5L,$.!0K^M0?@)CG;T\'!QL6F<UKCH
M$5SZ8]ZZ6:IHLQ7$JV(=6*G8_9XD!QV:%\"GI)4%N'SO-]E@[SIZ3[50<(B;
M\8K%9U"LT*#%$L@9;SB#;FD[=@7YQ79?:!13_=E:CXB]P_,@8I!'@FN!@]B@
MK8Q@4<(T2]F9R[LH9'D/[S2I\QSP #F69!I-\N_?_+9;'*AJN3$ %=7%1V*%
M%[B0$O[)G> K!<W4&V/?QX2CF,UEA3A_G;QN:+R%"+SR)/J#KR50T>1;H:BR
MV]Q"R44=Z[]]%$RTI5@4Z*&&T%WBU+\\VJHQ$-KFF=.G6=<-\T??]WZ??!!&
MK_DK<YSPT-]NM$"B(#_1,6KRBKOVU4&;/H;UX'?<- !^1?YXU^?EB?58;26L
MM,8WG :8-WE*S4,:1<!\K#@^4"WC$+JP=J!3)QR9&]I% ZC+P4O]R+_7!6J+
M-,+DJO_=.$,'8:V*,/N$"V01RI=@V>+[WR<77&QN_HPQ0:+21))T9'[XQ+)E
MB=V^]'XLU*4-M5A# U2)1GC#(WG=.R2EN@;U)W);XGOW?\?J$/XNA/_F=S/]
M$R+>!;(S(HI'-)!D@Q7J</$UF$.\=G+A#B<KW5CM2#Y)FK?H_>G3H[3^OEN^
M%3H'Q#W)#B*,M8QNOQI]^2_'0B[]_V'O/:.:[,*NP?A8$%$B M*)2N]*EY*(
M"H@(""A(,RHB0J2)])"H""@M @)*B])[I'<B1:J U @(H4D/)-3T?/%YYRTS
MOV;-GV^MF5DK)VME<2><NO>^[ON<?:FV/A1=>I)\K>N3!,$Q_<7MB_I4=G<H
MHC3RTQE/L@^4IY(.G$I#*/:3H5UK=I&G%\=4^=_D-3/O?'BVFU!36]VT%8)M
MHJRQE](0L.]JE.QG0&P;UK")AP40XF7W9VE=A<Q \\B+GG.NHE^3)SIR6 "\
MJ.VR62B!_<>7I%L(*7+  I3#26O3ZO&GV^BFQ.R<'"#Y!--ON\F)0U34QW+F
MPX)*)[X(W/=J3<XY/RQS[(LL4X A1-3S:.;'-JF9EVY%(?@3O^'/T VRNUL<
MW*AO?H;O.BUBF#J&#W"C5]U]K.,&K1?6K+T3W]3:A[9"G9"M9ZO%SO3M8^4*
M!6UOUPTOF5W*^29"GCF&?%MV"1\&O3!6RNO81!S'>!6XX6S/:HT_YWR0*2 G
M>4OG-"SE4ELHC$M/G_ CM7XZ::$E/SH_"I86G^_) N"N4:4Q'5BRW&9NMCNV
M5B9.^J?]L4K>:Z)YH 9/&RE>)OCI,[3CR!Z4+,_127!N,\ON6= -C[M!SZ^/
M.^*0+]C:MR"DW_U/TPFWS*4G"<9!DO'1NHUGG\@42FZ;[&&2YN*$,"FV&<';
MYFL]"@?FFZO^/VG<RO,;8+?("!#P6 DES7]C+"EM"]/M<>2QI6%H.85"52+Q
ML0#M=]C8>M%CSX 97^RFR3.M"TQ[/-XAA-T6?$C&+=^XS'^ HI_1ZDJ>42 C
M%X"1U.B@]V6>V=&08$Z#.*_^3[ %:"P$J SFI=N1@)'*D5LOTE;/#VB[#!B(
M_]+8ANLR^Z,Z_FQM]*6"$U@ )6#-/&J_Y"ROND.O'OLS7PAU_4#T.Y\E]![\
MQFU;_8+_PU. (<B(KS9%3M+VN<;T@*$7:G*SIVH2A :I%<5I;OH(RUJT)31]
M;]>6SJNVD$678'QY,+PE.9%+KK<U?Y_<UG4)TN!E[@#(;&L)>$?TQ;SVDX._
MF$P/90O85WNB$J@(T,4[Q4CN(N^4G!HZD@L-7FMX3)4N]''UXVWWA2D8*GI>
M[.[U-BC:V\71^4&S$+H\"Q"')\;;&?Q9!:M8/[_)&&T K7.,Q=T#WJ0D-SO6
MBIR\+RSXT4,*:3P&_[2P] E.U&[X:)_V?6KL!5*CP-*0?S)H[M^<<VS="IT\
M.RY7K1(AO!BU'UQ#V?W^@5ZRT>@2AMX"'!=O+&Y'>N G*KPF*A?,IF-X:O>Y
M2\R6DJ3!4$5T*J1(TPC26'6 D2,RL4%S3OZ#UB-+(2$$L$LFYYW9[,)N-L5^
MP0P-\KDU>-'YLO?5(J@_KX&BU;\KAGVI;384^4F5##NU*Z\/6_ YZ*WDCX.V
M%;M Y%ZD4.@T=$#RU.7>&2>5!<NF0DI7";+OS\0G)-$8.Y72CN BWD*?I-L5
M3*WL7/.3&H@/>-ZFZ\9#M)=^[ET"\OWGUY&+8L6;&''FSY;C9)>Y=WNQL.\Z
M8AFQ#0+*GD,3I &>.\G.&Y]3Z9QCN]$90.NZ\I;:A,GM 9N(IX\=U<WSC_"L
M'<^;AOZ&7B@Y$. M$BWJ4]"&?I;.5IUM JN=(5U*BTHNE0JAY+.%@.IVF?[W
M!][1G/+NYO(]-6,IUW$.<)0YHPKY%$5VATRJ=8BK1 AY[-+R[RE>2#PT/'/Q
MC.HW;\&"(S&9)DM-9:^]%=95?GDQ.2?\2)X.4/[ R1F8RDFY,P[WOBIH%JXV
M-GQ?_[TKN Z]]N[[P^<_Y/W$LOD2G)QJ3!O!KIRO.Y^0QPN5W?IK\(8!Q:$I
M=-7+*K\J]X%C6#<S<S%G&X=8E=:OVJJ.SL]JR<SCH:B %5W7W-!$4N+"<B3R
M"?!X^RS^J-U$5X'=]S^2%U\MKB[D.;)G?R8^4\?&@B!$L[.#ZX]8O(%S[0?F
M5EM4]OAY B*ZN36O<QR-Q!AL0>4']5*LFRJZMWLDS@;X_QZPL#)#BI"+%Y2>
MF=D]>#[A7N7A 3+?WE)*[G/"UNN!B. ([A@?2HY7B'IF' +;QSTTX]"L55ZZ
M'I I.5:F@MF4:FQJ>+[=)^&2/F8OBUFRNVF5^"%C:AH]9AGCS"]8+)5E8,AW
MY\-?N?&OHT,^.2C?CJXQKF?RQUBZ,"1XO,4-FBH;;_N'XW<"4IC:O0--19=K
M$:)9@),CQ??=)JN;OR]'5)L<&7X+4',P?=DX>N;0$<#Q[E6H;6 8\X0EL?;&
M4$Y]S>B6GT*X8VEI<S&G(!7^"SJ.S:D3B*IPOZRDHR'?F?XY-<%SX,!SO?E@
MF(%:X@;/*6ZVA-@TZZ@6"L=JU^4-VYC(3$[!/)=[H41+;*1P0#M^4CY(O3N[
M-M*^UF'B?*Q_R7-QP5?,H1XZK!7VE;Q%2KQ-WB/IWB8I9PNW2LUQ\1U_7D.2
M;3NG3[R4V&FAT86;_<24CY!1Q;QM*[YJY?%BF-$ #7D!^5(7P/FV[<^'B[]J
M@^.CK$+6DG'K'IAQ'!NFFL(F_@6KU#:FAS)5I-CM\>OYZ8[X&Y$G8RX?$8Z(
M<JO:?)4S]FF/XV\ZSZ+[:D3FJU-YA=FKP6,=\J>=U&,/UQT&? 6\GLF/P:'H
M"$:NGAG-:/WG# S'4]K\^<+XP&_^"$#(@E[YID5N$(-_<Z$N6[/SX;@ _WVK
M2-?Q:2HV8S"SCVPA^VW^O@IG9(P[N#CWH&("GO"W9KPK5__KL8+"9_)#XA);
MKV-B2ZJ<P)INRFA5;=%K@K0!1-C>A9KVN37;8F'UI#_2":;%3[1C#'7X<NTK
M_\18>[2\\PR!;,@1+?T(_E#!-<M7SCD)-2%=O=NODI%9F!UP4@=S'"ED_'WK
MW4AH4I^;CI&'Q^7YJ\!!F?G @Q,*DW]3=[[51 (0P%7F<2)-42LE>?Z,=43$
MH8/?+$ 5(1WYK;EX\>)%A5UEQ5(+^6_6<S_4FI+R[<HJ@PNH2A#N6HCVW E^
M-7BHN?1W!<,9OD=4 R\5.]A!2S*[@5@MB-F_?;_><A0.]GK' O#O>H \5YZD
MF_BL_I'Y0:$62)#*C%J*&6_HA[UF\4=@XMIC'(FB0PW7-R[''6>Z"89Z7UJ'
MFK52M/8S8>9OF$<H>539+END4XMK+RDS@)'R8:SCV@(LF:OX0Y7-+G[1%=EJ
MP#PO;YH=:#16T^6>M3UG[*G9";F ?X_Y!/O,7HH]3&GXU;'J'BK>_$=T^MN?
MWD7ZY?1U=$E=L39SI%]^'M<VG<WDSZ)K[#WY+<%F/A<7=6^O^9O;[#AHC*D3
M?"XK2F$9E?.?ICI*3X.OSYP;+]E0POE]W^@YXCSV<=9V#%I[# -\B> ,1+;Y
MNSX+."7JHH-8.A_/ J .W;>@\04"F;R0N+,IJM+K3J=.;40.=;$UUL*O8E"M
M2EQD-%BCQUEDL_;GP[/%@\9ZW9!CF"%5]#ZWP'?G^PD=)M:HK'&H3!$B<JF^
MBRY+>L)[I#I.7+D$V[&+ZM?56 N<9E-T!CKW^!VMVZ?<5NZKCM%5 E.$_0M#
M7=7A"L9JI["1-_NSRC),1E+T-4<VJY[XR;7E!,E+XIZ4H6R(M81"$D?[)8I'
MT;4B90-I)E"C?.6X!/]J"ULVOXXQOL0#:Q%QB3SL.VDNJ8C\_2![#Y,BBRGL
M(Z_KMTY8=YB4#1^D,,T"#M3AF0^_73ZFNEDF+'> :F !MAU4FM4V3)CJ<![R
MF)>HSCXZ3S)1[+78U6_9P&*C$ZA"]^XQR"R:!3B.D+BIK >!C_LJ<$SEKW&J
MFX:E"U*93UJL)"XTP_8EB1NI6UW->L4FHCIPKX!S-O(E=TY]?H4#[U%E3I%S
M/\Z3/GR]%W4I,?V#)T8 8U-M@;VV@Y FHI7:'A0M?-W+Y3=7MDG*J5I!-XSM
MCR\W,2?PE<G-)/S<D\0Y-B0ZN=58KE:^DXS;-C9,XK]B:%44)+CU"LH7B-\_
M3\Z8O3CH,Q==W.BWJI&8^\TKJQ#/UAJX$5#5 0$RCP+ ?>O*?_H91?291:@G
M3+_74VV4?71C/3[=3TP>$PZ9S4K=STSSBP5:C(I UI5R88[ /!$9$O]^4M/-
MGH(%^0<D;DOOQ&AXK5FI6+WGP3;X;$HX91HNIN<I9G0SYT["4E5"</&.G<<2
MW+CT:<",2-UVM8)"/]C*^\S:L7#4[#?A(FY#!&H"\0M_DGGA2PUN-Z]Z1^
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M(*-_I#SM&M&@&M-XD:VUP:Z17DI^@[&IP[ 1N3- ;C?SH0G2Z[-!V\(&OXH
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M@&1;%D",+E'J.<5 %W8L4A^S-=Q$<9AZ.PTN9N\TCQN8%$^VB**VZ,0B_WR
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M'5TDNVYA3&"4W[+_9EG]SZ8!'S'"P K(MFQ&@9Y6D&2:XMYE;*5RA+?0$XH
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M5CB.DV5>]E6D1&(VQV'& G2MA@":%;8#G[49W$70H%V"P@7&%D<5G1/6VP.
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MQC2B4:I7;T3QSRNX,->XV_?TUR&=]]5'F><"(Q;NC&WF-#77779U;HOKS:Y
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M[&T&#ENP<117[- ]'1ZW(+T?X%WA8+JL-:7:]K3.<$[Q9=5EE.>N46.P1)#
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M"A=$WQSG/#9Q; $M %4AH6G""!9C,*(\Q(,!-$,26S1,A/970[7=M-I#'?,
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M7YWS%?.R5A(_^;@ZC$B>#[WY]LV+,R<7HV:1SL!1B<?T-)J7:$EV,]N@GU$
MCV_9^8LS<@F_J-F7[]+9/!"#R,K35=1'>NC& &?/'-= &-^U\M#.3SE"IT8B
M^)2%C[U^A>0G+IG]NJBA;!I],+\3N(ZDG1Z>/)CZ$_0[2NT>)8PK1V17PJV\
M;AVSA^DJL[1:".AY19,0BU.#Y2R1PB:^36@?$Z*8?3SM^?,I826^@8.]%2UL
M+Z\9UG+L@ATR9(=Q!]6"8Z6_KCU["&#F::[:=16:8 ]_UAD2QXK9.G8(@)>
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M+"D.5%=__$PM\ZG!#HPKB6,7\C35E&/CU^V>&@],Y2' 0M9ZXL7B>_5T[4.
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M7V?Q0"B,H**8CL38ZG_3%1BP[KP(<>4MBQA2-OZ]_-N^UF^&0.."DG'T+X<
M>SZ\FQYF-*AY%!DEO29"TD2%(8:\HWU8SO\:FTM]$A_XS8[W5?&EDX_D#D[J
MC$)&\SM;O_/)DQQEWJ&3I';_%#<F0*/^*3?/ Y_#NR,I2J@YOP@UW6);*[@6
MQ2?]AGZ0X?L1&ZBX9N+M[8L3\15O$G^<S%/F:_8'KE&I(,8PJA)"X\2MSL8
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MG/9*9CSX.&$Q/7C^B%_E4FK<YZ;"$=<HT&)DM@:KL:$[5X9(18J$/(*&-6C
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M A@W:7-ZK+D-W>&E4%18B!RR80X156"]XQ3Q+NLW9!WS?QFY@&,6?O23&H>
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M"P5=HP/F*SUH=VMHO:>:]Q?!YB4HGS#5>-@^$40ZO2B=GM.@]^^B<FGLXY]
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MX1;)%MBU6'3%!@8AO:5@R*?5%6 M03(^H ,NH[O)=,#CI?+PSVH[%YK930?
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MPV+BJ("2XI;+3P@3W/Y,N;O=_3C&8=G=-V.:AG(]MSZ&10>H#EI@!@.J(70
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M^%$TMPAH\S<MF(]'R-[GU=(CXZ0PIOAFQAD#TR$@WF!W$D5A(\W>K;!SMQM
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M'(_E(;X?UKBUK@GRM_T\H4*6?.>.WAL ;\M07JV<TO<38+:NQ_>6P+Z;6>E
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M_I831YM,ZY#'.Y,1&@>EJX525^B KAJ0)YA<NKIZH)6W4R _QR9X('==S40
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M1+2O>)I4HI>7X(M1EKK+X(+,D\%,,\ QHSMXMWAB;IQ"Y!8G1Z.V(?@J%G2
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ML'.ZNF^2%9T68D,EQ)H,54,A*&1)'T:3^KF18:5V(4%B[47N6,7E6S&1/UG
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M9Y%MAE_8G2T>2M3Y' 8<"O"Z2KK>IV:<KE'?2-K;7EWR/6^:25(E?L2/1E/
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M.0<<+#9S;%(F5+T9%\9\@2R0:6N+H657GQ0>RFM7RPW^DZL^M;R:-ZDYG#-
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MZ/@@"NJEQ5SKYURC3#?SW:12194SI==+'N1\?.9]%%.NP6GR8>>*2O)'O:(
MNX59J[ ;153L@><_GVGM7GOX@KI7 @XD%/DE/!.#DJ1UO"N^#PU5%YZNK-YC
MH'H8CW^7U;8\#K2=/SJ=<O7[1E9JC05I?DO#FKI'$\IB<-.&BUW>4^%R3['T
M%^;CI3*QGNV@T3\SKP2)2N.(7J#HCM&8$%$3'^%W/W:Z\Q_I8)=ND[$+?7?6
MX48^(Q:GP0?1]C<JMD2&/.7GLZZJ"%:FI\E5VRJ#[A(86K)AUG=CM6R&' 2^
M;\#A0>-.^^L"QMJ!4L7_-1X4"E.F.1;!;"A/U.3"M_<J3MY]9FWO6?)CI=/H
M>.8@&Z"VS1L%+)YN!H5,"258#I:/0PJU#E03]85K9U_BICQOJ^X*MR&D1W$S
M\4&M<5!,0&FKJ<AJ\C'1#V=^.;]![*/ J5P'!Y2HP&:2@T$O0@R2;-74G&)C
MK@#/Z;P$N7#W.#UA0.Q/"Z*ID05TW(M]0-E9J5#I@BBYC*V:N;^J&7)A.1,G
M+(E:#DG.^;+?M%5UDY9SNF1?I,?N0QTSAR!P5-MK'VV] ,J?8/7[\J<?SG-E
M)*DRY8WQLYW,++?_T8-=)Z'_T.[.MK$4^\O5=9Y4#17-ENL^_Q Z(CN[II"P
MC>G#'$,VJ+&$EL0%PAKI=VRMR+KOH462R%NIHG'EKV\MMRV"4UG\%$W\VUK3
M[-4SU\]LZ?^,7>$/\M Y<8"JVD#%]!H=Y7 3(RUQM_33L9SWTC<83+KA7';J
MV#&8-U_IP8/CJI@A#>7\#PWFK.&YQ8'DM,L_@\;V[=@ K4FC/QI&F<T*5. (
M@Y&R%:P\L-"/KZRLG)0+WM;29&+8 &<:YP)%JXC(?.FW<?5_7#B?\-M[*?K!
M2%MTXB7,-\'YBF5@A6[;'I+#7Z)41'9'Q[I;59.&V__Q_L,??P=*?>_P)=@B
M%?_+.;Y1H['L%Y+[\^9^8."K39#V;X=H2S_!3\ASB3Y!XQ@T\D9&I'2[YK.,
MR)V>$<R,)IIT@%(TK3\D');@P%=3?5_5]=?2Y[5C,REK'60EKZI/SZ_ 3%WE
M/C=]=A+P5+7ZU*G;<&A\[]66QKL'!9["/LLI?HB"@$RJ)LV'B#Y:B9(*W:9;
MPT,OQD]J_/RF^0EDHEL/V3I-1+Y-)>":8X*;-N32QV2VAQ$N9[>4Y6U'=EO@
M*H*>AG(78]02%W*$E_W@(DL##. <#'>4,LP+2GSH>^'*0Y'1\2?;U1 *^'.H
MMH!%*_KEOVS>J9PA-3-IT194^TI$,Z;UF]^%7P^25??30RB8+(0@JUG$*,1W
M9[@6#O=HY%LXIYW@6&O+\E]I&W'("=J_'A6Z=6(,O%:\>V8K2#L(UV>+5D%3
M[&P3VIAY"/H8W[!1'Z*HHY,"#$&6M474*X%YU^C(LN459#!<5?HXK\<:XDMP
MY+YA4Q.:APVP9W*1+$IEOV$>U"I<B5]Q8#7ZQL#_]/PLTI\5(M4Y$U:/]-8>
M<#_AV5C_N'ZSL84#-[/UIIFS>_Z8%+\Z[ZWFZN_XL=!!?')"6K^!M(<3&[ :
MS".],N680%Z9ZS!IM@\:C-^]R 945>- ;=\VN:6[JQ*W%MP)Q1@W8P0#OSNM
M/4_ST^2>S2'I$7EC3.MJ;@WX/A[5O_*4P=I4,0=]H&(41(VU84>>?[;W&IJ2
M$E*Y58_9M$V.[V4*R73<J#K.?3+D[3LA[;WZPKVZNY%7BDY77<G>BZKQF._)
M=AW\#TMXK]"'$4<@X'.,^S**2YW*GG'4?#RPY@TR/XAWWO:IAAC,UH5 [O/^
MDA9OS2''<1TQK;V-CY.D3DN>U;;%EK)P_.A&HW=!N%:P8%O6\N,O+X37SR)6
M1M7+@,N#^$'6)8I**-(>%-:1O?Q';!T7D)IH+>X^P$&:>J#JD.)MQG*].BV$
M@!S!$>:"Q,-/6%C--SHZ2,F24#L#0"/M#=)PO39%ZKT2*$+\<@H;\+@JA6Y<
MGY#DH<\? '@E_MIBV4SZ>95AU+=PMVRUA_U)*_%PH4"DD0%P?GN)6%5?C8DP
M3/^'AQ+;G6\+YHPO?5M3!G06;D24>N^AY&ZU7(21M99 5X>4_ECCRG*!B=%R
M?S $: E9M%1]OHJ%E+EW">OMT<>K@7GQ"N-*I)1IQNESK6,J37I*/97+ VZ/
M;WN\Z.]5^21PLN7>MESL2&LPONN[NX3XUQFZ1;.3JBA>IKGI='3T-Q.C-+WU
M,?^ZG2'-C;P5^+#U)T?A;)$ FQ.9)A\M)#(J]?*MQER&A_NVM:*9V;B9;]7)
MI(/DY5HER->VKR-3 A"\"M(EL++X6?ZF;-_/.QM?++IO.G>XXX)%+<S(F3,]
M[[64:6^VIT\NE[H)\4FE2K^X[HEY5";^929HRX"62T8V@P_7ZBCB^%W[77<-
MTU\$JL<[LC:+5ZXNC!3@%<!C >NN<N'HI+Z!C%)]%N^G%[1'F=+(T:<\3_4M
MO7WLK';\/8SNU]OI+DVOS1*GPTM8W2+JEC9+K_;OFQ_PF/T\>_@I[]2Q W-?
M%C%6C!$:RBM[$G9G>*X/[Y0HN5;H!IC1K9H5GTH?BBVM;N[+KVYMN_XM=G@_
MTL-3NI]H*)/D'MI$R-*Y07V(M_75-U"T<L^=)_=PZ4JUV,O+%UY+'YWJR2[<
M'5JM?Z,=Q 8TX48<B%+-; " E]^UVCUOY'?8@TM5Z([T99U [3&?+Z(OHO'Q
MTT^[LJ8-(%ZGF[R@E[2O>]SHJ_YR"MYPR**;6#IA)_+E&O%JNWQ*K;7!Y5I4
M5J/3)PTSO?XFL^@L+E>) =>].&.[+?HU1&-*#DF&T%'H9F OQJT7YG#(T+VK
M.9D'(,7]\[;Q%V=-GY; 14X?J9@RTQ$2DP'^IO'J23'W*W?E8_)]3OL^4P_B
MZSZJD5XQ%/%;X?C9*TY*KDH/@ZZZ8MSE_! QA8:/0'R.0Y2!#I<APW+!";^!
M^LJRBAV]RNKD>F[6X)0BC<O!SY4P^5!U;>.8/S9=3ED)YA 4>Q3:)C[4[2:"
MBM!28=QW+9*H&E8BN3WC!M9=$D]OT)T[_.P>]\2CDM9"B?A3>7DW.XUN'X;7
MT$59'3'D67W4DT&98:/3;A$ $P6J!.@7:(Q%84A/$F!H^9Z5)CD_R;6K*^OC
MQG;ZD#KWK6 ;LBI&K2/@5?26H"'H:6Y&Z4,3!!1AE@GM@SJ4,).03C\0@@'V
MZD=A/ROT)_1^V+X9W.>EZMY9@2R1M!HU;_8]CWYN@<_5RLZC^311:(AF'9QB
M]($X-J 6V5@NO8\Z\.;;VZ8F[C#4]8L%R3OXFI6>N8FF&YC8YA[!]\F*<^O3
M.WTOD^]SIH)7HG?^ZVJ]#;JMSK56A2S7FA*I/#RP?6XU\5;K<>L:Y,-5Z2CF
M=]]*#KAUA@(MKZU#>GC<3@'4UROCD(4 Y,V;<.H^?OL"&W H@KR&X"#&M[XP
M^3"E<6J4\/IX;*',8/]I-@!EL34MQ:\RC/N&HTFP"E)Z&*=QA)<_&MX%F=[V
M&FG3^*'+4K<>&OF$OM>G+?CF_]:XOUL)[Y$-#QA:]9>9(5K7K4K#QPDU^:^/
MLJXD='&1KYQ$WCI/@G[#++$!K./"^47A]!,PJZJ7#BP^""TL.#GT Z) >N\7
MO8LVO%UY67<[D\X+*21"1P8(9MLQ/]<UI+(5@*;4IVW;&"%.\UM8(_7*S*CZ
M@S1(LSA757'EH)]!H._>V/J0AT"S^T("0.7>3Z$4*N^(E#Y<B"I)TX><=PRH
ME<Q^RVOGG@D:KM=G T)0H+E!#4$VP,&*#5B6['(&1JB)6W!41.3(KX4Y,;-!
M+]%< =(M(F'ARN&%FNT36?7)HC=OZ+N^L+DQ!_O]-[BDC%FJP4T78JAQ: W>
ME Y*^WG=E^XI43?X'=@@$"C<JO/T0WY<_$T%F@)'+I6VE_DWQ7L%*HP16%2P
MN3PE%DE]%<;W659TM#.NM>Z-LZ--^A'O $'P++@5&C%--D:.Z=/O+DSMVE'$
MZSQE? LO=^FW.9\Q_'T!3- 6EDC'*<C_N5R1J#ABLR]-3>>TFL:PHF%_3(S1
M1*U@&KV?$J/',R;=^.7R.U=#I5B?\^)6@O =6A>8Q8CK 9C'D,)[1#!*-MLG
MO@=CZ[5]CJSU%O< ]P))4PG1+>DK](-&6\T/43.OA;OSZG[2AD+1A*39PVEU
M]X-O:PJ'*^V8H1C\0E3OXH$S0XBSR]XZ^5@8%@OEF-B;S_[.E*PNP6)+=#3H
M&&@F:UI,BQO<I(RB2#?O\MW_E>INN+2BO*YYW*CVP';#KN"^Y5_=_&5G2\AR
MY;H<&HCHF(9ZQS"#K1Y.S_)H\>W2N?=+YX3>6QV-$R7F&HYZQ[V0$!Q-I:VA
M_BIY<B&+'+:_U12T?:5?^_N*D(Q7SA1?3U*I\HOWJ-N=W74' -Z@2PSWF4('
M BJZ0HS+IJ2ZWZ]0G$ J(CG;QH^WAQ_BVUE7U=058(X>^<'*S ]A9K !KL@C
MB'8TCX>&\2S<7DS*X-W:>Z,NS;E/OR//MLDN]GIR2;P^ADD S7Q"DTUMY5K0
MQ>8_BV#WAR)7T$=GK.'FQ'O5P71[WE&;?[PWZT]H%2P=HP_MP>D6B$$M#<YK
MQB+Z5N&2=<QM_"[P.9GZQD7$K/1]ZERD(C!P_&U7=,GB:X!P:WIUN/QV.(FC
M&JY_8#JTQ%S;IS#%,BQ9/#0^;K)#Q-8M ;,;=4.^#;V>%P^JA\PA!1&CTT(:
M[C\JAG,I"FW^IO(]:O/M>4P!U8/D?W#W0 X]-)7X8=LS>"M:5Z&MS%R[Q-\H
M7-W$)[=YR5U>(3_KS&\ VG@@JS'G6,<.TV^Y5-N/Y33)*/L9ATBVD";Z57XZ
M)2O!^JS.EX$$6,)_Z]H@E!F7!B]5]2&D AHT*D_.3:[(!7L@2A[9\LZ#,W#%
M0(90:0_1O,Z! (HVKQ0Y\^U5QTE,1"%7LJ-".J J.F'^-'-'_6;@T5M%.=2O
M?\MM(809=\C,(7R3=?[&P=65K!EL"E&_2_D5:S5<YIIS]KS]$<3R,O@#&R!2
MSQV00 VBI>8%Z+:DO!PS_)G9,6_$O7G6ST*',SHO)(8?.N5*+SUIS-30O=8E
M4GVSM+B]^-:AH$B_?Z41.@QR[YB.!1VMX VKEZB-W[(E7[\JFZI16*V?=BNV
M]]W.Y3-C/UFKK>H62Y+/)9WMW^+D0#-Y:+(9- I=:D'R^1$ :MC=EZF/@N98
MV638+.=JO)E#^<#:TBOVP\&A2++=QMX#NT(VX%DP+U/0PN#RSF7=:2!9!SB>
MT\8&5$Z'U\)]9FL*E5>,>&TL=9VI^DK8XY*6'8M0\ YDN"Z$.L:QCQB&.C-,
M\3"4WTXKBZC^@]$A<Z0YK+9*+&VKV7B1-E[$T]MLCY-"SJ3AR(]K0",J5#=:
MOF2T%SA@MAG_ZI3+JU+9I8RK8FV??>3R=.L\<<W-/$<>4,"A8"[6%63#?2W0
MI/5R%)R($828I-;I&]<D\(WGGA?.3L@X/P/0_.>'QG&,<^%4@\\DS@5#DVUK
M[8E.WFHBC--!X6,*_)>P_9G\MAR7Z4&\;>U??6C?HEL-3_*B6#?[=_G!*=)M
MR:;R$F6K>%V@$1KU%3.,&@UA'3U(QA+"DMW]*,>)NVUCZP?UA;Y0@UX:++T7
MYE<5+Z*!)L6DESJ@M,MLP"]K:V 9IA'TCV) *_AAS!P;4#]RAN&CJV'>X,2Q
M#[E_*<>;!@H6'5-IWCB3&//F%!BLQ/S9YB!*QP-#$>&LOPOE8%L5HE:),P$9
M;?Y*2VQ0EN.[B.=NF#2::QSP$I9H0F^\-97Z\-JISHB:P!%X&B9$:\NPT2-8
MGT.'5U/[GU4-S <6"M,#/SQH=F<#BAQY-S%MR+$$JBW%>2V$$D1OJ)<KLX;?
MQ?,W:-ROJ&,<2DNX/W(NKAA^]/S; X>.[[X0R=RWQE;%KD_=^A8G&6G&$QON
M79U^AZM*JWS_7W$W1Q!3N_7J QZ($P%Y>T50Q6!3?T+-^T^?Q4=!PU9S.YL-
M/"&E4#&!XTS% L=SZ@*">V@VX+ WY\9O# MF+,[-&GR,=HVNB^U;Z'6O.*)?
M>$L6V!7H;*Z.4FV4$]Q_#H[@J,"SAX%&<.ZSSTIFH7[F91?MG!ZAGV,=;>*(
M.D"+H7M M+3"V_R#; <1XF_;]4&EEC+U ]*/@.I!S!9,;?XFDG4RAPV(2R#B
MF4'+Z'VQ+D3QDQZ]?_Z>'X\+%;!0HD01W5$-N# U_/N*?[1ZOELKCA]K^\+D
MEU_O--,=+BNT$G!M+]1U:5&>?E'Q<ISW;I9;2::>G8FKY&0=/[TG C13! 3B
ML SG;!J745574<3AA>^"5<')X#A>4(-P#[."BHDI)$VM^T8J.<?K',_+E$A8
MDM9O$Y>OIX7,GM2W&<Q6$1K+ZI@T7*1]'BEI^[KX9L2BEC.V%1  -J!QAK;'
M4QC,]3DSX($,8SQ96F*/V8Z<OHWK5U@%_SG;/A(KV8,YN=+>02^QAO=9(!7H
MEP[?.]DXH>E*TE%)WOV^R['#[VOU#^A-5!4:/[IL^I<!4#M>R<"$H#6>6WE+
MA1]@J<<9WX>-:$>"\;G&VLBG,YZ^Q9\"GKM(ZQR37$+-3C2)69][GQM5M'$+
M*[4RR080WN)N(F=^( $X@AG#5^M\:4A''\-.9,T=G*0>A[J%Y#=C TC?MC$#
M;IN@\>"9:ZQ><!FU,*OI:(+%0!LU[)/75F!?R";O[F I_*GXT.9$X >DV[Q"
MSN&@#[N9*UBPDM^JPZJ&!E%N+7HAS2IV<''=J&^-(Q'OO(Q8G/N+96SA,W)G
MEJN'4Q6LIUW]Y2?OG&<)Z9P \:CY8T:A(<C3:_4*,+D^F$%.'!5N-^ITA0>6
MO$1!^WEVT"R(M27E-V\67VOWO",FO0ZD2>BV35_>,*<%(E4ZE/UDY+Q8YP$I
M\CN/B[CHLA#*QG$?-B!WP>B &3VQW,[4&KZRVC7"+&M9%]M?-R\[KC_]+7\K
M9'K]%>+AXF0Y1W4/@1U_3Z1P+8 9@IDLPUS0&C=GS'W3MQ5B\(U6,MPH\AH'
M,N0EJ$R&4C>G?ZU <RL)K%^5T_L"%3,(;AJZD*$Q4!'E+D[5%\07(EH"*&*E
M&NJ)D4=6#EQ3B,V\].TB+LGG1+^PO]!0VQ.#'T\22E<S2^D]J]'8J^G.#1\]
M!>8R5DS?UHRZI2*]=G-(KIS1<6\ <6[*UD7\8"S>>OC"Y5L[5[4@ZD[KIWAW
M"C1]RI$5OS&A""F8)\6YU< 2HV& <5,KK\%>Z[JZR8$-7D<$M2(!!=#C-%,3
MRG0$R3?M<O>L\2!FCN_.H2M6>D_W>0?3?YT&^[.Z@62]-*D')2$FM!B_RUFP
M&1#5['NV>@#\>QS"&;0N>' HU&/52^@L42*7#3BI632DNK^+#-X3I60V:9P.
MB\Y#"A:N99G8DACYZZA4YU_JEF%K\KM?=3H#3!")=&T"[VL6-_ED7E,FS>+V
MP! R4OKL+MJ[V4-J(L%J/_R-KX'51)-?YK*%L<J3I'X54QH?6->H(7)=*/WJ
MU5>/W>&,CDTMIYS8IW[J]XY)B:^[@FH26<Y$)W3>I,MNW(35A!'$B]M#[Y)W
M=/@@WV^E;>S:+$=M($IR8T=-,%!03RK*]_S=DC3<P%>[6WI&<BC=[B!'R.IT
M-)!LB D#G;D^?V.IA 9]_.R5K>OYVP+T%E8!"OP1Z 7^!S$X71(>B7.<?*JT
M+YOU=4)KW-9DTNCC8A%>S &&//9;8^:+*(RJ'D8+#W7<F5!DMM1^'0=3&6"C
M)_BTGN\=M,RPJFJ@<<N]791+EZ0<W5L?DVG4WK:BVPB*1HC1YF=&E'I.KO!Q
M^/%F%?!ZTD;TQ[B@?-Y[.\*'1%:$[Q4=_;VM1%NE*[#ZQW;7NBA'Q!ST$K/*
M/KS#%3M?/#=2DROVZ46BQ]?]MW>8;C0+BKH>K6U&3*4Y1:QM3)%I>.$BD!A3
M??/&6ONOMYK:B)8&#8B^1@;!^,KPV]W,/LP"*MFO;S\;(=GVA=OZ?%&>J<>3
MR\Q1/Z,]Q\71';L8F:79IX^OY>5A  =>7QTR/U1K^] IWMJ\S%'<Y/JCT@L;
M/[&GFI:.:*X,P3LMR?SF_ZG(U/]__;?Z,"A:S$S CKI>3NS9>3V!PN;K-4G:
MET[&3? -^@ONE5%F6<=,<U?8 /'"GI"YL)Y&M8'R7:.K/=0[OZ_G@2*4$<8[
MBX+[!3K:GO6WR-"1LY/C<NM/&3/(#@Y<?X3/35P\^Z7>(\"_NLS(;(XTZ:OQ
M9?I2HY/OK)$ IGT]I6\OGPI'=NXA()B#R 802T [T^55R80;GCLQXH.'WS$O
M5J73RJD@7^%?@'C(/# "S.>'C-223#4;]DA96+C["O.  %[/H +G\-\0>-P1
MI9YP%JAJ:$/6H\)6Q?S#)ZBC>HH"OAW1)#I[]BP3%JNX]<)L(O_GVW5-(8T7
M^$UDQ(1QRL*MF$?*MU1UY A01#\T'ZXFB35G XIA-PD:F=(=5XG>U)RKNL2'
MP[;VR:/Z&/,=.+^'*W7WIN6$KN)-O1-]-U[XVA>\\ST?>P?3!SS"\;.:B'-V
M,+ZRL$6C^%G3VF+]Y"%$_^J5Q(17\X"U,877RK-BWH&8'N2I98>[E,/,R-^7
MK:4_NS>'?'\C6K31)HQ!$WE.M\[U9EH(S+I%KB9.=5GK9N#MDNV<^SPWSC[S
M^3F<]<ZD3L6YL]!WO:@BR&6W;%,V()]XIFXV,=2O$/)DR'S"7K+Z9Z YR.2@
MJ/-TH?.R559K>)[UU&@G==<\_GIQ>_C)<P<_:,/_+F?0F!]AMRA[.VG6S8WZ
M'6+7S+"Q+9(NM:W2566)%TK> AI$0YZ"L#UKX]]8/<!3BD/D+0/QU +KSZ$%
MJ-KQ&_9'30*O>4U+W5K(PYYT H]"M'X,A'#Z$EN*2!X(WCNM&WD31W)NVAXP
MXV>9_:D8VZFLL>Y,(,HQ!"!M:'XMD1Y"381OE%+]N_')*>O['8J4N##1$K,)
M50F>Q;.8L^0CA0Y?:5O:]8,DUE#VZ/0]S4'5GE3^*MFJ74#D[ZX3!9\F"FK"
M='1N2O]I77PZX>ABT3+H)WG..M6V@@T(WQC<(=\2/WA0)P FIF2H4+?G6[?-
M!H21>IDW:+OTQPR5.F:Z7ZO(<'+>O3S7^#NNSL(GMAXLW074%3>+4EN#(AD]
M3,VZ:_CP;6[4Z56JE7OT76O20]_*-VK0N)%KT?1XZ67>]SCR(Q0_3(MFX44\
MZI<O\W#+$*NBDG3U ,KMRL0XV.O/XV/+W=*K"M$>[BW055_R:M*[EWL(5M'&
M'^F1O1/)!Q/(;_?3;/07,-)%4)DS[1UPZXKI;ULROJ 3+*E5X#&8@7ANYD2Y
MPM5_GO;(3\CMVOBS['_.>%_!A#81K_7FB@R^F+U2DUWNBD9&-/4WFR2*4$RB
M$U."LFM[RJ]7R'$A)K0 =,W&(C1F-&?R+%T[=3^7I=KSC07#=X#.L'@AX".P
M1_NO"GG;VY1WKX#\O-,^&VV)Q=C3P"UJX6]WQN'Z^M5)W=11K$3<%P37(/!>
M"]R=W#,+#&4#(,@C*F&U9E HM/ 0&V!N.*W(!O0\M<[#_F!]L5C^2#DK*YW]
M@VB5%?NP+ZDOWR.>)+?LFL&HS :*-0J*O;SF5WQRZO'4$\RPYBQ3TP\IVF>7
M2*%3'8?KN=QD%*171$0+(Z#&B WZ35X"M)=ND8)?M RS??\+GW1.B$NXS9<-
M4)I\!;FW78"]V3A+IK0\6\@Y]A(_1]=:7GD;>:7H4M7_M1^?;V48"L<\<B@I
MJZZ-TWG8Q ?CA3U142X=->PS$/C0'GXB_JHY^->0MYZL4[E4NLQF3J[8H1?&
MVGJZN3 A9@'#@/R>6.F::M$O\-I=UB;I#JMI!_SMMWCBAAL;<((->-DEM<#M
M@+FV]3ML\]+.\OG=\^@LF*.)E9U!SJ2N9FWI'0TI;[US@KY:7V.UX=D&K54%
M,G*YL_;YA"ER>B4;P#UIG;WL6T+>FS[X7-ZOON9-0A/QS$!8,AO WZ>^,UJ/
MU728Y5V#$C&A1$C^4S8 J_AC$T9WU'KAP"PGT4[;Z;0;CUI:6AH>O70(KAV<
MT\@[GM,L?ES>*N -"%N^LP=K?&6K YI:FHZ0V,?GVP4H$* DZ#.\VLO>$8CJ
M1!?@S.X5Y#AJ'8L7UJI8Z0CS_D((?O06*VFTMV,\R@:,EZ[2]LH#Y8E?9B41
M/1$N/@-L 'IP"%^0.4#>?$0;CMQ!1X%*VJ(0PHK)9ZB<[Z?8OV!F]!G.@2T,
M\_?P"=6*)H*.+QQ7"F[H$L G/SL^[3P,=HC.)L@IX3)']S,WO#NG#W_JI]*N
M17IM!@<5#FRZRO\K!=O]_]9W]3G,,#;@N;O<+#(4W&)W+6F5+I/M\G+M*U*.
M= &Q5>,WG@ZP$<U=J'N9(-'B5)7UKE'ZSVK1>\D::,GLXBCU])5&#2>E"H'^
M/MM*JIZ_UM.,^EIF!>B9F!#!^;6LAN7,GNQ7[,!OE<K3>@OG4=G;#EO_J+\U
M#+:OOU>H,!$N]-$>D1^MGX(W4,^NR6$J: &)HN(^H?M3Q[#G1K,+!M;P#+6_
MY=Q-)V26K)B[84HNT.WQCM1SXZ\F!<@/'.)X2X ==;ZX4R 7H C,M'^VA,+U
M7DGF8??-HV]&KK_4-6BX?1(%PP.U?4U;+7(,GSQ7SI3I=Y=:J40JI&?S\II\
MASQY9S-;YJI<)[XZ)V"L[9/V/U6TU1:[MD=I>LQ$:UT>I449Q7C /MA787U"
MJ][7;RZ6;&OFO\^HOE&55^76A[FSV2ZC2%?T(9++2Q0=PS'B+GJ* RN?=Y,C
M03,%XD)1C:C+J&\K ZL&P#^'V]^]5=GUZCB ?ZU  I^D93;[I]^@R'[+=^,/
MQ(^E-4W:Z$5#_25*&%W&&76U],@RT=DXA^\IL7^DI>NF,=LHKO  W>M_;DW]
M<_+6^GA-Z6@0TI"@_71 L:;0C2*S1EJHKOI >DJ\VVG ,6CPB(H=15W7C^B*
M*WZ)H+Q[7O0ER*<1;@A!7?WMM9=FY/SV^_SDMEWA4OT65I5X G<MA^0U]$1=
M%M,G YX(,$_-MEE5*1FW'._R\[IPP.$]MP(P*WBZ86-$Y2E%.);>XB-VINU<
M?>>[<\E TNE&!"XT2#F'(D4(7TMTHEII%JB,]<L*R_R.)Z#HWE_6N'J]2'9\
M%"BUBN+<8BI9]9/5UC]]WFHT/JN-#MU%51TZN QV9J(^S*53(::K@LF,FI!=
M4])5!,1(!W:ONRI$:]<[$FS^E0V8)VEO*#%'6$;@)\'H*)P++X#5L:^^5"]0
M4HD;S+0M%"O9NX<<L R\'CR[V0(;HEC,)K_7D@>7I[1L*57=BNV7BY^ZL%;'
M*DRP"9/7#A#>..M0=H5I:Y4F6*'J*E!+9VROQ6U;<AV>N?D'_GRJT+].;_4R
M X/ML".%"AB#K\ ]_^[96MB2@81FI)"6W)*X6(H/%)IG>]WG@1;9L!#++' 6
MW_D]Q/%. 2GT!H1$R5#Y:,H4&V"0)GO^ Y([]_=^K)I_4;3H\MU:*5N?.XIC
MZYB\O<Q4X>-E3=T"P.MC;G)EE:BYGL$XNCA,&<S%!M@C&Z6RX:@.^8TQ& L=
MW-F]MKL*3D&*:8FWD=&S7!&UZH>ZO*#?IS3X'DP')OSHP2EMEW(0E'7%!0)0
MBL5W#DKJD8..(?H1[=9B,%P=_HL')D'#E B9%J8ET2T&LR$Q]TS2BF0E-6W'
M<S']L-O=FZ)^QT^U9_R<K3&>+W<GUPGN[#P<7T$\)W1K-Y\]H1VXL F+MY*2
MA;1S_.S0N)'.1F4H9S#C9$%/CU_!P)A?0 [6&-% M<7(,P8@;?"4[LMI":S#
M(!O@!S(EV57JQSLH/+K;]&RV<[_^O3\T@Y64@TI;K+J><X+R='2S*"H?'L^!
MR3DOO'%EF+66/!AT,&D%>K.IB5Q_N5IZZQ'RIW@0VK37HA+V@OFU%D17#+"%
M79KI"+88>FY0B%V([8W;_0YJN; :._VUF9F!@P2#CKH6$N0.[-V0R8.G6_\&
M\(V_:7A0XSQ4!]_#)&=_7K\<*.$4KW>VK$:LLWE33_//#J:JU8FF)99Y_<BC
M00KOP\0:_VA0SU8P3)S[<IN73,#"K0F;&\M3:>+,+%,&3K*N2_?Q8*UKD8&?
M)SXE^YMOJYZHM/XEM,V!@>5?/]QE/11ES(43[;CS]0Y%BATOO7%+^$A]"QOP
M]O&*EE!%2'.4[[ Q+;/'/#3[5\):C<#S8VP ])67C1!#8&6KR1\I=AU7W)4*
M+DQ2,J]L'9#=2'ZE.HT590.L*/*B\G_BVC0#WLU?A6GZ0X(G._+-QZW3%X0B
M?VXMD_>;*LZV$9<A4A4%F84)]?M/-S3N<"BRC8$^(7JX<NI<$I#?QOKLB3#D
MMLN7(HU?\O$*OVU82I1,Y5TGS:?Q2)%'O>>4YIQM=#\Y=?.*:7EH.V;880R+
MQM*'=9MNO3(2;I/+Z>A>WX&Z8Z':_B_^!8*WF3\T0.2#5G@.CN'WJ"C%G_"6
M7,G>D.SEJZ@3>&L(OYTW37YL- 9M8@/*@9&*^DB>@H11%Z]V\?7[XXL*B03=
M79VINBT26,,X905F&1L(HEY.;]\=M]TK1.#QD+TO4>]N<*NQ)G?K"@MQ-0@[
MZ['QS>6ZZI%]!2H_,W8;/797T]J,<GA^PLHC^>(]L;K\0X&3I7I.YPFWQ0!_
M>HQC WO&PZG/2YFI,+BS>Y:MD5?FZF/%RE7U(RG\.2>^O[YYRT;47ZF#<8B9
M76M&5UVQ\ D((AYYRSC@!?%.)7R,)KWTO".L\59M&-J*B=4Z3Z,3-TCH4Q,2
M>.ZSD6<S;..LORZZH7*EI"3VR=)YE2")P$.>Q1FL"KCCU@:\,*NPOAX:'PM&
MZT8X1J4Y[NB[\L8ON^]5U%$'_L!]R.JLXV8S'#3$$!E8\UMU?R@&T:VPAEZ>
M O1-K)V]6Q@7_5HAKLT.,@N,J)># FF[3_$B@EBUBCFLG0D;T'&C\X'XW F?
MB3Z"7+CX><K*A/+[C!6UO+&BY9ARR6:'B6$-LAY$H>VBHK=.B^79YQ]COT8N
M=-,2%#J+RZ_,:AV%R0[7)19-FR<[Y%\DP##2+7C,&]H*3#^%6E,7OY2*_S_8
M>\^H)KMN73B*BH(0"T40B$I3$5 $42FQ(4U$0(C2HM()102DA43PH9<H" @*
M$9 B+=([4:J & $A]$#H)22AA)#ZY=G[.V/LYWWW.?OO&>/[?MPC@;O,M>::
M:\[KRKSG6A8$L",/FC0P:6Z4CN$8WYR$$.-4!Y^]I5VC<V$_]D022P0^NISX
M9;C01*;%T$F%B'[P<16X7N%-Z8R*"U>&?P0H-QGW^T[L*-8KA@W463-.TL#L
ME).=:1<#T>U6BTP%A4D7]UF.[@BHJ8WYBD:V>VQGNZH=<2'VW<27CJD^)3V5
MTC$:I/\*0_[W?%_A7-"^%>I^U[-#295NC=TM,?;XET.?&VIVKIN.%-.@KKHX
M(NGER(>8BV-.Q9BS0,-'P>@9T&WH\T!P:\PGFR#4IJW!-44Z?YX%!1P^>"]6
MZTORSLBN2.)Q"L=R$+*%!<Y=]<CEEY*1\"P.=634LEVKP*F!R=$^CW]=>?33
MF'"G0<_/>#O4/EM/!%(7>/J_PPL/W#/@P2WI/FYJZY$K"I$W0HKW I?<@\_R
M[0;0/TR/MDC#]?$L\/.26DF97)^"GH-SZN;J+ML6T"H"Q9L+:*>SW)@"R*>[
MC65PV=+)QQ4RQ5)Y7D?8@L:GN(!7&:Q-GM<8A1]*GJXED8@VA3.N6P2)+AFL
MZ_CS$J?]SA+;FTD66T_M45S  09GP(>ERB[8-MV[(BYCA:;N_:G\U;DU;CP4
M=X(+"+L[J%H_II1CW9Z2"W9;RHE=//M?W[[]7\<ND",80[T+C@)13*''K7?C
MI/&Q7B3UP -!'CT*<.3X55N$!OUVCIO%:D-?7D*)L_&'[J03;_Q=G@% ,1J,
M2UP OPABP(>.G>6/X$@L;Y:D<H[77D_]+$)160=L_&9^/J7)KL%\0$XG<0%[
M'>E,9B!=K"-[LXHM3&8&L]YNE%AAFVR9ZCD\=Q*&OZ.>T!V"QD*%M16R]M*#
M/BWY< '%_7ZK(?L8>L=XB. W;!I+O[K),;G]'4K3P'"2;/%+_HA 7A#L0F^X
MRPAP >6ER*VDA?*H=LUR^B"T%DVYXSURIHL63 <Z48_;EB>PO&?C+.MCYDW1
M]P8)0B+&Z(8!%3E?_'YQ^GVD#-*9$(FDU&-=5??1[WUQI(K5NA1T)W;+_8A'
M[I?#;_4_=1!.<Q J;8()-3?!1,P*6W,*O_&-[(D=+FD0D/MCIO?D 63.E"7E
MPM09H3L035_KRKG1E@]/*83;J3X\>VFAS^M(!\^%NG;.^RX?8T!6JQ%(7LL[
M&@0(G,XIB9;QS4>!94>$K_-7U_/O"C0@C^25TW%.1"6VED'3((FL\K3\C]')
MPF.WRB<\Y/*WE\8-Y5RR,2,X^FGQ-7$'2N7,?FP'[LAC?<U8N)W$=7#&J\PK
MWRC2H3(>8A/@^:S?NILN5"Y@9O&O?.H.JDI'@!"7X,X1/(%CFO\H!%N)LG4#
M]=O$L@Y1\M-SEJDE5ZZ;?+:RZ@][];8S3 0!$!CX7%)R-D/D/[JX &%)^5*$
M.W=F\.$<>1OK(O>7FETWF]/O'OYM@+I@@PI-D'J%Q-^&YE=3<2SQ$ ,[8\ZA
M(>*Y]( KZ"*WG4-=MUQX#.U=9!'H2%;7 IAU-(T()QS&3F>W[!]7&$<>T1[3
MZ%D\.1SXGC<;L#FR= AY&\DSCO*7-1PI-J9%?*K3J!H;N]6Y#XG_\PR;%]O0
M&'OZW[*AT(84.H07"-=YDB)6"#3^KUQ _\,O7L=T]>G(:1,+8E2B'U+8M:;"
M?H4Q/V=UY?FIA<>.3XITZF6SVC(X,>"GX!%L&X%WT[=&D.#RI3:?XOO%/J7N
M3R\IY/FCTBO_W*T_'S<:VGM\UX8W#=EPR5IZ#--M,C!R0R0#M&]I$'JSSL7S
M9\G7TZRC\[(30"-V0U&QLL=1'G@J/ZLT@Z2K(M?Z8507VFTNX*^QJ:'[S13:
MO(J8DUGSVH)_K&OWZJO.:SHU( NH'R25,\Z1-!7G='(!(E7+XB\F B'FW[:>
M>LJ>8QWDIQ3%5?+M<@'L&(0*CJ)(JZ*'$@L=+Y6EE8ZS/RV>+)UL]U6=/5['
M@C',^<]@4^AVG^JMXDE^3QXF=F(+O2,;9JB:;:5\YEXV#P8]UPVY (2\]ZJU
ME8+"$$*69YAMX(U0!I(=FPIEZ"Y@O92H((ZP!!>03.;QV[6'/.39OZ.AOB-5
MH^/P[QD\R!P7P#IIR@7(*G9@&-N#X"VM#/:3/ OBP36>$=UH;3G&<W*-<,2F
M5Q4Z*AA.N*#EKVSAQCES,/+REL0+\-AMJ#OK%K4/U0;F<Y\Z]>?SQII?'*3A
MW<Z37"W]^JN  #G(++C#-#J-((8XLRHC]^>#_T*YWP[PURU'2BX[Q?8L;2_V
M+-4A6O=+6DE+\LZJ]_Q^[-1:TQ!N1!LT0RAS-O]9A'F1..4;@IP^3^[>^,@.
M;62*<$:Q DAG9'@J0V<<9@X+&*B>RKM@9=3CJ'U^K^TQT1L@NZYFN)X>XOB;
MQ9&/N<>WF\['96;LI)!"247X@FSV_G9MK<A?7[$6'?5G[<#^8R3/4)E,SZFN
M93Q+)V#&=*=)C^?=E?YS 1V@'=V"33Z*G.9Y+*K_;IQ>*)JE5[+#1-,%N8 Y
M5#07$*W) U!;O%"P%\J*8?C_RRU^R#8\0H0+"&F'TO=B67:(9_WZ_^4!KSFG
M"$ N8!#'.H3<4$0R[Z].B5)=.DMA$(I;@QW0*HWD)D*)SC@$2C\",!AOE LY
MHF4%;$5%UQ(.(6276N0&/W@NH/S2#EY^-0U*!U:J/&0>M]T6W279>AH^RU*Y
M$O^QOGGR6$!+9@D-;)@75G#X_/>>C7"4:G.Q^S"^>9B-&T<! L>ZB/KA?J4A
M)LD_RX=(22O')PY(?-^1/KAVLS26CN4<.DG=9,):&PK:F+N;/GG'D?F1VE6'
M?<X#=VPCN8":J(&6WYC5=8E?V1GS5>7E4\93=I^K8.3QGBXJ5-31MWO3J.Z0
MI_AZ"S6X@SV^.\&+8SLH-%B-"Y@N!6WX_YTSM?%F"UCOIEX=<Q-]*.;,,QE,
M/O:?)V>1TVBHP R]DFE.#QY>T<CH,G8>4CD:>?N"[(O7:XX;WVD:K+3V1Q*S
M@3DUQ[(VBWM:O/"[H!&6QGN+;Y2\PT[0R$QYQ0U(+<Z!A*4K[JSYNS%UZ0<(
M=D.E5J82L <QBD'BR@5WOAW=RY")P/EVW5!::CB+6;E0<+YM?L3@":6H/Y9)
ML&)-K7'N_;H,O^\2GZ4IKM1C.I=VIU&^@N<IFF5[!7JIM>%5V.@6T99^_^*K
MWEN3MRZ+4'ZHG9"9_?WZA^R;&[(9?W+R\Z[^4CD.,;V;U2=^__.7[OO"?5KY
M56YEA2PDNPSI<A(WFC:[?R%*UE#WPU6FU8<7;3+PP_<OC[]X\Y!9%GS4?I:'
MZ=/9G_(HV'8;S!Z"+;*]L5T +W:>U XQJ#^%Q$I^9.;@JWCNX+&NV&TB891&
M:#<\P0R((!\A"VX&'3]Z4G40^0[)!\WB @[!89IMZ)@QX6:^JA=NFI1))],'
MB2=0V7S\(_A-&;<HN'+'T2R048"Y,3-IP&S7/2TG!#T4=/>T3\"AGBQ%ZU0?
M;R9U6&V76<JH+F?:Z5TY-+RP+^G*I%2LA,$Z\$PF=+!K(_I_OPK._W</\^L7
M"GMZ)!X]>3UAWG]#QH::.R.<2?3<2^RD]7OY-<Z/+-U]*=,>?'%-G[ZXB:&%
MT04+X8>I#M9]#;/&#?(E9>4;/["38)+P[!)L.Y$XJ?+)=<XR<.+INQU1GG%(
MZ_(O3UVFL'^E%=FP<^\U+6ARKH+*^2N%N^IPS7!3R>?^4F2A0&N-7$HO=@>:
MS))I'F3^.C#K/BJFF!J0<@@<K(-M!FG02[4T*#)IS,>L._T($!?0J@HCQBU5
M02^TRX[E/S1=CS'8W$O[YO&L::71.Q',5VT:-G4>=G+(;<U9OH0L D\[1%YJ
MJV,%2Q(?34,V%6#;="M&V9/Y/M/)J@_PX@KL_>&!<="0A"DMU ALW9LK8]VR
M34Q:")U,:B2'6O1GIGW'H;+.TP5+3$-F,@U+[)=OF9Z\6Z%W45JMY."/[=6'
M+>=9]E1@)U:DII)H<LOD%O-)S*$',<>$8XL^[0?=[)[;A+JR_@Y8S^G =O"^
MK0]];JH8_U+G3BU<C7Z W+.)GK _Y\\)O)P#OI<BMIRBA\UXTV\VA90N93VO
MYW1AL[I^2<MOS#E.TF<UUA?3%7Q2YK>>QGUA9F04?KF27+V=V+TZL/ISEQ6E
MTWW9H[.)\I +0)H:FG0H#)$^5WNZ>7K0?J]Q 8ZJ0JXR%]DY<,T"^H=>3X6@
MQ+DW,PIO#G<FK/6]TF\.C>*A'6$Z=#H33'O9\.>DR8!ZLWG'C,D5&]=C$B?2
M'CB<O#'1Z-MURA^#D_<L??M=^B#)VGHG7@,I*J=4Y)Z1^+EF]JA@<=2''M#:
MNB(H0AL=L_2DXN-=.POA@O.U59E5#34-T,G)QZ5ZF<_+9*4_/JV\'IAV<*":
MB"G-W!J>H@TT!!^E0]LAND>H*IG%CRM*%])\I2?V1]Y(NG*XGG4#\Z5%D>="
MS%7@OI1\YNT*2J\;H^R+^W":^ O;0Z<M_<=/WUE-.M1IV GKX0@BVCC7Z(O3
M>'Q5X072%FU".6/%+L%/?T?_*:>?V(3M0(AA*?HQJGX)YI,D#2%="Z%VY:$3
M_B47WT]L*GRO-U\H,&J8+)4ON#N<.&F9F1COS'_Z%[5(H][=JJWY7>9LT:1B
M4</H)/0F_/2,,5DJ$&W:OS72M$HR\J^-N/SJ<>(UG5<KII\P2#H/Y>R;H():
MP9'' Q.5G^$>>>I>DM\N>5#E*9E5\E=RHU>0S$<:AI^.G W!17*N#&R3P-[C
MZL41=?&:DQ[^%FMW]6>A1G >@0G/Z*7JS^C@H[9PPGUY4^YO=L73+M\OBRXX
MV?3UVN*)W49)0M3RW+%OS^S=%(IM)JJ9;C"W$')?7HNSE+Y%=.[[IZD6)QHT
MV?,D@@W!QL;+SGM#UX+_S.>JQM36E6LS20;.$:^[SERRNG7]B+Y1PMU^E)'2
M;++;),AUP/TG(VI:G(1R(7KJP"_/SASNG\"\21L\>^D7<(^S]&4.?GNA'.N*
M'6GQ!G9<:9X>@DTJ1WU0CLW<N'5]/7[;B;:BM.C;%Z*XMLJT<X<>DH\R'FHB
MF;:-CAWYV.NL\X +"&!G9:4PKD#;1^X-_/5BZLSPV*T*>C9'914[&XI?"$H3
M=% KN5-Y7[*_V46/=9P'8=Q>LI0KJ14"-0=/)1Z4S1/=WND CV):N8 JKTBX
MZ73CN$WHW6EO!] 1.\WGJRS@2N!B*;QX%KA_)0N =Q[TCSM7XGU:^_-K,O!!
MR.N1Q.I-UNW6NI_Y1KY5R\8S'_WCTTR"P:H-JQ;+5[WCG@>UV[I-B3I0+5*3
MXE8++!=:W'0.-YS-:7%DO/K4KP= ?$1\DQ'H;[K$O$Q';)I$$DC636"WELP;
M:L8J!J=1MH>? ^^'PCJ1TR4(_OX+GMJ:F-O2S2WU >JI&^_VV*^<VC,QU7C_
M '(<D\7A1^"SKK#15;L>?CJWKJEWOZ^OK(\W/':-(X]3HCOHK'Z@UU,+VM%2
M32;L4J+)37*9V<L[V;?T]C+."//7\RE*X5<E"J2<ZA)/)EK>C[,\%COZHN"D
MO>'4SDM2J!V+"SC5$RAXN<U'>S,V)3E__IS7[N>\$+UBZQXV*:<V34E/!#*W
MN#KS]Z\2YB,$DWQ[?1]/]9J=(YG=%^Z;_6:$7Q,5%9E5R/R=)S*4OHX60'H1
MC@5>O.U9UMG CH=[*_8VF*U- H?"-%:^ZQ[C##^@TD*4O6XFQ]O8GUL/E>LJ
MWJLT:_WP9<+0NQ2G:^;77Z]"O5.I"U=25(L6CC[* /?J0'ML"E9#_'2!:A0N
M@,\*,[RQ;"QDL_MEJ<5GM(Q6S<A:I%K0CE(5_]J79GTXCB@HVGOPCV>]&8=,
M!>4KM5<KJZS>;0H)Z0TJ=8DGN<[?*BD8:-:?09+>SH*B3I_*6/;OW3_;W2(_
MJE_))K==Q;@,< %NZ$BPC,= ;T>&AV3HH- GPB<GJ/_[4!Q.8TF[('+3.T0%
ML^V.6GM(]YY705\AO%TLF8VI0 :HM;'=,[B M'<M2D%MF&[Y!7B87JC%+'I$
MW) JFHVEO*P[;7B7/I/9M/0(63&;%6J(.<RCRVOD65!DJ:R[M7)_+:JTKVXS
MNXO9%KO+(KSV]6B<PAC6(=5#E]BKWIFHW.XZO.)/]H2.8P&K8L<),1S"*O/1
MH*FN\3'= KUGL*_ ,T"J9>NRL<OE7J?@V9T+B2_,<)2O'A]WA$A0:3\N8+7?
MUA:,?O8";MWYU#-$?7"TH#^S2:]MQ';U .51X]AR?JV)!_[^:C_:BS,)JN$"
M(N 02@ZY-4ND!?6X8?A5X@+Q]/LG4763DZA/R]"C9GK0HSYB2M<Z0F&BC@,5
MQHY8F9)$R9D2!<._&/G'2%?&O5\2\E*[3^7$*GW7??4?/P65 H%TTX=43WQR
MWC*^(7YR8$I6%MC3 *2[8&60OS\035E[D)2RGFN(\U5!2P/OTOS%\-.)UW<3
MC\77*UG&0UWDT,1?NK%KX)DL5A 7<,L[!DS9SPOTJ'_<7XHMYZEUDXBD'\;^
MZ&+"5+D -,]ROLUR7$!Z+T$4'$*;"\C6;$?3]W(!,_JLRP04>,F$JL@!8.EF
M;!2*=SG/D7QSXMQD5Z=Q 3@>F>=YV,NHG,9_MC.7(T'N0F\IT).Y  "4=9;3
MU<6[.H;'#W@<X11GK)<+6&2!*5>Y@/2N?KNH?\KA @[OS.(8Q^$\JO!*E2."
M=.#AH,5V+H B@7R#]'3B=8 #HDLA?\XNE;7]BR N(#*$NL@^U"+':Z8X%R
M_B\=!M?P6#./KP-9PN %GRW(TW^3U*9#W^3\13B&G.;QN C0")UW/17,.@"=
M XT_1O*\012''[1YE:'T]=\%_:OBU^!(%AW-X5/= ))*L!PDCU#RH78_AHJ.
M_*N8?U4[31?,@?/(^YZT77[:,)0+ ,]P 6%=K/]Y?'.9(!ZZT^4%^U>]K-?_
MT_@^0LA3=*NG1RTU0A4?#$HD NK#<KM9,,G1ERKO@E8&WD$"Q-*(":X+CZX/
MS.5:J86^2T:^<+83,;-U<?U/[*L[-65<GWHU-TC.(<+2-LF5<$=HW$HM=HNG
M)T(%,%$;L<0%C'I^'M-\3.8"_+L*+7H1HB1=$#L1SD])NV^GWQG\,Z 4)#=A
M0@MY,M46CDC(8+ P89MPCU!,)<V/T8-8J0WU1\K!O3R[ZG4/V/>.A1AEGC:=
M2F&ZY>Q6SF,%Z$H0:N?GFN"['X(*;<%ZD6HC.WTA/*60Z8K;0S]]I@+;S&U.
M(*A5U4^@(-*UZ9 P7+.?C!*[EB5/6?A>1=BW]';R OS<HY8^]P)V?SC!S%Z(
M>IN&HKITI 5N*QL9>-CD999O9'=E\Y&1WRKM>UHIG69E9[PE+$/?,ZL&-T,1
M)@P9V0X?*]_UF>42:45:'ODAK$='UPU\>:G49A;%"ZRC&7UK<$TG[T)WLX3X
MFD<NBOER'^<X^_"1+"LV1MN."OY9:X-9\]2@,S7>GGV$Y/&\0&;\[%A3;9[H
MW,*$S_O9<VSKN(>N6Q$:/:4+PYB-#1TX^M7&3U'3DN'[S9X3*[HN2+DM*/I]
M &/#-2>6/DCZ;\O,2Y88.H1HC:L>)9X+#8UU3][J2:Z[*#1X_P7=IT%.N/Z[
M>L SNC8>I;MQ,YJGZ/70*(66[ $6>!HZ\J$5Z=&4[NV_&DV+NJJIJ<\L!(==
MCD?GAT#PE)V#^)^GJ('IYZ^ZLBSE<[90 73XEJYF-+TGTD[C=9O><'OO3($T
MM*11I9EC_1ZYCPMPTA&?'D[@$54(2J$*5FRYF2IA<(5FG\YA,OUP'OA,3C^Z
M1B6;>FEA *X[Z-8 /+O!5P/K7P\N8@*[M"% :N4LK9[:]GBS^I!V@JY87W6\
MR\Z#1)Y?"&KNLV9G8IUQ1Q #+6?K!JMN>WL+Q5Y("_!=[*TY;& ;UJW(#PB6
MI%UJNK&JYVA[V:3S8Y4GW!]D1=!C>#ME$Z<#_<V2<?3\HA2#XL\\VS7T,_0/
M8+UL_+/Y^^)Y8^-KU8*%T[6)AOGIX9]=&].[EP 8/?9GL!/A".=G RFOK(*V
MD]KPRL$MR.M@XK.ZB8M!^QR?A^IY(%K11[3!%#PM;E!#]9A&DYCRX:_ZOA=E
M[$I*$\H,IP-V&R$_S+I7]"\EVB6R>U^8):>-8NW'8<U-:Z$I'BL?*[H7'@$)
M\N)G"]G%4#V\OTL>JRP($ZLM6,8"-T=H)"B:]:^?\(ZV;75P6%>2Y0+P4#_D
M=V.$!EVU \RO[&<'MACT#WT!^U&FS.D[\]/389_X,_W)PTTA^-;MH8['&H<Q
M,I3W[BT#YQ1#U;US:]*@15?IQMKMSJ,O.I^Y-IA[%L.*["S7>,1''>?.?JU[
M)! Y"^XRX,WLHV?K*JMJ8)^K5![8U2T52+VY_N8ZL3F-(V#,O!:H.;/3-JG:
M+BF#=LE> 7G86,5.!+GY11@R7R>T2?R0W@\/XGFR(X1 B\>U?]1[>Q-T&4.U
M;3[[(J_)ZF9'G:EN.<VRI6IVQ-4Y4\6JD<4Z#:1HTW-.T<B*Y@.A#7@$/[AW
M:<[_Q5B=T_F! (M!D]*RE<EC@]2KEU@ZZ5:XI06_<A7U)R4S98V3-BY]0\V0
M"=_/U#] W]^0I:YP7NC)1 NYT UA,'\G^86\ .<RQM?Z-X8+:G,&GZY\VZ-S
MZ74B;#.KF<^07:1[:LF>9ZY_N>/;&7]9@]\].3(G9H#;+\JA0)_X])D>7+QF
M#[U>\9/"&36ZDA@SNDV [5@7N]7#'9*<1^//=BFU,\4E[*VK_?-JIL:6M@+P
M#K'XK:'^ZM55]3?W4@/4;E0 9P4Z;K)\+)66D"-QM$L5[#Q/?Q.H]1^O4K]F
M7;.]>IXH->+MI!<&5_G&DTQ>$&I,UW"@M3ZJV%3GKPT;DI+%:Y(8YHKVG^]M
ML@YE5Q=;8)%8(8>9M N3K7\<MX:@$$=2,R;OUQI8Q&G[LF;RW0",:%%E32P)
M"ANW 3WX^YU/72TZZ 8[B^07DF!ATK_MJ6;HB#6.$5-XG_Q6%1SH.5;/!3BW
M&+$Q3;!L^$UV-DN_.-"WUU-EX>&A"P[NMM=SBG_P9S\)(N.;@[Y(8)ZQT\!.
MJYAXZZK@_"]2J9R3-?#*H]681\B](<$9.\B:RS*G6I_6(2)$@U]6VB55$^XD
M!;=@UK6!:_=JHRZ]+SO3;I529+^\XT6SL_$,*<YA#D>MI3&5NZGZ9BA[_.E
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M.$/OCV?PV0[-G?P6?9)B6Y"]=U2P8#>G?&OUI0?C?9I&]0.WEX?RW%)IY5Q
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MQ1'6Y@*2'U @[ 0>D_B<IL&0AF:!*3Z+K(RH<.P:#,J6JR\JH K8@ X@OY_
MSLLAA<&KI8N<-Q.0+3XH;H=U-(YCKD^9Y31,(9>%.I W-/P#1&[%GBV)%:!#
M.,)BO(<#>3.FO*R7"[AC!YFTI&!84CQTK !RX (<[-(XT0U%B<34K@53UC$T
MQUR"@N&TR7(!>LW(.Z(L'KO[?HX+F#^-YCFB-37PE@U^ZR8$XO/WRC0_/F&2
MD--UZ(T$PDDD?IBGSKRO^.&A?\O#%JZ_8AFSWX/GYC@@+F"DNX +6+[GS]:
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MIEM>0%J[G]CV9\*_]13VGBI)^,T3 .CL[A;BC)>2!-V66&!8$(5%%J66,4R
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M(O9\ ?2GJYOVR3XI<Y_+BK1@'"X26U6:(:[%R?T]NL6%#8LI"<YJZZ^F>'2
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MAYOEF#T$+(F!:.<. 0H1+!%G'M8;IT/ &]DMD JVE;7%\@V*8LXS5G<B6+S
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M/.Y?4PF/1S0AR<434^1(6@ 4_2]QB3,D0$=?[D7-X!B7[QX"6OH. 1>@?(>
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M550YD RT)))AO7T35;]Z7FN?U0LON7 !*%_I1:D=' 5WVXJG)T_>S[,*FC-
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M98I6,]8+BI%>D( CP(OW8[I_*2<.\D2O["ZT^![3@2[AA-+TZ63? @3T974
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M^ALJ,IJEB!ANW&WG9F=(;<K=ZVVK)>7D!<)\9<$^$O9?>!X]"QM(2I!95V!
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M8!K98/ + ?I0K6?UH+MB(G'29:,CS(B#@<Q^7ES_W,LDXOR&,+:7-3&VJ-"
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MS5W_Q2', \<CH.<\0\UM4SRK'  9\0ITQ$V V%+PHB'XGN4OFS/C+XU-W@9
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M!OO9!'A=8VA_J"":PDI(:@"EB/=XN=MG&<IO*(T? !PR25Y&OMA=_J\MB /
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M1U7U.MTJ@]!VK+:-T\'UP'=[Z]'K3>8E/2'%D+$7PLGB39O?['R9QANHCQS
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MG/W2B%BWLFY_@GH__CB7F.>[9ESR@ZVW<VYO%CZ?-H$?5**;!P)3YN"MX-R
M$ VXHQX"#U-AGU#@8;^Z#F0?XT:>[+();#/+40%3/(Q8+:P"ID8(:5*F&Q[5
M9E;/\)9:2416LL(=$[.>,:=&/X]TNJPAB0)L7BF*',V8JH:)I<J0Z\*9$F4V
M^O/Z]B&>G<]S\FW-Y#B _1W QQ^9L6LWM[E+[#N;%@AGGK,48 &\P4SAMO]J
M1_(_0YM"*9U&A8,T@U7JJ(7A3)-<>GBKQMWU,Y4NUQAB):?$UU\"3H<G><29
MISB#*8^1(]40>CYL*A,8#SG42+6?)2_^<$ZTN=/?Y]F'?FXV\KGR.6"W(0-4
MJKLK/!:^G,(!9+-6:"CZC1K@'F !3E>*^L]>,']WQ3O6A]]]/R/A5?"H9X.8
M"_3E-LS1@;4L?3YB=B=>#;'S^*;M]@$A79HW"\T^&4IP]@X58>I1L/'$CEJ\
M9*;GO42@MWLY_:^8OP^[AOU[(B#^;@5*DPYF!#&%61] \DLY!RCF[2@^>G)G
MAKQG7TBNI8$,L3Q)YLF,O.CIX(JEPH,;K04(VAQ=1V/US.211V29*"@Y\-LS
MT%GS1%1*:T#$G:,U$DB-B47]02?X><;;$$_L)K8YYZ]_G?\!QC@X_3+PJ])(
M>&<EW8TLW($_1#>&)"E?^MS4X)!NFK6_5>UI$X)\CF [C2#"280V:!B.#&J>
M-N(QHISJY"I[-^TY0X4$][RKAV5D$@Y[_<V";*5_&7_R]4*F4#+-\:>J@,"+
M-*A8\#%^)/E;/E(_;?64!BU,3TI/2O:U_/YO<87NXL45' #-EU6!$0DE2)[^
MY8./!%W[T03+710^/$1;-_)S6K4_(GUI-.6^[Q4=Y?"_6_*O,[&5N9\;WU/L
M0= ?!%5D) =P0AL\K6/8)GW<;/*^LVC9U8[#&]]RU_=?D\D/C/A[GMMQ /_#
MKQYP$:R# !_3B#+XRVS/OB"S9$4!Y@430;Q\/R4D+B03CKN[5>(-7C9?DLL4
M??>TTC2;=^O3M((Z-,IQSN?I9ISKJ1H/D<"JN$]K:#C"9UQE@^T4BM=.1#:+
MO0/-B)O7PUNTM05)6 GV#ZJ5?Y)64/3J2MZ7RCHDRZ;CJ]V^.VSYR[XX3VR$
M?T*!1XD-G!  WI(RS,?[N(6(TY1\)'XI-&@JQ!Z5 GU G6/)T1ERG;H\"871
M6:=_22/EEEVC:+ZP\!P-I>+("'VC[PI>BFG++)55-[JL1IO $;H;:>A-R?#P
M(A'2Y#8T<FI([35^G[[B7<5];;+!X]4Q])C&(C8P^$\ZSD^B/14D3<@S0=LW
M)LYLX"K?4D I(_ZV-%YJ9ZT)"ESM_644E:X<(,P& -@^VZ)#PL!VT=>5[_E.
MYXI>^!1;784>K;)$RB1.7V5+].2&]2K_?/=IM#&IH;$YJ=%7/VX8HIY99#6&
MJ^ERD;WW:NO"DRMXLMQJGRZ;MY+$0$3 @+2+^1S T7NI&,-;MV*-KU0<X_GN
MD>-1-ZJSG$[Q8PI&&=3:PUPLL-C$V^34[MJ%B6%8._MP<_)7<&5AA+;2#!H1
MN3*"L'"5<AY=^C/*;781ZMP:+-8A&EB\4L@K^ZEZKB8G4S5E<'#2"GBR4]RE
M-2"V8/E1MJ/1A'9=V!#!J%%+2S$-#*I1 M##.W?*5%G !Y@,L[%[[D(/C>N_
MLEQ^,8\Q#M$'VM?%7D#M?I!</YEMRD#I@.G?W;&Q-8C7<-O:)\QOJ[:/V!6G
M]WELB>ROJ^$  ,XTJ3D#&1VX_YCCPA6YL9[@/WJ*02_M+4Q#TAJPQ[ =DF<<
MI]7M'U^;*KZ=M,::IX^$\NVJD-:9@FUMUQ_E+KF%H(P;7>3J4OCA8] L^.3C
M-0PO*Z>,>?F@QV(#)#-?VM%UYC4/KF*]"2X(*3Y4YEM<>ZU?;>MQAP'THWT3
M.'5V:?BZ,B+#DK6V3@5K]%U+5NFUH:)GU4::P10A>[KX6CJ%/-0W.)?AG!T"
MN@%7A%N.50^4;VV-\BEW@D>$U(16)$5,]$X#_L$_^+^%QU;E9[XS0#XU5P7'
M/N#GS8H^\(GAHRQAW22S)_ Q+Y:7Q0[XF.G:QMJ3CR+#_GT^OQ[PQ-/K:$]_
M!NL="&ELV[.95@^U1R-Z<8SIXQ![,I(N,Q_F.@-KL)G+ZO4T:MK@KLCS=KQ[
MG3$;'NG\5K$$P5NG0L8>LQG6M,_6>AG/5-N>RPB-&(RN-6,/D'3@[*/->5Q)
MZ$@/-_GKS92UO"<'L'#.7(BL1)?1?U-&2GSI4ZY(GWHE'5^^N9L,S?4:MAJ'
MET6*@B=N#-Z>;@FT[]HMEP*NS<)3@H?DVER!Y1R 8@"\[;)2ZVHHSP!)^P%9
M%KC! :3# Y7A\<E,X\L#'UR,U(?.="X\NS,J^?$&N+N@>%LD2:SV"7OA ";@
M*WXY(PRSI%Q5!>)_V-C(NWO@/SG/I2CZ* ?PU(D#V/HDN\=N@K)YQ1BRD-#1
MR<K"!(S0L(M9J$0C-2*)J%\T?F.@S>6-R<:W/&621\OZ/?UN,,7%4HC+=8V<
M*D)-;8(>]$B>#E[^16@%UTB6YK$'@!0?Y.M1TK1>404"M?BF9-(BF+I;^_E<
MSJT>0L_7.*0IZ@F%AWF6P;@5K,+=AJ7."JS&%_O#6ZNJ16OB+RT-I;H"U]FS
M,B>3QC<TUS,8L>RC7+ER\#[=]G?AAQ!=JY]N:N S=(;EJYLAY./W*NBYX% Y
M[P<'/:KMDF[Z?N-KW_<J>7/@JPR8XE<8'>3@08>W5TPT+=-BZ$>IANRC4.YI
M?YV>3NTAUWW5 B.0O$R#$LBX8FZ)U?%;0W(N;T0_M7U#B3_2%S5M3_Q\XP/?
M<^SM)AWNR!:$&F.Z?&T^PU2C78+?2.9!LC]E8['ZV!?<B%0=+KO1P3.B.B%*
M9-T"*L&E>ZF3:%S'N!9.\F0UZ[/\RU!A^M#&2E>NC;^%XR^%,E=I!_5/FVZ9
M$6;#5Z8 /"\ ]$(V[SC7L),4:+L;_3RB;9N5LU6/D?27(<O$K*MRF<B";^$W
MF$Y8S:8E\[W)Z20[THW;NO$?Q,V'L9^-F6([#,4%>#6V%2O6D3ON']MY0K>0
M'J,D7%#GB8'U5]W/?VYQ"//U*Z#@JL>OY+Y 4!IW/H)TC=]_*DG0D>X-F,.F
M(<-@4"#Z6-&OW%\&>*+M]//I@KXO<BV',:Z_9=&80!RPFM"./R;+'F1+?:$_
M(\6[3II"CQ*[BG3=?$ZKE$T8ZLZ'(.=&([6N&'R_=&!NFZ[PB4N$'F&G9O#1
MH$/T\:))*/U1JW!@1$7:!\.@"U\:(T<\A,I>QI6%LRV5XR)A41DX%@;N #W*
M?4N*Z\"ZR7V$*0%:5 2)>F@MHRY0_OIKPNW3.4O7+D37E&V<3M44F_4])W30
M&_5#@'[9D2FVFL\>Y@" T_06"HZL6$SQ(V>>UKB>4IAQ[HN/V+VIUAYY+Z%O
M\G'[\.>&P"N'.(##JZB57<9]2Z8=?80*?4(G3;-$F7T7@SJ_^#]USS>SL"3E
M6$C?N/_5ZD5REMU^ ,B6E>>]#*=?%&:*CY# P+XZ PJXPSMI8WOL=70 I<KH
MA/33E^E/99;73;G&)TM9T7\R'K%'D.A-BUUB6F3-ZD-"VW>#1,O9Q.$[K[>5
M<3!ADDQ^R#8WY"7<A:2CP67 +9BCB+M4A\PII*#_U3V+3[_6Y?,:+!3RC2?^
M/&AWQ?9\^]?Y \^V45QI&/:<ZZ1KWMQ]"K$"Y6D-*F6 SUB_.#5N30]CP8B7
M?"Q<#^/VB<D+=O-^>6X\L?U!H?AWL8V#;PD^X%BP $C5A8A:09#QQ-P.""C#
MT I[4D_[4?SQ"?5GE7:1^@8:W\0"KV:7E!SI",2&@WB#G5A9\*E)*%&J!7Y&
M6XJ,.+Q(#,7"O$CC8,NXTING\^\52QIHZ?(EXGI[@S+VM,@RS+/;9!0@V)F@
MK<?0"OV9\P==XQ,]HC?M>O!52)LJ7/G9J2YGZ:!/-GUHJ+1C>8AH!;SEK%JS
M/ONH%1DQLF8<:YD6'6Q"7M5G6)E0_:+[K8:"PAZY=P;W9]H^T%"Y,B]-N70,
MJ,+U0#-7)QN'84^#GPL F$[4U"@?,D+R19UYW?60\:&/[I^=?NIKTWH.NDM%
M9X/,W^[&3*I&#0NDP^W6$<GPEI-LG=^%5(]L'^M V_U8<].^6*TBBY<-OU#[
MX_XQ[5/M1Y=34"-XNHSC2A668B0P#&P#\S.-R<TR9G44<>'D29?$UJ'4'-.T
M1]9NLC,IO%6O#'1,,YA<&1 VN03DX^9 *9 K5E_G"-*%RYPGK@ZAE^5L9"P(
MJH4:9_@[_>2Z6>N*YS4T1$A!#W@6@$PQ'H:T$0/$G906C&E?*@=OU:.^V-T>
MR7AP[\U+_F_[;+OX8ZI8$*Q^J0 IJJU9@\33YB9 -]9[\_0G4Z70:M',Y*_X
MMRUG.\/9NR96[TZ?+KKCD5!/3BKX? T3Q6Y0VOP@H$'!K8A--5ID3#/X8;<<
M/!D5%]YMW _D4YJ'9).0(P-&E*5V;Y;8W<^C@TE#UV: E'-'P?&!Y5AF$(Z]
M4$A(#^_R9"HQT$?T^_1D=HCS^7%X+W$HHR\ /V2$:J!I:L$COD%W" ^OT@X4
M,>%[@Q\=*0PC-%#5TXC-0,Y<D?.,V<)+APW<J_L,K \3:1X$J.G\&UPD_ ?_
MWX '2#:.2K)9DH35\GF>NC-]>1*C@F]^P %$./LM<0 [W7"JS^3/F]:X?1P
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MW*X2Z2=Y1^I-CHR&,V3*35\N$:PGMED)M EOT6($0WP@!S$]  ZY0(<#K86
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MM)RK8%786$O0!".>-K]JWT8->Q?NW2G?_Y?(/'TF BZE]/J$0!AR6(L;!)6
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M<QLTF;-+KYFY>TM*)*Z=**%.'/=5D5Q<$E75JAXRS?]\[WD2>]F_@SDX&-$
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M9VZY6,*N)[K[0+X[YUHRYOL=CK>UKIBI]?S;_R@(^<]S'',PZ ">)7Z;Q+@
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M?^>EN8.G0L0E%^+^K6P1D0L$'87"N("^#?,4.)14"6>U\'9FJPM=DO.LGA'
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M#U6=^L7J_U)N2"*2_C&R"SC)^6TG[K]AI'_HNAD ^TT?[I_ ZW>YLE^Z!(_
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MI6FJ@XK=]\?M0JK;3W:,].N$.C^H0M*,5/Q-W%6)U),Z]>[]X\ZB ^<P*44
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MT]YCV[8H#?/L+;JE$K_,H*=R!'=Q@>%.L'H&(P2V%$<@:#=YKU0>CV#"9;F
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M1O'ET SIG<SLSJ6ZI[2%+W7XT#LE"5-_'0N62=:]>C*O;HI_38?0AF9\FZ"
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M$PYU!HB/ ;"EXDD\-T,+*'/Z N0M1[M_DSB#B[\0:>'1GI?&%[;G13V'#T<
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M?"GR9=!I,Z1?B6:<UE5'<I7Y5V1NEN4&#D&58AQ7):U$_S O+\Y7NJHXB++
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MOCR?D2$$;VYC<<0PM$ G_1[D";Q?/:QQSIKKD!<+DV&NXZ;3>T/$D T)'L(
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MC8.N/N]@ZXC@6?:6"8$<2Q7]:(!F[#5)T& F]N(--Q"OZX0IK<BE5=XY']4
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MX/CUKB8H()/=@AD1M7*%DG#AR===TB(^]RZ-/N@?]L+4M9M2S?IC-N<C@OC
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M*TV%+7U4='5I5@DQ-]]Y5Q_;_"N&__ICQ1S).+.7_;,%P8*VNQ8"KU(TRU(
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MW=(L.]F1;PV\XT@AY,U2D1"B* : \(9)!M'L)XE73FB <A0!\ZEC/'.6OT9
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M,>^]"VLZGAXR.#KAJ'G<WR-C^Y5]E*8N$O6VOR:>/LQ3L^ZB*!@+=B$P VZ
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MM*=U-[*36P@)&"/VQF?3BXV55500WY?8=_9NS@X]%1RAZK'G] 45N3@W,5?
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M],2=H3=0:43UV'+#P6^TIX4R!:'V$;?9Y\^/I1[ 4U>.[N; 9$1>MU-WRVO
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M9%([Y.2-S<*JC#0O-:57NQIXFW73M[TWT'_OUR2I-ZT]^BGBWY>Q/@2&>#4
MGK-"L=%TKV;M"EN6._DRN/AE$=[LM4SF1G'V@[2?A[DP&-BA*P<D3YLYG'U%
MY$H^_%"^\ZRK3C5E/WQ'\P4QEK_%M1O+>RO?]LY=V%%2Y+WQG<?H/5Y3_CW!
M^[GP\0DK/+,9H;8*Z1\0^9YQ$FAU5IJMSX_\BN?4:HZWWY@IU)R<^)H4V5
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ME,M?"I4J7-MVJ^<O?1@@5M;:\_TNXO8($_"7LL?$N^]ED]TRZ;I5H+; >D0
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MER03]'CNI%%=9\"K5_>NGV%/WHE?U.A\<&?O9O$:O,XDQI8A+5 &Z=.SB=-
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MZ?KSOW_WZ_U;&'_WO__C7_[EW_X?"/_KIX_OP.N,;1[%N@2O<D%*P<&7M'P
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M6++/.7G<UK3?'7[972,GNYMUZ2Z3T&,1H0$,D:<*P D?QIZ(I>HBAP<Q<L+
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MHJX*SN2JR)3R+MN/ZXE\Z_VR+NL3/;T:@^F1-:N!#+J800L:T$T))&SP391
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MI@D[8B(!:VT!M3%5>4AE#MBW9P%VW;2UJ;KX[BK=9!*R.65W3178.4&W&8:
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MLF$WAN9T<],&O9PU^T64ROD[!A8/R!X?53$_E<+@2>3M*H3T=.3_93#D*C-
M3"@D$>$0"Q2$?I@X G.C2@''6IF;4.Q @B>%TC#C_U$B]43A8GK&]DYVS%0
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MJ?*G(N5-#>W.\EKQZD']>+NN9>A#<N*6;:H<=QE(V>#4<R#S4 01]B,8)WX
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M!8D?:B4?&=3ZW-3K_D'D@BB$P^N-G*=<SW$9C<B1)?"@VL@6^J(I(7!'4KX
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M[REH[;AG,%(CE>BMT=D&['[H1\>])&^/^GZK\)X::-S"NSVJ'M7:[;MV8!D
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M $8JD-,H<&UPV>CO@L/N8J+S.^(.8E?YW6U$9:+#3VXU# 3=)D,3_@X,H%R
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MXK'>[Z(8%BP54!0J(7D1RP)G+JO^N8&FMO9W<IK.-(T%[5S+[2*V=NS@ ['
M[# ,+&=ZN(2$5WHX.]BH]'!)Y4-ZN'B]YR/S7U<F)9RE5!0I09"A/(&(4!.+
M%Z60R#SA$<*(I-C3H7D]X+_*L3FX 0^KONSM(6!?>;+K#.#KGNW^VHN?O]/=
M/5C&.=]MAIS&">^>^M9GO/MW#?#'=U7#ENIN^?@H5USO;SZ6O.Y"6#Y\7U=U
MHN>VY!?A%"5$)E#0@D'$<09I%B<P2VF*"YHI2:VJ' T9?&H6RF[%M:T"H-4
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M)[>^UJ7^J5.Q__;Q<55Y&3XIA8I%6;#*33NC.$A0%*20((X@"L,(DER9["Q
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M7_[SM\IY?:]>'T6)!'Q6AN^BM.PI=O7<&7+DB#/BFS<;54"M2[4QKK4!777
M3I\;L--(4:H7,G6$KUN"O5:H<4G7$81'1.SJN0,CLE:/9-%D5"KSJ5S."UX'
MP"[XO?HNVB"]._FQ6) %*]0>NZTX4][2LK*W9C1A:1JG(>1)JLS6/.00RY1!
M$851@&,I4VD4F>I4JJG1=%>I&["G5L/4.\4TG6]5VQ5>*L$?K7:6I:K<S+,9
MFX\^>YXI?:R)LX]C<PFTV[@W)Y*-&R?G$LRCN#JG#Q^8^=;LI^]D??3V]X*+
MK^)5J"7FW<_?R?\L5^\WY7KYK*CPW<^OXD6GVB\>OXG'VN6JMP0S3E@J4!K
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M.&[WYU0!&VX:I[I!*QX'OWS_]AM0;P<HM;J_.NX Z/8],%M2ICNWGM<=DPZ
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M=- @"$0\4Y"$&8(QU[]5,L!AF+@D UJU.K5]A)OJP,S:<K<OV@[G,)6$18&
M&<O,$07]'V)$.@*.8RDI4A'A;DSI'>EQ*'2]H[NVW_FP@!WB=N3J'<6!67=C
M+ZP,/DB=+ =0]W("R2M;V[4\*HT[@;'/[VXW]U4+XTMS,O>=K/_WX^*=9O+E
MTC37R/_+<A:%:<(%BZ#(3.B&(@JI,BM.@M$X$F&0(.96T-ZJW>EEG;5&-EIB
M8&7,O (+Z5CKR YV.U;R!^58@F.UG>!-:_$O1B!D#>VF'DD'U_=0('- R;,<
MF4W+(VN3.8!Q*%3F<G./K=0OQ0N=KUYN5]_DLAF?"0I24QU)QT$1TK03<,AX
M%L" B$#/'F,JI54AYQ//GUJ,69GFL-UV!#&+K<S+<!B8)1KCKD!E7I\]R".@
M.&PQ7@;.2#N(NR!YVAL\[7GGUM^1V\;;V3MM\\[&7<=E/7CJ\[-YPJVJPK%J
MJE+FE:S@C"H4AH$0D"O"($I" JE4&&*5(CVOPP$/K%36NIN9&FO5AIKSO=28
M"NB6K0[?[6E8+3C-"U@#4UN#TZVJ)V'@VC=.#C3G!:^1V*X7;F[<=Q:.3@H\
M??=X3'C6@QU"/']UOVGE_\BYN"]^IRNC)?*RT11IBL<5SWMJ(G=%W>Z6YHCY
M]:9F9HC34"(.B3(5,3*&(4VI@B01-*,D1%)8Q7\#V3<U)CZJ]N.Z<N:[#^UF
MLZ_8,X/O@>QI-AE7X:J CXVS5_L]!EKG=K6<JC\-43YH(.R]SJ9]VSCJO'L@
M@/=GZ$,UTWN)L5T5,,5G9FE(4QT>QY P$QPKCDT=@@AF/$MIF@1)E#KM(NT]
M?VI<7!D&GK1ESDN$.[!9+P;V!6/X9;_ULEY5A<CKVMXQIWVOXNVT,?9ZW3$'
MCZS,';VLI[JFB0D_/NHW=VF"^YMO=/D@RQF6&+. 2\@3%$!$].=+$*<0AU&2
MZ8FOH(F3@OCQ9J;V%=<SCGQM)N"UG8Z2E\<AM?NT+P=JX"^\QFAC(;@Y@Y&[
MM&0G!'ZU(H\W-:[X8Z>[!VJ.W5=?.'B; Z\+GL_K=!/]\,6#_+AXOZ!&>,?\
M74<-,X:24/!4PHA*6N>7$IDQ*$@0AQSSF$5.A0N=6I\:91B;#$UH4RM)J/K'
MLJHN('4/T/F5^;W,'Q:Z2T!IM,' G/[H&298=9!C$.$;]H$)Z+U2DJ_R[W)K
M#Q%4W;#KR!6H73%=T3BSOO3*B$@]^]0-[X7F,+&+E06O$]FX@',R[G%ZR"N+
M0GV1>G:5&\-,"NXL1)%B4G&8IHF">GXD(4Y)!'$@&:6"$QQPZRV#X>R<',FN
MK:M2^5])ZV6O+RWV*:;10P/S\4 J+EM]?C.9/G\E49_^??^?K>1C^PZ\GGC/
M\9X93;%GK_G_3)F>XQ@.ILUSHKD>@<+[GW+)<U-0*>?RBPE#[G7/RR8-)8X2
MI9*,PR1-J:DXDD',40)9'"88T93S)+(>ZSN;FMIP_5\X^I4$\+](\FN<.!!W
M-YX6XZTWE(:>PC1V@LI04%D**E/[I$!UP^8P9'F#;Z11YQ(8W88,*V0Z6;_[
M">,1MY4G.]QK=T>_A:>VS/U]T5#VW=(425N]W,V-3/I"F$.+3^:264@8S0@E
MD";F6!*A9M5)$HAE@E,5H9B1S"T[W;YQJW=_U!3UNZ:67U63XZFQNPJD9&NT
MVPJ30T_8+2]Y1G<<8FZ-!JNB#4]!:_<5J"R_JE!^?Q9EYQ4D=\"\+A\Y-#_J
MVI$[+/L+1SV>T%.>8:T28RI%Y*(I0/WVY5X_[_IG7LXP33C"THB $P%1A#-(
M3$P8QSP*190BBH7+TOG9%J<6&F[I'^U8#-@+,#:#OXW5EM&//>YVE.45S8&9
MZE(@W349;,'QJ\=PMM5QM1AL03C08;"^L1_U_/'UM^*[7"X,B^T6>&NF 8&*
MD<J"5,]&6011(B+(LEC".*,Q":,@P2)S89YS#4Z->/[X]>NOX&%M,BC7]KIQ
MS5F@[:C&)WP#,\T?7\'&5K"7WSC T6);:+SRS-E&1Z496PCV6<;ZOAZ+7>_D
M=SDOJC#IBWPP^8/%\N6F>'PTLT,Z_SV?RW)5+&2I ZK[7"ZEJ,_A;+Z,E$@<
M)$)"R4(,$4=Z!J<Y"&91%&8RD21&]N=E+C9G:@2UY9!9^&Y=N@+_BSX^_1^P
M<0UL?*NF(K5W8.V>P\K1Y7UJL2@W:D\-S(7>.JG/.M_EO>6P%CAJKXVT7CC\
M)^:VJN@-X\Z5Q\M;&6]UTALB.RN8_I[:+SC?VH.:Q90%1' &L3 %P7" 3$XM
M@3B6A-$@8#0+9ZMB1>=V<?C6LYU&M'4+PWUN]Z8-]])-QU"S"ZI[8C'PF/')
M @#G(/F(JU[CX>WGCQKZ'G%L/\H]=DG/[8=EP:44Y0=M1G.01C_T;BF?FB7#
M2CIQ/B]OU==OQ7*EX\#'CXOOFBVJO\X"*54D40IE2O6D.J($LH0CR%*<*9JD
M 4F=#BQ>:,_40MK6'6"Z&;0'X,R.16FLA\9\D&_L=]RQN+#S++<QQNN2H?<V
M=GICX\L5V/*FT7K5_E0%W3?=]-&BF]RW//R ZW<?Y$*;QMT<\0/@P8Z)I\>.
M4</ZL_RYNO\AY]_E[\5B]:V<<9II\LT(5"@6$#&L((THAH(PQ!G"-,P2-UW%
MRPQRH8!Q!!?M*EM'0U:V/N@U.S8>KR<&)N,+:EW?+CPJ;?L!]!6+7A^8-.'J
MUZ?@NZP,]LFG^BQ"LE51HGS[LKFFV5N__D&7XO:I$A7Y35^Y*C\N[N0R+\1?
MTM1*D>):4QM]D#O)1+,HYEDDPP"B3&1Z,AQ3R)2@,%89"T44:2*7/BJ;#&+]
M]'B]LEV3QIL_OKX#3W*IPVSMZ2\^JJ4,T_]VI#_1/AUXA-BNZ[+M]W9QE]+L
M]A\M &.\OP*-_U>@1L"<A*LQN (M"J"! >PF4PY=)6;0WANA],PP]D^@GLV@
M'6-7)&=8$P8:%<\8>ON\*O5(+O+%@Q[2E_FBS'E=-X93GHA(A9#20(^!0@J(
MLX3#@%(>,J&4C!UEX >S=7HCWO7#P[+*MP5K2\_4HAFY=SV-<&/TV 3&,]OA
M;,O?*^N>]S]R7=HKXXY3O:V=UJAT*>C.8]#%#?8;<7Z7M'Q>5A9\7#P]K]:Y
MK!FMLH@)#'! (0HD@B0)(AC23.K?LS3B3LI:IQJ:VF["EIV@,K1_PO!);.WH
MV@=B [-M/["<*?(<$EX9[F1CHQ+4.9?W^>7L]?WHX?:I2B%>/!@-OZJ:FRJ6
MAI8T060Q95D:0AF;74DA&&2($2@Q#T,4IT1&U(4@3C<U-8I86PKF1CV3;]GJ
M1A =Z-I1A!_,!B:)#5R5V.B.F?XXXCP47EFBH[E1>>*\V_M,87%'WW-)CX_%
MXNNJX/^L0IGR8UD^2S$3B4H4Q0BJ(&,012@R1*$@(^9$@*(D#3/'0K''6YK>
MQ+$V%)3&4I!71H(WU7)IZ;A>>@I<.Y[P -C )-$@59EX5<_.] RL-M/GZ:).
M'#R?*3K>UL@GB3H=/CP_U'UYW_RGIJ;/X>L;92E*2<2A3%6L9QFI@D3&*90)
MB^,P0ZF.*-Q2FTXU-;4@8FVI#W;H0-@V_\@';H.G%K60[="$=Y8X#X;G5*"3
MS8V<Y7/.[<,$GK-W]&.,]W2YT!%*>2>7U5/OEL6'8OE(MVHX(,;2((%A'"40
MI:'0X40B8(:0T'1"0LJQ"V^<:W!J[/'9" C7NI1OS"3DEVHCEC?AAO'@O]T8
MY"SB=CSB$\>!V:0UU>Q5UDQB4A0+4-D[2$D$6W"\LLO91D?E&%L(]IG&^KZ>
M\N2<+Y^WSF/</&M6JT0;/FN_ZG_,>"0R'J 81EBF4/,,@IA&& I)<!:3)!"9
MTXJH3:-3XYW-R;+BAQZ'5P58?<N7 CS1I?O1"RO4[7C'-Y8#<T]CKL^C7GV0
M\"MR;M/PN)+G#E <"*"[W'M!O;\Z:/I:S,6M,@(QJY??Y>I;(>H\9VEDT/7\
M"#.-N*87S3H9@3JVH9!&,A$2D510*QETIU:G1CM5? E*;:\Y+R KB\%C97)S
MLD/J0"AO0A_;V9-;1W03T6#P#LQ$FSIXS63*6&W^6=L-:L-!:_D0P/:H,.@3
MX-$+#EX&=+\:A+: 694D//NP\2L4VOIWM&"A]<V7J0_J@/6+?&H4]6[57W19
MI97-,-- $YK A)F=]HQFD* D@EPAJ<(PY"D+^DD.GFC1ZNL856=P8Z7A]Q^-
MG?VD!4_!;+D0Y@&ZD44$S4&:70#_.@=@;]7 ,[ ,(A5XJLU7T0<\ \ I4<!S
MM[DQBY#Y[/UBI8GJ6HBE$:S6/]XN[XL?BUD49#+DB9&"#I7^3\(@)2C2Y"(8
M"]+4D(U-O-C1QM2BP]I,T-AY!6ZJX[]+8&RUXY N0+MYPQ-,0Z]U]4'(FB0L
M,#A"#*7DOSX4W_^WOKOBA'\A\R.L?ZR(H.NYHWS\%HZU'[S-I?W"A]]HOBCK
MFKNWB_<_S<[]<UY^,[1RJXS\UDP1FH4(,<@1-Q7B,8-,20PC1!CC/$-JHUE\
M;[\^=;;A'G'$_0AT4&69% L@C(:<W+';+:(XC[Q=3.$'R'&8PM@*WGRJMA0T
MAKO6FMC"V.LOKK"&QFMD<;[546,+:Q#VHPO[&WLNBW^G^=S4N]#ARU<ZE_;5
M?S_0?%FE)Z_WCS@2)& JA6$8QQ I&FF22A"4G""6R"#DF5NI3W^V32V>.2CN
MO?85ZE@?EMK;T^6]P=^?\H4$'U?RT35?V6=W6R[;OTXG#LRA(_2?^[: ?Z3]
M[AYXM&_<30;_P![L10S01+\!P;S9'Q?Z4<^URET[HZW+7,X2%4JE> (3D0J(
M8A1 @G "L101QSHF14BY<'QW<U.C[8U]E>+)<QTO55%HOG;"C9'/X&U'LOY0
M'(,W-Y9>;:]J^2ZD:@>*5XH[T^2HK&7G_CX16=[54X^IY:JMHRP?EO)?SW+!
M7]X5CSK6G64\H@D)=?R($#:GF#.(49K ,$JS+&8DQ8E585.'-J?&,L;D^@CJ
M%=@^?K4V&_Q=&^X8_-G ;\<WGD$=F'1Z8N@N@62/BE^=(XMVQQ4SL@?B0+'(
MX=:^)>KU-RS+52-Z-,-(!"Q,8Q@E00 1"RDD:20@"U&F4):AS+4<V%X+T]N+
M:PULA=I<2\CO FA'&7U &8<>UFB\/X-&CU+N1WWV7*Q]MXV1R[$?=?"PX/KQ
MRWJK.E)MW2=-$+)5\'UI=^'>/1\J B*B8DG" $:(,AU2, Y)EC&8*:(PETF8
M4*=U*5<#IA9?]))D=(/<,HP8$,B!2:,Q'52V7ZV+3K]<F819)L$=S<5 ,HN]
M(/,MK.AFQ-A2BKT@.B*>V.\Y?;7]N2;'?/%P_;"4M6956W$KS6*5< X3$0AS
M@BZ 5.J.X9%*LD@$F0Y<7/CK9$M3(ZJUH6!CJ:OT_RE0[1C*"U0#4]$QE :H
MIG46"L]E TZU-G(1@3-.'Y84.'=#WV79^AC>Q^I$V#W]V<12;^5"JGS5K!+K
M=INS_\6BW.S+81H3Q"C, F$J]H4$X@ E4 8X1(DB>J;#W-9L>]LR-89I75E+
M5K]AM1._.!ZNNZ1_;-=X1T%]\ 7@!O#:#:#]:.==X$WCRB]78.,-V+@SR(D]
M#[!Z7D+N;\_(Z\L7 W>X^'SY(WL<U'G[K E;EF55U+G>53M19?6N6.E?Y71^
M0\MOK82;$-4MY4SB1(11IF J(G-Z$*<Z3@L13)G,J(AXF 56<DD^C9H:X;:&
MT3G8*CQL4]EHN'[KYM_7ZHV!B;CU"&RYM-TEN[6@UUX!X]9&3K-U[!5ZS>%,
MT2OTWDA'CD;J1;<329[A[CRPY*NM\<XS>49GY[B3[V?[2"%I%W^_T)5\KY3D
MJ_R[O)/Z ]!?QX.<I41@/7(2*+(,F]D)AU1C"I'*4L*9$BIQ.G/OU/K4AL>U
MB6!IM*C?T!)0H_MAS'44#'+K!=LYR$#8#C[KV$L[6>_Y&-NOP ;VC?E#):)8
MHC9@7LHY"UXQ3<42G.ZL%=N']&2WO.3U1$2*K7G(0N@_/!4EG?^V+)Z?G&?W
M;D^=TK>U9?GV9-W4_VN-![7UPTS@^R'G]_MRM&'<+ZP?0 ??6,_'])B0WRT+
M\<Q7M3+'R]8H%6.1)H+'T%0WAHBQ")(T%E#B &<JSK(,6<4*G:U,+29H[ 3+
MVM!>04$WK!838!]@#4Q$+4Z-C39#N0-&#M--'UB--'_L@9G;7/ <%IV3NY,W
MCS=;.V?_SO3K[,7](HXO<D7UM$ZT"FG77+\;IOB\%.^DRGF^FJ529EQ2!F62
M<8B0$) BHB"6$4XRR8D*E9L \_E&75[G<;286YN!;(QVFS%9X&P7S/G%;F#:
M7(.V5DM\LV4O: P^/<XX!VSVZ'B-T2R:'34LLX=A/Q)SN-.-<,KE:O8I7^4/
MU:AS0TMI:DPTF>&4I@(I&4),@A0BRAC$*D10Q3'&*5$H"I!-[-75R-1"KXV=
M9L54.N;==\+9S22^0!J8.YSQL28+&P"ZZ$'?OT4-^E_[M-#9P"A$8.-B^^E;
M77M!04)VOFP5VR];]?[G4]XL)E=%$V<DS:(8:7((>"0U0V )&0DIY#%FE*H@
M0';[G]XMFQJM5$::E)/&2C.9TV;V*#7HI=_L@II7Z8V!^<M#*<&-=TU%7,]E
M WTB[K],H!?KQB\+Z!/4HV4 O3;08P5MIV+M%]/R[4(VF:\*(85"8DYO9Q%$
M:<RA#N8P9 %)2))&),;V<K,=#4V-=?\KC'Y-8OA?2?IKE#HL"75A:;%RY@FA
M@9EPMV@WJ.PT)Q?.)Q*[ >:PC.8)N)%6TOH#Z+:@9H%*YYI:U_WC+:M9>+&S
MLF9S?<_P5[\8LI93JB2HOQ5S?7-9B\0Z;N)9/6M"'_W:7J-BL6WQ_]-*%@^Q
M8>>$DM^0Q:KE<<,1%S .0@VGF_L*D'[(YW)YHUMZ*)8O,Z._(".$8!*0%"*<
MAI!QK/^9JCA-"!=)9'68\L3SIQ8TU":"RD;0&NFJ.+J+8#>7>,!EZ%#!"9(>
M$J-'';]07G3WF2-+BQYUZ%!6]/AE_25%C4S4[:*6.*].(LT4Q8D.\Q5,C7@H
M"IB #',,29:$2B(2)-PJ].]L96J?<*UW69?0,KT#RF_%<@5UTX]-98D>!PN/
MXVL7)ER,VL ?^)Y Z$<+C'JI@I[$P+L2Z&%+HZM_GG3VF.+GZ8LO6.-]>WY-
MXNW^FL1&7:XLGQ^?JI2?+WGYSP]+*;?3[&8T2D2(,(&)TO2"3"U@PL, XC!%
MA,B4*BK=-J 'MWF"^]?:2JBTF9J7FOS4B]. A^]ZA^7CJ73G])>5-QI@8,OO
M*V \-R)6<C>%V?.B\QC]Y'\Q>E"KQU^D'J,3CBY>C])POX'LCZ_WRTH8[&6C
MD-JJ9'"L(OUEPBR@(4222X@3)&! 2)*A2!*JG$ZYGVYJ:@%N:R=@^7SN&,=V
M &K'ZWY@&IB0__@*UB!MS!Q ).,\&EYIKZ.Y4?GJO-O[1&-Q1]]*] 674I0?
MM)'_(\6#K&5\C"*'.0=2-31CF4 8A1@&$0I,;>D$4I*9N)710!&I$N8T#[9I
M=&JLT=I<SXE9L1#@FS$=E'*UFDMW)6,KY.U(Q3>> ]/++I25P3J":TT&&YM]
M%K"W1\AS*7N+AD<N:F\/Q6%Y>X=[>^S#?^3T02[:C7<<Q9'4P0G)H@PB$:00
MQTS_$V-$HUC%L;#2\3IX\M2HI;;-8<=X!R:+/?6^S@_, [59?;;,=P!PV"/O
M"\1(F^)G7@2WG>]COG9N=>_<,-[>]C$[=S:SCUYPH:+ZEH)*HYPL;A=?3&BU
MU&2FIVMY^<>B8*5<?C=E)CXNGIY7^L_:'7U7]1;<RY^KM]J)?\X$2TD<RA!R
M3HB)CA D@C.844510!5F*NTEP>[1R*E1WE>N@Z?G>56;<]=D\YM/\KONO+B-
M">A\ZS"ZXX1MD!ZWB\I>NQ\'9N]MV?TM#UL)?F'V0M9.@LI+4^-GXR>H'-WO
M_K_OJ[\9CT'E\A"*\P/TR# 2]3X-?1U-^P&@/BF"/T1;ET^KJUR3VWJ-KTW,
M$C.<Q)F220AE8K+_8QY#$@0!C&4<1SQ.LE!D?>?41UN<VA#P6:[ T\Y,L#1F
M@Z*R&\C&[EH9X?W7N[O^T^OC/> ^M[X8UU$GUI6UH#$7K.T=9E+="<U@,^KC
MK;[:=+H3A*ZY=/>-?3>QB^7J7BX?MS,N2"@UZ<A(LPZC$$4RT7/J3$)!<1 J
MBL,T%&YGC@X;F1K1?/60OW(43-N=W,L@&GSS=8W.()DK7>Y[WM,\TM#(VY"G
M73W<.>RX=IA"'Z:ZPOV/8H82FD11K" /"=(<D&:0I A!RH6>Q6HFB&.G<X>6
M[4Z-%O1K%/LMZ]$";#D]] _;T#,^^R(>VO#QBGCL(35J[8ZV[4F5[-@#Q+52
MQ_[MO>DH7^GG?S<"U2O]'N5ZRG5=EG)5OGWYG?ZC6-[,:5E>_\S+62!PDN@
M!,9!+"!*<0PQCZA)2XBX"#"7F5.95(>VIT9+M>FPLAULC >U]28-JK(?5 Z
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M#F H@D"'46$,L= LGW!-/)*2),BX#<&<:F!J1-/86.V\-68Z';LZ"60W"_F
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MN_!Z/I</4LQ?/B[4TOQ)_/%4+&H-\YD2%"41(U"$E806$Y"(5$"."!4D2T6
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M*>=&+.2#CE=^S^>R7!4+:?BY*H!^MRS$,U]5/S?:EE((QI!,8)S&*43(G*!
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M8;P50BM/=M8([>[H0YG%8K6D?/5,YU]D?<2F_)8_E=IU.9__;-[;!$5AHG@
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MP#8E#HYJ9!O76W5L/7K\N7EAWF^],.;7^JH-"%>@AF%HG>SA.FX$S>P!C)^
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MY+Y%[BN-7%'\5[ #[Z5ZNCUC3C6/A?A1U9(]+<<Z:\ (%[0^W>?(5,DS517
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MRHAC)\,)82/["_JG_'+K?^;Z86JA":G_NER)XG/YPH4P#](<Z>H%4(J$*>U
M<DA$AI0U)"G&A"<BMSJ?=T;>U*RB!J>=>CC'J9F6<,B49V71( 4-U,J#V8 %
MKQJXIWT,ULK"D!BG.N.<S%%5AR$!QQK$]+8!FZB.0BJOU;ZLX%5CF67YL%([
M.BF4?/[;<L$I4=_*/$_C*$5849T+B#"*8"Y8KC1+DA!EN(6,I,9;K $ IJ9J
MMKB 7O!V\RJ+/<:0=3#8G'EFU[-ZZJHL-0,'$P"M&<S =@Z>B;?8^GE>@)$V
MANX7PF[K> &+O1O+(>..M^V\8-8'F])+QAF8$O6-% M]R$=]LCZ2]ED??0C]
M/=DT/_VSV#P6Y5TI_E>0U;YU$P[41R00$@9)@B B&$&"0ZD^-3&->$ACE%H=
M +P,SM0^-S5*L"P%^*%P6J9-7;8R9@;P>'Q[_@!5U2OVZ&=@-S,HERNHYS9K
M'::?@69N:O-]LZATFCYO7W+PL2@_+\3NSU4_JQG0TP9J^@[SLIPP[S99ZS)(
MXV9P.:'O15J7FU&'5$U3+\(C60NE^9^**K'L0/'KQ+*'I7X6YTQ0&7&<0IEF
M 41IB)4Y'\20Q#&+ XRYC,S[-AF+G9IJ/;1HJIK>FR7@QJE9EJ0;&/!>J/2L
M-;>8P1[TL;%XWU#[QA>U-C76?% \5K$U1U1;UEVS9:R_ )OQ:"-68K.=X6%)
M-NN[AYG9?R=%N3M?R?1)^JIG$@U"'A.J+.<$1Q#)/(2$8P*#@.8D"$E*I5$(
MO%_,U'2W1@D.8#:E'RQKLIT@U<SRO9PJS[IY $O61F@_"4Z-RQ.B1C4:^Z=[
M; R>N7I@+$@C+3>U>OE0K+_<_KA5HS\^D=67F^_%>HYH0C!61EW,&(&(ILJR
M"R(*PRA"DH02(6J5HW].X-24PP%>H &#'5[PAT9LJ27.,FX8*G+(H^]8T044
MVD>*#'EQ&RHZ)W3<6)$A!2^"1:;WN:@'^TD],<O51N<"OBG63)]ZF#/.$,&$
M0H$I4^:'H#!CL82\4C58A"0GVU:9#T/KPW8(-GI7#CME/HR1GK='"G@#%;RJ
MVT/I5.[G]M^UOZE8KY^K<\9LN>Z)O@Y<'3.]Y(;L*Y68;3.^Q>NKTFP/-1Y+
MSG9)O6+MV1X2^HO0]MWHL?M3;=%CJG21D"'DG.KF'LHFRD*)(48I35.$B9!6
M409ST5.SCBP:  W:4EDLBIEZ\D.U9SWED&4_+9/\;=,LQ$^OR5'O=F[ "*<4
M6WNUWZE__>TOV]^H_^A#0W_[R_\#4$L#!!0    ( &^+7%3_YMDHRND  +#2
M"@ 5    ;&=N9"TR,#(Q,3(S,5]P<F4N>&ULW+U9=ULYDB[ZWK\B;Y[7BTK,
M0Z_N/LLIVUU>[;1\;6?EZ?O"A2%@LXLB523EM.K7G\ FJ7G8(C>T8:^N=LJ2
M3,3P(1 1"$3\V__^=C+[Z2LL5]/%_-]_9G^A/_\$\[A(T_GG?__Y]T^OB?WY
M?__'O_S+O_T_A/R?7S^\_>GE(IZ=P'S]T]$2_!K23W].UU]^^B/!ZN\_Y>7B
MY*<_%LN_3[]Z0OZC^T='B]/SY?3SE_5/G')^\Z?+?TU2>Q5S)(9#(#((3T*B
MCD3KJ &:953I__W\KU19_+;5Q#@NB=1&D2#P'R3I7?#2.0:T^]#9=/[W?RU_
M!+^"GY"Y^:K[Z[___&6]/OW77W[Y\\\___(M+&=_62P__\(I%;_L?OOG[:]_
MN_7[?XKNMYES[I?NIQ>_NIK>]8OXL>R7__/;VX_Q"YQX,IVOUGX>RP*KZ;^N
MNF^^742_[F3^*%T_W?L;Y6]D]VND?(LP3@3[R[=5^OD__N6GGS;B6"YF\ 'R
M3^6_OW]X<VW)V?2SGZ>_Q,7)+^7'OQPM$ Q(:/</U^>G\.\_KZ8GIS/8?>_+
M$O*__SS[/$^X(&>,;Y;[7YM_^,OEJJ=+6"%0.B[?XC>V_[ZL\E0*X-L:Y@DV
M/.T^?[:(UWYI5B2ZN/B7,Q]@UGUWDF ZZ3[U15BMESZN)U%8XY(+1"A+B>0F
MDV"=(_B%T$X*'QV]SG A>(44=PI80?S+Y\777_"#?RE"^(<L7Y+-EYTT;BVY
MD<Q^M._VW"?\W8DPB7NE$/^XGXBTU!(G I H XM*^!Q9/)CTJRM>I_RJ5E\L
MXT^+98(E&H[=DGX9;VGX.FBWO_'+J5_B!Y'X93I+NW]=+,@0.ELO!I#>1C5(
M[L\_(=<9EDM(;S>:N9>YCK,UFE/H?G,(K;^8S\_\[ .<+I;KB0O!*,8M238K
M(KVGQ,E@2(@,M$R!)RD&T_[5E7NA@+>/@KVEV0@:WL-RNDBOYNDEGKX3H;AQ
M'CCAS'N4A@PD^"2(4HDS"RG0[ :#P[6E>^%!M(^'_>79"" ^+?U\-2V"WX$Z
MN:PA>N*L8D2"C<1:FDED(6?JD5(%PQT0-U;O!0O9/BP.DNK(R'@U7T_7YZ^G
M,WAW=A)@.6$:E+4Z$.>E1=K1PEGOT%$$:7,$9@RH@Q%Q<]5>2%#M(N$@*3:!
M@ _P>5J$,%^_\R=HVYB(/+F(099W1$K*4!!1$N:TYX9SAVP,A(+K*_="@FX=
M"0=(LPDTO,&H?HFFK!/\1Y0_'"W.YNOE^=$BP01-&-4\. *&9XROG2">9T>,
M,3&8G#-S0X'C04)Z8<6TCI7A9-T$=#[Y;V\2BF^:IYNDQ=8B^@PQ4Q0-MTKB
M'HB<N!@-R<QGK;P43 \%FGM(Z 47VSI<AI!O$T!YD1*J8+7]S]OI'-B$!6\T
MQQA+&/2KI49OVMH,)%M*N=$>8^ZA0'+'\KT XEH'R*%R;0D<1_CE\?+3XL_Y
MQ$I%66 .:>8E]XN2<=9ZA+MDR01GO0_#0N-R\7Y9+?J=(&-/H;:$B^Z8/%Z^
M7RZ^3N<1)HQJZA)@ ,X"R@6*\4/'B@AI0401E=:'IS8>HJ ?0AI.? XFWI9@
M\GZQ6OO9_S\]W;A2D>>LF2<J:8S)%)?$LBB(BMZD<C&4A!X6)-?6[P>1AK.B
M XEV9( 4Z_=B";ZC6Z=LK7",.*HU.DU*$YNX(C%$H"KFE$$>#(FK*_8#0<.I
MT+W%-[+:RQ7J[/V7Q?PB0^-="-9HHDP1@+:6A*0R24IF_!^71K"#57]SU7[J
M;SCE>9 81X; 1XAG2X0OX^'3=#V#B84@LC6"1$43>C\I(NW&8J@=76+64.H/
M]QINKMH/ @WG.@\2X\@0^+3TI5CEX_E)6,PF!GW?+),AVE-/9,R&8)B42)1<
MTH362WASL/ZO+=E/^0VG-_<78".;_]6W^,7//T.7E\T@> 0%)')P1.:,R-6"
M$@,B!XX1D!6'QY1WK=P/!PVG+@\69Q-APA\PF_W7' /AC^!7>*:E-ZO5&1YJ
M0IN,IUHH 4XDTGE!?!*&6&4<!.FT%/Q@7#Q(0C^ -)^L'$+ 32#E;XO9&2I@
MV=WQ+5>3E#,5Y;C+"'J$NL;8&#)"78:0;68LZ\./CCN7[H>,YK.4APBT"40<
MG2V+O#8W_N5(1"6<K28V9E Q6A+1&*)4T/Q9SBC1>$YJ2G4R::@DP]T4]*N]
M:CY7.8!XFX#)FSE^&HIC^A5>^K7?LC6)*M+L72D-\)E(*B(I(">*>^E]LD[0
MPQ,/#U'0#R;-)RP'$&\3,.FLX)%?P^?%\GRB+,9-/'D2)$._6N=$ K7(B-22
M96>"86D@=%Q;N!\HFD]1[B_,)K#P\<3/9K^>K:9S6*TFS"N>@DGH12<41?:,
M. L875.K=,X)K>'A)=QW+-P/"PUG*@\59A-8>'4"R\]X_/WG<O'G^LO1XN34
MS\\G/E@NHHX$1$+WF9>\JZ+H/D<73'  C!U>M?D  ?VPT7 :<RCACHR1-S$O
M7YRE*?[&B_4:5AL=O)[YSQ/@+K.4.%%!*"*55,2KH$A(FAL?HV,#%'O?OWX_
MA#2<Y1Q(M$T8D8]?, S?P3M(Y3)P0P(N1F3BB717NTZ 2U0@]@>KP[JZ;C]
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MJQ6L5Q>\*LM2TKIP&!*1-'OBC2EM,%-64%S;^) +L3^OU^D8Q[.HAHJ=:1E
MZ'O;%XQ[PN+ 8^8Z_=LHZ(*-$'G4Q4RB" R17B9B(^>$@4JE1CDX_9#O<2AV
M;I S+H0.T?"=8#E$V$U@YLBOOKR8I_*?5_\XFW[ULW)=\V)]Y)?+\^G\\]_\
M[ PFP@>GD@6BF<< FAI.0E"6)!=CBH:F]&#+I/TQU(N\%C!U$! 6M772!-0^
M?EDLUY\ ?;?Y5UBMNWO!250^9)8%D>@0$BD-!G4 CN3$4XZ,H@]7QSK=1<TX
M(5,](!TL\1%CIPNIQ%CZB:T^0 3<"F$&[V"]*Y0WTK-8P@>N-#)DG2>A/*](
M$*C%N"([^U"9X %GVP-4C1-QU4/18!IH $UE(\SQ5\Z1A8EQ*6NJ*7$:3WX)
MM)36.T-, I]TT%FH.J?:52K&Z2);#RU[2[B),ZK4J9S )_\-KL!]DFGI5!@%
MT4J7-QC(AE?2D\P]C4PH)^)##ZT/ <H=Y(S3;;8F8@Z5>0.&Y7C]!9;79#-Q
MRC%'/2?&!T5D"2RLRJ6D"5C@TI8'/%50<YN6<=K2UH/,@=)NPM1<)]]2AAZ\
MTR1*W[4X!.)H\'BL.NY"B%GF.B;FZ3@9O+RYHNNRMXSW-RF+M9\- I"7VV4O
M[..&FW*N"IMDMH&1#)$1&:1 'SXFA'UYU!&\Y[H.6NZGJ878:9#$SD!B;^!,
M>H,*F'^>XFEZP<*K;W%V5LJW_W.Q2'].9[-)@FA,0!?-9*J)9+@?O(N1('/.
M!P'69E_)MWF<NA9"J4% -;@JFCC"+BCWW@BO&2?6<X=1H S$VXP\4,<H<$D-
MJV./G@24RE'4($#92Z2C@J&[ZBTO16!9;F3>3B/,5_"AS,%;38+068/5!!P*
M0'I1 D!NB<^*Q>0CU_1&B'U/D<X]"[00"QVD]\&DU\!Y\WZY.(7E^OS]S)?A
M4ZDDKT]+TK&<G3PFIZ3+))3&6M(&2T*D!D&MJ#$T2Q[K)'H?HJJ%N&@0LS&8
MZ)LX5XZ1%U_:YKP%O]T,Q_GWU>;LG AA&>><$J:M(#)2CY$>4QCI2>F\5]%5
M\E@>)*N%T&D0* TG_ 9,TJ90 .YF)=)47I<1#;*T_Z5J4Q4,)J+=]=P;_M"K
MG?UQ] !1XPSYJ("BH03? (:N))O>+>9QUZ,)/13+K4(_G98A:1@+!L\BL<B/
ME=I$Y^M<'MQ)SCBS/VI8GX.%W<0)MN%@(A7PG/'DY3J@ Q=<*73DB2AMJ (4
MCZEU/]FM/]+@CVK5-D^29P,9O+=3'Z:SZ7H**_3)NG?T7Q8SE/JJ^&?K\PO1
M>,I,9@HC?QI%&<ZJB.-*$HP (7$*C(<Z1U%?"L?-[E6O_*NBJ"8,T17.;B;6
MH[&*6\N(PLU#9*8.[6D6!#331H&30M;QH^^G:=Q*KCHHN!]JARBD"7#M*D/>
M^_-R9[N[9TD*!'<JD!!,\>]*"C,"(UGJS)/E>) _],CA\*J<Z_0T ZJ#]'U/
M4<X!HF\%0LLS7/>6E";<:^]<CH3GTIW?:T><$YD QIPN,:Z$JE;;=3=)XQZ"
M]8 T@ (:R$!OJ'Y?^BTOYL=YQ]#YZ\7R:#$O"0W\<5<ZN\VNNIB%U%Z4\0^X
M5XI;:;/SI8%10@_52$UO7%K<EYM^ZM+C7FL-#*1GD'X#28#"1!'1']/UEZ.S
MU7IQ LL+)G<[)@L/TI=2!1YPQV0)Q%E!"?.!*:7Q_U*E,OD>U(U[15;)>@VN
ME@:@=CT!>XL;81PRDSD1.A@\XAT>]ASW43#2@=0898>'6MP-E?[>"U[5;N(J
MP6M 530 K*LYV5N\J @IQ:P(4(7VV (@&R(0+33--&J1:!VG_2&JQKV?JP2J
MP=30 *3N<!LA!2M]3L1"M$26%TJA1,C&"LZY F]=G;+7/1WV:G=RE>!SH,@;
M2(OBH8UN_[I40[V$L+Z2Y^=H4&WRDAC-42X2(K%1"$*U%4PK&FFJ$_/=2U(S
M,5^]C-0PZA@_ GP\YJ I:JMS)LRZTOH<(UJK$X9T3&1&;592WAA;<T_$]_U$
M>,/#IH*LF\A$W:K[O2+%4D43$ACP21&-8,"3N130>$Z)MC8Q@S&KK>1W/T)8
M,W%=/0LUI&H:<)KNB2JN&%X9?4I:9'0-T.9*4;KCHL- (/O((">>*Q7+/4I:
M,V%>/;0-JYX6\%9J*JYNF4M.K',".0%BO2KL!$U"%)RXY%" (5'@#XUG.K"*
MY4Z:FHGY*B)L&(4T<6Q>86/";!;483#C@D0[+'&'>!$<T8&7Q[Z1BUC'?;]"
M1#,QW[-<(3])Y$V$?B<GTTTCBM+A9.<YQL(*3=Y*H2+*  ):55.:^AE;7CQ0
M!M)8-*R5@K][B1JW'O.9PK]A5-*$-7I 1L%2EFQ"H:A 448V84#B$U$04O!<
M1:%J]8L[J*JJ6M7FLZ!K((4T :[WNY4[IC9=F!SS2BCC"<\!]T7,&.:JJ$@*
MSBB?;0ETJZ#J#F+&;L\WC*9OO6PY3.@-^-]7QBAMZ+<E>"B)-!^B(3*82+S.
MZ.DE;KQQ6;I*C_UO4C)V66<5Q!PD[B8,S8N4NMI6/WOOI^G-_,B?3M$#FRC-
M?981B(GE(ALL&F(&Z/L9K7+.SJ=HJN#F'H+&S7)6@L\0PF\#13&>G9S-RLBM
M+N L<Q^7\ 7FJ^E7V*32WBY6)8%VG#_Y;Q,)U/+L!4D>?'DF*$G9'41E0 %&
MH4.J<Y0]D=!Q$YZU4%=160T<@1]@[:=S2*_\<H[AQ>H*NR\A3^-T/0$FE*;2
M$,T41K(F2F*ME239B&YG-([SAZ9"[P^_QVD;-^E9"7$#JZ0)DW=;5!.G01LN
M-5'.E4%1*!WGM"1,11:B1./]8,?](<.^<3.;E6!TH,@;R$D]%@=/F!%@HF4D
M:5.NP7E _U%:PISE7K#$LZIS\_<892._[WON9.?AVAD,;<\S!N)]IX8OL)Y&
M=+:O\7#@3(CKGUQS0,0#/#SGM C)5'),&)(] D0Z4"181@G-3G&6J'2JCG?Q
M'-,BKN=(4.+'RV[9U,6_[V'936^><)D5RP!$.SS3)8^,A#(ZAP>F5=)2LTK5
M5?WH&SM]-3"*'DYD#:*D!AS[ZUQMIH2_.%M_62RG_X2$QMEKIB4E63E?7N\;
M8IEV1$,T/@N:E:WSQO1ANL;.>STKU Y22J,0>[-:G2$G-DJK. I)@<$ )2D@
M08E(N(Q)\2@\J]0'\WZ:QLZ)C0"M/931**R.S]:K-?HU& ]/9&0V6E^*\$M#
M8<8]"?@I1-G2/I8F:^ASW.S<(FSL]-<( -M7+0V@[,IEQ+U'OA/1<B,E 2BW
M[#Y@!!-0<"IDS7*B*JLZAV0/XL9.?55&V]#J:2(+=H6I6V>_HI0+\+(,?NE2
M/88$#,V)X !HHAW%;]?&VE[>6,6\V/-A["!UM(FM[>$/WD3**5)N!"-22$:L
M<(RX3+V(U/#DZIR6]Q T;AG@\V-J#S6TB:>K9WU0SAJ@@,>\+\TFM45N=""!
M6L>9-X^,31X05$_UOZJ5!#X_LO952/LC=S]^PC]_>_7NT\?CU\?O7WUX\>D-
M_O30/.L]GSIPCK4/[0/E5S>WSQ? NYSB;*TTD QN'EVJL!0G/KE(*#6@HRU-
M/FN-S[J3H,,O#[<?^*D;0!1 :LK!$RXRFE(>&/$Q"L*HU)R'TE&I<L;X4^]I
M3]6RHD/H_O:-X=YR'C&@6RW7I<MV.HMK#!-@^74:X<6WZ6HB(OIORF:BN\LM
M1RFQ(#)QS#,J I6AW^P#7. *1O!O-_%Q'P6-Y,WWT.9B0-&V 8WNCG+#P>KE
MXL1/YQ.)AW",R>$&*94Z7#KBO"LE]8ZFF ,-HE<!PE/P<9N,<4 RC&9OP^1
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MIY_.2\^<X_G+Z>IT6R-[G-^@IN:?R[2#[5!A*I*RR:"AU5&68"41[W,@5F*
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M)#IPG--(HDN12.M*!V%6:MF1#<]X9KI.ZNP>@AKI)C(D_@X3>A,NX#M87\D
M2LT"..]),J5!1=":.*90PYR!,B'G4&GXW#4R&ND.,@Q2]A=P [9EU]=^U\?K
MP@-13%+AHB2@2X=5H8%8+C)!,J7A3(C ZAR0]U$T[ABP@3$SB-@;R$S<Y.-7
MOYK&B38@L\N2J%@:X(#R)'!E28Y66 8VT%#G8+J3G''3IL-H^A'X/%WL382-
M?T"9@@[I!7ZH_PSOSLISM.-\JZ/2ACT C(!RTD1H9PM[0!PZ:H1!0-OJ!+!*
M#2"?1.:X2=4J:*NGI@,<I'45^_5R.CM#3B?9&.820ZJC<J7YLR86'3]B A[O
M1H;H69V)S_<0-&ZF]5ELV#ZB'QT_]VR-+2]W].5U3++D2J&1*7WK<R+!.4XX
M1&N,I,RY.B\0GTCHN!G8Y[1B@ZAJ(!P^2P^_H^/?WG]X]==7[SZ^^=NK-^_P
MKZ_>'G\<M*'??4M4[.[7BZOA1ZEL K]N(O2M2727R=P8DO51DR B121Q2SP7
MDF2C& ]!6U!U^N\_D=!A,PTL2&NX#21ECD&1*Y<8G&&,9%F9?"4\=W4>9CP]
MT_ <XU(&1\K#:8BG2+^!./*A:8XOOOKIK+0S>+U8ENY$'R&>+3>CKM+_G&WN
M]R\F/F9*/3"(&/0 6FT=T'Z7IM$Z2!#:"RITQ9KZ 3AHY 7M,P!V%)TWCG5D
M%]V4^=$9TC6/YY^6?KY".1?MSU/WM]D&"W=((3)(BGGB8P8B4]>]1W.250@*
M'-?,J6='_O[\-%+//?(^>"8\-+ K[A# !2N.)96U5"0"E#8VQA)'$R.1"N.S
M+,% G?8^#Q#52*WX,^!S*,VT/U;R(J X?OWQT_'1?_WU^.W+5Q\^OOK_?G_S
MZ;\'"Y#N_/!:H='CG P?%#TT0S<9DPP>T(R55F-:&.+0)<5]%QG/AF7KZE0N
M]B)OX-[H-O*4A$C$\3+AMSP'\TQF0J7PR@/0J.J8K99ZHP^/BT<ZI3]%Z@V<
M>Q?4;R12C.UB7NK>NP[0EJ%]-K;,\5+E2@<H"3%Q$FVP44F;DZ^3AWZ0K$80
MM8>^[X/.P<)O $DW>-@VB8S:1V<X)='+0"0>S,0JJXB6DFO*+*UVCW\7.8T@
MYW!UW[S,.%CV#0#HRE";;6=0"E& %):  $>D+Z_E2]T<1M96X?^#E-5'"XW9
M=7U ]=X_0&@/63< EA<I=:^2_>R]GZ8W\R-_.D4W?==2%D*.7@"Q4;+-AO(E
MZ !C<(\)EI*O YP'R1KY;GYP$ VG@Q8 %>/9R=FLU#W>EQ'9,A8R%=KXTLL6
M_42I,/RT/"%W,G#MDZ/&5@)77Q)'OJX?'FA5=-, Z#[ &F4#:7?CO+/%S(H$
M-!#<(F5 8'EYH4H"C7.(R4I';9U>*G?3,_)M_.!P&D#J(P\R.MILA]*2*F>(
MZ_>PG"[2<7Z1%J>=7HI#R=#$ZH0.9=(*]X+E&)D87SH,<9Z< *_<<#.-^E#4
MR-W2_G%;%=$W#J7M?E-)T)*R)\: 1(ZD)CXD1A)CN L=XXSUJGX<!$QC3\L:
M'@-/ -@>"FD<8I>W1[M3G%G(V@"AJ1CWC.CP+)?W\2$X[G7T:;AI?4^EKEW8
M[8.,IUBV0]34@+-UQQL*:YGU(0C"?&D%SQD2K[TCV4 64=J8^HV%W#^_^?9)
M@SOJ7S@/F-3<3\P-  4CBB7X%;R$S7_?S&]?'7Q8S&:O%\L__3)-G#? C)0D
MNBS0<12*!*=EN?EV00;K4J6BGR<2VDCV<T]<W'X@64U)#6#P=D&P-HH#3XI0
M[4I!,,H)S6PD1@J>00OI19VGD_M59]><=EQ/\3=MV4%:V!M&I]W)BQMF.<PS
M@=L"FJ"+X+FAFH O'1XB5\29X,MHIDA!4VI"G?+8V[2,&Q8^*YP.TT-;>'JS
M6IU!>GFVQ&VQ<14WNV7W(A"ZBB"8KS9=_ZD0F@/+1 O'T5DT KU284@4X(!F
M%D.EG-8>Q([KBST[(BMJLH63]&X6_^9G9W /AP[%9UA$EKCB);F(?DD.B42F
M1/080V5:JTSHJ;2.FYMM *I#Z;$!I%X&V*M/BWLNUSI.PTU./P"*>C5=PW;H
MRD8T'R N/L^[3^FD-%%,:9T8)4&6<DD 24)BD63T95 <5(=0)]RMS=FX3;6>
M<Q<TA9$&]DPGZ0]P>K:,7PK'MT^QB16@,[6)",$3D5IEXJ($(A+-(FL*OM*(
MGL=I&[=EUK-;[^'TU,Y$C(<8V^PH<#DJQC71Z";A*:0\L5%[HH%GK6CII5<G
M/?0H:>-VS&H%?D_74COH>PEA?>5QVHUG:[_/4;"SZ3\A[5I;3\!8GKK'Y)9)
M(ADH8B7^$5CIE\$#A'Z7PD\&XU,I';='UW-BLZH.&SBB*STPDTIG(:PED!W%
M#1M1"F DT=JQX%SBT=7IQS/B@\-J_<6>$^\-X*&!7=''D;]1^G2<CQ;SK[!<
MEQ$\Q6I, O=,*+"$*EMN8!U#F^ %T9RB'IB6: U&"^@>H[[?-0+]$2#_[,IN
M > Q+LY*V]S/'\OE"8IP]?MI0O?G57GQMRILO9VNUI,D#20PCBBN4:X._P@>
M-V_*%'#G9BIXG3=&/0GL!],?XKJKALI&1&)Y$-MKZ_WAEWBTK/&(^74Q3W^%
M]!G=KC^GVQ-G<_Z@VR6$CI;C_C,LE/C4$LN4(I(:G2$&F<R-#@>W7^0.2U(_
M:'[75V<CZK %&]J#\<Z=FEB:LH1 "21?TG:*$^=\(#KHR/"$T%J.YPET)/8#
MZP]QJU9';0W@\7J3)P$^QH#44O0\B%0VXV:R@G"3A',R<:!U(K ]6FS]$%=@
M^XN_ >S<KJ7Q3#,)5I.0='EUKR/QY?V%2B8(8RT$6ZGZ<K^*IA_B NDP-1Q8
M@O)J/LQ0@3L*:3P73H$QQ#-OB/04PW_&+$HG!Z%S,C[5,49[%C2Q'^=:9W]%
M# JGYVE?^N+C7U^_/?YCV(:E%Q]:LT7IW90/WW_GR*^^O)XM_KR<=.Y3U%*J
MB&YV+&V: +UNSQ3)E@HCI-6ZTO#NAZ@:P!<JG_E^N?@Z1?G]>O[["M"]NYA[
M_ )#CJ^;E/Z%',!$Q2QNC2AM*:NGQ$%V>'8;E;-P(M$ZDX*?3FLCM>*'HND.
M#ZJFTIH8:X#,Y>FZ<Q&5-;KK9A283T3&+(D51A/-M3;!HV$*=7)KES2,"Z3:
M^EX,(OH&O/-K(6LI"IK'Z0RN!1R?%D\5)?J5@CF+X2Q5LO1+UV70F25*2LN4
ML EXG0YD-;@9MTS]F8$\.AR:L*27 \'+3?QQ[G(V+U8K6&/T[71(I4N.D*RT
M:TJ,N!30:P[.8/1D0K2U9[/?(FI<6SL^9NZ=YWZ8^IJ8HW>3F5_/5M,YX$$3
M8K(@0GD\8LK DM(#55M+M(N416N"JU34>Q]%XQK*YE&XE^+&KSCK+F+>+>9%
M=$=?_/PSO)F_6JVG)^7C7_OILBNCZVZMBQ!1_MTW/I2I)\4;*H,)O2.&9KJI
M[?0:-U[.U*5DF'?V1G;FGKNS?2D8]TE/,Z!\/BTV831? JX=IYV>\>L9;"N)
M7IPLENOI/S>O1$22'&&6"6.VC#NGZ#$E;4M7 PX,K%>B3N:P#W7CON]I!K?5
M%#JJG]GMQBOGPQ=D BWUR9OY5]B*?9(DTT"!$DHE'A6E(97EU!-3VNAE)31G
MC^8=>ZPS[@N:9G VM$;&/[>OU/8L-[OERE8I\\=67<W/"C?1^R6<3,].5E>9
ME;AA1$;Y"5M,OM* 023N)<ZR#1:85*I.F+,?O>,^J&D&QL^H](80?HW'U].Y
M1_'//Q\M5AVC%TQ/P(<4'75$BUS&^$5 -Z8,]*-,*Q$\.M^5*@Y[4CCNNYSV
M4%Q#L0WD7,LYLRKB!#QJ7GTKDCN;KKYL[CVZDE\4C8S07<B6(3J!>^)D9H3;
MR&4N%R&5\O>/DC;N\YSF(#JL*L>WJ9NRRVO[KK0,AR7ZWK.WTPCS59GYTV74
M7J'X%R?3N L2)0U"<4%DMG3SD"Z(@'P+Y5*F4:?<LTQVG^7'?4;3#"Z?27\-
M&-%[6C\@DO @B(S@;D.A20;$&A4(T&BXI\G 9<G^\+5E^[7IJ/?6I1E<#JBU
M)FZ(;M=:O=R2LI'L)_\-,&(L4^<5S<0$@VR%<L^0D,%<1I^IZ%U*=8:@]")O
MY <NS6%S>)TVD0OM;/T=,ML5V%S4W$R<E%1RG@GHA"= +D^+L[*$T8P<>\A)
MU/$Z>Y,X\L.7YB!;1[<-G.ZW]^(%E]MW%!?RPWW(I,%M2(&[\BB-$@_:D6RY
MY RTA5BGV*0_C>->0CUS"4DEU35Z[&^?3J[0&L#T:]=$F4E&&;= 4GG@(T,"
MXKS$_69!L\Q]<JY.ZK0/=:WU<!T&&X]"\$ U-7&0W^:JY&[G^(^FQ2]1/*$5
M!Q(]QRV;2B&_+<6'+$'4*J<(=<I!'B2KM1ZOSP2W?173*,YVN^>]/R];I]R[
MQK@\P_6F/DQGW=DQR31S=(TYR3H%E*#/)' \,Y(PT3 GC*HT\7$_>EOK]?K,
MAG P53;I+%X)V*Y:_)"XYDH3)Q%%DH5,7.D]GT7T24F:=:6N*3T);*VGZ[,9
MRT.5-:K9[%*N=PCOCA0K%5HJ[C41JC21#YX3ZZ,GVD<6N*$LJ1M-V.Y)D?=:
MKK7FJ(/"J9+4F[1FI2BO".J/Z?K+T=EJC;MEN3/7YQ-' Q@F/&$!$I'@'7$Y
M4P*.,HH.AG*A3L;[B82VUO/TF:S;<,IK$IN;IFY=V[;U51="!D%S!$&$MQR%
MR#7Q.7OT?XUS$!)+[-FR,G>3V%H3U&?"XQ *:P")_9-:$^-48 R9LDRF$N@C
M9RIP$I/VDFL5%:O3U;\_C:TU/:V"Q4HJVQ^,"^2L)A@WI75W9UA=E$D'#+&,
MIJ67JZ,D!"N(S4DFQ2)3N8Y]?#JMC8QO?:8GX4,IK8E\-3(7 =+J-8IU\PKI
M#:IN_KET]-L^B..1:2N5)93+T@4$MYI5W!*F$C  (R#7L8Z/T];D$_+!\''[
M"?F0JFK@B'[OSW>MT.(_SJ9+V+V @U77O+=(=_N3- F2Y4A3),91M/A4.6*-
M"<0HZQQ^3^'!4P>&3Z"RR:?@U0!92WWC5SG>RR+*%KV1]?G[V::E9&EM=-K=
MGS/EG666$AI,]VX8B+>*DL24XI -10$_#S[OI;')6^9G0^<PJFOB N86;W<^
M1^+>9>6#0V:\(E)'])8A>L*%0O$9+I-\)D3N_:ZL6BY[;# >K+#Q;6278+WJ
ME-RJ(][5#7O)HJ !O1*,"U&(D7B)<K0T<C#.1K W<'A/4KO'8N.FM)\)554D
MWX(_>,O#O7.;Y*0@(S*(8S&6Q^:4E'HCW#5)")# DJLSMJL??>.FL4</2@Y6
M67-Q\6]^O1W!\WX)IUM+C@[$D9_-5EN&US<8#H9'H24C4I5'/=)RXGUBQ#)*
MO7+):%FG=<"!A(^;\QX1O+65W()YO>F$;/JR_@;K+XMTE2_T?5G@% C0TGL\
M:CPQ1,Y$\V0\V.2,KS,*K"^%XV;#Q_8=AU!;&V',E?WW<MI)#S?AE4Y(L)I
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M,ZHC03FB\*U"3\[I\FXY,,'*WJ]T85 ?S=629&V:^">I<F_<GG8'"4I@N6X
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MG#B.*-7.:3!":I;J=*MOXJ2YMG"GK?/+O4NUE=D8M"S.E5)<FHC+$?^@D(3
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M]>W%X)V\9DK(!=;<-R8RA"9DB$8)P"B9#$Q8D8;)V!U(\*^^/O;'WC'1Q(%
M&/L>V-:9WF31@U0BU2RZL"Q0\!4T.*<"Z&B-X3QG[]5SL<&.YX[NT0ROQWD_
M0AT;#P]:7;!LE/5*DW.'OJ;.!3AI,VA%O$3D3+MN>#B@.<B05ZY.BX<CA-K
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M2JUGA>07=?3WES6GRU=?ZY=O9R\N:X;E?7E.2GRBM>5*>@GH:CLD[0+Y2**
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M1P&@ Z@.U\;8$?"]2?:QU-Y[L3:BU;X&1^0/!QU H]8^:%."ZW@[Y<Y3VT/
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M=4%I+'5\=P >I99.:O)73K85MW0IUVAN4Z 0)W"F:A\F<MN\,&"E+MJ67-1
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MN"8 ^,^P6(39:D,^-^0T!X>@L$Z<*LE"3*+0(N*&>W*=6!BF)^,],IIR.MN
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MY,A-"6:@%G./DM0TO Y1_T. ]:*+D3VL#XMYODJK^\NN]EU3P3@H&#4M.Y'
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M-8'&#^''NBO>W6H3^FHY)85NFD5ODOKOOZU_0L)-J^GWZRFUV46--F.=CR1
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MZ@X3KZX658)W)V:4$LG@L3H*6&4,Q)724%!K'B239/Z&!LT#FD;V=(]5^.,
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M99*B#)=A[D!@R\ [!!E[0>\P-36/OL]_SC=L"6Z%%[414G8D.FDU1$/.")K
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M.8Y#/U##@^6/73S)3V=A]G@3Y@CO\L\3,^+C_(Z2.LX+/4=,UHK:",0)MT:
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M?L!E#9,K16-6'C#R7,N,* J0QD&V+MA<+!?89B[Y%L2-B[K! ;$MX/;43@>
M^U#*-.$U(Y>5;*8P071RX%%("F\]0E3U94@96T)&$UF;43&/DM,IJ/95^GQH
M#71Q7K[#L,2O\[/\]MOWQ?S'Q83U*V:\R2PQ"98%8J:6J#FG$"AW$<B1\XAM
MX/0$4>/>SK0&U5#:&!5:Z_#U]?S;]W/R=]<2JF7 \[+ZF^1\M0.>DR^/N9"%
M.(HAH@O@/+.@0S Z^5A25EOE,\]_:]Q[C5:H:2'H+IS21H&]N]XQ(8S%9%0
M[:N\R+F"L\X!0Y^"=B59WN:R^7G:>MG]/$8(OY^".@BH-G+T^Z+6&##E"YWH
MBJQ'DK"TR>!#IF->64.6&X/0YKAP6]/5:8BU)PJV!=GN*NG"J]VJ6[F]!YM^
M?89KE<WR[75=&]F?1.YE%"141$OL.^+<%2N@,*.09*IM:=/L-A0'G09QP\!V
M%#4?6M?4UH>^Q]6$Z=KL+ Q$76TV9%4GSC,(47GFK=2^43724U1U&A<V]I^[
MJN/4'J9^G\_SW],S^NN\OD6_OXNNR2/5MA]M^F"U%^='>;RR618ZL>OS!$MT
M6DO*7I5)X+@@I"6=6-HNV3O>X]43:S4O(FB4+ JF(I E1E#>U/(%I=;[W[E,
MWMO89I;X]C3V_("U"R0V/V -JJ4.$I$G^/GEYQ_A/^>+UV=AN5Q?B@<F9,C2
M@-:$$Z6BI=.!,CH2'"N4RY72:&[R#D3V\J U+$ZVW\![D-+ZQN,-8^_#M^N+
M+"<\"5"3!"6QYP1),%D&T:K"&$-A99LX;T="1Q^%U08PVP/S8.UU ,Z/E+O,
MUFU*Z>ML?C;_\O/RRI,';I,J"#[44?K,2O#>(8@DA&8Y"!7;5)9LHJA;N!T.
M@_MIQQ ZZ>+"YO,B9*Q2N1[9Q8D#;CQH3+9.["X0C9# M2#)!,5B;-/W?)^2
M<2]0CHFF@W30!8I>GR]7\V^X^(1G:PTMOTZ_7S%CD1MB7X.KNY=4H/_Q+#(@
MA\^4Q,*":P.H)X@:]T[DF-@:2C-]P.QF\?5Z7_H5(RD(S3&9VHZ208G$P0DI
M(5EK?1:U**'-2;B!H'&G4AT57@-HI(,8ZPF1W=Q3VMJ#&XJ!Z+6LQ:B&<GGM
M(4OFK!7%Y=2F5VX;ZGIYD!TK!=U/31U [^HZ<Q(22A.13GD6?;4;"5%$3F;H
M/%D+DZK1\.4K"KH-W_?4[7P 07< D"<$<_%('#(/,DB$4A>IJ1@IYPB:CG&N
M=9:>W+MI,UWE.<JZC>"' =2@BND;:+?>>V^_ZTX\4LP@$WEO0?:D) 6//GL#
MR0B,T62;V=&/Q VT=AOR-P?C$,KKXNW]/F/O<?5VEL[.\W3VY=J[:Z^4JM,F
M2L0 2B$Y=A0.I%.H,!OSX!%N($AN0UVWB<$P(!Q<0:?V*D^_6YP3B=,0IV>7
M6\5:+,C:^)FVJZ^VX^XH;^W1B5B'(E/45A!4+@J<= *RPX0UL#/2/"?@H[RU
M_T:JGO]$7%_ W!'>Z_-%M=J),IX57]:T4T:46(*H"OD7%0)SB:?"V\1OSY+6
M\\OZ+@"X[Z>&U4D'H=NE97Y<S LNEZ2?</8&;[A)F9E4O )*L#F=])@A&G+Q
M/"2K-4N<ZS97L$_3U?/6]T/@-: V^L%6'0"QK-L.IFN6+IEY-<OOY[-TR5FV
M3FIF&&1;JUV$+1"29Z"*3MEK);-MM -U:QK'20..AKFAM=0/_C[-?X:S6R[Z
M+D]>R)1J]7",C/RUM@F\#)1Y)ULHIY'2BS:-Q]M0-T[4?S3,#:>9L?>>WS:B
M3[@Z7\R6$\E+U@P%("^4KM27,A^B@)(%3R)8S_FSD?RF'[X5,/3I &,0(78"
M@G4&^RK]G_/IY8"EZ^.;$E6%,8 LN8!"J2$*2I6ETB;07R3OMQM1\\R'M@*'
M.4UP#"+<3H#RYWE,EZ^@\\5O_WS'V?(FUN-!)!%E@9RSIK.6&_"* KY0M%!.
M&A'-=FGJ%A_;"C#V- $SF)"[ <WW[V=3?,"*IP-21;20BB!63,2*_P@^A228
M"B(CVPTOCWYG*ZBX4X7*X:+M(.Q=R^GAC=NUHW2H;0RU8J=.2I#D+0/C$9+3
M:&R)-N0VO>%/T[45L/SI *N!-CK UF9&2GVJ--R29%AUI8J,Q/D,:%GAN5 L
M[]MT6QR&*,Y.#U+#*.'47D@NYN=^63> MGTD>?)+3=])MN?Q*$\E'!U:4\O1
M#:^]%89B:O0<# \\J)0TBK!53'&\ML1?SI?3&2Z7MU.$7W[>^MU%+5FL>Y22
M5N1VR?*4]P@AYP0Q&VN9<\J*-B\GNU+:\T/*+O#8W*+80&,=')2/<+5N5_)1
M<I<D@C#UXM1;#=[1H9\9UUF0Y*QJ<]VX@:!>&A!;H& ^O$HZ15;]Y0*ORK*#
M(O/+I4#QD>PR65.KQR38X%/)(M*QT>;1[EG2QD7;( #8 E3[:V/L.X;7/S/^
M\_%K6'P+"<]7TQ3.EF]GZ;(T/SAI=4H!K. %5#2<.)$"!$_!AE HA7%;A0-/
M?J8_C!R@SWD3X8X_P/ /"@5B6$Z7GRE&"-_7[%QU<*BB8JDKFE'Z! H]A062
M99#64:ZC%=.A; 63)SXR;H%P0Y ,)=CQ(?)Z\7-)B>(E[9G[D@M)@*1@"-Z*
M0:@OR2E1NBIS2#YMZ3MN_]AQ2W-;^HJ]A3?V$?(V!<I?KZ:R&D[4)@O!%4W\
M<SI9LT*@+*$HF9/ +9<RW/ZIXY;"-E3ZWJ(;6^<?"\[PGZL69+3:*DWL2^%
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M<V]B<%PBMKFT&YR5<9.-CFZD#E-R'RG"@2+X7Q<=,K-<5PS5B86?Y_6/'OH
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M+P^/V4%G3VWUI283J';GL<T<*F$]BT9:R-QE"E.4!R=CAJ+J0'F1DR]M_,[
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M=@B-6^(A:HN/B<Y&(PMQHCWX5 Q8$Y$S&P/3^^8K?^Z8!P]>/7UL>.PIUOX
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M$1!]"(7)@O<'E X$UT?)Z?P^KCE*YD.KK /<#9!7>NW02F<@5T$J.JY(AB8
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MJ.GD1FU(#!TL] Z 0R)Y35^=KFY'D^M0P'HTB?&Z?4S74( DXYD*$(R/EH6
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M;_8OV$:W[6IT/)X,3Z^WT%7[\&YT-1I>;_+LK9Z_!6:!78H5'&8.@BF462%
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MAF4.O"@S0@2#O[$$AFINE-M2#C%@;],4H>SUA!N*R1)P._X;?A=Q*$B7SG!
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MVZG,^@KI;5)F_Q2QTF.,-[Y'7L%:B M"P8Q=_XB6D>>E+B K$_EI07-!%MS
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M;'AMW^R!X_F:3?N0?6XB-]'3%7!+RQY#Q-8 S;W-< 2#-IS,=:%['=D&](&
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M_E0B]A9\/:&X[(&>$, )YL8:G&4-'] /*G%RM\ ^:E:/FN$)?9)AZ6MI?VC
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M73K*(V([\X@/B*U)3ANVN.OCJ:>2Y#J("C6-06A@T?.-10_1.@:;O7(9@YQ
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M'>EB_!KEH!ONM+,)J&Y 7 ::U86KCY\O8!OSD()[ !06JVP?QE3H1F(IS.2
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MIRJ*\3J&CFG#\YAB#5@I9ZJQT^XNQ[+F%-\E#JD%U ([@#_BK8LRX+8\+/[
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M6$_5H65&E?Q7C?@SA<_#,$5%7VXL ^V9')Y<D%P&VMJAO6-R-95$QO?2/V#
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M,/\Y3NF^=-$O30)UA#SIQ?EC41[OWNP,WKY%_2'SN^7!HEIV2+7H<=.-SPY
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MAQ,=P%"@)4&ST71EE%+0.YKLD0SB;5-T/3H#<7M1SV.(E@\&$CY<+$5M@YL
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M(U.Y0J,[.<OA$@K><T&87:)P I8L5>WA32?!+97Q8:LTMZZ,J@)65@ +E=X
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M^I(PC;R!0Z;:?&0J3X-2^=:EY]F.M_<X7"J_!6J%M]A_X!8=&&<]D4@';N7
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M.A=']<1L(=$H0"S25> S_HC.*3V-2&T/91*'?I\Q\/7K.*]LE^IYYJ7:M]E
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MZWWO:JX'&S[)]<CVK9-BV;X$G!JP1AF8=:,:A[)X&3YUKO[SY6[P1__Z?3@
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M1U-@L*H@%QMR?GN5)T!PM7ZBT*@G^LHJG6U7#]#*1-N'<,YTF[-U-5Z_GGB
MPYN9X L6U39B3K-/ZT<5O]N"]Y;:IUO,?+P0"WEO-;9\&.[S':A5IRA8&/B6
M/C"GCVZL58'@S9C_;_Z^\H!2_-#?'V"O'/X1?"O;KMQYW5[I^QO]$YZ_YJ I
M=!N*W,+.UO^[827?"VW_4P0'DM.%VBWR+V\+V!SS%Q=DKU#H_ U02P,$%
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M%I.N'UPF7@NP31&GF: .1%4^MX9)NQ)X6,A!C($M1@F>N+T(4TX,3SC5'"?
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M;C=YXC/<ZNB_"';?)E_\!U!+ P04    " !OBUQ4SQE,\T0(   Z/0  &@
M &QG;F1?,3(S,3(Q>&5X:&EB:70S,3(N:'1M[9MM;^,V$L??WZ=@'=PF"_C9
MB>TXV0!MDD6#;MM@D;O%O3K0XL@B0HDJ2=GQ??J;(>78B97&Z74OP5;[0FN)
M3Z.AYI?_D-+I=Q>_GM_\Z_J2)2Y5[/H?/WRZ.F>-5J?S97#>Z5S<7+ ?;W[^
MQ [;W1Z[,3RSTDF=<=7I7/[28(W$N7S2Z2P6B_9BT-9FUKGYW*&N#CM*:PMM
MX43C[)2NX!&X./O;Z7>M%KO049%"YEAD@#L0K+ RF[$O NPM:[7*6N<Z7QHY
M2QSK=_M]]D6;6SGGH=Q)I^!LU<]I)YR?=OP@IU,MEF>G0LZ9%!\:<LQ[?3[N
MB>ZP=WQX/#P>#^-^#./QL8A%W.7'_^ZAD1VL'MI8MU3PH9'*K)4 C3\9]7-W
MLI#")9->M_OWAJ]W=AKKS.%@!AN'GZ&/K9X<W+D65W*63?S]-$+357&DE3:3
MO:[_=T(EK9BG4BTG^S<R!<M^@07[K%.>[3<MSD'+@I%QJ&CE?P!M0O/\Z:*T
M%_M1,H.5_;T^&7UYE\BI=&S0:_<?6GQ_-U_/I,/')HT&:-)5D_W,G4NPMY^T
M@6P*9M9D$1@GXR5S"7?O]H[&)RMK'9\J6-DXU4: ::&IBN<6)JL?)T+:7/'E
M1&9^0-_H).5FAA,ZU<[I='*$ULUIE(BK<F;\)(7B]52WNV&Z'<ZQ$ZN1R^*V
M+^HX45'6;1\.QD\6=]N]IYO^3K?C47LP[._4;<>;',Q&S]B<9Q\:@\:J0<Z%
MP)";]/,[UD-G;#RB"N)MY^B\\3 X'KB3PJ/LL47-)X/AQA7_S/LZ__= V'KJ
M_'3VVH\"MG3F*_BIRDVOY)4KEO Y, -S"0MDLDND9=]G6<$5^PRY-H[IC'W4
M)F6];NLGIF/V2<YX)MAUPDW*(RB\*RR[RB)ML &A'>/W^*3"W?[Y[/C8?$"A
M.L3K$/\3'N9^'>(57OF!6PQLC.)TR6XSO5 @9M ,D6Y"B N-PV4:I1GVQF7&
M>+9D1>9,05&)$>UU&\8^9RF>&8ETB'F$EPS3*:H+IT.]K0H91& M-TNJDO);
MP'$W^K1X3: Q.*3RH@_'H J1-"CRL%J&S=$2! );)#)*F"WHL&Z_  -E)W0#
MJ;0*U2 )RX5T"=Z@S2'R!E*_.9JFZ8' ^46G3)>;;JBI55/K%>)S4%/K)=0"
M%LL,N4"(67.@R4B3:"PV&^4RBU&Y<$I?\7>D"H%](FLV@KZ)G))&+5F.J"#*
M$?V46F.L)(A]-#224OB\N$DU"H45D%T: >.'L]Z>B-N$Q4HO[ IL!F;2.DRJ
M'>-T,=B-5C8W^&17QFQ96R.J1M0K!.-AC:@*K]P\B.=W>^-^;W1B2PB5RQDD
M1'0<2SSUD7[%N '/%&2$I.#$V&=@*>:D3:@Z54M1A)$0HW.,SDAI6V [DF<&
M?>[KY$9'(/"R90?($@$(IP",R[LHX=D,V/>H?#X7"FOT!KS5.SJ ][YI[TB$
MLW"*8X') M2H?T;R:(-U@3UDR\X#Q0\&BG$@NL_'!,0:E'X^6.[YIJ@V;O<&
M3Q?_4:J-CMO#T6[=OB[51OTW%*[\?0VQ;:\(L'@+&,X^L7J>-4W*^2)>V-V;
M4/(U!78_4DCG=&&P Q0\<VF]C,):D/E^: EX+< V19P!Q3V(RGQN#9-F*?"H
M4*(80UNL5E+XG09;3*T4DAM)-R!#UNEE948]%98R0<]MZ]-&+[JT!33(H<BC
M1CFG*2\4)ZV(M^6-6&>4V"+DIYMI-?Z: E5$.8?MO^5UL1IT;R>DIS7HG@7=
MSI)GBW>[BZ6=L8>HG$M!-.-69S[FN442TNH7(8X;L<(- E#RJ532+2FEK!J6
MX.O)Y*$3N/F@ZL;JF1>?=^4-Y87)$7K6I\!1A+CQ!OAUM!EDF-DJ9!^60$Y0
MI2I%Y@+?$+XR1_U7$ZXFW->/Y:@F7(578,Y5X?4.A3_$,41.SC%P;<7RT[[=
M1;F%T^JU*(\R;(BJRX85KZDNW--C[Z(M^7UMH.6\^/E%>S9=+11Z.I<^0'L\
MB6B FD8UC;ZNLJAI5.65$.[;V*"]Q7+9R)=4+J*]0&51LJBCJ# $AXW,K*+7
M5%N'UR-:YX_1/NSHMP(3.^SZX(DF,5(.]<^CVJ7A$;+';XO2CJE_9R+8]3Y8
ME7![G\:2<O)4!.$EI?='*?>63,E;4.4>Z:/ZS?_91=\V">N-@S>\<7!4;QP\
MNW&P_^R6@7]%ZYZGS;7D(06VR;2U^B$JO2#'W5I.0Z-X(:33QMXGE/X"=I:F
MTCF 2DTYU9BL4HF0:)-O?H"T0PEG22+B_[28MT(T_%9(--GCN,@BOW'ZOMX-
MJ$5;O1OP2EY1BM%RE43\T X=[?5%$I 793)XORJ_ 'Y+V5U8+O+YG5_H\J^$
MK=Z">!&%R@7TL#]:H8RXP(86[H51!;'*A3&LC/!!$C1#<FDQL[1%BO. KO"W
M44K1RC=%OFVY5#/H[41;O5!?R2#,#V.#8J.)1 "OC) I_N7.$C[-D%[);*[5
M'"C'ROBL?$?5E&(*TESI)6#I(M%!0?$':$,4522@^R_(JZJT;34@'LT"SLYD
M>._?BH^)GIRXT6O,BO^.Z )][Y79N[W>L%MQ_ A3@]GQ,ISUQTW_ =?K?,0S
M/&IWAX=_A(_'X_9Q]S5 %NQ_4="^)92]VSL<G5A_W/ZXZZDX>=IYY1-"@8*^
M8WXGGZWNXJ_EV3_!FW\MAUW>0530Y@/[)^;0[-J@+A5 ;XA\] P/"O \D1"7
M5XCJOX:,NW;N[SOWX#IL]:+'MGQ7I6:>$LS/_^';_ HWU^$;Y$EX_V<.6]_E
MKL'A?=A=-^%3I$?AMIL\\REO>0Q?%?OOF\_^"U!+ P04    " !OBUQ4F,_X
MOBT'  #*,P  &@   &QG;F1?,3(S,3(Q>&5X:&EB:70S,C$N:'1M[5MM4R(Y
M$/Y^OR*'=:Y;!?/*.ZY5'F(MMZY:+KM[]^DJ,Y-A4LY,YI(@<K_^.AD0!'31
M1<43RZ)FDDZGNY-^TNF&_5^/SMJ]O\X[*)))C,Z__G[2;:-"R32_NVW3/.H=
MH8^]SR>H;%@VZG&<"BHI2W%LFIW3 BI$4F9-TQP.A\;0-1COF[T+4[$JFS%C
M@AB!# H'^ZH%/@D.#G[9_[540D?,'R0DE<CG!$L2H(&@:1]]#XBX1*72F*K-
MLA&G_4@BQW(<])WQ2WJ%\WY)94P.)GSVS?Q]W]23['LL&!WL!_0*T>!#@3J-
M2JW<P-6*0^QRI5K&Q*N6:[;E-!ROC%W_;QN$-($\'R/D*"8?"@E-2Q%1\S=K
M3B9;0QK(J&E;UF\%37>P'[)4PF0<!N>/.8\%3I)<RQ*.:3]M:GT*^=!)M\]B
MQIL[EOYKJ9Y2B!,:CYKO>C0A IV2(;I@"4[?%06L04D03L.<4-!_"<@$XNG7
MX5A>X!/3E$SDMVLN"-VYCJA')7(=P[XM\8]E7:+FK*DP[X.U/"8E2YI5D&:&
MC0\+1/@+Z=SN7/2ZQ]WV8:][=HK.CM'Y1?>TW3T_/$&=/SOMK[WNMPXT T7G
MXGZ;T#0 19HN:/?DNI27ZM)-D<_2E/C*!]&0R@C)B*##-!W@&%V0C'&)6(A.
M:!^G 3J/,$^P3P:2^C@6J)OZC .-=K@]-7)WI^XX5JO-D@RG(_UFM]XC8'[,
M>()LJ_0)A8SK648$<T3 !@$Z(CY)/,)W=^RJU7+MHO)/^,0"A30&@AO1OA!_
MP $RP 9*HLZU'^&T3\"SDX0*H=2 ?T49@%0H(IR _+.RY5I-1"NB;A']P:(4
MG1CH(^W#IA-%U(XH"8$Y3";I%4%G84A]PI4I%*>Q>D4$;9*&\) -N!A@6$#)
MD%U'7XTO1MM0PFK#VF[%TLK@@&7*5K/D$Z*&59WP_X*YAU,B2F?7,1FA0U\O
M@F-93A'ZL1Z6C-!ERH9@G#[9W:G46RNZ4FWB2K=WG\1>3"8C/,8#PDNP"V.<
M"=*</+0"*K(8CYHTU7M)#VK=YE\!_E?*++!#QNZJI\N[QY#7:!ANI:Y03P(&
MR& R\1@0#0V(I@P6^^I&I5:[L]<R[#O[[N7:,!S'78FMJ27.I0:["-@('PIN
M83(@PT$ !T_3R:Z1?1NU8A(NFH9EA7L62QT28XXEC9VJY?FQ0A]0>_;[N4-I
M;*IGM8(:WG0WR"P]\-<Q4(:#.!Z!.9(L5OAT@UF<_#.@G*BP0BA'GL+"'@9L
MY-.&RE[P/@>*#'CXRKV*-Z P1;X;U!LC@]UPR_FP1.,IX$&CI?!QR8+I_6MJ
MSYW!BA< @+K;> P V)8! =?:$<!Q#-<MKY]MQ:A7UR^M6S4:Y=6D72]>Y8OX
M4@CD3!%H'GL:;Q5[: KQ5((U?D L)S%0!="J,6,"3)AR0*:,$Z$PJ*BZ<1PC
M& 830Z0''1E@D"CJ42%-<>JK=F 8Z/N9#K: :A#G$,8RPO6<8BXF,NZ"',DG
MUIFHD-OM_FUIJ24LK'36/ /I>GTIH4$0DP=MODV*!XY@\RP)/!\7%6AE-@IL
MCHG'!YB/D%/7MQ'G3NCYJ?WU1"BU=*/<BOM?;N/L[I1K+:$_YV]>=X/'!GC_
M<M)QJ 0+U 1:)%A, S0QXI,@PKA%S?B0=7_6U,GRE;]WM5^OSIICDTJ8S5_!
M"G<D%]ZH-?;..85@(X-H8\$DRRZ<R^\O<[92EIEFU>[/-&Y(*D[%<A#)D3Y3
M>>L\L030H(,O*I!'5',XX"D5$01X@#,$0CK)$/;]//2:C?A6RD=!2 ><4R8G
MW'6J3:7G8'C&!)F]K>:I.>#U\.OHK:E ($]%K3.90V\$H65(.$E]U:-T FU
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M:6=A;F1P:&%R;6%C92YH=&U02P$"% ,4    " !OBUQ4T%F(T(Z,!  J2S$
M$0              @ $Y<@$ ;&=N9"TR,#(Q,3(S,2YH=&U02P$"% ,4
M" !OBUQ4JP+_+GT9  "K(0$ $0              @ 'V_@4 ;&=N9"TR,#(Q
M,3(S,2YX<V102P$"% ,4    " !OBUQ4Z<"G+?<R   Z& ( %0
M    @ &B& 8 ;&=N9"TR,#(Q,3(S,5]C86PN>&UL4$L! A0#%     @ ;XM<
M5!<!"L$PGP  E_L& !4              ( !S$L& &QG;F0M,C R,3$R,S%?
M9&5F+GAM;%!+ 0(4 Q0    ( &^+7%0X4.6\"2T  -U3   4
M  "  2_K!@!L9VYD+3(P,C$Q,C,Q7V<Q+FIP9U!+ 0(4 Q0    ( &^+7%1R
M@JK$X-0& ._3!P 4              "  6H8!P!L9VYD+3(P,C$Q,C,Q7V<R
M+FIP9U!+ 0(4 Q0    ( &^+7%09 FP0R# ! +<: @ 4              "
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M,#,W+FAT;5!+ 0(4 Q0    ( &^+7%2@PMJAD@0  )U!   :
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=,S(Q+FAT;5!+!08     $  0 $T$  #/M1(    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
